FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Metel, AS
AF Metel, Alexander S.
TI RETRACTED: Sharpening of ceramic knife-edges and production of plasma
   for cutting tools nitriding with the use of a broad fast molecule
   beam(Retracted article. See vol. 17, pg.703, 2016)
SO MECHANICS & INDUSTRY
LA English
DT Article; Retracted Publication
DE Tools; strengthening; nitriding; glow discharge; plasma; fast molecules;
   sputtering; cutting edges; sharpening
ID VACUUM-ARC DEPOSITION; ELECTROSTATIC CONFINEMENT; GLOW-DISCHARGE;
   ELECTRONS; STEEL; BEAM; IONS
AB A source of gas molecules with energy ranging from 0.5 up to 4 keV has been used for production of non-self-sustained glow discharge plasma. Cutting tools immersed in nitrogen plasma are heated by the fast molecules but they are not sputtered by ions from the plasma. During nitriding of a tool the fast molecules sputter its cutting edges with the same rate as the rest of the tool surface. It results in a decrease of the edge radius. For sharpening of ceramic knife-edges were used fast neutral argon atoms, which sputter materials more intensively than nitrogen molecules.
C1 [Metel, Alexander S.] Moscow State Univ Technol STANKIN, 1 Vadkovsky Per,GSP 4, Moscow 127994, Russia.
RP Metel, AS (reprint author), Moscow State Univ Technol STANKIN, 1 Vadkovsky Per,GSP 4, Moscow 127994, Russia.
EM a.metel@stankin.ru
OI Metel, Alexander/0000-0002-1465-2312
FU Ministry of Education and Science of Russian Federation [519]
FX This work was carried out with the financial support of the Ministry of
   Education and Science of Russian Federation in the framework of the
   state task in the field of scientific activity of MSTU "STANKIN" (No.
   519).
CR Avelar-Batista JC, 2005, SURF COAT TECH, V200, P1954, DOI 10.1016/j.surfcoat.2005.08.037
   Boxman RL, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2169539
   Boxman RL, 1996, SURF COAT TECH, V86, P243, DOI 10.1016/S0257-8972(96)03023-X
   Grigoriev S, 2004, NATO SCI SER II MATH, V155, P147, DOI 10.1007/1-4020-2222-0_14
   Grigoriev SN, 2012, MET SCI HEAT TREAT+, V54, P8
   Grigoriev SN, 2009, INSTRUM EXP TECH+, V52, P731, DOI 10.1134/S0020441209050170
   Kaminsky M., 1965, ATOMIC IONIC IMPACT
   Massey H. S. W., 1952, ELECT IONIC IMPACT P
   McDaniel E. W., 1964, COLLISION PHENOMENA
   Metel A, 2002, SURF COAT TECH, V156, P38, DOI 10.1016/S0257-8972(02)00070-1
   Metel' A. S., 1985, Soviet Physics - Technical Physics, V30, P1133
   Metel AS, 2012, INSTRUM EXP TECH+, V55, P122, DOI 10.1134/S0020441211060170
   Metel AS, 2011, PLASMA PHYS REP+, V37, P628, DOI 10.1134/S1063780X11050072
   Metel AS, 2011, PLASMA PHYS REP+, V37, P357, DOI 10.1134/S1063780X11040088
   Metel' A. S., 1986, Soviet Physics - Technical Physics, V31, P1395
   Musil J, 1996, J VAC SCI TECHNOL A, V14, P2187, DOI 10.1116/1.580045
   Musil J, 2001, J VAC SCI TECHNOL A, V19, P420, DOI 10.1116/1.1339018
   PHELPS AV, 1991, J PHYS CHEM REF DATA, V20, P557
   Veprek S, 2006, SURF COAT TECH, V200, P3876, DOI 10.1016/j.surfcoat.2004.11.023
   Veprek S, 2013, J VAC SCI TECHNOL A, V31, DOI 10.1116/1.4818590
   Zhitomirsky VN, 2000, SURF COAT TECH, V133, P114, DOI 10.1016/S0257-8972(00)00884-7
NR 21
TC 1
Z9 1
U1 3
U2 8
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
   FRANCE
SN 2257-7777
EI 2257-7750
J9 MECH IND
JI Mech. Ind.
PY 2016
VL 17
IS 7
AR 703
DI 10.1051/meca/2016069
PG 6
WC Engineering, Mechanical; Mechanics
SC Engineering; Mechanics
GA ER8BW
UT WOS:000399041900003
OA Bronze
DA 2018-12-27
ER

PT J
AU Volosova, M
   Grigoriev, S
AF Volosova, Marina
   Grigoriev, Sergey
TI RETRACTED: Cutting ceramic inserts: the influence of abrasive machining
   and surface coatings on the operational characteristics(Retracted
   article. See vol. 17, Issue 7, 2016)
SO MECHANICS & INDUSTRY
LA English
DT Article; Retracted Publication
DE Vacuum-plasma coating; difficult-to-cut alloys; ceramic cutting tool;
   planetary grinding; bearing steel; nitrides
ID SCALE MULTILAYERED COATINGS; ELECTROSTATIC CONFINEMENT; NITRIDE
   CERAMICS; GLOW-DISCHARGE; TOOLS; ELECTRONS; CHAMBER; PLATES; STEEL; BEAM
AB Ceramic cutting tools have a large potential by high speed processing of difficult-to-cut steels and alloys, however due to its fragility they don't assure the required reliability level of cutting process. For improving the operational characteristics of the ceramic cutting tool combined treatment can be used namely the preliminary planetary grinding of the insert surface and the following deposition of the vacuum-plasma coatings (TiCr)N, (ZrCrHf)N and other.
C1 [Volosova, Marina; Grigoriev, Sergey] Moscow State Univ Technol STANKIN, Vadkovsky Lane 3a, Moscow 127994, Russia.
RP Volosova, M (reprint author), Moscow State Univ Technol STANKIN, Vadkovsky Lane 3a, Moscow 127994, Russia.
EM m.volosova@stankin.ru
RI Grigoriev, Sergey/J-2463-2012; Volosova, Marina/B-3020-2013
OI Grigoriev, Sergey/0000-0002-8239-5354; Volosova,
   Marina/0000-0002-5302-5442
FU Russian Ministry of Education and Science [11.1052.2014/K]
FX The study is conducted at the sub-department "High effective
   technologies of machining" (MSTU "STANKIN") in conjunction with the
   Berlin Technical University and O. Ghan and L. Meitner Institute. The
   researches is performed with financial support of the Russian Ministry
   of Education and Science (project No. 11.1052.2014/K).
CR Andreev AA, 2013, METALLOFIZ NOV TEKH+, V35, P1151
   Benga GC, 2003, J MATER PROCESS TECH, V143, P237, DOI 10.1016/S0924-0136(03)00346-7
   Grigor'ev SN, 2011, GLASS CERAM+, V68, P253, DOI 10.1007/s10717-011-9366-0
   Grigoriev SN, 2009, INSTRUM EXP TECH+, V52, P602, DOI 10.1134/S002044120904023X
   Grigoriev SN, 2012, PROC CIRP, V1, P301, DOI 10.1016/j.procir.2012.04.054
   Kuzin VV, 2006, REFRACT IND CERAM+, V47, P204, DOI 10.1007/s11148-006-0089-7
   Kuzin VV, 2013, J FRICT WEAR+, V34, P199, DOI 10.3103/S1068366613030100
   Lalwani DI, 2008, J MATER PROCESS TECH, V206, P167, DOI 10.1016/j.jmatprotec.2007.12.018
   Metel AS, 2012, INSTRUM EXP TECH+, V55, P288, DOI 10.1134/S0020441212010186
   Metel AS, 2011, PLASMA PHYS REP+, V37, P628, DOI 10.1134/S1063780X11050072
   Metel AS, 2011, PLASMA PHYS REP+, V37, P357, DOI 10.1134/S1063780X11040088
   Sahin Y, 2009, J MATER PROCESS TECH, V209, P3478, DOI 10.1016/j.jmatprotec.2008.08.016
   Sobol' OV, 2012, MET SCI HEAT TREAT+, V54, P195, DOI 10.1007/s11041-012-9481-8
   Sobol O. V., 2011, PROBLEMS ATOMIC SCI, V4, P174
   Vereschaka AS, 2013, ADV MATER RES-SWITZ, V712-715, P391, DOI 10.4028/www.scientific.net/AMR.712-715.391
   Volosova MA, 2012, MET SCI HEAT TREAT+, V54, P41
   Zhao J, 2010, INT J REFRACT MET H, V28, P330, DOI 10.1016/j.ijrmhm.2009.11.007
   Zheng GM, 2012, INT J ADV MANUF TECH, V58, P19, DOI 10.1007/s00170-011-3379-2
NR 18
TC 2
Z9 2
U1 4
U2 8
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
   FRANCE
SN 2257-7777
EI 2257-7750
J9 MECH IND
JI Mech. Ind.
PY 2016
VL 17
IS 7
AR 705
DI 10.1051/meca/2016074
PG 8
WC Engineering, Mechanical; Mechanics
SC Engineering; Mechanics
GA ER8BW
UT WOS:000399041900005
OA Bronze
DA 2018-12-27
ER

PT J
AU Emodi, NV
   Entele, BR
   Ogbuagu, MN
   Emodi, CC
   Emodi, ASA
   Okoro, FC
AF Emodi, Nnaemeka Vincent
   Entele, Birku Reta
   Ogbuagu, Marc Nwosu
   Emodi, Chinenye Comfort
   Emodi, Adaeze Saratu Augusta
   Okoro, Felix Chimezirim
TI RETRACTED: Scenario analysis for low carbon development in Nigeria
   (Retracted article. See vol. 4, art no 1300981, 2017)
SO COGENT ENGINEERING
LA English
DT Article; Retracted Publication
DE scenario analysis; low-carbon development; Nigeria; LEAP model; energy
   forecasting; low-carbon technology
ID ENERGY; MODELS; CHINA
AB This study explores a scenario-based analysis of future energy consumption and GHG emissions for Nigeria between 2010 and 2040 using the LEAP model. The impact of different energy policies are analysed for the Nigerian energy system by considering four scenarios: The reference (REF) scenario, the low-carbon moderate (LCM) scenario, the low-carbon advanced (LCA) scenario, and the green optimistic (GO) scenario. By considering aggressive energy policies and strategies from LCM to LCA, and even more aggressive options in the GO scenario, we find that under the REF scenario energy demand is expected to reach 3,075 PJ and a corresponding increase in GHG emissions of 201.2 Mt Co2e by 2040. More aggressive policy intervention by the Nigerian government, as in the GO scenario, would lead to a decrease in energy demand (2,249 PJ) and GHG emissions (124.4 Mt Co2e) in 2040. A costbenefit analysis is also carried out in the study.
C1 [Emodi, Nnaemeka Vincent] James Cook Univ, Coll Business Law & Governance, POB 6811, Cairns, Qld 4870, Australia.
   [Entele, Birku Reta] Seoul Natl Univ, Dept Technol Management, Coll Engn, Econ & Policy Program, Seoul 151744, South Korea.
   [Ogbuagu, Marc Nwosu] Michael Okpara Univ Agr, Dept Chem, Coll Phys & Appl Sci, Umudike, Nigeria.
   [Emodi, Chinenye Comfort] Michael Okpara Univ Agr, Dept Comp Sci, Coll Phys & Appl Sci, Umudike, Nigeria.
   [Emodi, Adaeze Saratu Augusta] Abia State Univ, Fac Law, Uturu, Nigeria.
   [Okoro, Felix Chimezirim] Univ Nigeria, Dept Vocat Teacher Educ, Nsukka Rd, Nsukka 410001, Nigeria.
RP Emodi, NV (reprint author), James Cook Univ, Coll Business Law & Governance, POB 6811, Cairns, Qld 4870, Australia.
EM nnaemeka.emodi@my.jcu.edu.au; birku200@gmail.com;
   marc.ogbuagu@gmail.com; nnaemeka.emodi@my.jcu.edu.au;
   emodiadaeze@gmail.com; okorofelix62@yahoo.com
CR Agbo SN, 2006, PACIFIC J SCI TECHNO, V7, P191
   Avbovbo A. A, 1978, B CAN PET GEOL, V26, P268
   Birol F, 2008, WORLD EN OUTL
   Cai WJ, 2008, ENERG POLICY, V36, P1181, DOI 10.1016/j.enpol.2007.11.030
   Central Expenditure Evaluation Unit, 2013, GUID EC APPR CARR OU
   Cormio C, 2003, RENEW SUST ENERG REV, V7, P99, DOI 10.1016/S1364-0321(03)00004-2
   David R, 2013, S AFR J INF MANAG, V15, P1
   Eleri E., 2013, LOW CARBON ENERGY DE
   Eleri EO, 2012, EXPANDING ACCESS PRO
   Eleri EO, 2011, LOW CARBON AFRICA LE
   Emodi N. V., 2015, INT J ENERGY EC POLI, V5, P565
   Emodi NV, 2015, RENEW SUST ENERG REV, V51, P356, DOI 10.1016/j.rser.2015.06.016
   Emodi NV, 2015, INT J ENERGY EC POLI, V5, P580
   Feng YY, 2012, PROCEDIA ENVIRON SCI, V13, P632, DOI 10.1016/j.proenv.2012.01.055
   Gelnett RH, 1979, USE RADAR GROUND WAT
   Heaps C., 2008, UNFCCC RESOURCE GUID
   Heaps C. G., 2012, LONG RANGE ENERGY AL
   Ibitoye FI, 2013, MILLENNIUM DEV GOALS, V2, P1
   International Energy Agency, 2011, WORLD EN OUTL 2011
   Kurowska E., 2010, P WORLD GEOTH C 2010
   Lazarus ML, 1997, LONG RANGE ENERGY AL
   Mosto Onuoha K., 1999, J AFR EARTH SCI, V28, P641
   Moyo B., 2012, INT BUSINESS EC RES, V11, P1163
   NWACHUKWU SO, 1976, AAPG BULL, V60, P1073
   Nwankwo LI, 2009, GLOB J PURE APPL SCI, V15, P427
   Pandey R, 2002, ENERG POLICY, V30, P97, DOI 10.1016/S0301-4215(01)00062-3
   Spellman FR, 2015, EC ENV PROFESSIONALS
   Stockholm Environment Institute, 2008, US GUID LEAP LONG RA
   Suganthi L, 2012, RENEW SUST ENERG REV, V16, P1223, DOI 10.1016/j.rser.2011.08.014
   Sunday Olayinka O., 2013, AM J ENERGY RES, V1, P36
   United Nations, 1997, GLOSS ENV STAT, V67
   Van Ruijven B, 2008, WORLD DEV, V36, P2801, DOI 10.1016/j.worlddev.2008.01.011
   Webmeets, 2015, SCEN COST BEN AN GER
   Yusuf SD, 2015, INT J ENERGY EC POLI, V5, P333
NR 34
TC 2
Z9 2
U1 0
U2 4
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 2331-1916
J9 COGENT ENG
JI Cogent Eng.
PY 2016
VL 3
IS 1
DI 10.1080/23311916.2016.1218818
PG 18
WC Engineering, Multidisciplinary
SC Engineering
GA EP4XV
UT WOS:000397384100148
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Li, ZQ
   Zhang, S
   Luo, JY
   Cui, JJ
   Dong, SL
AF Li, Zhao-Qun
   Zhang, Shuai
   Luo, Jun-Yu
   Cui, Jin-Jie
   Dong, Shuang-Lin
TI RETRACTED: The complete mitochondrial genome of the tobacco budworm,
   Helicoverpa assulta (Retracted article. See vol. 29, pg. 974, 2018)
SO MITOCHONDRIAL DNA PART A
LA English
DT Article; Retracted Publication
DE Helicoverpa assulta; lepidoptera; mitochondrial genome; noctuidae
ID TRANSFER-RNA GENES; PROGRAM; PHYLOGENY; SEQUENCES
AB The complete mitochondrial genome of the tobacco budworm Helicoverpa assulta was sequenced. It is 15,351 bp in length, and contains 22 transfer RNA genes, 13 protein-coding genes (PCGs), 2 rRNA genes and a non-coding AT-rich region. The H. assulta mitogenome displays a very high level of identity (99.76%) with Helicoverpa armigera. The genome base composition is 40.50% A, 40.40% T, 11.32% C and 7.70% G. Similar to other Lepidoptera insects, all PCGs are initiated by a typical ATN codon, except CO1, which starts with CGA. Nine PCGs have the standard, complete stop codon (TAA), and the other four PCGs end with the incomplete stop codon TA-.
C1 [Li, Zhao-Qun; Zhang, Shuai; Luo, Jun-Yu; Cui, Jin-Jie] Chinese Acad Agr Sci, Inst Cotton Res, State Key Lab Cotton Biol, Anyang, Henan, Peoples R China.
   [Li, Zhao-Qun; Dong, Shuang-Lin] Nanjing Agr Univ, Coll Plant Protect, Educ Minist, Key Lab Integrated Management Crop Dis & Pests, Nanjing, Jiangsu, Peoples R China.
RP Cui, JJ (reprint author), Chinese Acad Agr Sci, Inst Cotton Res, Dept Plant Protect, 38 Huanghe Rd, Anyang 455000, Henan, Peoples R China.; Dong, SL (reprint author), Nanjing Agr Univ, Dept Entomol, 1 Weigang, Nanjing 210095, Jiangsu, Peoples R China.
EM cuijinjie@126.com; sldong@njau.edu.cn
FU Ministry of Agriculture of China [2014ZX08011-002]; National Natural
   Science Foundation of China [31071978]
FX The authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the article. This study was
   funded by research grants from the Ministry of Agriculture of China
   (2014ZX08011-002) and the National Natural Science Foundation of China
   (31071978).
CR Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573
   Cameron SL, 2007, SYST ENTOMOL, V32, P40, DOI 10.1111/j.1365-3113.2006.00355.x
   Coates BS, 2016, MITOCHONDRIAL DNA A, V27, P1938, DOI 10.3109/19401736.2014.971296
   Fenn JD, 2008, MOL PHYLOGENET EVOL, V49, P59, DOI 10.1016/j.ympev.2008.07.004
   Laslett D, 2008, BIOINFORMATICS, V24, P172, DOI 10.1093/bioinformatics/btm573
   Li HC, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-582
   Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955
   Song N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048778
   Wang YL, 2015, MITOCHONDR DNA, V26, P791, DOI 10.3109/19401736.2013.855755
   Yin JA, 2010, MITOCHONDR DNA, V21, P160, DOI 10.3109/19401736.2010.503242
   Zhang HX, 2016, MITOCHONDRIAL DNA A, V27, P1652, DOI 10.3109/19401736.2014.958713
   Zhao J, 2016, MITOCHONDRIAL DNA A, V27, P1575, DOI 10.3109/19401736.2014.958674
NR 12
TC 2
Z9 2
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2470-1394
EI 2470-1408
J9 MITOCHONDRIAL DNA A
JI Mitochondrial DNA Part A
PY 2016
VL 27
IS 6
BP 3882
EP +
DI 10.3109/19401736.2014.987245
PG 2
WC Genetics & Heredity
SC Genetics & Heredity
GA EJ6CW
UT WOS:000393307200013
PM 25541303
DA 2018-12-27
ER

PT J
AU Gunawardane, S
   Kapugama, K
AF Gunawardane, Sumith
   Kapugama, Kanchana
TI RETRACTED: A Rare Pathological Entity of Multiple Calcified Hyperplastic
   Dental Follicles (Retracted article. art no 5149065, 2017)
SO CASE REPORTS IN DENTISTRY
LA English
DT Article; Retracted Publication
ID ODONTOGENIC FIBROMA; HAMARTOMA; ERUPTION
AB Multiple calcified hyperplastic dental follicles (MCHDF) are an extremely rare condition which has been categorized as a separate pathological entity very recently. It was initially described by Sandler et al. Gardner and Radden proposed this as a separate pathological entity. This disease is characterized by multiple unerupted teeth with abundant calcifications and rests of odontogenic epithelium in enlarged dental follicles.
C1 [Gunawardane, Sumith; Kapugama, Kanchana] Univ Peradeniya, Fac Dent Sci, Dept Oral & Maxillofacial Surg, Peradeniya, Sri Lanka.
RP Gunawardane, S (reprint author), Univ Peradeniya, Fac Dent Sci, Dept Oral & Maxillofacial Surg, Peradeniya, Sri Lanka.
EM sumithgunawardane7@gmail.com
OI Gunawardane, Sumith/0000-0002-1309-3897
CR BUCHNER A, 1991, J ORAL MAXIL SURG, V49, P330, DOI 10.1016/0278-2391(91)90365-S
   Cho YA, 2011, J ORAL PATHOL MED, V40, P243, DOI 10.1111/j.1600-0714.2010.00968.x
   DOMINGUEZ FV, 1995, J ORAL MAXIL SURG, V53, P1115, DOI 10.1016/0278-2391(95)90136-1
   GARDNER DG, 1980, ORAL SURG ORAL MED O, V50, P425, DOI 10.1016/S0030-4220(80)80011-9
   GARDNER DG, 1995, ORAL SURG ORAL MED O, V79, P603, DOI 10.1016/S1079-2104(05)80102-7
   Gomez RS, 1998, J ORAL PATHOL MED, V27, P333
   Handschel Jorg Gk, 2005, Head Face Med, V1, P3, DOI 10.1186/1746-160X-1-3
   LUKINMAA PL, 1990, ORAL SURG ORAL MED O, V70, P313, DOI 10.1016/0030-4220(90)90147-K
   O'Connell S, 2014, EUR ARCH PAEDIATR DE, V15, P361, DOI 10.1007/s40368-013-0106-8
   Onishi T, 2003, J ORAL PATHOL MED, V32, P246, DOI 10.1111/j.1365-2842.2004.01357.x-i1
   PHILIPSEN HP, 1992, J ORAL PATHOL MED, V21, P38, DOI 10.1111/j.1600-0714.1992.tb00967.x
   Philipsen HP, 2000, ORAL ONCOL, V36, P17, DOI 10.1016/S1368-8375(99)00061-5
   Quintella C, 2008, AM J ORTHOD DENTOFAC, V133, P758, DOI 10.1016/j.ajodo.2006.05.037
   Roquebert D, 2008, ORAL SURG ORAL MED O, V106, P92, DOI 10.1016/j.tripleo.2007.12.039
   Walker Leah M, 2004, J Dent Child (Chic), V71, P77
   Wood NK, 1997, DIFFERENTIAL DIAGNOS, P415
NR 16
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND
SN 2090-6447
EI 2090-6455
J9 CASE REP DENT
JI Case Rep. Dent.
PY 2016
AR 4190827
DI 10.1155/2016/4190827
PG 3
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA EH7DB
UT WOS:000391932000001
PM 28386487
OA DOAJ Gold, Green Accepted
DA 2018-12-27
ER

PT J
AU Samoilenko, NB
AF Samoilenko, Natalia B.
TI RETRACTED: DEVELOPING ACADEMIC WRITING IN INTERCULTURAL UNIVERSITY
   SETTINGS: KEY FEATURES, EFFICIENCY AND CHALLENGES(Retracted article. See
   vol. 5, pg. 617, 2017)
SO JOURNAL OF TEACHING ENGLISH FOR SPECIFIC AND ACADEMIC PURPOSES
LA English
DT Article; Retracted Publication
DE EAP; ESP; EFL; the course book materials; contents; developing of
   intercultural competence; writing strategies; specialist of humanities;
   pedagogical institution of humanities
AB The paper introduces the course book materials for developing students' humanities intercultural competence in the process of academic writing teaching, describes the task examples from the text book; it proves the efficiency and challenges of such a course introduced at Sevastopol State University, Sevastopol, Crimea.
C1 [Samoilenko, Natalia B.] Sevastopol State Univ, Dept Foreign Languages & Methodol Teaching, Sevastopol, Ukraine.
RP Samoilenko, NB (reprint author), Sevastopol State Univ, Dept Foreign Languages & Methodol Teaching, Sevastopol, Ukraine.
EM sevschool@narod.ru
CR Anderson Janice, 2002, INTERCULTURAL COMMUN
   Beer J. E., 2003, COMMUNICATING CULTUR
   CALLOWAYTHOMAS C, 1999, INTERCULTURAL COMMUN
   Chen G. M., 2005, FDN INTERCULTURAL CO
   Cooper P. J., 2007, INTERCULTURAL COMMUN
   Gardenswartz L., 1994, MANAGING DIVERSITY S, P58
   Gudykunst W. B., 2003, CROSS CULTURAL INTER
   Klopf D. W., 2007, INTERCULTURAL COMMUN
   Kramsch C., 1995, CULTURAL COMPONENT L, P83
   Maule D., 1991, FOCUS ON BRITAIN
   Neuliep J. W., 2009, INTERCULTURAL COMMUN
   Peterson B., 2004, CULTURAL INTELLIGENC, P161
   Samojlenko N. B., 2013, NAUKA I STUDIA, P33
   Samojlenko N. B., 2013, SCI LETT ACAD SOC MI, V1, P82
   Samojlenko N. B., 2013, SCI TECHNOLOGY HIGHE, VII, P626
   Ting-Tomey Stella, 1999, COMMUNICATING CULTUR
   Yakhontova T. V., 2003, OSNOVI ANGLOMOVNY NA
NR 17
TC 1
Z9 1
U1 0
U2 3
PU UNIV NIS, FAC SCI MATH
PI NIS
PA PO BOX 224, VISEGRADSKA 33, NIS, 18000, SERBIA MONTENEG
SN 2334-9182
EI 2334-9212
J9 J TEACH ENGL SPECIF
JI J. Teach. Engl. Specif. Acad. Purp.
PY 2016
VL 4
IS 2
BP 337
EP 350
PG 14
WC Education & Educational Research
SC Education & Educational Research
GA EG4VA
UT WOS:000391040600009
DA 2018-12-27
ER

PT J
AU Das, P
   Mandal, S
AF Das, Payel
   Mandal, Santanu
TI RETRACTED: Evaluating the influence of social media on brand
   sacralization An empirical study among young online consumers (Retracted
   article. See vol. 6, pg. 192, 2017)
SO SOUTH ASIAN JOURNAL OF GLOBAL BUSINESS RESEARCH
LA English
DT Article; Retracted Publication
DE Social media; Purchase intention; Loyalty; Online shopping; Brand
   sacralization; Young consumers
ID WORD-OF-MOUTH; COMPANY IDENTIFICATION; PURCHASE INTENTIONS; ADULT
   CONSUMERS; EXTENDED SELF; GENERATION Y; FACEBOOK; TWITTER; DETERMINANTS;
   ANTECEDENTS
AB Purpose - The purpose of this paper is to reveal the influence of social media in the development of brand sacralization in young consumers in emerging Asian market. Brand sacralization is the phenomenon where consumers (especially young) become an adherent of brands and consider brands as sacred entities. The paper specifically explores the influence of social media interaction and social media usability on brand sacralization and consequently its influence on online purchase intention (PI) and brand loyalty.
   Design/methodology/approach - Perceptual responses were gathered from 232 undergraduate and postgraduate students (age: 17-27 years) studying in an Indian private university and is subsequently analyzed using structural equation modeling. The young population is chosen as the target sample as they possess majority stake in final product purchase decision nowadays and also contribute as a dominant consumer category in online market places.
   Findings - The researcher found a strong positive influence of social media interaction and social media usability on brand sacralization. Further, brand sacralization is found to have a positive and significant influence on online PI and brand loyalty of young consumers. However, social media interaction does not contribute significantly to usability of social media. The researcher has also found a significant influence of brand loyalty on online PI for these young shoppers.
   Originality/value - The study is the foremost to investigate the influence of social media in developing brand sacralization and its influence on online PI and brand loyalty. Further the study is the first to develop a measurement instrument for brand sacralization. The study is the foremost in developing measures for social media interaction and social media usability.
C1 [Das, Payel] Symbiosis Inst Media & Commun, Pune, Maharashtra, India.
   [Mandal, Santanu] IBS Hyderabad, Hyderabad, Andhra Pradesh, India.
RP Mandal, S (reprint author), IBS Hyderabad, Hyderabad, Andhra Pradesh, India.
EM shaan.nitw@gmail.com
CR Ahearne M, 2005, J APPL PSYCHOL, V90, P574, DOI 10.1037/0021-9010.90.3.574
   Ahuvia AC, 2005, J CONSUM RES, V32, P171, DOI 10.1086/429607
   Albert N., 2010, J MARKETING DEV COMP, V5, P57
   Albert N, 2008, J BUS RES, V61, P1062, DOI 10.1016/j.jbusres.2007.09.014
   Alexander M, 2005, INT J CLOTH SCI TECH, V17, P52, DOI 10.1108/0955220510577961
   ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037//0033-2909.103.3.411
   Anderson R. E., 1995, MULTIVARIATE DATA AN
   Batra R, 2012, J MARKETING, V76, P1, DOI 10.1509/jm.09.0339
   Baumgartner H, 1996, INT J RES MARK, V13, P139, DOI [10.1016/0167-8116(95)00038-0, DOI 10.1016/0167-8116(95)00038-0]
   Beese J., 2011, SOCIAL NETWORKS INFL
   BELK RW, 1989, J CONSUM RES, V16, P1, DOI 10.1086/209191
   BELK RW, 1988, J CONSUM RES, V15, P139, DOI 10.1086/209154
   Bevan N, 2001, INT J HUM-COMPUT ST, V55, P533, DOI 10.1006/ijhc.2001.0483
   Bhattacharya CB, 2003, J MARKETING, V67, P76, DOI 10.1509/jmkg.67.2.76.18609
   Bolander W, 2015, J MARKETING, V79, P1, DOI 10.1509/jm.14.0444
   Bolton RN, 2013, J SERV MANAGE, V24, P245, DOI 10.1108/09564231311326987
   Brexendorf TO, 2015, J ACAD MARKET SCI, V43, P548, DOI 10.1007/s11747-015-0445-6
   Bright LF, 2015, COMPUT HUM BEHAV, V44, P148, DOI 10.1016/j.chb.2014.11.048
   Brodie RJ, 2013, J BUS RES, V66, P105, DOI 10.1016/j.jbusres.2011.07.029
   Carroll BA, 2006, MARKET LETT, V17, P79, DOI 10.1007/s11002-006-4219-2
   Casalo LV, 2010, INT J INFORM MANAGE, V30, P357, DOI 10.1016/j.ijinfomgt.2010.01.004
   Chen YH, 2007, IND MANAGE DATA SYST, V107, P21, DOI 10.1108/02635570710719034
   Chernatony de L., 1999, J MARKETING MANAGEME, V15, P157, DOI DOI 10.1362/026725799784870432
   Chiu CM, 2012, DECIS SUPPORT SYST, V53, P835, DOI 10.1016/j.dss.2012.05.021
   Chu SC, 2011, INT J ADVERT, V30, P47, DOI 10.2501/IJA-30-1-047-075
   CHURCHILL GA, 1979, J MARKETING RES, V16, P64, DOI 10.2307/3150876
   Colliander J, 2015, INT J ADVERT, V34, P181, DOI 10.1080/02650487.2014.996197
   comScore, 2011, COMS 2010 M IN PRESS
   Cutright K. M., 2014, FINDING BRANDS LOSIN
   de Vries L, 2012, J INTERACT MARK, V26, P83, DOI 10.1016/j.intmar.2012.01.003
   Dehghani M, 2015, COMPUT HUM BEHAV, V49, P597, DOI 10.1016/j.chb.2015.03.051
   Dion D, 2015, J RETAIL CONSUM SERV, V22, P77, DOI 10.1016/j.jretconser.2014.09.005
   DOLL WJ, 1994, MIS QUART, V18, P453, DOI 10.2307/249524
   Dunn L, 2014, J CONSUM RES, V41, P152, DOI 10.1086/675377
   Elkaseh Ali Mohamed, 2016, International Journal of Information and Education Technology, V6, P192, DOI 10.7763/IJIET.2016.V6.683
   Ellis AW, 2010, J CONSUM PSYCHOL, V20, P43, DOI 10.1016/j.jcps.2009.08.001
   Flavian C, 2006, INFORM MANAGE-AMSTER, V43, P1, DOI 10.1016/j.im.2005.01.002
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Fournier S, 2012, J CONSUM PSYCHOL, V22, P177, DOI 10.1016/j.jcps.2011.10.003
   Gergely Szolnoki, 2013, WINE EC POLICY, V2, P57, DOI [DOI 10.1016/J.WEP.2013.10.001, 10.1016/j.wep.2013.10.001]
   Gronroos C, 2011, IND MARKET MANAG, V40, P240, DOI 10.1016/j.indmarman.2010.06.036
   Ha S, 2013, J BUS RES, V62, P565
   Ha S, 2009, J BUS RES, V62, P565, DOI 10.1016/j.jbusres.2008.06.016
   Hair J.F., 2006, MULTIVARIATE DATA AN, V6
   Hausman AV, 2009, J BUS RES, V62, P5, DOI 10.1016/j.jbusres.2008.01.018
   He H-W, 2009, J MARK COMMUN, V15, P1, DOI DOI 10.1080/13527260802018041
   Healey MK, 2009, J CONSUM PSYCHOL, V19, P17, DOI 10.1016/j.jcps.2008.12.003
   Hoffman DL, 2010, MIT SLOAN MANAGE REV, V52, P41
   Hong IB, 2011, INT J INFORM MANAGE, V31, P469, DOI 10.1016/j.ijinfomgt.2011.02.001
   Hooper D, 2008, STRUCTURAL EQUATION
   Hsu L., 2015, INT J RES MARK, V26, P734
   Hudson S, 2015, TOURISM MANAGE, V47, P68, DOI 10.1016/j.tourman.2014.09.001
   Hughes DJ, 2012, COMPUT HUM BEHAV, V28, P561, DOI 10.1016/j.chb.2011.11.001
   Jarvenpaa SL, 2000, J STRATEGIC INF SYST, V9, P129, DOI 10.1016/S0963-8687(00)00042-1
   Kamariah N., 2005, P INT C E COMM FEB 2
   Kaplan AM, 2010, BUS HORIZONS, V53, P59, DOI 10.1016/j.bushor.2009.09.003
   Kardaras D, 2003, INT J INFORM MANAGE, V23, P41, DOI 10.1016/S0268-4012(02)00067-1
   Kervyn N, 2012, J CONSUM PSYCHOL, V22, P166, DOI 10.1016/j.jcps.2011.09.006
   Kontopoulos E, 2013, EXPERT SYST APPL, V40, P4065, DOI 10.1016/j.eswa.2013.01.001
   Kubacki K, 2015, J BUS RES, V68, P2214, DOI 10.1016/j.jbusres.2015.03.023
   Langhe B, 2015, J CONSUM RES, P42
   Laroche M, 2013, INT J INFORM MANAGE, V33, P76, DOI 10.1016/j.ijinfomgt.2012.07.003
   Lee D, 2015, INFORM MANAGE-AMSTER, V52, P295, DOI 10.1016/j.im.2014.12.001
   Lee SH, 2010, J CONSUM PSYCHOL, V20, P66, DOI 10.1016/j.jcps.2009.10.001
   Lenhart A., 2010, SOCIAL MEDIA MOBILE
   Liang TP, 2002, INFORM MANAGE-AMSTER, V39, P431, DOI 10.1016/S0378-7206(01)00129-X
   Madden T. J., 1988, ADV CONSUM RES, V15, P163
   Madhavaram S, 2005, J ADVERTISING, V34, P69, DOI 10.1080/00913367.2005.10639213
   Malhotra A, 2013, MIT SLOAN MANAGE REV, V54, P18
   Mangold WG, 2009, BUS HORIZONS, V52, P357, DOI 10.1016/j.bushor.2009.03.002
   Marshall DA, 2010, SOCIOL THEOR, V28, P64, DOI 10.1111/j.1467-9558.2009.01366.x
   McAlexander J. H., 1998, SERVICESCAPES CONCEP, P377
   McAlexander JH, 2002, J MARKETING, V66, P38, DOI 10.1509/jmkg.66.1.38.18451
   Melancon JP, 2015, J SERV MARK, V29, P293, DOI 10.1108/JSM-04-2014-0148
   Mitchell V, 2015, ELECTRON COMMER R A, V14, P95, DOI 10.1016/j.elerap.2014.12.003
   Muniz AM, 2001, J CONSUM RES, V27, P412, DOI 10.1086/319618
   Ngai EWT, 2015, INT J INFORM MANAGE, V35, P33, DOI 10.1016/j.ijinfomgt.2014.09.004
   Nielsen J, 1999, DESIGNING WEB USABIL
   Nunally J. C., 1978, PSYCHOMETRIC THEORY
   Oliver RL, 1999, J MARKETING, V63, P33, DOI 10.2307/1252099
   Pappu R., 2016, EUR J MARKETING, V50, P234
   Park CW, 2013, J CONSUM PSYCHOL, V23, P229, DOI 10.1016/j.jcps.2013.01.002
   Pew Research Center, 2012, STAT SOC MED US
   Pichler EA, 2007, ADV CONSUM RES, V34, P194
   Poddar A, 2009, J BUS RES, V62, P441, DOI 10.1016/j.jbusres.2008.01.036
   Ranganathan C, 2002, INFORM MANAGE-AMSTER, V39, P457, DOI 10.1016/S0378-7206(01)00112-4
   RICHINS ML, 1994, J CONSUM RES, V21, P522, DOI 10.1086/209415
   ROBERTS KA, 1984, RELIG SOCIOLOGICAL P
   Rusli E. M., 2013, WALL STREET J, P23
   Saboo A. R., 2015, INT J RES MARK, V39, P127
   Sarkar JG, 2015, YOUNG CONSUM, V16, P264, DOI 10.1108/YC-12-2014-00499
   Schau HJ, 2009, J MARKETING, V73, P30, DOI 10.1509/jmkg.73.5.30
   Schiffman L. G., 2000, CONSUMER BEHAV
   Shachar R, 2011, MARKET SCI, V30, P92, DOI 10.1287/mksc.1100.0591
   Siamagka NT, 2015, IND MARKET MANAG, V51, P89, DOI 10.1016/j.indmarman.2015.05.005
   Simon C, 2016, J PROD BRAND MANAG, V25, P409, DOI 10.1108/JPBM-03-2015-0843
   Smith AN, 2012, J INTERACT MARK, V26, P102, DOI 10.1016/j.intmar.2012.01.002
   Sparkloft Media, 2011, STAT TRAV TOUR IND S
   Steiger JH, 2007, PERS INDIV DIFFER, V42, P893, DOI 10.1016/j.paid.2006.09.017
   Stephen AT, 2012, J MARKETING RES, V49, P624, DOI 10.1509/jmr.09.0401
   Thomson M, 2005, J CONSUM PSYCHOL, V15, P77, DOI 10.1207/s15327663jcp1501_10
   Urde M, 2016, J PROD BRAND MANAG, V25, P26, DOI 10.1108/JPBM-05-2015-0875
   van Laer T, 2013, J INTERACT MARK, V27, P14, DOI 10.1016/j.intmar.2012.09.002
   Vijayasarathy LR, 2004, INFORM MANAGE-AMSTER, V41, P747, DOI 10.1016/j.im.2003.08.011
   Wang HC, 2006, TECHNOVATION, V26, P1366, DOI 10.1016/j.technovation.2005.11.003
   Wang X, 2015, J CONSUM RES, V42, P5, DOI 10.1093/jcr/ucv009
   Wei YH, 2014, J ACAD MARKET SCI, V42, P49, DOI 10.1007/s11747-013-0337-6
   Yoon C, 2009, J CONSUM PSYCHOL, V19, P2, DOI 10.1016/j.jcps.2008.12.002
   Zhou ZY, 2011, INT J INFORM MANAGE, V31, P261, DOI 10.1016/j.ijinfomgt.2010.07.007
NR 109
TC 1
Z9 1
U1 3
U2 17
PU EMERALD GROUP PUBLISHING LTD
PI BINGLEY
PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND
SN 2045-4457
J9 SOUTH ASIAN J GLOB B
JI South Asian J. Glob. Bus. Res.
PY 2016
VL 5
IS 3
BP 424
EP 446
DI 10.1108/SAJGBR-12-2015-0085
PG 23
WC Business
SC Business & Economics
GA EG1DE
UT WOS:000390771200007
DA 2018-12-27
ER

PT J
AU Zhao, FQ
   Lei, WC
   Ma, WM
   Liu, Y
   Zhang, C
AF Zhao, Fuqing
   Lei, Wenchang
   Ma, Weimin
   Liu, Yang
   Zhang, Chuck
TI RETRACTED: An Improved SPEA2 Algorithm with Adaptive Selection of
   Evolutionary Operators Scheme for Multiobjective Optimization Problems
   (Retracted article. See art. 1492768, 2018)
SO MATHEMATICAL PROBLEMS IN ENGINEERING
LA English
DT Article; Retracted Publication
ID DYNAMIC PARAMETER ADAPTATION; DIFFERENTIAL EVOLUTION; HYBRID ALGORITHM;
   FUZZY-LOGIC; ANT COLONY; NSGA-II; DECOMPOSITION; MOEA/D
AB A fixed evolutionary mechanism is usually adopted in the multiobjective evolutionary algorithms and their operators are static during the evolutionary process, which causes the algorithm not to fully exploit the search space and is easy to trap in local optima. In this paper, a SPEA2 algorithm which is based on adaptive selection evolution operators (AOSPEA) is proposed. The proposed algorithm can adaptively select simulated binary crossover, polynomial mutation, and differential evolution operator during the evolutionary process according to their contribution to the external archive. Meanwhile, the convergence performance of the proposed algorithm is analyzed with Markov chain. Simulation results on the standard benchmark functions reveal that the performance of the proposed algorithm outperforms the other classical multiobjective evolutionary algorithms.
C1 [Zhao, Fuqing; Lei, Wenchang; Liu, Yang] Lanzhou Univ Technol, Sch Comp & Commun Technol, Lanzhou 730050, Peoples R China.
   [Ma, Weimin] Tongji Univ, Sch Econ & Management, Shanghai 200092, Peoples R China.
   [Zhang, Chuck] Georgia Inst Technol, H Milton Stewart Sch Ind & Syst Engn, Atlanta, GA 30332 USA.
RP Zhao, FQ (reprint author), Lanzhou Univ Technol, Sch Comp & Commun Technol, Lanzhou 730050, Peoples R China.
EM fzhao2000@hotmail.com
FU National Natural Science Foundation of China [61663023]; General and
   Special Program of the Postdoctoral Science Foundation of China; Science
   Foundation for Distinguished Youth Scholars of Lanzhou University of
   Technology; Lanzhou Science Bureau project [2012M521802, 2013T60889,
   J201405, 2013-4-64]
FX This work was financially supported by the National Natural Science
   Foundation of China under Grant no. 61663023. It was also supported by
   the General and Special Program of the Postdoctoral Science Foundation
   of China, the Science Foundation for Distinguished Youth Scholars of
   Lanzhou University of Technology, and Lanzhou Science Bureau project
   under Grant nos. 2012M521802, 2013T60889, J201405, and 2013-4-64,
   respectively.
CR Al-Hajri Muhammad Tami, 2011, Proceedings of the 2011 11th International Conference on Intelligent Systems Design and Applications (ISDA), P1097, DOI 10.1109/ISDA.2011.6121805
   Ali M, 2012, EUR J OPER RES, V217, P404, DOI 10.1016/j.ejor.2011.09.025
   Belgasmi Nabil, 2011, Learning and Intelligent Optimization. 5th International Conference, LION 5. Selected Papers, P364, DOI 10.1007/978-3-642-25566-3_27
   Bleuler S., 2001, P C EV COMP MAY
   Coello CAC, 2006, IEEE COMPUT INTELL M, V1, P28, DOI 10.1109/MCI.2006.1597059
   Corne D. W., 2000, P PAR PROBL SOLV NAT, P839
   Corne D. W., 2001, P GEN EV COMP C GECC
   Deb K, 2002, IEEE T EVOLUT COMPUT, V6, P182, DOI 10.1109/4235.996017
   Deb K., 1996, COMPUTER SCI INFORMA, V26, P30, DOI DOI 10.1109/TEVC.2007.895269
   Deb K., 2005, EVOLUTIONARY MULTIOB, P105, DOI DOI 10.1007/1-84628-137-7_6
   Deb K., 2011, MULTIOBJECTIVE EVOLU, P3, DOI DOI 10.1007/978-0-85729-652-8_1
   Deb K, 1994, COMPLEX SYST, V9, P1
   Deb K, 2014, IEEE T EVOLUT COMPUT, V18, P577, DOI 10.1109/TEVC.2013.2281535
   Torres MD, 2014, EXPERT SYST APPL, V41, P831, DOI 10.1016/j.eswa.2013.08.013
   EL-Sawy A. A., 2014, APPL MATH, V5, P1993
   Emmerich M., 2005, EMO ALGORITHM USING
   FONSECA CM, 1993, PROCEEDINGS OF THE FIFTH INTERNATIONAL CONFERENCE ON GENETIC ALGORITHMS, P416
   Gong M., 2011, P 13 ANN C GEN EV CO
   Hirano H, 2013, 2013 IEEE CONGRESS ON EVOLUTIONARY COMPUTATION (CEC), P1854
   Huang VL, 2009, IEEE C EVOL COMPUTAT, P190, DOI 10.1109/CEC.2009.4982947
   Iosifescu M., 1980, FINITE MARKOV PROCES
   Ishibuchi H, 2015, LECT NOTES COMPUT SC, V9019, P110, DOI 10.1007/978-3-319-15892-1_8
   Ke LJ, 2013, IEEE T CYBERNETICS, V43, P1845, DOI 10.1109/TSMCB.2012.2231860
   Kim M, 2004, LECT NOTES COMPUT SC, V3242, P742
   Knowles JD, 2000, EVOL COMPUT, V8, P149, DOI 10.1162/106365600568167
   Li H, 2009, IEEE T EVOLUT COMPUT, V13, P284, DOI 10.1109/TEVC.2008.925798
   Li K, 2014, IEEE T EVOLUT COMPUT, V18, P114, DOI 10.1109/TEVC.2013.2239648
   Li XY, 2012, EXPERT SYST APPL, V39, P288, DOI 10.1016/j.eswa.2011.07.019
   Li Zhihuan, 2010, Information Technology Journal, V9, P749
   Maheta HH, 2014, PROCEEDINGS OF THE 2014 INTERNATIONAL CONFERENCE ON ISSUES AND CHALLENGES IN INTELLIGENT COMPUTING TECHNIQUES (ICICT), P75, DOI 10.1109/ICICICT.2014.6781256
   Melin P, 2013, EXPERT SYST APPL, V40, P3196, DOI 10.1016/j.eswa.2012.12.033
   Nebro AJ, 2013, LECT NOTES COMPUT SC, V8109, P269, DOI 10.1007/978-3-642-40643-0_28
   Pulido G. T., 2003, EVOLUTIONARY MULTICR
   [戚玉涛 Qi Yutao], 2013, [软件学报, Journal of Software], V24, P1529
   rey Horn J., 1994, P 1 IEEE C EV COMP I
   Saxena DK, 2013, IEEE T EVOLUT COMPUT, V17, P77, DOI 10.1109/TEVC.2012.2185847
   Schaffer J. D., 1985, THESIS
   Sheng WX, 2012, COMPUT MATH APPL, V64, P944, DOI 10.1016/j.camwa.2012.01.063
   Silva GC, 2012, EXPERT SYST APPL, V39, P12474, DOI 10.1016/j.eswa.2012.04.066
   Srinivas N, 1994, EVOLUTIONARY COMPUTA, V2, P221, DOI DOI 10.1162/EVC0.1994.2.3.221
   Storn R, 1997, J GLOBAL OPTIM, V11, P341, DOI 10.1023/A:1008202821328
   Nguyen TT, 2014, EXPERT SYST APPL, V41, P2134, DOI 10.1016/j.eswa.2013.09.012
   Valdez F, 2014, EXPERT SYST APPL, V41, P6459, DOI 10.1016/j.eswa.2014.04.015
   Wang FK, 2014, EXPERT SYST APPL, V41, P3850, DOI 10.1016/j.eswa.2013.12.022
   Wang L, 2014, EXPERT SYST APPL, V41, P2496, DOI 10.1016/j.eswa.2013.09.049
   Wu Ting-Ting, 2009, 2009 1st International Conference on Information Science and Engineering (ICISE 2009), P125, DOI 10.1109/ICISE.2009.273
   Ying Gao, 2013, Advances in Neural Networks - ISNN 2013. 10th International Symposium on Neural Networks. Proceedings: LNCS 7952, P341, DOI 10.1007/978-3-642-39068-5_42
   Zhang QF, 2007, IEEE T EVOLUT COMPUT, V11, P712, DOI 10.1109/TEVC.2007.892759
   Zhang ZJ, 2014, EXPERT SYST APPL, V41, P2816, DOI 10.1016/j.eswa.2013.10.014
   Zheng Zhang-hua, 2009, Journal of Shanghai Jiaotong University, V43, P1222
   Zitzler E, 1999, IEEE T EVOLUT COMPUT, V3, P257, DOI 10.1109/4235.797969
   Zitzler E., 2002, EVOLUTIONARY METHODS, P95
   Zitzler E, 2000, EVOL COMPUT, V8, P173, DOI 10.1162/106365600568202
NR 53
TC 0
Z9 0
U1 7
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1024-123X
EI 1563-5147
J9 MATH PROBL ENG
JI Math. Probl. Eng.
PY 2016
AR 8010346
DI 10.1155/2016/8010346
PG 20
WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary
   Applications
SC Engineering; Mathematics
GA EE9GZ
UT WOS:000389935400001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Sinha, SK
   Mishra, V
   Afdaali, N
   Jha, MJ
   Kumar, A
   Asif, M
   Thakur, R
   Varma, CM
AF Sinha, Santosh Kumar
   Mishra, Vikas
   Afdaali, Nasar
   Jha, Mukesh Jitendra
   Kumar, Ashutosh
   Asif, Mohammad
   Thakur, Ramesh
   Varma, Chandra Mohan
TI RETRACTED: Coronary Angiography Safety between Transradial and
   Transfemoral Access (Retracted article. See art no 3045963, 2018)
SO CARDIOLOGY RESEARCH AND PRACTICE
LA English
DT Article; Retracted Publication
ID RADIATION-EXPOSURE; ANGIOPLASTY; INTERVENTION; METAANALYSIS; OUTCOMES;
   TRIAL
AB Background and Aim. The aim of study was to evaluate safety, feasibility, and procedural variables of transradial approach compared with transfemoral approach in a standard population of patients undergoing coronary catheterization as one of the major criticisms of the transradial approach is that it takes longer overall procedure and fluoroscopy time, thereby causing more radiation exposure. Method. Between January 2015 and December 2015, a total of 1,997 patients in LPS Institute of Cardiology, GSVM Medical College, Kanpur, UP, India, undergoing coronary catheterization were randomly assigned to the transradial or transfemoral approach. Result. Successful catheterization was achieved in 1045 of 1076 patients (97.1%) in the transradial group and in 918 of 921 patients (99.7%) in the transfemoral group (p = 0.001). Comparing the transradial and transfemoral approaches, fluoroscopy time (2.46 +/- 1.22 versus 2.83 +/- 1.31 min; p = 0.32), procedure time (8.89 +/- 2.72 versus 9.33 +/- 2.82 min; p = 0.56), contrast volume (67.52 +/- 22.54 versus 71.63 +/- 25.41 mL; p = 0.32), radiation dose as dose area product (24.2 +/- 4.21 versus 22.3 +/- 3.46 Gycm(2); p = 0.43), and postprocedural rise of serum creatinine (6 +/- 4.5% versus 8 +/- 2.6%; p = 0.41) were not significantly different while vascular access site complications were significantly lower in transradial group than transfemoral group (3.9% versus 7.6%; p = 0.04). Conclusion. The present study shows that transradial access for coronary angiography is safe among patients compared to transfemoral access with lower rate of local vascular complications.
C1 [Sinha, Santosh Kumar; Mishra, Vikas; Afdaali, Nasar; Jha, Mukesh Jitendra; Kumar, Ashutosh; Asif, Mohammad; Thakur, Ramesh; Varma, Chandra Mohan] GSVM Med Coll, LPS Inst Cardiol, Dept Cardiol, Kanpur 208002, Uttar Pradesh, India.
RP Sinha, SK (reprint author), GSVM Med Coll, LPS Inst Cardiol, Dept Cardiol, Kanpur 208002, Uttar Pradesh, India.
EM fionasan@rediffmail.com
CR Agostoni P, 2004, J AM COLL CARDIOL, V44, P349, DOI 10.1016/j.jacc.2004.04.034
   Brasselet C, 2008, EUR HEART J, V29, P63, DOI 10.1093/eurheartj/ehm508
   Brueck M, 2009, JACC-CARDIOVASC INTE, V2, P1047, DOI 10.1016/j.jcin.2009.07.016
   CAMPEAU L, 1989, CATHETER CARDIO DIAG, V16, P3, DOI 10.1002/ccd.1810160103
   Chag Milan, 2010, Indian Heart J, V62, P264
   International Commission on Radiological Protection, 1997, ANN ICRP, V26
   Jolly SS, 2011, LANCET, V377, P1409, DOI 10.1016/S0140-6736(11)60404-2
   Kawashima O, 2004, CATHETER CARDIO INTE, V61, P333, DOI 10.1002/ccd.10769
   KIEMENEIJ F, 1995, AM HEART J, V130, P14, DOI 10.1016/0002-8703(95)90229-5
   KIEMENEIJ F, 1995, AM HEART J, V129, P1, DOI 10.1016/0002-8703(95)90034-9
   Kim JY, 2011, KOREAN CIRC J, V41, P1, DOI 10.4070/kcj.2011.41.1.1
   Kim SM, 2006, INT J CARDIOVAS IMAG, V22, P295, DOI 10.1007/s10554-005-9029-8
   Louvard Y, 2004, AM J CARDIOL, V94, P1177, DOI 10.1016/j.amjcard.2004.07.089
   Philippe F, 2004, CATHETER CARDIO INTE, V61, P67, DOI 10.1002/ccd.10675
   Plourde G, 2015, LANCET, V386, P2192, DOI 10.1016/S0140-6736(15)00305-0
   Pristipino C, 2009, HEART, V95, P476, DOI 10.1136/hrt.2008.150714
   Pristipino C, 2007, AM J CARDIOL, V99, P1216, DOI 10.1016/j.amjcard.2006.12.038
   Rao SV, 2008, JACC-CARDIOVASC INTE, V1, P379, DOI 10.1016/j.jcin.2008.05.007
   Sciahbasi A, 2011, AM HEART J, V161, DOI 10.1016/j.ahj.2010.10.003
NR 19
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-8016
EI 2090-0597
J9 CARDIOL RES PRACT
JI Cardiol. Res. Pract.
PY 2016
AR UNSP 4013843
DI 10.1155/2016/4013843
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EB9GU
UT WOS:000387702000001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Abbas, A
   Ullah, M
   Ali, Q
   Zahid, I
   Abbas, S
   Wang, XL
AF Abbas, Aumber
   Ullah, Mudaser
   Ali, Qasim
   Zahid, Imran
   Abbas, Saleem
   Wang, Xianli
TI RETRACTED: An overview of CO2 electroreduction into hydrocarbons and
   liquid fuels on nanostructured copper catalysts (Retracted article. See
   vol. 10, pg. 29, 2017)
SO GREEN CHEMISTRY LETTERS AND REVIEWS
LA English
DT Article; Retracted Publication
DE CO2 reduction; hydrocarbons; liquid fuels; nanostructured copper
ID SELECTIVE ELECTROCHEMICAL REDUCTION; SINGLE-CRYSTAL ELECTRODES;
   CARBON-DIOXIDE REDUCTION; METAL-ELECTRODES; AQUEOUS-SOLUTIONS; CU
   NANOPARTICLES; NITRITE IONS; AB-INITIO; ETHYLENE; SURFACE
AB The increasing atmospheric levels of carbon dioxide (CO2) must be controlled or better reverted to avoid undesirable climate changes. The electrochemical reduction of CO2 into hydrocarbons is the best approach to solve this problem because it will recycle the 'spent' CO2, known as carbon neutral cycle, and will probably be able to remit the energy crises. Nanostructured copper is a novel material known for the efficient and selective reduction of CO2 into hydrocarbons. This review attempts to summarize the recent development of enlarged surface area nanostructured copper for the efficient reduction of CO2 into hydrocarbons using renewable energy resources at low overpotentials. The effects of different reaction conditions (e.g. applied potential, CO2 concentration and electrode surface) on the products and some relationships between these conditions and products are discussed here. Latest achievements in the CO2 electroreduction technology, remaining challenges and perspective research directions for practical applications are also presented.
   [GRAPHICS]
   .
C1 [Abbas, Aumber; Ullah, Mudaser; Wang, Xianli] Shandong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Liquid Solid Struct Evolut & Proc Mat, Jinan, Peoples R China.
   [Ali, Qasim; Zahid, Imran] Univ Sargodha, Univ Coll Engn & Technol, Sargodha, Pakistan.
   [Abbas, Saleem] Hebei Univ Technol, Sch Mat Sci & Engn, Tianjin, Peoples R China.
   [Abbas, Saleem] Hebei Univ Technol, Hebei Key Lab Boron Nitride Micro & Nano Mat, Tianjin, Peoples R China.
RP Ullah, M (reprint author), Shandong Univ, Sch Mat Sci & Engn, Minist Educ, Key Lab Liquid Solid Struct Evolut & Proc Mat, Jinan, Peoples R China.
EM mudaser_me150@yahoo.com
FU National Natural Science Foundation of China [NSFC] [51301096]; Shandong
   Provincial Natural Science Foundation [ZR2013EMQ012]; Fundamental
   Research Funds of Shandong University [2014JC017]
FX This work was supported by the National Natural Science Foundation of
   China [NSFC No. 51301096] and Shandong Provincial Natural Science
   Foundation [ZR2013EMQ012]. The work was also financially supported by
   the Fundamental Research Funds of Shandong University [No. 2014JC017].
CR Agarwal AS, 2011, CHEMSUSCHEM, V4, P1301, DOI 10.1002/cssc.201100220
   Bae JH, 2012, PHYS CHEM CHEM PHYS, V14, P448, DOI 10.1039/c1cp22927c
   Balzani V., 2010, ENERGY SUSTAINABLE W
   Baturina OA, 2014, ACS CATAL, V4, P3682, DOI 10.1021/cs500537y
   Benson EE, 2009, CHEM SOC REV, V38, P89, DOI 10.1039/b804323j
   Boo H, 2004, J AM CHEM SOC, V126, P4524, DOI 10.1021/ja0398316
   Calle-Vallejo F., 2013, ANGEW CHEM, V125, P7423
   Centi G, 2009, CATAL TODAY, V148, P191, DOI 10.1016/j.cattod.2009.07.075
   CHANDRASEKARAN K, 1987, SURF SCI, V185, P495, DOI 10.1016/S0039-6028(87)80173-5
   Chaplin RPS, 2003, J APPL ELECTROCHEM, V33, P1107, DOI 10.1023/B:JACH.0000004018.57792.b8
   Chen CS, 2015, J PHYS CHEM C, V119, P26875, DOI 10.1021/acs.jpcc.5b09144
   Chen CS, 2015, CATAL SCI TECHNOL, V5, P161, DOI 10.1039/c4cy00906a
   Chen YH, 2012, J AM CHEM SOC, V134, P19969, DOI 10.1021/ja309317u
   COOK RL, 1989, J ELECTROCHEM SOC, V136, P1982, DOI 10.1149/1.2097110
   Costentin C, 2013, CHEM SOC REV, V42, P2423, DOI 10.1039/c2cs35360a
   Costentin C, 2012, SCIENCE, V338, P90, DOI 10.1126/science.1224581
   DEWULF DW, 1989, J ELECTROCHEM SOC, V136, P1686, DOI 10.1149/1.2096993
   DiMeglio JL, 2013, J AM CHEM SOC, V135, P8798, DOI 10.1021/ja4033549
   Ding Y, 2004, J AM CHEM SOC, V126, P6876, DOI 10.1021/ja0320119
   Durand WJ, 2011, SURF SCI, V605, P1354, DOI 10.1016/j.susc.2011.04.028
   Ebbesen SD, 2009, J POWER SOURCES, V193, P349, DOI 10.1016/j.jpowsour.2009.02.093
   Erlebacher J, 2009, MRS BULL, V34, P561, DOI 10.1557/mrs2009.155
   Gattrell M, 2007, ENERG CONVERS MANAGE, V48, P1255, DOI 10.1016/j.enconman.2006.09.019
   Ge XB, 2013, ADV FUNCT MATER, V23, P4156, DOI 10.1002/adfm.201300114
   Goncalves MR, 2013, ELECTROCHIM ACTA, V102, P388, DOI 10.1016/j.electacta.2013.04.015
   Hashimoto K, 2001, MAT SCI ENG A-STRUCT, V304, P88, DOI 10.1016/S0921-5093(00)01457-X
   HORI Y, 1987, J AM CHEM SOC, V109, P5022, DOI 10.1021/ja00250a044
   HORI Y, 1986, CHEM LETT, P897, DOI 10.1246/cl.1986.897
   HORI Y, 1989, J CHEM SOC FARAD T 1, V85, P2309, DOI 10.1039/f19898502309
   Hori Y, 2003, J MOL CATAL A-CHEM, V199, P39, DOI 10.1016/S1381-1169(03)00016-5
   Hori Y, 2008, MOD ASP ELECTROCHEM, P89
   Hori Y, 2002, J PHYS CHEM B, V106, P15, DOI 10.1021/jp013478d
   HORI Y, 1985, CHEM LETT, P1695, DOI 10.1246/cl.1985.1695
   Hori Y, 1997, J PHYS CHEM B, V101, P7075, DOI 10.1021/jp970284i
   Kas R, 2014, PHYS CHEM CHEM PHYS, V16, P12194, DOI 10.1039/c4cp01520g
   Kim D, 2015, PHYS CHEM CHEM PHYS, V17, P824, DOI 10.1039/c4cp03172e
   KIM JJ, 1988, J ELECTROANAL CHEM, V245, P223, DOI 10.1016/0022-0728(88)80071-8
   Kleis J, 2011, CATAL LETT, V141, P1067, DOI 10.1007/s10562-011-0632-0
   Kramer D, 2004, NANO LETT, V4, P793, DOI 10.1021/nl049927d
   Kuhl KP, 2012, ENERG ENVIRON SCI, V5, P7050, DOI 10.1039/c2ee21234j
   Lackner KS, 2002, ANNU REV ENERG ENV, V27, P193, DOI 10.1146/annurev.energy.27.122001.083433
   Lang XY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3169
   Lang XY, 2011, NAT NANOTECHNOL, V6, P232, DOI 10.1038/nnano.2011.13
   Li CW, 2014, NATURE, V508, P504, DOI 10.1038/nature13249
   Li CW, 2012, J AM CHEM SOC, V134, P7231, DOI 10.1021/ja3010978
   Li L, 2013, J PHYS CHEM LETT, V4, P222, DOI 10.1021/jz3018286
   Manthiram K, 2014, J AM CHEM SOC, V136, P13319, DOI 10.1021/ja5065284
   Mignard D, 2003, INT J HYDROGEN ENERG, V28, P455, DOI 10.1016/S0360-3199(02)00082-4
   Montoya JH, 2013, CHEMCATCHEM, V5, P737, DOI 10.1002/cctc.201200564
   Olah GA, 2009, J ORG CHEM, V74, P487, DOI 10.1021/jo801260f
   Peterson AA, 2010, ENERG ENVIRON SCI, V3, P1311, DOI 10.1039/c0ee00071j
   Ponnurangam S, 2016, CHEMELECTROCHEM, V3, P74, DOI 10.1002/celc.201500421
   Qiao Y, 2011, J MATER CHEM, V21, P4027, DOI 10.1039/c0jm02871a
   Ren D, 2015, ACS CATAL, V5, P2814, DOI 10.1021/cs502128q
   Reske R, 2014, J AM CHEM SOC, V136, P6978, DOI 10.1021/ja500328k
   Rosen BA, 2011, SCIENCE, V334, P643, DOI 10.1126/science.1209786
   SAWYER JS, 1972, NATURE, V239, P23, DOI 10.1038/239023a0
   Schouten KJP, 2011, CHEM SCI, V2, P1902, DOI 10.1039/c1sc00277e
   Schouten KJP, 2014, J ELECTROANAL CHEM, V716, P53, DOI 10.1016/j.jelechem.2013.08.033
   Schouten KJP, 2013, ACS CATAL, V3, P1292, DOI 10.1021/cs4002404
   Schouten KJP, 2012, J AM CHEM SOC, V134, P9864, DOI 10.1021/ja302668n
   Schrag DP, 2007, SCIENCE, V315, P812, DOI 10.1126/science.1137632
   Sen S, 2014, ACS CATAL, V4, P3091, DOI 10.1021/cs500522g
   SHIBATA M, 1995, J ELECTROANAL CHEM, V387, P143, DOI 10.1016/0022-0728(95)03992-P
   Shibata M, 1998, J ELECTROANAL CHEM, V442, P67, DOI 10.1016/S0022-0728(97)00504-4
   Smith BD, 1997, J ELECTROCHEM SOC, V144, P4288, DOI 10.1149/1.1838180
   Specht M, 1998, INT J HYDROGEN ENERG, V23, P387, DOI 10.1016/S0360-3199(97)00077-3
   Tang W, 2012, PHYS CHEM CHEM PHYS, V14, P76, DOI 10.1039/c1cp22700a
   Tornow CE, 2012, J AM CHEM SOC, V134, P19520, DOI 10.1021/ja308217w
   Verdaguer-Casadevall A, 2015, J AM CHEM SOC, V137, P9808, DOI 10.1021/jacs.5b06227
   Volk T., 2010, CO2 RISING WORLDS GR
   WATANABE K, 1993, CHEM PHYS LETT, V209, P109, DOI 10.1016/0009-2614(93)87210-T
   WATANABE K, 1994, APPL SURF SCI, V75, P121, DOI 10.1016/0169-4332(94)90147-3
   Weimer T, 1996, ENERG CONVERS MANAGE, V37, P1351, DOI 10.1016/0196-8904(95)00345-2
   Whipple DT, 2010, J PHYS CHEM LETT, V1, P3451, DOI 10.1021/jz1012627
   Wittstock A, 2010, PHYS CHEM CHEM PHYS, V12, P12919, DOI 10.1039/c0cp00757a
   Yano H, 2004, J ELECTROANAL CHEM, V565, P287, DOI 10.1016/j.jelechem.2003.10.021
   Yuan DD, 2009, ELECTROCHIM ACTA, V54, P2912, DOI 10.1016/j.electacta.2008.11.006
NR 78
TC 6
Z9 6
U1 3
U2 49
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1751-8253
EI 1751-7192
J9 GREEN CHEM LETT REV
JI Green Chem. Lett. Rev.
PY 2016
VL 9
IS 3
BP 166
EP 178
DI 10.1080/17518253.2016.1188162
PG 13
WC Chemistry, Multidisciplinary; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY
SC Chemistry; Science & Technology - Other Topics
GA DW3RP
UT WOS:000383560600003
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Zhao, H
   Wei, Z
   Xu, SX
   Tang, MJ
   Deng, LD
   Zhang, JH
   Dong, AJ
AF Zhao, Hui
   Wei, Zhen
   Xu, Shuxin
   Tang, Minjie
   Deng, Liandong
   Zhang, Jianhua
   Dong, Anjie
TI RETRACTED: Preparation and properties of polymer micelle-embedded
   nanofibrous membranes for dual-drug co-delivery and multistep release
   (Retracted Article)
SO RSC ADVANCES
LA English
DT Correction; Retracted Publication
C1 [Zhao, Hui; Wei, Zhen; Xu, Shuxin; Tang, Minjie; Deng, Liandong; Zhang, Jianhua; Dong, Anjie] Tianjin Univ, Sch Chem Engn & Technol, Dept Polymer Sci & Technol, Tianjin 300072, Peoples R China.
   [Wei, Zhen] Tianjin Agr Univ, Dept Appl Chem, Coll Basic Sci, Tianjin 300384, Peoples R China.
RP Dong, AJ (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Dept Polymer Sci & Technol, Tianjin 300072, Peoples R China.
EM ajdong@tju.edu.cn
CR ZHUO H, 2015, RSC ADV, DOI DOI 10.1039/C5RA03345D
NR 1
TC 1
Z9 1
U1 3
U2 10
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 86
BP 82687
EP 82687
DI 10.1039/c6ra90077a
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA DX1VM
UT WOS:000384155100028
OA Other Gold
DA 2018-12-27
ER

PT J
AU Namazi, H
   Akrami, A
   Nazeri, S
   Kulish, VV
AF Namazi, Hamidreza
   Akrami, Amin
   Nazeri, Sina
   Kulish, Vladimir V.
TI RETRACTED: Analysis of the Influence of Complexity and Entropy of
   Odorant on Fractal Dynamics and Entropy of EEG Signal (Retracted
   article. See art no 2358107, 2018)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID CONFIRMED ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; STIMULI; RESPONSES;
   CANCER; MEMORY
AB An important challenge in brain research is to make out the relation between the features of olfactory stimuli and the electroencephalogram(EEG) signal. Yet, no one has discovered any relation between the structures of olfactory stimuli and the EEG signal. This study investigates the relation between the structures of EEG signal and the olfactory stimulus (odorant). We show that the complexity of the EEG signal is coupled with the molecular complexity of the odorant, where more structurally complex odorant causes less fractal EEG signal. Also, odorant having higher entropy causes the EEG signal to have lower approximate entropy. The method discussed here can be applied and investigated in case of patients with brain diseases as the rehabilitation purpose.
C1 [Namazi, Hamidreza; Kulish, Vladimir V.] Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore, Singapore.
   [Akrami, Amin] Univ Tehran, Sch Met & Mat Engn, Tehran, Iran.
   [Nazeri, Sina] Univ Malaysia Sarawak, Fac Cognit Sci & Human Dev, Kota Samarahan 94300, Malaysia.
RP Namazi, H (reprint author), Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore, Singapore.
EM hnamazi@ntu.edu.sg
OI Kulish, Vladimir/0000-0001-9978-5423
CR Adib M., 2013, COMP MATH MATH PHYS, V2013
   Al-Fahoum Amjed S, 2014, ISRN Neurosci, V2014, P730218, DOI 10.1155/2014/730218
   Burdock G. A., 2009, FENAROLIS HDB FLAVOR
   Gilbert PE, 2004, J CLIN EXP NEUROPSYC, V26, P779, DOI 10.1080/13803390490509439
   Gilbert PE, 2004, J INT NEUROPSYCH SOC, V10, P835, DOI 10.1017/S1355617704106024
   Harada H, 1998, CLIN ELECTROENCEPHAL, V29, P96, DOI 10.1177/155005949802900208
   HENDRICKSON JB, 1987, J CHEM INF COMP SCI, V27, P63, DOI 10.1021/ci00054a004
   Hosseini S A, 2011, INT J IMAGE GRAPH SI, V3, P30, DOI DOI 10.5815/IJIGSP.2011.05.05
   Huart C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033221
   Huh KH, 2011, IMAGNG SCI DENT, V41, P71, DOI 10.5624/isd.2011.41.2.71
   Ignaccolo M, 2010, J BIOL PHYS, V36, P185, DOI 10.1007/s10867-009-9171-y
   Kroupi Eleni, 2014, 2014 Sixth International Workshop on Quality of Multimedia Experience (QoMEX), P147, DOI 10.1109/QoMEX.2014.6982311
   Kurihara K., 1994, OLFACTION TASTE
   Lawhern V, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-101
   Manzanedo E., 2014, IFMBE P, V41, P815
   Martin C, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00218
   Masaoka Y, 2008, RESP PHYSIOL NEUROBI, V161, P136, DOI 10.1016/j.resp.2008.01.003
   Min BC, 2003, CHEM SENSES, V28, P741, DOI 10.1093/chemse/bjg066
   Murali S, 2007, INT J NEUROSCI, V117, P1383, DOI 10.1080/00207450600941130
   Musselman M, 2012, EXPERT SYST APPL, V39, P11413, DOI 10.1016/j.eswa.2012.04.023
   Namazi H., 2016, INT J NUMERICAL METH
   Namazi H, 2016, ONCOTARGET, V7, P56120, DOI 10.18632/oncotarget.11234
   Namazi H, 2016, SCI REP-UK, V6, DOI 10.1038/srep26639
   Namazi H, 2016, ONCOTARGET, V7, P342, DOI 10.18632/oncotarget.6341
   Namazi H, 2015, ONCOTARGET, V6, P42623, DOI 10.18632/oncotarget.6003
   Namazi H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13583
   Namazi H, 2015, COMPUT MATH METHOD M, DOI 10.1155/2015/148534
   PINCUS SM, 1991, J CLIN MONITOR, V7, P335, DOI 10.1007/BF01619355
   Placidi G, 2015, NEUROCOMPUTING, V160, P308, DOI 10.1016/j.neucom.2015.02.034
   Saha A, 2014, IEEE T HUM-MACH SYST, V44, P717, DOI 10.1109/THMS.2014.2344003
   Sell CS, 2014, CHEMISTRY AND THE SENSE OF SMELL, P1, DOI 10.1002/9781118522981
   Ubeyli ED, 2008, COMPUT BIOL MED, V38, P14, DOI 10.1016/j.compbiomed.2007.06.002
   Wattendorf E, 2009, J NEUROSCI, V29, P15410, DOI 10.1523/JNEUROSCI.1909-09.2009
NR 33
TC 2
Z9 2
U1 2
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2016
AR 5469587
DI 10.1155/2016/5469587
PG 5
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA DW2QJ
UT WOS:000383486600001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Bhandari, V
   Sriganesh, R
   Relekar, K
AF Bhandari, Vipul
   Sriganesh, R.
   Relekar, Kirti
TI RETRACTED: An unusual case of spontaneous Mycobacterium chelonae corneal
   ulcer in a healthy middle-aged adult(Retracted article. See vol.10,
   2017)
SO INTERNATIONAL MEDICAL CASE REPORTS JOURNAL
LA English
DT Article; Retracted Publication
DE spontaneous; M. chelonae; nonhealing corneal ulcer; healthy
ID IN-SITU KERATOMILEUSIS; KERATITIS; INFECTIONS; OUTBREAK
AB Background: To report a rare presentation of culture-positive Mycobacterium chelonae corneal ulcer and its management.
   Findings: We report a rare case of a patient with a history of chronic pain and blurriness of vision. Examination revealed a chronic nonhealing paracentral corneal ulcer inferiorly at the 5-7 o'clock meridian with anterior chamber reaction unresponsive to routine antibiotic and antifungal medications with Mantoux test positivity in a middle-aged nondiabetic patient with no prior history of trauma, ocular surgery, and contact lens usage. Ziehl-Neelsen staining of the nonhealing ulcer revealed acid-fast bacilli typical of M. chelonae, with subsequent culture positivity in Lwenstein-Jensen medium. Subsequent treatment with topical fortified amikacin and tobramycin resulted in rapid healing of the corneal ulcer.
   Conclusion: M. chelonae presenting as a chronic nonhealing corneal ulcer spontaneously occurring in a healthy adult with no predisposing factor draws attention towards the need to have a good index of suspicion by performing a Ziehl-Neelsen stain and culture, and subsequent successful management with topical fortified amikacin and tobramycin.
C1 [Bhandari, Vipul; Sriganesh, R.; Relekar, Kirti] Nethradhama Eye Hosp, Dept Cornea, Bengaluru, India.
RP Bhandari, V (reprint author), Nethradhama Eye Hosp, 7th Block Jayanagar,Kanakapura Rd, Bangalore 560070, Karnataka, India.
EM drvipulbhandari@gmail.com
CR Chandra NS, 2001, AM J OPHTHALMOL, V132, P819, DOI 10.1016/S0002-9394(01)01267-3
   Feder RS, 2010, BRIT J OPHTHALMOL, V94, P383, DOI 10.1136/bjo.2009.160853
   Freitas D, 2003, OPHTHALMOLOGY, V110, P276, DOI 10.1016/S0161-6420(02)01643-3
   Girgis DO, 2012, CLIN EXP OPHTHALMOL, V40, P467, DOI 10.1111/j.1442-9071.2011.02679.x
   Huang SCM, 1996, BRIT J OPHTHALMOL, V80, P962, DOI 10.1136/bjo.80.11.962
   Kheir WJ, 2015, BIOMED RES INT, V2015
   Lalitha P, 2004, Indian J Med Microbiol, V22, P231
   Malecha Monika A., 2002, CLAO Journal, V28, P228
   Moorthy RS, 2012, SURV OPHTHALMOL, V57, P202, DOI 10.1016/j.survophthal.2011.10.006
   O'Brien TP, 1996, OCULAR INFECT IMMUNI, P1033
   RUNYON EH, 1959, MED CLIN N AM, V43, P273, DOI 10.1016/S0025-7125(16)34193-1
   Siong RLB, 2013, CORNEA, V32, P625, DOI 10.1097/ICO.0b013e31826cf840
   Umapathy T, 2005, BRIT J OPHTHALMOL, V89, P1374, DOI 10.1136/bjo.2005.069856
   Yamaguchi T, 2011, J CATARACT REFR SURG, V37, P894, DOI 10.1016/j.jcrs.2010.11.034
NR 14
TC 1
Z9 1
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-142X
J9 INT MED CASE REP J
JI INT. MED. CASE REP. J.
PY 2016
VL 9
BP 121
EP 124
DI 10.2147/IMCRJ.S91518
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA DV2PL
UT WOS:000382762900006
PM 27274315
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Shan, BW
AF Shan, Bowei
TI RETRACTED: Estimation of Response Functions Based on Variational Bayes
   Algorithm in Dynamic Images Sequences(Retracted article.See Artn
   no.6898324, 2017)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID DECONVOLUTION; FMRI
AB We proposed a nonparametric Bayesian model based on variational Bayes algorithm to estimate the response functions in dynamic medical imaging. In dynamic renal scintigraphy, the impulse response or retention functions are rather complicated and finding a suitable parametric form is problematic. In this paper, we estimated the response functions using nonparametric Bayesian priors. These priors were designed to favor desirable properties of the functions, such as sparsity or smoothness. These assumptions were used within hierarchical priors of the variational Bayes algorithm. We performed our algorithm on the real online dataset of dynamic renal scintigraphy. The results demonstrated that this algorithm improved the estimation of response functions with nonparametric priors.
C1 [Shan, Bowei] Changan Univ, Sch Informat Engn, Xian 710064, Shaanxi, Peoples R China.
RP Shan, BW (reprint author), Changan Univ, Sch Informat Engn, Xian 710064, Shaanxi, Peoples R China.
EM bwshan@chd.edu.cn
FU National Natural Science Foundation of China [61473047, 61271262,
   61201407]; Undergraduate Training Program for Innovation and
   Entrepreneurship [201610710143]
FX This research work was supported by the National Natural Science
   Foundation of China (Grants nos. 61473047, 61271262, and 61201407) and
   Undergraduate Training Program for Innovation and Entrepreneurship
   (Grant no. 201610710143).
CR BENALI H, 1993, PHYS MED BIOL, V38, P1065, DOI 10.1088/0031-9155/38/8/005
   Bishop C. M., 2000, P 16 C UNC ART INT, P46
   Chen L, 2011, IEEE T MED IMAGING, V30, P2044, DOI 10.1109/TMI.2011.2160276
   DIFFEY BL, 1976, J NUCL MED, V17, P352
   Durand E, 2008, SEMIN NUCL MED, V38, P82, DOI 10.1053/j.semnuclrhed.2007.09.009
   Fleming JS, 1999, J NUCL MED, V40, P1503
   Goutte C, 2000, IEEE T MED IMAGING, V19, P1188, DOI 10.1109/42.897811
   Kershaw J., 2000, NEUROIMAGE, V11, pS474
   KURUC A, 1982, COMPUT BIOMED RES, V15, P46, DOI 10.1016/0010-4809(82)90052-0
   Martel AL, 2001, MED IMAGE ANAL, V5, P29, DOI 10.1016/S1361-8415(00)00032-3
   Miskin J., 2000, THESIS
   Smidl V, 2006, VARIATIONAL BAYES ME
   Steinberg DM, 2015, COMPUT VIS IMAGE UND, V131, P128, DOI 10.1016/j.cviu.2014.06.004
   Taxt T, 2012, IEEE T BIO-MED ENG, V59, P1012, DOI 10.1109/TBME.2011.2182195
   Tichy O., 2014, COMPUTER METHODBIO, V4, P135
   Tichy O, 2015, IEEE T MED IMAGING, V34, P258, DOI 10.1109/TMI.2014.2352791
   Tipping ME, 2001, J MACH LEARN RES, V1, P211, DOI 10.1162/15324430152748236
   Woolrich MW, 2012, NEUROIMAGE, V62, P801, DOI 10.1016/j.neuroimage.2011.10.047
NR 18
TC 0
Z9 0
U1 3
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2016
AR 4851401
DI 10.1155/2016/4851401
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA DU2GL
UT WOS:000382029100001
PM 27631007
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Lin, FO
   Yao, LJ
   Bhikoo, C
   Guo, J
AF Lin, Feiou
   Yao, Linjie
   Bhikoo, Chandradev
   Guo, Jing
TI RETRACTED: Impact of fixed orthodontic appliance or clear-aligner on
   daily performance, in adult patients with moderate need for
   treatment(Retracted article. See vol.10,pg.2321,2016)
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article; Retracted Publication
DE clear-aligner; fixed orthodontic appliance; OIDP; quality of life; oral
   health
ID QUALITY-OF-LIFE; ORAL-HEALTH; THERAPY; MOTIVATION; SEEKING; OIDP
AB Objective: To assess the impact of wearing fixed orthodontic appliance (FOA) or clear-aligner, on daily performance in adult patients.
   Methods: The Oral Impacts on Daily Performance (OIDP) index was assessed in 152 adults aged 25-35 years at baseline (T0), 6 months after bonding (T1), and 12 months after bonding (T2). Participants were randomly divided into two groups: CA group (participants treated with clear-aligner) and a control group (FOA group; participants treated with FOA). Baseline malocclusion severity was assessed using the Index of Orthodontic Treatment Need.
   Results: There were no significant differences in sociodemographic variables and OIDP scores at baseline between the two groups. Significant changes in OIDP total and subscale scores were observed while wearing FOA: OIDP total score and subscale scores of eating, cleaning teeth, smiling, and social relation at T1 and T2 were significantly higher than at baseline (P < 0.05 or P < 0.01). However, only OIDP total score was significantly increased at T1 compared to the baseline in the CA group. OIDP total score and subscale scores of eating, cleaning teeth, smiling, and social relation were significantly higher in patients wearing FOA than in patients wearing clear-aligner at T1 and T2 (P < 0.05 or P < 0.01).
   Conclusion: Patients wearing clear-aligner have fewer impacts on daily life than those wearing FOA during treatment, and have no significant changes in OIPD subscale scores at 12 months. FOA therapy significantly impacts daily performance in adult patients during treatment.
C1 [Lin, Feiou; Bhikoo, Chandradev] Wenzhou Med Univ, Sch Stomatol, Dept Orthodont, Wenzhou, Peoples R China.
   [Yao, Linjie] Wenzhou Med Univ, Sch Stomatol, Dept Pedodont, Wenzhou, Peoples R China.
   [Guo, Jing] Shandong Univ, Sch & Hosp Stomatol, Dept Orthodont, 44-1 Wenhua West Rd, Jinan 250012, Shandong, Peoples R China.
RP Guo, J (reprint author), Shandong Univ, Sch & Hosp Stomatol, Dept Orthodont, 44-1 Wenhua West Rd, Jinan 250012, Shandong, Peoples R China.
EM guojing@sdu.edu.cn
CR Azaripour A, 2015, BMC ORAL HEALTH, V15, DOI 10.1186/s12903-015-0060-4
   Bernabe E, 2008, ANGLE ORTHOD, V78, P482, DOI 10.2319/050207-212.1
   BROOK PH, 1989, EUR J ORTHODONT, V11, P309, DOI 10.1093/oxfordjournals.ejo.a035999
   Chen M, 2010, ANGLE ORTHOD, V80, P49, DOI 10.2319/010509-9.1
   Chenin DA, 2003, J AM DENT ASSOC, V134, P1232, DOI 10.14219/jada.archive.2003.0358
   Doll G M, 2000, J Orofac Orthop, V61, P398, DOI 10.1007/PL00001908
   Dorri Mojtaba, 2007, BMC Oral Health, V7, P2, DOI 10.1186/1472-6831-7-2
   Ellis CP, 2004, AM J ORTHOD DENTOFAC, V126, p20A, DOI 10.1016/j.ajodo.2004.05.002
   Feu D, 2010, AM J ORTHOD DENTOFAC, V138, P152, DOI 10.1016/j.ajodo.2008.09.033
   Hassan AH, 2010, AM J ORTHOD DENTOFAC, V137, P42, DOI 10.1016/j.ajodo.2008.02.024
   Heintze SD, 1996, AM J ORTHOD DENTOFAC, V110, P630, DOI 10.1016/S0889-5406(96)80040-0
   Kim Tae-Weon, 2007, World J Orthod, V8, P13
   Li HX, 2014, BMC ORAL HEALTH, V14, DOI 10.1186/1472-6831-14-158
   Liu ZJ, 2011, AM J ORTHOD DENTOFAC, V139, P214, DOI 10.1016/j.ajodo.2009.08.029
   Malik OH, 2013, DENT UPDATE, V40, P207
   Malik OH, 2013, DENT UPDATE, V40, P213
   Malik Ovais H, 2013, Dent Update, V40, P203
   Manjith C M, 2012, J Contemp Dent Pract, V13, P294
   Montero J, 2011, MED ORAL PATOL ORAL, V16, pE816, DOI 10.4317/medoral.16851
   Naito Mariko, 2007, J Oral Sci, V49, P259, DOI 10.2334/josnusd.49.259
   Purohit BM, 2012, COMMUNITY DENT HLTH, V29, P203, DOI 10.1922/CDH_2725Purohit06
   Rossini G, 2015, ANGLE ORTHOD, V85, P881, DOI 10.2319/061614-436.1
   Sergl HG, 2000, EUR J ORTHODONT, V22, P307, DOI 10.1093/ejo/22.3.307
   Tang X, 2015, PATIENT PREFER ADHER, V9, P249, DOI 10.2147/PPA.S78691
   Wedrychowska-Szulc B, 2010, EUR J ORTHODONT, V32, P447, DOI 10.1093/ejo/cjp131
   Wiechmann Dirk, 2002, J Orofac Orthop, V63, P234, DOI 10.1007/s00056-002-0211-5
   Yao LJ, 2015, PATIENT PREFER ADHER, V9, DOI 10.2147/PPA.S74104
   Zhang M, 2008, AM J ORTHOD DENTOFAC, V133, P25, DOI 10.1016/j.ajodo.2007.01.024
NR 28
TC 3
Z9 3
U1 6
U2 14
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2016
VL 10
BP 1639
EP 1645
DI 10.2147/PPA.S113466
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DU4TZ
UT WOS:000382206800001
PM 27616881
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Huang, XP
   Zhou, WH
   Zhang, YF
   Liu, Y
AF Huang, Xianping
   Zhou, Weihe
   Zhang, Yuefeng
   Liu, Yong
TI RETRACTED: High Expression of PTGR1 Promotes NSCLC Cell Growth via
   Positive Regulation of Cyclin-Dependent Protein Kinase Complex
   (Retracted article. Artn 7640820, 2017)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID PROSTAGLANDIN-REDUCTASE 1; PANCREATIC-CANCER CELLS; TGF-BETA; B-4
   12-HYDROXYDEHYDROGENASE; GENE-EXPRESSION; IN-VIVO; PROLIFERATION; LUNG;
   ACTIVATION; THERAPY
AB Lung cancer has been the most common cancer and the main cause of cancer-related deaths worldwide for several decades. PTGR1 (prostaglandin reductase 1), as a bifunctional enzyme, has been involved in the occurrence and progression of cancer. However, its impact on human lung cancer is rarely reported. In this study, we found that PTGR1 was overexpressed in lung cancer based on the analyses of Oncomine. Moreover, lentivirus-mediated shRNA knockdown of PTGR1 reduced cell viability in human lung carcinoma cells 95D and A549 by MTT and colony formation assay. PTGR1 depletion led to G2/M phase cell cycle arrest and increased the proportion of apoptotic cells in 95D cells by flow cytometry. Furthermore, silencing PTGR1 in 95D cells resulted in decreased levels of cyclin-dependent protein kinase complex (CDK1, CDK2, cyclin A2, and cyclin B1) by western blotting and then PTGR1 is positively correlated with cyclin-dependent protein by using the data mining of the Oncomine database. Therefore, our findings suggest that PTGR1 may play a role in lung carcinogenesis through regulating cell proliferation and is a potential new therapeutic strategy for lung cancer.
C1 [Huang, Xianping; Zhou, Weihe; Zhang, Yuefeng; Liu, Yong] Wenzhou Med Univ, Affiliated Hosp 2, Dept Cardiothorac Surg, Wenzhou 325027, Zhejiang, Peoples R China.
RP Huang, XP (reprint author), Wenzhou Med Univ, Affiliated Hosp 2, Dept Cardiothorac Surg, Wenzhou 325027, Zhejiang, Peoples R China.
EM xianpinghuang2015@163.com
CR Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504
   Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107
   Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200
   Chang EYC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147390
   Chang EYC, 2012, AM J PATHOL, V181, P1316, DOI 10.1016/j.ajpath.2012.07.006
   Chen X, 2004, CURR CANCER DRUG TAR, V4, P267, DOI 10.2174/1568009043333041
   Chiarugi V, 1997, PHARMACOL RES, V35, P257, DOI 10.1006/phrs.1997.0140
   Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200
   Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968
   Connolly EC, 2012, INT J BIOL SCI, V8, P964, DOI 10.7150/ijbs.4564
   Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023
   Erzinger MM, 2015, J BIOCHEM MOL TOXIC, V29, P10, DOI 10.1002/jbt.21601
   Ferlay J, 2015, INT J CANCER, pE359, DOI [DOI 10.1002/IJC.29210, 10.1002/ijc.29210]
   Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798
   Gudas JM, 1999, MOL CELL BIOL, V19, P612
   Haeggstrom JZ, 2011, CHEM REV, V111, P5866, DOI 10.1021/cr200246d
   Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037
   Hizli AA, 2013, MOL CELL BIOL, V33, P596, DOI 10.1128/MCB.01270-12
   Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312
   Jehmlich N, 2015, J PROTEOMICS, V125, P98, DOI 10.1016/j.jprot.2015.04.030
   Karam-Hage M, 2014, CA-CANCER J CLIN, V64, P273, DOI 10.3322/caac.21231
   Knab LM, 2014, WORLD J GASTROENTERO, V20, P10729, DOI 10.3748/wjg.v20.i31.10729
   Korkola JE, 2006, CANCER RES, V66, P820, DOI 10.1158/0008-5472.CAN-05-2445
   Lan YW, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0081-6
   Maher P, 1999, J BIOL CHEM, V274, P17491, DOI 10.1074/jbc.274.25.17491
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   MODAT G, 1987, PROSTAGLANDINS, V33, P531, DOI 10.1016/0090-6980(87)90276-0
   Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403
   Pietsch KE, 2011, CHEM RES TOXICOL, V24, P2044, DOI 10.1021/tx200401u
   POLLA B, 1985, BIOCHEM BIOPH RES CO, V129, P560, DOI 10.1016/0006-291X(85)90188-3
   Qiao M, 2006, J BIOL CHEM, V281, P7118, DOI 10.1074/jbc.M508162200
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Sanchez-Rodriguez R, 2014, INT J BIOCHEM CELL B, V53, P186, DOI 10.1016/j.biocel.2014.05.017
   Satpathy SR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8064
   Shepherd FA, 2011, J THORAC ONCOL, V6, P1763, DOI 10.1097/JTO.0b013e31822e28fc
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Song HY, 2015, INT J MOL SCI, V16, P178, DOI 10.3390/ijms16010178
   Tai HH, 2002, PROSTAG OTH LIPID M, V68-9, P483, DOI 10.1016/S0090-6980(02)00050-3
   Tapak L, 2015, GENOM PROTEOM BIOINF, V13, P169, DOI 10.1016/j.gpb.2015.04.001
   Timofeev O, 2010, J BIOL CHEM, V285, P16978, DOI 10.1074/jbc.M109.096552
   Tobin DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067828
   Tong WG, 2007, ANTI-CANCER DRUG, V18, P535, DOI 10.1097/01.cad.0000231477.22901.8a
   Tong WG, 2005, BIOCHEM BIOPH RES CO, V335, P949, DOI 10.1016/j.bbrc.2005.07.166
   van den Brandt J, 2004, GENESIS, V39, P94, DOI 10.1002/gene.20037
   Vanaja DK, 2003, CANCER RES, V63, P3877
   Yang J, 2015, ONCOTARGETS THER, V8, P1815, DOI 10.2147/OTT.S79498
   Yang S, 2015, INT J CLIN EXP PATHO, V8, P14493
   Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844
   Yu X, 2012, J PHARMACOL EXP THER, V343, P426, DOI 10.1124/jpet.112.195768
   Zhao XM, 2015, TUMOR BIOL, V36, P6733, DOI 10.1007/s13277-015-3371-9
   Zhao YH, 2010, LUNG CANCER, V68, P161, DOI 10.1016/j.lungcan.2009.06.011
NR 52
TC 3
Z9 3
U1 7
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2016
AR 5230642
DI 10.1155/2016/5230642
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA DQ8MJ
UT WOS:000379464900001
PM 27429979
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Chen, YF
   Jiang, WW
   Zhang, SQ
   Kan, JQ
   Liang, Y
AF Chen, Yong-Feng
   Jiang, Wen-wen
   Zhang, Shi-qi
   Kan, Jian-quan
   Liang, Yong
TI RETRACTED: Antioxidant Activity and Characterization of One New
   Polysaccharide Obtained from Perigord Truffle (Tuber
   huidongense)(Retracted article. See art no 9686012, 2018)
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article; Retracted Publication
ID WATER-SOLUBLE POLYSACCHARIDES; FRUITING BODIES; IN-VITRO; TUBER;
   DERIVATIVES
AB As a medicinal and edible fungus parasitizing on the trees, Perigord Truffle (Tuber huidongense) is well known for its delicious taste, unique smell, and high medical value for healthcare. One new water-soluble nonstarch polysaccharide (PST-W with the yield of 0.41%) from Perigord Truffle (Tuber huidongense) was purified and identified on structural characteristics for the first time. The characterizations of PST-W were studied on physicochemical properties, main components of monosaccharide(s), and molecular structure. The monosaccharide compositions of PST-W were studied and identified as glucan, only containing D-glucoses with the molecular structure of [-> 6) alpha-D-Glcp (1 -> 6) alpha-D-Glcp (1 ->](n) by methylation analysis and NMR. In the determination of total reducing capacity, the reducing abilities of polysaccharide extracts could be listed as vitamin C > PST-W > crude polysaccharides-3 > crude polysaccharides-2 > crude polysaccharides-1. All of PST-W, crude polysaccharides-2, and crude polysaccharides-3 were relatively good scavenger for 1,1-Diphenyl-2-picrylhydrazyl radical 2,2-Diphenyl-1-(2,4,6-trinitrophenyl)hydrazyl radicals with IC50 of 2.81, 4.17, and 3.44 mg/mL, respectively. However, O-2(-center dot) clearing abilities of PST-W and crude polysaccharides were obviously weaker. The activities of total crude extract were the worst, indicating that the impurities might negatively affect the antioxidant activity. Thus, the separation and purification of polysaccharides were significant to increase the antioxidant activity in some degree.
C1 [Chen, Yong-Feng] Taizhou Univ, Sch Med, Dept Basic Med Sci, Taizhou 318000, Zhejiang, Peoples R China.
   [Chen, Yong-Feng; Liang, Yong] Taizhou Univ, Inst Tumor, Sch Med, Taizhou 318000, Zhejiang, Peoples R China.
   [Jiang, Wen-wen] China Pharmaceut Univ, Ctr Drug Metab & Pharmacokinet, Nanjing 210009, Jiangsu, Peoples R China.
   [Zhang, Shi-qi; Kan, Jian-quan] Southwest Univ, Dept Food Sci, Chongqing 400715, Peoples R China.
RP Liang, Y (reprint author), Taizhou Univ, Inst Tumor, Sch Med, Taizhou 318000, Zhejiang, Peoples R China.; Kan, JQ (reprint author), Southwest Univ, Dept Food Sci, Chongqing 400715, Peoples R China.
EM ganjianquan@gmail.com; liangyongmd@outlook.com
FU Public Welfare Technology Application Research Project of Zhejiang
   Province [2015C37122]; National Natural Science Foundation of China
   [81373139]
FX This work was supported by the Public Welfare Technology Application
   Research Project of Zhejiang Province under Grant no. 2015C37122 and the
   National Natural Science Foundation of China under Grant no. 81373139.
   The authors thank all staff members in Department of Food Science for
   the technical guide of equipment and cooperation of projects.
CR Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292
   [过敏 Guo Min], 2012, [食品工业科技, Science & Technology of Food Industry], V33, P403
   Guo S. D., 2010, PERIODICAL OCEAN U C, V40, P5
   HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205
   Hu H. J., 1994, J CHINA PHARM U, V55, P289
   [孔庆龙 Kong Qinglong], 2012, [食品与发酵工业, Food and Fermentation Industries], V38, P175
   Lin CL, 2009, INT J BIOL MACROMOL, V45, P146, DOI 10.1016/j.ijbiomac.2009.04.014
   Luo Q, 2011, J MED FOOD, V14, P1609, DOI 10.1089/jmf.2011.1659
   Purama RK, 2009, CARBOHYD POLYM, V76, P30, DOI 10.1016/j.carbpol.2008.09.018
   Qi HM, 2012, CARBOHYD POLYM, V87, P1637, DOI 10.1016/j.carbpol.2011.09.073
   Tang YJ, 2008, BIORESOURCE TECHNOL, V99, P7606, DOI 10.1016/j.biortech.2008.02.006
   [田春宇 TIAN Chun-yu], 2009, [大连理工大学学报, Journal of Dalian University of Technology], V49, P44
   van Acker SABE, 1998, BIOCHEM PHARMACOL, V56, P935, DOI 10.1016/S0006-2952(98)00102-6
   Wu XD, 2014, FOOD CHEM, V145, P976, DOI 10.1016/j.foodchem.2013.09.019
   Xing RE, 2005, BIOORGAN MED CHEM, V13, P1573, DOI 10.1016/j.bmc.2004.12.022
   Xiong SL, 2011, CARBOHYD POLYM, V86, P1273, DOI 10.1016/j.carbpol.2011.06.025
   Yamaguchi Y, 2000, PHYTOTHER RES, V14, P647, DOI 10.1002/1099-1573(200012)14:8<647::AID-PTR670>3.0.CO;2-W
   Yi JM, 2001, CLIN CHIM ACTA, V312, P163, DOI 10.1016/S0009-8981(01)00613-1
   Yuan HM, 2005, CARBOHYD RES, V340, P685, DOI 10.1016/j.carres.2004.12.026
   [岳金玫 Yue Jinmei], 2013, [食品科学, Food Science], V34, P127
   Zhang S. Q., 2010, FOOD FERMENTATION TE, V46, P97
   [张世奇 ZHANG Shiqi], 2011, [食品科学, Food Science], V32, P281
   Zhao W, 2014, APPL MICROBIOL BIOT, V98, P1991, DOI 10.1007/s00253-013-5379-7
NR 23
TC 0
Z9 0
U1 5
U2 18
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2016
AR 3537193
DI 10.1155/2016/3537193
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA DQ8FX
UT WOS:000379445600001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zou, F
   Lu, FZ
   Ma, XS
   He, DW
   Tang, TT
   Xia, XL
   Jiang, JY
   Niu, YF
AF Zou, F.
   Lu, F. Z.
   Ma, X. S.
   He, D. W.
   Tang, T. T.
   Xia, X. L.
   Jiang, J. Y.
   Niu, Y. F.
TI RETRACTED: Cell orientation, proliferation, and differentiation on
   poly(L-lactide) spherulites (Retracted article. See vol. 7, pg. 21144,
   2017)
SO RSC ADVANCES
LA English
DT Article; Retracted Publication
ID OSTEOBLAST-LIKE CELLS; PEROXIDATION END-PRODUCT; BANDED SPHERULITES;
   PROTEIN ADSORPTION; GENE-EXPRESSION; SURFACES; BEHAVIOR;
   MECHANOTRANSDUCTION; COPOLYMERS; ALIGNMENT
AB The ringless spherulites of poly(L-lactide) (PLLA), fabricated via isothermal crystallization at temperatures of 100 degrees C and 140 degrees C (PLLA100 and PLLA140, respectively), were used to evaluate the effect of spherulites on MC3T3-E1 cell functions, including adhesion, proliferation, and differentiation. The atomic force microscopy (AFM) images indicated that PLLA100 presented a ridge width of 50-100 mm and a ride depth of 50-100 nm, whereas the values of PLLA140 were 25-50 mm and 100-350 nm, respectively. The cytoskeleton and nuclear alignment were observed on PLLA140, while no alignment was found on PLLA100. More interestingly, MC3T3-E1 cell proliferation and differentiation were also promoted significantly on PLLA140 compared with PLLA100. Our results, undoubtedly, provide a fundamental understanding regarding the effects of polymer spherulites on cell functions.
C1 [Zou, F.; Lu, F. Z.; Ma, X. S.; Xia, X. L.; Jiang, J. Y.] Fudan Univ, Huashan Hosp, Dept Orthopaed, Shanghai 200040, Peoples R China.
   [He, D. W.; Niu, Y. F.] Second Mil Med Univ, Changhai Hosp, Dept Orthopaed, Shanghai 200433, Peoples R China.
   [Tang, T. T.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Orthoped Implants, Dept Orthoped Surg,Shanghai Peoples Hosp 9, Shanghai 200011, Peoples R China.
RP Zou, F (reprint author), Fudan Univ, Huashan Hosp, Dept Orthopaed, Shanghai 200040, Peoples R China.
EM zillion-faculty@126.com; ny.ying126@126.com
FU National Natural Science Foundation of China [31271015]; Shanghai
   Science and Technology Development Fund [13DZ2294000, 13JC1403900]
FX This research was financially supported by the National Natural Science
   Foundation of China (No. 31271015) and the Shanghai Science and
   Technology Development Fund (No. 13DZ2294000, 13JC1403900).
CR Androsch R, 2013, POLYMER, V54, P6882, DOI 10.1016/j.polymer.2013.10.056
   Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142-9612(99)00242-2
   Childs MA, 2001, BIOMACROMOLECULES, V2, P526, DOI 10.1021/bm0100054
   CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514
   Crist B, 2016, PROG POLYM SCI, V56, P1, DOI 10.1016/j.progpolymsci.2015.11.006
   Cui XY, 2014, J AM CHEM SOC, V136, P5481, DOI 10.1021/ja5013382
   Curtis A, 1997, BIOMATERIALS, V18, P1573, DOI 10.1016/S0142-9612(97)00144-0
   Davidson PM, 2009, ADV MATER, V21, P3586, DOI 10.1002/adma.200900582
   Di Lorenzo M. L., 2005, EUR POLYM J, V41, P569
   Dong L, 2014, METHODS MOL BIOL, V1185, P79, DOI 10.1007/978-1-4939-1133-2_6
   Feng R, 2015, INT J CLIN EXP PATHO, V8, P9376
   Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev
   Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597
   Kenar H, 2006, BIOMATERIALS, V27, P885, DOI 10.1016/j.biomaterials.2005.07.001
   Kim SH, 2015, NEW J CHEM, V39, P3225, DOI 10.1039/c5nj00038f
   Kim SH, 2015, CHEM-EUR J, V21, P101, DOI 10.1002/chem.201404520
   Kweon S, 2016, ACS APPL MATER INTER, V8, P4266, DOI 10.1021/acsami.6b00318
   Lambert JD, 2006, J PHARM PHARMACOL, V58, P599, DOI 10.1211/jpp.58.5.0004
   Lim JY, 2007, TISSUE ENG, V13, P1879, DOI 10.1089/ten.2006.0154
   Matsuzaka K, 2003, BIOMATERIALS, V24, P2711, DOI 10.1016/S0142-9612(03)00085-1
   Mert O, 2008, LANGMUIR, V24, P749, DOI 10.1021/la701966d
   Miyata T, 1998, POLYMER, V39, P5515, DOI 10.1016/S0032-3861(97)10203-8
   Nurkhamidah S, 2011, J APPL POLYM SCI, V122, P1976, DOI 10.1002/app.34021
   Rechendorff K, 2006, LANGMUIR, V22, P10885, DOI 10.1021/la0621923
   Simon CG, 2004, J MICROSC-OXFORD, V216, P153, DOI 10.1111/j.0022-2720.2004.01401.x
   Sun Y, 2016, CHEM COMMUN, V52, P5254, DOI 10.1039/c6cc01195k
   Teixeira AI, 2003, J CELL SCI, V116, P1881, DOI 10.1242/jcs.00383
   Uchiyama S, 2007, INT J MOL MED, V19, P213
   Wan YQ, 2005, BIOMATERIALS, V26, P4453, DOI 10.1016/j.biomaterials.2004.11.016
   Wang JHC, 2000, J BIOMECH, V33, P729, DOI 10.1016/S0021-9290(00)00013-0
   Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988
   Xu J, 2005, POLYMER, V46, P9176, DOI 10.1016/j.polymer.2005.07.010
   Zhang J, 2013, BIOMATERIALS, V34, P9381, DOI 10.1016/j.biomaterials.2013.08.059
   Zheng RJ, 2014, TOXICOL APPL PHARM, V279, P43, DOI 10.1016/j.taap.2014.04.026
   Zheng RJ, 2014, TOXICOL APPL PHARM, V275, P113, DOI 10.1016/j.taap.2014.01.001
   Zheng RJ, 2014, FREE RADICAL BIO MED, V67, P1, DOI 10.1016/j.freeradbiomed.2013.10.011
   Zheng RJ, 2013, TOXICOL APPL PHARM, V272, P345, DOI 10.1016/j.taap.2013.06.025
   Zhou Y, 2013, BIOORG MED CHEM LETT, V23, P2974, DOI 10.1016/j.bmcl.2013.03.037
   Zhu BS, 2005, TISSUE ENG, V11, P825, DOI 10.1089/ten.2005.11.825
NR 39
TC 1
Z9 1
U1 4
U2 19
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 62
BP S7396
EP S7402
DI 10.1039/c6ra07524j
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA DP8NP
UT WOS:000378755200086
DA 2018-12-27
ER

PT J
AU Talukdar, D
   Talukdar, T
AF Talukdar, Dibyendu
   Talukdar, Tulika
TI RETRACTED: Karyotype analysis and identification of extra chromosomes in
   primary aneuploid stocks of grass pea (Lathyrus sativus L.) by
   fluorescence chromosome banding(Retracted article. See vol. 70, pg. 92,
   2017)
SO CARYOLOGIA
LA English
DT Article; Retracted Publication
DE Aneuploids; fluorescence chromosome banding; NOR chromosome; grass pea
ID ARABIDOPSIS-THALIANA; 3 VARIETIES; FABACEAE; DNA; MORPHOLOGY; EVOLUTION;
   TRISOMICS; CELLS
AB Prominent primary aneuploid stocks namely seven primary trisomics, seven primary tetrasomics, and six double trisomic types were earlier developed in grass pea (Lathyrus sativus L.), a hardy legume. Despite distinct morphological features, identity and nature of their extra chromosome(s) were elusive, hampering assignment of desirable breeding traits into specific linkage groups. The present study aims to analyze the banding pattern and to reveal the identity of extra chromosome(s) involved in these 20 aneuploid types in grass pea. Conventional orcein banding was first done using the root-tip squash technique in all aneuploids along with disomic (2n = 2x = 14) parent, and karyomorphological features were noted. Chromosomes were classified following the total length of individual chromosomes and arranged in order of decreasing sizes, keeping their centromeres in a straight line. DNA-base specific chromomycin A3 (CMA) and 4,6'diamidino-2-phenylindole (DAPI) banding pattern were finally employed to convincingly distinguish the chromosomes from each other. Molecular banding and idiograms revealed unique CMA and DAPI banding pattern in each of the seven chromosome pairs and identified extra chromosome(s) involved in aneuploidy. Fluorescence banding also showed differential CMA-specific GC-rich repeat region and DAPI-specific AT-rich repeat regions in chromosomes with the longest chromosome bearing GC-rich nucleolar organizing region. No polymorphism within homologous pairs was found. The result confirmed the primary nature of present aneuploids and identified the additional chromosome(s) in aneuploids. Based on the extra chromosome(s) involved, new designation of grass pea aneuploids has now been proposed. The results have immense significance in location of desired traits or mutations on specific linkage groups of grass pea.
C1 [Talukdar, Dibyendu] Univ Calcutta, RPM Coll, Dept Bot, Uttarpara, W Bengal, India.
   [Talukdar, Tulika] Univ N Bengal, APC Roy Govt Coll, Dept Bot, Siliguri, India.
RP Talukdar, D (reprint author), Univ Calcutta, RPM Coll, Dept Bot, Uttarpara, W Bengal, India.
EM dibyendutalukdar9@gmail.com
CR Akter Shahina, 2005, Cytologia (Tokyo), V70, P441, DOI 10.1508/cytologia.70.441
   Alam SS, 2007, BANGLADESH J BOTANY, V36, P167
   Alam Sk. S., 1995, AM J BOT, V82, P1278
   Ali H, 2000, GENOME, V43, P1027, DOI 10.1139/gen-43-6-1027
   Arzani A, 2006, IRAN J SCI TECHNOL A, V30, P9
   Ayaz E., 2008, International Journal of Agriculture and Biology, V10, P569
   BATTISTIN A, 1994, CARYOLOGIA, V47, P325, DOI 10.1080/00087114.1994.10797311
   Biswas SC, 1998, THESIS
   Ghasem K, 2011, CARYOLOGIA, V64, P42, DOI 10.1080/00087114.2011.10589763
   Grabowska-Joachimiak A, 2015, PROTOPLASMA, V252, P301, DOI 10.1007/s00709-014-0681-5
   Guerra M, 2000, GENET MOL BIOL, V23, P1029, DOI 10.1590/S1415-47572000000400049
   GWYN JJ, 1989, J HERED, V80, P209, DOI 10.1093/oxfordjournals.jhered.a110837
   Henry IM, 2005, GENETICS, V170, P1979, DOI 10.1534/genetics.104.037788
   Henry IM, 2010, GENETICS, V186, P1231, DOI 10.1534/genetics.110.121079
   Hillocks RJ, 2012, EUPHYTICA, V186, P647, DOI 10.1007/s10681-012-0702-4
   Ho T, 2008, BIOCHEM BIOPH RES CO, V368, P433, DOI 10.1016/j.bbrc.2008.01.110
   Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718
   Huang J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002167
   Ibarra-Laclette E, 2011, PLANT SIGNAL BEHAV, V6, P1631, DOI 10.4161/psb.6.11.17657
   Iwata A, 2013, PLANT GENOME-US, V6, DOI 10.3835/plantgenome2013.03.0004
   Khandaker Mahmuda, 2007, Cytologia (Tokyo), V72, P227, DOI 10.1508/cytologia.72.227
   Khawaja HIT, 1998, HEREDITAS, V129, P53, DOI 10.1111/j.1601-5223.1998.t01-1-00053.x
   Klamt A, 2000, GENET MOL BIOL, V23, P463, DOI 10.1590/S1415-47572000000200036
   Kumar S, 2011, FOOD CHEM TOXICOL, V49, P589, DOI 10.1016/j.fct.2010.06.051
   Mahbub Meher Nigar, 2007, Cytologia (Tokyo), V72, P221, DOI 10.1508/cytologia.72.221
   Mason A., 2014, CURR PLANT BIOL, V1, P10
   Nath S, 2015, PROTOPLASMA, V252, P283, DOI 10.1007/s00709-014-0679-z
   Raskina O, 2008, CYTOGENET GENOME RES, V120, P351, DOI 10.1159/000121084
   Seijo G, 2001, CARYOLOGIA, V54, P173, DOI 10.1080/00087114.2001.10589225
   Seijo JG, 2003, AM J BOT, V90, P980, DOI 10.3732/ajb.90.7.980
   Singh RJ, 2007, GENOME, V50, P525, DOI 10.1139/G07-037
   Singh R. J., 2003, PLANT CYTOGENETICS
   Talukdar D., 2015, DISCOV GENET, V1, P17
   Talukdar D., 2013, BRENNERS ENCY GENETI, P189
   Talukdar D., 2008, CARYOLOGIA, V61, P402
   Talukdar Dibyendu, 2007, Cytologia (Tokyo), V72, P385, DOI 10.1508/cytologia.72.385
   Talukdar D, 2014, TURK J BOT, V38, P696, DOI 10.3906/bot-1310-9
   Talukdar D, 2012, NUCLEUS CALCUTTA, V55, P73, DOI 10.1007/s13237-012-0059-z
   Talukdar Dibyendu, 2010, Chromosome Science, V13, P3
   Talukdar D, 2009, J GENET, V88, P165, DOI 10.1007/s12041-009-0024-z
   Torres EM, 2008, GENETICS, V179, P737, DOI 10.1534/genetics.108.090878
NR 41
TC 1
Z9 1
U1 1
U2 5
PU UNIV FLORENCE BOTANY INST
PI FLORENCE
PA VIA LAMARMORA 4, 50121 FLORENCE, ITALY
SN 0008-7114
EI 2165-5391
J9 CARYOLOGIA
JI Caryologia
PY 2016
VL 69
IS 3
BP 235
EP 248
DI 10.1080/00087114.2016.1169091
PG 14
WC Plant Sciences; Genetics & Heredity
SC Plant Sciences; Genetics & Heredity
GA DQ0NG
UT WOS:000378895400008
DA 2018-12-27
ER

PT J
AU Zhang, YQ
   Lin, Y
   Zhao, HY
   Guo, QY
   Yan, C
   Lin, N
AF Zhang, Yanqiong
   Lin, Ya
   Zhao, Haiyu
   Guo, Qiuyan
   Yan, Chen
   Lin, Na
TI RETRACTED: Revealing the Effects of the Herbal Pair of Euphorbia kansui
   and Glycyrrhiza on Hepatocellular Carcinoma Ascites with Integrating
   Network Target Analysis and Experimental Validation (Retracted article.
   See vol. 14, pg. 1503, 2018)
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE herb-herb combination; Euphorbia kansui; Glycyrrhiza; hepatocellular
   carcinoma ascites; network pharmacology
ID TRADITIONAL CHINESE MEDICINE; INTERACTION DATABASE; MALIGNANT ASCITES;
   CIRRHOSIS; CISPLATIN; RECEPTOR; LICORICE; KINASES; PROFILE; CANCER
AB Although the herbal pair of Euphorbia kansui (GS) and Glycyrrhiza (GC) is one of the so-called "eighteen antagonistic medicaments" in Chinese medicinal literature, it is prescribed in a classic Traditional Chinese Medicine (TCM) formula Gansui-Banxia-Tang for cancerous ascites, suggesting that GS and GC may exhibit synergistic or antagonistic effects in different combination designs. Here, we modeled the effects of GS/GC combination with a target interaction network and clarified the associations between the network topologies involving the drug targets and the drug combination effects. Moreover, the "edge-betweenness" values, which is defined as the frequency with which edges are placed on the shortest paths between all pairs of modules in network, were calculated, and the ADRB1-PIK3CG interaction exhibited the greatest edge-betweenness value, suggesting its crucial role in connecting the other edges in the network. Because ADRB1 and PIK3CG were putative targets of GS and GC, respectively, and both had functional interactions with AVPR2 approved as known therapeutic target for ascites, we proposed that the ADRB1-PIK3CG-AVPR2 signal axis might be involved in the effects of the GS-GC combination on ascites. This proposal was further experimentally validated in a H22 hepatocellular carcinoma (HCC) ascites model. Collectively, this systems-level investigation integrated drug target prediction and network analysis to reveal the combination principles of the herbal pair of GS and GC. Experimental validation in an in vivo system provided convincing evidence that different combination designs of GS and GC might result in synergistic or antagonistic effects on HCC ascites that might be partially related to their regulation of the ADRB1-PIK3CG-AVPR2 signal axis.
C1 [Zhang, Yanqiong; Lin, Ya; Zhao, Haiyu; Guo, Qiuyan; Yan, Chen; Lin, Na] China Acad Chinese Med Sci, Inst Chinese Mat Med, 16 Nanxiaojie, Beijing 100700, Peoples R China.
   [Lin, Ya] Fujian Univ Tradit Chinese Med, Coll Pharm, Fuzhou 350122, Peoples R China.
RP Zhang, YQ; Lin, N (reprint author), China Acad Chinese Med Sci, Inst Chinese Mat Med, 16 Nanxiaojie, Beijing 100700, Peoples R China.
EM yqzhang@icmm.ac.cn; nlin@icmm.ac.cn
FU National Basic Research Program of China (973 Program) [2011CB505300,
   2011CB505305]; National Natural Science Foundation of China [81303153];
   Beijing Nova program [Z1511000003150126]; Beijing Joint Project Specific
   Funds; Fundamental Research Funds for the Central public welfare
   research institutes [ZZ2014008]; Prospective Study Platform Project of
   Institute of Chinese Materia Medica; China Academy of Chinese Medical
   Sciences [QZPT002]
FX This study was supported by the National Basic Research Program of China
   (973 Program) (2011CB505300, 2011CB505305), the National Natural Science
   Foundation of China (81303153), Beijing Nova program
   (Z1511000003150126), Beijing Joint Project Specific Funds and the
   Fundamental Research Funds for the Central public welfare research
   institutes (ZZ2014008) and the Prospective Study Platform Project of
   Institute of Chinese Materia Medica, China Academy of Chinese Medical
   Sciences (QZPT002). All authors have read the journal's authorship
   agreement and policy on disclosure of potential conflicts of interest.
CR Aranda B, 2010, NUCLEIC ACIDS RES, V38, pD525, DOI 10.1093/nar/gkp878
   Beuming T, 2005, BIOINFORMATICS, V21, P827, DOI 10.1093/bioinformatics/bti098
   Brown KR, 2005, BIOINFORMATICS, V21, P2076, DOI 10.1093/bioinformatics/bti273
   Cavazzoni E, 2013, INT J CLIN ONCOL, V18, P1, DOI 10.1007/s10147-012-0396-6
   Ceol A, 2010, NUCLEIC ACIDS RES, V38, pD532, DOI 10.1093/nar/gkp983
   Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939
   Chen JY, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S1-S16
   Chung M, 2008, CURR TREAT OPTION ON, V9, P215, DOI 10.1007/s11864-008-0068-y
   Cushing TD, 2015, J MED CHEM, V58, P480, DOI 10.1021/jm501624r
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Habib S, 2012, THER ADV GASTROENTER, V5, P189, DOI 10.1177/1756283X12437357
   Hao CF, 2012, MOL CELL BIOCHEM, V367, P93, DOI 10.1007/s11010-012-1323-x
   Hou YC, 2012, FOOD CHEM, V135, P2307, DOI 10.1016/j.foodchem.2012.07.061
   Kessel I, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.1.e9
   Ladmakhi MH, 1997, AVIAN PATHOL, V26, P293, DOI 10.1080/03079459708419212
   Lehne Benjamin, 2009, Human Genomics, V3, P291
   Li MD, 2012, J TRADIT CHIN MED, V32, P299, DOI 10.1016/S0254-6272(13)60029-1
   Li S, 2007, IET SYST BIOL, V1, P51, DOI 10.1049/iet-syb:20060032
   Lin ZY, 2014, INT J CANCER, V135, P541, DOI 10.1002/ijc.28707
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863
   Nie S Q, 1996, CHINA J CHIN MAT MED, V21, P153
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Sakaida I, 2014, EXPERT REV GASTROENT, V8, P461, DOI 10.1586/17474124.2014.903797
   Sheela ML, 2006, INT IMMUNOPHARMACOL, V6, P494, DOI 10.1016/j.intimp.2005.07.002
   Sherman M, 2008, NEW ENGL J MED, V359, P2045, DOI 10.1056/NEJMe0807581
   Song W. Q., 1993, J TRADIT CHIN MED, V34, P492
   Tamsma J, 2007, Cancer Treat Res, V134, P109
   Tapia-Abellan A, CLIN EXP IM IN PRESS
   Tapia-Abellan A, 2013, LIVER INT, V33, P552, DOI 10.1111/liv.12072
   van der Greef J, 2010, PLANTA MED, V76, P2036, DOI 10.1055/s-0030-1250450
   Wang GP, 2010, J GASTROEN HEPATOL, V25, P985, DOI 10.1111/j.1440-1746.2009.06155.x
   Wang XY, 2013, J ETHNOPHARMACOL, V150, P781, DOI 10.1016/j.jep.2013.09.055
   Wang YZ, 2010, CURR DRUG METAB, V11, P507, DOI 10.2174/138920010791636149
   Warne T, 2011, NATURE, V469, P241, DOI 10.1038/nature09746
   Watson H, 2013, METAB BRAIN DIS, V28, P301, DOI 10.1007/s11011-013-9384-4
   Xu HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101432
   Yan XJ, 2014, MOLECULES, V19, P7237, DOI 10.3390/molecules19067237
   Yu FR, 2005, J PHARM PHARM SCI, V8, P528
   Zhang JS, 2008, CANCER LETT, V260, P127, DOI 10.1016/j.canlet.2007.10.023
   Zhang YQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep09463
   Zhang YQ, 2014, SCI REP-UK, V4, DOI 10.1038/srep04154
   Zhang YQ, 2014, MOL BIOSYST, V10, P215, DOI 10.1039/c3mb70400a
   Zhang YQ, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/548498
   Zhang YQ, 2012, FEBS LETT, V586, P4362, DOI 10.1016/j.febslet.2012.10.053
   Zhang Y, 2013, J MATER CHEM B, V1, P132, DOI 10.1039/c2tb00071g
   Zsoldos Z, 2006, CURR PROTEIN PEPT SC, V7, P421, DOI 10.2174/138920306778559412
NR 47
TC 8
Z9 11
U1 6
U2 32
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2016
VL 12
IS 5
BP 594
EP 606
DI 10.7150/ijbs.14151
PG 13
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA DP8WV
UT WOS:000378779500005
PM 27143956
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Naresh, P
   Reddy, MK
   Reddy, PHC
   Reddy, KM
AF Naresh, P.
   Reddy, M. Krishna
   Reddy, P. Hema Chandra
   Reddy, K. Madhavi
TI RETRACTED: Genetic inheritance and identification of a resistance gene
   analogue polymorphic (RGAP) marker linked to Chilli veinal mottle virus
   resistance in chilli (Capsicum annuum L.)(Retracted article. See vol.92,
   pg.445, 2017)
SO JOURNAL OF HORTICULTURAL SCIENCE & BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE ChiVMV; resistance gene; monogenic; recessive; RGAP marker
ID MOSAIC-VIRUS; STRIPE RUST; CAPSICUM; PEPPER; POPULATIONS; QTLS
AB Chilli veinal mottle virus (ChiVMV) is a most destructive virus, which causes severe yield losses in pepper. Host plant resistance is the only option to tackle this problem. Eleven ChiVMVresistant lines were selected from an initial screening of chilli pepper germplasm and their resistance was reconfirmed by artificial inoculation. To understand the genetic basis of inheritance and to identify a resistance gene analogue polymorphic (RGAP) marker associated with resistance, the ChiVMV-resistant chilli pepper line 'IHR 2451' (Parent 1) was crossed with the ChiVMV-susceptible line ` IHR 3476' (Parent 2) to develop six generations. Individual plants from all six generations (35 P1, 50 P 1, 30 F1, 200 F2, 44 B 1, and 41 B2) were artificially inoculated with ChiVMV (Bengaluru isolate) and the pattern of segregation of susceptibility or resistance was investigated using the chi-square (x(2)) test. All F1 progeny plants were susceptible to ChiVMV. The pattern of segregation of resistant and susceptible plants in the F2 and two back-cross generations (B-1 and B-2) revealed that resistance in 'IHR 2451' was monogenic recessive. A total of 108 RGAP primer combinations were used to search for parental (P-1 and P-2) polymorphisms, and three polymorphic RGAP markers, K5-HD6, K7-HD6, and K8-HD6, were found by bulk segregant analysis. Use of the K5-HD6 marker was extended to screen individual plants in the F-2 and B-1 generations and was found to co-segregate with ChiVMV resistance. Furthermore, K5-HD6 was validated in different ChiVMV-resistant lines, where it could clearly differentiate between resistant and susceptible lines. The RGAP marker K5-HD6 could differentiate homozygous resistant plants from susceptible plants, and therefore may be used effectively during marker-assisted selection and breeding of chilli pepper for resistance to ChiVMV.
C1 [Naresh, P.] Indian Inst Hort Res, Reg Stn, Cent Hort Expt Stn, Bhubaneswar 751019, Odisha, India.
   [Reddy, M. Krishna; Reddy, P. Hema Chandra] Indian Inst Hort Res, Div Plant Pathol, Bengaluru 560089, Karnataka, India.
   [Reddy, K. Madhavi] Indian Inst Hort Res, Div Vegetable Crops, Bengaluru 560089, Karnataka, India.
RP Reddy, MK (reprint author), Indian Inst Hort Res, Div Plant Pathol, Bengaluru 560089, Karnataka, India.
EM kmreddy14@gmail.com
FU INSPIRE Fellowship by Department of Science and Technology [IF10493]
FX This study was supported by an INSPIRE Fellowship provided by the
   Department of Science and Technology [grant number IF10493].
CR BARRIOS EP, 1971, PHYTOPATHOLOGY, V61, P1318, DOI 10.1094/Phyto-61-1318
   Basak J, 2004, MOL BREEDING, V14, P375, DOI 10.1007/s11032-004-0238-y
   Caranta C, 1997, THEOR APPL GENET, V94, P431, DOI 10.1007/s001220050433
   Chaim B. A., 2001, THEOR APPL GENET, V102, P1213
   Chen X. M., 1998, PHYTOPATHOLOGY, V88, P5
   Chen X. M., 2000, 8 INT PLANT AN GEN C, P9
   Chew B.H., 1990, P 3 INT C PLANT PROT, VV, P55
   CLARK MF, 1977, J GEN VIROL, V34, P475, DOI 10.1099/0022-1317-34-3-475
   Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.1313/1-92559-287-7:141
   Green S. K., 1994, USDA TECHNICAL B, P7
   GREEN SK, 1999, PETRIA, V9, P332
   Grube RC, 2000, THEOR APPL GENET, V101, P852, DOI 10.1007/s001220051552
   HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575
   Hwang J, 2009, MOL CELLS, V27, P329, DOI 10.1007/s10059-009-0042-y
   Kanazin V, 1996, P NATL ACAD SCI USA, V93, P11746, DOI 10.1073/pnas.93.21.11746
   Kyle MM, 1997, EUPHYTICA, V97, P183, DOI 10.1023/A:1003009721989
   Lee HR, 2013, EUPHYTICA, V193, P197, DOI 10.1007/s10681-013-0897-z
   MICHELMORE RW, 1991, P NATL ACAD SCI USA, V88, P9828, DOI 10.1073/pnas.88.21.9828
   Moury B, 2005, PHYTOPATHOLOGY, V95, P227, DOI 10.1094/PHYTO-95-0227
   Mutlu N, 2006, MOL BREEDING, V17, P127, DOI 10.1007/s11032-005-4474-6
   Mutlu N, 2008, THEOR APPL GENET, V117, P1303, DOI 10.1007/s00122-008-0864-6
   Noordam D., 1973, DILUTION END POINT D, P207
   Ong C. A., 1979, MARDI RES B, V7, P278
   Panse VG, 1967, STAT METHODS AGR WOR, P152
   Pflieger S, 1999, GENOME, V42, P1100, DOI 10.1139/gen-42-6-1100
   PROVVIDENTI R, 1992, ARCH VIROL, P189
   Reddy K. M., 2001, SAVERNET PHAS 2 P FI, P28
   Shah H, 2011, PAK J BOT, V43, P1707
   Srivastava RK, 2012, EUPHYTICA, V186, P855, DOI 10.1007/s10681-012-0650-z
   Tsai WS, 2008, PLANT PATHOL, V57, P408, DOI 10.1111/j.1365-3059.2007.01780.x
   WARD CW, 1991, INTERVIROLOGY, V32, P269, DOI 10.1159/000150211
   Yan GP, 2006, THEOR APPL GENET, V113, P529, DOI 10.1007/s00122-006-0319-x
   Yan GP, 2003, THEOR APPL GENET, V106, P636, DOI 10.1007/s00122-002-1109-8
   Yi YanJie, 2013, Australian Journal of Crop Science, V7, P454
NR 34
TC 1
Z9 1
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1462-0316
EI 2380-4084
J9 J HORTIC SCI BIOTECH
JI J. Horticult. Sci. Biotechnol.
PY 2016
VL 91
IS 3
BP 285
EP 291
DI 10.1080/14620316.2016.1155317
PG 7
WC Horticulture
SC Agriculture
GA DO9YS
UT WOS:000378144600011
DA 2018-12-27
ER

PT J
AU Ferrari, G
   Agnew-Davies, R
   Bailey, J
   Howard, L
   Howarth, E
   Peters, TJ
   Sardinha, L
   Feder, GS
AF Ferrari, Giulia
   Agnew-Davies, Roxane
   Bailey, Jayne
   Howard, Louise
   Howarth, Emma
   Peters, Tim J.
   Sardinha, Lynnmarie
   Feder, Gene Solomon
TI RETRACTED: Domestic violence and mental health: a cross-sectional survey
   of women seeking help from domestic violence support services (Retracted
   article. See vol. 9, 30899, 2016)
SO GLOBAL HEALTH ACTION
LA English
DT Article; Retracted Publication
DE domestic violence and abuse; intimate partner violence; mental health;
   posttraumatic stress disorder; anxiety; CORE-OM; depression; women;
   advocacy
ID INTIMATE PARTNER VIOLENCE; POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED
   CONTROLLED-TRIAL; PRIMARY-CARE; ADVOCACY INTERVENTION; CORE-OM; ABUSIVE
   PARTNERS; DEPRESSION; MULTICOUNTRY; PREVALENCE
AB Background: Domestic violence and abuse (DVA) are associated with increased risk of mental illness, but we know little about the mental health of female DVA survivors seeking support from domestic violence services.
   Objective: Our goal was to characterise the demography and mental health of women who access specialist DVA services in the United Kingdom and to investigate associations between severity of abuse and measures of mental health and health state utility, accounting for important confounders and moderators.
   Design: Baseline data on 260 women enrolled in a randomized controlled trial of a psychological intervention for DVA survivors were analysed. We report the prevalence of and associations between mental health status and severity of abuse at the time of recruitment. We used logistic and normal regression models for binary and continuous outcomes, respectively. The following mental health measures were used: Clinical Outcomes in Routine Evaluation - Outcome Measure (CORE-OM), Patient Health Questionnaire, Generalised Anxiety Disorder Assessment, and the Posttraumatic Diagnostic Scale to measure posttraumatic stress disorder (PTSD). The Composite Abuse Scale (CAS) measured abuse.
   Results: Exposure to DVA was high, with a mean CAS score of 56 (SD 34). The mean CORE-OM score was 18 (SD 8) with 76% above the clinical threshold (95% confidence interval: 70-81%). Depression and anxiety levels were high, with means close to clinical thresholds, and more than three-quarters of respondents recorded PTSD scores above the clinical threshold. Symptoms of mental illness increased stepwise with increasing severity of DVA.
   Conclusions: Women DVA survivors who seek support from DVA services have recently experienced high levels of abuse, depression, anxiety, and especially PTSD. Clinicians need to be aware that patients presenting with mental health conditions or symptoms of depression or anxiety may be experiencing or have experienced DVA. The high psychological morbidity in this population means that trauma-informed psychological support is needed for survivors who seek support from DVA services.
C1 [Ferrari, Giulia; Bailey, Jayne; Howarth, Emma; Peters, Tim J.; Sardinha, Lynnmarie; Feder, Gene Solomon] Univ Bristol, Sch Social & Community Med, Ctr Acad Primary Care, Canynge Hall,39 Whatley Rd, Bristol BS8 2PS, Avon, England.
   [Agnew-Davies, Roxane] Domest Violence Training Ltd, Surbiton, Surrey, England.
   [Howard, Louise] Kings Coll London, Inst Psychiat, London WC2R 2LS, England.
   [Peters, Tim J.] Univ Bristol, Sch Clin Sci, Canynge Hall,39 Whatley Rd, Bristol BS8 2PS, Avon, England.
RP Ferrari, G (reprint author), Univ Bristol, Sch Social & Community Med, Ctr Acad Primary Care, Canynge Hall,39 Whatley Rd, Bristol BS8 2PS, Avon, England.
EM giulia.ferrari@bristol.ac.uk
RI Ferrari, Giulia/K-3588-2016
OI Ferrari, Giulia/0000-0002-1670-4905; Howarth, Emma/0000-0002-3969-7883;
   Sardinha, LynnMarie/0000-0002-0519-6204; Howard,
   Louise/0000-0001-9942-744X; Peters, Tim/0000-0003-2881-4180; bailey,
   jayne/0000-0002-3601-3167
FU National Institute for Health Research (NIHR) under its Programme Grants
   for Applied Research scheme [RP-PG-0108-10084]
FX The authors report no conflicts of interest. This report presents
   independent research commissioned by the National Institute for Health
   Research (NIHR) under its Programme Grants for Applied Research scheme
   (RP-PG-0108-10084). The views expressed in this publication are those of
   the authors and not necessarily those of the NHS, the NIHR, or the
   Department of Health.
CR Abramsky T, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-109
   Barkham M, 2006, COUNS PSYCHOTHER RES, V6, P3, DOI 10.1080/14733140600581218
   Becker KD, 2010, J INTERPERS VIOLENCE, V25, P1699, DOI 10.1177/0886260509354578
   Bell ME, 2001, VIOLENCE AGAINST WOM, V7, P1377, DOI 10.1177/10778010122183919
   Brierley G, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-221
   Coid J, 2003, BRIT J PSYCHIAT, V183, P332, DOI 10.1192/bjp.183.4.332
   Coid J, 2001, LANCET, V358, P450, DOI 10.1016/S0140-6736(01)05622-7
   Coker AL, 2012, VIOLENCE AGAINST WOM, V18, P118, DOI 10.1177/1077801212437908
   Connell J, 2007, BRIT J PSYCHIAT, V190, P69, DOI 10.1192/bip.bp.105.017657
   Devries KM, 2013, SCIENCE, V340, P1527, DOI 10.1126/science.1240937
   Devries KM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001439
   Dutton MA, 2006, J INTERPERS VIOLENCE, V21, P955, DOI 10.1177/0886260506289178
   Duxbury F, 2006, BRIT J GEN PRACT, V56, P294
   El-Bassel N, 2005, AM J PUBLIC HEALTH, V95, P465, DOI 10.2105/AJPH.2003.023200
   Ellsberg M, 2008, LANCET, V371, P1165, DOI 10.1016/S0140-6736(08)60522-X
   European Union Agency for Fundamental Rights, 2014, VIOL WOM EU WID SURV
   Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445
   Forbes D, 2014, J CLIN PSYCHIAT, V75, P147, DOI 10.4088/JCP.13m08374
   Garcia-Moreno C, 2006, LANCET, V368, P1260, DOI 10.1016/S0140-6736(06)69523-8
   Gilbody S, 2007, BRIT J GEN PRACT, V57, P650
   Griffing S, 2006, J INTERPERS VIOLENCE, V21, P936, DOI 10.1177/0886260506288938
   Hegarty K, 2004, BRIT MED J, V328, P621, DOI 10.1136/bmj.328.7440.621
   Hegarty Kelsey, 2005, Violence Vict, V20, P529, DOI 10.1891/088667005780927548
   Hegarty K, 2013, LANCET, V382, P249, DOI 10.1016/S0140-6736(13)60052-5
   Hegarty KL, 2013, J INTERPERS VIOLENCE, V28, P273, DOI 10.1177/0886260512454722
   Howarth E, 2013, DOMESTIC VIOLENCE ME, P1
   Jewkes R, 2002, LANCET, V359, P1423, DOI 10.1016/S0140-6736(02)08357-5
   Kind P, 1999, UK POPULATION NORMS
   Koenig MA, 2003, DEMOGRAPHY, V40, P269, DOI 10.2307/3180801
   Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06
   Lacey KK, 2013, J INTERPERS VIOLENCE, V28, P359, DOI 10.1177/0886260512454743
   Mallender J, 2013, EC ANAL INTERVENTION
   Maruish M. E., 2012, USERS MANUAL SF 12V2
   Nathanson AM, 2012, PARTN ABUSE, V3, P59, DOI 10.1891/1946-6560.3.1.59
   Prosman GJ, 2014, FAM PRACT, V31, P71, DOI 10.1093/fampra/cmt058
   Queen Josie, 2009, Issues Ment Health Nurs, V30, P237, DOI 10.1080/01612840802701257
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Reinert DF, 2007, ALCOHOL CLIN EXP RES, V31, P185, DOI 10.1111/j.1530-0277.2006.00295.x
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   StataCorp LP, INVENTORSTATA STAT S
   SULLIVAN CM, 1992, AM J COMMUN PSYCHOL, V20, P309, DOI 10.1007/BF00937912
   Sullivan CM, 1999, J CONSULT CLIN PSYCH, V67, P43, DOI 10.1037/0022-006X.67.1.43
   Tiwari A, 2010, JAMA-J AM MED ASSOC, V304, P536, DOI 10.1001/jama.2010.1052
   Trevillion K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051740
   World Health Organization, 2013, RESP INT PARTN VIOL
NR 45
TC 8
Z9 9
U1 1
U2 22
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1654-9880
J9 GLOBAL HEALTH ACTION
JI Glob. Health Action
PY 2016
VL 9
AR 29890
DI 10.3402/gha.v9.29890
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA DO5AA
UT WOS:000377794800001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Depaoli, S
   Scott, S
AF Depaoli, S.
   Scott, S.
TI RETRACTED: Frequentist and Bayesian estimation of CFA measurement models
   with mixed item response types: A Monte Carlo investigation (Retracted
   Article)
SO STRUCTURAL EQUATION MODELING-A MULTIDISCIPLINARY JOURNAL
LA English
DT Correction; Retracted Publication
CR DEPAOLI S, 2015, STRUCTURAL EQUATION
NR 1
TC 0
Z9 0
U1 2
U2 8
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1070-5511
EI 1532-8007
J9 STRUCT EQU MODELING
JI Struct. Equ. Modeling
PY 2016
VL 23
IS 2
BP 318
EP 318
DI 10.1080/10705511.2015.1107439
PG 1
WC Mathematics, Interdisciplinary Applications; Social Sciences,
   Mathematical Methods
SC Mathematics; Mathematical Methods In Social Sciences
GA DN5SZ
UT WOS:000377132200014
DA 2018-12-27
ER

PT J
AU Yasar, E
   Kesikburun, S
   Duran, UD
   Demir, Y
   Adiguzel, E
   Guzelkucuk, U
   Yilmaz, B
   Alaca, R
AF Yasar, Evren
   Kesikburun, Serdar
   Duran, Ummugulsum Dogan
   Demir, Yasin
   Adiguzel, Emre
   Guzelkucuk, Umut
   Yilmaz, Bilge
   Alaca, Ridvan
TI RETRACTED: The effect of demographic and clinical characteristics of
   patients with stroke on rehabilitation outcomes (Retracted article. See
   vol. 30, pg. 1160, 2016)
SO BRAIN INJURY
LA English
DT Meeting Abstract; Retracted Publication
C1 [Yasar, Evren; Kesikburun, Serdar; Duran, Ummugulsum Dogan; Demir, Yasin; Adiguzel, Emre; Guzelkucuk, Umut; Yilmaz, Bilge; Alaca, Ridvan] Gulhane Mil Med Acad, Dept PMR, Turkish Armed Forces Rehabil Ctr, Ankara, Turkey.
NR 0
TC 0
Z9 0
U1 4
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PY 2016
VL 30
IS 5-6
MA 0519
BP 683
EP 683
PG 1
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA DM5KP
UT WOS:000376388200453
DA 2018-12-27
ER

PT J
AU Xuan, CJ
   Karasev, A
   Shibata, H
   Jonsson, PG
AF Xuan, Changji
   Karasev, Andrey
   Shibata, Hiroyuki
   Jonsson, Par Goran
TI RETRACTED: Wetting Behavior of Single Crystal TiO2 by Liquid Iron
   (Retracted article. See vol. 56, pg. 1117, 2016)
SO ISIJ INTERNATIONAL
LA English
DT Article; Retracted Publication
DE wettability; partial pressure oxygen; TiO2; decomposition
ID STEEL; WETTABILITY; TITANIUM; EQUILIBRIUM; DEOXIDATION; PRESSURES;
   ALUMINA; SYSTEM; AL2O3; TI2O3
AB The wetting behavior of TiO2 by liquid iron was investigated by using the sessile drop method. A partial melting behavior was found to appear at the temperature below the melting point of the pure iron. Also a solid solution TiOx-FeO phase was observed between the pure iron and TiO2 substrate. The formation of this reaction layer is due to the reaction among the pure iron, TiO2 substrate and the oxygen gas. The main source of the oxygen gas for reaction is from the TiO2 substrate decomposition and a low partial pressure of oxygen near the sample.
C1 [Xuan, Changji; Karasev, Andrey; Jonsson, Par Goran] KTH Royal Inst Technol, Dept Mat Sci & Engn, Brinellvagen 23, SE-10044 Stockholm, Sweden.
   [Shibata, Hiroyuki] Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Katahira 2-1-1, Sendai, Miyagi 9808577, Japan.
RP Xuan, CJ (reprint author), KTH Royal Inst Technol, Dept Mat Sci & Engn, Brinellvagen 23, SE-10044 Stockholm, Sweden.
EM changji@kth.se
FU KTH Royal Institute of Technology
FX The authors would like to acknowledge the financial support of KTH Royal
   Institute of Technology.
CR Amondarain Z, 2011, ISIJ INT, V51, P733, DOI 10.2355/isijinternational.51.733
   Chase M, 1998, J PHYS CHEM REF DATA, V9
   Cramb A. W., 1988, P PHILLR MEM C ISS A, P25
   HUMENIK M, 1954, J AM CERAM SOC, V37, P18, DOI 10.1111/j.1151-2916.1954.tb13972.x
   Itoh S, 1998, MATER T JIM, V39, P391, DOI 10.2320/matertrans1989.39.391
   Kapilashrami E, 2003, METALL MATER TRANS B, V34, P193, DOI 10.1007/s11663-003-0006-0
   Karasev AV, 2008, ISIJ INT, V48, P1507, DOI 10.2355/isijinternational.48.1507
   Knacke O., 1991, THERMOCHEMICAL PROPE, P811
   MACCHESNEY JB, 1961, AM MINERAL, V46, P572
   Mu WZ, 2014, ISIJ INT, V54, P2907, DOI 10.2355/isijinternational.54.2907
   Muu B. V., 1984, MEUE HUTTE, V29, P128
   Ogino K., 1973, TETSU TO HAGANE, V59, P1237
   Ogino K., 1973, TETSU TO HAGANE, V59, P1380, DOI 10.2355/tetsutohagane1955.59.10_1380
   Sasai K, 2001, ISIJ INT, V41, P1331, DOI 10.2355/isijinternational.41.1331
   Sasai K., 2015, TETSU TO HAGANE, V101, P275
   Shibata H, 2009, ISIJ INT, V49, P985, DOI 10.2355/isijinternational.49.985
   Stull D. R., 1971, 37 NSRDSNBS US DEP C
   SUZUKI KI, 1975, T IRON STEEL I JPN, V15, P618
   Turkdogan E. T., 1980, PHYS CHEM HIGH TEMPE
   Xuan C, 2015, ISIJ INT, V55, P1882, DOI 10.2355/isijinternational.ISIJINT-2014-820
   Xuan CJ, 2015, ISIJ INT, V55, P1642, DOI 10.2355/isijinternational.ISIJINT-2014-819
NR 21
TC 1
Z9 1
U1 2
U2 11
PU IRON STEEL INST JAPAN KEIDANREN KAIKAN
PI TOKYO
PA TEKKO KAIKAN-5F, 3-2-10, NIHONBASHI-KAYABACHO, TOKYO, CHUO-KU 103-0025,
   JAPAN
SN 0915-1559
EI 1347-5460
J9 ISIJ INT
JI ISIJ Int.
PY 2016
VL 56
IS 5
BP 765
EP 769
DI 10.2355/isijinternational.ISIJINT-2015-722
PG 5
WC Metallurgy & Metallurgical Engineering
SC Metallurgy & Metallurgical Engineering
GA DM7PS
UT WOS:000376553100006
OA Bronze
DA 2018-12-27
ER

PT J
AU Guan, TP
   Fang, CH
   Yang, J
   Xiang, N
   Chen, QS
   Zhong, SZ
AF Guan, Tian-pei
   Fang, Chi-hua
   Yang, Jian
   Xiang, Nan
   Chen, Qing-shan
   Zhong, Shi-zhen
TI RETRACTED: A Comparison between Three-Dimensional Visualization Guided
   Hepatectomy and Ultrasonography Guided Radiofrequency Ablation in the
   Treatment of Small Hepatocellular Carcinoma within the Milan
   Criteria(Retracted article. See vol.0, Artn.8014852, 2017)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID PROSPECTIVE RANDOMIZED-TRIAL; GLOBAL CANCER STATISTICS; SURGICAL
   RESECTION; RECONSTRUCTION TECHNIQUE; HEPATIC VEINS; SYSTEM; THERAPY;
   HEPATOLITHIASIS; MANAGEMENT; SOFTWARE
AB Background. Treatment selection for small hepatocellular carcinoma (sHCC) is controversial. We aimed to compare the outcomes of medical imaging three-dimensional visualization system(MI-3DVS) guided surgical resection (SR) and ultrasonography guided radiofrequency ablation (RFA) for sHCC. Methods. In total, 194 patients who underwent SR or RFA in our hospital between January 2006 and May 2010 were retrospectively enrolled. Overall survival (OS), recurrence-free survival (RFS), and postoperative complications were compared. Cox regression was used to estimate the benefits of MI-3DVS-guided SR on OS and RFS. Results. Ninety-two patients underwent SR and 102 underwent RFA. The SR group experienced more complications (41.3% versus 19.6%) and longer hospital stay (18.04 +/- 7.11 versus 13.06 +/- 5.59) (both p < 0.05). The 1-, 2-, 3-, 4-, and 5-year OS was 96.7%, 95.7%, 93.5%, 83.5%, and 61.1% in the SR group and 95.0%, 88.1%, 72.7%, 56.9%, and 39.5% in the RFA group. Corresponding RFS was 95.7%, 94.6%, 84.7%, 59.8%, and 40.2% in SR group and 91.2%, 80.3%, 60.5%, 32.3%, and 22.3% in RFA group. The 5-year OS and RFS were higher in SR group (both p < 0.001). Interestingly, there was no significance in OS and RFS among subgroups aged >60 years. Independent predictors of OS and RFS, respectively, were intervention (HR, 2.769 and 1.933), tumor number (HR, 5.128 and 3.903), and serum alpha-fetoprotein (AFP) (HR, 1.871 and 1.474) (all p < 0.05). Conclusions. MI-3DVS based hepatectomy should be considered primary treatment while RFA can be treated as alternative therapy for older patients. Intervention, tumor number, and AFP are independent predictors for both survival and recurrence.
C1 [Guan, Tian-pei; Fang, Chi-hua; Yang, Jian; Xiang, Nan; Chen, Qing-shan] Southern Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg, Guangzhou 510282, Guangdong, Peoples R China.
   [Zhong, Shi-zhen] Southern Med Univ, Clin Anat Inst, Guangzhou 510515, Guangdong, Peoples R China.
RP Fang, CH (reprint author), Southern Med Univ, Zhujiang Hosp, Dept Hepatobiliary Surg, Guangzhou 510282, Guangdong, Peoples R China.
EM fangchi_dr@163.com
FU National High Technology Research and Development Program of China (863
   Program) [2012AA021105]; National Natural Science Foundation of China
   and Government of Guangdong Province [U1401254]
FX This paper was supported by (1) the National High Technology Research
   and Development Program of China (863 Program) (Grant no. 2012AA021105)
   and (2) the United Fund of National Natural Science Foundation of China
   and Government of Guangdong Province (Grant no. U1401254).
CR Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Chen MS, 2006, ANN SURG, V243, P321, DOI 10.1097/01.sla.0000201480.65519.b8
   Chinnaratha MA, 2015, EUR J GASTROEN HEPAT, V27, P349, DOI 10.1097/MEG.0000000000000270
   Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2
   D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
   Fang CH, 2015, J AM COLL SURGEONS, V220, P28, DOI 10.1016/j.jamcollsurg.2014.09.023
   Fang CH, 2014, PANCREAS, V43, P389, DOI 10.1097/MPA.0000000000000035
   Fang CH, 2013, J AM COLL SURGEONS, V217, P280, DOI 10.1016/j.jamcollsurg.2013.03.017
   Fang CH, 2012, PANCREATOLOGY, V12, P364, DOI 10.1016/j.pan.2012.05.006
   Fang CH, 2012, WORLD J SURG, V36, P120, DOI 10.1007/s00268-011-1297-y
   Fang CH, 2010, HEPATOB PANCREAT DIS, V9, P370
   Fu CC, 2014, HEPATO-GASTROENTEROL, V61, P1722
   Gory I, 2015, SCAND J GASTROENTERO, V50, P567, DOI 10.3109/00365521.2014.953572
   Huang JW, 2010, ANN SURG, V252, P903, DOI 10.1097/SLA.0b013e3181efc656
   Huang ZP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107303
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kim YS, 2013, J HEPATOL, V58, P89, DOI 10.1016/j.jhep.2012.09.020
   Kurokohchi K, 2002, INT J ONCOL, V21, P841
   Liu H, 2016, BRIT J SURG, V103, P348, DOI 10.1002/bjs.10061
   Liu P. H., 2015, ANN SURG, V62
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001
   NAKAMURA S, 1981, SURG GYNECOL OBSTET, V152, P43
   OU QJ, 1984, SURGERY, V95, P381
   Park EK, 2014, ANN SURG TREAT RES, V87, P72, DOI 10.4174/astr.2014.87.2.72
   Pompili M, 2013, J HEPATOL, V59, P89, DOI 10.1016/j.jhep.2013.03.009
   Poon D, 2009, LANCET ONCOL, V10, P1111, DOI 10.1016/S1470-2045(09)70241-4
   Sala M, 2004, HEPATOLOGY, V40, P1352, DOI 10.1002/hep.20465
   Sasaki A, 2005, CANCER, V103, P299, DOI 10.1002/cncr.20797
   Shi M, 2007, ANN SURG, V245, P36, DOI 10.1097/01.sla.0000231758.07868.71
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
   Simpson AL, 2014, J AM COLL SURGEONS, V219, P199, DOI 10.1016/j.jamcollsurg.2014.02.027
   Takamoto T, 2013, AM J SURG, V206, P530, DOI 10.1016/j.amjsurg.2013.01.041
   Tateishi R, 2005, CANCER, V103, P1201, DOI 10.1002/cncr.20892
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Toyosaka A, 1996, AM J GASTROENTEROL, V91, P1610
   Xie AW, 2013, J GASTROEN HEPATOL, V28, P248, DOI 10.1111/jgh.12066
   Yang J, 2014, INT J MED ROBOT COMP, V10, P410, DOI 10.1002/rcs.1590
   Yoshida S, 2013, HEPATOLOGY, V58, P1667, DOI 10.1002/hep.26526
NR 40
TC 3
Z9 3
U1 3
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2016
AR 8931732
DI 10.1155/2016/8931732
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA DM4OR
UT WOS:000376327100001
PM 27294142
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wei, XJ
   Li, F
   Yang, FY
   Duan, CH
AF Wei, Xue-jun
   Li, Feng
   Yang, Feng-yong
   Duan, Chong-hao
TI RETRACTED: Serum protein biomarkers screening in patients with ischemic
   stroke by LC-MS/MS (Retracted article. See vol. 126, pg. 1051, 2016)
SO INTERNATIONAL JOURNAL OF NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE mannose-binding lectin; acute ischemic stroke; risk; Chinese
ID MANNOSE-BINDING LECTIN; CORONARY-ARTERY-DISEASE; CEREBRAL INFARCTION;
   REPERFUSION INJURY; MASS-SPECTROMETRY; PROGNOSTIC VALUE; COMPLEMENT;
   QUANTIFICATION; CLASSIFICATION; DEFICIENCY
AB Background: The purpose of this study was to investigate the serum proteins biomarkers by label-free liquid chromatography coupled to tandem mass spectrometry quantification methods in the Chinese patients with acute ischemic stroke (AIS). Method: In the study period, sera from 40 AIS patients and 40 normal cases were selected for screening study. The selected protein associations with disease risk were further evaluated by enzyme-linked immunosorbent assay (ELISA) testing of the remaining stroke cases and controls. Its value for biomarkers diagnosis was appreciated through receiver operating characteristic (ROC) curve. Results: Patients versus control levels differences were suggested for 19 proteins (nominal P < 0.05) for stroke, with three proteins having a false discovery rate < 0.05. The association of mannose-binding lectin (MBL) with stroke (P < 0.001) was confirmed using ELISA in replication studies. Based on the ROC curve, the optimal serum concentration of MBL as a surrogate marker to support the diagnosis of ischemic cerebral injury was found to be 1050 ug/L, which yielded a sensitivity of 81.8% and a specificity of 80.2%, the area under the curve was 0.812 (95% CI: 0.724-0.876). In multivariate analysis, there was an increased risk of AIS associated with MBL levels >= 1050 ug/L (OR: 4.76, 95% CI: 1.59-10.12) after adjusting for possible confounders. Conclusion: The discovery and replication studies presented here show MBL to be a risk marker for AIS in the Chinese population, which appears to be a novel finding.
C1 [Wei, Xue-jun; Yang, Feng-yong; Duan, Chong-hao] Peoples Hosp Laiwu City, Dept Intens Care Unit, Laiwu, Shandong, Peoples R China.
   [Li, Feng] Peoples Hosp Laiwu City, Dept Emergency, Laiwu, Shandong, Peoples R China.
RP Duan, CH (reprint author), 1 Xuehu St,Changshao North Rd, Laiwu City 271100, Shandong, Peoples R China.
EM duanchlw@163.com
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Albert MA, 2001, VASC MED, V6, P145, DOI 10.1177/1358836X0100600304
   Atkinson C, 2006, J IMMUNOL, V177, P7266, DOI 10.4049/jimmunol.177.10.7266
   BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O
   Best LG, 2004, CIRCULATION, V109, P471, DOI 10.1161/01.CIR.0000109757.95461.10
   BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864
   Cairns DA, 2011, PROTEOMICS, V11, P1037, DOI 10.1002/pmic.201000579
   Calvo-Alen J, 2006, ARTHRITIS RHEUM, V54, P1940, DOI 10.1002/art.21787
   Cervera A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008433
   Cowell RM, 2003, J NEUROSCI, V23, P9459
   De Simoni MG, 2004, AM J PATHOL, V164, P1857, DOI 10.1016/S0002-9440(10)63744-3
   Dommett RM, 2006, TISSUE ANTIGENS, V68, P193, DOI 10.1111/j.1399-0039.2006.00649.x
   Faca VM, 2008, PLOS MED, V5, P953, DOI 10.1371/journal.pmed.0050123
   Fahlman RP, 2014, J PROTEOMICS, V100, P79, DOI 10.1016/j.jprot.2013.09.006
   Fatima Naheed, 2009, Cancer Genomics & Proteomics, V6, P41
   Garred P, 2006, GENES IMMUN, V7, P85, DOI 10.1038/sj.gene.6364283
   Garred P, 2003, MOL IMMUNOL, V40, P73, DOI 10.1016/S0161-5890(03)00104-4
   Kang XN, 2010, J CANCER RES CLIN, V136, P1151, DOI 10.1007/s00432-010-0762-6
   Kiga C, 2008, LIFE SCI, V83, P625, DOI 10.1016/j.lfs.2008.08.013
   Levin Y, 2007, J SEP SCI, V30, P2198, DOI 10.1002/jssc.200700189
   Mocco J, 2006, NEUROSURGERY, V59, P28, DOI 10.1227/01.neu.0000243280.75920.f4
   Morrison H, 2011, CURR NEUROVASC RES, V8, P52, DOI 10.2174/156720211794520260
   Nahnsen S, 2013, MOL CELL PROTEOMICS, V12, P549, DOI 10.1074/mcp.R112.025163
   Osthoff M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021338
   Radulovic D, 2004, MOL CELL PROTEOMICS, V3, P984, DOI 10.1074/mcp.M400061-MCP200
   Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004
   Richards TJ, 2012, AM J RESP CRIT CARE, V185, P67, DOI 10.1164/rccm.201101-0058OC
   Rugonfalvi-Kiss S, 2002, CIRCULATION, V106, P1071, DOI 10.1161/01.CIR.0000027137.96791.6A
   Silva JC, 2006, MOL CELL PROTEOMICS, V5, P144, DOI 10.1074/mcp.M500230-MCP200
   Sims JR, 2009, NEUROLOGY, V72, P2104, DOI 10.1212/WNL.0b013e3181aa5329
   Tu WJ, 2013, J NEUROENDOCRINOL, V25, P771, DOI 10.1111/jne.12052
   Tu WJ, 2014, CLIN SCI, V126, P339, DOI 10.1042/CS20130284
   Tu WJ, 2014, J MOL NEUROSCI, V52, P507
   Wang ZY, 2014, NEUROCHEM RES, V39, P248, DOI 10.1007/s11064-013-1214-x
   Wiener MC, 2004, ANAL CHEM, V76, P6085, DOI 10.1021/ac0493875
   Zhang M, 2006, J IMMUNOL, V177, P4727, DOI 10.4049/jimmunol.177.7.4727
   Zhang ZG, 2015, MOL NEUROBIOL, V51, P230, DOI 10.1007/s12035-014-8682-0
   Zhu WH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/840518
NR 38
TC 1
Z9 1
U1 6
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7454
EI 1563-5279
J9 INT J NEUROSCI
JI Int. J. Neurosci.
PY 2016
VL 126
IS 8
BP 692
EP 699
DI 10.3109/00207454.2015.1033713
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA DM5MJ
UT WOS:000376392800003
PM 26000912
DA 2018-12-27
ER

PT J
AU Davalos, EA
   Cho, J
   Dave, H
   Shen, H
   Barank, D
   Shim, J
AF Davalos, Eric A.
   Cho, John
   Dave, Hiren
   Shen, Hong
   Barank, David
   Shim, John
TI RETRACTED: Transformation of a Nonfunctional Paraganglioma With I-123
   MIBG Scintigraphy Correlation A Case Report(Retracted article. See
   vol.95,pg.E5742,2016)
SO MEDICINE
LA English
DT Article; Retracted Publication
ID NEUROENDOCRINE TUMORS; PHEOCHROMOCYTOMA; LOCALIZATION
AB A 35-year-old woman presenting with abdominal pain was found to have mildly elevated catecholamine levels and a retroperitoneal mass. The patient underwent a negative I-123 MIBG scintigraphy scan and a nondiagnostic fine needle aspiration. Eleven years later the patient presented with a hypertensive emergency and markedly elevated catecholamine levels. A subsequent I-123 MIBG scintigraphy scan showed intense uptake corresponding to the previously seen retroperitoneal mass. The patient underwent surgical resection and pathology confirmed the presence of a paraganglioma
   A paraganglioma is an extra-adrenal pheochromocytoma that contains chromaffin cells and is thus capable of producing catecholamines. I-123 metaiodobenzylguanidine (MIBG) scintigraphy has become the imaging study of choice for paragangliomas and has a sensitivity of similar to 77% to 100% in detecting functional paragangliomas.1">(1) This case demonstrates scintigraphic correlation of the functional transformation of a nonfunctional paraganglioma in a time span of similar to 10 years. Although there are previously published case reports of scintigraphic positive, nonfunctional paragangliomas2 R3">(2,3) and scintigraphic negative chromaffin cell tumors,4 R5">(4,5) there has been no prior documented case of scintigraphic transformation on MIBG.
C1 [Davalos, Eric A.; Cho, John; Dave, Hiren; Barank, David; Shim, John] Harbor UCLA Med Ctr, Dept Radiol, Box 27,1000 West Carson St, Torrance, CA 90509 USA.
   [Shen, Hong] Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90509 USA.
RP Davalos, EA (reprint author), Harbor UCLA Med Ctr, Dept Radiol, Box 27,1000 West Carson St, Torrance, CA 90509 USA.
EM edavalos@dhs.lacounty.gov
CR Antoniou D, 2011, HELL J NUCL MED, V14, P163
   Castinetti F, 2015, ENDOCR-RELAT CANCER, V22, pT135, DOI 10.1530/ERC-15-0175
   Grassi I, 2011, CLIN NUCL MED, V36, P124, DOI 10.1097/RLU.0b013e318203bc4f
   Ilias I, 2004, J CLIN ENDOCR METAB, V89, P479, DOI 10.1210/jc.2003-031091
   Intenzo CM, 2007, RADIOGRAPHICS, V27, DOI 10.1148/rg.275065729
   Kaltsas G, 2004, EUR J ENDOCRINOL, V151, P15, DOI 10.1530/eje.0.1510015
   KHAFAGI F, 1987, J NUCL MED, V28, P528
   Milardovic R, 2010, NEUROENDOCRINOLOGY, V91, P94, DOI 10.1159/000242499
   van Berkel A, 2014, CLIN ENDOCRINOL, V81, P329, DOI 10.1111/cen.12482
   Vassilatou E, 2009, CLIN ENDOCRINOL, V70, P674, DOI 10.1111/j.1365-2265.2008.03492.x
NR 10
TC 0
Z9 0
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN
PY 2016
VL 95
IS 2
AR e2501
DI 10.1097/MD.0000000000002501
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA DE4WU
UT WOS:000370632100001
PM 26765464
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Atri, M
   Nagraj, A
   Atri, S
AF Atri, Mansi
   Nagraj, Anup
   Atri, Saatvik
TI RETRACTED: Aberrant anatomy of a maxillary first molar: A case report
   (Retracted article. See vol. 9, pg. 214, 2016)
SO ANNALS OF TROPICAL MEDICINE AND PUBLIC HEALTH
LA English
DT Article; Retracted Publication
DE Maxillary second molar; root canal; anatomy
ID 1ST MOLAR; 6 CANALS; ROOT
AB The first step of successful endodontic treatment is to gain access to the pulp chamber and find all of the canals. To achieve this goal, practitioners need to be familiar with all possible variations of the root canal and have adequate information of the tooth that needs treatment. The present case report describes an anatomical variant of the maxillary second molar with six canals, a variation that has not been previously reported. Helpful hints for the detection of the unusual canal are presented.
C1 [Atri, Mansi] ESIC Dent Coll & Hosp, Dept Publ Hlth Dent, New Delhi, India.
   [Atri, Saatvik] Dept Conservat & Endodont, New Delhi, India.
   [Nagraj, Anup] Jaipur Dent Coll, Dept Publ Hlth Dent, Jaipur, Rajasthan, India.
RP Atri, M (reprint author), ESIC Dent Coll & Hosp, Dept Publ Hlth Dent, New Delhi, India.
EM drmansiatri@gmail.com
CR BEATTY RG, 1984, J ENDODONT, V10, P156, DOI 10.1016/S0099-2399(84)80119-3
   BOND JL, 1988, J ENDODONT, V14, P258, DOI 10.1016/S0099-2399(88)80180-8
   Buhrley LJ, 2002, J ENDODONT, V28, P324, DOI 10.1097/00004770-200204000-00016
   Cleghorn BM, 2006, J ENDODONT, V32, P813, DOI 10.1016/j.joen.2006.04.014
   Hulsmann M, 1997, J ENDODONT, V23, P707, DOI 10.1016/S0099-2399(97)80407-4
   MARTINEZBERNA A, 1983, J ENDODONT, V9, P375, DOI 10.1016/S0099-2399(83)80188-5
   SABALA CL, 1994, J ENDODONT, V20, P38, DOI 10.1016/S0099-2399(06)80025-7
   WONG M, 1991, J ENDODONT, V17, P298, DOI 10.1016/S0099-2399(06)81871-6
NR 8
TC 1
Z9 1
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 1755-6783
EI 0974-6005
J9 Ann Trop Med Public
JI Ann. Trop. Med. Public Health
PD JAN-FEB
PY 2016
VL 9
IS 1
BP 61
EP 63
DI 10.4103/1755-6783.168688
PG 3
WC Tropical Medicine
SC Tropical Medicine
GA DK1GG
UT WOS:000374659900013
OA Other Gold
DA 2018-12-27
ER

PT J
AU Li, JY
   Yu, J
   Zhang, HM
   Wang, B
   Guo, H
   Bai, J
   Wang, JH
   Dong, Y
   Zhao, YL
   Wang, YL
AF Li, Jianying
   Yu, Jun
   Zhang, Huimin
   Wang, Bo
   Guo, Hua
   Bai, Jie
   Wang, Juanhong
   Dong, Ya
   Zhao, Yuling
   Wang, Yili
TI RETRACTED: Exosomes-Derived MiR-302b Suppresses Lung Cancer Cell
   Proliferation and Migration via TGF beta RII Inhibition (Retracted
   article. See vol. 39, pg. 1964, 2016)
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE Lung cancer; Exosome; MiR-302b; Suppress; TGF-beta 1/ERK
ID TO-MESENCHYMAL TRANSITION; BREAST-CANCER; SIGNALING PATHWAY;
   DOWN-REGULATION; IN-VITRO; GROWTH; EXPRESSION; METASTASIS; INVASION;
   MMP-9
AB Background/Aims:Several studies have reported that tumor-derived exosomes contain kinds of miRNAs, including oncogenic miRNAs and tumor suppressor miRNAs. It has been reported that miR-302b could inhibit cancer progression by targeting oncogenes post-transcriptionally. Whether miR-302b is involved in the regulation of tumor-derived exosomes on lung cancer cells proliferation has not yet been demonstrated. This study aimed to examine the effect of exosomes-derived miR-302b on lung cancer cells proliferation and explain the potential mechanism. Methods: The effect of exosomes derived from 95C cells and 95D cells with different metastatic ability on lung cancer cell proliferation and migration were analyzed by MTT assay and Transwell assays, respectively. Exosomes of 95C and 95D cells derived miR-302b was quantified by qRT-PCR, the effect of miR-302b on proliferation and migration of 95D cells was analyzed by MTT assays and Transwell assays respectively after transfection with miR-302b, while the expression of phosphorylated ERK1/2. MMP9 and TGF beta RII was analyzed by Western blot. The target gene of miRNA-302b was analyzed by Luciferase reporter assays. Results: 95C-derived exosomes significantly decreased the migration ability of 95D cells. miRNA-302b was significantly overexpressed in 95C cells and 95C-derived exosomes compared with 95D cells and 95D-derived exosomes. Transfection of miR-302b into 95D cells significantly suppressed cells proliferation and migration capabilities along with the down regulated expression of TGF beta RII, phosphorylated ERK1/2 and MMP9 induced by ICE-beta 1. Conclusions: Exosomes-derived miR-302b could suppress lung cancer cell proliferation and migration via the TGF beta RII/ERK pathway and thus provides a potential target for human lung cancer therapy. (C) 2016 The Author(s) Published by S. Karger AG, Basel
C1 [Li, Jianying; Wang, Yili] Xi An Jiao Tong Univ, Sch Basic Med Sci, Inst Canc Res, Xian 710049, Shaanxi Provinc, Peoples R China.
   [Yu, Jun] Xi An Jiao Tong Univ, Sch Med, Dept Gen Surg, Affiliated Hosp 2, Xian 710049, Shaanxi Provinc, Peoples R China.
   [Zhang, Huimin; Wang, Bo; Guo, Hua; Bai, Jie; Dong, Ya; Zhao, Yuling] Xi An Jiao Tong Univ, Sch Med, Dept Resp Dis, Affiliated Xian Cent Hosp, Xian 710049, Shaanxi Provinc, Peoples R China.
   [Yu, Jun] Xi An Jiao Tong Univ, Sch Med, Dept Gen Surg, Affiliated Xian Cent Hosp, Xian 710049, Shaanxi Provinc, Peoples R China.
   [Wang, Juanhong] Xi An Jiao Tong Univ, Sch Med, Dept Pathol, Affiliated Xian Cent Hosp, Xian 710049, Shaanxi Provinc, Peoples R China.
RP Wang, YL (reprint author), Xi An Jiao Tong Univ, Inst Canc Res, Sch Basic Med Sci, Hlth Sci Ctr, Xian 710006, Shaanxi Provinc, Peoples R China.
EM yiliwangs@163.com
FU Natural Science Foundation of Shaanxi Province [2012JC2-06]; Shaanxi
   Science and Technology Plan Projects Fund [2014K11-01-02-15]
FX This work was supported by Natural Science Foundation of Shaanxi
   Province 2012JC2-06 and Shaanxi Science and Technology Plan Projects
   Fund 2014K11-01-02-15.
CR Bell BM, 2016, NANOMED-NANOTECHNOL, V12, P163, DOI 10.1016/j.nano.2015.09.011
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chang HH, 2015, J ENDODONT, V41, P1272, DOI 10.1016/j.joen.2015.03.022
   Chen KC, 2013, LIFE SCI, V93, P924, DOI 10.1016/j.lfs.2013.10.004
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Fedorko M, 2016, INT J BIOL MARKER, V31, pE26, DOI 10.5301/jbm.5000174
   Fu H, 2009, ACTA BIOCH BIOPH SIN, V41, P648, DOI 10.1093/abbs/gmp053
   Ge TT, 2014, CELL PHYSIOL BIOCHEM, V34, P2209, DOI 10.1159/000369664
   Hawinkels LJAC, 2008, EUR J CANCER, V44, P1904, DOI 10.1016/j.ejca.2008.06.031
   HIMELSTEIN BP, 1994, INVAS METAST, V14, P246
   Hou YL, 2013, CANCER EPIDEMIOL, V37, P750, DOI 10.1016/j.canep.2013.04.013
   Hough C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042513
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jiang HL, 2015, ONCOTARGET, V6, P16352, DOI 10.18632/oncotarget.3877
   Jo E, 2015, NEOPLASIA, V17, P525, DOI 10.1016/j.neo.2015.06.004
   Katakowski M, 2013, CANCER LETT, V335, P201, DOI 10.1016/j.canlet.2013.02.019
   Khalili M, 2012, CELL J, V13, P251
   Kim SM, 2012, J ORTHOP RES, V30, P1040, DOI 10.1002/jor.22025
   Kim YM, 2013, ARCH PHARM RES, V36, P479, DOI 10.1007/s12272-013-0044-3
   Kong FF, 2014, ONCOL RES, V22, P29, DOI 10.3727/096504014X14078436004987
   Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x
   Li CY, 2004, ACTA BIOCH BIOPH SIN, V36, P405, DOI 10.1093/abbs/36.6.405
   Li JY, 2014, LUNG CANCER, V86, P144, DOI 10.1016/j.lungcan.2014.08.015
   Li LM, 2015, INT J MOL MED, V36, P113, DOI 10.3892/ijmm.2015.2222
   Li Y, 2015, FEBS OPEN BIO, V5, P466, DOI 10.1016/j.fob.2015.05.009
   Meehan K, 2016, CRIT REV CL LAB SCI, V53, P121, DOI 10.3109/10408363.2015.1092496
   Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8
   Muralidharan R, 2015, CANCER GENE THER, V22, P581, DOI 10.1038/cgt.2015.55
   Nagpal N, 2015, SCI REP-UK, V5, DOI 10.1038/srep09650
   Palma J, 2012, NUCLEIC ACIDS RES, V40, P9125, DOI 10.1093/nar/gks656
   Park SH, 2014, AM J CHINESE MED, V42, P1139, DOI 10.1142/S0192415X14500712
   Periyasamy S, 2000, ONCOGENE, V19, P4660, DOI 10.1038/sj.onc.1203822
   Poudel B, 2014, ONCOL LETT, V7, P215, DOI 10.3892/ol.2013.1655
   Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556
   Tian TA, 2010, J CELL BIOCHEM, V111, P488, DOI 10.1002/jcb.22733
   Toonkel RL, 2010, J THORAC ONCOL, V5, P153, DOI 10.1097/JTO.0b013e3181c8cc0c
   Wang LM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-448
   Watanabe-Takano H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127888
   Xiao L, 2012, FRONT BIOSCI-LANDMRK, V17, P2667, DOI 10.2741/4077
   Xu CC, 2011, MOL MED REP, V4, P1007, DOI 10.3892/mmr.2011.530
   Xu JH, 2015, CHINESE MED J-PEKING, V128, P1376, DOI 10.4103/0366-6999.156795
   Xu S, 2015, RNA BIOL, V12, P1355, DOI 10.1080/15476286.2015.1100795
   Xu YH, 2015, MOL MED REP, V11, P417, DOI 10.3892/mmr.2014.2678
   Yang DW, 2015, CANCER LETT, V365, P57, DOI 10.1016/j.canlet.2015.05.001
   Zhang CK, 2015, PROTEIN CELL, V6, P881, DOI 10.1007/s13238-015-0223-8
   Zhao LM, 2010, ONCOL REP, V24, P375, DOI 10.3892/or_00000870
NR 48
TC 22
Z9 26
U1 2
U2 23
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2016
VL 38
IS 5
BP 1715
EP 1726
DI 10.1159/000443111
PG 12
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA DL6ZE
UT WOS:000375787800006
PM 27160836
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Sun, E
   Zhang, WB
   Wang, LN
   Wang, AX
   Ma, CQ
   Lei, MD
   Zhou, XD
   Sun, Y
   Lu, BX
   Liu, LW
   Han, RF
AF Sun, Erlin
   Zhang, Wenbo
   Wang, Lining
   Wang, Aixiang
   Ma, Chengquan
   Lei, Mingde
   Zhou, Xiaodong
   Sun, Yan
   Lu, Bingxin
   Liu, Liwei
   Han, Ruifa
TI RETRACTED: Down-regulation of Sphk2 suppresses bladder cancer
   progression (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE SphK2; Bladder cancer; Apoptosis; Proliferation; Migration
ID SPHINGOSINE KINASE-1; SURVIVAL; PROLIFERATION; EXPRESSION; MIGRATION;
   GROWTH; ROLES
AB Bladder cancer is the second most common urological malignancy around the world and is by far the most frequent urological malignancy in China. The abnormal expression of sphingosine kinase 2 (SphK2) is associated with tumor progression and a poor patient survival rate, however, the effect of SphK2 on the bladder cancer cells remains unclear. The aim of the paper was to study the expression of SphK2 in bladder cancer and the role of SphK2 on the cell proliferation, metastasis, and apoptosis in bladder cancer in vitro. Our results showed that SphK2 is up-regulated in bladder cancer tissues compared with the corresponding adjacent non-neoplastic tissues, and the expression level of SphK2 was significantly higher in human bladder cancer cells in comparison with normal bladder epithelial cells. Silencing of SphK2 could inhibit the proliferation ability of T24 cells in vitro. In addition, SphK2 knockdown could induce a significant increase in the number of apoptotic cells. Furthermore, the transwell assay also showed significant cell migration inhibition in SphK2 siRNA transfectant compared with cell lines transfected with NC. Thus, this study suggested that SphK2 inhibition may provide a promising treatment for bladder cancer patients.
C1 [Sun, Erlin; Wang, Lining; Wang, Aixiang; Ma, Chengquan; Lei, Mingde; Zhou, Xiaodong; Sun, Yan; Lu, Bingxin; Liu, Liwei; Han, Ruifa] Tianjin Med Univ, Tianjin Inst Urol, Dept Urol, Hosp 2, 23 Pingjiang Rd, Tianjin, Peoples R China.
   [Zhang, Wenbo] Xinxiang Med Univ, Sch Life Sci & Technol, Xinxiang 453003, Henan, Peoples R China.
RP Sun, E (reprint author), Tianjin Med Univ, Tianjin Inst Urol, Dept Urol, Hosp 2, 23 Pingjiang Rd, Tianjin, Peoples R China.
EM irene_sunsun@yahoo.com
FU National Natural Science Foundation of China [81402095]; Science and
   Technology Foundation of Tianjin Public Health Bureau [2013KZ110]
FX This work is supported by the National Natural Science Foundation of
   China, 81402095; and the Science and Technology Foundation of Tianjin
   Public Health Bureau, 2013KZ110
CR French KJ, 2010, J PHARMACOL EXP THER, V333, P129, DOI 10.1124/jpet.109.163444
   French KJ, 2003, CANCER RES, V63, P5962
   Gao P, 2011, MOL CANCER RES, V9, P1509, DOI 10.1158/1541-7786.MCR-11-0336
   Gestaut MM, 2014, PHARMACOL REP, V66, P174, DOI 10.1016/j.pharep.2013.08.014
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200
   Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0
   Miller AV, 2008, MOL CELL BIOL, V28, P4142, DOI 10.1128/MCB.01465-07
   Oskeritzian CA, 2008, BLOOD, V111, P4193, DOI 10.1182/blood-2007-09-115451
   Ploeg M, 2009, WORLD J UROL, V27, P289, DOI 10.1007/s00345-009-0383-3
   Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402
   Shirodkar SP, 2009, CURR OPIN UROL, V19, P488, DOI 10.1097/MOU.0b013e32832eb3a0
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Suriano Francesca, 2013, Rev Urol, V15, P108
   Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c
   von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757
   Yang GL, 2012, J SURG ONCOL, V106, P57, DOI 10.1002/jso.23040
NR 17
TC 7
Z9 7
U1 3
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2016
VL 37
IS 1
BP 473
EP 478
DI 10.1007/s13277-015-3818-z
PG 6
WC Oncology
SC Oncology
GA DK0BA
UT WOS:000374576200051
PM 26224479
DA 2018-12-27
ER

PT J
AU Wang, HS
   Yang, MS
   Xu, J
   Zou, BK
   Zhou, Q
   Bian, JS
   Wang, XW
AF Wang, Huansheng
   Yang, Mingshan
   Xu, Jian
   Zou, Benkui
   Zhou, Qian
   Bian, Jiasheng
   Wang, Xingwu
TI RETRACTED: Survivin mRNA-circulating tumor cells are associated with
   prostate cancer metastasis (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Prostate cancer; Circulating tumor cell; Survivin mRNA; Metastasis
ID PERIPHERAL-BLOOD; LUNG-CANCER; CLINICAL-SIGNIFICANCE; COLORECTAL-CANCER;
   BREAST-CANCER; DNA; PCR
AB Detection of circulating tumor cells (CTCs) has been made to develop reliable assays for early diagnosis of various cancers. Overexpression of survivin in cancer cells is strongly associated with tumor progression. Although upregulation of survivin is observed in various tumors, its expression profile in the peripheral blood of prostate cancer (PCa) patients has not yet been investigated. In this study, we validated the application of survivin as the tumor marker to detect CTC and assessed its utility for diagnosis of PCa distant metastasis. Immunohistochemistry and quantitative real-time PCR (QRT-PCR) were performed to confirm the levels of surviving expression in PCa tissues. In addition, CTC values in 3 mL of peripheral blood from PCa patients, benign prostate hyperplasia (BPH) patients, and normal controls were also measured by the survivin-targeted PCR. Our results showed that surviving was overexpressed in PCa tissues. The median levels of blood surviving mRNA of PCa patients, BPH patients, and normal controls were 5.67 (range from 0 to 12.46), 2.24 (range from 0 to 6.55), and 1.85 (range from 0 to 3.82), respectively. The levels of survivin are positively associated with PCa distant metastasis. Our results concluded that quantitation of CTCs through survivin-PCR could be a promising marker for diagnosis of PCa metastasis.
C1 [Wang, Huansheng; Yang, Mingshan; Xu, Jian; Zou, Benkui; Zhou, Qian; Bian, Jiasheng] Shandong Canc Hosp, Dept Urol Surg, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China.
   [Wang, Xingwu] Shandong Canc Hosp, Dept Cent Lab, Jinan 250117, Shandong, Peoples R China.
RP Wang, HS (reprint author), Shandong Canc Hosp, Dept Urol Surg, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China.
EM frofwangsh@163.com
FU National Key Basic Research Development Plan (973 Plan) [2011CB504302]
FX This paper was supported by the National Key Basic Research Development
   Plan (973 Plan) (2011CB504302).
CR Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968
   Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113
   Bastian PJ, 2007, CLIN CANCER RES, V13, P5361, DOI 10.1158/1078-0432.CCR-06-2781
   Cao M, 2009, CLIN EXP METASTAS, V26, P751, DOI 10.1007/s10585-009-9274-7
   Cohen SJ, 2009, ANN ONCOL, V20, P1223, DOI 10.1093/annonc/mdn786
   Danila DC, 2007, CLIN CANCER RES, V13, P7053, DOI 10.1158/1078-0432.CCR-07-1506
   Heidenreich A, 2011, EUR UROL, V59, P61, DOI 10.1016/j.eururo.2010.10.039
   Jin JK, 2011, INT J CANCER, V128, P2545, DOI 10.1002/ijc.26024
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lou JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080458
   Lucci A, 2012, LANCET ONCOL, V13, P688, DOI 10.1016/S1470-2045(12)70209-7
   Metwalli AR, 2014, UROL ONCOL-SEMIN ORI, V32, P761, DOI 10.1016/j.urolonc.2014.03.024
   Palmer TD, 2011, ADV DRUG DELIVER REV, V63, P568, DOI 10.1016/j.addr.2011.04.008
   Punnoose EA, 2012, CLIN CANCER RES, V18, P2391, DOI 10.1158/1078-0432.CCR-11-3148
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Tang XP, 2013, LUNG CANCER, V81, P273, DOI 10.1016/j.lungcan.2013.05.005
   Yie SM, 2008, ANN SURG ONCOL, V15, P3073, DOI 10.1245/s10434-008-0069-x
   Yie SM, 2006, CLIN EXP METASTAS, V23, P279, DOI 10.1007/s10585-006-9037-7
   Yie SM, 2009, LUNG CANCER, V63, P284, DOI 10.1016/j.lungcan.2008.05.024
   Zhu Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121076
NR 20
TC 6
Z9 6
U1 3
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2016
VL 37
IS 1
BP 723
EP 727
DI 10.1007/s13277-015-3812-5
PG 5
WC Oncology
SC Oncology
GA DK0BA
UT WOS:000374576200078
PM 26242261
DA 2018-12-27
ER

PT J
AU Yan, JY
   Zhang, YL
   Shi, WS
   Ren, CL
   Liu, Y
   Pan, YY
AF Yan, Junyuan
   Zhang, Yanling
   Shi, Wenshuang
   Ren, Cuili
   Liu, Yan
   Pan, Yunyan
TI RETRACTED: The critical role of HMGA2 in regulation of EMT in epithelial
   ovarian carcinomas (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE HMGA2; Epithelial ovarian carcinomas; EMT
ID NEUROBLASTOMA-CELLS; BAG3; CANCER; ANGIOGENESIS; BEVACIZUMAB; APOPTOSIS;
   THERAPY; PROTEIN
AB The high mobility group A2 (HMGA2), an oncofetal protein, was shown to play a role in tumor development and progression. However, the molecular and clinical role of HMGA2 in epithelial ovarian carcinomas (EOCs) is still unknown. In the present study, EOC cell line SKOV3 was subjected to in vitro assays. Here, our findings showed that HMGA2 was highly expressed in EOC cell line SKOV3. HMGA2 knockdown promoted cell apoptosis and the cleavage of caspase 3, and decreased the B cell lymphoma 2 (Bcl-2)/Bax ratio in SKOV3. Functionally, HMGA2 knockdown resulted in reduction of SKOV3 cell migration and invasion. Mechanically, HMGA2 knockdown affected the occurrence of EMT by increasing E-cadherin gene and protein expression and decreasing the gene and protein expression of N-cadherin, slug, and vimentin. At the same time, HMGA2 also repressed the expression of matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), which was consistent with the decreased invasion capacity. In conclusion, HMGA2 is associated with migration and invasiveness and regulates the progression of EMT in the development of EOC, and HMGA2 gene and protein may be a novel therapeutic target against EOC in the clinical practice.
C1 [Yan, Junyuan; Liu, Yan; Pan, Yunyan] Shandong Acad Med Sci, Dept Obstet & Gynaecol, Affiliated Hosp, 38 Wuyingshan Rd, Jinan 250031, Shandong, Peoples R China.
   [Zhang, Yanling; Shi, Wenshuang; Ren, Cuili] Third Peoples Hosp Jinan City, Dept Obstet & Gynaecol, Jinan, Shandong, Peoples R China.
RP Pan, YY (reprint author), Shandong Acad Med Sci, Dept Obstet & Gynaecol, Affiliated Hosp, 38 Wuyingshan Rd, Jinan 250031, Shandong, Peoples R China.
EM panyunyan163@163.com
CR Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390
   Chiappetta G, 2007, J CLIN ENDOCR METAB, V92, P1159, DOI 10.1210/jc.2006-1712
   De A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072748
   Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012
   Falco A, 2012, ONCOGENE, V31, P5153, DOI 10.1038/onc.2012.17
   Festa M, 2011, AM J PATHOL, V178, P2504, DOI 10.1016/j.ajpath.2011.02.002
   Gentilella A, 2008, ONCOGENE, V27, P5011, DOI 10.1038/onc.2008.142
   Harter P, 2010, EXPERT REV ANTICANC, V10, P81, DOI 10.1586/ERA.09.165
   He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467
   Jayson GC, 2014, LANCET, VS0140-6736, P62146
   Kim KW, 2013, AUTOPHAGY, V9, P1579, DOI 10.4161/auto.25987
   Li N, 2013, ONCOGENE, V32, P4539, DOI 10.1038/onc.2012.466
   Pang RWC, 2008, ANN SURG ONCOL, V15, P962, DOI 10.1245/s10434-007-9730-z
   Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799
   Rosati A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.24
   Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1
   Staibano S, 2010, TUMOR BIOL, V31, P461, DOI 10.1007/s13277-010-0055-3
   STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545
   Suzuki M, 2011, CANCER LETT, V303, P65, DOI 10.1016/j.canlet.2011.01.019
   Wang HQ, 2010, J CELL PHYSIOL, V224, P94, DOI 10.1002/jcp.22097
NR 20
TC 6
Z9 6
U1 3
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2016
VL 37
IS 1
BP 823
EP 828
DI 10.1007/s13277-015-3852-x
PG 6
WC Oncology
SC Oncology
GA DK0BA
UT WOS:000374576200089
PM 26250458
DA 2018-12-27
ER

PT J
AU Wang, ZX
   Qu, K
   Niu, WQ
   Lin, T
   Xu, XS
   Huang, ZC
   Liu, SS
   Liu, SN
   Chang, HL
   Liu, YM
   Dong, XQ
   Liu, C
   Zhang, YL
AF Wang, Zhixin
   Qu, Kai
   Niu, Wenquan
   Lin, Ting
   Xu, Xinsen
   Huang, Zichao
   Liu, Sushun
   Liu, Sinan
   Chang, Hulin
   Liu, Yamin
   Dong, Xiaoqun
   Liu, Chang
   Zhang, Yuelang
TI RETRACTED: Glutathione S-transferase P1 gene rs4147581 polymorphism
   predicts overall survival of patients with hepatocellular carcinoma:
   evidence from an enlarged study (retracted article)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Glutathione S-transferase; Single nucleotide polymorphism(SNP);
   Hepatocellular carcinoma; Prognosis
ID TOBACCO-SMOKE EXPOSURE; GSTP1 GENE; CHEMICAL CARCINOGENS;
   OVARIAN-CANCER; RISK; GSTT1; SUSCEPTIBILITY; METAANALYSIS; ASSOCIATION;
   METHYLATION
AB As the most important detoxifying enzymes in liver, glutathione S-transferases (GSTs) can protect hepatocytes against carcinogens. We conducted a large cohort study to investigate the prognostic value of single nucleotide polymorphisms (SNPs) in seven encoding genes of GSTs for hepatocellular carcinoma (HCC). Twelve SNPs were genotyped and correlated with overall survival in 469 HCC patients. The median follow-up time of all patients was 21 (range 3-60) months, and the median survival time was 22 months. By the end of the study, 135 (28.8 %) patients were alive. Only rs4147581 in GSTP1 gene exhibited a significant association with survival of HCC patients (P = 0.006), with its mutant allele bearing a significantly lower risk of death (hazard ratio, 0.71; 95 % confidence interval 0.53-0.90), compared with the homozygous wide-type. A longer median survival time in patients with rs4147581 mutant allele was noticed than those homozygous wide-type (P = 0.03), and there was a marked adverse effect on survival conferred by smoking exposure in these patients. Conclusively, our findings provide supporting evidence for a contributory role of GSTP1 rs4147581 polymorphism in predicting the prognosis of HCC.
C1 [Wang, Zhixin; Zhang, Yuelang] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Imaging, West Yanta Rd 277, Xian 710061, Shaanxi, Peoples R China.
   [Wang, Zhixin; Qu, Kai; Lin, Ting; Xu, Xinsen; Huang, Zichao; Liu, Sushun; Liu, Sinan; Chang, Hulin; Liu, Chang] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, West Yanta Rd 277, Xian 710061, Shaanxi, Peoples R China.
   [Niu, Wenquan] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, State Key Lab Med Genom, Ruijin Second Rd 197, Shanghai 200025, Peoples R China.
   [Liu, Yamin] Xi An Jiao Tong Univ, Dept Cardiol & Periphery Vasc Med, Affiliated Hosp 1, West Yanta Rd 277, Xian 710061, Shaanxi, Peoples R China.
   [Dong, Xiaoqun] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Internal Med, 975 NE 10th St,Biomed Res Ctr BRC1366, Oklahoma City, OK 73104 USA.
RP Zhang, YL (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Imaging, West Yanta Rd 277, Xian 710061, Shaanxi, Peoples R China.; Niu, WQ (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, State Key Lab Med Genom, Ruijin Second Rd 197, Shanghai 200025, Peoples R China.; Dong, XQ (reprint author), Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Internal Med, 975 NE 10th St,Biomed Res Ctr BRC1366, Oklahoma City, OK 73104 USA.
EM niuwenquan_shcn@163.com; Xiaoqun-Dong@ouhsc.edu; 465352879@qq.com
FU National Natural Science Foundation of China [81201549, 81272644,
   81402022, 81472247]; Project of Innovative Research Team for Key Science
   and Technology in Shaanxi province [2013KCJ-23]
FX This study was supported by the National Natural Science Foundation of
   China (Grant Nos. 81201549, 81272644, 81402022, and 81472247) and the
   Project of Innovative Research Team for Key Science and Technology in
   Shaanxi province (Grant No. 2013KCJ-23).
CR Agalliu I, 2006, PROSTATE, V66, P1535, DOI 10.1002/pros.20491
   Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC
   Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9
   Chen YL, 2010, BMC MED GENET, V11, DOI [10.1186/1471-2350-11-46, 10.1186/1471-2350-11-17]
   Curran JE, 2000, CANCER LETT, V153, P113, DOI 10.1016/S0304-3835(00)00361-X
   DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794
   Ding S, 2004, WORLD J GASTROENTERO, V10, P3433
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Gross-Steinmeyer K, 2012, TOXICOLOGY, V299, P69, DOI 10.1016/j.tox.2012.05.016
   Howells REJ, 2004, INT J GYNECOL CANCER, V14, P242, DOI 10.1111/j.1048-891X.2004.014207.x
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kilburn L, 2010, CANCER-AM CANCER SOC, V116, P2242, DOI 10.1002/cncr.25006
   LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733
   Munaka M, 2003, J CANCER RES CLIN, V129, P355, DOI 10.1007/s00432-003-0439-5
   Nagle CM, 2007, EUR J CANCER, V43, P283, DOI 10.1016/j.ejca.2006.09.011
   Niu DD, 2009, MOL ONCOL, V3, P67, DOI 10.1016/j.molonc.2008.10.002
   Okcu MF, 2004, CLIN CANCER RES, V10, P2618, DOI 10.1158/1078-0432.CCR-03-0053
   Qu K, 2015, WORLD J GASTROENTERO, V21, P4310, DOI 10.3748/wjg.v21.i14.4310
   Sergentanis TN, 2010, BREAST CANCER RES TR, V121, P195, DOI 10.1007/s10549-009-0520-0
   Stoehlmacher J, 2002, J NATL CANCER I, V94, P936
   Wang Z, 2015, GLUTATHIONE S TRANSF
   Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275
   Wenzlaff AS, 2005, CARCINOGENESIS, V26, P395, DOI 10.1093/carcin/bgh326
   White DL, 2008, AM J EPIDEMIOL, V167, P377, DOI 10.1093/aje/kwm315
   Xu Z, 2012, CANCER-AM CANCER SOC, V118, P5489, DOI 10.1002/cncr.27599
   Yang G, 2005, CANCER-AM CANCER SOC, V103, P52, DOI 10.1002/cncr.20729
   Zhang YJ, 2005, CANCER LETT, V221, P135, DOI 10.1016/j.canlet.2004.08.028
   Zhao YP, 2010, INT J MED SCI, V7, P300
   Zhong S, 2002, CLIN CANCER RES, V8, P1087
NR 29
TC 3
Z9 4
U1 4
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2016
VL 37
IS 1
BP 943
EP 952
DI 10.1007/s13277-015-3871-7
PG 10
WC Oncology
SC Oncology
GA DK0BA
UT WOS:000374576200102
PM 26260272
DA 2018-12-27
ER

PT J
AU Calzavara-Pinton, PG
   Rossi, MT
   Zanca, A
   Arisi, M
   Gonzalez, S
   Venturini, M
AF Calzavara-Pinton, Pier Giacomo
   Rossi, Maria Teresa
   Zanca, Arianna
   Arisi, Mariachiara
   Gonzalez, Salvador
   Venturini, Marina
TI RETRACTED: Oral Polypodium leucomotos increases the anti-inflammatory
   and melanogenic responses of the skin to different modalities of sun
   exposures: a pilot study(Retracted article. See vol.32,pg.331, 2016)
SO PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE
LA English
DT Article; Retracted Publication
DE inflammation; Polypodium leucotomos; solar-simulated radiation;
   spectrophotometry; tanning
ID D-ALPHA-TOCOPHEROL; ASCORBIC-ACID; MELANOMA-CELLS; VITAMIN-C; IN-VIVO;
   ERYTHEMA; PIGMENTATION; TYROSINASE; LEUCOTOMOS; EXTRACT
AB Background
   The effects on the inflammatory and tanning responses of sunlight/UVR of several oral antioxidants are still unknown.
   Objective
   Assess intensity, time course of the inflammatory, and tanning responses to increasing dosages of solar-simulated radiation (SSR) at baseline and after oral supplementation of an extract of Polypodium leucotomos (PLE).
   Methods
   Ten healthy subjects underwent phototesting with SSR with a visual and spectrophotometrical assessment of the responses with or without daily oral supplementation of two tablets containing 240 mg of PLE for a total of 15 days.
   Results
   Polypodium leucotomos supplementation induced a significant increase of the minimal erythema dose (MED), a faster recovery of the inflammation following the delivery of super-erythemal doses, and no significant changes of the minimal melanogenic dose (MMD). Spectrophotometric assessment of the Delta a* in test areas exposed to equally doses of SSR did not show differences.
   Conclusions
   Polypodium leucotomos supplementation increased the MED and induced a faster recovery of the inflammation and a stronger tanning response with no changes in the melanogenic threshold.
C1 [Calzavara-Pinton, Pier Giacomo; Rossi, Maria Teresa; Zanca, Arianna; Arisi, Mariachiara; Venturini, Marina] Univ Brescia, Spedali Civili Brescia, Dept Dermatol, I-25123 Brescia, Italy.
   [Gonzalez, Salvador] Mem Sloan Kettering Canc Ctr, Dermatol Serv, 1275 York Ave, New York, NY 10021 USA.
RP Calzavara-Pinton, PG (reprint author), Univ Brescia, Dept Dermatol, Ple Spedali Civili 1, I-25123 Brescia, Italy.
EM fototerapia@spedalicivili.brescia.it
FU NCI NIH HHS [P30 CA008748]
CR Afaq F, 2003, TOXICOL APPL PHARM, V186, P28, DOI 10.1016/S0041-008X(02)00014-5
   An SM, 2008, PHYTOTHER RES, V22, P1200, DOI 10.1002/ptr.2435
   BURKE KE, 1992, NUTR CANCER, V17, P123, DOI 10.1080/01635589209514180
   Choo SJ, 2009, J PHARM PHARMACOL, V61, P663, DOI [10.1211/jpp/61.05.0016, 10.1211/jpp.61.05.0016]
   Chou TH, 2010, EXP DERMATOL, V19, P742, DOI 10.1111/j.1600-0625.2010.01091.x
   Commission Internationale de l'Eclairage (CIE), 2004, CIE PUB, V15
   Eberlein-Konig B, 1998, J AM ACAD DERMATOL, V38, P45, DOI 10.1016/S0190-9622(98)70537-7
   Elmets CA, 2001, J AM ACAD DERMATOL, V44, P425, DOI 10.1067/mjd.2001.112919
   Fullerton A, 1996, CONTACT DERMATITIS, V35, P1, DOI 10.1111/j.1600-0536.1996.tb02258.x
   Garmyn M, 1995, Exp Dermatol, V4, P104, DOI 10.1111/j.1600-0625.1995.tb00231.x
   Gonzalez S, 1997, PHOTODERMATOL PHOTO, V13, P50, DOI 10.1111/j.1600-0781.1997.tb00108.x
   Gonzalez S, 1996, PHOTODERMATOL PHOTO, V12, P45, DOI 10.1111/j.1600-0781.1996.tb00175.x
   Gonzalez S, 2011, INT J MOL SCI, V12, P8466, DOI 10.3390/ijms12128466
   Junkins-Hopkins JM, 2010, J AM ACAD DERMATOL, V62, P663, DOI 10.1016/j.jaad.2010.01.014
   Kim KS, 2006, PIGM CELL RES, V19, P90, DOI 10.1111/j.1600-0749.2005.00281.x
   Kong YH, 2008, BIOL PHARM BULL, V31, P946, DOI 10.1248/bpb.31.946
   Lee SA, 2011, ARCH DERMATOL RES, V303, P669, DOI 10.1007/s00403-011-1158-4
   MATHEWSROTH MM, 1972, J INVEST DERMATOL, V59, P349, DOI 10.1111/1523-1747.ep12627408
   McArdle F, 2002, FREE RADICAL BIO MED, V33, P1355, DOI 10.1016/S0891-5849(02)01042-0
   Middelkamp-Hup MA, 2004, J AM ACAD DERMATOL, V51, P910, DOI 10.1016/j.jaad.2004.06.027
   Middelkamp-Hup MA, 2004, J AM ACAD DERMATOL, V50, P41, DOI 10.1016/S0190-9622(03)02732-4
   Miller SA, 2008, BRIT J DERMATOL, V159, P921, DOI 10.1111/j.1365-2133.2008.08708.x
   Mireles-Rocha H, 2002, ACTA DERM-VENEREOL, V82, P21, DOI 10.1080/000155502753600830
   Nagata H, 2004, PIGM CELL RES, V17, P66, DOI 10.1046/j.1600-0749.2003.00113.x
   Ohguchi K, 2006, BIOSCI BIOTECH BIOCH, V70, P1499, DOI 10.1271/bbb.50635
   Panich U, 2011, ARCH PHARM RES, V34, P811, DOI 10.1007/s12272-011-0515-3
   Saija A, 2000, INT J PHARM, V199, P39, DOI 10.1016/S0378-5173(00)00358-6
   Shoji T, 2005, J AGR FOOD CHEM, V53, P6105, DOI 10.1021/jf050418m
   Stahl W, 2000, AM J CLIN NUTR, V71, P795
   Suh KS, 2007, SKIN RES TECHNOL, V13, P360, DOI 10.1111/j.1600-0846.2007.00238.x
   Sumiyoshi M, 2009, PHYTOMEDICINE, V16, P1137, DOI 10.1016/j.phymed.2009.06.003
   Tanew A, 2012, J AM ACAD DERMATOL, V66, P58, DOI 10.1016/j.jaad.2010.09.773
   Wagner JK, 2002, PIGM CELL RES, V15, P379, DOI 10.1034/j.1600-0749.2002.02042.x
   Wei HC, 2003, J NUTR, V133, p3811S, DOI 10.1093/jn/133.11.3811S
   WOLF C, 1988, J INVEST DERMATOL, V90, P55, DOI 10.1111/1523-1747.ep12462564
   Franco DCZ, 2012, MOLECULES, V17, P11816, DOI 10.3390/molecules171011816
NR 36
TC 3
Z9 4
U1 3
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-4383
EI 1600-0781
J9 PHOTODERMATOL PHOTO
JI Photodermatol. Photoimmunol. Photomed.
PD JAN
PY 2016
VL 32
IS 1
BP 22
EP 27
DI 10.1111/phpp.12209
PG 6
WC Dermatology
SC Dermatology
GA DJ6SL
UT WOS:000374343100003
PM 26408963
DA 2018-12-27
ER

PT J
AU Loukal, K
   Benalia, L
AF Loukal, Keltoum
   Benalia, Leila
TI RETRACTED: Type-2 Fuzzy Logic Controller of a Doubly Fed Induction
   Machine (Retracted article. See art no 1876396, 2018)
SO ADVANCES IN FUZZY SYSTEMS
LA English
DT Article; Retracted Publication
ID SYSTEMS; DRIVE
AB Interval type-2 fuzzy logic controller (IT2FLC) method for controlling the speed with a direct stator flux orientation control of doubly fed induction motor (DFIM) is proposed. The fuzzy controllers have demonstrated their effectiveness in the control of nonlinear systems, and in many cases it is proved that their robustness and performance are less sensitive to parameters variation over conventional controllers. The synthesis of stabilizing control laws design based on IT2FLC is developed. A comparative analysis between type-1 fuzzy logic controller (T1FLC) and IT2FLC of the DFIM is shown. Simulation results show the feasibility and the effectiveness of the suggested method to the control of the DFIM under different operating conditions such as load torque and in the presence of parameters variation.
C1 [Loukal, Keltoum; Benalia, Leila] Mohamed Boudiaf Univ Msila, Fac Technol, Dept Elect Engn, LGE Res Lab, BP 166, Ichbilia 28000, Msila, Algeria.
RP Loukal, K (reprint author), Mohamed Boudiaf Univ Msila, Fac Technol, Dept Elect Engn, LGE Res Lab, BP 166, Ichbilia 28000, Msila, Algeria.
EM muohtlek@yahoo.fr
CR Barkati S, 2008, ELECTR ENG, V90, P347, DOI 10.1007/s00202-007-0087-x
   Bekakra Y., 2010, ACTA ELECTROTECHNICA, V10, P75
   Ben Attous D., 2010, INT ELECT ENG INFORM, V2, P179
   Benalia Leila, 2011, Torque Control, P113
   Blaschke E., 1972, SIEMENS REV, V34, P217
   Castillo O, 2014, INFORM SCIENCES, V279, P615, DOI 10.1016/j.ins.2014.04.015
   Chaari A., 2007, INT J SCI TECHNIQUES, V1, P196
   Ezziani N., 2010, THESIS REIMS U REIMS
   Farrokh Payam A., 2010, WORLD APPL SCI J, V10, P1392
   Hagras HA, 2004, IEEE T FUZZY SYST, V12, P524, DOI 10.1109/TFUZZ.2004.832538
   Harbouche Y., 2007, ASIAN J INFORM TECHN, V6, P362
   Heber B, 1997, IEEE T POWER ELECTR, V12, P772, DOI 10.1109/63.622994
   John RI, 2007, IEEE COMPUT INTELL M, V2, P57, DOI 10.1109/MCI.2007.357194
   Liang QL, 2000, IEEE T FUZZY SYST, V8, P535, DOI 10.1109/91.873577
   Machmoum M., 2003, GE44 POLYTECHNIC I N
   Mendel J. M, 2001, UNCERTAIN RULE BASED
   Mendel JM, 2006, IEEE T FUZZY SYST, V14, P808, DOI 10.1109/TFUZZ.2006.879986
   Prescott J.C., 1958, Proceedings of the Institution of Electrical Engineers. C. Institution Monographs, V105, P319
   Salloum G., 2007, THESIS NATL POLYTECH
   Vicatos NS, 2003, IEEE T ENERGY CONVER, V18, P225, DOI 10.1109/TEC.2003.811732
   Vidal P. E., 2004, THESIS NATL POLYTECH
   ZADEH LA, 1975, INFORM SCIENCES, V8, P199, DOI 10.1016/0020-0255(75)90036-5
NR 22
TC 1
Z9 1
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-7101
EI 1687-711X
J9 ADV FUZZY SYST
JI Adv. Fuzzy Syst.
PY 2016
AR 8273019
DI 10.1155/2016/8273019
PG 10
WC Mathematics, Applied
SC Mathematics
GA DH7UQ
UT WOS:000372999700001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Singh, A
   Ahluwalia, P
   Rafiq, A
   Sharma, S
AF Singh, Arashdeep
   Ahluwalia, Preeti
   Rafiq, Aasima
   Sharma, Savita
TI RETRACTED: Biomarkers: Non-destructive Method for Predicting Meat
   Tenderization (Retracted Article)
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Correction; Retracted Publication
CR SINGH A, 2015, CRITICAL REV FOOD SC
NR 1
TC 0
Z9 0
U1 2
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8398
EI 1549-7852
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PY 2016
VL 56
IS 4
BP 710
EP 710
DI 10.1080/10408398.2015.1109378
PG 1
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA DH9OK
UT WOS:000373125300001
DA 2018-12-27
ER

PT J
AU Meulepas, JM
   Ronckers, CM
   Merks, J
   Weijerman, ME
   Lubin, JH
   Hauptmann, M
AF Meulepas, Johanna M.
   Ronckers, Cecile M.
   Merks, Johannes
   Weijerman, Michel E.
   Lubin, Jay H.
   Hauptmann, Michael
TI RETRACTED: Confounding of the Association between Radiation Exposure
   from CT Scans and Risk of Leukemia and Brain Tumors by Cancer
   Susceptibility Syndromes (Retracted article. See vol. 25, pg. 1192,
   2016)
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article; Retracted Publication
ID LARGE-SCALE COHORT; LHERMITTE-DUCLOS-DISEASE; CELL CARCINOMA SYNDROME;
   SILVER-RUSSELL-SYNDROME; HIPPEL-LINDAU-DISEASE; LI-FRAUMENI SYNDROME;
   OF-THE-LITERATURE; GENOTYPE-PHENOTYPE CORRELATIONS; FAMILIAL ADENOMATOUS
   POLYPOSIS; NEUROFIBROMATOSIS TYPE-1 NF1
AB Background: Recent studies linking radiation exposure from pediatric computed tomography (CT) to increased risks of leukemia and brain tumors lacked data to control for cancer susceptibility syndromes (CSS). These syndromes might be confounders because they are associated with an increased cancer risk and may increase the likelihood of CT scans performed in children.
   Methods: We identify CSS predisposing to leukemia and brain tumors through a systematic literature search and summarize prevalence and risk estimates. Because there is virtually no empirical evidence in published literature on patterns of CT use for most types of CSS, we estimate confounding bias of relative risks (RR) for categories of radiation exposure based on expert opinion about the current and previous patterns of CT scans among CSS patients.
   Results: We estimate that radiation-related RRs for leukemia are not meaningfully confounded by Down syndrome, Noonan syndrome, or other CSS. In contrast, RRs for brain tumors may be overestimated due to confounding by tuberous sclerosis complex (TSC) while von Hippel-Lindau disease, neurofibromatosis type 1, or other CSS do not meaningfully confound. Empirical data on the use of CT scans among CSS patients are urgently needed.
   Conclusions: Our assessment indicates that associations with leukemia reported in previous studies are unlikely to be substantially confounded by unmeasured CSS, whereas brain tumor risks might have been overestimated due to confounding by TSC.
   Impact: Future studies should identify TSC patients in order to avoid overestimation of brain tumor risks due to radiation exposure from CT scans. (C) 2015 AACR.
C1 [Meulepas, Johanna M.; Hauptmann, Michael] Netherlands Canc Inst, Dept Epidemiol & Biostat, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
   [Ronckers, Cecile M.; Merks, Johannes] Emma Childrens Hosp, Acad Med Ctr, Dept Paediat Oncol, Amsterdam, Netherlands.
   [Weijerman, Michel E.] Vrije Univ Amsterdam, Dept Paediat, Med Ctr, Amsterdam, Netherlands.
   [Lubin, Jay H.] NIH, Dept Hlth & Human Serv, Bldg 10, Bethesda, MD 20892 USA.
RP Hauptmann, M (reprint author), Netherlands Canc Inst, Dept Epidemiol & Biostat, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.
EM m.hauptmann@nki.nl
OI Hauptmann, Michael/0000-0001-8539-0148
FU European Community Seventh Framework Programme [269912-EPI-CT];
   Worldwide Cancer Research [12-1155]; Intramural Research Program of the
   NCI, NIH, Department of Health and Human Services; Dutch Cancer Society
FX This work was supported by the European Community Seventh Framework
   Programme (grant number FP7/2007-2013) under Grant Agreement Number
   269912-EPI-CT: "Epidemiological study to quantify risks for paediatric
   computerized tomography and to optimize doses" and by Worldwide Cancer
   Research formerly known as Association for International Cancer Research
   (AICR; grant number 12-1155). Dr. J.H. Lubin is supported by the
   Intramural Research Program of the NCI, NIH, Department of Health and
   Human Services. Dr. C.M. Ronckers is supported by the Dutch Cancer
   Society.
CR Abu-Amero S, 2008, J MED GENET, V45, P193, DOI 10.1136/jmg.2007.053017
   Adriaensen MEAPM, 2009, EUR J NEUROL, V16, P691, DOI 10.1111/j.1468-1331.2009.02567.x
   Alter BP, 2003, CANCER-AM CANCER SOC, V97, P425, DOI 10.1002/cncr.11046
   Asthagiri AR, 2009, LANCET, V373, P1974, DOI 10.1016/S0140-6736(09)60259-2
   Atahan IL, 1998, PEDIATR HEMAT ONCOL, V15, P187, DOI 10.3109/08880019809167234
   Attard TM, 2007, CANCER, V109, P761, DOI 10.1002/cncr.22475
   Axelson O, 1976, SCAND J WORK ENV HEA, V4, P98
   Bakhshi S, 2003, J PEDIAT HEMATOL ONC, V25, P248, DOI 10.1097/00043426-200303000-00013
   Baser ME, 2004, AM J HUM GENET, V75, P231, DOI 10.1086/422700
   Berlin AL, 2002, J AM ACAD DERMATOL, V47, P169, DOI 10.1067/mjd.2002.125949
   BILIR BM, 1990, AM J MED GENET, P69
   Birch JM, 2001, ONCOGENE, V20, P4621, DOI 10.1038/sj.onc.1204621
   Boice J. D. Jr., 2015, Annals of the ICRP, V44, P236, DOI 10.1177/0146645315575877
   de Basea MB, 2015, J RADIOL PROT, V35, P611, DOI 10.1088/0952-4746/35/3/611
   Burd L, 2004, PEDIAT BLOOD CANC, V61, P768
   Cardis E, 2015, BRIT J CANCER, V112, P1842, DOI 10.1038/bjc.2015.155
   CHOYKE PL, 1995, RADIOLOGY, V194, P629, DOI 10.1148/radiology.194.3.7862955
   Christoforidis A, 2005, J PEDIATR ENDOCR MET, V18, P651
   Chrzanowska KH, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-13
   Comi Anne M., 2007, Lymphatic Research and Biology, V5, P257, DOI 10.1089/lrb.2007.1016
   Cowan R, 1997, BRIT J CANCER, V76, P141, DOI 10.1038/bjc.1997.354
   Crawford TO, 2006, ARCH DIS CHILD, V91, P610
   Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9
   Derrey S, 2004, SURG NEUROL, V61, P447, DOI 10.1016/S0090-3019(03)00576-7
   Distel L, 2003, MED PEDIATR ONCOL, V41, P44, DOI 10.1002/mpo.10275
   DRAZNIN MB, 1980, J PEDIATR-US, V96, P887, DOI 10.1016/S0022-3476(80)80570-1
   ENG C, 1994, J MED GENET, V31, P458, DOI 10.1136/jmg.31.6.458
   Evans DG, 2010, AM J MED GENET A, V152A, P327, DOI 10.1002/ajmg.a.33139
   Evans DGR, 2005, J MED GENET, V42, P630, DOI 10.1136/jmg.2004.027953
   EVANS DGR, 1992, Q J MED, V84, P603
   Fenton E, 2008, BRIT J NEUROSURG, V22, P776, DOI 10.1080/02688690802044076
   Fickie MR, 2011, AM J MED GENET A, V155A, P2105, DOI 10.1002/ajmg.a.34156
   Fisher LM, 2007, OTOL NEUROTOL, V28, P1083, DOI 10.1097/MAO.0b013e31815a8411
   Freeman SB, 1998, AM J MED GENET, V80, P213, DOI 10.1002/(SICI)1096-8628(19981116)80:3<213::AID-AJMG6>3.3.CO;2-#
   Fukushima Y, 2004, NEUROL MED-CHIR, V44, P665, DOI 10.2176/nmc.44.665
   GARBER JE, 1991, CANCER RES, V51, P6094
   Gonzalez KD, 2009, J CLIN ONCOL, V27, P1250, DOI 10.1200/JCO.2008.16.6959
   GROOTLOONEN JJ, 1988, PEDIATR HEMAT ONCOL, V5, P287, DOI 10.3109/08880018809037368
   Guillamo JS, 2003, BRAIN, V126, P152, DOI 10.1093/brain/awg016
   Gutmann DH, 2002, NEUROLOGY, V59, P759, DOI 10.1212/WNL.59.5.759
   Hale NE, 2010, J AM OSTEOPATH ASSOC, V110, P21
   HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302
   Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2
   Hauptmann M, 2012, LANCET, V380, P1736, DOI 10.1016/S0140-6736(12)61983-7
   HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S
   Hennekam RCM, 2006, EUR J HUM GENET, V14, P981, DOI 10.1038/sj.ejhg.5201594
   HENNEKAM RCM, 1990, AM J MED GENET, P17
   HERSH JH, 1992, J PEDIATR-US, V120, P572, DOI 10.1016/S0022-3476(10)80004-6
   Hiel JA, 2000, ARCH DIS CHILD, V82, P400
   Hirsch B, 2004, BLOOD, V103, P2554, DOI 10.1182/blood-2003-06-1970
   Huang WY, 2014, BRIT J CANCER, V110, P2354, DOI 10.1038/bjc.2014.103
   Huber Rebekah S, 2011, J Clin Med Res, V3, P147, DOI 10.4021/jocmr581w
   HUSON SM, 1989, J MED GENET, V26, P704, DOI 10.1136/jmg.26.11.704
   Jeong Tae-Seok, 2014, Brain Tumor Res Treat, V2, P36, DOI 10.14791/btrt.2014.2.1.36
   Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590
   JONAS DM, 1978, J PEDIATR-US, V92, P851, DOI 10.1016/S0022-3476(78)80178-4
   Jongmans MCJ, 2011, EUR J HUM GENET, V19, P870, DOI 10.1038/ejhg.2011.37
   Journy N, 2015, BRIT J CANCER, V112, P1843, DOI 10.1038/bjc.2015.105
   Journy N, 2015, BRIT J CANCER, V112, P185, DOI 10.1038/bjc.2014.526
   KIESS W, 1984, EUR J PEDIATR, V143, P160, DOI 10.1007/BF00445810
   Kleijer WJ, 2008, DNA REPAIR, V7, P744, DOI 10.1016/j.dnarep.2008.01.014
   Korczak JF, 1997, AM J MED GENET, V69, P309, DOI 10.1002/(SICI)1096-8628(19970331)69:3<309::AID-AJMG17>3.0.CO;2-V
   KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018
   KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241
   Kratz CP, 2015, BRIT J CANCER, V112, P1392, DOI 10.1038/bjc.2015.75
   Krille L, 2015, RADIAT ENVIRON BIOPH, V54, P1, DOI 10.1007/s00411-014-0580-3
   Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170
   LACOMBE D, 1990, Genetic Counseling, V1, P273
   Lai Jin-Ping, 2013, Acta Neuropathol Commun, V1, P4, DOI 10.1186/2051-5960-1-4
   Lash TL, 2009, STAT BIOL HLTH
   Lauper JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059709
   Lehmann AR, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-70
   LINDBOE CF, 1995, CLIN NEUROPATHOL, V14, P327
   Lindor Noralane M, 2008, J Natl Cancer Inst Monogr, P1, DOI 10.1093/jncimonographs/lgn001
   LISTERNICK R, 1994, J PEDIATR-US, V125, P63, DOI 10.1016/S0022-3476(94)70122-9
   Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4
   Lonser RR, 2014, J NEUROSURG, V120, P1055, DOI 10.3171/2014.1.JNS131431
   Maher ER, 2011, EUR J HUM GENET, V19, P617, DOI 10.1038/ejhg.2010.175
   Maisonneuve P, 2013, JNCI-J NATL CANCER I, V105, P122, DOI 10.1093/jnci/djs481
   Makita Y, 2007, J PEDIAT HEMATOL ONC, V29, P287, DOI 10.1097/MPH.0b013e3180547136
   Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360
   Mautner VF, 1996, AM J ROENTGENOL, V166, P1231, DOI 10.2214/ajr.166.5.8615282
   McBride KA, 2014, NAT REV CLIN ONCOL, V11, P260, DOI 10.1038/nrclinonc.2014.41
   Merks JHM, 2012, PEDIATR ONCOL-BERLIN, P69, DOI 10.1007/978-3-642-04197-6_6
   Meulepas JM, 2014, EUR J EPIDEMIOL, V29, P293, DOI 10.1007/s10654-014-9900-9
   Mezei G, 2014, CANCER EPIDEMIOL, V38, P479, DOI 10.1016/j.canep.2014.07.006
   Michallet AS, 2003, ANN HEMATOL, V82, P515, DOI 10.1007/s00277-003-0697-y
   Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311
   Minic S, 2010, J CLIN PATHOL, V63, P657, DOI 10.1136/jcp.2009.074203
   Muirhead CR, 2015, BRIT J CANCER, V112, P1841, DOI 10.1038/bjc.2015.106
   National Institute for Public Health and the Environment (RIVM), 6100030012013 RIVM
   NCRP, 2012, 171 NCRP
   Nelen MR, 1999, EUR J HUM GENET, V7, P267, DOI 10.1038/sj.ejhg.5200289
   O'Callaghan FJK, 1998, LANCET, V351, P1490, DOI 10.1016/S0140-6736(05)78872-3
   Omar AO, 2009, AM J MED GENET A, V149A, P1056, DOI 10.1002/ajmg.a.32648
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087
   Otsuka G, 2003, J NEUROSURG, V99, P480, DOI 10.3171/jns.2003.99.3.0480
   Pagon RA, 1993, GENEREVIEWS
   PARRY DM, 1994, AM J MED GENET, V52, P450, DOI 10.1002/ajmg.1320520411
   Pascual-Castroviejo I, 2008, CAN J NEUROL SCI, V35, P301, DOI 10.1017/S0317167100008878
   Pascual-Castroviejo I, 2010, CHILD NERV SYST, V26, P1599, DOI 10.1007/s00381-010-1163-5
   Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0
   Peroos S, 2012, BMJ CASE REP, V2012
   Pier DB, 2014, EUR J MED GENET, V57, P269, DOI 10.1016/j.ejmg.2014.03.005
   Pilarski R, 2009, J GENET COUNS, V18, P13, DOI 10.1007/s10897-008-9187-7
   Poole C, 2006, INT J EPIDEMIOL, V35, P370, DOI 10.1093/ije/dyi248
   Proesmans M, 2008, EUR J PEDIATR, V167, P839, DOI 10.1007/s00431-008-0693-2
   Radhakrishnan R, 2014, PEDIATR RADIOL, V44, P506, DOI 10.1007/s00247-013-2859-y
   Rasmussen SA, 2001, AM J HUM GENET, V68, P1110, DOI 10.1086/320121
   Ratjen F, 2003, LANCET, V361, P681, DOI 10.1016/S0140-6736(03)12567-6
   Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947
   Resnick IB, 2002, J PEDIATR-US, V140, P355, DOI 10.1067/mpd.2002.122724
   RIVERA R, 1975, SOUTHERN MED J, V68, P1391, DOI 10.1097/00007611-197511000-00017
   Roach ES, 1999, J CHILD NEUROL, V14, P401, DOI 10.1177/088307389901400610
   Roberts A, 2006, J MED GENET, V43, P833, DOI 10.1136/jmg.2006.042796
   Rodriguez FJ, 2008, J NEUROPATH EXP NEUR, V67, P240, DOI 10.1097/NEN.0b013e318165eb75
   Rosenberg PS, 2008, BRIT J HAEMATOL, V140, P210, DOI 10.1111/j.1365-2141.2007.06897.x
   Rosenberg PS, 2003, BLOOD, V101, P822, DOI 10.1182/blood-2002-05-1498
   Roth J, 2013, PEDIATR NEUROL, V49, P439, DOI 10.1016/j.pediatrneurol.2013.08.017
   Ruijs MWG, 2010, J MED GENET, V47, P421, DOI 10.1136/jmg.2009.073429
   Schoemaker MJ, 2008, LANCET ONCOL, V9, P239, DOI 10.1016/S1470-2045(08)70033-0
   SHARLAND M, 1992, ARCH DIS CHILD, V67, P178, DOI 10.1136/adc.67.2.178
   Shaw AC, 2007, ARCH DIS CHILD, V92, P128, DOI 10.1136/adc.2006.104547
   SHEPHERD CW, 1991, MAYO CLIN PROC, V66, P792, DOI 10.1016/S0025-6196(12)61196-3
   Smucker PS, 2006, J NEUROSURG, V105, P315, DOI 10.3171/ped.2006.105.4.315
   Springett AL, 2014, J MED SCREEN, V21, P113, DOI 10.1177/0969141314543128
   Stiehm ER, 2005, PEDIATR RES, V57, P458, DOI 10.1203/01.PDR.0000151692.05422.4C
   STREISSGUTH AP, 1991, JAMA-J AM MED ASSOC, V265, P1961, DOI 10.1001/jama.265.15.1961
   Suarez F, 2015, J CLIN ONCOL, V33, P202, DOI 10.1200/JCO.2014.56.5101
   Sun Y, 2014, CANCER EPIDEMIOL, V38, P393, DOI 10.1016/j.canep.2014.04.001
   Taylor AMR, 1996, BLOOD, V87, P423
   Thomas-Sohl KA, 2004, PEDIATR NEUROL, V30, P303, DOI 10.1016/j.pediatrneurol.2003.12.015
   Traubici J, 2001, RADIOLOGY, V220, P463, DOI 10.1148/radiology.220.2.r01au11463
   Tseng BS, 2004, PEDIAT ONCOL, P183
   Tsukahara M, 1996, AM J MED GENET, V63, P277
   United Nations Scientific Committee on the Effects of Atomic Radiation UNSCEAR, 2006, EFF ION RAD REP GEN
   Vajdic CM, 2010, BLOOD, V116, P1228, DOI 10.1182/blood-2010-03-272351
   Van den Berg H, 1999, J MED GENET, V36, P799, DOI 10.1136/jmg.36.10.799
   Vasen HFA, 2001, GUT, V49, P231, DOI 10.1136/gut.49.2.231
   VINCHON M, 1994, J NEUROL NEUROSUR PS, V57, P699, DOI 10.1136/jnnp.57.6.699
   Walsh L, 2013, RE CANC RISK 680000
   Walsh L, 2014, J RADIOL PROT, V34, pE1, DOI 10.1088/0952-4746/34/1/E1
   Weijerman ME, 2008, J PEDIATR, V152, P15, DOI 10.1016/j.jpeds.2007.09.045
   Wilding A, 2012, J MED GENET, V49, P264, DOI 10.1136/jmedgenet-2011-100562
   Wimmer K, 2008, HUM GENET, V124, P105, DOI 10.1007/s00439-008-0542-4
   Wimmer K, 2010, HAEMATOL-HEMATOL J, V95, P699, DOI 10.3324/haematol.2009.021626
   Yang QH, 2002, LANCET, V359, P1019, DOI 10.1016/S0140-6736(02)08092-3
   Zopf DA, 2012, LANCET, V380, P1735, DOI 10.1016/S0140-6736(12)61982-5
NR 148
TC 2
Z9 2
U1 3
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JAN
PY 2016
VL 25
IS 1
BP 114
EP 126
DI 10.1158/1055-9965.EPI-15-0636
PG 13
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA DG6DC
UT WOS:000372171400015
PM 26598533
OA Bronze
DA 2018-12-27
ER

PT J
AU Kong, FL
   Zheng, F
   Hu, K
   Zhao, HY
   Fong, GL
   Fang, XY
   Luo, Y
AF Kong, Fanli
   Zheng, Fong
   Hu, Kang
   Zhao, Hongyuan
   Fong, Guoli
   Fang, Xiaoyu
   Luo, Yi
TI RETRACTED: Expression of miR-106a in thyroid carcinoma and its effect on
   the proliferation and invasion of thyroid cancer cell line SW579 by
   targeting CDH1(Retracted article. See vol.10, pg.8097, 2017)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE miR-106a; papillary thyroid carcinoma; E-cadherin in 1 (CDH1);
   proliferation; invasion and metastasis
ID EPITHELIAL-MESENCHYMAL TRANSITION; LUNG-CANCER; DIFFERENTIAL EXPRESSION;
   COLORECTAL-CANCER; MICRORNA; GROWTH; METASTASIS
AB Background: To investigate the expression of miR-106a in thyroid cancer and its effect on the proliferation, metastasis and invasion of thyroid cancer by targeting epithelial cadherin 1 (CDH1). Methods: Real-time quantitative reverse transcription polymer chain reaction (RT-qPCR) was used to quantify the expression of miR-106a in human papillary thyroid carcinoma (PTC) tissues and adjacent normal tissues. miR-106a inhibitor and miR-106a NC were transfected into human thyroid cancer cell line SW579 using Lipofectamine (TM) 2000 to assess their effect on cell viability and apoptosis using the MTT method and flow cytometry after Annexin V/PI double staining. The invasion ability was assayed with the Transwell method. The expression of CDH1 at protein and mRNA levels was analyzed using Western blot and RT-qPCR and confirmed using dual luciferase reporter assay. Finally, CDH1 low expression vector (siRNA-CDH1) were transfected into SW579 cells together with miR-106a inhibitor. The transfected cells were examined for apoptosis and invasion ability, as well as the expression of Snail, E-cadherin, Vimentin, retinal glioblastoma gene (Rb1) and transcriptional factor E2F1. Results: The expression of miR-106a in PTC tissues was higher than that in adjacent normal tissues (P<0.01). miR-106a inhibitor significantly reduced the viability and invasion ability of SW579 cells (P<0.01), increased apoptosis (P<0.01), and down regulated the expression of CDH1 at protein and mRNA levels (P<0.01). The luciferase reporter assay confirmed that CDH1 was a downstream target gene of miR-106a. Co-transfection of SW579 cells with SiRNA-CDH1 and miR-106a inhibitor significantly offset the inhibitory effect of the miR-106a inhibitor on the proliferation and invasion of SW579 cells (P<0.01), and the induction of apoptosis (P<0.01). These effects may result from up-regulated expression of E2F1, Snail and Vimentin (P<0.01), and down-regulated expression of Rb1 and E-cadherin (P<0.01). Conclusion: miR-106a is highly expressed in PTC. Down-regulation of its expression results in targeted up-regulation of CDH1, thus inhibiting the proliferation and invasion ability of SW579 cells. This process is likely mediated by up-regulation of Rb1 and E-cadherin expression and down-regulation of Snail and E2F1 and Vimentin expression.
C1 [Kong, Fanli; Zheng, Fong; Hu, Kang; Zhao, Hongyuan; Fong, Guoli; Fang, Xiaoyu; Luo, Yi] Zunyi Med Coll, Affiliated Hosp, Dept Thyroid Gland Surg, 149 Dalian Rd, Zunyi 563003, Guizhou, Peoples R China.
RP Kong, FL (reprint author), Zunyi Med Coll, Affiliated Hosp, Dept Thyroid Gland Surg, 149 Dalian Rd, Zunyi 563003, Guizhou, Peoples R China.
EM kongfanli761@163.com
CR Buehler D, 2013, MODERN PATHOL, V26, P54, DOI 10.1038/modpathol.2012.137
   Campenni A, 2015, HORM-INT J ENDOCRINO, V14, P451, DOI 10.14310/horm.2002.1606
   Conzo G, 2013, CLIN TER, V164, pE343, DOI 10.7417/CT.2013.1599
   Granata R, 2013, CURR OPIN ONCOL, V25, P224, DOI 10.1097/CCO.0b013e32835ff44b
   Guo JM, 2009, J GASTROEN HEPATOL, V24, P652, DOI 10.1111/j.1440-1746.2008.05666.x
   Halimulati M, 2012, CHINA ONCOLOGY, V22, P629
   Ivkovic TC, 2013, EXP MOL PATHOL, V94, P148, DOI 10.1016/j.yexmp.2012.11.002
   Jiang YG, 2011, TOXICOL SCI, V119, P50, DOI 10.1093/toxsci/kfq306
   Li P, 2013, J OPHTHALMOL, DOI 10.1155/2013/869101
   Liao L, 2011, CHINESE J PATHOPHYSI, V27, P1885
   Link A, 2010, CANCER EPIDEM BIOMAR, V19, P1766, DOI 10.1158/1055-9965.EPI-10-0027
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Ogunwobi OO, 2012, CRIT REV ONCOL HEMAT, V83, P319, DOI 10.1016/j.critrevonc.2011.11.007
   Palm T, 2013, NUCLEIC ACIDS RES, V41, P3699, DOI 10.1093/nar/gkt070
   Qiu ZL, 2015, NUCL MED BIOL, V42, P499, DOI 10.1016/j.nucmedbio.2015.01.009
   Reddy KB, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0185-1
   Shang Chao, 2014, Journal of China Medical University, V43, P106
   Wang HW, 2015, FEBS LETT, V589, P805, DOI 10.1016/j.febslet.2015.02.013
   Wang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125473
   Wang YX, 2012, ENDOCRINE, V41, P526, DOI 10.1007/s12020-011-9582-y
   Xie X, 2015, INT J CLIN EXP PATHO, V8, P3827
   [邢细红 Xing Xihong], 2012, [重庆医学, Chongqing Medicine], V41, P1818
   Xu W, 2015, INT J CLIN EXP PATHO, V8, P3864
   Xu XH, 2012, BIOCHEM BIOPH RES CO, V421, P640, DOI 10.1016/j.bbrc.2012.03.048
   Yang G, 2011, J MOL MED, V89, P1037, DOI 10.1007/s00109-011-0775-x
   Yang JD, 2011, SEMIN CANCER BIOL, V21, P35, DOI 10.1016/j.semcancer.2010.10.007
   Ye J, 2012, MOL MED REP, V6, P507, DOI 10.3892/mmr.2012.938
   Zhang XH, 2014, DRUG DEVELOP RES, V75, P195, DOI 10.1002/ddr.21170
NR 29
TC 1
Z9 1
U1 1
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 2
BP 521
EP 530
PG 10
WC Oncology; Pathology
SC Oncology; Pathology
GA DG1EU
UT WOS:000371809200009
DA 2018-12-27
ER

PT J
AU Tajima, S
   Koda, K
AF Tajima, Shogo
   Koda, Kenji
TI RETRACTED: Apocrine-differentiated cells are likely to express uroplakin
   II(Retracted article. See vol.10, pg.8095, 2017)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE Uroplakin II; breast; apocrine differentiation; invasive pleomorphic
   lobular carcinoma; apocrine carcinoma
ID PLEOMORPHIC LOBULAR CARCINOMA; UROTHELIAL CARCINOMA; BREAST; BLADDER;
   ADENOCARCINOMA; BIOMARKERS; FEATURES; MARKERS; DISEASE
AB Uroplakin II antibody is exclusively specific for urothelial carcinoma. Non-urothelial carcinoma has not been reported to be immunoreactive for uroplakin II. In the present study, we hypothesized that breast carcinoma showing apocrine differentiation, such as invasive pleomorphic lobular carcinoma (IPLC) and apocrine carcinoma (AC), stains positive for Uroplakin II. We identified 6 cases of IPLC between 2000 and 2014 by searching a computerized pathological database. We randomly selected 10 cases of each classic invasive lobular carcinoma (cILC) and AC, and five cases of apocrine metaplasia (AM) that coexisted in surgically resected breast carcinoma specimen. Immunohistochemistry was performed for Uroplakin II, GATA3, CK7, CK20, and other representative markers positive for urothelial carcinoma. All cases of IPLC, AC, and AM, except those of cILC, showed immunoreactivity for Uroplakin II. Poorly differentiated urothelial carcinoma sometimes shows similar morphology to IPLC with the immunophenotype: CK7+, CK20-, GATA3+, Uroplakin II+. In the present study, this immunophenotype was observed in all the cases of IPLC and AC. Therefore, when studying metastatic, poorly differentiated carcinoma showing the aforementioned immunophenotype, we should consider the possibility of it being IPLC in addition to metastatic urothelial carcinoma.
C1 [Tajima, Shogo; Koda, Kenji] Fujieda Municipal Gen Hosp, Dept Pathol, 4-1-11 Surugadai, Fujieda, Shizuoka 4268677, Japan.
RP Tajima, S (reprint author), Fujieda Municipal Gen Hosp, Dept Pathol, 4-1-11 Surugadai, Fujieda, Shizuoka 4268677, Japan.
EM stajima-tky@umin.ac.jp
CR Bentz JS, 1998, MODERN PATHOL, V11, P814
   Butler D, 2013, ARCH PATHOL LAB MED, V137, P1688, DOI 10.5858/arpa.2012-0603-RS
   Clark BZ, 2014, AM J CLIN PATHOL, V142, P64, DOI 10.1309/AJCP8H2VBDSCIOBF
   EUSEBI V, 1992, HUM PATHOL, V23, P655, DOI 10.1016/0046-8177(92)90321-S
   Hoang LL, 2015, APPL IMMUNOHISTO M M, V23, P711, DOI 10.1097/PAI.0000000000000143
   Hoang LL, 2014, ARCH PATHOL LAB MED, V138, P943, DOI 10.5858/arpa.2013-0221-OA
   Jacobs M, 2012, ANN DIAGN PATHOL, V16, P185, DOI 10.1016/j.anndiagpath.2011.10.001
   Longatto A, 1997, ACTA CYTOL, V41, P961, DOI 10.1159/000332774
   MAZOUJIAN G, 1983, AM J PATHOL, V110, P105
   Mohanty SK, 2014, AM J CLIN PATHOL, V142, P173, DOI 10.1309/AJCPK1OV6IMNPFGL
   Paner GP, 2014, HUM PATHOL, V45, P1473, DOI 10.1016/j.humpath.2014.02.024
   Smith SC, 2014, HISTOPATHOLOGY, V65, P132, DOI 10.1111/his.12360
   Sun Wei, 2004, Ann Diagn Pathol, V8, P17, DOI 10.1016/j.anndiagpath.2003.11.007
   Tian W, 2015, HUM PATHOL, V46, P58, DOI 10.1016/j.humpath.2014.09.007
   Tot T, 2002, EUR J CANCER, V38, P758, DOI 10.1016/S0959-8049(02)00008-4
   Vargas AC, 2009, FUTURE ONCOL, V5, P233, DOI 10.2217/14796694.5.2.233
   Wu XR, 2009, KIDNEY INT, V75, P1153, DOI 10.1038/ki.2009.73
NR 17
TC 1
Z9 1
U1 1
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 2
BP 1933
EP 1939
PG 7
WC Oncology; Pathology
SC Oncology; Pathology
GA DG1EU
UT WOS:000371809200165
DA 2018-12-27
ER

PT J
AU Issa, HM
AF Issa, Hayder Mohammed
TI RETRACTED: Power Consumption, Mixing Time, and Oxygen Mass Transfer in a
   Gas-Liquid Contactor Stirred with a Dual Impeller for Different
   Spacing(Retracted article. See Artn no.3906268, 2017)
SO JOURNAL OF ENGINEERING
LA English
DT Article; Retracted Publication
ID HOLD-UP; TRANSFER COEFFICIENT; TURBINE IMPELLERS; RUSHTON TURBINES;
   AERATION SYSTEM; AGITATED TANK; PITCHED BLADE; BUBBLE-SIZE; VESSELS;
   MULTIPLE
AB Multiple or dual impellers are widely implemented in stirred contactors used in various biological processes like fermentation, water treatment, and pharmaceutical production. The spacing between impellers is considered as a crucial factor in designing of these types of contactors resulting in variation of oxygen mass transfer, mixing time, or power consumption for such biological system. A study of three parts was conducted to characterize the effect of the spacing between impellers on the most important parameters that related to biological contactor performance: oxygen mass transfer coefficient k(i)a from the gas phase (air) to the liquid phase (water), mixing time, and power consumption for different operating rotational speeds (1.67-3.33 rps) and for three different spacing positions. The used impellers systemin the study is a dual impeller system which consists of an inverted and bladed rotated cone (IBRC) and a pitched-blade up-flow propeller (PBPU). The experimental results showed that the shorter spacing (the lower PBPU in a higher position) is more convenient, as the achieved oxygen mass transfer coefficient has showed an improvement in its values with lower mixing time and with a slight alteration in power consumption.
C1 [Issa, Hayder Mohammed] Salahaddin Univ Erbil, Coll Engn, Erbil, Iraq.
RP Issa, HM (reprint author), Salahaddin Univ Erbil, Coll Engn, Erbil, Iraq.
EM hayder.issa@su.edu.krd
CR Adachi T, 2015, CHEM ENG SCI, V126, P625, DOI 10.1016/j.ces.2015.01.009
   Albaek MO, 2008, CHEM ENG SCI, V63, P5813, DOI 10.1016/j.ces.2008.08.024
   Arjunwadkar SJ, 1998, BIOCHEM ENG J, V1, P99, DOI 10.1016/S1385-8947(97)00083-1
   Azzopardi BJ, 2011, HYDRODYNAMICS OF GAS-LIQUID REACTORS: NORMAL OPERATION AND UPSET CONDITIONS, P1, DOI 10.1002/9781119970712
   Bao YY, 2012, IND ENG CHEM RES, V51, P12411, DOI 10.1021/ie301150b
   Bouaifi M, 2001, CHEM ENG PROCESS, V40, P97, DOI 10.1016/S0255-2701(00)00129-X
   Broniarz-Press L., 2007, P EUR C CHEM ENG ECC, P1
   Capela S, 2004, WATER ENVIRON RES, V76, P183, DOI 10.2175/106143004X141726
   Chapple D, 2002, CHEM ENG RES DES, V80, P364, DOI 10.1205/026387602317446407
   Chern JM, 2003, IND ENG CHEM RES, V42, P6653, DOI 10.1021/ie030396y
   Gabelle JC, 2011, CAN J CHEM ENG, V89, P1139, DOI 10.1002/cjce.20571
   Gimbun J, 2009, CHEM ENG RES DES, V87, P437, DOI 10.1016/j.cherd.2008.12.017
   Hari-Prajitno D, 1998, CAN J CHEM ENG, V76, P1056, DOI 10.1002/cjce.5450760612
   Hsu YC, 1997, J CHEM TECHNOL BIOT, V68, P222, DOI 10.1002/(SICI)1097-4660(199702)68:2<222::AID-JCTB623>3.0.CO;2-K
   HUDCOVA V, 1989, BIOTECHNOL BIOENG, V34, P617, DOI 10.1002/bit.260340506
   Issa H. -M., 2012, P 14 EUR C MIX WARS, P169
   Karimi A., 2013, INT J OCCUPATIONAL H, V5, P109
   Lines PC, 2000, CHEM ENG RES DES, V78, P342, DOI 10.1205/026387600527455
   Magelli F, 2013, CHEM ENG SCI, V101, P712, DOI 10.1016/j.ces.2013.07.022
   MAHMOUDI SM, 1992, FLUID MEC A, V10, P11
   Markopoulos J, 2004, CHEM ENG TECHNOL, V27, P1212, DOI 10.1002/ceat.200402129
   Mavros P, 2001, CHEM ENG RES DES, V79, P113, DOI 10.1205/02638760151095926
   MERCHUK JC, 1990, BIOTECHNOL BIOENG, V35, P1161, DOI 10.1002/bit.260351113
   Montante G, 2004, CHEM ENG RES DES, V82, P1179, DOI 10.1205/cerd.82.9.1179.44163
   Montante G, 2010, IND ENG CHEM RES, V49, P2613, DOI 10.1021/ie9006276
   Moucha T, 2003, CHEM ENG SCI, V58, P1839, DOI 10.1016/S0009-2509(02)00682-6
   MUELLER JA, 1967, APPL MICROBIOL, V15, P674
   Patwardhan AW, 1999, IND ENG CHEM RES, V38, P49, DOI 10.1021/ie970504e
   Puthli MS, 2005, BIOCHEM ENG J, V23, P25, DOI 10.1016/j.bej.2004.10.006
   Sardeing R, 2005, CHEM ENG TECHNOL, V28, P587, DOI 10.1002/ceat.200500043
   Shao XM, 2003, CAN J CHEM ENG, V81, P1239
   Shewale SD, 2006, CHEM ENG SCI, V61, P489, DOI 10.1016/j.ces.2005.04.078
   Vasconcelos JMT, 2000, IND ENG CHEM RES, V39, P203, DOI 10.1021/ie9904145
   Xie MH, 2014, IND ENG CHEM RES, V53, P5941, DOI 10.1021/ie400831s
   Yapici K, 2008, CHEM ENG PROCESS, V47, P1346, DOI 10.1016/j.cep.2007.05.002
   You ST, 2014, REV CHEM ENG, V30, P323, DOI 10.1515/revce-2013-0028
NR 36
TC 4
Z9 4
U1 0
U2 22
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-4912
EI 2314-4904
J9 J ENG
JI J. Eng.
PY 2016
AR UNSP 3954305
DI 10.1155/2016/3954305
PG 7
WC Engineering, Multidisciplinary
SC Engineering
GA DF8DI
UT WOS:000371586900001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Liu, J
   Mao, Y
   Zhang, DK
   Hao, SN
   Zhang, ZC
   Li, ZJ
   Li, BS
AF Liu, Jia
   Mao, Yu
   Zhang, Dakai
   Hao, Shengnan
   Zhang, Zicheng
   Li, Zhenjiang
   Li, Baosheng
TI RETRACTED: MiR-143 inhibits tumor cell proliferation and invasion by
   targeting STAT3 in esophageal squamous cell carcinoma (Retracted
   article. See vol. 422, pg. 133, 2018)
SO CANCER LETTERS
LA English
DT Article; Retracted Publication
DE miR-143; Esophageal squamous cell carcinoma; STAT3; Progression
ID EPITHELIAL-MESENCHYMAL TRANSITION; LYMPH-NODE METASTASIS; GASTRIC-CANCER
   CELLS; CERVICAL-CANCER; MICRORNA EXPRESSION; SIGNALING PATHWAYS;
   GENE-EXPRESSION; BREAST-CANCER; GROWTH; APOPTOSIS
AB Although increasing evidence shows that miR-143 could act as a tumor suppressor in several cancers, little is known about the role of miR-143 in human esophageal squamous cell carcinoma (ESCC). In the present study, we found that the expression level of miR-143 is significantly reduced in clinical ESCC tissues compared with normal tissues and is correlated with lymph node metastasis (LNM), invasion and TNM stage groups. Kaplan-Meier analysis shows that miR-143 expression predicts a favorable outcome for ESCC patients. Functional experiments show that overexpression of miR-143 inhibits cell proliferation blocks the G1/S phase transition, and suppresses cell migration and invasion in vitro and in vivo. Dual luciferase assays reveal that STAT3 is a direct target gene of miR-143. Moreover, the restored expression of STAT3 protein in miR-143-overexpressing cells attenuated the suppressive effects of miR-143 on ESCC cells. Further studies verified that miR-143 repressed cell cycle and epithelial-mesenchymal transition (EMT) signaling pathways by targeting STAT3, resulting in suppressing ESCC cell proliferation, migration and invasion. We are the first to report the interaction between miR-143 and STAT3 in ESCC and in this study provide new insights into the role of miR-143 in the development of ESCC, and also implicate the potential application of miR-143 in cancer therapy. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Liu, Jia; Zhang, Dakai] Univ Jinan, Shandong Acad Med Sci, Sch Med & Life Sci, Jinan, Peoples R China.
   [Liu, Jia; Mao, Yu; Zhang, Dakai; Zhang, Zicheng; Li, Zhenjiang; Li, Baosheng] Shandong Acad Med Sci, Shandong Canc Hosp, Shandongs Key Lab Radiat Oncol, Dept Radiat Oncol,Chest Sect, Jinan 250117, Peoples R China.
   [Mao, Yu] Tianjin Med Univ, Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.
   [Mao, Yu; Zhang, Zicheng; Li, Baosheng] Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China.
   [Hao, Shengnan] Shandong Univ, Qilu Hosp, Inst Basic Med Sci, Jinan 250100, Peoples R China.
   [Li, Zhenjiang] Southeast Univ, Lab Image Sci & Technol, Nanjing, Jiangsu, Peoples R China.
RP Li, BS (reprint author), Shandong Acad Med Sci, Shandong Canc Hosp, Shandongs Key Lab Radiat Oncol, Dept Radiat Oncol,Chest Sect, Jinan 250117, Peoples R China.; Li, BS (reprint author), Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China.
EM baoshli1963@163.com
FU National Natural Science Foundation of China [81201526]; Natural Science
   Foundation of Shandong Province, China [ZR2012HQ009]
FX This study was funded by National Natural Science Foundation of China
   (Grant No. 81201526), Natural Science Foundation of Shandong Province,
   China (Grant No. ZR2012HQ009).
CR Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054
   Akao Y, 2009, LEUKEMIA RES, V33, P1530, DOI 10.1016/j.leukres.2009.04.019
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chen YJ, 2013, J BREAST CANCER, V16, P40, DOI 10.4048/jbc.2013.16.1.40
   Cheng Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1303-0
   Deng S, 2008, CELL CYCLE, V7, P2643, DOI 10.4161/cc.7.17.6597
   Fan ZY, 2015, ONCOTARGET, V6, P25266, DOI 10.18632/oncotarget.4457
   Farha AK, 2014, CELL BIOL TOXICOL, V30, P331, DOI 10.1007/s10565-014-9288-z
   Feng MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108502
   Ghosh A, 2015, HUM PATHOL, V46, P284, DOI 10.1016/j.humpath.2014.11.003
   Grille SJ, 2003, CANCER RES, V63, P2172
   Huang J, 2014, CELL PROLIFERAT, V47, P277, DOI 10.1111/cpr.12109
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kaz AM, 2014, CANCER LETT, V342, P193, DOI 10.1016/j.canlet.2012.02.036
   Kim MJ, 2013, CANCER LETT, V335, P145, DOI 10.1016/j.canlet.2013.02.010
   Kim SM, 2014, CANCER LETT, V354, P153, DOI 10.1016/j.canlet.2014.08.002
   Lakshmanan I, 2012, ONCOGENE, V31, P805, DOI 10.1038/onc.2011.297
   Lee JH, 2014, CANCER LETT, V345, P140, DOI 10.1016/j.canlet.2013.12.008
   Liu HD, 2011, MICROVASC RES, V82, P131, DOI 10.1016/j.mvr.2011.04.011
   Liu XL, 2015, CANCER LETT, V362, P45, DOI 10.1016/j.canlet.2015.03.014
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mathe EA, 2009, CLIN CANCER RES, V15, P6192, DOI 10.1158/1078-0432.CCR-09-1467
   Mayne GC, 2013, CURR PHARM DESIGN, V19, P1211
   Ni Y, 2013, GENE, V517, P197, DOI 10.1016/j.gene.2012.12.031
   Noguchi S, 2013, CANCER LETT, V328, P353, DOI 10.1016/j.canlet.2012.10.017
   Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.3.CO;2-D
   Proietti CJ, 2011, STEROIDS, V76, P381, DOI 10.1016/j.steroids.2010.12.008
   Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166
   Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77
   Wei Z, 2013, CELL SIGNAL, V25, P931, DOI 10.1016/j.cellsig.2013.01.011
   Wu Y, 2015, CANCER LETT, V356, P646, DOI 10.1016/j.canlet.2014.10.013
   Wu ZL, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-31
   Xu YF, 2015, INT J BIOCHEM CELL B, V61, P120, DOI 10.1016/j.biocel.2015.02.006
   Xuan XY, 2015, MOL BIOL REP, V42, P907, DOI 10.1007/s11033-014-3828-8
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zhao SG, 2013, CANCER LETT, V333, P253, DOI 10.1016/j.canlet.2013.01.039
   Zhu HW, 2014, CANCER LETT, V354, P142, DOI 10.1016/j.canlet.2014.07.044
NR 39
TC 27
Z9 28
U1 4
U2 23
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PY 2016
VL 373
IS 1
BP 97
EP 108
DI 10.1016/j.canlet.2016.01.023
PG 12
WC Oncology
SC Oncology
GA DF7PB
UT WOS:000371548900011
PM 26806810
DA 2018-12-27
ER

PT J
AU Saravanakumar, K
   Lavanya, TG
   Kubendran, TR
AF Saravanakumar, K.
   Lavanya, T. G.
   Kubendran, T. R.
TI RETRACTED: Density, viscosity and speed of sound of benzaldehyde with
   benzene at 303.15, 308.15, and 313.15 K (Retracted article. See vol. 25,
   pg. 299, 2016)
SO JOURNAL OF ENGINEERING THERMOPHYSICS
LA English
DT Article; Retracted Publication
ID BINARY-LIQUID MIXTURES; THERMOPHYSICAL PROPERTIES; THERMODYNAMIC
   PROPERTIES; ISOAMYL ACETATE; 0.1 MPA; ACETOPHENONE; TEMPERATURES;
   PRESSURE
AB The values of density, viscosity and speed of sound for the binary liquid mixture of Benzaldehyde with Benzene were measured over the entire range of composition at 303.15, 308.15, and 313.15 K. These values are used to calculate the excess molar volume (V (E)), deviation in viscosity (Delta eta), deviation in speed of sound (Delta U), deviation in isentropic compressibility (Delta beta (s) ), excess internal pressure (Delta pi), excess intermolecular free length (Delta L (f) ), excess free volume (V (E) (f) ) and excess acoustic impedance (Delta Z). McAllister's three-body interaction model is used for correlating Kinematic Viscosity of binary mixtures. The excess values were correlated using the Redlich-Kister polynomial equation to obtain their coefficients and standard deviations. The thermophysical properties (density, viscosity, and speed of sound) under the study were fit to the Jouyban-Acree model.
C1 [Saravanakumar, K.] Sathyabama Univ, Dept Chem Engn, Madras 600119, Tamil Nadu, India.
   [Lavanya, T. G.] Sri Venkateswara Coll Engn, Dept Chem Engn, Chennai, Tamil Nadu, India.
   [Kubendran, T. R.] Anna Univ, Dept Chem Engn, AC Coll Technol, Madras 600025, Tamil Nadu, India.
RP Saravanakumar, K (reprint author), Sathyabama Univ, Dept Chem Engn, Madras 600119, Tamil Nadu, India.
EM saroo_1978@yahoo.co.in
CR Azhagiri S, 2009, J SOLUTION CHEM, V38, P441, DOI 10.1007/s10953-009-9383-6
   Baskaran R, 2008, J CHEM ENG DATA, V53, P1956, DOI 10.1021/je8002699
   Desnoyers J., 1978, P INDIAN ACAD CHEM S, V98, P435
   Ewing M. B., 1970, J CHEM THERMODYN, V2, P689, DOI DOI 10.1016/0021-9614(70)90044-3
   FORT RJ, 1966, T FARADAY SOC, V62, P1112, DOI 10.1039/tf9666201112
   Jouyban A, 2005, CHEM PHARM BULL, V53, P519, DOI 10.1248/cpb.53.519
   Kinart CM, 2000, PHYS CHEM LIQ, V38, P155, DOI 10.1080/00319100008030266
   Laddha G. S., 1968, T INDIAN I CHEM ENGR, V10, P56
   MCALLISTER RA, 1960, AICHE J, V6, P427, DOI 10.1002/aic.690060316
   Rathnam MV, 2009, J CHEM ENG DATA, V54, P305, DOI 10.1021/je800325d
   REDLICH O, 1948, IND ENG CHEM, V40, P345, DOI 10.1021/ie50458a036
   Riddick J. A., 1986, ORGANIC SOLVENTS PHY
   Roy MN, 2008, J CHEM ENG DATA, V53, P1431, DOI 10.1021/je7006742
   Saravanakumar K, 2011, ORIENT J CHEM, V27, P1073
   Saravanakumar K, 2011, ASIAN J CHEM, V23, P2643
   Saravanakumar K, 2011, J SOLUTION CHEM, V40, P955, DOI 10.1007/s10953-011-9701-7
   TRESZCZANOWICZ AJ, 1981, J CHEM THERMODYN, V13, P253, DOI 10.1016/0021-9614(81)90125-7
NR 17
TC 2
Z9 2
U1 3
U2 9
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1810-2328
EI 1990-5432
J9 J ENG THERMOPHYS-RUS
JI J. Eng. Thermophys.
PD JAN
PY 2016
VL 25
IS 1
BP 106
EP 116
DI 10.1134/S1810232816010100
PG 11
WC Thermodynamics; Engineering, Mechanical; Mechanics
SC Thermodynamics; Engineering; Mechanics
GA DE7MX
UT WOS:000370822500010
DA 2018-12-27
ER

PT J
AU Khairnar, K
   Lynde, C
   Ralevski, F
   Keystone, J
   McCarthy, A
   Levine, J
   Pillai, DR
AF Khairnar, Krishna
   Lynde, Carrie
   Ralevski, Filip
   Keystone, Jay
   McCarthy, Anne
   Levine, Jeremy
   Pillai, Dylan R.
TI RETRACTED: Molecular diagnosis of leishmaniasis at the subgenus and
   species level (Retracted Article)
SO PARASITOLOGY RESEARCH
LA English
DT Correction; Retracted Publication
C1 [Khairnar, Krishna] CSIR, NEERI, Nagpur 440020, Maharashtra, India.
   [Lynde, Carrie; Keystone, Jay] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Ralevski, Filip] OAHPP, Publ Hlth Lab, Toronto, ON, Canada.
   [McCarthy, Anne; Levine, Jeremy] Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada.
   [Pillai, Dylan R.] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada.
RP Khairnar, K (reprint author), CSIR, NEERI, Nagpur 440020, Maharashtra, India.
EM kskhairnar@gmail.com
CR KHAIRNAR K, PARASITOL RES
NR 1
TC 0
Z9 0
U1 3
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0932-0113
EI 1432-1955
J9 PARASITOL RES
JI Parasitol. Res.
PD JAN
PY 2016
VL 115
IS 1
BP 49
EP 49
DI 10.1007/s00436-013-3663-1
PG 1
WC Parasitology
SC Parasitology
GA DE8EM
UT WOS:000370868600004
OA Bronze
DA 2018-12-27
ER

PT J
AU Wang, YY
   Li, L
   Wang, Y
   Tang, SN
   Zheng, WX
AF Wang, Yiying
   Li, Li
   Wang, Yue
   Tang, Sarah Ngocvi
   Zheng, Wenxin
TI RETRACTED: Fallopian tube secretory cell expansion: a sensitive
   biomarker for ovarian serous carcinogenesis (Retracted article. See vol.
   8, pg. 4510, 2016)
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article; Retracted Publication
DE Fallopian tube; tubal secretory cells; pelvic serous carcinoma; ovarian
   cancer; pathogenesis; carcinogenesis
ID INTRAEPITHELIAL CARCINOMA; CLINICAL-IMPLICATIONS; CANCER; PRECURSORS;
   PREVENTION; OVIDUCT; FIMBRIA; WOMEN; RISK; BRCA
AB Recent advances suggest that precancerous lesions of pelvic serous carcinoma originate from tubal secretory cells. The purpose of our study was to determine if an increased number of secretory cells vary with age or location in the fallopian tube and to examine its association with serous neoplasia. Three groups (benign control, high-risk, and pelvic serous carcinoma) of age-matched patients were studied. The age data were stratified into 10-year intervals ranging from 20-29 to older than 80. The number of secretory and ciliated cells from both tubal fimbria and ampulla segments was counted by microscopy and immunohistochemical staining methods. The data were analyzed by standard contingency table and Poisson distribution methods after age justification. We found that the absolute number of tubal secretory cells increased significantly with age in all three groups. But a more dramatic increase of secretory cells was observed in high-risk and pelvic serous carcinoma patients. Secretory cell expansion is more prevalent than secretory cell outgrowth in both fimbria and ampulla tubal segments and is significantly associated with serous neoplasia (p < 0.001). Furthermore, age remained a significant risk factor for serous neoplasia after age adjustment. These findings suggest that secretory cell expansion could serve as a potential sensitive biomarker for early serous carcinogenesis within the fallopian tube. The study also supports a relationship between serous neoplasia and increased secretory to ciliated cell ratios, and the relationship between frequency of secretory cell expansion within the fallopian tube and increasing age and-more significantly-presence of high-risk factors or co-existing serous cancers.
C1 [Wang, Yiying; Wang, Yue] Henan Prov Peoples Hosp, Dept Obstet & Gynecol, Zhengzhou, Peoples R China.
   [Wang, Yiying; Li, Li; Zheng, Wenxin] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
   [Li, Li] Shandong Univ, Sch Med, Dept Pathol, Jinan 250100, Shandong, Peoples R China.
   [Tang, Sarah Ngocvi] Univ Arizona, Coll Med, Tucson, AZ USA.
   [Zheng, Wenxin] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Dallas, TX 75390 USA.
   [Zheng, Wenxin] Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85721 USA.
   [Zheng, Wenxin] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan 250100, Shandong, Peoples R China.
   [Zheng, Wenxin] Univ Texas Dallas, Simon Canc Ctr, Dallas, TX 75230 USA.
RP Zheng, WX (reprint author), Univ Texas SW Med Ctr Dallas, Pathol, 6000 Harry Hines Blvd,NB6-408, Dallas, TX 75390 USA.; Zheng, WX (reprint author), Univ Texas SW Med Ctr Dallas, Obstet & Gynecol, 6000 Harry Hines Blvd,NB6-408, Dallas, TX 75390 USA.
EM wenxin.zheng@utsouthwestern.edu
FU Health Department, Henan Province, China; Postdoctoral International
   Exchange Program, China; Department of Pathology, University of Texas
   Southwestern Medical Center, USA; Better Than Ever Grant; University of
   Arizona Cancer Center [P30 CA23074]; University of Texas Southwestern
   Medical Center
FX Dr. Yiying Wang was partially supported by Health Department, Henan
   Province, China. Dr. Li Li was partially supported by Postdoctoral
   International Exchange Program, China. Both Drs. Wang and Li were
   partially supported by Department of Pathology, University of Texas
   Southwestern Medical Center, USA. The project was also funded in part by
   Better Than Ever Grant, P30 CA23074 grant from University of Arizona
   Cancer Center and University of Texas Southwestern Medical Center
   startup fund to WZ.
CR Bowen NJ, 2007, GYNECOL ONCOL, V104, P331, DOI 10.1016/j.ygyno.2006.08.052
   Brewer MA, 2003, CLIN CANCER RES, V9, P20
   Callahan MJ, 2007, J CLIN ONCOL, V25, P3985, DOI 10.1200/JCO.2007.12.2622
   CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108
   Carlson JW, 2008, J CLIN ONCOL, V26, P4160, DOI 10.1200/JCO.2008.16.4814
   Chen EY, 2010, J PATHOL, V222, P110, DOI 10.1002/path.2739
   Colgan TJ, 2003, INT J GYNECOL PATHOL, V22, P109, DOI 10.1097/01.PGP.0000055049.78118.63
   Crum CP, 2007, CURR OPIN OBSTET GYN, V19, P3, DOI 10.1097/GCO.0b013e328011a21f
   Crum CP, 2012, INT J GYNECOL CANCER, V22, pS29, DOI 10.1097/IGC.0b013e31824d7269
   Crum CP, 2012, CLIN OBSTET GYNECOL, V55, P24, DOI 10.1097/GRF.0b013e31824b1725
   Crum CP, 2009, MOL ONCOL, V3, P165, DOI 10.1016/j.molonc.2009.01.004
   DeLair D, 2012, HISTOPATHOLOGY, V61, P329, DOI 10.1111/j.1365-2559.2011.04167.x
   Folkins AK, 2009, GYNECOL ONCOL, V113, P391, DOI 10.1016/j.ygyno.2009.01.013
   Goodman MT, 2009, CANCER EPIDEM BIOMAR, V18, P132, DOI 10.1158/1055-9965.EPI-08-0771
   Hunn J, 2012, CLIN OBSTET GYNECOL, V55, P3, DOI 10.1097/GRF.0b013e31824b4611
   Jarboe E, 2008, INT J GYNECOL PATHOL, V27, P1, DOI 10.1097/pgp.0b013e31814b191f
   Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47
   Lang D, 2007, BIOCHEM PHARMACOL, V73, P1, DOI 10.1016/j.bcp.2006.06.024
   Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687
   Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091
   Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402
   Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107
   Li J, 2013, GYNECOL ONCOL, V131, P555, DOI 10.1016/j.ygyno.2013.09.018
   Li J, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-8
   Li J, 2011, MODERN PATHOL, V24, P1488, DOI 10.1038/modpathol.2011.106
   Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77
   Mehra Karishma, 2011, Front Biosci (Elite Ed), V3, P625, DOI 10.2741/e275
   Mittag J, 2007, ENDOCRINOLOGY, V148, P719, DOI 10.1210/en.2006-1054
   Nonaka D, 2008, AM J SURG PATHOL, V32, P1566, DOI 10.1097/PAS.0b013e31816d71ad
   Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000
   Quick CM, 2012, MODERN PATHOL, V25, P449, DOI 10.1038/modpathol.2011.175
   Semmel DR, 2009, MODERN PATHOL, V22, P985, DOI 10.1038/modpathol.2009.64
   Shaw PA, 2009, MODERN PATHOL, V22, P1133, DOI 10.1038/modpathol.2009.89
   Tang SG, 2012, INT J GYNECOL PATHOL, V31, P103, DOI 10.1097/PGP.0b013e31822ea955
   Tong GX, 2011, DIAGN CYTOPATHOL, V39, P567, DOI 10.1002/dc.21426
   Vang R, 2013, HISTOPATHOLOGY, V62, P44, DOI 10.1111/his.12046
   Wen Jia, 2012, Chinese Journal of Pathology, V41, P433, DOI 10.3760/cma.j.issn.0529-5807.2012.07.001
   Zhang W, 2015, HISTOL HISTOPATHOL, P11645
NR 38
TC 3
Z9 4
U1 3
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2016
VL 8
IS 1
BP 230
EP 238
PG 9
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA DE1EN
UT WOS:000370369600022
PM 27069556
DA 2018-12-27
ER

PT J
AU Rosen, A
   Lekander, M
   Jensen, K
   Sachs, L
   Petrovic, P
   Ingvar, M
   Enblom, A
AF Rosen, Annelie
   Lekander, Mats
   Jensen, Karin
   Sachs, Lisbeth
   Petrovic, Predrag
   Ingvar, Martin
   Enblom, Anna
TI RETRACTED: The Effects of Positive or Neutral Communication during
   Acupuncture for Relaxing Effects: A Sham-Controlled Randomized
   Trial(Retracted article.See 9362978,2016)
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article; Retracted Publication
ID EVIDENCE TELL US; PLACEBO ACUPUNCTURE; HEART-RATE; ANALGESIA; PAIN;
   EXPECTATIONS; EXPECTANCY; COMPONENTS; OUTCOMES; SCALE
AB Introduction. The link between patient-clinician communication and its effect on clinical outcomes is an important clinical issue that is yet to be elucidated. Objective. Investigating if communication type (positive or neutral) about the expected treatment outcome affected (i) participants(expectations and (ii) short-term relaxation effects in response to genuine or sham acupuncture and investigating if expectations were related to outcome. Methods. Healthy volunteers (n = 243, mean age of 42) were randomized to one treatment with genuine or sham acupuncture. Within groups, participants were randomized to positive or neutral communication, regarding expected treatment effects. Visual Analogue Scales (0-100 millimeters) were used to measure treatment expectations and relaxation, directly before and after treatment. Results. Participants in the positive communication group reported higher treatment expectancy, compared to the neutral communication group (md 12 versus 6 mm, p = 0.002). There was no difference in relaxation effects between acupuncture groups or between communication groups. Participants with high baseline expectancy perceived greater improvement in relaxation, compared to participants with low baseline levels (md 27 versus 15 mm, p = 0.022). Conclusion. Our data highlights the importance of expectations for treatment outcome and demonstrates that expectations can be effectively manipulated using a standardized protocol that in future research may be implemented in clinical trials.
C1 [Rosen, Annelie; Lekander, Mats; Jensen, Karin; Sachs, Lisbeth; Petrovic, Predrag; Ingvar, Martin; Enblom, Anna] Karolinska Inst, Osher Ctr Integrat Med, Dept Clin Neurosci, S-17177 Stockholm, Sweden.
   [Lekander, Mats] Stockholm Univ, Stress Res Inst, S-10691 Stockholm, Sweden.
   [Enblom, Anna] Linkoping Univ, Div Physiotherapy, Dept Med & Hlth Sci, S-58183 Linkoping, Sweden.
RP Rosen, A (reprint author), Karolinska Inst, Osher Ctr Integrat Med, Dept Clin Neurosci, S-17177 Stockholm, Sweden.
EM annelie.rosen@ki.se
CR Albring A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049477
   Anna E, 2008, COMPLEMENT THER MED, V16, P288, DOI 10.1016/j.ctim.2008.02.012
   Bausell RB, 2005, EVAL HEALTH PROF, V28, P9, DOI 10.1177/0163278704273081
   Benedetti F, 2013, PULM PHARMACOL THER, V26, P520, DOI 10.1016/j.pupt.2013.01.006
   Charron J, 2006, CLIN J PAIN, V22, P204, DOI 10.1097/01.ajp.0000161526.25374.e5
   Colagiuri B, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/857804
   Colloca L, 2004, LANCET NEUROL, V3, P679, DOI 10.1016/S1474-4422(04)00908-1
   Di Blasi Z, 2001, LANCET, V357, P757, DOI 10.1016/S0140-6736(00)04169-6
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Enblom A, 2011, EVID-BASED COMPL ALT, V2011
   Enblom A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014766
   Enck P, 2013, NAT REV DRUG DISCOV, V12, P191, DOI 10.1038/nrd3923
   Enck P, 2010, AUTON NEUROSCI-BASIC, V157, P68, DOI 10.1016/j.autneu.2010.03.005
   Ernst E, 2004, PAIN, V109, P203, DOI 10.1016/j.pain.2004.01.028
   Ernst E, 2012, J PAIN SYMPTOM MANAG, V43, pE11, DOI 10.1016/j.jpainsymman.2011.11.001
   Ernst E, 2009, J PAIN SYMPTOM MANAG, V37, P709, DOI 10.1016/j.jpainsymman.2008.04.009
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2
   Gallagher EJ, 2001, ANN EMERG MED, V38, P633, DOI 10.1067/mem.2001.118863
   Huang WD, 2012, J ALTERN COMPLEM MED, V18, P242, DOI 10.1089/acm.2010.0325
   Hui Kathleen K S, 2007, BMC Complement Altern Med, V7, P33, DOI 10.1186/1472-6882-7-33
   Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25
   Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591
   Kelley JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094207
   Kolahi J, 2009, COMMUNITY DENT ORAL, V37, P477, DOI 10.1111/j.1600-0528.2009.00494.x
   Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524
   Kong J, 2009, NEUROIMAGE, V45, P940, DOI 10.1016/j.neuroimage.2008.12.025
   Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006
   Linde K, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-75
   Longhurst J, 2013, MED ACUPUNCT, V25, P101, DOI 10.1089/acu.2013.0960
   McCambridge J, 2014, J CLIN EPIDEMIOL, V67, P267, DOI 10.1016/j.jclinepi.2013.08.015
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Mondloch MV, 2001, CAN MED ASSOC J, V165, P174
   Nasir LS, 2002, PRIMARY CARE, V29, P393, DOI 10.1016/S0095-4543(01)00007-0
   Nishijo K, 1997, NEUROSCI LETT, V227, P165, DOI 10.1016/S0304-3940(97)00337-6
   Palatini P, 2012, J CLIN HYPERTENS, V14, P139, DOI 10.1111/j.1751-7176.2011.00586.x
   Park J, 1999, ACUPUNCT MED, V17, P110, DOI DOI 10.1136/AIM.17.2.110
   Park SU, 2009, J ALTERN COMPLEM MED, V15, P1275, DOI 10.1089/acm.2009.0181
   Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Streitberger K, 2008, J ALTERN COMPLEM MED, V14, P505, DOI 10.1089/acm.2007.0552
   Suarez-Almazor ME, 2010, ARTHRIT CARE RES, V62, P1229, DOI 10.1002/acr.20225
   Vase L, 2013, PAIN, V154, P1659, DOI 10.1016/j.pain.2013.05.008
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007
   Zhang S, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/750140
   Zisapel N, 2003, J SLEEP RES, V12, P291, DOI 10.1046/j.0962-1105.2003.00365.x
NR 46
TC 0
Z9 0
U1 1
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2016
AR 3925878
DI 10.1155/2016/3925878
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA DE5WT
UT WOS:000370704600001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Nam, KB
   Kim, TJ
   Park, JS
   Chung, MJ
   Lee, KW
AF Nam, Kyung Bum
   Kim, Tae Jung
   Park, Jeong-Soo
   Chung, Myung Jin
   Lee, Kyung Won
TI RETRACTED: Long-Term Follow-Up Results From PET/CT Surveillance After
   Surgical Resection of Lung Adenocarcinoma Manifesting as Ground-Glass
   Opacity (Retracted article. See vol. 95, 2016)
SO MEDICINE
LA English
DT Article; Retracted Publication
ID LYMPH-NODE METASTASIS; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY;
   RESOLUTION COMPUTED-TOMOGRAPHY; CT FINDINGS; FDG-PET/CT; CANCER;
   RECURRENCE; MANAGEMENT; DIAGNOSIS; INVASION
AB The purpose of our study was to retrospectively evaluate the value of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for postoperative surveillance of lung adenocarcinoma manifesting as ground-glass opacity (GGO).
   From May 2003 to December 2007, 111 patients with surgically resected lung adenocarcinoma manifesting as GGO were included. Clinical findings of recurrence and survival, CT features, and maximum standardized uptake value (SUVmax) were reviewed and compared among 3 groups according to GGO proportion: Group I, GGO 100%; Group II, GGO >= 50%; Group III, GGO -free survival (DFS) was estimated using the Kaplan-Meier method. Diagnostic performances of CT and PET/CT for recurrence were compared during a long-term follow-up period of >5 years.
   Recurrence was identified in Group III (18 of 53, 34%) but not in Groups I (n = 25) or II (n = 33) over a mean follow-up period of 74 months. Group showed significant differences in GGO proportion, SUVmax, and DFS duration (P 0.001). PET/CT led to 6 false-positive and 5 false-negative interpretations of recurrence. For surveillance CT, sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 94.4%, 98.6%, 98.2%, 94.4%, and 98.9%, respectively; for PET/CT, sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 72.2%, 92.3%, 88.5%, 68.4%, and 93.5%, respectively. CT showed significantly higher accuracy than PET/CT (P = 0.0188).
   FDG-PET/CT showed no clear advantage for postoperative surveillance of lung cancer with predominant GGO because of low incidence of recurrence and frequent false-positive and false-negative results.
C1 Seoul Natl Univ, Bundang Hosp, Dept Radiol, 300 Gumi Dong, Songnam, South Korea.
   Dankook Univ, Coll Med, Dept Biochem, Cheonan, South Korea.
   [Kim, Tae Jung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiol, 81 Irwon Ro, Seoul, South Korea.
RP Kim, TJ (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Radiol, 81 Irwon Ro, Seoul, South Korea.
EM taejung.kim1@gmail.com
FU SNUBH Research Fund [02-2013-067]
FX this work was supported by grant #02-2013-067 from the SNUBH Research
   Fund.
CR Aoki T, 2001, RADIOLOGY, V220, P803, DOI 10.1148/radiol.2203001701
   Austin JHM, 2013, RADIOLOGY, V266, P62, DOI 10.1148/radiol.12120240
   Benamore R, 2007, J THORAC ONCOL, V2, P273, DOI 10.1097/01.JTO.0000263708.08332.76
   Cho S, 2010, J THORAC CARDIOV SUR, V139, P1447, DOI 10.1016/j.jtcvs.2009.09.055
   Choi CM, 2014, RADIOLOGY, V270, P574, DOI 10.1148/radiol.13121824
   Choi SH, 2011, ANN THORAC SURG, V92, P1826, DOI 10.1016/j.athoracsur.2011.07.005
   Colt HG, 2013, CHEST, V143, pE437, DOI 10.1378/chest.12-2365
   Dane B, 2013, AM J NUCL MED MOLEC, V3, P408
   Ginsberg Robert J., 1995, Annals of Thoracic Surgery, V60, P615, DOI 10.1016/0003-4975(95)00537-U
   Goldstraw P., 2009, IASLC STAGING MANUAL
   Gorenberg M, 2008, BRIT J RADIOL, V81, P821, DOI 10.1259/bjr/26210052
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Hellwig D, 2006, EUR J NUCL MED MOL I, V33, P13, DOI 10.1007/s00259-005-1919-4
   Kelsey CR, 2009, CANCER-AM CANCER SOC, V115, P5218, DOI 10.1002/cncr.24625
   Kim TJ, 2012, AM J ROENTGENOL, V198, P83, DOI 10.2214/AJR.11.6862
   Ko KH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000434
   Lee HJ, 2013, RADIOLOGY, V268, P254, DOI 10.1148/radiol.13112553
   Lee JW, 2009, EUR J NUCL MED MOL I, V36, P1794, DOI 10.1007/s00259-009-1155-4
   Lee SM, 2012, EUR RADIOL, V22, P1556, DOI 10.1007/s00330-012-2395-4
   Liao CY, 2012, EUR J RADIOL, V81, P3518, DOI 10.1016/j.ejrad.2012.02.007
   MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606
   Matsuguma H, 2002, J THORAC CARDIOV SUR, V124, P278, DOI 10.1067/mtc.122298
   Nair VS, 2010, CHEST, V137, P1150, DOI 10.1378/chest.09-2356
   Nakata M, 2005, J THORAC CARDIOV SUR, V129, P1226, DOI 10.1016/j.jtcvs.2004.10.032
   National Comprehensive Cancer Network, 2015, PRACT GUID NONSM CEL
   Nishio R, 2007, J THORAC ONCOL, V2, P29, DOI 10.1097/01243894-200701000-00007
   Okada M, 2004, J THORAC CARDIOV SUR, V127, P857, DOI 10.1016/j.jtcvs.2003.08.048
   Opoka Lucyna, 2013, Pneumonol Alergol Pol, V81, P214
   Shimada Y, 2012, J THORAC ONCOL, V7, P1263, DOI 10.1097/JTO.0b013e31825cca6e
   Toba H, 2012, INTERACT CARDIOV TH, V15, P859, DOI 10.1093/icvts/ivs368
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Truong MT, 2014, RADIOL CLIN N AM, V52, P17, DOI 10.1016/j.rcl.2013.08.005
   Tsuchiya T, 2007, LUNG CANCER, V56, P341, DOI 10.1016/j.lungcan.2007.01.019
   Um SW, 2009, J THORAC ONCOL, V4, P1331, DOI 10.1097/JTO.0b013e3181b6be3e
NR 34
TC 2
Z9 2
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN
PY 2016
VL 95
IS 4
AR e2634
DI 10.1097/MD.0000000000002634
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA DE3OQ
UT WOS:000370540000001
PM 26825922
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Karaarslan, AA
   Aycan, H
   Orgen, Y
   Karakasli, A
   Ertem, F
   Sesli, E
AF Karaarslan, Ahmet Adnan
   Aycan, Hakan
   Orgen, Yaman
   Karakasli, Ahmet
   Ertem, Fatih
   Sesli, Erhan
TI RETRACTED: A new femoral nail with single distal locking screw for
   maximum interfragment rotational stability(Retracted article. See
   vol.50, pg.482,2016)
SO ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA
LA English
DT Article; Retracted Publication
DE Femur fractures; fracture union; interfragmentary distraction;
   interfragmentary rotation
ID SHAFT FRACTURES; MECHANICAL CONDITIONS; INTRAMEDULLARY NAILS;
   RADIATION-EXPOSURE; INTERLOCKING; FEMUR; KNEE; STABILITY; STRENGTH;
   FORCES
AB Objective: One of the problems for interlocking nailing of the femur is interfragment rotation motion, affecting fracture healing. The nails with single distal locking screw are advantageous for decreasing operation time and radiation exposure. We investigated which single distal screw nail is the best for interfragment rotational stability.
   Methods: We used a total of 30 composite femurs, ten for each group. We determined interfragment rotational displacement of composite femurs with three types of single distal screw nails (10 interlocking nails, 10 compression nails and 10 Mehmet anti-rotation nails compressed by tube) at 6-Nm external 6 Nm internal and 10 Nm extern 6 Nm internal torques, which imitating respectively the level walking and descending stairs, using an axial distraction testing machine and a custom designed rotation apparatus.
   Results: Between 10 Nm external and 6 Nm internal torques with single distal locking screw, the interfragment rotational displacement in the Mehmet nail compressed by the 8 Nm torque wrench was mean 1.14 mm and 540% less than mean 7.31 mm in interlocking nails and 400% less than 5.72 mm in compression nails compressed by the 2.5 Nm torque wrench.
   Conclusion: The single distal screw Mehmet nail is superior than other single (or even some double) distal screw nails for maximum rotational stability, with no interfragment distraction gap, no superior nail migration, decreased operation time, and less radiation exposure in axially stable transverse and short oblique femur fractures in daily activities like stair descending or level walking.
C1 [Karaarslan, Ahmet Adnan; Aycan, Hakan; Orgen, Yaman; Sesli, Erhan] Sifa Univ, Fac Med, Dept Orthopaed & Traumatol, Izmir, Turkey.
   [Karakasli, Ahmet; Ertem, Fatih] Dokuz Eylul Univ, Fac Med, Dept Orthopaed & Traumatol, Izmir, Turkey.
RP Karaarslan, AA (reprint author), Sifa Univ, Fac Med, Dept Orthopaed & Traumatol, Izmir, Turkey.
EM aakaraarslan@yahoo.com
CR Aldemir C, 2014, EKLEM HAST CERRAHISI, V25, P64, DOI 10.5606/ehc.2014.15
   Boyer P, 2014, ORTHOP TRAUMATOL-SUR, V100, P901, DOI 10.1016/j.otsr.2014.09.012
   Brown NAT, 2007, CLIN BIOMECH, V22, P449, DOI 10.1016/j.clinbiomech.2006.11.009
   Chao CK, 2007, CLIN BIOMECH, V22, P59, DOI 10.1016/j.clinbiomech.2006.07.007
   Chen A L, 2001, Bull Hosp Jt Dis, V60, P80
   Chong ACM, 2007, ANN BIOMED ENG, V35, P1196, DOI 10.1007/s10439-007-9284-z
   Citak Mustafa, 2009, Technol Health Care, V17, P25, DOI 10.3233/THC-2009-0529
   Claes L, 2002, J ORTHOP RES, V20, P1099, DOI 10.1016/S0736-0266(02)00044-X
   Demirtas A, 2011, EKLEM HAST CERRAHISI, V22, P81
   DIBENNARDO R, 1979, AM J PHYS ANTHROPOL, V50, P635, DOI 10.1002/ajpa.1330500415
   Dursun Muhsin, 2014, Eur J Orthop Surg Traumatol, V24, P1005, DOI 10.1007/s00590-013-1269-z
   George CJ, 1998, J ORTHOP TRAUMA, V12, P267, DOI 10.1097/00005131-199805000-00009
   Gonschorek O, 1998, ARCH ORTHOP TRAUM SU, V117, P430, DOI 10.1007/s004020050287
   Griffin Lanny V, 2009, J Orthop Surg Res, V4, P11, DOI 10.1186/1749-799X-4-11
   GROVER J, 1995, ORTHOP CLIN N AM, V26, P139
   Hapa O, 2010, ULUS TRAVMA ACIL CER, V16, P33
   Hontzsch D, 2014, J BONE JOINT SURG AM, V96A, P1889, DOI 10.2106/JBJS.M.01355
   Hsu CC, 2010, MED ENG PHYS, V32, P454, DOI 10.1016/j.medengphy.2010.03.006
   Klein P, 2004, J ORTHOPAED RES, V22, P1072, DOI 10.1016/j.orthres.2004.02.006
   Klein P, 2003, J ORTHOPAED RES, V21, P662, DOI 10.1016/S0736-0266(02)00259-0
   Kneifel T, 1996, INJURY, V27, P271, DOI 10.1016/0020-1383(95)00116-6
   Kose N, 2000, J ORTHOP TRAUMA, V14, P414
   LEVIN PE, 1987, J BONE JOINT SURG AM, V69A, P761, DOI 10.2106/00004623-198769050-00019
   Muckley T, 2006, PRACTICE INTRAMEDULL, P85
   Schneider E, 2001, J BIOMECH, V34, P849, DOI 10.1016/S0021-9290(01)00037-9
   Solak S, 1998, ACTA ORTHOP TRAUMATO, V32, P37
   Somerson JS, 2014, J ORTHOP TRAUMA, V28, P417, DOI 10.1097/BOT.0000000000000029
   Taylor SJG, 2001, J BIOMECH, V34, P839, DOI 10.1016/S0021-9290(01)00042-2
   Taylor SJG, 1998, J ARTHROPLASTY, V13, P428, DOI 10.1016/S0883-5403(98)90009-2
   Uzel AP, 2011, SURG RADIOL ANAT, V33, P235, DOI 10.1007/s00276-010-0722-5
   Uzumcugil O, 2009, ACTA ORTHOP TRAUMATO, V43, P9
   Uzumcugil O, 2009, ACTA ORTHOP TRAUMATO, V43, P386, DOI 10.3944/AOTT.2009.386
   Wang GD, 2008, CLIN BIOMECH, V23, P305, DOI 10.1016/j.clinbiomech.2007.10.017
NR 33
TC 1
Z9 1
U1 1
U2 3
PU TURKISH ASSOC ORTHOPAEDICS TRAUMATOLOGY
PI ISTANBUL
PA SEHREMINI MAH KOYUNCU SK CIGDEM APT NO 4 D 5 FATIH, ISTANBUL, 00000,
   TURKEY
SN 1017-995X
J9 ACTA ORTHOP TRAUMATO
JI Acta Orthop. Traumatol. Turc.
PD JAN-FEB
PY 2016
VL 50
IS 1
BP 89
EP 96
DI 10.3944/AOTT.2016.15.0160
PG 8
WC Orthopedics
SC Orthopedics
GA DD7EY
UT WOS:000370087700016
PM 26854055
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Weng, XL
   Feng, Y
   Lou, YP
AF Weng, Xiaolin
   Feng, Ying
   Lou, Yuanpeng
TI RETRACTED: The Mechanical Performance of Shear Key of Immersed Tube
   Tunnel with Differential Foundation Settlement(Retracted article. See
   2017)
SO JOURNAL OF SENSORS
LA English
DT Article; Retracted Publication
ID OPTICAL-FIBER; STRAIN-MEASUREMENTS; CONCRETE; SENSORS; SYSTEM
AB A fiber Bragg grating (FBG) based sensor network was developed to monitor the strain distributions within immersed tube tunnel shear key, which was subjected to differential settlements. An improved packaging and installation method of the quasi-distributed sensor system was utilized, which not only ensured a high sensor survival rate but also achieved accurate measurement of axial strains. Based on the monitoring results, the stress variations of shear keys of the immersed tunnel joint, which originate from the buckling caused by the longitudinal differential siltation at seabed and the surface defects, were analyzed in detail.
C1 [Weng, Xiaolin; Feng, Ying; Lou, Yuanpeng] Changan Univ, Key Lab Special Area Highway Engn, Minist Educ, Xian 710064, Peoples R China.
RP Weng, XL (reprint author), Changan Univ, Key Lab Special Area Highway Engn, Minist Educ, Xian 710064, Peoples R China.
EM 49768532@qq.com
FU National Natural Science Foundation of China
FX The authors would like to acknowledge the financial support of the
   National Natural Science Foundation of China and the testing support
   provided by Dr. Ma Haohao and Dr. Bin Shenglin.
CR Bonfiglioli B, 2003, J MATER CIVIL ENG, V15, P125, DOI 10.1061/(ASCE)0899-1561(2003)15:2(125)
   HILL KO, 1993, APPL PHYS LETT, V62, P1035, DOI 10.1063/1.108786
   Kersey AD, 1997, J LIGHTWAVE TECHNOL, V15, P1442, DOI 10.1109/50.618377
   Lee W, 2004, CAN GEOTECH J, V41, P1222, DOI 10.1139/T04-059
   Li C, 2006, SMART MATER STRUCT, V15, pN107, DOI 10.1088/0964-1726/15/5/N01
   Li QB, 2004, MEASUREMENT, V35, P303, DOI 10.1016/j.measurement.2003.12.003
   Li QB, 2002, J ENG MECH, V128, P471, DOI 10.1061/(ASCE)0733-9399(2002)128:4(471)
   Mohamad H, 2012, J GEOTECH GEOENVIRON, V138, P957, DOI 10.1061/(ASCE)GT.1943-5606.0000656
   MOREY WW, 1990, P SOC PHOTO-OPT INS, V1169, P98
   Wang F, 2013, CMC-COMPUT MATER CON, V34, P63
   Zhu HH, 2014, SMART MATER STRUCT, V23, DOI 10.1088/0964-1726/23/9/095027
   Zhu HH, 2012, SMART STRUCT SYST, V9, P393, DOI 10.12989/sss.2012.9.5.393
   Zhu HH, 2010, ADV STRUCT ENG, V13, P249, DOI 10.1260/1369-4332.13.2.33110.1260/1369-4332.13.2.249
NR 13
TC 0
Z9 0
U1 6
U2 39
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-725X
EI 1687-7268
J9 J SENSORS
JI J. Sens.
PY 2016
AR UNSP 2841753
DI 10.1155/2016/2841753
PG 9
WC Engineering, Electrical & Electronic; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA DD4VZ
UT WOS:000369922200001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Shoman, ME
   Aly, OM
AF Shoman, Mai E.
   Aly, Omar M.
TI RETRACTED: Nitroxyl (HNO): A Reduced Form of Nitric Oxide with Distinct
   Chemical, Pharmacological, and Therapeutic Properties(Retracted article.
   See vol.00, pg.401817, 2016)
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review; Retracted Publication
ID GENE-RELATED PEPTIDE; NO-CENTER-DOT; PARAMAGNETIC-RESONANCE
   SPECTROSCOPY; CARDIAC SARCOPLASMIC-RETICULUM; SOLUBLE GUANYLATE-CYCLASE;
   DETERRENT AGENT CYANAMIDE; HYDROXY-L-ARGININE; ANGELIS SALT; IN-VIVO;
   ALDEHYDE DEHYDROGENASE
AB Nitroxyl (HNO), the one-electron reduced form of nitric oxide (NO), shows a distinct chemical and biological profile from that of NO. HNO is currently being viewed as a vasodilator and positive inotropic agent that can be used as a potential treatment for heart failure. The ability of HNO to react with thiols and thiol containing proteins is largely used to explain the possible biological actions of HNO. Herein, we summarize different aspects related to HNO including HNO donors, chemistry, biology, and methods used for its detection.
C1 [Shoman, Mai E.; Aly, Omar M.] Menia Univ, Fac Pharm, Dept Med Chem, Al Minya 61519, Egypt.
RP Aly, OM (reprint author), Menia Univ, Fac Pharm, Dept Med Chem, Al Minya 61519, Egypt.
EM omarsokkar@yahoo.com
CR Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200
   Andrews KL, 2015, CLIN SCI, V129, P179, DOI 10.1042/CS20140759
   Andrews KL, 2009, BRIT J PHARMACOL, V157, P540, DOI 10.1111/j.1476-5381.2009.00150.x
   Angeli A., 1896, GAZZ CHIM ITAL, V26, P17
   Angelico A. A. A. F., 1903, GAZZ CHIM ITAL, V33, P245
   Arcaro Alessia, 2014, Curr Heart Fail Rep, V11, P227, DOI 10.1007/s11897-014-0210-z
   ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203
   Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9
   Bari SE, 2003, J AM CHEM SOC, V125, P15272, DOI 10.1021/ja036370f
   Bartberger MD, 2001, P NATL ACAD SCI USA, V98, P2194, DOI 10.1073/pnas.041481598
   Bartberger MD, 2002, P NATL ACAD SCI USA, V99, P10958, DOI 10.1073/pnas.162095599
   Bechtold E, 2010, ACS CHEM BIOL, V5, P405, DOI 10.1021/cb900302u
   Bermejo E, 2005, THROMB HAEMOSTASIS, V94, P578, DOI 10.1160/TH05-01-0062
   BONNER FT, 1975, INORG CHEM, V14, P558, DOI 10.1021/ic50145a022
   Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003
   Calvet G, 2004, ORG LETT, V6, P2449, DOI 10.1021/ol0491336
   Cao N, 2015, CIRC-HEART FAIL, V8, P572, DOI 10.1161/CIRCHEARTFAILURE.114.001699
   Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199
   Cheong E, 2005, CELL CALCIUM, V37, P87, DOI 10.1016/j.ceca.2004.07.001
   Cho JY, 2003, ARCH BIOCHEM BIOPHYS, V417, P65, DOI 10.1016/S0003-9861(03)00335-7
   Cline MR, 2011, J PHYS ORG CHEM, V24, P993, DOI 10.1002/poc.1871
   Colton CA, 2001, J NEUROCHEM, V78, P1126, DOI 10.1046/j.1471-4159.2001.00509.x
   Cook NM, 2003, ARCH BIOCHEM BIOPHYS, V410, P89, DOI 10.1016/S0003-9861(02)00656-2
   Dai TY, 2007, J PHYSIOL-LONDON, V580, P951, DOI 10.1113/jphysiol.2007.129254
   De Witt BJ, 2001, EUR J PHARMACOL, V430, P311, DOI 10.1016/S0014-2999(01)01289-4
   DeMaster EG, 1998, BIOCHEM PHARMACOL, V55, P2007, DOI 10.1016/S0006-2952(98)00080-X
   Dierks EA, 1996, BIOCHEM PHARMACOL, V51, P1593, DOI 10.1016/0006-2952(96)00078-0
   Donzelli S, 2006, FREE RADICAL BIO MED, V40, P1056, DOI 10.1016/j.freeradbiomed.2005.10.058
   DOYLE MP, 1988, J AM CHEM SOC, V110, P593, DOI 10.1021/ja00210a047
   Dutton AS, 2006, INORG CHEM, V45, P2448, DOI 10.1021/ic051505z
   Dutton AS, 2004, J AM CHEM SOC, V126, P3795, DOI 10.1021/ja0391614
   Eberhardt M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5381
   Ellis A, 2000, BRIT J PHARMACOL, V129, P315, DOI 10.1038/sj.bjp.0703058
   Farmer PJ, 2005, J INORG BIOCHEM, V99, P166, DOI 10.1016/j.jinorgbio.2004.11.005
   Favaloro JL, 2007, CARDIOVASC RES, V73, P587, DOI 10.1016/j.cardiores.2006.11.018
   Filipovic MR, 2007, FREE RADICAL RES, V41, P62, DOI 10.1080/10715760600944296
   Flores-Santana W, 2009, ARCH PHARM RES, V32, P1139, DOI 10.1007/s12272-009-1805-x
   Froehlich J. P., 2004, INT J ONCOL, V24, P97
   Froehlich JP, 2008, BIOCHEMISTRY-US, V47, P13150, DOI 10.1021/bi801925p
   Fukuto JM, 2005, ANNU REV PHARMACOL, V45, P335, DOI 10.1146/annurev.pharmtox.45.120403.095959
   Fukuto JM, 2005, CHEM RES TOXICOL, V18, P790, DOI 10.1021/tx0496800
   Fukuto JM, 2005, CHEMBIOCHEM, V6, P612, DOI 10.1002/cbic.200400271
   FUKUTO JM, 1992, J PHARMACOL EXP THER, V263, P546
   FUKUTO JM, 1993, J MED CHEM, V36, P2666, DOI 10.1021/jm00070a010
   Fukuto JM, 2009, FREE RADICAL BIO MED, V47, P1318, DOI 10.1016/j.freeradbiomed.2009.06.014
   Giodati J. G., 1993, THROMB DIATH HAEMO, V70, P654
   GRATZEL M, 1970, BERICH BUNSEN GESELL, V74, P1003
   GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423
   GROSS P, 1985, CRC CR REV TOXICOL, V14, P87, DOI 10.3109/10408448509023765
   HAAKE M, 1972, TETRAHEDRON LETT, P3405
   Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)90687-8
   HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992
   Hoffman MD, 2009, MOL CELL PROTEOMICS, V8, P887, DOI 10.1074/mcp.M800230-MCP200
   Huang JM, 2004, J MED CHEM, V47, P3495, DOI 10.1021/jm030547z
   Irvine JC, 2003, HYPERTENSION, V41, P1301, DOI 10.1161/01.HYP.0000072010.54901.DE
   Irvine JC, 2007, HYPERTENSION, V49, P885, DOI 10.1161/01.HYP.0000259328.04159.90
   Irvine JC, 2008, TRENDS PHARMACOL SCI, V29, P601, DOI 10.1016/j.tips.2008.08.005
   Johnson GM, 2013, FREE RADICAL BIO MED, V63, P476, DOI 10.1016/j.freeradbiomed.2013.05.011
   Kayed H, 2006, INT J CANCER, V118, P43, DOI 10.1002/ijc.21257
   Kim HP, 2006, ANNU REV PHARMACOL, V46, P411, DOI 10.1146/annurev.pharmtox.46.120604.141053
   Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4
   King SB, 2005, CURR TOP MED CHEM, V5, P665, DOI 10.2174/1568026054679362
   Komarov AM, 2000, FREE RADICAL BIO MED, V28, P739, DOI 10.1016/S0891-5849(00)00156-8
   LEE MJC, 1992, J MED CHEM, V35, P3648, DOI 10.1021/jm00098a008
   Li YJ, 2002, EUR J PHARMACOL, V442, P173, DOI 10.1016/S0014-2999(02)01538-8
   Lopez BE, 2005, ARCH BIOCHEM BIOPHYS, V442, P140, DOI 10.1016/j.abb.2005.07.012
   Lopez BE, 2007, ARCH BIOCHEM BIOPHYS, V465, P430, DOI 10.1016/j.abb.2007.06.017
   Lopez BE, 2007, FREE RADICAL BIO MED, V42, P482, DOI 10.1016/j.freeradbiomed.2006.11.015
   Ma XL, 1999, P NATL ACAD SCI USA, V96, P14617, DOI 10.1073/pnas.96.25.14617
   MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013
   Miranda KM, 2005, CURR TOP MED CHEM, V5, P649, DOI 10.2174/1568026054679290
   Miranda KM, 2005, J MED CHEM, V48, P8220, DOI 10.1021/jm050151i
   Miranda KM, 2005, COORDIN CHEM REV, V249, P433, DOI 10.1016/j.ccr.2004.08.010
   Miranda KM, 2005, J AM CHEM SOC, V127, P722, DOI 10.1021/ja045480x
   Miranda KM, 2001, J BIOL CHEM, V276, P1720, DOI 10.1074/jbc.M006174200
   Miranda KM, 2003, P NATL ACAD SCI USA, V100, P9196, DOI 10.1073/pnas.1430507100
   Miranda KM, 2003, J INORG BIOCHEM, V93, P52, DOI 10.1016/S0162-0134(02)00498-1
   Miranda KM, 2002, ARCH BIOCHEM BIOPHYS, V401, P134, DOI 10.1016/S0003-9861(02)00031-0
   Mistry DK, 1998, BRIT J PHARMACOL, V124, P1131, DOI 10.1038/sj.bjp.0701940
   Mitroka S, 2013, J MED CHEM, V56, P6583, DOI 10.1021/jm400057r
   Mohamed HAH, 2015, BIOORGAN MED CHEM, V23, P6069, DOI 10.1016/j.bmc.2015.04.023
   MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x
   MORLEY D, 1993, J CARDIOVASC PHARM, V21, P670, DOI 10.1097/00005344-199304000-00023
   Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480
   NAGASAWA HT, 1990, J MED CHEM, V33, P3120, DOI 10.1021/jm00174a001
   Niketic V, 1999, FREE RADICAL BIO MED, V27, P992, DOI 10.1016/S0891-5849(98)00256-1
   Norris AJ, 2008, INT J CANCER, V122, P1905, DOI 10.1002/ijc.23305
   Pagliaro P, 2003, FREE RADICAL BIO MED, V34, P33, DOI 10.1016/S0891-5849(02)01179-6
   Paolocci J. P. F. L., 2009, USE NITROXYL HNO TRE
   Paolocci N, 2003, P NATL ACAD SCI USA, V100, P5537, DOI 10.1073/pnas.0937302100
   Paolocci N, 2001, P NATL ACAD SCI USA, V98, P10463, DOI 10.1073/pnas.181191198
   Paolocci N, 2007, PHARMACOL THERAPEUT, V113, P442, DOI 10.1016/j.pharmthera.2006.11.002
   PINO RZ, 1994, BIOCHEM BIOPH RES CO, V201, P54, DOI 10.1006/bbrc.1994.1668
   Poderoso JJ, 1999, FREE RADICAL BIO MED, V26, P925, DOI 10.1016/S0891-5849(98)00277-9
   PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014
   Reif A, 2001, FREE RADICAL BIO MED, V30, P803, DOI 10.1016/S0891-5849(01)00477-4
   Reisz JA, 2011, J AM CHEM SOC, V133, P11675, DOI 10.1021/ja203652z
   Reisz JA, 2010, DALTON T, V39, P5203, DOI 10.1039/c000980f
   Reisz JA, 2009, ORG LETT, V11, P2719, DOI 10.1021/ol900914s
   Rosselli M, 1998, HUM REPROD UPDATE, V4, P3, DOI 10.1093/humupd/4.1.3
   Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936
   Saleem M, 2004, BIOCHEM BIOPH RES CO, V315, P455, DOI 10.1016/j.bbrc.2004.01.081
   Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492
   Sha X, 2006, J AM CHEM SOC, V128, P9687, DOI 10.1021/ja062365a
   Shafirovich V, 2002, P NATL ACAD SCI USA, V99, P7340, DOI 10.1073/pnas.112202099
   Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009
   Shen B, 2005, BIOCHEMISTRY-US, V44, P14030, DOI 10.1021/bi0507478
   Sherman MP, 2010, J ORG CHEM, V75, P4014, DOI 10.1021/jo100172t
   Shiva S, 2004, BIOCHEM J, V379, P359, DOI 10.1042/BJ20031758
   Shoeman DW, 2000, ALCOHOL, V20, P55, DOI 10.1016/S0741-8329(99)00056-7
   Shoeman DW, 1998, NITRIC OXIDE-BIOL CH, V2, P66, DOI 10.1006/niox.1998.0166
   Shoman ME, 2011, J MED CHEM, V54, P1059, DOI 10.1021/jm101432z
   Sidky M. M., 1980, EGYPT J CHEM, V21, P29
   Spencer NY, 2003, FREE RADICAL BIO MED, V35, P1515, DOI 10.1016/j.freeradbiomed.2003.08.021
   Stasch JP, 2006, J CLIN INVEST, V116, P2552, DOI 10.1172/JCI28371
   Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274
   Switzer CH, 2009, BBA-BIOENERGETICS, V1787, P835, DOI 10.1016/j.bbabio.2009.04.015
   Thatcher RGJ, 1998, CHEM SOC REV, V27, P331
   Tocchetti CG, 2007, CIRC RES, V100, P96, DOI 10.1161/01.RES.0000253904.53601.c9
   TURK T, 1992, BIOCHEM BIOPH RES CO, V183, P983, DOI 10.1016/S0006-291X(05)80287-6
   Vaananen AJ, 2006, FREE RADICAL BIO MED, V41, P120, DOI 10.1016/j.freeradbiomed.2006.03.016
   Vaananen AJ, 2005, FREE RADICAL BIO MED, V38, P1102, DOI 10.1016/j.freeradbiomed.2005.01.007
   Vaananen AJ, 2004, FREE RADICAL RES, V38, P271, DOI 10.1080/10715760410001659764
   Vaananen AJ, 2003, FREE RADICAL RES, V37, P381, DOI 10.1080/1071576031000061011
   Vaananen AJ, 2008, FREE RADICAL BIO MED, V45, P749, DOI 10.1016/j.freeradbiomed.2008.05.025
   Wang R, 2003, ANTIOXID REDOX SIGN, V5, P493, DOI 10.1089/152308603768295249
   Wanstall JC, 2001, BRIT J PHARMACOL, V134, P463, DOI 10.1038/sj.bjp.0704269
   Wink DA, 1998, ARCH BIOCHEM BIOPHYS, V351, P66, DOI 10.1006/abbi.1997.0565
   Wink DA, 2003, AM J PHYSIOL-HEART C, V285, pH2264, DOI 10.1152/ajpheart.00531.2003
   WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068
   Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g
   Wrobel AT, 2014, J AM CHEM SOC, V136, P4697, DOI 10.1021/ja500315x
   Xia Y, 2000, FREE RADICAL BIO MED, V29, P793, DOI 10.1016/S0891-5849(00)00427-5
   Zeller A, 2009, MOL PHARMACOL, V76, P1115, DOI 10.1124/mol.109.059915
NR 134
TC 3
Z9 3
U1 3
U2 21
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2016
AR 4867124
DI 10.1155/2016/4867124
PG 15
WC Cell Biology
SC Cell Biology
GA DB9RX
UT WOS:000368855600001
PM 26770654
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Singh, G
   Kumar, A
   Singh, K
   Kaur, J
AF Singh, Gurpreet
   Kumar, Arbind
   Singh, Kashmir
   Kaur, Jagdeep
TI RETRACTED: Ebola virus: an introduction and its pathology (Retracted
   article. See vol. 27, Artn E1944, 2017)
SO REVIEWS IN MEDICAL VIROLOGY
LA English
DT Review; Retracted Publication
ID HEMORRHAGIC-FEVER; ENDOTHELIAL-CELLS; GUINEA-PIGS; NONHUMAN-PRIMATES;
   INFECTED PATIENTS; MARBURG VIRUSES; PATHOGENESIS; RESPONSES; VACCINES;
   COAGULATION
AB The Ebola viruses are causative agent of a severe Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF) in human and other primates. Transmission of EVD occurs through the contact of body fluids from infected persons or animals, making it one of the most epidemic diseases worldwide. Underestimating the Ebola virus has cost loss of precious human lives in recent years. Ebola virus outbreak in year 2014 created a history, affecting a larger population in a wide geographical region of African sub-continent. EVD outbreaks have a case fatality rate of up to 70%. Ebola viruses are endemic in regions of Africa. Ebola viruses mainly target the hepatocytes, endothelial, and macrophage-rich lymphoid tissues and are characterized by immune suppression and a systemic inflammatory response that causes impairment of the vascular, coagulation, and immune systems. This impairment leads to multifocal necrosis and multi organ failure, and thus, in some ways, resembling septic shock. Currently, neither a specific treatment nor a vaccine licensed for use in humans is available. This review is focused on general characteristic of Ebola viruses, its pathogenesis, immunological response of host, and recent approaches for vaccine development against EVD. Copyright (c) 2015 John Wiley & Sons, Ltd.
C1 [Singh, Gurpreet; Kumar, Arbind; Singh, Kashmir; Kaur, Jagdeep] Panjab Univ, Dept Biotechnol, Chandigarh 160014, India.
RP Kaur, J (reprint author), Panjab Univ, Dept Biotechnol, Chandigarh 160014, India.
EM jagsekhon@yahoo.com
CR Agnandji ST, 2016, NEW ENGL J MED, V374, P1647, DOI 10.1056/NEJMoa1502924
   [Anonymous], 1978, Bull World Health Organ, V56, P271
   Baize S, 2000, APOPTOSIS, V5, P5, DOI 10.1023/A:1009657006550
   Baize S, 1999, NAT MED, V5, P423, DOI 10.1038/7422
   Baize S, 2002, CLIN EXP IMMUNOL, V128, P163, DOI 10.1046/j.1365-2249.2002.01800.x
   BASKERVILLE A, 1985, J PATHOL, V147, P199, DOI 10.1002/path.1711470308
   Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297
   Basler CF, 2004, EBOLA AND MARBURG VIRUSES: MOLECULAR AND CELLULAR BIOLOGY, P305
   Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003
   Bray M, 1998, J INFECT DIS, V178, P651, DOI 10.1086/515386
   Bray M, 2001, J COMP PATHOL, V125, P243, DOI 10.1053/jcpa.2001.0503
   Breman JG, 1978, EBOLA VIRUS HAEMORRH, P103
   Centers for Disease Control and Prevention, 2010, BIOT AG DIS
   Connolly BM, 1999, J INFECT DIS, V179, pS203, DOI 10.1086/514305
   Deng IM, 1978, B WORLD HEALTH ORGAN, V56, P247
   Dowell SF, 1999, J INFECT DIS, V179, pS87, DOI 10.1086/514284
   Ebihara H, 2006, PLOS PATHOG, V2, P705, DOI 10.1371/journal.ppat.0020073
   EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541
   FISHERHOCH SP, 1985, J INFECT DIS, V152, P887, DOI 10.1093/infdis/152.5.887
   FISHERHOCH SP, 1992, J INFECT DIS, V166, P753, DOI 10.1093/infdis/166.4.753
   Geisbert TW, 2008, VACCINE, V26, P6894, DOI 10.1016/j.vaccine.2008.09.082
   Geisbert TW, 2000, LAB INVEST, V80, P171, DOI 10.1038/labinvest.3780021
   Geisbert TW, 2003, J INFECT DIS, V188, P1618, DOI 10.1086/379724
   Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2
   Geisbert TW, 2003, AM J PATHOL, V163, P2371, DOI 10.1016/S0002-9440(10)63592-4
   Geisbert TW, 2002, EMERG INFECT DIS, V8, P503
   GeorgesCourbot MC, 1997, EMERG INFECT DIS, V3, P59, DOI 10.3201/eid0301.970107
   Harcourt BH, 1998, VIROLOGY, V252, P179, DOI 10.1006/viro.1998.9446
   Harcourt BH, 1999, J VIROL, V73, P3491
   Hensley LE, 2002, IMMUNOL LETT, V80, P169, DOI 10.1016/S0165-2478(01)00327-3
   Hoenen T, 2012, EXPERT OPIN BIOL TH, V12, P859, DOI 10.1517/14712598.2012.685152
   ISAACSON M, 1978, EBOLA VIRUS HAEMORRH, P15
   Jaax NK, 1996, ARCH PATHOL LAB MED, V120, P140
   Jahrling PB, 1996, ARCH VIROL, P115
   Khan AS, 1999, J INFECT DIS, V179, pS76, DOI 10.1086/514306
   KILEY MP, 1982, INTERVIROLOGY, V18, P24, DOI 10.1159/000149300
   Ledgerwood JE, 2017, NEW ENGL J MED, V376, P928, DOI 10.1056/NEJMoa1410863
   Leroy EM, 2009, VECTOR-BORNE ZOONOT, V9, P723, DOI 10.1089/vbz.2008.0167
   Levi M, 2007, CRIT CARE MED, V35, P2191, DOI 10.1097/01.CCM.0000281468.94108.4B
   LUPTON HW, 1980, LANCET, V2, P1294
   Marzi A, 2015, SCIENCE, V349, P739, DOI 10.1126/science.aab3920
   MURPHY FA, 1978, EBOLA VIRUS HAEMORRH, P43
   Noda T, 2002, J VIROL, V76, P4855, DOI 10.1128/JVI.76.10.4855-4865.2002
   Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216
   Reid SP, 2006, J VIROL, V80, P5156, DOI 10.1128/JVI.02349-05
   Rodriguez LL, 1999, J INFECT DIS, V179, pS170, DOI 10.1086/514291
   Ryabchikova E, 1996, ARCH VIROL, V141, P909, DOI 10.1007/BF01718165
   Ryabchikova EI, 1999, J INFECT DIS, V179, pS199, DOI 10.1086/514293
   Sanchez A, 2004, J VIROL, V78, P10370, DOI 10.1128/JVI.78.19.10370-10377.2004
   Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602
   Schnittler HJ, 1998, CLIN INFECT DIS, V27, P404, DOI 10.1086/517704
   Stroher U, 2001, J VIROL, V75, P11025, DOI 10.1128/JVI.75.22.11025-11033.2001
   Sullivan N, 2003, J VIROL, V77, P9733, DOI 10.1128/JVI.77.18.9733-9737.2003
   Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108
   Takada A, 1997, P NATL ACAD SCI USA, V94, P14764, DOI 10.1073/pnas.94.26.14764
   Villinger F, 1999, J INFECT DIS, V179, pS188, DOI 10.1086/514283
   Volchkov VE, 2000, VIROLOGY, V277, P147, DOI 10.1006/viro.2000.0572
   Volchkov VE, 1995, VIROLOGY, V214, P421, DOI 10.1006/viro.1995.0052
   Yang ZY, 2000, NAT MED, V6, P886, DOI 10.1038/78654
   Zaki SR, 1999, J INFECT DIS, V179, pS36, DOI 10.1086/514319
   Zaki SR, 1999, CURR TOP MICROBIOL, V235, P97
   Zampieri CA, 2007, NAT IMMUNOL, V8, P1159, DOI 10.1038/ni1519
NR 62
TC 8
Z9 8
U1 4
U2 107
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1052-9276
EI 1099-1654
J9 REV MED VIROL
JI Rev. Med. Virol.
PD JAN
PY 2016
VL 26
IS 1
BP 49
EP 56
DI 10.1002/rmv.1863
PG 8
WC Virology
SC Virology
GA DB7NB
UT WOS:000368701200005
PM 26558534
DA 2018-12-27
ER

PT J
AU Ke, WJ
   Liu, LH
   Liu, J
   Chen, AL
   Deng, WP
   Zhang, PY
   Cao, XP
   Liao, ZH
   Xiao, HP
   Liu, JB
   Li, YB
AF Ke, Weijian
   Liu, Liehua
   Liu, Juan
   Chen, Ailing
   Deng, Wanping
   Zhang, Pengyuan
   Cao, Xiaopei
   Liao, Zhihong
   Xiao, Haipeng
   Liu, Jianbin
   Li, Yanbing
TI RETRACTED: Effects of Liraglutide Combined with Short-Term Continuous
   Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function
   in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study
   (Retracted article. See vol. 83, pg. 175, 2018)
SO JOURNAL OF DIABETES RESEARCH
LA English
DT Article; Retracted Publication
ID THERAPY; TRIAL; PRESERVATION; SENSITIVITY; INDUCTION; REMISSION; RATS
AB The objective of this paper is to investigate the effects of liraglutide in combination with short-term continuous subcutaneous insulin infusion (CSII) therapy on glycemic control and beta cell function in patients with newly diagnosed type 2 diabetes mellitus (T2DM). Thirty-nine eligible newly diagnosed T2DM patients were recruited and randomized to receive either of two therapies: short-term CSII alone (CSII alone group) or CSII in combination with liraglutide (CSII + Lira group) for 12 weeks. Blood glucose control, homeostasis model assessment (HOMA) indices, and acute insulin response (AIR) were compared between the two groups. The patients in CSII + Lira group achieved euglycemia with equivalent insulin dosage in shorter time (1 (0) versus 2 (3) days, P = 0.039). HbA1c at the end of study was comparable between two groups (6.3 +/- 0.7% versus 6.0 +/- 0.5%, for CSII alone group and CSII + Lira group, resp., P = 0.325). The increment of AIR was higher in CSII + Lira group (177.58 (351.57) mu U.min/mL versus 58.15 (51.30) mu U.min/mL, P < 0.001). However, after stopping liraglutide, its effect on beta cell function disappeared completely. Liraglutide combined with short-term CSII was effective in further improving beta cell function, but the beneficial effects did not sustain after suspension of the therapy.
C1 [Li, Yanbing] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou 510080, Guangdong, Peoples R China.
   Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Diabet, Guangzhou 510080, Guangdong, Peoples R China.
RP Li, YB (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Endocrinol, Guangzhou 510080, Guangdong, Peoples R China.
EM easd04lyb@126.com
RI Liao, Zhihong/O-5920-2018
OI Liao, Zhihong/0000-0003-1257-0767
FU Sun Yat-sen University Clinical Research 5010 Program; Doctoral Fund of
   Ministry of Education, China [20130171110067]; Guangzhou Municipal
   Science and Technology special fund [1346000270]; Industrial Technology
   Research and Development funding projects, Guangdong Province
   [2012A030400006]; technology special projects of Guangzhou
   [2014Y2-00127]; Medical Scientific Research Foundation of Guangdong
   Province [B2013107]; Key Medical Laboratory of Guangdong Province;
   National Key Clinical Specialty Discipline Construction Program of China
FX This study is funded by Sun Yat-sen University Clinical Research 5010
   Program, Doctoral Fund of Ministry of Education, China (no.
   20130171110067), Guangzhou Municipal Science and Technology special fund
   (no. 1346000270), Industrial Technology Research and Development funding
   projects, Guangdong Province (no. 2012A030400006), 2014 technology
   special projects of Guangzhou (no. 2014Y2-00127), Medical Scientific
   Research Foundation of Guangdong Province (B2013107), Key Medical
   Laboratory of Guangdong Province, and National Key Clinical Specialty
   Discipline Construction Program of China.
CR Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
   [Anonymous], 2014, CHINESE J DIABETES M, V6, P447
   Butler AE, 2013, DIABETES, V62, P2595, DOI 10.2337/db12-1686
   Chen AL, 2012, DIABETES CARE, V35, P474, DOI 10.2337/dc11-1638
   Diaz-Soto G, 2014, DIABETES RES CLIN PR, V104, P92, DOI 10.1016/j.diabres.2014.01.019
   Flint A, 2011, ADV THER, V28, P213, DOI 10.1007/s12325-010-0110-x
   Garber A, 2009, LANCET, V373, P473, DOI 10.1016/S0140-6736(08)61246-5
   Hu Y, 2011, DIABETES CARE, V34, P1848, DOI 10.2337/dc10-2105
   Huang ZM, 2013, DIABETES TECHNOL THE, V15, P859, DOI 10.1089/dia.2013.0013
   Ilkova H, 1997, DIABETES CARE, V20, P1353, DOI 10.2337/diacare.20.9.1353
   Lane W, 2014, DIABETES OBES METAB, V16, P827, DOI 10.1111/dom.12286
   Li YB, 2004, DIABETES CARE, V27, P2597, DOI 10.2337/diacare.27.11.2597
   Montane J, 2014, DIABET METAB SYND OB, V7, P25, DOI 10.2147/DMSO.S37649
   Mu J, 2011, DIABETOLOGIA, V54, P2381, DOI 10.1007/s00125-011-2217-2
   Retnakaran R, 2014, DIABETES CARE, V37, P3270, DOI 10.2337/dc14-0893
   Rigato M, 2014, DIABET METAB SYND OB, V7, P107, DOI 10.2147/DMSO.S37644
   Schwasinger-Schmidt T, 2013, PHARMACOL RES, V76, P58, DOI 10.1016/j.phrs.2013.07.005
   Shanik MH, 2008, DIABETES CARE, V31, pS262, DOI 10.2337/dc08-s264
   Sturis J, 2003, BRIT J PHARMACOL, V140, P123, DOI 10.1038/sj.bjp.0705397
   Vincent M, 2003, ENDOCRINOLOGY, V144, P4061, DOI 10.1210/en.2003-0088
   Wajchenberg BL, 2007, ENDOCR REV, V28, P187, DOI 10.1210/er.2006-0038
   Weng JP, 2008, LANCET, V371, P1753, DOI 10.1016/S0140-6736(08)60762-X
   Xu Y, 2013, JAMA-J AM MED ASSOC, V310, P948, DOI 10.1001/jama.2013.168118
NR 23
TC 4
Z9 7
U1 5
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6745
EI 2314-6753
J9 J DIABETES RES
JI J. Diabetes Res.
PY 2016
AR 6839735
DI 10.1155/2016/6839735
PG 7
WC Endocrinology & Metabolism; Medicine, Research & Experimental
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA DA7GI
UT WOS:000367972200001
PM 26640805
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Liao, AY
   Shi, RR
   Jiang, YL
   Tian, SQ
   Li, PP
   Song, FX
   Qu, YL
   Li, JN
   Yun, HQ
   Yang, XS
AF Liao, Anyan
   Shi, Ranran
   Jiang, Yuliang
   Tian, Suqing
   Li, Panpan
   Song, Fuxi
   Qu, Yalan
   Li, Jinna
   Yun, Haiqin
   Yang, Xiangshan
TI RETRACTED: SDF-1/CXCR4 Axis Regulates Cell Cycle Progression and
   Epithelial-Mesenchymal Transition via Up-regulation of Survivin in
   Glioblastoma (Retracted article. See vol. 54, pg. 7550, 2017)
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article; Retracted Publication
DE SDF-1/CXCR4; Survivin; Cell cycle progression; EMT
ID TGF-BETA; CANCER CELLS; D1; RADIOTHERAPY; MECHANISMS; EXPRESSION;
   CARCINOMA; GLIOMAS
AB Stromal cell-derived factor 1 (SDF-1)/CXCR4 ligand-receptor axis is widely recommended as an attractive target for cancer therapy. Meanwhile, epithelial-mesenchymal transition (EMT) process is linked to disease pathophysiology. As one of inhibitors of apoptosis proteins, survivin is implicated in the onset and development of cancer. In the present study, we tried to determine the cause-effect associations between SDF-1/CXCR4 axis and survivin expression in glioblastoma U-251 cell line. Survivin activation and inhibition were induced with exogenous SDF-1 and survivin small interfering RNA (survivin siRNA), respectively. Western blot was used to detect relevant proteins in SDF-1/CXCR4 axis. Western blot analysis revealed that survivin expression in U-251 increased in a dose- and time-dependent manner in response to SDF-1 treatment. However, the interference with MEK/ERK and PI3K/AKT pathway prohibited SDF-1-induced survivin up-regulation. Importantly, survivin knockdown abrogated cell cycle progression and the expression of snail and N-cadherin, compared with non-transfectants. In conclusion, the present study shows that SDF-1 up-regulates survivin via MEK/ERK and PI3K/AKT pathway, leading to cell cycle progression and EMT occurrence dependent on survivin. The blockade of survivin will allow for the treatment of glioblastoma.
C1 [Liao, Anyan; Jiang, Yuliang; Tian, Suqing; Li, Jinna] Peking Univ, Hosp 3, Dept Radiat Oncol, Beijing 100191, Peoples R China.
   [Shi, Ranran] Shandong Univ, Shandong Prov Hosp, Dept Gen Surg, Jinan, Shandong, Peoples R China.
   [Li, Panpan; Song, Fuxi; Qu, Yalan] Shandong Univ, Qilu Hosp, Sch Med, Jinan, Shandong, Peoples R China.
   [Yun, Haiqin] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Shandong, Peoples R China.
   [Yang, Xiangshan] Affiliated Hosp Shandong Acad Med Sci, Dept Pathol, Jinan, Shandong, Peoples R China.
RP Liao, AY (reprint author), Peking Univ, Hosp 3, Dept Radiat Oncol, 49 Hua Yuan Bei Lu, Beijing 100191, Peoples R China.
EM liaoanyan323@126.com
CR Ahn SH, 2014, CELL ONCOL, V37, P377, DOI 10.1007/s13402-014-0198-0
   Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   Balogh P, 2013, PATHOL ONCOL RES, V19, P141, DOI 10.1007/s12253-012-9595-8
   Buckner JC, 2003, SEMIN ONCOL, V30, P10, DOI 10.1053/j.seminoncol.2003.11.031
   Dave B, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2938
   Fuxe J, 2012, SEMIN CANCER BIOL, V22, P455, DOI 10.1016/j.semcancer.2012.05.004
   Gao DC, 2012, CANCER RES, V72, P4883, DOI 10.1158/0008-5472.CAN-12-1223
   Guha M, 2009, CELL CYCLE, V8, P2708, DOI 10.4161/cc.8.17.9457
   Kokontis JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109170
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Li TY, 2014, CELL PHYSIOL BIOCHEM, V34, P1351, DOI 10.1159/000366342
   Li W, 2013, INT J MOL MED, V32, P271, DOI 10.3892/ijmm.2013.1405
   Li YM, 2013, CURR CANCER DRUG TAR, V13, P957, DOI 10.2174/15680096113136660101
   Lladser A, 2011, ADV CANCER RES, V111, P1, DOI 10.1016/B978-0-12-385524-4.00001-5
   Miyazono K, 2009, P JPN ACAD B-PHYS, V85, P314, DOI 10.2183/pjab.85.314
   Moustakas A, 2014, BBA-GEN SUBJECTS, V1840, P2621, DOI 10.1016/j.bbagen.2014.02.004
   Ravikumar G, 2014, J CANCER RES THER, V10, P671, DOI 10.4103/0973-1482.138135
   Rekhi B, 2014, INDIAN J PATHOL MICR, V57, P606, DOI 10.4103/0377-4929.142689
   Roy I, 2014, SURGERY, V155, P961, DOI 10.1016/j.surg.2014.02.006
   Soppa U, 2014, CELL CYCLE, V13, P2084, DOI 10.4161/cc.29104
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333
   Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90
   Woodworth GE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00126
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yang Y, 2014, ONCOL REP, V31, P2759, DOI 10.3892/or.2014.3127
   Yoshie Osamu, 2013, Nihon Rinsho Meneki Gakkai Kaishi, V36, P189
NR 27
TC 18
Z9 18
U1 3
U2 12
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD JAN
PY 2016
VL 53
IS 1
BP 210
EP 215
DI 10.1007/s12035-014-9006-0
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA DB0CN
UT WOS:000368176300019
PM 25421212
DA 2018-12-27
ER

PT J
AU Lv, MY
   Deng, SL
   Long, XF
AF Lv, Ming-Yi
   Deng, Shu-Ling
   Long, Xiao-Feng
TI RETRACTED: rhBNP therapy can improve clinical outcomes and reduce
   in-hospital mortality compared with dobutamine in heart failure
   patients: a meta-analysis (Retracted article. See vol. 81, pg. 1005,
   2016)
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE dobutamine; heart failure; in-hospital mortality; meta-analysis;
   re-admission; recombinant human brain natriuretic peptide
ID BRAIN NATRIURETIC PEPTIDE; LEFT-VENTRICULAR FUNCTION; EJECTION FRACTION;
   SKELETAL-MUSCLE; ESC GUIDELINES; TASK-FORCE; METAANALYSIS; NESIRITIDE;
   HETEROGENEITY; DIAGNOSIS
AB AimsA meta-analysis was performed to compare the therapeutic outcomes in patients treated for heart failure (HF) with recombinant human brain natriuretic peptide (rhBNP) and dobutamine.
   MethodsPubMed, Embase and the Chinese Biomedical Database were exhaustively searched to identify studies relevant to this meta-analysis. Eight cohort studies were found suitable for inclusion. Data regarding trial validity, methodological processes and clinical outcomes were extracted.
   ResultsPatients treated with rhBNP showed statistically significant reduction of in-hospital mortality and re-admission rates compared with the dobutamine treated patient group (both P<0.05). Further, the rhBNP treated patient group showed higher survival outcomes, compared with dobutamine treated patients, when the post-treatment follow-up period was longer than 6months (P<0.05). Stratified analysis based on ethnicity showed a dramatic decrease of in-hospital mortality among mixed race HF patients receiving rhBNP treatment (P<0.05), but such decreases were not statistically significant in Asian and Caucasian populations (both P>0.05). On the other hand, re-admission rates were significantly lower in rhBNP treated Caucasian and mixed race populations (both P<0.05). Notably, in rhBNP treated group, dose levels of 0.015 and 0.03 incrementally lowered the re-admission rates, displaying dose effect, and the re-admission rates at both rhBNP doses were significantly lower than the dobutamine treated group (both P<0.05).
   ConclusionsOur meta-analysis results suggested that rhBNP therapy is associated with lower in-hospital mortality and re-admission rates in HF patients compared to the dobutamine regimen. Nevertheless, large scale prospective, randomized trials are necessary to confirm these findings.
C1 [Lv, Ming-Yi; Deng, Shu-Ling; Long, Xiao-Feng] Dalian Univ, Zhongshan Hosp, Dept Internal Med, ICU, Dalian 116000, Liaoning Provin, Peoples R China.
RP Long, XF (reprint author), Dalian Univ, Zhongshan Hosp, Dept Internal Med, ICU, 6 Jiefang St, Dalian 116000, Liaoning Provin, Peoples R China.
EM longxiaofeng88@sina.cn
CR Anguita M, 2012, REV ESP CARDIOL, V65, P874, DOI [10.1016/j.recesp.2012.07.013, 10.1016/j.rec.2012.07.005]
   Arnold LM, 2006, PHARMACOTHERAPY, V26, P1078, DOI 10.1592/phco.26.8.1078
   Barbosa MM, 2012, REV PORT CARDIOL, V31, P287, DOI 10.1016/j.repc.2012.02.002
   Bergh CH, 2010, EUR J HEART FAIL, V12, P404, DOI 10.1093/eurjhf/hfq032
   Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165
   Burger AJ, 2001, AM J CARDIOL, V88, P35, DOI 10.1016/S0002-9149(01)01581-8
   Casas JP, 2011, COCHRANE DB SYST REV, V2011, DOI [10.1002/14651858.ED000008, DOI 10.1002/14651858]
   Cataliotti A, 2012, MAYO CLIN PROC, V87, P413, DOI 10.1016/j.mayocp.2012.02.003
   Chen H, 2012, BIOMETRICS, V68, P1278, DOI 10.1111/j.1541-0420.2012.01761.x
   Cubbon RM, 2011, CIRC-HEART FAIL, V4, P396, DOI 10.1161/CIRCHEARTFAILURE.110.959882
   de Lissovoy G, 2003, AM J CARDIOL, V92, P631, DOI 10.1016/S0002-9149(03)00742-2
   densUil CA, 2014, PLOS ONE, V9
   Dickey DM, 2011, J MOL CELL CARDIOL, V51, P67, DOI 10.1016/j.yjmcc.2011.03.013
   Dickstein K, 2008, EUR J HEART FAIL, V10, P933, DOI 10.1016/j.ejheart.2008.08.005
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fox PR, 2015, J VET INTERN MED, V29, P171, DOI [10.1111/jvim.12474, 10.1111/jvim.12472]
   Fu XP, 2012, J SE U, V31, P93
   Gerhard T, 2006, PHARMACOTHERAPY, V26, P34, DOI 10.1592/phco.2006.26.1.34
   Gheorghiade M, 2011, AM HEART J, V161, P224, DOI 10.1016/j.ahj.2010.10.023
   Gielen S, 2012, CIRCULATION, V125, P2716, DOI 10.1161/CIRCULATIONAHA.111.047381
   Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONHA.105.167586
   Kitzman DW, 2014, AM J PHYSIOL-HEART C, V306, pH1364, DOI 10.1152/ajpheart.00004.2014
   Kogler H, 2006, CIRCULATION, V113, P2724, DOI 10.1161/CIRCULATIONHA.105.608828
   Kramer DB, 2011, NEW ENGL J MED, V365, P1547, DOI 10.1056/NEJMc1109292
   Liu SQ, 2012, HEART LUNG CIRC, V21, P551, DOI 10.1016/j.hlc.2012.04.013
   Monica F, 2014, OA BIOCH, V2, P3
   Morrissey RP, 2011, AM J CARDIOVASC DRUG, V11, P153, DOI 10.2165/11592090-000000000-00000
   Nakajima-Takenaka C, 2005, EXP PHYSIOL, V90, P635, DOI 10.1113/expphysiol.2005.030460
   O'Connor CM, 2011, NEW ENGL J MED, V365, P32, DOI 10.1056/NEJMoa1100171
   Pan HY, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-31
   Paraskevaidis IA, 2014, INT J CARDIOL, V176, P1438, DOI 10.1016/j.ijcard.2014.08.038
   Partovian C, 2012, J AM COLL CARDIOL, V60, P1402, DOI 10.1016/j.jacc.2012.07.011
   Pleister Adam P, 2011, Curr Heart Fail Rep, V8, P226, DOI 10.1007/s11897-011-0066-4
   Ren B, 2010, TRANSPL P, V42, P4496, DOI 10.1016/j.transproceed.2010.09.163
   Saito Y, 2010, J CARDIOL, V56, P262, DOI 10.1016/j.jjcc.2010.08.001
   Schiffer AA, 2010, INT J CARDIOL, V142, P230, DOI 10.1016/j.ijcard.2008.12.090
   Silver MA, 2002, J AM COLL CARDIOL, V39, P798, DOI 10.1016/S0735-1097(01)01818-6
   Steinberg BA, 2012, CIRCULATION, V126, P65, DOI 10.1161/CIRCULATIONAHA.111.080770
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Tacon CL, 2012, INTENS CARE MED, V38, P359, DOI 10.1007/s00134-011-2435-6
   Tuy T, 2012, SEMIN NEPHROL, V32, P112, DOI 10.1016/j.semnephrol.2011.11.014
   Vink S, 2012, TOXICON, V59, P434, DOI 10.1016/j.toxicon.2010.12.001
   Wang JC, 2013, J SURG RES, V183, P509, DOI 10.1016/j.jss.2013.02.051
   Wang SJ, 2014, PHARMAZIE, V69, P212, DOI 10.1691/ph.2014.3738
   Zhang J, 2010, ACTA RADIOL, V51, P641, DOI 10.3109/02841851.2010.486804
   Zhang JB, 2013, MOL MED REP, V7, P628, DOI 10.3892/mmr.2012.1185
   Zhang W, 2015, CARDIOVASC DIS PREV, P93
   Zhao FJ, 2014, CARDIOVASC THER, V32, P283, DOI 10.1111/1755-5922.12097
   Zhao Q, 2010, HEART VESSELS, V25, P97, DOI 10.1007/s00380-009-1171-0
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
   Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048
NR 53
TC 5
Z9 7
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD JAN
PY 2016
VL 81
IS 1
BP 174
EP 185
DI 10.1111/bcp.12788
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DA0EW
UT WOS:000367470800021
PM 26382927
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Banifatemi, SS
   Mohammadifard, H
   Amiri, MC
AF Banifatemi, Sina S.
   Mohammadifard, Hossein
   Amiri, Mohammad C.
TI RETRACTED: Influence of the Disk Diameter and Baffle Position on the
   Performance of Generated Colloidal Gas Aphrons (Retracted article. See
   vol. 19, pg. 1093, 2016)
SO JOURNAL OF SURFACTANTS AND DETERGENTS
LA English
DT Article; Retracted Publication
DE Colloidal gas aphrons; Performance; Spinning disk diameter; Baffle
   position; Drainage curve
ID SURFACTANT SOLUTIONS; CATIONIC SURFACTANT; ANIONIC SURFACTANT; NATURAL
   SURFACTANT; PROTEIN RECOVERY; WASTE-WATER; SEPARATION; SOIL; REMOVAL;
   FLOTATION
AB Aphrons are surfactant-stabilized microbubbles with thick soapy shells. Colloidal gas aphrons (CGA) with an average diameter of 50 mu m have some unique properties: a high interfacial area due to their small size, a thick soapy shell and, above all, high stability compared to conventional foams. Various factors that can influence the performance of CGA dispersion, such as the type and concentration of surfactant, mixing time and processing parameters, have already been extensively studied. However, although CGA applications in various fields continue to advance, the influence of the disk diameter and baffle position of the aphron generator on the performance of CGAs has not been well studied. In this experimental work, the influences of the spinning disk diameter and baffle position inside the aphron generator have been investigated. Analyzing the drainage curve of various experimental runs revealed that the disk diameter and baffle position might have a positive impact on the stability of CGA dispersion particularly when the generation time or surfactant concentration is low. The experimental findings have been supported by other techniques such as half-life time and a new stability index, T (0.1), the time elapsed when the drained liquid from CGA dispersion reaches ten percent of its final height.
C1 [Banifatemi, Sina S.; Mohammadifard, Hossein; Amiri, Mohammad C.] Isfahan Univ Technol, Dept Chem Engn, Esfahan, Iran.
RP Amiri, MC (reprint author), Isfahan Univ Technol, Dept Chem Engn, Esfahan, Iran.
EM amir33@cc.iut.ac.ir
FU Isfahan University of Technology
FX The authors wish to acknowledge the financial support from the research
   deputy at Isfahan University of Technology.
CR Abdullah SF, 2006, COLLOID SURFACE A, V280, P88, DOI 10.1016/j.colsurfa.2006.01.042
   AMIRI MC, 1990, CHEM ENG RES DES, V68, P154
   Amiri MC, 2004, SEP PURIF TECHNOL, V35, P161, DOI 10.1016/j.seppur.2003.08.007
   Basu S, 2001, SEPAR SCI TECHNOL, V36, P2997, DOI 10.1081/SS-100107642
   Couto HJB, 2009, J HAZARD MATER, V164, P1325, DOI 10.1016/j.jhazmat.2008.09.129
   Fuda E, 2005, BIOTECHNOL BIOENG, V90, P532, DOI 10.1002/bit.20412
   Fuda E, 2004, BIOTECHNOL PROGR, V20, P514, DOI 10.1021/bp034198d
   Gerken BM, 2006, SEP PURIF TECHNOL, V49, P291, DOI 10.1016/j.seppur.2005.09.015
   Huang Y, 2002, TSINGHUA SCI TECHNOL, V7, P46
   Jauregi P, 1998, BIOTECHNOL BIOENG, V59, P471, DOI 10.1002/(SICI)1097-0290(19980820)59:4<471::AID-BIT10>3.0.CO;2-D
   Jauregi P, 1997, CHEM ENG J, V65, P1
   Kefala MI, 1999, ENVIRON POLLUT, V104, P283, DOI 10.1016/S0269-7491(98)00178-X
   Kommalapati RR, 1997, WATER RES, V31, P2161, DOI 10.1016/S0043-1354(97)00052-3
   Mansur EHA, 2006, SEP PURIF TECHNOL, V48, P71, DOI 10.1016/j.seppur.2005.07.022
   MATIS KA, 2003, WATER AIR SOIL POLL, V3, P143
   MATSUSHITA K, 1992, COLLOID SURFACE, V69, P65, DOI 10.1016/0166-6622(92)80239-X
   Molaei A, 2015, ADV COLLOID INTERFAC, V216, P36, DOI 10.1016/j.cis.2014.12.001
   Moshkelani A, 2008, COLLOID SURFACE A, V317, P262, DOI 10.1016/j.colsurfa.2007.10.034
   Mukhopadhyay S, 2015, INT J ENVIRON SCI TE, V12, P617, DOI 10.1007/s13762-013-0441-7
   Mukhopadhyay S, 2013, J ENVIRON SCI-CHINA, V25, P2247, DOI 10.1016/S1001-0742(12)60295-2
   Mulligan CN, 2003, ENG GEOL, V70, P269, DOI 10.1016/S0013-7952(03)00095-4
   Noble MJ, 1999, J CHEM TECHNOL BIOT, V74, P231, DOI 10.1002/(SICI)1097-4660(199903)74:3<231::AID-JCTB20>3.3.CO;2-0
   Paul E.L, 2004, HDB IND MIXING SCI P
   Roghair I, 2013, AICHE J, V59, P1791, DOI 10.1002/aic.13949
   ROY D, 1992, SEPAR SCI TECHNOL, V27, P1555, DOI 10.1080/01496399208029223
   ROY D, 1992, SEPAR SCI TECHNOL, V27, P573, DOI 10.1080/01496399208018903
   SAVE SV, 1994, CHEM ENG COMMUN, V127, P35, DOI 10.1080/00986449408936224
   Sebba F., 1987, FOAMS BILIQUID FOAMS
   Sebba F, 1985, CHEM IND, V4, P91
   Spigno G, 2010, SEP PURIF TECHNOL, V71, P56, DOI 10.1016/j.seppur.2009.11.002
   Zouboulis AI, 2001, SEPAR SCI TECHNOL, V36, P349, DOI 10.1081/SS-100102932
NR 31
TC 1
Z9 1
U1 4
U2 13
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1097-3958
EI 1558-9293
J9 J SURFACTANTS DETERG
JI J. Surfactants Deterg.
PD JAN
PY 2016
VL 19
IS 1
BP 173
EP 181
DI 10.1007/s11743-015-1750-2
PG 9
WC Chemistry, Applied; Chemistry, Physical; Engineering, Chemical
SC Chemistry; Engineering
GA DA1FI
UT WOS:000367541300019
DA 2018-12-27
ER

PT J
AU Wong, SC
   Huang, JC
AF Wong, Shwin-Chung
   Huang, Jhong-Cing
TI RETRACTED: Visualization experiments on the condensation process in the
   vertical tube condenser of a loop thermosyphon (Retracted article. See
   vol. 96, pg. 705, 2016)
SO INTERNATIONAL JOURNAL OF HEAT AND MASS TRANSFER
LA English
DT Article; Retracted Publication
DE Thermosyphon; Loop thermosyphon; Heat pipe; Condensation; Condenser
   resistance; Dropwise condensation; Film condensation; Thin film
   evaporation; Evaporator resistance
ID RESISTANCE MEASUREMENT; HEAT PIPES; 2-PHASE; EVAPORATOR; INSTABILITY;
   WATER
AB This study investigates the condensation processes in the vertical tube condenser of a loop thermosyphon. For visualization, a glass condensation tube with an untreated (static contact angle of 44 degrees) or a hydrophobically-treated (static contact angle of 86 degrees) inner surface is tested. To avoid the interference from unstable boiling, the evaporator is designed to operate with stable thin-film evaporation. The condensation process in the untreated glass tube is in a composite dropwise-film condensation mode. It was essentially dropwise condensation in the upper section. In the middle and lower sections, the condensing drops were intermittently swept down by the liquid streams falling from the upper section. The lower section was mostly covered with liquid films with circumferentially non-uniform thickness. The condensation mode in the hydrophobically-treated tube is dropwise condensation, for which the condenser resistances are less than for untreated glass surface by 1-2 degrees C-cm(2)/W. No nucleate boiling is observed in the evaporator undergoing stable, quiescent thin-film evaporation. The water levels in the evaporator are nearly the same for all heat loads. The evaporator resistances range from 0.28-0.14 degrees C-cm(2)/W for heat loads of 35.6-92.5W. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Wong, Shwin-Chung; Huang, Jhong-Cing] Natl Tsing Hua Univ, Dept Power Mech Engn, Hsinchu 300, Taiwan.
RP Wong, SC (reprint author), Natl Tsing Hua Univ, Dept Power Mech Engn, Hsinchu 300, Taiwan.
FU Ministry of Science and Technology, Taiwan, R.O.C. [MOST
   102-2221-E-007-112-MY2]
FX This work was funded by Ministry of Science and Technology, Taiwan,
   R.O.C. under Contract MOST 102-2221-E-007-112-MY2.
CR Chang CC, 2010, EXP HEAT TRANSFER, V23, P144, DOI 10.1080/08916150903402807
   Chien CC, 2011, ENERGY, V36, P415, DOI 10.1016/j.energy.2010.10.023
   Chu R.C., 1999, 15 IEEE SEMITHERM S
   Dalkilic AS, 2009, INT J HEAT MASS TRAN, V52, P3409, DOI 10.1016/j.ijheatmasstransfer.2009.01.011
   Esen M, 2005, SOL ENERGY, V79, P459, DOI 10.1016/j.solener.2005.01.001
   Franco A, 2012, MICROGRAVITY SCI TEC, V24, P165, DOI 10.1007/s12217-011-9281-6
   Garrity PT, 2009, INT J HEAT MASS TRAN, V52, P1701, DOI 10.1016/j.ijheatmasstransfer.2008.10.005
   Huang ZH, 2012, APPL SURF SCI, V259, P142, DOI 10.1016/j.apsusc.2012.07.006
   Khodabandeh R, 2010, INT J THERM SCI, V49, P1183, DOI 10.1016/j.ijthermalsci.2010.01.016
   Liou JH, 2010, INT J HEAT MASS TRAN, V53, P1498, DOI 10.1016/j.ijheatmasstransfer.2009.11.046
   Milanez F.H., 2010, 15 INT HEAT PIP C CL
   Pal A, 2002, IEEE T COMPON PACK T, V25, P601, DOI 10.1109/TCAPT.2003.807997
   Qu W, 2010, FRONT HEAT PIPES, V1, P1
   Rose JW, 2002, P I MECH ENG A-J POW, V216, P115, DOI 10.1243/09576500260049034
   Samba A, 2013, APPL THERM ENG, V50, P1351, DOI 10.1016/j.applthermaleng.2012.05.023
   Tsai M.C., 2007, 14 INT HEAT PIP C 14
   Wang WC, 1998, INT J HEAT MASS TRAN, V41, P4341, DOI 10.1016/S0017-9310(98)00041-6
   Wong SC, 2012, INT J THERM SCI, V52, P154, DOI 10.1016/j.ijthermalsci.2011.09.020
NR 18
TC 5
Z9 5
U1 6
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0017-9310
EI 1879-2189
J9 INT J HEAT MASS TRAN
JI Int. J. Heat Mass Transf.
PD JAN
PY 2016
VL 92
BP 948
EP 956
DI 10.1016/j.ijheatmasstransfer.2015.09.066
PG 9
WC Thermodynamics; Engineering, Mechanical; Mechanics
SC Thermodynamics; Engineering; Mechanics
GA CW3ID
UT WOS:000364884500090
DA 2018-12-27
ER

PT J
AU Ramalingam, A
   Kanniayan, S
AF Ramalingam, Anantharaj
   Kanniayan, Sathishkumar
TI RETRACTED: Phase Equilibria upon Denitrification of Liquid Fuels Using
   Imidazolium-Based Ionic Liquids: Experiment and Quantum Chemical
   Calculations (Retracted article. See vol. 55, pg. 6551, 2016)
SO INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH
LA English
DT Article; Retracted Publication
ID AB-INITIO CALCULATIONS; COSMO-RS; NITROGEN-COMPOUNDS; HYDROGEN-BOND;
   SYSTEMS; DENSITY; EXTRACTION; PREDICTION; THIOPHENE; SOLVENTS
AB The interaction between pyrrole and pyridine with 1-ethyl-3-methylimidazolium ethyl sulfate ([EMIN] [EtSO4]) was investigated using quantum chemical calculations, the conductor-like screening model for real solvent (COSMO-RS) approach, and experimental ternary liquid liquid equilibrium (LLE) data. Geometry optimization was performed usign density functional theory (DFT) with B3LYP functional and 6-311+G* basis set for individual species and complexes of [EMIM] [EtSO4] with pyrrole/pyridine. The amount of charge transfer in [EMIM] [EtSO4] + pyrrole was found to be similar to 20% greater than that in [EMIM][EtSO4] + pyridine, indicating that CH-pi interaction was stronger with pyrrole. The more negative interaction energy for the complex [EMIM] [EtSO4] + pyrrole implies that [EMIM] [EtSO4] has a more favorable interaction with pyrrole than with pyridine. sigma-profile analysis using COSMO-RS confirmed the pivotal role of the CH-pi interaction between [EMIM][EtSO4] and pyrrole or pyridine. Ternary LLE experiments were performed at 298.15 K and atmospheric pressure to compare the extraction efficiency of pyrrole and pyridine from model diesel compound (n-hexadecane) using [EMIM][EtSO4]. The experimental data showed that [EMIM] [EtSO4] had a higher extraction efficiency for pyrrole than for pyridine, hence validating the computational results. The experimental data were well-correlated by the NRTL model with an average root-mean-square deviation (RNISD) of 0.28%, and COSMO-RS gave excellent prediction of the LLE data, with an average RMSD of 0.99%.
C1 [Ramalingam, Anantharaj; Kanniayan, Sathishkumar] SSN Coll Engn, Dept Chem Engn, Madras 603110, Tamil Nadu, India.
RP Ramalingam, A (reprint author), SSN Coll Engn, Dept Chem Engn, Madras 603110, Tamil Nadu, India.
EM anantharajr@ssn.edu.in
CR Anantharaj R, 2011, AICHE J, V57, P749, DOI 10.1002/aic.12281
   Anantharaj R, 2010, IND ENG CHEM RES, V49, P8705, DOI 10.1021/ie901341k
   [Anonymous], 2013, COSMOTHERMX GRAPH US
   AVENT AG, 1994, J CHEM SOC DALTON, P3405, DOI 10.1039/dt9940003405
   Banerjee T, 2006, IND ENG CHEM RES, V45, P3207, DOI 10.1021/ie051116c
   Banerjee T, 2008, AICHE J, V54, P1874, DOI 10.1002/aic.11495
   Banerjee T, 2007, IND ENG CHEM RES, V46, P1292, DOI 10.1021/ie060647d
   Banerjee T, 2006, J CHEM ENG DATA, V51, P2170, DOI 10.1021/je0602925
   BECKE AD, 1986, J CHEM PHYS, V84, P4524, DOI 10.1063/1.450025
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001
   Bondi A. A., 1968, PHYS PROPERTIES MOL
   BRENEMAN CM, 1990, J COMPUT CHEM, V11, P361, DOI 10.1002/jcc.540110311
   Cassol CC, 2007, INT J MOL SCI, V8, P593, DOI 10.3390/i8070593
   Deepa P, 2008, BIOPHYS CHEM, V136, P50, DOI 10.1016/j.bpc.2008.04.007
   Eckert F, 2002, AICHE J, V48, P369, DOI 10.1002/aic.690480220
   Foresman J. B., 1996, EXPLORING CHEM ELECT
   Frisch M. J., 2003, GAUSSIAN 03 REVISION
   Hand DB, 1930, J PHYS CHEM-US, V34, P1961, DOI 10.1021/j150315a009
   Hirota M, 2000, J PHYS ORG CHEM, V13, P620, DOI 10.1002/1099-1395(200010)13:10<620::AID-POC262>3.0.CO;2-F
   Hunt PA, 2007, AUST J CHEM, V60, P9, DOI 10.1071/CH06301
   Hwang IC, 2009, J CHEM ENG DATA, V54, P78, DOI 10.1021/je8006265
   KLAMT A, 1995, J PHYS CHEM-US, V99, P2224, DOI 10.1021/j100007a062
   KLAMT A, 1993, J CHEM SOC PERK T 2, P799, DOI 10.1039/p29930000799
   Klamt A, 2000, FLUID PHASE EQUILIBR, V172, P43, DOI 10.1016/S0378-3812(00)00357-5
   Klamt A., 2005, COSMO RS QUANTUM CHE
   Kumar AAP, 2009, FLUID PHASE EQUILIBR, V278, P1, DOI 10.1016/j.fluid.2008.11.019
   Meng Z, 2002, J MOL STRUC-THEOCHEM, V585, P119, DOI 10.1016/S0166-1280(02)00056-8
   Othmer DF, 1942, IND ENG CHEM, V34, P690, DOI 10.1021/ie50390a011
   PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822
   Poole CF, 2010, J CHROMATOGR A, V1217, P2268, DOI 10.1016/j.chroma.2009.09.011
   RENON H, 1968, AICHE J, V14, P135, DOI 10.1002/aic.690140124
   SCHAFER A, 1994, J CHEM PHYS, V100, P5829, DOI 10.1063/1.467146
   Schaftenaar G, 2000, J COMPUT AID MOL DES, V14, P123, DOI 10.1023/A:1008193805436
   Singh MK, 2005, COMPUT CHEM ENG, V29, P1712, DOI 10.1016/j.compchemeng.2005.02.020
   SOSA C, 1992, J PHYS CHEM-US, V96, P6630, DOI 10.1021/j100195a022
   Suezawa H, 2000, J CHEM SOC PERK T 2, V6, P1243
   Suezawa H, 2004, EUR J ORG CHEM, P4816, DOI 10.1002/ejoc.20040373
   Turaga UT, 2003, CATAL TODAY, V86, P265, DOI 10.1016/S0920-5861(03)00464-4
   Turner EA, 2003, J PHYS CHEM A, V107, P2277, DOI 10.1021/jp021694w
   United States Environmental Protection Agency (USEPA), 1999, CLEAN AIR ACT TIER, V2
   Zhang SG, 2004, IND ENG CHEM RES, V43, P614, DOI 10.1021/ie030561+
   Zhou JX, 2008, FUEL PROCESS TECHNOL, V89, P1456, DOI 10.1016/j.fuproc.2008.07.006
NR 42
TC 3
Z9 3
U1 4
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0888-5885
J9 IND ENG CHEM RES
JI Ind. Eng. Chem. Res.
PD DEC 30
PY 2015
VL 54
IS 51
BP 12948
EP 12959
DI 10.1021/acs.iecr.5b01962
PG 12
WC Engineering, Chemical
SC Engineering
GA DA3MQ
UT WOS:000367702200025
DA 2018-12-27
ER

PT J
AU Li, B
AF Li, Bin
TI RETRACTED: Shear and shuffle in {11(2)over-bar2}<
   11(2)over-bar(3)over-bar > twinning in titanium (Retracted article. See
   vol. 31, pg. 2361, 2016)
SO JOURNAL OF MATERIALS RESEARCH
LA English
DT Article; Retracted Publication
ID HCP METALS; PLASTIC-DEFORMATION; ZONAL DISLOCATIONS; CRYSTALS;
   MAGNESIUM; ZIRCONIUM; TWINS
AB In classical twinning theory, the K-2 plane of {11 (2) over bar2}< 11 (2) over bar(3) over bar > twinning mode was predicted to be {11 (2) over bar(4) over bar}, with a twinning shear of similar to 0.22 which was experimentally "confirmed". However, these twinning elements cannot be reproduced or verified in atomistic simulations. The K-2 plane in the simulations is always (0001), but this K-2 plane would lead to a nominal twining shear of 1.26 which is unrealistically large. In this work, atomistic simulations were performed to investigate the migration of {11 (2) over bar2} twin boundary in titanium (Ti). Shear and atomic shuffles for three different, reported K-2 planes were analyzed in great detail, for the first time. The analyses show that K-2 = {11 (2) over bar(4) over bar} leads to very complex shuffles despite the small twinning shear and is unfavorable. If K-2 = {11 (2) over bar(2) over bar}, only half of the parent atoms are involved in the shuffling, but the twinning shear is very large (0.96) and is also unfavorable. When K-2 = (0001), the parent atoms are carried to twin positions partly by shear and partly by a simple shuffle. Because shuffling makes no contribution to the twinning shear, the actual twinning shear is 0.66, instead of 1.26. Thus, K-2 = (0001) is the most favorable and the conflict between the simulation results and the classical twinning theory can be reconciled.
C1 [Li, Bin] Univ Nevada, Dept Chem & Mat Engn, Reno, NV 89557 USA.
RP Li, B (reprint author), Univ Nevada, Dept Chem & Mat Engn, Reno, NV 89557 USA.
EM binl@unr.edu
CR Abbaschian R., 2008, PHYS METALLURGY PRIN
   BILBY BA, 1965, PROC R SOC LON SER-A, V288, P240, DOI 10.1098/rspa.1965.0216
   CHRISTIAN JW, 1995, PROG MATER SCI, V39, P1, DOI 10.1016/0079-6425(94)00007-7
   DAW MS, 1984, PHYS REV B, V29, P6443, DOI 10.1103/PhysRevB.29.6443
   DAW MS, 1983, PHYS REV LETT, V50, P1285, DOI 10.1103/PhysRevLett.50.1285
   Hall E.O., 1954, TWINNING DIFFUSIONLE
   KELLY EW, 1968, T METALL SOC AIME, V242, P654
   KRONBERG ML, 1957, ACTA METALL MATER, V5, P507, DOI 10.1016/0001-6160(57)90090-1
   Li B, 2012, PHILOS MAG, V92, P1006, DOI 10.1080/14786435.2011.637985
   Li B, 2009, ACTA MATER, V57, P4500, DOI 10.1016/j.actamat.2009.06.014
   Li B, 2009, ACTA MATER, V57, P1734, DOI 10.1016/j.actamat.2008.12.016
   MAHAJAN S, 1973, ACTA METALL MATER, V21, P1353, DOI 10.1016/0001-6160(73)90085-0
   Mason TA, 2002, METALL MATER TRANS A, V33, P949
   MENDELSON S, 1969, MATER SCI ENG, V4, P231, DOI 10.1016/0025-5416(69)90067-6
   MENDELSON S, 1970, J APPL PHYS, V41, P1893, DOI 10.1063/1.1659139
   Nabarro F. R. N., 1979, DISLOCATIONS SOLIDS, V2
   Niewczas M, 2010, ACTA MATER, V58, P5848, DOI 10.1016/j.actamat.2010.06.059
   PATON NE, 1970, METALL TRANS, V1, P2839
   RAPPERPORT EJ, 1959, ACTA METALL MATER, V7, P254, DOI 10.1016/0001-6160(59)90018-5
   REEDHILL RE, 1957, ACTA METALL MATER, V5, P717, DOI 10.1016/0001-6160(57)90074-3
   REEDHILL RE, 1963, ACTA METALL MATER, V11, P73
   Serra A, 2005, MAT SCI ENG A-STRUCT, V400, P496, DOI 10.1016/j.msea.2005.01.067
   THOMPSON N, 1952, PHILOS MAG, V43, P422
   WESTLAKE DG, 1961, ACTA METALL MATER, V9, P327, DOI 10.1016/0001-6160(61)90226-7
   WONSIEWICZ BC, 1967, T METALL SOC AIME, V239, P1422
   Xu F, 2012, MAT SCI ENG A-STRUCT, V541, P190, DOI 10.1016/j.msea.2012.02.021
   Yu Q, 2010, NATURE, V463, P335, DOI 10.1038/nature08692
   Zope RR, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.024102
NR 28
TC 2
Z9 2
U1 3
U2 19
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0884-2914
EI 2044-5326
J9 J MATER RES
JI J. Mater. Res.
PD DEC 28
PY 2015
VL 30
IS 24
BP 3795
EP 3802
DI 10.1557/jmr.2015.371
PG 8
WC Materials Science, Multidisciplinary
SC Materials Science
GA CZ8FT
UT WOS:000367336300008
DA 2018-12-27
ER

PT J
AU Zhu, YW
   Lu, L
   Li, WX
   Zhang, LY
   Ji, C
   Lin, X
   Liu, HC
   Odle, J
   Luo, XG
AF Zhu, Yong-Wen
   Lu, Lin
   Li, Wen-Xiang
   Zhang, Li-Yang
   Ji, Cheng
   Lin, Xi
   Liu, Hsiao-Ching
   Odle, Jack
   Luo, Xu-Gang
TI RETRACTED: Effect of dietary manganese on antioxidant status and
   expression levels of heat-shock proteins and factors in tissues of
   laying broiler breeders under normal and high environmental temperatures
   (Retracted article. See vol. 119, pg. 117, 2018)
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article; Retracted Publication
DE Broiler breeders; Manganese; Heat stress; Antioxidant status; Heat-shock
   proteins/factors
ID RELATIVE BIOAVAILABILITY; TRANSCRIPTION FACTORS; METHIONINE COMPLEX;
   GALLUS-DOMESTICUS; GENE-EXPRESSION; THERMAL-STRESS; JAPANESE-QUAIL;
   FREE-RADICALS; CELLS; SUPPLEMENTATION
AB To investigate the effect of Mn on antioxidant status and expression levels of heat-shock proteins/factors in tissues of laying broiler breeders subjected to heat challenge, we used a completely randomised design (n 6) with a factorial arrangement of 2 environmental temperatures (normal, 21 (SEM 1)degrees C and high, 32 (SEM 1)degrees C)x3 dietary Mn treatments (an Mn-unsupplemented basal diet (CON), or a basal diet supplemented with 120 mg Mn/kg diet as inorganic Mn sulphate (iMn) or organic Mn proteinate (oMn)). There were no interactions (P>0.10) between environmental temperature and dietary Mn in all of the measured indices. High temperature decreased (P<0.003) Mn content, and also tended (P=0.07) to decrease copper zinc superoxide dismutase (CuZnSOD) activity in the liver and heart. However, an increased manganese superoxide dismutase (MnSOD) activity (P<0.05) and a slight increase of malondialdehyde level (P=0.06) were detected in breast muscle. Up-regulated (P<0.05) expression levels of heat-shock factor 1 (HSF1) and HSF3 mRNA and heat-shock protein 70 (HSP70) mRNA and protein were found in all three tissues. Broiler breeders fed either iMn or oMn had higher tissue Mn content (P<0.0001), heart MnSOD and CuZnSOD activities (P<0.01) and breast muscle MnSOD protein levels (P<0.05), and lower (P<0.05) breast muscle HSP70 mRNA and protein levels than those fed CON. Broiler breeders fed oMn had higher (P<0.03) bone Mn content than those fed iMn. These results indicate that high temperature decreases Mn retention and increases HSP70 and HSF1, HSF3 expression levels in tissues of laying broiler breeders. Furthermore, dietary supplementation with Mn in either source may enhance heart antioxidant ability and inhibit the expression of HSP70 in breast muscle. Finally, the organic Mn appears to be more available than inorganic Mn for bone in laying broiler breeders regardless of environmental temperatures.
C1 [Zhu, Yong-Wen; Lu, Lin; Li, Wen-Xiang; Zhang, Li-Yang; Luo, Xu-Gang] Chinese Acad Agr Sci, Inst Anim Sci, Mineral Nutr Res Div, Beijing 100193, Peoples R China.
   [Zhu, Yong-Wen; Ji, Cheng] China Agr Univ, Coll Anim Sci & Technol, Beijing 100193, Peoples R China.
   [Lin, Xi; Liu, Hsiao-Ching; Odle, Jack] N Carolina State Univ, Dept Anim Sci, Raleigh, NC 27695 USA.
RP Luo, XG (reprint author), Chinese Acad Agr Sci, Inst Anim Sci, Mineral Nutr Res Div, Beijing 100193, Peoples R China.
EM wlysz@263.net
RI Odle, Jack/K-9660-2017
OI Odle, Jack/0000-0003-4965-2096
FU Key International Cooperation Program of the National Natural Science
   Foundation of China (Beijing, People's Republic of China) [31110103916];
   Agricultural Science and Technology Innovation Program (Beijing,
   People's Republic of China) [ASTIP-IAS08]; China Agriculture Research
   System (Beijing, People's Republic of China) [CARS-42]
FX The present study was supported by the Key International Cooperation
   Program of the National Natural Science Foundation of China (project no.
   31110103916; Beijing, People's Republic of China), the Agricultural
   Science and Technology Innovation Program (ASTIP-IAS08; Beijing,
   People's Republic of China) and the China Agriculture Research System
   (project no. CARS-42; Beijing, People's Republic of China).
CR Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938
   Association of Official Analytical Chemists, 1990, OFFICIAL METHODS ANA
   Bai SP, 2012, BRIT J NUTR, V108, P267, DOI 10.1017/S0007114511005629
   BELAY T, 1992, POULTRY SCI, V71, P1043, DOI 10.3382/ps.0711043
   Burdon R H, 1987, Free Radic Res Commun, V3, P129, DOI 10.3109/10715768709069778
   DEROSA G, 1980, J NUTR, V110, P795
   Flanagan SW, 1998, FEBS LETT, V431, P285, DOI 10.1016/S0014-5793(98)00779-0
   Hai L, 2006, COMP BIOCHEM PHYS A, V144, P11, DOI 10.1016/j.cbpa.2006.01.032
   HENRY PR, 1992, J DAIRY SCI, V75, P3473, DOI 10.3168/jds.S0022-0302(92)78123-5
   HENRY PR, 1989, POULTRY SCI, V68, P107, DOI 10.3382/ps.0680107
   LI GC, 1989, INT J HYPERTHER, V5, P389, DOI 10.3109/02656738909140466
   Li S, 2004, J ANIM SCI, V82, P2352
   Li SF, 2005, ANIM FEED SCI TECH, V124, P703, DOI 10.1016/j.anifeedsci.2005.04.052
   Li SF, 2011, J NUTR, V141, P189, DOI 10.3945/jn.110.126680
   Lin H, 2008, COMP BIOCHEM PHYS C, V147, P30, DOI 10.1016/j.cbpc.2007.07.005
   Liu DH, 2007, ACTA PHARMACOL SIN, V28, P1907, DOI 10.1111/j.1745-7254.2007.00702.x
   Lu L, 2007, J ANIM SCI, V85, P812, DOI 10.2527/jas.2006-229
   Luo XG, 2003, CHIN J ANIM VET SCI, V34, P105
   Luo XG, 1991, CHIN J ANIM VET SCI, V22, P313
   Luo XG, 1992, CHIN J ANIM VET SCI, V23, P97
   Mahmoud KZ, 2003, COMP BIOCHEM PHYS B, V136, P921, DOI 10.1016/S1096-4959(03)00288-4
   Mashaly MM, 2004, POULTRY SCI, V83, P889, DOI 10.1093/ps/83.6.889
   Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001
   MCDANIEL CD, 1995, POULTRY SCI, V74, P1029, DOI 10.3382/ps.0741029
   Mustafi SB, 2009, CELL STRESS CHAPERON, V14, P579, DOI 10.1007/s12192-009-0109-x
   NAKAI A, 1995, MOL CELL BIOL, V15, P5268
   National Research Council, 1994, NUTR REQ POULTR
   OMAR R, 1993, EUR ARCH PSY CLIN N, V242, P262, DOI 10.1007/BF02190384
   Sahin K, 2004, J NUTR, V134, p1288S
   Sahin K, 2003, J NUTR, V133, P2808
   Sahin K, 2003, J NUTR, V133, P1882
   SAKAKIBARA Y, 1992, INT J HYPERTHER, V8, P329, DOI 10.3109/02656739209021788
   SMITH MO, 1995, POULTRY SCI, V74, P702, DOI 10.3382/ps.0740702
   Soleimani AF, 2012, POULTRY SCI, V91, P340, DOI 10.3382/ps.2011-01703
   Star L, 2008, POULTRY SCI, V87, P1022, DOI 10.3382/ps.2007-00142
   Stephanou A, 1998, BIOCHEM J, V330, P189, DOI 10.1042/bj3300189
   Stephanou A, 1997, BIOCHEM J, V321, P103, DOI 10.1042/bj3210103
   Stephanou A, 1999, GENE EXPRESSION, V7, P311
   Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389
   Tang L, 2013, THESIS
   Tedeschi JN, 2015, J THERM BIOL, V47, P42, DOI 10.1016/j.jtherbio.2014.11.006
   VAMVAKOPOULOS NO, 1993, MOL CELL ENDOCRINOL, V98, P49, DOI 10.1016/0303-7207(93)90235-C
   Wang SY, 1998, POULTRY SCI, V77, P1636, DOI 10.1093/ps/77.11.1636
   Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441
   Xie JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102204
   Yamashita N, 1997, J MOL CELL CARDIOL, V29, P1805, DOI 10.1006/jmcc.1997.0415
   Zhu YW, 2015, J ANIM SCI, V93, P3431, DOI 10.2527/jas.2015-8956
NR 47
TC 10
Z9 10
U1 5
U2 29
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD DEC 28
PY 2015
VL 114
IS 12
BP 1965
EP 1974
DI 10.1017/S0007114515003803
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CW9QG
UT WOS:000365332700002
PM 26435464
OA Bronze
DA 2018-12-27
ER

PT J
AU Huang, W
   Thomas, B
   Flynn, RA
   Gavzy, SJ
   Wu, L
   Kim, SV
   Hall, JA
   Miraldi, ER
   Ng, CP
   Rigo, FW
   Meadows, S
   Montoya, NR
   Herrera, NG
   Domingos, AI
   Rastinejad, F
   Myers, RM
   Fuller-Pace, FV
   Bonneau, R
   Chang, HY
   Acuto, O
   Littman, DR
AF Huang, Wendy
   Thomas, Benjamin
   Flynn, Ryan A.
   Gavzy, Samuel J.
   Wu, Lin
   Kim, Sangwon V.
   Hall, Jason A.
   Miraldi, Emily R.
   Ng, Charles P.
   Rigo, Frank W.
   Meadows, Sarah
   Montoya, Nina R.
   Herrera, Natalia G.
   Domingos, Ana I.
   Rastinejad, Fraydoon
   Myers, Richard M.
   Fuller-Pace, Frances V.
   Bonneau, Richard
   Chang, Howard Y.
   Acuto, Oreste
   Littman, Dan R.
TI RETRACTED: DDX5 and its associated lncRNA Rmrp modulate T(H)17 cell
   effector functions (Retracted article. See vol. 562, pg. 150, 2018)
SO NATURE
LA English
DT Article; Retracted Publication
ID ROR-GAMMA-T; LONG NONCODING RNA; P68 DDX5; HELICASE P68; TH17 CELLS;
   PHASE-I; DIFFERENTIATION; TRANSCRIPTION; PROTEINS; SUSCEPTIBILITY
AB T helper 17 (T(H)17) lymphocytes protect mucosal barriers from infections, but also contribute to multiple chronic inflammatory diseases. Their differentiation is controlled by ROR gamma t, a ligand-regulated nuclear receptor. Here we identify the RNA helicase DEAD-box protein 5 (DDX5) as a ROR gamma t partner that coordinates transcription of selective T(H)17 genes, and is required for T(H)17-mediated inflammatory pathologies. Surprisingly, the ability of DDX5 to interact with ROR gamma t and coactivate its targets depends on intrinsic RNA helicase activity and binding of a conserved nuclear long noncoding RNA (lncRNA), Rmrp, which is mutated in patients with cartilage-hair hypoplasia. A targeted Rmrp gene mutation in mice, corresponding to a gene mutation in cartilage-hair hypoplasia patients, altered lncRNA chromatin occupancy, and reduced the DDX5-ROR gamma t interaction and ROR gamma t target gene transcription. Elucidation of the link between Rmrp and the DDX5-ROR gamma t complex reveals a role for RNA helicases and lncRNAs in tissue-specific transcriptional regulation, and provides new opportunities for therapeutic intervention in T(H)17-dependent diseases.
C1 [Huang, Wendy; Gavzy, Samuel J.; Wu, Lin; Kim, Sangwon V.; Hall, Jason A.; Miraldi, Emily R.; Ng, Charles P.; Montoya, Nina R.; Herrera, Natalia G.; Littman, Dan R.] NYU, Sch Med, Kimmel Ctr Biol & Med, Skirball Inst, New York, NY 10016 USA.
   [Thomas, Benjamin; Acuto, Oreste] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
   [Flynn, Ryan A.; Chang, Howard Y.] Stanford Univ, Ctr Personal Dynam Regulomes, Stanford, CA 94305 USA.
   [Miraldi, Emily R.; Bonneau, Richard] NYU, Dept Biol, Ctr Genom & Syst Biol, New York, NY 10003 USA.
   [Miraldi, Emily R.; Bonneau, Richard] NYU, Courant Inst Math Sci, Dept Comp Sci, New York, NY 10012 USA.
   [Miraldi, Emily R.; Bonneau, Richard] Simons Fdn, Simons Ctr Data Anal, New York, NY 10010 USA.
   [Rigo, Frank W.] ISIS Pharmaceut, Carlsbad, CA 92010 USA.
   [Meadows, Sarah; Myers, Richard M.] HudsonAlpha Inst Biotechnol, Huntsville, AL 35806 USA.
   [Domingos, Ana I.] Inst Gulbenkian Ciencias, P-2780156 Oeiras, Portugal.
   [Rastinejad, Fraydoon] Sanford Burnham Prebys Med Discovery Inst, Integrat Metab Program, Orlando, FL 32827 USA.
   [Fuller-Pace, Frances V.] Univ Dundee, Div Canc Res, Dundee DD1 9SY, Scotland.
   [Littman, Dan R.] NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA.
RP Littman, DR (reprint author), NYU, Sch Med, Kimmel Ctr Biol & Med, Skirball Inst, New York, NY 10016 USA.
EM dan.littman@med.nyu.edu
OI Gavzy, Samuel/0000-0002-4880-0301; Flynn, Ryan/0000-0001-5013-0442;
   Domingos, Ana/0000-0002-7938-4814
FU Cancer Research Institute Irvington Postdoctoral Fellowship;
   Institutional NRSA [T32 CA009161_Levy]; National Multiple Sclerosis
   Society postdoctoral fellowship [FG 2089-A-1]; Crohn's and Colitis
   Foundation of America [329388]; Dale and Betty Frey Fellowship of the
   Damon Runyon Cancer Research Foundation [2105-12]; HHMI Exceptional
   Research Opportunities Program; NIH [F30 1F30CA189514-01, P50-HG007735,
   R01HG004361, R01AI080885, R01DK103358]; Howard Hughes Medical Institute
FX We thank M. V. Pokrovskii for unpublished ATAC-seq data and L. X.
   Garmire for suggestions on our manuscript. This work was supported by a
   Cancer Research Institute Irvington Postdoctoral Fellowship (W.H.),
   Institutional NRSA T32 CA009161_Levy (W.H.), National Multiple Sclerosis
   Society postdoctoral fellowship FG 2089-A-1 (L.W.), Career Development
   Award (329388) from the Crohn's and Colitis Foundation of America
   (S.V.K.), Dale and Betty Frey Fellowship of the Damon Runyon Cancer
   Research Foundation 2105-12 (J.A.H.), HHMI Exceptional Research
   Opportunities Program (N.R.M. and N.H.), NIH F30 1F30CA189514-01
   (R.A.F.), NIH P50-HG007735 and R01HG004361 (H.Y.C.), NIH R01AI080885
   (D.R.L.), NIH R01DK103358 (R.B. and D.R.L.), and the Howard Hughes
   Medical Institute (H.Y.C. and D.R.L.).
CR Arun G, 2012, MOL CELL BIOL, V32, P3140, DOI 10.1128/MCB.00006-12
   Bacchetta J, 2009, PEDIATR NEPHROL, V24, P2449, DOI 10.1007/s00467-009-1256-0
   Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550
   Bonafe L, 2005, PLOS GENET, V1, P444, DOI 10.1371/journal.pgen.0010047
   Bonasio R, 2014, ANNU REV GENET, V48, P433, DOI 10.1146/annurev-genet-120213-092323
   Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109
   Calo E, 2015, NATURE, V518, P249, DOI 10.1038/nature13923
   Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003
   Carpenter S, 2013, SCIENCE, V341, P789, DOI 10.1126/science.1240925
   Chien YH, 2013, TRENDS IMMUNOL, V34, P151, DOI 10.1016/j.it.2012.11.004
   Chu C, 2012, JOVE-J VIS EXP, DOI 10.3791/3912
   Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027
   Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016
   Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932
   Croswell A, 2009, INFECT IMMUN, V77, P2741, DOI 10.1128/IAI.00006-09
   Dardenne E, 2014, CELL REP, V7, P1900, DOI 10.1016/j.celrep.2014.05.010
   Esakova O, 2010, RNA, V16, P1725, DOI 10.1261/rna.2214510
   Flynn RA, 2015, RNA, V21, P135, DOI 10.1261/rna.047803.114
   Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1
   Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707
   Genovese MC, 2010, ARTHRITIS RHEUM-US, V62, P929, DOI 10.1002/art.27334
   Gomez JA, 2013, CELL, V152, P743, DOI 10.1016/j.cell.2013.01.015
   Hirota K, 2011, NAT IMMUNOL, V12, P255, DOI 10.1038/ni.1993
   HSIEH CL, 1990, GENOMICS, V6, P540, DOI 10.1016/0888-7543(90)90483-B
   Huang YL, 2002, J BIOL CHEM, V277, P12810, DOI 10.1074/jbc.M200182200
   Huh JR, 2013, ACS MED CHEM LETT, V4, P79, DOI 10.1021/ml300286h
   Huh JR, 2011, NATURE, V472, P486, DOI 10.1038/nature09978
   Ilik IA, 2013, MOL CELL, V51, P156, DOI 10.1016/j.molcel.2013.07.001
   Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035
   Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033
   Jalal C, 2007, NUCLEIC ACIDS RES, V35, P3590, DOI 10.1093/nar/gkm058
   Jensen ED, 2008, J CELL BIOCHEM, V103, P1438, DOI 10.1002/jcb.21526
   Kang HS, 2007, PHYSIOL GENOMICS, V31, P281, DOI 10.1152/physiolgenomics.00098.2007
   Kim SV, 2013, SCIENCE, V340, P1456, DOI 10.1126/science.1237013
   Kondo Y, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0606-5
   Lee YJ, 2013, NAT IMMUNOL, V14, P1146, DOI 10.1038/ni.2731
   Leppkes M, 2009, GASTROENTEROLOGY, V136, P257, DOI 10.1053/j.gastro.2008.10.018
   Lin CR, 2005, MOL CELL BIOL, V25, P7484, DOI 10.1128/MCB.25.17.7484-7493.2005
   Linder P, 2011, NAT REV MOL CELL BIO, V12, P505, DOI 10.1038/nrm3154
   Luci C, 2009, NAT IMMUNOL, V10, P75, DOI 10.1038/ni.1681
   Maenner S, 2013, MOL CELL, V51, P174, DOI 10.1016/j.molcel.2013.06.011
   Makitie O, 1998, EUR J PEDIATR, V157, P816, DOI 10.1007/s004310050943
   Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610
   Meng LY, 2015, NATURE, V518, P409, DOI 10.1038/nature13975
   Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206
   Nicol SM, 2013, ONCOGENE, V32, P3461, DOI 10.1038/onc.2012.426
   O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223
   Ostanin DV, 2009, AM J PHYSIOL-GASTR L, V296, pG135, DOI 10.1152/ajpgi.90462.2008
   POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0
   Rosenbluh J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026270
   Sano T., 2015, CELL
   Santori FR, 2015, CELL METAB, V21, P286, DOI 10.1016/j.cmet.2015.01.004
   Stanley S, 2013, CELL METAB, V18, P596, DOI 10.1016/j.cmet.2013.09.002
   Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369
   Takatori H, 2009, J EXP MED, V206, P35, DOI 10.1084/jem.20072713
   Wang Y, 2014, IMMUNITY, V40, P355, DOI 10.1016/j.immuni.2014.01.002
   Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557
   Wortham NC, 2009, ONCOGENE, V28, P4053, DOI 10.1038/onc.2009.261
   Yang JF, 2014, TRENDS PHARMACOL SCI, V35, P493, DOI 10.1016/j.tips.2014.07.006
   Yang Y, 2014, NATURE, V510, P152, DOI 10.1038/nature13279
NR 60
TC 81
Z9 84
U1 7
U2 64
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 24
PY 2015
VL 528
IS 7583
BP 517
EP +
DI 10.1038/nature16193
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CZ3GH
UT WOS:000366991900044
PM 26675721
OA Green Published, Green Accepted
DA 2018-12-27
ER

PT J
AU Adeniji, AA
   Rumak, S
   Oluwafemi, RA
AF Adeniji, A. A.
   Rumak, S.
   Oluwafemi, R. A.
TI RETRACTED: Effects of replacing groundnut cake with rumen content
   supplemented with or without enzyme in the diet of weaner rabbits
   (Retracted article. See vol. 15, 101, 2016)
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article; Retracted Publication
DE Rabbits; Groundnuts cake; Rumen contents and enzyme
AB Background: Rabbits are also herbivores which efficiently convert fodder to food. They are prolific and converter of plant proteins of little or no use to people as food into high-value animal protein. Rabbit meat is high in protein, low in calories and low in fat and cholesterol contents, being considered as a delicacy and a healthy food product. Feeding rabbits with concentrates is expensive and therefore in order to reduce cost of production, hence the use of rumen content in this study as alternative feedstuff without competition.
   Methods: A total of thirty six (36) weaner rabbits (oryctalagus cuniculus) of different body weight and age where use in this experiment to determine the effects of replacing rumen content with or without enzyme supplementation for groundnut cake. This feeding trial which lasted for 8 weeks was carried out in order to determine the replacement value of groundnut cake with rumen content with or without enzyme in the diet of weaner rabbit. A 3x2 factorial experiment was adopted such that there where three (3) replacement level of rumen content (0, 25 and 50 %) for groundnut cake by two supplemental level (no enzyme and enzyme supplement).
   Results: The results showed that increased inclusion level of rumen content has significant effects (p < 0.05) on daily feed intake, rate of weight gain, feed to gain ratio, nitrogen retention, faecal nitrogen, total nitrogen output and nitrogen digestibility. The weight gained by rabbits fed on 0, 25 and 50 % were all comparable (p > 0.05) with weight gained value of 7.62,7.44 and 7.36 g respectively. Similarly there was a significant (p < 0.05) effect of supplement added on the body weight gain of the experimental animals. There was significant effect (p < 0.05) of the diet on the obtained feed to gain ratio. However, there was no significant effect (p > 0.05) of the treatment on urinary nitrogen. Significant (p < 0.05) effects of supplementation was observed on the feed intake, weight gain, feed to gain ratio, faecal nitrogen, nitrogen retention and nitrogen digestibility but there was no significant effects (p > 0.05) of the supplementation on the nitrogen intake. The interaction between the varying levels of rumen content supplementation had significant effects (p < 0.05) on the feacal nitrogen, feed intake and feed to gain ratio but no significant (p < 0.05) effects on interaction of nitrogen intake.
   Conclusion: In conclusion, since the results from this study showed no negative effects on the performance of the experimental animals, the test ingredient can be used as alternative feedstuff at a lower inclusion level so as to reduce production cost and expand rabbit production.
C1 [Adeniji, A. A.; Rumak, S.; Oluwafemi, R. A.] Univ Abuja, Fac Agr, Dept Anim Sci, Fct Abuja, Nigeria.
RP Oluwafemi, RA (reprint author), Univ Abuja, Fac Agr, Dept Anim Sci, P-M-B 117, Fct Abuja, Nigeria.
EM oluwafemi.adebisi@uniabuja.edu.ng
CR Adeniji AA, 2001, NIGER J ANIMAL PROD, V29, P34
   Adeniji AA, 2008, J ANIM VET ADV, V3, P104
   Aduku OA, 1988, J APPL RABBIT RES, V11, P264
   Alawa JP, 1993, J ANIM PROD RES, V13, P63
   Dairo F. A. S., 2005, Nigerian Journal of Animal Production, V32, P67
   Dalle Zotte A., 2000, P 7 WORLD RABB C, P1
   Numbela ER, 2001, ANIMAL PROD J VOL, V2, P33
   Onu PN, 2011, INT J FOOD AGR VET S, V1, P10
   Steel RGD, 1980, PRINCIPLES PROCEDURE
   Suttle NF, 2010, MINERAL NUTRITION OF LIVESTOCK, 4TH EDITION, P1, DOI 10.1079/9781845934729.0000
   Xu G., 2008, ROLE FEED ENZYMES SW, V14, P164
NR 11
TC 1
Z9 1
U1 2
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-511X
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD DEC 18
PY 2015
VL 14
DI 10.1186/s12944-015-0158-3
PG 6
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA CZ1UU
UT WOS:000366891900001
PM 26683491
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kassai, M
   Nasr, MR
   Simonson, CJ
AF Kassai, Miklos
   Nasr, Mohammad Rafati
   Simonson, Carey J.
TI RETRACTED: A developed procedure to predict annual heating energy by
   heat- and energy-recovery technologies in different climate European
   countries (Retracted article. See vol. 167, pg. 384, 2018)
SO ENERGY AND BUILDINGS
LA English
DT Article; Retracted Publication
DE Heat recovery; Energy recovery; Ventilation; Defrosting; Energy
   consumption
ID AIR
AB Frosting inside heat/energy exchangers are common especially in cold climates and result a significant decrease in the performance of the exchangers. Using experimental effectiveness data from a previous research [1] and ambient temperature/enthalpy duration curves the effect of preheating the outdoor air and bypassing the outdoor airflow (supply side closing) techniques on annual heating energy consumption of ventilation are predicted in three different weather European locations (in Helsinki in Finland as Cold climate, in Krakow in Poland as North Temperate climate and in Palermo in Italy as Mediterranean climate). The results are presented separately based on the analyzed techniques: supply side closing, pre-heating and frosting effect ignoring. The results show the outdoor air preheating technique results higher energy saved than the supply side closing and if the indoor air quality requirements are lower, then using a sensible heat recovery unit is suitable for heat recovery and the investment cost is lower. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Kassai, Miklos] Budapest Univ Technol & Econ, Dept Bldg Serv Engn & Proc Engn, H-1111 Budapest, Hungary.
   [Nasr, Mohammad Rafati; Simonson, Carey J.] Univ Saskatchewan, Dept Mech Engn, Saskatoon, SK S7N 5A9, Canada.
RP Kassai, M (reprint author), Budapest Univ Technol & Econ, Dept Bldg Serv Engn & Proc Engn, Muegyetem Rkp 3-9, H-1111 Budapest, Hungary.
EM kassai@epgep.bme.hu
RI Kassai, Miklos/D-4447-2018
OI Kassai, Miklos/0000-0003-4618-3394; Rafati Nasr,
   Mohammad/0000-0002-0085-6808
FU Natural Sciences and Engineering Research Council of Canada (NSERC)
   through Smart Net-Zero Energy Building Strategic Research Network
   (SNEBRN); National Research, Development and Innovation Office of
   Hungary - Budapest, Hungary [NKFIH PD 115614]
FX This research was financially supported by the Natural Sciences and
   Engineering Research Council of Canada (NSERC) through Smart Net-Zero
   Energy Building Strategic Research Network (SNEBRN) and National
   Research, Development and Innovation Office of Hungary - NKFIH PD 115614
   - Budapest, Hungary.
CR ASHRAE, 2005, 2005 ASHRAE HDB FUND
   Asiedu Y, 2005, ASHRAE TRAN, V111, P857
   Cheng CH, 2001, INT COMMUN HEAT MASS, V28, P953, DOI 10.1016/S0735-1933(01)00299-8
   Emery A.F., 1990, P AIAA ASME THERM HE, P1
   Fisk W., 1985, AM SOC HEAT REFR AIR
   Gupta JK, 2007, INT J REFRIG, V30, P311, DOI 10.1016/j.ijrefrig.2006.06.006
   HAYASHI Y, 1977, J HEAT TRANS-T ASME, V99, P239, DOI 10.1115/1.3450675
   Jozsef N., 2014, ENERGY BUILD, V86, P268
   Laszlo K., 2012, ENERGY BUILD, V45, P54
   Melanie F., 2007, ASHRAE T, V113, P437
   Nasr MR, 2015, APPL ENERG, V151, P32, DOI 10.1016/j.apenergy.2015.04.022
   Nasr MR, 2014, RENEW SUST ENERG REV, V30, P538, DOI 10.1016/j.rser.2013.10.038
   Nguyen A, 2005, INT J REFRIG, V28, P242, DOI 10.1016/j.ijrefrig.2004.07.022
   Nyman M, 2005, BUILD ENVIRON, V40, P15, DOI 10.1016/j.buildenv.2004.04.011
   Poos T, 2012, DRY TECHNOL, V30, P1457, DOI 10.1080/07373937.2012.689402
   Robert S., 2002, ACTA POLYTECH HUNG, V9, P167
   Zhang LZ, 2005, ENERG BUILDINGS, V37, P279, DOI 10.1016/j.enbuild.2004.06.019
NR 17
TC 3
Z9 3
U1 2
U2 9
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0378-7788
EI 1872-6178
J9 ENERG BUILDINGS
JI Energy Build.
PD DEC 15
PY 2015
VL 109
BP 267
EP 273
DI 10.1016/j.enbuild.2015.10.008
PG 7
WC Construction & Building Technology; Energy & Fuels; Engineering, Civil
SC Construction & Building Technology; Energy & Fuels; Engineering
GA CZ5AU
UT WOS:000367115300024
DA 2018-12-27
ER

PT J
AU Ali, Z
   Anjum, A
   Khurshid, L
   Ahad, H
   Maajid, S
   Dhar, SA
AF Ali, Zameer
   Anjum, Afshan
   Khurshid, Lubna
   Ahad, Hamayun
   Maajid, Saheel
   Dhar, Shabir Ahmad
TI RETRACTED: Evaluation of low-cost custom made VAC therapy compared with
   conventional wound dressings in the treatment of non-healing lower limb
   ulcers in lower socio-economic group patients of Kashmir valley
   (Retracted article. See vol. 12, art no 62, 2017)
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article; Retracted Publication
DE DFU; VAC; NPWT
ID RANDOMIZED CONTROLLED-TRIAL; NEGATIVE-PRESSURE; ASSISTED CLOSURE;
   MULTICENTER
AB Background: Negative-pressure wound therapy is a technique to achieve wound healing in patients with non-healing wounds of the lower limb; vacuum-assisted closure (VAC) therapy is a technique to accelerate the healing of non-healing ulcers that fail to heal on their own (primary healing) (Plast Reconstr Surg 117:193-209S, 2006).
   Delayed wound healing or non-healing of ulcers is a significant health problem, particularly in older adults.
   The efficacy of VAC dressings has been demonstrated in several randomized controlled studies, which have shown significantly faster wound healing rates compared to conventional wound therapy (Lancet 366:1704-10, 2005; J Wound Care 17:426-32, 2008). However, commercially available VAC is costly.
   The aim of using custom made VAC was decided by our team due to lower socio-economic status of patients taken for study who could not have afforded charges of commercially available VAC unit.
   Objective: Objective was to evaluate VAC therapy compared with conventional dressings in the treatment of non-healing lower limb ulcers in lower socio-economic patients.
   Methods: Sixty patients of lower socio-economic status aged between 40 and 70 were prospectively studied for non-healing ulcers Wagner grade 2 or 3 and randomized into 2 groups. VAC dressing was kept for over a period of 2-7 weeks. Ulcers were treated until the wound closed spontaneously, surgically or until completion of the 50-day period, whichever was earlier.
   Results: By seventh week, discharge disappeared in 96 % in VAC and only 54 % in conventional dressing group. Granulation tissue appeared in 100 % of patients in VAC group and only 63 % in conventional dressing group. The patients treated with VAC dressing in our study showed comparable wound reduction capabilities with an average wound size reduction of 56 % in comparison to conventional dressing group which had average wound size reduction of 29 %.
   Majority of wounds in VAC group got closed in 7 weeks. Patient satisfaction was excellent in the majority of patients in VAC group compared to those in conventional dressing group.
   Conclusion: The application of VAC (TM) had shown good results in our study.
C1 [Ali, Zameer; Anjum, Afshan; Khurshid, Lubna; Ahad, Hamayun; Maajid, Saheel; Dhar, Shabir Ahmad] SKIMS Med Coll, Dept Orthopaed, Srinagar 190018, Jammu & Kashmir, India.
RP Ali, Z (reprint author), SKIMS Med Coll, Dept Orthopaed, Srinagar 190018, Jammu & Kashmir, India.
EM drzameeraliortho@gmail.com
CR *AM DIAB ASS, 1999, DIABETES CARE, V22, P1354, DOI DOI 10.2337/DIACARE.22.8.1354
   Argenta LC, 1997, ANN PLAS SURG, V38, P563, DOI 10.1097/00000637-199706000-00002
   Armstrong DG, 2005, LANCET, V366, P1704, DOI 10.1016/S0140-6736(05)67695-7
   Blume PA, 2008, DIABETES CARE, V31, P631, DOI 10.2337/dc07-2196
   Brem H, 2006, PLAST RECONSTR SURG, V117, p193S, DOI 10.1097/01.prs.0000225459.93750.29
   Eginton MT, 2003, ANN VASC SURG, V17, P645, DOI 10.1007/s10016-003-0065-3
   Fabian TS, 2000, AM SURGEON, V66, P1136
   Mark TE, 2003, ANN VASC SURG, V17, P645
   Morykwas MJ, 1997, ANN PLAS SURG, V38, P553, DOI 10.1097/00000637-199706000-00001
   Mullner T, 1997, BRIT J PLAST SURG, V50, P194, DOI 10.1016/S0007-1226(97)91369-2
   Peycru T, 2008, J CHIR-PARIS, V145, P188, DOI 10.1016/S0021-7697(08)73745-1
   Prabhdeep SN, 2011, J SURG TECH CASE REP, V3, P17
   Ramanujam CL, 2013, DIABET FOOT ANKLE, V4, DOI 10.3402/dfa.v4i0.20878
   Singh M, 2009, INTERNET J PLAST SUR, V6, P1
   Wagner F W Jr, 1981, Foot Ankle, V2, P64
   White R, 2008, J Wound Care, V17, P428
NR 16
TC 3
Z9 4
U1 3
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD DEC 10
PY 2015
VL 10
AR 183
DI 10.1186/s13018-015-0314-5
PG 10
WC Orthopedics
SC Orthopedics
GA CY3AE
UT WOS:000366278800001
PM 26654318
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Rabiei, A
AF Rabiei, Afsaneh
TI RETRACTED: Processing, characterization and failure analysis of a novel
   thin sheet metal (Retracted article. See vol. 101, pg. 366, 2016)
SO MATERIALS & DESIGN
LA English
DT Article; Retracted Publication
DE Roll bonding; Sheet metal; Foaming agent
ID ALUMINUM FOAM; ALLOY FOAMS; AL-ALLOY; STIFFNESS; DEFORMATION;
   FABRICATION; MECHANISMS; STRENGTH; BEHAVIOR
AB A novel light-weight thin sheet metal is processed by single roll-bonding of two sheet-metals that hold small amounts of foaming agent positioned carefully in between. Further heat treatment of the assembly releases the foaming agent creating small bubbles with controlled geometry and distribution through the entire material. The product is called a "metallic bubble wrap". In this study, we present our recent results on processing of this novel type of sheet metal foam through single roll bonding technique along with its mechanical and microstructural characteristics in comparison to a bulk sheet of aluminum. The failure of the material is also studied and reported. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Rabiei, Afsaneh] N Carolina State Univ, Dept Mech & Aerosp Engn, Adv Mat Res Lab, Raleigh, NC 27695 USA.
RP Rabiei, A (reprint author), N Carolina State Univ, Dept Mech & Aerosp Engn, 911 Oval Dr,Campus Box 7910, Raleigh, NC 27695 USA.
EM arabiei@ncsu.edu
CR Akiyama S., 1987, US Patent, Patent No. [4,712,277, 4712277]
   Andersen O, 2000, ADV ENG MATER, V2, P192, DOI 10.1002/(SICI)1527-2648(200004)2:4<192::AID-ADEM192>3.0.CO;2-#
   Ashby M. F., 2000, METAL FOAMS DESIGN G
   Barsoum I, 2007, INT J SOLIDS STRUCT, V44, P1768, DOI 10.1016/j.ijsolstr.2006.09.031
   Bart-Smith H, 1998, ACTA MATER, V46, P3583, DOI 10.1016/S1359-6454(98)00025-1
   Beals JT, 1997, J MATER SCI, V32, P3595, DOI 10.1023/A:1018670111305
   Degischer HP, 2002, HDB CELLULAR METALS
   Eizadjou M, 2008, MATER DESIGN, V29, P909, DOI 10.1016/j.matdes.2007.03.020
   Evans AG, 1998, PROG MATER SCI, V43, P171, DOI 10.1016/S0079-6425(98)00004-8
   Gibson LJ, 1997, CELLULAR SOLIDS
   Hyun SK, 2006, MATER SCI FORUM, V512, P337, DOI 10.4028/www.scientific.net/MSF.512.337
   Kenny LD, 1996, MATER SCI FORUM, V217, P1883, DOI 10.4028/www.scientific.net/MSF.217-222.1883
   Kitazono K, 2004, SCRIPTA MATER, V50, P495, DOI 10.1016/j.scriptamat.2003.10.035
   Kitazono K, 2007, MATER LETT, V61, P1771, DOI 10.1016/j.matlet.2006.07.127
   Li L, 2008, SCI TECHNOL ADV MAT, V9, DOI 10.1088/1468-6996/9/2/023001
   Liu A. F., 2005, MECH MECH FRACTURE I
   Lu TJ, 1998, ACTA MATER, V46, P3619, DOI 10.1016/S1359-6454(98)00031-7
   Miao D, 2014, PROC MAT SCI, V4, P3, DOI 10.1016/j.mspro.2014.07.563
   Miyoshi T, 2000, ADV ENG MATER, V2, P179, DOI 10.1002/(SICI)1527-2648(200004)2:4<179::AID-ADEM179>3.0.CO;2-G
   Nakajima H, 2001, COLLOID SURFACE A, V179, P209, DOI 10.1016/S0927-7757(00)00639-7
   Neville BP, 2008, MATER DESIGN, V29, P388, DOI 10.1016/j.matdes.2007.01.026
   Rabiei A, 2005, MAT SCI ENG A-STRUCT, V404, P159, DOI 10.1016/j.msea.2005.05.089
   Sanders WS, 2003, MAT SCI ENG A-STRUCT, V347, P70, DOI 10.1016/S0921-5093(02)00583-X
   Schaedler TA, 2011, SCIENCE, V334, P962, DOI 10.1126/science.1211649
   SHIMANSKY RA, 1995, MECH STRUCT MACH, V23, P439, DOI 10.1080/08905459508905246
   Simone AE, 1998, ACTA MATER, V46, P2139, DOI 10.1016/S1359-6454(97)00421-7
   Simone AE, 1998, ACTA MATER, V46, P3929, DOI 10.1016/S1359-6454(98)00072-X
   Sugimura Y, 1999, MAT SCI ENG A-STRUCT, V269, P38, DOI 10.1016/S0921-5093(99)00147-1
   Sugimura Y, 1997, ACTA MATER, V45, P5245, DOI 10.1016/S1359-6454(97)00148-1
   THORNTON PH, 1975, METALL TRANS A, V6, P1801, DOI 10.1007/BF02642310
   Topic I, 2008, ADV ENG MATER, V10, P1101, DOI 10.1002/adem.200800167
NR 31
TC 1
Z9 1
U1 2
U2 18
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-1275
EI 1873-4197
J9 MATER DESIGN
JI Mater. Des.
PD DEC 5
PY 2015
VL 86
BP 752
EP 760
DI 10.1016/j.matdes.2015.07.028
PG 9
WC Materials Science, Multidisciplinary
SC Materials Science
GA CT5PO
UT WOS:000362862700095
DA 2018-12-27
ER

PT J
AU Shafique, M
   Kim, R
AF Shafique, Muhammad
   Kim, Reeho
TI RETRACTED: LOW IMPACT DEVELOPMENT PRACTICES: A REVIEW OF CURRENT
   RESEARCH AND RECOMMENDATIONS FOR FUTURE DIRECTIONS (Retracted article.
   See vol. 23, pg. 709, 2016)
SO ECOLOGICAL CHEMISTRY AND ENGINEERING S-CHEMIA I INZYNIERIA EKOLOGICZNA S
LA English
DT Article; Retracted Publication
DE low impact development; green roof; bioretention; pervious pavement
ID PERMEABLE PAVEMENT SYSTEMS; WATER-QUALITY; BIORETENTION MEDIA;
   NORTH-CAROLINA; RUNOFF WATER; GREEN ROOFS; STORMWATER MANAGEMENT;
   POLLUTANT RETENTION; FIELD PERFORMANCE; POROUS PAVEMENT
AB A low impact development (LID) is an alternative land development approach for managing stormwater that has been recommended instead of the traditional stormwater design. The main purpose of LID is to reduce the impact of development on water related problems through the use of stormwater management practices that infiltrate, evaporate, or harvest and use stormwater on the site where it falls. In recent years, more research has been carried out on the individual practice of LID such as bioretention, pervious pavements, rain garden and grassed swales. Nowadays LID practices have been successfully used to manage stormwater runoff, improve water quality, protect the environmental and hydrological aspects of the developed areas. Bioretention cells have been effectively used in retaining large volumes of runoff and pollutants on site. Pervious pavements have been extremely effective practice in infiltrating stormwater runoff as early as possible as rain fall on site and store a large quantity of water. Nowadays, sand ditch a new water harvesting technique is used that significantly reduces runoff and sediment losses and increases infiltration and soil loss. This paper highlights evidence in the literature regarding the beneficial uses of LID practices and encourage to adopt these practices for environmental friendly construction and sustainable development in the world.
C1 [Shafique, Muhammad; Kim, Reeho] Univ Sci & Technol, Construct Environm Engn, Korea Inst Civil Engn & Bldg Technol Campus, Goyang Si, Geonggi Do, South Korea.
   [Kim, Reeho] Korea Inst Civil Engn & Bldg Technol, Environm & Plant Engn Res Inst, Goyang Si, Geonggi Do, South Korea.
RP Shafique, M (reprint author), Univ Sci & Technol, Construct Environm Engn, Korea Inst Civil Engn & Bldg Technol Campus, Goyang Si, Geonggi Do, South Korea.
EM shafique@kict.re.kr; rhkim@kict.re.kr
FU Advanced Water Management Research Program - Ministry of Land,
   Infrastructure and Transport of Korean government [15technology
   innovationC04]
FX This research was supported by a grant (15technology innovationC04) from
   Advanced Water Management Research Program funded by Ministry of Land,
   Infrastructure and Transport of Korean government.
CR Abu-Zreig M, 2011, AGR WATER MANAGE, V98, P1291, DOI 10.1016/j.agwat.2011.03.008
   Ahiablame LM, 2012, WATER AIR SOIL POLL, V223, P4253, DOI 10.1007/s11270-012-1189-2
   Alsup Sarah, 2010, Urban Ecosystems, V13, P91, DOI 10.1007/s11252-009-0106-y
   [Anonymous], 2007, BIOR MAN
   [Anonymous], 2002, BIOR MAN
   [Anonymous], 1993, DES MAN US BIOR STOR
   Backstrom M, 2003, WATER SCI TECHNOL, V48, P123, DOI 10.2166/wst.2003.0508
   Backstrom M, 2002, WATER SCI TECHNOL, V45, P41, DOI 10.2166/wst.2002.0115
   BALADES JD, 1995, WATER SCI TECHNOL, V32, P49, DOI 10.1016/0273-1223(95)00537-W
   Barrett ME, 1998, J ENVIRON ENG-ASCE, V124, P1121, DOI 10.1061/(ASCE)0733-9372(1998)124:11(1121)
   Bean EZ, 2007, J IRRIG DRAIN ENG, V133, P249, DOI 10.1061/(ASCE)0733-9437(2007)133:3(249)
   Berndtsson JC, 2006, SCI TOTAL ENVIRON, V355, P48, DOI 10.1016/j.scitotenv.2005.02.035
   Bianchini F, 2012, BUILD ENVIRON, V48, P57, DOI 10.1016/j.buildenv.2011.08.019
   Booth DB, 1997, J AM WATER RESOUR AS, V33, P1077, DOI 10.1111/j.1752-1688.1997.tb04126.x
   Booth DB, 1999, J AM PLANN ASSOC, V65, P314, DOI 10.1080/01944369908976060
   Brattebo BO, 2003, WATER RES, V37, P4369, DOI 10.1016/S0043-1354(03)00410-X
   Brown RA, 2012, WATER SCI TECHNOL, V65, P361, DOI 10.2166/wst.2012.860
   Brown RA, 2010, J HYDROL ENG, V15, P386, DOI 10.1061/(ASCE)HE.1943-5584.0000165
   CEI (Comprehensive Environmental Inc.), 2003, CIT NASH NEW HAMPS 1
   Chapman C, 2010, WATER ENVIRON RES, V82, P109, DOI 10.2175/106143009X426112
   Coffman L. S., 2002, Handbook of water sensitive planning and design, P97
   Collins KA, 2008, J HYDROL ENG, V13, P1146, DOI 10.1061/(ASCE)1084-0699(2008)13:12(1146)
   Collins KA, 2010, J HYDROL ENG, V15, P512, DOI 10.1061/(ASCE)HE.1943-5584.0000139
   Davis AP, 2008, J HYDROL ENG, V13, P90, DOI 10.1061/(ASCE)1084-0699(2008)13:2(90)
   Davis AP, 2007, ENVIRON ENG SCI, V24, P1048, DOI 10.1089/ees.2006.0190
   Davis AP, 2009, J ENVIRON ENG-ASCE, V135, P109, DOI 10.1061/(ASCE)0733-9372(2009)135:3(109)
   Davis AP, 2006, WATER ENVIRON RES, V78, P284, DOI 10.2175/106143005X94376
   Davis AP, 2005, ENVIRON SCI TECHNOL, V39, p338A, DOI 10.1021/es053327e
   Davis AP, 2003, WATER ENVIRON RES, V75, P73, DOI 10.2175/106143003X140854
   Davis AP, 2001, WATER ENVIRON RES, P5
   Debo T. N., 2002, MUNICIPAL STORMWATER
   DeBusk KM, 2011, J ENVIRON ENG-ASCE, V137, P800, DOI 10.1061/(ASCE)EE.1943-7870.0000388
   Dierkes C, 2002, P 9 INT C URB DRAIN, DOI [10.1061/40644(2002)40, DOI 10.1061/40644(2002)40]
   Dierkes C., 1999, P 8 INT C URB STORM
   Dietz ME, 2006, ENVIRON SCI TECHNOL, V40, P1335, DOI 10.1021/es051644f
   Dietz ME, 2007, WATER AIR SOIL POLL, V186, P351, DOI 10.1007/s11270-007-9484-z
   DoD (Department of Defense), 2004, UFC321010 DOD
   Dreelin EA, 2006, WATER RES, V40, P799, DOI 10.1016/j.watres.2005.12.002
   Ergas SJ, 2010, J ENVIRON ENG-ASCE, V136, P1105, DOI 10.1061/(ASCE)EE.1943-7870.0000243
   Fach S, 2005, WATER SCI TECHNOL, V51, P37
   Fach S, 2011, WATER SCI TECHNOL, V63, P2658, DOI 10.2166/wst.2011.153
   Fassman EA, 2010, J HYDROL ENG, V15, P475, DOI 10.1061/(ASCE)HE.1943-5584.0000238
   Ferguson B. K., 2005, POROUS PAVEMENTS
   Fitts G., 2002, ASPHALT, V17
   Glass C, 2005, T ECOL ENV, P699
   Gregoire BG, 2011, ECOL ENG, V37, P963, DOI 10.1016/j.ecoleng.2011.02.004
   Hathaway AM, 2008, T ASABE, V51, P37
   Hathaway AM, 2009, WORLD ENV WAT RES C, P1123, DOI [10.1061/41036(342)112, DOI 10.1061/41036(342)112]
   Hollis G. E., 1977, HYDROLOGICAL SCI B, V22, P61, DOI [10.1080/02626667709491694, 10. 1080/02626667709491694]
   Hong EY, 2006, WATER ENVIRON RES, V78, P141, DOI 10.2175/106143005X89607
   Hsieh CH, 2005, J ENVIRON ENG-ASCE, V131, P1521, DOI 10.1061/(ASCE)0733-9372(2005)131:11(1521)
   HUD (U.S. Department of Housing and Urban Development), 2003, H21314CA HUD NAHB RE
   Hunt WF, 2008, J ENVIRON ENG-ASCE, V134, P403, DOI 10.1061/(ASCE)0733-9372(2008)134:5(403)
   Hunt WF, 2006, J IRRIG DRAIN ENG, V132, P600, DOI 10.1061/(ASCE)0733-9437(2006)132:6(600)
   Hunt W. F., 2006, AGW58805 N CAR COOP
   Hunt W. F., 2002, P 9 INT C URB DRAIN
   Hunt W.F., 2006, URBAN WATERWAYS PERM
   Hunt WF, 2010, LOW IMPACT DEV PRACT, P308, DOI [10.1061/9780784410783, DOI 10.1061/9780784410783.CH12]
   James W, 1998, ADV MOD MANAG STORMW, V6, P321
   Jennings DB, 2002, LANDSCAPE ECOL, V17, P471, DOI 10.1023/A:1021211114125
   Kaushal SS, 2005, P NATL ACAD SCI USA, V102, P13517, DOI 10.1073/pnas.0506414102
   Kim H., 2003, WATER ENVIRON RES, P355
   Kirby JT, 2005, J HYDRAUL ENG-ASCE, V131, P65, DOI 10.1061/(ASCE)0733-9429(2005)131:1(65)
   Kwiatkowski M, 2007, J AM WATER RESOUR AS, V43, P1208, DOI 10.1111/j.1752-1688.2007.00104.x
   Legret M, 1999, WATER SCI TECHNOL, V39, P111, DOI 10.1016/S0273-1223(99)00014-1
   Leopold L. B., 1968, HYDROLOGY URBAN LAND
   Line DE, 2009, J IRRIG DRAIN ENG, V135, P217, DOI 10.1061/(ASCE)0733-9437(2009)135:2(217)
   Lloyd S., 2001, WATER SENSITIVE URBA
   Luell SK, 2011, WATER SCI TECHNOL, V64, P974, DOI 10.2166/wst.2011.736
   MAKEPEACE DK, 1995, CRIT REV ENV SCI TEC, V25, P93, DOI 10.1080/10643389509388476
   McNett JK, 2011, J ENVIRON ENG-ASCE, V137, P790, DOI 10.1061/(ASCE)EE.1943-7870.0000373
   Miller C., 1998, P 1998 PENNS STORMW
   Moglen GE, 2003, J AM WATER RESOUR AS, V39, P947, DOI 10.1111/j.1752-1688.2003.tb04418.x
   Moore WL, 1969, WATER RESOURCES S
   Myers B, 2011, P I CIVIL ENG-WAT M, V164, P361, DOI 10.1680/wama.2011.164.7.361
   Newman AP, 2002, WATER SCI TECHNOL, V45, P51
   Pagotto C, 2000, WATER RES, V34, P4446, DOI 10.1016/S0043-1354(00)00221-9
   Pezzaniti D, 2009, P I CIVIL ENG-WAT M, V162, P211, DOI 10.1680/wama.2009.00034
   Pitt R., 1999, URBAN WATER, V1, P217, DOI DOI 10.1016/S1462-0758(99)00014-X
   Prince George County MD Department of Environmental Resources Programs and Planning Division, 1999, LOW IMP DEV DES STRA
   Reese AJ, 2009, STORMWATER, V10, P54
   Roseen RM, 2006, TRANSPORT RES REC, P135
   Rowe DB, 2011, ENVIRON POLLUT, V159, P2100, DOI 10.1016/j.envpol.2010.10.029
   Roy-Poirier A, 2010, J ENVIRON ENG, V136, P878, DOI 10.1061/(ASCE)EE.1943-7870.0000227
   Rusciano GM, 2007, T ASABE, V50, P1261
   Rusciano G.M., 2005, N AM SURF WAT QUAL C
   Rushton BT, 2001, J WATER RES PL-ASCE, V127, P172, DOI 10.1061/(ASCE)0733-9496(2001)127:3(172)
   Scholz M, 2007, BUILD ENVIRON, V42, P3830, DOI 10.1016/j.buildenv.2006.11.016
   STENMARK C, 1995, WATER SCI TECHNOL, V32, P79, DOI 10.1016/0273-1223(95)00541-T
   Sun XL, 2007, CHEMOSPHERE, V66, P1601, DOI 10.1016/j.chemosphere.2006.08.013
   Toronto and Region Conservation, 2006, 2 TOR REG CONS AUTH
   Tota-Maharaj K, 2010, ENVIRON PROG SUSTAIN, V29, P358, DOI 10.1002/ep.10418
   Traver RG, STORMWATER       JUL, V20005, P30
   Trowsdale SA, 2011, J HYDROL, V397, P167, DOI 10.1016/j.jhydrol.2010.11.023
   US Environmental Protection Agency, 2000, EPA841B00005
   US EPA, 1983, PB84185552 US EPA NT
   USEPA S, 1999, STORMW TECHN FACT SH
   USEPA (US Environmental Protection Agency), 1999, 832F99012 USEPA OFF
   USEPA (US Environmental Protection Agency), 1999, 832F99006 USEPA OFF
   Vijayaraghavan K, 2012, WATER RES, V46, P1337, DOI 10.1016/j.watres.2011.12.050
   Widomski MK, 2010, SOIL SCI SOC AM J, V74, P213, DOI 10.2136/sssaj2009.0003
   Zhang L, 2011, J ENVIRON ENG-ASCE, V137, P669, DOI 10.1061/(ASCE)EE.1943-7870.0000365
   Zhang L, 2010, WATER ENVIRON RES, V82, P701, DOI 10.2175/106143010X12609736966441
   Zhang W, 2008, T ASABE, V51, P1247
   ZIMMER CA, 2007, CANADIAN WATER RESOU, V32, P193, DOI DOI 10.4296/CWRJ3203193
   Zobrist J, 2000, WATER RES, V34, P1455, DOI 10.1016/S0043-1354(99)00290-0
NR 106
TC 9
Z9 9
U1 5
U2 115
PU SOC ECOLOGICAL CHEMISTRY & ENGINEERING
PI OPOLE
PA OPOLE UNIV, OLESKA 48, OPOLE, 45-951, POLAND
SN 1898-6196
J9 ECOL CHEM ENG S
JI Ecol. Chem. Eng. S-
PD DEC
PY 2015
VL 22
IS 4
BP 543
EP 563
DI 10.1515/eces-2015-0032
PG 21
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA DD9LK
UT WOS:000370246800005
OA Other Gold
DA 2018-12-27
ER

PT J
AU Maran, JP
   Swathi, K
   Jeevitha, P
   Jayalakshmi, J
   Ashvini, G
AF Maran, J. Prakash
   Swathi, K.
   Jeevitha, P.
   Jayalakshmi, J.
   Ashvini, G.
TI RETRACTED: MULTIPLE RESPONSE ANALYSIS AND OPTIMIZATION OF
   MICROWAVE-ASSISTED EXTRACTION OF ANTIOXIDANT PHENOLIC COMPOUNDS OF WASTE
   MANGIFERA INDICA L PEEL (Retracted article. See vol. 40, pg. 348, 2016)
SO JOURNAL OF FOOD PROCESSING AND PRESERVATION
LA English
DT Article; Retracted Publication
ID ARTIFICIAL NEURAL-NETWORK; SURFACE METHODOLOGY; BIODIESEL PRODUCTION;
   RADIX-ASTRAGALI; BY-PRODUCTS; MANGO PEEL; PECTIN; OIL; TEMPERATURE;
   PIGMENTS
AB Mango (Mangifera indica L) processing produces significant amount of waste (peels) that can be utilized for the production of value-added functional ingredients for various food applications. Hence, the objectives of the present study was to investigate and optimize the effect of process variables such as microwave power (160-480 W), pH (2-4), time (60-180 s) and solid-liquid ratio (1: 10-1:30 g/mL) on the maximum extraction of total phenolic, flavonoid and antioxidant content from waste mango peel by microwave-assisted extraction using Box-Behnken design. From the results, it was observed that microwave power, pH and solid-liquid ratio have significant effect on the extraction process. The optimum extraction condition was found to be: microwave power of 390 W, pH of 2.82, time of 141 s and solid-liquid ratio of 1:22 g/mL, respectively.
C1 [Maran, J. Prakash; Swathi, K.; Jeevitha, P.; Jayalakshmi, J.; Ashvini, G.] Kongu Engn Coll, Dept Food Technol, Erode 638052, Tamil Nadu, India.
RP Maran, JP (reprint author), Kongu Engn Coll, Dept Food Technol, Erode 638052, Tamil Nadu, India.
EM prakashmaran@gmail.com
CR Ajila CM, 2007, FOOD CHEM, V105, P982, DOI 10.1016/j.foodchem.2007.04.052
   Balasubramani P, 2015, INT J BIOL MACROMOL, V72, P210, DOI 10.1016/j.ijbiomac.2014.08.011
   Berardini N, 2005, INNOV FOOD SCI EMERG, V6, P442, DOI 10.1016/j.ifset.2005.06.004
   Chemat S, 2005, CHEM ENG PROCESS, V44, P1320, DOI 10.1016/j.cep.2005.03.011
   Chen Y, 2007, J FOOD ENG, V81, P162, DOI 10.1016/j.jfoodeng.2006.10.018
   Dorta E, 2012, J FOOD SCI, V77, pC80, DOI 10.1111/j.1750-3841.2011.02477.x
   Eskilsson CS, 2000, J CHROMATOGR A, V902, P227
   GANZLER K, 1986, J CHROMATOGR, V371, P299, DOI 10.1016/S0021-9673(01)94714-4
   Gfrerer M, 2005, ANAL CHIM ACTA, V533, P203, DOI 10.1016/j.aca.2004.11.016
   Hemwimon S, 2007, SEP PURIF TECHNOL, V54, P44, DOI 10.1016/j.seppur.2006.08.014
   Li Y, 2012, J FOOD ENG, V109, P274, DOI 10.1016/j.jfoodeng.2011.09.021
   Luthria DL, 2012, J FUNCT FOODS, V4, P842, DOI 10.1016/j.jff.2012.06.001
   Manthey JA, 2009, J AGR FOOD CHEM, V57, P10825, DOI 10.1021/jf902606h
   Maran JP, 2015, J TAIWAN INST CHEM E, V47, P71, DOI 10.1016/j.jtice.2014.10.007
   Maran JP, 2015, CARBOHYD POLYM, V123, P67, DOI 10.1016/j.carbpol.2014.11.072
   Maran JP, 2015, FUEL, V143, P262, DOI 10.1016/j.fuel.2014.11.058
   Maran JP, 2015, INT J BIOL MACROMOL, V73, P202, DOI 10.1016/j.ijbiomac.2014.11.008
   Maran JP, 2015, INT J BIOL MACROMOL, V73, P92, DOI 10.1016/j.ijbiomac.2014.10.050
   Maran JP, 2015, IND CROP PROD, V63, P182, DOI 10.1016/j.indcrop.2014.09.059
   Maran JP, 2015, ULTRASON SONOCHEM, V23, P192, DOI 10.1016/j.ultsonch.2014.10.019
   Maran JP, 2015, CARBOHYD POLYM, V115, P732, DOI 10.1016/j.carbpol.2014.07.058
   Maran JP, 2015, J FOOD SCI TECH MYS, V52, P92, DOI 10.1007/s13197-013-0985-z
   Maran JP, 2013, IND CROP PROD, V49, P304, DOI 10.1016/j.indcrop.2013.05.012
   Maran JP, 2012, DYES PIGMENTS, V95, P465, DOI 10.1016/j.dyepig.2012.06.007
   Moorthy IG, 2015, INT J BIOL MACROMOL, V72, P1323, DOI 10.1016/j.ijbiomac.2014.10.037
   Pompeu DR, 2009, BIORESOURCE TECHNOL, V100, P6076, DOI 10.1016/j.biortech.2009.03.083
   Prieto P, 1999, ANAL BIOCHEM, V269, P337, DOI 10.1006/abio.1999.4019
   Schieber A, 2001, TRENDS FOOD SCI TECH, V12, P401, DOI 10.1016/S0924-2244(02)00012-2
   Xiao WH, 2008, SEP PURIF TECHNOL, V62, P614, DOI 10.1016/j.seppur.2008.03.025
   Yan MM, 2010, FOOD CHEM, V119, P1663, DOI 10.1016/j.foodchem.2009.09.021
NR 30
TC 3
Z9 3
U1 4
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-8892
EI 1745-4549
J9 J FOOD PROCESS PRES
JI J. Food Process Preserv.
PD DEC
PY 2015
VL 39
IS 6
BP 2276
EP 2285
DI 10.1111/jfpp.12473
PG 10
WC Food Science & Technology
SC Food Science & Technology
GA DA9JZ
UT WOS:000368126300191
DA 2018-12-27
ER

PT J
AU Maran, JP
   Priya, B
AF Maran, J. Prakash
   Priya, B.
TI RETRACTED: OPTIMIZATION OF ULTRASOUND-ASSISTED EXTRACTION OF NATURAL
   PIGMENTS FROM AMARANTHUS TRICOLOR L LEAVES (Retracted article. See vol.
   40, pg. 349, 2016)
SO JOURNAL OF FOOD PROCESSING AND PRESERVATION
LA English
DT Article; Retracted Publication
ID PECTIN; PEEL; PURIFICATION; WASTE; DESIGN; FOOD; OIL
AB A three-level, four-factor Box-Behnken response surface design was used in this study to investigate the influence of process variables (extraction temperature, ultrasonic power, extraction time and solid-liquid ratio) on the ultrasound-assisted extraction of natural pigments (betacyanin and betaxanthin) from Amaranthus tricolor L leaves. Second-order polynomial mathematical models were developed from the experimental data in order to predict the experimental data. Extraction temperature, ultrasonic power and solid-liquid ratio significantly influenced the extraction of natural pigments from A. tricolor L leaves. The optimal extraction was extraction temperature of 56C, ultrasonic power of 86 W, extraction time of 39 min and solid-liquid ratio of 1:14 g/mL, respectively.
C1 [Maran, J. Prakash] Kongu Engn Coll, Dept Food Technol, Erode 638052, Tamil Nadu, India.
   [Priya, B.] Sri Ramaswamy Mem Univ, Dept Food Proc Engn, Madras, Tamil Nadu, India.
RP Maran, JP (reprint author), Kongu Engn Coll, Dept Food Technol, Erode 638052, Tamil Nadu, India.
EM prakashmaran@gmail.com
CR Al-Dosari MS, 2010, AM J CHINESE MED, V38, P1051, DOI 10.1142/S0192415X10008469
   Awad TS, 2012, FOOD RES INT, V48, P410, DOI 10.1016/j.foodres.2012.05.004
   Balasubramani P, 2015, INT J BIOL MACROMOL, V72, P210, DOI 10.1016/j.ijbiomac.2014.08.011
   Cai YZ, 2005, TRENDS FOOD SCI TECH, V16, P370, DOI 10.1016/j.tifs.2005.03.020
   Cai YZ, 2001, J AGR FOOD CHEM, V49, P1971
   Ebringerova A, 2010, CENT EUR J CHEM, V8, P243, DOI 10.2478/s11532-010-0006-2
   Filgueiras AV, 2000, TALANTA, V53, P433, DOI 10.1016/S0039-9140(00)00510-5
   Galanakis CM, 2013, FOOD BIOPROD PROCESS, V91, P575, DOI 10.1016/j.fbp.2013.01.004
   Gupta BS, 2005, EUR FOOD RES TECHNOL, V221, P746, DOI 10.1007/s00217-005-0056-4
   Jayaprakasam B, 2004, J AGR FOOD CHEM, V52, P6939, DOI 10.1021/jf048836z
   Luque-Garcia JL, 2003, TRAC-TREND ANAL CHEM, V22, P41, DOI 10.1016/S0165-9936(03)00102-X
   Maran JP, 2015, J FOOD SCI TECH MYS, V52, P3617, DOI 10.1007/s13197-014-1429-0
   Maran JP, 2015, J TAIWAN INST CHEM E, V47, P71, DOI 10.1016/j.jtice.2014.10.007
   Maran JP, 2015, CARBOHYD POLYM, V123, P67, DOI 10.1016/j.carbpol.2014.11.072
   Maran JP, 2015, FUEL, V143, P262, DOI 10.1016/j.fuel.2014.11.058
   Maran JP, 2015, INT J BIOL MACROMOL, V73, P202, DOI 10.1016/j.ijbiomac.2014.11.008
   Maran JP, 2015, INT J BIOL MACROMOL, V73, P92, DOI 10.1016/j.ijbiomac.2014.10.050
   Maran JP, 2015, IND CROP PROD, V63, P182, DOI 10.1016/j.indcrop.2014.09.059
   Maran JP, 2015, CARBOHYD POLYM, V115, P732, DOI 10.1016/j.carbpol.2014.07.058
   Maran JP, 2013, IND CROP PROD, V49, P304, DOI 10.1016/j.indcrop.2013.05.012
   Maran JP, 2012, DYES PIGMENTS, V95, P465, DOI 10.1016/j.dyepig.2012.06.007
   Mishra A, 2008, J SCI IND RES INDIA, V67, P1098
   Moorthy IG, 2015, INT J BIOL MACROMOL, V72, P1323, DOI 10.1016/j.ijbiomac.2014.10.037
   Quan C, 2009, CAN J CHEM ENG, V87, P562, DOI 10.1002/cjce.20185
   Rastogi NK, 2011, CRIT REV FOOD SCI, V51, P705, DOI 10.1080/10408391003770583
   Roy S, 2006, PHYTOCHEMISTRY, V67, P1865, DOI 10.1016/j.phytochem.2006.06.011
   Sun RC, 2002, ULTRASON SONOCHEM, V9, P85, DOI 10.1016/S1350-4177(01)00106-7
   Tao Y, 2014, ULTRASON SONOCHEM, V21, P706, DOI 10.1016/j.ultsonch.2013.09.005
   Vinatoru M, 2001, ULTRASON SONOCHEM, V8, P303, DOI 10.1016/S1350-4177(01)00071-2
   Wang HS, 2006, LWT-FOOD SCI TECHNOL, V39, P496, DOI 10.1016/j.lwt.2005.04.001
   Wang XS, 2012, ULTRASON SONOCHEM, V19, P1155, DOI 10.1016/j.ultsonch.2012.03.012
   Xu YT, 2014, J FOOD ENG, V126, P72, DOI 10.1016/j.jfoodeng.2013.11.004
   Yang ZD, 2010, INNOV FOOD SCI EMERG, V11, P470, DOI 10.1016/j.ifset.2010.03.003
   Zhang YL, 2011, FOOD CHEM, V129, P660, DOI 10.1016/j.foodchem.2011.05.001
NR 34
TC 5
Z9 5
U1 3
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-8892
EI 1745-4549
J9 J FOOD PROCESS PRES
JI J. Food Process Preserv.
PD DEC
PY 2015
VL 39
IS 6
BP 2314
EP 2321
DI 10.1111/jfpp.12478
PG 8
WC Food Science & Technology
SC Food Science & Technology
GA DA9JZ
UT WOS:000368126300195
DA 2018-12-27
ER

PT J
AU Nieman, GF
   Gatto, LA
   Bates, JHT
   Habashi, NM
AF Nieman, Gary F.
   Gatto, Louis A.
   Bates, Jason H. T.
   Habashi, Nader M.
TI RETRACTED: Mechanical Ventilation as a Therapeutic Tool to Reduce ARDS
   Incidence (Retracted article. See vol. 150, pg. 988, 2016)
SO CHEST
LA English
DT Article; Retracted Publication
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; PRESSURE RELEASE
   VENTILATION; RANDOMIZED CONTROLLED-TRIAL; HIGH-FREQUENCY OSCILLATION;
   TIDAL-VOLUME VENTILATION; END-EXPIRATORY PRESSURE; GENERAL-ANESTHESIA;
   BREATH PROFILE; OUTCOMES
AB Trauma, hemorrhagic shock, or sepsis can incite systemic inflammatory response syndrome, which can result in early acute lung injury (EALI). As EALI advances, improperly set mechanical ventilation (MV) can amplify early injury into a secondary ventilator-induced lung injury that invariably develops into overt ARDS. Once established, ARDS is refractory to most therapeutic strategies, which have not been able to lower ARDS mortality below the current unacceptably high 40%. Low tidal volume ventilation is one of the few treatments shown to have a moderate positive impact on ARDS survival, presumably by reducing ventilator-induced lung injury. Thus, there is a compelling case to be made that the focus of ARDS management should switch from treatment once this syndrome has become established to the application of preventative measures while patients are still in the EALI stage. Indeed, studies have shown that ARDS incidence is markedly reduced when conventional MV is applied preemptively using a combination of low tidal volume and positive end-expiratory pressure in both patients in the ICU and in surgical patients at high risk for developing ARDS. Furthermore, there is evidence from animal models and high-risk trauma patients that superior prevention of ARDS can be achieved using preemptive airway pressure release ventilation with a very brief duration of pressure release. Preventing rather than treating ARDS may be the way forward in dealing with this recalcitrant condition and would represent a paradigm shift in the way that MV is currently practiced.
C1 [Nieman, Gary F.] SUNY Upstate Med Univ, Dept Surg, 750 E Adams St, Syracuse, NY 13210 USA.
   [Gatto, Louis A.] SUNY Coll Cortland, Cortland, NY 13045 USA.
   [Bates, Jason H. T.] Univ Vermont, Burlington, VT USA.
   [Habashi, Nader M.] Univ Maryland, Med Ctr, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA.
RP Nieman, GF (reprint author), SUNY Upstate Med Univ, Dept Surg, 750 E Adams St, Syracuse, NY 13210 USA.
EM niemang@upstate.edu
FU NHLBI NIH HHS [R01 HL124052]
CR Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639
   Andrews PL, 2013, J TRAUMA ACUTE CARE, V75, P635, DOI 10.1097/TA.0b013e31829d3504
   Brower RG, 2000, NEW ENGL J MED, V342, P1301
   Chung KK, 2010, CRIT CARE MED, V38, P1970, DOI 10.1097/CCM.0b013e3181eb9d0b
   Del Sorbo L, 2011, CURR OPIN CRIT CARE, V17, P1, DOI 10.1097/MCC.0b013e3283427295
   Determann RM, 2010, CRIT CARE, V14, DOI 10.1186/cc8230
   Emr B, 2013, JAMA SURG, V148, P1005, DOI 10.1001/jamasurg.2013.3746
   Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554
   Fuller BM, 2013, CRIT CARE, V17, DOI 10.1186/cc11936
   Gajic O, 2005, INTENS CARE MED, V31, P922, DOI 10.1007/s00134-005-2625-1
   Gajic O, 2004, CRIT CARE MED, V32, P1817, DOI 10.1097/01.CCM.0000133019.52531.30
   Gu WJ, 2015, CAN MED ASSOC J, V187, pE101, DOI 10.1503/cmaj.141005
   Habashi Nader M, 2005, Crit Care Med, V33, pS228, DOI 10.1097/01.CCM.0000155920.11893.37
   Hemmes SNT, 2014, LANCET, V384, P495, DOI 10.1016/S0140-6736(14)60416-5
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Jenkins JK, 2013, PEDIATR TRANSPLANT, V17, pE81, DOI 10.1111/petr.12058
   Jia XM, 2008, CHEST, V133, P853, DOI 10.1378/chest.07-1121
   Kaukonen KM, 2015, NEW ENGL J MED, V372, P1629, DOI 10.1056/NEJMoa1415236
   Kollisch-Singule M, 2014, J AM COLL SURGEONS, V219, P968, DOI 10.1016/j.jamcollsurg.2014.09.011
   Kollisch-Singule M, 2014, JAMA SURG, V149, P1138, DOI 10.1001/jamasurg.2014.1829
   Lam SM, 2013, NEW ENGL J MED, V369, P1861, DOI 10.1056/NEJMc1311316
   Lemyze M, 2013, NEW ENGL J MED, V369, P980, DOI 10.1056/NEJMc1308895
   Levin MA, 2014, BRIT J ANAESTH, V113, P97, DOI 10.1093/bja/aeu054
   Levitt JE, 2009, CHEST, V135, P936, DOI 10.1378/chest.08-2346
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331
   Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC
   McIntyre RC, 2000, CRIT CARE MED, V28, P3314, DOI 10.1097/00003246-200009000-00034
   Mikkelsen ME, 2012, AM J RESP CRIT CARE, V185, P1307, DOI 10.1164/rccm.201111-2025OC
   Neto AS, 2012, JAMA-J AM MED ASSOC, V308, P1651, DOI 10.1001/jama.2012.13730
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   Perlman CE, 2011, AM J RESP CELL MOL, V44, P34, DOI 10.1165/rcmb.2009-0005OC
   Protti A, 2013, CRIT CARE MED, V41, P1046, DOI 10.1097/CCM.0b013e31827417a6
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Retamal J, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0505-1
   Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435
   Roy S, 2013, SHOCK, V39, P28, DOI 10.1097/SHK.0b013e31827b47bb
   Roy S, 2012, J TRAUMA ACUTE CARE, V73, P391, DOI 10.1097/TA.0b013e31825c7a82
   Roy SK, 2013, SHOCK, V40, P210, DOI 10.1097/SHK.0b013e31829efb06
   Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976
   Neto AS, 2015, CURR OPIN CRIT CARE, V21, P65, DOI 10.1097/MCC.0000000000000165
   Severgnini P, 2013, ANESTHESIOLOGY, V118, P1307, DOI 10.1097/ALN.0b013e31829102de
   Smith BJ, 2015, J APPL PHYSIOL, V118, P932, DOI 10.1152/japplphysiol.00902.2014
   Spieth PM, 2014, CURR OPIN CRIT CARE, V20, P113, DOI 10.1097/MCC.0000000000000056
   Steinberg JM, 2004, AM J RESP CRIT CARE, V169, P57, DOI 10.1164/rccm.200304-544OC
   Sundar KM, 2012, J INTENSIVE CARE MED, V27, P184
   Uhlig U, 2011, COMPR PHYSIOL, V1, P635, DOI 10.1002/cphy.c100004
   Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4
   Villar J, 2010, CRIT CARE, V14, DOI 10.1186/cc8842
   WYSZOGRODSKI I, 1975, J APPL PHYSIOL, V38, P461
   Young D, 2013, NEW ENGL J MED, V368, P806, DOI 10.1056/NEJMoa1215716
NR 50
TC 11
Z9 11
U1 4
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0012-3692
J9 CHEST
JI Chest
PD DEC
PY 2015
VL 148
IS 6
BP 1396
EP 1404
DI 10.1378/chest.15-0990
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA DB1NC
UT WOS:000368273900024
PM 26135199
OA Green Published
DA 2018-12-27
ER

PT J
AU Abdin, Z
   Webb, CJ
   Gray, EM
AF Abdin, Z.
   Webb, C. J.
   Gray, E. MacA.
TI RETRACTED: Solar hydrogen hybrid energy systems for off-grid electricity
   supply: A critical review (Retracted article. See vol. 84, pg. 172,
   2018)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE Solar; Hybrid energy system; Energy vector; Hydrogen production;
   Hydrogen storage; Electrolysis; Fuel cell
ID NEUNBURG-VORM-WALD; RENEWABLE ENERGY; FUEL-CELL; POWER-SYSTEMS; STORAGE
   MATERIALS; SUSTAINABLE DEVELOPMENT; BIOHYDROGEN PRODUCTION; PERFORMANCE
   ASSESSMENT; ELECTROLYTIC HYDROGEN; DEMONSTRATION PROJECT
AB Large areas in many countries are populated but have no connection to a national electricity grid. Centralised electricity generating facilities burning fossil fuels have been the norm. Renewable energy resources, especially solar/wind energy, are now penetrating this sector. Long-term energy storage is the universal challenge in providing renewables-based electricity with high availability across the seasons. Here we review and discuss the use of hydrogen as the energy vector by means of which solar/wind energy is transformed, stored and made available as electricity. The dominant system configuration is presently photovoltaic electricity used to electrolyse water to produce hydrogen, which is stored as a pressurised gas or metal-hydride, then retrieved from storage to generate electricity in a fuel cell. We survey the demonstration projects reported in the literature and discuss the need for authoritative system modelling in order to size the system components for minimum cost at a designated availability of supply. Crown Copyright (c) 2015 Published by Elsevier Ltd. All rights reserved.
C1 [Abdin, Z.; Webb, C. J.; Gray, E. MacA.] Griffith Univ, Queensland Micro & Nanotechnol Ctr, Nathan, Qld 4111, Australia.
RP Webb, CJ (reprint author), Griffith Univ, Queensland Micro & Nanotechnol Ctr, Nathan, Qld 4111, Australia.
EM j.webb@griffith.edu.au
RI Griffith University, QMNC/I-5498-2013
CR Agbossou K, 2004, RENEW ENERG, V29, P1305, DOI 10.1016/j.renene.2003.12.006
   Ahlbrink N, 2009, P 7 MOD C COM IT SEP, P20
   Ai B, 2003, RENEW ENERG, V28, P1491, DOI 10.1016/S0960-1481(03)00011-9
   [Anonymous], 2014, HYDROGEN FUELING STA
   [Anonymous], 2013, FUELCELLTODAY
   Ares JR, 2004, MAT SCI ENG B-SOLID, V108, P76, DOI 10.1016/j.mseb.2003.10.083
   Azwar MY, 2014, RENEW SUST ENERG REV, V31, P158, DOI 10.1016/j.rser.2013.11.022
   Bajpai P, 2012, RENEW SUST ENERG REV, V16, P2926, DOI 10.1016/j.rser.2012.02.009
   Barthels H, 1998, INT J HYDROGEN ENERG, V23, P295, DOI 10.1016/S0360-3199(97)00055-4
   Belfkira R, 2008, INT POWER ELECT MOT, P1834, DOI 10.1109/EPEPEMC.2008.4635532
   Berube V, 2007, INT J ENERG RES, V31, P637, DOI 10.1002/er.1284
   Bockris JO, 2007, INT J HYDROGEN ENERG, V32, P1605, DOI 10.1016/j.ijhydene.2007.04.037
   Bogdanovic B, 2001, APPL PHYS A-MATER, V72, P221, DOI 10.1007/s003390100774
   Bogdanovic B, 2000, J ALLOY COMPD, V302, P36, DOI 10.1016/S0925-8388(99)00663-5
   Brinkhaus M, 2011, SOL ENERGY, V85, P2488, DOI 10.1016/j.solener.2011.07.007
   Budd PM, 2007, PHYS CHEM CHEM PHYS, V9, P1802, DOI 10.1039/b618053a
   Burress JW, 2010, ANGEW CHEM INT EDIT, V49, P8902, DOI 10.1002/anie.201003328
   Carmo M, 2013, INT J HYDROGEN ENERG, V38, P4901, DOI 10.1016/j.ijhydene.2013.01.151
   Cetin E, 2009, ENERG BUILDINGS, V41, P975, DOI 10.1016/j.enbuild.2009.04.004
   Challet S, 2007, J ALLOY COMPD, V439, P294, DOI 10.1016/j.jallcom.2006.08.070
   Chedid R, 1996, INT J ENERG RES, V20, P609, DOI 10.1002/(SICI)1099-114X(199607)20:7<609::AID-ER176>3.0.CO;2-O
   Chedid R, 1997, IEEE T ENERGY CONVER, V12, P79, DOI 10.1109/60.577284
   Chen J, 1996, J ALLOY COMPD, V244, P184, DOI 10.1016/S0925-8388(96)02426-7
   Chen P, 2002, NATURE, V420, P302, DOI 10.1038/nature01210
   Chlopek K, 2007, J MATER CHEM, V17, P3496, DOI 10.1039/b702723k
   Cho SW, 2007, J ALLOY COMPD, V430, P136, DOI 10.1016/j.jallcom.2006.04.068
   Christian M, 2010, NANOSCALE, V2, P2587, DOI 10.1039/c0nr00418a
   Chu S, 2012, NATURE, V488, P294, DOI 10.1038/nature11475
   Cote AP, 2005, SCIENCE, V310, P1166, DOI 10.1126/science.1120411
   Crabtree GW, 2004, PHYS TODAY, V57, P39, DOI 10.1063/1.1878333
   Cuevas F, 2012, PHYS CHEM CHEM PHYS, V14, P1200, DOI 10.1039/c1cp23030a
   Dalebrook AF, 2013, CHEM COMMUN, V49, P8735, DOI 10.1039/c3cc43836h
   Deshmukh MK, 2008, RENEW SUST ENERG REV, V12, P235, DOI 10.1016/j.rser.2006.07.011
   Dillon AC, 2001, APPL PHYS A-MATER, V72, P133, DOI 10.1007/s003390100788
   Dimitrakakis GK, 2008, NANO LETT, V8, P3166, DOI 10.1021/nl801417w
   Dincer I, 1998, ENERG SOURCE, V20, P427, DOI 10.1080/00908319808970070
   Ding J. J., 2000, Transactions of the Institution of Professional Engineers New Zealand, Electrical/Mechanical Chemical Engineering Section, V27, P1
   Ding SY, 2013, CHEM SOC REV, V42, P548, DOI 10.1039/c2cs35072f
   Dunn RI, 2012, P IEEE, V100, P504, DOI 10.1109/JPROC.2011.2163739
   Dursun E, 2012, INT J ELEC POWER, V34, P81, DOI 10.1016/j.ijepes.2011.08.025
   Eck M, 2007, PROCEEDINGS OF ISES SOLAR WORLD CONGRESS 2007: SOLAR ENERGY AND HUMAN SETTLEMENT, VOLS I-V, P1806
   Ehnberg SGJ, 2005, ELECTR POW SYST RES, V74, P119, DOI 10.1016/j.epsr.2004.09.009
   (EIA) UEIA, 2013, ANN EN REV
   Eltawil MA, 2010, RENEW SUST ENERG REV, V14, P112, DOI 10.1016/j.rser.2009.07.015
   Energy USDo, 2006, HYDR POST PLAN AN IN
   Fernandes TRC, 2005, INT J HYDROGEN ENERG, V30, P239, DOI 10.1016/j.ijhydene.2004.04.004
   Forsberg CW, 2007, J SOL ENERG-T ASME, V129, P141, DOI 10.1115/1.2710245
   Gahleitner G, 2013, INT J HYDROGEN ENERG, V38, P2039, DOI 10.1016/j.ijhydene.2012.12.010
   Gammon R, 2006, HARI HYDROGEN RENEWA
   Germain J, 2007, J MATER CHEM, V17, P4989, DOI 10.1039/b711509a
   Goettsche J, 2010, J SOL ENERGY ENG, V132
   Graetz J, 2009, CHEM SOC REV, V38, P73, DOI 10.1039/b718842k
   Gray EM, 2011, INT J HYDROGEN ENERG, V36, P654, DOI 10.1016/j.ijhydene.2010.09.051
   HANCOCK M, 1994, IEEE PHOT SPEC CONF, P1188, DOI 10.1109/WCPEC.1994.520176
   Hanna MC, 2006, J APPL PHYS, V100, DOI 10.1063/1.2356795
   Higuchi K, 1999, J ALLOY COMPD, V293, P484, DOI 10.1016/S0925-8388(99)00470-3
   Hirose K., 2010, HDB HYDROGEN STORAGE
   Hu YH, 2004, IND ENG CHEM RES, V43, P2464, DOI 10.1021/ie049947q
   Hu YH, 2003, IND ENG CHEM RES, V42, P5135, DOI 10.1021/ie030498o
   Ichikawa T, 2004, J ALLOY COMPD, V365, P271, DOI 10.1016/S0925-8388(03)00637-6
   IPCC, 2007, AGENDA, V6, P333
   Iqbal MT, 2003, RENEW ENERG, V28, P223, DOI 10.1016/S0960-1481(02)00016-2
   Ivy J, 2004, SUMMARY ELECTROLYTIC
   Jacobson MZ, 2009, SCI AM, V301, P58, DOI 10.1038/scientificamerican1109-58
   Jeon E, 2006, J ALLOY COMPD, V422, P273, DOI 10.1016/j.jallcom.2005.11.045
   Kaldellis JK, 2006, APPL ENERG, V83, P113, DOI 10.1016/j.apenergy.2005.01.003
   Karki R, 2001, IEEE T ENERGY CONVER, V16, P368, DOI 10.1109/60.969477
   Kato Y, 2005, CHEM ENG RES DES, V83, P900, DOI 10.1205/cherd.04321
   Khaselev O, 2001, INT J HYDROGEN ENERG, V26, P127, DOI 10.1016/S0360-3199(00)00039-2
   Klepper G, 2010, LANGERE LAUFZEITEN K
   Kodama T, 2007, CHEM REV, V107, P4048, DOI 10.1021/cr050188a
   Koutroulis E, 2006, SOL ENERGY, V80, P1072, DOI 10.1016/j.solener.2005.11.002
   Lehman PA, 2000, IEEE PHOT SPEC CONF, P1552, DOI 10.1109/PVSC.2000.916192
   Lehman PA, 1997, INT J HYDROGEN ENERG, V22, P465, DOI 10.1016/S0360-3199(96)00127-9
   Lenzen M, 2014, NAT RESOUR FORUM, V38, P27, DOI 10.1111/1477-8947.12030
   Levin DB, 2004, INT J HYDROGEN ENERG, V29, P173, DOI 10.1016/S0360-3199(03)00094-6
   Li YW, 2006, J AM CHEM SOC, V128, P726, DOI 10.1021/ja056831s
   Li ZS, 2013, ENERG ENVIRON SCI, V6, P347, DOI 10.1039/c2ee22618a
   Liu SS, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2206594
   Lozano Martinez GA, 2010, DEV HYDROGEN STORAGE
   Maeda K, 2010, J PHYS CHEM LETT, V1, P2655, DOI 10.1021/jz1007966
   McAllister MJ, 2007, CHEM MATER, V19, P4396, DOI 10.1021/cm0630800
   Mekhilef S, 2012, RENEW SUST ENERG REV, V16, P981, DOI 10.1016/j.rser.2011.09.020
   Meurer C, 1999, SOL ENERGY, V67, P131, DOI 10.1016/S0038-092X(00)00043-8
   Miland H, 2005, OPERATIONAL EXPERIEN
   Miland H, 2012, SOL ENERGY, V86, P666, DOI 10.1016/j.solener.2008.04.013
   Miwa K, 2007, J ALLOY COMPD, V446, P310, DOI 10.1016/j.jallcom.2006.11.140
   Moens L, 2003, J SOL ENERG-T ASME, V125, P112, DOI 10.1115/1.1531644
   Moens L, 2005, P INT SOL EN C, P791
   Moldrik P, 2011, RES HYDROGEN STORAGE
   Moore R, 2010, SAND20106978 SAND, P27
   Moriana I, 2010, 2010 International Symposium on Power Electronics, Electrical Drives, Automation and Motion (SPEEDAM 2010), P610, DOI 10.1109/SPEEDAM.2010.5542247
   Nakicenovic Nebojsa, 1998, GLOBAL ENERGY PERSPE
   Nath K, 2004, APPL MICROBIOL BIOT, V65, P520, DOI 10.1007/s00253-004-1644-0
   Navarro RM, 2007, CHEM REV, V107, P3952, DOI 10.1021/cr0501994
   Nehrir MH, 2011, IEEE T SUSTAIN ENERG, V2, P392, DOI 10.1109/TSTE.2011.2157540
   Ni M, 2007, INT J HYDROGEN ENERG, V32, P3238, DOI 10.1016/j.ijhydene.2007.04.038
   Nielsen TK, 2011, ACS NANO, V5, P4056, DOI 10.1021/nn200643b
   Niles K, 2014, USING POWER SECTOR R, P14
   Nowotny J, 2005, INT J HYDROGEN ENERG, V30, P521, DOI 10.1016/j.ijhydene.2004.06.012
   O'Keeffe M, 2000, J SOLID STATE CHEM, V152, P3, DOI 10.1006/jssc.2000.8723
   Olivier J. G., 2012, TRENDS GLOBAL CO2 EM
   Omani O, 2007, P 2007 IEEE POW ENG, P1
   Omer AM, 2008, RENEW SUST ENERG REV, V12, P2265, DOI 10.1016/j.rser.2007.05.001
   Orecchini F, 2006, INT J HYDROGEN ENERG, V31, P1951, DOI 10.1016/j.ijhydene.2006.01.015
   Orimo S, 2004, MAT SCI ENG B-SOLID, V108, P51, DOI 10.1016/j.mseb.2003 10.045
   Palo DR, 2007, CHEM REV, V107, P3992, DOI 10.1021/cr050198b
   Parambhath VB, 2012, LANGMUIR, V28, P7826, DOI 10.1021/la301232r
   Paul B, 2008, INT J HYDROGEN ENERG, V33, P490, DOI 10.1016/j.ijhydene.2007.10.040
   Pearce JM, 2009, ENERGY, V34, P1947, DOI 10.1016/j.energy.2009.08.012
   Peigney A, 2001, CARBON, V39, P507, DOI 10.1016/S0008-6223(00)00155-X
   Perlt E, 2011, CHEMPHYSCHEM, V12, P3474, DOI 10.1002/cphc.201100592
   Pinkerton FE, 2005, J PHYS CHEM B, V109, P6, DOI 10.1021/jp0455475
   Pitt MP, 2012, INT J HYDROGEN ENERG, V37, P15175, DOI 10.1016/j.ijhydene.2012.08.014
   Protogeropoulos C, 1997, INT J ENERG RES, V21, P465, DOI 10.1002/(SICI)1099-114X(199705)21:6<465::AID-ER273>3.0.CO;2-L
   Raballo S, 2010, CLEAN HYDROGEN PRODU
   Raj NT, 2011, RENEW SUST ENERG REV, V15, P3640, DOI 10.1016/j.rser.2011.06.003
   Razdan A., 2010, FUTURE ENERGY INDIA
   Reddy JB, 2004, P A REL MAI, P654, DOI 10.1109/RAMS.2004.1285521
   Ren N. Q., 2006, Aquatic Ecosystem Health & Management, V9, P39, DOI 10.1080/14634980500536030
   Ronnebro E, 2007, J PHYS CHEM B, V111, P12045, DOI 10.1021/jp0764541
   Sakintuna B, 2007, INT J HYDROGEN ENERG, V32, P1121, DOI 10.1016/j.ijhydene.2006.11.022
   Schlapbach L, 2001, NATURE, V414, P353, DOI 10.1038/35104634
   Schlesinger HI, 1940, J AM CHEM SOC, V62, P3429, DOI 10.1021/ja01869a039
   Schmitz M, 2009, RENEW ENERGY WORLD M
   Schucan T, 2000, INT ENERGY AGENCY HY
   Schucan T, 2000, CASE STUDIES INTEGRA
   Schucan T, 2000, INT AGENCY HYDROGEN
   Schwarzbozl P, 2006, SOL ENERGY, V80, P1231, DOI 10.1016/j.solener.2005.09.007
   Scrivano G, 2009, RENEW ENERG, V34, P634, DOI 10.1016/j.renene.2008.05.034
   SeelingHochmuth GC, 1997, SOL ENERGY, V61, P77, DOI 10.1016/S0038-092X(97)00028-5
   Senjyu T, 2005, IEEE T ENERGY CONVER, V20, P406, DOI 10.1109/TEC.2004.837275
   Shaahid SM, 2009, RENEW SUST ENERG REV, V13, P625, DOI 10.1016/j.rser.2007.11.017
   Shabani B, 2010, SOL ENERGY, V84, P144, DOI 10.1016/j.solener.2009.10.020
   Shahirinia A. H., 2005, 2005 International Conference on Future Power Systems (IEEE Cat. No.05EX1179C)
   Sharaf OZ, 2014, RENEW SUST ENERG REV, V32, P810, DOI 10.1016/j.rser.2014.01.012
   Sinai J, 2005, Proceedings of the ASME Turbo Expo 2005, Vol 5, P87
   Smith DG, 1981, CAMBRIDGE ENCY EARTH
   Suh MP, 2012, CHEM REV, V112, P782, DOI 10.1021/cr200274s
   Szyszka A, 1996, POWER ENG J, V10, P226, DOI 10.1049/pe:19960507
   Szyszka A, 1998, INT J HYDROGEN ENERG, V23, P849, DOI 10.1016/S0360-3199(97)00172-9
   Taggart S, 2008, RENEWABLE ENERGY FOC, V9, P51
   Tamura T, 2003, J ALLOY COMPD, V356, P505, DOI 10.1016/S0925-8388(02)01249-5
   Tina G, 2006, SOL ENERGY, V80, P578, DOI 10.1016/j.solener.2005.03.013
   Torstein Valand WB, 2000, MORTEN OTTESTAD MAGN
   Urgnani J, 2008, INT J HYDROGEN ENERG, V33, P3111, DOI 10.1016/j.ijhydene.2008.03.031
   Ursua A, 2012, P IEEE, V100, P410, DOI 10.1109/JPROC.2011.2156750
   Vajo JJ, 2005, J ALLOY COMPD, V390, P55, DOI 10.1016/j.jallcom.2004.08.042
   Valenciaga F, 2000, IEE P-CONTR THEOR AP, V147, P680, DOI 10.1049/ip-cta:20000803
   Valverde L, 2013, INT J HYDROGEN ENERG, V38, P11672, DOI 10.1016/j.ijhydene.2013.06.113
   van Helden WGJ, 2004, PROG PHOTOVOLTAICS, V12, P415, DOI 10.1002/pip.559
   van Setten MJ, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.165115
   Verhelst S, 2012, P IEEE, V100, P427, DOI 10.1109/JPROC.2011.2150190
   Vinayan B, 2014, NANO COMMUN, V1, P4
   von Spakovsky MR, 2002, ENERG CONVERS MANAGE, V43, P1249, DOI 10.1016/S0196-8904(02)00011-0
   Voss K, 1996, SOL ENERGY, V58, P17, DOI 10.1016/0038-092X(96)00046-1
   Voutetakis S, 2011, DESIGN OPTIMIZATION
   Wang Z, 2012, INT J HYDROGEN ENERG, V37, P16287, DOI 10.1016/j.ijhydene.2012.03.057
   Webb CJ, 2015, J PHYS CHEM SOLIDS, V84, P96, DOI 10.1016/j.jpcs.2014.06.014
   WEITKAMP J, 1995, INT J HYDROGEN ENERG, V20, P967, DOI 10.1016/0360-3199(95)00058-L
   Wood CD, 2007, CHEM MATER, V19, P2034, DOI 10.1021/cm070356a
   Woodruff A, 2007, EC ASSESSMENT RENEWA
   Wu B, 2001, SOL ENG, P445
   Yamada N, 2011, OPT EXPRESS, V19, P13140, DOI 10.1364/OE.19.013140
   Yilanci A, 2009, PROG ENERG COMBUST, V35, P231, DOI 10.1016/j.pecs.2008.07.004
   Zhang D, 2011, RENEW SUST ENERG REV, V15, P4673, DOI 10.1016/j.rser.2011.07.084
   Zhong Y, 2010, J PHYS CHEM C, V114, P21801, DOI 10.1021/jp1066567
   Zhou YF, 2012, DALTON T, V41, P10980, DOI 10.1039/c2dt30945a
   Zuttel A, 2007, SCRIPTA MATER, V56, P823, DOI 10.1016/j.scriptamat.2007.01.010
   Zuttel A, 2003, J ALLOY COMPD, V356, P515, DOI 10.1016/S0925-8388(02)01253-7
NR 170
TC 28
Z9 28
U1 4
U2 59
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD DEC
PY 2015
VL 52
BP 1791
EP 1808
DI 10.1016/j.rser.2015.08.011
PG 18
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA DA4GI
UT WOS:000367757800148
DA 2018-12-27
ER

PT J
AU Jean, CB
   Kyser, TK
   James, NP
   Stokes, MD
AF Jean, Christabel B.
   Kyser, T. Kurtis
   James, Noel P.
   Stokes, M. Dale
TI RETRACTED: THE ANTARCTIC BRACHIOPOD LIOTHYRELLA UVA AS A PROXY FOR
   AMBIENT OCEANOGRAPHIC CONDITIONS AT MCMURDO SOUND(Retracted article. See
   vol. 87, pg. 167, 2017)
SO JOURNAL OF SEDIMENTARY RESEARCH
LA English
DT Article; Retracted Publication
ID HIGH-RESOLUTION DISTRIBUTION; ISOTOPIC COMPOSITION; ARTICULATE
   BRACHIOPODS; CALCIUM-CARBONATE; PALEOZOIC OCEANS; MARINE CALCITE;
   LACEPEDE SHELF; SR/MG RATIOS; SOUND; PATTERNS
AB Brachiopods have been widely used as proxies to reconstruct ancient oceanographic conditions based on the assumption that their shell calcite is precipitated in near isotopic equilibrium with ambient seawater. Few studies, however, have tested the presumption of equilibrium precipitation for specimens from extreme polar environments. Furthermore, reported isotopic values for polar specimens are largely indicative of disequilibrium precipitation, leading to the conclusion that brachiopods living in extreme environments may be poor recorders of ambient oceanography. The results of shell chemistry of the Antarctic brachiopod Liothyrella uva (L. uva) are compared to the local oceanographic data at Cape Armitage, McMurdo Sound, to assess the suitability of extreme environment brachiopods as environmental proxies. Results reveal that significant kinetic fractionation occurs during primary-layer shell secretion, resulting in whole-shell isotopic compositions that do not reflect equilibrium with ambient seawater. Secondary-layer shell calcite, however, is less affected by biological fractionation and exhibits isotopic compositions that fall within the range of predicted equilibrium values. Additionally, whole-shell concentrations of elements including Ba, Cd, Cr, Fe, Mn, Na, Sr, and Zn exhibit trends that are interpreted to reflect their relative concentrations in ambient seawater. Concentrations of Mg and B, however, are found to be largely controlled by physiological processes related to brachiopod growth rate. While this study concludes that the shell chemistry of L. uva does reflect the local oceanographic conditions at McMurdo Sound, the reliability of extreme-environment brachiopods should be assessed on a species basis as differences in brachiopod physiology and microstructure can significantly influence the degree of equilibrium reflected in shell calcite.
C1 [Jean, Christabel B.; Kyser, T. Kurtis; James, Noel P.] Queens Univ, Dept Geol Sci, Kingston, ON K7L 3N6, Canada.
   [Stokes, M. Dale] Univ Calif San Diego, Marine Phys Lab, La Jolla, CA 92037 USA.
RP Jean, CB (reprint author), Queens Univ, Dept Geol Sci, Kingston, ON K7L 3N6, Canada.
EM christabel.jean@queensu.ca
FU Natural Sciences and Engineering Research Council of Canada
FX This research is funded by the Natural Sciences and Engineering Research
   Council of Canada Discovery Grant to T.K. Kyser and N.P. James. Many
   thanks to the staff of the Queen's Facility for Isotope Research: A.
   Vuletich, D. Chipley, K. Feige, E. Leduc, and S. Banerjee for their
   knowledge and patience in assisting with analyses and for their insights
   and guidance in interpreting results. Thanks to A. Grant for his time
   and patience with the SEM. This manuscript was kindly reviewed by Ryan
   Dhillon. The final manuscript benefited considerably from the
   suggestions of Editor Leslie Melim, Associate Editor Elias Samankassou,
   and reviewers Nancy Buening and Eugene Domack.
CR Auclair AC, 2003, CHEM GEOL, V202, P59, DOI 10.1016/S0009-2541(03)00233-X
   BARRERA E, 1994, PALAIOS, V9, P275, DOI 10.2307/3515202
   BARRERA E, 1990, Palaios, V5, P149, DOI 10.2307/3514811
   Barrett P.J., 1983, ANTARCTIC EARTH SCI, P550
   BARRETT P. J., 2007, ANTARCTIC DATA SEIRE, V25, P1
   BARRY J. P., 1995, INEL950362
   BARRY JP, 1988, POLAR BIOL, V8, P367, DOI 10.1007/BF00442028
   BARRY JP, 1988, POLAR BIOL, V8, P377, DOI 10.1007/BF00442029
   BATES NR, 1991, CHEM GEOL, V94, P67, DOI 10.1016/0168-9622(91)90041-T
   Brand U, 2003, CHEM GEOL, V198, P305, DOI 10.1016/S0009-2541(03)00032-9
   Brand U, 2001, PALAEOGEOGR PALAEOCL, V165, P321, DOI 10.1016/S0031-0182(00)00169-3
   Brand U, 2007, PALAEOGEOGR PALAEOCL, V256, P273, DOI 10.1016/j.palaeo.2007.02.034
   BREY T., 1995, MARINE BIOL ASS UK J, V75, P857
   Buening N, 1996, MAR BIOL, V127, P105, DOI 10.1007/BF00993650
   BUENING N, 1992, LETHAIA, V25, P331
   Burgess SN, 2010, EARTH PLANET SC LETT, V298, P385, DOI 10.1016/j.epsl.2010.08.015
   CARPENTER SJ, 1995, GEOCHIM COSMOCHIM AC, V59, P3749, DOI 10.1016/0016-7037(95)00291-7
   CARPENTER SJ, 1991, GEOCHIM COSMOCHIM AC, V55, P1991, DOI 10.1016/0016-7037(91)90038-7
   CARPENTER SJ, 1992, GEOCHIM COSMOCHIM AC, V56, P1837, DOI 10.1016/0016-7037(92)90314-9
   Curry GB, 2002, PALAEOGEOGR PALAEOCL, V182, P133, DOI 10.1016/S0031-0182(01)00456-4
   Cusack M, 2012, CHEM GEOL, V334, P139, DOI 10.1016/j.chemgeo.2012.10.021
   DAYTON PK, 1969, SCIENCE, V163, P273, DOI 10.1126/science.163.3864.273
   Donat John R., 1995, P247
   DUNBAR RB, 1989, MAR GEOL, V85, P155, DOI 10.1016/0025-3227(89)90152-7
   EMRICH K, 1970, EARTH PLANET SC LETT, V8, P363, DOI 10.1016/0012-821X(70)90109-3
   Foster M.W., 1974, Antarctic Res Ser Washington, V21, P1
   Frank TD, 2010, GEOLOGY, V38, P587, DOI 10.1130/G30849.1
   Friedman I., 1977, US GEOL SURV PROF PA, P1
   FURST M, 1976, GEOCHIM COSMOCHIM AC, V40, P1381, DOI 10.1016/0016-7037(76)90128-9
   GILMOUR AE, 1962, NZ J GEOLOGY GEOPHYS, V5, P778
   Goetz AJ, 2009, EUR J MINERAL, V21, P303, DOI 10.1127/0935-1221/2009/0021-1922
   Griesshaber E, 2007, AM MINERAL, V92, P722, DOI 10.2138/am.2007.2220
   Grossman EL, 1996, J SEDIMENT RES, V66, P1011
   HEATH R A, 1971, New Zealand Journal of Marine and Freshwater Research, V5, P497
   Heikoop JM, 2000, GEOCHIM COSMOCHIM AC, V64, P975, DOI 10.1016/S0016-7037(99)00363-4
   HEMMING NG, 1992, GEOCHIM COSMOCHIM AC, V56, P537, DOI 10.1016/0016-7037(92)90151-8
   HILLER N, 1988, LETHAIA, V21, P177, DOI 10.1111/j.1502-3931.1988.tb00809.x
   James NP, 1997, GEOLOGY, V25, P551, DOI 10.1130/0091-7613(1997)025<0551:BOVDRA>2.3.CO;2
   Leonard GH, 2006, J GEOPHYS RES-OCEANS, V111, DOI 10.1029/2005JC002952
   LEVENTER A, 1987, MAR MICROPALEONTOL, V12, P49, DOI 10.1016/0377-8398(87)90013-2
   Littlepage JL, 1965, BIOLOGY ANTARCTIC SE, VII, P1
   LOWENSTAM HA, 1961, J GEOL, V69, P241, DOI 10.1086/626740
   MACPHERSON A. J., 1987, THESIS
   Marshall JD, 1996, LETHAIA, V29, P203, DOI 10.1111/j.1502-3931.1996.tb01877.x
   MCCONNAUGHEY T, 1989, GEOCHIM COSMOCHIM AC, V53, P151, DOI 10.1016/0016-7037(89)90282-2
   MII HS, 1994, GEOLOGY, V22, P661, DOI 10.1130/0091-7613(1994)022<0661:LPSRIT>2.3.CO;2
   Milliman J. D, 1974, MARINE CARBONATES
   Morse J.W., 1990, DEV SEDIMENTOL, V33, P707
   Negri A, 2006, ENVIRON POLLUT, V143, P456, DOI 10.1016/j.envpol.2005.12.005
   NICHOLS RL, 1963, AM J SCI, V261, P20, DOI 10.2475/ajs.261.1.20
   ONEIL JR, 1969, J CHEM PHYS, V51, P5547, DOI 10.1063/1.1671982
   Parkinson D, 2005, CHEM GEOL, V219, P193, DOI 10.1016/j.chemgeo.2005.02.002
   Peck LS, 1997, PHILOS T ROY SOC B, V352, P851, DOI 10.1098/rstb.1997.0065
   PECK LS, 1989, J EXP MAR BIOL ECOL, V134, P25, DOI 10.1016/0022-0981(90)90054-G
   PECK LS, 1987, LETHAIA, V20, P33, DOI 10.1111/j.1502-3931.1987.tb00757.x
   PECK LS, 1987, J EXP MAR BIOL ECOL, V114, P85, DOI 10.1016/0022-0981(87)90142-0
   Perez-Huerta A, 2008, CHEM GEOL, V247, P229, DOI 10.1016/j.chemgeo.2007.10.014
   POPP BN, 1986, GEOL SOC AM BULL, V97, P1262, DOI 10.1130/0016-7606(1986)97<1262:BAIOOI>2.0.CO;2
   RahimpourBonab H, 1997, GEOCHIM COSMOCHIM AC, V61, P207, DOI 10.1016/S0016-7037(96)00317-1
   RICHARD FC, 1991, WATER RES, V25, P807, DOI 10.1016/0043-1354(91)90160-R
   RIVKIN RB, 1991, AM ZOOL, V31, P5
   Saito MA, 2008, LIMNOL OCEANOGR, V53, P266, DOI 10.4319/lo.2008.53.1.0266
   Siegert MJ, 2005, ANTARCT SCI, V17, P453, DOI 10.1017/S0954102005002889
   Tang YZ, 2007, GEOCHIM COSMOCHIM AC, V71, P1480, DOI 10.1016/j.gca.2006.12.010
   TAVIANI M, 1993, J SEDIMENT PETROL, V63, P84
   Toyota T, 2013, J GLACIOL, V59, P697, DOI 10.3189/2013JoG12J163
   TRESSLER W. L., 1962, 125 NAV OC OFF NSTL
   TURNER JV, 1982, GEOCHIM COSMOCHIM AC, V46, P1183, DOI 10.1016/0016-7037(82)90004-7
   Uemura T, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL046394
   Vander Putten E, 2000, GEOCHIM COSMOCHIM AC, V64, P997
   VEIZER J, 1986, GEOCHIM COSMOCHIM AC, V50, P1679, DOI 10.1016/0016-7037(86)90130-4
   VOGEL JC, 1970, Z PHYS, V230, P225, DOI 10.1007/BF01394688
   Yamamoto K, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL047134
NR 73
TC 4
Z9 4
U1 8
U2 23
PU SEPM-SOC SEDIMENTARY GEOLOGY
PI TULSA
PA 6128 EAST 38TH ST, STE 308, TULSA, OK 74135-5814 USA
SN 1527-1404
EI 1938-3681
J9 J SEDIMENT RES
JI J. Sediment. Res.
PD DEC
PY 2015
VL 85
IS 12
BP 1492
EP 1509
DI 10.2110/jsr.2015.94
PG 18
WC Geology
SC Geology
GA CZ9GK
UT WOS:000367405600006
DA 2018-12-27
ER

PT J
AU Gong, C
   Zhang, YX
   Chen, YJ
   Zhang, HF
   Liu, XR
   Xue, HQ
   Ji, L
   Wang, L
   Yang, LL
   Zhou, GX
   Wan, CH
AF Gong, Chen
   Zhang, Yixin
   Chen, Yinji
   Zhang, Haifeng
   Liu, Xiaorong
   Xue, Huaqing
   Ji, Li
   Wang, Liang
   Yang, Linlin
   Zhou, Guoxiong
   Wan, Chunhua
TI RETRACTED: High expression of ErbB3 binding protein 1 (EBP1) predicts
   poor prognosis of pancreatic ductal adenocarcinoma (PDAC) (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE EBP1; Pancreatic ductal adenocarcinoma (PDAC); Prognosis; Proliferation;
   Apoptosis
ID CELL-PROLIFERATION; LONG ISOFORM; CANCER; DIFFERENTIATION;
   TRANSCRIPTION; CARCINOMA; GROWTH; P53
AB Recent studies have identified that ErbB3 binding protein 1 (EBP1) is broadly expressed in various cancer tissues and critically involved in plenty of biological processes in this regard. However, the functional role of EBP1 in pancreatic ductal adenocarcinoma (PDAC) has never been elucidated. In this study, we found that EBP1 could serve as a prognostic biomarker of PDAC. Western blot analysis revealed that EBP1 was remarkably upregulated in PDAC tissues and cell lines. Using immunohistochemical analysis, we showed that the expression of EBP1 was correlated with tumor size (P = 0.004), histological differentiation (P = 0.041), and tumor node metastasis (TNM) stage (P = 0.000). Notably, Kaplan-Meier curve showed that high expression of EBP1 predicted significantly worsened prognosis of PDAC patients (P = 0.001). In addition, knockdown of EBP1 expression suppressed PDAC cell proliferation and retarded cell cycle progression. Furthermore, depletion of EBP1 induced the apoptosis of Panc-1 cells. Of great interest, we found that EBP1 interacted with anti-apoptotic protein, Bcl-xL, and promoted its accumulation. In summary, our results suggest that EBP1 is a novel prognostic indicator and potential therapeutic target of PDAC, shedding new insights into the important role of EBP1 in cancer development.
C1 [Gong, Chen; Zhang, Haifeng; Ji, Li; Wang, Liang; Zhou, Guoxiong] Nantong Univ, Affiliated Hosp, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China.
   [Gong, Chen; Liu, Xiaorong; Xue, Huaqing; Yang, Linlin; Wan, Chunhua] Nantong Univ, Jiangsu Prov Key Lab Inflammat & Mol Drug Target, Nantong 226001, Jiangsu, Peoples R China.
   [Zhang, Yixin] Nantong Univ, Canc Hosp, Dept Gen Surg, Nantong 226001, Jiangsu, Peoples R China.
   [Chen, Yinji] Nanjing Univ Finance & Econ, Natl Engn Lab Food Storage & Transportat, Nanjing 210023, Jiangsu, Peoples R China.
RP Zhou, GX (reprint author), Nantong Univ, Affiliated Hosp, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China.
EM zhougx@ntu.edu.cn; Chwan@ntu.edu.cn
FU National Natural Scientific Foundation of China [81072028]; Jiangsu
   Province's Outstanding Medical Academic Leader program [LJ101135]
FX This work was supported by the National Natural Scientific Foundation of
   China (No. 81072028) and Jiangsu Province's Outstanding Medical Academic
   Leader program (No. LJ101135).
CR Ahn JY, 2006, EMBO J, V25, P2083, DOI 10.1038/sj.emboj.7601111
   Bose SK, 2006, BIOCHEM J, V396, P99, DOI 10.1042/BJ20051548
   Costello E, 2012, NAT REV GASTRO HEPAT, V9, P435, DOI 10.1038/nrgastro.2012.119
   Hu BY, 2014, MOL CELL BIOCHEM, V396, P175, DOI 10.1007/s11010-014-2153-9
   Kim CK, 2012, EXP CELL RES, V318, P136, DOI 10.1016/j.yexcr.2011.08.013
   Kim CK, 2010, CANCER RES, V70, P9730, DOI 10.1158/0008-5472.CAN-10-1882
   Ko HR, 2014, BMB REP
   Ko HR, 2014, MOL CARCINOGENESIS
   Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1
   Lessor TJ, 2001, MOL CELL ENDOCRINOL, V175, P185, DOI 10.1016/S0303-7207(01)00387-2
   Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O
   Liles JS, 2010, CANCER BIOL THER, V10, P555, DOI 10.4161/cbt.10.6.12532
   Liu ZX, 2006, P NATL ACAD SCI USA, V103, P10917, DOI 10.1073/pnas.0602923103
   Liu ZX, 2009, MOL BIOL CELL, V20, P757, DOI 10.1091/mbc.E08-09-0983
   Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003
   Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107
   Oh SM, 2010, ONCOGENE, V29, P1017, DOI 10.1038/onc.2009.411
   Okada M, 2007, J BIOL CHEM, V282, P36744, DOI 10.1074/jbc.M706169200
   RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335
   Reichert M, 2007, CANCER RES, V67, P4149, DOI 10.1158/0008-5472.CAN-06-4484
   Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Squatrito M, 2006, BIOCHEM BIOPH RES CO, V344, P859, DOI 10.1016/j.bbrc.2006.03.205
   Sun J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-499
   Wan C, 2015, ONCOGENE, V34, P237, DOI 10.1038/onc.2013.536
   Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190
   Xia XM, 2001, BIOCHEM BIOPH RES CO, V289, P240, DOI 10.1006/bbrc.2001.5942
   Yoo JY, 2000, BRIT J CANCER, V82, P683
   Zhang YX, 2008, MOL CANCER THER, V7, P3176, DOI 10.1158/1535-7163.MCT-08-0526
   Zhang YX, 2003, NUCLEIC ACIDS RES, V31, P2168, DOI 10.1093/nar/gkg318
   Zhou H, 2010, NUCLEIC ACIDS RES, V38, P3619, DOI 10.1093/nar/gkq084
NR 32
TC 4
Z9 4
U1 4
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2015
VL 36
IS 12
BP 9189
EP 9199
DI 10.1007/s13277-015-3625-6
PG 11
WC Oncology
SC Oncology
GA CZ8DC
UT WOS:000367329300010
PM 26088450
DA 2018-12-27
ER

PT J
AU Ma, XR
   Li, XM
   Lu, XY
   Jia, LF
   Li, H
   Song, Q
AF Ma, Xiuru
   Li, Xiaoming
   Lu, Xiuying
   Jia, Lifeng
   Li, Hui
   Song, Qi
TI RETRACTED: Interaction between TNFR1 and TNFR2 dominates the
   clinicopathologic features of human hypopharyneal carcinoma (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Tumor necrosis factor receptor (TNFR); Hypopharyngeal squamous cell
   carcinoma; Clinicopathologic factor; Receptor interaction; Cell
   proliferation
ID SQUAMOUS-CELL CARCINOMA; HUMAN HEAD; ALPHA; NECROSIS; EXPRESSION;
   APOPTOSIS; RECEPTOR; ACTIVATION; SURVIVAL; CHEMORADIOTHERAPY
AB Although the expression of tumor necrosis factor receptors (TNFRs) has been associated with clinicopathologic features of some other cancers, their roles in hypopharyngeal squamous cell carcinoma (HPSCC) have not been documented. Forty-five HPSCC specimens were analyzed for the expression of TNFR1 and TNFR2 and its relationship with clinicopathologic factors. Interaction between the two receptors and its effects on TNF-alpha was investigated by neutralizing TNFR1 and upregulation of TNFR2. The results indicated that, in HPSCC specimens, the expression of TNFR1 but not TNFR2 is associated with clinical staging, T stage, cervical lymph node metastasis, and histologic grade in HPSCC. In Fadu cells, when conjugating with its receptors, TNF-alpha mediates proliferation effects, and neutralizing TNFR1 and/or upregulating TNFR2 evokes proliferation-inhibiting and apoptosis-inducing effects and potentiates cisplatin (DDP)-induced growth inhibition and apoptosis induction. In conclusion, interaction of TNFR1 with TNFR2 determines the biological characters of HPSCC, and TNFR1 may dominate this process. Moreover, interaction between the two receptors plays important roles in determining the fates of HPSCC cells and thus may serve as a therapeutic target for developing new therapeutic strategies for HPSCC.
C1 [Ma, Xiuru; Li, Xiaoming] Hebei Med Univ, Postgrad Sch, Shijiazhuang, Hebei, Peoples R China.
   [Ma, Xiuru; Li, Xiaoming; Lu, Xiuying; Jia, Lifeng; Li, Hui; Song, Qi] Bethune Int Peace Hosp, Dept Otolaryngol Head & Neck Surg, Shijiazhuang 050081, Peoples R China.
RP Li, XM (reprint author), Hebei Med Univ, Postgrad Sch, Shijiazhuang, Hebei, Peoples R China.
EM xmlmoo@yeah.net
FU National Natural Science Fund of China [30340005, 30371521]
FX The research work of this paper is supported by National Natural Science
   Fund of China (grant number 30340005, 30371521).
CR Ardestani S, 2013, CANCER RES, V73, P3938, DOI 10.1158/0008-5472.CAN-13-0002
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Benedetti G, 2013, BIOCHEM PHARMACOL, V85, P274, DOI 10.1016/j.bcp.2012.10.012
   Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200
   Chiechi A, 2013, CLIN CANCER RES, V19, P2473, DOI 10.1158/1078-0432.CCR-12-3416
   Chu PY, 2009, J CHIN MED ASSOC, V72, P351, DOI 10.1016/S1726-4901(09)70386-7
   Dobrzycka B, 2009, FOLIA HISTOCHEM CYTO, V47, P609, DOI 10.2478/v10042-008-0117-1
   Dou YL, 2014, TUMOR BIOL, V35, P7499, DOI 10.1007/s13277-014-1991-0
   Isonishi S, 1996, ONCOL REP, V3, P1049
   Jackson-Bernitsas DG, 2007, ONCOGENE, V26, P1385, DOI 10.1038/sj.onc.1209945
   Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718
   Krstevska V, 2012, J BUON, V17, P327
   Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a
   LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V
   Nakayama S, 2014, AM J SURG PATHOL, V38, P1138, DOI 10.1097/PAS.0000000000000219
   Nishimura H, 2012, J RADIAT RES, V53, P892, DOI 10.1093/jrr/rrs044
   Park B, 2011, BIOCHEM PHARMACOL, V82, P1134, DOI 10.1016/j.bcp.2011.07.062
   Ramesh G, 2003, AM J PHYSIOL-RENAL, V285, pF610, DOI 10.1152/ajprenal.00101.2003
   Ruspi G, 2014, CELL SIGNAL, V26, P683, DOI 10.1016/j.cellsig.2013.12.009
   Secchiero P, 2004, NEOPLASIA, V6, P364, DOI 10.1593/neo.03421
   TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O
   White LE, 2012, AM J PHYSIOL-LUNG C, V303, pL449, DOI 10.1152/ajplung.00301.2011
   Wilson DD, 2012, ARCH OTOLARYNGOL, V138, P556, DOI 10.1001/archoto.2012.950
   Yu Y, 2013, CHINESE MED J-PEKING, V126, P4139, DOI 10.3760/cma.j.issn.0366-6999.20131992
   Zhu GC, 2014, J CANCER, V5, P525, DOI 10.7150/jca.9207
   Ziprin P, 2003, CELL COMMUN ADHES, V10, P141, DOI 10.1080/15419060390262561
NR 26
TC 3
Z9 3
U1 3
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2015
VL 36
IS 12
BP 9421
EP 9429
DI 10.1007/s13277-015-3684-8
PG 9
WC Oncology
SC Oncology
GA CZ8DC
UT WOS:000367329300036
PM 26113409
DA 2018-12-27
ER

PT J
AU Li, JW
   Wu, ZM
   Magetic, D
   Zhang, LJ
   Chen, ZL
AF Li, Jian-Wei
   Wu, Zhong-Ming
   Magetic, Davor
   Zhang, Li-Jun
   Chen, Zhi-Long
TI RETRACTED: Antitumor effects evaluation of a novel porphyrin derivative
   in photodynamic therapy (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE TDPP; Porphyrin; Tumor; Photosensitizer; Photodynamic therapy
ID CHLORIN-BASED PHOTOSENSITIZER; IN-VITRO; ONCOLOGY; SINGLET; CANCER; VIVO
AB In this paper, the antitumor activity of a novel porphyrin-based photosensitizer 5,10,15,20-tetrakis[(5-diethylamino)pentyl] porphyrin (TDPP) was reported in vitro and in vivo. The photophysical and cellular properties of TDPP were investigated. The singlet oxygen generation quantum yield of TDPP was detected; it showed a high singlet oxygen quantum yield of 0.52. The intracellular distribution of photosensitizer was detected with laser scanning confocal microscopy. The efficiency of TDPP-photodynamic therapy (PDT) in vitro was analyzed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and in situ trypan blue exclusion test. Treated with a 630-nm laser, TDPP can kill cultured human esophageal cancer cell line (Eca-109) cells and reduce the growth of Eca-109 xenograft tumors significantly in BABL/c nude mice. And histopathological study was also used to confirm the antitumor effect. It has the perspective to be developed as a new antitumor drug in photodynamic therapy and deserves further investigation.
C1 [Li, Jian-Wei; Wu, Zhong-Ming] Yiwu City Cent Hosp, Yiwu 322000, Zhejiang, Peoples R China.
   [Magetic, Davor] Rudjer Boskovic Inst, Div Organ Chem & Biochem, Zagreb, Croatia.
   [Zhang, Li-Jun; Chen, Zhi-Long] Donghua Univ, Coll Chem & Biol, Dept Pharmaceut Sci & Technol, Shanghai 201620, Peoples R China.
RP Chen, ZL (reprint author), Donghua Univ, Coll Chem & Biol, Dept Pharmaceut Sci & Technol, Shanghai 201620, Peoples R China.
EM zlchen1967@yahoo.com
FU Chinese National Natural Science Foundation [21372042, 21402236,
   81101298, 81301878]; Foundation of Shanghai government [14431906200,
   14140903500, 13431900700, 13430722300, 13ZR1441000, 13ZR1440900,
   14ZR1439800, 14ZR1439900, 15ZR1439900, 15XD1523400, 14SJGGYY08, 201370];
   International Cooperation Foundation of China and Croatia [6-11];
   Foundation of Yiwu Science and Technology Bureau [2012-G3-02,
   2013-G3-03]
FX This work was supported by the Chinese National Natural Science
   Foundation (No. 21372042, 21402236, 81101298, 81301878), Foundation of
   Shanghai government (No. 14431906200, 14140903500, 13431900700,
   13430722300, 13ZR1441000, 13ZR1440900, 14ZR1439800, 14ZR1439900,
   15ZR1439900, 15XD1523400, 14SJGGYY08, 201370), International Cooperation
   Foundation of China and Croatia (6-11), and Foundation of Yiwu Science
   and Technology Bureau (No. 2012-G3-02, 2013-G3-03).
CR Allison RR, 2013, CLIN ENDOSC, V46, P24, DOI 10.5946/ce.2013.46.1.24
   Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894
   Celli JP, 2010, CHEM REV, V110, P2795, DOI 10.1021/cr900300p
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   DOUGHERTY TJ, 1995, SEMIN SURG ONCOL, V11, P333, DOI 10.1002/ssu.2980110502
   Ethirajan M, 2011, CHEM SOC REV, V40, P340, DOI 10.1039/b915149b
   HAMPTON JA, 1992, PHOTOCHEM PHOTOBIOL, V56, P235, DOI 10.1111/j.1751-1097.1992.tb02152.x
   Juarranz A, 2008, CLIN TRANSL ONCOL, V10, P148, DOI 10.1007/s12094-008-0172-2
   Kempa M, 2015, SPECTROCHIM ACTA A, V146, P249, DOI 10.1016/j.saa.2015.03.076
   Lim YC, 2009, CANCER SCI, V100, P2431, DOI 10.1111/j.1349-7006.2009.01326.x
   MacCormack Mollie A, 2006, Adv Dermatol, V22, P219, DOI 10.1016/j.yadr.2006.09.008
   Milanesio ME, 2001, BIOORGAN MED CHEM, V9, P1943
   O'Connor AE, 2009, PHOTOCHEM PHOTOBIOL, V85, P1053, DOI 10.1111/j.1751-1097.2009.00585.x
   Redmond RW, 1999, PHOTOCHEM PHOTOBIOL, V70, P391, DOI 10.1562/0031-8655(1999)070<0391:ACOSOY>2.3.CO;2
   Serra AC, 2008, J PHOTOCH PHOTOBIO B, V92, P59, DOI 10.1016/j.jphotobiol.2008.04.006
   Stockert JC, 2007, CURR MED CHEM, V14, P997, DOI 10.2174/092986707780362934
   Stylli SS, 2004, J CLIN NEUROSCI, V11, P584, DOI 10.1016/j.jocn.2004.02.001
   Stylli SS, 2006, J CLIN NEUROSCI, V13, P615, DOI 10.1016/j.jocn.2005.11.014
   Triesscheijn M, 2006, ONCOLOGIST, V11, P1034, DOI 10.1634/theoncologist.11-9-1034
   VANHILLEGERSBERG R, 1994, DRUGS, V48, P510, DOI 10.2165/00003495-199448040-00003
   Yan YJ, 2010, BIOORGAN MED CHEM, V18, P6282, DOI 10.1016/j.bmc.2010.07.027
   Zenkevich EI, 2014, MACROHETEROCYCLES, V7, P103, DOI 10.6060/mhc140597z
   Zhang LJ, 2014, J CANCER RES CLIN, V140, P1527, DOI 10.1007/s00432-014-1717-0
NR 23
TC 4
Z9 4
U1 3
U2 23
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2015
VL 36
IS 12
BP 9685
EP 9692
DI 10.1007/s13277-015-3745-z
PG 8
WC Oncology
SC Oncology
GA CZ8DC
UT WOS:000367329300064
PM 26152290
DA 2018-12-27
ER

PT J
AU Fang, CC
   Shen, YW
   Qi, P
   Liu, ZQ
   Zhang, M
   Pang, XY
AF Fang, Changcun
   Shen, Yuwen
   Qi, Peng
   Liu, Zhengqin
   Zhang, Min
   Pang, Xinyan
TI RETRACTED: Astrocyte-elevated gene-1 mediates insulin-like growth factor
   1-induced the progression of cardiac myxoma (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE IGF-1; AEG-1; Proliferation; Apoptosis; Cardiac myxoma
ID EPITHELIAL-MESENCHYMAL TRANSITION; CARNEY COMPLEX; BREAST-CANCER;
   METASTASIS; EXPRESSION; CELLS
AB Recently, astrocyte-elevated gene-1 (AEG-1) and insulin-like growth factor 1 (IGF-1) have been involved in the regulation of multiple signaling pathways in tumorigenesis. To date, the detailed mechanisms underlying IGF-1-AEG-1 pathway-induced proliferation and apoptosis in cardiac myxoma (CM) was not reported. In the present study, we used immnohistochemistry, immunoblotting, and qRT-PCR to detect the expression profile of IGF-1 and AEG-1 in 90 CM tissues, and then cultured CM cells were subjected to si-AEG-1, in vitro, and in vivo assays. Our findings showed that IGF-1 and AEG-1 were obviously upregulated in CM tissues and markedly associated with tumor size. When CM cells were treated with si-AEG-1, si-AEG-1 attenuated IGF-1-induced CM cell growth and enhanced cell apoptosis. Mechanically, we validated the expression of AEG-1, p-Erk1/2, and p-Akt increased in CM cells in response to IGF-1 treatment in a time-dependent manner. However, si-AEG-1 affected the expression of these proteins. Functionally, we found the knockdown of AEG-1-inhibited G1/S transition and tumor formation of CM cells. In conclusion, AEG-1 regulates IGF-1-induced proliferation and apoptosis via Erk1/2 and Akt signaling in CM development, which suggests IGF-1-AEG-1 signaling could be recommended to be a useful target to exert anti-tumor effects on CM.
C1 [Fang, Changcun; Shen, Yuwen; Qi, Peng; Liu, Zhengqin; Zhang, Min; Pang, Xinyan] Shandong Univ, Qilu Hosp, Dept Cardiosurg, Jinan 250012, Peoples R China.
RP Pang, XY (reprint author), Shandong Univ, Qilu Hosp, Dept Cardiosurg, 107 West Wenhua Rd, Jinan 250012, Peoples R China.
EM pangxinyanmd@163.com
CR Gonzalez-Juanatey C, 2008, INT J CARDIOL, V127, pE110, DOI 10.1016/j.ijcard.2007.04.102
   Goswami KC, 1998, INT J CARDIOL, V63, P251, DOI 10.1016/S0167-5273(97)00316-1
   He W, 2015, BMC CANCER, V15, P1124, DOI DOI 10.1186/S12885-015-1124-1
   Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013
   Kurtkaya-Yapicier O, 2002, ULTRASTRUCT PATHOL, V26, P345, DOI 10.1080/01913120290104656
   Lee SG, 2009, ONCOGENE, V28, P2476, DOI 10.1038/onc.2009.93
   Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054
   Lim C H, 1977, Singapore Med J, V18, P68
   Liu KM, 2013, ANTI-CANCER DRUG, V24, P494, DOI 10.1097/CAD.0b013e328360093b
   Mateus C, 2008, J AM ACAD DERMATOL, V59, P801, DOI 10.1016/j.jaad.2008.07.032
   Ouattara A, 2002, ANESTH ANALG, V94, P1458, DOI 10.1097/00000539-200206000-00013
   Raff SB, 2000, J PEDIATR ENDOCR MET, V13, P373
   Rahmanian Parwis B, 2007, Interact Cardiovasc Thorac Surg, V6, P479
   Sakamoto H, 2004, CIRC J, V68, P488, DOI 10.1253/circj.68.488
   Shan H, 2015, J TRACE ELEM MED BIO, V31, P85, DOI 10.1016/j.jtemb.2015.03.005
   Srivastava J, 2014, CANCER RES, V74, P4364, DOI 10.1158/0008-5472.CAN-14-0421
   Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj/onc/1205445
   Weber CE, 2012, J BURN CARE RES, V33, P311, DOI 10.1097/BCR.0b013e318240541e
   Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460
   Zheng JS, 2014, INT J BIOL MACROMOL, V64, P106, DOI 10.1016/j.ijbiomac.2013.11.034
NR 20
TC 1
Z9 2
U1 6
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2015
VL 36
IS 12
BP 9769
EP 9777
DI 10.1007/s13277-015-3739-x
PG 9
WC Oncology
SC Oncology
GA CZ8DC
UT WOS:000367329300074
PM 26156800
DA 2018-12-27
ER

PT J
AU Song, JG
   Xie, HH
   Li, N
   Wu, K
   Qiu, JG
   Shen, DM
   Huang, CJ
AF Song, Jiu-Gang
   Xie, Hua-Hong
   Li, Nan
   Wu, Kai
   Qiu, Ji-gang
   Shen, Da-Ming
   Huang, Chun-Jin
TI RETRACTED: SUMO-specific protease 6 promotes gastric cancer cell growth
   via deSUMOylation of FoxM1 (retracted article)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE SUMOylation; SENP6; FoxM1; Gastric cancer; Cell growth
ID TRANSCRIPTION FACTOR; CARCINOMA-CELLS; MOUSE MODELS; SUMOYLATION;
   REGULATOR; ANTAGONIZES; METASTASIS; INHIBITION; EXPRESSION; INTEGRITY
AB SUMOylation is a post-translational modification exerted various effects on the target proteins. SUMOylation is a highly dynamic and reversible process, which has been shown to play an important role in tumorigenesis. However, the roles of sentrin/SUMO-specific proteases (SENPs), which mediate the reverse process of SUMOylation, in tumorigenesis remains largely unexplored. Here, we uncover a critical role of SENP6 in promoting gastric cancer cells growth via regulating the deSUMOylation of a transcription factor forkhead box protein M1 (FoxM1). We demonstrated that the mRNA and protein levels were elevated in gastric cancer tissues. Overexpression of SENP6 promoted, while RNA interference depletion of endogenous SENP6 inhibited gastric cancer cells growth and the ability of colony formation. By using biochemical assays, we identified FoxM1 as a novel substrate of SENP6 in gastric cancer cells. Thus, our data suggest that SENP6, which is highly expressed in gastric cancer cells, regulates the transcriptional activity and stability of FoxM1 through deSUMOylation.
C1 [Song, Jiu-Gang; Li, Nan; Wu, Kai] Chinese Peoples Liberat Army, Hosp 309, Dept Gastroenterol, Beijing, Peoples R China.
   [Xie, Hua-Hong] Fourth Mil Med Univ, Xijing Hosp Digest Dis, State Key Lab Canc Biol, Xian 710032, Peoples R China.
   [Qiu, Ji-gang; Shen, Da-Ming; Huang, Chun-Jin] Fudan Univ, Huadong Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
RP Qiu, JG (reprint author), Fudan Univ, Huadong Hosp, Dept Gen Surg, Shanghai 200433, Peoples R China.
EM jigangqiu@126.com
FU National Natural Science Foundation of China [81101852]; National Health
   and Family Planning Commission of China [W2012FZ093]
FX We thank Dr. Liu at the Shanghai Institute of Materia Medica, Chinese
   Academy of Sciences for providing FoxM1-TATA-luciferase reporter
   plasmid. This work was supported by grants from the National Natural
   Science Foundation of China (No. 81101852) and the National Health and
   Family Planning Commission of China (No. W2012FZ093).
CR Baek SH, 2006, CELL CYCLE, V5, P1492, DOI 10.4161/cc.5.14.3008
   Bossis G, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-13
   Chen W, 2011, ASIAN PAC J CANCER P, V12, P1785
   Dou H, 2010, MOL CELL, V39, P333, DOI 10.1016/j.molcel.2010.07.021
   Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293
   Guo C, 2014, IUBMB LIFE, V66, P71, DOI 10.1002/iub.1244
   Halasi M, 2013, MOL CANCER THER, V12, P245, DOI 10.1158/1535-7163.MCT-12-0712
   Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6
   Hattersley N, 2011, MOL BIOL CELL, V22, P78, DOI 10.1091/mbc.E10-06-0504
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709
   Le Lay J, 2010, PHYSIOL REV, V90, P1, DOI 10.1152/physrev.00018.2009
   McDowall MD, 2009, NUCLEIC ACIDS RES, V37, pD651, DOI 10.1093/nar/gkn870
   Mukhopadhyay D, 2007, TRENDS BIOCHEM SCI, V32, P286, DOI 10.1016/j.tibs.2007.05.002
   Mukhopadhyay D, 2006, J CELL BIOL, V174, P939, DOI 10.1083/jcb.200510103
   Mukhopadhyay D, 2010, J CELL BIOL, V188, P681, DOI 10.1083/jcb.200909008
   Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415
   Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007
   Qian JX, 2013, CANCER BIOTHER RADIO, V28, P196, DOI 10.1089/cbr.2012.1288
   Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640
   Rojas-Fernandez A, 2014, MOL CELL, V53, P880, DOI 10.1016/j.molcel.2014.02.031
   Schimmel J, 2014, MOL CELL, V53, P1053, DOI 10.1016/j.molcel.2014.02.001
   Shen HJ, 2012, ASIAN PAC J CANCER P, V13, P3583, DOI 10.7314/APJCP.2012.13.8.3583
   Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265
   Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159
   Wierstra I, 2013, ADV CANCER RES, V118, P97, DOI 10.1016/B978-0-12-407173-5.00004-2
   Xu N, 2012, ASIAN PAC J CANCER P, V13, P4739, DOI 10.7314/APJCP.2012.13.9.4739
   Xu Xin-Sen, 2015, Asian Pac J Cancer Prev, V16, P23
   Zhang JL, 2015, J BIOL CHEM, V290, P3708, DOI 10.1074/jbc.M114.634386
NR 29
TC 7
Z9 9
U1 8
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2015
VL 36
IS 12
BP 9865
EP 9871
DI 10.1007/s13277-015-3737-z
PG 7
WC Oncology
SC Oncology
GA CZ8DC
UT WOS:000367329300085
PM 26164001
DA 2018-12-27
ER

PT J
AU Li, YJ
   Dong, M
   Kong, FM
   Zhou, JP
AF Li, Yuji
   Dong, Ming
   Kong, Fanmin
   Zhou, Jianping
TI RETRACTED: Octamer transcription factor 1 mediates
   epithelial-mesenchymal transition in colorectal cancer (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Colorectal cancer; Octamer transcription factor 1;
   Epithelial-to-mesenchymal transition; Proliferation; Migration
ID DETERMINANT; OCT1; MANAGEMENT; IMATINIB; CELLS
AB Colorectal cancer (CRC) is one of the most common cancer types worldwide. Octamer transcription factor 1 (OCT1) is associated with tumor progression and a poor patient survival rate. However, little is known regarding the effect of OCT1 in CRC. Moreover, because the epithelial-to-mesenchymal transition (EMT) is a key player in metastasis, whether OCT1 induces EMT in CRC remains unclear. In the present study, we investigate the role of OCT1 in CRC and its expression pattern and clinical significance. The expression of OCT1 in CRC tissues and the adjacent noncancerous tissues was detected using quantitative real-time PCR (QRT-PCR), Western blot, and immunohistochemistry analyses. In addition, silencing of OCT1 with small interfering RNA (siRNA) was performed in CRC cell lines, and the impact on proliferation, migration, and the EMT marker of CRC was analyzed. Our results found that OCT1 levels were significant higher in CRC tissues compared with the adjacent noncancerous tissues. Furthermore, OCT1 siRNA significantly reduced the proliferation rate of SW620 and LoVo cells, inhibited the migration and invasion, and could reverse EMT in these two CRC cells, indicating that OCT1 plays a critical role in CRC progression.
C1 [Li, Yuji; Dong, Ming; Kong, Fanmin; Zhou, Jianping] China Med Univ, Affiliated Hosp 1, Dept Gen Surg, Shenyang 110001, Liaoning, Peoples R China.
RP Dong, M (reprint author), China Med Univ, Affiliated Hosp 1, Dept Gen Surg, Shenyang 110001, Liaoning, Peoples R China.
EM drdongming6@163.com
FU  [2012-512]
FX This work was supported by Scientific Research of Special-Term Professor
   from the Educational Department of Liaoning Province, China (Liao Cai
   Zhi Jiao No. 2012-512).
CR Almeida R, 2005, J PATHOL, V207, P396, DOI 10.1002/path.1861
   Andres A, 2012, ANN SURG, V256, P772, DOI 10.1097/SLA.0b013e3182734423
   Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lieberman DA, 2012, GASTROENTEROLOGY, V143, P844, DOI 10.1053/j.gastro.2012.06.001
   Lin R, 2013, DIGEST DIS SCI, V58, P694, DOI 10.1007/s10620-012-2424-9
   Maddox J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003048
   Mayo SC, 2011, SURGERY, V150, P204, DOI 10.1016/j.surg.2011.06.013
   Moustakas A, 2014, BBA-GEN SUBJECTS, V1840, P2621, DOI 10.1016/j.bbagen.2014.02.004
   Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757
   Perencevich Molly, 2011, Gastroenterol Hepatol (N Y), V7, P420
   Qian J, 2015, GUT, V64, P37, DOI 10.1136/gutjnl-2013-306584
   Shakya A, 2009, NAT CELL BIOL, V11, P320, DOI 10.1038/ncb1840
   Shelton Brenda K, 2002, Semin Oncol Nurs, V18, P2, DOI 10.1053/sonu.2002.33074
   Spolverato G, 2013, WORLD J GASTRO ONCOL, V5, P207, DOI 10.4251/wjgo.v5.i12.207
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618
   Wang L, 2008, CLIN PHARMACOL THER, V83, P258, DOI 10.1038/sj.clpt.6100268
   Wang VEH, 2004, P NATL ACAD SCI USA, V101, P2005, DOI 10.1073/pnas.0307304101
   White DL, 2006, BLOOD, V108, P697, DOI 10.1182/blood-2005-11-4687
NR 20
TC 6
Z9 6
U1 3
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2015
VL 36
IS 12
BP 9941
EP 9946
DI 10.1007/s13277-015-3766-7
PG 6
WC Oncology
SC Oncology
GA CZ8DC
UT WOS:000367329300093
PM 26178483
DA 2018-12-27
ER

PT J
AU Akhil, K
   Chandran, P
   Khan, SS
AF Akhil, K.
   Chandran, Preethy
   Khan, S. Sudheer
TI RETRACTED: Influence of humic acid on the stability and bacterial
   toxicity of zinc oxide nanoparticles in water(Retracted article.See
   vol.166,pg.342,2017)
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article; Retracted Publication
DE Zinc oxide nanoparticles; Humic acid; Adsorption; Stability; Toxicity
ID NATURAL ORGANIC-MATTER; SILVER NANOPARTICLES; AGGREGATION KINETICS;
   ADSORPTION-ISOTHERMS; EXOPOLYSACCHARIDES; SUBSTANCES; MECHANISM; REMOVAL
AB The present study investigated the stability of zinc oxide nanoparticles (ZnO NPs) by the adsorption of humic acid (HA) and the mechanism of adsorption. The effect of humic acid on NP toxicity was determined by Escherichia coli (ATCC 13534), E. coli (ATCC 25922), and Pseudomonas putida (MTCC 4910). The nanoparticles showed low zeta potential and were least stable in the absence of HA. However, the negative surface charge of the particles increased in the presence of HA (0-50 mg/L) that reduced the propensity of nanoparticles to aggregate in water. A decrease in absorbance of ZnO NPs at 375 nm (plasmon peak) was noted in the presence of HA by UV-visible spectrophotometric analysis. A blue shift towards 370 nm was noted when the concentration of HA was above 20 mg/L. The HA adsorbed ZnO NPs showed higher zeta potential (>-30 mV) and were highly stable. HA reduced the photocatalytic activity of ZnO and at the same time increased the photostability of ZnO. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Akhil, K.; Khan, S. Sudheer] SASTRA Univ, Dept Chem & Biosci, Srinivasa Ramanujan Ctr, Kumbakonam 612001, Tamil Nadu, India.
   [Chandran, Preethy; Khan, S. Sudheer] SASTRA Univ, Sch Chem & Biotechnol, CeNTAB, Thanjavur 613401, Tamil Nadu, India.
RP Khan, SS (reprint author), SASTRA Univ, Sch Chem & Biotechnol, CeNTAB, Thanjavur 613401, Tamil Nadu, India.
EM ssudheerkhan@gmail.com
FU Science & Engineering Research Board (SERB), Department of Science &
   Technology, Government of India [SERB/LS-587/2012]
FX The authors sincerely thank Science & Engineering Research Board (SERB),
   Department of Science & Technology, Government of India for providing
   financial support (Registration No. SERB/LS-587/2012). The authors also
   thank the management of SASTRA University for providing facility to
   carry out their research.
CR Baalousha M, 2009, SCI TOTAL ENVIRON, V407, P2093, DOI 10.1016/j.scitotenv.2008.11.022
   Chen KL, 2007, J COLLOID INTERF SCI, V309, P126, DOI 10.1016/j.jcis.2007.01.074
   Dasari T.P., 2013, J ENVIRON SCI, P1925
   Dasari TP, 2010, SCI TOTAL ENVIRON, V408, P5817, DOI 10.1016/j.scitotenv.2010.08.030
   Dubas ST, 2008, MATER LETT, V62, P2661, DOI 10.1016/j.matlet.2008.01.033
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5
   Hyung H, 2007, ENVIRON SCI TECHNOL, V41, P179, DOI 10.1021/es061817g
   Khan SS, 2011, WATER RES, V45, P5184, DOI 10.1016/j.watres.2011.07.024
   Khan SS, 2011, COLLOID SURFACE A, V381, P99, DOI 10.1016/j.colsurfa.2011.03.032
   Lagergren S., 1898, KUNGLIGA SVENSKA VET, V24, P451
   Li KG, 2012, J HAZARD MATER, V209, P264, DOI 10.1016/j.jhazmat.2012.01.013
   Litvin VA, 2012, COLLOID SURFACE A, V414, P234, DOI 10.1016/j.colsurfa.2012.08.036
   Morgada ME, 2009, CATAL TODAY, V143, P261, DOI 10.1016/j.cattod.2008.09.038
   PIZARRO J, 1995, WATER RES, V29, P617, DOI 10.1016/0043-1354(94)00167-6
   Ravindran A, 2010, COLLOID SURFACE B, V76, P32, DOI 10.1016/j.colsurfb.2009.10.005
   Saleh NB, 2010, ENVIRON SCI TECHNOL, V44, P2412, DOI 10.1021/es903059t
   Sasidharan NP, 2013, COLLOID SURFACE B, V102, P195, DOI 10.1016/j.colsurfb.2012.07.034
   Sutton R, 2005, ENVIRON SCI TECHNOL, V39, P9009, DOI 10.1021/es050778q
   Thio BJR, 2011, J HAZARD MATER, V189, P556, DOI 10.1016/j.jhazmat.2011.02.072
   Vielkind M, 2013, ADV NANOPART, V2, P287, DOI DOI 10.4236/ANP.2013.24039
   Wang Q, 2011, PHYS CHEM EARTH, V36, P442, DOI 10.1016/j.pce.2010.03.020
   Wang Y.-S., 2012, CLEAN SOIL AIR WATER
   Wang Z. L., 2004, PHYS CONDENS MATTER, V16, P829, DOI DOI 10.1088/0953-8984/16/25/R01
   Xiang QJ, 2011, J COLLOID INTERF SCI, V357, P163, DOI 10.1016/j.jcis.2011.01.093
   Zhu BC, 2015, APPL SURF SCI, V344, P188, DOI 10.1016/j.apsusc.2015.03.086
NR 25
TC 6
Z9 8
U1 3
U2 29
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD DEC
PY 2015
VL 153
BP 289
EP 295
DI 10.1016/j.jphotobiol.2015.10.007
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA CY9ZR
UT WOS:000366765400035
PM 26496792
DA 2018-12-27
ER

PT J
AU Azimi, F
   Esmaeilzadeh, A
   Ramazani, A
AF Azimi, Fatemeh
   Esmaeilzadeh, Abdolreza
   Ramazani, Ali
TI RETRACTED: Clinical significance of ITPA rs67002563 polymorphism in
   patients with acute lymphoblastic leukemia treated with
   6-mercaptopurine(Retracted article. See vol. 121, pg. 254, 2017)
SO PHARMACOLOGICAL RESEARCH
LA English
DT Letter; Retracted Publication
ID THIOPURINE S-METHYLTRANSFERASE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE;
   INFLAMMATORY-BOWEL-DISEASE; MAINTENANCE THERAPY; JAPANESE CHILDREN; GENE
   POLYMORPHISM; MERCAPTOPURINE; TOXICITY; AZATHIOPRINE; INTOLERANCE
C1 [Ramazani, Ali] Zanjan Univ Med Sci, Fac Med, Dept Mol Med, Zanjan, Iran.
   Zanjan Univ Med Sci, Fac Med, Dept Genet, Zanjan, Iran.
   Zanjan Univ Med Sci, Canc Gene Therapy Res Ctr, Zanjan, Iran.
RP Ramazani, A (reprint author), Zanjan Univ Med Sci, Fac Med, Dept Mol Med, Zanjan, Iran.
EM ramazania@zums.ac.ir
RI Esmaeilzadeh, Abdolreza/O-5770-2016
OI Esmaeilzadeh, Abdolreza/0000-0002-5402-3967; Ramazani,
   Ali/0000-0003-0369-2981
CR Ando M, 2001, PHARMACOGENETICS, V11, P269, DOI 10.1097/00008571-200104000-00011
   Azimi F, 2015, LEUKEMIA RES, V39, P1048, DOI 10.1016/j.leukres.2015.06.016
   Bierau J, 2007, PHARMACOGENOMICS, V8, P1221, DOI 10.2217/14622416.8.9.1221
   Dervieux T, 2001, LEUKEMIA, V15, P1706, DOI 10.1038/sj.leu.2402259
   Desire S, 2010, MED ONCOL, V27, P1046, DOI 10.1007/s12032-009-9331-8
   Dogan RI, 2007, NUCLEIC ACIDS RES, V35, pW285, DOI 10.1093/nar/gkm407
   Dokmanovic L, 2006, THER DRUG MONIT, V28, P800, DOI 10.1097/01.ftd.0000249947.17676.92
   Dorababu P, 2012, EUR J CLIN PHARMACOL, V68, P379, DOI 10.1007/s00228-011-1133-1
   FAIRCHILD CR, 1986, BIOCHEM PHARMACOL, V35, P3533, DOI 10.1016/0006-2952(86)90623-4
   Fotoohi AK, 2010, BIOCHEM PHARMACOL, V79, P1211, DOI 10.1016/j.bcp.2010.01.006
   Hawwa AF, 2008, BRIT J CLIN PHARMACO, V66, P517, DOI 10.1111/j.1365-2125.2008.03248.x
   Kapoor G, 2010, LEUKEMIA RES, V34, P1023, DOI 10.1016/j.leukres.2010.01.029
   Kishi S, 2007, BLOOD, V109, P4151, DOI 10.1182/blood-2006-10-054528
   Kurzawski M, 2009, EUR J CLIN PHARMACOL, V65, P533, DOI 10.1007/s00228-009-0630-y
   LENNARD L, 1992, EUR J CLIN PHARMACOL, V43, P329, DOI 10.1007/BF02220605
   Lennard L, 1997, BRIT J CLIN PHARMACO, V44, P455, DOI 10.1046/j.1365-2125.1997.t01-1-00607.x
   Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603
   Relling MV, 1999, JNCI-J NATL CANCER I, V91, P2001, DOI 10.1093/jnci/91.23.2001
   Rosalina WRW, 2012, J CLIN PHARM THER, V37, P237, DOI 10.1111/j.1365-2710.2011.01272.x
   Shipkova M, 2011, THER DRUG MONIT, V33, P321, DOI 10.1097/FTD.0b013e31821a7c34
   Stocco G, 2009, CLIN PHARMACOL THER, V85, P164, DOI 10.1038/clpt.2008.154
   Tanaka Y, 2012, LEUKEMIA RES, V36, P560, DOI 10.1016/j.leukres.2011.11.015
   Uchiyama K, 2009, J GASTROENTEROL, V44, P197, DOI 10.1007/s00535-008-2307-1
NR 23
TC 7
Z9 7
U1 3
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD DEC
PY 2015
VL 102
BP 61
EP 62
DI 10.1016/j.phrs.2015.09.015
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CZ0KG
UT WOS:000366793100008
PM 26404543
DA 2018-12-27
ER

PT J
AU Fisher, CI
   Hahn, AC
   DeBruine, LM
   Jones, BC
AF Fisher, Claire I.
   Hahn, Amanda C.
   DeBruine, Lisa M.
   Jones, Benedict C.
TI RETRACTED: Women's Preference for Attractive Makeup Tracks Changes in
   Their Salivary Testosterone (Retracted article. See vol. 27, pg. 432,
   2016)
SO PSYCHOLOGICAL SCIENCE
LA English
DT Article; Retracted Publication
DE physical appearance; face perception; social behavior; human mate
   selection; neuroendocrinology; open data; open materials
ID MENSTRUAL-CYCLE; FACIAL ATTRACTIVENESS; HORMONAL PREDICTORS; COSMETICS;
   SEX; ESTRADIOL; OVULATION; APPEARANCE; PERCEPTION; MOTIVATION
AB Previous research suggests that women's motivation to appear attractive is increased around the time of ovulation. However, the specific hormonal correlates of within-woman changes in motivation to appear attractive have not been investigated. To address this issue, we used a longitudinal design and a data-driven visual preference task. We found that women's preference for attractive makeup increases when their salivary testosterone levels are high. The relationship between testosterone level and preference for attractive makeup was independent of estradiol level, progesterone level, and estradiol-to-progesterone ratio. These results suggest that testosterone may contribute to changes in women's motivation to wear attractive makeup and, potentially, their motivation to appear attractive in general. Our results are also consistent with recent models of the role of testosterone in social behavior, according to which testosterone increases the probability of behaviors that could function to support the acquisition of mates and competition for resources.
C1 [Fisher, Claire I.; Hahn, Amanda C.; DeBruine, Lisa M.; Jones, Benedict C.] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QB, Lanark, Scotland.
RP Fisher, CI (reprint author), Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QB, Lanark, Scotland.
EM claire.fisher@glasgow.ac.uk
FU European Research Council [282655]
FX This research was funded by European Research Council Grant 282655
   (OCMATE).
CR Bao AM, 2003, EUR J ENDOCRINOL, V148, P227, DOI 10.1530/eje.0.1480227
   Bates D., 2014, J STAT SOFTWAR UNPUB, DOI DOI 10.18637/JSS.V067.I01
   Beall AT, 2013, PSYCHOL SCI, V24, P1837, DOI 10.1177/0956797613476045
   Caruso S, 2014, J SEX MED, V11, P211, DOI 10.1111/jsm.12348
   DABBS JM, 1990, PHYSIOL BEHAV, V48, P83, DOI 10.1016/0031-9384(90)90265-6
   DABBS JM, 1991, HORM RES, V35, P182, DOI 10.1159/000181899
   Dixson AF, 1998, PRIMATE SEXUALITY CO
   Durante KM, 2008, PERS SOC PSYCHOL B, V34, P1451, DOI 10.1177/0146167208323103
   Durante KM, 2011, J CONSUM RES, V37, P921, DOI 10.1086/656575
   Eisenbruch AB, 2015, PSYCHOL SCI, V26, P1332, DOI 10.1177/0956797615586403
   Etcoff NL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025656
   Geller Lauren, 2014, J Clin Aesthet Dermatol, V7, P30
   Gueguen N, 2012, PSYCHOL REC, V62, P541, DOI 10.1007/BF03395819
   Hahn A. C., 2015, LONGITUDINAL A UNPUB
   Hahn AC, 2015, HORM BEHAV, V67, P54, DOI 10.1016/j.yhbeh.2014.11.010
   Hambridge HL, 2013, HUM REPROD, V28, P1687, DOI 10.1093/humrep/det090
   Haselton MG, 2007, HORM BEHAV, V51, P40, DOI 10.1016/j.yhbeh.2006.07.007
   Hedges LV, 2007, J EDUC BEHAV STAT, V32, P341, DOI 10.3102/1076998606298043
   Jones BC, 2015, PSYCHONEUROENDOCRINO, V56, P29, DOI 10.1016/j.psyneuen.2015.02.021
   Jonesu AL, 2015, PERCEPTION, V44, P79, DOI 10.1068/p7904
   Kuznetsova A, 2013, LMERTEST TESTS LINEA
   Law-Smith MJ, 2006, P ROY SOC B-BIOL SCI, V273, P135, DOI 10.1098/rspb.2005.3296
   MarketLine, 2014, GLOB MAK
   McCall C, 2012, NAT NEUROSCI, V15, P681, DOI 10.1038/nn.3084
   ModiFace, 2013, MAK MOD VERS 11 1 OS
   Mulhern R., 2003, International Journal of Cosmetic Science, V25, P199, DOI 10.1046/j.1467-2494.2003.00188.x
   Nash R, 2006, J APPL SOC PSYCHOL, V36, P493, DOI 10.1111/j.0021-9029.2006.00016.x
   Papacosta E, 2011, J SCI MED SPORT, V14, P424, DOI 10.1016/j.jsams.2011.03.004
   Pisanski K, 2014, HORM BEHAV, V66, P493, DOI 10.1016/j.yhbeh.2014.07.006
   R Core Team, 2013, R LANG ENV STAT COMP
   Re DE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017859
   Ritchie L. L., 2014, ADAPTIVE HUMAN BEHAV, V1, P231
   Roney JR, 2013, HORM BEHAV, V63, P636, DOI 10.1016/j.yhbeh.2013.02.013
   Russell R, 2003, PERCEPTION, V32, P1093, DOI 10.1068/p5101
   Russell R, 2009, PERCEPTION, V38, P1211, DOI 10.1068/p6331
   Samson N., 2010, International Journal of Cosmetic Science, V32, P167, DOI 10.1111/j.1468-2494.2009.00535.x
   Stephen ID, 2010, PERCEPTION, V39, P1104, DOI 10.1068/p6730
   Stoll S, 2001, J AM ACAD DERMATOL, V45, P957, DOI 10.1067/mjd.2001.117382
   Tiddeman B, 2001, IEEE COMPUT GRAPH, V21, P42, DOI 10.1109/38.946630
   van Anders SM, 2011, PSYCHONEUROENDOCRINO, V36, P1265, DOI 10.1016/j.psyneuen.2011.06.001
   VELDHUIS JD, 1988, J CLIN ENDOCR METAB, V66, P414, DOI 10.1210/jcem-66-2-414
   Wang HY, 2014, PSYCHONEUROENDOCRINO, V50, P246, DOI 10.1016/j.psyneuen.2014.08.022
NR 42
TC 2
Z9 2
U1 2
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0956-7976
EI 1467-9280
J9 PSYCHOL SCI
JI Psychol. Sci.
PD DEC
PY 2015
VL 26
IS 12
BP 1958
EP 1964
DI 10.1177/0956797615609900
PG 7
WC Psychology, Multidisciplinary
SC Psychology
GA CY8OM
UT WOS:000366668200014
PM 26525076
DA 2018-12-27
ER

PT J
AU Abou Msallem, J
   Chalhoub, H
   Al-Hariri, M
   Saad, L
   Jaffa, MA
   Ziyadeh, FN
   Jaffa, AA
AF Abou Msallem, J.
   Chalhoub, H.
   Al-Hariri, M.
   Saad, L.
   Jaffa, M. A.
   Ziyadeh, F. N.
   Jaffa, A. A.
TI RETRACTED: Mechanisms of bradykinin-induced expression of connective
   tissue growth factor and nephrin in podocytes (Retracted Article. See
   vol 311, pg F1085, 2016)
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article; Retracted Publication
DE diabetic nephropathy; podocytes; oxidative stress; kinin receptors;
   nephrin; connective tissue growth factor
ID EARLY NATURAL-HISTORY; SMOOTH-MUSCLE CELLS; DIABETIC-NEPHROPATHY;
   B-2-KININ RECEPTORS; GLOMERULAR INJURY; MESANGIAL CELLS; NADPH OXIDASE;
   FACTOR-BETA; MICE; KIDNEY
AB Diabetic nephropathy (DN) is the main cause of morbidity and mortality in diabetes and is characterized by mesangial matrix deposition and podocytopathy, including podocyte loss. The risk factors and mechanisms involved in the pathogenesis of DN are still not completely defined. In the present study, we aimed to understand the cellular mechanisms through which activation of B-2 kinin receptors contribute to the initiation and progression of DN. Stimulation of cultured rat podocytes with bradykinin (BK) resulted in a significant increase in ROS generation, and this was associated with a significant increase in NADPH oxidase (NOX) 1 and NOX4 protein and mRNA levels. BK stimulation also resulted in a signicant increase in the phosphorylation of ERK1/2 and Akt, and this effect was inhibited in the presence of NOX1 and Nox4 small interfering (si) RNA. Furthermore, podocytes stimulated with BK resulted in a significant increase in protein and mRNA levels of connective tissue growth factor (CTGF) and, at the same time, a significant decrease in protein and mRNA levels of nephrin. siRNA targeted against NOX1 and NOX4 significantly inhibited the BK-induced increase in CTGF. Nephrin expression was increased in response to BK in the presence of NOX1 and NOX4 siRNA, thus implicating a role for NOXs in modulating the BK response in podocytes. Moreover, nephrin expression in response to BK was also significantly increased in the presence of siRNA targeted against CTGF. These findings provide novel aspects of BK signal transduction pathways in pathogenesis of DN and identify novel targets for interventional strategies.
C1 [Abou Msallem, J.; Chalhoub, H.; Al-Hariri, M.; Saad, L.; Ziyadeh, F. N.; Jaffa, A. A.] Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Beirut, Lebanon.
   [Jaffa, M. A.] Amer Univ Beirut, Fac Hlth Sci, Epidemiol & Populat Hlth Dept, Beirut, Lebanon.
   [Jaffa, A. A.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
RP Jaffa, AA (reprint author), Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, Beirut, Lebanon.
EM aj24@aub.edu.lb
FU National Heart, Lung, and Blood Institute [HL-077192, HL-087986];
   Lebanese Council for Scientific Research Award [102676]; Medical
   Practice Plan, Faculty of Medicine, American University of Beirut
   Medical Center
FX This work was supported by National Heart, Lung, and Blood Institute
   Grants HL-077192 and HL-087986, Lebanese Council for Scientific Research
   Award 102676, and a grant from the Medical Practice Plan, Faculty of
   Medicine, American University of Beirut Medical Center (to A. A. Jaffa).
CR Benzing T, 2004, J AM SOC NEPHROL, V15, P1382, DOI 10.1097/01.ASN.0000130167.30769.55
   Blazquez-Medela AM, 2010, CURR DIABETES REV, V6, P68, DOI 10.2174/157339910790909422
   Brinkkoetter PT, 2013, NAT REV NEPHROL, V9, P328, DOI 10.1038/nrneph.2013.78
   Brown WV, 2008, AM J CARDIOL, V102, p10L, DOI 10.1016/j.amjcard.2008.09.068
   Busch M, 2010, EUR J CLIN INVEST, V40, P742, DOI 10.1111/j.1365-2362.2010.02317.x
   Christopher J, 2002, INT IMMUNOPHARMACOL, V2, P1771, DOI 10.1016/S1567-5769(02)00188-1
   Christopher J, 2001, AM J PHYSIOL-HEART C, V280, pH1537
   Diabet Control Complications DCCT Res Grp, 1995, KIDNEY INT, V47, P1703
   Douillet CD, 2000, AM J PHYSIOL-HEART C, V279, pH2829
   Dronavalli S, 2008, NAT CLIN PRACT ENDOC, V4, P444, DOI 10.1038/ncpendmet0894
   Drummond K, 2002, DIABETES, V51, P1580, DOI 10.2337/diabetes.51.5.1580
   Eid AA, 2009, DIABETES, V58, P1201, DOI 10.2337/db08-1536
   Gorin Y, 2015, AM J PHYSIOL-RENAL, V308, pF1276, DOI 10.1152/ajprenal.00396.2014
   Haneda M, 1997, KIDNEY INT, pS66
   HARVEY JN, 1990, DIABETES, V39, P299, DOI 10.2337/diabetes.39.3.299
   HARVEY JN, 1992, DIABETOLOGIA, V35, P857, DOI 10.1007/BF00399932
   Haseyama T, 2002, TOHOKU J EXP MED, V198, P233, DOI 10.1620/tjem.198.233
   Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x
   Jaffa AA, 2003, DIABETES, V52, P1215, DOI 10.2337/diabetes.52.5.1215
   Jaffa AA, 1997, AM J PHYSIOL-RENAL, V273, pF916, DOI 10.1152/ajprenal.1997.273.6.F916
   JAFFA AA, 1995, DIABETES, V44, P156, DOI 10.2337/diabetes.44.2.156
   Jaffa AA, 2008, J CLIN ENDOCR METAB, V93, P1893, DOI 10.1210/jc.2007-2544
   Jaffa MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044714
   James LR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070441
   Jha JC, 2014, J AM SOC NEPHROL, V25, P1237, DOI 10.1681/ASN.2013070810
   Jozwiak Lucyna, 2004, Mol Diagn, V8, P157, DOI 10.2165/00066982-200408030-00003
   Kakoki M, 2004, P NATL ACAD SCI USA, V101, P13302, DOI 10.1073/pnat.0405449101
   Kakoki M, 2010, P NATL ACAD SCI USA, V107, P10190, DOI 10.1073/pnas.1005144107
   Krtil J, 2007, KIDNEY BLOOD PRESS R, V30, P162, DOI 10.1159/000102520
   LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004
   Macconi D, 2006, AM J PATHOL, V168, P42, DOI 10.2353/ajpath.2006.050398
   Maltais I, 2002, CAN J PHYSIOL PHARM, V80, P323, DOI 10.1139/Y02-036
   Mauer M, 2002, DIABETES, V51, P1572, DOI 10.2337/diabetes.51.5.1572
   Mauer M, 2009, NEW ENGL J MED, V361, P40, DOI 10.1056/NEJMoa0808400
   Nakagawa T, 2011, NAT REV NEPHROL, V7, P36, DOI 10.1038/nrneph.2010.152
   Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002
   Rincon-Choles H, 2002, KIDNEY INT S, pS8
   Rutledge JC, 2010, NAT REV NEPHROL, V6, P361, DOI 10.1038/nrneph.2010.59
   Sakharova OV, 2001, CURR OPIN NEPHROL HY, V10, P727, DOI 10.1097/00041552-200111000-00001
   Singh DK, 2011, NAT REV ENDOCRINOL, V7, P176, DOI 10.1038/nrendo.2010.212
   Stitt-Cavanagh E, 2009, THESCIENTIFICWORLDJO, V9, P1127, DOI 10.1100/tsw.2009.133
   Tan Y, 2005, AM J PHYSIOL-RENAL, V288, pF483, DOI 10.1152/ajprenal.00165.2004
   Tan Y, 2007, AM J PHYSIOL-RENAL, V293, pF1026, DOI 10.1152/ajprenal.00203.2007
   Tang SCW, 2011, LAB INVEST, V91, P1351, DOI 10.1038/labinvest.2011.81
   Wang B, 2010, J MED GENET, V47, P391, DOI 10.1136/jmg.2009.073098
   Welsh GI, 2010, J PATHOL, V220, P328, DOI 10.1002/path.2661
   Yokoi H, 2008, KIDNEY INT, V73, P446, DOI 10.1038/sj.ki.5002722
   Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097
   Zuccollo A, 1996, CAN J PHYSIOL PHARM, V74, P586, DOI 10.1139/y96-047
NR 49
TC 1
Z9 1
U1 2
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
EI 1522-1466
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD DEC 1
PY 2015
VL 309
IS 11
BP F980
EP F990
DI 10.1152/ajprenal.00233.2015
PG 11
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA CX7QS
UT WOS:000365897700010
PM 26447218
OA Green Published
DA 2018-12-27
ER

PT J
AU Rondinelli, B
   Rosano, D
   Antonini, E
   Frenquelli, M
   Montanini, L
   Huang, D
   Segalla, S
   Yoshihara, K
   Amin, SB
   Lazarevic, D
   The, B
   Verhaak, RGW
   Futreal, PA
   Di Croce, L
   Chin, L
   Cittaro, D
   Tonon, G
AF Rondinelli, Beatrice
   Rosano, Dalia
   Antonini, Elena
   Frenquelli, Michela
   Montanini, Laura
   Huang, DaChuan
   Segalla, Simona
   Yoshihara, Kosuke
   Amin, Samir B.
   Lazarevic, Dejan
   The, Bin Tean
   Verhaak, Roel G. W.
   Futreal, P. Andrew
   Di Croce, Luciano
   Chin, Lynda
   Cittaro, Davide
   Tonon, Giovanni
TI RETRACTED: Histone demethylase JARID1C inactivation triggers genomic
   instability in sporadic renal cancer (Retracted Article. See vol 126, pg
   4387, 2016)
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article; Retracted Publication
ID LINKED MENTAL-RETARDATION; H3 LYSINE-9 METHYLATION; DNA-REPLICATION;
   PERICENTRIC HETEROCHROMATIN; FACULTATIVE HETEROCHROMATIN; SATELLITE
   REPEATS; RNA INTERFERENCE; S-PHASE; CHROMATIN; PROTEINS
AB Mutations in genes encoding chromatin-remodeling proteins are often identified in a variety of cancers. For example, the histone demethylase JARID1C is frequently inactivated in patients with clear cell renal cell carcinoma (ccRCC); however, it is largely unknown how JARID1C dysfunction promotes cancer. Here, we determined that JARID1C binds broadly to chromatin domains characterized by the trimethylation of lysine 9 (H3K9me3), which is a histone mark enriched in heterochromatin. Moreover, we found that JARID1C localizes on heterochromatin, is required for heterochromatin replication, and forms a complex with established players of heterochromatin assembly, including SUV39H1 and HP1 alpha, as well as with proteins not previously associated with heterochromatin assembly, such as the cullin 4 (CUL4) complex adaptor protein DDB1. Transcription on heterochromatin is tightly suppressed to safeguard the genome, and in ccRCC cells, JARID1C inactivation led to the unrestrained expression of heterochromatic noncoding RNAs (ncRNAs) that in turn triggered genomic instability. Moreover, ccRCC patients harboring JARID1C mutations exhibited aberrant ncRNA expression and increased genomic rearrangements compared with ccRCC patients with tumors endowed with other genetic lesions. Together, these data suggest that inactivation of JARID1C in renal cancer leads to heterochromatin disruption, genomic rearrangement, and aggressive ccRCCs. Moreover, our results shed light on a mechanism that underlies genomic instability in sporadic cancers.
C1 [Rondinelli, Beatrice; Rosano, Dalia; Antonini, Elena; Frenquelli, Michela; Segalla, Simona; Tonon, Giovanni] Ist Sci San Raffaele, Div Mol Oncol, Funct Genom Canc Unit, Ist Ricovero & Cura Carattere Sci, I-20132 Milan, Italy.
   [Rondinelli, Beatrice; Montanini, Laura] Univ Vita Salute San Raffaele, Milan, Italy.
   [Huang, DaChuan; The, Bin Tean] Natl Canc Ctr Singapore, Div Med Sci, Lab Canc Epigenome, Singapore, Singapore.
   [Yoshihara, Kosuke; Verhaak, Roel G. W.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
   [Amin, Samir B.; Verhaak, Roel G. W.; Futreal, P. Andrew; Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.
   [Lazarevic, Dejan; Cittaro, Davide] Ist Sci San Raffaele, Ctr Translat Genom & Bioinformat, IRCCS, I-20132 Milan, Italy.
   [Di Croce, Luciano] Univ Pompeu Fabra, Ctr Genom Regulat CRG, Barcelona, Spain.
   [Di Croce, Luciano] ICREA, Barcelona, Spain.
RP Tonon, G (reprint author), Ist Sci San Raffaele, Div Mol Oncol, Funct Genom Canc Unit, Via Olgettina 60, I-20132 Milan, Italy.
EM tonon.giovanni@hsr.it
RI Cittaro, Davide/K-2405-2018
OI Cittaro, Davide/0000-0003-0384-3700; Di Croce,
   Luciano/0000-0003-3488-6228; Yoshihara, Kosuke/0000-0002-2254-3378;
   HUANG, DACHUAN/0000-0002-7518-4081; lazarevic,
   dejan/0000-0003-4527-290X; Amin, Samir/0000-0002-3207-9505
FU Fondazione Italiana per la Ricerca sul Cancro (FIRC); Associazione
   Italiana per la Ricerca sul Cancro (AIRC) [9965]; ICREA
FX We thank all the members of the Tonon laboratory for discussions and
   support and for critical reading of the manuscript. We also thank the
   Caligaris, Ghia, Muzio, Brendolan, Bernardi, and Gabellini laboratories
   for helpful discussions and for exchanging reagents. This work was
   supported by a Fondazione Italiana per la Ricerca sul Cancro (FIRC)
   triennial fellowship (to B. Rondinelli) and by grants from the
   Associazione Italiana per la Ricerca sul Cancro (AIRC) (Investigator
   Grants and Special Program Molecular Clinical Oncology, 5 per mille no.
   9965) (to G. Tonon).
CR Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923
   ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Biegel JA, 1999, CANCER RES, V59, P74
   Bouzinba-Segard H, 2006, P NATL ACAD SCI USA, V103, P8709, DOI 10.1073/pnas.0508006103
   Brown SJ, 2012, HUM MOL GENET, V21, pR90, DOI 10.1093/hmg/dds353
   Buscaino A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002499
   Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038
   Cam HP, 2009, CELL, V136, P610, DOI 10.1016/j.cell.2009.02.004
   Canzio D, 2011, MOL CELL, V41, P67, DOI 10.1016/j.molcel.2010.12.016
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen ES, 2008, NATURE, V451, P734, DOI 10.1038/nature06561
   Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024
   Comfort NC, 2001, TRENDS GENET, V17, P475, DOI 10.1016/S0168-9525(01)02383-6
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Dimitrova DS, 2002, J CELL SCI, V115, P4037, DOI 10.1242/jcs.00087
   Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591
   Durand-Dubief M, 2008, BIOESSAYS, V30, P526, DOI 10.1002/bies.20763
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gopalakrishnan S, 2009, HUM MOL GENET, V18, P3178, DOI 10.1093/hmg/ddp256
   Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008
   Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030
   Guo GW, 2012, NAT GENET, V44, P17, DOI 10.1038/ng.1014
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Jensen LR, 2005, AM J HUM GENET, V76, P227, DOI 10.1086/427563
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kloc A, 2008, CURR BIOL, V18, P490, DOI 10.1016/j.cub.2008.03.016
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132
   Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   Li F, 2005, CURR BIOL, V15, P1448, DOI 10.1016/j.cub.2005.07.021
   Li F, 2008, CELL, V135, P272, DOI 10.1016/j.cell.2008.08.036
   Li F, 2011, NATURE, V475, P244, DOI 10.1038/nature10161
   Liang ZH, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-18
   Lindroth AM, 2004, EMBO J, V23, P4146, DOI 10.1038/sj.emboj.7600430
   Loyola A, 2009, EMBO REP, V10, P769, DOI 10.1038/embor.2009.90
   Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355
   Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545
   Mathieu O, 2005, EMBO J, V24, P2783, DOI 10.1038/sj.emboj.7600743
   Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005
   Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   Naumann K, 2005, EMBO J, V24, P1418, DOI 10.1038/sj.emboj.7600604
   Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858
   Neuwald AF, 2000, NUCLEIC ACIDS RES, V28, P3570, DOI 10.1093/nar/28.18.3570
   Niu X, 2012, ONCOGENE, V31, P776, DOI 10.1038/onc.2011.266
   Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150
   Outchkourov NS, 2013, CELL REP, V3, P1071, DOI 10.1016/j.celrep.2013.02.030
   Papait R, 2007, MOL BIOL CELL, V18, P1098, DOI 10.1091/mbc.E06-09-0874
   Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789
   Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Poot RA, 2004, NAT CELL BIOL, V6, P1236, DOI 10.1038/ncb1196
   Probst AV, 2010, DEV CELL, V19, P625, DOI 10.1016/j.devcel.2010.09.002
   Quivy JP, 2008, NAT STRUCT MOL BIOL, V15, P972, DOI 10.1038/nsmb.1470
   Ram O, 2011, CELL, V147, P1628, DOI 10.1016/j.cell.2011.09.057
   Ritchie K, 2008, J CELL BIOL, V180, P315, DOI 10.1083/jcb.200706083
   Rondinelli B, 2015, NUCLEIC ACIDS RES, V43, P2560, DOI 10.1093/nar/gkv090
   Rowbotham SP, 2011, MOL CELL, V42, P285, DOI 10.1016/j.molcel.2011.02.036
   Rudolph T, 2007, MOL CELL, V26, P103, DOI 10.1016/j.molcel.2007.02.025
   Rujirabanjerd S, 2010, EUR J HUM GENET, V18, P330, DOI 10.1038/ejhg.2009.175
   Ryan RJH, 2012, SCIENCE, V336, P1513, DOI 10.1126/science.1223730
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121
   Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040
   Tahiliani M, 2007, NATURE, V447, P601, DOI 10.1038/nature05823
   Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801
   Trojer P, 2007, MOL CELL, V28, P1, DOI 10.1016/j.molcel.2007.09.011
   van Nuland R, 2013, MOL CELL BIOL, V33, P2067, DOI 10.1128/MCB.01742-12
   Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639
   Vella P, 2013, MOL CELL, V49, P645, DOI 10.1016/j.molcel.2012.12.019
   Volpe T, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003731
   Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1
   Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95
   WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153
   Zaratiegui M, 2011, NATURE, V479, P135, DOI 10.1038/nature10501
   Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611
   Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371
NR 82
TC 16
Z9 16
U1 2
U2 7
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD DEC
PY 2015
VL 125
IS 12
BP 4625
EP 4637
DI 10.1172/JCI81040
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CX6SI
UT WOS:000365831300027
PM 26551685
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Sakr, M
AF Sakr, Mohammed
TI RETRACTED: Relationship between Installation Torque and Axial Capacities
   of Helical Piles in Cohesionless Soils (Retracted article. See vol. 32,
   art no 08217002, 2018)
SO JOURNAL OF PERFORMANCE OF CONSTRUCTED FACILITIES
LA English
DT Article; Retracted Publication
DE Helical piles; Screw piles; Torque; Capacity; Cohesionless; Sand;
   Compression; Tension
ID SAND
AB With the rapid growth of the helical piling industry, reliable installation torque estimates and measurements become crucial. This paper presents a theoretical model developed to estimate the torsional resistance of cohesionless soils to helical pile installation. The theoretical torque model was verified using installation records collected from different sites. The paper also highlights factors that affect helical pile installation including soil properties, fluctuation in groundwater levels, shape of pile shaft, pile geometry, and method of helical pile installation. Torque factors, Kt, commonly used in the industry to correlate between installation torque and pile capacities, were also assessed and presented in the paper. The results of the study indicated that the torque factor is a function of the load path (i.e., tension or compression). Therefore torque factors in compression and tension, K-c and K-t, were formulated and presented in the paper. (C) 2014 American Society of Civil Engineers.
C1 [Sakr, Mohammed] Univ Western Ontario, London, ON N6A 3K7, Canada.
RP Sakr, M (reprint author), 2604 Bowen Way, Edmonton, AB T6W 0E8, Canada.
EM mohammmed.sakr2011@gmail.com
CR Adams J. I., 1972, CANADIAN GEOTECHNICA, V9, P89, DOI DOI 10.1139/T72-007
   Canadian Geotechnical Society, 2006, CAN FDN ENG MAN
   Tsuha CDC, 2010, CAN GEOTECH J, V47, P635, DOI 10.1139/T09-128
   Cerato AB, 2009, J PERFORM CONSTR FAC, V23, P251, DOI 10.1061/(ASCE)CF.1943-5509.0000013
   Das B, 1975, J GEOTECH ENG DIV, P999
   Das B. M., 1990, EARTH ANCHORS
   Deardorff D, 2011, DFI HEL FDN TIEB SPE
   Dilley L., 2007, P ARCT EN SUMM I N A
   GHALY A, 1991, CAN GEOTECH J, V28, P353, DOI 10.1139/t91-046
   Hawkins K., 2009, GEOTECHNICAL SPECIAL, V185, P488, DOI [10.1061/41021(335)61, DOI 10.1061/41021(335)61]
   Hoyt R. M., 1989, P 12 INT C SOIL, V2, P1019
   Kraft D.C., 2003, P 28 ANN C DEEP FDN, P209
   Livneh B, 2008, CAN GEOTECH J, V45, P1142, DOI 10.1139/T08-044
   Perko H. A, 2009, HELICAL PILES PRACTI
   Perko H.A., 2001, NEW TECHNOLOGIES DES, P342, DOI [10.1061/40511(288)24, DOI 10.1061/40511(288)24]
   Sakr Mohammed, 2013, DFI Journal: The Journal of the Deep Foundations Institute, V7, P44
   Sakr M., 2009, 34 ANN DEEP FDN C DF
   Sakr M, 2011, 64 CAN GEOT C PAN AM
   Sakr M., 2011, INSTALLATION PERFORM
   Sakr M, 2009, CAN GEOTECH J, V46, P1046, DOI 10.1139/T09-044
   Tappenden K. M., 2007, THESIS
   Zhang DJY, 1999, THESIS
NR 22
TC 5
Z9 5
U1 3
U2 10
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 0887-3828
EI 1943-5509
J9 J PERFORM CONSTR FAC
JI J. Perform. Constr. Facil.
PD DEC
PY 2015
VL 29
IS 6
AR 04014173
DI 10.1061/(ASCE)CF.1943-5509.0000621
PG 11
WC Construction & Building Technology; Engineering, Civil
SC Construction & Building Technology; Engineering
GA CW6SM
UT WOS:000365127900007
DA 2018-12-27
ER

PT J
AU Liu, P
   Sun, L
   Zhou, DS
   Zhang, P
   Wang, YH
   Li, D
   Li, QH
   Feng, RJ
AF Liu, Ping
   Sun, Liang
   Zhou, Dong-sheng
   Zhang, Peng
   Wang, Yong-hui
   Li, Dong
   Li, Qing-hu
   Feng, Rong-jie
TI RETRACTED: Development of Alendronate-conjugated Poly
   (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of
   Cisplatin in Osteosarcoma (Retracted article. See vol. 6, 31938, 2016)
SO SCIENTIFIC REPORTS
LA English
DT Article; Retracted Publication
ID OF-THE-ART; DELIVERY; MICELLES; CURCUMIN; CHEMOTHERAPY;
   BIOCOMPATIBILITY; CARCINOMA; THERAPY
AB In this study, we developed a novel poly (lactic-co-glycolic acid)-dextran (PLD)-based nanodelivery system to enhance the anticancer potential of cisplatin (CDDP) in osteosarcoma cells. A nanosized CDDP-loaded PLGA-DX nanoparticle (PLD/CDDP) controlled the release rate of CDDP up to 48 h. In vitro cytotoxicity assay showed a superior anticancer effect for PLD/CDDP and with an appreciable cellular uptake via endocytosis-mediated pathways. PLD/CDDP exhibited significant apoptosis of MG63 cancer cells compared to that of free CDDP. Approximately similar to 25% of cells were in early apoptosis phase after PLD/CDDP treatment comparing to similar to 15% for free CDDP after 48h incubation. Similarly, PLD/CDDP exhibited similar to 30% of late apoptosis cells comparing to only similar to 8% for free drug treatment. PLD/CDDP exhibited significantly higher G2/M phase arrest in MG63 cells than compared to free CDDP with a nearly 2-fold higher arrest in case of PLD/CDDP treated group (similar to 60%). Importantly, PLD/CDDP exhibited a most significant anti-tumor activity with maximum tumor growth inhibition. The superior inhibitory effect was further confirmed by a marked reduction in the number of CD31 stained tumor blood vessels and decrease in the Ki67 staining intensity for PLD/CDDP treated animal group. Overall, CDDP formulations could provide a promising and most effective platform in the treatment of osteosarcoma.
C1 [Liu, Ping] Shandong Univ, Shandong Prov Hosp, Dept Pharm, Jinan 250021, Peoples R China.
   [Sun, Liang] Shandong Univ, Shandong Prov Hosp, Dept Urol, Jinan 250021, Peoples R China.
   [Zhou, Dong-sheng; Zhang, Peng; Wang, Yong-hui; Li, Dong; Li, Qing-hu; Feng, Rong-jie] Shandong Univ, Shandong Prov Hosp, Dept Orthopaed, Jinan 250021, Peoples R China.
RP Feng, RJ (reprint author), Shandong Univ, Shandong Prov Hosp, Dept Orthopaed, Jinan 250021, Peoples R China.
EM rongjiefeng867@gmail.com
FU National Natural Science Foundation of China [81300964]; China
   Postdoctoral Science Foundation [2013M531611, 2014T70648]; Science and
   Technology Development Plan Project of Shandong Province [2014GSF118092,
   2013GSF11850]; Natural Science Foundation of Shandong Province
   [ZR2011HM054, ZR2014HQ041]
FX This research was supported by grants from the National Natural Science
   Foundation of China (No. 81300964), the China Postdoctoral Science
   Foundation (No. 2013M531611), the China Postdoctoral Science Foundation
   (No. 2014T70648), Science and Technology Development Plan Project of
   Shandong Province (No. 2014GSF118092 and No. 2013GSF11850 and the
   Natural Science Foundation of Shandong Province (No. ZR2011HM054 and No.
   ZR2014HQ041).
CR Agarwal A, 2009, BIOMATERIALS, V30, P3588, DOI 10.1016/j.biomaterials.2009.03.016
   Altunbas A, 2011, BIOMATERIALS, V32, P5906, DOI 10.1016/j.biomaterials.2011.04.069
   Bachelder EM, 2010, MOL PHARMACEUT, V7, P826, DOI 10.1021/mp900311x
   Cao HQ, 2015, MOL PHARMACEUT, V12, P922, DOI 10.1021/mp500755j
   Cvitkovic E, 1998, CANCER TREAT REV, V24, P265, DOI 10.1016/S0305-7372(98)90061-5
   Dhar S, 2008, P NATL ACAD SCI USA, V105, P17356, DOI 10.1073/pnas.0809154105
   Dhule SS, 2014, MOL PHARMACEUT, V11, P417, DOI 10.1021/mp400366r
   Du YZ, 2010, ACS NANO, V4, P6894, DOI 10.1021/nn100927t
   Endo K, 2013, CANCER SCI, V104, P369, DOI 10.1111/cas.12079
   Horie T, 2010, CARDIOVASC RES, V87, P656, DOI 10.1093/cvr/cvq148
   Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n
   Kufe DW, 2003, HOLLAND FREI CANC ME
   Li Y, 2012, PHARM RES-DORDR, V29, P756, DOI 10.1007/s11095-011-0600-9
   Liu P, 2015, NANOMED-NANOTECHNOL, V11, P855, DOI 10.1016/j.nano.2015.02.002
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Mankin HJ, 1996, J BONE JOINT SURG AM, V78A, P656, DOI 10.2106/00004623-199605000-00004
   Mitra S, 2001, J CONTROL RELEASE, V74, P317, DOI 10.1016/S0168-3659(01)00342-X
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Pignatello R, 2009, NANOMEDICINE-UK, V4, P161, DOI 10.2217/17435889.4.2.161
   PosthumaDeBoer J, 2013, ONCOL DISCOVERY, V1, P8, DOI DOI 10.7243/2052
   Ramasamy T, 2014, J MATER CHEM B, V2, P6324, DOI 10.1039/c4tb00867g
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276
   Shahin M, 2014, J DRUG TARGET, V22, P629, DOI 10.3109/1061186X.2014.921925
   Song ZM, 2011, J COLLOID INTERF SCI, V354, P116, DOI 10.1016/j.jcis.2010.10.024
   Svenson S, 2005, ADV DRUG DELIVER REV, V57, P2106, DOI 10.1016/j.addr.2005.09.018
   Tan ML, 2010, BIOMATERIALS, V31, P541, DOI 10.1016/j.biomaterials.2009.09.069
   van Leeuwen BL, 2000, CANCER TREAT REV, V26, P363, DOI 10.1053/ctrv.2000.0180
   Yan XL, 2005, J CONTROL RELEASE, V106, P198, DOI 10.1016/j.jconrel.2005.05.005
   Yanand X., 1998, CANC TREAT REV, V24, P265
   Yang JH, 2012, BIOMATERIALS, V33, P604, DOI 10.1016/j.biomaterials.2011.09.067
NR 31
TC 10
Z9 10
U1 3
U2 45
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 1
PY 2015
VL 5
AR 17387
DI 10.1038/srep17387
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CX1VD
UT WOS:000365482800001
PM 26619950
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Spicer, J
   Tischer, B
   Peters, M
AF Spicer, J.
   Tischer, B.
   Peters, M.
TI RETRACTED: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND
   TREATMENT CHOICE IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): UK
   FINDINGS FROM A GLOBAL SURVEY (Retracted article. See vol. 71, pg. 222,
   2016)
SO THORAX
LA English
DT Meeting Abstract; Retracted Publication
CT Winter Meeting of the British-Thoracic-Society
CY DEC 02-04, 2015
CL London, ENGLAND
SP British Thorac Soc
C1 [Spicer, J.] Guys Hosp, London SE1 9RT, England.
   [Tischer, B.] Kantar Hlth, Munich, Germany.
   [Peters, M.] Concord Hosp, Sydney, NSW, Australia.
CR Spicer JBT, 2015, ANN ONCOL         S1, V26, pi57
NR 1
TC 1
Z9 1
U1 3
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0040-6376
EI 1468-3296
J9 THORAX
JI Thorax
PD DEC
PY 2015
VL 70
SU 3
MA P176
BP A165
EP A165
DI 10.1136/thoraxjnl-2015-207770.313
PG 1
WC Respiratory System
SC Respiratory System
GA CW9YH
UT WOS:000365353600314
DA 2018-12-27
ER

PT J
AU Autiero, SW
   Hallas, N
   Betts, CD
   Ockrim, JL
AF Autiero, Silke Walleser
   Hallas, Natalie
   Betts, Christopher D.
   Ockrim, Jeremy L.
TI RETRACTED: The cost-effectiveness of sacral nerve stimulation (SNS) for
   the treatment of idiopathic medically refractory overactive bladder
   (wet) in the UK (Retracted article. See vol. 122, 2018)
SO BJU INTERNATIONAL
LA English
DT Article; Retracted Publication
DE cost-effectiveness analysis; overactive bladder; sacral nerve
   stimulation
ID URINARY URGE INCONTINENCE; PLACEBO-CONTROLLED TRIAL; BOTULINUM-TOXIN;
   SIGNIFICANTLY IMPROVES; DOUBLE-BLIND; NEUROMODULATION; SYMPTOMS;
   ONABOTULINUMTOXINA; MULTICENTER; EFFICACY
AB Objective
   To estimate the long-term cost-effectiveness of specialised treatment options for medically refractory idiopathic overactive bladder (OAB) wet.
   Patients and Methods
   The cost-effectiveness of competing treatment options for patients with medically refractory idiopathic OAB wet was estimated from the perspective of the National Health Service in the UK. We compared sacral nerve stimulation (SNS) with percutaneous nerve evaluation (PNE) or tined-lead evaluation (TLE) with optimal medical therapy (OMT), botulinum toxin type A (BoNT-A) injections, and percutaneous tibial nerve stimulation (PTNS). We used a Markov model with a 10-year time horizon for all treatment options with the exception of PTNS, which has a time horizon of 5 years. Costs and effects (measured as quality-adjusted life years) were calculated to derive incremental cost-effectiveness ratios (ICERs). Direct medical resources included are: device and drug acquisition costs, pre-procedure and procedure costs, and the cost of managing adverse events. Deterministic sensitivity analyses were performed to test robustness of results.
   Results
   At 5 years, SNS (PNE or TLE) was more effective and less costly than PTNS. Compared with OMT at 10 years, SNS (PNE or TLE) was more costly and more effective, and compared with BoNT-A, SNS PNE was less costly and more effective, and SNS TLE was more costly and more effective. Decreasing the BoNT-A dose from 150 to 100 IU marginally increased the 10 year ICERs for SNS TLE and PNE (SNS PNE was no longer dominant). However, both SNS options remained cost-effective.
   Conclusion
   In the management of patients with idiopathic OAB wet, the results of this cost-utility analysis favours SNS (PNE or TLE) over PTNS or OMT, and the most efficient treatment strategy is SNS PNE over BoNT-A over a 10-year period.
C1 [Autiero, Silke Walleser] Medtronic Inc, Tolochenaz, Switzerland.
   [Hallas, Natalie] Medtronic UK, Watford, Herts, England.
   [Betts, Christopher D.] Salford Royal Hosp, Salford, Lancs, England.
   [Ockrim, Jeremy L.] Univ Coll London Hosp, Inst Urol, London, England.
RP Ockrim, JL (reprint author), Univ Coll Hosp, Inst Urol, 235 Euston Rd, London NW1 2PQ, England.
EM jeremy.ockrim@uclh.nhs.uk
CR Amundsen CL, 2014, CONTEMP CLIN TRIALS, V37, P272, DOI 10.1016/j.cct.2014.01.009
   Arlandis S, 2011, VALUE HEALTH, V14, P219, DOI 10.1016/j.jval.2010.08.006
   Baltussen Rob, 2006, Cost Eff Resour Alloc, V4, P14, DOI 10.1186/1478-7547-4-14
   Bosch JLHR, 2000, J UROLOGY, V163, P1219, DOI 10.1016/S0022-5347(05)67728-2
   Brazzelli M, 2006, J UROLOGY, V175, P835, DOI 10.1016/S0022-5347(05)00326-5
   Chapple C, 2005, EUR UROL, V48, P5, DOI 10.1016/j.eururo.2005.02.024
   Chapple CR, 2006, INT J CLIN PRACT, V60, P959, DOI 10.1111/j.1742-1241.2006.01067.x
   Chapple C, 2013, EUR UROL, V64, P249, DOI 10.1016/j.eururo.2013.04.001
   D'Ausilio A, 2012, VALUE HEALTH, V15, pA357, DOI 10.1016/j.jval.2012.08.917
   Devlin N, 2004, HEALTH ECON, V13, P437, DOI 10.1002/hec.864
   Dmochowski R, 2010, J UROLOGY, V184, P2416, DOI 10.1016/j.juro.2010.08.021
   Hassouna MM, 2000, J UROLOGY, V163, P1849, DOI 10.1016/S0022-5347(05)67558-1
   Kessler TM, 2007, EUR UROL, V51, P1357, DOI 10.1016/j.eururo.2006.11.011
   Klotz T, 2007, EUR UROL, V51, P1654, DOI 10.1016/j.eururo.2006.11.040
   Kuo HC, 2007, J UROLOGY, V178, P1359, DOI 10.1016/j.juro.2007.05.136
   Leong RK, 2011, BJU INT, V108, P558, DOI 10.1111/j.1464-410X.2010.09905.x
   MacDiarmid SA, 2010, J UROLOGY, V183, P234, DOI 10.1016/j.juro.2009.08.160
   Medtronic, 2013, INTERSTIM THER SYST
   Mohee A, 2013, BJU INT, V111, P106, DOI 10.1111/j.1464-410X.2012.11282.x
   National Collaborating Centre for Women's and Children's Health, 2013, UR INC WOM MAN UR IN
   National Institute for Health and Clinical Excellence, 2010, PERC POST TIB NERV S
   Nitti VW, 2013, J UROLOGY, V189, P2186, DOI 10.1016/j.juro.2012.12.022
   Peters KM, 2013, NEUROUROL URODYNAM, V32, P24, DOI 10.1002/nau.22266
   Peters KM, 2010, J UROLOGY, V183, P1438, DOI 10.1016/j.juro.2009.12.036
   Schmid DM, 2006, J UROLOGY, V176, P177, DOI 10.1016/S0022-5347(06)00590-8
   Schmidt RA, 1999, J UROLOGY, V162, P352, DOI 10.1016/S0022-5347(05)68558-8
   Siddiqui NY, 2009, J UROLOGY, V182, P2799, DOI 10.1016/j.juro.2009.08.031
   Siegel SW, 2000, UROLOGY, V56, P87, DOI 10.1016/S0090-4295(00)00597-5
   Staskin D, 2007, J UROLOGY, V178, P978, DOI 10.1016/j.juro.2007.05.058
   Szende A, 2004, MEASURING SELF REPOR
   Turner DA, 2004, BJU INT, V93, P1246, DOI 10.1111/j.1464-410X.2004.04806.x
   van Kerrebroeck PEV, 2007, J UROLOGY, V178, P2029, DOI 10.1016/j.juro.2007.07.032
   Van Voskuilen AC, 2007, BJU INT, V99, P107, DOI 10.1111/j.1464-410X.2006.06508.x
   Wu JM, 2009, J UROLOGY, V181, P2181, DOI 10.1016/j.juro.2009.01.037
NR 34
TC 9
Z9 9
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
EI 1464-410X
J9 BJU INT
JI BJU Int.
PD DEC
PY 2015
VL 116
IS 6
BP 945
EP 954
DI 10.1111/bju.12972
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA CV5TU
UT WOS:000364334900024
PM 25407358
DA 2018-12-27
ER

PT J
AU Saito, S
   Lin, YC
   Murayama, Y
   Nakamura, Y
   Eckner, R
   Niemann, H
   Yokoyama, KK
AF Saito, Shigeo
   Lin, Ying-Chu
   Murayama, Yoshinobu
   Nakamura, Yukio
   Eckner, Richard
   Niemann, Heiner
   Yokoyama, Kazunari K.
TI RETRACTED: In vitro derivation of mammalian germ cells from stem cells
   and their potential therapeutic application (Retracted article. See vol.
   73, pg. 1117, 2016)
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review; Retracted Publication
DE Animal reproduction; Embryonic stem cells; Gametes; Germ cells;
   Primordial germ cells; Spermatogonial stem cells; Sterility; Therapeutic
   use
ID MURINE SEMINIFEROUS TUBULES; ADULT HUMAN TESTIS; DNA METHYLATION; MOUSE
   TESTIS; MONO-(2-ETHYLHEXYL) PHTHALATE; ENDOCRINE DISRUPTORS; TRANSITION
   PROTEIN-2; TESTICULAR CELLS; PATERNAL GENOME; SELF-RENEWAL
AB Pluripotent stem cells (PSCs) are a unique type of cells because they exhibit the characteristics of self-renewal and pluripotency. PSCs may be induced to differentiate into any cell type, even male and female germ cells, suggesting their potential as novel cell-based therapeutic treatment for infertility problems. Spermatogenesis is an intricate biological process that starts from self-renewal of spermatogonial stem cells (SSCs) and leads to differentiated haploid spermatozoa. Errors at any stage in spermatogenesis may result in male infertility. During the past decade, much progress has been made in the derivation of male germ cells from various types of progenitor stem cells. Currently, there are two main approaches for the derivation of functional germ cells from PSCs, either the induction of in vitro differentiation to produce haploid cell products, or combination of in vitro differentiation and in vivo transplantation. The production of mature and fertile spermatozoa from stem cells might provide an unlimited source of autologous gametes for treatment of male infertility. Here, we discuss the current state of the art regarding the differentiation potential of SSCs, embryonic stem cells, and induced pluripotent stem cells to produce functional male germ cells. We also discuss the possible use of livestock-derived PSCs as a novel option for animal reproduction and infertility treatment.
C1 [Saito, Shigeo] Saito Lab Cell Technol, Yaita, Tochigi 3291571, Japan.
   [Saito, Shigeo] SPK Co Ltd, Aizu Wakamatsu, Fukushima 9650025, Japan.
   [Lin, Ying-Chu] Kaohsiung Med Univ, Coll Dent Med, Sch Dent, Kaohsiung 807, Taiwan.
   [Saito, Shigeo; Murayama, Yoshinobu] Nihon Univ, Coll Engn, Koriyama, Fukushima 9638642, Japan.
   [Nakamura, Yukio] RIKEN, Cell Engn Div, BioResource Ctr, Tsukuba, Ibaraki 3050074, Japan.
   [Eckner, Richard] Rutgers State Univ, Rutgers New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07101 USA.
   [Niemann, Heiner] Friedrich Loffler Inst, Inst Farm Anim Genet, D-31535 Neustadt, Germany.
   [Yokoyama, Kazunari K.] Kaohsiung Med Univ, Ctr Environm Med, Ctr Stem Cell Res, Grad Inst Med, Kaohsiung 807, Taiwan.
   [Yokoyama, Kazunari K.] Tokushima Bunri Univ, Fac Sci & Engn, Sanuki 7632193, Japan.
   [Yokoyama, Kazunari K.] Univ Tokyo, Grad Sch Med, Dept Mol Prevent Med, Tokyo 1130033, Japan.
RP Saito, S (reprint author), Saito Lab Cell Technol, Yaita, Tochigi 3291571, Japan.
EM saict@maple.ocn.ne.jp; heiner.niemann@fli.bund.de; kazu@kmu.edu.tw
RI Nakamura, Yukio/A-5263-2016
FU National Science Council [MOST-104-2320-B-037-033-My2,
   MOST-103-2314-B-037-002]; National Health Research Institutes
   [NHRI-Ex102-10109BI, NHRI-EX104-10416SI]; Kaohsiung Medical University
   [KMY-DT-104001, KMU-TP103G00, KMU-TP103G03, KMU-TP103G04, KMU-TP103G05,
   KMU-TP103A04]
FX The authors thank CC Ku for technical support and editing the
   manuscript. This work was partially supported by grants of Taiwan;
   National Science Council, MOST-104-2320-B-037-033-My2;
   MOST-103-2314-B-037-002; National Health Research Institutes,
   NHRI-Ex102-10109BI; NHRI-EX104-10416SI; Kaohsiung Medical University,
   KMY-DT-104001; KMU-TP103G00, KMU-TP103G03, KMU-TP103G04, KMU-TP103G05,
   KMU-TP103A04.
CR Angenard G, 2011, REPROD TOXICOL, V31, P470, DOI 10.1016/j.reprotox.2010.12.058
   Angenard G, 2010, ENVIRON HEALTH PERSP, V118, P331, DOI 10.1289/ehp.0900975
   Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190
   Aponte PM, 2008, REPRODUCTION, V136, P543, DOI 10.1530/REP-07-0419
   Awal MA, 2004, INT J TOXICOL, V23, P349, DOI 10.1080/10915810490901985
   Bao JQ, 2012, J BIOL CHEM, V287, P21686, DOI 10.1074/jbc.M111.328054
   Behboodi E, 2011, MOL REPROD DEV, V78, P202, DOI 10.1002/mrd.21290
   Bjork JK, 2010, DEVELOPMENT, V137, P3177, DOI 10.1242/dev.050955
   Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   BRACKETT BG, 1971, P NATL ACAD SCI USA, V68, P353, DOI 10.1073/pnas.68.2.353
   Brinster RL, 2007, SCIENCE, V316, P404, DOI 10.1126/science.1137741
   Brinster RL, 2002, SCIENCE, V296, P2174, DOI 10.1126/science.1071607
   BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298
   BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11303, DOI 10.1073/pnas.91.24.11303
   BRINSTER RL, 1989, CELL, V59, P239, DOI 10.1016/0092-8674(89)90282-1
   Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950
   Bucay N, 2009, STEM CELLS, V27, P68, DOI 10.1634/stemcells.2007-1018
   Buchold GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015317
   Casals-Casas C, 2011, ANNU REV PHYSIOL, V73, P135, DOI 10.1146/annurev-physiol-012110-142200
   Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403
   Clark AT, 2004, HUM MOL GENET, V13, P727, DOI 10.1093/hmg/ddh088
   Conrad S, 2008, NATURE, V456, P344, DOI 10.1038/nature07404
   Dai LS, 2011, J BIOL CHEM, V286, P44306, DOI 10.1074/jbc.M111.282756
   Duggal G, 2015, MOL HUM REPROD, V21, P410, DOI 10.1093/molehr/gav004
   Durruthy JD, 2014, HUM MOL GENET, V23, P3071, DOI 10.1093/hmg/ddu012
   Easley CA, 2015, STEM CELL RES, V14, P347, DOI 10.1016/j.scr.2015.03.002
   Easley CA, 2013, REPROD BIOMED ONLINE, V27, P75, DOI 10.1016/j.rbmo.2013.03.003
   Easley CA, 2012, CELL REP, V2, P440, DOI 10.1016/j.celrep.2012.07.015
   Eguizabal C, 2011, STEM CELLS, V29, P1186, DOI 10.1002/stem.672
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025
   FUJIWARA Y, 1994, P NATL ACAD SCI USA, V91, P12258, DOI 10.1073/pnas.91.25.12258
   Fukunaga N, 2010, CELL REPROGRAM, V12, P369, DOI [10.1089/cell.2009.0097, 10.1089/cell.2009.0086]
   Geens M, 2008, HUM REPROD UPDATE, V14, P121, DOI 10.1093/humupd/dmm047
   Geijsen N, 2004, NATURE, V427, P148, DOI 10.1038/nature02247
   Griswold MD, 2013, STEM CELLS, V31, P8, DOI 10.1002/stem.1253
   Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697
   Hajkova P, 2008, NATURE, V452, P877, DOI 10.1038/nature06714
   Hayashi K, 2012, SCIENCE, V338, P971, DOI 10.1126/science.1226889
   Hayashi K, 2011, CELL, V146, P519, DOI 10.1016/j.cell.2011.06.052
   Hayashi Y, 2012, FERTIL STERIL, V97, P1250, DOI 10.1016/j.fertnstert.2012.04.037
   Hermann BP, 2007, STEM CELLS, V25, P2330, DOI 10.1634/stemcells.2007-0143
   Hermann BP, 2012, CELL STEM CELL, V11, P715, DOI 10.1016/j.stem.2012.07.017
   Hermann BP, 2011, HUM REPROD, V26, P3222, DOI 10.1093/humrep/der343
   Hermann BP, 2010, REPRODUCTION, V139, P479, DOI 10.1530/REP-09-0255
   Herrid M, 2009, BIOL REPROD, V81, P898, DOI 10.1095/biolreprod.109.078279
   Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018
   Honaramooz A, 2003, BIOL REPROD, V69, P1260, DOI 10.1095/biolreprod.103.018788
   Hubner K, 2003, SCIENCE, V300, P1251, DOI 10.1126/science.1083452
   Ito T, 2010, BIOCHEM BIOPH RES CO, V398, P735, DOI 10.1016/j.bbrc.2010.07.012
   Izadyar F, 2003, REPRODUCTION, V126, P765, DOI 10.1530/reprod/126.6.765
   Jurewicz J, 2011, INT J OCCUP MED ENV, V24, P115, DOI 10.2478/s13382-011-0022-2
   Kanatsu-Shinohara M, 2004, CELL, V119, P1001, DOI 10.1016/j.cell.2004.11.011
   Kee K, 2009, NATURE, V462, P222, DOI 10.1038/nature08562
   Kim Y, 2008, REPRODUCTION, V136, P823, DOI 10.1530/REP-08-0226
   Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536
   Kossack N, 2009, STEM CELLS, V27, P138, DOI 10.1634/stemcells.2008-0439
   Kubota H, 2006, NAT CLIN PRACT ENDOC, V2, P99, DOI 10.1038/ncpendmet0098
   La Salle S, 2006, DEV BIOL, V296, P71, DOI 10.1016/j.ydbio.2006.04.436
   Lambrot R, 2009, ENVIRON HEALTH PERSP, V117, P32, DOI 10.1289/ehp.11146
   Lavitrano M, 1999, TRANSPLANT P, V31, P972, DOI 10.1016/S0041-1345(98)01863-6
   LAVITRANO M, 1989, CELL, V57, P717, DOI 10.1016/0092-8674(89)90787-3
   Li M, 2013, CELL PROLIFERAT, V46, P223, DOI 10.1111/cpr.12013
   Liang XX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033861
   Lin YC, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt447
   Lin YC, 2014, INT J MOL SCI, V15, P5011, DOI 10.3390/ijms15035011
   Liu T, 2013, STEM CELLS DEV, V22, P1839, DOI 10.1089/scd.2012.0653
   Liu Y, 2015, REPORTS, V5, P8084, DOI [10.1038/srep08084, DOI 10.1038/SREP08084]
   Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   Lyche JL, 2009, J TOXICOL ENV HEAL B, V12, P225, DOI 10.1080/10937400903094091
   Maatouk DM, 2008, BIOL REPROD, V79, P696, DOI 10.1095/biolreprod.108.067827
   Marcon E, 2008, CHROMOSOME RES, V16, P243, DOI 10.1007/s10577-007-1190-6
   Marques CJ, 2011, EPIGENETICS-US, V6, P1354, DOI 10.4161/epi.6.11.17993
   Marques-Mari AI, 2009, HUM REPROD UPDATE, V15, P379, DOI 10.1093/humupd/dmp001
   Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656
   McIver SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035553
   Medrano JV, 2012, STEM CELLS, V30, P441, DOI 10.1002/stem.1012
   Mikkola M, 2006, REPROD DOMEST ANIM, V41, P124, DOI 10.1111/j.1439-0531.2006.00651.x
   Mizrak SC, 2010, HUM REPROD, V25, P158, DOI 10.1093/humrep/dep354
   Muczynski V, 2012, TOXICOL APPL PHARM, V261, P97, DOI 10.1016/j.taap.2012.03.016
   Nagano MC, 2007, BIOL REPROD, V76, P546, DOI 10.1095/biolreprod.106.058271
   Nakaki F, 2013, NATURE, V501, P222, DOI 10.1038/nature12417
   Nayernia K, 2006, DEV CELL, V11, P125, DOI 10.1016/j.devcel.2006.05.010
   Nichols J, 2009, CELL STEM CELL, V4, P487, DOI 10.1016/j.stem.2009.05.015
   Oakes CC, 2007, DEV BIOL, V307, P368, DOI 10.1016/j.ydbio.2007.05.002
   Oatley JM, 2006, P NATL ACAD SCI USA, V103, P9524, DOI 10.1073/pnas.0603332103
   Oatley JM, 2004, BIOL REPROD, V71, P942, DOI 10.1095/biolreprod.104.028894
   Oatley JA, 2008, ANNU REV CELL DEV BI, V24, P263, DOI 10.1146/annurev.cellbio.24.110707.175355
   Oatley JM, 2006, METHOD ENZYMOL, V419, P259, DOI 10.1016/S0076-6879(06)19011-4
   Ogawa T, 2000, NAT MED, V6, P29, DOI 10.1038/71496
   Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6
   Panula S, 2011, HUM MOL GENET, V20, P752, DOI 10.1093/hmg/ddq520
   Papaioannou MD, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M900587-MCP200
   Papaioannou MD, 2009, DEV BIOL, V326, P250, DOI 10.1016/j.ydbio.2008.11.011
   Petersen B, 2015, TRANSGENIC RES, V24, P381, DOI 10.1007/s11248-015-9862-z
   Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829
   Rajpert-De Meyts E, 2006, HUM REPROD UPDATE, V12, P303, DOI 10.1093/humupd/dmk006
   Ramathal C, 2014, CELL REP, V7, P1284, DOI 10.1016/j.celrep.2014.03.067
   Romero Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025241
   Saito S, 2003, BIOCHEM BIOPH RES CO, V309, P104, DOI 10.1016/S0006-291X(03)01536-5
   Saito S, 2012, CURR MOL MED, V12, P1340, DOI 10.2174/156652412803833625
   SAITO S, 1992, ROUX ARCH DEV BIOL, V201, P134, DOI 10.1007/BF00188711
   Saito S, 2002, FEBS LETT, V531, P389, DOI 10.1016/S0014-5793(02)03550-0
   Saito Shigeo, 2004, Hum Cell, V17, P107
   Santos F, 2005, DEV BIOL, V280, P225, DOI 10.1016/j.ydbio.2005.01.025
   Sato T, 2012, P NATL ACAD SCI USA, V109, P16934, DOI 10.1073/pnas.1211845109
   Schlatt S, 2009, PEDIATR BLOOD CANCER, V53, P274, DOI 10.1002/pbc.22002
   Schlegel P N, 2009, Minerva Ginecol, V61, P261
   Seisenberger S, 2012, MOL CELL, V48, P849, DOI 10.1016/j.molcel.2012.11.001
   Seki Y, 2005, DEV BIOL, V278, P440, DOI 10.1016/j.ydbio.2004.11.025
   Shirakawa T, 2013, DEVELOPMENT, V140, P3565, DOI 10.1242/dev.094045
   SJOBERG P, 1986, ENVIRON HEALTH PERSP, V65, P237, DOI 10.2307/3430188
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Talluri TR, 2015, CELL REPROGRAM, V17, P131, DOI 10.1089/cell.2014.0080
   Teramura T, 2007, CLONING STEM CELLS, V9, P144, DOI 10.1089/clo.2006.0070
   Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972
   Tiido T, 2005, HUM REPROD, V20, P1903, DOI 10.1093/humrep/deh855
   Tilgner K, 2008, STEM CELLS, V26, P3075, DOI 10.1634/stemcells.2008-0289
   Toyooka Y, 2003, P NATL ACAD SCI USA, V100, P11457, DOI 10.1073/pnas.1932826100
   Valli H, 2014, FERTIL STERIL, V101, P3, DOI 10.1016/j.fertnstert.2013.10.052
   van den Berg DLC, 2010, CELL STEM CELL, V6, P369, DOI 10.1016/j.stem.2010.02.014
   Vogt M, 2011, VIRCHOWS ARCH, V458, P313, DOI 10.1007/s00428-010-1030-5
   Wang SW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.420
   West FD, 2008, STEM CELLS, V26, P2768, DOI 10.1634/stemcells.2008-0124
   White YAR, 2012, NAT MED, V18, P413, DOI 10.1038/nm.2669
   Wu JW, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-64
   Xie LC, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-014-0080-6
   Yamaguchi S, 2012, NATURE, V492, P443, DOI 10.1038/nature11709
   Yan NH, 2007, REPRODUCTION, V134, P73, DOI 10.1530/RFP-07-0056
   Yang S, 2014, STEM CELL REP, V3, P663, DOI 10.1016/j.stemcr.2014.08.004
   Yu M, 2014, J CELL BIOCHEM, V115, P232, DOI 10.1002/jcb.24655
   Yu ZR, 2005, BIOL REPROD, V73, P427, DOI 10.1095/biolreprod.105.040998
   Zhang H, 2012, P NATL ACAD SCI USA, V109, P12580, DOI 10.1073/pnas.1206600109
   Zimmermann C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107023
   Zou K, 2009, NAT CELL BIOL, V11, P631, DOI 10.1038/ncb1869
NR 137
TC 1
Z9 1
U1 3
U2 40
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD DEC
PY 2015
VL 72
IS 23
BP 4545
EP 4560
DI 10.1007/s00018-015-2020-1
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CV0PY
UT WOS:000363954200006
PM 26439925
OA Other Gold, Green Published
DA 2018-12-27
ER

PT J
AU Calvo-Guirado, JL
   Mate-Sanchez, JE
   Delgado-Ruiz, RA
   Romanos, GE
   De Aza-Moya, P
   Velazquez, P
AF Calvo-Guirado, Jose Luis
   Mate-Sanchez, Jose E.
   Delgado-Ruiz, Rafael A.
   Romanos, Georgios E.
   De Aza-Moya, Piedad
   Velazquez, Pablo
TI RETRACTED: Bone neo-formation and mineral degradation of 4Bone.(R) Part
   II: histological and histomorphometric analysis in critical size defects
   in rabbits (Retracted article. See vol. 29, pg. 813, 2018)
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article; Retracted Publication
DE HA/beta TCP; histological analysis; histomorphometric analysis;
   resorption; synthetic biomaterial
ID CALCIUM-PHOSPHATE BIOCERAMICS; AUGMENTATION TECHNIQUES; TRICALCIUM
   PHOSPHATE; ELECTRON-MICROSCOPY; SINUS AUGMENTATION; BIOMATERIALS;
   HYDROXYAPATITE; PLACEMENT; PARTICLES; CERAMICS
AB ObjectiveTo carry out the histological and histomorphometric plus radiological analysis of biphasic ceramic.
   Materials and methodIn this study, porous HA/TCP (4Bone (R)) ceramic material was tested for the bone repairing capacity and osteoinductive potential in a New Zealand rabbit model. The ratio of the ceramics components HA/TCP was 60/40 (in wt%).
   ResultsThe 4Bone (R) showed significantly more bone formation in the pores and in the periphery of the graft than the control group. Histomorphometric analysis revealed that the ceramic material (66.43%0.29) produced higher values of bone-to-implant contact (BIC) percentages (higher quality, closer contact); moreover, defect closure was significative higher in relation with control group (64.15%+/- 3.52).
   Conclusions4Bone (R) is a biocompatible, partially resorbable and osteoconductive grafting material. Biphasic graft material of HA/TCP with a porosity of 95% without loading favors new bone formation.
C1 [Calvo-Guirado, Jose Luis; Mate-Sanchez, Jose E.] Univ Murcia, Fac Med & Dent, Murcia 30007, Spain.
   [Delgado-Ruiz, Rafael A.; Romanos, Georgios E.] SUNY Stony Brook, Sch Dent Med, Stony Brook, NY 11794 USA.
   [De Aza-Moya, Piedad; Velazquez, Pablo] Miguel Hernandez Univ, Bioengn Inst, Elche, Spain.
RP Mate-Sanchez, JE (reprint author), Univ Murcia, Fac Med & Dent, Hosp Morales Meseguer, 2 Planta Clin Odontol,Calle Marques Velez S-N, Murcia 30007, Spain.
EM jmsodont@hotmail.com
RI Mate Sanchez de Va, Jose Eduardo/R-9750-2018; De Aza,
   Piedad/A-7621-2015; Velasquez, Pablo/O-5857-2015
OI Mate Sanchez de Va, Jose Eduardo/0000-0002-4216-421X; De Aza,
   Piedad/0000-0001-9316-4407; Velasquez, Pablo/0000-0002-5142-4992; calvo
   guirado, jose luis/0000-0002-4067-2253
CR Aghaloo TL, 2007, INT J ORAL MAX IMPL, V22, P49
   Araujo MG, 2010, CLIN ORAL IMPLAN RES, V21, P55, DOI 10.1111/j.1600-0501.2009.01854.x
   Browaeys H, 2007, CLIN IMPLANT DENT R, V9, P166, DOI 10.1111/j.1708-8208.2007.00050
   Calvo-Guirado JL, 2012, CLIN ORAL IMPLAN RES, V23, P667, DOI 10.1111/j.1600-0501.2011.02193.x
   Chopra PM, 2009, J BIOMED MATER RES B, V88B, P611, DOI 10.1002/jbm.b.31232
   Daculsi G, 2003, J MATER SCI-MATER M, V14, P195, DOI 10.1023/A:1022842404495
   Dorozhkin SV, 2010, BIOMATERIALS, V31, P1465, DOI 10.1016/j.biomaterials.2009.11.050
   Dorozhkin SV, 2009, J MATER SCI, V44, P2343, DOI 10.1007/s10853-008-3124-x
   Ebrahimi M, 2012, J BIOMED MATER RES A, V100A, P2260, DOI 10.1002/jbm.a.34160
   EGGLI PS, 1988, CLIN ORTHOP RELAT R, P127
   Fan HS, 2007, J NANOSCI NANOTECHNO, V7, P808, DOI 10.1166/jnn.2007.501
   Fischer H, 2002, DENT MATER, V18, P12, DOI 10.1016/S0109-5641(01)00005-7
   Gauthier O, 1999, J MATER SCI-MATER M, V10, P199, DOI 10.1023/A:1008949910440
   JASTY M, 1989, SCANNING MICROSCOPY, V3, P1051
   Jensen S S, 1996, Int J Oral Maxillofac Implants, V11, P55
   Legeros RZ, 2003, J MATER SCI-MATER M, V14, P201, DOI 10.1023/A:1022872421333
   de Val JEMS, 2015, CLIN ORAL IMPLAN RES, V26, P1165, DOI 10.1111/clr.12420
   Mate-Sanchez de Val Jose E, 2012, J Biomed Mater Res A, V100, P3446, DOI 10.1002/jbm.a.34259
   de Val JEMS, 2014, J BIOMED MATER RES A, V102, P1037, DOI 10.1002/jbm.a.34785
   McAllister BS, 2007, J PERIODONTOL, V78, P377, DOI 10.1902/jop.2007.060048
   Ono D, 2011, CLIN ORAL IMPLAN RES, V22, P1366, DOI 10.1111/j.1600-0501.2010.02117.x
   Orsini G, 2005, J BIOMED MATER RES B, V74B, P448, DOI 10.1002/jbm.b.30196
   Ramirez-Fernandez MP, 2011, CLIN ORAL IMPLAN RES, V22, P767, DOI 10.1111/j.1600-0501.2010.02058.x
   Rivera-Munoz E, 2001, J MATER SCI-MATER M, V12, P305, DOI 10.1023/A:1011290919642
   Rohanizadeh R, 1998, J BIOMED MATER RES, V42, P530, DOI 10.1002/(SICI)1097-4636(19981215)42:4<530::AID-JBM8>3.0.CO;2-6
   Saldana L, 2009, ACTA BIOMATER, V5, P1294, DOI 10.1016/j.actbio.2008.11.022
   Sharifi D, 2012, ACTA CIR BRAS, V27, P256, DOI 10.1590/S0102-86502012000300009
   SKEDROS JG, 1993, J BIOMED MATER RES, V27, P47, DOI 10.1002/jbm.820270107
   Wierzchos J, 2008, MICRON, V39, P1363, DOI 10.1016/j.micron.2008.01.022
   Wiltfang J, 2002, J BIOMED MATER RES, V63, P115, DOI 10.1002/jbm.10084
   Zyman ZZ, 2008, J MATER SCI-MATER M, V19, P2819, DOI 10.1007/s10856-008-3402-9
NR 31
TC 3
Z9 4
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-7161
EI 1600-0501
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD DEC
PY 2015
VL 26
IS 12
BP 1402
EP 1406
DI 10.1111/clr.12465
PG 5
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
SC Dentistry, Oral Surgery & Medicine; Engineering
GA CV5MF
UT WOS:000364314100008
PM 25163802
DA 2018-12-27
ER

PT J
AU Kheirollahi, I
   Abdellahi, M
   Emamalizadeh, M
   Sharifi, H
AF Kheirollahi, Iman
   Abdellahi, Majid
   Emamalizadeh, Mehdi
   Sharifi, Hassan
TI RETRACTED: Preparation and characterization of multilayer mesoporous
   alumina nano membrane via sol-gel method using new precursors (Retracted
   article. See vol. 42, pg. 11517, 2016)
SO CERAMICS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE Membrane; Mesoporous; Coating; Alumina; Sol-Gel
ID NANOFILTRATION; BOEHMITE; PERVAPORATION; FILMS
AB In the present study, a mesoporous gamma-alumina layer was coated on a macroporous alpha-alumina support via sol gel method to produce a multilayer mesoporous alumina membrane with high performance. Different parameters like homogeneity of colloidal solution, additive, working temperature, roughness of the membrane surface, membrane thickness and porosity of the membrane were analyzed. Two types of new different solvents and additives were considered and compared to have a perfect colloidal sol. A crack-free gamma-alumina membrane was obtained by adding Poly Vinyl Alcohol to the alumina solution in an optimum conditions. In order to investigate the thermal stability of the membrane, it was dried and heated up to 600 degrees C. The alumina sols showed particle size distributions in the range of 20-55 nm which was measured by a DLS zeta sizer. The roughness of the sub-layers was measured using a Roughness Checker and density and porosity were measured based on Archimedes principle. X-ray diffraction technique (XRD), atomic force microscopy (AFM) and scanning electron microscopy (SEM) were used to characterize the membrane layer. The thickness of the produced mesoporous membrane was about 4 gm with 16 nm of surface roughness and 5 am pore size. (C) 2015 Elsevier Ltd and Techna Group S.r.l. All rights reserved.
C1 [Kheirollahi, Iman] Islamic Azad Univ, Najafabad Branch, Young Researchers & Elite Club, Najafabad, Isfahan, Iran.
   [Abdellahi, Majid] Islamic Azad Univ, Najafabad Branch, Fac Mat Engn, Adv Mat Res Ctr, Najafabad, Isfahan, Iran.
   [Emamalizadeh, Mehdi] Univ Tabriz, Dept Chem, Tabriz, Iran.
   [Sharifi, Hassan] Islamic Azad Univ, Majlesi Branch, Dept Mat Sci & Engn, Esfahan, Iran.
RP Abdellahi, M (reprint author), Islamic Azad Univ, Najafabad Branch, Fac Mat Engn, Adv Mat Res Ctr, Najafabad, Isfahan, Iran.
EM Abdellahi@Pmt.iaun.ac.ir
CR Bouwmeester H. J. M., 1996, FUNDAMENTALS INORGAN, V4, P435
   Farhang Y., 2012, CERAM INT, V39, P2511
   Fernandez T, 2007, J SOL-GEL SCI TECHN, V41, P163, DOI 10.1007/s10971-006-0522-x
   Gestel T.V., 2008, SOLID STATE IONICS, V179, P1360
   Hsieh HP, 1996, INORGANIC MEMBRANES
   Hung KM, 2002, MATER MANUF PROCESS, V17, P323, DOI 10.1081/AMP-120005379
   Ismail AA, 2008, APPL CATAL A-GEN, V346, P200, DOI 10.1016/j.apcata.2008.05.031
   Khatib SJ, 2013, SEP PURIF TECHNOL, V111, P20, DOI 10.1016/j.seppur.2013.03.032
   Kim SM, 2007, MATER CHEM PHYS, V104, P56, DOI 10.1016/j.matchemphys.2007.02.044
   Kwon CH, 2003, CERAM INT, V29, P851, DOI 10.1016/S0272-8842(03)00019-1
   LARBOT A, 1994, J MEMBRANE SCI, V97, P167, DOI 10.1016/0376-7388(94)00159-V
   Li L., 2015, CHIN J CHEM IN PRESS
   Park JH, 2004, MAT SCI ENG A-STRUCT, V375, P1263, DOI 10.1016/j.msea.2003.10.155
   Prabhakaran K, 1999, J EUR CERAM SOC, V19, P2875, DOI 10.1016/S0955-2219(99)00075-8
   RADONJIC L, 1993, MATER CHEM PHYS, V33, P298, DOI 10.1016/0254-0584(93)90078-Z
   Schafer R, 2001, SEP PURIF TECHNOL, V25, P3, DOI 10.1016/S1383-5866(01)00085-5
   Sekulic-Kuzmanovic J., 2004, THESIS U TWENTE
   Stylianou SK, 2015, J CHEM-NY, DOI 10.1155/2015/214927
   Vacassy R, 1997, J MEMBRANE SCI, V132, P109, DOI 10.1016/S0376-7388(97)00051-3
   Van Gestel T, 2002, J MEMBRANE SCI, V207, P73, DOI 10.1016/S0376-7388(02)00053-4
   Van Gestel T, 2008, J MEMBRANE SCI, V318, P413, DOI 10.1016/j.memsci.2008.03.003
   Wee SL, 2008, SEP PURIF TECHNOL, V63, P500, DOI 10.1016/j.seppur.2008.07.010
   Williams M., 2008, APPL SURF SCI, V10, P3211
   Zhai JW, 1999, J NON-CRYST SOLIDS, V260, P160, DOI 10.1016/S0022-3093(99)00569-4
NR 24
TC 9
Z9 9
U1 2
U2 66
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0272-8842
EI 1873-3956
J9 CERAM INT
JI Ceram. Int.
PD DEC
PY 2015
VL 41
IS 10
BP 15083
EP 15088
DI 10.1016/j.ceramint.2015.08.074
PN B
PG 6
WC Materials Science, Ceramics
SC Materials Science
GA CT6JS
UT WOS:000362919900150
DA 2018-12-27
ER

PT J
AU Dai, CX
   Lv, SZ
   Shi, RR
   Ding, J
   Zhong, X
   Song, HS
   Ma, XC
   Fan, JZ
   Sun, BW
   Wang, RZ
   Ma, WB
AF Dai, Congxin
   Lv, Shunzeng
   Shi, Ranran
   Ding, Jing
   Zhong, Xiao
   Song, Huishu
   Ma, Xiaochen
   Fan, Jianzhen
   Sun, Bowen
   Wang, Renzhi
   Ma, Wenbin
TI RETRACTED: Nuclear Protein C23 on the Cell Surface Plays an Important
   Role in Activation of CXCR4 Signaling in Glioblastoma (Retracted
   article. See vol. 54, pg. 7549, 2017)
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article; Retracted Publication
DE C23; CXCR4 signaling; ERK; PI3K/AKT; Glioblastoma
ID GASTRIC-CANCER; CYCLIN D1; NUCLEOLIN; EXPRESSION; PROLIFERATION;
   GLIOMAS; INHIBITION; PATHWAYS; BINDING; PI3K
AB The chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 (SDF-1) plays an important role in tumor progression and are associated with angiogenesis. Meanwhile, the implications of C23 in multiple signaling pathways have been also investigated. However, the effects of C23 on CXCR4 pathway in glioblastoma are not fully characterized. In the present study, C23 and CXCR4 of U87 cell line were inhibited by anti-C23 and anti-CXCR4 antibodies, respectively; and then C23 and CXCR4 siRNAs were used to knock down endogenous C23 and CXCR4, respectively. In addition, MTT assay was also introduced. Our data showed that either anti-C23 or anti-CXCR4 antibodies efficaciously repressed the phosphorylation levels of ERK (p < 0.000) and AKT (p < 0.000) compared with SDF-1 alone and control. As expected, either C23 or CXCR4 siRNAs indeed resulted in C23 and CXCR4 knockdown and further suppressed the expression of p-ERK and p-AKT. Most importantly, immunoprecipitation revealed C23 interacted with CXCR4 once U87 was exposed to SDF-1 treatment. In addition, MTT assay identified that C23 or CXCR4 siRNAs could obviously decreased cell proliferation capacity (p = 0.002). In conclusion, our results suggest that C23 plays a crucial role in activation of SDF-1-induced ERK and PI3K/AKT pathways via interacting with CXCR4. Furthermore, C23 could be recommended as an important element in glioblastoma development and a new target for glioblastoma treatment.
C1 [Dai, Congxin; Lv, Shunzeng; Sun, Bowen; Wang, Renzhi; Ma, Wenbin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing 100730, Peoples R China.
   [Dai, Congxin; Lv, Shunzeng; Sun, Bowen; Wang, Renzhi; Ma, Wenbin] Peking Union Med Coll, Beijing 100730, Peoples R China.
   [Lv, Shunzeng; Shi, Ranran; Song, Huishu; Ma, Xiaochen; Fan, Jianzhen] Shandong Univ, Sch Med, Jinan, Shandong, Peoples R China.
   [Zhong, Xiao] Southern Med Univ, Xiaolan Peoples Hosp, Dept Paediat, Zhongshan, Guangdong, Peoples R China.
RP Ma, WB (reprint author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing 100730, Peoples R China.
EM mwbpumch@163.com
FU Shandong University of Science and Technology Innovation Fund [2013349]
FX This study was supported by Shandong University of Science and
   Technology Innovation Fund (2013349). We greatly thank Cheng Chi and
   Guoliang Li of Sandy & Yang Lab for the valuable suggestions and
   writing.
CR Agnihotri S, 2013, ARCH IMMUNOL THER EX, V61, P25, DOI 10.1007/s00005-012-0203-0
   Cherry AE, 2014, NEUROSCIENCE, V278, P222, DOI 10.1016/j.neuroscience.2014.08.015
   Dhanasekaran Danny N, 2006, Sci STKE, V2006, ppe31, DOI 10.1126/stke.3472006pe31
   Galzio R, 2012, J CELL BIOCHEM, V113, P571, DOI 10.1002/jcb.23381
   Gatti M, 2013, TOXICOLOGY, V314, P209, DOI 10.1016/j.tox.2013.10.003
   Gonzalez V, 2009, J BIOL CHEM, V284, P23622, DOI 10.1074/jbc.M109.018028
   Heckmann D, 2013, TRANSL ONCOL, V6, P124, DOI 10.1593/tlo.12268
   Hovanessian AG, 2006, CELL RES, V16, P174, DOI 10.1038/sj.cr.7310024
   Kirkpatrick JP, 2014, SEMIN RADIAT ONCOL, V24, P289, DOI 10.1016/j.semradonc.2014.06.006
   Lin CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104746
   Lv S, 2014, J MOL NEUROSCI
   Qiu CL, 2014, CELL PHYSIOL BIOCHEM, V33, P784, DOI 10.1159/000358652
   Qiu WS, 2013, APMIS, V121, P919, DOI 10.1111/apm.12131
   Said EA, 2005, FEBS J, V272, P4646, DOI 10.1111/j.1742-4658.2005.04870.x
   Schokoroy S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075269
   Sobolik T, 2014, MOL BIOL CELL, V25, P566, DOI 10.1091/mbc.E13-07-0360
   Tsubaki M, 2012, TOXICOL APPL PHARM, V259, P402, DOI 10.1016/j.taap.2012.01.024
   Turck N, 2006, J CELL PHYSIOL, V206, P545, DOI 10.1002/jcp.20501
   Wang HY, 2014, INT J MOL SCI, V15, P3507, DOI 10.3390/ijms15033507
   Wang Y, 2011, CELL BIOL INT, V35, P677, DOI 10.1042/CBI20100625
   Watanabe T, 2010, BIOL PHARM BULL, V33, P796, DOI 10.1248/bpb.33.796
   Weathers Shiao-Pei, 2014, F1000Prime Rep, V6, P46, DOI 10.12703/P6-46
   Wilson Taylor A, 2014, Surg Neurol Int, V5, P64, DOI 10.4103/2152-7806.132138
   Wua DM, 2014, FEBS LETT, V588, P1921, DOI 10.1016/j.febslet.2014.03.047
   Wurth R, 2014, FRONT CELL NEUROSCI, V8, DOI [10.3389/fncel.2014.00144, 10.3389/fnce1.2014.00144]
   Xu ZQ, 2012, J NEURO-ONCOL, V108, P59, DOI 10.1007/s11060-012-0827-2
NR 26
TC 11
Z9 11
U1 4
U2 16
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD DEC
PY 2015
VL 52
IS 3
BP 1521
EP 1526
DI 10.1007/s12035-014-8955-7
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA CS2LW
UT WOS:000361903400036
PM 25367885
DA 2018-12-27
ER

PT J
AU Attaullah
   Shah, T
AF Attaullah
   Shah, Tariq
TI RETRACTED: An algorithm based on 1D chaotic system and substitution box
   (Retracted article. See vol. 127, pg. 288, 2016)
SO SIGNAL PROCESSING
LA English
DT Article; Retracted Publication
DE Chaotic; Substitution box; Encryption
ID IMAGE ENCRYPTION SCHEME; CRYPTANALYSIS; TRANSFORM; MAPS
AB Chaos-based encryption showed up as of late in the mid 1990s as a unique use of nonlinear dynamics in the chaotic administration. This paper introduces a digital image encryption scheme based on the mixture of chaotic system along with S-box substitution, utilizing a combination of two subsisting one-dimension (1D) chaotic maps (seed maps). Simulations and performance evaluations show that the system is able to engender many 1D chaotic maps with more immensely colossal chaotic range sand better chaotic behaviours compared with their seed maps and S-box substitution increases the diffusion in the process of encryption. To investigate its applications in multimedia security, a novel image encryption algorithm is proposed. Utilizing a same set of security keys, this algorithm is able to engender an exceptionally different encrypted image each time when it is applied to the same pristine image. Experiments and security analysis demonstrate the algorithm's excellent performance in image encryption and several attacks. (C) 2015 Published by Elsevier B.V.
C1 [Attaullah; Shah, Tariq] Quaid I Azam Univ, Dept Math, Islamabad, Pakistan.
RP Attaullah (reprint author), Quaid I Azam Univ, Dept Math, Islamabad, Pakistan.
EM attaqau@gmail.com
CR Arroyo D, 2013, SIGNAL PROCESS, V93, P1358, DOI 10.1016/j.sigpro.2012.11.019
   Behnia S, 2008, CHAOS SOLITON FRACT, V35, P408, DOI 10.1016/j.chaos.2006.05.011
   Bhatnagar G, 2013, INFORM SCIENCES, V223, P297, DOI 10.1016/j.ins.2012.09.053
   Chen GR, 2004, CHAOS SOLITON FRACT, V21, P749, DOI 10.1016/j.chaos.2003.12.022
   Chen RJ, 2010, SIGNAL PROCESS-IMAGE, V25, P413, DOI 10.1016/j.image.2010.03.002
   Chen TH, 2012, INFORM SCIENCES, V189, P255, DOI 10.1016/j.ins.2011.11.026
   Chen TH, 2010, INFORM SCIENCES, V180, P1690, DOI 10.1016/j.ins.2009.12.021
   El-Latif A. A. A., 2011, 2011 Seventh International Conference on Intelligent Information Hiding and Multimedia Signal Processing, P369, DOI 10.1109/IIHMSP.2011.67
   Hussain I, 2013, NEURAL COMPUT APPL, V22, P1085, DOI 10.1007/s00521-012-0870-0
   Li CQ, 2009, IMAGE VISION COMPUT, V27, P1035, DOI 10.1016/j.imavis.2008.09.004
   Li L, 2012, SIGNAL PROCESS, V92, P1069, DOI 10.1016/j.sigpro.2011.10.020
   Liao XF, 2010, SIGNAL PROCESS, V90, P2714, DOI 10.1016/j.sigpro.2010.03.022
   Rhouma R, 2008, PHYS LETT A, V372, P5973, DOI 10.1016/j.physleta.2008.07.057
   Seyedzadeh SM, 2012, SIGNAL PROCESS, V92, P1202, DOI 10.1016/j.sigpro.2011.11.004
   SOBHY MI, 2001, ACOUST SPEECH SIG PR, P1001
   Wu Y., 2012, J ELECT IMAGING, V21
   Zhou YC, 2014, SIGNAL PROCESS, V97, P172, DOI 10.1016/j.sigpro.2013.10.034
   Zhou YC, 2013, IEEE T CYBERNETICS, V43, P515, DOI 10.1109/TSMCB.2012.2210706
   Zhou YC, 2012, OPT COMMUN, V285, P594, DOI 10.1016/j.optcom.2011.11.044
NR 19
TC 2
Z9 2
U1 2
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-1684
EI 1879-2677
J9 SIGNAL PROCESS
JI Signal Process.
PD DEC
PY 2015
VL 117
BP 219
EP 229
DI 10.1016/j.sigpro.2015.05.013
PG 11
WC Engineering, Electrical & Electronic
SC Engineering
GA CO4ZF
UT WOS:000359168700021
DA 2018-12-27
ER

PT J
AU Chen, FQ
   Zhang, N
   Ma, XY
   Huang, T
   Shao, Y
   Wu, C
   Wang, QY
AF Chen, Fenqin
   Zhang, Ning
   Ma, Xiaoyu
   Huang, Ting
   Shao, Ying
   Wu, Can
   Wang, Qiuyue
TI RETRACTED: Naringin Alleviates Diabetic Kidney Disease through
   Inhibiting Oxidative Stress and Inflammatory Reaction (Retracted
   article. See vol. 13, artn no. e0192465, 2018)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID NF-KAPPA-B; RENAL-DISEASE; NEPHROPATHY; RATS; HYPERGLYCEMIA; NRF2;
   COMPLICATIONS; ACCUMULATION; PROTEINURIA; SUPPRESSION
AB Naringin, a flavanone glycoside extracted from Citrus grandis Osbeck, has a wide range of pharmacological effects. In the present study we aimed at demonstrating the protective effect of naringin against diabetic kidney disease (DKD) and elucidating its possible molecular mechanism underlying. The beneficial effect of naringin was assessed in rats with streptozotocin (STZ)-induced diabetes and high glucose-induced HBZY-1 cells. According to our results, first we found that naringin relieved kidney injury, improved renal function and inhibited collagen formation and renal interstitial fibrosis. Second, we confirmed that naringin restrained oxidative stress by activating Nrf2 antioxidant pathway. Moreover, the results suggested that naringin significantly resisted inflammatory reaction by inhibiting NF-kappa B signaling pathway. Taken together, our results demonstrate that naringin effectively alleviates DKD, which provide theoretical basis for naringin clinically used to treatment of DKD.
C1 [Chen, Fenqin; Ma, Xiaoyu; Huang, Ting] China Med Univ, Dept Geratol Cadres, Affiliated Hosp 1, Shenyang 110001, Peoples R China.
   [Zhang, Ning] China Med Univ, Dept Pathphysiol, Coll Basic Med Sci, Shenyang 110013, Peoples R China.
   [Shao, Ying; Wu, Can; Wang, Qiuyue] China Med Univ, Dept Endocrine & Metab Dis, Affiliated Hosp 1, Shenyang 110001, Peoples R China.
RP Wang, QY (reprint author), China Med Univ, Dept Endocrine & Metab Dis, Affiliated Hosp 1, Shenyang 110001, Peoples R China.
EM qiuyuewangqy@163.com
FU High-Level Talents Team Construction Project for High School of Liaoning
   Province [2014-187]
FX This study was supported by a grant from the High-Level Talents Team
   Construction Project for High School of Liaoning Province (No.:
   2014-187).
CR Bharti S, 2014, PLANTA MED, V80, P437, DOI 10.1055/s-0034-1368351
   Bhatti F, 2005, KIDNEY INT, V67, P1371, DOI 10.1111/j.1523-1755.2005.00214.x
   Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161
   Buckley BJ, 2008, FREE RADICAL BIO MED, V44, P692, DOI 10.1016/j.freeradbiomed.2007.10.055
   Calcutt NA, 2009, NAT REV DRUG DISCOV, V8, P417, DOI 10.1038/nrd2476
   Chen JF, 2014, BASIC CLIN PHARMACOL, V114, P293, DOI 10.1111/bcpt.12153
   Crandall JP, 2008, NAT CLIN PRACT ENDOC, V4, P382, DOI 10.1038/ncpendmet0843
   Elmarakby AA, 2012, CARDIOVASC THER, V30, P49, DOI 10.1111/j.1755-5922.2010.00218.x
   FABRE J, 1982, KIDNEY INT, V21, P730, DOI 10.1038/ki.1982.90
   Fang TZ, 2006, J PHARMACEUT BIOMED, V40, P454, DOI 10.1016/j.jpba.2005.07.031
   Guijarro C, 2001, KIDNEY INT, V59, P415, DOI 10.1046/j.1523-1755.2001.059002415.x
   Han JG, 2014, MOL CANCER THER, V13, P2422, DOI 10.1158/1535-7163.MCT-14-0171
   Jung Un Ju, 2014, Exp Neurobiol, V23, P124, DOI 10.5607/en.2014.23.2.124
   Kandhare AD, 2014, CHEM-BIOL INTERACT, V219, P101, DOI 10.1016/j.cbi.2014.05.012
   Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100
   Kanwar YS, 2008, EXP BIOL MED, V233, P4, DOI 10.3181/0705-MR-134
   Kashihara N, 2010, CURR MED CHEM, V17, P4256, DOI 10.2174/092986710793348581
   Kedziora-Kornatowska K, 2003, NEPHRON EXP NEPHROL, V95, pE134, DOI 10.1159/000074840
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   King GL, 2008, J PERIODONTOL, V79, P1527, DOI 10.1902/jop.2008.080246
   Kitada M, 2011, DIABETES, V60, P634, DOI 10.2337/db10-0386
   Kumar A, 2012, BIOCHIMIE, V94, P1158, DOI 10.1016/j.biochi.2012.01.023
   de Faria JBL, 2011, HYPERTENS RES, V34, P413, DOI 10.1038/hr.2010.263
   Luis-Rodriguez D, 2012, WORLD J DIABETES, V3, P7, DOI 10.4239/wjd.v3.i1.7
   Lyu JH, 2011, J ETHNOPHARMACOL, V137, P1442, DOI 10.1016/j.jep.2011.08.024
   Mahmoud AM, 2012, J DIABETES COMPLICAT, V26, P483, DOI 10.1016/j.jdiacomp.2012.06.001
   Matough Fatmah A, 2012, Sultan Qaboos Univ Med J, V12, P5
   Mullen W, 2006, BRIT J NUTR, V96, P107, DOI 10.1079/BJN20061809
   Rivero A, 2009, CLIN SCI, V116, P479, DOI 10.1042/CS20080394
   Sanchez-Nino MD, 2012, AM J PHYSIOL-RENAL, V302, pF647, DOI 10.1152/ajprenal.00090.2011
   Shen GX, 2005, ANTIOXID REDOX SIGN, V7, P1648, DOI 10.1089/ars.2005.7.1648
   Shin EJ, 2013, FOOD CHEM, V141, P4115, DOI 10.1016/j.foodchem.2013.06.059
   Singh DK, 2011, NAT REV ENDOCRINOL, V7, P176, DOI 10.1038/nrendo.2010.212
   Taslipinar A, 2011, SCAND J CLIN LAB INV, V71, P606, DOI 10.3109/00365513.2011.598944
   Tesch GH, 2010, SEMIN NEPHROL, V30, P290, DOI 10.1016/j.semnephrol.2010.03.007
   Wu J, 2011, LAB INVEST, V91, P1459, DOI 10.1038/labinvest.2011.93
   Xulu S, 2012, J CARDIOVASC PHARM, V59, P133, DOI 10.1097/FJC.0b013e31823827a4
   Yi B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099633
   Zou W, 2012, ARZNEIMITTELFORSCH, V62, P181, DOI 10.1055/s-0031-1299746
NR 39
TC 16
Z9 17
U1 2
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 30
PY 2015
VL 10
IS 11
AR e0143868
DI 10.1371/journal.pone.0143868
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CX7NW
UT WOS:000365889800084
PM 26619044
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Tataroglu, O
   Zhao, XH
   Busza, A
   Ling, JL
   O'Neill, JS
   Emery, P
AF Tataroglu, Ozgur
   Zhao, Xiaohu
   Busza, Ania
   Ling, Jinli
   O'Neill, John S.
   Emery, Patrick
TI RETRACTED: Calcium and SOL Protease Mediate Temperature Resetting of
   Circadian Clocks (Retracted article. See vol. 171, pg. 256, 2017)
SO CELL
LA English
DT Article; Retracted Publication
ID DROSOPHILA-MELANOGASTER; PACEMAKER NEURONS; GENE-EXPRESSION;
   BODY-TEMPERATURE; LIGHT RESPONSE; PHASE-SHIFTS; ENTRAINMENT; RHYTHMS;
   CRYPTOCHROME; SYNCHRONIZATION
AB Circadian clocks integrate light and temperature input to remain synchronized with the day/night cycle. Although light input to the clock is well studied, the molecularmechanisms by which circadian clocks respond to temperature remain poorly understood. We found that temperature phase shifts Drosophila circadian clocks through degradation of the pacemaker protein TIM. This degradation is mechanistically distinct from photic CRY-dependent TIM degradation. Thermal TIM degradation is triggered by cytosolic calcium increase and CALMODULIN binding to TIM and ismediated by the atypical calpain protease SOL. This thermal input pathway and CRY-dependent light input thus converge on TIM, providing a molecular mechanism for the integration of circadian light and temperature inputs. Mammals use body temperature cycles to keep peripheral clocks synchronized with their brain pacemaker. Interestingly, downregulating the mammalian SOL homolog SOLH blocks thermal mPER2 degradation and phase shifts. Thus, we propose that circadian thermosensation in insects and mammals share common principles.
C1 [Tataroglu, Ozgur; Zhao, Xiaohu; Busza, Ania; Ling, Jinli; Emery, Patrick] Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA.
   [O'Neill, John S.] MRC Lab Mol Biol, Cambridge CB2 0QH, England.
RP Emery, P (reprint author), Univ Massachusetts, Sch Med, Dept Neurobiol, Worcester, MA 01605 USA.
EM patrick.emery@umassmed.edu
FU NIH [GM079182, GM066777]; Medical Research Council [MC_UP_1201/4];
   Wellcome Trust [093734/Z/10/Z]
FX We specially thank D. Weaver for discussions and help with mammalian
   experiments and antibodies and R. Stanewsky for sharing unpublished
   results. We thank D. Wentworth, D. Szydlik, and C. Yuan for technical
   assistance, Y. Zhang and S. Antolin for discussions, M. Nitabach for PV
   and GFP-Aequorin flies, M. Rosbash for LUC control flies, A. Seghal for
   anti-TIM antibody, R. Stanewsky for anti-PER antibody and BG-LUC flies,
   the Bloomington and VDRC Drosophila stock centers for fly stocks, and
   the UMass Medical School shRNA core for viruses expressing Solh shRNAs.
   This work was supported by NIH grants (GM079182 and GM066777) (to P.E.).
   J.S.O. is supported by the Medical Research Council (MC_UP_1201/4) and
   the Wellcome Trust (093734/Z/10/Z).
CR Allada R, 2003, EMBO J, V22, P3367, DOI 10.1093/emboj/cdg318
   Balsalobre A, 2000, CURR BIOL, V10, P1291, DOI 10.1016/S0960-9822(00)00758-2
   Baubet V, 2000, P NATL ACAD SCI USA, V97, P7260, DOI 10.1073/pnas.97.13.7260
   Boothroyd CE, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030054
   Brancaccio M, 2013, NEURON, V78, P714, DOI 10.1016/j.neuron.2013.03.011
   Brown SA, 2002, CURR BIOL, V12, P1574, DOI 10.1016/S0960-9822(02)01145-4
   BRUCE VG, 1956, P NATL ACAD SCI USA, V42, P676, DOI 10.1073/pnas.42.9.676
   BRUCE VG, 1960, COLD SPRING HARB SYM, V25, P29, DOI 10.1101/SQB.1960.025.01.005
   Buhr ED, 2010, SCIENCE, V330, P379, DOI 10.1126/science.1195262
   Busza A, 2004, SCIENCE, V304, P1503, DOI 10.1126/science.1096973
   Busza A, 2007, J NEUROSCI, V27, P10722, DOI 10.1523/JNEUROSCI.2479-07.2007
   Chen RM, 2009, MOL CELL, V36, P417, DOI 10.1016/j.molcel.2009.10.012
   Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6
   Currie J, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-49
   Davidson AJ, 2006, CURR BIOL, V16, pR914, DOI 10.1016/j.cub.2006.09.058
   Ding JM, 1998, NATURE, V394, P381
   Ding XZ, 1996, J INVEST MED, V44, P144
   Friedrich P, 2004, BIOESSAYS, V26, P1088, DOI 10.1002/bies.20106
   Gentile C, 2013, CURR BIOL, V23, P185, DOI 10.1016/j.cub.2012.12.023
   Glaser FT, 2005, CURR BIOL, V15, P1352, DOI 10.1016/j.cub.2005.06.056
   Goda T., 2014, P BIOL SCI, V281
   Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768
   Guo F, 2014, ELIFE, V3, DOI 10.7554/eLife.02780
   Harrisingh MC, 2007, J NEUROSCI, V27, P12489, DOI 10.1523/JNEUROSCI.3680-07.2007
   Helfrich-Forster C, 2001, NEURON, V30, P249, DOI 10.1016/S0896-6273(01)00277-X
   Kamei M, 2000, GENOMICS, V64, P82, DOI 10.1006/geno.1999.6098
   Kamei M, 1998, GENOMICS, V51, P197, DOI 10.1006/geno.1998.5395
   Kaushik R, 2007, PLOS BIOL, V5, P1257, DOI 10.1371/journal.pbio.0050146
   Knutsson A, 2003, OCCUP MED-OXFORD, V53, P103, DOI 10.1093/occmed/kqg048
   Ko HW, 2002, NATURE, V420, P673, DOI 10.1038/nature01272
   Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4
   Lamba P, 2014, CELL REP, V7, P601, DOI 10.1016/j.celrep.2014.03.044
   Lee E, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004545
   Lee Y, 2013, J NEUROSCI, V33, P6716, DOI 10.1523/JNEUROSCI.4237-12.2013
   Levine JD, 2002, SCIENCE, V298, P2010, DOI 10.1126/science.1076008
   Mazzoni EO, 2005, NEURON, V45, P293, DOI 10.1016/j.neuron.2004.12.038
   Melom JE, 2013, J NEUROSCI, V33, P1169, DOI 10.1523/JNEUROSCI.3920-12.2013
   Menegazzi P, 2012, J BIOL RHYTHM, V27, P433, DOI 10.1177/0748730412463181
   Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737
   Noguchi T, 2012, CHRONOBIOL INT, V29, P653, DOI 10.3109/07420528.2012.679330
   O'Neill JS, 2008, SCIENCE, V320, P949, DOI 10.1126/science.1152506
   O'Neill JS, 2008, J BIOL RHYTHM, V23, P483, DOI 10.1177/0748730408326682
   Ozturk N, 2011, P NATL ACAD SCI USA, V108, P516, DOI 10.1073/pnas.1017093108
   Peschel N, 2009, CURR BIOL, V19, P241, DOI 10.1016/j.cub.2008.12.042
   Picot M, 2009, J NEUROSCI, V29, P8312, DOI 10.1523/JNEUROSCI.0279-08.2009
   PITTENDRIGH CS, 1954, P NATL ACAD SCI USA, V40, P1018, DOI 10.1073/pnas.40.10.1018
   PRICE JL, 1995, EMBO J, V14, P4044, DOI 10.1002/j.1460-2075.1995.tb00075.x
   Reddy AB, 2010, TRENDS CELL BIOL, V20, P36, DOI 10.1016/j.tcb.2009.10.005
   Saini C, 2012, GENE DEV, V26, P567, DOI 10.1101/gad.183251.111
   Sandrelli F, 2007, SCIENCE, V316, P1898, DOI 10.1126/science.1138426
   Sehadova H, 2009, NEURON, V64, P251, DOI 10.1016/j.neuron.2009.08.026
   Shang YH, 2008, P NATL ACAD SCI USA, V105, P19587, DOI 10.1073/pnas.0809577105
   Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1
   Sidote D, 1998, MOL CELL BIOL, V18, P2004, DOI 10.1128/MCB.18.4.2004
   Simoni A, 2014, SCIENCE, V343, P525, DOI 10.1126/science.1245710
   Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4
   Stanewsky R, 1997, EMBO J, V16, P5006, DOI 10.1093/emboj/16.16.5006
   Sun YS, 2009, P NATL ACAD SCI USA, V106, P13606, DOI 10.1073/pnas.0906377106
   Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2
   Tang CHA, 2010, NEURON, V66, P378, DOI 10.1016/j.neuron.2010.04.015
   Vanin S, 2012, NATURE, V484, P371, DOI 10.1038/nature10991
   Weaver D.R., 2013, FUNDAMENTAL NEUROSCI, P819
   WHEELER DA, 1993, J BIOL RHYTHM, V8, P67, DOI 10.1177/074873049300800106
   Wolfgang W, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0959
   Xu XD, 2007, PLANT CELL, V19, P3474, DOI 10.1105/tpc.106.046011
   Yang ZH, 1998, NEURON, V21, P215, DOI 10.1016/S0896-6273(00)80528-0
   Yao Z, 2014, SCIENCE, V343, P1516, DOI 10.1126/science.1251285
   Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101
   Yoshii T, 2010, J BIOL RHYTHM, V25, P387, DOI 10.1177/0748730410381962
   Yoshii T, 2009, J BIOL RHYTHM, V24, P452, DOI 10.1177/0748730409348551
   Zhang Y, 2012, INSECT MOLECULAR BIOLOGY AND BIOCHEMISTRY, P513, DOI 10.1016/B978-0-12-384747-8.10015-7
   Zhao S, 2012, BMC EVOL BIOL, V12, DOI 10.1186/1471-2148-12-193
NR 72
TC 13
Z9 15
U1 3
U2 29
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD NOV 19
PY 2015
VL 163
IS 5
BP 1214
EP 1224
DI 10.1016/j.cell.2015.10.031
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CX9SD
UT WOS:000366044700019
PM 26590423
OA Green Accepted, Other Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yu, YH
   Chung, J
AF Yu, Yong-Ho
   Chung, Jinwook
TI RETRACTED: Combustion characteristics of paper and sewage sludge in a
   pilot-scale fluidized bed (Retracted article. See vol.39, pg. 682, 2018)
SO ENVIRONMENTAL TECHNOLOGY
LA English
DT Article; Retracted Publication
DE carbon monoxide; combustion; fluidized bed; nitrogen oxide; pressure
   fluctuation; sludge
ID PRESSURE-FLUCTUATIONS; INCINERATION; EMISSION; WASTE; VELOCITY; REACTOR;
   MODEL; COAL; NOX
AB This study characterizes the combustion of paper and sewage sludge in a pilot-scale fluidized bed. The highest temperature during combustion within the system was found at the surface of the fluidized bed. Paper sludge containing roughly 59.8% water was burned without auxiliary fuel, but auxiliary fuel was required to incinerate the sewage sludge, which contained about 79.3% water. The stability of operation was monitored based on the average pressure and the standard deviation of pressure fluctuations. The average pressure at the surface of the fluidized bed decreased as the sludge feed rate increased. However, the standard deviation of pressure fluctuations increased as the sludge feed rate increased. Finally, carbon monoxide (CO) emissions decreased as oxygen content increased in the flue gas, and nitrogen oxide (NOx) emissions were also tied with oxygen content.
C1 [Yu, Yong-Ho; Chung, Jinwook] Samsung Engn Co Ltd, R&D Ctr, Suwon 443823, Gyeonggi Do, South Korea.
RP Chung, J (reprint author), Samsung Engn Co Ltd, R&D Ctr, 415-10 Woncheon Dong, Suwon 443823, Gyeonggi Do, South Korea.
EM jin-wook.chung@samsung.com
CR Basu P, 1991, CIRCULATING FLUIDIZE
   Chen JC, 2004, ENVIRON TECHNOL, V25, P1285, DOI 10.1080/09593332508618373
   Davies CE, 2008, POWDER TECHNOL, V180, P307, DOI 10.1016/j.powtec.2007.02.026
   Felipe CAS, 2007, POWDER TECHNOL, V174, P104, DOI 10.1016/j.powtec.2007.01.015
   Font R, 2001, J ANAL APPL PYROL, V58, P927, DOI 10.1016/S0165-2370(00)00146-7
   Fytili D, 2008, RENEW SUST ENERG REV, V12, P116, DOI 10.1016/j.rser.2006.05.014
   Glarborg P, 2003, PROG ENERG COMBUST, V29, P89, DOI 10.1016/S0360-1285(02)00031-X
   HONG SC, 1990, POWDER TECHNOL, V60, P215, DOI 10.1016/0032-5910(90)80121-E
   Howard J., 1989, FLUIDIZED BED TECHNO
   Jang HT, 1999, KOREAN CHEM ENG RES, V37, P910
   Johari A, 2011, APPL THERM ENG, V31, P1861, DOI 10.1016/j.applthermaleng.2011.03.013
   Knoebig T, 1999, CHEM ENG SCI, V54, P2151, DOI 10.1016/S0009-2509(98)00359-5
   Lapa N, 2007, J HAZARD MATER, V147, P175, DOI 10.1016/j.jhazmat.2006.12.064
   Lasek JA, 2013, ENERGY, V62, P105, DOI 10.1016/j.energy.2013.04.079
   Latva-Somppi J, 1998, J AEROSOL SCI, V29, P461, DOI 10.1016/S0021-8502(97)00291-7
   Lee JK, 1992, KOREAN CHEM ENG RES, V30, P228
   Li S, 2011, COMPUT CHEM ENG, V35, P1281, DOI 10.1016/j.compchemeng.2010.07.015
   Lievens P, 2011, ENVIRON TECHNOL, V32, P1637, DOI 10.1080/09593330.2010.546813
   Magdziarz A, 2011, CHEM PROCESS ENG-INZ, V32, P299, DOI 10.2478/v10176-011-0024-4
   Nadziakiewicz J, 2003, APPL ENERG, V75, P239, DOI 10.1016/S0306-2619(03)00037-0
   Ogada T, 1996, FUEL, V75, P617, DOI 10.1016/0016-2361(95)00280-4
   Otero M, 2007, CHEMOSPHERE, V69, P1740, DOI 10.1016/j.chemosphere.2007.05.07
   PARK D, 1980, CHEM ENG SCI, V35, P295, DOI 10.1016/0009-2509(80)80099-6
   Park YS, 1994, KOREAN CHEM ENG RES, V32, P18
   Solimene R, 2010, EXP THERM FLUID SCI, V34, P387, DOI 10.1016/j.expthermflusci.2009.10.033
   Sotudeh-Gharebagh R, 2007, FUEL PROCESS TECHNOL, V88, P847, DOI 10.1016/j.fubroc.2007.04.009
   Stasta P, 2006, APPL THERM ENG, V26, P1420, DOI 10.1016/j.applthermaleng.2005.05.030
   Toftegaard MB, 2010, PROG ENERG COMBUST, V36, P581, DOI 10.1016/j.pecs.2010.02.001
   Urciuolo M, 2012, EXP THERM FLUID SCI, V43, P97, DOI 10.1016/j.expthermflusci.2012.03.019
   Vuthaluru HB, 2000, FUEL PROCESS TECHNOL, V67, P165, DOI 10.1016/S0378-3820(00)00104-1
   Werther J, 1999, PROG ENERG COMBUST, V25, P55, DOI 10.1016/S0360-1285(98)00020-3
   WERTHER J, 1994, CHEM-ING-TECH, V66, P1361, DOI 10.1002/cite.330661010
   Williams A, 2012, PROG ENERG COMBUST, V38, P113, DOI 10.1016/j.pecs.2011.10.001
   Xiao HM, 2010, ENERG CONVERS MANAGE, V51, P1976, DOI 10.1016/j.enconman.2010.02.030
NR 34
TC 2
Z9 2
U1 3
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0959-3330
EI 1479-487X
J9 ENVIRON TECHNOL
JI Environ. Technol.
PD NOV 17
PY 2015
VL 36
IS 22
BP 2903
EP 2910
DI 10.1080/09593330.2015.1052019
PG 8
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA CR9UU
UT WOS:000361703800010
PM 26061904
DA 2018-12-27
ER

PT J
AU Zhou, JM
   Dong, T
AF Zhou, Jianming
   Dong, Tao
TI RETRACTED: Invulnerability mechanism based on mobility prediction and
   opportunistic cloud computing with topological evolution for wireless
   multimedia sensor networks (Retracted article. See art no 25, 2017)
SO EURASIP JOURNAL ON WIRELESS COMMUNICATIONS AND NETWORKING
LA English
DT Article; Retracted Publication
DE Survivability; Opportunistic cloud computing; Mobility prediction;
   Wireless multimedia sensor networks; Topological evolution
AB According to the loss network problems caused by limited resources and environment interference factors, we presented a survivability mechanism based on mobility prediction and based on the topological evolution of cloud computing wireless multimedia sensor network (WMSN). First, based on cooperative neural network and opportunity Markov chain model, the multimedia mobile sensor node state and state transition probability could be predicted. Then, the opportunity computational scheme was given based on mobility prediction of dynamic topology evolution mechanism. Finally, using the network topology reconfiguration and opportunities for cloud computing, an enhanced WMSN survivability and end-to-end quality of service guarantee mechanism was proposed. Experimental results show that compared with the static scheme for WMSNs, the proposed survivability mechanism has the obvious advantage in the node protection, data communication, network life cycle, and decodable frame rate and other aspects, and can effectively improve the invulnerability of WMSNs.
C1 [Zhou, Jianming] Beijing Inst Technol, Sch Informat & Elect, Beijing 100081, Peoples R China.
   [Dong, Tao] Space Star Technol CO Ltd, State Key Lab Space Ground Integrated Informat Te, Beijing 100018, Peoples R China.
RP Zhou, JM (reprint author), Beijing Inst Technol, Sch Informat & Elect, Beijing 100081, Peoples R China.
EM zhoujm@bit.edu.cn
FU Open Research Fund of State Key Laboratory of Space-Ground Integrated
   Information Technology [2014_CXJJ-TX_08]
FX This work is supported in part by the Open Research Fund of State Key
   Laboratory of Space-Ground Integrated Information Technology under grant
   no. 2014_CXJJ-TX_08.
CR Alaybeyoglu A, 2015, J INTELL FUZZY SYST, V28, P1235, DOI 10.3233/IFS-141408
   Alshayeb M, 2014, ARAB J SCI ENG, V39, P7865, DOI 10.1007/s13369-014-1372-4
   Baccarelli E, 2014, IEEE WIREL COMMUN, V21, P20, DOI 10.1109/MWC.2014.6882292
   Chen J, SUPPORT VECTOR MACHI
   Chen SM, 2013, APPL MATH INFORM SCI, V7, P113, DOI 10.12785/amis/070112
   Colonnese S, 2013, IEEE T MULTIMEDIA, V15, P1800, DOI 10.1109/TMM.2013.2271475
   Demir K Alper, 2014, WIREL NETW, V20, P655
   Hefeeda M, 2015, IEEE T MULTIMEDIA, V17, P420, DOI 10.1109/TMM.2015.2389628
   Kim KI, 2015, WIREL COMMUN MOB COM, V15, P475, DOI 10.1002/wcm.2361
   Mendes DP Lucas, 2014, IEEE SYST J, V8, P235
   Nadembega A, 2015, IEEE T VEH TECHNOL, V64, P2561, DOI 10.1109/TVT.2014.2345255
   Nan GF, 2014, IEEE NETWORK, V28, P74, DOI 10.1109/MNET.2014.6863135
   Nan XM, 2014, J VIS COMMUN IMAGE R, V25, P928, DOI 10.1016/j.jvcir.2014.02.008
   Pirozmand P, 2014, J NETW COMPUT APPL, V42, P45, DOI 10.1016/j.jnca.2014.03.007
   Shen H, 2014, WIRELESS PERS COMMUN, V75, P1307, DOI 10.1007/s11277-013-1425-0
   Xing-Zhao P, 2014, ACTA PHYS SINICA, V63
   Xu YF, 2013, AUTOMATICA, V49, P3520, DOI 10.1016/j.automatica.2013.09.008
   Yang Y, 2014, SCI WORLD J, V2014
   Zheng XH, 2014, J INTERNET TECHNOL, V15, P1043, DOI 10.6138/JIT.2014.15.6.15
   Zhou Y, 2015, IEEE SENS J, V15, P1892, DOI 10.1109/JSEN.2014.2366511
NR 20
TC 2
Z9 2
U1 4
U2 10
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1687-1499
J9 EURASIP J WIREL COMM
JI EURASIP J. Wirel. Commun. Netw.
PD NOV 10
PY 2015
AR 243
DI 10.1186/s13638-015-0471-6
PG 11
WC Engineering, Electrical & Electronic; Telecommunications
SC Engineering; Telecommunications
GA V46AR
UT WOS:000209857600001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Ullal, P
   McDonald, NA
   Chen, JS
   Lo Presti, L
   Roberts-Galbraith, RH
   Gould, KL
   Martin, SG
AF Ullal, Pranav
   McDonald, Nathan A.
   Chen, Jun-Song
   Lo Presti, Libera
   Roberts-Galbraith, Rachel H.
   Gould, Kathleen L.
   Martin, Sophie G.
TI RETRACTED: The DYRK-family kinase Pornl phosphorylates the F-BAR protein
   Cdc15 to prevent division at cell poles(Retracted article. See vol. 216,
   2017)
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article; Retracted Publication
ID CYTOKINETIC CONTRACTILE RING; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE;
   ACTOMYOSIN RING; ACTIN RING; S-POMBE; CLP1/CDC14 PHOSPHATASE; SUBSTRATE
   RECOGNITION; DOWN-SYNDROME; SH3 DOMAINS
AB Division site positioning is critical for both symmetric and asymmetric cell divisions. In many organisms, positive and negative signals cooperate to position the contractile actin ring for cytokinesis. In rod-shaped fission yeast Schizosaccharomyces pombe cells, division at midcell is achieved through positive Mid1/anillin-dependent signaling emanating from the central nucleus and negative signals from the dual-specificity tyrosine phosphorylation-regulated kinase family kinase Poml at the cell poles. In this study, we show that Pom1 directly phosphorylates the F-BAR protein Cdc15, a central component of the cytokinetic ring. Poml -dependent phosphorylation blocks Cdcl 5 binding to paxillin Pxl1 and C2 domain protein Ficl and enhances Cdcl 5 dynamics. This promotes ring sliding from cell poles, which prevents septum assembly at the ends of cells with a displaced nucleus or lacking Mid 1. Pom 1 also slows down ring constriction. These results indicate that a strong negative signal from the Poml kinase at cell poles converts Cdc15 to its closed state, destabilizes the actomyosin ring, and thus promotes medial septation.
C1 [Ullal, Pranav; Lo Presti, Libera; Martin, Sophie G.] Univ Lausanne, Dept Fundamental Microbiol, CH-1015 Lausanne, Switzerland.
   [McDonald, Nathan A.; Chen, Jun-Song; Roberts-Galbraith, Rachel H.; Gould, Kathleen L.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA.
RP Martin, SG (reprint author), Univ Lausanne, Dept Fundamental Microbiol, CH-1015 Lausanne, Switzerland.
EM Sophie.Martin@unil.ch
OI Martin, Sophie/0000-0002-5317-2557; Gould, Kathleen/0000-0002-3810-4070;
   Lo Presti, Libera/0000-0002-5349-8469
FU American Heart Association [15PRE21780003]; National Institutes of
   Health [GM101035]; European Research Council; Swiss National Science
   Foundation [31003A_155944]
FX N.A. McDonald was supported by American Heart Association fellowship
   15PRE21780003. Research in the Gould laboratory was supported by
   National Institutes of Health grant GM101035 to K.L. Gould. Research in
   the Martin laboratory is funded by a European Research Council starting
   grant (GeometryCellCycle) and a Swiss National Science Foundation grant
   (31003A_155944) to S.G. Martin.
CR Akamatsu M, 2014, J CELL BIOL, V204, P977, DOI 10.1083/jcb.201307174
   Almonacid M, 2009, CURR BIOL, V19, P961, DOI 10.1016/j.cub.2009.04.024
   Arasada R, 2014, CELL REP, V8, P1533, DOI 10.1016/j.celrep.2014.07.048
   Arasada R, 2011, CURR BIOL, V21, P1450, DOI 10.1016/j.cub.2011.07.046
   Bahler J, 1998, GENE DEV, V12, P1356, DOI 10.1101/gad.12.9.1356
   Bahler J, 2001, EMBO J, V20, P1064, DOI 10.1093/emboj/20.5.1064
   Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y
   Bendezu FO, 2013, CURR BIOL, V23, P42, DOI 10.1016/j.cub.2012.10.042
   Bendezu FO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040248
   Bendezu FO, 2011, MOL BIOL CELL, V22, P44, DOI 10.1091/mbc.E10-08-0720
   Bhatia P, 2014, CELL CYCLE, V13, P538, DOI 10.4161/cc.27411
   Bohnert KA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003004
   Carnahan RH, 2003, J CELL BIOL, V162, P851, DOI 10.1083/job.200305012
   Celton-Morizur S, 2006, J CELL SCI, V119, P4710, DOI 10.1242/jcs.03261
   Chang F, 1996, J CELL SCI, V109, P131
   Chen JS, 2013, MOL CELL PROTEOMICS, V12, P1074, DOI 10.1074/mcp.M112.025924
   Clifford DM, 2008, J CELL BIOL, V181, P79, DOI 10.1083/jcb.200709060
   Daga RR, 2005, P NATL ACAD SCI USA, V102, P8228, DOI 10.1073/pnas.0409021102
   Deng L, 2014, CURR BIOL, V24, P428, DOI 10.1016/j.cub.2014.01.009
   Eggert US, 2006, ANNU REV BIOCHEM, V75, P543, DOI 10.1146/annurev.biochem.74.082803.133425
   FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8
   Ge WZ, 2008, MOL BIOL CELL, V19, P1680, DOI 10.1091/mbc.E07-07-0715
   GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x
   Gregory JA, 2008, GENE DEV, V22, P3475, DOI 10.1101/gad.1732408
   Hachet O, 2011, CELL, V145, P1116, DOI 10.1016/j.cell.2011.05.014
   Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431
   Huang YY, 2007, DEV CELL, V12, P987, DOI 10.1016/j.devcel.2007.03.015
   Huang YY, 2008, J CELL BIOL, V183, P979, DOI 10.1083/jcb.200806151
   Kettenbach AN, 2015, MOL CELL PROTEOMICS, V14, P1275, DOI 10.1074/mcp.M114.045245
   Lippincott J, 2000, MICROSC RES TECHNIQ, V49, P168, DOI 10.1002/(SICI)1097-0029(20000415)49:2<168::AID-JEMT9>3.0.CO;2-T
   Lo Presti L, 2012, MOL BIOL CELL, V23, P4579, DOI 10.1091/mbc.E12-07-0499
   Lutkenhaus J, 2007, ANNU REV BIOCHEM, V76, P539, DOI 10.1146/annurev.biochem.75.103004.142652
   Martin SG, 2005, DEV CELL, V8, P479, DOI 10.1016/j.devcel.2005.02.008
   Martin SG, 2009, NATURE, V459, P852, DOI 10.1038/nature08054
   Martin-Garcia R, 2014, J CELL SCI, V127, P4146, DOI 10.1242/jcs.146233
   Mishra M, 2008, CURR BIOL, V18, pR247, DOI 10.1016/j.cub.2008.01.029
   Moseley JB, 2009, NATURE, V459, P857, DOI 10.1038/nature08074
   Munoz J, 2013, J CELL BIOL, V203, P265, DOI 10.1083/jcb.201304132
   Murakami N, 2006, J BIOL CHEM, V281, P23712, DOI 10.1074/jbc.M513497200
   Oliferenko S, 2009, GENE DEV, V23, P660, DOI 10.1101/gad.1772009
   Padte NN, 2006, CURR BIOL, V16, P2480, DOI 10.1016/j.cub.2006.11.024
   Paoletti A, 2000, MOL BIOL CELL, V11, P2757, DOI 10.1091/mbc.11.8.2757
   Pardo M, 2003, SCIENCE, V300, P1569, DOI 10.1126/science.1084671
   Pinar M, 2008, MOL BIOL CELL, V19, P1727, DOI 10.1091/mbc.E07-07-0718
   Pollard TD, 2010, NAT REV MOL CELL BIO, V11, P149, DOI 10.1038/nrm2834
   Proctor SA, 2012, CURR BIOL, V22, P1601, DOI 10.1016/j.cub.2012.06.042
   Ren LP, 2015, MOL BIOL CELL, V26, P256, DOI 10.1091/mbc.E14-10-1451
   Rincon SA, 2014, J CELL BIOL, V206, P61, DOI 10.1083/jcb.201311097
   Roberts-Galbraith RH, 2010, CELL CYCLE, V9, P4091, DOI 10.4161/cc.9.20.13587
   Roberts-Galbraith RH, 2010, MOL CELL, V39, P86, DOI 10.1016/j.molcel.2010.06.012
   Roberts-Galbraith RH, 2009, J CELL BIOL, V184, P113, DOI 10.1083/jcb.200806044
   Roberts-Galbraith RH, 2008, GENE DEV, V22, P3082, DOI 10.1101/gad.1748908
   Saha S, 2012, MOL BIOL CELL, V23, P3982, DOI 10.1091/mbc.E12-07-0535
   Sohrmann M, 1996, GENE DEV, V10, P2707, DOI 10.1101/gad.10.21.2707
   Soundararajan M, 2013, STRUCTURE, V21, P986, DOI 10.1016/j.str.2013.03.012
   Tatebe H, 2005, CURR BIOL, V15, P1006, DOI 10.1016/j.cub.2005.04.061
   Tolic-Norrelykke IM, 2005, CURR BIOL, V15, P1212, DOI 10.1016/j.cub.2005.05.052
   Tran PT, 2000, BIOL BULL, V199, P205, DOI 10.2307/1542900
   Ubersax JA, 2007, NAT REV MOL CELL BIO, V8, P530, DOI 10.1038/nrm2203
   Vavylonis D, 2008, SCIENCE, V319, P97, DOI 10.1126/science.1151086
   Vjestica A, 2008, MOL BIOL CELL, V19, P1125, DOI 10.1091/mbc.E07-07-0663
   Wachtler V, 2006, MOL BIOL CELL, V17, P3254, DOI 10.1091/mbc.E05-11-1086
   Willet AH, 2015, J CELL BIOL, V208, P391, DOI 10.1083/jcb.201411097
   Wu JQ, 2006, J CELL BIOL, V174, P391, DOI 10.1083/jcb.200602032
   Wu JQ, 2003, DEV CELL, V5, P723, DOI 10.1016/S1534-5807(03)00324-1
   Wu JQ, 2005, SCIENCE, V310, P310, DOI 10.1126/science.1113230
NR 66
TC 8
Z9 8
U1 4
U2 6
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD NOV 9
PY 2015
VL 211
IS 3
BP 653
EP 668
DI 10.1083/jcb.201504073
PG 16
WC Cell Biology
SC Cell Biology
GA CX0GD
UT WOS:000365374000015
PM 26553932
OA Other Gold, Green Published
DA 2018-12-27
ER

PT J
AU Son, YO
   Pratheeshkumar, P
   Roy, RV
   Hitron, JA
   Wang, L
   Divya, SP
   Xu, M
   Luo, J
   Chen, G
   Zhang, Z
   Shi, XL
AF Son, Young-Ok
   Pratheeshkumar, Poyil
   Roy, Ram Vinod
   Hitron, John Andrew
   Wang, Lei
   Divya, Sasidharan Padmaja
   Xu, Mei
   Luo, Jia
   Chen, Gang
   Zhang, Zhuo
   Shi, Xianglin
TI RETRACTED: Antioncogenic and Oncogenic Properties of Nrf2 in
   Arsenic-induced Carcinogenesis (Retracted article. See vol. 293, pg.
   15456, 2018)
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article; Retracted Publication
ID TRANSCRIPTION FACTOR NRF2; ROS-DEPENDENT ACTIVATION; CANCER; AUTOPHAGY;
   P62; CELLS; MECHANISMS; PATHWAY; KEAP1; TUMORIGENESIS
AB Background: Arsenic induced cell transformation and carcinogenesis.
   Results: Arsenic-transformed cells have the property of apoptosis/autophagy resistance.
   Conclusion: The constitutive activation of Nrf2 in arsenic-transformed cells up-regulates antioxidants, decreases ROS generation, and causes apoptosis resistance and tumorigenesis.
   Significance: Antioncogenic role of inducible Nrf2 in normal cells and oncogenic role of constitutive activation of Nfr2 in cancer cells may increase our understanding of the mechanism of arsenic carcinogenesis and its prevention.
   Arsenic (As3+) is a carcinogen with considerable environmental and occupational relevancy. The present study shows that As3+-transformed human lung bronchial epithelial BEAS-2B cells (AsT cells) exhibit the property of apoptosis resistance. The level of basal reactive oxygen species (ROS) is very low in AsT cells in correlation with elevated expressions of both antioxidant enzymes and antiapoptotic proteins. Nuclear factor erythroid 2-related factor (Nrf2) and p62 are constitutively expressed. These two proteins up-regulate antioxidant enzymes and antiapoptotic proteins. The knockdown of Nrf2 or p62 by small interfering RNA (siRNA) enhanced both ROS levels and As3+-induced apoptosis in transformed cells. AsT cells have autophagy deficiency as evidenced by reduced formation of microtubule-associated protein 1 light chain 3 (LC3)-II, GFP-LC3 puncta, and autophagy flux. Results obtained using a soft agar assay and shRNA Nrf2-transfected cells show that Nrf2 plays an antioncogenic role before transformation, whereas this transcription factor plays an oncogenic role after transformation. In addition, depletion of Nrf2 by shRNA dramatically inhibited growth and proliferation of transformed cells. Furthermore, the Nrf2 protein levels and antiapoptotic and antioxidant enzyme levels are higher in lung adenocarcinoma than in normal tissues. Collectively, this study demonstrates that a constitutively high level of Nrf2 in AsT cells up-regulates the antioxidant proteins catalase and superoxide dismutase as well as the antiapoptotic proteins Bcl-2 and Bcl-xL. The final consequences are decreased ROS generation and increased apoptotic resistance, cell survival and proliferation, and tumorigenesis.
C1 [Son, Young-Ok; Pratheeshkumar, Poyil; Roy, Ram Vinod; Wang, Lei; Shi, Xianglin] Univ Kentucky, Coll Med, Ctr Res Environm Dis, Lexington, KY 40536 USA.
   [Son, Young-Ok; Pratheeshkumar, Poyil; Roy, Ram Vinod; Hitron, John Andrew; Wang, Lei; Divya, Sasidharan Padmaja; Zhang, Zhuo; Shi, Xianglin] Univ Kentucky, Dept Toxicol & Canc Biol, Coll Med, Lexington, KY 40536 USA.
   [Xu, Mei; Luo, Jia; Chen, Gang] Univ Kentucky, Dept Pharmacol & Nutr Sci, Coll Med, Lexington, KY 40536 USA.
RP Shi, XL (reprint author), Univ Kentucky, Coll Med, Ctr Res Environm Dis, Lexington, KY 40536 USA.
EM xshi5@email.uky.edu
RI Shi, Xianglin/B-8588-2012; Regan, Clinton/E-6250-2012; Son,
   Young-Ok/P-3675-2015
OI Son, Youngok/0000-0003-0154-4061
FU National Institutes of Health [R01 ES025515, R01 ES021771, R01
   ES020870]; University of Kentucky Markey Cancer Center (National
   Institutes of Health) [P30CA177558]
FX This work was supported by National Institutes of Health Grants R01
   ES025515, R01 ES021771, and R01 ES020870 and the Biospecimen and Tissue
   Procurement Shared Resource Facility and the Cytometry and Cell Sorting
   core facility of the University of Kentucky Markey Cancer Center
   (National Institutes of Health Grant P30CA177558). The authors declare
   that they have no conflicts of interest with the contents of this
   article.
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Agency for Toxic Substances and Disease Registry, 2013, PRIOR LIST HAZ SUBST
   Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3
   Chang QS, 2010, CANCER RES, V70, P5127, DOI 10.1158/0008-5472.CAN-10-0007
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Edwards MR, 2014, CELL REP, V6, P1017, DOI 10.1016/j.celrep.2014.01.043
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221
   Hu R, 2010, ANTIOXID REDOX SIGN, V13, P1679, DOI 10.1089/ars.2010.3276
   Hughes MF, 2002, TOXICOL LETT, V133, P1, DOI 10.1016/S0378-4274(02)00084-X
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Lau A, 2013, MOL CELL BIOL, V33, P2436, DOI 10.1128/MCB.01748-12
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Nezis IP, 2012, ANTIOXID REDOX SIGN, V17, P786, DOI 10.1089/ars.2011.4394
   Son YO, 2012, TOXICOL APPL PHARM, V264, P153, DOI 10.1016/j.taap.2012.07.028
   Son YO, 2011, TOXICOL APPL PHARM, V255, P287, DOI 10.1016/j.taap.2011.06.024
   Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278
   Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wickre JB, 2004, ARCH ENVIRON HEALTH, V59, P400, DOI 10.3200/AEOH.59.8.400-409
NR 25
TC 21
Z9 21
U1 1
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 6
PY 2015
VL 290
IS 45
BP 27090
EP 27100
DI 10.1074/jbc.M115.675371
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CW2AS
UT WOS:000364794000019
PM 26385919
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Madani, SS
   Zare, K
   Ghoranneviss, M
   Elahi, AS
AF Madani, S. S.
   Zare, K.
   Ghoranneviss, M.
   Elahi, A. Salar
TI RETRACTED: Synthesis of carbon nanotubes using the cobalt nanocatalyst
   by thermal chemical vapor deposition technique (Retracted article. See
   vol. 746, pg. 739, 2018)
SO JOURNAL OF ALLOYS AND COMPOUNDS
LA English
DT Article; Retracted Publication
DE Carbon nanotubes; Cobalt nanocatalyst; TCVD
ID GROWTH; CATALYST; FILMS
AB The three main synthesis methods of Carbon nanotubes (CNTs) are the arc discharge, the laser ablation and the chemical vapour deposition (CVD) with a special regard to the latter one. CNTs were produced on a silicon wafer by Thermal Chemical Vapor Deposition (TCVD) using acetylene as a carbon source, cobalt as a catalyst and ammonia as a reactive gas. The DC-sputtering system was used to prepare cobalt thin films on Si substrates. A series of experiments was carried out to investigate the effects of reaction temperature and deposition time on the synthesis of the nanotubes. The deposition time was selected as 15 and 25 min for all growth temperatures. Energy Dispersive X-ray (EDX) measurements were used to investigate the elemental composition of the Co nanocatalyst deposited on Si substrates. Atomic Force Microscopy (AFM) was used to characterize the surface topography of the Co nanocatalyst deposited on Si substrates. The as-grown CNTs were characterized under Field Emission Scanning Electron Microscopy (FESEM) to study the morphological properties of CNTs. Also, the grown CNTs have been investigated by High Resolution Transmission Electron Microscopy (HRTEM) and Raman spectroscopy. The results demonstrated that increasing the temperature leads to increasing the diameter of CNTs. The ideal reaction temperature was 850 degrees C and the deposition time was 15 min. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Madani, S. S.; Zare, K.] Islamic Azad Univ, Dept Chem, Sci & Res Branch, Tehran, Iran.
   [Zare, K.] Shahid Beheshti Univ, Dept Chem, Tehran, Iran.
   [Ghoranneviss, M.; Elahi, A. Salar] Islamic Azad Univ, Plasma Phys Res Ctr, Sci & Res Branch, Tehran, Iran.
RP Elahi, AS (reprint author), Islamic Azad Univ, Plasma Phys Res Ctr, Sci & Res Branch, Tehran, Iran.
EM Salari_phy@yahoo.com
RI Monajjemi, Majid/F-6526-2017
OI Monajjemi, Majid/0000-0002-6665-837X
CR Adhikari PD, 2013, THIN SOLID FILMS, V545, P50, DOI 10.1016/j.tsf.2013.07.030
   Aksak M., 2009, J OPTOELECTRON ADV M, V1, P3
   Bartelt NC, 2012, MRS BULL, V37, P1158, DOI 10.1557/mrs.2012.237
   Bower C, 2000, APPL PHYS LETT, V77, P2767, DOI 10.1063/1.1319529
   Collins PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/science.287.5459.1801
   Croin L, 2014, THIN SOLID FILMS, V573, P122, DOI 10.1016/j.tsf.2014.10.102
   Dresselhaus MS, 2001, CARBON NANOTUBES SYN
   Dupuis AC, 2005, PROG MATER SCI, V50, P929, DOI 10.1016/j.pmatsci.2005.04.003
   Gohier A, 2008, CARBON, V46, P1331, DOI 10.1016/j.carbon.2008.05.016
   Ismach A, 2010, NANO LETT, V10, P1542, DOI 10.1021/nl9037714
   Journet C, 1997, NATURE, V388, P756, DOI 10.1038/41972
   Juang ZY, 2004, DIAM RELAT MATER, V13, P1203, DOI 10.1016/j.diamond.2004.01.002
   Kaplas T, 2012, CARBON, V50, P1503, DOI 10.1016/j.carbon.2011.11.020
   Lee YH, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3324698
   Li GD, 2002, CARBON, V40, P917, DOI 10.1016/S0008-6223(01)00220-2
   Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477
   PRESLAND AE, 1972, SURF SCI, V29, P424, DOI 10.1016/0039-6028(72)90229-4
   Ramon ME, 2011, ACS NANO, V5, P7198, DOI 10.1021/nn202012m
   RINZLER AG, 1995, SCIENCE, V269, P1550, DOI 10.1126/science.269.5230.1550
   Song IK, 2004, DIAM RELAT MATER, V13, P1210, DOI 10.1016/j.diamond.2004.01.006
   Su CY, 2011, NANO LETT, V11, P3612, DOI 10.1021/nl201362n
   Szabo A, 2010, MATERIALS, V3, P3092, DOI 10.3390/ma3053092
   Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483
   Wang Q.H., 1998, APPL PHYS LETT, V72, P22
   Ye JP, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3480419
NR 25
TC 15
Z9 15
U1 4
U2 67
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-8388
EI 1873-4669
J9 J ALLOY COMPD
JI J. Alloy. Compd.
PD NOV 5
PY 2015
VL 648
BP 1104
EP 1108
DI 10.1016/j.jallcom.2015.07.063
PG 5
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering
GA CR2KN
UT WOS:000361158300157
DA 2018-12-27
ER

PT J
AU Yang, QL
   Wu, S
   Quan, ZJ
   Du, BX
   Wang, MM
   Li, PD
   Zhang, YP
   Lei, ZQ
   Wang, XC
AF Yang, Quanlu
   Wu, Shang
   Quan, Zhengjun
   Du, Baoxin
   Wang, Mingming
   Li, Peidong
   Zhang, Yinpan
   Lei, Ziqiang
   Wang, Xicun
TI RETRACTED: Reusable biomacromolecule-Pd complex catalyzed C-C
   cross-coupling reactions via C-S cleavage of disulfides(Retracted
   article. See vol.73,pg.222,2017)
SO TETRAHEDRON
LA English
DT Article; Retracted Publication
DE C-C coupling reaction; Pd(OAc)(2)-complex; Heterogeneous catalyst;
   Disulfide
ID UNSYMMETRICAL DIARYL CHALCOGENIDES; SUPPORTED PALLADIUM CATALYSTS;
   ACTIVE HETEROGENEOUS CATALYST; METAL-FREE SYNTHESIS; HECK REACTION;
   RECYCLABLE CATALYSTS; WOOL-PD; ASYMMETRIC HYDROGENATION; ORGANIC
   FRAMEWORKS; MESOPOROUS SILICA
AB A well-defined heterogeneous palladium catalyst, natural wool supported Pd(OAc)(2)-complex was found to be an effective catalyst for the C-S bonds cleavage and C-C bonds formation from 1,2-di(pyrimidin-2-yl)disulfane derivatives with arylboronic acids or terminal alkynes, giving the desired coupling products in moderate to excellent yields. The novel catalyst, which is stable and easy handling in experiment, was characterized by XPS, IR, SEM and ICP analysis. Subsequent analysis of the used catalyst after reaction revealed its negligible metal leaching and at least 10 rounds of recycled catalyzing capacity and wide range of substrate tolerance. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Yang, Quanlu; Wu, Shang; Quan, Zhengjun; Du, Baoxin; Lei, Ziqiang; Wang, Xicun] Northwest Normal Univ, Coll Chem & Chem Engn, Key Lab Polymer Mat, Lab Ecoenvironm Related Polymer Mat,Minist Educ, Lanzhou 730070, Gansu, Peoples R China.
   [Yang, Quanlu; Wang, Mingming; Li, Peidong; Zhang, Yinpan] Lanzhou Univ Arts & Sci, Coll Chem Engn, Lanzhou 730000, Gansu, Peoples R China.
   [Wu, Shang] Northwest Univ Nationalities, Coll Chem Engn, Lanzhou 730030, Gansu, Peoples R China.
RP Quan, ZJ (reprint author), Northwest Normal Univ, Coll Chem & Chem Engn, Key Lab Polymer Mat, Lab Ecoenvironm Related Polymer Mat,Minist Educ, Lanzhou 730070, Gansu, Peoples R China.
EM quanzhengjun@hotmail.com; wangxicun@nwnu.edu.cn
FU National Natural Science Foundation of China [21362032, 21362031,
   21464013]; Natural Science Foundation of Gansu Province [1208RJYA083];
   Scientific and Technological Innovation Engineering program of Northwest
   Normal University [nwnu-kjcxgc-03-64]
FX This work was financially supported by National Natural Science
   Foundation of China (Nos. 21362032, 21362031 and 21464013), the Natural
   Science Foundation of Gansu Province (No. 1208RJYA083), and the
   Scientific and Technological Innovation Engineering program of Northwest
   Normal University (No. nwnu-kjcxgc-03-64).
CR Ahrens T, 2015, CHEM REV, V115, P931, DOI 10.1021/cr500257c
   Arisawa M, 2008, J AM CHEM SOC, V130, P12214, DOI 10.1021/ja8049996
   Astruc D, 2005, ANGEW CHEM INT EDIT, V44, P7852, DOI 10.1002/anie.200500766
   Baldovino-Pantaleon O, 2006, ADV SYNTH CATAL, V348, P236, DOI 10.1002/adsc.200505207
   Buchwalter P, 2015, CHEM REV, V115, P28, DOI 10.1021/cr500208k
   Cantillo D, 2014, CHEMCATCHEM, V6, P3286, DOI 10.1002/cctc.201402483
   Cheng JH, 2012, CHEM COMMUN, V48, P8440, DOI 10.1039/c2cc33950a
   Corma A, 2010, CHEM REV, V110, P4606, DOI 10.1021/cr9003924
   Crudden CM, 2005, J AM CHEM SOC, V127, P10045, DOI 10.1021/ja0430954
   Deiana L, 2014, ANGEW CHEM INT EDIT, V53, P3447, DOI 10.1002/anie.201310216
   Djakovitch L, 2001, J AM CHEM SOC, V123, P5990, DOI 10.1021/ja001087r
   Du BX, 2015, ADV SYNTH CATAL, V357, P1270, DOI 10.1002/adsc.201400980
   Du BN, 2014, ORG LETT, V16, P3032, DOI 10.1021/ol5011449
   Duan ZY, 2009, CHEM-EUR J, V15, P3666, DOI 10.1002/chem.200900133
   Ge WL, 2012, GREEN CHEM, V14, P2066, DOI 10.1039/c2gc35337g
   Gogsig TM, 2009, ORG LETT, V11, P4886, DOI 10.1021/ol901975u
   Gunanathan C, 2014, CHEM REV, V114, P12024, DOI 10.1021/cr5002782
   Huang L, 2006, CATAL LETT, V112, P219, DOI 10.1007/s10562-006-0206-8
   Huang L, 2009, J PHYS CHEM C, V113, P10120, DOI 10.1021/jp811188f
   Jia B, 2003, REACT FUNCT POLYM, V57, P163, DOI 10.1016/j.reactfunctpolym.2003.08.006
   Kaur P, 2011, ACS CATAL, V1, P819, DOI 10.1021/cs200131g
   Kozlowski JT, 2013, ACS CATAL, V3, P1588, DOI 10.1021/cs400292f
   Lee KH, 2013, J COLLOID INTERF SCI, V403, P127, DOI 10.1016/j.jcis.2013.04.006
   Li L, 2004, CHEM COMMUN, P1990, DOI 10.1039/b404916k
   Ma HC, 2012, CATAL SCI TECHNOL, V2, P2291, DOI 10.1039/c2cy20126g
   Ma HC, 2012, CHINESE J CATAL, V33, P1594, DOI 10.3724/SP.J.1088.2012.20442
   Mehnert CP, 1998, J AM CHEM SOC, V120, P12289, DOI 10.1021/ja971637u
   MISONO M, 1990, APPL CATAL, V64, P1, DOI 10.1016/S0166-9834(00)81550-X
   Mizuno N, 1998, CHEM REV, V98, P199, DOI 10.1021/cr960401q
   Mukherjee N, 2013, J ORG CHEM, V78, P11110, DOI 10.1021/jo402071b
   Navalon S, 2014, CHEM REV, V114, P6179, DOI 10.1021/cr4007347
   Nestl BM, 2014, ANGEW CHEM INT EDIT, V53, P3070, DOI 10.1002/anie.201302195
   NOJIRI N, 1993, APPL CATAL A-GEN, V93, P103, DOI 10.1016/0926-860X(93)85187-T
   Okubo K, 2002, TETRAHEDRON LETT, V43, P7115, DOI 10.1016/S0040-4039(02)01320-5
   Okuhara T, 1996, ADV CATAL, V41, P113, DOI 10.1016/S0360-0564(08)60041-3
   Over H, 2012, CHEM REV, V112, P3356, DOI 10.1021/cr200247n
   Panziera N, 2007, J CATAL, V246, P351, DOI 10.1016/j.jcat.2006.12.017
   Prakash SP, 2014, CHEMCATCHEM, V6, P1641, DOI 10.1002/cctc.201400060
   Prasad CD, 2013, J ORG CHEM, V78, P1434, DOI 10.1021/jo302480j
   Prockl SS, 2004, ANGEW CHEM INT EDIT, V43, P1881, DOI 10.1002/anie.200353473
   Quan ZJ, 2014, ADV SYNTH CATAL, V356, P325, DOI 10.1002/adsc.201300776
   Quan ZJ, 2012, ADV SYNTH CATAL, V354, P2939, DOI 10.1002/adsc.201200402
   Ranjbar-Mohammadi M, 2013, J APPL POLYM SCI, V129, P707, DOI 10.1002/app.38796
   Ranu BC, 2004, J ORG CHEM, V69, P5793, DOI 10.1021/jo0493727
   Ren N, 2007, J CATAL, V246, P215, DOI 10.1016/j.jcat.2006.11.028
   Reynolds WR, 2014, CATAL SCI TECHNOL, V4, P948, DOI 10.1039/c3cy00836c
   Shi JL, 2013, CHEM REV, V113, P2139, DOI 10.1021/cr3002752
   Si WJ, 2013, ELECTROCHIM ACTA, V107, P397, DOI 10.1016/j.electacta.2013.06.065
   Sinha P, 2001, ORGANOMETALLICS, V20, P157, DOI 10.1021/om000533g
   Sun CL, 2014, CHEM REV, V114, P9219, DOI 10.1021/cr400274j
   Suresh R, 2013, ASIAN J ORG CHEM, V2, P169, DOI 10.1002/ajoc.201200169
   Uehara TN, 2013, ASIAN J ORG CHEM, V2, P938, DOI 10.1002/ajoc.201300172
   Wan Y, 2009, J AM CHEM SOC, V131, P4541, DOI 10.1021/ja808481g
   Wang D, 2014, CHEM REV, V114, P6949, DOI 10.1021/cr500134h
   Wang PF, 2014, ORG LETT, V16, P4586, DOI 10.1021/ol502144c
   Wang SQ, 2008, REACT FUNCT POLYM, V68, P424, DOI 10.1016/j.reactfunctpolym.2007.06.001
   Wu S, 2011, TETRAHEDRON, V67, P250, DOI 10.1016/j.tet.2010.10.062
   Xu XB, 2013, ORG LETT, V15, P550, DOI 10.1021/ol303366u
   Xu Y, 2008, J APPL POLYM SCI, V110, P2996, DOI 10.1002/app.28655
   Xue L, 2004, POLYM ADVAN TECHNOL, V15, P346, DOI 10.1002/pat.440
   Yan ZF, 2014, CHEM COMMUN, V50, P13555, DOI 10.1039/c4cc05090h
   Yang Z, 2012, ACS NANO, V6, P205, DOI 10.1021/nn203393d
   Yin MY, 1999, J MOL CATAL A-CHEM, V147, P93, DOI 10.1016/S1381-1169(99)00133-8
   Yoon H, 2007, CHEM COMMUN, P1468, DOI 10.1039/b616660a
   Zhang Y, 2012, CHEM REV, V112, P2467, DOI 10.1021/cr200260m
   Zhang ZH, 2006, J ORG CHEM, V71, P7485, DOI 10.1021/jo061179k
   Zhao FY, 2002, J MOL CATAL A-CHEM, V180, P211, DOI 10.1016/S1381-1169(01)00436-8
   Zhao JC, 2014, ADV SYNTH CATAL, V356, P2719, DOI 10.1002/adsc.201400032
   Zhou DQ, 2003, POLYM ADVAN TECHNOL, V14, P287, DOI 10.1002/pat.308
   Zhu JJ, 2014, ACS CATAL, V4, P2917, DOI 10.1021/cs500606g
NR 70
TC 3
Z9 3
U1 5
U2 52
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4020
J9 TETRAHEDRON
JI Tetrahedron
PD NOV 4
PY 2015
VL 71
IS 44
BP 8462
EP 8471
DI 10.1016/j.tet.2015.09.022
PG 10
WC Chemistry, Organic
SC Chemistry
GA CT6JY
UT WOS:000362920500010
DA 2018-12-27
ER

PT J
AU Babizhayev, MA
AF Babizhayev, Mark A.
TI RETRACTED: Patenting strategies, the authentication US fiscal
   methodology, discovery and development of imidazolecontaining peptide
   compounds with free-radical scavenging and transglycating properties
   acting as targeted drug regulators and homeostatic agents with diverse
   therapeutic activities for pharmacy of diabetes and metabolic diseases
   (Retracted article. See vol.27, pg.1363, 2017)
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Review; Retracted Publication
DE carcinine; D-carnosine; diabetes complications: nephropathy; neuropathy;
   retinopathy; atherosclerosis; excessive nonenzymatic glycosylation;
   hypothalamic histaminergic system; increased free radical production;
   leucyl-histidylhydrazide and patented formulations thereof;
   non-hydrolyzed carnosine; ophthalmic prodrug N-acetylcarnosine; patented
   carnosine mimetics resistant to enzymatic hydrolysis with human
   carnosinases; peptides; retinopathy; therapeutic management strategies
   for type 2 diabetes; universal form of antioxidant and transglycating
   agents
ID CARCININE BETA-ALANYLHISTAMINE; HISTIDINE-CONTAINING DIPEPTIDE;
   LUBRICANT EYE DROPS; N-ACETYLCARNOSINE; ADVANCED GLYCATION; NONSPECIFIC
   DIPEPTIDASE; PROTEIN MODIFICATION; CRYSTALLINE LENS; SCHIFF-BASES;
   AMINO-ACIDS
AB Introduction: Diabetes mellitus is the seventh-leading cause of death in the US and diabetic complications are interlaced with specific diverse microvascular and macrovascular pathologies resulting from hyperglycemia. The society should expand prowess and patenting of biotechnology to cure disease and complications.Areas covered: The work summarizes biological activities of patented carnosine mimetics resistant in formulations to enzymatic hydrolysis with human carnosinases that are acting as a universal form of antioxidant, deglycating and transglycating agents that inhibit sugar-mediated protein crosslinking, chelate or inactivate a number of transition metal ions (including ferrous and copper ions), possess lipid peroxidase type of activity and protection of antioxidant enzymes from inactivation. L-Carnosine released systemically from N-acetylcarnosine lubricant eye drops or from skeletal muscle during exercise is transported into hypothalamic tuberomammillary nucleus-histamine neurons and hydrolyzed. The resulting L-histidine is subsequently converted into histamine acting as metabolic fuel feeding for the hypothalamic histaminergic system. This mechanism is responsible for the effects of L-carnosine on autonomic neurotransmission and physiological function of pancreas, stimulating in vivo regeneration of insulin-producing cells.Expert opinion: Therapeutic benefits for imidazole-containing antioxidants (nutraceutical non-hydrolyzed carnosine, carcinine, D-carnosine, ophthalmic prodrug N-acetylcarnosine, leucyl-histidylhydrazide and patented formulations thereof) are an essential part of diabetes treatment.
C1 [Babizhayev, Mark A.] Innovat Vis Prod Inc, 3511 Silverside Rd,Suite 105, Delaware, OH USA.
RP Babizhayev, MA (reprint author), Innovat Vis Prod Inc, 3511 Silverside Rd,Suite 105, Delaware, OH USA.
EM markbabizhayev@yahoo.com
FU Innovative Vision Products, Inc. (County of New Castle, DE, USA)
FX This work was planned, organized and supported by Innovative Vision
   Products, Inc. (County of New Castle, DE, USA). Innovative Vision
   Products Inc. is a pharmaceutical and nanotechnology development company
   with a focus on innovative chemical entities, drug delivery systems and
   unique medical devices to target specific biomedical applications. Over
   the past decade, Innovative Vision Products has developed a track record
   in developing these technologies to effectively address the unmet needs
   of specific diseased populations. The biologically significant
   applications of carnosine mimetics including those in ophthalmology were
   patented by Dr Babizhayev and the alliance Groups (WO 2004/028536 A1; WO
   94/19325; WO 95/12581; WO 2004/064866 A1). The author (Dr Mark A.
   Babizhayev) is an employee of Innovative Vision Products and reports
   interest in the intellectual property of the described modalities
   protected with the patents. The author bears primary responsibility for
   the accuracy of the content of the paper.
CR Aldini G, 2005, BIOFACTORS, V24, P77, DOI 10.1002/biof.5520240109
   Aldini G, 2004, J MASS SPECTROM, V39, P1417, DOI 10.1002/jms.696
   Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042
   ARNOULD JM, 1977, ARCH INT PHYSIOL BIO, V85, P339, DOI 10.3109/13813457709058766
   ARNOULD JM, 1975, COMP BIOCHEM PHYS C, V50, P59
   Babizhayev M.A., 2004, PCT/JP2004/000351, Patent No. 2004000351
   Babizhayev M.A., 2004, Patent No. [WO 2004/064866, 2004064866]
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P363, DOI 10.1016/0005-2760(89)90085-4
   BABIZHAYEV MA, 1994, BBA-MOL BASIS DIS, V1225, P326, DOI 10.1016/0925-4439(94)90014-0
   Babizhayev MA, 2004, REJUV RES, V7, P186, DOI 10.1089/rej.2004.7.186
   Babizhayev MA, 2001, PEPTIDES, V22, P979, DOI 10.1016/S0196-9781(01)00407-7
   BABIZHAYEV MA, 1994, BIOCHEM J, V304, P509, DOI 10.1042/bj3040509
   Babizhayev MA, 2000, J ANTI-AGING MED, V3, P43, DOI 10.1089/rej.1.2000.3.43
   Babizhayev MA, 2006, J PHARM TOXICOL, V1, P201
   Babizhayev MA, 2004, PCT Patent Application, Patent No. [WO 2004/028536 A1, 2004028536]
   Babizhayev MA, 2006, CURR DRUG THER, V1, P91, DOI 10.2174/157488506775268425
   Babizhayev MA, 2008, DRUG DEV IND PHARM, V34, P1071, DOI [10.1080/03639040801958413, 10.1080/03639040801958413 ]
   Babizhayev Mark A, 2004, Drugs R D, V5, P125, DOI 10.2165/00126839-200405030-00001
   Babizhayev MA, 2012, FUND CLIN PHARMACOL, V26, P644, DOI 10.1111/j.1472-8206.2011.00963.x
   Babizhayev Mark A, 2002, Drugs R D, V3, P87, DOI 10.2165/00126839-200203020-00004
   Babizhayev Mark A, 2009, Recent Pat Drug Deliv Formul, V3, P229
   Babizhayev MA, 2009, J DRUG TARGET, V17, P36, DOI [10.1080/10611860802438736, 10.1080/10611860802438736 ]
   Bhatwadekar AD, 2008, INVEST OPHTH VIS SCI, V49, P1232, DOI 10.1167/iovs.07-1015
   BISBY RH, 1991, FEBS LETT, V290, P205, DOI 10.1016/0014-5793(91)81260-F
   BOLDYREV AA, 1990, ADV ENZYME REGUL, V30, P175
   Bonfanti L, 1999, PROG NEUROBIOL, V59, P333, DOI 10.1016/S0301-0082(99)00010-6
   Brotman D.N., 1989, FASEB J, V3, P1028
   BROTMAN DN, 1990, CRIT CARE MED, V18, P317, DOI 10.1097/00003246-199003000-00015
   FLANCBAUM L, 1990, LIFE SCI, V47, P1587, DOI 10.1016/0024-3205(90)90188-W
   Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982
   Guiotto A, 2007, BIOORGAN MED CHEM, V15, P6158, DOI 10.1016/j.bme.2007.06.029
   Hipkiss AR, 2006, ANN NY ACAD SCI, V1067, P369, DOI 10.1196/annals.1354.052
   Hipkiss AR, 2009, EXPERT REV NEUROTHER, V9, P583, DOI 10.1586/ERN.09.32
   JACKSON MC, 1991, CLIN CHIM ACTA, V196, P193, DOI 10.1016/0009-8981(91)90073-L
   Kang JH, 2007, B KOREAN CHEM SOC, V28, P1881
   KUNZE N, 1986, EUR J BIOCHEM, V160, P605, DOI 10.1111/j.1432-1033.1986.tb10081.x
   Lee YT, 2005, EUR J PHARMACOL, V513, P145, DOI 10.1016/j.ejphar.2005.02.010
   LENNEY JF, 1976, BIOCHIM BIOPHYS ACTA, V429, P214, DOI 10.1016/0005-2744(76)90044-9
   LENNEY JF, 1990, BIOL CHEM H-S, V371, P433, DOI 10.1515/bchm3.1990.371.1.433
   MCLAUGHLIN JA, 1980, P NATL ACAD SCI-BIOL, V77, P949, DOI 10.1073/pnas.77.2.949
   MOSSINE VV, 1994, CARBOHYD RES, V262, P257, DOI 10.1016/0008-6215(94)84183-7
   Nagai K, 2012, AMINO ACIDS, V43, P97, DOI 10.1007/s00726-012-1251-9
   NEGLIA CI, 1985, J BIOL CHEM, V260, P5406
   Orioli M, 2005, J CHROMATOGR B, V827, P109, DOI 10.1016/j.jchromb.2005.04.025
   Otani H, 2008, NEUROSCI LETT, V445, P166, DOI 10.1016/j.neulet.2008.09.008
   Peppa Melpomeni, 2005, Hormones (Athens), V4, P28
   Peppa M, 2008, CURR DIABETES REV, V4, P92, DOI 10.2174/157339908784220732
   QUINN PJ, 1992, MOL ASPECTS MED, V13, P379, DOI 10.1016/0098-2997(92)90006-L
   Rashid I, 2007, FEBS LETT, V581, P1067, DOI 10.1016/j.febslet.2007.01.082
   Reddy V Prakash, 2005, Sci Aging Knowledge Environ, V2005, ppe12, DOI 10.1126/sageke.2005.18.pe12
   Seguin M. C., 1998, U.S. Pat., Patent No. 5792784
   Sheetz MJ, 2002, JAMA-J AM MED ASSOC, V288, P2579, DOI 10.1001/jama.288.20.2579
   Shumaev KB, 2009, BIOCHEMISTRY-MOSCOW+, V74, P461, DOI 10.1134/S0006297909040154
   Szwergold BS, 2005, BIOCHEM BIOPH RES CO, V336, P36, DOI 10.1016/j.bbrc.2005.08.033
   Tarpey MM, 2004, AM J PHYSIOL-REG I, V286, pR431, DOI 10.1152/ajpregu.00361.2003
   Teufel M, 2003, J BIOL CHEM, V278, P6521, DOI 10.1074/jbc.M209764200
   Thornalley PJ, 2005, ANN NY ACAD SCI, V1043, P111, DOI 10.1196/annals.1333.014
   Unno H, 2008, J BIOL CHEM, V283, P27289, DOI 10.1074/jbc.M801657200
   Vander Jagt DL, 2001, CHEM-BIOL INTERACT, V130, P549, DOI 10.1016/S0009-2797(00)00298-2
   Vasan S, 2001, EXPERT OPIN INV DRUG, V10, P1977, DOI 10.1517/13543784.10.11.1977
   Vlassara H, 2002, J INTERN MED, V251, P87, DOI 10.1046/j.1365-2796.2002.00932.x
   Vlassara H, 2005, ANN NY ACAD SCI, V1043, P452, DOI 10.1196/annals.1333.051
   *WHO DEP NONC DIS, 1999, DEF DIAGN CLASS DIAB
   WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243
   YIM HS, 1995, J BIOL CHEM, V270, P28228
NR 65
TC 2
Z9 2
U1 3
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3776
EI 1744-7674
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD NOV 2
PY 2015
VL 25
IS 11
BP 1319
EP 1339
DI 10.1517/13543776.2015.1064899
PG 21
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DC6PL
UT WOS:000369342000001
PM 26372004
DA 2018-12-27
ER

PT J
AU Hawas, U
   Eltomy, S
   Nassif, R
   El-Hossary, G
   AbouZid, S
AF Hawas, U.
   Eltomy, S.
   Nassif, R.
   El-Hossary, G.
   AbouZid, S.
TI RETRACTED: A new antifungal labdane diterpene from the leaves of Saraca
   indica(Retracted article.See vol.30,pg.2505,2016)
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Retracted Publication
DE Saraca indica; labdane diterpene; epoxy marrubiinic acid; antifungal;
   cytotoxicity
ID FLAVONOIDS; BARK
AB A new labdane diterpene, along with 10 known sterols and flavonoids, was isolated from the hydroalcoholic extract of the leaves of Saraca indica. The chemical structure of the new compound was identified as 6,9-epoxy marrubiinic acid on the basis of spectroscopic analyses including two-dimensional NMR. The antimicrobial potential of the new compound was evaluated against Gram-positive and Gram-negative bacteria as well as fungi. It showed a significant antifungal activity against Geotrichum candidum with MIC 0.48g/mL. It also showed potential cytotoxicity against human cancer cell lines with IC50 ranging from 1.07 to 1.29g/well.
C1 [Hawas, U.] King Abdulaziz Univ, Fac Marine Sci, Marine Chem Dept, Jeddah 21413, Saudi Arabia.
   [Hawas, U.] Natl Res Ctr, Phytochem & Plant Systemat Dept, Giza, Egypt.
   [Eltomy, S.] Natl Res Ctr, Tanning Mat & Leather Technol Dept, Giza, Egypt.
   [Nassif, R.; El-Hossary, G.] Misr Univ Sci & Technol, Fac Pharm, Dept Pharmacognosy, Giza, Egypt.
   [AbouZid, S.] Beni Suef Univ, Fac Pharm, Dept Pharmacognosy, Bani Suwayf 62111, Egypt.
RP AbouZid, S (reprint author), Natl Res Ctr, Tanning Mat & Leather Technol Dept, Giza, Egypt.
EM sameh.zaid@pharm.bsu.edu.eg
OI Hawas, usama/0000-0003-3276-9001
CR Aguiar RM, 2005, PHYTOCHEMISTRY, V66, P2388, DOI 10.1016/j.phytochem.2005.07.011
   Ajay Sharma, 2011, Asian Journal of Pharmacy and Life Science, V1, P391
   BAUER AW, 1966, AM J CLIN PATHOL, V45, P493
   Conolly JD, 1992, DICT TERPENOIDS, P4506
   Darwish FM, 1992, B FAC SCI ASSIUT U, V45, P21
   Habib M Rowshanul, 2007, Pak J Biol Sci, V10, P4174
   Hawas U. W., 2012, Journal of Medicinal Plants Research, V6, P5604
   Kashyapa K, 2006, USEFUL PLANTS INDIA
   Kokate C K, 2007, PHARMACOGNOSY
   Maruthappan V., 2010, Journal of Pharmacy Research, V3, P17
   Meyre-Silva C., 2005, Farmaco (Lausanne), V60, P321, DOI 10.1016/j.farmac.2005.01.003
   Pradhan P., 2009, Journal of Chemical and Pharmaceutical Research, V1, P62
   Preethi F., 2010, Journal of Pharmacy Research, V3, P491
   Sadhu SK, 2007, J NAT MED, V61, P480, DOI 10.1007/s11418-007-0182-3
   Sainath RS, 2009, EUR REV MED PHARMACO, V13, P371
   SATYAVATI GV, 1970, INDIAN J MED RES, V58, P660
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Ye G, 2006, CHEM NAT COMPD+, V42, P232, DOI 10.1007/s10600-006-0089-3
   Zheng ZP, 2008, FOOD CHEM, V106, P529, DOI 10.1016/j.foodchem.2007.06.037
NR 19
TC 3
Z9 3
U1 1
U2 25
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD NOV 2
PY 2015
VL 29
IS 21
DI 10.1080/14786419.2013.855931
PG 6
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA CQ3AR
UT WOS:000360474400001
PM 24237384
DA 2018-12-27
ER

PT J
AU Parsaik, AK
   Singh, B
   Khosh-Chashm, D
   Mascarenhas, SS
AF Parsaik, Ajay K.
   Singh, Balwinder
   Khosh-Chashm, Darrow
   Mascarenhas, Soniya S.
TI RETRACTED: Efficacy of Ketamine in Bipolar Depression: Systematic Review
   and Meta-analysis (Retracted article. See vol. 24, pg. 307, 2018)
SO JOURNAL OF PSYCHIATRIC PRACTICE
LA English
DT Review; Retracted Publication
DE ketamine; bipolar depression; anhedonia; suicidal ideation
ID RESISTANT MAJOR DEPRESSION; D-ASPARTATE ANTAGONIST; ADD-ON TRIAL;
   ANTIDEPRESSANT EFFICACY; CLINICAL-TRIALS; RECEPTORS; DISORDER;
   DOPAMINE-D-2; REPLICATION; PREVALENCE
AB Objective: To consolidate the evidence from the literature to evaluate the role of ketamine in the treatment of bipolar depression.
   Methods: Major databases, including MEDLINE, EMBASE, Cochrane, and Scopus, were searched through October 2014, for studies reporting the role of ketamine in the treatment of bipolar depression. Only randomized controlled trials were included in the metaanalysis. We calculated standardized mean differences (SMDs) with SE for each study included in the meta-analysis. A random effect model was used to calculate the pooled SMDs. Heterogeneity was assessed using the Cochran Q test and I-2 statistic.
   Results: Of the 721 articles that were screened, 5 studies that enrolled a total of 125 subjects with bipolar depression (mean age, 44.6 +/- 4.3 y and 65.6% females) were included in the systematic review; 3 randomized controlled trials (69 subjects) were included in the meta-analysis. The meta-analysis showed significant improvement in depression among patients receiving a single dose of intravenous ketamine compared with those who received placebo (SMD=-1.01; 95% confidence interval, -1.37, -0.66; P< 0.0001). The maximum improvement was observed 40 minutes after the ketamine infusion. No heterogeneity was observed between the studies (Cochran Q test P= 0.38, I-2= 0%). The 2 studies that were excluded from the meta-analysis also showed significant improvement in depression after ketamine therapy. Individual studies also reported improvement in anhedonia and suicidal ideation after ketamine therapy. None of the subjects had serious side effects, and the side effects were similar between the ketamine and placebo groups.
   Conclusions: This study suggests that ketamine is effective in treatment-resistant bipolar depression and may reduce suicidal ideation and anhedonia.
C1 [Parsaik, Ajay K.; Khosh-Chashm, Darrow] Univ Texas Houston, Sch Med, Dept Psychiat & Behav Sci, 1941 East Rd,BBSB 3208, Houston, TX 77054 USA.
   [Singh, Balwinder] Univ N Dakota, Sch Med & Hlth Sci, Dept Psychiat & Behav Sci, Fargo, ND USA.
   [Singh, Balwinder] Mayo Clin, Dept Neurol, Rochester, MN USA.
   [Mascarenhas, Soniya S.] London Training Coll, Hlth Care Management, London, England.
RP Parsaik, AK (reprint author), Univ Texas Houston, Sch Med, Dept Psychiat & Behav Sci, 1941 East Rd,BBSB 3208, Houston, TX 77054 USA.
EM drajayparsaik@gmail.com
CR Aan Het Rot M, 2012, BIOL PSYCHIAT, V72, P537, DOI 10.1016/j.biopsych.2012.05.003
   Autry AE, 2011, NATURE, V475, P91, DOI 10.1038/nature10130
   Calabrese JR, 2008, BIPOLAR DISORD, V10, P323, DOI 10.1111/j.1399-5618.2007.00500.x
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Diazgranados N, 2010, ARCH GEN PSYCHIAT, V67, P793, DOI 10.1001/archgenpsychiatry.2010.90
   Fond G, 2014, PSYCHOPHARMACOLOGY, V231, P3663, DOI 10.1007/s00213-014-3664-5
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, COCHRANE COLLABORATI, V55, P48
   Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338
   Kapur S, 2002, MOL PSYCHIATR, V7, P837, DOI 10.1038/sj.mp.4001093
   Kapur S, 2001, BIOL PSYCHIAT, V49, P954, DOI 10.1016/S0006-3223(01)01110-6
   Lally N, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.105
   Lara DR, 2013, INT J NEUROPSYCHOPH, V16, P2111, DOI 10.1017/S1461145713000485
   Li NX, 2010, SCIENCE, V329, P959, DOI 10.1126/science.1190287
   Machado-Vieira R, 2008, J CLIN PSYCHIAT, V69, P946, DOI 10.4088/JCP.v69n0610
   Maeng S, 2008, BIOL PSYCHIAT, V63, P349, DOI 10.1016/j.biopsych.2007.05.028
   Merikangas KR, 2007, ARCH GEN PSYCHIAT, V64, P543, DOI 10.1001/archpsyc.64.5.543
   Murrough JW, 2013, AM J PSYCHIAT, V170, P1134, DOI 10.1176/appi.ajp.2013.13030392
   Nock MK, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000123
   Nordentoft M, 2011, ARCH GEN PSYCHIAT, V68, P1058, DOI 10.1001/archgenpsychiatry.2011.113
   Permoda-Osip A, 2014, PSYCHIATR POL, V48, P35
   Post RM, 2011, INT CLIN PSYCHOPHARM, V26, P96, DOI 10.1097/YIC.0b013e3283409419
   Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0
   Vollenweider FX, 2000, J PSYCHIAT RES, V34, P35, DOI 10.1016/S0022-3956(99)00031-X
   Welch J S, 1991, Oncol Nurs Forum, V18, P659
   Zarate CA, 2006, ARCH GEN PSYCHIAT, V63, P856, DOI 10.1001/archpsyc.63.8.856
   Zarate CA, 2012, BIOL PSYCHIAT, V71, P939, DOI 10.1016/j.biopsych.2011.12.010
NR 28
TC 13
Z9 13
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1527-4160
EI 1538-1145
J9 J PSYCHIATR PRACT
JI J. Psychiatr. Pract.
PD NOV
PY 2015
VL 21
IS 6
BP 427
EP 435
DI 10.1097/PRA.0000000000000106
PG 9
WC Psychiatry
SC Psychiatry
GA DD1VT
UT WOS:000369711600005
PM 26554325
DA 2018-12-27
ER

PT J
AU Posta, DS
   Camen, D
   Radulov, I
   Berbecea, A
AF Posta, Daniela Sabina
   Camen, Dorin
   Radulov, Isidora
   Berbecea, Adina
TI RETRACTED: Studies Regarding the Heavy Metal Content of the Leaves and
   Soil in Betula Pendula Roth. in the Main Parks of Timisoara, Romania
   (Retracted Article)
SO REVISTA DE CHIMIE
LA English
DT Article; Retracted Publication
DE heavy metals; pollution; birch; parks
AB Leaf and soil were sampled from three parks where there are lots of visitors and lots of pollution because of the heavy traffic and large numbers of cars and because of atmospheric pollution caused by the large companies. In this study on the heavy metals accumulated in the leaves and soil we chose the species Betula pendula Roth. because it has been planted intensely both in groups and isolated in the three locations and because they fix heavy metals in areas polluted by both soil and air.
C1 [Posta, Daniela Sabina; Camen, Dorin; Radulov, Isidora; Berbecea, Adina] Banats Univ Agr Sci & Vet Med King Mihai I Romani, 119 Calea Aradului, Timisoara 300645, Romania.
RP Camen, D (reprint author), Banats Univ Agr Sci & Vet Med King Mihai I Romani, 119 Calea Aradului, Timisoara 300645, Romania.
EM camendorin@yahoo.com
CR ABDUL G., 2011, EGYPT ACAD J BIOL SC, V2, P11
   Ajmone-Marsan F, 2010, WATER AIR SOIL POLL, V213, P121, DOI 10.1007/s11270-010-0372-6
   Al-Alawi MM, 2007, J HAZARD MATER, V148, P43, DOI 10.1016/j.jhazmat.2007.02.001
   ANKLEY GT, 1993, ENVIRON TOXICOL CHEM, V12, P315
   BI XIANGYANG, 2013, CHINESE SCI BULL, V58
   Bolea V., 2006, Analele Institutul de Cercetari si Amenajari Silvice, V49, P67
   CIUPA V., 2011, B AGIR, P3
   Fowler D, 2009, ATMOS ENVIRON, V43, P5193, DOI 10.1016/j.atmosenv.2009.07.068
   GY Z G, 2012, THESIS, P11
   Luo XS, 2012, SCI TOTAL ENVIRON, V421, P17, DOI 10.1016/j.scitotenv.2011.04.020
   Memon AR, 2009, ENVIRON SCI POLLUT R, V16, P162, DOI 10.1007/s11356-008-0079-z
   MILICA T., 2010, SERIES PHYS CHEM TEC, V8, P1
   Nouri J, 2009, ENVIRON EARTH SCI, V59, P315, DOI 10.1007/s12665-009-0028-2
   Rossini Oliva S, 2006, CHEMOSPHERE, V65, P177, DOI 10.1016/j.chemosphere.2006.03.003
   Serbula SM, 2013, AEROSOL AIR QUAL RES, V13, P563, DOI 10.4209/aaqr.2012.06.0153
   Stankovic S, 2013, ENV CHEM SUSTAIN WOR, V3, P151, DOI 10.1007/978-94-007-6836-9_5
   SUMALAN R., 2006, FIZIOLOGIE VEGETALA
   WOOD BRUCE W., NICKEL PLANT DIS, P1
NR 18
TC 0
Z9 0
U1 1
U2 7
PU CHIMINFORM DATA S A
PI BUCHAREST
PA CALEA PLEVNEI NR 139, SECTOR 6, BUCHAREST R-77131, ROMANIA
SN 0034-7752
J9 REV CHIM-BUCHAREST
JI Rev. Chim.
PD NOV
PY 2015
VL 66
IS 11
BP 1857
EP 1859
PG 3
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA DB0QV
UT WOS:000368213500031
DA 2018-12-27
ER

PT J
AU Guo, H
   Xu, YM
   Fu, Q
AF Guo, Hui
   Xu, Yuemin
   Fu, Qiang
TI RETRACTED: Curcumin inhibits growth of prostate carcinoma via
   miR-208-mediated CDKN1A activation (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Prostate cancer (PC); CDKN1A; miR-208
ID PANCREATIC-CANCER CELLS; KAPPA-B ACTIVITY; UP-REGULATION; MIR-21
   EXPRESSION; DIETARY CURCUMIN; IN-VIVO; PROLIFERATION; APOPTOSIS;
   THERAPY; PC-3
AB Prostate cancer (PC) is a prevalent cancer in aged men. Curcumin is an active ingredient that has been extracted from the rhizome of the plant Curcuma longa. Recently, a potential of Curcumin against PC has been reported in PC, whereas the underlying molecular mechanisms are not completely understood. Here, we studied the effects of low-dose Curcumin on PC cell growth. Curcumin (from 0.2 to 0.8 mu mol/l) dose-dependently inhibited the proliferation of PC cells, without affecting cell apoptosis. Further analyses showed that Curcumin dose-dependently increased a cell cycle suppressor CDKN1A at protein levels, but not mRNA levels, in PC cells, suggesting that Curcumin may regulate the translation of CDKN1A, as well as a possible involvement of miRNA intervention. From all CDKN1A-3'-UTR-binding miRNAs, we found that miR-208 was specifically inhibited in PC cells dose-dependently by Curcumin. Moreover, miR-208 was found to bind CDKN1A to suppress its expression. In a loss-of-function experiment, PC cells that overexpressed miR-208 failed to decrease cell proliferation in response to Curcumin. Together, these data suggest that Curcumin inhibits growth of PC via miR-208-mediated CDKN1A activation.
C1 [Guo, Hui; Xu, Yuemin; Fu, Qiang] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Urol, Shanghai 200233, Peoples R China.
RP Fu, Q (reprint author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Urol, Shanghai 200233, Peoples R China.
EM fuqiang_15@163.com
CR Aggarwal BB, 2008, CANCER BIOL THER, V7, P1438
   Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158/0008-5472.CAN-09-4598
   Cetnar JP, 2014, DRUG DISCOV TODAY, V19, P1483, DOI 10.1016/j.drudis.2014.07.006
   Chang AJ, 2014, NAT REV CLIN ONCOL, V11, P308, DOI 10.1038/nrclinonc.2014.68
   Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038/sj.onc.1207284
   Cort A, 2013, J PHYSIOL BIOCHEM, V69, P289, DOI 10.1007/s13105-012-0211-x
   Dorai Thambi, 2014, J Cancer Ther, V5, P369
   Fu XY, 2015, CELL PHYSIOL BIOCHEM, V35, P489, DOI 10.1159/000369714
   Ge Z, 2014, TUMOR BIOL, V35, P12441, DOI 10.1007/s13277-014-2562-0
   Gillies K, 2013, CELL PHYSIOL BIOCHEM, V32, P74, DOI 10.1159/000350126
   Horie S, 2012, KOREAN J UROL, V53, P665, DOI 10.4111/kju.2012.53.10.665
   Huang SQ, 2012, BRAZ J MED BIOL RES, V45, P995, DOI [10.1590/S0100-879X2012001100001, 10.1590/S0100-879X2012007500126]
   Huang SQ, 2014, TUMOR BIOL, V35, P6265, DOI 10.1007/s13277-014-1818-z
   Jian H, 2015, CELL SIGNAL, V27, P1208, DOI 10.1016/j.cellsig.2015.02.027
   Li HP, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-196
   Li LQ, 2012, CELL PHYSIOL BIOCHEM, V30, P631, DOI 10.1159/000341444
   Li TY, 2014, CELL PHYSIOL BIOCHEM, V34, P1351, DOI 10.1159/000366342
   Lin RK, 2015, CELL PHYSIOL BIOCHEM, V35, P926, DOI 10.1159/000369749
   Liu AA, 2014, CELL BIOCHEM BIOPHYS, V69, P341, DOI 10.1007/s12013-013-9805-3
   Manju M, 2013, FISH PHYSIOL BIOCHEM, V39, P1323, DOI 10.1007/s10695-013-9786-6
   Mihailidou C, 2010, CELL PHYSIOL BIOCHEM, V25, P761, DOI 10.1159/000315096
   Pu YF, 2013, CELL PHYSIOL BIOCHEM, V32, P1167, DOI 10.1159/000354516
   Qian Y, 2015, CELL PHYSIOL BIOCHEM, V35, P1381, DOI 10.1159/000373959
   Shankar S, 2007, INT J ONCOL, V30, P905
   Sicard F, 2013, MOL THER, V21, P986, DOI 10.1038/mt.2013.35
   Stockl S, 2013, CELL PHYSIOL BIOCHEM, V31, P703, DOI 10.1159/000350089
   Sundram V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035368
   Tavano F, 2012, PANCREAS, V41, P1280, DOI 10.1097/MPA.0b013e31824c11f4
   Wang W, 2015, TUMOR BIOL, V36, P447, DOI 10.1007/s13277-014-2674-6
   Wei XC, 2013, ANTICANCER RES, V33, P1343
   Wei XC, 2012, ONCOL LETT, V4, P279, DOI 10.3892/ol.2012.710
   Wong YNS, 2014, NAT REV CLIN ONCOL, V11, P365, DOI 10.1038/nrclinonc.2014.72
   Wu X, 2014, CELL PHYSIOL BIOCHEM, V34, P506, DOI 10.1159/000363018
   Xia Q, 2014, TUMOR BIOL, V35, P8537, DOI 10.1007/s13277-014-2368-0
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
NR 35
TC 21
Z9 22
U1 5
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2015
VL 36
IS 11
BP 8511
EP 8517
DI 10.1007/s13277-015-3592-y
PG 7
WC Oncology
SC Oncology
GA CY1CA
UT WOS:000366143100035
PM 26032092
DA 2018-12-27
ER

PT J
AU Liu, G
   Zhu, ZJ
   Lang, F
   Li, B
   Gao, DJ
AF Liu, Gang
   Zhu, Zengjun
   Lang, Fang
   Li, Bao
   Gao, Dianjun
TI RETRACTED: Clinical significance of CUL4A in human prostate cancer
   (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Prostate cancer; CUL4A; P53; Proliferation; Targeted therapy
ID HUMAN HOMOLOG; PROTEOLYSIS; OVEREXPRESSION; PROTEIN; CELLS; GENE
AB Aberrant expression of the Cullin 4A (CUL4A) is found in many tumor types, but the functions and mechanism of CUL4A in prostate cancer (PCa) development and progression remain largely unknown. The aim of this study was to investigate the possible role of CUL4A in prostate tumorigenesis. Immunohistochemistry was used to examine CUL4A expression in human PCa tissues and BPH tissues. Cell proliferation was assessed by MTT, and migration and invasion were analyzed by Transwell and Matrigel assays after CUL4A knockdown in PCa in vitro. The results showed that CUL4A protein was overexpressed in 86.21 % of PCa tissues. CUL4A knockdown with siRNA in PCa cells decreased cell proliferation, migration, and invasion. Mechanistically, CUL4A could modulate the expression of P53 in PCa cells. Our results indicate that CUL4A overexpression play an oncogenic role in the pathogenesis of PCa, and CUL4A may be a potential therapeutic target for PCa.
C1 [Liu, Gang; Zhu, Zengjun; Lang, Fang; Li, Bao; Gao, Dianjun] Affiliated Hosp Weifang Med Univ, Dept Urol, Weifang, Shandong, Peoples R China.
RP Zhu, ZJ (reprint author), Affiliated Hosp Weifang Med Univ, Dept Urol, 2428 Yuhe Rd, Weifang, Shandong, Peoples R China.
EM drzhzj6@163.com
CR Birner P, 2012, J CLIN PATHOL, V65, P507, DOI 10.1136/jclinpath-2011-200463
   Bondar T, 2006, MOL CELL BIOL, V26, P2531, DOI 10.1128/MCB.26.7.2531-2539.2006
   El-Mahdy MA, 2006, J BIOL CHEM, V281, P13404, DOI 10.1074/jbc.M511834200
   Gupta A, 2002, INT J RADIAT ONCOL, V52, P822, DOI 10.1016/S0360-3016(01)02739-0
   Hung MS, 2011, J CELL MOL MED, V15, P350, DOI 10.1111/j.1582-4934.2009.00971.x
   Lee J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00021
   Li BH, 2006, BLOOD, V107, P4291, DOI 10.1182/blood-2005-08-3349
   Liu LR, 2009, MOL CELL, V34, P451, DOI 10.1016/j.molcel.2009.04.020
   Ma Y, 2014, ONCOTARGET, V5, P9169, DOI 10.18632/oncotarget.2396
   Nag A, 2004, CANCER RES, V64, P8152, DOI 10.1158/0008-5472.CAN-04-2598
   Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200
   Schindl M, 2007, ANTICANCER RES, V27, P949
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Sugasawa K, 2009, MOL CELL, V34, P403, DOI 10.1016/j.molcel.2009.05.009
   Zhang L, 2011, ASIAN J ANDROL, V13, P574, DOI 10.1038/aja.2010.126
NR 15
TC 2
Z9 3
U1 3
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2015
VL 36
IS 11
BP 8553
EP 8558
DI 10.1007/s13277-015-3580-2
PG 6
WC Oncology
SC Oncology
GA CY1CA
UT WOS:000366143100040
PM 26036759
DA 2018-12-27
ER

PT J
AU Zhao, J
   Kong, ZY
   Xu, F
   Shen, W
AF Zhao, Jian
   Kong, Zhongyu
   Xu, Feng
   Shen, Wei
TI RETRACTED: A role of MMP-14 in the regulation of invasiveness of
   nasopharyngeal carcinoma (retracted article)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Matrix metalloproteinase 14 (MMP-14); Nasopharyngeal carcinoma (NPC);
   Metastasis; Epithelial-mesenchymal transition (EMT)
ID CELL-LUNG-CANCER; TYPE-1 MATRIX-METALLOPROTEINASE; FOXO1 NUCLEAR
   EXCLUSION; GASTRIC-CANCER; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE;
   SIGNALING PATHWAYS; COLORECTAL-CANCER; LARYNX-CARCINOMA; MMP9 ACTIVATION
AB Although matrix metalloproteinase 14 (MMP-14) has been shown to play a substantial role in the carcinogenesis of some types of cancer, its involvement in the pathogenesis of nasopharyngeal carcinoma (NPC) has not been reported. Here, we analyzed MMP-14 levels in the NPC specimens from patients and compared with the paired normal nasopharynx (NNP) tissues. We found that NPC had significantly higher messenger RNA (mRNA) and protein levels of MMP-14. Moreover, higher levels of MMP-14 correlated with more advanced status of clinical stage and lymphatic metastasis. In vitro, MMP-14 levels determined the potential of invasiveness of NPC cells, possibly through induction of EMT-associated genes. Our data thus highlight MMP-14 as a novel therapeutic target for NPC.
C1 [Zhao, Jian; Kong, Zhongyu; Xu, Feng; Shen, Wei] Shanghai Univ Tradit Chinese Med, Putuo Hosp, Dept Otorhinolaryngol, Shanghai 200062, Peoples R China.
RP Shen, W (reprint author), Shanghai Univ Tradit Chinese Med, Putuo Hosp, Dept Otorhinolaryngol, 164 Lanxi Rd, Shanghai 200062, Peoples R China.
EM wei_shen4@163.com
CR Adley BP, 2009, GYNECOL ONCOL, V112, P319, DOI 10.1016/j.ygyno.2008.09.025
   Ahmad R, 2014, CELL PHYSIOL BIOCHEM, V34, P929, DOI 10.1159/000366310
   Alcantara MB, 2013, CELL PHYSIOL BIOCHEM, V31, P487, DOI 10.1159/000350069
   Atkinson JM, 2007, EUR J CANCER, V43, P1764, DOI 10.1016/j.ejca.2007.05.009
   Baghy K, 2012, J HISTOCHEM CYTOCHEM, V60, P262, DOI 10.1369/0022155412438104
   Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-1
   Chou J, 2008, HEAD NECK-J SCI SPEC, V30, P946, DOI 10.1002/hed.20833
   Davidson B., 2002, Arkhiv Patologii, V64, P47
   Ding H, 2014, TUMOR BIOL, V35, P9987, DOI 10.1007/s13277-014-2067-x
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Gan Y. Y., 1996, Annals Academy of Medicine Singapore, V25, P71
   Harrison GM, 2006, ONCOL REP, V15, P199
   He L, 2013, DIGEST DIS SCI, V58, P1264, DOI 10.1007/s10620-012-2513-9
   Jian H, 2014, TUMOR BIOL, V35, P11051, DOI 10.1007/s13277-014-2409-8
   Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371
   Lan HY, 2011, CONTRIB NEPHROL, V170, P75, DOI 10.1159/000324949
   Laudanski P, 2010, FOLIA HISTOCHEM CYTO, V48, P101, DOI 10.2478/v10042-009-0085-0
   Liu G, 2014, TUMOR BIOL, V35, P9801, DOI 10.1007/s13277-014-2273-6
   Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Michael M, 1999, J CLIN ONCOL, V17, P1802, DOI 10.1200/JCO.1999.17.6.1802
   Nishida Y, 2008, CANCER RES, V68, P9096, DOI 10.1158/0008-5472.CAN-08-2522
   Pei J, 2014, TUMOR BIOL, V35, P6673, DOI 10.1007/s13277-014-1850-z
   Rhee JS, 2002, TRENDS CELL BIOL, V12, P209, DOI 10.1016/S0962-8924(02)02280-8
   Song HT, 2014, TUMOR BIOL, V35, P6679, DOI 10.1007/s13277-014-1883-3
   Tao Qian, 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000312
   Tetu B, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1503
   Tobar N, 2014, CARCINOGENESIS, V35, P1770, DOI 10.1093/carcin/bgu061
   Ulasov I, 2014, BBA-REV CANCER, V1846, P113, DOI 10.1016/j.bbcan.2014.03.002
   Wang F, 2014, TUMOR BIOL, V35, P8653, DOI 10.1007/s13277-014-2131-6
   Wang XR, 2014, TUMOR BIOL, V35, P8715, DOI 10.1007/s13277-014-2147-y
   Wang YZ, 2014, TUMOR BIOL, V35, P9815, DOI 10.1007/s13277-014-2237-x
   Weng CJ, 2012, ANN SURG ONCOL, V19, pS319, DOI 10.1245/s10434-011-1736-x
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Xie M, 2014, CELL PHYSIOL BIOCHEM, V33, P1475, DOI 10.1159/000358712
   Yang B, 2013, NEOPLASMA, V60, P254, DOI 10.4149/neo_2013_034
   Yang CQ, 2014, CELL PHYSIOL BIOCHEM, V34, P266, DOI 10.1159/000362997
   Yang X, 2013, CELL PHYSIOL BIOCHEM, V32, P1288, DOI 10.1159/000354527
   Ye YH, 2014, TUMOR BIOL, V35, P10891, DOI 10.1007/s13277-014-2383-1
   Zarrabi K, 2011, J BIOL CHEM, V286, P33167, DOI 10.1074/jbc.M111.256644
   Zhang HY, 2009, EUR ARCH OTO-RHINO-L, V266, P1427, DOI 10.1007/s00405-009-0943-6
   Zhang SX, 2014, CELL PHYSIOL BIOCHEM, V33, P1484, DOI 10.1159/000358713
   Zhou HY, 2014, ONCOL LETT, V7, P1395, DOI 10.3892/ol.2014.1920
   Zhou X, 2014, TUMOR BIOL, V35, P9381, DOI 10.1007/s13277-014-2232-2
NR 43
TC 7
Z9 9
U1 4
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2015
VL 36
IS 11
BP 8609
EP 8615
DI 10.1007/s13277-015-3558-0
PG 7
WC Oncology
SC Oncology
GA CY1CA
UT WOS:000366143100047
PM 26040767
DA 2018-12-27
ER

PT J
AU Chen, L
   Xu, L
   Wang, G
AF Chen, Lei
   Xu, Lei
   Wang, Gang
TI RETRACTED: Regulation of MET-mediated proliferation of thyroid carcinoma
   cells by miR-449b (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Thyroid carcinoma (TC); MiR-449b; MicroRNAs(miRNAs); Cancercell
   proliferation; Cancercell apoptosis; MET (hepatocyte growth factor
   receptor)
ID C-MET; CANCER-CELLS; IN-VITRO; ACTIVATION; GROWTH; MODEL; METASTASIS;
   PATHWAY; RISK; VIVO
AB Thyroid carcinoma (TC) is a lethal cancer worldwide, whereas its carcinogenesis is not fully understood. Although growing evidence has demonstrated that dysregulation of microRNAs (miRNAs) contributes to the development of various cancers, the role of miRNAs in the pathogenesis of TC is poorly characterized. Here, we analyzed the levels of miR-449b in TC tissues and detected significantly lower miR-449b levels in TC tissues. Moreover, the low miR-449b levels were associated with poor survival. We then overexpressed miR-449b by miRNA mimic transfection and inhibited miR-449b by miRNA antisense transfection. Cell growth was analyzed by CCK-8 assay and MTT assay, and apoptosis and cell proliferation were analyzed by flow cytometry. Overexpression of miR-449b significantly inhibited cell growth, while depletion of miR-449b increased cell growth. Moreover, the effects of miR-449b on cell growth were through modulation of cell proliferation rather than through modulation of cell apoptosis. Targeted genes were predicted by a bioinformatics algorithm and confirmed by a dual luciferase reporter assay, showing that miR-449b binds to the 3'-UTR of MET (hepatocyte growth factor receptor) mRNA, to inhibit its expression in TC cells. MET levels were regulated by miR-449b in TT cells. Together, we show that reduced miR-449b levels in TT tissues may promote TC growth, through MET-mediated cell proliferation.
C1 [Chen, Lei; Xu, Lei; Wang, Gang] Tongji Univ, Peoples Hosp 10, Dept Gen Surg, Shanghai 200072, Peoples R China.
RP Wang, G (reprint author), Tongji Univ, Peoples Hosp 10, Dept Gen Surg, 301 Middle Yanchang Rd, Shanghai 200072, Peoples R China.
EM wang_gang_15@163.com
CR Bao JQ, 2012, J BIOL CHEM, V287, P21686, DOI 10.1074/jbc.M111.328054
   Behr TM, 1997, CANCER RES, V57, P5309
   Bentzien F, 2013, THYROID, V23, P1569, DOI 10.1089/thy.2013.0137
   Chen JY, 2015, TUMOR BIOL, V36, P1081, DOI 10.1007/s13277-014-2731-1
   Chung TKH, 2012, INT J CANCER, V130, P1036, DOI 10.1002/ijc.26060
   Coronnello C, 2013, NUCLEIC ACIDS RES, V41, pW159, DOI 10.1093/nar/gkt379
   Deng XZ, 2015, CELL PHYSIOL BIOCHEM, V35, P71, DOI 10.1159/000369676
   Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   Dzikiewicz-Krawczyk A, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-43
   Fang YT, 2013, ONCOL REP, V30, P399, DOI 10.3892/or.2013.2465
   Garouniatis A, 2013, TUMOR BIOL, V34, P2109, DOI 10.1007/s13277-013-0776-1
   Grabellus F, 2010, TUMOR BIOL, V31, P157, DOI 10.1007/s13277-010-0021-0
   Huang JW, 2014, TUMOR BIOL, V35, P5833, DOI 10.1007/s13277-014-1774-7
   Koo BS, 2014, ANN SURG ONCOL, V21, P2310, DOI 10.1245/s10434-014-3553-5
   Li YC, 2011, TUMOR BIOL, V32, P1217, DOI 10.1007/s13277-011-0225-y
   Liu G, 2014, TUMOR BIOL, V35, P9801, DOI 10.1007/s13277-014-2273-6
   Liu H, 2014, TUMOR BIOL, V35, P9139, DOI 10.1007/s13277-014-2178-4
   Mei Q, 2014, CANCER SCI, V105, P755, DOI 10.1111/cas.12436
   Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Samadi AK, 2012, TUMOR BIOL, V33, P1179, DOI 10.1007/s13277-012-0363-x
   Scheffer AR, 2014, WORLD J UROL, V32, P353, DOI 10.1007/s00345-012-1010-2
   Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012
   Ulbrich C, 2011, CELL PHYSIOL BIOCHEM, V28, P185, DOI 10.1159/000331730
   Wan L, 2014, CELL PHYSIOL BIOCHEM, V34, P1273, DOI 10.1159/000366337
   Wang F, 2014, TUMOR BIOL, V35, P2723, DOI 10.1007/s13277-013-1359-x
   Wang F, 2014, TUMOR BIOL, V35, P8653, DOI 10.1007/s13277-014-2131-6
   Wang H, 2013, TUMOR BIOL, V34, P1635, DOI 10.1007/s13277-013-0696-0
   Yang XJ, 2009, GENE DEV, V23, P2388, DOI 10.1101/gad.1819009
   Zhang J, 2014, TUMOR BIOL, V35, P379, DOI 10.1007/s13277-013-1053-z
NR 30
TC 6
Z9 6
U1 5
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2015
VL 36
IS 11
BP 8653
EP 8660
DI 10.1007/s13277-015-3619-4
PG 8
WC Oncology
SC Oncology
GA CY1CA
UT WOS:000366143100052
PM 26044563
DA 2018-12-27
ER

PT J
AU Long, JT
   Ou, CW
   Xia, HM
   Zhu, YF
   Liu, DY
AF Long, Jianting
   Ou, Caiwen
   Xia, Haoming
   Zhu, Yifan
   Liu, Dayue
TI RETRACTED: MiR-503 inhibited cell proliferation of human breast cancer
   cells by suppressing CCND1 expression (Retracted article. See April,
   2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE miR-503; Breast cancer; CCND1; Cell proliferation; Cell cycle
ID TUMOR-SUPPRESSOR; LUNG-CANCER; COLORECTAL-CANCER; INVASION; TARGETS;
   METASTASIS; ONCOGENE; THERAPY; KINASE; BETA
AB Breast cancer is one of the most common malignancies and a major cause of cancer-related mortality all over the world. A growing body of reports revealed that microRNAs play essential roles in the progression of cancers. Aberrant expression of miR-503 has been reported in several kinds of cancer. The aim of the current study was to elucidate the role of miR-503 in the pathogenesis of breast cancer. In the present study, our results suggested that miR-503 expression was markedly downregulated in breast cancer tissues and cells. Overexpression of miR-503 in breast cancer cell lines reduced cell proliferation through inducing G(0)/G(1) cell cycle arrest by targeting CCND1. Together, our findings provide new knowledge regarding the role of miR-503 in the progression of breast cancer and indicate the role of miR-503 as a tumor suppressor microRNA (miRNA) in breast cancer.
C1 [Long, Jianting] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Med Oncol, Guangzhou 510080, Guangdong, Peoples R China.
   [Ou, Caiwen] Southern Med Univ, Key Lab Construct & Detect Guangdong Prov, Guangzhou 510515, Guangdong, Peoples R China.
   [Xia, Haoming; Zhu, Yifan; Liu, Dayue] Sun Yat Sen Univ, Affiliated Hosp 1, Breast Dis Ctr, Dept Surg, Guangzhou 510080, Guangdong, Peoples R China.
RP Liu, DY (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Breast Dis Ctr, Dept Surg, Guangzhou 510080, Guangdong, Peoples R China.
EM dayueliu2015@163.com
FU Science and Technology Planning Project of Guangdong Province
   [2012B031800055]; National Natural Science Foundation of China
   [31400858]
FX This work was supported by Science and Technology Planning Project of
   Guangdong Province (2012B031800055) and National Natural Science
   Foundation of China (31400858). All authors designed the study together,
   performed the experiment together, analyzed the data, and wrote the
   paper; all authors approved the final manuscript.
CR Brandt J, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-014-0429-x
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chai J, 2015, TUMOR BIOL, V36, P1313, DOI 10.1007/s13277-014-2766-3
   Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905
   Chong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114585
   Dalmay T, 2013, ESSAYS BIOCHEM, V54, P29, DOI [10.1042/bse0540029, 10.1042/BSE0540029]
   Feng SJ, 2014, TUMOR BIOL, V35, P12339, DOI 10.1007/s13277-014-2546-0
   Hao ZF, 2015, INT J CLIN EXP MED, V8, P480
   Humphries B, 2015, ONCOTARGET, DOI 10.18632/oncotarget.3052
   Jiang J, 2014, TUMOR BIOL, V35, P10019, DOI 10.1007/s13277-014-2294-1
   Krop IE, 2014, LANCET ONCOL, V15, P689, DOI 10.1016/S1470-2045(14)70178-0
   Li CY, 2012, EXPERT REV PROTEOMIC, V9, P549, DOI [10.1586/EPR.12.49, 10.1586/epr.12.49]
   Liang HW, 2015, J BIOL CHEM, V290, P926, DOI 10.1074/jbc.M114.621409
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Migliaccio I, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0280-0
   Park YH, 2015, BREAST EDINBURGH SCO
   Peng Y, 2014, ONCOL LETT, V7, P1233, DOI 10.3892/ol.2014.1868
   Polioudakis D, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1279-9
   Ruiz-Llorente L, 2014, ONCOTARGET, V5, P2918, DOI 10.18632/oncotarget.1577
   Schaal C, 2014, ADV CANCER RES, V121, P147, DOI 10.1016/B978-0-12-800249-0.00004-4
   Shen SN, 2014, TUMOR BIOL, V35, P631, DOI 10.1007/s13277-013-1087-2
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Sun BY, 2015, BIOMED PHARMACOTHER, V71, P58, DOI 10.1016/j.biopha.2015.02.014
   Sun Q, 2014, PROSTATE, V74, P1613, DOI 10.1002/pros.22878
   Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x
   Valinezhad Orang A, 2014, MECH MIRNA MEDIATED, V2014
   van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107
   Vidaurre S, 2014, J BIOL CHEM, V289, P27182, DOI 10.1074/jbc.M114.558841
   Wang TS, 2014, CHINESE MED J-PEKING, V127, P2357, DOI 10.3760/cma.j.issn.0366-6999.20140318
   Yang Y, 2014, INT J CANCER, V135, P1531, DOI 10.1002/ijc.28799
NR 30
TC 25
Z9 26
U1 3
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2015
VL 36
IS 11
BP 8697
EP 8702
DI 10.1007/s13277-015-3623-8
PG 6
WC Oncology
SC Oncology
GA CY1CA
UT WOS:000366143100057
PM 26047605
OA Bronze
DA 2018-12-27
ER

PT J
AU Du, YH
   Wang, YC
   Zhang, F
   Wu, WB
   Wang, W
   Li, H
   Xia, SJ
   Liu, HT
AF Du, Yiheng
   Wang, Yongchuan
   Zhang, Fei
   Wu, Wenbo
   Wang, Wei
   Li, Hao
   Xia, Shujie
   Liu, Haitao
TI RETRACTED: Regulation of metastasis of bladder cancer cells through the
   WNT signaling pathway (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Bladder cancer (BC); WNT signaling; MMP9; beta-Catenin
ID MMP-9 EXPRESSION; DOWN-REGULATION; APOPTOSIS; PROLIFERATION; PROSTATE;
   GENES; LUNG; ERK
AB Bladder cancer (BC) is the most popular malignant urinary cancer, with the highest incidence and mortality of all genitourinary system tumors worldwide. To date, the molecular regulation of the metastasis of BC remains ill defined. Here, we examined the levels of matrix metallopeptidase 9 (MMP9) and nuclear beta-catenin in the BC specimen. We used lithium chloride (LiCl) to inhibit cytosol beta-catenin phosphorylation and degradation to increase nuclear beta-catenin levels in BC cells. We used IWP-2 to enhance cytosol beta-catenin phosphorylation and degradation to decrease nuclear beta-catenin levels in BC cells. We examined MMP9 levels in these experimental settings by quantitative reverse transcription-PCR (RT-qPCR), Western blot, and ELISA. The cell invasiveness was evaluated by Transwell cell assay. We found significantly higher levels of MMP9 and nuclear beta-catenin in human BC specimen with metastasis, compared to those without metastasis. Moreover, a strong correlation was detected between MMP9 and nuclear beta-catenin. LiCl significantly increased nuclear beta-catenin, resulting in MMP9 activation in BC cells. IWP-2 significantly decreased nuclear beta-catenin, resulting in MMP9 inhibition in BC cells. MMP9 regulated cell invasiveness. Together, these data suggest that the WNT signaling pathway regulates metastasis of BC through activation of MMP9. Therapies targeting the WNT signaling pathway may be a promising treatment for BC.
C1 [Du, Yiheng; Zhang, Fei; Wu, Wenbo; Wang, Wei; Li, Hao; Xia, Shujie; Liu, Haitao] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Urol, 100 Haining Rd, Shanghai 200080, Peoples R China.
   [Wang, Yongchuan] Weifang Hosp Chinese Tradit Med, Dept Urol, Weifang 261041, Peoples R China.
RP Liu, HT (reprint author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Urol, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM liuhaitao4@163.com
FU Shanghai Jiao Tong University Medical and Engineering Collaborative
   Research Fund Project [YG2012MS45]
FX This work was financially supported by the Shanghai Jiao Tong University
   Medical and Engineering Collaborative Research Fund Project
   (YG2012MS45).
CR Ahmad R, 2014, CELL PHYSIOL BIOCHEM, V34, P929, DOI 10.1159/000366310
   Ao N, 2014, CELL PHYSIOL BIOCHEM, V33, P1863, DOI 10.1159/000362964
   Bai YL, 2006, CELL PHYSIOL BIOCHEM, V17, P57, DOI 10.1159/000091464
   Barker N, 2000, BIOESSAYS, V22, P961
   Fan Y, 2014, FEBS J, V281, P1750, DOI 10.1111/febs.12737
   Gray PJ, 2013, CURR OPIN UROL, V23, P429, DOI 10.1097/MOU.0b013e328363de04
   Gu SC, 2014, CELL PHYSIOL BIOCHEM, V34, P1402, DOI 10.1159/000366346
   Guo C, 2012, CELL PHYSIOL BIOCHEM, V30, P123, DOI 10.1159/000339052
   Guo YW, 2013, FEBS J, V280, P4531, DOI 10.1111/febs.12417
   Jiang HL, 2014, CELL PHYSIOL BIOCHEM, V34, P734, DOI 10.1159/000363038
   Kanno T, 2012, CELL PHYSIOL BIOCHEM, V30, P1159, DOI 10.1159/000343306
   Kaplan AL, 2014, NAT REV UROL, V11, P59, DOI 10.1038/nrurol.2013.180
   Lee DK, 2012, CELL PHYSIOL BIOCHEM, V30, P499, DOI 10.1159/000341433
   Li QZ, 2012, CELL PHYSIOL BIOCHEM, V29, P361, DOI 10.1159/000338491
   Lin RK, 2015, CELL PHYSIOL BIOCHEM, V35, P926, DOI 10.1159/000369749
   Noon AR, 2013, NAT REV UROL, V10, P67, DOI [10.1038/nruro1.2012.252, 10.1038/nrurol.2012.252]
   Payton S, 2013, NAT REV UROL, V10, P245, DOI [10.1038/nrurol.2013.85, 10.1038/nrurol.2013.95, 10.1038/nrurol.2013.100]
   Polakis P, 2012, COLD SPRING HARB PER, V4
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Prins PA, 2012, CELL PHYSIOL BIOCHEM, V29, P121, DOI 10.1159/000337593
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Song HY, 2015, CELL PHYSIOL BIOCHEM, V35, P875, DOI 10.1159/000369745
   Tan MY, 2013, CELL PHYSIOL BIOCHEM, V32, P542, DOI 10.1159/000354458
   Tan MY, 2014, J CELL BIOCHEM, V115, P1762, DOI 10.1002/jcb.24842
   Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885
   Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344
   Varol N, 2014, DNA CELL BIOL, V33, P408, DOI 10.1089/dna.2013.2285
   Wang R, 2015, CELL PHYSIOL BIOCHEM, V35, P969, DOI 10.1159/000369753
   Wang XB, 2012, ONCOL LETT, V4, P334, DOI 10.3892/ol.2012.713
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Yang CQ, 2014, CELL PHYSIOL BIOCHEM, V34, P266, DOI 10.1159/000362997
NR 32
TC 11
Z9 13
U1 3
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2015
VL 36
IS 11
BP 8839
EP 8844
DI 10.1007/s13277-015-3563-3
PG 6
WC Oncology
SC Oncology
GA CY1CA
UT WOS:000366143100073
PM 26069102
DA 2018-12-27
ER

PT J
AU Zhang, XT
   Zhang, Z
   Xin, YN
   Ma, XZ
   Xuan, SY
AF Zhang, Xiao-Tao
   Zhang, Zhen
   Xin, Yong-Ning
   Ma, Xue-Zhen
   Xuan, Shi-Ying
TI RETRACTED: Impairment of growth of gastric carcinoma by miR-133-mediated
   Her-2 inhibition (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Gastric carcinoma (GC); MiR-133; MicroRNAs (miRNA); Growth; Apoptosis;
   Her-2
ID MICRORNA TARGETS; FACTOR RECEPTOR; CANCER; METASTASIS; PREDICTION;
   ACTIVATION; INVASION; DATABASE; MIRGEN; MMP7
AB Gastric carcinoma (GC) is a leading cause of cancer-related death in China. Dysregulation of microRNAs (miRNAs) has been shown to contribute to the development of GC, whereas the role of miR-133 in GC is unknown. Here, we analyzed the levels of miR-133 in GC tissues by reverse and quantitative transcription polymerase chain reaction (RT-qPCR). We overexpressed or inhibited miR-133 in GC cells. Cell growth was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and cell apoptosis was evaluated by fluorescence-activated cell sorting (FACS) analysis. Targeted genes were predicted by a bioinformatics algorithm and confirmed by a dual-luciferase reporter assay. We detected lower miR-133 levels in GC tissues compared with normal gastric tissue. Moreover, the low miR-133 levels were correlated with low survival rate. Overexpression of miR-133 inhibited cell growth and promoted apoptosis, while depletion of miR-133 increased cell growth and suppressed apoptosis. Moreover, the 3'-untranslated region (3'UTR) of Her-2, the epidermal growth factor receptor (EGFR) that transduces cell growth signals, appeared to be targeted by miR-133. Together, these data suggest that reduced miR-133 levels in GC tissues promote GC growth, which possibly contributes to a low survival rate of GC patients. MiR-133 may target Her-2 to suppress GC cell growth.
C1 [Zhang, Xiao-Tao; Xin, Yong-Ning; Xuan, Shi-Ying] Ocean Univ China, Coll Med & Pharmaceut, Qingdao 266003, Peoples R China.
   [Zhang, Xiao-Tao; Zhang, Zhen; Ma, Xue-Zhen] Qingdao Canc Hosp, Qingdao 266042, Peoples R China.
   [Xin, Yong-Ning; Xuan, Shi-Ying] Qingdao Municipal Hosp, Qingdao 266021, Peoples R China.
RP Xuan, SY (reprint author), Ocean Univ China, Coll Med & Pharmaceut, Qingdao 266003, Peoples R China.
EM shiying_xuan@163.com
CR Alexiou P, 2010, NUCLEIC ACIDS RES, V38, pD137, DOI 10.1093/nar/gkp888
   Cheng ZG, 2014, CELL SIGNAL, V26, P2667, DOI 10.1016/j.cellsig.2014.08.012
   Coronnello C, 2013, NUCLEIC ACIDS RES, V41, pW159, DOI 10.1093/nar/gkt379
   Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   Dong YJ, 2013, MOL CANCER RES, V11, P1051, DOI 10.1158/1541-7786.MCR-13-0061
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   John Bino, 2006, V342, P101, DOI 10.1385/1-59745-123-1:101
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Li LP, 2014, ONCOL LETT, V8, P1533, DOI 10.3892/ol.2014.2370
   Liu G, 2014, TUMOR BIOL, V35, P9801, DOI 10.1007/s13277-014-2273-6
   Mao D, 2014, TUMOR BIOL, V35, P8217, DOI 10.1007/s13277-014-2095-6
   Megraw M, 2007, NUCLEIC ACIDS RES, V35, pD149, DOI 10.1093/nar/gkl904
   Mei Q, 2014, CANCER SCI, V105, P755, DOI 10.1111/cas.12436
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Tao J, 2012, ONCOL REP, V27, P1967, DOI 10.3892/or.2012.1711
   Wang F, 2014, TUMOR BIOL, V35, P8653, DOI 10.1007/s13277-014-2131-6
   Ye YH, 2014, TUMOR BIOL, V35, P10891, DOI 10.1007/s13277-014-2383-1
   Zhao XN, 2013, FRONT BIOSCI-LANDMRK, V18, P803, DOI 10.2741/4144
   Zhou YF, 2013, SCAND J UROL, V47, P423, DOI 10.3109/00365599.2012.748821
NR 19
TC 8
Z9 8
U1 3
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2015
VL 36
IS 11
BP 8925
EP 8930
DI 10.1007/s13277-015-3637-2
PG 6
WC Oncology
SC Oncology
GA CY1CA
UT WOS:000366143100083
PM 26076812
DA 2018-12-27
ER

PT J
AU Wang, L
   Zhang, YJ
   Lv, WJ
   Lu, JH
   Mu, JS
   Liu, YB
   Dong, P
AF Wang, Lei
   Zhang, Yunjiao
   Lv, Wenjie
   Lu, Jianhua
   Mu, Jiasheng
   Liu, Yingbin
   Dong, Ping
TI RETRACTED: Long Non-coding RNA Linc-ITGB1 Knockdown Inhibits Cell
   Migration and Invasion in GBC-SD/M and GBC-SD Gallbladder Cancer Cell
   Lines (Retracted article. See vol. 92, pg. 1815, 2018)
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article; Retracted Publication
DE epithelial-to-mesenchymal transition; gallbladder cancer; linc-ITGB1;
   metastasis; RNA interference
ID EPITHELIAL-MESENCHYMAL TRANSITION; REPRESSES E-CADHERIN; SURVIVAL;
   PROLIFERATION; CARCINOMA; POLARITY; HOTAIR; TARGET; EMT
AB Gallbladder cancer is a highly aggressive malignancy with a low 5-year survival rate. Despite advances in the molecular understanding of the initiation and progression in gallbladder cancer, treatment modalities such as surgery, radiotherapy, or chemotherapy in advanced cases did not yield promising outcomes. Therefore, it is of great importance to uncover new mechanism underlying gallbladder cancer growth and metastasis. In this study, we identified a differentially expressed long intergenic non-coding RNA, linc-ITGB1, in a pair of higher and lower metastatic gallbladder cancer cell sublines. Then, the potential role of linc-ITGB1 in gallbladder cancer cell proliferation, migration, and invasion was explored using a lentivirus-mediated RNA interference system. Functional analysis showed that knockdown of linc-ITGB1 significantly inhibited gallbladder cancer cell proliferation. Moreover, cell migration and invasion were reduced by over twofold in linc-ITGB1 knockdown cells probably due to upregulation of beta-catenin and downregulation of vimentin, slug, and TCF8. In conclusion, linc-ITGB1 potentially promoted gallbladder cancer invasion and metastasis by accelerating the process of epithelial-to-mesenchymal transition, and the application of RNA interference targeting linc-ITGB1 might be a potential form of gallbladder cancer treatment in advanced cases.
C1 [Wang, Lei; Zhang, Yunjiao; Lv, Wenjie; Lu, Jianhua; Mu, Jiasheng; Liu, Yingbin; Dong, Ping] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Gen Surg, Shanghai 200030, Peoples R China.
RP Dong, P (reprint author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Gen Surg, Shanghai 200030, Peoples R China.
EM pingdongdr@163.com
FU National Natural Science Foundation of China [81172026, 81272402,
   81172029]
FX This study was supported by the National Natural Science Foundation of
   China (grant nos. 81172026, 81272402, 81172029).
CR Alves CP, 2013, STEM CELLS, V31, P2827, DOI 10.1002/stem.1547
   Nieto MA, 2012, SEMIN CANCER BIOL, V22, P361, DOI 10.1016/j.semcancer.2012.05.003
   Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224
   Cho JY, 2010, ARCH SURG-CHICAGO, V145, P128, DOI 10.1001/archsurg.2009.261
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Gloss B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-3
   Gourgiotis S, 2008, AM J SURG, V196, P252, DOI 10.1016/j.amjsurg.2007.11.011
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hajra KM, 2002, CANCER RES, V62, P1613
   Huszthy PC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006314
   Isin M, 2014, CLIN CHIM ACTA, V431, P255, DOI 10.1016/j.cca.2014.02.010
   Jeong IH, 2009, EUR SURG RES, V42, P203, DOI 10.1159/000205974
   Kallifatidis G, 2008, CANCER GENE THER, V15, P231, DOI 10.1038/sj.cgt.7701097
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kim T, 2014, P NATL ACAD SCI USA, V111, P4173, DOI 10.1073/pnas.1400350111
   Li CH, 2013, INT J BIOCHEM CELL B, V45, P1895, DOI 10.1016/j.biocel.2013.05.030
   Li LH, 2011, CANCER CHEMOTH PHARM, V68, P207, DOI 10.1007/s00280-010-1468-9
   Li W, 2014, GASTROENTEROLOGY, V146, P1714, DOI 10.1053/j.gastro.2014.03.002
   Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107
   Liu Ying-bin, 2006, Zhonghua Yi Xue Za Zhi, V86, P2117
   Matsushita S, 2014, CANCER SCI, V105, P272, DOI 10.1111/cas.12354
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Miller G, 2008, EJSO-EUR J SURG ONC, V34, P306, DOI 10.1016/j.ejso.2007.07.206
   Ono H, 2014, CANCER MED-US, V3, P632, DOI 10.1002/cam4.220
   Ouchi Kiyoaki, 2002, J Hepatobiliary Pancreat Surg, V9, P256, DOI 10.1007/s005340200028
   Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Takahashi K, 2014, HEPATOLOGY, V60, P744, DOI 10.1002/hep.27043
   Wakai T, 2003, ANN SURG ONCOL, V10, P447, DOI 10.1245/ASO.2003.06.014
   Wakai T, 2001, BRIT J SURG, V88, P675, DOI 10.1046/j.1365-2168.2001.01749.x
   Wang SJ, 2008, J CLIN ONCOL, V26, P2112, DOI 10.1200/JCO.2007.14.7934
   Wu XS, 2014, CANCER BIOL THER, V15, P806, DOI 10.4161/cbt.28584
   Xiong L, 2014, CELL TISSUE RES, V355, P365, DOI 10.1007/s00441-013-1752-1
   Xu MD, 2014, MODERN PATHOL, V27, P1310, DOI 10.1038/modpathol.2014.33
   Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004
   Yang H, 2013, BIOCHEM PHARMACOL, V85, P1761, DOI 10.1016/j.bcp.2013.04.020
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zhang H, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-37
   Zhu AX, 2010, ONCOLOGIST, V15, P168, DOI 10.1634/theoncologist.2009-0302
   Zong HJ, 2014, MOL BIOL REP, V41, P4507, DOI 10.1007/s11033-014-3321-4
NR 42
TC 11
Z9 12
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-0277
EI 1747-0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD NOV
PY 2015
VL 86
IS 5
BP 1064
EP 1071
DI 10.1111/cbdd.12573
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA CX0RJ
UT WOS:000365404100012
PM 25893892
DA 2018-12-27
ER

PT J
AU Lu, HC
   Ma, J
   Zhuang, Z
   Zhang, Y
   Cheng, HL
   Shi, JX
AF Lu, Hu-Chen
   Ma, Jun
   Zhuang, Zong
   Zhang, Yao
   Cheng, Hui-Lin
   Shi, Ji-Xin
TI RETRACTED: Retinoic acid-incorporated glycol chitosan nanoparticles
   inhibit the expression of Ezh2 in U118 and U138 human glioma cells
   (Retracted article. See vol. 13, pg. 4939, 2016)
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article; Retracted Publication
DE glioblastoma multiforme; cell cycle arrest; palliation; glycol chitosan;
   retinoic acid
ID METHYLTRANSFERASE GENE EZH2; ALL-TRANS; DRUG-DELIVERY; MALIGNANT
   GLIOMAS; CANCER; DIFFERENTIATION; NANOTECHNOLOGY; MUTATIONS; COMPLEXES;
   APOPTOSIS
AB At present, one of the most life threatening types of adult brain tumor is glioblastoma multiforme (GBM). The molecular mechanism underlying the progression of GBM remains to be fully elucidated. The modern method of clinical treatment has only improved the average survival rates of a newly diagnosed patients with GBM by 15 months. Therefore, the discovery of novel molecules, which are involved in glioma inhibition is required. In the present study, U118 and U138 human glioma cells were transfected with all-trans retinoic acid (RA)-incorporated glycol chitosan (GC) nanoparticles. An MTT assay was used for the analysis of cell proliferation and flow cytometric analysis and ssDNA detection assays were performed for the determination of induction of cell apoptosis. Cell cycle distribution was analyzed by flow cytometry. Exposure of the U118 and U138 human glioma cells to the RA-incorporated GC nanoparticles for 24 h resulted in a concentration-dependent inhibition of cell proliferation. Among the range of experimental RA concentrations, the minimum effective treatment concentration was 10 mu M, with a half maximal inhibitory concentration of 25 mu M. The results also demonstrated that RA transfection resulted in the inhibition of cell proliferation, inhibition of the expression of Ezh2, and apoptosis through the mitochondrial signaling pathway by a decrease in membrane potential, the release of cytochrome c, and cell cycle arrest in the G(0)/G(1) phase.
C1 [Lu, Hu-Chen; Zhuang, Zong; Cheng, Hui-Lin; Shi, Ji-Xin] Nanjing Univ, Sch Clin Med, Jingling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China.
   [Ma, Jun; Zhang, Yao] Nanjing Med Univ, Nanjing Brain Hosp, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China.
RP Shi, JX (reprint author), Nanjing Univ, Sch Clin Med, Jingling Hosp, Dept Neurosurg, 305 Zhongshan East Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM shijixin66@outlook.com
CR Bharali DJ, 2009, INT J NANOMED, V4, P1
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chung KD, 2012, INT J PHARMACEUT, V422, P454, DOI 10.1016/j.ijpharm.2011.10.057
   Crocetti E, 2012, EUR J CANCER, V48, P1532, DOI 10.1016/j.ejca.2011.12.013
   Defer GL, 1997, J NEURO-ONCOL, V34, P169, DOI 10.1023/A:1005701507111
   Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621
   Giannini F, 1997, INT J CANCER, V70, P194
   HUANG ME, 1988, BLOOD, V72, P567
   Jain KK, 2005, TECHNOL CANCER RES T, V4, P407, DOI 10.1177/153303460500400408
   Jeong YI, 2006, J PHARM SCI-US, V95, P2348, DOI 10.1002/jps.20586
   KALEMKERIAN GP, 1994, CELL GROWTH DIFFER, V5, P55
   Kim K, 2010, J CONTROL RELEASE, V146, P219, DOI 10.1016/j.jconrel.2010.04.004
   KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511
   Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005
   LEHMAN PA, 1988, J INVEST DERMATOL, V91, P56, DOI 10.1111/1523-1747.ep12463289
   Morris-Kay G, 1992, RETINOIDS NORMAL DEV, P1339
   Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620
   NOLL E, 1994, DEVELOPMENT, V120, P649
   Norden AD, 2006, NEUROLOGIST, V12, P279, DOI 10.1097/01.nrl.0000250928.26044.47
   Orzan F, 2011, NEUROPATH APPL NEURO, V37, P381, DOI 10.1111/j.1365-2990.2010.01132.x
   Prezioso C, 2011, FEBS LETT, V585, P2067, DOI 10.1016/j.febslet.2011.04.062
   Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496
   Sinha R, 2006, MOL CANCER THER, V5, P1909, DOI 10.1158/1535-7163.MCT-06-0141
   Stummer W, 2009, CURR OPIN NEUROL, V22, P645, DOI 10.1097/WCO.0b013e3283320165
   Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   SZUTS EZ, 1991, ARCH BIOCHEM BIOPHYS, V287, P297, DOI 10.1016/0003-9861(91)90482-X
   Tanaka S, 2013, NAT REV CLIN ONCOL, V10, P14, DOI 10.1038/nrclinonc.2012.204
   Thunemann AF, 2000, MACROMOLECULES, V33, P6878, DOI 10.1021/ma000416x
   Thunemann AF, 2000, MACROMOLECULES, V33, P5906
   Tsang DPF, 2011, J GASTROEN HEPATOL, V26, P19, DOI 10.1111/j.1440-1746.2010.06447.x
   Wang JJ, 2011, INT J NANOMED, V6, P765, DOI 10.2147/IJN.S17296
   Yoo HS, 2005, J CONTROL RELEASE, V103, P235, DOI 10.1016/j.jconrel.2004.11.033
   Zhang RJ, 2012, ONCOL REP, V28, P2278, DOI 10.3892/or.2012.2033
NR 34
TC 2
Z9 3
U1 3
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD NOV
PY 2015
VL 12
IS 5
BP 6642
EP 6648
DI 10.3892/mmr.2015.4294
PN A
PG 7
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA CW3JP
UT WOS:000364888900032
PM 26351866
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Zhou, SH
   Ouyang, XP
   Tian, SW
   Yin, WL
   Hu, B
AF Zhou, Shou-hong
   Ouyang, Xin-ping
   Tian, Shao-wen
   Yin, Wei-lan
   Hu, Bi
TI RETRACTED: Apelin-13 Prevents the Delayed Neuropathy Induced by
   Tri-ortho-cresyl Phosphate Through Regulation the Autophagy Flux in Hens
   (Retracted article. See vol. 41, pg. 3160, 2016)
SO NEUROCHEMICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Organophosphorus ester-induced delayed neuropathy; Tri-ortho-cresyl
   phosphate; Apelin-13; Autophagy; Microtubule-associated protein light
   chain-3; p62
ID PERIPHERAL NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; CELL-DEATH;
   ACTIVATION; NEURONS; TOCP; DEGRADATION; PEPTIDE; POLYNEUROPATHY;
   NEUROFILAMENTS
AB Organophosphate-induced delayed neuropathy (OPIDN) is pathologically characterized by the swollen axon containing aggregations of microtubules, neurofilaments, smooth endoplasmic reticulum and multivesicular vesicles. At present, the exact mechanism of OPIDN is unclear and the effective therapeutic methods is not available to counter this syndrome. Recent studies had shown that the autophagy was involved in OPIDN. The adipocytokine Apelin is a peptide, Apelin and its receptor are abundantly expressed in the nervous system. Recent researches illuminated that Apelin was neuroprotective factor and Apelin could regulate the autophagy in vivo and vitro model. So we investigated the effect of Apelin-13 on the OPIDN induced by Tri-ortho-cresyl phosphate (TOCP) in hens and explored the role of autophagy in Apelin-13 preventing OPIDN. Adult Roman hens were given a single dose of 750 mg/kg TOCP by gavage for 21 days to induce OPIDN, and neural dysfunction were detected, and the formation of autophagosomes in spinal cord neurons was observed by transmission electron microscopy, and the molecular markers of autophagy microtubule-associated protein light chain-3 (LC3) and the autophagy substrates p62/SQSTM1 were determined by Western blot analysis. The results demonstrated that the obvious neurological dysfunction such as hindlimb paralysis and paralysis of gait was present, the number of autophagosomes in the neurons of spinal cords was significantly increased, the level of LC3-II and p62 expressions and the ratio of LC3-II/LC3-I in spinal cords and sciatic nerve were significantly increased in the OPIDN model group compared with the control group. Compared with the OPIDN model group, the neurological dysfunction of tens was obviously reduced, the clinical signs scores was significantly decreased, the number of autophagosomes in the neurons of hen spinal cords was significantly decreased, the level of LC3-II and p62 expressions and the ratio of LC3-II/LC3-I in spinal cords and sciatic nerve were significantly decreased in Apelin-13 treatment group. Our results suggested that Apelin-13 prevented against the OPIDN induced by TOCP in hens, which the mechanism might be associated with regulation autophagy flux by Apelin-13.
C1 [Zhou, Shou-hong; Ouyang, Xin-ping; Tian, Shao-wen; Yin, Wei-lan; Hu, Bi] Univ South China, Sch Med, Dept Physiol, Hengyang 421001, Hunan, Peoples R China.
   [Zhou, Shou-hong; Ouyang, Xin-ping; Tian, Shao-wen; Yin, Wei-lan; Hu, Bi] Univ South China, Sch Med, Inst Neurosci, Hengyang 421001, Hunan, Peoples R China.
RP Zhou, SH (reprint author), Univ South China, Sch Med, Dept Physiol, Hengyang 421001, Hunan, Peoples R China.
EM zhoushouhong@126.com
FU construct program of the key discipline in hunan province, China (Basic
   Medicine Sciences in University of South China); Zhengxiang Scholar
   Program of University of South China [2014-004]; National Natural
   Science Foundation of China [81171281]
FX The work was supported by the construct program of the key discipline in
   hunan province, China (Basic Medicine Sciences in University of South
   China), Zhengxiang Scholar Program of University of South China
   (2014-004) and the National Natural Science Foundation of China (Grant
   No. 81171281).
CR Bao HJ, 2015, NEUROCHEM RES, V40, P89, DOI 10.1007/s11064-014-1469-x
   Bodineau L, 2011, ENDOCRINOLOGY, V152, P3492, DOI 10.1210/en.2011-0206
   Carloni S, 2010, AUTOPHAGY, V6, P366, DOI 10.4161/auto.6.3.11261
   Castan-Laurell I, 2011, ENDOCRINE, V40, P1, DOI 10.1007/s12020-011-9507-9
   Chen A, 2013, MOL MED REP, V8, P1011, DOI 10.3892/mmr.2013.1628
   Dancourt J, 2014, AUTOPHAGY, V10, P1470, DOI 10.4161/auto.29468
   de Oliveira GH, 2002, TOXICOL LETT, V136, P143, DOI 10.1016/S0378-4274(02)00295-3
   Emerick GL, 2010, TOXICOL LETT, V192, P238, DOI 10.1016/j.toxlet.2009.10.032
   Fu MM, 2014, AUTOPHAGY, V10, P2079, DOI 10.4161/auto.34451
   Gambalunga A, 2010, CHEM-BIOL INTERACT, V187, P340, DOI 10.1016/j.cbi.2010.01.026
   Gao XG, 2013, NEUROCHEM RES, V38, P916, DOI 10.1007/s11064-013-0996-1
   Gimenez-Xavier P, 2008, INT J MOL MED, V22, P781, DOI 10.3892/ijmm_00000085
   He YY, 2014, TUMOR BIOL, V35, P7317, DOI 10.1007/s13277-014-2060-4
   Hou WY, 2008, TOXICOLOGY, V252, P56, DOI 10.1016/j.tox.2008.07.061
   Huang AC, 2013, INT J ONCOL, V43, P485, DOI 10.3892/ijo.2013.1952
   Jiang PD, 2015, METHODS, V75, P13, DOI 10.1016/j.ymeth.2014.11.021
   Jiang Y, 2014, J APPL TOXICOL, V34, P1352, DOI 10.1002/jat.2965
   Jokanovic M, 2011, CLIN NEUROL NEUROSUR, V113, P7, DOI 10.1016/j.clineuro.2010.08.015
   Jortner BS, 2011, TOXICOL PATHOL, V39, P66, DOI 10.1177/0192623310387618
   Jortner BS, 2000, TOXICOL PATHOL, V28, P54, DOI 10.1177/019262330002800108
   Lotti Marcello, 2005, Toxicol Rev, V24, P37, DOI 10.2165/00139709-200524010-00003
   Makhaeva GF, 2007, HUM EXP TOXICOL, V26, P273, DOI 10.1177/0960327106070463
   Masoud A, 2012, HUM EXP TOXICOL, V31, P1214, DOI 10.1177/0960327112446842
   Masoud A, 2011, TOXICOL MECH METHOD, V21, P1, DOI 10.3109/15376516.2010.529182
   Masoud A, 2009, CELL MOL NEUROBIOL, V29, P1245, DOI 10.1007/s10571-009-9420-4
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Moretto A, 2005, CHEM-BIOL INTERACT, V157, P285, DOI 10.1016/j.cbi.2005.10.038
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   O'Donnell LA, 2007, J NEUROCHEM, V102, P1905, DOI 10.1111/j.1471-4159.2007.04645.x
   ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Rayalam S, 2011, RECENT PAT ANTI-CANC, V6, P367, DOI 10.2174/157489211796957856
   Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787
   Simpkin JC, 2007, BASIC RES CARDIOL, V102, P518, DOI 10.1007/s00395-007-0671-2
   Son SM, 2012, AUTOPHAGY, V8, P1842, DOI 10.4161/auto.21861
   Song FY, 2014, NEUROCHEM INT, V64, P1, DOI 10.1016/j.neuint.2013.10.017
   Song FY, 2012, CHEM-BIOL INTERACT, V200, P114, DOI 10.1016/j.cbi.2012.10.001
   Song FY, 2012, TOXICOL LETT, V210, P276, DOI 10.1016/j.toxlet.2012.02.011
   Song FY, 2009, TOXICOLOGY, V262, P258, DOI 10.1016/j.tox.2009.06.018
   Song FY, 2009, TOXICOLOGY, V258, P94, DOI 10.1016/j.tox.2009.01.011
   Song JX, 2014, AUTOPHAGY, V10, P144, DOI 10.4161/auto.26751
   Strappazzon F, 2015, CELL DEATH DIFFER, V22, P419, DOI 10.1038/cdd.2014.139
   Su JY, 2014, NEUROCHEM RES, V39, P2068, DOI 10.1007/s11064-014-1396-x
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489
   Xin Q, 2015, PEPTIDES, V63, P55, DOI 10.1016/j.peptides.2014.09.016
   Yoon SY, 2008, J NEUROSCI RES, V86, P3230, DOI 10.1002/jnr.21760
   Zeng XJ, 2010, EXP CELL RES, V316, P1773, DOI 10.1016/j.yexcr.2010.02.005
   Zhang HY, 2014, J CELL MOL MED, V18, P542, DOI 10.1111/jcmm.12208
   Zhang XG, 2011, PEPTIDES, V32, P1793, DOI 10.1016/j.peptides.2011.08.006
   Zhao XL, 2006, TOXICOLOGY, V223, P127, DOI 10.1016/j.tox.2006.03.008
   Zou CS, 2013, NEUROCHEM INT, V62, P965, DOI 10.1016/j.neuint.2013.03.013
NR 52
TC 2
Z9 2
U1 5
U2 12
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0364-3190
EI 1573-6903
J9 NEUROCHEM RES
JI Neurochem. Res.
PD NOV
PY 2015
VL 40
IS 11
BP 2374
EP 2382
DI 10.1007/s11064-015-1725-8
PG 9
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA CW6CQ
UT WOS:000365085500022
PM 26453045
DA 2018-12-27
ER

PT J
AU Nie, YY
   Zhang, L
   Wu, YH
   Liu, HJ
   Mao, WW
   Du, J
   Xiu, HL
   Wu, XY
   Li, X
   Yan, YW
   Liu, GL
   Liu, HY
   Hu, SP
AF Nie, Yuan-Yuan
   Zhang, Lin
   Wu, Yun-Hua
   Liu, Hao-Jie
   Mao, Wei-Wei
   Du, Juan
   Xiu, Hai-Lin
   Wu, Xiao-Yu
   Li, Xia
   Yan, Yu-Wei
   Liu, Guo-Lan
   Liu, Hong-Yan
   Hu, Song-Ping
TI RETRACTED: Screening of candidate genes and fine mapping of drought
   tolerance quantitative trait loci on chromosome 4 in rice (Oryza sativa
   L.) under drought stress (Retracted article. See vol. 6, pg. 375, 2016)
SO ECOLOGY AND EVOLUTION
LA English
DT Article; Retracted Publication
DE Candidate genes; drought stress; drought tolerance; fine mapping;
   quantitative trait loci; rice (Oryza sativa L; )
ID CONTROLLING ROOT TRAITS; UPLAND RICE; REPRODUCTIVE STAGE; RESISTANCE;
   QTLS; AVOIDANCE
AB Due to severe water resource shortage, genetics of and breeding for DT (drought tolerance) in rice (Oryza sativa L.) have become one of the hot research topics. Identification of grain yield QTLs (quantitative trait loci) directly related to the DT trait of rice can provide useful information for breeding new drought-resistant and water-saving rice varieties via marker-assisted selection. A population of 105 advanced BILs (backcross introgression lines) derived from a cross between Zhenshan97B and IRAT109 in Zhenshan97B background were grown under drought stress in a field experiment and phenotypic traits were investigated. The results showed that in the target interval of RM273-RM255 on chromosome 4, three main-effect QTLs related to panicle length, panicle number, and spikelet number per panicle were identified (LOD [logarithm of the odds]>2.0). The panicle length-related QTL had two loci located in the neighboring intervals of RM17308-RM17305 and RM17349-RM17190, which explained 18.80% and 20.42%, respectively, of the phenotypic variation, while the panicle number-related QTL was identified in the interval of RM1354-RM17308, explaining 11.47% of the phenotypic variation. As far as the spikelet number per panicle-related QTL was concerned, it was found to be located in the interval of RM17308-RM17305, which explained 28.08% of the phenotypic variation. Using the online Plant-GE query system, a total of 13 matched ESTs (expressed sequence tags) were found in the target region, and of the 13 ESTs, 12 had corresponding predicted genes. For instance, the two ESTs CB096766 and CA765747 were corresponded to the same predicted gene LOC_Os04g46370, while the other four ESTs, CA754286, CB000011, CX056247, and CX056240, were corresponded to the same predicted gene LOC_Os04g46390.
C1 [Nie, Yuan-Yuan; Zhang, Lin; Wu, Yun-Hua; Liu, Hao-Jie; Mao, Wei-Wei; Du, Juan; Xiu, Hai-Lin; Wu, Xiao-Yu; Hu, Song-Ping] Jiangxi Agr Univ, Coll Biosci & Engn, Nanchang 330045, Peoples R China.
   [Nie, Yuan-Yuan; Li, Xia] Jiangxi Super Rice Res & Dev Ctr, Natl Engn Lab Rice, Nanchang 330200, Peoples R China.
   [Yan, Yu-Wei; Hu, Song-Ping] Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.
   [Liu, Guo-Lan; Liu, Hong-Yan] Shanghai Agrobiol Gene Ctr, Shanghai 201106, Peoples R China.
RP Hu, SP (reprint author), Jiangxi Agr Univ, Coll Biosci & Engn, Nanchang 330045, Peoples R China.
EM lhy@sagc.org.cn; sp6974hu@berkeley.edu
FU China Scholarship Council [201408360034]; National Natural Science
   Foundation of China [31260314, 31100237]; Natural Science Foundation of
   Jiangxi Province [S2016ZRZDB0043]
FX This study was jointly supported by grants from the Program of China
   Scholarship Council 201408360034, the National Natural Science
   Foundation of China (31260314 and 31100237) and the Great Project of
   Natural Science Foundation of Jiangxi Province (S2016ZRZDB0043).
CR Bernier J, 2009, FIELD CROP RES, V110, P139, DOI 10.1016/j.fcr.2008.07.010
   Bernier J, 2008, J SCI FOOD AGR, V88, P927, DOI 10.1002/jsfa.3153
   Cairns JE, 2009, FIELD CROP RES, V114, P108, DOI 10.1016/j.fcr.2009.07.009
   Chamareck V., 2004, MOL GEN GENET, V272, P35
   Courtois B, 2009, RICE, V2, P115, DOI 10.1007/s12284-009-9028-9
   Ding XP, 2011, THEOR APPL GENET, V123, P815, DOI 10.1007/s00122-011-1629-1
   Gowda VRP, 2011, FIELD CROP RES, V122, P1, DOI 10.1016/j.fcr.2011.03.001
   Hu SP, 2009, J INTEGR PLANT BIOL, V51, P879, DOI 10.1111/j.1744-7909.2009.00846.x
   *INS CORP, 2001, S PLUS 6 WIND US GUI
   Kamoshita A, 2008, FIELD CROP RES, V109, P1, DOI 10.1016/j.fcr.2008.06.010
   Lanceras JC, 2004, PLANT PHYSIOL, V135, P384, DOI 10.1104/pp.103.035527
   Liu G. L., 2007, THESIS HUAZHONG AGR, P31
   Luo LiJun, 2001, Chinese Journal of Rice Science, V15, P209
   [罗利军 LUO LiJun], 2011, [科学通报, Chinese Science Bulletin], V56, P804
   Nie Y. Y., 2012, ACTA AGRON SIN, V3, P988
   Steele KA, 2007, FIELD CROP RES, V101, P180, DOI 10.1016/j.fcr.2006.11.002
   Steele KA, 2006, THEOR APPL GENET, V112, P208, DOI 10.1007/s00122-005-0110-4
   Teng Sheng, 2002, Acta Genetica Sinica, V29, P235
   Wang DL, 1999, THEOR APPL GENET, V99, P1255, DOI 10.1007/s001220051331
   Yonemaru J, 2010, RICE, V3, P194, DOI 10.1007/s12284-010-9041-z
   Yue B, 2006, GENETICS, V172, P1213, DOI 10.1534/genetics.105.045062
   ZENG H, 2007, NUCLEIC ACIDS RES, V35, P879
   Zhang J, 2001, THEOR APPL GENET, V103, P19, DOI 10.1007/s001220000534
   Zou GH, 2005, THEOR APPL GENET, V112, P106, DOI 10.1007/s00122-005-0111-3
NR 24
TC 1
Z9 1
U1 2
U2 33
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7758
J9 ECOL EVOL
JI Ecol. Evol.
PD NOV
PY 2015
VL 5
IS 21
BP 5007
EP 5015
DI 10.1002/ece3.1786
PG 9
WC Ecology; Evolutionary Biology
SC Environmental Sciences & Ecology; Evolutionary Biology
GA CV5WF
UT WOS:000364341400024
PM 26640678
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhong, M
   Ye, YH
AF Zhong, M.
   Ye, Y. H.
TI RETRACTED: Effect of localized surface plasmon and surface plasmon
   polariton modes on properties of metamaterials(Retracted article. See
   vol. 95, pg. 103, 2017)
SO CANADIAN JOURNAL OF PHYSICS
LA English
DT Article; Retracted Publication
ID SUBWAVELENGTH HOLE ARRAYS; NANOPARTICLE ARRAY; TRANSMISSION; RESONANCE;
   FREQUENCIES
AB We present the effects of localized surface plasmon (LSP) and surface plasmon polariton (SPP) modes on transmission peaks and resonance frequency of a compound structure metamaterial consisting of periodic metallic particle and hole arrays. During simulation, the lateral interval (Lx) between the metal particle and hole arrays is increased but the longitudinal interval (L) remains unchanged. Simulated results indicate that the main transmittance peak is enhanced and the resonant frequency red-shifted when Lx is increased, while the high-frequency transmittance peak is reduced and its resonance frequency is unchanged. We find that the increase in the intensity of SPP modes leads to the variation of the main transmittance peak, and the increase of the intensity of LSP modes results in the reduction of the high-frequency transmittance peak with increasing Lx.
C1 [Zhong, M.] Hezhou Coll, Hezhou 542899, Guangxi, Peoples R China.
   [Zhong, M.; Ye, Y. H.] Nanjing Normal Univ, Dept Phys, Nanjing 210023, Jiangsu, Peoples R China.
RP Ye, YH (reprint author), Nanjing Normal Univ, Dept Phys, Nanjing 210023, Jiangsu, Peoples R China.
EM yeyonghong@njnu.edu.cn
FU National Basic Research Program of China (973 Program) [2012CB921801];
   Doctoral Fund of Ministry of Education of China [20133207110007];
   National Natural Science Foundation of China [61475073]
FX This research is financially supported by National Basic Research
   Program of China (973 Program, 2012CB921801), Doctoral Fund of Ministry
   of Education of China (grant No. 20133207110007), and National Natural
   Science Foundation of China (grant No. 61475073).
CR Alaee R, 2012, OPT EXPRESS, V20, P28017, DOI 10.1364/OE.20.028017
   Azad AK, 2006, OPT LETT, V31, P2637, DOI 10.1364/OL.31.002637
   Beruete M, 2007, IEEE T ANTENN PROPAG, V55, P1514, DOI 10.1109/TAP.2007.897324
   Cai W, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2783266
   Cao T, 2013, J PHYS D APPL PHYS, V46, DOI 10.1088/0022-3727/46/39/395103
   Degiron A, 2005, J OPT A-PURE APPL OP, V7, pS90, DOI 10.1088/1464-4258/7/2/012
   Dong ZG, 2009, J APPL PHYS, V105, DOI 10.1063/1.3077265
   Du YC, 2013, OPT COMMUN, V298, P232, DOI 10.1016/j.optcom.2013.02.024
   Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570
   Fang N, 2005, SCIENCE, V308, P534, DOI 10.1126/science.1108759
   Garcia-de-Abajo F. J., 2007, REV MOD PHYS, V79, P1267, DOI DOI 10.1103/REVMODPHYS.79.1267
   Guo LY, 2012, EUR PHYS J B, V85, DOI 10.1140/epjb/e2012-20935-3
   Hua YL, 2009, J APPL PHYS, V105, DOI 10.1063/1.3043885
   Jiang H, 2013, J APPL PHYS, V113, DOI 10.1063/1.4811235
   Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y
   Kocaman S, 2011, NAT PHOTONICS, V5, P499, DOI [10.1038/NPHOTON.2011.129, 10.1038/nphoton.2011.129]
   Li HM, 2011, J APPL PHYS, V109, DOI 10.1063/1.3587165
   Lu XC, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2902292
   Melo AM, 2008, APPL OPTICS, V47, P6064, DOI 10.1364/AO.47.006064
   Murray WA, 2006, NANO LETT, V6, P1772, DOI 10.1021/nl060812e
   Ni B, 2013, OPT COMMUN, V298, P237, DOI 10.1016/j.optcom.2013.02.002
   Ortuno R, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.075425
   Parsons J, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.073412
   Schurig D, 2006, SCIENCE, V314, P977, DOI 10.1126/science.1133628
   Shen HM, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/28/285502
   Takakura Y, 2001, PHYS REV LETT, V86, P5601, DOI 10.1103/PhysRevLett.86.5601
   Tang CJ, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.041402
   Wang XD, 2010, CHINESE PHYS LETT, V27, DOI 10.1088/0256-307X/27/9/094101
   Wang XD, 2010, APPL PHYS A-MATER, V100, P1029, DOI 10.1007/s00339-010-5958-8
   Wei ZY, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3496037
   Xie JJ, 2013, PLASMONICS, V8, P1309, DOI 10.1007/s11468-013-9525-y
   Ye YH, 2004, APPL PHYS LETT, V85, P654, DOI 10.1063/1.1775036
   Zhang S, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.137404
   Zhou W, 2011, NAT NANOTECHNOL, V6, P423, DOI [10.1038/nnano.2011.72, 10.1038/NNANO.2011.72]
   Zhu SL, 2008, SENSOR ACTUAT B-CHEM, V134, P193, DOI 10.1016/j.snb.2008.04.028
NR 35
TC 1
Z9 1
U1 5
U2 22
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008-4204
EI 1208-6045
J9 CAN J PHYS
JI Can. J. Phys.
PD NOV
PY 2015
VL 93
IS 11
BP 1330
EP 1334
DI 10.1139/cjp-2014-0724
PG 5
WC Physics, Multidisciplinary
SC Physics
GA CV2RI
UT WOS:000364103900019
DA 2018-12-27
ER

PT J
AU Ahmadi, N
   Rezazadeh, S
   Mirzaee, I
AF Ahmadi, Nima
   Rezazadeh, Sajad
   Mirzaee, Iraj
TI RETRACTED: Numerical study the effect of downward and upward deflected
   membrane electrode assembly on species distribution in Polymer
   Electrolyte Membrane Fuel Cell with experimental validations (Retracted
   article. See vol. 89, pg. 468, 2016)
SO JOURNAL OF THE ENERGY INSTITUTE
LA English
DT Article; Retracted Publication
DE Deflection; Computational fluid dynamic; Polymer Electrolyte Membrane
   Fuel Cell; Over potential
ID TRANSPORT PHENOMENA; PEMFC; PERFORMANCE; MODEL; CATALYST; CHANNEL; AIR
AB This article presents the results of numerical study with experimental validation, using computational fluid dynamics (CFD) analysis to investigate the species distribution in proton exchange membrane fuel cells (PEMFCs) with deflected membrane electrode assembly (MEA). These new geometry were examined while employing an empirical setup and a three-dimensional, single-phase, non-isothermal and parallel flow for model of a PEM fuel cell. This research has concentrated on the effect of new kind of deflected MEA while maintaining the same inlet and boundary condition. Initially the CFD result of all case study's polarization curve are validated with the experimental data which shown good concord and then studied deflected and flatted MEA at cathode and anode side. Investigation showed better results for the PEMFC with having both flatted and deflected MEA at cathode side than base model, because of having more reacting area, uniform distribution of reactants, better oxygen transportation to the GDL at shoulder region and having less Cathode Over potential (COP) which is the main losses is regard to it. To verifying all of results the polarization curve for base case is validated with Wang et al. data. (C) 2014 Energy Institute. Published by Elsevier Ltd. All rights reserved.
C1 [Ahmadi, Nima; Rezazadeh, Sajad; Mirzaee, Iraj] Urmia Univ Technol, Dept Mech Engn, Orumiyeh, Iran.
RP Ahmadi, N (reprint author), Urmia Univ Technol, Dept Mech Engn, Orumiyeh, Iran.
EM nima.ahmadi.eng@gmail.com
FU Renewable Energy Organization of Iran
FX This research was sponsored by Renewable Energy Organization of Iran.
CR Ahmadi N., 2012, JMST, V26, P1
   Ahmed D.H., 2008, J HEAT MASS TRANSFER, V51, P327
   Ahmed DH, 2006, J POWER SOURCES, V162, P327, DOI 10.1016/j.jpowsour.2006.06.083
   Amphlett J.C., PERFORMANCE MODELING
   Arabi A., 2012, INT J ENG, V25-3, P177
   Berning T, 2002, J POWER SOURCES, V106, P284, DOI 10.1016/S0378-7753(01)01057-6
   Carral C, 2014, INT J HYDROGEN ENERG, V39, P4516, DOI 10.1016/j.ijhydene.2014.01.036
   Chiang MS, 2006, J POWER SOURCES, V160, P340, DOI 10.1016/j.jpowsour.2006.01.086
   FULLER EN, 1966, IND ENG CHEM, V58, P18, DOI DOI 10.1021/IE50677A007
   Ge SH, 2003, J POWER SOURCES, V124, P1, DOI 10.1016/S0378-7753(03)00584-6
   Guvelioglu GH, 2005, J POWER SOURCES, V147, P95, DOI 10.1016/j.jpowsour.2005.01.011
   Haddad D, 2013, INT J HYDROGEN ENERG, V38, P8550, DOI 10.1016/j.ijhydene.2012.11.011
   Hu MR, 2014, INT J HYDROGEN ENERG, V39, P7940, DOI 10.1016/j.ijhydene.2014.03.072
   Jung HM, 2004, INT J HYDROGEN ENERG, V29, P945, DOI 10.1016/j.ijhydene.2003.03.001
   Lin GY, 2006, J ELECTROCHEM SOC, V153, pA372, DOI 10.1149/1.2142267
   Lum KW, 2005, J POWER SOURCES, V143, P103, DOI 10.1016/j.jpowsour.2004.11.032
   Mathieu-Potvin F, 2014, INT J HYDROGEN ENERG, V39, P7382, DOI 10.1016/j.ijhydene.2014.02.098
   Natarajan D, 2001, J ELECTROCHEM SOC, V148, pA1324, DOI 10.1149/1.1415032
   Perez LC, 2013, INT J HYDROGEN ENERG, V38, P16286, DOI 10.1016/j.ijhydene.2013.10.037
   Pourmahmoud N, 2012, J MECH SCI TECHNOL, V26, P2959, DOI 10.1007/s12206-012-0708-9
   Shimpalee S, 2006, J POWER SOURCES, V156, P355, DOI 10.1016/j.jpowsour.2005.05.073
   Su A, 2005, INT J ENERG RES, V29, P409, DOI 10.1002/er.1059
   Su A., 2013, J HYDROGEN ENERGY, V37, P7710
   Sun L, 2006, INT J THERM SCI, V45, P1021, DOI 10.1016/j.ijthermalsci.2006.01.005
   TICIANELLI EA, 1988, J ELECTROANAL CHEM, V251, P275, DOI 10.1016/0022-0728(88)85190-8
   Uribe FA, 2002, J ELECTROCHEM SOC, V149, pA293, DOI 10.1149/1.1447221
   Wang L, 2003, INT J HYDROGEN ENERG, V28, P1263, DOI 10.1016/S0360-3199(02)00284-7
   Weng FB, 2005, J POWER SOURCES, V145, P546, DOI 10.1016/j.jpowersour.2005.01.078
NR 28
TC 1
Z9 1
U1 4
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1743-9671
EI 1746-0220
J9 J ENERGY INST
JI J. Energy Inst.
PD NOV
PY 2015
VL 88
IS 4
BP 438
EP 449
DI 10.1016/j.joei.2014.09.012
PG 12
WC Energy & Fuels
SC Energy & Fuels
GA CU2JL
UT WOS:000363349700009
DA 2018-12-27
ER

PT J
AU Farazmand, P
   Fehli, S
   Elahi, AS
   Ghoranneviss, M
AF Farazmand, P.
   Fehli, S.
   Elahi, A. Salar
   Ghoranneviss, M.
TI RETRACTED: Morphological and Field Emission Properties of ZnO Deposited
   MWCNT by RF Sputtering and PECVD(Retracted article. See vol 27,pg
   1959,2017)
SO JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS AND MATERIALS
LA English
DT Article; Retracted Publication
DE Nanocomposite; MWCNT; ZnO
ID WALLED CARBON NANOTUBES; ZINC-OXIDE NANOWIRES; OPTICAL-PROPERTIES;
   FABRICATION; EMITTERS; ARRAYS; FUNCTIONALIZATION; NANOSTRUCTURES; FILMS
AB We have reviewed the synthesis of nanocomposite zinc oxide deposited carbon nanotube with two different methods. Initially the multi-walled carbon nanotubes (MWCNT) were prepared by the plasma enhanced chemical vapour deposition technique. Then By two different methods ZnO layers were coated on the tubes. RF sputtering was one of the ways to directly deposit ZnO thin layer on the MWCNTs. On the other hand, we used the thermally physical vapour deposition for making thin Zn film to oxidize it later. Scanning electron microscopy and also Raman spectroscopy measurements of the prepared samples confirmed the presence of ZnO nanolayers on the CNT bodies. By the field emission microscopy measurements we found that ZnO deposited CNTs have a more efficient emissivity than that of CNTs alone.
C1 [Farazmand, P.] Imam Khomeini Univ, Dept Phys, Qazvin, Iran.
   [Fehli, S.] Shahed Univ, Dept Phys, Tehran, Iran.
   [Elahi, A. Salar; Ghoranneviss, M.] Islamic Azad Univ, Plasma Phys Res Ctr, Sci & Res Branch, Tehran, Iran.
RP Elahi, AS (reprint author), Islamic Azad Univ, Plasma Phys Res Ctr, Sci & Res Branch, Tehran, Iran.
EM Salari_phy@yahoo.com
CR Bonard JM, 1999, APPL PHYS A-MATER, V69, P245, DOI 10.1007/s003390050998
   Chen CF, 2003, DIAM RELAT MATER, V12, P1500, DOI 10.1016/S0925-9635(03)00181-X
   Chen I.C., 2006, APPL PHYS LETT, V88
   Choi WB, 1999, APPL PHYS LETT, V75, P3129, DOI 10.1063/1.125253
   DAMEN TC, 1966, PHYS REV, V142, P570, DOI 10.1103/PhysRev.142.570
   de Jonge N, 2002, NATURE, V420, P393, DOI 10.1038/nature01233
   DEHEER WA, 1995, SCIENCE, V270, P1179, DOI 10.1126/science.270.5239.1179
   Dresselhaus MS, 2001, CARBON NANOTUBES SYN
   Du Y, 2003, APPL PHYS A-MATER, V76, P171, DOI 10.1007/s003390201404
   Fan SS, 1999, SCIENCE, V283, P512, DOI 10.1126/science.283.5401.512
   Geng CY, 2004, ADV FUNCT MATER, V14, P589, DOI 10.1002/adfm.200305074
   Green JM, 2006, J APPL PHYS, V99, DOI 10.1063/1.2194112
   Hirsch A, 2002, ANGEW CHEM INT EDIT, V41, P1853, DOI 10.1002/1521-3773(20020603)41:11<1853::AID-ANIE1853>3.0.CO;2-N
   Huang CS, 2009, DIAM RELAT MATER, V18, P452, DOI 10.1016/j.diamond.2008.10.058
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0
   Jiang LQ, 2005, MATER CHEM PHYS, V91, P313, DOI 10.1016/j.matchemphys.2004.11.028
   Jiao J, 2002, MATER RES SOC SYMP P, V706, P113
   Kim H, 2002, APPL PHYS LETT, V81, P2085, DOI 10.1063/1.1504877
   Lee CJ, 2002, APPL PHYS LETT, V81, P3648, DOI 10.1063/1.1518810
   Li WZ, 1997, APPL PHYS LETT, V70, P2684, DOI 10.1063/1.118993
   Li XL, 2010, NANOSCALE RES LETT, V5, P1836, DOI 10.1007/s11671-010-9721-z
   Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477
   Ng HT, 2003, APPL PHYS LETT, V82, P2023, DOI 10.1063/1.1564870
   Pearton SJ, 2003, SUPERLATTICE MICROST, V34, P3, DOI 10.1016/S0749-6063(03)00093-4
   RINZLER AG, 1995, SCIENCE, V269, P1550, DOI 10.1126/science.269.5230.1550
   Sveningsson M, 2001, APPL PHYS A-MATER, V73, P409, DOI 10.1007/s003390100923
   Sveningsson M, 2004, APPL PHYS LETT, V85, P4487, DOI 10.1063/1.1819521
   Tan PH, 1997, J RAMAN SPECTROSC, V28, P369
   TEMPLE D, 1995, J VAC SCI TECHNOL B, V13, P150, DOI 10.1116/1.587973
   Valentini L, 2003, DIAM RELAT MATER, V12, P821, DOI 10.1016/S0925-9635(02)00359-X
   Wang QH, 1997, APPL PHYS LETT, V70, P3308, DOI 10.1063/1.119146
   Wang ZL, 2004, J PHYS-CONDENS MAT, V16, pR829, DOI 10.1088/0953-8984/16/25/R01
   Wong SS, 1999, CHEM PHYS LETT, V306, P219, DOI 10.1016/S0009-2614(99)00488-1
   Xia YN, 2003, ADV MATER, V15, P353, DOI 10.1002/adma.200390087
   Zhu W, 1999, APPL PHYS LETT, V75, P873, DOI 10.1063/1.124541
   Zhu YW, 2006, ADV MATER, V18, P587, DOI 10.1002/adma.200501918
NR 36
TC 8
Z9 8
U1 2
U2 19
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1574-1443
EI 1574-1451
J9 J INORG ORGANOMET P
JI J. Inorg. Organomet. Polym. Mater.
PD NOV
PY 2015
VL 25
IS 6
BP 1470
EP 1477
DI 10.1007/s10904-015-0263-9
PG 8
WC Polymer Science
SC Polymer Science
GA CT8AB
UT WOS:000363036000021
DA 2018-12-27
ER

PT J
AU Sahu, IP
   Bisen, DP
   Brahme, N
   Tamrakar, RK
AF Sahu, Ishwar Prasad
   Bisen, D. P.
   Brahme, Nameeta
   Tamrakar, Raunak Kumar
TI RETRACTED: Luminescence enhancement of bluish-green Sr2Al2SiO7:Eu2+
   phosphor by dysprosium co-doping (Retracted article. See vol. 186 pg.
   326, 2017)
SO JOURNAL OF LUMINESCENCE
LA English
DT Article; Retracted Publication
DE Long afterglow phosphors; Thermoluminescence; Photoluminescence;
   Mechanoluminescence
ID STRESS-DISTRIBUTION; OPTICAL-PROPERTIES; LIGHT EMISSION; GLOW CURVES;
   AFTERGLOW; DY3+; MECHANOLUMINESCENCE; THERMOLUMINESCENCE;
   PHOTOLUMINESCENCE; CRYSTALS
AB In this paper, the Sr2Al2SiO7, Sr2Al2SiO7:Eu2+, Sr2Al2SiO7:Dy3+ and Sr2Al2SiO7:Eu2+, Dy3+ phosphors were synthesized under weak reducing atmosphere, excepting Sr2Al2SiO7 and Sr2Al2SiO7:Dy3+ phosphors by the traditional high temperature solid state reaction method. The crystal structures of sintered phosphors were gelhenite type structure which belongs to the tetragonal crystallography. The thermo-luminescence (TL) properties of these phosphors were investigated and results were also compared. Under the ultraviolet (UV) excitation, the emission spectra of Sr2Al2SiO7:Eu2+ and Sr2Al2SiO7:Eu2+, Dy3+ phosphors were composed of a broad band peaking at 490 nm (bluish-green), corresponds to the F-4(9/2) -> H-6(15/2), (13/2) transitions. When the Sr2Al2SiO7:Eu2+ phosphor is co-doped with Dy3+, the intensity of TL, photoluminescence (PL), long afterglow and mechanoluminescence (ML) were strongly enhanced. Afterglow graph indicate that both the sintered phosphors contains fast decay and slow decay process. The ML intensities of Sr2Al2SiO7:Dy3+, Sr2Al2SiO7:Eu2+ and Sr2Al2SiO7:Eu2+, Dy3+ phosphors were proportionally increased with the increasing impact velocity of the moving piston. Thus the present investigation indicates that the local piezoelectricity-induced electron bombardment model is responsible to produce ML in prepared phosphors. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Sahu, Ishwar Prasad; Bisen, D. P.; Brahme, Nameeta] Pt Ravishankar Shukla Univ, Sch Studies Phys & Astrophys, Raipur 492010, CG, India.
   [Tamrakar, Raunak Kumar] Bhilai Inst Technol, Dept Appl Phys, Durg 491001, CG, India.
RP Sahu, IP (reprint author), Pt Ravishankar Shukla Univ, Sch Studies Phys & Astrophys, Raipur 492010, CG, India.
EM ishwarprasad1986@gmail.com
RI Brahme, Nameeta/F-7829-2016; Bisen, Durga Prasad/F-5538-2016
OI Brahme, Nameeta/0000-0003-2326-8328; Bisen, Durga
   Prasad/0000-0001-9537-0888; Tamrakar, Raunak Kumar/0000-0003-1395-1318
CR Aitasallo T, 2006, J PHYS CHEM B, V110, P4589, DOI 10.1021/jp057185m
   Basun S, 2003, J LUMIN, V104, P283, DOI 10.1016/S0022-2313(03)00082-6
   Chandra BP, 2011, J LUMIN, V131, P1203, DOI 10.1016/j.jlumin.2011.02.027
   Chandra BP, 2010, J LUMIN, V130, P442, DOI 10.1016/j.jlumin.2009.10.010
   Chandra B.P., 2011, OPEN NANOSCI J, V5, P45
   CHANDRA BP, 1995, CRYST RES TECHNOL, V30, P885, DOI 10.1002/crat.2170300702
   CHEN R, 1969, J APPL PHYS, V40, P570, DOI 10.1063/1.1657437
   Chen R., 1981, ANAL THERMALLY STIMU, P167
   Chen R., 1997, THEORY THERMOLUMINES
   Chen YH, 2009, J LUMIN, V129, P531, DOI 10.1016/j.jlumin.2008.12.008
   CIE, 1931, PUBL CIE
   Clabau F, 2005, CHEM MATER, V17, P3904, DOI 10.1021/cm050763r
   Ding YL, 2009, J LUMIN, V129, P294, DOI 10.1016/j.jlumin.2008.10.009
   Eeckhout K.V.d., 2010, MATERIALS, V3, P2536, DOI DOI 10.3390/MA3042536
   He ZY, 2006, J LUMIN, V119, P309, DOI 10.1016/j.jlumin.2006.01.010
   Jung KY, 2006, CHEM MATER, V18, P2249, DOI 10.1021/cm060003w
   Katsumata T, 2003, J ELECTROCHEM SOC, V150, pH111, DOI 10.1149/1.1565141
   KIMATA M, 1984, Z KRISTALLOGR, V167, P103, DOI 10.1524/zkri.1984.167.1-2.103
   Kubo H, 2005, J CRYST GROWTH, V275, pE1767, DOI 10.1016/j.jcrysgro.2004.11.193
   Lakshminarasimhan N, 2008, MATER RES BULL, V43, P2946, DOI 10.1016/j.materresbull.2007.12.005
   Leverenz H. W., 1968, INTRO LUMINESCENCE S
   Li C.Y., 2003, J LUMIN, V24, P19
   Li XJ, 2006, MATER LETT, V60, P3673, DOI 10.1016/j.matlet.2006.03.081
   Luitel HN, 2013, MATER SCI ENG B-ADV, V178, P834, DOI 10.1016/j.mseb.2013.03.014
   Mashangva M, 2011, INDIAN J PURE AP PHY, V49, P585
   Merlini M., 2006, Z KRISTALL S, V23, pS419
   Murayama Y., 1995, US Patent, Patent No. [1995; 5: 424,006, 5424006, 5,424,006]
   Pagonis V., 2006, NUMERICAL PRACTICAL
   POORT SHM, 1995, CHEM MATER, V7, P1547, DOI 10.1021/cm00056a022
   Sahu I.P., 2014, J RAD RES APP SCI, V8, P104
   Sahu I.P., 2014, LUMIN J BIOL CHEM LU
   Sahu I.P., 2015, LUMIN J BIOL CHEM LU
   Sahu I.P., 2015, RES CHEM INTERMED
   Sahu I.P., 2014, RES CHEM INTERMED
   Sahu IP, 2015, J RADIAT RES APPL SI, V8, P381, DOI 10.1016/j.jrras.2015.02.007
   Sahu IP, 2015, DISPLAYS, V38, P68, DOI 10.1016/j.displa.2015.03.002
   Sakai R, 1999, J LUMIN, V85, P149, DOI 10.1016/S0022-2313(99)00061-7
   Shrivastava R., 2015, J BIOL CHEM LUMIN
   Shrivastava R., 2015, CHIN CHEM LETT
   Takasaki H, 1996, J CERAM SOC JPN, V104, P322, DOI 10.2109/jcersj.104.322
   Vij D. J., 1998, LUMINESCENCE SOLIDS
   Wu HY, 2011, J PHYS CHEM SOLIDS, V72, P1284, DOI 10.1016/j.jpcs.2011.07.022
   Wu HY, 2011, J LUMIN, V131, P2441, DOI 10.1016/j.jlumin.2011.06.024
   Wu HY, 2011, J ALLOY COMPD, V509, P4304, DOI 10.1016/j.jallcom.2011.01.051
   Xu CN, 1999, APPL PHYS LETT, V74, P2414, DOI 10.1063/1.123865
   Xu CN, 1999, MATER RES BULL, V34, P1491, DOI 10.1016/S0025-5408(99)00175-0
   Xu CN, 1999, THIN SOLID FILMS, V352, P273, DOI 10.1016/S0040-6090(99)00327-2
   Xu CN, 2000, APPL PHYS LETT, V76, P179, DOI 10.1063/1.125695
   Xu CN, 1999, APPL PHYS LETT, V74, P1236, DOI 10.1063/1.123510
   Yamamoto H, 1997, J LUMIN, V72-4, P287, DOI 10.1016/S0022-2313(97)00012-4
   Yuan ZX, 2004, J ALLOY COMPD, V377, P268, DOI 10.1016/j.jallcom.2004.01.063
   Zhang HW, 2010, PHYSICA E, V42, P2872, DOI 10.1016/j.physe.2010.02.013
   Zhang HW, 2009, THIN SOLID FILMS, V518, P610, DOI 10.1016/j.tsf.2009.07.124
   Zhang HW, 2009, INT J MOD PHYS B, V23, P1028, DOI 10.1142/S0217979209060415
   Zhang Q, 2008, APPL PHYS B-LASERS O, V92, P195, DOI 10.1007/s00340-008-3089-0
   Zhao CL, 2006, MAT SCI ENG B-SOLID, V133, P200, DOI 10.1016/j.mseb.2006.06.042
NR 56
TC 19
Z9 19
U1 3
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-2313
EI 1872-7883
J9 J LUMIN
JI J. Lumines.
PD NOV
PY 2015
VL 167
BP 278
EP 288
DI 10.1016/j.jlumin.2015.06.023
PG 11
WC Optics
SC Optics
GA CR5RM
UT WOS:000361401600040
DA 2018-12-27
ER

PT J
AU Altaee, A
   Sharif, A
   Zaragoza, G
AF Altaee, Ali
   Sharif, Adel
   Zaragoza, Guillermo
TI RETRACTED: Limitations of osmotic gradient resource and hydraulic
   pressure on the efficiency of dual stage PRO process (Retracted article.
   See vol. 87, pg. 834, 2016)
SO RENEWABLE ENERGY
LA English
DT Article; Retracted Publication
DE Dual stage PRO process; PRO process; Renewable energy; High efficiency
   PRO process; Osmotic energy
ID RETARDED OSMOSIS; POWER-GENERATION; SEAWATER DESALINATION; SALINITY
   GRADIENTS; MEMBRANES; WATER; POLARIZATION; SYSTEM
AB Dual stage PRO process has been proposed for power generation from a salinity gradient across a semipermeable membrane. Closed-loop and open-loop dual stage PRO system were evaluated using 2 M NaCl and Dead Sea as draw solutions whereas the feed solution was either fresh water or seawater. The impact of feed salinity gradient resource and feed pressure on the net power generation and water flux was evaluated. The results showed that power density in stage one reached a maximum amount at Delta P = pi/2 but the maximum net power generation occurred at Delta P < pi/2. This was mainly attributed to the variation of net driving pressure in stage one and two of the PRO process. The dual stage PRO process was found to perform better at high osmotic pressure gradient across the PRO membrane, for example when Dead Sea brine or highly concentrated NaCl is the draw solution. Total power generation in the dual stage PRO process is up to 40% higher than that in the conventional PRO process. This was achieved through harvesting the rest of energy remaining in the diluted draw solution. Therefore, dual stage PRO process has the potential of maximizing power generation from a salinity gradient resource. Crown Copyright (C) 2015 Published by Elsevier Ltd. All rights reserved.
C1 [Altaee, Ali; Sharif, Adel] Qatar Fdn, Qatar Energy & Environm Res Inst, Doha, Qatar.
   [Zaragoza, Guillermo] CIEMET, Plataforma Solar Almeria, Tabernas 04200, Almeria, Spain.
RP Altaee, A (reprint author), Qatar Fdn, Qatar Energy & Environm Res Inst, Doha, Qatar.
EM aaltaee@qf.org.qa
OI Zaragoza, Guillermo/0000-0002-4452-9980
CR Achilli A, 2009, J MEMBRANE SCI, V343, P42, DOI 10.1016/j.memsci.2009.07.006
   Altaee A, 2015, DESALINATION, V356, P31, DOI 10.1016/j.desal.2014.09.028
   Altaee A, 2014, DESALINATION, V352, P118, DOI 10.1016/j.desal.2014.08.017
   Altaee A, 2014, DESALINATION, V344, P108, DOI 10.1016/j.desal.2014.03.022
   Altaee A, 2014, DESALINATION, V336, P50, DOI 10.1016/j.desal.2014.01.002
   Altaee Ali, 2014, DESIGN OPTIMIZATION
   Efraty A., 2012, P 3 OSM MEMBR SUMM
   Kim YC, 2013, J MEMBRANE SCI, V429, P330, DOI 10.1016/j.memsci.2012.11.039
   Kurihara M, 2013, DESALINATION, V308, P131, DOI 10.1016/j.desal.2012.07.038
   LEE KL, 1981, J MEMBRANE SCI, V8, P141, DOI 10.1016/S0376-7388(00)82088-8
   Loeb S, 2002, DESALINATION, V143, P115, DOI 10.1016/S0011-9164(02)00233-3
   Loeb S, 1998, DESALINATION, V120, P247, DOI 10.1016/S0011-9164(98)00222-7
   Loeb S., 1975, United States Patent US, Patent No. [3,906,250, 3906250]
   McGinnis RL, 2007, J MEMBRANE SCI, V305, P13, DOI 10.1016/j.memsci.2007.08.027
   MEHTA GD, 1978, J MEMBRANE SCI, V4, P261, DOI 10.1016/S0376-7388(00)83301-3
   Nagy E, 2014, J MEMBRANE SCI, V460, P71, DOI 10.1016/j.memsci.2014.02.021
   Phillip WA, 2010, ENVIRON SCI TECHNOL, V44, P5170, DOI 10.1021/es100901n
   Saito K, 2012, DESALIN WATER TREAT, V41, P114, DOI 10.1080/19443994.2012.664696
   Skilhagen Stein Erik, 2006, P OWEMES 20 22 APR C, P20
   Thelin WR, 2013, J MEMBRANE SCI, V438, P46, DOI 10.1016/j.memsci.2013.03.020
   Nguyen TPN, 2013, J MEMBRANE SCI, V433, P49, DOI 10.1016/j.memsci.2013.01.027
   Thorsen T, 2009, J MEMBRANE SCI, V335, P103, DOI 10.1016/j.memsci.2009.03.003
   Wang R., 2012, P 3 OSM MEMBR SUMM
   Yip NY, 2011, ENVIRON SCI TECHNOL, V45, P4360, DOI 10.1021/es104325z
   Zhou ZZ, 2014, CHEM ENG J, V249, P236, DOI 10.1016/j.cej.2014.03.049
NR 25
TC 4
Z9 4
U1 1
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-1481
J9 RENEW ENERG
JI Renew. Energy
PD NOV
PY 2015
VL 83
BP 1234
EP 1244
DI 10.1016/j.renene.2015.05.059
PG 11
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA CN5FL
UT WOS:000358455100119
DA 2018-12-27
ER

PT J
AU Sieniawska, E
AF Sieniawska, Elwira
TI RETRACTED: Targeting Mycobacterial Enzymes with Natural Products
   (Retracted article. See vol. 24, pg. 532, 2017)
SO CHEMISTRY & BIOLOGY
LA English
DT Review; Retracted Publication
ID S-CONJUGATE AMIDASE; PROTEIN-TYROSINE PHOSPHATASES; ANTIMYCOBACTERIAL
   ACTIVITIES; ACID SYNTHESIS; CLPP PROTEASE; MURE LIGASE; FATTY-ACID;
   TUBERCULOSIS; THIOLACTOMYCIN; INHIBITORS
AB Tuberculosis (TB) is a recurring threat to contemporary civilization. It affects not only those within developing countries, but has also appeared again in places where it was once considered eradicated. TB co-infection in patients infected by HIV is, at the time of writing, the most common cause of death. In the field of searching for new antimycobacterial drug leads, compounds of natural origin still remain a promising source. The review is intended to gather information about natural products (metabolites of plants, fungi, bacteria, and marine sponges) that show activity against mycobacterial enzymes. Here, natural metabolites are presented as being inhibitors/activators of the mycobacterial enzymes involved in mycobacterial growth in vitro (ClpC1, ClpP, MurE ligase, mycothiol S-conjugate amidase, beta-ketoacyl-ACP synthase, InhA) and in vivo, as regards the host cell (PtpB). Each enzyme is briefly described so as to generate an understanding of its role in mycobacterial growth and engender a perception of the mechanism of action of the studied natural compounds. Furthermore, after the introduction of the enzyme, its inhibitors are listed and exactly characterized.
C1 [Sieniawska, Elwira] Med Univ Lublin, Dept Pharmacognosy, Med Plant Unit, PL-20093 Lublin, Poland.
RP Sieniawska, E (reprint author), Med Univ Lublin, Dept Pharmacognosy, Med Plant Unit, 1 Chodzki, PL-20093 Lublin, Poland.
EM elwira.sieniawska@gmail.com
FU Polish National Science Center [2013/11/D/NZ7/01613]
FX This work was supported by grant no. 2013/11/D/NZ7/01613 from the Polish
   National Science Center.
CR Adrien A., 2006, ANN NY ACAD SCI, V123, P5
   Akopian T, 2012, EMBO J, V31, P1529, DOI 10.1038/emboj.2012.5
   BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673
   Basavannacharya C, 2010, TUBERCULOSIS, V90, P16, DOI 10.1016/j.tube.2009.10.007
   Bloch K., 1977, ADV ENZYMOL RELAT AR, V45, P81
   Brotz-Oesterhelt H, 2005, NAT MED, V11, P1082, DOI 10.1038/nm1306
   Brown ED, 2005, CHEM REV, V105, P759, DOI 10.1021/cr030116o
   Chiaradia LD, 2012, J MED CHEM, V55, P390, DOI 10.1021/jm2012062
   Clardy J, 2006, NAT BIOTECHNOL, V24, P1541, DOI 10.1038/nbt1266
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159
   DeVinney R, 2000, TRENDS MICROBIOL, V8, P29, DOI 10.1016/S0966-842X(99)01657-1
   Gao W, 2015, ANTIMICROB AGENTS CH, V59, P880, DOI 10.1128/AAC.04054-14
   Gao W, 2014, ORG LETT, V16, P6044, DOI 10.1021/ol5026603
   Garcia A, 2012, EUR J MED CHEM, V49, P1, DOI 10.1016/j.ejmech.2011.12.029
   Gautam R, 2007, J ETHNOPHARMACOL, V110, P200, DOI 10.1016/j.jep.2006.12.031
   Gavrish E, 2014, CHEM BIOL, V21, P509, DOI 10.1016/j.chembiol.2014.01.014
   Greis KD, 2005, ANTIMICROB AGENTS CH, V49, P3428, DOI 10.1128/AAC.49.8.3428-3434.2005
   Guzman JD, 2010, J ANTIMICROB CHEMOTH, V65, P2101, DOI 10.1093/jac/dkq313
   HANEISHI T, 1988, ANTIMICROB AGENTS CH, V32, P110, DOI 10.1128/AAC.32.1.110
   Hartkoorn RC, 2012, EMBO MOL MED, V4, P1032, DOI 10.1002/emmm.201201689
   HAYASHI T, 1983, BIOCHEM BIOPH RES CO, V115, P1108, DOI 10.1016/S0006-291X(83)80050-3
   Iwatsuki M, 2006, J AM CHEM SOC, V128, P7486, DOI 10.1021/ja056780z
   Iwatsuki M, 2007, J ANTIBIOT, V60, P357, DOI 10.1038/ja.2007.48
   Khalil ZG, 2014, ORG LETT, V16, P5120, DOI 10.1021/ol502472c
   Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200
   Kirstein J, 2009, EMBO MOL MED, V1, P37, DOI 10.1002/emmm.200900002
   Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200
   Lewis K., 2012, Patent No. [WO 2012/135846 Al, 2012135846]
   MAEDA KENJI, 1953, JOUR ANTIBIOTICS [TOKYO], V6, P140
   Mascarello A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077081
   MICHEL KH, 1985, Patent No. 4492650
   Muller D, 2006, J MED CHEM, V49, P4871, DOI 10.1021/jm060327w
   Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996
   Newton SM, 2002, J ETHNOPHARMACOL, V79, P57, DOI 10.1016/S0378-8741(01)00350-6
   Nicholas GM, 2003, BIOORGAN MED CHEM, V11, P601, DOI 10.1016/S0968-0896(02)00345-0
   Nicholas GM, 2001, ORG LETT, V3, P1543, DOI 10.1021/ol015845+
   NOTO T, 1982, J ANTIBIOT, V35, P401, DOI 10.7164/antibiotics.35.401
   OISHI H, 1982, J ANTIBIOT, V35, P391, DOI 10.7164/antibiotics.35.391
   Okunade AL, 2004, PHYTOCHEMISTRY, V65, P1017, DOI 10.1016/j.phytochem.2004.02.013
   Ollinger J, 2012, J BACTERIOL, V194, P663, DOI 10.1128/JB.06142-11
   Osman K, 2012, INT J ANTIMICROB AG, V39, P124, DOI 10.1016/j.ijantimicag.2011.09.018
   Patel NR, 2009, J LEUKOCYTE BIOL, V86, P53, DOI [10.1189/JLB.0908574, 10.1189/jlb.0908574]
   Paul S, 2003, CELL MOL LIFE SCI, V60, P2465, DOI 10.1007/s00018-003-3123-7
   Raju RM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002511
   Salomon CE, 2012, CURR TOP MED CHEM, V12, P735
   Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100
   Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x
   Schmitt EK, 2011, ANGEW CHEM INT EDIT, V50, P5889, DOI 10.1002/anie.201101740
   Schultz AW, 2010, J NAT PROD, V73, P373, DOI 10.1021/np9006876
   Seibert SF, 2006, ORG BIOMOL CHEM, V4, P2233, DOI 10.1039/b601386d
   SHOMURA T, 1986, INT J SYST BACTERIOL, V36, P166, DOI 10.1099/00207713-36-2-166
   Singh R, 2003, MOL MICROBIOL, V50, P751, DOI 10.1046/j.1365-2958.2003.03712.x
   Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813
   Socha AM, 2010, BIOORGAN MED CHEM, V18, P7193, DOI 10.1016/j.bmc.2010.08.032
   Spigelman MK, 2007, J INFECT DIS, V196, pS28, DOI 10.1086/518663
   Srinivasa D.V., 2013, J BIOL CHEM, V288, P30883
   Steffek M, 2003, BIOCHEMISTRY-US, V42, P12067, DOI 10.1021/bi030080u
   Turk S, 2009, BIOORGAN MED CHEM, V17, P1884, DOI 10.1016/j.bmc.2009.01.052
   World Health Organization, 2014, GLOB TUB REP
   Zhou B, 2010, P NATL ACAD SCI USA, V107, P4573, DOI 10.1073/pnas.0909133107
   Zwang J, 2007, T ROY SOC TROP MED H, V101, P893, DOI 10.1016/j.trstmh.2007.04.023
NR 61
TC 9
Z9 9
U1 4
U2 37
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-5521
EI 1879-1301
J9 CHEM BIOL
JI Chem. Biol.
PD OCT 22
PY 2015
VL 22
IS 10
BP 1288
EP 1300
DI 10.1016/j.chembiol.2015.08.012
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CY1BG
UT WOS:000366140900002
PM 26441042
OA Bronze
DA 2018-12-27
ER

PT J
AU Kumar, SN
   Jacob, J
   Reshma, UR
   Rajesh, RO
   Kumar, BSD
AF Kumar, S. N.
   Jacob, Jubi
   Reshma, U. R.
   Rajesh, R. O.
   Kumar, B. S. D.
TI RETRACTED: Molecular characterization of forest soil based Paenibacillus
   elgii and optimization of various culture conditions for its improved
   antimicrobial activity (Retracted article. See vol. 8, pg. art no 2364,
   2017)
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article; Retracted Publication
DE Paenibacillus elgii; cultural condition; antimicrobial metabolites;
   improvement; carbon source
ID POLYKETIDE SYNTHASES; STREPTOMYCES; POLYMYXA; FERMENTATION; ANTIBIOTICS;
   RESISTANCE; DISCOVERY; BACTERIA; GLUCOSE; GENE
AB Microorganisms have provided a bounty of bioactive secondary metabolites with very exciting biological activities such as antibacterial, antifungal antiviral, and anticancer, etc. The present study aims at the optimization of culture conditions for improved antimicrobial production of Paenibacillus elgii obtained from Wayanad forest of Western Ghats region of Kerala, India. A bacterial strain isolated from the Western Ghats forest soil of Wayanad, Kerala, India was identified as P. elgii by 16S rRNA gene sequencing. P. elgii recorded significant board spectrum activity against all human and plant pathogenic microorganism tested except Candida albicans. It has been well known that even minor variations in the fermentation medium may impact not only the quantity of desired bioactive metabolites but also the general metabolic profile of the producing microorganisms. Thus, further studies were carried out to assess the impact of medium components on the antimicrobial production of P. elgii and to optimize an ideal fermentation medium to maximize its antimicrobial production. Out of three media [nutrient broth (NA), Luria broth (LB) and Trypticase soy broth (TSB)] used for fermentation, TSB medium recorded significant activity. Glucose and meat peptone were identified as the best carbon and nitrogen sources, which significantly affected the antibiotic production when supplemented with TSB medium. Next the effect of various fermentation conditions such as temperature, pH, and incubation time on the production of antimicrobial compounds was studied on TSB + glucose + meat peptone and an initial pH of 7 and a temperature of 30 degrees C for 3 days were found to be optimum for maximum antimicrobial production. The results indicate that medium composition in the fermentation media along with cultural parameters plays a vital role in the enhanced production of antimicrobial substances.
C1 [Kumar, S. N.; Jacob, Jubi; Reshma, U. R.; Rajesh, R. O.; Kumar, B. S. D.] CSIR, Agroproc & Nat Prod Div, Natl Inst Interdisciplinary Sci & Technol, Thiruvananthapuram, Kerala, India.
RP Kumar, BSD (reprint author), CSIR, Agroproc & Nat Prod Div, Natl Inst Interdisciplinary Sci & Technol, Thiruvananthapuram, Kerala, India.
EM kumardilleep@niist.res.in
RI TVM, NIIST/E-5132-2012
OI TVM, NIIST/0000-0002-5814-466X
FU Kerala State Council for Science, Technology and Engineering (KSCSTE);
   Department of Science and Technology (DST) [IF130648]
FX We thank Director CSIR-NIIST for his kind permission to carry out and
   publish this work. Dr. SK thanks, Kerala State Council for Science,
   Technology and Engineering (KSCSTE) for PDF fellowship. Acknowledgment
   to Department of Science and Technology (DST) for providing INSPIRE
   fellowship to JJ (IF130648).
CR Ajesh K, 2013, J APPL MICROBIOL, V115, P1287, DOI 10.1111/jam.12324
   ASH C, 1993, ANTON LEEUW INT J G, V64, P253
   Blunt JW, 2009, NAT PROD REP, V26, P170, DOI 10.1039/b805113p
   Calvo AM, 2002, MICROBIOL MOL BIOL R, V66, P447, DOI 10.1128/MMBR.66.3.447-459.2002
   Demain AL, 1999, APPL MICROBIOL BIOT, V52, P455, DOI 10.1007/s002530051546
   Drummond A, 2012, GENEIOUS V5 6
   Elo S, 2001, INT J SYST EVOL MICR, V51, P535, DOI 10.1099/00207713-51-2-535
   Feng JT, 2011, AFR J AGR RES, V6, P4424
   Gesheva V, 2005, MICROBIOL RES, V160, P243, DOI 10.1016/j.micres.2004.06.005
   Guimaraes LM, 2004, BIOTECHNOL APPL BIOC, V40, P107, DOI 10.1042/BA20030166
   Gunnarsson N, 2003, J IND MICROBIOL BIOT, V30, P150, DOI 10.1007/s10295-002-0024-6
   Hassan Maha A., 2001, Egyptian Journal of Biology, V3 (Botany), P1
   IWAI Y, 1982, J ANTIBIOT, V35, P123, DOI 10.7164/antibiotics.35.123
   Jose PA, 2011, J BASIC MICROB, V51, P348, DOI 10.1002/jobm.201000253
   Jose PA, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00240
   Kumar S. N., 2012, Journal of Microbiology, Biotechnology and Food Sciences, V1, P1424
   Li JR, 2007, APPL ENVIRON MICROB, V73, P3480, DOI 10.1128/AEM.02662-06
   Mitchell KF, 2013, ANTIMICROB AGENTS CH, V57, P1918, DOI 10.1128/AAC.02378-12
   Naing KW, 2014, ANN MICROBIOL, V64, P55, DOI 10.1007/s13213-013-0632-y
   Narayana K. J. P., 2008, RES J PHARM, V2, P4
   Nguyen T, 2008, NAT BIOTECHNOL, V26, P225, DOI 10.1038/nbt1379
   Nishanth Kumar, 2013, Archives of Phytopathology and Plant Protection, V46, P721, DOI 10.1080/03235408.2012.750815
   Pandey A, 2005, AFR J BIOTECHNOL, V4, P909
   Ridley CP, 2008, P NATL ACAD SCI USA, V105, P4595, DOI 10.1073/pnas.0710107105
   Rodriguez-Diaz M, 2005, INT J SYST EVOL MICR, V55, P2093, DOI 10.1099/ijs.0.63395-0
   Roux V, 2008, INT J SYST EVOL MICR, V58, P682, DOI 10.1099/ijs.0.65228-0
   Roy A, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00332
   Ryu CM, 2006, BIOL CONTROL, V39, P282, DOI 10.1016/j.biocontrol.2006.04.014
   Serrano NFG, 2012, CHEM PAP, V66, P1111, DOI 10.2478/s11696-012-0242-3
   Sole M, 1997, LETT APPL MICROBIOL, V25, P81, DOI 10.1046/j.1472-765X.1997.00171.x
   Vaara M, 2010, ANTIMICROB AGENTS CH, V54, P3341, DOI 10.1128/AAC.01439-09
   Velkov T, 2010, J MED CHEM, V53, P1898, DOI 10.1021/jm900999h
   Vijayakumari Siji Jinachandrannair, 2013, Iran J Microbiol, V5, P136
   VILCHES C, 1990, J GEN MICROBIOL, V136, P1447, DOI 10.1099/00221287-136-8-1447
   Wang YH, 2008, J APPL MICROBIOL, V104, P735, DOI 10.1111/j.1365-2672.2007.03599.x
   Wang YH, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-98
   Wright GD, 2007, TRENDS MOL MED, V13, P260, DOI 10.1016/j.molmed.2007.04.004
   Zhang HW, 2006, NAT PROD REP, V23, P753, DOI 10.1039/b609472b
NR 38
TC 3
Z9 3
U1 1
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD OCT 21
PY 2015
VL 6
AR 1167
DI 10.3389/fmicb.2015.01167
PG 11
WC Microbiology
SC Microbiology
GA CV0YN
UT WOS:000363979900001
PM 26539188
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wei, LM
   Zhu, YQ
   Liu, F
   Zhang, PL
   Li, XC
   Zhao, JG
   Lu, HT
AF Wei, Li-Ming
   Zhu, Yue-Qi
   Liu, Fang
   Zhang, Pei-Lei
   Li, Xiao-Cong
   Zhao, Jun-Gong
   Lu, Hai-Tao
TI RETRACTED: Percutaneous Aspiration Thrombectomy for Arterial
   Thromboembolism during Infrainguinal Endovascular Recanalization
   (Retracted article. See vol. 13, artn. e019676, 2018)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID EMBOLIC PROTECTION; LIMB ISCHEMIA; ANGIOPLASTY; OCCLUSIONS;
   REVASCULARIZATION; INTERVENTIONS; COMPLICATIONS; THROMBOLYSIS; DISEASE
AB Objectives
   To evaluate the efficacy of percutaneous aspiration thrombectomy (PAT) for infrainguinal arterial thromboembolism in patients undergoing endovascular recanalization (EVR) and to investigate the predictors for thromboembolic complications.
   Materials and Methods
   In total, 23 patients (23 limbs) who underwent PAT for thromboembolism (PAT group, PG) during EVR and 237 patients (302 limbs) who underwent successful EVR without thromboembolic complications (control group, CG) were enrolled. Immediate post-operation and follow-up outcomes were compared between the two groups. Multivariate analysis was performed to identify the predictors of thromboembolic complications. Technical success of PAT was defined as achievement of <30% residual stenosis and restoration of mTIMI grade 3.
   Results
   The technical success rate was 95.7% in PG. After intervention, the ankle-brachial index (ABI), restoration of blood flow and improvement in dorsal/plantar arterial pulse score showed no significant differences between PG and CG. During follow-up in PG, a sustained ABI improvement was observed in 63.6% (70.9% in CG), an improvement in walking distance in 68.8%(79.9% in CG,), ulcer healing in 75.0%(71.7% in CG) and restenosis/occlusion in 31.8% (25.2% in CG). The limb salvage rate was 100% in PG (96.0% in CG), and pain relief was observed in 66.7% patients with critical limb ischaemia (81.6% in CG). Superficial femoral artery involvement [0.233; 95% confidence interval (CI), 0.108-0.461; P < 0.001], de-novo lesion occlusion (683.8; 95% CI, 36.5-12804.6; P < 0.001) and intraluminal angioplasty (118.4; 95% CI, 8.0-1758.0; P = 0.001) was associated with high incidence of thromboembolism.
   Conclusion
   PAT is a safe and effective treatment for thromboembolism during infrainguinal arterial EVR. SFA involvement, de-novo lesion occlusion and intraluminal angioplasty may be predictors of thromboembolic complications.
C1 [Wei, Li-Ming; Zhu, Yue-Qi; Zhang, Pei-Lei; Li, Xiao-Cong; Zhao, Jun-Gong; Lu, Hai-Tao] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Diagnost & Intervent Radiol, Shanghai 200030, Peoples R China.
   [Liu, Fang] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Endocrinol, Shanghai 200030, Peoples R China.
RP Zhao, JG (reprint author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Diagnost & Intervent Radiol, Shanghai 200030, Peoples R China.
EM zhaojungong6th@hotmail.com
FU National Natural Science Foundation of China [81000652, 81370041,
   81271683]
FX This study received funding from the National Natural Science Foundation
   of China (Nos. 81000652; 81370041, 81271683).
CR CLEVELAND TJ, 1994, CLIN RADIOL, V49, P549, DOI 10.1016/S0009-9260(05)82935-6
   FOGARTY TJ, 1963, SURG GYNECOL OBSTET, V116, P241
   Gray WA, 2006, J VASC SURG, V44, P258, DOI 10.1016/j.jvs.2006.03.044
   Horvath L II, 1978, PERCUTANEOUS VASCULA, P126
   Karnabatidis D, 2006, J ENDOVASC THER, V13, P269, DOI 10.1583/05-1771.1
   Ko YG, 2007, J ENDOVASC THER, V14, P374, DOI 10.1583/06-1983.1
   Li J, 2011, ACAD RADIOL, V18, P755, DOI 10.1016/j.acra.2011.01.013
   Lookstein RA, 2010, TECH VASC INTERV RAD, V13, P54, DOI 10.1053/j.tvir.2009.10.007
   Mendes BC, 2014, J VASC SURG, V59, P359, DOI 10.1016/j.jvs.2013.07.119
   Schleder S, 2015, CARDIOVASC INTER RAD, V38, P60, DOI 10.1007/s00270-014-0857-6
   Sianos G, 2007, J AM COLL CARDIOL, V50, P573, DOI 10.1016/j.jacc.2007.04.059
   Spiliopoulos S, 2014, J ENDOVASC THER, V21, P474, DOI 10.1583/14-4703.1
   Spiliopoulos S, 2012, J VASC SURG, V56, P1308, DOI 10.1016/j.jvs.2012.04.036
   Sumitsuji S, 2011, JACC-CARDIOVASC INTE, V4, P941, DOI 10.1016/j.jcin.2011.06.011
   Vorwerk D, 2006, CARDIOVASC INTER RAD, V29, P7, DOI 10.1007/s00270-005-8888-7
   Ward TJ, 2014, J VASC INTERV RADIOL, V25, P1533, DOI 10.1016/j.jvir.2014.07.016
   Wei LM, 2014, ACAD RADIOL, V21, P1475, DOI 10.1016/j.acra.2014.05.023
   Zafar N, 2008, CATHETER CARDIO INTE, V71, P972, DOI 10.1002/ccd.21561
   Zhang FX, 2014, ANN VASC SURG, V28, P590, DOI 10.1016/j.avsg.2013.05.015
NR 19
TC 2
Z9 2
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 20
PY 2015
VL 10
IS 10
AR e0140494
DI 10.1371/journal.pone.0140494
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CT7XI
UT WOS:000363028100037
PM 26484672
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Song, YG
   Park, SJ
AF Song, Yoo Geun
   Park, Seok Jae
TI RETRACTED: AXISYMMETRIC, NONSTATIONARY BLACK HOLE MAGNETOSPHERES:
   REVISITED (Retracted article. See vol. 815, pg. 79, 2015)
SO ASTROPHYSICAL JOURNAL
LA English
DT Article; Retracted Publication
DE accretion, accretion disks; black hole physics; magnetohydrodynamics
   (MHD)
ID ELECTRODYNAMICS
AB An axisymmetric, stationary, general-relativistic, electrodynamic engine model of an active galactic nucleus was formulated by Macdonald and Thorne that consisted of a supermassive black hole surrounded by a plasma magnetosphere and a magnetized accretion disk. Based on this initial formulation, a nonstationary, force-free version of their model was constructed by Park & Vishniac (PV), with the simplifying assumption that the poloidal component of the magnetic field line velocity be confined along the radial direction in cylindrical polar coordinates. In this paper, we derive the new, nonstationary "Transfield Equation," which was not specified in PV. If we can solve this "Transfield Equation" numerically, then we will understand the axisymmetric, nonstationary black hole magnetosphere in more rigorous ways.
C1 [Song, Yoo Geun; Park, Seok Jae] Korea Astron & Space Sci Inst, Taejon 305348, South Korea.
   [Song, Yoo Geun; Park, Seok Jae] Univ Sci & Technol, Taejon 305350, South Korea.
RP Song, YG (reprint author), Korea Astron & Space Sci Inst, Taejon 305348, South Korea.
EM ygsong@kasi.re.kr; sjpark@kasi.re.kr
CR Alic D, 2012, ASTROPHYS J, V754, DOI 10.1088/0004-637X/754/1/36
   Beskin VS, 2010, ASTRON ASTROPHYS LIB, P1, DOI 10.1007/978-3-642-01290-7
   MACDONALD D, 1982, MON NOT R ASTRON SOC, V198, P345, DOI 10.1093/mnras/198.2.345
   MACDONALD DA, 1984, MON NOT R ASTRON SOC, V211, P313, DOI 10.1093/mnras/211.2.313
   OKAMOTO I, 1992, MON NOT R ASTRON SOC, V254, P192, DOI 10.1093/mnras/254.2.192
   Palenzuela C, 2011, CLASSICAL QUANT GRAV, V28, DOI 10.1088/0264-9381/28/13/134007
   Palenzuela C, 2010, SCIENCE, V329, P927, DOI 10.1126/science.1191766
   PARK SJ, 1989, ASTROPHYS J, V337, P78, DOI 10.1086/167088
   Punsly B, 2008, ASTROPHYS SPACE SC L, V355, P1, DOI 10.1007/978-3-540-76957-6
   Tchekhovskoy A, 2010, ASTROPHYS J, V711, P50, DOI 10.1088/0004-637X/711/1/50
   Thorne K. S, 1986, BLACK HOLES MEMBRANE
NR 11
TC 1
Z9 1
U1 2
U2 8
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0004-637X
EI 1538-4357
J9 ASTROPHYS J
JI Astrophys. J.
PD OCT 10
PY 2015
VL 812
IS 1
AR 8
DI 10.1088/0004-637X/812/1/8
PG 5
WC Astronomy & Astrophysics
SC Astronomy & Astrophysics
GA CV4KC
UT WOS:000364234700008
OA Bronze
DA 2018-12-27
ER

PT J
AU Taheriazam, A
   Talaei, AJ
   Jamshidi, M
   Shakeri, M
   Khoshbakht, S
   Yahaghi, E
   Shokrani, M
AF Taheriazam, Afshin
   Talaei, Amir Jouya
   Jamshidi, Mohammad
   Shakeri, Mohammadreza
   Khoshbakht, Samaneh
   Yahaghi, Emad
   Shokrani, Marjan
TI RETRACTED: Up-regulation of miR-130b expression level and
   down-regulation of miR-218 serve as potential biomarker in the early
   detection of human osteosarcoma(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Mir-130b/218; Osteosarcoma; Regulation; Patient; Diagnosis
ID GASTRIC-CANCER; HEPATOCELLULAR-CARCINOMA; MICRORNA EXPRESSION;
   TUMOR-SUPPRESSOR; CELL-MIGRATION; INVASION; TARGETS
AB Background: Osteosarcoma (OS) is a primary malignant bone tumor with high morbidity that principally emerges in children and adolescents. MiRNAs regulate a variety of normal physiologic processes and are involved in tumorigenesis and development of multiple malignancies, including OS. This study was aimed to evaluate the clinical significance of miR-130b and miR-218 in osteosarcoma patient.
   Methods: We utilized quantitative real-time PCR to evaluate the level of miR-130b and miR-218 expressions in OS patients and normal tissues and their relationship with clinicopathological features and survival in OS patients.
   Results: QRT-PCR indicated that miR-130b expression in tumor tissues was strongly elevated than adjacent non-tumor tissues (P < 0.001), while the level of miR-218 expression in osteosarcoma tissues was down-regulated than adjacent non-tumor tissues (P < 0.001). We evaluated the clinical significance of miR-130b and miR-218 in osteosarcoma. Clinical correlation analysis showed that increased expression of miR-130b and decreased expression of miR-218 were significantly associated with advanced tumor stage (x(2) = 6.285, P < 0.009; x(2) = 7.172, P < 0.007), distant metastasis (x(2) = 5.528; P < 0.001; x(2) = 4.617, P < 0.001) and size of tumor (x(2) = 5.01, P = 0.013; x(2) = 4.271, P = 0.019).
   Conclusions: Taken together, our data indicated that high miR-130b level and low level of miR-218 are associated with poor clinicopathological characteristics. Furthermore, miR-130b may play a key role in the progression of osteosarcoma.
C1 [Taheriazam, Afshin] Islamic Azad Univ, Tehran Med Sci Branch, Dept Orthoped Surg, Tehran, Iran.
   [Talaei, Amir Jouya] Azad Univ, Tehran Med Sci Branch, Fac Life Sci, Dept Genet, Tehran, Iran.
   [Jamshidi, Mohammad] Zahedan Univ Med Sci, Cellular & Mol Res Ctr, Zahedan, Iran.
   [Jamshidi, Mohammad] Zahedan Univ Med Sci, Sch Med, Dept Clin Biochem, Zahedan, Iran.
   [Shakeri, Mohammadreza] Birjand Univ Med Sci, Dept Orthopaed & Trauma Surg, Birjand, Iran.
   [Khoshbakht, Samaneh] Islamic Azad Univ, Mashhad Branch, Dept Stat, Fac Sci, Mashhad, Iran.
   [Yahaghi, Emad] Baqiyatallah Univ Med Sci, Dept Mol Biol, Tehran, Iran.
   [Shokrani, Marjan] Univ Tehran Med Sci, Fac Med, Tehran, Iran.
RP Shokrani, M (reprint author), Univ Tehran Med Sci, Fac Med, Tehran, Iran.
EM drshokrani.tums@gmail.com
OI Taheriazam, Afshin/0000-0002-3907-925X
CR Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043
   Bottai G, 2014, EXPERT OPIN BIOL TH, V14, P1667, DOI 10.1517/14712598.2014.950650
   Botter SM, 2014, CURR OPIN PHARMACOL, V16, P15, DOI 10.1016/j.coph.2014.02.002
   Chang SJ, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-65
   Colangelo T, 2013, NEOPLASIA, V15, P1204, DOI 10.1593/neo.13998
   D'Anzeo M, 2014, MOLECULES, V19, P6393, DOI 10.3390/molecules19056393
   Davidson MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012560
   Dong P, 2013, ONCOGENE, V32, P3286, DOI 10.1038/onc.2012.334
   Drusco A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096670
   Gill J, 2013, PHARMACOL THERAPEUT, V137, P89, DOI 10.1016/j.pharmthera.2012.09.003
   He XQ, 2012, MOL MED, V18, P1491, DOI 10.2119/molmed.2012.00304
   Hirata H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051056
   Hu H, 2012, ONCOL LETT, V4, P1037, DOI 10.3892/ol.2012.866
   Jin J, 2013, ASIAN PAC J CANCER P, V14, P3681, DOI 10.7314/APJCP.2013.14.6.3681
   Kang SM, 2014, EXP BIOL MED, V239, P1505, DOI 10.1177/1535370214533887
   Kim BH, 2013, J SURG ONCOL, V107, P505, DOI 10.1002/jso.23271
   Lai KW, 2010, EUR J CANCER, V46, P1456, DOI 10.1016/j.ejca.2010.01.036
   Leone V, 2014, MOL CELL ENDOCRINOL, V390, P1, DOI 10.1016/j.mce.2014.03.002
   Li BL, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0484-0
   Li Z, 2015, CELL PROLIFERAT, V48, P1, DOI 10.1111/cpr.12160
   Liu G, 2014, TUMOR BIOL, V35, P9801, DOI 10.1007/s13277-014-2273-6
   Liu YW, 2012, ONCOL REP, V28, P1013, DOI 10.3892/or.2012.1902
   Montanaro L, 2007, CELL PROLIFERAT, V40, P532, DOI 10.1111/j.1365-2184.2007.00448.x
   Nishikawa R, 2014, CANCER SCI, V105, P802, DOI 10.1111/cas.12441
   Nugent M, 2014, CANCER MANAG RES, V6, P15, DOI 10.2147/CMAR.S53928
   Sand M, 2013, CELL TISSUE RES, V351, P85, DOI 10.1007/s00441-012-1514-5
   Scheffer AR, 2014, WORLD J UROL, V32, P353, DOI 10.1007/s00345-012-1010-2
   Shah NR, 2014, WORLD J CLIN ONCOL, V5, P48, DOI 10.5306/wjco.v5.i2.48
   Tang J, 2014, CELL PROLIFERAT, V47, P427, DOI 10.1111/cpr.12129
   Tatarano S, 2011, INT J ONCOL, V39, P13, DOI 10.3892/ijo.2011.1012
   Thayanithy V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043720
   Tu KS, 2014, ONCOL REP, V32, P1571, DOI 10.3892/or.2014.3386
   Xin SY, 2014, WORLD J GASTROENTERO, V20, P6906, DOI 10.3748/wjg.v20.i22.6906
   Yip L, 2011, ANN SURG ONCOL, V18, P2035, DOI 10.1245/s10434-011-1733-0
   Yu X, 2014, INT J MOL MED, V34, P923, DOI 10.3892/ijmm.2014.1853
   Zhao G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073803
NR 36
TC 6
Z9 7
U1 4
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD OCT 7
PY 2015
VL 10
AR 184
DI 10.1186/s13000-015-0422-x
PG 5
WC Pathology
SC Pathology
GA CT0FX
UT WOS:000362470400001
PM 26446495
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU El Fakih, RO
   Champlin, R
   Oran, B
AF El Fakih, Riad O.
   Champlin, Richard
   Oran, Betul
TI RETRACTED: 5-Azacitidine for treating acute myelogenous leukemia
   (Retracted article. See vol. 4, pg. 562, 2016)
SO EXPERT OPINION ON ORPHAN DRUGS
LA English
DT Review; Retracted Publication
DE azacitidine; leukemia; myelodysplastic syndromes; transplant
ID ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; RISK MYELODYSPLASTIC
   SYNDROMES; CONVENTIONAL CARE REGIMENS; DONOR LYMPHOCYTE INFUSIONS;
   LOW-DOSE AZACITIDINE; TRANS-RETINOIC ACID; NEWLY-DIAGNOSED AML;
   REGULATORY T-CELLS; OLDER PATIENTS
AB Introduction: 5-Azacytidine is a chemically synthesized nucleoside analogue that was manufactured in the 1960s. It is a DNA methyltransferase (DNMT) inhibitor that has in vitro and in vivo demethylating effects. On 19 May 2004, the US FDA approved azacitidine as injectable suspension for treatment of patients with myelodysplastic syndromes (MDS).Areas covered: Hypomethylating therapy has been increasingly used in place of standard intensive chemotherapy for the treatment of unfit' elderly patients with acute myeloid leukemia (AML). In the USA, azacitidine and decitabine are the most commonly used low-intensity therapies. In this article, we review the current literature about azacitidine for the treatment of MDS, AML and in the stem cell transplant field.Expert opinion: Azacitidine is an old/new drug that gained more attention after its FDA approval for MDS. It is the only drug that showed survival benefit in MDS, in a Phase III randomized controlled trial. Azacitidine also has an important role in treating relapsed AML and MDS post-allogeneic hematopoietic stem cell transplantation. Combination therapy is promising, especially with the availability of low toxicity targeted therapies, but trials in this setting are missing and much needed to provide a tolerable, effective and personalized strategy for these patients in great need for such therapy.
C1 [El Fakih, Riad O.; Oran, Betul] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat, Houston, TX 77030 USA.
   [Champlin, Richard] Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.
RP El Fakih, RO (reprint author), Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat, Houston, TX 77030 USA.
EM riadfakih@hotmail.com
CR Al-Ali HK, 2012, LEUKEMIA LYMPHOMA, V53, P110, DOI 10.3109/10428194.2011.606382
   Alibhai SMH, 2009, CANCER, V115, P2903, DOI 10.1002/cncr.24373
   Antar A, 2013, BONE MARROW TRANSPL, V48, P994, DOI 10.1038/bmt.2012.256
   ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Appelbaum FR, 2001, HEMATOL-AM SOC HEMAT, V6, P62
   Barrett AJ, 2008, SEMIN HEMATOL, V45, P49, DOI 10.1053/j.seminhematol.2007.1.0.005
   BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x
   BHAGWAT AS, 1987, J BACTERIOL, V169, P1537, DOI 10.1128/jb.169.4.1537-1546.1987
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   BIRD AP, 1979, CELL, V17, P889, DOI 10.1016/0092-8674(79)90329-5
   Blum W, 2010, P NATL ACAD SCI USA, V107, P7473, DOI 10.1073/pnas.1002650107
   Bolanos-Meade J, 2011, BIOL BLOOD MARROW TR, V17, P754, DOI 10.1016/j.bbmt.2010.10.008
   Bories P, 2011, BLOOD, V118, P2614
   Buchner T, 2009, J CLIN ONCOL, V27, P61, DOI 10.1200/JCO.2007.15.4245
   Burnett AK, 2007, CANCER, V109, P1114, DOI 10.1002/cncr.22496
   Cashen AF, 2010, J CLIN ONCOL, V28, P556, DOI 10.1200/JCO.2009.23.9178
   CHESON BD, 1992, SEMIN ONCOL, V19, P85
   CHESON BD, 1987, SEMIN ONCOL, V14, P126
   Cheson BD, 2006, BLOOD, V108, P419, DOI 10.1182/blood-2005-10-4149
   CHITAMBAR CR, 1991, AM J HEMATOL, V37, P100, DOI 10.1002/ajh.2830370207
   Choi J, 2010, BLOOD, V116, P129, DOI 10.1182/blood-2009-12-257253
   Christiansen DH, 2003, LEUKEMIA, V17, P1813, DOI 10.1038/sj.leu.2403054
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Czibere A, 2010, BONE MARROW TRANSPL, V45, P872, DOI 10.1038/bmt.2009.266
   de Lima M, 2010, CANCER-AM CANCER SOC, V116, P5420, DOI 10.1002/cncr.25500
   de Witte T, 2001, BLOOD, V98, P2326, DOI 10.1182/blood.V98.8.2326
   Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426
   Derissen EJB, 2013, ONCOLOGIST, V18, P619, DOI 10.1634/theoncologist.2012-0465
   Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358
   Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664
   Estey E, 2013, MEDITERR J HEMATOL I, V5
   Estey EH, 2001, BLOOD, V98, P3575, DOI 10.1182/blood.V98.13.3575
   Faderl S, 2012, J CLIN ONCOL, V30, P2492, DOI 10.1200/JCO.2011.37.9743
   Falantes JF, 2014, CL LYMPH MYELOM LEUK, V14, P80, DOI 10.1016/j.clml.2013.09.014
   Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Field T, 2006, BLOOD, V3664
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Gandhi S, 2013, BLOOD, V122
   Garcia-Manero G, 2011, ASH ANN M, P608
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Gavillet M, 2012, HAEMATOL-HEMATOL J, V97, P1929, DOI 10.3324/haematol.2012.065151
   Goodyear O, 2010, BLOOD, V116, P1908, DOI 10.1182/blood-2009-11-249474
   Goodyear OC, 2012, BLOOD, V119, P3361, DOI 10.1182/blood-2011-09-377044
   Gore SD, 2013, HAEMATOLOGICA, V98, P1067, DOI 10.3324/haematol.2012.074831
   Graef T, 2007, LEUKEMIA RES, V31, P257, DOI 10.1016/j.leukres.2006.03.003
   Greenberg P, 1997, BLOOD, V89, P2079
   Greenberg PL, 2012, BLOOD, V120, P2454, DOI 10.1182/blood-2012-03-420489
   Gryn J, 2002, LEUKEMIA RES, V26, P893, DOI 10.1016/S0145-2126(02)00028-0
   HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6
   Harris NL, 1999, J CLIN ONCOL, V17, P3835, DOI 10.1200/JCO.1999.17.12.3835
   HELLSTROMLINDBERG E, 1992, BRIT J HAEMATOL, V81, P503, DOI 10.1111/j.1365-2141.1992.tb02982.x
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Itzykson R, 2015, LEUKEMIA RES, V39, P124, DOI 10.1016/j.leukres.2014.11.009
   Jabbour E, 2009, CANCER-AM CANCER SOC, V115, P1899, DOI 10.1002/cncr.24198
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   JONES PA, 1981, NUCLEIC ACIDS RES, V9, P2933, DOI 10.1093/nar/9.12.2933
   JONES PA, 1983, RECENT RES CANCER, V84, P202
   Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135
   Kantarjian H, 2006, CANCER, V106, P1794, DOI 10.1002/cncr.21792
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1090, DOI 10.1002/cncr.21723
   Kantarjian H, 2006, CANCER, V106, P1099, DOI 10.1002/cncr.21699
   Kantarjian HM, 2012, J CLIN ONCOL, V30, P2670, DOI 10.1200/JCO.2011.38.9429
   Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109
   Kim SY, 2010, BONE MARROW TRANSPL, V45, P1375, DOI 10.1038/bmt.2009.355
   Knipp S, 2007, CANCER-AM CANCER SOC, V110, P345, DOI 10.1002/cncr.22779
   List AF, 2004, HEMATOL-AM SOC HEMAT, V2004, P297
   Lubbert M, 2010, BONE MARROW TRANSPL, V45, P627, DOI 10.1038/bmt.2009.222
   Lubbert M, 2012, HAEMATOL-HEMATOL J, V97, P393, DOI 10.3324/haematol.2011.048231
   Maslak P, 2006, LEUKEMIA, V20, P212, DOI 10.1038/sj.leu.2404050
   Maurillo L, 2012, CANCER-AM CANCER SOC, V118, P1014, DOI 10.1002/cncr.26354
   Moon C, 2009, TRANSPL P, V41, P1848, DOI 10.1016/j.transproceed.2009.02.101
   Nand S, 2012, BLOOD, V3584
   Oran B, 2012, HAEMATOL-HEMATOL J, V97, P1916, DOI 10.3324/haematol.2012.066100
   Platzbecker U, 2012, LEUKEMIA, V26, P381, DOI 10.1038/leu.2011.234
   Pleyer L, 2013, HEMATOL ONCOL, V6, P32, DOI DOI 10.1186/1756-8722-6-32
   Pollyea DA, 2013, HAEMATOLOGICA, V98, P591, DOI 10.3324/haematol.2012.076414
   Prebet T, 2004, HEMATOL J, V5, P209, DOI 10.1038/sj.thj.6200363
   Quintas-Cardama A, 2012, BLOOD, V120, P4840, DOI 10.1182/blood-2012-06-436055
   Raffoux E, 2010, ONCOTARGET, V1, P34, DOI 10.18632/oncotarget.106
   Raj Kavita, 2006, Ther Clin Risk Manag, V2, P377, DOI 10.2147/tcrm.2006.2.4.377
   Raj KK, 2005, BLOOD, V2530
   Ramos F, 2015, LEUKEMIA RES, V39, P296, DOI 10.1016/j.leukres.2014.12.013
   Ravandi F, 2013, BLOOD, V121, P4655, DOI 10.1182/blood-2013-01-480228
   Ritchie EK, 2013, LEUKEMIA LYMPHOMA, V54, P2003, DOI 10.3109/10428194.2012.762093
   Sarkozy C, 2013, AM J HEMATOL, V88, P758, DOI 10.1002/ajh.23498
   Schmid C, 2012, BLOOD, V119, P1599, DOI 10.1182/blood-2011-08-375840
   Schroeder T, 2013, LEUKEMIA, V27, P1910, DOI 10.1038/leu.2013.64
   Schroeder T, 2013, LEUKEMIA, V27, P1229, DOI 10.1038/leu.2013.7
   Schroeder T, 2015, BIOL BLOOD MARROW TR, V21, P653, DOI 10.1016/j.bbmt.2014.12.016
   Silverman LR, 2006, J CLIN ONCOL, V24, P3895, DOI 10.1200/JCO.2005.05.4346
   SILVERMAN LR, 1993, LEUKEMIA, V7, P21
   Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117
   Tang KF, 2008, BIOCHEM BIOPH RES CO, V370, P578, DOI 10.1016/j.bbrc.2008.03.131
   Tawfik B, 2014, ANN HEMATOL, V93, P47, DOI 10.1007/s00277-013-1940-9
   Tessoulin B, 2014, BONE MARROW TRANSPL, V49, P567, DOI 10.1038/bmt.2013.233
   Thepot S, 2014, AM J HEMATOL, V89, P410, DOI 10.1002/ajh.23654
   Uchida T, 1997, BLOOD, V90, P1403
   van der Helm LH, 2013, LEUKEMIA RES, V37, P877, DOI 10.1016/j.leukres.2013.03.022
   van der Helm LH, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-29
   van der Straaten HM, 2005, HAEMATOL-HEMATOL J, V90, P1339
   Verbeek W, 1997, ANN HEMATOL, V74, P205, DOI 10.1007/s002770050285
   Walter RB, 2014, HAEMATOLOGICA, V99, P54, DOI 10.3324/haematol.2013.096545
   Wei A, 2015, BRIT J HAEMATOL, V169, P199, DOI 10.1111/bjh.13281
NR 104
TC 2
Z9 2
U1 1
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 2167-8707
J9 EXPERT OPIN ORPHAN D
JI Exp. Opin. Orphan Drugs
PD OCT 3
PY 2015
VL 3
IS 10
BP 1197
EP 1207
DI 10.1517/21678707.2015.1089168
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA DC7KV
UT WOS:000369399700009
DA 2018-12-27
ER

PT J
AU Lai, YY
   Li, YM
   Lang, JD
   Tong, XL
   Zhang, LN
   Fang, JH
   Xing, JL
   Cai, M
   Xu, HT
   Deng, Y
   Xiao, F
   Tian, G
AF Lai, Yi Yu
   Li, Yanming
   Lang, Jidong
   Tong, Xunliang
   Zhang, Lina
   Fang, Jianhuo
   Xing, Jingli
   Cai, Meng
   Xu, Hongtao
   Deng, Yan
   Xiao, Fei
   Tian, Geng
TI RETRACTED: Metagenomic Human Repiratory Air in a Hospital Environment
   (Retracted article. See vol. 11, e0147243, 2016)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID SALINE FLUSH; MICROBES; EXPOSURE; CULTURE; GENOME; PNEUMONIA; SEQUENCES;
   PATHOGEN; OUTBREAK; DISEASE
AB Hospital-acquired infection (HAI) or nosocomial infection is an issue that frequent hospital environment. We believe conventional regulated Petri dish method is insufficient to evaluate HAI. To address this problem, metagenomic sequencing was applied to screen airborne microbes in four rooms of Beijing Hospital. With air-in amount of sampler being setup to one person's respiration quantity, metagenomic sequencing identified huge numbers of species in the rooms which had already qualified widely accepted petridish exposing standard, imposing urgency for new technology. Meanwhile, the comparative culture only got small portion of recovered species and remain blind for even cultivable pathogens reminded us the limitations of old technologies. To the best of our knowledge, the method demonstrated in this study could be broadly applied in hospital indoor environment for various monitoring activities as well as HAI study. It is also potential as a transmissible pathogen real-time modelling system worldwide.
C1 [Lai, Yi Yu; Lang, Jidong; Zhang, Lina; Fang, Jianhuo; Xing, Jingli; Tian, Geng] Tsinghua Univ, Genom & Synthet Biol Ctr, Beijing 100084, Peoples R China.
   [Li, Yanming; Tong, Xunliang] Beijing Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China.
   [Lang, Jidong; Tian, Geng] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.
   [Cai, Meng] Beijing Hosp, Dept Hosp Infect Control, Beijing, Peoples R China.
   [Xu, Hongtao] Beijing Hosp, Dept Lab Med, Beijing, Peoples R China.
   [Deng, Yan] Tsinghua Univ, State Key Lab Precis Measurement Technol & Instru, Beijing 100084, Peoples R China.
   [Xiao, Fei] Beijing Hosp, Minist Hlth, Beijing Inst Geriatr, Key Lab Geriatr, Beijing, Peoples R China.
RP Xiao, F (reprint author), Beijing Hosp, Minist Hlth, Beijing Inst Geriatr, Key Lab Geriatr, Beijing, Peoples R China.
EM xiaofei@bjhmoh.cn; tiangeng@biomed.tsinghua.edu.cn
FU Tsinghua University initiative scientific research program
   [20131089296]; Innocentive grant [9932993]
FX Support was provided by Tsinghua University initiative scientific
   research program under Grant 20131089296 and Innocentive grant no.
   9932993.
CR Aimanianda V, 2009, NATURE, V460, P1117, DOI 10.1038/nature08264
   Bowman JP, 1997, INT J SYST BACTERIOL, V47, P1040, DOI 10.1099/00207713-47-4-1040
   Cao C, 2014, ENVIRON SCI TECHNOL, V48, P1499, DOI 10.1021/es4048472
   Chen K, 2005, PLOS COMPUT BIOL, V1, P106, DOI 10.1371/journal.pcbi.0010024
   Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182
   Committee on Metagenomics: Challenges and Functional Applications National Research Council, 2007, NEW SCI MET REV SECR
   Dali P, 2001, ANTIMICROB AGENTS CH, V45, P2969, DOI 10.1128/AAC.45.10.2969-2970.2001
   Dijkshoorn L, 2007, NAT REV MICROBIOL, V5, P939, DOI 10.1038/nrmicro1789
   Eames I, 2009, J R SOC INTERFACE, V6, pS697, DOI 10.1098/rsif.2009.0407.focus
   Eisen JA, 2007, PLOS BIOL, V5, P384, DOI 10.1371/journal.pbio.0050082
   Embers ME, 2011, VET MICROBIOL, V147, P367, DOI 10.1016/j.vetmic.2010.06.029
   Gershman MD, 2008, CLIN INFECT DIS, V47, P1372, DOI 10.1086/592968
   GILRANE T, 1985, AM J MED, V78, P1038, DOI 10.1016/0002-9343(85)90230-X
   Gomez-Alvarez V, 2009, ISME J, V3, P1314, DOI 10.1038/ismej.2009.72
   Greninger AL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013381
   Griffith CJ, 2000, J HOSP INFECT, V45, P19, DOI 10.1053/jhin.1999.0717
   Handelsman J, 1998, CHEM BIOL, V5, pR245, DOI 10.1016/S1074-5521(98)90108-9
   Hensel M, 2009, SECRETED PROTEINS VI
   Holt KE, 2012, NAT GENET, V44, P1056, DOI 10.1038/ng.2369
   Hugenholtz P, 1998, J BACTERIOL, V180, P4765
   Jain SK, 2005, EMERG INFECT DIS, V11, P1097, DOI 10.3201/eid1107.050092
   Kishore J, 2012, INDIAN J MED RES, V135, P341
   Klevens RM, 2002, PUBLIC HLTH REP, V122, P160
   Koulenti D, 2009, CRIT CARE MED, V37, P2360, DOI 10.1097/CCM.0b013e3181a037ac
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605
   Li J, 2013, ENVIRON SCI TECHNOL, V47, P10660, DOI 10.1021/es402848d
   Loman NJ, 2013, JAMA-J AM MED ASSOC, V309, P1502, DOI 10.1001/jama.2013.3231
   McLean JS, 2013, GENOME RES, V23, P867, DOI 10.1101/gr.150433.112
   Mokili JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058404
   Moon HS, 2009, ENVIRON SCI TECHNOL, V43, P5857, DOI 10.1021/es900078z
   MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46
   Pasanen AL, 2001, INDOOR AIR, V11, P87, DOI 10.1034/j.1600-0668.2001.110203.x
   Patterson MJ, 1996, BARONS MED MICROBIOL
   Peccia J, 2008, ENVIRON SCI TECHNOL, V42, P4631
   Podschun R, 1998, CLIN MICROBIOL REV, V11, P589, DOI 10.1128/CMR.11.4.589
   Poinar HN, 2006, SCIENCE, V311, P392, DOI 10.1126/science.1123360
   Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450
   Ryan K., 2004, SHERRIS MED MICROBIO
   Salyers AA, 2004, TRENDS MICROBIOL, V12, P412, DOI 10.1016/j.tim.2004.07.004
   Seth-Smith HMB, 2013, GENOME RES, V23, P855, DOI 10.1101/gr.150037.112
   Tringe SG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001862
   Tronel H, 2001, CLIN MICROBIOL INFEC, V7, P275, DOI 10.1046/j.1469-0691.2001.00241.x
   Tyson GW, 2004, NATURE, V428, P37, DOI 10.1038/nature02340
   Wan XF, 2013, VIRUS GENES, V46, P441, DOI 10.1007/s11262-013-0878-2
   Xu BL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002369
   Yooseph S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081862
NR 47
TC 12
Z9 12
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 2
PY 2015
VL 10
IS 10
AR e0139044
DI 10.1371/journal.pone.0139044
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS6HH
UT WOS:000362178700029
PM 26431488
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Roy, S
   Lahiri, D
   Maji, T
   Biswas, J
AF Roy, Sanjoy
   Lahiri, Debarshi
   Maji, Tapas
   Biswas, Jaydip
TI RETRACTED: Recurrent Glioblastoma: Where we stand(Retracted article. See
   vol. 6, pg. 153, 2017)
SO SOUTH ASIAN JOURNAL OF CANCER
LA English
DT Review; Retracted Publication
DE Chemotherapy; glioblastoma multiforme; glioma; targeted therapy;
   temozolomide
ID PHASE-II TRIAL; SUPRATENTORIAL MALIGNANT GLIOMA; SINGLE-INSTITUTION
   EXPERIENCE; BEVACIZUMAB PLUS IRINOTECAN; BRAIN-TUMOR CONSORTIUM;
   GROWTH-FACTOR RECEPTOR; LONG-TERM SURVIVAL; HIGH-GRADE GLIOMA;
   STEREOTACTIC RADIOSURGERY; INTRACRANIAL GLIOBLASTOMA
AB Current first-line treatment regimens combine surgical resection and chemoradiation for Glioblastoma that provides a slight increase in overall survival. Age on its own should not be used as an exclusion criterion of glioblastoma multiforme (GBM) treatment, but performance should be factored heavily into the decision-making process for treatment planning. Despite aggressive initial treatment, most patients develop recurrent diseases which can be treated with re-resection, systemic treatment with targeted agents or cytotoxic chemotherapy, reirradiation, or radiosurgery. Research into novel therapies is investigating alternative temozolomide regimens, convection-enhanced delivery, immunotherapy, gene therapy, antiangiogenic agents, poly ADP ribose polymerase inhibitors, or cancer stem cell signaling pathways. Given the aggressive and resilient nature of GBM, continued efforts to better understand GBM pathophysiology are required to discover novel targets for future therapy.
C1 [Roy, Sanjoy; Lahiri, Debarshi; Maji, Tapas; Biswas, Jaydip] Chittaranjan Natl Canc Inst, Dept Radiotherapy, Kolkata, W Bengal, India.
RP Roy, S (reprint author), Chittaranjan Natl Canc Inst, Dept Radiotherapy, Kolkata, W Bengal, India.
EM sanjoyroy56@gmail.com
CR Addeo R, 2011, J NEURO-ONCOL, V102, P417, DOI 10.1007/s11060-010-0329-z
   Ahluwalia Manmeet S, 2011, Expert Rev Anticancer Ther, V11, P161, DOI 10.1586/era.10.227
   AMMIRATI M, 1987, NEUROSURGERY, V21, P607, DOI 10.1227/00006123-198711000-00001
   Apuzzo ML, 1990, NEUROSURGICAL TOPICS, V2
   Balana C, 2011, EXPERT REV ANTICANC, V11, P1719, DOI [10.1586/ERA.11.152, 10.1586/era.11.152]
   Barbagallo GMV, 2008, BRIT J NEUROSURG, V22, P452, DOI 10.1080/02688690802182256
   Batchelor T, 2010, NEURO-ONCOLOGY, V12, P75
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Batchelor TT, 2010, J CLIN ONCOL, V28, P2817, DOI 10.1200/JCO.2009.26.3988
   Baumann F, 2004, J NEURO-ONCOL, V67, P191, DOI 10.1023/B:NEON.0000021803.01170.03
   Berrocal A, 2010, J NEURO-ONCOL, V96, P417, DOI 10.1007/s11060-009-9980-7
   Brada M, 2010, J CLIN ONCOL, V28, P4601, DOI 10.1200/JCO.2009.27.1932
   Brandes AA, 2004, NEUROLOGY, V63, P1281, DOI 10.1212/01.WNL.0000140495.33615.CA
   Brandes AA, 2008, J CLIN ONCOL, V26, P2192, DOI 10.1200/JCO.2007.14.8163
   Brandes AA, 2009, CANCER CHEMOTH PHARM, V64, P769, DOI 10.1007/s00280-009-0926-8
   Brandsma D, 2008, LANCET ONCOL, V9, P453, DOI 10.1016/S1470-2045(08)70125-6
   BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6
   Chang Julie E, 2007, Clin Adv Hematol Oncol, V5, P894
   Chen W, 2007, J CLIN ONCOL, V25, P4714, DOI 10.1200/JCO.2006.10.5825
   CHOUCAIR AK, 1986, J NEUROSURG, V65, P654, DOI 10.3171/jns.1986.65.5.0654
   Combs SE, 2005, CANCER, V104, P2168, DOI 10.1002/cncr.21429
   Combs SE, 2005, J NEURO-ONCOL, V74, P167, DOI 10.1007/s11060-004-2463-y
   Combs SE, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-167
   Davis FG, 1998, J NEUROSURG, V88, P1, DOI 10.3171/jns.1998.88.1.0001
   de Groot JF, 2008, J NEURO-ONCOL, V90, P89, DOI 10.1007/s11060-008-9637-y
   de Groot JF, 2011, J CLIN ONCOL, V29, P2689, DOI 10.1200/JCO.2010.34.1636
   DEEN DF, 1993, J NEURO-ONCOL, V16, P243, DOI 10.1007/BF01057041
   Desjardins A, 2012, CANCER-AM CANCER SOC, V118, P1302, DOI 10.1002/cncr.26381
   Dhermain F, 2004, B CANCER, V91, P883
   Eisenstat D. D., 2011, J CLIN ONCOL S15, V29
   Elliott RE, 2011, WORLD NEUROSURG, V76, P128, DOI 10.1016/j.wneu.2010.12.053
   Fabrini MG, 2009, J NEURO-ONCOL, V92, P79, DOI 10.1007/s11060-008-9739-6
   Fogh SE, 2010, J CLIN ONCOL, V28, P3048, DOI 10.1200/JCO.2009.25.6941
   Franceschi E, 2005, CANCER, V104, P2473, DOI 10.1002/cncr.21564
   Fraum TJ, 2011, J NEURO-ONCOL, V105, P281, DOI 10.1007/s11060-011-0579-4
   Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721
   GASPAR LE, 1992, INT J RADIAT ONCOL, V24, P55, DOI 10.1016/0360-3016(92)91021-E
   Gaviani P, 2011, J NEURO-ONCOL, V104, P617, DOI 10.1007/s11060-010-0515-z
   Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110
   Gilbert MR, 2009, J CLIN ONCOL, V27
   Gutin PH, 2009, INT J RADIAT ONCOL, V75, P156, DOI 10.1016/j.ijrobp.2008.10.043
   Haas-Kogan DA, 2005, J NATL CANCER I, V97, P880, DOI 10.1093/jnci/dji161
   HALPERIN EC, 1988, INT J RADIAT ONCOL, V15, P505, DOI 10.1016/S0360-3016(98)90036-0
   Hammond A, 2011, J CLIN ONCOL, V29, P2038
   Jaeckle KA, 2003, J CLIN ONCOL, V21, P2305, DOI 10.1200/JCO.2003.12.097
   Kleihues P, 2000, CANCER, V88, P2887, DOI 10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F
   Kong DS, 2008, CANCER-AM CANCER SOC, V112, P2046, DOI 10.1002/cncr.23402
   Kong DS, 2006, ONCOL REP, V16, P1117
   Kong DS, 2010, NEURO-ONCOLOGY, V12, P289, DOI 10.1093/neuonc/nop030
   Kreisl TN, 2009, J CLIN ONCOL, V27, P740, DOI 10.1200/JCO.2008.16.3055
   Lee SW, 1999, INT J RADIAT ONCOL, V43, P79, DOI 10.1016/S0360-3016(98)00266-1
   LOEFFLER JS, 1990, INT J RADIAT ONCOL, V19, P1455, DOI 10.1016/0360-3016(90)90358-Q
   MACDONALD DR, 1990, J CLIN ONCOL, V8, P1277, DOI 10.1200/JCO.1990.8.7.1277
   McLendon RE, 2003, CANCER, V98, P1745, DOI 10.1002/cncr.11666
   Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918
   Moscatello DK, 1997, CANCER RES, V57, P1419
   Narayana A, 2009, J NEUROSURG, V110, P173, DOI 10.3171/2008.4.17492
   Nghiemphu PL, 2009, NEUROLOGY, V72, P1217, DOI 10.1212/01.wnl.0000345668.03039.90
   Nieder C, 2000, CANCER TREAT REV, V26, P397, DOI 10.1053/ctrv.2000.0191
   Nieder C, 2008, AM J CLIN ONCOL-CANC, V31, P300, DOI 10.1097/COC.0b013e31815e3fdc
   Oh J, 2011, CAN J NEUROL SCI, V38, P621, DOI 10.1017/S0317167100012166
   Park JK, 2010, J CLIN ONCOL, V28, P3838, DOI 10.1200/JCO.2010.30.0582
   PEGG AE, 1984, CANCER INVEST, V2, P223, DOI 10.3109/07357908409104376
   Perry JR, 2010, J CLIN ONCOL, V28, P2051, DOI 10.1200/JCO.2009.26.5520
   Quant EC, 2009, NEURO-ONCOLOGY, V11, P550, DOI 10.1215/15228517-2009-006
   Raymond E, 2008, J CLIN ONCOL, V26, P4659, DOI 10.1200/JCO.2008.16.9235
   Reardon DA, 2009, BRIT J CANCER, V101, P1986, DOI 10.1038/sj.bjc.6605412
   Reardon DA, 2011, J NEURO-ONCOL, V101, P57, DOI 10.1007/s11060-010-0217-6
   Reardon DA, 2008, J CLIN ONCOL, V26, P5610, DOI 10.1200/JCO.2008.16.7510
   Reithmeier T, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-30
   Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110
   Romanelli P, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.9.FOCUS09187
   Salvati M, 1998, J NEURO-ONCOL, V36, P61, DOI 10.1023/A:1017926603341
   Sathornsumetee S, 2010, NEURO-ONCOLOGY, V12, P1300, DOI 10.1093/neuonc/noq099
   Scoccianti S, 2008, ANTI-CANCER DRUG, V19, P613, DOI 10.1097/CAD.0b013e3283005075
   Scott JN, 1998, CAN J NEUROL SCI, V25, P197, DOI 10.1017/S0317167100034016
   Stockhammer F, 2010, J NEURO-ONCOL, V100, P407, DOI 10.1007/s11060-010-0192-y
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R., 2007, J CLIN ONCOL S18S, V25
   Taal W, 2008, CANCER, V113, P405, DOI 10.1002/cncr.23562
   Tolcher AW, 2003, BRIT J CANCER, V88, P1004, DOI 10.1038/sj.bjc.6600827
   van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984
   Vredenburgh JJ, 2007, J CLIN ONCOL, V25, P4722, DOI 10.1200/JCO.2007.12.2440
   Vredenburgh JJ, 2007, CLIN CANCER RES, V13, P1253, DOI 10.1158/1078-0432.CCR-06-2309
   Weller M, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.tps154
   Wen Patrick Y, 2010, Expert Rev Anticancer Ther, V10, P1367, DOI 10.1586/era.10.117
   Wen PY, 2010, ASCO M ABSTR S, V28, P2006, DOI DOI 10.1200/JC0.2010.28.15_
   Wick A, 2009, J NEUROL, V256, P734, DOI 10.1007/s00415-009-5006-9
   Wick W, 2010, J CLIN ONCOL, V28, P1168, DOI 10.1200/JCO.2009.23.2595
   Wick W, 2008, NEURO-ONCOLOGY, V10, P1019, DOI 10.1215/15228517-2008-058
   Wong ET, 2011, J NATL COMPR CANC NE, V9, P403, DOI 10.6004/jnccn.2011.0037
   Wong ET, 1999, J CLIN ONCOL, V17, P2572, DOI 10.1200/JCO.1999.17.8.2572
   Yoshida T, 2000, NEUROL MED-CHIR, V40, P224, DOI 10.2176/nmc.40.224
   Yung WKA, 2000, BRIT J CANCER, V83, P588, DOI 10.1054/bjoc.2000.1316
NR 94
TC 12
Z9 13
U1 0
U2 5
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 2278-330X
EI 2278-4306
J9 SOUTH ASIAN J CANCER
JI South Asian J. Cancer
PD OCT-DEC
PY 2015
VL 4
IS 4
BP 163
EP 173
DI 10.4103/2278-330X.175953
PG 11
WC Oncology
SC Oncology
GA DE2DB
UT WOS:000370435500004
PM 26981507
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Sun, ZP
   Tang, W
   Sakamoto, Y
   Hasegawa, K
   Kokudo, N
AF Sun, Zhipeng
   Tang, Wei
   Sakamoto, Yoshihiro
   Hasegawa, Kiyoshi
   Kokudo, Norihiro
TI RETRACTED: A systematic review and meta-analysis of feasibility, safety
   and efficacy of associating liver partition and portal vein ligation for
   staged hepatectomy (ALPPS) versus two-stage hepatectomy (TSH) (Retracted
   article. See vol. 10, pg. E1, 2016)
SO BIOSCIENCE TRENDS
LA English
DT Article; Retracted Publication
DE Associating liver partition and portal vein ligation for staged
   hepatectomy (ALPPS); portal vein embolization (PVE); two-staged
   Hepatectomy (TSH); liver regeneration
ID REMNANT VOLUME; EMBOLIZATION; METASTASES; REGENERATION; RESECTION;
   GROWTH
AB This meta-analysis aimed to review the regeneration rate of future liver remnant (FLR) and perioperative outcomes after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and two-stage hepatectomy (TSH). A web search was performed in "MEDLINE", "EMBASE", and "SCIENCE DIRECT" databases using both subject headings (MeSH) and truncated word to identify all the articles published that related to this topic. Pooled risk ratios were calculated for categorical variables and mean differences for continuous variables using the fixed-effects and random-effects models for meta-analysis. Three studies involved 282 patients, of whom 234 were in the TSH group and 48 in the ALPPS group. Morbidity was experienced in 56.3% patients in the ALPPS group and 36.1% in the TSH group. There was a statistical difference (RR = 1.08; Z = 3.24; 95% CI, p = 0.001). Second surgeries were performed successfully in 79.1% patients in the portal vein embolization (PVE) group and 100% in the ALPPS group. There was a statistical difference (Z = 2.48; 95% CI, p = 0.01). The mean regeneration rate of FLR in the ALPPS group was 56.4% compared with 52.8% in the TSH group. There was no statistical difference (95% CI, p = 0.34). So from the outcome of this meta-analysis, TSH had a similar remnant liver regeneration ability compared to ALPPS while the morbidity and mortality rates were relatively low. Cancer progression while waiting for the staged liver resection after portal vein embolization was a drawback for TSH.
C1 [Sun, Zhipeng] Capital Med Univ, Dept Surg Oncol, Sch Clin Med 9, Canc Ctr,Beijing Shijitan Hosp,Peking Univ, Beijing, Peoples R China.
   [Sun, Zhipeng; Tang, Wei; Sakamoto, Yoshihiro; Hasegawa, Kiyoshi; Kokudo, Norihiro] Univ Tokyo, Grad Sch Med, Hepatobiliary Pancreat Surg Div, Dept Surg, Tokyo, Japan.
RP Tang, W (reprint author), Univ Tokyo, Grad Sch Med, Hepatobiliary Pancreat Surg Div, Dept Surg,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM tang-sur@h.u-tokyo.ac.jp
RI Sun, Zhipeng/D-7054-2016
OI Sun, Zhipeng/0000-0001-9840-4705
FU Japan-China Sasakawa Medical Fellowship, Sasakawa Memorial Health
   Foundation
FX This research was funded by the Japan-China Sasakawa Medical Fellowship,
   which is a project of the Sasakawa Memorial Health Foundation. The
   authors wish to thank the Foundation for its support.
CR Fernandez-Ros N, 2014, HPB, V16, P243, DOI 10.1111/hpb.12095
   Heinrich S, 2006, J HEPATOL, V45, P35, DOI 10.1016/j.jhep.2006.02.020
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Jaeck D, 2004, ANN SURG, V240, P1037, DOI 10.1097/01.sla.0000145965.86383.89
   Kokudo N, 2001, HEPATOLOGY, V34, P267, DOI 10.1053/jhep.2001.26513
   Martin B, 2003, BRIT J CANCER, V89, P55, DOI 10.1038/sj.bjc.6601095
   Nagino M, 2000, SURGERY, V127, P155, DOI 10.1067/msy.2000.101273
   Okabe H, 2013, J GASTROINTEST SURG, V17, P1447, DOI 10.1007/s11605-013-2237-y
   Ratti F, 2015, ANN SURG ONCOL, V22, P1933, DOI 10.1245/s10434-014-4291-4
   Schadde E, 2015, ANN SURG ONCOL, V22, P3109, DOI 10.1245/s10434-014-4213-5
   Schnitzbauer AA, 2012, ANN SURG, V255, P405, DOI 10.1097/SLA.0b013e31824856f5
   Shindoh J, 2013, J AM COLL SURGEONS, V217, P126, DOI 10.1016/j.jamcollsurg.2013.03.004
   TAKAYASU K, 1986, RADIOLOGY, V160, P389, DOI 10.1148/radiology.160.2.3014598
   Tanaka K, 2015, EJSO-EUR J SURG ONC, V41, P506, DOI 10.1016/j.ejso.2015.01.031
   Yao LB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105511
NR 15
TC 9
Z9 12
U1 5
U2 7
PU IRCA-BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003,
   JAPAN
SN 1881-7815
EI 1881-7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD OCT
PY 2015
VL 9
IS 5
BP 284
EP 288
DI 10.5582/bst.2015.01139
PG 5
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA DC4EL
UT WOS:000369173100003
PM 26559020
OA Bronze
DA 2018-12-27
ER

PT J
AU Romano, ME
   Enquobahrie, DA
   Simpson, CD
   Checkoway, H
   Williams, MA
AF Romano, Megan E.
   Enquobahrie, Daniel A.
   Simpson, Christopher D.
   Checkoway, Harvey
   Williams, Michelle A.
TI RETRACTED: A Case-Cohort Study of Cadmium Body Burden and Gestational
   Diabetes Mellitus in American Women(Retracted article. See vol. 125, pg.
   A64, 2017)
SO ENVIRONMENTAL HEALTH PERSPECTIVES
LA English
DT Article; Retracted Publication
ID BIOLOGICAL SAMPLES; GLUCOSE-TOLERANCE; URINARY CADMIUM; TOXIC METALS;
   EXPOSURE; RISK; PREGNANCY; HEALTH; POPULATION; DISEASE
AB BACKGROUND: Environmental cadmium (Cd) exposure is associated with type 2 diabetes. However, the association of Cd and gestational diabetes mellitus (GDM) is unknown.
   OBJECTIVES: We examined the association between body burden of Cd and GDM risk.
   METHODS: We used 140 GDM cases and 481 randomly selected noncase subcohort members from the Omega Study to conduct a case-cohort study. Creatinine (Cr)-corrected Cd in early pregnancy urine (U-Cd) was measured by inductively coupled plasma mass spectrometry. Tertiles (< 0.29; 0.29-0.42; >= 0.43 mu g/g Cr) were defined using the subcohort's U-Cd distribution. GDM was diagnosed using the 2004 American Diabetes Association guidelines. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression.
   RESULTS: GDM cases had higher geometric mean U-Cd (0.39 mu g/g Cr; 95% CI: 0.37, 0.41) than noncases (0.31 mu g/g Cr; 95% CI: 0.29, 0.33). Odds ratios for GDM increased with increasing U-Cd tertile (OR = 1.64; 95% CI: 0.88, 3.05 for middle vs. low tertile; OR = 2.07; 95% CI: 1.15, 3.73 for high vs. low tertile; p-trend = 0.015). Overweight/obesity (body mass index >= 25 kg/m(2)) did not modify the association between U-Cd and GDM (p = 0.26).
   CONCLUSIONS: Our findings suggest that body burden of Cd increases risk of GDM in a dose-dependent manner. Improved understanding of environmental factors influencing GDM may facilitate early identification of women at high risk of GDM.
C1 [Romano, Megan E.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
   [Enquobahrie, Daniel A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
   [Enquobahrie, Daniel A.; Williams, Michelle A.] Swedish Med Ctr, Ctr Perinatal Studies, Seattle, WA USA.
   [Simpson, Christopher D.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA.
   [Checkoway, Harvey] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
   [Williams, Michelle A.] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
RP Romano, ME (reprint author), Brown Univ, Ctr Environm Hlth & Technol, Box G-S121-2, Providence, RI 02912 USA.
EM megan_romano@brown.edu
FU National Institutes of Health [R01HD-32562, K01HL103174]; Reproductive,
   Perinatal and Pediatric Epidemiology Training Program of the National
   Institute of Child Health and Human Development [T32 HD052462]
FX This research was supported by awards R01HD-32562 and K01HL103174 from
   the National Institutes of Health. M.E.R. was supported by the
   Reproductive, Perinatal and Pediatric Epidemiology Training Program of
   the National Institute of Child Health and Human Development (T32
   HD052462).
CR Adams SV, 2011, SCI TOTAL ENVIRON, V409, P1632, DOI 10.1016/j.scitotenv.2011.01.037
   Afridi HI, 2008, DIABETES RES CLIN PR, V80, P280, DOI 10.1016/j.diabres.2007.12.021
   Afridi HI, 2013, CLIN CHIM ACTA, V415, P207, DOI 10.1016/j.cca.2012.10.029
   American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS88
   ATSDR. (Agency for Toxic Substances and Disease Registry), 2012, ATSDR TOX PROF CADM
   Barr DB, 2005, ENVIRON HEALTH PERSP, V113, P192, DOI 10.1289/ehp.7337
   Barregard L, 2013, ENVIRON RES, V121, P104, DOI 10.1016/j.envres.2012.11.005
   Blackburn S., 2013, MATERNAL FETAL NEONA
   Centers for Disease Control and Prevention, 2013, 4 REP HUM EXP ENV CH
   Chang KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054374
   Chen YW, 2009, ISLETS, V1, P169, DOI 10.4161/isl.1.3.9262
   Chevrier C, 2011, ENVIRON HEALTH PERSP, V119, P1034, DOI 10.1289/ehp.1002775
   Cypryk Katarzyna, 2008, Endokrynol Pol, V59, P393
   Edwards JR, 2009, TOXICOL APPL PHARM, V238, P289, DOI 10.1016/j.taap.2009.03.007
   El Muayed M, 2012, ISLETS, V4, P405, DOI 10.4161/isl.23101
   England LJ, 2004, AM J EPIDEMIOL, V160, P1205, DOI 10.1093/aje/kwh340
   Engstrom A, 2012, BONE, V50, P1372, DOI 10.1016/j.bone.2012.03.018
   Ettinger AS, 2009, ENVIRON HEALTH PERSP, V117, P1059, DOI 10.1289/ehp0800533
   Haswell-Elkins M, 2007, J EXPO SCI ENV EPID, V17, P372, DOI 10.1038/sj.jes.7500520
   Heitland P, 2004, J ANAL ATOM SPECTROM, V19, P1552, DOI 10.1039/b410630j
   Hernandez M, 1996, BIOL TRACE ELEM RES, V53, P205, DOI 10.1007/BF02784556
   Hopenhayn C, 2003, ENVIRON HEALTH PERSP, V111, P1888, DOI 10.1289/ehp.6254
   Institute of Medicine Panel on Micronutrients, 2001, DIET REF INT VIT A V
   IPCS WHO (International Programme on Chemical Safety World Health Organization), 1996, BIOL MON CHEM EXP WO
   Jarup L, 2009, TOXICOL APPL PHARM, V238, P201, DOI 10.1016/j.taap.2009.04.020
   Julin B, 2012, CANCER RES, V72, P1459, DOI 10.1158/0008-5472.CAN-11-0735
   Kass PH, 2005, HANDBOOK OF EPIDEMIOLOGY, P321
   Kido T, 2003, CLIN NEPHROTOXINS RE, P507
   King County Environmental Health Services, 2010, FINDINGS SOIL SAMPLI
   Kippler M, 2009, ENVIRON RES, V109, P914, DOI 10.1016/j.envres.2009.07.006
   Kolachi NF, 2011, BIOL TRACE ELEM RES, V143, P196, DOI 10.1007/s12011-010-8879-7
   Lei LJ, 2007, BIOMED ENVIRON SCI, V20, P295
   Metzger BE, 2007, CLIN OBSTET GYNECOL, V50, P972, DOI 10.1097/GRF.0b013e31815a61d6
   Moon SS, 2013, DIABETIC MED, V30, pe143, DOI 10.1111/dme.12103
   Orloff K, 2009, J TOXICOL ENV HEAL B, V12, P509, DOI 10.1080/10937400903358934
   Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6
   PRENTICE RL, 1986, BIOMETRIKA, V73, P1
   Qiu CF, 2011, DIABETES CARE, V34, P1564, DOI 10.2337/dc11-0135
   Schwartz GG, 2003, DIABETES CARE, V26, P468, DOI 10.2337/diacare.26.2.468
   Shvetsov YB, 2009, EPIDEMIOLOGY, V20, P36, DOI 10.1097/EDE.0b013e318187865e
   Swaddiwudhipong W, 2012, ENVIRON RES, V112, P194, DOI 10.1016/j.envres.2011.10.004
   Swaddiwudhipong W, 2010, ENVIRON RES, V110, P612, DOI 10.1016/j.envres.2010.06.002
   Tellez-Plaza M, 2013, EPIDEMIOLOGY, V24, P421, DOI 10.1097/EDE.0b013e31828b0631
   Torloni MR, 2009, OBES REV, V10, P194, DOI 10.1111/j.1467-789X.2008.00541.x
   Yassine H, 2012, CARDIORENAL MED, V2, P26, DOI 10.1159/000334225
NR 45
TC 8
Z9 8
U1 1
U2 15
PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE
PI RES TRIANGLE PK
PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233,
   RES TRIANGLE PK, NC 27709-2233 USA
SN 0091-6765
EI 1552-9924
J9 ENVIRON HEALTH PERSP
JI Environ. Health Perspect.
PD OCT
PY 2015
VL 123
IS 10
BP 993
EP 998
DI 10.1289/ehp.1408282
PG 6
WC Environmental Sciences; Public, Environmental & Occupational Health;
   Toxicology
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health; Toxicology
GA CY8ZW
UT WOS:000366698200020
PM 25712731
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ramirez, V
   Gonzalez, B
   Lopez, A
   Castello, MJ
   Gil, MJ
   Zheng, B
   Chen, P
   Vera, P
AF Ramirez, Vicente
   Gonzalez, Beatriz
   Lopez, Ana
   Castello, Maria Jose
   Gil, Maria Jose
   Zheng, Bo
   Chen, Peng
   Vera, Pablo
TI RETRACTED: Loss of a Conserved tRNA Anticodon Modification Perturbs
   Plant Immunity(Retracted article. See vol.13, ARTN.e1006747, 2017)
SO PLOS GENETICS
LA English
DT Article; Retracted Publication
ID YEAST TRANSFER-RNA; DNA-DAMAGE RESPONSE; SACCHAROMYCES-CEREVISIAE;
   SALICYLIC-ACID; ARABIDOPSIS-THALIANA; OXIDATIVE STRESS; MUTANT REVEALS;
   GENE; METHYLTRANSFERASE; RESISTANCE
AB tRNA is the most highly modified class of RNA species, and modifications are found in tRNAs from all organisms that have been examined. Despite their vastly different chemical structures and their presence in different tRNAs, occurring in different locations in tRNA, the biosynthetic pathways of the majority of tRNA modifications include a methylation step(s). Recent discoveries have revealed unprecedented complexity in the modification patterns of tRNA, their regulation and function, suggesting that each modified nucleoside in tRNA may have its own specific function. However, in plants, our knowledge on the role of individual tRNA modifications and how they are regulated is very limited. In a genetic screen designed to identify factors regulating disease resistance and activation of defenses in Arabidopsis, we identified SUPPRESSOR OF CSB3 9 (SCS9). Our results reveal SCS9 encodes a tRNA methyltransferase that mediates the 2'-O-ribose methylation of selected tRNA species in the anticodon loop. These SCS9-mediated tRNA modifications enhance during the course of infection with the bacterial pathogen Pseudomonas syringae DC3000, and lack of such tRNA modification, as observed in scs9 mutants, severely compromise plant immunity against the same pathogen without affecting the salicylic acid (SA) signaling pathway which regulates plant immune responses. Our results support a model that gives importance to the control of certain tRNA modifications for mounting an effective immune response in Arabidopsis, and therefore expands the repertoire of molecular components essential for an efficient disease resistance response.
C1 [Ramirez, Vicente; Gonzalez, Beatriz; Lopez, Ana; Castello, Maria Jose; Gil, Maria Jose; Vera, Pablo] Univ Politecn Valencia, CSIC, Ciudad Politecn Innovac, Inst Biol Mol & Celular Plantas, E-46071 Valencia, Spain.
   [Zheng, Bo] Huazhong Agr Univ, Coll Hort & Forestry Sci, Wuhan, Peoples R China.
   [Chen, Peng] HuaZhong Agr Univ, Natl Key Lab Crop Genet Improvement, Wuhan, Peoples R China.
   [Chen, Peng] HuaZhong Agr Univ, Natl Ctr Plant Gene Res, Wuhan, Peoples R China.
RP Ramirez, V (reprint author), Univ Politecn Valencia, CSIC, Ciudad Politecn Innovac, Inst Biol Mol & Celular Plantas, E-46071 Valencia, Spain.
EM vera@ibmcp.upv.es
OI Etherington, Graham/0000-0002-5003-1425; Vera, Pablo/0000-0002-7787-7519
FU National Science Foundation of China [31100268]; Spanish MINECO
   [BFU2012]; Generalitat Valenciana [Prometeo2014/020]
FX This work was supported by the National Science Foundation of China
   (grant 31100268 to PC) and the Spanish MINECO (BFU2012 to PV) and
   Generalitat Valenciana (Prometeo2014/020 to PV). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agris PF, 2007, J MOL BIOL, V366, P1, DOI 10.1016/j.jmb.2006.11.046
   Anderson J, 2000, P NATL ACAD SCI USA, V97, P5173, DOI 10.1073/pnas.090102597
   Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a
   Austin RS, 2011, PLANT J, V67, P715, DOI 10.1111/j.1365-313X.2011.04619.x
   Begley U, 2007, MOL CELL, V28, P860, DOI 10.1016/j.molcel.2007.09.021
   BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023
   Bethke G, 2009, P NATL ACAD SCI USA, V106, DOI 10.1073/pnas.0810206106
   Bugl H, 2000, MOL CELL, V6, P349, DOI 10.1016/S1097-2765(00)00035-6
   Bujnicki JM, 2001, GENOME BIOL, V2
   Caldas T, 2000, J BIOL CHEM, V275, P16414, DOI 10.1074/jbc.M001854200
   Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9
   Chan CTY, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1938
   Chan CTY, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001247
   Chen P, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-201
   CHERNOFF YO, 1994, EMBO J, V13, P906, DOI 10.1002/j.1460-2075.1994.tb06334.x
   Clay NK, 2009, SCIENCE, V323, P95, DOI 10.1126/science.1164627
   Coego A, 2005, PLANT J, V42, P283, DOI 10.1111/j.1365-313X.2005.02372.x
   DeFraia CT, 2008, PLANT METHODS, V4, DOI 10.1186/1746-4811-4-28
   El Yacoubi B, 2012, ANNU REV GENET, V46, P69, DOI 10.1146/annurev-genet-110711-155641
   ELLIS SR, 1986, J BIOL CHEM, V261, P9703
   Garcia-Andrade J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003713
   Garcia-Andrade J, 2011, PLANT J, V67, P783, DOI 10.1111/j.1365-313X.2011.04633.x
   Gerber A, 1998, EMBO J, V17, P4780, DOI 10.1093/emboj/17.16.4780
   Gil MJ, 2005, PLANT J, V44, P155, DOI 10.1111/j.1365-313X.2005.02517.x
   Hori H, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00144
   Huang WE, 2005, ENVIRON MICROBIOL, V7, P1339, DOI 10.1111/j.1462-2920.2005.00821.x
   Jackman JE, 2003, RNA, V9, P574, DOI 10.1261/rna.5070303
   Jorda L, 2000, PLANT PHYSIOL, V124, P1049, DOI 10.1104/pp.124.3.1049
   Castello MJ, 2011, PLANT PHYSIOL, V157, P2206, DOI 10.1104/pp.111.188953
   Juhling F, 2009, NUCLEIC ACIDS RES, V37, pD159, DOI 10.1093/nar/gkn772
   Kadaba S, 2004, GENE DEV, V18, P1227, DOI 10.1101/gad.1183804
   Kalhor HR, 2003, MOL CELL BIOL, V23, P9283, DOI 10.1128/MCB.23.24.9283-9292.2003
   Khoury CM, 2008, FEMS YEAST RES, V8, P540, DOI 10.1111/j.1567-1364.2008.00367.x
   Kramer EB, 2013, P NATL ACAD SCI USA, V110, P21042, DOI 10.1073/pnas.1316579110
   KUCHINO Y, 1982, NUCLEIC ACIDS RES, V10, P6421, DOI 10.1093/nar/10.20.6421
   Lapin D, 2013, TRENDS PLANT SCI, V18, P546, DOI 10.1016/j.tplants.2013.05.005
   Lee YS, 2009, GENE DEV, V23, P2639, DOI 10.1101/gad.1837609
   Lopez A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002434
   Lu J, 2005, RNA, V11, P1648, DOI 10.1261/rna.2172105
   Machnicka MA, 2013, NUCLEIC ACIDS RES, V41, pD262, DOI 10.1093/nar/gks1007
   Mauro VP, 2007, CELL CYCLE, V6, P2246, DOI 10.4161/cc.6.18.4739
   Maute RL, 2013, P NATL ACAD SCI USA, V110, P1404, DOI 10.1073/pnas.1206761110
   Miyawaki K, 2006, P NATL ACAD SCI USA, V103, P16598, DOI 10.1073/pnas.0603522103
   Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201
   Motorin Y, 2010, BIOCHEMISTRY-US, V49, P4934, DOI 10.1021/bi100408z
   Nawrath C, 1999, PLANT CELL, V11, P1393
   Novoa EM, 2012, CELL, V149, P202, DOI 10.1016/j.cell.2012.01.050
   Pajerowska-Mukhtar KM, 2012, CURR BIOL, V22, P103, DOI 10.1016/j.cub.2011.12.015
   Pederson T, 2010, RNA, V16, P1865, DOI 10.1261/rna.2266510
   Phizicky EM, 2010, GENE DEV, V24, P1832, DOI 10.1101/gad.1956510
   Pintard L, 2002, EMBO J, V21, P1811, DOI 10.1093/emboj/21.7.1811
   POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421
   Raina M, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00171
   Ramirez V, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003445
   Ramirez V, 2010, BMC PLANT BIOL, V10, DOI 10.1186/1471-2229-10-199
   ROZANOWSKA M, 1995, J PHOTOCH PHOTOBIO B, V29, P71, DOI 10.1016/1011-1344(95)07138-R
   Takano K, 2008, AM J MED GENET B, V147B, P479, DOI 10.1002/ajmg.b.30638
   Thompson DM, 2008, RNA, V14, P2095, DOI 10.1261/rna.1232808
   Thompson DM, 2009, CELL, V138, P215, DOI 10.1016/j.cell.2009.07.001
   WALDEN TL, 1982, J BIOL CHEM, V257, P13218
   Wang X, 2014, MOL CELL, V56, P5, DOI 10.1016/j.molcel.2014.09.001
   Wilkinson ML, 2007, RNA, V13, P404, DOI 10.1261/rna.399607
   Yan SP, 2014, CURR OPIN PLANT BIOL, V20, P64, DOI 10.1016/j.pbi.2014.04.006
   Yewdell JW, 1996, J IMMUNOL, V157, P1823
NR 64
TC 4
Z9 5
U1 7
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD OCT
PY 2015
VL 11
IS 10
AR e1005586
DI 10.1371/journal.pgen.1005586
PG 27
WC Genetics & Heredity
SC Genetics & Heredity
GA CV6SU
UT WOS:000364401600050
PM 26492405
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Vallati, A
   Grignaffini, S
   Romagna, M
AF Vallati, Andrea
   Grignaffini, Stefano
   Romagna, Marco
TI RETRACTED: A New Method to Energy Saving in a Micro Grid (Retracted
   article. See vol. 8, 401, 2016)
SO SUSTAINABILITY
LA English
DT Article; Retracted Publication
DE multi-energy system; cost of energy; energy storage
ID HYBRID POWER-SYSTEM; WIND; OPTIMIZATION; SIMULATION; STORAGE; HUB
AB Optimization of energy production systems is a relevant issue that must be considered in order to follow the fossil fuels consumption reduction policies and CO2 emission regulation. Increasing electricity production from renewable resources (e.g., photovoltaic systems and wind farms) is desirable but its unpredictability is a cause of problems for the main grid stability. A system with multiple energy sources represents an efficient solution, by realizing an interface among renewable energy sources, energy storage systems, and conventional power generators. Direct consequences of multi-energy systems are a wider energy flexibility and benefits for the electric grid, the purpose of this paper is to propose the best technology combination for electricity generation from a mix of renewable energy resources to satisfy the electrical needs. The paper identifies the optimal off-grid option and compares this with conventional grid extension, through the use of HOMER software. The solution obtained shows that a hybrid combination of renewable energy generators at an off-grid location can be a cost-effective alternative to grid extension and it is sustainable, techno-economically viable, and environmentally sound. The results show how this innovative energetic approach can provide a cost reduction in power supply and energy fees of 40% and 25%, respectively, and CO2 emission decrease attained around 18%. Furthermore, the multi-energy system taken as the case study has been optimized through the utilization of three different type of energy storage (Pb-Ac batteries, flywheels, and micro-Compressed Air Energy Storage (C.A.E.S.).
C1 [Vallati, Andrea; Grignaffini, Stefano; Romagna, Marco] Univ Roma La Sapienza, Dept Astronaut Elect & Energet Engn, I-00184 Rome, Italy.
RP Vallati, A (reprint author), Univ Roma La Sapienza, Dept Astronaut Elect & Energet Engn, Via Eudossiana 18, I-00184 Rome, Italy.
EM andrea.vallati@uniroma1.it; stefano.grignaffini@uniroma1.it;
   marco.romagna@uniroma1.it
OI Romagna, Marco/0000-0001-9828-4010; GRIGNAFFINI,
   STEFANO/0000-0003-3404-192X
CR Alessandrini F., 2010, STUDIO FATTIBILITA T
   Allegrini J, 2015, RENEW SUST ENERG REV, V52, P1391, DOI 10.1016/j.rser.2015.07.123
   [Anonymous], 2009, OFFICIAL J EUROPEAN
   Bekele G, 2010, APPL ENERG, V87, P487, DOI 10.1016/j.apenergy.2009.06.006
   Bhattacharyya SC, 2012, ENERGY SUSTAIN DEV, V16, P260, DOI 10.1016/j.esd.2012.05.002
   Bottillo S, 2014, SOL ENERGY, V102, P212, DOI 10.1016/j.solener.2014.01.029
   Bottillo S, 2014, SOL ENERGY, V99, P1, DOI 10.1016/j.solener.2013.10.031
   Brenna M., 2012, P 2 IEEE ENERGYCON C
   de Lieto Vollaro R., 2013, Advanced Materials Research, V650, P653, DOI 10.4028/www.scientific.net/AMR.650.647
   European Union, 2004, OFFICIAL J EUROPEAN
   Fabrizio E., 2008, VALUTAZIONE SISTEMA
   Ferreira HL, 2013, ENERGY, V53, P288, DOI 10.1016/j.energy.2013.02.037
   Galli G., 2013, INT J ENG TECHNOL, V5, P4495
   Geidl M, 2007, IEEE T POWER SYST, V22, P145, DOI 10.1109/TPWRS.2006.888988
   Geidl M, 2006, EUR T ELECTR POWER, V16, P463, DOI 10.1002/etep.112
   Givler T., USING HOMER SOFTWARE
   Hafez O, 2012, RENEW ENERG, V45, P7, DOI 10.1016/j.renene.2012.01.087
   Himri Y, 2008, ENERGY, V33, P1128, DOI 10.1016/j.energy.2008.01.016
   Inage S.-I., 2009, PROSPECT LARGE SCALE
   La Scala M, 2014, APPL THERM ENG, V71, P658, DOI 10.1016/j.applthermaleng.2013.10.031
   Liu WY, 2014, ENERGIES, V7, P4988, DOI 10.3390/en7084988
   Lund H, 2009, ENERGY, V34, P524, DOI 10.1016/j.energy.2008.04.003
   Mancarella P, 2014, ENERGY, V65, P1, DOI 10.1016/j.energy.2013.10.041
   Manwell JF, 2004, ENCY ENERGY, V3, P215
   Nandi SK, 2010, ENERGY, V35, P3040, DOI 10.1016/j.energy.2010.03.044
   Nazar MS, 2009, ELECTR POW SYST RES, V79, P899, DOI 10.1016/j.epsr.2008.12.002
   Nfah EM, 2008, RENEW ENERG, V33, P1064, DOI 10.1016/j.renene.2007.05.045
   Parisio A, 2012, INT J ELEC POWER, V42, P98, DOI 10.1016/j.ijepes.2012.03.015
   Pazouki S, 2014, INT J ELEC POWER, V61, P335, DOI 10.1016/j.ijepes.2014.03.038
   Sharif A, 2014, INT J ENERG RES, V38, P363, DOI 10.1002/er.3050
   Vollaro AD, 2014, SUSTAINABILITY-BASEL, V6, P7894, DOI 10.3390/su6117894
NR 31
TC 7
Z9 7
U1 3
U2 28
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2071-1050
J9 SUSTAINABILITY-BASEL
JI Sustainability
PD OCT
PY 2015
VL 7
IS 10
BP 13904
EP 13919
DI 10.3390/su71013904
PG 16
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Environmental Sciences;
   Environmental Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA CV5RI
UT WOS:000364328300046
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Zeng, YF
   Xie, HJ
   Qiao, YD
   Wang, JM
   Zhu, XL
   He, GY
   Li, YL
   Ren, XL
   Wang, FF
   Liang, L
   Ding, YQ
AF Zeng, Yuanfeng
   Xie, Huijun
   Qiao, Yudan
   Wang, Jianmei
   Zhu, Xiling
   He, Guoyang
   Li, Yuling
   Ren, Xiaoli
   Wang, Feifei
   Liang, Li
   Ding, Yanqing
TI RETRACTED: Formin-like2 regulates Rho/ROCK pathway to promote actin
   assembly and cell invasion of colorectal cancer (Retracted Article. See
   vol. 107, pg. 1060, 2016)
SO CANCER SCIENCE
LA English
DT Article; Retracted Publication
DE Colorectal cancer; FMNL2; invasion; LARG; Rho; ROCK signaling
ID NUCLEOTIDE EXCHANGE FACTOR; SERUM RESPONSE FACTOR; POOR-PROGNOSIS;
   METASTASIS; FORMINS; MDIA1; FMNL2; CARCINOMA; MOTILITY; RHOC
AB Formin-like2 (FMNL2) is a member of the diaphanous-related formins family, which act as effectors and upstream modulators of Rho GTPases signaling and control the actin-dependent processes, such as cell motility or invasion. FMNL2 has been identified as promoting the motility and metastasis in colorectal carcinoma (CRC). However, whether FMNL2 regulates Rho signaling to promote cancer cell invasion remains unclear. In this study, we demonstrated an essential role for FMNL2 in the activations of Rho/ROCK pathway, SRF transcription or actin assembly, and subsequent CRC cell invasion. FMNL2 could activate Rho/ROCK pathway, and required ROCK to promote CRC cell invasion. Moreover, FMNL2 promoted the formation of filopodia and stress fiber, and activated the SRF transcription in a Rho-dependent manner. We also demonstrated that FMNL2 was necessary for LPA-induced invasion, RhoA/ROCK activation, actin assembly and SRF activation. FMNL2 was an essential component of LPA signal transduction toward RhoA by directly interacting with LARG. LARG silence inhibited RhoA/ROCK pathway and CRC cell invasion. Collectively, these data indicate that FMNL2, acting as upstream of RhoA by interacting with LARG, can promote actin assembly and CRC cell invasion through a Rho/ROCK-dependent mechanism.
C1 [Zeng, Yuanfeng; Xie, Huijun; Qiao, Yudan; Wang, Jianmei; Zhu, Xiling; He, Guoyang; Li, Yuling; Ren, Xiaoli; Wang, Feifei; Liang, Li; Ding, Yanqing] Southern Med Univ, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.
   [Zeng, Yuanfeng] Peoples Hosp, Dept Pathol, Nanchang, Peoples R China.
   [Xie, Huijun; Qiao, Yudan; Wang, Jianmei; He, Guoyang; Li, Yuling; Ren, Xiaoli; Wang, Feifei; Liang, Li; Ding, Yanqing] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou, Guangdong, Peoples R China.
   [Zhu, Xiling] Gen Hosp Armed Police Forces, Dept Oncol, Beijing, Peoples R China.
RP Liang, L (reprint author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.
EM redsnow007@hotmail.com; dyq@fimmu.com
FU National Basic Research Program of China (973 program) [2015CB554002];
   National Natural Science Foundation of China by the NSFC-Guangdong Joint
   Fund [U1201226]; National Natural Science Foundation of China [81472313,
   81071735, 81272759, 81172382]; Guangdong Provincial Natural Science
   Foundation of China [S2013010014544]; Guangzhou Science & Technology
   Plan Project [201300000056]
FX This work was supported by the National Basic Research Program of China
   (973 program, 2015CB554002), the Project of the National Natural Science
   Foundation of China supported by the NSFC-Guangdong Joint Fund
   (U1201226), the National Natural Science Foundation of China (81472313,
   81071735, 81272759, 81172382), the Guangdong Provincial Natural Science
   Foundation of China (S2013010014544) and the Guangzhou Science &
   Technology Plan Project (201300000056).
CR Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046
   Block J, 2012, CURR BIOL, V22, P1005, DOI 10.1016/j.cub.2012.03.064
   Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406
   Chan DC, 1996, J BIOL CHEM, V271, P23472, DOI 10.1074/jbc.271.38.23472
   Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092
   Eisenmann KM, 2007, CURR BIOL, V17, P579, DOI 10.1016/j.cub.2007.03.024
   Faix J, 2006, DEV CELL, V10, P693, DOI 10.1016/j.devcel.2006.05.001
   Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647
   Goulimari P, 2008, MOL BIOL CELL, V19, P30, DOI 10.1091/mbc.E06-11-1045
   Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6
   Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805
   Imamura F, 1996, INT J CANCER, V65, P627, DOI 10.1002/(SICI)1097-0215(19960301)65:5<627::AID-IJC12>3.0.CO;2-4
   Kedrin D, 2007, J MAMMARY GLAND BIOL, V12, P143, DOI 10.1007/s10911-007-9046-4
   Kitzing TM, 2010, ONCOGENE, V29, P2441, DOI 10.1038/onc.2009.515
   Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807
   Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197
   Li YF, 2010, MOL CANCER RES, V8, P1579, DOI 10.1158/1541-7786.MCR-10-0081
   Liang L, 2013, GASTROENTEROLOGY, V144, P624, DOI 10.1053/j.gastro.2012.11.033
   Liang L, 2011, HUM PATHOL, V42, P1603, DOI 10.1016/j.humpath.2010.08.025
   Lu J, 2007, J MOL BIOL, V369, P1258, DOI 10.1016/j.jmb.2007.04.002
   Matusek T, 2006, DEVELOPMENT, V133, P957, DOI 10.1242/dev.02266
   Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2
   Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011
   Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Sarmiento C, 2008, J CELL BIOL, V180, P1245, DOI 10.1083/jcb.200708123
   Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831
   Schirenbeck A, 2005, NAT CELL BIOL, V7, P619, DOI 10.1038/ncb1266
   Seth A, 2006, J CELL BIOL, V174, P701, DOI 10.1083/jcb.200605006
   Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9
   Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8
   van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200
   Vega FM, 2011, J CELL BIOL, V193, P655, DOI 10.1083/jcb.201011038
   Wang S, 2009, J PATHOL, V219, P114, DOI 10.1002/path.2575
   Watanabe N, 1999, NAT CELL BIOL, V1, P136
   Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012
   Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065
   Yang C, 2007, PLOS BIOL, V5, P2624, DOI 10.1371/journal.pbio.0050317
   Young KG, 2010, BBA-MOL CELL RES, V1803, P183, DOI 10.1016/j.bbamcr.2008.09.017
   Zhang Yan-Fei, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P126
   Zhu XL, 2008, INT J COLORECTAL DIS, V23, P1041, DOI 10.1007/s00384-008-0520-2
   Zhu XL, 2011, J PATHOL, V224, P377, DOI 10.1002/path.2871
   Zhu Xi-ling, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P1775
NR 45
TC 11
Z9 12
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD OCT
PY 2015
VL 106
IS 10
BP 1385
EP 1393
DI 10.1111/cas.12768
PG 9
WC Oncology
SC Oncology
GA CU7ON
UT WOS:000363731300016
PM 26258642
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ivanov, RV
AF Ivanov, Roman V.
TI RETRACTED: The distribution of the maximum of a variance gamma process
   and path-dependent option pricing (Retracted article. See vol. 20, pg.
   805, 2016)
SO FINANCE AND STOCHASTICS
LA English
DT Article; Retracted Publication
DE Variance gamma process; Distribution of maximum; Path-dependent options;
   Exact formula; Hypergeometric function
ID LEVY PROCESSES; MODEL
AB Although numerical procedures often supply a required accuracy, closed-form expressions allow one to escape any accumulation of errors. In this paper, we discuss the possibility of obtaining explicit results for a variance gamma process. We derive the exact distribution of the maximum of the variance gamma process over a finite interval of time and establish the prices of path-dependent options including digital barrier, fixed-strike lookback, and lookback options. The obtained formulas are based on values of hypergeometric functions.
C1 RAS, Trapeznikov Inst Control Sci, Lab Control Incomplete Informat, Moscow 117997, Russia.
RP Ivanov, RV (reprint author), RAS, Trapeznikov Inst Control Sci, Lab Control Incomplete Informat, Profsoyuznaya 65, Moscow 117997, Russia.
EM roivanov@yahoo.com
CR Almendral A., 2007, APPL MATH FINANCE, V14, P131, DOI DOI 10.1080/13504860600724885
   Bateman H, 1953, HIGHER TRANSCENDENTA, V1-3
   Bianchi ML, 2010, MATHEMATICAL AND STATISTICAL METHODS FOR ACTUARIAL SCIENCES AND FINANCE, P33
   Boyarchenko M., 2014, PREPRINT
   Boyarchenko S., 2015, PREPRINT
   Carr P, 2004, J FINANC ECON, V71, P113, DOI 10.1016/S0304-405X(03)00171-5
   Carr P., 1999, J COMPUT FINANC, V2, P61, DOI DOI 10.21314/JCF.1999.043
   Carr P, 2012, FINANC STOCH, V16, P335, DOI 10.1007/s00780-011-0157-9
   Eberlein E., 2014, QUANTITATIVE ENERGY, P85
   Eberlein E, 2008, FINANC STOCH, V12, P265, DOI 10.1007/s00780-008-0061-0
   Eberlein E, 2010, J RISK, V13, P3, DOI 10.21314/JOR.2010.219
   Finlay R, 2006, J APPL PROBAB, V43, P441, DOI 10.1239/jap/1152413733
   Gradshteyn I. S., 1980, TABLE INTEGRALS SERI
   Guillaume F, 2013, REV DERIV RES, V16, P25, DOI 10.1007/s11147-012-9080-2
   HIRSA A, 2004, J COMPUT FINANC, V7, P63
   Ivanov R. V., 2012, STOCH ANAL APP UNPUB
   Ivanov R. V., 2013, COMMUN STOCH ANAL, V7, P511
   Ivanov R. V., 2012, ELECTRON COMMUN PROB, V17, P745
   Ivanov RV, 2013, STOCH MODELS, V29, P435, DOI 10.1080/15326349.2013.838509
   Korn K., 2010, MONTE CARLO METHODS
   Madan D., 1998, EUROPEAN FINANCE REV, V2, P79, DOI DOI 10.1023/A:1009703431535
   MADAN DB, 1990, J BUS, V63, P511, DOI 10.1086/296519
   MADAN DB, 1991, MATH FINANC, V1, P39, DOI DOI 10.1111/J.1467-9965.1991.TB00018.X)
   Musiela M., 2005, MARTINGALE METHODS F
   Rosinski J, 2007, STOCH PROC APPL, V117, P677, DOI 10.1016/j.spa.2006.10.003
   Schoutens W, 2011, REV DERIV RES, V14, P263, DOI 10.1007/s11147-010-9057-y
   Semeraro P, 2008, INT J THEOR APPL FIN, V11, P1, DOI 10.1142/S0219024908004701
   Seneta E., 2000, ADV MATH FINANCE, P3
   SHIRYAEV AN, 1999, ESSENTIALS STOCHASTI
   WHITTAKER ET, 1990, COURSE MODERN ANAL
   Yor M, 2007, APPL NUMER HARMON AN, P37, DOI 10.1007/978-0-8176-4545-8_3
NR 31
TC 1
Z9 1
U1 3
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0949-2984
EI 1432-1122
J9 FINANC STOCH
JI Financ. Stoch.
PD OCT
PY 2015
VL 19
IS 4
BP 979
EP 993
DI 10.1007/s00780-015-0277-8
PG 15
WC Business, Finance; Mathematics, Interdisciplinary Applications; Social
   Sciences, Mathematical Methods; Statistics & Probability
SC Business & Economics; Mathematics; Mathematical Methods In Social
   Sciences
GA CU1HU
UT WOS:000363272300009
DA 2018-12-27
ER

PT J
AU Al-Shammari, ET
   Amirmojahedi, M
   Shamshirband, S
   Petkovic, D
   Pavlovic, NT
   Bonakdari, H
AF Al-Shammari, Eiman Tamah
   Amirmojahedi, Mohsen
   Shamshirband, Shahaboddin
   Petkovic, Dalibor
   Pavlovic, Nenad T.
   Bonakdari, Hossein
TI RETRACTED: Estimation of wind turbine wake effect by adaptive
   neuro-fuzzy approach (Retracted article. See vol. 61, pg. 95, 2018)
SO FLOW MEASUREMENT AND INSTRUMENTATION
LA English
DT Article; Retracted Publication
DE Wind turbine; Wake model; Wind speed; Neuro-fuzzy; ANFIS
ID LARGE-EDDY SIMULATION; INFERENCE SYSTEM; HORIZONTAL-AXIS; SPEED; ANFIS;
   PREDICTION; MODEL; OPTIMIZATION; PLACEMENT; TUNNEL
AB The grouping of turbines in large farms introduces that a wind turbine operating in the wake of another turbine and has a reduced power production because of a lower wind speed after rotor. The flow field in the wake behind the first row turbines is characterized by a significant deficit in wind velocity and increased levels of turbulence intensity. Consequently, the downstream turbines in a wind farm cannot extract as much power from the wind as the first row turbines. Therefore modeling wake effect is necessary because it has a great influence on the actual energy output of a wind farm. In this study, the adaptive neuro-fuzzy inference system (ANFIS) is designed and adapted to estimate wake effect in a wind farm according to wind turbine positions in wind farm, distances between turbines in the wind farm and rotor radius as well. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Al-Shammari, Eiman Tamah] Kuwait Univ, Dept Informat Sci, Coll Comp Sci & Engn, Kuwait, Kuwait.
   [Amirmojahedi, Mohsen] Univ Malaya, Dept Civil Engn, Fac Engn, Kuala Lumpur 50603, Malaysia.
   [Shamshirband, Shahaboddin] Univ Malaya, Fac Comp Sci & Informat Technol, Dept Comp Syst & Technol, Kuala Lumpur, Malaysia.
   [Petkovic, Dalibor; Pavlovic, Nenad T.] Univ Nis, Fac Mech Engn, Deparment Mechatron & Control, Nish 18000, Serbia.
   [Bonakdari, Hossein] Univ Razi, Dept Civil Engn, Kermanshah, Iran.
RP Shamshirband, S (reprint author), Univ Malaya, Fac Comp Sci & Informat Technol, Dept Comp Syst & Technol, Kuala Lumpur, Malaysia.
EM dr.eiman@ku.edu.kw; shamshirband1396@gmail.com
RI Bonakdari, Hossein/B-9305-2018; Amirmojahedi, Mohsen/J-2508-2015
OI Bonakdari, Hossein/0000-0001-6169-3654; Amirmojahedi,
   Mohsen/0000-0001-9661-4821; Shamshirband,
   Shahaboddin/0000-0002-6605-498X
FU Project "Research and development of new generation wind turbines of
   high-energy efficiency" - Ministry of Education, Science and
   Technological Development, Republic of Serbia [TR35005]
FX This paper is supported by Project Grant TR35005 "Research and
   development of new generation wind turbines of high-energy efficiency"
   (2011-2015) financed by Ministry of Education, Science and Technological
   Development, Republic of Serbia.
CR Adaramola MS, 2011, RENEW ENERG, V36, P2078, DOI 10.1016/j.renene.2011.01.024
   Al-Ghandoor A, 2009, JORDAN J MECH IND EN, V3, P69
   Ata R, 2010, EXPERT SYST APPL, V37, P5454, DOI 10.1016/j.eswa.2010.02.068
   Aubrun S, 2013, J WIND ENG IND AEROD, V120, P1, DOI 10.1016/j.jweia.2013.06.007
   Bartl J, 2012, ENRGY PROCED, V24, P305, DOI 10.1016/j.egypro.2012.06.113
   Bououden S, 2012, RENEW ENERG, V37, P434, DOI 10.1016/j.renene.2011.06.025
   Cao L, 2012, PROCEDIA ENGINEER, V31, P245, DOI 10.1016/j.proeng.2012.01.1019
   Castellani F, 2013, APPL ENERG, V101, P432, DOI 10.1016/j.apenergy.2012.04.039
   Chkir S, 2011, ENRGY PROCED, V6, P777, DOI 10.1016/j.egypro.2011.05.088
   Christiansen MB, 2005, REMOTE SENS ENVIRON, V98, P251, DOI 10.1016/j.rse.2005.07.009
   Gil MD, 2012, ENERGY, V37, P455, DOI 10.1016/j.energy.2011.11.010
   Ekici BB, 2011, EXPERT SYST APPL, P38
   Eroglu Y, 2013, RENEW ENERG, V58, P95, DOI 10.1016/j.renene.2013.02.019
   Gonzalez-Longatt F, 2012, RENEW ENERG, V39, P329, DOI 10.1016/j.renene.2011.08.053
   Grant I, 2000, J WIND ENG IND AEROD, V85, P177, DOI 10.1016/S0167-6105(99)00139-7
   Han YF, 2011, COMP MATER SCI, V50, P2273, DOI 10.1016/j.commatsci.2011.03.004
   Hossain MZ, 2007, RENEW ENERG, V32, P2247, DOI 10.1016/j.renene.2006.11.016
   Hu DM, 2009, J HYDRODYN, V21, P285, DOI 10.1016/S1001-6058(08)60147-X
   Husien W, 2013, RENEW ENERG, V49, P128, DOI 10.1016/j.renene.2012.01.048
   Inal M, 2008, J MATER PROCESS TECH, V195, P34, DOI 10.1016/j.jmatprotec.2007.04.106
   Ituarte-Villarreal CM, 2011, PROCEDIA COMPUT SCI, V6, DOI 10.1016/j.procs.2011.08.087
   JANG JSR, 1993, IEEE T SYST MAN CYB, V23, P665, DOI 10.1109/21.256541
   Jensen N. O., 1983, NOTE WIND GENERATOR
   Karaagac B, 2012, MATER DESIGN, V35, P833, DOI 10.1016/j.matdes.2011.03.062
   Khajeh A, 2009, EXPERT SYST APPL, V36, P5728, DOI 10.1016/j.eswa.2008.06.051
   Khalifehzadeh R, 2007, COMP MATER SCI, V40, P359, DOI 10.1016/j.commatsci.2007.01.007
   Kurnaz S, 2010, EXPERT SYST APPL, V37, P1229, DOI 10.1016/j.eswa.2009.06.009
   Lo SP, 2005, J MATER PROCESS TECH, V168, P250, DOI 10.1016/j.jmatprotec.2005.01.010
   Meharrar A, 2011, EXPERT SYST APPL, V38, P7659, DOI 10.1016/j.eswa.2010.12.163
   Mo JO, 2013, J WIND ENG IND AEROD, V117, P38, DOI 10.1016/j.jweia.2013.03.007
   Mo JO, 2013, J WIND ENG IND AEROD, V112, P11, DOI 10.1016/j.jweia.2012.09.002
   Mohandes M, APPL ENERGY
   Oguz Y, 2010, TURK J ELECTR ENG CO, V18, P625, DOI 10.3906/elk-0907-115
   Petkovic D, 2012, NEURAL COMPUT APPL, V21, P2065
   Petkovic D, 2012, EXPERT SYST APPL, V39, P13295, DOI 10.1016/j.eswa.2012.05.072
   Petkovic D, 2012, EXPERT SYST APPL, V39, P9477, DOI 10.1016/j.eswa.2012.02.111
   Pookpunt S, 2013, RENEW ENERG, V55, P266, DOI 10.1016/j.renene.2012.12.005
   Qi YS, 2012, ENRGY PROCED, V16, P1635, DOI 10.1016/j.egypro.2012.01.254
   Schumann H, 2013, ENRGY PROCED, V35, P285, DOI 10.1016/j.egypro.2013.07.181
   Singh R, 2012, APPL SOFT COMPUT, V12, P40, DOI 10.1016/j.asoc.2011.09.010
   Song MX, 2012, RENEW ENERG, V41, P185, DOI 10.1016/j.renene.2011.10.016
   Thomsen K, 1999, J WIND ENG IND AEROD, V80, P121, DOI 10.1016/S0167-6105(98)00194-9
   Tian LF, 2005, MECHATRONICS, V15, P1305, DOI 10.1016/j.mechatronics.2005.02.001
   Vairappan C, 2009, NEUROCOMPUTING, V72, P1870, DOI 10.1016/j.neucom.2008.05.010
   Vermeer LJ, 2003, PROG AEROSP SCI, V39, P467, DOI 10.1016/S0376-0421(03)00078-2
   Wagner M, 2013, RENEW ENERG, V51, P64, DOI 10.1016/j.renene.2012.09.008
   Whale J, 2000, J WIND ENG IND AEROD, V84, P1, DOI 10.1016/S0167-6105(98)00201-3
   Wu S, 2013, NEUROCOMPUTING, V102, P163, DOI 10.1016/j.neucom.2011.12.051
   Yang Z, 2011, P 29 AIAA APPL AER C, P1
   Yilmaz AS, 2009, EXPERT SYST APPL, V36, P9767, DOI 10.1016/j.eswa.2009.02.014
   Zhang Z, 2003, COMPOS SCI TECHNOL, V63, P2029, DOI 10.1016/S0266-3538(03)00106-4
NR 51
TC 6
Z9 6
U1 1
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0955-5986
EI 1873-6998
J9 FLOW MEAS INSTRUM
JI Flow Meas. Instrum.
PD OCT
PY 2015
VL 45
BP 1
EP 6
DI 10.1016/j.flowmeasinst.2015.04.002
PG 6
WC Engineering, Mechanical; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA CT2AR
UT WOS:000362604900001
DA 2018-12-27
ER

PT J
AU Hsu, CL
   Chiang, CH
AF Hsu, Chien-Lung
   Chiang, Chun-Hao
TI RETRACTED: The financial crisis research: a bibliometric analysis
   (Retracted article. See vol. 113, pg. 1827, 2017)
SO SCIENTOMETRICS
LA English
DT Article; Retracted Publication
DE Bibliometrics; Bradford's law; Citation model
ID SOVEREIGN; IMPACT; GREEK
AB In previous research (Chiang and Yang in Appl Econ 44(22):2827-2839, 2012 ), they has been studied to analyze the growth of publication, the subject types, and the journal distributions, etc. for financial risk literatures through the perspective of bibliometrics from 1991 to 2009. From the growing incidence of financial risk Since 2008 year, The event of financial risk greater more impact on the economy, for example, the Lehman Brothers Holdings Inc bankruptcy, the Greek debt crisis, the Latin American sovereign Crisis etc. In this study, we extended previous research up to 2013 and investigates the features of financial crisis literature based on bibliometric methods from: (1) TP: the number of "total articles" of an institution or a country; (2) SP: the number of "single country article" (3) CP: the number of "internationally collaborative article" (4) FP: the number of "first author article", and (5) RP: the number of "corresponding author article". The distribution of journal articles was also examined utilizing Bradford's law and Citation model (Chiu and Ho in Scientometrics 63(1):3-23, 2005). Data were based on the Science Social Citation Index, from the Institute of Scientific Information Web of Science database. A total of 8485 entries from 1926 to 2013 were collected. This paper implemented the following publication type and language, characteristics of articles outputs, country, subject categories and journals, and the frequency of title-words and keywords used. Meanwhile, the analysis indicated the most relevant disciplines for financial crisis subject category provided by economics, business finance, and political science.
C1 [Hsu, Chien-Lung] Takming Univ Sci & Technol, Dept Mkt Management, Taipei 11451, Taiwan.
   [Hsu, Chien-Lung] Natl Chi Nan Univ, Dept Banking & Finance, Puli 54561, Nantou County, Taiwan.
   [Chiang, Chun-Hao] Mega Financial Holding Co, Dept Risk Control Management, Taipei 100, Taiwan.
RP Chiang, CH (reprint author), Mega Financial Holding Co, Dept Risk Control Management, 14F,123,Sect 2,Jhongsiao E Rd, Taipei 100, Taiwan.
EM alanhsu8399@takming.edu.tw; uuuddd@hotmail.com
CR Afonso A, 2012, J INT MONEY FINANC, V31, P606, DOI 10.1016/j.jimonfin.2012.01.016
   Baltussen A, 2004, ANESTH ANALG, V98, P443, DOI 10.1213/01.ANE.0000096185.13474.0A
   Bradford S. C., 1948, DOCUMENTATION, P154
   Brandt JS, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.07.025
   CAMPBELL FM, 1990, B MED LIBR ASSOC, V78, P376
   Chen YH, 2011, APPL ECON, V43, P1399, DOI 10.1080/00036840802600467
   Chiu WT, 2005, SCIENTOMETRICS, V63, P3, DOI 10.1007/s11192-005-0201-7
   Chouard V, 2014, APPL ECON, V46, P2711, DOI 10.1080/00036846.2014.887193
   Chun-Hao C, 2012, APPL ECON, V44, P2827, DOI 10.1080/00036846.2011.566208
   Constancio V., 2011, LECT BOCC U INT SANP
   De Santis R. A., 2012, 1419 EUR CENTR BANK
   Gagnon J, 2011, INT J CENT BANK, V7, P3
   Grammatikos T, 2012, J INT MONEY FINANC, V31, P517, DOI 10.1016/j.jimonfin.2011.10.004
   Hennessey K, 2009, CUAJ-CAN UROL ASSOC, V3, P293
   Huang C. Y., 2010, AFRICAN J BUSINESS M, V5, P276
   Joyce MAS, 2011, INT J CENT BANK, V7, P113
   Kelly JC, 2010, J BONE JOINT SURG BR, V92B, P1338, DOI 10.1302/0301-620X.92B10.24867
   Mink M, 2013, J INT MONEY FINANC, V34, P102, DOI 10.1016/j.jimonfin.2012.11.006
   Q.E. (Quantitative Easing Explained), 2011, PUTT MOR MON OUR EC
   Wang AT, 2014, APPL ECON, V46, P1665, DOI 10.1080/00036846.2014.881976
   Zartaloudis S, 2014, SOC POLICY ADMIN, V48, P430, DOI 10.1111/spol.12069
   Zhou P, 2008, ISSI NEWSLETTER  MAR, V2008, P7
NR 22
TC 6
Z9 7
U1 5
U2 81
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0138-9130
EI 1588-2861
J9 SCIENTOMETRICS
JI Scientometrics
PD OCT
PY 2015
VL 105
IS 1
BP 161
EP 177
DI 10.1007/s11192-015-1698-z
PG 17
WC Computer Science, Interdisciplinary Applications; Information Science &
   Library Science
SC Computer Science; Information Science & Library Science
GA CS3RP
UT WOS:000361992800011
DA 2018-12-27
ER

PT J
AU Bingol, UA
   Cinar, C
   Arslan, H
   Oksuz, S
   Cetinkale, O
AF Bingol, Ugur Anil
   Cinar, Can
   Arslan, Hakan
   Oksuz, Sinan
   Cetinkale, Oguz
TI RETRACTED: Origin, Reality, and Clinical Importance of the Arcade of
   Struthers An Anatomic Study (Retracted article. See vol. 76, pg. 473,
   2016)
SO ANNALS OF PLASTIC SURGERY
LA English
DT Article; Retracted Publication
DE arcade of Struthers; cubital tunnel; internal brachial ligament; medial
   intermuscular septum; ulnar nerve
ID ULNAR NERVE
AB The literature contains confusing and opposing views about the naming, prevalence, anatomic structure, and clinical significance of the arcade of Struthers. The conflicting rates of arcade (between 0% and 100%) prevalence found in the literature may be due to the varying definition of the arcade among the authors, as well as the dissection method. The present study aims to examine the structure to determine whether or not the arcade of Struthers exists through an anatomic dissection study of a fresh human cadaver and seeks to compare its findings with those in the literature. Twenty arms from fresh frozen cadavers were dissected. An arcade of Struthers was not found in any specimen. Study concluded that its existence is unproven, and the arcade of Struthers does not exist.
C1 [Bingol, Ugur Anil; Cinar, Can] Yeditepe Univ, Fac Med, Dept Plast Reconstruct & Aesthet Surg, TR-34752 Istanbul, Turkey.
   [Arslan, Hakan; Cetinkale, Oguz] Istanbul Univ, Cerrahpasa Fac Med, Dept Plast Reconstruct & Aesthet Surg, Istanbul, Turkey.
   [Oksuz, Sinan] Haydarpasa Training Hosp, Gulhane Mil Med Acad, Dept Plast Reconstruct & Aesthet Surg, Istanbul, Turkey.
RP Bingol, UA (reprint author), Yeditepe Univ, Fac Med, Dept Plast Reconstruct & Aesthet Surg, Devlet Yolu Ankara Cad 102-104, TR-34752 Istanbul, Turkey.
EM ugur.bingol@yeditepe.edu.tr
RI arslan, hakan/A-1770-2017
CR ALQATTAN MM, 1991, J HAND SURG-BRIT EUR, V16B, P311, DOI 10.1016/0266-7681(91)90059-W
   AMADIO PC, 1986, SURG RADIOL ANAT, V8, P155, DOI 10.1007/BF02427843
   Bartels RHMA, 2003, ACTA NEUROCHIR, V145, P295, DOI 10.1007/s00701-003-0006-5
   De Jesus R, 2003, J HAND SURG-AM, V28A, P528, DOI 10.1053/jhsu.2003.50071
   DELLON AL, 1986, J HAND SURG-BRIT EUR, V11B, P175
   Gonzalez MH, 2001, J HAND SURG-BRIT EUR, V26, P142, DOI 10.1054/jhsb.2000.0532
   Iyer Vasudeva, 2010, Hand (N Y), V5, P453, DOI 10.1007/s11552-010-9280-x
   KANE E, 1973, ANN CHIR, V27, P487
   Loukas Marios, 2010, Neurosurgery, V66, P1170, DOI 10.1227/01.NEU.0000369197.08381.BE
   Mackinnon SE, 1998, SURG PERIPHERAL NEVR
   OCHIAI N, 1992, J HAND SURG-BRIT EUR, V17B, P629, DOI 10.1016/0266-7681(92)90188-8
   Ochiai N, 2000, CLIN ORTHOP RELAT R, P129
   Osterman A, 1996, SURG HAND UPPER EXTR, P1339
   SIMAMURA T, 1984, TOUHOKUSEISAIKIYO, V28, P82
   Siqueira MG, 2005, SURG NEUROL, V64, pS17, DOI 10.1016/j.surneu.2005.04.017
   SPINNER M, 1974, CLIN ORTHOP RELAT R, P46, DOI 10.1097/00003086-197410000-00007
   Spinner M, 1976, Hand, V8, P239, DOI 10.1016/0072-968X(76)90008-5
   Tiyaworanan P, 2010, J HAND SURG-ASIAN-PA, V15, P157, DOI 10.1142/S0218810410004941
   Tubbs R Shane, 2011, Surg Neurol Int, V2, P184, DOI 10.4103/2152-7806.91139
   von Schroeder HP, 2003, J HAND SURG-AM, V28A, P1018, DOI 10.1016/S0363-5023(03)00421-0
   Wehrli L, 2005, PLAST RECONSTR SURG, V115, P471, DOI 10.1097/01.PRS.0000150144.73603.24
NR 21
TC 3
Z9 3
U1 2
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0148-7043
EI 1536-3708
J9 ANN PLAS SURG
JI Ann. Plast. Surg.
PD OCT
PY 2015
VL 75
IS 4
BP 430
EP 434
DI 10.1097/SAP.0000000000000610
PG 5
WC Surgery
SC Surgery
GA CR8MY
UT WOS:000361609000015
PM 26360652
DA 2018-12-27
ER

PT J
AU Yang, J
   Zhang, X
   Xiong, XF
   Wu, QH
   Zhao, LY
   Liu, LY
   Qin, YN
   Song, TS
   Huang, C
AF Yang, Juan
   Zhang, Xin
   Xiong, Xiaofan
   Wu, Qiuhua
   Zhao, Lingyu
   Liu, Liying
   Qin, Yannan
   Song, Tusheng
   Huang, Chen
TI RETRACTED: Effects of a Terrified-Sound Stress on Serum Proteomic
   Profiling in Mice (Retracted Article. See vol. 60, pg 276, 2016)
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE Terrified-sound-induced stress; Serum proteomic profiling; Stress
   release; Protein expression
ID FLAVIN-CONTAINING MONOOXYGENASES; PSYCHOLOGICAL STRESS; RAT HIPPOCAMPUS;
   CANCER; METABOLISM; PEPTIDOME; DISEASE; BRAIN; MODEL; IRON
AB The serum proteomic profiles of mice exposed to terrified-sound-induced stress and after stress release were investigated. Serum samples from 32 mice were divided into four groups (n = 8 each) and analyzed using matrix-assisted laser desorption and ionization time-of-flight mass spectrometry techniques (MALDI-TOF MS) combined with magnetic bead-based weak cation-exchange chromatography. ClinProTools software identified several distinct markers that differed between the stressed and control groups and between the stress released and stressed released controls. Of 33 m/z peaks that differed among the four groups, 17 were significantly different (P < 0.05). Five peaks (m/z: 2793.37, 2924.86, 1979.90, 3492.49, 3880.24) showed significant differences in expression after exposure to terrified-sound stress and returned to control levels after stress release. These were sequence identified as peptide regions of dimethylaniline monooxygenase, myosin-9, uncharacterized protein in Rattus norvegicus, apolipoprotein C-I, and plasma serine protease inhibitor (Serpina 5). Our study provides the first evidence of significant changes in serum proteomic profiles in mice exposed to terrified-sound stress, which suggests that protein expression profiles are affected by the stress. Normal expression levels were restored after stress release, suggesting the activation of self-adjustment mechanisms for the recovery of protein expression levels altered by this stress.
C1 [Yang, Juan; Xiong, Xiaofan; Wu, Qiuhua; Zhao, Lingyu; Qin, Yannan; Song, Tusheng; Huang, Chen] Xi An Jiao Tong Univ, Basic Med Sch, Dept Cell Biol & Genet, Xian 710061, Shaanxi, Peoples R China.
   [Yang, Juan; Liu, Liying; Huang, Chen] Xi An Jiao Tong Univ, Key Lab Environm & Dis Related Gene, Minist Educ, Xian 710061, Shaanxi, Peoples R China.
   [Zhang, Xin] Maternal & Child Hlth Care Hosp, Assisted Reprod Ctr, Xian 710003, Shaanxi, Peoples R China.
RP Huang, C (reprint author), Xi An Jiao Tong Univ, Basic Med Sch, Dept Cell Biol & Genet, 76 Western Yanta Rd, Xian 710061, Shaanxi, Peoples R China.
EM hchen@mail.xjtu.edu.cn
FU National Natural Science Foundation of China [81200845]; Key Science and
   Technology Program of Shaanxi province [2015SF166]
FX This work was supported by the National Natural Science Foundation of
   China (grant number: 81200845) and the Key Science and Technology
   Program of Shaanxi province (grant number: 2015SF166).
CR Aloe L, 2002, PHARMACOL BIOCHEM BE, V73, P159, DOI 10.1016/S0091-3057(02)00757-8
   Arrondel C, 2002, J AM SOC NEPHROL, V13, P65
   Biondi M, 1997, PSYCHOTHER PSYCHOSOM, V66, P3, DOI 10.1159/000289101
   Biondi M, 2001, PSYCHONEUROIMMUNOLOG, V2
   Birkett MA, 2011, JOVE-J VIS EXP, DOI 10.3791/3238
   Carney RA, 2002, STROKE, V33, P5, DOI 10.1161/str.33.1.5
   Cashman JR, 2006, ANNU REV PHARMACOL, V46, P65, DOI 10.1146/annurev.pharmtox.46.120604.141043
   Dhabhar FS, 2009, NEUROIMMUNOMODULAT, V16, P300, DOI 10.1159/000216188
   Diamandis EP, 2006, J PROTEOME RES, V5, P2079, DOI 10.1021/pr060225u
   Eskandari F, 2002, ANN NY ACAD SCI, V966, P20, DOI 10.1111/j.1749-6632.2002.tb04198.x
   Geiger M, 2007, THROMB HAEMOSTASIS, V97, P343, DOI 10.1160/TH06-09-0488
   Giannoglou GD, 2015, ANGIOLOGY, V66, P5, DOI 10.1177/0003319714525032
   Hu LL, 2014, PHYSIOL BEHAV, V123, P105, DOI 10.1016/j.physbeh.2013.09.010
   JONES KC, 1986, J BIOL CHEM, V261, P2553
   Krueger SK, 2005, PHARMACOL THERAPEUT, V106, P357, DOI 10.1016/j.pharmthera.2005.01.001
   Li BY, 2014, NEUROSCI LETT, V566, P11, DOI 10.1016/j.neulet.2013.11.036
   Liotta LA, 2006, J CLIN INVEST, V116, P26, DOI 10.1172/JCI27467
   Lloyd C, 2005, DIABETES SPECTR, V18, P121, DOI [DOI 10.2337/DIASPECT.18.2.121, 10.2337/diaspect.18.2.121]
   POULSEN LL, 1995, CHEM-BIOL INTERACT, V96, P57, DOI 10.1016/0009-2797(94)03583-T
   Reiche EMV, 2004, LANCET ONCOL, V5, P617, DOI 10.1016/S1470-2045(04)01597-9
   Singh N, 2009, AM J KIDNEY DIS, V54, P732, DOI 10.1053/j.ajkd.2009.06.023
   Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786
   Wang L, 2008, NEUROSCIENCE, V155, P24, DOI 10.1016/j.neuroscience.2008.03.091
   Wei CL, 2008, INT J HEMATOL, V88, P52, DOI 10.1007/s12185-008-0105-4
   Yang J, 2014, J MOL NEUROSCI, V53, P158, DOI 10.1007/s12031-014-0242-6
   Yang J, 2014, PHYSIOL BEHAV, V128, P32, DOI 10.1016/j.physbeh.2014.01.038
   Yang J, 2012, CLIN EXP MED, V12, P79, DOI 10.1007/s10238-011-0149-2
   Yu J, 2011, FUNCT INTEGR GENOMIC, V11, P203, DOI 10.1007/s10142-010-0198-8
   Zhao M, 2008, BIOCHEM BIOPH RES CO, V373, P90, DOI 10.1016/j.bbrc.2008.05.166
NR 29
TC 1
Z9 1
U1 1
U2 12
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD OCT
PY 2015
VL 57
IS 2
BP 211
EP 218
DI 10.1007/s12031-015-0607-5
PG 8
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA CR7VN
UT WOS:000361560000008
PM 26156200
DA 2018-12-27
ER

PT J
AU Cheng, HY
   Ou, KL
   Chiang, HJ
   Lin, LH
AF Cheng, Han-Yi
   Ou, Keng-Liang
   Chiang, Hsi-Jen
   Lin, Li-Hsiang
TI RETRACTED: Effect of Anti-Sticking Nanostructured Surface Coating on
   Minimally Invasive Electrosurgical Device in Brain(Retracted article.
   See vol. 45, pg.1161, 2017)
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article; Retracted Publication
DE Electrosurgical device; Nanostructured film; Thermal injury
ID FINITE-ELEMENT-ANALYSIS; BIPOLAR FORCEPS; CARBON-FILMS; TEMPERATURE;
   MODEL; IMPLANT; TISSUE; OSSEOINTEGRATION; EMBOLIZATION; COAGULATION
AB The purpose of the present study was to examine the extent of thermal injury in the brain after the use of a minimally invasive electrosurgical device with a nanostructured copper-doped diamond-like carbon (DLC-Cu) surface coating. To effectively utilize an electrosurgical device in clinical surgery, it is important to decrease the thermal injury to the adjacent tissues. The surface characteristics and morphology of DLC-Cu thin film was evaluated using a contact angle goniometer, scanning electron microscopy, and atomic force microscopy. Three-dimensional biomedical brain models were reconstructed using magnetic resonance images to simulate the electrosurgical procedure. Results indicated that the temperature was reduced significantly when a minimally invasive electrosurgical device with a DLC-Cu thin film coating (DLC-Cu-SS) was used. Temperatures decreased with the use of devices with increasing film thickness. Thermographic data revealed that surgical temperatures in an animal model were significantly lower with the DLC-Cu-SS electrosurgical device compared to an untreated device. Furthermore, the DLC-Cu-SS device created a relatively small region of injury and lateral thermal range. As described above, the biomedical nanostructured film reduced excessive thermal injury with the use of a minimally invasive electrosurgical device in the brain.
C1 [Cheng, Han-Yi; Ou, Keng-Liang; Chiang, Hsi-Jen] Taipei Med Univ, Grad Inst Biomed Mat & Tissue Engn, Taipei 110, Taiwan.
   [Cheng, Han-Yi; Ou, Keng-Liang; Chiang, Hsi-Jen; Lin, Li-Hsiang] Taipei Med Univ, Res Ctr Biomed Devices & Prototyping Prod, Taipei 110, Taiwan.
   [Cheng, Han-Yi; Ou, Keng-Liang] Taipei Med Univ, Res Ctr Biomed Implants & Microsurg Devices, Taipei 110, Taiwan.
   [Ou, Keng-Liang; Chiang, Hsi-Jen] Taipei Med Univ, Dept Dent, Shuang Ho Hosp, Taipei 110, Taiwan.
   [Chiang, Hsi-Jen; Lin, Li-Hsiang] Taipei Med Univ, Sch Dent, Coll Oral Med, Taipei 110, Taiwan.
RP Lin, LH (reprint author), Taipei Med Univ, Sch Dent, Coll Oral Med, Taipei 110, Taiwan.
EM chytmu@gmail.com; lisa@tmu.edu.tw
FU Department of Health, Executive Yuan, Taiwan [MOHW103-TDU-N-211-133001,
   MOHW103-TD-B-111-01]
FX The authors would like to thank the Department of Health, Executive
   Yuan, Taiwan for financially supporting this research under contract No.
   MOHW103-TDU-N-211-133001 and No. MOHW103-TD-B-111-01 (Health and welfare
   surcharge of tobacco products).
CR Andrzejak RG, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.061907
   Chan YH, 2011, SURF COAT TECH, V206, P1037, DOI 10.1016/j.surfcoat.2011.07.034
   Cheng HY, 2013, INT J ORAL MAX SURG, V42, P386, DOI 10.1016/j.ijom.2012.07.005
   Cheng HY, 2015, J BIOMED MATER RES A, V103, P269, DOI 10.1002/jbm.a.35172
   Cheng HY, 2013, J BIOMED MATER RES A, V101, P1158, DOI 10.1002/jbm.a.34415
   Chu KT, 2013, J BIOMED MATER RES A, V101, P1195, DOI 10.1002/jbm.a.34404
   dos Santos I, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-21
   Elliott-Lewis EW, 2009, NEUROSURGERY, V65, P1182, DOI 10.1227/01.NEU.0000356985.27936.93
   Ferrant M, 2001, IEEE T MED IMAGING, V20, P1384, DOI 10.1109/42.974933
   Fine R, 2011, J MED CASE REP, V5, P1
   Habermann W, 2013, HEAD NECK-J SCI SPEC, V35, P535, DOI 10.1002/hed.22986
   Hensman C, 1998, SURG ENDOSC-ULTRAS, V12, P1017, DOI 10.1007/s004649900771
   Koch C, 2003, ULTRASOUND MED BIOL, V29, P301, DOI 10.1016/S0301-5629(02)00727-5
   LEDBETTER HM, 1980, J APPL PHYS, V51, P305, DOI 10.1063/1.327371
   Mikami T, 2004, J NEUROSURG, V100, P133, DOI 10.3171/jns.2004.100.1.0133
   Mikami T, 2007, NEUROSURGERY, V60, P157, DOI 10.1227/01.NEU.0000249252.86417.85
   Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X
   Munro MG, 2001, J AM ASSOC GYN LAP, V8, P488, DOI 10.1016/S1074-3804(05)60609-3
   Nelson DA, 1998, EUR J APPL PHYSIOL O, V78, P353, DOI 10.1007/s004210050431
   OLSEN RW, 1985, J BIOMECH ENG-T ASME, V107, P354, DOI 10.1115/1.3138569
   SAVVIDES N, 1992, J APPL PHYS, V72, P2791, DOI 10.1063/1.351530
   SAVVIDES N, 1993, THIN SOLID FILMS, V228, P289, DOI 10.1016/0040-6090(93)90618-Y
   SCHEIBE HJ, 1994, THIN SOLID FILMS, V246, P92, DOI 10.1016/0040-6090(94)90737-4
   Sevimay M, 2005, J PROSTHET DENT, V93, P227, DOI 10.1016/j.prosdent.2004.12.019
   Sutton PA, 2010, BRIT J SURG, V97, P428, DOI 10.1002/bjs.6901
   TANAKA E, 1994, MED ENG PHYS, V16, P316, DOI 10.1016/1350-4533(94)90058-2
   Zhang GY, 2013, J BIOMED MATER RES A, V101, P3192, DOI 10.1002/jbm.a.34617
NR 27
TC 1
Z9 1
U1 4
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0090-6964
EI 1573-9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD OCT
PY 2015
VL 43
IS 10
BP 2383
EP 2393
DI 10.1007/s10439-015-1304-9
PG 11
WC Engineering, Biomedical
SC Engineering
GA CR5NS
UT WOS:000361390400007
PM 25851468
DA 2018-12-27
ER

PT J
AU Ni, ZL
   Zhao, HJ
   Ye, FX
AF Ni, Zenglei
   Zhao, Hongjian
   Ye, Fuxing
TI RETRACTED: Influence of sintering temperature on the mechanical
   properties and thermal expansion of SiCp/Al-30Si composites(Retracted
   article. See vol.141,pg.328,2017)
SO VACUUM
LA English
DT Article; Retracted Publication
DE Sintering temperature; Mechanical properties; Thermal expansion; Vacuum
   hot-pressing plus sintering
ID METAL-MATRIX COMPOSITES; CU ALLOY COMPOSITES; AL-SIC COMPOSITES; VOLUME
   FRACTION; PARTICLE-SIZE; DIMENSIONAL STABILITY; TENSILE PROPERTIES;
   FRACTURE-BEHAVIOR; MICROSTRUCTURE
AB In this investigation, SiCp/Al-30Si (SiC particle reinforced Al-30Si alloy matrix) composites were fabricated by vacuum hot-pressing plus sintering in the temperature range of 560-590 degrees C. The microstructure, phases and thermal expansion were studied using XRD, TEM, OM, SEM and thermomechanical analysis equipment. It is found that, as increasing the sintering temperature, the size of Si phase and relative density increased, the tensile strength first increased and then decreased, but the coefficient of thermal expansion failed to decrease. Overall, the results reveal that the sintering temperature has a significant effect on the tensile strength and thermal expansion of the composites. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ni, Zenglei; Zhao, Hongjian; Ye, Fuxing] Tianjin Univ, Sch Mat Sci & Engn, Tianjin 300072, Peoples R China.
RP Ni, ZL (reprint author), Tianjin Univ, Sch Mat Sci & Engn, Weijin Rd 92, Tianjin 300072, Peoples R China.
EM zlni@tju.edu.cn
FU Natural Science Foundation of Tianjin [12JCYBJ12300]
FX The authors are grateful for the financial support from Natural Science
   Foundation of Tianjin under grant NO. 12JCYBJ12300.
CR Arpon R, 2003, ACTA MATER, V51, P3145, DOI 10.1016/S1359-6454(03)00126-5
   Chawla N, 1998, METALL MATER TRANS A, V29, P2843, DOI 10.1007/s11661-998-0325-5
   Diler EA, 2012, MAT SCI ENG A-STRUCT, V548, P43, DOI 10.1016/j.msea.2012.03.066
   El-Gallab M, 1998, J MATER PROCESS TECH, V83, P151, DOI 10.1016/S0924-0136(98)00054-5
   Elomari S, 1998, COMPOS SCI TECHNOL, V58, P369, DOI 10.1016/S0266-3538(97)00124-3
   FINOT M, 1994, METALL MATER TRANS A, V25, P2403, DOI 10.1007/BF02648860
   Ghosh SK, 2011, MATER DESIGN, V32, P139, DOI 10.1016/j.matdes.2010.06.020
   Huber T, 2006, COMPOS SCI TECHNOL, V66, P2206, DOI 10.1016/j.compscitech.2005.12.012
   IBRAHIM IA, 1991, J MATER SCI, V26, P1137, DOI 10.1007/BF00544448
   Kaneda H, 1997, J MATER SCI, V32, P47, DOI 10.1023/A:1018558612135
   LEVY A, 1990, METALL TRANS A, V21, P411, DOI 10.1007/BF02782421
   LEWANDOWSKI JJ, 1989, MAT SCI ENG A-STRUCT, V107, P241, DOI 10.1016/0921-5093(89)90392-4
   Matsuura K, 2003, MATER CHEM PHYS, V81, P393, DOI 10.1016/S0254-0584(03)00030-0
   MUMMERY P, 1991, MAT SCI ENG A-STRUCT, V135, P221, DOI 10.1016/0921-5093(91)90566-6
   Murray J. L, 1984, B ALLOY PHASE DIAGRA, V5, P74, DOI DOI 10.1007/BF02868729
   Nam TH, 2008, COMPOS PART A-APPL S, V39, P856, DOI 10.1016/j.compositesa.2008.01.011
   NEITE G, 1991, MAT SCI ENG A-STRUCT, V148, P85, DOI 10.1016/0921-5093(91)90868-N
   Ogel B, 2001, MAT SCI ENG A-STRUCT, V301, P213, DOI 10.1016/S0921-5093(00)01656-7
   Ozben T, 2008, J MATER PROCESS TECH, V198, P220, DOI 10.1016/j.jmatprotec.2007.06.082
   Park CS, 2004, MATER CHEM PHYS, V88, P46, DOI 10.1016/j.matchemphys.2004.05.046
   Rabiei A, 2008, COMPOS PART A-APPL S, V39, P294, DOI 10.1016/j.compositesa.2007.10.018
   RIBES H, 1990, METALL TRANS A, V21, P2489, DOI 10.1007/BF02646993
   Wang ZW, 2011, MAT SCI ENG A-STRUCT, V528, P1131, DOI 10.1016/j.msea.2010.11.028
   Wang ZW, 2010, MAT SCI ENG A-STRUCT, V527, P6537, DOI 10.1016/j.msea.2010.07.017
   Zhang Q, 2003, MATER CHEM PHYS, V82, P780, DOI 10.1016/j.matchemphys.2003.07.001
   Zhang ZH, 2010, MAT SCI ENG A-STRUCT, V527, P7235, DOI 10.1016/j.msea.2010.07.043
NR 26
TC 5
Z9 5
U1 3
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-207X
J9 VACUUM
JI Vacuum
PD OCT
PY 2015
VL 120
BP 101
EP 106
DI 10.1016/j.vacuum.2015.06.031
PN A
PG 6
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA CR5ST
UT WOS:000361405000019
DA 2018-12-27
ER

PT J
AU Sun, J
   Yang, C
   Zhao, H
   Zheng, P
   Wilkinson, J
   Ng, B
   Yuan, Y
AF Sun, J.
   Yang, C.
   Zhao, H.
   Zheng, P.
   Wilkinson, J.
   Ng, B.
   Yuan, Y.
TI RETRACTED: Randomised clinical trial: the clinical efficacy and safety
   of an alginate-antacid (Gaviscon Double Action) versus placebo, for
   decreasing upper gastrointestinal symptoms in symptomatic
   gastroesophageal reflux disease (GERD) in China (Retracted article. See
   vol. 48, pg. 1039, 2018)
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Article; Retracted Publication
ID PROTON PUMP INHIBITORS; QUALITY-OF-LIFE; ACID POCKET; SODIUM ALGINATE;
   DOUBLE-BLIND; OMEPRAZOLE; QUESTIONNAIRE; EPIDEMIOLOGY; PRODUCTIVITY;
   VALIDATION
AB BackgroundThere is a paucity of large-scale studies evaluating the clinical benefit of the Gaviscon Double Action (DA) alginate-antacid formulation for treating gastroesophageal reflux disease (GERD) symptoms.
   AimRandomised double-blind placebo-controlled parallel-group study to evaluate efficacy and safety of Gaviscon DA in reducing heartburn, regurgitation and dyspepsia symptoms in individuals with mild-to-moderate GERD in China.
   MethodsParticipants with symptomatic GERD (n=1107) were randomised to receive Gaviscon DA or placebo (two tablets four times daily) for seven consecutive days. The primary endpoint compared the change in Reflux Disease Questionnaire (RDQ) score for the GERD (heartburn + regurgitation) dimension between Gaviscon DA and placebo. Secondary endpoints compared the change in RDQ scores for individual heartburn, regurgitation and dyspepsia dimensions, overall treatment evaluation (OTE) scores and incidence of adverse events (AEs).
   ResultsMean RDQ GERD scores: 2.51 for Gaviscon DA and 2.50 for placebo at baseline; 1.25 for Gaviscon DA and 1.46 for placebo post treatment. Gaviscon DA was statistically superior to placebo in reducing GERD and dyspepsia RDQ scores [least-squares mean (LSM) difference: GERD -0.21, P<0.0001; dyspepsia -0.18, P=0.0004], despite a substantial placebo response. The Gaviscon DA group reported more favourable overall treatment responses than the placebo group across all OTE categories (P<0.0001). Superior relief of GERD symptoms was observed both in those with non-erosive and those with erosive reflux disease (LSM difference -0.14 [P=0.038] and -0.29 [P<0.0001] respectively). Incidence of AEs was similar in both groups.
   ConclusionGaviscon DA tablets provide effective and safe reduction in acid reflux and dyspepsia symptoms in Chinese individuals with mild-to-moderate GERD. ClinicalTrials.gov: NCT01869491
C1 [Sun, J.; Yuan, Y.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai 200025, Peoples R China.
   [Yang, C.] Shanghai Tongji Hosp, Shanghai, Peoples R China.
   [Zhao, H.] China Japan Friendship Hosp, Beijing, Peoples R China.
   [Zheng, P.] Zhejiang Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Wilkinson, J.; Ng, B.] Reckitt Benckiser, Slough, Berks, England.
RP Yuan, Y (reprint author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gastroenterol, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.
EM yyz28@medmail.com.cn
FU Reckitt Benckiser
FX This study was funded in full by Reckitt Benckiser. Writing support was
   provided by Tech Observer and was funded by Reckitt Benckiser.
CR Cao Y, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-37
   Carlsson R, 1998, EUR J GASTROEN HEPAT, V10, P119, DOI 10.1097/00042737-199802000-00004
   CHEVREL B, 1980, J INT MED RES, V8, P300, DOI 10.1177/030006058000800411
   Cremonini F, 2010, ALIMENT PHARM THER, V32, P29, DOI 10.1111/j.1365-2036.2010.04315.x
   De Ruigh A, 2014, ALIMENT PHARM THER, V40, P531, DOI 10.1111/apt.12857
   Dean BB, 2004, CLIN GASTROENTEROL H, V2, P656, DOI 10.1053/S1542-3565(04)00288-5
   Dettmar PW, 2006, INT J CLIN PRACT, V60, P275, DOI 10.1111/j.1368-5031.2005.00800.x
   DeVault KR, 2005, AM J GASTROENTEROL, V100, P190, DOI 10.1111/j.1572-0241.2005.41217.x
   El-Serag HB, 2014, GUT, V63, P871, DOI 10.1136/gutjnl-2012-304269
   Gisbert JP, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-90
   Guillemot FO, 2005, GASTROEN CLIN BIOL, V29, P243, DOI 10.1016/S0399-8320(05)80756-0
   Hampson FC, 2010, DRUG DEV IND PHARM, V36, P614, DOI 10.3109/03639040903388290
   JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6
   Jung HK, 2011, J NEUROGASTROENTEROL, V17, P14, DOI 10.5056/jnm.2011.17.1.14
   JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1
   Kahrilas PJ, 2013, AM J GASTROENTEROL, V108, P1058, DOI 10.1038/ajg.2013.132
   Kwiatek MA, 2011, ALIMENT PHARM THER, V34, P59, DOI 10.1111/j.1365-2036.2011.04678.x
   Lai IR, 2006, WORLD J GASTROENTERO, V12, P747, DOI 10.3748/wjg.v12.i5.747
   MALMUD LS, 1979, J NUCL MED, V20, P1023
   Manabe N, 2012, DIS ESOPHAGUS, V25, P373, DOI 10.1111/j.1442-2050.2011.01276.x
   Mandel KG, 2000, ALIMENT PHARM THER, V14, P669
   Pilichiewicz AN, 2009, CLIN GASTROENTEROL H, V7, P317, DOI 10.1016/j.cgh.2008.09.007
   Portale G, 2007, DIS ESOPHAGUS, V20, P47, DOI 10.1111/j.1442-2050.2007.00650.x
   Pouchain D, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-18
   Reckitt Benckiser Healthcare (UK) Ltd, 0900901 STUD DAT FIL
   Reckitt Benckiser Healthcare (UK) Ltd, GA0917 STUD DAT FIL
   Rohof WO, 2014, CLIN GASTROENTEROL H, V12, P1101, DOI 10.1016/j.cgh.2014.04.003
   Rohof WO, 2013, CLIN GASTROENTEROL H, V11, P1585, DOI 10.1016/j.cgh.2013.04.046
   Shaw MJ, 2001, AM J GASTROENTEROL, V96, P52
   Thomas E, 2014, ALIMENT PHARM THER, V39, P595, DOI 10.1111/apt.12640
   Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x
   Wahlqvist P, 2008, ALIMENT PHARM THERAP, V27, P960, DOI 10.1111/j.1365-2036.2008.03671.x
   Washington N, 1998, ALIMENT PHARM THERAP, V12, P53
NR 33
TC 18
Z9 19
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD OCT
PY 2015
VL 42
IS 7
BP 845
EP 854
DI 10.1111/apt.13334
PG 10
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA CQ8ZO
UT WOS:000360900300006
PM 26228097
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Manoranjitham, GE
   Alagarsamy, S
AF Manoranjitham, Emily G.
   Alagarsamy, Shunmugalatha
TI RETRACTED: Application of firefly algorithm on optimal power flow
   control incorporating simplified impedance UPFC model (Retracted
   article. See vol. 83, pg. 603, 2016)
SO INTERNATIONAL JOURNAL OF ELECTRICAL POWER & ENERGY SYSTEMS
LA English
DT Article; Retracted Publication
DE Component; UPFC; Negative impedance model; Optimal power flow; Firefly
   algorithm
AB This paper proposes an algorithm to solve optimal power flow (OPF) in power system which has a unified power flow controller (UPFC). This UPFC can improve power transfer capability and transient stability and can reduce the transmission loss and fuel cost of generation. In this paper a new and simplified model of UPFC based on circuit elements for enhancing power flow is presented. Several power flow models of UPFC which are discussed in the literature require complex program codes for computing power injections. Further modification of Jacobian matrix and load flow program structure is a major problem. To reduce these complexities an alternative model of UPFC is proposed and in this model the power injected by the series converter is designed as negative impedance. In order to overcome the nonlinearity of OPE problem it is essential to use a heuristic algorithm. As a result in this paper a firefly algorithm (FFA) to solve the OPF problem is presented. Significantly, firefly algorithm is very efficient in dealing with multimodal global optimization problems. The proposed model is developed with two bus system and the firefly algorithm is tested with standard IEEE 30 bus network using Matlab. The firefly algorithm approach can obtain better solutions than other optimization algorithms. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Manoranjitham, Emily G.] SACS MAVMM Engn Coll, Madurai, Tamil Nadu, India.
   [Alagarsamy, Shunmugalatha] Velammal Coll Engn & Technol, Madurai, Tamil Nadu, India.
RP Manoranjitham, GE (reprint author), SACS MAVMM Engn Coll, Madurai, Tamil Nadu, India.
EM emilymanoranjitham@gmail.com; asl@vcet.ac.in
CR Acha E, 2004, FACTS MODELING SIMUL
   Alomoush M. I., 2002, IEEE Power Engineering Review, V22, P54, DOI 10.1109/MPER.2002.1098050
   Ara AL, 2012, IEEE T POWER DELIVER, V27, P481, DOI 10.1109/TPWRD.2011.2176559
   Bhowmick S, 2008, IEEE T POWER DELIVER, V23, P2079, DOI 10.1109/TPWRD.2008.923105
   Farrag MEA, 2012, IEEE T POWER DELIVER, V27, P53, DOI 10.1109/TPWRD.2011.2171061
   Fuerte-Esquivel CR, 2000, IEEE T POWER SYST, V15, P102, DOI 10.1109/59.852107
   Gokulakrishnan G., 2014, Journal of Theoretical and Applied Information Technology, V59, P172
   Haque MH, 2004, IEE P-GENER TRANSM D, V151, P299, DOI 10.1049/ip-gtd:20040379
   Hingorani N. G., 2000, UNDERSTANDING FACTS, P1
   Kannan S, 2004, IEEE T POWER SYST, V19, P1454, DOI 10.1109/TPWRS.2004.831690
   Li NH, 2000, IEEE T POWER SYST, V15, P257
   Nayeripour M., 2011, INT J MODELING OPTIM, V1, P191
   Noroozian M, 1997, IEEE T POWER DELIVER, V12, P1629, DOI 10.1109/61.634183
   Ramesh P, 2013, INT J ADV RES ELECT, V2, P4657
   Sheng HL, 2009, IEEE T, V1, P27
   Yang X., 2013, INT J SWARM INTELLIG, V1, P36, DOI DOI 10.1504/IJSI.2013.055801
   Yang X. S, 2008, NATURE INSPIRED META
   Yang XS, 2009, LECT NOTES COMPUT SC, V5792, P169, DOI 10.1007/978-3-642-04944-6_14
   Zhang YK, 2006, IEEE T POWER SYST, V21, P1550, DOI 10.1109/TPWRS.2006.882458
NR 19
TC 12
Z9 13
U1 1
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-0615
EI 1879-3517
J9 INT J ELEC POWER
JI Int. J. Electr. Power Energy Syst.
PD OCT
PY 2015
VL 71
BP 358
EP 363
DI 10.1016/j.ijepes.2015.03.009
PG 6
WC Engineering, Electrical & Electronic
SC Engineering
GA CI2QJ
UT WOS:000354591800037
DA 2018-12-27
ER

PT J
AU Arabkheradmand, A
   Safari, A
   Seifoleslami, M
   Yahaghi, E
   Gity, M
AF Arabkheradmand, Ali
   Safari, Aghdas
   Seifoleslami, Mehri
   Yahaghi, Emad
   Gity, Masoumeh
TI RETRACTED: Down-regulated microRNA-124 expression as predictive
   biomarker and its prognostic significance with clinicopathological
   features in breast cancer patients(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
ID HEPATOCELLULAR-CARCINOMA; TARGETS; PROGRESSION; METASTASIS
AB Background: MicroRNAs (miRNAs) have been documented as playing important roles in cancer development. In this study, we investigated to clarify the clinicopathological significance and prognostic value of miR-124 in breast cancer.
   Methods: Quantitative Real-time PCR method was used to assess the expression levels of miR-124 in breast cancer patients and the association of miR-124 expression levels with the clinicopathological characteristics in breast cancer patients. Survival and Multivariate Cox proportional hazards model analysis was used to evaluate whether the miR-124 expression level and various clinicopathological characteristics were independent prognostic marker for breast cancer patients.
   Results: We found that the lower expression of miR-124 in breast cancer specimens compared with corresponding adjacent normal breast tissues P < 0.05. Results showed that decreased expression of miR-124 was significantly related to advanced clinical stage (stage III and IV) (P = 0.021) and positive lymph node-metastasis (P = 0.011). Patients with low expression of miR-124 had significantly shorter overall survival (70.2 %) than patients who had cancers with high miR-124 expression (29.8), (logrank test P = 0.021). Moreover, Multivariate Cox proportional hazards model analysis indicated that lowr miR-124 expression was found to be independently linked to poor survival of patients with breast cancer and other factors were not significantly associated with survival of patients.
   Conclusion: Our data suggested that decreased expression of miR-124 has prognostic value in breast cancer and may serve as a prognostic marker for breast cancer, and also downregulation of miR-124 was inversely associated with the lymph node metastasis in breast cancer.
C1 [Arabkheradmand, Ali] Univ Tehran Med Sci, Sch Med, Inst Canc, Dept Surg, Tehran, Iran.
   [Safari, Aghdas; Seifoleslami, Mehri] AJA Univ Med Sci, Khanevadeh Hosp, Dept Gynecol, Tehran, Iran.
   [Yahaghi, Emad] Baqiyatallah Univ Med Sci, Dept Mol Biol, Tehran, Iran.
   [Gity, Masoumeh] Univ Tehran Med Sci, Med Imaging Ctr, Dept Radiol, Tehran, Iran.
RP Gity, M (reprint author), Univ Tehran Med Sci, Med Imaging Ctr, Dept Radiol, Tehran, Iran.
EM p_gity@yahoo.com
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cimino D, 2013, FASEB J, V27, P1223, DOI 10.1096/fj.12-214692
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fan MY, 2013, J BIOL CHEM, V288, P27480, DOI 10.1074/jbc.M113.491803
   Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298
   Han ZB, 2013, CELL PHYSIOL BIOCHEM, V31, P823, DOI 10.1159/000350100
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Khoshnaw SM, 2009, J CLIN PATHOL, V62, P422, DOI 10.1136/jcp.2008.060681
   Kim JL, 2014, ASIAN PAC J CANCER P, V15, P433, DOI 10.7314/APJCP.2014.15.1.433
   Kim Yeonju, 2015, Asian Pac J Cancer Prev, V16, P2857
   Li LS, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-163
   Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383
   Lv Xiao-Bin, 2011, Chin J Cancer, V30, P821, DOI 10.5732/cjc.011.10289
   Pierson J, 2008, J NEURO-ONCOL, V90, P1, DOI 10.1007/s11060-008-9624-3
   Wang P, 2014, ONCOGENE, V33, P514, DOI 10.1038/onc.2012.598
   Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167
   Zhang ZY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0984-6
   Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145
NR 21
TC 9
Z9 9
U1 2
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD SEP 29
PY 2015
VL 10
AR 178
DI 10.1186/s13000-015-0391-0
PG 4
WC Pathology
SC Pathology
GA CS0XY
UT WOS:000361786700001
PM 26415857
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Jafari, A
   Ghoranneviss, M
   Hantehzadeh, MR
   Elahi, AS
AF Jafari, A.
   Ghoranneviss, M.
   Hantehzadeh, M. R.
   Elahi, A. Salar
TI RETRACTED: Morphological and electrical properties of few layer graphene
   after nitrogen doping by LPCVD technique (Retracted article. See vol.
   746, pg. 741, 2018)
SO JOURNAL OF ALLOYS AND COMPOUNDS
LA English
DT Article; Retracted Publication
DE LPCVD; Graphene; Nitrogen doped; Conductivity
ID OXYGEN REDUCTION REACTION; DOPED GRAPHENE; CARBON NANOTUBES; FILMS;
   SPECTROSCOPY; SINGLE; BORON
AB Carbon materials doped with only one kind of C-N bonding configuration are a great outlook for studying doping effects on the electronic structure and electrical properties. Synthesis of nitrogen-doped few-layer graphene films on Cu foil is achieved by low pressure chemical vapor deposition (LPCVD). For investigation of nitrogen doped effect on structural, morphological and electrical properties of graphene the reactive gas was a mixture of CH4 and NH3 with the different ratio CH4 and NH3 by volume at the constant pressure of the growth chamber. The N-doped graphene (NG) samples were characterized by Raman spectroscopy, scanning electron microscopy (SEM), X-ray photoelectron spectroscopy (XPS). Also in this experiment, the I-V characteristic carried out for study of electrical property of N-doped graphene at different gases mixing ratio with keithley 2361 system. The Raman spectroscopy showed D, G and 2D bound in doped and undoped graphene while we find the intensity of the 2D peak decreases and D peak intensity increases with the increase in the percent of NH3 in gas mixture. Likewise the presence of weak 2D band in all sample suggest that the produced samples are few layer graphene. SEM images showed dendritic-like morphology in undoped graphene and we observed that point like defect created among this morphology by increasing the nitrogen in synthesis process. The XPS results of sample with 25% NH3 in gas mixture confirm the existence of nitrogen in doped graphene which indicates the nitrogen atoms doped in the graphene lattice are mainly in the form of pyridinic nitrogen. The study on electrical properties emphasized that the dependence of current with voltage for all samples was linear like behavior, and sample conductivity was decreased with increasing the percent of nitrogen in gas mixture. The results showed that nitrogen-doped graphene can be successfully synthesized and also chemical nitrogen doping can be change the electrical conductivity of the graphene. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Jafari, A.; Ghoranneviss, M.; Hantehzadeh, M. R.; Elahi, A. Salar] Islamic Azad Univ, Sci & Res Branch, Plasma Phys Res Ctr, Tehran, Iran.
RP Elahi, AS (reprint author), Islamic Azad Univ, Sci & Res Branch, Plasma Phys Res Ctr, Tehran, Iran.
EM Salari_phy@yahoo.com
OI Hantehzadeh, Mohammad Reza/0000-0002-9655-6155
CR Ayala P, 2007, J PHYS CHEM C, V111, P2879, DOI 10.1021/jp0658288
   Bao WZ, 2009, NAT NANOTECHNOL, V4, P562, DOI [10.1038/nnano.2009.191, 10.1038/NNANO.2009.191]
   Chauhan SS, 2014, APPL NANOSCI, V4, P461, DOI 10.1007/s13204-013-0220-2
   Ferrari AC, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187401
   Gammon WJ, 2003, CARBON, V41, P1917, DOI [10.1016/S0008-6223(03)00170-2, 10.1016/S008-6223(03)00170-2]
   Gong KP, 2009, SCIENCE, V323, P760, DOI 10.1126/science.1168049
   Graf D, 2007, NANO LETT, V7, P238, DOI 10.1021/nl061702a
   Lin YM, 2009, NANO LETT, V9, P422, DOI 10.1021/nl803316h
   Lin YC, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3368697
   Liu XA, 2010, DIAM RELAT MATER, V19, P875, DOI 10.1016/j.diamond.2010.02.011
   Nagaiah TC, 2010, ELECTROCHEM COMMUN, V12, P338, DOI 10.1016/j.elecom.2009.12.021
   Niwa H, 2009, J POWER SOURCES, V187, P93, DOI 10.1016/j.jpowsour.2008.10.064
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   Panchokarla LS, 2009, ADV MATER, V21, P4726, DOI 10.1002/adma.200901285
   Rao CV, 2010, J PHYS CHEM LETT, V1, P2622, DOI 10.1021/jz100971v
   Reddy ALM, 2010, ACS NANO, V4, P6337, DOI 10.1021/nn101926g
   Riedl C, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.246804
   Santangelo S, 2014, DIAM RELAT MATER, V41, P73, DOI 10.1016/j.diamond.2013.11.006
   Schedin F, 2007, NAT MATER, V6, P652, DOI 10.1038/nmat1967
   Shao YY, 2008, APPL CATAL B-ENVIRON, V79, P89, DOI 10.1016/j.apcatb.2007.09.047
   Shao YY, 2010, J MATER CHEM, V20, P7491, DOI 10.1039/c0jm00782j
   Wang XR, 2009, SCIENCE, V324, P768, DOI 10.1126/science.1170335
   Wang Y, 2010, ACS NANO, V4, P1790, DOI 10.1021/nn100315s
   Wei DC, 2009, NANO LETT, V9, P1752, DOI 10.1021/nl803279t
   Xiang B, 2007, NANO LETT, V7, P323, DOI 10.1021/nl062410c
NR 25
TC 13
Z9 13
U1 2
U2 88
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-8388
EI 1873-4669
J9 J ALLOY COMPD
JI J. Alloy. Compd.
PD SEP 25
PY 2015
VL 644
BP 97
EP 100
DI 10.1016/j.jallcom.2015.04.202
PG 4
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering
GA CL7HU
UT WOS:000357143900016
DA 2018-12-27
ER

PT J
AU Silva, M
   Martins, D
   Tavares, I
   Morgado, C
AF Silva, M.
   Martins, D.
   Tavares, I.
   Morgado, C.
TI RETRACTED: INHIBITION OF SPINAL 5-HT3R REVERTED DIABETES-INDUCED
   MECHANICAL HYPERSENSITIVITY IN A GABA(A)R-MEDIATED
   NEUROTRANSMISSION-DEPENDENT MANNER (Retracted article. See vol. 313, pg.
   236, 2016)
SO NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE pronociception; ERK1/2; 5-HT3 receptor; GABA(A)R; diabetic neuropathic
   pain
ID DESCENDING SEROTONERGIC FACILITATION; INDUCED NEUROPATHIC PAIN;
   DORSAL-HORN NEURONS; KINASE ACTIVATION; TACTILE ALLODYNIA; ERK
   ACTIVATION; DNA-DAMAGE; RAT; RECEPTORS; MODEL
AB Spinal 5-HT3 receptor (5-HT3R) has been implicated in chronic pain development. The extent to which 5-HT3R contributes to spinal sensitization and diabetic neuropathic pain (DNP) remains elusive and the mechanisms subserving the effects of 5-HT3R activation on spinal pain processing during chronic pain are still unclear. In this study, we evaluated the contribution of spinal 5-HT3R to pain facilitation and spinal sensitization during DNP, exploiting the role of GABA(A)R-mediated neurotransmission and glial activation in the effects elicited by intrathecal administration of a 5-HT3R antagonist. Mechanical nociception was evaluated by paw pressure test in streptozotocin (STZ)-diabetic and control rats after intrathecal (i.t.) administration of a 5-HT3R antagonist (Y25130). The spinal activation of extracellular signal-regulated kinases (ERKs) pathway and the expression of 5-HT3R, glial fibrillary acidic protein (GFAP; marker of astroglia activation) and ionized calcium binding adaptor molecule 1 (IBA-1; marker of microglia activation) were evaluated at the peak maximum effect of Y25130. The involvement of GABA(A)R-mediated neurotransmission in the behavioral pain effect of Y25130, was assessed in STZ-diabetic animals receiving i.t. administrations of muscimol (GABA(A)R agonist). Intrathecal administration of Y25130 reverted mechanical hyperalgesia and decreased the activation of ERKs in STZ-diabetic rats, while no effects were observed in control animals. The spinal activation of GABA(A)R by i.t. administration of muscimol abolished Y25130-driven antinociception. The expression of IBA-1, GFAP and 5-HT3R was unaltered by treatment. These findings point to a GABA-mediated pronociceptive role of spinal 5-HT3R during DNP. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 Univ Porto, Fac Med, Dept Biol Expt, P-4100 Oporto, Portugal.
   Univ Porto, i3S, P-4100 Oporto, Portugal.
RP Tavares, I (reprint author), Fac Med Porto, Dept Expt Biol, Alameda Prof Hernani Monteiro, P-4200319 Oporto, Portugal.
EM isatav@med.up.pt
OI Martins, Daniel/0000-0002-0239-8206; Tavares, Isaura/0000-0001-5696-1239
FU FPF7 EU Project REDDSTAR [FP7-Health-2012.2.4.3-1]
FX Supported by FPF7 EU Project REDDSTAR (FP7-Health-2012.2.4.3-1).
CR ALHAIDER AA, 1991, J NEUROSCI, V11, P1881
   Brahmachari S, 2006, J NEUROSCI, V26, P4930, DOI 10.1523/JNEUROSCI.5480-05.2006
   BURCHIEL KJ, 1985, DIABETES, V34, P1210, DOI 10.2337/diabetes.34.11.1210
   Calcutt N. A., 2004, METHODS MOL MED PAIN, V99, P1
   Chen SR, 2002, J NEUROPHYSIOL, V87, P2726, DOI 10.1152/jn.00607.2001
   Chen X, 2001, NEUROSCIENCE, V102, P185, DOI 10.1016/S0306-4522(00)00454-1
   Coull JAM, 2003, NATURE, V424, P938, DOI 10.1038/nature01868
   COURTEIX C, 1993, PAIN, V53, P81, DOI 10.1016/0304-3959(93)90059-X
   Daulhac L, 2006, MOL PHARMACOL, V70, P1246, DOI 10.1124/mol.106.025478
   Davidson E, 2009, EXP DIABETES RES, DOI 10.1155/2009/431980
   DIRIG DM, 1995, J PHARMACOL EXP THER, V275, P219
   Dogrul A, 2009, BRAIN RES, V1280, P52, DOI 10.1016/j.brainres.2009.05.001
   Fei ZL, 2011, J BIOL CHEM, V286, P27761, DOI 10.1074/jbc.M111.248435
   Fukushima T, 2009, J NEUROPHYSIOL, V102, P1459, DOI 10.1152/jn.91160.2008
   Galer BS, 2000, DIABETES RES CLIN PR, V47, P123, DOI 10.1016/S0168-8227(99)00112-6
   Gao Yong-Jing, 2009, Open Pain J, V2, P11
   GIESLER GJ, 1981, BRAIN RES, V204, P184, DOI 10.1016/0006-8993(81)90661-2
   GLAUM SR, 1990, BRAIN RES, V510, P12, DOI 10.1016/0006-8993(90)90721-M
   Guo W, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-35
   Han Mei, 2011, Shengli Xuebao, V63, P106
   Hayashida K, 2012, ANESTHESIOLOGY, V117, P389, DOI 10.1097/ALN.0b013e318260d381
   Hwang JH, 1997, PAIN, V70, P15, DOI 10.1016/S0304-3959(96)03249-6
   Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040
   Ji RR, 2002, J NEUROSCI, V22, P478, DOI 10.1523/JNEUROSCI.22-02-00478.2002
   Ji RR, 2013, PAIN, V154, pS10, DOI 10.1016/j.pain.2013.06.022
   Jolivalt CG, 2008, PAIN, V140, P48, DOI 10.1016/j.pain.2008.07.005
   Kanazawa A, 2002, EUR J LIPID SCI TECH, V104, P439, DOI 10.1002/1438-9312(200207)104:7<439::AID-EJLT439>3.0.CO;2-K
   Kaur J, 2013, BBA-MOL CELL RES, V1833, P1028, DOI 10.1016/j.bbamcr.2013.01.029
   Kawamata T, 2003, BRAIN RES, V978, P250, DOI 10.1016/S0006-8993(03)02952-4
   KIA HK, 1995, NEUROREPORT, V6, P257, DOI 10.1097/00001756-199501000-00008
   Kim YS, 2014, NEURON, V81, P873, DOI 10.1016/j.neuron.2013.12.011
   Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7
   LEI S, 1990, EUR J PHARMACOL, V183, P1438, DOI 10.1016/0014-2999(90)94575-I
   Li JQ, 2010, J NEUROCHEM, V112, P162, DOI 10.1111/j.1471-4159.2009.06437.x
   Martindale, 1989, EXTR PHARM, P649
   McCleane GJ, 2003, ANESTH ANALG, V97, P1474, DOI 10.1213/01.ANE.0000085640.69855.51
   MILLIGAN CE, 1991, J COMP NEUROL, V314, P125, DOI 10.1002/cne.903140112
   Morgado C, 2007, DIABETES-METAB RES, V23, P644, DOI 10.1002/dmrr.751
   Morgado C, 2011, DIABETES OBES METAB, V13, P150, DOI 10.1111/j.1463-1326.2010.01333.x
   Morgado C, 2008, NEUROSCI LETT, V438, P102, DOI 10.1016/j.neulet.2008.04.032
   Morgado C, 2011, NEUROBIOL DIS, V43, P275, DOI 10.1016/j.nbd.2011.04.001
   Morgado C, 2010, EUR J PAIN, V14, P693, DOI 10.1016/j.ejpain.2009.11.011
   Ohsawa K, 2004, J NEUROCHEM, V88, P844, DOI 10.1046/j1471-4159.2003.02213.x
   Oyama T, 1996, NEUROSCI RES, V25, P129
   Paulson PE, 2007, EXP NEUROL, V208, P305, DOI 10.1016/j.expneurol.2007.09.001
   Paxinos G, 2007, RAT BRAIN STEREOTAXI
   Pertovaara A, 2001, EXP NEUROL, V167, P425, DOI 10.1006/exnr.2000.7574
   Peters CM, 2010, BRAIN RES, V1352, P83, DOI 10.1016/j.brainres.2010.07.020
   Rahman W, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-45
   Ralph E, 2006, EMBO REP, V7, P1134, DOI 10.1038/sj.embor.7400827
   Silva M, 2013, BRAIN RES BULL, V96, P39, DOI 10.1016/j.brainresbull.2013.04.008
   Suzuki R, 2002, NAT NEUROSCI, V5, P1319, DOI 10.1038/nn966
   Svensson CI, 2006, FEBS LETT, V580, P6629, DOI 10.1016/j.febslet.2006.11.012
   Tsuda M, 2008, GLIA, V56, P378, DOI 10.1002/glia.20623
   Uslu K, 2014, J IMMUNOL, V192, P3582, DOI 10.4049/jimmunol.1203468
   Wang YF, 2009, J NEUROSCI, V29, P1743, DOI 10.1523/JNEUROSCI.4669-08.2009
   Wodarski R, 2009, EUR J PAIN, V13, P807, DOI 10.1016/j.ejpain.2008.09.010
   Zeitz KP, 2002, J NEUROSCI, V22, P1010, DOI 10.1523/JNEUROSCI.22-03-01010.2002
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 59
TC 2
Z9 2
U1 2
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD SEP 24
PY 2015
VL 304
BP 228
EP 239
DI 10.1016/j.neuroscience.2015.07.050
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA CP6PD
UT WOS:000360008800021
PM 26210577
DA 2018-12-27
ER

PT J
AU Mirghasemi, A
   Taheriazam, A
   Karbasy, SH
   Torkaman, A
   Shakeri, M
   Yahaghi, E
   Mokarizadeh, A
AF Mirghasemi, Alireza
   Taheriazam, Afshin
   Karbasy, Seyyed Hasan
   Torkaman, Ali
   Shakeri, Mohammadreza
   Yahaghi, Emad
   Mokarizadeh, Aram
TI RETRACTED: Down-regulation of miR-133a and miR-539 are associated with
   unfavorable prognosis in patients suffering from osteosarcoma(Retracted
   article. See vol.16, pg.84,2016)
SO CANCER CELL INTERNATIONAL
LA English
DT Article; Retracted Publication
DE MicRNA; Survival; Patient; Marker; Cancer
ID EXPRESSION; CELLS; PROLIFERATION; SUPPRESSES; MIGRATION; APOPTOSIS;
   INVASION; CANCER
AB Background: MicroRNAs (miRNAs) play key roles in cancer development and progression. The purpose of the present study was to determine the expression levels of miR-133a and miR-539 in osteosarcoma patients and to further investigate the clinicopathological, and prognostic value of these miRNAs.
   Methods: The expression levels of miR-133a and miR-539 were determined by qRT-PCR. Associations between miRNAs expressions and various clinicopathological characteristics were analyzed. Survival rate was determined with Kaplan-Meier and statistically analyzed with the log-rank method between groups. Survival data were evaluated through multivariate Cox regression analysis
   Results: Our findings revealed that the miR-133a expression was significantly decreased in clinical osteosarcoma tissues compared to adjacent normal bone tissues. The expression level of miR-539 was decreased in clinical osteosarcoma tissues as compared to those adjacent normal tissues. Low expressions of miR-133a and miR-539 were significantly association with advanced TNM stage (P = 0.002; P = 0.001), and metastasis or recurrence (P = 0.001; P = 0.01). Furthermore, Kaplan-Meier survival analysis and log-rank test showed that the low expressions of miR-133a and miR-539 were correlated with the reduced overall survival of osteosarcoma patients. Multivariate Cox proportional hazards model showed that decreased expressions of miR-133a and miR-539 (P = 0.007; P = 0.02), TNM stage (P = 0.001; P = 0.002), and metastasis or recurrence (P = 0.005; P = 0.026) were independent prognostic markers of overall survival of patients.
   Conclusion: These results suggest that decreased miR-133a and miR-539 expressions may participate in the progression of osteosarcoma. Together, these results showed that miR-133a and miR-539 may have their role in both progression and prognosis of osteosarcoma.
C1 [Mirghasemi, Alireza] Qom Univ Med Sci, Dept Orthoped, Qom, Iran.
   [Taheriazam, Afshin] Islamic Azad Univ, Tehran Med Sci Branch, Dept Orthoped Surg, Tehran, Iran.
   [Karbasy, Seyyed Hasan] Birjand Univ Med Sci, Dept Anesthesiol, Birjand, Iran.
   [Torkaman, Ali] Iran Univ Med Sci, Firoozgar Hosp, Dept Orthoped, Tehran, Iran.
   [Shakeri, Mohammadreza] Birjand Univ Med Sci, Dept Orthopaed & Trauma Surg, Birjand, Iran.
   [Yahaghi, Emad] Baqiyatallah Univ Med Sci, Dept Mol Biol, Tehran, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Cellular & Mol Res Ctr, Sanandaj, Iran.
RP Mokarizadeh, A (reprint author), Kurdistan Univ Med Sci, Cellular & Mol Res Ctr, Sanandaj, Iran.
EM a.mokarizadeh@muk.ac.ir
RI karbasi, seyyedhasan/J-4669-2017
OI karbasi, seyyedhasan/0000-0002-5407-9346; Abdi,
   Mohammad/0000-0002-4766-0423; Mokarizadeh, Aram/0000-0002-2630-8308;
   Mirghasemi, Alireza/0000-0001-7569-8456; Taheriazam,
   Afshin/0000-0002-3907-925X
CR Bao BL, 2010, J NUTR, V140, P1546, DOI 10.3945/jn.110.126359
   Bramer JAM, 2009, EJSO-EUR J SURG ONC, V35, P1030, DOI 10.1016/j.ejso.2009.01.011
   Broadhead Matthew L., 2011, Sarcoma, P959248, DOI 10.1155/2011/959248
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Federman N, 2009, CURR TREAT OPTION ON, V10, P82, DOI 10.1007/s11864-009-0087-3
   Gu LX, 2015, BIOCHEM BIOPH RES CO, V464, P1128, DOI 10.1016/j.bbrc.2015.07.090
   Hu H, 2012, ONCOL LETT, V4, P1037, DOI 10.3892/ol.2012.866
   Huang GX, 2012, CANCER RES, V72, P908, DOI 10.1158/0008-5472.CAN-11-1460
   Ji F, 2013, BONE, V56, P220, DOI 10.1016/j.bone.2013.05.020
   Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284
   Kobayashi Eisuke, 2012, Sarcoma, P359739, DOI 10.1155/2012/359739
   Lee YN, 2011, BLOOD, V117, P3629, DOI 10.1182/blood-2010-07-293548
   Liu LH, 2011, BIOCHEM BIOPH RES CO, V416, P31, DOI 10.1016/j.bbrc.2011.10.117
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Miao JL, 2013, TUMOR BIOL, V34, P2093, DOI 10.1007/s13277-013-0940-7
   Muthusamy S, 2014, J BIOL CHEM, V289, P29665, DOI 10.1074/jbc.M114.578682
   Tao J, 2012, ONCOL REP, V27, P1967, DOI 10.3892/or.2012.1711
   Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596
   Wang YM, 2011, MOL CANCER RES, V9, P1100, DOI 10.1158/1541-7786.MCR-11-0007
   Wang ZX, 2010, BONE, V47, P445, DOI 10.1016/j.bone.2010.05.027
   Yoshino H, 2011, BRIT J CANCER, V104, P808, DOI 10.1038/bjc.2011.23
   Zhu JF, 2012, AM J PATHOL, V180, P2440, DOI 10.1016/j.ajpath.2012.02.023
NR 22
TC 24
Z9 24
U1 2
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD SEP 17
PY 2015
VL 15
AR 86
DI 10.1186/s12935-015-0237-6
PG 5
WC Oncology
SC Oncology
GA CR7EP
UT WOS:000361511100003
PM 26388701
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ghasemkhani, N
   Shadvar, S
   Masoudi, Y
   Talaei, AJ
   Yahaghi, E
   Goudarzi, PK
   Shakiba, E
AF Ghasemkhani, Naeemeh
   Shadvar, Sahar
   Masoudi, Yasamin
   Talaei, Amir Jouya
   Yahaghi, Emad
   Goudarzi, Peyman Karimi
   Shakiba, Ebrahim
TI RETRACTED: Down-regulated MicroRNA 148b expression as predictive
   biomarker and its prognostic significance associated with
   clinicopathological features in non-small-cell lung cancer
   patients(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
ID TUMOR-SUPPRESSOR; MIR-148B FUNCTIONS; PANCREATIC-CANCER; BIOGENESIS;
   CARCINOMA; SURVIVAL
AB Background: Lung cancer is most common and is the leading cause of cancer-related death in both men and women worldwide. Understanding of the molecular mechanisms underlying non-small cell lung cancer (NSCLC) development and progression are important. In the present study, we investigated the potential role of miR-148b expression analysis as potential lung cancer biomarker with the correlation of circulating miR-148b to clinicopathological features.
   Methods: A total of 104 NSCLC patients were diagnosed and cancer tissues together with adjacent normal tissues were evaluated. Quantitative Real-time PCR method was utilized to evaluate the expression levels of miR-148b. In addition, we investigated to clarify the relationship of miR-148b with clinicopathological features and survival in patients with NSCLC.
   Results: Our findings showed that miR-148b was downregulated in tumor tissues when compared with corresponding adjacent normal lung tissues (0.34 +/- 0.13 vs. 1.00 +/- 0.57, P < 0.05). Moreover decreased expression of miR-148b was significantly related to TNM stage (P = 0.001) and lymph node-metastasis (P = 0.023). This findings suggested that miR-148b was down-regulated in NSCLC patients and may play a key role as a tumor suppressor gene in NSCLC. Kaplan-Meier survival analysis and log-rank test suggested that low-expression group of patients had significantly shorter overall survival than high-expression group (log-rank test: P = 0.031). Multivariate Cox proportional hazards model analysis indicated that low miR-148b expression was independently linked to poor survival of patients with NSCLC (HR = 3.215, 95 % CI: 1.543-10.621, P = 0.021) and other factors were not significant independent predictor of survival in patients with NSCLC.
   Conclusion: Our findings demonstrated that miR-148b may play a role as independent prognostic factor for patients with NSCLC.
C1 [Ghasemkhani, Naeemeh; Shadvar, Sahar] Univ Tehran Med Sci, Neurosci Inst, Brain & Spinal Injury Res Ctr, Tehran, Iran.
   [Masoudi, Yasamin] Azad Univ, Varamin Pishva Branch, Fac Life Sci, Dept Biophys, Varamin, Iran.
   [Talaei, Amir Jouya] Azad Univ, Tehran Med Sci Branch, Fac Life Sci, Dept Genet, Tehran, Iran.
   [Yahaghi, Emad] Baqiyatallah Univ Med Sci, Dept Mol Biol, Tehran, Iran.
   [Goudarzi, Peyman Karimi] AJA Univ Med Sci, Dept Neurosurg, Tehran, Iran.
   [Shakiba, Ebrahim] Kermanshah Univ Med Sci, Sch Med, Dept Biochem, Kermanshah, Iran.
RP Goudarzi, PK (reprint author), AJA Univ Med Sci, Dept Neurosurg, Tehran, Iran.
EM Pedram_kg@yahoo.com
RI Shakiba, Ebrahim/R-9984-2017
OI Shakiba, Ebrahim/0000-0002-9603-4293
CR Azizi M, 2014, CANCER BIOL THER, V15, P419, DOI 10.4161/cbt.27630
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chang H, 2012, MOL MED REP, V5, P1277, DOI 10.3892/mmr.2012.794
   Cimino D, 2013, FASEB J, V27, P1223, DOI 10.1096/fj.12-214692
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Ge H, 2015, INT J CLIN EXP PATHO, V8, P800
   Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Li L, 2015, MED SCI MONITOR, V21, P1155, DOI 10.12659/MSM.892940
   Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140
   Liu GL, 2014, INT J CLIN EXP MED, V7, P1990
   Liu Q, 2015, BIOSCI REP
   Ponn RB, 2005, GEN THORACIC SURG, V6, P1548
   Sadeghian Y, 2015, TUMOUR BIOL
   Shen J, 2014, ONCOTARGET, V5, P5284, DOI 10.18632/oncotarget.2014
   Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1
   Song YX, 2012, INT J CANCER, V131, P1042, DOI 10.1002/ijc.26485
   Soon YY, 2009, J CLIN ONCOL, V27, P3277, DOI 10.1200/JCO.2008.19.4522
   Sui CG, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0488-y
   Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2
   Verdecchia A, 2007, LANCET ONCOL, V8, P784, DOI 10.1016/S1470-2045(07)70246-2
   Zhang ZY, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0984-6
   Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T
NR 24
TC 10
Z9 10
U1 2
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD SEP 17
PY 2015
VL 10
AR 164
DI 10.1186/s13000-015-0393-y
PG 5
WC Pathology
SC Pathology
GA CR4DI
UT WOS:000361281600003
PM 26377406
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Taheriazam, A
   Bahador, R
   Karbasy, SH
   Jamshidi, SMMM
   Torkaman, A
   Yahaghi, E
   Shakeri, M
AF Taheriazam, Afshin
   Bahador, Reza
   Karbasy, Seyyed Hasan
   Jamshidi, Seyed Mir Mansoor Moazen
   Torkaman, Ali
   Yahaghi, Emad
   Shakeri, Mohammadreza
TI RETRACTED: Down-regulation of microRNA-26a and up-regulation of
   microRNA-27a contributes to aggressive progression of human osteosarcoma
   (Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
ID CANCER CELLS; LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; PROMOTES
   PROLIFERATION; POOR-PROGNOSIS; MIR-27A; EXPRESSION; ADENOCARCINOMA;
   METASTASIS; RESISTANCE
AB Background: Osteosarcoma is the most common primary bone malignancy with high local aggressiveness and rapid metastasizing potential, resulting in poor survival. Increasing reports suggest that deregulated microRNAs (miRNAs) might provide novel therapeutic targets for cancers. However, the expression of miR-26a and miR-27a in osteosarcoma need further investigation in clinical samples. In our study, we evaluate the expression of these miRNAs in osteosarcoma tissues and compared with paired adjacent non-tumor bone tissues using RT-qPCR.
   Methods: Total RNA was purified from patients with osteosarcoma and noncancerous bone tissues. Real-time PCR was applied to quantify the expression level of miR-26a and miR-27a. Moreover, the correlation of these markers with clinicopathological characteristics was also evaluated in osteosarcoma patients. A cox proportional hazards model was performed to assess multivariate analyses of prognostic values.
   Results: Our result suggested that miR-26aexpression level in osteosarcoma bone tissue was significantly lower than that in the paired noncancerous bone tissues. MiR-27a expression was higher in osteosarcoma bone tissue in comparison with paired noncancerous bone tissues. The results indicated that low expression level of miR-26a and high expression of miR-27a were associated with high TNM stage (P = 0.001; P = 0.012), tumor grade (P = 0.007; P = 0.016), and distant metastasis (P = 0.004; P = 0.001). Kaplan-Meier analysis and log-rank test indicated that patients with low expression of miR-26a and high expression of miR-27a had shorter overall survival (log-rank test: P < 0.001). Multivariate Cox proportional hazards model analysis showed that low expression of miR-26a and high expression of miR-27a (P = 0.021; P = 0.011), high TNM stage (P = 0.001; P = 0.003), tumor grade (P = 0.005; P = 0.01), and distant metastasis.(P = 0.002; P = 0.005) were independent prognostic factors for overall survival patients with osteosarcoma cancer.
   Conclusions: In conclusion, our findings suggested that expression level of miR-26a and miR-27a contributes to aggressive progression of this malignancy. Therefore, may have clinical potentials as a non-invasive diagnostic/prognostic biomarker for osteosarcoma patients.
C1 [Taheriazam, Afshin] Islamic Azad Univ, Tehran Med Sci Branch, Dept Orthoped Surg, Tehran, Iran.
   [Bahador, Reza; Shakeri, Mohammadreza] Birjand Univ Med Sci, Dept Orthopaed & Trauma Surg, Birjand, Iran.
   [Karbasy, Seyyed Hasan] Birjand Univ Med Sci, Dept Anesthesiol, Birjand, Iran.
   [Jamshidi, Seyed Mir Mansoor Moazen] Zanjan Univ Med Sci, Dept Orthoped, Zanjan, Iran.
   [Torkaman, Ali] Iran Univ Med Sci, Firoozgar Hosp, Dept Orthoped, Tehran, Iran.
   [Yahaghi, Emad] Baqiyatallah Univ Med Sci, Dept Mol Biol, Tehran, Iran.
RP Shakeri, M (reprint author), Birjand Univ Med Sci, Dept Orthopaed & Trauma Surg, Birjand, Iran.
EM mshakeri7@yahoo.com
RI Moazen Jamshidi, Seyed Mir Mansour/R-7348-2017; karbasi,
   seyyedhasan/J-4669-2017
OI Moazen Jamshidi, Seyed Mir Mansour/0000-0002-1653-8505; karbasi,
   seyyedhasan/0000-0002-5407-9346; Taheriazam, Afshin/0000-0002-3907-925X
CR Ajdarkosh H, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0371-4
   Bao YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105991
   Bao YP, 2013, ASIAN PAC J CANCER P, V14, P3751, DOI 10.7314/APJCP.2013.14.6.3751
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Cabrera R, 2013, HEPATOLOGY, V58, P1, DOI 10.1002/hep.26377
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Croce C, 2012, CANCER J, V18, P213, DOI 10.1097/PPO.0b013e31825efb41
   Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398
   Huang JH, 2014, TUMOR BIOL, V35, P1095, DOI 10.1007/s13277-013-1146-8
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   Li JP, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-193
   Li XR, 2010, ENDOCRINOLOGY, V151, P2462, DOI 10.1210/en.2009-1150
   Liu BN, 2012, BBA-MOL BASIS DIS, V1822, P1692, DOI 10.1016/j.bbadis.2012.07.019
   Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011
   Ma YH, 2010, CANCER LETT, V298, P150, DOI 10.1016/j.canlet.2010.06.012
   Miao YJ, 2013, ONCOL REP, V29, P161, DOI 10.3892/or.2012.2095
   Ottaviani G, 2009, CANC TREAT, V152, P3, DOI 10.1007/978-1-4419-0284-9_1
   Pan WB, 2014, CELL PHYSIOL BIOCHEM, V33, P402, DOI 10.1159/000356679
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Song QC, 2014, ONCOL REP, V31, P1263, DOI 10.3892/or.2014.2989
   Tang J, 2015, BIOMED PHARMACOTHER, V71, P222, DOI 10.1016/j.biopha.2015.01.025
   Tang MJ, 2013, ONCOTARGETS THER, V6, P833, DOI 10.2147/OTT.S40080
   Tian Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-678
   Xia J, 2014, CURR PHARM DESIGN, V20, P5348, DOI 10.2174/1381612820666140128215756
   Xu LL, 2013, ANTI-CANCER AGENT ME, V13, P1126, DOI 10.2174/18715206113139990006
   Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008
   Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906
   Zhao XH, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-55
NR 31
TC 6
Z9 8
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD SEP 17
PY 2015
VL 10
AR 166
DI 10.1186/s13000-015-0400-3
PG 6
WC Pathology
SC Pathology
GA CR4DI
UT WOS:000361281600005
PM 26377680
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Smith, JA
   Benbow, SJ
AF Smith, Jennifer A.
   Benbow, Sarah J.
TI RETRACTED: Meeting Report: Inaugural Chemotherapy-Induced Peripheral
   Neuropathy Symposium, Santa Barbara, CA, February 2015 (Retracted
   article. See vol. 75, pg. 4665, 2015)
SO CANCER RESEARCH
LA English
DT Editorial Material; Retracted Publication
ID PACLITAXEL; MITOTOXICITY; RAT
AB Chemotherapy-induced peripheral neuropathy is a common, dose-limiting side effect of cancer treatment. This conference was the first of its kind to bring together a wide range of clinicians, researchers, and industry professionals to address the potential causes, preventions, and treatments for this drug toxicity. Intraepidermal nerve fiber loss, axonal degeneration, immune cell infiltration, alterations in tubulin protein expression and microtubule stability, axonal transport, and mitochondrial dysfunction were addressed as possible mechanisms. Problems with animal models of the disease were discussed, as well as the potential of patient-derived induced sensory neurons to serve as a novel in vitro model. (C) 2015 AACR.
C1 [Smith, Jennifer A.; Benbow, Sarah J.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.
RP Smith, JA (reprint author), Univ Calif Santa Barbara, 1203 Life Sci Bldg, Santa Barbara, CA 93106 USA.
EM jsmith@lifesci.ucsb.edu
CR Bennett GJ, 2014, NAT REV NEUROL, V10, P326, DOI 10.1038/nrneurol.2014.77
   Bennett GJ, 2011, EUR J NEUROSCI, V33, P1667, DOI 10.1111/j.1460-9568.2011.07652.x
   Chambers SM, 2012, NAT BIOTECHNOL, V30, P715, DOI 10.1038/nbt.2249
   Jaggi AS, 2012, TOXICOLOGY, V291, P1, DOI 10.1016/j.tox.2011.10.019
   Li Y, 2014, J PAIN, V15, P712, DOI 10.1016/j.jpain.2014.04.001
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Pogorzelski Robert, 2004, Neurol Neurochir Pol, V38, P257
   Poon KA, 2013, TOXICOL APPL PHARM, V273, P298, DOI 10.1016/j.taap.2013.09.003
   Takeda Kiyoshi, 2015, Curr Protoc Immunol, V109, DOI 10.1002/0471142735.im1412s109
   Wozniak KM, 2013, NEUROTOX RES, V24, P338, DOI 10.1007/s12640-013-9394-3
   Xiao WH, 2012, NEUROSCIENCE, V203, P194, DOI 10.1016/j.neuroscience.2011.12.023
   Xiao WH, 2011, NEUROSCIENCE, V199, P461, DOI 10.1016/j.neuroscience.2011.10.010
   Xiao WH, 2008, PAIN, V135, P262, DOI 10.1016/j.pain.2007.06.001
   Zheng H, 2012, EXP NEUROL, V238, P225, DOI 10.1016/j.expneurol.2012.08.023
NR 14
TC 3
Z9 3
U1 2
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD SEP 15
PY 2015
VL 75
IS 18
BP 3696
EP 3698
DI 10.1158/0008-5472.CAN-15-1145
PG 3
WC Oncology
SC Oncology
GA CU2EJ
UT WOS:000363335800003
PM 26081810
OA Other Gold
DA 2018-12-27
ER

PT J
AU Norouzi-Javidan, A
   Javanbakht, J
   Barati, F
   Fakhraei, N
   Mohammadi, F
   Dehpour, AR
AF Norouzi-Javidan, Abbas
   Javanbakht, Javad
   Barati, Fardin
   Fakhraei, Nahid
   Mohammadi, Fatemeh
   Dehpour, Ahmad Reza
TI RETRACTED: Serotonin 5-HT7 receptor agonist, LP-211, exacerbates Na+,
   K+-ATPase/Mg2+-ATPase imbalances in spinal cord-injured male
   rats(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
ID SMOOTH-MUSCLE-CELLS; DEPENDENT ADENOSINE-TRIPHOSPHATASE;
   PROTEIN-KINASE-C; ANTAGONIST SB-269970; ATPASE ACTIVITY; BLOOD-FLOW;
   METHYLPREDNISOLONE TREATMENT; PHOSPHOINOSITIDE HYDROLYSIS;
   PHARMACOLOGICAL BLOCKADE; LIPID-PEROXIDATION
AB Background: The observed controversy that N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide (LP-211), a selective serotonin (5-HT7) receptor agonist, may either modify or exacerbate imbalances in serum electrolyte concentrations and renal tissue of spinal cord trauma cases has not been reported yet. The aim of this study was to better understand the effects of a new 5-HT7 receptor agonist, LP-211, on serum electrolyte changes in spinal cord injured-(SCI) rats.
   Methods: Sixty male rats were assigned to the following groups: A) Intact (saline as vehicle, 1 ml/kg, i.p.), B) Intact [LP-211, (0.003-0.3 mg/kg, i.p.)], C) Sham-operated [laminectomy + vehicle (1 ml/kg, i.p.)], D) Sham-operated [laminectomy + LP-211 (0.003-0.3 mg/kg, i.p.)], E) Treatment [laminectomy + spinal trauma (SCI) + vehicle (1 ml/kg, i.p.)], F) Treatment [laminectomy + spinal trauma + LP-211 (0.003-0.3 mg/kg, i.p.)]. SCI was performed by placing an aneurysm clip, extradurally at the level of T10. After two weeks, LP-211 was administered cumulatively and each dose was injected (i.p.) with 20 min interval. At the end of the experiment, blood samples were collected for biochemical evaluations of the electrolytes employing standard commercial kits.
   Results: The present results indicate elevated serum levels of Na+, K+, and Mg2+ in SCI rats and significant differences demonstrated between the groups [P < 0.001, F(5, 35) = 23.92], [P < 0.001, F(5, 35) = 67.63], [P < 0.001, F(5, 35) = 71.144], respectively. So that, in groups B, D and F, there was a significant increase in K+ and Mg2+ serum levels compared to the groups A, C, and E (P < 0.001). Furthermore, Na+ serum levels in SCI (LP-211), laminectomy (LP-211), and intact (LP-211) groups tended to be statistically lower than SCI (saline), laminectomy (saline) and intact (saline) groups. Infact, hyponatremia, hyperkalemia and hypermagnesemia was obtained in group F. Nevertheless, in the remaining measured serum electrolytes such as calcium (Ca2+), iron (Fe2+) and phosphorus (P3-), chlorine (Cl-), copper (Cu+), and zinc (Zu(+)), no significant changes were observed.
   Conclusion: It was shown that acute additive LP-211 treatments in the SCI group led to hyponatremia, hyperkalemia and hypermagnesemia, it may be stated that LP-211 treatment as a promising candidate for treating SCI complications in some systems especially urinary tract might take into consideration and further studies would be needed to clarify its benefits or drawbacks. The observed discrepancies, nevertheless; will also pose new questions. Altogether, this will ultimately contribute to further understanding the pathophysiological role regarding 5-HT7 receptor activation.
C1 [Norouzi-Javidan, Abbas; Javanbakht, Javad; Barati, Fardin; Fakhraei, Nahid; Mohammadi, Fatemeh; Dehpour, Ahmad Reza] Univ Tehran Med Sci, Neurosci Inst, Brain & Spinal Cord Injury Res Ctr, Tehran, Iran.
   [Dehpour, Ahmad Reza] Univ Tehran Med Sci, Sch Med, Expt Med Res Ctr, Tehran, Iran.
   [Dehpour, Ahmad Reza] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran.
RP Dehpour, AR (reprint author), Univ Tehran Med Sci, Neurosci Inst, Brain & Spinal Cord Injury Res Ctr, Tehran, Iran.
EM dehpour@yahoo.com
OI Mohammadi, Fatemeh/0000-0002-5714-8060; dehpour, ahmad
   reza/0000-0002-8001-5565; norouzi javidan, abbas/0000-0002-6611-3919
FU Tehran University of Medical Sciences [2014-02/85/2527]
FX This study was supported by Tehran University of Medical Sciences (Grant
   No.2014-02/85/2527).
CR Abbas AI, 2009, PSYCHOPHARMACOLOGY, V205, P119, DOI 10.1007/s00213-009-1521-8
   Abraham J, 1985, Cent Nerv Syst Trauma, V2, P45
   AIKAWA JK, 1981, MAGNESIUM ITS BIOL S, P21
   Ambrozaitis Kazys Vytautas, 2006, Medicina (Kaunas), V42, P255
   ANDERSON DK, 1980, J NEUROSURG, V52, P387, DOI 10.3171/jns.1980.52.3.0387
   ANDERSON DK, 1980, J NEUROSURG, V53, P375, DOI 10.3171/jns.1980.53.3.0375
   ANDERSON DK, 1982, J NEUROSURG, V56, P106, DOI 10.3171/jns.1982.56.1.0106
   Aslan A, 2009, EUR SPINE J, V18, P336, DOI 10.1007/s00586-008-0872-x
   Bara M, 1984, Magnesium, V3, P215
   Bara Michel, 1993, Magnesium Research, V6, P167
   BARD JA, 1993, J BIOL CHEM, V268, P23422
   BAUMGARTNER RA, 1990, J PHARMACOL EXP THER, V255, P165
   Bonaventure P, 2007, J PHARMACOL EXP THER, V321, P690, DOI 10.1124/jpet.107.119404
   BRODNER RA, 1980, SURG NEUROL, V13, P337
   Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179
   Chen JS, 2013, J UROLOGY, V189, P1982, DOI 10.1016/j.juro.2012.11.049
   CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428
   CLENDENON NR, 1978, J NEUROSURG, V49, P563, DOI 10.3171/jns.1978.49.4.0563
   Dogrul A, 2009, BRAIN RES, V1280, P52, DOI 10.1016/j.brainres.2009.05.001
   Dolber PC, 2007, AM J PHYSIOL-REG I, V292, pR1699, DOI 10.1152/ajpregu.00142.2006
   FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x
   FERNANDEZALFONSO MS, 1992, EUR J PHARMACOL, V221, P185, DOI 10.1016/0014-2999(92)90699-5
   FERNANDEZALFONSO MS, 1992, N-S ARCH PHARMACOL, V345, P108
   FISONE G, 1995, J BIOL CHEM, V270, P2427, DOI 10.1074/jbc.270.6.2427
   FRANCISCO LL, 1981, P SOC EXP BIOL MED, V168, P382
   Galici R, 2008, BEHAV PHARMACOL, V19, P153, DOI 10.1097/FBP.0b013e3282f62d8c
   Glass JD, 2003, J NEUROSCI, V23, P7451
   Guscott M, 2005, NEUROPHARMACOLOGY, V48, P492, DOI 10.1016/j.neuropharm.2004.11.015
   Guscott MR, 2003, NEUROPHARMACOLOGY, V44, P1031, DOI 10.1016/S0028-3908(03)00117-5
   Hedlund PB, 2005, BIOL PSYCHIAT, V58, P831, DOI 10.1016/j.biopsych.2005.05.012
   Hedlund PB, 2010, NEUROSCI LETT, V481, P12, DOI 10.1016/j.neulet.2010.06.036
   Hedlund PB, 2009, PSYCHOPHARMACOLOGY, V206, P345, DOI 10.1007/s00213-009-1626-0
   HERNANDEZ J, 1992, NEUROCHEM INT, V20, P1, DOI 10.1016/0197-0186(92)90119-C
   Houston DS, 1981, J PHARMACOL EXP THER, V244, P1
   Huang CL, 2007, J AM SOC NEPHROL, V18, P2649, DOI 10.1681/ASN.2007070792
   ILDAN F, 1995, NEUROSURG REV, V18, P35, DOI 10.1007/BF00416476
   Kim JJ, 2013, J IMMUNOL, V190, P4795, DOI 10.4049/jimmunol.1201887
   KURIHARA M, 1985, J NEUROSURG, V62, P743, DOI 10.3171/jns.1985.62.5.0743
   Kvachnina E, 2005, J NEUROSCI, V25, P7821, DOI 10.1523/JNEUROSCI.1790-05.2005
   LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4
   Leopoldo A, 2004, CURR MED CHEM, V11, P629, DOI 10.2174/0929867043455828
   Leopoldo M, 2011, PHARMACOL THERAPEUT, V129, P120, DOI 10.1016/j.pharmthera.2010.08.013
   LOVENBERG TW, 1993, NEURON, V11, P449, DOI 10.1016/0896-6273(93)90149-L
   LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0
   Mahe C, 2005, NEUROPHARMACOLOGY, V49, P40, DOI 10.1016/j.neuropharm.2005.01.025
   Manuel-Apolinar L, 2004, BEHAV BRAIN RES, V148, P179, DOI 10.1016/S0166-4328(03)00186-4
   MARTIN GR, 1995, BRIT J PHARMACOL, V114, pP383
   MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0
   Mnie-Filali O, 2011, NEUROPSYCHOPHARMACOL, V36, P1275, DOI 10.1038/npp.2011.13
   MORELAND RS, 1985, J PHARMACOL EXP THER, V232, P322
   NAVRAN SS, 1991, J PHARMACOL EXP THER, V256, P297
   Oyinbo CA, 2011, ACTA NEUROBIOL EXP, V71, P281
   Pittala V, 2007, MINI-REV MED CHEM, V7, P945, DOI 10.2174/138955707781662663
   Politi HC, 2003, NEUROREPORT, V14, P659, DOI 10.1097/01.wnr.0000067304.99338.c8
   SADEE W, 1982, J NEUROCHEM, V39, P659, DOI 10.1111/j.1471-4159.1982.tb07943.x
   SHARMA HS, 1993, NEUROSCIENCE, V57, P443, DOI 10.1016/0306-4522(93)90076-R
   SHARMA HS, 1990, NEUROSCIENCE, V36, P725, DOI 10.1016/0306-4522(90)90014-U
   SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D
   SLEIGHT AJ, 1995, MOL PHARMACOL, V47, P99
   SoaresdaSilva P, 1996, BRIT J PHARMACOL, V117, P1199, DOI 10.1111/j.1476-5381.1996.tb16716.x
   Stepp LR, 1997, ARCH BIOCHEM BIOPHYS, V337, P43, DOI 10.1006/abbi.1996.9762
   Stowe RL, 1998, NEUROPHARMACOLOGY, V37, P1611, DOI 10.1016/S0028-3908(98)00117-8
   TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x
   TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015
   Terron JA, 1999, BRIT J PHARMACOL, V127, P609, DOI 10.1038/sj.bjp.0702580
   Terron JA, 1998, ANN NY ACAD SCI, V861, P283, DOI 10.1111/j.1749-6632.1998.tb10226.x
   Terron JA, 2007, EUR J PHARMACOL, V560, P56, DOI 10.1016/j.ejphar.2007.01.019
   TO ZP, 1995, BRIT J PHARMACOL, V115, P107, DOI 10.1111/j.1476-5381.1995.tb16327.x
   TOLLOCZKO B, 1995, AM J PHYSIOL-LUNG C, V269, pL234
   ULLMER C, 1995, FEBS LETT, V370, P215, DOI 10.1016/0014-5793(95)00828-W
   Villalon CM, 1997, BRIT J PHARMACOL, V120, P1319, DOI 10.1038/sj.bjp.0701020
   VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8
   VINK R, 1988, J BIOL CHEM, V263, P757
   Waters KA, 2012, BEHAV BRAIN RES, V228, P211, DOI 10.1016/j.bbr.2011.12.009
   WATTS SW, 1994, J PHARMACOL EXP THER, V271, P832
   Wesolowska A, 2006, NEUROPHARMACOLOGY, V51, P578, DOI 10.1016/j.neuropharm.2006.04.017
   Wesolowska A, 2006, EUR J PHARMACOL, V553, P185, DOI 10.1016/j.ejphar.2006.09.064
   WHEELER KP, 1975, BIOCHEM J, V146, P713, DOI 10.1042/bj1460713
   Wolf FI, 2008, CLIN SCI, V114, P27, DOI 10.1042/CS20070129
   WONG NLM, 1985, CLIN SCI, V69, P625, DOI 10.1042/cs0690625
   Wu G, 2014, NEUROUROL URODYNAM, V33, P1165, DOI 10.1002/nau.22463
   YANG CM, 1994, BRIT J PHARMACOL, V111, P777, DOI 10.1111/j.1476-5381.1994.tb14805.x
   YANG CM, 1994, CELL CALCIUM, V16, P194, DOI 10.1016/0143-4160(94)90022-1
NR 83
TC 4
Z9 4
U1 4
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD SEP 14
PY 2015
VL 10
AR 157
DI 10.1186/s13000-015-0397-7
PG 8
WC Pathology
SC Pathology
GA CR1RV
UT WOS:000361103400001
PM 26369408
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Tanno, Y
   Susumu, H
   Kawamura, M
   Sugimura, H
   Honda, T
   Watanabe, Y
AF Tanno, Yuji
   Susumu, Hiroaki
   Kawamura, Miyuki
   Sugimura, Haruhiko
   Honda, Takashi
   Watanabe, Yoshinori
TI RETRACTED: The inner centromere-shugoshin network prevents chromosomal
   instability (Retracted article. See vol. 357, pg. 981, 2017)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID KINETOCHORE ORIENTATION; CHROMATID COHESION; CANCER; CELLS;
   HETEROCHROMATIN; ANEUPLOIDY; PHOSPHORYLATION; TUMORIGENESIS; PROTECTION;
   MECHANISM
AB Chromosomal instability (CIN) is a major trait of cancer cells and a potent driver of tumor progression. However, the molecular mechanisms underlying CIN still remain elusive. We found that a number of CIN+ cell lines have impairments in the integrity of the conserved inner centromere-shugoshin (ICS) network, which coordinates sister chromatid cohesion and kinetochore-microtubule attachment. These defects are caused mostly by the loss of histone H3 lysine 9 trimethylation at centromeres and sometimes by a reduction in chromatin-associated cohesin; both pathways separately sustain centromeric shugoshin stability. Artificial restoration of the ICS network suppresses chromosome segregation errors in a wide range of CIN+ cells, including RB- and BRCA1-deficient cells. Thus, dysfunction of the ICS network might be a key mechanism underlying CIN in human tumorigenesis.
C1 [Tanno, Yuji; Susumu, Hiroaki; Kawamura, Miyuki; Honda, Takashi; Watanabe, Yoshinori] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Chromosome Dynam, Tokyo 1130032, Japan.
   [Susumu, Hiroaki; Kawamura, Miyuki; Watanabe, Yoshinori] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130032, Japan.
   [Sugimura, Haruhiko] Hamamatsu Univ Sch Med, Dept Pathol 1, Hamamatsu, Shizuoka 4313192, Japan.
RP Watanabe, Y (reprint author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Chromosome Dynam, Tokyo 1130032, Japan.
EM ywatanab@iam.u-tokyo.ac.jp
FU JSPS KAKENHI [24770180, 26440093]; JSPS; MEXT KAKENHI grants [S-001,
   25000014]
FX We thank S. Hauf for critically reading the manuscript; T. Akiyama, Y.
   Gotoh, K. Shirahige, T. Hirota, K. Miyagawa, A. Enomoto, M. Ohsugi, T.
   Kitamura, H. Suzuki, and T. Ohta for kindly providing materials; K.
   Funai for clinical arrangements; Y. Hirabayashi, Y. Kanki, S.
   Koitabashi, M. Okada, T. Kahyo, A. R. Maia, R. Nakato, and D. Izawa for
   valuable technical advice; and all members of our laboratory,
   particularly Y. Yamagishi, for their valuable support and discussions.
   Supported by JSPS KAKENHI grants 24770180 and 26440093 (Y.T.), a JSPS
   research fellowship (H. Sus.), and MEXT KAKENHI grants S-001 (H. Sug.)
   and 25000014 (Y.W.).
CR Bakhoum SF, 2014, CURR BIOL, V24, pR148, DOI 10.1016/j.cub.2014.01.019
   Bakhoum SF, 2009, CURR BIOL, V19, P1937, DOI 10.1016/j.cub.2009.09.055
   Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105
   Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625
   Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935
   Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Daum JR, 2011, CURR BIOL, V21, P1018, DOI 10.1016/j.cub.2011.05.032
   Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136
   Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002
   Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254
   Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015
   Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663
   Lampson MA, 2011, TRENDS CELL BIOL, V21, P133, DOI 10.1016/j.tcb.2010.10.007
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Lee J, 2008, NAT CELL BIOL, V10, P42, DOI 10.1038/ncb1667
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Liu H, 2013, CURR BIOL, V23, P1927, DOI 10.1016/j.cub.2013.07.078
   Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0
   Nishiyama T, 2010, CELL, V143, P737, DOI 10.1016/j.cell.2010.10.031
   Peters JM, 2008, GENE DEV, V22, P3089, DOI 10.1101/gad.1724308
   Salimian KJ, 2011, CURR BIOL, V21, P1158, DOI 10.1016/j.cub.2011.06.015
   Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619
   Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Tanaka TU, 2010, EMBO J, V29, P4070, DOI 10.1038/emboj.2010.294
   Tanno Y, 2010, GENE DEV, V24, P2169, DOI 10.1101/gad.1945310
   Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029
   Watanabe Y, 2012, NAT REV MOL CELL BIO, V13, P370, DOI 10.1038/nrm3349
   Yamada HY, 2012, CELL CYCLE, V11, P479, DOI 10.4161/cc.11.3.18994
   Yamagishi Y, 2008, NATURE, V455, P251, DOI 10.1038/nature07217
NR 30
TC 30
Z9 31
U1 3
U2 25
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 11
PY 2015
VL 349
IS 6253
BP 1237
EP 1240
DI 10.1126/science.aaa2655
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CQ9XH
UT WOS:000360968400046
PM 26359403
DA 2018-12-27
ER

PT J
AU Sun, CY
   Wang, Y
AF Sun Chuanyu
   Wang Yu
TI RETRACTED: Synthesis and characterization of graphene oxide composite
   with Fe3O4 (Retracted article. See vol. 34, pg. 2, 2016)
SO MATERIALS SCIENCE-POLAND
LA English
DT Article; Retracted Publication
DE graphene oxide; composite; magnetic Fe3O4
ID DRUG-DELIVERY; NANOPARTICLES; FABRICATION
AB In the paper, a magnetic composite of graphene oxide (MGO) has been successfully synthesized through decomposition of iron (III) acetylacetonate in the mixture solution of triethylene glycol and graphene oxide (GO). Atomic force microscopy (AFM), transmission electron microscopy (TEM), X-ray diffraction (XRD) and superconducting quantum interference device were used to characterize the material. The results show that the magnetic Fe3O4 nanoparticles modified graphene oxide composite with superparamagnetic properties, and magnetization saturation of 16.4 emu/g has been obtained. The MGO has a good sustained-release performance, and in vitro cytotoxicity confirming its secure use as a potential drug carrier.
C1 [Sun Chuanyu; Wang Yu] Yinuo Inst, Dept Chem Mat, Changchun 130033, Peoples R China.
RP Sun, CY (reprint author), Yinuo Inst, Dept Chem Mat, Changchun 130033, Peoples R China.
EM chuanyuvip@tom.com
CR Bertorelle F, 2006, LANGMUIR, V22, P5385, DOI 10.1021/la052710u
   Chen DY, 2011, ACS APPL MATER INTER, V3, P3078, DOI 10.1021/am200592r
   Hu CF, 2013, CARBON, V51, P255, DOI 10.1016/j.carbon.2012.08.051
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017
   Koo AN, 2008, CHEM COMMUN, P6570, DOI 10.1039/b815918a
   Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451
   Ma XX, 2012, NANO RES, V5, P199, DOI 10.1007/s12274-012-0200-y
   Manjunatha R, 2010, SENSOR ACTUAT B-CHEM, V145, P643, DOI 10.1016/j.snb.2010.01.011
   Nam T, 2010, BIOCONJUGATE CHEM, V21, P578, DOI 10.1021/bc900408z
   Tian G, 2011, J PHYS CHEM C, V115, P23790, DOI 10.1021/jp209055t
   Yang XY, 2009, J MATER CHEM, V19, P2710, DOI 10.1039/b821416f
   Zeng LX, 2012, ELECTROCHIM ACTA, V68, P158, DOI 10.1016/j.electacta.2012.02.045
NR 13
TC 1
Z9 1
U1 4
U2 15
PU DE GRUYTER OPEN LTD
PI WARSAW
PA BOGUMILA ZUGA 32A ST, 01-811 WARSAW, POLAND
SN 2083-134X
J9 MATER SCI-POLAND
JI Mater. Sci.
PD SEP
PY 2015
VL 33
IS 3
BP 488
EP 490
DI 10.1515/msp-2015-0068
PG 3
WC Materials Science, Multidisciplinary
SC Materials Science
GA DD9OE
UT WOS:000370254500005
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Chen, B
   Hou, ZH
   Li, CD
   Tong, Y
AF Chen, Bing
   Hou, Zhaohui
   Li, Chundong
   Tong, Ying
TI RETRACTED: MiRNA-494 inhibits metastasis of cervical cancer through
   Pttg1 (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Cervical cancer; Pituitary tumor-transforming gene 1; miR-494; Cancer
   metastasis
ID TUMOR-TRANSFORMING GENE; SQUAMOUS-CELL CARCINOMA; OF-THE-LITERATURE;
   PROSTATE-CANCER; DOWN-REGULATION; OVARIAN-CANCER; LUNG-CANCER; MIR-494;
   PROLIFERATION; THERAPY
AB Many cervical cancer (CC) patients experience early cancer metastasis, resulting in poor therapeutic outcome after resection of primary cancer. Hence, there is a compelling requirement for understanding of the molecular mechanisms underlying the invasiveness control of CC. Pituitary tumor-transforming gene 1 (Pttg1) has been recently reported to promote cancer cell growth and metastasis in a number of various tumors. However, its regulation by microRNAs (miRNAs) as well as its role in CC have not been clarified. Here, we reported significantly higher levels of Pttg1 and significantly lower levels of miR-494 in the resected CC tissue, compared with the adjacent normal cervical tissue from the same patient. Interestingly, Pttg1 levels inversely correlated with miR-494 levels. In vitro, Pttg1 levels determined CC cell invasiveness and were inhibited by miR-494 levels. However, miR-494 levels were not affected by Pttg1 levels. Furthermore, miR-494 inhibited Pttg1 expression in CC cells, through directly binding and inhibition on 3'-UTR of Pttg1 mRNA. Together, our data suggest that Pttg1 may increase CC cell metastasis, which is negatively regulated by miR-494. Our work thus highlights a novel molecular regulatory machinery in metastasis of CC.
C1 [Chen, Bing; Hou, Zhaohui; Li, Chundong; Tong, Ying] Air Force Gen Hosp PLA, Dept Obstet & Gynecol, Beijing 100142, Peoples R China.
RP Tong, Y (reprint author), Air Force Gen Hosp PLA, Dept Obstet & Gynecol, 30th Fucheng Rd, Beijing 100142, Peoples R China.
EM ying_tong15@163.com
CR Ai JK, 2004, SCI CHINA SER C, V47, P148, DOI 10.1360/03yc0043
   Asuthkar S, 2014, ONCOGENE, V33, P1922, DOI 10.1038/onc.2013.151
   Bacac M, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000032
   Bai YF, 2014, ONCOTARGET, V5, P7760, DOI 10.18632/oncotarget.2305
   Cao XL, 2012, ASIAN PAC J CANCER P, V13, P3083, DOI 10.7314/APJCP.2012.13.7.3083
   Caporali S, 2012, BIOCHEM PHARMACOL, V84, P598, DOI 10.1016/j.bcp.2012.06.004
   Castilla C, 2014, MOL CANCER THER, V13, P2372, DOI 10.1158/1535-7163.MCT-13-0405
   Castilla C, 2012, CLIN EXP METASTAS, V29, P349, DOI 10.1007/s10585-012-9455-7
   Chen BH, 2014, TUMOR BIOL, V35, P11587, DOI 10.1007/s13277-014-2463-2
   Chen Gang, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P369
   Crosby ME, 2007, ONCOGENE, V26, P1897, DOI 10.1038/sj.onc.1209998
   Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140
   El-Naggar SM, 2007, INT J ONCOL, V31, P137
   He WL, 2014, J GASTROEN HEPATOL, V29, P1427, DOI 10.1111/jgh.12558
   Huang SQ, 2012, BRAZ J MED BIOL RES, V45, P995, DOI [10.1590/S0100-879X2012001100001, 10.1590/S0100-879X2012007500126]
   Huang SQ, 2014, TUMOR BIOL, V35, P6265, DOI 10.1007/s13277-014-1818-z
   Kanayama T, 2012, EUR J GYNAECOL ONCOL, V33, P524
   Kim DS, 2007, CARCINOGENESIS, V28, P749, DOI 10.1093/carcin/bgl202
   Kwak SY, 2014, BBA-MOL CELL RES, V1843, P508, DOI 10.1016/j.bbamcr.2013.11.021
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Liborio-Kimura TN, 2015, ORAL ONCOL, V51, P151, DOI 10.1016/j.oraloncology.2014.11.019
   Panguluri SK, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-6
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Peters P, 2010, J CLIN NEUROSCI, V17, P1211, DOI 10.1016/j.jocn.2010.01.021
   PUCK TT, 1956, J EXP MED, V103, P273, DOI 10.1084/jem.103.2.273
   Ries J, 2014, ONCOL REP, V31, P1429, DOI 10.3892/or.2014.2983
   Romano G, 2012, P NATL ACAD SCI USA, V109, P16570, DOI 10.1073/pnas.1207917109
   Setoodeh R, 2012, INT J CLIN EXP PATHO, V5, P710
   Shibata Y, 2002, JPN J CLIN ONCOL, V32, P233, DOI 10.1093/jjco/hyf058
   Singh SV, 2008, CANCER RES, V68, P9503, DOI 10.1158/0008-5472.CAN-08-1677
   Solbach C, 2005, ANTICANCER RES, V25, P121
   Tfelt-Hansen J, 2006, CLIN MED RES, V4, P130, DOI 10.3121/cmr.4.2.130
   Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042
   Yamanaka S, 2012, CELL CYCLE, V11, P2729, DOI 10.4161/cc.21105
   Yan S, 2009, CANCER RES, V69, P3283, DOI 10.1158/0008-5472.CAN-08-0367
   Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137
   Zhang ML, 2008, HEPATOB PANCREAT DIS, V7, P313
   Zhou C, 2014, ONCOGENE, V33, P851, DOI 10.1038/onc.2013.16
   Zhou CQ, 2005, INT J CANCER, V113, P891, DOI 10.1002/ijc.20642
   Zhou RP, 2014, ASIAN PAC J CANCER P, V15, P1241, DOI 10.7314/APJCP.2014.15.3.1241
   Zhu XH, 2006, ANTICANCER RES, V26, P1253
NR 42
TC 24
Z9 26
U1 4
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2015
VL 36
IS 9
BP 7143
EP 7149
DI 10.1007/s13277-015-3440-0
PG 7
WC Oncology
SC Oncology
GA CW5KA
UT WOS:000365033100064
PM 25877755
DA 2018-12-27
ER

PT J
AU Li, R
   Shi, XJ
   Ling, FY
   Wang, CG
   Liu, JX
   Wang, W
   Li, M
AF Li, Rui
   Shi, Xuejun
   Ling, Fengyu
   Wang, Chunguang
   Liu, Junxia
   Wang, Wei
   Li, Ming
TI RETRACTED: MiR-34a suppresses ovarian cancer proliferation and motility
   by targeting AXL (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Ovarian cancer; MiR-34a; AXL; P53; Proliferation; Migration
ID MICRORNAS; METHYLATION; INHIBITION; RESISTANCE; ACTIVATION; EXPRESSION;
   APOPTOSIS; GENES; CELLS
AB Increasing evidence has suggested that dysregulation of microRNAs (miRNAs) could contribute to tumor progression. The miR-34 family is directly transactivated by tumor suppressor p53 which is frequently mutated in various cancers; however, the effect of miR-34a on the ovarian cancer cells remains unclear. The aim of the paper was to study the expression of miR-34a in ovarian cancer and miR-34a's relation to the cell proliferation and metastasis in ovarian cancer in vitro. miR-34a expression was determined by quantitative RT-PCR in a panel of 60 human ovarian cancer samples. Functional characterization of miR-34a was accomplished by reconstitution of miR-34a expression in ovarian cancer cells by determining changes in proliferation, migration, and invasion. Our results showed that miR-34a is downregulated in ovarian cancer tissues compared with the corresponding adjacent non-neoplastic tissues, and the expression level of miR-34a was significantly lower in ovarian cancer cell lines in comparison with normal human fallopian tube epithelial cell line. The 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-diphenytetrazoliumromide (MTT) assay revealed significant cell proliferation inhibition in miR-34a transfectant compared with the control from HO8910 and SKOV3 cells, which displayed lowest expressions of miR-34a. Furthermore, the transwell assay also showed significant cell migration inhibition in miR-34a transfectant, compared with cell lines transfected with NC. Overexpression of miR-34a led to the inhibition of AXL expression, indicating that AXL is a target gene for miR-34a. Our data suggest that miR-34a may function as a tumor suppressor through repression of oncogenic AXL in ovarian cancer.
C1 [Li, Rui; Shi, Xuejun; Ling, Fengyu; Wang, Chunguang; Liu, Junxia; Wang, Wei; Li, Ming] Chongqing Med Univ, Dept Oncol, Yongchuan Hosp, Chongqing 402160, Peoples R China.
RP Shi, XJ (reprint author), Chongqing Med Univ, Dept Oncol, Yongchuan Hosp, 439 Xuanhua Rd, Chongqing 402160, Peoples R China.
EM drshixj6@163.com
FU medical research project of Chongqing Municipal Health Bureau
   [2012-2-159]
FX This study was supported by the grants from the medical research project
   of Chongqing Municipal Health Bureau (No. 2012-2-159)
CR Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   Brouwer-Visser J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100165
   Chen WY, 2015, ONCOTARGET, V6, P441, DOI 10.18632/oncotarget.2690
   Cheung HH, 2010, BRIT J CANCER, V102, P419, DOI 10.1038/sj.bjc.6605505
   Concepcion CP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002797
   Hafizi S, 2006, FEBS J, V273, P5231, DOI 10.1111/j.1742-4658.2006.05659.x
   Jelovac D, 2011, CA-CANCER J CLIN, V61, P183, DOI 10.3322/caac.20113
   Li XY, 2015, MOL MED REP, V11, P577, DOI 10.3892/mmr.2014.2726
   Liu N, 2012, NATURE, V482, P519, DOI 10.1038/nature10810
   Mudduluru G, 2011, ONCOGENE, V30, P2888, DOI 10.1038/onc.2011.13
   Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731
   Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162
   Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017
   Suh YA, 2015, INT J ONCOL, V46, P1405, DOI 10.3892/ijo.2014.2808
   Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Wang X, 2015, CELL SIGNAL, V27, P443, DOI 10.1016/j.cellsig.2014.12.003
   Wu MY, 2014, CANCER LETT, V354, P311, DOI 10.1016/j.canlet.2014.08.031
   Xiao XS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112720
NR 21
TC 25
Z9 27
U1 3
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2015
VL 36
IS 9
BP 7277
EP 7283
DI 10.1007/s13277-015-3445-8
PG 7
WC Oncology
SC Oncology
GA CW5KA
UT WOS:000365033100078
PM 25895459
DA 2018-12-27
ER

PT J
AU Zhang, MS
   Kirsch, DG
AF Zhang, Minsi
   Kirsch, David G.
TI RETRACTED: The generation and characterization of novel Col1a1
   FRT-Cre-ER-T2-FRT and Col1a1 FRT-STOP-FRT-Cre-ER-T2 mice for sequential
   mutagenesis(Retracted article. See vol.9,pg.1513,2016)
SO DISEASE MODELS & MECHANISMS
LA English
DT Article; Retracted Publication
DE Mouse models; Sequential mutagenesis; Dual recombinase technology
ID CELL LUNG-CANCER; ONCOGENIC K-RAS; DNA RECOMBINATION; MAMMALIAN-CELLS;
   SOMATIC INACTIVATION; CRE RECOMBINASE; TRANSGENIC MICE; MOUSE MODEL;
   GENE; PROGRESSION
AB Novel genetically engineered mouse models using the Cre-loxP or the Flp-FRT systems have generated useful reagents to manipulate the mouse genome in a temporally-regulated and tissue-specific manner. By incorporating a constitutive Cre driver line into a mouse model in which FRT-regulated genes in other cell types are regulated by Flp-FRT recombinase, gene expression can be manipulated simultaneously in separate tissue compartments. This application of dual recombinase technology can be used to dissect the role of stromal cells in tumor development and cancer therapy. Generating mice in which Cre-ERT2 is expressed under Flp-FRT-mediated regulation would enable step-wise manipulation of the mouse genome using dual recombinase technology. Such next-generation mouse models would enable sequential mutagenesis to better model cancer and define genes required for tumor maintenance. Here, we generated novel genetically engineered mice that activate or delete Cre-ERT2 in response to Flp recombinase. To potentially utilize the large number of Cre-loxP-regulated transgenic alleles that have already been targeted into the Rosa26 locus, such as different reporters and mutant genes, we targeted the two novel Cre-ERT2 alleles into the endogenous Col1a1 locus for ubiquitous expression. In the Col1a1(FRT-Cre-ER-T2-FRT) mice, Flp deletes Cre-ERT2, so that Cre-ERT2 is only expressed in cells that have never expressed Flp. In contrast, in the Col1a1(FRT-STOP-FRT-Cre-ER-T2) mice, Flp removes the STOP cassette to allow Cre-ERT2 expression so that Cre-ERT2 is only expressed in cells that previously expressed Flp. These two new novel mouse strains will be complementary to each other and will enable the exploration of complex biological questions in development, normal tissue homeostasis and cancer.
C1 [Zhang, Minsi; Kirsch, David G.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA.
   [Kirsch, David G.] Duke Univ, Dept Radiat Oncol, Med Ctr, Durham, NC 27708 USA.
RP Kirsch, DG (reprint author), Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA.
EM david.kirsch@duke.edu
FU NIH [F30 CA180680, R01 CA169220]; Cancer Center Support Grant [CA014236]
FX This work was supported by NIH grants F30 CA180680 (M.Z.) and R01
   CA169220 (D.G.K.), and partially by the Cancer Center Support Grant
   CA014236.
CR Blum JM, 2013, CELL REP, V5, P933, DOI 10.1016/j.celrep.2013.10.020
   Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191
   El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042
   Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115
   Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602
   Lee CL, 2012, DIS MODEL MECH, V5, P397, DOI 10.1242/dmm.009084
   Marino S, 2000, GENE DEV, V14, P994
   Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4
   Moding EJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4214
   Moding EJ, 2014, J CLIN INVEST, V124, P3325, DOI 10.1172/JCI73932
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642
   ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861
   Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014
   Raymond CS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000162
   Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071
   Sanchez-Rivera FJ, 2014, NATURE, V516, P428, DOI 10.1038/nature13906
   SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166
   Schonhuber N, 2014, NAT MED, V20, P1340, DOI 10.1038/nm.3646
   Shai A, 2015, CANCER RES, V75, P3167, DOI 10.1158/0008-5472.CAN-14-3701
   Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111
   Sutherland KD, 2011, CANCER CELL, V19, P754, DOI 10.1016/j.ccr.2011.04.019
   Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932
   Xue W, 2014, NATURE, V514, P380, DOI 10.1038/nature13589
   Young NP, 2011, CANCER RES, V71, P4040, DOI 10.1158/0008-5472.CAN-10-4563
NR 27
TC 6
Z9 6
U1 2
U2 7
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754-8403
EI 1754-8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD SEP
PY 2015
VL 8
IS 9
BP 1155
EP 1166
DI 10.1242/dmm.021204
PG 12
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA CV0UO
UT WOS:000363969100014
PM 26183214
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhang, Y
   Li, A
   Peng, WZ
   Sun, J
   Xu, FM
   Xu, JH
AF Zhang, Yong
   Li, Ao
   Peng, Weizhen
   Sun, Jue
   Xu, Fangming
   Xu, Jianhua
TI RETRACTED: Efficient inhibition of growth of metastatic cancer cells
   after resection of primary colorectal cancer by soluble Flt-1 (retracted
   article) (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Colorectal cancer; Vascular endothelial growth factor A(VEGF-A);
   Placental growth factor (PLGF); Soluble Flt-1 (sFlt-1); SQDBT; SWT; SJZT
ID JUZEN-TAIHO-TO; DA-BU-TANG; TUMOR-GROWTH; LOCAL RECURRENCE; HERBAL
   MEDICINE; VEGF; ANGIOSTATIN; ENDOSTATIN; MICE; CHEMOTHERAPY
AB Removal of primary tumors often leads to increases in growth of metastatic tumor cells. Thus, development of an efficient treatment to inhibit the growth of metastatic tumor cells after resection of primary tumors appears to be critical for cancer therapy. Here, we reported that administration of a Chinese medicine Shiquandabutao (SQDBT) after removal of the primary cancer significantly inhibited the growth of metastatic cancer cells in mouse liver. Further analyses showed that the effect of SQDBT resulted from one of its main component, Siwutang (SWT), rather than from another main component, Sijunzitang (SJZT). Moreover, we found that the soluble Flt-1 from SWT neutralized the increased placental growth factor (PLGF) secreted by the metastatic cancer cells after primary cancer resection and subsequently inhibited the cancer neovascularization to suppress the metastatic cancer growth. Thus, our study reveals an essential role of SQDBT in inhibiting the growth of metastatic cancer after removal of primary cancer and further highlights PLGF as a potential target for metastatic cancer treatment.
C1 [Zhang, Yong; Li, Ao; Peng, Weizhen; Sun, Jue; Xu, Fangming; Xu, Jianhua] Shanghai Univ Tradit Chinese Med, Putuo Hosp, Dept Oncol, Shanghai 200062, Peoples R China.
RP Xu, JH (reprint author), Shanghai Univ Tradit Chinese Med, Putuo Hosp, Dept Oncol, 164 Lanxi Rd, Shanghai 200062, Peoples R China.
EM xujianhua2011@126.com
FU National Nature Science Foundation of China [81273733]
FX This work was financially supported by National Nature Science
   Foundation of China (no. 81273733).
CR Abramovitch R, 1999, BRIT J CANCER, V79, P1392, DOI 10.1038/sj.bjc.6690223
   Aliperti LA, 2011, ANN SURG ONCOL, V18, P603, DOI 10.1245/s10434-010-1442-0
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Curcio LD, 1997, ANN SURG ONCOL, V4, P24, DOI 10.1007/BF02316807
   Demicheli R, 2008, ANN ONCOL, V19, P1821, DOI 10.1093/annonc/mdn386
   Eichmann A, 2012, CURR OPIN CELL BIOL, V24, P188, DOI 10.1016/j.ceb.2012.02.002
   Eriksson A, 2002, CANCER CELL, V1, P99, DOI 10.1016/S1535-6108(02)00028-4
   Ferrara N, 2009, ARTERIOSCL THROM VAS, V29, P789, DOI 10.1161/ATVBAHA.108.179663
   Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   Harris AL, 1998, LANCET, V351, P1598, DOI 10.1016/S0140-6736(98)22022-8
   Huang SM, 2013, INTEGR CANCER THER, V12, P136, DOI 10.1177/1534735412450513
   Indraccolo S, 1999, INT J BIOL MARKER, V14, P251
   Kosari K, 2002, J GASTROINTEST SURG, V6, P255, DOI 10.1016/S1091-255X(02)00002-1
   Lian ZL, 2002, CANCER LETT, V182, P19, DOI 10.1016/S0304-3835(02)00059-9
   Mita Y, 2002, METHOD FIND EXP CLIN, V24, P67, DOI 10.1358/mf.2002.24.2.677128
   Nishiuchi T, 2013, J ALTERN COMPLEM MED, V19, P593, DOI 10.1089/acm.2012.0177
   Saiki I, 2000, BIOL PHARM BULL, V23, P677
   Sakagami Y, 1988, Arerugi, V37, P57
   SAKAMOTO S, 1991, AM J CHINESE MED, V19, P233, DOI 10.1142/S0192415X91000314
   SCOTT ADN, 1990, J ROY SOC MED, V83, P48
   TATSUTA M, 1994, EUR J CANCER, V30A, P74, DOI 10.1016/S0959-8049(05)80022-X
   Wu YB, 1998, J ETHNOPHARMACOL, V61, P153, DOI 10.1016/S0378-8741(98)00027-0
   Xiao XW, 2014, DIABETOLOGIA, V57, P991, DOI 10.1007/s00125-014-3179-y
   Xiao XW, 2013, J BIOL CHEM, V288, P8636, DOI 10.1074/jbc.M112.422949
   Yokoyama Y, 2000, CANCER RES, V60, P2190
   Zee-Cheng Robert K.-Y, 1992, Methods and Findings in Experimental and Clinical Pharmacology, V14, P725
NR 26
TC 5
Z9 5
U1 4
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2015
VL 36
IS 10
BP 7399
EP 7407
DI 10.1007/s13277-015-3434-y
PG 9
WC Oncology
SC Oncology
GA CT7CD
UT WOS:000362969900009
PM 25895458
DA 2018-12-27
ER

PT J
AU Jiang, YS
   Meng, QH
   Qi, JQ
   Shen, HY
   Sun, SC
AF Jiang, Yongsheng
   Meng, Qinghua
   Qi, Jiaqin
   Shen, Haiyu
   Sun, Shaochuan
TI RETRACTED: MiR-497 promotes metastasis of colorectal cancer cells
   through Nrdp1 inhibition (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Neuregulin receptor degradation protein-1 (Nrdp1); Colorectal cancer
   (CRC); MMP7; miR-497
ID BREAST-CANCER; GROWTH; CRC; MODULATION; EXPRESSION
AB We have recently shown that Nrdp1 inhibits phosphorylation of ErB3 in colorectal cancer (CRC) cells, to suppress epidermal growth factor receptor (EGFR) signaling-stimulated MMP7 activation for CRC metastasis. In this study, we examined the control of Nrdp1 in CRC cells. We detected significant increases in miR-497 in CRC specimen, compared to paired normal colorectal tissue. Moreover, we detected a strong positive correlation between miR-497 levels and Nrdp1 levels, and a strong inverse correlation between miR-497 levels and MMP7 levels. In vitro, overexpression of miR-497 in human CRC cells significantly decreased Nrdp1 transcripts and protein, and vice versa. Moreover, overexpression of miR-497 in human CRC cells also significantly increased MMP7 transcripts, cellular protein, and secreted protein, resulting in increases in cell invasiveness in a transwell cell migration assay. Furthermore, we found that MiR-497 directly targeted 3'-UTR of Nrdp1 mRNA to inhibit its translation. Together, our data suggest that the regulation of MMP7 by Nrdp1 in CRC cells could be inhibited by miR-497 through suppressing Nrdp1 translation. Our work thus highlights a novel molecular regulatory machinery that regulates metastasis of CRC.
C1 [Jiang, Yongsheng; Meng, Qinghua; Qi, Jiaqin; Shen, Haiyu; Sun, Shaochuan] Shandong Univ, Dept Gen Surg, Jinan Cent Hosp, Jinan 250013, Peoples R China.
RP Sun, SC (reprint author), Shandong Univ, Dept Gen Surg, Jinan Cent Hosp, 105 Jiefang Rd, Jinan 250013, Peoples R China.
EM jun_niu14@163.com
CR Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   East JE, 2013, NAT REV GASTRO HEPAT, V10, P69, DOI 10.1038/nrgastro.2012.245
   Jiang YS, 2015, TUMOR BIOL, V36, P1129, DOI 10.1007/s13277-014-2726-y
   Labianca R, 2005, ANN ONCOL, V16, P37, DOI 10.1093/annonc/mdi906
   Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800
   Lu H, 2014, TUMOR BIOL, V35, P8639, DOI 10.1007/s13277-014-2132-5
   Luo QF, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-95
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Shen L, 2012, EXP THER MED, V3, P475, DOI 10.3892/etm.2011.428
   Song WF, 2015, CELL PHYSIOL BIOCHEM, V35, P184, DOI 10.1159/000369686
   Van Schaeybroeck S, 2011, NAT REV CLIN ONCOL, V8, P222, DOI 10.1038/nrclinonc.2011.15
   von Kleist S, 1975, J Natl Cancer Inst, V55, P555
   Wang L, 2014, CELL PHYSIOL BIOCHEM, V33, P1316, DOI 10.1159/000358699
   Wang SH, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-172
   Yao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078086
   Yen L, 2006, CANCER RES, V66, P11279, DOI 10.1158/0008-5472.CAN-06-2319
NR 16
TC 17
Z9 18
U1 3
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2015
VL 36
IS 10
BP 7641
EP 7647
DI 10.1007/s13277-015-3489-9
PG 7
WC Oncology
SC Oncology
GA CT7CD
UT WOS:000362969900035
PM 25926384
DA 2018-12-27
ER

PT J
AU Zhao, ZM
   Xi, H
   Xu, DB
   Li, CG
AF Zhao, Zhiming
   Xi, Hao
   Xu, Dabin
   Li, Chenggang
TI RETRACTED: Transforming growth factor beta receptor signaling restrains
   growth of pancreatic carcinoma cells (Retracted article. See April,
   2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Pancreatic ductal adenocarcinoma (PDAC); TGF beta; Cancer growth;
   Intraductal infusion
ID ADENOASSOCIATED VIRAL VECTORS; ONCOGENIC K-RAS; TGF-BETA; PROLIFERATION;
   MACROPHAGES; PROGRESSION; INFUSION; CANCER
AB Pancreatic ductal adenocarcinoma (PDAC) is extremely malignant. Efficient control of cancer growth may substantially improve the survival of PDAC patients. However, no efficient treatments are so far available. Here, we inhibited transforming growth factor beta (TGF beta) receptor signaling by overexpression of a key inhibitor of this pathway, SMAD7, in the mouse pancreas, using a recently developed intraductal infusion method. Overexpression of SMAD7 significantly increased growth of both implanted PDAC and PDAC by K-ras modification. Our data thus suggest that TGF beta receptor signaling restrains growth of PDAC, and modulation of TGF beta receptor signaling may be an effective treatment for PDAC.
C1 [Zhao, Zhiming; Xu, Dabin; Li, Chenggang] Chinese Peoples Liberat Army Gen Hosp, Dept Surg Oncol, Beijing 100853, Peoples R China.
   [Xi, Hao] Hosp Shunyi Dist, Dept Hepatobiliary Surg, Beijing 101300, Peoples R China.
   [Zhao, Zhiming] Chinese Peoples Liberat Army Gen Hosp, Dept Surg Oncol, Beijing 100853, Peoples R China.
RP Zhao, ZM (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Surg Oncol, Beijing 100853, Peoples R China.
EM zhiming_zhao@163.com
CR Cao XC, 2014, INT J BIOCHEM CELL B, V53, P372, DOI 10.1016/j.biocel.2014.06.003
   di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071
   El-Gohary Y, 2013, DEV BIOL, V378, P83, DOI 10.1016/j.ydbio.2013.04.003
   Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027
   Grieger JC, 2006, NAT PROTOC, V1, P1412, DOI 10.1038/nprot.2006.207
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   Jimenez V, 2011, DIABETOLOGIA, V54, P1075, DOI 10.1007/s00125-011-2070-3
   Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959
   Khan IF, 2011, NAT PROTOC, V6, P482, DOI 10.1038/nprot.2011.301
   Koerber JT, 2006, NAT PROTOC, V1, P701, DOI 10.1038/nprot.2006.93
   LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505
   Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Muller-Pillasch F, 1999, HEPATO-GASTROENTEROL, V46, P2751
   Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734
   Perides G, 2010, NAT PROTOC, V5, P335, DOI 10.1038/nprot.2009.243
   Shi WD, 2014, TUMOR BIOL, V35, P11147, DOI 10.1007/s13277-014-2423-x
   Song W, 2015, CELL PHYSIOL BIOCHEM, V35, P184
   Truty MJ, 2007, PANCREATOLOGY, V7, P423, DOI 10.1159/000108959
   Xiao XW, 2014, NAT PROTOC, V9, P2719, DOI 10.1038/nprot.2014.183
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Xiao XW, 2013, DIABETES, V62, P1217, DOI 10.2337/db12-1428
   Yi JJ, 2010, CELL, V142, P144, DOI 10.1016/j.cell.2010.06.010
   Zhang H, 2015, TUMOR BIOL, V36, P1613, DOI 10.1007/s13277-014-2757-4
NR 23
TC 4
Z9 4
U1 3
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2015
VL 36
IS 10
BP 7711
EP 7716
DI 10.1007/s13277-015-3466-3
PG 6
WC Oncology
SC Oncology
GA CT7CD
UT WOS:000362969900043
PM 25934336
DA 2018-12-27
ER

PT J
AU Qi, YY
   Hu, TH
   Li, K
   Ye, RQ
   Ye, ZD
AF Qi, Yuying
   Hu, Tinghui
   Li, Kai
   Ye, Renqing
   Ye, Zuodong
TI RETRACTED: Lentivirus-Mediated Short-Hairpin RNA Targeting Protein
   Phosphatase 4 Regulatory Subunit 1 Inhibits Growth in Breast Cancer
   (Retracted article. See vol. 21, pg. 102, 2018)
SO JOURNAL OF BREAST CANCER
LA English
DT Article; Retracted Publication
DE Apoptosis; Breast neoplasms; Cell proliferation; Protein phosphatase 4
   regulatory subunit 1
ID MAMMALIAN-CELLS; INTERFERENCE; PP4; EXPRESSION; APOPTOSIS; COMPLEX
AB Purpose: Protein phosphatase 4 regulatory subunit 1 (PP4R1), as an interaction partner of the catalytic serine/threonine-protein phosphatase 4 catalytic subunit has been shown to involve in cellular processes and nuclear factor KB signaling. However, the functions of PP4R1 in human breast cancers remain unclear. This study is designed to explore the effect of PP4R1 knockdown on the biological characteristics of breast cancer cells. Methods: A lentivirus-mediated short hairpin RNA (shRNA) was designed to knockdown the expression of PP4R1 in ZR-75-30 breast cancer cells. The efficiency of lentivirus-mediated shRNA infection was determined using fluorescence microscopy to observe lentivirus-mediated green fluorescent protein expression and confirmed to be over 80%. PP4R1 expression in infected ZR-75-30 cells was detected by quantitative real-time polymerase chain reaction and western blot analysis. Cell proliferation and colony formation ability were measured by 3-(4,5-dimethy1-2-thiazoly1)-2,5-dipheny1-2-H-tetrazolium bromide (MTT) assay and colony formation assay, respectively. Flow cytometry was used to measure cell cycle progression and cell apoptosis. In addition, apoptosis makers, including poly-ADP-ribose polymerase (PARP) and caspase-3, were investigated in PP4R1-silenced ZR-75-30 cells by western blot assay. Results: We successfully constructed lentivirus-mediated shRNA to target PP4R1 in.ZR-75-30 cells. MIT assay and colony formation assay showed the loss of PP4R1 suppressed the proliferation of ZR-75-30 cells. Flow cytometry analysis indicated cell cycle arrest and increased cell apoptosis in PP4R1 knockdown cells. Further, the apoptosis response in cells depleted of PP4R1 was illustrated by downregulation of PARP and upregulation of caspase-3. Conclusion: Our results suggest that PP4R1 could promote breast cancer cell proliferation and might play a vital role in breast cancer occurrence.
C1 [Qi, Yuying; Ye, Renqing; Ye, Zuodong] Fujian Med Univ, Affiliated Ningde Municipal Hosp, Dept Lab, Jiaocheng Dist 352100, Ningde, Peoples R China.
   [Hu, Tinghui; Li, Kai] Fujian Med Univ, Affiliated Ningde Municipal Hosp, Dept Surg Oncol, Jiaocheng Dist 352100, Ningde, Peoples R China.
RP Qi, YY (reprint author), Fujian Med Univ, Affiliated Ningde Municipal Hosp, Dept Lab, 7 North Jiaocheng Rd, Jiaocheng Dist 352100, Ningde, Peoples R China.
EM yuying_qi@126.com
CR Allgayer H, 2008, ADV MED SCI-POLAND, V53, P130, DOI 10.2478/v10039-008-0025-9
   Anderson BO, 2006, BREAST J, V12, pS54, DOI 10.1111/j.1075-122X.2006.00203.x
   Bressenot A, 2009, J HISTOCHEM CYTOCHEM, V57, P289, DOI 10.1369/jhc.2008.952044
   Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Chen GI, 2008, J BIOL CHEM, V283, P29273, DOI 10.1074/jbc.M803443200
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   He PX, 2014, ACTA PHARMACOL SIN, V35, P1055, DOI 10.1038/aps.2014.47
   Inostroza J, 2005, BIOL RES, V38, P163, DOI 10.4067/S0716-97602005000200006
   Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339
   Lee DH, 2010, NAT STRUCT MOL BIOL, V17, P365, DOI 10.1038/nsmb.1769
   Li CI, 2005, CANCER EPIDEM BIOMAR, V14, P1008, DOI 10.1158/1055-9965.EPI-04-0849
   Lin HC, 2014, CLIN ORAL INVEST, V18, P1277, DOI 10.1007/s00784-013-1088-y
   Mourtada-Maarabouni M, 2009, LEUKEMIA RES, V33, P1539, DOI 10.1016/j.leukres.2009.05.013
   Parkin DM, 2006, BREAST J, V12, pS70, DOI 10.1111/j.1075-122X.2006.00205.x
   Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941
   Ren WH, 2014, MOL CELL BIOCHEM, V390, P253, DOI 10.1007/s11010-014-1976-8
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Takeshita F, 2006, CANCER SCI, V97, P689, DOI 10.1111/j.1349-7006.2006.00234.x
   Toyo-oka K, 2008, J CELL BIOL, V180, P1133, DOI 10.1083/jcb.200705148
   Wang B, 2008, CELL RES, V18, P974, DOI 10.1038/cr.2008.274
   Wang Y, 2006, ANN BIOMED ENG, V34, P114, DOI 10.1007/s10439-005-9007-2
   Zhang XH, 2005, GENE DEV, V19, P827, DOI 10.1101/gad.1286005
NR 24
TC 2
Z9 2
U1 3
U2 7
PU KOREAN BREAST CANCER SOC
PI SEOUL
PA 163 SINMUNRO 1-GA JONGRO-GU, OFFICIA  BUILDING, SUITE 2024, SEOUL,
   110-999, SOUTH KOREA
SN 1738-6756
EI 2092-9900
J9 J BREAST CANCER
JI J. Breast Canc.
PD SEP
PY 2015
VL 18
IS 3
BP 218
EP 224
DI 10.4048/jbc.2015.18.3.218
PG 7
WC Oncology
SC Oncology
GA CT2HY
UT WOS:000362623800002
PM 26472971
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Yu, Z
   Zhou, F
   Ge, LF
   Liu, XM
   Fang, Y
   Xie, LN
   Kong, FS
   Song, NX
   Yu, QQ
AF Yu, Zhe
   Zhou, Fang
   Ge, Lin-Fu
   Liu, Xi-Min
   Fang, Yuan
   Xie, Lin-Na
   Kong, Fan-Sheng
   Song, Ning-Xia
   Yu, Qing-Qing
TI RETRACTED: Assessment of the use of immunosuppressants combined with
   cord blood for severe aplastic anemia (Retracted article. See vol. 33,
   pg. 349, 2015)
SO ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY
LA English
DT Article; Retracted Publication
DE aplastic anemia; cord blood; cytokine; interleukin-17; interleukin-22
ID T-CELLS; TH17; TRANSPLANTATION; EXPERIENCE
AB Background: The objective of this study was twofold: 1) to investigate the changes of cytokines concentration in relation to severe aplastic anemia (SAA) when treated with immunosuppressants combined with cord blood (IS + CBI). and 2) to assess the curative effect of umbilical cord blood chimerism engraftment.
   Methods: We selected 43 patients with SAA all treated with IS + CBI (newly diagnosed group). Among them, a total of 33 patients were treated effectively (effective group) while 10 cases were treated invalidly (invalid group). An additional 20 healthy individuals were selected as control (control group). The expression levels of IL-17, IL-22 and other cytokines in each group were detected by ELISA. The engraftment of cord blood stem cells was detected by using short tandem repeat-polymerase chain reaction (STR-PCR).
   Results: 1. IL-17, IL-22 and other cytokines expressions in the newly diagnosed group were significantly higher than in the control group. 2. After six months, the levels in the effective group were significantly lower than pre-therapy levels (P < 0.05). The levels in the invalid group did not differ to those observed prior treatment. 3. After one and three months of treatment, a small amount of engraftment was found in the effective group. However, after six months, transplant rejection was observed in all patients. No effective engraftment was observed in the invalid group.
   Conclusion: 1) Th17 and Th22 producing cells in SAA patients significantly increased indicating a positive correlation between these biomarkers and the progression of SAA. 2) During the IS + CBI treatment the maintenance of a normal hematopoietic function depended on immunesuppressants. Early umbilical cord blood chimerism engraftment may promote hematopoietic recovery.
C1 [Yu, Zhe; Zhou, Fang; Ge, Lin-Fu; Liu, Xi-Min; Fang, Yuan; Xie, Lin-Na; Kong, Fan-Sheng; Song, Ning-Xia; Yu, Qing-Qing] Jinan Mil Gen Hosp, Dept Hematol, Jinan 250031, Shandong, Peoples R China.
RP Zhou, F (reprint author), Jinan Mil Gen Hosp, Dept Hematol, Jinan 250031, Shandong, Peoples R China.
EM yzdoccn@126.com
CR Andrea C, 2012, CHEM IMMUNOL ALLERGY, V96, P39
   Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC
   Bettelli E, 2007, CURR OPIN IMMUNOL, V19, P652, DOI 10.1016/j.coi.2007.07.020
   de Latour RP, 2010, BLOOD, V116, P4175, DOI 10.1182/blood-2010-01-266098
   Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202
   GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Kim S, 2012, CYTOKINE, V60, P815, DOI 10.1016/j.cyto.2012.08.005
   Kordasti S, 2012, BLOOD, V119, P2033, DOI 10.1182/blood-2011-08-368308
   Korthof ET, 2013, AM J HEMATOL, V88, P472, DOI 10.1002/ajh.23435
   Marsh J., 2010, CELL THER TRANSPL, V3, P2010
   Maury S, 2013, AM J HEMATOL, V88, P868, DOI 10.1002/ajh.23522
   Muranski P, 2011, IMMUNITY, V35, P972, DOI 10.1016/j.immuni.2011.09.019
   Papadopoulos KI, 2011, RESTOR NEUROL NEUROS, V29, P17, DOI 10.3233/RNN-2011-0572
   Pitombeira BS, 2013, BONE MARROW RES, V2013
   Prihartono N, 2011, ASIA-PAC J PUBLIC HE, V23, P369, DOI 10.1177/1010539511403605
   Ramirez P, 2013, TRANSPL P, V45, P3734, DOI 10.1016/j.transproceed.2013.08.093
   Rubinstein P, 2001, E SCHERING RES FDN W, V33, P47
   Wolk K, 2010, SEMIN IMMUNOPATHOL, V32, P17, DOI 10.1007/s00281-009-0188-x
NR 19
TC 2
Z9 2
U1 2
U2 8
PU ALLERGY IMMUNOL SOC THAILAND,
PI BANGKOK
PA MAHIDOL UNIV, DEPT MICROBIOL IMMUNOL, FACULTY TROPICAL MED, BANGKOK
   10400, THAILAND
SN 0125-877X
EI 2228-8694
J9 ASIAN PAC J ALLERGY
JI Asian Pac. J. Allergy Immunol.
PD SEP
PY 2015
VL 33
IS 3
BP 245
EP 252
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA CS5XK
UT WOS:000362151400011
PM 26342122
DA 2018-12-27
ER

PT J
AU Jiao, JT
   Sun, J
   Ma, JF
   Dai, MC
   Huang, J
   Jiang, C
   Wang, C
   Cheng, C
   Shao, JF
AF Jiao, Jian-tong
   Sun, Jun
   Ma, Jian-fen
   Dai, Min-chao
   Huang, Jin
   Jiang, Chen
   Wang, Cheng
   Cheng, Chao
   Shao, Jun-fei
TI RETRACTED: Relationship between inflammatory cytokines and risk of
   depression, and effect of depression on the prognosis of high grade
   glioma patients (Retracted article. See vol. 134, pg. 475, 2017)
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article; Retracted Publication
DE High grade glioma; Depression; Inflammatory cytokines; Survival; Quality
   of life
ID NECROSIS-FACTOR-ALPHA; QUALITY-OF-LIFE; BRAIN-TUMOR PATIENTS;
   CANCER-PATIENTS; MAJOR DEPRESSION; INTERFERON-ALPHA;
   GLIOBLASTOMA-MULTIFORME; NERVOUS-SYSTEM; IMMUNE-SYSTEM;
   INTERLEUKIN-1-BETA
AB Depression is found to be associated with up-regulation of inflammatory cytokines. However, the relationship in high grade glioma (HGG) patients is still unclear. In this prospective study, a total 132 HGG patients participated in blood sample collection for inflammatory cytokines detection by ELISA, mental status, quality of life (QOL) and physical functional status testing. The association between inflammatory cytokines and depression risk was assessed using conditional logistic regression. The incidences of depressive symptoms and depression in high grade glioama patients were 45.5 and 25 % respectively during 12 months follow-up. We found the risk of depression was elevated with increased C-reactive protein (CRP) and interleukin-6 (IL-6) in high grade glioma patients after adjustment of confounders. The serum levels of CRP and IL-6 in patients with transient depression and depression were higher than those without depressive symptoms. In addition, depression had significant effects on the survival, QOL and physical functional status of patients. Depression is prevalent among patients with HGG. The present study suggests that serum CRP and IL-6 may serve as a depression marker for HGG patients. The survival and quality of life of HGG patients may be improved by an effective management for depression.
C1 [Jiao, Jian-tong; Sun, Jun; Ma, Jian-fen; Dai, Min-chao; Huang, Jin; Jiang, Chen; Wang, Cheng; Cheng, Chao; Shao, Jun-fei] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Neurosurg, Wuxi 214023, Peoples R China.
RP Shao, JF (reprint author), Nanjing Med Univ, Wuxi Peoples Hosp, Dept Neurosurg, Wuxi 214023, Peoples R China.
EM tongjianjiao@126.com; wxhneurosurgery@126.com
FU National Natural Science Foundation of China [NSFC. 81272791]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC. 81272791).
CR ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7
   American Psychiatric Association, 1994, DIAGN STAT MAN MENT
   Bailey RK, 2005, INT J GYNECOL CANCER, V15, P203, DOI 10.1111/j.1525-1438.2005.15204.x
   Beck AT., 1996, BECK DEPRESSION INVE
   Benros ME, 2009, INT J CANCER, V124, P2917, DOI 10.1002/ijc.24274
   Bernardino L, 2008, STEM CELLS, V26, P2361, DOI 10.1634/stemcells.2007-0914
   Boele Florien W, 2014, CNS Oncol, V3, P37, DOI 10.2217/cns.13.65
   Bower JE, 2007, BRAIN BEHAV IMMUN, V21, P251, DOI 10.1016/j.bbi.2006.08.001
   Capuron L, 2003, BIOL PSYCHIAT, V54, P906, DOI 10.1016/S0006-3223(03)00173-2
   Capuron L, 2002, NEUROPSYCHOPHARMACOL, V26, P643, DOI 10.1016/S0893-133X(01)00407-9
   Cheng JX, 2009, NEURO-ONCOLOGY, V11, P41, DOI 10.1215/15228517-2008-050
   Dalton SO, 2009, J CLIN ONCOL, V27, P1440, DOI 10.1200/JCO.2008.20.5526
   Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033
   Gathinji M, 2009, SURG NEUROL, V71, P299, DOI 10.1016/j.surneu.2008.07.016
   Giovagnoli AR, 1996, J NEURO-ONCOL, V30, P71
   Goshen I, 2007, PSYCHONEUROENDOCRINO, V32, P1106, DOI 10.1016/j.psyneuen.2007.09.004
   Harbuz MS, 2003, ANN NY ACAD SCI, V992, P99, DOI 10.1111/j.1749-6632.2003.tb03141.x
   Howren MB, 2009, PSYCHOSOM MED, V71, P171, DOI 10.1097/PSY.0b013e3181907c1b
   Jehn CF, 2006, CANCER, V107, P2723, DOI 10.1002/cncr22294
   Kim JW, 2013, PSYCHIAT INVEST, V10, P294, DOI 10.4306/pi.2013.10.3.294
   Kitagami T, 2003, BRAIN RES, V978, P104, DOI 10.1016/S0006-8993(03)02776-8
   Kore RA, 2014, BIOCHEM BIOPH RES CO, V453, P326, DOI 10.1016/j.bbrc.2014.09.068
   Kumar R, 2006, ONCOL REP, V15, P1513
   Litofsky NS, 2009, J NEURO-ONCOL, V94, P153, DOI 10.1007/s11060-009-9825-4
   Litofsky NS, 2004, NEUROSURGERY, V54, P358, DOI 10.1227/01.NEU.0000103450.94724.A2
   Lucas M, 2014, BRAIN BEHAV IMMUN, V36, P46, DOI 10.1016/j.bbi.2013.09.014
   Lucchiari C, 2015, SUPPORT CARE CANCER, V23, P3427, DOI 10.1007/s00520-015-2691-z
   MACKWORTH N, 1992, J NEURO-ONCOL, V14, P243
   MAES M, 1995, J AFFECT DISORDERS, V34, P301, DOI 10.1016/0165-0327(95)00028-L
   MAES M, 1993, AM J PSYCHIAT, V150, P1189
   Mainio A, 2005, J NEUROSURG, V103, P841, DOI 10.3171/jns.2005.103.5.0841
   Miller AH, 2009, BRAIN BEHAV IMMUN, V23, P149, DOI 10.1016/j.bbi.2008.08.006
   Musselman DL, 2001, AM J PSYCHIAT, V158, P1252, DOI 10.1176/appi.ajp.158.8.1252
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
   Raison CL, 2010, MOL PSYCHIATR, V15, P535, DOI 10.1038/mp.2008.58
   Raison CL, 2009, BIOL PSYCHIAT, V65, P296, DOI 10.1016/j.biopsych.2008.08.010
   Rich T, 2005, CLIN CANCER RES, V11, P1757, DOI 10.1158/1078-0432.CCR-04-2000
   Rooney AG, 2011, J NATL CANCER I, V103, P61, DOI 10.1093/jnci/djq458
   Satin JR, 2009, CANCER-AM CANCER SOC, V115, P5349, DOI 10.1002/cncr.24561
   Schiepers OJG, 2005, PROG NEURO-PSYCHOPH, V29, P201, DOI 10.1016/j.pnpbp.2004.11.003
   Sellick SM, 1999, PSYCHO-ONCOL, V8, P315, DOI 10.1002/(SICI)1099-1611(199907/08)8:4<315::AID-PON391>3.0.CO;2-G
   Soygur H, 2007, PROG NEURO-PSYCHOPH, V31, P1242, DOI 10.1016/j.pnpbp.2007.05.001
   Vedder H, 2007, J PSYCHIAT RES, V41, P280, DOI 10.1016/j.jpsychires.2006.07.014
   Wang Y, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0921-8
   WEITZNER MA, 1995, CANCER, V75, P1151, DOI 10.1002/1097-0142(19950301)75:5<1151::AID-CNCR2820750515>3.0.CO;2-Q
   Wu CW, 2007, J NEUROCHEM, V103, P2471, DOI 10.1111/j.1471-4159.2007.04987.x
   Yirmiya R, 2000, WESTERN J MED, V173, P333, DOI 10.1136/ewjm.173.5.333
   Zhu CB, 2006, NEUROPSYCHOPHARMACOL, V31, P2121, DOI 10.1038/sj.npp.1301029
NR 48
TC 3
Z9 4
U1 5
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD SEP
PY 2015
VL 124
IS 3
BP 475
EP 484
DI 10.1007/s11060-015-1861-7
PG 10
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA CS2LJ
UT WOS:000361902000016
PM 26215876
DA 2018-12-27
ER

PT J
AU Zhou, Y
   Xie, ZG
AF Zhou, Yao
   Xie, Zhi-Gang
TI RETRACTED: A neutralizing scFv antibody against infectious bursal
   disease virus screened by flow cytometry (Retracted article. See vol.
   437, pg. 70, 2016)
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article; Retracted Publication
DE Anchored periplasm expression; Antibody library; Fluorescence-activated
   cell sorting; Neutralizing antibody; Infectious bursal disease virus
ID ANCHORED PERIPLASMIC EXPRESSION; CHICKENS; LIBRARIES; VACCINES; THERAPY;
   CANCER
AB Infectious bursal disease (IBD) is considered a vital viral disease that threatens the poultry industry worldwide. In this study, a recombinant single chain variable fragment (scFv) antibody library derived from chickens immunized with VP2 protein of infectious bursal disease virus (IBDV) was constructed. The library was subjected to three rounds of screening by flow cytometty (FCM) against VP2/IBDV through a bacteria display technology, resulting in the enrichment of scFvs. Three scFv clones with different fluorescence intensity were obtained by colony pick up at random. The obtained scFv antibodies were expressed and purified. Relative affinity assay showed the three clones had different sensitivity to VP2, in accordance with fluorescence activity cell sorting analysis (FACS). The potential use of the isolated IBDV-specific scFv antibodies was demonstrated by the successful application of these antibodies in Western blotting and ELISA assay. What's more, in vitro neutralization measurement showed that one of the three isolated antibodies possessed the neutralization function against IBDV. This study provides new strategies for screening of antibody library, and scFv antibodies isolated in this study may be utilized as lead candidates for further development of diagnostic or therapeutic antibodies for detection and treatment of IBDV infection. (C) 2015 Published by Elsevier B.V.
C1 [Zhou, Yao; Xie, Zhi-Gang] Qiqihar Univ, Coll Life Sci & Agroforest, Qiqihar 161000, Peoples R China.
RP Xie, ZG (reprint author), Qiqihar Univ, Coll Life Sci & Agroforest, Qiqihar 161000, Peoples R China.
EM 2731848980@qq.com
FU Scientific Research Fund of Heilongjiang Provincial Education Department
   [12521808]; Science and Technology Plan Projects of Qiqihar
   [NYGGZD-201109]; Qiqihar University Science Foundation for Youth
   [2011k-m41]
FX This study was supported by grants of the Scientific Research Fund of
   Heilongjiang Provincial Education Department (No. 12521808), the Science
   and Technology Plan Projects of Qiqihar (NYGGZD-201109), and the Qiqihar
   University Science Foundation for Youth (2011k-m41).
CR BURKHARDT E, 1987, ARCH VIROL, V94, P297, DOI 10.1007/BF01310722
   Chen YC, 2010, MOL THER, V18, P1650, DOI 10.1038/mt.2010.136
   Corley MM, 2002, AVIAN DIS, V46, P810, DOI 10.1637/0005-2086(2002)046[0810:IISPFB]2.0.CO;2
   Dane KY, 2006, J IMMUNOL METHODS, V309, P120, DOI 10.1016/j.jim.2005.11.021
   Eterradossi N, 1997, ARCH VIROL, V142, P255, DOI 10.1007/s007050050075
   FAHEY KJ, 1991, AVIAN DIS, V35, P365, DOI 10.2307/1591191
   Harvey BR, 2006, J IMMUNOL METHODS, V308, P43, DOI 10.1016/j.jim.2005.09.017
   Harvey BR, 2004, P NATL ACAD SCI USA, V101, P9193, DOI 10.1073/pnas.0400187101
   Jeong KJ, 2007, P NATL ACAD SCI USA, V104, P8247, DOI 10.1073/pnas.0702650104
   Jung ST, 2007, BIOTECHNOL BIOENG, V98, P39, DOI 10.1002/bit.21405
   KAKUK TJ, 1977, AVIAN DIS, V21, P280, DOI 10.2307/1589347
   Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000
   Malik MW, 2006, J VET SCI, V7, P43, DOI 10.4142/jvs.2006.7.1.43
   Muller H, 2012, AVIAN PATHOL, V41, P133, DOI 10.1080/03079457.2012.661403
   Pantin-Jackwood MJ, 2003, AVIAN DIS, V47, P681, DOI 10.1637/7018
   Qi JY, 2012, INT IMMUNOPHARMACOL, V14, P770, DOI 10.1016/j.intimp.2012.10.005
   Staak C., 1996, ALTEX S, V13, P73
   Staneloudi C, 2007, IMMUNOLOGY, V120, P512, DOI 10.1111/j.1365-2567.2006.02522.x
   Xu LM, 2014, BIOTECHNOL LETT, V36, P1029, DOI 10.1007/s10529-014-1463-z
   Xu Li-ming, 2011, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V27, P1090
   Xu YP, 2011, BIOTECHNOL ADV, V29, P860, DOI 10.1016/j.biotechadv.2011.07.003
NR 21
TC 1
Z9 2
U1 2
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD SEP
PY 2015
VL 424
BP 80
EP 84
DI 10.1016/j.jim.2015.05.003
PG 5
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA CS1SV
UT WOS:000361848900010
PM 26003676
DA 2018-12-27
ER

PT J
AU Diogo, R
   Ziermann, JM
AF Diogo, Rui
   Ziermann, Janine M.
TI RETRACTED: Development, metamorphosis, morphology, and diversity: The
   evolution of chordate muscles and the origin of vertebrates (Retracted
   article. See vol. 244, pg. 1179, 2015)
SO DEVELOPMENTAL DYNAMICS
LA English
DT Review; Retracted Publication
DE amphioxus; cephalochordates; urochordates; cyclostomes; gnathostomes;
   life history; heterochrony; paedomorphosis; peramorphosis
ID FORELIMB-HINDLIMB ENIGMA; NEURAL CREST CELLS; 2ND HEART FIELD;
   CRANIOFACIAL MUSCLES; LAMPREY METAMORPHOSIS; AMBYSTOMA-MEXICANUM;
   AMPHIOXUS; MORPHOGENESIS; DERIVATIVES; TUNICATES
AB Recent findings that urochordates are the closest sister-group of vertebrates have dramatically changed our understanding of chordate evolution and vertebrate origins. To continue to deepen our understanding of chordate evolution and diversity, in particular the morphological and taxonomical diversity of the vertebrate clade, one must explore the origin, development, and comparative anatomy of not only hard tissues, but also soft tissues such as muscles. Building on a recent overview of the discovery of a cardiopharyngeal field in urochordates and the profound implications for reconstructing the origin and early evolution of vertebrates, in this study we focus on the broader comparative and developmental anatomy of chordate cephalic muscles and their relation to life history, and to developmental, morphological and taxonomical diversity. We combine our recent findings on cephalochordates, urochordates, and vertebrates with a literature review and suggest that developmental changes related to metamorphosis and/or heterochrony (e.g., peramorphosis) played a crucial role in the early evolution of chordates and vertebrates. Recent studies reviewed here supported de Beer's law of diversity that peramorphic animals (e.g., ascidians, lampreys) are taxonomically and morphologically less diverse than nonperamorphic animals (e.g., gnathostomes), probably because their too specialized development and adult anatomy constrain further developmental and evolutionary innovations. (c) 2014 Wiley Periodicals, Inc.
C1 [Diogo, Rui; Ziermann, Janine M.] Howard Univ, Dept Anat, Coll Med, Washington, DC 20059 USA.
RP Diogo, R (reprint author), Howard Univ, Dept Anat, Coll Med, 520 W St NW, Washington, DC 20059 USA.
EM rui.diogo@howard.edu
FU Howard University College of Medicine
FX We thank Shigeru Kuratani and Tetsuto Miyashita in particular for
   discussions on issues reviewed in this study. Research by J.M.Z. and
   R.D. has been supported by a start-up package from the Howard University
   College of Medicine.
CR Darwin C., 1871, DESCENT MAN SELECTIO
   Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336
   desBeer G., 1940, EMBRYOS ANCESTORS
   Diogo R, 2010, MUSCLES VERTEBRATES
   Diogo R, 2015, NATURE, V520, P466, DOI 10.1038/nature14435
   Diogo R, 2014, J EXP ZOOL PART B, V322, P106, DOI 10.1002/jez.b.22552
   Diogo R, 2014, J EXP ZOOL PART B, V322, P86, DOI 10.1002/jez.b.22549
   Diogo R, 2013, BIOL REV, V88, P196, DOI 10.1111/j.1469-185X.2012.00247.x
   Diogo R, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-24
   Edgeworth F. H., 1935, CRANIAL MUSCLES VERT
   Elinson RP, 2013, CURR TOP DEV BIOL, V103, P259, DOI 10.1016/B978-0-12-385979-2.00009-5
   FRITZSCH B, 1993, ACTA ANAT, V148, P96
   GANS C, 1989, BIOL REV, V64, P221, DOI 10.1111/j.1469-185X.1989.tb00471.x
   GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268
   Garstang W, 1929, Q J MICROSC SCI, V72, P51
   Gee H, 2001, SYST ASSOC SPEC VOL, V61, P1
   GEE H, 1996, BACKBONE VIEWS ORIGI
   Gegenbaur C., 1878, ELEMENTS COMP ANATOM
   Gillis JA, 2012, P ROY SOC B-BIOL SCI, V279, P237, DOI 10.1098/rspb.2011.0599
   Gillis JA, 2009, P NATL ACAD SCI USA, V106, P5720, DOI 10.1073/pnas.0810959106
   Gould S. J., 1977, ONTOGENY PHYLOGENY
   Graham A, 2013, J ANAT, V222, P32, DOI 10.1111/j.1469-7580.2012.01506.x
   Hall BK, 2007, J HUM EVOL, V52, P473, DOI 10.1016/j.jhevol.2006.11.010
   Hall BK, 2013, J ANAT, V222, P19, DOI 10.1111/j.1469-7580.2012.01495.x
   Hall BK, 2013, DEV PSYCHOBIOL, V55, P4, DOI 10.1002/dev.21039
   Hardisty M. W., 2006, LAMPREYS LIFE JAWS
   Harel I, 2013, CRANIOFACIAL MUSCLES, P11
   Heimberg AM, 2010, P NATL ACAD SCI USA, V107, P19379, DOI 10.1073/pnas.1010350107
   Heyland A, 2005, BIOESSAYS, V27, P64, DOI 10.1002/bies.20136
   Holland LZ, 2008, INTEGR COMP BIOL, V48, P630, DOI 10.1093/icb/icn060
   Holland LZ, 2015, J EXP ZOOL PART B, V324, P342, DOI 10.1002/jez.b.22569
   HOLLAND ND, 1993, DEV GROWTH DIFFER, V35, P153
   JEFFERIES RPS, 1986, ANCESTRY VERTEBRATES
   JORGENSEN JM, 1998, BIOL HAGFISHES
   Knight RD, 2011, DEVELOPMENT, V138, P2015, DOI 10.1242/dev.061002
   Kontges G, 1996, DEVELOPMENT, V122, P3229
   Kuratani S, 2004, J EXP ZOOL PART B, V302B, P458, DOI 10.1002/jez.b.21011
   Kuratani S, 2002, GENESIS, V34, P175, DOI 10.1002/gene.10142
   Kuratani S, 2013, J ANAT, V222, P41, DOI 10.1111/j.1469-7580.2012.01505.x
   Kusakabe R, 2011, DEV BIOL, V350, P217, DOI 10.1016/j.ydbio.2010.10.029
   Lemaire P, 2011, DEVELOPMENT, V138, P2143, DOI 10.1242/dev.048975
   Lescroart Fabienne, 2012, Results Probl Cell Differ, V55, P263, DOI 10.1007/978-3-642-30406-4_15
   Lescroart F, 2010, DEVELOPMENT, V137, P3269, DOI 10.1242/dev.050674
   Lours-Calet C, 2014, DEV BIOL, V390, P231, DOI 10.1016/j.ydbio.2014.03.003
   Mahadevan NR, 2004, DEV GENES EVOL, V214, P559, DOI 10.1007/s00427-004-0433-1
   Mallatt J, 2003, J MORPHOL, V258, P1, DOI 10.1002/jmor.10081
   Mallatt J, 2008, ZOOL SCI, V25, P990, DOI 10.2108/zsj.25.990
   Marinelli W., 1954, P1
   Marinelli W., 1956, VERGLEICHENDE ANATOM, P81
   Matsuoka T, 2005, NATURE, V436, P347, DOI 10.1038/nature03837
   Mazet F, 2005, DEV BIOL, V282, P494, DOI 10.1016/j.ydbio.2005.02.021
   McNamara K.J., 1990, P59
   MCNAMARA KJ, 1986, J PALEONTOL, V60, P4, DOI 10.1017/S0022336000021454
   Minchin JEN, 2013, DEVELOPMENT, V140, P2972, DOI 10.1242/dev.090050
   Miyashita T., 2012, THESIS U ALBERTA EDM
   Miyashita T, 2016, BIOL REV, V91, P611, DOI 10.1111/brv.12187
   Nelson J. S., 2006, FISHES WORLD
   NODEN DM, 1986, DEV BIOL, V116, P347, DOI 10.1016/0012-1606(86)90138-7
   NODEN DM, 1983, AM J ANAT, V168, P257, DOI 10.1002/aja.1001680302
   Noden DM, 2006, ADV EXP MED BIOL, V589, P1
   Noden DM, 2006, DEV DYNAM, V235, P1194, DOI 10.1002/dvdy.20697
   Northcutt RG, 2005, J EXP ZOOL PART B, V304B, P274, DOI 10.1002/jez.b.21063
   Oisi Y, 2013, ZOOL SCI, V30, P944, DOI 10.2108/zsj.30.944
   Oisi Y, 2013, NATURE, V493, P175, DOI 10.1038/nature11794
   Paris M, 2008, CURR BIOL, V18, P825, DOI 10.1016/j.cub.2008.04.078
   Paris M, 2010, INTEGR COMP BIOL, V50, P63, DOI 10.1093/icb/icq052
   Paris M, 2008, GENESIS, V46, P657, DOI 10.1002/dvg.20443
   Piekarski N, 2007, EVOL DEV, V9, P566, DOI 10.1111/j.1525-142X.2007.00197.x
   Piotrowski T, 2000, DEV BIOL, V225, P339, DOI 10.1006/dbio.2000.9842
   Presley R, 1996, ISR J ZOOL, V42, pS97
   Prunotto C, 2004, DEV DYNAM, V231, P582, DOI 10.1002/dvdy.20177
   Rose CS, 2005, TRENDS ECOL EVOL, V20, P129, DOI 10.1016/j.tree.2005.01.005
   Sambasivan R, 2011, DEVELOPMENT, V138, P2401, DOI 10.1242/dev.040972
   Sauka-Spengler Tatjana, 2002, Gene Expression Patterns, V2, P99, DOI 10.1016/S0925-4773(02)00301-5
   Shearman RM, 2009, J EXPT BIOL MOL DE B, V312B, P602
   STOKES MD, 1995, BIOL BULL, V188, P231, DOI 10.2307/1542300
   Stolfi A, 2010, SCIENCE, V329, P565, DOI 10.1126/science.1190181
   Tulenko FJ, 2013, P NATL ACAD SCI USA, V110, P11899, DOI 10.1073/pnas.1304210110
   Valentine J. W, 2004, ORIGIN PHYLA
   Vargas AO, 2005, EVOL DEV, V7, P171, DOI 10.1111/j.1525-142X.2005.05029.x
   Willey A, 1894, AMPHIOXUS ANCESTRY V
   YALDEN DW, 1985, ZOOL J LINN SOC-LOND, V84, P291, DOI 10.1111/j.1096-3642.1985.tb01802.x
   Yasui K, 2014, J MORPHOL, V275, P465, DOI 10.1002/jmor.20228
   Youson JH, 1997, AM ZOOL, V37, P441
   YOUSON JH, 1980, CAN J FISH AQUAT SCI, V37, P1687, DOI 10.1139/f80-216
   Zhu M, 2013, NATURE, V502, P188, DOI 10.1038/nature12617
   Ziermann JM, 2014, ZOOL J LINN SOC-LOND, V172, P771, DOI 10.1111/zoj.12186
   Ziermann JM, 2014, J MORPHOL, V275, P398, DOI 10.1002/jmor.20223
   Ziermann JM, 2013, ANAT REC, V296, P1031, DOI 10.1002/ar.22713
NR 89
TC 8
Z9 8
U1 4
U2 61
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1058-8388
EI 1097-0177
J9 DEV DYNAM
JI Dev. Dyn.
PD SEP
PY 2015
VL 244
IS 9
SI SI
BP 1046
EP 1057
DI 10.1002/DVDY.24245
PG 12
WC Anatomy & Morphology; Developmental Biology
SC Anatomy & Morphology; Developmental Biology
GA CQ1OI
UT WOS:000360366700003
PM 26095777
OA Bronze
DA 2018-12-27
ER

PT J
AU Shen, ZT
   Wu, XH
   Li, B
   Shen, JS
   Wang, Z
   Li, J
   Zhu, XX
AF Shen, Ze-Tian
   Wu, Xin-Hu
   Li, Bing
   Shen, Jun-shu
   Wang, Zhen
   Li, Jing
   Zhu, Xi-Xu
TI RETRACTED: CYP2E1 Rsa/Pst polymorphism and lung cancer susceptibility: a
   meta-analysis involving 10,947 subjects (Retracted article. See vol. 22,
   pg. 3703, 2018)
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article; Retracted Publication
DE CYP2E1; polymorphism; lung cancer; susceptibility; meta-analysis
ID SQUAMOUS-CELL CARCINOMA; HUMAN LIVER-MICROSOMES; GENETIC POLYMORPHISMS;
   N-NITROSODIALKYLAMINES; JAPANESE POPULATION; POOLED-ANALYSIS; RISK;
   TOBACCO; CYP1A1; GSTM1
AB Many studies have examined the association between the CYP2E1 Rsa /Pst (rs3813867) polymorphism gene polymorphisms and lung cancer risk in various populations, but their results have been inconsistent. The PubMed and CNKI database was searched for case-control studies published up to October 2013. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. In this meta-analysis, we assessed 23 published studies involving comprising 4727 lung cancer cases and 6220 controls of the association between CYP2E1 Rsa /Pst polymorphism and lung cancer risk. For the homozygote c2/c2 and c2 allele carriers (c1/c2 + c2/c2), the pooled ORs for all studies were 0.73(95% CI=0.62-0.84; P=0.005 for heterogeneity) and 0.84 (95% CI=0.77-0.92; P=0.001 for heterogeneity) when compared with the homozygous wild-type genotype (c1/c1). In the stratified analysis by ethnicity, the same significantly risks were found among Asians and mixed population for both the c2 allele carriers and homozygote c2/c2. However, no significant associations were found in Caucasian population all genetic models. This updated meta-analysis suggests that CYP2E1 Rsa /Pst c2 allele is a decreased risk factor for the developing lung cancer among Asians and mixed population.
C1 [Shen, Ze-Tian; Wu, Xin-Hu; Li, Bing; Shen, Jun-shu; Wang, Zhen; Li, Jing; Zhu, Xi-Xu] Nanjing Univ, Sch Med, Jinling Hosp, Dept Radiat Oncol, Nanjing 210008, Jiangsu, Peoples R China.
RP Zhu, XX (reprint author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Radiat Oncol, Nanjing 210008, Jiangsu, Peoples R China.
EM zhuxxnj@163.com
CR Alberg AJ, 2003, CHEST, V123, p21S, DOI 10.1378/chest.123.1_suppl.21S
   Bellec G, 1996, CARCINOGENESIS, V17, P2029, DOI 10.1093/carcin/17.9.2029
   Cao L, 2014, TUMOR BIOL, V35, P455, DOI 10.1007/s13277-013-1063-x
   Carlsten C, 2008, AM J EPIDEMIOL, V167, P759, DOI 10.1093/aje/kwm383
   COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eom SY, 2009, CANCER CAUSE CONTROL, V20, P137, DOI 10.1007/s10552-008-9225-7
   Gu Yan-Fei, 2007, Zhonghua Yi Xue Za Zhi, V87, P3064
   HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   HOFFMANN D, 1985, CANCER RES, V45, P935
   Huang Y, 2000, CHIN J CLIN PHARM, V16, P350
   KATO S, 1992, CANCER RES, V52, P6712
   Le Marchand L, 1998, CANCER RES, V58, P4858
   Le Marchand LC, 2003, CANCER CAUSE CONTROL, V14, P339
   Lee KM, 2006, ONCOL REP, V16, P1035
   [李代蓉 LI Dairong], 2008, [第三军医大学学报, Acta Academiae Medicinae Militaris Tertiae], V30, P1231
   Li WY, 2012, LUNG, V190, P91, DOI 10.1007/s00408-011-9338-8
   Li Zhishan, 2000, Zhonghua Zhongliu Zazhi, V22, P5
   [梁戈玉 Liang Geyu], 2004, [遗传, Hereditas(Beijing)], V26, P584
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Minegishi Y, 2007, CANCER-AM CANCER SOC, V110, P353, DOI 10.1002/cncr.22795
   Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584
   Oyama T, 1997, ANTICANCER RES, V17, P583
   PERSSON I, 1993, FEBS LETT, V319, P207, DOI 10.1016/0014-5793(93)80547-8
   Qu YH, 1998, CARCINOGENESIS TERAT, V10, P355
   Quinones L, 2001, CANCER LETT, V174, P35, DOI 10.1016/S0304-3835(01)00686-3
   Raimondi S, 2006, AM J EPIDEMIOL, V164, P1027, DOI 10.1093/aje/kwj321
   Rodriguez C, 1997, EPIDEMIOLOGY, V8, P653, DOI 10.1097/00001648-199710000-00007
   SATO S, 1994, CANCER RES, V54, P5652
   [石云 Shi Yun], 2002, [华中科技大学学报. 医学版, Journal of Huazhong University of Science and Technology], V31, P14
   Tobias A, 1999, STATA TECH B, V47, P15
   Toh CK, 2006, J CLIN ONCOL, V24, P2245, DOI 10.1200/JCO.2005.04.8033
   UEMATSU F, 1991, JPN J CANCER RES, V82, P254, DOI 10.1111/j.1349-7006.1991.tb01838.x
   Wang DS, 2006, WSCG 2006: POSTERS PROCEEDINGS, P9
   Wang JW, 2003, CANCER SCI, V94, P448, DOI 10.1111/j.1349-7006.2003.tb01463.x
   Wang SL, 1999, LUNG CANCER-J IASLC, V26, P27, DOI 10.1016/S0169-5002(99)00070-7
   WATANABE J, 1995, JPN J CANCER RES, V86, P245, DOI 10.1111/j.1349-7006.1995.tb03046.x
   Wu XF, 1997, CARCINOGENESIS, V18, P967, DOI 10.1093/carcin/18.5.967
   YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789
   [叶蔚云 YE WeiYun], 2006, [肿瘤, Tumor], V26, P450
   Zienolddiny S, 2008, CARCINOGENESIS, V29, P1164, DOI 10.1093/carcin/bgn020
NR 43
TC 4
Z9 4
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD SEP
PY 2015
VL 19
IS 9
BP 2136
EP 2142
DI 10.1111/jcmm.12579
PG 7
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA CQ7EX
UT WOS:000360766900012
PM 25945422
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Nagarkar, AA
   Kilbinger, AFM
AF Nagarkar, Amit A.
   Kilbinger, Andreas F. M.
TI RETRACTED: Catalytic living ring-opening metathesis polymerization
   (Retracted article. See vol. 10, pg. 573, 2018)
SO NATURE CHEMISTRY
LA English
DT Article; Retracted Publication
ID HCV PROTEASE INHIBITOR; CATHEPSIN K-INHIBITOR; RUTHENIUM BY-PRODUCTS;
   LARGE-SCALE SYNTHESIS; OLEFIN METATHESIS; CLOSING METATHESIS;
   FUNCTIONALIZED POLY(NORBORNENE)S; RADICAL POLYMERIZATION; CONVENIENT
   METHOD; BLOCK-COPOLYMERS
AB In living ring-opening metathesis polymerization (ROMP), a transition-metal-carbene complex polymerizes ring-strained olefins with very good control of the molecular weight of the resulting polymers. Because one molecule of the initiator is required for each polymer chain, however, this type of polymerization is expensive for widespread use. We have now designed a chain-transfer agent (CTA) capable of reducing the required amount of metal complex while still maintaining full control over the living polymerization process. This new method introduces a degenerative transfer process to ROMP. We demonstrate that substituted cyclohexene rings are good CTAs, and thereby preserve the 'living' character of the polymerization using catalytic quantities of the metal complex. The resulting polymers show characteristics of a living polymerization, namely narrow molecular-weight distribution, controlled molecular weights and block copolymer formation. This new technique provides access to well-defined polymers for industrial, biomedical and academic use at a fraction of the current costs and significantly reduced levels of residual ruthenium catalyst.
C1 [Nagarkar, Amit A.; Kilbinger, Andreas F. M.] Univ Fribourg, Dept Chem, CH-1700 Fribourg, Switzerland.
RP Kilbinger, AFM (reprint author), Univ Fribourg, Dept Chem, Chemin Musee 9, CH-1700 Fribourg, Switzerland.
EM andreas.kilbinger@unifr.ch
RI Kilbinger, Andreas/F-4035-2018
OI Kilbinger, Andreas/0000-0002-2929-7499
FU Swiss National Science Foundation
FX The authors thank the Swiss National Science Foundation for funding.
CR Abraham S, 2006, J POLYM SCI POL CHEM, V44, P2774, DOI 10.1002/pola.21377
   Ahn YM, 2001, ORG LETT, V3, P1411, DOI 10.1021/ol010045k
   Ajellal N, 2010, DALTON T, V39, P8363, DOI 10.1039/c001226b
   Baughman TW, 2005, ADV POLYM SCI, V176, P1, DOI 10.1007/b101318
   Bielawski CW, 2007, PROG POLYM SCI, V32, P1, DOI 10.1016/j.progpolymsci.2006.08.006
   Bielawski CW, 2001, MACROMOLECULES, V34, P8610, DOI 10.1021/ma010878q
   Buchmeiser MR, 2009, CHEM REV, V109, P303, DOI 10.1021/cr800207n
   CALDERON N, 1976, ANGEW CHEM INT EDIT, V15, P401, DOI 10.1002/anie.197604011
   CALDERON N, 1972, ACCOUNTS CHEM RES, V5, P127, DOI 10.1021/ar50052a002
   Chemtob A, 2002, MACROMOLECULES, V35, P9262, DOI 10.1021/ma020871o
   Chiefari J, 1998, MACROMOLECULES, V31, P5559, DOI 10.1021/ma9804951
   Cho JH, 2003, ORG LETT, V5, P531, DOI 10.1021/ol027423l
   Clavier H, 2007, ANGEW CHEM INT EDIT, V46, P6786, DOI 10.1002/anie.200605099
   Committee for Medicinal Products for Human Use, 2008, GUID SPEC LIM RES ME
   Demel S, 2003, INORG CHIM ACTA, V345, P363, DOI 10.1016/S0020-1693(02)01285-9
   Farina V, 2009, ORG PROCESS RES DEV, V13, P250, DOI 10.1021/op800225f
   Galan BR, 2007, ORG LETT, V9, P1203, DOI 10.1021/ol0631399
   Gordon EJ, 1998, NATURE, V392, P30, DOI 10.1038/32073
   Hanik N, 2013, J POLYM SCI POL CHEM, V51, P4183, DOI 10.1002/pola.26832
   Herisson P. J.-L., 1970, MAKROMOL CHEM, V141, P161
   Hilf S, 2009, NAT CHEM, V1, P537, DOI [10.1038/nchem.347, 10.1038/NCHEM.347]
   IVIN KJ, 1997, OLEFIN METATHESIS ME
   Kang EH, 2011, J AM CHEM SOC, V133, P11904, DOI 10.1021/ja204309d
   Keitz BK, 2012, J AM CHEM SOC, V134, P2040, DOI 10.1021/ja211676y
   Kemp R, 2007, CHEM-EUR J, V13, P2764, DOI 10.1002/chem.200601842
   Knight DW, 2010, TETRAHEDRON LETT, V51, P638, DOI 10.1016/j.tetlet.2009.11.092
   Kovacic S, 2013, MACROMOL RAPID COMM, V34, P581, DOI 10.1002/marc.201200754
   Kovacic S, 2010, CHEM COMMUN, V46, P7504, DOI 10.1039/c0cc02610g
   Kreutzwiesner E, 2010, J POLYM SCI POL CHEM, V48, P4504, DOI 10.1002/pola.24241
   Lehman S. E., 2003, HDB METATHESIS, P283
   Lin YYA, 2009, CHEMBIOCHEM, V10, P959, DOI 10.1002/cbic.200900002
   LINDMARKHAMBERG M, 1987, MACROMOLECULES, V20, P2949, DOI 10.1021/ma00177a053
   Liu WD, 2009, TETRAHEDRON LETT, V50, P6103, DOI 10.1016/j.tetlet.2009.08.055
   Lober A, 2008, ANGEW CHEM INT EDIT, V47, P9138, DOI 10.1002/anie.200801872
   Manning DD, 1997, J AM CHEM SOC, V119, P3161, DOI 10.1021/ja964046x
   Matson JB, 2009, J AM CHEM SOC, V131, P3355, DOI 10.1021/ja809081h
   Maynard HD, 2000, MACROMOLECULES, V33, P6239, DOI 10.1021/ma000460c
   Maynard HD, 1999, TETRAHEDRON LETT, V40, P4137, DOI 10.1016/S0040-4039(99)00726-1
   Mayr B, 2001, ANAL CHEM, V73, P4071, DOI 10.1021/ac010452+
   Mayr M, 2005, ADV SYNTH CATAL, V347, P484, DOI 10.1002/adsc.200404197
   Mendez-Andino J, 2000, ORG LETT, V2, P1263, DOI 10.1021/ol000037o
   MORTELL KH, 1994, J AM CHEM SOC, V116, P12053, DOI 10.1021/ja00105a056
   Mortell KH, 1996, J AM CHEM SOC, V118, P2297, DOI 10.1021/ja953574q
   Nagarkar AA, 2014, CHEM SCI, V5, P4687, DOI 10.1039/c4sc02242d
   Nagarkar AA, 2012, MACROMOLECULES, V45, P4447, DOI 10.1021/ma300602p
   Nguyen S. T., 2003, HDB METATHESIS, V1, P61
   Paquette LA, 2000, ORG LETT, V2, P1259, DOI 10.1021/ol000036w
   Park H, 2013, J AM CHEM SOC, V135, P10769, DOI 10.1021/ja4039278
   Park H, 2012, J AM CHEM SOC, V134, P7270, DOI 10.1021/ja3017335
   Percec V, 1997, MACROMOLECULES, V30, P5783, DOI 10.1021/ma970157k
   PUGH C, 1992, MACROMOLECULES, V25, P6593, DOI 10.1021/ma00050a032
   Schrock R. R., 2015, HDB METATHESIS, V1, P1
   Schrock RR, 2014, ACCOUNTS CHEM RES, V47, P2457, DOI 10.1021/ar500139s
   Sommer WJ, 2007, COORDIN CHEM REV, V251, P860, DOI 10.1016/j.ccr.2006.07.004
   Song AR, 2009, J AM CHEM SOC, V131, P3444, DOI 10.1021/ja809661k
   Sveinbjornsson BR, 2012, P NATL ACAD SCI USA, V109, P14332, DOI 10.1073/pnas.1213055109
   Tan L, 2014, MACROMOLECULES, V47, P6572, DOI 10.1021/ma5012039
   Uchiyama M, 2015, ANGEW CHEM INT EDIT, V54, P1924, DOI 10.1002/anie.201410858
   Wang H, 2008, ORG PROCESS RES DEV, V12, P226, DOI 10.1021/op700288p
   Wang H, 2009, TETRAHEDRON, V65, P6291, DOI 10.1016/j.tet.2009.06.022
   Yee NK, 2006, J ORG CHEM, V71, P7133, DOI 10.1021/jo0285j
   Zha YP, 2012, J AM CHEM SOC, V134, P4493, DOI 10.1021/ja211365r
   Zhang YH, 2003, J AM CHEM SOC, V125, P9062, DOI 10.1021/ja029780x
NR 63
TC 19
Z9 19
U1 2
U2 93
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1755-4330
EI 1755-4349
J9 NAT CHEM
JI Nat. Chem.
PD SEP
PY 2015
VL 7
IS 9
BP 718
EP 723
DI 10.1038/NCHEM.2320
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA CP9CR
UT WOS:000360191800009
PM 26291943
DA 2018-12-27
ER

PT J
AU Simon, YC
   Weder, C
AF Simon, Yoan C.
   Weder, Christoph
TI RETRACTED: METAL-ORGANIC FRAMEWORKS Framing upconversion
   materials(Retracted article. See vol.16, pg.153,2017)
SO NATURE MATERIALS
LA English
DT News Item; Retracted Publication
ID DELAYED FLUORESCENCE
C1 [Simon, Yoan C.; Weder, Christoph] Univ Fribourg, Adolphe Merkle Inst, CH-1700 Fribourg, Switzerland.
RP Simon, YC (reprint author), Univ Fribourg, Adolphe Merkle Inst, CH-1700 Fribourg, Switzerland.
EM yoan.simon@unifr.ch; christoph.weder@unifr.ch
RI Simon, Yoan/B-3101-2012
OI Simon, Yoan/0000-0002-5235-6127; Merkle Institute,
   Adolphe/0000-0002-6220-424X; Weder, Christoph/0000-0001-7183-1790
CR Bagnich SA, 2003, CHEM PHYS LETT, V381, P464, DOI 10.1016/j.cplett.2003.09.140
   Goldschmidt JC, 2015, ADV OPT MATER, V3, P510, DOI 10.1002/adom.201500024
   Islangulov RR, 2007, J AM CHEM SOC, V129, P12652, DOI 10.1021/ja075014k
   Keivanidis PE, 2003, ADV MATER, V15, P2095, DOI 10.1002/adma.200305717
   Lee SH, 2015, J POLYM SCI POL CHEM, V53, P1629, DOI 10.1002/pola.27626
   Mahato P, 2015, NAT MATER, V14, P924, DOI [10.1038/NMAT4366, 10.1038/nmat4366]
   Ogawa T, 2015, SCI REP-UK, V5, DOI 10.1038/srep10882
   PARKER CA, 1962, P CHEM SOC LONDON, P386
NR 8
TC 9
Z9 9
U1 10
U2 162
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-1122
EI 1476-4660
J9 NAT MATER
JI Nat. Mater.
PD SEP
PY 2015
VL 14
IS 9
BP 864
EP 865
DI 10.1038/nmat4375
PG 2
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA CP9CT
UT WOS:000360192000013
PM 26237126
DA 2018-12-27
ER

PT J
AU Mahato, P
   Monguzzi, A
   Yanai, N
   Yamada, T
   Kimizuka, N
AF Mahato, Prasenjit
   Monguzzi, Angelo
   Yanai, Nobuhiro
   Yamada, Teppei
   Kimizuka, Nobuo
TI RETRACTED: Fast and long-range triplet exciton diffusion in
   metal-organic frameworks for photon upconversion at ultralow excitation
   power (Retracted article. See vol. 16, pg. 153, 2017)
SO NATURE MATERIALS
LA English
DT Article; Retracted Publication
ID LOW-POWER; ENERGY-TRANSFER; ANNIHILATION; LIGHT; POLYMERS;
   PHOTOCATALYSIS; LUMINESCENCE; MIGRATION; CRYSTALS; SYSTEMS
AB The conversion of low-energy light into photons of higher energy based on sensitized triplet-triplet annihilation upconversion (TTA-UC) has emerged as a promising wavelength-shifting methodology because it permits UC at excitation powers as low as the solar irradiance. However, its application has been significantly hampered by the slow diffusion of excited molecules in solid matrices. Here, we introduce metal-organic frameworks (MOFs) that promote TTA-UC by taking advantage of triplet exciton migration among fluorophores that are regularly aligned with spatially controlled chromophore orientations. We synthesized anthracene-containing MOFs with different molecular orientations, and the analysis of TTA-UC emission kinetics unveiled a high triplet diffusion rate with a micrometre-scale diffusion length. Surface modification of MOF nanocrystals with donor molecules and their encapsulation in glassy poly(methyl methacrylate) (PMMA) allowed the construction of molecular-diffusion-free solid-state upconverters, which lead to an unprecedented maximization of overall UC quantum yield at excitation powers comparable to or well below the solar irradiance.
C1 [Mahato, Prasenjit; Yanai, Nobuhiro; Yamada, Teppei; Kimizuka, Nobuo] Kyushu Univ, Dept Chem & Biochem, Grad Sch Engn, CMS, Fukuoka 8190395, Japan.
   [Monguzzi, Angelo] Univ Milano Bicocca, Dipartimento Sci Mat, I-20135 Milan, Italy.
   [Yanai, Nobuhiro; Yamada, Teppei] JST, PRESTO, Kawaguchi, Saitama 3320012, Japan.
RP Yanai, N (reprint author), Kyushu Univ, Dept Chem & Biochem, Grad Sch Engn, CMS, Fukuoka 8190395, Japan.
EM yanai@mail.cstm.kyushu-u.ac.jp; n-kimi@mail.cstm.kyushu-u.ac.jp
RI U-ID, Kyushu/C-5291-2016; Monguzzi, Angelo/K-1692-2016
OI Monguzzi, Angelo/0000-0001-9768-4573
FU Ministry of Education, Culture Sports, Science and Technology of Japan
   [25220805, 26810036, 26104529]; JSPS-NSF International Collaborations in
   Chemistry (ICC) program; Noguchi Institute; JSPS postdoctoral
   fellowships
FX This work was partly supported by a Grants-in-Aid for Scientific
   Research (S) (25220805), a Grants-in-Aid for Young Scientists (B)
   (26810036), a Grant-in-Aid for Scientific Research on Innovative Area
   (26104529) from the Ministry of Education, Culture Sports, Science and
   Technology of Japan, the JSPS-NSF International Collaborations in
   Chemistry (ICC) program, and a research grant from The Noguchi
   Institute. P.M. and A.M. acknowledge JSPS postdoctoral fellowships for
   foreign researchers. The authors acknowledge M.-a. Morikawa and R.
   Yoshida in Kyushu University for their help in TEM measurements.
CR Baluschev S, 2007, J APPL PHYS, V101, DOI 10.1063/1.2409618
   Baluschev S, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.143903
   Cheng YY, 2010, PHYS CHEM CHEM PHYS, V12, P66, DOI 10.1039/b913243k
   Deria P, 2014, CHEM SOC REV, V43, P5896, DOI [10.1039/c4cs00067f, 10.1039/C4CS00067F]
   Duan PF, 2015, J AM CHEM SOC, V137, P1887, DOI 10.1021/ja511061h
   Duan PF, 2013, J AM CHEM SOC, V135, P19056, DOI 10.1021/ja411316s
   ERN V, 1969, PHYS REV LETT, V22, P343, DOI 10.1103/PhysRevLett.22.343
   Ferey G, 2009, CHEM SOC REV, V38, P1380, DOI 10.1039/b804302g
   Furukawa H, 2013, SCIENCE, V341, P974, DOI 10.1126/science.1230444
   Furukawa S, 2014, CHEM SOC REV, V43, P5700, DOI 10.1039/c4cs00106k
   Gray V, 2014, PHYS CHEM CHEM PHYS, V16, P10345, DOI 10.1039/c4cp00744a
   Grisanti L, 2013, PHYS REV B, V88, DOI 10.1103/PhysRevB.88.035450
   Haefele A, 2012, J PHYS CHEM LETT, V3, P299, DOI 10.1021/jz300012u
   Hauptvogel IM, 2011, INORG CHEM, V50, P8367, DOI 10.1021/ic200937u
   INOKUTI M, 1965, J CHEM PHYS, V43, P1978, DOI 10.1063/1.1697063
   Islangulov RR, 2007, J AM CHEM SOC, V129, P12652, DOI 10.1021/ja075014k
   Jiang Z, 2013, J AM CHEM SOC, V135, P16446, DOI 10.1021/ja406020r
   JORTNER J, 1963, PHYS REV LETT, V11, P323, DOI 10.1103/PhysRevLett.11.323
   Kent CA, 2012, J AM CHEM SOC, V134, P3991, DOI 10.1021/ja211271m
   Kent CA, 2011, J AM CHEM SOC, V133, P12940, DOI 10.1021/ja204214t
   Kent CA, 2010, J AM CHEM SOC, V132, P12767, DOI 10.1021/ja102804s
   Kim JH, 2012, J AM CHEM SOC, V134, P17478, DOI 10.1021/ja308789u
   Kim JH, 2012, CHEM MATER, V24, P2250, DOI 10.1021/cm3012414
   Kitagawa S, 2004, ANGEW CHEM INT EDIT, V43, P2334, DOI 10.1002/anie.200300610
   Kohler A, 2011, J MATER CHEM, V21, P4003, DOI 10.1039/c0jm02886j
   Kondo M, 2010, ANGEW CHEM INT EDIT, V49, P5327, DOI 10.1002/anie.201001063
   Li JR, 2012, CHEM REV, V112, P869, DOI 10.1021/cr200190s
   Lin JDA, 2014, MATER HORIZONS, V1, P280, DOI 10.1039/c3mh00089c
   Lin JX, 2013, J PHYS CHEM C, V117, P22250, DOI 10.1021/jp401515r
   Liu Q, 2013, J AM CHEM SOC, V135, P5029, DOI 10.1021/ja3104268
   Monguzzi A, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.195112
   Monguzzi A, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.155122
   Monguzzi A, 2013, ADV ENERGY MATER, V3, P680, DOI 10.1002/aenm.201200897
   Monguzzi A, 2012, PHYS CHEM CHEM PHYS, V14, P4322, DOI 10.1039/c2cp23900k
   Pope M., 1982, ELECT PROCESSES ORGA
   Quarti C, 2011, PHYS CHEM CHEM PHYS, V13, P18615, DOI 10.1039/c1cp21246j
   Scholes GD, 2003, ANNU REV PHYS CHEM, V54, P57, DOI 10.1146/annurev.physchem.54.011002.103746
   Simon YC, 2012, J MATER CHEM, V22, P20817, DOI 10.1039/c2jm33654e
   Sindoro M, 2014, ACCOUNTS CHEM RES, V47, P459, DOI 10.1021/ar400151n
   Singh-Rachford TN, 2010, COORDIN CHEM REV, V254, P2560, DOI 10.1016/j.ccr.2010.01.003
   Son HJ, 2013, J AM CHEM SOC, V135, P862, DOI 10.1021/ja310596a
   Trupke T, 2002, J APPL PHYS, V92, P4117, DOI 10.1063/1.1505677
   Wei ZW, 2014, J AM CHEM SOC, V136, P8269, DOI 10.1021/ja5006866
   Yaghi OM, 2003, NATURE, V423, P705, DOI 10.1038/nature01650
   Yanai N, 2012, ANGEW CHEM INT EDIT, V51, P5638, DOI 10.1002/anie.201109132
   Zhang C, 2010, CHEM COMMUN, V46, P4959, DOI 10.1039/c0cc00347f
   ZHANG GH, 1995, J PHYS CHEM-US, V99, P11203, DOI 10.1021/j100028a023
   Zhang T, 2014, CHEM SOC REV, V43, P5982, DOI 10.1039/c4cs00103f
   Zhao JZ, 2011, RSC ADV, V1, P937, DOI 10.1039/c1ra00469g
NR 49
TC 82
Z9 83
U1 23
U2 429
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-1122
EI 1476-4660
J9 NAT MATER
JI Nat. Mater.
PD SEP
PY 2015
VL 14
IS 9
BP 924
EP +
DI 10.1038/NMAT4366
PG 8
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA CP9CT
UT WOS:000360192000027
PM 26237125
DA 2018-12-27
ER

PT J
AU Gonchenko, AS
   Gonchenko, SV
AF Gonchenko, A. S.
   Gonchenko, S. V.
TI RETRACTED: Lorenz-like attractors in a nonholonomic model of a
   rattleback (Retracted article. See vol. 30, pg. C3-C3, 2017)
SO NONLINEARITY
LA English
DT Article; Retracted Publication
DE strange attractor; Lorenz attractor; Celtic stone; bifurcation
ID STRANGE ATTRACTORS; DYNAMICS; PLANE; MAPS
AB We study chaotic dynamics in a nonholonomic model of a rattleback stone. We show that, for certain values of parameters that characterise geometrical and physical properties of the stone, a strange Lorenz-like attractor is observed in the model. We also study bifurcation scenarios for the appearance and break-down of this attractor.
C1 [Gonchenko, A. S.; Gonchenko, S. V.] Nizhnii Novgorod State Univ, Nizhnii Novgorod, Russia.
RP Gonchenko, AS (reprint author), Nizhnii Novgorod State Univ, Nizhnii Novgorod, Russia.
EM agonchenko@mail.ru
RI Gonchenko, Alexander/F-8349-2017
FU Russian Scientific Foundation [14-41-00044]; RFBR [13-01-00589,
   14-01-00344]; RSciF-grant [14-12-00811]; Russian Ministry of Education
   and Science
FX The authors are grateful to M Malkin for fruitful discussions and useful
   comments. This work has been partially supported by the Russian
   Scientific Foundation Grant 14-41-00044 and the RFBR grants 13-01-00589
   and 14-01-00344. Section 3 was carried out by the RSciF-grant (project
   No. 14-12-00811). A Gonchenko is supported by basic funding from the
   Russian Ministry of Education and Science.
CR Afraimovich V. S., 1977, Soviet Physics - Doklady, V22, P253
   Afraimovich V. S., 1982, T MOSCOW MATH SOC, V44, P153
   Aframovich V S, 1983, NONLINEAR DYNAMICS T
   Anosov D. V., 1967, P STEKLOV I MATH, V90, P3
   ASTAPOV IS, 1980, VESTN MOSK U MAT M+, P97
   BONATTI C., 2005, ENCY MATH SCI, V102
   Borisov A. V., 2014, Russian Journal of Nonlinear Dynamics, V10, P361
   Borisov A V, 2002, NONHOLONOMIC DYNAMIC, P296
   Borisov A V, 2001, MOSC IZHEVSK REGULAR
   Borisov AV, 2012, REGUL CHAOTIC DYN, V17, P512, DOI 10.1134/S1560354712060044
   Borisov AV, 2003, PHYS-USP+, V46, P393, DOI 10.1070/PU2003v046n04ABEH001306
   CAUGHEY TK, 1980, INT J NONLINEAR MECH, V15, P293, DOI 10.1016/0020-7462(80)90014-1
   Franti L, 2013, CENT EUR J PHYS, V11, P162, DOI 10.2478/s11534-012-0161-5
   Gonchenko A. S., 2012, Russian Journal of Nonlinear Dynamics, V8, P507
   Gonchenko A S, 2014, INT J BIFURCAT CHAOS, V24, P25, DOI DOI 10.1142/50218127414400057
   Gonchenko A S, 2013, MATH MODEL NAT PHENO, V8, P80
   Gonchenko A S, 2015, RUSS NONLINEAR DYN, V11, P447
   [Гонченко Александр Сергеевич Gonchenko Alexander S.], 2012, [Нелинейная динамика, Russian Journal of Nonlinear Dynamics, Nelineinaya dinamika], V8, P3
   Gonchenko AS, 2013, REGUL CHAOTIC DYN, V18, P521, DOI 10.1134/S1560354713050055
   Gonchenko SV, 2006, REGUL CHAOTIC DYN, V11, P191, DOI 10.1070/RD2006v011n02ABEH000345
   Gonchenko SV, 2005, INT J BIFURCAT CHAOS, V15, P3493, DOI 10.1142/S0218127405014180
   Guckenheimer J., 1979, I HAUTES ETUDES SCI, V50, P59, DOI [10.1007/BF02684769, DOI 10.1007/BF02684769]
   Hanias M, 2014, SCI WORLD J, DOI 10.1155/2014/569386
   KANE TR, 1982, INT J NONLINEAR MECH, V17, P175, DOI 10.1016/0020-7462(82)90017-8
   Karapetyan A. V., 1981, APPL MATH MECH, V45, P808
   Kazakov AO, 2013, REGUL CHAOTIC DYN, V18, P508, DOI 10.1134/S1560354713050043
   LINDBERG RE, 1983, ACTA MECH, V49, P81, DOI 10.1007/BF01181756
   Markeev A P, 2011, MOSC IZHEVSK REGULAR
   Markeev A. P, 1983, PMM-J APPL MATH MEC, V47, P473
   Newhouse S. E., 1979, PUBL MATH-PARIS, V50, P101, DOI DOI 10.1007/BF02684771
   [Сатаев Е.А. Sataev E.A.], 2010, [Нелинейная динамика, Russian Journal of Nonlinear Dynamics, Nelineinaya dinamika], V6, P187
   Shil'nikov AL, 1993, INT J BIFURCAT CHAOS, V3, P1123, DOI 10.1142/S0218127493000933
   SHILNIKOV AL, 1993, PHYSICA D, V62, P338, DOI 10.1016/0167-2789(93)90292-9
   Shilnikov L P, 1980, BIFURKATSIYA ROZHDEN, P317
   Turaev DV, 2008, DOKL MATH, V77, P17, DOI 10.1134/S1064562408010055
   Turaev DV, 1998, SB MATH+, V189, P291, DOI 10.1070/SM1998v189n02ABEH000300
NR 36
TC 3
Z9 3
U1 2
U2 11
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0951-7715
EI 1361-6544
J9 NONLINEARITY
JI Nonlinearity
PD SEP
PY 2015
VL 28
IS 9
BP 3403
EP 3417
DI 10.1088/0951-7715/28/9/3403
PG 15
WC Mathematics, Applied; Physics, Mathematical
SC Mathematics; Physics
GA CQ3KD
UT WOS:000360499900016
DA 2018-12-27
ER

PT J
AU Paidar, M
   Khodabandeh, A
   Najafi, H
   Rouh-aghdam, AS
AF Paidar, Moslem
   Khodabandeh, Alireza
   Najafi, Hamidreza
   Rouh-aghdam, Alireza Sabour
TI RETRACTED: An investigation on mechanical and metallurgical properties
   of 2024-T3 aluminum alloy spot friction welds (Retracted article. See
   vol. 91, pg. 4383, 2017)
SO INTERNATIONAL JOURNAL OF ADVANCED MANUFACTURING TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Microhardness; Pin geometry; Spot friction welding; Stir zone; Tensile
   shear load
ID TOOL GEOMETRY; FAILURE MECHANISMS; STATIC STRENGTH; SHEETS;
   MICROSTRUCTURE; PARAMETERS; MODES
AB In this study, the spot friction welding of 2024-T3 aluminum alloy with 1.6 mm in thickness has been investigated. The effects of the tool rotational speed (630, 1000, and 1600 rpm), shoulder penetration depth (0.3 and 0.7 mm), and pin geometry (cylindrical and triangular shape) have been discussed on the metallurgical and mechanical properties. Results indicated that the pin geometry has a considerable effect on the shape of the stir zone. The results of tensile shear tests showed that the tensile shear load increased with increasing rotational speed in the shoulder penetration depth of 0.3 mm, while high shoulder penetration depth had a bilateral effect on the tensile shear load. In addition, the results showed that the tensile shear load of welds made with the triangular pin at a low rotational speed, and a low shoulder penetration depth was more than of welds made with the cylindrical one, which was attributed to a finer grain size generated in the stir zone. Observation of the failed specimens indicated two types of failure modes under tensile shear loading conditions including the fractures that occurred in the vicinity of keyhole (shear fracture) and the fractures that occurred in shoulder indentation (tensile shear-mixed fracture mode). The microhardness tests with both pins showed that the minimum hardness was measured in the heat-affected zone.
C1 [Paidar, Moslem] Islamic Azad Univ, Dept Mat Engn, South Tehran Branch, Tehran, Iran.
   [Khodabandeh, Alireza; Najafi, Hamidreza] Islamic Azad Univ, Dept Mat Engn, Sci & Res Branch, Tehran, Iran.
   [Rouh-aghdam, Alireza Sabour] Tarbiat Modares Univ, Dept Mat Engn, Tehran, Iran.
RP Paidar, M (reprint author), Islamic Azad Univ, Dept Mat Engn, South Tehran Branch, Tehran, Iran.
EM m.paidar@srbiau.ac.ir
FU Novin Sazan industrial group; Ms. Mahsa Laali Sarab
FX This work was supported by the Novin Sazan industrial group. The authors
   are grateful for their support during this project. The authors would
   like to thank Dr. Rasool Paidar, Mr. Ali Poshteban, and Mr. Amin Bagheri
   Dana for the beneficial discussions and Ms. Mahsa Laali Sarab for the
   financial support.
CR Addison A. C., 2004, P 5 INT FSW S METZ F
   Badarinarayan H, 2009, INT J MACH TOOL MANU, V49, P814, DOI 10.1016/j.ijmachtools.2009.06.001
   Badarinarayan H, 2009, INT J MACH TOOL MANU, V49, P142, DOI 10.1016/j.ijmachtools.2008.09.004
   Bilici MK, 2012, MATER DESIGN, V33, P545, DOI 10.1016/j.matdes.2011.04.062
   Bozzi S, 2010, J MATER PROCESS TECH, V210, P1429, DOI 10.1016/j.jmatprotec.2010.03.022
   Brooks CR, 1982, AM SOC MET, V4, P115
   Choi DH, 2010, MATER TRANS, V51, P1028, DOI 10.2320/matertrans.M2009405
   Fujimoto M, 2004, REPRINTS NATL ME JAP, V74, P6
   Hirasawa S, 2010, J MATER PROCESS TECH, V210, P1455, DOI 10.1016/j.jmatprotec.2010.04.003
   Lathabai S, 2006, SCRIPTA MATER, V55, P899, DOI 10.1016/j.scriptamat.2006.07.046
   Merzoug M, 2010, MATER DESIGN, V31, P3023, DOI 10.1016/j.matdes.2009.12.029
   Mitlin D, 2006, MAT SCI ENG A-STRUCT, V441, P79, DOI 10.1016/j.msea.2006.06.126
   Paidar M, 2014, J MECH SCI TECHNOL, V28, P4893, DOI 10.1007/s12206-014-1108-0
   Pan TY, 2004, P 5 INT S FRICT STIR
   Pathak N, 2013, J MATER ENG PERFORM, V22, P131, DOI 10.1007/s11665-012-0244-x
   Rosendo T, 2011, MATER DESIGN, V32, P1094, DOI 10.1016/j.matdes.2010.11.017
   Shen ZK, 2013, MATER DESIGN, V49, P181, DOI 10.1016/j.matdes.2013.01.066
   Su P, 2007, METALL MATER TRANS A, V38A, P584, DOI 10.1007/s11661-006-9067-4
   Sun YF, 2012, MATER DESIGN, V37, P384, DOI 10.1016/j.matdes.2012.01.027
   Tozaki Y, 2010, J MATER PROCESS TECH, V210, P844, DOI 10.1016/j.jmatprotec.2010.01.015
   Tozaki Y, 2007, INT J MACH TOOL MANU, V47, P2230, DOI 10.1016/j.ijmachtools.2007.07.005
   Tran VX, 2009, J MATER PROCESS TECH, V209, P3724, DOI 10.1016/j.jmatprotec.2008.08.028
   Wang DA, 2007, J MATER PROCESS TECH, V186, P291, DOI 10.1016/j.jmatprotec.2006.12.045
   Wang DA, 2010, J MATER PROCESS TECH, V210, P1942, DOI 10.1016/j.jmatprotec.2010.07.005
   Yang Q, 2008, P 7 INT S FRICT STIR
   Yin YH, 2010, J MATER PROCESS TECH, V210, P2062, DOI 10.1016/j.jmatprotec.2010.07.029
   Yuan W, 2011, J MATER PROCESS TECH, V211, P972, DOI 10.1016/j.jmatprotec.2010.12.014
   Zhang ZH, 2011, MATER DESIGN, V32, P4461, DOI 10.1016/j.matdes.2011.03.058
NR 28
TC 11
Z9 11
U1 3
U2 17
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268-3768
EI 1433-3015
J9 INT J ADV MANUF TECH
JI Int. J. Adv. Manuf. Technol.
PD SEP
PY 2015
VL 80
IS 1-4
BP 183
EP 197
DI 10.1007/s00170-015-6997-2
PG 15
WC Automation & Control Systems; Engineering, Manufacturing
SC Automation & Control Systems; Engineering
GA CP4EO
UT WOS:000359835000014
DA 2018-12-27
ER

PT J
AU Zheng, L
   Yan, WH
   Kong, Y
   Liang, P
   Mu, YM
AF Zheng, Lei
   Yan, Wenhua
   Kong, Yue
   Liang, Ping
   Mu, Yiming
TI RETRACTED: An Epidemiological Study of Risk Factors of Thyroid Nodule
   and Goiter in Chinese Women (Retracted article. See vol. 12, pg. 14114,
   2015)
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article; Retracted Publication
DE epidemiology; prevalence; risk factor; metabolic syndrome
ID METABOLIC SYNDROME; PREVALENCE; VOLUME; AREA; NODULARITY; MALIGNANCY;
   SPECTRUM; DISEASES
AB Thyroid nodule (TN) and goiter are two common disorders of the thyroid. Despite their benign nature, both conditions can be associated with multiple pathologic conditions including thyroid cancer. In this study, we conducted a large-scale epidemiological study in Chinese women to identify the risk factors implicated in the occurrence of TN and goiter. We analyzed demographic data, lifestyle, medical history, body height, weight, waist circumference, body mass index (BMI), blood pressure, serum glucose and lipids. In addition, thyroid ultrasonography was performed for all subjects. Our results showed that age, menopause, waist circumference, BMI, hypertension, dyslipidemia, and hyperglycemia were associated with both TN and goiter. Furthermore, we found that the prevalence of TN was significantly affected by the medical management of hypertension. Our study suggests that postmenopausal Chinese women with advanced age, obesity, diabetes, and hypertension have an increased awareness of thyroid examination in the annual physical check. Conversely, patients with TN and goiter of the same population may have a higher incidence of age- and obesity-related metabolic disorders.
C1 [Zheng, Lei; Yan, Wenhua; Mu, Yiming] Chinese Peoples Liberat Army PLA Gen Hosp, Dept Endocrinol, Beijing 100853, Peoples R China.
   [Zheng, Lei] Chinese Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Endocrinol, Beijing 100048, Peoples R China.
   [Kong, Yue; Liang, Ping] Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Ultrasound, Beijing 100853, Peoples R China.
   [Kong, Yue] Peking Univ, Clin Med Coll 9, Beijing Shijitan Hosp, Dept Ultrasound, Beijing 100038, Peoples R China.
RP Mu, YM (reprint author), Chinese Peoples Liberat Army PLA Gen Hosp, Dept Endocrinol, 28 Fu Xing Rd, Beijing 100853, Peoples R China.
EM zhenglei79541@163.com; yanwenhua301@163.com; kongyue79541@163.com;
   liangping301@hotmail.com; muyiming@301hospital.com.cn
FU National Science and Technology Major Project [2011ZX09307-001-08]
FX This study was supported by the National Science and Technology Major
   Project (Project number 2011ZX09307-001-08).
CR Ajmal S, 2015, J AM COLL SURGEONS, V220, P987, DOI 10.1016/j.jamcollsurg.2014.12.010
   Akushevich I, 2013, AGE AGEING, V42, P494, DOI 10.1093/ageing/aft032
   Amihesei I. C., 2013, REV MED CHIR SOC MED, V118, P896
   Anil C, 2013, METABOLISM, V62, P970, DOI 10.1016/j.metabol.2013.01.009
   Arduc A., 2014, CLIN ENDOCRINOL, DOI [10.1111/cen.1262825296952, DOI 10.1111/CEN.1262825296952]
   Aydin LY, 2011, MINERVA ENDOCRINOL, V36, P273
   Aydin Y, 2014, MED ULTRASON, V16, P100, DOI 10.11152/mu.2013.2066.162.ya1fhb2
   Biswas Akhil Bandhu, 2014, Indian J Public Health, V58, P129, DOI 10.4103/0019-557X.132291
   Canete EJ, 2014, ENDOCRINOL METAB, V29, P489, DOI 10.3803/EnM.2014.29.4.489
   Cappelli C, 2008, CLIN ENDOCRINOL, V68, P16, DOI 10.1111/j.1365-2265.2007.02982.x
   Carle A, 2014, BEST PRACT RES CL EN, V28, P465, DOI 10.1016/j.beem.2014.01.001
   Cheng TO, 2004, CIRCULATION, V109, pE180, DOI 10.1161/01.CIR.0000124882.83145.E6
   Chuot Chep C, 2014, BMC Res Notes, V7, P751, DOI 10.1186/1756-0500-7-751
   Damasceno DC, 2013, OBESITY, V21, P1596, DOI 10.1002/oby.20152
   Diez JJ, 2014, CLIN ENDOCRINOL, V80, P356, DOI 10.1111/cen.12169
   Fuhrer D, 2012, DTSCH ARZTEBL INT, V109, P506, DOI 10.3238/arztebl.2012.0506
   Guo HW, 2014, ENDOCRINE, V45, P230, DOI 10.1007/s12020-013-9968-0
   Huan Q, 2014, CHINESE MED J-PEKING, V127, P2286, DOI 10.3760/cma.j.issn.0366-6999.20140246
   Kim MH, 2010, ENDOCR J, V57, P615, DOI 10.1507/endocrj.K10E-024
   Knudsen N, 2002, THYROID, V12, P879, DOI 10.1089/105072502761016502
   Krishnan E, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000157
   Li H, 2015, MINERVA MED, V106, P109
   Luo J, 2012, J SURG RES, V174, P207, DOI 10.1016/j.jss.2011.11.1035
   de Sousa PAM, 2013, ARQ BRAS ENDOCRINOL, V57, P120, DOI 10.1590/S0004-27302013000200004
   Rendina D, 2015, HORM METAB RES, V47, P214, DOI 10.1055/s-0034-1387702
   Reverter JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104174
   Shinkov A, 2014, ARQ BRAS ENDOCRINOL, V58, P926, DOI 10.1590/0004-2730000003538
   Smith JJ, 2013, ANN SURG ONCOL, V20, P1336, DOI 10.1245/s10434-012-2725-4
   Tamer G, 2011, ENDOKRYNOL POL, V62, P421
   TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x
   VANDER JB, 1968, ANN INTERN MED, V69, P537, DOI 10.7326/0003-4819-69-3-537
   You LL, 2014, J ATHEROSCLER THROMB, V21, P355, DOI 10.5551/jat.20529
   Zhang J., 2014, INT J ENDOCRINOL, V2014, DOI [10.1155/2014/28950325214835, DOI 10.1155/2014/28950325214835]
NR 33
TC 6
Z9 8
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD SEP
PY 2015
VL 12
IS 9
BP 11608
EP 11620
DI 10.3390/ijerph120911608
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA CS2HF
UT WOS:000361889100070
PM 26389933
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Peng, H
   Jiang, B
   Zhao, JN
   Chen, B
   Wang, PC
AF Peng, Hao
   Jiang, Bing
   Zhao, Jiannong
   Chen, Bing
   Wang, Pengchang
TI RETRACTED: Risperidone promotes differentiation of glioma stem-like
   cells through the Wnt signaling pathway (Retracted Article)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
C1 [Peng, Hao; Jiang, Bing] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Peoples R China.
   [Zhao, Jiannong; Wang, Pengchang] Hainan Prov Peoples Hosp, Dept Neurosurg, Haikou 570311, Peoples R China.
   [Chen, Bing] Affiliated Hosp Guangdong Med Coll, Dept Neurosurg, Guangdong 524023, Peoples R China.
RP Peng, H (reprint author), Cent S Univ, Xiangya Hosp, Dept Neurosurg, 87 Xiangya Rd, Changsha 410008, Peoples R China.
EM bing_jiang14@163.com
NR 0
TC 1
Z9 1
U1 2
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2015
VL 36
IS 9
BP 6677
EP 6677
DI 10.1007/s13277-015-3087-x
PG 1
WC Oncology
SC Oncology
GA CW5KA
UT WOS:000365033100100
OA Bronze
DA 2018-12-27
ER

PT J
AU Shuai, L
   Zhou, YH
   Bi, MS
   Ren, JJ
   Cai, Z
AF Shuai, Lu
   Zhou, Yihui
   Bi, Mingshu
   Ren, Jingjie
   Cai, Zhen
TI RETRACTED: An integrated optimization model and application of MEE-TVC
   desalination system (Retracted article. See vol. 378, pg. 117, 2016)
SO DESALINATION
LA English
DT Article; Retracted Publication
DE MEE-TVC; Lingo; Optimization design; Suction position; Desalination
ID MULTIPLE EFFECT EVAPORATION; EXPERIENCE; DESIGN; IRAN
AB Multi-effects evaporation with thermal vapor compression (MEE-TVC) is one of the most effective desalination method in which the TVC plays a main role with consideration of energy consumption. In this paper, the steady-state mathematical model of MEE-TVC based on LINGO algorithm is developed and is examined against commercial desalination plants. The model can be adapted to conventional equal temperature difference design method and equal heat transfer area design method as well because of the generality of the model and the maintainability of the programs. By inducing suction position variable the influence of parameters of TVC including suction position, suction pressure, motive vapor pressure, top brine temperature etc. on the operation of MEE-TVC system is investigated. It is found that the improvement of performance ratio and decreasing energy consumption can be achieved by optimization of integrating TVC suction position with operations of each effect. The end effect is almost the optimal position for TVC expect for some cases in equal temperature difference design situation with regards of the gain output ratio as objective. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Shuai, Lu; Zhou, Yihui; Bi, Mingshu; Ren, Jingjie; Cai, Zhen] Dalian Univ Technol, Sch Chem Machinery, Dalian 116023, Peoples R China.
RP Zhou, YH (reprint author), Dalian Univ Technol, Sch Chem Machinery, Dalian 116023, Peoples R China.
EM zflower@dlut.edu.cn
CR Al-Habshi S.O., 2002, SIMULATION EC STUDY
   Al-Mutaz IS, 2014, DESALINATION, V351, P9, DOI 10.1016/j.desal.2014.07.018
   Alasfour FN, 2005, DESALINATION, V174, P39, DOI 10.1016/j.desal.2004.08.039
   AlNajem NM, 1997, DESALINATION, V110, P223, DOI 10.1016/S0011-9164(97)00101-X
   Bin Amer AO, 2009, DESALINATION, V249, P1315, DOI 10.1016/j.desal.2009.06.026
   Darwish MA, 1996, APPL THERM ENG, V16, P523, DOI 10.1016/1359-4311(95)00034-8
   Darwish MA, 2004, DESALINATION, V170, P223, DOI 10.1016/j.desal.2004.01.006
   EI-Dessouky H.T., 2002, FUNDAMENTALS SALT WA
   El-Dessouky H, 1998, CHEM ENG TECHNOL, V21, P437, DOI 10.1002/(SICI)1521-4125(199805)21:5<437::AID-CEAT437>3.0.CO;2-D
   El-Dessouky HT, 2000, CHEM ENG RES DES, V78, P662, DOI 10.1205/026387600527626
   Kamali RK, 2008, DESALINATION, V222, P639, DOI 10.1016/j.desal.2007.01.182
   Kamali RK, 2008, DESALINATION, V222, P596, DOI 10.1016/j.desal.2007.01.120
   Kamali RK, 2009, DESALINATION, V235, P340, DOI 10.1016/j.desal.2008.01.019
   Kouhikamali R, 2012, APPL THERM ENG, V40, P174, DOI 10.1016/j.applthermaleng.2012.02.002
   MICHELS T, 1993, DESALINATION, V93, P111, DOI 10.1016/0011-9164(93)80098-8
   Power R. B., 1993, STEAM JET EJECTORS P
   Schrage L., 2006, LINGO USERS GUIDE
   Shakib SE, 2012, DESALIN WATER TREAT, V37, P84, DOI 10.5004/dwt.2012.2509
   Temstet C, 1996, DESALINATION, V105, P109, DOI 10.1016/0011-9164(96)00064-1
NR 19
TC 4
Z9 4
U1 5
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0011-9164
EI 1873-4464
J9 DESALINATION
JI Desalination
PD SEP 1
PY 2015
VL 371
BP 1
EP 8
DI 10.1016/j.desal.2015.05.022
PG 8
WC Engineering, Chemical; Water Resources
SC Engineering; Water Resources
GA CN2RT
UT WOS:000358270300001
DA 2018-12-27
ER

PT J
AU Fadaee, M
AF Fadaee, M.
TI RETRACTED: A novel approach for free vibration of circular/annular
   sector plates using Reddy's third order shear deformation theory
   (Retracted article. See vol. 52, pg. 2247, 2017)
SO MECCANICA
LA English
DT Article; Retracted Publication
DE Exact closed-form; Vibration; Reddy plate theory; Sector plate
ID DIFFERENTIAL QUADRATURE METHOD; SUPPORTED RADIAL EDGES; HIGHER-ORDER
   THEORY; TRANSVERSE VIBRATION; THIN; STABILITY; MOTION
AB A new exact closed-form solution based on Reddy' third-order shear deformation plate theory for free vibration of thick circular/annular sector plates is presented. Characteristic equations are given for sector plates having hard simply supported radial edges and all combinations of free, soft simply supported, hard simply supported and clamped boundary conditions along the circular edges. Based on the present solution, the governing equations of the vibrated thick circular/annular sector plates were exactly solved by introducing the new auxiliary and potential functions as well as using the separation method of variables. To clarify the efficiency and accuracy of the present solution, several comparison studies are examined with the available data in the literature. Also, natural frequencies of the circular/annular sector plates are presented for different thickness-radius ratios, inner-outer radius ratios, sector angle values and boundary conditions.
C1 Qom Univ Technol, Dept Mech Engn, Coll Engn, Qom, Iran.
RP Fadaee, M (reprint author), Qom Univ Technol, Dept Mech Engn, Coll Engn, Qom, Iran.
EM fadaee@qut.ac.ir
CR Bapu Rao MN, 1977, NUCL ENG DES, V41, P247
   BHATTACHARYA AP, 1975, J SOUND VIB, V41, P503, DOI 10.1016/S0022-460X(75)80113-1
   BHIMARADDI A, 1984, J APPL MECH-T ASME, V51, P195, DOI 10.1115/1.3167569
   CHEUNG MS, 1981, COMPUT STRUCT, V14, P79, DOI 10.1016/0045-7949(81)90086-9
   Dauge M, 2000, INT J SOLIDS STRUCT, V37, P2443, DOI 10.1016/S0020-7683(99)00004-9
   DOONG JL, 1987, J SOUND VIB, V113, P425, DOI 10.1016/S0022-460X(87)80131-1
   HANNA NF, 1994, J SOUND VIB, V170, P545, DOI 10.1006/jsvi.1994.1083
   HARIK IE, 1989, J ENG MECH-ASCE, V115, P2709, DOI 10.1061/(ASCE)0733-9399(1989)115:12(2709)
   Hosseini-Hashemi S, 2010, INT J MECH SCI, V52, P1025, DOI 10.1016/j.ijmecsci.2010.04.009
   Hosseini-Hashemi S, 2010, J SOUND VIB, V329, P3382, DOI 10.1016/j.jsv.2010.02.024
   Houmat A, 2004, J SOUND VIB, V276, P181, DOI 10.1016/j.jsv.2003.07.020
   HUANG CS, 1994, INT J SOLIDS STRUCT, V31, P1609, DOI 10.1016/0020-7683(94)90018-3
   HUANG CS, 1993, J APPL MECH-T ASME, V60, P478, DOI 10.1115/1.2900818
   IRIE T, 1979, J SOUND VIB, V67, P89, DOI 10.1016/0022-460X(79)90504-2
   KANT T, 1982, COMPUT METHOD APPL M, V31, P1, DOI 10.1016/0045-7825(82)90043-3
   KIM CS, 1989, J SOUND VIB, V134, P407, DOI 10.1016/0022-460X(89)90566-X
   Li X, 2003, J QINHUA
   Liew KM, 2000, J SOUND VIB, V230, P335, DOI 10.1006/jsvi.1999.2623
   Liew KM, 2001, J ACOUST SOC AM, V110, P233, DOI 10.1121/1.1377868
   Liu FL, 1999, COMPUT METHOD APPL M, V177, P77, DOI 10.1016/S0045-7825(98)00376-4
   LO KH, 1977, J APPL MECH-T ASME, V44, P663, DOI 10.1115/1.3424154
   MATSUNAGA H, 1994, INT J SOLIDS STRUCT, V31, P3113
   MCGEE OG, 1995, INT J MECH SCI, V37, P537, DOI 10.1016/0020-7403(94)00050-T
   MIZUSAWA T, 1991, J SOUND VIB, V150, P245, DOI 10.1016/0022-460X(91)90619-U
   RAMAKRISHNAN R, 1973, J SOUND VIB, V30, P127, DOI 10.1016/S0022-460X(73)80055-0
   REDDY JN, 1985, J SOUND VIB, V98, P157, DOI 10.1016/0022-460X(85)90383-9
   REDDY JN, 1984, INT J SOLIDS STRUCT, V20, P881, DOI 10.1016/0020-7683(84)90056-8
   Seok JW, 2004, J SOUND VIB, V271, P757, DOI 10.1016/S0022-460X(03)00414-0
   Sharma A, 2005, AIAA J, V43, P1109, DOI 10.2514/1.4683
   Speigel R, 1999, MATH HDB FORMULAS TA
   SRINIVASAN RS, 1985, J SOUND VIB, V101, P193, DOI 10.1016/S0022-460X(85)81215-3
   Srinivasan RS, 1983, J SOUND VIBRATION, V80, P275
   Tranter C.J., 1968, BESSEL FUNCTIONS SOM
   Wang XW, 2004, COMPUT METHOD APPL M, V193, P3957, DOI 10.1016/j.cma.2004.02.010
   WHITNEY JM, 1973, J SOUND VIB, V30, P85, DOI 10.1016/S0022-460X(73)80052-5
   XIANG Y, 1993, J ENG MECH-ASCE, V119, P1579, DOI 10.1061/(ASCE)0733-9399(1993)119:8(1579)
   YONGQIANG L, 2007, J SOUND VIB, V305, P457
   Zhou D, 2009, J SOUND VIB, V320, P421, DOI 10.1016/j.jsv.2008.08.001
NR 38
TC 3
Z9 3
U1 3
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0025-6455
EI 1572-9648
J9 MECCANICA
JI Meccanica
PD SEP
PY 2015
VL 50
IS 9
BP 2325
EP 2351
DI 10.1007/s11012-015-0158-4
PG 27
WC Mechanics
SC Mechanics
GA CN8BH
UT WOS:000358661200007
DA 2018-12-27
ER

PT J
AU Motamedi, S
   Shamshirband, S
   Hashim, R
   Petkovic, D
   Roy, C
AF Motamedi, Shervin
   Shamshirband, Shahaboddin
   Hashim, Roslan
   Petkovic, Dalibor
   Roy, Chandrabhushan
TI RETRACTED: Estimating unconfined compressive strength of cockle
   shell-cement-sand mixtures using soft computing methodologies (Retracted
   article. See vol. 170, pg. 196. 2018)
SO ENGINEERING STRUCTURES
LA English
DT Article; Retracted Publication
DE Cockle shell; Ground improvement; Unconfined compressive strength;
   ANFIS; SVR
ID SUPPORT VECTOR REGRESSION; RECYCLED CONCRETE AGGREGATE; NEURO-FUZZY
   CONTROLLER; TIME-SERIES PREDICTION; VARIABLE SELECTION; COARSE
   AGGREGATE; OYSTER-SHELL; WASTE; NETWORKS; MODELS
AB The accuracy of soft computing techniques was used in this research to estimate the unconfined compressive strength according to series of unconfined compressive tests for multiple mixtures of cockle shell, cement and sand under different curing periods. We developed a process for simulating the unconfined compressive strength through two techniques of soft computing, the support vector regression (SVR) and the adaptive neuro-fuzzy inference (ANFIS). The developed SVR and ANFIS networks have one neuron (UCS) in the output layer and four neurons in the input layer. The inputs were percentage of cockle shell, cement and sand content in the mixtures, and age (in days). First, the ANFIS network was used to select the most effective parameters on the UCS. The linear, polynomial, and radial basis functions were employed as the SVR's kernel function. The simulation results proved the performance of proposed optimizers. Additionally, the results of SVR and ANFIS were compared through the Pearson correlation coefficient and the root-mean-square error. The findings show that the predictive accuracy and capability of generalization can be an improved by the ANFIS approach in comparison to the SVR estimation. The simulation results confirmed the effectiveness of the proposed optimization strategies. (C)2015 Elsevier Ltd. All rights reserved.
C1 [Motamedi, Shervin; Hashim, Roslan; Roy, Chandrabhushan] Univ Malaya, Dept Civil Engn, Fac Engn, Kuala Lumpur 50603, Malaysia.
   [Motamedi, Shervin; Hashim, Roslan] Univ Malaya, Inst Ocean & Earth Sci, Kuala Lumpur 50603, Malaysia.
   [Shamshirband, Shahaboddin] Univ Malaya, Fac Comp Sci & Informat Technol, Dept Comp Syst & Informat Technol, Kuala Lumpur 50603, Malaysia.
   [Petkovic, Dalibor] Univ Nis, Fac Mech Engn, Dept Mechatron & Control, Nish 18000, Serbia.
RP Shamshirband, S (reprint author), Univ Malaya, Dept Civil Engn, Fac Engn, Kuala Lumpur 50603, Malaysia.
EM shamshirband@um.edu.my; roslan@um.edu.my
RI Salim, Siti Mawarni/B-7940-2010; Shamshirband, Shahaboddin/K-2544-2013;
   husain, haslina/B-7959-2010; Engineering, Faculty/I-7935-2015
OI Salim, Siti Mawarni/0000-0001-5543-5384; Shamshirband,
   Shahaboddin/0000-0002-6605-498X; husain, haslina/0000-0001-9904-3067;
   Engineering, Faculty/0000-0002-4848-7052
FU HIR-MOHE, University of Malaya [UM.C/HIR/MOHE/ENG/34]
FX The authors express their sincere thanks for the funding support by the
   HIR-MOHE, University of Malaya under the Grant No. UM.C/HIR/MOHE/ENG/34.
CR Altin N, 2012, ENERG CONVERS MANAGE, V56, P130, DOI 10.1016/j.enconman.2011.11.017
   Andersson FO, 2000, CHEMOMETR INTELL LAB, V51, P61, DOI 10.1016/S0169-7439(00)00057-5
   Areed FG, 2010, AIN SHAMS ENG J, V1, P71, DOI 10.1016/j.asej.2010.09.008
   ASTM, 2012, C150 ASTM INT
   ASTM, 2010, D2487 ASTM INT
   ASTM International, 2005, D2166 ASTM INT
   ASTM International, 2012, C311 ASTM INT
   ASTM International, 2009, C118 ASTM INT
   ASTM International, 2009, D5381 ASTM INT
   ASTM International, 2012, D698 ASTM INT
   Ballester P, 2007, CEMENT CONCRETE RES, V37, P559, DOI 10.1016/j.cemconres.2007.01.004
   Banu W., 2011, INT J MODELING OPTIM, V1, P24, DOI DOI 10.7763/IJM0.2011.V1.5
   Barros MC, 2009, J CLEAN PROD, V17, P400, DOI 10.1016/j.jclepro.2008.08.013
   Basha EA, 2005, CONSTR BUILD MATER, V19, P448, DOI 10.1016/j.conbuildmat.2004.08.001
   Castellano G, 2000, NEUROCOMPUTING, V31, P1, DOI 10.1016/S0925-2312(99)00146-0
   Chaya W, 2007, J CLEAN PROD, V15, P1463, DOI 10.1016/j.jclepro.2006.03.008
   Chiemchaisri C, 2007, ENVIRON MONIT ASSESS, V135, P13, DOI 10.1007/s10661-007-9707-1
   Cibas T, 1996, NEUROCOMPUTING, V12, P223, DOI 10.1016/0925-2312(95)00121-2
   Dastorani M T, 2010, Journal of Applied Sciences, V10, P2387
   Dieterle F, 2003, ANAL CHIM ACTA, V490, P71, DOI 10.1016/S0003-2670(03)00338-6
   Donald AS, 2002, P 2002 INT C MACH LE
   Eguchi K, 2007, CONSTR BUILD MATER, V21, P1542, DOI 10.1016/j.conbuildmat.2005.12.023
   FALADE F, 1995, BUILD ENVIRON, V30, P573, DOI 10.1016/0360-1323(94)00057-Y
   Gocic M, 2015, STOCH ENV RES RISK A
   Hong WC, 2008, APPL MATH COMPUT, V200, P41, DOI 10.1016/j.amc.2007.10.046
   Lee SC, 2014, SCI WORLD J, V2014
   Lertwattanaruk P, 2012, J ENVIRON MANAGE, V111, P133, DOI 10.1016/j.jenvman.2012.06.032
   Limbachiya M, 2012, CONSTR BUILD MATER, V27, P439, DOI 10.1016/j.conbuildmat.2011.07.023
   Malhotra SK, 1999, CEMENT CONCRETE COMP, V21, P285, DOI 10.1016/S0958-9465(99)00006-2
   Mosher S, 2012, ENVIRON TOXICOL, V27, P268, DOI 10.1002/tox.20639
   Motamedi S, 2014, SCI WORLD J, V2014, P1
   Motamedi S, 2013, MAT STRUCT
   Motamedi S, 2015, POWDER TECHNOL, V278, P278, DOI 10.1016/j.powtec.2015.02.045
   Petkovic D, 2012, NEURAL COMPUT APPL, V21, P2065, DOI 10.1007/s00521-011-0629-z
   Petkovic D, 2013, EXPERT SYST APPL, V40, P1265, DOI 10.1016/j.eswa.2012.08.064
   Petkovic D, 2012, EXPERT SYST APPL, V39, P13295, DOI 10.1016/j.eswa.2012.05.072
   Petkovic D, 2012, EXPERT SYST APPL, V39, P9477, DOI 10.1016/j.eswa.2012.02.111
   Pourtahmasb MS, 2015, CONSTR BUILD MATER, V82, P257, DOI 10.1016/j.conbuildmat.2015.02.030
   Rao, 2011, J ENV RES DEV, V5
   de Juan MS, 2009, CONSTR BUILD MATER, V23, P872, DOI 10.1016/j.conbuildmat.2008.04.012
   Shamshirband S, 2015, AGR FOREST METEOROL, V200, P57, DOI 10.1016/j.agrformet.2014.09.020
   Sivapragasam C, 2001, J HYDROINFORM, V3, P141
   Talei A, 2010, EXPERT SYST APPL, V37, P7456, DOI 10.1016/j.eswa.2010.04.015
   Thomas C, 2013, CONSTR BUILD MATER, V40, P1054, DOI 10.1016/j.conbuildmat.2012.11.106
   Tian LF, 2005, MECHATRONICS, V15, P1305, DOI 10.1016/j.mechatronics.2005.02.001
   Wei Z, 2013, RELIAB ENG SYST SAFE, V119, P109, DOI 10.1016/j.ress.2013.05.021
   Wu CL, 2013, ENG APPL ARTIF INTEL, V26, P997, DOI 10.1016/j.engappai.2012.05.023
   Yang EI, 2005, CEMENT CONCRETE RES, V35, P2175, DOI 10.1016/j.cemconres.2005.03.016
   Yang EI, 2010, CONSTR BUILD MATER, V24, P758, DOI 10.1016/j.conbuildmat.2009.10.032
   Yang HQ, 2009, NEUROCOMPUTING, V72, P2659, DOI 10.1016/j.neucom.2008.09.014
   Yoon GL, 2003, WASTE MANAGE, V23, P825, DOI 10.1016/S0956-053X(02)00159-9
   Zhang L, 2013, NEUROCOMPUTING, V99, P411, DOI 10.1016/j.neucom.2012.06.030
NR 52
TC 18
Z9 18
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0141-0296
EI 1873-7323
J9 ENG STRUCT
JI Eng. Struct.
PD SEP 1
PY 2015
VL 98
BP 49
EP 58
DI 10.1016/j.engstruct.2015.03.070
PG 10
WC Engineering, Civil
SC Engineering
GA CM0EK
UT WOS:000357351000005
DA 2018-12-27
ER

PT J
AU Ata, R
AF Ata, Rasit
TI RETRACTED: Artificial neural networks applications in wind energy
   systems: a review (Retracted article. See vol. 84, pg. 173, 2018)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE Artificial neural networks; Wind energy sytems; System modeling; System
   performance prediction
ID PARTICLE SWARM OPTIMIZATION; PITCH-ANGLE CONTROL; SPEED TIME-SERIES;
   HEAT-PUMP SYSTEM; POWER PREDICTION; MULTILAYER PERCEPTRON; HYBRID MODEL;
   INTELLIGENCE TECHNIQUES; SPATIAL CORRELATION; CONVERSION SYSTEM
AB Neural networks approaches are becoming useful as an alternate way to classical methods. As a computation and learning paradigm, they are presented as a different modeling approach to solve complicated problems. They have been used to solve complicated practical problems in various areas, such as engineering, medicine, business, manufacturing, military etc. They have also been applied for modeling, identification, optimization, prediction, forecasting, evaluation, classification, and control of complex systems. During the last three decades, artificial neural network have been extensively employed in numerous fields of science and technology. They are not programmed in the conventional procedure but they are trained using data exemplifying the behaviour of a system. This study presents various applications of neural networks used in wind energy systems. The applications of neural networks in wind energy systems could be grouped in three major categories: forecasting and prediction, prediction and control, identification and evaluation. The main purpose of this paper is to present an overview of the neural network applications in wind energy systems. Published literature presented in this study indicate the potential of ANN as a useful tool for wind energy systems. Author strongly believes that this survey will be very much useful to the researchers, scientific engineers working in this area to find out the relevant references and current state of the field. (C) 2015 Elsevier Ltd. All rights reserved.
C1 Celal Bayar Univ, Dept Elect & Elect Engn, Manisa, Turkey.
RP Ata, R (reprint author), Celal Bayar Univ, Dept Elect & Elect Engn, Manisa, Turkey.
EM rasit.ata@cbu.edu.tr
OI Ata, Rasit/0000-0001-8534-7182
CR Akinci TC, 2011, ELEKTRON ELEKTROTECH, P41
   Alanis AY, 2012, P WORLD AUT C WAC, P1
   Alexiadis M, 1988, SOL ENERGY, V63, P61
   Alexiadis MC, 1999, IEEE T ENERGY CONVER, V14, P836, DOI 10.1109/60.790962
   Alpaydin E, 2004, INTRO MACHINE LEARNI
   Ata R, 2010, EXPERT SYST APPL, V37, P5454, DOI 10.1016/j.eswa.2010.02.068
   Bangalore P., 2013, P IEEE POWERTECH C G, P1
   Bansal RC, 2007, 2007 CONFERENCE PROCEEDINGS IPEC, VOLS 1-3, P982
   Bansal RC, 2008, ENERG CONVERS MANAGE, V49, P357, DOI 10.1016/j.enconman.2007.06.004
   Barambones O, 2010, 2010 INT JOINT C NEU, P1
   Barambones O, 2010, IEEE MEDITERR ELECT, P1383, DOI 10.1109/MELCON.2010.5476008
   Barbounis TG, 2007, INFORM SCIENCES, V177, P5775, DOI 10.1016/j.ins.2007.05.024
   Barbounis TG, 2006, NEUROCOMPUTING, V69, P466, DOI 10.1016/j.neucom.2005.02.003
   Barbounis TG, 2006, IEEE T ENERGY CONVER, V21, P273, DOI 10.1109/TEC.2005.847954
   Beccali M, 2008, RENEW SUST ENERG REV, V12, P2040, DOI 10.1016/j.rser.2007.04.010
   Beccali M, 2010, APPL ENERG, V87, P884, DOI 10.1016/j.apenergy.2009.05.026
   Bechrakis DA, 2004, SOL ENERGY, V76, P725, DOI 10.1016/j.solener.2004.01.004
   BIANCHINI M, 1995, IEEE T NEURAL NETWOR, V6, P749, DOI 10.1109/72.377979
   Bigdeli N, 2013, RENEW SUST ENERG REV, V27, P20, DOI 10.1016/j.rser.2013.06.022
   Bilgili M, 2007, RENEW ENERG, V32, P2350, DOI 10.1016/j.renene.2006.12.001
   Bouzgou H, 2011, APPL ENERG, V88, P2463, DOI 10.1016/j.apenergy.2011.01.037
   Brahmi J, 2009, P 6 INT MULT SYST SI, P1
   Cadenas E, 2009, RENEW ENERG, V34, P274, DOI 10.1016/j.renene.2008.03.014
   Cadenas E, 2007, RENEW ENERG, V32, P2116, DOI 10.1016/j.renene.2006.10.005
   Cadenas E, 2010, RENEW ENERG, V35, P2732, DOI 10.1016/j.renene.2010.04.022
   Cam E, 2005, RENEW ENERG, V30, P227, DOI 10.1016/j.renene.2004.05.008
   Castellani F, 2014, ENRGY PROCED, V45, P188, DOI 10.1016/j.egypro.2014.01.021
   Catalao JPS, 2011, RENEW ENERG, V36, P1245, DOI 10.1016/j.renene.2010.09.016
   Chen B., 2009, P IEEE C SENS MESH A, P1, DOI DOI 10.1007/978-3-642-04425-0_36
   Cong TL, 2013, PROG NUCL ENERG, V62, P54, DOI 10.1016/j.pnucene.2012.09.003
   De Giorgi MG, 2011, ENERGY, V36, P3968, DOI 10.1016/j.energy.2011.05.006
   De Giorgi MG, 2011, APPL ENERG, V88, P1298, DOI 10.1016/j.apenergy.2010.10.035
   Dervilis N, 2014, J SOUND VIB, V333, P1833, DOI 10.1016/j.jsv.2013.11.015
   Dong B, 2011, P 14 EUR C POW EL AP, P1
   Esen H, 2008, EXPERT SYST APPL, V35, P1940, DOI 10.1016/j.eswa.2007.08.081
   Esen H, 2008, ENERG BUILDINGS, V40, P1074, DOI 10.1016/j.enbuild.2007.10.002
   Esen H, 2008, INT J THERM SCI, V47, P431, DOI 10.1016/j.ijthermalsci.2007.03.004
   Esen H, 2009, EXPERT SYST APPL, V36, P11240, DOI 10.1016/j.eswa.2009.02.073
   Eskander MN, 2002, RENEW ENERG, V26, P463, DOI 10.1016/S0960-1481(01)00140-9
   Fadare DA, 2010, APPL ENERG, V87, P934, DOI 10.1016/j.apenergy.2009.09.005
   Fernandez E, 2006, P INT C POW EL DRIV
   Flores P, 2005, RENEW ENERG, V30, P523, DOI 10.1016/j.renene.2004.07.015
   Fonte P. M., 2005, WSEAS Transactions on Systems, V4, P379
   Gamez ME, 2011, P INT JOINT C NEUR N, V69
   Ganjefar S, 2014, ENERGY, V67, P444, DOI 10.1016/j.energy.2014.02.023
   Gardner MW, 1998, ATMOS ENVIRON, V32, P2627, DOI 10.1016/S1352-2310(97)00447-0
   Gavrilas M, 2010, Proceedings 10th Symposium on Neural Network Applications in Electrical Engineering (NEUREL 2010), P31, DOI 10.1109/NEUREL.2010.5644050
   Giraud F, 1999, ELECTR POW SYST RES, V50, P155, DOI 10.1016/S0378-7796(98)00137-0
   Grassi G, 2010, COMMUN NONLINEAR SCI, V15, P2262, DOI 10.1016/j.cnsns.2009.10.005
   Guo ZH, 2011, KNOWL-BASED SYST, V24, P1048, DOI 10.1016/j.knosys.2011.04.019
   Guo ZH, 2011, ENERGY, V36, P1668, DOI 10.1016/j.energy.2010.12.063
   Han S., 2011, ENERGY PROCEDIA, V12, P733
   Haque AU, 2012, RENEW SUST ENERG REV, V16, P4563, DOI 10.1016/j.rser.2012.05.042
   Hasanien H. M., 2012, P IEEE 15 INT C EL M, P1
   Hasanien HM, 2012, ELECTR POW SYST RES, V84, P206, DOI 10.1016/j.epsr.2011.11.019
   Hassan B, 2013, BULL ENVIRON PHARMAC, V2, P30
   He D, 2012, P IEEE 7 INT POW EL
   Hervas-Martinez C, 2012, NEURAL COMPUT APPL, V21, P993, DOI 10.1007/s00521-011-0582-x
   Hong CM, 2014, INT J ELEC POWER, V60, P14, DOI 10.1016/j.ijepes.2014.02.015
   Hou GL, 2010, 2010 8TH WORLD CONGRESS ON INTELLIGENT CONTROL AND AUTOMATION (WCICA), P4875, DOI 10.1109/WCICA.2010.5554883
   Hussain MA, 1999, ARTIF INTELL ENG, V13, P55, DOI 10.1016/S0954-1810(98)00011-9
   Jayaraj S, 2004, P EUR WIND EN C LOND
   Jie Shi, 2011, 2011 4th International Conference on Electric Utility Deregulation and Restructuring and Power Technologies (DRPT 2011), P162, DOI 10.1109/DRPT.2011.5993881
   Jung S, 2013, APPL ENERG, V111, P778, DOI 10.1016/j.apenergy.2013.05.060
   Jursa R, 2008, INT J FORECASTING, V24, P694, DOI 10.1016/j.ijforecast.2008.08.007
   Kalogirou S, 1999, P EUR S INT TECHN ES
   Kalogirou SA, 2003, PROG ENERG COMBUST, V29, P515, DOI 10.1016/S0360-1285(03)00058-3
   Kalogirou SA, 2001, RENEW SUST ENERG REV, V5, P373, DOI 10.1016/S1364-0321(01)00006-5
   Kalogirou SA, 2000, APPL ENERG, V67, P17, DOI 10.1016/S0306-2619(00)00005-2
   Kalogirou SA, 1999, ENERG CONVERS MANAGE, V40, P1073, DOI 10.1016/S0196-8904(99)00012-6
   Kalogirou SA, 2006, INT J LOW-CARBON TEC, V1, P201, DOI 10.1093/ijlct/1.3.201
   Kani SAP, 2011, ENERG CONVERS MANAGE, V52, P738, DOI 10.1016/j.enconman.2010.07.053
   Kani S.P., 2008, EL POW C 2008 EPEC 2, P1
   Kariniotakis GN, 1996, IEEE T ENERGY CONVER, V11, P762, DOI 10.1109/60.556376
   Kelouwani S, 2004, IEEE T ENERGY CONVER, V19, P607, DOI 10.1109/TEC.2004.827715
   Kimura K, 2013, INT C POWER ELECT DR, P1, DOI 10.1109/PEDS.2013.6526978
   Kolhe M, 2011, P AS PAC POW EN ENG, P1
   Kulkarni MA, 2008, J EARTH SYST SCI, V117, P457, DOI 10.1007/s12040-008-0045-7
   Li G, 2011, RENEW ENERG, V36, P352, DOI 10.1016/j.renene.2010.06.049
   Li G, 2010, APPL ENERG, V87, P2313, DOI 10.1016/j.apenergy.2009.12.013
   Li H, 2005, IEEE T IND APPL, V41, P1548, DOI [10.1109/TIA.2005.858282, 10.1109/TIA.2005.0858282]
   Li Ran, 2011, 2011 International Conference on Consumer Electronics, Communications and Networks (CECNet), P358, DOI 10.1109/CECNET.2011.5768746
   Li SH, 2001, IEEE T ENERGY CONVER, V16, P276, DOI 10.1109/60.937208
   Li SH, 2001, J SOL ENERG-T ASME, V123, P327, DOI 10.1115/1.1413216
   Li Xingpei, 2009, 2009 4th IEEE Conference on Industrial Electronics and Applications, P2448, DOI 10.1109/ICIEA.2009.5138642
   Lin CH, 2013, INT J ELEC POWER, V52, P143, DOI 10.1016/j.ijepes.2013.03.021
   Lin WM, 2011, IEEE T POWER ELECTR, V26, P473, DOI 10.1109/TPEL.2010.2085454
   Liu H, 2013, INT J ELEC POWER, V52, P161, DOI 10.1016/j.ijepes.2013.03.034
   Liu H, 2013, APPL ENERG, V107, P191, DOI 10.1016/j.apenergy.2013.02.002
   Liu H, 2012, RENEW ENERG, V48, P545, DOI 10.1016/j.renene.2012.06.012
   Liu H, 2012, APPL ENERG, V98, P415, DOI 10.1016/j.apenergy.2012.04.001
   Liu QS, 2011, CHIN CONTR CONF, P5159
   Liu Z, 2012, P IEEE EN CONV C EXP, P15
   Lopez P, 2008, RENEW ENERG, V33, P2266, DOI 10.1016/j.renene.2007.12.020
   Ma L, 2009, RENEW SUST ENERG REV, V13, P915, DOI 10.1016/j.rser.2008.02.002
   Mabel MC, 2008, RENEW ENERG, V33, P986, DOI 10.1016/j.renene.2007.06.013
   Mellit A, 2009, RENEW SUST ENERG REV, V13, P406, DOI 10.1016/j.rser.2008.01.006
   Mellit A, 2008, PROG ENERG COMBUST, V34, P574, DOI 10.1016/j.pecs.2008.01.001
   Mesemanolis A, 2012, P 8 MED C POW GEN TR, P1
   Methaprayoon K, 2007, IEEE T IND APPL, V43, P1441, DOI 10.1109/TIA.2007.908203
   Minghao Z, 2009, INT C MAN SERV SCI M, P1
   Mishra A.K., 2009, P INT C SUST POW GEN, P1
   Mohamed AM, 1998, RENEW ENERG, V13, P345
   Mohandes MA, 2004, RENEW ENERG, V29, P939, DOI 10.1016/j.renene.2003.11.009
   Mohanraj M, 2015, INT J THERM SCI, V90, P150, DOI 10.1016/j.ijthermalsci.2014.11.030
   Mohanraj M, 2012, RENEW SUST ENERG REV, V16, P1340, DOI 10.1016/j.rser.2011.10.015
   Mohseni M, 2012, P 3 IEEE INT PEDSTC, P330
   Monfared M, 2009, RENEW ENERG, V34, P845, DOI 10.1016/j.renene.2008.04.017
   Murat YS, 2006, ENERG POLICY, V34, P3165, DOI 10.1016/j.enpol.2005.02.010
   Muyeen SM, 2014, ENERG CONVERS MANAGE, V78, P412, DOI 10.1016/j.enconman.2013.10.039
   Muyeen SM, 2012, IET RENEW POWER GEN, V6, P226, DOI 10.1049/iet-rpg.2010.0126
   Nasr GE, 2003, ENERG CONVERS MANAGE, V44, P893, DOI 10.1016/S0196-8904(02)00087-0
   Nouali S, 2011, P 8 INT MULT SYST SI, P1
   Olaofe Z.O., 2012, P IEEE POW EL MACH W, P1
   Olaofe ZO, 2014, SUSTAIN ENERGY TECHN, V6, P1, DOI 10.1016/j.seta.2013.12.001
   Osorio GJ, 2015, RENEW ENERG, V75, P301, DOI 10.1016/j.renene.2014.09.058
   Papathanassiou S. A., 2000, Wind Engineering, V24, P317, DOI 10.1260/0309524001495701
   Peng HW, 2013, RENEW ENERG, V50, P590, DOI 10.1016/j.renene.2012.07.022
   Phan Quoc Dzung, 2011, 2011 IEEE Ninth International Conference on Power Electronics and Drive Systems (PEDS 2011), P219, DOI 10.1109/PEDS.2011.6147250
   Philippopoulos K, 2012, RENEW ENERG, V38, P75, DOI 10.1016/j.renene.2011.07.007
   Poultangari I, 2012, ISA T, V51, P641, DOI 10.1016/j.isatra.2012.06.001
   Pourmousavi Kani SA, 2008, P INT C POW SYST AN
   Pousinho HMI, 2011, ENERG CONVERS MANAGE, V52, P397, DOI 10.1016/j.enconman.2010.07.015
   Pucci M, 2011, IEEE T IND ELECTRON, V58, P37, DOI 10.1109/TIE.2010.2043043
   Qin SS, 2015, ENERGY REP, V1, P8, DOI 10.1016/j.egyr.2014.11.003
   RAHIM AHMA, 2013, RES J APPL SCI ENG T, V6, P4271
   Ren C, 2014, KNOWL-BASED SYST, V56, P226, DOI 10.1016/j.knosys.2013.11.015
   Ren YF, 2010, P AS PAC POW EN ENG, P1
   Ro K, 2005, ELECTR ENG, V88, P45, DOI 10.1007/s00202-004-0254-2
   Rumelhart D. E., 1986, PARALLEL DISTRIBUTED, VI
   Safavieh E, 2007, P INT C POW SYST ICP
   Salcedo-Sanz S, 2009, RENEW ENERG, V34, P1451, DOI 10.1016/j.renene.2008.10.017
   Sanz S Salcedo, 2008, 2008 8th International Conference on Hybrid Intelligent Systems (HIS), P608, DOI 10.1109/HIS.2008.36
   Sargolzaei J, 2009, SIMUL MODEL PRACT TH, V17, P1290, DOI 10.1016/j.simpat.2009.05.003
   Schlechtingen M, 2011, MECH SYST SIGNAL PR, V25, P1849, DOI 10.1016/j.ymssp.2010.12.007
   Senjyu T, 2006, IEEE T ENERGY CONVER, V21, P467, DOI 10.1109/TEC.2006.874253
   SENKAL S, 2013, P 8 INT C EL EL ENG, P196
   Sfetsos A, 2000, RENEW ENERG, V21, P23, DOI 10.1016/S0960-1481(99)00125-1
   Sfetsos A, 2002, RENEW ENERG, V27, P163, DOI 10.1016/S0960-1481(01)00193-8
   Sharma P, 2014, POW EN SYST C SUST E
   Sheeja V, 2010, P INT C POW EL DRIV, P1
   Sheela KG, 2014, SOFT COMPUT, V18, P607, DOI 10.1007/s00500-013-1084-9
   Sheela KG, 2013, NEUROCOMPUTING, V122, P425, DOI 10.1016/j.neucom.2013.06.008
   Shi J, 2012, RENEW SUST ENERG REV, V16, P3471, DOI 10.1016/j.rser.2012.02.044
   Shulian Yang, 2008, Proceedings of 2008 International Conference on Condition Monitoring and Diagnosis, CMD 2008, P1327, DOI 10.1109/CMD.2008.4580221
   Singh S, 2007, J ENERG ENG-ASCE, V133, P46, DOI 10.1061/(ASCE)0733-9402(2007)133:1(46)
   Soman SS, 2010, P 42 N AM POW S NAPS
   Sreelakshmi K, 2008, WORLD ACAD SCI ENG T, V18, P721
   Sudheer KP, 2004, HYDROLOGICAL ENG, V8, P161
   Tu YL, 2012, ENERG CONVERS MANAGE, V59, P114, DOI 10.1016/j.enconman.2012.02.022
   Turbelin G, 2009, RENEW ENERG, V34, P1024, DOI 10.1016/j.renene.2008.08.016
   Upadhyay K. G., 2011, INT J ENG SCI TECHNO, V3, P107
   Vasconcelos H, 2006, 9 INT C PROB METH AP
   Velazquez S, 2011, APPL ENERG, V88, P3869, DOI 10.1016/j.apenergy.2011.05.007
   Velazquez S, 2011, RENEW SUST ENERG REV, V15, P1556, DOI 10.1016/j.rser.2010.11.036
   Wang Jialong, 2011, Proceedings of the 2011 6th International Forum on Strategic Technology (IFOST 2011), P443, DOI 10.1109/IFOST.2011.6021059
   Wang JZ, 2015, RENEW ENERG, V76, P91, DOI 10.1016/j.renene.2014.11.011
   Xiaomei Wu, 2011, 2011 4th International Conference on Electric Utility Deregulation and Restructuring and Power Technologies (DRPT 2011), P1879, DOI 10.1109/DRPT.2011.5994206
   Yanping Liu, 2009, Proceedings of the 2009 Second International Conference on Intelligent Networks and Intelligent Systems (ICINIS 2009), P581, DOI 10.1109/ICINIS.2009.153
   Yeh WC, 2014, INT J ELEC POWER, V55, P741, DOI 10.1016/j.ijepes.2013.10.001
   Yilmaz AS, 2009, EXPERT SYST APPL, V36, P9767, DOI 10.1016/j.eswa.2009.02.014
   Yin CG, 2003, SIMUL MODEL PRACT TH, V11, P211, DOI 10.1016/S1569-190X(03)00044-3
   You XY, 2012, PROCEDIA ENGINEER, V29, P3132, DOI 10.1016/j.proeng.2012.01.453
   Yurdusev MA, 2006, ENERGY, V31, P2153, DOI 10.1016/j.energy.2005.09.007
   Zhang GQ, 1998, INT J FORECASTING, V14, P35, DOI 10.1016/S0169-2070(97)00044-7
   Zhang WY, 2013, APPL SOFT COMPUT, V13, P3225, DOI 10.1016/j.asoc.2013.02.016
   Zhao P, 2012, RENEW ENERG, V43, P234, DOI 10.1016/j.renene.2011.11.051
NR 167
TC 78
Z9 80
U1 7
U2 123
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD SEP
PY 2015
VL 49
BP 534
EP 562
DI 10.1016/j.rser.2015.04.166
PG 29
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA CL7HA
UT WOS:000357141900045
DA 2018-12-27
ER

PT J
AU Wang, YH
   Kirtley, JR
   Katmis, F
   Jarillo-Herrero, P
   Moodera, JS
   Moler, KA
AF Wang, Y. H.
   Kirtley, J. R.
   Katmis, F.
   Jarillo-Herrero, P.
   Moodera, J. S.
   Moler, K. A.
TI RETRACTED: Observation of chiral currents at the magnetic domain
   boundary of a topological insulator (retracted article see vol 350, pg
   1482, 2015)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID SURFACE; LIMIT
AB A magnetic domain boundary on the surface of a three-dimensional topological insulator is predicted to host a chiral edge state, but direct demonstration is challenging. We used a scanning superconducting quantum interference device to show that current in a magnetized topological insulator heterostructure (EuS/Bi2Se3) flows at the edge when the Fermi level is gate-tuned to the surface band gap. We further induced micrometer-scale magnetic structures on the heterostructure and detected a chiral edge current at the magnetic domain boundary. The chirality of the current was determined by magnetization of the surrounding domain, and its magnitude by the local chemical potential rather than the applied current. Such magnetic structures provide a platform for detecting topological magnetoelectric effects and may enable progress in quantum information processing and spintronics.
C1 [Wang, Y. H.; Kirtley, J. R.; Moler, K. A.] Stanford Univ, Dept Phys & Appl Phys, Stanford, CA 94305 USA.
   [Wang, Y. H.; Moler, K. A.] SLAC Natl Accelerator Lab, Stanford Inst Mat & Energy Sci, Menlo Pk, CA 94025 USA.
   [Katmis, F.; Moodera, J. S.] MIT, Francis Bitter Magnet Lab, Cambridge, MA 02139 USA.
   [Katmis, F.; Moodera, J. S.] MIT, Plasma Sci & Fus Ctr, Cambridge, MA 02139 USA.
   [Katmis, F.; Jarillo-Herrero, P.; Moodera, J. S.] MIT, Dept Phys, Cambridge, MA 02139 USA.
RP Wang, YH (reprint author), Stanford Univ, Dept Phys & Appl Phys, Stanford, CA 94305 USA.
EM wangyhv@stanford.edu; kmoler@stanford.edu
FU Center for Function Accelerated nanoMaterial Engineering (FAME), one of
   six centers of STARnet, a Semiconductor Research Corporation program -
   Microelectronics Advanced Research Corp. (MARCO); Defense Advanced
   Research Projects Agency (DARPA); Department of Energy (DOE), Office of
   Science, Basic Energy Sciences, Materials Sciences and Engineering
   Division [DE-AC02-76SF00515]; NSF-NSEC [0830228]; NSF IMR-MIP [0957616];
   Urbanek Fellowship of the Department of Applied Physics at Stanford
   University; Massachusetts Institute of Technology's Materials Research
   Science and Engineering Center (MRSEC) through MRSEC Program of the
   National Science Foundation [DMR-0819762]; NSF [DMR-1207469]; ONR
   [N00014-13-1-0301]; DOE, Basic Energy Sciences Office, Division of
   Materials Sciences and Engineering [DE-SC0006418]
FX These measurements were supported by the Center for Function Accelerated
   nanoMaterial Engineering (FAME), one of six centers of STARnet, a
   Semiconductor Research Corporation program sponsored by the
   Microelectronics Advanced Research Corp. (MARCO) and the Defense
   Advanced Research Projects Agency (DARPA). Preliminary measurements and
   analysis were supported by the Department of Energy (DOE), Office of
   Science, Basic Energy Sciences, Materials Sciences and Engineering
   Division, under contract DE-AC02-76SF00515. The SQUID microscope and
   sensors were developed with support from NSF-NSEC 0830228 and NSF
   IMR-MIP 0957616. Y.H.W. is partially supported by the Urbanek Fellowship
   of the Department of Applied Physics at Stanford University. For sample
   preparation, F.K., P.J-H., and J.S.M. acknowledge support by the
   Massachusetts Institute of Technology's Materials Research Science and
   Engineering Center (MRSEC) through the MRSEC Program of the National
   Science Foundation under award DMR-0819762. Partial support for sample
   development was provided by NSF (DMR-1207469), ONR (N00014-13-1-0301)
   (F.K. and J.S.M.), and by the DOE, Basic Energy Sciences Office,
   Division of Materials Sciences and Engineering, under award no.
   DE-SC0006418 (F.K. and P.J-H.). We are grateful for the assistance from
   G. Gibson, M. Ketchen, and M. Huber on developing the SQUID sensors and
   from I. Sochnikov, E. Spanton, J. Palmstrom, and K. C. Nowack on the
   measurement, as well as for stimulating discussions with S.-C. Zhang,
   X.-L. Qi, J. Wang, D. Goldhaber-Gordon, and B. I. Halperin.
CR Akhmerov AR, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.216404
   Analytis JG, 2010, NAT PHYS, V6, P960, DOI [10.1038/nphys1861, 10.1038/NPHYS1861]
   Chang CZ, 2013, SCIENCE, V340, P167, DOI 10.1126/science.1234414
   Checkelsky JG, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.196801
   Checkelsky JG, 2012, NAT PHYS, V8, P729, DOI [10.1038/NPHYS2388, 10.1038/nphys2388]
   Datta S., 1995, ELECT TRANSPORT MESO
   Ferreira GJ, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.106802
   Fu L, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.096407
   Gardner BW, 2001, REV SCI INSTRUM, V72, P2361, DOI 10.1063/1.1364668
   Ghosh DB, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.115211
   Hammer R, 2013, PHYS REV B, V88, DOI 10.1103/PhysRevB.88.235119
   Hasan MZ, 2010, REV MOD PHYS, V82, P3045, DOI 10.1103/RevModPhys.82.3045
   Huber ME, 2001, IEEE T APPL SUPERCON, V11, P4048, DOI 10.1109/77.947383
   Kirtley J. R., 2013, P 14 INT SUP EL C IS
   Kitaev A. Y., 2001, PHYS USPEKHI, V44, P131
   Kou XF, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.137201
   Lee AT, 2014, PHYS REV B, V90, DOI 10.1103/PhysRevB.90.155103
   Liu CX, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.041307
   Mellnik AR, 2014, NATURE, V511, P449, DOI 10.1038/nature13534
   Men'shov VN, 2013, PHYS REV B, V88, DOI 10.1103/PhysRevB.88.224401
   Meng QL, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.176803
   MOODERA JS, 1988, PHYS REV LETT, V61, P637, DOI 10.1103/PhysRevLett.61.637
   Nowack KC, 2013, NAT MATER, V12, P787, DOI [10.1038/NMAT3682, 10.1038/nmat3682]
   O'Mahony D, 2005, THIN SOLID FILMS, V488, P200, DOI 10.1016/j.tsf.2005.04.081
   PANKRATOV OA, 1987, PHYS LETT A, V121, P360, DOI 10.1016/0375-9601(87)90307-0
   Qi XL, 2011, REV MOD PHYS, V83, DOI 10.1103/RevModPhys.83.1057
   Spanton EM, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.026804
   Tserkovnyak Y, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.187201
   Wang YH, 2013, SCIENCE, V342, P453, DOI 10.1126/science.1239834
   Wang YH, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.207602
   Wei P, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.186807
   Wickles C, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.035151
   Xia Y, 2009, NAT PHYS, V5, P398, DOI 10.1038/NPHYS1274
   Yang QI, 2013, PHYS REV B, V88, DOI 10.1103/PhysRevB.88.081407
   Yokoyama T., 2013, PHYSICA E
   Yoshioka D., 2002, QUANTUM HALL EFFECT
   Yu R, 2010, SCIENCE, V329, P61, DOI 10.1126/science.1187485
   Zhang Y, 2010, NAT PHYS, V6, P584, DOI 10.1038/NPHYS1689
   Zyuzin AA, 2011, PHYS REV B, V83, DOI 10.1103/PhysRevB.83.195413
NR 39
TC 11
Z9 11
U1 5
U2 107
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD AUG 28
PY 2015
VL 349
IS 6251
BP 948
EP 952
DI 10.1126/science.aaa0508
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CQ5LW
UT WOS:000360646800046
PM 26272905
DA 2018-12-27
ER

PT J
AU Namazi, H
   Kulish, VV
   Wong, A
AF Namazi, Hamidreza
   Kulish, Vladimir V.
   Wong, Albert
TI RETRACTED: Mathematical Modelling and Prediction of the Effect of
   Chemotherapy on Cancer Cells (Retracted article. See vol. 8, art no
   46986, 2018)
SO SCIENTIFIC REPORTS
LA English
DT Article; Retracted Publication
ID BREAST-CANCER; TUMORS; DNA
AB Cancer is a class of diseases characterized by out-of-control cells' growth which affect DNAs and make them damaged. Many treatment options for cancer exist, with the primary ones including surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy and palliative care. Which treatments are used depends on the type, location, and grade of the cancer as well as the person's health and wishes. Chemotherapy is the use of medication (chemicals) to treat disease. More specifically, chemotherapy typically refers to the destruction of cancer cells. Considering the diffusion of drugs in cancer cells and fractality of DNA walks, in this research we worked on modelling and prediction of the effect of chemotherapy on cancer cells using Fractional Diffusion Equation (FDE). The employed methodology is useful not only for analysis of the effect of special drug and cancer considered in this research but can be expanded in case of different drugs and cancers.
C1 [Namazi, Hamidreza; Kulish, Vladimir V.] Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore 639798, Singapore.
   [Wong, Albert] Sarawak Gen Hosp, Dept Radiotherapy Oncol & Palliat Care, Kuching, Malaysia.
RP Namazi, H (reprint author), Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore 639798, Singapore.
EM m080012@e.ntu.edu.sg
RI Kulish, Vladimir/A-3829-2011
OI Kulish, Vladimir/0000-0001-9978-5423
CR de Pillis LG, 2006, J THEOR BIOL, V238, P841, DOI 10.1016/j.jtbi.2005.06.037
   de Pillis L, 2009, COMPUT MATH METHOD M, V10, P165, DOI 10.1080/17486700802216301
   Dixit D. S., 2012, ADV APPL MATH BIOSCI, V3, P1
   Esteller M, 1999, CANCER RES, V59, P67
   Ghaffari A., 2009, IRANIAN J ELECT ELEC, V5, P151
   Ghatak Souvik, 2013, J Biomol Tech, V24, P224, DOI 10.7171/jbt.13-2404-001
   Hashmi M. U., 2014, W J ZOOLOGY, V9, P190
   Hinow P, 2009, MATH BIOSCI ENG, V6, P521, DOI 10.3934/mbe.2009.6.521
   Kaowumpai W, 2007, PROC WRLD ACAD SCI E, V26, P287
   Lankelma J, 2000, MICROVASC RES, V59, P149, DOI 10.1006/mvre.1999.2218
   Liu WX, 2005, MATH COMPUT MODEL, V42, P1089, DOI 10.1016/j.mcm.2004.09.008
   Namazi H., 2015, COMPUT MATH METHOD M, V2015, P1, DOI DOI 10.1155/2015/242695
   Namazi H., COMPUT MATH IN PRESS
   Norris ES, 2006, MATH COMPUT MODEL, V43, P820, DOI 10.1016/j.mcm.2005.09.026
   Oldham KB, 1974, FRACTIONAL CALCULUS
   Pathak AK, 2006, CLIN CHEM, V52, P1833, DOI 10.1373/clinchem.2005.062893
   Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136
   Weber B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-294
   Zohdi TI, 2004, COMPUT METHOD APPL M, V193, P679, DOI 10.1016/j.cma.2003.11.006
NR 19
TC 12
Z9 12
U1 1
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 28
PY 2015
VL 5
AR 13583
DI 10.1038/srep13583
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CP9TQ
UT WOS:000360237900001
PM 26316014
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU La Sala, GB
   Nicoli, A
   Fornaciari, E
   Falbo, A
   Rondini, I
   Morini, D
   Valli, B
   Villani, MT
   Palomba, S
AF La Sala, Giovanni Battista
   Nicoli, Alessia
   Fornaciari, Eleonora
   Falbo, Angela
   Rondini, Ilaria
   Morini, Daria
   Valli, Barbara
   Villani, Maria Teresa
   Palomba, Stefano
TI RETRACTED: Intracytoplasmic morphologically selected sperm injection
   versus conventional intracytoplasmic sperm injection: a randomized
   (Retracted article. See vol. 15, Artn 62, 2017)
SO REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
LA English
DT Article; Retracted Publication
DE Intracytoplasmic sperm injection; ICSI; Intracytoplasmic morphologically
   selected sperm injection; IMSI; MSOME; RCT
ID WORLD-HEALTH-ORGANIZATION; CLINICAL-OUTCOMES; CONSORT STATEMENT; FINE
   MORPHOLOGY; ICSI; INFERTILITY; OOCYTE; IMSI; SPERMATOZOA; PREGNANCIES
AB Background: Intracytoplasmic morphologically selected sperm injection (IMSI) is still proposed and employed in the clinical practice to improve the reproductive outcome in infertile couples scheduled for conventional intracytoplasmic sperm injection (cICSI). The aim of the current randomized controlled trial (RCT) was to test the hypothesis that IMSI gives a better live birth delivery rate than cICSI.
   Methods: Infertile couples scheduled for their first cICSI cycle for male factor were allocated using a simple randomization procedure. All available biological and clinical data were recorded and analyzed in a triple-blind fashion.
   Results: Our final analysis involved the first 121 patients (48 and 73 subjects for IMSI and cICSI arm, respectively) because the trial was stopped prematurely on the advice of the data safety and monitoring Committee because of concerns about IMSI efficacy at the first interim analysis. No significant difference between arms was detected in rates of clinical pregnancy per embryo transferred [11/34 (32.3 %) vs. 15/64 (23.4 %); odds ratio (OR) 1.56, 95 % (confidence interval) CI 0.62-3.93, P = 0.343] and of live birth delivery [9/48 (18.8 %) vs. 11/73 (15.1 %); OR 1.30, 95% CI 0.49-3.42, P = 0.594).
   Conclusion: Current data did not support the routine use of IMSI in the clinical practice for improving cICSI results in unselected infertile couples with male factor.
C1 [La Sala, Giovanni Battista; Nicoli, Alessia; Fornaciari, Eleonora; Falbo, Angela; Rondini, Ilaria; Morini, Daria; Valli, Barbara; Villani, Maria Teresa; Palomba, Stefano] Arcispedale S Maria Nuova Reggio Emilia, IRCCS, Obstet & Gynecol Unit, I-42123 Reggio Emilia, Italy.
   [La Sala, Giovanni Battista] Univ Modena & Reggio Emilia, I-41124 Modena, Italy.
RP Palomba, S (reprint author), Arcispedale S Maria Nuova Reggio Emilia, IRCCS, Obstet & Gynecol Unit, Viale Risorgimento 80, I-42123 Reggio Emilia, Italy.
EM stefanopalomba@tin.it
RI La Sala, Giovanni Battista/F-4613-2017
OI La Sala, Giovanni Battista/0000-0002-8616-1731; Palomba,
   Stefano/0000-0003-2767-8295
CR Antinori M, 2008, REPROD BIOMED ONLINE, V16, P835, DOI 10.1016/S1472-6483(10)60150-2
   Balaban B, 2011, REPROD BIOMED ONLINE, V22, P472, DOI 10.1016/j.rbmo.2010.11.003
   BARTOOV B, 1994, HUM REPROD, V9, P2069, DOI 10.1093/oxfordjournals.humrep.a138395
   Bartoov B, 2003, FERTIL STERIL, V80, P1413, DOI 10.1016/j.fertnstert.2003.05.016
   Bartoov B, 2002, J ANDROL, V23, P1
   Berkovitz A, 2007, FERTIL STERIL, V88, pS20, DOI 10.1016/j.fertnstert.2007.07.083
   Berkovitz A, 2006, REPROD BIOMED ONLINE, V12, P634, DOI 10.1016/S1472-6483(10)61191-1
   Berkovitz A, 2005, HUM REPROD, V20, P185, DOI 10.1093/humrep/deh545
   Boitrelle F, 2014, REPROD BIOMED ONLINE, V28, P6, DOI 10.1016/j.rbmo.2013.09.019
   Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008
   Cassuto NG, 2014, REPROD BIOMED ONLINE, V28, P47, DOI 10.1016/j.rbmo.2013.08.013
   El Khattabi L, 2013, FERTIL STERIL, V100, P62, DOI 10.1016/j.fertnstert.2013.02.048
   Holte J, 2007, HUM REPROD, V22, P548, DOI 10.1093/humrep/del403
   Kato Yoku, 2012, Reproductive Medicine and Biology, V11, P165, DOI 10.1007/s12522-012-0126-9
   Knez K, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-123
   KRUGER TF, 1987, UROLOGY, V30, P248, DOI 10.1016/0090-4295(87)90246-9
   Leandri RD, 2013, ANDROLOGY-US, V1, P692, DOI 10.1111/j.2047-2927.2013.00104.x
   Legro RS, 2014, FERTIL STERIL, V102, P952, DOI 10.1016/j.fertnstert.2014.08.002
   Mansour R, 1998, HUM REPROD UPDATE, V4, P43, DOI 10.1093/humupd/4.1.43
   Nadalini M, 2009, REPROD BIOMED ONLINE, V19, P45, DOI 10.1016/S1472-6483(10)60283-0
   Nicoli A, 2010, REPROD BIOL ENDOCRIN, V8, DOI 10.1186/1477-7827-8-77
   PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F
   Palomba S, 2010, BJOG-INT J OBSTET GY, V117, P711, DOI 10.1111/j.1471-0528.2010.02525.x
   Palomba S, 2011, FERTIL STERIL, V96, P1384, DOI 10.1016/j.fertnstert.2011.09.020
   Peer S, 2007, FERTIL STERIL, V88, P1589, DOI 10.1016/j.fertnstert.2007.01.069
   Perrin A, 2013, EXPERT REV OBSTET GY, V8, P261
   Practice Comm Amer Soc Reprod Med, 2012, FERTIL STERIL, V98, P1395, DOI 10.1016/j.fertnstert.2012.08.026
   Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232
   Setti AS, 2013, EUR J OBSTET GYN R B, V171, P286, DOI 10.1016/j.ejogrb.2013.09.006
   Setti AS, 2014, EUR J OBSTET GYN R B, V183, P96, DOI 10.1016/j.ejogrb.2014.10.008
   Setti AS, 2011, FERTIL STERIL, V95, P2711, DOI 10.1016/j.fertnstert.2011.03.003
   Setti AS, 2015, J ASSIST REPROD GEN, V32, P445, DOI 10.1007/s10815-014-0422-x
   Setti AS, 2013, REPROD BIOMED ONLINE, V27, P338, DOI 10.1016/j.rbmo.2013.06.011
   Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352
   Teixeira DM, 2013, COCHRANE DB SYST REV, V7
   Wold Health Organization (WHO), 2010, LAB MAN EX HUM SEM
   Zegers-Hochschild F, 2009, HUM REPROD, V24, P2683, DOI 10.1093/humrep/dep343
NR 37
TC 5
Z9 5
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1477-7827
J9 REPROD BIOL ENDOCRIN
JI Reprod. Biol. Endocrinol.
PD AUG 27
PY 2015
VL 13
AR 97
DI 10.1186/s12958-015-0096-y
PG 11
WC Endocrinology & Metabolism; Reproductive Biology
SC Endocrinology & Metabolism; Reproductive Biology
GA CQ0IM
UT WOS:000360278700001
PM 26307050
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Haghayeghi, R
   Kapranos, P
AF Haghayeghi, R.
   Kapranos, P.
TI RETRACTED: Microstructure evolution and mechanical properties of Al-6%
   Mg alloys processed by equal channel angular pressing (Retracted
   article. See vol. 647, pg. 353, 2015)
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Retracted Publication
DE Equal channel angular processing; Aluminum alloys; Grain refinement
ID GRAIN-REFINEMENT; SC ALLOY; TENSILE PROPERTIES; ALUMINUM-ALLOYS;
   HALL-PETCH; TEMPERATURE; BEHAVIOR; DEFORMATION; ADDITIONS; STEEL
AB Materials processed by Severe Plastic Deformation (SPD) typically possess high strength but low uniform elongation (similar to 5%). An Al-6 wt% Mg processed up to 8 passes by ECAP at room temperature with interpass annealing where high ductility (elongation similar to 15.2%) and strength (UTS similar to 550 MPa) acquired. Upon annealing at 300 degrees C, discontinuous recrystallization is initiated in the early stages with subsequent grain growth. Slow recovery and recrystallization kinetics in association with the bimodal structure and grain refinement with high dislocation density provided appropriate ductility and strength simultaneously. Annealed ECAP offers an approach that could be applicable to hard-to-deform Al alloys with high content of solid solutions. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Haghayeghi, R.] Islamic Azad Univ, Dept Mat Engn, Sci & Res Branch, Tehran, Iran.
   [Kapranos, P.] Univ Sheffield, Dept Mat Sci & Engn, Sheffield S1 3JD, S Yorkshire, England.
RP Haghayeghi, R (reprint author), Islamic Azad Univ, Dept Mat Engn, Sci & Res Branch, Tehran, Iran.
EM rhaghayeghi@yahoo.com
CR AXON HJ, 1948, PROC R SOC LON SER-A, V193, P1, DOI 10.1098/rspa.1948.0030
   Chen YJ, 2011, MATER LETT, V65, P3472, DOI 10.1016/j.matlet.2011.07.067
   Chen YJ, 2010, METALL MATER TRANS A, V41A, P787, DOI 10.1007/s11661-009-0040-x
   Fang DR, 2007, MAT SCI ENG A-STRUCT, V459, P137, DOI 10.1016/j.msea.2007.01.062
   Furukawa M, 1998, PHILOS MAG A, V78, P203, DOI 10.1080/01418619808244809
   Furukawa M, 2001, ACTA MATER, V49, P3829, DOI 10.1016/S1359-6454(01)00262-2
   Goloborodko A, 2004, MAT SCI ENG A-STRUCT, V381, P121, DOI 10.1016/j.msea.2004.04.049
   Gubicza J, 2004, MAT SCI ENG A-STRUCT, V387, P55, DOI 10.1016/j.msea.2004.03.076
   Gubicza J, 2009, J ALLOY COMPD, V483, P271, DOI 10.1016/j.jallcom.2008.07.200
   Haghayeghi R, 2014, MATER LETT, V129, P182, DOI 10.1016/j.matlet.2014.05.044
   Han BQ, 2003, PHIL MAG LETT, V83, P89, DOI 10.1080/0950083021000048154
   Hansen N, 2004, SCRIPTA MATER, V51, P801, DOI 10.1016/j.scriptamat.2004.06.002
   Hong SG, 2005, J NUCL MATER, V340, P307, DOI 10.1016/j.jnucmat.2004.12.012
   Horita Z, 2000, METALL MATER TRANS A, V31, P691, DOI 10.1007/s11661-000-0011-8
   Huarte B, 2005, J MATER PROCESS TECH, V162, P317, DOI 10.1016/j.jmatprotec.2005.02.057
   Humphreys F. J., 2004, RECRYSTALLIZATION RE
   Iwahashi Y, 1998, METALL MATER TRANS A, V29, P2503, DOI 10.1007/s11661-998-0222-y
   Kaibyshev R, 2010, MATER SCI FORUM, V638-642, P1952, DOI 10.4028/www.scientific.net/MSF.638-642.1952
   KAIBYSHEV R, 2009, THERMEC, V638-642, P1952
   Kapoor R, 2007, ACTA MATER, V55, P5408, DOI 10.1016/j.actamat.2007.05.049
   Lee S, 2003, MAT SCI ENG A-STRUCT, V342, P294, DOI 10.1016/S0921-5093(02)00319-2
   Morris DG, 2002, ACTA MATER, V50, P4047, DOI 10.1016/S1359-6454(02)00203-3
   Munoz-Morris MA, 2003, SCRIPTA MATER, V48, P213, DOI 10.1016/S1359-6462(02)00501-8
   Nikulin I, 2005, MAT SCI ENG A-STRUCT, V407, P62, DOI 10.1016/j.msea.2005.06.014
   Ryen O, 2006, METALL MATER TRANS A, V37A, P1999, DOI 10.1007/s11661-006-0142-7
   Sabirov I, 2013, MAT SCI ENG A-STRUCT, V560, P1, DOI 10.1016/j.msea.2012.09.020
   Sitdikov O, 2008, ACTA MATER, V56, P821, DOI 10.1016/j.actamat.2007.10.029
   Valiev RZ, 2010, SCRIPTA MATER, V63, P949, DOI 10.1016/j.scriptamat.2010.07.014
   Yamashita A, 2000, MAT SCI ENG A-STRUCT, V287, P100, DOI 10.1016/S0921-5093(00)00836-4
   Zhang XD, 2012, ACTA MATER, V60, P5933, DOI 10.1016/j.actamat.2012.07.037
NR 30
TC 4
Z9 4
U1 3
U2 21
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
EI 1873-4936
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD AUG 26
PY 2015
VL 642
BP 84
EP 90
DI 10.1016/j.msea.2015.06.076
PG 7
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA CO4YR
UT WOS:000359167300011
DA 2018-12-27
ER

PT J
AU Le, AW
   Wang, ZH
   Shan, LL
   Xiao, TH
   Zhuo, R
   Luo, GN
AF Le, Aiwen
   Wang, Zhonghai
   Shan, Lili
   Xiao, Tianhui
   Zhuo, Rong
   Luo, Guangnan
TI RETRACTED: Peritoneal vaginoplasty by Luohu I and Luohu II technique: a
   comparative study of the outcomes(Retracted article. See vol. 22, Artn.
   No. 26, 2017)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE MRKH syndrome; Vaginoplasty; Peritoneum; Laparoscope
ID KUSTER-HAUSER-SYNDROME; VAGINAL AGENESIS; SIGMOID VAGINOPLASTY;
   FUNCTIONAL OUTCOMES; NEOVAGINA; CREATION; EXPERIENCE; MANAGEMENT; WOMEN;
   VERSION
AB Background: Surgical vaginoplasty is the standard treatment for women suffering from Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome. This study compares the advantages and disadvantages of Luohu I technique or its modification, Luohu II technique.
   Methods: Women with MRKH syndrome undergoing laparoscopic peritoneal vaginoplasty using either the Luohu I (N = 145) or Luohu II (N = 155) technique were recruited. We compare the effectiveness of the Luohu II and one of Luohu I. Sexual satisfaction was checked by Female Sexual Function Index.
   Results: There was no significant difference in the mean operation time, volume of intraoperative blood loss, time for the first passage of gas, sexual satisfaction (and hospital stay for patients in either group (P > 0.05). But patients in the Luohu II group had a significantly lower incidence of complications than patients in the Luohu I group. All patients had vaginal depths more than 9 cm over 3 months post-surgery.
   Conclusions: Compared with the traditional Luohu I laparoscopic peritoneal vaginoplasty, the Luohu II operation is easier to perform and causes less damage to the bladder and rectum. The physiological and anatomical features of the artificial vagina resemble the normal vagina in both techniques.
C1 [Le, Aiwen; Wang, Zhonghai; Shan, Lili; Xiao, Tianhui; Zhuo, Rong] Guaongdong Med Univ, Affiliated Shenzhen Nanshan Peoples Hosp, Dept Obstet & Gynecol, Shenzhen 518052, Guangdong, Peoples R China.
   [Luo, Guangnan] Guaongdong Med Univ, Affiliated Shenzhen Luohu Peoples Hosp, Dept Obstet & Gynecol, Shenzhen 518052, Guangdong, Peoples R China.
RP Wang, ZH (reprint author), Guaongdong Med Univ, Affiliated Shenzhen Nanshan Peoples Hosp, Dept Obstet & Gynecol, Shenzhen 518052, Guangdong, Peoples R China.
EM leaiwen19@126.com
FU Research Funding: Shen zhen city technology creative committee
   [JCYJ2014041109115144]
FX This work was supported by operation room and Ultrasound departments. We
   appreciate the valuable comments from other members of our hospital.
   Research supported by a grant from the Research Funding: Shen zhen city
   technology creative committee. No: JCYJ2014041109115144.
CR Abramowicz S, 2013, GYNECOL OBSTET FERTI, V41, P4, DOI 10.1016/j.gyobfe.2012.11.002
   Alessandrescu D, 1996, AM J OBSTET GYNECOL, V175, P131, DOI 10.1016/S0002-9378(96)70262-4
   Allen LM, 2010, FERTIL STERIL, V94, P2272, DOI 10.1016/j.fertnstert.2010.02.008
   Borkowski A, 2008, BJU INT, V101, P1433, DOI 10.1111/j.1464-410X.2008.07520.x
   Carrard C, 2012, FERTIL STERIL, V97, P691, DOI 10.1016/j.fertnstert.2011.12.015
   Cleary RK, 2006, DIS COLON RECTUM, V49, P1203, DOI 10.1007/s10350-006-0620-y
   Creatsas G, 2001, FERTIL STERIL, V76, P1036, DOI 10.1016/S0015-0282(01)02836-9
   Csermely T, 2011, J PEDIATR ADOL GYNEC, V24, P147, DOI 10.1016/j.jpag.2010.12.008
   Davies MC, 2007, CURR OPIN UROL, V17, P415, DOI 10.1097/MOU.0b013e3282f0d5b3
   Dessy LA, 2014, PLAST RECONSTR SURG, V133, P158, DOI 10.1097/01.prs.0000435844.95551.35
   El-Sayed HM, 2007, INT UROGYNECOL J, V18, P1043, DOI 10.1007/s00192-006-0287-3
   Imparato E, 2007, INT UROGYNECOL J, V18, P1465, DOI 10.1007/s00192-007-0358-0
   Ismail-Pratt IS, 2007, HUM REPROD, V22, P2020, DOI 10.1093/humrep/dem074
   Jo EJ, 2013, J MINIM INVAS GYN, V20, P166, DOI 10.1016/j.jmig.2012.10.008
   Kdous Moez, 2013, Tunis Med, V91, P371
   Khen-Dunlop N, 2007, J UROLOGY, V177, P1107, DOI 10.1016/j.juro.2006.11.003
   Lee MH, 2006, YONSEI MED J, V47, P892, DOI 10.3349/ymj.2006.47.6.892
   Liao L- M, 2006, J Obstet Gynaecol, V26, P144
   Luo GN, 2009, VAGINOPLASTY
   Ma JH, 2014, J SEX MED, V11, P909, DOI 10.1111/jsm.12451
   Marianowski P, 2007, NEUROENDOCRINOL LETT, V28, P704
   Miller PB, 2009, JSLS-J SOC LAPAROEND, V13, P221
   Morcel K, 2013, EUR J OBSTET GYN R B, V169, P317, DOI 10.1016/j.ejogrb.2013.03.005
   Nakhal RS, 2012, J PEDIATR ADOL GYNEC, V25, P352, DOI 10.1016/j.jpag.2011.06.003
   Nowier A, 2012, INT BRAZ J UROL, V38, P380, DOI 10.1590/S1677-55382012000300011
   Prakash V, 2011, J OBSTET GYNAECOL RE, V37, P501, DOI 10.1111/j.1447-0756.2010.01388.x
   Schober Justine M, 2007, J Pediatr Urol, V3, P167, DOI 10.1016/j.jpurol.2006.07.010
   Shi L, 2005, CHIN J MIN INV SURG, V5, P65
   Shi L, 2003, CHIN J OBSTET GYNECO, V38, P312
   Ugur MG, 2012, EUR J OBSTET GYN R B, V163, P85, DOI 10.1016/j.ejogrb.2012.03.024
   Zhu L, 2010, FEMALE GENITAL ABNOR
NR 31
TC 3
Z9 4
U1 2
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD AUG 22
PY 2015
VL 20
AR 69
DI 10.1186/s40001-015-0165-x
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CP6NV
UT WOS:000360005200002
PM 26297245
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ma, Y
   Wang, GW
   Sun, ST
   Song, XN
AF Ma Yong
   Wang Guang-Wei
   Sun Shao-Tao
   Song Xiu-Neng
TI RETRACTED: First-Principles Study on the Near-Edge X-ray Absorption Fine
   Structure Spectroscopy of the Fullerene-Derivative PCBM (Retracted
   article. See vol. 32, pg. 2092, 2016)
SO ACTA PHYSICO-CHIMICA SINICA
LA Chinese
DT Article; Retracted Publication
DE Density functional theory; X-ray; Fine structure; Fullerene-derivative;
   Full core hole
ID ELECTRONIC-STRUCTURE; SOLAR-CELLS; BLEND FILMS; SPECTRA; STATES; C-60;
   APPROXIMATION; PERFORMANCE; EXCHANGE; ISOMERS
AB Fullerene-derivative [6,6]-phenyl-C61-butyric acid methyl ester (PCBM) plays an important role in terms of electron transport in polymer solar cells. The electronic structure of PCBM is of much importance to investigate. In this study, the near-edge X-ray absorption fine structure spectroscopy and unoccupied orbitals of PCBM were researched with density functional theory. By comparing the calculated sum spectra of nonequivalent carbon atoms, we assigned the main resonances of PCBM. The origin of the shoulder in the right side of the first pi* resonance was analyzed, and the results showed that this absorption peak was mainly contributed by the transitions to higher unoccupied orbitals of the unmodified carbons in the C-60 cage.
C1 [Ma Yong; Wang Guang-Wei; Song Xiu-Neng] Shandong Normal Univ, Sch Phys & Elect, Jinan 250014, Peoples R China.
   [Sun Shao-Tao] Shandong Acad Informat & Commun Technol, Adm Ctr, Jinan 250101, Peoples R China.
RP Song, XN (reprint author), Shandong Normal Univ, Sch Phys & Elect, Jinan 250014, Peoples R China.
EM xiuneng@sdnu.edu.cn
FU National Natural Science Foundation of China [21303096, 11374195];
   Promotive Research Fund for Young and Middle-Aged Scientists of Shandong
   Province, China [BS2013CL016]; China Postdoctoral Science Foundation
   [2013M541951]; Scientific Research Foundation for the Returned Overseas
   Chinese Scholars, Ministry of Education, China
FX The project was supported by the National Natural Science Foundation of
   China (21303096, 11374195), Promotive Research Fund for Young and
   Middle-Aged Scientists of Shandong Province, China (BS2013CL016), China
   Postdoctoral Science Foundation (2013M541951), and Scientific Research
   Foundation for the Returned Overseas Chinese Scholars, Ministry of
   Education, China.
CR Anselmo A. S., 2013, J POLM SCI B, V51, P76
   Anselmo AS, 2011, CHEM MATER, V23, P2295, DOI 10.1021/cm1021596
   Bazylewski PF, 2011, CHEM PHYS LETT, V508, P90, DOI 10.1016/j.cplett.2011.04.017
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   Carlegrim E, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.054420
   DeLongchamp Dean M, 2005, Proceedings of the SPIE - The International Society for Optical Engineering, V5940, p59400A, DOI 10.1117/12.616776
   Dresselhaus M., 1996, SCI FULLERENES CARBO
   Friedrich D, 2011, BIONANOSCIENCE, V1, P218, DOI 10.1007/s12668-011-0025-2
   Frisch M.J., 2009, GAUSSIAN 09 REVISION
   Gao B, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2800028
   Germack DS, 2010, MACROMOLECULES, V43, P3828, DOI 10.1021/ma100027b
   Germack DS, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3149706
   Guo HL, 2014, ACTA POLYM SIN, P179, DOI 10.3724/SP.J.1105.2014.13303
   Hellgren N, 2001, APPL PHYS LETT, V79, P4348, DOI 10.1063/1.1428108
   Hermann K., 2007, STOBE VERSION 3 0 ST
   Kutzelnigg W, 1990, NMR BASIC PRINCIPLES, V213
   Li D, 2012, ACTA PHYS-CHIM SIN, V28, P1373, DOI 10.3866/PKU.WHXB201204061
   Luo Y, 2001, CHEM PHYS LETT, V337, P176, DOI 10.1016/S0009-2614(01)00181-6
   McNeill CR, 2013, J MATER CHEM C, V1, P187, DOI 10.1039/c2tc00001f
   Mikoushkin VM, 2008, FULLER NANOTUB CAR N, V16, P588, DOI 10.1080/15363830802286574
   Nyberg M, 1999, PHYS REV B, V60, P7956, DOI 10.1103/PhysRevB.60.7956
   Pacile D, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.066806
   Patnaik A, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1880952
   PERDEW JP, 1986, PHYS REV B, V33, P8822, DOI 10.1103/PhysRevB.33.8822
   Qi JY, 2012, CHEM PHYS LETT, V539, P222, DOI 10.1016/j.cplett.2012.05.015
   Rassolov VA, 1998, J CHEM PHYS, V109, P1223, DOI 10.1063/1.476673
   Richter MH, 2012, BIONANOSCIENCE, V2, P59, DOI 10.1007/s12668-011-0034-1
   SCHAFER A, 1994, J CHEM PHYS, V100, P5829, DOI 10.1063/1.467146
   Song XN, 2012, J PHYS CHEM C, V116, P12649, DOI 10.1021/jp302716w
   Stohr J, 1996, NEXAFS SPECTROSCOPY, P1
   Tang YH, 2002, CHEM PHYS LETT, V366, P636, DOI 10.1016/S0009-2614(02)01620-2
   TERMINELLO LJ, 1991, CHEM PHYS LETT, V182, P491, DOI 10.1016/0009-2614(91)90113-N
   Tillack AF, 2011, ACS APPL MATER INTER, V3, P726, DOI 10.1021/am101055r
   Triguero L, 1998, PHYS REV B, V58, P8097, DOI 10.1103/PhysRevB.58.8097
   Triguero L, 1999, J ELECTRON SPECTROSC, V104, P195, DOI 10.1016/S0368-2048(99)00008-0
   von Barth U., 1979, Solid State Communications, V32, P645, DOI 10.1016/0038-1098(79)90719-1
   VONBARTH U, 1982, PHYS REV B, V25, P5150, DOI 10.1103/PhysRevB.25.5150
   Watts B, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3506636
   Xue BF, 2010, J PHYS CHEM C, V114, P15797, DOI 10.1021/jp104695j
   YI L, 1995, PHYS REV B, V52, P14479, DOI 10.1103/PhysRevB.52.14479
   Zhao T, 2009, CHINESE PHYS C, V33, P954, DOI 10.1088/1674-1137/33/11/005
   Zhu MQ, 2005, ACTA PHYS-CHIM SIN, V21, P1378, DOI 10.3866/PKU.WHXB20051210
   Zhuo ZL, 2011, ACTA PHYS-CHIM SIN, V27, P875, DOI 10.3866/PKU.WHXB20110414
NR 44
TC 1
Z9 2
U1 8
U2 25
PU PEKING UNIV PRESS
PI BEIJING
PA PEKING UNIV, CHEMISTRY BUILDING, BEIJING 100871, PEOPLES R CHINA
SN 1000-6818
J9 ACTA PHYS-CHIM SIN
JI Acta Phys.-Chim. Sin.
PD AUG 12
PY 2015
VL 31
IS 8
BP 1483
EP 1488
DI 10.3866/PKU.WHXB201505251
PG 6
WC Chemistry, Physical
SC Chemistry
GA CR1XK
UT WOS:000361118400006
DA 2018-12-27
ER

PT J
AU Anju, S
   Kumar, NS
   Krishnakumar, B
   Kumar, BSD
AF Anju, S.
   Kumar, Nishanth S.
   Krishnakumar, B.
   Kumar, B. S. Dileep
TI RETRACTED: Synergistic combination of violacein and azoles that leads to
   enhanced killing of major human pathogenic dermatophytic fungi
   Trichophyton rubrum (Retracted article. See vol. 7, art no 496, 2017)
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article; Retracted Publication
DE azoles; dermatophytosis; Trichophyton rubrum; violacein; synergistic
ID VITRO ANTIFUNGAL ACTIVITY; IN-VITRO; CANDIDA-ALBICANS; ONYCHOMYCOSIS;
   INHIBITION; BIOSYNTHESIS; FLUCONAZOLE; INFECTIONS; EXPRESSION
AB Superficial mycoses caused by dermatophytic fungi such as Trichophyton rubrum represent the most common type of worldwide human infection affecting various keratinized tissues in our body such as the skin, hair, and nails, etc. The dermatophytic infection is a significant public health threat due to its persistent nature and high recurrence rates, and thus alternative treatments to cure this fungal infection are urgently required. The present study mainly focused on the synergistic activity of violacein with four azole drugs (ketoconazole, fluconazole, clotrimazole, and itraconazole) against T. rubrum. The synergistic antifungal activities of violacein and azoles were measured by checkerboard microdilution and time-kill assays. In our study, combinations of violacein and azoles predominantly recorded synergistic effect (FIG index < 0.5). Significant synergistic value was recorded by the combination of violacein and clotrimazole. Time-kill assay by the combination of MIC concentration of violacein and azoles recorded that the growth of the T rubrum was significantly arrested after 4-12 h of treatment. The combination of violacein and azoles leads to the enhanced inhibition of mycelial growth and conidial germination. Moreover combination enhanced the rate of release of intracellular materials. Morphological changes by SEM analysis were also prominent with the combination. A normal human cell line [Foreskin (FS) normal fibroblast] was used to check the cytotoxicity of violacein. Interestingly violacein recorded no cytotoxicity up to 100 mu g/ml. The in vitro synergistic effect of violacein and azoles against clinically relevant fungi, T rubrum, is reported here for the first time. Finally, our findings support the potential use of the violacein as an antifungal agent especially against dermatophytic fungi T. rubrum.
C1 [Anju, S.; Krishnakumar, B.] CSIR Natl Inst Interdisciplinary Sci & Technol, Environm Technol, Thiruvananthapuram 695019, Kerala, India.
   [Kumar, Nishanth S.; Kumar, B. S. Dileep] CSIR Natl Inst Interdisciplinary Sci & Technol, Agroproc & Nat Prod Div, Thiruvananthapuram 695019, Kerala, India.
RP Kumar, BSD (reprint author), CSIR Natl Inst Interdisciplinary Sci & Technol, Agroproc & Nat Prod Div, Estate PO, Thiruvananthapuram 695019, Kerala, India.
EM kumardileep@niist.res.in
RI TVM, NIIST/E-5132-2012
OI TVM, NIIST/0000-0002-5814-466X
FU ICMR (Government of India); Kerala State Council for Science Technology
   and Engineering (KSCSTE)
FX The research fellowship from ICMR (Government of India) to Ms. SA and
   infrastructural support from CSIR-NIIST are highly acknowledged in this
   study. The authors are thankful to CSIR 12th FYP project NaPHA (CSC 130)
   for financial assistance. NK acknowledges Kerala State Council for
   Science Technology and Engineering (KSCSTE) for providing PDF
   fellowship.
CR Aala F, 2010, AFR J MICROBIOL RES, V4, P380
   Almeida SR, 2008, MYCOPATHOLOGIA, V166, P277, DOI 10.1007/s11046-008-9103-6
   Anto RJ, 2003, J BIOL CHEM, V278, P25490, DOI 10.1074/jbc.M301790200
   Asticcioli S, 2008, NEW MICROBIOL, V31, P543
   Baltazar LD, 2013, J ANTIMICROB CHEMOTH, V68, P354, DOI 10.1093/jac/dks414
   Bitencourt TA, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-229
   Bruton L. L., 2006, GOODMAN GILMANS PHAR, P1102
   Cazoto LL, 2011, J ANTIBIOT, V64, P395, DOI 10.1038/ja.2011.13
   Chang CH, 2007, AM J MED, V120, P791, DOI 10.1016/j.amjmed.2007.03.021
   Clinical and Laboratory Standards Institute, 2008, CLIN LAB STAND I REF
   Cronin L, 2014, J BIOPHOTONICS, V7, P410, DOI 10.1002/jbio.201200168
   Endo EH, 2010, RES MICROBIOL, V161, P534, DOI 10.1016/j.resmic.2010.05.002
   Ghannoum M, 2013, ANTIMICROB AGENTS CH, V57, P4369, DOI 10.1128/AAC.01084-13
   Jin J, 2010, LETT APPL MICROBIOL, V51, P351, DOI 10.1111/j.1472-765X.2010.02900.x
   Khan MSA, 2011, APPL MICROBIOL BIOT, V90, P1083, DOI 10.1007/s00253-011-3152-3
   Kumar SN, 2014, MED MYCOL, V52, P480, DOI 10.1093/mmy/myu012
   Lewis RE, 2001, PHARMACOTHERAPY, V21, p149S, DOI 10.1592/phco.21.12.149S.34505
   Martinez-Rossi NM, 2008, MYCOPATHOLOGIA, V166, P369, DOI 10.1007/s11046-008-9110-7
   Michaelsen A, 2010, MICROB ECOL, V60, P69, DOI 10.1007/s00248-010-9667-9
   Minnebruggen G. van, 2010, Open Mycology Journal, V4, P22, DOI 10.2174/1874437001004010022
   Mishra BB, 2011, EUR J MED CHEM, V46, P4769, DOI 10.1016/j.ejmech.2011.07.057
   Mukherjee PK, 2005, CLIN MICROBIOL REV, V18, P163, DOI 10.1128/CMR.18.1.163-194.2005
   Ohara T, 2004, EUKARYOT CELL, V3, P1412, DOI 10.1128/EC.3.6.1412-1422.2004
   Park Shawna T, 2014, Microbiol Insights, V7, P1, DOI 10.4137/MBI.S13639
   Pereira FD, 2015, PHARM BIOL, V53, P228, DOI 10.3109/13880209.2014.913299
   Pereira FD, 2013, MED MYCOL, V51, P507, DOI 10.3109/13693786.2012.742966
   Reuk-Ngam N, 2014, BIOMED RES INT, DOI 10.1155/2014/581985
   Seebacher C, 2008, MYCOPATHOLOGIA, V166, P335, DOI 10.1007/s11046-008-9100-9
   Soares LA, 2014, EVID-BASED COMPL ALT, DOI 10.1155/2014/957860
   Subramaniam S, 2014, PHARM BIOL, V52, P86, DOI 10.3109/13880209.2013.815634
   Szepietowski JC, 2009, MYCOSES, V52, P343, DOI 10.1111/j.1439-0507.2008.01618.x
   Tchernev G, 2013, WIEN MED WOCHENSCHR, V163, P1, DOI 10.1007/s10354-012-0139-3
   Uppuluri P, 2008, ANTIMICROB AGENTS CH, V52, P1127, DOI 10.1128/AAC.01397-07
   Wang HS, 2012, BIOCHEM ENG J, V67, P148, DOI 10.1016/j.bej.2012.06.005
   Warshaw EM, 2006, J AM PODIAT MED ASSN, V96, P38, DOI 10.7547/0960038
   Woodfolk JA, 2005, CLIN MICROBIOL REV, V18, P30, DOI 10.1128/CMR.18.1.30-43.2005
NR 36
TC 12
Z9 12
U1 2
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD AUG 11
PY 2015
VL 5
AR 57
DI 10.3389/fcimb.2015.00057
PG 11
WC Immunology; Microbiology
SC Immunology; Microbiology
GA CP8VV
UT WOS:000360173800001
PM 26322275
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Hamilton, C
AF Hamilton, Carol
TI RETRACTED: Growth attenuation and young people with profound
   disabilities - why we need to talk about Charley (Retracted article. See
   vol. 31, pg. 304, 2016)
SO DISABILITY & SOCIETY
LA English
DT Article; Retracted Publication
DE growth; attenuation; profound; disability
ID DISCOURSE; CHILDREN
AB In 2004 an intervention known as the Ashley Treatment (AT) was sought on behalf of Ashley X, a girl with severe developmental disabilities. A discursive interpretive framework is used to investigate use of the AT in the case of Charley Hooper in New Zealand in 2009. This investigation found that use of the AT is intimately bound up in ideas about worthiness of life related to the ability to act as an autonomous agent within social structures. Questions this case raises about ethical decision-making and future physical and social requirements for profoundly disabled young people in the future are posed.
C1 Univ Waikato, Human Dev & Counseling, Hamilton, New Zealand.
RP Hamilton, C (reprint author), Univ Waikato, Human Dev & Counseling, Hamilton, New Zealand.
EM hamiltca@waikato.ac.nz
OI Hamilton, Carol/0000-0002-3942-3938
CR Adolph VR, 2013, OCHSNER J, V13, P180
   Allen DB, 2009, PEDIATRICS, V123, P1556, DOI 10.1542/peds.2008-2951
   [Anonymous], 2007, ETHICS, V5, P45
   Arda B, 2010, REV ROM BIOET, V8, P143
   Braswell H, 2015, HYPATIA, V30, P234, DOI 10.1111/hypa.12125
   BURMAN E, 1993, DISCOURSE ANAL RES R
   Butler J., 2003, STUDIES GENDER SEXUA, V4, P9, DOI DOI 10.1080/15240650409349213
   Butler Judith, 2009, FRAMES WAR
   Campbell A., 2009, LEARNING DISABILITY, V12, P24
   Chisholm D., 2014, N S, V4, P66
   Clark Peter, 2006, INTERNET J LAW HEALT, P11
   Clarren Rebecca, SALON
   Davies B, 2011, CHILD SOC, V25, P278, DOI 10.1111/j.1099-0860.2011.00380.x
   Debrett M, 2004, MEDIA CULT SOC, V26, P5, DOI 10.1177/0163443704038202
   Ellis C., 2000, HDB QUALITATIVE RES, P703
   Foucault M, 1978, HIST SEXUALITY, V1
   Garland-Thomson R., 2002, DISABILITY STUDIES E, P56
   Goodley D, 2011, SOCIOL HEALTH ILL, V33, P602, DOI 10.1111/j.1467-9566.2010.01302.x
   Gunther DF, 2006, ARCH PEDIAT ADOL MED, V160, P1013, DOI 10.1001/archpedi.160.10.1013
   Hamilton C, 2012, KOTUITUI, V7, P61, DOI 10.1080/1177083X.2012.724693
   Hamilton C., 2011, J SOCIAL INCLUSION, V2, P24
   Hodder I, 2000, HDB QUALITATIVE RES, P703
   Holstein J. A., 2000, CONSTRUCTING LIFE CO
   Human Rights Commission, CAR DIS FAM MEMB
   Inahara M, 2009, BODY SOC, V15, P47, DOI 10.1177/1357034X08100146
   Ingram S., 2009, MY BABY RIDES SHORT, P41
   Jennings Sheila K, 2013, CJDS, V2, P55
   Jordan J., 2005, Q J SPEECH, V92, P20
   Kafer Alison, 2013, FEMINIST QUEER CRIP
   Kittay EF, 2011, HYPATIA, V26, P610, DOI 10.1111/j.1527-2001.2011.01205.x
   Kumari Campbell F, 2009, CONTOURS ABELISM REP
   Liao SM, 2007, HASTINGS CENT REP, V37, P16, DOI 10.1353/hcr.2007.0027
   McAvoy J., 2014, QUALITATIVE RES PSYC, V12, P22
   McAvoy J, 2015, QUAL RES PSYCHOL, V12, P22, DOI 10.1080/14780887.2014.958357
   McGuire A., 2010, DISABILITY STUDIES Q, V30
   Newsom Robert W 3rd, 2007, Nurs Philos, V8, P291, DOI 10.1111/j.1466-769X.2007.00317.x
   Oliver Michael, 1990, POLITICS DISABLEMENT
   OUELLETTE AR, 2008, HOUSTON J HLTH LAW P, V8, P207
   Peace W., 2007, ASHLEY TREATMENT MAK
   Peace W., 2014, J PHILOS SCI LAW DIS, V14, P33
   Shakespeare T., 2006, HONEY WE SHRUNK DEV
   Shildrick Margrit, 2002, EMBODYING MONSTER EN
   Sollied Sissel, 2009, UNDRING UBEHAG BLIKK
   Squire C., 2005, GROUP ANAL, V1, P91, DOI DOI 10.1177/0533316405049373
   Stace H., 2007, HUMAN RIGHTS RES, V5
   Stake R. E., 2000, HDB QUALITATIVE RES, P435
   Starr A, 2005, J MED HUMANIT, V26, P97, DOI 10.1007/s10912-005-2912-4
   TVNZ, 2009, TVNZ            0416
   TVNZ, 2014, TVNZ            0518
   United Nations, 2007, CONV RIGHTS PERS DIS
   WALTON J, 1995, CRIT INQUIRY, V21, P775, DOI 10.1086/448774
NR 51
TC 1
Z9 1
U1 3
U2 9
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0968-7599
EI 1360-0508
J9 DISABIL SOC
JI Disabil. Soc.
PD AUG 9
PY 2015
VL 30
IS 7
BP 1055
EP 1070
DI 10.1080/09687599.2015.1069732
PG 16
WC Rehabilitation; Social Sciences, Interdisciplinary
SC Rehabilitation; Social Sciences - Other Topics
GA CQ6EK
UT WOS:000360697000007
DA 2018-12-27
ER

PT J
AU Ajdarkosh, H
   Dadpay, M
   Yahaghi, E
   Pirzaman, ER
   Fayyaz, AF
   Darian, EK
   Mokarizadeh, A
AF Ajdarkosh, Hossein
   Dadpay, Masoomeh
   Yahaghi, Emad
   Pirzaman, Elham Rostami
   Fayyaz, Amir Farshid
   Darian, Ebrahim Khodaverdi
   Mokarizadeh, Aram
TI RETRACTED: Decrease expression and clinicopathological significance of
   miR-148a with poor survival in hepatocellular carcinoma
   tissues(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
ID CELL LUNG-CANCER; MICRORNA-148B; MARKERS
AB Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, mainly due to its high rates of postoperative recurrence and metastasis. Please remove, it currently ranks as the third most common cause of cancer-related deaths. MiRNAs are a set of small, single-stranded, non-coding RNA molecules that negatively regulate gene expression at the post-transcriptional level. In this study, we demonstrated the down-regulation of miR-148a in HCC and non-cancerous tissues using qRT-PCR.
   Methods: Ninety six HCC samples and their noncancerous normal liver tissues were collected. Total mRNA including miRNA was extracted, and miR-148a expression was determined using qRT-PCR. Furthermore, the correlation between the miR-148a expression and clinicopathological parameters was investigated.
   Results: The result showed that reduction of miR-148a expression was associated with TNM stage, metastasis, and number of tumor nodes. Multivariate Cox proportional hazards model analysis showed that low expression of miR-148a was independently associated with recurrence of HCC in the current study. Moreover, our result showed that lower expression in tumor tissues in comparison with corresponding normal control tissues.
   Conclusion: Down-regulation of miR-148a is related to HCC carcinogenesis and deterioration of HCC. MicroRNA-148a may act as a suppressor miRNA of HCC, and it is therefore a potential prognostic biomarker for HCC patients.
C1 [Ajdarkosh, Hossein] Iran Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr GILDRC, Firoozgar Hosp, Tehran, Iran.
   [Dadpay, Masoomeh] AJA Univ Med Sci, Dept Pathol, Imam Reza Hosp, Tehran, Iran.
   [Yahaghi, Emad] Baqiyatallah Univ Med Sci, Tehran, Iran.
   [Pirzaman, Elham Rostami] Zanjan Univ Med Sci, Dept Biotechnol & Nanotechnol, Zanjan, Iran.
   [Fayyaz, Amir Farshid] AJA Univ Med Sci, Dept Legal Med, Tehran, Iran.
   [Darian, Ebrahim Khodaverdi] Islamic Azad Univ, Young Researchers & Elite Club, Karaj Branch, Karaj, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Cellular & Mol Res Ctr, Sanandaj, Iran.
RP Mokarizadeh, A (reprint author), Kurdistan Univ Med Sci, Cellular & Mol Res Ctr, Sanandaj, Iran.
EM a.mokarizadeh@muk.ac.ir
OI Mokarizadeh, Aram/0000-0002-2630-8308; Abdi,
   Mohammad/0000-0002-4766-0423; tajik, zahra/0000-0002-4059-5657; Zamani,
   Farhad/0000-0001-7409-3412
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chang H, 2012, MOL MED REP, V5, P1277, DOI 10.3892/mmr.2012.794
   Chen Y, 2010, J GASTROINTEST SURG, V14, P1170, DOI 10.1007/s11605-010-1202-2
   Cuk K, 2013, INT J CANCER, V132, P1602, DOI 10.1002/ijc.27799
   Gailhouste L, 2013, HEPATOLOGY, V58, P1153, DOI 10.1002/hep.26422
   Ge H, 2015, INT J CLIN EXP PATHO, V8, P800
   Heo MJ, 2014, ONCOTARGET, V5, P2792, DOI 10.18632/oncotarget.1920
   Hu L, 2010, HEPATOL INT, V4, P423, DOI 10.1007/s12072-010-9164-8
   Huang Y, 2011, J PHYSIOL BIOCHEM, V67, P129, DOI 10.1007/s13105-010-0050-6
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Li L, 2015, MED SCI MONITOR, V21, P1155, DOI 10.12659/MSM.892940
   Omelia EJ, 2013, ANAL BIOCHEM, V435, P120, DOI 10.1016/j.ab.2012.12.024
   Penna E, 2015, J INVEST DERMATOL, V135, P960, DOI 10.1038/jid.2014.479
   Perera RF, 2007, BIODRUGS, V21, P97, DOI 10.2165/00063030-200721020-00004
   Qureshi AT, 2015, ACTA BIOMATER, V12, P166, DOI 10.1016/j.actbio.2014.10.010
   Rong MH, 2014, UPSALA J MED SCI, V119, P19, DOI 10.3109/03009734.2013.856970
   Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1
   Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2
   Wu Y, 2012, J RADIAT RES, V53, P516, DOI 10.1093/jrr/rrs002
   Yang JD, 2010, INFECT DIS CLIN N AM, V24, P899, DOI 10.1016/j.idc.2010.07.004
   Zhang JP, 2014, ONCOGENE, V33, P4069, DOI 10.1038/onc.2013.369
   Zhang SL, 2015, EXP THER MED, V9, P579, DOI 10.3892/etm.2014.2137
NR 23
TC 9
Z9 10
U1 2
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD AUG 7
PY 2015
VL 10
AR 135
DI 10.1186/s13000-015-0371-4
PG 4
WC Pathology
SC Pathology
GA CO3ZC
UT WOS:000359098800001
PM 26248880
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yurttas, V
   Ural, A
   Kutluhan, A
   Bozdemir, K
AF Yurttas, Veysel
   Ural, Ahmet
   Kutluhan, Ahmet
   Bozdemir, Kazim
TI RETRACTED: Prognostic factors for graft success in tympanoplasty with
   mastoidectomy (Retracted article. See vol. 6, pg. 54, 2016)
SO ENT UPDATES
LA English
DT Article; Retracted Publication
DE Tympanoplasty; mastoidectomy; prognostic factors; epitympanic patency
ID CHRONIC OTITIS-MEDIA; TYMPANIC MEMBRANE PERFORATION; MYRINGOPLASTY;
   CHILDREN
AB Objective: The aim of this study was to evaluate the different factors that may affect graft success in tympanoplasty with mastoidectomy.
   Methods: Patients who underwent tympanoplasty with mastoidectomy between September 2004 and July 2010 were included in this study. Patient data were collected retrospectively. The effects of the epitympanic patency, duration of the dry period of the ear, presence of preoperative otorrhea, location of the perforation, status of the middle ear mucosa, and status of the tympanic membrane on the rate of postoperative graft success in patients who underwent tympanoplasty with mastoidectomy were investigated. The chi-square test and Fisher's exact test were used for statistical analysis.
   Results: A total of 130 patients, 74 male and 56 female, with an average age of 35.7 (range: 11 to 56) years were included. The overall success rate for full postoperative graft success was 75%. A >3-month dry period of the ear, absence of preoperative otorrhea, preoperative normal middle ear mucosa, and presence of epitympanic patency significantly increased the postoperative success rate of graft (p<0.001). The presence of preoperative otorrhea and granulation tissue in the middle ear mucosa, presence of preoperative myringosclerosis, and lack of epitympanic patency were significantly associated with graft failure after tympanoplasty with mastoidectomy (p<0.001).
   Conclusion: Epitympanic patency, middle ear infection, and the morphology of the tympanic membrane and middle ear mucosa should be considered prognostic factors in patients who undergo tympanoplasty with mastoidectomy.
C1 [Yurttas, Veysel] Abant Izzet Baysal Univ, Fac Med, Dept Otorhinolaryngol, Bolu, Turkey.
   [Ural, Ahmet; Kutluhan, Ahmet; Bozdemir, Kazim] Ankara Ataturk Training & Res Hosp, Dept Otorhinolaryngol, Ankara, Turkey.
RP Ural, A (reprint author), Karadeniz Tech Univ, Sch Med, Dept Otorhinolaryngol, TR-61080 Trabzon, Turkey.
EM ahmetural2001@yahoo.com
CR ADKINS WY, 1984, LARYNGOSCOPE, V94, P916
   Albu S, 1998, AM J OTOL, V19, P136
   Balyan FR, 1997, OTOLARYNG HEAD NECK, V117, P592, DOI 10.1016/S0194-5998(97)70038-X
   Bluestone CD, 1998, INT J PEDIATR OTORHI, V42, P207, DOI 10.1016/S0165-5876(97)00147-X
   Caylan R, 1998, OTOLARYNG HEAD NECK, V118, P709, DOI 10.1016/S0194-5998(98)70250-5
   Hulka GF, 1998, AM J OTOL, V19, P574
   KOCH WM, 1990, ARCH OTOLARYNGOL, V116, P35
   Kotecha B, 1999, CLIN OTOLARYNGOL, V24, P126
   LAU T, 1986, AM J OTOLARYNG, V7, P341, DOI 10.1016/S0196-0709(86)80022-9
   Lee P, 2002, CLIN OTOLARYNGOL, V27, P331, DOI 10.1046/j.1365-2273.2002.00590.x
   McGrew BM, 2004, LARYNGOSCOPE, V114, P506, DOI 10.1097/00005537-200403000-00023
   Merenda D, 2007, OTOLARYNG HEAD NECK, V136, P189, DOI 10.1016/j.otohns.2006.10.036
   Mishiro Y, 2001, EUR ARCH OTO-RHINO-L, V258, P13, DOI 10.1007/PL00007516
   Mishiro Y, 2009, EUR ARCH OTO-RHINO-L, V266, P819, DOI 10.1007/s00405-008-0816-4
   Mutoh T, 2007, AURIS NASUS LARYNX, V34, P9, DOI 10.1016/j.anl.2006.05.017
   Onal K, 2005, CLIN OTOLARYNGOL, V30, P115, DOI 10.1111/j.1365-2273.2004.00947.x
   Pignataro L, 2001, J LARYNGOL OTOL, V115, P369
   Pinar E, 2008, OTOLARYNG HEAD NECK, V139, P386, DOI 10.1016/j.otohns.2008.05.623
   SADE J, 1981, J LARYNGOL OTOL, V95, P653, DOI 10.1017/S0022215100091246
   Sheehy JL, 1994, OTOLOGIC SURG, P211
   Singh GB, 2005, INT J PEDIATR OTORHI, V69, P1071, DOI 10.1016/j.ijporl.2005.02.016
   Tos M, 1993, MANUAL MIDDLE EAR SU, P5
   VARTIAINEN E, 1992, OTOLARYNG HEAD NECK, V106, P230, DOI 10.1177/019459989210600304
NR 23
TC 1
Z9 1
U1 0
U2 3
PU DEOMED PUBL, ISTANBUL
PI ISTANBUL
PA GUR SOK 7-B, FIKIRTEPE 34720 KADIKOY, ISTANBUL, 00000, TURKEY
SN 2149-7109
EI 2149-6498
J9 ENT UPDATES
JI ENT Updates
PD AUG
PY 2015
VL 5
IS 2
BP 72
EP 75
DI 10.2399/jmu.2015002005
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CY8RD
UT WOS:000366675100005
OA Other Gold
DA 2018-12-27
ER

PT J
AU Elliott, HR
   Tillin, T
AF Elliott, Hannah R.
   Tillin, Therese
TI RETRACTED: Commentary: Migrant study designs for epigenetic studies of
   disease risk(Retracted article. See vol.46, pg.772, 2017)
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material; Retracted Publication
C1 [Elliott, Hannah R.] Univ Bristol, Sch Social & Community Med, MRC Integrat Epidemiol Unit, Oakfield House,Oakfield Rd, Bristol BS8 2BN, Avon, England.
   [Tillin, Therese] UCL, Inst Cardiovasc Sci, London, England.
RP Elliott, HR (reprint author), Univ Bristol, Sch Social & Community Med, MRC Integrat Epidemiol Unit, Oakfield House,Oakfield Rd, Bristol BS8 2BN, Avon, England.
EM Hannah.Elliott@bristol.ac.uk
CR Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285
   Bonifazi C., 2000, INT J POPULATION GEO, V6, P111, DOI DOI 10.1002/(SICI)1099-1220(200003/04)6:2<111::AID-IJPG172>3.0.CO;2-L
   Campanella G, 2015, INT J EPIDEMIOL, V44, P1442, DOI 10.1093/ije/dyu198
   Jaffe AE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r31
   Kington R, 1998, SOC SCI MED, V47, P831, DOI 10.1016/S0277-9536(98)00145-2
   National Center for Health Statistics (US), 2014, HLTH US 2013 SPEC FE
   WORTH RM, 1975, AM J EPIDEMIOL, V102, P481, DOI 10.1093/oxfordjournals.aje.a112186
NR 7
TC 2
Z9 2
U1 2
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD AUG
PY 2015
VL 44
IS 4
BP 1449
EP +
DI 10.1093/ije/dyv010
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CT8JK
UT WOS:000363061500041
PM 25710513
OA Bronze
DA 2018-12-27
ER

PT J
AU Benferrah, N
   Hammadi, M
   Berthiol, F
AF Benferrah, N.
   Hammadi, M.
   Berthiol, F.
TI RETRACTED: Potassium fluoride-barium oxide catalysis in an easy and
   efficient synthesis of methysticin from piperonal under microwave
   irradiation (Retracted article. See vol. 00, pg. 00, 0000)
SO RUSSIAN JOURNAL OF GENERAL CHEMISTRY
LA English
DT Article; Retracted Publication
DE Solid basic catalyst; 4-methoxy-6-methylpyran-2-one; piperonal;
   microwave irradiation; natural kavalactones derivatives; methysticin
ID DEHYDROACETIC ACID; NATURAL-PRODUCTS; ACETIC ESTER; KAVA; PYRONES;
   KAVALACTONES; SYNTHON
AB Condensation of compounds containing active methylene group with aromatic aldehyde (piperonal) in the presence of BaO on KF without a solvent under microwave irradiation is an efficient synthetic approach to methysticin and derivatives of kavalactones (4-methoxy-6-styryl-pyran-2-ones).
C1 [Benferrah, N.; Hammadi, M.] Univ Mhamed Bougara Boumerdes, URMPE Res Unit Mat Proc & Environm, Fac Engn Sci, Boumerdes 35000, Algeria.
   [Benferrah, N.] Ctr Sci & Tech Res Phys Chem Anal CRAPC, Boumerdes 35000, Algeria.
   [Berthiol, F.] Univ Grenoble 1, Dept Mol Chem SERCO, UMR 5250, ICMG FR 2607, F-38041 Grenoble 9, France.
RP Benferrah, N (reprint author), Univ Mhamed Bougara Boumerdes, URMPE Res Unit Mat Proc & Environm, Fac Engn Sci, Boumerdes 35000, Algeria.
EM benferrahnassima@gmail.com
CR Altomare C, 1997, CEREAL RES COMMUN, V25, P349
   Amaral PA, 2008, TETRAHEDRON LETT, V49, P6607, DOI 10.1016/j.tetlet.2008.07.102
   Arndt F, 1936, BER DTSCH CHEM GES, V69, P2373, DOI 10.1002/cber.19360691030
   Arndt F, 1924, BER DTSCH CHEM GES, V57, P1489, DOI 10.1002/cber.19240570852
   ARNDT F, 1955, ORG SYNTH, V3, P231
   BACARDIT R, 1982, J HETEROCYCLIC CHEM, V19, P157, DOI 10.1002/jhet.5570190130
   Beckert C, 1997, PHYTOCHEMISTRY, V44, P275, DOI 10.1016/S0031-9422(96)00543-2
   Bilia AR, 2002, LIFE SCI, V70, P2581, DOI 10.1016/S0024-3205(02)01555-2
   BLOOMER JL, 1974, J ORG CHEM, V39, P3615, DOI 10.1021/jo00938a047
   BULOCK JD, 1960, J CHEM SOC, P502, DOI 10.1039/jr9600000502
   CHMIELEWSKA I, 1958, TETRAHEDRON, V4, P36, DOI 10.1016/0040-4020(58)88004-7
   Coolie J.N., 1891, J CHEM SOC, V59, P609, DOI [10.1039/CT8915900607, DOI 10.1039/CT8915900607]
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   Demuner AJ, 2009, MOLECULES, V14, P4973, DOI 10.3390/molecules14124973
   Dharmaratne HRW, 2002, PHYTOCHEMISTRY, V59, P429
   Duarte FS, 2007, PHARMACOL BIOCHEM BE, V86, P150, DOI 10.1016/j.pbb.2006.12.019
   Emboden W, 1979, NARCOTIC PLANTS
   Ernst E, 2007, BRIT J CLIN PHARMACO, V64, P415, DOI 10.1111/j.1365-2125.2007.02932.x
   FINDLAY JA, 1976, CAN J CHEM, V54, P270, DOI 10.1139/v76-040
   FUJITA T, 1994, PHYTOCHEMISTRY, V36, P23, DOI 10.1016/S0031-9422(00)97005-5
   HANSEL R, 1968, PAC SCI, V22, P293
   Hashimoto T, 2003, PHYTOMEDICINE, V10, P309, DOI 10.1078/094471103322004802
   Hosseinzadeh R, 2008, TETRAHEDRON LETT, V49, P840, DOI 10.1016/j.tetlet.2007.11.180
   ISRAILI ZH, 1976, J ORG CHEM, V41, P4070, DOI 10.1021/jo00888a004
   Kabashima H, 2000, APPL CATAL A-GEN, V194, P227, DOI 10.1016/S0926-860X(99)00370-1
   Kampf R., 1970, SCHWEIZ APOTHEK ZTG, V108, P520
   KLOHS MW, 1959, J ORG CHEM, V24, P1829, DOI 10.1021/jo01093a632
   Lasme P, 2008, J AGR FOOD CHEM, V56, P4976, DOI 10.1021/jf800439g
   LYGO B, 1995, TETRAHEDRON, V51, P12859, DOI 10.1016/0040-4020(95)00820-X
   McGlacken GP, 2005, NAT PROD REP, V22, P369, DOI 10.1039/b416651p
   Moreno-Manas A.J.M., 1992, ADV HETEROCYCLIC CHE, V53, P1, DOI [10.1016/S0065-2725(08)60861-2, DOI 10.1016/S0065-2725(08)60861-2]
   MORS WB, 1962, FORTSCHR CHEM ORG NA, V20, P131
   Nagawade RR, 2005, EUR J MED CHEM, V40, P1325, DOI 10.1016/j.ejmech.2005.05.012
   Nazari M, 2009, TETRAHEDRON LETT, V50, P1453, DOI 10.1016/j.tetlet.2009.01.068
   Scherer I, 1998, ADV THER, V15, P261
   Seitz U, 1997, PLANTA MED, V63, P548, DOI 10.1055/s-2006-957761
   SHULGIN AT, 1973, B NARCOTICS, V25, P59
   Stephen T., 2012, BIO MED CHEM, V20, P1482, DOI [10.1016/j.bmc.2011.12.053, DOI 10.1016/J.BMC.2011.12.053]
   SUZUKI E, 1975, SYNTHESIS-STUTTGART, P192
   Yanping F., 2009, CHINESE J CHEM ENG, V17, P883, DOI [10.1016/S1004-9541(08)60292-X., DOI 10.1016/S1004-9541(08)60292-X]
   Younis YM, 2000, AUST J CHEM, V53, P589, DOI 10.1071/CH99119
   ZHANG G, 1988, APPL CATAL, V36, P189, DOI 10.1016/S0166-9834(00)80114-1
NR 42
TC 3
Z9 3
U1 3
U2 5
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 1070-3632
EI 1608-3350
J9 RUSS J GEN CHEM+
JI Russ. J. Gen. Chem.
PD AUG
PY 2015
VL 85
IS 8
BP 1939
EP 1944
DI 10.1134/S107036321508023X
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA CS2GV
UT WOS:000361888100023
DA 2018-12-27
ER

PT J
AU Yang, JW
   Kim, YE
AF Yang, Ji-Won
   Kim, Young Eon
TI RETRACTED: Effect of CaO Treatment on Quality Characteristics and
   Storage of Mulberry (Morus alba L.) Fruits in Yecheon (Retracted
   article. See vol. 35, pg. 148, 2017)
SO KOREAN JOURNAL OF HORTICULTURAL SCIENCE & TECHNOLOGY
LA English
DT Article; Retracted Publication
DE calcium oxide; Morus alba L.; storage; quality characteristics; Yecheon;
   Gwasang No. 2
ID SCALLOP-SHELL POWDER; STAPHYLOCOCCUS-AUREUS; CALCINATED CALCIUM;
   CHLORINE DIOXIDE; KINETIC-ANALYSIS; EXTRACTS; LIFE; BACTERIA; CABBAGE;
   GROWTH
AB The effects of aqueous calcium oxide (CaO) treatment on the quality characteristics and shelf life of mulberry (Morus alba L.) were investigated. Mulberry fruits were immersed in 0, 0.5, 1, and 2 g.L-1 CaO solutions for 0, 1, 3, 6, and 12 min. Mulberries were then rinsed with potable tap water for 1 min and stored at -1 degrees C for 14 days. CaO treatment was effective at promoting the retention of titratable acid, pH, and ascorbic acid as well as total flavonoid contents. CaO concentration and treatment time were significant factors affecting the sensory qualities of the fruits, including off-odor, flavor, and texture. For shelf life determinations, the total bacterial count was reduced by CaO treatment so that the samples treated with 1 g.L-1 CaO for 12 mm had bacterial levels at 14 days comparable to those of the control at 4 day, and no coliform group was detected after CaO treatment These results indicate that calcium oxide treatment is a promising approach for the preservation of mulberry fruit.
C1 [Yang, Ji-Won; Kim, Young Eon] Korea Food Res Inst, Div Metab & Funct Res, Funct Evaluat Res Grp, Songnam 463746, South Korea.
RP Kim, YE (reprint author), Korea Food Res Inst, Div Metab & Funct Res, Funct Evaluat Res Grp, Songnam 463746, South Korea.
EM radog@kfri.re.kr
FU High Value-added Food Technology Development Program, Ministry of
   Agriculture, Food and Rural Affairs [311025-3]
FX This research was supported by the High Value-added Food Technology
   Development Program (311025-3), Ministry of Agriculture, Food and Rural
   Affairs.
CR Bae DH, 2006, ARCH PHARM RES, V29, P298, DOI 10.1007/BF02968574
   Bari ML, 1999, J FOOD PROTECT, V62, P128, DOI 10.4315/0362-028X-62.2.128
   Bodur T, 2012, FOOD CONTROL, V25, P1, DOI 10.1016/j.foodcont.2011.09.032
   Chen Z, 2011, J BIOSCI BIOENG, V111, P675, DOI 10.1016/j.jbiosc.2011.01.010
   Choi YM, 2006, FOOD CONTROL, V17, P695, DOI 10.1016/j.foodcont.2005.04.005
   Doymaz I, 2004, J FOOD ENG, V65, P205, DOI 10.1016/j.jfoodeng.2004.01.016
   Ercisli S, 2007, FOOD CHEM, V103, P1380, DOI 10.1016/j.foodchem.2006.10.054
   Gandhi M, 2003, INT J FOOD MICROBIOL, V87, P301, DOI 10.1016/S0168-1605(03)00108-9
   Gomez-Lopez VM, 2008, INT J FOOD MICROBIOL, V121, P74, DOI 10.1016/j.ijfoodmicro.2007.11.036
   연지혜, 2005, [Korean Journal of Food Science and Technology, 한국식품과학회지], V37, P844
   Jeong JC, 2010, NUTR CANCER, V62, P402, DOI 10.1080/01635580903441287
   Kim I.J., 2006, J FOOD HYG SAFETY, V21, P60
   Kim S. K., 1991, BONCHOHAK, P598
   성지혜, 2012, [Food Engineering Progress, 산업식품공학], V16, P100
   Korea Food and Drug Administration (KFDA), 2006, KOR FOOD ADD COD
   Kubo M., 2013, J BIOMATER NANOBIOTE, V4, P10
   LANE J. H., 1934, DETERMINATION REDUCI
   Lee B.G., 2005, J FD HYG SAFETY, V20, P114
   Lee J, 2008, J ETHNOPHARMACOL, V115, P263, DOI 10.1016/j.jep.2007.09.029
   Lee Y.J., 2011, NAT SCI RES COLLECT, V9, P1
   Li HM, 2009, FOOD CHEM, V114, P547, DOI 10.1016/j.foodchem.2008.09.085
   [林青松 LIN Qingsong], 2006, [安徽农业科学, Journal of anhui agricultural sciences], V34, P1209
   Liu LK, 2008, J FOOD SCI, V73, pH113, DOI 10.1111/j.1750-3841.2008.00801.x
   Nagasawa K., 2011, Bokin Bobai - Journal of Antibacterial and Antifungal Agents, V39, P587
   Pawlowska AM, 2008, J AGR FOOD CHEM, V56, P3377, DOI 10.1021/jf703709r
   Sawai J, 2003, J FOOD PROTECT, V66, P1482, DOI 10.4315/0362-028X-66.8.1482
   Sawai J, 2003, J MICROBIOL METH, V54, P177, DOI 10.1016/S0167-7012(03)00037-X
   Sawai J, 2001, INT J FOOD MICROBIOL, V71, P211, DOI 10.1016/S0168-1605(01)00619-5
   Sawai J, 2001, INT BIODETER BIODEGR, V47, P23, DOI 10.1016/S0964-8305(00)00115-3
   Sawai J, 2001, J FOOD PROTECT, V64, P1579, DOI 10.4315/0362-028X-64.10.1579
   Sawai J., 2007, BOKIN BOBAI, V35, P3
   Sawai J, 2013, FOOD SCI TECHNOL RES, V19, P561, DOI 10.3136/fstr.19.561
   Sawai J, 2011, BIOCONTROL SCI, V16, P95, DOI 10.4265/bio.16.95
   Terefe NS, 2009, INNOV FOOD SCI EMERG, V10, P297, DOI 10.1016/j.ifset.2008.12.003
   Wright KP, 1997, POSTHARVEST BIOL TEC, V10, P39, DOI 10.1016/S0925-5214(96)00061-0
NR 35
TC 0
Z9 0
U1 1
U2 10
PU KOREAN SOC HORTICULTURAL SCIENCE
PI JEOLLABUK-DO
PA C/O NATL INST HORTICULTURAL & HERBAL SCIENCE, 100, NONGSAENGMYEONG-RO,
   ISEO-MYEON, WANJU-GUN, JEOLLABUK-DO, 565-852, SOUTH KOREA
SN 1226-8763
J9 KOREAN J HORTIC SCI
JI Korean J. Hortic. Sci. Technol.
PD AUG
PY 2015
VL 33
IS 4
BP 525
EP 534
DI 10.7235/hort.2015.14198
PG 10
WC Horticulture
SC Agriculture
GA CS0VM
UT WOS:000361780300009
OA Bronze
DA 2018-12-27
ER

PT J
AU Herndon, JM
AF Herndon, J. Marvin
TI RETRACTED: Evidence of Coal-Fly-Ash Toxic Chemical Geoengineering in the
   Troposphere: Consequences for Public Health (Retracted article. See vol.
   12, pg. 10941, 2015)
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article; Retracted Publication
DE geoengineering; coal fly ash; aerosol particulates; chemtrails; autism
   spectrum disorder (ASD); Alzheimer's disease; Parkinson's disease;
   attention deficit hyperactivity disorder (ADHD); neurological disorders;
   chemically mobile aluminum
ID ACID-RAIN; ALZHEIMERS-DISEASE; ARSENIC EXPOSURE; DRINKING-WATER;
   AIR-POLLUTION; UNITED-STATES; ALUMINUM; COMBUSTION; MORTALITY; PLANTS
AB The widespread, intentional and increasingly frequent chemical emplacement in the troposphere has gone unidentified and unremarked in the scientific literature for years. The author presents evidence that toxic coal combustion fly ash is the most likely aerosolized particulate sprayed by tanker-jets for geoengineering, weather-modification and climate-modification purposes and describes some of the multifold consequences on public health. Two methods are employed: (1) Comparison of 8 elements analyzed in rainwater, leached from aerosolized particulates, with corresponding elements leached into water from coal fly ash in published laboratory experiments, and (2) Comparison of 14 elements analyzed in dust collected outdoors on a high-efficiency particulate air (HEPA) filter with corresponding elements analyzed in un-leached coal fly ash material. The results show: (1) the assemblage of elements in rainwater and in the corresponding experimental leachate are essentially identical. At a 99% confidence interval, they have identical means (T-test) and identical variances (F-test); and (2) the assemblage of elements in the HEPA dust and in the corresponding average un-leached coal fly ash are likewise essentially identical. The consequences on public health are profound, including exposure to a variety of toxic heavy metals, radioactive elements, and neurologically-implicated chemically mobile aluminum released by body moisture in situ after inhalation or through transdermal induction.
C1 Transdyne Corp, San Diego, CA 92131 USA.
RP Herndon, JM (reprint author), Transdyne Corp, 11044 Red Rock Dr, San Diego, CA 92131 USA.
EM mherndon@san.rr.com
CR Bondy SC, 2014, TOXICOLOGY, V315, P1, DOI 10.1016/j.tox.2013.10.008
   CAPE JN, 1993, ENVIRON POLLUT, V82, P167, DOI 10.1016/0269-7491(93)90114-4
   Carson R, 1962, SILENT SPRING
   Chakraborty R, 2009, ECOTOX ENVIRON SAFE, V72, P838, DOI 10.1016/j.ecoenv.2008.09.023
   Chiou HY, 1997, STROKE, V28, P1717, DOI 10.1161/01.STR.28.9.1717
   CHO K, 1994, CHEST, V106, P309, DOI 10.1378/chest.106.1.309
   DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401
   Exley C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127665
   Gilmour MI, 2004, J AIR WASTE MANAGE, V54, P286, DOI 10.1080/10473289.2004.10470906
   GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310
   Goodarzi F, 2006, FUEL, V85, P1418, DOI 10.1016/j.fuel.2005.11.022
   Hendryx M, 2009, INT ARCH OCC ENV HEA, V82, P243, DOI 10.1007/s00420-008-0328-y
   Herndon JM, 2015, CURR SCI INDIA, V108, P2173
   Hvistendahl M, COAL ASH IS MORE RAD
   Kile ML, 2008, JAMA-J AM MED ASSOC, V300, P845, DOI 10.1001/jama.300.7.845
   Klein JP, 2014, REPROD TOXICOL, V50, P43, DOI 10.1016/j.reprotox.2014.10.001
   KOWALL NW, 1989, NEUROSCIENCE, V29, P329, DOI 10.1016/0306-4522(89)90060-2
   LIKENS GE, 1972, ENVIRONMENT, V14, P33, DOI 10.1080/00139157.1972.9933001
   Long JCS, 2015, NATURE, V518, P29, DOI 10.1038/518029a
   McNutt M, 2015, SCIENCE, V347, P1293, DOI 10.1126/science.aab1102
   Moreno N, 2005, FUEL, V84, P1351, DOI 10.1016/j.fuel.2004.06.038
   Nelson PF, 2010, FUEL, V89, P810, DOI 10.1016/j.fuel.2009.03.002
   Pope CA, 2009, NEW ENGL J MED, V360, P376, DOI 10.1056/NEJMsa0805646
   Prasunpriya S., 2002, ENVIRON RES, V82, P101
   Rondeau V, 2009, AM J EPIDEMIOL, V169, P489, DOI 10.1093/aje/kwn348
   Ruhl L, 2009, ENVIRON SCI TECHNOL, V43, P6326, DOI 10.1021/es900714p
   Singh A, 2008, J ENVIRON BIOL, V29, P15
   SMITH AH, 1992, ENVIRON HEALTH PERSP, V97, P259, DOI 10.2307/3431362
   Sparling DW, 1996, REV ENVIRON CONTAM T, V145, P1
   Stuart B.O., 1984, ENV HLTH PERSPECT, V55, P373, DOI DOI 10.1289/EHP.8455369
   SUEDEL BC, 1994, REV ENVIRON CONTAM T, V136, P21
   Tseng CH, 2003, TOXICOL LETT, V137, P15, DOI 10.1016/S0378-4274(02)00377-6
   Twining J, 2005, ENVIRON SCI TECHNOL, V39, P7749, DOI 10.1021/es0502369
   Vahter M, 2009, ANNU REV NUTR, V29, P381, DOI 10.1146/annurev-nutr-080508-141102
   Yellamma K, 2010, Toxicol Int, V17, P106, DOI 10.4103/0971-6580.72682
   Yokel RA, 2001, TOXICOL SCI, V64, P77, DOI 10.1093/toxsci/64.1.77
NR 36
TC 2
Z9 2
U1 3
U2 58
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD AUG
PY 2015
VL 12
IS 8
BP 9375
EP 9390
DI 10.3390/ijerph120809375
PG 16
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA CQ4PT
UT WOS:000360587800050
PM 26270671
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Al-Ekabi, AHS
AF Al-Ekabi, Afrah Hasan Saleh
TI RETRACTED: Microfacies and environmental study of the Mishrif Formation
   in Noor Field(Retracted article. See vol. 10, artn no.205, 2017)
SO ARABIAN JOURNAL OF GEOSCIENCES
LA English
DT Article; Retracted Publication
DE Microfacies; Noor oil field; South Iraq
ID CARBONATES; BASIN
AB Mishrif Formation is one of the most important formations in Iraq, both economically and geologically, which was deposited during the Cretaceous period in the secondary sedimentary cycle (Cenomanian-Early Turonian) and is regarded as the principal carbonate reservoir in central and southern Iraq. A petrographic and microfacies study has been carried out by examining available thin sections for well nos. 1 and 2 as well as well log data for environmental subdivision. The microfacies analysis shows that the Mishrif succession comprises six paleoenvironments which are deep marine, shallow open marine, rudist biostrome, shoal, back shoal, and lagoon. Petrographic study from thin-section examination shows that the skeletal grains included rudist, coral Foraminifera (benthonic, planktonic), echinoderms, ostracods, and molluscs. The rudists are very important contributors in building the Mishrif carbonate platform, and the corals are very common in the Mishrif succession and along with the rudists. Non-skeletal grains included pellets, micrite, and intraclasts. Six digenetic processes affected Mishrif Formation, and the most effective is dolomitization and dissolution. The lateral extension of these microfacies has been identified by integrating the thin-section data and well log character variation with similar characteristic for microfacies.
C1 Univ Baghdad, Dept Geol, Coll Sci, Baghdad, Iraq.
RP Al-Ekabi, AHS (reprint author), Univ Baghdad, Dept Geol, Coll Sci, Baghdad, Iraq.
EM d.afrah@yahoo.com
CR Ahr W. M, 2008, GEOLOGY CARBONATE RE, P296
   Al-Khersan H., 1973, MISHRIF FORMAT UNPUB
   Aqrawi A.A.M., 2010, GEO 2010 MIDDL E C E
   Aqrawi AAM, 1998, J PETROL GEOL, V21, P57, DOI 10.1111/j.1747-5457.1998.tb00646.x
   Boggs Jr S, 2009, PETROLOGY SEDIMENTAR, P602
   Burchette T. P., 1985, SEDIMENTOLOGY RECENT, P311
   BURCHETTE TP, 1993, AAPG MEMOIR, V56, P185
   CHOQUETTE PW, 1970, AM ASSOC PETR GEOL B, V54, P207
   Davis G. R., 1979, AAPG SHORT COURSE CA
   E Flugel, 1982, MICROFACIES ANAL LIM
   Flugel E, 2004, MICROFACIES CARBONAT
   Ginsburg N, 1957, NATURAL RESOURCES EC, V1
   HARRIS PM, 1984, AAPG BULL, V68, P649
   McKee E.D., 1969, GEOL SOC AM MEM, V114, P1
   Moore C. H., 1997, DEV SEDIMENTOLOGY, V46
   Schlumberger, 1982, NAT GAMM RAY SPECTR
   SCOTT RW, 1979, AAPG BULL, V63, P1108
   Sherwani G.H, 1983, THESIS U BAGHDAD
   Skelton Peter W., 1997, Boletin de la Real Sociedad Espanola de Historia Natural Seccion Geologica, V92, P225
   van Buchem F.S.P., 2002, GEOARABIA, V7, P461
   Wayne M. AHR, 2008, GEOLOGY CARBONATE RE
   Wilson J.L., 1975, CARBONATE FACIES GEO
NR 22
TC 3
Z9 3
U1 4
U2 12
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1866-7511
EI 1866-7538
J9 ARAB J GEOSCI
JI Arab. J. Geosci.
PD AUG
PY 2015
VL 8
IS 8
BP 5779
EP 5794
DI 10.1007/s12517-014-1589-2
PG 16
WC Geosciences, Multidisciplinary
SC Geology
GA CP7LD
UT WOS:000360068200036
DA 2018-12-27
ER

PT J
AU Vien, VV
AF Vo Van Vien
TI RETRACTED: Lepton Mixing and CP Violation Phase in the 3-3-1 Model with
   Neutral Leptons Based on T-13 Flavor Symmetry (Retracted article. See
   vol. 45, pg. 807, 2015)
SO BRAZILIAN JOURNAL OF PHYSICS
LA English
DT Article; Retracted Publication
DE Neutrino mass and mixing; Non-standard-model neutrinos; Right-handed
   neutrinos; Discrete symmetries
ID DOUBLE-BETA DECAY; MASS MATRIX; PERMUTATION SYMMETRY; DISCRETE SYMMETRY;
   S-3 SYMMETRY; ELECTROWEAK INTERACTIONS; A(4) SYMMETRY; NEUTRINOS; QUARK;
   OSCILLATIONS
AB We study a 3-3-1 model based on non-Abelian discrete symmetry group T-13 which accommodates lepton mixing with non-zero theta(13) and CP violation phase. The neutrinos get small masses and mixing with CP violation phase from SU(3)(L) antisextets which are all in triplets under T-13. If both breakings T-13 -> Z(3) and Z(3) -> {Identity} are taken place in neutrino sector, and T-13 is broken into Z(3) in lepton sector, the realistic neutrino mixing form is obtained as a natural consequence of P-l and T-13 symmetries. The model predicts the lepton mixing with non-zero theta(13), and also gives a remarkable prediction of Dirac CP violation delta(CP) = 292.5 degrees in the normal spectrum, and delta(CP) = 303.161 degrees in the inverted spectrum which is still missing in the neutrino mixing matrix. There exist some regions of model parameters that can fit the experimental data in 2014 on neutrino masses and mixing without perturbation.
C1 Tay Nguyen Univ, Dept Phys, Buon Ma Thuot, Daklak, Vietnam.
RP Vien, VV (reprint author), Tay Nguyen Univ, Dept Phys, Buon Ma Thuot, Daklak, Vietnam.
EM wvienk16@gmail.com
FU Vietnam National Foundation for Science and Technology Development
   (NAFOSTED) [103.01-2014.51]
FX This research is funded by Vietnam National Foundation for Science and
   Technology Development (NAFOSTED) under grant number 103.01-2014.51.
CR Abe H, 2009, NUCL PHYS B, V820, P317, DOI [10.1016/j.nuclphysb.2009.05.024, 10.1010/j.nuclphysb.2009.05.024]
   Ade PAR, 2014, ASTRON ASTROPHYS, V571, DOI 10.1051/0004-6361/201321591
   Adulpravitchai A., 2009, JHEP, V0903, P046, DOI DOI 10.1088/1126-6708/2009/03/046
   Adulpravitchai A, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/6/063026
   Ahn YH, 2013, PHYS REV D, V87, DOI 10.1103/PhysRevD.87.113012
   Ahn YH, 2010, PHYS REV D, V82, DOI 10.1103/PhysRevD.82.093005
   Ahn YH, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.105013
   Altarelli G, 2005, NUCL PHYS B, V720, P64, DOI 10.1016/j.nuclphysb.2005.05.005
   Altarelli G, 2013, NUOVO CIM C-COLLOQ C, V36, P68, DOI 10.1393/ncc/i2014-11618-5
   Altarelli G, 2013, NUCL PHYS B-PROC SUP, V241, P77, DOI 10.1016/j.nuclphysbps.2013.06.013
   Altarelli G., 2008, JHEP, V0803
   Altarelli G, 2010, REV MOD PHYS, V82, P2701, DOI 10.1103/RevModPhys.82.2701
   Altarelli G, 2009, J PHYS G NUCL PARTIC, V36, DOI 10.1088/0954-3899/36/8/085005
   Araki T, 2008, NUCL PHYS B, V805, P124, DOI 10.1016/j.nuclphysb.2008.07.005
   Babu KS, 2003, PHYS LETT B, V552, P207, DOI 10.1016/S0370-2693(02)03153-2
   Babu KS, 2005, PHYS REV D, V71, DOI 10.1103/PhysRevD.71.056006
   Barry J, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.093002
   Bazzocchi F., 2008, JHEP, V0803
   Bazzocchi F, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.096005
   Bazzocchi F, 2009, NUCL PHYS B, V816, P204, DOI 10.1016/j.nuclphysb.2009.03.005
   Bazzocchi F, 2008, PHYS REV D, V78, DOI 10.1103/PhysRevD.78.116018
   Bhattacharyya G, 2011, PHYS REV D, V83, DOI 10.1103/PhysRevD.83.011701
   Bilenky SM, 2012, MOD PHYS LETT A, V27, DOI 10.1142/S0217732312300157
   Blum A, 2008, PHYS REV D, V77, DOI 10.1103/PhysRevD.77.076004
   Branco GC, 2002, PHYS LETT B, V526, P104, DOI 10.1016/S0370-2693(01)01472-1
   Buras A J, 2014, J HIGH ENERGY PHYS, VJHEP1402, P112, DOI DOI 10.1007/JHEP02(2014)112.ARXIV:1311.6729
   CABIBBO N, 1963, PHYS REV LETT, V10, P531, DOI 10.1103/PhysRevLett.10.531
   Caravaglios F., ARXIV0503234HEPPH
   Chang D, 2006, PHYS REV D, V73, DOI 10.1103/PhysRevD.73.053006
   Chen C. S., 2011, J HIGH ENERGY PHYS, V1104, P015
   Chen CS, 2013, PROG THEOR EXP PHYS, DOI 10.1093/ptep/ptt071
   Chen CY, 2008, PHYS REV D, V77, DOI 10.1103/PhysRevD.77.093009
   Chen MC, 2007, PHYS LETT B, V652, P34, DOI 10.1016/j.physletb.2007.06.064
   Chen SL, 2004, PHYS REV D, V70, DOI 10.1103/PhysRevD.70.073008
   Cooper IK, 2013, NUCL PHYS B, V875, P650, DOI 10.1016/j.nuclphysb.2013.07.027
   Daikoku Y., PHYS REV D, V88
   Daikoku Y., ARXIV10080914HEPPH
   Datta A, 2003, NUCL PHYS B, V671, P383, DOI 10.1016/jnuclphysb.2003.08.026
   De Fazio F., 2013, POS EPS HEP, V2013, P339
   DERMAN E, 1979, PHYS REV D, V20, P1207, DOI 10.1103/PhysRevD.20.1207
   Dev S, 2011, PHYS LETT B, V702, P28, DOI 10.1016/j.physletb.2011.06.055
   Dicus DA, 2010, PHYS REV D, V82, DOI 10.1103/PhysRevD.82.033005
   Ding GJ, 2012, NUCL PHYS B, V857, P219, DOI 10.1016/j.nuclphysb.2011.12.004
   Ding GJ, 2012, NUCL PHYS B, V855, P21, DOI 10.1016/j.nuclphysb.2011.10.001
   Ding GJ, 2011, NUCL PHYS B, V853, P635, DOI 10.1016/j.nuclphysb.2011.08.012
   Ding GJ, 2010, NUCL PHYS B, V827, P82, DOI 10.1016/j.nuclphysb.2009.10.021
   Ding GJ, 2008, PHYS REV D, V78, DOI 10.1103/PhysRevD.78.036011
   Dong PV, 2007, PHYS REV D, V75, DOI 10.1103/PhysRevD.75.073006
   Dong PV, 2006, PHYS REV D, V74, DOI 10.1103/PhysRevD.74.053003
   Dong PV, 2012, PHYS REV D, V85, DOI 10.1103/PhysRevD.85.053001
   Dong PV, 2011, EUR PHYS J C, V71, DOI 10.1140/epjc/s10052-011-1544-2
   Dong PV, 2008, ADV HIGH ENERGY PHYS, DOI 10.1155/2008/739492
   Dong PV, 2010, PHYS REV D, V81, DOI 10.1103/PhysRevD.81.053004
   Dong PV, 2008, PHYS REV D, V77, DOI 10.1103/PhysRevD.77.057302
   Dong PV, 2006, PHYS REV D, V73, DOI 10.1103/PhysRevD.73.035004
   Dorame L, 2012, PHYS REV D, V86, DOI 10.1103/PhysRevD.86.056001
   Everett LL, 2011, PHYS LETT B, V698, P131, DOI 10.1016/j.physletb.2011.02.054
   Everett LL, 2009, PHYS REV D, V79, DOI 10.1103/PhysRevD.79.085005
   Feruglio F., 2011, JHEP, V1103, P101, DOI DOI 10.1007/JHEP03(2011)101
   Feruglio F, 2007, NUCL PHYS B, V775, P120, DOI 10.1016/j.nuclphysb.2007.04.002
   Feruglio F, 2014, EUR PHYS J C, V74, DOI 10.1140/epjc/s10052-014-2753-2
   FOOT R, 1994, PHYS REV D, V50, pR34, DOI 10.1103/PhysRevD.50.R34
   FOOT R, 1993, PHYS REV D, V47, P4158, DOI 10.1103/PhysRevD.47.4158
   Frampton P. H., 2007, JHEP, V0709, P110
   Frampton PH, 2009, PHYS LETT B, V679, P347, DOI 10.1016/j.physletb.2009.08.001
   FRAMPTON PH, 1995, INT J MOD PHYS A, V10, P4689, DOI 10.1142/S0217751X95002187
   Frampton PH, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.086007
   FRAMPTON PH, 1992, PHYS REV LETT, V69, P2889, DOI 10.1103/PhysRevLett.69.2889
   Frigerio M, 2005, PHYS REV D, V71, DOI 10.1103/PhysRevD.71.011901
   Fritzsch H, 2004, PHYS LETT B, V598, P237, DOI 10.1016/j.physletb.2004.07.061
   Fritzsch H, 1996, PHYS LETT B, V372, P265, DOI 10.1016/0370-2693(96)00107-4
   Fritzsch H, 1998, PHYS LETT B, V440, P313, DOI 10.1016/S0370-2693(98)01106-X
   Fritzsch H, 2000, PHYS REV D, V61, DOI 10.1103/PhysRevD.61.073016
   Fujii M, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.115012
   Fukugita M, 1998, PHYS REV D, V57, P4429, DOI 10.1103/PhysRevD.57.4429
   Canales FG, 2013, PHYS REV D, V88, DOI 10.1103/PhysRevD.88.096004
   Felipe RG, 2013, PHYS REV D, V87, DOI 10.1103/PhysRevD.87.055010
   Gonzalez-Garcia MC, 2012, J HIGH ENERGY PHYS, DOI 10.1007/JHEP12(2012)123
   Grimus W., 2004, JHEP-Journal of High Energy Physics, V2004, DOI 10.1088/1126-6708/2004/07/078
   Grimus W, 2013, J PHYS G NUCL PARTIC, V40, DOI 10.1088/0954-3899/40/7/075008
   Grimus W, 2003, PHYS LETT B, V572, P189, DOI 10.1016/j.physletb.2003.08.032
   Grimus W., 2004, ARXIVHEPPH0405261, P433
   Grimus W, 2005, JHEP, V0508, P013
   Hagedorn C, 2006, PHYS REV D, V74, DOI 10.1103/PhysRevD.74.025007
   Hagedorn C, 2006, JHEP, V0606, P042
   Harrison PF, 2002, PHYS LETT B, V530, P167, DOI 10.1016/S0370-2693(02)01336-9
   Harrison PF, 2003, PHYS LETT B, V557, P76, DOI 10.1016/S0370-2693(03)00183-7
   Hartmann C, 2011, NUCL PHYS B, V853, P105, DOI 10.1016/j.nuclphysb.2011.07.023
   Hashimoto K., ARXIV11103640HEPPH
   He XG, 2003, PHYS REV D, V68, DOI 10.1103/PhysRevD.68.037302
   He XG, 2003, PHYS LETT B, V560, P87, DOI 10.1016/S0370-2693(03)00390-3
   HE XG, 2006, JHEP, V604
   Hernandez D, 2012, PHYS REV D, V86, DOI 10.1103/PhysRevD.86.053014
   Hirsch M, 2008, PHYS REV D, V78, DOI 10.1103/PhysRevD.78.093007
   Honda M., 2006, JHEP, V0601, P042
   Ishimori H, 2011, PROG THEOR PHYS, V125, P653, DOI 10.1143/PTP.125.653
   Ishimori H, 2011, PHYS REV D, V83, DOI 10.1103/PhysRevD.83.033004
   Ishimori H, 2009, PROG THEOR PHYS, V121, P769, DOI 10.1143/PTP.121.769
   Ishimoria H, 2008, PHYS LETT B, V662, P178, DOI 10.1016/j.physletb.2008.03.007
   Jora R, 2006, INT J MOD PHYS A, V21, P5875, DOI 10.1142/S0217751X0603391X
   Jora R, 2010, PHYS REV D, V82, DOI 10.1103/PhysRevD.82.079902
   Jora R, 2010, PHYS REV D, V82, DOI 10.1103/PhysRevD.82.053006
   Jora R, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.093007
   Kajiyama Y, 2011, NUCL PHYS B, V848, P303, DOI 10.1016/j.nuclphysb.2011.02.020
   Kajiyama Y, 2007, PHYS REV D, V76, DOI 10.1103/PhysRevD.76.117301
   Kaneko T, 2011, PHYS LETT B, V697, P329, DOI 10.1016/j.physletb.2011.02.017
   Kang K, 1997, MOD PHYS LETT A, V12, P1175, DOI 10.1142/S0217732397001205
   Kang KS, 1996, Z PHYS C PART FIELDS, V72, P671, DOI 10.1007/s002880050291
   Kim J. E., 2006, JHEP, V0605
   King SF, 2013, REP PROG PHYS, V76, DOI 10.1088/0034-4885/76/5/056201
   KOBAYASHI M, 1973, PROG THEOR PHYS, V49, P652, DOI 10.1143/PTP.49.652
   Kobayashi T, 2007, NUCL PHYS B, V768, P135, DOI 10.1016/j.nuclphysb.2007.01.018
   Koide Y, 1999, PHYS REV D, V60, DOI 10.1103/PhysRevD.60.077301
   Koide Y., 2007, JHEP, V0708, P086
   Koide Y, 2007, EUR PHYS J C, V50, P809, DOI 10.1140/epjc/s10052-007-0261-3
   Krishnan R, 2013, J PHYS CONF SER, V447, DOI 10.1088/1742-6596/447/1/012043
   Krishnan R, 2013, J HIGH ENERGY PHYS, DOI 10.1007/JHEP04(2013)087
   Kubo J, 2005, PROG THEOR PHYS, V114, P287, DOI 10.1143/PTP.114.287
   Kubo J, 2003, PROG THEOR PHYS, V109, P795, DOI 10.1143/PTP.109.795
   Lam CS, 2007, PHYS LETT B, V656, P193, DOI 10.1016/j.physletb.2007.09.032
   Lin Y, 2009, NUCL PHYS B, V813, P91, DOI 10.1016/j.nuclphysb.2008.12.025
   Long HN, 1996, PHYS REV D, V53, P437, DOI 10.1103/PhysRevD.53.437
   Long HN, 1998, MOD PHYS LETT A, V13, P1865, DOI 10.1142/S0217732398001959
   Luhn C, 2007, J MATH PHYS, V48, DOI 10.1063/1.2823978
   Luhn C, 2013, NUCL PHYS B, V875, P80, DOI 10.1016/j.nuclphysb.2013.07.003
   Luhn C, 2008, J MATH PHYS, V49, DOI 10.1063/1.2932334
   Ma E, 2006, PHYS REV D, V73, DOI 10.1103/PhysRevD.73.077301
   Ma E, 2006, PHYS LETT B, V632, P352, DOI 10.1016/j.physletb.2005.10.019
   Ma E, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.113012
   Ma E, 2013, PHYS LETT B, V725, P402, DOI 10.1016/j.physletb.2013.07.015
   Ma E, 2009, PHYS LETT B, V671, P366, DOI 10.1016/j.physletb.2008.12.038
   Meloni D, 2011, J PHYS G NUCL PARTIC, V38, DOI 10.1088/0954-3899/38/1/015003
   Merle A, 2013, INT J MOD PHYS D, V22, DOI 10.1142/S0218271813300206
   Mitra M, 2012, NUCL PHYS B, V856, P26, DOI 10.1016/j.nuclphysb.2011.10.035
   Mohapatra RN, 2006, PHYS LETT B, V639, P318, DOI 10.1016/j.physletb.2006.06.032
   Mohapatra RN, 2004, PHYS REV D, V69, DOI 10.1103/PhysRevD.69.053007
   Mondragon A, 2007, PHYS REV D, V76, DOI 10.1103/PhysRevD.76.076003
   Mondragon A, 2008, AIP CONF PROC, V1026, P164, DOI 10.1063/1.2965040
   MONTERO JC, 1993, PHYS REV D, V47, P2918, DOI 10.1103/PhysRevD.47.2918
   Morisi S, 2011, PHYS REV D, V84, DOI 10.1103/PhysRevD.84.053002
   Morisi S, 2011, PHYS LETT B, V701, P451, DOI 10.1016/j.physletb.2011.06.024
   Morisi S, 2007, PHYS REV D, V75, DOI 10.1103/PhysRevD.75.075015
   Olive KA, 2014, CHINESE PHYS C, V38, DOI 10.1088/1674-1137/38/9/090001
   PAKVASA S, 1979, PHYS LETT B, V82, P105, DOI 10.1016/0370-2693(79)90436-2
   PAKVASA S, 1978, PHYS LETT B, V73, P61, DOI 10.1016/0370-2693(78)90172-7
   Picariello M, 2008, INT J MOD PHYS A, V23, P4435, DOI 10.1142/S0217751X08041517
   PISANO F, 1992, PHYS REV D, V46, P410, DOI 10.1103/PhysRevD.46.410
   Ponce WA, 2003, PHYS REV D, V67, DOI 10.1103/PhysRevD.67.075001
   Rodejohann W, 2012, J PHYS G NUCL PARTIC, V39, DOI 10.1088/0954-3899/39/12/124008
   Rodejohann W, 2011, INT J MOD PHYS E, V20, P1833, DOI 10.1142/S0218301311020186
   SINGER M, 1980, PHYS REV D, V22, P738, DOI 10.1103/PhysRevD.22.738
   Smirnov A. Yu., 2013, NUCL PHYS B, V235-236, P431
   Tanimoto M, 2000, PHYS LETT B, V483, P417, DOI 10.1016/S0370-2693(00)00550-5
   Tegmark M, 2004, PHYS REV D, V69, DOI 10.1103/PhysRevD.69.103501
   VALLE JWF, 1983, PHYS REV D, V28, P540, DOI 10.1103/PhysRevD.28.540
   Varzielas ID, 2013, J PHYS G NUCL PARTIC, V40, DOI 10.1088/0954-3899/40/8/085002
   Vien VV, 2014, J HIGH ENERGY PHYS, DOI 10.1007/JHEP04(2014)133
   Vien VV, 2014, ADV HIGH ENERGY PHYS, DOI 10.1155/2014/192536
   Vien VV, 2013, INT J MOD PHYS A, V28, DOI 10.1142/S0217751X13501595
   Vien V. V., 2014, SOV PHYS JETP, V145, P991
   Vien V. V., ARXIV14054665HEPPH
   WOLFENSTEIN L, 1978, PHYS REV D, V18, P958, DOI 10.1103/PhysRevD.18.958
   Xing ZZ, 2010, PHYS LETT B, V690, P304, DOI 10.1016/j.physletb.2010.05.045
   Xing ZZ, 2002, PHYS LETT B, V533, P85, DOI 10.1016/S0370-2693(02)01649-0
   YAMANAKA Y, 1982, PHYS REV D, V25, P1895, DOI 10.1103/PhysRevD.25.1895
   Yang RZ, 2011, PHYS LETT B, V700, P316, DOI 10.1016/j.physletb.2011.05.014
   Zhang H, 2007, PHYS LETT B, V655, P132, DOI 10.1016/j.physletb.2007.09.003
   Zhao ZH, 2012, PHYS REV D, V86, DOI 10.1103/PhysRevD.86.096010
   Zhou S, 2011, PHYS LETT B, V704, P291, DOI 10.1016/j.physletb.2011.09.027
NR 169
TC 1
Z9 1
U1 7
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0103-9733
EI 1678-4448
J9 BRAZ J PHYS
JI Braz. J. Phys.
PD AUG
PY 2015
VL 45
IS 4
BP 467
EP 480
DI 10.1007/s13538-015-0330-2
PG 14
WC Physics, Multidisciplinary
SC Physics
GA CP7TR
UT WOS:000360091700015
DA 2018-12-27
ER

PT J
AU Luo, W
   Jiang, X
   Wei, XF
   Li, SS
   Li, MX
AF Luo, Wei
   Jiang, Xun
   Wei, Xiaofeng
   Li, Shanshan
   Li, Mengxiong
TI RETRACTED: A study on cognitive impairment and gray matter volume
   abnormalities in silent cerebral infarction patients (Retracted article.
   See vol. 58, pg. 109, 2016)
SO NEURORADIOLOGY
LA English
DT Article; Retracted Publication
DE Silent cerebral infarction (SCI); Magnetic resonance imaging (MRI);
   Cognitive function; Gray matter volume (GMV)
ID VOXEL-BASED MORPHOMETRY; STRUCTURAL MRI; DISEASE; UTILITY; MEMORY;
   BRAIN; ATHEROSCLEROSIS; SCHIZOPHRENIA; RECOLLECTION; FAMILIARITY
AB The relationship between silent cerebral infarction (SCI) and the integrity of cognitive function is unknown. We intended to investigate whether cognitive impairment is associated with gray matter volume (GMV) in the SCI patients.
   Sixty-two patients with SCI and 62 age- and gender-matched healthy controls (HC) were evaluated with P300 test, Montreal Cognitive Assessment (MoCA) test, Hamilton Anxiety Scale (HAMA), and Hamilton Depression Scale (HDRS). Whole brain high-resolution T1-weighted images were processed with SPM12b software and analyzed by voxel-based morphometry (VBM). Correlation analysis was performed between the GMV and the scores of MoCA Scale, P300 latency, P300 amplitude, HAMA, HDRS, age, and educational level.
   The brains of the SCI patients have a significant reduction in GMV in the left superior and inferior frontal gyrus, left superior temporal gyrus, right middle temporal gyrus, and bilateral hippocampus gyrus (p < 0.01, FDR correction). No significant increase of GMV was detected. The GMV of their frontal and temporal lobes is positively correlated with the score of MoCA scale and P300 amplitude (r a parts per thousand yenaEuro parts per thousand 0.62, p < 0.01). The GMV of frontal, temporal, and hippocampus is negatively correlated with P300 latency (r a parts per thousand currency signaEuro parts per thousand a'0.71, p < 0.05). No significant correlation between the GMV of abnormal brain regions and another two clinical characteristics was found.
   SCI patients have impaired cognitive function and reduced GMV compared to the HC subjects. The neuropathological basis of such cognitive deficits in SCI patients might be a reduced GMV.
C1 [Luo, Wei; Wei, Xiaofeng; Li, Mengxiong] Yangtze Univ, Affiliated Hosp 1, Biomed Engn Lab, Jingzhou, Hubei, Peoples R China.
   [Jiang, Xun] Wuhan Univ, Renmin Hosp, Biomed Engn Lab, Wuhan 430072, Hubei, Peoples R China.
   [Li, Shanshan] JingZhou City Cent Blood Bank, Jingzhou 434000, Hubei, Peoples R China.
RP Li, SS (reprint author), JingZhou City Cent Blood Bank, 199 Jiangjin Middle Rd, Jingzhou 434000, Hubei, Peoples R China.
EM lishanshanbel@163.com
FU Study Guide project of Hubei Provincial Health Department [2011 JX5C12]
FX This work was supported by the Study Guide project of Hubei Provincial
   Health Department (2011 JX5C12).
CR Chee MWL, 2009, NEUROIMAGE, V46, P257, DOI 10.1016/j.neuroimage.2009.01.036
   Das RR, 2008, STROKE, V39, P2929, DOI 10.1161/STROKEAHA.108.516575
   David E, 2005, NEUROSCIENTIST, V11, P563
   Duarte A, 2004, COGNITIVE BRAIN RES, V18, P255, DOI 10.1016/j.cogbrainres.2003.10.010
   Duarte A, 2006, NEUROSCI LETT, V406, P60, DOI 10.1016/j.neulet.2006.07.029
   Ehlers MR, 2014, CLIN NEUROPHYSIOL
   Frodl T, 2002, INT J PSYCHOPHYSIOL, V43, P237, DOI 10.1016/S0167-8760(01)00182-9
   Hayakawa YK, 2013, J AFFECT DISORDERS, V144, P263, DOI 10.1016/j.jad.2012.10.023
   Himani A, 1999, Indian J Physiol Pharmacol, V43, P367
   Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559
   Kopelman MD, 2001, J NEUROL NEUROSUR PS, V71, P23, DOI 10.1136/jnnp.71.1.23
   Larner AJ, 2012, INT PSYCHOGERIATR, V24, P391, DOI 10.1017/S1041610211001839
   Li JP, 2012, EPILEPSY RES, V98, P97, DOI 10.1016/j.eplepsyres.2011.10.002
   Matsuda H, 2012, AM J NEURORADIOL, V33, P1109, DOI 10.3174/ajnr.A2935
   MEADOR KJ, 1989, J CLIN EXP NEUROPSYC, V11, P252, DOI 10.1080/01688638908400887
   Mechelli A, 2005, CURR MED IMAGING REV, V1, P105, DOI 10.2174/1573405054038726
   Pantoni L, 2007, CURR OPIN NEUROL, V20, P390, DOI 10.1097/WCO.0b013e328172d661
   Perico CAM, 2005, NEUROSCI LETT, V384, P265, DOI 10.1016/j.neulet.2005.04.088
   Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9
   Poggesi A, 2011, CEREBROVASC DIS, V32, P577, DOI 10.1159/000334498
   Polich John, 2005, Current Alzheimer Research, V2, P515, DOI 10.2174/156720505774932214
   Polich John, 2004, Phys Med Rehabil Clin N Am, V15, P133, DOI 10.1016/S1047-9651(03)00109-8
   Romero JR, 2009, STROKE, V40, P1590, DOI 10.1161/STROKEAHA.108.535245
   Shiga T, 2008, INTERNAL MED, V47, P1, DOI 10.2169/internalmedicine.47.0341
   Smith M. E., 1990, CLIN NEUROPHYSIOL, V76, P235, DOI [10.1016/0013-4694(90)90018-F, DOI 10.1016/0013-4694(90)90018-F]
   Swartz RH, 2008, STROKE, V39, P822, DOI 10.1161/STROKEAHA.107.491936
   Turetsky BI, 2015, SCHIZOPHR RES, V163, P53, DOI 10.1016/j.schres.2014.09.024
   van Oijen M, 2007, ANN NEUROL, V61, P403, DOI 10.1002/ana.21073
   Verdelho A, 2007, J NEUROL NEUROSUR PS, V78, P1325, DOI 10.1136/jnnp.2006.110361
   Yonelinas AP, 2002, NAT NEUROSCI, V5, P1236, DOI 10.1038/nn961
   Zhao J, 2012, METAB BRAIN DIS, V27, P17, DOI 10.1007/s11011-011-9275-5
NR 31
TC 4
Z9 5
U1 3
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0028-3940
EI 1432-1920
J9 NEURORADIOLOGY
JI Neuroradiology
PD AUG
PY 2015
VL 57
IS 8
BP 783
EP 789
DI 10.1007/s00234-015-1535-3
PG 7
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA CQ2NS
UT WOS:000360438600004
PM 25903433
DA 2018-12-27
ER

PT J
AU Gamez, M
   Hu, K
   Harrison, LB
AF Gamez, Mauricio
   Hu, Kenneth
   Harrison, Louis B.
TI RETRACTED: Laryngeal Function After Radiation Therapy(Retracted
   article.See vol.50, pg.XV-XV, 2017)
SO OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA
LA English
DT Article; Retracted Publication
DE Function; Speech; Voice; Dysphagia
ID QUALITY-OF-LIFE; SQUAMOUS-CELL CARCINOMA; INTENSITY-MODULATED
   RADIOTHERAPY; LOCALLY ADVANCED HEAD; NECK-CANCER; RADIATION-THERAPY;
   GLOTTIC CANCER; INDUCTION CHEMOTHERAPY; SWALLOWING DYSFUNCTION;
   ORGAN-PRESERVATION
AB Laryngeal function after oncologic treatment is a key aspect and focus of interest in the contemporary management of head and neck cancers. Although historically the treatment of most locally advanced laryngeal cancers has been total laryngectomy, recent innovations in radiation therapy and combined chemotherapy and radiation therapy have shown that organ and function preservation can be achieved with good oncologic outcomes. Technical improvements, along with better understanding of tumor biology and dose tolerance of critical organs involved in speech and swallowing function, have paved the way for better outcomes. This article reviews in comprehensive detail the recent data of laryngeal function after radiotherapy.
C1 [Gamez, Mauricio] Mayo Clin Hosp, Mayo Clin Arizona, Dept Radiat Oncol, Phoenix, AZ 85054 USA.
   [Hu, Kenneth] NYU Langone Med Ctr, Dept Radiat Oncol, New York, NY 10016 USA.
   [Harrison, Louis B.] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL 33612 USA.
RP Harrison, LB (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.
EM Louis.harrison@moffitt.org
CR Aaltonen LM, 2014, INT J RADIAT ONCOL, V90, P255, DOI 10.1016/j.ijrobp.2014.06.032
   Agarwal J, 2011, DYSPHAGIA, V26, P399, DOI 10.1007/s00455-011-9326-4
   Al-Mamgani A, 2013, CLIN OTOLARYNGOL, V38, P306, DOI 10.1111/coa.12139
   Ang KK, 2010, ONCOLOGIST, V15, P25, DOI 10.1634/theoncologist.2010-S3-25
   Berg EE, 2011, ANN OTO RHINOL LARYN, V120, P748, DOI 10.1177/000348941112001109
   Best SR, 2011, HEAD NECK-J SCI SPEC, V33, P1727, DOI 10.1002/hed.21657
   Bhandare N, 2012, J NUCL MED RAD THER
   Bhayani M, 2011, DYSPHAGIA, V26, P471
   Boscolo-Rizzo P, 2011, ANN ONCOL, V22, P1894, DOI 10.1093/annonc/mdq681
   Caglar HB, 2008, INT J RADIAT ONCOL, V72, P1110, DOI 10.1016/j.ijrobp.2008.02.048
   Carnaby-Mann G, 2007, DYSPHAGIA, V22, P381
   Carroll WR, 2008, LARYNGOSCOPE, V118, P39, DOI 10.1097/MLG.0b013e31815659b0
   Caudell JJ, 2009, INT J RADIAT ONCOL, V73, P410, DOI 10.1016/j.ijrobp.2008.04.048
   Chao KSC, 2001, INT J RADIAT ONCOL, V49, P907, DOI 10.1016/S0360-3016(00)01441-3
   Chen AY, 2006, OTOLARYNG HEAD NECK, V135, P831, DOI 10.1016/j.otohns.2006.07.012
   Chen AY, 2001, ARCH OTOLARYNGOL, V127, P870
   DESANTO LW, 1995, ANN OTO RHINOL LARYN, V104, P763, DOI 10.1177/000348949510401003
   Dornfeld K, 2007, INT J RADIAT ONCOL, V68, P750, DOI 10.1016/j.ijrobp.2007.01.047
   Eisbruch A, 2001, INT J RADIAT ONCOL, V50, P695, DOI 10.1016/S0360-3016(01)01512-7
   Eisbruch A, 2004, INT J RADIAT ONCOL, V60, P1425, DOI 10.1016/j.ijrobp.2004.05.050
   Eisbruch A, 2002, INT J RADIAT ONCOL, V53, P23, DOI 10.1016/S0360-3016(02)02712-8
   Eisbruch A, 1999, INT J RADIAT ONCOL, V45, P577, DOI 10.1016/S0360-3016(99)00247-3
   Eisbruch A, 2007, INT J RADIAT ONCOL, V69, pS40, DOI 10.1016/j.ijrobp.2007.04.083
   Eisbruch A, 2010, INT J RADIAT ONCOL, V76, P1333, DOI 10.1016/j.ijrobp.2009.04.011
   Feng FY, 2007, INT J RADIAT ONCOL, V68, P1289, DOI 10.1016/j.ijrobp.2007.02.049
   Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317
   Forastiere AA, 2013, J CLIN ONCOL, V31, P845, DOI 10.1200/JCO.2012.43.6097
   Francis DO, 2010, ANN OTO RHINOL LARYN, V119, P391, DOI 10.1177/000348941011900605
   Fu KK, 1982, CANCER, V49, P6555
   Fung K, 2005, INT J RADIAT ONCOL, V63, P1395, DOI 10.1016/j.ijrobp.2005.05.004
   Fung K, 2001, J OTOLARYNGOL, V30, P133, DOI 10.2310/7070.2001.20192
   Fung K, 2001, LARYNGOSCOPE, V111, P1920, DOI 10.1097/00005537-200111000-00009
   Gamez ME, 2014, INT J RADIAT ONCOL, V90, pS513, DOI 10.1016/j.ijrobp.2014.05.1574
   Gillespie MB, 2004, LARYNGOSCOPE, V114, P1362, DOI 10.1097/00005537-200408000-00008
   Goguen LA, 2006, OTOLARYNG HEAD NECK, V134, P916, DOI 10.1016/j.otohns.2006.02.001
   HARRISON LB, 1990, INT J RADIAT ONCOL, V19, P123, DOI 10.1016/0360-3016(90)90144-9
   Harrison LB, 2013, HEAD NECK CANC MULTI, P441
   Hogikyan ND, 1999, J VOICE, V13, P557, DOI 10.1016/S0892-1997(99)80010-1
   Hutcheson KA, 2008, ARCH OTOLARYNGOL, V134, P178, DOI 10.1001/archoto.2007.33
   Hutcheson KA, 2014, HEAD NECK-J SCI SPEC, V36, P474, DOI 10.1002/hed.23330
   Hutcheson KA, 2012, CURR ONCOL REP, V14, P158, DOI 10.1007/s11912-012-0216-1
   Jacobi I, 2010, EUR ARCH OTO-RHINO-L, V267, P1495, DOI 10.1007/s00405-010-1316-x
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jensen K, 2007, RADIOTHER ONCOL, V85, P74, DOI 10.1016/j.radonc.2007.06.004
   Johns MM, 2012, LARYNGOSCOPE, V122, pSS107, DOI 10.1002/lary.23735
   Kazi R, 2008, INT J RADIAT ONCOL, V70, P344, DOI 10.1016/j.ijrobp.2007.06.040
   Kulbersh BD, 2006, LARYNGOSCOPE, V116, P883, DOI 10.1097/01.mlg.0000217278.96901.fc
   LAZARUS C, 1993, HEAD NECK-J SCI SPEC, V15, P419, DOI 10.1002/hed.2880150509
   Lee WT, 2006, HEAD NECK-J SCI SPEC, V28, P808, DOI 10.1002/hed.20427
   Levendag PC, 2007, RADIOTHER ONCOL, V85, P64, DOI 10.1016/j.radonc.2007.07.009
   Logemann JA, 2003, HEAD NECK-J SCI SPEC, V25, P432, DOI 10.1002/hed.10255
   Martin Bonnie J. W., 1993, Dysphagia, V8, P11, DOI 10.1007/BF01351472
   Martin M, 2000, INT J RADIAT ONCOL, V47, P277, DOI 10.1016/S0360-3016(00)00435-1
   Martin S, 2010, DYSPHAGIA, V25, P358
   Meleca RJ, 2003, LARYNGOSCOPE, V113, P720, DOI 10.1097/00005537-200304000-00025
   Mendenhall WM, 2006, AM J CLIN ONCOL-CANC, V29, P290, DOI 10.1097/01.coc.0000209510.19360.f9
   Mittal BB, 2003, INT J RADIAT ONCOL, V57, P1219, DOI 10.1016/S0360-3016(03)01454-8
   Mourad WF, 2014, AM J CLIN ONCOL-CANC, V37, P57, DOI 10.1097/COC.0b013e31826b9920
   Mourad WF, 2013, ANTICANCER RES, V33, P4483
   Mourad WF, 2013, ONKOLOGIE, V36, P433, DOI 10.1159/000353750
   Mourad WF, 2013, AM J CLIN ONCOL-CANC, V36, P580, DOI 10.1097/COC.0b013e318256f5fd
   Myers C, 2012, J OTOLARYNGOL-HEAD N, V41, P108, DOI 10.2310/7070.2011.110211
   Nguyen Nam P, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P130, DOI 10.1097/MOO.0b013e32801da0e8
   Nguyen NP, 2005, INT J RADIAT ONCOL, V61, P772, DOI 10.1016/j.ijrobp.2004.06.017
   Nguyen NP, 2004, ANN ONCOL, V15, P383, DOI 10.1093/annonc/mdh101
   O'Sullivan B, 2001, INT J RADIAT ONCOL, V51, P332, DOI 10.1016/S0360-3016(01)01613-3
   Oridate N, 2009, ARCH OTOLARYNGOL, V135, P363, DOI 10.1001/archoto.2009.8
   Peeters AJGE, 2004, EUR ARCH OTO-RHINO-L, V261, P534, DOI 10.1007/s00405-003-0697-5
   Pfister DG, 2006, J CLIN ONCOL, V24, P3693, DOI 10.1200/JCD.2006.07.4559
   PFISTER DG, 1991, J CLIN ONCOL, V9, P850, DOI 10.1200/JCO.1991.9.5.850
   PFISTER DG, 1995, J CLIN ONCOL, V13, P671, DOI 10.1200/JCO.1995.13.3.671
   Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014
   Rancati T, 2010, INT J RADIAT ONCOL, V76, pS64, DOI 10.1016/j.ijrobp.2009.03.079
   Rogers SN, 2002, HEAD NECK-J SCI SPEC, V24, P521, DOI 10.1002/hed.10106
   Rosen CA, 2004, LARYNGOSCOPE, V114, P1549, DOI 10.1097/00005537-200409000-00009
   Rosenthal DI, 2007, HEAD NECK-J SCI SPEC, V29, P923, DOI 10.1002/hed.20602
   Rosenthal DI, 2006, J CLIN ONCOL, V24, P2636, DOI 10.1200/JCO.2006.06.0079
   Sanguineti G, 2007, INT J RADIAT ONCOL, V68, P741, DOI 10.1016/j.ijrobp.2007.01.010
   Schwartz DL, 2010, INT J RADIAT ONCOL, V78, P1356, DOI 10.1016/j.ijrobp.2009.10.002
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Solares CA, 2009, LARYNGOSCOPE, V119, P1130, DOI 10.1002/lary.20225
   Staton J, 2002, OTOLARYNG HEAD NECK, V127, P43, DOI 10.1067/mhn.2002.124473
   Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8
   WOLF GT, 1991, NEW ENGL J MED, V324, P1685
NR 84
TC 4
Z9 4
U1 4
U2 15
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0030-6665
EI 1557-8259
J9 OTOLARYNG CLIN N AM
JI Otolaryngol. Clin. N. Am.
PD AUG
PY 2015
VL 48
IS 4
BP 585
EP +
DI 10.1016/j.otc.2015.04.005
PG 16
WC Otorhinolaryngology
SC Otorhinolaryngology
GA CQ0YO
UT WOS:000360324700005
PM 26092763
DA 2018-12-27
ER

PT J
AU Liu, H
   Li, WZ
   Chen, CY
   Pei, YG
   Long, XY
AF Liu, Hui
   Li, Wenzheng
   Chen, Changyong
   Pei, Yigang
   Long, Xueying
TI RETRACTED: MiR-335 acts as a potential tumor suppressor miRNA via
   downregulating ROCK1 expression in hepatocellular carcinoma (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE MiR-335; Hepatocellular carcinoma; ROCK1; Proliferation; Migration
ID UP-REGULATION; CANCER; MICRORNA-335; INVASION; METASTASIS; APOPTOSIS;
   PROGNOSIS; TARGETS
AB Increasing evidence has suggested that dysregulation of microRNAs (miRNAs) could contribute to tumor progression. Previous miRNA microarray analysis illustrated that miR-335 is downregulated in various cancers; however, the role of miR-335 on hepatocellular carcinoma (HCC) has not been well elucidated. In this study, we investigated the biological functions and molecular mechanisms of miR-335 in human HCC in vitro, discussing whether it could be a therapeutic biomarker of HCC in the future. Four HCC cell lines and samples from 62 patients with HCC were analyzed for the expression of miR-335 by quantitative RT-PCR. Overexpression of miR-335 was established by transfecting mimics into HepG2 and HuH7 cells. Cell proliferation and cell migration were assessed by cell viability assay and transwell assay. Luciferase reporter assay and Western blot were to verify ROCK1 as a novel target gene of miR-335. We observed that miR-335 was downregulated in human HCC tissues and in all four HCC cell lines. The MTT assay revealed that overexpression of miR-335 subsequently inhibited cell growth. Furthermore, the transwell assay also showed significant cell migration inhibition in miR-335 transfectant. The expression of ROCK1 was decreased evidently after overexpression of miR-335, indicating that ROCK1 is a target gene for miR-335. Our data revealed that miR-335 could inhibit the proliferation and migration invasion of HCC cells via regulating ROCK1, suggesting that miR-335 could be a therapeutic biomarker of HCC in the future.
C1 [Liu, Hui; Li, Wenzheng; Chen, Changyong; Pei, Yigang; Long, Xueying] Cent S Univ, Xiangya Hosp, Dept Radiol, Changsha 410008, Hunan, Peoples R China.
RP Long, XY (reprint author), Cent S Univ, Xiangya Hosp, Dept Radiol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM drlongxueying@163.com
FU National Natural Science Foundation of China [30900266]
FX This study was supported by the grants from the National Natural Science
   Foundation of China (No. 30900266).
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557
   Braconi C, 2012, CURR CANCER DRUG TAR, V12, P1073
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Giordano S, 2013, HEPATOLOGY, V57, P840, DOI 10.1002/hep.26095
   He XX, 2014, ONCOL REP, V32, P1200, DOI 10.3892/or.2014.3306
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Liu SJ, 2011, MOL BIOL REP, V38, P1363, DOI 10.1007/s11033-010-0238-4
   Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7
   Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211
   Schmitz KJ, 2011, J CLIN PATHOL, V64, P529, DOI 10.1136/jcp.2010.085621
   Shi L, 2012, J NEURO-ONCOL, V110, P155, DOI 10.1007/s11060-012-0951-z
   Takaki Y, 2014, CANCER SCI, V105, P1254, DOI 10.1111/cas.12498
   Wang HQ, 2013, TUMOR BIOL, V34, P3101, DOI 10.1007/s13277-013-0878-9
   Wang Y, 2013, MOL CELL BIOCHEM, V384, P105, DOI 10.1007/s11010-013-1786-4
   Xu LB, 2014, J HEPATOL, V60, P590, DOI 10.1016/j.jhep.2013.10.028
   Xu Y, 2012, ONCOGENE, V31, P1398, DOI 10.1038/onc.2011.340
   Yu LX, 2014, CANCER EPIDEMIOL, V38, P408, DOI 10.1016/j.canep.2014.05.001
   Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817
NR 19
TC 22
Z9 23
U1 3
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2015
VL 36
IS 8
BP 6313
EP 6319
DI 10.1007/s13277-015-3317-2
PG 7
WC Oncology
SC Oncology
GA CP9DL
UT WOS:000360193800068
PM 25804796
DA 2018-12-27
ER

PT J
AU Ozkan, G
   Ulusoy, S
   Mentese, A
   Guvercin, B
   Karahan, SC
   Yavuz, A
   Altay, DU
   Ocal, M
AF Ozkan, Gulsum
   Ulusoy, Sukru
   Mentese, Ahmet
   Guvercin, Beyhan
   Karahan, S. Caner
   Yavuz, Adnan
   Altay, Diler Us
   Ocal, Mustafa
TI RETRACTED: Can be galectin-3 a novel marker in determining mortality in
   hemodialysis patients?(Retracted article. See vol.49,pg.942,2016)
SO CLINICAL BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE Galectin 3; Hemodialysis; Mortality; Cardiac mortality
ID HEART-FAILURE; PROGNOSTIC VALUE; CLINICAL-TRIALS; DIALYSIS;
   HEMODIALYSIS; EPIDEMIOLOGY; ASSOCIATION; POPULATION; ADULTS; TIME
AB Background: Cardiovascular (CV) mortality is common in hemodialysis (HD) patients. There are some difficulties involved in determining CV risk. Galectin-3 is a molecule with a demonstrated correlation with CV mortality and which is approved in the stratification of heart failure (HF) risk. The purpose of this study was to assess the previously uninvestigated relationship between galectin-3 and cardiac mortality in HD patients.
   Methods: Two hundred ninety clinically stable HD patients aged over 18 and on a thrice-weekly intermittent HD program lasting >3 months and 30 healthy individuals were enrolled in this multi-center, prospective, observational study and monitored over 24 months. Blood specimens were collected at the start of the study for the measurement of galectin-3 and other biochemical parameters. At the end of the study, the relations between galectin-3 and other biochemical and demographic parameters and mortality were analyzed.
   Results: Galectin-3 levels were significantly higher in the HD group compared to the control group (p < 0.001). All-cause mortality was observed in 63 (21%) patients. At multivariate Cox regression analysis, age, low albumin, low DBP, high galectin-3 and high HsCRP were identified as prognostic determinants of all-cause mortality, while age, low albumin, high galectin-3 and high SBP were identified as prognostic determinants of cardiac mortality.
   Conclusion: This study shows, for the first time in the literature, that galectin-3 may be a novel biomarker of cardiac mortality in HD patients. We think that, when supported by further studies, galectin-3 can be a promising biomarker in predicting cardiac mortality in HD patients. (C) 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
C1 [Ozkan, Gulsum] Antakya State Hosp, Dept Nephrol, TR-31000 Antakya, Turkey.
   [Ulusoy, Sukru] Karadeniz Tech Univ, Sch Med, Dept Nephrol, Trabzon, Turkey.
   [Mentese, Ahmet; Karahan, S. Caner; Altay, Diler Us] Karadeniz Tech Univ, Sch Med, Dept Clin Biochem, Trabzon, Turkey.
   [Guvercin, Beyhan] Karadeniz Tech Univ, Sch Med, Dept Internal Med, Trabzon, Turkey.
   [Yavuz, Adnan] Trabzon RTS Hemodialysis Ctr, Trabzon, Turkey.
   [Ocal, Mustafa] Antakya Sifa Hemodialysis Ctr, Antakya, Turkey.
RP Ozkan, G (reprint author), Antakya State Hosp, Dept Nephrol, TR-31000 Antakya, Turkey.
EM gulsumozkan78@hotmail.com
FU Turkish Society of Hypertension and Renal Diseases [2012-45]
FX This study was supported by the Turkish Society of Hypertension and
   Renal Diseases (Grant number: 2012-45).
CR ACCHIARDO SR, 1983, KIDNEY INT S16, V24, P199
   Bian XH, 2014, IRAN J KIDNEY DIS, V8, P314
   Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905
   Coburn E, 2014, CARDIOL REV, V22, P171, DOI 10.1097/CRD.0000000000000013
   Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X
   Daniels LB, 2014, AM HEART J, V167, DOI 10.1016/j.ahj.2013.12.031
   de Boer RA, 2012, J INTERN MED, V272, P55, DOI 10.1111/j.1365-2796.2011.02476.x
   de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488
   Hemodialysis Adequacy 2006 Work Group, 2006, AM J KIDNEY DIS S, V48, pS2
   Henderson NC, 2009, IMMUNOL REV, V230, P160, DOI 10.1111/j.1600-065X.2009.00794.x
   Herselman M, 2010, NUTRITION, V26, P10, DOI 10.1016/j.nut.2009.07.009
   Kalantar-Zadeh K, 2005, NEPHROL DIAL TRANSPL, V20, P1880, DOI 10.1093/ndt/gfh941
   Kalantar-Zadeh K, 2003, KIDNEY INT, V63, P793, DOI 10.1046/j.1523-1755.2003.00803.x
   Meijers WC, 2014, AM HEART J, V167, P853, DOI 10.1016/j.ahj.2014.02.011
   Nishizawa Y, 2001, AM J KIDNEY DIS, V38, pS4, DOI 10.1053/ajkd.2001.27380
   Ortiz A, 2014, LANCET, V383, P1831, DOI 10.1016/S0140-6736(14)60384-6
   Savic J, 2014, SCAND J CLIN LAB INV, V74, P637, DOI 10.3109/00365513.2014.928944
   Sharma UC, 2004, CIRCULATION, V110, P3121, DOI 10.1161/01.CIR.0000147181.65298.4D
   Szadkowska I, 2013, BIOMARKERS, V18, P655, DOI 10.3109/1354750X.2013.840801
   van der Velde AR, 2013, CIRC-HEART FAIL, V6, P219, DOI 10.1161/CIRCHEARTFAILURE.112.000129
   van Kimmenade RR, 2006, J AM COLL CARDIOL, V48, P1217, DOI 10.1016/j.jacc.2006.03.061
   Yilmaz H., 2014, HERZ
NR 22
TC 4
Z9 4
U1 3
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD AUG
PY 2015
VL 48
IS 12
BP 768
EP 773
DI 10.1016/j.clinbiochem.2015.05.003
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA CO5DO
UT WOS:000359180000006
PM 25977067
DA 2018-12-27
ER

PT J
AU Lee, I
AF Lee, Inhee
TI RETRACTED: The effect of postural control intervention for congenital
   muscular torticollis: a randomized controlled trial (Retracted article.
   See vol. 32, pg. 425, 2018)
SO CLINICAL REHABILITATION
LA English
DT Article; Retracted Publication
DE Congenital muscular torticollis; infants; sternocleidomastoid muscle;
   manual stretching; postural control
ID INFANT-DEATH-SYNDROME; TREATMENT DURATION; PRONE POSITION; RISK;
   DETERMINANTS
AB Objective: To compare the effects of manual stretching and postural control intervention in infants with congenital muscular torticollis and to investigate the factors that predict treatment duration.
   Design: Randomized, controlled trial.
   Setting: An outpatient rehabilitation clinic in a tertiary university hospital.
   Subjects: Infants <6 months of age with congenital muscular torticollis.
   Intervention: Group 1 included 38 infants who received postural control intervention. Group 2 included 38 infants who received manual stretching.
   Main measures: The thickness of the sternocleidomastoid tumor, rear head and facial asymmetry, and head tilt were variables measured before and after treatment. Additionally, the treatment duration was measured.
   Results: The mean treatment duration was 92.53 +/- 34.38 days for group 1 and 88.21 +/- 37.23 days for group 2. The mean change of thickness of the sternocleidomastoid tumor was 6.88 +/- 1.90 mm for group 1 and 6.05 +/- 2.85 mm for group 2. There were no statistically significant differences in the mean treatment duration and the mean change of thickness of the sternocleidomastoid tumor between the groups (P > 0.05). The first treatment day after birth was associated with the treatment duration. In addition, facial asymmetry, the first treatment day, tumor thickness, and head tilt were associated with the treatment duration (P < 0.05). This regression model had a 57.4% explanatory power.
   Conclusions: There was no difference between these treatments regarding the treatment duration and the change of thickness of the sternocleidomastoid tumor. Infants with congenital muscular torticollis who were treated earlier had a shorter treatment length.
C1 [Lee, Inhee] Keimyung Univ, Dept Phys Med & Rehabil, Dongsan Hosp, Taegu 700712, South Korea.
RP Lee, I (reprint author), Keimyung Univ, Dept Phys Med & Rehabil, 56 Dalseong Ro, Taegu 700712, South Korea.
EM einhee@email.com
CR Association APT, 2003, GUID PHYS THER PRACT
   BINDER H, 1987, ARCH PHYS MED REHAB, V68, P222
   Cheng JCY, 2001, CLIN ORTHOP RELAT R, P237
   Cheng JCY, 2001, J BONE JOINT SURG AM, V83A, P679, DOI 10.2106/00004623-200105000-00006
   Demirbilek S, 1999, J PEDIATR SURG, V34, P549, DOI 10.1016/S0022-3468(99)90070-2
   EMERY C, 1994, PHYS THER, V74, P921, DOI 10.1093/ptj/74.10.921
   GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359
   Ho B. C. S., 1999, SMJ, V40, P675
   Jeffery HE, 1999, PEDIATRICS, V104, P263, DOI 10.1542/peds.104.2.263
   Karmel-Ross Karen, 1997, Physical and Occupational Therapy in Pediatrics, V17, P21, DOI 10.1300/J006v17n02_03
   Ohman A, 2013, J NOV PHYSIOTHER, V3, P2
   Peitsch WK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e72
   Petronic I, 2010, EUR J PHYS REHAB MED, V46, P153
   PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601
   Rahlin Mary, 2005, Pediatr Phys Ther, V17, P209, DOI 10.1097/01.pep.0000179176.20035.f0
   STAHELI LT, 1971, SURGERY, V69, P469
   Tatli B, 2006, PEDIATR NEUROL, V34, P41, DOI 10.1016/j.pediati-neurol.2005.06.010
   Taylor JL, 1997, PEDIAT PHYS THER, V9, P173
   Tien YC, 2001, J PEDIATR ORTHOPED, V21, P343, DOI 10.1097/00004694-200105000-00016
   이인희, 2009, [Physical Therapy Korea, 한국전문물리치료학회지], V16, P34
NR 20
TC 5
Z9 5
U1 2
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0269-2155
EI 1477-0873
J9 CLIN REHABIL
JI Clin. Rehabil.
PD AUG
PY 2015
VL 29
IS 8
BP 795
EP 802
DI 10.1177/0269215514555037
PG 8
WC Rehabilitation
SC Rehabilitation
GA CO0YN
UT WOS:000358880000007
PM 25352616
DA 2018-12-27
ER

PT J
AU Earl, CS
   Keong, TW
   An, SQ
   Murdoch, S
   McCarthy, Y
   Garmendia, J
   Ward, J
   Dow, JM
   Yang, L
   O'Toole, GA
   Ryan, RP
AF Earl, Chris S.
   Keong, Teh Wooi
   An, Shi-qi
   Murdoch, Sarah
   McCarthy, Yvonne
   Garmendia, Junkal
   Ward, Joseph
   Dow, J. Maxwell
   Yang, Liang
   O'Toole, George A.
   Ryan, Robert P.
TI RETRACTED: Haemophilus influenzae responds to glucocorticoids used in
   asthma therapy by modulation of biofilm formation and antibiotic
   resistance (Retracted article. See vol. 10, 2018)
SO EMBO MOLECULAR MEDICINE
LA English
DT Article; Retracted Publication
DE antibiotic resistance; asthma; biofilm; Haemophilus influenzae; steroids
ID BECLOMETHASONE DIPROPIONATE; PSEUDOMONAS-AERUGINOSA; EPITHELIAL-CELLS;
   SIGMA-FACTOR; MOUSE MODEL; PROTEIN F; INFECTION; AZITHROMYCIN; GENES;
   IRON
AB Glucocorticosteroids are used as a main treatment to reduce airway inflammation in people with asthma who suffer from neutrophilic airway inflammation, a condition frequently associated with Haemophilus influenzae colonization. Here we show that glucocorticosteroids have a direct influence on the behavior of H.influenzae that may account for associated difficulties with therapy. Using a mouse model of infection, we show that corticosteroid treatment promotes H.influenzae persistence. Transcriptomic analysis of bacteria either isolated from infected mouse airway or grown in laboratory medium identified a number of genes encoding regulatory factors whose expression responded to the presence of glucocorticosteroids. Importantly, a number of these corticosteroid-responsive genes also showed elevated expression in H.influenzae within sputum from asthma patients undergoing steroid treatment. Addition of corticosteroid to H.influenzae led to alteration in biofilm formation and enhanced resistance to azithromycin, and promoted azithromycin resistance in an animal model of respiratory infection. Taken together, these data strongly suggest that H.influenzae can respond directly to corticosteroid treatment in the airway potentially influencing biofilm formation, persistence and the efficacy of antibiotic treatment.
C1 [Earl, Chris S.; An, Shi-qi; Murdoch, Sarah; Ryan, Robert P.] Univ Dundee, Coll Life Sci, Div Mol Microbiol, Dundee, Scotland.
   [Keong, Teh Wooi; Yang, Liang] Nanyang Technol Univ, Singapore Ctr Environm Life Sci Engn, Singapore 639798, Singapore.
   [McCarthy, Yvonne; Dow, J. Maxwell] Natl Univ Ireland Univ Coll Cork, Sch Microbiol, Biosci Inst, Cork, Ireland.
   [Garmendia, Junkal] Univ Publ Navarra, Gobierno Navarra, CSIC, Inst Agrobiotecnol, Mutilva, Spain.
   [Garmendia, Junkal] Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain.
   [Ward, Joseph] Univ Dundee, Coll Life Sci, Div Mol Med, Dundee, Scotland.
   [O'Toole, George A.] Geisel Sch Med Dartmouth, Dept Microbiol & Immunol, Hanover, NH USA.
RP Ryan, RP (reprint author), Univ Dundee, Coll Life Sci, Div Mol Microbiol, Dundee, Scotland.
EM rpryan@dundee.ac.uk
RI Garmendia, Juncal/G-4360-2011
OI Garmendia, Juncal/0000-0002-7440-2737; Ryan, Rober/0000-0002-7353-0913;
   An, Shi-qi/0000-0002-2593-9642
FU Wellcome Trust [WT100204AIA]; European Union's Seventh Framework
   Programme [603038]; National Institutes of Health [2 R37 AI83256-06]
FX We thank Laura Filkins and Francesca Short for technical support and
   help with data analysis. We express gratitude to members of the Ryan
   laboratory for their helpful comments on the manuscript. We also must
   thank Paul Webster for the permission to use one of his wonderful
   scanning electron microscope images. The work of the authors has been
   supported in part by grants awarded by the Wellcome Trust (WT100204AIA
   senior fellowship grant to R.P.R.), European Union's Seventh Framework
   Programme (Grant No. 603038 to R.P.R.) and the National Institutes of
   Health (R01 Grant 2 R37 AI83256-06 to G.A.O).
CR Allen S, 2005, INFECT IMMUN, V73, P5291, DOI 10.1128/IAI.73.9.5291-5300.2005
   An SQ, 2013, MOL MICROBIOL, V88, P1058, DOI 10.1111/mmi.12229
   Anderson GG, 2008, INFECT IMMUN, V76, P1423, DOI 10.1128/IAI.01373-07
   AZOULAYDUPUIS E, 1991, ANTIMICROB AGENTS CH, V35, P1024, DOI 10.1128/AAC.35.6.1024
   Barchinger Sarah E, 2013, Subcell Biochem, V66, P129, DOI 10.1007/978-94-007-5940-4_6
   Beigelman A, 2014, CURR OPIN ALLERGY CL, V14, P137, DOI 10.1097/ACI.0000000000000036
   Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429
   Brian SEO, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-45
   Craig JE, 2002, INFECT IMMUN, V70, P708, DOI 10.1128/IAI.70.2.708-715.2002
   Craig JE, 2001, FEMS MICROBIOL LETT, V203, P55, DOI 10.1016/S0378-1097(01)00328-7
   Cruz-Topete D, 2015, NEUROIMMUNOMODULAT, V22, P20, DOI 10.1159/000362724
   Daley-Yates PT, 2001, BRIT J CLIN PHARMACO, V51, P400, DOI 10.1046/j.0306-5251.2001.01374.x
   Deiwick J, 1999, MOL MICROBIOL, V31, P1759, DOI 10.1046/j.1365-2958.1999.01312.x
   Ducey TF, 2005, J BACTERIOL, V187, P4865, DOI 10.1128/JB.187.14.4865-4874.2005
   Essilfie AT, 2012, THORAX, V67, P588, DOI 10.1136/thoraxjnl-2011-200160
   Essilfie AT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002244
   Friedman HS, 2010, AM J MANAG CARE, V16, pE151
   Gawronski JD, 2009, P NATL ACAD SCI USA, V106, P16422, DOI 10.1073/pnas.0906627106
   Gerber AN, 2011, NEW ENGL J MED, V365, P2435, DOI 10.1056/NEJMc1112547
   Girard D, 2005, J ANTIMICROB CHEMOTH, V56, P365, DOI 10.1093/jac/dki241
   Green BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100645
   HANSEN EJ, 1988, INFECT IMMUN, V56, P182
   Humphreys S, 1999, INFECT IMMUN, V67, P1560
   Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032
   Jalalvand F, 2013, J INFECT DIS, V207, P803, DOI 10.1093/infdis/jis754
   Jurcisek JA, 2011, JOVE-J VIS EXP, V20, P47
   Lesic B, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-20
   Lima S, 2013, SCIENCE, V340, P837, DOI 10.1126/science.1235358
   McCarthy Y, 2010, MOL MICROBIOL, V77, P1220, DOI 10.1111/j.1365-2958.2010.07285.x
   Morey P, 2013, INFECT IMMUN, V81, P4100, DOI 10.1128/IAI.00492-13
   RODRIGUEZ AF, 1991, ANTIMICROB AGENTS CH, V35, P1980, DOI 10.1128/AAC.35.10.1980
   Sambrook J, 1989, MOL CLONING LAB MANU, V10, P51
   Sekiya Y, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-15
   Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200
   Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x
   Singanayagam A, 2010, QJM-INT J MED, V103, P379, DOI 10.1093/qjmed/hcq023
   Starner TD, 2008, ANTIMICROB AGENTS CH, V52, P137, DOI 10.1128/AAC.00607-07
   Steele KH, 2012, J BACTERIOL, V194, P6162, DOI 10.1128/JB.01465-12
   Su YC, 2013, MOL MICROBIOL, V87, P1245, DOI 10.1111/mmi.12164
   Swords WE, 2004, INFECT IMMUN, V72, P106, DOI 10.1128/IAI.72.1.106-113.2004
   VALLEE E, 1992, ANTIMICROB AGENTS CH, V36, P1412, DOI 10.1128/AAC.36.7.1412
   Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8
   Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678
   Whitby PW, 2006, J BACTERIOL, V188, P5640, DOI 10.1128/JB.00417-06
   Wu HY, 1997, J INFECT DIS, V175, P839, DOI 10.1086/513980
NR 45
TC 12
Z9 12
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD AUG
PY 2015
VL 7
IS 8
BP 1018
EP 1033
PG 16
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CO3PM
UT WOS:000359070600006
PM 25995336
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Boquete-Castro, A
   Gomez-Moreno, G
   Aguilar-Salvatierra, A
   Delgado-Ruiz, RA
   Romanos, GE
   Calvo-Guirado, JL
AF Boquete-Castro, Ana
   Gomez-Moreno, Gerardo
   Aguilar-Salvatierra, Antonio
   Delgado-Ruiz, Rafael A.
   Romanos, Georgios E.
   Luis Calvo-Guirado, Jose
TI RETRACTED: Influence of the implant design on osseointegration and
   crestal bone resorption of immediate implants: a histomorphometric study
   in dogs (Retracted article. See vol. 29, pg. 538, 2018)
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article; Retracted Publication
DE animal experiments; clinical research; clinical trials; periodontology
ID FRESH EXTRACTION SOCKETS; TISSUE FORMATION ADJACENT; TITANIUM IMPLANTS;
   ENDOSSEOUS IMPLANTS; SURFACE-TOPOGRAPHY; PLACEMENT; SITES; ROUGHNESS;
   CONTACT; DEFECTS
AB Purpose: The aim of this study was to evaluate bone-to-implant contact after immediate implant placement at different levels in relation to crestal bone in American foxhound dogs.
   Materials and methods: The mandibular second, third, and fourth premolars of six American foxhound dogs were extracted bilaterally. Randomly, three immediate implants were placed in the hemimandible of each dog at the bone crest ( control group) or 2 mm subcrestally ( test group). Three dogs were allowed an 8-week healing period; the other three were left a 12-week healing period. After healing periods, histomorphometric analyses of the specimens were carried out to measure BIC values and bone remodeling.
   Results: All implants healed uneventfully and were available for histological analysis. The total BIC mean values were 44.52% ( +/- 8.67) and 39.50% (+/- 9.25) at 8 and 12 weeks, respectively, for the control group, and 47.33% (+/- 5.23) and 53.85% (+/- 4.21) at 8 and 12 weeks after healing for the test group, respectively. There was observed less bone resorption in the group of implants placed subcrestally.
   Conclusion: Our findings suggest that less resorption may be expected when implants are inserted 2 mm subcrestally. Moreover, higher BIC values in the group of subcrestal implants were found.
C1 [Boquete-Castro, Ana; Aguilar-Salvatierra, Antonio; Delgado-Ruiz, Rafael A.; Luis Calvo-Guirado, Jose] Univ Murcia, Fac Med & Dent, Murcia, Spain.
   [Gomez-Moreno, Gerardo] Univ Granada, Fac Dent, Granada, Spain.
   [Romanos, Georgios E.] SUNY Stony Brook, Sch Dent Med, Stony Brook, NY 11794 USA.
RP Calvo-Guirado, JL (reprint author), Univ Murcia 2, Fac Med & Dent, Hosp Morales Meseguer, Murcia 30007, Spain.
EM joseluis.calvo@um.es
OI calvo guirado, jose luis/0000-0002-4067-2253; Gomez-Moreno,
   Gerardo/0000-0001-9094-4985
CR Abrahamsson I, 2004, CLIN ORAL IMPLAN RES, V15, P381, DOI 10.1111/j.1600-0501.2004.01082.x
   Abrahamsson I, 2008, CLIN ORAL IMPLAN RES, V19, P153, DOI 10.1111/j.1600-0501.2007.01454.x
   Araujo MG, 2006, CLIN ORAL IMPLAN RES, V17, P606, DOI 10.1111/j.1600-0501.2006.01315.x
   Araujo MG, 2005, J CLIN PERIODONTOL, V32, P212, DOI 10.1111/j.1600-051X.2005.00642.x
   Araujo MG, 2005, J CLIN PERIODONTOL, V32, P645, DOI 10.1111/j.1600-051X.2005.00726.x
   Berglundh T, 2003, CLIN ORAL IMPLAN RES, V14, P251, DOI 10.1034/j.1600-0501.2003.00972.x
   Bornstein MM, 2008, CLIN ORAL IMPLAN RES, V19, P233, DOI 10.1111/j.1600-0501.2007.01473.x
   Bornstein MM, 2003, INT J ORAL MAX IMPL, V18, P659
   Bornstein MM, 2005, CLIN ORAL IMPLAN RES, V16, P631, DOI 10.1111/j.1600-0501.2005.01209.x
   Botticelli D, 2004, J CLIN PERIODONTOL, V31, P820, DOI 10.1111/j.1600-051X.2004.00565.x
   Botticelli D, 2005, J CLIN PERIODONTOL, V32, P448, DOI 10.1111/j.1600-051X.2005.00693.x
   Botticelli D, 2003, CLIN ORAL IMPLAN RES, V14, P1, DOI 10.1034/j.1600-0501.2003.140101.x
   Botticelli D, 2006, CLIN ORAL IMPLAN RES, V17, P351, DOI 10.1111/j.1600-0501.2006.01270.x
   BUSER D, 1991, J BIOMED MATER RES, V25, P889, DOI 10.1002/jbm.820250708
   BUSER D, 1992, J PERIODONTOL, V63, P225, DOI 10.1902/jop.1992.63.3.225
   Buser D, 1999, Adv Dent Res, V13, P153
   Calvo-Guirado JL, 2010, CLIN ORAL IMPLAN RES, V21, P308, DOI 10.1111/j.1600-0501.2009.01841.x
   Caneva M, 2010, CLIN ORAL IMPLAN RES, V21, P885, DOI 10.1111/j.1600-0501.2010.01931.x
   Cardaropoli G, 2006, CLIN ORAL IMPLAN RES, V17, P165, DOI 10.1111/j.1600-0501.2005.01210.x
   Cho George C, 2004, J Calif Dent Assoc, V32, P983
   Cooper LF, 2000, J PROSTHET DENT, V84, P522, DOI 10.1067/mpr.2000.111966
   Davies John E, 2003, J Dent Educ, V67, P932
   Gotfredsen K, 2000, Clin Implant Dent Relat Res, V2, P120, DOI 10.1111/j.1708-8208.2000.tb00002.x
   Gottlow J, 2012, CLIN IMPLANT DENT R, V14, pe204, DOI 10.1111/j.1708-8208.2012.00439.x
   Hammerle CHF, 1996, CLIN ORAL IMPLAN RES, V7, P111, DOI 10.1034/j.1600-0501.1996.070204.x
   Khang W, 2001, J PERIODONTOL, V72, P1384, DOI 10.1902/jop.2001.72.10.1384
   Le Guehennec L, 2007, DENT MATER, V23, P844, DOI 10.1016/j.dental.2006.06.025
   Lincks J, 1998, BIOMATERIALS, V19, P2219, DOI 10.1016/S0142-9612(98)00144-6
   London RM, 2002, INT J ORAL MAX IMPL, V17, P369
   Negri B, 2012, CLIN ORAL IMPLAN RES, V23, P236, DOI 10.1111/j.1600-0501.2011.02290.x
   Orsini E, 2009, Minerva Stomatol, V58, P263
   Paolantonio M, 2001, J PERIODONTOL, V72, P1560, DOI 10.1902/jop.2001.72.11.1560
   Romanos G, 2001, J PERIODONTOL, V72, P506, DOI 10.1902/jop.2001.72.4.506
   Romanos GE, 2003, J PERIODONTOL, V74, P1483, DOI 10.1902/jop.2003.74.10.1483
   Romanos GE, 2012, ADVANCED IMMEDIATE LOADING, P1
   Romanos GE, 2015, CLIN IMPLANT DENT R, V17, P133, DOI 10.1111/cid.12084
   Sanz M, 2010, CLIN ORAL IMPLAN RES, V21, P13, DOI 10.1111/j.1600-0501.2009.01824.x
   Schropp L., 2009, INT J PERIODONT REST, V23, P313
   Shalabi MM, 2006, J DENT RES, V85, P496, DOI 10.1177/154405910608500603
   Spray J R, 2000, Ann Periodontol, V5, P119, DOI 10.1902/annals.2000.5.1.119
   Tomasi C, 2010, CLIN ORAL IMPLAN RES, V21, P30, DOI 10.1111/j.1600-0501.2009.01848.x
   Tran BLT, 2010, CLIN ORAL IMPLAN RES, V21, P794, DOI 10.1111/j.1600-0501.2010.01911.x
   Trisi P, 2003, J PERIODONTOL, V74, P945, DOI 10.1902/jop.2003.74.7.945
   Trisi P, 2002, INT J PERIODONT REST, V22, P535
   Welander M, 2009, J PERIODONTOL, V80, P324, DOI [10.1902/jop.2009.080375, 10.1902/jop.2009.080375 ]
   Wennerberg A, 1996, BIOMATERIALS, V17, P15, DOI 10.1016/0142-9612(96)80750-2
   Zechner W, 2003, CLIN ORAL IMPLAN RES, V14, P150, DOI 10.1034/j.1600-0501.2003.140203.x
NR 47
TC 5
Z9 6
U1 2
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-7161
EI 1600-0501
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD AUG
PY 2015
VL 26
IS 8
BP 876
EP 881
DI 10.1111/clr.12381
PG 6
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
SC Dentistry, Oral Surgery & Medicine; Engineering
GA CN7MJ
UT WOS:000358618400004
PM 24665897
DA 2018-12-27
ER

PT J
AU Li, XL
   Hu, GP
   Wang, Y
   Xu, J
AF Li, Xiaoling
   Hu, Guangping
   Wang, Yao
   Xu, Jing
TI RETRACTED: Varieties of bands with a semilattice transversal (Retracted
   article. See vol. 93, pg. 734, 2016)
SO SEMIGROUP FORUM
LA English
DT Article; Retracted Publication
DE Varieties; Bands; Lattice; Semilattice transveral
ID REGULAR-SEMIGROUPS; LATTICE
AB The lattice of varieties of bands with a semilattice transversal is a replica of the lattice of all band varieties. We solve the word problem for the free band with a semilattice transversal and for all relatively free objects.
C1 [Li, Xiaoling; Hu, Guangping; Wang, Yao; Xu, Jing] Nanjing Univ Informat Sci & Technol, Sch Math & Stat, Nanjing 210044, Jiangsu, Peoples R China.
RP Li, XL (reprint author), Nanjing Univ Informat Sci & Technol, Sch Math & Stat, Nanjing 210044, Jiangsu, Peoples R China.
EM lxl871@nuist.edu.cn
FU National Natural Science Foundation of China [11101217]; Natural Science
   Foundation of Jiang Su Province Foundation [BK20141476]
FX The authors are very grateful to the anonymous reviewers for their
   careful reading of the manuscript and valuable comments. This research
   was partially supported by the National Natural Science Foundation of
   China (No. 11101217) and the Natural Science Foundation of Jiang Su
   Province Foundation (No. BK20141476).
CR Biryukov P.A., 1970, ALGEBRA LOGIKA+, V9, P255
   BLYTH TS, 1982, P ROY SOC EDINB A, V92, P253, DOI 10.1017/S0308210500032522
   FENNEMOR.CF, 1971, MATH NACHR, V48, P253
   FENNEMORE CF, 1971, MATH NACHR, V48, P237, DOI 10.1002/mana.19710480118
   Gerhard J.A., 1989, P LOND MATH SOC, V58, P250
   GERHARD JA, 1970, J ALGEBRA, V15, P195, DOI 10.1016/0021-8693(70)90073-6
   GREEN JA, 1952, P CAMB PHILOS SOC, V48, P35
   Howie J. M, 1995, FUNDAMENTALS SEMIGRO
   Koryakov I.O., 1978, LINEAR SEMIGROUPS ID, P54
   Koryakov I.O., 1981, BASIS RANKS VARIETIE, P47
   MCALISTER DB, 1978, J ALGEBRA, V51, P491, DOI 10.1016/0021-8693(78)90118-7
   McKenzie R.N., 1987, ALGEBRAS LATTICES VA, VI
   McLean D., 1954, AM MATH MONTHLY, V61, P110
   PASTIJN F, 1990, J AUST MATH SOC A, V49, P24, DOI 10.1017/S1446788700030214
   Petrich M., 1977, LETURES IN SEMIGROUP
   Petrich M., 1973, INTRO SEMIGROUPS
   POLAK L, 1987, SEMIGROUP FORUM, V36, P253, DOI 10.1007/BF02575021
   POLAK L, 1985, SEMIGROUP FORUM, V32, P97, DOI 10.1007/BF02575527
   POLAK L, 1988, SEMIGROUP FORUM, V37, P1, DOI 10.1007/BF02573119
   SAITO T, 1986, SEMIGROUP FORUM, V33, P149, DOI 10.1007/BF02573188
   Tang XL, 2006, SEMIGROUP FORUM, V73, P377, DOI 10.1007/s00233-006-0634-1
   Yoshida R., 1984, P 8 S SEM SHIM U MAT, P26
NR 22
TC 1
Z9 1
U1 6
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0037-1912
EI 1432-2137
J9 SEMIGROUP FORUM
JI Semigr. Forum
PD AUG
PY 2015
VL 91
IS 1
BP 185
EP 199
DI 10.1007/s00233-015-9706-4
PG 15
WC Mathematics
SC Mathematics
GA CM9WL
UT WOS:000358060100013
DA 2018-12-27
ER

PT J
AU Haut, ER
   Haider, AH
   Cotton, BA
   Stevens, KA
   Cornwell, EE
   Efron, DT
AF Haut, Elliott R.
   Haider, Adil H.
   Cotton, Bryan A.
   Stevens, Kent A.
   Cornwell, Edward E.
   Efron, David T.
TI RETRACTED: Reply to Letter: "ATLS Protocols of Initial Intravenous Fluid
   Administration for Trauma Patients; Needing a Revision?" (Retracted
   article. See vol. 262, pg. 402, 2015)
SO ANNALS OF SURGERY
LA English
DT Letter; Retracted Publication
ID RESUSCITATION
C1 [Haut, Elliott R.; Haider, Adil H.; Stevens, Kent A.; Efron, David T.] Johns Hopkins Univ, Sch Med, Dept Surg, Div Acute Care Surg, Baltimore, MD 21205 USA.
   [Haut, Elliott R.; Haider, Adil H.; Stevens, Kent A.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Cotton, Bryan A.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA.
   [Cotton, Bryan A.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX 77030 USA.
   [Cornwell, Edward E.] Howard Univ, Dept Surg, Washington, DC 20059 USA.
RP Haut, ER (reprint author), Johns Hopkins Univ, Sch Med, Dept Surg, Div Acute Care Surg, Baltimore, MD 21205 USA.
FU AHRQ HHS [K08 1K08HS017952-01]; NIGMS NIH HHS [K23GM093112-01]
CR American College of Surgeons Committee on Trauma, 2012, ADV TRAUM LIF SUPP A, P73
   Cotton BA, 2011, ANN SURG, V254, P598, DOI 10.1097/SLA.0b013e318230089e
   Cotton BA, 2009, J TRAUMA, V67, P389, DOI 10.1097/TA.0b013e3181a8b26f
   Haut ER, 2011, ANN SURG, V253, P371, DOI 10.1097/SLA.0b013e318207c24f
   Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad
NR 5
TC 0
Z9 0
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-4932
EI 1528-1140
J9 ANN SURG
JI Ann. Surg.
PD AUG
PY 2015
VL 262
IS 2
BP e41
EP e41
DI 10.1097/SLA.0000000000000484
PG 1
WC Surgery
SC Surgery
GA CM8KJ
UT WOS:000357949100003
PM 24441797
DA 2018-12-27
ER

PT J
AU Tariq, M
   Hasnain, SM
AF Tariq, M.
   Hasnain, S. M.
TI RETRACTED: Effects of Surface Coating on Physical Properties of Silver
   Nanoparticles (Retracted article. See vol. 44, pg. 4653, 2015)
SO JOURNAL OF ELECTRONIC MATERIALS
LA English
DT Article; Retracted Publication
DE Silver nanoparticles; coating; composite; resistivity
ID IRON-OXIDE NANOPARTICLES; ELECTRICAL-TRANSPORT; NANOCOMPOSITE; DESIGN;
   FILMS; GOLD
AB Polymer-coated nanoparticles improve the stability of materials against aggregation and enhance the physical properties, thus making it possible to use different applications in vast fields of science. In this work, silver nanoparticles were synthesized by a chemical reduction method and were further coated with the polymers polyvinyl alcohol (PVA) and polystyrene (PS). The influence of the polymer coating on the optical and electrical properties of the silver nanoparticles were investigated and compared with that of as-prepared silver nanoparticles. The nature of the prepared silver nanoparticles in the face-centered cubic structure is confirmed by peaks in the x-ray diffraction pattern. The temperature dependence of resistivity of the silver nanoparticles exhibit semiconducting behavior in the temperature range 100-300 K.
C1 [Tariq, M.; Hasnain, S. M.] Quaid I Azam Univ, Dept Phys, Islamabad 45320, Pakistan.
RP Hasnain, SM (reprint author), Quaid I Azam Univ, Dept Phys, Islamabad 45320, Pakistan.
EM msyed.hasnainshah@gmail.com
CR Choudhury A, 2009, SENSOR ACTUAT B-CHEM, V138, P318, DOI 10.1016/j.snb.2009.01.019
   DEMICHELIS F, 1993, PHILOS MAG B, V67, P331
   Ekinci KL, 2004, APPL PHYS LETT, V84, P4469, DOI 10.1063/.1.1755417
   Filippo E, 2009, SENSOR ACTUAT B-CHEM, V138, P625, DOI 10.1016/j.snb.2009.02.056
   FRANKS A, 1987, J PHYS E SCI INSTRUM, V20, P1442, DOI 10.1088/0022-3735/20/12/001
   Geddes CD, 2003, J PHYS CHEM A, V107, P3443, DOI 10.1021/jp022040q
   Godet C., 2002, J NONCRYST SOLIDS, V333, P299
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Harris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088-200140070-00005
   Hong SH, 2006, J VAC SCI TECHNOL B, V24, P136, DOI 10.1116/1.2150227
   Hussain I, 2003, LANGMUIR, V19, P4831, DOI 10.1021/la020710d
   Khan MW, 2008, J PHYS D APPL PHYS, V41, DOI 10.1088/0022-3727/41/17/175409
   Khan MAM, 2011, NANOSCALE RES LETT, V6, DOI 10.1186/1556-276X-6-434
   Krenn JR, 1999, PHYS REV B, V60, P5029, DOI 10.1103/PhysRevB.60.5029
   Kulkarni S., 2009, NANOTECHNOLOGY PRINC, P263
   Kumar RV, 2002, ULTRASON SONOCHEM, V9, P65, DOI 10.1016/S1350-4177(01)00100-6
   Lee WC, 2007, CURR APPL PHYS, V7, P139, DOI 10.1016/j.cap.2006.03.001
   Mahmoudi M, 2008, J PHYS CHEM B, V112, P14470, DOI 10.1021/jp803016n
   Qian XF, 2001, MATER CHEM PHYS, V68, P95, DOI 10.1016/S0254-0584(00)00288-1
   Roos C, 1999, ADV MATER, V11, P761
   Sackler A. M., 2001, NANOSCIENCE UNDERLYI, V99, P8
   Solomon Sally D., 2007, J CHEM ED, V84
   Velev OD, 1999, LANGMUIR, V15, P3693, DOI 10.1021/la981729c
   Zavyalov SA, 2002, SOLID STATE IONICS, V147, P415, DOI 10.1016/S0167-2738(02)00038-3
   Zhang ZP, 2003, J MATER CHEM, V13, P641, DOI 10.1039/b212428a
NR 25
TC 1
Z9 1
U1 2
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0361-5235
EI 1543-186X
J9 J ELECTRON MATER
JI J. Electron. Mater.
PD AUG
PY 2015
VL 44
IS 8
BP 2574
EP 2577
DI 10.1007/s11664-015-3696-6
PG 4
WC Engineering, Electrical & Electronic; Materials Science,
   Multidisciplinary; Physics, Applied
SC Engineering; Materials Science; Physics
GA CL5YL
UT WOS:000357041400004
DA 2018-12-27
ER

PT J
AU Bachmann, C
   Brucker, SY
   Kraemer, B
   Rothmund, R
   Staebler, A
   Fend, F
   Wallwiener, D
   Grischke, EM
AF Bachmann, Cornelia
   Brucker, Sara Y.
   Kraemer, Bernhard
   Rothmund, Ralf
   Staebler, Anette
   Fend, Falko
   Wallwiener, Diethelm
   Grischke, Eva-Maria
TI RETRACTED: The prognostic relevance of node metastases in optimally
   cytoreduced advanced ovarian cancer (Retracted article. See vol. 142,
   pg. 529, 2016)
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE Advanced ovarian cancer; Node ratio; Lymphadenectomy; Prognosis;
   Residual; Tumour; Node metastases
ID PARAAORTIC LYMPHADENECTOMY; SYSTEMATIC LYMPHADENECTOMY; PELVIC
   LYMPHADENECTOMY; EXPLORATORY ANALYSIS; SURVIVAL; CARCINOMA; IMPACT;
   MANAGEMENT; DEBULKING; RESECTION
AB Purpose To delineate the relevance of pelvic and paraaortic node involvement in optimally cytoreduced (residual tumour <1 cm) stage IIIC ovarian cancer patients.
   Methods Ninety-five consecutive optimally cytoreduced (R <= 1 cm) patients with primary stage IIIc ovarian cancer underwent stage-related surgery and got adjuvant platinum-based chemotherapy. Median follow-up: 53.5 months. All patients got systematic lymphadenectomy. On average, 24.7 pelvic and para-aortic lymph nodes were removed per patient (range 1-60 nodes). Patients were stratified into three groups to evaluate node involvement (ratio: affected to resected nodes): (1) (= 0); (2) (> 0-<= 0.5) >0 and <= 50 % of affected nodes; (3) (> 0.5-<= 1) > 50 % of affected nodes. Clinical parameters were retrospectively evaluated. Kaplan-Meier survival curve was used to evaluate the prognostic value.
   Results Most often serous histology, histologic grade 3 and a node ratio > 0-<=.5 (61.1 %) were detected. Complete cytoreduction (R = 0 mm) has significant best prognostic impact compared to R > 0 mm-1 cm (OS: p = 0.047, PFS: p = 0.00). Node involvement was associated with serous histology and grade 3. Increasing node ratio leads to significant decreased OS (p = 0.019) and significant best OS was associated with node ratio > 0-<= 0.5.
   Conclusions The goal is optimal cytoreduction in advanced ovarian cancer. More extensive lymphadenectomy seems to play an important role in providing an accurate staging, and the node ratio might give prognostic information. Current prospective studies like the LION study (AGO-Ovar) had to investigate if these data have therapeutic implications and may be considered in future staging.
C1 [Bachmann, Cornelia; Brucker, Sara Y.; Kraemer, Bernhard; Rothmund, Ralf; Wallwiener, Diethelm; Grischke, Eva-Maria] Univ Tubingen, Dept Gynecol, D-72070 Tubingen, Germany.
   [Staebler, Anette; Fend, Falko] Univ Tubingen, Dept Pathol, D-72076 Tubingen, Germany.
RP Bachmann, C (reprint author), Univ Tubingen, Dept Gynecol, Calwer Str 7, D-72070 Tubingen, Germany.
EM cornelia.bachmann@med.uni-tuebingen.de
CR Abe A, 2010, J OBSTET GYNAECOL RE, V36, P1023, DOI 10.1111/j.1447-0756.2010.01274.x
   Aletti GD, 2006, AM J OBSTET GYNECOL, V195, P1862, DOI 10.1016/j.ajog.2006.06.068
   Bachmann C, 2012, J CANCER RES CLIN, V138, P261, DOI 10.1007/s00432-011-1094-x
   Bakkar R, 2014, INT J GYNECOL PATHOL, V33, P302, DOI 10.1097/PGP.0b013e3182988dfd
   Balbi G, 2009, EUR J GYNAECOL ONCOL, V30, P289
   Bristow RE, 2002, J CLIN ONCOL, V20, P1248, DOI 10.1200/JCO.20.5.1248
   Carnino F, 1997, GYNECOL ONCOL, V65, P467, DOI 10.1006/gyno.1997.4633
   Chan JK, 2007, BRIT J CANCER, V96, P1817, DOI 10.1038/sj.bjc.6603803
   Chang SJ, 2012, GYNECOL ONCOL, V126, P381, DOI 10.1016/j.ygyno.2012.05.014
   Chekerov R, 2013, INT J GYNECOL CANCER, V23, P268, DOI 10.1097/IGC.0b013e31827de6b9
   Denny L, 2012, INT J GYNECOL OBSTET, V119, pS89, DOI 10.1016/S0020-7292(12)00458-4
   diRe F, 1996, GYNECOL ONCOL, V62, P360, DOI 10.1006/gyno.1996.0249
   du Bois A, 2009, CANCER, V115, P1234, DOI 10.1002/cncr.24149
   Harter P, 2007, INT J GYNECOL CANCER, V17, P1238, DOI 10.1111/j.1525-1438.2007.00931.x
   Hohn AK, 2014, PATHOLOGE, V35, P322, DOI 10.1007/s00292-014-1908-0
   HOSKINS WJ, 1994, AM J OBSTET GYNECOL, V170, P974, DOI 10.1016/S0002-9378(94)70090-7
   Kim HS, 2010, INT J GYNECOL CANCER, V20, P520, DOI 10.1111/IGC.0b013e3181d6de1d
   Mahdi H, 2011, J SURG ONCOL, V103, P724, DOI 10.1002/jso.21869
   Nomura H, 2011, J SURG ONCOL
   Onda T, 1998, CANCER, V83, P1555, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1555::AID-CNCR10>3.0.CO;2-R
   Panici PB, 2005, J NATL CANCER I, V97, P560, DOI 10.1093/jnci/dji102
   Pereira A, 2012, INT J GYNECOL CANCER, V22, P987, DOI 10.1097/IGC.0b013e318257b958
   Scarabelli C, 1997, INT J GYNECOL CANCER, V7, P18, DOI 10.1046/j.1525-1438.1997.00418.x
   Suh DH, 2013, J GYNECOL ONCOL, V24, P352, DOI 10.3802/jgo.2013.24.4.352
   Takeshima N, 2005, GYNECOL ONCOL, V99, P427, DOI 10.1016/j.ygyno.2005.06.051
   Ulker V, 2014, ARCH GYNECOL OBSTET, V289, P1087, DOI 10.1007/s00404-013-3078-3
   Wimberger P, 2007, GYNECOL ONCOL, V106, P69, DOI 10.1016/j.ygyno.2007.02.026
NR 27
TC 8
Z9 8
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD AUG
PY 2015
VL 141
IS 8
BP 1475
EP 1480
DI 10.1007/s00432-015-1945-y
PG 6
WC Oncology
SC Oncology
GA CK7DZ
UT WOS:000356392800015
PM 25739827
DA 2018-12-27
ER

PT J
AU Huang, WH
   Li, HF
   Luo, RC
AF Huang, Weihua
   Li, Huifen
   Luo, Rongcheng
TI RETRACTED: The microRNA-1246 promotes metastasis in non-small cell lung
   cancer by targeting cytoplasmic polyadenylation element-binding protein
   4(Retracted article. See vol. 12, 2017)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE miR-1246; CPEB4; NSCLC; Metastasis
ID EXPRESSION; GENES; CPEB4; RNA; P53; CARCINOMA; MIGRATION; LYMPHOMA;
   SURVIVAL; INVASION
AB Background: The microRNAs present a class of non-coding RNAs which are usually implicated in tumor biology. Recent report has unraveled that a novel member of microRNA family called miR-1246. However, the functional role and molecular mechanisms of miR-1246 in non-small cell lung cancer (NSCLC) is still elusive.
   Methods: Using RT-PCR, luciferase reporter, mRNA microarrays, invasion and migration assays, we investigated the potential role of miR-1246 in the pathogenesis of NSCLC.
   Results: In this study, we showed that miR-1246 markedly promoted NSCLC cell migration and invasion. Meanwhile, we found that cytoplasmic polyadenylation element binding protein 4 (CPEB4) might be involved and serve as a direct target of miR-1246 in NSCLC. CPEB4 knockdown substantially enhanced NSCLC migration and invasion resembling the effect of miR-1246 in NSCLC. CPEB4 is also frequently downregulated in NSCLC and decreased CPEB4 expression correlated with poor survival.
   Conclusions: These results suggested that the miR-1246 may promote cell metastasis by targeting CPEB4. Meanwhile, the level of CPEB4 could be used as a potential marker in NSCLC patients. Our findings unraveled novel functions of miR-1246 in lung cancer cells and shed light on NSCLC prognosis.
C1 [Huang, Weihua; Luo, Rongcheng] Southern Med Univ, TCM Integrated Hosp, Ctr Canc, Guangzhou 510315, Guangdong, Peoples R China.
   [Li, Huifen] Zhongshan Peoples Hosp, Dept Chemotherapy, Zhongshan 528400, Guangdong, Peoples R China.
RP Luo, RC (reprint author), Southern Med Univ, TCM Integrated Hosp, Ctr Canc, 13 Shiliugang Rd, Guangzhou 510315, Guangdong, Peoples R China.
EM jackieluorongcheng@163.com
CR Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043
   Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014
   Borkowski R, 2015, CANCER RES, V75, P666, DOI 10.1158/0008-5472.CAN-14-1329
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Dykxhoorn DM, 2010, CANCER RES, V70, P6401, DOI 10.1158/0008-5472.CAN-10-1346
   Fabbri M, 2010, EXPERT REV MOL DIAGN, V10, P435, DOI 10.1586/ERM.10.27
   FORTUNATO O, 2014, BIOMED RES INT, V2014
   Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352
   Huang YS, 2006, EMBO J, V25, P4865, DOI 10.1038/sj.emboj.7601322
   Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027
   Igea A, 2010, EMBO J, V29, P2182, DOI 10.1038/emboj.2010.111
   Ishiguro H, 2014, WORLD J GASTROENTERO, V20, P5694, DOI 10.3748/wjg.v20.i19.5694
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Kan MC, 2010, MOL CELL BIOL, V30, P5658, DOI 10.1128/MCB.00716-10
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Liao JM, 2012, CELL CYCLE, V11, P2624, DOI 10.4161/cc.20809
   Lim EL, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0568-y
   Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Morgan M, 2010, NUCLEIC ACIDS RES, V38, P7698, DOI 10.1093/nar/gkq635
   Ortiz-Zapater E, 2012, NAT MED, V18, P83, DOI 10.1038/nm.2540
   Qi LQ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-163
   Sun Z, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-616
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Wang R, 2011, ONCOGENE, V30, P2644, DOI 10.1038/onc.2010.642
   Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858
   Zhang S, 2012, ONCOGENE, V31, P3607, DOI 10.1038/onc.2011.523
   Zhang Y, 2011, EMBO REP, V12, P811, DOI 10.1038/embor.2011.98
   Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010
NR 30
TC 12
Z9 12
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUL 25
PY 2015
VL 10
AR 127
DI 10.1186/s13000-015-0366-1
PG 10
WC Pathology
SC Pathology
GA CN4NF
UT WOS:000358406200009
PM 26209100
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Li, HF
   Huang, WH
   Luo, RC
AF Li, Huifen
   Huang, Weihua
   Luo, Rongcheng
TI RETRACTED: The microRNA-325 inhibits hepatocellular carcinoma
   progression by targeting high mobility group box 1 (Retracted article.
   See vol. 13, artn. 26, 2018)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE miR-325; HMGB1; Proliferation; Invasion; Hepatocarcinoma carcinoma
ID CELL LUNG-CANCER; COLORECTAL-CANCER; POOR-PROGNOSIS; OVARIAN-CANCER;
   UP-REGULATION; IN-VITRO; HMGB1; EXPRESSION; INVASION; APOPTOSIS
AB Background: MicroRNAs (miRNAs) can serve as tumor suppressors and might provide an efficient strategy for annihilating tumor cells. Nevertheless, the potential role of miR-325 in hepatocellular carcinoma (HCC) is still unknown.
   Methods: Using RT-PCR, immunoblots invasion assays and bioinformatics strategies, we investigated the potential role of miR-325 in HCC.
   Results: We showed that miR-325 was decreased and HMGB1 was increased in 99 patients with hepatocellular carcinoma. MiR-325 inhibition promoted cell invasion and proliferation, while miR-325 upregulation inhibited cell invasion and proliferation by using transwell and CCK8 assays. We further showed that HMGB1 might be a direct target of miR-325 and is negatively regulated by miR-325. Down-regulation of miR-325 predicts poor prognosis for HCC patients.
   Conclusions: These findings implied that miR-325 regulates cell invasion and proliferation via targeting HMGB1 and may be a potential prognostic marker for HCC.
C1 [Li, Huifen] Zhongshan Peoples Hosp, Dept Chemotherapy, Zhongshan 528400, Guangdong, Peoples R China.
   [Huang, Weihua; Luo, Rongcheng] Southern Med Univ, TCM Integrated Hosp, Ctr Canc, Guangzhou 510315, Guangdong, Peoples R China.
RP Luo, RC (reprint author), Southern Med Univ, TCM Integrated Hosp, Ctr Canc, 13 Shiliugang Rd, Guangzhou 510315, Guangdong, Peoples R China.
EM manuluorongcheng@163.com
CR ALEXANDROVA EA, 1988, BIOCHEM BIOPH RES CO, V154, P918, DOI 10.1016/0006-291X(88)90227-6
   Altekruse SF, 2012, HEPATOLOGY, V55, P476, DOI 10.1002/hep.24710
   Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014
   Bian HB, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-20
   Chen CG, 2012, PATHOL ONCOL RES, V18, P1021, DOI 10.1007/s12253-012-9539-3
   Chen J, 2012, GYNECOL ONCOL, V126, P109, DOI 10.1016/j.ygyno.2012.03.051
   Cillo U, 2004, J HEPATOL, V40, P124, DOI 10.1016/j.jhep.2003.09.027
   Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50
   Du BW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088022
   Dykxhoorn DM, 2010, CANCER RES, V70, P6401, DOI 10.1158/0008-5472.CAN-10-1346
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fabbri M, 2010, EXPERT REV MOL DIAGN, V10, P435, DOI 10.1586/ERM.10.27
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027
   Kim MK, 2014, VIRCHOWS ARCH, V465, P463, DOI 10.1007/s00428-014-1640-4
   Levy I, 2002, GUT, V50, P881, DOI 10.1136/gut.50.6.881
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li T, 2009, BIOCHEM BIOPH RES CO, V383, P280, DOI 10.1016/j.bbrc.2009.03.077
   Liu FR, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-135
   Liu Y, 2010, EUR J CANCER, V46, P3007, DOI 10.1016/j.ejca.2010.07.016
   Minagawa M, 2007, ANN SURG, V245, P909, DOI 10.1097/01.sla.0000254368.65878.da
   Ohmori H, 2011, EXPERT OPIN THER TAR, V15, P183, DOI 10.1517/14728222.2011.546785
   Price NL, 2014, CRIT REV CLIN LAB SC, V51, P1
   Shen XK, 2009, ONCOL REP, V22, P535, DOI 10.3892/or_00000468
   Shiiba Masashi, 2010, Cancers (Basel), V2, P653, DOI 10.3390/cancers2020653
   Su J, 2014, MOL CELL BIOCHEM, V392, P289, DOI 10.1007/s11010-014-2039-x
   Suren D, 2014, MED SCI MONITOR, V20, P530, DOI 10.12659/MSM.890531
   Tang XQ, 2011, METHODS MOL BIOL, V732, P69, DOI 10.1007/978-1-61779-083-6_6
   Tsang FH, 2014, DIGEST DIS SCI, V59, P2477, DOI 10.1007/s10620-014-3184-5
   Wang LL, 2014, WORLD J GASTROENTERO, V20, P11340, DOI 10.3748/wjg.v20.i32.11340
   Wang R, 2011, ONCOGENE, V30, P2644, DOI 10.1038/onc.2010.642
   Wang TY, 2014, GENET MOL RES, V13, P5574, DOI 10.4238/2014.July.25.12
   Wong QWL, 2010, CLIN CANCER RES, V16, P867, DOI 10.1158/1078-0432.CCR-09-1840
   Xu F, 2014, CLIN TRANSL ONCOL, V16, P980, DOI 10.1007/s12094-014-1183-9
   Zhang J, 2015, CLIN TRANSL ONCOL, V17, P209, DOI 10.1007/s12094-014-1213-7
   Zhang J, 2014, INT J ONCOL, V44, P1268, DOI 10.3892/ijo.2014.2285
   Zhang WQ, 2014, TUMOR BIOL, V35, P2175, DOI 10.1007/s13277-013-1288-8
NR 37
TC 13
Z9 14
U1 5
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUL 22
PY 2015
VL 10
AR 117
DI 10.1186/s13000-015-0323-z
PG 11
WC Pathology
SC Pathology
GA CN3QN
UT WOS:000358341500001
PM 26194496
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Abkhezr, M
   Kim, EY
   Roshanravan, H
   Nikolos, F
   Thomas, C
   Hagmann, H
   Benzing, T
   Dryer, SE
AF Abkhezr, Mousa
   Kim, Eun Young
   Roshanravan, Hila
   Nikolos, Fotis
   Thomas, Christoforos
   Hagmann, Henning
   Benzing, Thomas
   Dryer, Stuart E.
TI RETRACTED: Pleiotropic signaling evoked by tumor necrosis factor in
   podocytes (Retracted article. See vol. 310, pg. F1423, 2016)
SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
LA English
DT Article; Retracted Publication
DE podocyte; glomerulosclerosis; inflammation; transient receptor potential
   cation channel; subfamily C; member 6; tumor necrosis factor
ID NF-KAPPA-B; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; ACUTE-RENAL-FAILURE;
   FACTOR-ALPHA; TRPC6 CHANNELS; NEPHROTIC SYNDROME; ANGIOTENSIN-II;
   TNF-ALPHA; GLOMERULAR-DISEASES; MONONUCLEAR-CELLS
AB TNF has been implicated in glomerular diseases, but its actions on podocytes are not well understood. Endogenous TNF expression is markedly increased in mouse podocytes exposed to sera from patients with recurrent focal segmental glomerulosclerosis, and TNF is able to increase its own expression in these cells. Exposure of podocytes to TNF increased phosphorylation of NF-kappa B p65-RelA followed by increased tyrosine phosphorylation of STAT3. STAT3 activation was blocked by the NF-kappa B inhibitor JSH-23 and by the STAT3 inhibitor stattic, whereas TNF-evoked NF-kappa B activation was not affected by stattic. TNF treatment increased nuclear accumulation of nuclear factor of activated T cells (NFAT) c1 in podocytes, a process that occurred downstream of STAT3 activation. TNF also increased expression of cyclin D1 but had no effect on cyclin-dependent kinase 4, p27(kip), or podocin. Despite its effects on cyclin D1, TNF treatment for up to 72 h did not cause podocytes to reenter the cell cycle. TNF increased total expression of transient receptor potential (TRP)C6 channels through a pathway dependent on NFATc1 and increased the steady-state expression of TRPC6 subunits on the podocyte cell surface. TNF effects on TRPC6 trafficking required ROS. Consistent with this, La3+-sensitive cationic currents activated by a diacylglycerol analog were increased in TNF-treated cells. The effects of TNF on NFATc1 and TRPC6 expression were blocked by cyclosporine A but were not blocked by the pan-TRP inhibitor SKF-96365. TNF therefore influences multiple pathways previously implicated in podocyte pathophysiology and is likely to sensitize these cells to other insults.
C1 [Abkhezr, Mousa; Kim, Eun Young; Roshanravan, Hila; Nikolos, Fotis; Thomas, Christoforos; Dryer, Stuart E.] Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.
   [Hagmann, Henning; Benzing, Thomas] Univ Cologne, Dept Internal Med, D-50931 Cologne, Germany.
   [Nikolos, Fotis; Thomas, Christoforos] Univ Houston, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA.
   [Dryer, Stuart E.] Baylor Coll Med, Div Nephrol, Houston, TX 77030 USA.
RP Dryer, SE (reprint author), Univ Houston, 4800 Calhoun St, Houston, TX 77204 USA.
EM sdryer@uh.edu
FU Juvenile Diabetes Research Foundation
FX This work was supported in part by a grant from the Juvenile Diabetes
   Research Foundation.
CR Abkhezr M, 2015, MOL PHARMACOL, V87, P231, DOI 10.1124/mol.114.094508
   Abkhezr M, 2014, MOL PHARMACOL, V86, P150, DOI 10.1124/mol.114.092536
   Al-Lamki RS, 2015, KIDNEY INT, V87, P281, DOI 10.1038/ki.2014.285
   Aliprantis AO, 2010, ADV EXP MED BIOL, V658, P69, DOI 10.1007/978-1-4419-1050-9_8
   Anderson M, 2014, J CELL PHYSIOL, V229, P434, DOI 10.1002/jcp.24461
   Anderson M, 2013, AM J PHYSIOL-CELL PH, V305, pC276, DOI 10.1152/ajpcell.00095.2013
   Aringer M, 2005, LUPUS, V14, P13, DOI 10.1191/0961203305lu2053oa
   Ashizawa M, 2003, AM J KIDNEY DIS, V42, P76, DOI 10.1016/S0272-6386(03)00411-6
   Assadi F, 2010, PEDIATR NEPHROL, V26, P1
   Bakr A, 2003, PEDIATR NEPHROL, V18, P516, DOI 10.1007/s00467-003-1122-4
   Barisoni L, 2007, CLIN J AM SOC NEPHRO, V2, P529, DOI 10.2215/CJN.04121206
   BAUD L, 1992, KIDNEY INT, V41, P600, DOI 10.1038/ki.1992.90
   BERTANI T, 1989, AM J PATHOL, V134, P419
   Bitzan M, 2012, PEDIATR NEPHROL, V27, P2217, DOI 10.1007/s00467-012-2163-3
   BUSTOS C, 1994, EUR J CLIN INVEST, V24, P799, DOI 10.1111/j.1365-2362.1994.tb02022.x
   Chana RS, 2003, KIDNEY INT, V63, P889, DOI 10.1046/j.1523-1755.2003.00828.x
   Chugh SS, 2012, AM J KIDNEY DIS, V59, P284, DOI 10.1053/j.ajkd.2011.07.024
   D'Agati VD, 2012, CURR OPIN NEPHROL HY, V21, P243, DOI 10.1097/MNH.0b013e32835200df
   Dai Y, 2013, KIDNEY INT, V84, P950, DOI 10.1038/ki.2013.197
   Drewe E, 2000, NEW ENGL J MED, V343, P1044, DOI 10.1056/NEJM200010053431412
   Dryer SE, 2010, AM J PHYSIOL-RENAL, V299, pF689, DOI 10.1152/ajprenal.00298.2010
   Feng XB, 2009, J AM SOC NEPHROL, V20, P2138, DOI 10.1681/ASN.2008080879
   Gu LY, 2013, AIDS, V27, P1091, DOI 10.1097/QAD.0b013e32835f1ea1
   Heeringa SF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007771
   Hofstra JM, 2013, NEPHROL DIAL TRANSPL, V28, P1830, DOI 10.1093/ndt/gfs572
   Husni NR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087068
   Ilatovskaya DV, 2014, KIDNEY INT, V86, P506, DOI 10.1038/ki.2014.71
   Jung S, 2003, J BIOL CHEM, V278, P3562, DOI 10.1074/jbc.M211484200
   Kao YH, 2010, CRIT CARE MED, V38, P217, DOI 10.1097/CCM.0b013e3181b4a854
   Kastl L, 2014, FEBS LETT, V588, P175, DOI 10.1016/j.febslet.2013.11.033
   Kim EY, 2013, AM J PHYSIOL-CELL PH, V305, pC960, DOI 10.1152/ajpcell.00191.2013
   Kim EY, 2012, AM J PHYSIOL-RENAL, V302, pF298, DOI 10.1152/ajprenal.00423.2011
   Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x
   King CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018713
   Kistler AD, 2013, J BIOL CHEM, V288, P36598, DOI 10.1074/jbc.M113.488122
   Kong SK, 1997, ONCOLOGY-BASEL, V54, P55
   Krall P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012859
   Kriz W, 2005, KIDNEY INT, V67, P404, DOI 10.1111/j.1523-1755.2005.67097.x
   Kuwahara K, 2006, J CLIN INVEST, V116, P3114, DOI 10.1172/JCI27702
   Lama G, 2002, AM J KIDNEY DIS, V39, P958, DOI 10.1053/ajkd.2002.32769
   Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015
   Leroy S, 2009, AM J TRANSPLANT, V9, P858, DOI 10.1111/j.1600-6143.2009.02550.x
   Li ZP, 2006, CELL CYCLE, V5, P2440, DOI 10.4161/cc.5.21.3428
   Mantovani A, 2010, CURR MOL MED, V10, P369, DOI 10.2174/156652410791316968
   McCarthy ET, 1998, J AM SOC NEPHROL, V9, P433
   Moeller CC, 2007, J AM SOC NEPHROL, V18, P29, DOI 10.1681/ASN.2006091010
   Mori K, 2005, J ENDOCRINOL, V187, P17, DOI 10.1677/joe.1.05887
   MURPHY HS, 1992, AM J PHYSIOL, V263, pL51
   NAKAMURA T, 1993, CLIN SCI, V84, P349, DOI 10.1042/cs0840349
   Nakayama S, 2010, HUM PATHOL, V41, P1196, DOI 10.1016/j.humpath.2010.01.021
   Navarro-Gonzalez JF, 2009, CYTOKINE GROWTH F R, V20, P165, DOI 10.1016/j.cytogfr.2009.02.005
   Nijenhuis T, 2011, AM J PATHOL, V179, P1719, DOI 10.1016/j.ajpath.2011.06.033
   Pestell RG, 2013, AM J PATHOL, V183, P3, DOI 10.1016/j.ajpath.2013.03.001
   Pogan Anna, 2005, Wiad Lek, V58 Suppl 1, P39
   Ramesh G, 2003, AM J PHYSIOL-RENAL, V285, pF610, DOI 10.1152/ajprenal.00101.2003
   Ramseyer VD, 2013, AM J PHYSIOL-RENAL, V304, pF1231, DOI 10.1152/ajprenal.00557.2012
   Reiser J, 2005, NAT GENET, V37, P739, DOI 10.1038/ng1592
   Rosa AC, 2012, INFLAMM RES, V61, P311, DOI 10.1007/s00011-011-0412-8
   Roshanravan H, 2014, AM J PHYSIOL-RENAL, V306, pF1088, DOI 10.1152/ajprenal.00661.2013
   Ryu M, 2012, J PATHOL, V226, P120, DOI 10.1002/path.2979
   Schlondorff J, 2009, AM J PHYSIOL-CELL PH, V296, pC558, DOI 10.1152/ajpcell.00077.2008
   Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018
   Shin HM, 2004, FEBS LETT, V571, P50, DOI 10.1016/j.febslet.2004.06.056
   Sittampalam GS, 2004, ASSAY GUIDANCE MANUA
   SPRIGGS DR, 1990, CANCER RES, V50, P7101
   SURANYI MG, 1993, AM J KIDNEY DIS, V21, P251, DOI 10.1016/S0272-6386(12)80742-6
   Tchakarska G, 2011, CANCER RES, V71, P1690, DOI 10.1158/0008-5472.CAN-10-2564
   Tian DQ, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001200
   Tsai CT, 2015, CARDIOVASC RES, V105, P318, DOI 10.1093/cvr/cvv008
   VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211
   Wang YQ, 2010, J AM SOC NEPHROL, V21, P1657, DOI 10.1681/ASN.2009121253
   Wiggins RC, 2007, KIDNEY INT, V71, P1205, DOI 10.1038/sj.ki.5002222
   Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215
   Yu ZY, 2002, BIOCHEM J, V367, P97, DOI 10.1042/BJ20020588
   Zager RA, 2006, AM J PHYSIOL-RENAL, V291, pF546, DOI 10.1152/ajprenal.00072.2006
   Zheng L, 2006, VIRCHOWS ARCH, V448, P172, DOI 10.1007/s00428-005-0061-9
NR 76
TC 5
Z9 5
U1 2
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1931-857X
EI 1522-1466
J9 AM J PHYSIOL-RENAL
JI Am. J. Physiol.-Renal Physiol.
PD JUL 15
PY 2015
VL 309
IS 2
BP F98
EP F108
DI 10.1152/ajprenal.00146.2015
PG 11
WC Physiology; Urology & Nephrology
SC Physiology; Urology & Nephrology
GA CM8PD
UT WOS:000357963200003
PM 26017975
DA 2018-12-27
ER

PT J
AU Xu, L
   Tang, HW
   Chen, DW
   El-Naggar, AK
   Wei, P
   Sturgis, EM
AF Xu, Li
   Tang, Hongwei
   Chen, Diane W.
   El-Naggar, Adel K.
   Wei, Peng
   Sturgis, Erich M.
TI RETRACTED: Genome-wide association study identifies common genetic
   variants associated with salivary gland carcinoma and its subtypes
   (Retracted article. See vol. 124, pg. 869, 2018)
SO CANCER
LA English
DT Article; Retracted Publication
DE salivary gland; adenoid cystic carcinoma; mucoepidermoid carcinoma;
   genetics; genome-wide association study (GWAS)
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; ATOMIC-BOMB SURVIVORS; PROTEIN
   IDENTIFICATION; RISK-FACTORS; CANCER; MUTATIONS; TUMORS
AB BACKGROUNDSalivary gland carcinomas (SGCs) are a rare malignancy with unknown etiology. The objective of the current study was to identify genetic variants modifying the risk of SGC and its major subtypes: adenoid cystic carcinoma and mucoepidermoid carcinoma.
   METHODSThe authors conducted a genome-wide association study in 309 well-defined SGC cases and 535 cancer-free controls. A single-nucleotide polymorphism (SNP)-level discovery study was performed in non-Hispanic white individuals followed by a replication study in Hispanic individuals. A logistic regression analysis was applied to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs). A meta-analysis of the results was conducted.
   RESULTSA genome-wide significant association with SGC in non-Hispanic white individuals was detected at coding SNPs in CHRNA2 (cholinergic receptor, nicotinic, alpha 2 [neuronal]) (OR, 8.55; 95% CI, 4.53-16.13 [P=3.6 x 10(-11)]), OR4F15 (olfactory receptor, family 4, subfamily F, member 15) (OR, 5.26; 95% CI, 3.13-8.83 [P=3.5 x 10(-10)]), ZNF343 (zinc finger protein 343) (OR, 3.28; 95% CI, 2.12-5.07 [P=9.1 x 10(-8)]), and PARP4 (poly(ADP-ribose) polymerase family, member 4) (OR, 2.00; 95% CI, 1.54-2.59 [P=1.7 x 10(-7)]). Meta-analysis of the non-Hispanic white and Hispanic cohorts identified another genome-wide significant SNP in ELL2 (meta-OR, 1.86; 95% CI, 1.48-2.34 [P=1.3 x 10(-7)]). Risk alleles were largely enriched in mucoepidermoid carcinoma, in which the SNPs in CHRNA2, OR4F15, and ZNF343 had ORs of 15.71 (95% CI, 6.59-37.47 [P=5.2 x 10(-10)]), 15.60 (95% CI, 6.50-37.41 [P=7.5 x 10(-10)]), and 6.49 (95% CI, 3.36-12.52 [P=2.5 x 10(-8)]), respectively. None of these SNPs retained a significant association with adenoid cystic carcinoma.
   CONCLUSIONSTo the best of the authors' knowledge, the current study is the first to identify a panel of SNPs associated with the risk of SGC. Confirmation of these findings along with functional analysis of identified SNPs are needed. Cancer 2015;121:2367-2374. (c) 2015 American Cancer Society.
   Salivary gland carcinomas are a rare malignancy with unknown etiology. In the current study, the authors perform a genome-wide association analysis of salivary gland carcinomas and identify a panel of coding single-nucleotide polymorphisms associated with the risk of salivary gland carcinoma and its mucoepidermoid carcinoma subtype.
C1 [Xu, Li; Sturgis, Erich M.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA.
   [Tang, Hongwei] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
   [Chen, Diane W.] Baylor Coll Med, Clincal Res, Qual Improvement, Houston, TX 77030 USA.
   [El-Naggar, Adel K.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
   [Wei, Peng] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Biostat, Houston, TX 77030 USA.
   [Wei, Peng] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA.
   [Sturgis, Erich M.] Univ Texas Hlth Sci Ctr Houston, Dept Epidemiol, Houston, TX 77030 USA.
RP Sturgis, EM (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Unit 1445,1515 Holcombe Blvd, Houston, TX 77030 USA.
EM esturgis@mdanderson.org
OI Wei, Peng/0000-0001-7758-6116
FU University of Texas MD Anderson Cancer Center start-up funds; National
   Institutes of Health (NIH) [U01 DE019765-01]; Cancer Center [CA016672];
   NIH [R01CA169122]
FX Supported in part by The University of Texas MD Anderson Cancer Center
   start-up funds (to Dr. Sturgis), National Institutes of Health (NIH)
   grant U01 DE019765-01 (to Dr. El-Naggar; Dr. Sturgis is project 2
   leader), and Cancer Center Support Grant CA016672 to The University of
   Texas MD Anderson Cancer Center (to Dr. Ronald DePinho). Dr. Wei was
   partially supported by NIH grant R01CA169122.
CR Adzhubei I, 2013, CURR PROTOC HUM GENE, DOI [10.1002/0471142905.hg0720s76, 10. 1002/0471142905. hg0720s76, DOI 10.1002/0471142905.HG0720S76]
   Adzhubei IA, 1999, NUCLEIC ACIDS RES, V27, P268, DOI 10.1093/nar/27.1.268
   Adzhubei IA, 1998, NUCLEIC ACIDS RES, V26, P327, DOI 10.1093/nar/26.1.327
   Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112
   Do R, 2015, NAT GENET, V47, P126, DOI 10.1038/ng.3186
   Forrest J, 2008, NUTR CANCER, V60, P469, DOI 10.1080/01635580802143851
   Ho T, 2007, CANCER, V110, P318, DOI 10.1002/cncr.22794
   Horn-Ross PL, 1999, EPIDEMIOLOGY, V10, P528, DOI 10.1097/00001648-199909000-00011
   HornRoss PL, 1997, EPIDEMIOLOGY, V8, P414, DOI 10.1097/00001648-199707000-00011
   Howlader N, 2013, SEER CANC STAT REV 1
   Jin L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049361
   Jordan IK, 2005, NATURE, V433, P633, DOI 10.1038/nature03306
   Junqueira M, 2008, J PROTEOMICS, V71, P346, DOI 10.1016/j.jprot.2008.07.003
   Junqueira M, 2008, J PROTEOME RES, V7, P3382, DOI 10.1021/pr800140v
   Kondo S, 2009, INT J CLIN EXP MED, V2, P68
   Leshchiner I, 2012, GENOME RES, V22, P1541, DOI 10.1101/gr.135541.111
   Liu WJ, 2012, MED ONCOL, V29, P677, DOI 10.1007/s12032-011-9838-7
   Liu Weijia, 2011, Cancer Epidemiol, V35, pe12, DOI 10.1016/j.canep.2010.11.001
   Muscat JE, 1998, OTOLARYNG HEAD NECK, V118, P195, DOI 10.1016/S0194-5998(98)80013-2
   Petrovski S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003709
   Saku T, 1997, CANCER-AM CANCER SOC, V79, P1465, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1465::AID-CNCR4>3.3.CO;2-7
   Schmidt S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000281
   SPITZ MR, 1990, ARCH OTOLARYNGOL, V116, P1163
   Stamatoyannopoulos JA, 2009, NAT GENET, V41, P393, DOI 10.1038/ng.363
   THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892
   Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231
   Xu L, 2012, ORAL ONCOL, V48, P842, DOI 10.1016/j.oraloncology.2012.03.012
NR 29
TC 9
Z9 9
U1 3
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD JUL 15
PY 2015
VL 121
IS 14
BP 2367
EP 2374
DI 10.1002/cncr.29381
PG 8
WC Oncology
SC Oncology
GA CM0AI
UT WOS:000357340200013
PM 25823930
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Maghsoudi, O
   Mirjalili, SH
   Dolatabadi, M
   Joshaghani, MF
   Zarea, M
   Yahaghi, E
   Mokarizadeh, A
AF Maghsoudi, Omid
   Mirjalili, Seyed Hesamoddin
   Dolatabadi, Mojtaba
   Joshaghani, Mostafa Fallah
   Zarea, Mojtaba
   Yahaghi, Emad
   Mokarizadeh, Aram
TI RETRACTED: Investigations of renal function using the level of
   neutrophil gelatinase-associated lipocalin associated with single-dose
   of cisplatin during chemotherapy(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Pathology; Kidney; Tumor; Cisplatin; Marker
ID ACUTE KIDNEY INJURY; ADULT CARDIAC-SURGERY; BIOMARKERS; NEPHROTOXICITY;
   NGAL; INCREASES; MORTALITY; DIAGNOSIS; SEVERITY; PLASMA
AB Background: Neutrophil gelatinase-associated lipocalin (NGAL) is known as a primary indicator of acute and chronic renal and can be effective in chronic kidney injury (CKI) with kidney tumors cisplatin (CP) chemotherapy. The aim of this study was to evaluate serum and urinary biomarker including NGAL (sNGAL and uNGAL) in canine with solid renal tumors who suffered from cisplatin after short and long-term chemotherapy.
   Methods: In this study, in treatment and control groups, canine (n = 10 and n = 5) were administered cisplatin at 1.2 mg/kg/day (i.v.) for five consecutive days with CKI and without CKI, respectively. Serum and urine NGAL levels (ng/mL) were evaluated at 0, 1, 5, 9, 13, 17, 21, 25 and 29 days after drug injection versus baseline in treated and control groups.
   Results: Canine in treatment group had shown symptoms of toxicity of cisplatin. The results indicated the higher concentrations of serum, sNGAL and uNGAL (P = 0.024; P = 0.011) compared with control group (P = 0.701, P = 0.612), (Table 2, Figs. 1 and 2). Indeed, our results showed that canine with CKI were associated with higher levels of sNGAL and uNGAL compared with control group without CKI. Moreover, the highest level of uNGAL was seen in comparison with sNGAL, after a high dose (1.2 mg/kg) administration of CP.
   Conclusion: Our data suggested that U-NGAL may be useful for monitoring of renal injury in CKI patients that exposed with cisplatin. Furthermore, a primary elevate in urinary NGAL expulsion may help in identifying cases at danger of cisplatin-induced CKI that might profit from innovative remedies to prevent cisplatin nephrotoxicity.
C1 [Maghsoudi, Omid] Islamic Azad Univ, Karaj Branch, Fac Vet Med, Karaj, Iran.
   [Joshaghani, Mostafa Fallah] Islamic Azad Univ, Karaj Branch, Fac Vet Med, Vet Med, Karaj, Iran.
   [Zarea, Mojtaba] Indian Inst Chem Technol, Ctr Chem Biol, Hyderabad 500007, Andhra Pradesh, India.
   [Yahaghi, Emad] Baqiyatallah Univ Med Sci, Tehran, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Cellular & Mol Res Ctr, Sanandaj, Iran.
RP Mokarizadeh, A (reprint author), Kurdistan Univ Med Sci, Cellular & Mol Res Ctr, Sanandaj, Iran.
EM a.mokarizadeh@muk.ac.ir
OI Abdi, Mohammad/0000-0002-4766-0423; Mokarizadeh,
   Aram/0000-0002-2630-8308
CR Alavi-Shoushtari Sayed Mortaza, 2014, Vet Res Forum, V5, P115
   Ali BH, 2008, FOOD CHEM TOXICOL, V46, P3355, DOI 10.1016/j.fct.2008.07.030
   Arany I, 2003, SEMIN NEPHROL, V23, P460, DOI 10.1016/S0270-9295(03)00089-5
   Bennett M, 2008, CLIN J AM SOC NEPHRO, V3, P665, DOI 10.2215/CJN.04010907
   Coca SG, 2008, KIDNEY INT, V73, P1008, DOI 10.1038/sj.ki.5002729
   Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0
   Devarajan P, 2010, NEPHROLOGY, V15, P419, DOI 10.1111/j.1440-1797.2010.01317.x
   Emberson JR, 2010, J INTERN MED, V268, P145, DOI 10.1111/j.1365-2796.2010.02214.x
   Haase-Fielitz A, 2009, NEPHROL DIAL TRANSPL, V24, P3349, DOI 10.1093/ndt/gfp234
   Hosohata K, 2012, J PHARMACOL EXP THER, V341, P656, DOI 10.1124/jpet.112.192807
   Koag MC, 2014, J BIOL CHEM, V289, P31341, DOI 10.1074/jbc.M114.605451
   Liebetrau C, 2014, SCAND J CLIN LAB INV, V74, P81, DOI 10.3109/00365513.2013.860615
   McCullough PA, 2013, CONTRIB NEPHROL, V182, P13, DOI 10.1159/000349963
   Mishra J, 2004, J AM SOC NEPHROL, V15, P3073, DOI 10.1097/01.ASN.0000145013.44578.45
   Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6
   Mokarizadeh A, 2015, TOXICOL MECH METHOD, P1
   Negishi K, 2009, AM J PATHOL, V174, P1154, DOI 10.2353/ajpath.2009.080644
   Nickolas TL, 2008, ANN INTERN MED, V148, P810, DOI 10.7326/0003-4819-148-11-200806030-00003
   Noiri E, 2009, AM J PHYSIOL-RENAL, V296, pF669, DOI 10.1152/ajprenal.90513.2008
   Pabla N, 2008, KIDNEY INT, V73, P994, DOI 10.1038/sj.ki.5002786
   Parikh CR, 2011, J AM SOC NEPHROL, V22, P1748, DOI 10.1681/ASN.2010121302
   Segev G, 2013, J VET INTERN MED, V27, P1362, DOI 10.1111/jvim.12180
   Shavit L, 2011, KIDNEY BLOOD PRESS R, V34, P116, DOI 10.1159/000323897
   Shin YJ, 2014, ENVIRON TOXICOL PHAR, V37, P1028, DOI 10.1016/j.etap.2014.03.014
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   Steinbach S, 2014, J VET INTERN MED, V28, P264, DOI 10.1111/jvim.12282
   Supavekin S, 2003, KIDNEY INT, V63, P1714, DOI 10.1046/j.1523-1755.2003.00928.x
   Tavasoly A, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-173
   Trachtman H, 2006, PEDIATR NEPHROL, V21, P989, DOI 10.1007/s00467-006-0146-y
   Wagener G, 2006, ANESTHESIOLOGY, V105, P485, DOI 10.1097/00000542-200609000-00011
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   Yuen PST, 2006, PHYSIOL GENOMICS, V25, P375, DOI 10.1152/physiolgenomics.00223.2005.
   Zager RA, 2012, J AM SOC NEPHROL, V23, P1048, DOI 10.1681/ASN.2011121147
NR 33
TC 4
Z9 4
U1 2
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUL 14
PY 2015
VL 10
AR 98
DI 10.1186/s13000-015-0338-5
PG 7
WC Pathology
SC Pathology
GA CM6CE
UT WOS:000357774600001
PM 26170013
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Forbes, MM
   Rothhamel, S
   Jenny, A
   Marlow, FL
AF Forbes, Meredyth M.
   Rothhaemel, Sophie
   Jenny, Andreas
   Marlow, Florence L.
TI RETRACTED: Maternal dazap2 Regulates Germ Granules by Counteracting
   Dynein in Zebrafish Primordial Germ Cells (Retracted article. See vol.
   15, pg. 909, 2016)
SO CELL REPORTS
LA English
DT Article; Retracted Publication
ID GENE-EXPRESSION; BALBIANI BODY; RNA; LOCALIZATION; STRESS; OOCYTE;
   PLASM; SPECIFICATION; MAINTENANCE; PROTEINS
AB Primordial germ cells (PGCs) are the stem cells of the germline. Generally, germline induction occurs via zygotic factors or the inheritance of maternal determinants called germ plasm (GP). GP is packaged into ribonucleoprotein complexes within oocytes and later promotes the germline fate in embryos. Once PGCs are specified by either mechanism, GP components localize to perinuclear granular-like structures. Although components of zebrafish PGC germ granules have been studied, the maternal factors regulating their assembly and contribution to germ cell development are unknown. Here, we show that the scaffold protein Dazap2 binds to Bucky ball, an essential regulator of oocyte polarity and GP assembly, and colocalizes with the GP in oocytes and in PGCs. Mutational analysis revealed a requirement for maternal Dazap2 (MDazap2) in germ-granule maintenance. Through molecular epistasis analyses, we show that MDazap2 is epistatic to Tdrd7 and maintains germ granules in the embryonic germline by counteracting Dynein activity.
C1 [Forbes, Meredyth M.; Rothhaemel, Sophie; Jenny, Andreas; Marlow, Florence L.] Yeshiva Univ, Dept Dev & Mol Biol, Albert Einstein Coll Med, Bronx, NY 10461 USA.
   [Marlow, Florence L.] Yeshiva Univ, Dept Neurosci, Albert Einstein Coll Med, Bronx, NY 10461 USA.
   [Jenny, Andreas] Yeshiva Univ, Dept Genet, Albert Einstein Coll Med, Bronx, NY 10461 USA.
RP Marlow, FL (reprint author), Yeshiva Univ, Dept Dev & Mol Biol, Albert Einstein Coll Med, Bronx, NY 10461 USA.
EM florence.marlow@einstein.yu.edu
FU NIH [R01GM089979, T32-GM007491, R01GM088202]
FX This work was supported by NIH R01GM089979 to F.L.M., T32-GM007491
   support of M.M.F., and NIH R01GM088202 support to A.J. We thank our fish
   care; H. Knaut, R. Ketting, and E. Raz for reagents; members of F.L.M.'s
   lab for discussions; O. Hartung for comments on the manuscript; and the
   Analytical Imaging Facility at Einstein for microscopy support.
CR Anderson P, 2008, TRENDS BIOCHEM SCI, V33, P141, DOI 10.1016/j.tibs.2007.12.003
   Beer RL, 2013, DEV BIOL, V374, P308, DOI 10.1016/j.ydbio.2012.12.003
   Bontems F, 2009, CURR BIOL, V19, P414, DOI 10.1016/j.cub.2009.01.038
   Buchan J.R., 2014, RNA BIOL, V11, P1
   Campbell PD, 2015, DEVELOPMENT, V142, P1368, DOI 10.1242/dev.118968
   Dosch R, 2004, DEV CELL, V6, P771, DOI 10.1016/j.devcel.2004.05.002
   Draper BW, 2007, DEV BIOL, V305, P589, DOI 10.1016/j.ydbio.2007.03.007
   Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617
   Extavour CG, 2003, DEVELOPMENT, V130, P5869, DOI 10.1242/dev.00804
   Gross-Thebing T, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0055-7
   Hartung O., 2014, ZEBRAFISH TOPICS REP, P65
   Hartung O, 2014, MOL REPROD DEV, V81, P946, DOI 10.1002/mrd.22414
   Hashimoto Y, 2004, DEV BIOL, V268, P152, DOI 10.1016/j.ydbio.2003.12.013
   Heim AE, 2014, DEVELOPMENT, V141, P842, DOI 10.1242/dev.090449
   Houwing S, 2007, CELL, V129, P69, DOI 10.1016/j.cell.2007.03.026
   Hwang WY, 2013, NAT BIOTECHNOL, V31, P227, DOI 10.1038/nbt.2501
   Kim B, 2012, DEVELOPMENT, V139, P568, DOI 10.1242/dev.075846
   Kim JE, 2008, MOL CELL BIOL, V28, P803, DOI 10.1128/MCB.01226-07
   Kloc M, 2014, ARTHROPOD STRUCT DEV, V43, P341, DOI 10.1016/j.asd.2013.12.003
   Knaut H, 2000, J CELL BIOL, V149, P875, DOI 10.1083/jcb.149.4.875
   Koprunner M, 2001, GENE DEV, V15, P2877
   Kosaka K, 2007, MECH DEVELOP, V124, P279, DOI 10.1016/j.mod.2007.01.003
   Kwan KM, 2007, DEV DYNAM, V236, P3088, DOI 10.1002/dvdy.21343
   Lee KH, 2006, EMBO J, V25, P4263, DOI 10.1038/sj.emboj.7601304
   Leu DH, 2010, DEV DYNAM, V239, P2714, DOI 10.1002/dvdy.22404
   Marlow FL, 2008, DEV BIOL, V321, P40, DOI 10.1016/j.ydbio.2008.05.557
   Nair S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003448
   Santos-Ledo A, 2013, GENE EXPR PATTERNS, V13, P30, DOI 10.1016/j.gep.2012.09.002
   THISSE C, 2004, FAST RELEASE CLONES
   Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514
   Tsui SL, 2000, GENOMICS, V65, P266, DOI 10.1006/geno.2000.6169
   Villefranc JA, 2007, DEV DYNAM, V236, P3077, DOI 10.1002/dvdy.21354
   Voronina E, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a002774
   Westerfield M., 1995, ZEBRAFISH BOOK GUIDE
NR 34
TC 5
Z9 5
U1 3
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JUL 7
PY 2015
VL 12
IS 1
BP 49
EP 57
DI 10.1016/j.celrep.2015.06.010
PG 9
WC Cell Biology
SC Cell Biology
GA CM4RV
UT WOS:000357673300007
PM 26119733
OA DOAJ Gold, Green Accepted
DA 2018-12-27
ER

PT J
AU Kauffman, L
   Balatti, V
   Cascione, L
   Fadda, P
   Racke, F
   Santhanam, R
   Costinean, S
AF Kauffman, Lauren
   Balatti, Veronica
   Cascione, Luciano
   Fadda, Paolo
   Racke, Frederick
   Santhanam, Ramasamy
   Costinean, Stefan
TI RETRACTED: Gradual Rarefaction of Hematopoietic Precursors and Atrophy
   in a Depleted microRNA 29a, b and c Environment (Retracted article. See
   vol. 12, art no E0187454, 2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID CELLS
AB Background
   The self-renewing ability of HSCs is fundamental for the maintenance of a pool of bone marrow precursors throughout the life of an individual. The genetic mechanisms underlying such a complex process are still poorly understood.
   Results and Significance
   Here, we show that constitutive in vivo deletion of miR29ab1 leads to reduced number of HSCs and that miR29ab1 deficient bone marrow cannot repopulate the bone marrow of irradiated mice. An Affymetrix analysis of the miR29ab1 knockout mice identifies key proteins that could be responsible for this phenotype, as DNMT3a and b. Moreover, our findings reveal that whereas miR29b2c knockout mice do not exhibit any spontaneous abnormality, the double knock out - miR29ab1b2c - has marked generalized atrophy, raising the possibility that the two bi-cistrons might cooperate in order to maintain the stem cell number in general, not only limited to the bone marrow.
C1 [Racke, Frederick; Costinean, Stefan] Ohio State Wexner Med Ctr, Dept Pathol, Columbus, OH 43210 USA.
   [Kauffman, Lauren; Balatti, Veronica; Fadda, Paolo; Santhanam, Ramasamy] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Cascione, Luciano] Oncol Res Inst, Bellinzona, Switzerland.
RP Costinean, S (reprint author), Ohio State Wexner Med Ctr, Dept Pathol, Columbus, OH 43210 USA.
EM stefan.costinean@unmc.edu
OI Cascione, Luciano/0000-0002-4606-0637
FU Ohio State University funds
FX This study was supported by the Ohio State University funds.
CR Bartel DP, 2004, CELL
   Bryder D, 2006, AM J PATHOL, V169, P338, DOI 10.2353/jmoldx.2006.050079
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   GARZON R, 2009, BLOOD
   Han YC, 2010, J EXP MED
   Hu W, 2015, BLOOD
   Kamran F, 2015, MOL ENDOCRINOL
   Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860
   Reya T, 2001, NATURE
   Smith KM, 2012, J IMMUNOL
   Steiner DF, 2011, IMMUNITY, V35, P169, DOI 10.1016/j.immuni.2011.07.009
   Zhou Q, 2015, GASTROENTEROLOGY
NR 12
TC 3
Z9 3
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 6
PY 2015
VL 10
IS 7
AR e0131981
DI 10.1371/journal.pone.0131981
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1DQ
UT WOS:000358157600174
PM 26147501
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Lin, D
   Xu, X
AF Lin, Da
   Xu, Xin
TI RETRACTED: Semisupervised Satellite Image Classification Using Label
   Propagation-Based Canonical Correlation Analysis (Retracted article. See
   vol. 42, pg. 73, 2016)
SO CANADIAN JOURNAL OF REMOTE SENSING
LA English
DT Article; Retracted Publication
ID FACE RECOGNITION; REPRESENTATION; FORMULATION; ALGORITHM
AB Different and complementary features extracted from the same satellite image always reflect distinct characteristics of the data. As a consequence, it is worthwhile to implement the fusion on multiple features. In this study, we solve the problem of fusion in multiple features for satellite image classification. To this end, a new method named label propagation-based semisupervised canonical correlation analysis (LPS2-CCA) is suggested, which incorporates a new, sparse, representation-based label propagation algorithm to infer label information of unlabeled data. In this regard, LPS2-CCA possesses superiority in discriminant capability in contrast to many existing related methods that cannot take full advantage of given label information for classification. Extensive experimental results on the satellite images demonstrate that the suggested method can obtain better classification performances and robustness compared with existing related methods.Resume. Des caracteristiques differentes et complementaires extraites de la meme image satellitaire refletent toujours des attributs distincts des donnees. Consequemment, il est utile de fusionner plusieurs caracteristiques. Dans cet article, nous resolvons le probleme de la fusion de plusieurs caracteristiques pour la classification d'images satellitaires. cette fin, une nouvelle methode, appelee la propagation d'etiquettes, basee sur l'analyse de correlation canonique semi-supervisee (LPS2-CCA) est proposee qui integre un nouvel algorithme de propagation d'etiquettes permettant de deduire l'information d'etiquettes de donnees non etiquetees. cet egard, LPS2-CCA est superieur en capacite discriminante par rapport a de nombreuses methodes similaires existantes, qui ne peuvent pas profiter pleinement de l'information des etiquettes pour la classification. Une grande quantite de resultats experimentaux sur des images satellitaires montre que la methode proposee peut obtenir de meilleures performances de classification et de robustesse en comparaison avec des methodes connexes existantes.
C1 [Lin, Da; Xu, Xin] Wuhan Univ, Sch Elect Informat, Wuhan 430072, Peoples R China.
RP Lin, D (reprint author), Wuhan Univ, Sch Elect Informat, Wuhan 430072, Peoples R China.
EM linda_giggle@whu.edu.cn
FU National Basic Research Program of China (973 Program) [2011CB707102];
   National High Technology Research and Development Program of China (863
   Program) [2013AA122301]
FX This work was supported in part by the National Basic Research Program
   of China (973 Program) under grant No. 2011CB707102 and the National
   High Technology Research and Development Program of China (863 Program)
   under grant No. 2013AA122301.
CR Balakrishnama S., 1998, P INT JOINT C NEUR N, V3, P387
   Banerjee B, 2015, IEEE GEOSCI REMOTE S, V12, P741, DOI 10.1109/LGRS.2014.2360833
   Bharatkar PS, 2014, J INDIAN SOC REMOTE, V42, P435, DOI 10.1007/s12524-013-0331-y
   BJORCK A, 1973, MATH COMPUT, V27, P579, DOI 10.2307/2005662
   Camps-Valls G, 2007, IEEE T GEOSCI REMOTE, V45, P3044, DOI 10.1109/TGRS.2007.895416
   Chapelle O., 2006, SEMISUPERVISED LEARN, V41
   Chen XH, 2012, PATTERN RECOGN, V45, P2005, DOI 10.1016/j.patcog.2011.11.008
   Cheng B, 2010, IEEE T IMAGE PROCESS, V19, P858, DOI 10.1109/TIP.2009.2038764
   Chu DL, 2013, IEEE T PATTERN ANAL, V35, P3050, DOI 10.1109/TPAMI.2013.104
   Chung F. R. K., 1997, SPECTRAL GRAPH THEOR, V41
   Dai DX, 2011, IEEE GEOSCI REMOTE S, V8, P173, DOI 10.1109/LGRS.2010.2055033
   Hardoon DR, 2004, NEURAL COMPUT, V16, P2639, DOI 10.1162/0899766042321814
   Hotelling H, 1936, BIOMETRIKA, V28, P321, DOI 10.1093/biomet/28.3-4.321
   Hou CP, 2010, PATTERN RECOGN, V43, P720, DOI 10.1016/j.patcog.2009.07.015
   Ito K., 2008, SIAM REV, V79, P398
   Jolliffe I, 2005, PRINCIPAL COMPONENT
   Kim TK, 2007, IEEE T PATTERN ANAL, V29, P1005, DOI 10.1109/TPAMI.2007.1037
   Kuang Z., 2013, BRIT MACH VIS C BMVC
   Liu W, 2016, MULTIMED TOOLS APPL, V75, P1481, DOI 10.1007/s11042-014-2004-4
   Lu JW, 2012, IEEE T INF FOREN SEC, V7, P944, DOI 10.1109/TIFS.2012.2188389
   Matasci G, 2015, IEEE T GEOSCI REMOTE, V53, P3550, DOI 10.1109/TGRS.2014.2377785
   Nie FP, 2009, PATTERN RECOGN, V42, P2615, DOI 10.1016/j.patcog.2009.04.001
   Peng Y, 2010, NEURAL PROCESS LETT, V31, P1, DOI 10.1007/s11063-009-9123-3
   Peng Yan, 2008, Journal of Software, V19, P2822, DOI 10.3724/SP.J.1001.2008.02822
   Singh PP, 2014, J APPL REMOTE SENS, V8, DOI 10.1117/1.JRS.8.083526
   Sun LA, 2011, IEEE T PATTERN ANAL, V33, P194, DOI 10.1109/TPAMI.2010.160
   Sun QS, 2005, PATTERN RECOGN, V38, P449, DOI 10.1016/j.patcog.2004.08.009
   Sun TK, 2007, IMAGE VISION COMPUT, V25, P531, DOI 10.1016/j.imavis.2006.04.014
   TAN TSC, 1994, IEE P-VIS IMAGE SIGN, V141, P403, DOI 10.1049/ip-vis:19941420
   Tan XY, 2010, IEEE T IMAGE PROCESS, V19, P1635, DOI 10.1109/TIP.2010.2042645
   Wang F, 2008, IEEE T KNOWL DATA EN, V20, P55, DOI 10.1109/TKDE.2007.190672
   Wang JD, 2009, IEEE T PATTERN ANAL, V31, P1600, DOI 10.1109/TPAMI.2008.216
   Wright J, 2009, IEEE T PATTERN ANAL, V31, P210, DOI 10.1109/TPAMI.2008.79
   Yu J, 2012, IEEE T IMAGE PROCESS, V21, P3262, DOI 10.1109/TIP.2012.2190083
   Zhang YS, 2014, IEEE GEOSCI REMOTE S, V11, P464, DOI 10.1109/LGRS.2013.2267091
NR 35
TC 1
Z9 1
U1 5
U2 15
PU CANADIAN AERONAUTICS & SPACE INST
PI KANATA
PA 350 TERRY FOX DR, STE 104, KANATA, ON K2K 2W5, CANADA
SN 0703-8992
EI 1712-7971
J9 CAN J REMOTE SENS
JI Can. J. Remote Sens.
PD JUL 4
PY 2015
VL 41
IS 4
BP 262
EP 270
DI 10.1080/07038992.2015.1089161
PG 9
WC Remote Sensing
SC Remote Sensing
GA CS4RE
UT WOS:000362062800001
DA 2018-12-27
ER

PT J
AU Abedinzadeh, N
   Pedram, B
   Sadeghian, Y
   Nodushan, SMHT
   Gilasgar, M
   Darvish, M
   Mokarizadeh, A
AF Abedinzadeh, Negin
   Pedram, Behnam
   Sadeghian, Yasan
   Nodushan, Seyed Mohamad Hossein Tabatabaei
   Gilasgar, Maryam
   Darvish, Mahsa
   Mokarizadeh, Aram
TI RETRACTED: A histopathological analysis of the epidemiology of coronary
   atherosclerosis: an autopsy study(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Atherosclerosis; Coronary artery; Autopsy; Inflammation; Plaque
ID ARTERY CALCIFICATION; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION;
   HEART-DISEASE; RISK-FACTORS; ASSOCIATION; PLAQUE; WOMEN; COMMUNITIES;
   PREVENTION
AB Background: Atherosclerosis accounts for a large proportion of cardiovascular system associated morbidity and mortality. We studied the possible association between the histopathological changes of the coronary atherosclerotic lesions and the risk of sudden cardiac death (SCD) using autopsy cases.
   Methods: We performed an autopsy analysis (n = 13, 4 women, 9 men mean age 67.5 years; age range 56-93 years) of SCD which occurred in patients aged over 50 years during March 2010 to December 2013. The following variables were considered: sex, age, medical history, autopsy findings to macroscopic and histological evaluation of the heart. The autopsies were performed according to standard techniques. In all subjects, the heart was dissected following standard autopsy protocol and a 5 cm section of the right coronary artery (RCA) in the atrio-ventricular groove from its origin, a 5 cm segment of the left anterior descending artery (LADA) distal to the origin of the circumflex artery, but including the region of origin of the circumflex branch and left coronary artery (LCA) from its origin till the circumflex branch were excised, dissected out, fixed in 10 % formalin, marked for identification and sent for histopathological analysis.
   Results: Atherosclerotic plaques were identified in 6.5 % of specimens, 69.34 % of males and 30.66 % of female. Such plaques were typically concentric and more represented with necrosis, calcification, cholesterol crystals, and giant cells, as well as had a higher inflammatory cell count. Furthermore, intima and media thickness of coronary arteries were significantly higher in studied specimens with visualize the connective tissue layers of the adventitia and the fatty acid containing adipose cells in the periadventitial tissue. Furthermore, the degree of microscopic lesion of atherosclerosis increased proportionally with the increase in the intensity of lipid deposition and with the percentage of collagen in the atherosclerotic plaques.
   Conclusion: In this study, age estimate to be a risk factor for coronary atherosclerosis in individuals more than 50 years old and may be used to predict SCD. Altogether, an enhanced understanding of the pathobiologic processes responsible for atherosclerotic changes might allow for early identification of a high-risk coronary plaque and thereby provide a rationale for innovative diagnostic and/or therapeutic strategies for the management of coronary patients and prevention of acute coronary syndromes.
C1 [Abedinzadeh, Negin] Univ Tehran Med Sci, Fac Med, Tehran, Iran.
   [Pedram, Behnam] Islamic Azad Univ, Dept Pathobiol, Susangerd Branch, Susangerd, Iran.
   [Sadeghian, Yasan; Nodushan, Seyed Mohamad Hossein Tabatabaei; Gilasgar, Maryam; Darvish, Mahsa] Shahid Beheshti Univ Med Sci & Hlth Serv, Fac Med, Tehran, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Cellular Mol Res Ctr, Sanandaj, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Dept Immunol, Sanandaj, Iran.
RP Mokarizadeh, A (reprint author), Kurdistan Univ Med Sci, Cellular Mol Res Ctr, Sanandaj, Iran.
EM a.mokarizadeh@muk.ac.ir
OI Abdi, Mohammad/0000-0002-4766-0423; Mokarizadeh,
   Aram/0000-0002-2630-8308
CR Alioglu E, 2009, J CARDIOVASC MED, V10, P494, DOI 10.2459/JCM.0b013e3283293349
   Assemat P, 2014, COMPUT STRUCT BIOTEC, V10, P98, DOI 10.1016/j.csbj.2014.07.004
   Bavelaar FJ, 2004, VET QUART, V26, P50, DOI 10.1080/01652176.2004.9695168
   Bertomeu A, 2003, BRIT MED J, V327, P591, DOI 10.1136/bmj.327.7415.591
   Bielak LF, 2008, ATHEROSCLEROSIS, V196, P888, DOI 10.1016/j.atherosclerosis.2007.01.041
   BRUNKWALL J, 1992, EICOSANOIDS, V5, P197
   Budoff MJ, 2003, PROG CARDIOVASC DIS, V46, P135, DOI 10.1016/S0033-0620(030)00083-5
   Campbell LA, 2015, ARCH MED RES
   Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P113
   Cherian S M, 2000, Heart Lung Circ, V9, P39, DOI 10.1046/j.1444-2892.2000.009001039.x
   Chirinos JA, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001335
   Deb S, 2013, JAMA-J AM MED ASSOC, V310, P2086, DOI 10.1001/jama.2013.281718
   Ford ES, 2003, CIRCULATION, V108, P1053, DOI 10.1161/01.CIR.0000080913.81393.B8
   Fricke C, 2009, AVIAN DIS, V53, P466, DOI 10.1637/8521-111908-Case.1
   Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620
   Gauss S, 2015, INFLAMM RES, V64, P313, DOI 10.1007/s00011-015-0809-x
   Greenland P, 2010, J AM COLL CARDIOL, V56, pE50, DOI 10.1016/j.jacc.2010.09.001
   Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882
   Hassantash Seyed-Ahmad, 2008, Asian Cardiovasc Thorac Ann, V16, P331
   He ZX, 2000, CIRCULATION, V101, P244, DOI 10.1161/01.CIR.101.3.244
   Huber SA, 2001, CIRCULATION, V103, P2610
   Jefferis BJ, 2014, J AM GERIATR SOC, V62, P599, DOI 10.1111/jgs.12748
   Karakas M, 2011, J THROMB HAEMOST, V9, P1078, DOI 10.1111/j.1538-7836.2011.04229.x
   KENSEY KR, 2001, ORIGIN ATHEROSCLEROS, V1
   Knuiman MW, 2001, NEUROEPIDEMIOLOGY, V20, P96, DOI 10.1159/000054767
   Koopal C, 2015, ATHEROSCLEROSIS, V240, P90, DOI 10.1016/j.atherosclerosis.2015.02.046
   Lakoski SG, 2007, ARCH INTERN MED, V167, P2437, DOI 10.1001/archinte.167.22.2437
   Leonard S, PATHOPHYSIOLOGY HEAR
   Merz CNB, 2003, J AM COLL CARDIOL, V41, P413, DOI 10.1016/S0735-1097(02)02763-8
   Mokarizadeh A, 2015, MED HYPOTHESES
   Mokarizadeh A, 2012, IMMUNOL LETT, V147, P47, DOI 10.1016/j.imlet.2012.06.001
   Mollet N, 2011, RADIOL MED, V116, P1174, DOI 10.1007/s11547-011-0722-5
   Mosca, 2011, CIRCULATION, V123, pE624, DOI 10.1161/CIR.0b013e318222b330
   Newman AB, 2002, ARTERIOSCL THROM VAS, V22, P424, DOI 10.1161/hq0302.105357
   Otto MCD, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000506
   Packard RRS, 2009, SEMIN IMMUNOPATHOL, V31, P5, DOI 10.1007/s00281-009-0153-8
   Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75
   Rodrigues AN, 2007, J PEDIAT-BRAZIL, V83, P429, DOI 10.2223/JPED.1696
   Rodriguez-Saldana J, 2014, CARDIOL RES PRACT, DOI 10.1155/2014/264205
   Rumberger JA, 1999, MAYO CLIN PROC, V74, P243, DOI 10.4065/74.3.243
   Sharma K, 2013, GLOB HEART, V8, P105, DOI 10.1016/j.gheart.2013.02.001
   Silverman S, 2006, REPTILE MED SURG
   Singh H, 2005, JIAFM, V27, P236
   Smith SC, 2001, J HERED, V92, P439, DOI 10.1093/jhered/92.5.439
   Soraya H, 2015, BIOIMPACTS, V5, P3, DOI 10.15171/bi.2015.02
   Stetter MD, 2006, REPTILE MED SURG
   Tabatabaei Yazdi SA, 2009, IRANIAN J PATHOL, V4, P101
   Tanaka A, 2008, EUR HEART J, V29, P38, DOI 10.1093/eurheartj/ehm507
   Taylor AJ, 2000, CIRCULATION, V101, P1243, DOI 10.1161/01.CIR.101.11.1243
   Thej Mothakapalli Jagadish, 2012, J Cardiovasc Dis Res, V3, P265, DOI 10.4103/0975-3583.102692
   THOMAS AC, 1988, BRIT MED J, V297, P1453, DOI 10.1136/bmj.297.6661.1453
   Tintut Y, 2002, CIRCULATION, V105, P650, DOI 10.1161/hc0502.102969
   VANDERWAL AC, 1992, EUR J CARDIO-THORAC, V6, P469, DOI 10.1016/1010-7940(92)90242-P
   Virmani R, 2007, VULNERABLE ATHEROSCL, P37
   Willecke F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128996
   Wong ND, 2014, NAT REV CARDIOL, V11, P276, DOI 10.1038/nrcardio.2014.26
   Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P1153, DOI 10.1001/jama.287.9.1153
   Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488
NR 58
TC 4
Z9 4
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUL 3
PY 2015
VL 10
AR 87
DI 10.1186/s13000-015-0324-y
PG 8
WC Pathology
SC Pathology
GA CL8VJ
UT WOS:000357251900001
PM 26137939
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ostvar, O
   Shadvar, S
   Yahaghi, E
   Azma, K
   Fayyaz, AF
   Ahmadi, K
   Nowrouzian, I
AF Ostvar, Omid
   Shadvar, Sahar
   Yahaghi, Emad
   Azma, Kamran
   Fayyaz, Amir Farshid
   Ahmadi, Koorosh
   Nowrouzian, Iradj
TI RETRACTED: Effect of platelet-rich plasma on the healing of cutaneous
   defects exposed to acute to chronic wounds: a clinico-histopathologic
   study in rabbits (Retracted article. See vol. 11, art no 113, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Platelet-rich plasma; Histopathology; Wound; Regeneration; Rabbit
ID GUIDED TISSUE REGENERATION; GROWTH-FACTORS; COMBINATION; BIOLOGY;
   QUANTIFICATION; FIBROBLASTS; CYTOKINES; SURGERY; HUMANS; TENDON
AB Background: Platelet-rich plasma (PRP) contains numerous growth factors to promote wound healing and angiogenesis. The aim of this study was to gain further information about the benefits of platelet-rich-plasma for healing cutaneous acute to chronic wounds.
   Methods: A total of 30 New Zealand albino rabbits (n = 15/group) were randomly assigned to two experimental groups: control group, and PRP group. Bilateral resection defects measuring 3 cm were surgically created on the dorsolateral of the cutaneous in animals and the defects were randomly divided into two mentioned groups. Wound area, neovascularization, size and epithelialization were compared on days 7, 14 and 21 post-wounding. Histopathological analyses were conducted on 15 specimens from each group after sacrifice by the cellular aspects of the regeneration of the tissue.
   Results: Our results were indicated that the wound area of PRP was smaller than that in the non-treated group on days 7, 14 and 21. Furthermore, a significant decrease of the wound size was observed in PRP groups that were significantly greater than that in the control group. A significant increase of the mean vascular density was noted in the PRP treated groups compared to the control groups at day 14 and especially day 21. This results indicated that PRP treated group' enhanced angiogenesis at the wound beds as compared to no treatment group.
   Conclusion: These results could be useful for researchers in the growing fields of tissue repair and experimental wound healing. Further studies will be essential to determine the role of PRP in clinical practice.
C1 [Ostvar, Omid] Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
   [Shadvar, Sahar] Univ Tehran Med Sci, Brain & Spinal Injury Res Ctr, Tehran, Iran.
   [Yahaghi, Emad] Baqiyatallah Univ Med Sci, Tehran, Iran.
   [Azma, Kamran] AJA Univ Med Sci, Clin Biomech & Rehabil Engn Res Ctr, Dept Phys Med & Rehabil, Tehran, Iran.
   [Fayyaz, Amir Farshid] AJA Univ Med Sci, Dept Legal Med, Tehran, Iran.
   [Ahmadi, Koorosh] Alborz Univ Med Sci, Dept Emergency Med, Karaj, Iran.
   [Nowrouzian, Iradj] Univ Tehran, Fac Vet Med, Dept Clin Sci, Tehran, Iran.
RP Ahmadi, K (reprint author), Alborz Univ Med Sci, Dept Emergency Med, Karaj, Iran.
EM ahmadik@mums.ac.ir
CR Aghaloo TL, 2002, J ORAL MAXIL SURG, V60, P1176, DOI 10.1053/joms.2002.34994
   Ahmad Zafar, 2012, JRSM Short Rep, V3, P40, DOI 10.1258/shorts.2011.011148
   Barati F, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-120
   Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x
   Bhanot Sumeet, 2002, Facial Plast Surg, V18, P27, DOI 10.1055/s-2002-19824
   Bir SC, 2009, J VASC SURG, V50, P870, DOI 10.1016/j.jvs.2009.06.016
   Camargo PM, 2002, J PERIODONTAL RES, V37, P300, DOI 10.1034/j.1600-0765.2002.01001.x
   Carter MJ, 2009, ADV SKIN WOUND CARE, V22, P316, DOI 10.1097/01.ASW.0000305486.06358.e0
   Cervelli V, 2009, TISSUE ENG PART C-ME, V15, P625, DOI [10.1089/ten.tec.2008.0518, 10.1089/ten.TEC.2008.0518]
   Crovetti G, 2004, TRANSFUS APHER SCI, V30, P145, DOI 10.1016/j.transci.2004.01.004
   El-Sharkawy H, 2007, J PERIODONTOL, V78, P661, DOI 10.1902/jop.2007.060302
   Eppley BL, 2006, PLAST RECONSTR SURG, V118, p147E, DOI 10.1097/01.prs.0000239606.92676.cf
   Eppley BL, 2004, PLAST RECONSTR SURG, V114, P1502, DOI 10.1097/01.PRS.0000138251.07040.51
   Everts PA, 2007, THESIS
   Frechette JP, 2005, J DENT RES, V84, P434, DOI 10.1177/154405910508400507
   Gotterbarm T, 2006, BIOMATERIALS, V27, P3387, DOI 10.1016/j.biomaterials.2006.01.041
   Henderson Jenifer L, 2003, Ear Nose Throat J, V82, P598
   Hobbenaghi R, 2012, J CLIN EXP PATHOL, V2, P124
   Hom DB, 2007, ARCH FACIAL PLAST S, V9, P174, DOI 10.1001/archfaci.9.3.174
   Javanbakht J, 2013, PATHOL BIOL, V61, P250, DOI 10.1016/j.patbio.2013.03.007
   Karayannopoulou M, 2015, VET COMP ORTHOPAED, V28, P172, DOI 10.3415/VCOT-14-06-0088
   Kassolis JD, 2000, J PERIODONTOL, V71, P1654, DOI 10.1902/jop.2000.71.10.1654
   Kim SG, 2002, INT J ORAL MAX IMPL, V17, P86
   Knox Rebecca L, 2006, J Extra Corpor Technol, V38, P260
   Lee HW, 2008, J PERIODONTOL, V79, P691, DOI [10.1902/jop.2008.070449, 10.1902/jop.2008.070449 ]
   Lekovic V, 2003, J CLIN PERIODONTOL, V30, P746, DOI 10.1034/j.1600-051X.2003.00368.x
   Lindeboom JAH, 2007, CLIN ORAL IMPLAN RES, V18, P133, DOI 10.1111/j.1600-0501.2006.01288.x
   Loots MAM, 2002, EUR J CELL BIOL, V81, P153, DOI 10.1078/0171-9335-00228
   Mishra A, 2009, CLIN SPORT MED, V28, P113, DOI 10.1016/j.csm.2008.08.007
   Nikolidakis D, 2008, TISSUE ENG PART B-RE, V14, P249, DOI 10.1089/ten.teb.2008.0062
   Pietrzak WS, 2005, J CRANIOFAC SURG, V16, P1043, DOI 10.1097/01.scs.0000186454.07097.bf
   Prades M, 2007, P SO EUR VET C C NAC
   Saldalamacchia G, 2004, GIORNALE ITALIANO DI, V24, P103
   SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584
   Sharma P., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P181
   Shashikiran N D, 2006, J Clin Pediatr Dent, V30, P283
   Shin HS, 2012, ARCH PLAST SURG-APS, V39, P106, DOI 10.5999/aps.2012.39.2.106
   Sun Y, 2010, INT ORTHOP, V34, P589, DOI 10.1007/s00264-009-0793-2
   Tavasoly A, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-173
   Tehrani Ali Asghar, 2011, Biochemical and Cellular Archives, V11, P221
   Weibrich G, 2002, GROWTH FACTORS, V20, P93, DOI 10.1080/08977190290031950
   Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.00031.2002
   Wrotniak Maciej, 2007, Ortop Traumatol Rehabil, V9, P227
   Zimmermann R, 2001, TRANSFUSION, V41, P1217, DOI 10.1046/j.1537-2995.2001.41101217.x
   2008, J PLAST RECONSTR AES, V45, P61
NR 45
TC 14
Z9 14
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUL 2
PY 2015
VL 10
AR 85
DI 10.1186/s13000-015-0327-8
PG 6
WC Pathology
SC Pathology
GA CL8VD
UT WOS:000357251300001
PM 26134399
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Casan-Pitarch, R
AF Casan-Pitarch, Ricardo
TI RETRACTED: Project Work in CLIL: A Bibliographical Review (Retracted
   article. See vol. 9, pg. 16, 2016)
SO LATIN AMERICAN JOURNAL OF CONTENT & LANGUAGE INTEGRATED-LACLIL
LA English
DT Article; Retracted Publication
DE CLIL; project work; bilingualism; language teaching; education
AB Learning foreign languages has become necessary in present society, yet most government policies to promote multilingualism seem to have been insufficient. In fact, the European Commission reports that only 35% of Europeans regularly use foreign languages in their daily lives. As a result, there is a real need for new language teaching approaches that improve the current educational system. The CLIL approach has been considered an alternative to other more traditional methods, since it involves the integration of language and content. Additionally, project work can be used in support of CLIL approaches in order to increase interaction among participants and promote learning autonomy, making this a desirable part of CLIL programs. To examine the issues surrounding project work in CLIL more closely, this paper provides bibliographical review that analyses the application of project work in CLIL and identifies its main features and possible benefits.
C1 [Casan-Pitarch, Ricardo] Univ Catolica San Antonio Murcia, Murcia, Spain.
RP Casan-Pitarch, R (reprint author), Univ Catolica San Antonio Murcia, Murcia, Spain.
EM rcasan@ucam.edu
CR Anderson L., 2001, TAXONOMY LEARNING TE
   Applebee A. N., 1986, TEACHING WRITING, P95
   AUSUBEL DP, 1978, REV EDUC RES, V48, P251, DOI 10.2307/1170083
   BAUERSFELD H, 1995, CONSTRUCTIVISM IN EDUCATION, P137
   Bloom B. S, 1956, TAXONOMY ED OBJECTIV, V1
   BLUMENFELD PC, 1991, EDUC PSYCHOL, V26, P369, DOI 10.1207/s15326985ep2603&4_8
   Brumfit Ch, 2001, INDIVIDUAL FREEDOM L
   Byrd D, 2014, ELECT J FOREIGN LANG, V11, P76
   Byrne D, 1984, TEACHING WRITING SKI
   Cano W., 2014, MANUAL CLIL CTR BILI
   Chamot A, 1994, CALLA HDB IMPLEMENTI
   Coffey H., 2008, PROJECT BASED LEARNI
   Coyle D., 2009, CONTENT LANGUAGE INT, P107
   Coyle D., 2010, CLIL CONTENT LANGUAG
   Coyle D., 2007, INT J BILING EDUC BI, V10, P543, DOI DOI 10.2167/BEB459.0
   Cummins J., 1984, BILINGUALISM SPECIAL
   Cummins J., 2000, LANGUAGE POWER PEDAG
   Cummins J., 2005, INFORM TECHNOLOGY IN, P105
   CURTAIN H, 1991, FOREIGN LANG ANN, V24, P323, DOI 10.1111/j.1944-9720.1991.tb00477.x
   De Graaff E, 2003, INT J ENG EDUC, V19, P657
   Eaude T, 2013, PRIMARY ED LIT REV
   EUROPEAN COMMISSION, 2012, EUR THEIR LANG SPEC, V386
   Eurydice, 2006, CONT LANG INT LEARN
   Fried-Booth D., 1986, PROJECT WORK
   Hall S., 1980, CULTURE MEDIA LANGUA
   Istanto J.W., 2013, ELECT J FOREIGN LANG, V10, P276
   JONES B. F., 1997, REAL LIFE PROBLEM SO
   Kolmos A., 1999, THEM VAR PBL REF P 1
   Kramsch C., 2014, ELECT J FOREIGN LANG, V11, P249
   Krashen S., 1985, INPUT HYPOTHESIS ISS
   Kubon V., 2013, P 27 PAC AS C LANG I, P222
   Llinares A., 2012, ROLES LANGUAGE CLIL
   Long M., 1996, HDB 2 LANGUAGE ACQUI, P413, DOI DOI 10.1016/B978-012589042-7/50015-3
   LONG MH, 1983, APPL LINGUIST, V4, P126, DOI 10.1093/applin/4.2.126
   Banegas DL, 2013, INT PERSP ENG LANG T, P82
   Perez-Canado ML, 2012, INT J BILING EDUC BI, V15, P315, DOI 10.1080/13670050.2011.630064
   Juarez MM, 2013, LFE-REV LENGUAS FINE, V19, P183
   Mehisto P, 2008, UNCOVERING CLIL CONT
   Munoz C., 2007, REV ESPANOLA LINGUIS, V1, P17
   NUNAN D, 1991, TESOL QUART, V25, P279, DOI 10.2307/3587464
   Oura G. K., 2001, SOPHIA JUNIOR COLL F, V21, P65
   Peirce C, 1960, COLLECTED PAPERS CS
   Perez Gracia E, 2014, C P ICT LANGUAGE LEA, P42
   Perez Vidal C, 1997, LANGUAGE TEACHER TRA
   Prince M, 2004, J ENG EDUC, V93, P223, DOI 10.1002/j.2168-9830.2004.tb00809.x
   Richards J., 2001, APPROACHES METHODS L
   Saussure F., 1922, COURS LINGUISTIQUE G
   SEARLE J. R., 2002, CONSCIOUSNESS LANGUA
   Sierra J. M., 2011, CONTENT FOREIGN LANG, P211
   Sinclair Anne, 1978, CHILDS CONCEPTION LA, P241
   Swain M., 1985, INPUT 2 LANGUAGE ACQ, P235
   Sylven LK, 2013, INT J BILING EDUC BI, V16, P301, DOI 10.1080/13670050.2013.777387
   Thomas J. W., 2000, REV RES PROJECT BASE
   Thomas J. W., 1999, PROJECT BASED LEARNI
   Towomey C., 2005, CONSTRUCTIVISM THEOR
   Vygotsky L, 1978, MIND SOC DEV HIGHER
   WRENLEWIS J, 1983, MEDIA CULT SOC, V5, P179, DOI 10.1177/016344378300500205
NR 57
TC 1
Z9 1
U1 0
U2 5
PU UNIV SABANA, FAC ENFERMARIA
PI CHIA
PA CAMPUS UNIV PUENTE COMUN, KM 21 AUTOPISTA NORTE BOGOTA, D C, CHIA,
   CUNDINAMARCA 00000, COLOMBIA
SN 2011-6721
EI 2322-9721
J9 LAT AM J CONTENT LAN
JI Lat. Am. J. Content Lang. Integr.
PD JUL-DEC
PY 2015
VL 8
IS 2
BP 212
EP 236
DI 10.5294/laclil.2015.8.2.7
PG 25
WC Education & Educational Research
SC Education & Educational Research
GA CX5OR
UT WOS:000365752000007
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Win, AZ
AF Win, Aung Zaw
TI RETRACTED: Child Farm Laborers (Retracted article. See vol. 105, pg.
   1726, 2015)
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Editorial Material; Retracted Publication
ID HEALTH
C1 Notre Dame de Namur Univ, Belmont, CA 94002 USA.
RP Win, AZ (reprint author), Notre Dame de Namur Univ, 1500 Ralston Ave, Belmont, CA 94002 USA.
EM aungzwin@gmail.com
CR DERICKSON A, 1992, AM J PUBLIC HEALTH, V82, P1280, DOI 10.2105/AJPH.82.9.1280
   Markel H, 2005, PEDIATRICS, V115, P1129, DOI 10.1542/peds.2004-2825D
   North Carolina Farmworker Advocacy Network, CHILDR FIELDS FACTS
   The Los Angeles County Museum of Art, RUR FIELD WORK NZ
   Troncale Anthony T., LW HINE
   Villarejo D, 1999, OCCUP MED, V14, P613
   Wasson R. G., 1977, AM L HINE PHOTOGRAPH, P9
NR 7
TC 1
Z9 1
U1 3
U2 9
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD JUL
PY 2015
VL 105
IS 7
BP 1312
EP 1312
DI 10.2105/AJPH.2015.302623
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CT6FX
UT WOS:000362909400011
PM 25973808
DA 2018-12-27
ER

PT J
AU Chen, YQ
   Tian, Y
   Ji, ZG
   Liu, Z
   Shang, DH
AF Chen, Yongqian
   Tian, Ye
   Ji, Zhengguo
   Liu, Zhi
   Shang, Donghao
TI RETRACTED: CC-chemokine receptor 7 is overexpressed and correlates with
   growth and metastasis in prostate cancer (Retracted article. See April,
   2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Prostate cancer; Chemokine receptors; CCR7; Proliferation; Migration;
   Metastasis
ID SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASIS; TUMOR; EXPRESSION;
   PROLIFERATION; MIGRATION; INVASION; CXCR4
AB Multiple studies have shown that CC-chemokine receptor 7 (CCR7) promotes cell proliferation in several human cancers. We investigated the expression and clinical significance of CCR7 in our large collection of prostate cancer (PCa) samples and explored its function on the proliferation and migration of PCa cells. In this study, the expression of CCR7 was examined by immunohistochemical staining and quantitative RT-PCR in primary PCa tissues from 60 patients who underwent radical prostatectomy. Then, we investigated the functional role of CCR7 in PCa cell proliferation and migration by small interfering RNA-mediated depletion. The positive rate of CCR7 staining was 88.33 % (53/60) in the PCa group and 16.67 % (10/60) in cases of benign prostate hyperplasia (BPH); the difference of CCR7 expression between PCa and BPH was statistically significant. The results were confirmed by quantitative real-time PCR. CCR7 was significantly elevated in all five PCa cell lines when compared to the RWPE-1 cells. Silencing of CCR7 inhibited the proliferation of PC3 cells which have a relatively high level of CCR7 in a time-dependent manner, and the invasion and migration of PC3 cells were distinctly suppressed. Our data suggest that the pathogenesis of human PCa maybe mediated by the CCR7, and thus CCR7 could represent selective targets for the molecularly targeted treatments of PCa.
C1 [Chen, Yongqian; Tian, Ye; Ji, Zhengguo; Liu, Zhi; Shang, Donghao] Capital Med Univ, Dept Urol, Beijing Friendship Hosp, Beijing 100050, Peoples R China.
RP Shang, DH (reprint author), Capital Med Univ, Dept Urol, Beijing Friendship Hosp, Beijing 100050, Peoples R China.
EM drshdh6@163.com
CR Ammirante M, 2014, P NATL ACAD SCI USA, V111, P14776, DOI 10.1073/pnas.1416498111
   Chiba F, 2014, INT J ONCOL, V44, P177, DOI 10.3892/ijo.2013.2180
   Ding YZ, 2003, CLIN CANCER RES, V9, P3406
   Gao J, 2013, ONCOL RES, V21, P73, DOI 10.3727/096504013X13775486749173
   Gollmer K, 2009, BLOOD, V114, P580, DOI 10.1182/blood-2009-01-200923
   Hirao M, 2000, CANCER RES, V60, P2209
   Itakura M, 2001, J IMMUNOL, V166, P2071, DOI 10.4049/jimmunol.166.3.2071
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Johrer K, 2008, EXPERT OPIN BIOL TH, V8, P269, DOI 10.1517/14712598.8.3.269 
   Liu FY, 2010, BRIT J ORAL MAX SURG, V48, P291, DOI 10.1016/j.bjoms.2009.06.007
   Liu FY, 2014, INT J ONCOL
   Maxwell PJ, 2014, ONCOTARGET, V5, P4895, DOI 10.18632/oncotarget.2052
   Qu YY, 2013, ASIAN J ANDROL, V15, P110, DOI 10.1038/aja.2012.110
   Rudd BD, 2005, J VIROL, V79, P3350, DOI 10.1128/JVI.79.6.3350-3357.2005
   Shang ZJ, 2009, ORAL ONCOL, V45, P480, DOI 10.1016/j.oraloncology.2008.06.005
   Sumida H, 2014, J IMMUNOL, V192, P4361, DOI 10.4049/jimmunol.1302959
   van den Bosch T, 2013, INVEST OPHTH VIS SCI, V54, P7354, DOI 10.1167/iovs.13-12407
   Wagner PL, 2008, ANN SURG ONCOL, V15, P2833, DOI 10.1245/s10434-008-0064-2
   Xu Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021119
NR 19
TC 6
Z9 6
U1 3
U2 10
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2015
VL 36
IS 7
BP 5537
EP 5541
DI 10.1007/s13277-015-3222-8
PG 5
WC Oncology
SC Oncology
GA CP0MI
UT WOS:000359569000081
PM 25682287
DA 2018-12-27
ER

PT J
AU Metchat, A
   Eguren, M
   Hossain, JM
   Politi, AZ
   Huet, S
   Ellenberg, J
AF Metchat, Aicha
   Eguren, Manuel
   Hossain, Julius M.
   Politi, Antonio Z.
   Huet, Sebastien
   Ellenberg, Jan
TI RETRACTED: An actin-dependent spindle position checkpoint ensures the
   asymmetric division in mouse oocytes (Retracted article. See vol. 6, pg.
   8124, 2015)
SO NATURE COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID ASSEMBLY CHECKPOINT; MEIOSIS-I; CHROMOSOME BIORIENTATION; MAMMALIAN
   OOCYTES; CELL-CYCLE; ANEUPLOIDY; APC/C; KINETOCHORES; PROTEOLYSIS;
   PROGRESSION
AB Faithful chromosome segregation, during meiosis, is of critical importance to prevent aneuploidy in the resulting embryo. In mammalian oocytes, the segregation of homologous chromosomes takes place with the spindle located at the cell's periphery. The spindle is often assembled close to the centre of the cell, which necessitates the actin network for spindle transport to the cell cortex. In this study, we investigate how the segregation of chromosomes is coordinated with the positioning of the metaphase I spindle. We develop different assays to perturb the spindle's position and to delay its relocation to the cell periphery. We find that anaphase is delayed until the spindle is positioned in close proximity with the oocyte cortex. We further show that the metaphase arrest is dependent on a functional actin network, in addition to the spindle assembly checkpoint. Our work provides the first evidence for the existence of a functional spindle position checkpoint.
C1 [Metchat, Aicha; Eguren, Manuel; Hossain, Julius M.; Politi, Antonio Z.; Huet, Sebastien; Ellenberg, Jan] European Mol Biol Lab, Heidelberg, Germany.
RP Metchat, A (reprint author), European Mol Biol Lab, Meyerhofstr 1, Heidelberg, Germany.
EM metchat@embl.de
OI Eguren, Manuel/0000-0003-0850-939X; Politi, Antonio/0000-0003-4788-0933
FU Marie Curie Long-Term Fellowships (FP7); German Research Council:
   Deutsche Forschungsgemeinschaft [SPP 1384]
FX We gratefully acknowledge Kim Nasmyth, Andrea Musacchio and Melina
   Schuh, respectively, for Cdc20<SUP>R132A</SUP> cDNA, Mad2<SUP>Delta
   C</SUP>, Rab11a-mCherry cDNA, for discussions and advices. We would like
   to thank Marvin Albert, Kota Miura and the members of Ellenberg lab for
   discussions; the members of EMBL Laboratory Animal Resources,
   especially, Yvonne Peterson, Silke Brohn, Angela Burro, Andrea Genthner,
   Marika Krudwig and Klaus Schmitt for excellent support. This work was
   supported by Marie Curie Long-Term Fellowships (FP7; A.M.) and by the
   German Research Council: Deutsche Forschungsgemeinschaft (SPP 1384;
   J.E.).
CR Almonacid M, 2015, NAT CELL BIOL, V17, P470, DOI 10.1038/ncb3131
   Azoury J, 2008, CURR BIOL, V18, P1514, DOI 10.1016/j.cub.2008.08.044
   Burkel BM, 2007, CELL MOTIL CYTOSKEL, V64, P822, DOI 10.1002/cm.20226
   Chaigne A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7027
   Chaigne A, 2013, NAT CELL BIOL, V15, P958, DOI 10.1038/ncb2799
   Dumont J, 2007, DEV BIOL, V301, P254, DOI 10.1016/j.ydbio.2006.08.044
   Fraschini R, 2008, BIOCHEM SOC T, V36, P416, DOI 10.1042/BST0360416
   Gui LM, 2012, DEVELOPMENT, V139, P1941, DOI 10.1242/dev.078352
   Hached K, 2011, DEVELOPMENT, V138, P2261, DOI 10.1242/dev.061317
   Herbert M, 2003, NAT CELL BIOL, V5, P1023, DOI 10.1038/ncb1062
   Hoffmann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027143
   Holubcova Z, 2013, NAT CELL BIOL, V15, P937, DOI 10.1038/ncb2802
   Homer HA, 2005, GENE DEV, V19, P202, DOI 10.1101/gad.328105
   Homer H, 2009, SCIENCE, V326, P991, DOI 10.1126/science.1175326
   Hunt P, 2010, CURR BIOL, V20, pR699, DOI 10.1016/j.cub.2010.08.011
   Jin F, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001147
   Jones KT, 2013, DEVELOPMENT, V140, P3719, DOI 10.1242/dev.090589
   Kitajima TS, 2011, CELL, V146, P568, DOI 10.1016/j.cell.2011.07.031
   Kolano A, 2012, P NATL ACAD SCI USA, V109, pE1858, DOI 10.1073/pnas.1204686109
   Kotani T, 2013, J CELL BIOL, V202, P1041, DOI 10.1083/jcb.201302139
   Kubiak JZ, 2008, INT J DEV BIOL, V52, P201, DOI 10.1387/ijdb.072337jk
   Lane SIR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4444
   Madgwick S, 2004, DEV BIOL, V275, P68, DOI 10.1016/j.ydbio.2004.07.024
   MARO B, 1986, J EMBRYOL EXP MORPH, V92, P11
   McGulnness BE, 2009, CURR BIOL, V19, P369, DOI 10.1016/j.cub.2009.01.064
   Musacchio A, 2011, PHILOS T R SOC B, V366, P3595, DOI 10.1098/rstb.2011.0072
   Nabti I, 2014, J CELL BIOL, V204, P891, DOI 10.1083/jcb.201305049
   Nagaoka SI, 2011, CURR BIOL, V21, P651, DOI 10.1016/j.cub.2011.03.003
   Overlack K, 2014, EMBO REP, V15, P326, DOI 10.1002/embr.201438574
   Pfender S, 2011, CURR BIOL, V21, P955, DOI 10.1016/j.cub.2011.04.029
   Rattani A, 2014, CURR BIOL, V24, P630, DOI 10.1016/j.cub.2014.01.033
   Reis A, 2007, NAT CELL BIOL, V9, P1192, DOI 10.1038/ncb1640
   RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941
   Santaguida S, 2011, EMBO J, V30, P1508, DOI 10.1038/emboj.2011.70
   Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036
   Schuh M, 2007, CELL, V130, P484, DOI 10.1016/j.cell.2007.06.025
   Schuh M, 2011, NAT CELL BIOL, V13, P1431, DOI 10.1038/ncb2353
   Schuh M, 2008, CURR BIOL, V18, P1986, DOI 10.1016/j.cub.2008.11.022
   Tsurumi C, 2004, J CELL BIOL, V167, P1037, DOI 10.1083/jcb.200405165
   Uchida KSK, 2009, J CELL BIOL, V184, P383, DOI 10.1083/jcb.200811028
   Verlhac MH, 2000, CURR BIOL, V10, P1303, DOI 10.1016/S0960-9822(00)00753-3
   Verlhac MH, 2000, EMBO J, V19, P6065, DOI 10.1093/emboj/19.22.6065
   Wassmann K, 2003, EMBO J, V22, P797, DOI 10.1093/emboj/cdg071
   Yamagishi Y, 2012, NAT CELL BIOL, V14, P746, DOI 10.1038/ncb2515
   Yi KX, 2013, J CELL BIOL, V200, P567, DOI 10.1083/jcb.201211068
NR 45
TC 5
Z9 5
U1 4
U2 25
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL
PY 2015
VL 6
AR 7784
DI 10.1038/ncomms8784
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CO0RL
UT WOS:000358859800010
PM 26174204
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Matsuno, K
   Ihara, S
AF Matsuno, Kei
   Ihara, Setsunosuke
TI RETRACTED: Ultrastructural analysis between fetal and adult wound
   healing process of marsupial opossum skin (Retracted article. See vol.
   64, 2015)
SO EXPERIMENTAL ANIMALS
LA English
DT Article; Retracted Publication
DE Electron microscopy; opossum; skin
ID MONODELPHIS-DOMESTICA; SCAR FORMATION; RAT SKIN; TRANSITION; ONTOGENY;
   REPAIR; TISSUE; MODEL
AB The opossum delivers a newborn baby equivalent to tremature fetus state by postpregnancy. The peculiarity is advantageous for studies of fetus, because operations to take out fetus from the uterus of a mother are not necessary. When mammalian skin is wounded by full-thickness excision, fetal and adult wound healing processes differ. Fetal-type wound healing does not leave a scar. However, studies of how the fetal wound healing process differs in detail from the adult type are not advanced. We first observed the normal skin development of the gray short-tailed opossum (Monodelphis domestica) using an electron microscope. As for normal skin, an epidermis became multi-layered, and thickened from birth through to 7 days after birth. The quantity of extracellular matrix of the dermis increased thereafter, and several types of cells were found in the dermis. To examine the wound healing, we used material from a 1 day-old newborn baby, and from another 15 days after birth, and compared the wound healing style morphologically. Differences in the constitution of cells and fine structures of the skin were observed, it was obviously suggested that change in the wound healing style from fetal-type to adult-type occurred between 1 to 15 days after birth.
C1 [Matsuno, Kei; Ihara, Setsunosuke] Tottori Univ, Grad Sch Agr, Matsue, Shimane 6908504, Japan.
RP Matsuno, K (reprint author), Tottori Univ, Grad Sch Agr, Nishikawatsu 1060, Matsue, Shimane 6908504, Japan.
CR Adachi T., 2012, THESIS SHIMANE U
   ARMSTRONG JR, 1995, DEV BIOL, V169, P242, DOI 10.1006/dbio.1995.1141
   Beanes SR, 2002, PLAST RECONSTR SURG, V109, P160, DOI 10.1097/00006534-200201000-00026
   Coolen NA, 2010, WOUND REPAIR REGEN, V18, P291, DOI 10.1111/j.1524-475X.2010.00585.x
   Coolen NA, 2010, ARCH DERMATOL RES, V302, P47, DOI 10.1007/s00403-009-0989-8
   DESMOULIERE A, 1995, AM J PATHOL, V146, P56
   Diegelmann RF, 2004, FRONT BIOSCI-LANDMRK, V9, P283, DOI 10.2741/1184
   Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427
   IHARA S, 1990, DEVELOPMENT, V110, P671
   IHARA S, 1992, DEVELOPMENT, V114, P573
   LORENZ HP, 1993, ANN SURG, V217, P391, DOI 10.1097/00000658-199304000-00011
   Mast Bruce A., 1997, Wound Repair and Regeneration, V5, P243, DOI 10.1046/j.1524-475X.1997.50308.x
   MATE KE, 1994, MOL REPROD DEV, V39, P365
   MORYKWAS MJ, 1991, ANN PLAS SURG, V27, P327, DOI 10.1097/00000637-199110000-00007
   Redd MJ, 2004, PHILOS T R SOC B, V359, P777, DOI 10.1098/rstb.2004.1466
   Wulff BC, 2012, J INVEST DERMATOL, V132, P458, DOI 10.1038/jid.2011.324
NR 16
TC 1
Z9 1
U1 3
U2 8
PU INT PRESS EDITING CENTRE INC
PI TOKYO
PA 1-2-3 SUGAMO, TOSHIMA-KU, TOKYO, 170 0002, JAPAN
SN 1341-1357
EI 1881-7122
J9 EXP ANIM TOKYO
JI Exp. Anim.
PD JUL
PY 2015
VL 64
IS 3
BP 323
EP 332
DI 10.1538/expanim.15-0003
PG 10
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA CN9FX
UT WOS:000358753700011
PM 25912322
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Song, H
   Jung, J
AF Song, Haeyeop
   Jung, Jaemin
TI RETRACTED: Antecedents and Consequences of Gender Swapping in Online
   Games(Retracted article. See vol. 22, pg. 53, 2017)
SO JOURNAL OF COMPUTER-MEDIATED COMMUNICATION
LA English
DT Article; Retracted Publication
DE Gender; Online Games; Gender Swapping; Anonymity; Perceived Benefits;
   Virtual Goods Purchasing
ID SELF-REPRESENTATION; VIRTUAL WORLDS; BEHAVIOR; GAMES; CYBERSPACE; ROLES;
   PLAY
AB This study examines the reasons underlying gender swapping and its impacts on online gaming behavior. While previous studies considered gender swapping to be an abnormal or rare exception in one's self-presentation, this study hypothesized that people swap genders as a rational choice based on practical benefits. An online survey was conducted with 318 male players of MMORPGs in Korea. Players swapped gender in games to gain benefits from other players under the condition of anonymity rather than to represent their own gender identity. Men playing female avatars displayed more socially amiable behaviors conventionally characterized as more feminine. Moreover, players were more willing to purchase virtual goods to decorate their gender swapped avatars, mediated by their emotional attachment to their avatar.
C1 [Song, Haeyeop] Korea Adv Inst Sci & Technol, Dept Engn Management, Seoul, South Korea.
   [Jung, Jaemin] Korea Adv Inst Sci & Technol, Grad Sch Informat & Media Management, Seoul, South Korea.
RP Song, H (reprint author), Korea Adv Inst Sci & Technol, Dept Engn Management, 85 Hoegi Ro, Seoul, South Korea.
EM kismet@kaist.ac.kr; nettong@kaist.ac.kr
RI Jung, Jaemin/C-2064-2011
OI Song, Haeyeop/0000-0002-7044-4710
CR Anderson C., 2009, FREE FUTURE RADICAL
   Animesh A, 2011, MIS QUART, V35, P789
   [Anonymous], 2013, FIREBURNS       0616
   Avatar, MERR WEBST ONL DICT
   Banks J, 2016, NEW MEDIA SOC, V18, P1257, DOI 10.1177/1461444814554898
   BELK RW, 1988, J CONSUM RES, V15, P139, DOI 10.1086/209154
   Bergstrom K., 2012, P INT C FDN DIG GAM, P97
   BERK Laura E., 2006, CHILD DEV
   Boler M, 2007, NEW MEDIA SOC, V9, P139, DOI 10.1177/1461444807067586
   Butler Judith, 1999, GENDER TROUBLE FEMIN
   Colley A, 2009, PERS INDIV DIFFER, V46, P384, DOI 10.1016/j.paid.2008.11.005
   COOK EP, 1990, J COUNS DEV, V68, P371, DOI 10.1002/j.1556-6676.1990.tb02513.x
   DEANDREA DC, 2012, J COMMUN, V62, P400, DOI DOI 10.1111/J.1460-2466.2012.01646.X
   DiGiuseppe N., 2007, 1 MONDAY, V12, DOI [10.5210/fm.v12i5.1831, DOI 10.5210/FM.V12I5.1831]
   Dill KE, 2007, SEX ROLES, V57, P851, DOI 10.1007/s11199-007-9278-1
   Donath J., 1999, COMMUNITIES CYBERSPA, P29
   Ducheneaut N., 2006, GAMES CULTURE, V1, P281, DOI DOI 10.1177/1555412006292613
   Ducheneaut N., 2011, GENDER BENDING
   Eklund L, 2011, CONVERGENCE, V17, P323, DOI DOI 10.1177/1354856511406472
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   Fornell C., 1982, ASSESSMENT MARKETING, V48, P405
   Gohr M., 2012, MP ONLINE FEMINIST J, V3
   Griffiths MD, 2004, J ADOLESCENCE, V27, P87, DOI 10.1016/j.adolescence.2003.10.007
   Grimes SM, 2009, INFORM SOC, V25, P105, DOI 10.1080/01972240802701643
   Guo Y, 2009, ELECTRON COMMER RES, V9, P77, DOI 10.1007/s10660-009-9032-6
   Harrison LA, 2005, SEX ROLES, V52, P227, DOI 10.1007/s11199-005-1297-1
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Huh S, 2010, HUM-COMPUT INT-SPRIN, P161, DOI 10.1007/978-1-84882-825-4_13
   Hussain Z, 2008, CYBERPSYCHOL BEHAV, V11, P47, DOI 10.1089/cpb.2007.0020
   Jarvenppa S., 2007, CALL PAPERS MISQ SPE
   Kafai Y. B., 2007, DIG GAM RES ASS C 20, P1
   Lehdonvirta M, 2012, GAMES CULT, V7, P29, DOI 10.1177/1555412012440307
   Lehdonvirta V, 2009, ELECTRON COMMER RES, V9, P97, DOI 10.1007/s10660-009-9028-2
   Lewis ML, 2008, CYBERPSYCHOL BEHAV, V11, P515, DOI 10.1089/cpb.2007.0137
   Lou JK, 2013, P 22 INT C WORLD WID, P827
   MacCallum-Stewart E., 2008, Eludamos Journal for Computer Game Culture, V2, P27
   Mahalik JR, 2000, J SOC CLIN PSYCHOL, V19, P276, DOI 10.1521/jscp.2000.19.2.276
   Martey RM, 2014, INFORM COMMUN SOC, V17, P286, DOI 10.1080/1369118X.2013.874493
   MINTZ LB, 1990, J COUNS DEV, V68, P381, DOI 10.1002/j.1556-6676.1990.tb02515.x
   Murphy P., 1994, TEACHING SCI, P131
   Nerad S., 2010, SOCIAL GAME VIRTUAL
   Nowak KL, 2006, J COMPUT-MEDIAT COMM, V11, P153
   Nunnally JC, 1994, PSYCHOMETRIC THEORY
   Ratan R, 2010, PSYCHNOLOGY J, V8, P11
   Roberts L. D., 1999, Information Communication & Society, V2, P521
   Sirin Selcuk R., 2004, J MENS STUDIES, V12, P119, DOI DOI 10.3149/JMS.1202.119
   Thomson M, 2005, J CONSUM PSYCHOL, V15, P77, DOI 10.1207/s15327663jcp1501_10
   Turkle S., 2011, LIFE SCREEN IDENTITY
   Vincent Jane, 2006, KNOWLEDGE TECHNOLOGY, V19, P39, DOI DOI 10.1007/S12130-006-1013-7
   Wang CC, 2008, CYBERPSYCHOL BEHAV, V11, P344, DOI 10.1089/cpb.2007.0045
   Yee N, 2007, HUM COMMUN RES, V33, P271, DOI 10.1111/j.1468-2958.2007.00299.x
   Yee N, 2006, CYBERPSYCHOL BEHAV, V9, P772, DOI 10.1089/cpb.2006.9.772
   Yee N, 2009, COMMUN RES, V36, P285, DOI 10.1177/0093650208330254
   Zhong CB, 2010, PSYCHOL SCI, V21, P311, DOI 10.1177/0956797609360754
NR 54
TC 3
Z9 3
U1 3
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-6101
J9 J COMPUT-MEDIAT COMM
JI J. Comput.-Mediat. Commun.
PD JUL
PY 2015
VL 20
IS 4
BP 434
EP 449
DI 10.1111/jcc4.12119
PG 16
WC Communication; Information Science & Library Science
SC Communication; Information Science & Library Science
GA CN1RR
UT WOS:000358198300005
OA Bronze
DA 2018-12-27
ER

PT J
AU Ye, XX
   Tse, ZTH
   Tang, GY
   Song, GL
AF Ye, Xiaoxin
   Tse, Zion T. H.
   Tang, Guoyi
   Song, Guolin
TI RETRACTED: Effect of High-Energy Electropulsing on the Phase Transition
   and Mechanical Properties of Two-Phase Titanium Alloy Strips(Retracted
   article. See vol.19, artn.1770028, 2017)
SO ADVANCED ENGINEERING MATERIALS
LA English
DT Article; Retracted Publication
ID HEAT-TREATMENT; SOLID SOLUBILITY; TI-6AL-4V ALLOY; MICROSTRUCTURE;
   EVOLUTION; TEXTURE; MICROHARDNESS; DEFORMATION; BEHAVIOR; COPPERS
AB The effect of high-energy electropulsing treatment (EPT) on the phase transition and mechanical properties of the two-phase Ti-6Al-4V alloy strips (in the solid solution state) was studied with the help of uniaxial tensile machine, X-ray diffraction, optical stereo-microscope, scanning electron microscope, and electrical resistance meters. Results show that the ductility of the titanium alloy strips under EPT could be enhanced remarkably at most by 225% while keeping the tensile strength nearly unchanged. EPT facilitates beta-Ti phase precipitation noticeably with increasing percentage of the beta phase and the average size of the beta phase. In addition, precipitated beta phase gathers coarsening, forms into continuous strips and migrates from the interior grains to the inter-granular regions transforming the wormlike microstructure into the equiaxed microstructure. The mechanism for rapid phase change during EPT is put forward with increasing the nucleation rate of the alpha -> beta phase transformation and accelerating the diffusion flux of vanadium atoms under the coupling of the thermal and athermal effects. Therefore, a highly efficient aging treatment method for titanium alloys is provided to prepare advanced engineering materials with outstanding mechanical properties, which can be widely applied in the aerospace and biomedical fields.
C1 [Ye, Xiaoxin; Tang, Guoyi; Song, Guolin] Tsinghua Univ, Grad Sch Shenzhen, Adv Mat Inst, Shenzhen 518055, Peoples R China.
   [Ye, Xiaoxin; Tang, Guoyi] Tsinghua Univ, Dept Mat Sci & Engn, Minist Educ, Key Lab Adv Mat, Beijing 100084, Peoples R China.
   [Tse, Zion T. H.] Univ Georgia, Coll Engn, Athens, GA 30602 USA.
RP Ye, XX (reprint author), Tsinghua Univ, Grad Sch Shenzhen, Adv Mat Inst, Shenzhen 518055, Peoples R China.
EM xiaoxinye905@gmail.com; tanggy@mails.tsinghua.edu.cn
FU National Natural Science Foundation of China [50571048]; Shenzhen
   Science and Technology Research funding project of China
   [SGLH2012100814475694]
FX The work is supported by National Natural Science Foundation of China
   (No. 50571048) and Shenzhen Science and Technology Research funding
   project of China (No. SGLH2012100814475694).
CR BAZAYKIN VI, 1991, INT J SOLIDS STRUCT, V27, P1639, DOI 10.1016/0020-7683(91)90066-O
   Bell A, 1997, MAT SCI ENG A-STRUCT, V226, P1039, DOI 10.1016/S0921-5093(96)10854-6
   Buffa G, 2013, MAT SCI ENG A-STRUCT, V581, P56, DOI 10.1016/j.msea.2013.06.009
   Clemens H, 2013, ADV ENG MATER, V15, P191, DOI 10.1002/adem.201200231
   Clouet E, 2007, ACTA MATER, V55, P391, DOI 10.1016/j.actamat.2006.08.021
   Dobeson RG, 2012, ADV ENG MATER, V14, P473, DOI 10.1002/adem.201200106
   GROMOV VY, 1992, FIZ MET METALLOVED+, P129
   Gurao NP, 2013, METALL MATER TRANS A, V44A, P1497, DOI 10.1007/s11661-012-1484-y
   Jiang JF, 2013, MAT SCI ENG A-STRUCT, V560, P473, DOI 10.1016/j.msea.2012.09.092
   Jiang YB, 2009, ACTA MATER, V57, P4797, DOI 10.1016/j.actamat.2009.06.044
   Konovalov SV, 2010, MAT SCI ENG A-STRUCT, V527, P3040, DOI 10.1016/j.msea.2010.01.048
   Kumaran V, 1998, J CHEM PHYS, V108, P3038, DOI 10.1063/1.475691
   Lee J, 2004, METALL MATER TRANS A, V35A, P493, DOI 10.1007/s11661-004-0360-9
   Lefebvre LP, 2013, ADV ENG MATER, V15, P159, DOI 10.1002/adem.201200154
   Li C, 2011, ADV ENG MATER, V13, P418, DOI 10.1002/adem.201000377
   Liao HM, 2011, MAT SCI ENG A-STRUCT, V529, P138, DOI 10.1016/j.msea.2011.09.007
   Liu CM, 2014, MAT SCI ENG A-STRUCT, V590, P30, DOI 10.1016/j.msea.2013.10.002
   Mei SL, 2012, ADV ENG MATER, V14, pB166, DOI 10.1002/adem.201180056
   Nakai M, 2014, MAT SCI ENG A-STRUCT, V594, P103, DOI 10.1016/j.msea.2013.11.055
   Okutani T, 2013, J ALLOY COMPD, V551, P607, DOI 10.1016/j.jallcom.2012.11.022
   Peters M, 2003, ADV ENG MATER, V5, P419, DOI 10.1002/adem.200310095
   Ryu EK, 2008, MATER LETT, V62, P3081, DOI 10.1016/j.matlet.2008.01.108
   Saito Y, 2011, INT J PLASTICITY, V27, P1640, DOI 10.1016/j.ijplas.2010.10.007
   Shi BQ, 2011, J ALLOY COMPD, V509, P3357, DOI 10.1016/j.jallcom.2010.12.065
   Sosnin O. V., 2003, FIZ KHIM OBRAB MATER, V4, P63
   Tanimura M., 2007, PHYS REV B, V6, P76
   Wang MJ, 2006, RARE METALS, V25, P687, DOI 10.1016/S1001-0521(07)60013-8
   Weber L, 2002, METALL MATER TRANS A, V33, P1145, DOI 10.1007/s11661-002-0216-0
   Xiaoxin Y., J MAT SCI M IN PRESS
   Xu ZH, 2006, J MATER PROCESS TECH, V182, P128, DOI 10.1016/j.jmatprotec.2006.07.019
   Yan M, 2014, ACTA MATER, V68, P196, DOI 10.1016/j.actamat.2014.01.015
   Yang Q, 2012, MATER LETT, V73, P136, DOI 10.1016/j.matlet.2012.01.027
   Yao ZK, 2003, RARE METAL MAT ENG, V32, P538
   Ye XX, 2014, SURF COAT TECH, V258, P467, DOI 10.1016/j.surfcoat.2014.08.052
   Ye XX, 2015, J ALLOY COMPD, V621, P66, DOI 10.1016/j.jallcom.2014.09.192
   Ye XX, 2014, APPL PHYS A-MATER, V117, P2251, DOI 10.1007/s00339-014-8655-1
   Ye XX, 2014, J MECH BEHAV BIOMED, V40, P287, DOI 10.1016/j.jmbbm.2014.08.022
   Ye XX, 2014, J ALLOY COMPD, V616, P173, DOI 10.1016/j.jallcom.2014.07.143
   Ye XX, 2014, J MATER RES, V29, P1500, DOI 10.1557/jmr.2014.171
   Ye XX, 2014, J ALLOY COMPD, V599, P1, DOI 10.1016/j.jallcom.2014.02.055
   Yuan Y, 2006, J ALLOY COMPD, V424, P108, DOI 10.1016/j.jallcom.2005.12.063
   Zhou TH, 2011, METALL MATER TRANS A, V42A, P3349, DOI 10.1007/s11661-011-0747-3
   Zhu RF, 2012, J ALLOY COMPD, V544, P203, DOI 10.1016/j.jallcom.2012.07.150
NR 43
TC 9
Z9 9
U1 27
U2 69
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1438-1656
EI 1527-2648
J9 ADV ENG MATER
JI Adv. Eng. Mater.
PD JUL
PY 2015
VL 17
IS 7
BP 995
EP 1007
DI 10.1002/adem.201400273
PG 13
WC Materials Science, Multidisciplinary
SC Materials Science
GA CM4UO
UT WOS:000357680700010
DA 2018-12-27
ER

PT J
AU Khatri, R
   Shah, P
   Guha, R
   Rassool, FV
   Tomkinson, AE
   Brodie, A
   Jaiswal, AK
AF Khatri, Raju
   Shah, Preeti
   Guha, Rupa
   Rassool, Feyruz V.
   Tomkinson, Alan E.
   Brodie, Angela
   Jaiswal, Anil K.
TI RETRACTED: Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1)
   Leads to Increased Nrf2 and Resistance in Breast Cancer (Retracted
   article. See vol. 17, pg. 2491, 2018)
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article; Retracted Publication
ID MULTIDRUG-RESISTANCE; STEM-CELLS; CLINICAL-IMPLICATIONS; ENDOCRINE
   RESISTANCE; RESPONSIVE ELEMENTS; EXPRESSION; GENE; TRANSPORTERS;
   SULFORAPHANE; CHEMOTHERAPY
AB Aromatase inhibitors are effective drugs that reduce or eliminate hormone-sensitive breast cancer. However, despite their efficacy, resistance to these drugs can occur in some patients. The INrf2 (Keap1): Nrf2 complex serves as a sensor of drug/radiation-induced oxidative/electrophilic stress. INrf2 constitutively suppresses Nrf2 by functioning as an adapter protein for the Cul3/Rbx1-mediated ubiquitination/degradation of Nrf2. Upon stress, Nrf2 dissociates from INrf2, is stabilized, translocates to the nucleus, and coordinately induces a battery of cytoprotective gene expression. Current studies investigated the role of Nrf2 in aromatase inhibitor resistance. RT-PCR and immunoblot assays showed that aromatase inhibitor-resistant breast cancer LTLTCa and AnaR cells express lower INrf2 and higher Nrf2 protein levels, as compared with drug-sensitive MCF-7Ca and AC1 cells, respectively. The increase in Nrf2 was due to lower ubiquitination/degradation of Nrf2 in aromatase inhibitor-resistant cells. Higher Nrf2-mediated levels of biotransformation enzymes, drug transporters, and antiapoptotic proteins contributed to reduced efficacy of drugs and aversion to apoptosis that led to drug resistance. shRNA inhibition of Nrf2 in LTLTCa (LTLTCa-Nrf2KD) cells reduced resistance and sensitized cells to aromatase inhibitor exemestane. Interestingly, LTLTCa-Nrf2KD cells also showed reduced levels of aldehyde dehydrogenase, a marker of tumor-initiating cells and significantly decreased mammosphere formation, as compared with LTLTCa-Vector control cells. The results together suggest that persistent aromatase inhibitor treatment downregulated INrf2 leading to higher expression of Nrf2 and Nrf2-regulated cytoprotective proteins that resulted in increased aromatase inhibitor drug resistance. These findings provide a rationale for the development of Nrf2 inhibitors to overcome resistance and increase efficacy of aromatase inhibitors. (C) 2015 AACR.
C1 [Khatri, Raju; Shah, Preeti; Guha, Rupa; Rassool, Feyruz V.; Brodie, Angela; Jaiswal, Anil K.] Univ Maryland, Sch Med, Dept Pharmacol, Baltimore, MD 21201 USA.
   [Khatri, Raju; Shah, Preeti; Guha, Rupa; Rassool, Feyruz V.; Brodie, Angela; Jaiswal, Anil K.] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA.
   [Tomkinson, Alan E.] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA.
RP Jaiswal, AK (reprint author), Univ Maryland, Sch Med, 655 West Baltimore St, Baltimore, MD 21201 USA.
EM ajaiswal@som.umaryland.edu
FU NIH [RO1 ES012265, RO1 ES021483, RO1 CA62483, RO1 GM047466];
   V-Foundation Fund; Endow Fund
FX This work was supported by NIH grant RO1 ES012265 (to A.K. Jaiswal), RO1
   ES021483 (to A.K. Jaiswal), RO1 CA62483 (to A. Brodie), RO1 GM047466 (to
   A.K. Jaiswal), and a grant from V-Foundation and Endow Funds (to A.K.
   Jaiswal).
CR Abdullah A, 2012, PHARMACOL REP, V64, P680, DOI 10.1016/S1734-1140(12)70863-0
   Akhtar M, 2011, J STEROID BIOCHEM, V125, P2, DOI 10.1016/j.jsbmb.2010.11.003
   Awad O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013943
   Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098
   CHEN SU, 1988, DNA-J MOLEC CELL BIO, V7, P27, DOI 10.1089/dna.1988.7.27
   Chumsri S, 2008, CURR OPIN MOL THER, V10, P323
   Chumsri S, 2011, J STEROID BIOCHEM, V125, P13, DOI 10.1016/j.jsbmb.2011.02.001
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Decraene C, 2005, PHYSIOL GENOMICS, V23, P132, DOI 10.1152/physiolgenomics.00141.2004
   Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506
   Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025
   Geisler J, 2002, J CLIN ONCOL, V20, P751, DOI 10.1200/JCO.20.3.751
   Gilabert M, 2014, B CANCER, V101, P325, DOI 10.1684/bdc.2014.1910
   Gilani RA, 2012, BREAST CANCER RES TR, V135, P681, DOI 10.1007/s10549-012-2148-8
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Giuliano M, 2011, BREAST, V20, pS42, DOI 10.1016/S0960-9776(11)70293-4
   Goel A, 2010, NUTR CANCER, V62, P919, DOI 10.1080/01635581.2010.509835
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Gutierrez C, 2011, ARCH PATHOL LAB MED, V135, P55, DOI 10.1043/2010-0454-RAR.1
   Harada N, 1997, J STEROID BIOCHEM, V61, P175
   Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086
   Hu XM, 2006, MOL CELL BIOL, V26, P940, DOI 10.1128/MCB.26.3.940-954.2006
   Huang Y, 2004, CANCER RES, V64, P4294, DOI 10.1158/0008-5472.CAN-03-3884
   Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906
   Iizuka T, 2005, GENES CELLS, V10, P1113, DOI 10.1111/j.1365-2443.2005.00905.x
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Jelovac D, 2005, CANCER RES, V65, P5380, DOI 10.1158/0008-5472.CAN-04-4502
   Kwak MK, 2007, FREE RADICAL BIO MED, V43, P809, DOI 10.1016/j.freeradbiomed.2007.05.029
   Kweon MH, 2006, J BIOL CHEM, V281, P33761, DOI 10.1074/jbc.M604748200
   Li XX, 2008, J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Liu H, 2013, P NATL ACAD SCI USA, V110, P19065, DOI 10.1073/pnas.1318247110
   Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811
   Macedo LF, 2009, ANN NY ACAD SCI, V1155, P162, DOI 10.1111/j.1749-6632.2008.03689.x
   Maher JM, 2007, HEPATOLOGY, V46, P1597, DOI 10.1002/hep.21831
   Mansilla Sylvia, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P589, DOI 10.2174/187152006778699086
   Nicolini A, 2011, CURR PHARM BIOTECHNO, V12, P196, DOI 10.2174/138920111794295657
   Niture SK, 2014, FREE RADICAL BIO MED, V66, P36, DOI 10.1016/j.freeradbiomed.2013.02.008
   Niture SK, 2012, J BIOL CHEM, V287, P9873, DOI 10.1074/jbc.M111.312694
   Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185
   Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013
   Penney RB, 2013, BBA-REV CANCER, V1836, P60, DOI 10.1016/j.bbcan.2013.02.005
   Provenzano A, 2013, EXPERT REV ANTICANC, V13, P143, DOI [10.1586/era.12.173, 10.1586/ERA.12.173]
   Rachakonda G, 2010, ONCOGENE, V29, P3703, DOI 10.1038/onc.2010.118
   Raguz S, 2008, BRIT J CANCER, V99, P387, DOI 10.1038/sj.bjc.6604510
   Rassool FV, 2010, CELL MOL LIFE SCI, V67, P3699, DOI 10.1007/s00018-010-0493-5
   Satoh H, 2010, CARCINOGENESIS, V31, P1833, DOI 10.1093/carcin/bgq105
   Shu LM, 2010, CANCER METAST REV, V29, P483, DOI 10.1007/s10555-010-9239-y
   Sreerama L, 2001, CHEM-BIOL INTERACT, V130, P247, DOI 10.1016/S0009-2797(00)00269-6
   Taguchi K, 2012, P NATL ACAD SCI USA, V109, P13561, DOI 10.1073/pnas.1121572109
   Tobin LA, 2012, MOL CANCER RES, V10, P96, DOI 10.1158/1541-7786.MCR-11-0255
   Ushida Y, 2013, ALCOHOL ALCOHOLISM, V48, P526, DOI 10.1093/alcalc/agt063
   ZHOU D, 1990, CANCER RES, V50, P6949
NR 54
TC 10
Z9 10
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2015
VL 14
IS 7
BP 1728
EP 1737
DI 10.1158/1535-7163.MCT-14-0672
PG 10
WC Oncology
SC Oncology
GA CM9UZ
UT WOS:000358055900020
PM 25976679
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Zhao, J
   Li, YP
   Zhang, Q
   Wang, YG
AF Zhao, Jing
   Li, Yanping
   Zhang, Qiong
   Wang, Yonggang
TI RETRACTED: Does ovarian stimulation for IVF increase gynaecological
   cancer risk? A systematic review and meta-analysis (Retracted article.
   See vol. 33, pg. 534, 2016)
SO REPRODUCTIVE BIOMEDICINE ONLINE
LA English
DT Article; Retracted Publication
DE breast cancer; cervical cancer; endometrial cancer; ovarian cancer;
   ovarian stimulation
ID IN-VITRO FERTILIZATION; ASSISTED REPRODUCTIVE TECHNOLOGY;
   GONADOTROPIN-RELEASING-HORMONE; POPULATION-BASED COHORT; FERTILITY
   DRUGS; BREAST-CANCER; ENDOMETRIAL CANCER; CERVICAL-CANCER; INFERTILE
   WOMEN; LUTEINIZING-HORMONE
AB The aim of this study was to evaluate whether ovarian stimulation for IVF increases the risk of gynaecological cancer, including ovarian, endometrial, cervical and breast cancers, as an independent risk factor. A systematic review and meta-analysis was conducted. Clinical trials that examined the association between ovarian stimulation for IVF and gynaecologic cancers were included. The outcomes of interest were incidence rate of gynaecologic cancers. Twelve cohort studies with 178,396 women exposed to IVF were included; 10 studies were used to analyse ovarian (167,640 women) and breast (151,702 women) cancers, and six studies were identified in the analysis of endometrial (116,672 women) and cervical cancer (114,799 women). Among these studies, 175 ovarian, 48 endometrial, 502 cervical and 866 cases of breast cancer were reported. The meta-analysis found no significant association between ovarian stimulation for IVF and increased ovarian, endometrial, cervical and breast cancer risk (odds ratio [OR] 1.06, 95% confidence interval [CI] 0.85 to 1.32; OR 0.97, 95% CI 0.58 to 1.63; OR 0.43, 95% CI 0.30 to 0.60; OR 0.69, 95% CI 0.63 to 0.76, respectively). Ovarian stimulation for IVF, therefore, does not increase the gynaecologic cancer risk, whether hormone-dependent endometrial and breast cancer or non-hormone-dependent ovarian and cervical cancer. (C) 2015 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
C1 [Zhao, Jing; Li, Yanping; Zhang, Qiong; Wang, Yonggang] Cent S Univ, Xiangya Hosp, Reprod Med Ctr, Changsha, Hunan, Peoples R China.
RP Li, YP (reprint author), Cent S Univ, Xiangya Hosp, Reprod Med Ctr, Changsha, Hunan, Peoples R China.
EM zhaojing19840427@sina.com
CR Akhmedkhanov A, 2001, ANN NY ACAD SCI, V943, P296, DOI 10.1111/j.1749-6632.2001.tb03811.x
   Akhmedkhanov A, 2001, AM J EPIDEMIOL, V154, P43, DOI 10.1093/aje/154.1.43
   Althuis MD, 2005, AM J EPIDEMIOL, V161, P607, DOI 10.1093/aje/kwi084
   Andersen AN, 2004, HUM REPROD, V19, P490, DOI 10.1093/humrep/deh129
   Appleby P, 2006, INT J CANCER, V119, P1108, DOI 10.1002/ijc.21953
   Ayhan A, 2004, ACTA OBSTET GYN SCAN, V83, P1104, DOI 10.1111/j.0001-6349.2004.00669.x
   Bamberger AM, 1998, HUM REPROD UPDATE, V4, P526, DOI 10.1093/humupd/4.5.526
   Boomsma CM, 2010, FERTIL STERIL, V94, P1764, DOI 10.1016/j.fertnstert.2009.10.044
   BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7
   Brinton LA, 2005, FERTIL STERIL, V83, P261, DOI 10.1016/j.fertnstert.2004.09.016
   Brinton L, 2007, REPROD BIOMED ONLINE, V15, P38, DOI 10.1016/S1472-6483(10)60689-X
   Brinton LA, 2013, FERTIL STERIL, V99, P1189, DOI 10.1016/j.fertnstert.2012.12.029
   Bu SZ, 1997, CANCER, V79, P1944, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V
   Bukovic Damir, 2011, Med Arh, V65, P312
   Calderon-Margalit R, 2009, AM J EPIDEMIOL, V169, P365, DOI 10.1093/aje/kwn318
   Calderon-Margalit R, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.06.057
   CDC, 2010, OUTL NAT PLAN PREV D
   Cetin I, 2008, PLACENTA, V29, pS169, DOI 10.1016/j.placenta.2008.08.007
   Choi JH, 2007, ENDOCR REV, V28, P440, DOI 10.1210/er.2006-0036
   Chung SH, 2010, TRENDS ENDOCRIN MET, V21, P504, DOI 10.1016/j.tem.2010.03.005
   Clinton GM, 1997, CRIT REV ONCOL HEMAT, V25, P1, DOI 10.1016/S1040-8428(96)00216-8
   CONN PM, 1994, ANNU REV MED, V45, P391, DOI 10.1146/annurev.med.45.1.391
   Connolly M, 2009, HUM REPROD, V24, P626, DOI 10.1093/humrep/den435
   Devesa M, 2010, MINERVA ENDOCRINOL, V35, P247
   Dor J, 2002, FERTIL STERIL, V77, P324, DOI 10.1016/S0015-0282(01)02986-7
   Doyle P, 2002, HUM REPROD, V17, P2209, DOI 10.1093/humrep/17.8.2209
   ESCOBEDO LG, 1991, OBSTET GYNECOL, V77, P124
   FISHEL S, 1989, BRIT MED J, V299, P309, DOI 10.1136/bmj.299.6694.309
   Garg PP, 1998, OBSTET GYNECOL, V92, P472, DOI 10.1016/S0029-7844(98)00139-2
   Glud E, 1998, EPIDEMIOL REV, V20, P237, DOI 10.1093/oxfordjournals.epirev.a017983
   Gregory CW, 2002, J CLIN ENDOCR METAB, V87, P2960, DOI 10.1210/jc.87.6.2960
   Homburg R, 1996, HUM REPROD, V11, P29
   HSIEH CC, 1993, INT J CANCER, V54, P81, DOI 10.1002/ijc.2910540114
   Huhtaniemi I, 2010, MOL CELL ENDOCRINOL, V329, P56, DOI 10.1016/j.mce.2010.04.028
   Impicciatore GG, 2011, CURR DRUG SAF, V6, P250, DOI 10.2174/157488611798280870
   Jensen A, 2008, AM J EPIDEMIOL, V168, P49, DOI 10.1093/aje/kwn094
   Jensen A, 2009, AM J EPIDEMIOL, V170, P1408, DOI 10.1093/aje/kwp290
   Jensen A, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b249
   Ji J, 2007, ENDOCR-RELAT CANCER, V14, P703, DOI 10.1677/ERC-07-0088
   Joo BS, 2010, FERTIL STERIL, V93, P442, DOI 10.1016/j.fertnstert.2009.02.066
   Kallen B, 2005, BJOG-INT J OBSTET GY, V112, P1529, DOI 10.1111/j.1471-0528.2005.00745.x
   Kallen B, 2011, HUM REPROD, V26, P253, DOI 10.1093/humrep/deq307
   Kallen B, 2008, BEST PRACT RES CL OB, V22, P549, DOI 10.1016/j.bpobgyn.2008.02.001
   Kanakas N, 2006, ANN NY ACAD SCI, V1092, P265, DOI 10.1196/annals.1365.022
   Kashyap S, 2004, OBSTET GYNECOL, V103, P785, DOI 10.1097/01.AOG.0000119226.39514.1d
   Kimberly Liu, 2012, Int J Gynaecol Obstet, V117, P95
   Konishi I, 2006, INT J GYNECOL CANCER, V16, P16, DOI 10.1111/j.1525-1438.2006.00425.x
   Konishi I, 1999, ONCOLOGY-BASEL, V57, P45, DOI 10.1159/000055274
   Kristiansson P, 2007, HUM REPROD, V22, P421, DOI 10.1093/humrep/de1411
   Land J. A., 2003, Human Reproduction (Oxford), V18, P455, DOI 10.1093/humrep/deg081
   Lerner-Geva L, 2010, WOMENS HEALTH, V6, P831, DOI 10.2217/WHE.10.67
   Liat LG, 2012, GYNECOL ENDOCRINOL, V28, P809, DOI 10.3109/09513590.2012.671391
   Liberati Alessandro, 2009, J Clin Epidemiol, V62, pe1, DOI 10.1016/j.jclinepi.2009.06.006
   MACLACHLAN V, 1989, NEW ENGL J MED, V320, P1233, DOI 10.1056/NEJM198905113201902
   Mahdavi A, 2006, FERTIL STERIL, V85, P819, DOI 10.1016/j.fertnstert.2005.08.061
   Meirow D, 1996, HUM REPROD UPDATE, V2, P63, DOI 10.1093/humupd/2.1.63
   Merviel P, 2009, GYNECOL OBSTET FERTI, V37, P926, DOI 10.1016/j.gyobfe.2009.06.007
   Navaratnarajah R, 2008, SEMIN REPROD MED, V26, P62, DOI 10.1055/s-2007-992926
   Nechuta S, 2010, CANCER CAUSE CONTROL, V21, P967, DOI 10.1007/s10552-010-9524-7
   Ness RB, 2003, AM J OBSTET GYNECOL, V189, P280, DOI 10.1067/mob.2003.408
   Ness RB, 2002, AM J EPIDEMIOL, V155, P217, DOI 10.1093/aje/155.3.217
   Nezhat F, 2002, CANCER-AM CANCER SOC, V94, P2935, DOI 10.1002/cncr.10566
   NOGUCHI T, 1993, J STEROID BIOCHEM, V44, P657, DOI 10.1016/0960-0760(93)90275-2
   Olivennes F, 2006, CLIN OBSTET GYNECOL, V49, P12, DOI 10.1097/01.grf.0000197520.53682.32
   Opdahl S, 2012, BRIT J CANCER, V107, P176, DOI 10.1038/bjc.2012.195
   Pappo I, 2008, ANN SURG ONCOL, V15, P1048, DOI 10.1245/s10434-007-9800-2
   Parikh S, 2003, INT J CANCER, V105, P687, DOI 10.1002/ijc.11141
   Raz R, 2012, PUBLIC HEALTH, V126, DOI 10.1016/j.puhe.2012.04.005
   Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774
   ROSSING MA, 1994, NEW ENGL J MED, V331, P771, DOI 10.1056/NEJM199409223311204
   Sergentanis TN, 2014, HUM REPROD UPDATE, V20, P106, DOI 10.1093/humupd/dmt034
   Silva ID, 2009, BRIT J CANCER, V100, P1824, DOI 10.1038/sj.bjc.6605086
   Siristatidis C, 2013, HUM REPROD UPDATE, V19, P105, DOI 10.1093/humupd/dms051
   Sovino Hugo, 2002, Reprod Biomed Online, V4, P303
   Stephen EH, 1998, FERTIL STERIL, V70, P30, DOI 10.1016/S0015-0282(98)00103-4
   Stewart LM, 2013, GYNECOL ONCOL, V129, P372, DOI 10.1016/j.ygyno.2013.01.027
   Stewart LM, 2012, FERTIL STERIL, V98, P334, DOI 10.1016/j.fertnstert.2012.04.019
   van Hamont D, 2006, HUM REPROD, V21, P2359, DOI 10.1093/humrep/del132
   van Leeuwen FE, 2011, HUM REPROD, V26, P3456, DOI 10.1093/humrep/der322
   Varras M, 2003, EUR J GYNAECOL ONCOL, V24, P258
   Venn A, 2003, BEST PRACT RES CL OB, V17, P343, DOI 10.1053/ybeog.2003.350
   VENN A, 1995, LANCET, V346, P995, DOI 10.1016/S0140-6736(95)91687-3
   Venn A, 1999, LANCET, V354, P1586, DOI 10.1016/S0140-6736(99)05203-4
   Vlahos NF, 2010, ANN NY ACAD SCI, V1205, P214, DOI 10.1111/j.1749-6632.2010.05668.x
   Vlahos NF, 2010, BEST PRACT RES CL OB, V24, P39, DOI 10.1016/j.bpobgyn.2009.08.004
   WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427
   Wright Victoria Clay, 2005, Morbidity and Mortality Weekly Report, V54, P1
   Yli-Kuha AN, 2012, HUM REPROD, V27, P1149, DOI 10.1093/humrep/des031
   Zreik TG, 2008, CURR OPIN OBSTET GYN, V20, P313, DOI 10.1097/GCO.0b013e3282fdc6c3
   Zreik TG, 2010, BREAST CANCER RES TR, V124, P13, DOI 10.1007/s10549-010-1140-4
NR 90
TC 9
Z9 10
U1 2
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1472-6483
EI 1472-6491
J9 REPROD BIOMED ONLINE
JI Reprod. Biomed. Online
PD JUL
PY 2015
VL 31
IS 1
BP 20
EP 29
DI 10.1016/j.rbmo.2015.03.008
PG 10
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA CM0TU
UT WOS:000357392300005
PM 26003452
DA 2018-12-27
ER

PT J
AU Li, J
   Li, XC
   Wang, JP
   Wang, Y
   Qiu, HF
AF Li, Jing
   Li, Xiaocui
   Wang, Jingpu
   Wang, Yuan
   Qiu, Haifeng
TI RETRACTED: MicroRNA-218 increases cellular sensitivity to Rapamycin via
   targeting Rictor in cervical cancer (Retracted article. See vol. 125,
   pg. 176, 2017)
SO APMIS
LA English
DT Article; Retracted Publication
DE MicroRNA-218; mTOR signal pathway; mTORC1; mTORC2; Rictor; cervical
   cancer
ID MTOR SIGNALING PATHWAY; CERVICAL-CANCER CELLS; CLINICAL-TRIALS GROUP;
   PHASE-II; CARCINOMA; RECURRENT; TEMSIROLIMUS; EXPRESSION; STATISTICS;
   ACTIVATION
AB We previously reported that microRNA-218 was frequently lost in cervical cancer and restoration of microRNA-218 increased cellular radio-sensitivity via inhibiting. Herein, we aim to investigate the effects of microRNA-218 on cellular response to mTOR inhibition. The expression of microRNA-218 and Rictor were measured by Taqman PCR and real time PCR in a panel of 15 cervical cancer tissues. MicroRNA-218 was stably overexpressed in four cervical cancer cell lines and a series of in vitro and in vivo experiments were performed to investigate cellular sensitivity to Rapamycin. In primary cultured cervical cancer cells, the expression of microRNA-218 was negatively correlated with the mRNA level of Rictor, which predicted cellular sensitivity to Rapamycin (p=0.002, R-2=0.6810). In vitro, overexpression of microRNA-218 significantly reduced the level of Rictor and enhanced the growth-inhibition, cell cycle arrest, and apoptosis induced by Rapamycin. In vivo, overexpression of microRNA-218 further enhanced the suppressive effects of Rapamycin on tumor growth. In conclusion, we demonstrated that microRNA-218 could re-sensitize cervical cancer to Rapamycin through targeting Rictor. Moreover, patients with loss of microRNA-218 presented notable resistance to Rapamycin, indicating that microRNA-218 might be a valid marker for patients-stratification in future clinical trials.
C1 [Li, Jing] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou 450052, Henan Province, Peoples R China.
   [Li, Jing; Qiu, Haifeng] Zhengzhou Univ, Affiliated Hosp 1, Inst Clin Med, Zhengzhou 450052, Henan Province, Peoples R China.
   [Li, Xiaocui] Shanghai Jiao Tong Univ, Dept Gynecol, Int Peace Matern & Child Hlth Hosp, Shanghai 200030, Peoples R China.
   [Wang, Jingpu] Yantai Longkuang Ctr Hosp, Special Inspect Dept, Yantai, Peoples R China.
   [Wang, Yuan] Jiangnan Univ, Dept Obstet & Gynecol, Affiliated Hosp, Wuxi, Peoples R China.
   [Qiu, Haifeng] Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Zhengzhou 450052, Henan Province, Peoples R China.
RP Qiu, HF (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Zhengzhou 450052, Henan Province, Peoples R China.
EM haifengqiu120@gmail.com
FU Scientific Bureau of Wuxi [CSE31N1418]; Health Bureau of Wuxi [MS201417,
   FYKY201401]
FX Our study was supported by grants from the Scientific Bureau of Wuxi
   (CSE31N1418) and the Health Bureau of Wuxi (MS201417, FYKY201401) to
   Yuan Wang.
CR Albanell J, 2007, CLIN TRANSL ONCOL, V9, P484, DOI 10.1007/s12094-007-0092-6
   Banerjee R, 2014, IN J WOMENS HEALTH, V6, P555, DOI 10.2147/IJWH.S46247
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Behbakht K, 2011, GYNECOL ONCOL, V123, P19, DOI 10.1016/j.ygyno.2011.06.022
   Chen WQ, 2014, CHINESE J CANCER RES, V26, P48, DOI 10.3978/j.issn.1000-9604.2014.01.08
   Ding H, 2014, ASIAN PAC J CANCER P, V15, P1675, DOI 10.7314/APJCP.2014.15.4.1675
   Feng W, 2009, INT J CLIN EXP PATHO, V2, P249
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Ji J, 2010, GYNECOL ONCOL, V117, P103, DOI 10.1016/j.ygyno.2009.12.020
   Jiang BH, 2013, CURR CANCER DRUG TAR, V13, P233, DOI 10.2174/1568009611313030001
   Kim MK, 2010, J GYNECOL ONCOL, V21, P181, DOI 10.3802/jgo.2010.21.3.181
   Martin SK, 2015, STEM CELLS, V33, P1359, DOI 10.1002/stem.1931
   Molinolo AA, 2012, CLIN CANCER RES, V18, P2558, DOI 10.1158/1078-0432.CCR-11-2824
   Oza AM, 2011, J CLIN ONCOL, V29, P3278, DOI 10.1200/JCO.2010.34.1578
   Proud CG, 2009, BIOCHEM SOC T, V37, P227, DOI 10.1042/BST0370227
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Slomovitz BM, 2010, CANCER-AM CANCER SOC, V116, P5415, DOI 10.1002/cncr.25515
   Tinker AV, 2013, GYNECOL ONCOL, V130, P269, DOI 10.1016/j.ygyno.2013.05.008
   Villegas-Ruiz V, 2014, INT J CLIN EXP PATHO, V7, P1389
   Wan G, 2014, AUTOPHAGY, V10, P70, DOI 10.4161/auto.26534
   Wang L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0934-3
   Wang Y, 2014, INT J MED SCI, V11, P691, DOI 10.7150/ijms.8880
   Yee GPC, 2013, CURR CANCER DRUG TAR, V13, P205
   Yu JJ, 2012, J CANCER RES CLIN, V138, P671, DOI 10.1007/s00432-012-1147-9
   Zhang XY, 2008, EUR J OBSTET GYN R B, V139, P237, DOI 10.1016/j.ejogrb.2007.12.021
NR 30
TC 5
Z9 5
U1 4
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
EI 1600-0463
J9 APMIS
JI APMIS
PD JUL
PY 2015
VL 123
IS 7
BP 562
EP 570
DI 10.1111/apm.12387
PG 9
WC Immunology; Microbiology; Pathology
SC Immunology; Microbiology; Pathology
GA CL5AU
UT WOS:000356972400003
PM 25908215
DA 2018-12-27
ER

PT J
AU Tayeb, HT
   Bakheet, DH
   Zaza, K
   Wakil, SM
   Dzimiri, N
AF Tayeb, Hamsa T.
   Bakheet, Dana H.
   Zaza, Khaled
   Wakil, Salma M.
   Dzimiri, Nduna
TI RETRACTED: Genotyping of CYP2C19 polymorphisms and its clinical
   validation in the ethnic Arab population (Retracted article. See vol.
   68, pg. 421, 2016)
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article; Retracted Publication
DE CYP2C19 polymorphisms; data validation; intra-ethical difference;
   personalized medicine; SNP arrays
ID PERCUTANEOUS CORONARY INTERVENTION; OF-FUNCTION POLYMORPHISM; SEROTONIN
   REUPTAKE INHIBITORS; TREATMENT PLATELET REACTIVITY; GENETIC
   POLYMORPHISMS; CYP2C19-ASTERISK-17 ALLELE; CLOPIDOGREL RESPONSIVENESS;
   LINKAGE DISEQUILIBRIUM; RESPONSE VARIABILITY; S-MEPHENYTOIN
AB ObjectivesThe drug-metabolizing enzymes and transporters (DMET) Plus microarray and x-Tag assays have recently been developed for genotyping individuals in personalized medicine. Furthermore, the cytochrome 450-2C19 (CYP2C19) is a key metabolic enzyme encoded by a polymorphic gene commonly associated with diminished metabolism and variable clinical responses to several drugs in an ethnicity-dependent fashion. Therefore, validation of these clinical procedures as well as knowledge of the ethnic-specific incidences of these gene variants is prerequisite for determining their clinical relevance in any given population.
   MethodsWe determined the distribution of familiar CYP2C19 variants by the DMET Plus chip in 600 candidates and replicated the findings by the Affymetrix Axiom Genome-Wide Asian Structure Identification Array in 5413 individuals, all Saudis of ethic Arab origin. We then tested the robustness of employing the Luminex xMAP system clinically by comparing the results of genotyping 500 Saudi individuals visiting the Blood Bank of our institution with the findings of the two platforms.
   Key findingsThe DMET Plus genotyping revealed that eight of the CYP2C19 variants showed some changes. Thereby, the CYP2C19*17 exhibited the highest minor allele frequency (MAF) of 0.256, followed by the CYP2C19_801 (frequency=0.055). Six other variants, including the CYP2C19*3, showed MAF in the range of 0.001-0.002. We replicated the frequencies of the CYP2C19*17 and CYP2C19*3, and additionally established that of the CYP2C19*2 (0.099) using the Axiom platform. The xTag genotyping also indicated that 0.834 of the 500 Saudi individuals were extensive metabolizers (*1/*1), 0.158 carried the *1/*2 genotype, 0.01% carried *2/*2 (poor metabolizers) and one each (0.2%) harboured the *1/*8, *2/*3 (intermediate metabolizers) and *8/*8 (poor metabolizers) genotypes.
   ConclusionsThe results showed reproducible genotyping of the CYP2C19 variants in the Saudi Arab population using two Affymetrix platforms and phenotyping using the Luminex xTag assay. The prevalence of two clinically relevant genotypes (CYP2C19*2 and CYP2C19*3) were similar to other ethnic groups, while that of the CYP2C19*17 was comparably higher.
C1 [Tayeb, Hamsa T.; Bakheet, Dana H.; Wakil, Salma M.; Dzimiri, Nduna] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh 11211, Saudi Arabia.
   [Zaza, Khaled] Al Faisal Univ, Fac Med, Riyadh, Saudi Arabia.
RP Dzimiri, N (reprint author), King Faisal Specialist Hosp & Res Ctr, Dept Genet, MBC 03-05,POB 3354, Riyadh 11211, Saudi Arabia.
EM dzimiri@kfshrc.edu.sa
FU King Faisal Specialist Hospital [13-MED1171-20]
FX This study was funded by the King Faisal Specialist Hospital through the
   Royal Research grant number 13-MED1171-20, for which the authors express
   their deep-felt gratitude. We would also like to thank Abdul Kareem,
   Hamoud AlHarbi and Mohammed Hamad AlKhudiry for the assistance rendered
   in carrying out the experimental work.
CR Al-Jenoobi FI, 2013, BASIC CLIN PHARMACOL, V112, P50, DOI 10.1111/j.1742-7843.2012.00919.x
   Beelen K, 2013, BREAST CANCER RES TR, V139, P649, DOI 10.1007/s10549-013-2568-0
   Boso V, 2013, DRUG METAB DISPOS, V41, P480, DOI 10.1124/dmd.112.047977
   Bramness JG, 2003, PHARMACOGENETICS, V13, P383, DOI 10.1097/01.fpc.0000054098.48725.88
   Brandt JT, 2007, J THROMB HAEMOST, V5, P2429, DOI 10.1111/j.1538-7836.2007.02775.x
   Collet JP, 2009, LANCET, V373, P309, DOI 10.1016/S0140-6736(08)61845-0
   Coutts RT., 1994, J PSYCHIAT NEUROSCI, V19, P30
   Cuisset T, 2012, JACC-CARDIOVASC INTE, V5, P1280, DOI 10.1016/j.jcin.2012.07.015
   DEHENAUW S, 1994, INT J EPIDEMIOL, V23, P465
   Dunbar L, 2009, NEW ZEAL MED J, V122, P29
   Fagerholm U, 2007, J PHARM PHARMACOL, V59, P1463, DOI 10.1211/jpp.59.11.0002
   Ferguson RJ, 1998, J PHARMACOL EXP THER, V284, P356
   Fontana P, 2007, J THROMB HAEMOST, V5, P2153, DOI 10.1111/j.1538-7836.2007.02722.x
   Geisler T, 2008, PHARMACOGENOMICS, V9, P1251, DOI 10.2217/14622416.9.9.1251
   Giusti B, 2007, PHARMACOGENET GENOM, V17, P1057, DOI 10.1097/FPC.0b013e3282f1b2be
   Hardenbol P, 2003, NAT BIOTECHNOL, V21, P673, DOI 10.1038/nbt821
   Ibeanu GC, 1998, PHARMACOGENETICS, V8, P129, DOI 10.1097/00008571-199804000-00006
   Ingelman-Sundberg M, 2007, PHARMACOL THERAPEUT, V116, P496, DOI 10.1016/j.pharmthera.2007.09.004
   Jaja C, 2008, COMMUNITY GENET, V11, P141, DOI 10.1159/000113876
   Jakovski K, 2013, PHARMAZIE, V68, P893, DOI 10.1691/ph.2013.3579
   Jazdzewski K, 2011, J CLIN ENDOCR METAB, V96, pE546, DOI 10.1210/jc.2010-1594
   Kazui M, 2010, DRUG METAB DISPOS, V38, P92, DOI 10.1124/dmd.109.029132
   Kim KA, 2008, CLIN PHARMACOL THER, V84, P236, DOI 10.1038/clpt.2008.20
   Kim KA, 2010, J CLIN PHARM THER, V35, P697, DOI 10.1111/j.1365-2710.2009.01069.x
   Kurose K, 2012, DRUG METAB PHARMACOK, V27, P9, DOI 10.2133/dmpk.DMPK-11-RV-111
   Kurzawski M, 2006, EUR J CLIN PHARMACOL, V62, P877, DOI 10.1007/s00228-006-0183-2
   Lewis JP, 2013, J THROMB HAEMOST, V11, P1640, DOI 10.1111/jth.12342
   Li-Wan-Po A, 2010, BRIT J CLIN PHARMACO, V69, P222, DOI 10.1111/j.1365-2125.2009.03578.x
   Matakidou A, 2004, CARCINOGENESIS, V25, P369, DOI 10.1093/carcin/bgh027
   Mazer-Amirshahi M, 2013, J CLIN PHARMACOL, V53, P359, DOI 10.1002/jcph.18
   McGraw J, 2012, EXPERT OPIN DRUG MET, V8, P371, DOI 10.1517/17425255.2012.657626
   Mega JL, 2009, CIRCULATION, V119, P2553, DOI 10.1161/CIRCULATIONAHA.109.851949
   Mejin M, 2013, INT J CLIN PHARM-NET, V35, P621, DOI 10.1007/s11096-013-9783-y
   Mihaljevic-Peles A, 2010, PSYCHIAT DANUB, V22, P335
   Musumba CO, 2013, CLIN PHARMACOL THER, V93, P195, DOI 10.1038/clpt.2012.215
   Namazi S, 2012, BIOCHEM PHARMACOL, V83, P903, DOI 10.1016/j.bcp.2012.01.003
   Oestreich JH, 2014, AM HEART J, V167, P413, DOI 10.1016/j.ahj.2013.10.028
   Park MW, 2013, PHARMACOGENET GENOM, V23, P558, DOI 10.1097/FPC.0b013e328364eb92
   Pedersen RS, 2013, CLIN EXP PHARMACOL P, V40, P683, DOI 10.1111/1440-1681.12153
   Pedersen RS, 2010, EUR J CLIN PHARMACOL, V66, P1199, DOI 10.1007/s00228-010-0864-8
   Pendyala LK, 2013, AM HEART J, V166, P266, DOI 10.1016/j.ahj.2013.04.008
   Pimenoff VN, 2012, PHARMACOGENET GENOM, V22, P846, DOI 10.1097/FPC.0b013e32835a3a6d
   Polimanti R, 2012, PHARMACOGENOMICS, V13, P1951, DOI [10.2217/pgs.12.163, 10.2217/PGS.12.163]
   Preskorn SH, 1997, CLIN PHARMACOKINET, V32, P1, DOI 10.2165/00003088-199700321-00003
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ragia G, 2009, PHARMACOGENOMICS, V10, P43, DOI 10.2217/14622416.10.1.43
   Rehmel JLF, 2006, DRUG METAB DISPOS, V34, P600, DOI 10.1124/dmd.105.007989
   Riemann K, 2008, PHARMACOGENET GENOM, V18, P999, DOI 10.1097/FPC.0b013e3283117d79
   Rothenbacher D, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-61
   Saeed LH, 2013, INT J MED SCI, V10, P1497, DOI 10.7150/ijms.6795
   Santos PCJL, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-13
   Shalia Kavita K, 2013, Indian Heart J, V65, P158, DOI 10.1016/j.ihj.2013.02.012
   Sibbing D, 2009, EUR HEART J, V30, P916, DOI 10.1093/eurheartj/ehp041
   Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227
   Sipeky C, 2013, MOL BIOL REP, V40, P4727, DOI 10.1007/s11033-013-2569-4
   Subraja K, 2013, EUR J CLIN PHARMACOL, V69, P415, DOI 10.1007/s00228-012-1381-8
   Sugimoto K, 2008, BRIT J CLIN PHARMACO, V65, P437, DOI 10.1111/j.1365-2125.2007.03057.x
   Sukasem C, 2013, PHARMACOGN PERS MED, V6, P85, DOI 10.2147/PGPM.S42332
   Sviri S, 1999, CLIN PHARMACOL THER, V65, P275, DOI 10.1016/S0009-9236(99)70106-2
   Tamm R, 2008, CLIN CHEM LAB MED, V46, P974, DOI 10.1515/CCLM.2008.187
   Taylor MRG, 2009, PHARMACOGENET GENOM, V19, P35, DOI 10.1097/FPC.0b013e328317cc57
   Tribut Olivier, 2002, Med Sci Monit, V8, pRA152
   Tsai SJ, 2008, PHARMACOGENOMICS, V9, P1353, DOI 10.2217/14622416.9.9.1353
   Vaswani M, 2003, PROG NEURO-PSYCHOPH, V27, P85, DOI 10.1016/S0278-5846(02)00338-X
   Vicente J, 2014, MOL BIOL REP, V41, P1267, DOI 10.1007/s11033-013-2971-y
   Wang TH, 2014, AAPS J, V16, P206, DOI 10.1208/s12248-013-9535-x
   Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815
   Zhang LN, 2013, THROMB RES, V132, P81, DOI 10.1016/j.thromres.2013.05.006
NR 68
TC 1
Z9 2
U1 3
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD JUL
PY 2015
VL 67
IS 7
BP 972
EP 979
DI 10.1111/jphp.12391
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA CL1CZ
UT WOS:000356681400008
PM 25684066
DA 2018-12-27
ER

PT J
AU Zhao, S
   Gao, BY
   Yue, QY
   Song, WC
   Jia, RB
   Liu, P
AF Zhao, Shuang
   Gao, Baoyu
   Yue, Qinyan
   Song, Wuchang
   Jia, Ruibao
   Liu, Pan
TI RETRACTED: Evaluation of floc properties and membrane fouling in
   coagulation-ultrafiltration system: The role of enteromorpha
   polysaccharides (Retracted article. See vol. 397, pg. 215, 2016)
SO DESALINATION
LA English
DT Article; Retracted Publication
DE Enteromorpha polysaccharides; Coagulation-ultrafiltration; Humic acid
   removal; Floc properties; Membrane fouling
ID FLOCCULATION; WATER; SIZE; FILTRATION; STRENGTH; BEHAVIOR; REMOVAL;
   SALTS
AB The effects of a new coagulant aid - enteromorpha polysaccharides (Ep) on floc characteristics and the subsequent membrane fouling were investigated in this paper. Ep was used with polyaluminum chloride (PACl) to improve HA removal efficiency, and the variations of floc characteristics ascribed to the addition of Ep were studied systematically. Moreover, membrane fouling caused by coagulation effluent was also investigated using a dead-end batch ultrafiltration unit. Experiment results showed that the addition of adequate Ep could improve HA removal efficiency, and the optimal Ep dosage was 0.3 mg/L. Floc sizes, growth rates and their recovery abilities could be improved apparently due to Ep addition, while the fragile and much loosely constructed flocs were obtained. In addition, the results of ultrafiltration experiments indicated that when Ep was used, membrane fouling could be significantly reduced due to the loosely structured flocs. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zhao, Shuang; Gao, Baoyu; Yue, Qinyan; Liu, Pan] Shandong Univ, Shandong Key Lab Water Pollut Control & Resource, Sch Environm Sci & Engn, Jinan 250100, Peoples R China.
   [Song, Wuchang; Jia, Ruibao] Jinan Water & Wastewater Monitoring Ctr, Jinan 250033, Peoples R China.
RP Gao, BY (reprint author), Shandong Univ, Shandong Key Lab Water Pollut Control & Resource, Sch Environm Sci & Engn, Jinan 250100, Peoples R China.
EM baoyugao_sdu@aliyun.com
FU National Natural Science Foundation of China [51478250]; Shanghai Tongji
   Gao Tingyao Environmental Science and Technology Development Foundation
   (STGEF); Science and Technology Program for Public Wellbeing
   [2013GS370202-004]
FX This work was supported by the National Natural Science Foundation of
   China (No. 51478250), Shanghai Tongji Gao Tingyao Environmental Science
   and Technology Development Foundation (STGEF), and the Science and
   Technology Program for Public Wellbeing (No. 2013GS370202-004). The kind
   suggestions from the anonymous reviewers are highly appreciated.
CR Aguilar MI, 2002, WATER RES, V36, P2910, DOI 10.1016/S0043-1354(01)00508-5
   Biggs CA, 2000, WATER RES, V34, P2542, DOI 10.1016/S0043-1354(99)00431-5
   Blankert B, 2007, J MEMBRANE SCI, V301, P39, DOI 10.1016/j.memsci.2007.05.033
   Bridgeman J, 2008, CHEM ENG RES DES, V86, P941, DOI 10.1016/j.cherd.2008.02.007
   Carroll T, 2000, WATER RES, V34, P2861, DOI 10.1016/S0043-1354(00)00051-8
   Choo KH, 2007, DESALINATION, V202, P262, DOI 10.1016/j.desal.2005.12.063
   Costa AR, 2005, J MEMBRANE SCI, V255, P49, DOI 10.1016/j.memsci.2005.01.016
   Divakaran R, 2002, WATER RES, V36, P2414, DOI 10.1016/S0043-1354(01)00436-5
   Fong P, 2004, AQUAT BOT, V78, P83, DOI 10.1016/j.aquabot.2003.09.006
   [高宝玉 Gao Baoyu], 2005, [环境化学, Environmental Chemistry], V24, P569
   Hauxwell J, 2001, ECOLOGY, V82, P1007, DOI 10.1890/0012-9658(2001)082[1007:MCCTEZ]2.0.CO;2
   Hayden HS, 2003, EUR J PHYCOL, V38, P277, DOI 10.1080/1364253031000136321
   Hu CZ, 2006, ENVIRON SCI TECHNOL, V40, P325, DOI 10.1021/es051423+
   Korbutowicz M.K., 2005, DESALINATION, V174, P13
   Lee JD, 2000, ENVIRON SCI TECHNOL, V34, P3780, DOI 10.1021/es9907461
   Li DM, 2010, CHEM ENG RES DES, V88, P647, DOI 10.1016/j.cherd.2009.10.011
   Li WW, 2008, BIORESOURCE TECHNOL, V99, P6893, DOI 10.1016/j.biortech.2008.01.050
   Lin Y.T., 2009, FEED IND, V30, P46
   Ozacar M, 2003, COLLOID SURFACE A, V229, P85, DOI 10.1016/j.colsurfa.2003.07.006
   Ozacar Mahmut, 2003, Turkish Journal of Engineering and Environmental Sciences, V27, P227
   Panek D, 2009, DESALINATION, V241, P197, DOI 10.1016/j.desa1.2007.11.085
   Park PK, 2006, ENVIRON SCI TECHNOL, V40, P2699, DOI 10.1021/es0515304
   Pefferkorn E, 2006, ADV COLLOID INTERFAC, V120, P33, DOI 10.1016/j.cis.2006.01.003
   Qi XH, 2012, CARBOHYD POLYM, V90, P1804, DOI 10.1016/j.carbpol.2012.07.077
   Richardson SD, 2003, TRAC-TREND ANAL CHEM, V22, P666, DOI 10.1016/S0165-9936(03)01003-3
   Rieker TP, 2000, LANGMUIR, V16, P5588, DOI 10.1021/la991636a
   Tian JY, 2010, WATER RES, V44, P59, DOI 10.1016/j.watres.2009.08.053
   Wang J, 2008, J MEMBRANE SCI, V321, P132, DOI 10.1016/j.memsci.2008.04.008
   Wang Y, 2008, CHEM ENG J, V142, P175, DOI 10.1016/j.cej.2007.11.022
   Wang Y, 2009, J COLLOID INTERF SCI, V332, P354, DOI 10.1016/j.jcis.2009.01.002
   Wei JC, 2009, WATER RES, V43, P724, DOI 10.1016/j.watres.2008.11.004
   Xiao F, 2010, DESALINATION, V250, P902, DOI 10.1016/j.desal.2008.12.050
   Yu WZ, 2009, POWDER TECHNOL, V189, P439, DOI 10.1016/j.powtec.2008.07.008
   Yukselen MA, 2004, INT J MINER PROCESS, V73, P251, DOI 10.1016/S0301-7516(03)00077-2
   Zhou Q, 2000, IND WATER TREAT, V20, P18
NR 35
TC 2
Z9 4
U1 7
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0011-9164
EI 1873-4464
J9 DESALINATION
JI Desalination
PD JUL 1
PY 2015
VL 367
BP 126
EP 133
DI 10.1016/j.desal.2015.03.041
PG 8
WC Engineering, Chemical; Water Resources
SC Engineering; Water Resources
GA CJ3GN
UT WOS:000355371500013
DA 2018-12-27
ER

PT J
AU Huang, P
   Wu, J
   Li, XM
   Liu, XZ
   Li, YH
   Cui, GH
AF Huang, Ping
   Wu, Jun
   Li, Ximeng
   Liu, Xiaozheng
   Li, Yinghuan
   Cui, Guohui
TI RETRACTED: RGD Peptide-Pegylated PLLA Nanoparticles Containing
   Epirubicin Hydrochloride Exhibit Receptor-Dependent Tumor Trafficking In
   Vitro and In Vivo (Retracted article. See vol. 33, pg. 1050, 2016)
SO PHARMACEUTICAL RESEARCH
LA English
DT Article; Retracted Publication
DE cellular uptake; nanoparticles; PEG; RGD; tumor targeting
ID LIPOSOMAL DOXORUBICIN; TARGETED DELIVERY; CANCER; CHEMOTHERAPY;
   PACLITAXEL; DOCETAXEL; MICELLES; RELEASE; BINDING; MODEL
AB A novel hydrophilic conjugate of arginine-glycine-aspartic acid (RGD) and polyethylene glycol (PEG), i.e., RGD-PEG (Mw) (M (W) = 300, 600, 1000 or 4000), was synthesized and employed in epirubicin (EPI) loaded poly L-lactic acid (PLLA) nanoparticles (NPs) to improve its tumor targeting effect.
   In vitro studies were performed to assess EPI release from NPs in tumor-mimic acidic medium, cytotoxicity and cell cycle assay in HepG2 cells, and cellular uptake kinetics in four types of tumor cells including A375 cells (high integrin receptor expression), HeLa cells (low integrin receptor expression), and metabolic HepG2/SMMC7721 cells. In vivo pharmacodynamics (PD) and pharmacokinetic (PK) studies were determined in a murine ascites tumor model.
   Cellular uptake kinetics showed integrin receptor-dependent binding and internalization. In vitro release results showed that PLLA and PEG groups retarded EPI release from NPs and promoted drug release amount in acidic medium, which benefited in vivo trafficking to the acidic tumors. In vivo PD and PK studies revealed that RGD-PEG (Mw) (M (W) = 600 similar to 1000) improved tumor targeting capacity of NPs by similar to 2.4-fold, compared to conventional EPI NPs.
   RGD-PEG (Mw) (M (W) = 600 similar to 1000) modified PLLA NPs provide a promising strategy to improve tumor selectivity in cancer treatment.
C1 [Huang, Ping; Li, Ximeng; Liu, Xiaozheng; Li, Yinghuan; Cui, Guohui] Capital Med Univ, Sch Chem Biol & Pharmaceut Sci, Beijing 100069, Peoples R China.
   [Wu, Jun] Univ S Carolina, Coll Pharm, Greenville, SC 29607 USA.
RP Li, YH (reprint author), Capital Med Univ, Sch Chem Biol & Pharmaceut Sci, 10 Xitoutiao, Beijing 100069, Peoples R China.
EM liyinghuan@ccmu.edu.cn; cgh@ccmu.edu.cn
FU National Natural Science Foundation of China [81202486]; Beijing Natural
   Science Foundation [7133228]
FX This research was supported by the National Natural Science Foundation
   of China Grant 81202486 and Beijing Natural Science Foundation Grant
   7133228.
CR Bellis SL, 2011, BIOMATERIALS, V32, P4205, DOI 10.1016/j.biomaterials.2011.02.029
   Borgne-Sanchez A, 2007, CELL DEATH DIFFER, V14, P422, DOI 10.1038/sj.cdd.4402018
   Chang LC, 2009, INT J PHARMACEUT, V376, P195, DOI 10.1016/j.ijpharm.2009.04.045
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Du HR, 2011, MOL PHARMACEUT, V8, P1224, DOI 10.1021/mp200039s
   Fairbanks BD, 2009, MACROMOLECULES, V42, P211, DOI 10.1021/ma801903w
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Jiang XY, 2011, BIOMATERIALS, V32, P9457, DOI 10.1016/j.biomaterials.2011.08.055
   Kim J, 2011, BIOMATERIALS, V32, P5158, DOI 10.1016/j.biomaterials.2011.03.084
   Kim KL, 2009, BIOMATERIALS, V30, P3742, DOI 10.1016/j.biomaterials.2009.03.053
   Ko J, 2007, J CONTROL RELEASE, V123, P109, DOI 10.1016/j.jconrel.2007.07.012
   Li YH, 2004, J CONTROL RELEASE, V95, P381, DOI 10.1016/j.jconrel.2003.11.023
   Li YH, 2014, INT J PHARMACEUT, V468, P133, DOI 10.1016/j.ijpharm.2014.04.001
   Li YH, 2012, ADV DRUG DELIVER REV, V64, P29, DOI 10.1016/j.addr.2011.04.006
   Li YH, 2011, AAPS J, V13, P585, DOI 10.1208/s12248-011-9298-1
   Mao SR, 2005, BIOMATERIALS, V26, P6343, DOI 10.1016/j.biomaterials.2005.03.036
   Miller JS, 2010, BIOMATERIALS, V31, P3736, DOI 10.1016/j.biomaterials.2010.01.058
   Ogawara KI, 2004, HUM GENE THER, V15, P433, DOI 10.1089/10430340460745766
   Pan H, 2008, J CONTROL RELEASE, V125, P228, DOI 10.1016/j.jconrel.2007.10.016
   Park HS, 2002, BIOPOLYMERS, V63, P298, DOI 10.1002/bip.10067
   Shao W, 2013, BIOMATERIALS, V34, P10109, DOI 10.1016/j.biomaterials.2013.09.007
   Shiraga E, 2008, INT J PHARM, V353, P65, DOI 10.1016/j.ijpharm.2007.11.020
   Song WT, 2014, BIOMATERIALS, V35, P3005, DOI 10.1016/j.biomaterials.2013.12.018
   Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142-9612(00)00193-9
   Wang F, 2012, J PHARM SCI-US, V101, P4559, DOI 10.1002/jps.23326
   Xu Q, 2012, BIOMATERIALS, V33, P1627, DOI 10.1016/j.biomaterials.2011.11.012
   Yang HW, 2012, BIOMATERIALS, V33, P3919, DOI 10.1016/j.biomaterials.2012.02.020
   Zhang HZ, 2009, COLLOID SURFACE B, V71, P19, DOI 10.1016/j.colsurfb.2008.12.039
   Zhang QW, 2012, BIOMATERIALS, V33, P5067, DOI 10.1016/j.biomaterials.2012.03.063
   Zhang Y, 2002, BIOMATERIALS, V23, P1553, DOI 10.1016/S0142-9612(01)00267-8
NR 30
TC 3
Z9 3
U1 4
U2 55
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD JUL
PY 2015
VL 32
IS 7
BP 2328
EP 2343
DI 10.1007/s11095-015-1625-2
PG 16
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA CJ1SH
UT WOS:000355264100016
PM 25592551
DA 2018-12-27
ER

PT J
AU Taat, AR
   Akbari, H
   Naghash, HJ
AF Taat, Ahmad R.
   Akbari, Hamideh
   Naghash, Hamid Javaherian
TI RETRACTED: Synthesis and characterization of three novel alkoxysilanes
   and their uses in the acrylate functionalized alkyds through free
   radical copolymerization (Retracted article. See vol. 121, pg. 265.
   2018)
SO PROGRESS IN ORGANIC COATINGS
LA English
DT Article; Retracted Publication
DE Coatings; Allyl-containing alkoxysilanes; Hybrid copolymer; Free radical
   chemistry; Acrylated-alkyds
ID HYBRID MINIEMULSION POLYMERIZATION; EMULSION COPOLYMERS; FILM
   PROPERTIES; GRAFTING MECHANISMS; SILICONE
AB Three novel allyl-containing alkoxysilanes, allyl 3-(trimethoxysilyl) propyl ether (ATSE), allyl 3-(trimethoxysilyl) propyl thioether (ATST) and 4-(trimethoxysilyl) propyloxy-4-methacryloxydiphenyl sulfone (TSMS) were prepared by the condensation reaction of allyl alcohol with chloropropyltrimethoxysilane (CPTS), allyl chloride with (3-mercaptopropyl)-trimethoxysilane (MPTS) and methacrylic acid with bis (4-hydroxyphenyl) sulfone and also with CPTS, respectively. Also acrylic groups were hybrid with alkyds via free radical chemistry. The alkyd comprised soybean oil, glycerol and phthalic anhydride. To closely model acrylated-alkyds, a mixture of acrylic monomers were copolymerized with the alkyd including: methyl methacrylate (MMA), butyl acrylate (BA), methacrylic acid (MM), and alkoxysilanes ATSE, ATST and/or MPTS. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Taat, Ahmad R.; Akbari, Hamideh; Naghash, Hamid Javaherian] Islamic Azad Univ, Dept Chem, Shahreza Branch, Shahreza 86145, Isfahan, Iran.
RP Naghash, HJ (reprint author), Islamic Azad Univ, Dept Chem, Shahreza Branch, POB 311, Shahreza 86145, Isfahan, Iran.
EM Javaherian@iaush.ac.ir
CR [Anonymous], 1996, G53 ASTM
   Chakraborty R, 2010, SILICON-NETH, V2, P61, DOI 10.1007/s12633-010-9036-9
   Chakraborty R, 2009, J COAT TECHNOL RES, V6, P471, DOI 10.1007/s11998-008-9155-z
   Cheng H.N., 2003, NMR SPECTROSCOPY POL, P448
   DUBIN PL, 1999, COLLOID POLYM INTERA
   Dziczkowski J, 2012, PROG ORG COAT, V73, P330, DOI 10.1016/j.porgcoat.2011.03.005
   Dziczkowski J, 2012, PROG ORG COAT, V73, P308, DOI 10.1016/j.porgcoat.2010.12.006
   Edwin A. M., 2011, WITOLD BROSTOW, V72, P292
   Gao J. G., 2013, APPL MECH MAT, V43, P380
   Gao J.G., 2013, APPL MECH MAT, V43, P40
   Grassie N., 1985, POLYM DEGRADATION ST, P72
   Guner FS, 2002, J COATING TECHNOL, V74, P55, DOI 10.1007/BF02698369
   Hudda L., 2005, J POLYM, V4, P993
   Karandikar V.C., 2006, PAINTINDIA, V2, P74
   KARANDIKAR VC, 2006, PAINTINDIA, V2, P62
   KARANDIKAR VC, 2006, PAINTINDIA, V2, P60
   KARANDIKAR VC, 2006, PAINTINDIA, V2, P55
   KARANDIKAR VC, 2006, PAINTINDIA, V2, P72
   KARANDIKAR VC, 2006, PAINTINDIA, V2, P64
   KARANDIKAR VC, 2006, PAINTINDIA, V2, P58
   KARANDIKAR VC, 2006, PAINTINDIA, V2, P66
   KARANDIKAR VC, 2006, PAINTINDIA, V2, P70
   KARANDIKAR VC, 2006, PAINTINDIA, V2, P68
   Lambourne R., 1987, THEORY PRACTICE, P60
   Lowry T. H., 1987, MECH THEORY ORGANIC
   Nabuurs T, 1996, PROG ORG COAT, V27, P163, DOI 10.1016/0300-9440(95)00533-1
   Naghash H.J., 2011, PROG ORG COAT, V72, P724
   Naghash H. J., 2012, PROG ORG COAT, V73, P155
   Naghash HJ, 2010, PROG ORG COAT, V69, P486, DOI 10.1016/j.porgcoat.2010.09.003
   Naghash HJ, 2009, PROG ORG COAT, V65, P275, DOI 10.1016/j.porgcoat.2008.12.005
   Naghash HJ, 2009, J APPL POLYM SCI, V112, P1037, DOI 10.1002/app.29555
   Naghash HJ, 2006, PROG ORG COAT, V55, P375, DOI 10.1016/j.porgcoat.2006.02.001
   Naghash HJ, 2005, IRAN POLYM J, V14, P211
   Oyman ZO, 2005, PROG ORG COAT, V54, P198, DOI 10.1016/j.porgcoat.2005.06.004
   Sailer RA, 1998, PROG ORG COAT, V33, P117, DOI 10.1016/S0300-9440(98)00033-2
   Savant DM, 2007, MACROMOLECULES, V40, P4199, DOI 10.1021/ma070327l
   Schork F.J., 1998, 6 INT WORKSH POL REA, P355
   Schork FJ, 2004, PROG COLL POL SCI S, V124, P126
   Shim F.J., 1997, P INT WAT HIGH SOL P, P159
   Tsavalas JG, 2003, POLYM REACT ENG, V11, P277, DOI 10.1081/PRE-120023904
   Tsavalas JG, 2003, J APPL POLYM SCI, V87, P1825, DOI 10.1002/app.11916
   Tsavalas JG, 2000, J APPL POLYM SCI, V75, P916
   Wang C., 2000, J COATING TECHNOL, V904, P55
   Wang ST, 1996, J APPL POLYM SCI, V60, P2069, DOI 10.1002/(SICI)1097-4628(19960620)60:12<2069::AID-APP4>3.0.CO;2-K
   Wicks Jr Z., 1999, ORGANIC COATINGS SCI, V2, P630
   Wu XQ, 1999, J POLYM SCI POL CHEM, V37, P4159, DOI 10.1002/(SICI)1099-0518(19991115)37:22<4159::AID-POLA15>3.0.CO;2-N
   Wutticharoenwong K, 2012, PROG ORG COAT, V73, P283, DOI 10.1016/j.porgcoat.2011.03.017
NR 47
TC 2
Z9 3
U1 4
U2 43
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0300-9440
J9 PROG ORG COAT
JI Prog. Org. Coat.
PD JUL
PY 2015
VL 84
BP 89
EP 96
DI 10.1016/j.porgcoat.2015.02.004
PG 8
WC Chemistry, Applied; Materials Science, Coatings & Films
SC Chemistry; Materials Science
GA CJ2XY
UT WOS:000355349200011
DA 2018-12-27
ER

PT J
AU Lu, YY
   An, LJ
   Wang, SQ
   Wang, ZG
AF Lu, Yuyuan
   An, Lijia
   Wang, Shi-Qing
   Wang, Zhen-Gang
TI RETRACTED: Molecular Mechanisms for Conformational and Rheological
   Responses of Entangled Polymer Melts to Startup Shear(Retracted article.
   See vol. 50, pg. 2602, 2017)
SO MACROMOLECULES
LA English
DT Article; Retracted Publication
ID IMPROVED THEORETICAL DESCRIPTION; CONVECTIVE CONSTRAINT RELEASE;
   COX-MERZ RULE; MICROSCOPIC THEORY; STRESS OVERSHOOT; DYNAMICS
   SIMULATIONS; COMPUTER-SIMULATIONS; NONLINEAR RHEOLOGY; SEGMENTAL
   STRETCH; REPTATION MODEL
AB In this work, we have carried out Brownian dynamics simulation to describe the detailed characteristics of conformational and rheological responses to startup shear. In addition to the evaluation of the contour length of the primitive chain, the state of chain entanglement and the first normal stress difference as a function of strain, three methods are applied to determine the time-dependent shear stress. Our results show significant stretching of the primitive chain up to many Rouse times, followed by retraction, as the primary origin of stress overshoot for deformation rates lower than the reciprocal of the Rouse time but higher than the reciprocal of the reptation time. The analysis of such results reveals heterogeneous local chain stretching, demonstrating the coupling between stretching and orientation that extends to times considerably longer than the Rouse time. Explicit comparison between the simulation and the theoretical description from the GLaMM theory shows marked differences. For example, the simulation indicates a slower decline in the number of original entanglements than that at equilibrium up to many Rouse times whereas the GLaMM theory predicts a faster decrease. Moreover, contrary to the simulation that depicts a nearly constant slope in the stress strain relationship during startup shear, the GLaMM theory shows an immediate and precipitous strain softening.
C1 [Lu, Yuyuan; An, Lijia; Wang, Zhen-Gang] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Polymer Phys & Chem, Changchun 130022, Peoples R China.
   [Wang, Shi-Qing] Univ Akron, Dept Polymer Sci, Akron, OH 44325 USA.
   [Wang, Zhen-Gang] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.
RP An, LJ (reprint author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Polymer Phys & Chem, Changchun 130022, Peoples R China.
EM ljan@ciac.ac.cn
FU National Natural Science Foundation of China [21120102037, 21334007];
   Special Funds for National Basic Research Program of China
   [2012CB821500]
FX This work is supported, in part, by the National Natural Science
   Foundation of China (Nos. 21120102037 and 21334007) and is further
   subsidized by the Special Funds for National Basic Research Program of
   China (No. 2012CB821500). We thank the anonymous reviewers, whose
   comments have helped improve the presentation of our work.
CR Adams JM, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.219802
   Adams JM, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.067801
   [Anonymous], 1978, J CHEM SOC FARADAY T
   Archer LA, 1999, J RHEOL, V43, P1555, DOI 10.1122/1.551060
   Astarita G, 1974, PRINCIPLES NONNEWTON
   Auhl D, 2008, J RHEOL, V52, P801, DOI 10.1122/1.2890780
   Auhl R, 2003, J CHEM PHYS, V119, P12718, DOI 10.1063/1.1628670
   Baig C, 2010, MACROMOLECULES, V43, P6886, DOI 10.1021/ma100826u
   Bisbee W, 2011, MACROMOLECULES, V44, P8972, DOI 10.1021/ma2012333
   Boukany PE, 2009, MACROMOLECULES, V42, P6261, DOI 10.1021/ma9004346
   Boukany PE, 2009, J RHEOL, V53, P617, DOI 10.1122/1.3086872
   Cao J, THESIS
   Cao J, 2015, MACROMOLECULES, V48, P99, DOI 10.1021/ma5010315
   Cao J, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.028302
   Collis MW, 2005, J RHEOL, V49, P501, DOI 10.1122/1.1849180
   Dealy J. M., 2006, STRUCTURE RHEOLOGY M
   DEGENNES PG, 1971, J CHEM PHYS, V55, P572, DOI 10.1063/1.1675789
   Divoux T, 2011, SOFT MATTER, V7, P9335, DOI 10.1039/c1sm05740e
   DOI M, 1983, J POLYM SCI POL PHYS, V21, P667, DOI 10.1002/pol.1983.180210501
   DOI M, 1979, J CHEM SOC FARAD T 2, V75, P38, DOI 10.1039/f29797500038
   Doi M, 1986, THEORY POLYM DYNAMIC
   Graham RS, 2013, MACROMOLECULES, V46, P9849, DOI 10.1021/ma401183w
   Graham RS, 2006, MACROMOLECULES, V39, P2700, DOI 10.1021/ma052357z
   Graham RS, 2003, J RHEOL, V47, P1171, DOI 10.1122/1.1595099
   GREEN MS, 1946, J CHEM PHYS, V14, P80, DOI 10.1063/1.1724109
   Hernadez A. R., 2013, J MACROMOLECULES, V46, P6287
   Hyun K, 2011, PROG POLYM SCI, V36, P1697, DOI 10.1016/j.progpolymsci.2011.02.002
   Ianniruberto G, 1996, J NON-NEWTON FLUID, V65, P241, DOI 10.1016/0377-0257(96)01433-4
   Ianniruberto G., 2000, P INT C RHEOL, V2, P102
   Inoue T, 2002, MACROMOLECULES, V35, P4718, DOI 10.1021/ma012149g
   KREMER K, 1988, PHYS REV LETT, V61, P566, DOI 10.1103/PhysRevLett.61.566
   KREMER K, 1990, J CHEM PHYS, V92, P5057, DOI 10.1063/1.458541
   Kroger M, 1997, MACROMOLECULES, V30, P526, DOI 10.1021/ma960317c
   Kroger M, 2000, PHYS REV LETT, V85, P1128, DOI 10.1103/PhysRevLett.85.1128
   Kroger M, 2005, COMPUT PHYS COMMUN, V168, P209, DOI 10.1016/j.cpc.2005.01.020
   KROGER M, 1993, J RHEOL, V37, P1057
   Kumar S, 2001, J CHEM PHYS, V114, P6937, DOI 10.1063/1.1358860
   Larson RG, 2007, J POLYM SCI POL PHYS, V45, P3240, DOI 10.1002/polb.21332
   LEES AW, 1972, J PHYS PART C SOLID, V5, P1921, DOI 10.1088/0022-3719/5/15/006
   Levine AJ, 1998, MACROMOLECULES, V31, P8623, DOI 10.1021/ma980347a
   Li X, 2009, J RHEOL, V53, P1255, DOI 10.1122/1.3193713
   Likhtman AE, 2000, PHYS REV LETT, V85, P4550, DOI 10.1103/PhysRevLett.85.4550
   Likhtman AE, 2003, J NON-NEWTON FLUID, V114, P1, DOI 10.1016/S0377-0257(03)00114-9
   Likhtman AE, 2002, MACROMOLECULES, V35, P6332, DOI 10.1021/ma0200219
   Likhtman AE, 2009, J NON-NEWTON FLUID, V157, P158, DOI 10.1016/j.jnnfm.2008.11.008
   Lodge TP, 1999, PHYS REV LETT, V83, P3218, DOI 10.1103/PhysRevLett.83.3218
   Lu YY, 2014, MACROMOLECULES, V47, P5432, DOI 10.1021/ma500131f
   Lu YY, 2014, ACS MACRO LETT, V3, P569, DOI 10.1021/mz500260h
   Lu YY, 2013, ACS MACRO LETT, V2, P561, DOI 10.1021/mz400145m
   MARRUCCI G, 1988, GAZZ CHIM ITAL, V118, P179
   Marrucci G, 1996, J NON-NEWTON FLUID, V62, P279, DOI 10.1016/0377-0257(95)01407-1
   Masubuchi Y, 2014, ACS MACRO LETT, V3, P1183, DOI 10.1021/mz500627r
   McLeish TCB, 2002, ADV PHYS, V51, P1379, DOI 10.1080/00018730210153216
   MEAD DW, 1995, RHEOL ACTA, V34, P360, DOI 10.1007/BF00367152
   MEAD DW, 1995, RHEOL ACTA, V34, P339, DOI 10.1007/BF00367151
   MENEZES EV, 1982, J POLYM SCI POL PHYS, V20, P1817, DOI 10.1002/pol.1982.180201006
   Milner ST, 1998, PHYS REV LETT, V81, P725, DOI 10.1103/PhysRevLett.81.725
   Milner ST, 1996, J RHEOL, V40, P303, DOI 10.1122/1.550742
   Milner ST, 2001, J RHEOL, V45, P539, DOI 10.1122/1.1349122
   Moorcroft RL, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.086001
   Nielsen JK, 2009, J RHEOL, V53, P1327, DOI 10.1122/1.3208073
   Osaki K, 2000, J POLYM SCI POL PHYS, V38, P1917, DOI 10.1002/1099-0488(20000715)38:14<1917::AID-POLB100>3.0.CO;2-6
   Osaki K, 2000, J POLYM SCI POL PHYS, V38, P3271, DOI 10.1002/1099-0488(20001215)38:24<3271::AID-POLB80>3.0.CO;2-6
   PEARSON D, 1991, J POLYM SCI POL PHYS, V29, P1589, DOI 10.1002/polb.1991.090291304
   PEARSON DS, 1989, J RHEOL, V33, P517, DOI 10.1122/1.550026
   Qin J, 2012, J RHEOL, V56, P707, DOI 10.1122/1.4708594
   Ravindranath S, 2008, J RHEOL, V52, P681, DOI 10.1122/1.2899147
   Ravindranath S, 2008, MACROMOLECULES, V41, P2663, DOI 10.1021/ma7027352
   Ravindranath S, 2008, J RHEOL, V52, P341, DOI 10.1122/1.2833453
   Read DJ, 2008, MACROMOLECULES, V41, P6843, DOI 10.1021/ma8009855
   RUBINSTEIN M, 1988, J CHEM PHYS, V89, P5291, DOI 10.1063/1.455620
   Sanchez-Reyes J, 2002, MACROMOLECULES, V35, P5194, DOI 10.1021/ma020321q
   SHAFFER JS, 1994, J CHEM PHYS, V101, P4205, DOI 10.1063/1.467470
   SMITH SW, 1995, PHYS REV LETT, V75, P1316, DOI 10.1103/PhysRevLett.75.1316
   Sukumaran SK, 2009, MACROMOLECULES, V42, P4300, DOI 10.1021/ma802059p
   Sukumaran SK, 2005, J POLYM SCI POL PHYS, V43, P917, DOI 10.1002/polb.20384
   Sussman DM, 2012, MACROMOLECULES, V45, P3270, DOI 10.1021/ma300006s
   Sussman DM, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.078102
   Tapadia P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.016001
   Tzoumanekas C, 2006, MACROMOLECULES, V39, P4592, DOI 10.1021/ma0607057
   VIOVY JL, 1991, MACROMOLECULES, V24, P3587, DOI 10.1021/ma00012a020
   Wang SQ, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2753156
   Wang SQ, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187801
   Wang SQ, 2013, MACROMOLECULES, V46, P3147, DOI 10.1021/ma300398x
   Wang SQ, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.219801
   Wang SQ, 2008, J POLYM SCI POL PHYS, V46, P2660, DOI 10.1002/polb.21588
   Wang YY, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.237801
   Watanabe H, 1999, PROG POLYM SCI, V24, P1253, DOI 10.1016/S0079-6700(99)00029-5
   Yamamoto R, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.041801
   Yamamoto R, 2002, J CHEM PHYS, V117, P2359, DOI 10.1063/1.1488589
   Zhou Q, 2005, MACROMOLECULES, V38, P5761, DOI 10.1021/ma050347s
   Zhou Q, 2006, MACROMOLECULES, V39, P6737, DOI 10.1021/ma060670a
NR 92
TC 18
Z9 20
U1 5
U2 102
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0024-9297
EI 1520-5835
J9 MACROMOLECULES
JI Macromolecules
PD JUN 23
PY 2015
VL 48
IS 12
BP 4164
EP 4173
DI 10.1021/ma502236m
PG 10
WC Polymer Science
SC Polymer Science
GA CL5GV
UT WOS:000356988700042
DA 2018-12-27
ER

PT J
AU Song, XX
   Zhang, YT
   Wang, R
   Cao, MX
   Che, YL
   Wang, JL
   Wang, HY
   Jin, LF
   Dai, HT
   Ding, X
   Zhang, GZ
   Yao, JQ
AF Song, Xiaoxian
   Zhang, Yating
   Wang, Ran
   Cao, Mingxuan
   Che, Yongli
   Wang, Jianlong
   Wang, Haiyan
   Jin, Lufan
   Dai, Haitao
   Ding, Xin
   Zhang, Guizhong
   Yao, Jianquan
TI RETRACTED: Bulk- and layer-heterojunction phototransistors based on poly
   [2-methoxy-5-(2 '-ethylhexyloxy-p-phenylenevinylene)] and PbS quantum
   dot hybrids(Retracted article. See vol. 110, Artn No.089901 ,2017)
SO APPLIED PHYSICS LETTERS
LA English
DT Article; Retracted Publication
ID INFRARED PHOTODETECTORS; COLLOIDAL NANOCRYSTALS; CARRIER MOBILITY;
   THIN-FILMS; MEH-PPV; GRAPHENE; HETEROSTRUCTURES; PERFORMANCE;
   TRANSISTORS; DISSOCIATION
AB The responsivity (R) of a thin film photodetector is proportional to the product of its photo-induced carrier density (n) and mobility (mu). However, when choosing between layer heterojunction (LH) and bulk heterojunction (BH) field-effect phototransistors (FEpTs), it is still unclear which of the two device structures is more conducive to photodetection. A comparison study is performed on the two structures based on polymer and PbS quantum dot hybrids. Both devices exhibit ambipolar behavior, with mu(E) approximate to mu(H) = 3.7 cm(2) V-1 s(-1) for BH-FEpTs and mu(H) = 36 cm(2) V-1 s(-1) and mu(E) = 52 cm(2) V-1 s(-1) for LH-FEpTs. Because of the improvements in mu and the channel order degree (alpha), the responsivity of LH-FEpTs is as high as 10(1) A/W, which is as much as two orders of magnitude higher than that of BH-FEpTs (10(-1) A/W) under the same conditions. Although the large area of the BH improves both the exciton separation degree (beta) and n in the BH-FEpT, the lack of an effective transport mechanism becomes the main constraint on high device responsivity. Therefore, LH-FEpTs are better candidates for use as photo detectors, and a "three-high" principle of high alpha, beta, and mu is found to be required for high responsivity. (C) 2015 AIP Publishing LLC.
C1 [Song, Xiaoxian; Zhang, Yating; Wang, Ran; Cao, Mingxuan; Che, Yongli; Wang, Jianlong; Wang, Haiyan; Jin, Lufan; Ding, Xin; Zhang, Guizhong; Yao, Jianquan] Tianjin Univ, Inst Laser & Optoelect, Coll Precis Instruments & Optoelect Engn, Tianjin 300072, Peoples R China.
   [Song, Xiaoxian; Zhang, Yating; Wang, Ran; Cao, Mingxuan; Che, Yongli; Wang, Jianlong; Wang, Haiyan; Jin, Lufan; Ding, Xin; Zhang, Guizhong; Yao, Jianquan] Tianjin Univ, Key Lab Optoelect Informat, Minist Educ, Tianjin 300072, Peoples R China.
   [Dai, Haitao] Tianjin Univ, Sch Sci, Tianjin Key Lab Low Dimens Mat Phys & Preparing T, Tianjin 300072, Peoples R China.
RP Zhang, YT (reprint author), Tianjin Univ, Inst Laser & Optoelect, Coll Precis Instruments & Optoelect Engn, Tianjin 300072, Peoples R China.
EM yating@tju.edu.cn
FU National Natural Science Foundation of China [61271066]; Foundation of
   Independent Innovation of Tianjin University [60302070]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 61271066) and the Foundation of Independent Innovation
   of Tianjin University (Grant No. 60302070).
CR Amorim CA, 2012, J NON-CRYST SOLIDS, V358, P484, DOI 10.1016/j.jnoncrysol.2011.11.001
   Bisri SZ, 2012, ADV MATER, V24, P6147, DOI 10.1002/adma.201202699
   Britnell L, 2013, SCIENCE, V340, P1311, DOI 10.1126/science.1235547
   Britnell L, 2012, SCIENCE, V335, P947, DOI 10.1126/science.1218461
   Buonsanti R, 2013, CHEM MATER, V25, P1305, DOI 10.1021/cm304104m
   Chung DS, 2012, NANO LETT, V12, P1813, DOI 10.1021/nl203949n
   Feng W, 2014, SCI REP-UK, V4, DOI 10.1038/srep03777
   Hetsch F, 2013, MATER TODAY, V16, P312, DOI 10.1016/j.mattod.2013.08.011
   Inigo AR, 2010, J CHIN CHEM SOC-TAIP, V57, P459, DOI 10.1002/jccs.201000068
   Kang I, 1997, J OPT SOC AM B, V14, P1632, DOI 10.1364/JOSAB.14.001632
   Kim CO, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4249
   Kim JY, 2013, ADV MATER, V25, P4986, DOI 10.1002/adma.201301947
   Konstantatos G, 2006, NATURE, V442, P180, DOI 10.1038/nature04855
   Konstantatos G, 2012, NAT NANOTECHNOL, V7, P363, DOI [10.1038/NNANO.2012.60, 10.1038/nnano.2012.60]
   Kramer IJ, 2014, CHEM REV, V114, P863, DOI 10.1021/cr400299t
   Li JH, 2014, ADV MATER, V26, P5239, DOI 10.1002/adma.201400349
   Li MM, 2015, CHEM MATER, V27, P2218, DOI 10.1021/acs.chemmater.5b00341
   Liao HC, 2012, ACS NANO, V6, P1657, DOI 10.1021/nn204654h
   McDonald SA, 2005, NAT MATER, V4, P138, DOI 10.1038/nmat1299
   Mingqing W., 2009, P ISES WORLD C 2007, VI
   Mingqing W., 2009, P ISES WORLD C 2007, V1303- 1307, P263
   Rauch T, 2009, NAT PHOTONICS, V3, P332, DOI 10.1038/NPHOTON.2009.72
   Sun ZH, 2014, ACS NANO, V8, P4133, DOI 10.1021/nn500508c
   Sun ZH, 2012, ADV MATER, V24, P5878, DOI 10.1002/adma.201202220
   Sun ZH, 2012, J MATER CHEM, V22, P21673, DOI 10.1039/c2jm34773c
   Yang Y, 2014, COORDIN CHEM REV, V263, P229, DOI 10.1016/j.ccr.2013.11.013
   Yang Y, 2012, NANO LETT, V12, P4235, DOI 10.1021/nl301847r
   Yu H, 2013, ADV FUNCT MATER, V23, P629, DOI 10.1002/adfm.201201848
   Zaiats G, 2014, MATERIALS, V7, P7243, DOI 10.3390/ma7117243
   Zhang S, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2137895
   Zhang WJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep03826
   Zhou YF, 2010, ENERG ENVIRON SCI, V3, P1851, DOI 10.1039/c0ee00143k
NR 32
TC 9
Z9 9
U1 7
U2 56
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0003-6951
EI 1077-3118
J9 APPL PHYS LETT
JI Appl. Phys. Lett.
PD JUN 22
PY 2015
VL 106
IS 25
AR 253501
DI 10.1063/1.4922917
PG 5
WC Physics, Applied
SC Physics
GA CL5XG
UT WOS:000357036600038
DA 2018-12-27
ER

PT J
AU Ebrahimi, T
   Behdad, B
   Abbasi, MA
   Rabati, RG
   Fayyaz, AF
   Behnod, V
   Asgari, A
AF Ebrahimi, Tahereh
   Behdad, Behnoosh
   Abbasi, Maryam Agha
   Rabati, Rahman Ghaffarzadegan
   Fayyaz, Amir Farshid
   Behnod, Vahid
   Asgari, Ali
TI RETRACTED: High doses of garlic extract significantly attenuated the
   ratio of serum LDL to HDL level in rat-fed with hypercholesterolemia
   diet(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Garlic; Low density lipoprotein cholesterol; High density lipoprotein
   cholesterol; Rat; Pharmacology
ID CHOLESTEROL-FED RATS; BLOOD-PRESSURE; VASCULAR REACTIVITY; VOLATILE
   COMPOUNDS; CLINICAL-TRIALS; ALLIUM-SATIVUM; HEART-DISEASE; RISK-FACTORS;
   LIPIDS; ALLICIN
AB Background: Hypercholesterolemia is associated with an increased risk of heart disease. In this study, we investigated the antihyperlipidemic effects of garlic (Allium sativum L.) in rat models of hypercholesterolemic.
   Methods: Wistar male rats were randomly divided into 4 diet groups with garlic supplementation. Male Wistar rats were fed by standard pellet diet (group I), standard diet supplemented with 4 % garlic (group II), lipogenic diet (containing sunflower oil, cholesterol and ethanol) equivalent to 200 mg raw garlic/kg body weight (raw) (group III) and lipogenic diet equivalent to 400 mg raw garlic/kg body weight (raw) (group IV).
   Results: Rats fed 400 g/kg garlic extract(GE), had a significantly lower concentration of serum low-density lipoprotein cholesterol (LDL-C) cholesterol and elevated HDL -C cholesterol at day 28 (P < 0.05). In addition, serum levels of LDL-C was lower in the III and IV group than those in the IV group (P < 0.001 for each). However, cholesterol efflux capacity was positively correlated with HDL cholesterol concentration (P < 0.0001). It was also directly correlated with garlic supplementation (P < 0.0001).
   Conclusion: Together Taken, the results are clearly indicative of the beneficial effects of garlic in reducing lateral side effects of hyperlipidemia. Our data demonstrate that GE has protective effects on HDL in rats with high LDL intake. Therefore, it could be used to remedy hypercholesterolemia with help reduce risk of coronary heart disease
C1 [Ebrahimi, Tahereh] Sari Agr Sci & Nat Resources Univ, Dept Agr Biotechnol, Sari, Iran.
   [Behdad, Behnoosh] Shahid Beheshti Univ Med Sci, Tehran, Iran.
   [Abbasi, Maryam Agha] Islamic Azad Univ, Kurdistan Sci & Res Branch, Coll Sci, Dept Biochem, Sanandaj, Iran.
   [Abbasi, Maryam Agha] Danesh Pathobiol Lab, Tehran, Iran.
   [Rabati, Rahman Ghaffarzadegan] Shahid Abbas Abdollahi, Shahid Mahallati Hosp, Mol Biol Res Ctr, Tabriz, Iran.
   [Fayyaz, Amir Farshid] AJA Univ Med Sci, Dept Legal Med, Tehran, Iran.
   [Behnod, Vahid] Baqiyatallah Univ Med Sci, Tehran, Iran.
   [Asgari, Ali] AJA Univ Med Sci, Dept Infect Dis, Tehran, Iran.
RP Asgari, A (reprint author), AJA Univ Med Sci, Dept Infect Dis, Tehran, Iran.
EM aliasgari296@yahoo.com
CR Abdalla FH, 2010, FOOD CHEM TOXICOL, V48, P417, DOI 10.1016/j.fct.2009.10.033
   Abdel-Wahhab MA, 2003, J AGR FOOD CHEM, V51, P2409, DOI 10.1021/jf0209185
   Agarwal KC, 1996, MED RES REV, V16, P111, DOI 10.1002/(SICI)1098-1128(199601)16:1<111::AID-MED4>3.0.CO;2-5
   Ali M, 2000, PROSTAG LEUKOTR ESS, V62, P253, DOI 10.1054/plef.2000.0152
   Auer W, 1990, Br J Clin Pract Suppl, V69, P3
   Aviello G, 2009, NAT PROD COMMUN, V4, P1785
   Azuma K, 2007, J CLIN BIOCHEM NUTR, V40, P131, DOI 10.3164/jcbn.40.131
   Banerjee SK, 2002, NUTR J, V1, DOI 10.1186/1475-2891-1-4
   Bordia A, 1998, PROSTAG LEUKOTR ESS, V58, P257, DOI 10.1016/S0952-3278(98)90034-5
   Bordia A, 1977, J Assoc Physicians India, V25, P509
   Castelli W P, 1992, Ann Epidemiol, V2, P23
   Cellini L, 1996, FEMS IMMUNOL MED MIC, V13, P273, DOI 10.1111/j.1574-695X.1996.tb00251.x
   Durak I, 2004, J NUTR BIOCHEM, V15, P373, DOI 10.1016/j.jnutbio.2004.01.005
   Eilat S, 1995, CORONARY ARTERY DIS, V6, P985
   Elkayam A, 2003, AM J HYPERTENS, V16, P1053, DOI 10.1016/j.amjhyper.2003.07.011
   FOUSHEE DB, 1982, CYTOBIOS, V34, P145
   Gardner CD, 2007, ARCH INTERN MED, V167, P346, DOI 10.1001/archinte.167.4.346
   Gorinstein S, 2006, LIFE SCI, V78, P655, DOI 10.1016/j.lfs.2005.05.069
   Gorinstein S, 2007, MOL NUTR FOOD RES, V51, P1365, DOI 10.1002/mnfr.200700064
   Heidarian E, 2011, FOOD CHEM TOXICOL, V49, P1110, DOI 10.1016/j.fct.2011.02.001
   Kandziora J., 1988, ARZTL FORSCH, V35, P1
   KANDZIORA J, 1988, ARZTL FORSCH, V1, P1
   KLEIJNEN J, 1989, BRIT J CLIN PHARMACO, V28, P535, DOI 10.1111/j.1365-2125.1989.tb03539.x
   Kumar GPS, 2013, J CLIN DIAGN RES, V7, P2449, DOI 10.7860/JCDR/2013/7304.3571
   Kwon MJ, 2003, LIFE SCI, V72, P2953, DOI 10.1016/S0024-3205(03)00234-0
   Lau BHS, 2006, J NUTR, V136, p765S, DOI 10.1093/jn/136.3.765S
   Law MR, 1999, EUR HEART J SUPPL, V1, pS3
   Mahmoodi M, 2006, Pak J Pharm Sci, V19, P295
   McKenney JM, 2001, CARDIOVASC DRUG THER, V15, P413, DOI 10.1023/A:1013341606476
   MCMAHON FG, 1993, PHARMACOTHERAPY, V13, P406
   Ozaki MR, 2013, EXP TOXICOL PATHOL, V65, P297, DOI 10.1016/j.etp.2011.09.006
   Rahman K, 2006, J NUTR, V136, p736S, DOI 10.1093/jn/136.3.736S
   Sangeetha T, 2006, J PHARM PHARMACOL, V58, P617, DOI 10.1211/jpp.58.5.0006
   SANTOS OSD, 1993, BR J CLIN RES, V4, P37
   Sharma V, 2010, FOOD CHEM TOXICOL, V48, P928, DOI 10.1016/j.fct.2010.01.002
   SHATEN BJ, 1991, PREV MED, V20, P655, DOI 10.1016/0091-7435(91)90061-8
   SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900
   SILAGY CAS, 1994, J HYPERTENS, V12, P463
   Singh DK, 2006, J NUTR, V136, p759S, DOI 10.1093/jn/136.3.759S
   Slowing K, 2001, J NUTR, V131, p994S, DOI 10.1093/jn/131.3.994S
   Sohn CW, 2012, J MED FOOD, V15, P435, DOI 10.1089/jmf.2011.1922
   Stevinson C, 2000, ANN INTERN MED, V133, P420, DOI 10.7326/0003-4819-133-6-200009190-00009
   Sumioka Isao, 2006, Hiroshima Journal of Medical Sciences, V55, P59
   Thomson M, 2006, J NUTR, V136, p800S, DOI 10.1093/jn/136.3.800S
   Vorberg G, 1990, Br J Clin Pract Suppl, V69, P7
   YEH YY, 1994, LIPIDS, V29, P189, DOI 10.1007/BF02536728
   YU TH, 1989, J AGR FOOD CHEM, V37, P725, DOI 10.1021/jf00087a032
   YU TH, 1989, J AGR FOOD CHEM, V37, P730, DOI 10.1021/jf00087a033
NR 48
TC 4
Z9 4
U1 3
U2 32
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD JUN 20
PY 2015
VL 10
AR 74
DI 10.1186/s13000-015-0322-0
PG 9
WC Pathology
SC Pathology
GA CL0SV
UT WOS:000356654300002
PM 26088761
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Carwana, B
AF Carwana, Brian
TI RETRACTED: Homespun Gospel: The Triumph of Sentimentality in
   Contemporary American Evangelicalism (Retracted article. See vol. 76,
   pg. 368, 2015)
SO SOCIOLOGY OF RELIGION
LA English
DT Book Review; Retracted Publication
C1 [Carwana, Brian] Univ Toronto, Toronto, ON M5S 1A1, Canada.
RP Carwana, B (reprint author), Univ Toronto, Toronto, ON M5S 1A1, Canada.
CR Brenneman T. M., 2014, HOMESPUN GOSPEL TRIU
NR 1
TC 0
Z9 0
U1 1
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1069-4404
EI 1759-8818
J9 SOCIOL RELIG
JI Sociol. Relig.
PD SUM
PY 2015
VL 76
IS 2
BP 240
EP 241
DI 10.1093/socrel/srv017
PG 2
WC Sociology; Religion
SC Sociology; Religion
GA CQ0TI
UT WOS:000360309700006
DA 2018-12-27
ER

PT J
AU Pedram, B
   Moghadam, AT
   Kamyabi-Moghaddam, Z
   Mavedati, O
   Beigi, BA
   Sharabiyani, AK
   Dezfuli, AB
   Khalili, S
   Bahrami, AM
   Nasoori, A
AF Pedram, Behnam
   Moghadam, Ahmad Taghavi
   Kamyabi-Moghaddam, Zahra
   Mavedati, Omid
   Beigi, Babak Abbas
   Sharabiyani, Adel Khodaei
   Dezfuli, Ali Bashiri
   Khalili, Soheil
   Bahrami, Ali Mohammad
   Nasoori, Alireza
TI RETRACTED: Urinary parameters predictive and electrolyte disturbances of
   cisplatin-induced acute renal associated with cancer as a critical
   target of the chemotherapeutic agent in patients with solid tumors
   (Retracted article. See vol.37, pg. 16411, 2016)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Cisplatin; Dog; Electrolyte disturbance; Urea; Creatinine
ID PLATINUM COMPOUNDS; MITOCHONDRIAL-DNA; RANDOMIZED-TRIAL;
   METAL-COMPLEXES; P53 ACTIVATION; IN-VITRO; NEPHROTOXICITY; DOGS;
   MECHANISMS; AMIFOSTINE
AB Cisplatin (CP) is a remarkably effective Pt-based anticancer drug, but it also exhibits severe toxic side effects, including nephrotoxicity and ototoxicity, and CP nephrotoxicity is a major constraint for the treatment of solid tumors. This study was designed to evaluate the electrolyte and biochemical changes in dogs with acute kidney injury (acute renal failure) following administration of CP as a chemotherapeutic agent to exhibit broad efficacy in solid tumors. A total of 10 adult male dogs were selected (treated dogs = 7 and control dogs = 3). Cisplatin-treated animals were received 0.75 mg/kg via intravenous for 5 consecutive days. Urine and blood samples on days 0 (pre-dosing), 1, 2, 3, 4, 7, 10, 14, and 28 (post-dosing) were collected. For tracking the signs of toxicity with cisplatin, clinical examination was performed for 2 times a day. Serum samples were assayed urea, creatinine, sodium, chloride, potassium, calcium, phosphorus, and urine samples were used to measure creatinine. Serum creatinine levels indicating renal function (glomerular filtration rate) was 0.66 and 0.94 mg/dL in day 0, respectively, in treatment and control animals. After day 2, a significant change in creatinine was observed in treatment animals. On the end day of the study control and treatments, creatinine was measured with mean of 1.35 and 1.00 mg/dL, respectively. Electrolyte disturbances were observed after several days of cisplatin administration including changes in levels of sodium, potassium, phosphorus, calcium, and chloride. Clinical observations also identified CP toxicity. This study for the first time showed that compensation electrolyte abnormalities in dogs following administration of cisplatin is essential to prevent deaths by daily monitoring and measurement of electrolytes in patients. This may be advantageous if repetitive cycles of chemotherapy or subsequent administration of high dose chemotherapy were planned.
C1 [Pedram, Behnam] Islamic Azad Univ, Susangerd Branch, Dept Pathobiol, Susangerd, Iran.
   [Moghadam, Ahmad Taghavi] Razi Vaccine & Serum Res Inst, Ahwaz Branch, Ahwaz, Iran.
   [Kamyabi-Moghaddam, Zahra] TU Muenchen, Dept Med 2, Klinikum Rechts Isar, Munich, Germany.
   [Mavedati, Omid] Univ Tehran, Dept Clin Sci, Fac Vet Med, Tehran, Iran.
   [Beigi, Babak Abbas] Mazandaran Univ Med Sci, Dept Med Hist, Sari, Iran.
   [Sharabiyani, Adel Khodaei; Khalili, Soheil; Nasoori, Alireza] Islamic Azad Univ, Karaj Branch, Grad Fac Vet Med, Karaj, Iran.
   [Dezfuli, Ali Bashiri] Univ Tehran, Dept Toxicol, Fac Vet Med, Tehran, Iran.
   [Bahrami, Ali Mohammad] Ilam Univ, Fac Para Vet Med, Ilam, Iran.
   [Kamyabi-Moghaddam, Zahra] Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
RP Bahrami, AM (reprint author), Ilam Univ, Fac Para Vet Med, Ilam, Iran.
EM am.bahrami@ilam.ac.ir
RI Vaccine & Serum Research Institute, Razi/A-3892-2017; taghavi moghadam,
   ahmad/H-1509-2017
OI taghavi moghadam, ahmad/0000-0003-0503-7462
CR Aoki K, 2012, METAL IONS LIFE SCI, V10, P43, DOI 10.1007/978-94-007-2172-2_2
   Arany I, 2003, SEMIN NEPHROL, V23, P460, DOI 10.1016/S0270-9295(03)00089-5
   BOULIKAS T, 1992, ANTICANCER RES, V12, P885
   Brady H, 2000, BRENNER RECTORS KIDN, P1201
   Che CM, 2010, CURR OPIN CHEM BIOL, V14, P255, DOI 10.1016/j.cbpa.2009.11.015
   Chen D, 2009, CURR PHARM DESIGN, V15, P777, DOI 10.2174/138161209787582183
   Cullen KJ, 2007, J BIOENERG BIOMEMBR, V39, P43, DOI 10.1007/s10863-006-9059-5
   CUNNINGHAM SG, 1982, NURS CLIN N AM, V17, P579
   DAUGAARD G, 1987, RENAL PHYSIOL BIOCH, V10, P54
   Daugaard G, 1987, Contrib Nephrol, V56, P7
   Desoize B, 2002, CRIT REV ONCOL HEMAT, V42, P317, DOI 10.1016/S1040-8428(01)00219-0
   Endo T, 2000, TOXICOLOGY, V146, P187, DOI 10.1016/S0300-483X(00)00176-1
   Forterre S, 2004, J VET DIAGN INVEST, V16, P271, DOI 10.1177/104063870401600403
   Frezza M, 2010, CURR PHARM DESIGN, V16, P1813, DOI 10.2174/138161210791209009
   Guyton A, 2000, TXB MED PHYSL, p[369, 373]
   Hartmann JT, 2003, EXPERT OPIN PHARMACO, V4, P889, DOI 10.1517/14656566.4.6.889
   Hartmann JT, 2000, INVEST NEW DRUG, V18, P281, DOI 10.1023/A:1006490226104
   HRUSKA KA, 1995, NEW ENGL J MED, V333, P166, DOI 10.1056/NEJM199507203330307
   Jiang M, 2007, BIOCHEM PHARMACOL, V73, P1499, DOI 10.1016/j.bcp.2007.01.010
   Kolb RJ, 2003, CANCER CHEMOTH PHARM, V51, P132, DOI 10.1007/s00280-002-0537-0
   Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004
   Llach F, 2000, BRENNER RECTORS KIDN, P2103
   Mashhadi MA, 2013, IRAN J KIDNEY DIS, V7, P23
   McDuffie JE, 2010, CYTOKINE, V52, P156, DOI 10.1016/j.cyto.2010.06.005
   Miller RP, 2010, TOXINS, V2, P2490, DOI 10.3390/toxins2112490
   Momekov G, 2006, ARCH TOXICOL, V80, P555, DOI 10.1007/s00204-006-0078-0
   Olivero OA, 1997, MUTAT RES-GEN TOX EN, V391, P79, DOI 10.1016/S0165-1218(97)00037-2
   Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200
   Pan H, 2009, J PHARMACOL EXP THER, V328, P708, DOI 10.1124/jpet.108.147181
   Panichpisal Kessarin, 2006, BMC Nephrol, V7, P10, DOI 10.1186/1471-2369-7-10
   Price PM, 2006, J AM SOC NEPHROL, V17, P2434, DOI 10.1681/ASN.2006020162
   Rebecca AA, 2006, J CHEM EDUC, V83, P724
   SAFIRSTEIN R, 1984, KIDNEY INT, V25, P753, DOI 10.1038/ki.1984.86
   Santoso JT, 2003, CANCER CHEMOTH PHARM, V52, P13, DOI 10.1007/s00280-003-0620-1
   Sastry J, 2005, PEDIATR HEMAT ONCOL, V22, P441, DOI 10.1080/08880010590964381
   SCHAEPPI U, 1973, TOXICOL APPL PHARM, V25, P230, DOI 10.1016/S0041-008X(73)80009-2
   Shah N, 2009, FUTURE ONCOL, V5, P33, DOI 10.2217/14796694.5.1.33
   Sharkey LC, 2009, JAVMA-J AM VET MED A, V234, P767, DOI 10.2460/javma.234.6.767
   UECHI M, 1994, J VET MED SCI, V56, P555, DOI 10.1292/jvms.56.555
   Yoshida Y, 2003, CANCER RES, V63, P3729
   Zhang JC, 2010, ANTI-CANCER AGENT ME, V10, P272, DOI 10.2174/187152010791162270
NR 41
TC 2
Z9 2
U1 2
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2015
VL 36
IS 6
BP 4495
EP 4500
DI 10.1007/s13277-015-3091-1
PG 6
WC Oncology
SC Oncology
GA CO7ZP
UT WOS:000359383700056
PM 25596088
DA 2018-12-27
ER

PT J
AU Li, SL
   Lei, XF
   Zhang, JN
   Yang, HL
   Liu, JY
   Xu, CQ
AF Li, Shuangling
   Lei, Xiaofei
   Zhang, Jianna
   Yang, Hongli
   Liu, Jiyong
   Xu, Changqing
TI RETRACTED: Insulin-like growth factor 1 promotes growth of gastric
   cancer by inhibiting foxo1 nuclear retention (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Gastric cancer; Insulin-like growth factor 1 (IGF-1); Akt; mTOR; FoxO1;
   Cancer growth
ID METASTASIS; EXCLUSION; ACTIVATION; CARCINOMA; PATHWAY; MMP7
AB Gastric cancer (GC) is the fourth most common malignant human cancer. So far, the molecular mechanisms underlying the tumorigenesis of GC are not completely understood. Here, we reported significantly higher levels of serum insulin-like growth factor (IGF)-1 in GC patients and significantly higher levels of phosphorylated IGF-1 receptor (IGF-1R) in the GC specimen. Moreover, IGF-1 induced phosphorylation of IGF-1R and then phosphorylation of its downstream factor Akt in the GC cells. Further, IGF-1/Akt-induced forkhead box protein O1 (FoxO1) nuclear exclusion, but not IGF-1/Akt-induced mTOR phosphorylation, was essential for the augment in GC cell growth. Together, IGF-1/Akt/FoxO1 regulatory machinery appears to be a previously unappreciated signaling axis involved in the carcinogenesis of GC.
C1 [Li, Shuangling; Lei, Xiaofei; Zhang, Jianna; Yang, Hongli; Xu, Changqing] Shandong Univ, Dept Gastroenterol, Shandong Prov Qianfoshan Hosp, Jinan 250014, Peoples R China.
   [Li, Shuangling] Shandong Univ, Sch Med, Jinan 250012, Peoples R China.
   [Liu, Jiyong] Shandong Univ, Dept Gastroenterol, Prov Hosp, Jinan 250021, Peoples R China.
RP Xu, CQ (reprint author), Shandong Univ, Dept Gastroenterol, Shandong Prov Qianfoshan Hosp, 16766 Jingshi Rd, Jinan 250014, Peoples R China.
EM Lele20070828@126.com; xuchangqing15@163.com
CR Chen J, 2014, TUMOR BIOL, V35, P7195, DOI 10.1007/s13277-014-1913-1
   Ding H, 2014, TUMOR BIOL, V35, P9987, DOI 10.1007/s13277-014-2067-x
   Ewing GP, 2010, CLIN COLORECTAL CANC, V9, P219, DOI 10.3816/CCC.2010.n.032
   Gross DN, 2008, ONCOGENE, V27, P2320, DOI 10.1038/onc.2008.25
   Liu G, 2014, TUMOR BIOL, V35, P9801, DOI 10.1007/s13277-014-2273-6
   Machida S, 2003, J CELL PHYSIOL, V196, P523, DOI 10.1002/jcp.10339
   Mao D, 2014, TUMOR BIOL, V35, P8217, DOI 10.1007/s13277-014-2095-6
   Pei J, 2014, TUMOR BIOL, V35, P6673, DOI 10.1007/s13277-014-1850-z
   Puig O, 2006, CELL CYCLE, V5, P503, DOI 10.4161/cc.5.5.2501
   Tao Y, 2007, NAT CLIN PRACT ONCOL, V4, P591, DOI 10.1038/ncponc0934
   Tognon CE, 2012, EXPERT OPIN THER TAR, V16, P33, DOI 10.1517/14728222.2011.638626
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Yang SY, 2011, J BIOL CHEM, V286, P19149, DOI 10.1074/jbc.M110.197905
   Ye YH, 2014, TUMOR BIOL, V35, P10891, DOI 10.1007/s13277-014-2383-1
   Zhao XN, 2013, FRONT BIOSCI-LANDMRK, V18, P803, DOI 10.2741/4144
NR 15
TC 10
Z9 10
U1 3
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2015
VL 36
IS 6
BP 4519
EP 4523
DI 10.1007/s13277-015-3096-9
PG 5
WC Oncology
SC Oncology
GA CO7ZP
UT WOS:000359383700059
PM 25596089
DA 2018-12-27
ER

PT J
AU Guo, ZX
   Liu, DH
   Su, ZX
AF Guo, Zexiong
   Liu, Dehao
   Su, Zexuan
TI RETRACTED: CIP2A mediates prostate cancer progression via the c-Myc
   signaling pathway (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Prostate cancer; Cancerous inhibitor of protein phosphatase 2A; Small
   interfering RNA; Proliferation; Invasion; Targeted therapy
ID GASTRIC-CANCER; TUMOR-CELLS; DOCETAXEL
AB Recent evidence suggests that cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that acts as a novel therapeutic target in a variety of tumors. In this study, we investigated the clinical significance of CIP2A and its function in our large collection of prostate samples. Between August 2000 and December 2013, 126 patients with histologically confirmed prostate cancer (PCa) and 92 with benign prostate hyperplasia (BPH) were recruited into the study. Quantitative real-time PCR (RT-PCR), Western blot, and immunohistochemistry analyses were used to quantify CIP2A expression in PCa clinical samples and cell lines. The relationships between CIP2A expression and clinicopathological features were analyzed. The functional role of CIP2A in PCa cells was evaluated by small interfering RNA-mediated depletion of the protein followed by analyses of cell proliferation and invasion. High expression of CIP2A staining was 86.51 % (109/126) in 126 cases of PCa and 17.39 % (16/92) in 92 cases of BPH; the difference of CIP2A expression between PCa and BPH was statistically significant. CIP2A was significantly elevated in all five PCa cell lines when compared to the RWPE-1 cells at both the messenger RNA (mRNA) and protein levels. Silencing of CIP2A inhibited the proliferation of DU-145 cells which have a relatively high level of CIP2A in a time- and concentration-dependent manner, and the invasion and migration of DU-145 cells were distinctly suppressed. Furthermore, CIP2A knockdown led to substantial reductions in c-Myc levels in DU-145 cells, but no significant change in phosphorylated Akt expression after CIP2A knockdown in DU-145 cells. Our data suggest that the pathogenesis of human PCa maybe mediated by CIP2A, and CIP2A inhibition treatment may provide a promising strategy for the antitumor therapy of PCa, and thus, CIP2A could represent selective targets for the molecularly targeted treatments of PCa.
C1 [Guo, Zexiong; Liu, Dehao; Su, Zexuan] Jinan Univ, Affiliated Hosp 1, Dept Urol, Guangzhou 510630, Guangdong, Peoples R China.
RP Su, ZX (reprint author), Jinan Univ, Affiliated Hosp 1, Dept Urol, 613 West Huangpu Dadao, Guangzhou 510630, Guangdong, Peoples R China.
EM drsuzx6@163.com
FU Science and Technology Research Projects of Guangzhou [11A72070508]
FX This study was supported by the grants from the Science and Technology
   Research Projects of Guangzhou (No. 11A72070508).
CR Bockelman C, 2011, BRIT J CANCER, V105, P989, DOI 10.1038/bjc.2011.346
   Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Heidenreich A, 2011, EUR UROL, V59, P61, DOI 10.1016/j.eururo.2010.10.039
   Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044
   Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103
   Lassi K, 2009, CURR OPIN ONCOL, V21, P260, DOI 10.1097/CCO.0b013e32832a1868
   Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Qu YY, 2013, ASIAN J ANDROL, V15, P110, DOI 10.1038/aja.2012.110
   Ren J, 2011, BRIT J CANCER, V105, P1905, DOI 10.1038/bjc.2011.492
   Ren SC, 2013, ASIAN J ANDROL, V15, P350, DOI 10.1038/aja.2013.37
   Saad F, 2012, FUTURE ONCOL, V8, P321, DOI [10.2217/fon.12.3, 10.2217/FON.12.3]
   Wiegering A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075292
   Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110
NR 15
TC 2
Z9 4
U1 2
U2 18
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2015
VL 36
IS 6
BP 4777
EP 4783
DI 10.1007/s13277-015-3129-4
PG 7
WC Oncology
SC Oncology
GA CO7ZP
UT WOS:000359383700090
PM 25636449
DA 2018-12-27
ER

PT J
AU Yu, HY
   Cai, YB
   Lu, Z
AF Yu, Hai-Ya
   Cai, Yu-Bing
   Lu, Zhan
TI RETRACTED: Activation of AMPK improves lipopolysaccharide-induced
   dysfunction of the blood-brain barrier in mice (Retracted article. See
   vol. 32, pg. 1442, 2018)
SO BRAIN INJURY
LA English
DT Article; Retracted Publication
DE Ageing; AMPK; BBB; LPS; NAD(P)H oxidase; ROS
ID TIGHT-JUNCTION DYNAMICS; PROTEIN-KINASE; IN-VIVO; DIABETES-MELLITUS;
   ENDOTHELIAL-CELLS; INFLAMMATION; EXPRESSION; STRESS; SEPSIS; IMPACT
AB Primary objective: Lipopolysaccharide (LPS) is known to alter the integrity of the blood-brain barrier (BBB) in sepsis, although the underlying mechanism remains unknown. The aim of this study was to elucidate the molecular mechanisms underlying disruption of the BBB in LPS-induced sepsis.
   Research design: Both in vitro and in vivo experiments were designed to test the role of AMP-activated protein kinase (AMPK) in LPS-induced BBB dysfunction.
   Methods and procedures: Human brain microvascular endothelial cells (HBMECs) were cultured. The protein expressions were detected by western blot. BBB integrity was determined by Evans Blue.
   Main outcomes and results: LPS (1 mu g ml(-1)) dramatically increased the permeability of the BBB and the ROS productions, as well as reducing the expression levels of occludin and claudin-5 in cultured HBMECs. Inhibition of NAD(P)H oxidase by apocynin or up-regulation of AMPK reversed the LPS-induced abnornnities in HBMECs. In LPS-induced sepsis in mice, it was found that LPS dramatically increased NAD(P)H oxidase protein expressions and ROS productions in the brain and disrupted BBB function assayed by Evans blue staining, which were abolished by AICAR treatment.
   Conclusions: It is concluded that AMPK activation improves the functions of the BBB impaired by LPS through suppression of NAD(P)H oxidase-derived ROS in mice.
C1 [Yu, Hai-Ya; Lu, Zhan] Peoples Hosp Xishui, Dept Neurol, Huang Gang, Hubei, Peoples R China.
   [Cai, Yu-Bing] Peoples Hosp Xishui, Dept Otorhinolaryngol, Huang Gang, Hubei, Peoples R China.
   [Lu, Zhan] Hunan Normal Univ, Peoples Hosp Hunan Prov, Dept Gastroenterol, Changsha, Hunan, Peoples R China.
RP Lu, Z (reprint author), Peoples Hosp Hunan Prov, 61 West Liberat Rd, Changsha 410005, Hunan, Peoples R China.
EM liuzhan2004@126.com
FU Provincial Natural Science Foundation of Hunan [11JJ5068]; Healthy
   Department of Hunan Province [B2011-078]; Department of Science and
   Technology of Hunan Province [2013FJ3119]
FX This work was supported by the Provincial Natural Science Foundation of
   Hunan (11JJ5068), the Healthy Department of Hunan Province (B2011-078)
   and the Department of Science and Technology of Hunan Province
   (2013FJ3119).
CR Akrout N, 2009, CURR NEUROPHARMACOL, V7, P296, DOI 10.2174/157015909790031175
   Cardoso FL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035919
   Castanares-Zapatero D, 2012, CRITIAL CARE, V16, P30
   Castanares-Zapatero D, 2013, CRIT CARE MED, V41, pE411, DOI 10.1097/CCM.0b013e31829866dc
   Dohgu S, 2008, EXP NEUROL, V210, P740, DOI 10.1016/j.expneurol.2007.12.028
   Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009
   Harford-Wright E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097002
   Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4
   Jin L, 2013, ANTIMICROB AGENTS CH, V57, P4336, DOI 10.1128/AAC.00765-13
   Liu C, 2012, FREE RADICAL BIO MED, V53, P1213, DOI 10.1016/j.freeradbiomed.2012.07.003
   Liu WY, 2012, CNS NEUROSCI THER, V18, P609, DOI 10.1111/j.1755-5949.2012.00340.x
   Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055
   Nagyoszi P, 2010, NEUROCHEM INT, V57, P556, DOI 10.1016/j.neuint.2010.07.002
   Nishikawa T, 2007, ANTIOXID REDOX SIGN, V9, P343, DOI 10.1089/ars.2006.1458
   Pasquier F, 2006, DIABETES METAB, V32, P403, DOI 10.1016/S1262-3636(07)70298-7
   Ristow M, 2004, J MOL MED, V82, P510, DOI 10.1007/s00109-004-0552-1
   Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109-011-0748-0
   Schreibelt G, 2007, FASEB J, V21, P3666, DOI 10.1096/fj.07-8329com
   Singh AK, 2004, TOXICOLOGY, V201, P197, DOI 10.1016/j.tox.2004.04.015
   Song P, 2012, FREE RADICAL BIO MED, V52, P1607, DOI 10.1016/j.freeradbiomed.2012.01.025
   Song P, 2011, CIRC RES, V109, P1230, DOI 10.1161/CIRCRESAHA.111.250423
   Veszelka S, 2007, NEUROCHEM INT, V50, P219, DOI 10.1016/j.neuint.2006.08.006
   Wang SB, 2012, CLIN SCI, V122, P555, DOI 10.1042/CS20110625
   Wang SX, 2012, NAT MED, V18, P902, DOI 10.1038/nm.2711
   Wang SX, 2010, CIRC RES, V106, P1117, DOI 10.1161/CIRCRESAHA.109.212530
   Wang SX, 2009, DIABETES, V58, P1893, DOI 10.2337/db09-0267
   Wang X., 2008, P IEEE VPPC, V1, P1, DOI DOI 10.1063/1.2838221
   Xie ZL, 2008, DIABETES, V57, P3222, DOI 10.2337/db08-0610
NR 28
TC 13
Z9 14
U1 1
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0269-9052
EI 1362-301X
J9 BRAIN INJURY
JI Brain Inj.
PD JUN
PY 2015
VL 29
IS 6
BP 777
EP 784
DI 10.3109/02699052.2015.1004746
PG 8
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA CL8RL
UT WOS:000357241700014
PM 25794165
DA 2018-12-27
ER

PT J
AU Blake, DF
   Naidoo, P
   Brown, LH
   Young, D
   Lippmann, J
AF Blake, Denise F.
   Naidoo, Philip
   Brown, Lawrence H.
   Young, Derelle
   Lippmann, John
TI RETRACTED: A comparison of the tissue oxygenation achieved using
   different oxygen delivery devices and flow rates (Retracted article. See
   vol. 46, pg. 55, 2016)
SO DIVING AND HYPERBARIC MEDICINE
LA English
DT Article; Retracted Publication
DE Scuba diving; decompression illness; first aid; oxygen; equipment;
   transcutaneous oximetry; medical kits; DAN (Divers Alert Network)
ID DECOMPRESSION ILLNESS; NORMAL VALUES; THERAPY
AB Introduction: High-concentration normobaric oxygen (O-2) administration is the first-aid priority in treating divers with suspected decompression illness. The best O-2 delivery device and flow rate are yet to be determined.
   Aim: To determine whether administering O-2 with a non-rebreather mask (NRB) at a flow rate of 10 or 15 L.min(-1) or with a demand valve with oronasal mask significantly affects the tissue partial pressure of O-2 (PtcO2) in healthy volunteer scuba divers.
   Methods: Fifteen certified scuba divers had PtcO2 measured at six positions on the arm and leg. Measurements were taken with subjects lying supine whilst breathing O-2 from a NRB at 10 or 15 L.min(-1), a demand valve with an adult Tru-Fit oronasal mask and, as a reference standard, an oxygen 'head hood'. End-tidal carbon dioxide was also measured.
   Results: While none of the emergency delivery devices performed as well as the head hood, limb tissue oxygenation was greatest when O-2 was delivered via the NRB at 15 L.min(-1). There were no clinically significant differences in end-tidal carbon dioxide regardless of the delivery device or flow rate.
   Conclusion: Based on transcutaneous oximetry values, of the commonly available emergency O-2 delivery devices, the NRB at 15 L.min(-1) is the device and flow rate that deliver the most O-2 to body tissues and, therefore, should be considered as a first-line pre-hospital treatment in divers with suspected decompression illness.
C1 [Blake, Denise F.; Naidoo, Philip] Townsville Hosp, Emergency Dept, Townsville, Qld 4814, Australia.
   [Blake, Denise F.] James Cook Univ, Coll Marine & Environm Sci, Townsville, Qld 4811, Australia.
   [Brown, Lawrence H.] James Cook Univ, Mt Isa Ctr Rural & Remote Hlth, Townsville, Qld 4811, Australia.
   [Young, Derelle] Townsville Hosp, Hyperbar Med Unit, Townsville, Qld 4814, Australia.
   [Lippmann, John] Divers Alert Network Asia Pacific, Melbourne, Vic, Australia.
RP Blake, DF (reprint author), Townsville Hosp, Emergency Dept, Townsville, Qld 4814, Australia.
EM denise.blake@health.qld.gov.au
FU Divers Alert Network Asia-Pacific
FX The authors gratefully acknowledge financial assistance from the Divers
   Alert Network Asia-Pacific and technical assistance from Stuart
   McIntyre, Biomedical Technical Services Department, The Townsville
   Hospital. We also thank our subjects for their participation and Katy
   Corkill for posing for the photos.
CR Acott C, 1998, SPUMS J S, V28, P16
   Bird N, 2012, EMERGENCY OXYGEN SCU
   Blake DF, 2014, DIVING HYPERB MED, V44, P146
   BROWN JT, 1984, CAN ANAESTH SOC J, V31, P91, DOI 10.1007/BF03011489
   Brubakk A, 2000, SPUMS J, V30, P155
   Davis M, 1998, SPUMS J, V28, P165
   EBERHARD P, 1975, MED BIOL ENG, V13, P436, DOI 10.1007/BF02477116
   Hobbs GW, 2000, DIVERS ALERT NETWORK
   HYLDEGAARD O, 1991, UNDERSEA BIOMED RES, V18, P361
   Komesaroff D, 1998, SPUMS J S, V28, P20
   Lippmann J, 2012, DECOMPRESSION ILLNES
   Lippmann J, 2003, SPUMS J, V33, P192
   Lippmann J, 2011, OXYGEN 1 AID
   Longphre JM, 2007, UNDERSEA HYPERBAR M, V34, P43
   Moon RE, 2009, DIVING HYPERB MED, V39, P81
   Stephenson RN, 1996, UNDERSEA HYPERBAR M, V23, P185
   Vann RD, 2011, LANCET, V377, P153, DOI 10.1016/S0140-6736(10)61085-9
   Walker R, 2002, DIVING SUBAQUATIC ME, P137
   Wendling J, 1997, SPUMS J, V27, P101
   Young DA, 2012, DIVING HYPERB MED, V42, P208
NR 20
TC 4
Z9 4
U1 2
U2 5
PU SOUTH PACIFIC UNDERWATER MED SOC
PI MELBOURNE
PA C/O AUSTRALIAN & NEW ZEALAND COLL ANAESTHETISTS, 630 ST KILDA RD,
   MELBOURNE, VIC 3004, AUSTRALIA
SN 1833-3516
J9 DIVING HYPERB MED
JI Diving Hyperb. Med.
PD JUN
PY 2015
VL 45
IS 2
BP 79
EP 83
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA CL4RE
UT WOS:000356940200003
PM 26165528
DA 2018-12-27
ER

PT J
AU Petkovic, D
   Shamshirband, S
   Tong, CW
   Al-Shammari, ET
AF Petkovic, Dalibor
   Shamshirband, Shahaboddin
   Tong, Chong Wen
   Al-Shammari, Eiman Tamah
TI RETRACTED: Generalized adaptive neuro-fuzzy based method for wind speed
   distribution prediction (Retracted article. See vol. 61, pg. 94, 2018)
SO FLOW MEASUREMENT AND INSTRUMENTATION
LA English
DT Article; Retracted Publication
DE Wind energy; Wind speed distribution; Weibull distribution; Maximum
   likelihood method; Adaptive neuro-fuzzy system (ANFIS)
ID INFERENCE SYSTEM; WEIBULL FUNCTION; ENERGY; ANFIS; PARAMETERS; TURBINES
AB The probabilistic distribution of wind speed is one of the important wind characteristics for the assessment of wind energy potential and for the performance of wind energy conversion systems. When the wind speed probability distribution is known, the wind energy distribution can easily be obtained. Therefore, the probability distribution of wind speed is a very important piece of information needed in the assessment of wind energy potential. For this reason, a large number of studies have been published concerning the use of a variety of probability density functions to describe wind speed frequency distributions. Two parameter Weibull distribution is widely used and accepted method. Artificial neural networks (ANN) can be used as an alternative to analytical approach as ANN offers advantages such as no required knowledge of internal system parameters, compact solution for multi-variable problems. In this investigation adaptive neuro-fuzzy inference system (ANFIS), which is a specific type of the ANN family, was used to predict the annual probability density distribution of wind speed. The simulation results presented in this paper show the effectiveness of the developed method. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Petkovic, Dalibor] Univ Nis, Fac Mech Engn, Deparment Mech & Control, Nish 18000, Serbia.
   [Shamshirband, Shahaboddin] Univ Malaya, Fac Comp Sci & Informat Technol, Dept Comp Syst & Technol, Kuala Lumpur 50603, Malaysia.
   [Tong, Chong Wen] Univ Malaya, Fac Engn, Dept Mech Engn, Kuala Lumpur 50603, Malaysia.
   [Al-Shammari, Eiman Tamah] Kuwait Univ, Coll Comp Sci & Engn, Dept Informat Sci, Kuwait, Kuwait.
RP Petkovic, D (reprint author), Univ Nis, Fac Mech Engn, Deparment Mech & Control, Aleksandra Medvedeva 14, Nish 18000, Serbia.
EM dalibortc@gmail.com; dr.eiman@ku.edu.kw
RI Chong, Wen Tong/B-8396-2010; Engineering, Faculty/I-7935-2015
OI Chong, Wen Tong/0000-0002-9208-9908; Engineering,
   Faculty/0000-0002-4848-7052
FU University of Malaya [RP015C-13AET]; High Impact Research Grant
   [HIR-D000015-16001]; Malaysian Ministry of Education (MOE) [FP053-2013B]
FX The authors would like to thank the University of Malaya for the
   research grants allocated for the financial support (RP015C-13AET) and
   High Impact Research Grant (HIR-D000015-16001). Special appreciation is
   also credited to the Malaysian Ministry of Education (MOE) for the
   Fundamental Research Grant Scheme (FP053-2013B).
CR Akdag SA, 2009, ENERG CONVERS MANAGE, V50, P1761, DOI 10.1016/j.enconman.2009.03.020
   Al-Ghandoor A, 2009, JORDAN J MECH IND EN, V3, P69
   Almalki SJ, 2014, RELIAB ENG SYST SAFE, V124, P32, DOI 10.1016/j.ress.2013.11.010
   Ata R, 2010, EXPERT SYST APPL, V37, P5454, DOI 10.1016/j.eswa.2010.02.068
   Carta JA, 2007, RENEW ENERG, V32, P518, DOI 10.1016/j.renene.2006.05.005
   Celik AN, 2013, APPL ENERG, V101, P582, DOI 10.1016/j.apenergy.2012.06.040
   Celik AN, 2003, J WIND ENG IND AEROD, V91, P693, DOI 10.1016/S0167-6105(02)00471-3
   Celik AN, 2003, ENERG CONVERS MANAGE, V44, P3057, DOI 10.1016/S0196-8904(03)00075-X
   Chang TP, 2011, APPL ENERG, V88, P272, DOI 10.1016/j.apenergy.2010.06.018
   Ekici BB, 2011, EXPERT SYST APPL, P38
   Gocic M, 2006, COMPUT ELECTRON AGR, V113, P164
   Gocic M, RISK, P1
   Inal M, 2008, J MATER PROCESS TECH, V195, P34, DOI 10.1016/j.jmatprotec.2007.04.106
   JANG JSR, 1993, IEEE T SYST MAN CYB, V23, P665, DOI 10.1109/21.256541
   Kantar YM, 2008, ENERG CONVERS MANAGE, V49, P962, DOI 10.1016/j.enconman.2007.10.008
   Kurnaz S, 2010, EXPERT SYST APPL, V37, P1229, DOI 10.1016/j.eswa.2009.06.009
   Li MS, 2005, RENEW ENERG, V30, P1221, DOI 10.1016/j.renene.2004.10.003
   Lo SP, 2005, J MATER PROCESS TECH, V168, P250, DOI 10.1016/j.jmatprotec.2005.01.010
   Marziye Yousefi, RISK, P1
   Mohandes M, 2011, APPL ENERG, V88, P4024, DOI 10.1016/j.apenergy.2011.04.015
   Petkovic D, 2012, NEURAL COMPUT APPL, V21, P2065
   Petkovic D, 2012, EXPERT SYST APPL, V39, P13295, DOI 10.1016/j.eswa.2012.05.072
   Petkovic D, 2012, EXPERT SYST APPL, V39, P9477, DOI 10.1016/j.eswa.2012.02.111
   Ramirez P, 2005, ENERG CONVERS MANAGE, V46, P2419, DOI 10.1016/j.enconman.2004.11.004
   Shamshirband S, 2006, INT J ELEC POWER, V63, P618
   Shamshirband S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103414
   Shamshirband S, 2013, ENG APPL ARTIF INTEL, V26, P2105, DOI 10.1016/j.engappai.2013.04.010
   Singh R, 2012, APPL SOFT COMPUT, V12, P40, DOI 10.1016/j.asoc.2011.09.010
   Stevens M. J. M., 1979, Wind Engineering, V3, P132
   Sunderland K, 2013, J WIND ENG IND AEROD, V121, P70, DOI 10.1016/j.jweia.2013.08.001
   Tian LF, 2005, MECHATRONICS, V15, P1305, DOI 10.1016/j.mechatronics.2005.02.001
NR 31
TC 20
Z9 20
U1 4
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0955-5986
EI 1873-6998
J9 FLOW MEAS INSTRUM
JI Flow Meas. Instrum.
PD JUN
PY 2015
VL 43
BP 47
EP 52
DI 10.1016/j.flowmeasinst.2015.03.003
PG 6
WC Engineering, Mechanical; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA CK3HC
UT WOS:000356106200006
DA 2018-12-27
ER

PT J
AU Zhang, AG
   Zhang, X
   Tan, XL
   Cai, B
   Ge, WJ
   Dai, GD
   Cai, JP
AF Zhang, Aiguo
   Zhang, Xian
   Tan, Xiangling
   Cai, Bin
   Ge, Wenjie
   Dai, Guoda
   Cai, Jianping
TI RETRACTED: Resveratrol rescued the TNF-alpha-induced impairments of
   osteogenesis of bone-marrow derived mesenchymal stem cells and inhibited
   the TNF-alpha-activated NP-kappa B signaling pathway (Retracted article.
   See vol. 29, pg. 974, 2015)
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Resveratrol; Bone marrow derived mesenchymal stem cells; TNF-alpha;
   NE-kappa B signaling; Inflammatory bone disease
ID NECROSIS-FACTOR-ALPHA; OSTEOBLAST DIFFERENTIATION; EPITHELIAL-CELLS;
   INFLAMMATION; MODEL; OSTEOCLASTOGENESIS; EXPRESSION; RECEPTORS; LIGANDS;
   TISSUE
AB Resveratrol, trans-3,4'-trihydroxystilbene, is a natural phytoalexin. Its anti-inflammatory activity has attracted more and more attention in clinic over the years for the treatment of inflammatory diseases. However, its effect on bone repair and new bone formation in an inflammatory microenvironment is quite little understood, especially when bone-marrow derived mesenchymal stem cells (MSCs) are used in stem cell therapy for the treatment of inflammatory bone diseases. In the present study, we investigated the effect of resveratrol on osteogenic differentiation of primary mouse bone marrow derived MSCs and potential mechanism involved when cells were exposed to TNF-alpha treatment. We found that resveratrol reversed the apoptotic effect of TNF-alpha and abrogated its inhibitory effect on osteogenic differentiation of bone marrow derived MSCs. Mechanistic studies demonstrated that resveratrol rescued the TNF-alpha-induced impairments of osteogenesis, and inhibited TNF-alpha-activated NF-kappa B signaling. Our study may help understand the mechanism involved in the inhibitory effect of inflammatory cytokines on osteogenic differentiation, and highlights the role of resveratrol as a potential therapeutic agent for bone repair and especially in MSC-based cell therapy for the treatment of inflammation-associated bone diseases. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Zhang, Xian; Ge, Wenjie; Dai, Guoda; Cai, Jianping] Wuxi Tradit Chinese Med Hosp, Wuxi 214071, Jiangsu, Peoples R China.
   [Zhang, Aiguo] Wuxi Peoples Hosp, Wuxi 214194, Jiangsu, Peoples R China.
   [Tan, Xiangling] Nantong Univ, Sch Life Sci, Nantong 226019, Jiangsu, Peoples R China.
   [Cai, Bin] Guangxi Med Univ, Nanning 530021, Guangxi, Peoples R China.
RP Cai, JP (reprint author), Wuxi Tradit Chinese Med Hosp, Wuxi 214071, Jiangsu, Peoples R China.
EM jpcai123@163.com
CR Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Ahn J, 2007, BIOCHEM BIOPH RES CO, V364, P972, DOI 10.1016/j.bbrc.2007.10.109
   Alexander NS, 2011, LARYNGOSCOPE, V121, P1313, DOI 10.1002/lary.21798
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bereswill S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015099
   Bertelli AAE, 2001, THERAPIE, V56, P613
   Cerqueira AM, 2013, CAN J PHYSIOL PHARM, V91, P248, DOI 10.1139/cjpp-2012-0268
   Ehnert S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014073
   Fu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102535
   Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gomez-Zorita S, 2013, NUTRITION, V29, P1374, DOI 10.1016/j.nut.2013.04.014
   Gorbunov N, 2012, J CELL MOL MED, V16, P174, DOI 10.1111/j.1582-4934.2011.01281.x
   Horowitz MC, 2001, CYTOKINE GROWTH F R, V12, P9, DOI 10.1016/S1359-6101(00)00030-7
   Konyalioglu S, 2013, NEURAL REGEN RES, V8, P485, DOI 10.3969/j.issn.1673-5374.2013.06.001
   Kristjansson B., 2014, STEM CELLS INT, V2014
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-70
   Larrosa M, 2011, EUR J NUTR, V50, P673, DOI 10.1007/s00394-011-0178-3
   Larrosa M, 2009, J AGR FOOD CHEM, V57, P2211, DOI 10.1021/jf803638d
   Losso JN, 2010, J AGR FOOD CHEM, V58, P8246, DOI 10.1021/jf1012067
   MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549
   Marino A, 2013, PATHOG DIS, V68, P61, DOI 10.1111/2049-632X.12046
   Martin AR, 2006, BRIT J PHARMACOL, V147, P873, DOI 10.1038/sj.bjp.0706469
   Moon SJ, 2013, INT J MOL MED, V31, P769, DOI 10.3892/ijmm.2013.1269
   Mukai T, 2007, BIOCHEM BIOPH RES CO, V356, P1004, DOI 10.1016/j.bbrc.2007.03.099
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Palmieri D, 2011, J SURG RES, V171, pE237, DOI 10.1016/j.jss.2011.07.041
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Sanchez-Fidalgo S, 2010, EUR J PHARMACOL, V633, P78, DOI 10.1016/j.ejphar.2010.01.025
   Tian J, 2013, RHEUMATOL INT, V33, P1829, DOI 10.1007/s00296-012-2657-0
   Tili E., 2011, J NUCL ACIDS, V2011, DOI DOI 10.4061/2011/102431
   Uguralp S, 2008, PEDIATR SURG INT, V24, P425, DOI 10.1007/s00383-008-2116-x
   Wang DT, 2014, INT IMMUNOPHARMACOL, V19, P206, DOI 10.1016/j.intimp.2014.02.002
   Xiao J, 2013, J DIABETES RES, V2013
   Zhu XX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027081
NR 36
TC 4
Z9 6
U1 4
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD JUN
PY 2015
VL 26
IS 2
BP 409
EP 415
DI 10.1016/j.intimp.2015.04.026
PG 7
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA CK3JW
UT WOS:000356113400016
PM 25921029
DA 2018-12-27
ER

PT J
AU Zhang, YB
   Wei, C
   Xi, JH
   Tang, ZG
   Liang, CZ
AF Zhang, Yanbin
   Wei, Can
   Xi, Junhua
   Tang, Zhiguo
   Liang, Chaozhao
TI RETRACTED: Glucose transporter 3 performs a critical role in
   mTOR-mediated oncogenic glycolysis and tumorigenesis (Retracted article.
   See vol. 10, pg. 3332, 2015)
SO ONCOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE mTOR; Glut3; glycolysis; tumorigenesis
ID AEROBIC GLYCOLYSIS; UP-REGULATION; NULL-CELLS; GLUT3; PATHWAY; GROWTH;
   CANCER; EXPRESSION; CARCINOMA; TSC2
AB The present study aimed to examine the relationship between mammalian target of rapamycin (mTOR) and glucose transporter 3 (Glut3) in the process of mTOR-mediated oncogenic glycolysis and tumorigenesis. Western blot analysis and quantitative polymerase chain reaction were used to compare the expression of Glut3 in mouse embryonic fibroblasts (MEFs) null for tuberous sclerosis complex 2 (Tsc2(-/-)) and control Tsc2(+/+) MEFs. In addition, the glycolytic rate was tested following siRNA-mediated knockdown of Glut3 in Tsc2(-/-) cells. To determine whether Glut3 depletion affects the ability of cells to form tumors in vivo. Tsc2(-/-) MEFs infected shGlut3 and shControl were injected into nude mice subcutaneously. The present study demonstrated that the expression of Glut3 is controlled by mTOR in Tsc2(-/-) cells and that downregulation of Glut3 reduced the glycolytic rate in Tsc2(-/-) cells. cells. Further studies in nude mice demonstrated that reduced Glut3 expression levels reduced the tumorigenetic effect in cells with hyperactive mTOR complex 1 (mTORC1). The present study indicates for the first time that Glut3 is a downstream target of mTORC1 and that Glut3 is critical in mTORC1-associated tumorigenesis. Therefore, Glut3 is a potential target for the treatment of diseases associated with dysregulated mTORC1 signaling.
C1 [Zhang, Yanbin; Wei, Can; Xi, Junhua; Tang, Zhiguo; Liang, Chaozhao] Anhui Med Univ, Dept Urol, Affiliated Hosp 1, Hefei 230032, Anhui, Peoples R China.
   [Zhang, Yanbin; Wei, Can; Liang, Chaozhao] Anhui Med Univ, Dept Urol, Hefei Hosp Affiliated, Hefei 230032, Anhui, Peoples R China.
   [Zhang, Yanbin; Wei, Can; Liang, Chaozhao] Second Peoples Hosp Hefei, Hefei 230011, Anhui, Peoples R China.
RP Liang, CZ (reprint author), Anhui Med Univ, Dept Urol, Affiliated Hosp 1, 218 Jixi Rd, Hefei 230032, Anhui, Peoples R China.
EM docliangchaozhao@163.com
FU National Natural Science Foundation of China [81101524]
FX The present study was supported by the National Natural Science
   Foundation of China (grant no. 81101524).
CR Adekola K, 2012, CURR OPIN ONCOL, V24, P650, DOI 10.1097/CCO.0b013e328356da72
   Cho CH, 2011, EXP MOL MED, V43, P231, DOI 10.3858/emm.2011.43.5.032
   Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007
   Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Ha TK, 2012, CANCER RES, V72, P4097, DOI 10.1158/0008-5472.CAN-12-0448
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Honjo S, 2014, INT J ONCOL, V45, P567, DOI 10.3892/ijo.2014.2450
   Huang JX, 2009, BIOCHEM SOC T, V37, P217, DOI 10.1042/BST0370217
   Jewell JL, 2013, TRENDS BIOCHEM SCI, V38, P233, DOI 10.1016/j.tibs.2013.01.004
   Jozwiak P, 2012, MOL MED REP, V6, P601, DOI 10.3892/mmr.2012.969
   Krueger DA, 2013, PEDIATR NEUROL, V49, P255, DOI 10.1016/j.pediatrneurol.2013.08.002
   Krzeslak A, 2012, PATHOL ONCOL RES, V18, P721, DOI 10.1007/s12253-012-9500-5
   Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lopez-Rivera E, 2014, CANCER RES, V74, P1067, DOI 10.1158/0008-5472.CAN-13-0588
   Masin M, 2014, CANC METAB, V29, P11
   Moolthiya P, 2014, ONCOL LETT, V7, P854, DOI 10.3892/ol.2014.1799
   Ayala FRR, 2010, MOLECULES, V15, P2374, DOI 10.3390/molecules15042374
   Simpson IA, 2008, AM J PHYSIOL-ENDOC M, V295, pE242, DOI 10.1152/ajpendo.90388.2008
   Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470
   Younes M, 1997, CANCER, V80, P1046, DOI 10.1002/(SICI)1097-0142(19970915)80:6<1046::AID-CNCR6>3.0.CO;2-7
NR 24
TC 1
Z9 1
U1 2
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUN
PY 2015
VL 9
IS 6
BP 2809
EP 2814
DI 10.3892/ol.2015.3075
PG 6
WC Oncology
SC Oncology
GA CJ4ZS
UT WOS:000355497800067
PM 26137152
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Bachmann, C
   Bachmann, R
   Brucker, SY
   Staebler, A
   Fend, F
   Grischke, EM
   Wallwiener, D
AF Bachmann, Cornelia
   Bachmann, Robert
   Brucker, Sara Y.
   Staebler, Anette
   Fend, Falko
   Grischke, Eva-Maria
   Wallwiener, Diethelm
TI RETRACTED: Role of Pelvic and Para-aortic Lymph Node Metastases in
   Optimally Cytoreduced Advanced Ovarian Cancer (Retracted article. See
   vol. 35, pg. 4372, 2015)
SO ANTICANCER RESEARCH
LA English
DT Article; Retracted Publication
DE Advanced ovarian cancer; node ratio; lymphadenectomy; prognosis;
   residual tumor; node metastases
ID EXPLORATORY ANALYSIS; LYMPHADENECTOMY; SURVIVAL; IMPACT; MANAGEMENT;
   CARCINOMA; RESECTION
AB Aim: To delineate the role of pelvic and paraaortic node involvement in patients with optimally cytoreduced (R <= 1 cm; R=residual tumor) stage IIIC ovarian cancer. Patients and Methods: Ninety-five consecutive optimally cytoreduced patients with primary stage IIIc ovarian cancer underwent stage-related surgery and adjuvant platinum-based chemotherapy, with a median follow-up of 53.5 months. All patients underwent systematic lymphadenectomy. On average, 24.7 pelvic and para-aortic lymph nodes were removed per patient (range= 1-60 nodes); Patients were stratified into three groups to evaluate nodal involvement (ratio of affected to resected nodes): 0: no lymph node metastases; > 0-0.5: > 0 and fewer than 50% of involved nodes; > 0.5-1: more than 50% of nodes involved. Clinical parameters were retrospectively evaluated. Results: Most often, serous histology, histological grade 3 and a node ratio > 0-= 0.5 (61.1%) were detected. Complete cytoreduction (R= 0 mm) had significant best prognostic impact compared to R> 0 mm(-1) cm (overall survival: p= 0.047, progression-free survival: p< 0.001). Nodal involvement was associated with serous histology and grade 3 tumor. Best overall survival was associated with a node ratio > 0-= 0.5 (p= 0.011). A solitary affection of the pelvic or rather para-aortic nodes was detected in 22.1% vs. 16.%, respectively; a combined affection of pelvic and paraaortic nodes were detected in 34.8%. Conclusion: The goal is optimal cytoreduction in advanced ovarian cancer. More extensive pelvic and para-aortic lymphadenectomy seems to play an important role in providing accurate staging in optimally-cytoreduced advanced ovarian cancer and the node ratio might give prognostic information. Current prospective studies should investigate if these data have therapeutic implications and may be considered in future staging.
C1 [Bachmann, Cornelia; Brucker, Sara Y.; Grischke, Eva-Maria; Wallwiener, Diethelm] Univ Tubingen, Dept Gynecol, D-72070 Tubingen, Germany.
   [Staebler, Anette; Fend, Falko] Univ Tubingen, Dept Pathol, D-72070 Tubingen, Germany.
   [Bachmann, Robert] Univ Tubingen Hosp, Dept Gen Visceral & Transplant Surg, Tubingen, Germany.
RP Bachmann, C (reprint author), Univ Tubingen, Dept Gynecol, Calwer Str 7, D-72070 Tubingen, Germany.
EM cornelia.bachmann@med.uni-tuebingen.de
CR Abe A, 2010, J OBSTET GYNAECOL RE, V36, P1023, DOI 10.1111/j.1447-0756.2010.01274.x
   Aletti GD, 2006, AM J OBSTET GYNECOL, V195, P1862, DOI 10.1016/j.ajog.2006.06.068
   Bachmann C, 2012, J CANCER RES CLIN, V138, P261, DOI 10.1007/s00432-011-1094-x
   Bakkar R, 2014, INT J GYNECOL PATHOL, V33, P302, DOI 10.1097/PGP.0b013e3182988dfd
   Balbi G, 2009, EUR J GYNAECOL ONCOL, V30, P289
   Carnino F, 1997, GYNECOL ONCOL, V65, P467, DOI 10.1006/gyno.1997.4633
   Chan JK, 2007, BRIT J CANCER, V96, P1817, DOI 10.1038/sj.bjc.6603803
   Chekerov R, 2013, INT J GYNECOL CANCER, V23, P268, DOI 10.1097/IGC.0b013e31827de6b9
   diRe F, 1996, GYNECOL ONCOL, V62, P360, DOI 10.1006/gyno.1996.0249
   du Bois A, 2009, CANCER, V115, P1234, DOI 10.1002/cncr.24149
   Harter P, 2007, INT J GYNECOL CANCER, V17, P1238, DOI 10.1111/j.1525-1438.2007.00931.x
   Hohn AK, 2014, PATHOLOGE, V35, P322, DOI 10.1007/s00292-014-1908-0
   HOSKINS WJ, 1994, AM J OBSTET GYNECOL, V170, P974, DOI 10.1016/S0002-9378(94)70090-7
   Kim HS, 2010, INT J GYNECOL CANCER, V20, P520, DOI 10.1111/IGC.0b013e3181d6de1d
   Mahdi H, 2011, J SURG ONCOL, V103, P724, DOI 10.1002/jso.21869
   Nomura H, 2010, INT J GYNECOL CANCER, V20, P341, DOI 10.1111/IGC.0b013e3181cf6271
   Onda T, 1998, CANCER, V83, P1555, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1555::AID-CNCR10>3.0.CO;2-R
   Panici PB, 2005, J NATL CANCER I, V97, P560, DOI 10.1093/jnci/dji102
   Pereira A, 2012, INT J GYNECOL CANCER, V22, P987, DOI 10.1097/IGC.0b013e318257b958
   Scarabelli C, 1997, INT J GYNECOL CANCER, V7, P18, DOI 10.1046/j.1525-1438.1997.00418.x
   Suh DH, 2013, J GYNECOL ONCOL, V24, P352, DOI 10.3802/jgo.2013.24.4.352
   Takeshima N, 2005, GYNECOL ONCOL, V99, P427, DOI 10.1016/j.ygyno.2005.06.051
   Ulker V, 2014, ARCH GYNECOL OBSTET, V289, P1087, DOI 10.1007/s00404-013-3078-3
   Wimberger P, 2007, GYNECOL ONCOL, V106, P69, DOI 10.1016/j.ygyno.2007.02.026
NR 24
TC 3
Z9 4
U1 1
U2 9
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUN
PY 2015
VL 35
IS 6
BP 3479
EP 3484
PG 6
WC Oncology
SC Oncology
GA CJ1VW
UT WOS:000355273800042
PM 26026113
DA 2018-12-27
ER

PT J
AU Sakr, M
AF Sakr, Mohammed
TI RETRACTED: Relationship between installation torque and axial capacities
   of helical piles in cohesionless soils (Retracted article. See vol. 54,
   pg.1356, 2017)
SO CANADIAN GEOTECHNICAL JOURNAL
LA English
DT Article; Retracted Publication
DE helical piles; screw piles; torque; capacity; cohesionless; sand;
   compression; tension
ID SAND; TENSILE
AB With the rapid growth of the helical piling industry for oil and gas projects and transmission lines, reliable installation torque estimates and measurements become crucial. This paper presents a theoretical model developed to estimate the torsional resistance of cohesionless soils to helical pile installation. The theoretical torque model was verified using installation records collected from different sites. The paper also highlights factors that affect helical pile installation, including soil properties, fluctuation in groundwater levels, shape of pile shaft, pile geometry, and method of helical pile installation. The proposed torsional resistance model was then used to establish the traditional torque factors to proportionally correlate the axial capacity of helical pile and the installation torque. The results of the study indicated that the torque factor is a function of the load path (i.e., tension or compression). Therefore, torque factors in compression and tension, K-c and K-t, respectively, were formulated and presented in the paper.
C1 [Sakr, Mohammed] Univ Western Ontario, London, ON, Canada.
RP Sakr, M (reprint author), 2604 Bowen Way, Edmonton, AB, Canada.
EM mohammed.sakr2011@gmail.com
CR Adams J. I., 1972, CANADIAN GEOTECHNICA, V9, P89, DOI DOI 10.1139/T72-007
   Tsuha CDC, 2010, CAN GEOTECH J, V47, P635, DOI 10.1139/T09-128
   Cerato AB, 2009, J PERFORM CONSTR FAC, V23, P251, DOI 10.1061/(ASCE)CF.1943-5509.0000013
   CFEM, 2006, CAN FDN ENG MAN
   Das B, 1975, J GEOTECH ENG DIV, P999
   Das B. M., 1990, EARTH ANCHORS
   Deardorff D., 2011, SEM DFI HEL FDN TIEB
   DENICOLA A, 1993, J GEOTECH ENG-ASCE, V119, P1952, DOI 10.1061/(ASCE)0733-9410(1993)119:12(1952)
   Dilley L., 2007, P ARCT EN SUMM ANCH
   GHALY A, 1991, CAN GEOTECH J, V28, P353, DOI 10.1139/t91-046
   Hawkins K., 2009, GEOTECHNICAL SPECIAL, V185, P488, DOI [10.1061/41021(335)61, DOI 10.1061/41021(335)61]
   Hoyt R. M., 1989, P 12 INT C SOIL, V2, P1019
   Kraft D.C., 2003, P 28 ANN C DEEP FDN, P209
   Livneh B, 2008, CAN GEOTECH J, V45, P1142, DOI 10.1139/T08-044
   Perko H. A, 2009, HELICAL PILES PRACTI
   Perko H.A., 2001, NEW TECHNOLOGIES DES, P342, DOI [10.1061/40511(288)24, DOI 10.1061/40511(288)24]
   Sakr M., 2009, 34 ANN DEEP FDN C DF
   Sakr M, 2011, 64 CAN GEOT C PAN AM
   Sakr M, 2012, DFI J, V6, P41, DOI [10.1179/dfi.2012.004, DOI 10.1179/DFI.2012.004]
   Sakr M, 2015, J PERFORM CONSTR FAC, V29, DOI 10.1061/(ASCE)CF.1943-5509.0000621
   Sakr M, 2009, CAN GEOTECH J, V46, P1046, DOI 10.1139/T09-044
   Spagnoli G, 2013, SOIL MECH FOUND ENG+, V50, P102, DOI 10.1007/s11204-013-9219-7
   Tappenden K. M., 2007, THESIS
   Zhang DJY, 1999, THESIS
NR 24
TC 9
Z9 10
U1 1
U2 5
PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008-3674
EI 1208-6010
J9 CAN GEOTECH J
JI Can. Geotech. J.
PD JUN
PY 2015
VL 52
IS 6
BP 747
EP 759
DI 10.1139/cgj-2013-0395
PG 13
WC Engineering, Geological; Geosciences, Multidisciplinary
SC Engineering; Geology
GA CJ1PG
UT WOS:000355255400008
DA 2018-12-27
ER

PT J
AU Noor, MJ
   Sultana, S
   Fatima, S
   Ahmad, M
   Zafar, M
   Sarfraz, M
   Balkhyour, MA
   Safi, SZ
   Ashraf, MA
AF Noor, Mehwish Jamil
   Sultana, Shazia
   Fatima, Sonia
   Ahmad, Mushtaq
   Zafar, Muhammad
   Sarfraz, Maliha
   Balkhyour, Masour A.
   Safi, Sher Zaman
   Ashraf, Muhammad Aqeel
TI RETRACTED: Estimation of Anticipated Performance Index and Air Pollution
   Tolerance Index and of vegetation around the marble industrial areas of
   Potwar region: bioindicators of plant pollution response (Retracted
   article. See vol. 39, pg. 705, 2017)
SO ENVIRONMENTAL GEOCHEMISTRY AND HEALTH
LA English
DT Article; Retracted Publication
DE Pollution; Plants; Biomonitoring; Marble
ID ENVIRONMENTAL-POLLUTION; DUST ACCUMULATION; PIGMENT CONTENT; INDIA;
   INDICATORS; STRESS; PARAMETERS; GROWTH; BRAZIL; WASTE
AB Mitigating industrial air pollution is a big challenge, in such scenario screening of plants as a bio monitor is extremely significant. It requires proper selection and screening of sensitive and tolerant plant species which are bio indicator and sink for air pollution. The present study was designed to evaluate the Air Pollution Tolerance Index (APTI) and Anticipated Performance Index (API) of the common flora. Fifteen common plant species from among trees, herb and shrubs i.e. Chenopodium album (Chenopodiaceae), Parthenium hysterophorus (Asteraceae), Amaranthus viridis (Amaranthaceae), Lantana camara (Verbenaceaea), Ziziphus nummulari (Rhamnaceae), Silibum merianum (Asteraceae), Cannabis sativa (Cannabinaceae), Calatropis procera (Asclepediaceae), Ricinus communis (Euphorbiaceae), Melia azadirachta (Meliaceae), Psidium guajava (Myrtaceae), Eucalyptus globules (Myrtaceae), Broussonetia papyrifera (Moraceae), Withania somnifera (Solanaceae) and Sapium sabiferum (Euphorbiaceae) were selected growing frequently in vicinity of Marble industries in Potwar region. APTI and API of selected plant species were analyzed by determining important biochemical parameter i.e. total chlorophyll, ascorbic acid, relative water content and pH etc. Furthermore the selected vegetation was studied for physiological, economic, morphological and biological characteristics. The soil of studied sites was analyzed. It was found that most the selected plant species are sensitive to air pollution. However B. papyrifera, E. globulus and R. communis shows the highest API and therefore recommended for plantation in marble dust pollution stress area.
C1 [Noor, Mehwish Jamil; Sultana, Shazia; Fatima, Sonia] Fatima Jinnah Women Univ, Dept Environm Sci, Rawalpindi 46000, Pakistan.
   [Ahmad, Mushtaq; Zafar, Muhammad] Quaid I Azam Univ, Dept Plant Sci, Islamabad 45320, Pakistan.
   [Sarfraz, Maliha] Univ Agr Faisalabad, Dept Physiol & Pharmacol, Faisalabad 38040, Pakistan.
   [Balkhyour, Masour A.] King Abdulaziz Univ, Dept Environm Sci, Jeddah 22254, Saudi Arabia.
   [Safi, Sher Zaman] Univ Malaya, Dept Med, Fac Med, Kuala Lumpur 50603, Malaysia.
   [Ashraf, Muhammad Aqeel] Univ Malaya, Dept Geol, Fac Sci, Kuala Lumpur 50603, Malaysia.
   [Ashraf, Muhammad Aqeel] Univ Malaya, Ctr Res Waste Management, Kuala Lumpur 50603, Malaysia.
RP Ashraf, MA (reprint author), Univ Malaya, Dept Geol, Fac Sci, Kuala Lumpur 50603, Malaysia.
EM aqeelashraf@um.edu.my
RI Safi, Sher/G-9599-2014; Ahmad, Mushtaq/I-7263-2015
OI ASHRAF, MUHAMMAD AQEEL/0000-0003-3151-3397
FU High Impact Research MoE from the Ministry of Education Malaysia
   [UM.C/625/1/HIR/MoE/SC/04]; UMRG [RG257-13AFR]; FRGS [FP038-2013B]
FX This research is supported by High Impact Research MoE Grant
   UM.C/625/1/HIR/MoE/SC/04 from the Ministry of Education Malaysia. Thanks
   also for the support by UMRG (RG257-13AFR) and FRGS (FP038-2013B).
CR Ademoroti CMA, 1996, ENV CHEM TOXICOLOGY
   Agbaire P. O., 2009, Journal of Applied Sciences and Environmental Management, V13, P11
   Agrawal S., 1997, Indian Forester, V123, P319
   Ashraf MA, 2014, ENVIRON GEOCHEM HLTH, V36, P1165, DOI 10.1007/s10653-014-9620-9
   Babu G. B., 2013, INDIAN J ADV CHEM SC, V2, P16
   Bakiyaraj R., 2014, INT J MODERN RES REV, V2, P1
   Beckett K. Paul, 2000, Journal of Arboriculture, V26, P12
   Belardi G, 2013, ENVIRON SCI POLLUT R, V20, P4711, DOI 10.1007/s11356-012-1434-7
   BRANDT C J, 1973, Environmental Pollution, V4, P207
   Celik MY, 2008, J ENVIRON MANAGE, V87, P106, DOI 10.1016/j.jenvman.2007.01.004
   Deepalakshmi A., 2013, IOSR J ENV SCI TOXIC, V3, P10
   Grover A, 2001, CURR SCI INDIA, V80, P206
   Iqbal Muhammad Zafar, 2001, Turkish Journal of Botany, V25, P19
   Joshi N., 2011, REPORT OPINION, V3, P42
   Joshi P. C., 2007, Environmentalist, V27, P365, DOI 10.1007/s10669-007-9049-0
   Jyothi SJ, 2010, J ENVIRON BIOL, V31, P379
   Kabas S, 2012, J GEOCHEM EXPLOR, V123, P69, DOI 10.1016/j.gexplo.2012.07.008
   KELLER T, 1977, EUR J FOREST PATHOL, V7, P338
   Klumpp G, 2000, SCI TOTAL ENVIRON, V246, P79, DOI 10.1016/S0048-9697(99)00453-2
   Kuddus M, 2011, J ENV RES MANAGEMENT, V2, P42
   Kumar M, 2013, INT J EMERGING TECHN, V13, P388
   Lakshmi P.S., 2009, J ENVIRON SCI, V2, P203
   Lima JS, 2000, ECOTOX ENVIRON SAFE, V46, P275, DOI 10.1006/eesa.1999.1894
   Liu Y.J., 2008, WSEAS T ENV DEV, V4, P24
   Loganathan M., 2012, PHARM GLOBALE IJCP, V11, P23
   Mahecha G., 2013, INT J INNOVATIVE RES, V2, P7927
   Martos I, 2000, J AGR FOOD CHEM, V48, P1498, DOI 10.1021/jf991166q
   Ninave SY, 2001, B ENVIRON CONTAM TOX, V67, P133, DOI 10.1007/s00128-001-0101-3
   Nowak D. J., 1994, AIR POLLUTION REMOVA, P63
   Nowak David J., 2006, Urban Forestry & Urban Greening, V4, P115, DOI 10.1016/j.ufug.2006.01.007
   Nwadinigwe A. O., 2014, African Journal of Biotechnology, V13, P1231, DOI 10.5897/AJB2014.13616
   Overstreet C., 2011, P BELTW COTT C 2011, P252
   PANDEY J, 1994, NEW PHYTOL, V126, P53, DOI 10.1111/j.1469-8137.1994.tb07529.x
   Prajapati S. K., 2012, ENV SKEPTICS CRITICS, V1, P12
   Prajapati SK, 2008, J ENVIRON QUAL, V37, P865, DOI 10.2134/jeq2006.0511
   Prusty BAK, 2005, ECOTOX ENVIRON SAFE, V60, P228, DOI 10.1016/j.ecoenv.2003.12.013
   Radhapriya P, 2012, J ENVIRON BIOL, V33, P635
   Rai PK, 2014, AIR QUAL ATMOS HLTH, V7, P93, DOI 10.1007/s11869-013-0217-8
   Raina A., 2008, NATURAL ENV POLLUT T, V7, P279
   Randhi U. D., 2012, Universal Journal of Environmental Research and Technology, V2, P300
   Rawat J.S., 1996, J ENERGY ENV MONITOR, V12, P109
   Raza S. H., 1988, HYDERABAD INDIAN J B, V11, P91
   Saini Y., 2011, J ENVIRON BIOL, V32, P340
   Salami A., 2004, TANZANIA J SCI, V28, P69
   Saxena P, 2013, ENVIRON TECHNOL, V34, P3059, DOI 10.1080/09593330.2013.800590
   Seyyednejad S. M., 2011, P INT C ENV BIOM BIO, P98
   SHARMA GK, 1980, ANN BOT-LONDON, V45, P77, DOI 10.1093/oxfordjournals.aob.a085802
   Singh Pramod Kumar, 2005, Indian Forester, V131, P71
   SINGH SK, 1983, P S AIR POLL CONTR I, P218
   Sudhalakhsmi C., 2007, Research Journal of Agriculture and Biological Sciences, V3, P299
   Swami A., 2004, HIMALAYAN J ENV ZOOL, V18, P57
   Thakar B., 2010, BIOSCAN, V3, P603
   Tripathi AK, 2007, J ENVIRON BIOL, V28, P127
   Tripathi A, 2009, J ENVIRON BIOL, V30, P545
   Tsega YC, 2014, J ENVIRON BIOL, V35, P185
NR 55
TC 13
Z9 13
U1 4
U2 57
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0269-4042
EI 1573-2983
J9 ENVIRON GEOCHEM HLTH
JI Environ. Geochem. Health
PD JUN
PY 2015
VL 37
IS 3
BP 441
EP 455
DI 10.1007/s10653-014-9657-9
PG 15
WC Engineering, Environmental; Environmental Sciences; Public,
   Environmental & Occupational Health; Water Resources
SC Engineering; Environmental Sciences & Ecology; Public, Environmental &
   Occupational Health; Water Resources
GA CJ2LY
UT WOS:000355317500003
PM 25503327
DA 2018-12-27
ER

PT J
AU Gatto, NM
   Martinez, LC
   Spruijt-Metz, D
   Davis, JN
AF Gatto, Nicole M.
   Martinez, Lauren C.
   Spruijt-Metz, Donna
   Davis, Jaimie N.
TI RETRACTED: LA sprouts randomized controlled nutrition and gardening
   program reduces obesity and metabolic risk in latino youth (Retracted
   article. See vol. 23, pg. 2522, 2015)
SO OBESITY
LA English
DT Article; Retracted Publication
ID VEGETABLE CONSUMPTION; DIETARY INTERVENTION; CONTROLLED-TRIAL; CHILDRENS
   FRUIT; SCHOOL GARDEN; ADOLESCENTS; KNOWLEDGE; PREFERENCES; OVERWEIGHT;
   EDUCATION
AB ObjectiveTo assess the effects of a 12-week gardening, nutrition, and cooking intervention (LA Sprouts) on dietary intake, obesity parameters, and metabolic disease risk among low-income, primarily Hispanic/Latino youth in Los Angeles.
   MethodsThe randomized controlled trial involved four elementary schools [two schools randomized to intervention (172 third-through fifth-grade students); two schools randomized to control (147 third-through fifth-grade students)]. Classes were taught in 90-minute sessions once a week to each grade level for 12 weeks. Data collected at pre- and postintervention included dietary intake via food frequency questionnaire (FFQ), anthropometric measures [BMI, waist circumference (WC)], body fat, and fasting blood samples.
   ResultsLA Sprouts participants had significantly greater reductions in BMI z-scores (0.1-vs. 0.04-point decrease, respectively; P=0.01) and WC (-1.2 cm vs. no change; P<0.001). Fewer LA Sprouts participants had the metabolic syndrome (MetSyn) after the intervention than before, while the number of controls with MetSyn increased. LA Sprouts participants had improvements in dietary fiber intake (+3.5% vs. -15.5%; P=0.04) and less decreases in vegetable intake (-3.6% vs. -26.4%; P=0.04). Change in fruit intake before and after the intervention did not significantly differ between LA Sprouts and control subjects.
   ConclusionsLA Sprouts was effective in reducing obesity and metabolic risk.
C1 [Gatto, Nicole M.] Loma Linda Univ, Sch Publ Hlth, Ctr Nutr Hlth Lifestyles & Dis Prevent, Loma Linda, CA 92350 USA.
   [Martinez, Lauren C.; Spruijt-Metz, Donna] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
   [Spruijt-Metz, Donna] Univ So Calif, Ctr Econ & Social Res, Los Angeles, CA USA.
   [Spruijt-Metz, Donna] Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA.
   [Davis, Jaimie N.] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA.
RP Gatto, NM (reprint author), Loma Linda Univ, Sch Publ Hlth, Ctr Nutr Hlth Lifestyles & Dis Prevent, Loma Linda, CA 92350 USA.
EM ngatto@llu.edu
FU NIH [5R21DK094066]; Keck Foundation
FX This study was supported by funding from the NIH (grant number
   5R21DK094066). A grant from the Keck Foundation provided funding to
   build the school gardens.
CR Bross R, 2010, SEMIN DIALYSIS, V23, P359, DOI 10.1111/j.1525-139X.2010.00743.x
   Centre for Disease Control, 2007, NAT HLTH NUTR EX SUR
   Christian MS, 2014, INT J BEHAV NUTR PHY, V11, DOI 10.1186/s12966-014-0099-7
   Cook S, 2003, ARCH PEDIAT ADOL MED, V157, P821, DOI 10.1001/archpedi.157.8.821
   Cullen KW, 2008, J AM DIET ASSOC, V108, P862, DOI 10.1016/j.jada.2008.02.015
   Daniels SR, 2005, CIRCULATION, V111, P1999, DOI 10.1161/01.CIR.0000161369.71722.10
   Davis JN, 2007, AM J CLIN NUTR, V86, P1331
   Davis JN, 2011, J AM DIET ASSOC, V111, P1224, DOI 10.1016/j.jada.2011.05.009
   Domel SB, 1996, J AM COLL NUTR, V15, P56
   Gatto NM, 2012, J ACAD NUTR DIET, V112, P913, DOI 10.1016/j.jand.2012.01.014
   Gibbs L, 2013, J NUTR EDUC BEHAV, V45, P137, DOI 10.1016/j.jneb.2012.09.004
   Gower BA, 2013, CLIN ENDOCRINOL, V79, P550, DOI 10.1111/cen.12175
   Heim S, 2009, J AM DIET ASSOC, V109, P1220, DOI 10.1016/j.jada.2009.04.009
   Hermann JR, 2006, J NUTR EDUC BEHAV, V38, P201, DOI 10.1016/j.jneb.2006.02.002
   Hunsberger M, 2012, MATERN CHILD NUTR
   International Diabetes Foundation, 2007, IDF CONS DEF MET SYN
   Kamath CC, 2008, J CLIN ENDOCR METAB, V93, P4606, DOI 10.1210/jc.2006-2411
   KIRBY SD, 1995, J NUTR EDUC, V27, P261, DOI 10.1016/S0022-3182(12)80794-1
   Kuczmarski R. J., 2000, VITAL HLTH STAT, V11, P1, DOI DOI 10.1016/J.BBRC.2015.06.114
   Lineberger S. E., 2000, HortTechnology, V10, P593
   Martinez LC, CONT CLIN T IN PRESS
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   McAleese JD, 2007, J AM DIET ASSOC, V107, P662, DOI 10.1016/j.jada.2007.01.015
   Mirza NM, 2013, AM J CLIN NUTR, V97, P276, DOI 10.3945/ajcn.112.042630
   Morgan PJ, 2010, PUBLIC HEALTH NUTR, V13, P1931, DOI 10.1017/S1368980010000959
   Morris JL, 2002, J AM DIET ASSOC, V102, P91, DOI 10.1016/S0002-8223(02)90027-1
   Narayan KMV, 2003, JAMA-J AM MED ASSOC, V290, P1994
   Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732
   Parmer SM, 2009, J NUTR EDUC BEHAV, V41, P212, DOI 10.1016/j.jneb.2008.06.002
   Ratcliffe MM, 2011, HEALTH PROMOT PRACT, V12, P36, DOI 10.1177/1524839909349182
   Reilly JJ, 2003, ARCH DIS CHILD, V88, P748, DOI 10.1136/adc.88.9.748
   Sobal J, 1998, HDB OBESITY TREATMEN, P515
   THOMPSON FE, 1994, J NUTR, V124, pS2245, DOI 10.1093/jn/124.suppl_11.2245s
   U.S. Department of Education National Center for Education Statistics America's Children, 2002, KEY NAT IND WELL BEI
   Ventura E, 2009, ARCH PEDIAT ADOL MED, V163, P320, DOI 10.1001/archpediatrics.2009.11
   Wang M, 2010, J ADOLESCENT HEALTH, V46, P1
   Wardle J, 2002, J EPIDEMIOL COMMUN H, V56, P595, DOI 10.1136/jech.56.8.595
   Waters E, 2011, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD001871.PUB3
NR 38
TC 7
Z9 9
U1 5
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD JUN
PY 2015
VL 23
IS 6
BP 1244
EP 1251
DI 10.1002/oby.21077
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA CJ0FG
UT WOS:000355150300017
PM 25960146
OA Green Accepted, Bronze
DA 2018-12-27
ER

PT J
AU Shelton, R
AF Shelton, Richard
TI RETRACTED: FISHES A guide to their diversity(Retracted article.See
   vol.65,pg.1122,2016)
SO TLS-THE TIMES LITERARY SUPPLEMENT
LA English
DT Book Review; Retracted Publication
C1 [Shelton, Richard] Buckland Fdn, Mansfield, PA USA.
RP Shelton, R (reprint author), Buckland Fdn, Mansfield, PA USA.
CR HASTINGS PA, FISHES GUIDE THEIR D
NR 1
TC 0
Z9 0
U1 1
U2 2
PU TIMES SUPPLEMENTS LIMITED
PI MARKET HARBOROUGH
PA TOWER HOUSE, SOVEREIGN PARK, MARKET HARBOROUGH LE87 4JJ, ENGLAND
SN 0307-661X
EI 1366-7211
J9 TLS-TIMES LIT SUPPL
JI TLS-Times Lit. Suppl.
PD MAY 29
PY 2015
IS 5852
BP 24
EP 24
PG 1
WC Humanities, Multidisciplinary
SC Arts & Humanities - Other Topics
GA CJ6AJ
UT WOS:000355575100040
DA 2018-12-27
ER

PT J
AU Krishnamoorthy, S
   Alli, P
AF Krishnamoorthy, Somasundaram
   Alli, P.
TI RETRACTED: A Novel Image Recuperation Approach for Diagnosing and
   Ranking Retinopathy Disease Level Using Diabetic Fundus Image(Retracted
   article. See vol.12, art no. e0181891, 2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
AB Retinal fundus images are widely used in diagnosing and providing treatment for several eye diseases. Prior works using retinal fundus images detected the presence of exudation with the aid of publicly available dataset using extensive segmentation process. Though it was proved to be computationally efficient, it failed to create a diabetic retinopathy feature selection system for transparently diagnosing the disease state. Also the diagnosis of diseases did not employ machine learning methods to categorize candidate fundus images into true positive and true negative ratio. Several candidate fundus images did not include more detailed feature selection technique for diabetic retinopathy. To apply machine learning methods and classify the candidate fundus images on the basis of sliding window a method called, Diabetic Fundus Image Recuperation (DFIR) is designed in this paper. The initial phase of DFIR method select the feature of optic cup in digital retinal fundus images based on Sliding Window Approach. With this, the disease state for diabetic retinopathy is assessed. The feature selection in DFIR method uses collection of sliding windows to obtain the features based on the histogram value. The histogram based feature selection with the aid of Group Sparsity Non-overlapping function provides more detailed information of features. Using Support Vector Model in the second phase, the DFIR method based on Spiral Basis Function effectively ranks the diabetic retinopathy diseases. The ranking of disease level for each candidate set provides a much promising result for developing practically automated diabetic retinopathy diagnosis system. Experimental work on digital fundus images using the DFIR method performs research on the factors such as sensitivity, specificity rate, ranking efficiency and feature selection time.
C1 [Krishnamoorthy, Somasundaram] PSNA Coll Engn & Technol, Dept Comp Sci & Engn, Dindigul, Tamil Nadu, India.
   [Alli, P.] Velammal Coll Engn & Technol, Dept Comp Sci & Engn, Madurai, Tamil Nadu, India.
RP Krishnamoorthy, S (reprint author), PSNA Coll Engn & Technol, Dept Comp Sci & Engn, Dindigul, Tamil Nadu, India.
EM soma@psnacet.edu.in
CR Aibinu AM, 2010, COMPUT BIOL MED, V40, P81, DOI 10.1016/j.compbiomed.2009.11.004
   Akara S, 2011, PROCEEDINGS OF THE W
   Akara SK., 2008, ELSEVIER JOURNAL, V32, P720
   Atul K, 2012, SECOND INTERNATIONAL
   Deepak KS, 2012, IEEE T MED IMAGING, V31, P766, DOI 10.1109/TMI.2011.2178856
   Dorota RN, 2014, MEDIAT INFLAMM, V14, P1
   Giancardo L, 2012, MED IMAGE ANAL, V16, P216, DOI 10.1016/j.media.2011.07.004
   Girish SR, 2011, EXPERT SYST APPL, V39, P1141
   Jaya K C, 2012, PROCEDIA ENGINEERING, V30, P297
   Jianfei X, 2014, INT J ENDOCRINOL, V14, P65
   Kauppi T., 2013, COMPUT MATH METHOD M, V2013, P1
   Kung YH, 2010, J CHIN MED ASSOC, V73, P396, DOI 10.1016/S1726-4901(10)70085-X
   Midena E, 2011, SAUDI J OPHTHALMOL, V25, P131, DOI 10.1016/j.sjopt.2011.01.010
   Ponnalagu M, 2014, PLOS ONE, V10, P1
   Shraddha T, 2013, INT J ENGG TECH, V13, P85
   Usman AM, 2012, PATTERN RECOGN, V12, P319
   Usman AM, 2012, ENGCOMPUT, V29, P165
NR 17
TC 4
Z9 4
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2015
VL 10
IS 5
AR UNSP e0125542
DI 10.1371/journal.pone.0125542
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI2AC
UT WOS:000354545600019
PM 25974230
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yang, XW
   Li, PZ
   Zhu, LY
   Zhu, SH
AF Yang, Xiang-wu
   Li, Peng-zhou
   Zhu, Li-yong
   Zhu, Shai-hong
TI RETRACTED: Effects of Bariatric Surgery on Incidence of Obesity-Related
   Cancers: A Meta-Analysis (Retracted article. See vol. 22, pg. 1751,
   2016)
SO MEDICAL SCIENCE MONITOR
LA English
DT Article; Retracted Publication
DE Bariatric Surgery; Colorectal Neoplasms; Obesity
ID TERM WEIGHT-LOSS; CONTROLLED INTERVENTION; COLORECTAL-CANCER; GASTRIC
   BYPASS; METAANALYSIS; RISK; MORTALITY; HETEROGENEITY; EXERCISE; TRENDS
AB Background: The aim of this meta-analysis was to investigate possible relationships between bariatric surgery and incidence of obesity-related cancers. Obesity is an established risk factor for obesity-related cancers but the effects of bariatric surgery on incidence of obesity-related cancers are uncertain.
   Material/Methods: We searched 4 electronic databases to identify eligible studies: PubMed, Embase, Web of Science, and Google Scholar. Five observational studies were eligible and included in this meta-analysis. Random-effects or fixed-effects odds ratio (OR) and its corresponding 95% confidence interval (CI) were pooled.
   Results: Meta-analysis of these 5 observational studies revealed that bariatric surgery was associated with a significantly (p=0.0004) reduced incidence of obesity-related cancers (OR=0.43, 95% CI, 0.27-0.69) when compared with control individuals. Pooled estimated data showed that bariatric surgery is associated with a 24% lower colorectal cancer (CRC) risk. No publication bias was detected by Egger's or Begg's tests.
   Conclusions: Although bariatric surgery may significantly reduce incidence of obesity-related cancers, considering the limitations of these included studies, these findings should be confirmed by further well-designed studies.
C1 [Yang, Xiang-wu; Li, Peng-zhou; Zhu, Li-yong; Zhu, Shai-hong] Ctr South Univ, Xiangya Hosp 3, Changsha, Hunan, Peoples R China.
RP Zhu, SH (reprint author), Ctr South Univ, Xiangya Hosp 3, Changsha, Hunan, Peoples R China.
EM zhushaihong@yeah.net
CR Adams TD, 2009, OBESITY, V17, P796, DOI 10.1038/oby.2008.610
   Anderson JW, 2001, AM J CLIN NUTR, V74, P579
   Buchwald H, 2007, SURGERY, V142, P621, DOI 10.1016/j.surg.2007.07.018
   Buchwald H, 2009, AM J MED, V122, P248, DOI 10.1016/j.amjmed.2008.09.041
   Christou NV, 2008, SURG OBES RELAT DIS, V4, P691, DOI 10.1016/j.soard.2008.08.025
   Curioni CC, 2005, INT J OBESITY, V29, P1168, DOI 10.1038/sj.ijo.0803015
   Derogar M, 2013, ANN SURG, V258, P983, DOI 10.1097/SLA.0b013e318288463a
   Egger M, 1998, BRIT MED J, V316, P140
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hofer T, 2008, REJUV RES, V11, P793, DOI 10.1089/rej.2008.0712
   Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80
   Kant P, 2011, GUT, V60, DOI 10.1136/gut.2011.239301.241
   KRAMER FM, 1989, INT J OBESITY, V13, P123
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lynch J, 2012, OBES SURG, V22, P1507, DOI 10.1007/s11695-012-0693-1
   Ma J, 2015, MED SCI MONITOR, V21, P283, DOI 10.12659/MSM.892035
   McCawley GM, 2009, J AM COLL SURGEONS, V208, P1093, DOI 10.1016/j.jamcollsurg.2009.01.045
   Ning Y, 2010, OBES REV, V11, P19, DOI 10.1111/j.1467-789X.2009.00613.x
   O'Brien PE, 2006, OBES SURG, V16, P1032, DOI 10.1381/096089206778026316
   O'Callaghan NJ, 2009, REJUV RES, V12, P169, DOI 10.1089/rej.2008.0819
   Rao SR, 2012, INFLAMM RES, V61, P789, DOI 10.1007/s00011-012-0473-3
   Roberts DL, 2010, ANNU REV MED, V61, P301, DOI 10.1146/annurev.med.080708.082713
   Sainsbury A, 2008, CANCER EPIDEM BIOMAR, V17, P1401, DOI 10.1158/1055-9965.EPI-07-2874
   Shuster JJ, 2011, REV COCHRANE HDB SYS
   Sjostrom L, 2013, J INTERN MED, V273, P219, DOI 10.1111/joim.12012
   Sjostrom L, 2009, LANCET ONCOL, V10, P653, DOI 10.1016/S1470-2045(09)70159-7
   Tacconelli E., 2010, THE LANCET INFECTIOU, V10, P226, DOI [10.1016/S1473-3099(10)70065-7, DOI 10.1016/S1473-3099(10)70065-7]
   Wells GA, 2000, NEWCASTLE OTTAWA SCA
   Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X
NR 29
TC 10
Z9 10
U1 2
U2 13
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD MAY 11
PY 2015
VL 21
BP 1350
EP 1357
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CI0PM
UT WOS:000354439600002
PM 25961664
OA Green Published
DA 2018-12-27
ER

PT J
AU Huo, YJ
   Qiao, L
   Zheng, XW
   Cui, C
   Ma, YF
   Lu, F
AF Huo, Yu-Jia
   Qiao, Ling
   Zheng, Xiao-Wei
   Cui, Cheng
   Ma, Yuan-Fang
   Lu, Feng
TI RETRACTED: MreBCD-associated Cytoskeleton is Required for Proper
   Segregation of the Chromosomal Terminus during the Division Cycle of
   Escherichia Coli (Retracted article. See vol. 128, pg. 3263, 2015)
SO CHINESE MEDICAL JOURNAL
LA English
DT Article; Retracted Publication
DE Cytoskeleton; Escherichia Coli; MreBCD; Segregation of Chromosomal
   Terminus
ID RECOMBINATION; REPLICATION
AB Background: In prokaryotic organisms, the mechanism responsible for the accurate partition of newly replicated chromosomes into daughter cells is incompletely understood. Segregation of the replication terminus of the circular prokaryotic chromosome poses special problems that have not previously been addressed. The aim of this study was to investigate the roles of several protein components (MreB, MreC, and MreD) of the prokaryotic cytoskeleton for the faithful transmission of the chromosomal terminus into daughter cells.
   Methods: Strain LQ1 (mreB::cat), LQ2 (mreC::cat), and LQ3 (mreD::cat) were constructed using the Red recombination system. LQ11/pLAU53, LQ12/pLAU53, LQ13/pLAU53, LQ14/pLAU53, and LQ15/pLAU53 strains were generated by P1transduction of (tetO) 240 -Gm and (lacO) 240 -Km cassettes from strains IL2 and IL29. Fluorescence microscopy was performed to observe localization pattern of fluorescently-labeled origin and terminus foci in wild-type and mutant cells. SOS induction was monitored as gfp fluorescence from PsulA-gfp in log phase cells grown in Luria-Bertani medium at 37 degrees C by measurement of emission at 525 nm with excitation at 470 nm in a microplate fluorescence reader.
   Results: Mutational deletion of the mreB, mreC, or mreD genes was associated with selective loss of the terminus region in approximately 40% of the cells within growing cultures. This was accompanied by significant induction of the SOS DNA damage response, suggesting that deletion of terminus sequences may have occurred by chromosomal cleavage, presumably caused by ingrowth of the division septum prior to segregation of the replicated terminal.
   Conclusions: These results imply a role for the MreBCD cytoskeleton in the resolution of the final products of terminus replication and/or in the specific movement of newly replicated termini away from midcell prior to completion of septal ingrowth. This would identify a previously unrecognized stage in the overall process of chromosome segregation.
C1 [Huo, Yu-Jia; Qiao, Ling; Zheng, Xiao-Wei; Cui, Cheng; Ma, Yuan-Fang; Lu, Feng] Henan Univ, Sch Med, Henan Engn Lab Antibody Med, Kaifeng 475001, Henan, Peoples R China.
RP Lu, F (reprint author), Henan Univ, Sch Med, Henan Engn Lab Antibody Med, Kaifeng 475001, Henan, Peoples R China.
EM Lufeng@henu.edu.cn
FU Natural Science Foundation of China [81372147]; Education Department of
   Henan Province Natural Science Foundation [2010B320001]; Province and
   Ministry [SBGJ090713]; Henan University Fund
FX This work was supported by grants from the Natural Science Foundation of
   China (No. 81372147), the Education Department of Henan Province Natural
   Science Foundation (No. 2010B320001) and Henan University Fund
   co-sponsored by Province and Ministry (No. SBGJ090713).
CR Aertsen A, 2004, J BACTERIOL, V186, P6133, DOI 10.1128/jb.186.18.6133-6141.2004
   Barre FX, 2001, P NATL ACAD SCI USA, V98, P8189, DOI 10.1073/pnas.111008998
   Bigot S, 2004, MOL MICROBIOL, V54, P876, DOI 10.1111/j.1365-2958.2004.04335.x
   Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297
   DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2
   Duggin IG, 2008, MOL MICROBIOL, V70, P1323, DOI 10.1111/j.1365-2958.2008.06500.x
   Espeli O, 2004, MOL MICROBIOL, V52, P925, DOI 10.1111/j.1365-2958.2004.04047.x
   Feng L, 2013, J BIOL CHEM, V288, P2741
   Gitai Z, 2004, P NATL ACAD SCI USA, V101, P8643, DOI 10.1073/pnas.0402638101
   Kruse T, 2003, EMBO J, V22, P5283, DOI 10.1093/emboj/cdg504
   Lau IF, 2003, MOL MICROBIOL, V49, P731, DOI 10.1046/j.1365-2958.2003.03640.x
   Maniatis T., 1982, MOL CLONING LAB MANU
   Miller JH, 1992, SHORT COURSE BACTERI, P268
   Ptacin JL, 2010, NAT CELL BIOL, V12, P791, DOI 10.1038/ncb2083
   Shih YL, 2005, MOL MICROBIOL, V58, P917, DOI 10.1111/j.1365-2958.2005.04841.x
   Shih YL, 2006, MICROBIOL MOL BIOL R, V70, P729, DOI 10.1128/MMBR.00017-06
   Vats P, 2009, MOL MICROBIOL, V72, P170, DOI 10.1111/j.1365-2958.2009.06632.x
NR 17
TC 2
Z9 3
U1 3
U2 12
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD MAY 5
PY 2015
VL 128
IS 9
BP 1209
EP 1214
DI 10.4103/0366-6999.156131
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA CH7AB
UT WOS:000354186800013
PM 25947405
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Nerkar, R
   Yadav, S
   Mehta, V
   Joshi, P
AF Nerkar, Radha
   Yadav, Sonal
   Mehta, Vanisha
   Joshi, Prajakta
TI RETRACTED: Root Canal Preparation in Primary Teeth with Nickel-Titanium
   Rotary Files: A Review (Retracted article. See vol. 6, pg. 55, 2015)
SO JOURNAL OF ADVANCED ORAL RESEARCH
LA English
DT Review; Retracted Publication
DE Nickel titanium; Pulpectomy; Endodontics
ID HANDPIECE
AB Pediatric endodontics is one of the important clinical procedures for pulpaly involved teeth. The use of nickel-titanium rotary files for root canal instrumentation in primary teeth is reviewed in this article. The use of rotary files in primary teeth has several advantages when compared with manual K-files. The pulpectomy technique is described, and the advantages and disadvantages of using rotary files are discussed. This article mainly focuses on the use of rotary endodontic techniques in pulpectomy procedure in primary teeth.
C1 [Nerkar, Radha; Yadav, Sonal; Mehta, Vanisha; Joshi, Prajakta] Vyas Dent Coll & Hosp, Dept Pedodont & Prevent Dent, Pali Rd, Jodhpur, Rajasthan, India.
RP Nerkar, R (reprint author), Vyas Dent Coll & Hosp, Dept Pedodont & Prevent Dent, Pali Rd, Jodhpur, Rajasthan, India.
EM radhaharry6@gmail.com
CR Azar Mohammad-Reza, 2011, Indian J Dent Res, V22, P363, DOI 10.4103/0970-9290.84283
   Barr Elizabeth S., 2000, Pediatric Dentistry, V22, P77
   Barr ES, 2000, J DENT SCI, V22, P77
   Cheung GSP, 1996, J ENDODONT, V22, P131, DOI 10.1016/S0099-2399(96)80289-5
   Farhin K, 2014, I J PRE CLIN DENT RE, V1, P48
   GOLDMAN M, 1987, J ENDODONT, V13, P429, DOI 10.1016/S0099-2399(87)80060-2
   LEHMAN JW, 1982, ORAL SURG ORAL MED O, V53, P417, DOI 10.1016/0030-4220(82)90445-5
   Makarem Abbas, 2014, J Dent Res Dent Clin Dent Prospects, V8, P84, DOI 10.5681/joddd.2014.015
   Nazari Moghaddam K, 2009, IRAN ENDOD J, V4, P53
   Pinheiro SL, 2012, RSBO, V9, P238
NR 10
TC 1
Z9 1
U1 1
U2 6
PU INT SOC PREVENTIVE & COMMUNITY DENTISTRY
PI GUJARAT
PA G/5 ASHRAY TOWER, NEAR SHIV TEMPLE, RAMDEVNAGAR-ANANDNAGAR RD,
   AHMEDABAD, GUJARAT, 380 015, INDIA
SN 2320-2068
EI 2320-2076
J9 J ADV ORAL RES
JI J. Adv. Oral Res.
PD MAY-AUG
PY 2015
VL 6
IS 2
BP 1
EP 4
PG 4
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA DC3RN
UT WOS:000369136500001
DA 2018-12-27
ER

PT J
AU Amdani, SM
   Mendez, M
AF Amdani, Shahnawaz M.
   Mendez, Magda
TI RETRACTED: 7-year-old Girl With Swelling in the Arm (Retracted article)
SO PEDIATRICS IN REVIEW
LA English
DT Review; Retracted Publication
ID SOFT-TISSUE SARCOMAS; SYNOVIAL SARCOMA; CHILDREN
C1 [Amdani, Shahnawaz M.; Mendez, Magda] Lincoln Med & Mental Hlth Ctr, Dept Pediat, Bronx, NY 10451 USA.
RP Amdani, SM (reprint author), Lincoln Med & Mental Hlth Ctr, Dept Pediat, Bronx, NY 10451 USA.
CR Chotel F, 2008, J BONE JOINT SURG BR, V90B, P1090, DOI 10.1302/0301-620X.90B8.19815
   Deshmukh R, 2004, CLIN ORTHOP RELAT R, P155, DOI 10.1097/01.blo.0000111887.82016.b0
   McCarville MB, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.3.1790797
   Park K, 2008, CANCER IMAGING, V8, P102, DOI 10.1102/1470-7330.2008.0014
   Paz-Priel I, 2007, J CLIN ONCOL, V25, P1519, DOI 10.1200/JCO.2006.06.9930
   SCHMIDT D, 1991, CANCER, V67, P1667, DOI 10.1002/1097-0142(19910315)67:6<1667::AID-CNCR2820670631>3.0.CO;2-U
   Stein-Wexler R, 2011, SEMIN ULTRASOUND CT, V32, P470, DOI 10.1053/j.sult.2011.03.006
NR 7
TC 1
Z9 1
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0191-9601
EI 1526-3347
J9 PEDIATR REV
JI Pediatr. Rev.
PD MAY
PY 2015
VL 36
IS 5
BP e14
EP e17
DI 10.1542/pir.36-5-e14
PG 4
WC Pediatrics
SC Pediatrics
GA CO6EZ
UT WOS:000359251300001
PM 25934915
DA 2018-12-27
ER

PT J
AU Raslau, D
AF Raslau, David
TI RETRACTED: Letter to the Editor re: Risk of Prostate Cancer in Pilots: A
   Meta-Analysis Response (Retracted article. See vol. 86, pg. 112, 2015)
SO AEROSPACE MEDICINE AND HUMAN PERFORMANCE
LA English
DT Letter; Retracted Publication
C1 Mayo Clin, Rochester, MN 55905 USA.
RP Raslau, D (reprint author), Mayo Clin, Rochester, MN 55905 USA.
NR 0
TC 1
Z9 1
U1 6
U2 14
PU AEROSPACE MEDICAL ASSOC
PI ALEXANDRIA
PA 320 S HENRY ST, ALEXANDRIA, VA 22314-3579 USA
SN 2375-6314
EI 2375-6322
J9 AEROSP MED HUM PERF
JI Aerosp. Med.Hum. Perform.
PD MAY
PY 2015
VL 86
IS 5
BP 490
EP 491
PG 3
WC Biophysics; Public, Environmental & Occupational Health; Medicine,
   Research & Experimental
SC Biophysics; Public, Environmental & Occupational Health; Research &
   Experimental Medicine
GA CM0OM
UT WOS:000357377800015
PM 25945672
DA 2018-12-27
ER

PT J
AU Al-Salem, SM
AF Al-Salem, S. M.
TI RETRACTED: Carbon dioxide (CO2) estimation from Kuwait's petroleum
   refineries (Retracted article. See vol. 99, pg. 236, 2016)
SO PROCESS SAFETY AND ENVIRONMENTAL PROTECTION
LA English
DT Article; Retracted Publication
DE Carbon dioxide (CO2); Petroleum; Refinery; Heaters; Hydrogen production;
   API; Reforming
ID CAPTURE
AB A detailed study of carbon dioxide (CO2) sources from petroleum refineries in Kuwait was conducted. The aim was to estimate the amount of CO2 being emitted and determine the influencing factors on physical and chemical process in refineries. Three refineries were considered in this work, processing around 900 Mbpd of crude oil. Process heaters stacks constituted 62-75% of the CO2 emissions, ranking at the top of the sources. Hydrogen production (HP) units via steam-methane reforming ranked seconded, in the final assessment, ranging from 12% to 25% in the studied refineries. The configuration of the refinery was determined to be a critical factor in such work. The properties of the processed oil, in terms of density, sulfur content and API were essential in comparing results obtained in this work to other refineries specific rates. Carbon capture and storage (CCS) presents itself as a viable solution for the reduction of the carbon footprint of Kuwait downstream sector, especially when considering the purity of the HP units product gas. The work presented in this paper can be considered as the cornerstone of future carbon mitigation plans in the country. (C) 2015 The Institution of Chemical Engineers. Published by Elsevier B.V. All rights reserved.
C1 Kuwait Inst Sci Res, Petr Res Ctr, Safat 13109, Kuwait.
RP Al-Salem, SM (reprint author), Kuwait Inst Sci Res, Petr Res Ctr, POB 24885, Safat 13109, Kuwait.
EM ssalem@kisr.edu.kw
OI Al-Salem, S.M./0000-0003-0652-4502
FU Kuwait Institute for Scientific Research [PF066K]
FX The author wishes to thank the Kuwait Institute for Scientific Research
   for funding project PF066K. Eng. Ahmed Al-Terkait (Chem. Eng./Energy
   Management Eng.) is gratefully acknowledged for his contribution to this
   work for without which it would have been impossible to conduct. Eng.
   Ayed Al-Fadhlee (Kuwait Petroleum Corporation) has also graciously
   contributed to this workload and is thanked for his support. Eng. Faisal
   Al-Qattan (R&T Department-KNPC) is gratefully acknowledged for his
   contribution in providing process and operational manuals of MAA, SHU
   and MAB.
CR Al-Ajmi A.F., 2010, P OAPEC NOGA JOINT C
   Al-Fadhlee, 2014, COMMUNICATION
   Al-Hajri I., 2008, THESIS U WATERLOO CA, P2008
   Al-Qattan F., 2014, COMMUNICATION
   Al-Salem SM, 2010, INT J CHEM ENG, DOI 10.1155/2010/879836
   Allam R, 2005, CARBON DIOXIDE CAPTURE FOR STORAGE IN DEEP GEOLOGIC FORMATIONS - RESULTS FROM THE CO2 CAPTURE PROJECT, VOLS 1 AND 2, P513
   [Anonymous], 2011, LIBERTY GASES CO2 FA
   API - American Petroleum Institute, 2000, TECHN ROADM
   Brunet S, 2005, APPL CATAL A-GEN, V278, P143, DOI 10.1016/j.apcata.2004.10.012
   Chehadeh D., 2004, P EN CONS ENV PROT P
   Cheremisinoff NP, 2009, HANDBOOK OF POLLUTION PREVENTION AND CLEANER PRODUCTION, VOL 1: BEST PRACTICES IN THE PETROLEUM INDUSTRY, P179, DOI 10.1016/B978-0-8155-2035-1.10006-5
   De Mello L., 2012, P GREENH GAS TECHN W
   DNV - Det Norske Veritas, 2008, 12P5TPP9 DNV
   EC - European Commission, 2014, EU EM TRAD SYST ETS
   Ecofys, 2009, METH FREE ALL EM ALL
   Fahim MA, 2010, FUNDAMENTALS OF PETROLEUM REFINING, P423, DOI 10.1016/B978-0-444-52785-1.00019-X
   Fisher P. W., 2005, HYDROCARB PROCESS, V81, P83
   Gary J. H., 1994, PETROLEUM REFINING T
   HCPC - Hydrocarbon Publishing Company, 2010, REF CO2 MAN STRAT
   Hurst P, 2005, CARBON DIOXIDE CAPTURE FOR STORAGE IN DEEP GEOLOGIC FORMATIONS - RESULTS FROM THE CO2 CAPTURE PROJECT, VOLS 1 AND 2, P117
   IEA, 2004, PROSP CO2 CAPT STOR
   IPCC (Intergovernmental Panel on Climate Change), 2005, IPCC WGH 4 ASS REP C
   IPIECA, 2014, OIL GAS IND GUID VOL
   JNOC - Japan National Oil Corporation, 1998, INV CO2 SOURC KUW
   Johansson D, 2013, ENERG CONVERS MANAGE, V66, P127, DOI 10.1016/j.enconman.2012.09.026
   Johansson D, 2012, ENERGY, V42, P375, DOI 10.1016/j.energy.2012.03.039
   Kam E., 2005, 7629 KUW I SCI RES
   Karras G., 2011, OIL REFINERY CO2 PER
   Lowe C, 2011, ENRGY PROCED, V4, P1058, DOI 10.1016/j.egypro.2011.01.155
   Lu Y., 2007, INVENTORY IND STATIO
   Martin J., 2014, TESTING FLARE EMISSI
   Moore I, 2004, REDUCING CO2 EMISSIO, P1
   Pagano M., 2010, P HYDR PROC INT REF
   Peterson J, 2007, HYDROCARB PROCESS, V86, P111
   Petrick M., 1999, ANLESDTM158
   Romano MC, 2013, ENRGY PROCED, V37, P7176, DOI 10.1016/j.egypro.2013.06.655
   Salman M., 2004, 7238 KUW I SCI RES
   Stockle M., 2008, P ERTC SUST REF C BR
   Szklo A, 2007, ENERGY, V32, P1075, DOI 10.1016/j.energy.2006.08.008
   United States Environmental Protection Agency, 2010, AV EM TECHN RED GREE
   van Straelen J, 2009, ENRGY PROCED, V1, P179, DOI 10.1016/j.egypro.2009.01.026
   van Straelen J, 2010, INT J GREENH GAS CON, V4, P316, DOI 10.1016/j.ijggc.2009.09.022
   Wilkinson MB, 2003, GREENHOUSE GAS CONTROL TECHNOLOGIES, VOLS I AND II, PROCEEDINGS, P69
   Wolschlag L. M., 2009, UOP FCC DESIGN ADVAN
NR 44
TC 2
Z9 2
U1 1
U2 12
PU INST CHEMICAL ENGINEERS
PI RUGBY
PA 165-189 RAILWAY TERRACE, DAVIS BLDG, RUGBY CV21 3HQ, ENGLAND
SN 0957-5820
EI 1744-3598
J9 PROCESS SAF ENVIRON
JI Process Saf. Environ. Protect.
PD MAY
PY 2015
VL 95
BP 38
EP 50
DI 10.1016/j.psep.2015.02.011
PG 13
WC Engineering, Environmental; Engineering, Chemical
SC Engineering
GA CJ3DU
UT WOS:000355364400004
DA 2018-12-27
ER

PT J
AU Wiese, MN
   Kawel-Boehm, N
   de la Santa, PM
   Al-Shahrabani, F
   Toffel, M
   Rosenthal, R
   Schafer, J
   Tamm, M
   Bremerich, J
   Lardinois, D
AF Wiese, Mark Nikolaj
   Kawel-Boehm, Nadine
   de la Santa, Pablo Moreno
   Al-Shahrabani, Feras
   Toffel, Melanie
   Rosenthal, Rachel
   Schaefer, Juliane
   Tamm, Michael
   Bremerich, Jens
   Lardinois, Didier
TI RETRACTED: Functional results after chest wall stabilization with a new
   screwless fixation device (Retracted article. See vol. 53, pg. 695,
   2018)
SO EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
LA English
DT Article; Retracted Publication
DE Chest wall; Trauma; Surgery techniques; Outcome; Imaging
ID MULTIPLE RIB FRACTURES; FLAIL CHEST; OPERATIVE STABILIZATION; SURGICAL
   STABILIZATION; INJURIES; MANAGEMENT; MORBIDITY; OUTCOMES; TRAUMA; PAIN
AB OBJECTIVES: This is the experience with the Stratos system in two surgical centres for the management of two types of rib fractures: flail chest and multiple dislocated rib fractures with significant chest wall deformity.
   METHODS: From January 2009 to May 2012, 94 consecutive patients were included. Selected indications were extended anterolateral flail chest (n = 68) and dislocated painful rib fractures (n = 26). The open reduction internal fixation (ORIF) system consists of flexible titanium rib clamps and connecting plates. The postoperative course was assessed. Clinical and functional outcomes were evaluated at 6 months. Functional assessment consisted of measurement of the functional vital capacity (FVC) and magnetic resonance imaging (MRI) examination with determination of the radiological vital capacity (rVC) in patients with a flail chest.
   RESULTS: The median operation time and length of hospital stay were 122 min and 19 days, respectively, in patients with a flail chest, and 67 min and 11 days, respectively, in patients with dislocated painful rib fractures. The morbidity rate was 6.4% and the overall 30-day mortality rate was 1.1%. Clinical evaluation and pulmonary function testing at 6 months revealed no deformity of the chest wall, symmetrical shoulder girdle mobility in 88% and a feeling of stiffness on the operated side in 19% of the patients operated for a flail chest. Median ratio of FVC was 88%, not suggesting any restriction after stabilization. MRI was performed in 53% (36 of 68) of the patients with a flail chest. The analysis of the rVC showed, on average, no clinically relevant restriction related to the operation, with a mean rVC of the operated relative to the non-operated side of 92% (95% confidence interval: 83, 100). Stabilization of more than four ribs was associated with a lower median rVC than stabilization of four or less ribs.
   CONCLUSIONS: Our results suggest that stabilization of the chest wall with this screwless rib fixation device can be performed with a low morbidity and lead to early restoration of chest wall integrity and respiratory pump function, without clinically relevant functional restriction. Owing to the simplicity of the fixation technique, indications for stabilization can be safely enlarged to selected patients with dislocated and painful rib fractures.
C1 [Wiese, Mark Nikolaj; Al-Shahrabani, Feras; Toffel, Melanie; Lardinois, Didier] Univ Basel Hosp, Div Thorac Surg, CH-4031 Basel, Switzerland.
   [Kawel-Boehm, Nadine; Bremerich, Jens] Univ Basel Hosp, Dept Radiol, CH-4031 Basel, Switzerland.
   [de la Santa, Pablo Moreno] POVISA Hosp, Div Thorac Surg, Vigo, Spain.
   [Rosenthal, Rachel; Schaefer, Juliane] Univ Basel Hosp, Div Gen Surg, CH-4031 Basel, Switzerland.
   [Schaefer, Juliane] Univ Basel Hosp, Basel Inst Clin Epidemiol & Biostat, CH-4031 Basel, Switzerland.
   [Tamm, Michael] Univ Basel Hosp, Div Pneumol, CH-4031 Basel, Switzerland.
RP Lardinois, D (reprint author), Univ Basel Hosp, Div Thorac Surg, Spitalstr 21, CH-4031 Basel, Switzerland.
EM didier.lardinois@usb.ch
OI Bremerich, Jens/0000-0002-1002-8483
CR Aaron SD, 1999, CHEST, V115, P869, DOI 10.1378/chest.115.3.869
   Athanassiadi K, 2004, EUR J CARDIO-THORAC, V26, P373, DOI 10.1016/j.ejcts.2004.04.011
   Bhatnagar A, 2012, J AM COLL SURGEONS, V215, P201, DOI 10.1016/j.jamcollsurg.2012.02.023
   Cacchione RN, 2000, J TRAUMA, V48, P319, DOI 10.1097/00005373-200002000-00023
   Barajas PMD, 2010, CIR ESPAN, V88, P180, DOI 10.1016/j.ciresp.2010.06.004
   de Moya M, 2011, J TRAUMA, V71, P1750, DOI 10.1097/TA.0b013e31823c85e9
   Engel C, 2005, J TRAUMA, V58, P181, DOI 10.1097/01.TA.0000063612.25756.60
   Fitzpatrick DC, 2010, EUR J TRAUMA EMERG S, V36, P427, DOI 10.1007/s00068-010-0027-8
   Girsowicz E, 2012, INTERACT CARDIOV TH, V14, P312, DOI 10.1093/icvts/ivr028
   Granetzny Andreas, 2005, Interact Cardiovasc Thorac Surg, V4, P583, DOI 10.1510/icvts.2005.111807
   Khandelwal G, 2011, INT J SURG, V9, P478, DOI 10.1016/j.ijsu.2011.06.003
   Lafferty PM, 2011, J BONE JOINT SURG AM, V93A, P97, DOI 10.2106/JBJS.I.00696
   Lardinois D, 2001, EUR J CARDIO-THORAC, V20, P496, DOI 10.1016/S1010-7940(01)00818-1
   Liman ST, 2003, EUR J CARDIO-THORAC, V23, P374, DOI 10.1016/S1010-7940(02)00813-8
   Mayberry JC, 2009, AM SURGEON, V75, P389
   Mouton W, 1997, THORAC CARDIOV SURG, V45, P242, DOI 10.1055/s-2007-1013735
   Ng ABY, 2001, INJURY, V32, P637, DOI 10.1016/S0020-1383(01)00017-1
   Nirula R, 2009, WORLD J SURG, V33, P14, DOI 10.1007/s00268-008-9770-y
   Richardson JD, 2007, AM SURGEON, V73, P591
   Tanaka H, 2002, J TRAUMA, V52, P727, DOI 10.1097/00005373-200204000-00020
   Velmahos GC, 2002, INT SURG, V87, P240
   ZIEGLER DW, 1994, J TRAUMA, V37, P975, DOI 10.1097/00005373-199412000-00018
NR 22
TC 6
Z9 7
U1 3
U2 10
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1010-7940
EI 1873-734X
J9 EUR J CARDIO-THORAC
JI Eur. J. Cardio-Thorac. Surg.
PD MAY
PY 2015
VL 47
IS 5
BP 868
EP 875
DI 10.1093/ejcts/ezu318
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA CJ0YV
UT WOS:000355208200031
PM 25193951
OA Bronze
DA 2018-12-27
ER

PT J
AU Liu, MY
   Zhang, KY
   Zhao, YG
   Guo, Q
   Guo, D
   Zhang, JQ
AF Liu, Mengying
   Zhang, Kaiyuan
   Zhao, Yangang
   Guo, Qiang
   Guo, Deyu
   Zhang, Jiqiang
TI RETRACTED: Evidence for involvement of steroid receptors and
   coactivators in neuroepithelial and meningothelial tumors (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Brain tumor; Meningioma; Medulloblastoma; Ependymoma; Oligodendroglioma;
   Steroid receptor; Steroid receptor coactivator
ID ASTROCYTOMA CELL-LINES; BETA ER-BETA; HORMONE RECEPTORS;
   IMMUNOHISTOCHEMICAL EXPRESSION; MEDULLOBLASTOMA DEVELOPMENT;
   PROGESTERONE-RECEPTORS; SYNAPTIC PLASTICITY; ANDROGEN RECEPTORS;
   ESTROGEN-RECEPTORS; BRAIN-TUMORS
AB Steroid receptors such as androgen receptor (AR) and estrogen receptors (ER) ER-alpha and ER-beta, and their receptor coactivators (steroid receptor coactivator, SRC) are widely localized in the brain. Although previous studies have investigated the expression of steroid receptors in brain tumors like astrocytoma, the studies on the expression of steroid receptors and SRCs in other brain tumors are lacking. Here, we investigated the expression of AR, ERs, and SRCs in neuroepithelial (medulloblastoma, ependymoma, oligodendroglioma) and meningothelial meningioma using tissue microarray immunohistochemistry. Compared to normal brain tissue, we found that the expression of SRC-1, SRC-3, and ER-alpha significantly decreased in meningothelial tumor and neuroepithelial tumor, suggesting that the SRC-1/SRC-3 levels may be regulated by ER-alpha. Moreover, the levels of AR strongly correlated to the levels of ER-beta. Furthermore, correlation was also detected between SRC-3 and AR in neuroepithelial tumor, and between ER-alpha and ER-beta in meningothelial tumor. In addition, the decreased ratio of SRC-1/SRC-3 was associated with an increase of ER-beta in neuroepithelial tumor. These results indicate that expressions of different steroid receptors and activators may be tumor type dependent. While AR, ER-alpha, and ER-beta may be involved in the pathogenesis of meningothelial tumor, SRCs/ER-beta axis and SRC-3/AR axis may play a role in the pathogenesis of neuroepithelial tumor.
C1 [Liu, Mengying; Zhang, Kaiyuan; Zhao, Yangang; Guo, Qiang; Zhang, Jiqiang] Third Mil Med Univ, Chongqing Key Lab Neurobiol, Dept Neurobiol, Chongqing 400038, Peoples R China.
   [Liu, Mengying; Zhang, Kaiyuan] Third Mil Med Univ, Chongqing 400038, Peoples R China.
   [Guo, Deyu] Third Mil Med Univ, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China.
RP Zhang, JQ (reprint author), Third Mil Med Univ, Chongqing Key Lab Neurobiol, Dept Neurobiol, Chongqing 400038, Peoples R China.
EM gdy007@mail.tmmu.com.cn; zhangjiqiang14@163.com
RI Zhang, Jiqiang/B-4488-2008
OI Zhang, Jiqiang/0000-0002-1905-8750
FU National Natural Science Foundation of China [81171526]
FX This study was supported by a grant from the National Natural Science
   Foundation of China (No. 81171526).
CR Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Bao XH, 2014, J CANCER RES CLIN, V140, P583, DOI 10.1007/s00432-013-1493-2
   Batistatou A, 2006, J NEURO-ONCOL, V77, P17, DOI 10.1007/s11060-005-9005-0
   Batistatou A, 2004, J CANCER RES CLIN, V130, P405, DOI 10.1007/s00432-004-0548-9
   Baudry M, 2013, NEUROSCIENCE, V239, P280, DOI 10.1016/j.neuroscience.2012.10.051
   Baxter DS, 2014, J CLIN NEUROSCI, V21, P421, DOI 10.1016/j.jocn.2013.06.008
   Bean LA, 2014, NEUROSCIENTIST
   Belcher SM, 2009, ENDOCRINOLOGY, V150, P1112, DOI 10.1210/en.2008-1363
   Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557
   Bian C, 2012, STEROIDS, V77, P149, DOI 10.1016/j.steroids.2011.11.002
   Bian C, 2011, STEROIDS, V76, P269, DOI 10.1016/j.steroids.2010.11.009
   CARROLL RS, 1995, NEUROSURGERY, V37, P496, DOI 10.1227/00006123-199509000-00019
   Carroll RS, 1995, NEUROSURGERY, V37, P503
   Chung Yong Gu, 1996, Journal of Korean Medical Science, V11, P517
   Clipperton-Allen AE, 2012, PHYSIOL BEHAV, V105, P915, DOI 10.1016/j.physbeh.2011.10.025
   Concolino G, 1984, Neurol Res, V6, P121
   Cowppli-Bony A, 2011, CANCER CAUSE CONTROL, V22, P697, DOI 10.1007/s10552-011-9742-7
   Deval B, 2014, OBSTET GYNECOL, V123, P488, DOI 10.1097/AOG.0000000000000077
   Dong SM, 2001, J NEUROPATH EXP NEUR, V60, P808, DOI 10.1093/jnen/60.8.808
   Fakhrjou Ashraf, 2012, Pak J Biol Sci, V15, P530
   Favaro R, 2014, CANC RES
   Fernandez-Guasti A, 2000, J COMP NEUROL, V425, P422, DOI 10.1002/1096-9861(20000925)425:3<422::AID-CNE7>3.0.CO;2-H
   FUJIMOTO M, 1984, CLIN NEUROPHARMACOL, V7, P357, DOI 10.1097/00002826-198412000-00015
   Gonzalez-Arenas A, 2012, BBA-MOL CELL RES, V1823, P379, DOI 10.1016/j.bbamcr.2011.11.004
   Hernandez-Hernandez OT, 2010, ENDOCRINE, V37, P194, DOI 10.1007/s12020-009-9288-6
   Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948
   Jones BA, 2005, PHYSIOL BEHAV, V85, P135, DOI 10.1016/j.physbeh.2005.03.023
   Kefalopoulou Z, 2012, J NEURO-ONCOL, V106, P23, DOI 10.1007/s11060-011-0637-y
   Kruijver FPM, 2001, J CLIN ENDOCR METAB, V86, P818, DOI 10.1210/jc.86.2.818
   LEE LS, 1989, NEUROSURGERY, V25, P541, DOI 10.1227/00006123-198910000-00006
   Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479
   Liu C, 2014, CANCER EPIDEMIOL, DOI [10.1016/j.canep.2014.1003.1001, DOI 10.1016/J.CANEP.2014.1003.1001]
   Liu C, 2014, CANCER EPIDEMIOL, V38, P291, DOI 10.1016/j.canep.2014.03.001
   Liu F, 2008, NAT NEUROSCI, V11, P334, DOI 10.1038/nn2057
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Mancuso M, 2011, CANCER LETT, V308, P197, DOI 10.1016/j.canlet.2011.05.004
   Mancuso M, 2010, INT J CANCER, V127, P2749, DOI 10.1002/ijc.25293
   Matsuyama A, 2010, PATHOL INT, V60, P241, DOI 10.1111/j.1440-1827.2009.02509.x
   Nishihara E, 2003, J NEUROSCI, V23, P213
   Ogawa H, 2001, BRAIN RES, V890, P197, DOI 10.1016/S0006-8993(00)03158-9
   ONATE SA, 1995, SCIENCE, V270, P1354
   Pencovich N, 2014, ACTA NEUROCHIR WIEN
   Ramachandran C, 2004, J NEURO-ONCOL, V67, P19, DOI 10.1023/B:NEON.0000021738.77612.1b
   SCHNEGG JF, 1981, SURG NEUROL, V15, P415, DOI 10.1016/S0090-3019(81)80024-9
   Leaes CGS, 2010, NEUROPATHOLOGY, V30, P44, DOI 10.1111/j.1440-1789.2009.01047.x
   Stolnicu S, 2011, HUM PATHOL, V42, P403, DOI 10.1016/j.humpath.2010.07.017
   Takei H, 2008, NEUROPATHOLOGY, V28, P62, DOI 10.1111/j.1440-1789.2007.00852.x
   Tao YQ, 2012, BRIT J NEUROSURG, V26, P700, DOI 10.3109/02688697.2012.685780
   TILZER LL, 1982, CANCER, V49, P633, DOI 10.1002/1097-0142(19820215)49:4<633::AID-CNCR2820490404>3.0.CO;2-4
   Vest RS, 2013, HORM BEHAV, V63, P301, DOI 10.1016/j.yhbeh.2012.04.006
   Walsh CA, 2012, INT J BIOL SCI, V8, P470, DOI 10.7150/ijbs.4125
   Wang HD, 2010, J HISTOCHEM CYTOCHEM, V58, P1121, DOI 10.1369/jhc.2010.956979
   Zhang DM, 2011, BRAIN RES, V1382, P88, DOI 10.1016/j.brainres.2011.01.024
   Zhang JQ, 2002, BRAIN RES, V935, P73, DOI 10.1016/S0006-8993(02)02460-5
NR 54
TC 10
Z9 10
U1 3
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2015
VL 36
IS 5
BP 3251
EP 3261
DI 10.1007/s13277-014-2954-1
PG 11
WC Oncology
SC Oncology
GA CJ0WK
UT WOS:000355199800016
PM 25534237
DA 2018-12-27
ER

PT J
AU Xu, YZ
   Lu, YN
   Song, JJ
   Dong, BJ
   Kong, W
   Xue, W
   Zhang, J
   Huang, YR
AF Xu, Yunze
   Lu, Yongning
   Song, Jiajia
   Dong, Baijun
   Kong, Wen
   Xue, Wei
   Zhang, Jin
   Huang, Yiran
TI RETRACTED: Cancer-associated fibroblasts promote renal cell carcinoma
   progression (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Cancer-associated fibroblasts; Renal cell carcinoma; Everolimus; Tumor
   microenvironment; Targeted therapies
ID STROMA; STAGE
AB The aim of this study was to determine the effect of cancer-associated fibroblasts (CAFs) on renal cell carcinoma (RCC) tumor proliferation, migration, and development of drug resistance, thus underlying their potential as therapeutic targets in RCC patients. CAFs were grown in primary cultures. The in vitro model of interaction of RCC cell lines with CAFs was established. The influence of CAFs on the proliferation and migration ability as well as sensitivity to everolimus of RCC cells was further analyzed. Furthermore, Western blotting analysis was performed to examine the mechanisms mediating the effect of CAFs on RCC cells. The results of the MTT assay showed that coculture with CAFs increased the proliferation activity of both 786-O and Caki-1 cells compared with serum-free medium controls. The migration ability of RCC cell lines was also significantly enhanced after coculture treatment compared with untreated control. The inhibition effect of everolimus on 786-O and Caki-1 cells abrogated in cocultures with CAFs. The sensitivity of both two cell lines to everolimus was dramatically decreased when cocultured with CAFs. RCC cells cocultured with CAFs resulted in the activation of both proliferation-related (Erks) and survival-related (Akt) pathways. These data indicate that CAFs have an important role in supporting and promoting RCC. The interaction of CAFs with RCC cell lines stimulates tumor cell proliferation and migration and induces resistance to everolimus in RCC cells, suggesting that target of the tumor microenvironment may be a novel targeted therapies for RCC.
C1 [Xu, Yunze; Lu, Yongning; Song, Jiajia; Dong, Baijun; Kong, Wen; Xue, Wei; Zhang, Jin; Huang, Yiran] Shanghai Jiao Tong Univ, Dept Urol, Ren Ji Hosp, Sch Med, Shanghai 200127, Peoples R China.
RP Zhang, J (reprint author), Shanghai Jiao Tong Univ, Dept Urol, Ren Ji Hosp, Sch Med, 200 Pujian Rd, Shanghai 200127, Peoples R China.
EM med-zhangjin@vip.sina.com; huangyrrenji@163.com
FU National Natural Science Foundation of China [81472378, 81272841,
   91129725]; Shanghai Committee of Science and Technology [13ZR1425100];
   National S&T Major Projects [2012ZX09301001-007]
FX This study was supported by the grants from the National Natural Science
   Foundation of China (No. 81472378, No. 81272841, No. 91129725), Shanghai
   Committee of Science and Technology (13ZR1425100), and National S&T
   Major Projects (2012ZX09301001-007).
CR Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Haubeiss S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-168
   Hellevik T, 2013, TRANSL ONCOL, V6, P66, DOI 10.1593/tlo.12349
   Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714
   Iacovelli R, 2014, CANCER TREAT REV, V40, P271, DOI 10.1016/j.ctrv.2013.09.003
   Janzen NK, 2003, UROL CLIN N AM, V30, P843, DOI 10.1016/S0094-0143(03)00056-9
   Jiang Z, 2008, CLIN CANCER RES, V14, P5579, DOI 10.1158/1078-0432.CCR-08-0504
   Jonasch E, 2012, MOL CANCER RES, V10, P859, DOI 10.1158/1541-7786.MCR-12-0117
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Ljungberg B, 2011, EUR UROL, V60, P615, DOI 10.1016/j.eururo.2011.06.049
   Markman B, 2010, ONCOTARGET, V1, P530
   Patil S, 2010, CANCER-AM CANCER SOC, V116, P347, DOI 10.1002/cncr.24713
   Santoni M, 2014, BBA-REV CANCER, V1845, P221, DOI 10.1016/j.bbcan.2014.01.007
   Tlsty T, 2008, NATURE, V453, P604, DOI 10.1038/453604a
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
NR 15
TC 8
Z9 8
U1 4
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2015
VL 36
IS 5
BP 3483
EP 3488
DI 10.1007/s13277-014-2984-8
PG 6
WC Oncology
SC Oncology
GA CJ0WK
UT WOS:000355199800042
PM 25613067
DA 2018-12-27
ER

PT J
AU Guo, ZX
   Liu, DH
   Su, ZX
AF Guo, Zexiong
   Liu, Dehao
   Su, Zexuan
TI RETRACTED: CIP2A mediates prostate cancer progression via the c-MYC
   signaling pathway (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Prostate cancer; Cancerous inhibitor of protein phosphatase 2A; Small
   interfering RNA; Proliferation; Invasion; Targeted therapy
ID GASTRIC-CANCER; TUMOR-CELLS; DOCETAXEL
AB Recent evidence suggests that cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that acts as a novel therapeutic target in a variety of tumors. In this study, we investigated the clinical significance of CIP2A and its function in our large collection of prostate samples. Between August 2000 and December 2013, 126 patients with histologically confirmed PCa and 92 with benign prostate hyperplasia (BPH) were recruited into the study. Quantitative RT-PCR, Western blot, and immunohistochemistry analyses were used to quantify CIP2A expression in PCa clinical samples and cell lines. The relationships between CIP2A expression and clinicopathological features were analyzed. The functional role of CIP2A in PCa cells was evaluated by small interfering RNA-mediated depletion of the protein followed by analyses of cell proliferation and invasion. High expression of CIP2A staining was 86.51 % (109/126) in 126 cases of PCa and 17.39 % (16/92) in 92 cases of BPH, and the difference of CIP2A expression between PCa and BPH was statistically significant. CIP2A was significantly elevated in all five PCa cell lines when compared to the RWPE-1 cells at both the messenger RNA (mRNA) and protein levels. Silencing of CIP2A inhibited the proliferation of DU-145 cells which have a relatively high level of CIP2A in a time- and concentration-dependent manner, and the invasion and migration of DU-145 cells were distinctly suppressed. Furthermore, CIP2A knockdown led to substantial reductions in c-Myc levels in PCa cell lines, but no significant change in phosphorylated Akt expression after CIP2A knockdown in DU-145 cells. Our data suggest that the pathogenesis of human PCa maybe mediated by CIP2A, and CIP2A inhibition treatment may provide a promising strategy for the antitumor therapy of PCa, and thus CIP2A could represent selective targets for the molecularly targeted treatments of PCa.
C1 [Guo, Zexiong; Liu, Dehao; Su, Zexuan] Jinan Univ, Dept Urol, Affiliated Hosp 1, Guangzhou 510630, Guangdong, Peoples R China.
RP Su, ZX (reprint author), Jinan Univ, Dept Urol, Affiliated Hosp 1, 613 West Huangpu Dadao, Guangzhou 510630, Guangdong, Peoples R China.
EM drsuzx6@163.com
FU Science and Technology Research Projects of Guangzhou [11A72070508,
   2011Y-00003]
FX This study was supported by the grants from the Science and Technology
   Research Projects of Guangzhou (No. 11A72070508, 2011Y-00003)
CR Bockelman C, 2011, BRIT J CANCER, V105, P989, DOI 10.1038/bjc.2011.346
   Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Heidenreich A, 2011, EUR UROL, V59, P61, DOI 10.1016/j.eururo.2010.10.039
   Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044
   Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103
   Lassi K, 2009, CURR OPIN ONCOL, V21, P260, DOI 10.1097/CCO.0b013e32832a1868
   Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Qu YY, 2013, ASIAN J ANDROL, V15, P110, DOI 10.1038/aja.2012.110
   Ren J, 2011, BRIT J CANCER, V105, P1905, DOI 10.1038/bjc.2011.492
   Ren SC, 2013, ASIAN J ANDROL, V15, P350, DOI 10.1038/aja.2013.37
   Saad F, 2012, FUTURE ONCOL, V8, P321, DOI [10.2217/fon.12.3, 10.2217/FON.12.3]
   Wiegering A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075292
   Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110
NR 15
TC 7
Z9 7
U1 3
U2 17
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2015
VL 36
IS 5
BP 3583
EP 3589
DI 10.1007/s13277-014-2995-5
PG 7
WC Oncology
SC Oncology
GA CJ0WK
UT WOS:000355199800053
PM 25560487
DA 2018-12-27
ER

PT J
AU Valipour, M
AF Valipour, Mohammad
TI RETRACTED: Comparative Evaluation of Radiation-Based Methods for
   Estimation of Potential Evapotranspiration (Retracted article. See vol.
   22, 2017)
SO JOURNAL OF HYDROLOGIC ENGINEERING
LA English
DT Article; Retracted Publication
DE Calibration; Evapotranspiration; Food and Agriculture Organization
   Penman-Monteith; Iran; Radiation; Sunshine
ID REFERENCE CROP EVAPOTRANSPIRATION; ARTIFICIAL NEURAL-NETWORK;
   INFILTRATION PARAMETERS; PRIESTLEY-TAYLOR; SOLAR-RADIATION; MONTHLY
   INFLOW; EVAPORATION; IRRIGATION; EQUATION; MODEL
AB Evapotranspiration has a major role in agricultural and forest meteorology researches, hydrological cycle, irrigation scheduling, and water resources management. There are many methods to estimate the potential evapotranspiration including mass transfer, radiation, temperature, and pan evaporation-based methods. The present study aims to compare radiation-based methods to determine the best method under different weather conditions. The results discussed in this paper are from the data collected in the study area, but the method can be used in other similar regions. For this purpose, weather data was collected from 181 synoptic stations in 31 provinces of Iran. The potential evapotranspiration was estimated using 22 radiation-based methods and compared with the Food and Agriculture Organization of the United Nations (FAO) Penman-Monteith method. The results show that the Stephens method estimates the potential evapotranspiration better than other methods for provinces of Iran. However, the values of R2 varied from 0.93 to 0.98 for 15 provinces of Iran. Therefore, the methods were calibrated and precision of estimation was increased (the values of R2 were less than 0.99 for 4 provinces in the modified methods). The radiation-based methods estimated the potential evapotranspiration in the central provinces of Iran (solar radiation between 24.0 and 25.0MJm-2day-1, annual relative humidity less than 50%, and sunshine more than 250hmonth-1) better than other provinces. The most precise methods were the Berengena-Gavilan method for Esfahan (ES) (before calibration), the Stephens method for Zanjan (ZA) and Lorestan (LO), and the Stephens-Stewart method for Semnan (SE) (after calibration). Finally, a list of the best performances of each method is presented to use in other region studies according to mean, maximum, and minimum temperature, relative humidity, solar radiation, elevation, sunshine, and wind speed. The best temperatures to use radiation-based equations are 10-26 degrees C, 16.5-24.0 degrees C (with the exception of Jones-Ritchie), and 5-13 degrees C for mean, maximum, and minimum temperature, respectively. The results are also useful for selecting the best model when radiation-based models must be applied based on available data.
C1 Islamic Azad Univ, Kermanshah Branch, Dept Water Engn, Kermanshah, Iran.
RP Valipour, M (reprint author), Islamic Azad Univ, Kermanshah Branch, Dept Water Engn, Kermanshah, Iran.
EM vali-pour@hotmail.com
CR ABBASPOUR KC, 1991, ATMOS OCEAN, V29, P687
   Abtew W, 1996, WATER RESOUR BULL, V32, P465
   Alexandris S, 2006, AGR WATER MANAGE, V82, P371, DOI 10.1016/j.agwat.2005.08.001
   Alexandris S, 2003, AGR WATER MANAGE, V60, P157, DOI 10.1016/S0378-3774(02)00172-5
   Allen R. G., 1998, FAO Irrigation and Drainage Paper
   Banihabib ME, 2012, J ENV SCI TECHNOL, V13, P1
   Berengena J, 2005, J IRRIG DRAIN ENG, V131, P147, DOI 10.1061/(ASCE)0733-9437(2005)131:2(147)
   Bois B, 2008, AGR FOREST METEOROL, V148, P619, DOI 10.1016/j.agrformet.2007.11.005
   Caprio J. M., 1974, Phenology and seasonality modeling., P353
   Castaneda L, 2005, J ENV HYDROL, V13, P1
   Christiansen J, 1968, J IRRIG DRAIN DIV, V94, P243
   de Bruin HAR, 1998, HYDROL PROCESS, V12, P1053, DOI 10.1002/(SICI)1099-1085(19980615)12:7<1053::AID-HYP639>3.0.CO;2-E
   De Bruin HAR, 2000, HYDROLOG SCI J, V45, P391, DOI 10.1080/02626660009492337
   DeBruin H.A.R., 1981, EVAPORATION RELATION, V28, P25
   Ding RS, 2013, AGR FOREST METEOROL, V168, P140, DOI 10.1016/j.agrformet.2012.08.003
   Doorenbos J, 1977, 24 FAO, P144
   Estevez J, 2009, HYDROL PROCESS, V23, P3342, DOI 10.1002/hyp.7439
   HANSEN S, 1984, NORD HYDROL, V15, P205
   Hargreaves GH, 2003, J IRRIG DRAIN ENG, V129, P53, DOI 10.1061/(ASCE)0733-9437(2003)129:1(53)
   Irmak S, 2003, J IRRIG DRAIN ENG, V129, P336, DOI 10.1061/(ASCE)0733-9437(2003)129:5(336)
   Jensen M. E, 1966, EVAPOTRANSPIRATION I, V64, P49
   Jensen M. E., 1963, J IRRIGATION DRAINAG, V89, P15
   Jones J. W, 1990, ASAE MONOGRAPH, V9, P63
   Kisi O, 2007, HYDROL PROCESS, V21, P1925, DOI 10.1002/hyp.6403
   Makkink G., 1957, J I WATER ENG, V11, P277
   Martinez CJ, 2010, J IRRIG DRAIN ENG, V136, P494, DOI 10.1061/(ASCE)IR.1943-4774.0000214
   McGuinness J. L., 1972, TECHN B AGR RES SERV, V1452
   PRIESTLEY CHB, 1972, MON WEATHER REV, V100, P81, DOI 10.1175/1520-0493(1972)100<0081:OTAOSH>2.3.CO;2
   Rahimi S, 2015, ARCH AGRON SOIL SCI, V61, P695, DOI 10.1080/03650340.2014.944904
   SAMANI ZA, 1986, T ASAE, V29, P522
   Schrader F, 2013, PROCEDIA ENVIRON SCI, V19, P543, DOI 10.1016/j.proenv.2013.06.061
   STEPHENS J. C., 1963, Publ. Int. Ass. sci. Hydrol. 62 gen. Assembly Berkeley, P123
   Stephens J. C., 1965, J HYDRAUL DIV, V91, P171
   Suleiman AA, 2007, J IRRIG DRAIN ENG, V133, P175, DOI 10.1061/(ASCE)0733-9437(2007)133:2(175)
   Thepadia M, 2012, J IRRIG DRAIN ENG, V138, P111, DOI 10.1061/(ASCE)IR.1943-4774.0000394
   Tian F, 2013, J HYDROL, V498, P210, DOI 10.1016/j.jhydrol.2013.06.038
   Tian H, 2012, ENVIRON EARTH SCI, V67, P2301, DOI 10.1007/s12665-012-1677-0
   Trajkovic S, 2009, WATER RESOUR MANAG, V23, P3057, DOI 10.1007/s11269-009-9423-4
   Trajkovic S, 2009, HYDROL RES, V40, P45, DOI 10.2166/nh.2009.002
   TURC L., 1961, Ann. agron. Paris, V12, P13
   Valipour M., 2013, Advances in Agriculture, Sciences and Engineering Research, V3, P631
   Valipour Mohammad, 2012, Journal of Mathematics and Statistics, V8, P330
   Valipour M., 2013, Advances in Agriculture, Sciences and Engineering Research, V3, P587
   Valipour M., 2012, Journal of Agricultural Science (Toronto), V4, P125
   Valipour M., 2012, Journal of Agricultural Science (Toronto), V4, P68
   Valipour M., 2012, Journal of Applied Sciences, V12, P2139
   Valipour M., 2012, Advances in Environmental Biology, V6, P2574
   Valipour M., 2012, Australian Journal of Basic and Applied Sciences, V6, P132
   Valipour M., 2014, HDB IRRIGATION ENG P
   Valipour M, 2014, ACTA ADV AG IN PRESS, P1350
   Valipour M., 2014, HDB DRAINAGE ENG PRO
   Valipour M, 2014, J AGR RES, V52, P245
   Valipour M, 2012, J BASIC APPL SCI RES, V2, P12365
   Valipour M., 2014, HDB WATER ENG PROBLE
   Valipour M., 2014, ACTA ADV AGR SCI, V2, P32
   Valipour M., 2012, INT J ENG SCI, V1, P37, DOI DOI 10.5897/AJAR2015.9610
   Valipour M, 2013, IRRIG DRAIN SYS EN S, VS9, DOI DOI 10.4172/2168-9768.S9-E001
   Valipour M, 2014, METEOROL AP IN PRESS
   Valipour M., 2014, ACTA ADV AGR SCI, V2, P40
   Valipour M, 2012, INT J ADV SCI TECHNI, V5, P703
   Valipour M, 2014, ARCH AGRON IN PRESS
   VALIPOUR M, 2012, EUR J SCI RES, V84, P600
   Valipour M., 2012, AM J SCI RES, V74, P79
   Valipour M., 2013, J CIVIL ENV ENG, V2013, P1, DOI DOI 10.4172/2165-784X.1000127
   Valipour M, 2012, IOSR J MECH CIVIL EN, V4, P7, DOI [10.9790/1684-0410712, DOI 10.9790/1684-0410712]
   Valipour M., 2014, HDB ENV ENG PROBLEMS
   Valipour M., 2014, HDB HYDRAULIC ENG PR
   Valipour M., 2012, ARPN J AGRIC BIOL SC, V7, P968
   Valipour M., 2013, IRRIGAT DRAIN SSYT E, V2, pe114, DOI [10.4172/2168-9768.1000e114, DOI 10.4172/2168-9768.1000E114]
   Valipour M., 2014, HDB HYDROLOGIC ENG P
   Valipour M, 2012, IOSR J AGR VETER SCI, V1, P1, DOI DOI 10.9790/2380-0150111
   Valipour M., 2014, APPL WATER IN PRESS
   Valipour M, 2012, IOSR J APPL PHYS, V2, P44, DOI [DOI 10.9790/4861-0234450, 10.9790/4861-0234450]
   Valipour M, 2012, AM J SCI RES, V69, P128
   Valipour M., 2013, AGROTECHNOL S, VS10, DOI [10.4172/2168-9881.S10-e001, DOI 10.4172/2168-9881.S10-E001]
   Valipour M, 2014, ACTA ADV AGR SCI, V2, P1
   Valipour M, 2012, IOSR J AGR VET SCI, V1, P10, DOI [10.9790/2380-0141018, DOI 10.9790/2380-0141018]
   VALIPOUR M, 2013, ARPN J AGRIC BIOL SC, V8, P35
   Valipour M, 2014, METEOROL AP IN PRESS, DOI [10.1002/met.14651350-4827, DOI 10.1002/MET.14651350-4827]
   Valipour M, 2015, THEOR APPL CLIMATOL, V121, P267, DOI 10.1007/s00704-014-1240-x
   Valipour M, 2015, ARCH AGRON SOIL SCI, V61, P657, DOI 10.1080/03650340.2014.944903
   Valipour M, 2015, ARCH AGRON SOIL SCI, V61, P679, DOI 10.1080/03650340.2014.941823
   Valipour M, 2015, ARCH AGRON SOIL SCI, V61, P239, DOI 10.1080/03650340.2014.925107
   Valipour M, 2014, J APPL WATER ENG RES, V2, P33, DOI 10.1080/23249676.2014.923790
   Valipour M, 2015, APPL WATER SCI, V5, P367, DOI 10.1007/s13201-014-0199-1
   Valipour M, 2014, WATER RESOUR MANAG, V28, P4237, DOI 10.1007/s11269-014-0741-9
   Valipour M, 2014, ARCH AGRON SOIL SCI, V60, P1641, DOI 10.1080/03650340.2014.905675
   Valipour M, 2014, ARCH AGRON SOIL SCI, V60, P1625, DOI 10.1080/03650340.2014.905676
   Valipour M, 2013, J HYDROL, V476, P433, DOI 10.1016/j.jhydrol.2012.11.017
   Willmott CJ, 2006, INT J GEOGR INF SCI, V20, P89, DOI 10.1080/13658810500286976
   Xu C., 2008, IEEE IEDM M, V1, P1, DOI DOI 10.1109/IEDM.2008.4796651
   Xu CY, 2005, HYDROL PROCESS, V19, P3717, DOI 10.1002/hyp.5853
   Xu CY, 2000, HYDROL PROCESS, V14, P339, DOI 10.1002/(SICI)1099-1085(20000215)14:2<339::AID-HYP928>3.3.CO;2-F
   Xu JZ, 2013, ARCH AGRON SOIL SCI, V59, P845, DOI 10.1080/03650340.2012.683425
   Ye JS, 2009, J IRRIG DRAIN ENG, V135, P134, DOI 10.1061/(ASCE)0733-9437(2009)135:2(134)
   Zhai LX, 2010, IRRIG DRAIN, V59, P477, DOI 10.1002/ird.502
NR 96
TC 35
Z9 35
U1 3
U2 45
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 1084-0699
EI 1943-5584
J9 J HYDROL ENG
JI J. Hydrol. Eng.
PD MAY
PY 2015
VL 20
IS 5
AR 04014068
DI 10.1061/(ASCE)HE.1943-5584.0001066
PG 14
WC Engineering, Civil; Environmental Sciences; Water Resources
SC Engineering; Environmental Sciences & Ecology; Water Resources
GA CH4HU
UT WOS:000353995400009
DA 2018-12-27
ER

PT J
AU Haghayeghi, R
   Kapranos, P
AF Haghayeghi, R.
   Kapranos, P.
TI RETRACTED: Investigation on Heterogeneous Nucleation of MgAl2O4 in Al-Mg
   Alloys (Retracted article. See vol. 22, pg. 348, 2016)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE solidification; nucleation; alloys; oxides; grain refinement
ID GRAIN-REFINEMENT; ALUMINUM-ALLOYS; INOCULATION; OXIDATION; METALS; MELTS
AB This work investigates the mechanisms of grain refinement of Al-Mg alloys through ultrasonic treatment and varying Mg content. MgAl2O4 particles display an equiaxed and faceted morphology with {111} planes and when exposed to {111} of alpha-Al, can act as heterogeneous and potent nuclei for aluminium. Intensive vibrations by ultrasonic treatment lead to significant grain refinement through effective dispersion of MgAl2O4 particles. The equiaxed and faceted morphology of MgAl2O4 along with a well-defined cube-on-cube orientation relationship (1 (1) over bar1)[110] MgAl2O4//(1 (1) over bar1)[110] alpha-Al, provide improved refinement. Furthermore, multiplication of solidification sites by the ultrasonic pulses enhances heterogeneous nucleation. The resulting improved grain refinement relates in all probability to the increased nucleation sites, due to grain multiplications and wetting of impurities, the lowering of surface tension due to the segregation of magnesium to the surface of liquid aluminium, the appropriate growth restriction factor and the low lattice mismatch coupled with strong dispersion of oxides.The filtration test confirms these particles as potent refiners.
C1 [Haghayeghi, R.] Islamic Azad Univ, Sci & Res Branch, Dept Mat Engn, Tehran, Iran.
   [Kapranos, P.] Univ Sheffield, Dept Mat Sci & Engn, Sheffield S1 3JD, S Yorkshire, England.
RP Haghayeghi, R (reprint author), Islamic Azad Univ, Sci & Res Branch, Dept Mat Engn, Tehran, Iran.
EM Reza.Haghayeghi@Brunel.ac.uk
CR [Anonymous], 1987, TP1 AL ASS
   Anson JP, 1999, METALL MATER TRANS B, V30, P1027, DOI 10.1007/s11663-999-0108-4
   ASTM Int, 2002, STAND TEST DET AV GR, V14, P256
   Atamanenko TV, 2010, METALL MATER TRANS A, V41A, P2056, DOI 10.1007/s11661-010-0232-4
   Cao X, 2003, METALL MATER TRANS A, V34A, P1409, DOI 10.1007/s11661-003-0253-3
   Contreras A, 2004, ACTA MATER, V52, P985, DOI 10.1016/j.actamat.2003.10.034
   DELANNAY F, 1987, J MATER SCI, V22, P1, DOI 10.1007/BF01160545
   Duval H, 2009, METALL MATER TRANS B, V40, P233, DOI 10.1007/s11663-008-9222-y
   Easton M, 2005, METALL MATER TRANS A, V36A, P1911, DOI 10.1007/s11661-005-0054-y
   Eskin DG, 1996, Z METALLKD, V87, P295
   Eskin G I., 1998, ULTRASONIC TREATMENT, P177
   Fang X, 2006, SCRIPTA MATER, V54, P789, DOI 10.1016/j.scriptamat.2005.11.021
   Gibbs J. W., 1878, AM J SCI, P441, DOI DOI 10.2475/AJS.S3-16.96.441
   Greer AL, 2003, PHILOS T R SOC A, V361, P479, DOI 10.1098/rsta.2002.1147
   Greer AL, 2000, ACTA MATER, V48, P2823, DOI 10.1016/S1359-6454(00)00094-X
   Haghayeghi R, 2013, MET MATER INT, V19, P959, DOI 10.1007/s12540-013-5008-0
   Haghayeghi R, 2013, MATER LETT, V95, P121, DOI 10.1016/j.matlet.2012.12.082
   Haghayeghi R, 2009, J ALLOY COMPD, V481, P358, DOI 10.1016/j.jallcom.2009.02.135
   HAGINOYA I, 1983, T JPN I MET, V24, P613, DOI 10.2320/matertrans1960.24.613
   MCCARTNEY DG, 1989, INT MATER REV, V34, P247, DOI 10.1179/imr.1989.34.1.247
   SCAMANS GM, 1975, METALL TRANS A, V6, P2055, DOI 10.1007/BF03161831
   Shackelford J. F., 2000, CRC MAT SCI ENG HDB, P70
   Vives C., 1992, P 2 INT C SEM ALL CO, P346
   Zhang ZT, 2009, J ALLOY COMPD, V484, P458, DOI 10.1016/j.jallcom.2009.04.125
NR 24
TC 1
Z9 1
U1 2
U2 15
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD MAY
PY 2015
VL 21
IS 3
BP 554
EP 560
DI 10.1007/s12540-015-4260-x
PG 7
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA CH6IT
UT WOS:000354141000018
DA 2018-12-27
ER

PT J
AU Rajendran, PS
   Raj, MXJ
AF Rajendran, P. S.
   Raj, M. Xavier James
TI RETRACTED: Analytical orbit predictions for low and high eccentricity
   orbits using uniformly regular KS canonical elements in an oblate
   atmosphere (Retracted article. See vol. 119, pg. 252, 2016)
SO ACTA ASTRONAUTICA
LA English
DT Article; Retracted Publication
DE Equations of motion; Canonical elements; Orbit prediction; Oblate
   atmosphere
ID SATELLITE ORBITS; AIR DRAG; CONTRACTION; ALTITUDE
AB Orbit prediction of satellites is an important requirement for mission planning, spacecraft navigation, re-entry, orbital lifetime estimates, etc. The prediction becomes complicated in near Earth environment as Earth's gravitational field and atmosphere influences the orbit. The effects of atmosphere are difficult to determine, since the atmospheric density undergoes large fluctuations. Method of KS elements was employed to generate analytical solutions with different atmospheric models. Particular form of KS elements known as uniformly regular KS canonical elements are used to generate number of analytical solutions with different atmospheric models, which are found to be better than KS theory. But, all are for low eccentric (e < 0.2) orbits only.
   In this paper, a non singular analytical theory for the motion of Earth satellite for high eccentricity orbits (e > 0.2) in an oblate exponential atmosphere using uniformly regular KS canonical elements is developed, and integrated with the low eccentricity theory. Due to symmetry, only two of the ten equations need to be solved analytically to get complete solutions. Comparison of the important orbital parameters semi-major axis and eccentricity, which define the size and shape of orbit with KS theory, shows the superiority of the present theory. (C) 2015 IAA. Published by Elsevier Ltd. All rights reserved.
C1 [Rajendran, P. S.] Manonmaniam Sundernar Univ, Tirunelveli, Tamil Nadu, India.
   [Raj, M. Xavier James] Vikram Sarabhai Space Ctr, Div Appl Math, Orbital Analyt Sect, Trivandrum 695022, Kerala, India.
   [Rajendran, P. S.] Coll Engn, Dept Math, Trivandrum, Kerala, India.
RP Raj, MXJ (reprint author), Vikram Sarabhai Space Ctr, Div Appl Math, Orbital Analyt Sect, Trivandrum 695022, Kerala, India.
EM xavierjamesraj@gmail.com
CR COOK GE, 1963, PROC R SOC LON SER-A, V275, P357, DOI 10.1098/rspa.1963.0175
   COOK GE, 1961, PROC R SOC LON SER-A, V264, P88, DOI 10.1098/rspa.1961.0186
   GRAF OF, 1977, NASACR151607
   King-Hele D., 1987, SATELLITE ORBITS ATM
   KINGHELE D, 1964, THEORY SATELLITE ORB
   KINGHELE DG, 1962, PROC R SOC LON SER-A, V267, P541, DOI 10.1098/rspa.1962.0117
   KUSTAANHEIMO P, 1965, J REINE ANGEW MATH, V218, P204
   Raj MXJ, 2009, PLANET SPACE SCI, V57, P34, DOI 10.1016/j.pss.2008.09.015
   Raj MXJ, 2003, ADV SPACE RES, V31, P2019, DOI 10.1016/S0273-1177(03)00175-3
   Sharma RK, 2009, ACTA ASTRONAUT, V65, P1336, DOI 10.1016/j.actaastro.2009.03.032
   Sharma R.K., 1988, EARTH MOON PLANETS, V32, P63
   Sharma RK, 2010, ACTA ASTRONAUT, V66, P864, DOI 10.1016/j.actaastro.2009.09.010
   Sterne T. E., 1960, INTRO CELESTIAL MECH
   STIEFEL EL, 1971, LINEAR REGULAR CELES
NR 14
TC 1
Z9 1
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
EI 1879-2030
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD MAY-JUN
PY 2015
VL 110
BP 214
EP 224
DI 10.1016/j.actaastro.2015.01.021
PG 11
WC Engineering, Aerospace
SC Engineering
GA CG8YC
UT WOS:000353600600020
DA 2018-12-27
ER

PT J
AU Tariq, M
   Zubair, M
AF Tariq, M.
   Zubair, M.
TI RETRACTED: The Effect of Preparation Temperature on the Superconducting
   Parameters of Cu1-xTlx Ba2Ca2Cu3 O(10-delta)Superconductor (Retracted
   article. See vol. 28, pg. 3713, 2015)
SO JOURNAL OF SUPERCONDUCTIVITY AND NOVEL MAGNETISM
LA English
DT Article; Retracted Publication
DE Cu1-xTlxBa2Ca2Cu3O10-delta superconductor; Preparation temperature;
   Fluctuation-induced conductivity
ID FLUCTUATION CONDUCTIVITY; EXCESS CONDUCTIVITY
AB The effect of preparation temperature on the superconducting properties of Cu1-x Tl (x) Ba2Ca2Cu3 O (10-delta) samples has been explored. With the increase of preparation temperature beyond 840 A degrees C, the observed superconducting parameters are suppressed which might be due to impurities caused by the volatility of some constituents such as thallium and oxygen deficiencies as well in the final compound. The shift of three-dimensional (3D) Aslamazov-Larkin (AL) regions to the lower temperature and the decrease in the crossover temperature and with the increase of preparation temperature beyond 840 A degrees C is observed by using the fluctuation-induced conductivity (FIC) analysis. A direct correlation between the zero resistivity critical temperature T (c) (R = 0), the zero-temperature coherence length xi (c) (0), the crossover temperature T (o) , as well as carrier concentration has also been observed.
C1 [Tariq, M.; Zubair, M.] Quaid I Azam Univ, Dept Phys, Mat Sci Lab, Islamabad 45320, Pakistan.
RP Tariq, M (reprint author), Quaid I Azam Univ, Dept Phys, Mat Sci Lab, Islamabad 45320, Pakistan.
EM mtariq.phy1@gmail.com
CR ASLAMAZOV LG, 1968, FIZ TVERD TELA+, V10, P875
   Han SH, 1997, PHYSICA C, V282, P1571, DOI 10.1016/S0921-4534(97)00937-4
   Ibrahim EMM, 2007, SUPERCOND SCI TECH, V20, P672, DOI 10.1088/0953-2048/20/7/014
   IHARA H, 1994, JPN J APPL PHYS 2, V33, pL503, DOI 10.1143/JJAP.33.L503
   Ihara H, 2001, PHYSICA C, V364, P289, DOI 10.1016/S0921-4534(01)00774-2
   MORI N, 1992, PHYS REV B, V45, P10633, DOI 10.1103/PhysRevB.45.10633
   PATAPIS SK, 1995, PHYSICA C, V244, P198, DOI 10.1016/0921-4534(95)00058-5
   Sato Y, 2003, PHYSICA C, V392, P643, DOI 10.1016/S0921-4534(03)00992-4
   Wang C., 2010, SUPERCOND SCI TECH, V23
NR 9
TC 1
Z9 1
U1 2
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1939
EI 1557-1947
J9 J SUPERCOND NOV MAGN
JI J. Supercond. Nov. Magn
PD MAY
PY 2015
VL 28
IS 5
BP 1455
EP 1459
DI 10.1007/s10948-014-2894-4
PG 5
WC Physics, Applied; Physics, Condensed Matter
SC Physics
GA CF5TJ
UT WOS:000352619700005
DA 2018-12-27
ER

PT J
AU Mallakpour, S
   Ahmadizadegan, H
AF Mallakpour, Shadpour
   Ahmadizadegan, Hashem
TI RETRACTED: Manufacture of zinc oxide/chiral
   poly(amide-imide)-functionalized amino acid and thiazole
   bionanocomposites: Using ionic liquid and ultrasonic irradiation
   (Retracted article. See vol. 510, pg. 418, 2018)
SO JOURNAL OF THERMOPLASTIC COMPOSITE MATERIALS
LA English
DT Article; Retracted Publication
DE Poly(amide-imide); L-valine; ionic liquid; zinc oxide; ultrasonic
   techniques
ID SILANE-COUPLING AGENT; SURFACE MODIFICATION; MICROWAVE IRRADIATION; ZNO;
   NANOCOMPOSITES; POLYMERS; NANOSTRUCTURES; NANOPARTICLES; NANOCRYSTALS;
   OXIDE
AB In this work, novel optically active poly(amide-imide)/zinc oxide bionanocomposites (PAI/ZnO BNCs) containing l-valine moiety in the main chain were prepared via a simple and inexpensive ultrasonic irradiation process. Chiral PAI was synthesized by direct polycondensation reaction of N,N-(pyromellitoyl)-bis-valine with 3,5-diamino-N-(thiazol-2-yl)benzamide in the tetrabutyl ammonium bromide/triphenylphosphite as a green solvent system. Due to the high surface energy and the tendency for agglomeration, the surface of ZnO nanoparticles (NPs) was modified with -aminopropyltriethoxysilane. PAI/ZnO BNCs containing 4, 8, and 12% of NPs were successfully fabricated through ultrasonic irradiation technique. The obtained BNCs were characterized by Fourier transform infrared spectroscopy, thermogravimetric analysis (TGA), x-ray diffraction, ultraviolet-visible spectroscopy, field emission scanning electron microscopy, and transmission electron microscopy (TEM) techniques. TGA data indicated an increase in thermal stability of the BNCs when compared with the pure polymer. From the TEM image of PAI/ZnO BNCs, it can be found that the surface-modified ZnO NPs, with a diametric size of less than 35nm, are uniformly dispersed in the PAI matrix.
C1 [Mallakpour, Shadpour; Ahmadizadegan, Hashem] Isfahan Univ Technol, Dept Chem, Organ Polymer Chem Res Lab, Esfahan 8415683111, Iran.
   [Mallakpour, Shadpour] Isfahan Univ Technol, Nanotechnol & Adv Mat Inst, Esfahan 8415683111, Iran.
RP Mallakpour, S (reprint author), Isfahan Univ Technol, Dept Chem, Organ Polymer Chem Res Lab, Esfahan 8415683111, Iran.
EM mallak@cc.iut.ac.ir
FU Research Affairs Division Isfahan University of Technology (IUT); Center
   of Excellency in Sensors and Green Chemistry Research (IUT)
FX This work was financially supported by the Research Affairs Division
   Isfahan University of Technology (IUT) and Center of Excellency in
   Sensors and Green Chemistry Research (IUT).
CR Abdolmaleki A, 2012, POLYM BULL, V69, P15, DOI 10.1007/s00289-011-0685-7
   Althues H, 2007, CHEM SOC REV, V36, P1454, DOI 10.1039/b608177k
   Alvarez JC, 2001, MACROMOL CHEM PHYSIC, V202, P3142, DOI 10.1002/1521-3935(20011101)202:16<3142::AID-MACP3142>3.0.CO;2-R
   Balas F, 2007, J MATER SCI-MATER M, V18, P1167, DOI 10.1007/s10856-007-0130-5
   Becheri A, 2008, J NANOPART RES, V10, P679, DOI 10.1007/s11051-007-9318-3
   Cheng GJ, 2006, T NONFERR METAL SOC, V16, P1252
   CHIANG CH, 1980, J COLLOID INTERF SCI, V74, P396, DOI 10.1016/0021-9797(80)90209-X
   Corso CD, 2008, BIOSENS BIOELECTRON, V24, P805, DOI 10.1016/j.bios.2008.07.011
   Ding KL, 2007, J AM CHEM SOC, V129, P6362, DOI 10.1021/ja070809c
   Fernandes DM, 2011, MATER CHEM PHYS, V128, P371, DOI 10.1016/j.matchemphys.2011.03.002
   Gupta SK, 2010, J CHEM SCI, V122, P57, DOI 10.1007/s12039-010-0006-y
   Hong RY, 2006, POWDER TECHNOL, V163, P160, DOI 10.1016/j.powtec.2006.01.015
   Iijima M, 2009, COLLOID SURFACE A, V352, P88, DOI 10.1016/j.colsurfa.2009.10.005
   Impens NREN, 1999, MICROPOR MESOPOR MAT, V28, P217, DOI 10.1016/S1387-1811(98)00239-X
   Kickelbick G, 2003, PROG POLYM SCI, V28, P83, DOI 10.1016/S0079-6700(02)00019-9
   Leadbeater NE, 2002, J ORG CHEM, V67, P3145, DOI 10.1021/jo016297g
   Li YQ, 2006, POLYMER, V47, P2127, DOI 10.1016/j.polymer.2006.01.071
   Liufu SC, 2005, POLYM DEGRAD STABIL, V87, P103, DOI 10.1016/j.polymdegradstab.2004.07.011
   Ma DL, 2005, NANOTECHNOLOGY, V16, P724, DOI 10.1088/0957-4484/16/6/016
   Mallakpour S, 2005, IRAN POLYM J, V14, P473
   Mallakpour S, 2007, POLYM BULL, V59, P587, DOI 10.1007/s00289-007-0802-9
   Mallakpour S, 2013, HIGH PERFORM POLYM, V25, P156, DOI 10.1177/0954008312459547
   Mallakpour S, 2012, POLYM BULL, V68, P1201, DOI 10.1007/s00289-011-0598-5
   Mallakpour S, 2011, PROG POLYM SCI, V36, P1754, DOI 10.1016/j.progpolymsci.2011.03.001
   Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017
   Pradhan D, 2008, J PHYS CHEM C, V112, P7093, DOI 10.1021/jp800799b
   Rajeshwar K, 2001, CHEM MATER, V13, P2765, DOI 10.1021/cm010254z
   Rhodes R, 2010, J COLLOID INTERF SCI, V344, P261, DOI 10.1016/j.jcis.2009.12.062
   Sun SP, 2010, J MEMBRANE SCI, V363, P232, DOI 10.1016/j.memsci.2010.07.038
   Tjong SC, 2006, MATER CHEM PHYS, V100, P1, DOI 10.1016/j.matchemphys.2005.11.029
   Tu Y, 2010, J MATER CHEM, V20, P1594, DOI 10.1039/b914156a
   Ukaji E, 2007, APPL SURF SCI, V254, P563, DOI 10.1016/j.apsusc.2007.06.061
   VANKREVELEN DW, 1976, PROPERTIES POLYM
   Wacharawichanant S., 2010, SCI J UBU, V1, P21
   Wang ZL, 2007, APPL PHYS A-MATER, V88, P7, DOI 10.1007/s00339-007-3942-8
   Wasserscheid P, 2000, ANGEW CHEM INT EDIT, V39, P3772, DOI 10.1002/1521-3773(20001103)39:21<3772::AID-ANIE3772>3.0.CO;2-5
   Wu QZ, 2008, CRYST GROWTH DES, V8, P3010, DOI 10.1021/cg800126r
   Wu YL, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/21/215604
   Wu YL, 2007, APPL SURF SCI, V253, P5473, DOI 10.1016/j.apsusc.2006.12.091
   Xiong Y, 2010, J POLYM RES, V17, P273, DOI 10.1007/s10965-009-9314-7
NR 40
TC 2
Z9 2
U1 4
U2 28
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0892-7057
EI 1530-7980
J9 J THERMOPLAST COMPOS
JI J. Thermoplast. Compos. Mater.
PD MAY
PY 2015
VL 28
IS 5
BP 672
EP 685
DI 10.1177/0892705713487187
PG 14
WC Materials Science, Composites
SC Materials Science
GA CG7ET
UT WOS:000353465900006
DA 2018-12-27
ER

PT J
AU Arab, M
   Naghash, HJ
AF Arab, Mozhgan
   Naghash, Hamid Javaherian
TI RETRACTED: Synthesis and characterization of an alkoxy and methacryloxy
   propyl terminated polydimethylsiloxane for uses in the core-shell latex
   particles (Retracted article. See vol. 121, pg. 264. 2018)
SO PROGRESS IN ORGANIC COATINGS
LA English
DT Article; Retracted Publication
DE Alkoxy and methacryloxy propyl end caped polydimethylsiloxane;
   Core-shell; Semi continuous seeded emulsion
ID EMULSION COPOLYMERS; NANOCOMPOSITE EMULSION; STYRENE/BUTYL ACRYLATE;
   POLYMER EMULSIONS; SILICONE; SILANE; MONOMER; BUTYLACRYLATE; SURFACTANT
AB Alkoxy and methacryloxy propyl end caped polydimethylsiloxane (AMP-PDMS) was successfully synthesized. The preparation included four steps, which are hydrolysis, hydroxyl formation, alkylation and alkoxylation. Then, the latex particles with a polyacrylate core and a polydimethylsiloxane shell via AMP-PDMS as the space arm to link the core and shell have been prepared by semi continuous seeded emulsion polymerization. And several key polymerization reaction conditions such as the surfactant content, AMP-PDMS concentration, feeding sequence and the acrylates/siloxanes ratio were detailedly discussed. Also the optimal condition to prepare stable core/shell particles was selected and a proper preparation process has been established. The as-synthesized particles were characterized by TEM and laser light scattering. The clear core/shell structure of the particles could be observed through analysis TEM. In addition, the obtained results manifested that siloxanes had been grafted on the surface of the polyacrylate particles and they distributed on the outmost layer of the particles. Finally, the surface hydrophobicity of the film formed by latex particles was investigated by the water absorption ratio measurement. The results indicated the developed latex particle provided with a fair water-repellency property. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Arab, Mozhgan; Naghash, Hamid Javaherian] Islamic Azad Univ, Dept Chem, Shahreza Branch, Shahreza, Isfahan, Iran.
RP Naghash, HJ (reprint author), Islamic Azad Univ, Dept Chem, Shahreza Branch, POB 311-86145, Shahreza, Isfahan, Iran.
EM Javaherian@iaush.ac.ir
CR Abe Y, 2000, J NON-CRYST SOLIDS, V261, P39, DOI 10.1016/S0022-3093(99)00614-6
   Beltran AB, 2011, APPL SURF SCI, V258, P337, DOI 10.1016/j.apsusc.2011.08.061
   Chen MJ, 1997, J COATING TECHNOL, V69, P49, DOI 10.1007/BF02720170
   Cheng SY, 2002, J APPL POLYM SCI, V85, P1147, DOI 10.1002/app.10622
   Ge CY, 2010, ADV POLYM TECH, V29, P161, DOI 10.1002/adv.20182
   Grandi S, 2006, J NON-CRYST SOLIDS, V352, P273, DOI 10.1016/j.jnoncrysol.2005.11.033
   GRASSIE N, 1952, T FARADAY SOC, V48, P379, DOI 10.1039/tf9524800379
   Guo TY, 2006, J APPL POLYM SCI, V100, P1824, DOI 10.1002/app.23081
   Javaheriannaghash H, 2012, J COAT TECHNOL RES, V9, P323, DOI 10.1007/s11998-011-9373-7
   Jiang HM, 2007, POLYM BULL, V59, P53, DOI 10.1007/s00289-007-0748-y
   Junli L., 2011, POLYM-PLAST TECHNOL, V50, P1525
   Kan CY, 2001, J APPL POLYM SCI, V80, P2251, DOI 10.1002/app.1329
   Kan CY, 1997, POLYM ADVAN TECHNOL, V8, P631, DOI 10.1002/(SICI)1099-1581(199711)8:11<631::AID-PAT691>3.0.CO;2-K
   Kan CY, 1996, POLYM ADVAN TECHNOL, V7, P95
   Khorasani MT, 2005, APPL SURF SCI, V242, P339, DOI 10.1016/j.apsusc.2004.08.035
   Kishore K., 2007, IND ENG CHEM RES, V46, P6408
   Kobayashi M, 2002, J MOL STRUCT, V602, P321, DOI 10.1016/S0022-2860(01)00776-1
   Landfester K, 2005, POLYMER, V46, P9892, DOI 10.1016/j.polymer.2005.07.080
   Naghash H.J., 2011, PROG ORG COAT, V72, P724
   Naghash H. J., 2012, PROG ORG COAT, V73, P155
   Naghash HJ, 2013, POLYM SCI SER B+, V55, P620, DOI 10.1134/S1560090413130022
   Naghash HJ, 2013, POLYM SCI SER B+, V55, P611, DOI 10.1134/S1560090413130010
   Naghash HJ, 2014, SYNTH REACT INORG M, V44, P514, DOI 10.1080/15533174.2013.778880
   Naghash HJ, 2013, PROG ORG COAT, V76, P318, DOI 10.1016/j.porgcoat.2012.09.008
   Naghash HJ, 2013, POLYM ADVAN TECHNOL, V24, P307, DOI 10.1002/pat.3084
   Naghash HJ, 2012, POLYM SCI SER B+, V54, P505, DOI 10.1134/S1560090412100089
   Naghash HJ, 2012, J APPL POLYM SCI, V123, P1227, DOI 10.1002/app.34601
   Naghash HJ, 2010, PROG ORG COAT, V69, P486, DOI 10.1016/j.porgcoat.2010.09.003
   Naghash HJ, 2011, PROG ORG COAT, V70, P32, DOI 10.1016/j.porgcoat.2010.09.015
   Naghash HJ, 2010, POLYM-KOREA, V34, P306, DOI 10.7317/pk.2010.34.4.306
   Naghash HJ, 2010, J APPL POLYM SCI, V116, P382, DOI 10.1002/app.30856
   Naghash HJ, 2009, PROG ORG COAT, V65, P275, DOI 10.1016/j.porgcoat.2008.12.005
   Naghash HJ, 2009, J APPL POLYM SCI, V112, P1037, DOI 10.1002/app.29555
   Okamoto Y, 1996, PROG ORG COAT, V29, P175, DOI 10.1016/S0300-9440(96)00660-1
   Valencia M, 2007, MACROMOLECULES, V40, P40, DOI 10.1021/ma0613032
   Wang HH, 2010, EXPRESS POLYM LETT, V4, P670, DOI 10.3144/expresspolymlett.2010.82
   Wu R.J., 1998, SURFACE INTERFACE HI, P89
   Zhu B, 2000, POLYMER, V41, P7559, DOI 10.1016/S0032-3861(00)00027-6
NR 38
TC 3
Z9 3
U1 5
U2 46
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0300-9440
J9 PROG ORG COAT
JI Prog. Org. Coat.
PD MAY
PY 2015
VL 82
BP 113
EP 122
DI 10.1016/j.porgcoat.2015.01.008
PG 10
WC Chemistry, Applied; Materials Science, Coatings & Films
SC Chemistry; Materials Science
GA CE7UQ
UT WOS:000352047700014
DA 2018-12-27
ER

PT J
AU Wang, XH
   Wang, JQ
   Xu, Y
   Huang, LP
AF Wang, Xiao-Hong
   Wang, Jun-Qing
   Xu, Yan
   Huang, Li-Ping
TI RETRACTED: Therapeutic effects of metformin and laparoscopic ovarian
   drilling in treatment of clomiphene and insulin-resistant polycystic
   ovary syndrome (Retracted article. See vol. 293, pg. 693, 2016)
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article; Retracted Publication
DE Clomiphene resistance; Insulin resistance; Laparoscopic ovarian
   drilling; Metformin; Polycystic; Ovary syndrome
ID OVULATION INDUCTION; DOUBLE-BLIND; WOMEN; SURGERY; CITRATE; GROWTH;
   TRIAL
AB To compare the therapeutic effects of metformin (Met) and laparoscopic ovarian drilling (LOD) in clomiphene and insulin-resistant patients with polycystic ovary syndrome (CIRPCOS).
   A total of 110 patients were randomly divided into two groups. One group was administered Met (n = 55), while the other group underwent LOD (n = 55). Rates of ovulation, pregnancy, and abortion were compared between both groups.
   Rates of normal menstruation, ovulation, and pregnancy in the LOD group were higher than in the Met group: 76.4 % (42/55) vs. 58.2 % (32/55), P < 0.04; 50.8 % (11/258) vs. 33.5 % (94/281), P < 0.001; 38.2 % (21/55) vs. 20.0 % (11/55), P < 0.03. The difference in the early abortion rate between both groups was not statistically significant.
   Although Met can significantly improve a patient's insulin resistance, we found that in patients diagnosed with CIRCPOS, LOD can be much more effective in improving rates of normal menstruation, ovulation, and pregnancy.
C1 [Wang, Xiao-Hong; Wang, Jun-Qing] 101st Hosp PLA, Dept Obstet & Gynecol, Wuxi 214044, Peoples R China.
   [Xu, Yan] 101st Hosp PLA, Dept Endocrinol, Wuxi 214044, Peoples R China.
   [Huang, Li-Ping] Southern Med Univ, Dept Obstet & Gynecol, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China.
RP Huang, LP (reprint author), Southern Med Univ, Dept Obstet & Gynecol, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China.
EM lipinghuangcn@126.com
CR Api M, 2005, EUR J OBSTET GYN R B, V119, P76, DOI 10.1016/j.ejogrb.2004.07.023
   Api M, 2009, GYNECOL ENDOCRINOL, V25, P159, DOI 10.1080/09513590802585605
   Chang J, 2004, FERTIL STERIL, V81, P19, DOI 10.1016/j.fertnstert.2003.10.004
   DABIRASHRAFI H, 1989, FERTIL STERIL, V52, P878
   De Leo V, 2003, ENDOCR REV, V24, P633, DOI 10.1210/er.2002-0015
   Dursun P, 2007, FERTIL STERIL, V88, pS244, DOI 10.1016/j.fertnstert.2007.07.833
   Elsherbnyw Alinanyh, 26 ANN M ESHRE ROM J
   Farquhar C, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD001122.PUB4
   Farquhar CM, 2004, BEST PRACT RES CL OB, V18, P789, DOI 10.1016/j.bpobgyn.2004.06.002
   Gabir MM, 2000, DIABETES CARE, V23, P1108, DOI 10.2337/diacare.23.8.1108
   Hart R, 2006, BEST PRACT RES CL OB, V20, P751, DOI 10.1016/j.bpobgyn.2006.04.006
   Homburg R, 2008, BEST PRACT RES CL OB, V22, P261, DOI 10.1016/j.bpobgyn.2007.07.009
   Kandil M, 2005, BJOG-INT J OBSTET GY, V112, P1427, DOI 10.1111/j.1471-0528.2005.00684.x
   Legro RS, 2007, NEW ENGL J MED, V356, P551, DOI 10.1056/NEJMoa063971
   Lord JM, 2008, COCHRANE DB SYST REV, V3
   Malkawi H Y, 2003, J Obstet Gynaecol, V23, P289
   Norman RJ, 2004, J CLIN ENDOCR METAB, V89, P4797, DOI 10.1210/jc.2004-1658
   Palomba S, 2005, J CLIN ENDOCR METAB, V90, P4068, DOI 10.1210/jc.2005-0110
   Palomba S, 2004, J CLIN ENDOCR METAB, V89, P4801, DOI 10.1210/jc.2004-0689
   Palomba S, 2006, FERTIL STERIL, V86, pS26, DOI 10.1016/j.fertnstert.2006.03.018
   Pirwany I, 2003, FERTIL STERIL, V80, P241, DOI 10.1016/S0015-0282(03)00875-6
   Pirwany IR, 1999, HUM REPROD, V14, P2963, DOI 10.1093/humrep/14.12.2963
   Saleh A, 2001, FERTIL STERIL, V75, P501, DOI 10.1016/S0015-0282(00)01736-2
   Seow KM, 2008, SEMIN REPROD MED, V26, P101, DOI 10.1055/s-2007-992930
   Tan S, 2007, EUR J ENDOCRINOL, V157, P669, DOI 10.1530/EJE-07-0294
   Tang T, 2006, HUM REPROD, V21, P80, DOI 10.1093/humrep/dei311
   Tulandi T, 2000, FERTIL STERIL, V74, P585, DOI 10.1016/S0015-0282(00)00684-1
   Weerakiet S, 2007, GYNECOL ENDOCRINOL, V23, P455, DOI 10.1080/09513590701485212
   Youssef H, 2007, REPROD BIOMED ONLINE, V15, P457, DOI 10.1016/S1472-6483(10)60373-2
NR 29
TC 3
Z9 4
U1 4
U2 17
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD MAY
PY 2015
VL 291
IS 5
BP 1089
EP 1094
DI 10.1007/s00404-014-3486-z
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CE0BN
UT WOS:000351467600021
PM 25304269
DA 2018-12-27
ER

PT J
AU Qin, ZQ
   Fang, Y
   Wang, YJ
   Li, HR
   Liang, JS
AF Qin, Zhiqiao
   Fang, Yi
   Wang, Yanji
   Li, Huanrong
   Liang, Jinsheng
TI RETRACTED: Ionic liquid assisted synthesis of flexible and
   super-hydrophobic porous gels (Retracted article. See vol. 214, pg. 249,
   2015)
SO MICROPOROUS AND MESOPOROUS MATERIALS
LA English
DT Article; Retracted Publication
DE Robust stability; Flexible; Super-hydrophobic; Porous gels
ID SELECTIVE ABSORPTION; AQUEOUS-SOLUTIONS; SILICA AEROGELS; WATER;
   NANOPARTICLES; SEPARATION; SPONGE; OIL
AB Herein we demonstrate the preparation of polysilane network-based aerogels through a facile one-pot reaction from co-precursor of trimethoxysilane and dimethoxysilane assisted with a carboxyl-functionalized ionic liquid for the first time. The gels show good absorption performance such as good selectivity, outstanding recyclability, simple recycling route, and robust stability, which make them highly appealing in the application as a sponge for quick separation of oily targets from water by absorption and simple mechanical squeezing. The resultant porous gels are highly flexible and super-hydrophobic, which are much lighter (0.075 g cm(-3)) and show larger absorption capacity for n-hexane than those obtained from diluted acetic acid. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Qin, Zhiqiao; Fang, Yi; Wang, Yanji; Li, Huanrong] Hebei Univ Technol, Sch Chem Engn & Technol, Hebei Prov Key Lab Green Chem Technol & High Effi, Tianjin 300130, Peoples R China.
   [Liang, Jinsheng] Hebei Univ Technol, Sch Mat Sci & Engn, Tianjin 300130, Peoples R China.
RP Li, HR (reprint author), Hebei Univ Technol, Sch Chem Engn & Technol, Hebei Prov Key Lab Green Chem Technol & High Effi, Tianjin 300130, Peoples R China.
EM lihuanrong@hebut.edu.cn
FU National Key Basic Research Program [2012CB626804]; National Natural
   Science Foundation of China [21171046, 21271060, 21236001]; Educational
   Committee of Hebei Province [2011141, LJRC021]
FX Financial support by the National Key Basic Research Program
   (2012CB626804), the National Natural Science Foundation of China
   (21171046, 21271060, and 21236001), and Educational Committee of Hebei
   Province (2011141, LJRC021) is gratefully acknowledged.
CR Ariga K, 2014, CHEM LETT, V43, P36, DOI 10.1246/cl.130987
   Choi SJ, 2011, ACS APPL MATER INTER, V3, P4552, DOI 10.1021/am201352w
   Dorcheh AS, 2008, J MATER PROCESS TECH, V199, P10, DOI 10.1016/j.jmatprotec.2007.10.060
   Dubreuil JF, 2000, TETRAHEDRON LETT, V41, P7351, DOI 10.1016/S0040-4039(00)01237-5
   Dupont J, 2002, J AM CHEM SOC, V124, P4228, DOI 10.1021/ja025818u
   Hayase G, 2013, ANGEW CHEM INT EDIT, V52, P1986, DOI 10.1002/anie.201207969
   Hayase G, 2011, J MATER CHEM, V21, P17077, DOI [10.1039/c1jm3664j, 10.1039/c1jm13664j]
   Lahann J, 2008, NAT NANOTECHNOL, V3, P320, DOI 10.1038/nnano.2008.143
   Lee JS, 2009, J AM CHEM SOC, V131, P4596, DOI 10.1021/ja900686d
   Lei WW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2818
   Leventis N, 2002, NANO LETT, V2, P957, DOI 10.1021/nl025690e
   Li HR, 2009, J MATER CHEM, V19, P5533, DOI 10.1039/b902663k
   Liang H. W., 2012, ANGEW CHEM, V124, P5191
   Ma ML, 2006, CURR OPIN COLLOID IN, V11, P193, DOI 10.1016/j.cocis.2006.06.002
   Ma Z, 2010, ADV MATER, V22, P261, DOI 10.1002/adma.200900603
   Miao QQ, 2013, CHEM COMMUN, V49, P6980, DOI 10.1039/c3cc42818d
   Miao WS, 2006, ACCOUNTS CHEM RES, V39, P897, DOI 10.1021/ar030252f
   Nakanishi K, 1997, J POROUS MAT, V4, P67, DOI 10.1023/A:1009627216939
   Nicolas M, 2006, ANGEW CHEM, V118, P2309
   Peng L, 2013, ANGEW CHEM INT EDIT, V52, P1792, DOI 10.1002/anie.201209255
   Plechkova NV, 2008, CHEM SOC REV, V37, P123, DOI 10.1039/b006677j
   Rao AV, 2001, J NON-CRYST SOLIDS, V296, P165
   Ruan CP, 2014, ANGEW CHEM INT EDIT, V53, P5556, DOI 10.1002/anie.201400775
   Sun HY, 2013, ADV MATER, V25, P2554, DOI 10.1002/adma.201204576
   Tao GH, 2006, GREEN CHEM, V8, P639, DOI 10.1039/b600813e
   Torimoto T, 2010, ADV MATER, V22, P1196, DOI 10.1002/adma.200902184
   Visser AE, 2001, CHEM COMMUN, P135, DOI 10.1039/b008041l
   von Prondzinski N, 2010, CHEM COMMUN, V46, P4393, DOI 10.1039/c000817f
   Wang DY, 2013, ACS APPL MATER INTER, V5, P6268, DOI 10.1021/am401318a
   Yuan JK, 2008, NAT NANOTECHNOL, V3, P332, DOI 10.1038/nnano.2008.136
   Zhang C, 2010, CHEM COMMUN, V46, P592, DOI 10.1039/b919044a
   Zhang JP, 2011, ADV FUNCT MATER, V21, P4699, DOI 10.1002/adfm.201101090
   Zhang L, 2014, J MATER CHEM A, V2, P7666, DOI 10.1039/c3ta15429g
   Zhang P, 2014, ADV MATER, V26, P6810, DOI 10.1002/adma.201305448
   Zhao Y, 2012, ANGEW CHEM INT EDIT, V51, P11371, DOI 10.1002/anie.201206554
   Zhao YJ, 2011, ANGEW CHEM INT EDIT, V50, P636, DOI 10.1002/anie.201005314
   Zhou Y, 2003, ADV MATER, V15, P1452, DOI 10.1002/adma.200305265
   Zhu X, 2009, AICHE J, V55, P198, DOI 10.1002/aic.11645
NR 38
TC 3
Z9 3
U1 6
U2 72
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1387-1811
EI 1873-3093
J9 MICROPOR MESOPOR MAT
JI Microporous Mesoporous Mat.
PD MAY 1
PY 2015
VL 207
BP 78
EP 83
DI 10.1016/j.micromeso.2014.12.037
PG 6
WC Chemistry, Applied; Chemistry, Physical; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA CC6ZX
UT WOS:000350518600011
DA 2018-12-27
ER

PT J
AU Paulik, LB
   Donald, CE
   Smith, BW
   Tidwell, LG
   Hobbie, KA
   Kincl, L
   Haynes, EN
   Anderson, KA
AF Paulik, L. Blair
   Donald, Carey E.
   Smith, Brian W.
   Tidwell, Lane G.
   Hobbie, Kevin A.
   Kincl, Laurel
   Haynes, Erin N.
   Anderson, Kim A.
TI RETRACTED: Impact of Natural Gas Extraction on PAH Levels in Ambient Air
   (Retracted article. See vol. 50, pg. 7936, 2016)
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article; Retracted Publication
ID POLYCYCLIC AROMATIC-HYDROCARBONS; SEMIPERMEABLE-MEMBRANE DEVICES; WOOD
   COMBUSTION; BARNETT SHALE; OPERATIONS; EMISSION; SAMPLERS; RATIOS; RISK;
   IDENTIFICATION
AB Natural gas extraction, often referred to as "fracking," has increased rapidly in the U.S. in recent years. To address potential health impacts, passive air samplers were deployed in a rural community heavily affected by the natural gas boom. Samplers were analyzed for 62 polycyclic aromatic hydrocarbons (PAHs). Results were grouped based on distance' from each sampler to the nearest active well. PAR levels were highest when samplers were closest to active wells. Additionally, PAR levels closest to natural gas activity were an order of magnitude higher than levels previously reported in rural areas. Sourcing ratios indicate that PAHs were predominantly petrogenic, suggesting that elevated PAR levels were influenced by direct releases from the earth. Quantitative human health risk assessment estimated the excess lifetime cancer risks associated with exposure to the measured PAHs. Closest to active wells, the risk estimated for maximum residential exposure was 2.9 in 10 000, which is above the U.S. EPA's acceptable risk level. Overall, risk estimates decreased 30% when comparing results froth samplers closest to active wells to those farthest. This work suggests that natural gas extraction may be contributing significantly to PAHs in air, at levels that are relevant to human health.
C1 [Paulik, L. Blair; Donald, Carey E.; Smith, Brian W.; Tidwell, Lane G.; Hobbie, Kevin A.; Anderson, Kim A.] Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.
   [Kincl, Laurel] Oregon State Univ, Coll Publ Hlth & Human Sci, Corvallis, OR 97331 USA.
   [Haynes, Erin N.] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA.
RP Anderson, KA (reprint author), Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA.
EM kim.anderson@oregonstate.edu
OI Donald, Carey/0000-0002-1246-2961
FU National Institute of Environmental Health Sciences [P30-ES000210,
   P30-ES06096]
FX This work was funded by the National Institute of Environmental Health
   Sciences grants to Oregon State University: P30-ES000210 and to the
   University of Cincinnati: P30-ES06096. We thank Glenn Wilson, Ricky
   Scott, Jorge Padilla, Gary Points, and Melissa McCartney of the OSU FSES
   Program for help with analysis. Thank you to Dr. Diana Rohlman of the
   OSU Environmental Health Sciences Center Community Outreach and
   Engagement Core (COEC), Sarah Elam of the University of Cincinnati (UC)
   Environmental Health Sciences Center COEC, Jody Alden of UC, and Paul
   Feezel of Carroll Concerned Citizens, all for assistance with volunteer
   recruitment and communication. Thank you to Pierce Kuhnell of UC for
   mapping sample sites. Finally, thank you to the volunteer participants
   in Ohio for making this study possible.
CR Adgate JL, 2014, ENVIRON SCI TECHNOL, V48, P8307, DOI 10.1021/es404621d
   Anderson KA, 2008, ENVIRON SCI TECHNOL, V42, P4486, DOI 10.1021/es702657n
   Bartkow ME, 2004, ENVIRON SCI TECHNOL, V38, P2701, DOI 10.1021/es0348849
   Brasier K. J., 2011, J RURAL SOCIAL SCI, V26, P32
   Budzinski H, 1997, MAR CHEM, V58, P85, DOI 10.1016/S0304-4203(97)00028-5
   Bunch AG, 2014, SCI TOTAL ENVIRON, V468, P832, DOI 10.1016/j.scitotenv.2013.08.080
   Caldwell JC, 1998, TOXICOL IND HEALTH, V14, P429, DOI 10.1177/074823379801400304
   Carlton AG, 2014, ENVIRON SCI TECHNOL, V48, P893, DOI 10.1021/es405672t
   Centner TJ, 2014, SCI TOTAL ENVIRON, V476, P359, DOI 10.1016/j.scitotenv.2013.12.112
   Colborn T, 2014, HUM ECOL RISK ASSESS, V20, P86, DOI 10.1080/10807039.2012.749447
   Colborn T, 2011, HUM ECOL RISK ASSESS, V17, P1039, DOI 10.1080/10807039.2011.605662
   EU, 2004, OFF J EUR UNION E, VC104E, P204
   Fabbri D, 2003, MAR CHEM, V84, P123, DOI 10.1016/S0304-4203(03)00135-X
   Fry M, 2013, ENERG POLICY, V62, P79, DOI 10.1016/j.enpol.2013.07.107
   Goldstein BD, 2014, TOXICOL SCI, V139, P271, DOI 10.1093/toxsci/kfu061
   Hassan SK, 2012, ENVIRON MONIT ASSESS, V184, P3593, DOI 10.1007/s10661-011-2210-8
   Huckins J. N., 2006, MONITORS ORGANIC CHE
   Ingraffea A. R., 2014, P NATL ACAD SCI USA, V111, P10955, DOI DOI 10.1073/PNAS.1323422111
   Jackson RB, 2014, P NATL ACAD SCI USA, V111, P10902, DOI 10.1073/pnas.1410786111
   Kameda Y, 2005, SCI TOTAL ENVIRON, V340, P71, DOI 10.1016/j.scitotenv.2004.08.009
   Khairy MA, 2012, ENVIRON SCI TECHNOL, V46, P3990, DOI 10.1021/es300012u
   Litovitz A, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/1/014017
   Macey G. P., 2014, ENV HLTH, V13, P1, DOI DOI 10.2139/SSM.2516589
   McKenzie LM, 2014, ENVIRON HEALTH PERSP, V122, P412, DOI 10.1289/ehp.1306722
   McKenzie LM, 2012, SCI TOTAL ENVIRON, V424, P79, DOI 10.1016/j.scitotenv.2012.02.018
   Ohio DNR, 2014, UTIC POINT PLEAS SHA
   Perera FP, 2009, PEDIATRICS, V124, pE195, DOI 10.1542/peds.2008-3506
   PETTY JD, 1993, CHEMOSPHERE, V27, P1609, DOI 10.1016/0045-6535(93)90143-S
   Pies C, 2008, CHEMOSPHERE, V72, P1594, DOI 10.1016/j.chemosphere.2008.04.021
   Prest HF, 1995, MAR POLLUT BULL, V31, P306, DOI 10.1016/0025-326X(95)00146-E
   Rabinowitz PM, 2015, ENVIRON HEALTH PERSP, V123, P21, DOI 10.1289/ehp.1307732
   Rafferty MA, 2013, PUBLIC HEALTH NURS, V30, P454, DOI 10.1111/phn.12036
   RAMDAHL T, 1983, NATURE, V306, P580, DOI 10.1038/306580a0
   Ravindra K, 2006, ATMOS ENVIRON, V40, P771, DOI 10.1016/j.atmosenv.2005.10.011
   Ravindra K, 2008, ATMOS ENVIRON, V42, P2895, DOI 10.1016/j.atmosenv.2007.12.010
   Roy AA, 2014, J AIR WASTE MANAGE, V64, P19, DOI 10.1080/10962247.2013.826151
   Shen GF, 2012, ENVIRON SCI TECHNOL, V46, P4666, DOI 10.1021/es300144m
   Shonkoff SBC, 2014, ENVIRON HEALTH PERSP, V122, P787, DOI 10.1289/ehp.1307866
   Simcik MF, 1997, ENVIRON SCI TECHNOL, V31, P2141, DOI 10.1021/es9609765
   Small MJ, 2014, ENVIRON SCI TECHNOL, V48, P8289, DOI 10.1021/es502111u
   Sommariva R, 2014, ENVIRON SCI TECHNOL, V48, P8891, DOI 10.1021/es502508w
   Tidwell LG, 2015, ENVIRON SCI TECHNOL, V49, P141, DOI 10.1021/es503827y
   Tobiszewski M, 2012, ENVIRON POLLUT, V162, P110, DOI 10.1016/j.envpol.2011.10.025
   Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063
   U.S. EIA, 2011, OIL NAT GAS DRILL OH
   U.S. EPA, 2014, MEM REC DEF EXP FACT
   United States Environmental Protection Agency (US EPA), 2009, RISK ASS GUID SUP
   US EIA (United States Energy Information Administration), 2011, REV EM RES US SHAL G
   US Energy Information Administration (EIA), 2011, ANN EN OUTL 2011 PRO
   US Environmental Protection Agency, 2005, GUID CARC RISK ASS
   US EPA, 2010, DEV REL POT FACT RPF
   Wang ZD, 1999, ENVIRON SCI TECHNOL, V33, P3100, DOI 10.1021/es990031y
   World Health Organization, 2000, AIR QUAL GUID EUR
   Yunker MB, 2002, ORG GEOCHEM, V33, P489, DOI 10.1016/S0146-6380(02)00002-5
   Zhang W, 2008, ENVIRON POLLUT, V153, P594, DOI 10.1016/j.envpol.2007.09.004
NR 55
TC 25
Z9 25
U1 2
U2 73
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
EI 1520-5851
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD APR 21
PY 2015
VL 49
IS 8
BP 5203
EP 5210
DI 10.1021/es506095e
PG 8
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA CG9BV
UT WOS:000353610300050
PM 25810398
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Tan, L
   Tan, L
   Wang, HF
   Wang, J
   Tan, CC
   Tan, MS
   Meng, XF
   Wang, C
   Yu, JT
AF Tan, Lin
   Tan, Lan
   Wang, Hui-Fu
   Wang, Jun
   Tan, Chen-Chen
   Tan, Meng-Shan
   Meng, Xiang-Fei
   Wang, Chong
   Yu, Jin-Tai
TI RETRACTED: Efficacy and safety of atypical antipsychotic drug treatment
   for dementia: a systematic review and meta-analysis (Retracted article.
   See vol. 8, 28, 2016)
SO ALZHEIMERS RESEARCH & THERAPY
LA English
DT Article; Retracted Publication
ID PLACEBO-CONTROLLED-TRIAL; ALZHEIMERS-DISEASE; DOUBLE-BLIND;
   NEUROPSYCHIATRIC SYMPTOMS; BEHAVIORAL DISTURBANCES;
   PHARMACOLOGICAL-TREATMENT; QUETIAPINE TREATMENT; CLINICAL-TRIAL;
   NURSING-HOME; PSYCHOSIS
AB Introduction: A wide variety of atypical antipsychotic drugs (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone and clozapine) are widely used in the management of neuropsychiatric symptoms, which are commonly seen in dementia, but results from randomised controlled trials (RCTs) on the efficacy and safety of these agents are conflicting. We aimed to quantify the efficacy and safety of atypical antipsychotic drugs on neuropsychiatric symptoms in dementia patients.
   Methods: PubMed, EMBASE, the Cochrane Controlled Trials Register and the Cochrane Database of Systematic Reviews for reports published before August 2014 were searched for eligible randomized controlled trials of atypical antipsychotic drugs therapy in patients with psychotic symptoms of dementia. Two reviewers independently assessed the quality of the trials and extracted information.
   Results: Overall, 23 relevant RCTs with 5,819 participants were identified. This meta-analysis demonstrated a significant efficacy of atypical antipsychotics on psychiatric symptoms and cognitive functions compared to placebo. In the meta-analysis, the weighted mean differences (WMDs) in change scores for psychiatric symptoms were in favor of aripiprazole (-4.4, 95% confidence interval (CI) -7.04 to -1.77) and risperidone (-1.48, 95% CI -2.35 to -0.61) compared to placebo. In cognitive effects, WMDs in change scores for the Clinical Global Impression-Change (CGI-C) were in favor of aripiprazole, risperidone, olanzapine and quetiapine which ranged from a -0.30 points mean difference (95% CI:-0.59 to -0.01) in the aripiprazole trials to -0.43 (95% CI:-0.62 to -0.25) in the risperidone group. Patients receiving atypical antipsychotics showed no difference in risk for injuries or falls (P > 0.05), significantly higher risks (P < 0.05) for somnolence, urinary tract infection, edema and abnormal gait. However, there was no significant evidence for death reported.
   Conclusion: Aripiprazole and risperidone are able to improve psychiatric symptoms and slow decline in cognition function at average 12 weeks in patients with neuropsychiatric symptoms of dementia. However, high adverse events may offset the efficacy of atypical antipsychotics in dementia.
C1 Ocean Univ China, Coll Med & Pharmaceut, Qingdao 266000, Peoples R China.
   Qingdao Univ, Sch Med, Qingdao Municipal Hosp, Dept Neurol, Qingdao 266071, Peoples R China.
   Nanjing Med Univ, Qingdao Municipal Hosp, Dept Neurol, Nanjing 210000, Jiangsu, Peoples R China.
RP Tan, L (reprint author), Ocean Univ China, Coll Med & Pharmaceut, Qingdao 266000, Peoples R China.
EM dr.tanlan@163.com
OI Yu, Jin-Tai/0000-0002-7686-0547
FU National Natural Science Foundation of China [81000544, 81171209,
   81371406]; Shandong Provincial Natural Science Foundation, China
   [ZR2010HQ004, ZR2011HZ001]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81000544, 81171209, 81371406) and Shandong
   Provincial Natural Science Foundation, China (ZR2010HQ004, ZR2011HZ001).
CR ALEXOPOULOS GS, 2005, POSTGRAD MED
   Ballard C, 2005, BRIT MED J, V330, P874, DOI 10.1136/bmj.38369.459988.8F
   Ballard CG, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003476.PUB2
   Ballard C, 2009, LANCET NEUROL, V8, P151, DOI 10.1016/S1474-4422(08)70295-3
   Brodaty H, 2005, INT J GERIATR PSYCH, V20, P1153, DOI 10.1002/gps.1409
   Brodaty H, 2003, J CLIN PSYCHIAT, V64, P134, DOI 10.4088/JCP.v64n0205
   Butler R, 2012, CLIN EVID, V2012, P1001
   COHENMANSFIELD J, 1989, J GERONTOL, V44, pM77, DOI 10.1093/geronj/44.3.M77
   COOPER J, 1995, BRIT J PSYCHIAT, V166, P4, DOI 10.1192/bjp.166.1.4
   CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308
   De Deyn P, 2005, J CLIN PSYCHOPHARM, V25, P463, DOI 10.1097/01.jcp.0000178415.22309.8f
   De Deyn PP, 2013, EXPERT OPIN PHARMACO, V14, P459, DOI 10.1517/14656566.2013.764989
   De Deyn PP, 1999, NEUROLOGY, V53, P946, DOI 10.1212/WNL.53.5.946
   De Deyn PP, 2004, INT J GERIATR PSYCH, V19, P115, DOI 10.1002/gps.1032
   Deberdt WG, 2005, AM J GERIAT PSYCHIAT, V13, P722, DOI 10.1176/appi.ajgp.13.8.722
   Declercq T, 2013, COCHRANE DB SYST REV, V3
   Franco KN, 2006, J AM MED DIR ASSOC, V7, P201, DOI 10.1016/j.jamda.2005.12.024
   Gill Sudeep S, 2013, Evid Based Ment Health, V16, P81, DOI 10.1136/eb-2013-101372
   Higgins JP, 2011, COCHRANE HDB SYSTEMA
   Jeste DV, 2000, AM J GERIAT PSYCHIAT, V8, P29, DOI 10.1097/00019442-200002000-00004
   Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207
   Kurlan R, 2007, NEUROLOGY, V68, P1356, DOI 10.1212/01.wnl.0000260060.60870.89
   Maher AR, 2011, JAMA-J AM MED ASSOC, V306, P1359, DOI 10.1001/jama.2011.1360
   Mintzer J, 2006, AM J GERIAT PSYCHIAT, V14, P280, DOI 10.1097/01.JGP.0000194643.63245.8c
   Mintzer JE, 2007, AM J GERIAT PSYCHIAT, V15, P918, DOI 10.1097/JGP.0b013e3181557b47
   OVERALL JE, 1984, J GERONTOL, V39, P187, DOI 10.1093/geronj/39.2.187
   Paleacu D, 2008, INT J GERIATR PSYCH, V23, P393, DOI 10.1002/gps.1892
   REISBERG B, 1987, J CLIN PSYCHIAT, V48, P9
   Schneider LS, 2006, NEW ENGL J MED, V355, P1525, DOI 10.1056/NEJMoa061240
   Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22
   Schneider LS, 2006, AM J GERIAT PSYCHIAT, V14, P191, DOI 10.1097/01.JGP.0000200589.01396.6d
   Seitz DP, 2013, INT PSYCHOGERIATR, V25, P185, DOI 10.1017/S1041610212001627
   Sink KM, 2005, JAMA-J AM MED ASSOC, V293, P596, DOI 10.1001/jama.293.5.596
   Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968
   Streim JE, 2008, AM J GERIAT PSYCHIAT, V16, P537, DOI 10.1097/JGP.0b013e318165db77
   Sultzer DL, 2008, AM J PSYCHIAT, V165, P844, DOI 10.1176/appi.ajp.2008.07111779
   Tariot PN, 2006, AM J GERIAT PSYCHIAT, V14, P767, DOI 10.1097/01.JGP.0000196628.12010.35
   Zhong KX, 2007, CURR ALZHEIMER RES, V4, P81, DOI 10.2174/156720507779939805
NR 38
TC 26
Z9 29
U1 3
U2 25
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1758-9193
J9 ALZHEIMERS RES THER
JI Alzheimers Res. Ther.
PD APR 20
PY 2015
VL 7
AR 20
DI 10.1186/s13195-015-0102-9
PG 13
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA CG2QK
UT WOS:000353119300001
PM 25897331
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Van Weelden, MT
   Bennett, G
   Buczkowski, G
AF Van Weelden, M. T.
   Bennett, G.
   Buczkowski, G.
TI RETRACTED: The Effects of Colony Structure and Resource Abundance on
   Food Dispersal in Tapinoma sessile (Hymenoptera: Formicidae)(Retracted
   article. See vol. 15, 2015)
SO JOURNAL OF INSECT SCIENCE
LA English
DT Article; Retracted Publication
DE foraging; odorous house ant; immunomarking; polydomy; food dispersal
ID INVASIVE ARGENTINE ANT; ODOROUS HOUSE ANT; LINEPITHEMA-HUMILE; NATIVE
   ANT; STRATEGIES; POLYDOMY; QUEENS
AB The odorous house ant, Tapinoma sessile (Say) (Hymenoptera: Formicidae), exhibits a high degree of variation in colony spatial structure, which may have direct and indirect effects on foraging. Protein marking and mark-release-recapture techniques were utilized to examine the effect of colony spatial structure on food dispersal. Sucrose water spiked with rabbit IgG protein was presented to colonies with varying spatial configurations in laboratory and field experiments. In monodomous laboratory colonies, the rate and extent of food dispersal was rapid due to a decrease in foraging area. In polydomous colonies, food dispersal was slower because conspecifics were forced to forage and share food over longer distances. However, over time, food was present in all extremities of the colony. Experiments conducted in the field produced similar results, with nests in close proximity to food yielding higher percentages of workers scoring positive for the marker. However, the percentage of workers possessing the marker decreased over time. Results from this study provide experimental data on mechanisms of food dispersal in monodomous and polydomous colonies of ants and may be important for increasing the efficacy of management strategies against T. sessile and other pest ant species.
C1 [Van Weelden, M. T.; Bennett, G.; Buczkowski, G.] Purdue Univ, Dept Entomol, W Lafayette, IN 47906 USA.
RP Van Weelden, MT (reprint author), Purdue Univ, Dept Entomol, W Lafayette, IN 47906 USA.
EM mvanwe2@lsu.edu
FU Industrial Affiliates Program at Purdue University
FX We thank the three anonymous reviewers for their helpful comments on the
   manuscript, A. Salyer and T. Carroll for assistance in the field, and M.
   El-Nour for maintenance of laboratory colonies. This study was supported
   in part by the Industrial Affiliates Program at Purdue University.
CR BHATKAR A, 1970, Florida Entomologist, V53, P229, DOI 10.2307/3493193
   Boulay R, 2000, ANIM BEHAV, V59, P1127, DOI 10.1006/anbe.2000.1408
   Buczkowski G, 2006, INSECT SOC, V53, P282, DOI 10.1007/s00040-006-0870-0
   Buczkowski G, 2009, INSECT SOC, V56, P185, DOI 10.1007/s00040-009-0011-7
   Buczkowski G, 2008, ECOL ENTOMOL, V33, P780, DOI 10.1111/j.1365-2311.2008.01034.x
   Buczkowski G, 2010, ENVIRON ENTOMOL, V39, P1936, DOI 10.1603/EN10148
   Buczkowski G, 2010, BIOL INVASIONS, V12, P3343, DOI 10.1007/s10530-010-9727-6
   Choe JC, 1997, EVOLUTION SOCIAL BEH
   Debout G, 2007, BIOL J LINN SOC, V90, P319, DOI 10.1111/j.1095-8312.2007.00728.x
   Fisher BL, 2007, ANTS N AM GUIDE GENE
   Fournier D, 2001, ANIM BEHAV, V62, P1039, DOI 10.1006/anbe.2001.1848
   Hagler J.R., 1997, TRENDS ENTOMOLOGY, V1, P105
   HAGLER JR, 1992, ENVIRON ENTOMOL, V21, P896, DOI 10.1093/ee/21.4.896
   Hagler JR, 1998, ENVIRON ENTOMOL, V27, P1010, DOI 10.1093/ee/27.4.1010
   Heller NE, 2008, INSECT SOC, V55, P397, DOI 10.1007/s00040-008-1019-0
   HOLLDOBLER B, 1977, NATURWISSENSCHAFTEN, V64, P8, DOI 10.1007/BF00439886
   HOLLDOBLER B, 1980, SCIENCE, V210, P732, DOI 10.1126/science.210.4471.732
   Holway DA, 2001, ANIM BEHAV, V61, P1181, DOI 10.1006/anbe.2000.1698
   Holway DA, 2000, ANIM BEHAV, V59, P433, DOI 10.1006/anbe.1999.1329
   Human KG, 1996, OECOLOGIA, V105, P405, DOI 10.1007/BF00328744
   MARKIN GP, 1970, ANN ENTOMOL SOC AM, V63, P1238, DOI 10.1093/aesa/63.5.1238
   MARKIN GP, 1970, INSECT SOC, V17, P127, DOI 10.1007/BF02223074
   MCIVER JD, 1991, INSECT SOC, V38, P129, DOI 10.1007/BF01240963
   Menke SB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009194
   Newell Wilmon, 1913, U S Department of Agriculture Bureau of Entomology Bulletin, VNo. 122
   ROSENGREN R, 1983, Acta Entomologica Fennica, V42, P65
   SAS Institute, 2008, SAS STAT GUID PERS C
   SMITH MARION R., 1928, ANN ENT SOC AMER, V21, P307
   TRANIELLO JFA, 1989, ANNU REV ENTOMOL, V34, P191, DOI 10.1146/annurev.en.34.010189.001203
   Vail K. M., 2002, PB1629 U TENN AGR EX
   WILSON EO, 1971, SCIENCE, V172, P406, DOI 10.1126/science.172.3981.406
NR 31
TC 2
Z9 2
U1 4
U2 27
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1536-2442
EI 2250-2645
J9 J INSECT SCI
JI J Insect Sci.
PD APR 16
PY 2015
VL 15
AR 46
DI 10.1093/jisesa/iev011
PG 7
WC Entomology
SC Entomology
GA CG3UX
UT WOS:000353206200004
PM 25881634
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yan, ZR
   Peng, Y
   Wu, Y
   Di, JW
AF Yan, Ziren
   Peng, Yang
   Wu, Ying
   Di, Junwei
TI RETRACTED: Controllable Electrochemical Synthesis of Silver
   Nanoparticles on Indium-Tin-Oxide-Coated Glass (Retracted article. See
   vol. 2, pg. 1072, 2015)
SO CHEMELECTROCHEM
LA English
DT Article; Retracted Publication
DE electrochemical deposition; nanostructures; seed-mediated growth;
   silver; square-wave cyclic voltammetry
ID ENHANCED RAMAN-SCATTERING; SURFACE-PLASMON RESONANCE; GOLD
   NANOPARTICLES; OPTICAL-PROPERTIES; AG NANOPARTICLES; ITO; ELECTRODE;
   CARBON; SENSOR; SIZE
AB A simple electrochemical approach, which integrates nanoseed nucleation and a square-wave cyclic voltammetry (SWCV) growth strategy, was developed to construct silver nanoparticles (AgNPs) on indium tin oxide (ITO)-coated glass surfaces. Ag nanoseeds were first deposited on the ITO surface by using pulse chronoamperometry and the particles were then grown during the SWCV process. Factors that have great effects on the characterization of AgNPs during the electrochemical process were systematically investigated. It is demonstrated that the growth process can be controlled separately. AgNPs and clusters were deposited and grown onto the ITO substrate. Moreover, the nanoparticles grew monotonically with increasing number of cycles, which provides a powerful tool to control the nanoparticle size by simply changing the number of SWCV cycles.
C1 [Yan, Ziren; Peng, Yang; Wu, Ying; Di, Junwei] Soochow Univ, Coll Chem Chem Engn & Mat Sci, Suzhou Ind Pk, Suzhou 215123, Peoples R China.
RP Yan, ZR (reprint author), Soochow Univ, Coll Chem Chem Engn & Mat Sci, Suzhou Ind Pk, Suzhou 215123, Peoples R China.
EM djw@suda.edu.cn
FU National Natural Science Foundation of China [21075086]; Natural Science
   Foundation of Jiangsu Province [BK2011273]; Project of Scientific and
   Technologic Infrastructure of Suzhou [SZS201207]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 21075086), Natural Science Foundation of
   Jiangsu Province (BK2011273), the Project of Scientific and Technologic
   Infrastructure of Suzhou (SZS201207), and the Priority Academic Program
   Development of Jiangsu Higher Education Institutions.
CR Ballarin B, 2008, ELECTROCHIM ACTA, V53, P8034, DOI 10.1016/j.electacta.2008.06.020
   Bansal V, 2010, CRYSTENGCOMM, V12, P4280, DOI 10.1039/c0ce00215a
   Cassar RN, 2014, VIB SPECTROSC, V71, P41, DOI 10.1016/j.vibspec.2014.01.004
   Cheng ML, 2010, J RAMAN SPECTROSC, V41, P167, DOI 10.1002/jrs.2422
   Cobley CM, 2009, PLASMONICS, V4, P171, DOI 10.1007/s11468-009-9088-0
   Dai XA, 2006, ANAL SCI, V22, P567, DOI 10.2116/analsci.22.567
   Deng JJ, 2010, BIOSENS BIOELECTRON, V26, P615, DOI 10.1016/j.bios.2010.07.014
   Ding YF, 2007, CHINESE J CHEM, V25, P1094, DOI 10.1002/cjoc.200790204
   Dong PP, 2013, PLASMONICS, V8, P1577, DOI 10.1007/s11468-013-9574-2
   Fan MK, 2010, ANAL CHEM, V82, P6350, DOI 10.1021/ac101495m
   Fan M, 2009, PHYS CHEM CHEM PHYS, V11, P7381, DOI 10.1039/b904744a
   Fu YY, 2014, ELECTROCHIM ACTA, V120, P314, DOI 10.1016/j.electacta.2013.12.082
   Giovanni M, 2012, ELECTROANAL, V24, P615, DOI 10.1002/elan.201100690
   Gonzalez AL, 2014, J PHYS CHEM C, V118, P9128, DOI 10.1021/jp5018168
   Guerrini L, 2010, J RAMAN SPECTROSC, V41, P508, DOI 10.1002/jrs.2469
   Hajizadeh S, 2011, ANAL METHODS-UK, V3, P2599, DOI 10.1039/c1ay05567d
   Huang CJ, 2006, J COLLOID INTERF SCI, V303, P430, DOI 10.1016/j.jcis.2006.07.073
   Ivanova OS, 2010, J AM CHEM SOC, V132, P70, DOI 10.1021/ja908780g
   Jiang B, 2013, CRYST RES TECHNOL, V48, P1044, DOI 10.1002/crat.201300192
   Jiang ZJ, 2005, J PHYS CHEM B, V109, P1730, DOI 10.1021/jp046032g
   Jones SEW, 2008, J PHYS CHEM C, V112, P17820, DOI 10.1021/jp807093q
   Kelly KL, 2003, J PHYS CHEM B, V107, P668, DOI 10.1021/jp026731y
   Kityk IV, 2006, PHYSICA E, V31, P38, DOI 10.1016/j.physe.2005.08.012
   Lee S, 2011, CHEM PHYS LETT, V511, P121, DOI 10.1016/j.cplett.2011.06.025
   Li XY, 2013, ELECTROCHIM ACTA, V113, P170, DOI 10.1016/j.electacta.2013.09.049
   Lin JH, 2007, ANAL BIOCHEM, V360, P288, DOI 10.1016/j.ab.2006.10.030
   Prabhu S, 2012, INT NANO LETT, V2, DOI 10.1186/2228-5326-2-32
   Raoof JB, 2012, APPL SURF SCI, V258, P2788, DOI 10.1016/j.apsusc.2011.10.133
   Rycenga M, 2011, CHEM REV, V111, P3669, DOI 10.1021/cr100275d
   Sandmann G, 2000, J ELECTROANAL CHEM, V491, P78, DOI 10.1016/S0022-0728(00)00301-6
   Shon YS, 2009, PLASMONICS, V4, P95, DOI 10.1007/s11468-009-9079-1
   Siek M, 2013, ELECTROCHIM ACTA, V89, P284, DOI 10.1016/j.electacta.2012.11.037
   Tao H, 2014, ELECTROCHEM COMMUN, V40, P75, DOI 10.1016/j.elecom.2014.01.002
   Toh HS, 2013, NANOSCALE, V5, P4884, DOI 10.1039/c3nr00898c
   Tsai YC, 2009, ELECTROCHEM COMMUN, V11, P542, DOI 10.1016/j.elecom.2008.12.046
   Umar AA, 2005, CRYST GROWTH DES, V5, P599, DOI 10.1021/cg049711p
   Upender G, 2011, CHEM PHYS LETT, V511, P309, DOI 10.1016/j.cplett.2011.06.039
   Wang YL, 2007, J RAMAN SPECTROSC, V38, P515, DOI [10.1002/jrs.1674, 10.1002/jrs. 1674]
NR 38
TC 2
Z9 3
U1 6
U2 33
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2196-0216
J9 CHEMELECTROCHEM
JI ChemElectroChem
PD APR 15
PY 2015
VL 2
IS 4
BP 578
EP 583
DI 10.1002/celc.201402369
PG 6
WC Electrochemistry
SC Electrochemistry
GA CG1VR
UT WOS:000353063900014
DA 2018-12-27
ER

PT J
AU Larranaga, A
   Cardenas-Avendano, A
   Torres, DA
AF Larranaga, Alexis
   Cardenas-Avendano, Alejandro
   Alexdy Torres, Daniel
TI RETRACTED: On a general class of regular rotating black holes based on a
   smeared mass distribution (Retracted article. See vol. 747, pg. 564,
   2015)
SO PHYSICS LETTERS B
LA English
DT Article; Retracted Publication
DE Physics of black holes; Noncommutative geometry
ID NEWMAN-JANIS ALGORITHM; NONCOMMUTATIVE GEOMETRY; PLANE
AB In this work we investigate the behavior of a new general class of rotating regular black holes based on a non-Gaussian smeared mass distribution. It is shown that the existence of a fundamental minimal length cures the well-known problems in the terminal phase of black hole evaporation, since we find that there is a finite maximum temperature that the black hole reaches before cooling down to absolute zero, so that the evaporation ends up in a zero temperature extremal black hole whose mass and size depends on the value of the fundamental length and on the rotation parameter of the black hole. We also study the geodesic structure in these spacetimes and calculate the shadows that these black holes produce. (C) 2015 The Authors. Published by Elsevier B.V.
C1 [Larranaga, Alexis; Cardenas-Avendano, Alejandro] Univ Nacl Colombia, Natl Astron Observ, Bogota, Colombia.
   [Cardenas-Avendano, Alejandro] Konrad Lorenz Univ, Dept Math, Bogota, Colombia.
   [Alexdy Torres, Daniel] Univ Nacl Colombia, Dept Phys, Bogota, Colombia.
RP Larranaga, A (reprint author), Univ Nacl Colombia, Natl Astron Observ, Bogota, Colombia.
EM ealarranaga@unal.edu.co; alcardenasav@unal.edu.co;
   daatorresba@unal.edu.co
FU Universidad Nacional de Colombia [28281]; Department of Mathematics,
   Konrad Lorenz University
FX This work was partially supported by the Universidad Nacional de
   Colombia, Hermes Project Code 28281. A.C. also thanks the Department of
   Mathematics, Konrad Lorenz University, for financial support.
CR Ansoldi S, 2007, PHYS LETT B, V645, P261, DOI 10.1016/j.physletb.2006.12.020
   Banerjee R, 2008, PHYS REV D, V77, DOI 10.1103/PhysRevD.77.124035
   CARTER B, 1968, PHYS REV, V174, P1559, DOI 10.1103/PhysRev.174.1559
   Drake SP, 2000, GEN RELAT GRAVIT, V32, P445, DOI 10.1023/A:1001920232180
   HAWKING SW, 1975, COMMUN MATH PHYS, V43, P199, DOI 10.1007/BF02345020
   HERRERA L, 1982, J MATH PHYS, V23, P2339, DOI 10.1063/1.525325
   Hioki K, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.084011
   Larranaga A, 2014, ROM J PHYS, V59, P57
   Liang J, 2014, CHINESE PHYS C, V38, DOI 10.1088/1674-1137/38/2/025101
   LUMINET JP, 1979, ASTRON ASTROPHYS, V75, P228
   Modesto L, 2010, PHYS REV D, V82, DOI 10.1103/PhysRevD.82.104035
   Mureika JR, 2011, PHYS REV D, V84, DOI 10.1103/PhysRevD.84.044020
   Myung Y S, 2007, JHEP, V0702
   Myung YS, 2009, EUR PHYS J C, V62, P405, DOI 10.1140/epjc/s10052-009-1036-9
   Myung YS, 2009, GEN RELAT GRAVIT, V41, P1051, DOI 10.1007/s10714-008-0690-9
   NEWMAN ET, 1965, J MATH PHYS, V6, P915, DOI 10.1063/1.1704350
   Nicolini P, 2005, J PHYS A-MATH GEN, V38, pL631, DOI 10.1088/0305-4470/38/39/L02
   Nicolini P, 2006, PHYS LETT B, V632, P547, DOI 10.1016/j.physletb.2005.11.004
   Nicolini P., 2006, ESA SP, V637, P111
   Nicolini P, 2013, ADV HIGH ENERGY PHYS, DOI 10.1155/2013/812084
   Nicolini P, 2009, INT J MOD PHYS A, V24, P1229, DOI 10.1142/S0217751X09043353
   Park MI, 2009, PHYS REV D, V80, DOI 10.1103/PhysRevD.80.084026
   Rizzo T. G., 2006, JHEP, V0609, DOI DOI 10.1088/1126-6708/2006/09/021
   Seiberg N, 1999, J HIGH ENERGY PHYS, DOI 10.1088/1126-6708/1999/09/032
   Smailagic A, 2003, J PHYS A-MATH GEN, V36, pL517, DOI 10.1088/0305-4470/36/39/103
   Smailagic A, 2003, J PHYS A-MATH GEN, V36, pL467, DOI 10.1088/0305-4470/36/33/101
   Smailagic A, 2010, PHYS LETT B, V688, P82, DOI 10.1016/j.physletb.2010.03.075
   SNYDER HS, 1947, PHYS REV, V71, P38, DOI 10.1103/PhysRev.71.38
   Spallucci E, 2009, PHYS LETT B, V670, P449, DOI 10.1016/j.physletb.2008.11.030
   SUSSKIND L, 1993, PHYS REV LETT, V71, P2367, DOI 10.1103/PhysRevLett.71.2367
   Tejeiro J. M., 2012, PRAMANA-J PHYS, V78, P1
   Wei S. W., 2015, ARXIV150106298
   Witten E, 1996, NUCL PHYS B, V460, P335, DOI 10.1016/0550-3213(95)00610-9
NR 33
TC 8
Z9 8
U1 4
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0370-2693
EI 1873-2445
J9 PHYS LETT B
JI Phys. Lett. B
PD APR 9
PY 2015
VL 743
BP 492
EP 502
DI 10.1016/j.physletb.2015.03.024
PG 11
WC Astronomy & Astrophysics; Physics, Nuclear; Physics, Particles & Fields
SC Astronomy & Astrophysics; Physics
GA CE9EU
UT WOS:000352147500073
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Nasoori, A
   Pedram, B
   Kamyabi-Moghaddam, Z
   Mokarizadeh, A
   Pirasteh, H
   Fayyaz, AF
   Shooshtari, MB
AF Nasoori, Alireza
   Pedram, Behnam
   Kamyabi-Moghaddam, Zahra
   Mokarizadeh, Aram
   Pirasteh, Hamid
   Fayyaz, Amir Farshid
   Shooshtari, Mohammad Barat
TI RETRACTED: Clinicopathologic characterization of visceral gout of
   various internal organs -a study of 2 cases from a venom and toxin
   research center(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Gout; Visceral; Snake; Pathology; Cells
ID CRYSTAL-INDUCED INFLAMMATION; INTERLEUKIN-8; MODEL
AB Background: Gout is a metabolic disorder that results in hyperuricemia and the deposition of positively birefringent monosodium urate crystals in various parts of the body. The purpose of this study was to characterize the incidence and diagnostic features of visceral gout found at necropsy in two patients.
   Case presentation: The authors present an unusual report of untreated gout leading to major structure destructions in visceral organs. Gross post-mortem examination revealed a white powdery substance and display needle-like crystalline symmetry under the macroscopic on the visceral surfaces. Microscopically, the presence of crystalline deposits (urate tophi) were detected in visceral organs, such as; kidney, liver, lung and mesentery. Irrespective of its location, gout was observed, by H&E, as intracellular and extracellular eosinophilic deposits that compressed surrounding tissues. Moreover, numerous necrotizing granulomas of multifarious sizes were observed that were compounded by large aggregations of eosinophilic material (gout), surrounded by epithelioid macrophages, lymphoplasmacytic cells, foreign body multinucleated giant cells, fibrosis, fibroplasia and few edema. On the other hand, our results revealed that granulomatous nodules in the mesentery and kidney contained large numbers of gout foci compared with lung and liver. Furthermore, the immediate cause of death in these cases were not identified, but appeared to result from multiple factors, including the visceral gout due to unsuitable environmental conditions.
   Conclusion: In summary, we have identified a valid histopathologic damage index for use in laboratory studies of visceral gout. This system provides a feasible method of representing visceral damage in gout, and may allow for better understanding of the natural history, pathophysiology and the management of acute attacks of gouty visceral in this disease. Finally, to the best of our knowledge, understanding of the distribution of monosodium urate crystals within the body can aid clinical diagnosis and further understanding of the resulting pathology.
C1 [Nasoori, Alireza] Biotechnol Res Ctr, Dept Med Biotechnol, Venom & Toxin Unit, Pasteur Inst Iran, Tehran, Iran.
   [Pedram, Behnam] Islamic Azad Univ, Dept Pathobiol, Susangerd Branch, Susangerd, Iran.
   [Kamyabi-Moghaddam, Zahra] TU Muenchen, Klinikum Rechts Isar, Dept Med 2, Munich, Germany.
   [Kamyabi-Moghaddam, Zahra] Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Cellular & Mol Res Ctr, Sanandaj, Iran.
   [Pirasteh, Hamid] AJA Univ Med Sci, Dept Nephrol, Tehran, Iran.
   [Fayyaz, Amir Farshid] AJA Univ Med Sci, Dept Legal Med, Tehran, Iran.
   [Shooshtari, Mohammad Barat] Biotechnol Res Ctr, Inst Sci & Technol, Tehran, Iran.
RP Shooshtari, MB (reprint author), Biotechnol Res Ctr, Inst Sci & Technol, Tehran, Iran.
EM behzadshoshtary@gmail.com
OI Abdi, Mohammad/0000-0002-4766-0423; Mokarizadeh,
   Aram/0000-0002-2630-8308
CR Bieber JD, 2004, ARTHRITIS RHEUM-US, V50, P2400, DOI 10.1002/art.20438
   Brown LA, 2007, ANN INTERN MED, V147, P819, DOI DOI 10.7326/0003-4819-147-11-2007
   Dehghani R, 2014, TOXICON, V90, P291, DOI 10.1016/j.toxicon.2014.08.063
   Dessauer HC, 1970, BIOL REPTILIA, V3, P25
   Dumonceaux G, 2001, AVIAN MED PRINCIPLES, P1036
   FAIRES JS, 1962, LANCET, V2, P682
   Feofanov AV, 2004, BIOCHEMISTRY-MOSCOW+, V69, P1148, DOI 10.1023/B:BIRY.0000046890.46901.7e
   Funk RS, 2005, REPTILE MED SURG, P346
   Guo X, 2005, BRIT POULTRY SCI, V46, P641, DOI 10.1080/00071660500302661
   Holzinger D, 2013, J ROTH PEDIAT RHEUMA, V11, pA99
   Holzinger D, 2014, ARTHRITIS RHEUMATOL, V66, P1327, DOI 10.1002/art.38369
   Liu-Bryan R, 2012, GOUT OTHER CRYSTAL A, P59
   Mader D., 2005, REPTILE MED SURG, P374
   Mader DR, 2006, REPTILE MED SURG, P793
   MONTALI RJ, 1979, VET PATHOL, V16, P108, DOI 10.1177/030098587901600111
   MORRIS JH, 1984, PATHOLOGIC BASIS DIS, P1370
   Mubarak M, 1999, ENVIRON TOXICOL PHAR, V7, P227, DOI 10.1016/S1382-6689(99)00020-4
   Nasoori A, 2014, ASIAN PAC J TROP MED, V7, pS137, DOI 10.1016/S1995-7645(14)60220-0
   NAYAK NC, 1988, INDIAN VET J, V65, P1080
   Oaks J. Lindsay, 2004, P241
   Patel A. K., 2007, Indian Journal of Veterinary Pathology, V31, P24
   Rao T. B., 1993, Poultry Adviser, V26, P43
   Robbins SL, 1984, PATHOLOGIC BASIS DIS, P991
   Ronco C, 2005, HYPERURICEMIC SYNDRO, V147, P1
   Roudybush TE, 1999, VET CLIN N AM EXOTIC
   Swimmer JY, 2000, J WILDLIFE DIS, V36, P102, DOI 10.7589/0090-3558-36.1.102
   TERKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894, DOI 10.1002/art.1780340716
   Terkeltaub R, 1998, ARTHRITIS RHEUM, V41, P900, DOI 10.1002/1529-0131(199805)41:5<900::AID-ART18>3.0.CO;2-K
   Tran TH, 2013, PHARMACOTHERAPY, V33, P744, DOI 10.1002/phar.1265
   WARD F P, 1968, Bulletin of the Wildlife Disease Association, V4, P91
NR 30
TC 1
Z9 1
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD APR 9
PY 2015
VL 10
AR 23
DI 10.1186/s13000-015-0251-y
PG 6
WC Pathology
SC Pathology
GA CF8UE
UT WOS:000352836600001
PM 25884935
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Adib-Hashemi, F
   Farahmand, F
   Hesari, SF
   Rezakhaniha, B
   Fallah, E
   Fayyaz, AF
   Dadpay, M
AF Adib-Hashemi, Farajollah
   Farahmand, Farshad
   Hesari, Shamim Fattah
   Rezakhaniha, Bijan
   Fallah, Ehsan
   Fayyaz, Amir Farshid
   Dadpay, Masoomeh
TI RETRACTED: Anti-inflammatory and protective investigations on the
   effects of Theranekron (R) "an alcoholic extract of the Tarantula
   cubensis" on wound healing of peritoneal in the rat: an in vivo
   comparative study(Retracted article. See vol. 11, 2016)
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article; Retracted Publication
DE Theranekron; Histopathology; Wound; Regeneration; Rat
ID NIGELLA-SATIVA; DIABETIC-RATS; REGENERATION; EFFICACY; DISEASE; REPAIR;
   CATTLE; MODEL
AB Background: The present study sought to investigate the effects of Tarantula cubensis extract (TC; Theranekron (R)) on the histopathological scores of peritoneal wound healing after laparotomy in the rats.
   Methods: This study was designed to investigate the effects of Theranekron on the peritoneal wound healing after wound creation, on days9, 14, 19, 24 and 29 post-injury in rats. Twenty-four mature Wister-albino male rats were randomly divided into two groups. In the experimental group, TC was repeatedly injected subcutaneously (SC) over the lesion 9, 14,19 and 24 days after laparotomy, whereas the control group received only normal saline by subcutaneous injection and then the animal groups were euthanized9, 14, 19, 24, and 29 days after wounding respectively by intravenous injections of pentobarbital (50 mg/kg). Finally, assessment of the peritoneal wound healing between the groups was carried out by histopathologic data and statistical tests as Mann-Whitney U, Wilcoxon W and Z
   Results: Histopathological examination indicated significant improvement in angiogenesis, re-epithelialization and less inflammatory response in comparison to control and also, revealed matured, compact and parallel deposition of collagen fibrils on day 29. So, at long term, treatment reduced the inflammation and increased the quality and rate of wound re-epithelialization compared to controls(P < 0.05). Furthermore, excluding the control group, rats exhibited the most pronounced effect on wound closure, with the statistically significant improvement in wound healing being seen at post-operative day 29. Moreover, collagen content on days 24 and 29 in the test group was found to be higher than in the healthy group. To warp up, treated groups had a significant increase in peritoneal wound healing area compared to the control group on all days (P < 0.05).
   Conclusions: Our results suggested that Theranekron have delivered a novel therapeutic route for wound treatment in clinical practice.
C1 [Adib-Hashemi, Farajollah] Univ Tehran, Fac Vet Med, Dept Clin Sci, Tehran, Iran.
   [Farahmand, Farshad] Islamic Azad Univ, Garmsar Branch, Fac Vet Med, Garmsar, Iran.
   [Hesari, Shamim Fattah] Imam Reza Hosp, Dept Surg, Tehran, Iran.
   [Rezakhaniha, Bijan] Imam Reza Hosp, Dept Urol, Tehran, Iran.
   [Fallah, Ehsan] AJA Univ Med Sci, Dept Orthoped & Trauma Surg, Tehran, Iran.
   [Fayyaz, Amir Farshid] AJA Univ Med Sci, Dept Legal Med, Tehran, Iran.
   [Dadpay, Masoomeh] AJA Univ Med Sci, Imam Reza Hosp, Dept Pathol, Tehran, Iran.
RP Dadpay, M (reprint author), AJA Univ Med Sci, Imam Reza Hosp, Dept Pathol, Tehran, Iran.
EM mdadpay@yahoo.com
OI Rezakhaniha, Bijan/0000-0001-7426-4875
CR Abramov Y, 2007, WOUND REPAIR REGEN, V15, P80, DOI 10.1111/j.1524-475X.2006.00188.x
   Achuth HN, 2005, WOUND REPAIR REGEN, V13, P383, DOI 10.1111/j.1067-1927.2005.130405.x
   Albay MK, 2010, KAFKAS UNIV VET FAK, V16, P593
   Amadeu Thais Porto, 2003, Int J Low Extrem Wounds, V2, P60, DOI 10.1177/1534734603256155
   Andres C, 2013, PAIN, V154, P2216, DOI 10.1016/j.pain.2013.07.005
   Barati F, 2013, DIAGN PATHOL, V17, P120
   Burkitt HG, 1990, ESSENTIAL SURG, P771
   Clark RA, 1991, CUTANEOUS WOUND REPA, P576
   Connolly AJ, 1997, AM J PATHOL, V151, P1199
   de Fatima A, 2008, MINI-REV MED CHEM, V8, P879
   Dinc S, 2006, CAN J SURG, V49, P321
   Gangopadhyay KS, 2014, INT J LOW EXTR WOUND, V13, P41, DOI 10.1177/1534734614520705
   Godwin JW, 2014, DIFFERENTIATION, V87, P66, DOI 10.1016/j.diff.2014.02.002
   Gultekin N, 2007, JIVS, V2, P13
   Hobbenaghi R, 2014, J NEUROL SCI, V337, P74, DOI 10.1016/j.jns.2013.11.019
   Hobbenaghi R, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-59
   Jacobs S, 2009, J PLAST RECONSTR AES, V62, P1331, DOI 10.1016/j.bjps.2008.03.024
   Januszyk M, 2014, ORGANOGENESIS, V16, P10
   Javanbakht J, 2013, PATHOL BIOL, V61, P250, DOI 10.1016/j.patbio.2013.03.007
   Kacar C, 2007, KAFKAS UNIV VET FAK, V13, P11
   Khodr B, 2001, FREE RADICAL BIO MED, V30, P1, DOI 10.1016/S0891-5849(00)00378-6
   Kinis V, 2014, AM J OTOLARYNG, V35, P482, DOI 10.1016/j.amjoto.2014.02.008
   KOCH H, 1980, PRAKT TIERARZT, V61, P116
   Kumar V, 2003, BASIC PATHOLOGY, P873
   Lodhi S, 2006, J ETHNOPHARMACOL, V108, P204, DOI 10.1016/j.jep.2006.05.011
   Marcelo BT, 2003, INT J MORPHOL, V21, P143
   Mates N., 2008, Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca. Veterinary Medicine, V65, P182
   Menetrey J, 2000, J BONE JOINT SURG BR, V82B, P131, DOI 10.1302/0301-620X.82B1.8954
   Naik HRP, 2009, EUR J MED CHEM, V44, P981, DOI 10.1016/j.ejmech.2008.07.006
   NEWMAN ME, 1986, J AM ANIM HOSP ASSOC, V22, P757
   Oryan Ahmad, 2012, Am J Orthop (Belle Mead NJ), V41, P554
   Rasik A. M., 1996, Indian Journal of Pharmacology, V28, P107
   Richardson-Boedler C, 2002, Homeopathy, V91, P166, DOI 10.1054/homp.2002.0029
   Sankar R, 2014, J MAT SCI MAT MED
   Sardari K, 2007, COMP CLIN PATHOL, V16, P197
   Sayar H, 2014, MED SCI MONIT BASIC, V20, P36, DOI 10.12659/MSMBR.890337
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   STAMPA S, 1986, J S AFR VET ASSOC, V57, P91
   SWAIM SF, 1987, J AM VET MED ASSOC, V190, P1588
   Swaim SF, 1997, SMALL ANIMAL WOUND M, P34
   Toda M, 2008, BIOMED PHARMACOTHER, V62, P352, DOI 10.1016/j.biopha.2008.02.003
   Whelan HT, 2003, J CLIN LASER MED SUR, V21, P67, DOI 10.1089/104454703765035484
   Wiatrek Rebecca L, 2008, Clin Colon Rectal Surg, V21, P76, DOI 10.1055/s-2008-1055325
   Yan H, 2013, CHINESE MED J-PEKING, V126, P1700, DOI 10.3760/cma.j.issn.0366-6999.20122728
   Yuksel EP, 2014, ADV SKIN WOUND CARE, V27, P216, DOI 10.1097/01.ASW.0000445920.14039.64
NR 45
TC 1
Z9 1
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD APR 2
PY 2015
VL 10
AR 19
DI 10.1186/s13000-015-0252-x
PG 10
WC Pathology
SC Pathology
GA CF7TJ
UT WOS:000352758900001
PM 25889956
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Jin, T
   Chu, FL
   Ling, C
   Nzongo, DLM
AF Jin, Tao
   Chu, Fuliang
   Ling, Cong
   Nzongo, Daniel Legrand Mon
TI RETRACTED: A Robust WLS Power System State Estimation Method Integrating
   a Wide-Area Measurement System and SCADA Technology (Retracted article.
   See vol. 8, pg. 10995, 2015)
SO ENERGIES
LA English
DT Article; Retracted Publication
ID BAD DATA DETECTION; IDENTIFICATION; TRANSITION
AB With the development of modern society, the scale of the power system is rapidly increased accordingly, and the framework and mode of running of power systems are trending towards more complexity. It is nowadays much more important for the dispatchers to know exactly the state parameters of the power network through state estimation. This paper proposes a robust power system WLS state estimation method integrating a wide-area measurement system (WAMS) and SCADA technology, incorporating phasor measurements and the results of the traditional state estimator in a post-processing estimator, which greatly reduces the scale of the non-linear estimation problem as well as the number of iterations and the processing time per iteration. This paper firstly analyzes the wide-area state estimation model in detail, then according to the issue that least squares does not account for bad data and outliers, the paper proposes a robust weighted least squares (WLS) method that combines a robust estimation principle with least squares by equivalent weight. The performance assessment is discussed through setting up mathematical models of the distribution network. The effectiveness of the proposed method was proved to be accurate and reliable by simulations and experiments.
C1 [Jin, Tao; Chu, Fuliang; Nzongo, Daniel Legrand Mon] Fuzhou Univ, Coll Elect Engn & Automat, Fuzhou 350108, Peoples R China.
   [Ling, Cong] Univ London Imperial Coll Sci Technol & Med, Dept Elect & Elect Engn, London SW7 2BT, England.
RP Jin, T (reprint author), Fuzhou Univ, Coll Elect Engn & Automat, Fuzhou 350108, Peoples R China.
EM jintly@fzu.edu.cn; fuliangchu@fzu.edu.cn; cling@imperial.ac.uk;
   monnzongodaniel@yahoo.fr
FU European Community [909880]; Chinese National Natural Science Foundation
   [50907011]; Fujian Science Foundation for Distinguished Young Scholars
   [2012J06012]; Education office of Fujian province [JA1108]; Fuzhou
   University [022222]
FX This work was primarily supported by European Community 7th Framework
   Programme (Number: 909880), Chinese National Natural Science Foundation
   (Number: 50907011), Fujian Science Foundation for Distinguished Young
   Scholars (Number: 2012J06012). We also appreciate the support from
   Education office of Fujian province (Number: JA1108) and Fuzhou
   University (Number: 022222). The authors would like to thank all the
   reviewers for their advices and suggestions on improving this paper.
CR BRAMELLER A, 1979, P I ELECTR ENG, V126, P246, DOI 10.1049/piee.1979.0057
   Chen J, 2006, IEEE T POWER SYST, V21, P1608, DOI 10.1109/TPWRS.2006.881149
   Dobakhshari AS, 2013, INT T ELECTR ENERGY, V23, P1272, DOI 10.1002/etep.1654
   Guo Y, 2014, ENERGIES, V7, P1288, DOI 10.3390/en7031288
   Haughton DA, 2013, IEEE T POWER SYST, V28, P1187, DOI 10.1109/TPWRS.2012.2212921
   Huang CH, 2010, EUR T ELECTR POWER, V20, P1082, DOI 10.1002/etep.386
   Huang Y, 2013, IEEE COMMUN MAG, V51, P27, DOI 10.1109/MCOM.2013.6400435
   Jiang WQ, 2007, IEEE T POWER SYST, V22, P563, DOI 10.1109/TPWRS.2007.894859
   Kamwa I, 2009, IEEE T POWER SYST, V24, P258, DOI 10.1109/TPWRS.2008.2009430
   Kundu P, 2014, INT J ELEC POWER, V63, P546, DOI 10.1016/j.ijepes.2014.06.009
   Luque J, 1996, IEEE T POWER DELIVER, V11, P1195, DOI 10.1109/61.517471
   Phadke AG, 2008, IEEE POWER ENERGY M, V6, P52, DOI 10.1109/MPE.2008.927476
   Ree D. L., 2010, IEEE T SMART GRID, V1, p20 27, DOI [10.1109/TSG.2010.2044815, DOI 10.1109/TSG.2010.2044815]
   Singh D, 2005, IEEE T POWER SYST, V20, P1570, DOI 10.1109/TPWRS.2005.852086
   Song HL, 2014, ENERGIES, V7, P2631, DOI 10.3390/en7042631
   Thomas MS, 2004, IEEE T POWER SYST, V19, P1582, DOI 10.1109/TPWRS.2004.826770
   Wang B, 2013, IEEE T POWER SYST, V28, P4875, DOI 10.1109/TPWRS.2013.2264917
   Xu WY, 2013, IEEE T SIGNAL PROCES, V61, P6175, DOI 10.1109/TSP.2013.2282463
   Yang T, 2011, IEEE T POWER SYST, V26, P46, DOI 10.1109/TPWRS.2010.2050078
   Yang T, 2011, IEEE T POWER SYST, V26, P54, DOI 10.1109/TPWRS.2010.2050077
   Yao W, 2011, IEEE T POWER SYST, V26, P233, DOI 10.1109/TPWRS.2010.2093031
   Yu KKC, 2007, IEEE T POWER DELIVER, V22, P1680, DOI 10.1109/TPWRD.2007.901147
   Yu KKC, 2005, IEEE T POWER DELIVER, V20, P1045, DOI 10.1109/TPWRD.2004.833895
   Zhang JH, 2014, IEEE T SUSTAIN ENERG, V5, P629, DOI 10.1109/TSTE.2013.2280246
   Zhong Z, 2005, IEEE T POWER SYST, V20, P1914, DOI 10.1109/TPWRS.2005.857386
NR 25
TC 5
Z9 5
U1 3
U2 12
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1996-1073
J9 ENERGIES
JI Energies
PD APR
PY 2015
VL 8
IS 4
BP 2769
EP 2787
DI 10.3390/en8042769
PG 19
WC Energy & Fuels
SC Energy & Fuels
GA CH3XD
UT WOS:000353963400021
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Tedford, CE
   DeLapp, S
   Jacques, S
   Anders, J
AF Tedford, Clark E.
   DeLapp, Scott
   Jacques, Steven
   Anders, Juanita
TI RETRACTED: Quantitative Analysis of Transcranial and Intraparenchymal
   Light Penetration in Human Cadaver Brain Tissue (Retracted article. See
   vol. 47, pg. 466, 2015)
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Article; Retracted Publication
DE central nervous system; isotropic optical fibers; low level light
   therapy; photobiomodulation; transcranial light therapy; 808 nm
   wavelength
ID INVASIVE BLADDER-CANCER; PHOSPHATE LASER VAPORIZATION; SINGLE-CENTER
   EXPERIENCE; TRANSURETHRAL RESECTION; TUMOR; UROLOGY; IMPLANTATION;
   MANAGEMENT; CARCINOMA; PROSTATE
AB Background and Objective: Photobiomodulation (PBM) also known as low-level light therapy has been used successfully for the treatment of injury and disease of the nervous system. The use of PBM to treat injury and diseases of the brain requires an in-depth understanding of light propagation through tissues including scalp, skull, meninges, and brain. This study investigated the light penetration gradients in the human cadaver brain using a Transcranial Laser System with a 30mmdiameter beam of 808nm wavelength light. In addition, the wavelengthdependence of light scatter and absorbance in intraparenchymal brain tissue using 660, 808, and 940nm wavelengths was investigated.
   Study Design/Material and Methods: Intact human cadaver heads (n = 8) were obtained for measurement of light propagation through the scalp/skull/meninges and into brain tissue. The cadaver heads were sectioned in either the transverse or mid-sagittal. The sectioned head was mounted into a cranial fixture with an 808nm wavelength laser system illuminating the head from beneath with either pulsed-wave (PW) or continuouswave (CW) laser light. A linear array of nine isotropic optical fibers on a 5mm pitch was inserted into the brain tissue along the optical axis of the beam. Light collected from each fiber was delivered to a multichannel power meter. As the array was lowered into the tissue, the power from each probe was recorded at 5mmincrements until the inner aspect of the dura mater was reached. Intraparenchymal light penetration measurements were made by delivering a series of wavelengths (660, 808, and 940 nm) through a separate optical fiber within the array, which was offset from the array line by 5mm. Local light penetration was determined and compared across the selected wavelengths.
   Results: Unfixed cadaver brains provide good anatomical localization and reliable measurements of light scatter and penetration in theCNStissues. Transcranial application of 808nm wavelength light penetrated the scalp, skull, meninges, and brain to a depth of approximately 40mm with an effective attenuation coefficient for the system of 2.22 cm(-1). No differences were observed in the results between the PW and CW laser light. The intraparenchymal studies demonstrated less absorption and scattering for the 808 nm wavelength light compared to the 660 or 940 nm wavelengths.
   Conclusions: Transcranial light measurements of unfixed human cadaver brains allowed for determinations of light penetration variables. While unfixed human cadaver studies do not reflect all the conditions seen in the living condition, comparisons of light scatter and penetration and estimates of fluence levels can be used to establish further clinical dosing. The 808 nm wavelength light demonstrated superior CNS tissue penetration. Lasers Surg. Med. 47: 312-322, 2015. (C) 2015 Wiley Periodicals, Inc.
C1 [Tedford, Clark E.; DeLapp, Scott] LumiThera Inc, Poulsbo, WA 98370 USA.
   [Jacques, Steven] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
   [Anders, Juanita] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA.
RP Anders, J (reprint author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
EM juanita.anders@usuhs.edu
CR Babjuk M, 2011, EUR UROL, V59, P997, DOI 10.1016/j.eururo.2011.03.017
   Dorotta I, 2003, ANESTH ANALG, V97, P1536, DOI 10.1213/01.ANE.0000085299.24288.8C
   Gao X, 2008, BJU INT, V102, P1115, DOI 10.1111/j.1464-410X.2008.07814.x
   Hall MC, 2007, J UROLOGY, V178, P2314, DOI 10.1016/j.juro.2007.09.003
   Kramer MW, 2011, WORLD J UROL, V29, P433, DOI 10.1007/s00345-011-0680-5
   Marks AJ, 2007, WORLD J UROL, V25, P227, DOI 10.1007/s00345-007-0163-x
   Nieder AM, 2005, J UROLOGY, V174, P2307, DOI 10.1097/01.ju.0000181797.19385.03
   O'Donnell MA, 2007, SEMIN ONCOL, V34, P85, DOI 10.1053/j.seminoncol.2006.12.012
   PAGE BH, 1978, BRIT J UROL, V50, P237, DOI 10.1111/j.1464-410X.1978.tb02816.x
   Pierre SA, 2007, WORLD J UROL, V25, P275, DOI 10.1007/s00345-007-0185-4
   Pietrow PK, 2001, J ENDOUROL, V15, P415, DOI 10.1089/089277901300189466
   PODE D, 1986, J UROLOGY, V136, P482, DOI 10.1016/S0022-5347(17)44926-3
   Reich O, 2004, J UROLOGY, V171, P2502, DOI 10.1097/01.ju.0000128803.04158.76
   SOLOWAY MS, 1980, CANCER-AM CANCER SOC, V46, P1158, DOI 10.1002/1097-0142(19800901)46:5<1158::AID-CNCR2820460514>3.0.CO;2-E
   Song XS, 2010, J ENDOUROL, V24, P69, DOI 10.1089/end.2009.0171
   Teichmann HO, 2007, WORLD J UROL, V25, P221, DOI 10.1007/s00345-007-0184-5
   Tsivian A, 2003, J UROLOGY, V170, P2241, DOI 10.1097/01.ju.0000096273.64448.e7
   Volkan T, 2005, EUR UROL, V48, P608, DOI 10.1016/j.eururo.2005.07.013
   Zhong C, 2010, WORLD J UROL, V28, P157, DOI 10.1007/s00345-010-0532-8
   Zhu YF, 2008, UROLOGY, V72, P608, DOI 10.1016/j.urology.2008.05.028
NR 20
TC 43
Z9 43
U1 5
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD APR
PY 2015
VL 47
IS 4
BP 312
EP 322
DI 10.1002/lsm.22343
PG 11
WC Dermatology; Surgery
SC Dermatology; Surgery
GA CG4DN
UT WOS:000353233100005
PM 25772014
DA 2018-12-27
ER

PT J
AU Hart, W
   Tullett, AM
   Shreves, WB
   Fetterman, Z
AF Hart, William
   Tullett, Alexa M.
   Shreves, Wyley B.
   Fetterman, Zachary
TI RETRACTED: Fueling doubt and openness: Experiencing the unconscious,
   constructed nature of perception induces uncertainty and openness to
   change(Retracted article. See vol 169,pg 165,2017)
SO COGNITION
LA English
DT Article; Retracted Publication
DE Cognition; Confidence; Judgment and decision making; Naive realism
ID INTROSPECTION ILLUSION; OVERCONFIDENCE; INFORMATION; CONFIDENCE;
   BEHAVIOR; ACCESSIBILITY; PREDICTION; ACCURACY; BIAS; SAW
AB Because people lack access to the many unconscious thought processes that influence perception, they often have the experience of seeing things "as they are". Psychologists have long presumed that this "naive realism" plays a role in driving human confidence and closed-mindedness. Yet, surprisingly, these intuitive links have not been empirically demonstrated. Presumably, if naive realism drives confidence and closed-mindedness, then disabusing people of naive realism should reduce confidence in one's judgments and instill openness to change. In the present experiment, we found that participants who read about naive realism and also experienced various perceptual illusions showed reduced confidence in their social judgments and indicated a greater willingness to change their judgments relative to participants who merely read about naive realism and perceptual illusions, participants who received failure feedback on an earlier task, or participants left in a baseline state. Broadly, the present research provides evidence for an untested origin of human confidence and closed-mindedness and may have broad implications for decision making. (c) 2014 Elsevier B.V. All rights reserved.
C1 [Hart, William; Tullett, Alexa M.; Shreves, Wyley B.; Fetterman, Zachary] Univ Alabama, Tuscaloosa, AL 35487 USA.
RP Hart, W (reprint author), Univ Alabama, Dept Psychol, Box 873048, Tuscaloosa, AL 35487 USA.
EM wphart@gmail.com; atullett@ua.edu
CR Asch S. E., 1952, SOCIAL PSYCHOL
   Bartlett F. C., 1932, REMEMBERING STUDY EX
   Bornstein BH, 1999, J EXP PSYCHOL-APPL, V5, P76, DOI 10.1037//1076-898X.5.1.76
   BRUNER JS, 1957, PSYCHOL REV, V64, P123, DOI 10.1037/h0043805
   DUNNING D, 1990, J PERS SOC PSYCHOL, V58, P568, DOI 10.1037/0022-3514.58.4.568
   FAZIO RH, 1986, J PERS SOC PSYCHOL, V51, P505, DOI 10.1037//0022-3514.51.3.505
   FISCHHOFF B, 1977, J EXP PSYCHOL HUMAN, V3, P552, DOI 10.1037//0096-1523.3.4.552
   GILOVICH T, 1990, J PERS SOC PSYCHOL, V59, P623, DOI 10.1037//0022-3514.59.4.623
   Hart W, 2009, PSYCHOL BULL, V135, P555, DOI 10.1037/a0015701
   HASTORF AH, 1954, J ABNORM SOC PSYCH, V49, P129, DOI 10.1037/h0057880
   Ichheiser G, 1943, CHARACT PERSON, V12, P145
   James W, 1890, PRINCIPLES PSYCHOL
   KAHNEMAN D, 1973, PSYCHOL REV, V80, P237, DOI 10.1037/h0034747
   Kahneman D., 2011, THINKING FAST SLOW
   Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121
   Kruglanski AW, 1996, PSYCHOL REV, V103, P263, DOI 10.1037/0033-295X.103.2.263
   McKenzie CRM, 2008, ORGAN BEHAV HUM DEC, V107, P179, DOI 10.1016/j.obhdp.2008.02.007
   NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037//0033-295X.84.3.231
   Oppenheimer DM, 2009, J EXP SOC PSYCHOL, V45, P867, DOI 10.1016/j.jesp.2009.03.009
   Pronin E, 2007, J EXP SOC PSYCHOL, V43, P565, DOI 10.1016/j.jesp.2006.05.011
   Pronin E, 2009, ADV EXP SOC PSYCHOL, V41, P1, DOI 10.1016/S0065-2601(08)00401-2
   REGAN DT, 1977, J EXP SOC PSYCHOL, V13, P28, DOI 10.1016/0022-1031(77)90011-7
   Roets A, 2011, PERS INDIV DIFFER, V50, P90, DOI 10.1016/j.paid.2010.09.004
   Ross L, 1996, J PIAGET SY, P103
   SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037//0033-295X.84.2.127
   SMITH VL, 1989, J APPL PSYCHOL, V74, P356, DOI 10.1037//0021-9010.74.2.356
   Soll JB, 2004, J EXP PSYCHOL LEARN, V30, P299, DOI 10.1037/0278-7393.30.2.299
   SRULL TK, 1979, J PERS SOC PSYCHOL, V37, P1660, DOI 10.1037//0022-3514.37.10.1660
   West RF, 1997, PSYCHON B REV, V4, P387, DOI 10.3758/BF03210798
   WILSON TD, 1994, PSYCHOL BULL, V116, P117, DOI 10.1037/0033-2909.116.1.117
NR 30
TC 5
Z9 5
U1 1
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0010-0277
EI 1873-7838
J9 COGNITION
JI Cognition
PD APR
PY 2015
VL 137
BP 1
EP 8
DI 10.1016/j.cognition.2014.12.003
PG 8
WC Psychology, Experimental
SC Psychology
GA CF7NZ
UT WOS:000352744900001
PM 25584463
DA 2018-12-27
ER

PT J
AU Kou, YW
   Qiao, L
   Wang, Q
AF Kou, Youwei
   Qiao, Lei
   Wang, Qiang
TI RETRACTED: Identification of core miRNA based on small RNA-seq and
   RNA-seq for colorectal cancer by bioinformatics (Retracted article. See
   vol. 36, pg. 7329, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE RNA-seq; MicroRNAs; Molecular mechanism
ID AND-9 PROMOTER POLYMORPHISMS; HUMAN COLON-CANCER; METASTASIS;
   EXPRESSION; MICRORNAS; CARCINOMA; TISSUE; METALLOPROTEINASES;
   METAANALYSIS; BIOMARKERS
AB We aimed to identify the potential microRNA (miRNA) targets for colorectal cancer (CRC). Small RNA-seq and RNA-seq data of GSE46622 were downloaded from Gene Expression Omnibus (GEO) database, including samples of tumor tissue, metastasis tissue, and normal tissue from eight CRC patients. Data comparison of small RNA-seq and RNA-seq was performed through Bowtie and TopHat softwares, respectively. Then the expressed values of each sample were calculated by Cufflinks and Cuffdiff based on fragments per kilobase of exon per millionfragments mapped (FPKM) methods. The differentially expressed miRNAs and core miRNAs were identified by paired t-test. Besides, miRNA target genes were integrated through miRanda, MirTarget2, PicTar, PITI, TargetScan, and miRecords databases, followed by functional analysis of specific miRNA. The average comparison rate of sequence reads in miRNA, noncoding RNA, and other areas of the genome is 49.75, 2.90, and 47.35 %, respectively. A total of 49 miRNAs was differentially expressed. Compared with normal controls, 3 miRNAs were upregulated and 13 miRNAs were downregulated in tumor samples as well as 48 miRNAs were upregulated and 20 miRNAs were downregulated in the metastasis samples. Among them, 18 metastasis-specific expressed miRNAs, 2 tumor-specific expressed miRNAs, and 11 normal expressed miRNA were found. miRNA-1, miRNA-338-5p, miRNA-326, and miR-490-5p were selected as important miRNAs. Besides, miRNA-338-5p target gene RAB6B, FAP, and CTGF were identified as oncogenes. The miRNAs, such as miRNA-1, miRNA-338-5p, and miRNA-326 may be used as potential targets for CRC diagnosis and treatment.
C1 [Kou, Youwei; Wang, Qiang] China Med Univ, Shengjing Hosp, Dept Gastrointestinal & Nutriol Surg, Shenyang 110004, Peoples R China.
   [Qiao, Lei] China Med Univ, Shengjing Hosp, Dept Colorectal Surg & Oncol, Shenyang 110004, Peoples R China.
RP Wang, Q (reprint author), China Med Univ, Shengjing Hosp, Dept Gastrointestinal & Nutriol Surg, Sanhao St 36, Shenyang 110004, Peoples R China.
EM wangq@sj-hospital.org
CR Ahmed Farid E., 2009, Cancer Genomics & Proteomics, V6, P281
   Albasri A, 2011, ONCOGENE, V30, P2997, DOI 10.1038/onc.2011.26
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Asano T, 2008, J SURG RES, V146, P32, DOI 10.1016/j.jss.2007.02.011
   Atkin WS, 2010, LANCET, V375, P1624, DOI 10.1016/S0140-6736(10)60551-X
   Bardou M, 2013, GUT, V62, P933, DOI 10.1136/gutjnl-2013-304701
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Botteri E, 2008, JAMA-J AM MED ASSOC, V300, P2765, DOI 10.1001/jama.2008.839
   Burge SW, 2013, NUCLEIC ACIDS RES, V41, P3
   Chan DSM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020456
   Chan SK, 2008, CANCER EPIDEM BIOMAR, V17, P543, DOI 10.1158/1055-9965.EPI-07-2615
   Chen JS, 2013, BIOINFORMATICS, V29, P420, DOI 10.1093/bioinformatics/bts715
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9
   Elander N, 2006, ANTICANCER RES, V26, P791
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Ju Y-cH J-A, 2012, GENOMIC MED BIOMARKE, V4, P19
   Kontou N, 2012, DIS COLON RECTUM, V55, P703, DOI 10.1097/DCR.0b013e31824e612a
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, P30
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lin BR, 2011, CLIN CANCER RES, V17, P3077, DOI 10.1158/1078-0432.CCR-09-3256
   Migliore C, 2012, CLIN CANCER RES, V18, P737, DOI 10.1158/1078-0432.CCR-11-1699
   Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817
   Reid JF, 2012, MOL CANCER RES, V10, P504, DOI 10.1158/1541-7786.MCR-11-0342
   Rohr C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067461
   Rutter CM, 2012, CANCER CAUSE CONTROL, V23, P289, DOI 10.1007/s10552-011-9878-5
   Schee K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066165
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Sun Zheng, 2012, Zhonghua Wei Chang Wai Ke Za Zhi, V15, P1166
   Suzuki H, 2011, CANCER RES, V71, P5646, DOI 10.1158/0008-5472.CAN-11-1076
   Ting WC, 2013, INT J MED SCI, V10, P1022, DOI 10.7150/ijms.6686
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Valeri N, 2013, LANCET, V381, P17
   Van Der Jagt MFP, 2010, J SURG ONCOL, V101, P259, DOI 10.1002/jso.21462
   Woo M, 2007, J GASTROEN HEPATOL, V22, P1064, DOI 10.1111/j.1440-1746.2007.04424.x
   Xu EP, 2007, MOL CARCINOGEN, V46, P924, DOI 10.1002/mc.20323
   Xue Q, 2014, JPN J CLIN ONCOL, V44, P13, DOI 10.1093/jjco/hyt181
   Yong FL, 2013, BMC CANCER, V13, P1471
   Zhang GJ, 2014, MOL MED REP, V10, P283, DOI 10.3892/mmr.2014.2144
   Zhao M, 2013, NUCLEIC ACIDS RES, V41, P12
NR 42
TC 10
Z9 11
U1 3
U2 36
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2015
VL 36
IS 4
BP 2249
EP 2255
DI 10.1007/s13277-014-2832-x
PG 7
WC Oncology
SC Oncology
GA CF9LJ
UT WOS:000352885900006
PM 25412953
DA 2018-12-27
ER

PT J
AU Shafiee, R
   Shariat, A
   Khalili, S
   Malayeri, HZ
   Mokarizadeh, A
   Anissian, A
   Ahmadi, MRH
   Hosseini, E
   Naderafif, M
   Mohsenzadeh, S
   Rasoulian, MH
   Rezapour, R
   Pourzaer, M
AF Shafiee, Radmehr
   Shariat, Alireza
   Khalili, Soheil
   Malayeri, Hamed Zamankhan
   Mokarizadeh, Aram
   Anissian, Ali
   Ahmadi, Mohammad Reza Hafezi
   Hosseini, Ehsan
   Naderafif, Mostafa
   Mohsenzadeh, Siamak
   Rasoulian, Mohammad Hosein
   Rezapour, Reza
   Pourzaer, Maryam
TI RETRACTED: Diagnostic investigations of canine prostatitis incidence
   together with benign prostate hyperplasia, prostate malignancies, and
   biochemical recurrence in high-risk prostate cancer as a model for human
   study (Retracted article. See vol.37, pg. 16419, 2016)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Prostate; Sonography; Cytology; Pathology; Canine
ID RETROSPECTIVE ANALYSIS; CASTRATED DOGS; CARCINOMA; INFLAMMATION;
   ADENOCARCINOMA; SYMPTOMS; CYTOLOGY; FEATURES; DISEASE; ATROPHY
AB The aim of this study was to evaluate the prevalence of acute and chronic inflammation, benign prostatic hyperplasia (BPH), and cancer of the prostate glands in the canine as a human model in prostate disorders. The study was carried out on 12 cases of different male dogs of terrier (50 %), German shepherd (25 %) breeds, and Greden (25 %), and the age of the dogs ranged from 6 to 13 years (average age 7.8 +/- 3.6). The bodyweight ranged from 3.6 to 7.9 kg. Signalment, clinical signs, and diagnostic tools such as ultrasonography, urinary cytology, and histopathology are presented. Dysuria was the most common clinical sign in this study and occurred in 10/12 canine (83.3 %) included. Other clinical signs included lameness (5/12 canine, 41.6 %) and constipation (3/12 canine, 25 %). The range of duration of clinical signs was 5 days to 7 months. Moreover, in the present study, the urinary biochemical markers of different prostate lesions include blood, protein, and glucose and were detected in 11/12 cases (91.6 %), 5/12 cases (41.6 %), and 2/12 cases (16.6 %), respectively. Taken together, sonographic data were classified into four groups based on histological diagnosis. In 7/12 cases (58.4 %), the prostate appeared to have BPH lesions, and the remaining lesions included inflammation (3/12 cases, 25 %), abscess (1 case, 8.3 %), and adenocarcinoma (1 case, 8/3 %) on ultrasound. In all cases, prostate tissue had an irregular echotexture. None of the dogs had sonographic evidence of sublumbar lymph node enlargement. Histopathologically, we looked at the prevalence of inflammation (33.3 % chronic and 8.3% acute) and BPH (58.4 %) in dogs of different ages and breeds, and also, we observed chronic inflammation in >20 % of dogs, which was about 25 % in 3 cases of the 12 cases referred. More chronic inflammation was associated with more BPH. The majority of the asymptomatic inflammation that is detected in the prostate is classified as chronic inflammation (i.e., as evidenced by the presence of monocytic and/or lymphoplasmacytic inflammatory cell infiltrates); however, acute inflammation is also observed to a lesser degree. Acute inflammation, as is typically evidenced by the infiltration of neutrophils, is classically an indicator of an infectious process. Finally, the patients included seven castrated, four castrated together with antibiotic therapy, and one castrated together with chemotherapy intact male dogs, which were treated with the mentioned cases. In conclusion, chronic prostatic inflammation could be a central mechanism in BPH progression, but the pathological features of tissue inflammation were different between BPH and prostate cancer (PCa). Nevertheless, the histological examination of prostate biopsies remains the only way to diagnose prostatic disorders.
C1 [Shafiee, Radmehr] Univ Tehran, Fac Vet Med, Tehran, Iran.
   [Shariat, Alireza; Khalili, Soheil] Islamic Azad Univ, Karaj Branch, Fac Vet Med, Karaj, Iran.
   [Malayeri, Hamed Zamankhan] Univ Tehran, Fac Vet Med, Dept Internal Med, Tehran, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Dept Immunol, Fac Med, Sanandaj, Iran.
   [Anissian, Ali] Islamic Azad Univ, Abhar Branch, Coll Agr, Dept Vet, Abhar, Iran.
   [Ahmadi, Mohammad Reza Hafezi] Ilam Univ Med Sci, Dept Pathol, Fac Med, Ilam, Iran.
   [Hosseini, Ehsan] Ilam Univ, Fac Para Vet Med, Ilam, Iran.
   [Naderafif, Mostafa; Mohsenzadeh, Siamak] Ferdowsi Univ Mashhad, Dept Pathobiol, Fac Vet Med, Mashhad, Iran.
   [Rasoulian, Mohammad Hosein; Rezapour, Reza] Urmia Univ, Fac Vet Med, Orumiyeh, Iran.
   [Pourzaer, Maryam] Islamic Azad Univ, Damghan Branch, Fac Basic Sci, Dept Biol, Damghan, Iran.
RP Anissian, A (reprint author), Islamic Azad Univ, Abhar Branch, Coll Agr, Dept Vet, Abhar, Iran.
EM aanissian@gmail.com; Hafezi-m@medilam.ac.ir
OI Mokarizadeh, Aram/0000-0002-2630-8308; Abdi,
   Mohammad/0000-0002-4766-0423
CR Badmus T A, 2013, Niger Postgrad Med J, V20, P52
   Bardales RH, 1998, CANCER CYTOPATHOL, V84, P335, DOI 10.1002/(SICI)1097-0142(19981225)84:6<335::AID-CNCR4>3.0.CO;2-W
   BELL FW, 1991, J AM VET MED ASSOC, V199, P1623
   Boland LE, 2003, J AM ANIM HOSP ASSOC, V39, P151, DOI 10.5326/0390151
   Cornell KK, 2000, PROSTATE, V45, P173
   De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4
   Di Silverio F, 2003, EUR UROL, V43, P164, DOI 10.1016/S0302-2838(02)00548-1
   FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P617, DOI 10.1002/path.1700680234
   Gobello C, 2002, COMP CONT EDUC PRACT, V24, P99
   Johnston SD, 2001, DISORDERS CANINE PRO, P337
   Kamolpatana K, 2000, VET RADIOL ULTRASOUN, V41, P73, DOI 10.1111/j.1740-8261.2000.tb00430.x
   Keller JM, 2013, PROSTATE, V73, P952, DOI 10.1002/pros.22642
   KOHNEN PW, 1979, J UROLOGY, V121, P755, DOI 10.1016/S0022-5347(17)56980-3
   KRAWIEC DR, 1992, J AM VET MED ASSOC, V200, P1119
   KRAWIEC DR, 1989, VET CLIN N AM-SMALL, V19, P75, DOI 10.1016/S0195-5616(89)50006-8
   Kutzler MA, 2005, TXB VET INTERNAL MED, V2, P1809
   L'Eplattenier HF, 2006, VET SURG, V35, P406, DOI 10.1111/j.1532-950X.2006.00165.x
   Leav I, 2001, PROSTATE, V47, P149, DOI 10.1002/pros.1058
   Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002-9440(10)61676-8
   LEAV I, 1968, CANCER, V22, P1329, DOI 10.1002/1097-0142(196811)22:6<1329::AID-CNCR2820220633>3.0.CO;2-X
   LeBlanc CJ, 2004, VET CLIN PATH, V33, P253, DOI 10.1111/j.1939-165X.2004.tb00384.x
   LIAVAG I, 1968, ACTA PATHOL MIC SC, V73, P338
   MacLachlan NJ, 2002, TUMORS DOMESTIC ANIM, P568
   Memon MA, 2007, THERIOGENOLOGY, V68, P322, DOI 10.1016/j.theriogenology.2007.04.025
   Nakanishi Y, 2012, ASIAN J ANDROL, V14, P703, DOI 10.1038/aja.2012.31
   Nickel J C, 1994, Can J Urol, V1, P1
   Nickel JC, 2008, EUR UROL, V54, P1379, DOI 10.1016/j.eururo.2007.11.026
   Nickel JC, 2007, J UROLOGY, V178, P896, DOI 10.1016/j.juro.2007.05.041
   Nickel JC, 1999, BJU INT, V84, P976
   Obradovich J, 1987, J Vet Intern Med, V1, P183
   ODUNJO E O, 1971, British Journal of Urology, V43, P333
   Rodrigues M M P, 2013, Pak J Biol Sci, V16, P1324
   Root Kustritz MV, 2006, THERIOGENOLOGY, V66, P567
   RUPP M, 1990, Acta Cytologica, V34, P744
   Sciarra A, 2008, J STEROID BIOCHEM, V108, P254, DOI 10.1016/j.jsbmb.2007.09.013
   Sirinarumitr K, 2001, J AM VET MED ASSOC, V218, P1275, DOI 10.2460/javma.2001.218.1275
   Smith J, 2008, THERIOGENOLOGY, V70, P375, DOI 10.1016/j.theriogenology.2008.04.039
   Teske E, 2002, MOL CELL ENDOCRINOL, V197, P251, DOI 10.1016/S0303-7207(02)00261-7
   Teske E, 1996, VET QUART, V18, P112, DOI 10.1080/01652176.1996.9694630
   VARMA VA, 1988, DIAGN CYTOPATHOL, V4, P300, DOI 10.1002/dc.2840040406
   Waters DJ, 1996, J NATL CANCER I, V88, P1686, DOI 10.1093/jnci/88.22.1686-b
   White RAS, 2000, CLIN TECH SMALL AN P, V15, P46, DOI 10.1053/svms.2000.7304
   Young JM, 2000, BJU INT, V85, P1037, DOI 10.1046/j.1464-410x.2000.00659.x
   Zambelli D, 2012, REPROD DOMEST ANIM, V47, P229, DOI 10.1111/rda.12084
NR 44
TC 2
Z9 2
U1 3
U2 31
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2015
VL 36
IS 4
BP 2437
EP 2445
DI 10.1007/s13277-014-2854-4
PG 9
WC Oncology
SC Oncology
GA CF9LJ
UT WOS:000352885900027
PM 25420908
DA 2018-12-27
ER

PT J
AU Liao, AY
   Wang, WJ
   Sun, DW
   Jiang, YL
   Tian, SQ
   Li, JN
   Yang, XS
   Shi, RR
AF Liao, Anyan
   Wang, Weijie
   Sun, Dawei
   Jiang, Yuliang
   Tian, Suqing
   Li, Jinna
   Yang, Xiangshan
   Shi, Ranran
TI RETRACTED: Bone morphogenetic protein 2 mediates epithelial-mesenchymal
   transition via AKT and ERK signaling pathways in gastric cancer
   (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE BMP2; EMT; AKT; ERK; Gastric cancer
ID TGF-BETA; LUNG CARCINOMAS; TUMOR-GROWTH; EXPRESSION; CELLS; ACTIVATION;
   COLON; EMT
AB Although deregulation of bone morphogenetic protein 2 (BMP2) signaling has been linked to various types of cancers, the relationships between abnormal activation of these signaling pathways and tumorigenesis are not clear in gastric cancer. We hypothesized that BMP2 might be involved in epithelial-mesenchymal transition (EMT) process of gastric cancer. Here, BMPR-II activation and inhibition in gastric cancer cell line AGS were induced with exogenous BMP2 and with BMPR-II small interfering RNA (siRNA), respectively. BMPR-II downstream signal molecules AKT, ERK phosphorylation, and EMT biomarkers (vimentin, snail, N-cadherin, and E-cadherin) were tested using the Western blot. In the present study, our results showed that BMP2 can induce AKT and ERK phosphorylation in a dose-dependent method, and endogenous BMPR-II can be inhibited completely by BMPR-II siRNA in AGS. Notably BMP2 alone treatment can induce the up-regulation of vimentin, snail, and N-cadherin in AGS cells, besides, the down-regulation of E-cadherin also occurred. On the contrary, BMPR-II siRNA significantly prohibited BMP2-induced AKT and ERK phosphorylation, at the same time, EMT biomarkers changes were not observed. On the other hand, BMPR-II knockdown could significantly affect AGS wound closure and the migration ability (p<0.001) compared to control siRNA and BMP2 alone. In conclusion, this study suggested that EMT process can be triggered by the BMP2/BMPR axis in gastric cancer and then involved in the tumor cell migration, invasion, and metastasis via the activation of PI3K/AKT and MEK/ERK pathways. Our study lays a new foundation for the treatment of gastric cancer through antagonizing BMP2 system.
C1 [Liao, Anyan; Jiang, Yuliang; Tian, Suqing; Li, Jinna] Peking Univ, Dept Radiat Oncol, Hosp 3, Beijing 100191, Peoples R China.
   [Wang, Weijie] Shandong Univ, Dept Emergency Surg, Qilu Hosp, Jinan 250100, Shandong, Peoples R China.
   [Sun, Dawei] Jilin Univ, Dept Hepatobiliary & Pancreat Surg, Hosp 1, Changchun 130023, Jilin, Peoples R China.
   [Yang, Xiangshan] Shandong Acad Med Sci, Dept Pathol, Affiliated Hosp, Jinan, Shandong, Peoples R China.
   [Shi, Ranran] Shandong Univ, Dept Gen Surg, Shandong Prov Hosp Affiliated, Jinan 250100, Shandong, Peoples R China.
RP Liao, AY (reprint author), Peking Univ, Dept Radiat Oncol, Hosp 3, Beijing 100191, Peoples R China.
EM liaoanyan323@126.com
CR Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   Balogh P, 2013, PATHOL ONCOL RES, V19, P141, DOI 10.1007/s12253-012-9595-8
   Bates RC, 2004, EXP CELL RES, V299, P315, DOI 10.1016/j.yexcr.2004.05.033
   Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23
   Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7
   Gao DC, 2012, CANCER RES, V72, P4883, DOI 10.1158/0008-5472.CAN-12-1223
   Hardwick JCH, 2004, GASTROENTEROLOGY, V126, P111, DOI 10.1053/j.gastro.2003.10.067
   Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6
   Koessler T, 2014, Rev Med Suisse, V10, P1118
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Langenfeld EM, 2006, ONCOGENE, V25, P685, DOI 10.1038/sj.onc.1209110
   Langenfeld EM, 2005, ANN THORAC SURG, V80, P1028, DOI 10.1016/j.athoracsur.2005.03.094
   Langenfeld EM, 2004, MOL CANCER RES, V2, P141
   Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100
   Li YM, 2013, CURR CANCER DRUG TAR, V13, P957, DOI 10.2174/15680096113136660101
   Miao RL, 2014, WORLD J GASTROENTERO, V20, P11586, DOI 10.3748/wjg.v20.i33.11586
   Moustakas A, 2014, BBA-GEN SUBJECTS, V1840, P2621, DOI 10.1016/j.bbagen.2014.02.004
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Rothhammer T, 2005, CANCER RES, V65, P448
   Sugimori K, 2005, J BONE MINER METAB, V23, P411, DOI 10.1007/s00774-005-0622-7
   Wu YY, 2012, MOL CANCER RES, V10, P1597, DOI 10.1158/1541-7786.MCR-12-0155-T
   Xu C, 2005, GENE, V357, P1, DOI 10.1016/j.gene.2005.06.017
NR 22
TC 19
Z9 20
U1 6
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2015
VL 36
IS 4
BP 2773
EP 2778
DI 10.1007/s13277-014-2901-1
PG 6
WC Oncology
SC Oncology
GA CF9LJ
UT WOS:000352885900063
PM 25448881
DA 2018-12-27
ER

PT J
AU Li, CG
   Zhao, ZM
   Zhou, ZP
   Liu, R
AF Li, Chenggang
   Zhao, Zhiming
   Zhou, Zhipeng
   Liu, Rong
TI RETRACTED: Augmented TGF beta receptor signaling induces apoptosis of
   pancreatic carcinoma cells (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Pancreatic ductal adenocarcinoma; TGF beta; Apoptosis
ID PROLIFERATION; PROGRESSION; CANCER
AB Pancreatic ductal adenocarcinoma (PDAC) is an extremely malignant tumor in humans. Thus, understanding the tumorigenesis of PDAC appears to help develop efficient therapy. Here, we show that activated TGF beta receptor signaling induces apoptosis of pancreatic carcinoma cells in vitro and in vivo, suggesting that activation of TGF beta receptor signaling may prevent development of PDAC.
C1 [Li, Chenggang; Zhao, Zhiming; Zhou, Zhipeng; Liu, Rong] Chinese Peoples Liberat Army Gen Hosp, Dept Surg Oncol, Beijing 100853, Peoples R China.
RP Li, CG (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Surg Oncol, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM chenggang_li14@163.com
CR di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071
   El-Gohary Y, 2013, DEV BIOL, V378, P83, DOI 10.1016/j.ydbio.2013.04.003
   Gidekel Friedlander S. Y., 2009, CANCER CELL, V16, P379, DOI DOI 10.1016/J.CCR.2009.09.027]
   Han Haiyong, 2013, Cancer Cell, V23, P424, DOI 10.1016/j.ccr.2013.03.008
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   Jimenez V, 2011, DIABETOLOGIA, V54, P1075, DOI 10.1007/s00125-011-2070-3
   Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959
   LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505
   Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Mei Q, 2014, CANCER SCI, V105, P755, DOI 10.1111/cas.12436
   Muller-Pillasch F, 1999, HEPATO-GASTROENTEROL, V46, P2751
   Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734
   Shi W, 2014, TUMOUR BIOL
   Truty MJ, 2007, PANCREATOLOGY, V7, P423, DOI 10.1159/000108959
   Xiao XW, 2014, NAT PROTOC, V9, P2719, DOI 10.1038/nprot.2014.183
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Xiao XW, 2013, DIABETES, V62, P1217, DOI 10.2337/db12-1428
   Yi JJ, 2010, CELL, V142, P144, DOI 10.1016/j.cell.2010.06.010
NR 18
TC 2
Z9 2
U1 3
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2015
VL 36
IS 4
BP 2815
EP 2819
DI 10.1007/s13277-014-2908-7
PG 5
WC Oncology
SC Oncology
GA CF9LJ
UT WOS:000352885900069
PM 25476855
DA 2018-12-27
ER

PT J
AU Tsao, SM
   Yin, MC
AF Tsao, Shih-ming
   Yin, Mei-chin
TI RETRACTED: Antioxidative and Antiinflammatory Activities of Asiatic
   Acid, Glycyrrhizic Acid, and Oleanolic Acid in Human Bronchial
   Epithelial Cells (Retracted article. See vol. 65, pg. 3251, 2017)
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article; Retracted Publication
DE triterpenic acids; bronchial epithelial cells; ROS; NF-kappa B; MAPK
ID NF-KAPPA-B; OXIDATIVE STRESS; CIGARETTE-SMOKE; URSOLIC ACID;
   LUNG-CANCER; HYDROGEN-PEROXIDE; APOPTOSIS; INJURY; TRITERPENOIDS;
   INVOLVEMENT
AB Protective effects of triterpenic acids, asiatic acid (AA), glycyrrhizic acid (GA), or oleanolic acid (OA), for two human bronchial epithelial cells, 16HBE and BEAS-2B cells, against hydrogen peroxide (H2O2) induced injury were examined. Cells were pretreated by triterpenic acid at 4 or 8 mu mol/L and followed by H2O2 treatment. Results showed that H2O2 significantly upregulated both Bax and cleaved caspase-3 expression, and also downregulated Bcl-2 expression in test cells. AA at these doses retained Bcl-2 expression, but GA and OA only at 8 mu mol/L reserved Bcl-2 expression. Test triterpenic acids lowered cleaved caspase-3 expression dose-dependently. H2O2 treatment lowered Na+-K+-ATPase activity and mitochondrial membrane potential in cells. Triterpenic acid pretreatments significantly maintained mitochondrial membrane potential and Na+-K+-ATPase activity. H2O2 enhanced reactive oxygen species, interleukin-6, tumor necrosis factor-a, and prostaglandin E-2 levels in test cells. Three triterpenic acid treatments dose-dependently reversed these changes. H2O2 promoted the protein expression of p47(phox), gp91(phox), cyclooxygenase-2 (COX-2), mitogen-activated protein kinase, and nuclear factor-kappa B (NF-kappa B). AA, GA, or OA pretreatments dose-dependently downregulated the expression of p47(phox), COX-2, NF-kappa B p65, and p-p38 but only at 8 mu mol/L decreased gp91(phox) expression. These results support that these triterpenic acids could protect bronchial epithelial cells to attenuate apoptotic, oxidative, and inflammatory stress.
C1 [Tsao, Shih-ming] Chung Shan Med Univ, Inst Med, Taichung 40201, Taiwan.
   [Tsao, Shih-ming] Chung Shan Med Univ Hosp, Dept Internal Med, Sect Infect Dis & Chest Med, Taichung 40201, Taiwan.
   [Yin, Mei-chin] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan.
   [Yin, Mei-chin] China Med Univ, Dept Nutr, Taichung, Taiwan.
RP Yin, MC (reprint author), China Med Univ, Dept Nutr, 91 Hsueh Shih Rd, Taichung, Taiwan.
EM mcyin@mail.cmu.edu.tw
FU Ministry of Science and Technology, Taipei City, Taiwan [NSC
   102-2313-B-039-002-MY3]
FX This study was partially supported by a grant from Ministry of Science
   and Technology, Taipei City, Taiwan (NSC 102-2313-B-039-002-MY3).
CR Ahn EK, 2008, TOXICOL LETT, V176, P178, DOI 10.1016/j.toxlet.2007.11.005
   Antognelli C, 2014, APOPTOSIS, V19, P102, DOI 10.1007/s10495-013-0902-y
   Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362
   Caligiani A, 2013, FOOD CHEM, V136, P735, DOI 10.1016/j.foodchem.2012.08.011
   Chan CY, 2014, FREE RADICAL RES, V48, P402, DOI 10.3109/10715762.2014.880113
   Cho IH, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-122
   Deng Z, 2014, J PHARMACOL SCI, V125, P39, DOI 10.1254/jphs.13206FP
   Dergham M, 2012, CHEM RES TOXICOL, V25, P904, DOI 10.1021/tx200529v
   Domej W, 2014, INT J CHRONIC OBSTR, V9, P1207, DOI 10.2147/COPD.S51226
   Downs CA, 2011, MICROVASC RES, V82, P311, DOI 10.1016/j.mvr.2011.09.013
   Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje
   Goldkorn T, 2010, AM J RESP CELL MOL, V43, P259, DOI 10.1165/rcmb.2010-0220RT
   Griffith B, 2009, ANTIOXID REDOX SIGN, V11, P2505, DOI [10.1089/ars.2009.2599, 10.1089/ARS.2009.2599]
   Huang RY, 2011, BBA-REV CANCER, V1815, P158, DOI 10.1016/j.bbcan.2010.11.005
   Kao TC, 2014, J AGR FOOD CHEM, V62, P542, DOI 10.1021/jf404939f
   Kao TC, 2013, PHYTOMEDICINE, V20, P295, DOI 10.1016/j.phymed.2012.10.013
   Kastner PE, 2011, TOXICOL LETT, V200, P109, DOI 10.1016/j.toxlet.2010.11.003
   Liu N, 2013, ONCOL LETT, V6, P475, DOI 10.3892/ol.2013.1406
   Liu WB, 2012, MOLECULES, V17, P9104, DOI 10.3390/molecules17089104
   Mukherjee B, 2014, ENVIRON TOXICOL PHAR, V38, P341, DOI 10.1016/j.etap.2014.06.010
   Musa MA, 2014, ANTICANCER RES, V34, P1601
   Park GY, 2007, CLIN EXP IMMUNOL, V150, P245, DOI 10.1111/j.1365-2249.2007.03478.x
   Park WH, 2013, ONCOL LETT, V5, P1633, DOI 10.3892/ol.2013.1216
   Ramachandran V, 2013, PHYTOMEDICINE, V20, P230, DOI 10.1016/j.phymed.2012.09.023
   Raphael TJ, 2003, PHYTOMEDICINE, V10, P483, DOI 10.1078/094471103322331421
   Sharifi AM, 2009, NEUROSCI LETT, V459, P47, DOI 10.1016/j.neulet.2009.03.100
   Sin Y., 2010, TOXICOL LETT, V196, P21
   Tesfaigzi Y, 2006, AM J RESP CELL MOL, V34, P537, DOI 10.1165/rcmb.2006-0014OC
   Torlinska T, 2004, J PHYSIOL PHARMACOL, V55, P457
   Wachter GA, 1999, PHYTOMEDICINE, V6, P341
   Wang X, 2013, MOL CELL ENDOCRINOL, V376, P70, DOI 10.1016/j.mce.2013.06.014
   Xiao H, 2007, CELL CYCLE, V6, P2826, DOI 10.4161/cc.6.22.4891
   Yang J, 2011, MOL CELL BIOCHEM, V351, P29, DOI 10.1007/s11010-010-0708-y
   Yao H, 2007, BIOCHEM SOC T, V35, P1151, DOI 10.1042/BST0351151
   Yi S, 2014, ENVIRON TOXICOL, V29, P226, DOI 10.1002/tox.21750
   Yin MC, 2012, J AGR FOOD CHEM, V60, P7697, DOI 10.1021/jf302529x
NR 36
TC 25
Z9 26
U1 3
U2 38
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD APR 1
PY 2015
VL 63
IS 12
BP 3196
EP 3204
DI 10.1021/acs.jafc.5b00102
PG 9
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
SC Agriculture; Chemistry; Food Science & Technology
GA CF0OX
UT WOS:000352245200016
PM 25779760
DA 2018-12-27
ER

PT J
AU Li, YL
   Gao, YS
   Xu, Y
   Sun, XJ
   Song, XL
   Ma, H
   Yang, MS
AF Li, Yanliang
   Gao, Yongsheng
   Xu, Yue
   Sun, Xianjun
   Song, Xilin
   Ma, Heng
   Yang, Mingshan
TI RETRACTED: si-RNA-Mediated Knockdown of PDLIM5 Suppresses Gastric Cancer
   Cell Proliferation in Vitro (Retracted article. See vol. 92, pg. 2035,
   2018)
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article; Retracted Publication
DE cell cycle; gastric cancer; growth; PDLIM5; si-RNA
ID BIPOLAR DISORDER; GROWTH; GENE; ASSOCIATION; PROGRESSION
AB Gastric cancer is the second most prominent cause of cancer mortality in the world. This study was designed to identify the possible use of si-RNA-mediated PDLIM5 gene silencing as a therapeutic tool for gastric cancer. Expression levels of PDLIM5 were detected in several gastric cancer cell lines using Western blot and qRT-PCR. We found PDLIM5 is highly expressed in all cultured gastric cancer cell lines. Small interfering RNA (si-RNA) was then employed to knock down PDLIM5 expression in MGC80-3 gastric cancer cells. Knockdown of PDLIM5 significantly inhibited cell proliferation and colony formation. Moreover, the absence of PDLIM5 in MGC80-3 cells led to S phase cell cycle arrest and apoptosis. This study highlights the critical role of PDLIM5 in gastric cancer cell growth and suggests that si-RNA-mediated silencing of PDLIM5 might serve as a potential therapeutic approach for the treatment of gastric cancer.
C1 [Li, Yanliang; Sun, Xianjun; Song, Xilin; Ma, Heng] Shandong Tumor Hosp, Dept Gastrointestinal Surg, Jinan 250117, Peoples R China.
   [Gao, Yongsheng] Shandong Tumor Hosp, Dept Pathol, Jinan 250117, Peoples R China.
   [Xu, Yue] Wucheng Peoples Hosp, Dept Intens Care Unit, Wucheng 253300, Shandong, Peoples R China.
   [Yang, Mingshan] Shandong Tumor Hosp, Dept Urol, Jinan 250117, Peoples R China.
RP Yang, MS (reprint author), Shandong Tumor Hosp, Dept Urol, Jinan 250117, Peoples R China.
EM mingshanyang@yeah.net
CR Bank A, 2005, ANN NY ACAD SCI, V1054, P308, DOI 10.1196/annals.1345.007
   Begnami MD, 2011, J CLIN ONCOL, V29, P3030, DOI 10.1200/JCO.2010.33.6313
   Butkiewicz D, 2011, MOL BIOL REP, V38, P5231, DOI 10.1007/s11033-010-0674-1
   Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623
   Catalano V, 2009, CRIT REV ONCOL HEMAT, V71, P127, DOI 10.1016/j.critrevonc.2009.01.004
   Edlund K, 2012, INT J CANCER, V131, P2264, DOI 10.1002/ijc.27518
   Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006
   Fang JG, 2012, MOL CELL BIOCHEM, V360, P301, DOI 10.1007/s11010-011-1069-x
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fujita T, 2013, CANCER SCI, V104, P214, DOI [10.1111/cas.12070, 10.1111/cas.12054]
   Gardezi SR, 2009, NAT NEUROSCI, V12, P957, DOI 10.1038/nn0809-957a
   Gorringe KL, 2005, GENE CHROMOSOME CANC, V42, P247, DOI 10.1002/gcc.20136
   Heiliger KJ, 2012, ENDOCR-RELAT CANCER, V19, P409, DOI 10.1530/ERC-11-0387
   Kang MY, 2014, GENE, V536, P59, DOI 10.1016/j.gene.2013.11.087
   Koutros S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058195
   Liu ZC, 2013, INT J CLIN EXP MED, V6, P677
   Nagini S, 2012, WORLD J GASTRO ONCOL, V4, P156, DOI 10.4251/wjgo.v4.i7.156
   Pinheiro H, 2010, HUM MOL GENET, V19, P943, DOI 10.1093/hmg/ddp537
   Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238
   Sun M, 2014, TUMOR BIOL, V35, P1065, DOI 10.1007/s13277-013-1142-z
   Tekedereli I, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.45
   Wang Q, 2013, ASIAN PAC J CANCER P, V14, P5391, DOI 10.7314/APJCP.2013.14.9.5391
   Wang YC, 2014, APOPTOSIS, V19, P643, DOI 10.1007/s10495-013-0949-9
   Wu S, 2013, CANCER LETT, V337, P293, DOI 10.1016/j.canlet.2013.04.003
   Zain MA, 2012, BMC MED GENET, V13, DOI 10.1186/1471-2350-13-91
   Zhao T, 2009, J PSYCHIATR NEUROSCI, V34, P199
   Zhong J, 2013, DIGEST DIS SCI, V58, P3189, DOI 10.1007/s10620-013-2796-5
NR 27
TC 9
Z9 9
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-0277
EI 1747-0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD APR
PY 2015
VL 85
IS 4
BP 447
EP 453
DI 10.1111/cbdd.12428
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA CD6EC
UT WOS:000351181300005
PM 25215606
DA 2018-12-27
ER

PT J
AU Calvo-Guirado, JL
   Gomez-Moreno, G
   Mate-Sanchez, JE
   Lopez-Mari, L
   Delgado-Ruiz, R
   Romanos, GE
AF Calvo-Guirado, Jose-Luis
   Gomez-Moreno, Gerardo
   Mate-Sanchez, Jose-Eduardo
   Lopez-Mari, Laura
   Delgado-Ruiz, Rafael
   Romanos, Georgios E.
TI RETRACTED: New bone formation in bone defects after melatonin and
   porcine bone grafts: experimental study in rabbits (Retracted article.
   See vol. 29, pg. 817, 2018)
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article; Retracted Publication
DE bone grafts; bone grafts; melatonin; porcine bone implant
ID MAXILLARY SINUS AUGMENTATION; MESENCHYMAL STEM-CELLS; DENTAL IMPLANTS;
   IN-VITRO; OSTEOBLASTIC DIFFERENTIATION; STIMULATES OSTEOINTEGRATION;
   HISTOLOGICAL-FINDINGS; OXIDATIVE STRESS; TOOTH REMOVAL; RECEPTOR MT1
AB ObjectiveThe aim of this study was to evaluate the effect of the topical application of melatonin compared with collagenized porcine bone grafts to accelerate bone formation 2months after their insertion in tibiae rabbits.
   Material and MethodsTwenty New Zealand rabbits weighing 3,900-4,500g were used. Twenty collagenized porcine bone (MP3) grafts, twenty melatonin-impregnated bone grafts, and twenty control areas were placed in the proximal metaphyseal area of both rear tibias. Four groups were formed according to the moment in which animal killing was carried out: Group I (15days), Group II (30days), Group III (45days) and Group IV (60days). Cortical width and cortical length of bone formation was measured. Following implantation, an anteroposterior and lateral radiological study was carried out. Samples were sectioned at 5m and stained using hematoxylin-Eeosin, Masson's trichromic, and Gordon-Switt reticulin stains.
   ResultsAfter 60days of treatment period, melatonin increased the length of cortical bone formation 99.030.61% like control 98.90 +/- 3.82% compared with porcine bone 92.73 +/- 1.08%. Related to perimeter of cortical bone of the tibiae melatonin new bone was 98.35 +/- 1.14% like control 98.0 +/- 1.43% more than porcine bone 92.05 +/- 1.03%. Histomorphometric values related to porcine bone were connective tissue 49.16 +/- 2.4%, graft material (MP3) 23.52 +/- 2.3%, and new bone formation 27.32 +/- 1.4% compared with test group with melatonin 24.5 +/- 1.2%, connective tissue 45.1 +/- 1.2%, and new bone formation of 30.4 +/- 1.0%.
   ConclusionMelatonin has proven to regenerate the width and length of cortical bone in tibiae rabbits more quickly than collagenized porcine bone. Melatonin acts as a bone stimulator compared with porcine bone and control sites.
C1 [Calvo-Guirado, Jose-Luis] Univ Murcia, Fac Med & Dent, Gen Dent, Murcia, Spain.
   [Gomez-Moreno, Gerardo] Univ Granada, Fac Dent, Pharmacol Interact Dent & Special Care Dent, Granada, Spain.
   [Mate-Sanchez, Jose-Eduardo] Univ Murcia, Restorat Dent, Murcia, Spain.
   [Lopez-Mari, Laura] Univ Murcia, Gen Dent, Murcia, Spain.
   [Delgado-Ruiz, Rafael] SUNY Stony Brook, Prosthodont & Digital Technol, Stony Brook, NY 11794 USA.
   [Romanos, Georgios E.] SUNY Stony Brook, Stony Brook, NY 11794 USA.
RP Calvo-Guirado, JL (reprint author), Mozart 4 1 Floor,C-D 30002, Murcia, Spain.
EM joseluis.calvo@um.es
RI Mate Sanchez de Va, Jose Eduardo/R-9750-2018
OI Mate Sanchez de Va, Jose Eduardo/0000-0002-4216-421X; Gomez-Moreno,
   Gerardo/0000-0001-9094-4985; calvo guirado, jose
   luis/0000-0002-4067-2253
CR Bai XC, 2005, J BIOL CHEM, V280, P17497, DOI 10.1074/jbc.M409332200
   Barone A, 2005, INT J ORAL MAX IMPL, V20, P519
   Berglundh T, 2003, CLIN ORAL IMPLAN RES, V14, P251, DOI 10.1034/j.1600-0501.2003.00972.x
   Cajochen C, 2003, J NEUROENDOCRINOL, V15, P432, DOI 10.1046/j.1365-2826.2003.00989.x
   Calvo-Guirado JL, 2010, J PINEAL RES, V49, P356, DOI 10.1111/j.1600-079X.2010.00801.x
   Cardinali DP, 2003, J PINEAL RES, V34, P81, DOI 10.1034/j.1600-079X.2003.00028.x
   Cutando A, 2007, J PINEAL RES, V42, P419, DOI 10.1111/j.1600-079X.2007.00425.x
   Cutando A, 2008, J PINEAL RES, V45, P174, DOI 10.1111/j.1600-079X.2008.00573.x
   Cutando A, 2007, J PERIODONTOL, V78, P576, DOI 10.1902/jop.2007.060244
   Dai J, 2007, J DENT RES, V86, P937, DOI 10.1177/154405910708601006
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600-0714.1982.tb00172.x
   Girgert R, 2009, J PINEAL RES, V47, P23, DOI 10.1111/j.1600-079X.2009.00684.x
   Gomez-Moreno G, 2007, J PERIODONTAL RES, V42, P536, DOI 10.1111/j.1600-0765.2007.00978.x
   Gomez-Moreno G, 2010, ORAL DIS, V16, P242, DOI 10.1111/j.1601-0825.2009.01610.x
   Guardia J, 2011, CLIN IMPLANT DENT R, V13, P262, DOI 10.1111/j.1708-8208.2009.00211.x
   HAKANSON DO, 1987, PEDIATR RES, V22, P414, DOI 10.1203/00006450-198710000-00010
   Imbesi M, 2009, J PINEAL RES, V46, P87, DOI 10.1111/j.1600-079X.2008.00634.x
   Kim SH, 2004, J BIOMED MATER RES B, V68B, P69, DOI 10.1002/jbm.b.10084
   Koyama H, 2002, J BONE MINER RES, V17, P1219, DOI 10.1359/jbmr.2002.17.7.1219
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood-2004-09-3662
   Lopes CD, 2002, ANN ANAT, V184, P359, DOI 10.1016/S0940-9602(02)80056-5
   Calvo-Guirado JL, 2009, J PINEAL RES, V47, P164, DOI 10.1111/j.1600-079X.2009.00696.x
   Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462
   Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002
   McAllister BS, 2007, J PERIODONTOL, V78, P377, DOI 10.1902/jop.2007.060048
   Mitri FF, 2005, ANN ANAT, V187, P93, DOI 10.1016/j.aanat.2004.07.003
   Munoz F, 2012, CLIN IMPLANT DENT R, V14, P226, DOI 10.1111/j.1708-8208.2009.00242.x
   Nakade O, 1999, J PINEAL RES, V27, P106, DOI 10.1111/j.1600-079X.1999.tb00603.x
   Nannmark U, 2008, CLIN IMPLANT DENT R, V10, P264, DOI 10.1111/j.1708-8208.2007.00080.x
   Orsini G, 2006, J PERIODONTOL, V77, P1984, DOI 10.1902/jop.2006.060181
   Ostrowska Z, 2010, ENDOKRYNOL POL, V61, P117
   Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600-079X.2011.00875.x
   Piattelli M, 1999, INT J ORAL MAX IMPL, V14, P835
   Ramirez-Fernandez MP, 2013, CLIN ORAL INVEST, V17, P147, DOI 10.1007/s00784-012-0684-6
   POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x
   Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600-079X.2006.00318.x
   Reiter Russel J, 2008, Interdiscip Toxicol, V1, P137, DOI 10.2478/v10102-010-0030-2
   Roth JA, 1999, J BIOL CHEM, V274, P22041, DOI 10.1074/jbc.274.31.22041
   Satomura K, 2007, J PINEAL RES, V42, P231, DOI 10.1111/j.1600-079X.2006.00410.x
   Shi ZB, 2010, TISSUE CELL, V42, P314, DOI 10.1016/j.tice.2010.07.007
   Simko F, 2007, J PINEAL RES, V42, P319, DOI 10.1111/j.1600-079X.2007.00436.x
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Takechi M, 2008, J MATER SCI-MATER M, V19, P2949, DOI 10.1007/s10856-008-3416-3
   Tresguerres IF, 2002, CLIN ORAL IMPLAN RES, V13, P631, DOI 10.1034/j.1600-0501.2002.130609.x
   Wasdell MB, 2008, J PINEAL RES, V44, P57, DOI 10.1111/j.1600-079X.2007.00528.x
   Yamada Y, 2008, CLIN ORAL IMPLAN RES, V19, P1003, DOI 10.1111/j.1600-0501.2008.01554.x
NR 46
TC 14
Z9 14
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-7161
EI 1600-0501
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD APR
PY 2015
VL 26
IS 4
BP 399
EP 406
DI 10.1111/clr.12364
PG 8
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
SC Dentistry, Oral Surgery & Medicine; Engineering
GA CD0IT
UT WOS:000350755400018
PM 24602080
DA 2018-12-27
ER

PT J
AU Calvo-Guirado, JL
   Ramirez-Fernandez, MP
   Mate-Sanchez, JE
   Bruno, N
   Velasquez, P
   de Aza, PN
AF Luis Calvo-Guirado, Jose
   Ramirez-Fernandez, Maria P.
   Mate-Sanchez, Jose E.
   Bruno, Negri
   Velasquez, Pablo
   de Aza, Piedad N.
TI RETRACTED: Enhanced bone regeneration with a novel synthetic bone
   substitute in combination with a new natural crosslinked collagen
   membrane: radio-graphic and histomorphometric study (Retracted article.
   See vol. 29, pg. 664, 2018)
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article; Retracted Publication
DE bone substitute; collagen membrane; critical size defects; guided bone
   regeneration; hydroxyapatite; tricalcium phosphate
ID BETA-TRICALCIUM PHOSPHATE; MAXILLARY SINUS AUGMENTATION; ANORGANIC
   BOVINE BONE; IMPLANT PLACEMENT; PHYSICAL-PROPERTIES; DEHISCENCE DEFECTS;
   CALCIUM PHOSPHATES; RIDGE AUGMENTATION; BARRIER MEMBRANES; CERAMIC
   SCAFFOLDS
AB Objectives4Bone is a fully synthetic bioactive bone substitute composed of 60% hydroxyapatite (HA) and 40% beta-tricalcium phosphate (ss-TCP). This study aimed to investigate the effect of resorbable collagen membranes (RCM) on critical size defects in rabbit tibiae filled with this novel biphasic calcium phosphate at 15, 30, 45, and 60days by radiological and histomorphometric analysis.
   Material and methodsThree critical size defects of 6mm diameter were created in both tibiae of 20 New Zealand rabbits and divided into three groups according to the filling material: Group A (4Bone), Group B (4Bone plus RCM), and Group C (unfilled control group). At each of the four study periods, five rabbits were sacrificed. Anteroposterior and lateral radiographs were taken. Samples were processed for observation under light microscopy.
   ResultsAt the end of treatment, radiological analysis found that cortical defect closure was greater in Group B than Group A, and radiopacity was clearly lower and more heterogeneous in Group A cortical defects than in Group B. There was no cortical defect closure in Group C. Histomorphometric evaluation showed significant differences in newly formed bone and cortical closure in Group B compared with Groups A and C, with the presence of higher density newly formed bone in cortical and medullar zones.
   ConclusionsBiphasic calcium phosphate functioned well as a scaffolding material allowing bone ingrowth and mineralization. The addition of absorbable collagen membranes enhanced bone gain compared with non-membrane-treated sites. This rabbit study provides radiological and histological evidence confirming the suitability of this new material for guided tissue regeneration of critical defects.
C1 [Luis Calvo-Guirado, Jose; Ramirez-Fernandez, Maria P.; Mate-Sanchez, Jose E.; Bruno, Negri] Univ Murcia, Fac Med & Dent, Dept Implant Dent, Murcia, Spain.
   [Velasquez, Pablo; de Aza, Piedad N.] Miguel Hernandez Univ, Bioengn Inst, Elche, Spain.
RP Ramirez-Fernandez, MP (reprint author), Hosp Morales Meseguer, Murcia 30530, Spain.
EM mpramirezfern@hotmail.com
RI Velasquez, Pablo/O-5857-2015; De Aza, Piedad/A-7621-2015; Mate Sanchez
   de Va, Jose Eduardo/R-9750-2018
OI Velasquez, Pablo/0000-0002-5142-4992; De Aza,
   Piedad/0000-0001-9316-4407; Mate Sanchez de Va, Jose
   Eduardo/0000-0002-4216-421X; calvo guirado, jose
   luis/0000-0002-4067-2253; RAMIREZ FERNANDEZ, MARIA
   PIEDAD/0000-0003-1913-9902
CR Aghaloo TL, 2007, INT J ORAL MAX IMPL, V22, P49
   Araujo MVF, 2010, CLIN ORAL IMPLAN RES, V21, P632, DOI 10.1111/j.1600-0501.2009.01864.x
   Araujo MG, 2010, CLIN ORAL IMPLAN RES, V21, P445, DOI 10.1111/j.1600-0501.2009.01876.x
   Becker J, 2009, CLIN ORAL IMPLAN RES, V20, P742, DOI 10.1111/j.1600-0501.2008.01689.x
   Bornstein MM, 2007, J PERIODONTOL, V78, P1943, DOI 10.1902/jop.2007.070102
   Bornstein MM, 2009, J PERIODONTOL, V80, P1289, DOI 10.1902/jop.2009.090075
   Calvo-Guirado JL, 2012, CLIN ORAL IMPLAN RES, V23, P667, DOI 10.1111/j.1600-0501.2011.02193.x
   Calvo-Guirado JL, 2014, CLIN ORAL IMPLAN RES, V25, P1228, DOI 10.1111/clr.12258
   Carpio L, 2000, J PERIODONTOL, V71, P1743, DOI 10.1902/jop.2000.71.11.1743
   Chazono M, 2004, J BIOMED MATER RES A, V70A, P542, DOI 10.1002/jbm.a.30094
   Chiapasco M, 2006, CLIN ORAL IMPLAN RES, V17, P136, DOI 10.1111/j.1600-0501.2006.01357.x
   Cordaro L, 2002, CLIN ORAL IMPLAN RES, V13, P103, DOI 10.1034/j.1600-0501.2002.130113.x
   Ersanli S, 2004, J PERIODONTOL, V75, P750, DOI 10.1902/jop.2004.75.5.750
   Esposito M, 2006, INT J ORAL MAX IMPL, V21, P696
   Ezirganli S, 2013, CLIN ORAL IMPLAN RES, V24, P312, DOI 10.1111/j.1600-0501.2011.02323.x
   Fan HS, 2007, J NANOSCI NANOTECHNO, V7, P808, DOI 10.1166/jnn.2007.501
   Fiorellini Joseph P, 2003, Ann Periodontol, V8, P321, DOI 10.1902/annals.2003.8.1.321
   Fotek PD, 2009, J PERIODONTOL, V80, P776, DOI 10.1902/jop.2009.080514
   Frenken JWFH, 2010, CLIN ORAL IMPLAN RES, V21, P201, DOI 10.1111/j.1600-0501.2009.01821.x
   Galindo-Moreno P, 2013, CLIN IMPLANT DENT R, V15, P858, DOI 10.1111/j.1708-8208.2012.00445.x
   Gauthier O, 1999, J PERIODONTOL, V70, P375, DOI 10.1902/jop.1999.70.4.375
   Geiger M, 2003, ADV DRUG DELIVER REV, V55, P1613, DOI 10.1016/j.addr.2003.08.010
   Horch HH, 2006, INT J ORAL MAX SURG, V35, P708, DOI 10.1016/j.ijom.2006.03.017
   Jones AC, 2009, BIOMATERIALS, V30, P1440, DOI 10.1016/j.biomaterials.2008.10.056
   Jovanovic SA, 2007, CLIN ORAL IMPLAN RES, V18, P224, DOI 10.1111/j.1600-0501.2006.01324.x
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Kolerman R, 2012, J ORAL MAXIL SURG, V70, P1835, DOI 10.1016/j.joms.2012.04.034
   Le Guehennec L, 2005, J BIOMED MATER RES B, V72B, P69, DOI 10.1002/jbm.b.30118
   Legeros RZ, 2003, J MATER SCI-MATER M, V14, P201, DOI 10.1023/A:1022872421333
   LeGeros RZ, 2002, CLIN ORTHOP RELAT R, P81
   Llambes F, 2007, J PERIODONTOL, V78, P2036, DOI 10.1902/jop.2007.070017
   Machtei EE, 2001, J PERIODONTOL, V72, P512, DOI 10.1902/jop.2001.72.4.512
   de Val JEMS, 2012, J BIOMED MATER RES A, V100A, P3446, DOI 10.1002/jbm.a.34259
   de Val JEMS, 2014, J BIOMED MATER RES A, V102, P1037, DOI 10.1002/jbm.a.34785
   Nemcovsky CE, 2002, J PERIODONTOL, V73, P754, DOI 10.1902/jop.2002.73.7.754
   Nolff MC, 2010, J CRANIO MAXILL SURG, V38, P38, DOI 10.1016/j.jcms.2009.07.010
   Ogose A, 2006, BIOMATERIALS, V27, P1542, DOI 10.1016/j.biomaterials.2005.08.034
   Oh TJ, 2003, CLIN ORAL IMPLAN RES, V14, P80, DOI 10.1034/j.1600-0501.2003.140111.x
   Ooms EM, 2003, BIOMATERIALS, V24, P989, DOI 10.1016/S0142-9612(02)00438-6
   Park SH, 2008, CLIN ORAL IMPLAN RES, V19, P32, DOI 10.1111/j.1600-0501.2007.01408.x
   Pekkan G, 2012, J CRANIO MAXILL SURG, V40, pE1, DOI 10.1016/j.jcms.2011.01.018
   Rossa Maria Leticia, 2006, J Int Acad Periodontol, V8, P115
   Rothamel D, 2005, CLIN ORAL IMPLAN RES, V16, P369, DOI 10.1111/j.1600-0501.2005.01108.x
   Rothamel D, 2004, CLIN ORAL IMPLAN RES, V15, P443, DOI 10.1111/j.1600-0501.2004.01039.x
   Schopper C, 2005, J BIOMED MATER RES B, V74B, P458, DOI 10.1002/jbm.b.30199
   Schwarz F, 2008, CLIN ORAL IMPLAN RES, V19, P402, DOI 10.1111/j.1600-0501.2007.01486.x
   Schwarz F, 2014, CLIN ORAL IMPLAN RES, V25, P1010, DOI 10.1111/clr.12220
   Simion M, 2007, CLIN ORAL IMPLAN RES, V18, P86, DOI 10.1111/j.1600-0501.2006.01291.x
   Teramoto H, 2005, ACTA MED OKAYAMA, V59, P201
   von Arx T, 2005, INT J ORAL MAX IMPL, V20, P843
   Walsh WR, 2008, BIOMATERIALS, V29, P266, DOI 10.1016/j.biomaterials.2007.09.035
   Wang HL, 2002, J PERIODONTAL RES, V37, P340, DOI 10.1034/j.1600-0765.2002.01625.x
   Zitzmann NU, 2001, INT J ORAL MAX IMPL, V16, P355
NR 53
TC 7
Z9 7
U1 1
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-7161
EI 1600-0501
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD APR
PY 2015
VL 26
IS 4
BP 454
EP 464
DI 10.1111/clr.12399
PG 11
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
SC Dentistry, Oral Surgery & Medicine; Engineering
GA CD0IT
UT WOS:000350755400026
PM 24720519
DA 2018-12-27
ER

PT J
AU Tanekhy, M
AF Tanekhy, Mahmoud
TI RETRACTED: Lead poisoning in Nile tilapia (Oreochromis niloticus):
   oxidant and antioxidant relationship(Retracted article. See vol. 189,
   2017)
SO ENVIRONMENTAL MONITORING AND ASSESSMENT
LA English
DT Article; Retracted Publication
DE Selenium; Vitamin E; Malondialdehyde; Superoxide dismutase; Glutathione
ID VITAMIN-E; OXIDATIVE STRESS; MELATONIN; SELENIUM; RAT; GLUTATHIONE;
   PERFORMANCE; POLLUTION; GROWTH; LIVER
AB Selenium and vitamin E are very effective antioxidant agents which play important roles in improving and development of aquaculture sector. This study was conducted to determine the protective and treatment effects of vitamin E and selenium against lead toxicity. Administration of both vitamin E and selenium ameliorated the adverse effects of lead acetate toxicity through significant increase in hemoglobin, packed cell volume, RBC count, WBC count, and lymphocytes compared to lead acetate-exposed groups especially after the 10th week. Also, it is revealed that severe decrease of total protein, calcium, phosphorous, and magnesium in lead acetate intoxicated group. On contrary, significant increase of blood parameters upon addition of vitamin E and selenium combined with/without lead. On the other hand, insignificant decreases of sAST, sALT, urea, and creatinine in group fed on vitamin E and selenium, while increase in lead acetate intoxicated group. Lead acetate caused increasing of lipid peroxidation level (malondialdehyde) and decreasing of superoxide dismutase activity and reduced glutathione level. From these results, it is concluded that exposure to lead acetate is considered as hepatotoxic environmental pollutant. Exposure to lead acetate induced significant effects on antioxidant status. Antioxidants (vitamin E and selenium) showed important roles to protect body against lipid peroxidation, which considered as the first step of cell membrane damage, in addition to the improvement of the endogenous antioxidant enzyme activities.
C1 Univ Alexandria, Fac Vet Med, Dept Poultry & Fish Dis, Edfina 22758, Rosetta, Egypt.
RP Tanekhy, M (reprint author), Univ Alexandria, Fac Vet Med, Dept Poultry & Fish Dis, Edfina 22758, Rosetta, Egypt.
EM tanekhyvet2020@yahoo.com
CR Ahmed A. S. A., 2014, ECOTOXICOLOGY ENV SA, V104, P28
   Arita M, 1998, FEBS LETT, V436, P424, DOI 10.1016/S0014-5793(98)01176-4
   Boldyrev AA, 1995, BIOCHEMISTRY-MOSCOW+, V60, P1293
   Burits C. A., 2001, TIETZ FUNDAMENTAL CL
   BURTON GW, 1994, P NUTR SOC, V53, P251, DOI 10.1079/PNS19940030
   Chanarin I, 1989, TXB LAB HEMATOLOGY A, P107
   Chen CY, 2006, ENVIRON HEALTH PERSP, V114, P297, DOI 10.1289/ehp.7861
   Cogun H. Y., 2013, CURRENT PROGR BIOL R, V12, P277, DOI DOI 10.5772/53076
   DROKE EA, 1989, J ANIM SCI, V67, P1350
   El-Shebly AA, 2009, INT J APPL RES VET M, V7, P97
   El-Sokkary GH, 2003, CELL MOL BIOL LETT, V8, P461
   Finney D. J., 1971, PROBIT ANAL
   Firat O, 2011, FISH PHYSIOL BIOCHEM, V37, P657, DOI 10.1007/s10695-011-9466-3
   Flora SJS, 2003, CHEM-BIOL INTERACT, V145, P267, DOI 10.1016/S0009-2797(03)00025-5
   Fridovich I., 1989, ANNU REV BIOCHEM, V264, P7761
   GIANNOPOLITIS CN, 1977, PLANT PHYSIOL, V59, P309, DOI 10.1104/pp.59.2.309
   GITELMAN HJ, 1967, ANAL BIOCHEM, V18, P521, DOI 10.1016/0003-2697(67)90110-8
   HAOUR F, 1982, ANN NY ACAD SCI, V383, P231, DOI 10.1111/j.1749-6632.1982.tb23171.x
   Henry RJ, 1974, CLIN CHEM PRINCIPLES
   Jain H. C., 1986, SCHLAMS VET HEMATOLO
   Khidr Bothaina M., 2008, Egyptian Journal of Zoology, V50, P89
   Lehninger A. L., 1984, PRINCIPLES BIOCH, P784
   Leonard SS, 2002, MOL CELL BIOCHEM, V234, P309, DOI 10.1023/A:1015917922980
   Liu F, 2000, BIOCHEM CELL BIOL, V78, P447, DOI 10.1139/bcb-78-4-447
   Mahboob Shahid, 2013, Life Science Journal Acta Zhengzhou University Overseas Edition, V10, P336
   Maita M., 1984, B JPN SOC SCI FISH, V51, P205
   Meki ARMA, 2001, COMP BIOCHEM PHYS C, V130, P305, DOI 10.1016/S1532-0456(01)00248-4
   Mekkawy I. A. A., 2012, Journal of Fisheries and Aquatic Science, V7, P240, DOI 10.3923/jfas.2012.240.265
   MEYDANI M, 1995, LANCET, V345, P170, DOI 10.1016/S0140-6736(95)90172-8
   Patra N., 2001, J APPL TOXICOL, V21, P507
   Patton G. J., 1997, ANAL CHEM, V49, P464
   PETERS T, 1968, CLIN CHEM, V14, P1147
   Rand G. M, 2003, FUNDAMENTALS AQUATIC, P123
   REITMAN S, 1957, AM J CLIN PATHOL, V28, P56
   Sahar H. O., 2008, MINUFIYA VET J, V5, P187
   Saleh AA, 2013, PAK VET J, V33, P450
   Sener G, 2003, LIFE SCI, V72, P2707, DOI 10.1016/S0024-3205(03)00187-5
   SKAKUN NP, 1987, FARMAKOL TOKSIKOL, V50, P97
   SRIVASTAV AK, 2013, INT AQUAT RES, V5, DOI DOI 10.1186/2008-6970-5-4
   Upasani CD, 2003, PHYTOTHER RES, V17, P330, DOI 10.1002/ptr.1135
   YashKochi Y., 1979, J BIOL CHEM, V251, P5337
NR 41
TC 6
Z9 6
U1 2
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6369
EI 1573-2959
J9 ENVIRON MONIT ASSESS
JI Environ. Monit. Assess.
PD APR
PY 2015
VL 187
IS 4
DI 10.1007/s10661-015-4387-8
PG 13
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA CC9JG
UT WOS:000350685000001
PM 25732982
DA 2018-12-27
ER

PT J
AU Ye, XX
   Wang, LS
   Tse, ZTH
   Tang, GY
   Song, GL
AF Ye, Xiaoxin
   Wang, Lingsheng
   Tse, Zion T. H.
   Tang, Guoyi
   Song, Guolin
TI RETRACTED: Effects of high-energy electro-pulsing treatment on
   microstructure, mechanical properties and corrosion behavior of
   Ti-6Al-4V alloy (Retracted article. See vol.90, pg.781, 2018)
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article; Retracted Publication
DE Titanium alloy; Biomaterials; Electro-pulsing treatment; Microstructure;
   Mechanical properties; Corrosion property
ID AL-V ALLOY; TITANIUM-ALLOY; HYDROTHERMAL TREATMENT; HIGH-TEMPERATURE;
   BINARY-ALLOYS; OXIDATION; RESISTANCE; STRIPS; RECRYSTALLIZATION;
   MICROHARDNESS
AB The effect of electro-pulsing treatment (EPT) on the microstructure, mechanical properties and corrosion behavior of cold-rolled Ti-6Al-4V alloy strips was investigated in this paper. It was found that the elongation to failure of materials obtains a noticeable enhancement with increased EPT processing time while slightly sacrificing strength. Fine recrystallized grains and the relative highest elongation to failure (32.5%) appear in the 11 second-EPT samples. Grain coarsening and decreased ductility were brought in with longer EPT duration time. Fracture surface analysis shows that transition from intergranular brittle facture to transgranular dimple fracture takes place with an increase in processing time of EPT. Meanwhile, corrosion behavior of titanium alloys is greatly improved with increased EPT processing time, which is presented by polarization test and surface observation with the beneficial effect of forming a protective anatase-TiO2 film on the surface of alloys. The rapid recrystallization behavior and oxide formation of the titanium alloy strip under EPTs are attributed to the enhancement of nucleation rate, atomic diffusion and oxygen migration resulting from the coupling of the thermal and athermal effects. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Ye, Xiaoxin; Wang, Lingsheng; Tang, Guoyi; Song, Guolin] Tsinghua Univ, Grad Sch Shenzhen, Adv Mat Inst, Shenzhen 518055, Peoples R China.
   [Ye, Xiaoxin; Wang, Lingsheng; Tang, Guoyi] Tsinghua Univ, Dept Mat Sci & Engn, Minist Educ, Key Lab Adv Mat, Beijing 100084, Peoples R China.
   [Tse, Zion T. H.] Univ Georgia, Coll Engn, Athens, GA 30602 USA.
RP Tang, GY (reprint author), Tsinghua Univ, Grad Sch Shenzhen, Adv Mat Inst, Shenzhen 518055, Peoples R China.
EM xiaoxinye905@gmail.com; tanggy@sz.tsinghua.edu.cn
FU National Natural Science Foundation of China [50571048]; Shenzhen
   Science and Technology Research Funding Project of China
   [SGLH20121008144756946]
FX The work is supported by National Natural Science Foundation of China
   (No. 50571048) and Shenzhen Science and Technology Research Funding
   Project of China (No. SGLH20121008144756946).
CR Abdullah A, 2012, MATER DESIGN, V38, P7, DOI 10.1016/j.matdes.2012.01.040
   Afzal MAF, 2012, MAT SCI ENG C-MATER, V32, P1164, DOI 10.1016/j.msec.2012.03.003
   Anandan S, 2012, MAT SCI ENG A-STRUCT, V536, P159, DOI 10.1016/j.msea.2011.12.095
   Antunes RA, 2012, ACTA BIOMATER, V8, P937, DOI 10.1016/j.actbio.2011.09.012
   Bai Y, 2013, MAT SCI ENG C-MATER, V33, P2159, DOI 10.1016/j.msec.2013.01.036
   Baszkiewicz J, 2005, VACUUM, V78, P143, DOI 10.1016/j.vacuum.2005.01.017
   Cui WF, 2013, MAT SCI ENG C-MATER, V33, P3775, DOI 10.1016/j.msec.2013.05.011
   Dunleavy S, 2013, APPL SURF SCI, V268, P397, DOI 10.1016/j.apsusc.2012.12.109
   Gromov VE, 2013, J SURF INVEST-X-RAY+, V7, P94, DOI 10.1134/S1027451013010114
   Jiang YB, 2008, J MATER RES, V23, P2685, DOI 10.1557/JMR.2008.0328
   Jiang YB, 2009, ACTA MATER, V57, P4797, DOI 10.1016/j.actamat.2009.06.044
   LI M, 1995, J MATER SCI, V30, P5093, DOI 10.1007/BF00356054
   Li S, 2012, NANOSCALE RES LETT, V7, P1, DOI 10.1186/1556-276X-7-79
   Man HC, 2000, SURF COAT TECH, V132, P11, DOI 10.1016/S0257-8972(00)00729-5
   Mordyuk BN, 2012, SURF COAT TECH, V210, P54, DOI 10.1016/j.surfcoat.2012.08.063
   Qiu KJ, 2014, MAT SCI ENG C-MATER, V34, P474, DOI 10.1016/j.msec.2013.10.004
   Sandhyarani M, 2013, J ALLOY COMPD, V553, P324, DOI 10.1016/j.jallcom.2012.11.147
   Shao W, 2012, J ELECTROCHEM SOC, V159, pD671, DOI 10.1149/2.065211jes
   Tao BW, 2005, ACTA METALL SIN, V41, P633
   Tarakci M, 2011, MATER CHARACT, V62, P1214, DOI 10.1016/j.matchar.2011.10.010
   Ueda M, 2009, MATER TRANS, V50, P2147, DOI 10.2320/matertrans.MAW200910
   Wang JF, 2013, MAT SCI ENG C-MATER, V33, P3832, DOI 10.1016/j.msec.2013.05.020
   [王少楠 Wang Shaonan], 2010, [材料科学与工艺, Material Science and Technology], V18, P339
   Xiaoxin Y., 2014, J MATER SCI-MATER M, V26, P1
   Xiaoxin Y., 2014, J MAT RES
   Xu ZH, 2006, MAT SCI ENG A-STRUCT, V424, P300, DOI 10.1016/j.msea.2006.03.012
   Xu ZH, 2006, J MATER PROCESS TECH, V182, P128, DOI 10.1016/j.jmatprotec.2006.07.019
   Yamaguchi A, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1847714
   Yang Si-qin, 2013, Zhonghua Kou Qiang Yi Xue Za Zhi, V48, P41
   Ye X., 2014, ADV ENG MAT
   Ye XX, 2015, MAT SCI ENG A-STRUCT, V622, P1, DOI 10.1016/j.msea.2014.11.003
   Ye XX, 2015, SURF COAT TECH, V261, P213, DOI 10.1016/j.surfcoat.2014.11.028
   Ye XX, 2015, J MECH BEHAV BIOMED, V42, P100, DOI 10.1016/j.jmbbm.2014.11.009
   Ye XX, 2014, MATER CHARACT, V98, P147, DOI 10.1016/j.matchar.2014.10.026
   Ye XX, 2014, SURF COAT TECH, V258, P467, DOI 10.1016/j.surfcoat.2014.08.052
   Ye XX, 2015, J ALLOY COMPD, V621, P66, DOI 10.1016/j.jallcom.2014.09.192
   Ye XX, 2014, APPL PHYS A-MATER, V117, P2251, DOI 10.1007/s00339-014-8655-1
   Ye XX, 2014, J MECH BEHAV BIOMED, V40, P287, DOI 10.1016/j.jmbbm.2014.08.022
   Ye XX, 2014, J ALLOY COMPD, V616, P173, DOI 10.1016/j.jallcom.2014.07.143
   Ye XX, 2014, J MATER RES, V29, P1500, DOI 10.1557/jmr.2014.171
   Ye XX, 2014, J ALLOY COMPD, V599, P1, DOI 10.1016/j.jallcom.2014.02.055
   ZHANG XC, 1990, APPL PHYS LETT, V56, P1011, DOI 10.1063/1.102601
   Zhao Q, 2009, APPL SURF SCI, V255, P6397, DOI 10.1016/j.apsusc.2009.02.024
NR 43
TC 18
Z9 19
U1 29
U2 70
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD APR 1
PY 2015
VL 49
BP 851
EP 860
DI 10.1016/j.msec.2015.01.081
PG 10
WC Materials Science, Biomaterials
SC Materials Science
GA CC6YE
UT WOS:000350514100098
PM 25687017
DA 2018-12-27
ER

PT J
AU Azadfar, P
   Ghoranneviss, M
   Elahi, SM
   Farhadyar, N
   Elahi, AS
AF Azadfar, P.
   Ghoranneviss, M.
   Elahi, S. M.
   Farhadyar, N.
   Elahi, A. Salar
TI RETRACTED: Growth of boron-doped diamond nanoclusters using the HFCVD
   technique (Retracted article. See vol. 490, pg. 116, 2018)
SO JOURNAL OF CRYSTAL GROWTH
LA English
DT Article; Retracted Publication
DE Boron-doped diamond; Nanocrystals
ID NANOCRYSTALLINE DIAMOND; ELECTRICAL-PROPERTIES; FILMS; PRESSURE
AB Boron doped diamond nanocrystals were grown on Si wafers through introduction of the gas mixture of B2O3 dissolved in ethanol and hydrogen by a hot filament chemical vapor deposition (HFCVD) technique. Boron level in diamond films were controlled in the range from 100 to 500 ppm by adjusting the B/C ratios of gas mixtures in order to synthesize and improve the conductivity and quality of HFCVD diamond films with cluster size of nanometer To investigate the effect of different boron percentage in the chamber on deposited films, Raman spectroscopy, field emission scanning electron microscopy and four point probe techniques were applied to characterize the properties of diamond films. Experimental results indicated that higher boron incorporation in the diamond films introduced bigger crystal clusters, better crystal quality and smaller film resistivity when the level of boron increased from 100 to 300 ppm, while they showed an opposite trend with a further increase of boron level from 300 to 500 ppm. However, in any case the higher boron-doping level led to a decrease of the non-diamond phase in the nanodiamond films. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Azadfar, P.; Ghoranneviss, M.; Elahi, S. M.; Elahi, A. Salar] Islamic Azad Univ, Sci & Res Branch, Plasma Phys Res Ctr, Tehran, Iran.
   [Farhadyar, N.] Islamic Azad Univ, Dept Chem, Varamin Pishva, Iran.
RP Elahi, AS (reprint author), Islamic Azad Univ, Sci & Res Branch, Plasma Phys Res Ctr, Tehran, Iran.
EM Salari_phy@yahoo.com
CR Baranauskas V, 2000, THIN SOLID FILMS, V377, P182, DOI 10.1016/S0040-6090(00)01320-1
   Barbosa DC, 2010, DIAM RELAT MATER, V19, P768, DOI 10.1016/j.diamond.2010.01.040
   Ghoranneviss Mahmood, 2013, INT J MOD ENG, V14, P97
   Hu XJ, 2009, DIAM RELAT MATER, V18, P210, DOI 10.1016/j.diamond.2008.07.009
   Jia FC, 2010, NEW CARBON MATER, V25, P357, DOI 10.1016/S1872-5805(09)60039-1
   Jiang X, 2002, J APPL PHYS, V92, P2880, DOI 10.1063/1.1498965
   Lee YC, 2005, J APPL PHYS, V97, DOI 10.1063/1.1852068
   Li HD, 2010, J CRYST GROWTH, V312, P1986, DOI 10.1016/j.jcrysgro.2010.03.020
   Lisi N, 2010, DIAM RELAT MATER, V19, P1382, DOI 10.1016/j.diamond.2010.08.002
   Rakha SA, 2010, CURR APPL PHYS, V10, P171, DOI 10.1016/j.cap.2009.05.014
   Salgueiredo E, 2011, VACUUM, V85, P701, DOI 10.1016/j.vacuum.2010.10.010
   Silva LLG, 2007, DIAM RELAT MATER, V16, P174, DOI 10.1016/j.diamond.2006.04.010
   Teng CC, 2010, J NANOMATER, DOI 10.1155/2010/365614
   Wang ZL, 2006, DIAM RELAT MATER, V15, P659, DOI 10.1016/j.diamond.2005.12.035
   Wang ZL, 2009, DIAM RELAT MATER, V18, P132, DOI 10.1016/j.diamond.2008.10.040
   Wang ZL, 2009, APPL SURF SCI, V255, P9522, DOI 10.1016/j.apsusc.2009.07.086
   Williams OA, 2011, DIAM RELAT MATER, V20, P621, DOI 10.1016/j.diamond.2011.02.015
   Won JH, 1996, APPL PHYS LETT, V68, P2822, DOI 10.1063/1.116336
NR 18
TC 9
Z9 9
U1 1
U2 37
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-0248
EI 1873-5002
J9 J CRYST GROWTH
JI J. Cryst. Growth
PD APR 1
PY 2015
VL 415
BP 166
EP 169
DI 10.1016/j.jcrysgro.2015.01.001
PG 4
WC Crystallography; Materials Science, Multidisciplinary; Physics, Applied
SC Crystallography; Materials Science; Physics
GA CB4NC
UT WOS:000349603500028
DA 2018-12-27
ER

PT J
AU Savaliya, ML
   Dholakiya, BZ
AF Savaliya, Mehulkumar L.
   Dholakiya, Bharatkumar Z.
TI RETRACTED: Silica supported microporous melamine tri sulfonic acid
   catalyst towards biodiesel fuel production from waste cooking oil and
   utilization of side stream (Retracted article. See vol. 557, pg. 154,
   2018)
SO APPLIED CATALYSIS A-GENERAL
LA English
DT Article; Retracted Publication
DE Lauric acid; Crude glycerol; Green fuel; Waste cooking oil; Fatty acid
   methyl ester (FAME); Free fatty acid (FFA)
ID JATROPHA-CURCAS; VEGETABLE-OILS; BASE CATALYST; FATTY-ACID;
   ESTERIFICATION; TRANSESTERIFICATION; PERFORMANCE; MICROALGAE; ENGINE;
   ENERGY
AB A novel silica based melamine tri sulfonic acid catalyst was successfully prepared by chlorosulfonation of melamine at ambient conditions and applied to the transesterification of waste cooking oil for the production of biodiesel. Glycerol obtained as a side stream at the end of the transesterification reaction along with biodiesel molecules. However, world is facing the problems of disposal of glycerol obtained from biodiesel synthesis as a byproduct and simultaneously they are facing the problem of the abundance of feedstocks for biodiesel synthesis. Therefore, obtained crude glycerol was also successfully converted into triglyceride via esterification of lauric acid over same catalyst. Biodiesel yields were calculated using gas chromatography. Highest biodiesel (%) yield was observed up to 98.00%. Synthesized SMTSA revealed optimistic catalytic activity for transesterification of waste cooking oil with 5% catalyst dose (w/w). SMTSA catalyst was duly characterized by FF-IR, XRD, BET, TPD-NH3 and SEM analysis. While, synthesized biodiesel and triglycerides of lauric acid were well characterized by FT-IR as well as H-1 and C-13 NMR spectroscopic techniques. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Savaliya, Mehulkumar L.; Dholakiya, Bharatkumar Z.] SV Natl Inst Technol, Dept Appl Chem, Surat 395007, Gujarat, India.
RP Dholakiya, BZ (reprint author), SV Natl Inst Technol, Dept Appl Chem, Surat 395007, Gujarat, India.
EM bzdholakiya@ashd.svnit.ac.in
FU Technical Education Quality Improvement Programme (TEQIP), Phase-II; S.
   V. National institute of Technology, Surat; Council of Scientific and
   Industrial Research (CSIR), New Delhi, India [02(0170)/13/EMR-II]
FX This work was financially supported by Technical Education Quality
   Improvement Programme (TEQIP), Phase-II, S. V. National institute of
   Technology, Surat and Council of Scientific and Industrial Research
   (CSIR), New Delhi, India (Sanction Order Letter No. 02(0170)/13/EMR-II).
   For spectral characterization, we are thankful to Mr. Shivaji Bhanvase,
   Institute of Chemical Technology, Mumbai and Mr. Avtar Singh from SAIF,
   Punjab University Chandigarh, India are gratefully acknowledged.
CR Atabani AE, 2013, RENEW SUST ENERG REV, V18, P211, DOI 10.1016/j.rser.2012.10.013
   Brito A, 2007, ENERG FUEL, V21, P3280, DOI 10.1021/ef700455r
   Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023
   Canakci M, 2007, BIORESOURCE TECHNOL, V98, P183, DOI 10.1016/j.biortech.2005.11.022
   Choubisa B, 2013, RES CHEM INTERMEDIAT, V39, P3063, DOI 10.1007/s11164-012-0819-z
   Dholakiya B. Z., 2012, Archives of Applied Science Research, V4, P551
   Di Serio M, 2008, ENERG FUEL, V22, P207, DOI 10.1021/ef700250g
   Farrell AE, 2006, SCIENCE, V311, P506, DOI 10.1126/science.1121416
   FREDDY G, 2006, IND BIOPROCESS, V28, P8
   Garcia-Moreno PJ, 2014, RENEW ENERG, V68, P618, DOI 10.1016/j.renene.2014.03.014
   Gauglitz Gunter, 2003, HDB SPECTROSCOPY
   Hammond GP, 2008, APPL ENERG, V85, P506, DOI 10.1016/j.apenergy.2007.09.005
   Harmer MA, 2001, APPL CATAL A-GEN, V221, P45, DOI 10.1016/S0926-860X(01)00794-3
   Hutnan M., 2009, P 36 INT C SLOV SOC
   Kazemian H, 2013, FUEL, V103, P719, DOI 10.1016/j.fuel.2012.07.058
   Kiss AA, 2006, ADV SYNTH CATAL, V348, P75, DOI 10.1002/adsc.200505160
   Kumar D, 2010, ULTRASON SONOCHEM, V17, P555, DOI 10.1016/j.ultsonch.2009.10.018
   Lam MK, 2009, APPL CATAL B-ENVIRON, V93, P134, DOI 10.1016/j.apcatb.2009.09.022
   de Araujo CDM, 2013, RENEW SUST ENERG REV, V27, P445, DOI 10.1016/j.rser.2013.06.014
   Meher LC, 2013, RENEW SUST ENERG REV, V26, P397, DOI 10.1016/j.rser.2013.05.065
   Melero JA, 2009, ENERG FUEL, V23, P539, DOI 10.1021/ef8005756
   Okuhara T, 2002, CHEM REV, V102, P3641, DOI 10.1021/cr0103569
   Oner C, 2009, APPL ENERG, V86, P2114, DOI 10.1016/j.apenergy.2009.01.005
   Openshaw K, 2000, BIOMASS BIOENERG, V19, P1, DOI 10.1016/S0961-9534(00)00019-2
   Patel A, 2013, RENEW ENERG, V51, P227, DOI 10.1016/j.renene.2012.09.040
   Pinzi S, 2014, BIOFUEL BIOPROD BIOR, V8, P126, DOI 10.1002/bbb.1435
   Rawat I, 2013, APPL ENERG, V103, P444, DOI 10.1016/j.apenergy.2012.10.004
   Sani YM, 2013, J ENVIRON CHEM ENG, V1, P113, DOI 10.1016/j.jece.2013.04.006
   Sani YM, 2014, APPL CATAL A-GEN, V470, P140, DOI 10.1016/j.apcata.2013.10.052
   Saunders J.K.M., 1993, MODERN NMR SPECTROSC
   Scherrer P., 1918, NACHR GES WISS GOTT, V2, P98, DOI DOI 10.1007/978-3-662-33915-2
   Schuchardt U, 1998, J BRAZIL CHEM SOC, V9, P199
   Sharma Y., 2008, J HAZARD MATER, V153, P194
   Shu Q, 2010, BIORESOURCE TECHNOL, V101, P5374, DOI 10.1016/j.biortech.2010.02.050
   Siddiquee MN, 2011, CHEM ENG TECHNOL, V34, P1983, DOI 10.1002/ceat.201100119
   Singh B, 2014, RENEW SUST ENERG REV, V29, P216, DOI 10.1016/j.rser.2013.08.067
   Valente OS, 2011, FUEL, V90, P1700, DOI 10.1016/j.fuel.2010.10.045
   Valle-Vigon P, 2012, APPL SURF SCI, V261, P574, DOI 10.1016/j.apsusc.2012.08.059
   Vicente G, 2004, BIORESOURCE TECHNOL, V92, P297, DOI 10.1016/j.biortech.2003.08.014
   Wawer I, 2001, CURR ORG CHEM, V5, P987, DOI 10.2174/1385272013374905
   Wibowo TY, 2010, SAINS MALAYS, V39, P811
   Xu LL, 2008, GREEN CHEM, V10, P746, DOI 10.1039/b803220c
   Yan J, 2009, APPL ENERG, V86, pS1, DOI 10.1016/j.apenergy.2009.07.004
   Zeng An-Ping, 2002, Adv Biochem Eng Biotechnol, V74, P239
   Zhang JJ, 2008, BIORESOURCE TECHNOL, V99, P8995, DOI 10.1016/j.biortech.2008.05.004
   Zhang PB, 2014, APPL SURF SCI, V317, P1125, DOI 10.1016/j.apsusc.2014.09.043
NR 46
TC 5
Z9 5
U1 6
U2 33
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0926-860X
EI 1873-3875
J9 APPL CATAL A-GEN
JI Appl. Catal. A-Gen.
PD MAR 25
PY 2015
VL 494
BP 12
EP 21
DI 10.1016/j.apcata.2015.01.015
PG 10
WC Chemistry, Physical; Environmental Sciences
SC Chemistry; Environmental Sciences & Ecology
GA CF9ZN
UT WOS:000352926500002
DA 2018-12-27
ER

PT J
AU El-Sayed, YS
   Lebda, MA
   Hassinin, M
   Neoman, SA
AF El-Sayed, Yasser S.
   Lebda, Mohamed A.
   Hassinin, Mohammed
   Neoman, Saad A.
TI RETRACTED: Chicory (Cichorium intybus L.) Root Extract Regulates the
   Oxidative Status and Antioxidant Gene Transcripts in CCl4-Induced
   Hepatotoxicity (Retracted article. See vol. 12, e0173587, 2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID INDUCED DIABETIC-RATS; INDUCED LIVER-INJURY; PARAOXONASE ACTIVITY;
   LIPID-PEROXIDATION; GLUTATHIONE; EXPRESSION; STRESS; SERUM; MICE;
   ARYLESTERASE
AB The ability of Cichorium intybus root extract (chicory extract) to protect against carbon tetrachloride (CCl4)-induced oxidative stress and hepatotoxicity was evaluated in male rats. The rats were divided into four groups according to treatment: saline (control); chicory extract (100 mg/kg body weight daily, given orally for 2 weeks); CCl4 (1 ml/kg body weight by intraperitoneal injection for 2 consecutive days only); or chicory extract (100 mg/kg body weight daily for 2 weeks) + CCl4 injection on days 16 and 17. The levels of hepatic lipid peroxidation, antioxidants, and molecular biomarkers were estimated twenty-four hours after the last CCl4 injection. Pretreatment with chicory extract significantly reduced CCl4-induced elevation of malondialdehyde levels and nearly normalized levels of glutathione and activity of glutathione S-transferase, glutathione peroxidase (GPx), glutathione reductase, catalase (CAT), paraoxonase-1 (PON1), and arylesterase in the liver. Chicory extract also attenuated CCl4-induced downregulation of hepatic mRNA expression levels of GPx1, CAT and PON1 genes. Results of DNA fragmentation support the ability of chicory extract to ameliorate CCl4-induced liver toxicity. Taken together, our results demonstrate that chicory extract is rich in natural antioxidants and able to attenuate CCl4-induced hepatocellular injury, likely by scavenging reactive free radicals, boosting the endogenous antioxidant defense system, and overexpressing genes encoding antioxidant enzymes.
C1 [El-Sayed, Yasser S.] Damanhour Univ, Fac Vet Med, Dept Vet Forens Med & Toxicol, Damanhour, Egypt.
   [Lebda, Mohamed A.] Univ Alexandria, Fac Vet Med, Dept Biochem, Edfina, Egypt.
   [Hassinin, Mohammed] King Abdulaziz Univ, Coll Med, Dept Clin Biochem, Jeddah 21413, Saudi Arabia.
   [Hassinin, Mohammed; Neoman, Saad A.] Tanta Univ, Fac Med, Dept Med Biochem, Tanta, Egypt.
RP El-Sayed, YS (reprint author), Damanhour Univ, Fac Vet Med, Dept Vet Forens Med & Toxicol, Damanhour, Egypt.
EM yasser_tf@yahoo.com
RI Hassanien, Mohammed/B-7061-2012; El-Sayed, Yasser/E-6400-2010
OI El-Sayed, Yasser/0000-0003-3915-4640
CR AEBI H, 1984, METHOD ENZYMOL, V105, P121
   Al-Akhras MAH, 2012, ELECTROMAGN BIOL MED, V31, P299, DOI 10.3109/15368378.2012.662193
   Al-Harbi NO, 2014, INT IMMUNOPHARMACOL, V21, P383, DOI 10.1016/j.intimp.2014.05.014
   Ali EMM, 2009, CLIN BIOCHEM, V42, P1394, DOI 10.1016/j.clinbiochem.2009.06.007
   Alloush GA, 2003, J AGRON CROP SCI, V189, P96, DOI 10.1046/j.1439-037X.2003.00014.x
   Amirghofran Z, 2000, J ETHNOPHARMACOL, V72, P167, DOI 10.1016/S0378-8741(00)00234-8
   Aquilano K, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00196
   Ashry KM, 2010, FOOD CHEM TOXICOL, V48, P236, DOI 10.1016/j.fct.2009.10.006
   Azay-Milhau J, 2013, J ETHNOPHARMACOL, V150, P755, DOI 10.1016/j.jep.2013.09.046
   Beltowski J, 2002, ACTA BIOCHIM POL, V49, P927
   BEUTLER E, 1963, J LAB CLIN MED, V61, P882
   Bulera SJ, 2001, HEPATOLOGY, V33, P1239, DOI 10.1053/jhep.2001.23560
   Cavin C, 2005, BIOCHEM BIOPH RES CO, V327, P742, DOI 10.1016/j.bbrc.2004.12.061
   Cemek M, 2010, FOOD CHEM TOXICOL, V48, P2827, DOI 10.1016/j.fct.2010.07.013
   CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V37, P301, DOI 10.1016/0003-9861(52)90194-X
   Costa LG, 2003, ANNU REV MED, V54, P371, DOI 10.1146/annurev.med.54.101601.152421
   Dalar A, 2014, IND CROP PROD, V60, P79, DOI 10.1016/j.indcrop.2014.05.043
   Djeridane A, 2006, J ENZYM INHIB MED CH, V21, P719, DOI 10.1080/14756360600810399
   Djordjevic VB, 2004, INT REV CYTOL, V237, P57, DOI 10.1016/S0074-7696(04)37002-6
   Goldberg D M., 1983, METHOD ENZYMAT AN, V3, P258
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   Harries HM, 2001, TOXICOL IN VITRO, V15, P399, DOI 10.1016/S0887-2333(01)00043-1
   Hassan HA, 2010, FOOD CHEM TOXICOL, V48, P2163, DOI 10.1016/j.fct.2010.05.023
   Hazra B, 2002, FITOTERAPIA, V73, P730, DOI 10.1016/S0367-326X(02)00232-0
   Ichi I, 2009, TOXICOLOGY, V261, P33, DOI 10.1016/j.tox.2009.04.040
   Ilaiyaraja N., 2010, International Journal of Integrative Biology, V10, P101
   Jaeschke H, 2002, TOXICOL SCI, V65, P166, DOI 10.1093/toxsci/65.2.166
   Jarvik GP, 2002, ARTERIOSCL THROM VAS, V22, P1329, DOI 10.1161/01.ATV.0000027101.40323.3A
   Jia XD, 2002, CANCER EPIDEM BIOMAR, V11, P1663
   Kanter M, 2005, WORLD J GASTROENTERO, V11, P6684, DOI 10.3748/wjg.v11.i42.6684
   Khan RA, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-90
   Kilic SS, 2005, WORLD J GASTROENTERO, V11, P7351, DOI 10.3748/wjg.v11.i46.7351
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x
   Kim JH, 2002, INT IMMUNOPHARMACOL, V2, P733, DOI 10.1016/S1567-5769(02)00008-5
   Kim MY, 1996, J NUTR, V126, P2236
   Kim TW, 2001, ARCH PHARM RES, V24, P431, DOI 10.1007/BF02975190
   Kiyici A, 2010, J MED FOOD, V13, P725, DOI 10.1089/jmf.2009.0232
   Krylova S. G., 2006, Eksperimental'naya i Klinicheskaya Farmakologiya, V69, P34
   Kuo JHS, 2005, J CONTROL RELEASE, V108, P442, DOI 10.1016/j.jconrel.2005.08.026
   Lee KT, 2000, BIOL PHARM BULL, V23, P1005
   Liu HT, 2013, J FOOD SCI, V78, pM258, DOI 10.1111/1750-3841.12040
   Manubolu M, 2014, J ETHNOPHARMACOL, V153, P744, DOI 10.1016/j.jep.2014.03.040
   Mares D, 2005, MYCOPATHOLOGIA, V160, P85, DOI 10.1007/s11046-004-6635-2
   Marsillach J, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-3
   MORON MS, 1979, BIOCHIM BIOPHYS ACTA, V582, P67, DOI 10.1016/0304-4165(79)90289-7
   Mulabagal V, 2009, EUR FOOD RES TECHNOL, V230, P47, DOI 10.1007/s00217-009-1144-7
   Nallamilli BR, 2013, DRUG INVENT TODAY, V5, P311, DOI [10.1016/j.dit.2013.08.005, DOI 10.1016/J.DIT.2013.08.005]
   Ng TB, 2005, BIOCHEM CELL BIOL, V83, P78, DOI 10.1139/O04-100
   Nguyen SD, 2003, FREE RADICAL RES, V37, P1319, DOI 10.1080/1071-5760310001621351
   Noll C, 2009, J NUTR BIOCHEM, V20, P586, DOI 10.1016/j.jnutbio.2008.06.002
   PAGLIA DE, 1967, J LAB CLIN MED, V70, P158
   Petrovic J, 2004, FITOTERAPIA, V75, P737, DOI 10.1016/j.fitote.2004.05.001
   PLACER ZA, 1966, ANAL BIOCHEM, V16, P359, DOI 10.1016/0003-2697(66)90167-9
   Preethi KC, 2009, INDIAN J EXP BIOL, V47, P163
   Pushparaj PN, 2007, J ETHNOPHARMACOL, V111, P430, DOI 10.1016/j.jep.2006.11.028
   Rosenblat M, 2006, ATHEROSCLEROSIS, V187, P363, DOI 10.1016/j.atherosclerosis.2005.09.006
   Saggu S, 2014, FOOD CHEM TOXICOL, V72, P138, DOI 10.1016/j.fct.2014.06.029
   Samarghandian Saeed, 2013, Cardiovascular & Hematological Disorders - Drug Targets, V13, P231
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Singh N, 2008, ENVIRON TOXICOL PHAR, V26, P241, DOI 10.1016/j.etap.2008.05.006
   Sofowara A., 1993, MED PLANTS TRADITION
   Street RA, 2013, EVID-BASED COMPL ALT, V2013, DOI [10.1155/2013/579319, DOI 10.1155/2013/579319]
   Szymonik-Lesiuk Stanislawa, 2003, J Hepatobiliary Pancreat Surg, V10, P309, DOI 10.1007/s00534-002-0824-5
   Takaeidi MR, 2014, JUNDISHAPUR J NAT PH, V9, P30
   Trease G. E, 1989, PHARMACOGNOSY
   Ustundag B, 2007, DIGEST DIS SCI, V52, P2006, DOI 10.1007/s10620-006-9251-9
   Zafar R, 1998, J ETHNOPHARMACOL, V63, P227, DOI 10.1016/S0378-8741(98)00087-7
   Zhang C, 2008, J GENE MED, V10, P94, DOI 10.1002/jgm.1128
NR 68
TC 30
Z9 30
U1 2
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 25
PY 2015
VL 10
IS 3
AR e0121549
DI 10.1371/journal.pone.0121549
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CE5MO
UT WOS:000351880000162
PM 25807561
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhou, W
   Zhang, SX
   Hu, YC
   Na, JR
   Wang, N
   Ma, X
   Yuan, LZ
   Meng, FZ
AF Zhou, Wei
   Zhang, Shuxiang
   Hu, Yingchun
   Na, Jianrong
   Wang, Na
   Ma, Xuan
   Yuan, Lizhi
   Meng, Fanzhen
TI RETRACTED: Meta-analysis of the associations between TNF-alpha or IL-6
   gene polymorphisms and susceptibility to lung cancer (Retracted article.
   See vol. 21, 31, 2016)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Lung cancer; Tumor necrosis factor-alpha; Interleukin 6; Gene
   polymorphisms; Meta-analysis
ID PROLIFERATION; METAANALYSIS; SURVIVAL; DISEASE; CELLS; RISK; BETA
AB Background: Several studies have indicated an association between tumor necrosis factor-alpha (TNF-alpha) or interleukin (IL)-6 gene polymorphisms and lung cancer risk. However, the conclusions remain controversial.
   Methods: An English literature screening about case-control trials with regard to TNF-alpha (-308G/A) or IL-6 (174G/C) polymorphisms and lung cancer susceptibility was performed on PubMed, EMBASE, and EBSCO until November 2012. The pooled odds ratio (OR) and 95% confidence intervals (CI) were calculated using STATA 11.0. Sensitivity analysis was performed by sequential omission of individual studies. Publication bias was evaluated by Egger's linear regression test and funnel plots.
   Results: Eight eligible studies, including 1,690 patients and 1,974 controls, were identified in this meta-analysis. Compared with the control, no significant association was revealed between TNF-alpha-308G/A (GG + GC vs. CC: OR = 1.10, 95% CI: 0.73 to 1.64; GG vs. GC + CC: OR = 1.02, 95% CI: 0.81 to 1.27; GC vs. CC: OR = 1.13, 95% CI: 0.73 to 1.77; GG vs. CC: OR = 1.04, 95% CI: 0.80 to 1.36; G vs. C: OR = 1.03, 95% CI: 0.90 to 1.18) or IL-6 174G/C (GG + GC vs. CC: OR = 1.10, 95% CI: 0.73 to 1.64; GG vs. GC + CC: OR = 1.02, 95% CI: 0.81 to 1.27; GC vs. CC: OR = 1.13, 95% CI: 0.73 to 1.77; GG vs. CC: OR = 1.04, 95% CI: 0.80 to 1.36; G vs. C: OR = 1.03, 95% CI: 0.90 to 1.18) and lung cancer risk. The pooled OR remained unchanged after removing the maximum-weight study and no publication bias was observed.
   Conclusions: The study raises the possibility of no correlation between the polymorphisms of the two genes and lung cancer susceptibility. However, further researches with large-sample or subgroup analyses are necessary to validate the conclusions.
C1 [Zhou, Wei; Zhang, Shuxiang; Hu, Yingchun; Na, Jianrong; Wang, Na; Ma, Xuan; Yuan, Lizhi; Meng, Fanzhen] Ningxia Med Univ, Dept Respirat, Gen Hosp, Yinchuan 750004, Peoples R China.
RP Zhou, W (reprint author), Ningxia Med Univ, Dept Respirat, Gen Hosp, Shengli St, Yinchuan 750004, Peoples R China.
EM zhouweieiie@163.com
CR Ballaz Santiago, 2003, Clin Lung Cancer, V5, P46, DOI 10.3816/CLC.2003.n.021
   Bodelon C, 2013, ANN ONCOL, V24, P2073, DOI 10.1093/annonc/mdt175
   Brennan P, 2011, LANCET ONCOL, V12, P399, DOI 10.1016/S1470-2045(10)70126-1
   Campa D, 2004, CARCINOGENESIS, V25, P229, DOI 10.1093/carcin/bgh008
   Colakogullari M, 2008, CELL BIOCHEM FUNCT, V26, P283, DOI 10.1002/cbf.1419
   Dong LM, 2008, JAMA-J AM MED ASSOC, V299, P2423, DOI 10.1001/jama.299.20.2423
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Flego V, 2009, MED SCI MONITOR, V15, pCR361
   Gupta SC, 2010, CANCER METAST REV, V29, P405, DOI 10.1007/s10555-010-9235-2
   Helmig S, 2010, BIOMARKERS, V15, P400, DOI 10.3109/1354750X.2010.481365
   Ilonidis G, 2006, J BIOL REG HOMEOS AG, V20, P41
   Liang J, 2013, MOL BIOL REP, V40, P1541, DOI 10.1007/s11033-012-2199-2
   Liu RY, 2012, EXP THER MED, V3, P655, DOI 10.3892/etm.2012.454
   Pope CA, 2011, ENVIRON HEALTH PERSP, V119, P1616, DOI 10.1289/ehp.1103639
   Seifart C, 2005, DIS MARKERS, V21, P157, DOI 10.1155/2005/707131
   Shen C, 2011, BREAST CANCER RES TR, V126, P763, DOI 10.1007/s10549-010-1184-5
   Shih CM, 2006, LUNG CANCER-J IASLC, V52, P15, DOI 10.1016/j.lungcan.2005.11.011
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Stankovioc MM, 2009, NEOPLASMA, V56, P348, DOI 10.4149/neo_2009_04_348
   Terry CF, 2000, J BIOL CHEM, V275, P18138, DOI 10.1074/jbc.M000379200
   Vogel U, 2008, MUTAT RES-FUND MOL M, V639, P89, DOI 10.1016/j.mrfmmm.2007.11.004
   Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195
   Yang HA, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-92
   Yu KD, 2010, BREAST CANCER RES TR, V122, P483, DOI 10.1007/s10549-009-0706-5
NR 24
TC 4
Z9 4
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD MAR 21
PY 2015
VL 20
AR 28
DI 10.1186/s40001-015-0113-9
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CS4RL
UT WOS:000362063500001
PM 25889486
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Kivrak, I
AF Kivrak, Ibrahim
TI RETRACTED: Chemical constituents: water-soluble vitamins, free amino
   acids and sugar profile from Ganoderma adspersum (Retracted article. See
   vol. 29, 2015)
SO NATURAL PRODUCT RESEARCH
LA English
DT Article; Retracted Publication
DE Ganoderma adspersum; valine; phenylalanine; water-soluble vitamins;
   UPLC-ESI-MS/MS
ID CULTIVATED MUSHROOMS; NUTRITIONAL-VALUE
AB Ganoderma adspersum presents a rigid fruiting body owing to chitin content and having a small quantity of water or moisture. The utility of bioactive constituent of the mushroom can only be available by extraction for human usage. In this study, carbohydrate, water-soluble vitamin compositions and amino acid contents were determined in G. adspersum mushroom. The composition in individual sugars was determined by HPLC-RID, mannitol (13.04g/100g) and trehalose (10.27g/100g) being the most abundant sugars. The examination of water-soluble vitamins and free amino acid composition was determined by UPLC-ESI-MS/MS. Essential amino acid constituted 67.79% of total amino acid, which is well worth the attention with regard to researchers and consumers. In addition, G. adspersum, which is also significantly rich in B group vitamins and vitamin C, can provide a wide range of notable applications in the pharmaceutics, cosmetics, food and dietary supplement industries. G. adspersum revealed its value for pharmacy and nutrition fields.
C1 [Kivrak, Ibrahim] Mugla Sitki Kocman Univ, Mugla Vocat Sch Higher Educ, Dept Chem & Chem Treatment Tech, TR-48000 Kotekli, Mugla, Turkey.
   [Kivrak, Ibrahim] Mugla Sitki Kocman Univ, Res Lab Ctr, Food Anal Lab, TR-48000 Kotekli, Mugla, Turkey.
RP Kivrak, I (reprint author), Mugla Sitki Kocman Univ, Mugla Vocat Sch Higher Educ, Dept Chem & Chem Treatment Tech, TR-48000 Kotekli, Mugla, Turkey.
EM kivrakibrahim@gmail.com
CR Bernal J, 2011, J PHARMACEUT BIOMED, V55, P758, DOI 10.1016/j.jpba.2010.11.033
   Blumenthal H.J., 1976, FILAMENTOUS FUNGI, V2, P292
   Callejon RM, 2010, TALANTA, V81, P1143, DOI 10.1016/j.talanta.2010.02.040
   Cheung PCK, 2010, NUTR BULL, V35, P292, DOI 10.1111/j.1467-3010.2010.01859.x
   Fiechter G, 2011, J CHROMATOGR B, V879, P1361, DOI 10.1016/j.jchromb.2011.02.005
   Hamano H., 1997, Food Industry and Nutrition, V2, P1
   Heleno SA, 2012, FOOD RES INT, V46, P135, DOI 10.1016/j.foodres.2011.12.009
   Kalac P, 2013, J SCI FOOD AGR, V93, P209, DOI 10.1002/jsfa.5960
   Kim MY, 2009, FOOD CHEM, V113, P386, DOI 10.1016/j.foodchem.2008.07.045
   Kivrak I, 2014, FOOD CHEM, V158, P88, DOI 10.1016/j.foodchem.2014.02.108
   Kvrak Kvrak S, 2014, MITT KLOSTERNEUBURG, V64, P216
   Mattila P, 2002, J AGR FOOD CHEM, V50, P6419, DOI 10.1021/jf020608m
   Reis FS, 2012, FOOD CHEM TOXICOL, V50, P191, DOI 10.1016/j.fct.2011.10.056
   Sanmee R, 2003, FOOD CHEM, V82, P527, DOI 10.1016/S0308-8146(02)00595-2
   Wang XM, 2014, FOOD CHEM, V151, P279, DOI 10.1016/j.foodchem.2013.11.062
   Furlani RPZ, 2008, FOOD CHEM, V106, P816, DOI 10.1016/j.foodchem.2007.06.007
NR 16
TC 4
Z9 4
U1 4
U2 58
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD MAR 19
PY 2015
VL 29
IS 6
BP 518
EP 523
DI 10.1080/14786419.2014.952234
PG 6
WC Chemistry, Applied; Chemistry, Medicinal
SC Chemistry; Pharmacology & Pharmacy
GA AY6UZ
UT WOS:000347702200004
PM 25169839
DA 2018-12-27
ER

PT J
AU Sun, B
   Li, CM
AF Sun, Bai
   Li, Chang Ming
TI RETRACTED: Light-controlled resistive switching memory of multiferroic
   BiMnO3 nanowire arrays (Retracted article. See vol. 19, pg. 10699, 2017)
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID GRAPHENE OXIDE; NANOPARTICLES; DEPOSITION; REDUCTION; NANOTUBES;
   MEMRISTOR; CERAMICS; BEHAVIOR; DEVICES; FILMS
AB A multiferroic BiMnO3 nanowire array was prepared using a hydrothermal process and its resistive switching memory behaviors were further investigated. The prominent ferroelectricity can be well controlled by white-light illumination, thus offering an excellent light-controlled resistive switching memory device using a Ag/BiMnO3/Ti structure at room temperature.
C1 [Sun, Bai; Li, Chang Ming] Southwest Univ, ICEAM, Chongqing 400715, Peoples R China.
   [Sun, Bai; Li, Chang Ming] Southwest Univ, Fac Mat & Energy, Chongqing 400715, Peoples R China.
   [Sun, Bai; Li, Chang Ming] Chongqing Key Lab Adv Mat & Technol Clean Energie, Chongqing 400715, Peoples R China.
RP Li, CM (reprint author), Southwest Univ, ICEAM, Chongqing 400715, Peoples R China.
EM ecmli@swu.edu.cn
RI Sun, Bai/P-7421-2018; Li, Chang Ming/F-9340-2017
OI Sun, Bai/0000-0002-5840-509X; Li, Chang Ming/0000-0002-4041-2574
FU Institute for Clean Energy & Advanced Materials (Southwest University,
   Chongqing, China); Chongqing Key Laboratory for Advanced Materials and
   Technologies of Clean Energies (Chongqing, China); start-up grant from
   Southwest University (Chongqing, China) [SWU111071]; Chongqing Science
   and Technology Commission (Chongqing, China) [cstc2012gjhz90002]
FX This work was financially supported by the Institute for Clean Energy &
   Advanced Materials (Southwest University, Chongqing, China), Chongqing
   Key Laboratory for Advanced Materials and Technologies of Clean Energies
   (Chongqing, China), a start-up grant under SWU111071 from Southwest
   University (Chongqing, China) and the Chongqing Science and Technology
   Commission under cstc2012gjhz90002 (Chongqing, China).
CR Adachi M, 2012, J MATER RES, V27, P440, DOI 10.1557/jmr.2011.393
   Akin I, 2014, RSC ADV, V4, P32549, DOI 10.1039/c4ra04199b
   Belik AA, 2007, J AM CHEM SOC, V129, P971, DOI 10.1021/ja0664032
   Belik AA, 2011, INORG CHEM, V50, P7685, DOI 10.1021/ic2007233
   Bhunia P, 2012, CHEM COMMUN, V48, P913, DOI 10.1039/c1cc16225j
   Bibes M, 2012, NAT MATER, V11, P354, DOI 10.1038/nmat3318
   Cava CE, 2014, NANOSCALE, V6, P378, DOI 10.1039/c3nr04320g
   Chanthbouala A, 2012, NAT MATER, V11, P860, DOI [10.1038/NMAT3415, 10.1038/nmat3415]
   Deng XL, 2012, NANOSCALE, V4, P2029, DOI 10.1039/c2nr12100j
   DIMOS D, 1994, J APPL PHYS, V76, P4305, DOI 10.1063/1.357316
   Dutta DP, 2010, NANOSCALE, V2, P1149, DOI 10.1039/c0nr00100g
   He L, 2011, NANO LETT, V11, P4601, DOI 10.1021/nl202017k
   Huang TH, 2013, J MATER CHEM C, V1, P7593, DOI 10.1039/c3tc31542h
   Jeong DS, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/7/076502
   Jin C, 2012, CHEM COMMUN, V48, P4235, DOI 10.1039/c2cc30973d
   Jin CC, 2013, APPL SURF SCI, V283, P348, DOI 10.1016/j.apsusc.2013.06.114
   Kim HJ, 2013, RSC ADV, V3, P20978, DOI 10.1039/c3ra42683a
   Kimura T, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.180401
   Kolar J, 2014, J MATER CHEM C, V2, P349, DOI 10.1039/c3tc31969e
   Li S, 2013, CHEM COMMUN, V49, P5856, DOI 10.1039/c3cc40363g
   Liu RZ, 2010, J MATER CHEM, V20, P10665, DOI 10.1039/c0jm02602f
   Luca G., 2013, APPL PHYS LETT, V103
   Maso N, 2014, PHYS CHEM CHEM PHYS, V16, P19408, DOI 10.1039/c4cp02580f
   Mazumder B, 2007, J MATER CHEM, V17, P3910, DOI 10.1039/b706154d
   Mukherjee A, 2014, J MATER CHEM C, V2, P5885, DOI 10.1039/c4tc00591k
   Park J, 2013, ADV MATER, V25, P6423, DOI 10.1002/adma.201303017
   Park J, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/38/385707
   Park TJ, 2004, CHEM COMMUN, P2708, DOI 10.1039/b409988e
   Shirolkar MM, 2014, NANOSCALE, V6, P4735, DOI 10.1039/c3nr05973a
   Ungureanu M, 2012, ADV MATER, V24, P2496, DOI 10.1002/adma.201200382
   Yang H, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.024114
   Yoo HG, 2014, RSC ADV, V4, P20017, DOI 10.1039/c4ra02536a
   Zazpe R, 2014, J MATER CHEM C, V2, P3204, DOI 10.1039/c3tc31819b
   Zhang WB, 2014, CHEM COMMUN, V50, P11496, DOI 10.1039/c4cc05233a
NR 34
TC 66
Z9 67
U1 10
U2 148
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
EI 1463-9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PD MAR 14
PY 2015
VL 17
IS 10
BP 6718
EP 6721
DI 10.1039/c4cp04901b
PG 4
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA CD9LM
UT WOS:000351419800007
PM 25683955
DA 2018-12-27
ER

PT J
AU Choi, BK
   Kim, JY
   Cha, MY
   Mook-Jung, I
   Shin, YK
   Lee, NK
AF Choi, Bong-Kyu
   Kim, Jae-Yeol
   Cha, Moon-Yong
   Mook-Jung, Inhee
   Shin, Yeon-Kyun
   Lee, Nam Ki
TI RETRACTED: beta-Amyloid and alpha-Synuclein Cooperate To Block
   SNARE-Dependent Vesicle Fusion(Retracted article. See vol. 56,
   pg.1026,2017)
SO BIOCHEMISTRY
LA English
DT Article; Retracted Publication
ID LEWY BODY PATHOLOGY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; A-BETA;
   MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; PRECURSOR PROTEIN; IN-VITRO;
   OLIGOMERS; DOPAMINE
AB Alzheimers disease (AD) and Parkinsons disease (PD) are caused by beta-amyloid (A beta) and a-synuclein (alpha S), respectively. Ample evidence suggests that these two pathogenic proteins are closely linked and have a synergistic effect on eliciting neurodegenerative disorders. However, the pathophysiological consequences of A beta and alpha S coexistence are still elusive. Here, we show that large-sized alpha S oligomers, which are normally difficult to form, are readily generated by A beta(42)-seeding and that these oligomers efficiently hamper neuronal SNARE-mediated vesicle fusion. The direct binding of the A beta-seeded alpha S oligomers to the N-terminal domain of synaptobrevin-2, a vesicular SNARE protein, is responsible for the inhibition of fusion. In contrast, large-sized A beta(42) oligomers (or aggregates) or the products of alpha S incubated without A beta(42) have no effect on vesicle fusion. These results are confirmed by examining PC12 cell exocytosis. Our results suggest that A beta and alpha S cooperate to escalate the production of toxic oligomers, whose main toxicity is the inhibition of vesicle fusion and consequently prompts synaptic dysfunction.
C1 [Choi, Bong-Kyu; Lee, Nam Ki] Pohang Univ Sci & Technol, Sch Interdisciplinary Biosci & Bioengn, Pohang 790784, South Korea.
   [Kim, Jae-Yeol; Lee, Nam Ki] Pohang Univ Sci & Technol, Dept Phys, Pohang 790784, South Korea.
   [Cha, Moon-Yong; Mook-Jung, Inhee] Seoul Natl Univ, Coll Med, Dept Biochem & Biomed Sci, Seoul 110799, South Korea.
   [Shin, Yeon-Kyun] Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.
RP Lee, NK (reprint author), Pohang Univ Sci & Technol, Sch Interdisciplinary Biosci & Bioengn, Pohang 790784, South Korea.
EM colishin@iastate.edu; nklee@postech.ac.kr
RI Lee, Nam/C-9477-2013
FU National Research Foundation of Korea - MEST [NRF-2013R1A1A2063302];
   Nano Material Technology Development Program of MSIP/NRF
   [NRF-2014M3A7B6034580]; National Institutes of Health [R01 GM051290]
FX This work was supported by the National Research Foundation of Korea
   funded by MEST (NRF-2013R1A1A2063302) and Nano Material Technology
   Development Program (NRF-2014M3A7B6034580) of MSIP/NRF to N.K.L. and a
   National Institutes of Health grant (R01 GM051290) to Y.-K.S.
CR Ahmed M, 2010, NAT STRUCT MOL BIOL, V17, P561, DOI 10.1038/nsmb.1799
   Armstrong RA, 1997, NEUROSCI LETT, V227, P193, DOI 10.1016/S0304-3940(97)00343-1
   Binolfi A, 2006, J AM CHEM SOC, V128, P9893, DOI 10.1021/ja0618649
   Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a
   Burre J, 2010, SCIENCE, V329, P1663, DOI 10.1126/science.1195227
   Cappai R, 2005, FASEB J, V19, P1377, DOI 10.1096/fj.04-3437fje
   Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901
   Choi BK, 2013, P NATL ACAD SCI USA, V110, P4087, DOI 10.1073/pnas.1218424110
   Chui DH, 1999, NAT MED, V5, P560
   Clifford PM, 2007, BRAIN RES, V1142, P223, DOI 10.1016/j.brainres.2007.01.070
   Clinton LK, 2010, J NEUROSCI, V30, P7281, DOI 10.1523/JNEUROSCI.0490-10.2010
   Comellas G, 2012, J AM CHEM SOC, V134, P5090, DOI 10.1021/ja209019s
   Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522
   Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443
   DeWitt DC, 2013, BIOCHEMISTRY-US, V52, P2385, DOI 10.1021/bi4002369
   Diao JJ, 2013, ELIFE, V2, DOI 10.7554/eLife.00592
   Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538
   Gitler AD, 2008, P NATL ACAD SCI USA, V105, P145, DOI 10.1073/pnas.0710685105
   Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1
   Halliday GM, 1996, J CLIN NEUROSCI, V3, P52, DOI 10.1016/S0967-5868(96)90083-1
   Hamilton RL, 2000, BRAIN PATHOL, V10, P378
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0
   Irwin DJ, 2013, NAT REV NEUROSCI, V14, P626, DOI 10.1038/nrn3549
   IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X
   Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002
   Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200
   Kim HY, 2009, J AM CHEM SOC, V131, P17482, DOI 10.1021/ja9077599
   Kim JY, 2012, EMBO J, V31, P2144, DOI 10.1038/emboj.2012.57
   Kyoung M, 2011, P NATL ACAD SCI USA, V108, pE304, DOI 10.1073/pnas.1107900108
   LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168
   Lai Y, 2014, BIOCHEMISTRY-US, V53, P3889, DOI 10.1021/bi5002536
   Larsen KE, 2006, J NEUROSCI, V26, P11915, DOI 10.1523/JNEUROSCI.3821-06.2006
   Leverenz JB, 2006, ARCH NEUROL-CHICAGO, V63, P370, DOI 10.1001/archneur.63.3.370
   Lorenzen N, 2014, J AM CHEM SOC, V136, P3859, DOI 10.1021/ja411577t
   Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983
   Mandal PK, 2006, NEUROCHEM RES, V31, P1153, DOI 10.1007/s11064-006-9140-9
   Marsh SE, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt109
   Masliah E, 2001, P NATL ACAD SCI USA, V98, P12245, DOI 10.1073/pnas.211412398
   Morales R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003537
   Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000
   Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023
   Ono K, 2012, J NEUROCHEM, V122, P883, DOI 10.1111/j.1471-4159.2012.07847.x
   Rekas A, 2010, EUR BIOPHYS J BIOPHY, V39, P1407, DOI 10.1007/s00249-010-0595-x
   Rosenberg CK, 2000, ACTA NEUROPATHOL, V100, P145, DOI 10.1007/s004019900155
   Sakono M, 2010, FEBS J, V277, P1348, DOI 10.1111/j.1742-4658.2010.07568.x
   Sharma M, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004028
   Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166
   Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412
   Sudhof TC, 2009, SCIENCE, V323, P474, DOI 10.1126/science.1161748
   SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290
   Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X
   Tsigelny IF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003135
   Tsuang DW, 2006, J ALZHEIMERS DIS, V9, P235
   Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200
   Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398
   Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X
   Yavich L, 2004, J NEUROSCI, V24, P11165, DOI 10.1523/JNEUROSCI.2559-04.2004
NR 58
TC 12
Z9 12
U1 1
U2 19
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAR 10
PY 2015
VL 54
IS 9
BP 1831
EP 1840
DI 10.1021/acs.blochem.5b00087
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CD2OR
UT WOS:000350919400012
PM 25714795
DA 2018-12-27
ER

PT J
AU Kesten, AS
   Ergun, M
AF Kesten, Ali Sercan
   Ergun, Murat
TI RETRACTED: Efficiency analysis of the dynamic traffic control for an
   urban highway (Retracted article. See 185, 2016)
SO EURASIP JOURNAL ON WIRELESS COMMUNICATIONS AND NETWORKING
LA English
DT Article; Retracted Publication
DE Intelligent transportation systems; Dynamic ramp metering; Dynamic speed
   limit control
AB In this study, dynamic traffic control strategies, namely dynamic ramp metering and dynamic speed limit control, have been examined through microscopic traffic simulation based on site measurements. In this context, the traffic flow data at a particular highway intersection have been analyzed to determine the pattern of the traffic. Then, the traffic model has been built in a traffic micro-simulation software and calibrated with the field data. The foci of the study are to measure the efficiency of the dynamic traffic control strategies and to compare it with the uncontrolled case considering various performance indicators such as total travel time, average delay time per vehicle, and average number of stops per vehicle. For the dynamic ramp metering strategies, the ALINEA (Asservissement Lineaire d'Entree Autoroutiere - French for Linear Utilization for Highway Entrances) control algorithm is implemented with different fixed-time cycle lengths. It has been observed that various ramp metering implementations decreased the average delay time per vehicle up to 30%. The dynamic speed limit control strategies are set according to the occupancy rates that are measured at the bottleneck downstream. The examined speed limit control strategies decreased the average delay time per vehicle to around 7%. The results also revealed that the implemented dynamic traffic control strategies help alleviate congestion by increasing the capacity of the bottleneck section.
C1 [Kesten, Ali Sercan] Isik Univ, Dept Engn, Div Civil Engn, Istanbul, Turkey.
   [Ergun, Murat] Istanbul Tech Univ, Dept Civil Engn, Transportat Engn Study Grp, TR-80626 Istanbul, Turkey.
RP Kesten, AS (reprint author), Isik Univ, Dept Engn, Div Civil Engn, Istanbul, Turkey.
EM sercan.kesten@isikun.edu.tr
FU Ministry of Education, Culture, Sports, Science & Technology of Japan
FX The first author would like to thank PTV Japan for providing the license
   key of PTV VISSIM. The Ministry of Education, Culture, Sports, Science &
   Technology of Japan supported the PhD research of the first author.
CR Akbas A, 2006, INDIAN J ENG MATER S, V13, P322
   [Anonymous], 2010, TRB HIGHW CAP MAN HC
   Chaudhary N. A., 2004, RAMP METERING ALGORI
   Corcoran LJ, 1989, I TRANSP ENG M
   Daganzo CF, 1997, FUNDAMENTALS TRANSPO
   Fellendorf M, 2010, INT SER OPER RES MAN, V145, P63, DOI 10.1007/978-1-4419-6142-6_2
   Gartner NH, 2005, REVISED MONOGRAPH TR
   Hegyi A, 2005, TRANSPORT RES C-EMER, V13, P185, DOI 10.1016/j.trc.2004.08.001
   Jacobson LN, 1989, REAL TIME METERING A, P1232
   Kachroo P, 2004, FEEDBACK RAMP METERI
   Kesten AS, 2012, 10 INT C ADV CIV ENG
   Lau R., 1997, RAMP METERING ZONE M
   Paesani G, 1997, MERGING TRANSPORTATI
   Papageorgiou M, 2003, P IEEE, V91, P2043, DOI 10.1109/JPROC.2003.819610
   Papageorgiou M., 1991, TRANSPORT RES REC, V1320, P58
   Papageorgiou M., 1997, TRANSPORT RES REC, V1603, P90, DOI DOI 10.3141/1603-12
   PTV AG, 2011, VISSIM 5 40 US MAN
   Taylor C, 2000, EVALUATION FUZZY LOG
   Whitham G. B, 1974, LINEAR NONLINEAR WAV
   Wiedemann R, 1974, SIMULATION STRASSENV
   Wiedemann R., 1991, ADV TELEMATICS ROAD
   Xin WP, 2004, TRANSPORT RES REC, P69, DOI 10.3141/1867-09
NR 22
TC 1
Z9 1
U1 2
U2 21
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1687-1499
J9 EURASIP J WIREL COMM
JI EURASIP J. Wirel. Commun. Netw.
PD MAR 7
PY 2015
AR 52
DI 10.1186/s13638-015-0287-4
PG 9
WC Engineering, Electrical & Electronic; Telecommunications
SC Engineering; Telecommunications
GA CE3SK
UT WOS:000351748600001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Gomha, SM
   Abdulla, MM
   Abou-Seri, SM
AF Gomha, Sobhi M.
   Abdulla, Mohamed M.
   Abou-Seri, Sahar M.
TI RETRACTED: Identification of novel aminothiazole and aminothiadiazole
   conjugated cyanopyridines as selective CHK1 inhibitors (Retracted
   article. See vol. 121, pg. 939, 2016)
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article; Retracted Publication
DE 2-Aminocyanopyridine; 1,3,4-Thiadiazoles; Hydrazonoyl halides; Selective
   CHK1 inhibitors
ID STRUCTURE-BASED DESIGN; CELL-CYCLE CHECKPOINTS; PYRIDYL AMINOTHIAZOLES;
   ANTICANCER ACTIVITY; ON-CHIP; KINASE; POTENT; OPTIMIZATION; DISCOVERY;
   HETEROCYCLES
AB Inhibitors of checkpoint kinase 1 (CHK1) are of current interest as potential anti-tumor agents. Novel series of cyanopyridyl-aminothiadiazoles (synthesized from reaction of 1-(3-cyano-4,6-diphenylpyridin-2-yl)-3-phenylthiourea (14) with hydrazonoyl halides) and cyanopyridyl-aminothiazolyl-thiadiazoles (synthesized from treatment of 14 with ethyl chloroacetate followed by reaction of the obtained cyanopyridyl-aminothiazole with hydrazonoyl halides) were synthesized and evaluated for their CHK1 inhibitory potential using a cell-based assay cascade. The tested compounds exhibited a potent and selective CHK1 inhibitory activity at nanomolar levels that reflected their ability to abrogate cell cycle arrest and potentiate the cytotoxic effect of the genotoxic drug gemcitabine in colon cancer cells. Molecular modeling simulation revealed that, the most active compound 28a docked well into the enzyme active site and their complex is stabilized by a key H-bonding with the backbone amide of Cys-87 as well as multiple favorable hydrophobic interactions with different hydrophobic binding regions of the enzyme. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Gomha, Sobhi M.] Cairo Univ, Fac Sci, Dept Chem, Giza 12613, Egypt.
   [Abdulla, Mohamed M.] Saco Pharm Co, Res Unit, 6th October City, Egypt.
   [Abou-Seri, Sahar M.] Cairo Univ, Fac Pharm, Dept Pharmaceut Chem, Giza 12613, Egypt.
RP Gomha, SM (reprint author), Cairo Univ, Fac Sci, Dept Chem, Giza 12613, Egypt.
EM s.m.gomha@hotmail.com
CR Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251
   Blasina A, 2008, MOL CANCER THER, V7, P2394, DOI 10.1158/1535-7163.MCT-07-2391
   CHAUDHARY M, 1976, J PHARM SCI, V65, P443, DOI 10.1002/jps.2600650336
   Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029
   Davis AM, 1999, ANGEW CHEM INT EDIT, V38, P737, DOI 10.1002/(SICI)1521-3773(19990315)38:6<736::AID-ANIE736>3.0.CO;2-R
   Dawood KM, 2013, EUR J MED CHEM, V70, P740, DOI 10.1016/j.ejmech.2013.10.042
   Dudkin VY, 2012, BIOORG MED CHEM LETT, V22, P2609, DOI 10.1016/j.bmcl.2012.01.110
   Dudkin VY, 2012, BIOORG MED CHEM LETT, V22, P2613, DOI 10.1016/j.bmcl.2012.01.120
   DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670
   Dunne J, 2004, ASSAY DRUG DEV TECHN, V2, P121, DOI 10.1089/154065804323056468
   EWEISS NF, 1980, J HETEROCYCLIC CHEM, V17, P1713, DOI 10.1002/jhet.5570170814
   Foloppe N, 2005, J MED CHEM, V48, P4332, DOI 10.1021/jm049022c
   Garrett MD, 2011, TRENDS PHARMACOL SCI, V32, P308, DOI 10.1016/j.tips.2011.02.014
   Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689
   Gomha S. M., 2013, INT J PHARM PHARM SC, V5, P42
   Gomha SM, 2014, EUR J MED CHEM, V82, P472, DOI 10.1016/j.ejmech.2014.05.082
   Gomha SM, 2013, J SERB CHEM SOC, V78, P1119, DOI 10.2298/JSC120914013G
   Gomha SM, 2013, HETEROCYCLES, V87, P1109, DOI 10.3987/COM-13-12696
   Gomha SM, 2013, HETEROCYCLES, V87, P341, DOI 10.3987/COM-12-12625
   Gomha SM, 2012, B KOREAN CHEM SOC, V33, P2985, DOI 10.5012/bkcs.2012.33.9.2985
   Gomha SM, 2012, MOLECULES, V17, P9335, DOI 10.3390/molecules17089335
   Gomha SM, 2011, MOLECULES, V16, P8244, DOI 10.3390/molecules16108244
   Gomha SM, 2009, MONATSH CHEM, V140, P213, DOI 10.1007/s00706-008-0060-z
   Gomha SM, 2014, TURK J CHEM, V38, P865, DOI 10.3906/kim-1311-12
   GUPTA RC, 1978, J INDIAN CHEM SOC, V55, P832
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Huang XH, 2013, BIOORG MED CHEM LETT, V23, P2590, DOI 10.1016/j.bmcl.2013.02.108
   Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097
   Kubinyi H, 2001, PHARMACOKINETIC OPTIMIZATION IN DRUG RESEARCH, P513, DOI 10.1002/9783906390437.ch28
   Lainchbury M, 2012, J MED CHEM, V55, P10229, DOI 10.1021/jm3012933
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009
   Opkins A.L., 2004, DRUG DISCOV TODAY, V9, P430
   Oza V, 2012, J MED CHEM, V55, P5130, DOI 10.1021/jm300025r
   Perrin D, 2006, J BIOMOL SCREEN, V11, P359, DOI 10.1177/1087057106286653
   Qiu XL, 2009, J MED CHEM, V52, P1757, DOI 10.1021/jm8015969
   Reader JC, 2011, J MED CHEM, V54, P8328, DOI 10.1021/jm2007326
   Rzeski W, 2007, BIOORGAN MED CHEM, V15, P3201, DOI 10.1016/j.bmc.2007.02.041
   SHAWALI AS, 1973, B CHEM SOC JPN, V46, P3625, DOI 10.1246/bcsj.46.3625
   SHAWALI ASA, 1971, TETRAHEDRON, V27, P2517, DOI 10.1016/S0040-4020(01)90753-7
   Siddiqui N, 2012, ARCH PHARM, V345, P185, DOI 10.1002/ardp.201100140
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4
   Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212
   Tame JRH, 1999, J COMPUT AID MOL DES, V13, P99, DOI 10.1023/A:1008068903544
   Tsou HR, 2010, BIOORG MED CHEM LETT, V20, P2321, DOI 10.1016/j.bmcl.2010.01.135
   Turan-Zitouni G, 2011, PHOSPHORUS SULFUR, V186, P233, DOI 10.1080/10426507.2010.494643
   Walton MI, 2010, MOL CANCER THER, V9, P89, DOI 10.1158/1535-7163.MCT-09-0938
   Weiss GJ, 2013, INVEST NEW DRUG, V31, P136, DOI 10.1007/s10637-012-9815-9
   Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200
   Zhao B, 2002, J BIOL CHEM, V277, P46609, DOI 10.1074/jbc.M20133200
   Zohdi H.F., 1998, J CHEM RES S, V12, P3329
NR 52
TC 16
Z9 16
U1 2
U2 13
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD MAR 6
PY 2015
VL 92
BP 459
EP 470
DI 10.1016/j.ejmech.2015.01.019
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA CD2OO
UT WOS:000350919100037
PM 25594740
DA 2018-12-27
ER

PT J
AU Kievani, MB
   Edraki, M
AF Kievani, Mohammad Banimahd
   Edraki, Milad
TI RETRACTED: Synthesis, characterization and assessment thermal properties
   of clay based nanopigments (Retracted article. See vol. 10, pg. 440,
   2016)
SO FRONTIERS OF CHEMICAL SCIENCE AND ENGINEERING
LA English
DT Article; Retracted Publication
DE nanopigment; layered silicate; cationic dye; thermal properties
ID RHODAMINE-B; MONTMORILLONITE; SURFACE
AB Nano-clay based pigments (NCP) are new type of pigments composed of organic dyes and layered silicate-clay nano-particles, and have already been used in polymeric coatings to improve mechanical thermal and stability properties. In this paper, the basic blue 41(BB41) was intercalated into Na+-montmorillonite in an aqueous medium. The dye-intercalated montmorillonite was centrifuged, dried, and milled to prepare the nanopigment particles. X-ray diffraction showed an increase in the basal spacing, thus confirming intercalation of the BB41 molecules within the nanostructures of the interlayer spaces. Fourier transform infrared spectroscopy was used for identifying the functional groups and chemical bounding of Na+-montmorillonite, BB41 and montmorillonite-BB41. The morphology of NCP was also studied by transmission electron microscopy. Finally, thermogravimetric analysis and differential thermograms suggested the thermal stability of the intercalated dye was improved.
C1 [Kievani, Mohammad Banimahd] Payame Noor Univ, Dept Chem, Tehran, Iran.
   [Edraki, Milad] Islamic Azad Univ, South Tehran Branch, Young Res & Elite Club, Tehran, Iran.
RP Kievani, MB (reprint author), Payame Noor Univ, Dept Chem, Tehran, Iran.
EM mbkeivani@shargh.tpnu.ac.ir
RI edraki, mohammad reza/I-2357-2015
CR Baez E, 2009, ADV POWDER TECHNOL, V20, P267, DOI 10.1016/j.apt.2009.02.005
   Batenburg L F, 2001, J E POLYM
   Beltran MI, 2014, APPL CLAY SCI, V97-98, P43, DOI 10.1016/j.clay.2014.06.001
   Bujdak J, 2007, LANGMUIR, V23, P1851, DOI 10.1021/la062437b
   Capkova P, 2004, J COLLOID INTERF SCI, V277, P128, DOI 10.1016/j.jcis.2004.03.035
   Edraki M, 2013, J PHYS THEORETICAL C, V10, P69
   Kaya M, 2015, J PHYS CHEM SOLIDS, V78, P95, DOI 10.1016/j.jpcs.2014.10.016
   Klika Z, 2004, J COLLOID INTERF SCI, V275, P243, DOI 10.1016/j.jcis.2004.02.040
   Marchante Rodriguez V., 2013, J APPL POLYM SCI, V129, P2716
   Pospisil M, 2003, J MOL MODEL, V9, P39, DOI 10.1007/s00894-002-0107-8
   Raha S, 2012, J DYE PIGMENTS, V93, P1515
   Raha S, 2009, APPL CLAY SCI, V42, P661, DOI 10.1016/j.clay.2008.06.008
   Smitha VS, 2011, J AM CERAM SOC, V94, P1731, DOI 10.1111/j.1551-2916.2010.04326.x
   Tahmassebi N, 2012, J ADV MAT NOVEL COAT, V2, P3
   Validi M, 2012, CERAM-SILIKATY, V56, P152
   Wang CC, 2004, J COLLOID INTERF SCI, V273, P80, DOI 10.1016/j.jcis.2003.12.028
   Zaarei D, 2008, J COAT TECHNOL RES, V5, P241, DOI 10.1007/s11998-007-9065-5
NR 17
TC 1
Z9 1
U1 6
U2 22
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 2095-0179
EI 2095-0187
J9 FRONT CHEM SCI ENG
JI Front. Chem. Sci. Eng.
PD MAR
PY 2015
VL 9
IS 1
BP 40
EP 45
DI 10.1007/s11705-015-1505-7
PG 6
WC Engineering, Chemical
SC Engineering
GA CI6WK
UT WOS:000354904300004
DA 2018-12-27
ER

PT J
AU Nanba, Y
   Miyamoto, S
   Takemasa, S
   Uesugi, M
   Inoue, Y
   Ootani, Y
   Fujii, S
   Hirotsu, T
   Tanaka, H
AF Nanba, Yoshifumi
   Miyamoto, Shigenori
   Takemasa, Seiichi
   Uesugi, Masayuki
   Inoue, Yuri
   Ootani, Yoshitaka
   Fujii, Shun
   Hirotsu, Takaaki
   Tanaka, Hideki
TI RETRACTED: Effect of exercise at light loads with manipulative
   resistance on infraspinatus, trapezius (upper fiber) and deltoid (middle
   fiber) muscle activities in shoulder joint elevation (Retracted article.
   See vol. 27, pg. R1, 2015)
SO JOURNAL OF PHYSICAL THERAPY SCIENCE
LA English
DT Article; Retracted Publication
DE Shoulder joint; IEMG; CKC
ID INTRAARTICULAR PRESSURE
AB [Purpose] To clarify rotator cuff muscular activity in the raised position of the closed kinetic chain (CKC) exercise. [Subjects] Twenty-nine cases were studied, 19 men and 10 women (average age 21.5 +/- 4.7 years old, average body weight 60.1 kg +/- 11.4). [Methods] To determine the effects of the closed kinetic chain exercise on the upper limb, we measured the surface EMG of the infraspinatus muscle, the trapezius (upper fiber) and the deltoid (middle fiber) with the arm elevated. [Results] Our results show that at an elevation angle of 150 degrees in the scapular plane of the upper limb, with 5% body weight load, the EMG activities of the infraspinatus muscle are approximately 30% of maximum voluntary contraction (MVC). [Conclusion] The raised position of the CKC exercise is effective in physical therapy for functional recovery of the infraspinatus muscle.
C1 [Nanba, Yoshifumi; Miyamoto, Shigenori; Takemasa, Seiichi; Uesugi, Masayuki; Inoue, Yuri; Ootani, Yoshitaka; Fujii, Shun] Kobe Int Univ, Fac Rehabil Sci, Higashinada Ku, Kobe, Hyogo 6580032, Japan.
   [Hirotsu, Takaaki] Okubo Hosp, Dept Rehabil, Tokyo, Japan.
   [Tanaka, Hideki] Okubo Hosp, Dept Orthoped, Tokyo, Japan.
RP Nanba, Y (reprint author), Kobe Int Univ, Fac Rehabil Sci, Higashinada Ku, 9-1-6 Kouyouchounaka, Kobe, Hyogo 6580032, Japan.
EM nanba@kobe-kiu.ac.jp
CR Basmajian JV, 1985, MUSCLES ALIVE THEIR, P187
   HAGBERG M, 1981, J APPL PHYSIOL, V51, P1
   Hosoda T, 2010, KINETIC THERAPY TEXT, P122
   Hurschler C, 2000, CLIN BIOMECH, V15, P306, DOI 10.1016/S0268-0033(99)00088-1
   Inokuchi W, 1997, J SHOULDER ELB SURG, V6, P144, DOI 10.1016/S1058-2746(97)90035-5
   Ito F, 2000, 3 EDITION BASIC RES, P345
   Iwakura H, 2008, RIGAKURYOUHOUSI TAME, P36
   JARVHOLM U, 1991, J ORTHOP RES, V9, P609, DOI 10.1002/jor.1100090418
   Jung J, 2012, J PHYS THER SCI, V24, P1173, DOI 10.1589/jpts.24.1173
   Kang MH, 2014, J PHYS THER SCI, V26, P895, DOI 10.1589/jpts.26.895
   Kozuka T, 2000, STATE MUSCLE ACTIVIT, V16, P117
   Kuroki Y, 1997, J PHYS MED, V8, P28
   Lind T, 1992, Acta Orthop Belg, V58, P81
   LIPPOLD OCJ, 1952, J PHYSIOL-LONDON, V117, P492, DOI 10.1113/jphysiol.1952.sp004763
   Nakamura R, 2006, KISOUNDOUGAKU, P203
   Ogino S, 2005, SHOULDER EXTERNAL RO, V26, P165
   Ooizumi N, 2002, ANAL COOPERATIVE ABD, V23, P417
   Shim J, 2010, J PHYS THER SCI, V22, P227, DOI 10.1589/jpts.22.227
   Shimono T, 2010, MANUAL SURFACE EMG, P124
   Tsutsui H, 1992, JJ SPORTS SCI, V11-12, P762
   Yamaguchi K, 1997, TECHNIQUES THEORY OR, P269
NR 21
TC 2
Z9 2
U1 2
U2 12
PU SOC PHYSICAL THERAPY SCIENCE
PI TOKYO
PA C/O PUBLICATION CENTER, 1-24-12 SUGAMO, TOSHIMA-KU, TOKYO, 170-0002,
   JAPAN
SN 0915-5287
EI 2187-5626
J9 J PHYS THER SCI
JI J. Phys. Ther. Sci.
PD MAR
PY 2015
VL 27
IS 3
BP 627
EP 629
DI 10.1589/jpts.27.627
PG 3
WC Rehabilitation
SC Rehabilitation
GA CF3ZB
UT WOS:000352486600019
PM 25931695
OA Bronze, Green Published
DA 2018-12-27
ER

PT J
AU Gonzalez-Valdes, I
   Hidalgo, I
   Bujarrabal, A
   Lara-Pezzi, E
   Padron-Barthe, L
   Garcia-Pavia, P
   Gomez, P
   Redondo, JM
   Ruiz-Cabello, JM
   Jimenez-Borreguero, LJ
   Enriquez, JA
   de la Pompa, JL
   Hidalgo, A
   Gonzalez, S
AF Gonzalez-Valdes, I.
   Hidalgo, I.
   Bujarrabal, A.
   Lara-Pezzi, E.
   Padron-Barthe, L.
   Garcia-Pavia, P.
   Gomez, P.
   Redondo, J. M.
   Ruiz-Cabello, J. M.
   Jimenez-Borreguero, L. J.
   Enriquez, J. A.
   de la Pompa, J. L.
   Hidalgo, A.
   Gonzalez, S.
TI RETRACTED: Bmi1 limits dilated cardiomyopathy and heart failure by
   inhibiting cardiac senescence (Retracted article. S1ee vol. 8, art no
   14006, 2017)
SO NATURE COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID POLYCOMB GROUP PROTEINS; HEMATOPOIETIC STEM-CELLS; CELLULAR SENESCENCE;
   BMI1-DEFICIENT MICE; TUMOR SUPPRESSION; IN-VIVO; CANCER; INK4A; LOCUS;
   PROLIFERATION
AB Dilated cardiomyopathy (DCM) is the most frequent cause of heart failure and the leading indication for heart transplantation. Here we show that epigenetic regulator and central transcriptional instructor in adult stem cells, Bmi1, protects against DCM by repressing cardiac senescence. Cardiac-specific Bmi1 deletion induces the development of DCM, which progresses to lung congestion and heart failure. In contrast, Bmi1 overexpression in the heart protects from hypertrophic stimuli. Transcriptome analysis of mouse and human DCM samples indicates that p16(INK4a) derepression, accompanied by a senescence-associated secretory phenotype (SASP), is linked to severely impaired ventricular dimensions and contractility. Genetic reduction of p16(INK4a) levels reverses the pathology of Bmi1-deficient hearts. In parabiosis assays, the paracrine senescence response underlying the DCM phenotype does not transmit to healthy mice. As senescence is implicated in tissue repair and the loss of regenerative potential in aging tissues, these findings suggest a source for cardiac rejuvenation.
C1 [Gonzalez-Valdes, I.; Hidalgo, I.; Bujarrabal, A.; Gonzalez, S.] CNIC, Stem Cell Aging Grp, E-28029 Madrid, Spain.
   [Lara-Pezzi, E.; Padron-Barthe, L.] CNIC, Mol Regulat Heart Dev & Dis Grp, E-28029 Madrid, Spain.
   [Padron-Barthe, L.; Garcia-Pavia, P.] Hosp Univ Puerta Hierro Majadahonda, Heart Failure & Inherited Cardiac Dis Unit, E-28222 Madrid, Spain.
   [Gomez, P.; Redondo, J. M.] CNIC, Gene Regulat Cardiovasc Remodelling & Inflammat G, E-28029 Madrid, Spain.
   [Redondo, J. M.; Ruiz-Cabello, J. M.] CNIC, Adv Imaging Unit, Ciber Enfermedades Resp, E-28029 Madrid, Spain.
   [Ruiz-Cabello, J. M.; Jimenez-Borreguero, L. J.] CNIC, UCM, E-28029 Madrid, Spain.
   [Enriquez, J. A.] CNIC, Funct Genet Oxidat Phosphorylat Syst, E-28029 Madrid, Spain.
   [de la Pompa, J. L.] CNIC, Intercellular Signaling Cardiovasc Dev & Dis Grp, E-28029 Madrid, Spain.
   [Hidalgo, A.] CNIC, Imaging Cardiovasc Inflammat & Immune Response, E-28029 Madrid, Spain.
RP Gonzalez, S (reprint author), CNIC, Stem Cell Aging Grp, E-28029 Madrid, Spain.
EM sgonzalez@cnic.es
RI Ruiz-Cabello, Jesus/A-9570-2012; Gonzalez, Susana/I-3154-2015; Gomez-del
   Arco, Pablo/L-2728-2013
OI Ruiz-Cabello, Jesus/0000-0001-8681-5056; Gonzalez,
   Susana/0000-0002-7443-6195; Gomez-del Arco, Pablo/0000-0001-6748-7157;
   Jimenez-Borreguero, Luis Jesus/0000-0001-5870-237X
FU Human Frontiers Science Program Organization; Spanish Ministries of
   Economy and Competitiveness [SAF2010-15386, SAF2013-42252-R]; Ministery
   of Economy and Competitiveness; Pro-CNIC Foundation
FX We thank Miguel Torres and Jose Antonio Enriquez for helpful
   discussions; Rebeca Diges for excellent technical assistance; and Simon
   Bartlett for text editing. S.G. is funded by the Human Frontiers Science
   Program Organization and the Spanish Ministries of Economy and
   Competitiveness (SAF2010-15386 and SAF2013-42252-R). The CNIC is
   supported by the Ministery of Economy and Competitiveness and the
   Pro-CNIC Foundation.
CR Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784
   Addis RC, 2013, NAT MED, V19, P829, DOI 10.1038/nm.3225
   Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509
   Agherbi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005622
   Akala OO, 2008, NATURE, V453, P228, DOI 10.1038/nature06869
   Arranz L, 2012, CELL CYCLE, V11, P65, DOI 10.4161/cc.11.1.18097
   Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736
   Breckenridge RA, 2009, J MOL CELL CARDIOL, V47, P133, DOI 10.1016/j.yjmcc.2009.04.007
   Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305
   Campisi J, 2011, CURR OPIN GENET DEV, V21, P107, DOI 10.1016/j.gde.2010.10.005
   Chang CP, 2012, ANNU REV PHYSIOL, V74, P41, DOI 10.1146/annurev-physiol-020911-153242
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI [10.1146/annurev-pathol-121808-102144, 10.1140/annurev-pathol-121808-102144]
   Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191
   Delgado-Olguin P, 2012, NAT GENET, V44, P343, DOI 10.1038/ng.1068
   Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669
   Dobreva G, 2012, CIRC RES, V110, P372, DOI 10.1161/CIRCRESAHA.111.263145
   Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585
   Gonzalez S, 2008, CELL CYCLE, V7, P2601, DOI 10.4161/cc.7.16.6541
   Hang CT, 2010, NATURE, V466, P62, DOI 10.1038/nature09130
   Harvey PA, 2011, J CELL BIOL, V194, P355, DOI 10.1083/jcb.201101100
   Hidalgo I, 2012, CELL STEM CELL, V11, P649, DOI 10.1016/j.stem.2012.08.001
   Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002
   Jacobs JJL, 1999, NATURE, V397, P164
   Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084
   Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015
   Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098
   McNally EM, 2013, J CLIN INVEST, V123, P19, DOI 10.1172/JCI62862
   Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091
   Moses Kelvin A., 2001, Genesis The Journal of Genetics and Development, V31, P176, DOI 10.1002/gene.10022
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646
   North BJ, 2012, CIRC RES, V110, P1097, DOI 10.1161/CIRCRESAHA.111.246876
   Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477
   Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Schmitt JP, 2003, SCIENCE, V299, P1410, DOI 10.1126/science.1081578
   Shioya T, 2007, J PHYSIOL SCI, V57, P327, DOI 10.2170/physiolsci.RP010107
   Sohal DS, 2001, CIRC RES, V89, P20, DOI 10.1161/hh1301.092687
   Takeda N, 2010, J CLIN INVEST, V120, P254, DOI 10.1172/JCI40295
   Wamstad JA, 2012, CELL, V151, P206, DOI 10.1016/j.cell.2012.07.035
NR 43
TC 10
Z9 10
U1 2
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR
PY 2015
VL 6
AR 6473
DI 10.1038/ncomms7473
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CF6WJ
UT WOS:000352697100014
PM 25751743
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wu, XN
   Zhang, T
   Qian, NS
   Guo, XD
   Yang, HJ
   Huang, KB
   Luo, GQ
   Xiang, W
   Deng, WT
   Dai, GH
   Peng, KR
   Pan, SY
AF Wu, Xiao-Na
   Zhang, Tao
   Qian, Nian-Song
   Guo, Xiao-Dong
   Yang, Hong-Jun
   Huang, Kai-Bin
   Luo, Gao-Quan
   Xiang, Wei
   Deng, Wen-Ting
   Dai, Guang-Hai
   Peng, Kai-Run
   Pan, Su-Yue
TI RETRACTED: Antinociceptive effects of endomorphin-2: Suppression of
   substance P release in the inflammatory pain model rat (Retracted
   article. See vol. 97, pg. 200, 2016)
SO NEUROCHEMISTRY INTERNATIONAL
LA English
DT Article; Retracted Publication
DE Neuropeptide; Spinal cord; Analgesia; Microdialysis; Electron microscopy
ID NEURONS; RECEPTOR; STIMULATION; NOCICEPTION; MECHANISMS; COLOCALIZATION;
   INJURY
AB Endomorphin-2 (EM2) and Substance P (SP) exert suppressive and facilitative influences upon nociception, respectively. Although EM2 and SP were often co-expressed in single neurons in dorsal root ganglion (DRG), it is still unknown if and how the nociception-suppressive influences of EM2 might be exerted upon nociception-facilitative effects of SP in the DRG neurons. We examined these issues in the inflammatory pain model rats produced by subcutaneous injection of the complete Freund's adjuvant into the hind paw. The paw withdrawal threshold for mechanical allodynia was measured. Changes of EM2 and SP release were estimated by measuring intrathecal levels of EM2 and SP through in vivo microdialysis analysis of cerebrospinal fluid. The mechanical allodynia was dose-dependently attenuated by intrathecal injection of EM2 or a neurokinin-1 receptor antagonist, and facilitated by intrathecal injection of SP or a mu-opioid receptor (MOR) antagonist. Importantly, intrathecal level of SP was found to be lowered by intrathecal injection of EM2. Morphologically, colocalization of EM2-, MOR- and SP-immunoreactivity in single DRG neurons was observed by immunofluorescent histochemistry, and co-expression of EM2 and SP in large, dense-cored presynaptic vesicles in primary afferents, as well as localization of MOR on pre- and postsynaptic membrane in spinal dorsal horn, was also confirmed electron miscroscopically. Thus, the results indicated that analgesic influences of EM2 upon inflammatory pain might be exerted through suppression of SP release, supporting the assumptions that binding of EM2 to presynaptic MOR might induce such effects. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Wu, Xiao-Na; Huang, Kai-Bin; Xiang, Wei; Deng, Wen-Ting; Pan, Su-Yue] Southern Med Univ, Dept Neurol, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China.
   [Wu, Xiao-Na; Yang, Hong-Jun; Luo, Gao-Quan; Xiang, Wei; Peng, Kai-Run] Guangzhou Mil Command, Guangzhou Gen Hosp, Dept Neurol, Guangzhou 510010, Guangdong, Peoples R China.
   [Zhang, Tao] Guangzhou Mil Command, Guangzhou Gen Hosp, Dept Orthopaed, Guangzhou 510010, Guangdong, Peoples R China.
   [Qian, Nian-Song; Dai, Guang-Hai] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Unit 2, Beijing 100853, Peoples R China.
   [Guo, Xiao-Dong] 153th Hosp PLA, Dept Neurosurg, Zhengzhou 450042, Peoples R China.
RP Dai, GH (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Unit 2, Beijing 100853, Peoples R China.
EM daigh60@sohu.com; 13889902718@139.com; fimmuneurologypsy@163.com
FU China Postdoctoral Science Foundation [2014M552650, 43628]; National
   Natural Science Foundation of China [81400991, 81200324, 81171135,
   81172095]; Beijing City Science and Technology Plan of Nova of Nian-Song
   Qian [XX2013107]; Natural Science Foundation of Hainan Province [813222]
FX This study was supported by the China Postdoctoral Science Foundation
   funded project (2014M552650 for Postdoctor No. 43628), the National
   Natural Science Foundation of China (Nos. 81400991, 81200324, 81171135,
   81172095), the Beijing City Science and Technology Plan of Nova of
   Nian-Song Qian (XX2013107), the Natural Science Foundation of Hainan
   Province (813222). We wish to take this opportunity to show our
   gratitude for the experimental technical support from Huabo
   Biopharmaceutical Institute, Guangzhou 510010, China. We are grateful to
   Prof. Xi-Tuan Ji and Dr. Bei Liu from Fourth Military Medical
   University, Van 710032, China for their critical reading and suggestions
   on the manuscript.
CR Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028
   Calcutt NA, 2000, BRAIN RES, V856, P20, DOI 10.1016/S0006-8993(99)02345-8
   DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205
   Fichna J, 2007, PHARMACOL REV, V59, P88, DOI 10.1124/pr.59.1.3
   Greenwell TN, 2007, J COMP NEUROL, V503, P319, DOI 10.1002/cne.21374
   Hao JX, 1999, ACTA ANAESTH SCAND, V43, P1027, DOI 10.1034/j.1399-6576.1999.431010.x
   Hao S, 2009, EUR J PAIN, V13, P380, DOI 10.1016/j.ejpain.2008.05.008
   Honore P, 2002, J PAIN, V3, P3, DOI 10.1054/jpai.2002.27001
   Ishigooka M, 2001, PAIN, V93, P43, DOI 10.1016/S0304-3959(01)00288-3
   Kondo I, 2005, J NEUROSCI, V25, P3651, DOI 10.1523/JNEUROSCI.0252-05.2005
   Luo DS, 2014, NEUROL SCI, V35, P1421, DOI 10.1007/s10072-014-1774-9
   MANTYH PW, 1995, SCIENCE, V268, P1629, DOI 10.1126/science.7539937
   Marsala M, 1995, J NEUROSCI METH, V62, P43, DOI 10.1016/0165-0270(95)00053-4
   Marvizon JCG, 1997, J NEUROSCI, V17, P8129
   Nazarian A, 2008, NEUROSCIENCE, V152, P119, DOI 10.1016/j.neuroscience.2007.11.037
   Niu L, 2009, NEUROCHEM INT, V55, P542, DOI 10.1016/j.neuint.2009.05.010
   Nydahl KS, 2004, EUR J NEUROSCI, V19, P1789, DOI 10.1111/j.1460.9568.2004.03284.x
   Schechtmann G, 2008, PAIN, V139, P136, DOI 10.1016/j.pain.2008.03.023
   Stein C, 2009, BRAIN RES REV, V60, P90, DOI 10.1016/j.brainresrev.2008.12.017
   Storkson RV, 1996, J NEUROSCI METH, V65, P167, DOI 10.1016/0165-0270(95)00164-6
   Takasusuki T, 2011, ANESTHESIOLOGY, V115, P153, DOI 10.1097/ALN.0b013e31821950c2
   Xie H, 2008, ANESTH ANALG, V106, P1873, DOI 10.1213/ane.0b013e31817300be
   Yu L, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-61
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 24
TC 10
Z9 10
U1 2
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0197-0186
EI 1872-9754
J9 NEUROCHEM INT
JI Neurochem. Int.
PD MAR
PY 2015
VL 82
BP 1
EP 9
DI 10.1016/j.neuint.2015.01.004
PG 9
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA CE9NF
UT WOS:000352170000001
PM 25661513
DA 2018-12-27
ER

PT J
AU Zhang, ZJ
   Yan, ZY
   Yuan, Z
   Sun, YZ
   He, HF
   Mai, CY
AF Zhang, Zijie
   Yan, Zhenyu
   Yuan, Zheng
   Sun, Yanzhen
   He, Haifa
   Mai, Chunyang
TI RETRACTED: SPHK1 inhibitor suppresses cell proliferation and invasion
   associated with the inhibition of NF-kappa B pathway in hepatocellular
   carcinoma (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Hepatocellular carcinoma; Sphingosine kinase1; Microvessel density; DMS;
   Targeted therapy
ID SPHINGOSINE KINASE; CANCER-CELLS; APOPTOSIS
AB Sphingosine kinase 1 (SphK1) is an oncogenic enzyme promoting transformation, proliferation, and angiogenesis of a number of human tumors. However, its effect on hepatocellular carcinoma (HCC) behavior has not been fully clarified. The purpose of this study was to determine the correlation between HCC and SphK1, and to evaluate the effect of SphK1 inhibitor N,N-dimethylsphingosine (DMS) in HCC. The expression of SphK1 was measured in tissue samples from 76 HCC and paired adjacent noncancerous liver tissues (NT) by immunohistochemistry, quantitative real-time PCR, and Western blotting analysis. The effect of DMS was tested on HCC cells by evaluating cell viability in vitro. Transwell cell migration and invasion assay were carried out for functional analysis. Furthermore, Western blotting analysis was performed to examine the impact of DMS on the PI3K/Akt/NF-kB signaling. High expression of Sphk1 was observed in 84.21 % (64/76) of the HCC versus 15.79 % (12/76) of the adjacent non-tumorous liver tissues; the difference of Sphk1 expression between HCC and the adjacent non-tumorous liver tissues was statistically significant (P < 0.001). The results were confirmed by Western blot analyses and quantitative real-time PCR. DMS inhibited the proliferation of SK-Hep1 and MHCCLM3 cells which have a relatively high level of SphK1 in a time- and concentration-dependent manner, and the invasion and migration of SK-Hep1 cells were distinctly suppressed after undergoing treatment with DMS. Furthermore, DMS markedly suppressed the expression of phosphorylations of Akt and NF-kappa B in HCC cells. Our data suggest that the pathogenesis of human HCC maybe mediated by Sphk1, and the specific Sphk1 inhibitor DMS can play a therapeutic role in the treatment of HCC and thus, Sphk1 could represent selective targets for the molecularly targeted treatments of HCC.
C1 [Zhang, Zijie; Yan, Zhenyu; Yuan, Zheng; Sun, Yanzhen; He, Haifa; Mai, Chunyang] Cent Hosp Nanyang, Dept Pathol, Nanyang 473009, Peoples R China.
RP Zhang, ZJ (reprint author), Cent Hosp Nanyang, Dept Pathol, 312 Gongnong Rd, Nanyang 473009, Peoples R China.
EM zjzhang6@163.com
CR Ades S, 2009, ONCOLOGY-NY, V23, P162
   Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557
   Chen K, 2014, INT J MOL MED, V33, P17, DOI 10.3892/ijmm.2013.1541
   Frangov T, 2007, Khirurgiia (Sofiia), P36
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664
   Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200
   Nava VE, 2000, CANCER RES, V60, P4468
   Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658
   Pchejetski D, 2008, MOL CANCER THER, V7, P1836, DOI 10.1158/1535-7163.MCT-07-2322
   Pitson SM, 2011, ANTI-CANCER AGENT ME, V11, P799
   Schwartz GK, 1997, CLIN CANCER RES, V3, P537
   Song LB, 2011, CLIN CANCER RES, V17, P1839, DOI 10.1158/1078-0432.CCR-10-0720
   Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1
   Yang YB, 2007, SURGERY, V141, P196, DOI 10.1016/j.surg.2006.06.033
NR 15
TC 14
Z9 14
U1 3
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2015
VL 36
IS 3
BP 1503
EP 1509
DI 10.1007/s13277-014-2665-7
PG 7
WC Oncology
SC Oncology
GA CE5OC
UT WOS:000351884000021
PM 25537088
DA 2018-12-27
ER

PT J
AU Huang, JM
   Jia, JY
   Tong, Q
   Liu, J
   Qiu, J
   Sun, R
   Yao, LX
   Yang, C
AF Huang, Jinming
   Jia, Jiaoyuan
   Tong, Qiang
   Liu, Jun
   Qiu, Jun
   Sun, Rong
   Yao, Lixin
   Yang, Chun
TI RETRACTED: Knockdown of cancerous inhibitor of protein phosphatase 2A
   may sensitize metastatic castration-resistant prostate cancer cells to
   cabazitaxel chemotherapy (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Prostate cancer; Cancerous inhibitor of protein phosphatase 2A;
   Cabazitaxel; Small interfering RNA; Proliferation; Chemoresistance
ID BONE METASTASIS; DOCETAXEL; MITOXANTRONE; PREDNISONE; CARCINOMA
AB Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified human oncoprotein that can stabilize some proteins by inhibiting degradation mediated by protein phosphatase 2A (PP2A), and its level in cancer is associated with resistance to chemotherapy. However, whether CIP2A could increase chemoresistance of prostate cancer (PCa) cells to chemotherapeutic agent cabazitaxel remains unclear. To determine whether CIP2A serves as a potential therapeutic target of human PCa, we utilized small interference RNA (siRNA) to knock down CIP2A expression in human PCa cells and analyzed their phenotypic changes. The data demonstrated that CIP2A was significantly elevated in mCRPC cell lines C4-2 and ARCaP(M) at both the mRNA and protein levels. CIP2A silencing led to decreased proliferation and enhanced chemosensitivity and apoptosis to cabazitaxel in human PCa cells, as well as reduced Akt phosphorylation. Our data suggesting critical roles of CIP2A in PCa cells chemoresistance to cabazitaxel and raising the possibility of CIP2A inhibition as a promising approach for chemosensitization of metastatic castration-resistant prostate cancer (mCRPC).
C1 [Huang, Jinming; Tong, Qiang; Liu, Jun; Qiu, Jun; Sun, Rong; Yao, Lixin] 85 Hosp PLA, Dept Urol, Shanghai, Peoples R China.
   [Jia, Jiaoyuan] Jilin Univ, Hosp 2, Dept Hematol & Oncol, Changchun 130023, Peoples R China.
   [Yang, Chun] Nanjing Med Univ, Wuxi Peoples Hosp 2, Dept Urol, Nanjing, Jiangsu, Peoples R China.
RP Yao, LX (reprint author), 85 Hosp PLA, Dept Urol, Shanghai, Peoples R China.
EM dryaolx@163.com; yang-chun@126.com
FU National Natural Science Foundation of China [81202036, 31471033]
FX This study was supported by the grants from the National Natural Science
   Foundation of China (No. 81202036, 31471033)
CR Chen KF, 2010, ONCOGENE, V29, P6257, DOI 10.1038/onc.2010.357
   Chen M, 2014, CLIN CANCER RES, V20, P3057, DOI 10.1158/1078-0432.CCR-12-3680
   Choi YA, 2011, FEBS LETT, V585, P755, DOI 10.1016/j.febslet.2011.01.018
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
   Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   KEIZMAN D, 2012, AM J CLIN ONCOL-CANC, V37, P289
   Keizman D, 2012, AM J CLIN ONCOL-CANC, V37, P289
   Lassi K, 2010, CURR OPIN ONCOL, V22, P263, DOI 10.1097/CCO.0b013e3283380939
   Lheureux S, 2012, B CANCER, V99, P875, DOI 10.1684/bdc.2012.1617
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Pienta KJ, 2005, CA-CANCER J CLIN, V55, P300, DOI 10.3322/canjclin.55.5.300
   Qu YY, 2013, ASIAN J ANDROL, V15, P110, DOI 10.1038/aja.2012.110
   Ren SC, 2013, ASIAN J ANDROL, V15, P350, DOI 10.1038/aja.2013.37
   Seruga B, 2011, J CLIN ONCOL, V29, P3686, DOI 10.1200/JCO.2010.34.3996
   Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136
   Singh P, 2010, CANCER LETT, V293, P1, DOI 10.1016/j.canlet.2009.11.019
   Suzman DL, 2014, THER ADV MED ONCOL, V6, P167, DOI 10.1177/1758834014529176
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   THALMANN GN, 1994, CANCER RES, V54, P2577
   Wiegering A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075292
   Wu D, 2007, ONCOGENE, V26, P5070, DOI 10.1038/sj.onc.1210316
   Zhang SM, 2013, PROSTATE, V73, P1681, DOI 10.1002/pros.22705
NR 23
TC 4
Z9 7
U1 3
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2015
VL 36
IS 3
BP 1589
EP 1594
DI 10.1007/s13277-014-2748-5
PG 6
WC Oncology
SC Oncology
GA CE5OC
UT WOS:000351884000031
PM 25377160
DA 2018-12-27
ER

PT J
AU Liu, J
   Li, J
   Li, HL
   Li, AD
   Liu, B
   Han, L
AF Liu, Jie
   Li, Jun
   Li, Hali
   Li, Aidong
   Liu, Biou
   Han, Liou
TI RETRACTED: A comprehensive analysis of candidate genes and pathways in
   pancreatic cancer (Retracted article. See vol. 36, pg. 7327, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Pancreatic cancer; Pathway crosstalk; Protein-protein interaction;
   Differentially expressed genes; Gene ontology
ID NF-KAPPA-B; INTERACTION NETWORKS; PROBE LEVEL; CROSSTALK; RECEPTOR;
   ADENOCARCINOMA; PROGRESSION; CELL; INTERLEUKIN-6; ACTIVATION
AB The study aimed to dissect the molecular mechanism of pancreatic cancer by a range of bioinformatics approaches. Three microarray datasets (GSE32676, GSE21654, and GSE14245) were downloaded from Gene Expression Omnibus database. Differentially expressed genes (DEGs) with logarithm of fold change (|logFC|) > 0.585 and p value < 0.05 were identified between pancreatic cancer samples and normal controls. Transcription factors (TFs) were selected from the DEGs based on TRASFAC database. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed for the DEGs using The Database for Annotation, Visualization and Integrated Discovery (p value < 0.05), followed by construction of protein-protein interaction (PPI) network using Search Tool for the Retrieval of Interacting Genes software. Latent pathway identification analysis was applied to analyze the DEGs-related pathways crosstalk and the pathways with high weight value were included in the pathway crosstalk network using Cytoscape. Sixty-five DEGs were screened out. CCAAT/enhancer-binding protein delta (CEBPD), FBJ osteosarcoma oncogene B (FOSB), Stratifin (SFN), Kruppel-like factor 5 (KLF5), Pentraxin 3 (PTX3), and nuclear receptor subfamily 4, group A, member 3 (NR4A3) were important TFs. Interleukin-6 (IL-6) was the hub node of the PPI network. DEGs were significantly enriched in NOD-like receptor signaling pathway which was primarily interacted with inflammation and immune related pathways (cytosolic DNA-sensing, hematopoietic cell lineage, intestinal immune network for IgA production and chemokine pathways). The study suggested CEBPD, FOSB, SFN, KLF5, PTX3, NR4A3, IL-6, and NOD-like receptor pathways were involved in pancreatic cancer.
C1 [Liu, Jie; Li, Jun; Li, Hali; Li, Aidong; Liu, Biou; Han, Liou] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Harbin 150001, Peoples R China.
RP Liu, B (reprint author), Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, 23 youzheng St, Harbin 150001, Peoples R China.
EM WeidongZangwtr@163.com
FU Overseas Scholars Funds [1054HQ081]; National Natural Science Foundation
   of China [30340058]
FX This study was supported by Overseas Scholars Funds (grant no.
   1054HQ081) and National Natural Science Foundation of China (grant no.
   30340058).
CR Arakawa Kazuharu, 2005, In Silico Biology, V5, P419
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Basu A, 2006, CANCER RES, V66, P4309, DOI 10.1158/0008-5472.CAN-05-2657
   Becker AE, 2014, WORLD J GASTROENTERO, V20, P11182, DOI 10.3748/wjg.v20.i32.11182
   Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dima SO, 2012, PANCREAS, V41, P1001, DOI 10.1097/MPA.0b013e3182546e13
   Donahue TR, 2012, CLIN CANCER RES, V18, P1352, DOI 10.1158/1078-0432.CCR-11-1539
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Fukata M, 2009, SEMINARS IMMUNOLOGY
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Guan J, 2013, CANC LETT
   Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012
   Guweidhi A, 2004, CARCINOGENESIS, V25, P1575, DOI 10.1093/carcin/bgh159
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Hasegawa M, 2008, EMBO J, V27, P373, DOI 10.1038/sj.emboj.7601962
   Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999
   Huang MZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092161
   Huzarski T, 2005, BREAST CANCER RES TR, V89, P91, DOI 10.1007/s10549-004-1250-y
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Kim JH, 2010, TUMOR BIOL, V31, P541, DOI 10.1007/s13277-010-0067-z
   Lee SO, 2010, CANCER RES, V70, P6824, DOI 10.1158/0008-5472.CAN-10-1992
   Leek JT, 2007, SURROGATE VARIABLE A
   Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009
   Li Y, 2008, BIOINFORMATICS, V24, P1442, DOI 10.1093/bioinformatics/btn200
   Locatelli M, 2013, J NEUROIMMUNOL, V260, P99, DOI 10.1016/j.jneuroim.2013.04.009
   Loos M, 2008, ANN NY ACAD SCI, V1138, P169, DOI 10.1196/annals.1414.024
   Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797
   Maupin KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013002
   Moore F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031062
   Mori A, 2009, MOL CANCER RES, V7, P1390, DOI 10.1158/1541-7786.MCR-08-0525
   Pang H, 2006, BIOINFORMATICS, V22, P2028, DOI 10.1093/bioinformatics/btl344
   Papaconstantinou L, 2005, INT J CANCER, V114, P433, DOI 10.1002/ijc.20747
   Park JH, 2007, J IMMUNOL, V178, P2380, DOI 10.4049/jimmunol.178.4.2380
   Pham L, 2011, P NATL ACAD SCI USA, V108, P13347, DOI 10.1073/pnas.1100891108
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Rincon M, 2012, TRENDS IMMUNOL, V33, P571, DOI 10.1016/j.it.2012.07.003
   Seufferlein T, 2012, ANN ONCOL, V23, P33, DOI 10.1093/annonc/mds224
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Song JM, 2009, BIOINFORMATICS, V25, P3143, DOI 10.1093/bioinformatics/btp551
   Tsuji M, 2008, SEMINARS IMMUNOLOGY
   Wingender E, 2008, BRIEF BIOINFORM, V9, P326, DOI 10.1093/bib/bbn016
   Young SH, 2010, BIOCHEM BIOPH RES CO, V401, P154, DOI 10.1016/j.bbrc.2010.09.036
   Zhang L, 2010, GASTROENTEROLOGY, V138, P949, DOI 10.1053/j.gastro.2009.11.010
NR 46
TC 9
Z9 9
U1 2
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2015
VL 36
IS 3
BP 1849
EP 1857
DI 10.1007/s13277-014-2787-y
PG 9
WC Oncology
SC Oncology
GA CE5OC
UT WOS:000351884000060
PM 25409614
DA 2018-12-27
ER

PT J
AU Lin, ZY
   Song, QQ
   Chen, J
   Wan, RJ
   Zheng, H
   Chen, ZW
   Chen, YP
   Hua, WC
AF Lin, Zheng-Yu
   Song, Qian-Qian
   Chen, Jin
   Wan, Ren-Jun
   Zheng, Hui
   Chen, Zhong-Wu
   Chen, Yi-Ping
   Hua, Wang-Chun
TI RETRACTED: Local curative effect of MRI-guided radiofrequency ablation
   on small hepatocellular carcinoma (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Radiofrequency ablation; Small hepatocellular carcinoma; Magnetic
   resonance imaging; Ultrasound; Guidance
ID LIVER; ULTRASONOGRAPHY; METAANALYSIS; VESSELS; LESIONS
AB Radiofrequency ablation (RFA) is one of the treatment modes for liver cancer. The trauma caused by RFA is small, and its local curative effect is reliable. Computed tomography (CT) can only be used for axial scans, and parts of the lesion are unclear on plain scans. The aim of this study is to compare the local curative effect of RFA percutaneously guided by MRI and ultrasound for small hepatocellular carcinoma (HCC). This study is a retrospective study. In this study, we examined 60 cases of 88 liver lesions and 50 cases of 52 lesions, in which RFA was guided by MRI and ultrasound, respectively. All cases were clinically diagnosed. The therapeutic effect of ablation lesions was examined by postoperative imaging follow-up. The results indicated that there were 5 (5/88) recurrences of liver lesions with MRI-guided RFA and 14 (14/52) recurrences of liver lesions with ultrasound-guided RFA. The median time to recurrence in the case of recurrent lesions was 7 months. Postoperative ablation lesions showed a low-intensity signal surrounded by a thin high-intensity signal ring on T2WI images. On T1WI images, the ablation lesion showed a concentric pattern and the central area of the original lesion continued to show a low-intensity signal with a clear ring of high-intensity signal that had a clear boundary. In conclusion, the local curative effect of MRI-guided RFA for small HCC is superior to that of ultrasound-guided RFA.
C1 [Lin, Zheng-Yu; Song, Qian-Qian; Chen, Jin; Wan, Ren-Jun; Zheng, Hui; Chen, Zhong-Wu; Chen, Yi-Ping] Fujian Med Univ, Dept Intervent, Affiliated Hosp 1, Fuzhou 350005, Peoples R China.
   [Hua, Wang-Chun] Shaxian Hosp, Dept Radiol, Shaxian 365500, Peoples R China.
RP Lin, ZY (reprint author), Fujian Med Univ, Dept Intervent, Affiliated Hosp 1, 20 Chazhong Rd, Fuzhou 350005, Peoples R China.
EM lzyfujian@yeah.net
FU Natural Science Foundation of Fujian Province, China [2012J01337]; Key
   Project of Fujian Province Science and Technology, China [2013Y0036];
   Medical Elite Cultivation Program of Fujian, PRC [2013-ZQN-ZD-20]
FX This study was sponsored by the Natural Science Foundation of Fujian
   Province, China (2012J01337); the Key Project of Fujian Province Science
   and Technology, China (2013Y0036); and the Medical Elite Cultivation
   Program of Fujian, PRC (2013-ZQN-ZD-20).
CR [Anonymous], 2011, DIAGN THER CRIT PRIM
   Jiang GS, 2014, TUMOR BIOL, V35, P3405, DOI 10.1007/s13277-013-1449-9
   Khankan AA, 2008, J MAGN RESON IMAGING, V27, P546, DOI 10.1002/jmri.21050
   Kim YJ, 2013, ABDOM IMAGING, V38, P98, DOI 10.1007/s00261-012-9883-5
   Lin ZY, 2012, EUR J RADIOL, V81, P3079, DOI 10.1016/j.ejrad.2012.05.007
   Liu Y, 2014, TUMOR BIOL, V35, P8103, DOI 10.1007/s13277-014-2056-0
   Lu DSK, 2002, AM J ROENTGENOL, V178, P47, DOI 10.2214/ajr.178.1.1780047
   Lu DSK, 2005, RADIOLOGY, V234, P954, DOI 10.1148/radiol.2343040153
   Lu DSK, 2003, J VASC INTERV RADIOL, V14, P1267, DOI 10.1097/01.RVI.0000092666.72261.6B
   Ma XL, 2014, TUMOR BIOL, V35, P4489, DOI 10.1007/s13277-013-1591-4
   Niu YH, 2013, TUMOR BIOL, V34, P3667, DOI 10.1007/s13277-013-0948-z
   Rajesh S, 2013, J VASC INTERV RADIOL, V24, P1235, DOI 10.1016/j.jvir.2013.04.013
   Sironi S, 1999, AM J ROENTGENOL, V173, P1225, DOI 10.2214/ajr.173.5.10541093
NR 13
TC 3
Z9 3
U1 3
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2015
VL 36
IS 3
BP 2105
EP 2110
DI 10.1007/s13277-014-2819-7
PG 6
WC Oncology
SC Oncology
GA CE5OC
UT WOS:000351884000086
PM 25501700
DA 2018-12-27
ER

PT J
AU Khan, NM
   Khan, FA
   Mu, TH
   Khan, ZU
   Khan, M
   Ahmad, S
   Behram, T
AF Khan, Nasir Mehmood
   Khan, Farman Ali
   Mu, Tai-Hua
   Khan, Zia Ullah
   Khan, Midrarullah
   Ahmad, Shujaat
   Behram, Tayyeba
TI RETRACTED: POTENTIALITY OF NEEM (AZADIRACHTA INDICA) POWDER IN RHEOLOGY
   MODIFICATION OF OIL-IN-WATER EMULSION(Retracted article. See vol. 40,
   2017)
SO JOURNAL OF FOOD PROCESS ENGINEERING
LA English
DT Article; Retracted Publication
ID EMULSIONS; STABILITY
AB Rheology modification of the complex fluids has been addressed using the competency of the selected natural materials. This article reports the efficacy of the microparticles of the naturally available material neem (Azadirachta indica) powder as rheology modifier, which in turn offers better consistency, firmness, as well as nutrient value to the emulsions containing juice of Aloe barbadenisMiller, which can be effectively used for the preparation of foods, pharmaceuticals and personal care products. These results showed that the oil-water emulsions containing aloe vera juice emulsified with coconut milk protein exhibited useful dynamic viscoelastic behavior, with improved consistency and rheology because of the addition of microparticles of neem. Neem microparticles offered higher yield stress and apparent viscosity. This rheology modifier material can potentially eliminate or reduce the use of synthetic chemical thickeners, texturizers, etc.
   Practical ApplicationsThe present work on neem powder application in emulsion production provides a new direction for further fundamental research to explore the mechanism of interactions of such particles with the main phase of emulsions. Present findings demonstrate the design of novel emulsions, which offers additional value because of the high therapeutic, nutrient and medicinal characteristics of such materials of natural origin.
C1 [Khan, Nasir Mehmood; Khan, Midrarullah; Behram, Tayyeba] Shaheed Benazir Bhutto Univ Sheringal, Dept Biotechnol, Upper Dir, Khyber Pakhtunk, Pakistan.
   [Khan, Farman Ali] Shaheed Benazir Bhutto Univ Sheringal, Dept Chem, Upper Dir, Khyber Pakhtunk, Pakistan.
   [Ahmad, Shujaat] Shaheed Benazir Bhutto Univ Sheringal, Dept Pharm, Upper Dir, Khyber Pakhtunk, Pakistan.
   [Khan, Nasir Mehmood; Mu, Tai-Hua] Chinese Acad Agr Sci, Inst Agro Food Sci & Technol, Minist Agr, Key Lab Agroprod Proc, Beijing 100193, Peoples R China.
   [Khan, Zia Ullah] Zhejiang Univ, Coll Biosyst Engn & Food Sci, Hangzhou, Zhejiang, Peoples R China.
RP Khan, NM (reprint author), Shaheed Benazir Bhutto Univ Sheringal, Dept Biotechnol, Upper Dir, Khyber Pakhtunk, Pakistan.
EM nasirsikanderi@gmail.com
CR Altlng AC, 2003, J AGR FOOD CHEM, V51, P3150, DOI 10.1021/jf0209342
   BARNES HA, 1994, COLLOID SURFACE A, V91, P89, DOI 10.1016/0927-7757(93)02719-U
   Biswas K, 2002, CURR SCI INDIA, V82, P1336
   Bradtke B., 2013, DISCOVER NEEM, P76
   Chen J, 2011, COLLOID SURFACE A, V382, P238, DOI 10.1016/j.colsurfa.2011.02.003
   Chopra R. N., 1956, GLOSS IND MEDI 224 P
   Chopra RN, 1958, INDIGENOUS DRUGS IND, P51
   Frelichowska J, 2009, COLLOID SURFACE A, V343, P70, DOI 10.1016/j.colsurfa.2009.01.031
   Gilbert L, 2013, CHEMOMETR INTELL LAB, V124, P21, DOI 10.1016/j.chemolab.2013.03.002
   Kirtikar K. R., 1975, MED PLANTS, P536
   KOUL O, 1990, CAN J BOT, V68, P1, DOI 10.1139/b90-001
   Lad VN, 2013, J FOOD ENG, V115, P279, DOI 10.1016/j.jfoodeng.2012.10.036
   Lad VN, 2012, IND ENG CHEM RES, V51, P4222, DOI 10.1021/ie202764f
   McClements D. J., 2005, FOOD EMULSIONS PRINC
   Mitra C.R., 1963, NEEM, P69
   Otsubo Y, 1999, LANGMUIR, V15, P1960, DOI 10.1021/la9811362
   Pal R, 1996, AICHE J, V42, P3181, DOI 10.1002/aic.690421119
   Peixinho J, 2010, LANGMUIR, V26, P11699, DOI 10.1021/la101141j
   Rousseau D, 2013, CURR OPIN COLLOID IN, V18, P283, DOI 10.1016/j.cocis.2013.04.009
   Ruiz-Agudo E, 2010, LANGMUIR, V26, P3868, DOI 10.1021/la903430z
   Sherman P., 1964, RHEOLOGY EMULSION EM
   Tadros T, 2004, ADV COLLOID INTERFAC, V108, P227, DOI 10.1016/j.cis.2003.10.025
   Thakur R. S., 1981, JUSS REV CROMAP, V3, P135
   Varma G. S., 1976, MIRACLES NEEM TREE
NR 24
TC 1
Z9 1
U1 4
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-8876
EI 1745-4530
J9 J FOOD PROCESS ENG
JI J. Food Process Eng.
PD MAR
PY 2015
VL 38
IS 2
BP 190
EP 196
DI 10.1111/jfpe.12132
PG 7
WC Engineering, Chemical; Food Science & Technology
SC Engineering; Food Science & Technology
GA CE0YT
UT WOS:000351538100010
DA 2018-12-27
ER

PT J
AU Chuang, TY
   Jaw, JJ
AF Chuang, Tzu-Yi
   Jaw, Jen-Jer
TI RETRACTED: AUTOMATED 3D FEATURE MATCHING (Retracted article. See vol.
   31, pg. 8, 2016)
SO PHOTOGRAMMETRIC RECORD
LA English
DT Article; Retracted Publication
DE 3D; feature integration; feature matching; lidar; registration; spatial
   features
ID LIDAR POINT CLOUDS; SIMILARITY; REGISTRATION
AB Three-dimensional (3D) feature-matching techniques, which are essential for progress towards an automated feature-based procedure, have attracted considerable research attention in both the photogrammetry and computer vision communities. This study introduces a novel matching approach, called RSTG, that comprises four major phases: rotation alignment; scale estimation; translation alignment; and geometry checks. These steps efficiently determine a feature-based correspondence and frame transformation between datasets. RSTG analyses the similarity and relative geometry of features by employing feature observations and their uncertainty; this allows different types of features to be matched exclusively or simultaneously. This study validates the proposed method with both simulated and real datasets, demonstrating its effectiveness with satisfactory matching rates in a diverse range of feature-based point cloud registration tasks.
   ResumeLes techniques de mise en correspondance de primitives en 3D, qui sont essentielles pour le developpement d'une procedure automatisee basee sur les primitives, ont suscite des efforts de recherche dans les deux communautes de la photogrammetrie et de la vision par ordinateur. Cette etude presente une nouvelle approche d'appariement, appelee RSTG, qui comprend quatre phases principales: l'ajustement par rotation; l'estimation de l'echelle; l'ajustement par translation; et les controles geometriques. Ces etapes determinent efficacement une mise en correspondance et une transformation geometrique basees sur les primitives. La methode RSTG analyse la similitude et la geometrie relative des primitives en utilisant les observations des objets et leurs incertitudes; ce qui permet la mise en correspondance de differents types de primitives, separement ou simultanement. Cette etude valide la methode proposee a partir de donnees reelles et simulees, demontrant son efficacite avec des taux d'appariement satisfaisants dans un large eventail de travaux de mise en correspondance de nuages de points bases sur les primitives.
   ZusammenfassungFur die dreidimensionale, merkmalsgestutzte Zuordnung finden sowohl im Bereich der Photogrammetrie, als auch im Computervision Bereich umfangreiche Forschungsaktivitaten statt. In dieser Studie wird eine neuartige Bildzuordnungsmethode genannt RSTG vorgestellt. Sie besteht aus vier Hauptphasen: einer Rotationsschatzung, einer Ma ss stabsschatzung, einer Schatzung der Translation und einer letzte Phase mit geometrischen Kontrollen. Durch diese Schritte konnen auf effiziente Art eine merkmalsgestutzte Zuordnung und eine Transformation zwischen Datensatzen bestimmt werden. RSTG analysiert die Ahnlichkeit und die relative Geometrie von Merkmalen durch Anwendung von Merkmalsbeobachtungen und ihren Unsicherheiten. Damit konnen verschiedenartige Merkmale exklusiv oder simultan zugeordnet werden. Fur verschiedenartige Aufgabenstellungen der Registrierung von Punktwolken wird mit simulierten und realen Datensatzen die Effektivitat der vorgeschlagenen Methode validiert und dabei zufriedenstellende Zuordnungsraten erzielt.
   ResumenLas tecnicas de correspondencia de caracteristicas 3D, esenciales para el desarrollo de procedimientos automaticos, han atraido un considerable interes en la investigacion en fotogrametria y vision por ordenador. Este estudio presenta una novedosa aproximacion para la correspondencia, llamada RSTG, que consta de cuatro fases principales: la alineacion de rotacion; estimacion de la escala; traslacion de la alineacion; y comprobaciones de geometria. Estos pasos determinan de manera eficiente una correspondencia basada en caracteristicas y un marco de transformacion entre conjuntos de datos. RSTG analiza la geometria relativa y similitud de caracteristicas mediante el empleo de observaciones de caracteristicas y su incertidumbre; esto permite que diferentes tipos de caracteristicas puedan tener correspondientes exclusivos o simultaneos. Este estudio valida el metodo propuesto con conjuntos de datos simulados y reales, lo que demuestra su eficacia con tasas satisfactorias de correspondencia en una amplia gama de nubes de puntos.
   ?? ??????(3D feature matching)????????(feature-based)??????????????,??????????????????????????RSTG????????????????,??????????????????????RSTG???????????????,?????(rotation alignment)?????(scale estimation)?????(translation alignment)?????(geometry checks)????????????????????,RSTG???????????????????????,??????????????????,????????????????????????????RSTG????????,???????????????????????????????????
C1 [Chuang, Tzu-Yi; Jaw, Jen-Jer] Natl Taiwan Univ, Taipei 10764, Taiwan.
RP Chuang, TY (reprint author), Natl Taiwan Univ, Taipei 10764, Taiwan.
EM chuangtyj@gmail.com; jejaw@ntu.edu.tw
FU Ministry of Science and Technology, Taiwan, ROC [NSC 100-2221-E-002-216,
   98-2221-E-002-177-MY2]
FX The authors express the most sincere thanks to the Ministry of Science
   and Technology (formerly the National Science Council), Taiwan, ROC for
   granting this study through projects NSC 100-2221-E-002-216 and
   98-2221-E-002-177-MY2. In addition, this publication would not be
   possible without the constructive suggestions from two reviewers and
   tremendous efforts in polishing this paper by the editor, which are
   greatly appreciated.
CR Ankerst M, 1999, LECT NOTES COMPUT SC, V1651, P207
   ARUN KS, 1987, IEEE T PATTERN ANAL, V9, P699, DOI 10.1109/TPAMI.1987.4767965
   Belongie S, 2001, 8 INT C COMP VIS, V1, P454
   Chen DY, 2003, COMPUT GRAPH FORUM, V22, P223, DOI 10.1111/1467-8659.00669
   Chua CS, 1997, INT J COMPUT VISION, V25, P63, DOI 10.1023/A:1007981719186
   Chuang T. Y., 2012, THESIS NATL TAIWAN U
   Eden I, 2008, LECT NOTES COMPUT SC, V5305, P172, DOI 10.1007/978-3-540-88693-8_13
   Gal R, 2006, ACM T GRAPHIC, V25, P130, DOI 10.1145/1122501.1122507
   Gelfand N., 2005, S GEOM PROC, V2, P197
   Gruen A, 2005, ISPRS J PHOTOGRAMM, V59, P151, DOI 10.1016/j.isprsjprs.2005.02.006
   Han JY, 2013, TUNN UNDERGR SP TECH, V33, P186, DOI 10.1016/j.tust.2012.08.008
   Heczko M., 2002, DATENBANK SPEKTRUM, V2, P54
   Heuel S, 2001, PROC CVPR IEEE, P517
   Jaw JJ, 2010, INT ARCH PHOTOGRAMM, V38, P60
   Jaw JJ, 2008, J CHIN INST ENG, V31, P1031, DOI 10.1080/02533839.2008.9671456
   KAMGARPARSI B, 2011, IEEE C COMP VIS PATT, P2425
   Kim CS, 2011, J HIGH ENERGY PHYS, DOI 10.1007/JHEP11(2011)003
   Li X., 2005, P 3 EUR S GEOM PROC, V242, P217
   XU Z, 2000, INT ARCH PHOTOGRAMME, V33, P1000
NR 19
TC 4
Z9 4
U1 2
U2 21
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-868X
EI 1477-9730
J9 PHOTOGRAMM REC
JI Photogramm. Rec.
PD MAR
PY 2015
VL 30
IS 149
BP 8
EP 29
DI 10.1111/phor.12089
PG 22
WC Geography, Physical; Geosciences, Multidisciplinary; Remote Sensing;
   Imaging Science & Photographic Technology
SC Physical Geography; Geology; Remote Sensing; Imaging Science &
   Photographic Technology
GA CD9CS
UT WOS:000351395400002
DA 2018-12-27
ER

PT J
AU Lee, HB
AF Lee, Hang Bok
TI RETRACTED: DNAPL Migration in a Rough Fracture Under Various Wettability
   and Flow Conditions (Retracted article. See vol. 109, pg. 799, 2015)
SO TRANSPORT IN POROUS MEDIA
LA English
DT Article; Retracted Publication
DE Wettability; DNAPL migration; Groundwater flow condition; MIP model;
   Flow regime
ID WALLED FRACTURES; CRUDE-OIL; SIMULATIONS; SANDSTONE; SYSTEMS; ROCK
AB We conducted laboratory experiments to investigate the influence of surface wettability on Dense Nonaqueous Phase Liquid (DNAPL) migration in a rough-walled fracture at various groundwater flow conditions. A glass replica of a granite sample containing a rough-walled single fracture was made, and DNAPL migration experiments were carried out with the replica whose surface wettability was controlled by using several NAPL exposures. In the experiments, we observed different migration paths of DNAPL among the hydrophilic, weakly hydrophobic, and strongly hydrophobic surfaces in the linear flow regime, whereas there was little difference in the nonlinear flow regime. The modified invasion percolation model was used to analyze the quantitative influence of the wettability change and groundwater flow on DNAPL migration paths in a rough-walled fracture, and suggested that the wettability is important to determine the DNAPL migration path in the linear flow regime but inertial force of groundwater becomes strong enough to overcome the influence of the wettability in the nonlinear flow regime.
C1 Korea Inst Geosci & Mineral Resources, Underground Space Dept, Taejon 305350, South Korea.
RP Lee, HB (reprint author), Korea Inst Geosci & Mineral Resources, Underground Space Dept, Taejon 305350, South Korea.
EM leehb@kigam.re.kr
FU Basic Research Project of the Korea Institute of Geoscience and Mineral
   Resources (KIGAM); Ministry of Science, ICT and Future Planning of Korea
FX This research was supported by the Basic Research Project of the Korea
   Institute of Geoscience and Mineral Resources (KIGAM) and funded by the
   Ministry of Science, ICT and Future Planning of Korea.
CR Amro MM, 2004, CHEM ENG TECHNOL, V27, P890, DOI 10.1002/ceat.200401977
   Amundsen H, 1999, WATER RESOUR RES, V35, P2619, DOI 10.1029/1999WR900147
   Bergslien E, 2006, J CONTAM HYDROL, V88, P153, DOI 10.1016/j.jconhyd.2006.06.009
   Brush DJ, 2003, WATER RESOUR RES, V39, DOI 10.1029/2002WR001346
   Buckley J.S., 1989, SPE RESERVOIR ENG, V4, P332, DOI DOI 10.2118/16964-PA
   Graue A, 1999, J PETROL SCI ENG, V24, P85, DOI 10.1016/S0920-4105(99)00033-9
   Harrold G, 2001, ENVIRON SCI TECHNOL, V35, P1504, DOI 10.1021/es0000504
   Jadhunandan P.P., 1991, SPE 66 ANN TECHN C E
   JADHUNANDAN PP, 1995, SPE RESERVOIR ENG, V10, P40, DOI 10.2118/22597-PA
   Kervin J., 1997, PATE VERRE KILN CAST
   Lord DL, 1997, ENVIRON SCI TECHNOL, V31, P2052, DOI 10.1021/es9608555
   MORROW NR, 1986, SPE FORMATION EVAL, V1, P89, DOI DOI 10.2118/13215-PA
   Powers S.E., 1996, J ENV ENG, V122, P1915
   Reynolds DA, 2002, GROUND WATER, V40, P368, DOI 10.1111/j.1745-6584.2002.tb02515.x
   Su GW, 1999, WATER RESOUR RES, V35, P1019, DOI 10.1029/1998WR900127
   Tang G.Q., 1996, SPE 66 ANN TECHN C E
   Zheng JZ, 2001, J COLLOID INTERF SCI, V244, P365, DOI 10.1006/jcis.2001.7934
NR 17
TC 1
Z9 1
U1 1
U2 24
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0169-3913
EI 1573-1634
J9 TRANSPORT POROUS MED
JI Transp. Porous Media
PD MAR
PY 2015
VL 107
IS 2
BP 321
EP 333
DI 10.1007/s11242-014-0438-9
PG 13
WC Engineering, Chemical
SC Engineering
GA CD9DV
UT WOS:000351398700002
DA 2018-12-27
ER

PT J
AU Buttar, HM
AF Buttar, Haroon Muzaffar
TI RETRACTED: formation of entrepreneurial career intentions: the role of
   sociocognitive factors(Retracted article. See vol.53,pg.144,2016)
SO JOURNAL OF EMPLOYMENT COUNSELING
LA English
DT Article; Retracted Publication
DE entrepreneurial career intention; social capital; theory of planned
   behavior
ID SELF-EFFICACY; PLANNED BEHAVIOR; SOCIAL-PSYCHOLOGY; VENTURE CREATION;
   MODELS; DETERMINANTS; EMBEDDEDNESS; MOTIVATION; FRAMEWORK
AB An individual's intention to enter into an entrepreneurial career in the future is a complex phenomenon. Existing cognitive models of entrepreneurial intention ignore the significant role of social conditions of an individual. In this article, the author incorporates social capital into a cognitive entrepreneurial intention model based on the theory of planned behavior. Using a sample of 636 Turkish and Pakistani undergraduate business students, the author finds that social capital shapes the entrepreneurial intentions of young people through the cognitive infrastructure. This study contributes to determining the influences of social and cognitive factors on the entrepreneurial intention process.
C1 Yildirim Beyazit Univ, Sch Business, Ankara, Turkey.
RP Buttar, HM (reprint author), Yildirim Beyazit Univ, Sch Business, 16 Guven Mahallesi,Cinnah Caddesi, Ankara, Turkey.
EM hmuzaffer@ybu.edu.tr
CR Ajzen I, 2005, HANDBOOK OF ATTITUDES, P173
   AJZEN I, 1987, ADV EXP SOC PSYCHOL, V20, P1, DOI 10.1016/S0065-2601(08)60411-6
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Ajzen I, 1980, UNDERSTANDING ATTITU
   Ajzen I., 2000, EUROPEAN REV SOCIAL, V11, P1, DOI DOI 10.1080/14792779943000116
   Armitage CJ, 2001, BRIT J SOC PSYCHOL, V40, P471, DOI 10.1348/014466601164939
   Autio E., 2001, ENTERPRISE INNOVATIO, V2, P145, DOI DOI 10.1080/14632440110094632
   Bamberg S, 2003, BASIC APPL SOC PSYCH, V25, P175, DOI 10.1207/S15324834BASP2503_01
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037//0033-295X.84.2.191
   Bandura A., 1997, SELF EFFICACY EXERCI
   Baron RA, 2004, J BUS VENTURING, V19, P221, DOI 10.1016/S0883-9026(03)00008-9
   Begley TM, 2001, J INT BUS STUD, V32, P537, DOI 10.1057/palgrave.jibs.8490983
   BIRD B, 1988, ACAD MANAGE REV, V13, P442, DOI 10.2307/258091
   Boyd N. G., 1994, ENTREP THEORY PRACT, V18, P63, DOI DOI 10.1177/104225879401800404
   Bruderl J, 1998, SMALL BUS ECON, V10, P213, DOI 10.1023/A:1007997102930
   Coleman J. S., 1990, FDN SOCIAL THEORY
   DAVIDSSON P, 1991, J BUS VENTURING, V6, P405, DOI 10.1016/0883-9026(91)90028-C
   Davidsson P, 2003, J BUS VENTURING, V18, P301, DOI 10.1016/S0883-9026(02)00097-6
   Davidsson P., 1995, RENT 9 C PIAZ IT
   De Carolis DM, 2006, ENTREP THEORY PRACT, V30, P41, DOI 10.1111/j.1540-6520.2006.00109.x
   De Noble A. F., 1999, FRONTIERS ENTREPRENE
   Elfving J., 2009, UNDERSTANDING ENTREP, P23, DOI DOI 10.1007/978-1-4419-0443-0_2
   Fitzsimmons JR, 2011, J BUS VENTURING, V26, P431, DOI 10.1016/j.jbusvent.2010.01.001
   FORNELL C, 1981, J MARKETING RES, V18, P39, DOI 10.2307/3151312
   GECAS V, 1989, ANNU REV SOCIOL, V15, P291, DOI 10.1146/annurev.so.15.080189.001451
   Gelderen M, 2008, CAREER DEV INT, V13, P538, DOI DOI 10.1108/13620430810901688
   Glaser B. G., 1967, DISCOVERY GROUNDED T
   Hair Jr J. F., 1998, MULTIVARIATE DATA AN
   Harman H. H, 1976, MODERN FACTOR ANAL
   HARVEY M, 1995, J BUS VENTURING, V10, P331, DOI 10.1016/0883-9026(95)00037-9
   Hindle K, 2010, ENTREP REGION DEV, V22, P599, DOI 10.1080/08985626.2010.522057
   Hindle Kevin, 2009, UNDERSTANDING ENTREP, P35, DOI DOI 10.1007/978-1-4419-0443-0_3
   Jones M. A., 2000, J SERV MARK, V14, P147, DOI DOI 10.1108/08876040010371555
   Joreskog K. G., 1993, LISREL 8 STRUCTURAL
   Kickul J, 2009, ENTREP THEORY PRACT, V33, P439, DOI 10.1111/j.1540-6520.2009.00298.x
   Kolvereid L., 1996, ENTREP THEORY PRACT, V21, P23
   Kolvereid L, 2006, J BUS VENTURING, V21, P866, DOI 10.1016/j.jbusvent.2005.06.008
   KRUEGER Jr N. F., 1993, ENTREP THEORY PRACT, V18, P5
   Krueger N.F., 2006, USASBE C TUSC AZ
   Krueger NF, 2000, J BUS VENTURING, V15, P411, DOI 10.1016/S0883-9026(98)00033-0
   Kuckertz A, 2010, J BUS VENTURING, V25, P524, DOI 10.1016/j.jbusvent.2009.09.001
   Li J, 2001, J PSYCHOL, V135, P501, DOI 10.1080/00223980109603715
   Liao JW, 2005, J SMALL BUS MANAGE, V43, P345, DOI 10.1111/j.1540-627X.2005.00141.x
   Linan F, 2011, ENTREP REGION DEV, V23, P187, DOI 10.1080/08985620903233929
   Linan F, 2007, INT ADV ECON RES, V13, P443, DOI 10.1007/s11294-007-9109-8
   Linan F, 2009, ENTREP THEORY PRACT, V33, P593, DOI 10.1111/j.1540-6520.2009.00318.x
   Moriano JA, 2012, J CAREER DEV, V39, P162, DOI 10.1177/0894845310384481
   Na EY, 1998, J CROSS CULT PSYCHOL, V29, P595, DOI 10.1177/0022022198295001
   Nahapiet J, 1998, ACAD MANAGE REV, V23, P242, DOI 10.2307/259373
   Oinas P, 1999, GEOFORUM, V30, P351, DOI 10.1016/S0016-7185(99)00026-3
   Onyx J., 2000, J APPL BEHAV SCI, V36, P23, DOI [10.1177/0021886300361002, DOI 10.1177/0021886300361002]
   PORTES A, 1993, AM J SOCIOL, V98, P1320, DOI 10.1086/230191
   Portes A, 1998, ANNU REV SOCIOL, V24, P1, DOI 10.1146/annurev.soc.24.1.1
   Reitan B, 1997, ICSB WORLD C SAN FRA
   Schermelleh-Engel K., 2003, METHODS PSYCHOL RES, V8, P23, DOI DOI 10.1002/0470010940
   Schwenk G, 2009, QUAL QUANT, V43, P743, DOI 10.1007/s11135-007-9162-7
   Shapero A., 1982, ENCY ENTREPRENEURSHI, P72
   Shepherd D., 2002, ENTREPRENEURIAL THEO, V27, P167, DOI DOI 10.1111/1540-8520.00005
   Steel P, 2006, ACAD MANAGE REV, V31, P889, DOI 10.5465/AMR.2006.22527462
   STEIGER JH, 1990, MULTIVAR BEHAV RES, V25, P173, DOI 10.1207/s15327906mbr2502_4
   The Global Entrepreneurship Monitor, 2010, ENTR TURK
   TUBBS ME, 1991, ACAD MANAGE REV, V16, P180, DOI 10.2307/258611
   Wheaton B., 1977, SOCIOL METHODOL, P84, DOI DOI 10.2307/270754
   Widaman KF, 2003, PSYCHOL METHODS, V8, P16, DOI 10.1037/1082-989X.8.1.16
   Wilson F, 2007, ENTREP THEORY PRACT, V31, P387, DOI 10.1111/j.1540-6520.2007.00179.x
   Zhao H, 2005, J APPL PSYCHOL, V90, P1265, DOI 10.1037/0021-9010.90.6.1265
NR 66
TC 5
Z9 5
U1 2
U2 38
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-0787
EI 2161-1920
J9 J EMPLOYMENT COUNS
JI J. Employ. Couns.
PD MAR
PY 2015
VL 52
IS 1
BP 2
EP 17
DI 10.1002/j.2161-1920.2015.00052.x
PG 16
WC Psychology, Applied
SC Psychology
GA CC7JB
UT WOS:000350542400001
DA 2018-12-27
ER

PT J
AU Ai, F
   Chen, MH
   Li, W
   Yang, Y
   Xu, GZ
   Gui, F
   Liu, ZX
   Bai, XY
   Chen, Z
AF Ai, Fen
   Chen, Manhua
   Li, Wei
   Yang, Yang
   Xu, Guizhong
   Gui, Feng
   Liu, Zhenxing
   Bai, Xiangyan
   Chen, Zhen
TI RETRACTED: Protective role of Klotho on cardiomyocytes upon
   hypoxia/reoxygenation via downregulation of Akt and FOXO1
   phosphorylation (Retracted article. See vol. 11, pg. 4009, 2015)
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article; Retracted Publication
DE Klotho; hypoxia/reoxygenation; cardiomyocyte; forkhead box protein O1;
   Akt
ID MYOCARDIAL ISCHEMIA/REPERFUSION INJURY; OXIDATIVE STRESS;
   CARDIAC-HYPERTROPHY; EXPRESSION; RESISTANCE; INFARCTION; PATHWAY; KIDNEY
AB Klotho is a novel anti-aging hormone involved in human coronary artery disease. The present study aimed to detect the effects and mechanism of Klotho on cardiomyocytes in a hypoxia/reoxygenation (H/R) model in vitro. Neonatal Sprague-Dawley rat cardiomyocytes were randomly distributed into experimental groups as follows: Control group; H/R group, 4-h hypoxia followed by 3-h reoxygenation; and. H/R+Klotho group, incubated with 0.1, 0.2 or 0.4 mu g/ml Klotho protein for 16 h and then subjected to 4-h hypoxia/3-h reoxygenation. In order to evaluate cardiomyocyte damage, cell viability and lactate dehydrogenase (LDH) levels were measured. Cell apoptosis was measured by flow cytometry. The 2',7'-dichlorofluorescein diacetate reagent was used to estimate the intracellular generation of reactive oxygen species (ROS). Immunofluorescence staining was used to test whether Klotho induced decreased nuclear translocation of forkhead box protein O1 (FOXO1). Western blot analysis was performed to detect protein levels of FOXO1, phospho-FOXO1, Akt, phospho-Akt and superoxide dismutase 2 (SOD2). Cell viability was significantly decreased, levels of LDH in the cardiomyocyte culture medium were significantly increased and the apoptotic rate was enhanced in the H/R group when compared with those of the control group. Compared with the H/R group, cell viability of the H/R+Klotho groups was significantly higher (P<0.05). Treatment with Klotho protein resulted in a significant resistance of cardiomyocytes to apoptosis and the release of LDH was decreased. Intracellular ROS levels in the H/R group were significantly elevated above those of the control group (P<0.05). Following treatment with Klotho, intracellular ROS levels were significantly decreased compared with those of the H/R group (P<0.05). Western blot analysis confirmed that Klotho protein treatment increased FOXO1 levels in the nucleus and decreased FOXO1 levels in the cytoplasm. Furthermore, exogenous Klotho protein promoted translocation of FOXO1 from cytoplasm to nucleus. In addition, the administration of Klotho protein suppressed phosphorylation of FOXO1 and Akt, and markedly increased the protein expression levels of SOD2. In conclusion, treatment with Klotho protein had beneficial effects on cardiomyocytes undergoing H/R injury. The mechanism of this effect may be associated with suppressed apoptosis of cardiomyocytes, inhibition of phosphorylation of FOXO1 and Akt as well as suppression of cytoplasm transfer of FOXO1.
C1 [Ai, Fen; Li, Wei; Yang, Yang; Xu, Guizhong; Gui, Feng; Liu, Zhenxing; Bai, Xiangyan; Chen, Zhen] Huazhong Univ Sci & Technol, Dept Emergency, Cent Hosp Wuhan, Tongji Med Coll, Wuhan 430014, Hubei, Peoples R China.
   [Chen, Manhua] Huazhong Univ Sci & Technol, Dept Cardiol, Cent Hosp Wuhan, Tongji Med Coll, Wuhan 430014, Hubei, Peoples R China.
RP Chen, Z (reprint author), Huazhong Univ Sci & Technol, Dept Emergency, Cent Hosp Wuhan, Tongji Med Coll, 26 Shengli St, Wuhan 430014, Hubei, Peoples R China.
EM c_z_s_s_@163.com
FU Natural Science Foundation of Hubei Province [2012FFA107]
FX The authors would like to thank all members of the Department of
   Emergency (The Central Hospital of Wuhan, Wuhan, China) for their expert
   technical assistance and advice. The present study was supported by
   grants from the Natural Science Foundation of Hubei Province (no.
   2012FFA107).
CR Adijiang A, 2011, J RENAL NUTR, V21, P105, DOI 10.1053/j.jrn.2010.10.020
   Arslan F, 2013, STEM CELL RES, V10, P301, DOI 10.1016/j.scr.2013.01.002
   Berg K, 2005, FREE RADICAL RES, V39, P629, DOI 10.1080/1071570400028027
   Cai Y, 2014, MOL MED REP, V9, P1542, DOI 10.3892/mmr.2014.2034
   Chateau MT, 2010, AGING-US, V2, P567, DOI 10.18632/aging.100195
   Fan YH, 2010, J CARDIOVASC PHARM, V55, P489, DOI 10.1097/FJC.0b013e3181d706ae
   Fujita J, 2007, STEM CELLS, V25, P2750, DOI 10.1634/stemcells.2007-0275
   Guo J, 2013, ATHEROSCLEROSIS, V231, P384, DOI 10.1016/j.atherosclerosis.2013.10.003
   Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015
   Huang H, 2010, HYPERTENSION, V56, P232, DOI 10.1161/HYPERTENSIONAHA.110.149963
   Ikushima M, 2006, BIOCHEM BIOPH RES CO, V339, P827, DOI 10.1016/j.bbrc.2005.11.094
   Jiang DS, 2013, HYPERTENSION, V61, P1193, DOI 10.1161/HYPERTENSIONAHA.111.00614
   Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285
   Lauten A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092833
   Li SA, 2004, CELL STRUCT FUNCT, V29, P91, DOI 10.1247/csf.29.91
   Lorenzi O, 2010, PFLUG ARCH EUR J PHY, V459, P465, DOI 10.1007/s00424-009-0735-2
   Mitobe M, 2005, NEPHRON EXP NEPHROL, V101, pE67, DOI 10.1159/00086500
   Nagasu H, 2011, BIOCHEM BIOPH RES CO, V407, P39, DOI 10.1016/j.bbrc.2011.02.089
   Qiao X, 2013, AM J PHYSIOL-RENAL, V304, pF112, DOI 10.1152/ajprenal.00054.2012
   Slagsvold KH, 2014, CIRC RES, V114, P851, DOI 10.1161/CIRCRESAHA.114.302751
   Turan K, 2011, GENET MOL RES, V10, P2009, DOI 10.4238/vol10-3gmr1261
   Wang K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043922
   Wang Y, 2013, EXP THER MED, V5, P315, DOI 10.3892/etm.2012.766
   Xiao NM, 2004, CHINESE MED J-PEKING, V117, P742
   Yamamoto M, 2005, J BIOL CHEM, V280, P38029, DOI 10.1074/jbc.M509039200
   Yang JJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020219
   Zhong Xiaozheng, 2012, J Biomed Res, V26, P346, DOI 10.7555/JBR.26.20110124
NR 27
TC 3
Z9 3
U1 4
U2 32
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2015
VL 11
IS 3
BP 2013
EP 2019
DI 10.3892/mmr.2014.2899
PG 7
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA CD2OA
UT WOS:000350917700065
PM 25377663
OA Bronze
DA 2018-12-27
ER

PT J
AU Tang, JB
   Liu, XY
   Peng, J
   Tang, Y
   Zhang, Y
AF Tang, Jingbo
   Liu, Xingyan
   Peng, Jian
   Tang, Yong
   Zhang, Yang
TI RETRACTED: Genome sequence and genome mining of a marine-derived
   antifungal bacterium Streptomyces sp M10 (Retracted article. See vol.
   100, pg. 519, 2016)
SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE Streptomyces sp M10; Genome mining; Secondary metabolites; Polyketide
   synthase; Polyene
ID ARGANIA-SPINOSA L; RHIZOSPHERE SOIL; NATURAL-PRODUCTS; DISCOVERY;
   METABOLITES; SALINISPORA; STRATEGIES; DATABASE; STRAINS; COMPLEX
AB A marine-derived actinobacteria Streptomyces sp. M10 was identified as a prolific antifungal compounds producer and shared a 99.02 % 16S ribosomal RNA (rRNA) sequence similarity with that of Streptomyces marokkonensis Ap1(T), which can produce polyene macrolides. To further evaluate its biosynthetic potential, the 7,207,169 bp Streptomyces sp. M10 linear chromosome was sequenced and mined for identifiable secondary metabolite-associated gene clusters. A total of 20 secondary metabolite-associated gene clusters were deduced, including three polyketide synthases (PKSs), four non-ribosomal peptide synthetases (NRPSs), four hybrid NRPS-PKSs, three NRPS-independent siderophores, and two lantibiotic and four terpene biosynthetic gene clusters. One of the type I PKS gene cluster, pks1, shared a 85 % nucleotide similarity with candicidin/FR008 gene cluster, indicating the capacity of this organism to produce polyene macrolides. This assumption was verified by a scale-up culturing of Streptomyces sp. M10 on A1 agar plates, which lead to the isolation of two polyene families PF1 and PF2, with characteristic UV adsorption at 269, 278, and 290 nm (PF1) and 363, 386, and 408 nm (PF2), respectively. Compound 9-04 was further purified from PF1, and its chemical structure was partially elucidated to be a typical polyene macrolide by NMR and UV spectrum. This study affirmatively identified Streptomyces sp. M10 as a source of polyene metabolites and highlighted genome mining of interested organism as a powerful tool for natural product discovery.
C1 [Tang, Jingbo; Peng, Jian; Zhang, Yang] Cent S Univ, Xiangya Hosp, Hepatobiliary & Enter Surg Res Ctr, Changsha 410008, Hunan, Peoples R China.
   [Tang, Jingbo; Liu, Xingyan] Guangdong Med Coll, China Amer Canc Res Inst, Dongguan, Peoples R China.
   [Tang, Jingbo; Tang, Yong] Cent S Univ, Xiangya Sch Med, Inst Biomed Engn, Changsha 410008, Hunan, Peoples R China.
RP Peng, J (reprint author), Cent S Univ, Xiangya Hosp, Hepatobiliary & Enter Surg Res Ctr, Changsha 410008, Hunan, Peoples R China.
EM pengjian_csu@163.com
FU National Natural Science Foundation of China [30672047]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 30672047).
CR Barreiro C, 2012, J BACTERIOL, V194, P3756, DOI 10.1128/JB.00692-12
   Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a
   Berdy J, 2005, J ANTIBIOT, V58, P1, DOI 10.1038/ja.2005.1
   Blin K, 2013, NUCLEIC ACIDS RES, V41, pW204, DOI 10.1093/nar/gkt449
   Blunt JW, 2013, NAT PROD REP, V30, P237, DOI 10.1039/c2np20112g
   Bouizgarne B, 2006, WORLD J MICROB BIOT, V22, P423, DOI 10.1007/s11274-005-9051-y
   Bouizgarne B, 2009, INT J SYST EVOL MICR, V59, P2857, DOI 10.1099/ijs.0.011387-0
   Carver T, 2008, BIOINFORMATICS, V24, P2672, DOI 10.1093/bioinformatics/btn529
   Chen S, 2003, CHEM BIOL, V10, P1065, DOI 10.1016/j.chembiol.2003.10.007
   Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159
   Corre C, 2009, NAT PROD REP, V26, P977, DOI 10.1039/b713024b
   Dong YS, 2006, J NAT PROD, V69, P128, DOI 10.1021/np0502894
   DUTCHER JD, 1963, J ORG CHEM, V28, P995, DOI 10.1021/jo01039a029
   Fukuda T, 2003, J ANTIBIOT, V56, P454, DOI 10.7164/antibiotics.56.454
   Helfrich EJN, 2014, CURR OPIN BIOTECH, V29, P107, DOI 10.1016/j.copbio.2014.03.004
   Hyatt D, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-119
   Ishikawa J, 2004, P NATL ACAD SCI USA, V101, P14925, DOI 10.1073/pnas.0406410101
   Kim DG, 2012, J NAT PROD, V75, P959, DOI 10.1021/np3001915
   Kim OS, 2012, INT J SYST EVOL MICR, V62, P716, DOI 10.1099/ijs.0.038075-0
   Komaki H, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-323
   Kwon HC, 2009, J ORG CHEM, V74, P675, DOI 10.1021/jo801944d
   Lautru S, 2005, NAT CHEM BIOL, V1, P265, DOI 10.1038/nchembio731
   Li RQ, 2008, BIOINFORMATICS, V24, P713, DOI 10.1093/bioinformatics/btn025
   Malin G, 1996, J BACTERIOL, V178, P385, DOI 10.1128/jb.178.2.385-395.1996
   MARGALITH P., 1960, MYCOPATHOL ET MYCOL APPL, V13, P321, DOI 10.1007/BF02089930
   Nett M, 2009, NAT PROD REP, V26, P1362, DOI 10.1039/b817069j
   Ohnishi Y, 2008, J BACTERIOL, V190, P4050, DOI 10.1128/JB.00204-08
   Omura S, 2001, P NATL ACAD SCI USA, V98, P12215, DOI 10.1073/pnas.211433198
   OURA M, 1955, Antibiot Annu, V3, P566
   Rebets Y, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-885
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   Scheffler RJ, 2013, APPL MICROBIOL BIOT, V97, P969, DOI 10.1007/s00253-012-4609-8
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Udwary DW, 2007, P NATL ACAD SCI USA, V104, P10376, DOI 10.1073/pnas.0700962104
   Yoshikawa K, 2000, APPL ENVIRON MICROB, V66, P718, DOI 10.1128/AEM.66.2.718-722.2000
   Zerikly M, 2009, CHEMBIOCHEM, V10, P625, DOI 10.1002/cbic.200800389
   Ziemert N, 2014, P NATL ACAD SCI USA, V111, pE1130, DOI 10.1073/pnas.1324161111
NR 38
TC 6
Z9 7
U1 2
U2 45
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0175-7598
EI 1432-0614
J9 APPL MICROBIOL BIOT
JI Appl. Microbiol. Biotechnol.
PD MAR
PY 2015
VL 99
IS 6
BP 2763
EP 2772
DI 10.1007/s00253-015-6453-0
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA CC4YJ
UT WOS:000350362500026
PM 25687447
DA 2018-12-27
ER

PT J
AU Glance, LG
   Kellermann, AL
   Hannan, EL
   Fleisher, LA
   Eaton, MP
   Dutton, RP
   Lustik, SJ
   Li, Y
   Dick, AW
AF Glance, Laurent G.
   Kellermann, Arthur L.
   Hannan, Edward L.
   Fleisher, Lee A.
   Eaton, Michael P.
   Dutton, Richard P.
   Lustik, Stewart J.
   Li, Yue
   Dick, Andrew W.
TI RETRACTED: The Impact of Anesthesiologists on Coronary Artery Bypass
   Graft Surgery Outcomes (Retracted article. See vol. 122, pg. 1730, 2016)
SO ANESTHESIA AND ANALGESIA
LA English
DT Article; Retracted Publication
ID NEW-YORK-STATE; HEALTH-CARE; AMERICAN-COLLEGE; ADVERSE EVENTS; PATIENT
   SAFETY; QUALITY; MORTALITY; PERFORMANCE; HOSPITALS; VOLUME
AB BACKGROUND: One of every 150 hospitalized patients experiences a lethal adverse event; nearly half of these events involves surgical patients. Although variations in surgeon performance and quality have been reported in the literature, less is known about the influence of anesthesiologists on outcomes after major surgery. Our goal of this study was to determine whether there is significant variation in outcomes between anesthesiologists after controlling for patient case mix and hospital quality.
   METHODS: Using clinical data from the New York State Cardiac Surgery Reporting System, we conducted a retrospective observational study of 7920 patients undergoing isolated coronary artery bypass graft surgery. Multivariable logistic regression modeling was used to examine the variation in death or major complications (Q-wave myocardial infarction, renal failure, stroke) across anesthesiologists, controlling for patient demographics, severity of disease, comorbidities, and hospital quality.
   RESULTS: Anesthesiologist performance was quantified using fixed-effects modeling. The variability across anesthesiologists was highly significant (P < 0.001). Patients managed by low-performance anesthesiologists (corresponding to the 25th percentile of the distribution of anesthesiologist risk-adjusted outcomes) experienced nearly twice the rate of death or serious complications (adjusted rate 3.33%; 95% confidence interval [CI], 3.09%-3.58%) as patients managed by high-performance anesthesiologists (corresponding to the 75th percentile) (adjusted rate 1.82%; 95% CI, 1.58%-2.10%). This performance gap was observed across all patient risk groups.
   CONCLUSIONS: The rate of death or major complications among patients undergoing coronary artery bypass graft surgery varies markedly across anesthesiologists. These findings suggest that there may be opportunities to improve perioperative management to improve outcomes among high-risk surgical patients.
C1 [Glance, Laurent G.; Eaton, Michael P.; Lustik, Stewart J.] Univ Rochester, Sch Med, Dept Anesthesiol, Rochester, NY 14642 USA.
   [Li, Yue] Univ Rochester, Sch Med, Dept Publ Hlth Sci, Rochester, NY 14642 USA.
   [Glance, Laurent G.; Dick, Andrew W.] RAND, RAND Hlth, Boston, MA USA.
   [Kellermann, Arthur L.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Bethesda, MD 20814 USA.
   [Hannan, Edward L.] SUNY Albany, Sch Publ Hlth, Albany, NY 12222 USA.
   [Fleisher, Lee A.] Univ Penn Hlth Syst, Dept Anesthesiol & Crit Care, Philadelphia, PA USA.
   [Dutton, Richard P.] Anesthesia Qual Inst, Park Ridge, IL USA.
RP Glance, LG (reprint author), Univ Rochester, Med Ctr, Dept Anesthesiol, 601 Elmwood Ave,Box 604, Rochester, NY 14642 USA.
EM laurent_glance@urmc.rochester.edu
FU Department of Anesthesiology at the University of Rochester School of
   Medicine
FX Funding: This project was supported with funding from the Department of
   Anesthesiology at the University of Rochester School of Medicine.
CR [Anonymous], 2009, CARD SURG REP AD INS
   BEECHER HK, 1954, ANN SURG, V140, P2, DOI 10.1097/00000658-195407000-00001
   Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205
   Birkmeyer JD, 2013, NEW ENGL J MED, V369, P1434, DOI 10.1056/NEJMsa1300625
   Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281
   Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106
   Chen LM, 2013, MED CARE, V51, P832, DOI 10.1097/MLR.0b013e31829fa92a
   de Vries EN, 2008, QUAL SAF HEALTH CARE, V17, P216, DOI 10.1136/qshc.2007.023622
   DEANDA A, 1991, ANESTH ANALG, V72, P308
   DeLong ER, 1997, STAT MED, V16, P2645, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2645::AID-SIM696>3.0.CO;2-D
   Devereaux PJ, 2012, ANESTHESIOLOGY, V116, P1169, DOI 10.1097/ALN.0b013e31825037bc
   Dimick JB, 2013, ANN SURG, V257, P67, DOI 10.1097/SLA.0b013e31827b6be6
   Gaba DM, 2000, BRIT MED J, V320, P785, DOI 10.1136/bmj.320.7237.785
   Gawande AA, 1999, SURGERY, V126, P66, DOI 10.1067/msy.1999.98664
   Glance LG, 2014, ANN SURG, V259, P682, DOI 10.1097/SLA.0000000000000334
   Glance LG, 2011, ANESTH ANALG, V112, P958, DOI 10.1213/ANE.0b013e31820e778d
   Glance LG, 2010, MED CARE, V48, P466, DOI 10.1097/MLR.0b013e3181d568f7
   Gurses AP, 2012, BMJ QUAL SAF, V21, P810, DOI 10.1136/bmjqs-2011-000625
   Hall BL, 2009, ANN SURG, V250, P363, DOI 10.1097/SLA.0b013e3181b4148f
   Hannan EL, 2012, J AM COLL CARDIOL, V59, P2309, DOI 10.1016/j.jacc.2011.12.051
   HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209
   Hunt LP, 2013, LANCET, V382, P1097, DOI 10.1016/S0140-6736(13)61749-3
   Jha AK, 2006, HEALTH AFFAIR, V25, P844, DOI 10.1377/hlthaff.25.3.844
   Kohn LT, 2000, ERR IS HUMAN BUILDIN
   Krumholz HM, 2006, CIRCULATION, V113, P456, DOI 10.1161/CIRCULATIONAHA.105.170769
   Lagasse RS, 2002, ANESTHESIOLOGY, V97, P1609, DOI 10.1097/00000542-200212000-00038
   MERRY AF, 1992, BRIT J ANAESTH, V68, P6, DOI 10.1093/bja/68.1.6
   Mukamel DB, 2010, AM J PUBLIC HEALTH, V100, P264, DOI 10.2105/AJPH.2008.153759
   Murdoch TB, 2013, JAMA-J AM MED ASSOC, V309, P1351, DOI 10.1001/jama.2013.393
   Ross JS, 2013, JAMA-J AM MED ASSOC, V309, P1355, DOI 10.1001/jama.2013.1299
   ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270
   Sessler DI, 2009, ANESTHESIOLOGY, V111, P1, DOI 10.1097/ALN.0b013e3181a913e1
   Shahian DM, 2009, ANN THORAC SURG, V88, pS2, DOI 10.1016/j.athoracsur.2009.05.053
   SILBER JH, 1992, MED CARE, V30, P615, DOI 10.1097/00005650-199207000-00004
   Silber JH, 2002, ANESTHESIOLOGY, V96, P1044, DOI 10.1097/00000542-200205000-00004
   SLOGOFF S, 1985, ANESTHESIOLOGY, V62, P107, DOI 10.1097/00000542-198502000-00002
   WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934
NR 37
TC 57
Z9 59
U1 2
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-2999
J9 ANESTH ANALG
JI Anesth. Analg.
PD MAR
PY 2015
VL 120
IS 3
BP 526
EP 533
DI 10.1213/ANE.0000000000000522
PG 8
WC Anesthesiology
SC Anesthesiology
GA CB8CM
UT WOS:000349856000010
PM 25695571
DA 2018-12-27
ER

PT J
AU Zong, HF
   Zhang, Y
   You, Y
   Cai, TT
   Wang, YH
AF Zong, Haifeng
   Zhang, Yang
   You, Yong
   Cai, Tiantian
   Wang, Yehuang
TI RETRACTED: Decreased Warburg effect induced by ATP citrate lyase
   suppression inhibits tumor growth in pancreatic cancer (Retracted
   article. See vol. 32, pg. 243, 2015)
SO MEDICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE ACLY; Pancreatic cancer; Growth; Warburg effect
ID CELL-GROWTH; METABOLISM; PATHWAYS; ACTIVATION; TARGETS; ENZYMES
AB ATP citrate lyase (ACLY) is responsible for the conversion of cytosolic citrate into acetyl-CoA and oxaloacetate, and the first rate-limiting enzyme involved in de novo lipogenesis. Recent studies have demonstrated that inhibition of elevated ACLY results in growth arrest and apoptosis in a subset of cancers; however, the expression pattern and underlying biological function of ACLY in pancreatic ductal adenocarcinoma (PDAC) remains unclear. In the current study, overexpressed ACLY was more commonly observed in PDAC compared to normal pancreatic tissues. Kaplan-Meier survival analysis showed that high expression level of ACLY resulted in a poor prognosis of PDAC patients. Silencing of endogenous ACLY expression by siRNA in PANC-1 cells led to reduced cell viability and increased cell apoptosis. Furthermore, significant decrease in glucose uptake and lactate production was observed after ACLY was knocked down, and this effect was blocked by 2-deoxy-D-glucose, indicating that ACLY functions in the Warburg effect affect PDAC cell growth. Collectively, this study reveals that suppression of ACLY plays an anti-tumor role through decreased Warburg effect, and ACLY-related inhibitors might be potential therapeutic approaches for PDAC.
C1 [Zong, Haifeng; Zhang, Yang; Cai, Tiantian; Wang, Yehuang] Nanjing Municipal Hosp TCM, Dept Anorectal Surg, Nanjing 210001, Jiangsu, Peoples R China.
   [You, Yong] Zhangjiagang Wandong Anorectal Hosp, Zhangjiagang 215600, Peoples R China.
RP Wang, YH (reprint author), Nanjing Municipal Hosp TCM, Dept Anorectal Surg, 1 Jinling Rd, Nanjing 210001, Jiangsu, Peoples R China.
EM yehuangwang@126.com
FU Health Bureau of Nanjing, China [ZKX12040]
FX This research is supported by Health Bureau of Nanjing, China (Grant No.
   ZKX12040).
CR Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773
   Beckner ME, 2010, INT J CANCER, V126, P2282, DOI 10.1002/ijc.24918
   Beigneux AP, 2004, J BIOL CHEM, V279, P9557, DOI 10.1074/jbc.M310512200
   Finley LWS, 2013, CELL METAB, V17, P466, DOI 10.1016/j.cmet.2013.02.016
   Gao YJ, 2014, CANCER LETT, V349, P15, DOI 10.1016/j.canlet.2014.03.015
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008
   Lancet Oncology, 2014, LANCET ONCOL, V15, P241, DOI 10.1016/S1470-2045(14)70097-X
   Lee JH, 2015, FEBS J, V282, P361, DOI 10.1111/febs.13139
   MacDonald MJ, 2009, DIABETOLOGIA, V52, P1087, DOI 10.1007/s00125-009-1319-6
   MacDonald MJ, 2007, J BIOL CHEM, V282, P30596, DOI 10.1074/jbc.M702732200
   Mashima T, 2009, BRIT J CANCER, V100, P1369, DOI 10.1038/sj.bjc.6605007
   Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235
   Migita T, 2013, AM J PATHOL, V182, P1800, DOI 10.1016/j.ajpath.2013.01.048
   Potapova IA, 2000, BIOCHEMISTRY-US, V39, P1169, DOI 10.1021/bi992159y
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Turyn J, 2003, HORM METAB RES, V35, P565, DOI 10.1055/s-2003-43500
   Varis A, 2002, CANCER RES, V62, P2625
   WARBURG O, 1956, SCIENCE, V124, P269, DOI 10.1126/science.124.3215.267
   WATSON JA, 1969, ARCH BIOCHEM BIOPHYS, V135, P209, DOI 10.1016/0003-9861(69)90532-3
   Yancy Haile F, 2007, J Carcinog, V6, P8
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112
   Zhou YF, 2013, MOL CANCER THER, V12, P2782, DOI 10.1158/1535-7163.MCT-13-0098
NR 24
TC 4
Z9 5
U1 2
U2 15
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD MAR
PY 2015
VL 32
IS 3
AR 85
DI 10.1007/s12032-015-0540-z
PG 7
WC Oncology
SC Oncology
GA CC0WP
UT WOS:000350060000047
PM 25701462
DA 2018-12-27
ER

PT J
AU Zhang, Q
   Tang, QC
   Qin, DD
   Yu, L
   Huang, R
   Lv, GX
   Zou, ZX
   Jiang, XC
   Zou, CD
   Liu, W
   Luo, J
   Zhao, ZX
   Muhammad, S
   Wang, GY
   Chen, YG
   Wang, XS
AF Zhang, Qian
   Tang, Qingchao
   Qin, Dandan
   Yu, Lei
   Huang, Rui
   Lv, Guixiang
   Zou, Zhaoxia
   Jiang, Xiao-chen
   Zou, Chendan
   Liu, Wei
   Luo, Jing
   Zhao, Zhixun
   Muhammad, Shan
   Wang, Guiyu
   Chen, Ying-gang
   Wang, Xishan
TI RETRACTED: Role of MicroRNA 30a Targeting Insulin Receptor Substrate 2
   in Colorectal Tumorigenesis(Retracted article. See vol.37, UNSP e00246,
   2017)
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article; Retracted Publication
ID BREAST-CANCER METASTASIS; CELL LUNG-CANCER; HEPATOCELLULAR-CARCINOMA;
   SIGNALING PATHWAY; TUMOR-GROWTH; EXPRESSION; INVASION; PROTEIN;
   PROGRESSION; SIGNATURES
AB MicroRNAs (miRNAs) are dysregulated in many types of malignant diseases, including colorectal cancer. miRNA 30a (miR-30a) is a member of the miR-30 family and has been implicated in many types of cancers. In this study, we determined the expression of miR-30a in human colon cancer tissues and cell lines. miR-30a was found to be significantly downregulated in both the tissues and cell lines. Furthermore, overexpression of miR-30a inhibited, while silencing of miR-30a promoted, cell proliferation, migration, and invasion in vitro. Consistently, stable overexpression of miR-30a suppressed the growth of colon cancer cell xenografts in vivo. Moreover, bioinformatic algorithms and luciferase reporter assays revealed that insulin receptor substrate 2 (IRS2) is a direct target of miR-30a. Further functional studies suggested that repression of IRS2 by miR-30a partially mediated the tumor suppressor effect of miR-30a. In addition, miR-30a inhibited constitutive phosphorylation of Akt by targeting IRS2. Additionally, clinicopathological analysis indicated that miR-30a has an inverse correlation with the staging in patients with colon cancer. Taken together, our study provides the first evidence that miR-30a suppressed colon cancer cell growth through inhibition of IRS2. Thus, miR-30a might serve as a promising therapeutic strategy for colon cancer treatment.
C1 [Zhang, Qian; Tang, Qingchao; Yu, Lei; Huang, Rui; Zhao, Zhixun; Muhammad, Shan; Wang, Guiyu; Chen, Ying-gang; Wang, Xishan] Harbin Med Univ, Affiliated Hosp 2, Dept Colorectal Canc Surg, Harbin, Heilongjiang, Peoples R China.
   [Zhang, Qian; Tang, Qingchao; Yu, Lei; Huang, Rui; Zhao, Zhixun; Muhammad, Shan; Wang, Guiyu; Chen, Ying-gang; Wang, Xishan] Harbin Med Univ, Colorectal Canc Inst, Harbin, Heilongjiang, Peoples R China.
   [Qin, Dandan] Harbin Med Univ, Affiliated Hosp 2, Dept Nephrol, Harbin, Heilongjiang, Peoples R China.
   [Lv, Guixiang; Zou, Zhaoxia; Jiang, Xiao-chen; Zou, Chendan; Liu, Wei; Luo, Jing] Harbin Med Univ, Dept Biochem & Mol Biol, Harbin, Heilongjiang, Peoples R China.
RP Wang, XS (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Colorectal Canc Surg, Harbin, Heilongjiang, Peoples R China.
EM wxshan1208@126.com
CR Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Arndt GM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-374
   Baraniskin A, 2012, CARCINOGENESIS, V33, P732, DOI 10.1093/carcin/bgs020
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bjornholm M, 2002, DIABETOLOGIA, V45, P1697, DOI 10.1007/s00125-002-0945-z
   Blaskovich MA, 2003, CANCER RES, V63, P1270
   Boissan M, 2005, AM J PATHOL, V167, P869, DOI 10.1016/S0002-9440(10)62058-5
   Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160
   Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101
   Chan SH, 2014, ONCOGENE, V33, P4496, DOI 10.1038/onc.2014.10
   Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30
   Cheng CW, 2012, BREAST CANCER RES TR, V134, P1081, DOI 10.1007/s10549-012-2034-4
   Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879
   Day E, 2013, INT J EXP PATHOL, V94, P203, DOI 10.1111/iep.12021
   Fernandez S, 2014, ONCOGENE, P0
   Gao L, 2014, ONCOTARGET, V5, P2562, DOI 10.18632/oncotarget.1812
   Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577
   Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006
   Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027
   Gibson SL, 2007, CELL CYCLE, V6, P631, DOI 10.4161/cc.6.6.3987
   Hsu YL, 2013, ONCOGENE, V32, P4436, DOI 10.1038/onc.2012.444
   Hu ZB, 2010, J CLIN ONCOL, V28, P1721, DOI 10.1200/JCO.2009.24.9342
   Ichikawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031422
   Judd LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095993
   Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11
   Kornmann M, 1998, CANCER RES, V58, P4250
   Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218
   Lavan BE, 1997, J BIOL CHEM, V272, P11439
   Li N, 2012, CANCER RES, V72, P154, DOI 10.1158/0008-5472.CAN-11-2484
   Li XH, 2010, GUT, V59, P579, DOI 10.1136/gut.2008.175497
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   Lips EH, 2007, J PATHOL, V212, P269, DOI 10.1002/path.2180
   Liu N, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70102-X
   Madhunapantula Subbarao V, 2011, Enzyme Res, V2011, P327923, DOI 10.4061/2011/327923
   Martin ES, 2007, CANCER RES, V67, P10736, DOI 10.1158/0008-5472.CAN-07-2742
   Monzo M, 2008, CELL RES, V18, P823, DOI 10.1038/cr.2008.81
   Quintavalle C, 2013, ONCOGENE, V32, P4001, DOI 10.1038/onc.2012.410
   Sarver AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-401
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0
   SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0
   Tian D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031965
   Visone R, 2007, ONCOGENE, V26, P7590, DOI 10.1038/sj.onc.1210564
   Wang YH, 2014, BIOCHEM BIOPH RES CO, V444, P199, DOI 10.1016/j.bbrc.2014.01.028
   Wu FT, 2009, CLIN CANCER RES, V15, P1550, DOI 10.1158/1078-0432.CCR-08-0820
   Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107
   Yao J, 2010, HEPATOLOGY, V51, P846, DOI 10.1002/hep.23443
   Zhang N, 2014, ONCOGENE, V33, P3119, DOI 10.1038/onc.2013.286
   Zhong M, 2013, CELL PHYSIOL BIOCHEM, V31, P209, DOI 10.1159/000343362
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
NR 52
TC 42
Z9 43
U1 2
U2 14
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD MAR
PY 2015
VL 35
IS 6
BP 988
EP 1000
DI 10.1128/MCB.01242-14
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA CB9KS
UT WOS:000349951100006
PM 25582198
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Labite, HE
   Cummins, E
AF Labite, Herve E.
   Cummins, Enda
TI RETRACTED: Development of a screening tool to assess the temporal risk
   of pesticides leaching to groundwater using the source, target, vector
   approach. An Irish case study for shallow groundwater (Retracted
   article. See vol. 187, 533, 2015)
SO ENVIRONMENTAL MONITORING AND ASSESSMENT
LA English
DT Article; Retracted Publication
DE Screening tool; Score; Pesticide; Monte Carlo; Groundwater
   contamination; Risk assessment
ID SENSITIVITY-ANALYSIS; ORGANIC-MATTER; SURFACE WATERS; SOIL; DEGRADATION;
   UNCERTAINTY; TEMPERATURE; POLLUTION; MODEL; SUSTAINABILITY
AB During this study, a groundwater screening tool was developed to assess the temporal risk of groundwater contamination from the use of pesticides. It is based on a source, vector, target approach. The method utilised in this study uses a semi-quantitative probabilistic risk assessment where the input parameters were classified and assigned a relative score from 1 to 5 (i.e. 1=no risk and 5=high risk). The model was parameterised by using national data and calibrated with 2 years of national pesticide groundwater monitoring data. After calibration, two specific sites were selected for model validation. Based on the presence of the source, vector and target, the evaluation indicated that the temporal risk is site specific (i.e. May to December for the country model, June to September for the Oak Park site and September for the Castledockrell site). A sensitivity analysis performed on the national scale revealed that the groundwater vulnerability category (gv), the clay content (cc%), the persistence of pesticides in soil (DT50) and the rainfall represented by wet day (wd) were the most important parameters that affected model predictions (correlation coefficients of 0.54, -0.39, 0.35 and 0.31, respectively), highlighting the importance of soil hydrogeological conditions, soil type and rainfall in influencing water model predictions. The model developed can help to identify the temporal risk from pesticides to groundwater and guide regulators in highlighting at-risk periods, therefore allowing more focused monitoring programmes.
C1 [Labite, Herve E.; Cummins, Enda] Univ Coll Dublin, UCD Sch Biosyst Engn, Coll Engn & Architecture, Dublin 4, Ireland.
RP Cummins, E (reprint author), Univ Coll Dublin, UCD Sch Biosyst Engn, Coll Engn & Architecture, Dublin 4, Ireland.
EM labher@yahoo.fr; enda.cummins@ucd.ie
CR Accinelli C, 2002, AGRONOMIE, V22, P399, DOI 10.1051/agro:2002018
   Ali M, 2014, CHEMOSPHERE, V102, P68, DOI 10.1016/j.chemosphere.2013.12.022
   ALLEN R, 1987, PESTIC SCI, V18, P95, DOI 10.1002/ps.2780180204
   Arias-Estevez M, 2008, AGR ECOSYST ENVIRON, V123, P247, DOI 10.1016/j.agee.2007.07.011
   Brennan FP, 2010, APPL ENVIRON MICROB, V76, P1449, DOI 10.1128/AEM.02335-09
   Carter AD, 2000, WEED RES, V40, P113, DOI 10.1046/j.1365-3180.2000.00157.x
   Chapman D., 1996, GUIDE USE BIOTA SEDI
   ChemSpider, 2014, DAT SOURC
   DAFF, 2004, PEST US SURV AR CROP
   DAFF, 2010, SOIL ORG MATT MAINT
   DAFF Department of Agriculture Fisheries and Food, 2003, PEST US SURV GRASSL
   Castillo MD, 2007, J AGR FOOD CHEM, V55, P5725, DOI 10.1021/jf0707637
   Dubus IG, 2003, SCI TOTAL ENVIRON, V317, P53, DOI 10.1016/S0048-9697(03)00362-0
   Dubus IG, 2002, J ENVIRON QUAL, V31, P227
   Dungan RS, 2001, PEST MANAG SCI, V57, P1107, DOI 10.1002/ps.400
   ECPA, 2008, COUNT ILL PEST
   ECPA European Crop Protection Association, 2008, COUNT PEST EUR
   EPA, 2011, GROUNDW QUAL IR
   EPA, 2009, PROV QUAL DRINK WAT
   EPA, 2012, GROUNDW MON
   EPA Environmental Protection Agency, 2008, DRINK WAT REG GUID, V4. 22
   Fageria NK, 2012, COMMUN SOIL SCI PLAN, V43, P2063, DOI 10.1080/00103624.2012.697234
   Farenhorst A, 2006, SOIL SCI SOC AM J, V70, P1005, DOI 10.2136/sssaj2005.0158
   Fleiss J., 1986, DESIGN ANAL CLIN EXP
   FOOTPRINT, 2006, FOOTPRINT PEST PROP
   Forester D. L., 2000, WATER QUALITY CREDIT
   Gardiner M. J., 1980, SOIL SURVEY B, V36
   Griffini O, 1997, B ENVIRON CONTAM TOX, V59, P202, DOI 10.1007/s001289900465
   GSI Geological Survey of Ireland, 2012, GROUNDW PROT SCHEM, P4
   GUSTAFSON DI, 1989, ENVIRON TOXICOL CHEM, V8, P339, DOI 10.1897/1552-8618(1989)8[339:GUSASM]2.0.CO;2
   HAMBY DM, 1994, ENVIRON MONIT ASSESS, V32, P135, DOI 10.1007/BF00547132
   Kellogg RL, 2000, ENV INDICATORS PESTI
   Konstantinou IK, 2006, ENVIRON POLLUT, V141, P555, DOI 10.1016/j.envpol.2005.07.024
   Labite H, 2012, HUM ECOL RISK ASSESS, V18, P1156, DOI 10.1080/10807039.2012.722797
   Labite H., 2011, HUM ECOL RISK ASSESS, V17, P1
   LARSON SJ, 1999, 984222 US GEOL SURV
   Li H, 2007, PEST MANAG SCI, V63, P1116, DOI 10.1002/ps.1431
   McManus S. L., 2012, THESIS TRINITY COLL
   Met Eireann (the Irish National Meteorological Service), 2013, CLIM DAT PROD
   Misstear B., 2007, 2002 W MS 16 RECHARG
   Misstear BDR, 2009, HYDROGEOL J, V17, P693, DOI 10.1007/s10040-008-0376-0
   Oliver DP, 2012, AGR WATER MANAGE, V106, P60, DOI 10.1016/j.agwat.2011.06.004
   Pahl-Wostl C, 2008, ECOL SOC, V13
   Pavlis M, 2010, HUM ECOL RISK ASSESS, V16, P621, DOI 10.1080/10807031003788881
   Piwowarczyk A., 2013, THESIS U COLL DUBLIN
   Planas C, 1997, CHEMOSPHERE, V34, P2393, DOI 10.1016/S0045-6535(97)00085-4
   Quevauviller P., 2005, J ENVIRON MONITOR, V7, P02
   Rodger C, 1999, UNCERTAINTY RISK ANA
   Samadder S. R., 2010, WATER ENV RES, V82
   SHOOK G, 1993, J ENVIRON MANAGE, V37, P201, DOI 10.1006/jema.1993.1016
   SMITH AE, 1992, RISK ANAL, V12, P467, DOI 10.1111/j.1539-6924.1992.tb00703.x
   Soderman P, 2001, CLIN ORTHOP RELAT R, P189
   Tani K, 2012, WATER RES, V46, P741, DOI 10.1016/j.watres.2011.11.036
   ter Laak TL, 2012, SCI TOTAL ENVIRON, V427, P308, DOI 10.1016/j.scitotenv.2012.04.013
   THURMAN EM, 1991, ENVIRON SCI TECHNOL, V25, P1794, DOI 10.1021/es00022a018
   Tiktak A, 2006, J ENVIRON QUAL, V35, P1213, DOI 10.2134/jeq2005.0377
   TURNER BL, 1990, GLOBAL ENVIRON CHANG, V1, P14, DOI 10.1016/0959-3780(90)90004-S
   UNESCO, 2002, IHP VI SER GROUNDW, V2
   USEPA, 2014, ECOTOX DAT
   van Alphen BJ, 2002, J ENVIRON QUAL, V31, P797, DOI 10.2134/jeq2002.0797
   Vose D., 2008, RISK ANAL QUANTITATI
   Wang JJ, 2012, SCI TOTAL ENVIRON, V432, P216, DOI 10.1016/j.scitotenv.2012.06.005
   Wu JQ, 1999, J ENVIRON QUAL, V28, P92, DOI 10.2134/jeq1999.00472425002800010010x
   Xiao LH, 2004, CLIN MICROBIOL REV, V17, P72, DOI 10.1128/CMR.17.1.72-97.2004
NR 64
TC 2
Z9 2
U1 3
U2 25
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6369
EI 1573-2959
J9 ENVIRON MONIT ASSESS
JI Environ. Monit. Assess.
PD MAR
PY 2015
VL 187
IS 3
AR 91
DI 10.1007/s10661-015-4325-9
PG 17
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA CB2CS
UT WOS:000349434900036
PM 25663403
DA 2018-12-27
ER

PT J
AU Amouch, M
   Benharrat, M
   Messirdi, B
AF Amouch, M.
   Benharrat, M.
   Messirdi, B.
TI RETRACTED: Spectral mapping theorem for generalized Kato spectrum
   (Retracted article. See vol. 433, pg. 747, 2016)
SO JOURNAL OF MATHEMATICAL ANALYSIS AND APPLICATIONS
LA English
DT Article; Retracted Publication
DE Pseudo Fredholm operators; Generalized Kato decomposition;
   Quasi-nilpotent part; Analytical core; Quasi-normally decomposable
   operators; Spectral mapping theorem
ID FREDHOLM OPERATORS; DECOMPOSITION; RESOLVENT
AB In this paper, we give an affirmative answer to Mbekhta's conjecture (Mbekhta, 1990 [13]) about the pseudo Fredholm operators in Hilbert space. As a consequence, we characterize pseudo Fredholm operators and we prove that the generalized Kato spectrum satisfies the spectral mapping theorem in the Hilbert spaces setting. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Amouch, M.] Univ Chouaib Doukkali, Fac Sci, Dept Math & Informat, El Jadida, Morocco.
   [Benharrat, M.] Natl Polytech Sch, Dept Math & Informat, Oran, Algeria.
   [Messirdi, B.] Univ Oran, Dept Math, Oran, Algeria.
RP Amouch, M (reprint author), Univ Chouaib Doukkali, Fac Sci, Dept Math & Informat, BP 20, El Jadida, Morocco.
EM amouch.m@ucd.ac.ina; mohammed.benharrat@gmail.com;
   messirdi.bekkai@univ-oran.dz
CR Aiena P., 2004, FREDHOLM LOCAL SPECT
   Benharrat M, 2011, SERDICA MATH J, V37, P283
   Berkani M, 2000, STUD MATH, V140, P163
   Berkani M, 1997, P AM MATH SOC, V125, P763, DOI 10.1090/S0002-9939-97-03431-X
   Berkani M, 2002, P AM MATH SOC, V130, P1717, DOI 10.1090/S0002-9939-01-06291-8
   Berkani M, 1999, INTEGR EQUAT OPER TH, V34, P244, DOI 10.1007/BF01236475
   Jiang QF, 2012, FRONT MATH CHINA, V7, P695, DOI 10.1007/s11464-012-0207-4
   Jiang QF, 2009, J MATH ANAL APPL, V356, P322, DOI 10.1016/j.jmaa.2009.03.017
   Kordula V, 1996, P AM MATH SOC, V124, P3055, DOI 10.1090/S0002-9939-96-03306-0
   Labrousse J.P, 1980, REND CIRC MATH PAL 2, V29, P161
   MBEKHTA M, 1990, J OPERAT THEOR, V24, P255
   MBEKHTA M, 1989, J OPERAT THEOR, V21, P69
   MBEKHTA M, 1987, GLASGOW MATH J, V29, P159, DOI 10.1017/S0017089500006807
   VRBOVA P, 1973, CZECH MATH J, V23, P483
NR 14
TC 2
Z9 2
U1 1
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-247X
EI 1096-0813
J9 J MATH ANAL APPL
JI J. Math. Anal. Appl.
PD MAR 1
PY 2015
VL 423
IS 1
BP 1
EP 9
DI 10.1016/j.jmaa.2014.09.043
PG 9
WC Mathematics, Applied; Mathematics
SC Mathematics
GA CB5ZH
UT WOS:000349706000001
DA 2018-12-27
ER

PT J
AU Hasheminezhad, A
AF Hasheminezhad, Araz
TI RETRACTED: Analytical study on longitudinal crack control for B70
   mono-block pre-stressed concrete sleepers (Retracted article. See vol.
   72, pg. 92, 2017)
SO ENGINEERING FAILURE ANALYSIS
LA English
DT Article; Retracted Publication
DE Pre-stressed concrete sleepers; Railway; Tensile stress; Longitudinal
   crack; Pre-stressing force
AB The B70 mono-block pre-stressed concrete sleeper is one of the most widely used types of concrete sleepers for railways. One of the most important defects of this type of sleepers is longitudinal cracks both before and during railway track operation, which usually begins at the rawlplugs positions and continues up to the central and regional area of the sleeper. In this research, creation of longitudinal cracks before track operation has been studied. For this purpose, effects of exerted applied loads on the sleeper including pre-stressed loading and cylindrical pressure loading in the circular hole of rawlplugs positions (four different types) in creating longitudinal cracks were investigated using the ABAQUS Finite Element software. In addition, a sensitivity analysis of the tensile stress in the rawlplugs positions of the B70 pre-stressed concrete sleeper was carried out against changes in the pre-stressing force as one of the most important parameters in the structural design of this type of sleeper. According to the research results, the cylindrical pressure inside the rawlplug holes increases the tensile stresses around the holes and eventually leads to extension of longitudinal cracks. Furthermore, the implementation of loadings on the B70 mono-block prestressed concrete sleeper increases the intensity of the damage significantly. The numerical model also shows the linear behaviour of the changes in the pre-stressing force and, as a result, high values of pre-stressing force can be a main factor in creating longitudinal cracks. (C) 2014 Elsevier Ltd. All rights reserved.
C1 Iran Univ Sci & Technol, Sch Railway Engn, Tehran 16844, Iran.
RP Hasheminezhad, A (reprint author), Iran Univ Sci & Technol, Sch Railway Engn, Tehran 16844, Iran.
EM Araz_hasheminezhad@rail.iust.ac.ir
CR Alex Remennikov, 2008, DYNAMIC DESIGN GUIDE, P743
   Chen Zhe, 2014, J RAIL RAPID TRANSIT
   Kaewunruen S., 2006, FAC ENG PAPER, P319
   Kaewunruen Sakdirat, 2007, INVESTIGATIONS STATI
   Rezaie F, 2012, ENG FAIL ANAL, V26, P21, DOI 10.1016/j.engfailanal.2012.07.001
   Sadeghi JM, 2006, IRAN J SCI TECHNOL T, V30
   Sakdirat Kaewunruen, 2008, COR INT TRANSP CORE, P97
   Sakdirat Kaewunruen, 2009, ENG STRUCT, V31, P2460
   Sykorov J, 2011, MECHANIKA
   Wahid Ferdous, 2014, ENG FAIL ANAL, V44, P17
NR 10
TC 4
Z9 4
U1 2
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-6307
EI 1873-1961
J9 ENG FAIL ANAL
JI Eng. Fail. Anal.
PD MAR
PY 2015
VL 49
BP 1
EP 10
DI 10.1016/j.engfailanal.2014.12.005
PG 10
WC Engineering, Mechanical; Materials Science, Characterization & Testing
SC Engineering; Materials Science
GA CB2HW
UT WOS:000349448900001
DA 2018-12-27
ER

PT J
AU Krika, F
   Azzouz, N
   Ncibi, MC
AF Krika, F.
   Azzouz, N.
   Ncibi, M. C.
TI RETRACTED: Adsorptive removal of cadmium from aqueous media using
   Posidonia oceanica biomass: equilibrium, dynamic and thermodynamic
   studies (Retracted article. See vol. 15, pg. 687, 2018)
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Biosorption; Cadmium; Posidonia oceanica; Kinetics; Isotherms;
   Thermodynamics; Desorption
ID WASTE BIOMASS; HEAVY-METALS; HUMIC-ACID; BIOSORPTION; SORPTION; PB(II);
   IONS
AB Posidonia oceanica (L.), a marine biomass, has been used as an effective and efficient biosorbent for the removal of Cd(II) from aqueous media. The physico-chemical properties of biosorbent were investigated by elemental analysis, BET surface area, FT-IR, SEM and EDX methods before and after adsorption. Batch adsorption experiments were carried out to investigate the effects of solution pH, dosage of biosorbent, contact time and temperature. The biosorbent exhibited the maximum uptake of 58.82 mg/g under the optimal adsorption condition. Kinetics experiments indicated that the pseudo-second-order model displayed the best correlation with adsorption kinetics data. Besides, experimental data could be better described by the Langmuir isotherm model. Desorption experiments were carried out to explore the feasibility of regenerating the biosorbent. The regeneration efficiency was 96.03 % using desorption agent of 0.2 M HCl. The thermodynamic parameters (Delta H (0), Delta S (0) and Delta G (0)) of the cadmium ion uptake onto P.O indicated that the process is endothermic and proceeds spontaneously. The findings of the present study indicate that P.O can be successfully used for separation of Cd(II) from aqueous solutions. The results suggested that the adsorbent is promising for use as an effective and economical adsorbent for Cd(II) ions removal.
C1 [Krika, F.; Azzouz, N.] Univ Jijel, Fac Sci & Technol, LIME Lab, BP 98, Ouled Aissa 18000, Jijel, Algeria.
   [Ncibi, M. C.] Univ Antilles Guyane, COVACHIMM, EA Lab 3592, Pointe a Pitre 97157, Guadeloupe, Guadeloupe.
RP Krika, F (reprint author), Univ Jijel, Fac Sci & Technol, LIME Lab, BP 98, Ouled Aissa 18000, Jijel, Algeria.
EM f.krika@hotmail.fr
OI Ncibi, Mohamed Chaker/0000-0001-6015-8588
CR Al-Degs YS, 2006, WATER RES, V40, P2645, DOI 10.1016/j.watres.2006.05.018
   Chen JH, 2012, DESALINATION, V285, P54, DOI 10.1016/j.desal.2011.09.033
   Coates J., 2000, ENCY ANAL CHEM
   Febrianto J, 2009, J HAZARD MATER, V162, P616, DOI 10.1016/j.jhazmat.2008.06.042
   Freundlich H., 1906, PHYS CHEM SOC, V40, P1361
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5
   HOLAN ZR, 1993, BIOTECHNOL BIOENG, V41, P819, DOI 10.1002/bit.260410808
   Kellner R., 1998, ANAL CHEM
   Kumar Reddy D. H., 2012, ENV ENG RES, V17, P125, DOI DOI 10.4491/EER.2012.17.3.125
   Lagergren S., 1898, HANDLINGAR, V24, P1, DOI DOI 10.1007/BF01501332
   Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004
   Laus R, 2010, J HAZARD MATER, V183, P233, DOI 10.1016/j.jhazmat.2010.07.016
   LeyvaRamos R, 1997, WATER SCI TECHNOL, V35, P205, DOI 10.1016/S0273-1223(97)00132-7
   Li QZ, 2009, APPL SURF SCI, V255, P4298, DOI 10.1016/j.apsusc.2008.11.024
   Liu CX, 2006, J MEMBRANE SCI, V284, P313, DOI 10.1016/j.memsci.2006.07.045
   Lu DD, 2009, J HAZARD MATER, V166, P239, DOI 10.1016/j.jhazmat.2008.11.018
   Mansour MS, 2011, DESALINATION, V272, P301, DOI 10.1016/j.desal.2011.01.037
   Nomanbhay SM, 2005, ELECTRON J BIOTECHN, V8, P43
   Puranik PR, 1997, J BIOTECHNOL, V55, P113, DOI 10.1016/S0168-1656(97)00067-9
   Reddy DHK, 2011, DESALINATION, V268, P150, DOI 10.1016/j.desal.2010.10.011
   REDLICH O, 1959, J PHYS CHEM-US, V63, P1024, DOI 10.1021/j150576a611
   Saeed A, 2003, WATER RES, V37, P3472, DOI 10.1016/S0043-1354(03)00175-1
   Sari A, 2009, DESALINATION, V249, P260, DOI 10.1016/j.desal.2008.12.057
   Tsezos M, 2001, HYDROMETALLURGY, V59, P241, DOI 10.1016/S0304-386X(99)00056-0
   Valdman E, 2000, BIOPROCESS ENG, V22, P171, DOI 10.1007/s004490050027
   Wang SB, 2008, SEP PURIF TECHNOL, V58, P353, DOI 10.1016/j.seppur.2007.05.009
   Weber W J, 1963, J SANITARY ENGINEERI, V89, P31, DOI DOI 10.1016/J.DESAL.2010.08.036
   Yao ZY, 2010, J HAZARD MATER, V174, P137, DOI 10.1016/j.jhazmat.2009.09.027
NR 28
TC 6
Z9 6
U1 1
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1735-1472
EI 1735-2630
J9 INT J ENVIRON SCI TE
JI Int. J. Environ. Sci. Technol.
PD MAR
PY 2015
VL 12
IS 3
BP 983
EP 994
DI 10.1007/s13762-013-0483-x
PG 12
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA CB1JA
UT WOS:000349382100019
DA 2018-12-27
ER

PT J
AU Alizadeh-Choobari, O
AF Alizadeh-Choobari, O.
TI RETRACTED: Large-eddy simulation of the hurricane boundary layer:
   Evaluation of the planetary boundary-layer parametrizations (Retracted
   article. See vol. 167, pg. 314, 2016)
SO ATMOSPHERIC RESEARCH
LA English
DT Article; Retracted Publication
DE Hurricane boundary layer; Large-eddy simulation; Organized roll
   vortices; Planetary boundary layer
ID NONLOCAL CLOSURE-MODEL; ROLL VORTICES; DOPPLER RADAR; INSTABILITIES;
   SCHEMES; PACKAGE
AB The organized roll vortices are the integral part of the hurricane boundary layer (HBL) where they have an important contribution in the vertical transport of momentum, heat and moisture. Large-eddy simulations (LESs) were conducted to explicitly resolve the organized roll vortices in the HBL over the ocean using the Weather Research and Forecasting (WRF) model. The LESs were nested within the WRF mesoscale model to provide two-way up-scale and down-scale exchange at the nest interfaces, and explicitly resolve large eddies. Downdrafts in the organized roll vortices correspond to transport of high-momentum air down to the surface, while updrafts tend to transport low-momentum air upwards. The downdrafts and updrafts therefore lead to a well-organized band-like structure of alternating strong and relatively weak near-surface winds, respectively. The upward legs of the roll vortices are also associated with transport of moist air to the upper levels, while drier air is brought down to the surface in the downward legs. Organized roll vortices contribute a significant portion to the vertical transport of heat and moisture. Three planetary boundary-layer (PBL) parametrizations were examined against the LES. Results indicate that PBL parametizations cannot capture the band-like structure of alternating strong and relatively weak near-surface winds as they are subgrid scale features, and are unable to adequately represent the surface heat fluxes and wind profiles in the hurricane conditions. PBL parametrizations show overall less variability in the extremes of the wind field. (C) 2014 Elsevier B.V. All rights reserved.
C1 Univ Tehran, Inst Geophys, Tehran, Iran.
RP Alizadeh-Choobari, O (reprint author), Univ Tehran, Inst Geophys, Tehran, Iran.
EM omid.alizadeh@ut.ac.ir
CR Bergqvist R, 2013, TRANSP SOC, P1
   Bleck R, 2002, OCEAN MODEL, V4, P55, DOI 10.1016/S1463-5003(01)00012-9
   BROWN RA, 1980, REV GEOPHYS, V18, P683, DOI 10.1029/RG018i003p00683
   Chen SYS, 2007, B AM METEOROL SOC, V88, P311, DOI 10.1175/BAMS-88-3-311
   Choobari OA, 2012, ATMOS ENVIRON, V61, P294, DOI 10.1016/j.atmosenv.2012.07.038
   Cuxart J, 2006, BOUND-LAY METEOROL, V118, P273, DOI 10.1007/s10546-005-3780-1
   DUDHIA J, 1989, J ATMOS SCI, V46, P3077, DOI 10.1175/1520-0469(1989)046<3077:NSOCOD>2.0.CO;2
   Emanuel K, 2012, J ATMOS SCI, V69, P988, DOI 10.1175/JAS-D-11-0177.1
   ETLING D, 1993, BOUND-LAY METEOROL, V65, P215, DOI 10.1007/BF00705527
   Foster RC, 2005, J ATMOS SCI, V62, P2647, DOI 10.1175/JAS3475.1
   Franklin JL, 2003, WEATHER FORECAST, V18, P32, DOI 10.1175/1520-0434(2003)018<0032:GDWPIH>2.0.CO;2
   Gayno G., 1994, 10 C NUM WEATH PRED, P18
   Gray W. M., 1965, J APPL METEOR, V4, P463
   Hariprasad KBRR, 2014, ATMOS RES, V145, P27, DOI 10.1016/j.atmosres.2014.03.023
   Hong SY, 2006, MON WEATHER REV, V134, P2318, DOI 10.1175/MWR3199.1
   Hu XM, 2010, J APPL METEOROL CLIM, V49, P1831, DOI 10.1175/2010JAMC2432.1
   Huang HY, 2013, MON WEATHER REV, V141, P2265, DOI 10.1175/MWR-D-12-00292.1
   JANJIC ZI, 1990, MON WEATHER REV, V118, P1429, DOI 10.1175/1520-0493(1990)118<1429:TSMCPP>2.0.CO;2
   Li XF, 2013, B AM METEOROL SOC, V94, P215, DOI 10.1175/BAMS-D-11-00211.1
   Lorsolo S, 2008, MON WEATHER REV, V136, P2871, DOI 10.1175/2008MWR2273.1
   Madala S, 2014, ATMOS RES, V139, P1, DOI 10.1016/j.atmosres.2013.12.017
   Mlawer EJ, 1997, J GEOPHYS RES-ATMOS, V102, P16663, DOI 10.1029/97JD00237
   Morrison I, 2005, J ATMOS SCI, V62, P2662, DOI 10.1175/JAS3508.1
   Nakanishi M, 2004, BOUND-LAY METEOROL, V112, P1, DOI 10.1023/B:BOUN.0000020164.04146.98
   Nakanishi M, 2012, J ATMOS SCI, V69, P3558, DOI 10.1175/JAS-D-11-0237.1
   Nolan DS, 2005, DYNAM ATMOS OCEANS, V40, P209, DOI 10.1016/j.dynatmoce.2005.03.002
   Palmen E., 1948, GEOPHYSICA, V3, P26
   PLEIM JE, 1992, ATMOS ENVIRON A-GEN, V26, P965, DOI 10.1016/0960-1686(92)90028-J
   Pleim JE, 2007, J APPL METEOROL CLIM, V46, P1383, DOI 10.1175/JAM2539.1
   Reasor PD, 2000, MON WEATHER REV, V128, P1653, DOI 10.1175/1520-0493(2000)128<1653:LWSAEO>2.0.CO;2
   Rogers R, 2012, MON WEATHER REV, V140, P77, DOI 10.1175/MWR-D-10-05075.1
   Rotunno R, 2009, B AM METEOROL SOC, V90, P1783, DOI 10.1175/2009BAMS2884.1
   SHAPIRO LJ, 1983, J ATMOS SCI, V40, P1984, DOI 10.1175/1520-0469(1983)040<1984:TABLFU>2.0.CO;2
   Skamarock WC, 2008, J COMPUT PHYS, V227, P3465, DOI 10.1016/j.jcp.2007.01.037
   Smith RK, 2009, Q J ROY METEOR SOC, V135, P1321, DOI 10.1002/qj.428
   STENSRUD DJ, 1988, J ATMOS SCI, V45, P1007, DOI 10.1175/1520-0469(1988)045<1007:DOBLRF>2.0.CO;2
   Wurman J, 1998, SCIENCE, V280, P555, DOI 10.1126/science.280.5363.555
   ZHANG D, 1982, J APPL METEOROL, V21, P1594, DOI 10.1175/1520-0450(1982)021<1594:AHRMOT>2.0.CO;2
   Zhang JA, 2008, BOUND-LAY METEOROL, V128, P173, DOI 10.1007/s10546-008-9281-2
   Zhu P, 2010, J ATMOS SCI, V67, P3793, DOI 10.1175/2010JAS3437.1
   Zhu P, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009643
NR 41
TC 2
Z9 4
U1 2
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0169-8095
EI 1873-2895
J9 ATMOS RES
JI Atmos. Res.
PD MAR 1
PY 2015
VL 154
BP 73
EP 88
DI 10.1016/j.atmosres.2014.11.004
PG 16
WC Meteorology & Atmospheric Sciences
SC Meteorology & Atmospheric Sciences
GA CA0RZ
UT WOS:000348625500006
DA 2018-12-27
ER

PT J
AU Kenix, LJ
AF Kenix, Linda Jean
TI RETRACTED: Culture as Constitutive: An Exploration of Audience and
   Journalist Perceptions of Journalism in Samoa(Retracted article. See
   vol. 10, pg. 184, 2017)
SO COMMUNICATION CULTURE & CRITIQUE
LA English
DT Article; Retracted Publication
DE Culture; Journalism; Audience; Journalist; Hierarchy of Influences Model
ID MEDIA BIAS; NEWS; WORK
AB Much research implicitly suggests that journalism values arise from culturally removed organizational structures or shared occupational training and few studies examine the perspective of journalism from both audiences and journalists. These omissions are important given the essentiality of mutually constructed and culturally embedded normative behaviors within journalism. This research examines audiences and journalists in Samoa, a recently independent, postcolonial country that relies upon a very traditional, shared national identity for its relatively nascent cohesion. This study aims to gain a better understanding of how local culture can set parameters and expectations for journalism; how journalists negotiate culture into their own professional ideology; and how audiences understand journalism within a cultural context.
C1 [Kenix, Linda Jean] Univ Canterbury, Dept Media & Commun, Christchurch 8120, New Zealand.
RP Kenix, LJ (reprint author), Univ Canterbury, Dept Media & Commun, Christchurch 8120, New Zealand.
EM lindajean.kenix@canterbury.ac.nz
OI Kenix, Linda Jean/0000-0001-8462-5152
CR [Anonymous], 2000, SAV SANO MAL SAM
   [Anonymous], 2001, COMMUNICATION
   Bauman Z., 2000, LIQUID MODERNITY
   Bell A, 1991, LANGUAGE NEWS MEDIA
   Besnier N, 2009, CONTEMP PACIFIC, V21, P215
   Bogaerts J, 2011, PACIFIC JOURNALISM R, V5, P399
   Bogaerts J, 2011, JOURNAL PRACT, V5, P399, DOI 10.1080/17512786.2010.540131
   Bourdieu P, 2005, BOURDIEU JOURNALISTI, P29, DOI DOI 10.1080/10584600701313157
   BRENNEN B, 2000, JOURNALISM, V1, P106, DOI DOI 10.1177/146488490000100112
   Conboy Martin, 2009, JOURNALISM THEORY PR, V10, P306, DOI [10.1177/1464884909102572, DOI 10.1177/1464884909102572]
   Creswell J. W., 1998, QUALITATIVE INQUIRY
   De Beer A. S., 2004, ECQUID NOVI-AFR JOUR, V25, P186
   De Cillia R, 1999, DISCOURSE SOC, V10, P149, DOI 10.1177/0957926599010002002
   Deuze M, 2008, INT J COMMUNICATION, V2, P848
   Deuze Mark, 2005, JOURNALISM, V6, P442, DOI [10.1177/1464884905056815, DOI 10.1177/1464884905056815]
   Donsbach W, 1993, GAZETTE, V51, P53, DOI DOI 10.1177/001654929305100104
   Donsbach W., 2008, INT ENCY COMMUNICATI, V6, P2605
   Durante R., 2009, NBERWORKING PAPER SE, Vw14762
   Enoka T. K., 2011, SAMOA DIRE NEED TRAI
   Eveland WP, 2003, POLIT PSYCHOL, V24, P101, DOI 10.1111/0162-895X.00318
   Fairclough N., 1995, MEDIA DISCOURSE
   Gentzkow M, 2006, J POLIT ECON, V114, P280, DOI 10.1086/499414
   Grieves K, 2011, JOURNALISM STUD, V12, P239, DOI 10.1080/1461670X.2010.490654
   Grinblatt M, 2001, J FINANC, V56, P1053, DOI 10.1111/0022-1082.00355
   Hallin D, 2012, COMP MEDIA SYSTEMS W
   Hallin D, 2004, COMP MEDIA SYSTEMS 3
   Hanitzsch T., 2011, INT COMMUNICATION GA, V73, P477, DOI DOI 10.1177/1748048511412279
   Hanitzsch T, 2011, INT J PRESS/POLIT, V16, P404, DOI 10.1177/1940161211407334
   Heider D, 2005, JOURNALISM MASS COMM, V82, P952, DOI 10.1177/107769900508200412
   Herman E. S., 1988, MANUFACTURING CONSEN
   Jones P., 1996, AUSTR PLANNER, V33, P1
   Journalists Association of Western Samoa, 2006, HISTORY
   Kinefuchi E, 2010, J INT INTERCULT COMM, V3, P228, DOI 10.1080/17513057.2010.487220
   Kohut A., 2004, NY TIMES
   Kovach B., 2007, ELEMENTS JOURNALISM
   Kovach B., 2001, ELEMENTS JOURNALISM
   Krueger R. A., 1988, FOCUS GROUPS PRACTIC
   Kvale S, 1996, INTERVIEWS INTRO QUA
   Lawson S., 1996, TRADITION VERSUS DEM
   Macpherson C., 1990, SAMOAN MED BELIEF PR
   Malifa S. S., 2012, US
   Malifa S. S., 2011, SAMOA OBSERVER  0707
   Malifa SS, 2010, PACIFIC JOURNALISM R, V16, P37
   Merleau-Ponty M, 1962, PHENOMENOLOGY PERCEP
   Moran D., 2000, INTRO PHENOMENOLOGY
   Oyserman D, 2008, PSYCHOL BULL, V134, P311, DOI 10.1037/0033-2909.134.2.311
   Pearson M., 2000, ASIA PACIFIC MEDIA E, V8, P22
   Pyne L., 2011, MEDIA SAMOA JOURNALI
   REESE SD, 1990, CRIT STUD MASS COMM, V7, P390, DOI 10.1080/15295039009360187
   Robie D., 2004, MEKIM NIUS
   Robinson D., 2005, PACIFIC WASY TALK HU
   Rosen J., 2000, JOURNALISM STUD, V1, P679, DOI [10.1080/146167000441376, DOI 10.1080/146167000441376]
   Shoemaker P. J., 1990, MEDIATING MESSAGE TH
   Singh S., 2008, MED DEV ISS CHALL PA
   So'o A., 2006, ESTABLISHMENT OPERAT
   Strauss A. L., 1998, BASICS QUALITATIVE R
   Taule'alo T. u. u. I., 2004, SAMOAN CUSTOMARY LAN
   Tsfati Yariv, 2006, JOURNALISM, V7, P152, DOI [10.1177/1464884906062603, DOI 10.1177/1464884906062603]
   Tuchman G, 1978, MAKING NEWS STUDY CO
   Weaver David H., 2006, AM JOURNALIST 21 CEN
   Weaver DH, 1996, AM JOURNALIST 1990S
   Wickham A., 1996, COMMUNICATION ALL
   Zelizer B., 2004, TAKING JOURNALISM SE
   Zelizer B, 2008, MEM STUD, V1, P79, DOI 10.1177/1750698007083891
   Zelizer V. A., 2011, EC LIVES CULTURE SHA
NR 65
TC 2
Z9 2
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1753-9129
EI 1753-9137
J9 COMMUN CULT CRIT
JI Commun. Cult. Crit.
PD MAR
PY 2015
VL 8
IS 1
BP 37
EP 54
DI 10.1111/cccr.12076
PG 18
WC Communication
SC Communication
GA DE4PJ
UT WOS:000370611500003
DA 2018-12-27
ER

PT J
AU Soltani, M
   Moghaddam, TB
   Karim, MR
   Shamshirband, S
   Sudheer, C
AF Soltani, Mehrtash
   Moghaddam, Taher Baghaee
   Karim, Mohamed Rehan
   Shamshirband, Shahaboddin
   Sudheer, Ch
TI RETRACTED: Stiffness performance of polyethylene terephthalate modified
   asphalt mixtures estimation using support vector machine-firefly
   algorithm (Retracted article. See vol. 121, pg. 360, 2018)
SO MEASUREMENT
LA English
DT Article; Retracted Publication
DE Firefly algorithm; Support vector machine; Pavement performance; PET
   modified asphalt mixtures; Environmental conditions; Estimation
ID STONE MASTIC ASPHALT; RESILIENT MODULUS; NEURAL-NETWORKS; PREDICTION;
   REGRESSION; CONCRETE; MODEL; OPTIMIZATION; BITUMEN; MIX
AB Predicting asphalt pavement performance is an important matter which can save cost and energy. To ensure an accurate estimation of performance of the mixtures, new soft computing techniques can be used. In this study, in order to estimate the stiffness property of Polyethylene Terephthalate (PET) modified asphalt mixture, different soft computing methods were developed, namely: support vector machine-firefly algorithm (SVM-FFA), genetic programming (GP), artificial neural network (ANN) and support vector machine. The support vector machine-firefly algorithm (SVM-FFA) is a metaheuristic search algorithm developed according to the socially dashing manners of fireflies in nature. To develop the models, experiments were performed. The process, which simulates the mixtures' stiffness, was created with a soft computing method, the inputs being PET percentages, stress levels and environmental temperatures. The performance of the proposed system was confirmed by the simulation results. Soft computing methodologies show very good learning and prediction capabilities and the results obtained in this study indicate that the SVM-FFA contributed the most significant effect on stiffness performance estimation since the SVM-FFA model had a better correlation coefficient than the SVM, ANN and GP approaches. R-2 and RMSE were utilized for making comparisons between the expected and actual values of SVM-FFA, GP, ANN and SVM. The proposed SVM-FFA methodology predicted the output values with 254.4743 (mm/day) and 0.9957 RMSE and R-2 respectively. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Soltani, Mehrtash; Moghaddam, Taher Baghaee; Karim, Mohamed Rehan] Univ Malaya, Dept Civil Engn, Ctr Transportat Res, Fac Engn, Kuala Lumpur 50603, Malaysia.
   [Shamshirband, Shahaboddin] IAU, Dept Comp Sci, Chalous Branch, Chalous 46615397, Mazandaran, Iran.
   [Shamshirband, Shahaboddin] Univ Malaya, Fac Comp Sci & Informat Technol, Dept Comp Syst & Technol, Kuala Lumpur 50603, Malaysia.
   [Sudheer, Ch] Indian Inst Technol Delhi, Dept Civil Engn, New Delhi, India.
RP Shamshirband, S (reprint author), Univ Malaya, Fac Comp Sci & Informat Technol, Dept Comp Syst & Technol, Kuala Lumpur 50603, Malaysia.
EM shamshirband@um.edu.my
RI Engineering, Faculty/I-7935-2015; Shamshirband, Shahaboddin/K-2544-2013
OI Engineering, Faculty/0000-0002-4848-7052; Shamshirband,
   Shahaboddin/0000-0002-6605-498X; Baghaee Moghaddam,
   Taher/0000-0002-2297-1567
FU University of Malaya [RP010A-13SUS]
FX The authors express their sincere thanks for the funding support they
   received from University of Malaya Grant no.: RP010A-13SUS.
CR Abtahi SM, 2010, CONSTR BUILD MATER, V24, P871, DOI 10.1016/j.conbuildmat.2009.11.009
   Ahmadinia E, 2011, MATER DESIGN, V32, P4844, DOI 10.1016/j.matdes.2011.06.016
   Arabani M, 2011, MAT SCI ENG A-STRUCT, V528, P3866, DOI 10.1016/j.msea.2011.01.099
   Arabani M, 2010, CONSTR BUILD MATER, V24, P1060, DOI 10.1016/j.conbuildmat.2009.11.011
   Asefa T, 2006, J HYDROL, V318, P7, DOI 10.1016/j.jhydrol.2005.06.001
   Bianchini A, 2010, COMPUT-AIDED CIV INF, V25, P39, DOI 10.1111/j.1467-8667.2009.00615.x
   Casey D, 2008, RESOUR CONSERV RECY, V52, P1167, DOI 10.1016/j.resconrec.2008.06.002
   Collobert R., 2000, IDIAPRR0017, P1
   Ghanizadeh AR, 2013, PROCD SOC BEHV, V104, P79, DOI 10.1016/j.sbspro.2013.11.100
   Goktepe A.B., 2005, ARI B ISTANBUL TU, V54, P65
   Goktepe AB, 2006, ADV ENG SOFTW, V37, P421, DOI 10.1016/j.advengsoft.2005.10.001
   Gopalakrishnan K, 2011, J ENG MECH-ASCE, V137, P138, DOI 10.1061/(ASCE)EM.1943-7889.0000214
   Gopalakrishnan Kasthurirangan, 2010, J CIV ENG IEB, V38, P173
   Hassani A, 2005, WASTE MANAGE RES, V23, P322, DOI 10.1177/0734242X05056739
   Hinishoglu S, 2004, MATER LETT, V58, P267, DOI 10.1016/S0167-577X(03)00458-0
   Huang C, 2002, INT J REMOTE SENS, V23, P725, DOI 10.1080/01431160110040323
   Ji Y, 2013, PATTERN RECOGN, V46, P914, DOI 10.1016/j.patcog.2012.08.010
   Joachims T., 1998, TEXT CATEGORIZATION
   Khodaii A, 2009, CONSTR BUILD MATER, V23, P2586, DOI 10.1016/j.conbuildmat.2009.02.015
   Kisi O, 2011, IRRIGATION SCI, V29, P241, DOI 10.1007/s00271-010-0232-6
   Lee S. W, 2003, SUPPORT VECTOR MACHI
   Li J, 2008, CONSTR BUILD MATER, V22, P1067, DOI 10.1016/j.conbuildmat.2007.03.007
   Li Shoutao, 2012, INT C MECH AUT ICMA
   Lu WZ, 2005, CHEMOSPHERE, V59, P693, DOI 10.1016/j.chemosphere.2004.10.032
   Lukasik S, 2009, LECT NOTES ARTIF INT, V5796, P97
   Mirzahosseini MR, 2011, EXPERT SYST APPL, V38, P6081, DOI 10.1016/j.eswa.2010.11.002
   Moghaddam TB, 2014, MATER DESIGN, V53, P317, DOI 10.1016/j.matdes.2013.07.015
   Mohammadi K., ENERGY CONV IN PRESS
   Mukkamala S, 2002, IEEE IJCNN, P1702, DOI 10.1109/IJCNN.2002.1007774
   Ozen H, 2008, BUILD ENVIRON, V43, P1270, DOI 10.1016/j.buildenv.2007.03.010
   Ozgan E, 2012, ADV ENG SOFTW, V45, P100, DOI 10.1016/j.advengsoft.2011.09.015
   Ozgan E, 2011, EXPERT SYST APPL, V38, P6025, DOI 10.1016/j.eswa.2010.11.018
   Ozgan E, 2009, ADV ENG SOFTW, V40, P527, DOI 10.1016/j.advengsoft.2008.10.005
   Ozsahin TS, 2008, CONSTR BUILD MATER, V22, P1436, DOI 10.1016/j.conbuildmat.2007.01.031
   Pellinen TK, 2002, TRANSPORT RES REC, P80, DOI 10.3141/1789-09
   Radziszewski P., 2007, J CIV ENG MANAG, VXIII, P307, DOI DOI 10.1080/13923730.2007.9636451
   Rajasekaran S, 2008, OCEAN ENG, V35, P1578, DOI 10.1016/j.oceaneng.2008.08.004
   Ren Yanjun, 2013, TELKOMNIKA, V11, P5169
   Saltan M., 2002, Pakistan Journal of Information and Technology, V1, P180
   Sun SL, 2013, NEURAL COMPUT APPL, V23, P2031, DOI 10.1007/s00521-013-1362-6
   Sung AH, 2003, 2003 SYMPOSIUM ON APPLICATIONS AND THE INTERNET, PROCEEDINGS, P209, DOI 10.1109/SAINT.2003.1183050
   Tapkin S, 2010, EXPERT SYST APPL, V37, P4660, DOI 10.1016/j.eswa.2009.12.042
   Tayebali A.A., 1994, SHRP A 388 STIFFNESS
   Tayfur S, 2007, CONSTR BUILD MATER, V21, P328, DOI 10.1016/j.conbuildmat.2005.08.014
   Vapnik V, 1997, ADV NEUR IN, V9, P281
   Vapnik V. N., 1995, NATURE STAT LEARNING, P314
   Vapnik VN, 1998, STAT LEARNING THEORY, P736
   Wallach D., 2005, PSYCHOL KOGNITION RE, P115
   Wu KP, 2009, PATTERN RECOGN, V42, P710, DOI 10.1016/j.patcog.2008.08.030
   Yan Ke-Zhen, 2014, INT J PAVEMENT RES T, V7, P31
   Yang HQ, 2009, NEUROCOMPUTING, V72, P2659, DOI 10.1016/j.neucom.2008.09.014
   Yang XS, 2010, INT J BIO-INSPIR COM, V2, P78, DOI 10.1504/IJBIC.2010.032124
   Yang XS, 2010, RESEARCH AND DEVELOPMENT IN INTELLIGENT SYSTEMS XXVI, P209, DOI 10.1007/978-1-84882-983-1_15
   Ye QS, 2009, INT J FATIGUE, V31, P1598, DOI 10.1016/j.ijfatigue.2009.04.008
NR 54
TC 13
Z9 13
U1 2
U2 22
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0263-2241
EI 1873-412X
J9 MEASUREMENT
JI Measurement
PD MAR
PY 2015
VL 63
BP 232
EP 239
DI 10.1016/j.measurement.2014.11.022
PG 8
WC Engineering, Multidisciplinary; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA AZ1YE
UT WOS:000348030500026
DA 2018-12-27
ER

PT J
AU Wang, H
   Liu, JH
   Sun, YD
   Hong, XF
   Huang, HW
   Yin, RC
   Zhang, Y
   Yin, CG
AF Wang, Hui
   Liu, Jinhong
   Sun, Yongduo
   Hong, Xiaofeng
   Huang, Huawei
   Yin, Rongcai
   Zhang, Yong
   Yin, Changgeng
TI RETRACTED: Research on preparation technology, sintering performance,
   microstructure of UO2-x fuel pellets (Retracted article. See vol. 36,
   pg. 3549, 2016)
SO JOURNAL OF THE EUROPEAN CERAMIC SOCIETY
LA English
DT Article; Retracted Publication
DE UO2-x fuel pellets; Sintering; Nuclear fuel element; Microstructure;
   Densification
ID URANIA
AB Reducing O/U of UO2 +/- x, fuel can increase the compatibility of fuel pellets and cladding at high temperatures. The preparation of UO2-x, fuel pellets by powder metallurgy process is discussed, O/U of fuel pellets is tested by thermogravimetric test (TG), fuel pellet density is measured by water immersion method, the phase change process of compact is tested by differential thermal analyzer (DTA), the quality change process of fuel compact is tested with TG curve, the metallographic microstructure and phase structure of the fuel pellets are observed by optical microscope (OM) and XRD. Experimental results show that through powder metallurgy technology UO2 and U are mixed and pressed to be compacts, which are sintered under strong reducing atmosphere at 1750 degrees C. Then UO2-x pellets can be prepared, whose O/U <= 1.995, relative theoretical density is 97.5% TD and the average grain size is 13-18 mu m. After sintered at 1750 degrees C, UO2-x pellets show good microstructures and uniform phases. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Wang, Hui; Liu, Jinhong; Sun, Yongduo; Hong, Xiaofeng; Huang, Huawei; Yin, Rongcai; Zhang, Yong; Yin, Changgeng] Nucl Power Inst China, Natl Key Lab Reactor Fuel & Mat, Chengdu 610041, Peoples R China.
RP Wang, H (reprint author), Nucl Power Inst China, Natl Key Lab Reactor Fuel & Mat, Chengdu 610041, Peoples R China.
EM qinghe5525@163.com
CR ADAMSON MG, 1985, J NUCL MATER, V130, P349, DOI 10.1016/0022-3115(85)90323-X
   [Anonymous], 1962, J NUCL MAT, V43, P219
   Baichi M, 2006, J NUCL MATER, V349, P57, DOI 10.1016/j.jnucmat.2005.10.001
   FRYXELL RE, 1968, J NUCL MATER, V25, P97, DOI 10.1016/0022-3115(68)90145-1
   Gontar AS, 1990, BRANCH JUB IEE C NUC
   Haiding JH, 1989, J NUCL MATER, V166, P223
   JAVED NA, 1972, J NUCL MATER, V43, P219, DOI 10.1016/0022-3115(72)90053-0
   KAPSHUKOV II, 1990, J RADIOAN NUCL CH AR, V143, P213, DOI 10.1007/BF02117563
   Kink JF, 1981, J NUCL MATER, V102, P17
   LINDEMER TB, 1985, J NUCL MATER, V130, P473, DOI 10.1016/0022-3115(85)90334-4
   MARKIN TL, 1968, J INORG NUCL CHEM, V30, P807, DOI 10.1016/0022-1902(68)80441-5
   Nikolaev YV, 1993, 4 BRANCH C NUCL POW
NR 12
TC 2
Z9 2
U1 4
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0955-2219
EI 1873-619X
J9 J EUR CERAM SOC
JI J. Eur. Ceram. Soc.
PD MAR
PY 2015
VL 35
IS 3
BP 1081
EP 1087
DI 10.1016/j.jeurceramsoc.2014.10.020
PG 7
WC Materials Science, Ceramics
SC Materials Science
GA AY6GF
UT WOS:000347664500023
DA 2018-12-27
ER

PT J
AU Chen, G
   Wang, YZ
   Mei, YH
   Yu, L
   Li, X
   Chen, X
AF Chen, Gang
   Wang, Yi-Zhe
   Mei, Yunhui
   Yu, Lin
   Li, Xin
   Chen, Xu
TI RETRACTED: Influence of temperature and microstructure on the mechanical
   properties of sintered nanosilver joints (Retracted article. See vol.
   636, pg. 613, 2015)
SO MATERIALS SCIENCE AND ENGINEERING A-STRUCTURAL MATERIALS PROPERTIES
   MICROSTRUCTURE AND PROCESSING
LA English
DT Article; Retracted Publication
DE Nanosilver; Non-contact measurement; Fatigue; Particle size; Die
   attachment
ID TIME STRAIN-MEASUREMENT; LIGHT-EMITTING-DIODES; SN-PB SOLDER; SILVER
   PASTE; FATIGUE BEHAVIOR; RATCHETING BEHAVIOR; NANOSCALE SILVER;
   CONTROL-SYSTEM; EPOXY-RESIN; INTERCONNECTION
AB In order to study the effect of temperature on the mechanical behavior of sintered nanosilver joint for die attachment in power electronics, we developed a non-contact displacement detecting system (NDDS) for measuring the evolution of displacement of joints. Based on a digital image correlation method, the NDDS is capable of detecting a minimum displacement of 3 mu m. With the aid of this NDDS, stresscontrolled monotonic and cyclic shear tests were conducted on sintered nanosilver joints at various temperatures using an electronic fatigue testing machine. Scanning electron microscopy (SEM) was used to investigate the correlation between loading conditions of the joints and particle size of the sintered nanosilver. The particle size was found susceptible to deformation mode, temperature and holding time. While the particle size is always larger in the cyclic tests than in the shear tests, temperature and holding time play a more important role in the process of particle growth. The shear strength and fatigue life of the sintered nanosilver joints were found to decrease with increasing particle size. This is attributed to the dissolving of the grain boundaries along with the particle growth, which impairs the ability of the sintered nanosilver in inhibiting deformation and retarding crack propagation. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Chen, Gang; Wang, Yi-Zhe; Yu, Lin; Chen, Xu] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Mei, Yunhui; Li, Xin] Tianjin Univ, Tianjin Key Lab Adv Joining Technol, Tianjin 300072, Peoples R China.
   [Mei, Yunhui; Li, Xin] Tianjin Univ, Sch Mat Sci & Engn, Tianjin 300072, Peoples R China.
RP Mei, YH (reprint author), Tianjin Univ, Sch Mat Sci & Engn, Tianjin 300072, Peoples R China.
EM yunhui@tju.edu.cn
FU National Natural Science Foundation of China [61334010, 11172202];
   Tianjin Municipal Natural Science Foundation [13JCQNJC06600,
   13JCZDJC33600]
FX The authors gratefully acknowledge financial support from National
   Natural Science Foundation of China (Nos. 61334010, and 11172202) and
   Tianjin Municipal Natural Science Foundation (under Grant 13JCQNJC06600
   and 13JCZDJC33600).
CR Alias R., 2012, SINTER CERAM NEW EME, P60
   Bai JG, 2007, IEEE T ELECTRON PACK, V30, P241, DOI 10.1109/TEPM.2007.906508
   Bai JG, 2006, IEEE T COMPON PACK T, V29, P589, DOI 10.1109/TCAPT.2005.853167
   Chen G, 2014, MAT SCI ENG A-STRUCT, V591, P121, DOI 10.1016/j.msea.2013.10.091
   Chen X, 2008, J ELECTRON MATER, V37, P1574, DOI 10.1007/s11664-008-0516-2
   Dai CY, 2013, MAT SCI ENG A-STRUCT, V575, P217, DOI 10.1016/j.msea.2013.03.064
   Hanlon T, 2003, SCRIPTA MATER, V49, P675, DOI 10.1016/S1359-6462(03)00393-2
   Johnson R. W., 2004, Advancing Microelectronics, V31, P8
   Johnson RW, 2004, IEEE T ELECTRON PACK, V27, P164, DOI 10.1109/TEPM.2004.843109
   Kanchanomai C, 2002, INT J FATIGUE, V24, P987, DOI 10.1016/S0142-1123(02)00011-7
   Kanchanomai C, 2002, INT J FATIGUE, V24, P671, DOI 10.1016/S0142-1123(01)00186-4
   Kanchanomai C, 2002, INT J FATIGUE, V24, P57, DOI 10.1016/S0142-1123(01)00052-4
   Knoerr M., 2010, P 12 EL PACK TECHN C, P56
   Lei TG, 2010, IEEE T COMPON PACK T, V33, P98, DOI 10.1109/TCAPT.2009.2021256
   Li X, 2013, MAT SCI ENG A-STRUCT, V579, P108, DOI 10.1016/j.msea.2013.05.001
   Li X, 2013, MICROELECTRON RELIAB, V53, P174, DOI 10.1016/j.microrel.2012.07.028
   Li Y, 2006, MAT SCI ENG R, V51, P1, DOI 10.1016/j.mser.2006.01.001
   Liu YG, 2010, MAT SCI ENG A-STRUCT, V527, P1719, DOI 10.1016/j.msea.2009.11.033
   McCluskey F.P., 2007, P ESTC 2006 1 EL SYS, P444
   Mei YH, 2011, IEEE T DEVICE MAT RE, V11, P312, DOI 10.1109/TDMR.2010.2056372
   NAKAMURA S, 1993, APPL PHYS LETT, V62, P2390, DOI 10.1063/1.109374
   Ogura H, 2010, J ELECTRON MATER, V39, P1233, DOI 10.1007/s11664-010-1236-y
   Pande CS, 2009, PROG MATER SCI, V54, P689, DOI 10.1016/j.pmatsci.2009.03.008
   Quintero PO, 2011, IEEE T DEVICE MAT RE, V11, P531, DOI 10.1109/TDMR.2011.2140114
   Riches S.T., 2008, P INT C HIGH TEMP EL, P265
   Sakamoto S, 2013, J MATER SCI-MATER EL, V24, P2593, DOI 10.1007/s10854-013-1138-x
   Sousa M.F., 2010, P 3 EL SYST INT TECH, P1
   Streubel K, 2002, IEEE J SEL TOP QUANT, V8, P321, DOI 10.1109/2944.999187
   Suganuma K, 2009, JOM-US, V61, P64, DOI 10.1007/s11837-009-0013-y
   Tao G, 2005, POLYM TEST, V24, P844, DOI 10.1016/j.polymertesting.2005.06.013
   Tao G, 2007, INT J FATIGUE, V29, P2180, DOI 10.1016/j.ijfatigue.2006.12.009
   Tao G, 2007, POLYM TEST, V26, P451, DOI 10.1016/j.polymertesting.2006.12.010
   Tao G, 2007, POLYM ENG SCI, V47, P780, DOI 10.1002/pen.20754
   Tian XL, 2010, CRYST GROWTH DES, V10, P3990, DOI 10.1021/cg1005727
   Wang T, 2007, J ELECTRON MATER, V36, P1333, DOI 10.1007/s11664-007-0230-5
   Wang T, 2010, MAT SCI ENG A-STRUCT, V527, P6714, DOI 10.1016/j.msea.2010.07.012
   Zhang XF, 2010, MAT SCI ENG A-STRUCT, V527, P2297, DOI 10.1016/j.msea.2009.12.005
   Zhang Z, 2002, IEEE T ELECTRON PACK, V25, P279, DOI 10.1109/TEPM.2002.807719
   Zheng H.G., 2013, IEEE T COMPON PACK T, V3, P6
NR 39
TC 2
Z9 2
U1 3
U2 35
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0921-5093
EI 1873-4936
J9 MAT SCI ENG A-STRUCT
JI Mater. Sci. Eng. A-Struct. Mater. Prop. Microstruct. Process.
PD FEB 25
PY 2015
VL 626
BP 390
EP 399
DI 10.1016/j.msea.2014.12.066
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Metallurgy & Metallurgical Engineering
SC Science & Technology - Other Topics; Materials Science; Metallurgy &
   Metallurgical Engineering
GA CC2QI
UT WOS:000350189300049
DA 2018-12-27
ER

PT J
AU Pandey, G
   Khamrai, J
   Mishra, A
AF Pandey, Ganesh
   Khamrai, Jagadish
   Mishra, Akash
TI RETRACTED: An Expeditious Route to Both Enantiomers of All Carbon
   Quaternary Stereocenters at C-3 Carbon of Lactams via [3,3]-Sigmatropic
   Rearrangement: Total Synthesis of (-)-Physostigmine (Retracted article.
   See vol. 19, pg. 6264, 2017)
SO ORGANIC LETTERS
LA English
DT Article; Retracted Publication
ID CATALYTIC ASYMMETRIC-SYNTHESIS; INTRAMOLECULAR HECK REACTIONS; CALABAR
   BEAN ALKALOIDS; ENANTIOSELECTIVE SYNTHESIS; CLAISEN REARRANGEMENT;
   NATURAL-PRODUCTS; ALLYLIC ALKYLATION; ORGANIC-SYNTHESIS; MICHAEL
   ADDITION; ALPHA-ARYLATION
AB A diastereoselective route to all carbon quaternary stereocenters at the C-3 position of cyclic lactams has been developed via JohnsonClaisen rearrangement of gamma-hydroxy-alpha, beta-unsaturated lactams. It has been observed that olefin geometry plays an important role in the development of the absolute stereochemistry of the product. The dependence of the product configuration on the olefin geometry is explained by postulating probable transition states. The success of this method has been shown for the multigram scale synthesis of these substituted lactams from commercially available cheap starting materials. The synthetic usefulness of this method is also demonstrated by carrying out the total synthesis of (-)-physostigmine.
C1 [Pandey, Ganesh; Khamrai, Jagadish; Mishra, Akash] Ctr Biomed Res, Mol Synth & Drug Discovery Lab, Lucknow 226014, Uttar Pradesh, India.
RP Pandey, G (reprint author), Ctr Biomed Res, Mol Synth & Drug Discovery Lab, SGPGIMS Campus, Lucknow 226014, Uttar Pradesh, India.
EM gp.pandey@cbmr.res.in
FU DST, New Delhi; CSIR, New Delhi
FX We thank DST, New Delhi for financial support, and J.K. and A.M. thank
   CSIR, New Delhi, for the award of a research fellowship.
CR Adhikari S, 2005, ORG LETT, V7, P2795, DOI 10.1021/ol051172+
   Amat M, 2007, J ORG CHEM, V72, P4431, DOI 10.1021/jo070397q
   Antonchick AP, 2010, NAT CHEM, V2, P735, DOI 10.1038/nchem.730
   ASHIMORI A, 1993, J ORG CHEM, V58, P6949, DOI 10.1021/jo00077a005
   Ashimori A, 1998, J AM CHEM SOC, V120, P6488, DOI 10.1021/ja980787h
   Ashimori A, 1998, J AM CHEM SOC, V120, P6477, DOI 10.1021/ja980786p
   Badiola E, 2014, J AM CHEM SOC, V136, P17869, DOI 10.1021/ja510603w
   Behenna DC, 2012, NAT CHEM, V4, P130, DOI [10.1038/nchem.1222, 10.1038/NCHEM.1222]
   BROSSI A, 1990, J MED CHEM, V33, P2311, DOI 10.1021/jm00171a001
   Bui T, 2009, J AM CHEM SOC, V131, P8758, DOI 10.1021/ja903520c
   Busacca CA, 2003, ORG LETT, V5, P595, DOI 10.1021/ol0340179
   Cao YM, 2011, ANGEW CHEM INT EDIT, V50, P9124, DOI 10.1002/anie.201104216
   Castro AMM, 2004, CHEM REV, V104, P2939, DOI 10.1021/cr020703u
   Chen XH, 2009, J AM CHEM SOC, V131, P13819, DOI 10.1021/ja905302f
   Crimmins MT, 2014, ORG LETT, V16, P2458, DOI 10.1021/ol5008422
   Dalpozzo R, 2012, CHEM SOC REV, V41, P7247, DOI 10.1039/c2cs35100e
   DEUTSCH HF, 1994, J PHARMACEUT BIOMED, V12, P1283, DOI 10.1016/0731-7085(94)00066-2
   El-Azab AS, 2000, ORG LETT, V2, P2757, DOI 10.1021/o1006065o
   Enders D, 2001, EUR J ORG CHEM, P4463
   Enders D, 1996, TETRAHEDRON-ASYMMETR, V7, P1847, DOI 10.1016/0957-4166(96)00220-0
   Frei R, 2013, ANGEW CHEM INT EDIT, V52, P13373, DOI 10.1002/anie.201305533
   Fuji K, 1998, HETEROCYCLES, V47, P951, DOI 10.3987/COM-97-S(N)107
   Galliford CV, 2007, ANGEW CHEM INT EDIT, V46, P8748, DOI 10.1002/anie.200701342
   Gigant B, 2005, NATURE, V435, P519, DOI 10.1038/nature03566
   GREIG NH, 1995, MED RES REV, V15, P3, DOI 10.1002/med.2610150103
   Groaning MD, 2000, TETRAHEDRON, V56, P9843, DOI 10.1016/S0040-4020(00)00926-1
   He RJ, 2009, J AM CHEM SOC, V131, P16620, DOI 10.1021/ja906821y
   He RJ, 2009, ANGEW CHEM INT EDIT, V48, P4559, DOI 10.1002/anie.200901277
   Hills ID, 2003, ANGEW CHEM INT EDIT, V42, P3921, DOI 10.1002/anie.200351666
   Hoffmann H. M. R., 1959, BER, V92, P2499
   Ito H, 1999, CHEM SOC REV, V28, P43, DOI 10.1039/a706415b
   Jiang K, 2010, CHEM-EUR J, V16, P2852, DOI 10.1002/chem.200903009
   JOBST J, 1864, LIEBIGS ANN CHEM, V129, P115
   JOHNSON WS, 1970, J AM CHEM SOC, V92, P741, DOI 10.1021/ja00706a074
   Katoh T, 1999, HETEROCYCLES, V50, P833
   Kawahara M, 2000, ORG LETT, V2, P675, DOI 10.1021/ol005513p
   Kundig EP, 2007, ANGEW CHEM INT EDIT, V46, P8484, DOI 10.1002/anie.200703408
   Lee S, 2001, J ORG CHEM, V66, P3402, DOI 10.1021/jo005761z
   LEE TBK, 1991, J ORG CHEM, V56, P872, DOI 10.1021/jo00002a074
   Lim HJ, 2011, ORG LETT, V13, P6596, DOI 10.1021/ol203052y
   Lim KH, 2008, J NAT PROD, V71, P1591, DOI 10.1021/np800435c
   Linton EC, 2008, J AM CHEM SOC, V130, P16162, DOI 10.1021/ja807026z
   Liu RR, 2013, CHEM-EUR J, V19, P7319, DOI 10.1002/chem.201300977
   Ma S, 2009, ANGEW CHEM INT EDIT, V48, P8037, DOI 10.1002/anie.200902943
   Majumdar KC, 2013, TETRAHEDRON, V69, P6921, DOI 10.1016/j.tet.2013.06.003
   MALAWIST.SE, 1968, SCIENCE, V160, P770, DOI 10.1126/science.160.3829.770
   MARINO JP, 1992, J AM CHEM SOC, V114, P5566, DOI 10.1021/ja00040a013
   Marshall J. A., 2005, ORG SYNTH, V81, P157
   Marti C, 2003, EUR J ORG CHEM, P2209, DOI 10.1002/ejoc.200300050
   Matsuura T, 1998, J AM CHEM SOC, V120, P6500, DOI 10.1021/ja980788+
   May JA, 2006, TETRAHEDRON, V62, P5262, DOI 10.1016/j.tet.2006.01.105
   MITSUNOBU O, 1981, SYNTHESIS-STUTTGART, P1, DOI 10.1055/s-1981-29317
   Mitsunuma H, 2012, ANGEW CHEM INT EDIT, V51, P5217, DOI 10.1002/anie.201201132
   Mohr JT, 2008, NATURE, V455, P323, DOI 10.1038/nature07370
   NODE M, 1991, HETEROCYCLES, V32, P1705, DOI 10.3987/COM-91-5814
   Node M, 1996, CHEM PHARM BULL, V44, P715
   NODE M, 1991, CHEM LETT, P57, DOI 10.1246/cl.1991.57
   Nowicki J, 2000, MOLECULES, V5, P1033, DOI 10.3390/50801033
   Ogawa S, 2007, ANGEW CHEM INT EDIT, V46, P8666, DOI 10.1002/anie.200703317
   PALLAVICINI M, 1994, TETRAHEDRON-ASYMMETR, V5, P111, DOI 10.1016/S0957-4166(00)80490-5
   PALLAVICINI M, 1994, TETRAHEDRON-ASYMMETR, V5, P363, DOI 10.1016/S0957-4166(00)86207-2
   Pandey G, 2005, ORG LETT, V7, P3713, DOI 10.1021/ol051321o
   Pandey G, 2011, EUR J ORG CHEM, P7372, DOI 10.1002/ejoc.201101256
   Pandey G, 2011, EUR J ORG CHEM, P4571, DOI 10.1002/ejoc.201100601
   Pandey G, 2011, ORG LETT, V13, P4672, DOI 10.1021/ol201892j
   Pandey G, 2011, EUR J ORG CHEM, P740, DOI 10.1002/ejoc.201001263
   Pandey G, 2009, ORG LETT, V11, P2547, DOI 10.1021/ol900806m
   Repka LM, 2013, J ORG CHEM, V78, P12314, DOI 10.1021/jo4017953
   SANO M, 1993, CLIN NEUROPHARMACOL, V16, P61, DOI 10.1097/00002826-199302000-00007
   Shaw SA, 2006, J AM CHEM SOC, V128, P925, DOI 10.1021/ja056150x
   TAKANO S, 1982, CHEM PHARM BULL, V30, P2641
   TAKANO S, 1991, J ORG CHEM, V56, P5982, DOI 10.1021/jo00021a006
   TAKANO S, 1990, CHEM LETT, P109, DOI 10.1246/cl.1990.109
   TAKANO S, 1990, HETEROCYCLES, V31, P411, DOI 10.3987/COM-89-5284
   TAKANO S, 1989, ALKALOIDS, V36, P225
   Tan B, 2011, J AM CHEM SOC, V133, P12354, DOI 10.1021/ja203812h
   Tan B, 2011, NAT CHEM, V3, P473, DOI [10.1038/NCHEM.1039, 10.1038/nchem.1039]
   Tan B, 2011, J AM CHEM SOC, V133, P4672, DOI 10.1021/ja110147w
   Tian X, 2008, ORG LETT, V10, P3583, DOI 10.1021/ol801351j
   Trost BM, 2007, J AM CHEM SOC, V129, P14548, DOI 10.1021/ja0755717
   Trost BM, 2007, J AM CHEM SOC, V129, P12396, DOI 10.1021/ja075335w
   Trost BM, 2006, ORG LETT, V8, P2027, DOI 10.1021/ol060298j
   WADSWORTH W, 1961, J AM CHEM SOC, V83, P1733, DOI 10.1021/ja01468a042
   Wang C, 2012, CHEM-EUR J, V18, P4832, DOI 10.1002/chem.201200079
   Williams DR, 2014, ORG LETT, V16, P1956, DOI 10.1021/ol5005092
   Yasui Y, 2008, ORG LETT, V10, P3303, DOI 10.1021/ol801168j
   YU QS, 1993, HETEROCYCLES, V36, P1279
   Zheng WH, 2011, J AM CHEM SOC, V133, P3339, DOI 10.1021/ja109824x
   Zhong FR, 2011, ANGEW CHEM INT EDIT, V50, P7837, DOI 10.1002/anie.201102094
   Zhou F, 2010, ADV SYNTH CATAL, V352, P1381, DOI 10.1002/adsc.201000161
   Zhu QA, 2010, ANGEW CHEM INT EDIT, V49, P7753, DOI 10.1002/anie.201003837
NR 91
TC 15
Z9 15
U1 2
U2 51
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1523-7060
EI 1523-7052
J9 ORG LETT
JI Org. Lett.
PD FEB 20
PY 2015
VL 17
IS 4
BP 952
EP 955
DI 10.1021/d503766y
PG 4
WC Chemistry, Organic
SC Chemistry
GA CB9HM
UT WOS:000349942600048
PM 25671392
DA 2018-12-27
ER

PT J
AU Ji, QS
   Qi, B
   Wen, YC
   Liu, L
   Guo, XL
   Yu, GC
   Zhong, JX
AF Ji, Qing-Shan
   Qi, Bing
   Wen, Yue-Chun
   Liu, Lian
   Guo, Xiao-Ling
   Yu, Guo-Cheng
   Zhong, Jing-Xiang
TI RETRACTED: The association of LOXL1 polymorphisms with exfoliation
   syndrome/glaucoma: Meta-analysis (Retracted article. See vol. 10, pg.
   1149, 2017)
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article; Retracted Publication
DE lysyl oxidase-like 1; polymorphism; exfoliation syndrome; glaucoma;
   Meta-analysis
ID OPEN-ANGLE GLAUCOMA; SINGLE NUCLEOTIDE POLYMORPHISMS; COMMON SEQUENCE
   VARIANTS; NORMAL-TENSION GLAUCOMA; GENE POLYMORPHISMS; PSEUDOEXFOLIATION
   SYNDROME; LYSYL OXIDASE; JAPANESE POPULATION; UNITED-STATES; RISK
AB AIM: To investigate the association of lysyl oxidase like i (LOXL1) single nucleotide polymorphisms (SNPs) with exfoliation syndrome (XFS)/exfoliation glaucoma (XFG).
   METHODS: Published manuscripts from PubMed and EMBASE were identified until May 2014. Summary odds ratios (ORs) and 95% confidence intervals (Cis) for LOXL1 (rs1048661, rs2165241 and rs3825942) polymorphisms and the risk of XFS/XFG were estimated using random-or fixed-effect model.
   RESULTS: The three LOXL1 polymorphisms (rs 1048661, rs3825942, and rs2165241) were associated with an increased risk for XFS/XFG among Caucasians, with OR 2.19(1.96-2.45), 8.8 (6.05-12.79) and 3.41 (3.11-3.73), respectively. On the contrast, the rs1048661 and rs2165241, but not rs3825942 polymorphism, have a potential protective effect on XFS/XFG in Asians, with OR 0.06 (0.02-0.18), 0.15 (0.09-0.25), respectively.
   CONCLUSION: There is strong evidence that LOXL1 polymorphisms are associated with XFS/XFG risk. The strength of risk might be ethnicity-dependent.
C1 [Ji, Qing-Shan; Wen, Yue-Chun] Anhui Med Univ, Affiliated Anhui Prov Hosp, Dept Ophthalmol, Hefei 230001, Anhui, Peoples R China.
   [Qi, Bing; Liu, Lian; Yu, Guo-Cheng; Zhong, Jing-Xiang] Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou 510632, Guangdong, Peoples R China.
   [Guo, Xiao-Ling] Jinan Univ, Inst Cell Biol, Dept Cell Biol, Guangzhou 510632, Guangdong, Peoples R China.
RP Zhong, JX (reprint author), Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou 510632, Guangdong, Peoples R China.
EM zjx85221206@126.com
FU Natural Science Foundation of Guangdong Province [S2013010016037];
   National Science and Tecnology Plan Project of China (973 program)
   [2011CB707501]
FX Supported by Natural Science Foundation of Guangdong Province
   (No.S2013010016037) and the National Science and Tecnology Plan Project
   of China (973 program, No. 2011CB707501).
CR Abu-Amero KK, 2010, MOL VIS, V16, P2805
   Aragon-Martin JA, 2008, MOL VIS, V14, P533
   Boehringer S, 2000, HUM GENET, V107, P197, DOI 10.1007/s004390000353
   Challa P, 2008, MOL VIS, V14, P146
   Chen HY, 2010, MOL VIS, V16, P167
   Chen L, 2009, MOL VIS, V15, P2349
   Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8
   Fan BJ, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-5
   Fan BJ, 2011, INVEST OPHTH VIS SCI, V52, P2372, DOI 10.1167/iovs.10-6268
   Fingert JH, 2007, AM J OPHTHALMOL, V144, P974, DOI 10.1016/j.ajo.2007.09.034
   Fuse N, 2008, MOL VIS, V14, P1338
   Hayashi H, 2008, AM J OPHTHALMOL, V145, P582, DOI 10.1016/j.ajo.2007.10.023
   Hewitt AW, 2008, HUM MOL GENET, V17, P710, DOI 10.1093/hmg/ddm342
   Jaimes M, 2012, OPHTHALMIC GENET, V33, P12, DOI 10.3109/13816810.2011.615078
   Kasim B, 2013, MOL VIS, V19, P114
   KENYON K, 1993, J BIOL CHEM, V268, P18435
   KIM YH, 1995, J BIOL CHEM, V270, P7176, DOI 10.1074/jbc.270.13.7176
   Lee KYC, 2009, MOL VIS, V15, P1120
   Lemmela S, 2009, J HUM GENET, V54, P289, DOI 10.1038/jhg.2009.28
   Mabuchi F, 2008, MOL VIS, V14, P1303
   Malukiewicz G, 2011, ACTA OPHTHALMOL, V89, pE64, DOI 10.1111/j.1755-3768.2010.02083.x
   Mayinu, 2011, MOL VIS, V17, P1734
   Micheal S, 2012, MOL VIS, V18, P1040
   Mori K, 2008, MOL VIS, V14, P1037
   Mossbock G, 2008, MOL VIS, V14, P857
   Naumann GOH, 1998, OPHTHALMOLOGY, V105, P951, DOI 10.1016/S0161-6420(98)96020-1
   Ozaki M, 2008, INVEST OPHTH VIS SCI, V49, P3976, DOI 10.1167/iovs.08-1805
   Park DY, 2013, MOL VIS, V19, P448
   Pasutto F, 2008, INVEST OPHTH VIS SCI, V49, P1459, DOI 10.1167/iovs.07-1449
   Ramprasad VL, 2008, MOL VIS, V14, P318
   Rautenbach RM, 2011, ARCH OPHTHALMOL-CHIC, V129, P206, DOI 10.1001/archophthalmol.2010.349
   Ritch R, 1994, J Glaucoma, V3, P176
   Ritch R, 2001, SURV OPHTHALMOL, V45, P265, DOI 10.1016/S0039-6257(00)00196-X
   Sagong M, 2011, MOL VIS, V17, P2808
   Schlotzer-Schrehardt U, 2012, OPHTHALMOLOGY, V119, P1832, DOI 10.1016/j.ophtha.2012.03.015
   Schlotzer-Schrehardt U, 2006, AM J OPHTHALMOL, V141, P921, DOI 10.1016/j.ajo.2006.01.047
   Sein J, 2013, CURR OPIN OPHTHALMOL, V24, P167, DOI 10.1097/ICU.0b013e32835d5d11
   Tanito M, 2008, MOL VIS, V14, P1898
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Williams SEI, 2010, MOL VIS, V16, P705
   Wolf C, 2010, J GLAUCOMA, V19, P136, DOI 10.1097/IJG.0b013e31819f9330
   Yang X, 2008, CELL CYCLE, V7, P521, DOI 10.4161/cc.7.4.5388
NR 42
TC 9
Z9 11
U1 3
U2 12
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD FEB 18
PY 2015
VL 8
IS 1
BP 148
EP 156
DI 10.3980/j.issn.2222-3959.2015.01.27
PG 9
WC Ophthalmology
SC Ophthalmology
GA CB3GW
UT WOS:000349517200027
PM 25709925
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Briones, TL
   Woods, J
   Wadowska, M
AF Briones, Teresita L.
   Woods, Julie
   Wadowska, Magdalena
TI RETRACTED: Involvement of insulin-like growth factor-1 in
   chemotherapy-related cognitive impairment (Retracted article. See vol.
   296, pg. 468, 2016)
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article; Retracted Publication
DE Apoptosis; Rat; Akt signaling; Erk1/2 signaling
ID HIPPOCAMPAL CELL-PROLIFERATION; BREAST-CANCER; ADJUVANT CHEMOTHERAPY;
   DENTATE GYRUS; MEMORY; RAT; 5-FLUOROURACIL; METHOTREXATE; MICE; NEURONS
AB Here we examined the involvement of insulin-like growth factor 1 (IGF-1) on chemotherapy-induced cognitive impairment. Sixty-four ovariectomized female Sprague-Dawley rats were included in the study and given cyclophosphamide, methothrexate, and 5-fluorouracil (CMF) drug combination or saline (control). CMF was-given once a week for 4-weeks. In one-experiment, behavioral testing using the cued learning and spontaneous object recognition tasks were performed either: at the end of treatment or 4 weeks after treatment. In another experiment, rats from the chemotherapy and saline groups received either: continuous insulin-like growth factor 1 (IGF-1) or vehicle delivered subcutaneously via osmotic pump for 21 days (started the week after completion of therapy). Bromodeoxyuridine injections were given for 3 consecutive days starting at 2 weeks after completion of chemotherapy to assess the survival of proliferating cells. Increased levels of IGF-1 and activation of its receptor as well as increased activation of Akt and Erk1/2, its downstream signaling pathways was seen immediately after completion of chemotherapy but decreased 4 weeks after treatment. Behavioral testing showed CMF-induced cognitive impairment after completion of therapy and persisted for 4 weeks. We also found that giving IGF-1 significantly increased activation of its receptor, and the Akt and Erk1/2 pathways, and most importantly attenuated chemotherapy-induced cognitive impairment. CMF-induced neuronal apoptosis was also seen and the ratio of surviving cells that proliferate was higher compared to the number of apoptotic cells in the CMF rats given IGF-1. These results suggest that IGF-1 is involved in CMF-induced cognitive impairment by modulating cell death and cell proliferation. (C) 2014 The Authors. Published by Elsevier B.V.
C1 [Briones, Teresita L.] Wayne State Univ, Dept Adult Hlth, Detroit, MI 48202 USA.
   [Woods, Julie; Wadowska, Magdalena] Univ Illinois, Dept Biobehav Hlth Sci, Chicago, IL 60612 USA.
RP Briones, TL (reprint author), Wayne State Univ, Dept Adult Hlth, 5557 Cass Ave,Cohn Bldg,Rm 344, Detroit, MI 48202 USA.
EM tbriones@wayne.edu
FU National Institutes of Health; NINR [RO1 NR007666]; Wayne State
   University Katharine Faville Endowment Funds
FX We are also grateful for the assistance of Maria Palu in tissue imaging.
   We would also like to thank Melanie Cortez and Marilyn Cruz for
   technical assistance in tissue processing. This work was supported in
   part by the National Institutes of Health, NINR grant # RO1 NR007666 (to
   TLB) and the Wayne State University Katharine Faville Endowment Funds
   (TLB).
CR Ahles TA, 2007, NAT REV CANCER, V7, P192, DOI 10.1038/nrc2073
   Ahles Tim A, 2002, Clin Breast Cancer, V3 Suppl 3, pS84, DOI 10.3816/CBC.2002.s.018
   Aleman A, 2009, PROG NEUROBIOL, V89, P256, DOI 10.1016/j.pneurobio.2009.07.008
   Anderson-Hanley C, 2003, J INT NEUROPSYCH SOC, V9, P967, DOI 10.1017/S1355617703970019
   Bender CM, 2006, PSYCHO-ONCOL, V15, P422, DOI 10.1002/pon.964
   Briones TL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-244
   Briones TL, 2011, J NEUROTRAUM, V28, P2485, DOI 10.1089/neu.2011.1842
   Briones TL, 2011, BMC NEUROSCI, V9, P124
   Briones TL, 2013, BRAIN BEHAV IMMUN, V35, P23
   Bruchim I, 2009, EXPERT OPIN THER TAR, V13, P1179, DOI 10.1517/14728220903201702
   Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675
   Donovan KA, 2005, CANCER, V104, P2499, DOI 10.1002/cncr.21482
   Fernandez AM, 2012, NAT REV NEUROSCI, V13, P225, DOI 10.1038/nrn3209
   Fremouw T, 2012, BEHAV BRAIN RES, V226, P154, DOI 10.1016/j.bbr.2011.09.013
   GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x
   Janelsins MC, 2010, ANN BEHAV MED, V2010, P2010
   Janelsins MC, 2011, SEMIN ONCOL, V38, P431, DOI 10.1053/j.seminoncol.2011.03.014
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Lee GD, 2006, CLIN CANCER RES, V12, P198, DOI 10.1158/1078-0432.CCR-05-1286
   Levine MN, 2006, NEW ENGL J MED, V355, P1920, DOI 10.1056/NEJMe068204
   Liu W, 2009, J NEUROSCI RES, V87, P2821, DOI 10.1002/jnr.22129
   MacLeod JE, 2007, BEHAV BRAIN RES, V181, P168, DOI 10.1016/j.bbr.2007.04.003
   Mustafa S, 2008, EUR J NEUROSCI, V28, P323, DOI 10.1111/j.1460-9568.2008.06325.x
   Nelson TJ, 2008, EUR J PHARMACOL, V585, P76, DOI 10.1016/j.ejphar.2008.01.051
   Quesnel C, 2009, BREAST CANCER RES TR, V116, P113, DOI 10.1007/s10549-008-0114-2
   Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002
   Reiriz AB, 2006, CLIN CANCER RES, V12, P5000, DOI 10.1158/1078-0432.CCR-06-0138
   Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021
   Sakane T, 1999, J DRUG TARGET, V7, P233, DOI 10.3109/10611869909085506
   Scherwath A, 2006, ANN ONCOL, V17, P415, DOI 10.1093/annonc/mdj108
   Seigers R, 2008, BEHAV BRAIN RES, V186, P168, DOI 10.1016/j.bbr.2007.08.004
   Seigers R, 2010, BRAIN RES BULL, V81, P472, DOI 10.1016/j.brainresbull.2009.10.006
   Seigers R, 2009, BEHAV BRAIN RES, V201, P279, DOI 10.1016/j.bbr.2009.02.025
   Torres-Aleman I, 2010, DEV NEUROBIOL, V70, P384, DOI 10.1002/dneu.20778
   West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9
   Williams-Brown Shanita, 2005, Semin Oncol Nurs, V21, P236, DOI 10.1016/j.soncn.2005.06.004
   Winocur G, 2006, PHARMACOL BIOCHEM BE, V85, P66, DOI 10.1016/j.pbb.2006.07.010
NR 37
TC 4
Z9 4
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD FEB 15
PY 2015
VL 279
BP 112
EP 122
DI 10.1016/j.bbr.2014.02.052
PG 11
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA AZ5IO
UT WOS:000348255200016
PM 24632471
OA Other Gold, Green Accepted
DA 2018-12-27
ER

PT J
AU Liu, GJ
   Wu, Q
   Liu, GL
   Song, XY
   Zhang, JH
AF Liu, Guijuan
   Wu, Qiang
   Liu, Guilan
   Song, Xueying
   Zhang, Jihong
TI RETRACTED: Psoriasin (S100A7) is a novel biomarker for lung squamous
   cell carcinoma in humans (Retracted article. See vol. 16, 40, 2016)
SO CANCER CELL INTERNATIONAL
LA English
DT Article; Retracted Publication
DE Lung squamous cell carcinoma; S100A7; NF-kappa B
ID CALCIUM-BINDING PROTEINS; NF-KAPPA-B; BREAST-CANCER; EXPRESSION; SKIN;
   GENE; IDENTIFICATION; INFLAMMATION; METASTASIS; ACTIVATION
AB Objective: Psoriasin (S100A7) plays a role in the malignant potential of several epithelial cancers, and could candidate diagnostic marker or therapeutic target. Nuclear factor kappa B (NF-.B) regulates cancer cell growth and is modulated by phospholipase activity in many cancer cells. In the present study, we first evaluate the involvement of S100A7 in lung squamous cell carcinoma and its clinical usefulness for diagnosis. We then study whether knockdown of S100A7 in lung squamous cell carcinoma cells would reduce cell proliferation and NF-.B activity in vitro and attenuate tumor growth in vivo.
   Methods: We examined S100A7 expression in lung squamous cell carcinoma tissues by immunohistology. The human lung squamous cell carcinoma cell line NCI-H520 were transduced with short hairpin RNA targeting S100A7. Quantitative reverse transcriptase-polymerase chain reaction and immunoblotting confirmed knockdown of S100A7 messenger RNA and protein, respectively. Cell proliferation was evaluated by the MTT assay. NF-.B phosphorylation was assayed by western blot. 1 x 106 of NCI-H520/S100A7 knockdown cells were injected into the left flanks of nude mice (aged 6 to 8 weeks). Tumors were followed for 35 days, then removed and stained with hematoxylin and eosin, stained with Ki-67, and analyzed for S100A7 protein expression.
   Results: S100A7 protein levels were significantly higher in carcinoma specimens than in nonneoplastic tissues. S100A7 might be a useful marker for diagnosis of lung squamous cell carcinoma. In vitro data showed that inhibition of S100A7 decreased proliferation of NCI-H520 cells. S100A7 knockdown reduced NF-.B phosphorylation and tumor growth in vivo and vivo. Explanted knockdown tumors maintained lower S100A7 levels compared with wild-type, confirmed by immunohistology. Ki-67 staining was more prominent throughout the wild-type tumors compared with knockdown tumors.
   Conclusions: Our present results suggest that S100A7 level is a promising tool for diagnosis of lung squamous cell carcinoma. Knockdown of S100A7 suppresses lung cancer growth in part by attenuating NF-.B activity. S100A7 may be a promising therapeutic target for lung squamous cell carcinoma.
C1 [Liu, Guijuan] Peoples Hosp Linyi, Dept Cytol Lab, Linyi 276300, Shandong, Peoples R China.
   [Wu, Qiang; Liu, Guilan; Zhang, Jihong] Peoples Hosp Yinan, Dept Nursing, Linyi 276300, Shandong, Peoples R China.
   [Song, Xueying] Peoples Hosp Rizhao, Dept Thorac Surg, Rizhao, Peoples R China.
RP Zhang, JH (reprint author), Peoples Hosp Yinan, Dept Nursing, Linyi 276300, Shandong, Peoples R China.
EM zjhchina@sohu.com
CR Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1
   Alowami S, 2007, BMC DERMATOL, V3, P1
   Alowami Salem, 2003, BMC Dermatol, V3, P1, DOI 10.1186/1471-5945-3-1
   Celis JE, 1996, J UROLOGY, V155, P2105, DOI 10.1016/S0022-5347(01)66118-4
   Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837
   El-Rifai W, 2002, CANCER RES, V62, P6823
   Enerback C, 2002, CANCER RES, V62, P43
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/j.cell.2011.02.013
   HOFFMANN HJ, 1994, J INVEST DERMATOL, V103, P370, DOI 10.1111/1523-1747.ep12395202
   Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Khromova N, 2012, ONCOGENE, V31, P1389, DOI 10.1038/onc.2011.330
   Leygue E, 1996, CANCER RES, V56, P4606
   Liu HM, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-93
   MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041
   Marek L, 2009, MOL PHARMACOL, V75, P196, DOI 10.1124/mol.108.049544
   Moubayed N, 2007, J CANCER RES CLIN, V133, P253, DOI 10.1007/s00432-006-0164-y
   Ostergaard M, 1997, CANCER RES, V57, P4111
   Ovstebo R, 2003, CLIN CHEM, V49, P425, DOI 10.1373/49.3.425
   Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8
   Sobin L, 2002, TNM CLASSIFICATION M
   Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284
   Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2
   Nguyen TT, 2012, J DERMATOL SCI, V68, P63, DOI 10.1016/j.jdermsci.2012.07.010
   VIGNAUD JM, 1994, CANCER RES, V54, P5455
   Watson PH, 1998, INT J BIOCHEM CELL B, V30, P567, DOI 10.1016/S1357-2725(97)00066-6
   Webb M, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-17
   *WHO, 1999, HIST TYP LUNG PLEUR
   Zhang H, 2008, THORAX, V63, P352, DOI 10.1136/thx.2007.087015
   Zhang H, 2007, LUNG CANCER, V57, P37, DOI 10.1016/j.lungcan.2007.02.020
NR 30
TC 4
Z9 4
U1 3
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD FEB 12
PY 2015
VL 15
AR 18
DI 10.1186/s12935-014-0154-0
PG 9
WC Oncology
SC Oncology
GA CC6VR
UT WOS:000350507600001
PM 25745359
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Zhou, T
   Wang, NP
   Xue, Y
   Ding, TT
   Liu, X
   Mo, XM
   Sun, J
AF Zhou, Tian
   Wang, Nanping
   Xue, Yang
   Ding, Tingting
   Liu, Xin
   Mo, Xiumei
   Sun, Jiao
TI RETRACTED: Development of Biomimetic Tilapia Collagen Nanofibers for
   Skin Regeneration through Inducing Keratinocytes Differentiation and
   Collagen Synthesis of Dermal Fibroblasts (Retracted article. See vol. 7,
   pg. 19863, 2015)
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article; Retracted Publication
DE electospinning tilapia collagen naofibers; HaCats differentiation;
   TGF-beta 1; collagen synthesis; skin regeneration
ID FISH; SALMON; SCALE; BONE; COMPOSITE; SCAFFOLDS
AB In this study, tilapia skin collagen sponge and electrospun nanofibers were developed for wound dressing. The collagen sponge was composed of at least two a-peptides, and its denaturation temperature was 44.99 degrees C. It did not change the number of spleen-derived lymphocytes in BALB/c mice, the ratio of CD4(+)/CD8(+) lymphocytes, and the level of IgG or IgM in Sprague-Dawley rat. The contact angle, tensile strength, and weight loss temperature of collagen nanofibers were 21.2 degrees, 6.72 +/- 0.44 MPa, and 300 degrees C, respectively. The nanofibers could promote the viabilities of human keratinocytes (HaCaTs) and human dermal fibroblasts (HDFs), inducing epidermal differentiation through the gene expression of involucrin, filaggrin, and type I transglutaminase of HaCaTs, and they could also accelerate migration of HaCaTs with the expression of matrix metalloproteinase-9 and transforming growth factor-beta 1 (TGF-beta 1). Besides, the nanofibers could upregulate the protien level of Col-I in HDFs both via a direct effect and TGF-beta 1 secreted from HaCaTs, thus facilitating the formation of collagen fibers. Furthermore, the collagen nanofibers stimulated the skin regeneration rapidly and effectively in vivo. These biological effects could be explained as the contributions from the biomimic extracellular cell matrix structure, hydrophilicity, and the multiple amino acids of the collagen nanofibers.
C1 [Zhou, Tian; Xue, Yang; Ding, Tingting; Liu, Xin; Sun, Jiao] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Shanghai Biomat Res & Testing Ctr,Shanghai Key La, Shanghai 200023, Peoples R China.
   [Wang, Nanping] Shanghai Fisheries Res Inst, Shanghai 200433, Peoples R China.
   [Mo, Xiumei] Donghua Univ, Chem Engn & Biotechnol, Coll Chem, Shanghai 201620, Peoples R China.
RP Mo, XM (reprint author), Donghua Univ, Chem Engn & Biotechnol, Coll Chem, Shanghai 201620, Peoples R China.
EM xmm@dhu.edu.cn; jiaosun59@l26.com
RI mo, xiumei/C-9340-2013
FU Natural Science Foundation of China [31470917, 31470941]
FX This work was supported by grants from Natural Science Foundation of
   China (nos. 31470917, 31470941).
CR Annaidh AN, 2012, J MECH BEHAV BIOMED, V5, P139, DOI 10.1016/j.jmbbm.2011.08.016
   Barton L, 2014, MEAT SCI, V96, P346, DOI 10.1016/j.meatsci.2013.07.016
   Bentkover SH, 2009, FACIAL PLAST SURG, V25, P73, DOI 10.1055/s-0029-1220646
   BURJANADZE TV, 1992, BIOPOLYMERS, V32, P941, DOI 10.1002/bip.360320805
   Chen LC, 2004, FISHERIES SCI, V70, P293, DOI 10.1111/j.1444-2906.2003.00803.x
   Chen S, 2011, ACTA BIOMATER, V7, P644, DOI 10.1016/j.actbio.2010.09.014
   Duan HC, 2013, INT J NANOMED, V8, P2077, DOI 10.2147/IJN.S42384
   Duan R, 2009, FOOD CHEM, V112, P702, DOI 10.1016/j.foodchem.2008.06.020
   Fu XL, 2014, BIOMATERIALS, V35, P1496, DOI 10.1016/j.biomaterials.2013.11.013
   Gomez-Guillen MC, 2011, FOOD HYDROCOLLOID, V25, P1813, DOI 10.1016/j.foodhyd.2011.02.007
   Hata S, 2014, J PHARMACOL SCI, V124, P230, DOI 10.1254/jphs.13209FP
   Hoyer B, 2012, BIOMACROMOLECULES, V13, P1059, DOI 10.1021/bm201776r
   Kumar PTS, 2013, TISSUE ENG PT A, V19, P380, DOI [10.1089/ten.tea.2012.0376, 10.1089/ten.TEA.2012.0376]
   Thuy LTM, 2014, FOOD CHEM, V149, P264, DOI 10.1016/j.foodchem.2013.10.094
   Li HYS, 2007, J AUTOIMMUN, V28, P171, DOI 10.1016/j.jaut.2007.01.001
   Liu C, 2014, BIOMACROMOLECULES, V15, P436, DOI 10.1021/bm401780v
   Lu HJ, 2008, MICROBIOL IMMUNOL, V52, P440, DOI 10.1111/j.1348-0421.2008.00057.x
   Matsumoto Y, 2011, BIOMED RES-TOKYO, V32, P29, DOI 10.2220/biomedres.32.29
   Muthukumar T, 2014, COLLOID SURFACE B, V113, P207, DOI 10.1016/j.colsurfb.2013.09.019
   Nagiah N, 2013, MAT SCI ENG C-MATER, V33, P4444, DOI 10.1016/j.msec.2013.06.042
   Narins RS, 2007, DERMATOL SURG, V33, pS213, DOI 10.1111/j.1524-4725.2007.33364.x
   Pereira RF, 2013, NANOMEDICINE-UK, V8, P603, DOI [10.2217/NNM.13.50, 10.2217/nnm.13.50]
   Sankar S, 2008, INT J BIOL MACROMOL, V42, P6, DOI 10.1016/j.ijbiomac.2007.08.003
   Shen XR, 2008, J MATER SCI-MATER M, V19, P3473, DOI 10.1007/s10856-008-3512-4
   Terada M, 2012, J BIOMED MATER RES B, V100B, P1792, DOI 10.1002/jbm.b.32746
   Tian F, 2008, J BIOMED MATER RES A, V84A, P291, DOI 10.1002/jbm.a.31304
   Wang L, 2007, J FOOD SCI, V72, pE450, DOI 10.1111/j.1750-3841.2007.00478.x
   Yamamoto K., 2014, BIOMED RES INT, V2014, DOI [10. 1155/2014/630757 24809058, DOI 10.1155/2014/63075724809058]
   Yoshioka SA, 2008, J MATER SCI-MATER M, V19, P1215, DOI 10.1007/s10856-007-0151-0
   Zablocka A, 2014, BIOFACTORS, V40, P501, DOI 10.1002/biof.1174
   Zhu XF, 2012, MOL CELL BIOCHEM, V369, P255, DOI 10.1007/s11010-012-1389-5
NR 31
TC 18
Z9 18
U1 4
U2 84
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD FEB 11
PY 2015
VL 7
IS 5
BP 3253
EP 3262
DI 10.1021/am507990m
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA CB4EK
UT WOS:000349580800031
PM 25598076
DA 2018-12-27
ER

PT J
AU Gomez-Selles, JL
   Claverie, A
   Sklenard, B
   Benistant, F
   Martin-Bragado, I
AF Gomez-Selles, Jose L.
   Claverie, Alain
   Sklenard, Benoit
   Benistant, Francis
   Martin-Bragado, Ignacio
TI RETRACTED: Atomistic simulation of damage accumulation and amorphization
   in Ge(Retracted article.See vol.121,ARTN 049901,2017)
SO JOURNAL OF APPLIED PHYSICS
LA English
DT Article; Retracted Publication
ID ION-IMPLANTATION; CRYSTALLINE GERMANIUM; RADIATION-DAMAGE; SILICON;
   RECRYSTALLIZATION; DEFECTS; ACTIVATION; DIFFUSION; GE
AB Damage accumulation and amorphization mechanisms by means of ion implantation in Ge are studied using Kinetic Monte Carlo and Binary Collision Approximation techniques. Such mechanisms are investigated through different stages of damage accumulation taking place in the implantation process: from point defect generation and cluster formation up to full amorphization of Ge layers. We propose a damage concentration amorphization threshold for Ge of similar to 1.3 x 10(22) cm(-3) which is independent on the implantation conditions. Recombination energy barriers depending on amorphous pocket sizes are provided. This leads to an explanation of the reported distinct behavior of the damage generated by different ions. We have also observed that the dissolution of clusters plays an important role for relatively high temperatures and fluences. The model is able to explain and predict different damage generation regimes, amount of generated damage, and extension of amorphous layers in Ge for different ions and implantation conditions. (C) 2015 AIP Publishing LLC.
C1 [Gomez-Selles, Jose L.; Martin-Bragado, Ignacio] IMDEA Mat Inst, Madrid 28906, Spain.
   [Claverie, Alain] CNRS, CEMES, F-31055 Toulouse, France.
   [Sklenard, Benoit] CEA, LETI, F-38054 Grenoble 9, France.
   [Benistant, Francis] GLOBALFOUNDRIES Singapore Pte Ltd, Singapore 738406, Singapore.
RP Gomez-Selles, JL (reprint author), IMDEA Mat Inst, Eric Kandel 2, Madrid 28906, Spain.
EM joseluis.gomezselles@imdea.org
OI Gomez-Selles, Jose Luis/0000-0001-8144-4241
FU GLOBALFOUNDRIES; Spanish Ministry of Economy and Competitiveness
   (MINECO) under Ramon y Cajal fellowship [RYC-2012-10639]
FX J.L.G.-S. acknowledges L. Agudo-Merida (IMDEA Materials Institute) and
   R. Gonzalez-Arrabal (NFI-UPM) for enlightening discussions. IMDEA
   Materials Institute acknowledges funding by GLOBALFOUNDRIES. I.M.-B.
   acknowledges funding from the Spanish Ministry of Economy and
   Competitiveness (MINECO) under Ramon y Cajal fellowship RYC-2012-10639.
CR [Anonymous], SENT PROC US GUID
   Boninelli S, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4759031
   Boninelli S, 2012, NUCL INSTRUM METH B, V282, P21, DOI 10.1016/j.nimb.2011.08.039
   Chao YL, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2076440
   Chroneos A, 2014, APPL PHYS REV, V1, DOI 10.1063/1.4838215
   CLAVERIE A, 1989, MAT SCI ENG B-SOLID, V2, P99, DOI 10.1016/0921-5107(89)90083-4
   Claverie A, 2010, THIN SOLID FILMS, V518, P2307, DOI 10.1016/j.tsf.2009.09.162
   CLAVERIE A, 1988, J APPL PHYS, V64, P4415, DOI 10.1063/1.341264
   Darby BL, 2013, J APPL PHYS, V113, DOI 10.1063/1.4776718
   Decoster S, 2009, J PHYS D APPL PHYS, V42, DOI 10.1088/0022-3727/42/16/165404
   Duffy R., 2013, 13 INT WORKSH JUNCT, P16
   Goley PS, 2014, MATERIALS, V7, P2301, DOI 10.3390/ma7032301
   Guo B. N., 2002, P 14 INT C ION IMPL, P131
   Impellizzeri G, 2011, APPL PHYS A-MATER, V103, P323, DOI 10.1007/s00339-010-6123-0
   Impellizzeri G, 2009, J APPL PHYS, V105, DOI 10.1063/1.3091289
   KEATING PN, 1966, PHYS REV, V145, P637, DOI 10.1103/PhysRev.145.637
   Koffel S, 2009, J APPL PHYS, V105, DOI 10.1063/1.3041653
   Kuhn KJ, 2012, IEEE T ELECTRON DEV, V59, P1813, DOI 10.1109/TED.2012.2193129
   LU GQ, 1990, APPL PHYS LETT, V56, P137, DOI 10.1063/1.103053
   Martin-Bragado I, 2004, APPL PHYS LETT, V84, P4962, DOI 10.1063/1.1762696
   Martin-Bragado I, 2013, COMPUT PHYS COMMUN, V184, P2703, DOI 10.1016/j.cpc.2013.07.011
   Martin-Bragado I, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3236535
   MAZZONE AM, 1988, PHIL MAG LETT, V57, P85, DOI 10.1080/09500838808229615
   Mirabella S, 2013, J APPL PHYS, V113, DOI 10.1063/1.4763353
   MITCHELL EWJ, 1957, BRIT J APPL PHYS, V8, P179, DOI 10.1088/0508-3443/8/5/301
   Mok KRC, 2008, J APPL PHYS, V103, DOI 10.1063/1.2829815
   Morehead F. F.  Jr., 1970, Radiation Effects, V6, P27, DOI 10.1080/00337577008235042
   Napolitani E, 2014, PHYS STATUS SOLIDI A, V211, P118, DOI 10.1002/pssa.201300324
   Olson G. L., 1988, Material Science Reports, V3, P1, DOI 10.1016/S0920-2307(88)80005-7
   Pelaz L, 2004, J APPL PHYS, V96, P5947, DOI 10.1063/1.1808484
   Pillarisetty R, 2011, NATURE, V479, P324, DOI 10.1038/nature10678
   Posselt M, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2360238
   Satta A, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2117631
   Spiewak P, 2008, J APPL PHYS, V103, DOI 10.1063/1.2907730
   Stoller RE, 2013, NUCL INSTRUM METH B, V310, P75, DOI 10.1016/j.nimb.2013.05.008
   Sueoka K, 2006, MAT SCI SEMICON PROC, V9, P494, DOI 10.1016/j.mssp.2006.08.004
   Vanhellemont J, 2007, J APPL PHYS, V101, DOI 10.1063/1.2429718
   Vieu C., 1992, PHASE TRANSFORMATION
   Wittmann R, 2007, SOLID STATE ELECTRON, V51, P982, DOI 10.1016/j.sse.2007.03.019
   Ziegler J. F., 2008, SRIM STOPPING RANGE
NR 40
TC 3
Z9 3
U1 5
U2 19
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0021-8979
EI 1089-7550
J9 J APPL PHYS
JI J. Appl. Phys.
PD FEB 7
PY 2015
VL 117
IS 5
AR 055703
DI 10.1063/1.4907211
PG 7
WC Physics, Applied
SC Physics
GA CB4QT
UT WOS:000349613600063
OA Green Published
DA 2018-12-27
ER

PT J
AU Deng, Y
   Xie, M
   Xie, L
   Wang, J
   Li, TJ
   He, Y
   Li, RL
   Li, S
   Qin, X
AF Deng, Yan
   Xie, Ming
   Xie, Li
   Wang, Jian
   Li, Taijie
   He, Yu
   Li, Ruolin
   Li, Shan
   Qin, Xue
TI RETRACTED: Association between Polymorphism of the Interleukin-13 Gene
   and Susceptibility to Hepatocellular Carcinoma in the Chinese
   Population(Retracted article. See vol. 12, Artn. No. E0181509, 2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID HEPATITIS-B-VIRUS; ALLERGIC INFLAMMATION; COLORECTAL-CANCER; IL-13;
   RISK; METAANALYSIS; PATHOGENESIS; VARIANTS; RHINITIS; ASTHMA
AB Objective
   Interleukin-13 (IL-13) is a potent pleiotropic cytokine that is produced by activated CD4 T cells. This study was undertaken to determine the relationship between two IL-13 gene single nucleotide polymorphisms (SNP rs1800925 and SNP rs20541) and the incidence of hepatitis B virus-related (HBV) hepatocellular carcinoma (HCC).
   Method
   Three hundred and ninety-eight HBV-positive individuals (192 HCC and 206 patients with chronic hepatitis) and one hundred and ninety-two healthy participants from the First Affiliated Hospital of Guangxi Medical University were enrolled in this study.
   Results
   The results showed no significant differences between the genotype and allele frequencies of the IL-13 gene rs1800925 and rs20541 polymorphisms and chronic hepatitis B risk after adjusting for age, sex, tobacco use, and alcohol intake using binary logistic regression analyses. Regarding the rs20541 SNP, the GA genotype was significantly related to a decreased risk of HCC after adjusting for age, sex, tobacco use, and alcohol intake using binary logistic regression analyses (The odds ratio (OR) = 0.54, 95% confidence intervals (CI) 0.34-0.87). The adjusted OR for the GA and AA genotypes combined was 0.68 (95% CI 0.39-0.90).
   Conclusion
   This study indicates that the functional IL-13 rs20541 polymorphism may contribute to the risk of HCC and that the rs20541 polymorphism is a protective factor for HCC.
C1 [Deng, Yan; Xie, Ming; Xie, Li; Wang, Jian; Li, Taijie; He, Yu; Li, Shan; Qin, Xue] Guangxi Med Univ, Affiliated Hosp 1, Dept Clin Lab, Nanning, Guangxi, Peoples R China.
   [Li, Ruolin] Guangxi Med Univ, Affiliated Hosp 1, Dept Med Res, Nanning, Guangxi, Peoples R China.
RP Li, S (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Clin Lab, Nanning, Guangxi, Peoples R China.
EM lis8858@126.com; qinxue919@126.com
FU Youth Science Foundation of Guangxi Medical University [GXMUYSF201334]
FX This research was supported by Youth Science Foundation of Guangxi
   Medical University (GXMUYSF201334). The funder had a role in the
   preparation of this manuscript.
CR Chiurillo MA, 2014, WORLD J GASTROENTERO, V20, P4503, DOI 10.3748/wjg.v20.i16.4503
   BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J
   Bottema RWB, 2010, INT ARCH ALLERGY IMM, V153, P259, DOI 10.1159/000314366
   Brenner AV, 2007, CARCINOGENESIS, V28, P2543, DOI 10.1093/carcin/bgm210
   Brombacher F, 2000, BIOESSAYS, V22, P646, DOI 10.1002/1521-1878(200007)22:7<646::AID-BIES7>3.3.CO;2-0
   Cameron L, 2006, J IMMUNOL, V177, P8633, DOI 10.4049/jimmunol.177.12.8633
   Chang JJ, 2007, IMMUNOL CELL BIOL, V85, P16, DOI 10.1038/sj.icb.7100009
   Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044
   Chu HY, 2012, MOL BIOL REP, V39, P5349, DOI 10.1007/s11033-011-1334-9
   Cui L, 2012, CLIN BIOCHEM, V45, P285, DOI 10.1016/j.clinbiochem.2011.12.012
   Formentini A, 2012, INT J COLORECTAL DIS, V27, P1369, DOI 10.1007/s00384-012-1456-0
   Gelfand EW, 2004, J ALLERGY CLIN IMMUN, V114, pS135, DOI 10.1016/j.jaci.2004.08.043
   Grzegorzewska AE, 2013, MOL BIOL REP, V40, P6899, DOI 10.1007/s11033-013-2809-7
   Hohler T, 2005, HEPATOLOGY, V42, P72, DOI 10.1002/hep.20740
   Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016
   Lesina M, 2014, SEMIN IMMUNOL, V26, P80, DOI 10.1016/j.smim.2014.01.002
   Li S, 2011, INFECT GENET EVOL, V11, P2083, DOI 10.1016/j.meegid.2011.09.025
   Liu HY, 2000, CANCER IMMUNOL IMMUN, V49, P319, DOI 10.1007/s002620000110
   McKillop IH, 2006, J SURG RES, V136, P125, DOI 10.1016/j.jss.2006.04.013
   Moradpour D, 2005, EUR J GASTROEN HEPAT, V17, P477, DOI 10.1097/00042737-200505000-00002
   Sainz J, 2012, J CLIN ENDOCR METAB, V97, pE845, DOI 10.1210/jc.2011-2565
   Skinnider BF, 2001, INT ARCH ALLERGY IMM, V126, P267, DOI 10.1159/000049523
   Su T, 2013, GENE, V515, P56, DOI 10.1016/j.gene.2012.11.035
   Sun G, 2013, CANCER EPIDEMIOL, V37, P306, DOI 10.1016/j.canep.2013.01.003
   Terabe M, 2004, CANCER IMMUNOL IMMUN, V53, P79, DOI 10.1007/s00262-003-0445-0
   Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771
   Vercelli Donata, 2002, Curr Opin Allergy Clin Immunol, V2, P389, DOI 10.1097/00130832-200210000-00004
   Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818
   Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142
   Ying XJ, 2013, GENE, V521, P222, DOI 10.1016/j.gene.2013.03.088
   YU MW, 1994, CRIT REV ONCOL HEMAT, V17, P71, DOI 10.1016/1040-8428(94)90020-5
   Zhu VF, 2012, CANCER LETT, V316, P139, DOI 10.1016/j.canlet.2011.11.001
NR 32
TC 6
Z9 6
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 6
PY 2015
VL 10
IS 2
AR e0116682
DI 10.1371/journal.pone.0116682
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CB2GK
UT WOS:000349444900056
PM 25658755
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ben Mustapha, N
   Mahmoudi, M
   Bejaoui, M
   Laabidi, A
   Serghini, M
   Kallel, L
   Fekih, M
   Matri, S
   Boubaker, J
   Filali, A
AF Ben Mustapha, N.
   Mahmoudi, M.
   Bejaoui, M.
   Laabidi, A.
   Serghini, M.
   Kallel, L.
   Fekih, M.
   Matri, S.
   Boubaker, J.
   Filali, A.
TI RETRACTED: Mean platelet volume and neutrophil-tolymphocyte ratio as new
   biomarkers of predicting response to infliximab therapy in Crohn's
   Disease patients (Retracted article. See vol. 9, pg. 596, 2015)
SO JOURNAL OF CROHNS & COLITIS
LA English
DT Meeting Abstract; Retracted Publication
C1 [Ben Mustapha, N.; Mahmoudi, M.; Bejaoui, M.; Laabidi, A.; Serghini, M.; Kallel, L.; Fekih, M.; Matri, S.; Boubaker, J.; Filali, A.] La Rabta Hosp, Gastroenterol A, Tunis, Tunisia.
NR 0
TC 0
Z9 0
U1 4
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1873-9946
EI 1876-4479
J9 J CROHNS COLITIS
JI J. Crohns Colitis
PD FEB
PY 2015
VL 9
SU 1
MA P635
BP S399
EP S399
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CH1VW
UT WOS:000353811200750
DA 2018-12-27
ER

PT J
AU Hu, XM
   Liu, YN
   Zhang, HL
   Cao, SB
   Zhang, T
   Chen, LP
   Shen, W
AF Hu, Xue-Ming
   Liu, Yan-Nan
   Zhang, Hai-Long
   Cao, Shou-Bin
   Zhang, Ting
   Chen, Li-Ping
   Shen, Wen
TI RETRACTED: CXCL12/CXCR4 chemokine signaling in spinal glia induces pain
   hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer
   rats (Retracted article. See vol. 141, pg. 473, 2017)
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article; Retracted Publication
DE astrocytes; bone cancer pain; chemokine; mitogen-activated protein
   kinase; microglia; neuroinflammation
ID NEUROPATHIC PAIN; PROTEIN-KINASES; CELLS; CORD; CONTRIBUTES; ACTIVATION;
   EXPRESSION; ALLODYNIA; RECEPTOR; CXCR4
AB The activation of MAPK pathways in spinal cord and subsequent production of proinflammatory cytokines in glial cells contribute to the development of spinal central sensitization, the basic mechanism underlying bone cancer pain (BCP). Our previous study showed that spinal CXCL12 from astrocytes mediates BCP generation by binding to CXCR4 in both astrocyters and microglia. Here, we verified that CXCL12/CXCR4 signaling contributed to BCP through a MAPK-mediated mechanism. In naive rats, a single intrathecal administration of CXCL12 considerably induced pain hyperalgesia and phosphorylation expression of spinal MAPK members (including extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinase), which could be partially prevented by pre-treatment with CXCR4 inhibitor AMD3100. This CXCL12-induced hyperalgesia was also reduced by MAPK inhibitors. In bone cancer rats, tumor cell inoculation into the tibial cavity caused prominent and persistent pain hyperalgesia, and associated with up-regulation of CXCL12 and CXCR4, activation of glial cells, phosphorylation of MAPKs, and production of proinflammatory cytokines in the spinal cord. These tumor cell inoculation-induced behavioral and neurochemical alterations were all suppressed by blocking CXCL12/CXCR4 signaling or MAPK pathways. Taken together, these results demonstrate that spinal MAPK pathways mediated CXCL12/CXCR4-induced pain hypersensitivity in bone cancer rats, which could be druggable targets for alleviating BCP and glia-derived neuroinflammation.
C1 [Hu, Xue-Ming; Chen, Li-Ping; Shen, Wen] Xuzhou Med Coll, Affiliated Hosp, Dept Pain Med, Xuzhou 221002, Peoples R China.
   [Liu, Yan-Nan; Zhang, Hai-Long; Cao, Shou-Bin; Zhang, Ting; Shen, Wen] Xuzhou Med Coll, Jiangsu Prov Key Lab Anesthesiol, Xuzhou 221002, Peoples R China.
RP Shen, W (reprint author), Xuzhou Med Coll, Affiliated Hosp, Dept Pain Med, 99 Huaihai West Rd, Xuzhou 221002, Peoples R China.
EM shenwen19962@163.com
OI Hu, Xue-Ming/0000-0002-4133-4942
FU natural science research project of Jiangsu Province Higher Education
   Institutions [12KJB320013]; Ministry of Health of the People's Republic
   of China [W201203]
FX This study was supported by a natural science research project of
   Jiangsu Province Higher Education Institutions (12KJB320013) and a
   scientific research fund from Ministry of Health of the People's
   Republic of China (W201203).
CR Austin PJ, 2010, J NEUROIMMUNOL, V229, P26, DOI 10.1016/j.jneuroim.2010.08.013
   Bhangoo SK, 2007, BRAIN BEHAV IMMUN, V21, P581, DOI 10.1016/j.bbi.2006.12.003
   Bian C, 2014, BRAIN BEHAV IMMUN, V37, P220, DOI 10.1016/j.bbi.2013.12.011
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Duan KZ, 2012, PAIN, V153, P562, DOI 10.1016/j.pain.2011.11.020
   Dubovy P, 2010, HISTOCHEM CELL BIOL, V133, P323, DOI 10.1007/s00418-010-0675-0
   Falk S, 2014, J CLIN ONCOL, V32, P1647, DOI 10.1200/JCO.2013.51.7219
   Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002
   Gosselin RD, 2010, NEUROSCIENTIST, V16, P519, DOI 10.1177/1073858409360822
   Guo W, 2007, J NEUROSCI, V27, P6006, DOI 10.1523/JNEUROSCI.0176-07.2007
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7
   Hu S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-278
   Hui J, 2013, J PAIN, V14, P747, DOI 10.1016/j.jpain.2013.02.003
   Ji RR, 2013, PAIN, V154, pS10, DOI 10.1016/j.pain.2013.06.022
   Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kiguchi N, 2012, CURR OPIN PHARMACOL, V12, P55, DOI 10.1016/j.coph.2011.10.007
   Knerlich-Lukoschus F, 2011, J NEUROSURG-SPINE, V14, P583, DOI 10.3171/2010.12.SPINE10480
   Knopp KL, 2011, CURR PHARM BIOTECHNO, V12, P1627
   Li MZ, 2008, PROG NEUROBIOL, V84, P116, DOI 10.1016/j.pneurobio.2007.11.003
   Liu WT, 2010, J NEUROSCI, V30, P7613, DOI 10.1523/JNEUROSCI.1358-10.2010
   Luo DH, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-203
   Mao-Ying QL, 2012, MOL BRAIN, V5, DOI 10.1186/1756-6606-5-16
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7
   Miyoshi K, 2008, J NEUROSCI, V28, P12775, DOI 10.1523/JNEUROSCI.3512-08.2008
   Ohtani Y, 1998, NEUROSCI LETT, V249, P163, DOI 10.1016/S0304-3940(98)00425-X
   Raghavendra V, 2004, EUR J NEUROSCI, V20, P467, DOI 10.1111/j.1460-9568.2004.03514.x
   Reaux-Le Goazigo A, 2012, EUR J NEUROSCI, V36, P2619, DOI 10.1111/j.1460-9568.2012.08179.x
   Ruan JP, 2010, ANESTHESIOLOGY, V112, P1234, DOI 10.1097/ALN.0b013e3181d3e0df
   Sagar DR, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-88
   Shen W, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-75
   Shi JS, 2014, FUTURE ONCOL, V10, P749, DOI 10.2217/fon.13.193
   Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x
   Xu Q, 2013, J NEUROSCI, V33, P19099, DOI 10.1523/JNEUROSCI.4852-12.2013
   Zhang YK, 2013, J CLIN INVEST, V123, P2268, DOI 10.1172/JCI65364
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 36
TC 29
Z9 30
U1 2
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD FEB
PY 2015
VL 132
IS 4
BP 452
EP 463
DI 10.1111/jnc.12985
PG 12
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA CD8ZD
UT WOS:000351384400009
PM 25393328
OA Bronze
DA 2018-12-27
ER

PT J
AU Ahn, YS
   Kasahara, T
   Otsuki, K
   Wakana, I
   Satoh, H
   Nakamura, F
   Takamura, N
   Einarsson, A
   Park, CM
   Seo, JI
   Chun, KW
AF Ahn, Young-Sang
   Kasahara, Tamao
   Otsuki, Kyoichi
   Wakana, Isamu
   Satoh, Hiroki
   Nakamura, Futoshi
   Takamura, Noriko
   Einarsson, Arni
   Park, Chong-Min
   Seo, Jung-Il
   Chun, Kun-Woo
TI RETRACTED: Long-Term Fluctuation in Sedimentary Remains of Aegagropila
   linnaei in Lake Takkobu in Kushiro Mire, Northern Japan (Retracted
   article. See vol. 60, pg. 583, 2015)
SO JOURNAL OF THE FACULTY OF AGRICULTURE KYUSHU UNIVERSITY
LA English
DT Article; Retracted Publication
DE Kushiro Mire; lake ball; phytoplankton; sediment accumulation; tephra;
   nutrient
ID SUSPENDED SEDIMENT; ORGANIC-MATTER; CHANNELIZATION; COMMUNITIES;
   DEPOSITION; VEGETATION; CATCHMENT; ECOLOGY; IMPACT; RECORD
AB The purpose of this study was to examine the long term fluctuation in remains of Aegagropila linnaei associated with phytoplankton dynamics and sediment accumulation in Lake Takkobu, northern Japan. A. linnaei is a green alga requiring good light conditions (low phytoplankton production and a low density of fine sediment particles) for growth. Six lake sediment core samples were obtained, and lake sediment core samples contained two tephra layers as Ko-c2 (1694) and Ta-a (1739). Fresh tephra deposition is the source of phosphorus in the lake, and induces an increase in phytoplankton. For the period 1694-1739, low sediment accumulations and low phytoplankton productions were observed, and A. linnaei remains were low, likely due to nutrient deficiency. Ko-c2 tephra deposition had no detectable influence on phytoplankton and A. linnaei dynamics, as insufficient tephra was deposited to induce a nutrient deficiency. However, phytoplankton productivity was attributed to Ta-a tephra deposition, which was at a higher influx than that of Ko-c2, in addition to human activities, such as deforestation and agricultural development. A. linnaei remains in 1739-1898 were increased despite the enhanced phytoplankton productivity caused by Ta-a tephra deposition. This evidence indicates that a phytoplankton impact on the transparency from 1739-1898 was probably insignificant, but the released nutrient from Ta-a tephra acted as a stimulus to make the A. linnaei grow. Therefore, A. linnaei existence depends on interaction between light conditions and sediment accumulation as well as nutrient conditions. Human activities after 1898 have directly influenced increased phytoplankton productivity and sediment accumulation, and result in A. linnaei degraded. Moreover, A. linnaei remains mainly were concentrated in sediment from northern zone close to lake outflow because their spherical form and free floating filaments tend to be moved by water flow. In recent years, the distribution of A. linnaei in the lake was reduced due to the shading effect caused by the increase in phytoplankton production and the attenuation of sunlight by high sediment accumulation.
C1 [Ahn, Young-Sang] Chonnam Natl Univ, Forest Resources Div, Coll Agr & Life Sci, Kwangju 500757, South Korea.
   [Wakana, Isamu] Lake Akan Ecomuseum Ctr, Marimo Lab, Akan, Hokkaido 0850467, Japan.
   [Satoh, Hiroki; Nakamura, Futoshi] Hokkaido Univ, Grad Sch Agr, Dept Forest Sci, Sapporo, Hokkaido 0608589, Japan.
   [Takamura, Noriko] Natl Inst Environm Studies, Tsukuba, Ibaraki 3058506, Japan.
   [Einarsson, Arni] Myvatn Res Stn, IS-660 Myvatn, Iceland.
   [Park, Chong-Min] Chonbuk Natl Univ, Dept Forest Environm Sci, Coll Agr & Life Sci, Jeonju Si 561756, Jeollabuk Do, South Korea.
   [Seo, Jung-Il] Kongju Natl Univ, Coll Ind Sci, Dept Forest Resources, Yesangun 340702, Chungcheongnamd, South Korea.
   [Chun, Kun-Woo] Kangwon Natl Univ, Coll Forest & Environm Sci, Dept Forest Resources, Chunchon 200701, Gangwondo, South Korea.
RP Ahn, YS (reprint author), Kyushu Univ, Lab Forest Ecosyst Management, Dept Agroenvironm Sci, Div Forest Sci,Fac Agr, Fukuoka 8112415, Japan.
EM ysahn@jnu.ac.kr
OI Nakamura, Futoshi/0000-0003-4351-2578
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, JOT and Future Planning
   [2013R1A1A1008790]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, JOT and Future Planning (No. 2013R1A1A1008790). The
   authors are grateful for advice on the interpretation of isotopes
   provided by Dr. Atsuko Sugimoto of the Graduate School of Environmental
   Earth Science of Hokkaido University, Japan, and for isotopes analysis
   assistance provided by Megumi Nakagawa of the National Institute for
   Environmental Studies, Tsukuba, Japan. We wish to thank Mr. Yoshifusa
   Suzuki of the Ocean Research and Systems Co. Ltd. for the collection of
   sediment cores, providing the basis of this study.
CR Ahn YS, 2008, ENVIRON MONIT ASSESS, V145, P267, DOI 10.1007/s10661-007-0036-1
   Ahn YS, 2010, GEOMORPHOLOGY, V114, P284, DOI 10.1016/j.geomorph.2009.07.009
   Ahn YS, 2009, EARTH SURF PROC LAND, V34, P1650, DOI 10.1002/esp.1854
   Ahn YS, 2006, GEOMORPHOLOGY, V78, P321, DOI 10.1016/j.geomorph.2006.01.036
   Bengtsson L, 1986, HDB HOLOCENE PALAEOE, P423
   Brenner M, 1999, J PALEOLIMNOL, V22, P205, DOI 10.1023/A:1008078222806
   BRUTON MN, 1985, HYDROBIOLOGIA, V125, P221, DOI 10.1007/BF00045937
   Einarsson A, 2004, AQUAT ECOL, V38, P317, DOI 10.1023/B:AECO.0000032090.72702.a9
   Einarsson Arni, 1993, Journal of Paleolimnology, V8, P15
   Fogel M. L., 1993, ORGANIC GEOCHEMISTRY, P73, DOI DOI 10.1007/978-1-4615-2890-6_3
   FOSTER IDL, 1985, EARTH SURF PROC LAND, V10, P45, DOI 10.1002/esp.3290100108
   Foster IDL, 1999, HYDROL PROCESS, V13, P1137
   GORHAM EVILLE, 1961, CANADIAN JOUR BOT, V39, P333
   Gu BH, 1996, CAN J FISH AQUAT SCI, V53, P875, DOI 10.1139/cjfas-53-4-875
   Hodell DA, 1998, LIMNOL OCEANOGR, V43, P200, DOI 10.4319/lo.1998.43.2.0200
   Hokkaido Institute of Environmental Sciences, 2005, LAK MARSH HOKK
   Jeppesen E, 2001, TRENDS ECOL EVOL, V16, P191, DOI 10.1016/S0169-5347(01)02100-0
   KANDA F, 1982, Japanese Journal of Phycology, V30, P147
   KANDA F, 1980, Japanese Journal of Phycology, V28, P123
   Kumagai Y, 2008, J FOREST RES-JPN, V13, P223, DOI 10.1007/s10310-008-0075-7
   Leavitt Peter R., 1993, Journal of Paleolimnology, V9, P109, DOI 10.1007/BF00677513
   MCKENZIE JA, 1985, CHEM PROCESSES LAKES, P99, DOI DOI 10.1007/S10933-004-7634-5
   Nakamura F, 2004, CATENA, V55, P213, DOI 10.1016/S0341-8162(03)00119-X
   Nakamura F, 2002, RIVER RES APPL, V18, P65, DOI 10.1002/rra.621
   Nakamura F, 1997, GEOMORPHOLOGY, V18, P279, DOI 10.1016/S0169-555X(96)00031-1
   Routh J, 2004, LIMNOL OCEANOGR, V49, P1560, DOI 10.4319/lo.2004.49.5.1560
   Takamura N, 2003, ECOL RES, V18, P381, DOI 10.1046/j.1440-1703.2003.00563.x
   Telford RJ, 2004, QUATERNARY SCI REV, V23, P2337, DOI 10.1016/j.quascirev.2004.03.014
   Teranes JL, 2000, LIMNOL OCEANOGR, V45, P801, DOI 10.4319/lo.2000.45.4.0801
   Waters MN, 2005, J PALEOLIMNOL, V33, P53, DOI 10.1007/s10933-004-1691-7
   Wetzel R. G, 2001, LIMNOLOGY LAKE RIVER
   Yamada H, 2002, RIVER RES APPL, V18, P481, DOI 10.1002/rra.688
NR 32
TC 1
Z9 1
U1 1
U2 11
PU KYUSHU UNIV, FACULTY AGRICULTURAL PUBLICATIONS
PI FUKUOKA-SHI
PA 6-10-1 HAKOZAKI, HIGASHI-KU, FUKUOKA-SHI, 812-0053, JAPAN
SN 0023-6152
J9 J FAC AGR KYUSHU U
JI J. Fac. Agric. Kyushu Univ.
PD FEB
PY 2015
VL 60
IS 1
BP 225
EP 233
PG 9
WC Agriculture, Multidisciplinary
SC Agriculture
GA CD8FD
UT WOS:000351329700031
DA 2018-12-27
ER

PT J
AU Peng, WG
   He, YR
   Wang, XZ
   Zhu, JQ
   Han, JC
AF Peng Wengen
   He Yurong
   Wang Xinzhi
   Zhu Jiaqi
   Han Jiecai
TI RETRACTED: Thermal protection mechanism of heat pipe in leading edge
   under hypersonic conditions (Retracted article. See vol. 30, pg. A1-A1,
   2017)
SO CHINESE JOURNAL OF AERONAUTICS
LA English
DT Article; Retracted Publication
DE Aerodynamic heating; Hypersonic vehicles; Metallic heat pipe; Thermal
   protection; Thermoanalysis
ID DISSOCIATED AIR; BLUNT-BODY; FLIGHT; VEHICLE; SYSTEM; SPEEDS; BODIES
AB Sharp local structure, like the leading edge of hypersonic aircraft, confronts a severe aerodynamic heating environment at a Mach number greater than 5. To eliminate the danger of a material failure, a semi-active thermal protection system is proposed by integrating a metallic heat pipe into the structure of the leading edge. An analytical heat-balance model is established from traditional aerodynamic theories, and then thermal and mechanical characteristics of the structure are studied at Mach number 6-8 for three refractory alloys, Inconel 625, C-103, and T-111. The feasibility of this simple analytical method as an initial design tool for hypersonic aircraft is assessed through numerical simulations using a finite element method. The results indicate that both the isothermal and the maximum temperatures fall but the von Mises stress increases with a longer design length of the leading edge. These two temperatures and the stress rise remarkably at a higher Mach number. Under all investigated hypersonic conditions, with a 3 mm leading edge radius and a 0.15 m design length, the maximum stress exceeds the yield strength of Inconel 625 at Mach numbers greater than 6, which means a material failure. Moreover, both C-103 and T-111 meet all requirements at Mach number 6-8. (C) 2015 Production and hosting by Elsevier Ltd. on behalf of CSAA & BUAA.
C1 [Peng Wengen; He Yurong; Wang Xinzhi] Harbin Inst Technol, Sch Energy Sci & Engn, Harbin 150001, Peoples R China.
   [Zhu Jiaqi; Han Jiecai] Harbin Inst Technol, Ctr Composite Mat, Harbin 150001, Peoples R China.
RP He, YR (reprint author), Harbin Inst Technol, Sch Energy Sci & Engn, Harbin 150001, Peoples R China.
EM rong@hit.edu.cn
FU Foundation for Innovative Research Groups of the National Natural
   Science Foundation of China [51121004]; Fundamental Research Funds for
   the Central Universities [HIT. BRETIV. 201315]
FX This work is financially supported by the Foundation for Innovative
   Research Groups of the National Natural Science Foundation of China (No.
   51121004) and the Fundamental Research Funds for the Central
   Universities (No. HIT. BRETIV. 201315).
CR Bertin J. J., 1994, HYPERSONIC AEROTHERM
   Bertin JJ, 2003, PROG AEROSP SCI, V39, P511, DOI 10.1016/S0376-0421(03)00079-4
   Buckley JD, 1993, CARBON CARBON MAT CO, P267
   COLWELL GT, 1992, J THERMOPHYS HEAT TR, V6, P492, DOI 10.2514/3.387
   Committee on Extension to the Standard Atmosphere (COESA), 1976, US STAND ATM 1976, P50
   Cotter TP., 1965, LA3246MS
   E. Rudy, 1969, AFMLTR652
   FAY JA, 1958, J AERONAUT SCI, V25, P73, DOI 10.2514/8.7517
   Glass DE, 2002, NASATM2002211752
   Glass DE, 1998, CR1998208720 NASA
   Graves R.E., 2001, AIAA20012960
   GROVER GM, 1964, J APPL PHYS, V35, P1990, DOI 10.1063/1.1713792
   HOSHIZAKI H, 1965, AIAA J, V3, P1614, DOI 10.2514/3.55179
   ISHII I, 1984, AIAA J, V22, P831
   Johnson DB, 2001, AIAA20011926
   JOSYULA E, 1991, AIAA J, V29, P704, DOI 10.2514/3.10644
   LEES L, 1956, JET PROPULSION, V26, P259, DOI 10.2514/8.6977
   LIBBY PA, 1970, AIAA J, V8, P1671, DOI 10.2514/3.49858
   LIU JTC, 1969, AIAA J, V7, P1273, DOI 10.2514/3.5334
   Lu HB, 2013, CHINESE J AERONAUT, V26, P287, DOI 10.1016/j.cja.2013.02.005
   Mallinson SG, 1996, AIAA J, V34, P2284, DOI 10.2514/3.13392
   Martin RA, 1992, AIAA19923809
   Moses PL, 2004, ACTA ASTRONAUT, V55, P619, DOI 10.1016/j.actaastro.2004.05.045
   NIBLOCK GA, 1974, J SPACECRAFT ROCKETS, V11, P314
   Peterson GP., 1994, INTRO HEAT PIPES MOD, P178
   RAULT DFG, 1994, J SPACECRAFT ROCKETS, V31, P719, DOI 10.2514/3.26504
   Sakurai H, 1997, ACTA ASTRONAUT, V40, P105, DOI 10.1016/S0094-5765(97)00149-5
   Santos W. F. N., 2005, J. Braz. Soc. Mech. Sci. & Eng., V27, P236, DOI 10.1590/S1678-58782005000300004
   Sutton K., 1971, NASATRR376
   Svehla RA, 1962, NASATRR132
   Tauber ME, 1989, NASATP2914
   TEWFIK OK, 1960, J AEROSP SCI, V27, P721, DOI 10.2514/8.8737
   Voland RT, 2006, ACTA ASTRONAUT, V59, P181, DOI 10.1016/j.actaastro.2006.02.021
NR 33
TC 8
Z9 9
U1 6
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1000-9361
J9 CHINESE J AERONAUT
JI Chin. J. Aeronaut.
PD FEB
PY 2015
VL 28
IS 1
BP 121
EP 132
DI 10.1016/j.cja.2014.12.018
PG 12
WC Engineering, Aerospace
SC Engineering
GA CD6XQ
UT WOS:000351234300013
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Lu, JK
   Yin, XJ
   Jiang, JZ
AF Lu, Jinkui
   Yin, Xiaojian
   Jiang, Jiazhen
TI RETRACTED: Sports-induced blood sugar utilization prevents development
   of pancreatic ductal adenocarcinoma (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Pancreatic ductal adenocarcinoma; Sports; Blood sugar; Insulin pellet
ID DIABETES-MELLITUS; EXOCRINE PANCREAS; RISK-FACTORS; ENDOCRINE;
   PROGRESSION; REGULATOR
AB Pancreatic ductal adenocarcinoma (PDAC) is a malignant tumor of extremely high lethality in humans. Pancreatic intraepithelial neoplasia (PanIN) is the predominant precancerous lesion for PDAC and is frequently detected in the normal and inflamed pancreas. However, only a few of PanIN eventually progress into PDAC. Thus, understanding of the regulation of PanIN-to-PDAC conversion appears to be critical for prevention of the occurrence of PDAC. Here, we evaluated the effect of sports on the progression of PanIN into PDAC in an established mouse PDAC model (Ptf1a-Cre; K-ras fx/fx). We found that swimming (3 min twice per day) since 12 weeks of age significantly decreased the incidence of the development of PDAC in these PanIN-baring mice at 24 weeks of age. Moreover, swimming significantly decreased fasting blood sugar and improved glucose response in these mice, compared to the control. Furthermore, implantation of insulin pellets into the mice not only reduced fasting blood sugar and improved glucose response, but also significantly reduced the incidence of development of PDAC, which mimicked the effect of swimming. Taken together, our study suggests that sports-induced blood sugar utilization may prevent development of PDAC.
C1 [Lu, Jinkui; Yin, Xiaojian] E China Normal Univ, Sch Phys Educ & Hlth, Key Lab Adolescent Hlth Assessment & Exercise Int, Minist Educ, Shanghai 200241, Peoples R China.
   [Jiang, Jiazhen] Aichi Med Univ, Sch Med Sci, Nagakute, Aichi 4801195, Japan.
RP Lu, JK (reprint author), E China Normal Univ, Sch Phys Educ & Hlth, Key Lab Adolescent Hlth Assessment & Exercise Int, Minist Educ, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
EM jinkui_lu@163.com
CR Arda HE, 2013, DEV CELL, V25, P5, DOI 10.1016/j.devcel.2013.03.016
   BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910
   Can A, 2012, JOVE-J VIS EXP, V59, P3638, DOI DOI 10.3791/3638
   Czako L, 2009, PANCREATOLOGY, V9, P351, DOI 10.1159/000181169
   di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071
   Gidekel Friedlander S. Y., 2009, CANCER CELL, V16, P379, DOI DOI 10.1016/J.CCR.2009.09.027]
   Han Haiyong, 2013, Cancer Cell, V23, P424, DOI 10.1016/j.ccr.2013.03.008
   HENDERSON JR, 1981, GUT, V22, P158, DOI 10.1136/gut.22.2.158
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959
   Malka D, 2000, GASTROENTEROLOGY, V119, P1324, DOI 10.1053/gast.2000.19286
   MASOERO G, 1980, MT SINAI J MED, V47, P261
   Shi W, 2014, TUMOUR BIOL
   Stanger BZ, 2013, GASTROENTEROLOGY, V144, P1170, DOI 10.1053/j.gastro.2013.01.074
   Wang W, 2011, PANCREAS, V40, P206, DOI 10.1097/MPA.0b013e31820032ae
   Xiao XW, 2013, J BIOL CHEM, V288, P8636, DOI 10.1074/jbc.M112.422949
   Xiao XW, 2013, DIABETES, V62, P1217, DOI 10.2337/db12-1428
NR 17
TC 2
Z9 2
U1 4
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD FEB
PY 2015
VL 36
IS 2
BP 663
EP 667
DI 10.1007/s13277-014-2684-4
PG 5
WC Oncology
SC Oncology
GA CC6MD
UT WOS:000350478200024
PM 25283383
DA 2018-12-27
ER

PT J
AU Zhai, JH
   Gu, WC
   Xu, XL
   Wu, J
   Hu, XJ
   Hou, KZ
AF Zhai, Jin-Hai
   Gu, Wen-Chao
   Xu, Xiao-Lin
   Wu, Jiang
   Hu, Xue-Jun
   Hou, Ke-Zhu
TI RETRACTED: Prognostic value of CD133 expression in cancer patients
   treated with chemoradiotherapy: a meta-analysis (Retracted article. See
   vol. 36, pg. 7317, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE CD133; Prognosis value; Cancer; Chemoradiotherapy; Meta-analysis
ID CELL LUNG-CANCER; STEM-CELLS; RECTAL-CANCER; PREOPERATIVE
   CHEMORADIOTHERAPY; TUMOR-REGRESSION; RADIORESISTANCE; STATISTICS;
   RESISTANCE; INDUCTION; THERAPY
AB Many studies evaluated the correlations of CD133 expression with the clinical outcomes in patients treated with chemoradiotherapy (CRT) but yielded controversial results. This meta-analysis was performed to identify the impacts of CD133 expression on the prognosis of cancer patients treated with CRT. Electronic databases updated up to March 2014 were searched to find relevant studies. Relevant literatures without any language restrictions were searched via electronic databases as follows: Web of Science (1945 similar to 2013), the Cochrane Library Database (Issue 12, 2013), PubMed (1966 similar to 2013), EMBASE (1980 similar to 2013), CINAHL (1982 similar to 2013), and the Chinese Biomedical Database (CBM) (1982 similar to 2013). STATA software was used for the current meta-analysis. Hazard ratios (HR) and its corresponding 95 % confidence interval (95 % CI) were calculated. Six studies were identified with a total of 470 cancer patients treated with CRT. The meta-analysis results showed that CD133-positive patients had poorer overall survival (OS) than that of CD133-negative patients (HR = 2.13, 95 % CI = 1.20 similar to 3.07, P < 0.001). Furthermore, CD133-positive patients displayed shorter disease-free survival (DFS) than that of CD133-negative patients (HR = 1.74, 95 % CI = 0.08 similar to 3.40, P = 0.039). Ethnicity-stratified analysis indicated that CD133 expression positively correlated with shorter OS among the Japanese, Chinese, and Spanish populations (all P < 0.05). In conclusion, our findings suggest that CD133 expression may be positively correlated with poorer prognosis in cancer patients treated with CRT.
C1 [Zhai, Jin-Hai; Wu, Jiang; Hu, Xue-Jun] Wuxi TCM Hosp, GI Med, Wuxi 214000, Peoples R China.
   [Gu, Wen-Chao] Shanghai Pudong New Area Peoples Hosp, Dept Resp Med, Shanghai 200000, Peoples R China.
   [Xu, Xiao-Lin] Fudan Univ, Huashan Hosp, Dept Cardiothorac Surg, Shanghai 200032, Peoples R China.
   [Hou, Ke-Zhu] Shi Dong Hosp, Dept Gen Surg 1, Shanghai 200438, Peoples R China.
RP Hou, KZ (reprint author), Shi Dong Hosp, Dept Gen Surg 1, 999 Shiguang Rd, Shanghai 200438, Peoples R China.
EM houkezhu611@126.com
CR Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419
   Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5
   Casado E, 2012, INT J RADIAT ONCOL, V84, P1151, DOI 10.1016/j.ijrobp.2012.01.083
   Chen AB, 2013, J CLIN ONCOL, V31, P558, DOI 10.1200/JCO.2012.43.7954
   Choi D, 2009, WORLD J GASTROENTERO, V15, P2258, DOI 10.3748/wjg.15.2258
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Fehrman-Ekholm I, 2009, SCAND J CLIN LAB INV, V69, P606, DOI 10.1080/00365510903015771
   Gille TM, 2012, CASE REP ONCOL MED, V2012
   Hartley A, 2005, BRIT J RADIOL, V78, P934, DOI 10.1259/bjr/86650067
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Hongo K, 2012, MED ONCOL, V29, P2849, DOI 10.1007/s12032-012-0161-8
   Horst D, 2009, EUR J CANCER, V45, P2034, DOI 10.1016/j.ejca.2009.04.004
   Jao SW, 2012, ANN SURG ONCOL, V19, P3432, DOI 10.1245/s10434-012-2394-3
   Kojima M, 2010, CANCER SCI, V101, P906, DOI 10.1111/j.1349-7006.2009.01478.x
   Lang C, 2013, J MED CHEM, V56, P9361, DOI 10.1021/jm401491e
   Lin CH, 2012, VIRCHOWS ARCH, V460, P447, DOI 10.1007/s00428-012-1210-6
   Liu H, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0685-6
   Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402
   Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017
   Garcia VM, 2011, COLORECTAL DIS, V13, P989, DOI 10.1111/j.1463-1318.2010.02386.x
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895
   Saigusa S, 2011, CLIN ONCOL-UK, V23, P323, DOI 10.1016/j.clon.2010.09.012
   Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z
   Shien K, 2012, LUNG CANCER, V77, P162, DOI 10.1016/j.lungcan.2012.02.006
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Simard EP, 2012, CA CANC J CLIN
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Ward RJ, 2007, ANNU REV PATHOL-MECH, V2, P175, DOI 10.1146/annurev.pathol.2.010506.091847
   Yasuda H, 2009, ONCOL REP, V22, P709, DOI 10.3892/or_00000491
   Yin SY, 2007, INT J CANCER, V120, P1444, DOI 10.1002/ijc.22476
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
NR 37
TC 4
Z9 5
U1 2
U2 18
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD FEB
PY 2015
VL 36
IS 2
BP 701
EP 709
DI 10.1007/s13277-014-2251-z
PG 9
WC Oncology
SC Oncology
GA CC6MD
UT WOS:000350478200029
PM 25286754
DA 2018-12-27
ER

PT J
AU Ai, C
   Jiang, RJ
   Fu, L
   Chen, YD
AF Ai, Cheng
   Jiang, Rujian
   Fu, Li
   Chen, Youdong
TI RETRACTED: MicroRNA-495 mimics delivery inhibits lung tumor progression
   (Retracted article. See vol. 37, pg. 15347, 2016)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE miR-495; Systematic delivery; Lung cancer; Cancer therapy
ID HUMAN GASTRIC-CANCER; GENE-THERAPY; EXPRESSION; MIGRATION; INVASION;
   MIR-495; CELLS
AB MicroRNAs (miRNAs) can function as tumor suppressors and might provide an efficient strategy for annihilating cancer. Specific miRNAs can be reintroduced into tumor cells to elicit the tumor suppressor activities. We show that systemically delivered, synthetic miRNA mimics in complex with a novel neutral lipid emulsion are preferentially targeted to lung tumors and show therapeutic benefit in mouse models of lung cancer. The delivery was demonstrated using mimics of the tumor suppressor microRNA-495 which is found downregulated in most lung cancer. Systemic treatment of a Kras-activated autochthonous mouse model of non-small cell lung cancer (NSCLC) led to a significant decrease in tumor burden. Specifically, mice treated with microRNA-495 displayed a large reduction in tumor area compared to mice treated with a miRNA control. These findings provide direct evidence that systematically delivered synthetic miRNA mimics to the mammalian lung can inhibit tumor proliferation and support the promise of miRNAs as a targeted therapy for lung cancer in future.
C1 [Ai, Cheng; Jiang, Rujian; Fu, Li; Chen, Youdong] Panzhihua Cent Hosp Sichuan Prov, Dept Cardiothorac Surg, 34 Yi Kang St, Panzhihua, Sichuan, Peoples R China.
RP Ai, C (reprint author), Panzhihua Cent Hosp Sichuan Prov, Dept Cardiothorac Surg, 34 Yi Kang St, Panzhihua, Sichuan, Peoples R China.
EM manuaicheng@163.com
CR Bader AG, 2010, CANCER RES, V70, P7027, DOI 10.1158/0008-5472.CAN-10-2010
   Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Brown RH, 1999, J APPL PHYSIOL, V87, P2362
   Chen SM, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-87
   Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-1
   Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834
   Guo JM, 2009, J GASTROEN HEPATOL, V24, P652, DOI 10.1111/j.1440-1746.2008.05666.x
   Iorio MVCroce CM, 2012, MICRORNA INVOLVEMENT
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   JEMAL A, 2008, J CLIN, V58, P71, DOI DOI 10.3322/CA.2007.0010
   Jiang X, 2012, P NATL ACAD SCI USA, V109, P19397, DOI 10.1073/pnas.1217519109
   Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530
   Li ZR, 2012, CANCER LETT, V323, P41, DOI 10.1016/j.canlet.2012.03.029
   McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008
   Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317
   Motoyama K, 2008, CLIN CANCER RES, V14, P2334, DOI 10.1158/1078-0432.CCR-07-4667
   Roth JA, 2006, EXPERT OPIN BIOL TH, V6, P55, DOI 10.1517/14712598.6.1.55
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655
   Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010
NR 21
TC 14
Z9 15
U1 3
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD FEB
PY 2015
VL 36
IS 2
BP 729
EP 735
DI 10.1007/s13277-014-2687-1
PG 7
WC Oncology
SC Oncology
GA CC6MD
UT WOS:000350478200032
PM 25286762
DA 2018-12-27
ER

PT J
AU Ma, M
   Jin, GJ
   Yun, K
   Mu, RQ
   Zhao, M
   Yu, XO
   Wang, S
   Shang, H
AF Ma, Ming
   Jin, Guo-Jiang
   Yun, Ke
   Mu, Run-Qing
   Zhao, Min
   Yu, Xiao-Ou
   Wang, Shuo
   Shang, Hong
TI RETRACTED: Correlation of IL-1F genetic polymorphisms with the risk of
   colorectal cancer among Chinese populations (Retracted article. See vol.
   36, pg. 7325, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Interleukin-17F; Colorectal cancer; Single nucleotide polymorphism
ID INTERLEUKIN-17A AND-17F GENES; SEQUENCE VARIANT HIS161ARG;
   INFLAMMATORY-BOWEL-DISEASE; GASTRIC-CANCER; TH17 CELLS; CYTOKINE FAMILY;
   COLON-CANCER; T-CELLS; ASSOCIATION; IL17F
AB Inflammatory/immune cells have the power of infiltrating almost all human solid tumors and influencing all stages of carcinogenesis because of their stimulation of various cytokine subsets. This study aims to determine the correlation of single nucleotide polymorphisms in the IL-17F gene and the risk of colorectal cancer (CRC). One thousand patients diagnosed with CRC and a control group of 354 healthy controls were involved. Peripheral blood samples were collected. The PCR-RFLP method was used to detect the 7383A > G (rs2397084) and 7488T > C (rs763780) in the IL-17F gene. Statistical analyses were conducted with version 12.0 STATA statistical software. We found that the allele model suggested that patients carrying C allele were 1.67 times more likely to develop CRC than healthy controls (odds ratio (OR) = 1.67, 95 % confidence interval (CI) = 1.22-2.27, P = 0.001). Similarly, the homozygous and dominant models also revealed that the minor IL-17F 7488C allele conferred an increased CRC risk compared to the major T allele among our study participants (CC vs. TT: OR = 4.15, 95 % CI = 1.26-13.36, P = 0.011; TC+CC vs. TT: OR = 1.46, 95 % CI = 1.04-2.05, P = 0.027). However, all genetic models indicated that the IL-17F 7383A > G (rs2397084) polymorphism was not associated with CRC risk (all P > 0.05). The results of this study indicate that the 7488T > C (rs763780) in the IL-17F gene may be correlated with increased risk of CRC.
C1 [Ma, Ming; Jin, Guo-Jiang; Yun, Ke; Mu, Run-Qing; Zhao, Min; Yu, Xiao-Ou; Wang, Shuo; Shang, Hong] China Med Univ, Hosp 1, Dept Lab Med, Shenyang 110000, Peoples R China.
RP Shang, H (reprint author), China Med Univ, Hosp 1, Dept Lab Med, Nanjing St 155, Shenyang 110000, Peoples R China.
EM hongshang100@hotmail.com
CR Adelstein BA, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-65
   Arisawa T, 2008, J CLIN IMMUNOL, V28, P44, DOI 10.1007/s10875-007-9125-8
   Astin Margaret, 2011, Br J Gen Pract, V61, pe231, DOI 10.3399/bjgp11X572427
   Awasthi A, 2009, INT IMMUNOL, V21, P489, DOI 10.1093/intimm/dxp021
   Carlson MJ, 2009, BLOOD, V113, P1365, DOI 10.1182/blood-2008-06-162420
   Chang SH, 2009, CYTOKINE, V46, P7, DOI 10.1016/j.cyto.2008.12.024
   Chen JG, 2011, INT J BIOL SCI, V7, P53, DOI 10.7150/ijbs.7.53
   Ciric B, 2009, J IMMUNOL, V182, P5296, DOI 10.4049/jimmunol.0900036
   Contie M, 2013, BIOTECHNOL BIOENG, V110, P1153, DOI 10.1002/bit.24763
   Council for International Organizations of Medical Sciences, 2002, Bull Med Ethics, P17
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   De Simone V, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26617
   Elias D, 2010, ANN SURG, V251, P896, DOI 10.1097/SLA.0b013e3181d9765d
   Hizawa N, 2006, CLIN EXP ALLERGY, V36, P1109, DOI 10.1111/j.1365-2222.2006.02550.x
   Hundorfean G, 2012, INFLAMM BOWEL DIS, V18, P180, DOI 10.1002/ibd.21677
   Iida T, 2011, ONCOL REP, V25, P1271, DOI 10.3892/or.2011.1201
   Iwakura Y, 2011, IMMUNITY, V34, P149, DOI 10.1016/j.immuni.2011.02.012
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jeong TD, 2014, CLIN CHIM ACTA, V435, P14, DOI 10.1016/j.cca.2014.04.015
   Kaabachi W, 2014, CYTOKINE, V66, P23, DOI 10.1016/j.cyto.2013.12.012
   Kawaguchi M, 2006, J ALLERGY CLIN IMMUN, V117, P795, DOI 10.1016/j.jaci.2005.12.1346
   Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9
   Metzger K, 2008, BIOCHEM BIOPH RES CO, V376, P231, DOI 10.1016/j.bbrc.2008.08.135
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9
   Omrane I, 2014, IMMUNOL LETT, V158, P189, DOI 10.1016/j.imlet.2014.01.002
   Ota K, 2014, J IMMUNOL RES, DOI 10.1155/2014/602846
   Pappu R, 2011, IMMUNOLOGY, V134, P8, DOI 10.1111/j.1365-2567.2011.03465.x
   Paradowska-Gorycka A, 2010, SCAND J IMMUNOL, V72, P134, DOI 10.1111/j.1365-3083.2010.02411.x
   Park H, 2014, TRANSPL P, V46, P121, DOI 10.1016/j.transproceed.2013.05.015
   Rafiei A, 2013, WORLD J GASTROENTERO, V19, P5693, DOI 10.3748/wjg.v19.i34.5693
   Ramsey CD, 2005, GENES IMMUN, V6, P236, DOI 10.1038/sj.gene.6364170
   Reynolds JM, 2010, CYTOKINE GROWTH F R, V21, P413, DOI 10.1016/j.cytogfr.2010.10.002
   Seiderer J, 2008, INFLAMM BOWEL DIS, V14, P437, DOI 10.1002/ibd.20339
   Shi YP, 2013, CANCER BIOTHER RADIO, V28, P429, DOI 10.1089/cbr.2012.1396
   Shibata T, 2009, HUM IMMUNOL, V70, P547, DOI 10.1016/j.humimm.2009.04.030
   Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Tong Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034959
   Wang LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034400
   Watson AJM, 2011, DIGEST DIS, V29, P222, DOI 10.1159/000323926
   Wu D, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/436307
   Wu XAQ, 2010, INT J CANCER, V127, P86, DOI 10.1002/ijc.25027
   Yan N, 2012, AUTOIMMUNITY, V45, P533, DOI 10.3109/08916934.2012.702814
   Zarogoulidis P, 2014, CANCER INVEST, V32, P197, DOI 10.3109/07357907.2014.898156
   Zhang XK, 2014, TUMOR BIOL, V35, P1575, DOI 10.1007/s13277-013-1217-x
NR 46
TC 4
Z9 4
U1 2
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD FEB
PY 2015
VL 36
IS 2
BP 807
EP 814
DI 10.1007/s13277-014-2653-y
PG 8
WC Oncology
SC Oncology
GA CC6MD
UT WOS:000350478200040
PM 25296730
DA 2018-12-27
ER

PT J
AU Hosseini, E
   Pedram, B
   Bahrami, AM
   Touni, SR
   Malayeri, HZ
   Mokarizadeh, A
   Pourzaer, M
   Pourzaer, M
   Zehtabian, S
   Mohajer, S
   Ahmadi, S
AF Hosseini, Ehsan
   Pedram, Behnam
   Bahrami, Ali Mohammad
   Touni, Seyed Rashid
   Malayeri, Hamed Zamankhan
   Mokarizadeh, Aram
   Pourzaer, Mehdi
   Pourzaer, Maryam
   Zehtabian, Shahram
   Mohajer, Sheida
   Ahmadi, Sharareh
TI RETRACTED: Diagnostic procedures for improving of the KIT (CD117)
   expressed allele burden for the liver metastases from uterus mast cell
   tumors: prognostic value of the metastatic pattern and tumor biology
   (Retracted article. See vol.37, pg. 16415, 2016)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Immunohistochemistry; Histopathology; KIT; Neoplasia; Uterine; Liver
ID ENDOTHELIAL GROWTH-FACTOR; PROTOONCOGENE C-KIT; DOGS; ANGIOGENESIS;
   SURVIVAL; MASTOCYTOSIS; MUTATION; DENSITY; TISSUES
AB The activating KIT marker plays a central role in the pathogenesis, diagnosis, and targeted treatment of systemic mastocytosis (SM). Recent studies have identified the KIT (CD117) as a marker that distinguishes nonneoplastic from neoplastic mast cells in human systemic mastocytosis. In this study, we conclude that immunohistopathology assays for KIT staining pattern are useful complimentary tools for diagnosis and evaluation of prognosis in uterus mast cell tumor (MCT) metastasis to the liver in 10 patients. Uterine and hepatic cytology revealed mast cell neoplasia, which was confirmed as visceral mast cell tumor on postmortem examination. Histological changes of densely packed, poorly differentiated neoplastic mast cells, sheets of neoplastic round to pleomorphic cells that formed nonencapsulated nodules, high mitotic figures, necrosis, and fibrosis were found. In addition, eosinophils were scattered among the mast cells at the periphery of the nodules. These findings indicate tumors of high-grade malignancy with infiltrative cells resembling the uterus MCT in the intraparenchymal and periparenchymal areas of the liver. Immunohistochemically, tumors were positive for KIT. The histopathologic features coupled with the KIT immunoreactivity led to diagnosis of high-grade uterus MCTs. Taken together, these findings suggest that CD117 may play a critical role in early uterus MCT development and may be a stimulatory factor in grade 3 MCT. Therefore, the result has supported our hypothesis that there was an increased opportunity to observe a higher CD117 staining pattern in high-grade MCTs.
C1 [Hosseini, Ehsan; Bahrami, Ali Mohammad] Ilam Univ, Fac Vet Med, Ilam, Iran.
   [Pedram, Behnam] Islamic Azad Univ, Susangerd Branch, Dept Pathobiol, Susangerd, Iran.
   [Touni, Seyed Rashid] Urmia Univ, Dept Basic Sci, Fac Vet Med, Orumiyeh, Iran.
   [Malayeri, Hamed Zamankhan] Univ Tehran, Fac Vet Med, Dept Internal Med, Tehran, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Dept Immunol, Fac Med, Sanandaj, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Cellular & Mol Res Ctr, Sanandaj, Iran.
   Islamic Azad Univ, Karaj Branch, Fac Vet Sci, Alborz, Iran.
   Islamic Azad Univ, Damghan Branch, Fac Basic Sci, Dept Biol, Damghan, Iran.
   [Zehtabian, Shahram] Kermanshah Univ Med Sci, Dept Microbiol, Fac Med, Kermanshah, Iran.
   [Mohajer, Sheida] Shahid Beheshti Univ Med, Massih Daneshvary Hosp, Natl Res Inst TB & Lung Dis, Chron Resp Dis Res Ctr, Tehran, Iran.
   [Ahmadi, Sharareh] Kermanshah Univ Med Sci, Fac Med, Kermanshah, Iran.
RP Bahrami, AM (reprint author), Ilam Univ, Fac Vet Med, Ilam, Iran.
EM am.bahrami@ilam.ac.ir; A.mokarizadeh@muk.ac.ir
OI Mokarizadeh, Aram/0000-0002-2630-8308; Abdi,
   Mohammad/0000-0002-4766-0423; Zehtabian, Shahram/0000-0002-9907-5031
CR Arber DA, 1998, HUM PATHOL, V29, P498, DOI 10.1016/S0046-8177(98)90066-1
   BALDWIN CJ, 1992, COMP CONT EDUC PRACT, V14, P731
   Book AP, 2011, VET RADIOL ULTRASOUN, V52, P548, DOI 10.1111/j.1740-8261.2011.01839.x
   BRODEY RS, 1967, J AM VET MED ASSOC, V151, P1294
   Bronden LB, 2010, ACTA VET SCAND, V22, P52
   BROWN CA, 1990, VET PATHOL, V27, P366, DOI 10.1177/030098589002700511
   COTCHIN E., 1954, Veterinary Record, V66, P879
   Crafts G. A., 1975, Feline Practice, V5, P57
   Escribano L, 1998, LEUKEMIA LYMPHOMA, V30, P459, DOI 10.3109/10428199809057558
   Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025
   Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158
   Gieger TL, 2003, J VET INTERN MED, V17, P687, DOI 10.1892/0891-6640(2003)017<0687:BBAPFF>2.3.CO;2
   Gilda Costa RM, 2007, BMC VET RES, V3, P19
   Gross TL, 2005, EPITHELIAL NEOPLASMS, P641
   Haines D M, 1991, J Vet Diagn Invest, V3, P101
   Hosseini E, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-9
   Hume CT, 2011, J AM ANIM HOSP ASSOC, V47, P37, DOI 10.5326/JAAHA-MS-5557
   Javanbakht J, 2014, TUMOR BIOL, V35, P5493, DOI 10.1007/s13277-014-1723-5
   Kawai K, 2006, J VET MED SCI, V68, P105, DOI 10.1292/jvms.68.105
   Khaki F, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-33
   Kiupel M, 2004, VET PATHOL, V41, P371, DOI 10.1354/vp.41-4-371
   Kube P, 1998, HISTOCHEM CELL BIOL, V110, P129, DOI 10.1007/s004180050274
   Letard S, 2008, MOL CANCER RES, V6, P1137, DOI 10.1158/1541-7786.MCR-08-0067
   Lin TY, 2010, J VET DIAGN INVEST, V22, P808, DOI 10.1177/104063871002200531
   London CA, 1996, J COMP PATHOL, V115, P399, DOI 10.1016/S0021-9975(96)80074-0
   London CA, 2003, VET CLIN N AM-SMALL, V33, P473, DOI 10.1016/S0195-5616(03)00003-2
   London CA, 1999, EXP HEMATOL, V27, P689, DOI 10.1016/S0301-472X(98)00075-7
   Maiolino P, 2000, J COMP PATHOL, V123, P141, DOI 10.1053/jcpa.2000.0404
   Manesh JY, 2014, TUMOUR BIOL
   Marone G, 2005, ADV IMMUNOL, V88, P97, DOI 10.1016/S0065-2776(05)88004-6
   Matsumoto I, 2001, J EXP MED, V194, P71, DOI 10.1084/jem.194.1.71
   Miller MA, 2003, J VET DIAGN INVEST, V15, P515, DOI 10.1177/104063870301500602
   MYLES AD, 1995, VET IMMUNOL IMMUNOP, V46, P223, DOI 10.1016/0165-2427(94)05358-Y
   Nakaichi M, 2007, RES VET SCI, V82, P271, DOI 10.1016/j.rvsc.2006.07.007
   Noli C, 2001, VET DERMATOL, V12, P303, DOI 10.1046/j.0959-4493.2001.00272.x
   Norrby K, 2002, APMIS, V110, P355, DOI 10.1034/j.1600-0463.2002.100501.x
   Passantino L, 2008, IMMUNOPHARM IMMUNOT, V30, P609, DOI 10.1080/08923970801949265
   PATNAIK AK, 1984, VET PATHOL, V21, P469, DOI 10.1177/030098588402100503
   Peeters D, 2005, J COMP PATHOL, V133, P128, DOI 10.1016/j.jcpa.2005.02.004
   Preziosi R, 2007, VET RES COMMUN, V31, P287, DOI 10.1007/s11259-006-3427-9
   Preziosi R, 2004, J COMP PATHOL, V130, P143, DOI 10.1016/j.jcpa.2003.10.003
   Restucci B, 2003, J COMP PATHOL, V128, P252, DOI 10.1053/jcpa.2002.0630
   Romansik EM, 2007, VET PATHOL, V44, P335, DOI 10.1354/vp.44-3-335
   Sailasuta A, 2014, Vet Med Int, V2014, P787498, DOI 10.1155/2014/787498
   Sawatsubashi M, 2000, VIRCHOWS ARCH, V436, P243, DOI 10.1007/s004280050037
   Schumacher JA, 2008, J CLIN PATHOL, V61, P109, DOI 10.1136/jcp.2007.047928
   SIMOES JPC, 1994, J VET DIAGN INVEST, V6, P458, DOI 10.1177/104063879400600410
   TSUJIMURA T, 1994, BLOOD, V83, P2619
   Webster JD, 2007, VET PATHOL, V44, P298, DOI 10.1354/vp.44-3-298
   Webster JD, 2006, NEOPLASIA, V8, P104, DOI 10.1593/neo.05622
   Welle MM, 2008, VET DERMATOL, V19, P321, DOI 10.1111/j.1365-3164.2008.00694.x
   Withrow SJ, 2013, WITHROW MACEWENS SMA, V20, P335
   Yamamoto K, 2000, J VET MED SCI, V62, P1183, DOI 10.1292/jvms.62.1183
NR 53
TC 5
Z9 5
U1 1
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD FEB
PY 2015
VL 36
IS 2
BP 929
EP 937
DI 10.1007/s13277-014-2666-6
PG 9
WC Oncology
SC Oncology
GA CC6MD
UT WOS:000350478200055
PM 25315185
DA 2018-12-27
ER

PT J
AU Jiang, YS
   Sun, SC
   Liu, GQ
   Yan, B
   Niu, J
AF Jiang, Yongsheng
   Sun, Shaochuan
   Liu, Guoqin
   Yan, Bing
   Niu, Jun
TI RETRACTED: Nrdp1 inhibits metastasis of colorectal cancer cells by EGFR
   signaling-dependent MMP7 modulation (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Neuregulin receptor degradation protein-1 (Nrdp1); Epidermal growth
   factor (EGF); Colorectal cancer; MMP7
ID GROWTH-FACTOR; PATHWAYS; CRC; PREVENTION; TARGETS; FOCUS; BETA
AB The molecular mechanism underlying cancer invasiveness and metastasis of colorectal cancer (CRC) remains elusive. Here we reported a strong correlation of the levels of neuregulin receptor degradation protein-1 (Nrdp1) and matrix metalloproteinase-7 (MMP7) in CRC from the patients. We then used a human CRC line, Caco-2, to study the underlying molecular basis. We found that Nrdp1 inhibited the phosphorylation of ErB3, a key player in epidermal growth factor receptor (EGFR) signaling in Caco-2 cells, which is required for activation of MMP7 to promote cell invasion. Our findings thus reveal Nrdp1, EGFR signaling, and MMP7 as promising therapeutic targets for preventing the metastasis of CRC.
C1 [Jiang, Yongsheng; Sun, Shaochuan; Liu, Guoqin; Yan, Bing] Shandong Univ, Jinan Cent Hosp, Dept Gen Surg, Jinan 250013, Peoples R China.
   [Niu, Jun] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan 250012, Peoples R China.
RP Niu, J (reprint author), Shandong Univ, Qilu Hosp, Dept Gen Surg, 107 West Wenhua Rd, Jinan 250012, Peoples R China.
EM jun_niu14@163.com
CR Ashraf SQ, 2012, P NATL ACAD SCI USA, V109, P21046, DOI 10.1073/pnas.1218750110
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   East JE, 2013, NAT REV GASTRO HEPAT, V10, P69, DOI 10.1038/nrgastro.2012.245
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Jimeno A, 2009, J CLIN ONCOL, V27, P1130, DOI 10.1200/JCO.2008.19.8168
   Jurchott K, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001231
   Labianca R, 2005, ANN ONCOL, V16, P37, DOI 10.1093/annonc/mdi906
   LAHM H, 1993, GROWTH FACTORS, V9, P1, DOI 10.3109/08977199308991577
   Li LH, 2010, INT J ONCOL, V37, P951, DOI 10.3892/ijo_00000746
   Liu G, 2014, TUMOR BIOL IN PRESS
   Lu H, 2014, TUMOR BIOL, V35, P8639, DOI 10.1007/s13277-014-2132-5
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Qi J, 2008, CURR DRUG TARGETS, V9, P548, DOI 10.2174/138945008784911769
   Song HT, 2014, TUMOR BIOL, V35, P6679, DOI 10.1007/s13277-014-1883-3
   Van Schaeybroeck S, 2011, NAT REV CLIN ONCOL, V8, P222, DOI 10.1038/nrclinonc.2011.15
   von Kleist S, 1975, J Natl Cancer Inst, V55, P555
   Wang F, 2014, TUMOR BIOL IN PRESS
   Winder T, 2010, GASTROENTEROLOGY, V138, P2163, DOI 10.1053/j.gastro.2010.02.005
   Xu YF, 2007, HUM MOL GENET, V16, pR14, DOI 10.1093/hmg/ddl486
   Yao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078086
   Ye Q, 2014, ONCOGENE, V33, P1828, DOI 10.1038/onc.2013.122
   Yen L, 2006, CANCER RES, V66, P11279, DOI 10.1158/0008-5472.CAN-06-2319
NR 22
TC 11
Z9 11
U1 3
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD FEB
PY 2015
VL 36
IS 2
BP 1129
EP 1133
DI 10.1007/s13277-014-2726-y
PG 5
WC Oncology
SC Oncology
GA CC6MD
UT WOS:000350478200078
PM 25330950
DA 2018-12-27
ER

PT J
AU Wei, ZK
   Yao, MJ
   Li, YM
   Yang, ZT
   Feng, XS
AF Wei, Zhengkai
   Yao, Minjun
   Li, Yimeng
   Yang, Zhengtao
   Feng, Xiaosheng
TI RETRACTED: Inhibition of Lipopolysaccharide (LPS)-Induced Inflammatory
   Responses by Selenium in Bovine Mammary Epithelial Cells in Primary
   Culture (Retracted article. See vol. 38, pg. 1662, 2015)
SO INFLAMMATION
LA English
DT Article; Retracted Publication
DE selenium; bovine mammary epithelial cell; LPS
ID NF-KAPPA-B; DAIRY-COWS; EXPRESSION; MASTITIS; MACROPHAGES; ACTIVATION;
   HEALTH; CYCLOOXYGENASE-2; INTERLEUKIN-1; DEFICIENCY
AB Selenium, in the form of selenoproteins, plays a pivotal role in anti-inflammatory processes and antioxidant defense system. The aim of this study was to examine the effects of selenium on lipopolysaccharide (LPS)-induced inflammatory responses in bovine mammary epithelial cells (bMEC) and to investigate the potential mechanism. bMEC viability was measured by MTT assay. TNF-alpha, IL-1 beta, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) messenger RNA (mRNA) expressions were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR). The activation of nuclear factor-kappa B (NF-kappa B) was determined by Western blotting. The results showed that the mRNA expressions of these inflammatory factors were significantly inhibited by selenium in a dose-dependent manner. At protein levels, Western blot analysis demonstrated that selenium dose-dependently decreased NF-kappa B p65 translocating from the cytoplasm to the nucleus. Taken together, these results suggest that the anti-inflammatory property of selenium in LPS-stimulated primary bMEC may be attributed to the downregulation of NF-kappa B activation.
C1 [Wei, Zhengkai; Yao, Minjun; Li, Yimeng; Yang, Zhengtao] Jilin Univ, Coll Vet Med, Changchun 130062, Jilin Province, Peoples R China.
   [Feng, Xiaosheng] Guangdong Haid Inst Anim Husb & Vet, Guangzhou 510000, Guangdong, Peoples R China.
RP Feng, XS (reprint author), Guangdong Haid Inst Anim Husb & Vet, Guangzhou 510000, Guangdong, Peoples R China.
EM fxs_2005@hotmail.com
FU China Postdoctoral Science Foundation [2013 M540255]
FX This study was supported by China Postdoctoral Science Foundation (2013
   M540255).
CR Andrieu S, 2008, VET J, V176, P77, DOI 10.1016/j.tvj1.2007.12.022
   Buraczynska M, 2006, CYTOKINE, V36, P167, DOI 10.1016/j.cyto.2006.11.011
   Cavero D, 2008, LIVEST SCI, V114, P280, DOI 10.1016/j.livsci.2007.05.012
   Duntas LH, 2009, HORM METAB RES, V41, P443, DOI 10.1055/s-0029-1220724
   FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842
   Fu YH, 2013, VET IMMUNOL IMMUNOP, V151, P20, DOI 10.1016/j.vetimm.2012.09.039
   Fu YH, 2013, J ETHNOPHARMACOL, V145, P193, DOI 10.1016/j.jep.2012.10.051
   Guo FW, 2012, CURR DRUG SAF, V7, P321, DOI 10.2174/157488612804096579
   Hoffmann PR, 2008, MOL NUTR FOOD RES, V52, P1273, DOI 10.1002/mnfr.200700330
   Hwang PA, 2011, J AGR FOOD CHEM, V59, P2062, DOI 10.1021/jf1043647
   Ibeagha-Awemu E. M., 2008, Veterinary Research, V39, P1
   Kravtsiv R., 2003, UKRAINSKII BIOKHIMIC, V76, P90
   Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291
   Lee JW, 2006, VET RES, V37, P219, DOI 10.1051/vetres:2005051
   Li DP, 2013, EUR J PHARMACOL, V705, P79, DOI 10.1016/j.ejphar.2013.02.021
   Miggiano G., 2004, CLIN TER, V156, P115
   Oviedo-Boyso J, 2007, J INFECTION, V54, P399, DOI 10.1016/j.jinf.2006.06.010
   Pantano C, 2006, ANTIOXID REDOX SIGN, V8, P1791, DOI 10.1089/ars.2006.8.1791
   Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988
   Prabhu KS, 2002, BIOCHEM J, V366, P203, DOI 10.1042/bj20020256
   Rayman MP, 2012, LANCET, V379, P1256, DOI 10.1016/S0140-6736(11)61452-9
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Rossol M., 2011, CRITICAL REV IMMUNOL, P31
   Seegers H, 2003, VET RES, V34, P475, DOI 10.1051/vetres:2003027
   Sharma N, 2011, ASIAN AUSTRAL J ANIM, V24, P429, DOI 10.5713/ajas.2011.10233
   Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271
   Spears JW, 2008, VET J, V176, P70, DOI 10.1016/j.tvj1.2007.12.015
   Vunta H, 2008, MOL NUTR FOOD RES, V52, P1316, DOI 10.1002/mnfr.200700346
   Vunta H, 2007, J BIOL CHEM, V282, P17964, DOI 10.1074/jbc.M703075200
   Zamamiri-Davis F, 2002, FREE RADICAL BIO MED, V32, P890, DOI 10.1016/S0891-5849(02)00775-X
   Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837
   Zhang W, 2013, IEEE 26 CAN C COMP E, P1
NR 32
TC 3
Z9 3
U1 2
U2 26
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD FEB
PY 2015
VL 38
IS 1
BP 152
EP 158
DI 10.1007/s10753-014-0017-9
PG 7
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA CA6IS
UT WOS:000349015900017
PM 25231122
DA 2018-12-27
ER

PT J
AU Im, NK
   Zhou, W
   Na, M
   Jeong, GS
AF Im, Nam-Kyung
   Zhou, Wei
   Na, MinKyun
   Jeong, Gil-Saeng
TI RETRACTED: Pierisformoside B exhibits neuroprotective and
   anti-inflammatory effects in murine hippocampal and microglial cells via
   the HO-1/Nrf2-mediated pathway (Retracted article. See vol. 49, pg. 232,
   2017)
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article; Retracted Publication
DE Pierisformoside B; HO (heme oxygenase)-1; Nrf2 (nuclear transcription
   factor erythroid-2 related factor 2); Hippocampal HT22; Microglial BV2;
   MAPKs
ID NRF2-ARE TRANSCRIPTIONAL RESPONSE; HEME OXYGENASE-1 EXPRESSION;
   PULMONARY EPITHELIAL-CELLS; OXIDATIVE STRESS; RHODODENDRON-BRACHYCARPUM;
   GRAYANANE DITERPENOIDS; DALBERGIA-ODORIFERA; THERAPEUTIC TARGET; SPECIES
   PRODUCTION; NEURONAL CELLS
AB Oxidative stress and neuroinflammation are involved in the pathogenesis of neurodegenerative disease such as Alzheimer's disease (AD) and Parkinson's disease (PD). Pierisformoside B (PFB) isolated from Rhododendron brachycarpum exhibits neuroprotective effects. In the present study, we examined the effect of PFB in neuroprotection and neuroinflammation by using murine hippocampal HT22 cells and BV2 microglial cells. PFB strongly inhibited glutamate-induced cytotoxicity in HT22 cells. Furthermore, in BV2 cells, PFB strongly inhibited LPS-induced inducible nitric oxide synthase (iNOS), cyclooxygenase (COX-2) protein expression and nitrite (NO), prostaglandin E-2 (PGE(2)), tumor necrosis factor alpha (TNF-alpha), and interleukin-1beta (IL-1 beta) production. PFB-induced heme oxygenase-1 (HO-1) expression and elevated HO-1 activity in the two cell lines were studied. Additionally, PFB treatment induced nuclear transcription factor erythroid-2 related factor 2 (Nrf2) and increased the promoter activity of antioxidant response elements (AREs). These results suggested that PFB may have preventive and therapeutic potential against neurodegenerative diseases that are induced by oxidative stress and neuroinflammation. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Im, Nam-Kyung; Jeong, Gil-Saeng] Keimyung Univ, Coll Pharm, Taegu 704701, South Korea.
   [Zhou, Wei; Na, MinKyun] Chungnam Natl Univ, Coll Pharm, 99 Daehak Ro, Taejon 305764, South Korea.
RP Na, M (reprint author), Chungnam Natl Univ, Coll Pharm, 99 Daehak Ro, Taejon 305764, South Korea.
EM mkna@cnu.ac.kr; gsjeong@lanu.ac.kr
CR Bae K.H., 2000, MED PLANTS KOREA
   Choi JH, 2010, EXP MOL MED, V42, P811, DOI 10.3858/emm.2010.42.12.084
   Deecher DC, 2005, J CELL BIOCHEM, V95, P302, DOI 10.1002/jcb.20413
   Dilshara MG, 2014, CELL IMMUNOL, V290, P21, DOI 10.1016/j.cellimm.2014.04.009
   Foresti R, 2013, PHARMACOL RES, V76, P132, DOI 10.1016/j.phrs.2013.07.010
   Han J, 2014, NEUROCHEM RES, V39, P1292, DOI 10.1007/s11064-014-1311-5
   Huang XZ, 2005, J NAT PROD, V68, P1646, DOI 10.1021/np050261s
   Im NK, 2013, BIOL PHARM BULL, V36, P796, DOI 10.1248/bpb.b12-00964
   Immenschuh S, 2000, BIOCHEM PHARMACOL, V60, P1121, DOI 10.1016/S0006-2952(00)00443-3
   Itoh K, 2004, MOL CELL BIOL, V24, P36, DOI 10.1128/MCB.24.1.36-45.2004
   Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074
   Jazwa A, 2010, CURR DRUG TARGETS, V11, P1517, DOI 10.2174/1389450111009011517
   Kawamoto S, 2011, TISSUE ENG PT A, V17, P1605, DOI 10.1089/ten.tea.2010.0447
   KUTTY RK, 1982, J BIOL CHEM, V257, P9944
   Lee DS, 2014, PHYTOTHER RES, V28, P1216, DOI 10.1002/ptr.5119
   Lee DS, 2013, INT IMMUNOPHARMACOL, V17, P828, DOI 10.1016/j.intimp.2013.08.024
   Lee DS, 2013, TOXICOL IN VITRO, V27, P874, DOI 10.1016/j.tiv.2013.01.003
   Lee JW, 2014, MOL CELL BIOCHEM, V390, P143, DOI 10.1007/s11010-014-1965-y
   Lee JW, 2013, BIOMOL THER, V21, P60, DOI 10.4062/biomolther.2012.091
   Lee SW, 2002, SILVAE GENET, V51, P215
   Liu J, 2009, LIFE SCI, V84, P267, DOI 10.1016/j.lfs.2008.12.008
   Ma JQ, 2014, FOOD CHEM TOXICOL, V71, P264, DOI 10.1016/j.fct.2014.06.017
   Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6
   Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5
   Papaiahgari S, 2006, ANTIOXID REDOX SIGN, V8, P43, DOI 10.1089/ars.2006.8.43
   Papaiahgari S, 2004, J BIOL CHEM, V279, P42302, DOI 10.1074/jbc.M408275200
   Rossler OG, 2004, NEUROSCI LETT, V362, P253, DOI 10.1016/j.neulet.2004.03.033
   Sarady-Andrews JK, 2005, AM J PHYSIOL-LUNG C, V289, pL1131, DOI 10.1152/ajplung.00458.2004
   Son Y, 2013, AMINO ACIDS, V45, P393, DOI 10.1007/s00726-013-1518-9
   Syapin PJ, 2008, BRIT J PHARMACOL, V155, P623, DOI 10.1038/bjp.2008.342
   Takahashi T, 2004, CURR MED CHEM, V11, P1545, DOI 10.2174/0929867043365080
   Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423
   Thuong PT, 2009, J NAT PROD, V72, P2040, DOI 10.1021/np900215r
   Wang WG, 2013, CHEM BIODIVERS, V10, P1061, DOI 10.1002/cbdv.201200046
   Zhong LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032195
   Zhou W, 2014, BIOCHEM SYST ECOL, V56, P231, DOI 10.1016/j.bse.2014.06.003
   장기욱, 2005, [YAKHAK HOEJI, 약 학 회 지], V49, P244
NR 37
TC 10
Z9 10
U1 2
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD FEB
PY 2015
VL 24
IS 2
BP 353
EP 360
DI 10.1016/j.intimp.2014.12.014
PG 8
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA CC2OD
UT WOS:000350183600027
PM 25529993
DA 2018-12-27
ER

PT J
AU Wang, YC
AF Wang, Yi-Chia
TI RETRACTED: How ICT Penetration Influences Productivity Growth: Evidence
   From 17 OECD Countries (Retracted article. See vol. 29, pg. 194, 2015)
SO ECONOMIC DEVELOPMENT QUARTERLY
LA English
DT Article; Retracted Publication
DE information and communication technology; ICT; productivity growth
ID INFORMATION AGE; ECONOMIC-GROWTH
AB This article constructs an unbalanced panel data set based on a varying sample period of 1980-2004 for 17 OECD countries to analyze the impact of information and communication technology (ICT) on productivity growth. This article divides ICT capital stock into three categories, namely communication equipment, information technology (IT) equipment (hardware), and software, and uses them together with telecommunication demand and personal computer (PC) penetration rate as productivity-related explanatory variables. It then estimates a macro production function using micro models for ICT investment, telecommunication demand, and PC penetration. The estimation results suggest that the three categories of ICT capital stock, together with telephone and PC penetration rates, positively and significantly influence productivity growth in the selected high-income economies. Moreover, once the level of digitalization reaches 20%, it also provides a networked contribution to productivity growth.
C1 [Wang, Yi-Chia] Tunghai Univ, Taichung 40704, Taiwan.
RP Wang, YC (reprint author), Tunghai Univ, Dept Econ, Box 882, Taichung 407, Taiwan.
EM ycwang@thu.edu.tw
CR Crepon B., 2002, REV INCOME WEALTH, V1, P1
   Draca M., 2006, 749 CEP
   Guest C., 2004, LABOR EC, V11, P33
   HAUSMAN JA, 1978, ECONOMETRICA, V46, P1251, DOI 10.2307/1913827
   Jorgenson D. W., 2004, CURRENT ISSUES ECONO, V10
   Jorgenson DW, 2005, HANDB ECON, V22, P743
   JORGENSON DW, 1967, REV ECON STUD, V34, P249, DOI 10.2307/2296675
   Jorgenson DW, 2000, BROOKINGS PAP ECO AC, P125
   Oulton N., 2005, 259 BANK ENGL
   Roller LH, 2001, AM ECON REV, V91, P909, DOI 10.1257/aer.91.4.909
   ROMER PM, 1990, J POLIT ECON, V98, pS71, DOI 10.1086/261725
   Schreyer P, 2002, REV INCOME WEALTH, P15
   SOLOW RM, 1987, NEW YORK TIMES BK R, P36
   SOLOW RM, 1956, Q J ECON, V70, P65, DOI 10.2307/1884513
   Timmer M. P., 2003, GD67 GGDC U GRON
NR 15
TC 2
Z9 3
U1 1
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0891-2424
EI 1552-3543
J9 ECON DEV Q
JI Econ. Dev. Q.
PD FEB
PY 2015
VL 29
IS 1
BP 79
EP 92
DI 10.1177/0891242413478650
PG 14
WC Economics; Planning & Development; Urban Studies
SC Business & Economics; Public Administration; Urban Studies
GA CB3KB
UT WOS:000349525600007
DA 2018-12-27
ER

PT J
AU Jafarzadeh, H
   Abrinia, K
AF Jafarzadeh, H.
   Abrinia, K.
TI RETRACTED: Numerical and experimental analyses of repetitive tube
   expansion and shrinking processed AZ91 magnesium alloy tubes (Retracted
   article. See vol. 29, pg. 3039, 2015)
SO JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Severe plastic deformation; Ultrafine grain; Micro hardness; Repetitive
   tube expansion and shrinking; FEM
ID SEVERE PLASTIC-DEFORMATION; NANOSTRUCTURED MATERIALS; EXTRUSION;
   BEHAVIOR; METALS
AB A novel severe plastic deformation (SPD) technique entitled repetitive tube expansion and shrinking (RTES) has been developed to fabricate ultra-fine grained and nanostructured AZ91 tubular components. This method includes two different half-cycles and is based on pressing a tubular part through an angular channel die with two shear zones. In order to primarily demonstrate the deformation behavior and refinement ability of RTES method, the FE simulations and experimental analyses were both done. Analytical calculations and FE simulations of this method accompanied by Abaqus/explicit indicate that the large amount of equivalent plastic strain of 5.8 is imposed in each cycle. In experimental investigations of a single-cycle of RTES, microstructural observations showed a significant grain refinement from the initial value of similar to 150 mu m to similar to 700 nm. The distribution characteristic of refinement and hardness were consistent with that of simulated effective strain. This novel SPD method seems to be very promising for future commercial practice.
C1 [Jafarzadeh, H.; Abrinia, K.] Univ Tehran, Coll Engn, Dept Mech Engn, Tehran, Iran.
RP Jafarzadeh, H (reprint author), Univ Tehran, Coll Engn, Dept Mech Engn, Tehran, Iran.
EM h.jafarzadeh@ut.ac.ir
CR Babaei A, 2014, J MATER SCI, V49, P3158, DOI 10.1007/s10853-014-8017-6
   Chen ZH, 2007, MATER MANUF PROCESS, V22, P51, DOI 10.1080/10426910601015907
   Faraji G, 2012, MATER DESIGN, V35, P251, DOI 10.1016/j.matdes.2011.09.057
   Furukawa M, 2001, J MATER SCI, V36, P2835, DOI 10.1023/A:1017932417043
   Jafarzadeh H., 2014, J MECH SCI TECHNOL, V28, P1
   Kim HS, 2000, ACTA MATER, V48, P493, DOI 10.1016/S1359-6454(99)00353-5
   LANGUILLAUME J, 1993, ACTA METALL MATER, V41, P2953, DOI 10.1016/0956-7151(93)90110-E
   Luis CJ, 2012, MATER MANUF PROCESS, V27, P1276, DOI 10.1080/10426914.2012.663128
   Mohebbi MS, 2010, MAT SCI ENG A-STRUCT, V528, P180, DOI 10.1016/j.msea.2010.08.081
   Saito Y, 1999, ACTA MATER, V47, P579, DOI 10.1016/S1359-6454(98)00365-6
   Toth LS, 2009, SCRIPTA MATER, V60, P175, DOI 10.1016/j.scriptamat.2008.09.029
   Valdera J., 2011, MAT MANUFACTURING PR, V27, P986
   Valiev RZ, 2000, PROG MATER SCI, V45, P103, DOI 10.1016/S0079-6425(99)00007-9
   Valiev RZ, 1999, NANOSTRUCT MATER, V12, P35, DOI 10.1016/S0965-9773(99)00061-6
   Varyukhin V, 2006, MATER SCI FORUM, V503-504, P335, DOI 10.4028/www.scientific.net/MSF.503-504.335
   Zangiabadi A, 2011, MAT SCI ENG A-STRUCT, V528, P5066, DOI 10.1016/j.msea.2011.03.012
   Zhang J, 2007, MATER SCI FORUM, V546-549, P2293, DOI 10.4028/www.scientific.net/MSF.546-549.2293
NR 17
TC 2
Z9 2
U1 2
U2 18
PU KOREAN SOC MECHANICAL ENGINEERS
PI SEOUL
PA KSTC NEW BLD. 7TH FLOOR, 635-4 YEOKSAM-DONG KANGNAM-KU, SEOUL 135-703,
   SOUTH KOREA
SN 1738-494X
EI 1976-3824
J9 J MECH SCI TECHNOL
JI J. Mech. Sci. Technol.
PD FEB
PY 2015
VL 29
IS 2
BP 733
EP 738
DI 10.1007/s12206-015-0133-y
PG 6
WC Engineering, Mechanical
SC Engineering
GA CB1WT
UT WOS:000349419400032
DA 2018-12-27
ER

PT J
AU Wang, HW
   Zhu, B
   Hou, LJ
   Lu, GJ
   Jiao, LY
   Shen, BS
AF Wang, Hong-Wei
   Zhu, Bin
   Hou, Li-Juan
   Lu, Guang-Jian
   Jiao, Lu-Yang
   Shen, Bao-Sheng
TI RETRACTED: An infectious molecular clone in early infection with HIV-1
   subtype CRF01_AE strains: construction and biological properties
   (Retracted article. See vol. 42, pg. 1495, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Infectious molecular clone; CRF01_AE; Early infection; Human
   immunodeficiency virus type 1; Construction and biological properties
ID IMMUNODEFICIENCY-VIRUS; MEN MSM; CHINA; TRANSMITTED/FOUNDER;
   TRANSMISSION; IDENTIFICATION; EMERGENCE; EPIDEMIC; VARIANT; DESIGN
AB Our aim was to construct infectious molecular clones of the CRF01_AE subtype in the primary infection phase of an acute HIV-1 infections in people screened from MSM populations, as well as continue preliminary research on this virus and its biological properties pertaining to deriving viruses. Walking sequencing was performed on a half-molecular clone with target fragment inserted. Western Blot was used to detect protein expression in HIV-1 infected 293T cells. Sequence analysis of HIV-1 genomic clones showed full-length HIV-1 genomic clones without frame shift mutation or termination codon. HIV-1 p24 antigens generated from 08-IMC were slightly greater than those from infectious molecular clones pNL4-3 3 and 93JP-NH1, but without statistical difference (all P > 0.05). The relative light units of 08-ISO was higher than those of 08-IMC, but no significant difference was observed (all P > 0.05). 08-IMC-driven virus was linked to lower replication kinetics. The replication levels of pNL4-3 and 08-ISO were significantly higher than the 08-IMC replication level but close to NH1 replication level (all P < 0.05). 08-IMC could infect the cells expressing CCR5 and be replicated in the CCR5-expressing cells with a positive percentage of 24.3 %, 08-ISO may use CCR5-using macrophage-tropic isolates as coreceptor, while pNL4-3 viruses with T cell tropisms utilize the CXCR4 coreceptor. Our study showed that the infectious molecular clones of viruses in the primary infection phase have a close relationship with the major prevalent CRF01_AE strains and have high homology with the viral RNA in plasma.
C1 [Wang, Hong-Wei; Hou, Li-Juan; Shen, Bao-Sheng] Xinxiang Med Univ, Affiliated Hosp 1, Dept Infect 1, Weihui 453100, Peoples R China.
   [Zhu, Bin] Xinxiang Med Univ, Dept Infect 2, Affiliated Hosp 1, Weihui 453100, Peoples R China.
   [Lu, Guang-Jian; Jiao, Lu-Yang] Xinxiang Med Univ, Dept Inspect, Affiliated Hosp 1, Weihui 453100, Peoples R China.
RP Shen, BS (reprint author), Xinxiang Med Univ, Affiliated Hosp 1, Dept Infect 1, Weihui 453100, Peoples R China.
EM shenbaosheng1029@126.com
CR An MH, 2012, J VIROL, V86, P12402, DOI 10.1128/JVI.00262-12
   Baalwa J, 2013, VIROLOGY, V436, P33, DOI 10.1016/j.virol.2012.10.009
   Bahuon C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047666
   Bon I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076482
   Chhatwal P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036029
   Feng Y, 2013, AIDS, V27, P1793, DOI 10.1097/QAD.0b013e328360db2d
   Finlayson Teresa J., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
   Keele BF, 2010, CURR OPIN HIV AIDS, V5, P327, DOI 10.1097/COH.0b013e32833a0b9b
   Kijak GH, 2011, DRUG ALCOHOL DEPEN, V116, P24, DOI 10.1016/j.drugalcdep.2010.11.013
   Kondo M, 2013, J VIROL, V87, P5351, DOI 10.1128/JVI.02370-12
   Lau KA, 2007, AIDS REV, V9, P218
   McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674
   Nishimura Y, 2011, J VIROL, V85, P10617, DOI 10.1128/JVI.05010-11
   Nomura T, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00234
   Ochsenbauer C, 2012, J VIROL, V86, P2715, DOI 10.1128/JVI.06157-11
   Panos G, 2015, CRIT REV MICROBIOL, V41, P473, DOI 10.3109/1040841X.2013.867829
   Ping LH, 2013, J VIROL, V87, P7218, DOI 10.1128/JVI.03577-12
   Rodriguez MA, 2006, VIROLOGY, V345, P328, DOI 10.1016/j.virol.2005.09.053
   Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07
   Saunders KO, 2012, AIDS, V26, P1293, DOI 10.1097/QAD.0b013e32835474d2
   Tee KK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006666
   Troyer RM, 2013, J VIROL, V87, P7940, DOI 10.1128/JVI.00752-13
   Wang Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079177
   Wilen CB, 2011, J VIROL, V85, P8514, DOI 10.1128/JVI.00736-11
   Ye JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054238
   Zeng HY, 2012, AIDS RES HUM RETROV, V28, P1352, DOI 10.1089/aid.2011.0364
   Zhang QW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031233
   Zhang Y, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003310
   Zhang Y, 2006, PLOS MED, V3, P2065, DOI 10.1371/journal.pmed.0030443
NR 33
TC 1
Z9 1
U1 2
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD FEB
PY 2015
VL 42
IS 2
BP 329
EP 336
DI 10.1007/s11033-014-3754-9
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CA6FZ
UT WOS:000349006900002
PM 25374426
DA 2018-12-27
ER

PT J
AU Dang, NN
   Pang, SG
   Song, HY
   Bian, H
   Zhang, XR
   An, LG
   Ma, XL
AF Dang, Ningning
   Pang, Shuguang
   Song, Haiyan
   Bian, Hong
   Zhang, Xiaoran
   An, Liguo
   Ma, Xiaoli
TI RETRACTED: Knockdown of filaggrin influences the epidermal terminal
   differentiation via MAPK pathway in normal human epidermal keratinocytes
   (Retracted article. See vol. 42, pg. 1497, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Epidermal terminal differentiation; Keratinocytes; Mitogen-activated
   protein kinase (MAPK) pathway; Normal human epidermal keratinocytes
   (NHEKs)
ID NF-KAPPA-B; ATOPIC-DERMATITIS; EPITHELIAL-CELLS; MESSENGER-RNA;
   EXPRESSION; P38; ERK; PROLIFERATION; PROMOTES; KINASE
AB We aimed to gain further insight into the role of the MAPK signaling pathway in terminal differentiation of normal human epidermal keratinocytes (NHEKs) with filaggrin knockdown. Filaggrin expression was knocked down by shRNA technology and the MAPK pathways were inhibited by three different inhibitors in NHEKs. The associated mRNAs and proteins were investigated by RTPCR and western blot. Filaggrin absence inhibited the expression of differentiation-associated proteins, and blocked the protein expression of p38 MAPK, ERK1/2, JNK, Akt and NF-kappa B. Moreover, inhibited p38 MAPK, instead of ERK1/2 or JNK, lead to decreases in the expressions of Akt, NF-kappa B, and differentiation-associated proteins. In conclusion, Filaggrin might affect the epidermal terminal differentiation mainly through the p38 MAPK, NF-kappa B and Akt pathways. ERK1/2 and JNK might also be involved in the process.
C1 [Dang, Ningning; Song, Haiyan; Zhang, Xiaoran] Shandong Univ, Dept Dermatol, Jinan Cent Hosp, Jinan 250013, Shandong, Peoples R China.
   [Dang, Ningning; An, Liguo] Shandong Normal Univ, Coll Life Sci, Jinan 250014, Shandong, Peoples R China.
   [Pang, Shuguang] Shandong Univ, Dept Endocrinol, Jinan Cent Hosp, Jinan 250013, Shandong, Peoples R China.
   [Bian, Hong] Shandong Univ, Dept Neurol, Jinan Cent Hosp, Jinan 250013, Shandong, Peoples R China.
   [Ma, Xiaoli] Shandong Univ, Cent Lab, Jinan Cent Hosp, Jinan 250013, Shandong, Peoples R China.
RP Dang, NN (reprint author), Shandong Univ, Dept Dermatol, Jinan Cent Hosp, 105 Jiefang Rd, Jinan 250013, Shandong, Peoples R China.
EM ddningning@163.com; xiaoommlii@hotmail.com
FU National Natural Science Foundation of China (NSFC) [81101183, 81170771,
   81272588]; China Postdoctoral Science Foundation (CPSF) [2014M550370]
FX The study was supported by National Natural Science Foundation of China
   (NSFC) (No. 81101183, 81170771, 81272588) and China Postdoctoral Science
   Foundation (CPSF) (No. 2014M550370).
CR Alam H, 2011, MOL BIOL CELL, V22, P4068, DOI 10.1091/mbc.E10-08-0703
   Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200
   Chen YW, 2014, J INVEST DERMATOL, V134, P405, DOI 10.1038/jid.2013.320
   CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005
   Connelly JT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027259
   Cookson WOCM, 2001, J AM ACAD DERMATOL, V45, pS7, DOI 10.1067/mjd.2001.117026
   COULOMBE PA, 1989, J CELL BIOL, V109, P2295, DOI 10.1083/jcb.109.5.2295
   De D, 2012, INDIAN J DERMATOL VE, V78, P545, DOI 10.4103/0378-6323.100518
   Eichenfield LF, 2012, SEMIN CUTAN MED SURG, V31, pS3, DOI 10.1016/j.sder.2012.07.002
   Gazel A, 2008, J CELL PHYSIOL, V215, P292, DOI 10.1002/jcp.21394
   Gazel A, 2006, J BIOL CHEM, V281, P20530, DOI 10.1074/jbc.M602712200
   Hara T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.40
   Harmon RM, 2013, J CLIN INVEST, V123, P1556, DOI 10.1172/JCI65220
   Ivanova P, 2008, ARCH DERMATOL RES, V300, P139, DOI 10.1007/s00403-008-0832-7
   Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200
   Jonak C, 2011, J DERMATOL SCI, V61, P32, DOI 10.1016/j.jdermsci.2010.10.009
   Kang JS, 2006, MOL PHARMACOL, V69, P941, DOI 10.1124/mol.105.017442
   Kobayashi H, 2003, EXP DERMATOL, V12, P734, DOI 10.1111/j.0906-6705.2003.00045.x
   Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011
   Lopez-Pajares V, 2013, TRENDS GENET, V29, P31, DOI 10.1016/j.tig.2012.10.005
   Oh JH, 2009, INT IMMUNOPHARMACOL, V9, P614, DOI 10.1016/j.intimp.2009.02.002
   Popp T, 2011, TOXICOL LETT, V204, P43, DOI 10.1016/j.toxlet.2011.04.007
   Presland RB, 1997, J INVEST DERMATOL, V108, P170, DOI 10.1111/1523-1747.ep12333356
   Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392
   Rauhala L, 2013, J BIOL CHEM, V288, P17999, DOI 10.1074/jbc.M113.472530
   Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0
   Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873
NR 27
TC 1
Z9 1
U1 2
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD FEB
PY 2015
VL 42
IS 2
BP 337
EP 343
DI 10.1007/s11033-014-3765-6
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CA6FZ
UT WOS:000349006900003
PM 25374427
DA 2018-12-27
ER

PT J
AU Lv, J
   Zhu, YX
   Liu, YQ
   Xue, X
AF Lv, Jing
   Zhu, Yi-Xin
   Liu, Ying-Qun
   Xue, Xin
TI RETRACTED: Distinctive pathways characterize A. actinomycetemcomitans
   and P. gingivalis (Retracted article. See vol. 42, pg. 1499, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Porphuromonas gingivalis; Aggregatibacter actinomycetemcomitans;
   Differentially expressed genes; Protein-protein interaction; Pathways;
   Periodontitis
ID PORPHYROMONAS-GINGIVALIS; AGGREGATIBACTER-ACTINOMYCETEMCOMITANS; GENETIC
   DIVERSITY; IMMUNE-RESPONSE; INFECTION; KINASE; EXPRESSION; VIRULENCE
AB The study aimed to compare the molecular mechanism of Porphuromonas gingivalis (P. gingivalis) and Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans). With microarray dataset (GSE9723) from Gene Expression Omnibus, differentially expressed genes (DEGs) were identified comparing normal cell samples with A. actinomycetemcomitans-infected and P. gingivalis-infected periodontitis cell samples, respectively (vertical bar logFC vertical bar > 1, p value <0.01), followed by hierarchical cluster analysis using Cluster software. Network topological features of A. actinomycetemcomitans-related and P. gingivalis-related protein-protein interaction networks, and background network, which included average shortest path length (ASPL), degree, closeness centrality (CC), eccentricity (EC), betweenness centrality (BC) and topological coefficient (TC) were compared using network analysis plugin of Cytoscape, followed by pathway enrichment analysis (p value <0.05) using FISHER hyper-geometric algorithm and calculation of pathway alter scores using LIMMA. Totally, 839 DEGs and 251 DEGs were screened for A. actinomycetemcomitans and P. gingivalis, respectively. A. actinomycetemcomitans-related network had lower ASPL, degree and EC but higher CC and TC (p < 0.01), while P. gingivalis-related network had lower EC but higher CC and BC (p < 0.01) compared to background network. P. gingivalis-related network had lower ASPL, degree and EC, but higher CC than the A. actinomycetemcomitans-related network (p < 0.05). A. actinomycetemcomitans was associated with the pathways relating to endothelial cells function, while neuroactive ligand-receptor interaction and MAPK pathways were important for P. gingivalis, which had higher alter scores in hematopoietic cell lineage, hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy pathways than A. actinomycetemcomitans. Genes and pathways of the two pathogens were distinctive. The findings aided in preventing and treating relevant diseases.
C1 [Lv, Jing; Zhu, Yi-Xin; Liu, Ying-Qun; Xue, Xin] Harbin Med Univ, Sch Stomatol, Dept Pediat, Harbin 150001, Heilongjiang Pr, Peoples R China.
RP Xue, X (reprint author), Harbin Med Univ, Sch Stomatol, Dept Pediat, 143 Yiman St, Harbin 150001, Heilongjiang Pr, Peoples R China.
EM xinxuedr@163.com
FU Scientific Research Project of Heilongjiang Province Health Department
   [2011-042]; Educational Bureau of Heilongjiang Province [11551186,
   12541564]
FX This study was supported by grant from the Scientific Research Project
   of Heilongjiang Province Health Department (No. 2011-042), Educational
   Bureau of Heilongjiang Province (No. 11551186) and Educational Bureau of
   Heilongjiang Province (No. 12541564).
CR Ando-Suguimoto ES, 2014, CYTOKINE, V66, P46, DOI 10.1016/j.cyto.2013.12.014
   Brage M, 2011, J PERIODONTAL RES, V46, P170, DOI 10.1111/j.1600-0765.2010.01325.x
   Bullon P, 2011, FREE RADICAL BIO MED, V50, P1336, DOI 10.1016/j.freeradbiomed.2011.02.018
   Chan F, 2010, AUSTR NZ DIV GOLD JU
   Chatr-aryamontri A, 2013, NUCLEIC ACIDS RES, V41, pD816, DOI 10.1093/nar/gks1158
   Dickinson BC, 2011, MOL ORAL MICROBIOL, V26, P210, DOI 10.1111/j.2041-1014.2011.00609.x
   Dietmann A, 2013, MICROB PATHOGENESIS, V61-62, P43, DOI 10.1016/j.micpath.2013.05.001
   DUNCAN MJ, 1993, INFECT IMMUN, V61, P2260
   Han XZ, 2014, VACCINE, V32, P297, DOI 10.1016/j.vaccine.2013.09.004
   Handfield M, 2005, CELL MICROBIOL, V7, P811, DOI 10.1111/j.1462-5822.2005.00513.x
   Haraguchi A, 2014, MOL ORAL MICROBIOL, V29, P131, DOI 10.1111/omi.12051
   Hokamura K, 2010, J PERIODONTAL RES, V45, P337, DOI 10.1111/j.1600-0765.2009.01242.x
   Kawamoto D, 2009, ORAL MICROBIOL IMMUN, V24, P493, DOI 10.1111/j.1399-302X.2009.00547.x
   Kelk P, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.6
   Kinloch AJ, 2011, ARTHRITIS RHEUM-US, V63, P3818, DOI 10.1002/art.30639
   Lee SD, 2006, EUR J ORAL SCI, V114, P154, DOI 10.1111/j.1600-0722.2006.00299.x
   Liu B, 2012, J PERIODONTOL, V83, P955, DOI 10.1902/jop.2011.110406
   Marchesan JT, 2012, MOL ORAL MICROBIOL, V27, P483, DOI 10.1111/omi.12001
   Nam H, 2009, BIOTECHNOL BIOENG, V103, P835, DOI 10.1002/bit.22320
   Park SR, 2014, INFECT IMMUN, V82, P1914, DOI 10.1128/IAI.01226-13
   Przulj N, 2004, BIOINFORMATICS, V20, P340, DOI 10.1093/bioinformatics/btg415
   Qin W, 2014, AFR J MICROBIOL RES, V8, P1394
   Saito R, 2012, NAT METHODS, V9, P1069, DOI [10.1038/NMETH.2212, 10.1038/nmeth.2212]
   Shaik-Dasthagirisaheb Y, 2012, J IMMUNOL, V188, P26
   SLOTS J, 1976, SCAND J DENT RES, V84, P1
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Silveira VRS, 2013, J APPL ORAL SCI, V21, P430, DOI 10.1590/1679-775720130252
   Tribble GD, 2013, FUTURE MICROBIOL, V8, P607, DOI [10.2217/FMB.13.30, 10.2217/fmb.13.30]
   Vernal R, 2008, J PERIODONTAL RES, V43, P689, DOI 10.1111/j.1600-0765.2007.01073.x
   Wang M, 2007, J IMMUNOL, V179, P2349, DOI 10.4049/jimmunol.179.4.2349
   Watanabe K, 2001, INFECT IMMUN, V69, P6731, DOI 10.1128/IAI.69.11.6731-6737.2001
   Weinberg A, 1997, INFECT IMMUN, V65, P313
   Xu JZ, 2006, BIOINFORMATICS, V22, P2800, DOI 10.1093/bioinformatics/btl467
   Zhang P, 2005, INFECT IMMUN, V73, P3990, DOI 10.1128/IAI.73.7.3990-3998.2005
   Zhang W, 2014, J BONE MINER RES, V29, P1232, DOI 10.1002/jbmr.2116
NR 35
TC 4
Z9 5
U1 4
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD FEB
PY 2015
VL 42
IS 2
BP 441
EP 449
DI 10.1007/s11033-014-3785-2
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CA6FZ
UT WOS:000349006900014
PM 25351486
DA 2018-12-27
ER

PT J
AU Xian, SL
   Cao, W
   Zhang, XD
   Lu, YF
AF Xian, Shu-Lin
   Cao, Wei
   Zhang, Xiao-Dong
   Lu, Yun-Fei
TI RETRACTED: 3-Bromopyruvate inhibits human gastric cancer tumor growth in
   nude mice via the inhibition of glycolysis(Retracted article. See
   vol.12, pg.5377,2016)
SO ONCOLOGY LETTERS
LA English
DT Article; Retracted Publication
DE 3-bromopyruvate; hexokinase; nude mouse; apoptosis; treatment
ID DOWN-REGULATION; APOPTOSIS; CELLS; BCL-2; THERAPY; ARREST; BAX
AB Tumor cells primarily depend upon glycolysis in order to gain energy. Therefore, the inhibition of glycolysis may inhibit tumor growth. Our previous study demonstrated that 3-bromopyruvate (3-BrPA) inhibited gastric cancer cell proliferation in vitro. However, the ability of 3-BrPA to suppress tumor growth in vivo, and its underlying mechanism, have yet to be elucidated. The aim of the present study was to investigate the inhibitory effect of 3-BrPA in an animal model of gastric cancer. It was identified that 3-BrPA exhibited strong inhibitory effects upon xenograft tumor growth in nude mice. In addition, the antitumor function of 3-BrPA exhibited a dose-effect association, which was similar to that of the chemotherapeutic agent, 5-fluorouracil. Furthermore, 3-BrPA exhibited low toxicity in the blood, liver and kidneys of the nude mice. The present study hypothesized that the inhibitory effect of 3-BrPA is achieved through the inhibition of hexokinase activity, which leads to the downregulation of B-cell lymphoma 2 (Bcl-2) expression, the upregulation of Bcl-2-associated X protein expression and the subsequent activation of caspase-3. These data suggest that 3-BrPA may be a novel therapy for the treatment of gastric cancer.
C1 [Xian, Shu-Lin; Cao, Wei; Zhang, Xiao-Dong; Lu, Yun-Fei] Guangxi Med Univ, Affiliated Hosp 1, Dept Gastrointestinal & Gland Surg, Guangxi 530021, Peoples R China.
RP Lu, YF (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Gastrointestinal & Gland Surg, 6 Shuangyong Rd, Guangxi 530021, Peoples R China.
EM xian837111@163.com
FU National Natural Science Foundation of China [81260366]; Guangxi
   Scientific Research and Technology Development Project [11217011]
FX This study was supported by grants from the National Natural Science
   Foundation of China (no. 81260366) and the Guangxi Scientific Research
   and Technology Development Project (no. 11217011).
CR Banadyga L, 2009, J VIROL, V83, P7085, DOI 10.1128/JVI.00437-09
   Cali U, 2013, CLIN EXP OBSTET GYN, V40, P45
   Cardaci S, 2012, J BIOENERG BIOMEMBR, V44, P17, DOI 10.1007/s10863-012-9422-7
   Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825
   Deyhimi P, 2013, J ORAL PATHOL MED, V42, P409, DOI 10.1111/jop.12022
   Doudican N, 2008, MOL CANCER RES, V6, P1308, DOI 10.1158/1541-7786.MCR-07-2159
   El Sayed SM, 2013, MED HYPOTHESES, V81, P866, DOI 10.1016/j.mehy.2013.08.024
   Floridi A, 1989, J Neurosurg Sci, V33, P55
   Ganapathy-Kanniappan S, 2010, CURR PHARM BIOTECHNO, V11, P510, DOI 10.2174/138920110791591427
   Geschwind JFH, 2002, CANCER RES, V62, P3909
   Grosse J, 2014, APOPTOSIS, V19, P480, DOI 10.1007/s10495-013-0937-0
   Han CR, 2014, APOPTOSIS, V19, P224, DOI 10.1007/s10495-013-0928-1
   Khatri S, 2010, J BIOL CHEM, V285, P15960, DOI 10.1074/jbc.M110.121871
   Liapi E, 2010, J HEPATO-BIL-PAN SCI, V17, P405, DOI 10.1007/s00534-009-0236-x
   Liu L, 2013, EXP THER MED, V5, P338, DOI 10.3892/etm.2012.787
   Liu XH, 2009, CHINESE MED J-PEKING, V122, P1681, DOI 10.3760/cma.j.issn.0366-6999.2009.14.014
   Lu YF, 2011, ANTICANCER RES, V31, P797
   Nelson K, 2002, LANCET ONCOL, V3, P524, DOI 10.1016/S1470-2045(02)00867-7
   NWAGWU M, 1982, ACTA TROP, V39, P61
   Ota S, 2013, TARGET ONCOL, V8, P145, DOI 10.1007/s11523-013-0273-x
   Qiu HB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-374
   Nguyen QD, 2013, CLIN CANCER RES, V19, P3914, DOI 10.1158/1078-0432.CCR-12-3814
   Rahman KMW, 2009, CANCER RES, V69, P4468, DOI 10.1158/0008-5472.CAN-08-4423
   Tokumoto M, 2013, J TOXICOL SCI, V38, P815
   Xian SL, 2013, CHIN PRACT MED J, V12, P78
   Xu J, 2013, MOL CANCER THER, V12, P717, DOI 10.1158/1535-7163.MCT-12-1016-T
   Yamamoto M, 2013, ONCOLOGY-BASEL, V85, P241, DOI 10.1159/000354420
NR 27
TC 9
Z9 10
U1 2
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD FEB
PY 2015
VL 9
IS 2
BP 739
EP 744
DI 10.3892/ol.2014.2779
PG 6
WC Oncology
SC Oncology
GA CB3CR
UT WOS:000349506300043
PM 25621044
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Savaliya, ML
   Dhorajiya, BD
   Dholakiya, BZ
AF Savaliya, Mehulkumar L.
   Dhorajiya, Bhaveshkumar D.
   Dholakiya, Bharatkumar Z.
TI RETRACTED: Recent advancement in production of liquid biofuels from
   renewable resources: a review (Retracted article. See vol.44, pg.1439,
   2018)
SO RESEARCH ON CHEMICAL INTERMEDIATES
LA English
DT Article; Retracted Publication
DE Biofuel; Fossil fuel; Greenhouse gas (GHG); Fischer-Tropsch liquids
   (FTL); Hemicellulose and hydroxymethyl furfural (HMF)
ID KLUYVEROMYCES-MARXIANUS IMB3; 45 DEGREES-C; CATALYTIC REACTIVE
   DISTILLATION; CONTINUOUS ETHANOL FERMENTATION; SUPERCRITICAL METHANOL
   PROCESS; FATTY-ACID ESTERIFICATION; BIODIESEL FUEL PRODUCTION;
   CLOSTRIDIUM-BEIJERINCKII; SACCHAROMYCES-CEREVISIAE; BUTANOL PRODUCTION
AB This work was carried out in search of a suitable fuel alternative to fast-depleting fossil fuel and oil reserves and in serious consideration of the environmental problems associated with the major use of fuels based on petrochemicals; research work is in progress worldwide. Researchers have been re-directing their interests to biomass-dependent fuels, which currently seem to be the only logical substitute for green development in the context of economical and environmental aspects. Renewable bioresources are available worldwide in the form of residual agricultural biomass and wastes, which can be converted into liquid biofuels. However, the process of converting, or chemical conversions, can be very expensive and not worthwhile to use for an economical large-scale commercial supply of biofuels. Hence, there is still need for souch research to be done on an effective, economical, and efficient conversion process. The objective of this review is to provide a deep overview of liquid biofuels and the present knowledge produced by scientists throughout the world.
C1 [Savaliya, Mehulkumar L.; Dhorajiya, Bhaveshkumar D.; Dholakiya, Bharatkumar Z.] SV Natl Inst Technol, Dept Appl Chem, Surat 395007, Gujarat, India.
RP Dholakiya, BZ (reprint author), SV Natl Inst Technol, Dept Appl Chem, Surat 395007, Gujarat, India.
EM msmehulsavaliya@gmail.com; bhavesh.orgchem@gmail.com;
   bzd.svnit@gmail.com
CR A National Vision of America's Transition to a Hydrogen Economy - To 2030 and Beyond, 2002, NAT VIS AM TRANS HYD
   Abdel-Fattah WR, 2000, BIOTECHNOL BIOENG, V68, P531, DOI 10.1002/(SICI)1097-0290(20000605)68:5<531::AID-BIT7>3.3.CO;2-P
   Agarwal AK, 2007, PROG ENERG COMBUST, V33, P233, DOI 10.1016/j.pecs.2006.08.003
   Aggarwal N.K., 2001, WORLD J MICROB BIOT, V17, P125
   Aleklett K, 2003, MINER ENERGY, V18, P35
   Armbruster W.J., 2006, PACIFIC FOOD SYSTEM
   AZHAR AF, 1981, BIOTECHNOL BIOENG, P293
   AZZAM AM, 1989, J ENVIRON SCI HEAL B, V24, P421, DOI 10.1080/03601238909372658
   Bajpai D, 2006, J OLEO SCI, V55, P487, DOI DOI 10.5650/JOS.55.487
   Balat M, 2008, ENERG CONVERS MANAGE, V49, P2727, DOI 10.1016/j.enconman.2008.03.016
   Banat I.M., 2000, RES ADV FOOD SCI, V1, P41
   Banat I.M., 1998, ADV BIOTECHNOL, P105
   BANAT IM, 1992, WORLD J MICROB BIOT, V8, P259, DOI 10.1007/BF01201874
   Banat IM, 1998, WORLD J MICROB BIOT, V14, P809, DOI 10.1023/A:1008802704374
   Barron N, 1996, PROGR BIOTECHNOL, V11, P379
   BEGUIN P, 1994, FEMS MICROBIOL REV, V13, P25, DOI 10.1016/0168-6445(94)90099-X
   BENGHEDALIA D, 1981, BIOTECHNOL BIOENG, V23, P823, DOI 10.1002/bit.260230412
   Bhatti HN, 2008, FUEL, V87, P2961, DOI 10.1016/j.fuel.2008.04.016
   Billaud F, 2003, J MOL CATAL A-CHEM, V192, P281, DOI 10.1016/S1381-1169(02)00447-8
   Bisaria VS, 1991, BIOCONVERSION WASTE, P210
   BLANCHETTE RA, 1991, ANNU REV PHYTOPATHOL, V29, P381, DOI 10.1146/annurev.py.29.090191.002121
   BOOMINATHAN K, 1992, P NATL ACAD SCI USA, V89, P5586, DOI 10.1073/pnas.89.12.5586
   BOOPATHY R, 1991, CURR MICROBIOL, V23, P327, DOI 10.1007/BF02104134
   Bournay L, 2005, CATAL TODAY, V106, P190, DOI 10.1016/j.cattod.2005.07.181
   Brady D, 1997, BIOPROCESS ENG, V17, P31
   Brady D, 1997, BIOPROCESS ENG, V16, P101, DOI 10.1007/s004490050295
   Brady D, 1996, BIOTECHNOL LETT, V18, P1213, DOI 10.1007/BF00128595
   Brekke K., 2007, ETHANOL TODAY, P36
   Brennan L, 2010, RENEW SUST ENERG REV, V14, P557, DOI 10.1016/j.rser.2009.10.009
   Brown LM, 1996, ENERG CONVERS MANAGE, V37, P1363, DOI 10.1016/0196-8904(95)00347-9
   Bruinsma J. E, 2003, WORLD AGR 2015 2030
   Canakci M, 2003, T ASAE, V46, P945
   Canakci M, 2009, EXPERT SYST APPL, V36, P9268, DOI 10.1016/j.eswa.2008.12.005
   Celinska E, 2009, BIOTECHNOL ADV, V27, P715, DOI 10.1016/j.biotechadv.2009.05.002
   CHEN JC, 1992, J FERMENT BIOENG, V73, P412, DOI 10.1016/0922-338X(92)90290-B
   Choudary BM, 2000, J MOL CATAL A-CHEM, V159, P411, DOI 10.1016/S1381-1169(00)00209-0
   COLMAN B, 1995, PLANT CELL ENVIRON, V18, P919, DOI 10.1111/j.1365-3040.1995.tb00601.x
   Coughlan M. P., 1988, Biochemistry and genetics of cellulose degradation, P11
   Dale BE, 2003, J CHEM TECHNOL BIOT, V78, P1093, DOI 10.1002/jctb.850
   Darnoko D, 2000, J AM OIL CHEM SOC, V77, P1269, DOI 10.1007/s11746-000-0199-x
   Demirbas A, 2009, ENERG CONVERS MANAGE, V50, P14, DOI 10.1016/j.enconman.2008.09.001
   Demirbas A, 2008, ENERG CONVERS MANAGE, V49, P125, DOI 10.1016/j.enconman.2007.05.002
   Demirbas MF, 2006, ENERG CONVERS MANAGE, V47, P2371, DOI 10.1016/j.enconman.2005.11.014
   Dien BS, 2000, APPL BIOCHEM BIOTECH, V84-6, P181, DOI 10.1385/ABAB:84-86:1-9:181
   Dossin TF, 2006, APPL CATAL B-ENVIRON, V67, P136, DOI 10.1016/j.apcatb.2006.04.008
   Duff SJB, 1996, BIORESOURCE TECHNOL, V55, P1, DOI 10.1016/0960-8524(95)00122-0
   EBTP, 2009, BIOB
   Escobar JC, 2009, RENEW SUST ENERG REV, V13, P1275, DOI 10.1016/j.rser.2008.08.014
   European Union (EU), 2009, OFF J EUR UNION, VL140, P16
   Ezeji, 2005, US Provisional Patent, Patent No. [No. 60/504,280, 60504280, 60/ 504,280]
   Ezeji T, 2007, BIOTECHNOL BIOENG, V97, P1460, DOI 10.1002/bit.21373
   Ezeji T, 2007, PROCESS BIOCHEM, V42, P34, DOI 10.1016/j.procbio.2006.07.020
   Ezeji Thaddeus C., 2005, P797, DOI 10.1201/9780203489819.pt7
   Ezeji TC, 2006, CHEM IND-SER, V112, P99
   Ezeji TC, 2007, CURR OPIN BIOTECH, V18, P220, DOI 10.1016/j.copbio.2007.04.002
   Fakas S, 2007, ENZYME MICROB TECH, V40, P1321, DOI 10.1016/j.enzmictec.2006.10.005
   FAO, 2008, STAT FOOD AGR BIOFUE
   Fargione J, 2008, SCIENCE, V319, P1235, DOI 10.1126/science.1152747
   Farias FEM, 2007, LAT AM APPL RES, V37, P283
   Farrell EA, 1998, BIOPROCESS ENG, V19, P217
   FULTON L, 2004, BIOFUELS TRANSPORT I
   Furuta S, 2004, CATAL COMMUN, V5, P721, DOI 10.1016/j.catcom.2004.09.001
   GIBBONS WR, 1989, BIOMASS, V18, P43, DOI 10.1016/0144-4565(89)90080-2
   Gough S, 1997, BIOPROCESS ENG, V16, P389, DOI 10.1007/PL00008950
   Grant B., 2009, SCIENTIST        FEB, V37-41
   Groom MJ, 2008, CONSERV BIOL, V22, P602, DOI 10.1111/j.1523-1739.2007.00879.x
   Gullison RE, 2007, SCIENCE, V316, P985, DOI 10.1126/science.1136163
   Gutierrez T, 2002, APPL BIOCHEM BIOTECH, V98, P327, DOI 10.1385/ABAB:98-100:1-9:327
   Ha SH, 2007, ENZYME MICROB TECH, V41, P480, DOI 10.1016/j.enzmictec.2007.03.017
   Han HW, 2005, PROCESS BIOCHEM, V40, P3148, DOI 10.1016/j.procbio.2005.03.014
   Hanna MA, 2005, J SCI IND RES INDIA, V64, P854
   He BB, 2006, T ASABE, V49, P107
   He HY, 2007, FUEL, V86, P442, DOI 10.1016/j.fuel.2006.07.035
   He YA, 2010, ENERG ECON, V32, P868, DOI 10.1016/j.eneco.2009.12.005
   Helwani Z, 2009, FUEL PROCESS TECHNOL, V90, P1502, DOI 10.1016/j.fuproc.2009.07.016
   Hoekman SK, 2009, RENEW ENERG, V34, P14, DOI 10.1016/j.renene.2008.04.030
   Hsueh HT, 2007, CHEMOSPHERE, V66, P878, DOI 10.1016/j.chemosphere.2006.06.022
   Hu Q, 2008, PLANT J, V54, P621, DOI 10.1111/j.1365-313X.2008.03492.x
   Huang C, 2009, BIORESOURCE TECHNOL, V100, P4535, DOI 10.1016/j.biortech.2009.04.022
   Huang CF, 2009, BIORESOURCE TECHNOL, V100, P3914, DOI 10.1016/j.biortech.2009.02.064
   Huang WC, 2004, APPL BIOCHEM BIOTECH, V113, P887
   Huertas IE, 2000, J PHYCOL, V36, P314, DOI 10.1046/j.1529-8817.2000.99142.x
   *IEA, 2004, BIOF TRANSP INT PERS
   Jaecker-Voirol A, 2008, OIL GAS SCI TECHNOL, V63, P395, DOI 10.2516/ogst:2008033
   Johnson J, 2008, CHEM ENG NEWS, V86, P10
   Karmee SK, 2005, BIORESOURCE TECHNOL, V96, P1425, DOI [10.1016/j.biortech.2004.12.011, 10.1016/j.biotech.2004.12.011]
   Kiss A.A., 2006, CHEM IND SERIES, V115, P405
   Kiss AA, 2006, ADV SYNTH CATAL, V348, P75, DOI 10.1002/adsc.200505160
   Kiss AA, 2008, ENERG FUEL, V22, P598, DOI 10.1021/ef700265y
   Kiss AA, 2006, TOP CATAL, V40, P141, DOI 10.1007/s11244-006-0116-4
   Kiss AA, 2010, COMPUT CHEM ENG, V34, P812, DOI 10.1016/j.compchemeng.2009.09.005
   Knothe G, 2005, FUEL PROCESS TECHNOL, V86, P1059, DOI 10.1016/j.fuproc.2004.11.002
   Knothe G, 1997, ACS SYM SER, V666, P172, DOI 10.1021/bk-1997-0666.ch010
   Kusdiana D, 2001, FUEL, V80, P693, DOI 10.1016/S0016-2361(00)00140-X
   Kusdiana D, 2004, APPL BIOCHEM BIOTECH, V113, P781
   Larson ED, 2008, UN C TRAD DEV NEW YO
   Licht F.O., WORLD ETHANOL BIOFUE
   Lotero E, 2005, IND ENG CHEM RES, V44, P5353, DOI 10.1021/ie049157g
   Love G, 1996, BIOPROCESS ENG, V15, P275, DOI 10.1007/PL00008938
   Love G, 1998, BIOPROCESS ENG, V18, P187, DOI 10.1007/s004490050429
   Lynd LR, 1999, BIOTECHNOL PROGR, V15, P777, DOI 10.1021/bp990109e
   Lynd LR, 2005, CURR OPIN BIOTECH, V16, P577, DOI 10.1016/j.copbio.2005.08.009
   Ma FR, 1999, BIORESOURCE TECHNOL, V70, P1, DOI 10.1016/S0960-8524(99)00025-5
   Marchetti JM, 2007, RENEW SUST ENERG REV, V11, P1300, DOI 10.1016/j.rser.2005.08.006
   Mata TM, 2010, RENEW SUST ENERG REV, V14, P217, DOI 10.1016/j.rser.2009.07.020
   MCMILLAN JD, 1994, ACS SYM SER, V566, P292
   Meher LC, 2006, BIORESOURCE TECHNOL, V97, P1392, DOI 10.1016/j.biortech.2005.07.003
   Meng X, 2009, RENEW ENERG, V34, P1, DOI 10.1016/j.renene.2008.04.014
   MERCK, 2009, BIOB HIGH EN ADD FUE
   Miao XL, 2006, BIORESOURCE TECHNOL, V97, P841, DOI 10.1016/j.biortech.2005.04.008
   Minami E, 2006, FUEL, V85, P2479, DOI 10.1016/j.fuel.2006.04.017
   MORJANOFF PJ, 1987, BIOTECHNOL BIOENG, V29, P733, DOI 10.1002/bit.260290610
   Murray D., 2005, ETHANOLS POTENTIAL L
   Naik SN, 2010, RENEW SUST ENERG REV, V14, P578, DOI 10.1016/j.rser.2009.10.003
   Narasimharao K, 2007, J BIOBASED MATER BIO, V1, P19, DOI 10.1166/jbmb.2007.002
   NEXANT, 2007, LIQ BIOF SUBST PETR
   Nigam P, 1997, WORLD J MICROB BIOT, V13, P283, DOI 10.1023/A:1018578806605
   Nigam P., 2008, ECI C US CAL 3 7 AUG
   Nigam P, 2008, HIGHER ED INNOVATION
   Nikolic S, 2009, J CHEM TECHNOL BIOT, V84, P497, DOI 10.1002/jctb.2068
   Omota F, 2003, CHEM ENG SCI, V58, P3159, DOI 10.1016/S0009-2509(03)00165-9
   Patil V, 2008, INT J MOL SCI, V9, P1188, DOI 10.3390/ijms9071188
   Pelkmans L., 2006, IMPACT ASSESSMENT ME
   Peterson CL, 2002, APPL ENG AGRIC, V18, P5
   Pickett J, 2008, SUSTAINABLE BIOFUELS
   Prasad S, 2007, ENERG FUEL, V21, P2415, DOI 10.1021/ef060328z
   Prasad S, 2007, RESOUR CONSERV RECY, V50, P1, DOI 10.1016/j.resconrec.2006.05.007
   PULZ O, 1998, ADV BIOCHEM ENG BIOT, V59, P123, DOI DOI 10.1007/BFB0102298
   Qureshi N, 2008, BIOMASS BIOENERG, V32, P1353, DOI 10.1016/j.biombioe.2008.04.009
   Qureshi N, 2008, BIORESOURCE TECHNOL, V99, P5915, DOI 10.1016/j.biortech.2007.09.087
   Qureshi N, 2008, BIOMASS BIOENERG, V32, P168, DOI 10.1016/j.biombioe.2007.07.004
   Qureshi N, 2007, BIOPROC BIOSYST ENG, V30, P419, DOI 10.1007/s00449-007-0137-9
   Qureshi N, 2010, BIOMASS BIOENERG, V34, P566, DOI 10.1016/j.biombioe.2009.12.023
   Qureshi N, 2010, BIOMASS BIOENERG, V34, P559, DOI 10.1016/j.biombioe.2009.12.024
   Ramey D., 2004, BUTANOL ADV BIOFUELS
   Ranatunga TD, 1997, APPL BIOCHEM BIOTECH, V67, P185, DOI 10.1007/BF02788797
   Rathore V, 2007, FUEL, V86, P2650, DOI 10.1016/j.fuel.2007.03.014
   Riordan C, 1996, BIORESOURCE TECHNOL, V55, P171, DOI 10.1016/0960-8524(95)00163-8
   Royal Society of London, 2008, SUST BIOF PROSP CHAL
   Royon D, 2007, BIORESOURCE TECHNOL, V98, P648, DOI 10.1016/j.biortech.2006.02.021
   Saka S, 2001, FUEL, V80, P225, DOI 10.1016/S0016-2361(00)00083-1
   SAXENA A, 1992, BIORESOURCE TECHNOL, V42, P13, DOI 10.1016/0960-8524(92)90082-9
   Schuchardt U, 1998, J BRAZIL CHEM SOC, V9, P199
   SCHURZ J, 1978, BIOCONVERSION CELLUL, P37
   SCHWAB AW, 1988, J AM OIL CHEM SOC, V65, P1781, DOI 10.1007/BF02542382
   Shahid EM, 2008, RENEW SUST ENERG REV, V12, P2484, DOI 10.1016/j.rser.2007.06.001
   Sharma YC, 2008, FUEL, V87, P2355, DOI 10.1016/j.fuel.2008.01.014
   Sheoran A., 1998, J BASIC MICROB, V38, P73
   Singh A., 1992, Advances in Biochemical Engineering/Biotechnology, V45, P29
   Singh AK, 2007, CHEM ENG TECHNOL, V30, P1716, DOI 10.1002/ceat.200700274
   Singh A, 2010, BIORESOURCE TECHNOL, V101, P5003, DOI 10.1016/j.biortech.2009.11.062
   Singh A, 2010, RENEW SUST ENERG REV, V14, P277, DOI 10.1016/j.rser.2009.07.004
   SINGH D, 1995, J BASIC MICROB, V35, P117, DOI 10.1002/jobm.3620350209
   Singh D, 1998, BIOTECHNOL LETT, V20, P753, DOI 10.1023/A:1005390804500
   Singh D, 1998, WORLD J MICROB BIOT, V14, P823, DOI 10.1023/A:1008852424846
   SIVERS MV, 1995, BIORESOURCE TECHNOL, V51, P43
   Stamenkovic OS, 2007, BIORESOURCE TECHNOL, V98, P2688, DOI 10.1016/j.biortech.2006.09.024
   Stephenson AL, 2008, PROCESS SAF ENVIRON, V86, P427, DOI 10.1016/j.psep.2008.06.005
   Stevens D. J., 2004, BIOFUELS TRANSPORTAT
   Suh IS, 2003, BIOTECHNOL BIOPROC E, V8, P313, DOI 10.1007/BF02949274
   Sukumaran RK, 2009, RENEW ENERG, V34, P421, DOI 10.1016/j.renene.2008.05.008
   Sun Y, 2002, BIORESOURCE TECHNOL, V83, P1, DOI 10.1016/S0960-8524(01)00212-7
   Suresh K, 1999, BIORESOURCE TECHNOL, V68, P301, DOI 10.1016/S0960-8524(98)00135-7
   Suwannakarn K, 2009, IND ENG CHEM RES, V48, P2810, DOI 10.1021/ie800889w
   TARKOW H, 1969, ADV CHEM SER, P197
   Tsao G.T., 2009, ADV BIOTECHNOL
   Tsukahara K, 2005, J JPN PETROL INST, V48, P251, DOI 10.1627/jpi.48.251
   TURHOLLOW AF, 1986, ENERG AGR, V5, P309, DOI 10.1016/0167-5826(86)90029-X
   United States Department of Agriculture-USDA, 2003, PROD EST CROP ASS DI, P1
   Usta N, 2005, ENERG CONVERS MANAGE, V46, P741, DOI 10.1016/j.enconman.2004.05.001
   Van Gerpen J, 2005, FUEL PROCESS TECHNOL, V86, P1097, DOI 10.1016/j.fuproc.2004.11.005
   Verma G, 2000, BIORESOURCE TECHNOL, V72, P261, DOI 10.1016/S0960-8524(99)00117-0
   Vicente G, 2004, BIORESOURCE TECHNOL, V92, P297, DOI 10.1016/j.biortech.2003.08.014
   Vicente G, 2005, IND ENG CHEM RES, V44, P5447, DOI 10.1002/ie040208j
   VIDAL PF, 1988, BIOMASS, V16, P1, DOI 10.1016/0144-4565(88)90012-1
   WANG P, 1994, BIOTECHNOL LETT, V16, P977, DOI 10.1007/BF00128637
   Wang Y, 2008, BIORESOURCE TECHNOL, V99, P7232, DOI 10.1016/j.biortech.2007.12.062
   Wati L, 1996, GENET ENG BIOTECHNOL, V16, P19
   Widjaja A, 2009, J TAIWAN INST CHEM E, V40, P13, DOI 10.1016/j.jtice.2008.07.007
   Wiesenthal T, 2009, RENEW SUST ENERG REV, V13, P789, DOI 10.1016/j.rser.2008.01.011
   Wu M., 2007, ANLESD0710
   Wyman CE, 1999, ANNU REV ENERG ENV, V24, P189, DOI 10.1146/annurev.energy.24.1.189
   Xiong W, 2008, APPL MICROBIOL BIOT, V78, P29, DOI 10.1007/s00253-007-1285-1
   Yadav BS, 1996, J BASIC MICROB, V36, P205, DOI 10.1002/jobm.3620360307
   Zaldivar J, 1999, BIOTECHNOL BIOENG, V65, P24, DOI 10.1002/(SICI)1097-0290(19991005)65:1<24::AID-BIT4>3.0.CO;2-2
   ZHANG M, 1995, SCIENCE, V267, P240, DOI 10.1126/science.267.5195.240
   Zhao R, 2009, J CEREAL SCI, V49, P230, DOI 10.1016/j.jcs.2008.10.006
   Zheng YZ, 1998, BIOTECHNOL PROGR, V14, P890, DOI 10.1021/bp980087g
   Zhu LY, 2008, BIORESOURCE TECHNOL, V99, P7881, DOI 10.1016/j.biortech.2008.02.033
NR 189
TC 8
Z9 9
U1 1
U2 100
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0922-6168
EI 1568-5675
J9 RES CHEM INTERMEDIAT
JI Res. Chem. Intermed.
PD FEB
PY 2015
VL 41
IS 2
BP 475
EP 509
DI 10.1007/s11164-013-1231-z
PG 35
WC Chemistry, Multidisciplinary
SC Chemistry
GA AZ6QN
UT WOS:000348343900001
DA 2018-12-27
ER

PT J
AU Qiu, JG
   Yuan, HC
   Chen, ST
   Wu, H
AF Qiu, Jianguo
   Yuan, Haichao
   Chen, Shuting
   Wu, Hong
TI RETRACTED: Laparoscopic Common Bile Duct Exploration in Cirrhotic
   Patients With Choledocholithiasis (Retracted article. See vol. 25, pg.
   184, 2015)
SO SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES
LA English
DT Article; Retracted Publication
DE laparoscopy; cholecystectomy; common bile duct; liver; cirrhosis
ID ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; LIVER-CIRRHOSIS;
   MANAGEMENT; STONES; DRAINAGE; ERCP; CHOLECYSTECTOMY; COMPLICATIONS;
   SURGERY; CANCER
AB Background: Although laparoscopic common bile duct exploration (LCBDE) has become the standard procedure for most choledocholithiasis patients, the application of this procedure to liver cirrhosis is still in debate. The aim of current study was to evaluate the feasibility and safety of LCBDE in choledocholithiasis patients with compensated liver cirrhosis.
   Materials and Methods: From January 2006 to December 2012, 346 LCBDE performed in our hospital. According to previous defined liver condition, the patients were divided into group A (liver cirrhosis, n=132) and group B (without cirrhosis, n=214). The perioperative data for the 2 groups were retrospectively reviewed and compared.
   Results: LCBDE was successfully completed in 326 patients. Conversion from laparoscopic to open surgery was necessary for 20 patients (5.7%) mainly because of hemorrhage (5, 25%) and severe adhesions (8, 40%); a T-tube was placed in 211 patients (64.7%), and primary closure was done in 115 (35.3%). There was significant difference for groups A and B in term of intraoperative blood loss (85 vs. 35 mL; P<0.01). However, the 2 groups showed no significant differences with respect to mean operation time (2.1 vs. 1.9 h; P=0.07), complication rates (10.6% vs. 8.8%; P=0.6), and mean hospital stay (4.2 vs. 4.0 d; P=0.6), conversion rate (5.3% vs. 6.1%; P=0.77), and retained choledocholithiasis rate (8.3% vs. 7.1%; P=0.65). There was no mortality in both the groups.
   Conclusion: LCBDE is a feasible, effective, and safe surgical procedure for choledocholithiasis patients with compensated cirrhosis.
C1 [Qiu, Jianguo; Chen, Shuting; Wu, Hong] Sichuan Univ, West China Hosp, Dept Hepatobiliary Pancreat Surg, Chengdu 610041, Sichuan, Peoples R China.
   [Yuan, Haichao] Sichuan Univ, West China Hosp, Dept Urol Surg, Chengdu 610041, Sichuan, Peoples R China.
RP Wu, H (reprint author), Sichuan Univ, West China Hosp, Dept Hepatobiliary Pancreat Surg, Chengdu 610041, Sichuan, Peoples R China.
EM wuhongjoy@163.com
FU Science and Technology Support Project of Sichuan Province [2009FC0093]
FX Supported by Science and Technology Support Project of Sichuan Province
   (2009FC0093).
CR Chander J, 2011, SURG ENDOSC, V25, P172, DOI 10.1007/s00464-010-1152-5
   Chen CM, 2005, ANZ J SURG, V75, P1070, DOI 10.1111/j.1445-2197.2005.03620.x
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   El-Awadi S, 2009, INT J SURG, V7, P66, DOI 10.1016/j.ijsu.2008.10.013
   Fritz E, 2006, GASTROINTEST ENDOSC, V64, P899, DOI 10.1016/j.gie.2006.05.010
   Hamad MA, 2010, J LAPAROENDOSC ADV S, V20, P405, DOI 10.1089/lap.2009.0476
   Hanif F, 2010, SURG ENDOSC, V24, P1552, DOI 10.1007/s00464-009-0809-4
   Hungness ES, 2006, J GASTROINTEST SURG, V10, P612, DOI 10.1016/j.gassur.2005.08.015
   Kusano T, 1999, HEPATO-GASTROENTEROL, V46, P2776
   Lo HC, 2012, WORLD J SURG, V36, P2455, DOI 10.1007/s00268-012-1696-8
   Morino M, 1998, SURG ENDOSC-ULTRAS, V12, P968, DOI 10.1007/s004649900758
   Nathanson LK, 2005, ANN SURG, V242, P188, DOI 10.1097/01.sla.0000171035.57236.d7
   Ney Marcus Vinicius Silva, 2005, Arq. Gastroenterol., V42, P239, DOI 10.1590/S0004-28032005000400009
   Omari A, 2007, J LAPAROENDOSC ADV S, V17, P419, DOI 10.1089/lap.2006.0160
   Paik KY, 2013, J LAPAROENDOSC ADV S, V23, P137, DOI 10.1089/lap.2012.0331
   Qiu JG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060153
   Qiu JG, 2013, SURG LAPARO ENDO PER, V23, P1, DOI 10.1097/SLE.0b013e3182747af7
   Talar-Wojnarowska R, 2009, POL ARCH MED WEWN, V19, P136
   Taylor EF, 2013, BRIT J SURG, V100, P553, DOI 10.1002/bjs.9023
   Tinoco R, 2008, ANN SURG, V247, P674, DOI 10.1097/SLA.0b013e3181612c85
   Verbesey JE, 2008, SURG CLIN N AM, V88, P1315, DOI 10.1016/j.suc.2008.08.002
   Wang P, 2009, AM J GASTROENTEROL, V104, P31, DOI 10.1038/ajg.2008.5
   Williams EJ, 2008, GUT, V57, P1004, DOI 10.1136/gut.2007.121657
   Yu WK, 2007, POSTGRAD MED J, V83, P187, DOI 10.1136/pgmj.2006.047746
   Zhu JH, 2009, SURG LAPARO ENDO PER, V19, P258, DOI 10.1097/SLE.0b013e3181a6ec7c
   Zhu QD, 2011, LANGENBECK ARCH SURG, V396, P53, DOI 10.1007/s00423-010-0660-z
NR 26
TC 2
Z9 2
U1 2
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1530-4515
EI 1534-4908
J9 SURG LAPARO ENDO PER
JI Surg. Laparosc. Endosc. Pct. Tech.
PD FEB
PY 2015
VL 25
IS 1
BP 64
EP 68
DI 10.1097/SLE.0000000000000018
PG 5
WC Surgery
SC Surgery
GA CB2IL
UT WOS:000349450500026
PM 24732744
DA 2018-12-27
ER

PT J
AU Andersson, L
AF Andersson, L.
TI RETRACTED: Response on the author's reply to the Letter to the Editor:
   Contradictory data on type 1 diabetes in a recently published article
   'Risks of neurological and immune-related diseases, including
   narcolepsy, after vaccination with Pandemrix' (Retracted article. See
   vol. 284, pg. 329, 2018)
SO JOURNAL OF INTERNAL MEDICINE
LA English
DT Letter; Retracted Publication
C1 Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Solna, Sweden.
RP Andersson, L (reprint author), Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Solna, Sweden.
EM lars.andersson2@outlook.com
NR 0
TC 5
Z9 5
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0954-6820
EI 1365-2796
J9 J INTERN MED
JI J. Intern. Med.
PD FEB
PY 2015
VL 277
IS 2
BP 272
EP 273
DI 10.1111/joim.12327
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA CA2AG
UT WOS:000348710700011
PM 25359510
OA Bronze
DA 2018-12-27
ER

PT J
AU Suzuki, M
   Nojima, M
   Fujii, M
   Seki, T
   Matsuo, J
AF Suzuki, Masato
   Nojima, Masashi
   Fujii, Makiko
   Seki, Toshio
   Matsuo, Jiro
TI RETRACTED: Mass analysis by Ar-GCIB-dynamic SIMS for organic materials
   (Retracted article. See vol. 48, pg. 383, 2016)
SO SURFACE AND INTERFACE ANALYSIS
LA English
DT Article; Retracted Publication
DE dynamic SIMS; Ar-GCIB; arginine; glycine; blended polymer; principal
   component analysis
ID CLUSTER ION-BEAMS; SPECTROMETRY; POLYMERS; SURFACE; ENERGY
AB Generally, dynamic secondary ion mass spectrometry (SIMS) has been mainly used as one of the most powerful tools for inorganic mass analysis. On the other hand, an Ar gas cluster ion beam (GCIB) has been developed and spread as a processing tool for surface flattening and also a projectile for time-of-flight (ToF) SIMS. In this study, we newly introduced an Ar-GCIB as a primary ion source to a commercially available dynamic SIMS apparatus, and investigated mass spectra of amino acid films (such as Arginine and Glycine) and polymer films (Polyethylene: PE and Polypropylene: PP) as organic model samples. As a result, each characteristic fragment peak indicating the original molecular organic structure was observed in the acquired mass spectra. In addition, their own molecular ions of the amino acids were also clearly observed. Mass spectra of PE/PP blended-polymer films acquired using Ar-GCIB-dynamic SIMS could be identified between pure PE and PE:PP=1:3 mixture by applying principal component analysis (PCA).
C1 [Suzuki, Masato] Tokyo Univ Sci, Fac Sci & Technol, JP-2788510 Noda, Chiba, Japan.
   [Nojima, Masashi] Tokyo Univ Sci, RIST, JP-2788510 Noda, Chiba, Japan.
   [Fujii, Makiko; Matsuo, Jiro] Kyoto Univ, Quantum Sci & Engn Ctr, JP-6110011 Uji, Kyoto, Japan.
   [Seki, Toshio] Kyoto Univ, Dept Nucl Engn, JP-6110011 Uji, Kyoto, Japan.
RP Suzuki, M (reprint author), Tokyo Univ Sci, Fac Sci & Technol, 2641 Yamazaki, JP-2788510 Noda, Chiba, Japan.
EM j7213640@ed.tus.ac.jp
CR Aoyagi S, 2004, APPL SURF SCI, V231, P470, DOI 10.1016/j.apsusc.2004.03.181
   DELCORTE A, 1995, NUCL INSTRUM METH B, V100, P213, DOI 10.1016/0168-583X(94)00842-6
   Gillen G, 2006, APPL SURF SCI, V252, P6521, DOI 10.1016/j.apsusc.2006.02.234
   Lee JLS, 2010, ANAL CHEM, V82, P98, DOI 10.1021/ac901045q
   Mahoney CM, 2006, APPL SURF SCI, V252, P6502, DOI 10.1016/j.apsusc.2006.02.078
   Matsuo J, 2012, SURF INTERFACE ANAL, V44, P729, DOI 10.1002/sia.4856
   Matsuo J, 2010, SURF INTERFACE ANAL, V42, P1612, DOI 10.1002/sia.3585
   Miyasaka T, 2008, APPL SURF SCI, V255, P1576, DOI 10.1016/j.apsusc.2008.05.137
   Moritani K, 2011, SURF INTERFACE ANAL, V43, P241, DOI 10.1002/sia.3551
   Ninomiya S, 2011, SURF INTERFACE ANAL, V43, P221, DOI 10.1002/sia.3656
   Ninomiya S, 2008, APPL SURF SCI, V255, P1588, DOI 10.1016/j.apsusc.2008.05.004
   Seki T, 2006, NUCL INSTRUM METH B, V242, P179, DOI 10.1016/j.nimb.2005.08.023
   vans Ooij W. J., 1988, SURF INTERFACE ANAL, V11, P430
NR 13
TC 1
Z9 1
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0142-2421
EI 1096-9918
J9 SURF INTERFACE ANAL
JI Surf. Interface Anal.
PD FEB
PY 2015
VL 47
IS 2
BP 295
EP 297
DI 10.1002/sia.5705
PG 3
WC Chemistry, Physical
SC Chemistry
GA AZ9GY
UT WOS:000348523000018
DA 2018-12-27
ER

PT J
AU ReddyPrasad, P
   Ofomaja, AE
   Naidoo, EB
AF ReddyPrasad, P.
   Ofomaja, A. E.
   Naidoo, E. Bobby
TI RETRACTED: Preparation of CN-dots/F-NiO nanocomposite for enhanced
   photocatalytic degradation of selected organic pollutants (Retracted
   article. See vol. 441, pg. 1089, 2018)
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Retracted Publication
DE CN-dots; F-NiO; Organic pollutants and photocatalytic; degradation
ID QUANTUM DOTS; EMERGENT NANOLIGHTS; ZNO NANOPARTICLES; TITANIUM-DIOXIDE;
   MALACHITE GREEN; VISIBLE-LIGHT; UV-LIGHT; WATER; DYES; CATALYSTS
AB High fluorescence CN-dots with high purity were synthesized through a facile, hydrothermal approach with citric acid and ethylenediamine. The high fluorescence productivity method makes the synthetic process of CN-dots both economical as well as environment-friendly. The prepared CN-dots are predominantly multi-layer graphene oxide with high photoluminescence properties. The novel CN-dots modified F-NiO nanocomposite are characterized by different spectroscopy techniques. The resulting photocatalyst demonstrates synergistically enhanced ultraviolet light photocatalytic activity on degradation of 2,4-dichlorophenoxyacetic acid and rodamine B. The photocatalyst maintains above 82% degradation efficiency with excellent stability and reusability after four successive cycles. The proposed novel photocatalyst was found to be effective in the photodegradation of organic pollutants, which were considered for the present investigation. (C) 2014 Elsevier B.V. All rights reserved.
C1 [ReddyPrasad, P.; Ofomaja, A. E.; Naidoo, E. Bobby] Vaal Univ Technol, Dept Chem, ZA-1900 Vanderbiljpark, South Africa.
RP Naidoo, EB (reprint author), Vaal Univ Technol, Dept Chem, P Bag X021, ZA-1900 Vanderbiljpark, South Africa.
EM bobby@vut.ac.za
OI Ofomaja, Augustine/0000-0003-1467-5714
CR Al-Sehemi AG, 2014, J MOL STRUCT, V1058, P56, DOI 10.1016/j.molstruc.2013.10.065
   Aziz HA, 2001, ENVIRON INT, V26, P395, DOI 10.1016/S0160-4120(01)00018-6
   Bahadur J, 2008, J SOLID STATE CHEM, V181, P1227, DOI 10.1016/j.jssc.2008.01.050
   Baker SN, 2010, ANGEW CHEM INT EDIT, V49, P6726, DOI 10.1002/anie.200906623
   Bremner DH, 2009, APPL CATAL B-ENVIRON, V90, P380, DOI 10.1016/j.apcatb.2009.03.028
   Cabras P, 2000, J AGR FOOD CHEM, V48, P967, DOI 10.1021/jf990727a
   Chai XJ, 1997, J MEMBRANE SCI, V123, P235
   Chen X, 2007, CHEM REV, V107, P2891, DOI 10.1021/cr0500535
   Doong RA, 2000, WATER SCI TECHNOL, V42, P253
   Hongxia Q., 2009, NANOMATERIALS, V2009, P1
   Jing LQ, 2006, J MOL CATAL A-CHEM, V244, P193, DOI 10.1016/j.molcata.2005.09.020
   Kim SS, 2006, SOL ENERG MAT SOL C, V90, P283, DOI 10.1016/j.solmat.2005.03.015
   Lachheb H, 2002, APPL CATAL B-ENVIRON, V39, P75, DOI 10.1016/S0926-3373(02)00078-4
   Li HT, 2010, ANGEW CHEM INT EDIT, V49, P4430, DOI 10.1002/anie.200906154
   Lin SH, 1996, WATER RES, V30, P587, DOI 10.1016/0043-1354(95)00210-3
   Liu SL, 1999, CATAL LETT, V63, P167, DOI 10.1023/A:1019006129861
   Ma G, 2014, APPL SURF SCI, V313, P817, DOI 10.1016/j.apsusc.2014.06.079
   Moussavi G, 2009, CHEM ENG J, V152, P1, DOI 10.1016/j.cej.2009.03.014
   Needham SA, 2006, J POWER SOURCES, V159, P254, DOI 10.1016/j.jpowsour.2006.04.025
   Rai HS, 2005, CRIT REV ENV SCI TEC, V35, P219, DOI 10.1080/10643380590917932
   Rajabi HR, 2013, J HAZARD MATER, V250, P370, DOI 10.1016/j.jhazmat.2013.02.007
   Reddy KR, 2003, J GEOTECH GEOENVIRON, V129, P263, DOI 10.1061/(ASCE)1090-0241(2003)129:3(263)
   Sabhi S, 2001, WATER RES, V35, P1994, DOI 10.1016/S0043-1354(00)00460-7
   Saha P, 2010, CHEM ENG J, V165, P874, DOI 10.1016/j.cej.2010.10.048
   SATO H, 1993, THIN SOLID FILMS, V236, P27, DOI 10.1016/0040-6090(93)90636-4
   Shaban YA, 2013, CHEMOSPHERE, V91, P307, DOI 10.1016/j.chemosphere.2012.11.035
   Shen JH, 2012, CHEM COMMUN, V48, P3686, DOI 10.1039/c2cc00110a
   Smith YR, 2009, IND ENG CHEM RES, V48, P10268, DOI 10.1021/ie801851p
   Solis M, 2012, PROCESS BIOCHEM, V47, P1723, DOI 10.1016/j.procbio.2012.08.014
   Song Y, 2011, NANOSCALE, V3, P1984, DOI 10.1039/c0nr00953a
   Sun JH, 2007, DYES PIGMENTS, V74, P647, DOI 10.1016/j.dyepig.2006.04.006
   Ullah R, 2008, J HAZARD MATER, V156, P194, DOI 10.1016/j.jhazmat.2007.12.033
   Wang CH, 2009, INORG CHEM, V48, P1105, DOI 10.1021/ic8018138
   Yu H, 2012, NEW J CHEM, V36, P1031, DOI 10.1039/c2nj20959d
   Yu JG, 2007, J PHYS CHEM C, V111, P10582, DOI 10.1021/jp0707889
   Yu JG, 2007, J CATAL, V249, P59, DOI 10.1016/j.jcat.2007.03.032
   Zhang HC, 2011, DALTON T, V40, P10822, DOI 10.1039/c1dt11147g
   Zhang YH, 2010, ACS NANO, V4, P7303, DOI 10.1021/nn1024219
   Zhu GX, 2007, J MATER CHEM, V17, P2301, DOI 10.1039/b615942g
   Zhu HB, 2014, CATAL TODAY, V228, P58, DOI 10.1016/j.cattod.2013.11.061
NR 40
TC 6
Z9 6
U1 5
U2 63
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD FEB 1
PY 2015
VL 327
BP 13
EP 21
DI 10.1016/j.apsusc.2014.11.042
PG 9
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA AZ8GQ
UT WOS:000348453800003
DA 2018-12-27
ER

PT J
AU Aramli, MS
   Habibi, E
   Aramli, S
   Nouri, HA
AF Aramli, M. S.
   Habibi, E.
   Aramli, S.
   Nouri, H. A.
TI RETRACTED: Determination of some blood and seminal plasma ions in the
   beluga, Huso huso (Linnaeus, 1758) (Retracted article. See vol. 102, pg.
   818, 2018)
SO JOURNAL OF ANIMAL PHYSIOLOGY AND ANIMAL NUTRITION
LA English
DT Article; Retracted Publication
DE ions; blood; semen; Huso huso
ID ACIPENSER-PERSICUS; SIBERIAN STURGEON; SPERM MOTILITY; SPERMATOZOA;
   PARAMETERS; STERLET; SEMEN
AB Blood and seminal plasma ionic parameters are essential for monitoring health status, detecting illnesses, fish stock conservation and development of artificial propagation methods via extender improvement. In this study, comparison of blood and seminal plasma ionic parameters in beluga, Huso huso (30-45kg, 1-2m, n=10), was made. The results obtained show that Na+ (82.54 +/- 5.46), Cl- (15.95 +/- 0.72) and K+ (3.57 +/- 0.15) were predominant ions in the seminal plasma (as mm). Blood ionic values (as mm) were determined for Na+ (110.2 +/- 1.26), K+ (3.77 +/- 0.081), Cl- (60.12 +/- 1.5), Ca2+ (2.05 +/- 0.35) and Mg2+ (1.9 +/- 0.16). Results of the comparison between ionic parameters of seminal and blood plasma indicated that the concentrations of all parameters of blood plasma with the exception of K+ were significantly (p<0.05) higher than those of seminal plasma.
C1 [Aramli, M. S.] Islamic Azad Univ, Ardabil Branch, Young Researchers & Elites Club, Ardebil 3156756157, Iran.
   [Habibi, E.] Tarbiat Modares Univ, Marine Sci Fac, Dept Fisheries, Noor, Mazandaran, Iran.
   [Aramli, S.] Ardebil Univ Med Sci, Med Lab, Alavi Educ & Treatment Ctr, Ardebil, Iran.
   [Nouri, H. A.] Rajaee Sturgeon Hatchery Ctr, Sari, Mazandaran, Iran.
RP Aramli, MS (reprint author), Islamic Azad Univ, Ardabil Branch, Young Researchers & Elites Club, Ardebil 3156756157, Iran.
EM msaramli@gmail.com
RI Habibi, Emran/D-8035-2011
OI Habibi, Emran/0000-0002-7367-1484
CR Aramli MS, 2014, J APPL ICHTHYOL, V30, P18, DOI 10.1111/jai.12347
   Aramli MS, 2013, ITAL J ZOOL, V80, P490, DOI 10.1080/11250003.2013.859309
   Aramli MS, 2013, REPROD DOMEST ANIM, V48, P1013, DOI 10.1111/rda.12207
   Aramli Mohammad Sadegh, 2014, Comparative Clinical Pathology, V23, P1241, DOI 10.1007/s00580-013-1769-6
   Aramli MS, 2013, FISH AQUAC J, V4, P79
   Bemis WE, 1997, ENVIRON BIOL FISH, V48, P25, DOI 10.1023/A:1007370213924
   Billard R, 1995, BROODSTOCK MANAGEMEN, P25
   Bozkurt Y, 2008, AQUAC RES, V39, P1666, DOI 10.1111/j.1365-2109.2008.02041.x
   Cataldi E, 1998, COMP BIOCHEM PHYS A, V121, P351, DOI 10.1016/S1095-6433(98)10134-4
   Celik Ekrem Sanver, 2004, Journal of Biological Sciences, V4, P716
   Ciereszko A, 2000, CRYOPRESERVATION AQU, P20
   Ciereszko Andrzej, 2008, P215
   Hatef A, 2007, AQUAC RES, V38, P1175, DOI 10.1111/j.1365-2109.2007.01784.x
   Li P, 2011, REPROD DOMEST ANIM, V46, P247, DOI 10.1111/j.1439-0531.2010.01651.x
   Linhart O, 2003, AQUACULT INT, V11, P357, DOI 10.1023/A:1025773707439
   Ludwig A, 2008, J APPL ICHTHYOL, V24, P2, DOI 10.1111/j.1439-0426.2008.01085.x
   Nazari RM, 2010, AQUACULT INT, V18, P837, DOI 10.1007/s10499-009-9304-0
   PERCHEC G, 1995, AQUACULTURE, V129, P135, DOI 10.1016/0044-8486(95)91958-X
   Pikitch EK, 2005, FISH FISH, V6, P233, DOI 10.1111/j.1467-2979.2005.00190.x
   Piros B, 2002, FISH PHYSIOL BIOCHEM, V26, P289, DOI 10.1023/A:1026280218957
   Psenicka M, 2008, CYBIUM, V32, P179
   Shahsavani Davar, 2010, Comparative Clinical Pathology, V19, P57
   Shi XT, 2006, FISH PHYSIOL BIOCHEM, V32, P63, DOI 10.1007/s10695-006-7134-9
   Toth GP, 1997, AQUACULTURE, V154, P337, DOI 10.1016/S0044-8486(97)00066-5
   Verma DK, 2009, TURK J FISH AQUAT SC, V9, P67
   VLOK W, 1988, COMP BIOCHEM PHYS A, V90, P49, DOI 10.1016/0300-9629(88)91003-1
NR 26
TC 1
Z9 1
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0931-2439
EI 1439-0396
J9 J ANIM PHYSIOL AN N
JI J. Anim. Physiol. Anim. Nutr.
PD FEB
PY 2015
VL 99
IS 1
BP 17
EP 20
DI 10.1111/jpn.12225
PG 4
WC Agriculture, Dairy & Animal Science; Veterinary Sciences
SC Agriculture; Veterinary Sciences
GA AZ7UM
UT WOS:000348423100003
PM 25041321
DA 2018-12-27
ER

PT J
AU Govindaraju, RS
   McCuen, RH
   Hantush, MM
AF Govindaraju, R. S.
   McCuen, R. H.
   Hantush, M. M.
TI RETRACTED: Publishing in the Journal of Hydrologic Engineering
   (Retracted article. See vol. 20, pg. 15002, 2015)
SO JOURNAL OF HYDROLOGIC ENGINEERING
LA English
DT Editorial Material; Retracted Publication
C1 [Govindaraju, R. S.] Purdue Univ, W Lafayette, IN 47907 USA.
   [McCuen, R. H.] Univ Maryland, College Pk, MD 20742 USA.
   [Hantush, M. M.] US EPA, Cincinnati, OH 45268 USA.
RP McCuen, RH (reprint author), Univ Maryland, College Pk, MD 20742 USA.
EM rhmccuen@eng.umd.edu
NR 0
TC 0
Z9 0
U1 4
U2 17
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 1084-0699
EI 1943-5584
J9 J HYDROL ENG
JI J. Hydrol. Eng.
PD FEB
PY 2015
VL 20
IS 2
DI 10.1061/(ASCE)HE.1943-5584.0001128
PG 1
WC Engineering, Civil; Environmental Sciences; Water Resources
SC Engineering; Environmental Sciences & Ecology; Water Resources
GA AZ1ZN
UT WOS:000348034000001
DA 2018-12-27
ER

PT J
AU Wang, RH
   Cao, HM
   Tian, ZJ
   Jin, B
   Wang, Q
   Ma, H
   Wu, J
AF Wang, Rong-Hua
   Cao, Hong-Mei
   Tian, Zhi-Ju
   Jin, Bo
   Wang, Qing
   Ma, Hong
   Wu, Jing
TI RETRACTED: Efficacy of dual-functional liposomes containing paclitaxel
   for treatment of lung cancer (Retracted article. See vol. 38, pg. 3285,
   2017)
SO ONCOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE dual-ligand; cell-penetrating peptide; transferrin receptor; liposome
ID CELL-PENETRATING PEPTIDE; BLOOD-BRAIN-BARRIER; POLYMER HYBRID
   NANOPARTICLES; TRANSFERRIN-RECEPTOR; DRUG-DELIVERY; INTRACELLULAR
   DELIVERY; TARGETED LIPOSOMES; TAT PEPTIDE; TUMOR-CELLS; IN-VIVO
AB This study was mainly focused on the development of a dual-ligand liposomal delivery system for targeting the delivery of paclitaxel (PTX) to lung cancer. The specific ligand peptide HAIYPRH (T7) and the cationic cell-penetrating peptide TAT were connected with phospholipid via a polyethylene glycol (PEG) spacer to prepare the dual-ligand liposomes (T7/TAT-LP-PTX). Physicochemical characterizations of T7/TAT-LP-PTX, such as particle size, zeta potential, morphology, encapsulation efficiency, and in vitro PTX release, were also evaluated. In the cellular uptake study, the T7/TAT-LP endocytosed by the A549 cells was 2.26-, 3.48- and 8.56-fold higher than TAT-LP, T7-LP and LP, respectively. The IC50 values of TAT-LP-PTX, T7-LP-PTX and LP-PTX were much higher than those of T7/TAT-LP-PTX, respectively. The homing specificity of T7/TAT-LP was evaluated on the tumor spheroids, which revealed that T7/TAT-LP was more efficaciously internalized in tumor cells than TAT-LP, T7-LP and LP, respectively. Compared to LP, TAT-LP and T7-LP, T7/TAT-LP showed the strongest cell uptake property, and the highest accumulation ability in tumor spheroids in vitro. In the in vivo study, the T7/TAT-LP-PTX exhibited the best inhibitory effect of tumor growth for A549-bearing mice. Collectively, these results suggested that T7/TAT-LP-PTX is a promising drug delivery system for the treatment of lung cancer.
C1 [Wang, Rong-Hua; Jin, Bo] Peoples Hosp Zhangqiu, Dept Cardiothorac Surg, Zhangqiu 250200, Shandong, Peoples R China.
   [Cao, Hong-Mei; Tian, Zhi-Ju] Peoples Hosp Zhangqiu, Pharm Intravenous Admixture Serv, Zhangqiu 250200, Shandong, Peoples R China.
   [Wang, Qing] Peoples Hosp Zhangqiu, Dept Orthoped Surg, Zhangqiu 250200, Shandong, Peoples R China.
   [Ma, Hong] Peoples Hosp Zhangqiu, Dept Oral Pendulum Med, Zhangqiu 250200, Shandong, Peoples R China.
   [Wu, Jing] Shandong Univ, Hosp 2, Pharm Intravenous Admixture Serv, Jinan 250033, Shandong, Peoples R China.
RP Wang, RH (reprint author), Peoples Hosp Zhangqiu, Dept Cardiothorac Surg, Huiquan Rd 1920, Zhangqiu 250200, Shandong, Peoples R China.
EM 529827419@qq.com
CR ALLEN TM, 1995, BBA-BIOMEMBRANES, V1237, P99, DOI 10.1016/0005-2736(95)00085-H
   Banks WA, 2005, EXP NEUROL, V193, P218, DOI 10.1016/j.expneurol.2004.11.019
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Du J, 2009, MOL PHARMACEUT, V6, P905, DOI 10.1021/mp800218q
   Du SL, 2007, J PHARMACOL EXP THER, V322, P560, DOI 10.1124/jpet.107.12481
   Fukumura D, 2001, CANCER RES, V61, P6020
   Gao HL, 2012, BIOMATERIALS, V33, P6264, DOI 10.1016/j.biomaterials.2012.05.020
   Gao LY, 2014, BIOMATERIALS, V35, P2066, DOI 10.1016/j.biomaterials.2013.11.046
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Han LA, 2011, BIOMATERIALS, V32, P2989, DOI 10.1016/j.biomaterials.2011.01.005
   Han LA, 2010, MOL PHARMACEUT, V7, P2156, DOI 10.1021/mp100185f
   Jain RK, 2001, ADV DRUG DELIVER REV, V46, P149, DOI 10.1016/S0169-409X(00)00131-9
   Jiang TY, 2012, BIOMATERIALS, V33, P9246, DOI 10.1016/j.biomaterials.2012.09.027
   Jiang XY, 2013, BIOMATERIALS, V34, P1739, DOI 10.1016/j.biomaterials.2012.11.016
   Jinturkar KA, 2012, BIOMATERIALS, V33, P2492, DOI 10.1016/j.biomaterials.2011.11.067
   Kibria G, 2011, J CONTROL RELEASE, V153, P141, DOI 10.1016/j.jconrel.2011.03.012
   KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294
   Kuai R, 2010, MOL PHARMACEUT, V7, P1816, DOI 10.1021/mp100171c
   Lee JH, 2001, EUR J BIOCHEM, V268, P2004, DOI 10.1046/j.1432-1327.2001.02073.x
   Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005
   Li F, 2008, J CONTROL RELEASE, V131, P77, DOI 10.1016/j.jconrel.2008.07.021
   Liu YT, 2010, BIOMATERIALS, V31, P330, DOI 10.1016/j.biomaterials.2009.09.036
   Maeda H, 2012, J CONTROL RELEASE, V164, P138, DOI 10.1016/j.jconrel.2012.04.038
   Maeda N, 2004, J CONTROL RELEASE, V100, P41, DOI 10.1016/j.jconrel.2004.07.033
   McNeeley KM, 2009, BIOMATERIALS, V30, P3986, DOI 10.1016/j.biomaterials.2009.04.012
   Mei DY, 2011, AFR J PHARM PHARMACO, V5, P409
   Oh S, 2009, CANCER LETT, V274, P33, DOI [10.1016/j.canlet.2008.08.031, 10.1016/j.canlet.2008.08.03l]
   Owen SC, 2013, J CONTROL RELEASE, V172, P395, DOI 10.1016/j.jconrel.2013.07.011
   Qin Y, 2011, INT J PHARMACEUT, V420, P304, DOI 10.1016/j.ijpharm.2011.09.008
   ROSSIELLO R, 1984, J CLIN PATHOL, V37, P51, DOI 10.1136/jcp.37.1.51
   Sengupta S, 2000, PHARMACOL RES, V42, P459, DOI 10.1006/phrs.2000.0714
   Sharma G, 2012, J PHARM SCI-US, V101, P2468, DOI 10.1002/jps.23152
   SHINDELMAN JE, 1981, INT J CANCER, V27, P329, DOI 10.1002/ijc.2910270311
   Shmeeda H, 2010, J CONTROL RELEASE, V146, P76, DOI 10.1016/j.jconrel.2010.04.028
   Tang J, 2013, INT J PHARMACEUT, V454, P31, DOI 10.1016/j.ijpharm.2013.06.048
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Yang T, 2007, J CONTROL RELEASE, V120, P169, DOI 10.1016/j.jconrel.2007.05.011
   Zhang LF, 2008, ACS NANO, V2, P1696, DOI 10.1021/nn800275r
   Zhang QY, 2013, BIOMATERIALS, V34, P7980, DOI 10.1016/j.biomaterials.2013.07.014
NR 39
TC 9
Z9 10
U1 3
U2 54
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD FEB
PY 2015
VL 33
IS 2
BP 783
EP 791
DI 10.3892/or.2014.3644
PG 9
WC Oncology
SC Oncology
GA AZ6OJ
UT WOS:000348338500036
PM 25482610
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Hu, S
   Dai, HB
   Zhang, TC
   Fu, WY
   Berezov, SD
   Chen, C
   Jorissen, D
   Takeda, H
   Bethune, AN
AF Hu, Shi
   Dai, Haibin
   Zhang, Tiancheng
   Fu, Wenyan
   Berezov, Sandra D.
   Chen, Cheng
   Jorissen, Daniel
   Takeda, Hiroaki
   Bethune, Augus N.
TI RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain
   II/IV antibody(Retracted article.See vol.401, pg.81, 2017)
SO CANCER LETTERS
LA English
DT Article; Retracted Publication
DE EGFR; Cancer; Transmembrane signal transduction; Epitope; Cetuximab
   resistance
ID EPIDERMAL-GROWTH-FACTOR; CELL LUNG-CANCER; FACTOR RECEPTOR; ACTIN
   CYTOSKELETON; THERAPEUTIC TARGET; CAPPING PROTEIN; BREAST-CANCER;
   FISSION YEAST; TUMOR-GROWTH; INHIBITION
AB Dysfunction of the epidermal growth factor receptor (EGFR) family, is the key process in tumorigenesis, and anti-EGFR therapeutic strategies such as cetuximab therapy now are used in the treatment of cancer. However, resistance to cetuximab is commonly reported. Comprehensive blockade of EGFR signaling using different antibodies might be critical to treat cancer effectively and limit drug resistance with potent novel mechanisms. Here, we launch a screen of a phage display library to isolate a novel anti-EGFR antibody, YAH627. YAH627 exhibits superior efficacy in inhibiting EGFR activation, particularly by blocking EGF/HRG-induced EGFR/HER3 heterodimerization and signaling, verifying it as an impressive candidate for clinical translation as a therapeutic antibody. Moreover, we use epitope analysis validates that the epitope of this antibody is within domains II and IV of EGFR and traps EGFR in a silent conformation. Moreover, combining YAH627 with cetuximab produces synergistic antitumor activity in vitro and in vivo. Taken together, our report establishes that YAH627 possesses a novel mechanism of action that, in combination with cetuximab, may achieve clinical efficacy in EGFR-driven cancers. (c) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Hu, Shi; Zhang, Tiancheng; Bethune, Augus N.] Second Mil Med Univ, Translat Med Res Inst, Shanghai 200433, Peoples R China.
   [Hu, Shi; Zhang, Tiancheng; Bethune, Augus N.] Second Mil Med Univ, Int Joint Canc Inst, Shanghai 200433, Peoples R China.
   [Hu, Shi; Fu, Wenyan] Peoples Liberat Army Gen Hosp, PLA Postgrad Sch Med, Ctr Canc, Beijing 100853, Peoples R China.
   [Hu, Shi; Zhang, Tiancheng; Fu, Wenyan; Berezov, Sandra D.; Bethune, Augus N.] Asian Pacific Biosignatures Ctr, Tianjin Joint Acad Biomed & Technol, Tianjin 300457, Peoples R China.
   [Dai, Haibin] Nanjing Univ, Sch Med, Jinling Hosp, Dept Anesthesiol, Nanjing 210002, Jiangsu, Peoples R China.
   [Chen, Cheng] Tianjin Univ, Sch Life Sci, Tianjin 300072, Peoples R China.
   [Jorissen, Daniel; Takeda, Hiroaki; Bethune, Augus N.] Xian Jinwa Pharmaceut Co Ltd, Mol Drug Discovery Ctr, Xian 710000, Shaanxi, Peoples R China.
RP Hu, S (reprint author), Second Mil Med Univ, Translat Med Res Inst, Shanghai 200433, Peoples R China.
EM hus@aftertumor.com; augus.bethune@aftertumor.com
RI Hu, Shi/A-2140-2015
OI Hu, Shi/0000-0002-7905-4284
FU Chinese National Natural Science Foundation [81273311, 81172119,
   31470897]
FX This work was supported by the Chinese National Natural Science
   Foundation (Grant Nos.: 81273311, 81172119, and 31470897).
CR Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1
   Arteaga CL, 2001, J CLIN ONCOL, V19, p32S
   Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890
   Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216
   BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241
   Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2
   Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   de Bono JS, 2002, TRENDS MOL MED, V8, pS19, DOI 10.1016/S1471-4914(02)02306-7
   Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2
   Fu WY, 2014, MABS-AUSTIN, V6, P978, DOI 10.4161/mabs.28786
   Galizia G, 2006, ANN SURG ONCOL, V13, P823, DOI 10.1245/ASO.2006.05.052
   Garner AP, 2013, CANCER RES, V73, P6024, DOI 10.1158/0008-5472.CAN-13-1198
   Hu S, 2013, J BIOL CHEM, V288, P27059, DOI 10.1074/jbc.M113.491530
   Kawano S, 2009, J BIOL CHEM, V284, P23793, DOI 10.1074/jbc.M109.025155
   Kritsky MS, 2005, MOL BIOL+, V39, P602
   Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504
   Moisenovich M, 2002, EUR J CELL BIOL, V81, P529, DOI 10.1078/0171-9335-00263
   Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845
   Nakano K, 2001, MOL BIOL CELL, V12, P3515, DOI 10.1091/mbc.12.11.3515
   Nakano K, 2006, GENES CELLS, V11, P893, DOI 10.1111/j.1365-2443.2006.00987.x
   Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7
   Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073
   Perosa F, 2003, J IMMUNOL, V171, P1918, DOI 10.4049/jimmunol.171.4.1918
   Ren XL, 2009, CANCER LETT, V281, P134, DOI 10.1016/j.canlet.2009.02.036
   Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846
   SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I
   Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003
   Sliwkowski MX, 2013, SCIENCE, V341, P1192, DOI 10.1126/science.1241145
   Su L, 2008, NEUROMOL MED, V10, P316, DOI 10.1007/s12017-008-8042-1
   Tao RH, 2008, J CELL SCI, V121, P3207, DOI 10.1242/jcs.033399
   Wosikowski K, 1997, CLIN CANCER RES, V3, P2405
NR 34
TC 3
Z9 3
U1 3
U2 22
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD FEB 1
PY 2015
VL 357
IS 1
BP 374
EP 383
DI 10.1016/j.canlet.2014.11.053
PG 10
WC Oncology
SC Oncology
GA AZ2TB
UT WOS:000348084100037
PM 25434797
DA 2018-12-27
ER

PT J
AU Abkhezr, M
   Dryer, SE
AF Abkhezr, Mousa
   Dryer, Stuart E.
TI RETRACTED: STAT3 Regulates Steady-State Expression of Synaptopodin in
   Cultured Mouse Podocytes (Retracted article.See vol.90,pg.161,2016)
SO MOLECULAR PHARMACOLOGY
LA English
DT Article; Retracted Publication
ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; HIV-ASSOCIATED NEPHROPATHY; FOOT
   PROCESS EFFACEMENT; SIGNAL TRANSDUCER; GLOMERULAR PODOCYTES; ACTIN
   CYTOSKELETON; KIDNEY PODOCYTES; ACTIVATION; GLOMERULONEPHRITIS;
   ORGANIZATION
AB The transcription factor signal transducer and activator of transcription-3 (STAT3) is activated by proinflammatory cytokines and circulating factors in many cell types. Synaptopodin (Synpo) is a cytoskeleton regulatory protein expressed in podocyte foot processes that regulates the dynamics of actin filaments and the stability of small GTPases. Here we show that inhibition of STAT3 signaling using the small-molecule inhibitor benzo[b]thiophene, 6-nitro-, 1,1-dioxide (Stattic), or by STAT3 knockdown by small interfering RNA, caused a decrease in Synpo mRNA and protein in an immortalized mouse podocyte cell line. This loss of Synpo, which occurred in 30-80 minutes, was also seen after treatment with the translational inhibitor cycloheximide. The loss of Synpo protein after Stattic or cycloheximide treatment did not occur when podocytes were simultaneously exposed to 1-[N-[(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucyl]amino]-4-guanidinobutane (E-64), an inhibitor of thiol proteases such as cathepsin L. Treatment with interleukin-6 (IL-6) increased tyrosine phosphorylation of STAT3 and evoked a parallel increase in Synpo levels in podocytes. The stimulatory effect of IL-6 on Synpo was completely inhibited by pretreatment with Stattic. By contrast, 30-60-minute exposure to angiotensin II (Ang II) inhibited STAT3 signaling and concurrently reduced Synpo protein levels. The Ang II-evoked loss of Synpo was prevented by E-64 but not by inhibition of calcineurin or blockade of transient receptor potential cation channels. Inhibition of STAT3 by Stattic causedmarked changes in the distribution of podocyte actin filaments, and caused a nearly complete suppression of the migration of these cells in wound assays, consistent with the loss of Synpo. Stattic treatment also caused loss of RhoA protein.
C1 [Abkhezr, Mousa; Dryer, Stuart E.] Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.
   [Dryer, Stuart E.] Baylor Coll Med, Div Nephrol, Houston, TX 77030 USA.
RP Dryer, SE (reprint author), Univ Houston, Dept Biol & Biochem, 4800 Calhoun, Houston, TX 77204 USA.
EM sdryer@uh.edu
FU American Society of Nephrology; Pfizer, Inc.
FX Supported in part by an M. James Scherbenske award from the American
   Society of Nephrology to S.E.D., and by a contract from Pfizer, Inc., to
   S.E.D. The corresponding author had full control over the conduct of
   these experiments and controlled the decision to publish.
CR Abkhezr M, 2014, MOL PHARMACOL, V86, P150, DOI 10.1124/mol.114.092536
   Alvarez JV, 2004, CANCER BIOL THER, V3, P1045, DOI 10.4161/cbt.3.11.1172
   ANDERSON S, 1986, J HYPERTENS, V4, pS236
   Arakawa T, 2008, NEPHROL DIAL TRANSPL, V23, P3418, DOI 10.1093/ndt/gfn314
   Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400
   Asanuma K, 2005, J CLIN INVEST, V115, P1188, DOI 10.1172/JCI200523371
   Atsumi T, 2014, CANCER RES, V74, P8, DOI 10.1158/0008-5472.CAN-13-2322
   Barisoni L, 1999, J AM SOC NEPHROL, V10, P51
   Dai Y, 2013, KIDNEY INT, V84, P950, DOI 10.1038/ki.2013.197
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   DRENCKHAHN D, 1988, LAB INVEST, V59, P673
   Faul C, 2008, NAT MED, V14, P931, DOI 10.1038/nm.1857
   Faul C, 2007, TRENDS CELL BIOL, V17, P428, DOI 10.1016/j.tcb.2007.06.006
   Feng XB, 2009, J AM SOC NEPHROL, V20, P2138, DOI 10.1681/ASN.2008080879
   Greka A, 2012, SEMIN NEPHROL, V32, P319, DOI 10.1016/j.semnephrol.2012.06.003
   Gu LY, 2013, AIDS, V27, P1091, DOI 10.1097/QAD.0b013e32835f1ea1
   Haghikia Arash, 2012, JAKSTAT, V1, P143, DOI 10.4161/jkst.19573
   Haraldsson B, 2008, PHYSIOL REV, V88, P451, DOI 10.1152/physrev.00055.2006
   HASHIDA S, 1980, J BIOCHEM-TOKYO, V88, P1805, DOI 10.1093/oxfordjournals.jbchem.a133155
   Huber TB, 2006, J CLIN INVEST, V116, P1337, DOI 10.1172/JCI27400
   Ichimura K, 2007, CELL TISSUE RES, V329, P541, DOI 10.1007/s00441-007-0440-4
   Kim EY, 2012, AM J PHYSIOL-RENAL, V302, pF298, DOI 10.1152/ajprenal.00423.2011
   Kriz W, 2013, AM J PHYSIOL-RENAL, V304, pF333, DOI 10.1152/ajprenal.00478.2012
   Lasagni L, 2013, CURR MOL MED, V13, P13, DOI 10.2174/156652413804486250
   Le Hir M, 2001, J AM SOC NEPHROL, V12, P2060
   Liapis H, 2013, AM J PATHOL, V183, P1364, DOI 10.1016/j.ajpath.2013.06.033
   Lu TC, 2007, NEPHRON CLIN PRACT, V106, pC67, DOI 10.1159/000101800
   Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193
   Narumiya S, 2006, CURR OPIN CELL BIOL, V18, P199, DOI 10.1016/j.ceb.2006.02.002
   Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200
   Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002
   Reddy GR, 2007, ENDOCRINOLOGY, V148, P2045, DOI 10.1210/en.2006-1285
   SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201
   Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018
   SEILER MW, 1975, SCIENCE, V189, P390, DOI 10.1126/science.1145209
   Shirato I, 1996, AM J PATHOL, V148, P1283
   Yanagida-Asanuma E, 2007, AM J PATHOL, V171, P415, DOI 10.2353/ajpath.2007.070075
   ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422
   Zhu L, 2011, J AM SOC NEPHROL, V22, P1621, DOI 10.1681/ASN.2010111146
NR 39
TC 8
Z9 8
U1 3
U2 8
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD FEB
PY 2015
VL 87
IS 2
BP 231
EP 239
DI 10.1124/mol.114.094508
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AY8NY
UT WOS:000347811600009
PM 25425624
OA Bronze
DA 2018-12-27
ER

PT J
AU Kratochviilova, I
   Ashcheulov, P
   Kovalenko, A
   Zalis, S
   Ledvina, M
   Micova, J
AF Kratochvilova, Irena
   Ashcheulov, Petr
   Kovalenko, Alexander
   Zalis, Stanislav
   Ledvina, Miroslav
   Micova, Julia
TI RETRACTED: Luminescent Diamond Nanoparticles: Physical, Chemical and
   Biological Aspects of the Phenomenon (Retracted Article)
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article; Retracted Publication
DE Nanodiamonds Luminiscence; NV Centres; In-Cells Imaging; In-Vivo Imaging
ID SINGLE-PHOTON SOURCE; NANODIAMONDS; NANOCRYSTALS; DEFECTS
AB Biosensors based on nanodiamonds are able to penetrate through the cell membrane in a targeted manner and probe changes in real-time in the inner cellular space. In this work we performed exclusive theoretical and experimental study of nanodiamond particles adjusted for application in optically-traceable intracellular nanodiamond sensors. Theoretical and experimental study of specific optical properties of high-pressure high-temperature nanodiamonds containing NV- and NV0 centres were performed. The results are supported by theoretical modeling. The final result of this study was detection of luminescence ND in living cells and in vivo application od luminiscence NDs in chicken embryo, showing the detectability of luminescence ND using a standard confocal microscope. On the level of in cells selectivity numerous clusters of ND particles were present within the cytoplasm and at the same time no particles were absent in the nucleus-ND particles can be used as imaging or delivery system for specific cell parts targeting. From our study we can say that biosensors based on nanodiamonds (NDs) are able to penetrate through the cell membrane in a targeted manner and probe changes in the inner cellular space.
C1 [Kratochvilova, Irena; Ashcheulov, Petr] Acad Sci Czech Republ, Inst Phys, Vvi, CZ-18221 Prague 8, Czech Republic.
   [Kratochvilova, Irena] Czech Tech Univ, Fac Nucl Phys & Phys Engn, Prague 16000 8, Czech Republic.
   [Kovalenko, Alexander] Brno Univ Technol, Mat Res Ctr, Fac Chem, CZ-61200 Brno, Czech Republic.
   [Zalis, Stanislav] AS CR, Vvi, J Heyrovsky Inst Phys Chem, CZ-18223 Prague 8, Czech Republic.
   [Ledvina, Miroslav; Micova, Julia] Acad Sci Czech Republ, Vvi, Inst Organ Chem & Biochem, CZ-16610 Prague 6, Czech Republic.
   [Micova, Julia] Slovak Acad Sci, Inst Chem, SK-84538 Bratislava 4, Slovakia.
RP Kratochviilova, I (reprint author), Acad Sci Czech Republ, Inst Phys, Vvi, Slovance 2, CZ-18221 Prague 8, Czech Republic.
RI Ashcheulov, Petr/H-2004-2014; Kovalenko, Alexander/A-7336-2016
OI Ashcheulov, Petr/0000-0001-8085-3609; 
FU IOCB [61388963];  [TA01011165];  [GA14-10279S];  [GA 1331783S]
FX We gratefully acknowledge the support by grants TA01011165, GA14-10279S
   and GA 1331783S. The support by grant under the IOCB's research project
   RVO: 61388963 is also gratefully acknowledged. Computer time at the Meta
   Centrum Brno is also gratefully acknowledged.
CR Aharonovich I, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.235316
   Ahlrichs R., 2007, TURBOMOLE PROGRAM PA
   Chow EK, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001713
   Frisch M.J., 2009, GAUSSIAN 09 REVISION
   Gaebel T, 2004, NEW J PHYS, V6, DOI 10.1088/1367-2630/6/1/098
   Garoufalis CS, 2006, PHYS CHEM CHEM PHYS, V8, P808, DOI 10.1039/b513184g
   Koizumi S., 2008, PHYS APPL CVD DIAMON
   Kratochvilova I, 2011, J MATER CHEM, V21, P18248, DOI 10.1039/c1jm13525b
   Kratochvilova-Hruba I, 2001, J NON-CRYST SOLIDS, V290, P224, DOI 10.1016/S0022-3093(01)00794-3
   Krueger A, 2008, CHEM-EUR J, V14, P1382, DOI 10.1002/chem.200700987
   Larico R, 2006, BRAZ J PHYS, V36, P267, DOI 10.1590/S0103-97332006000300009
   Maier F, 2000, PHYS REV LETT, V85, P3472, DOI 10.1103/PhysRevLett.85.3472
   Masek J., 2011, J CONTROL RELEASE, P1220
   Neu E, 2011, NEW J PHYS, V13, DOI 10.1088/1367-2630/13/2/025012
   Petrakova V, 2011, ACTA POLYTECH, V51, P89
   Tachiki M, 2005, SURF SCI, V581, P207, DOI 10.1016/j.susc.2005.02.054
   Wu E, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/12/434
   Xiao JS, 2013, BIOMATERIALS, V34, P9648, DOI 10.1016/j.biomaterials.2013.08.056
   Yu SJ, 2005, J AM CHEM SOC, V127, P17604, DOI 10.1021/ja0567081
   Zhou ZY, 2003, NANO LETT, V3, P163, DOI 10.1021/nl025890q
   Zyubin AS, 2009, J PHYS CHEM C, V113, P10432, DOI 10.1021/jp9012703
   Zyubin AS, 2009, J COMPUT CHEM, V30, P119, DOI 10.1002/jcc.21042
NR 22
TC 0
Z9 0
U1 7
U2 114
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD FEB
PY 2015
VL 15
IS 2
BP 1000
EP 1005
DI 10.1166/jnn.2015.9740
PG 6
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AT6NB
UT WOS:000345054100008
PM 26353605
DA 2018-12-27
ER

PT J
AU Li, J
   Li, X
   Wang, Q
   Hu, S
   Wang, YF
   Masoudi, FA
   Spertus, JA
   Krumholz, HM
   Jiang, LX
AF Li, Jing
   Li, Xi
   Wang, Qing
   Hu, Shuang
   Wang, Yongfei
   Masoudi, Frederick A.
   Spertus, John A.
   Krumholz, Harlan M.
   Jiang, Lixin
CA China PEACE Collaborative Grp
TI RETRACTED: ST-segment elevation myocardial infarction in China from 2001
   to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction
   Study): a retrospective analysis of hospital data (Retracted article.
   See vol. 385, pg. 402, 2015)
SO LANCET
LA English
DT Article; Retracted Publication
ID ACUTE CORONARY SYNDROMES; COOPERATIVE CARDIOVASCULAR PROJECT;
   STANDARDIZED MORTALITY-RATES; QUALITY-OF-CARE; REPERFUSION THERAPY;
   PRACTICE PATTERNS; CONTROLLED-TRIAL; IMPROVEMENT; INTERVENTION;
   TRANSITION
AB Background Despite the importance of ST-segment elevation myocardial infarction (STEMI) in China, no nationally representative studies have characterised the clinical profiles, management, and outcomes of this cardiac event during the past decade. We aimed to assess trends in characteristics, treatment, and outcomes for patients with STEMI in China between 2001 and 2011.
   Methods In a retrospective analysis of hospital records, we used a two-stage random sampling design to create a nationally representative sample of patients in China admitted to hospital for STEMI in 3 years (2001, 2006, and 2011). In the first stage, we used a simple random-sampling procedure stratified by economic-geographical region to generate a list of participating hospitals. In the second stage we obtained case data for rates of STEMI, treatments, and baseline characteristics from patients attending each sampled hospital with a systematic sampling approach. We weighted our findings to estimate nationally representative rates and assess changes from 2001 to 2011. This study is registered with ClinicalTrials.gov, number NCT01624883.
   Findings We sampled 175 hospitals (162 participated in the study) and 18 631 acute myocardial infarction admissions, of which 13 815 were STEMI admissions. 12 264 patients were included in analysis of treatments, procedures, and tests, and 11 986 were included in analysis of in-hospital outcomes. Between 2001 and 2011, estimated national rates of hospital admission for STEMI per 100 000 people increased (from 3.5 in 2001, to 7.9 in 2006, to 15.4 in 2011; p(trend)<0.0001) and the prevalence of risk factors-including smoking, hypertension, diabetes, and dyslipidaemia-increased. We noted significant increases in use of aspirin within 24 h (79.7% [95% CI 77.9-81.5] in 2001 vs 91.2% [90.5-91.8] in 2011, p(trend)<0.0001) and clopidogrel (1.5% [95% CI 1.0-2.1] in 2001 vs 82.1% [81.1-83.0] in 2011, p(trend)<0.0001) in patients without documented contraindications. Despite an increase in the use of primary percutaneous coronary intervention (10.6% [95% CI 8.6-12.6] in 2001 vs 28.1% [26.6-29.7] in 2011, p(trend)<0.0001), the proportion of patients who did not receive reperfusion did not significantly change (45.3% [95% CI 42.1-48.5] in 2001 vs 44.8% [43.1-46.5] in 2011, p(trend)=0.69). The median length of hospital stay decreased from 12 days (IQR 7-18) in 2001 to 10 days (6-14) in 2011 (p(trend)<0.0001). Adjusted in-hospital mortality did not significantly change between 2001 and 2011 (odds ratio 0.82, 95% CI 0.62-1.10, p(trend)=0.07).
   Interpretation During the past decade in China, hospital admissions for STEMI have risen; in these patients, comorbidities and the intensity of testing and treatment have increased. Quality of care has improved for some treatments, but important gaps persist and in-hospital mortality has not decreased. National efforts are needed to improve the care and outcomes for patients with STEMI in China.
C1 [Li, Jing; Li, Xi; Wang, Qing; Hu, Shuang; Jiang, Lixin] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Natl Clin Res Ctr Cardiovasc Dis,Fuwai Hosp, Beijing 100730, Peoples R China.
   [Li, Jing; Li, Xi; Wang, Qing; Hu, Shuang; Jiang, Lixin] Peking Union Med Coll, Beijing 100021, Peoples R China.
   [Wang, Yongfei; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
   [Wang, Yongfei; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06510 USA.
   [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA.
   [Krumholz, Harlan M.] Yale Univ, Dept Hlth Policy & Management, Sch Publ Hlth, New Haven, CT USA.
   [Masoudi, Frederick A.] Univ Colorado, Div Cardiol, Aurora, CO USA.
   [Spertus, John A.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA.
RP Jiang, LX (reprint author), Fuwai Hosp, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Natl Clin Res Ctr Cardiovasc Dis, Beijing 100037, Peoples R China.
EM jiangl@fwoxford.org
FU National Health and Family Planning Commission of China
FX National Health and Family Planning Commission of China.
CR [Anonymous], 2007, CHIN STAT YB
   [Anonymous], 2012, CHIN STAT YB
   [Anonymous], 2000, 5 CENSUS DATA COUNTY
   Antman EM, 2008, CIRCULATION, V117, P296, DOI 10.1161/CIRCULATIONAHA.107.188209
   Bradley EH, 2005, MED CARE, V43, P282, DOI 10.1097/00005650-200503000-00011
   Chen J, 2010, CIRCULATION, V121, P1322, DOI 10.1161/CIRCULATIONAHA.109.862094
   Chen Z, 2009, LANCET, V373, P1322, DOI 10.1016/S0140-6736(09)60753-4
   Chen ZM, 2005, LANCET, V366, P1607
   China Society of Cardiology of Chinese Medical Association Editorial Board of Chinese Journal of Cardiology, 2010, ZHONGHUA XIN XUE GUA, V38, P675
   China Society of Cardiology of Chinese Medical Association Editorial Board of Chinese Journal of Cardiology Editorial Board of Chinese Journal of Circulation, 2001, CHIN J CIRC, V16, P407
   Chung SC, 2014, LANCET, V383, P1305, DOI 10.1016/S0140-6736(13)62070-X
   COLLINS R, 1995, LANCET, V345, P669
   Dharmarajan K, 2013, CIRC-CARDIOVASC QUAL, V6, P732, DOI 10.1161/CIRCOUTCOMES.113.000441
   Drye EE, 2012, ANN INTERN MED, V156, P19, DOI 10.7326/0003-4819-156-1-201201030-00004
   Du X, 2014, CIRC-CARDIOVASC QUAL, V7, P217, DOI 10.1161/CIRCOUTCOMES.113.000526
   Gale CP, 2012, EUR HEART J, V33, P630, DOI 10.1093/eurheartj/ehr381
   Gao R, 2008, HEART, V94, P554, DOI 10.1136/hrt.2007.119750
   Gershlick AH, 2013, LANCET, V382, P624, DOI 10.1016/S0140-6736(13)61454-3
   Gibson CM, 2008, AM HEART J, V156, P1035, DOI 10.1016/j.ahj.2008.07.029
   Krumholz HM, 2009, JAMA-J AM MED ASSOC, V302, P767, DOI 10.1001/jama.2009.1178
   Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623
   Li J, 2007, COCHRANE DB SYST REV, V2
   Liu Qun, 2009, Zhonghua Xinxueguanbing Zazhi, V37, P213, DOI 10.3760/cma.j.issn.0253-3758.2009.03.004
   Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351
   Masoudi FA, 2013, J AM COLL CARDIOL, V62, P1931, DOI 10.1016/j.jacc.2013.05.099
   Mehta RH, 2004, J AM COLL CARDIOL, V43, P2166, DOI 10.1016/j.jacc.2003.08.067
   Ministry of Health of the People's Republic of China, 2011, QUAL STAND TERT GEN
   Ministry of Health of the People's Republic of China, 2012, CHIN PUBL HLTH STAT
   OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375
   Ranasinghe I, 2014, CIRC-CARDIOVASC QUAL, V7, P209, DOI 10.1161/CIRCOUTCOMES.113.000527
   Roe MT, 2010, J AM COLL CARDIOL, V56, P254, DOI 10.1016/j.jacc.2010.05.008
   Rubin DB, 1987, MULTIPLE IMPUTATION
   *SAS I, MI PROC
   Simms AD, 2012, HEART, V99, P35
   Tang SL, 2008, LANCET, V372, P1493, DOI 10.1016/S0140-6736(08)61364-1
   The L, 2010, LANCET, V376, P657
   Thygesen K, 2007, EUR HEART J, V28, P2525
   Widimsky P, 2010, EUR HEART J, V31, P943, DOI 10.1093/eurheartj/ehp492
   *WORLD BANK, HLTH HARM LIF CHIN S
   WU T, 2008, COCHRANE DB SYST REV, V16
   Yang GH, 2013, LANCET, V381, P1987, DOI 10.1016/S0140-6736(13)61097-1
NR 41
TC 103
Z9 150
U1 13
U2 67
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JAN 31
PY 2015
VL 385
IS 9966
BP 441
EP 451
DI 10.1016/S0140-6736(14)60921-1
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AZ9CT
UT WOS:000348509900031
PM 24969506
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Zhang, P
   Cohen, RE
   Haule, K
AF Zhang, Peng
   Cohen, R. E.
   Haule, K.
TI RETRACTED: Effects of electron correlations on transport properties of
   iron at Earth's core conditions(Retracted article.See
   vol.536,pg.112,2016)
SO NATURE
LA English
DT Article; Retracted Publication
ID MEAN-FIELD THEORY; HIGH-PRESSURE; CONDUCTIVITY; TRANSITION; RESISTIVITY;
   MAGNETISM; TEMPERATURE; RESISTANCE; SYSTEMS; METALS
AB Earth's magnetic field has been thought to arise from thermal convection of molten iron alloy in the outer core, but recent density functional theory calculations have suggested that the conductivity of iron is too high to support thermal convection(1-4), resulting in the investigation of chemically driven convection(5,6). These calculations for resistivity were based on electron-phonon scattering. Here we apply self-consistent density functional theory plus dynamical meanfield theory (DFT+DMFT)(7) to iron and find that at high temperatures electron-electron scattering iscomparable to the electron-phonon scattering, bringing theory into agreement with experiments and solving the transport problem in Earth's core. The conventional thermal dynamo picture is safe. We find that electron-electron scattering of d electrons is important at high temperatures in transition metals, in contrast to textbook analyses since Mott(8,9), and that 4s electron contributions to transport are negligible, in contrast to numerous models used for over fifty years. The DFT+DMFT method should be applicable to other high-temperature systems where electron correlations are important.
C1 [Zhang, Peng; Cohen, R. E.] Carnegie Inst Sci, Geophys Lab, Washington, DC 20015 USA.
   [Cohen, R. E.] UCL, Dept Earth Sci, London WC1E 6BT, England.
   [Haule, K.] Rutgers State Univ, Dept Phys, Piscataway, NJ 08854 USA.
RP Cohen, RE (reprint author), Carnegie Inst Sci, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.
EM rcohen@carnegiescience.edu
RI Zhang, Peng/C-2845-2015
FU National Science Foundation (NSF) [EAR-1214807, DMS-1025392,
   DMR-1405303]; Carnegie Institution; European Research Council Advanced
   Grant ToMCaT; NSF [DMR-1405303]; Office of Science of the US Department
   of Energy [DE-AC05-000R22725]
FX This work is supported by National Science Foundation (NSF) grants
   EAR-1214807, DMS-1025392, and DMR-1405303. R.E.C. is supported by the
   Carnegie Institution and the European Research Council Advanced Grant
   ToMCaT. K.H. is supported by NSF grant DMR-1405303. This research used
   the NSF Extreme Science and Engineering Discovery Environment (XSEDE)
   supercomputer 'Stampede', and also used the resources of the Oak Ridge
   Leadership Computing Facility at the Oak Ridge National Laboratory,
   which is supported by the Office of Science of the US Department of
   Energy under contract number DE-AC05-000R22725. R.E.C. and P.Z. thank I.
   Mazin,S. Labrosse and R. Caracas for discussions. We also acknowledge J.
   Robb for assistance with the manuscript preparation.
CR Allen PB, 2006, CONT CONCEPT CONDENS, P165, DOI 10.1016/S1572-0934(06)02006-3
   Anisimov VI, 1997, J PHYS-CONDENS MAT, V9, P767, DOI 10.1088/0953-8984/9/4/002
   BALCHAN AS, 1961, REV SCI INSTRUM, V32, P308, DOI 10.1063/1.1717350
   Basov DN, 2011, REV MOD PHYS, V83, P471, DOI 10.1103/RevModPhys.83.471
   Bi Y, 2002, J PHYS-CONDENS MAT, V14, P10849, DOI 10.1088/0953-8984/14/44/389
   Blaha P., 2001, WIEN2K
   BLOCHL PE, 1994, PHYS REV B, V49, P16223, DOI 10.1103/PhysRevB.49.16223
   BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485
   Buffett B, 2012, NATURE, V485, P319, DOI 10.1038/485319a
   Cohen RE, 1998, MATER RES SOC SYMP P, V499, P27
   CZYZYK MT, 1994, PHYS REV B, V49, P14211, DOI 10.1103/PhysRevB.49.14211
   de Koker N, 2012, P NATL ACAD SCI USA, V109, P4070, DOI 10.1073/pnas.1111841109
   Deng LW, 2013, GEOPHYS RES LETT, V40, P33, DOI 10.1029/2012GL054347
   Deng XY, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.086401
   DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7
   ELSASSER WM, 1946, PHYS REV, V70, P202, DOI 10.1103/PhysRev.70.202
   Georges A, 1996, REV MOD PHYS, V68, P13, DOI 10.1103/RevModPhys.68.13
   Gomi H, 2013, PHYS EARTH PLANET IN, V224, P88, DOI 10.1016/j.pepi.2013.07.010
   GURVITCH M, 1987, PHYS REV LETT, V59, P1337, DOI 10.1103/PhysRevLett.59.1337
   Haule K, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.155113
   Haule K, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.195107
   Jarrell M, 1996, PHYS REP, V269, P133, DOI 10.1016/0370-1573(95)00074-7
   Keeler R. N, 1971, PHYS HIGH ENERGY DEN, V48, P106
   KEELER RN, 1969, SOLID STATE COMMUN, V7, P271, DOI 10.1016/0038-1098(69)90397-4
   KHURANA A, 1990, PHYS REV LETT, V64, P1990, DOI 10.1103/PhysRevLett.64.1990
   Kotliar G, 2006, REV MOD PHYS, V78, P865, DOI 10.1103/RevModPhys.78.865
   Lay T, 2008, NAT GEOSCI, V1, P25, DOI 10.1038/ngeo.2007.44
   Liu MS, 2012, NAT PHYS, V8, P376, DOI [10.1038/NPHYS2268, 10.1038/nphys2268]
   Mandal S, 2014, PHYS REV B, V89, DOI 10.1103/PhysRevB.89.220502
   MOTT NF, 1964, ADV PHYS, V13, P325, DOI 10.1080/00018736400101041
   Nguyen JH, 2004, NATURE, V427, P339, DOI 10.1038/nature02248
   Ohta K, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.026403
   Olson P, 2013, SCIENCE, V342, P431, DOI 10.1126/science.1243477
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Pourovskii LV, 2013, PHYS REV B, V87, DOI 10.1103/PhysRevB.87.115130
   Pozzo M, 2014, EARTH PLANET SC LETT, V393, P159, DOI [10.1016/j.epsl.2014.02.047, 10.1016/j.eps1.2014.02.047]
   Pozzo M, 2012, NATURE, V485, P355, DOI 10.1038/nature11031
   REICHLIN RL, 1983, REV SCI INSTRUM, V54, P1674, DOI 10.1063/1.1137308
   Seagle CT, 2013, GEOPHYS RES LETT, V40, P5377, DOI 10.1002/2013GL057930
   Sha XW, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.064103
   Sha XW, 2011, J PHYS-CONDENS MAT, V23, DOI 10.1088/0953-8984/23/7/075401
   Sha XW, 2010, GEOPHYS RES LETT, V37, DOI 10.1029/2009GL042224
   Sha XW, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.094105
   Shim JH, 2007, SCIENCE, V318, P1615, DOI 10.1126/science.1149064
   Shim JH, 2007, NATURE, V446, P513, DOI 10.1038/nature05647
   Stacey FD, 2001, PHYS EARTH PLANET IN, V124, P153, DOI 10.1016/S0031-9201(01)00186-8
   Steinle-Neumann G, 2004, P NATL ACAD SCI USA, V101, P33, DOI 10.1073/pnas.2237239100
   Steinle-Neumann G, 2004, J PHYS-CONDENS MAT, V16, pS1109, DOI 10.1088/S0953-8984/16/14/020
   Stixrude L, 1997, J GEOPHYS RES-SOL EA, V102, P24729, DOI 10.1029/97JB02125
   Tarduno JA, 2010, SCIENCE, V327, P1238, DOI 10.1126/science.1183445
   Werner P, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.076405
   Wu BJ, 2011, J GEOPHYS RES-SOL EA, V116, DOI 10.1029/2011JB008511
   Wu ZG, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.235116
   Xu WH, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.036401
   Yin ZP, 2011, NAT MATER, V10, P932, DOI [10.1038/NMAT3120, 10.1038/nmat3120]
   YOO CS, 1995, SCIENCE, V270, P1473, DOI 10.1126/science.270.5241.1473
NR 56
TC 41
Z9 42
U1 7
U2 86
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD JAN 29
PY 2015
VL 517
IS 7536
BP 605
EP U376
DI 10.1038/nature14090
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA2ZL
UT WOS:000348775000041
PM 25631449
DA 2018-12-27
ER

PT J
AU Ju, BX
   Tang, R
   Zhang, DY
   Yang, BL
   Yu, MA
   Liao, CR
AF Ju, Benxiang
   Tang, Rui
   Zhang, Dengyou
   Yang, Bailian
   Yu, Miao
   Liao, Changrong
TI RETRACTED: Temperature-dependent dynamic mechanical properties of
   magnetorheological elastomers under magnetic field (Retracted article.
   See vol. 374, pg. 283, 2015)
SO JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS
LA English
DT Article; Retracted Publication
DE Magnetorheological elastomer; MR effect; Magneto-induced modulus; Loss
   factor
ID NATURAL-RUBBER; MODEL
AB Both anisotropic and isotropic magnetorheological elastomer (MRE) samples were fabricated by using as-prepared polyurethane (PU) matrix and carbonyl iron particles. Temperature-dependent dynamic mechanical properties of MRE were investigated and analyzed. Due to the unique structural features of as-prepared matrix, temperature has a greater impact on the properties of as-prepared MRE, especially isotropic MRE. With increasing of temperature and magnetic field, MR effect of isotropic MRE can each up to as high as 4176.5% at temperature of 80 degrees C, and the mechanism of the temperature-dependent in presence of magnetic held was discussed. These results indicated that MRE is a kind of temperature-dependent material, and can be cycled between MRE and MR plastomer (MRP) by varying temperature. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Ju, Benxiang; Tang, Rui; Zhang, Dengyou; Yang, Bailian] Natl Instrument Funct Mat Engn Technol Res Ctr, Chongqing 400707, Peoples R China.
   [Yu, Miao; Liao, Changrong] Chongqing Univ, Coll Optoelect Engn, Chongqing 400044, Peoples R China.
RP Ju, BX (reprint author), Natl Instrument Funct Mat Engn Technol Res Ctr, Chongqing 400707, Peoples R China.
EM jubenxiang@qq.com
FU China Chongqing Research Program of Application Foundation and Advanced
   Technology [cstc2014jcyjA50029, CSTC2013JJB60001]; National Technology
   R&D Program of the Ministry of Science and Technology [2012BAF06B04]
FX Financial supports from China Chongqing Research Program of Application
   Foundation and Advanced Technology (no. cstc2014jcyjA50029 and
   CSTC2013JJB60001); National Technology R&D Program of the Ministry of
   Science and Technology (no. 2012BAF06B04).
CR Bica I, 2010, MATER SCI ENG B-ADV, V166, P94, DOI 10.1016/j.mseb.2009.10.020
   Bica I, 2009, J IND ENG CHEM, V15, P605, DOI 10.1016/j.jiec.2009.02.005
   Boczkowska A, 2009, J MATER SCI, V44, P4104, DOI 10.1007/s10853-009-3592-7
   Carlson JD, 2000, MECHATRONICS, V10, P555, DOI 10.1016/S0957-4158(99)00064-1
   Chen L, 2007, J MATER SCI, V42, P5483, DOI 10.1007/s10853-006-0975-x
   Chen L, 2008, CHINESE J CHEM PHYS, V21, P581, DOI 10.1088/1674-0068/21/06/581-585
   Davis LC, 1999, J APPL PHYS, V85, P3348, DOI 10.1063/1.369682
   Ginder JM, 1999, P SOC PHOTO-OPT INS, V3675, P131, DOI 10.1117/12.352787
   Gong XL, 2012, IND ENG CHEM RES, V51, P6395, DOI 10.1021/ie300317b
   Gong XL, 2005, POLYM TEST, V24, P669, DOI 10.1016/j.polymertesting.2005.03.015
   Gordaninejad F, 2012, J INTEL MAT SYST STR, V23, P1033, DOI 10.1177/1045389X12448286
   Guan XC, 2008, J MAGN MAGN MATER, V320, P158, DOI 10.1016/j.jmmm.2007.05.043
   Guo CY, 2012, J MAGN MAGN MATER, V324, P1218, DOI 10.1016/j.jmmm.2011.11.013
   Ju BX, 2012, SMART MATER STRUCT, V21, DOI 10.1088/0964-1726/21/3/035001
   Li W., 2008, RECENT PATENTS MECH, V1, P161, DOI DOI 10.2174/2212797610801030161
   Lokander M, 2004, POLYM DEGRAD STABIL, V86, P467, DOI 10.1016/j.polymdegradstab.2004.05.019
   Wu JK, 2010, SMART MATER STRUCT, V19, DOI 10.1088/0964-1726/19/10/105007
   Xu YG, 2011, SOFT MATTER, V7, P5246, DOI 10.1039/c1sm05301a
   Yu M, 2012, J MAGN MAGN MATER, V324, P2147, DOI 10.1016/j.jmmm.2012.02.033
   Zhang W, 2010, SMART MATER STRUCT, V19, DOI 10.1088/0964-1726/19/8/085008
   Zhang W, 2011, IND ENG CHEM RES, V50, P6704, DOI 10.1021/ie200386x
NR 21
TC 14
Z9 15
U1 4
U2 68
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-8853
EI 1873-4766
J9 J MAGN MAGN MATER
JI J. Magn. Magn. Mater.
PD JAN 15
PY 2015
VL 374
BP 283
EP 288
DI 10.1016/j.jmmm.2014.08.012
PG 6
WC Materials Science, Multidisciplinary; Physics, Condensed Matter
SC Materials Science; Physics
GA AT4YL
UT WOS:000344949000044
DA 2018-12-27
ER

PT J
AU Patra, S
   Roy, E
   Madhuri, R
   Sharma, PK
AF Patra, Santanu
   Roy, Ekta
   Madhuri, Rashmi
   Sharma, Prashant K.
TI RETRACTED: An imprinted Ag@CdS core shell nanoparticle based
   optical-electrochemical dual probe for trace level recognition of
   ferritin (Retracted article. See vol. 111, pg. 184, 2018)
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article; Retracted Publication
DE Ag@CdS core shell nanoparticle; Molecular imprinting; Ferritin;
   ARGET-ATRP; Surface imprinting; Dual sensing
ID PROTEIN RECOGNITION; IRON-OVERLOAD; RESOLUTION; POLYMERS; SURFACE; SERUM
AB In this work, we present a new approach to prepare the Ag@CdS core-shell fluorescent nanoparticles wrapped with molecularly imprinted polymer for ferritin macromolecule by capping with vinyl derivative of cysteine. The imprinted Ag@CdS nanoparticle was prepared via activator regenerated by electron transfer-atom transfer radical polymerization (ARGET-ATRP) method onto the surface of vinyl silane modified pencil graphite electrode. Combination of Ag and CdS in a single motif causes the dual behavior of core shell nanoparticle, which shows enhanced fluorescence as well as electrochemical properties. The performance of the obtained imprinted sensor was investigated by cyclic voltammetry, electrochemical impedance spectroscopy, chronocoulometry, differential pulse voltammetiy and fluorescence spectrophotometry. Under the optimal experimental conditions, the current response of the electrochemical sensor was linear to ferritin concentrations in the range from 1.99 to 23.43 mu g L-1, with the detection limit of 0.65 mu g L-1. Similarly, a linear response was obtained between fluorescence quenching of imprinted Ag@CdS and concentration of ferritin in the range from 4.0 to 91.0 mu g L-1, with limit of detection (LOD) of 1.3 mu g L-1. The method was successfully applied to the analysis of blood serum samples of five different men and women with acceptable recoveries of 99.7% and 100.3% (RSD in %=1.0-2.0). (C) 2014 Elsevier B.V. All rights reserved.
C1 [Patra, Santanu; Roy, Ekta; Madhuri, Rashmi] Indian Sch Mines, Dept Appl Chem, Dhanbad 826004, Jharkhand, India.
   [Sharma, Prashant K.] Indian Sch Mines, Dept Appl Phys, Funct Nanomat Res Lab, Dhanbad 826004, Jharkhand, India.
RP Madhuri, R (reprint author), Indian Sch Mines, Dept Appl Chem, Dhanbad 826004, Jharkhand, India.
EM rshmmadhuri@gmail.com
RI Sharma, Dr. Prashant Kumar/E-4846-2011; Patra, Santanu/E-4682-2016
OI Sharma, Dr. Prashant Kumar/0000-0001-5283-0901; 
FU Department of Science and Technology, Government of India
   [SB/FT/CS-155/2012, SR/FTP/PS-157/2011]; Indian School of Mines, Dhanbad
   [FRS/34/2012-2013/APH, FRS/43/2013-2014/AC]
FX Authors are thankful to Department of Science and Technology, Government
   of India for sanction of Fast Track Research Project for Young
   Scientists to Dr. Rashmi Madhuri (Ref. no. SB/FT/CS-155/2012) and Dr.
   Prashant K. Sharma (Ref. no. SR/FTP/PS-157/2011). Dr. Sharma
   (FRS/34/2012-2013/APH) and Dr. Madhuri (FRS/43/2013-2014/AC) are also
   thankful to Indian School of Mines, Dhanbad for grant of Major Research
   Project under Faculty Research Scheme. We are also thankful to Board of
   Research in Nuclear Sciences (BRNS), Department of Atomic Energy,
   Government of India for major research project. S.P. & E.R. are also
   thankful to Indian School of Mines, Dhanbad for Junior Research
   Fellowship.
CR Allen KJ, 2008, NEW ENGL J MED, V358, P221, DOI 10.1056/NEJMoa073286
   BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0
   Chatterjee K, 2014, ADV COLLOID INTERFAC, V209, P8, DOI 10.1016/j.cis.2013.12.008
   Dong H, 2008, MACROMOLECULES, V41, P6868, DOI 10.1021/ma8017553
   Du XZ, 2005, BIOSENS BIOELECTRON, V20, P2053, DOI 10.1016/j.bios.2004.08.044
   Duan HL, 2014, SOL ENERG MAT SOL C, V121, P8, DOI 10.1016/j.solmat.2013.10.011
   Hota G, 2004, COLLOID SURFACE A, V232, P119, DOI 10.1016/j.colsurfa.2003.10.021
   Hu CH, 2014, FOOD CHEM, V158, P366, DOI 10.1016/j.foodchem.2014.02.143
   JACOBS A, 1972, BRIT MED J, V4, P206, DOI 10.1136/bmj.4.5834.206
   Jeang EH, 2004, B KOR CHEM SOC, V25, P934
   Jia F, 2013, J CONTROL RELEASE, V172, P1020, DOI 10.1016/j.jconrel.2013.10.012
   Kamat PV, 2002, PURE APPL CHEM, V74, P1693, DOI 10.1351/pac200274091693
   Kamat PV, 1997, J PHYS CHEM B, V101, P7675, DOI 10.1021/jp9709464
   KRICKA LJ, 1987, J PHARMACEUT BIOMED, V5, P829, DOI 10.1016/0731-7085(87)80101-2
   Kumar A, 2007, J PHOTOCH PHOTOBIO A, V189, P272, DOI 10.1016/j.jphotochem.2007.02.013
   Lowe AB, 1998, MACROMOLECULES, V31, P5991, DOI 10.1021/ma980558f
   Lv YQ, 2013, BIOTECHNOL ADV, V31, P1172, DOI 10.1016/j.biotechadv.2013.02.005
   Ma J, 2010, ULTRASON SONOCHEM, V17, P534, DOI 10.1016/j.ultsonch.2009.11.008
   Shi HQ, 1999, NATURE, V398, P593
   Skale S, 2007, CORROS SCI, V49, P1045, DOI 10.1016/j.corsci.2006.06.027
   Skoog DA, 1998, PRINCIPAL INSTRUMENT
   Suprun E.V., 2014, ELECTROCHIM ACTA
   Turner NW, 2007, J COLLOID INTERF SCI, V308, P71, DOI 10.1016/j.jcis.2006.12.037
   VANOOST BA, 1984, CLIN BIOCHEM, V17, P263, DOI 10.1016/S0009-9120(84)90189-9
   WULFF G, 1972, ANGEW CHEM INT EDIT, V11, P341
   Zhang L, 2008, BIOSENS BIOELECTRON, V24, P690, DOI 10.1016/j.bios.2008.06.025
NR 26
TC 24
Z9 26
U1 5
U2 332
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD JAN 15
PY 2015
VL 63
BP 301
EP 310
DI 10.1016/j.bios.2014.07.063
PG 10
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA AR1HT
UT WOS:000343337000042
PM 25113048
DA 2018-12-27
ER

PT J
AU Babakhanian, A
   Ehzari, H
   Kaki, S
   Hamidi, Z
AF Babakhanian, Arash
   Ehzari, Hosna
   Kaki, Samineh
   Hamidi, Zohreh
TI RETRACTED: A novel modified electrode as GC/PPy-AuNPs-rGO/L-Cys/Ag@MUA
   nanostructure configuration for determination of CCP and CRP antibodies
   in human blood serum samples (Retracted article. See vol. 74, pg. 1087,
   2015)
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article; Retracted Publication
DE Glassy carbon (GC) electrode; Modified electrode; Electrochemical
   impedance spectroscopy (EIS); Cyclic voltametry (CV); Cytochrome c
   protein (CCP); C-reactive protein (CRP)
ID C-REACTIVE PROTEIN; IMMOBILIZED CYTOCHROME-C; CARDIOVASCULAR RISK;
   ELECTROCHEMICAL-BEHAVIOR; RHEUMATOID-ARTHRITIS; L-CYSTEINE; CARBON;
   BIOSENSOR; SENSOR; NANOPARTICLES
AB In this work, silver nanoparticles were synthesized and stabilized with 11-mercaptoundecanoateanions to produce a new Ag@MUA core shell structure, and its utilizing for fabrication of a new sensing film. Gold nanoparticles (AuNPs) were electrochemically produced and simultaneously immobilized into the electropolymerized polypyrrole (PPy) film with the reduced graphene oxide (rGO). The Ag@MUA was then grafted to the surface of GC/PPy-AuNPs-rGO film using L-cysteine (L-Cys) linker agent and trifluoromethanesulfonic anhydride (TF2O), at ambient temperature and under the electrode stirring. The characterization of the sensor was studied by scanning electron microscopy, electrochemical impedance spectroscopy, cyclic and square wave voltammetry techniques. The utility of the modified electrode for clinical diagnosis has been successfully demonstrated by the analysis of human blood serums with a certified CRP and CCP content. Thus, the proposed sensor shows simple preparation, accuracy and precision in the analysis of cytochrome c protein (CCP) and C-reactive protein (CRP (with less side interferences. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Babakhanian, Arash; Ehzari, Hosna; Hamidi, Zohreh] Islamic Azad Univ, Kermanshah Branch, Dept Chem, Kermanshah, Iran.
   [Babakhanian, Arash; Kaki, Samineh] Islamic Azad Univ, Kermanshah Sci & Res Branch, Dept Food Chem Engn, Kermanshah, Iran.
RP Babakhanian, A (reprint author), Islamic Azad Univ, Kermanshah Branch, Dept Chem, Kermanshah, Iran.
EM arash.babakhanian@gmail.com
CR Buch M, 2008, ELECTROANAL, V20, P2592, DOI 10.1002/elan.200804358
   Carvalhal RF, 2007, INT J ELECTROCHEM SC, V2, P973
   Chen XJ, 2008, ANAL CHEM, V80, P2133, DOI 10.1021/ac7021376
   COLLINSON M, 1992, LANGMUIR, V8, P1247, DOI 10.1021/la00041a004
   COOPER JM, 1993, J ELECTROANAL CHEM, V347, P267, DOI 10.1016/0022-0728(93)80094-X
   Dell'Erba IE, 2010, LANGMUIR, V26, P2042, DOI 10.1021/la902568v
   Devi P, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-1172-2
   Fei SD, 2005, ANAL BIOCHEM, V339, P29, DOI 10.1016/j.ab.2005.01.002
   Firestein GS, 2005, JCR-J CLIN RHEUMATOL, V11, pS39, DOI 10.1097/01.rhu.0000166673.34461.33
   Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607
   Gholivand MB, 2011, ELECTROANAL, V23, P364, DOI 10.1002/elan.201000395
   Gu K, 1999, CHINESE J ANAL CHEM, V27, P1172
   HANSSON LO, 1987, J IMMUNOL METHODS, V100, P191, DOI 10.1016/0022-1759(87)90189-X
   Heinz A., 1975, ALTE METHODS, V12, P847
   Hennessey H, 2009, ANAL CHIM ACTA, V643, P45, DOI 10.1016/j.aca.2009.04.009
   Ignacio E., 2010, LANGMUIR, V26, P2042
   Jia JB, 2002, ANAL CHEM, V74, P2217, DOI 10.1021/ac011116w
   John E., 1978, LOW CLEM, V23, P285
   Joseph W., 2005, ANALYST, V4, P421
   Kushner I, 2002, ARCH INTERN MED, V162, P867, DOI 10.1001/archinte.162.8.867
   LAVIRON E, 1979, J ELECTROANAL CHEM, V100, P263, DOI 10.1016/S0022-0728(79)80167-9
   Liao KP, 2013, RHEUMATOLOGY, V52, P45, DOI 10.1093/rheumatology/kes243
   Malinauskas A, 2004, SENSOR ACTUAT B-CHEM, V100, P387, DOI 10.1016/j.snb.2004.02.006
   Martin CR, 1998, ANAL CHEM, V70, p322A, DOI 10.1021/ac9818430
   Matthew J. Picklo, 1999, ANAL BIOCHEM, V276, P166
   May A, 2007, EXPERT REV MOL DIAGN, V7, P793, DOI 10.1586/14737159.7.6.793
   Mygind ND, 2011, INFLAMM RES, V60, P281, DOI 10.1007/s00011-010-0266-5
   Neumann E, 2010, TRENDS MOL MED, V16, P458, DOI 10.1016/j.molmed.2010.07.004
   Omidfar K, 2004, TUMOR BIOL, V25, P296, DOI 10.1159/000081395
   Pumera M, 2010, TRAC-TREND ANAL CHEM, V29, P954, DOI 10.1016/j.trac.2010.05.011
   Pumera M, 2009, CHEM REC, V9, P211, DOI 10.1002/tcr.200900008
   Qureshi A, 2010, PHYS CHEM CHEM PHYS, V12, P9176, DOI 10.1039/c004133e
   Ricci F, 2005, BIOSENS BIOELECTRON, V21, P389, DOI 10.1016/j.bios.2004.12.001
   Saerens D, 2008, SENSORS-BASEL, V8, P4669, DOI 10.3390/s8084669
   Steiner G, 2007, CLIN REV ALLERG IMMU, V32, P23, DOI 10.1007/s12016-007-0017-8
   Vidal JC, 2004, TALANTA, V64, P655, DOI 10.1016/j.talanta.2004.03.038
   Wang J, 2003, ANAL CHEM, V75, P2075, DOI 10.1021/ac030007+
   Wang L, 2004, ELECTROCHEM COMMUN, V6, P225, DOI 10.1016/j.elecom.2003.12.004
   Zhuang Q, 2008, SENSOR ACTUAT B-CHEM, V128, P500, DOI 10.1016/j.snb.2007.07.040
NR 39
TC 3
Z9 3
U1 7
U2 208
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD JAN 15
PY 2015
VL 63
BP 490
EP 498
DI 10.1016/j.bios.2014.07.082
PG 9
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA AR1HT
UT WOS:000343337000067
PM 25129512
DA 2018-12-27
ER

PT J
AU Cassani, RSL
   Fassini, PG
   Silvah, JH
   Lima, CMM
   Marchini, JS
AF Lara Cassani, Roberta Soares
   Fassini, Priscila Giacomo
   Silvah, Jose Henrique
   Martires Lima, Cristiane Maria
   Marchini, Julio Sergio
TI RETRACTED: Impact of weight loss diet associated with flaxseed on
   inflammatory markers in men with cardiovascular risk factors: a clinical
   study (Retracted article. See vol. 15, pg. 59, 2016)
SO NUTRITION JOURNAL
LA English
DT Article; Retracted Publication
DE Flaxseed; Inflammation; Weight loss; Obesity
ID C-REACTIVE PROTEIN; BLOOD-PRESSURE; INSULIN-RESISTANCE; ABDOMINAL
   OBESITY; LIPID PROFILE; ADIPONECTIN; DISEASE; PLASMA; OIL;
   OMEGA-3-FATTY-ACIDS
AB Background: Flaxseed has received attention for its anti-inflammatory and antioxidant role. The present study hypothesizes if flaxseed added to a weight loss diet could improve the lipid and metabolic profiles and decrease risk factors related to cardiovascular disease.
   Methods: In a prospective, single blinded 42 days protocol, subjects were allocated into two groups with low carbohydrates intake: G(riceLC) (35% of carbohydrate and 60g of raw rice powder per day) and G(flaxLC) (32% of carbohydrate and 60g of flaxseed powder per day). Blood pressure, anthropometric measures and serum levels of isoprostane, C-reactive protein, Tumor Necrosis Factor-alpha, glucose, lipidic profile, uric acid, adiponectin, leptin and insulin were measured at baseline and at the end of interventions. Serum and urinary enterodiol and enterolactione were also measured.
   Results: A total of 27 men with cardiovascular risk factors were evaluated, with mean age of 33 +/- 10 years to G(riceLC) and 40 +/- 9 years to G(flaxLC). Both groups experienced weight loss and systolic blood pressure reduction. A decrease in inflammatory markers (CRP and TNF-alpha) was observed after flaxseed intake (mean decrease of 25% and 46% for G(flaxLC) respectively). All groups also showed improvement in levels of total cholesterol, LDL-c, uric acid and adiponectin. Only G(flaxLC) group showed a decrease in triglyceride levels.
   Conclusion: This study suggests that flaxseed added to a weight loss diet could be an important nutritional strategy to reduce inflammation markers such as CRP and TNF-alpha.
C1 [Lara Cassani, Roberta Soares] Inst Nutr Itu, Sao Paulo, Brazil.
   [Fassini, Priscila Giacomo; Silvah, Jose Henrique; Martires Lima, Cristiane Maria; Marchini, Julio Sergio] Univ Sao Paulo, Ribeirao Preto Med Sch, Div Med Nutr, Dept Med, BR-14049900 Sao Paulo, Brazil.
RP Fassini, PG (reprint author), Univ Sao Paulo, Ribeirao Preto Med Sch, Div Med Nutr, Dept Med, Ave Bandeirantes,3900 Bairro Monte Alegre, BR-14049900 Sao Paulo, Brazil.
EM priscilafassini@usp.br
RI Fassini, Priscila/D-2259-2016
OI Fassini, Priscila/0000-0002-7428-6641; Marchini, Julio
   Sergio/0000-0001-9999-9149; Silvah, Jose/0000-0001-5882-6815
FU CNPq [304127/2009-4]; FAEPA - Fundacao de Apoio ao Ensino, Pesquisa e
   Assistencia do Hospital das Clinicas da Faculdade de Medicina de
   Ribeirao Preto/University of Sao Paulo [2012/22543-3, 2012/21579-4,
   2012/21626-2]; CNPq; FAEPA; FAPESP
FX This study was partially financed by CNPq grant (304127/2009-4) intended
   to JSM and also by FAEPA - Fundacao de Apoio ao Ensino, Pesquisa e
   Assistencia do Hospital das Clinicas da Faculdade de Medicina de
   Ribeirao Preto/University of Sao Paulo. PGF, JHS and CMML received
   scholarships 2012/22543-3, 2012/21579-4 and 2012/21626-2, respectively
   from FAPESP Fundacao de Amparo a Pesquisa de Sao Paulo. CNPq, FAEPA and
   FAPESP are government agencies that provide financial resources, but
   generated no influences in the study.
CR Arts ICW, 2005, AM J CLIN NUTR, V81, p317S
   Balk EM, 2006, ATHEROSCLEROSIS, V189, P19, DOI 10.1016/j.atherosclerosis.2006.02.012
   Bassett CMC, 2009, APPL PHYSIOL NUTR ME, V34, P965, DOI 10.1139/H09-087
   Bloedon LT, 2008, J AM COLL NUTR, V27, P65, DOI 10.1080/07315724.2008.10719676
   Guimares ICB, 2008, ARQ BRAS CARDIOL, V90, P426, DOI 10.1590/S0066-782X2008000600007
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Couillard C, 2005, J CLIN ENDOCR METAB, V90, P6454, DOI 10.1210/jc.2004-2438
   Dandona P, 2004, TRENDS IMMUNOL, V25, P4, DOI 10.1016/j.it.2003.10.013
   Esmaillzadeh A, 2005, AM J CLIN NUTR, V81, P55
   Esmaillzadeh A, 2006, AM J CLIN NUTR, V84, P1489
   Fantuzzi G, 2007, ARTERIOSCL THROM VAS, V27, P996, DOI 10.1161/ATVBAHA.106.131755
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Fukumitsu S, 2008, BRIT J NUTR, V100, P669, DOI 10.1017/S0007114508911570
   Hallund J, 2008, NUTR METAB CARDIOVAS, V18, P497, DOI 10.1016/j.numecd.2007.05.007
   Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220
   Harris WS, 1997, AM J CLIN NUTR, V65, P1645, DOI 10.1093/ajcn/65.5.1645S
   IDF, IDF CONS WORLDW DEF
   Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee
   Jump DB, 2012, J LIPID RES, V53, P2525, DOI 10.1194/jlr.R027904
   Kivela AM, 2008, J NUTR, V138, P1263
   Kontogianni MD, 2013, METABOLISM, V62, P686, DOI 10.1016/j.metabol.2012.11.007
   Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94
   Lemieux I, 2001, ARTERIOSCL THROM VAS, V21, P961, DOI 10.1161/01.ATV.21.6.961
   Madsen EL, 2008, EUR J ENDOCRINOL, V158, P179, DOI 10.1530/EJE-07-0721
   Matarese LE, 2014, NUTR CLIN PRACT, V29, P759, DOI 10.1177/0884533614550251
   Mion Jr D, 2004, ARQ BRAS CARDIOL, V82, P15
   NHANES III. National Health and Nutrition Examination Survey, 2009, NAT HLTH NUTR EX SUR
   Nicoletti CF, 2014, NUTRITION, V30, P569, DOI 10.1016/j.nut.2013.10.013
   Pan A, 2008, BRIT J NUTR, V74, P1
   Pan A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001148
   Paschos GK, 2007, EUR J NUTR, V46, P315, DOI 10.1007/s00394-007-0668-5
   Prasad K, 2005, ATHEROSCLEROSIS, V179, P269, DOI 10.1016/j.athersclerosis.2004.11.012
   Prim CR, 2012, BRIT J NUTR, V107, P660, DOI 10.1017/S0007114511003539
   Radulian G, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-5
   Redman LM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004377
   Santos RD, 2012, ARQ BRAS CARDIOL, V99, P1, DOI [10.5935/abc.20120202, 10.1590/S0066-782X2013000900001]
   Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069
   Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007
   Vanharanta M, 2002, ATHEROSCLEROSIS, V160, P465, DOI 10.1016/S0021-9150(01)00603-7
   Vasques ACJ, 2008, ARQ BRAS ENDOCRINOL, V2, P52
   WHO, 1998, OB PRES MAN GOAL EP
NR 42
TC 15
Z9 15
U1 5
U2 22
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2891
J9 NUTR J
JI Nutr. J.
PD JAN 10
PY 2015
VL 14
AR 5
DI 10.1186/1475-2891-14-5
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA CA3OE
UT WOS:000348815500001
PM 25577201
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Tidwell, LG
   Allan, SE
   O'Connell, SG
   Hobbie, KA
   Smith, BW
   Anderson, KA
AF Tidwell, Lane G.
   Allan, Sarah E.
   O'Connell, Steven G.
   Hobbie, Kevin A.
   Smith, Brian W.
   Anderson, Kim A.
TI RETRACTED: Polycyclic Aromatic Hydrocarbon (PAH) and Oxygenated PAH
   (OPAH) Air-Water Exchange during the Deepwater Horizon Oil Spill
   (Retracted article. See vol. 50, pg. 7935, 2016)
SO ENVIRONMENTAL SCIENCE & TECHNOLOGY
LA English
DT Article; Retracted Publication
ID SEMIPERMEABLE-MEMBRANE DEVICES; PERFORMANCE REFERENCE COMPOUNDS;
   TROPICAL ATLANTIC-OCEAN; DIFFUSIVE EXCHANGE; CHESAPEAKE BAY; AMBIENT
   AIR; URBAN; POLYETHYLENE; SAMPLERS; GAS
AB Passive sampling devices were used to measure air vapor and water dissolved phase concentrations of 33 polycyclic aromatic hydrocarbons (PAHs) and 22 oxygenated PAHs (OPAHs) at four Gulf of Mexico coastal sites prior to, during, and after shoreline oiling from the Deepwater Horizon oil spill (DWH). Measurements were taken at each site over a 13 month period, and flux across the water-air boundary was determined. This is the first report of vapor phase and flux of both PAHs and OPAHs during the DWH. Vapor phase sum PAH and OPAH concentrations ranged between 1 and 24 ng/m(3) and 0.3 and 27 ng/m(3), respectively. PAH and OPAH concentrations in air exhibited different spatial and temporal trends than in water, and air-water flux of 13 individual PAHs were strongly associated with the DWH incident. The largest PAH volatilizations occurred at the sites in Alabama and Mississippi in the summer, each nominally 10?000 ng/m(2)/day. Acenaphthene was the PAH with the highest observed volatilization rate of 6800 ng/m(2)/day in September 2010. This work represents additional evidence of the DWH incident contributing to air contamination, and provides one of the first quantitative air-water chemical flux determinations with passive sampling technology.
C1 [Tidwell, Lane G.; Allan, Sarah E.; O'Connell, Steven G.; Hobbie, Kevin A.; Smith, Brian W.; Anderson, Kim A.] Oregon State Univ, Environm & Mol Toxicol Dept, Corvallis, OR 97331 USA.
RP Anderson, KA (reprint author), Oregon State Univ, Environm & Mol Toxicol Dept, ALS 1007,2750 SW Campus Way, Corvallis, OR 97331 USA.
EM kim.anderson@orst.edu
FU National Institute of Environmental Health Sciences [P42 ES016465, P30
   ES000210, R21 ES020120]
FX This project was supported in part by awards P42 ES016465 and the
   associated Analytical Chemistry Facility Core, P30 ES000210, and R21
   ES020120 from the National Institute of Environmental Health Sciences.
   The content is solely the responsibility of the authors and does not
   necessarily represent the official views of the NIEHS or the National
   Institutes of Health. We appreciate valuable help from Alan Bergmann,
   Ricky Scott, Gary Points, and Glenn Wilson. We thank Grand Isle State
   Park, Gulfport Harbor, Bon Secour National Wildlife Refuge, and Gulf
   Shores National Seashore. Gulf Shores National Seashore permits:
   GUIS-2010-SCI-0022, GUIS-2011-SCI-0042. Bon Secour National Wildlife
   Refuge permits: 10011, 11-002. Grand Isle State Park permit issue dates:
   May 18, 2010 and May 18, 2011.
CR Aeppli C, 2012, ENVIRON SCI TECHNOL, V46, P8799, DOI 10.1021/es3015138
   ALBAIGES J, 1991, MIKROCHIM ACTA, V2, P13
   Albinet A, 2007, SCI TOTAL ENVIRON, V384, P280, DOI 10.1016/j.scitotenv.2007.04.028
   Allan SE, 2012, ENVIRON SCI TECHNOL, V46, P2033, DOI 10.1021/es202942q
   Allen A. A., 2011, INT OIL SPILL C P IO
   Anderson KA, 2008, ENVIRON SCI TECHNOL, V42, P4486, DOI 10.1021/es702657n
   Aurell J, 2010, AEROSTAT SAMPLING PC
   BAKER JE, 1990, ENVIRON SCI TECHNOL, V24, P342, DOI 10.1021/es00073a009
   Bamford HA, 1999, ENVIRON SCI TECHNOL, V33, P2138, DOI 10.1021/es981324e
   Bartkow ME, 2004, ATMOS ENVIRON, V38, P5983, DOI 10.1016/j.atmosenv.2004.06.036
   Bartkow ME, 2006, ENVIRON POLLUT, V144, P365, DOI 10.1016/j.envpol.2005.12.043
   BLUMER M, 1975, SCIENCE, V188, P53, DOI 10.1126/science.188.4183.53
   Booij K, 2002, CHEMOSPHERE, V46, P1157, DOI 10.1016/S0045-6535(01)00200-4
   Brubaker WW, 1998, J PHYS CHEM A, V102, P915, DOI 10.1021/jp9721199
   Camilli R, 2012, P NATL ACAD SCI USA, V109, P20235, DOI 10.1073/pnas.1100385108
   Cincinelli A, 2007, CHEMOSPHERE, V68, P472, DOI 10.1016/j.chemosphere.2006.12.089
   Eiguren-Fernandez A, 2007, AEROSOL SCI TECH, V41, P438, DOI 10.1080/02786820701213511
   Fang MD, 2012, J ENVIRON MANAGE, V110, P179, DOI 10.1016/j.jenvman.2012.06.001
   G.S.I, ENV CHEM PROP DAT BA
   Gustafson KE, 1997, ENVIRON TOXICOL CHEM, V16, P452, DOI 10.1897/1551-5028(1997)016<0452:DOPAHI>2.3.CO;2
   He J., 2009, ATMOS CHEM PHYS DISC, V9, P13235
   Huckins J. N., 2006, MONITORS ORGANIC CHE
   Huckins JN, 2002, ENVIRON SCI TECHNOL, V36, P85, DOI 10.1021/es010991w
   Johnson MT, 2010, OCEAN SCI, V6, P913, DOI 10.5194/os-6-913-2010
   Jones KC, 1999, ENVIRON POLLUT, V100, P209, DOI 10.1016/S0269-7491(99)00098-6
   Khairy MA, 2012, ENVIRON SCI TECHNOL, V46, P3990, DOI 10.1021/es300012u
   Knecht AL, 2013, TOXICOL APPL PHARM, V271, P266, DOI 10.1016/j.taap.2013.05.006
   Kujawinski EB, 2011, ENVIRON SCI TECHNOL, V45, P1298, DOI 10.1021/es103838p
   Larsen RK, 2003, ENVIRON SCI TECHNOL, V37, P1873, DOI 10.1021/es0206184
   Layshock JA, 2010, ENVIRON TOXICOL CHEM, V29, P2450, DOI 10.1002/etc.301
   Lehr B., 2010, OIL BUDGET CALCULATO
   Leifer I, 2012, REMOTE SENS ENVIRON, V124, P185, DOI 10.1016/j.rse.2012.03.024
   Liu YN, 2007, CHEMOSPHERE, V66, P1922, DOI 10.1016/j.chemosphere.2006.07.076
   Lohmann R, 2013, ENVIRON SCI TECHNOL, V47, P13967, DOI 10.1021/es403494b
   Lohmann R, 2013, ENVIRON SCI TECHNOL, V47, P2570, DOI 10.1021/es304764e
   Lohmann R, 2011, ENVIRON SCI TECHNOL, V45, P2655, DOI 10.1021/es1025883
   Lundstedt S, 2007, AMBIO, V36, P475, DOI 10.1579/0044-7447(2007)36[475:SFATHO]2.0.CO;2
   Matzke MM, 2012, ENVIRON TOXICOL CHEM, V31, P2888, DOI 10.1002/etc.2014
   McDonough CA, 2014, ENVIRON SCI TECHNOL, V48, P7789, DOI 10.1021/es501074r
   Middlebrook AM, 2012, P NATL ACAD SCI USA, V109, P20280, DOI 10.1073/pnas.1110052108
   National Research Council, 2005, OIL SPILL DISP EFF E
   O'Connell S. G., 2013, ANAL BIOANAL CHEM, P1
   O'Connell SG, 2014, ENVIRON POLLUT, V193, P71, DOI 10.1016/j.envpol.2014.06.019
   PREST HF, 1995, CHEMOSPHERE, V30, P1351, DOI 10.1016/0045-6535(95)00027-6
   Ramirez N, 2011, ENVIRON HEALTH PERSP, V119, P1110, DOI 10.1289/ehp.1002855
   Ramseur J., 2010, DEEPWATER HORIZON OI
   Ravindra K, 2006, ATMOS ENVIRON, V40, P771, DOI 10.1016/j.atmosenv.2005.10.011
   Reddy CM, 2012, P NATL ACAD SCI USA, V109, P20229, DOI 10.1073/pnas.1101242108
   Soderstrom HS, 2004, ENVIRON SCI TECHNOL, V38, P4828, DOI 10.1021/es049637z
   Sower GJ, 2008, ENVIRON SCI TECHNOL, V42, P9065, DOI 10.1021/es801286z
   Terzi E, 2004, ENVIRON SCI TECHNOL, V38, P4973, DOI 10.1021/es040042d
   Tsai PJ, 2002, J HAZARD MATER, V91, P25, DOI 10.1016/S0304-3894(01)00384-3
   Wang Z., 2010, OIL SPILL ENV FORENS
   WILSON NK, 1995, ATMOS ENVIRON, V29, P2575, DOI 10.1016/1352-2310(95)00189-6
   Wischmann H, 1997, CHEMOSPHERE, V35, P1681, DOI 10.1016/S0045-6535(97)00249-X
   Zhang W, 2008, ENVIRON POLLUT, V153, P594, DOI 10.1016/j.envpol.2007.09.004
NR 56
TC 11
Z9 11
U1 3
U2 59
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0013-936X
EI 1520-5851
J9 ENVIRON SCI TECHNOL
JI Environ. Sci. Technol.
PD JAN 6
PY 2015
VL 49
IS 1
BP 141
EP 149
DI 10.1021/es503827y
PG 9
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA AY5BW
UT WOS:000347589300016
PM 25412353
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Berzoff, J
AF Berzoff, Joan
TI RETRACTED: H. S. Sullivan and His Contribution to the Relational
   School(Retracted article. See vol. 86, pg. 397, 2016)
SO SMITH COLLEGE STUDIES IN SOCIAL WORK
LA English
DT Article; Retracted Publication
DE dissociation; theory of anxiety; contributions to relational and
   intersubjective theories; detailed injury; consensual validation;
   developmental theory; Sullivan's personal life
ID PATIENT; WORK
AB Harry Stack Sullivan's contributions to the interpersonal school foreshadowed much of relational theory and practice today. His key ideas included consensual validation, dissociation, anxiety, a developmental theory about the need for others, and also practice techniques including empathy and a detailed inquiry into understanding clients. These are discussed as they relate to current relational and intersubjective practice including how the therapist and client always shape each other. Ideas from relational and intersubjective practice are discussed in light of Sullivan's contributions.
C1 [Berzoff, Joan] Smith Coll, Sch Social Work, End Life Certificate Program, Northampton, MA 01063 USA.
   [Berzoff, Joan] Smith Coll, Sch Social Work, Northampton, MA 01063 USA.
RP Berzoff, J (reprint author), Smith Coll, Sch Social Work, 23 West St,Lilly Hall, Northampton, MA 01063 USA.
EM jberzoff@smith.edu
CR Aron L., 1991, PSYCHOANAL DIALOGUES, V1, P29, DOI [10.1080/10481889109538884, DOI 10.1080/10481889109538884]
   Aron L., 1996, M MINDS MUTUALITY PS
   Benjamin J, 2004, PSYCHOANAL QUART, V73, P5, DOI 10.1002/j.2167-4086.2004.tb00151.x
   Benjamin J., 1990, PSYCHOANALYTIC PSY S, V7, P33, DOI [10.1037/h0085258, DOI 10.1037/H0085258]
   Benjamin Jessica, 1988, BONDS LOVE PSYCHOANA
   Benjamin Jessica, 1995, SUBJECTS LOVE OBJECT
   Berzoff J., 2011, FALLING CRACKS PSYCH, V16-17
   Berzoff J., 2011, INSIDE OUT OUTSIDE P, P222
   Bollas C., 1987, SHADOW OBJECT PSYCHO
   BRENNER C, 1955, ELEMENTARY TXB PSYCH
   Bromberg Philip M., 1998, STANDING SPACES ESSA
   Chatelaine K. L., 1981, HS SULLIVAN FORMATIV
   Delacour E., 1996, INSIDE OUT OUSIDE PS, P199
   Ehrenberg D., 1992, INTIMATE EDGE EXTEND
   Freud A., 1936, EGO MECH DEFENSE
   Freud S., 1923, STANDARD EDITION, V19, P3
   Greenberg J, 1983, OBJECT RELATIONS PSY
   Hoffman I., 1998, RITUAL SPONTANEITY P
   Hoffman IZ, 1996, PSYCHOANAL QUART, V65, P102, DOI 10.1080/21674086.1996.11927485
   HOFFMAN IZ, 1983, CONTEMP PSYCHOANAL, V19, P389
   Kanter J, 2013, J SOC WORK PRACT, V27, P273, DOI 10.1080/02650533.2013.818943
   Levenson E. A, 1985, MODELS MIND THEIR RE, P49
   LEVENSON EA, 1987, J AM ACAD PSYCHOAN, V15, P481, DOI 10.1521/jaap.1.1987.15.4.481
   LEVENSON EA, 1993, CONTEMP PSYCHOANAL, V29, P383
   Mitchell S. A., 1993, HOPE DREAD PSYCHOANA
   Mitchell SA, 1988, RELATIONAL CONCEPTS
   Mitchell Stephen, 1995, FREUD HIST MODERN PS
   Ogden T, 1997, INT J PSYCHOANAL, V78, P719
   OGDEN TH, 1994, INT J PSYCHOANAL, V75, P3
   Ortmeyer D. H, 1995, HDB INTERPERSONAL PS, P11
   Perry H. S, 1982, PSYCHIAT AM LIFE HS
   RENIK O, 1993, PSYCHOANAL QUART, V62, P553, DOI 10.1080/21674086.1993.11927393
   RENIK O, 1995, PSYCHOANAL QUART, V64, P466, DOI 10.1080/21674086.1995.11927461
   Schafer R., 1992, RETELLING LIFE NARRA
   Stern Daniel N, 1985, INTERPERSONAL WORLD
   Sullivan H, 1940, CONCEPTIONS MODERN P
   Sullivan H. S., 1956, CLIN STUDIES PSYCHIA
   Sullivan H. S., 1954, COMMUNICATION
   Sullivan H. S., 1964, FUSION PSYCHIAT SOCI
   Thompson C., 1962, SCHIZOPHRENIA HUMAN, pxxxii
   Tronick EZ, 2001, PSYCHOANAL DIALOGUES, V11, P187, DOI 10.1080/10481881109348606
   Wachtel P. L., 2008, RELATIONAL THEORY PR
NR 42
TC 1
Z9 1
U1 1
U2 3
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0037-7317
EI 1553-0426
J9 SMITH COLL STUD SOC
JI Smith Coll. Stud. Soc. Work
PD JAN 2
PY 2015
VL 85
IS 1
BP 54
EP 71
DI 10.1080/00377317.2015.957600
PG 18
WC Social Work
SC Social Work
GA CA1GS
UT WOS:000348661500004
DA 2018-12-27
ER

PT B
AU Wang, JP
   Liu, J
   Yang, SM
   Li, D
AF Wang Jingpei
   Liu Jie
   Yang Shengming
   Li Dan
GP IEEE
TI RETRACTED: Integrated Trusted Protection Technologies for Industrial
   Control Systems (Retracted article)
SO 2015 IEEE SEVENTH INTERNATIONAL CONFERENCE ON INTELLIGENT COMPUTING AND
   INFORMATION SYSTEMS (ICICIS)
LA English
DT Proceedings Paper; Retracted Publication
CT IEEE Seventh International Conference on Intelligent Computing and
   Information Systems (ICICIS)
CY DEC 12-14, 2015
CL CAIRO, EGYPT
DE industrial control systems; information security; trusted protection;
   integrated model
ID SECURITY
AB Security vulnerabilities in industrial control systems (ICS) and its open interconnected trends lead to security risks escalating. The existed security protection technologies, with poor applicability, are hard to meet the special need of information security for ICS. In this paper, trusted protection theories and technologies for ICS were studied and an integrated trusted protection model was proposed. The proposed method protected data and system security of ICS from aspects of trusted computing platform, trusted data protection mechanism and trust management network. The trusted protection technologies were deployed on each of the three network layers of ICS according to differentiated resource and security requirements of each layer. Analysis and simulation results indicate the effectiveness and superiority of the proposed method. The establishing of trusted protection model assists realizing the systematic security protection for heterogeneous industrial control systems.
C1 [Wang Jingpei; Liu Jie; Yang Shengming; Li Dan] China CEPREI Lab, Informat Secur Res Ctr, Guangzhou 510610, Guangdong, Peoples R China.
RP Wang, JP (reprint author), China CEPREI Lab, Informat Secur Res Ctr, Guangzhou 510610, Guangdong, Peoples R China.
EM wangjp@ceprei.com
CR Daci G., 2011, 2011 3 INT C ULTR TE, V5-7, P1
   Eisenhauer J., 2006, ROADMAP SECURE CONTR
   Fadul J. E., 2011, P 44 HAW INT C SYST, P1
   Fera MA, 2015, PROCEDIA COMPUT SCI, V48, P198, DOI 10.1016/j.procs.2015.04.170
   ICSJWG Roadmap Working Group, 2011, CROSS SECT ROADM CYB
   Kargl F, 2014, IEEE SECUR PRIV, V12, P75, DOI 10.1109/MSP.2014.120
   Mansfield-Devine S., 2014, NETWORK SECURITY, V2014, P1
   Nagarajan A, 2011, FUTURE GENER COMP SY, V27, P564, DOI 10.1016/j.future.2010.10.008
   Okhravi H, 2009, INT J CRIT INFR PROT, V2, P84, DOI 10.1016/j.ijcip.2009.07.001
NR 9
TC 1
Z9 1
U1 3
U2 8
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 978-1-5090-1949-6
PY 2015
BP 418
EP 423
PG 6
WC Computer Science, Information Systems; Computer Science, Theory &
   Methods; Engineering, Electrical & Electronic
SC Computer Science; Engineering
GA BF2IK
UT WOS:000380470400062
DA 2018-12-27
ER

PT J
AU Mtunzi, B
   Meyer, EL
   Michael, S
AF Mtunzi, Busiso
   Meyer, Edson L.
   Michael, Simon
TI RETRACTED: THERMAL AND ELECTRICAL ENERGY YIELD ANALYSIS OF A DIRECTLY
   WATER COOLED PHOTOVOLTAIC MODULE (Retracted article. See vol. 20, pg.
   770, 2016)
SO THERMAL SCIENCE
LA English
DT Article; Retracted Publication
DE solar energy utilisation; performance ratio; thermal response
AB Electrical energy of photovoltaic modules drops by 0.5% for each degree increase in temperature. Direct water cooling of photovoltaic modules was found to give improved electrical and thermal yield. A prototype was put in place to analyse the field data for a period of a year. The results showed an initial high performance ratio and electrical power output. The monthly energy saving efficiency of the directly water cooled module was found to be approximately 61%. The solar utilisation of the naturally cooled photovoltaic module was found to be 8.79% and for the directly water cooled module its solar utilisation was 47.93%. Implementation of such systems on households may reduce the load from the utility company, bring about huge savings on electricity bills and help in reducing carbon emissions.
C1 [Mtunzi, Busiso; Meyer, Edson L.; Michael, Simon] Univ Ft Hare, Ft Hare Inst Technol, Alice, South Africa.
RP Mtunzi, B (reprint author), Univ Ft Hare, Ft Hare Inst Technol, Alice, South Africa.
EM bmtunzi@ufh.ac.za
RI Meyer, Edson/C-8127-2018
OI Meyer, Edson/0000-0002-9912-311X
CR Carl von Carlowitz H., SUSTAINABILITY ENERG
   Colli A., 2010, Proceedings of the 25th European Photovoltaic Solar Energy Conference and Exhibition and the 5th World Conference on Photovoltaic Energy Conversion, P4344
   Duffle J. A., 2006, SOLAR ENG THERMAL PR
   Eikelboom J. A., 2000, ECNC00067
   He W, 2006, APPL ENERG, V83, P199, DOI 10.1016/j.apenergy.2005.02.007
   Huang BJ, 2001, SOL ENERGY, V70, P443, DOI 10.1016/S0038-092X(00)00153-5
   Malik AQ, 2010, ASEAN J SCI TECHNOL, V26, P61
   Meyer EL, 2012, 2012 38TH IEEE PHOTOVOLTAIC SPECIALISTS CONFERENCE (PVSC), P1296, DOI 10.1109/PVSC.2012.6317839
   Moodley S., 2005, J ENERGY SOUTH AFR, V16, P34
   Mtunzi B, 2014, THERM SCI, V18, pS317, DOI 10.2298/TSCI110815088M
   Simon M., 2009, THESIS U FORT HARE S
NR 11
TC 1
Z9 1
U1 2
U2 10
PU VINCA INST NUCLEAR SCI
PI BELGRADE
PA MIHAJLA PETROVICA-ALASA 12-14 VINCA, 11037 BELGRADE. POB 522, BELGRADE,
   11001, SERBIA
SN 0354-9836
EI 2334-7163
J9 THERM SCI
JI Therm. Sci.
PY 2015
VL 19
SU 2
BP S547
EP S555
DI 10.2298/TSCI130118144M
PG 9
WC Thermodynamics
SC Thermodynamics
GA DC9RN
UT WOS:000369558800029
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Sun, YJ
   Ye, LC
   Jiang, C
   Jiang, J
   Hong, HF
   Qiu, LS
AF Sun, Yanjun
   Ye, Lincai
   Jiang, Chuan
   Jiang, Jun
   Hong, Haifa
   Qiu, Lisheng
TI RETRACTED: Over-expression of HSPA12B protects mice against myocardium
   ischemic/reperfusion injury through a PPAR gamma-dependent PI3K/Akt/eNOS
   pathway (Retracted article. See vol. 8, pg. 1625, 2016)
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article; Retracted Publication
DE HSPA12B; myocardium ischemic/reperfusion injury; PPAR gamma; PI3K; Akt;
   eNOS
ID ISCHEMIA-REPERFUSION INJURY; NITRIC-OXIDE SYNTHASE; PULMONARY
   ARTERIAL-HYPERTENSION; ISCHEMIA/REPERFUSION INJURY; CARDIAC DYSFUNCTION;
   ENDOTHELIAL-CELLS; IN-VITRO; MECHANISMS; CARDIOPROTECTION; TELMISARTAN
AB Acute myocardial ischemia/reperfusion (MIR) injury leads to severe arrhythmias and a high lethality. We aim to determine the effect of heat shock protein A12B (HSPA12B), a newly discovered member of the Hsp70 family, on heart injury parameters following MIR surgery. We used HSPA12B transgenic mice to determine its effects on heart function parameters, infarct size and cellular apoptosis following MIR surgery. Proinflammatory cytokines, oxidative products and anti-oxidative enzymes in the myocardium were measured to evaluate the anti-inflammatory and anti-oxidative effects of HSPA12B over-expression. The role of PPARs/eNOS/PI3k/Akt pathway was investigated using their inhibitors. The alteration of hemodynamic parameters, histopathological, apoptotic and infarct size caused by MIR was greatly attenuated in HSPA12B over-expressed mice. HSPA12B also greatly mitigated the inflammatory response, demonstrated by the decrease in the levels of IL-1 beta, IL-6, TNF-a and MPO. Anti-oxidative enzymes (SOD, Catalase and GPx) were restored by HSPA12B; oxidative products (8-OHdG, MDA and protein carbonyl) were decreased. HSPA12B activated the PPAR.-dependent eNOS/PI3k/Akt pathway, and the influence of HSPA12B on cardiac function was reversed by the inhibitors of eNOS, PPAR gamma, Akt and PI3K. Our results present a novel signaling mechanism that HSPA12B protects MIR injury through a PPAR gamma-dependent PI3K/Akt/eNOS pathway.
C1 [Sun, Yanjun; Ye, Lincai; Jiang, Chuan; Jiang, Jun; Hong, Haifa; Qiu, Lisheng] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Thorac & Cardiovasc Surg, Shanghai 200127, Peoples R China.
RP Hong, HF (reprint author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Thorac & Cardiovasc Surg, Shanghai 200127, Peoples R China.
EM hhfsmallboat@163.com; qiulisheng66@163.com
FU National Basic Research Program of China [2013CB945304]
FX This study was funded by National Basic Research Program of China (No.
   2013CB945304).
CR Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018
   Bi R, 2015, BIOCHEM BIOPH RES CO, V460, P469, DOI 10.1016/j.bbrc.2015.03.057
   Bolli R, 2004, CIRC RES, V95, P125, DOI 10.1161/01.RES.0000137171.97172.d7
   Bozlu M, 2003, J UROLOGY, V169, P1870, DOI 10.1097/01.ju.0000049228.37887.4d
   Chi W, 2014, NEUROSCIENCE, V277, P111, DOI 10.1016/j.neuroscience.2014.06.062
   Cui ZM, 2010, J NEUROL SCI, V294, P29, DOI 10.1016/j.jns.2010.04.009
   Gao XM, 2000, CARDIOVASC RES, V45, P330, DOI 10.1016/S0008-6363(99)00274-6
   Han ZH, 2003, P NATL ACAD SCI USA, V100, P1256, DOI 10.1073/pnas.252764399
   Hausenloy DJ, 2004, CARDIOVASC RES, V61, P448, DOI 10.1016/j.cardiores.2003.09.024
   Hu G, 2006, J CELL SCI, V119, P4117, DOI 10.1242/jcs.03179
   Kang LH, 2013, NEUROCHEM RES, V38, P311, DOI 10.1007/s11064-012-0922-y
   Karpe PA, 2014, DIABETES, V63, P1124, DOI 10.2337/db13-1267
   Kielstein JT, 2005, ARTERIOSCL THROM VAS, V25, P1414, DOI 10.1161/01.ATV.0000168414.06853.f0
   Levine RL, 2000, METH MOL B, V99, P15
   Li H, 2014, PULM PHARMACOL THER, V28, P17, DOI 10.1016/j.pupt.2013.11.003
   Li JJ, 2013, CARDIOVASC RES, V99, P674, DOI 10.1093/cvr/cvt139
   Li Q, 2015, AM J PHYSIOL-CELL PH, V309, pC100, DOI 10.1152/ajpcell.00332.2014
   Ma YJ, 2013, BBA-MOL BASIS DIS, V1832, P57, DOI 10.1016/j.bbadis.2012.10.003
   Maejima Y, 2011, LAB INVEST, V91, P932, DOI 10.1038/labinvest.2011.45
   MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F
   Martin-Nizard F, 2002, J CARDIOVASC PHARM, V40, P822, DOI 10.1097/00005344-200212000-00003
   Garcia IM, 2012, NITRIC OXIDE-BIOL CH, V27, P95, DOI 10.1016/j.niox.2012.05.006
   Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5
   Monassier JP, 2008, ARCH CARDIOVASC DIS, V101, P491, DOI 10.1016/j.acvd.2008.06.014
   Park JL, 1999, ANN THORAC SURG, V68, P1905, DOI 10.1016/S0003-4975(99)01073-5
   Polikandriotis JA, 2005, ARTERIOSCL THROM VAS, V25, P1810, DOI 10.1161/01.ATV.0000177805.65864.d4
   Qian GQ, 2015, PHARMACOGN MAG, V11, P292, DOI 10.4103/0973-1296.153081
   Sharma S, 2013, PEDIATR RES, V74, P39, DOI 10.1038/pr.2013.71
   Shinmura K, 2015, AM J PHYSIOL-HEART C, V308, pH894, DOI 10.1152/ajpheart.00333.2014
   Steagall RJ, 2006, ARTERIOSCL THROM VAS, V26, P2012, DOI 10.1161/01.ATV.0000235720.61091.c7
   Umemura T, 2009, TOXICOLOGY, V257, P46, DOI 10.1016/j.tox.2008.12.007
   Uryash A, 2012, LIFE SCI, V91, P178, DOI 10.1016/j.lfs.2012.06.031
   Wei G, 2013, INFLAMMATION, V36, P592, DOI 10.1007/s10753-012-9581-z
   Weng D, 2007, TOXICOLOGY, V232, P15, DOI 10.1016/j.tox.2006.12.010
   Yang J, 2009, MOL CELL BIOCHEM, V330, P39, DOI 10.1007/s11010-009-0098-1
   Yang ZQ, 2006, CIRCULATION, V114, P2056, DOI 10.1161/CIRCULATIONAHA.106.649244
   Yellon DM, 2007, NEW ENGL J MED, V357, P1121, DOI 10.1056/NEJMra071667
   Yuen CY, 2011, CARDIOVASC RES, V90, P122, DOI 10.1093/cvr/cvq392
   Zhou HM, 2011, CARDIOVASC RES, V89, P109, DOI 10.1093/cvr/cvq268
NR 39
TC 7
Z9 7
U1 3
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2015
VL 7
IS 12
BP 2724
EP 2737
PG 14
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA DE1EJ
UT WOS:000370369200017
PM 26885270
DA 2018-12-27
ER

PT J
AU Wu, HX
   Wang, WX
   Tong, SL
   Wu, C
AF Wu, Hongxue
   Wang, Weixing
   Tong, Shilun
   Wu, Chong
TI RETRACTED: Nucleostemin regulates proliferation and migration of gastric
   cancer and correlates with its malignancy (Retracted article. See vol.
   10, pg. 15800, 2017)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Gastric cancer (GC); nucleostemin (NS); SGC-7901; small interfering RNA;
   apoptosis; target therapy
ID DNA-DAMAGE; CELLS; EXPRESSION; INVASION; PROTEIN; GROWTH;
   OVEREXPRESSION; ACTIVATION; BIOMARKERS; RESISTANCE
AB Objective: The aim of this study was to investigate the effects of nucleostemin (NS) knocking down in SGC-7901 gastric cancer cell line and investigates its correlation with the metastasis and TNM stage ingastric cancer (GC) patients. Methods: NS expression was assessed using immunohistochemistry in 421 patients with GC. The correlation between NS expression, clinicopathological features and prognosis was analyzed. NS gene silencing was performed using a specific small interfering RNA (NS-siRNA). The gene expression level of NS was evaluated by PCR. The viability and growth rate of SGC-7901 cells were determined by trypan blue exclusion test. Cell cycle distribution of the cells was analyzed by flow cytometry. Results: High NS expression was correlated with node metastasis, distant metastasis and TNM stage. Kaplan-Meier survival analysis revealed that patients with low NS expression had significantly longer survival than those with high NS expression. Moreover, our results showed that NS knocking down inhibited proliferation and viability of SGC-7901 cells in a time-dependent manner. Cell cycle studies revealed that NS depletion resulted in G1 cell cycle arrest at short times of transfection (24 h) followed with apoptosis at longer times (48 and 72 h), suggest that post-G1 arrest apoptosis is occurred in SGC-7901 cells. Conclusion: Overall, these results point to essential role of NS in SGC-7901 cells, thus, this gene might be considered as a promising target for treatment of GC.
C1 [Wu, Hongxue; Wang, Weixing; Tong, Shilun; Wu, Chong] Wuhan Univ, Renmin Hosp, Dept Gastrointestinal, Wuhan 430072, Hubei Province, Peoples R China.
RP Wang, WX (reprint author), Wuhan Univ, Renmin Hosp, Dept Gastrointestinal, Wuhan 430072, Hubei Province, Peoples R China.
EM wangweixingvip1234@163.com
CR Aprile G, 2014, EXPERT OPIN INV DRUG, V23, P925, DOI 10.1517/13543784.2014.912631
   Cao WG, 2014, TUMOR BIOL, V35, P1287, DOI 10.1007/s13277-013-1171-7
   Chen J, 2014, HEPATO-GASTROENTEROL, V61, P518, DOI 10.5754/hge12954
   Choi MR, 2014, APMIS, V122, P1207, DOI 10.1111/apm.12286
   Fang Y, 2013, ACTA BIOCH BIOPH SIN, V45, P963, DOI 10.1093/abbs/gmt106
   Guan SS, 2014, ONCOTARGET, V5, P4868, DOI 10.18632/oncotarget.2050
   Guo LH, 2013, INT J MOL SCI, V14, P14171, DOI 10.3390/ijms140714171
   Hong KJ, 2014, J CELL PHYSIOL, V229, P191, DOI 10.1002/jcp.24434
   Iwaya T, 2013, CLIN CANCER RES, V19, P6438, DOI 10.1158/1078-0432.CCR-12-3186
   Kim YM, 2013, MOL MED REP, V8, P11, DOI 10.3892/mmr.2013.1492
   Kurokawa Y, 2014, ANN SURG ONCOL, V21, pS584, DOI 10.1245/s10434-014-3690-x
   Li XS, 2014, J CANCER RES CLIN, V140, P1305, DOI 10.1007/s00432-014-1698-z
   Li Y, 2014, NEOPLASMA, V61, P291, DOI 10.4149/neo_2014_037
   Liu QS, 2010, CANCER SCI, V101, P1807, DOI 10.1111/j.1349-7006.2010.01600.x
   Luo BH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099922
   McLean MIH, 2014, NAT REV GASTRO HEPAT, V11, P664, DOI 10.1038/nrgastro.2014.143
   Musiani D, 2014, FASEB J, V28, P4055, DOI 10.1096/fj.13-247924
   Nakadate Y, 2013, BIOCHEM BIOPH RES CO, V441, P793, DOI 10.1016/j.bbrc.2013.10.134
   Nielsen TO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094606
   Oo HZ, 2014, ONCOL REP, V32, P403, DOI 10.3892/or.2014.3166
   Rasul A, 2013, ARCH PHARM RES, V36, P1262, DOI 10.1007/s12272-013-0217-0
   Shen JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104510
   Shin VY, 2014, WORLD J GASTROENTERO, V20, P10432, DOI 10.3748/wjg.v20.i30.10432
   Shiotani A, 2013, BRIT J CANCER, V109, P2323, DOI 10.1038/bjc.2013.596
   Tong FY, 2014, DIGEST DIS SCI, V59, P24, DOI 10.1007/s10620-013-2887-3
   Vaiopoulos AG, 2014, ANTICANCER RES, V34, P3083
   Pertino MW, 2013, MOLECULES, V18, P7661, DOI 10.3390/molecules18077661
   Won KJ, 2014, INT J CANCER, V134, P2595, DOI 10.1002/ijc.28600
   Wu XJ, 2013, ONKOLOGIE, V36, P573, DOI 10.1159/000355518
   Xu L, 2014, ONCOL REP, V32, P318, DOI 10.3892/or.2014.3183
   Yang B, 2014, CLIN TRANSL ONCOL, V16, P374, DOI 10.1007/s12094-013-1081-6
   Yang Y, 2014, ONCOL REP, V32, P45, DOI 10.3892/or.2014.3188
   Yoon JH, 2013, BIOCHEM BIOPH RES CO, V440, P689, DOI 10.1016/j.bbrc.2013.09.123
   Yu SY, 2014, NEOPLASMA, V61, P257, DOI 10.4149/neo_2014_033
   Zhao HY, 2014, MOL CELL BIOCHEM, V385, P207, DOI 10.1007/s11010-013-1829-x
NR 35
TC 8
Z9 8
U1 0
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 10
BP 17634
EP 17643
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA DA3BB
UT WOS:000367669800061
PM 26770353
DA 2018-12-27
ER

PT J
AU Orak, I
   Korkut, H
   Yildirim, N
   Turut, A
AF Orak, I.
   Korkut, H.
   Yildirim, N.
   Turut, A.
TI RETRACTED: Illumination response on the electrical characterizations of
   Cr/n-GaAs/In photodiode (Retracted article. See vol. 127, pg. 3095,
   2016)
SO OPTIK
LA English
DT Article; Retracted Publication
DE Illumination respond; Photovoltaic impact; Ideality factor; Open circuit
   voltage; Short circuit current
ID SCHOTTKY DIODES; PHOTOVOLTAIC PROPERTIES; BARRIER HEIGHT; SOLAR-CELLS;
   HETEROJUNCTION; INTERFACE; FILMS; INP
AB In this study, we were investigated current-voltage (I-V) measurements of Cr/n type-GaAs photodiode and performed under dark, room light and illumination conditions at room temperature. The ideality factor (n) and barrier height (phi(beta)) values of the device was calculated to be 1.1 and 0.91 eV, respectively. The photovoltaic parameters, such as short circuit current (I-sc) and open circuit voltage (V-oc) were acquired as 280 mV, 0.18 mu A and 460 mV, 13.1 mu A room light and under 30 mW/cm(2) light intensity, respectively. The obtained results recommend that Grin-GaAs diode can be used as a photodevice in optoelectronic and photovoltaic applications. The device under light illumination shows a good photovoltaic behavior. (C) 2015 Elsevier GmbH. All rights reserved.
C1 [Orak, I.] Bingol Univ, Vocat Sch Hlth Serv, TR-12000 Bingol, Turkey.
   [Orak, I.; Yildirim, N.] Bingol Univ, Fac Sci & Arts, Dept Phys, TR-12000 Bingo, Turkey.
   [Korkut, H.] Sinop Univ, Dept Nucl Energy Engn, Fac Engn, TR-57000 Sinop, Turkey.
   [Turut, A.] Istanbul Medeniyet Univ, Dept Engn Phys, Fac Sci, TR-34730 Istanbul, Turkey.
RP Orak, I (reprint author), Bingol Univ, Vocat Sch Hlth Serv, TR-12000 Bingol, Turkey.
EM ikramorak@gmail.com
CR ABOELFOTOH MO, 1989, PHYS REV B, V39, P5070, DOI 10.1103/PhysRevB.39.5070
   Aldemir DA, 2012, MICROELECTRON ENG, V98, P6, DOI 10.1016/j.mee.2012.04.012
   Ayyildiz E, 1999, SOLID STATE ELECTRON, V43, P521, DOI 10.1016/S0038-1101(98)00287-1
   El-Nahass MM, 2007, SOL ENERG MAT SOL C, V91, P1120, DOI 10.1016/j.solmat.2007.03.016
   EVERAERT JL, 1990, SEMICOND SCI TECH, V5, P60, DOI 10.1088/0268-1242/5/1/007
   Farag AAM, 2009, INT J HYDROGEN ENERG, V34, P4906, DOI 10.1016/j.ijhydene.2009.03.034
   Gullu O, 2008, SOL ENERG MAT SOL C, V92, P1205, DOI 10.1016/j.solmat.2008.04.009
   KALIBJIAN R, 1971, SOLID STATE ELECTRON, V14, P529, DOI 10.1016/0038-1101(71)90128-6
   Kasap S. O., 2001, OPTOELECTRONICS PHOT
   Lee JH, 2007, THIN SOLID FILMS, V515, P6089, DOI 10.1016/j.tsf.2006.12.097
   Lizon P., 2004, THESIS U TORONTO TOR
   Makita Y., 1997, P FUT GEN PHOT TECHN, P704
   Markvart T, 2000, SOLAR ELECT
   Murugan AV, 2001, MATER CHEM PHYS, V71, P98
   Rhoderick E.H., 1988, METAL SEMICONDUCTOR
   Saglam M, 1997, SEMICOND SCI TECH, V12, P1028, DOI 10.1088/0268-1242/12/8/016
   SANDS T, 1988, APPL PHYS LETT, V52, P197, DOI 10.1063/1.99518
   SHI ZQ, 1991, SOLID STATE ELECTRON, V34, P285, DOI 10.1016/0038-1101(91)90186-3
   Soliman HS, 2012, J ALLOY COMPD, V530, P157, DOI 10.1016/j.jallcom.2012.03.053
   Soylu M, 2011, THIN SOLID FILMS, V519, P1950, DOI 10.1016/j.tsf.2010.10.030
   Sze S. M., 2007, PHYS SEMICONDUCTOR D
   Tatar B, 2009, INT J HYDROGEN ENERG, V34, P5208, DOI 10.1016/j.ijhydene.2008.10.040
   Turut A, 1996, PHYS SCRIPTA, V53, P118, DOI 10.1088/0031-8949/53/1/023
   Tyagi M. S., 1991, INTRO SEMICONDUCTOR
   Wang QQ, 2005, J SOLID STATE CHEM, V178, P2680, DOI 10.1016/j.jssc.2005.06.005
   WILLIAMS RH, 1985, PHYS CHEM 3 5 COMPOU
   Yahia IS, 2013, CURR APPL PHYS, V13, P537, DOI 10.1016/j.cap.2012.09.018
   Yakuphanoglu F, 2007, PHYSICA B, V400, P208, DOI 10.1016/j.physb.2007.07.010
NR 28
TC 1
Z9 1
U1 7
U2 17
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0030-4026
J9 OPTIK
JI Optik
PY 2015
VL 126
IS 24
BP 4946
EP 4948
DI 10.1016/j.ijleo.2015.09.225
PG 3
WC Optics
SC Optics
GA DB6UI
UT WOS:000368650800031
DA 2018-12-27
ER

PT J
AU Zhao, YY
   O'Brien, TP
AF Zhao, Yingying
   O'Brien, Timothy P.
TI RETRACTED: Spry2 regulates signalling dynamics and terminal bud
   branching behaviour during lung development (Retracted article. See vol.
   97, pg. E12, 2015)
SO GENETICS RESEARCH
LA English
DT Article; Retracted Publication
ID PIEBALD DELETION COMPLEX; SONIC HEDGEHOG SHH; MOUSE LUNG; TARGETED
   MISEXPRESSION; SPROUTY GENES; MORPHOGENESIS; GROWTH; FGF; DROSOPHILA;
   LIMB
AB Development of mammalian lung involves reiterative outgrowth and branching of an epithelial tube into the surrounding mesenchymal bed. Each coordinated growth and branching cycle is driven by reciprocal signalling between epithelial and adjacent mesenchymal cells. This signalling network includes FGF, SHH, BMP4 and other pathways. We have characterized lung defects in 36Pub mice carrying a deletion that removes an antagonist of FGF signalling, Spry2. Spry2 deficient mice show an enlarged cystic structure located in the terminus of each lobes. Our study shows that Spry2 deficient lungs have reduced lung branching and the cystic structure forms in the early lung development stage. Furthermore, mice carrying a targeted disruption of Spry2 fail to complement the lung phenotype characterized in 36Pub mice. A Spry2-BAC transgene rescues the defect. Interestingly, cystic structure growth is accompanied by the reduced and spatially disorganized expression of Fgf10 and elevated expression of Shh and Bmp4. Altered signalling balance due to the loss of Spry2 causes a delayed branch cycle and cystic growth. Our data underscores the importance of restricting cellular responsiveness to signalling and highlights the interplay between morphogenesis events and spatial localization of gene expression.
C1 [Zhao, Yingying] Shenzhen Univ, Hlth Sci Ctr, AstraZeneca Shenzhen Univ Joint Inst Nephrol, Shenzhen Univ Diabet Ctr,Dept Phys, Shenzhen 518060, Peoples R China.
   [Zhao, Yingying; O'Brien, Timothy P.] Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA.
RP O'Brien, TP (reprint author), Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA.
EM tpo5@cornell.edu
FU National Institutes of Health (NIH) [HD41066]; Cornell University
FX We thank Dr. Gail Martin for providing Spry2.ORF mice. We also thank Ian
   Welsh and Randal Babiuk for technical assistance. This work was
   supported by National Institutes of Health (NIH) (T. P. O., grant number
   HD41066) and a Presidential Life Sciences fellowship from Cornell
   University (Y. Z., 2006-2007).
CR Affolter M, 2003, DEV CELL, V4, P11, DOI 10.1016/S1534-5807(02)00410-0
   Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895
   Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004
   Bellusci S, 1996, DEVELOPMENT, V122, P1693
   Bellusci S, 1997, DEVELOPMENT, V124, P4867
   Bellusci S, 1997, DEVELOPMENT, V124, P53
   BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010
   Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0
   Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642
   Davies JA, 2002, BIOESSAYS, V24, P937, DOI 10.1002/bies.10161
   Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8
   Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867
   Hansen J, 2003, P NATL ACAD SCI USA, V100, P9918, DOI 10.1073/pnas.1633296100
   Hogan BLM, 2002, NAT REV GENET, V3, P513, DOI 10.1038/nrg840
   Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0
   Klein OD, 2006, DEV CELL, V11, P181, DOI 10.1016/j.devcel.2006.05.014
   Kramer S, 1999, DEVELOPMENT, V126, P2515
   Lebeche D, 1999, MECH DEVELOP, V86, P125, DOI 10.1016/S0925-4773(99)00124-0
   Litingtung Y, 1998, NAT GENET, V20, P58
   Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6
   Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635
   Metzger RJ, 2008, NATURE, V453, P745, DOI 10.1038/nature07005
   Miller LAD, 2001, J HISTOCHEM CYTOCHEM, V49, P1593, DOI 10.1177/002215540104901213
   Minowada G, 1999, DEVELOPMENT, V126, P4465
   OBrien TP, 1996, GENETICS, V143, P447
   Park WY, 1998, DEV BIOL, V201, P125, DOI 10.1006/dbio.1998.8994
   Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4
   Peterson KA, 2002, GENOMICS, V80, P172, DOI 10.1006/geno.2002.6818
   Rice R, 2004, J CLIN INVEST, V113, P1692, DOI 10.1172/JCI200420384
   Roix JJ, 2001, GENETICS, V157, P803
   Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096
   Shim K, 2005, DEV CELL, V8, P553, DOI 10.1016/j.devcel.2005.02.009
   Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6
   Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3
   van Tuyl M, 2000, Respir Res, V1, P30, DOI 10.1186/rr9
   Weaver M, 2000, DEVELOPMENT, V127, P2695
   Welsh IC, 2007, MECH DEVELOP, V124, P746, DOI 10.1016/j.mod.2007.06.007
   Zhang YD, 2000, DEVELOPMENT, V127, P1431
   Zhang ZY, 2000, DEV BIOL, V220, P154, DOI 10.1006/dbio.2000.9637
NR 39
TC 2
Z9 2
U1 2
U2 9
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0016-6723
EI 1469-5073
J9 GENET RES
JI Genet. Res.
PY 2015
VL 97
AR e5
DI 10.1017/S0016672315000026
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA CZ5ZO
UT WOS:000367181100004
PM 25825238
DA 2018-12-27
ER

PT J
AU Seshadri, S
   Al-Akash, S
   Gharaybeh, S
AF Seshadri, Sheshashree
   Al-Akash, Samhar
   Gharaybeh, Salam
TI RETRACTED: Rash, Recalcitrant Tachycardia, and Hypertension in a
   16-Year-Old Girl (Retracted article)
SO PEDIATRICS IN REVIEW
LA English
DT Editorial Material; Retracted Publication
C1 [Seshadri, Sheshashree; Al-Akash, Samhar; Gharaybeh, Salam] Driscoll Childrens Hosp, Corpus Christi, TX 78411 USA.
RP Seshadri, S (reprint author), Driscoll Childrens Hosp, Corpus Christi, TX 78411 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0191-9601
EI 1526-3347
J9 PEDIATR REV
JI Pediatr. Rev.
PD JAN
PY 2015
VL 36
IS 1
BP 31
EP +
DI 10.1542/pir.36-1-31
PG 2
WC Pediatrics
SC Pediatrics
GA CU7DN
UT WOS:000363696400006
PM 25554109
DA 2018-12-27
ER

PT J
AU Habertheuer, A
   Wiedemann, D
   Kocher, A
   Laufer, G
   Vallabhajosyula, P
AF Habertheuer, Andreas
   Wiedemann, Dominik
   Kocher, Alfred
   Laufer, Guenther
   Vallabhajosyula, Prashanth
TI RETRACTED: How to Perfuse: Concepts of Cerebral Protection during Arch
   Replacement (Retracted article. See 7147584, 2016)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review; Retracted Publication
ID HYPOTHERMIC CIRCULATORY ARREST; ACUTE AORTIC DISSECTION; RISK-FACTOR
   ANALYSIS; MODERATE HYPOTHERMIA; BRAIN PROTECTION; SURGICAL-TREATMENT;
   ASCENDING AORTA; THORACIC AORTA; A DISSECTION; INTERNATIONAL REGISTRY
AB Arch surgery remains undoubtedly among the most technically and strategically challenging endeavors in cardiovascular surgery. Surgical interventions of thoracic aneurysms involving the aortic arch require complete circulatory arrest in deep hypothermia (DHCA) or elaborate cerebral perfusion strategies with varying degrees of hypothermia to achieve satisfactory protection of the brain from ischemic insults, that is, unilateral/bilateral antegrade cerebral perfusion (ACP) and retrograde cerebral perfusion (RCP). Despite sophisticated and increasingly individualized surgical approaches for complex aortic pathologies, there remains a lack of consensus regarding the optimal method of cerebral protection and circulatory management during the time of arch exclusion. Many recent studies argue in favor of ACP with various degrees of hypothermic arrest during arch reconstruction and its advantages have been widely demonstrated. In fact ACP with more moderate degrees of hypothermia represents a paradigm shift in the cardiac surgery community and is widely adopted as an emergent strategy; however, many centers continue to report good results using other perfusion strategies. Amidst this important discussion we review currently available surgical strategies of cerebral protection management and compare the results of recent European multicenter and single-center data.
C1 [Habertheuer, Andreas; Vallabhajosyula, Prashanth] Univ Penn, Med Ctr, Div Cardiovasc Surg, Philadelphia, PA 19104 USA.
   [Habertheuer, Andreas; Wiedemann, Dominik; Kocher, Alfred; Laufer, Guenther] Med Univ Vienna, Vienna Gen Hosp, Dept Cardiac Surg, A-1090 Vienna, Austria.
RP Habertheuer, A (reprint author), Univ Penn, Med Ctr, Div Cardiovasc Surg, Philadelphia, PA 19104 USA.
EM andreas.habertheuer@uphs.upenn.edu
CR Algarni KD, 2014, J THORAC CARDIOV SUR, V148, P2888, DOI 10.1016/j.jtcvs.2014.01.020
   Angeloni E, 2015, ANN THORAC SURG, V99, P2024, DOI 10.1016/j.athoracsur.2015.01.070
   Angeloni E, 2014, J THORAC CARDIOV SUR, V147, P60, DOI 10.1016/j.jtcvs.2012.10.029
   Appoo JJ, 2006, J CARDIOTHOR VASC AN, V20, P3, DOI 10.1053/j.jvca.2005.08.005
   Bachet J, 1999, ANN THORAC SURG, V67, P1874, DOI 10.1016/S0003-4975(99)00411-7
   Bachet J, 2012, EUR J CARDIO-THORAC, V42, P710, DOI 10.1093/ejcts/ezs134
   Bashir M, 2013, ANN CARDIOTHORAC SUR, V2, P239, DOI 10.3978/j.issn.2225-319X.2013.02.04
   Bavaria J E, 1997, Semin Thorac Cardiovasc Surg, V9, P222
   Bavaria JE, 2002, ANN THORAC SURG, V74, pS1848, DOI 10.1016/S0003-4975(02)04128-0
   Bavaria JE, 2001, ANN SURG, V234, P336, DOI 10.1097/00000658-200109000-00007
   BORST HG, 1964, J THORAC CARDIOV SUR, V48, P443
   Bucerius J, 2003, ANN THORAC SURG, V75, P472, DOI 10.1016/S0003-4975(02)04370-9
   COOLEY DA, 1956, JAMA-J AM MED ASSOC, V162, P1158, DOI 10.1001/jama.1956.72970290003013a
   Coselli JS, 1997, J CARDIAC SURG, V12, P322
   Czerny M, 2003, J THORAC CARDIOV SUR, V126, P1296, DOI 10.1016/S0022-5223(03)01046-8
   DEBAKEY ME, 1957, SURG GYNECOL OBSTET, V105, P657
   DEBAKEY ME, 1954, JAMA-J AM MED ASSOC, V155, P1398
   Di Bartolomeo R, 2001, EUR J CARDIO-THORAC, V19, P765, DOI 10.1016/S1010-7940(01)00728-X
   Di Bartolomeo R., 2011, MULTIMEDIA MANUAL CA, V2011
   Di Eusanio M, 2003, ANN THORAC SURG, V76, P1181, DOI 10.1016/S0003-4975(03)00824-5
   Di Eusanio M, 2003, J THORAC CARDIOV SUR, V125, P849, DOI 10.1067/mtc.2003.8
   Di Eusanio M, 2002, J THORAC CARDIOV SUR, V124, P1080, DOI 10.1067/mtc.2002.124994
   Dumfarth J, 2013, TEX HEART I J, V40, P564
   Ehrlich MP, 2003, CIRCULATION, V108, P318, DOI 10.1161/01.cir.0000087428.63818.50
   Ehrlich MP, 2002, ANN THORAC SURG, V73, P191, DOI 10.1016/S0003-4975(01)03273-8
   Ehrlich MR, 2001, J THORAC CARDIOV SUR, V122, P331, DOI 10.1067/mtc.2001.115244
   Ergin MA, 1999, ANN THORAC SURG, V67, P1887, DOI 10.1016/S0003-4975(99)00432-4
   Etz CD, 2009, EUR J CARDIO-THORAC, V36, P946, DOI 10.1016/j.ejcts.2009.05.046
   Fischer GW, 2011, J THORAC CARDIOV SUR, V141, P815, DOI 10.1016/j.jtcvs.2010.05.017
   Fleck TM, 2003, ANN THORAC SURG, V76, P1198, DOI 10.1016/S0003-4975(03)00832-4
   FRIST WH, 1986, ANN THORAC SURG, V42, P273, DOI 10.1016/S0003-4975(10)62733-6
   Ganapathi AM, 2014, J THORAC CARDIOV SUR, V148, P2896, DOI 10.1016/j.jtcvs.2014.04.014
   Gega A, 2007, ANN THORAC SURG, V84, P759, DOI 10.1016/j.athoracsur.2007.04.107
   Goldstein LJ, 2001, J THORAC CARDIOV SUR, V122, P935, DOI 10.1067/mtc.2001.117276
   Griepp RB, 2001, J THORAC CARDIOV SUR, V121, P425, DOI 10.1067/mtc.2001.113594
   GRIEPP RB, 1975, J THORAC CARDIOV SUR, V70, P1051
   GUILMET D, 1986, PRESSE MED, V15, P1096
   Hagl C, 2003, EUR J CARDIO-THORAC, V24, P371, DOI 10.1016/S1010-7940(03)00337-3
   Hagl C, 2001, ANN THORAC SURG, V72, P1457, DOI 10.1016/S0003-4975(01)02897-1
   Haldenwang PL, 2010, ANN THORAC SURG, V90, P1975, DOI 10.1016/j.athoracsur.2010.06.111
   Halkos ME, 2009, J THORAC CARDIOV SUR, V138, P1081, DOI 10.1016/j.jtcvs.2009.07.045
   Halstead JC, 2008, J THORAC CARDIOV SUR, V135, P784, DOI 10.1016/j.jtcvs.2007.09.035
   Halstead JC, 2007, ANN THORAC SURG, V84, P768, DOI 10.1016/j.athoracsur.2007.04.051
   Harrington DK, 2007, ANN THORAC SURG, V83, pS799, DOI 10.1016/j.athoracsur.2006.11.018
   Harrington DK, 2004, ANN THORAC SURG, V78, P596, DOI 10.1016/j.athoracsur.2004.01.012
   Haverich A, 2003, J THORAC CARDIOV SUR, V125, P460, DOI 10.1067/mtc.2003.291
   Jacobs MJ, 2001, CARDIOVASC SURG, V9, P396, DOI 10.1016/S0967-2109(01)00009-6
   Jonsson O, 2011, ANN THORAC SURG, V91, P1198, DOI 10.1016/j.athoracsur.2010.12.066
   Kamiya H., 2007, J THORACIC CARDIOVAS, V133, p501e2
   Kazui T, 2000, ANN THORAC SURG, V70, P3, DOI 10.1016/S0003-4975(00)01535-6
   KAZUI T, 1994, ANN THORAC SURG, V57, P904, DOI 10.1016/0003-4975(94)90201-1
   Kazui T, 1986, Rinsho Kyobu Geka, V6, P7
   Kazui T, 2001, J THORAC CARDIOV SUR, V121, P491, DOI 10.1067/mtc.2001.112469
   Khaladj N, 2008, J THORAC CARDIOV SUR, V135, P908, DOI 10.1016/j.jtcvs.2007.07.067
   Krahenbuhl ES, 2010, EUR J CARDIO-THORAC, V38, P46, DOI 10.1016/j.ejcts.2010.01.016
   Kruger T, 2011, CIRCULATION, V124, P434, DOI 10.1161/CIRCULATIONAHA.110.009282
   Leshnower BG, 2015, ANN THORAC SURG, V100, P1563, DOI 10.1016/j.athoracsur.2015.05.032
   Leshnower BG, 2012, ANN THORAC SURG, V93, P1910, DOI 10.1016/j.athoracsur.2012.02.069
   Leshnower BG, 2010, ANN THORAC SURG, V90, P547, DOI 10.1016/j.athoracsur.2010.03.118
   Luehr M, 2014, EUR J CARDIO-THORAC, V45, P27, DOI 10.1093/ejcts/ezt154
   Ma M., 2015, J THORACIC CARDIOVAS
   Malvindi Pietro Giorgio, 2008, Interact Cardiovasc Thorac Surg, V7, P891, DOI 10.1510/icvts.2008.184184
   Mazzeffi M, 2012, ANN CARD ANAESTH, V15, P266, DOI 10.4103/0971-9784.101855
   McCullough JN, 1999, ANN THORAC SURG, V67, P1895, DOI 10.1016/S0003-4975(99)00441-5
   Milewski RK, 2010, ANN THORAC SURG, V89, P1448, DOI 10.1016/j.athoracsur.2010.01.056
   MILLS NL, 1980, J THORAC CARDIOV SUR, V80, P708
   Misfeld M, 2012, ANN THORAC SURG, V93, P1502, DOI 10.1016/j.athoracsur.2012.01.106
   Okita Y, 1998, J THORAC CARDIOV SUR, V115, P129, DOI 10.1016/S0022-5223(98)70451-9
   Okita Y, 2001, ANN THORAC SURG, V72, P72, DOI 10.1016/S0003-4975(01)02671-6
   Okita Y, 2015, J THORAC CARDIOV SUR, V149, pS65, DOI 10.1016/j.jtcvs.2014.08.070
   Olsson C, 2006, ANN THORAC SURG, V81, P868, DOI 10.1016/j.athoracsur.2005.08.079
   Panos A, 2006, EUR J CARDIO-THORAC, V29, P1036, DOI 10.1016/j.ejcts.2006.03.032
   Pape LA, 2015, J AM COLL CARDIOL, V66, P350, DOI 10.1016/j.jacc.2015.05.029
   Reich DL, 1999, J THORAC CARDIOV SUR, V117, P156, DOI 10.1016/S0022-5223(99)70481-2
   Tsai TT, 2009, EUR J VASC ENDOVASC, V37, P149, DOI 10.1016/j.ejvs.2008.11.032
   Ueda Y, 1999, ANN THORAC SURG, V67, P1879, DOI 10.1016/S0003-4975(99)00415-4
   UEDA Y, 1990, J CARDIOVASC SURG, V31, P553
   Urbanski PP, 2012, EUR J CARDIO-THORAC, V41, P185, DOI 10.1016/j.ejcts.2011.03.060
   Usui A, 1997, J THORAC CARDIOV SUR, V114, P440, DOI 10.1016/S0022-5223(97)70192-2
   Westaby S, 1997, Semin Thorac Cardiovasc Surg, V9, P246
   Wiedemann D., 2013, J THORACIC CARDIOVAS, V146, p647e1
   Zierer A, 2005, THORAC CARDIOV SURG, V53, P74, DOI 10.1055/s-2004-830458
   Zierer A, 2012, J THORAC CARDIOV SUR, V144, P1042, DOI 10.1016/j.jtcvs.2012.07.063
NR 83
TC 0
Z9 0
U1 2
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 981813
DI 10.1155/2015/981813
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CY6QL
UT WOS:000366533800001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Jayawardena, N
   Watawana, MI
   Jayathilaka, RT
   Waisundara, VY
AF Jayawardena, Nilakshi
   Watawana, Mindani I.
   Jayathilaka, Ruchini T.
   Waisundara, Viduranga Y.
TI RETRACTED: The Antioxidant and Starch Hydrolase Inhibitory Activity of
   Ten Spices in an In Vitro Model of Digestion: Bioaccessibility of
   Anthocyanins and Carotenoids(Retracted article.See 4142104,2016)
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article; Retracted Publication
AB The antioxidant and starch hydrolase inhibitory activities of cardamom, cloves, coriander, cumin seeds, curry leaves, fenugreek, mustard seeds, nutmeg, sweet cumin, and star anise extracts were investigated in an in vitro model of digestion mimicking the gastric and duodenal conditions. The total phenolic contents in all spice extracts had statistically significantly (P < 0.05) increased following both gastric and duodenal digestion. This was also in correlation with the antioxidant assays quantifying the water-soluble antioxidant capacity of the extracts. The lipophilic Oxygen Radical Absorbance Capacity assay did not indicate a statistically significant change in the values during any of the digestion phases. Statistically significant (P < 0.05) reductions in the anthocyanin contents were observed during the digestion phases in contrast to the carotenoid contents. With the exception of the cumin seed extract, none of the spice extracts showed statistically significant changes in the initial starch hydrolase enzyme inhibitory values prior to gastric and duodenal digestion. In conclusion, this study was able to prove that the 10 spices were a significant source of total phenolics, antioxidant, and starch hydrolase inhibitory activities.
C1 [Jayawardena, Nilakshi; Watawana, Mindani I.; Jayathilaka, Ruchini T.; Waisundara, Viduranga Y.] Natl Inst Fundamental Studies, Funct Food Prod Dev Project, Kandy 20000, Sri Lanka.
RP Waisundara, VY (reprint author), Natl Inst Fundamental Studies, Funct Food Prod Dev Project, Hantane Rd, Kandy 20000, Sri Lanka.
EM viduranga@gmail.com
FU National Institute of Fundamental Studies, Kandy, Sri Lanka
FX The authors acknowledge the funding and analytical support provided by
   the National Institute of Fundamental Studies, Kandy, Sri Lanka.
NR 0
TC 0
Z9 0
U1 1
U2 11
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2015
AR 764238
DI 10.1155/2015/764238
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA CY6GA
UT WOS:000366505500001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Ortega-Requena, S
   Rebouillat, S
AF Ortega-Requena, S.
   Rebouillat, S.
TI RETRACTED: Bigger data open innovation: potential applications of
   value-added products from milk and sustainable valorization of
   by-products from the dairy industry (Retracted article. See vol. 19, pg.
   3164, 2017)
SO GREEN CHEMISTRY
LA English
DT Review; Retracted Publication
ID WHEY-PROTEIN ISOLATE; ENZYMATIC CROSS-LINKING; CASEIN CONCENTRATE
   MANUFACTURE; ALPHA-LACTALBUMIN; EMULSIFYING PROPERTIES;
   BETA-LACTOGLOBULIN; CHEESE WHEY; MICROBIAL TRANSGLUTAMINASE;
   BIOSURFACTANT PRODUCTION; FUNCTIONAL-PROPERTIES
AB Milk is a natural suspension of essential nutrients and can be exploited not only as a beverage consumed directly or transformed into a range of traditional dairy foods, but also as a source of ingredients for food product innovation. In addition, by-products from the dairy industry, which used to constitute an economical and environmental problem, are still rich in proteins, lactose and minerals. Therefore, from a green point of view, they can be valorized and are being exploited for multiple food and non-food applications. This paper aims to give an overview of the different applications of milk ingredients and by-products from the dairy industry. Additionally, enzymatic modification and production of bioactive peptides and bioemulsifiers broaden their functionality and applicability. Finally, a critical review of the most promising aspects as well as some features that need further development is presented. The unmet needs, the cross fertilization in between protein domains, the carbon footprint requirements, the environmental necessities, the health and wellness new demands, etc. are dominant factors in the search for an innovation approach outlining the potential that these "apparent" constraints oblige science and technology to account for. The adjacent technology analysis opportunity that such a review generates is, in essence, an open innovation step.
C1 [Ortega-Requena, S.] Univ Murcia, Dept Chem Engn, E-30100 Murcia, Spain.
   [Rebouillat, S.] DuPont Int European Headquarters, CH-1218 Geneva, Switzerland.
RP Ortega-Requena, S (reprint author), Univ Murcia, Dept Chem Engn, Campus Espinardo, E-30100 Murcia, Spain.
EM dortega@um.es; Serge.Rebouillat@dupont.com
RI Ortega-Requena, Salvadora/L-4788-2014
OI Ortega-Requena, Salvadora/0000-0003-1536-4168
CR Adjonu R, 2014, J FOOD ENG, V122, P15, DOI 10.1016/j.jfoodeng.2013.08.034
   Audic JL, 2003, LAIT, V83, P417, DOI 10.1051/lait:2003027
   Banach JC, 2013, LWT-FOOD SCI TECHNOL, V54, P397, DOI 10.1016/j.lwt.2013.06.023
   Banaszewska A, 2014, J DAIRY SCI, V97, P1893, DOI 10.3168/jds.2013-7283
   Bendixen N., 2008, [No title captured], Patent No. [US 20080171119, 20080171119]
   Benkerroum N, 2010, INT J DAIRY TECHNOL, V63, P320, DOI 10.1111/j.1471-0307.2010.00584.x
   Bonnaillie Laetitia M, 2014, Foods, V3, P94, DOI 10.3390/foods3010094
   Brans G, 2004, J MEMBRANE SCI, V243, P263, DOI 10.1016/j.memsci.2004.06.029
   Campos JM, 2014, APPL BIOCHEM BIOTECH, V172, P3234, DOI 10.1007/s12010-014-0761-1
   Darewicz M, 2014, MED WETER, V70, P348
   Davis JP, 2005, J COLLOID INTERF SCI, V288, P412, DOI 10.1016/j.jcis.2005.03.002
   Dickinson E, 1999, COLLOID SURFACE B, V12, P139, DOI 10.1016/S0927-7765(98)00070-8
   Dickinson E, 1999, COLLOID SURFACE B, V15, P161, DOI 10.1016/S0927-7765(99)00042-9
   Dickinson E, 1997, J DAIRY SCI, V80, P2607, DOI 10.3168/jds.S0022-0302(97)76218-0
   Dickinson E, 1998, J CHEM SOC FARADAY T, V94, P1657, DOI 10.1039/a801167b
   Dickinson E, 2001, COLLOID SURFACE B, V20, P197, DOI 10.1016/S0927-7765(00)00204-6
   Dubey K, 2001, WORLD J MICROB BIOT, V17, P61, DOI 10.1023/A:1016606509385
   Ettelaie R, 2014, BIOPOLYMERS, V101, P945, DOI 10.1002/bip.22487
   Etzel M., 2014, [No title captured], Patent No. [WO 2014/127339, 2014127339]
   Faergemand M, 1998, INT DAIRY J, V8, P715, DOI 10.1016/S0958-6946(98)00111-3
   Faergemand M, 1997, J AGR FOOD CHEM, V45, P2514, DOI 10.1021/jf9609789
   Faure M., 2009, [No title captured], Patent No. [WO 2009103716-A2, 2009103716]
   Foegeding E.A., 2011, ENCY DAIRY SCI
   Fox PF, 2008, INT DAIRY J, V18, P677, DOI 10.1016/j.idairyj.2008.03.002
   Fox PF, 2001, INT J DAIRY TECHNOL, V54, P41, DOI 10.1046/j.1471-0307.2001.00014.x
   Gaonkar G., 2010, African Journal of Food Science, V4, P16
   Gauthier SF, 2003, J DAIRY SCI, V86, pE78, DOI 10.3168/jds.S0022-0302(03)74041-7
   Gilani GS, 2008, J AOAC INT, V91, P892
   Graveland-Bikker JF, 2006, TRENDS FOOD SCI TECH, V17, P196, DOI 10.1016/j.tifs.2005.12.009
   Guimaraes PMR, 2010, BIOTECHNOL ADV, V28, P375, DOI 10.1016/j.biotechadv.2010.02.002
   Han XQ, 1996, J AGR FOOD CHEM, V44, P1211, DOI 10.1021/jf950569x
   Balada EH, 2009, J AM LEATHER CHEM AS, V104, P122
   Hernandez-Ledesma B, 2011, ADV COLLOID INTERFAC, V165, P23, DOI 10.1016/j.cis.2010.11.001
   Hinz K, 2007, INT DAIRY J, V17, P289, DOI 10.1016/j.idairyj.2006.05.001
   Hoffman JR, 2004, J SPORT SCI MED, V3, P118
   Hurt E, 2010, J DAIRY SCI, V93, P5588, DOI 10.3168/jds.2010-3169
   Hurt E, 2010, J DAIRY SCI, V93, P4928, DOI 10.3168/jds.2010-3121
   Hwang JS, 2010, FOOD RES INT, V43, P133, DOI 10.1016/j.foodres.2009.09.007
   IKURA K, 1984, AGR BIOL CHEM TOKYO, V48, P2347, DOI 10.1080/00021369.1984.10866489
   Innocente N, 1998, INT DAIRY J, V8, P981, DOI 10.1016/S0958-6946(99)00021-7
   Innocente N, 2002, INT DAIRY J, V12, P69, DOI 10.1016/S0958-6946(01)00166-2
   Ipsen R, 2007, BIOTECHNOL ADV, V25, P602, DOI 10.1016/j.biotechadv.2007.07.006
   JENSEN RG, 1991, J DAIRY SCI, V74, P3228, DOI 10.3168/jds.S0022-0302(91)78509-3
   Jovanovic S., 2005, Mljekarstvo, V55, P215
   Kamau SM, 2010, FOOD REV INT, V26, P386, DOI 10.1080/87559129.2010.496025
   Karamoko G, 2013, BIOTECHNOL AGRON SOC, V17, P373
   Karasu K, 2010, INT J DAIRY TECHNOL, V63, P284, DOI 10.1111/j.1471-0307.2010.00582.x
   Kim DA, 2005, J COLLOID INTERF SCI, V285, P100, DOI 10.1016/j.jcis.2004.10.044
   Kim HO, 2006, APPL BIOCHEM BIOTECH, V131, P694, DOI 10.1385/ABAB:131:1:694
   Koutinas AA, 2009, BIORESOURCE TECHNOL, V100, P3734, DOI 10.1016/j.biortech.2009.01.058
   Kumar HRH, 2001, J SCI FOOD AGR, V81, P42, DOI 10.1002/1097-0010(20010101)81:1<42::AID-JSFA771>3.3.CO;2-H
   Kuraishi C, 2001, FOOD REV INT, V17, P221, DOI 10.1081/FRI-100001258
   Lagrange V, 2015, J FOOD SCI, V80, pA16, DOI 10.1111/1750-3841.12801
   Lapray M., 2014, INT J INNOVATION APP, V6, P299
   Lawrence ND, 2008, SEP PURIF TECHNOL, V60, P237, DOI 10.1016/j.seppur.2007.08.016
   Liu Y, 2006, CHEM ENG TECHNOL, V29, P1424, DOI 10.1002/ceat.200600223
   Lorenzen PC, 2002, INT J DAIRY TECHNOL, V55, P152, DOI 10.1046/j.1471-0307.2002.00065.x
   Lorenzen PC, 1999, KIELER MILCHW FORSCH, V51, P89
   Ma H, 2011, J AGR FOOD CHEM, V59, P1406, DOI 10.1021/jf103591p
   MAWSON AJ, 1994, BIORESOURCE TECHNOL, V47, P195, DOI 10.1016/0960-8524(94)90180-5
   Mehravar R, 2009, AFR J BIOTECHNOL, V8, P6822
   Miller G. D., 2006, HDB DAIRY FOODS NUTR, P1
   Moro A, 2013, FOOD RES INT, V51, P1, DOI 10.1016/j.foodres.2012.11.011
   Motoki M, 1998, TRENDS FOOD SCI TECH, V9, P204, DOI 10.1016/S0924-2244(98)00038-7
   Mukhopadhyay R, 2003, PROCESS BIOCHEM, V39, P381, DOI 10.1016/S0032-9592(03)00126-2
   Nagpal R, 2011, FOOD FUNCT, V2, P18, DOI 10.1039/c0fo00016g
   Nicolai T, 2011, FOOD HYDROCOLLOID, V25, P1945, DOI 10.1016/j.foodhyd.2011.02.006
   Nitschke M, 2007, TRENDS FOOD SCI TECH, V18, P252, DOI 10.1016/j.tifs.2007.01.002
   Nitschke M, 2004, BRAZ J MICROBIOL, V35, P81, DOI 10.1590/S1517-83822004000100013
   O'Regan J, 2010, FOOD CHEM, V123, P21, DOI 10.1016/j.foodchem.2010.03.115
   O'Sullivan MM, 2002, J DAIRY RES, V69, P433, DOI 10.1017/S0022029902005617
   OMahony J. A., 2007, [No title captured], Patent No. [2007055932, WO 2007/055932]
   Panyam D, 1996, TRENDS FOOD SCI TECH, V7, P120, DOI 10.1016/0924-2244(96)10012-1
   PAQUET D, 1989, LAIT, V69, P1, DOI 10.1051/lait:198911
   Patel SR, 2011, DAIRY SCI TECHNOL, V91, P53, DOI 10.1051/dst/2010036
   Phadungath C., 2005, SONGKLANAKARIN J SCI, V27, P201
   Phelan M, 2009, INT DAIRY J, V19, P643, DOI 10.1016/j.idairyj.2009.06.001
   Pouliot Y, 2008, INT DAIRY J, V18, P735, DOI 10.1016/j.idairyj.2008.03.005
   Prazeres AR, 2012, J ENVIRON MANAGE, V110, P48, DOI 10.1016/j.jenvman.2012.05.018
   Regester GO, 1999, DRUG DEVELOP RES, V46, P286, DOI 10.1002/(SICI)1098-2299(199903/04)46:3/4<286::AID-DDR14>3.3.CO;2-Y
   Rodrigues L, 2006, BIOCHEM ENG J, V28, P109, DOI 10.1016/j.bej.2005.06.001
   Roman JA, 2006, INT J FOOD SCI TECH, V41, P609, DOI 10.1111/j.1365-2621.2005.01090.x
   Rutherfurd-Markwick KJ, 2012, BRIT J NUTR, V108, pS149, DOI 10.1017/S000711451200253X
   Saboya LV, 2000, LAIT, V80, P541, DOI 10.1051/lait:2000144
   Sharma R, 2002, FOOD CHEM, V79, P493, DOI 10.1016/S0308-8146(02)00225-X
   Shete AM, 2006, J SCI IND RES INDIA, V65, P91
   Siso MIG, 1996, BIORESOURCE TECHNOL, V57, P1, DOI 10.1016/0960-8524(96)00036-3
   Skrzypek M, 2010, DESALINATION, V250, P1095, DOI 10.1016/j.desal.2009.09.116
   Smith K. E., 2001, BACKGROUND MILK PROT
   Tarhan O, 2014, BIOTECHNOL PROGR, V30, P1301, DOI 10.1002/btpr.1956
   Tenovuo J, 2002, ORAL DIS, V8, P23, DOI 10.1034/j.1601-0825.2002.1o781.x
   Udenigwe CC, 2012, J FOOD SCI, V77, pR11, DOI 10.1111/j.1750-3841.2011.02455.x
   Walstra P, 1999, INT DAIRY J, V9, P189, DOI 10.1016/S0958-6946(99)00059-X
   Wang X., 2003, [No title captured], Patent No. [CN 1415312-A, 1415312]
   Wilcox CP, 2002, J AGR FOOD CHEM, V50, P5546, DOI 10.1021/jf0117154
   Wilcox CP, 2002, J AGR FOOD CHEM, V50, P3723, DOI 10.1021/jf011603c
   Xiaohui, 2012, [No title captured], Patent No. [CN 101824085, 101824085]
   Yadav JSS, 2014, BIOPROC BIOSYST ENG, V37, P1017, DOI 10.1007/s00449-013-1072-6
   Yang ST, 1995, J DAIRY SCI, V78, P2541, DOI 10.3168/jds.S0022-0302(95)76884-9
   Yver AL, 2012, INT J MOL SCI, V13, P240, DOI 10.3390/ijms13010240
NR 100
TC 6
Z9 6
U1 3
U2 48
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9262
EI 1463-9270
J9 GREEN CHEM
JI Green Chem.
PY 2015
VL 17
IS 12
BP 5100
EP 5113
DI 10.1039/c5gc01428j
PG 14
WC Chemistry, Multidisciplinary; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY
SC Chemistry; Science & Technology - Other Topics
GA CX7XV
UT WOS:000365917200001
DA 2018-12-27
ER

PT J
AU Li, JZ
   Zhang, Y
   Wen, B
   Li, M
   Wang, YJ
AF Li, Jiu-Zhi
   Zhang, Yu
   Wen, Bin
   Li, Ming
   Wang, Yu-jie
TI RETRACTED: Ability of PITX2 methylation to predict survival in patients
   with prostate cancer (Retracted article. See vol. 9, pg. 613, 2016)
SO ONCOTARGETS AND THERAPY
LA English
DT Article; Retracted Publication
DE DNA methylation; PITX2; prognostic biomarkers; prostatic cancer
ID DNA METHYLATION; PROGRESSION; EXPRESSION
AB Background: The aim of this study was to explore whether candidate gene methylation can effectively predict death from prostate cancer.
   Methods: After reviewing the literature to identify likely candidate genes, we assembled a case-control cohort (in a 1: 2 ratio) to explore the distribution of PITX2, WNT5a, SPARC, EPB41L3, and TPM4 methylation levels. The case group comprised 45 patients with a Gleason score <= 7 who had died as a result of prostate cancer, and the control group comprised 90 current prostate cancer patients or those who died of other causes. The methylation possibility of each of the candidate genes were maximized. Univariate conditional logistic was applied for data analysis and to evaluate prediction efficiency of gene methylation on prostate cancer.
   Results: The results indicated that a raised level of PITX2 methylation increased the likelihood of death due to prostate cancer by 10% (odds ratio 1.56, 95% confidence interval 1.17-2.08; P=0.005). Methylation of SPARC was found to be able to distinguish between benign prostate hyperplasia and prostate cancer.
   Conclusion: Methylation of PITX2 is an effective biomarker to predict death from prostate cancer, particularly in patients with a low Gleason score.
C1 [Li, Jiu-Zhi; Wang, Yu-jie] Xinjiang Med Univ, Affiliated Hosp 1, Dept Urol, Urumqi 830000, Peoples R China.
   [Li, Jiu-Zhi; Zhang, Yu; Wen, Bin; Li, Ming] Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept Urol, Urumqi, Peoples R China.
RP Wang, YJ (reprint author), Xinjiang Med Univ, Affiliated Hosp 1, Dept Urol, 393 Xinyi Rd, Urumqi 830000, Peoples R China.
EM wangyujiexj@yeah.net
CR Banez LL, 2010, J UROLOGY, V184, P149, DOI 10.1016/j.juro.2010.03.012
   Berney DM, 2009, BRIT J CANCER, V100, P888, DOI 10.1038/sj.bjc.6604951
   Chao C, 2013, CANCER CAUSE CONTROL, V24, P1615, DOI 10.1007/s10552-013-0249-2
   Chou R, 2011, ANN INTERN MED, V155, P762, DOI 10.7326/0003-4819-155-11-201112060-00375
   Cuzick J, 2006, BRIT J CANCER, V95, P1186, DOI 10.1038/sj.bjc.6603411
   Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3
   DeRosa CA, 2012, PROSTATE CANCER P D, V15, P150, DOI 10.1038/pcan.2011.61
   Egevad L, 2013, HISTOPATHOLOGY, V62, P247, DOI 10.1111/his.12008
   Hernandez HG, 2013, BIOTECHNIQUES, V55, P181, DOI 10.2144/000114087
   Hessels D, 2004, EXPERT REV MOL DIAGN, V4, P513, DOI 10.1586/14737159.4.4.513
   Hou CP, 2014, ONCO TARGETS THER, V8, P15
   Li LC, 2007, FRONT BIOSCI-LANDMRK, V12, P3377, DOI 10.2741/2320
   Lin PC, 2013, NEOPLASIA, V15, P373, DOI 10.1593/neo.122146
   Majid S, 2012, CANCER RES, V72, P6435, DOI 10.1158/0008-5472.CAN-12-2181
   Richiardi L, 2009, J CLIN ONCOL, V27, P3161, DOI 10.1200/JCO.2008.18.2485
   Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Sha JJ, 2013, ONCOTARGETS THER, V6, P1501, DOI 10.2147/OTT.S47165
   Vasiljevic N, 2013, PROSTATE CANCER P D, V16, P35, DOI 10.1038/pcan.2012.47
   Weiss G, 2009, J UROLOGY, V181, P1678, DOI 10.1016/j.juro.2008.11.120
   Wilt TJ, 2008, ANN INTERN MED, V148, P435, DOI 10.7326/0003-4819-148-6-200803180-00209
   Wilt TJ, 2012, NEW ENGL J MED, V367, P203, DOI 10.1056/NEJMoa1113162
   Wong SY, 2007, P NATL ACAD SCI USA, V104, P12784, DOI 10.1073/pnas.0705499104
   Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496
   Yang Mihi, 2012, Methods Mol Biol, V863, P67, DOI 10.1007/978-1-61779-612-8_5
   Yegnasubramanian S, 2008, CANCER RES, V68, P8954, DOI 10.1158/0008-5471.CAN-07-6088
NR 25
TC 5
Z9 5
U1 2
U2 6
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2015
VL 8
BP 3507
EP 3511
DI 10.2147/OTT.S83914
PG 5
WC Biotechnology & Applied Microbiology; Oncology
SC Biotechnology & Applied Microbiology; Oncology
GA CX9PF
UT WOS:000366037000001
PM 26648742
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Cheng, J
   Liu, BJ
   Yu, HR
   Fu, QN
   Li, FH
   Zhao, Y
AF Cheng, Jun
   Liu, Bujin
   Yu, Huarong
   Fu, Qining
   Li, Fenghe
   Zhao, Yu
TI RETRACTED: Effect of early external X-ray radiation on arterial
   restenosis post percutaneous transluminal angioplasty (Retracted
   article. See vol. 9, pg. 466, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Radiotherapy; restenosis; percutaneous transluminal angioplasty; PTA;
   intimal injury; vascular smooth muscle; VSMC
ID CYTOCHROME-C RELEASE; SMOOTH-MUSCLE-CELLS; INDUCED APOPTOSIS;
   BETA-IRRADIATION; ACTIVATION; THERAPY; DISEASE
AB Background: Arterial restenosis after percutaneous transluminal angioplasty (PTA) significantly reduces its therapeutic efficacy in treating lower extremity atherosclerotic occlusive diseases (LEAOD). Early external X-ray external radiation has demonstrated positive effects on restenosis; however, effective dosing and the mechanism(s) underlying its efficacy remain unknown. This study explored the effect of early external X-ray radiation on preventing post-PTA restenosis in an iliac intimal injury model. Methods: Twenty rabbits underwent iliac intimal injury via PTA and received five different radiation doses: 0 Gy (n=4), 3 Gy (n=4), 6 Gy (n=4), 9 Gy (n=4), and 12 Gy (n=4). Four rabbits were used as controls. All subjects were fed a high-fat diet prior to PTA and for an additional four-week period post-PTA and then sacrificed for immunohistochemical and Western blotting analysis. Results: Arterial stenosis was significantly improved post-PTA. Alpha smooth muscle actin (alpha-SMA) expression in the 0 Gy to 9 Gy groups was significantly increased post-PTA. Cytochrome C (Cyt C) expression was significantly increased post-PTA and was positively correlated with radiation intensity. Proliferating cell nuclear antigen (PCNA) expression was significantly increased post-PTA with the 0 Gy group showing significantly higher expression than the 3 Gy group. No significant differences were found in CD34 levels between the groups. Conclusions: Early external X-ray radiation at 6-24 Gy doses effectively restrained VSMC hyperplasia post-PTA, likely through inducing VSMC apoptosis via mitochondrial Cyt C release. However, this technique did not significantly affect the integrity of the vascular endothelium. Therefore, early external X-ray radiation shows promise in preventing post-PTA restenosis.
C1 [Cheng, Jun; Liu, Bujin; Yu, Huarong; Fu, Qining; Li, Fenghe; Zhao, Yu] Chongqing Med Univ, Affiliated Hosp 1, Dept Vasc Surg, Chongqing 400016, Peoples R China.
RP Zhao, Y (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Vasc Surg, 1 Yixueyuan Rd, Chongqing 400016, Peoples R China.
EM zhaoyu8623@163.com
FU Medical Scientific Research Project of Chongqing [2010-2-037]
FX This work was supported by the Medical Scientific Research Project of
   Chongqing (Grant No. 2010-2-037).
CR Chen J YZ, 2006, CHIN J RADIOL MED PR, V26, P118
   Chereau D, 2005, BIOCHEMISTRY-US, V44, P4971, DOI 10.1021/bi047360+
   Crocker I, 2002, SEMIN RADIAT ONCOL, V12, P3, DOI 10.1053/srao.2002.28659
   Faglia E, 2002, J INTERN MED, V252, P225, DOI 10.1046/j.1365-2796.2002.01015.x
   Ferrario CM, 2002, AM J HYPERTENS, V15, p9S, DOI 10.1016/S0895-7061(01)02274-9
   Friesen C, 2008, Q J NUCL MED MOL IM, V52, P289
   Gao WH, 2001, J CELL SCI, V114, P2855
   Gierga DP, 2001, INT J RADIAT ONCOL, V49, P847, DOI 10.1016/S0360-3016(00)01510-8
   Heckenkamp J, 2004, J VASC SURG, V39, P1097, DOI 10.1016/j.jvs.2003.12.021
   Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585
   Kotzerke J, 2000, EUR J NUCL MED, V27, P223, DOI 10.1007/s002590050032
   Lijnen H R, 2001, Verh K Acad Geneeskd Belg, V63, P605
   Ogawa Y, 2002, INT J MOL MED, V10, P263
   Pasternak RC, 2004, CIRCULATION, V109, P2605, DOI 10.1161/01.CIR.0000128518.26834.93
   Selvin E, 2004, CIRCULATION, V110, P738, DOI 10.1161/01.CIR.0000137913.26087.F0
   van der Loo B, 2005, EUR J VASC ENDOVASC, V30, P469, DOI 10.1016/j.ejvs.2005.06.017
   Verin V, 2000, INT J RADIAT ONCOL, V46, P661, DOI 10.1016/S0360-3016(99)00426-5
   Voisard Rainer, 2006, BMC Cardiovasc Disord, V6, P32, DOI 10.1186/1471-2261-6-32
   Wang Jie, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P221
   [王志成 WANG Zhicheng], 2006, [中华放射医学与防护杂志, Chinese Journal of Radiological Medicine and Protection], V26, P151
   Wiemer M, 2011, EUROINTERVENTION, V6, P687, DOI 10.4244/EIJV6I6A117
   Yang Z, 2005, J VASC SURG, V42, P532, DOI 10.1016/j.jvs.2005.05.035
   Zhou XF YY, 2007, MED RECAPITULATE, V13, P16
   Zhu LH SW, 2001, J RAD ONCOL, V10, P126
   毕亚艳, 2005, [中国实用内科杂志, Chinese Journal of Practical Internal Medicine], V25, P245
NR 25
TC 3
Z9 3
U1 44
U2 48
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 9
BP 14944
EP 14952
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CW8TX
UT WOS:000365273300037
PM 26628976
DA 2018-12-27
ER

PT J
AU Yang, RH
   Liu, YF
   Wang, XJ
   Liang, JG
   Liu, JC
AF Yang, Rong-Hai
   Liu, Ying-Feng
   Wang, Xue-Jun
   Liang, Jian-Guang
   Liu, Jia-Chao
TI RETRACTED: Correlation between high density lipoprotein and monocyte
   subpopulations among stable coronary atherosclerotic heart disease
   patients(Retracted article.See vol.9,pg.14989,2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE High density lipoprotein; atherosclerosis; monocyte subpopulations;
   inflammation
ID CARDIOVASCULAR-DISEASE; ANGINA-PECTORIS; ARTERY-DISEASE; RISK; SUBSETS;
   HETEROGENEITY; CHOLESTEROL; EVENTS; HDL3; TNF
AB High density lipoprotein (HDL) is a structurally and functionally heterogeneous molecular particle whose function is unclear in atherosclerosis at present. Studies show that small HDL functional imbalance may exist in Coronary Atherosclerotic Heart Disease (CAD) patients. Monocyte is considered to play an important role in atherosclerosis, in accordance with the expression of superficial CD14 and CD16, it can be divided into three subpopulations. The purpose of this study was to explore the relation between HDL and monocyte subpopulations among CAD patients. We report 90 cases of stable CAD patients and define the monocyte subpopulations as classical monocyte (CD14++CD16-; CM), intermediate monocyte (CD14+CD16+; IM), and non-classical monocyte (CD14+CD16++; NCM); HDL group is measured by polyacrylamide gel electrophoresis. The results indicated that the small HDL in blood serum has a correlation with proinflammatory NCM in circulation but a negative correction with CM and no relationship with diabetes, saccharify hemoglobin, hypertension, smoking history and taking dose of statins drugs and severity of disease. In conclusion, this study primarily confirms that micromolecule HDL level correlates with the increase of non-classical monocyte subpopulations and decrease of classical monocyte quantity. Thus demonstrates the proinflammatory correlation between micromolecule HDL and internal immunity in the development of stable atherosclerosis.
C1 [Yang, Rong-Hai; Liu, Ying-Feng] Southern Med Univ, Zhujiang Hosp, Dept Cardiol, Guangzhou 510280, Guangdong, Peoples R China.
   [Yang, Rong-Hai] Sanshui Hosipital, Dept Emergency, Foshan 528100, Peoples R China.
   [Wang, Xue-Jun] Sanshui Hosipital, Dept Neurol, Foshan 528100, Peoples R China.
   [Liang, Jian-Guang; Liu, Jia-Chao] Sanshui Hosipital, Dept Cardiol, Foshan 528100, Peoples R China.
RP Liu, YF (reprint author), Southern Med Univ, Zhujiang Hosp, Dept Cardiol, Ind Ave 253, Guangzhou 510280, Guangdong, Peoples R China.
EM liuy-ingfnj@yeah.net
FU Foshan medical science research project fund [201208307]
FX The present work was granted by Foshan medical science research project
   fund (No: 201208307).
CR Arsenault BJ, 2009, ATHEROSCLEROSIS, V206, P276, DOI 10.1016/j.atherosclerosis.2009.01.044
   Barter P, 2007, NEW ENGL J MED, V357, P1301, DOI 10.1056/NEJMoa064278
   Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628
   Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536
   Camont L, 2011, TRENDS MOL MED, V17, P594, DOI 10.1016/j.molmed.2011.05.013
   Goliasch G, 2012, EUR J CLIN INVEST, V42, P631, DOI 10.1111/j.1365-2362.2011.02629.x
   Hristov M, 2011, THROMB HAEMOSTASIS, V106, P757, DOI 10.1160/TH11-07-0500
   Kashiwagi M, 2010, ATHEROSCLEROSIS, V212, P171, DOI 10.1016/j.atherosclerosis.2010.05.004
   Lagos KG, 2009, LIPIDS, V44, P9, DOI 10.1007/s11745-008-3251-9
   lmanishi T, 2010, ATHEROSCLEROSIS, V212, P628
   Nichols M, 2013, EUR HEART J, V34, P3028, DOI 10.1093/eurheartj/eht356
   Nobecourt E, 2005, DIABETOLOGIA, V48, P529, DOI 10.1007/s00125-004-1655-5
   Ottestad HO, 2006, J NUTR, V136, P877
   Pelidou Sigliti-Henrietta, 2008, Ther Clin Risk Manag, V4, P627
   Pirillo A, 2013, CARDIOLOGY, V124, P116, DOI 10.1159/000346463
   Rogacev KS, 2010, EUR HEART J, V31, P369, DOI 10.1093/eurheartj/ehp308
   Saitoh T, 2000, J AM COLL CARDIOL, V35, P655, DOI 10.1016/S0735-1097(99)00583-5
   Schlitt A, 2004, THROMB HAEMOSTASIS, V92, P419, DOI 10.1160/TH04-02-0095
   Shantsila E, 2014, ATHEROSCLEROSIS, V234, P4, DOI 10.1016/j.atherosclerosis.2014.02.009
   Zawada AM, 2012, IMMUNOBIOLOGY, V217, P1273, DOI 10.1016/j.imbio.2012.07.001
   Zhu H, 2015, INT J CLIN EXP MED, V8, P4038
   Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558
NR 22
TC 4
Z9 4
U1 1
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 9
BP 16969
EP 16977
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CW8TX
UT WOS:000365273300191
PM 26629252
DA 2018-12-27
ER

PT S
AU McLaren, BM
   van Gog, T
   Ganoe, C
   Yaron, D
   Karabinos, M
AF McLaren, Bruce M.
   van Gog, Tamara
   Ganoe, Craig
   Yaron, David
   Karabinos, Michael
BE Conati, C
   Heffernan, N
   Mitrovic, A
   Verdejo, MF
TI RETRACTED: Worked Examples are More Efficient for Learning than
   High-Assistance Instructional Software (Retracted Article. See vol. 26,
   pg. 1117, 2016)
SO ARTIFICIAL INTELLIGENCE IN EDUCATION, AIED 2015
SE Lecture Notes in Artificial Intelligence
LA English
DT Proceedings Paper; Retracted Publication
CT 17th International Conference on Artificial Intelligence in Education
   (AIED)
CY JUN 22-26, 2015
CL Univ Natl Educac Distancia, Madrid, SPAIN
SP Pearson, Carnegie Learning, Carney Inc, Univ Complutense Madrid
HO Univ Natl Educac Distancia
DE Assistance dilemma; Classroom studies; Empirical studies; Worked
   examples; Erroneous examples; Tutored problems to solve; Problem solving
AB The 'assistance dilemma', an important issue in the Learning Sciences, is concerned with how much guidance or assistance should be provided to help students learn. A recent study comparing three high-assistance approaches (worked examples, tutored problems, and erroneous examples) and one low-assistance (conventional problems) approach, in a multi-session classroom experiment, showed equal learning outcomes, with worked examples being much more efficient. To rule out that the surprising lack of differences in learning outcomes was due to too much feedback across the conditions, the present follow-up experiment was conducted, in which feedback was curtailed. Yet the results in the new experiment were the same: there were no differences in learning outcomes, but worked examples were much more efficient. These two experiments suggest that there are efficiency benefits of worked example study. Yet, questions remain. For instance, why didn't high instructional assistance benefit learning outcomes and would these results hold up in other domains?
C1 [McLaren, Bruce M.; Ganoe, Craig; Yaron, David; Karabinos, Michael] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
   [van Gog, Tamara] Erasmus Univ, Rotterdam, Netherlands.
RP McLaren, BM (reprint author), Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
EM bmclaren@cs.cmu.edu; vangog@fsw.eur.nl; ganoe@acm.org; yaron@cmu.edu;
   mk7@andrew.cmu.edu
OI Yaron, David J./0000-0001-8485-8685
CR Koedinger KR, 2007, EDUC PSYCHOL REV, V19, P239, DOI 10.1007/s10648-007-9049-0
   McLaren BM, 2014, LECT NOTES COMPUT SC, V8474, P354, DOI 10.1007/978-3-319-07221-0_44
   PAAS FGWC, 1992, J EDUC PSYCHOL, V84, P429, DOI 10.1037//0022-0663.84.4.429
NR 3
TC 3
Z9 3
U1 0
U2 6
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0302-9743
BN 978-3-319-19773-9; 978-3-319-19772-2
J9 LECT NOTES ARTIF INT
PY 2015
VL 9112
BP 710
EP 713
DI 10.1007/978-3-319-19773-9_98
PG 4
WC Computer Science, Artificial Intelligence; Computer Science,
   Interdisciplinary Applications; Computer Science, Theory & Methods
SC Computer Science
GA BD9OU
UT WOS:000365041100098
DA 2018-12-27
ER

PT J
AU Zhou, JM
AF Zhou, Jianming
TI RETRACTED: A Design of 45-Degree Dual-Polarization Broadband Plane
   Station Antenna(Retracted article. See Artn 6371861,2016)
SO INTERNATIONAL JOURNAL OF ANTENNAS AND PROPAGATION
LA English
DT Article; Retracted Publication
ID MICROSTRIP PATCH ANTENNA; PROBE
AB A new broadband planar dual-polarization base station antenna is proposed, the antenna consists of two broadband plane coplanar base station antenna units, and so it has features of plane antenna. Two broadband plane station antenna units can, respectively, form double polarization in the direction. We analyzed the relative positions between the two antenna units and their effects on the performances of the antenna, especially for the influence of isolation. Broadband antenna has the characteristics of the broadband station antenna, and bandwidth is also guaranteed. The measured results show that the antenna can obtain 45% relative bandwidth, and 30 dB isolation degree also can be got, and the radiation performance is also good. Measurement results confirmed that the antenna gain can be guaranteed among 48% relative bandwidth, 15 dB of gain is got among bandwidth of 1.69-2.78GHz, the isolation degree of different polarization method can reach 30 dB, and the measurement gain of two polarization methods of antenna both can reach 8.5 dBi.
C1 [Zhou, Jianming] Beijing Inst Technol, Sch Informat & Elect, Beijing 100081, Peoples R China.
RP Zhou, JM (reprint author), Beijing Inst Technol, Sch Informat & Elect, Beijing 100081, Peoples R China.
EM zhoujm@bit.edu.cn
CR Abass Ademola, 2010, P IEEE AS PAC C APPL, P1
   Bao Z., 2013, P INT S ANT PROP ISA, P1237
   Bao Z. D., 2014, IEEE T ANTENN PROPAG, V62, P450
   Denidni T. A., 1999, P INT MICR OPT C SBM, V2, P654
   Guo YX, 2003, IEEE T ANTENN PROPAG, V51, P1955, DOI 10.1109/TSP.2003.815430
   Kasemodel JA, 2010, IEEE ANTENN WIREL PR, V9, P787, DOI 10.1109/LAWP.2010.2063010
   Kishk AA, 2004, IEEE T ANTENN PROPAG, V52, P59, DOI 10.1109/TAP.2003.820979
   Li BA, 2012, IEEE ANTENN WIREL PR, V11, P427, DOI 10.1109/LAWP.2012.2195149
   Luk KM, 1998, ELECTRON LETT, V34, P1442, DOI 10.1049/el:19981009
   Mak CL, 2000, IEEE T ANTENN PROPAG, V48, P777, DOI 10.1109/8.855497
   Mak CL, 2005, IEEE T VEH TECHNOL, V54, P33, DOI 10.1109/TVT.2004.838899
   Mak KM, 2007, IEEE ANTENN WIREL PR, V6, P126, DOI 10.1109/LAWP.2007.893106
   POZAR DM, 1985, ELECTRON LETT, V21, P49, DOI 10.1049/el:19850034
   Su DY, 2005, IEEE ANTENN WIREL PR, V4, P433, DOI 10.1109/LAWP.2005.860191
   VANDENBOSCH GAE, 1994, IEEE T ANTENN PROPAG, V42, P1648, DOI 10.1109/8.362807
NR 15
TC 2
Z9 2
U1 3
U2 9
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA
SN 1687-5869
EI 1687-5877
J9 INT J ANTENN PROPAG
JI Int. J. Antennas Propag.
PY 2015
AR 297521
DI 10.1155/2015/297521
PG 9
WC Engineering, Electrical & Electronic; Telecommunications
SC Engineering; Telecommunications
GA CW8DV
UT WOS:000365230600001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Liang, X
   Zhou, M
   Feng, JJ
   Wu, L
   Fang, SP
   Ge, XY
   Sun, HJ
   Ren, PC
   Lv, X
AF Liang, Xiao
   Zhou, Miao
   Feng, Jiao-Jiao
   Wu, Liang
   Fang, Shang-Ping
   Ge, Xin-Yu
   Sun, Hai-Jing
   Ren, Peng-Cheng
   Lv, Xin
TI RETRACTED: Efficacy of dexmedetomidine on postoperative nausea and
   vomiting: a meta-analysis of randomized controlled trials(Retracted
   article. See vol.9, pg.20465,2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Dexmedetomidine; meta-analysis; nausea; vomiting
ID TOTAL INTRAVENOUS ANESTHESIA; PATIENT-CONTROLLED ANALGESIA; SINGLE-DOSE
   DEXMEDETOMIDINE; CONTROLLED-TRIAL; DOUBLE-BLIND; SPINAL-ANESTHESIA;
   INTRAOPERATIVE DEXMEDETOMIDINE; PEDIATRIC ADENOTONSILLECTOMY;
   PERIOPERATIVE HEMODYNAMICS; INTRANASAL DEXMEDETOMIDINE
AB Purpose: Postoperative nausea and vomiting (PONV) is a frequent complication in postoperative period. The aim of the current meta-analysis was to assess the efficacy of dexmedetomidine on PONV. Methods: Two researchers independently searched PubMed, Embase and Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs). The meta-analysis was performed with Review Manager. Results: Eighty-two trials with 6,480 patients were included in this meta-analysis. Dexmedetomidine reduced postoperative nausea (Risk Ratio (RR) = 0.61, 95% confidence interval (CI): 0.50 to 0.73) and vomiting (RR = 0.48, 95% CI: 0.36 to 0.64) compared with placebo, with an effective dose of 0.5 ug/kg (RR = 0.46, 95% CI: 0.34 to 0.62) and 1.0 ug/kg (RR = 0.29, 95% CI: 0.12 to 0.75), respectively. The antiemetic effect can only be achieved intravenously, not epidurally or intrathecally. The efficacy of dexmedetomidine was similar to that of widely used agents, such as propofol, midazolam etc., but better than opioid analgesics. Moreover, application of dexmedetomidine reduced intraoperative requirement of fentanyl (Standard Mean Difference = -1.91, 95% CI: -3.20 to -0.62). Conclusions: The present meta-analysis indicates that dexmedetomidine shows superiority to placebo, but not to all other anesthetic agents on PONV. And this efficacy may be related to a reduced consumption of intraoperative opioids.
C1 [Liang, Xiao] Jiangsu Univ, Affiliated Peoples Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China.
   [Zhou, Miao; Wu, Liang] Xuzhou Med Coll, Jiangsu Prov Key Lab Anesthesiol, Xuzhou, Peoples R China.
   [Zhou, Miao; Wu, Liang] Xuzhou Med Coll, Jiangsu Prov Key Lab Anesthesia & Analgesia Appli, Xuzhou, Peoples R China.
   [Feng, Jiao-Jiao] Second Mil Med Univ, Sch Basic Med, Dept Med Microbiol & Parasitol, Nanjing, Jiangsu, Peoples R China.
   [Fang, Shang-Ping; Sun, Hai-Jing] Second Mil Med Univ, Changzheng Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China.
   [Ge, Xin-Yu] Hebei North Univ, Sch Med, Zhangjiakou, Hebei, Peoples R China.
   [Ren, Peng-Cheng] Fourth Mil Med Univ, Affiliated Tangdu Hosp, Dept Anesthesiol, Xian 710038, Peoples R China.
   [Lv, Xin] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Anesthesiol, Shanghai 200433, Peoples R China.
RP Lv, X (reprint author), Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Anesthesiol, 507 Zhengmin Rd, Shanghai 200433, Peoples R China.
EM tdrpch@163.com; xinlvg@126.com
FU Shanghai Municipal Science and Technology Commission [12ZR1439400];
   Shanghai Municipal Bureau of Health Fund [201243423]
FX This study was supported by the funds from Shanghai Municipal Science
   and Technology Commission (12ZR1439400) and Shanghai Municipal Bureau of
   Health Fund (201243423).
CR Abdelmageed WM, 2011, SAUDI J ANAESTH, V5, P150, DOI 10.4103/1658-354X.82782
   Agarwal Sandhya, 2014, J Anaesthesiol Clin Pharmacol, V30, P36, DOI 10.4103/0970-9185.125701
   Aksu R, 2009, CURR THER RES CLIN E, V70, P209, DOI 10.1016/j.curtheres.2009.06.003
   Ali Monaz Abdulrahman, 2013, Saudi J Anaesth, V7, P296, DOI 10.4103/1658-354X.115363
   Almarakbi WA, 2014, SAUDI J ANAESTH, V8, P161, DOI 10.4103/1658-354X.130683
   Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022
   Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x
   Bajwa Sukhminder Jit Singh, 2012, J Anaesthesiol Clin Pharmacol, V28, P86, DOI 10.4103/0970-9185.92452
   Bajwa SJS, 2011, SAUDI J ANAESTH, V5, P365, DOI 10.4103/1658-354X.87264
   Bajwa SJS, 2011, INDIAN J ANAESTH, V55, P116, DOI 10.4103/0019-5049.79883
   Bakhamees Hassan S., 2007, Middle East Journal of Anesthesiology, V19, P537
   Bindu Barkha, 2013, J Anaesthesiol Clin Pharmacol, V29, P162, DOI 10.4103/0970-9185.111665
   Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb
   Bulow NMH, 2007, J CLIN ANESTH, V19, P280, DOI 10.1016/j.jclinane.2007.01.004
   Carlisle JB, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CS004125.pub2
   Chaves Thatiany Pereira, 2003, Rev. Bras. Anestesiol., V53, P419, DOI 10.1590/S0034-70942003000400001
   Chen JY, 2013, CAN J ANESTH, V60, P385, DOI 10.1007/s12630-013-9886-x
   Cheung CW, 2011, CLIN J PAIN, V27, P377, DOI 10.1097/AJP.0b013e318208c8c5
   Cicek Muslum, 2006, Pain Clinic, V18, P395, DOI 10.1179/016911106779499028
   Demiraran Y, 2007, CAN J GASTROENTEROL, V21, P25, DOI 10.1155/2007/350279
   Dinesh CN, 2014, SAUDI J ANAESTH, V8, P202, DOI 10.4103/1658-354X.130719
   EISENACH JC, 1994, ANESTHESIOLOGY, V80, P1349, DOI 10.1097/00000542-199406000-00023
   El Shamaa HA, 2014, SAUDI J ANAESTH, V8, P155, DOI 10.4103/1658-354X.130677
   Elcicek K, 2010, J ANESTH, V24, P544, DOI 10.1007/s00540-010-0939-9
   Elkassem SA, 2008, EGYPT J ANAESTH, V24, P261
   Elvan EG, 2008, EUR J ANAESTH, V25, P357, DOI 10.1017/S0265021507003110
   Erdil F, 2009, ANAESTH INTENS CARE, V37, P571
   Esmaoglu A, 2013, BALK MED J, V30, P186, DOI 10.5152/balkanmedj.2013.7082
   Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233
   Goksu S, 2008, EUR J ANAESTH, V25, P22, DOI 10.1017/S0265021507001317
   Green S, 2008, COCHRANE HDB SYSTEMA, P649, DOI DOI 10.1002/9780470712184
   Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x
   Gupta M, 2014, J CLIN DIAGN RES, V8, P114, DOI 10.7860/JCDR/2014/7883.4023
   Gupta N, 2013, J NEUROSURG ANESTH, V25, P271, DOI 10.1097/ANA.0b013e31828cb6c0
   Gupta R, 2011, INDIAN J ANAESTH, V55, P347, DOI 10.4103/0019-5049.84841
   Gupta Rajni, 2011, J Anaesthesiol Clin Pharmacol, V27, P339, DOI 10.4103/0970-9185.83678
   Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622
   Gyanesh P, 2014, J ANESTH, V28, P12, DOI 10.1007/s00540-013-1657-x
   Hasanin AS, 2014, EGYPT J ANAESTH, V30, P21, DOI 10.1016/j.egja.2013.09.006
   Herr DL, 2003, J CARDIOTHOR VASC AN, V17, P576, DOI 10.1053/S1053-0770(03)00200-3
   Hong JY, 2012, ACTA ANAESTH SCAND, V56, P382, DOI 10.1111/j.1399-6576.2011.02614.x
   Hoy SM, 2011, DRUGS, V71, P1481, DOI 10.2165/11207190-000000000-00000
   Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x
   Jain D, 2012, SOUTH AFR J ANAESTH, V18, P105, DOI 10.1080/22201173.2012.10872835
   Jalowiecki P, 2005, ANESTHESIOLOGY, V103, P269, DOI 10.1097/00000542-200508000-00009
   Jung HS, 2011, J INT MED RES, V39, P1890, DOI 10.1177/147323001103900533
   Kamal MM, 2014, EGYPT J ANAESTH, V30, P137, DOI 10.1016/j.egja.2013.12.001
   Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x
   Karaaslan K, 2007, CURR THER RES CLIN E, V68, P69, DOI 10.1016/j.curtheres.2007.04.001
   Kaygusuz K, 2008, ANESTH ANALG, V106, P114, DOI 10.1213/01.ane.0000296453.75494.64
   Kim SH, 2013, MINERVA ANESTESIOL, V79, P1248
   Kim SY, 2013, J VASC INTERV RADIOL, V24, P779, DOI 10.1016/j.jvir.2013.02.034
   Lee C, 2013, KOREAN J ANESTHESIOL, V64, P301, DOI 10.4097/kjae.2013.64.4.301
   Lin YY, 2012, CRIT CARE, V16, DOI 10.1186/cc11646
   Manuar MB, 2014, SAUDI J ANAESTH, V8, P233, DOI 10.4103/1658-354X.130727
   Massad IM, 2009, SAUDI MED J, V30, P1537
   Mazanikov M, 2013, SURG ENDOSC, V27, P2163, DOI 10.1007/s00464-012-2734-1
   Mizrak A, 2013, J SURG RES, V179, P94, DOI 10.1016/j.jss.2012.09.014
   Mizrak A, 2010, J SURG RES, V164, P242, DOI 10.1016/j.jss.2009.03.005
   Mizrak A, 2010, J SURG RES, V159, pE11, DOI 10.1016/j.jss.2009.07.031
   Mountain Brian W, 2011, AANA J, V79, P219
   Nasr Dalia Abdelhamid Mohamed, 2011, J Opioid Manag, V7, P337
   Neogi M, 2010, J ANAESTHESIOL CLIN, V26, P149
   Nie YY, 2014, EUR J ANAESTH, V31, P197, DOI 10.1097/EJA.0000000000000011
   Ohtani N, 2011, J ANESTH, V25, P872, DOI 10.1007/s00540-011-1239-8
   Olutoye OA, 2010, ANESTH ANALG, V111, P490, DOI 10.1213/ANE.0b013e3181e33429
   Ozkose Z, 2006, TOHOKU J EXP MED, V210, P153, DOI 10.1620/tjem.210.153
   Peng K, 2014, J RES MED SCI, V19, P549
   Piao GY, 2014, ARCH MED SCI, V10, P19, DOI 10.5114/aoms.2014.40730
   Rashiq Saifudin, 2003, BMC Med Inform Decis Mak, V3, P3, DOI 10.1186/1472-6947-3-3
   Rutkowska K, 2009, EUR J ANAESTH, V26, P851, DOI 10.1097/EJA.0b013e32832a2244
   Salman N, 2009, SAUDI MED J, V30, P77
   Sato M, 2010, J ANESTH, V24, P675, DOI 10.1007/s00540-010-0976-4
   Sethl P, 2014, INDIAN J ANAESTH, V58, P18, DOI 10.4103/0019-5049.126782
   Shahi Vaibhav, 2014, J Anaesthesiol Clin Pharmacol, V30, P538, DOI 10.4103/0970-9185.142852
   Shehabi Y, 2009, ANESTHESIOLOGY, V111, P1075, DOI 10.1097/ALN.0b013e3181b6a783
   Sheta SA, 2014, PEDIATR ANESTH, V24, P181, DOI 10.1111/pan.12287
   Shin HW, 2013, KOREAN J ANESTHESIOL, V65, P114, DOI 10.4097/kjae.2013.65.2.114
   Singh C, 2014, PEDIATR ANESTH, V24, P1252, DOI 10.1111/pan.12493
   Smith I, 2008, EUR J ANAESTH, V25, P790, DOI 10.1017/S026502150800464X
   Sun Y, 2014, PEDIATR ANESTH, V24, P863, DOI 10.1111/pan.12391
   Tarbeeh GA, 2013, EGYPT J ANAESTH, V29, P13, DOI 10.1016/j.egja.2012.08.008
   Techanivate Anchalee, 2012, Journal of the Medical Association of Thailand, V95, P383
   Tekin M, 2007, CURR THER RES CLIN E, V68, P313, DOI 10.1016/j.curtheres.2007.10.006
   Tufanogullari B, 2008, ANESTH ANALG, V106, P1741, DOI 10.1213/ane.0b013e318172c47c
   Turan G, 2008, EUR J ANAESTH, V25, P816, DOI 10.1017/S0265021508004201
   Turgut N, 2008, MINERVA ANESTESIOL, V74, P469
   Turgut Namigar, 2009, Middle East Journal of Anesthesiology, V20, P63
   Unlugenc H, 2005, EUR J ANAESTH, V22, P386, DOI 10.1017/S0265021505000669
   Verma R, 2014, INDIAN J OTOL, V20, P70, DOI 10.4103/0971-7749.131872
   Visser K, 2001, ANESTHESIOLOGY, V95, P616, DOI 10.1097/00000542-200109000-00012
   Wan Lin-jun, 2011, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V23, P543
   WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023
   WATCHA MF, 1995, INT ANESTHESIOL CLIN, V33, P1, DOI 10.1097/00004311-199500000-00001
   Wellisch OM, 2012, REG ANESTH PAIN MED, P37
   Wu HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093114
   Wu Yawen, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P611
   Wu Zi-Lin, 2011, Nan Fang Yi Ke Da Xue Xue Bao, V31, P701
   Yektas A, 2014, PAIN RES MANAG, V19, P75, DOI 10.1155/2014/956825
   Yildiz Munise, 2006, Drugs R D, V7, P43, DOI 10.2165/00126839-200607010-00004
   Zhang CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099718
   Zhao Xiaochun, 2014, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V26, P239, DOI 10.3760/cma.j.issn.2095-4352.2014.04.008
NR 102
TC 8
Z9 8
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 8
BP 12113
EP 12134
PG 22
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CW8TJ
UT WOS:000365271900025
PM 26550123
DA 2018-12-27
ER

PT J
AU Zhao, J
   Zhang, ZR
   Zhao, N
   Ma, BA
   Fan, QY
AF Zhao, Jian
   Zhang, Zi-Ru
   Zhao, Na
   Ma, Bao-An
   Fan, Qing-Yu
TI RETRACTED: VEGF silencing inhibits human osteosarcoma angiogenesis and
   promotes cell apoptosis via PI3K/AKT signaling pathway(Retracted
   article. See vol. 75, pg. 255, 2017)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Cell apoptosis; angiogenesis; lentivirus-mediated short hairpin RNA
   (Lv-shRNA); U2OS cells; vascular endothelial growth factor (VEGF)
ID TUMOR ANGIOGENESIS; GENE-THERAPY; GROWTH; RECEPTOR; CANCER; METASTASIS;
   EXPRESSION; INDUCTION; SECRETION; SARCOMA
AB Vascular endothelial growth factor (VEGF) is one of the most potently angiogenic factors which promotes generation of tumor vasculature. VEGF is usually up-regulated in multiple cancers include osteosarcoma and gliomas. To further explore the potential molecular mechanism that inhibits tumor growth induced by interference of VEGF expression, we constructed an Lv-shVEGF vector and assessed the efficiency of VEGF silencing and its influence on U2OS cells. Our data demonstrated that Lv-shVEGF has high inhibition efficiency on VEGF expression, which inhibits proliferation and promotes apoptosis of U2OS cells in vitro. Our results also indicated that inhibition of VEGF expression suppresses osteosarcoma tumor growth in vivo, VEGF inhibition reduces osteosarcoma angiogenesis. We also found that the phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) activation was considerably reduced after osteosarcoma cells were treated with Lv-shVEGF. Taken together, our data demonstrated that VEGF silencing suppresses cells proliferation, promotes cells apoptosis and reduces osteosarcoma angiogenesis through inactivation of PI3K/AKT signaling pathway.
C1 [Zhao, Jian; Zhang, Zi-Ru; Ma, Bao-An; Fan, Qing-Yu] Fourth Mil Med Univ, Tangdu Hosp, Orthoped Oncol Inst Chinese PLA, Dept Orthoped Surg, Xian 710038, Shaanxi Provinc, Peoples R China.
   [Zhao, Na] Fourth Mil Med Univ, Tangdu Hosp, Dept Outpatient, Xian 710038, Shaanxi Provinc, Peoples R China.
RP Fan, QY (reprint author), Fourth Mil Med Univ, Tangdu Hosp, Orthoped Oncol Inst Chinese PLA, Dept Orthoped Surg, 569 Xinsi Rd, Xian 710038, Shaanxi Provinc, Peoples R China.
EM bonetm@fmmu.edu.cn
CR Baker GJ, 2014, NEOPLASIA, V16, P543, DOI 10.1016/j.neo.2014.06.003
   Bielack S, 2008, ANN ONCOL, V19, P94, DOI 10.1093/annonc/mdn102
   Courties G, 2009, EXPERT OPIN BIOL TH, V9, P535, DOI [10.1517/14712590902926089, 10.1517/14712590902926089 ]
   DuBois S, 2007, CANCER, V109, P813, DOI 10.1002/cncr.22455
   Fukuhara Munehisa, 2005, Journal of Nippon Medical School, V72, P155, DOI 10.1272/jnms.72.155
   Jendreyko N, 2005, P NATL ACAD SCI USA, V102, P8293, DOI 10.1073/pnas.0503168102
   Jin X, 2011, CANCER RES, V71, P7125, DOI 10.1158/0008-5472.CAN-11-1330
   Kawashima H, 2003, CANCER SCI, V94, P70, DOI 10.1111/j.1349-7006.2003.tb01354.x
   Kitamura T, 2008, NAT CELL BIOL, V10, P329, DOI 10.1038/ncb1695
   Lee L, 2006, CANCER CHEMOTH PHARM, V57, P761, DOI 10.1007/s00280-005-0120-6
   Leidi M, 2010, EUR J CELL BIOL, V89, P654, DOI 10.1016/j.ejcb.2010.05.001
   Majeti BK, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-213
   Mikulic D, 2004, PEDIATR HEMAT ONCOL, V21, P611, DOI 10.1080/08880010490501015
   Mosch B, 2010, J ONCOL, V2010, DOI DOI 10.1155/2010/135285
   Ohba T, 2014, MOL CANCER RES, V12, P1100, DOI 10.1158/1541-7786.MCR-14-0037
   Qi L, 2014, GENET MOL RES, V13, P5094, DOI 10.4238/2014.July.7.2
   Roorda BD, 2010, EUR J CANCER, V46, P974, DOI 10.1016/j.ejca.2009.12.027
   Valdehita A, 2012, MOL CELL ENDOCRINOL, V348, P241, DOI 10.1016/j.mce.2011.08.031
   Wang SW, 2015, CARCINOGENESIS, V36, P104, DOI 10.1093/carcin/bgu218
   Wei MH, 1996, HUM GENET, V97, P794
   Weiss KR, 2006, CLIN ORTHOP RELAT R, P111, DOI 10.1097/01.blo.0000229333.98781.56
   Won YW, 2012, J CONTROL RELEASE, V160, P525, DOI 10.1016/j.jconrel.2012.03.010
   Wu J, 2012, INT J MOL SCI, V13, P12573, DOI 10.3390/ijms131012573
   Xu M, 2015, TECHNOL CANCER RES T, V14, P369, DOI 10.1177/1533034614500424
   YAMAGUCHI H, 1988, INT ORTHOP, V12, P305, DOI 10.1007/BF00317829
   Zhu KQ, 2005, BURNS, V31, P5, DOI 10.1016/j.burns.2004.08.010
NR 26
TC 14
Z9 14
U1 2
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 8
BP 12411
EP 12417
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CW8TJ
UT WOS:000365271900054
PM 26550152
DA 2018-12-27
ER

PT J
AU Bao, J
   Li, JS
   Li, DY
   Li, ZJ
AF Bao, Jie
   Li, Jiansheng
   Li, Dongying
   Li, Zhenjie
TI RETRACTED: Correlation between expression of NF-E2-related factor 2 and
   progression of gastric cancer(Retracted article. See vol.10,pg.770,2017)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Nuclear factor E2-related factor 2 (Nrf2); gastric cancer; antioxidant
ID SQUAMOUS-CELL CARCINOMAS; LUNG-CANCER; GASTRIC-CANCER;
   CLINICOPATHOLOGICAL FEATURES; ANTIOXIDANT RESPONSE; GALLBLADDER CANCER;
   SIGNALING PATHWAY; OXIDATIVE STRESS; NRF2; RESISTANCE
AB Objective: Nuclear factor E2-related factor 2 (Nrf2) plays a part in antioxidant and phase II detoxification enzymes in cells by the up regulation of many antioxidant response elements (ARE) related gene transcription. Nrf2 not only protect the normal cells, but also can protect cancer cells from the effect of cell stress, which is helpful to the survival of cancer cell. Some studies show that the expression of Nrf2 has important clinical significance in cancer patients, but the analysis of gastrointestinal tumor Nrf2 comprehensive expression has not been reported. The aim of this study is to evaluate the expression of Nrf2 in gastric cancer by immunohistochemistry and analyze its related clinical significance. Methods: 180 cases of gastric cancer patients receive the gastrectomy and lymphadenectomy, and the resection of tissue is expressesd in paraffin embedded sections by immunohistochemical analysis of Nrf2. And the difference between groups use chi(2) (chi-square criterion) test, and will be analyzed by Fisher's exact test and Mann-Whitney U test. Use univariate and multivariate analysis, Kaplan-Meier curve and log-rank to test and evaluate the correlation between the expression of Nrf2 and the clinical pathological features. Results: The immune reaction of Nrf2 is mainly found in gastric cancer cell nucleus, which positive expression is closely related to the tumor size, depth of invasion, lymph node metastasis, lymphatic invasion and histological analysis (all P<0.05). The log-rank test shows that the survival rate of Nrf2 positive expression group is significantly lower than that of the negative expression group (P<0.01). The Nrf2 positive expression is closely related to the drug resistance of adjuvant chemotherapy on the basis of 5FU (P=0.022). Conclusion: There is a positive correlation between the expression of Nrf2 and the invasion of gastric cancer, which can be used as a potential indicator of patients' poor prognosis.
C1 [Bao, Jie; Li, Jiansheng; Li, Dongying; Li, Zhenjie] Zhengzhou Univ, Affiliated Hosp 1, Dept Gastroenterol, Zhengzhou 450052, Peoples R China.
RP Li, JS (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Gastroenterol, Zhengzhou 450052, Peoples R China.
EM jiansheng_li11@126.com
CR Banning A, 2005, MOL CELL BIOL, V25, P4914, DOI 10.1128/MCB.25.12.4914-4923.2005
   Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23
   Chen Y, 2007, MOL INTERV, V7, P147, DOI 10.1124/mi.7.3.6
   Cho JM, 2008, CANCER LETT, V260, P96, DOI 10.1016/j.canlet.2007.10.022
   Engin AB, 2011, MOL BIOL REP, V38, P5379, DOI 10.1007/s11033-011-0690-9
   Grogan TM, 2000, HUM PATHOL, V31, P475, DOI 10.1053/hp.2000.6546
   Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822
   Hu XF, 2013, ASIAN PAC J CANCER P, V14, P5231, DOI 10.7314/APJCP.2013.14.9.5231
   Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023
   Katoh Y, 2001, GENES CELLS, V6, P857, DOI 10.1046/j.1365-2443.2001.00469.x
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kim HR, 2008, LUNG CANCER, V60, P47, DOI 10.1016/j.lungcan.2007.09.021
   Kim JH, 2007, CLIN CANCER RES, V13, P3875, DOI 10.1158/1078-0432.CCR-06-2893
   Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653
   Lagarde SM, 2006, J CLIN ONCOL, V24, P4347, DOI 10.1200/JCO.2005.04.9445
   Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003
   Li WG, 2009, MOL CARCINOGEN, V48, P91, DOI 10.1002/mc.20465
   Ma XD, 2012, CANCER CHEMOTH PHARM, V69, P485, DOI 10.1007/s00280-011-1722-9
   Ni JM, 2012, HEPATO-GASTROENTEROL, V59, P671, DOI 10.5754/hge12177
   Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082
   Shibata T, 2010, CANCER RES, V70, P9095, DOI 10.1158/0008-5472.CAN-10-0384
   Shigematsu H, 2005, J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055
   Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352
   Stacy DR, 2006, HEAD NECK-J SCI SPEC, V28, P813, DOI 10.1002/hed.20430
   Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960
   Wang JS, 2010, J SURG RES, V164, pE99, DOI 10.1016/j.jss.2010.05.058
   Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095
   Warneke VS, 2011, J CLIN ONCOL, V29, P2364, DOI 10.1200/JCO.2010.34.4358
   Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004
   Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974
   Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589
NR 33
TC 7
Z9 7
U1 3
U2 9
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 8
BP 13235
EP 13242
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CW8TJ
UT WOS:000365271900150
PM 26550248
DA 2018-12-27
ER

PT J
AU Wu, GZ
   Pan, CX
   Jiang, D
   Zhang, Q
   Li, Y
   Zheng, SY
AF Wu, Guang-Zhou
   Pan, Chun-Xia
   Jiang, Dong
   Zhang, Qiang
   Li, Yin
   Zheng, Shi-Ying
TI RETRACTED: Clinicopathological significance of Fas and Fas ligand
   expressions in esophageal cancer (Retracted article. See vol. 6, pg.
   126, 2016)
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article; Retracted Publication
DE Esophageal carcinoma; Fas ligand (FasL); counterattack; immune privilege
ID DEATH FACTOR; T-CELLS; IN-VIVO; CARCINOMA; APOPTOSIS; LYMPHOCYTES;
   REJECTION
AB Esophageal carcinomas have recently been shown to express Fas ligand (FasL) and down-regulate Fas to escape from host immune surveillance. However, the prognostic importance of Fas/FasL and their correlation with clinicopathological characteristics are yet to be delineated in this highly malignant carcinoma. Specimens from 106 esophageal squamous cell carcinoma patients were used for immuno-histochemical evaluation of Fas, FasL, and CD8 expressions. Fifty-two (49%) and 34 (32%) patients were positive for FasL and Fas, respectively. There were no associations between FasL expression and clinicopathological characteristics except lymph vessel invasion. Strong FasL expression correlated with significant (P < 0.001) decrease in tumor nest CD81 cells. However, neither FasL nor CD81 had any impact on patient survival. Strong Fas expression was correlated with depth of invasion (40.3% in pT1, T2 versus 20.5% in pT3, T4; P5 0.0308), histological differentiation (45.7% in well versus 25.4% in nonwell; P < 0.05), and lymph node metastasis (22.6% in positive versus 45.5% in negative; P < 0.01). Fas expression was one of the independent favorable prognosticators for patients' survival (risk ratio, 3.26; P < 0.01) in esophageal SCC. Fas expression was an independent prognosticator for recurrencefree survival, whereas FasL expression did not influence the survival in esophageal squamous cell carcinoma. Down-regulation of tumor Fas may be the hallmark of immune privilege for the tumor, thus causing the patients' poorer outcome. Tumor FasL may counterattack the host immune cells to such an extent that the prognosis is not affected.
C1 [Wu, Guang-Zhou] First Peoples Hosp Yancheng, Dept Cardiothorac Surg, Yancheng 224006, Jiangsu, Peoples R China.
   [Jiang, Dong; Zhang, Qiang; Zheng, Shi-Ying] Soochow Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Suzhou 215006, Jiangsu, Peoples R China.
   [Li, Yin] Tumor Hosp Henan, Dept Thorac Surg, Zhengzhou 450008, Henan Province, Peoples R China.
   [Pan, Chun-Xia] Third Peoples Hosp Dalian, Dalian 116000, Peoples R China.
RP Zheng, SY (reprint author), Soochow Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, Suzhou 215006, Jiangsu, Peoples R China.
EM shiyingzhengdoc@163.com
FU Jiangsu Province's Key Discipline of Medicine [XK201118]; Medical
   Scientific Foundation of Jiangsu Province [H200147, H200354]
FX This work was supported by Jiangsu Province's Key Discipline of Medicine
   (XK201118) and the Medical Scientific Foundation of Jiangsu Province,
   No. H200147, H200354.
CR Ademmer K, 1998, CLIN EXP IMMUNOL, V112, P21
   BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0
   Bennett MW, 1998, J IMMUNOL, V160, P5669
   BUSCH C, 1988, ANTICANCER RES, V8, P81
   Daly JM, 1996, CANCER, V78, P1820, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z
   FREEMAN MR, 1995, CANCER RES, V55, P4140
   Glass A, 1996, J IMMUNOL, V156, P3638
   Gratas C, 1998, CANCER RES, V58, P2057
   Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363
   HAHNE M, 1995, INT IMMUNOL, V7, P1381, DOI 10.1093/intimm/7.9.1381
   IIZUKA T, 1989, CHEST, V96, P1005, DOI 10.1378/chest.96.5.1005
   International Union Against Cancer staff, 1997, TNM CLASSIFICATION M
   KAJITANI T, 1981, JPN J SURG, V11, P127
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Naito Y, 1998, CANCER RES, V58, P3491
   Niehans GA, 1997, CANCER RES, V57, P1007
   OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075
   OHBU M, 1995, VIRCHOWS ARCH, V427, P271
   Rabinowich H, 1998, J CLIN INVEST, V101, P2579, DOI 10.1172/JCI1518
   Rosenberg SA, 1996, ANNU REV MED, V47, P481
   Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273
   Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420
   Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361
   Tachibana M, 1999, ARCH SURG-CHICAGO, V134, P50, DOI 10.1001/archsurg.134.1.50
   Tachibana M, 1999, AM J GASTROENTEROL, V94, P757
   Yano H, 1996, J HEPATOL, V25, P454, DOI 10.1016/S0168-8278(96)80204-2
NR 28
TC 11
Z9 12
U1 3
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2015
VL 5
IS 9
BP 2865
EP 2871
PG 7
WC Oncology
SC Oncology
GA CW1SZ
UT WOS:000364773000026
PM 26609492
DA 2018-12-27
ER

PT J
AU Zhao, XH
   Wu, YF
   Lv, ZP
AF Zhao, Xiaohua
   Wu, Yingfen
   Lv, Zhiping
TI RETRACTED: miR-128 modulates hepatocellular carcinoma by inhibition of
   ITGA2 and ITGA5 expression (Retracted article. See vol. 8, pg. 1919,
   2016)
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article; Retracted Publication
DE miR-128; ITGA2; ITGA5; hepatocellular carcinoma
ID CELLS; CANCER; TUMORIGENESIS; GROWTH
AB Dysregulation of miRNAs is a common feature in human cancers, but this phenomenon has not been studied extensively in hepatocellular carcinoma (HCC). miR-128 has been found to be downregulated in cancer. However its role in HCC remains unclear. miR-128 was underexpressed in HCC tissues and cell lines compared with their normal controls. Additionally, ITGA2 and ITGA5 were predicted as the target genes of miR-128. ITGA2 and ITGA5 were inversely correlated with the expression of miR-128 in HCC cells. Importantly, we demonstrate that the overexpression of miR-128 significantly inhibits HCC cell metastasis and stem-cell like properties via ITGA2 and ITGA5. Our results suggest the existence of a novel miR-128-ITGA pathway and indicate that miR-128 acts as a tumor suppressor during hepatocellular carcinogenesis. These results may provide a promising alternative strategy for the therapeutic treatment of HCC.
C1 [Zhao, Xiaohua; Lv, Zhiping] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Zhao, Xiaohua; Wu, Yingfen] Kangwei Hosp, Xinji, Peoples R China.
RP Lv, ZP (reprint author), Southern Med Univ, Sch Tradit Chinese Med, 1023 Shatai South Rd, Guangzhou, Guangdong, Peoples R China.
EM lv_zhiping@163.com
FU National Key Sci-Tech Special Project of China [2008-ZX10002-018,
   2008ZX10002-019]
FX This work was supported by National Key Sci-Tech Special Project of
   China grant (2008-ZX10002-018 and 2008ZX10002-019).
CR Callegari E, 2015, CELL DEATH DIFFER, V22, P46, DOI 10.1038/cdd.2014.136
   Dong QS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098651
   Fu BH, 2010, MOL BIOL REP, V37, P1665, DOI 10.1007/s11033-009-9790-1
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Hu J, 2014, EUR J CANCER, V50, P2336, DOI 10.1016/j.ejca.2014.06.005
   Li ML, 2013, EXP CELL RES, V319, P3059, DOI 10.1016/j.yexcr.2013.07.031
   Lin LN, 2013, ONCOL REP, V30, P1239, DOI 10.3892/or.2013.2596
   Ma L, 2014, WORLD J GASTROENTERO, V20, P333, DOI 10.3748/wjg.v20.i2.333
   Morise Z, 2014, WORLD J GASTROENTERO, V20, P14381, DOI 10.3748/wjg.v20.i39.14381
   Papagiannakopoulos T, 2012, ONCOGENE, V31, P1884, DOI 10.1038/onc.2011.380
   Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337
   Peruzzi P, 2013, NEURO-ONCOLOGY, V15, P1212, DOI 10.1093/neuonc/not055
   Scaggiante B, 2014, WORLD J GASTROENTERO, V20, P1268, DOI 10.3748/wjg.v20.i5.1268
   Seca H, 2014, CURR PHARM BIOTECHNO, V15, P492, DOI 10.2174/1389201015666140519122524
   Shen L, 2014, TUMOR BIOL, V35, P2069, DOI 10.1007/s13277-013-1274-1
   Shi Z, 2012, REPROD SYS SEX DISOR, V1, P102, DOI [10.4172/2161-038X.1000102, DOI 10.4172/2161-038X.1]
   Tao T, 2014, TUMOR BIOL, V35, P8543, DOI 10.1007/s13277-014-2057-z
   Woo HH, 2013, MOL CANCER, V11, DOI 10.1186/1476-4598-11-58
   Yang JD, 2010, INFECT DIS CLIN N AM, V24, P899, DOI 10.1016/j.idc.2010.07.004
   Zhu YH, 2011, CLIN CANCER RES, V17, P7105, DOI 10.1158/1078-0432.CCR-11-0071
   Zhu ZX, 2014, HEPAT MON, V14, DOI 10.5812/hepatmon.18672
NR 21
TC 17
Z9 18
U1 2
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2015
VL 7
IS 9
BP 1564
EP 1573
PG 10
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA CW1SL
UT WOS:000364771500008
PM 26550456
DA 2018-12-27
ER

PT J
AU Watawana, MI
   Jayawardena, N
   Ranasinghe, SJ
   Waisundara, VY
AF Watawana, Mindani I.
   Jayawardena, Nilakshi
   Ranasinghe, Shakkya J.
   Waisundara, Viduranga Y.
TI RETRACTED: Evaluation of the Stability of the Total Antioxidant
   Capacity, Polyphenol Contents, and Starch Hydrolase Inhibitory
   Activities of Kombucha Teas Using an In Vitro Model of
   Digestion(Retracted article.See 2560103,2016)
SO JOURNAL OF CHEMISTRY
LA English
DT Article; Retracted Publication
ID FUNGUS METABOLITES; PHENOLIC-COMPOUNDS; BLACK TEA; FERMENTATION;
   COMPONENTS; SAMPLES; HEALTH; ASSAY
AB The objective of this study was to evaluate and compare antioxidant and starch hydrolase inhibitory activity of three different types of Kombucha beverages prepared by three pellicles with different microbial compositions. The fermentation process was carried out for 7 days and the assessments of antioxidant and starch hydrolase inhibitory activities as well as tea phenolic compounds were carried out. These parameters were also evaluated after subjecting the final fermented samples to gastric and duodenal digestion in an in vitro digestion model. The pH had a statistically significant decrease during the period of fermentation. The total phenolics content and antioxidant activities had increased during the fermentation process as well as when subjected to digestion. The starch hydrolase inhibitory activities also increased in a similar manner during the different phases. The alpha-amylase and alpha-glucosidase inhibitory activities showed statistically significant increases (P < 0.05) as the fermentation progressed, while an increase was observed after being subjected to pancreatic and duodenal digestion as well. All three types of tea showed a higher alpha-amylase inhibitory activity than alpha-glucosidase inhibitory activity.
C1 [Watawana, Mindani I.; Jayawardena, Nilakshi; Ranasinghe, Shakkya J.; Waisundara, Viduranga Y.] Natl Inst Fundamental Studies, Funct Food Prod Dev Project, Kandy 20000, Sri Lanka.
RP Waisundara, VY (reprint author), Natl Inst Fundamental Studies, Funct Food Prod Dev Project, Hantane Rd, Kandy 20000, Sri Lanka.
EM viduranga@gmail.com
FU National Institute of Fundamental Studies, Hantane Road, Kandy, Sri
   Lanka
FX The financial and analytical support provided by the National Institute
   of Fundamental Studies, Hantane Road, Kandy, Sri Lanka, is acknowledged.
CR Alakomi HL, 2007, J AGR FOOD CHEM, V55, P3905, DOI 10.1021/jf070190y
   Balentine DA, 1997, CRIT REV FOOD SCI, V37, P693, DOI 10.1080/10408399709527797
   Blanc PJ, 1996, BIOTECHNOL LETT, V18, P139, DOI 10.1007/BF00128667
   Chen C, 2000, J APPL MICROBIOL, V89, P834, DOI 10.1046/j.1365-2672.2000.01188.x
   Chu SC, 2006, FOOD CHEM, V98, P502, DOI 10.1016/j.foodchem.2005.05.080
   Dufresne C, 2000, FOOD RES INT, V33, P409, DOI 10.1016/S0963-9969(00)00067-3
   Fukumoto LR, 2000, J AGR FOOD CHEM, V48, P3597, DOI 10.1021/jf000220w
   Goh W. N., 2012, International Food Research Journal, V19, P109
   Greenwalt CJ, 2000, J FOOD PROTECT, V63, P976, DOI 10.4315/0362-028X-63.7.976
   Hasler Clare M, 2004, J Am Diet Assoc, V104, P814
   Huang DJ, 2002, J AGR FOOD CHEM, V50, P1815, DOI 10.1021/jf0113732
   Jayabalan R, 2008, FOOD CHEM, V109, P227, DOI 10.1016/j.foodchem.2007.12.037
   Jayabalan R, 2008, J AGR FOOD CHEM, V56, P9064, DOI 10.1021/jf8020893
   Jayabalan R, 2014, COMPR REV FOOD SCI F, V13, P538, DOI 10.1111/1541-4337.12073
   Jayawardena N, 2015, PLANT FOOD HUM NUTR, V70, P71, DOI 10.1007/s11130-014-0463-4
   Kabiri N., 2013, World Applied Sciences Journal, V27, P524
   Koh LW, 2010, J AGR FOOD CHEM, V58, P148, DOI 10.1021/jf903011g
   Kozyrovska N. O., 2012, Biopolymers and Cell, V28, P103
   Lee Y. H., 2014, J FUNCTIONAL FOODS
   Liu TT, 2011, J AGR FOOD CHEM, V59, P9756, DOI 10.1021/jf202939d
   Malbasa RV, 2011, FOOD CHEM, V127, P1727, DOI 10.1016/j.foodchem.2011.02.048
   Markov SL, 2001, ACTA PERIODICA TECHN, V32, P133
   Marsh AJ, 2014, FOOD MICROBIOL, V38, P171, DOI 10.1016/j.fm.2013.09.003
   Pasha C, 2005, FOOD CHEM, V89, P449, DOI 10.1016/j.foodchem.2004.02.054
   Prior RL, 2003, J AGR FOOD CHEM, V51, P3273, DOI 10.1021/jf0262256
   REISS J, 1994, Z LEBENSM UNTERS FOR, V198, P258, DOI 10.1007/BF01192606
   Ryan L, 2008, PLANT FOOD HUM NUTR, V63, P127, DOI 10.1007/s11130-008-0081-0
   Srihari T., 2012, J PHARM SCI RES, V4, P1978
   THANARAJ SNS, 1990, J SCI FOOD AGR, V51, P57, DOI 10.1002/jsfa.2740510107
   Watawana M. I., 2015, J FOOD PROCESSING PR
   Watawana MI, 2016, FOOD CHEM, V194, P304, DOI 10.1016/j.foodchem.2015.08.033
   Yavari N., 2011, Australian Journal of Basic and Applied Sciences, V5, P1788
NR 32
TC 1
Z9 1
U1 6
U2 40
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-9063
EI 2090-9071
J9 J CHEM-NY
JI J. Chem.
PY 2015
AR 684561
DI 10.1155/2015/684561
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA CW0UJ
UT WOS:000364704700001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Zhou, JM
AF Zhou, Jianming
TI RETRACTED: A Design of Dual Broadband Antenna in Mobile Communication
   System(Retracted article. See Artn.3826235,2016)
SO INTERNATIONAL JOURNAL OF ANTENNAS AND PROPAGATION
LA English
DT Article; Retracted Publication
ID INTEGRATED BALUN; PRINTED DIPOLE; CIRCUIT
AB A design of dual broadband antenna is proposed in this paper; it consists of one low frequency unit and two high frequency units. The low frequency unit consists of a pair of printing vibrators; the high frequency unit consists of a pair of printing oscillators, which is bent at its end, and high frequency unit and low frequency unit are set on the same dielectric substrate. Through adding a parasitic unit on antenna, it can enhance frequency bandwidth without affecting the bandwidth. In the high frequency unit, it adopts gap-coupled microstrip line feeding method in order to get enough bandwidth. Through the test of dual broadband antenna, it can be found that, in the low frequency part, the antenna covers 20% bandwidth of the total bandwidth, and it covers the frequency from 800 MHz to 980 MHz. In the high frequency, the antenna covers 60% of total bandwidth and its frequency is from 1540 MHz to 2860 MHz, so the designed antenna can satisfy the frequency requirements of 2G/3G/LTE (4G) communication system.
C1 Beijing Inst Technol, Sch Informat & Elect, Beijing 100081, Peoples R China.
RP Zhou, JM (reprint author), Beijing Inst Technol, Sch Informat & Elect, Beijing 100081, Peoples R China.
EM zhoujm@bit.edu.cn
CR Balanis CA, 2005, ANTENNA THEORY ANAL
   Chin CHK, 2007, IEEE T ANTENN PROPAG, V55, P2461, DOI 10.1109/TAP.2007.904118
   Chuang HR, 2003, IEEE T MICROW THEORY, V51, P374, DOI 10.1109/TMTT.2002.807838
   Li RL, 2009, IEEE T ANTENN PROPAG, V57, P2180, DOI 10.1109/TAP.2009.2021967
   Liu Y, 2010, PROCEEDINGS OF 2010 INTERNATIONAL CONFERENCE ON PUBLIC ADMINISTRATION (6TH), VOL III, P278, DOI 10.1109/ICCIS.2010.74
   Revankar U. K., 2001, P IEEE INT S ANT PRO, V4, P796
   Sabatier C, 2003, IEEE ANTENN PROPAG M, V45, P9, DOI 10.1109/MAP.2003.1282176
   WOOD C, 1980, IEE PROC-H, V127, P231, DOI 10.1049/ip-h-1.1980.0049
   Wu D., 2005, P IEEE 2005 INT S MI, P454
NR 9
TC 1
Z9 1
U1 2
U2 5
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA
SN 1687-5869
EI 1687-5877
J9 INT J ANTENN PROPAG
JI Int. J. Antennas Propag.
PY 2015
AR 975825
DI 10.1155/2015/975825
PG 9
WC Engineering, Electrical & Electronic; Telecommunications
SC Engineering; Telecommunications
GA CV2NQ
UT WOS:000364093800001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Peng, CH
   Wu, X
AF Peng, Changhai
   Wu, Xiao
TI RETRACTED: Case Study of Carbon Emissions from a Building's Life Cycle
   Based on BIM and Ecotect (Retracted article. See art no 2193505, 2017)
SO ADVANCES IN MATERIALS SCIENCE AND ENGINEERING
LA English
DT Article; Retracted Publication
ID ENERGY-CONSUMPTION; EMBODIED ENERGY; CO2 EMISSION; LCA; CONSTRUCTION;
   PERFORMANCE; SIMULATION; DESIGN; STAGE; CHINA
AB Using building information modeling (BIM) and Ecotect, this paper estimated carbon emissions during an office building's life cycle. This building's life cycle CO2 emissions were divided into three parts: the construction, operation, and demolition stages. Among these, the statistics on the schedule of quantities were generated using BIM, and the energy consumption during the building's operational stage was obtained using ECOTECT simulation. Sensitivity analysis was performed by changing several alternative parameters, to identify which parameter has more impacts on building performance. The paper demonstrated that (1) BIM and Ecotect are very helpful in estimating carbon emissions from a building's life cycle, (2) the primary and effective measures to reduce the building's CO2 emissions in hot and humid climate should be arranged as follows: (a) within the limits of comfort, reducing the fresh air volume; (b) extending the indoor temperature range; (c) improving the thermal insulation performance of exterior windows, walls, and roofs; (d) exploiting natural ventilation during transition seasons, and (3) currently there are some limitations in performing LCA based on BIM and Ecotect.
C1 [Peng, Changhai; Wu, Xiao] Southeast Univ, Sch Architecture, Nanjing 210096, Jiangsu, Peoples R China.
   [Peng, Changhai; Wu, Xiao] Southeast Univ, Key Lab Urban & Architectural Heritage Conservat, Minist Educ, Nanjing 210096, Jiangsu, Peoples R China.
   [Peng, Changhai] Univ Colorado, Coll Engn & Appl Sci, Denver, CO 80217 USA.
RP Peng, CH (reprint author), Southeast Univ, Sch Architecture, Nanjing 210096, Jiangsu, Peoples R China.
EM pengchanghai@foxmail.com
FU National Natural Science Foundation of China [51278107]; China
   Scholarship Council [201406095032]; Key Program of the Natural Science
   Foundation of Jiangsu Province [BK2010061]; R&D Program of the Ministry
   of Housing and Urban-Rural Development of the People's Republic of China
   [2011-K1-2]; Open Project Program of the Key Laboratory of Urban and
   Architectural Heritage Conservation (Southeast University); Ministry of
   Education [KLUAHC1212]
FX The research presented in this paper was supported by the National
   Natural Science Foundation of China (51278107), China Scholarship
   Council (201406095032), the Key Program of the Natural Science
   Foundation of Jiangsu Province (BK2010061), the R&D Program of the
   Ministry of Housing and Urban-Rural Development of the People's Republic
   of China (2011-K1-2), the Open Project Program of the Key Laboratory of
   Urban and Architectural Heritage Conservation (Southeast University),
   and the Ministry of Education (KLUAHC1212).
CR Abdullah A. H., 2013, INT J CONSTRUCTION T, V1, P33
   Adalberth K, 1997, BUILD ENVIRON, V32, P317, DOI 10.1016/S0360-1323(96)00068-6
   [Anonymous], 2006, 14044 ISO
   Ardente F, 2008, ENERG BUILDINGS, V40, P1, DOI 10.1016/j.enbuild.2006.12.009
   Associated General Contractors of America, 2006, CONTR GUID BIM
   Attia S, 2011, P 12 INT BUILD PERF
   Basbagill J, 2013, BUILD ENVIRON, V60, P81, DOI 10.1016/j.buildenv.2012.11.009
   Bayer C., 2010, AIA GUIDE BUILDING L
   Blengini GA, 2010, INT J LIFE CYCLE ASS, V15, P652, DOI 10.1007/s11367-010-0190-5
   BUCHANAN AH, 1994, ENERG BUILDINGS, V20, P205, DOI 10.1016/0378-7788(94)90024-8
   Crawley DB, 2008, BUILD ENVIRON, V43, P661, DOI 10.1016/j.buildenv.2006.10.027
   Department of Climate Change and National Development and Reform Commission, 2012, 2012 BAS EM FACT REG
   Dixit MK, 2013, RENEW SUST ENERG REV, V21, P153, DOI 10.1016/j.rser.2012.12.037
   Eastman C., 2011, BIM HDB GUIDE BUILDI
   Eggleston H. S., 2006, 2006 IPCC GUIDELINES
   Erlandsson M, 2003, BUILD ENVIRON, V38, P919, DOI 10.1016/S0360-1323(03)00031-3
   Garg A., 2006, 2006 IPCC GUIDELINES
   Glaumann M., 2010, GUIDELINES LCA CALCU
   Hoyt T., 2009, ENERGY SAVINGS EXTEN
   Ibarra D. I., 2009, P 11 INT IBPSA C GLA, P196
   ISO, 2006, 14040 ISO
   Japan Resource Institute, 1996, RESOURCE, V6, P26
   Junnila S, 2003, INFRASTRUCTURE SYST, V9, P157, DOI DOI 10.1061/(ASCE)1076-0342(2003)9:4(157)
   Kivits RA, 2013, SCI WORLD J, DOI 10.1155/2013/983721
   Lee K, 2009, RENEW SUST ENERG REV, V13, P1994, DOI 10.1016/j.rser.2009.01.002
   Marsh A., 2003, BUILD ENERGY SIM USE, V24, P24
   MOHURD (Ministry of Housing and Urban-Rural Development of the People's Republic of China), 2005, GB501892005 MOHURD
   OKA T, 1993, ENERG BUILDINGS, V19, P303, DOI 10.1016/0378-7788(93)90016-N
   Ortiz O, 2009, CONSTR BUILD MATER, V23, P28, DOI 10.1016/j.conbuildmat.2007.11.012
   Pachauri RK, 2008, CLIMATE CHANGE 2007
   Peng B., 2012, CASE STUDY LIFE CYCL
   Peng CH, 2014, ENERG BUILDINGS, V78, P123, DOI 10.1016/j.enbuild.2014.04.023
   Ramesh T, 2010, ENERG BUILDINGS, V42, P1592, DOI 10.1016/j.enbuild.2010.05.007
   Reddy BVV, 2003, ENERG BUILDINGS, V35, P129
   Rist T., 2011, THESIS NORWEGIAN U S
   Sartori I, 2007, ENERG BUILDINGS, V39, P249, DOI 10.1016/j.enbuild.2006.07.001
   SHANG Chun-jing, 2010, J ENG MANAGEMENT, V24, P7
   Suzuki M, 1998, ENERG BUILDINGS, V28, P33, DOI 10.1016/S0378-7788(98)00010-3
   Thormark C, 2000, INT J LOW ENERGY SUS, V1, P1
   Vangimalla PR, 2011, WINT SIMUL C PROC, P3383, DOI 10.1109/WSC.2011.6148034
   Wang E, 2011, P 47 ASC ANN INT C A
   Wang J., 2009, CALCULATION ANAL LIF
   Wu HJJ, 2012, INT J LIFE CYCLE ASS, V17, P105, DOI 10.1007/s11367-011-0342-2
   Yan Y., 2011, RES ENERGY CONSUMPTI
   Yohanis YG, 2006, P I MECH ENG A-J POW, V220, P271, DOI 10.1243/095765006X76009
   ZABALZA Ignacio, 2009, BUILD ENVIRON, P2510, DOI DOI 10.1016/J.BUILDENV.2009.05.001
   Zhang XL, 2013, RENEW SUST ENERG REV, V17, P160, DOI 10.1016/j.rser.2012.09.024
NR 47
TC 2
Z9 2
U1 10
U2 45
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-8434
EI 1687-8442
J9 ADV MATER SCI ENG
JI Adv. Mater. Sci. Eng.
PY 2015
AR 954651
DI 10.1155/2015/954651
PG 15
WC Materials Science, Multidisciplinary
SC Materials Science
GA CU6LT
UT WOS:000363644300001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Li, QS
   Li, X
AF Li, Qingsheng
   Li, Xiao
TI RETRACTED: Dynamic Generation and Editing System for Wrongly Written
   Chinese Characters Font (Retracted article. See 5415809, 2016)
SO MATHEMATICAL PROBLEMS IN ENGINEERING
LA English
DT Article; Retracted Publication
AB The uniqueness of Chinese makes Chinese language a hotspot in language learning. In view of the problem of wrongly written character teaching in Chinese language teaching, it provides a simple, convenient, and efficient input method of wrongly written characters and realizes a dynamic generation and editing system for wrongly written Chinese character font, which solves the problems of real-time edit, coding, and input of wrongly written character in editing process using dynamic editing technology, and provides a convenient input method of wrongly written character in editing, printing, typesetting, and the research of digital Chinese language teaching. This method can also be used in dynamic editing, generation and processing of ancient variants, Oracle bone inscriptions, Bronze inscription, folk combined characters, and other fonts.
C1 [Li, Qingsheng] Wuhan Univ Technol, Sch Informat Engn, Wuhan 430070, Peoples R China.
   [Li, Qingsheng; Li, Xiao] Anyang Normal Univ, Sch Comp & Informat Engn, Anyang 455002, Henan, Peoples R China.
RP Li, X (reprint author), Anyang Normal Univ, Sch Comp & Informat Engn, Anyang 455002, Henan, Peoples R China.
EM joylx@163.com
FU National Natural Science Foundation of China [60973051]; Science and
   Technology Department of Henan Province Key Scientific and Technological
   Project [112102210375]
FX The authors received funding from the National Natural Science
   Foundation of China (60973051) and Science and Technology Department of
   Henan Province Key Scientific and Technological Project (112102210375).
CR Han D. M., 2007, STUDY CHINESE GLYPH
   Li Qingsheng, 2013, Acta Scientiarum Naturalium Universitatis Pekinensis, V49, P61
   Li X. Q., 2010, DESIGN IMPLEMENTATIO
   Li Xiao-qing, 2010, Computer Engineering and Design, V31, P2388
   Lin Min, 2009, Journal of Computer Aided Design & Computer Graphics, V21, P1298
   [林民 Lin Min], 2010, [计算机研究与发展, Journal of Computer Research and Development], V47, P318
   [林民 LIN Min], 2008, [中文信息学报, Journal of Chinese Information Processing], V22, P115
   Wang Yu, 1997, Mini-Micro Systems, V18, P75
   Wu Q. X., 2012, SCI TECHNOLOGY ENG, V8, P28
   Zheng J., 2009, CHINESE INPUTTING OU
   Zhu Q. M., 2005, CHINESE INFORM PROCE
NR 11
TC 1
Z9 2
U1 3
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1024-123X
EI 1563-5147
J9 MATH PROBL ENG
JI Math. Probl. Eng.
PY 2015
AR 282408
DI 10.1155/2015/282408
PG 7
WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary
   Applications
SC Engineering; Mathematics
GA CU0CJ
UT WOS:000363183000001
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Lv, WJ
   Wang, L
   Lu, JH
   Mu, JS
   Liu, YB
   Dong, P
AF Lv, Wenjie
   Wang, Lei
   Lu, Jianhua
   Mu, Jiasheng
   Liu, Yingbin
   Dong, Ping
TI RETRACTED: Long Noncoding RNA KIAA0125 Potentiates Cell Migration and
   Invasion in Gallbladder Cancer (Retracted article. Artn 3471417, 2017)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID EPITHELIAL-MESENCHYMAL TRANSITION; LUNG-CANCER; CARCINOMA;
   PROLIFERATION; PROGRESSION; METASTASIS; MALAT-1; PREDICT; HOTAIR; 8Q24
AB Gallbladder cancer (GBC) is one of the mostly aggressive diseases with poor prognosis due to the lack of severe symptoms. To date, little is known about the potential roles and underlying mechanisms of long noncoding RNAs (lncRNAs) in GBC initiation and progression. Thus, it provides us with a novel insight into the contribution of lncRNAs to GBC development. Remarkably, we found the differential expression of a lncRNA, namely, KIAA0125, in a pair of GBC cell sublines which possess different metastatic potentials. Then the effects of KIAA0125 on GBC cell migration, invasion, and epithelial-mesenchymal transitions (EMT) were investigated by using a lentivirus-mediated RNA interference (RNAi) system. Notably, cell migration and invasion were strongly inhibited by KIAA0125 suppression. Moreover, the expression of beta-Catenin was increased and the expression of Vimentin was decreased in GBC-SD/M cells after KIAA0125 knockdown. Thus, our findings suggested that KIAA0125 promoted the migration and invasion of GBC cells and could serve as a potential therapeutic target in advanced GBC.
C1 [Lv, Wenjie; Wang, Lei; Lu, Jianhua; Mu, Jiasheng; Liu, Yingbin; Dong, Ping] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Gen Surg, Shanghai 200092, Peoples R China.
RP Dong, P (reprint author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Gen Surg, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.
EM pingdongdr@163.com
FU National Natural Science Foundation of China [81172026, 81272402,
   81172029]
FX This study was supported by the National Natural Science Foundation of
   China (Grant nos. 81172026, 81272402, and 81172029).
CR Alves CP, 2013, STEM CELLS, V31, P2827, DOI 10.1002/stem.1547
   Bonnomet A, 2010, J MAMMARY GLAND BIOL, V15, P261, DOI 10.1007/s10911-010-9174-0
   Chung SY, 2011, CANCER SCI, V102, P245, DOI 10.1111/j.1349-7006.2010.01737.x
   Davies JA, 1996, ACTA ANAT, V156, P187
   Gourgiotis S, 2008, AM J SURG, V196, P252, DOI 10.1016/j.amjsurg.2007.11.011
   HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X
   Jeong IH, 2009, EUR SURG RES, V42, P203, DOI 10.1159/000205974
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112
   Liu Ying-bin, 2006, Zhonghua Yi Xue Za Zhi, V86, P2117
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu LG, 2012, BREAST CANCER RES TR, V136, P875, DOI 10.1007/s10549-012-2314-z
   Lv XB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063516
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Miller G, 2008, EJSO-EUR J SURG ONC, V34, P306, DOI 10.1016/j.ejso.2007.07.206
   Ono H, 2014, CANCER MED-US, V3, P632, DOI 10.1002/cam4.220
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pD239, DOI 10.1093/nar/gks1246
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Satelli A, 2011, CELL MOL LIFE SCI, V68, P3033, DOI 10.1007/s00018-011-0735-1
   Schulze F, 2007, Verh Dtsch Ges Pathol, V91, P250
   Takahashi K, 2014, HEPATOLOGY, V60, P744, DOI 10.1002/hep.27043
   Tan ZJ, 2013, GENE, V528, P261, DOI 10.1016/j.gene.2013.06.064
   Tan ZJ, 2012, MOL CELL BIOCHEM, V369, P27, DOI 10.1007/s11010-012-1365-0
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616
   Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992
   Xu C., 2014, INT J ONCOL, V39, P169
   Yang H, 2013, BIOCHEM PHARMACOL, V85, P1761, DOI 10.1016/j.bcp.2013.04.020
   Ying L, 2012, MOL BIOSYST, V8, P2289, DOI 10.1039/c2mb25070e
   Zajchowski DA, 2001, CANCER RES, V61, P5168
   Zhu AX, 2010, ONCOLOGIST, V15, P168, DOI 10.1634/theoncologist.2009-0302
   Zong HJ, 2014, MOL BIOL REP, V41, P4507, DOI 10.1007/s11033-014-3321-4
NR 33
TC 5
Z9 5
U1 3
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
AR 108458
DI 10.1155/2015/108458
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CS3SY
UT WOS:000361996400001
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Shahar, S
   Aziz, AF
   Ismail, SNA
   Yahya, HM
   Din, NC
   Manaf, ZA
   Badrasawi, MM
AF Shahar, Suzana
   Aziz, Ainor Farahin
   Ismail, Siti Nur Arina
   Yahya, Hanis Mastura
   Din, Normah Che
   Manaf, Zahara Abdul
   Badrasawi, Manal M.
TI RETRACTED: The effect of Polygonum minus extract on cognitive and
   psychosocial parameters according to mood status among middle-aged
   women: a randomized, double-blind, placebo-controlled study (Retracted
   article. See vol. 12, pg. 1635, 2017)
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article; Retracted Publication
DE cognitive function; P. minus; psychosocial; women; phytochemicals;
   quality of life
ID MENTAL-HEALTH; MAJOR DEPRESSION; STRESS; ANTIOXIDANT; QUERCETIN;
   DISEASE; GENDER; MODEL; COMBINATION; FLAVONOIDS
AB Background: Polygonum minus (PM) or locally known in Malaysia, as "kesum" is rich in micronutrients and natural antioxidants. However, its beneficial effect on outcome associates with oxidative stress including cognitive function is yet to be discovered. We assessed the efficacy of PM extract (LineMinus (TM)) on cognitive function and psychosocial status among middle-aged women in Klang Valley of Malaysia.
   Methods: A randomized, double-blind, placebo-controlled trial among 35 healthy middle-aged women was performed, and subjects were randomized to receive either 250 mg PM or placebo of 100 mg maltodextrin each were taken twice daily for 6 weeks. Subjects were assessed for neuropsychological test, psychosocial status, and anthropometric at baseline, week 3, and week 6. Biomarkers were also determined at baseline and week 6.
   Results: The supplementation of PM showed significant intervention effect on Digit Span test (P<0.05) social functioning domain of 36-Item Short Form Health Survey (P<0.05) among subjects with mood disturbance. While, among subjects with good mood, PM supplementation improved Wechsler Abbreviated Scale of Intelligence (WASI) for IQ verbal (P=0.016) and Full Scale IQ of WASI (P=0.004). There were no adverse effects reported for the supplementation as indicated using biomarkers, including liver function and clinical symptoms.
   Conclusion: Supplementation of PM is safe to be consumed for 6 weeks, with potential benefits to attention, short-term memory, improved quality of life, and mood, as well as IQ.
C1 [Shahar, Suzana; Manaf, Zahara Abdul; Badrasawi, Manal M.] Univ Kebangsaan Malaysia, Dietet Programme, Fac Hlth Sci, Sch Healthcare Sci, Kuala Lumpur 50300, Malaysia.
   [Aziz, Ainor Farahin; Ismail, Siti Nur Arina; Yahya, Hanis Mastura] Univ Kebangsaan Malaysia, Nutr Sci Programme, Fac Hlth Sci, Sch Healthcare Sci, Kuala Lumpur 50300, Malaysia.
   [Din, Normah Che] Univ Kebangsaan Malaysia, Hlth Psychol Programme, Fac Hlth Sci, Sch Healthcare Sci, Kuala Lumpur 50300, Malaysia.
RP Shahar, S (reprint author), Univ Kebangsaan Malaysia, Fac Hlth Sci, Sch Healthcare Sci, Dietet Programme, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia.
EM suzana.shahar@ukm.edu.my
OI , Manal/0000-0003-4803-1052
FU Biotropics Malaysia Berhad
FX This study was funded by Biotropics Malaysia Berhad. The authors thank
   all participating schools and institution who gave their utmost
   cooperation in completing the study. The authors also thank all the
   fieldworkers involved during the data collection period.
CR Bell A, 2014, SOC SCI MED, V120, P21, DOI 10.1016/j.socscimed.2014.09.008
   Bhutada P, 2010, PROG NEURO-PSYCHOPH, V34, P955, DOI 10.1016/j.pnpbp.2010.04.025
   Bijl RV, 2002, SOC PSYCH PSYCH EPID, V37, P372, DOI 10.1007/s00127-002-0566-3
   BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160
   Carroll D, 2000, PSYCHOPHARMACOLOGY, V150, P220, DOI 10.1007/s002130000406
   Ching LS, 2001, J AGR FOOD CHEM, V49, P3101, DOI 10.1021/jf000891u
   Christapher PV, 2015, PHARMACOGN RES, V7, P1, DOI 10.4103/0974-8490.147125
   Clays E, 2007, SCAND J WORK ENV HEA, V33, P252, DOI 10.5271/sjweh.1140
   Cyranowski JM, 2000, ARCH GEN PSYCHIAT, V57, P21, DOI 10.1001/archpsyc.57.1.21
   Ekkekakis P., 2012, MEASUREMENT SPORT EX, P321, DOI DOI 10.1017/CBO9780511820724
   Fazlin A.S.M., 2002, COMPENDIUM MED PLANT, V2
   George A, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-161
   Gold EB, 2001, AM J EPIDEMIOL, V153, P865, DOI 10.1093/aje/153.9.865
   Groth-Marnat G, 2000, NEUROPSYCHOLOGICAL A
   Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007
   GUTTERIDGE JMC, 1993, FREE RADICAL RES COM, V19, P141, DOI 10.3109/10715769309111598
   Hamarat E, 2001, EXP AGING RES, V27, P181, DOI 10.1080/036107301750074051
   Hartman RE, 2006, NEUROBIOL DIS, V24, P506, DOI 10.1016/j.nbd.2006.08.006
   Husain M, 2011, TRENDS COGN SCI, V15, P28, DOI 10.1016/j.tics.2010.11.002
   Imelda F., 2014, International Food Research Journal, V21, P553
   Jager AK, 2011, MOLECULES, V16, P1471, DOI 10.3390/molecules16021471
   Kawabata K, 2010, J NUTR BIOCHEM, V21, P374, DOI 10.1016/j.jnutbio.2009.01.008
   Keri S, 2014, J AFFECT DISORDERS, V164, P118, DOI 10.1016/j.jad.2014.04.030
   Kumar A, 2008, J MED FOOD, V11, P469, DOI 10.1089/jmf.2006.0207
   Laditka JN, 2012, AM J ALZHEIMERS DIS, V27, P55, DOI 10.1177/1533317511435662
   Maizura M, 2011, INT FOOD RES J, V18, P529
   McNair D. M, 1971, MANUAL PROFILE MOOD
   Ming YK, 2013, INT J PHARM PHARM SC, V5
   Ng TP, 2006, AM J EPIDEMIOL, V164, P898, DOI 10.1093/aje/kwj267
   Oldehinkel AJ, 2011, NEUROSCI BIOBEHAV R, V35, P1757, DOI 10.1016/j.neubiorev.2010.10.013
   Parkinson B., 1996, CHANGING MOODS PSYCH
   Pathak L, 2013, EXPERT OPIN INV DRUG, V22, P863, DOI 10.1517/13543784.2013.794783
   Pipingas A, 2008, PHYTOTHER RES, V22, P1168, DOI 10.1002/ptr.2388
   Qader SW, 2011, MOLECULES, V16, P3433, DOI 10.3390/molecules16043433
   Rey A, 1964, EXAMEN CLIN PSYCHOL
   Reynolds C. R., 2002, COMPREHENSIVE TRAIL
   Schlebusch L, 2000, S AFR MED J, V90, P1216
   Scholey A, 2013, 114 ABB NUTR RES C A
   Scholey A, 2010, PSYCHOPHARMACOLOGY, V212, P345, DOI 10.1007/s00213-010-1964-y
   Seedat S, 2009, ARCH GEN PSYCHIAT, V66, P785, DOI 10.1001/archgenpsychiatry.2009.36
   Solomon MB, 2009, PHYSIOL BEHAV, V97, P250, DOI 10.1016/j.physbeh.2009.02.033
   Spencer JPE, 2009, GENES NUTR, V4, P243, DOI 10.1007/s12263-009-0136-3
   Sullivan DM, 1993, METHODS ANAL NUTR LA, P33
   Sumazian Y, 2010, J MED PLANTS RES, V4, P881
   U.S. Environmental Protection Agency, 1995, 5252 US EPA
   Udani JK, 2014, EVID-BASED COMPL ALT, DOI 10.1155/2014/179529
   Udani JK, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/238454
   Valenza G, 2013, AUTONOMIC NERVOUS SY
   Vikram Paritala, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P430, DOI 10.12980/APJTB.4.2014C1255
   Wang WX, 2007, ZHONG CAO YAO, V38, P900
   Wechsler D., 1999, WECHSLER ABBREVIATED
   Wen J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-38
   World Health Organisation, 2001, WORLD HLTH REP 2001
   *WORLD MED ASS, 2000, ETH PRINC MED RES IN
NR 54
TC 4
Z9 4
U1 2
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2015
VL 10
BP 1505
EP 1520
DI 10.2147/CIA.S86411
PG 16
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA CR8OR
UT WOS:000361614100001
PM 26445532
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wang, QQ
   Wang, T
   Wang, Z
   Zheng, H
AF Wang, Qianqian
   Wang, Tao
   Wang, Zhu
   Zheng, Hong
TI RETRACTED: Diagnostic value of IMP3 in pancreatic cancer: a
   meta-analysis (Retracted article. See vol. 9, pg. 12417, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Pancreatic cancer; IMP3; diagnosis; accuracy; meta-analysis
ID FINE-NEEDLE-ASPIRATION; DUCTAL ADENOCARCINOMA; MESOTHELIN; ACCURACY;
   METAANALYSIS; EXPRESSION; CARCINOMA; PANEL; IMMUNOHISTOCHEMISTRY;
   IDENTIFICATION
AB Background and objectives: An increasing number of studies have examined the ability of IMP3 (insulin-like growth factor 2 messenger RNA binding protein 3) to be a marker for the diagnosis of pancreatic cancer (PCa). The exact role of IMP3 needs to be elucidated. The aim of this study is to determine the overall accuracy of IMP3 in PCa through a meta-analysis of published studies. Materials and methods: Publications addressing the accuracy of IMP3 in the diagnosis of PCa were selected from Pubmed, Embase, Cochrane Library, Web of Science, and The Chinese Journals Full-text Database (CNKI). The following indexes of test accuracy were computed for each study: sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). The diagnostic threshold identified for each study was used to plot a summary receiver operating characteristic (SROC) curve. Statistical analysis was performed by Meta-Disc 1.4 and STATA 12.0 software. Results: 10 studies met the inclusion criteria. The summary estimates for IMP3 in the diagnosis of PCa were: sensitivity 0.82 (95% CI, 0.78-0.85), specificity 0.87 (95% CI, 0.83-0.90), positive likelihood ratio (PLR) 15.04 (95% CI, 1.83-123.26), negative likelihood ratio (NLR) 0.21 (95% CI, 0.10-0.46) and diagnostic odds ratio 70.10 (95% CI, 16.74-293.56). The SROC curve indicated that the maximum joint sensitivity and specificity (Q-value) was 0.87; the area under the curve was 0.94. Conclusion: Our findings suggest that IMP3 may be a useful diagnostic adjunctive tool for confirming PCa. However, further large scale studies are needed to confirm these findings.
C1 [Wang, Qianqian; Wang, Zhu; Zheng, Hong] Sichuan Univ, West China Hosp, Ctr Canc, Lab Mol Diag Canc, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Tao] Peoples Hosp Zhengzhou, Dept Stomotol, Zhengzhou 450003, Henan, Peoples R China.
RP Zheng, H (reprint author), Sichuan Univ, West China Hosp, Ctr Canc, Lab Mol Diag Canc, Chengdu 610041, Sichuan, Peoples R China.
EM zhenghong-scu@126.com
CR Agarwal B, 2008, CLIN GASTROENTEROL H, V6, P1425, DOI 10.1016/j.cgh.2008.08.010
   Ali A, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-35
   Argani P, 2001, CLIN CANCER RES, V7, P3862
   Baker WL, 2009, INT J CLIN PRACT, V63, P1426, DOI 10.1111/j.1742-1241.2009.02168.x
   Baruch AC, 2007, DIAGN CYTOPATHOL, V35, P143, DOI 10.1002/dc.20594
   Bond-Smith G, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2476
   Chen ZR, 2008, CLIN MED, V15, P359
   Dabizzi Emanuele, 2011, Cancers (Basel), V3, P494, DOI 10.3390/cancers3010494
   Deeks JJ, 2005, J CLIN EPIDEMIOL, V58, P882, DOI 10.1016/j.jclinepi.2005.01.016
   Dim DC, 2014, DIAGN CYTOPATHOL, V42, P193, DOI 10.1002/dc.21684
   Frierson HF, 2003, HUM PATHOL, V34, P605, DOI 10.1016/S0046-8177(03)00177-1
   Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X
   Glass JP, 2011, INT J SURG PATHOL, V19, P588, DOI 10.1177/1066896911409575
   Harewood GC, 2002, GASTROINTEST ENDOSC, V55, P669, DOI 10.1067/mge.2002.123419
   Hassan R, 2005, AM J CLIN PATHOL, V124, P838, DOI 10.1309/F1B64CL7H8VJKEAF
   Hornick JL, 2005, AM J SURG PATHOL, V29, P381, DOI 10.1097/01.pas.0000149710.01559.fe
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Jhala N, 2006, AM J CLIN PATHOL, V126, P572, DOI 10.1309/CEV30BE088CBDQD9
   Jiang J, 2007, CHEST, V131, P1133, DOI 10.1378/chest.06-2273
   Jones CM, 2010, INT J CARDIOL, V140, P138, DOI 10.1016/j.ijcard.2009.05.063
   Karmazanovsky G, 2005, ABDOM IMAGING, V30, P488, DOI 10.1007/s00261-004-0279-z
   Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8
   Li DD, 2014, TUMOR BIOL, V35, P6003, DOI 10.1007/s13277-014-1795-2
   Liu HY, 2012, ARCH PATHOL LAB MED, V136, P601, DOI 10.5858/arpa.2011-0326-OA
   Lok T, 2014, HUM PATHOL, V45, P394, DOI 10.1016/j.humpath.2013.10.004
   McCarthy DM, 2003, APPL IMMUNOHISTO M M, V11, P238
   Miura Fumihiko, 2006, HPB (Oxford), V8, P337, DOI 10.1080/13651820500540949
   MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121403
   Niu YH, 2013, TUMOR BIOL, V34, P3667, DOI 10.1007/s13277-013-0948-z
   Ordonez NG, 2003, AM J SURG PATHOL, V27, P1031, DOI 10.1097/00000478-200308000-00001
   Plate JMD, 2012, DISCOV MED, V14, P89
   Scholler N, 1999, P NATL ACAD SCI USA, V96, P11531, DOI 10.1073/pnas.96.20.11531
   Sopha SC, 2013, INT J CLIN EXP PATHO, V6, P2476
   Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25
   Zhu QY, 2007, ACTA ACAD MED SIN, V27, P615
NR 35
TC 2
Z9 3
U1 1
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 7
BP 10603
EP 10610
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CR7UR
UT WOS:000361557500037
PM 26379850
DA 2018-12-27
ER

PT J
AU Mao, Y
   Qin, ZH
AF Mao, Yong
   Qin, Zong-He
TI RETRACTED: Association of apneic oxygenation with decreased desaturation
   rates during rapid sequence intubation by a Chinese emergency medicine
   service (Retracted article. See vol. 8, pg. 22577, 2015)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Emergency medicine; anaesthesiology; intubation
ID AIRWAY MANAGEMENT; VASCULAR EMERGENCIES; VENTILATION; ANESTHESIA
AB Rapid and safe airway management has always been of paramount importance in successful management of critically ill and injured patients in the emergency department. The achievement rate of emergency medicine inhabitants in airway management improved enhanced essentially subsequent to finishing anaesthesiology turn. There was a slightly higher rate of quick sequence intubation in the postapneic oxygenation groups (preapneic oxygenation 6.4%; postapneic oxygenation 9.1%). The majority of patients intubated in both groups were men (preapneic oxygenation 72.3%; postapneic oxygenation 63.5%). A higher percentage of patients in the preapneic oxygenation group had a Cormack-Lehane grade III or worse view (23.2% versus 11.8%). Anaesthesiology turns should be considered as an essential component of emergency medicine training programs. A collateral curriculum of this nature should also focus on the acquisition of skills in airway management.
C1 [Mao, Yong; Qin, Zong-He] Shanghai Jiao Tong Univ, Dept Intens Care Unit, Shanghai Peoples Hosp 9, Sch Med, Shanghai 200011, Peoples R China.
RP Qin, ZH (reprint author), Shanghai Jiao Tong Univ, Dept Intens Care Unit, Shanghai Peoples Hosp 9, Sch Med, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM qinzonghe503@gmail.com
CR [Anonymous], 2010, ACGME PROGRAM REQUIR
   Carley SD, 2002, EMERG MED J, V19, P109, DOI 10.1136/emj.19.2.109
   Chung SP, 1999, J KOREAN SOC EMERG M, V10, P379
   Ghosh SM, 2013, ANAEST INTENS CARE M, V14, P204, DOI 10.1016/j.mpaic.2013.02.018
   GUTTMAN T G, 1992, Journal of Emergency Medicine, V10, P357, DOI 10.1016/0736-4679(92)90344-S
   Howard-Alpe G, 2007, ANAEST INTENS CARE M, V8, P263, DOI 10.1016/j.mpaic.2007.03.011
   Kim BC, 1999, J KOREAN SOC EMERG M, V10, P579
   Langeron O, 2009, MINERVA ANESTESIOL, V75, P307
   Langeron O, 2000, ANESTHESIOLOGY, V92, P1229, DOI 10.1097/00000542-200005000-00009
   Mason RA, 1998, BRIT J ANAESTH, V81, P305, DOI 10.1093/bja/81.3.305
   Mort TC, 2005, CRIT CARE MED, V33, P2672, DOI 10.1097/01.CCM.0000187131.67594.9E
   Newton A, 2008, J TRAUMA, V64, P487, DOI 10.1097/TA.0b013e31802e7476
   Peter JV, 2006, LANCET, V367, P1155, DOI 10.1016/S0140-6736(06)68506-1
   Rao B, 2004, IND J CRITIC CARE ME, V8, P98
   SCHWARTZ DE, 1995, ANESTHESIOLOGY, V82, P367, DOI 10.1097/00000542-199502000-00007
   Walls R, 1998, J ACCID EMERG MED, V15, P392
   Wiler JL, 2015, J EMERG MED, V48, pE49, DOI 10.1016/j.jemermed.2014.09.033
   Wimalasena YH, 2014, EMERGEN MED J
NR 18
TC 1
Z9 1
U1 1
U2 8
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 7
BP 11428
EP 11434
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CR7UR
UT WOS:000361557500146
PM 26379959
DA 2018-12-27
ER

PT J
AU Luo, SL
   Wu, LF
   Zhou, J
   Xu, SC
   Yang, QS
   Li, Y
   Shen, HQ
   Zhang, SG
AF Luo, Shilin
   Wu, Longfei
   Zhou, Jiang
   Xu, Shicheng
   Yang, Qingsong
   Li, Yao
   Shen, Huaqiang
   Zhang, Shiguo
TI RETRACTED: Tracheobronchopathia osteochondroplastica: two cases and a
   review of the literature (Retracted article. See vol. 9, pg. 2753, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE Tracheobronchopathia osteochondroplastica
ID OSTEOPLASTICA; DIAGNOSIS; BRONCHOSCOPY; INTUBATION
AB Introduction: Tracheobronchopathia osteochondroplastica (TO) is a rare disorder involving the lumen of the trachea-bronchial tree and characterized by multiple sub-mucosal osseous and cartilaginous nodules in the trachea and bronchus, sparing the posterior wall. We here report two cases of patients with tracheobronchopathia osteochondroplastica and review the relevant literature briefly. Case presentation. Case 1 was a 64-year-old woman with a history of Chronic Obstructive Pulmonary Disease (COPD) who presented with frequent non-productive cough for 2 years. Chest computed tomography (CT) showed signs consistent with COPD and evident irregular narrowing of the tracheal and both main bronchial lumen caused by calcific foci. Fibre optic bronchoscope (FOB) was performed and showed dozens of sub-mucosal nodules protruding into the lumen of lower half of the trachea and both main bronchi. Histopathological exam demonstrated sub-mucosal ossification and cartilage in the sample. Her follow-up has been uneventful for 3 years. Case 2 was a 37-year-old man presented with hoarseness, exertional dyspnea, and intermittent dry cough for about 3 years. Chest CT scans showed irregular nodules around the entire circumference of the trachea extending from sub-glottic region to lower trachea. FOB showed glottic stenosis and diffused sub-mucosal calcified nodules protruding from the antero-lateral portion of the trachea in the subglottic region. Over the following 12 months, his disease is stable. Conclusions. TO is a rare, benign disease with slow progression, clinicians should be aware of TO and should consider it in patients with chronic cough, recurrent respiratory infection and evolving exertional dyspnea.
C1 [Luo, Shilin; Zhou, Jiang; Zhang, Shiguo] Bazhong Cent Hosp, Dept Resp Med, Sichuan 636000, Peoples R China.
   [Wu, Longfei] Bazhong Cent Hosp, Dept Cardiol, Sichuan 636000, Peoples R China.
   [Xu, Shicheng; Shen, Huaqiang] Bazhong Cent Hosp, Intens Care Unit, Sichuan 636000, Peoples R China.
   [Yang, Qingsong] Bazhong Cent Hosp, Dept Pathol, Sichuan 636000, Peoples R China.
   [Li, Yao] Bazhong Cent Hosp, Dept Radiol, Sichuan 636000, Peoples R China.
RP Wu, LF (reprint author), Bazhong Cent Hosp, Dept Cardiol, 1 Nanchihe St, Bazhong 636000, Sichuan, Peoples R China.
EM taoguox@hotmail.com
CR Bachy A, 2012, EUR ANN OTORHINOLARY, V129, P211, DOI 10.1016/j.anorl.2011.11.002
   Danckers M, 2015, AM J CASE REP, V16, P45, DOI 10.12659/AJCR.892427
   GAUTAM HP, 1968, POSTGRAD MED J, V44, P186, DOI 10.1136/pgmj.44.508.186
   Hantous-Zannad S, 2003, EUR J RADIOL, V45, P113, DOI 10.1016/S0720-048X(02)00028-1
   HODGES MK, 1988, CHEST, V94, P842, DOI 10.1378/chest.94.4.842
   Jindal S, 2013, J RADIOL CASE REP, V7, P16, DOI 10.3941/jrcr.v7i3.1305
   Leske V, 2001, MEDICINE, V80, P378, DOI 10.1097/00005792-200111000-00004
   Martens Patrick R, 2012, J Cardiothorac Vasc Anesth, V26, pe35, DOI 10.1053/j.jvca.2012.01.030
   Meyer CN, 1997, RESP MED, V91, P499, DOI 10.1016/S0954-6111(97)90117-7
   PAASKE PB, 1985, J LARYNGOL OTOL, V99, P305, DOI 10.1017/S0022215100096742
   Raess PW, 2011, ANN DIAGN PATHOL, V15, P431, DOI 10.1016/j.anndiagpath.2011.04.009
   Sant'Anna CC, 2012, INDIAN PEDIATR, V49, P985, DOI 10.1007/s13312-012-0223-1
   Sarinc Ulasli S, 2014, CLIN RESP J
   Sellon RK, 2004, J VET INTERN MED, V18, P359, DOI 10.1892/0891-6640(2004)18<359:TOIAD>2.0.CO;2
   Swamy T L N, 2010, Indian J Chest Dis Allied Sci, V52, P119
   Thakur A, 2013, MED PRIN PRACT, V22, P503, DOI 10.1159/000346662
   Thomas D, 2001, BRIT J ANAESTH, V87, P515, DOI 10.1093/bja/87.3.515
   Warner MA, 2013, J CLIN ANESTH, V25, P659, DOI 10.1016/j.jclinane.2013.05.010
   Willms Hinrich, 2008, Cough, V4, P4, DOI 10.1186/1745-9974-4-4
   Zhu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102068
NR 20
TC 3
Z9 3
U1 1
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 7
BP 8585
EP 8590
PG 6
WC Oncology; Pathology
SC Oncology; Pathology
GA CR7OB
UT WOS:000361538900107
PM 26339438
DA 2018-12-27
ER

PT J
AU Chen, ZW
   Shek, CH
   Wu, CML
AF Chen, Zhiwen
   Shek, Chan-Hung
   Wu, C. M. Lawrence
TI RETRACTED: Insights from investigations of tin dioxide and its
   composites: electron-beam irradiation, fractal assessment, and
   mechanism(Retracted article. See vol. 9, pg. 13343, 2017)
SO NANOSCALE
LA English
DT Review; Retracted Publication
ID LITHIUM-ION BATTERIES; FUNCTIONALIZED GRAPHENE SHEETS; PULSED-LASER
   DEPOSITION; THIN-FILM PARTICLES; IN-SITU SYNTHESIS; ANODE MATERIAL;
   GRAPHITE OXIDE; SENSING CHARACTERISTICS; NANOCRYSTALLINE SNO2;
   RAMAN-SCATTERING
AB Tin dioxide (SnO2) is a unique strategic functional material with widespread technological applications, particularly in fields such as solar batteries, optoelectronic devices, and solid-state gas sensors owing to advances in its optical and electronic properties. In this review, we introduce the recent progress of tin dioxide and its composites, including the synthesis strategies, microstructural evolution, related formation mechanism, and performance evaluation of SnO2 quantum dots (QDs), thin films, and composites prepared by electron-beam irradiation, pulsed laser ablation, and SnO2 planted graphene strategies, highlighting contributions from our laboratory. First, we present the electron-beam irradiation strategies for the growth behavior of SnO2 nanocrystals. This method is a potentially powerful technique to achieve the nucleation and growth of SnO2 QDs. In addition, the fractal assessment strategies and gas sensing behavior of SnO2 thin films with interesting micro/nanostructures induced by pulsed delivery will be discussed experimentally and theoretically. Finally, we emphasize the fabrication process and formation mechanism of SnO2 QD planted graphene nanosheets. This review may provide a new insight that the versatile strategies for microstructural evolution and related performance of SnO2-based functional materials are of fundamental importance in the development of new materials.
C1 [Chen, Zhiwen] Shanghai Univ, Sch Environm & Chem Engn, Shanghai 200444, Peoples R China.
   [Chen, Zhiwen; Shek, Chan-Hung; Wu, C. M. Lawrence] City Univ Hong Kong, Dept Phys & Mat Sci, Kowloon Tong, Hong Kong, Peoples R China.
RP Chen, ZW (reprint author), Shanghai Univ, Sch Environm & Chem Engn, Shanghai 200444, Peoples R China.
EM zwchen@shu.edu.cn; apcmlwu@cityu.edu.hk
RI SHEK, Chan Hung/J-3857-2015; Chen, Zhiwen/S-7256-2016; Wu,
   Chi-Man/J-3920-2016
OI SHEK, Chan Hung/0000-0002-6870-523X; Chen, Zhiwen/0000-0001-9625-8556;
   Wu, Chi-Man/0000-0002-7190-8855
FU National Natural Science Foundation of China [11375111, 11428410,
   11074161]; Research Fund for Doctoral Program of Higher Education of
   China [20133108110021]; Shanghai Municipal Education Commission
   [14ZZ098, 10ZZ64]; Science and Technology Commission of Shanghai
   Municipality [14JC1402000, 10JC1405400]; Shanghai Pujiang Program
   [10PJ1404100]; Program for Innovative Research Team in University
   [IRT13078]; General Research Fund from Research Grants Council, Hong
   Kong [CityU 119212]
FX The work described in this article was financially supported by the
   National Natural Science Foundation of China (Project Number: 11375111,
   11428410 and 11074161), the Research Fund for the Doctoral Program of
   Higher Education of China (Project Number: 20133108110021), the Key
   Innovation Fund of Shanghai Municipal Education Commission (Project
   Number: 14ZZ098 and 10ZZ64), the Science and Technology Commission of
   Shanghai Municipality (Project Number: 14JC1402000 and 10JC1405400), the
   Shanghai Pujiang Program (Project Number: 10PJ1404100), and the Program
   for Innovative Research Team in University (Project Number: IRT13078).
   This work was also supported by a General Research Fund from the
   Research Grants Council, Hong Kong (Project Number: CityU 119212).
CR Abello L, 1998, J SOLID STATE CHEM, V135, P78, DOI 10.1006/jssc.1997.7596
   Abergel DSL, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.155430
   Badawy WA, 2002, SOL ENERG MAT SOL C, V71, P281, DOI 10.1016/S0927-0248(01)00087-3
   Badawy WA, 2008, J ALLOY COMPD, V464, P347, DOI 10.1016/j.jallcom.2007.09.122
   Balazs AC, 2006, SCIENCE, V314, P1107, DOI 10.1126/science.1130557
   Berger C, 2004, J PHYS CHEM B, V108, P19912, DOI 10.1021/jp040650f
   Berthe L, 1997, J APPL PHYS, V82, P2826, DOI 10.1063/1.366113
   Castillo JD, 2005, NANOTECHNOLOGY, V16, pS300
   Chen C, 2013, LANGMUIR, V29, P4111, DOI 10.1021/la304753x
   Chen SQ, 2010, J MATER CHEM, V20, P9735, DOI 10.1039/c0jm01573c
   Chen ZW, 2011, PROG MATER SCI, V56, P901, DOI 10.1016/j.pmatsci.2011.02.001
   Chen ZW, 2008, CRIT REV SOLID STATE, V33, P197, DOI 10.1080/10408430802415006
   Chen ZW, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2399352
   Chen ZW, 2012, CHEM REV, V112, P3833, DOI 10.1021/cr2004508
   Chen ZW, 2011, J PHYS CHEM C, V115, P9871, DOI 10.1021/jp200227y
   Chen ZW, 2010, ACS NANO, V4, P1202, DOI 10.1021/nn901635f
   Chen ZW, 2006, APPL PHYS LETT, V88, DOI [10.1063/1.2162689, 10.1063/j.2162689]
   Chen ZW, 2006, CHEM PHYS LETT, V422, P1, DOI 10.1016/j.cplett.2006.02.036
   Chen ZW, 2005, J NON-CRYST SOLIDS, V351, P3619, DOI 10.1016/j.jnoncrysol.2005.09.027
   Chen ZW, 2005, PHYS LETT A, V345, P391, DOI 10.1016/j.physleta.2005.07.041
   Chen ZW, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.165314
   Chen ZW, 2005, APPL PHYS A-MATER, V81, P959, DOI 10.1007/s00339-004-3099-7
   Chen ZW, 1998, THIN SOLID FILMS, V322, P194, DOI 10.1016/S0040-6090(97)00907-3
   Chen ZW, 1998, J VAC SCI TECHNOL A, V16, P2292, DOI 10.1116/1.581343
   Cheng B, 2004, J AM CHEM SOC, V126, P5972, DOI 10.1021/ja0493244
   Cho YS, 2006, THIN SOLID FILMS, V515, P1864, DOI 10.1016/j.tsf.2006.07.022
   Cicera A., 1999, SENSOR ACTUAT B-CHEM, V58, P360
   COOPER RB, 1981, J ELECTRON MATER, V10, P455, DOI 10.1007/BF02654585
   Cullity B. D., 1978, ELEMENTS XRAY DIFFRA
   Dahlan HM, 2002, RADIAT PHYS CHEM, V64, P429, DOI 10.1016/S0969-806X(01)00491-1
   Dai ZR, 2002, J PHYS CHEM B, V106, P1274, DOI 10.1021/jp013214r
   Dai ZR, 2003, ADV FUNCT MATER, V13, P9, DOI 10.1002/adfm.200390013
   DEMARNE V, 1988, SENSOR ACTUATOR, V13, P301, DOI 10.1016/0250-6874(88)80043-X
   Dieguez A, 2001, J APPL PHYS, V90, P1550, DOI 10.1063/1.1385573
   Ding SJ, 2011, CHEM COMMUN, V47, P5780, DOI 10.1039/c1cc10687b
   Dos Santos O, 2001, SENSOR ACTUAT B-CHEM, V75, P83, DOI 10.1016/S0925-4005(01)00537-8
   Dresselhaus MS, 2002, ADV PHYS, V51, P1, DOI 10.1080/00018730110113644
   Du J, 2011, J NANOSCI NANOTECHNO, V11, P9709, DOI 10.1166/jnn.2011.5293
   Du ZF, 2010, MATER LETT, V64, P2076, DOI 10.1016/j.matlet.2010.06.039
   Falla PH, 2005, MATER SCI FORUM, V498-499, P636, DOI 10.4028/www.scientific.net/MSF.498-499.636
   Fallah HR, 2007, PHYSICA E, V39, P69, DOI 10.1016/j.physe.2007.01.003
   Feder J., 1988, FRACTAL, P15
   Gu F, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/9/095708
   Harbeck S, 2003, THIN SOLID FILMS, V436, P76, DOI 10.1016/S0040-6090(03)00512-1
   He HY, 1998, CHEM PHYS LETT, V287, P53, DOI 10.1016/S0009-2614(98)00144-4
   Hirata M, 2005, CARBON, V43, P503, DOI 10.1016/j.carbon.2004.10.009
   Hirata M, 2004, CARBON, V42, P2929, DOI 10.1016/j.carbon.2004.07.003
   HOU JG, 1989, PHYS REV B, V40, P1008, DOI 10.1103/PhysRevB.40.1008
   JARZEBSKI ZM, 1976, J ELECTROCHEM SOC, V123, pC199, DOI 10.1149/1.2132647
   JIANG YJ, 1989, PHYS STATUS SOLIDI B, V156, P145, DOI 10.1002/pssb.2221560115
   Kim D, 2001, J APPL PHYS, V89, P5703, DOI 10.1063/1.1366663
   Kim H, 2011, CARBON, V49, P326, DOI 10.1016/j.carbon.2010.09.033
   Kim YJ, 1997, J VAC SCI TECHNOL A, V15, P1103, DOI 10.1116/1.580437
   Korosi L, 2005, COLLOID SURFACE A, V268, P147, DOI 10.1016/j.colsurfa.2005.05.074
   Krishnakumar T, 2009, MATER LETT, V63, P896, DOI 10.1016/j.matlet.2009.01.032
   LANTTO V, 1987, SURF SCI, V192, P243, DOI 10.1016/S0039-6028(87)81174-3
   Lee EJH, 2004, APPL PHYS LETT, V84, P1745, DOI 10.1063/1.1655693
   Lee JW, 2012, CHEM MATER, V24, P1158, DOI 10.1021/cm203697w
   Lerf A, 1998, J PHYS CHEM B, V102, P4477, DOI 10.1021/jp9731821
   Li BJ, 2011, J MATER CHEM, V21, P5069, DOI 10.1039/c0jm03717f
   Li BJ, 2011, INORG CHEM, V50, P1628, DOI 10.1021/ic1023086
   Li L, 2012, J MATER CHEM, V22, P3600, DOI 10.1039/c2jm15075a
   Li Z, 2008, COLLOID SURFACE A, V313, P40, DOI 10.1016/j.colsurfa.2007.04.069
   Lian PC, 2011, ELECTROCHIM ACTA, V56, P4532, DOI 10.1016/j.electacta.2011.01.126
   Lian PC, 2010, ELECTROCHIM ACTA, V56, P834, DOI 10.1016/j.electacta.2010.09.086
   Liang JF, 2012, ACS APPL MATER INTER, V4, P454, DOI 10.1021/am201541s
   Lin YJ, 1997, SURF COAT TECH, V88, P239, DOI 10.1016/S0257-8972(96)02926-X
   Liu HP, 2009, ELECTROCHIM ACTA, V54, P5782, DOI 10.1016/j.electacta.2009.05.030
   Liu Y, 2005, CHEM MATER, V17, P3997, DOI 10.1021/cm050451o
   Lou XW, 2008, ADV MATER, V20, P3987, DOI 10.1002/adma.200800854
   Mikko U., 2000, MIKROCHIM ACTA, V133, P119
   Nair RR, 2008, SCIENCE, V320, P1308, DOI 10.1126/science.1156965
   Ng HT, 2003, SCIENCE, V300, P1249, DOI 10.1126/science.1082542
   Noerochim L, 2010, ELECTROCHIM ACTA, V56, P314, DOI 10.1016/j.electacta.2010.08.078
   Novoselov KS, 2005, NATURE, V438, P197, DOI 10.1038/nature04233
   Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896
   OYABU T, 1982, J APPL PHYS, V53, P2785, DOI 10.1063/1.331079
   Paek SM, 2009, NANO LETT, V9, P72, DOI 10.1021/nl802484w
   Pan ZW, 2001, SCIENCE, V291, P1947, DOI 10.1126/science.1058120
   Pandey PC, 1999, SENSOR ACTUAT B-CHEM, V56, P112, DOI 10.1016/S0925-4005(99)00166-5
   Paraguay-Delgado F, 2005, NANOTECHNOLOGY, V16, P688, DOI 10.1088/0957-4484/16/6/011
   Patzke GR, 2002, ANGEW CHEM INT EDIT, V41, P2446, DOI 10.1002/1521-3773(20020715)41:14<2446::AID-ANIE2446>3.0.CO;2-K
   Peng CX, 2012, ACS NANO, V6, P1074, DOI 10.1021/nn202888d
   Penn RL, 1998, SCIENCE, V281, P969, DOI 10.1126/science.281.5379.969
   Penn RL, 1999, GEOCHIM COSMOCHIM AC, V63, P1549, DOI 10.1016/S0016-7037(99)00037-X
   Qin LP, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/18/185705
   Qiu YC, 2010, ACS NANO, V4, P6515, DOI 10.1021/nn101603g
   Ramanathan T, 2008, NAT NANOTECHNOL, V3, P327, DOI 10.1038/nnano.2008.96
   ROMPPAINEN P, 1988, J APPL PHYS, V63, P5159, DOI 10.1063/1.340419
   Salmas CE, 2005, LANGMUIR, V21, P11146, DOI 10.1021/la0508644
   Shek CH, 1999, J PHYS CHEM SOLIDS, V60, P189, DOI 10.1016/S0022-3697(98)00269-8
   Shimizu Y, 2005, SENSOR ACTUAT B-CHEM, V108, P56, DOI 10.1016/j.snb.2004.10.047
   Shukla S, 2004, SENSOR ACTUAT B-CHEM, V97, P256, DOI 10.1016/j.snb.2003.08.025
   Stankovich S, 2006, NATURE, V442, P282, DOI 10.1038/nature04969
   Sun SH, 2003, CHEM PHYS LETT, V376, P103, DOI 10.1016/S0009-2614(03)00965-5
   Szabo T, 2005, CARBON, V43, P87, DOI 10.1016/j.carbon.2004.08.025
   TUINSTRA F, 1970, J CHEM PHYS, V53, P1126, DOI 10.1063/1.1674108
   Wang B, 2010, J MATER CHEM, V20, P10661, DOI 10.1039/c0jm01941k
   Wang DH, 2010, ACS NANO, V4, P1587, DOI 10.1021/nn901819n
   Wang F, 2008, SCIENCE, V320, P206, DOI 10.1126/science.1152793
   Wang HL, 2010, J AM CHEM SOC, V132, P13978, DOI 10.1021/ja105296a
   Wang J, 2011, J PHYS CHEM C, V115, P20523, DOI 10.1021/jp207673r
   Wang WZ, 2002, J APPL PHYS, V92, P2740, DOI 10.1063/1.1497718
   Wang X, 2005, NATURE, V437, P121, DOI 10.1038/nature03968
   Wang XY, 2011, CARBON, V49, P133, DOI 10.1016/j.carbon.2010.08.052
   Wang Y, 2006, ADV MATER, V18, P645, DOI 10.1002/adma.200501883
   Wang Z. L., 1998, FUNCTIONAL SMART MAT
   Wang ZL, 2003, ADV MATER, V15, P432, DOI 10.1002/adma.200390100
   WINDISCHMANN H, 1979, J ELECTROCHEM SOC, V126, P627, DOI 10.1149/1.2129098
   Wu ZS, 2010, ACS NANO, V4, P3187, DOI 10.1021/nn100740x
   Xi GC, 2010, INORG CHEM, V49, P2302, DOI 10.1021/ic902131a
   Xia YN, 2009, ANGEW CHEM INT EDIT, V48, P60, DOI 10.1002/anie.200802248
   Xu C, 2009, J SOLID STATE CHEM, V182, P2486, DOI 10.1016/j.jssc.2009.07.001
   Xu YX, 2008, J AM CHEM SOC, V130, P5856, DOI 10.1021/ja800745y
   Yin Y, 2005, NATURE, V437, P664, DOI 10.1038/nature04165
   Ying Z, 2004, NANOTECHNOLOGY, V15, P1682, DOI 10.1088/0957-4484/15/11/053
   YU KN, 1995, NANOSTRUCT MATER, V5, P819, DOI 10.1016/0965-9773(95)00284-L
   Yu MF, 2000, SCIENCE, V287, P637, DOI 10.1126/science.287.5453.637
   Zeng H, 2002, NATURE, V420, P395, DOI 10.1038/nature01208
   Zeng YF, 2009, J HAZARD MATER, V162, P682, DOI 10.1016/j.jhazmat.2008.05.094
   Zhang LS, 2010, J MATER CHEM, V20, P5462, DOI 10.1039/c0jm00672f
   Zhang SL, 2010, J PHYS CHEM C, V114, P19284, DOI 10.1021/jp107780q
   Zhang YB, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.176803
   Zhang YB, 2005, NATURE, V438, P201, DOI 10.1038/nature04235
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
   Zhong A., 2011, J PHYS CHEM C, V115, P25115
   Zhong LS, 2007, CHEM MATER, V19, P4557, DOI 10.1021/cm0714032
   Zhu HL, 2006, NANOTECHNOLOGY, V17, P2386, DOI 10.1088/0957-4484/17/9/052
   Zhu JX, 2011, J PHYS CHEM C, V115, P8400, DOI 10.1021/jp2002113
   Zhu JJ, 2002, MATER LETT, V53, P12, DOI 10.1016/S0167-577X(01)00445-1
   Zhu S, 2001, APPL PHYS LETT, V79, P1396, DOI 10.1063/1.1400086
   Zhu S, 2001, J APPL PHYS, V89, P2400, DOI 10.1063/1.1342200
   Zhu XJ, 2011, ACS NANO, V5, P3333, DOI 10.1021/nn200493r
   Zou YQ, 2011, NANOSCALE, V3, P2615, DOI 10.1039/c1nr10070j
NR 134
TC 6
Z9 6
U1 10
U2 92
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2015
VL 7
IS 38
BP 15532
EP 15552
DI 10.1039/c5nr04255k
PG 21
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CS1NV
UT WOS:000361834100001
PM 26365058
DA 2018-12-27
ER

PT J
AU Zhao, XG
   Liu, P
   Song, YC
   Zhang, AP
   Chen, XM
   Zhou, JP
AF Zhao, Xiao-gang
   Liu, Peng
   Song, Yue-Chan
   Zhang, An-ping
   Chen, Xiao-ming
   Zhou, Jian-ping
TI RETRACTED: Origin of colossal permittivity in (In1/2Nb1/2)TiO2 via
   broadband dielectric spectroscopy (Retracted article. See vol. 18, pg.
   26310, 2016)
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article; Retracted Publication
ID HIGH-DIELECTRIC-CONSTANT; CACU3TI4O12 CERAMICS; RAMAN-SPECTROSCOPY;
   RELAXATION; TIO2
AB (In1/2Nb1/2)TiO2 (IN-T) ceramics were prepared via a solid-state reaction route. X-ray diffraction (XRD) and Raman spectroscopy were used for the structural and compositional characterization of the synthesized compounds. The results indicated that the sintered ceramics have a single phase of rutile TiO2. Dielectric spectroscopy (frequency range from 20 Hz to 1 MHz and temperature range from 10 K to 270 K) was performed on these ceramics. The IN-T ceramics showed extremely high permittivities of up to similar to 10(3), which can be referred to as colossal permittivity, with relatively low dielectric losses of similar to 0.05. Most importantly, detailed impedance data analyses of IN-T demonstrated that electron-pinned defect-dipoles, interfacial polarization and polaron hopping polarization contribute to the colossal permittivity at high temperatures (270 K); however, only the complexes (pinned electron) and polaron hopping polarization are active at low temperatures (below 180 K), which is consistent with UDR analysis.
C1 [Zhao, Xiao-gang; Liu, Peng; Song, Yue-Chan; Zhang, An-ping; Chen, Xiao-ming; Zhou, Jian-ping] Shaanxi Normal Univ, Coll Phys & Informat Technol, Xian 710062, Peoples R China.
RP Liu, P (reprint author), Shaanxi Normal Univ, Coll Phys & Informat Technol, Xian 710062, Peoples R China.
EM liupeng@snnu.edu.cn
FU National Natural Science Foundation of China [51372147]; Fundamental
   Research Funds for the Central Universities [GK201502005, GK201401003];
   Shaanxi Normal outstanding doctoral dissertation [S2012YB05, X2013YB01];
   Specialized Research Fund for the Doctoral Program of Higher Education
   [20120202110004]
FX This study is supported by the National Natural Science Foundation of
   China (No. 51372147), the Fundamental Research Funds for the Central
   Universities (GK201502005, GK201401003), Shaanxi Normal outstanding
   doctoral dissertation (S2012YB05, X2013YB01), Specialized Research Fund
   for the Doctoral Program of Higher Education (No. 20120202110004).
CR Abrams H., 1971, Metallography, V4, P59, DOI 10.1016/0026-0800(71)90005-X
   Adams TB, 2002, ADV MATER, V14, P1321, DOI 10.1002/1521-4095(20020916)14:18<1321::AID-ADMA1321>3.0.CO;2-P
   Buscaglia MT, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.064114
   Cheng XJ, 2015, J MATER CHEM A, V3, P5805, DOI 10.1039/c5ta00141b
   Gai ZG, 2014, J MATER CHEM C, V2, P6790, DOI 10.1039/c4tc00500g
   Gajovic A, 2001, J MOL STRUCT, V563, P315, DOI 10.1016/S0022-2860(00)00790-0
   Guillemet-Fritsch S, 2008, ADV MATER, V20, P551, DOI 10.1002/adma.200700245
   Homes CC, 2001, SCIENCE, V293, P673, DOI 10.1126/science.1061655
   Hu WB, 2013, NAT MATER, V12, P821, DOI [10.1038/nmat3691, 10.1038/NMAT3691]
   Ikeda N, 2005, NATURE, V436, P1136, DOI 10.1038/nature04039
   Jonscher AK, 1999, J PHYS D APPL PHYS, V32, pR57, DOI 10.1088/0022-3727/32/14/201
   Krohns S, 2011, NAT MATER, V10, P899, DOI 10.1038/nmat3180
   Krohns S, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3105993
   Krohns S, 2008, J APPL PHYS, V103, DOI 10.1063/1.2902374
   Li J., 2015, SCI REP, P5
   Li JL, 2014, J APPL PHYS, V116, DOI 10.1063/1.4893316
   Li M, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2200732
   Li YH, 2012, MATER SCI ENG B-ADV, V177, P673, DOI 10.1016/j.mseb.2012.03.054
   Liu Y, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.134104
   Lunkenheimer P, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.052105
   Lunkenheimer P, 2010, EUR PHYS J-SPEC TOP, V180, P61, DOI 10.1140/epjst/e2010-01212-5
   Macdonald J. R., 1987, IMPEDANCE SPECTROSCO
   MELENDRES CA, 1989, J MATER RES, V4, P1246, DOI 10.1557/JMR.1989.1246
   Nowick AS, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.184115
   Ramirez AP, 2000, SOLID STATE COMMUN, V115, P217, DOI 10.1016/S0038-1098(00)00182-4
   Sinclair DC, 2002, APPL PHYS LETT, V80, P2153, DOI 10.1063/1.1463211
   Subramanian MA, 2000, J SOLID STATE CHEM, V151, P323, DOI 10.1006/jssc.2000.8703
   Swamy V, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2364123
   Wang CC, 2007, NEW J PHYS, V9, DOI 10.1088/1367-2630/9/7/210
   Wang CC, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2168495
   Wu JB, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.217601
   Zhang L, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.174306
   Zhu Y, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.037602
NR 33
TC 36
Z9 36
U1 7
U2 79
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
EI 1463-9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PY 2015
VL 17
IS 35
BP 23132
EP 23139
DI 10.1039/c5cp02741a
PG 8
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA CQ2RH
UT WOS:000360448300079
PM 26278381
DA 2018-12-27
ER

PT J
AU Liu, J
   Yang, WJ
   Wu, XY
   Hu, XR
AF Liu, Juan
   Yang, Wenjun
   Wu, Xiangyan
   Hu, Xiangrong
TI RETRACTED: Invasive cystic hypersecretory carcinoma of the breast: a
   case report (Retracted article. See vol. 9, pg. 2757, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE Breast; neoplasms; carcinoma; cystic hypersecretory carcinoma; cystic
   hypersecretory hyperplasia
ID DUCTAL CARCINOMA; IN-SITU; HYPERPLASIA
AB Purpose: To report a new case of invasive cystic hypersecretory carcinoma. The clinical and pathological characteristics of the lesion and a review of the literature are both described. Methods: A descriptive study of a case of invasive CHC occurring in a 60-yr-old woman is presented. Tumor was standard processed and stained by hematoxylin & eosin, PAS, immunohistochemically examined for ER, PR, C-erbB-2, CEA, thyroglobulin, E-cadherin, S-100 protein, and Cytokeratin5/6. Results: The tumor, which was 4.7x3.7x3.0 cm, was localized in the upper region of the left breast. This tumor revealed multiple cystic spaces, which were filled with PAS. It was positive for CEA, ER, E-cadherin, and S-100 protein, but negative for thyroglobulin, PR, and C-erbB-2. Cytokeratin5/6 was expressed in the cystic hypersecretory hyperplasia region, but not in the invasive area. The ten-month follow-up period was uneventful. Conclusions: Cystic hypersecretory carcinoma of the breast is a rare and distinctive variant of ductal carcinoma in situ. It has the potential for invasive growth. As there are few recorded cases, the prognosis in patients with invasive CHC is still uncertain and a matter of intensive debate.
C1 [Liu, Juan; Yang, Wenjun; Wu, Xiangyan; Hu, Xiangrong] Hangzhou Normal Univ, Affiliated Hosp, Dept Pathol, Hangzhou 310015, Zhejiang, Peoples R China.
RP Liu, J (reprint author), Hangzhou Normal Univ, Affiliated Hosp, Dept Pathol, Hangzhou 310015, Zhejiang, Peoples R China.
EM liujuan-tj@163.com
CR Bi Rui, 2014, Zhonghua Bing Li Xue Za Zhi, V43, P25
   Chen Ding-bao, 2010, Chinese Journal of Pathology, V39, P54, DOI 10.3760/cma.j.issn.0529-5807.2010.01.014
   D'Alfonso TM, 2014, AM J SURG PATHOL, V38, P45, DOI 10.1097/PAS.0b013e31829fc47b
   GUERRY P, 1988, CANCER, V61, P1611, DOI 10.1002/1097-0142(19880415)61:8<1611::AID-CNCR2820610819>3.0.CO;2-O
   Herrmann ME, 1999, ARCH PATHOL LAB MED, V123, P1108
   Lee JS, 2001, J KOREAN MED SCI, V16, P516, DOI 10.3346/jkms.2001.16.4.516
   Mourad W, 1998, ANN SAUDI MED, V18, P296, DOI 10.5144/0256-4947.1998.296
   ROSEN PP, 1984, AM J SURG PATHOL, V8, P31, DOI 10.1097/00000478-198401000-00003
   Shah AK, 2000, BREAST J, V6, P269
NR 9
TC 1
Z9 1
U1 1
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 6
BP 7499
EP 7502
PG 4
WC Oncology; Pathology
SC Oncology; Pathology
GA CO6PD
UT WOS:000359277700183
PM 26261660
DA 2018-12-27
ER

PT J
AU Gu, JS
   Sun, RR
   Shen, S
   Yu, ZJ
AF Gu, Junsheng
   Sun, Ranran
   Shen, Shen
   Yu, Zujiang
TI RETRACTED: The influence of TLR4 agonist lipopolysaccharides on
   hepatocellular carcinoma cells and the feasibility of its application in
   treating liver cancer (Retracted article. See vol. 9, pg. 615, 2016)
SO ONCOTARGETS AND THERAPY
LA English
DT Article; Retracted Publication
DE water soluble tetrazolium-1; propidium iodide single staining; Annexin
   V/PI double staining; cell proliferation; signaling pathway; LPS
AB Objective: This study was designed to explore the influence of Toll-like receptor 4 (TLR4) agonist lipopolysaccharides (LPS) on liver cancer cell and the feasibility to perform liver cancer adjuvant therapy.
   Methods: Human liver cancer cell lines HepG2, H7402, and PLC/PRF/5 were taken as models, and the expression of TLRs mRNA was detected by real time-polymerase chain reaction method semiquantitatively. WST-1 method was used to detect the influence of LPS on the proliferation ability of liver cancer cells; propidium iodide (PI) single staining and Annexin V/PI double staining were used to test the influence of LPS on the cell cycle and apoptosis, respectively, on human liver cancer cell line H7402. Fluorescent quantitative polymerase chain reaction and Western blot method were used to determine the change of expression of Cyclin D1.
   Results: The results demonstrated that most TLRs were expressed in liver cancer cells; stimulating TLR4 by LPS could upregulate TLR4 mRNA and the protein level, activate NF-kappa B signaling pathway downstream of TLR4, and mediate the generation of inflammatory factors IL-6, IL-8, and TNF-alpha; LPS was found to be able to strengthen the proliferation ability of liver cancer cells, especially H7402 cells; the expression of Cyclin D1 rose and H7402 cells were promoted to transit from G(1) stage to S stage under the stimulation of LPS, but cell apoptosis was not affected. It was also found that LPS was able to activate signal transducer and activator of transcription -3 (STAT3) signaling pathway in H7402 cells and meanwhile significantly increase the initiation activity of STAT3; proliferation promoting effect of LPS to liver cancer cells remarkably lowered once STAT3 was blocked or inhibited.
   Conclusion: Thus, TLR4 agonist LPS is proved to be able to induce liver cancer cells to express inflammation factors and mediate liver cancer cell proliferation and generation of multidrug resistance by activating the cyclooxygenase-2/prostaglandin signal axis as well as the STAT3 pathway.
C1 [Gu, Junsheng; Sun, Ranran; Shen, Shen; Yu, Zujiang] Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, Zhengzhou 450052, Henan, Peoples R China.
RP Yu, ZJ (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
EM yzj@ibhsedu.com
CR Alexander G., 2009, CARCINOGENESIS, V30, P377
   Anding G, 2013, CHINESE J BIOCH MOL, V29, P397
   Chengfang Y, 2012, MED RECAPITULATE, V18, P524
   Claire JG, 2011, J IMMUNOL, V186, P1199
   Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002
   Elke MB, 2000, J IMMUNOL, V165, P1612
   Folkert S, 2011, VACCINE, V29, P3341
   Han C, 2006, BIOL CHEM, V28, P24831
   Hoebe CJPA, 2012, VACCINE, V30, P6734, DOI 10.1016/j.vaccine.2012.08.074
   Hong W, 2014, CHIN J GERONTOL, V34, P3076
   Hua S, 2011, CARCINOGENESIS, V32, P667
   Huajun Z, 2014, CHIN J IMMUNOL, V30, P30
   Jia F, 2011, PRACT J CLIN MED, V8, P16
   Krieg AM, 2008, ONCOGENE, V27, P161, DOI 10.1038/sj.onc.1210911
   Lihua Z, 2014, CHIN J CELL MOL IMMU, V30, P767
   Ornella F, 2002, HEPATOLOGY, V35, P843
   Sheau-Fang Y, 2007, J CLIN PATHOL, V60, P642
   Szczepanski MJ, 2009, CANCER RES, V69, P3105, DOI 10.1158/0008-5472.CAN-08-3838
   Xiaoxia S, 2008, CANC LETT, V262, P201
   Xulong Z, 2011, PLOS ONE, V6
   Yutong H, 2009, ACTA ACAD MED MILITA, V31, P1119
NR 21
TC 7
Z9 9
U1 3
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2015
VL 8
BP 2215
EP 2225
DI 10.2147/OTT.S86536
PG 11
WC Biotechnology & Applied Microbiology; Oncology
SC Biotechnology & Applied Microbiology; Oncology
GA CP7GA
UT WOS:000360054000006
PM 26345468
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wang, T
   Chen, SS
   Chen, R
   Yu, DM
   Yu, P
AF Wang, Tong
   Chen, Si-Si
   Chen, Rui
   Yu, De-Min
   Yu, Pei
TI RETRACTED: Reduced beta 2 glycoprotein I improve diabetic nephropathy
   via inhibiting TGF-beta 1-p38 MAPK pathway (Retracted article. See vol.
   8, pg. 19792, 2015)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Beta 2 glycoprotein I; diabetic nephropathy; TGF-beta 1
ID BETA(2)-GLYCOPROTEIN I; ANTIPHOSPHOLIPID ANTIBODIES; OXIDATIVE STRESS;
   MESANGIAL CELLS; HIGH GLUCOSE; ATHEROSCLEROSIS; BINDING; EXPRESSION;
   PROTEIN; KINASE
AB Purpose: Beta 2 glycoprotein I (beta 2GPI) has been shown the positive effect on diabetic atherosclerosis and retinal neovascularization. beta 2GPI can be reduced by thioredoxin-1, resulting in the reduced state of beta 2GPI. The possible protective effects of beta 2GPI and reduced beta 2GPI on diabetic nephropathy (DN) are not fully elucidated. The purpose of this study was to test a hypothesis that beta 2GPI and reduced beta 2GPI would improve DN in streptozotocin (STZ) induced diabetic mice and high-glucose (HG) exposed rat mesangial cell (RMC). Methods: The STZ-induced Balb/c mice and HG exposed RMCs were administrated with beta 2-GPI and reduced beta 2-GPI at different time and concentrations gradient respectively. The changes of glomerular structure and expression of collagen IV, TGF-beta 1, p38 MAPK and phospho-p38 MAPK in renal cortical and mesangial cells were observed by immunohistochemical techniques, quantitative real-time PCR and western blot with or without the treatment of beta 2-GPI and reduced beta 2-GPI. Results: beta 2GPI and reduced beta 2GPI improved early clinical and pathological changes of DN in STZ-diabetic mice. Treatment with beta 2GPI and reduced beta 2GPI in the STZ-diabetic mice and HG exposed RMCs resulted in decrease expression levels of TGF-beta 1 and collagen IV, with concomitant decrease in phospho-p38 MAPK expression. Conclusions: beta 2GPI and reduced beta 2GPI improved renal structural damage and kidney function. The renoprotective and antifibrosis effects of beta 2GPI and reduced beta 2GPI on DN were closely associated with suppressing the activation of the TGF-beta 1-p38 MAPK pathway.
C1 [Yu, Pei] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Key Lab Hormones & Dev, Minist Hlth,Metab Dis Hosp, Tianjin 300070, Peoples R China.
   Tianjin Med Univ, Tianjin Inst Endocrinol, Tianjin 300070, Peoples R China.
RP Yu, P (reprint author), Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Key Lab Hormones & Dev, Minist Hlth,Metab Dis Hosp, Tianjin 300070, Peoples R China.
EM peiyudoc@yeah.net
FU National Natural Science Foundation of China [30971393, 81070645];
   Tianjin natural science fund [10JCYBJC12000]
FX This work was supported by the National Natural Science Foundation of
   China (No. 30971393 and No. 81070645), the Tianjin natural science fund
   (No. 10JCYBJC12000).
CR Advani A, 2009, J AM SOC NEPHROL, V20, P730, DOI 10.1681/ASN.2008020142
   Agar C, 2011, THROMB HAEMOSTASIS, V106, P1069, DOI 10.1160/TH11-05-0333
   Arad A, 2011, BLOOD, V117, P3453, DOI 10.1182/blood-2010-08-300715
   Choi ME, 2012, SEMIN NEPHROL, V32, P244, DOI 10.1016/j.semnephrol.2012.04.003
   de Groot PG, 2011, J THROMB HAEMOST, V9, P1275, DOI 10.1111/j.1538-7836.2011.04327.x
   de Laat B, 2009, BLOOD, V114, P3656, DOI 10.1182/blood-2009-03-212910
   Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x
   Ioannou Y, 2011, ARTHRITIS RHEUM-US, V63, P2774, DOI 10.1002/art.30383
   Ioannou Y, 2010, BLOOD, V116, P1961, DOI 10.1182/blood-2009-04-215335
   Jankowski M, 2003, BLOOD, V101, P157, DOI 10.1182/blood-2002-05-1310
   Lin KY, 2005, J CELL BIOCHEM, V94, P485, DOI 10.1002/jcb.20314
   Mahimainathan L, 2006, DIABETES, V55, P2115, DOI 10.2337/db05-1326
   McGowan Tracy A, 2004, Curr Diab Rep, V4, P447, DOI 10.1007/s11892-004-0055-z
   MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120
   Nilsson M, 2008, MOL MICROBIOL, V67, P482, DOI 10.1111/j.1365-2958.2007.05974.x
   Noh H, 2002, NEPHRON, V90, P78, DOI 10.1159/000046318
   Passam FH, 2010, J THROMB HAEMOST, V8, P1754, DOI 10.1111/j.1538-7836.2010.03944.x
   Petri M, 2010, LUPUS, V19, P419, DOI 10.1177/0961203309360541
   Raptis AE, 2001, EXP CLIN ENDOCR DIAB, V109, pS424, DOI 10.1055/s-2001-18600
   RIOCHE M, 1974, BIOMED EXPRESS, V21, P420
   Rossing Peter, 2006, Curr Diab Rep, V6, P479, DOI 10.1007/s11892-006-0083-y
   SCHULTZE HE, 1961, NATURWISSENSCHAFTEN, V48, P719, DOI 10.1007/BF00620967
   Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228
   SEGER R, 1995, FASEB J, V9, P726
   Staub HL, 2006, AUTOIMMUN REV, V6, P104, DOI 10.1016/j.autrev.2006.06.014
   Vaarala O, 1996, LUPUS, V5, P442, DOI 10.1177/096120339600500522
   Yu P, 2008, J THROMB HAEMOST, V6, P1215, DOI 10.1111/j.1538-7836.2008.03000.x
   Yu YX, 2005, AM J MED SCI, V330, P227, DOI 10.1097/00000441-200511000-00005
   Zhang R, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-42
NR 29
TC 4
Z9 4
U1 1
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 5
BP 6852
EP 6865
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CO6UV
UT WOS:000359293200023
PM 26221223
DA 2018-12-27
ER

PT J
AU Aksekili, MAE
   Bicici, V
   Isik, C
   Aksekili, H
   Ugurlu, M
   Akkurt, A
   Dogan, M
AF Aksekili, Mehmet Atif Erol
   Bicici, Vedat
   Isik, Cetin
   Aksekili, Hatice
   Ugurlu, Mahmut
   Akkurt, Adem
   Dogan, Metin
TI RETRACTED: Comparison of early postoperative period electrophysiological
   and clinical findings following carpal tunnel syndrome: is EMG
   necessary? (Retracted article. See vol. 8, pg. 17022, 2015)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Carpal tunnel syndrome; electromyography; clinical findings
ID SELF-ADMINISTERED QUESTIONNAIRE; NERVE-CONDUCTION; SURGERY;
   DECOMPRESSION
AB Background: In this study, we aimed to compare the clinical findings and ENMG results of the patients who underwent surgery due to CTS, in the preoperative and early postoperative period. Methods: 33 wrists of 29 patients who underwent open carpal tunnel surgery in our clinic due to CTS, between 2009 and 2011, were evaluated. Electrophysiological progress was evaluated with ENMG and clinical state with Boston scale. Results: A significant decrease was observed in the postoperative BS symptomatic (SSS) and functional (FSS) scores of patients as compared to preoperative period (P=0.00), In the electrophysiological findings, statistically significant improvement was observed in all groups but very severe CTS group (P<0.05). When preoperative and postoperative EMG findings were compared, changes in DSL and DSA values were statistically significant (P<0.05). However, no statistically significant difference was seen between DML (P=0.085) and DMA (P=246) values on the 3rd month. When an examination was conducted on the patients whose DML and DSL values could not be obtained in the preoperative EMG, DML values were obtained in the early postoperative period in 6 of 7 cases (85.71% P<0.001), and DSL values were obtained in 17 of 24 cases (70.8% P<0.000). Conclusions: Sensory nerve findings were more significant, showed faster recovery compared to motor nerve findings, and accompanied the clinical recovery. Performance of an EMG test, especially on sensory nerves, will be more effective in patients selected in the early period, with the exception of patients with very severe CTS.
C1 [Aksekili, Mehmet Atif Erol; Isik, Cetin; Dogan, Metin] Yildirim Beyazit Univ, Sch Med, Dept Orthoped, Ankara, Turkey.
   [Bicici, Vedat] Ataturk Training & Res Hosp, Orthopeady & Traumatol, Ankara, Turkey.
   [Aksekili, Hatice] Ataturk Training & Res Hosp, Phys Therapy & Rehabil, Ankara, Turkey.
   [Ugurlu, Mahmut] Yildirim Beyazit Univ, Sch Med, Dept Orthoped, Ankara, Turkey.
   [Akkurt, Adem] Samsun Med Pk Hosp, Dept Neurol, Samsun, Turkey.
RP Aksekili, MAE (reprint author), Yildirim Beyazit Univ, Sch Med, Dept Orthoped, Ankara, Turkey.
EM atifaksekili@yahoo.com
CR Aulisa L, 1998, J HAND SURG-AM, V23A, P687, DOI 10.1016/S0363-5023(98)80056-7
   Bland JDP, 2001, MUSCLE NERVE, V24, P935, DOI 10.1002/mus.1091
   Green TP, 2012, NEUROPHYSIOL CLIN, V42, P231, DOI 10.1016/j.neucli.2012.02.133
   Gulsen I, 2013, ISRN NEUROL, V2013
   Itsubo T, 2009, J ORTHOP SCI, V14, P17, DOI 10.1007/s00776-008-1290-y
   JABLECKI CK, 1993, MUSCLE NERVE, V16, P1392
   Kim JY, 2012, MUSCLE NERVE, V45, P183, DOI 10.1002/mus.22264
   LEVINE DW, 1993, J BONE JOINT SURG AM, V75A, P1585, DOI 10.2106/00004623-199311000-00002
   Lo Yew-Long, 2012, J Clin Neuromuscul Dis, V13, P153, DOI 10.1097/CND.0b013e31822b19a5
   Andreu JL, 2014, CLIN NEUROPHYSIOL, V125, P1479, DOI 10.1016/j.clinph.2013.11.010
   Mondelli M, 2004, J PERIPHER NERV SYST, V9, P168, DOI 10.1111/j.1085-9489.2004.09309.x
   Naidu S H, 2003, Electromyogr Clin Neurophysiol, V43, P393
   Padua L, 1996, ACTA NEUROL SCAND, V94, P343, DOI 10.1111/j.1600-0404.1996.tb07077.x
   Rotman MB, 2004, J HAND SURG-AM, V29A, P367, DOI 10.1016/j.jhsa.2004.01.011
   Tahririan Mohammad A, 2012, Adv Biomed Res, V1, P46, DOI 10.4103/2277-9175.100151
   Tuncali D, 2004, TURK PLASTIK REKONST, V12, P182
   Viera AJ, 2003, AM FAM PHYSICIAN, V68, P265
   Yazgan P, 2009, TURK J RHEUMATOL, V24, P10
   Yilmaz N, 2010, INT J NEUROSCI, V120, P261, DOI 10.3109/00207451003615748
NR 19
TC 1
Z9 1
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 6
BP 10011
EP 10015
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CO6VS
UT WOS:000359295600213
PM 26309691
DA 2018-12-27
ER

PT J
AU Wei, B
   Huang, QY
   Zhong, XG
AF Wei, Bin
   Huang, Qiaoying
   Zhong, Xiaogang
TI RETRACTED: Upregulation of nucleostemin in colorectal cancer and its
   effects on cell malignancy (Retracted article. See vol. 9, pg. 2625,
   2016)
SO ONCOTARGETS AND THERAPY
LA English
DT Article; Retracted Publication
DE apoptosis; colorectal cancer; nucleostemin; small interfering RNA;
   Sw620; target therapy
ID EARLY-DIAGNOSIS; POOR-PROGNOSIS; UP-REGULATION; METAANALYSIS;
   EXPRESSION; MICRORNAS; SUSCEPTIBILITY; PROLIFERATION; ASSOCIATION;
   METASTASIS
AB Objective: Nucleostemin (NS) is a new protein localized in the nucleolus of most stem cells and tumor cells, which regulates their self-renewal and cell cycle progression. The aim of this study was to investigate the expression of NS in colorectal cancer (CRC) and the effects of NS knockdown in the Sw620 cell line to provide basis for clinical target therapy.
   Methods: NS expression in 372 patients with CRC and 367 normal participants was assessed using immunohistochemistry. The expression level of NS gene was evaluated by polymerase chain reaction. Then, the relationship among NS expression, clinicopathological features, and prognosis was analyzed. Silencing of NS expression was achieved by using NS-specific small-interfering RNAs. The viability and growth rate of Sw620 cells were determined by proliferation and invasion assays. Cell cycle distribution of the cells was analyzed by flow cytometry.
   Results: High NS expression was positively related with node metastasis, distant metastasis, and TNM stage. In Kaplan-Meier survival analysis, patients with low NS expression always had significantly longer survival time than those with high expression. Moreover, our results showed that knockdown of NS expression inhibited proliferation and viability of Sw620 cells in a time-dependent manner. Cell cycle studies revealed that NS depletion resulted in G1 cell cycle arrest at short times of transfection (24 hours), followed with apoptosis at longer times (48 hours and 72 hours), suggesting that post-G1 arrest apoptosis occurred in Sw620 cells.
   Conclusion: Overall, these results point to the essential role of NS in Sw620 cells; thus, this gene might be considered a promising target for treatment of CRC.
C1 [Wei, Bin; Zhong, Xiaogang] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Gastroenterol & Peripheral Vasc Surg, Nanning 530021, Guangxi, Peoples R China.
   [Huang, Qiaoying] Guangxi Univ Chinese Med Res, Affiliated Hosp 1, Dept Med Mol Biol, Nanning, Guangxi, Peoples R China.
RP Zhong, XG (reprint author), Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Gastroenterol & Peripheral Vasc Surg, 6 Taoyuan Rd, Nanning 530021, Guangxi, Peoples R China.
EM zhongxiaogang1234@163.com
CR Achyut BR, 2009, DNA CELL BIOL, V28, P295, DOI 10.1089/dna.2008.0842
   Adams SV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108668
   Boisen MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109430
   Cao Y, 2014, GENET MOL RES, V13, P7420, DOI 10.4238/2014.September.12.8
   Du ML, 2014, CARCINOGENESIS, V35, P2723, DOI 10.1093/carcin/bgu189
   Feng JL, 2014, J CELL MOL MED, V18, P2125, DOI 10.1111/jcmm.12398
   Goossens-Beumer IJ, 2015, CANCER EPIDEM BIOMAR, V24, P187, DOI 10.1158/1055-9965.EPI-14-0544-T
   Hara T, 2014, ONCOTARGET, V5, P7635, DOI 10.18632/oncotarget.2284
   Jiang JX, 2014, ASIAN PAC J CANCER P, V15, P7583, DOI 10.7314/APJCP.2014.15.18.7583
   Kamata I, 2009, J GASTROEN HEPATOL, V24, P1527, DOI 10.1111/j.1440-1746.2009.05810.x
   Li L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081967
   Li ZW, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0256-5
   Lin Z, 2014, ASIAN PAC J CANCER P, V15, P7251, DOI 10.7314/APJCP.2014.15.17.7251
   Nomura T, 2009, J HEPATO-BILIARY-PAN, V16, P493, DOI 10.1007/s00534-009-0081-y
   Nonaka R, 2014, ONCOL REP, V32, P2354, DOI 10.3892/or.2014.3515
   Orang AV, 2014, ASIAN PAC J CANCER P, V15, P6989, DOI 10.7314/APJCP.2014.15.17.6989
   Patel SAA, 2014, BRIT J CANCER, V111, P2287, DOI 10.1038/bjc.2014.540
   Peacock O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110267
   Peng TL, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-27
   Ress AL, 2014, MOL CARCINOG
   Runtsch MC, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00347
   Saadatian Z, 2014, IRAN RED CRESCENT ME, V16, DOI 10.5812/ircmj.16659
   Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671
   Wang J, 2014, CANC LETT B, V356, P404
   Xie WQ, 2014, J DIGEST DIS, V15, P647, DOI 10.1111/1751-2980.12201
   Xu LL, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-714
   Yamada N, 2014, BBA-GENE REGUL MECH, V1839, P1256, DOI 10.1016/j.bbagrm.2014.09.002
   Yao YL, 2014, INT J MOL SCI, V15, P18985, DOI 10.3390/ijms151018985
   Yau TO, 2014, BRIT J CANCER, V111, P1765, DOI 10.1038/bjc.2014.484
   Zhang HG, 2014, BIOCHEM BIOPH RES CO, V452, P775, DOI 10.1016/j.bbrc.2014.08.150
   Zhang JW, 2014, ONCOTARGET, V5, P12083, DOI 10.18632/oncotarget.2499
   Zhao HJ, 2014, THERANOSTICS, V4, P1193, DOI 10.7150/thno.8712
   Zheng G, 2014, BRIT J CANCER, V111, P1985, DOI 10.1038/bjc.2014.489
   Zhou Jiao-Jiao, 2014, World J Biol Chem, V5, P301, DOI 10.4331/wjbc.v5.i3.301
   Zhou Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081203
NR 35
TC 1
Z9 1
U1 3
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2015
VL 8
BP 1805
EP 1814
DI 10.2147/OTT.S78461
PG 10
WC Biotechnology & Applied Microbiology; Oncology
SC Biotechnology & Applied Microbiology; Oncology
GA CN2CN
UT WOS:000358228100001
PM 26229488
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Li, YH
   Li, DY
   Ren, BP
   Hu, J
   Li, BG
   Krzton, A
   Li, M
AF Li, Yanhong
   Li, Dayong
   Ren, Baoping
   Hu, Jie
   Li, Baoguo
   Krzton, Ali
   Li, Ming
TI RETRACTED: DETERMINANTS OF DIFFERENCES IN THE ACTIVITY BUDGETS OF
   RHINOPITHECUS BIETI BY AGE/SEX CLASS AT XIANGGUQING IN THE BAIMAXUESHAN
   NATURE RESERVE, CHINA (Retracted article. See vol. 68, pg. 237, 2016)
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Rhinopithecus bieti; activity budgets; age-sex class; reproductive
   investment
ID JAPANESE MACAQUES; ACTIVITY PATTERNS; SEASONAL-VARIATIONS;
   SEX-DIFFERENCES; TIME BUDGETS; MONKEYS; YAKUSHIMA; BEHAVIOR; BABOONS;
   LEMURS
AB Ecological factors are known to influence the activity budgets of Yunnan snub-nosed monkeys (Rhinopithecus bieti). However, little is known about how activity budgets vary between age/sex classes, because the species is difficult to observe in the wild. This study provides the first detailed activity budgets subdivided by age/sex classes based on observations of the largest habituated group at Xiangguqing in Baimaxueshan Nature Reserve. This study was conducted from June 2008 to May 2009. We found that adult females spent more time feeding (44.8%) than adult males (39.5%), juveniles (39.1%), and infants (14.2%). Adult males allocated more time to miscellaneous activities (12.5%) than did adult females (3.8%). Infants were being groomed 6.9% of the time, which was the highest proportion among all age/sex classes. Adults spent more time feeding, while immature individuals allocated more time to moving and other activities. There are several reasons activity budgets may vary by age/sex class: 1) differential reproductive investment between males and females; 2) developmental differences among the age categories; 3) social relationships between members of different age/sex classes, particularly dominance. In addition, group size and adult sex ratio may also impact activity budgets. These variations in activity budgets among the different age/sex classes may become a selective pressure that shapes the development and growth pattern in this species.
C1 [Li, Yanhong; Li, Dayong; Hu, Jie] China West Normal Univ, Key Lab Southwest China Wildlife Resources Conser, Minist Educ, Nanchong 637009, Peoples R China.
   [Li, Dayong; Ren, Baoping; Li, Ming] Chinese Acad Sci, Inst Zool, Key Lab Anim Ecol & Conservat Biol, Beijing 100101, Peoples R China.
   [Li, Dayong; Li, Baoguo] NW Univ Xian, Coll Life Sci, Xian 710069, Peoples R China.
   [Krzton, Ali] Texas A&M Univ, Dept Anthropol, College Stn, TX 77843 USA.
RP Li, DY (reprint author), China West Normal Univ, Key Lab Southwest China Wildlife Resources Conser, Minist Educ, Nanchong 637009, Peoples R China.
EM 980119lsc@163.com
OI Krzton, Alicia/0000-0001-9979-2471
FU NSFC [31200294, 31370410, 31370412]; Foundation of key Laboratory of
   Southwest China Wildlife Resources Conservation (Ministry of Education),
   China West Normal University
FX We are grateful to our field assistants Xinming He, Rong Yang, Jianhua
   Yu, Jianjun Yu and Xiaohua Yu. We thank Baimaxueshan Nature Reserve for
   our work permit. Financial support was provided by the project of NSFC
   (No. 31200294; 31370410; 31370412), Foundation of key Laboratory of
   Southwest China Wildlife Resources Conservation (Ministry of Education),
   China West Normal University.
CR Agetsuma N, 1998, PRIMATES, V39, P275, DOI 10.1007/BF02573077
   Agetsuma N, 2001, ECOL RES, V16, P759, DOI 10.1046/j.1440-1703.2001.00431.x
   ALTMANN J, 1974, BEHAVIOUR, V49, P227, DOI 10.1163/156853974X00534
   Altmann J., 1980, BABOON MOTHERS INFAN, P242
   [Anonymous], 1979, PRIMATE ECOLOGY HUMA
   Clutton-Brock T. H, 1977, P557
   CLUTTONBROCK TH, 1974, FOLIA PRIMATOL, V21, P161, DOI 10.1159/000155599
   Coelho A.M., 1974, PRIMATES, V15, P263
   Daan S., 1982, P305
   DEMMENT MW, 1983, AFR J ECOL, V21, P219, DOI 10.1111/j.1365-2028.1983.tb00323.x
   Doran D.M., 2001, MOUNTAIN GORILLAS 3, P123
   DUNBAR RIM, 1988, ANIM BEHAV, V36, P970, DOI 10.1016/S0003-3472(88)80055-1
   DUNBAR RIM, 1983, Z TIERPSYCHOL, V63, P265
   FOSTER SA, 1985, ECOLOGY, V66, P773, DOI 10.2307/1940538
   Fox EA, 2004, AM J PHYS ANTHROPOL, V125, P162, DOI 10.1002/ajpa.10386
   Grueter CC, 2010, BEHAV ECOL, V21, P63, DOI 10.1093/beheco/arp149
   Hanya G, 2004, AM J PRIMATOL, V63, P165, DOI 10.1002/ajp.20049
   Hanya G, 2003, PRIMATES, V44, P51, DOI 10.1007/s10329-002-0007-7
   Harrison M. J. S., 1983, ANIM BEHAV, V31, P967
   HARRISON MJS, 1985, INT J PRIMATOL, V6, P351, DOI 10.1007/BF02736383
   Hill RA, 2003, BEHAV ECOL SOCIOBIOL, V53, P278, DOI 10.1007/s00265-003-0590-7
   Key C, 1999, P ROY SOC B-BIOL SCI, V266, P2479, DOI 10.1098/rspb.1999.0949
   Kirkpatrick RC, 1998, INT J PRIMATOL, V19, P13, DOI 10.1023/A:1020302809584
   Li D. Y., 2010, THESIS N W U XIAN
   LONG YC, 1994, PRIMATES, V35, P241, DOI 10.1007/BF02382060
   Masi S, 2009, AM J PRIMATOL, V71, P91, DOI 10.1002/ajp.20629
   McNab B.K., 1978, P153
   MILTON K, 1980, FORAGING STRATEGY HO
   MORLAND HS, 1990, AM J PRIMATOL, V20, P253, DOI 10.1002/ajp.1350200402
   Oates J.F., 1987, P197
   Portman O. W., 1970, FEEDING NUTRITION NO, P87
   ROSE LM, 1994, INT J PRIMATOL, V15, P95, DOI 10.1007/BF02735236
   Sauther ML, 1998, FOLIA PRIMATOL, V69, P309
   STEVENSON PR, 1994, AM J PRIMATOL, V32, P123, DOI 10.1002/ajp.1350320205
   STRIER KB, 1987, AM J PRIMATOL, V13, P385, DOI 10.1002/ajp.1350130404
   Takahashi H, 2002, AM J PRIMATOL, V57, P141, DOI 10.1002/ajp.10041
   Tan CL, 2007, INT J PRIMATOL, V28, P577, DOI 10.1007/s10764-007-9147-3
   Vasey N, 2005, AM J PRIMATOL, V66, P23, DOI 10.1002/ajp.20126
   Watts D.P., 1988, AM J PRIMATOL, V15, P295
   Xi WZ, 2008, INT J PRIMATOL, V29, P593, DOI 10.1007/s10764-008-9260-y
   Zhou Q, 2007, INT J PRIMATOL, V28, P657, DOI 10.1007/s10764-007-9144-6
NR 41
TC 2
Z9 2
U1 3
U2 28
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2015
VL 67
IS 2
BP 675
EP 683
DI 10.2298/ABS140917033L
PG 9
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA CN2ZH
UT WOS:000358291600031
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Barczak, T
   Debek-Jankowska, A
   Bennewicz, J
AF Barczak, Tadeusz
   Debek-Jankowska, Amelia
   Bennewicz, Janina
TI RETRACTED: PRIMARY PARASITOID AND HYPERPARASITOID GUILDS (HYMENOPTERA)
   OF GRAIN APHID (SITOBION AVENAE F.) IN NORTHERN POLAND (Retracted
   article. See vol. 67, pg. 1443, 2015)
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article; Retracted Publication
DE Aphidiinae (Braconidae); hyperparasitoids; guilds; cereals
ID CEREAL APHIDS; RELATIVE ABUNDANCE; SOUTHERN ENGLAND; NATURAL ENEMIES;
   BRACONIDAE; HEMIPTERA; WINTER
AB The aim of this study was to determine and compare the guilds of parasitic Hymenoptera associated with the grain aphid on rye and winter wheat in northern Poland. Of the seven species of primary parasitoids (Braconidae: Aphidiinae, Aphelinidae), parasitizing colonies of Sitobion avenae, the most numerous and most frequently occurring, included Praon volucre, Aphidius ervi and Aphidius uzbekistanicus. Primary parasitoids of grain aphids were largely eliminated by hyperparasitoids, mostly of the families Megaspilidae (Dendrocerus carpenteri), Figitidae-Alloxystini (Alloxysta spp. and Phaenoglyphis villosa) and Pteromalidae (Pachyneuron aphidis, Asaphes vulgaris, Coruna clavata), but D. carpenteri and Alloxysta spp. belonged to dominants and subdominants, respectively.
C1 [Barczak, Tadeusz; Bennewicz, Janina] Univ Technol & Life Sci Bydgoszcz, Fac Anim Breeding & Biol, Dept Zool, PL-85225 Bydgoszcz, Poland.
   [Debek-Jankowska, Amelia] Univ Technol & Life Sci Bydgoszcz, Fac Agr & Biotechnol, Dept Appl Entomol, PL-85225 Bydgoszcz, Poland.
RP Barczak, T (reprint author), Univ Technol & Life Sci Bydgoszcz, Fac Anim Breeding & Biol, Dept Zool, Kordeckiego 20, PL-85225 Bydgoszcz, Poland.
EM tadbar@utp.edu.pl
FU "BS Project" of the Faculty of Animal Breeding and Biology of the
   University of Technology; Life Sciences Bydgoszcz
FX This study was partly financed by the "BS Project" of the Faculty of
   Animal Breeding and Biology of the University of Technology and Life
   Sciences Bydgoszcz.
CR Abo Kaf Nabiel, 1992, Roczniki Nauk Rolniczych Seria E Ochrona Roslin, V21, P103
   Abo Kaf Nabiel, 1992, Roczniki Nauk Rolniczych Seria E Ochrona Roslin, V21, P93
   ABOKAF N, 1991, BEHAVIOUR AND IMPACT OF APHIDOPHAGA, P17
   Barczak T., 1988, Wiadomosci Entomologiczne, V8, P13
   Barczak T, 2013, ARCH BIOL SCI, V65, P71, DOI 10.2298/ABS1301071B
   Barczak T., 1993, WYDAWNICTWA UCZELNIA, V57, P1
   Barczak Tadeusz, 1992, Materialy Sesji Naukowej IOR (Instytut Ochrony Roslin), V31, P226
   Bilewicz-Pawinska Teresa, 1995, Wiadomosci Entomologiczne, V14, P103
   Ceryngier P., 2001, APHIDS OTHER HOMOPTE, V8, P355
   CHAMBERS RJ, 1986, ANN APPL BIOL, V108, P219, DOI 10.1111/j.1744-7348.1986.tb07644.x
   Coaker T.H., 1980, CEREAL APHIDS CASE S, P1
   DEAN GJ, 1981, B ENTOMOL RES, V71, P307, DOI 10.1017/S0007485300008336
   Debek-Jankowska A., 2005, J APHIDOLOGY, V19, P1
   Debek-Jankowska A., 2005, SITOBION AVENAE F PR, V55, P51
   EHLER LE, 1990, ISSUES SCI TECHNOL, V7, P91
   Hagvar E.B., 1991, Biocontrol News and Information, V12, P13
   Kajak A., 1998, EKOLOGIA WYSP LESNYC, P267
   Kakol E., 2001, APHIDS OTHER HOMOPTE, V8, P169
   Krober T., 1991, Biocontrol News and Information, V12, P357
   Lumbierres B, 2007, J PEST SCI, V80, P125, DOI 10.1007/s10340-006-0159-0
   OLSZAK R. W., 1999, APHIDS OTHER HEMIPTE, V7, P277
   Pankanin-Franczyk M., 1983, Polish Ecological Studies, V8, P521
   Pankanin-Franczyk M., 1999, APHIDS OTHER HOMOPTE, V7, P289
   Pankanin-Franczyk M., 1995, HARMF CONTR APH GARD, P1
   Pankanin-Franczyk Malgorzata, 1995, Polish Ecological Studies, V21, P7
   PANKANINFRANCZY.M, 1987, POL ECOL STUD, V13, P215
   PANKANINFRANCZYK M, 1978, B ACAD POL SCI BIOL, V26, P871
   Paretas-Martiez J, 2007, ZOOL SCR, V36, P153, DOI 10.1111/j.1463-6409.2006.00269.x
   POWELL W, 1991, B ENTOMOL RES, V81, P449, DOI 10.1017/S0007485300032028
   RABASSE JM, 1983, AGRONOMIE, V3, P779, DOI 10.1051/agro:19830809
   Rakhshani E, 2013, ARCH BIOL SCI, V65, P667, DOI 10.2298/ABS1302667R
   Sobota G., 1999, APHIDS OTHER HOMOPTE, V7, P305
   Sobota G., 1992, APHIDS OTHER HOMOPTE, V3, P83
   Sobota G., 1999, APHIDS OTHER HOMOPTE, V7, P297
   STARY P, 1976, ACTA ENTOMOL BOHEMOS, V73, P216
   Sullivan D.J., 1988, P189
   Sullivan D.J., 1986, ECOLOGY APHIDOPHAGA, V2, P511
   SULLIVAN DJ, 1987, ANNU REV ENTOMOL, V32, P49, DOI 10.1146/annurev.ento.32.1.49
   Tomanovic Z, 2008, EUR J ENTOMOL, V105, P495, DOI 10.14411/eje.2008.064
   VORLEY WT, 1986, B ENTOMOL RES, V76, P491, DOI 10.1017/S0007485300014978
NR 40
TC 1
Z9 1
U1 4
U2 26
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2015
VL 67
IS 2
BP 695
EP 703
DI 10.2298/ABS140915038B
PG 9
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA CN2ZH
UT WOS:000358291600033
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Yao, Y
   Feng, ST
   Xiao, MM
   Li, Y
   Yang, L
   Gong, J
AF Yao, Yuan
   Feng, Shuting
   Xiao, Mingming
   Li, Yan
   Yang, Li
   Gong, Jiao
TI RETRACTED: MTA1 promotes proliferation and invasion in human gastric
   cancer cells (Retracted article. See vol. 10, pg. 1519, 2017)
SO ONCOTARGETS AND THERAPY
LA English
DT Article; Retracted Publication
DE cell cycle; cell adhesion; migration
ID METASTASIS-ASSOCIATED PROTEIN-1; CELL LUNG-CANCER; BREAST-CANCER;
   TRANSCRIPTIONAL REPRESSION; DOWN-REGULATION; OVARIAN-CANCER; E-CADHERIN;
   IN-VITRO; GENE; OVEREXPRESSION
AB Although metastasis-associated protein 1 (MTA1) has been widely linked to tumor metastasis, the relevant mechanisms remain to be elucidated, especially in gastric cancer. The aim of this study was to examine whether the MTA1 gene is associated with the process of proliferation and invasion by regulating several molecular targets in gastric cancer. MTA1 expression in 61 gastric cancer tissue and adjacent noncancerous tissues was analyzed by immunohistochemistry. The prognostic value of MTA1 for overall survival and disease-free survival was determined by Kaplan-Meier estimates, and the significance of differences between curves was evaluated by the log-rank test. Furthermore, overexpression of MTA1 in SGC7901 and BGC823 cells promoted cell cycle progression, cell adhesion, and cell invasion. Our study found that MTA1 is overexpressed in gastric cancers, which contributes to malignant cell growth by facilitating cell cycle progression through upregulation of cyclin D1 and accelerates the migration and invasion of human gastric cancer cells by regulating expression of fibronectin and MMP2/MMP9. Taken together, MTA1 was involved in the pathogenesis of gastric cancer and might be a candidate therapeutic target in gastric cancer.
C1 [Yao, Yuan; Feng, Shuting; Li, Yan; Yang, Li; Gong, Jiao] Peoples Hosp Liaoning Prov, Digest Syst Dept, Wenyi Rd 33, Shenyang 110016, Liaoning, Peoples R China.
   [Xiao, Mingming] Peoples Hosp Liaoning Prov, Dept Pathol, Shenyang 110016, Liaoning, Peoples R China.
RP Yao, Y (reprint author), Peoples Hosp Liaoning Prov, Digest Syst Dept, Wenyi Rd 33, Shenyang 110016, Liaoning, Peoples R China.
EM yaoyuan_sy@163.com
FU National Natural Science Foundation of the People's Republic of China
   [31201053]
FX This research was supported by a research grant from the National
   Natural Science Foundation of the People's Republic of China (number
   31201053).
CR Bae GY, 2013, ONCOTARGET, V4, P2512, DOI 10.18632/oncotarget.1463
   Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001
   Cagatay ST, 2013, TUMOR BIOL, V34, P1189, DOI 10.1007/s13277-013-0662-x
   Gururaj AE, 2006, CELL CYCLE, V5, P1407, DOI 10.4161/cc.5.13.2924
   He X, 2014, IRISH J MED SCI, V183, P433, DOI 10.1007/s11845-013-1034-7
   Iguchi H, 2000, INT J ONCOL, V16, P1211
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jiang QM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-60
   Kai L, 2011, PROSTATE, V71, P268, DOI 10.1002/pros.21240
   Kaur E, 2014, CANCER METAST REV, V33, P1017, DOI 10.1007/s10555-014-9527-z
   Lin CY, 2011, CANCER SCI, V102, P815, DOI 10.1111/j.1349-7006.2011.01861.x
   Liu J, 2014, ONCOTARGET, V5, P5153, DOI 10.18632/oncotarget.2095
   Marzook H, 2014, CANCER METAST REV, V33, P953, DOI 10.1007/s10555-014-9521-5
   Mazumdar A, 2001, NAT CELL BIOL, V3, P30
   Nagaraj SRM, 2015, MOL CARCINOGEN, V54, P333, DOI 10.1002/mc.22104
   Pakala SB, 2013, CANCER RES, V73, P3761, DOI 10.1158/0008-5472.CAN-12-3998
   Salot S, 2013, EUR J CANCER, V49, P492, DOI 10.1016/j.ejca.2012.06.019
   Sen N, 2014, CANCER METAST REV, V33, P879, DOI 10.1007/s10555-014-9515-3
   Singh RR, 2007, J MAMMARY GLAND BIOL, V12, P115, DOI 10.1007/s10911-007-9043-7
   Song QC, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-54
   Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.0.CO;2-4
   Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8
   Weng WH, 2014, INT J ONCOL, V44, P812, DOI 10.3892/ijo.2014.2253
   Xue HS, 2015, ONCOL REP, V33, P885, DOI 10.3892/or.2014.3671
   Yang QY, 2014, GENET MOL RES, V13, P10269, DOI 10.4238/2014.December.4.21
NR 25
TC 14
Z9 16
U1 3
U2 5
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2015
VL 8
BP 1785
EP 1794
DI 10.2147/OTT.S85383
PG 10
WC Biotechnology & Applied Microbiology; Oncology
SC Biotechnology & Applied Microbiology; Oncology
GA CN1GO
UT WOS:000358166800005
PM 26229486
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Singh, S
   Garg, M
   Batra, NK
AF Singh, Satnam
   Garg, Manish
   Batra, N. K.
TI RETRACTED: Analysis of Dry Sliding Behavior of Al2O3/B4C/Gr Aluminum
   Alloy Metal Matrix Hybrid Composite Using Taguchi Methodology(Retracted
   article.See vol.59,pg.1159,2016)
SO TRIBOLOGY TRANSACTIONS
LA English
DT Article; Retracted Publication
DE Hybrid; Metal Matrix Composite; Sliding Wear; Ceramic Composite;
   Graphite; Carbide; Vickers Microhardness; ANOVA; Taguchi Methodology
ID WEAR BEHAVIOR; TRIBOLOGICAL BEHAVIOR; MECHANICAL-PROPERTIES;
   POWDER-METALLURGY; CARBON NANOTUBES; MICROSTRUCTURE; REINFORCEMENT;
   PARTICLES; GRAPHITE
AB Aluminum metal matrix composites are widely used in aerospace and automotive industries due to favorable properties such as low weight and functionally graded properties obtained by incorporating different reinforcements. The present work is based on the analysis of dry sliding wear behavior and parametric optimization of aluminum composites reinforced with alumina, graphite, and boron carbide particles using Taguchi's technique. Specimens were prepared via a stir-casting process and optimal percentages of reinforcements were determined by Vickers microhardness tests. An L-9 orthogonal array was selected and analysis of variance (ANOVA) was used to investigate the influence of wear parameters involving normal load, track diameter, and sliding distance on dry sliding wear of the developed composites. All three selected parameters were varied at three levels. The results revealed that lower values of graphite (3%) and boron carbide (1%) in combination with higher values (10%) of alumina as reinforcements contributed to the higher Vickers microhardness. ANOVA revealed that the p-value for normal load was 0.006 and was the most significant factor in the weight loss with a 65.05% contribution. Further, confirmatory tests were carried out to validate the optimized results and results obtained with optimum parameters were within +/- 5%.
C1 [Singh, Satnam] Thapar Univ, Dept Mech Engn, Patiala 147004, Punjab, India.
   [Garg, Manish; Batra, N. K.] Maharishi Markandeshwar Univ, Dept Mech Engn, Mullana 133207, Haryana, India.
RP Singh, S (reprint author), Thapar Univ, Dept Mech Engn, Patiala 147004, Punjab, India.
CR Alaneme KK, 2013, J MATER RES TECHNOL, V2, P60, DOI 10.1016/j.jmrt.2013.03.012
   Beygi H, 2014, MAT SCI ENG A-STRUCT, V607, P81, DOI 10.1016/j.msea.2014.03.050
   Ezatpour HR, 2014, MATER DESIGN, V55, P921, DOI 10.1016/j.matdes.2013.10.060
   GIBSON PR, 1984, WEAR, V95, P193, DOI 10.1016/0043-1648(84)90117-0
   Gopal krishna U.B., 2013, INT J METALLURGICAL, V3, P41
   Hashim J, 1999, J MATER PROCESS TECH, V93, P1
   Hipke T, 2014, PROCEDIA MAT SCI, V4, P127
   Koksal S, 2012, MATER DESIGN, V42, P124, DOI 10.1016/j.matdes.2012.05.048
   Kumar R, 2013, MATER DESIGN, V50, P351, DOI 10.1016/j.matdes.2013.02.038
   Liu ZY, 2013, CARBON, V62, P35, DOI 10.1016/j.carbon.2013.05.049
   Mahapatra SS, 2007, INT J ADV MANUF TECH, V34, P911, DOI 10.1007/s00170-006-0672-6
   Mordyuk BN, 2014, WEAR, V319, P84, DOI 10.1016/j.wear.2014.07.011
   Niranjan K, 2013, MATER DESIGN, V47, P167, DOI 10.1016/j.matdes.2012.11.035
   Rajkumar K, 2013, TRIBOL INT, V57, P282, DOI 10.1016/j.triboint.2012.06.023
   Rajmohan T, 2013, T NONFERR METAL SOC, V23, P2509, DOI 10.1016/S1003-6326(13)62762-4
   Ravindran P, 2013, CERAM INT, V39, P1169, DOI 10.1016/j.ceramint.2012.07.041
   Ravindran P, 2013, MATER DESIGN, V45, P561, DOI 10.1016/j.matdes.2012.09.015
   Sahoo R, 2013, TRIBOL T, V56, P555, DOI 10.1080/10402004.2013.767400
   Saravanan SD, 2013, TRIBOL T, V56, P1156, DOI 10.1080/10402004.2013.831962
   Sharma A., 2015, IND LUBRICATION TRIB, V67
   Singh S., 2014, MAT MANUFACTURING PR, V30, P1
   Singh S., 2014, P INT C RES INN MECH, P451
   Singh S, 2015, P I MECH ENG J-J ENG, V229, P597, DOI 10.1177/1350650114556399
   Stein J, 2012, CARBON, V50, P2264, DOI 10.1016/j.carbon.2012.01.044
   Surappa MK, 2003, SADHANA-ACAD P ENG S, V28, P319, DOI 10.1007/BF02717141
   Suresha S, 2010, MATER DESIGN, V31, P1804, DOI 10.1016/j.matdes.2009.11.015
   Trehan R., 2013, P I MECH ENG L
   Yang QR, 2014, MATER DESIGN, V57, P442, DOI 10.1016/j.matdes.2013.12.064
   Yigezu BS, 2013, TRIBOL T, V56, P546, DOI 10.1080/10402004.2013.767401
NR 29
TC 5
Z9 5
U1 2
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-2004
EI 1547-397X
J9 TRIBOL T
JI Tribol. Trans.
PY 2015
VL 58
IS 4
BP 758
EP 765
DI 10.1080/10402004.2015.1015757
PG 8
WC Engineering, Mechanical
SC Engineering
GA CM0TE
UT WOS:000357390600023
DA 2018-12-27
ER

PT J
AU Yang, Y
AF Yang, Yong
TI RETRACTED: Identifying the inhibitory mechanism of apigenin on the
   insulin ligand-receptor binding (Retracted article. See vol. 7, pg.
   1449, 2016)
SO MEDCHEMCOMM
LA English
DT Article; Retracted Publication
ID BREAST-CANCER CELLS; INDUCED ACTIVATION; GLUCOSE-UPTAKE; DIMERIZATION;
   REVEALS
AB Although apigenin, a plant flavone, has been shown to inhibit the activation of insulin receptor signaling, its inhibitory mechanism is largely unknown. In this work, using single-molecule force measurement and fluorescence imaging, we demonstrate that apigenin inhibits insulin-induced dimerization of the insulin receptor (IR) through blocking ligand-receptor interactions. This inhibitory effect is also confirmed by flow cytometry and molecular docking. Furthermore we show that apigenin impairs cancer cell proliferation. The role of apigenin in suppressing tumor growth was also evident in an in vivo model, indicating a potential future application of apigenin in cancer therapy.
C1 China Med Univ, Inst Metab Dis Res & Drug Dev, Shenyang 110001, Liaoning, Peoples R China.
RP Yang, Y (reprint author), China Med Univ, Inst Metab Dis Res & Drug Dev, Shenyang 110001, Liaoning, Peoples R China.
EM yyang@mail.cmu.edu.cn
FU Setup Fund Program of China Medical University
FX We thank Dr. Chunguang Ding for helping in the measurement of the tumor
   volumes. This research was partly supported by the fund from the Setup
   Fund Program of China Medical University.
CR Baer K, 2001, BIOCHEMISTRY-US, V40, P14268, DOI 10.1021/bi015588g
   Belfiore A, 2009, ENDOCR REV, V30, P586, DOI 10.1210/er.2008-0047
   Burroughs KD, 1999, J NATL CANCER I, V91, P579, DOI 10.1093/jnci/91.7.579
   Chan KF, 2009, CHEMMEDCHEM, V4, P594, DOI 10.1002/cmdc.200800413
   Harmon AW, 2004, BREAST CANCER RES TR, V85, P103, DOI 10.1023/B:BREA.0000025397.56192.e2
   Kiselyov VV, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.78
   McKern NM, 2006, NATURE, V443, P218, DOI 10.1038/nature05106
   Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452
   Narasimhan SD, 2009, CURR BIOL, V19, pR657, DOI 10.1016/j.cub.2009.06.013
   Nomura M, 2008, BIOL PHARM BULL, V31, P1403, DOI 10.1248/bpb.31.1403
   Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536
   Siddle K, 2011, J MOL ENDOCRINOL, V47, pR1, DOI 10.1530/JME-11-0022
   Singh A, 2000, MOL CELL ENDOCRINOL, V160, P61, DOI 10.1016/S0303-7207(99)00256-7
   Ulbrich MH, 2007, NAT METHODS, V4, P319, DOI 10.1038/NMETH1024
   Wang F, 2014, BREAST CANCER RES TR, V147, P203, DOI 10.1007/s10549-014-3068-6
   Ward CW, 2009, BIOESSAYS, V31, P422, DOI [10.1002/bies200800210, 10.1002/bies.200800210]
   Xie XS, 1998, ANNU REV PHYS CHEM, V49, P441, DOI 10.1146/annurev.physchem.49.1.441
   Yang Y, 2011, CHEM COMMUN, V47, P5440, DOI 10.1039/c1cc10778j
   Zhang W, 2010, CELL RES, V20, P1216, DOI 10.1038/cr.2010.105
   Zhang W, 2009, P NATL ACAD SCI USA, V106, P15679, DOI 10.1073/pnas.0908279106
NR 20
TC 0
Z9 1
U1 2
U2 15
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-2503
EI 2040-2511
J9 MEDCHEMCOMM
JI MedChemComm
PY 2015
VL 6
IS 6
BP 1190
EP 1195
DI 10.1039/c5md00142k
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA CK1RS
UT WOS:000355985500024
DA 2018-12-27
ER

PT J
AU Wang, C
   Sun, HR
   Song, Y
   Ma, ZS
   Zhang, G
   Gu, XH
   Zhao, L
AF Wang, Chen
   Sun, Hourong
   Song, Yi
   Ma, Zengshan
   Zhang, Gong
   Gu, Xinghua
   Zhao, Lei
TI RETRACTED: Pterostilbene attenuates inflammation in rat heart subjected
   to ischemia-reperfusion: role of TLR4/NF-kappa B signaling pathway
   (Retracted article. See vol. 8, pg. 14565, 2015)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Pterostilbene; ischemia/reperfusion injury; apoptosis; TLR4/NF-kappa B
   signaling; neutrophil; TNF-alpha
ID NECROSIS-FACTOR-ALPHA; TOLL-LIKE-RECEPTORS; MYOCARDIAL-ISCHEMIA;
   NITRIC-OXIDE; KAPPA-B; INJURY; TLR4; ISCHEMIA/REPERFUSION; CHEMOKINE;
   TOLL-LIKE-RECEPTOR-4
AB Objective: The aim of the present study was to investigate whether pterostilbene could modulate the TLR4/NF-kappa B signaling, reduce neutrophil accumulation and TNF-alpha induction in an ischemia/reperfusion injured rat heart model. Materials and Methods: Rats were randomly exposed to sham operation, myocardial ischemia and reperfusion (MI/R), MI/R + pterostilbene, MI/R + pterostilbene + L-NAME. And myocardial infarct size, apoptosis, TLR4 expression, NF-kappa B expression, MPO level and TNF-alpha level were detected. Results: The results demonstrated that after MI/R, the expressions of myocardial TLR4, NF-kappa B and caspase-3 increased significantly in ischemia area. Compared with MI/R, pterostilbene significantly attenuated the expressions of TLR4, NF-kappa B and caspase-3. In addition, it also reduced myeloperoxidase (MPO) levels, both serum and myocardial TNF-alpha production, myocardial infarct sizes (INF/AAR%) and myocardial apoptosis induced by MI/R. All the effects of pterostilbene were abolished by L-NAME, a nitric oxide synthase inhibitor. Conclusion: These data provide evidence that pterostilbene inhibits TLR4/NF-kappa B signaling and apoptosis in the rat heart subjected to MI/R, which is associated with NO production.
C1 [Wang, Chen; Zhao, Lei] Fourth Mil Med Univ, Sch Clin Med, Xian 710032, Peoples R China.
   [Sun, Hourong; Song, Yi; Ma, Zengshan; Zhang, Gong; Gu, Xinghua] Shandong Univ, Qilu Hosp, Dept Cardiovasc Surg, Jinan 250012, Peoples R China.
RP Zhao, L (reprint author), Fourth Mil Med Univ, Sch Clin Med, Xian 710032, Peoples R China.
EM conrad03037@163.com
FU Independent Innovation Foundation of Shandong University, IIFSDU
   [2012TS171]; Research Award Fund for outstanding young scientists of
   Shandong Province in China [2006BS-03014]
FX This study was supported by the Independent Innovation Foundation of
   Shandong University, IIFSDU, NO. 2012TS171 and the Research Award Fund
   for outstanding young scientists of Shandong Province in China, NO.
   2006BS-03014.
CR Arumugam TV, 2009, SHOCK, V32, P4, DOI 10.1097/SHK.0b013e318193e333
   Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025
   Batista ML, 2010, CYTOKINE, V49, P102, DOI 10.1016/j.cyto.2009.10.007
   Chandrasekar B, 2001, CIRCULATION, V103, P2296
   Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709
   Gurevitch J, 1997, J AM COLL CARDIOL, V30, P1554, DOI 10.1016/S0735-1097(97)00328-8
   Ha TZ, 2005, CARDIOVASC RES, V68, P224, DOI 10.1016/j.cardiores.2005.05.025
   Hoshino K, 1999, J IMMUNOL, V162, P3749
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Kaczorowski DJ, 2009, CURR CARDIOL REV, V5, P196, DOI 10.2174/157340309788970405
   Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023
   Kapetanovic IM, 2011, CANCER CHEMOTH PHARM, V68, P593, DOI 10.1007/s00280-010-1525-4
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Khimenko PL, 1998, J APPL PHYSIOL, V85, P2005
   LEFER AM, 1993, AGENT ACTION SUPPL, V41, P127
   Li J, 2008, CRIT CARE MED, V36, P1551, DOI 10.1097/CCM.0b013e3181782335
   Li J, 2009, J MOL CELL CARDIOL, V47, P512, DOI 10.1016/j.yjmcc.2009.07.010
   Lin HS, 2009, BIOMED CHROMATOGR, V23, P1308, DOI 10.1002/bmc.1254
   Liu PT, 1997, AM J PHYSIOL-HEART C, V272, pH2327
   Liu YY, 2008, J IMMUNOL, V180, P7349, DOI 10.4049/jimmunol.180.11.7349
   MA XL, 1992, CIRCULATION, V86, P937, DOI 10.1161/01.CIR.86.3.937
   McCormack D., 2013, OXID MED CELL LONGEV, V2013
   McCormack D, 2012, J SURG RES, V173, pE53, DOI 10.1016/j.jss.2011.09.054
   Meldrum DR, 1998, ANN THORAC SURG, V65, P439, DOI 10.1016/S0003-4975(97)01297-6
   Naidu BV, 2004, J HEART LUNG TRANSPL, V23, P128, DOI 10.1016/S1053-2498(03)00102-5
   Otsui K, 2007, HEART VESSELS, V22, P416, DOI 10.1007/s00380-007-1001-1
   Perecko T, 2010, NEUROENDOCRINOL LETT, V31, P84
   Roupe KA, 2006, CURR CLIN PHARMACOL, V1, P81, DOI 10.2174/157488406775268246
   Shimamoto A, 2006, CIRCULATION, V114, pI270, DOI 10.1161/CIRCULATIONAHA.105.000901
   Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887
   Speyer CL, 2011, J INVEST SURG, V24, P18, DOI 10.3109/08941939.2010.521232
   Su H, 2007, AM J PHYSIOL-ENDOC M, V293, pE629, DOI 10.1152/ajpendo.00221.2007
   Takahashi T, 2008, CARDIOVASC RES, V78, P3, DOI 10.1093/cvr/cvn044
   Xiong J, 2010, CHINESE MED J-PEKING, V123, P2720, DOI 10.3760/cma.j.issn.0366-6999.2010.19.019
   Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82
   Zhu JX, 2006, CYTOKINE, V34, P96, DOI 10.1016/j.cyto.2006.04.010
NR 36
TC 19
Z9 21
U1 1
U2 13
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 2
BP 1737
EP 1746
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CJ2HX
UT WOS:000355306000019
PM 25932102
DA 2018-12-27
ER

PT J
AU Pan, ZY
   Yang, Y
   Pan, H
   Zhang, J
   Liu, H
   Yang, Y
   Huang, G
   Yin, L
   Huang, J
   Zhou, WP
AF Pan, Ze-Ya
   Yang, Yun
   Pan, Hao
   Zhang, Jin
   Liu, Hui
   Yang, Yuan
   Huang, Gang
   Yin, Lei
   Huang, Jian
   Zhou, Wei-Ping
TI RETRACTED: Lentivirus-mediated TPD52L2 depletion inhibits the
   proliferation of liver cancer cells in vitro (Retracted article. See
   vol. 9, pg. 12416, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE TPD52L2; liver cancer; RNA interference; lentivirus; proliferation
ID TUMOR PROTEIN D52; YEAST 2-HYBRID SYSTEM; PROSTATE-CANCER; GENE FAMILY;
   IDENTIFICATION; AMPLIFICATION; PROGRESSION; ORTHOLOGUE; SEQUENCE;
   DISEASE
AB Tumor protein D52-like 2, known as hD54 in previous studies (TPD52L2), is a member of TPD52 family which has been implicated in multiple human cancers. In recent reports, TPD52 proteins were indicated to be associated with several malignancies, but very little is known about the function of TPD52L2 in liver cancers. In our present study, in order to explore the role of TPD52L2 in liver cancer, TPD52L2 was knocked down in SMMC-7721 liver cancer cell line by lentivirus mediated RNA interference. The results demonstrated that depletion of TPD52L2 could remarkably inhibit proliferation and colony forming ability of cancer cell SMMC-7721. Furthermore, cell cycle in TPD52L2 depleted cells was verified to be arrested in G0/G1 phase as determined by FACS assay, in consistence with the observation of cell proliferation inhibition. These results unraveled that TPD52L2 played an important role in tumorigenesis pathways of liver cancer and might serve as a promising target in human liver cancer diagnosis and therapy.
C1 [Pan, Ze-Ya; Yang, Yun; Zhang, Jin; Liu, Hui; Yang, Yuan; Huang, Gang; Yin, Lei; Huang, Jian; Zhou, Wei-Ping] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 3, Shanghai 200438, Peoples R China.
   [Pan, Hao] Shanghai Municipal Ctr Dis Control & Prevent, Dept Infect Dis Control & Prevent, Shanghai 200336, Peoples R China.
RP Pan, ZY (reprint author), Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 3, Shanghai 200438, Peoples R China.
EM zeya_pan@yeah.net
FU Shanghai Municipal Education Commission [12ZZ077]
FX The authors are thankful for the support of the Innovation Program of
   Shanghai Municipal Education Commission (grant no. 12ZZ077).
CR Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166
   Boutros R, 2003, J MOL BIOL, V332, P675, DOI 10.1016/S0022-2836(03)00944-6
   BYRNE JA, 1995, CANCER RES, V55, P2896
   Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393
   Byrne JA, 1998, ONCOGENE, V16, P873, DOI 10.1038/sj.onc.1201604
   Byrne JA, 2005, INT J CANCER, V117, P1049, DOI 10.1002/ijc.21250
   Byrne JA, 1998, CYTOGENET CELL GENET, V81, P199, DOI 10.1159/000015029
   Cao QH, 2006, BIOCHEM BIOPH RES CO, V344, P798, DOI 10.1016/j.bbrc.2006.03.208
   Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146
   Chen SL, 1996, ONCOGENE, V12, P741
   Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585
   Grimm Dirk, 2007, Hematology Am Soc Hematol Educ Program, P473
   Guo WH, 2011, J CANCER RES CLIN, V137, P65, DOI 10.1007/s00432-010-0860-5
   Huszthy PC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006314
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Katanoda K, 2014, JPN J CLIN ONCOL, V44, P302, DOI 10.1093/jjco/hyu025
   Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051
   Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008
   Lewis JD, 2007, MOL CANCER RES, V5, P133, DOI 10.1158/1541-7786.MCR-06-0245
   Li GQ, 2011, SCI CHINA LIFE SCI, V54, P403, DOI 10.1007/s11427-011-4163-0
   Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0
   Luke C, 2010, ASIAN PAC J CANCER P, V11, P1479
   Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900
   Micklem DR, 2007, CURR PHARM BIOTECHNO, V8, P337, DOI 10.2174/138920107783018426
   Nourse CR, 1998, BBA-GENE STRUCT EXPR, V1443, P155, DOI 10.1016/S0167-4781(98)00211-5
   Okoli AS, 2012, INT J HEPATOL, V2012
   PARK CH, 1971, JNCI-J NATL CANCER I, V46, P411
   Proux-Gillardeaux V, 2003, BIOCHEM J, V370, P213, DOI 10.1042/BJ20021309
   Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881
   Sathasivam P, 2001, BIOCHEM BIOPH RES CO, V288, P56, DOI 10.1006/bbrc.2001.5721
   Seyhan AA, 2011, HUM GENET, V130, P583, DOI 10.1007/s00439-011-0995-8
   Thomas DDH, 2002, J BIOL CHEM, V277, P35496, DOI 10.1074/jbc.M110917200
   Tyner J, 2009, CELL CYCLE, V8, P2144
   Wang RX, 2004, CANCER RES, V64, P1589, DOI 10.1158/0008-5472.CAN-03-3331
   Wilson SHD, 2001, GENOMICS, V76, P81, DOI 10.1006/geno.2001.6610
   Zeng GQ, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013946
   Zhu H, 2007, CANCER LETT, V245, P303, DOI 10.1016/j.canlet.2006.01.020
   Zufferey R, 1998, J VIROL, V72, P9873
NR 38
TC 6
Z9 6
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 2
BP 2334
EP 2341
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CJ2HX
UT WOS:000355306000086
PM 25932170
DA 2018-12-27
ER

PT J
AU Li, GY
   Li, SQ
   Sun, LZ
   Lin, FC
   Wang, BG
AF Li, Guoyan
   Li, Shuqin
   Sun, Lizhi
   Lin, Fangcai
   Wang, Baoguo
TI RETRACTED: A comparison study of immune-inflammatory response in
   electroacupuncture and transcutaneous electrical nerve stimulation for
   patients undergoing supratentorial craniotomy(Retracted article. See
   vol.9,pg.20464,2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Transcutaneous electrical nerve stimulation (TENS); electroacupuncture
   (EA); immuno-inflammatory; supratentorial craniotomy
ID LOW-BACK-PAIN; RATS; RELEASE; BLOCK
AB Objective: The effect of transcutaneous electrical nerve stimulation (TENS) on immuno-inflammatory response was tested and the differences between electroacupuncture (EA) and TENS in immuno-inflammatory response in patients undergoing supratentorial craniotomy were explored. Methods: 51 patients received craniotomy were divided randomly into 3 groups: control (group C, n=18), EA (group A, n=19) and TENS (group T, n=14) groups. Blood samples were collected before anesthesia (T0) and 30 min (T1), 2 h (T2) and 4 h (T3) after induction of anesthesia to measure the levels of tumor necrosis factor-a (TNF-alpha), interleukin (IL)-8, IL-10, IgM, IgA and IgG.. Results: No significant difference existed between groups A and group T during craniotomy. IgM and IgA decreased significantly in group C compared with groups A and T at T2 and T3 time points. Compared with group C, there were significant difference in TNF-alpha, IgM and IgA level at T0 in groups A and T; no significant difference was found in the levels of IgG, IL-10 and IL-8. Conclusion: EA and TENS could reduce immunosuppression in patients undergoing supratentorial craniotomy and it has significance in choice of treatment in immunosuppressive therapy.
C1 [Li, Guoyan; Sun, Lizhi] Beijing Elect Power Hosp, North China Grid Co Ltd, Dept Anesthesiol, Beijing, Peoples R China.
   [Li, Shuqin] Beijing Tiantan Hosp, Dept Anesthesiol, Beijing, Peoples R China.
   [Lin, Fangcai] Beijing Elect Power Hosp, North China Grid Co Ltd, Dept Gen Surg, Beijing, Peoples R China.
   [Wang, Baoguo] Beijing Sanbo Brain Hosp, Dept Anesthesiol & Pain Management, Beijing, Peoples R China.
RP Wang, BG (reprint author), Sanbo Brain Hosp, Dept Anesthesiol, 50 Xiang Shan Yi Ke Song, Beijing 100093, Peoples R China.
EM baoguowang77@126.com
FU National Key Basic Research Program [2013-CB531901]; 
   [SGHBOOO-AJJS1400182]
FX This work was supported by the multidisciplinary study on chronic
   diseases in electric power system employees and the subprogram "the
   effect of different anesthetic methods on immune-inflammatory response
   in patients undergoing supratentorial craniotomy" (The state grid
   program of science and technology, SGHBOOO-AJJS1400182) and the National
   Key Basic Research Program on innovation and application study of
   combined acupuncture drug (2013-CB531901).
CR Arai YCP, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/727121
   Cecen D, 2013, EVID-BASED COMPL ALT, V2013
   Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873
   Chu H, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-84
   DeSantana Josimari M, 2008, Curr Rheumatol Rep, V10, P492
   Ding LC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057477
   Fang JF, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-134
   Gu G, 2011, J INT MED RES, V39, P1783, DOI 10.1177/147323001103900521
   Keskin EA, 2012, GYNECOL OBSTET INVES, V74, P76, DOI 10.1159/000337720
   Khalil Z, 2000, J GERONTOL A-BIOL, V55, pB257, DOI 10.1093/gerona/55.6.B257
   Kita K, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-55
   Kloth L C, 1996, Adv Wound Care, V9, P42
   Lan F, 2012, MINERVA ANESTESIOL, V78, P887
   Li GY, 2013, ACUPUNCT MED, V31, P51, DOI 10.1136/acupmed-2012-010254
   Liu SJ, 2011, ANESTH ANALG, V113, P572, DOI 10.1213/ANE.0b013e3182278237
   Pinosky ML, 1996, ANESTH ANALG, V83, P1256, DOI 10.1097/00000539-199612000-00022
   Sabino GS, 2008, J PAIN, V9, P157, DOI 10.1016/j.jpain.2007.09.003
   Sluka KA, 2006, ARCH PHYS MED REHAB, V87, P1137, DOI 10.1016/j.apmr.2006.04.023
   Stein C, 2013, REV BRAS FISIOTER, V17, P93, DOI 10.1590/S1413-35552012005000083
   Trinh K, 2007, SPINE, V32, P236, DOI 10.1097/01.brs.0000252100.61002.d4
   WANG JQ, 1992, INT J NEUROSCI, V65, P117, DOI 10.3109/00207459209003283
   Yokoyama M, 2001, ANESTH ANALG, V92, P463, DOI 10.1213/00000539-200102000-00035
   Zaniewska R, 2012, MED PR, V63, P295
   Zhang WT, 2003, NEUROREPORT, V14, P1591, DOI 10.1097/01.wnr.0000085243.71403.6a
NR 24
TC 3
Z9 3
U1 1
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 2
BP 2662
EP 2667
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CJ2HX
UT WOS:000355306000132
PM 25932216
DA 2018-12-27
ER

PT J
AU Zhang, QG
   Qian, J
   Zhu, YC
AF Zhang, Qinggang
   Qian, Jing
   Zhu, Yuchang
TI RETRACTED: Parathyroid hormone plus alendronate in osteoporosis: a
   meta-analysis of randomized controlled trials (Retracted article. See
   vol. 9, pg. 467, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article; Retracted Publication
DE Osteoporosis; parathyroid hormone; alendronate; meta-analysis
ID BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; VERTEBRAL FRACTURES;
   CLINICAL-TRIALS; THERAPY; TERIPARATIDE; QUALITY; MEN; RISK; BIAS
AB Background: Parathyroid hormone (PTH) increases both bone formation (BMD) and bone resorption, whereas alendronate reduces bone resorption. It is possible that the combination therapy of PTH with alendronate will enhance their effects on BMD. Therefore, we conducted this meta-analysis to evaluate the efficacy of the combination therapy of PTH with alendronate in the treatment of patients with osteoporosis. Methods: A comprehensive literature search of PubMed, Embase, and Web of Science was conducted to identify relative studies. Eligible studies were randomized controlled trials (RCT), which assessed the efficacy of combination therapy in patients with osteoporosis. The outcomes included the mean percent increases in BMD of lumbar spine, femoral neck, total hip, and distal radius. Weighted mean difference (WMD) with 95% confidence intervals (CIs) were calculated using of random-effects or fixed-effects model, depending on the heterogeneity between the included studies. Results: Six RCTs with a total number of 833 patients were included in this meta-analysis. The pooled estimates showed that, the combination therapy of PTH with alendronate resulted in a higher mean percent change of increased BMD in distal radius (WMD = 2.45, 95% CI: 1.58, 3.31; P = 0.000), but not in lumbar spine (WMD = -0.83, 95% CI: -3.48, 1.81; P = 0.538), femoral neck (WMD = -0.99, 95% CI: -2.04, 0.07; P = 0.068), and total hip (WMD = -0.06, 95% CI: -0.93, 0.81; P = 0.892). The subgroup analysis based on the dosage and schedule of PTH, study duration, gender of patients, and anabolic agents, were conducted. And results revealed that among the patients in the combination therapy group, greater increases in the spine BMD were observed when the PTH was administered with a dosage of 20 mu g (WMD = 2.33, 95% CI: 1.24, 3.43; P = 0.000), or the treatment duration lasted more than 12 months (WMD = 2.23, 95% CI: 1.00, 3.47; P = 0.000), or the combination therapy was used in osteoporosis women (WMD = 1.58, 95% CI: 0.63, 2.53; P = 0.001). However, the combination of PTH of 40 mu g with alendronate produced a decrease in the BMD at spine (WMD = -4.56, 95% CI: -7.56, -1.56; P = 0.003) and femoral neck (WMD = -5.82, 95% CI: -9.91, -1.72; P = 0.005). Conclusion: Our findings indicated that the addition of alendronate to PTH in the treatment of osteoporosis, reduced the ability of PTH therapy to increase the BMD at the lumbar spine, femoral neck, and total hip.
C1 [Zhang, Qinggang; Qian, Jing; Zhu, Yuchang] Tongji Univ, Peoples Hosp 10, Dept Orthopaed, Shanghai 200072, Peoples R China.
RP Zhu, YC (reprint author), Tongji Univ, Peoples Hosp 10, Dept Orthopaed, 301 Yanchang Middle Rd, Shanghai 200072, Peoples R China.
EM zhuyuchang@hotmail.com
CR American Association of Clinical Endocrinologists Osteoporosis Task Force, 2001, Endocr Pract, V7, P293
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007-0711
   Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008-2719
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001-2002
   Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   EINHORN TA, 1992, CALCIFIED TISSUE INT, V51, P333, DOI 10.1007/BF00316875
   Finkelstein JS, 2010, J CLIN ENDOCR METAB, V95, P1838, DOI 10.1210/jc.2009-1703
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HODSMAN AB, 1993, BONE, V14, P523, DOI 10.1016/8756-3282(93)90190-L
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008-0353
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   PECK WA, 1993, AM J MED, V94, P646
   REEVE J, 1980, BMJ-BRIT MED J, V280, P1340, DOI 10.1136/bmj.280.6228.1340
   Rittmaster RS, 2000, J CLIN ENDOCR METAB, V85, P2129, DOI 10.1210/jc.85.6.2129
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rosen CJ, 2001, J CLIN ENDOCR METAB, V86, P957, DOI 10.1210/jc.86.3.957
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756-3282(99)00116-7
   TAM CS, 1982, ENDOCRINOLOGY, V110, P506, DOI 10.1210/endo-110-2-506
NR 33
TC 5
Z9 6
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 3
BP 3338
EP 3348
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA CJ2IK
UT WOS:000355307300029
PM 26064224
DA 2018-12-27
ER

PT J
AU Wang, T
   Chen, SS
   Chen, R
   Yu, DM
   Yu, P
AF Wang, Tong
   Chen, Si-Si
   Chen, Rui
   Yu, De-Min
   Yu, Pei
TI RETRACTED: Reduced beta 2 glycoprotein I improves diabetic nephropathy
   via inhibiting TGF-beta 1-p38 MAPK pathway (Retracted article. See vol.
   8, pg. 19792, 2015)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE Beta 2 glycoprotein I; diabetic nephropathy; TGF-beta 1
ID BETA(2)-GLYCOPROTEIN I; ANTIPHOSPHOLIPID ANTIBODIES; OXIDATIVE STRESS;
   MESANGIAL CELLS; HIGH GLUCOSE; ATHEROSCLEROSIS; BINDING; EXPRESSION;
   PROTEIN; KINASE
AB Purpose: Beta 2 glycoprotein I (beta 2GPI) has been shown the positive effect on diabetic atherosclerosis and retinal neovascularization. beta 2GPI can be reduced by thioredoxin-1, resulting in the reduced state of beta 2GPI. The possible protective effects of beta 2GPI and reduced beta 2GPI on diabetic nephropathy (DN) are not fully elucidated. The purpose of this study was to test a hypothesis that beta 2GPI and reduced beta 2GPI would improve DN in streptozotocin (STZ) induced diabetic mice and high-glucose (HG) exposed rat mesangial cell (RMC). Methods: The STZ-induced Balb/c mice and HG exposed RMCs were administrated with beta 2-GPI and reduced beta 2-GPI at different time and concentrations gradient respectively. The changes of glomerular structure and expression of collagen IV, TGF-beta 1, p38 MAPK and phospho-p38 MAPK in renal cortical and mesangial cells were observed by immunohistochemical techniques, quantitative real-time PCR and western blot with or without the treatment of beta 2-GPI and reduced beta 2-GPI. Results: beta 2GPI and reduced beta 2GPI improved early clinical and pathological changes of DN in STZ-diabetic mice. Treatment with beta 2GPI and reduced beta 2GPI in the STZ-diabetic mice and HG exposed RMCs resulted in decrease expression levels of TGF-beta 1 and collagen IV, with concomitant decrease in phospho-p38 MAPK expression. Conclusions: beta 2GPI and reduced beta 2GPI improved renal structural damage and kidney function. The renoprotective and antifibrosis effects of beta 2GPI and reduced beta 2GPI on DN were closely associated with suppressing the activation of the TGF-beta 1-p38 MAPK pathway.
C1 [Yu, Pei] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Key Lab Hormones & Dev, Minist Hlth,Metab Dis Hosp, Tianjin 300070, Peoples R China.
   Tianjin Med Univ, Tianjin Inst Endocrinol, Tianjin 300070, Peoples R China.
RP Yu, P (reprint author), Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Key Lab Hormones & Dev, Minist Hlth,Metab Dis Hosp, Tianjin 300070, Peoples R China.
EM peiyudoc@yeah.net
FU National Natural Science Foundation of China [30971393, 81070645];
   Tianjin natural science fund [10JCYBJC12000]
FX This work was supported by the National Natural Science Foundation of
   China (No. 30971393 and No. 81070645), the Tianjin natural science fund
   (No. 10JCYBJC12000).
CR Advani A, 2009, J AM SOC NEPHROL, V20, P730, DOI 10.1681/ASN.2008020142
   Agar C, 2011, THROMB HAEMOSTASIS, V106, P1069, DOI 10.1160/TH11-05-0333
   Arad A, 2011, BLOOD, V117, P3453, DOI 10.1182/blood-2010-08-300715
   Choi ME, 2012, SEMIN NEPHROL, V32, P244, DOI 10.1016/j.semnephrol.2012.04.003
   de Groot PG, 2011, J THROMB HAEMOST, V9, P1275, DOI 10.1111/j.1538-7836.2011.04327.x
   de Laat B, 2009, BLOOD, V114, P3656, DOI 10.1182/blood-2009-03-212910
   Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x
   Ioannou Y, 2011, ARTHRITIS RHEUM-US, V63, P2774, DOI 10.1002/art.30383
   Ioannou Y, 2010, BLOOD, V116, P1961, DOI 10.1182/blood-2009-04-215335
   Jankowski M, 2003, BLOOD, V101, P157, DOI 10.1182/blood-2002-05-1310
   Lin KY, 2005, J CELL BIOCHEM, V94, P485, DOI 10.1002/jcb.20314
   Mahimainathan L, 2006, DIABETES, V55, P2115, DOI 10.2337/db05-1326
   McGowan Tracy A, 2004, Curr Diab Rep, V4, P447, DOI 10.1007/s11892-004-0055-z
   MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120
   Nilsson M, 2008, MOL MICROBIOL, V67, P482, DOI 10.1111/j.1365-2958.2007.05974.x
   Noh H, 2002, NEPHRON, V90, P78, DOI 10.1159/000046318
   Passam FH, 2010, J THROMB HAEMOST, V8, P1754, DOI 10.1111/j.1538-7836.2010.03944.x
   Petri M, 2010, LUPUS, V19, P419, DOI 10.1177/0961203309360541
   Raptis AE, 2001, EXP CLIN ENDOCR DIAB, V109, pS424, DOI 10.1055/s-2001-18600
   RIOCHE M, 1974, BIOMED EXPRESS, V21, P420
   Rossing Peter, 2006, Curr Diab Rep, V6, P479, DOI 10.1007/s11892-006-0083-y
   SCHULTZE HE, 1961, NATURWISSENSCHAFTEN, V48, P719, DOI 10.1007/BF00620967
   Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228
   SEGER R, 1995, FASEB J, V9, P726
   Staub HL, 2006, AUTOIMMUN REV, V6, P104, DOI 10.1016/j.autrev.2006.06.014
   Vaarala O, 1996, LUPUS, V5, P442, DOI 10.1177/096120339600500522
   Yu P, 2008, J THROMB HAEMOST, V6, P1215, DOI 10.1111/j.1538-7836.2008.03000.x
   Yu YX, 2005, AM J MED SCI, V330, P227, DOI 10.1097/00000441-200511000-00005
   Zhang R, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-42
NR 29
TC 7
Z9 8
U1 2
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 3
BP 2321
EP 2333
PG 13
WC Oncology; Pathology
SC Oncology; Pathology
GA CJ2KD
UT WOS:000355312200006
PM 26045739
DA 2018-12-27
ER

PT J
AU Albawardi, A
   Almarzooqi, S
   Saraswathiamma, D
   Abdul-Kader, HM
   Souid, AK
   Alfazari, AS
AF Albawardi, Alia
   Almarzooqi, Saeeda
   Saraswathiamma, Dhanya
   Abdul-Kader, Hidaya Mohammed
   Souid, Abdul-Kader
   Alfazari, Ali S.
TI RETRACTED: The mTOR inhibitor sirolimus suppresses renal, hepatic, and
   cardiac tissue cellular respiration (Retracted article. See vol. 8, pg.
   13783, 2015)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE mTOR; rapamycin; sirolimus; tacrolimus; cyclosporine; O-2 consumption;
   oxidative phosphorylation
ID PI3K/AKT/MTOR PATHWAY; DUAL INHIBITORS; CANCER; PHOSPHORESCENCE
AB The purpose of this in vitro study was to develop a useful biomarker (e.g., cellular respiration, or mitochondrial O-2 consumption) for measuring activities of mTOR inhibitors. It measured the effects of commonly used immunosuppressants (sirolimus-rapamycin, tacrolimus, and cyclosporine) on cellular respiration in target tissues (kidney, liver, and heart) from C57BL/6 mice. The mammalian target of rapamycin (mTOR), a serine/threonine kinase that supports nutrient-dependent cell growth and survival, is known to control energy conversion processes within the mitochondria. Consistently, inhibitors of mTOR (e.g., rapamycin, also known as sirolimus or Rapamune (R)) have been shown to impair mitochondrial function. Inhibitors of the calcium-dependent serine/threonine phosphatase calcineurin (e.g., tacrolimus and cyclosporine), on the other hand, strictly prevent lymphokine production leading to a reduced T-cell function. Sirolimus (10 mu M) inhibited renal (22%, P = 0.002), hepatic (39%, P < 0.001), and cardiac (42%, P = 0.005) cellular respiration. Tacrolimus and cyclosporine had no or minimum effects on cellular respiration in these tissues. Thus, these results clearly demonstrate that impaired cellular respiration (bioenergetics) is a sensitive biomarker of the immunosuppressants that target mTOR.
C1 [Albawardi, Alia; Almarzooqi, Saeeda; Saraswathiamma, Dhanya] UAE Univ, Dept Pathol, Abu Dhabi 17666, U Arab Emirates.
   [Abdul-Kader, Hidaya Mohammed; Alfazari, Ali S.] UAE Univ, Dept Med, Abu Dhabi 17666, U Arab Emirates.
   [Souid, Abdul-Kader] UAE Univ, Dept Pediat, Abu Dhabi 17666, U Arab Emirates.
RP Alfazari, AS (reprint author), UAE Univ, Dept Med, Abu Dhabi 17666, U Arab Emirates.
EM a.almelaih@uaeu.ac.ae
FU UAE University, NRF [31M096]
FX This research was supported by a grant from the UAE University, NRF
   (31M096).
CR Alfazari Ali S, 2013, BMC Pharmacol Toxicol, V14, P15, DOI 10.1186/2050-6511-14-15
   Alfazari Ali S, 2013, BMC Res Notes, V6, P70, DOI 10.1186/1756-0500-6-70
   Alfazari AS, 2014, J CLIN TOXICOLOGY, V4, P207
   Almarzooqi S, J CLIN TOXICOLOGY
   Berridge MJ, 2009, CELL SIGNALING BIOL, P121
   Chen JZ, 2014, CURR MED CHEM, V21, P3070, DOI 10.2174/0929867321666140414095605
   Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322
   Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112
   Dehnhardt CM, 2011, BIOORG MED CHEM LETT, V21, P4773, DOI 10.1016/j.bmcl.2011.06.063
   Dykens JA, 2007, DRUG DISCOV TODAY, V12, P777, DOI 10.1016/j.drudis.2007.07.013
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144
   Markman B, 2010, ONCOTARGET, V1, P530
   Ravaud A, 2010, B CANCER, V97, pS45, DOI 10.1684/bdc.2010.1069
   Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200
   Shaban S, 2010, COMPUT METH PROG BIO, V100, P265, DOI 10.1016/j.cmpb.2010.04.009
   Tao ZM, 2008, ANAL BIOCHEM, V381, P43, DOI 10.1016/j.ab.2008.06.020
   Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817
   Vandewalle A, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-8
NR 20
TC 2
Z9 2
U1 1
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 3
BP 2955
EP 2962
PG 8
WC Oncology; Pathology
SC Oncology; Pathology
GA CJ2KD
UT WOS:000355312200071
PM 26045804
DA 2018-12-27
ER

PT J
AU Mast, B
   Merkt, N
   Hernandez, R
   French, WT
   Claupein, W
   Graeff-Honninger, S
AF Mast, Benjamin
   Merkt, Nikolaus
   Hernandez, Rafael
   French, W. Todd
   Claupein, Wilhelm
   Graeff-Hoenninger, Simone
TI RETRACTED: Characterization of Different Biomasses Based on Their Sugar
   Profile with Focus on Their Utilization for Microbial Biodiesel
   Production (Retracted article. See vol. 12, pg. 995, 2015)
SO INTERNATIONAL JOURNAL OF GREEN ENERGY
LA English
DT Article; Retracted Publication
DE Lignocellulosic biomass; Second generation biodiesel; Oleaginous
   microorganisms; Sugar content; C/N-ratio
ID BIOFUELS; ENERGY; SYSTEMS; LIPIDS; CROPS; WATER
AB The investigation and characterization of different biomasses as potential feedstocks for microbial lipid production was the aim of the present work. Twenty-eight biomasses were analyzed for total sugar content (glucose and xylose) and C/N-ratio as two major criteria for a suitable lipid production by oleaginous microorganisms. Considering both parameters, 9 out of 28 biomasses seemed to be suitable feedstocks for microbial lipid production. To allow for a broad evaluation of the suitability of the potential feedstocks, the estimated sugar and potential energy yield per area were calculated and the production costs and energy demand of the feedstock production were considered.
C1 [Mast, Benjamin; Merkt, Nikolaus; Claupein, Wilhelm; Graeff-Hoenninger, Simone] Univ Hohenheim, Inst Crop Sci, D-70599 Stuttgart, Germany.
   [French, W. Todd] Mississippi State Univ, Dave C Swalm Sch Chem Engn, Starkville, MS USA.
   [Hernandez, Rafael] Univ Louisiana Lafayette, Dept Chem Engn, Lafayette, LA USA.
RP Mast, B (reprint author), Univ Hohenheim, Inst Crop Sci, Fruwirthstr 23, D-70599 Stuttgart, Germany.
EM benjamin.mast@uni-hohenheim.de
CR Ageitos JM, 2011, APPL MICROBIOL BIOT, V90, P1219, DOI 10.1007/s00253-011-3200-z
   Angerbauer C, 2008, BIORESOURCE TECHNOL, V99, P3051, DOI 10.1016/j.biortech.2007.06.045
   Antizar-Ladislao B, 2008, BIOFUEL BIOPROD BIOR, V2, P455, DOI 10.1002/bbb.97
   Bayern LfL, 2007, VERSUCHSERGEBNISSE B
   Boehmel C, 2008, AGR SYST, V96, P224, DOI 10.1016/j.agsy.2007.08.004
   Boelcke B., 2008, Pflanzenbauwissenschaften, V12, P78
   Bozbas K, 2008, RENEW SUST ENERG REV, V12, P542, DOI 10.1016/j.rser.2005.06.001
   Claassen PAM, 1999, APPL MICROBIOL BIOT, V52, P741, DOI 10.1007/s002530051586
   Davis S. C., 2011, FRONT ECOL ENVIRON, V10, P69, DOI DOI 10.1890/110003
   Dufreche S, 2007, J AM OIL CHEM SOC, V84, P181, DOI 10.1007/s11746-006-1022-4
   Dumas A., 1962, STICKSTOFFBESTIMMUNG
   EU, 2009, OFFICIAL J EUROPEAN, VL140
   FAL Bundesforschungsanstalt fur Landwirtschaft (Federal Agricultural research Centre; FAL), 2001, GIAN REED ARUND DON
   Galafassi S, 2012, BIORESOURCE TECHNOL, V111, P398, DOI 10.1016/j.biortech.2012.02.004
   Gauder M, 2011, BIOMASS BIOENERG, V35, P1646, DOI 10.1016/j.biombioe.2010.12.041
   Gonzalez-Garcia Y., 2011, ENV PROGR SUSTAINABL, P1
   Hamelinck CN, 2006, ENERG POLICY, V34, P3268, DOI 10.1016/j.enpol.2005.06.012
   Heaton E, 2004, BIOMASS BIOENERG, V27, P21, DOI 10.1016/j.biombioe.2003.10.005
   IEA, 2010, WORLD ENERGY OUTLOOK
   Johnson GA, 2013, BIOMASS BIOENERG, V58, P267, DOI 10.1016/j.biombioe.2013.10.013
   Knothe G., 2009, BIODIESEL HDB
   KTBL Kuratorium fur Technik und Bauwesen in der Landwirtschaft (Association for Technology and Structures in Agriculture), 2006, ENERGIEPFLANZEN
   Kumar P, 2009, IND ENG CHEM RES, V48, P3713, DOI 10.1021/ie801542g
   LTZ Augustenberg Landwirtschftliches Technologiezentrum Augustenberg (Agricultural Technology Centre Baden-Wurttemberg), 2011, PROD TECHN VERS 2011
   Mondala A, 2009, BIORESOURCE TECHNOL, V100, P1203, DOI 10.1016/j.biortech.2008.08.020
   Mondala AH, 2012, AICHE J, V58, P1279, DOI 10.1002/aic.12655
   Nedunchezhiyan M, 2010, FOOD SCI TECHNOL, P1
   Nigam PS, 2011, PROG ENERG COMBUST, V37, P52, DOI 10.1016/j.pecs.2010.01.003
   OECD/ FAO, 2012, OECD FAO AGR OUTL 20
   Ratledge C., 2010, SINGLE CELL OILS MIC
   Ratledge C, 2008, LIPID TECHNOL, V20, P155, DOI DOI 10.1002/LITE.200800044
   Rossi M, 2011, BIODIESEL - FEEDSTOCKS AND PROCESSING TECHNOLOGIES, P71
   Sattur A. P., 1988, BIOTECHNOL BIOENG, V34, P872
   Tao J, 2010, INT J GREEN ENERGY, V7, P387, DOI 10.1080/15435075.2010.493809
   Tao J, 2008, INT J SUSTAIN ENERGY, V27, P73, DOI 10.1080/14786450802283364
   Tilman D, 2009, SCIENCE, V325, P270, DOI 10.1126/science.1177970
   Timilsina GR, 2011, ENERGY, V36, P2055, DOI 10.1016/j.energy.2010.08.023
   van Gerpen J., 2005, BIODIESEL HDB
   Yu XC, 2011, BIORESOURCE TECHNOL, V102, P6134, DOI 10.1016/j.biortech.2011.02.081
NR 39
TC 4
Z9 4
U1 5
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1543-5075
EI 1543-5083
J9 INT J GREEN ENERGY
JI Int. J. Green Energy
PY 2015
VL 12
IS 9
BP 930
EP 938
DI 10.1080/15435075.2014.888661
PG 9
WC Thermodynamics; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Thermodynamics; Science & Technology - Other Topics; Energy & Fuels
GA CG8PM
UT WOS:000353571100006
DA 2018-12-27
ER

PT J
AU Qian, Y
   Ma, JF
   Guo, XY
   Sun, J
   Yu, YT
   Cao, BQ
   Zhang, L
   Ding, XP
   Huang, J
   Shao, JF
AF Qian, Yu
   Ma, Jianfen
   Guo, Xiaoyi
   Sun, Jun
   Yu, Yongtao
   Cao, Boqiang
   Zhang, Lei
   Ding, Xiaopeng
   Huang, Jin
   Shao, Jun Fei
TI RETRACTED: Curcumin Enhances the Radiosensitivity of U87 Cells by
   Inducing DUSP-2 Up-Regulation (Retracted article. See vol. 39, pg. 814,
   2016)
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE Glioma; Curcumin; Radiosensitizer; Cell cycle; DUSP-2
ID IN-VITRO; RADIATION-THERAPY; CANCER-CELLS; CYCLE ARREST; HEAD; NECK;
   PROTEIN; CARCINOMA; APOPTOSIS; PATHWAYS
AB Objective: Glioblastoma multiforme (GBM), an aggressive primary brain tumor, is radioresistant and recurs despite aggressive surgery, chemotherapy, and radiotherapy. Curcumin as a potential radiosensitizer has received extensive attention in cancer treatment. To explore an effectiveness of this radiosensitizer for GBM treatment, we evaluated the radiosensitizing effect of curcumin and investigated its potential molecular mechanisms in the human glioma cell line U87. Methods: The cytotoxic effects of curcumin on U87 cells were evaluated using the Cell Counting Kit-8 assay, and the radiosensitivity of U87 cells treated with curcumin was accessed by colony information assay. The effects of curcumin on cell proliferation and cell cycle regulation were determined using the 5-ethynyl-2-deoxyuridine incorporation assay and flow cytometry, respectively. Western blotting was applied to determine the effects of curcumin on protein expression of dual-specificity phosphatase-2 (DUSP-2), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) as well as phosphorylated ERK and JNK. Results: Curcumin significantly inhibited the proliferation of U87 cells in a dose- and time-dependent manner. Curcumin treatment at the concentrations of 5 mu M and 10 M could significantly reduce the clonogenic activity and enhance the radiosensitivity of U87 cells with sensitive enhancement ratios (SERs) of 1.71 and 4.65, respectively. Curcumin resulted in G2/M cell cycle arrest in U87 cells, which were radiosensitive. Pre-treatment of U87-MG cells with 5 mu M curcumin enhanced radiation-induced cell proliferation inhibition and apoptosis. Furthermore, we observed that curcumin increased DUSP-2 protein expression and decreased the phosphorylation of ERK and JNK. Conclusion: Our results suggest that low-dose curcumin may enhance the radiosensitivity of human glioma U87 cells in vitro by inducing G2/M cell cycle arrest through up-regulation of DUSP-2 expression and inhibition of ERK and JNK phosphorylation. Copyright (C) 2015 S. Karger AG, Basel
C1 [Qian, Yu; Ma, Jianfen; Guo, Xiaoyi; Sun, Jun; Yu, Yongtao; Cao, Boqiang; Zhang, Lei; Ding, Xiaopeng; Huang, Jin; Shao, Jun Fei] Nanjing Med Univ, Dept Neurosurg, Wuxi Peoples Hosp, Wuxi 214023, Peoples R China.
RP Shao, JF (reprint author), Nanjing Med Univ, Dept Neurosurg, Wuxi Peoples Hosp, Qing Yang Rd 299, Wuxi 214023, Peoples R China.
EM wxbrain@163.com
FU National Natural Science Foundation [81272791]
FX This study was supported by a grant from the National Natural Science
   Foundation (81272791).
CR Bjork-Eriksson T, 2000, INT J RADIAT ONCOL, V46, P13, DOI 10.1016/S0360-3016(99)00373-9
   Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373
   Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038/sj.onc.1207284
   Fernet M, 2010, DNA REPAIR, V9, P48, DOI 10.1016/j.dnarep.2009.10.006
   Ge YF, 2013, ASIAN PAC J CANCER P, V14, P963, DOI 10.7314/APJCP.2013.14.2.963
   Gerhardt D, 2014, UROL ONCOL, V32
   Harrison L, 2004, ONCOLOGIST, V9, P31, DOI 10.1634/theoncologist.9-90005-31
   Holy JM, 2002, MUTAT RES-GEN TOX EN, V518, P71, DOI 10.1016/S1383-5718(02)00076-1
   Huang HC, 2011, J AGR FOOD CHEM, V59, P6765, DOI 10.1021/jf201096v
   Jagetia GC, 2007, ADV EXP MED BIOL, V595, P301
   Khafif A, 2009, LARYNGOSCOPE, V119, P2019, DOI 10.1002/lary.20582
   Kunnumakkara AB, 2008, CLIN CANCER RES, V14, P2128, DOI 10.1158/1078-0432.CCR-07-4722
   Kvols LK, 2005, J NUCL MED, V46, p187S
   Leonard CE, 1996, CANCER RES, V56, P5198
   Lin SC, 2011, J CLIN INVEST, V121, P1905, DOI 10.1172/JCI44362
   MacCorkle RA, 2005, CELL BIOCHEM BIOPHYS, V43, P451, DOI 10.1385/CBB:43:3:451
   McKenna FW, 2009, PHYS MED BIOL, V54, P1593, DOI 10.1088/0031-9155/54/6/013
   Pauwels B, 2010, FUTURE ONCOL, V6, P1485, DOI [10.2217/fon.10.104, 10.2217/FON.10.104]
   ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221
   Shah MA, 2001, CLIN CANCER RES, V7, P2168
   Shao JF, 2011, ACTA BIOCH BIOPH SIN, V43, P267, DOI 10.1093/abbs/gmr011
   Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Simoens C, 2006, CANCER CHEMOTH PHARM, V58, P210, DOI 10.1007/s00280-005-0147-8
   Wilken R, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-12
   Yang CW, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-22
   Zhang BL, 2014, MOL BIOL REP, V41, P3659, DOI 10.1007/s11033-014-3230-6
NR 28
TC 25
Z9 27
U1 4
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 35
IS 4
BP 1381
EP 1393
DI 10.1159/000373959
PG 13
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA CF3OC
UT WOS:000352457400011
PM 25792385
OA DOAJ Gold
DA 2018-12-27
ER

PT J
AU Iso, Y
   Matsumoto, T
   Sakuraoka, Y
   Shiraki, T
   Kato, M
   Shimoda, M
   Aoki, T
   Kubota, K
AF Iso, Yukihiro
   Matsumoto, Takatsugu
   Sakuraoka, Yuki
   Shiraki, Takayuki
   Kato, Masato
   Shimoda, Mitsugi
   Aoki, Taku
   Kubota, Keiichi
TI RETRACTED: Preoperative Neutrophil-to-Lymphocyte Ratio for
   Prognostication of Patients with Distal Bile Duct Carcinomas Undergoing
   Surgery(Retracted article. See vol. 32, pg. 352, 2015)
SO DIGESTIVE SURGERY
LA English
DT Article; Retracted Publication
DE Neutrophil-to-lymphocyte ratio; Prognostication; Distal bile duct
   carcinoma; Pancreatoduodenectomy; Outcome of surgical resection
ID AMERICAN JOINT COMMITTEE; HEPATOCELLULAR-CARCINOMA;
   LIVER-TRANSPLANTATION; CURATIVE RESECTION; COLORECTAL-CANCER; TUMOR
   RECURRENCE; GASTRIC-CANCER; PHASE-II; CHOLANGIOCARCINOMA; SURVIVAL
AB Background: Surgical resection continues to be the current standard treatment for distal bile duct carcinoma (DBC), as no effective alternative treatment exists. However, even after resection, the long-term prognosis is poor. Simple biomarkers that can predict response or toxicity, and which are applicable to all community oncology settings worldwide, have not been identified. Differential white-cell counts, such as the neutrophil-to-lymphocyte ratio (NLR), as markers of inflammation, may be simple and readily available biomarkers. This study aimed to determine whether the NLR can be used as a predictor of surgical outcome in patients with DBC. Materials and Methods: We enrolled 91 DBC patients who had undergone pancreatoduodenectomy (PD) at a single institution between April 2000 and December 2013. Blood was sampled on admission for determination of NLR. An NLR of >= 5 was selected as the cut-off value for validation. Results: Seventeen patients had an NLR of >= 5 (Group 1; 18.7%), while 74 had an NLR of <5 (Group 2; 81.3%). The 1-, 3- and 5-year survival rates for Group 1 patients were 75.9, 34.5 and 34.5%, respectively, while those for Group 2 patients were 94.8, 55.2 and 46.6%, respectively (p = 0.02). There were no significant inter-group differences in clinico-laboratory background factors such as the mean operation time, bleeding volume, tumor size, CRP, neutrophil count and lactate dehydrogenase (LDH) level. On the other hand, there were significant inter-group differences for albumin level (p = 0.011), lymphocyte count (p = 0.001) and NLR (p < 0.001). Multivariate analyses were performed for factors such as gender, age, maximum tumor diameter, drainage method, operation time, bleeding volume, pathology, albumin, CRP, neutrophil count, lymphocyte count, LDH and NLR. The results revealed that NLR (odds ratio, 2.032; 95% CI, 0.999-4.134; p = 0.040) was associated with postoperative overall survival. Conclusions: An NLR of = 5 predicts a poor outcome in patients undergoing PD for DBC. NLR is an independent indicator of overall survival for such patients. (C) 2015 S. Karger AG, Basel
C1 [Iso, Yukihiro; Matsumoto, Takatsugu; Sakuraoka, Yuki; Shiraki, Takayuki; Kato, Masato; Shimoda, Mitsugi; Aoki, Taku; Kubota, Keiichi] Dokkyo Med Univ, Dept Surg Gastroenterol, Mibu, Tochigi 3210293, Japan.
RP Iso, Y (reprint author), Dokkyo Med Univ, Dept Surg Gastroenterol, 880 Mibu, Mibu, Tochigi 3210293, Japan.
EM karinaiso@yahoo.co.jp
CR Allavena P, 2008, CURR OPIN GENET DEV, V18, P3, DOI 10.1016/j.gde.2008.01.003
   Bhatti I, 2010, AM J SURG, V200, P197, DOI 10.1016/j.amjsurg.2009.08.041
   Cheng QB, 2007, ANN SURG ONCOL, V14, P1212, DOI 10.1245/s10434-006-9260-0
   DeOliveira ML, 2007, ANN SURG, V245, P755, DOI 10.1097/01.sla.0000251366.62632.d3
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   Ebata T, 2007, WORLD J SURG, V31, P2008, DOI 10.1007/s00268-007-9173-5
   ELHAG A, 1987, J IMMUNOL, V139, P2406
   Fondevila C, 2004, BRIT J CANCER, V90, P206, DOI 10.1038/sj.bjc.6601455
   Fu SJ, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0721-6
   Ganeshan D, 2012, WORLD J RADIOL, V4, P345, DOI 10.4329/wjr.v4.i8.345
   Garcea G, 2011, WORLD J SURG, V35, P868, DOI 10.1007/s00268-011-0984-z
   Gomez D, 2008, WORLD J SURG, V32, P1757, DOI 10.1007/s00268-008-9552-6
   Gomez D, 2008, J SURG ONCOL, V97, P513, DOI 10.1002/jso.21001
   Halazun KJ, 2008, EJSO-EUR J SURG ONC, V34, P55, DOI 10.1016/j.ejso.2007.02.014
   Halazun KJ, 2009, ANN SURG, V250, P141, DOI 10.1097/SLA.0b013e3181a77e59
   Hong SM, 2009, SURGERY, V146, P250, DOI 10.1016/j.surg.2009.02.023
   Idowu OK, 2012, BIOMARKERS, V17, P539, DOI 10.3109/1354750X.2012.699554
   Ishizuka M, 2013, BRIT J CANCER, V109, P401, DOI 10.1038/bjc.2013.350
   Iso Yukihiro, 2014, Med Sci Monit, V20, P471, DOI 10.12659/MSM.889714
   Jung MR, 2011, J SURG ONCOL, V104, P504, DOI 10.1002/jso.21986
   Kameda R, 2013, JPN J CLIN ONCOL, V43, P636, DOI 10.1093/jjco/hyt059
   Kishi Y, 2009, ANN SURG ONCOL, V16, P614, DOI 10.1245/s10434-008-0267-6
   Kubota K, 2000, HEPATO-GASTROENTEROL, V47, P269
   Kwon HC, 2012, BIOMARKERS, V17, P216, DOI 10.3109/1354750X.2012.656705
   Lee JK, 2013, BRIT J CANCER, V109, P915, DOI 10.1038/bjc.2013.432
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mukaiya M, 2007, RINSHOGEKA, V11, P251
   Murakami Y, 2007, J SURG ONCOL, V95, P207, DOI 10.1002/jso.20668
   Park SW, 2004, HEPATO-GASTROENTEROL, V51, P1612
   PETRIE HT, 1985, J IMMUNOL, V134, P230
   Ramirez-Merino N, 2013, WORLD J GASTRO ONCOL, V5, P171, DOI 10.4251/wjgo.v5.i7.171
   Schaider H, 2003, INT J CANCER, V103, P335, DOI 10.1002/ijc.10775
   Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889
   Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014
   Sharaiha RZ, 2011, ANN SURG ONCOL, V18, P3362, DOI 10.1245/s10434-011-1754-8
   Sobin L, 2002, TNM CLASSIFICATION M
   Sohn BS, 2013, TUMORI, V99, P139, DOI 10.1700/1283.14182
   Stotz M, 2013, BRIT J CANCER, V109, P416, DOI 10.1038/bjc.2013.332
   Sugita R, 2013, WORLD J HEPATOL, V5, P654, DOI 10.4254/wjh.v5.i12.654
   Sugiura T, 2013, ANN SURG ONCOL, V20, P4330, DOI 10.1245/s10434-013-3227-8
   Wang DS, 2012, MED ONCOL, V29, P3092, DOI 10.1007/s12032-012-0226-8
   Watanapa P, 1996, BRIT J SURG, V83, P1062, DOI 10.1002/bjs.1800830809
   Xiao GQ, 2013, WORLD J GASTROENTERO, V19, P8398, DOI 10.3748/wjg.v19.i45.8398
   Yang R, 2013, ANTI-CANCER DRUG, V24, P871, DOI 10.1097/CAD.0b013e3283637292
   Yoshida T, 2002, ARCH SURG-CHICAGO, V137, P69, DOI 10.1001/archsurg.137.1.69
NR 45
TC 1
Z9 1
U1 2
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0253-4886
EI 1421-9883
J9 DIGEST SURG
JI Dig. Surg.
PY 2015
VL 32
IS 2
BP 142
EP 149
DI 10.1159/000380958
PG 8
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA CF9GC
UT WOS:000352870800011
PM 25791693
DA 2018-12-27
ER

PT J
AU Yang, HY
   Wang, C
   Guo, MZ
   Zhou, YH
   Feng, ZH
   Yin, ZY
AF Yang, Haiyan
   Wang, Chun
   Guo, Meizi
   Zhou, Yihua
   Feng, Zhenhua
   Yin, Zhenyu
TI RETRACTED: Correlations between peroxisome proliferator activator
   receptor gamma Cystatin C, or advanced oxidation protein product, and
   atherosclerosis in diabetes patients (Retracted article)
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article; Retracted Publication
DE Atherosclerosis; Diabetes; Peroxisome proliferator activator receptor;
   Cystatin C; Advanced oxidation protein product
ID CORONARY-ARTERY-DISEASE; METABOLIC SYNDROME; PPAR-GAMMA; MELLITUS;
   INFLAMMATION; EXPRESSION; DYSFUNCTION; PROGRESSION; MECHANISMS;
   ATTENUATE
AB We aimed to explore the relationship between peroxisome proliferator activator receptor gamma (PPAR gamma), Cystatin C or advanced oxidation protein product (AOPP) and atherosclerosis (AS), and identify their diagnostic values for AS. Eighty AS patients above the age of 75 with type 2 diabetes were screened by brachial-ankle pulse wave velocity (baPWV) and ankle brachial index (ABI). The baseline level of patients was firstly analyzed, and then the expression of PPAR gamma was detected by reverse transcriptase-polymerase chain reaction (RT-PCR). Meanwhile, a double-antibody sandwich enzyme-linked immunosorbent assay was performed to analyze the concentration of AOPP, and immunonephelometry was carried out to detect the concentration of Cystatin C. The baseline level of patients was basically consistent. The expression of PPAR gamma was significantly higher in severe AS than mild AS patients (P<0.05), while no differences were found in serum Cystatin C and AOPP between severe AS and mild AS patients (P>0.05). Thus, PPAR gamma exhibited a high diagnostic value for severe AS (AUC=0.850), but not Cystatin C and AOPP (AUC=0.553, AUC=0.4780). Moreover, the combination of PPAR gamma, Cystatin C and AOPP exhibited a quite high diagnostic value in AS (AUC=0.961, Sen=0.9, Spe=0.975), which was also higher than PPAR gamma alone. In conclusion, the contents of PPAR gamma Cystatin C and AOPP were closely related to AS in diabetes, indicating a potential clinical diagnostic value of PPAR gamma, Cystatin C and AOPP in diabetes with AS. (C) 2014 Elsevier GmbH. All rights reserved.
C1 [Yang, Haiyan; Wang, Chun; Guo, Meizi; Yin, Zhenyu] Nanjing Univ Sch, Affiliated Hosp, Nanjing Drum Tower Hosp, Cadre Hlth Care Ward, Nanjing 210008, Jiangsu, Peoples R China.
   [Zhou, Yihua; Feng, Zhenhua] Nanjing Univ Sch, Affiliated Hosp, Nanjing Drum Tower Hosp, Dept Lab Med, Nanjing 210008, Jiangsu, Peoples R China.
RP Wang, C (reprint author), Nanjing Drum Tower Hosp, Cadre Hlth Care Ward, 321 Zhongshan Rd, Nanjing 210008, Jiangsu, Peoples R China.
EM chunwangdr@163.com
FU Nanjing Medical Science and Technology Development Project [YKK 11102]
FX This study was supported by grant from Nanjing Medical Science and
   Technology Development Project Funding in 2011 (YKK 11102).
CR A.a.O.D. Educators, 2009, DIABETES ED S3, V35, p53S
   Akash M. S., 2012, J PHARM SCI, V101
   Akash MSH, 2013, J CELL BIOCHEM, V114, P525, DOI 10.1002/jcb.24402
   Amoruso A., J PHARM EXP THER, P331
   Baliga Bantwal Suresh, 2006, Curr Cardiol Rep, V8, P23, DOI 10.1007/s11886-006-0006-1
   Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570
   Bengtsson E., 2005, ARTERIOSCLER THROMB, V25
   Bochi GV, 2012, INFLAMMATION, V35, P1786, DOI 10.1007/s10753-012-9498-6
   Chen SX, 2008, EUR J PHARMACOL, V584, P368, DOI 10.1016/j.ejphar.2008.02.020
   Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017
   Dinarello CA, 2011, J INTERN MED, V269, P16, DOI 10.1111/j.1365-2796.2010.02313.x
   Drueke T, 2002, CIRCULATION, V106, P2212, DOI 10.1161/01.CIR.0000035250.66458.67
   Edmonds M, 2006, DRUGS, V66, P913, DOI 10.2165/00003495-200666070-00003
   Fernandez AZ, 2008, PPAR RES, DOI 10.1155/2008/285842
   Gabir MM, 2000, DIABETES CARE, V23, P1108, DOI 10.2337/diacare.23.8.1108
   Guo ZJ, 2008, ANTIOXID REDOX SIGN, V10, P1699, DOI 10.1089/ars.2007.1999
   Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Herder C, 2013, DIABETES OBES METAB, V15, P39, DOI 10.1111/dom.12155
   Herder C., 2006, DIABETOLOGIA, V49
   Hoke M, 2010, STROKE, V41, P674, DOI 10.1161/STROKEAHA.109.573162
   Jay MA, 2007, CURR DIABETES REV, V3, P33, DOI 10.2174/157339907779802067
   Kalousova M, 2002, PHYSIOL RES, V51, P597
   Kurtz TW, 2005, ACTA DIABETOL, V42, pS9, DOI 10.1007/s00592-005-0176-0
   Lee YW, 2010, BIOMOL THER, V18, P135, DOI 10.4062/biomolther.2010.18.2.135
   LEUNGTACK J, 1990, INFLAMMATION, V14, P247, DOI 10.1007/BF00915809
   Lincoff AM, 2013, AM HEART J, V166, P429, DOI 10.1016/j.ahj.2013.05.013
   Maahs DM, 2007, DIABETES, V56, P2774, DOI 10.2337/db07-0539
   Matsuyama M., 2009, Endocrine Metabolic & Immune Disorders-Drug Targets, V9, P76
   Matteucci E, 2000, DIABETES CARE, V23, P1182, DOI 10.2337/diacare.23.8.1182
   Minamikawa J, 1998, J CLIN ENDOCR METAB, V83, P1818, DOI 10.1210/jc.83.5.1818
   Namgaladze D, 2013, CARDIOVASC RES, V98, P479, DOI 10.1093/cvr/cvt073
   Peng KF, 2006, CHINESE MED J-PEKING, V119, P1088
   Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614
   Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709
   Sueyoshi S, 2010, PATHOL RES PRACT, V206, P429, DOI 10.1016/j.prp.2010.01.010
   Tuttolomondo A., 2012, CURR PHARM DES, V18
   Weir GC, 2004, DIABETES, V53, pS16, DOI 10.2337/diabetes.53.suppl_3.S16
   Wong T, 2008, EPIDEMIOLOGY DIABETE, P475
   Yu J, 2007, METABOLISM, V56, P1396, DOI 10.1016/j.metabot.2007.05.011
   Zernecke A, 2008, ARTERIOSCL THROM VAS, V28, P1897, DOI 10.1161/ATVBAHA.107.161174
NR 41
TC 2
Z9 2
U1 5
U2 12
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0344-0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PY 2015
VL 211
IS 3
BP 235
EP 239
DI 10.1016/j.prp.2014.11.006
PG 5
WC Pathology
SC Pathology
GA CD8BQ
UT WOS:000351320600008
PM 25543292
DA 2018-12-27
ER

PT J
AU Eni, SE
   Rowland, M
   Best, MD
AF Eni, Sammy Eni
   Rowland, Meng
   Best, Michael D.
TI RETRACTED: Synthesis of diacylglycerol analogs bearing photoaffinity
   tags for labelling mammalian diacylglycerol kinase (Retracted article.
   See vol. 6, pg. 62768, 2016)
SO RSC ADVANCES
LA English
DT Article; Retracted Publication
ID BIOORTHOGONAL CHEMISTRY; PHOSPHATIDIC-ACID; CLICK CHEMISTRY; ACTIVATION;
   SELECTIVITY; ISOFORMS; AFFINITY; DOMAINS; PROBES
AB Signaling lipids such as diacylglycerol (DAG), phosphatidic acid, and the phosphatidylinositol polyphosphates are site-specific ligands for protein binding partners. Herein, we report the apotheoses of our initial approach to the development of diverse probes which are vital for understanding lipid-protein interactions. When incorporated into liposomes, these probes reduce mammalian diacylglycerol kinase's (DGK) enzymatic activity in a concentration, time, and light dependent manner.
C1 [Eni, Sammy Eni; Rowland, Meng; Best, Michael D.] Univ Tennessee, Dept Chem, Knoxville, TN 37996 USA.
RP Eni, SE (reprint author), Univ Tennessee, Dept Chem, 1420 Circle Dr, Knoxville, TN 37996 USA.
EM senieni@vols.utk.edu
CR Ananthanarayanan B, 2003, J BIOL CHEM, V278, P46886, DOI 10.1074/jbc.M307853200
   Best MD, 2011, ACCOUNTS CHEM RES, V44, P686, DOI 10.1021/ar200060y
   Best MD, 2010, NAT PROD REP, V27, P1403, DOI 10.1039/b923844c
   Best MD, 2009, BIOCHEMISTRY-US, V48, P6571, DOI 10.1021/bi9007726
   Carrasco S, 2007, TRENDS BIOCHEM SCI, V32, P27, DOI 10.1016/j.tibs.2006.11.004
   Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337
   Dorman G, 2000, TRENDS BIOTECHNOL, V18, P64, DOI 10.1016/S0167-7799(99)01402-X
   Gomez-Fernandez JC, 2007, CHEM PHYS LIPIDS, V148, P1, DOI 10.1016/j.chemphyslip.2007.04.003
   Hatanaka Yasumaru, 2002, Current Topics in Medicinal Chemistry, V2, P271, DOI 10.2174/1568026023394182
   KODALI DR, 1990, CHEM PHYS LIPIDS, V52, P163, DOI 10.1016/0009-3084(90)90111-4
   Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.3.CO;2-X
   Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328
   Nemoz G, 1997, MOL PHARMACOL, V51, P242
   Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801
   Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v
   Rowland MM, 2011, BIOCHEMISTRY-US, V50, P11143, DOI 10.1021/bi201636s
   Sletten EM, 2009, ANGEW CHEM INT EDIT, V48, P6974, DOI 10.1002/anie.200900942
   Smith MD, 2008, BIOCONJUGATE CHEM, V19, P1855, DOI 10.1021/bc8001002
   Sprong H, 2001, NAT REV MOL CELL BIO, V2, P698
   Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200
   Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002
   Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335
NR 22
TC 2
Z9 2
U1 1
U2 20
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 32
BP 25457
EP 25461
DI 10.1039/c4ra16730a
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA CD8OE
UT WOS:000351354000078
DA 2018-12-27
ER

PT J
AU Khan, MA
   Khan, MZ
   Zaman, K
   Sajjad, F
AF Khan, Muhammad Azhar
   Khan, Muhammad Zahir
   Zaman, Khalid
   Sajjad, Faiza
TI RETRACTED: Environmental Indicators and Energy Outcomes: Evidence From
   the World Bank's Classification Countries (Retracted article. See vol.
   12, pg. 995, 2015)
SO INTERNATIONAL JOURNAL OF GREEN ENERGY
LA English
DT Article; Retracted Publication
DE Energy consumption; Carbon dioxide emissions; Methane emissions;
   Industrial nitrous oxide emissions; Causality
ID ECONOMIC-GROWTH; COINTEGRATION; CONSUMPTION; EMISSIONS
AB The objective of the study is to examine the causal relationship between energy consumption and environmental indicators, i.e., carbon dioxide emissions; industrial nitrous oxide emissions; methane emissions; arable land; net forest depletion; water pollution from chemical industry; water pollution from food industry; and water pollution from textile industry, using a consistent data set and methodology for over 100 countries listed as the World Bank's classification countries. The results reveal that around 87.2 to 99.2% data are stationary at their first differences, while 5.6 to 32.8% data show the long-run relationship between variables in different countries of the world. Results of the Granger-causality show that there is uni-directional causality runs toward energy consumption to carbon dioxide emissions in 98 countries out of 125 countries (78.4% of the total); energy consumption to industrial nitrous oxide emissions in 100 countries (80.0%); energy consumption to methane emissions in 106 countries (84.8%); energy consumption to arable land in 64 countries (51.2%); energy consumption to forest depletion in 109 countries (87.2%); energy consumption to water pollution from chemical industry, food industry, and textile industry in 96 countries (76.8%), 102 countries (81.6%), and 92 countries (73.6%) respectively. The existence of causal relationships has implications for implementing effective policies to control alarming increase in the emission of contaminating gases, and contribute toward conservation of global environment.
C1 [Khan, Muhammad Azhar] Haripur Univ, Abbottabad, Pakistan.
   [Khan, Muhammad Zahir] Islamia Univ, Abbottabad, Pakistan.
   [Zaman, Khalid; Sajjad, Faiza] COMSATS Inst Informat Technol, Abbottabad, Pakistan.
RP Zaman, K (reprint author), COMSATS Inst Informat Technol, Abbottabad, Pakistan.
EM khalidzaman@ciit.net.pk
CR Acaravci A, 2010, ENERGY, V35, P5412, DOI 10.1016/j.energy.2010.07.009
   Agyei Y., 1998, AFRICAN TECHNOLOGY F, V8, P11
   AKAIKE H, 1970, ANN I STAT MATH, V22, P203, DOI 10.1007/BF02506337
   Anees M., 2011, EC B, V31, P1
   Ang JB, 2008, J POLICY MODEL, V30, P271, DOI 10.1016/j.jpolmod.2007.04.010
   Apergis N, 2009, ENERG POLICY, V37, P3282, DOI 10.1016/j.enpol.2009.03.048
   Chontanawat J, 2008, J POLICY MODEL, V30, P209, DOI 10.1016/j.jpolmod.2006.10.003
   ENGLE RF, 1987, ECONOMETRICA, V55, P251, DOI 10.2307/1913236
   GRANGER CWJ, 1981, J ECONOMETRICS, V16, P121, DOI 10.1016/0304-4076(81)90079-8
   Halder P, 2013, INT J GREEN ENERGY, V10, P797, DOI 10.1080/15435075.2012.706244
   Halicioglu F, 2009, ENERG POLICY, V37, P1156, DOI 10.1016/j.enpol.2008.11.012
   HSIAO C, 1981, J MONETARY ECON, V7, P85, DOI 10.1016/0304-3932(81)90053-2
   International Energy Agency (IEA), 2012, WORLD EN OUTL 2012
   JOHANSEN S, 1991, ECONOMETRICA, V59, P1551, DOI 10.2307/2938278
   Kang CQ, 2012, SCI REP-UK, V2, DOI 10.1038/srep00479
   Koroneos C, 2013, INT J GREEN ENERGY, V10, P860, DOI 10.1080/15435075.2012.727929
   Li JS, 2013, RENEW SUST ENERG REV, V22, P23, DOI 10.1016/j.rser.2012.11.072
   Lin HP, 2013, INT J GREEN ENERGY, V10, P754, DOI 10.1080/15435075.2012.727115
   OECD/IEA, 2007, TRACK IND EN EFF CO2
   PHILLIPS PCB, 1990, ECONOMETRICA, V58, P165, DOI 10.2307/2938339
   Prindle W., 2009, ENERGY EFFICIENCY LO
   Salahuddin M., 2013, J DEV AREAS, V47, P81
   Soytas U, 2009, ECOL ECON, V68, P1667, DOI 10.1016/j.ecolecon.2007.06.014
   The World Bank, 2012, WORLD DEV IND
   World Policy Institute, 2011, WAT EN NEX ADD WAT E
NR 25
TC 1
Z9 1
U1 3
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1543-5075
EI 1543-5083
J9 INT J GREEN ENERGY
JI Int. J. Green Energy
PY 2015
VL 12
IS 7
BP 714
EP 727
DI 10.1080/15435075.2014.884500
PG 14
WC Thermodynamics; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Thermodynamics; Science & Technology - Other Topics; Energy & Fuels
GA CD3RM
UT WOS:000350997900006
DA 2018-12-27
ER

PT J
AU Taucare-Rios, A
   Bustamante, RO
AF Taucare-Rios, Andres
   Bustamante, Ramiro O.
TI RETRACTED: Alien spiders in Chile: evaluating Darwin's naturalization
   hypothesis (Retracted article. See vol. 43, pg. 228, 2015)
SO JOURNAL OF ARACHNOLOGY
LA English
DT Article; Retracted Publication
DE Aerial dispersal; biological invasion; geographic range; residence time;
   phylogenetic relatedness
ID PLANT INVASIONS; ARANEAE SALTICIDAE; RESIDENCE TIME; BIOLOGY;
   DISPLACEMENT; THERIDIIDAE; POPULATION; ARACHNIDA; DIVERSITY; ECOLOGY
AB Darwin's naturalization hypothesis (DNH) states that the successful establishment of alien species is favored when the phylogenetic relationship between the colonizer and the recipient community is distant. From a population perspective, the establishment involves both the progressive increase in size and spatial distribution of the invasive population. In this study, we focused our attention on the spatial component of establishment, assessing the role of phylogenetic relatedness as a determinant of its extension. Following DNH, it is expected that alien species closely related to the native spiders would show narrower distribution ranges than alien taxa less related to the native species. We found 18 alien spider species in Chile; all of these are synanthropic and most are of African origin. Our results indicate a difference in range size between related and unrelated species but it was not statistically significant. Consequently, the results do not support DNH as an explanation of the distributional component of establishment of alien spider species in Chile. We conclude that ecological constraints do not affect the process of invasion of spiders; therefore, it is only time that determines the spread of alien spiders in this country.
C1 [Taucare-Rios, Andres; Bustamante, Ramiro O.] Univ Chile, Fac Ciencias, Inst Ecol & Biodiversidad, Dept Ciencias Ecol, Santiago, Chile.
RP Taucare-Rios, A (reprint author), Univ Chile, Fac Ciencias, Inst Ecol & Biodiversidad, Dept Ciencias Ecol, Las Palmeras 3425, Santiago, Chile.
EM and.taucare26@gmail.com
FU CONICYT [21130014];  [ICM -PO5 - 002]
FX Thanks to Leonardo Bacigalupe, Rick Vetter and Wolfgang Nentwig for
   critical comments on the manuscript. Thanks also to anonymous reviewers
   for their thorough evaluation and constructive recommendations for
   improving this manuscript. Finally, the first author thanks CONICYT
   grant No. 21130014 for National Doctoral studies. This project was
   partially funded by project ICM -PO5 - 002 to ROB.
CR Adler PB, 2007, ECOL LETT, V10, P95, DOI 10.1111/j.1461-0248.2006.00996.x
   Bell JR, 2005, B ENTOMOL RES, V95, P69, DOI 10.1079/BER2004350
   Brandt AJ, 2009, ECOLOGY, V90, P1063, DOI 10.1890/08-0054.1
   Brescovit Antonio D., 2000, Bulletin of the British Arachnological Society, V11, P320
   Cahill JF, 2008, PERSPECT PLANT ECOL, V10, P41, DOI 10.1016/j.ppees.2007.10.001
   Castro SA, 2005, DIVERS DISTRIB, V11, P183, DOI 10.1111/j.1366-9516.2005.00145.x
   Cavender-Bares J, 2009, ECOL LETT, V12, P693, DOI 10.1111/j.1461-0248.2009.01314.x
   Cekalovic K.T., 1976, Gayana (Zool), VNo. 37, P1
   Chesson P, 2000, ANNU REV ECOL SYST, V31, P343, DOI 10.1146/annurev.ecolsys.31.1.343
   Daehler CC, 2001, AM NAT, V158, P324, DOI 10.1086/321316
   Darwin C., 1859, ORIGIN SPECIES
   Davis M. A., 2009, INVASION BIOL
   Duncan RP, 2002, NATURE, V417, P608, DOI 10.1038/417608a
   Gruner DS, 2005, BIOL INVASIONS, V7, P541, DOI 10.1007/s10530-004-2509-2
   Hamilton MA, 2005, ECOL LETT, V8, P1066, DOI 10.1111/j.1461-0248.2005.00809.x
   HANN SW, 1990, NEW ZEAL J ZOOL, V17, P295, DOI 10.1080/03014223.1990.10422937
   Hubbel S. P., 2001, UNIFIED NEUTRAL THEO
   Instituto Geografico Militar, 2010, ATL GEOGRA ED IGM CH
   Kobelt M, 2008, DIVERS DISTRIB, V14, P273, DOI 10.1111/j.1472-4642.2007.00426.x
   Kolar CS, 2001, TRENDS ECOL EVOL, V16, P199, DOI 10.1016/S0169-5347(01)02101-2
   Lambdon PW, 2006, J BIOGEOGR, V33, P1116, DOI 10.1111/j.1365-2699.2006.01486.x
   LEVI H W, 1968, Bulletin of the Museum of Comparative Zoology, V136, P319
   LEVI H W, 1967, Bulletin of the Museum of Comparative Zoology, V136, P1
   LEVI H W, 1974, Bulletin of the Museum of Comparative Zoology, V146, P267
   Lockwood JL, 2007, INVASION ECOLOGY
   Mayfield MM, 2010, ECOL LETT, V13, P1085, DOI 10.1111/j.1461-0248.2010.01509.x
   McKinney ML, 2006, BIOL INVASIONS, V8, P415, DOI 10.1007/s10530-005-6418-9
   Mello-Leitao C.F., 1951, REV CHIL HIST NAT, V53, P327
   Mitchell CE, 2006, ECOL LETT, V9, P726, DOI 10.1111/j.1461-0248.2006.00908.x
   Nentwig Wolfgang, 2010, BioRisk, V4, P131
   Nicolet A. C., 1849, ZOOLOGIA, P319
   Niemela J, 1997, ECOGRAPHY, V20, P643, DOI 10.1111/j.1600-0587.1997.tb00433.x
   NYFFELER M, 1986, CAN J ZOOL, V64, P867, DOI 10.1139/z86-130
   Platnick N., 1984, AM MUS NOVIT, V2792, P1
   Platnick Norman I., 2006, Bulletin of the American Museum of Natural History, V298, P1, DOI 10.1206/0003-0090(2006)298[1:AROTAG]2.0.CO;2
   Proches S, 2008, GLOBAL ECOL BIOGEOGR, V17, P5, DOI 10.1111/j.1466-8238.2007.00333.x
   Rabitsch W, 2011, BIOCONTROL, V56, P551, DOI 10.1007/s10526-011-9370-x
   Ramirez Martin J., 2004, Revista Iberica de Aracnologia, V9, P179
   Rejmanek M, 1996, ECOLOGY, V77, P1655, DOI 10.2307/2265768
   Rejmanek M, 2000, AUSTRAL ECOL, V25, P497, DOI 10.1046/j.1442-9993.2000.01080.x
   Ricciardi A, 2006, BIOL INVASIONS, V8, P1403, DOI 10.1007/s10530-006-0005-6
   Richardson David M., 2000, Diversity and Distributions, V6, P93, DOI 10.1046/j.1472-4642.2000.00083.x
   Roth V. D., 1968, American Museum Novitates, VNo. 2323, P1
   Sakai AK, 2001, ANNU REV ECOL SYST, V32, P305, DOI 10.1146/annurev.ecolsys.32.081501.114037
   Santos AJ, 2003, J NAT HIST, V37, P239, DOI 10.1080/00222930110104249
   Sax DF, 2007, TRENDS ECOL EVOL, V22, P465, DOI 10.1016/j.tree.2007.06.009
   Shigesada N, 2001, BIOL INVASIONS THEOR
   Shine C., 2009, EUR COMM I EUR ENV P
   Simon E., 1904, ANN SOC ENTOMOLOGIQU, V48, P83
   Snyder WE, 2004, OECOLOGIA, V140, P559, DOI 10.1007/s00442-004-1612-5
   Snyder WE, 2006, ANNU REV ECOL EVOL S, V37, P95, DOI 10.1146/annurev.ecolsys.37.091305.110107
   *STATSOFT INC, 1999, STATISTICA WIND COMP
   Strauss SY, 2006, P NATL ACAD SCI USA, V103, P5841, DOI 10.1073/pnas.0508073103
   TAUCARE-RIOS A., 2012, REVISTA CHILENA DE E, V37, P81
   Taucare-Rios Andres, 2013, Revista Iberica de Aracnologia, V23, P49
   Taucare-Ríos Andrés, 2013, Idesia, V31, P103, DOI 10.4067/S0718-34292013000200015
   Taucare-Rios A, 2013, REV CHIL HIST NAT, V86, P103, DOI 10.4067/S0716-078X2013000100009
   Taucare-Rios Andres, 2012, Peckhamia, V102.1, P1
   Taucare-Rios Andres, 2011, Boletin de Biodiversidad de Chile, V5, P39
   Taucare-Rios Andres O., 2011, Revista Chilena de Entomologia, V36, P39
   Taucare-Rios Andres O., 2010, Boletin de Biodiversidad de Chile, V4, P87
   Thebaud C, 2001, AM NAT, V157, P231, DOI 10.1086/318635
   Walter A, 2005, J ARACHNOL, V33, P516, DOI 10.1636/04-78.1
   Williamson M., 1996, BIOL INVASIONS
   Wilson JRU, 2007, DIVERS DISTRIB, V13, P11, DOI 10.1111/j.1472-4642.2006.00302.x
   World Spider Catalog, 2014, WORLD SPID CAT VERS
NR 66
TC 1
Z9 1
U1 4
U2 85
PU AMER ARACHNOLOGICAL SOC
PI COLLEGE PARK
PA UNIV MARYLAND, DEPT ENTOMOLOGY, 4112 PLANT SCIENCES BLDG, COLLEGE PARK,
   MD 20742-4454 USA
SN 0161-8202
EI 1937-2396
J9 J ARACHNOL
JI J. Arachnol.
PY 2015
VL 43
IS 1
BP 90
EP 96
DI 10.1636/P14-52.1
PG 7
WC Entomology
SC Entomology
GA CC7LB
UT WOS:000350547900011
DA 2018-12-27
ER

PT J
AU Wang, YX
   Yu, ZM
   Ren, HM
   Wang, J
   Wu, JJ
   Chen, Y
   Ding, ZT
AF Wang, Yixuan
   Yu, Zheming
   Ren, Huimin
   Wang, Jian
   Wu, Jianjun
   Chen, Yan
   Ding, Zhengtong
TI RETRACTED: The synergistic effect between beta-amyloid(1-42) and
   alpha-synuclein on the synapses dysfunction in hippocampal neurons
   (Retracted article. See vol. 63, pg. 1, 2015)
SO JOURNAL OF CHEMICAL NEUROANATOMY
LA English
DT Article; Retracted Publication
DE alpha-Synuclein; beta-Amyloid(1-42); Synapse; Hippocampal neuron
ID A-BETA; CSP-ALPHA; PARKINSONS-DISEASE; RAT-BRAIN; PROTEIN; DEMENTIA;
   PATHOLOGY; MICE; NEURODEGENERATION; EXPRESSION
AB Objective: This study was to explore the molecular mechanisms underpinning the synergetic effect between beta-amyloid (A beta) and alpha-synuclein (alpha-syn) on synapses dysfunction during the development of neurodegenerative disorders including Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Alzheimer disease (AD).
   Methods: The primary cultured hippocampal neurons prepared from the fetal tissue of mice were divided into six groups and treated with DMSO, A beta(42-1), alpha-syn, A beta(1-42), alpha-syn plus A beta(42-1) and a-syn plus A beta(1-42), respectively. After incubation for 24 h, the synapsin I content was calculated by immunofluorescence and the synaptic vesicle recycling was monitored by FM1-43 staining. Furthermore, the expression of cysteine string protein-alpha (CSP alpha) detected by western blot was also conducted.
   Results: Either A beta(1-42) or alpha-syn alone could induce a significant synapses dysfunction through reducing the content of synapsin I, inhibiting the synaptic vesicle recycling as well as down-regulating the expression of CSP alpha compared with the controls (P < 0.05). However, simultaneous intervention with both alpha-syn and A beta(1-42) aggravated these effects in cultured hippocampal neurons compared with the treatment with alpha-syn (synapsin I content: P < 0.001; synaptic vesicle recycling: P = 0.007; CSP alpha expression: P < 0.001) or A beta(1-42) (synapsin I number: P < 0.001; synaptic vesicle recycling: P = 0.007 CSP alpha expression: P < 0.001) alone.
   Conclusion: There was synergistic effect between A beta and alpha-syn on synapses dysfunction through reducing the synapsin I content, inhibiting the synaptic vesicle recycling and down-regulating the expression of CSP alpha in several neurodegenerative diseases. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Wang, Yixuan; Yu, Zheming; Ren, Huimin; Wang, Jian; Wu, Jianjun; Chen, Yan; Ding, Zhengtong] Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai 200040, Peoples R China.
   [Wang, Yixuan; Yu, Zheming; Ren, Huimin; Wang, Jian; Wu, Jianjun; Chen, Yan; Ding, Zhengtong] Fudan Univ, Shanghai Med Coll, Dept & Inst Neurol, Shanghai 200040, Peoples R China.
RP Ding, ZT (reprint author), Fudan Univ, Huashan Hosp, Dept Neurol, 12 Wulumuqi M Rd, Shanghai 200040, Peoples R China.
EM dingzhengtong123@163.com
FU National Natural Science Foundation of China [30872723]
FX This study was supported by the grants (30872723) from the National
   Natural Science Foundation of China.
CR Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7
   Bate C, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-55
   Bonini NM, 2005, CELL, V123, P359, DOI 10.1016/j.cell.2005.10.017
   Cabin DE, 2002, J NEUROSCI, V22, P8797
   Calkins MJ, 2011, BBA-MOL BASIS DIS, V1812, P507, DOI 10.1016/j.bbadis.2011.01.007
   Chung CY, 2009, J NEUROSCI, V29, P3365, DOI 10.1523/JNEUROSCI.5427-08.2009
   Clinton LK, 2010, J NEUROSCI, V30, P7281, DOI 10.1523/JNEUROSCI.0490-10.2010
   Counts SE, 2006, J NEUROPATH EXP NEUR, V65, P592, DOI 10.1097/00005072-200606000-00007
   Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106
   Fernandez-Chacon R, 2004, NEURON, V42, P237, DOI 10.1016/S0896-6273(04)00190-4
   Ferreira A, 1998, MOL MED, V4, P22, DOI 10.1007/BF03401726
   Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450
   HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374
   Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37
   Johnson JN, 2010, BIOCHEM CELL BIOL, V88, P157, DOI [10.1139/O09-124, 10.1139/o09-124]
   Kitada T, 2007, P NATL ACAD SCI USA, V104, P11441, DOI 10.1073/pnas.0702717104
   Kramer ML, 2007, J NEUROSCI, V27, P1405, DOI 10.1523/JNEUROSCI.4564-06.2007
   Kraybill ML, 2005, NEUROLOGY, V64, P2069, DOI 10.1212/01.WNL.0000165987.89198.65
   Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007
   Rozas JL, 2012, NEURON, V74, P151, DOI 10.1016/j.neuron.2012.02.019
   Mandal PK, 2006, NEUROCHEM RES, V31, P1153, DOI 10.1007/s11064-006-9140-9
   Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023
   Olivares D, 2009, INT J MOL SCI, V10, P1226, DOI 10.3390/ijms10031226
   Parodi J, 2010, J BIOL CHEM, V285, P2506, DOI 10.1074/jbc.M109.030023
   Piccoli G, 2011, J NEUROSCI, V31, P2225, DOI 10.1523/JNEUROSCI.3730-10.2011
   Resende R, 2013, NEUROCHEM RES, V38, P797, DOI 10.1007/s11064-013-0982-7
   Sharma M, 2012, EMBO J, V31, P829, DOI 10.1038/emboj.2011.467
   Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X
   Yu S, 2007, NEUROSCIENCE, V145, P539, DOI 10.1016/j.neuroscience.2006.12.028
   Zou K, 2003, J NEUROCHEM, V87, P609, DOI 10.1046/j.1471-4159.2003.02018.x
NR 30
TC 11
Z9 12
U1 2
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0891-0618
EI 1873-6300
J9 J CHEM NEUROANAT
JI J. Chem. Neuroanat.
PD JAN
PY 2015
VL 63
BP 1
EP 5
DI 10.1016/j.jchemneu.2014.11.001
PG 5
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA CD2WF
UT WOS:000350939000001
PM 25445382
DA 2018-12-27
ER

PT J
AU Yu, P
   Liu, YP
   Zhang, JD
   Qu, XJ
   Jin, B
   Zhang, Y
AF Yu, Ping
   Liu, Yun-Peng
   Zhang, Jing-Dong
   Qu, Xiu-Juan
   Jin, Bo
   Zhang, Ye
TI RETRACTED: Correlation between PARP-1 Val762Ala polymorphism and the
   risk of lung cancer in a Chinese population (Retracted article. See vol.
   36, pg. 7319, 2015)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Lung cancer; PARP-1; Single nucleotide polymorphisms; Adenocarcinoma
ID POLY(ADP-RIBOSE) POLYMERASE-1; BREAST-CANCER; CELL-DEATH; EPIDEMIOLOGY;
   ASSOCIATION; VARIANTS; GENE
AB The aim of this study was to investigate the relationship of the PARP-1 Val762Ala (rs1136410 T>C) polymorphism and the risk of lung cancer. A population-based case-control study of 373 lung cancer patients and 360 healthy control subjects (individually matched on age and gender) in a Chinese population was conducted. Genomic DNA was extracted by the phenol-chloroform method from the peripheral blood. PARP-1 Val762Ala polymorphism was identified using polymerase chain reaction-restriction fragments length polymorphism technique. After adjusting for age, tobacco smoking, gender, smoking index, and drinking status, logistic regression analysis demonstrated that CC genotype in PARP-1 Val762Ala polymorphism had an increased risk of lung cancer compared with TT genotype (OR=1.59, 95% CI=1.03 similar to 2.50, P=0.048), a statistically difference that still existed when merging CC and TC genotypes (OR=1.56, 95 % CI=1.03 similar to 2.44, P=0.042). However, no obvious difference was found between TT and TC (OR=1.54, 95 % CI=0.96 similar to 2.44, P=0.073). Subgroup analysis by histological type indicated that adenocarcinoma patients had higher frequencies of CC or TC+CC genotypes than healthy controls (CC: OR=1.85, 95 % CI=1.12 similar to 3.03, P=0.015; TC+CC: OR=1.67, 95 % CI=1.06 similar to 2.63, P=0.027, respectively), but no statistically significant difference within each genotype in squamous cell carcinoma or small cell lung cancer (all P>0.05). Our findings support the view that PARP-1 Val762Ala polymorphism may contribute to an increased risk of lung cancer in the Chinese population, especially for adenocarcinoma.
C1 [Yu, Ping; Liu, Yun-Peng; Zhang, Jing-Dong; Qu, Xiu-Juan; Jin, Bo; Zhang, Ye] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang 110001, Peoples R China.
RP Liu, YP (reprint author), China Med Univ, Dept Med Oncol, Hosp 1, Nanjing South St 155, Shenyang 110001, Peoples R China.
EM liuyunpeng717@126.com
CR Alberg AJ, 2005, J CLIN ONCOL, V23, P3175, DOI 10.1200/JCO.2005.10.462
   Albert JM, 2007, CLIN CANCER RES, V13, P3033, DOI 10.1158/1078-0432.CCR-06-2872
   Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085
   Bey EA, 2007, P NATL ACAD SCI USA, V104, P11832, DOI 10.1073/pnas.0702176104
   Boffetta P, 2003, BRIT MED BULL, V68, P71, DOI 10.1093/bmb/ldg023
   Brevik A, 2010, CANCER EPIDEM BIOMAR, V19, P3167, DOI 10.1158/1055-9965.EPI-10-0606
   Broderick P, 2009, CANCER RES, V69, P6633, DOI 10.1158/0008-5472.CAN-09-0680
   Buch SC, 2012, MOL CARCINOGEN, V51, pE11, DOI 10.1002/mc.20858
   Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112
   Cao WH, 2007, MUTAT RES-GEN TOX EN, V632, P20, DOI 10.1016/j.mrgentox.2007.04.011
   Choi JE, 2003, CANCER EPIDEM BIOMAR, V12, P947
   Corner J, 2005, THORAX, V60, P314, DOI 10.1136/thx.2004.029264
   Demirci E, 2013, ASIAN PAC J CANCER P, V14, P1989, DOI 10.7314/APJCP.2013.14.3.1989
   Hua RX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087057
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Kim IB, 2007, BIOCONJUGATE CHEM, V18, P815, DOI 10.1021/bc0603440
   Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805
   Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250
   Lam WK, 2004, INT J TUBERC LUNG D, V8, P1045
   Lockett KL, 2004, CANCER RES, V64, P6344, DOI 10.1158/0008-5472.CAN-04-0338
   Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584
   Nguewa PA, 2005, PROG BIOPHYS MOL BIO, V88, P143, DOI 10.1016/j.pbiomolbio.2004.01.001
   Pabalan N, 2012, MOL BIOL REP, V39, P11061, DOI 10.1007/s11033-012-2009-x
   Samet JM, 2009, CLIN CANCER RES, V15, P5626, DOI 10.1158/1078-0432.CCR-09-0376
   Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963
   Shiokawa M, 2005, JPN J CLIN ONCOL, V35, P97, DOI 10.1093/jjco/hyi028
   Swindall Amanda F, 2013, Cancers (Basel), V5, P943, DOI 10.3390/cancers5030943
   Tang LY, 2013, GENE, V524, P84, DOI 10.1016/j.gene.2013.04.064
   Tentori L, 2005, PHARMACOL RES, V52, P25, DOI 10.1016/j.phrs.2005.02.010
   Wang XG, 2007, BIOCHEM BIOPH RES CO, V354, P122, DOI 10.1016/j.bbrc.2006.12.162
   Yu HP, 2012, GENET EPIDEMIOL, V36, P56, DOI 10.1002/gepi.20663
NR 31
TC 1
Z9 1
U1 2
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2015
VL 36
IS 1
BP 177
EP 181
DI 10.1007/s13277-014-2373-3
PG 5
WC Oncology
SC Oncology
GA CC6LU
UT WOS:000350477300017
PM 25179837
DA 2018-12-27
ER

PT J
AU Zhang, GF
   Zhao, QC
   Yu, SL
   Lin, R
   Yi, XH
AF Zhang, Guofeng
   Zhao, Qicheng
   Yu, Songlin
   Lin, Rui
   Yi, Xianghua
TI RETRACTED: Pttg1 inhibits TGF beta signaling in breast cancer cells to
   promote their growth (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Pituitary Tumor Transforming Gene 1; SMAD3; Breast cancer; Transforming
   growth factor beta
ID TUMOR TRANSFORMING GENE; OVARIAN-CANCER; PROLIFERATION; THERAPY;
   CARCINOMA; PATHWAY; OVEREXPRESSION; IDENTIFICATION; METASTASIS; HPTTG
AB Increased expression of Pituitary Tumor Transforming Gene 1 (Pttg1) has been shown in various tumor cells, including breast cancer (BC). However, the precise role of Pttg1 in the tumorigenesis is not clarified yet. Here, we examined BC from the patients and detected significant increases and correlation in Pttg1 and phosphorylated SMAD3 (pSMAD3), a key effector of activated transforming growth factor beta (TGF beta) receptor signaling pathway. Pttg1 levels were then modulated by transgene or small hairpin RNA (shRNA) in a human BC cell line, BT474, respectively. We found that Pttg1 overexpression increased the proliferation of BC cells in vitro and in vivo, while Pttg1 inhibition decreased proliferation of BC cells in vitro and in vivo. Moreover, phosphorylation of SMAD3 by TGF beta 1 was significantly inhibited by Pttg1 overexpression, suggesting that Pttg1 may promote growth of BC cells by inhibiting pSMAD3-mediated cell-growth inhibition. Thus, Pttg1 appears to be a novel therapeutic target for controlling the tumorigenesis of BC.
C1 [Zhang, Guofeng; Yu, Songlin; Lin, Rui] Tongji Univ, Sch Med, Dept Gen Surg, Tongji Hosp, Shanghai 200065, Peoples R China.
   [Zhao, Qicheng] Tongji Univ, Tongji Hosp, Dept Oncol, Sch Med, Shanghai 200065, Peoples R China.
   [Yi, Xianghua] Tongji Univ, Tongji Hosp, Dept Pathol, Sch Med, Shanghai 200065, Peoples R China.
RP Zhang, GF (reprint author), Tongji Univ, Sch Med, Dept Gen Surg, Tongji Hosp, 389 Xincun Rd, Shanghai 200065, Peoples R China.
EM zhangtjsh@126.com; xianghua_yi14@163.com
CR Ai JK, 2004, SCI CHINA SER C, V47, P148, DOI 10.1360/03yc0043
   Band AM, 2011, J MAMMARY GLAND BIOL, V16, P109, DOI 10.1007/s10911-011-9203-7
   Buck MB, 2006, ANN NY ACAD SCI, V1089, P119, DOI 10.1196/annals.1386.024
   Chen CC, 2006, ONCOLOGY-BASEL, V70, P438, DOI 10.1159/000098557
   Chen GH, 2004, SEP PURIF TECHNOL, V34, P3, DOI 10.1016/S1383-5866(03)00168-0
   Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140
   Drabsch Y, 2011, J MAMMARY GLAND BIOL, V16, P97, DOI 10.1007/s10911-011-9217-1
   El-Naggar SM, 2007, INT J ONCOL, V31, P137
   EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4
   Ghayad SE, 2009, J MOL ENDOCRINOL, V42, P87, DOI 10.1677/JME-08-0076
   Huang SQ, 2012, BRAZ J MED BIOL RES, V45, P995, DOI [10.1590/S0100-879X2012001100001, 10.1590/S0100-879X2012007500126]
   Huang SQ, 2014, TUMOR BIOL, V35, P6265, DOI 10.1007/s13277-014-1818-z
   Imamura T, 2012, BREAST CANCER-TOKYO, V19, P118, DOI 10.1007/s12282-011-0321-2
   Kim DS, 2007, CARCINOGENESIS, V28, P749, DOI 10.1093/carcin/bgl202
   LASFARGUES EY, 1978, J NATL CANCER I, V61, P967
   LIPPMAN ME, 1993, SCIENCE, V259, P631, DOI 10.1126/science.8430312
   Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734
   Panguluri SK, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-6
   Prosperi JR, 2010, CURR DRUG TARGETS, V11, P1074
   Rajamannan NM, 2007, J CELL BIOCHEM, V100, P315, DOI 10.1002/jcb.21049
   Reedijk M, 2012, ADV EXP MED BIOL, V727, P241, DOI 10.1007/978-1-4614-0899-4_18
   Sachdev D, 2010, CURR DRUG TARGETS, V11, P1121, DOI 10.2174/138945010792006816
   Shibata Y, 2002, JPN J CLIN ONCOL, V32, P233, DOI 10.1093/jjco/hyf058
   Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Xiao XW, 2013, DIABETES, V62, P1217, DOI 10.2337/db12-1428
   Yan S, 2009, CANCER RES, V69, P3283, DOI 10.1158/0008-5472.CAN-08-0367
   Yi JJ, 2010, CELL, V142, P144, DOI 10.1016/j.cell.2010.06.010
   Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137
   Zhang J, 2013, ACTA HISTOCHEM
   Zhang ML, 2008, HEPATOB PANCREAT DIS, V7, P313
   Zhou C, 2014, ONCOGENE, V33, P851, DOI 10.1038/onc.2013.16
   Zhou CQ, 2005, INT J CANCER, V113, P891, DOI 10.1002/ijc.20642
NR 34
TC 8
Z9 9
U1 3
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2015
VL 36
IS 1
BP 199
EP 203
DI 10.1007/s13277-014-2609-2
PG 5
WC Oncology
SC Oncology
GA CC6LU
UT WOS:000350477300020
PM 25227666
DA 2018-12-27
ER

PT J
AU Han, GP
   Xie, S
   Fang, HM
   Li, G
   Han, YQ
   Qin, Z
AF Han, Guoping
   Xie, Song
   Fang, Hongming
   Li, Gang
   Han, Yinquan
   Qin, Zhen
TI RETRACTED: The AIB1 gene polyglutamine repeat length polymorphism
   contributes to risk of epithelial ovarian cancer risk: a case-control
   study (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE AIB1; Poly-Q; Ovarian cancer; Repeat; Polymorphism
ID RECEPTOR GENE; BREAST; STATISTICS
AB Genes coding for proteins involved in steroid hormone signaling have been identified as ovarian cancer risk-modifier candidates. AIB1 gene (amplified in breast cancer-1), an androgen receptor (AR) coactivator, expresses a polyglutamine (poly-Q) sequence within the carboxyl-terminal coding region. We hypothesized that genotypic variations in the androgen-signaling pathway promote aggressive epithelial ovarian cancer biology and sought to examine the effect of AIB1 poly-Q repeat length on ovarian cancer risk with a case-control study. The genotype analysis of the AIB1 poly-Q repeat was conducted in 3,000 epithelial ovarian cancer (EOC) cases and 3,000 healthy controls. When analyzed as a categorical variable with cutoff of <28 or <29, both of results showed significant asociations. Compared to those with the shorter (<29) AIB1 poly-Q repeat length, women in the category of longer (>= 29) poly-Q repeats had a significantly 20 % increased EOC risk (odds ratio (OR)=1.20; 95 % confidence interval (CI), 1.08-1.33; P=5.88x10(-4)). When analyzed as a continuous covariate, women with longer average poly-Q repeat length had a significantly increased risk of developing EOC (OR=1.05 for per poly-Q repeat; 95 % CI, 1.00-1.08; P=0.013). The association was more stronger for per longer allele (OR=1.07; 95 % CI, 1.01-1.12; P=0.010). These results strongly suggest that there is a significant effect of AIB1 genetic variation on ovarian cancer risk, and AIB1 underlies the development of ovarian cancer.
C1 [Han, Guoping; Xie, Song; Fang, Hongming; Li, Gang] Xiaoshan Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Han, Yinquan] Special Rehabil Ctr Xiaoshan Dist, Hangzhou, Zhejiang, Peoples R China.
   [Qin, Zhen] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.
RP Qin, Z (reprint author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, Qingchun Rd 79, Hangzhou 310003, Zhejiang, Peoples R China.
EM qinzhenzhejiang@126.com
CR Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Han XY, 2008, J SICHUAN U MED SCI, V39, P619
   Janavicius R, 2014, CANCER GENET-NY, V207, P195, DOI 10.1016/j.cancergen.2014.05.002
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.1002/caac.20073, 10.3322/caac.20073]
   Kleibl Z, 2011, J CANCER RES CLIN, V137, P331, DOI 10.1007/s00432-010-0889-5
   Li AJ, 2005, CANCER EPIDEM BIOMAR, V14, P2919, DOI 10.1158/1055-9965.EPI-05-0540
   Lux MP, 2006, J MOL MED, V84, P16, DOI 10.1007/s00109-005-0696-7
   Otani Y, 2014, CANC SCI
   Paul BT, 2014, ONCOGENE
   Permuth-Wey Jennifer, 2009, V472, P413, DOI 10.1007/978-1-60327-492-0_20
   Plaxe SC, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2008.01.035
   Rebbeck TR, 2001, CANCER RES, V61, P5420
   Sankaranarayanan R, 2006, BEST PRACT RES CL OB, V20, P207, DOI 10.1016/j.bpobgyn.2005.10.007
   Schildkraut JM, 2007, CANCER EPIDEM BIOMAR, V16, P473, DOI 10.1158/1055-9965.EPI-06-0868
   Shirazi SK, 1998, CLIN GENET, V54, P102
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Tanner MM, 2000, CLIN CANCER RES, V6, P1833
   Terry KL, 2005, CANCER RES, V65, P5974, DOI 10.1158/0008-5472.CAN-04-3885
   Terry KL, 2005, AM J EPIDEMIOL, V161, P442, DOI 10.1093/aje/kwi064
   Ying HC, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-9
NR 21
TC 3
Z9 3
U1 3
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JAN
PY 2015
VL 36
IS 1
BP 371
EP 374
DI 10.1007/s13277-014-2661-y
PG 4
WC Oncology
SC Oncology
GA CC6LU
UT WOS:000350477300039
PM 25263716
DA 2018-12-27
ER

PT J
AU Wu, H
   Yao, L
   Mei, JZ
   Li, F
AF Wu, Hong
   Yao, Li
   Mei, Jiazhuan
   Li, Feng
TI RETRACTED: Development of synthetic of peptide-functionalized liposome
   for enhanced targeted ovarian carcinoma therapy (Retracted article. See
   vol. 10, pg. 14159-14159, 2017)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE Ovarian carcinoma; transferrin receptor; liposome; tumor targeting
ID GYNECOLOGIC-ONCOLOGY-GROUP; METASTATIC NASOPHARYNGEAL CARCINOMA;
   TAT-MODIFIED CHOLESTEROL; BRAIN DELIVERY; DRUG-DELIVERY; PHASE-II;
   PACLITAXEL; CISPLATIN; CANCER; CERVIX
AB In this study, we report an active targeting liposomal formulation directed by a novel peptide (T7) that specifically binds to the transferrin receptor (TfR) overexpressed on ovarian carcinoma cells. The objectives of this study were to evaluate the in vitro and in vivo tumor drug targeting delivery of T7-anchored liposomes on A2780 cells. T7 conjugated to the distal end of DSPE-PEG2000-maleimide was incorporated into the liposomes via a post-insertion method, the liposome could keep stability in 50% FBS for more than 24 h. The uptake efficiency of T7-LP was 3.7 times higher than that of LP on A2780 cells. The anti-proliferative activity of T7-LP-PTX against A2780 cells was much stronger compared to that of LP-PTX and free PTX, respectively. The homing specificity and anticancer efficacy of T7-LP-PTX were also evaluated on the tumor spheroids, which revealed that T7-LP-PTX was more efficaciously internalized into tumor cells than LP. Compared to LP, T7-LP-PTX showed the highest accumulation capability into tumor spheroids, and the greatest tumor growth inhibitory effect in vitro. In the in vivo study, the T7-LP-PTX showed the best inhibition effect of the tumor growth for the A2780-bearing mice and tumor accumulation. In brief, the T7-LP may be an efficient targeting drug delivery system for ovarian carcinoma.
C1 [Wu, Hong; Yao, Li; Li, Feng] Zhengzhou Peoples Hosp, Dept Gynecol, Zhengzhou 450003, Peoples R China.
   [Mei, Jiazhuan] Zhengzhou Peoples Hosp, Dept Oncol, Zhengzhou 450003, Peoples R China.
RP Yao, L (reprint author), Zhengzhou Peoples Hosp, Dept Gynecol, 33 Huanghe Rd, Zhengzhou 450003, Peoples R China.
EM yaolizzrmyy@163.com
CR Bidros DS, 2009, NEUROTHERAPEUTICS, V6, P539, DOI 10.1016/j.nurt.2009.04.004
   Chao HT, 2012, CANC LETT, V2, P29
   Chua DTT, 2005, ORAL ONCOL, V41, P589, DOI 10.1016/j.oraloncology.2005.01.008
   Curtin JP, 2001, J CLIN ONCOL, V19, P1275, DOI 10.1200/JCO.2001.19.5.1275
   Despierre E, 2010, GYNECOL ONCOL, V117, P358, DOI 10.1016/j.ygyno.2010.02.012
   Du WW, 2013, BIOMATERIALS, V34, P794, DOI 10.1016/j.biomaterials.2012.10.003
   Gao HL, 2014, BIOMATERIALS, V35, P2374, DOI 10.1016/j.biomaterials.2013.11.076
   Gao HL, 2012, BIOMATERIALS, V33, P5115, DOI 10.1016/j.biomaterials.2012.03.058
   Gao HL, 2011, BIOMATERIALS, V32, P8669, DOI 10.1016/j.biomaterials.2011.07.069
   Gould N, 2012, GYNECOL ONCOL, V125, P54, DOI 10.1016/j.ygyno.2011.12.417
   Horwitz S. B., 1994, ANN ONCOL, V5, pS3
   LIEBMANN J, 1993, LANCET, V342, P1428, DOI 10.1016/0140-6736(93)92789-V
   McCarthy JS, 2002, ORAL ONCOL, V38, P686, DOI 10.1016/S1368-8375(01)00134-8
   McGuire WP, 1996, J CLIN ONCOL, V14, P792, DOI 10.1200/JCO.1996.14.3.792
   Miyata S, 2011, NEUROSURGERY, V68, P1380, DOI 10.1227/NEU.0b013e31820b52aa
   Pillai JJ, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-25
   Qin Y, 2011, INT J PHARMACEUT, V420, P304, DOI 10.1016/j.ijpharm.2011.09.008
   Qin Y, 2011, INT J PHARMACEUT, V419, P85, DOI 10.1016/j.ijpharm.2011.07.021
   Rose PG, 1999, J CLIN ONCOL, V17, P2676, DOI 10.1200/JCO.1999.17.9.2676
   Shahzad MK, 2012, CANC LETT, V18, P76
   Yin YJ, 2013, PHARM RES-DORDR, V30, P2050, DOI 10.1007/s11095-013-1058-8
NR 21
TC 10
Z9 10
U1 2
U2 19
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 1
BP 207
EP 216
PG 10
WC Oncology; Pathology
SC Oncology; Pathology
GA CB7WG
UT WOS:000349838700020
PM 25755707
DA 2018-12-27
ER

PT J
AU Cheng, Y
   Wang, WL
   Liang, JJ
AF Cheng, Yuan
   Wang, Wei-Lin
   Liang, Jun-Jun
TI RETRACTED: Genistein attenuates glucocorticoid-induced bone deleterious
   effects through regulation Eph/ephrin expression in aged mice(Retracted
   article. See vol. 9, pg. 12178, 2016)
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article; Retracted Publication
DE Eph/ephrin; bone; genistein; dexamethasone
ID MESENCHYMAL STEM-CELLS; INDUCED OSTEOPOROSIS; C-FOS; DIFFERENTIATION;
   ACTIVATION; FRACTURE; THERAPY; RATS; OSTEOCLASTOGENESIS; PHYTOESTROGENS
AB Objective: This study was performed to investigate bone deteriorations and the involvement of skeletal Eph/ephrin signaling pathway of GIOP aged mice in response to the treatment of genistein. Methods: The biomarkers in serum and urine were measured, tibias were taken for the measurement on gene and protein expression and histomorphology analysis, and femurs were taken for the measurement on bone Ca and three-dimensional architecture of trabecular bone. Results: Genistein showed a greater increase in bone Ca, BMD and significantly increased FGF-23 and OCN, reduced TRACP-5b, PTH and CTX in GIOP mice. Genistein reversed DXM-induced trabecular deleterious effects and stimulated bone remodeling. The treatment of DXM group with genistein significantly elevated the ratio of OPG/RANKL. Moreover, genistein administration down-regulated the mRNA and protein expression of Eph A2 and ephrin A2 in tibia of the GIOP mice. In contrast, the mRNA and protein expression of Eph B4 and ephrin B2 were increased in mice treated by DXM with genistein as compared to the DXM single treatment. Conclusions: DXM-induced trabecular bone micro-structure deterioration in aged mice was involved in the regulation of the Eph receptors and ephrin ligands. Genistein might represent a therapy with bone-forming as well as an anti-resorptive activity in GIOP mice. The underlying mechanism was mediated, at least partially, through regulation Eph/ephrin signaling.
C1 [Cheng, Yuan] Anhui Med Univ, Affiliated Hosp 2, Dept Endocrinol, Hefei 230601, Peoples R China.
   [Wang, Wei-Lin] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Key Lab Hormones & Dev, Minist Hlth,Metab Dis Hosp, Tianjin 300070, Peoples R China.
   [Wang, Wei-Lin] Tianjin Med Univ, Tianjin Inst Endocrinol, Tianjin 300070, Peoples R China.
   [Liang, Jun-Jun] Peoples Hosp Anqiu, Dept Neurosurg, Weifang 262100, Peoples R China.
RP Cheng, Y (reprint author), Anhui Med Univ, Affiliated Hosp 2, Dept Endocrinol, 678 Furong Rd, Hefei 230601, Peoples R China.
EM chengyuan_SAH@163.com
CR Arthur A, 2011, BONE, V48, P533, DOI 10.1016/j.bone.2010.10.180
   Bitto A, 2009, BRIT J PHARMACOL, V156, P1287, DOI 10.1111/j.1476-5381.2008.00100.x
   Bitto A, 2009, J ENDOCRINOL, V201, P321, DOI 10.1677/JOE-08-0552
   Campbell IA, 2009, SCOT MED J, V54, P21, DOI 10.1258/rsmsmj.54.1.21
   Capozzi A, 2013, CLIN CASES MINER BON, V10, P199, DOI 10.11138/ccmbm/2013.10.3.199
   Cheng SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032887
   Davy A, 2004, GENE DEV, V18, P572, DOI 10.1101/gad.1171704
   Davy A, 2006, PLOS BIOL, V4, P1763, DOI 10.1371/journal.pbio.0040315
   de Vries F, 2007, ARTHRITIS RHEUM-US, V56, P208, DOI 10.1002/art.22294
   Elshal MF, 2013, AFR J TRADIT COMPLEM, V10, P267, DOI 10.4314/ajtcam.v10i5.8
   Irie N, 2009, J BIOL CHEM, V284, P14637, DOI 10.1074/jbc.M807598200
   Jahn K, 2012, EUR CELLS MATER, V24, P197
   Jahn K, 2012, EUR CELLS MATER, V24, P209
   Koromila T, 2014, J CELL BIOCHEM, V115, P27, DOI 10.1002/jcb.24646
   Lee CH, 2014, J PHARMACOL SCI, V124, P344, DOI 10.1254/jphs.13174FP
   Lin H, 2014, DRUG DES DEV THER, V8, P973, DOI 10.2147/DDDT.S65410
   Ma XL, 2013, INT ORTHOP, V37, P1399, DOI 10.1007/s00264-013-1902-9
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Matsuo K, 2012, CELL ADHES MIGR, V6, P148, DOI 10.4161/cam.20888
   Miao Q, 2012, INT J MOL SCI, V13, P56, DOI 10.3390/ijms13010056
   Nadhanan RR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071592
   Oikonomou KA, 2014, J CLIN DENSITOM, V17, P177, DOI 10.1016/j.jocd.2013.03.019
   Razzaque MS, 2009, NAT REV ENDOCRINOL, V5, P611, DOI 10.1038/nrendo.2009.196
   Sirtori CR, 2001, DRUG SAFETY, V24, P665, DOI 10.2165/00002018-200124090-00003
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Steinbuch M, 2004, OSTEOPOROSIS INT, V15, P323, DOI 10.1007/s00198-003-1548-3
   Tat SK, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2782
   Turner RT, 2013, MENOPAUSE, V20, P677, DOI [10.1097/GME.0b013e31827d44df, 10.1097/gme.0b013e31827d44df]
   Van Staa TP, 2003, ARTHRITIS RHEUM, V48, P3224, DOI 10.1002/art.11283
   Watanabe T, 2009, P NATL ACAD SCI USA, V106, P7467, DOI 10.1073/pnas.0902859106
   Xing WR, 2010, MOL CELL BIOL, V30, P711, DOI 10.1128/MCB.00610-09
   Zhang Y, 2009, J NUTR, V139, P2230, DOI 10.3945/jn.109.108399
   Zhang YT, 2014, ENDOCRINE, V47, P598, DOI 10.1007/s12020-014-0196-z
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
   Zhou DA, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-239
NR 35
TC 7
Z9 8
U1 1
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 1
BP 394
EP 403
PG 10
WC Oncology; Pathology
SC Oncology; Pathology
GA CB7WG
UT WOS:000349838700040
PM 25755727
DA 2018-12-27
ER

PT J
AU Ye, XX
   Tang, GY
AF Ye, Xiaoxin
   Tang, Guoyi
TI RETRACTED: Effect of coupling asynchronous acoustoelectric effects on
   the corrosion behavior, microhardness and biocompatibility of biomedical
   titanium alloy strips (Retracted article. See vol. 27, 2016)
SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE
LA English
DT Article; Retracted Publication
ID RECRYSTALLIZATION BEHAVIOR; SURFACE-PROPERTIES; TI6AL4V ALLOY;
   RESISTANCE; ROUGHNESS; ADDITIONS; PHASE; STEEL; FILMS
AB The coupling asynchronous acoustoelectric effects (CAAE) of the high-energy electropulsing treatment (EPT) technique and ultrasonic surface strengthening modification (USSM) are innovatively combined in improving the surface microhardness, corrosion behavior and biocompatibility of the pre-deformed titanium alloy strips. Experimental results show that EPT and USSM processes facilitate the surface grain refining and USSM brings in the micro-dimples on the materials surface, which is attributed to the atoms diffusion acceleration under EPT and severe surface plastic deformation under USSM. These microstructure changes can not only enhance the corrosion resistance in the acidic simulated body fluids and fluoridated acidic artificial saliva but also improve the biocompatibility of the titanium alloy strip materials. Moreover, the surface microhardness of the titanium alloy strips is enhanced to improve the wear resistance. Therefore, CAAE processing is a high-efficiency and energy-saving method for obtaining biomedical titanium alloys with superior anti-corrosion performance, microhardness and biocompatibility, which can be widely applied in dental implants and artificial joint.
C1 [Ye, Xiaoxin; Tang, Guoyi] Tsinghua Univ, Grad Sch Shenzhen, Adv Mat Inst, Shenzhen 518055, Peoples R China.
   [Ye, Xiaoxin; Tang, Guoyi] Tsinghua Univ, Key Lab Adv Mat, Minist Educ, Dept Mat Sci & Engn, Beijing 100084, Peoples R China.
RP Ye, XX (reprint author), Tsinghua Univ, Grad Sch Shenzhen, Adv Mat Inst, Shenzhen 518055, Peoples R China.
EM xiaoxinye905@gmail.com; tanggy@mail.sz.tsinghua.edu.cn
FU National Natural Science Foundation of China [50571048]; Shenzhen
   science and technology research funding project of China [SGLH20
   121008144756946]
FX The work is supported by National Natural Science Foundation of China
   (No. 50571048) and Shenzhen science and technology research funding
   project of China (No. SGLH20 121008144756946).
CR Allenstein U, 2013, ACTA BIOMATER, V9, P5845, DOI 10.1016/j.actbio.2012.10.040
   BAILEY J, 1991, PHYS REV B, V44, P13116, DOI 10.1103/PhysRevB.44.13116
   BAILEY JM, 1960, J APPL PHYS, V31, P215, DOI 10.1063/1.1735406
   Candan S, 2010, ACTA METALL SIN-ENGL, V23, P197, DOI 10.11890/1006-7191-103-197
   Chou TS, 1997, MAT SCI ENG A-STRUCT, V223, P78, DOI 10.1016/S0921-5093(96)10473-1
   Guan L, 2009, J ALLOY COMPD, V487, P309, DOI 10.1016/j.jallcom.2009.07.114
   Hayakawa S, 2014, J MATER SCI-MATER M, V25, P375, DOI 10.1007/s10856-013-5078-z
   Jiang YB, 2009, ACTA MATER, V57, P4797, DOI 10.1016/j.actamat.2009.06.044
   Lee YH, 2010, APPL SURF SCI, V256, P5882, DOI 10.1016/j.apsusc.2010.03.069
   Li XY, 2012, APPL SURF SCI, V258, P1981, DOI 10.1016/j.apsusc.2011.05.083
   Liu G, 2000, MAT SCI ENG A-STRUCT, V286, P91, DOI 10.1016/S0921-5093(00)00686-9
   Lu YP, 2011, ACTA MATER, V59, P3229, DOI 10.1016/j.actamat.2011.01.063
   Luo R, 2013, APPL SURF SCI, V266, P57, DOI 10.1016/j.apsusc.2012.11.074
   Martinesi M, 2013, J MATER SCI-MATER M, V24, P1501, DOI 10.1007/s10856-013-4902-9
   Mordyuk BN, 2007, J SOUND VIB, V308, P855, DOI 10.1016/j.jsv.2007.03.054
   Nakagawa M, 2005, BIOMATERIALS, V26, P2239, DOI 10.1016/j.biomaterials.2004.07.022
   Rosalbino F, 2012, J MATER SCI-MATER M, V23, P1129, DOI 10.1007/s10856-012-4591-9
   Schiff N, 2004, BIOMATERIALS, V25, P4535, DOI 10.1016/j.biomaterials.2003.11.042
   Schiff N, 2002, BIOMATERIALS, V23, P1995, DOI 10.1016/S0142-9612(01)00328-3
   Sharon JA, 2014, SCRIPTA MATER, V75, P10, DOI 10.1016/j.scriptamat.2013.10.016
   Sun YS, 2013, THIN SOLID FILMS, V528, P130, DOI 10.1016/j.tsf.2012.06.088
   Wei CH, 2013, SURF COAT TECH, V224, P8, DOI 10.1016/j.surfcoat.2013.02.038
   Wirth C, 2005, MAT SCI ENG C-BIO S, V25, P51, DOI 10.1016/j.msec.2004.06.001
   Xu Z, 2007, APPL PHYS A-MATER, V88, P429, DOI 10.1007/s00339-007-4007-8
   Yang XJ, 2012, MATER DESIGN, V36, P477, DOI 10.1016/j.matdes.2011.11.023
   Ye XX, 2014, APPL PHYS A-MATER, V117, P2251, DOI 10.1007/s00339-014-8655-1
   Ye XX, 2014, J ALLOY COMPD, V616, P173, DOI 10.1016/j.jallcom.2014.07.143
   Ye XX, 2014, J ALLOY COMPD, V599, P1, DOI 10.1016/j.jallcom.2014.02.055
   Zareidoost A, 2012, J MATER SCI-MATER M, V23, P1479, DOI 10.1007/s10856-012-4611-9
   Zhang ZM, 2010, T NONFERR METAL SOC, V20, pS697, DOI 10.1016/S1003-6326(10)60565-1
NR 30
TC 2
Z9 2
U1 14
U2 33
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-4530
EI 1573-4838
J9 J MATER SCI-MATER M
JI J. Mater. Sci.-Mater. Med.
PD JAN
PY 2015
VL 26
IS 1
AR UNSP 53
DI 10.1007/s10856-014-5371-5
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA CA6IZ
UT WOS:000349016900053
PM 25596862
DA 2018-12-27
ER

PT J
AU Hong, Y
   Liu, GD
   Gu, ZB
AF Hong, Yan
   Liu, Guodong
   Gu, Zhengbiao
TI RETRACTED: Preparation and characterization of hydrophilic debranched
   starch modified by pullulanase on swollen granule starch(Retracted
   article. See vol.94,pg.115,2017)
SO FOOD RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
DE Starch; Swollen granule; Pullulanase; Hydrogel; Viscosity reduction
ID SLOW DIGESTION PROPERTY; WAXY MAIZE STARCH; PHYSICAL MODIFICATION;
   POTATO STARCH; CORN STARCH; DIGESTIBILITY; HYDROLYSIS; AMYLOSE; TABLETS;
   RELEASE
AB The purpose of this paper is to investigate the feasibility of reducing viscosity of high-concentration starch slurry by adding pullulanase at lower temperatures. The hydrophilic properties of pullulanase debranched starch (DBS) were simultaneously evaluated. The results of GPC and reducing sugar content showed that short linear glucan chains were generated in the debranched starch swollen at 60 degrees C, and the percentage of glucan chains increased with the swelling temperatures (70 degrees C, 80 degrees C). The crystalline structure of swollen starches after pullulanase hydrolysis was changed from double-helical A-type crystalline to a mixture of B-type and single-helical V-type crystalline. This modified starch was partially soluble in cold water, and possessed good water holding capacity. The results of rheological properties showed swollen starches after pullulanase modification was able to form gel structure. (C) 2014 Elsevier Ltd. All rights reserved.
C1 Jiangnan Univ, Sch Food Sci & Technol, Wuxi 214122, Peoples R China.
   Jiangnan Univ, Synerget Innovat Ctr Food Safety & Nutr, Wuxi 214122, Peoples R China.
RP Gu, ZB (reprint author), Jiangnan Univ, Synerget Innovat Ctr Food Safety & Nutr, Sch Food Sci & Technol, State Key Lab Food Sci & Technol, Lihu Ave 1800, Wuxi 214122, Peoples R China.
EM zhengbiaogu@jiangnan.edu.cn
OI Liu, Guodong/0000-0002-1790-2225
FU Key Program of the National Natural Science Foundation of China
   [31230057]; Twelfth Five-Year National Key Technology Research and
   Development Program of the Ministry of Science and Technology of the
   People's Republic of China [2012BAD37B01]; National Natural Science
   Foundation of China [31371787]
FX This research was supported by the Key Program of the National Natural
   Science Foundation of China (No. 31230057), the Twelfth Five-Year
   National Key Technology Research and Development Program of the Ministry
   of Science and Technology of the People's Republic of China (No.
   2012BAD37B01), the National Natural Science Foundation of China (No.
   31371787).
CR Aberle T., 1997, MACR S
   Al-Karawi AJM, 2010, CARBOHYD POLYM, V79, P769, DOI 10.1016/j.carbpol.2009.10.003
   Andersson L, 2002, CARBOHYD POLYM, V47, P53, DOI 10.1016/S0144-8617(01)00162-X
   Birkett A. M., 2005, U.S. Patent, Patent No. [US20100944465, 20100944465]
   Birkett A. M., 2006, U.S. Patent, Patent No. [US20020145186, 20020145186]
   Cai LM, 2013, J AGR FOOD CHEM, V61, P10787, DOI 10.1021/jf402570e
   Cai LM, 2010, CARBOHYD POLYM, V81, P385, DOI 10.1016/j.carbpol.2010.02.036
   Cai LM, 2010, CARBOHYD POLYM, V79, P1117, DOI 10.1016/j.carbpol.2009.10.057
   Chiu C.-W., 1993, U.S. Patent, Patent No. [U519920837443, 19920837443]
   Chiu C. -W., 1998, U.S. Patent, Patent No. [US39492995A, 39492995]
   Chou CF, 2010, J FOOD AGRIC ENVIRON, V8, P230
   Chung HJ, 2002, CARBOHYD POLYM, V48, P287, DOI 10.1016/S0144-8617(01)00259-4
   Fornal J, 2012, J FOOD ENG, V108, P515, DOI 10.1016/j.jfoodeng.2011.09.016
   Kapusniak J, 2011, PRZEM CHEM, V90, P1521
   Liakopoulou-Kyriakides M, 2001, CEREAL CHEM, V78, P603, DOI 10.1094/CCHEM.2001.78.5.603
   Limberger VM, 2008, QUIM NOVA, V31, P84, DOI 10.1590/S0100-40422008000100018
   Liu GD, 2013, CARBOHYD POLYM, V98, P995, DOI 10.1016/j.carbpol.2013.05.097
   lmmel S., 2000, STARCH, V52, P27
   MANNERS DJ, 1989, CARBOHYD POLYM, V11, P87, DOI 10.1016/0144-8617(89)90018-0
   Miao M, 2009, CARBOHYD POLYM, V76, P214, DOI 10.1016/j.carbpol.2008.10.007
   MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030
   NARA S, 1983, STARKE, V35, P407, DOI 10.1002/star.19830351202
   Onofre FO, 2010, INT J PHARMACEUT, V385, P104, DOI 10.1016/j.ijpharm.2009.10.038
   Pohja S, 2004, J CONTROL RELEASE, V94, P293, DOI 10.1016/j.jconrel.2003.09.017
   Shi YC, 1998, J CEREAL SCI, V27, P289, DOI 10.1006/jcrs.1997.9998
   Song EB, 2008, FOOD SCI BIOTECHNOL, V17, P234
   Tester RF, 2001, J CEREAL SCI, V33, P193, DOI 10.1006/jcrs.2000.0350
   Therien-Aubin H, 2009, CARBOHYD POLYM, V75, P369, DOI 10.1016/j.carbpol.2008.08.010
   Van der Veen ME, 2006, J FOOD ENG, V75, P178, DOI 10.1016/j.jfoodeng.2005.04.006
   Waliszewski KN, 2003, CARBOHYD POLYM, V52, P237, DOI 10.1016/S0144-8617(02)00270-9
   Wurzburg O. B., 1986, MODIFIED STARCHES PR, V2, p[1, 1]
   Zeeman SC, 2010, ANNU REV PLANT BIOL, V61, P209, DOI 10.1146/annurev-arplant-042809-112301
   Zhang GY, 2008, J AGR FOOD CHEM, V56, P4695, DOI 10.1021/jf072823e
   Zhang GY, 2006, BIOMACROMOLECULES, V7, P3252, DOI 10.1021/bm060342i
NR 34
TC 7
Z9 8
U1 4
U2 59
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0963-9969
EI 1873-7145
J9 FOOD RES INT
JI Food Res. Int.
PD JAN
PY 2015
VL 67
BP 212
EP 218
DI 10.1016/j.foodres.2014.11.020
PG 7
WC Food Science & Technology
SC Food Science & Technology
GA CA0PP
UT WOS:000348619600026
DA 2018-12-27
ER

PT J
AU Xu, WK
   Cai, CX
   Zou, Y
AF Xu, Wenkang
   Cai, Chenxiao
   Zou, Yun
TI RETRACTED: Cascade controller design and stability analysis in FES-aided
   upper arm stroke rehabilitation robotic system (Retracted article. See
   vol. 82, pg. 1609, 2015)
SO NONLINEAR DYNAMICS
LA English
DT Article; Retracted Publication
DE Cascade control; Iterative learning control; Stroke rehabilitation;
   Exoskeleton robot; Internal stability
ID ITERATIVE LEARNING CONTROL; FUNCTIONAL ELECTRICAL-STIMULATION; UPPER
   EXTREMITY
AB A three-dimensional stroke rehabilitation system is studied which combines the functional electrical stimulation (FES) with a robotic support to provide assistance to stroke patients who are required to perform upper extremity trajectory-tracking exercises with their residual voluntary efforts. When not enough voluntary efforts can be supplied, FES-based assistance is provided by applying electrical stimulation to the actuated muscles. In order to realize more rapid and accurate control of trajectory tracking, a new cascade control scheme is developed for the combined muscle and supported arm system. The stability of the cascade-controlled system and the internal stability of the unactuated dynamics are rigorously studied. The parameter optimal iterative learning control is then employed to further improve the trajectory-tracking accuracy of the cascade-based robotic system. Performance evaluation results confirm the effectiveness of the proposed method for upper arm trajectory-tracking-oriented stroke rehabilitation.
C1 [Xu, Wenkang; Cai, Chenxiao; Zou, Yun] Nanjing Univ Sci & Technol, Sch Automat, Nanjing 210094, Jiangsu, Peoples R China.
RP Cai, CX (reprint author), Nanjing Univ Sci & Technol, Sch Automat, Nanjing 210094, Jiangsu, Peoples R China.
EM ccx5281@vip.163.com
FU National Natural Science Foundation of China [61174038, 61104064,
   61170054]; Fundamental Research Funds for the Central Universities
   [30920140112005]
FX The work has been supported by the National Natural Science Foundation
   of China under Grant Nos. 61174038, 61104064, 61170054 and Fundamental
   Research Funds for the Central Universities under Grant No.
   30920140112005.
CR BAKER LL, 1993, NEUROMUSCULAR ELECT
   BARATTA R, 1990, IEEE T BIO-MED ENG, V37, P243, DOI 10.1109/10.52326
   Bristow DA, 2006, IEEE CONTR SYST MAG, V26, P96, DOI 10.1109/MCS.2006.1636313
   Burridge JH, 2001, NEUROMODULATION, V4, P147, DOI 10.1046/j.1525-1403.2001.00147.x
   Colombo R., 2002, NEUROREHAB NEURAL RE, V22, P494
   de Kroon JR, 2002, CLIN REHABIL, V16, P350, DOI 10.1191/0269215502cr504oa
   Fateh MM, 2013, NONLINEAR DYNAM, V74, P277, DOI 10.1007/s11071-013-0964-y
   Fateh MM, 2012, NONLINEAR DYNAM, V67, P2549, DOI 10.1007/s11071-011-0167-3
   Freeman C, 2007, INT J CONTROL, V80, P569, DOI 10.1080/00207170601136726
   Freeman C., 2012, AM CONTR C, P27
   Freeman CT, 2011, P I MECH ENG I-J SYS, V225, P850, DOI 10.1177/0959651811408976
   Freeman CT, 2009, CONTROL ENG PRACT, V17, P368, DOI 10.1016/j.conengprac.2008.08.003
   Freeman CT, 2012, IEEE CONTR SYST MAG, V32, P18, DOI 10.1109/MCS.2011.2173261
   Hassan K., 2002, NONLINEAR SYSTEMS
   Hendricks HT, 2002, ARCH PHYS MED REHAB, V83, P1629, DOI 10.1053/apmr.2002.35473
   Hughes AM, 2009, NEUROREHAB NEURAL RE, V23, P559, DOI 10.1177/1545968308328718
   Hunt K J, 1997, IEEE Trans Rehabil Eng, V5, P331, DOI 10.1109/86.650287
   Isidori A., 1989, NONLINEAR CONTROL SY
   Krebs HI, 2003, AUTON ROBOT, V15, P7, DOI 10.1023/A:1024494031121
   Le FM, 2010, CONTROL ENG PRACT, V18, P396, DOI 10.1016/j.conengprac.2009.12.007
   Lum PS, 2004, IEEE T NEUR SYS REH, V12, P186, DOI 10.1109/TNSRE.2004.827225
   Meadmore KL, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-32
   Moore K. L., 1992, ITERATIVE LEARNING C
   *NAT AUD OFF, RED BRAIN DAM FAST A
   Owens DH, 2009, INT J ROBUST NONLIN, V19, P634, DOI 10.1002/rnc.1338
   Owens DH, 2005, ANNU REV CONTROL, V29, P57, DOI 10.1016/j.arcontrol.2005.01.003
   Previdi F, 2004, IEEE T CONTR SYST T, V12, P176, DOI 10.1109/TCST.2003.821967
   Rushton DN, 2003, MED ENG PHYS, V25, P75, DOI 10.1016/S1350-4533(02)00040-1
   Sage HG, 1999, INT J CONTROL, V72, P1498, DOI 10.1080/002071799220137
   Schmidt R.A., 1999, MOTOR CONTROL LEARNI, P261
   Slotine J. E., 1991, APPL NONLINEAR CONTR
   Soltanpour MR, 2013, NONLINEAR DYNAM, V74, P467, DOI 10.1007/s11071-013-0983-8
   Spong Mark W., 2004, ROBOT DYNAMICS CONTR
   van der Putten JJMF, 1999, J NEUROL NEUROSUR PS, V66, P480, DOI 10.1136/jnnp.66.4.480
   Watanabe T., 2003, SYST COMPUT JPN, V34, P319
   Xu WK, 2013, IEEE DECIS CONTR P, P6688, DOI 10.1109/CDC.2013.6760948
   Xu WK, 2014, T I MEAS CONTROL, V36, P999, DOI 10.1177/0142331214528971
   Xu WK, 2014, CONTROL ENG PRACT, V31, P63, DOI 10.1016/j.conengprac.2014.05.009
   Zhang D., 2007, 1 INT CONV REH ENG A
NR 39
TC 1
Z9 2
U1 3
U2 27
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0924-090X
EI 1573-269X
J9 NONLINEAR DYNAM
JI Nonlinear Dyn.
PD JAN
PY 2015
VL 79
IS 2
BP 1099
EP 1114
DI 10.1007/s11071-014-1726-1
PG 16
WC Engineering, Mechanical; Mechanics
SC Engineering; Mechanics
GA AZ6FS
UT WOS:000348315100024
DA 2018-12-27
ER

PT J
AU Haghayeghi, R
   Ezzatneshan, E
   Bahai, H
AF Haghayeghi, R.
   Ezzatneshan, E.
   Bahai, H.
TI RETRACTED: Grain Refinement of AA5754 Aluminum Alloy by Ultrasonic
   Cavitation: Experimental Study and Numerical Simulation (Retracted
   article. See vol. 22, pg. 347, 2016)
SO METALS AND MATERIALS INTERNATIONAL
LA English
DT Article; Retracted Publication
DE liquid; Solidification; ultrasonic; nucleation; grain refinement
ID ELABORATION; REACTORS; HORN
AB In this work, an experimental investigation was carried out on the grain refinement of molten AA5754 Aluminum alloy through ultrasonic treatment. The cavitation induced heterogeneous nucleation was suggested as the major mechanism for grain refinement in the AA5754 aluminum alloy. A numerical simulation was performed to predict the formation, growth and collapse of cavitation bubbles in the molten AA5754 Aluminum alloy. Moreover, the acoustic pressure distribution and the induced acoustic streaming by ultrasonic horn reactor were investigated. It is suggested that the streaming by ultrasonic could transport the small bubbles formed in the ultrasonic cavitation zone into the bulk of melt rapidly. These micro-bubbles are collapsed due to acoustic vibrations where the resulting micro-jets are strong enough to break the oxide layer and to wet the impurities. These exogenous particles, intermetallics and oxides could contribute to the formation of fine, uniform and equiaxed microstructure across the treated melt. The experimental results confirmed the simulation predictions.
C1 [Haghayeghi, R.] Islamic Azad Univ, Sci & Res Branch, Dept Mat Sci, Tehran, Iran.
   [Ezzatneshan, E.] Sharif Univ Technol, Dept Aerosp Engn, Tehran, Iran.
   [Bahai, H.] Brunel Univ, Dept Mech Aerosp 8z Civil Engn, Uxbridge UB8 3PH, Middx, England.
RP Haghayeghi, R (reprint author), Islamic Azad Univ, Sci & Res Branch, Dept Mat Sci, Tehran, Iran.
EM Reza.Haghayeghi@Brunel.ac.uk
CR Abramov O. V., 1994, ULTRASOUND LIQUID SO
   ABRAMOV OT, 1998, HIGH INTENSITY ULTRA
   Abramov V, 1998, MATER LETT, V37, P27, DOI 10.1016/S0167-577X(98)00064-0
   [Anonymous], 2000, GAMBIT TUTORIAL GUID
   ANSYS Inc, 2007, ANSYS REL 14 0 COUPL
   ASTM International, 2010, STAND TEST DET AV GR
   Campbell J., 1981, International Metals Reviews, V26, P71
   CHIVATE MM, 1995, ULTRASON SONOCHEM, V2, pS19, DOI 10.1016/1350-4177(94)00007-F
   Coutier-Delgosha O., 2003, FLUIDS ENG, V125, P38
   ESKIN GI, 1995, ULTRASON SONOCHEM, V2, pS137, DOI 10.1016/1350-4177(95)00020-7
   Eskin GI, 2001, ULTRASON SONOCHEM, V8, P319, DOI 10.1016/S1350-4177(00)00074-2
   ESKIN GI, 1998, ULTRASONIC TREATMENT
   FAN Z, 2000, Patent No. 0213993
   Gabathuler J. P., 1992, EVALUATION VARIOUS P, P33
   Haghayeghi R, 2013, MET MATER INT, V19, P959, DOI 10.1007/s12540-013-5008-0
   Kojima Y, 2010, ULTRASON SONOCHEM, V17, P978, DOI 10.1016/j.ultsonch.2009.11.020
   MENTER FR, 1994, AIAA J, V32, P1598, DOI 10.2514/3.12149
   Nastac L, 2004, MODELING SIMULATION
   Nastac L, 2012, IOP CONF SER-MAT SCI, V33, DOI 10.1088/1757-899X/33/1/012079
   Schenker MC, 2013, ULTRASON SONOCHEM, V20, P502, DOI 10.1016/j.ultsonch.2012.04.014
   Schnerr GH, 2001, PHYS NUMERICAL MODEL
   Sutkar VS, 2010, CHEM ENG J, V158, P290, DOI 10.1016/j.cej.2010.01.049
   Trujillo FJ, 2011, ULTRASON SONOCHEM, V18, P1263, DOI 10.1016/j.ultsonch.2011.04.004
   VIVES C, 1992, METALL TRANS B, V23, P189, DOI 10.1007/BF02651854
   VIVES C, 1993, METALL TRANS B, V24, P493, DOI 10.1007/BF02666433
   Youn JI, 2009, JPN J APPL PHYS, V48, DOI 10.1143/JJAP.48.07GM14
NR 26
TC 6
Z9 6
U1 3
U2 35
PU KOREAN INST METALS MATERIALS
PI SEOUL
PA KIM BLDG 6TH FLOOR, SEOCHO-DAERO 56 GIL 38, SEOCHO-GU, SEOUL 137-881,
   SOUTH KOREA
SN 1598-9623
EI 2005-4149
J9 MET MATER INT
JI Met. Mater.-Int.
PD JAN
PY 2015
VL 21
IS 1
BP 109
EP 117
DI 10.1007/s12540-014-6015-5
PG 9
WC Materials Science, Multidisciplinary; Metallurgy & Metallurgical
   Engineering
SC Materials Science; Metallurgy & Metallurgical Engineering
GA AZ5FH
UT WOS:000348245300013
DA 2018-12-27
ER

PT J
AU Chen, ZW
   Wu, MH
   Shek, CH
   Wu, CML
   Lai, JKL
AF Chen, Zhiwen
   Wu, Minghong
   Shek, Chan-Hung
   Wu, C. M. Lawrence
   Lai, Joseph K. L.
TI RETRACTED: Multifunctional tin dioxide materials: advances in
   preparation strategies, microstructure, and performance (Retracted
   article. See vol. 53, pg. 10232, 2017)
SO CHEMICAL COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID PULSED-LASER DEPOSITION; SNO2 THIN-FILMS; SEMICONDUCTING OXIDES;
   OPTICAL-PROPERTIES; CHARGE-TRANSPORT; GE NANOCRYSTALS; QUANTUM DOTS;
   GROWTH; NANOWIRES; NANORODS
AB Tin oxide materials are a class of unique semiconductor materials with widespread technological applications because of their valuable semiconducting, gas sensing, electrical and optical properties in the fields of macro/mesoscopic materials and micro/nanodevices. In this review, we describe the efforts toward understanding the synthetic strategies and formation mechanisms of the micro/nanostructures of various tin dioxide thin films prepared by pulsed laser ablation, highlighting contributions from our laboratory. First, we present the preparation and formation processes of tetragonal-phase tin dioxide thin films with interesting fractal clusters. In addition, the quantum-dot formation and dynamic scaling behavior in tetragonal-phase tin dioxide thin films induced by pulsed delivery will be discussed experimentally and theoretically. Finally, we emphasize the fabrication, properties and formation mechanism of orthorhombic-phase tin dioxide thin films by using pulsed laser deposition. This research may provide a novel approach to modulate their competent performance and promote rational design of micro/nanodevices. Once mastered, tin dioxide thin films with a variety of fascinating micro/nanostructures will offer vast and unforeseen opportunities in the semiconductor industry as well as in other fields of science and technology.
C1 [Chen, Zhiwen; Wu, Minghong] Shanghai Univ, Shanghai Appl Radiat Inst, Shanghai 200444, Peoples R China.
   [Chen, Zhiwen; Wu, Minghong] Shanghai Univ, Sch Environm & Chem Engn, Shanghai 200444, Peoples R China.
   [Chen, Zhiwen; Shek, Chan-Hung; Wu, C. M. Lawrence; Lai, Joseph K. L.] City Univ Hong Kong, Dept Phys & Mat Sci, Kowloon, Hong Kong, Peoples R China.
RP Chen, ZW (reprint author), Shanghai Univ, Shanghai Appl Radiat Inst, Shanghai 200444, Peoples R China.
EM zwchen@shu.edu.cn; mhwu@staff.shu.edu.cn
RI Wu, Chi-Man/J-3920-2016; SHEK, Chan Hung/J-3857-2015; Chen,
   Zhiwen/S-7256-2016
OI Wu, Chi-Man/0000-0002-7190-8855; SHEK, Chan Hung/0000-0002-6870-523X;
   Chen, Zhiwen/0000-0001-9625-8556; Lai, Joseph Ki
   Leuk/0000-0002-8257-9436
FU National Natural Science Foundation of China [11375111, 11428410,
   11074161, 11025526, 41373098, 41430644]; Research Fund for the Doctoral
   Program of Higher Education of China [20133108110021]; Key Innovation
   Fund of Shanghai Municipal Education Commission [14ZZ098, 10ZZ64];
   Science and Technology Commission of Shanghai Municipality [14JC1402000,
   10JC1405400]; Shanghai Pujiang Program [10PJ1404100]; Program for
   Changjiang Scholars and Innovative Research Team in University
   [IRT13078]; Research Grants Council of the Hong Kong Special
   Administrative Region, China [CityU 119212]
FX The work described in this article was financially supported by the
   National Natural Science Foundation of China (Project Numbers: 11375111,
   11428410, 11074161, 11025526, 41373098 and 41430644), the Research Fund
   for the Doctoral Program of Higher Education of China (Project Number:
   20133108110021), the Key Innovation Fund of Shanghai Municipal Education
   Commission (Project Numbers: 14ZZ098 and 10ZZ64), the Science and
   Technology Commission of Shanghai Municipality (Project Numbers:
   14JC1402000 and 10JC1405400), the Shanghai Pujiang Program (Project
   Number: 10PJ1404100), and the Program for Changjiang Scholars and
   Innovative Research Team in University (Project Number: IRT13078). This
   work was also supported by a grant from the Research Grants Council of
   the Hong Kong Special Administrative Region, China [Project No. (RGC
   Ref. No.), CityU 119212].
CR Arbiol J, 2008, J CRYST GROWTH, V310, P253, DOI 10.1016/j.jcrysgro.2007.10.024
   Batzill M, 2005, PROG SURF SCI, V79, P47, DOI 10.1016/j.progsurf.2005.09.002
   Chen C, 2013, LANGMUIR, V29, P4111, DOI 10.1021/la304753x
   Chen ZW, 2011, PROG MATER SCI, V56, P901, DOI 10.1016/j.pmatsci.2011.02.001
   Chen ZW, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2399352
   Chen ZW, 2014, CHEM REV, V114, P7442, DOI 10.1021/cr4007335
   Chen ZW, 2012, CHEM REV, V112, P3833, DOI 10.1021/cr2004508
   Chen ZW, 2011, INORG CHEM, V50, P6756, DOI 10.1021/ic200787t
   Chen ZW, 2011, J PHYS CHEM C, V115, P9871, DOI 10.1021/jp200227y
   Chen ZW, 2011, MATER TODAY, V14, P106, DOI 10.1016/S1369-7021(11)70060-8
   Chen ZW, 2010, ACS NANO, V4, P1202, DOI 10.1021/nn901635f
   Chen ZW, 2006, APPL PHYS LETT, V88, DOI [10.1063/1.2162689, 10.1063/j.2162689]
   Chen ZW, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.165314
   Chen ZW, 2005, PHYS LETT A, V345, P218, DOI 10.1016/j.physleta.2005.05.104
   Chen ZW, 2005, APPL PHYS A-MATER, V81, P959, DOI 10.1007/s00339-004-3099-7
   Chen ZW, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.165413
   Cheng B, 2004, J AM CHEM SOC, V126, P5972, DOI 10.1021/ja0493244
   Combe N, 1998, PHYS REV B, V57, P15553, DOI 10.1103/PhysRevB.57.15553
   Dai ZR, 2002, J PHYS CHEM B, V106, P1274, DOI 10.1021/jp013214r
   DEMARNE V, 1988, SENSOR ACTUATOR, V13, P301, DOI 10.1016/0250-6874(88)80043-X
   Ding XH, 2010, SENSOR ACTUAT B-CHEM, V149, P336, DOI 10.1016/j.snb.2010.06.057
   Dos Santos O, 2001, SENSOR ACTUAT B-CHEM, V75, P83, DOI 10.1016/S0925-4005(01)00537-8
   Giordano L, 2011, ACCOUNTS CHEM RES, V44, P1244, DOI 10.1021/ar200139y
   Haines J, 1997, PHYS REV B, V55, P11144, DOI 10.1103/PhysRevB.55.11144
   Harbeck S, 2003, THIN SOLID FILMS, V436, P76, DOI 10.1016/S0040-6090(03)00512-1
   KAPLAN L, 1994, THIN SOLID FILMS, V253, P1, DOI 10.1016/0040-6090(94)90284-4
   Kim D, 2001, J APPL PHYS, V89, P5703, DOI 10.1063/1.1366663
   KRASEVEC V, 1985, PHYS STATUS SOLIDI A, V87, P127, DOI 10.1002/pssa.2210870110
   Lamelas FJ, 1999, PHYS REV B, V60, P9347, DOI 10.1103/PhysRevB.60.9347
   Leite ER, 2003, APPL PHYS LETT, V83, P1566, DOI 10.1063/1.1605241
   Li QB, 2012, INORG CHEM, V51, P8473, DOI 10.1021/ic301046z
   LIU LG, 1978, SCIENCE, V199, P422, DOI 10.1126/science.199.4327.422
   Mazeina L, 2009, J CRYST GROWTH, V311, P3158, DOI 10.1016/j.jcrysgro.2009.03.025
   MULLER E, 1984, ACTA CRYSTALLOGR B, V40, P359, DOI 10.1107/S0108768184002305
   Ng HT, 2003, SCIENCE, V300, P1249, DOI 10.1126/science.1082542
   Nguyen P, 2005, ADV MATER, V17, P1773, DOI 10.1002/adma.200401717
   Nilius N, 2009, SURF SCI REP, V64, P595, DOI 10.1016/j.surfrep.2009.07.004
   Pan ZW, 2001, SCIENCE, V291, P1947, DOI 10.1126/science.1058120
   Penn RL, 1998, SCIENCE, V281, P969, DOI 10.1126/science.281.5379.969
   Persson MP, 2008, NANO LETT, V8, P4146, DOI 10.1021/nl801128f
   Qin LP, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/18/185705
   Sangaletti L, 1997, SENSOR ACTUAT B-CHEM, V44, P268, DOI 10.1016/S0925-4005(97)00218-9
   Shek CH, 1997, J PHYS CHEM SOLIDS, V58, P13, DOI 10.1016/S0022-3697(96)00112-6
   Shek CH, 1999, J PHYS CHEM SOLIDS, V60, P189, DOI 10.1016/S0022-3697(98)00269-8
   Shukla S, 2004, SENSOR ACTUAT B-CHEM, V97, P256, DOI 10.1016/j.snb.2003.08.025
   STJERNA B, 1994, J APPL PHYS, V76, P3797, DOI 10.1063/1.357383
   SUITO K, 1975, MATER RES BULL, V10, P677, DOI 10.1016/0025-5408(75)90050-1
   Tamai T, 1997, CHEM MATER, V9, P2674, DOI 10.1021/cm970276e
   Wang J, 2014, SOL ENERG MAT SOL C, V128, P254, DOI 10.1016/j.solmat.2014.05.038
   Wang J, 2011, J PHYS CHEM C, V115, P20523, DOI 10.1021/jp207673r
   Wang LJ, 2012, J PHYS CHEM C, V116, P21012, DOI 10.1021/jp3075546
   Wang Y, 2004, J PHYS CHEM B, V108, P13589, DOI 10.1021/jp048454w
   Wang ZL, 2003, ADV MATER, V15, P432, DOI 10.1002/adma.200390100
   Wijeratne K, 2012, ELECTROCHIM ACTA, V72, P192, DOI 10.1016/j.electacta.2012.04.016
   Xue XY, 2010, J PHYS CHEM C, V114, P3968, DOI 10.1021/jp908343r
   Zhu S, 2001, APPL PHYS LETT, V79, P1396, DOI 10.1063/1.1400086
NR 56
TC 4
Z9 5
U1 11
U2 83
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2015
VL 51
IS 7
BP 1175
EP 1184
DI 10.1039/c4cc06970f
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA AX4IT
UT WOS:000346897300001
PM 25364791
DA 2018-12-27
ER

PT J
AU Zare, J
   Zare, A
AF Zare, Jafar
   Zare, Alireza
TI RETRACTED: An intelligent stochastic method based on fuzzy cloud theory
   for modeling uncertainty effects in the renewable micro-grids (Retracted
   article. See vol. 30, pg. 3727, 2016)
SO JOURNAL OF INTELLIGENT & FUZZY SYSTEMS
LA English
DT Article; Retracted Publication
DE Uncertainty; cloud model (CM); optimization; renewable micro-grid
ID DISTRIBUTION FEEDER RECONFIGURATION; ENERGY MANAGEMENT-SYSTEM; OPERATION
   MANAGEMENT; STORAGE DEVICES; POWER-PLANTS; FUEL-CELL; WIND; PROPAGATION
AB This paper suggests a new stochastic framework based on cloud theory to model the uncertainty effects in the optimal energy management in renewable micro-grids (MGs). Cloud theory is constructed based on the fuzzy theory and probability concept to provide an intelligent model called cloud model (CM). In comparison with the popular Monte Carlo simulation (MCS) method, CM can capture more uncertainty of the problem through the cloud drops. The basic idea is to incorporate the fuzziness and randomness of qualitative concepts and afterward transform them to the quantitative model. According to the high complexity and nonlinearity of the problem, a novel optimization algorithm called modified krill herd (MKH) algorithm is suggested to explore the problem search space globally. The proposed modification method will increase both the search ability and convergence of the algorithm effectively. The feasibility and satisfying performance of the proposed intelligent stochastic framework is demonstrated though a typical MG including different types of renewable energy sources and storage device. Comparative studies reveal the reliable superiority of the proposed stochastic framework to solve the problem.
C1 [Zare, Jafar; Zare, Alireza] Islamic Azad Univ, Sarvestan Branch, Dept Elect Engn, Sarvestan, Iran.
RP Zare, A (reprint author), Islamic Azad Univ, Sarvestan Branch, Dept Elect Engn, Sarvestan, Iran.
EM mar.hey.87@gmail.com
CR Baziar A, 2013, RENEW ENERG, V59, P158, DOI 10.1016/j.renene.2013.03.026
   Brown CT, 2007, HUM ECOL, V35, P129, DOI 10.1007/s10745-006-9083-4
   Chakraborty S, 2007, IEEE T IND ELECTRON, V54, P97, DOI 10.1109/TIE.2006.888766
   Chedid R, 1997, IEEE T ENERGY CONVER, V12, P79, DOI 10.1109/60.577284
   Chen C, 2011, IET RENEW POWER GEN, V5, P258, DOI 10.1049/iet-rpg.2010.0052
   Dukpa A, 2010, IET RENEW POWER GEN, V4, P165, DOI 10.1049/iet-rpg.2009.0016
   Gandomi AH, 2012, COMMUN NONLINEAR SCI, V17, P4831, DOI 10.1016/j.cnsns.2012.05.010
   Hafez O, 2012, RENEW ENERG, V45, P7, DOI 10.1016/j.renene.2012.01.087
   HAHN GJ, 1967, STAT MODELS ENG
   KAPLAN S, 1981, RISK ANAL, V1, P189, DOI DOI 10.1111/J.1539-6924.1981.TB01415.X
   Kavousi-Fard A, 2014, IEEE T POWER DELIVER, V29, P1344, DOI 10.1109/TPWRD.2013.2292951
   Kavousi-Fard A, 2014, ENERGY, V64, P342, DOI 10.1016/j.energy.2013.08.060
   Kavousi-Fard A, 2014, INT J ELEC POWER, V55, P680, DOI 10.1016/j.ijepes.2013.10.028
   Kavousi-Fard A, 2013, NEUROCOMPUTING, V106, P1, DOI 10.1016/j.neucom.2012.08.033
   Khodr HM, 2012, RENEW ENERG, V48, P269, DOI 10.1016/j.renene.2012.05.008
   Li D. Y., 1995, J COMPUTER RES DEV, V32, P15
   Li D. Y., 2005, ARTIFICIAL INTELLIGE
   Moghaddam AA, 2011, ENERGY, V36, P6490, DOI 10.1016/j.energy.2011.09.017
   Mohammadi S, 2014, INT J ELEC POWER, V54, P525, DOI 10.1016/j.ijepes.2013.08.004
   Morais H, 2010, RENEW ENERG, V35, P151, DOI 10.1016/j.renene.2009.02.031
   Niknam T, 2012, IET GENER TRANSM DIS, V6, P831, DOI 10.1049/iet-gtd.2011.0775
   Niknam T, 2011, J POWER SOURCES, V196, P8881, DOI 10.1016/j.jpowsour.2011.05.081
   Pipattanasomporn M, 2012, RENEW ENERG, V39, P166, DOI 10.1016/j.renene.2011.07.049
   Samet H, 2012, INT J ELEC POWER, V36, P127, DOI 10.1016/j.ijepes.2011.10.033
   Schellenberg A, 2004, 2004 INTERNATIONAL CONFERENCE ON PROBABILISTIC METHODS APPLIED TO POWER SYSTEMS, P506
   Thiam DR, 2010, RENEW ENERG, V35, P1615, DOI 10.1016/j.renene.2010.01.015
   Tsikalakis AG, 2008, IEEE T ENERGY CONVER, V23, P241, DOI 10.1109/TEC.2007.914686
   ZHANG Q, 1993, RELIAB ENG SYST SAFE, V41, P107, DOI 10.1016/0951-8320(93)90023-R
   ZHANG Q, 1989, RELIAB ENG SYST SAFE, V26, P231, DOI 10.1016/0951-8320(89)90013-6
NR 29
TC 1
Z9 1
U1 2
U2 19
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1064-1246
EI 1875-8967
J9 J INTELL FUZZY SYST
JI J. Intell. Fuzzy Syst.
PY 2015
VL 28
IS 1
BP 421
EP 431
DI 10.3233/IFS-141318
PG 11
WC Computer Science, Artificial Intelligence
SC Computer Science
GA AX5PI
UT WOS:000346978800038
DA 2018-12-27
ER

PT J
AU Zhang, F
   Li, SF
   Yang, SM
   Wang, LK
   Guo, WZ
AF Zhang, Feng
   Li, Shufen
   Yang, Shuming
   Wang, Like
   Guo, Wangzhen
TI RETRACTED: Overexpression of a cotton annexin gene, GhAnn1, enhances
   drought and salt stress tolerance in transgenic cotton (Retracted
   article. See vol. 98, pg. 185, 2018)
SO PLANT MOLECULAR BIOLOGY
LA English
DT Article; Retracted Publication
DE Cotton; Gossypium hirsutum; GhAnn1; Drought stress; Salt stress; Abiotic
   stress tolerance
ID ACID SIGNAL-TRANSDUCTION; MEMBRANE-BINDING PROTEINS; HYDROGEN-PEROXIDE;
   SUPEROXIDE-DISMUTASE; GOSSYPIUM-HIRSUTUM; PLANT-CELLS;
   ARABIDOPSIS-THALIANA; POTENTIAL ROLE; CALCIUM; IDENTIFICATION
AB Plant annexins are members of a diverse, multigene protein family that has been associated with a variety of cellular processes and responses to abiotic stresses. GhAnn1, which encodes a putative annexin protein, was isolated from a cotton (Gossypium hirsutum L. acc 7235) cDNA library. Tissue-specific expression showed that GhAnn1 is expressed at differential levels in all tissues examined and strongly induced by various phytohormones and abiotic stress. In vivo and in vitro subcellular localization suggested that GhAnn1 is located in the plasma membrane. In response to drought and salt stress, transgenic cotton plants overexpressing GhAnn1 showed significantly higher germination rates, longer roots, and more vigorous growth than wild-type plants. In addition, plants overexpressing GhAnn1 had higher total chlorophyll content, lower lipid peroxidation levels, increased peroxidase activities, and higher levels of proline and soluble sugars, all of which contributed to increased salt and drought stress tolerance. However, transgenic cotton plants in which the expression of GhAnn1 was suppressed showed the opposite results compared to the overexpressing plants. These findings demonstrated that GhAnn1 plays an important role in the abiotic stress response, and that overexpression of GhAnn1 in transgenic cotton improves salt and drought tolerance.
C1 [Zhang, Feng; Li, Shufen; Yang, Shuming; Wang, Like; Guo, Wangzhen] Nanjing Agr Univ, Hybrid Cotton R&D Engn Res Ctr, State Key Lab Crop Genet & Germplasm Enhancement, MOE, Nanjing 210095, Jiangsu, Peoples R China.
RP Guo, WZ (reprint author), Nanjing Agr Univ, Hybrid Cotton R&D Engn Res Ctr, State Key Lab Crop Genet & Germplasm Enhancement, MOE, Nanjing 210095, Jiangsu, Peoples R China.
EM moelab@njau.edu.cn
FU National Science Foundation in China [31171590]; National Transgenic
   Program [2011ZX08005-004]; Jiangsu Agriculture Science and Technology
   Innovation Fund [CX(14)2065]; PAPD-JHEI; JCIC-MCP
FX This program was financially supported in part by National Science
   Foundation in China (31171590), the National Transgenic Program
   (2011ZX08005-004), Jiangsu Agriculture Science and Technology Innovation
   Fund (CX(14)2065), and a project funded by PAPD-JHEI and JCIC-MCP.
CR Adie BAT, 2007, PLANT CELL, V19, P1665, DOI 10.1105/tpc.106.048041
   Ahuja I, 2010, TRENDS PLANT SCI, V15, P664, DOI 10.1016/j.tplants.2010.08.002
   ANDRAWIS A, 1993, PLANT J, V3, P763, DOI 10.1111/j.1365-313X.1993.00763.x
   Anjum F, 2003, SEEDS, V105, P266
   ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1
   Bai L, 2007, CHINESE SCI BULL, V52, P1142, DOI 10.1007/s11434-007-0179-z
   BATES LS, 1973, PLANT SOIL, V39, P205, DOI 10.1007/BF00018060
   BATTEY NH, 1993, NEW PHYTOL, V125, P307, DOI 10.1111/j.1469-8137.1993.tb03883.x
   Baucher M, 2011, J EXP BOT, V62, P4055, DOI 10.1093/jxb/err112
   BOUSTEAD CM, 1989, FEBS LETT, V244, P456, DOI 10.1016/0014-5793(89)80582-4
   BOWLER C, 1992, ANNU REV PLANT PHYS, V43, P83, DOI 10.1146/annurev.pp.43.060192.000503
   Breton G, 2000, PLANT CELL PHYSIOL, V41, P177
   BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9
   Christmann A, 2006, PLANT BIOLOGY, V8, P314, DOI 10.1055/s-2006-924120
   Chyzhykova O. A., 2006, Ukrainskii Biokhimicheskii Zhurnal, V78, P124
   CLARK GB, 1994, ADV SPACE RES, V14, P341, DOI 10.1016/0273-1177(94)90421-9
   Clark GB, 2012, NEW PHYTOL, V196, P695, DOI 10.1111/j.1469-8137.2012.04308.x
   CREUTZ CE, 1978, J BIOL CHEM, V253, P2858
   de Carvalho-Niebel F, 2002, PLANT J, V32, P343, DOI 10.1046/j.1365-313X.2002.01429.x
   Delmer DP, 1997, CELL MOL LIFE SCI, V53, P546, DOI 10.1007/s000180050070
   Devoto A, 2003, ANN BOT-LONDON, V92, P329, DOI 10.1093/aob/mcg151
   Divya K, 2010, PLANT MOL BIOL, V73, P293, DOI 10.1007/s11103-010-9615-6
   Draeger A, 2011, BIOCHEM PHARMACOL, V81, P703, DOI 10.1016/j.bcp.2010.12.027
   Dunand C, 2007, NEW PHYTOL, V174, P332, DOI 10.1111/j.1469-8137.2007.01995.x
   Farooq M, 2009, SUSTAINABLE AGRICULTURE, P153, DOI 10.1007/978-90-481-2666-8_12
   Finn RD, 2011, NUCLEIC ACIDS RES, V39, pW29, DOI 10.1093/nar/gkr367
   Galvez-Valdivieso G, 2009, PLANT CELL, V21, P2143, DOI 10.1105/tpc.108.061507
   Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001
   Goda H, 2008, PLANT J, V55, P526, DOI [10.1111/j.1365-313X.2008.03510.x, 10.1111/j.0960-7412.2008.03510.x]
   Gorecka KM, 2005, BIOCHEM BIOPH RES CO, V336, P868, DOI 10.1016/j.bbrc.2005.08.181
   GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053
   He YJ, 2008, J AGR BIOTECHNOL, V17, P84
   HEATH RL, 1968, ARCH BIOCHEM BIOPHYS, V125, P189, DOI 10.1016/0003-9861(68)90654-1
   Hofmann A, 2003, EUR J BIOCHEM, V270, P2557, DOI 10.1046/j.1432-1033.2003.03612.x
   Huang YQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066160
   Hubbard KE, 2010, GENE DEV, V24, P1695, DOI 10.1101/gad.1953910
   Huh SM, 2010, PLANT CELL PHYSIOL, V51, P1499, DOI 10.1093/pcp/pcq111
   Hung SH, 2005, BOT BULL ACAD SINICA, V46, P1
   Jami SK, 2012, PLANT CELL REP, V31, P813, DOI 10.1007/s00299-011-1201-0
   Jami SK, 2009, PLANT PHYSIOL BIOCH, V47, P977, DOI 10.1016/j.plaphy.2009.08.005
   Jami SK, 2008, PLANT PHYSIOL BIOCH, V46, P1019, DOI 10.1016/j.plaphy.2008.07.006
   Jaspers P, 2010, PLANT SIGNAL BEHAV, V5, P78, DOI 10.4161/psb.5.1.10293
   [蒋建雄 Jiang Jianxiong], 2003, [棉花学报, Cotton Science], V15, P166
   Kerepesi I, 2000, CROP SCI, V40, P482, DOI 10.2135/cropsci2000.402482x
   Ketting Rene F, 2006, CSH Protoc, V2006, DOI 10.1101/pdb.prot4318
   Kiba T, 2005, PLANT CELL PHYSIOL, V46, P339, DOI 10.1093/pcp/pci033
   KOHEL R J, 1970, Crop Science, V10, P670
   Konopka-Postupolska D, 2007, PROTOPLASMA, V230, P203, DOI 10.1007/s00709-006-0234-7
   Konopka-Postupolska D, 2009, PLANT PHYSIOL, V150, P1394, DOI 10.1104/pp.109.135228
   Korbei B, 2013, J INTEGR PLANT BIOL, V55, P809, DOI 10.1111/jipb.12059
   Krasensky J, 2012, J EXP BOT, V63, P1593, DOI 10.1093/jxb/err460
   Kudla J, 2010, PLANT CELL, V22, P541, DOI 10.1105/tpc.109.072686
   Laohavisit A, 2011, NEW PHYTOL, V189, P40, DOI 10.1111/j.1469-8137.2010.03533.x
   Lee S, 2004, PLANT CELL, V16, P1378, DOI 10.1105/tpc.021683
   Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199
   Li B, 2013, J INTEGR PLANT BIOL, V55, P902, DOI 10.1111/jipb.12063
   Li FF, 2009, PLANT CELL TISS ORG, V97, P225, DOI 10.1007/s11240-009-9521-2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu YG, 2012, GENE, V499, P14, DOI 10.1016/j.gene.2012.03.026
   Massacci A, 2008, PLANT PHYSIOL BIOCH, V46, P189, DOI 10.1016/j.plaphy.2007.10.006
   Meloni DA, 2003, ENVIRON EXP BOT, V49, P69, DOI 10.1016/S0098-8472(02)00058-8
   Monastyrskaya K, 2009, CELL MOL LIFE SCI, V66, P2623, DOI 10.1007/s00018-009-0027-1
   Mortimer JC, 2008, J EXP BOT, V59, P533, DOI 10.1093/jxb/erm344
   Moss SE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-219
   Mullineaux PM, 2010, PLANT PHYSIOL, V154, P521, DOI 10.1104/pp.110.161406
   Neill SJ, 2002, J EXP BOT, V53, P1237, DOI 10.1093/jexbot/53.372.1237
   Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249
   PAOLETTI F, 1986, ANAL BIOCHEM, V154, P536, DOI 10.1016/0003-2697(86)90026-6
   Paterson A. H., 1993, Plant Molecular Biology Reporter, V11, P122, DOI 10.1007/BF02670470
   Pitzschke A, 2009, PLANT PHYSIOL, V149, P606, DOI 10.1104/pp.108.131557
   Qian SY, 1992, SCI AGR SINICA, V25, P44
   Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736
   Richards SL, 2014, PLANT J, V77, P136, DOI 10.1111/tpj.12372
   Sairam RK, 2005, BIOL PLANTARUM, V49, P85, DOI 10.1007/s10535-005-5091-2
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406
   Santner A, 2010, PLANT J, V61, P1029, DOI 10.1111/j.1365-313X.2010.04112.x
   Schapire AL, 2009, TRENDS PLANT SCI, V14, P645, DOI 10.1016/j.tplants.2009.09.004
   Shang X, 2007, J CELL BIOCHEM, V101, P600, DOI 10.1002/jcb.21219
   Shin HS, 1999, PLANT PHYSIOL, V119, P925, DOI 10.1104/pp.119.3.925
   Smyth DR, 1997, CURR BIOL, V7, pR793, DOI 10.1016/S0960-9822(06)00407-6
   Sparkes IA, 2006, NAT PROTOC, V1, P2019, DOI 10.1038/nprot.2006.286
   Sun YC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019751
   Talukdar T, 2009, ACTA BIOCHIM POL, V56, P199
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Tang WX, 2014, PLANT MOL BIOL, V85, P613, DOI 10.1007/s11103-014-0208-7
   Thonat C, 1997, PLANT PHYSIOL, V114, P981, DOI 10.1104/pp.114.3.981
   Ton J, 2009, TRENDS PLANT SCI, V14, P310, DOI 10.1016/j.tplants.2009.03.006
   Tsukagoshi H, 2010, CELL, V143, P606, DOI 10.1016/j.cell.2010.10.020
   Vandeputte O, 2007, MOL PLANT PATHOL, V8, P185, DOI [10.1111/j.1364-3703.2007.00385.x, 10.1111/J.1364-3703.2007.00385.X]
   Wang LK, 2010, MOL BIOL REP, V37, P3327, DOI 10.1007/s11033-009-9919-2
   Xin ZY, 2005, PLANT PHYSIOL, V139, P1350, DOI 10.1104/pp.105.068064
   Zhou L, 2011, J INTEGR PLANT BIOL, V53, P347, DOI 10.1111/j.1744-7909.2011.01034.x
   Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329
NR 93
TC 23
Z9 28
U1 8
U2 66
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-4412
EI 1573-5028
J9 PLANT MOL BIOL
JI Plant Mol.Biol.
PD JAN
PY 2015
VL 87
IS 1-2
BP 47
EP 67
DI 10.1007/s11103-014-0260-3
PG 21
WC Biochemistry & Molecular Biology; Plant Sciences
SC Biochemistry & Molecular Biology; Plant Sciences
GA AX0LE
UT WOS:000346643100004
PM 25330941
DA 2018-12-27
ER

PT J
AU Lu, SM
AF Lu, Shyi-Min
TI RETRACTED: A global survey of gas hydrate development and reserves:
   Specifically in the marine field (Retracted article. See vol. 64, pg.
   851, 2016)
SO RENEWABLE & SUSTAINABLE ENERGY REVIEWS
LA English
DT Review; Retracted Publication
DE Gas hydrate; Methane hydrate; Exploitation and planning; Reserve
ID SOUTH CHINA SEA; ENERGY
AB Gas hydrates, also known as methane hydrates, are formed due to the high hydraulic pressures present under the cold seabed over long periods of time. Gas hydrates are mainly composed of methane produced in the seabed by bacteria in the use of the remains of animals and plants as food. Often appearing as translucent or opaque ice, gas hydrates can be separated into water and methane gas, which can be burned at normal temperatures and pressures, giving this substance the nickname "combustible ice." As global oil reserves continue to be depleted, scientists are regarding methane hydrates as a new energy source that is very likely to replace oil in the 21st century. According to reports by the United States Geological Survey, the potential natural gas energy that can be recovered from global methane hydrate formations is two times the amount of fossil fuel energy available to the world. Therefore, many countries that are deeply engaged in the development of gas hydrates, such as the United States, Japan, Canada, China, India, and Taiwan, hope that this new energy source can become a substitute for more conventional petroleum sources. Japan-the first country to develop methane hydrates-will be ready for commercial mass production in the eastern Japanese Nankai Trough prior to 2018, according to Japan's Methane Hydrate R&D Program-MH 21. However, the exploitation of methane hydrates in terrestrial permafrost requires less technical risk and costs. Joint explorations in areas of Alaska by the United States, Japan, and Canada will enter the preparation phase for commercial output as early as 2015. In Taiwan, cooperation with Germany and the United States has led to methane hydrate exploration and the initiation of drilling sampling in the South China Sea that is expected to be completed in 2016, with commercial production ready as soon as 2026. (C) 2014 Elsevier Ltd. All rights reserved.
C1 Ind Technol Res Inst, Energy & Environm Res Labs, Hsinchu 310, Taiwan.
RP Lu, SM (reprint author), Ind Technol Res Inst, Energy & Environm Res Labs, Hsinchu 310, Taiwan.
EM shyimin@gmail.com
CR [Anonymous], 2014, BP STAT REV WORLD EN
   Best A.I., 2006, EOS, V87, P213, DOI DOI 10.1029/2006E0220001
   Bohannon J, 2008, SCIENCE, V319, P1753, DOI 10.1126/science.319.5871.1753
   Boswell R, 2006, GAS HYDRATES RESOURC
   Boswell R, 2011, ENERG ENVIRON SCI, V4, P1206, DOI 10.1039/c0ee00203h
   Bureau of Energy MOEA, 2011, EN STAT HDB
   Bureau of Energy MOEA, 2013, EN STAT HDB 2012
   Chen SC, 2007, SCI DEV, V412, P26
   Chung SH, 2012, B CENT GEOL SURV, V25, P95
   Chung SH, 2011, B CENT GEOL SURV, V24, P65
   Chung SH, 2007, TAIWAN GAS HYDRATE F
   Chung SH, 2013, J TAIWAN ENERGY, V1, P51
   Collett TS, 2004, GEOTIMES, V49, P24
   Collett TS, 1998, INT J OFFSHORE POLAR, V8, P22
   COLLETT TS, 2008, NATURAL GAS HYDRATES
   Collett TS, 1955, US GEOLOGICAL SURVEY, V30
   Dickens GR, 2004, GEOTIMES, V49, P18
   Dillon W.P., 2001, GEOPHYS MONOGR SER, V124, P211, DOI DOI 10.1029/GM124
   Dillon WP, 2001, NATURAL GAS HYDRATES, V124, P211
   EIA, 2014, INT EN STAT STAT EN
   Fujii T., 2008, P 6 INT C GAS HYDR V
   Ginsburg GD, 1994, B GEOL SOC DENMARK, V41, P95
   Ginsburg G.D., 1992, INT GEOL REV, V34, P765, DOI DOI 10.1080/00206819209465635
   Ginsburg GD, 2000, GEOL GEOFIZ, V41, P1165
   Grubler A, 1996, TECHNOL FORECAST SOC, V53, P97, DOI 10.1016/0040-1625(96)00049-2
   Han XQ, 2008, MAR GEOL, V249, P243, DOI 10.1016/j.margeo.2007.11.012
   IPCC, 2007, CLIM CHANG 2007 MIT
   Johnson A. H., 2006, Leading Edge, V25, P648, DOI 10.1190/1.2202672
   Kannan R, 2010, UK MARKAL MODEL
   Kennett J. P., 2003, AM GEOPHYS UNION SPE, P216
   Kennett J. P., 2003, AGU SPECIAL PUBLICAT, V54, P216, DOI DOI 10.1029/054SP
   Krewitt W, 2009, ROLE POTENTIAL RENEW
   Krey V, 2009, ENVIRON RES LETT, V4, DOI 10.1088/1748-9326/4/3/034007
   Kumar P, 2014, GAS HYDRATE EXPLORAT
   Kvenvolden KA, 2005, MAR PETROL GEOL, V22, P579, DOI 10.1016/j.marpetgeo.2004.08.004
   Kvenvolden KA, 1998, GEOL SOC SPEC PUBL, V137, P9, DOI 10.1144/GSL.SP.1998.137.01.02
   Lin TS, 2011, 10024F MOEA
   Liu CS., 2008, TAIWAN SW WATERS EME
   Lu SM, 2014, FUEL GAS Q, V107, P14
   Lu SM, 2013, COMMERCIAL TIMES
   Lu SM, 2011, SCI DEV, V464, P60
   Lu Z, 2010, GAS HYDRATE FEATURES, P6
   Majorowicz JA, 2001, AAPG BULL, V85, P1211
   Makogon YF, 2007, J PETROL SCI ENG, V56, P14, DOI 10.1016/j.petrol.2005.10.009
   Masumoto R, 1995, PETROTEC, V18, P27
   METI, 2001, JAP METH HYDR DEV PL
   MH21, 2014, PHAS 1 COMPR REP RES
   Nakicenovic N., 2002, International Journal of Global Energy Issues, V18, P6, DOI 10.1504/IJGEI.2002.000950
   Okuda Y, 1996, JOUR GEOL SOC JAPAN, V102, P959
   Okuda Y., 1993, J JPN I ENG, V6, P425
   Okuda Y., 2005, ICOGS ASIA PACIFIC N, V7, P24
   Rogner HH, 1997, ANNU REV ENERG ENV, V22, P217, DOI 10.1146/annurev.energy.22.1.217
   Ruppel C, 2011, 4 MIT EN IN STUD, P25
   Schultheiss P, 2007, FRESH WATER HYDRATES, P13
   Shyi-Min L, 2013, LOW CARBON EC, V4, P1
   Sloan ED, 1998, GEOL SOC SPEC PUBL, V137, P31, DOI 10.1144/GSL.SP.1998.137.01.03
   Song YC, 2014, RENEW SUST ENERG REV, V31, P778, DOI 10.1016/j.rser.2013.12.025
   Taiwan Power Company, GLOB GAS MARK
   Tianto Info (Beijing) Consulting, 2014, GLOB COMB IC DEV STA
   USDOE, 1998, STRAT METH HYDR RES
   Wang XJ, 2011, MAR PETROL GEOL, V28, P1625, DOI 10.1016/j.marpetgeo.2011.07.002
   Weng TW, 2013, MIN METALL, V57, P56
   Zhao JF, 2013, ENERGY, V52, P308, DOI 10.1016/j.energy.2013.01.066
NR 63
TC 42
Z9 49
U1 8
U2 115
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1364-0321
J9 RENEW SUST ENERG REV
JI Renew. Sust. Energ. Rev.
PD JAN
PY 2015
VL 41
BP 884
EP 900
DI 10.1016/j.rser.2014.08.063
PG 17
WC GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY; Energy & Fuels
SC Science & Technology - Other Topics; Energy & Fuels
GA AX0DA
UT WOS:000346622400066
DA 2018-12-27
ER

PT J
AU Yu, L
   Wang, XL
   Zhu, D
   Ding, WC
   Wang, LM
   Zhang, CL
   Jiang, XH
   Shen, H
   Liao, SJ
   Ma, D
   Hu, Z
   Wang, H
AF Yu, Lan
   Wang, Xiaoli
   Zhu, Da
   Ding, Wencheng
   Wang, Liming
   Zhang, Changlin
   Jiang, Xiaohui
   Shen, Hui
   Liao, Shujie
   Ma, Ding
   Hu, Zheng
   Wang, Hui
TI RETRACTED: Disruption of human papillomavirus 16 E6 gene by clustered
   regularly interspaced short palindromic repeat/Cas system in human
   cervical cancer cells(Retracted article.See vol.10, pg.2835-2835, 2017)
SO ONCOTARGETS AND THERAPY
LA English
DT Article; Retracted Publication
DE CRISPR/Cas system; E6; p53; SiHa; CaSki; cervical cancer
ID ZINC-FINGER NUCLEASES; CRISPR-CAS SYSTEM; RNA-INTERFERENCE; HUMAN-CELLS;
   MOUSE
AB High-risk human papillomavirus (HPV), especially HPV16, is considered a main causative agent of cervical cancer. Upon HPV infection, the viral oncoprotein E6 disrupts the host tumor-suppressor protein p53, thus promoting malignant transformation of normal cervical cells. Here, we used the newly developed programmable ribonucleic acid-guided clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system to disrupt the HPV16 E6 gene. We showed that HPV16 E6 deoxyribonucleic acid was cleaved at specific sites, leading to apoptosis and growth inhibition of HPV16-positive SiHa and CaSki cells, but not HPV-negative C33A or human embryonic kidney 293 cells. We also observed downregulation of the E6 protein and restoration of the p53 protein. These data proved that the HPV16 E6 ribonucleic acid-guided CRISPR/Cas system might be an effective therapeutic agent in treating HPV infection-related cervical malignancy.
C1 [Yu, Lan; Wang, Xiaoli; Zhu, Da; Ding, Wencheng; Wang, Liming; Zhang, Changlin; Jiang, Xiaohui; Shen, Hui; Liao, Shujie; Ma, Ding; Hu, Zheng; Wang, Hui] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Canc Biol Res Ctr, Wuhan 430030, Hubei, Peoples R China.
RP Ma, D (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, 13 Hang Kong Lu, Wuhan 430030, Hubei, Peoples R China.
EM dma@tjh.tjmu.edu.cn; huit71@sohu.com
FU National Development Program (973) for Key Basic Research of China
   [2009CB521808, 2013CB911304]; National Natural Science Funding of China
   [81230038, 81372805, 81301126, 81172466, 81302266, 81402158,
   2013M531699]
FX This work was supported by funds from the National Development Program
   (973) for Key Basic Research of China (2009CB521808 and 2013CB911304)
   and National Natural Science Funding of China (81230038, 81372805,
   81301126, 81172466, 81302266, 81402158, and 2013M531699). The authors
   thank Professor David Segal for pSSA Rep3-1, GZF3-L3, and GZF1-R3 ZFN
   plasmids.
CR Armstrong EP, 2010, J MANAGE CARE PHARM, V16, P217, DOI 10.18553/jmcp.2010.16.3.217
   Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140
   Bhakta MS, 2010, METHODS MOL BIOL, V649, P3, DOI 10.1007/978-1-60761-753-2_1
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507
   Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688
   Heidenreich E, 2003, EMBO J, V22, P2274, DOI 10.1093/emboj/cdg203
   Hwang WY, 2013, NAT BIOTECHNOL, V31, P227, DOI 10.1038/nbt.2501
   Jonson AL, 2008, GYNECOL ONCOL, V111, P356, DOI 10.1016/j.ygyno.2008.06.033
   Katic I, 2013, GENETICS, V195, P1173, DOI 10.1534/genetics.113.155754
   Kim HJ, 2009, GENOME RES, V19, P1279, DOI 10.1101/gr.089417.108
   Li DL, 2013, NAT BIOTECHNOL, V31, P681, DOI 10.1038/nbt.2661
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Mussolino C, 2013, NAT BIOTECHNOL, V31, P208, DOI 10.1038/nbt.2527
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Rassool FV, 2003, CANCER LETT, V193, P1, DOI 10.1016/S0304-3835(02)00692-4
   Santiago Y, 2008, P NATL ACAD SCI USA, V105, P5809, DOI 10.1073/pnas.0800940105
   Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439
   Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902
   Tang S, 2006, ONCOGENE, V25, P2094, DOI 10.1038/sj.onc.1209244
   Zanier K, 2005, J MOL BIOL, V349, P401, DOI 10.1016/j.jmb.2005.03.071
   zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798
NR 22
TC 22
Z9 23
U1 3
U2 30
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2015
VL 8
BP 37
EP 44
DI 10.2147/OTT.S64092
PG 8
WC Biotechnology & Applied Microbiology; Oncology
SC Biotechnology & Applied Microbiology; Oncology
GA AX1TF
UT WOS:000346728200001
PM 25565864
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Patra, S
   Roy, E
   Madhuri, R
   Sharma, PK
AF Patra, Santanu
   Roy, Ekta
   Madhuri, Rashmi
   Sharma, Prashant K.
TI RETRACTED: Imprinted ZnO nanostructure-based electrochemical sensing of
   calcitonin: A clinical marker for medullary thyroid carcinoma (Retracted
   article. See vol. 1023, pg. 121, 2018)
SO ANALYTICA CHIMICA ACTA
LA English
DT Article; Retracted Publication
DE Calcitonin; Zinc oxide nanostructure; Surface imprinting; Activator
   regenerated by electron transfer-atom transfer radical polymerization;
   (ARGET-ATRP); Biomarker-sensor
ID SALMON-CALCITONIN; GLASSY-CARBON; ELECTRODE; SENSOR; NANOPARTICLES;
   RECOGNITION; POLYMERS; SURFACES; QUALITY; ASSAY
AB The present work describes an exciting method for the selective and sensitive determination of calcitonin in human blood serum samples. Adopting the surface molecular imprinting technique, a calcitonin-imprinted polymer was prepared on the surface of the zinc oxide nanostructure. Firstly, a biocompatible tyrosine derivative as a monomer was grafted onto the surface of zinc oxide nanostructure followed by their polymerization on vinyl functionalized electrode surface by activator regenerated by electron transfer-atom transfer radical polymerization (ARGET-ATRP) technique. Such sensor can predict the small change in the concentration of calcitonin in the human body and it may also consider to be as cost-effective, renewable, disposable, and reliable for clinical studies having no such cross-reactivity and matrix effect from real samples. The morphologies and properties of the proposed sensor were characterized by scanning electron microscopy, cyclic voltammetry, difference pulse voltammetry and chronocoulometry. The linear working range was found to be 9.99 ng L-1 to 7.919 mg L-1 and the detection limit as low as 3.09 +/- 0.01 ng L-1 (standard deviation for three replicate measurements) (S/ N = 3). (C) 2014 Elsevier B.V. All rights reserved.
C1 [Patra, Santanu; Roy, Ekta; Madhuri, Rashmi] Indian Sch Mines, Dept Appl Chem, Dhanbad 826004, Jharkhand, India.
   [Sharma, Prashant K.] Indian Sch Mines, Dept Appl Phys, Funct Nanomat Res Lab, Dhanbad 826004, Jharkhand, India.
RP Madhuri, R (reprint author), Indian Sch Mines, Dept Appl Chem, Dhanbad 826004, Jharkhand, India.
EM rshmmadhuri@gmail.com
RI Patra, Santanu/E-4682-2016
FU Indian School of Mines, Dhanbad [FRS/34/2012-2013/APH, FRS/43/
   2013-2014/AC]; Board of Research in Nuclear Sciences (BRNS), Department
   of Atomic Energy, Government of India [34/14/21/2014-BRNS]
FX Authors are thankful to Department of Science and Technology, Government
   of India for sanction of Fast Track Research Project for Young
   Scientists to Dr. Rashmi Madhuri (Ref. No.: SB/FT/CS-155/ 2012) and Dr.
   Prashant K. Sharma (Ref. No.: SR/FTP/PS-157/2011). Dr. Sharma
   (FRS/34/2012-2013/APH) and Dr. Madhuri (FRS/43/ 2013-2014/AC) are also
   thankful to Indian School of Mines, Dhanbad for grant of Major Research
   Project under Faculty Research Scheme. Authors are also thankful to
   Board of Research in Nuclear Sciences (BRNS), Department of Atomic
   Energy, Government of India for granting a major research project (No.
   34/14/21/2014-BRNS). E.R. and S.P are also thankful to Indian School of
   Mines, Dhanbad for Junior Research Fellowship.
CR Arya SK, 2012, ANAL CHIM ACTA, V737, P1, DOI 10.1016/j.aca.2012.05.048
   Aslanoglu M, 2005, TURK J CHEM, V29, P477
   Bard A. J., 1980, ELECTROCHEMICAL METH
   Boyle P, 2008, WORLD CANC REPORT 20
   BUCK RH, 1990, J PHARMACEUT BIOMED, V8, P761, DOI 10.1016/0731-7085(90)80118-9
   Cavalier E, 2008, CLIN CHEM, V54, P929, DOI 10.1373/clinchem.2007.100636
   COPP DH, 1961, P CAN FED BIOL SCI, V4, P17
   Cormack PAG, 2004, J CHROMATOGR B, V804, P173, DOI 10.1016/j.jchromb.2004.02.013
   Costante G, 2009, NAT CLIN PRACT ENDOC, V5, P35, DOI 10.1038/ncpendmet1023
   D'Hondt M, 2010, J PHARMACEUT BIOMED, V53, P939, DOI 10.1016/j.jpba.2010.06.028
   Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509
   Fu GQ, 2011, ANAL CHEM, V83, P1431, DOI 10.1021/ac1029924
   Gagel R.F., 2003, WILLIAMS TXB ENDOCRI, P1717
   Gao DM, 2007, J AM CHEM SOC, V129, P7859, DOI 10.1021/ja070975k
   Gao RX, 2011, J MATER CHEM, V21, P17863, DOI 10.1039/c1jm12414e
   Gulia S., 2013, ADV MAT LETT, V4, P876
   Karimian N, 2014, BIOSENS BIOELECTRON, V59, P160, DOI 10.1016/j.bios.2014.03.013
   Karimian N, 2013, ELECTROCHEM COMMUN, V36, P92, DOI 10.1016/j.elecom.2013.09.014
   Karimian N, 2013, BIOSENS BIOELECTRON, V50, P492, DOI 10.1016/j.bios.2013.07.013
   Kong YC, 2001, APPL PHYS LETT, V78, P407, DOI 10.1063/1.1342050
   Kumar D., 2011, ADV MAT LETT, V2, P294, DOI [10.5185/amlett.indias.207, DOI 10.5185/AMLETT.INDIAS.207]
   Kuriakose S, 2013, BEILSTEIN J NANOTECH, V4, P763, DOI 10.3762/bjnano.4.87
   Li SJ, 2010, ADV MAT LETT, V1, P4, DOI DOI 10.5185/AMLETT.2010.4110
   Liu JM, 2012, ANAL CHIM ACTA, V744, P60, DOI 10.1016/j.aca.2012.07.017
   Lowe AB, 1998, MACROMOLECULES, V31, P5991, DOI 10.1021/ma980558f
   LYNCH C, 1988, J IMMUNOASSAY, V9, P179, DOI 10.1080/15321818808057039
   Majdi S, 2009, J SOLID STATE ELECTR, V13, P407, DOI 10.1007/s10008-008-0567-6
   Nanotechnology Biosensors, 2014, ADV MAT SERIES
   Nishino H, 2006, ANGEW CHEM INT EDIT, V45, P2392, DOI 10.1002/anie.200503760
   Osteryoung JG, 1997, ANAL CHIM ACTA, V351, P65, DOI 10.1016/S0003-2670(97)00356-5
   Ouyang RZ, 2008, CHEM COMMUN, P5761, DOI 10.1039/b810248a
   RONG HQ, 1994, CLIN CHEM, V40, P1774
   Rong HQ, 1997, CLIN CHEM, V43, P71
   Roy E, 2014, RSC ADV, V4, P32881, DOI 10.1039/c4ra04868g
   Roy E, 2014, TALANTA, V120, P198, DOI 10.1016/j.talanta.2013.11.074
   Shi HQ, 1999, NATURE, V398, P593
   Shiomi T, 2005, BIOMATERIALS, V26, P5564, DOI 10.1016/j.biomaterials.2005.02.007
   Silvestro L, 1996, RAPID COMMUN MASS SP, V10, P151, DOI 10.1002/(SICI)1097-0231(19960131)10:2<151::AID-RCM434>3.0.CO;2-C
   Skoog D.A., 1998, PRINCIPLES INSTRUMEN
   Tiwari A, 2012, BIOSENS BIOELECTRON, V35, P224, DOI 10.1016/j.bios.2012.02.053
   Tiwari M.P., 2011, ADV MAT LETT, V2, P276, DOI [10.5185/amlett.indias.202, DOI 10.5185/AMLETT.INDIAS.202]
   Toledo SPA, 2009, CLINICS, V64, P699, DOI 10.1590/S1807-59322009000700015
   Tong D, 2001, CHROMATOGRAPHIA, V54, P7, DOI 10.1007/BF02491825
   Varghese C., 2014, 50 YEARS CANC CONTRO, P48
   Vasapollo G, 2011, INT J MOL SCI, V12, P5908, DOI 10.3390/ijms12095908
   Vega-Poot AG, 2010, NANOSCALE, V2, P2710, DOI 10.1039/c0nr00439a
   WANG JS, 1995, J AM CHEM SOC, V117, P5614, DOI 10.1021/ja00125a035
   Wang YT, 2010, SENSOR ACTUAT B-CHEM, V146, P381, DOI 10.1016/j.snb.2010.02.032
   Yin Y, 2005, NATURE, V437, P664, DOI 10.1038/nature04165
   Zhang L, 2008, BIOSENS BIOELECTRON, V24, P690, DOI 10.1016/j.bios.2008.06.025
   Zhang W, 2011, BIOSENS BIOELECTRON, V26, P2553, DOI 10.1016/j.bios.2010.11.004
   Zhang Y, 2014, J INORG BIOCHEM, V130, P74, DOI 10.1016/j.jinorgbio.2013.10.004
   Zhao ZW, 2010, SENSORS-BASEL, V10, P1216, DOI 10.3390/s100201216
NR 53
TC 25
Z9 25
U1 3
U2 68
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0003-2670
EI 1873-4324
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD JAN 1
PY 2015
VL 853
BP 271
EP 284
DI 10.1016/j.aca.2014.10.030
PG 14
WC Chemistry, Analytical
SC Chemistry
GA AU5MT
UT WOS:000345652000024
PM 25467469
DA 2018-12-27
ER

PT J
AU Pouran, SR
   Aziz, ARA
   Daud, WMAW
   Shamshirband, S
AF Pouran, Shima Rahim
   Aziz, A. R. Abdul
   Daud, Wan Mohd Ashri Wan
   Shamshirband, Shahaboddin
TI RETRACTED: Estimation of the effect of catalyst physical characteristics
   on Fenton-like oxidation efficiency using adaptive neuro-fuzzy computing
   technique (Retracted article. See vol. 125, pg. 704, 2018)
SO MEASUREMENT
LA English
DT Article; Retracted Publication
DE Adaptive neuro-fuzzy system (ANFIS); Adsorption capacity; Central
   composite design; Heterogeneous Fenton treatment
ID RESPONSE-SURFACE METHODOLOGY; METHYLENE-BLUE; NEUTRAL PH; MAGNETITE;
   OPTIMIZATION; DEGRADATION; REMOVAL; CARBON; DECOLORIZATION;
   CARBAMAZEPINE
AB Catalyst size, which determines surface area, is one of the major factors in catalytic performance. In this study, response surface methodology (RSM) and an adaptive neuro-fuzzy inference system (ANFIS) were applied to quantify the effects of physical characteristics of magnetite on Fenton-like oxidation efficiency of methylene blue. For this purpose, two magnetite samples (M and N) were used and characterized by XRD, BET surface area, particle size analyzer and FE-SEM. Central composite design (CCD) was applied to design the experiments, develop regression models, optimize and evaluate the individual and interactive effects of five independent variables: H2O2 and catalyst concentrations, pH, reaction time (numeric factors) and the type of catalyst (categorical factor). For each categorical factor, three quadratic models were developed regarding target responses: decolorization (Y-MB), COD (Y-COD) and TOC (Y-TOC) removal efficiencies (%). The quadratic models were estimated by CCD and ANFIS methodologies. ANFIS was implemented using Matlab/Simulink and the performances were investigated. ANFIS models performed better for catalyst N compared to catalyst M, for color, COD and TOC separately. On contrary, it performed better for catalyst M compared to catalyst N, for combinations of color, COD and TOC. The obtained RMSE and R-2 for the ANFIS networks show the effectiveness of catalyst N compared to catalyst M in Fenton oxidation process. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Pouran, Shima Rahim; Aziz, A. R. Abdul; Daud, Wan Mohd Ashri Wan] Univ Malaya, Fac Engn, Dept Chem Engn, Kuala Lumpur 50603, Malaysia.
   [Shamshirband, Shahaboddin] Univ Malaya, Fac Comp Sci & Informat Technol, Dept Comp Syst & Technol, Kuala Lumpur 50603, Malaysia.
   [Shamshirband, Shahaboddin] IAU, Dept Comp Sci, Chalous Branch, Chalous 46615397, Iran.
RP Aziz, ARA (reprint author), Univ Malaya, Fac Comp Sci & Informat Technol, Dept Comp Syst & Technol, Kuala Lumpur 50603, Malaysia.
EM azizraman@um.edu.my; shamshirband@um.edu.my
RI Engineering, Faculty/I-7935-2015; WAN DAUD, WAN MOHD ASHRI/C-1022-2010
OI Engineering, Faculty/0000-0002-4848-7052; ABDUL RAMAN, ABDUL
   AZIZ/0000-0001-7586-1903
FU University of Malaya High Impact Research Grant from the Ministry of
   Higher Education, Malaysia [HIR-MOHE-D000037-16001]
FX The authors are grateful to the University of Malaya High Impact
   Research Grant (HIR-MOHE-D000037-16001) from the Ministry of Higher
   Education, Malaysia which financially supported this work.
CR Ai LH, 2011, J HAZARD MATER, V198, P282, DOI 10.1016/j.jhazmat.2011.10.041
   Aleboyeh A, 2008, CHEM ENG PROCESS, V47, P827, DOI 10.1016/j.cep.2007.01.033
   Arami-Niya A, 2012, CHEM ENG RES DES, V90, P776, DOI 10.1016/j.cherd.2011.10.001
   Arslan-Alaton I, 2009, J PHOTOCH PHOTOBIO A, V202, P142, DOI 10.1016/j.jphotochem.2008.11.019
   Chun J, 2012, CHEMOSPHERE, V89, P1230, DOI 10.1016/j.chemosphere.2012.07.046
   Cornell R. M, 2003, IRON OXIDES STRUCTUR
   Ghafari S, 2009, J HAZARD MATER, V163, P650, DOI 10.1016/j.jhazmat.2008.07.090
   Ghotli RA, 2013, J TAIWAN INST CHEM E, V44, P192, DOI 10.1016/j.jtice.2012.10.010
   JANG JSR, 1993, IEEE T SYST MAN CYB, V23, P665, DOI 10.1109/21.256541
   Jeong J, 2005, WATER RES, V39, P2893, DOI 10.1016/j.watres.2005.5.014
   Khataee AR, 2010, DESALINATION, V258, P112, DOI 10.1016/j.desal.2010.03.028
   Liang XL, 2012, J HAZARD MATER, V199, P247, DOI 10.1016/j.jhazmat.2011.11.007
   Mitsika EE, 2013, CHEMOSPHERE, V93, P1818, DOI 10.1016/j.chemosphere.2013.06.033
   Ozkar S, 2009, APPL SURF SCI, V256, P1272, DOI 10.1016/j.apsusc.2009.10.036
   Petkovic D, 2012, EXPERT SYST APPL, V39, P9477, DOI 10.1016/j.eswa.2012.02.111
   Petrova T.M., 2011, INT REV CHEM ENG, V3, P134
   Pignatello JJ, 2006, CRIT REV ENV SCI TEC, V36, P1, DOI 10.1080/10643380500326564
   Pouran SR, 2014, J CLEAN PROD, V64, P24, DOI 10.1016/j.jclepro.2013.09.013
   Ramankutty CG, 2001, APPL CATAL A-GEN, V218, P39, DOI 10.1016/S0926-860X(01)00610-X
   Sanchez-Romeu J, 2008, BIOCHEM ENG J, V38, P1, DOI 10.1016/j.bej.2007.05.016
   Shafeeyan MS, 2012, FUEL, V94, P465, DOI 10.1016/j.fuel.2011.11.035
   Sun SP, 2014, CHEM ENG J, V244, P44, DOI 10.1016/j.cej.2014.01.039
   Sun SP, 2013, J MOL CATAL A-CHEM, V371, P94, DOI 10.1016/j.molcata.2013.01.027
   Sun SP, 2011, J MOL CATAL A-CHEM, V349, P71, DOI 10.1016/j.molcata.2011.08.022
   Sun ZX, 1998, J COLLOID INTERF SCI, V197, P151, DOI 10.1006/jcis.1997.5239
   Usman M, 2012, APPL CATAL B-ENVIRON, V117, P10, DOI 10.1016/j.apcatb.2012.01.007
   Usman M, 2012, FUEL, V96, P270, DOI 10.1016/j.fuel.2012.01.017
   Xavier S., 2013, DESALINAT WATER TREA, P1
   Xu TY, 2013, APPL SURF SCI, V280, P926, DOI 10.1016/j.apsusc.2013.05.098
   Xue XF, 2009, J HAZARD MATER, V166, P407, DOI 10.1016/j.jhazmat.2008.11.089
   Yang SJ, 2009, APPL CATAL B-ENVIRON, V89, P527, DOI 10.1016/j.apcatb.2009.01.012
   Zhong YH, 2013, J MOL CATAL A-CHEM, V372, P29, DOI 10.1016/j.molcata.2013.01.038
NR 32
TC 15
Z9 15
U1 1
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0263-2241
EI 1873-412X
J9 MEASUREMENT
JI Measurement
PD JAN
PY 2015
VL 59
BP 314
EP 328
DI 10.1016/j.measurement.2014.09.060
PG 15
WC Engineering, Multidisciplinary; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA AU8PY
UT WOS:000345859800035
DA 2018-12-27
ER

PT J
AU Paganelli, L
   Caillaud, MC
   Quentin, M
   Damiani, I
   Govetto, B
   Lecomte, P
   Karpov, PA
   Abad, P
   Chaboute, ME
   Favery, B
AF Paganelli, Laetitia
   Caillaud, Marie-Cecile
   Quentin, Michael
   Damiani, Isabelle
   Govetto, Benjamin
   Lecomte, Philippe
   Karpov, Pavel A.
   Abad, Pierre
   Chaboute, Marie-Edith
   Favery, Bruno
TI RETRACTED: Three BUB1 and BUBR1/MAD3-related spindle assembly checkpoint
   proteins are required for accurate mitosis in Arabidopsis (Retracted
   Article. See vol 212, pg 1106, 2016)
SO NEW PHYTOLOGIST
LA English
DT Article; Retracted Publication
DE cell cycle; checkpoint; giant cell; kinetochore; mitosis; nematode
ID MICROTUBULE-ASSOCIATED PROTEIN; HISTONE H3 VARIANT; CELL-CYCLE; MITOTIC
   CHECKPOINT; CHROMOSOME MISSEGREGATION; SACCHAROMYCES-CEREVISIAE; LIVING
   CELLS; KINETOCHORES; MAD2; LOCALIZATION
AB The spindle assembly checkpoint (SAC) is a refined surveillance mechanism which ensures that chromosomes undergoing mitosis do not segregate until they are properly attached to the spindle microtubules (MT). The SAC has been extensively studied in metazoans and yeast, but little is known about its role in plants. We identified proteins interacting with a MT-associated protein MAP65-3, which plays a critical role in organising mitotic MT arrays, and carried out a functional analysis of previously and newly identified SAC components. We show that Arabidopsis SAC proteins BUB3.1, MAD2, BUBR1/MAD3s and BRK1 interact with each other and with MAP65-3. We found that two BUBR1/MAD3s interacted specifically at centromeres. When stably expressed in Arabidopsis, BRK1 localised to the kinetochores during all stages of the mitotic cell cycle. Early in mitosis, BUB3.1 and BUBR1/MAD3.1 localise to the mitotic spindle, where MAP65-3 organises spindle MTs. A double-knockout mad3.1 mad3.2 mutant presented spindle MT abnormalities, chromosome misalignments on the metaphase plate and the production of lagging chromosomes and micronuclei during mitosis. We conclude that BRK1 and BUBR1/MAD3-related proteins play a key role in ensuring faithful chromosome segregation during mitosis and that their interaction with MAP65-3 may be important for the regulation of MT-chromosome attachment.
C1 [Paganelli, Laetitia; Quentin, Michael; Damiani, Isabelle; Govetto, Benjamin; Abad, Pierre; Favery, Bruno] INRA, Inst Sophia Agrobiotech, UMR 1355, F-06903 Sophia Antipolis, France.
   [Paganelli, Laetitia; Quentin, Michael; Damiani, Isabelle; Govetto, Benjamin; Abad, Pierre; Favery, Bruno] CNRS, UMR 7254, F-06903 Sophia Antipolis, France.
   [Paganelli, Laetitia; Quentin, Michael; Damiani, Isabelle; Govetto, Benjamin; Abad, Pierre; Favery, Bruno] Univ Nice Sophia Antipolis, UMR 1355, F-06903 Sophia Antipolis, France.
   [Caillaud, Marie-Cecile] John Innes Ctr, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.
   [Lecomte, Philippe] Univ Clermont Ferrand, INRA, UMR 1095, F-63039 Clermont Ferrand, France.
   [Karpov, Pavel A.] Natl Acad Sci Ukraine, Inst Food Biotechnol & Genom, Kiev, Ukraine.
   [Chaboute, Marie-Edith] Univ Strasbourg, Inst Biol Mol Plantes, Unite Propre Rech Convent Avec 2357, CNRS, F-67084 Strasbourg, France.
RP Favery, B (reprint author), INRA, Inst Sophia Agrobiotech, UMR 1355, 400 Route Chappes, F-06903 Sophia Antipolis, France.
EM favery@sophia.inra.fr
RI Caillaud, Marie-Cecile/G-9320-2018
OI Caillaud, Marie-Cecile/0000-0002-0348-7024
FU INRA; French Government (National Research Agency, ANR)
   [ANR-08-GENM-014, ANR-11-LABX-0028-01]; Ministere de la Recherche et
   l'Enseignement Superieure
FX We thank Marylin Vantard (iRTSV, Grenoble, France), Anne-Catherine
   Schmit (IBMP, Strasbourg, France), Ariane Abrieu and Anna Castro (CRBM,
   Montpellier, France) and Paulo Vieira (Evora University, Evora,
   Portugal) for fruitful discussions. We thank the Microscopy
   Platform-Sophia Agrobiotech Institut-INRA 1355-UNS-CNRS 7254-INRA
   PACA-Sophia Antipolis for access to instruments and technical advices.
   We thank Richard Cyr (Pennsylvania State University, PA, USA) for
   generously providing us with Pro<INF>35S</INF>:MBD: GFP seeds, Steve
   Henikoff for generously providing us with HTR12 antibodies and Frederic
   Berger (Temasek LifeSciences Laboratory, Singapore) for
   Pro<INF>35S</INF>: H2B: YFP and Pro<INF>35S</INF>:HTR12: GFP seeds,
   Catherine Mura for growing tobacco plants, Mansour Karimi (VIB Ghent,
   Belgium) for the plant Gateway vectors, and Imre E. Somssich (Max-Planck
   Institut, Koln, Germany) for the split-ubiquitin system. This work was
   funded by INRA and by the French Government (National Research Agency,
   ANR) through the ANR-08-GENM-014 'SCRIPS' and 'Investments for the
   Future' LABEX SIGNALIFE: program reference # ANR-11-LABX-0028-01. L.P.
   was supported by a fellowship from the Ministere de la Recherche et
   l'Enseignement Superieure.
CR Ambrose JC, 2007, PLANT CELL, V19, P2763, DOI 10.1105/tpc.107.053777
   Basu J, 1999, J CELL BIOL, V146, P13, DOI 10.1083/jcb.146.1.13
   Bolanos-Garcia VM, 2009, STRUCTURE, V17, P105, DOI 10.1016/j.str.2008.10.015
   Boruc J, 2010, PLANT CELL, V22, P1264, DOI 10.1105/tpc.109.073635
   Buffin E, 2007, NAT CELL BIOL, V9, P565, DOI 10.1038/ncb1570
   Caillaud MC, 2008, PLANT CELL, V20, P423, DOI 10.1105/tpc.107.057422
   Caillaud MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006757
   Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242
   Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6
   Daniel JA, 2006, GENETICS, V172, P53, DOI 10.1534/genetics.105.046441
   De Almeida Engler J, 2011, GENOMICS MOL GENETIC, P320
   De Almeida-Engler J, 2011, EXPLOITING GENOMICS, P369
   Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2
   Heckmann S, 2011, PLANT J, V68, P646, DOI 10.1111/j.1365-313X.2011.04715.x
   Ho CMK, 2012, PLANT CELL, V24, P2071, DOI 10.1105/tpc.111.092569
   Houben A, 2003, CURR OPIN PLANT BIOL, V6, P554, DOI 10.1016/j.pbi.2003.09.007
   Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233
   Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053
   HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3
   HUANG CS, 1969, PHYTOPATHOLOGY, V59, P447
   Hussey PJ, 2002, PLANT MOL BIOL, V50, P915, DOI 10.1023/A:1021236307508
   Jammes F, 2005, PLANT J, V44, P447, DOI 10.1111/j.1365-313X.2005.02532.x
   Janski N, 2012, PLANT CELL, V24, P1171, DOI 10.1105/tpc.111.094904
   Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500
   Karimi M, 2002, TRENDS PLANT SCI, V7, P193, DOI 10.1016/S1360-1385(02)02251-3
   Karpov PA, 2010, CYTOL GENET+, V44, P376, DOI 10.3103/S0095452710060095
   Kerscher O, 2003, MOL CELL BIOL, V23, P6406, DOI 10.1128/MCB.23.18.6406-6418.2003
   Khodjakov Alexey, 2009, Journal of Biology (London), V8, P1, DOI 10.1186/jbiol195
   Kimbara J, 2004, CHROMOSOME RES, V12, P703, DOI 10.1023/B:CHRO.0000045760.42880.8c
   Kitagawa R, 1999, NAT CELL BIOL, V1, P514, DOI 10.1038/70309
   Kiyomitsu T, 2007, DEV CELL, V13, P663, DOI 10.1016/j.devcel.2007.09.005
   Kiyomitsu T, 2011, MOL CELL BIOL, V31, P998, DOI 10.1128/MCB.00815-10
   Kosetsu K, 2010, PLANT CELL, V22, P3778, DOI 10.1105/tpc.110.077164
   Kurasawa Y, 2004, EMBO J, V23, P3237, DOI 10.1038/sj.emboj.7600347
   Lampson MA, 2005, NAT CELL BIOL, V7, P93, DOI 10.1038/ncb1208
   Lermontova I, 2008, FRONT BIOSCI-LANDMRK, V13, P5202, DOI 10.2741/3076
   Lermontova I, 2013, PLANT CELL, V25, P3389, DOI 10.1105/tpc.113.114736
   Lermontova I, 2011, CHROMOSOMA, V120, P633, DOI 10.1007/s00412-011-0338-5
   LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5
   Masoud K, 2013, PLANT J, V75, P245, DOI 10.1111/tpj.12179
   Menges M, 2005, PLANT J, V41, P546, DOI 10.1111/j.1365-313X.2004.02319.x
   Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006
   Muller S, 2004, CURR BIOL, V14, P412, DOI 10.1016/j.cub.2004.02.032
   Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163
   Musacchio A, 2011, PHILOS T R SOC B, V366, P3595, DOI 10.1098/rstb.2011.0072
   Pines J, 2011, NAT REV MOL CELL BIO, V12, P427, DOI 10.1038/nrm3132
   Rahmani Z, 2009, J CELL BIOL, V187, P597, DOI 10.1083/jcb.200905026
   Sasabe M, 2011, PLANT SIGNAL BEHAV, V6, P743, DOI 10.4161/psb.6.5.15146
   Sczaniecka M, 2008, J BIOL CHEM, V283, P23039, DOI 10.1074/jbc.M803594200
   Smertenko AP, 2008, PLANT CELL, V20, P3346, DOI 10.1105/tpc.108.063362
   Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093
   Suijkerbuijk SJE, 2012, DEV CELL, V22, P1321, DOI 10.1016/j.devcel.2012.03.009
   Syrovatkina V, 2013, CURR BIOL, V23, P2423, DOI 10.1016/j.cub.2013.10.023
   Talbert PB, 2002, PLANT CELL, V14, P1053, DOI 10.1105/tpc.010425
   Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1
   Van Leene J, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.53
   Vos JW, 2008, PLANT CELL, V20, P2783, DOI 10.1105/tpc.107.056796
   Wang M, 2012, PLANT CELL, V24, P4961, DOI 10.1105/tpc.112.105874
   Wei YC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021557
   Yu HG, 1999, J CELL BIOL, V145, P425, DOI 10.1083/jcb.145.3.425
NR 60
TC 10
Z9 10
U1 2
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0028-646X
EI 1469-8137
J9 NEW PHYTOL
JI New Phytol.
PD JAN
PY 2015
VL 205
IS 1
BP 202
EP 215
DI 10.1111/nph.13073
PG 14
WC Plant Sciences
SC Plant Sciences
GA AU4QL
UT WOS:000345596700023
PM 25262777
OA Bronze
DA 2018-12-27
ER

PT J
AU Qin, LY
   Yang, F
   Zhou, CD
   Chen, Y
   Zhang, HS
   Su, ZD
AF Qin, Lingyun
   Yang, Fei
   Zhou, Cindy
   Chen, Yao
   Zhang, Huashan
   Su, Zhengding
TI RETRACTED: Efficient Reactivation of p53 in Cancer Cells by a Dual
   MdmX/Mdm2 Inhibitor (Retracted article. See vol. 137, pg. 14546, 2015)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article; Retracted Publication
ID SUPPRESSOR TRANSACTIVATION DOMAIN; IN-VIVO; HIGH-AFFINITY; MDM2;
   THERAPY; PATHWAY; DERIVATIVES; ACTIVATION; COMPLEX; MUTANT
AB The aberrant interaction between p53 and Mdm2/MdmX is an attractive target for cancer drug discovery because the overexpression of Mdm2 and/or MdmX ultimately impairs the function of p53 in approximately half of all human cancers. Recent studies have shown that inhibition of both Mdm2 and MdmX is more efficient than that of a single target in promoting cellular apoptosis in cancers. In this study, we demonstrate that a dual small-molecule antagonist of Mdm2/MdmX can efficiently reactivate the p53 pathway in model cancer cells overexpressing MdmX and/or Mdm2. The dual antagonist was rationally designed based on segmental mutational analysis of the N-terminal domain of MdmX and the crystal structure of the N-terminal domain of Mdm2 in complex with nutlin-3a (an Mdm2-specific inhibitor). The current work establishes a small molecule therapeutic candidate that targets cancers overexpressing Mdm2 and/or MdmX.
C1 [Qin, Lingyun; Yang, Fei; Chen, Yao; Zhang, Huashan; Su, Zhengding] Hubei Univ Technol, Dept Biotechnol, Wuhan 430068, Peoples R China.
   [Qin, Lingyun; Yang, Fei; Chen, Yao; Zhang, Huashan; Su, Zhengding] Hubei Univ Technol, Collaborat Innovat Ctr Ind Fermentat, Wuhan 430068, Peoples R China.
   [Zhou, Cindy; Su, Zhengding] Amersino Biodevelop Inc, Waterloo, ON N2L 3G1, Canada.
   [Su, Zhengding] St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA.
RP Su, ZD (reprint author), Hubei Univ Technol, Dept Biotechnol, Wuhan 430068, Peoples R China.
EM z2su@uwaterloo.ca
FU Key Laboratory of Fermentation Engineering (Ministry of Education)
FX We thank Dr. David Duda for his excellent technical assistance. This
   work was partially funded by the Key Laboratory of Fermentation
   Engineering (Ministry of Education).
CR Anil B, 2013, ACTA CRYSTALLOGR D, V69, P1358, DOI 10.1107/S0907444913004459
   Bharatham N, 2014, J CHEM INF MODEL, V54, P648, DOI 10.1021/ci4004656
   Blackburn TJ, 2013, MEDCHEMCOMM, V4, P1297, DOI 10.1039/c3md00161j
   Carrillo AM, 2015, ONCOGENE, V34, P846, DOI 10.1038/onc.2014.27
   Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110
   Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174
   Davis TA, 2011, CHEM SCI, V2, P1076, DOI 10.1039/c1sc00061f
   Dutta K, 2004, BIOCHEMISTRY-US, V43, P8094, DOI 10.1021/bi030268d
   FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280
   Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111
   Graves B, 2012, P NATL ACAD SCI USA, V109, P11788, DOI 10.1073/pnas.1203789109
   Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108
   Kallen J, 2009, J BIOL CHEM, V284, P8803, DOI 10.1074/jbc.M809096200
   Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126
   Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050
   Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948
   Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194
   Macchiarulo A, 2011, MEDCHEMCOMM, V2, P455, DOI 10.1039/c0md00238k
   MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004
   Michelsen K, 2012, J AM CHEM SOC, V134, P17059, DOI 10.1021/ja305839b
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641
   Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004
   Pazgiera M, 2009, P NATL ACAD SCI USA, V106, P4665, DOI 10.1073/pnas.0900947106
   Popowicz GM, 2008, CELL CYCLE, V7, P2441, DOI 10.4161/cc.6365
   Popowicz GM, 2007, CELL CYCLE, V6, P2386, DOI 10.4161/cc.6.19.4740
   Popowicz GM, 2011, ANGEW CHEM INT EDIT, V50, P2680, DOI 10.1002/anie.201003863
   Su Z. D., 2012, S BIOMOLECULAR STRUC
   Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541
   Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430
   Wade M, 2009, MOL CANCER RES, V7, P1, DOI 10.1158/1541-7786.MCR-08-0423
   Zak K, 2013, EXPERT OPIN THER PAT, V23, P425, DOI 10.1517/13543776.2013.765405
   Zhuang CL, 2012, J MED CHEM, V55, P9630, DOI 10.1021/jm300969t
NR 34
TC 10
Z9 12
U1 4
U2 63
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD DEC 31
PY 2014
VL 136
IS 52
BP 18023
EP 18033
DI 10.1021/ja509223m
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA AY2SB
UT WOS:000347438300025
PM 25453499
DA 2018-12-27
ER

PT J
AU Boudaghpour, S
   Bagheri, M
   Bagheri, Z
AF Boudaghpour, Siamak
   Bagheri, Majid
   Bagheri, Zahra
TI RETRACTED: Estimation of flood environmental effects using flood zone
   mapping techniques in Halilrood Kerman, Iran (Retracted article. See
   vol. 13, 32, 2015)
SO JOURNAL OF ENVIRONMENTAL HEALTH SCIENCE AND ENGINEERING
LA English
DT Article; Retracted Publication
DE Catchment area; Environmental damages; HEC-HMS; HEC-RAS; GIS; Jiroft dam
ID WATER-QUALITY; HEC-HMS; RIVER; INUNDATION; MODELS; SIMULATION;
   MANAGEMENT; RUNOFF; BASIN; GIS
AB High flood occurrences with large environmental damages have a growing trend in Iran. Dynamic movements of water during a flood cause different environmental damages in geographical areas with different characteristics such as topographic conditions. In general, environmental effects and damages caused by a flood in an area can be investigated from different points of view. The current essay is aiming at detecting environmental effects of flood occurrences in Halilrood catchment area of Kerman province in Iran using flood zone mapping techniques. The intended flood zone map was introduced in four steps. Steps 1 to 3 pave the way to calculate and estimate flood zone map in the understudy area while step 4 determines the estimation of environmental effects of flood occurrence. Based on our studies, wide range of accuracy for estimating the environmental effects of flood occurrence was introduced by using of flood zone mapping techniques. Moreover, it was identified that the existence of Jiroft dam in the study area can decrease flood zone from 260 hectares to 225 hectares and also it can decrease 20% of flood peak intensity. As a result, 14% of flood zone in the study area can be saved environmentally.
C1 [Boudaghpour, Siamak; Bagheri, Majid] KN Toosi Univ Technol, Dept Civil Engn, Tehran, Iran.
   [Bagheri, Zahra] PUK Univ, Dept & Fac Basic Sci, Kermanshah, Iran.
RP Bagheri, M (reprint author), KN Toosi Univ Technol, Dept Civil Engn, Vanak Sq, Tehran, Iran.
EM bagherimajead@yahoo.com
CR Alexandrov Y, 2003, J ARID ENVIRON, V53, P73, DOI 10.1006/jare.2002.1020
   Amini A, 2011, ARAB J SCI ENG, V36, P713, DOI 10.1007/s13369-011-0075-3
   Anderson ML, 2002, J HYDROL ENG, V7, P312, DOI 10.1061/(ASCE)1084-0699(2002)7:4(312)
   Andrew D. E., 2005, STANDARD METHODS EXA
   Aronica GT, 2012, PHYS CHEM EARTH, V42-44, P119, DOI 10.1016/j.pce.2011.04.001
   Auynirundronkool K, 2012, INT J APPL EARTH OBS, V14, P245, DOI 10.1016/j.jag.2011.09.017
   Bajwa H, 2002, P 22 ESRI US C
   Baky AA, 2012, APCBEE PROC, V1, P318, DOI 10.1016/j.apcbee.2012.03.052
   Boardman J, 2003, ENVIRON SCI POLICY, V6, P69, DOI 10.1016/S1462-9011(02)00125-9
   Charrier R, 2012, APPL GEOGR, V34, P38, DOI 10.1016/j.apgeog.2011.10.012
   Claret C, 1997, MICROB ECOL
   De-Campos AB, 2009, SOIL SCI SOC AM J, V73, P550, DOI 10.2136/sssaj2007.0425
   Dikbas F, 2013, ARAB J SCI ENG, V38, P1313, DOI 10.1007/s13369-013-0542-0
   Dunkerley D, 1999, HYDROL PROCESS, V13, P1577, DOI 10.1002/(SICI)1099-1085(19990815)13:11<1577::AID-HYP827>3.0.CO;2-L
   Elmolla ES, 2011, J HAZARD MATER, V192, P1418, DOI 10.1016/j.jhazmat.2011.06.057
   Erdlenbruch K, 2009, J ENVIRON MANAGE, V91, P363, DOI 10.1016/j.jenvman.2009.09.002
   Fan C, 2009, J ENVIRON MANAGE, V90, P1824, DOI 10.1016/j.jenvman.2008.11.011
   Feldman A. D., 2000, HYDROLOGIC MODELING
   Habib-ur-Rehman, 2012, ARAB J SCI ENG, V37, P945, DOI 10.1007/s13369-012-0227-0
   Hadadin N, 2013, ARAB J SCI ENG, V38, P3275, DOI 10.1007/s13369-013-0812-x
   Halwatura D, 2013, ENVIRON MODELL SOFTW, V46, P155, DOI 10.1016/j.envsoft.2013.03.006
   Haque C. E., 2002, GLOB ENVIRON CHANG P, V4, P87
   Hinderer M, 2012, SEDIMENT GEOL, V280, P21, DOI 10.1016/j.sedgeo.2012.03.009
   Horritt MS, 2002, J HYDROL, V268, P87, DOI 10.1016/S0022-1694(02)00121-X
   Howitt JA, 2007, ECOL MODEL, V203, P229, DOI 10.1016/j.ecolmodel.2006.11.017
   Khazaei MR, 2013, ARAB J SCI ENG, P1
   Knebl MR, 2005, J ENVIRON MANAGE, V75, P325, DOI 10.1016/j.jenvman.2004.11.024
   Lianqing X., 2011, PROCEDIA ENV SCI, V12, P1089
   Lind N, 2004, J AM WATER RESOUR AS, V40, P89, DOI 10.1111/j.1752-1688.2004.tb01012.x
   Liu XS, 2012, ENRGY PROCED, V16, P1225, DOI 10.1016/j.egypro.2012.01.195
   Marston RA, 2005, GEOMORPHOLOGY, V71, P79, DOI 10.1016/j.geomorph.2005.03.005
   Mauclaire L, 1998, HYDROBIOLOGIA, V389, P141, DOI 10.1023/A:1003566101271
   Metcalf I., 2003, WASTEWATER ENG TREAT
   Sanders BF, 2007, ADV WATER RESOUR, V30, P1831, DOI 10.1016/j.advwatres.2007.02.005
   Scanlon BR, 2002, HYDROGEOL J, V10, P18, DOI 10.1007/s10040-001-0176-2
   Siddiqui QTM, 2011, ARAB J SCI ENG, V36, P1203, DOI 10.1007/s13369-011-0112-2
   Smith P.N., 1997, TRANSPORT RES, V1599, P118, DOI DOI 10.3141/1599-15
   Sun DP, 2008, J HYDRODYN, V20, P662, DOI 10.1016/S1001-6058(08)60110-9
   Svendsen J, 2003, SEDIMENT GEOL, V160, P7, DOI 10.1016/S0037-0738(02)00334-2
   Tariq MAUR, 2012, PHYS CHEM EARTH, V47-48, P11, DOI 10.1016/j.pce.2011.08.014
   Vazquez RF, 2007, J HYDROL, V334, P73, DOI 10.1016/j.jhydrol.2006.10.001
   Xia C, 2012, ENVIRON INNOV SOC TR, V5, P60, DOI 10.1016/j.eist.2012.10.001
NR 42
TC 2
Z9 2
U1 3
U2 19
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 2052-336X
J9 J ENVIRON HEALTH SCI
JI J. Environ. Health Sci. Eng
PD DEC 27
PY 2014
VL 12
AR 153
DI 10.1186/s40201-014-0153-z
PG 18
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA CC9YM
UT WOS:000350727100001
PM 25649059
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Sun, SJ
   Zhang, GQ
   Wu, ZY
   Shi, WW
   Yang, B
   Li, Y
AF Sun, Shengjie
   Zhang, Guoqing
   Wu, Zhiyong
   Shi, Weiwei
   Yang, Bo
   Li, Ying
TI RETRACTED: MicroRNA-302a Functions as a Putative Tumor Suppressor in
   Colon Cancer by Targeting Akt (Retracted article. See vol. 10, e0139497,
   2015)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID STEM-CELLS; SELF-RENEWAL; CARCINOMA; PROLIFERATION; REPRESSION
AB Micro RNAs (miRNAs) are important regulators involved in various physical and pathological processes, including cancer. The miRNA-302 family has been documented as playing a critical role in carcinogenesis. In this study, we investigated the role of miRNA-302a in colon cancer. MiRNA-302a expression was detected in 44 colon cancer tissues and 10 normal colon tissues, and their clinicopathological significance was analyzed. Cell proliferation and cell cycle analysis were performed on colon cancer cells that stably expressed miRNA-302a. The target gene of miRNA-302a and the downstream pathway were further investigated. Compared with normal colon tissues, miRNA-302a expression was downregulated in colon cancer tissues. Overexpression of miRNA-302a induced G1/S cell cycle arrest in colon cancer cells, and suppressed colon cancer cell proliferation both in vitro and in vivo. Furthermore, miRNA-302a inhibited AKT expression by directly binding to its 3' untranslated region, resulting in subsequent alterations of the AKT-GSK3 beta-cyclin D1 pathway. These results reveal miRNA-302a as a tumor suppressor in colon cancer, suggesting that miRNA-302a may be used as a potential target for therapeutic intervention in colon cancer.
C1 [Sun, Shengjie; Zhang, Guoqing; Wu, Zhiyong; Shi, Weiwei; Yang, Bo; Li, Ying] Gen Hosp Peoples Liberat Army, Dept Oncol, Beijing 100853, Peoples R China.
RP Li, Y (reprint author), Gen Hosp Peoples Liberat Army, Dept Oncol, Beijing 100853, Peoples R China.
EM Marydong001@aliyun.com
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bourguignon LYW, 2012, J BIOL CHEM, V287, P32800, DOI 10.1074/jbc.M111.308528
   Cai N, 2013, RNA, V19, P85, DOI 10.1261/rna.035295.112
   Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08
   Chang GJ, 2012, DIS COLON RECTUM, V55, P831, DOI 10.1097/DCR.0b013e3182567e13
   Chen WQ, 2013, CHINESE J CANCER RES, V25, P10, DOI 10.3978/j.issn.1000-9604.2012.12.04
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834
   Fareh M, 2012, CELL DEATH DIFFER, V19, P232, DOI 10.1038/cdd.2011.89
   FIDLER IJ, 1990, CANCER RES, V50, P6130
   Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698
   Hu SJ, 2013, STEM CELLS, V31, P259, DOI 10.1002/stem.1278
   Huang JX, 2012, ONCOL LETT, V4, P607, DOI 10.3892/ol.2012.814
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Liang ZX, 2013, PHARM RES-DORDR, V30, P1008, DOI 10.1007/s11095-012-0936-9
   Lin SL, 2010, CANCER RES, V70, P9473, DOI 10.1158/0008-5472.CAN-10-2746
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Toker A, 2014, ADV BIOL REGULATION
   Wang LM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-448
   Zhu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032170
NR 21
TC 3
Z9 5
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2014
VL 9
IS 12
AR e115980
DI 10.1371/journal.pone.0115980
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AX9RO
UT WOS:000347239900123
PM 25542007
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Wang, JG
   Cai, ZD
   Liu, JJ
AF Wang, Jianguang
   Cai, Zhengdong
   Liu, Junjian
TI RETRACTED: Microarray analysis for differentially expressed genes of
   patients undergoing total knee arthroplasty with ischemia
   preconditioning (Retracted article. See vol. 10, 45, 2015)
SO JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
LA English
DT Article; Retracted Publication
DE Ischemia preconditioning; microRNA; Transcriptional factor;
   Protein-protein interaction network
ID GLYCOGEN-SYNTHASE KINASE-3-BETA; REPERFUSION INJURY; MYOCARDIAL
   ISCHEMIA/REPERFUSION; SKELETAL-MUSCLE; PROTECTION; APOPTOSIS;
   PHOSPHORYLATION; PATHWAY; CARDIOPROTECTION; ADAPTATION
AB Background: Ischemia preconditioning (IPC) has been proved as a powerful method of protecting tissues against ischemia reperfusion insults. We aimed to elucidate the mechanism of IPC in ischemia reperfused tissues.
   Methods: GSE21164 containing 16 muscle biopsies taken from the operative knee of four IPC-treated patients and four control at the onset of surgery (T = 0) and 1 h into surgery (T = 1) undergoing primary total knee arthroplasty was downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) between IPC group and control were screened with Limma package in R language. KEGG pathway enrichment analysis was performed by the DAVID online tool. Meanwhile, potential regulatory microRNAs (miRNAs) for downregulated DEGs and targets of transcription factors for upregulated DEGs were screened out. Based on the above DEGs, protein-protein interaction (PPI) networks were constructed by the STRING software.
   Results: Significantly upregulated DEGs at T1 were mainly enriched in asthma and p53 signaling pathway. Meanwhile, significantly enriched transcriptional factor NOTCH1 at T1 and GABP at T0 were obtained. Moreover, miRNA analysis showed that targets of miR141/200a were enriched in downregulated DEGs both at T0 and T1. Mostly, RPA1 and JAK2 in PPI network at T1 were with higher degree.
   Conclusions: In our study, obtained DEGs, regulatory transcriptional factors, and miRNA might play a vital role in the protection of ischemia reperfusion injury. This finding will provide a deeper understanding to the mechanism of IPC.
C1 [Wang, Jianguang] Nanjing Med Univ, Affiliated Shanghai Peoples Hosp 10, Shanghai 200080, Peoples R China.
   [Wang, Jianguang; Liu, Junjian] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Orthoped, Shanghai 200072, Peoples R China.
   [Cai, Zhengdong] Nanjing Med Univ, Affiliated Shanghai Peoples Hosp 1, Shanghai 200080, Peoples R China.
   [Cai, Zhengdong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Orthoped, Shanghai 200080, Peoples R China.
   [Cai, Zhengdong; Liu, Junjian] Shanghai First Peoples Hosp, Dept Orthoped, Shanghai 200080, Peoples R China.
RP Cai, ZD (reprint author), Nanjing Med Univ, Affiliated Shanghai Peoples Hosp 1, Shanghai 200080, Peoples R China.
EM amarantine@163.com; junjianliu0917@163.com
FU National Natural Science Foundation of China [31370986]
FX This study was supported by the National Natural Science Foundation of
   China (No. 31370986).
CR Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403
   Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265
   BEYERSDORF F, 1991, J CARDIOVASC SURG, V32, P664
   Bolli R, 2003, TRENDS CARDIOVAS MED, V13, P72, DOI 10.1016/S1050-1738(02)00230-X
   Chen Shenxi, 1999, Hunan Yike Daxue Xuebao, V24, P357
   Choi PS, 2008, NEURON, V57, P41, DOI 10.1016/j.neuron.2007.11.018
   Cinel I, 2003, SHOCK, V19, P588, DOI 10.1097/01.shk.0000055817.40894.84
   Clavien PA, 2003, ANN SURG, V238, P843, DOI 10.1097/01.sla.0000098620.27623.7d
   Cohen MV, 2000, ANNU REV PHYSIOL, V62, P79, DOI 10.1146/annurev.physiol.62.1.79
   Cohen O, 1999, J CELL BIOL, V146, P141
   Dawn B, 2004, CARDIOVASC RES, V64, P61, DOI 10.1016/j.cardiores.2004.05.011
   DEUTSCH E, 1990, CIRCULATION, V82, P2044, DOI 10.1161/01.CIR.82.6.2044
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   GOTO M, 1995, CIRC RES, V77, P611, DOI 10.1161/01.RES.77.3.611
   GRACE PA, 1994, BRIT J SURG, V81, P637, DOI 10.1002/bjs.1800810504
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Hattori R, 2001, J MOL CELL CARDIOL, V33, P1929, DOI 10.1006/jmcc.2001.1456
   Hausenloy DJ, 2008, CARDIOVASC RES, V79, P377, DOI 10.1093/cvr/cvn114
   Hecker JG, 2011, CELL STRESS CHAPERON, V16, P119, DOI 10.1007/s12192-010-0224-8
   HOSHI M, 1995, J BIOCHEM-TOKYO, V118, P683, DOI 10.1093/oxfordjournals.jbchem.a124965
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jenkins DP, 1997, HEART, V77, P314, DOI 10.1136/hrt.77.4.314
   Kamphuis W, 2007, MOL VIS, V13, P1892
   Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466
   Lee ST, 2010, STROKE, V41, P1646, DOI 10.1161/STROKEAHA.110.579649
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Li JS, 2012, MOL NEUROBIOL, V45, P200, DOI 10.1007/s12035-011-8231-z
   LIU GS, 1991, CIRCULATION, V84, P350, DOI 10.1161/01.CIR.84.1.350
   Murphy T, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-46
   MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124
   Otani H, 2008, ANTIOXID REDOX SIGN, V10, P207, DOI 10.1089/ars.2007.1679
   Pei HF, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0373-x
   Rudiger HA, 2002, GASTROENTEROLOGY, V122, P202, DOI 10.1053/gast.2002.30304
   Saita Y, 2002, BRIT J PLAST SURG, V55, P241, DOI 10.1054/bjps.2002.3809
   Sha Y, 2014, EUR REV MED PHARMACO, V18, P1559
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Sola A, 2000, TRANSPLANTATION, V69, P767
   Stokman G, 2010, NEPHROL DIAL TRANSPL, V25, P3852, DOI 10.1093/ndt/gfq311
   Sun NK, 2012, BIOCHEM J, V444, P303, DOI 10.1042/BJ20112223
   Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007
   Takeshita K, 2007, CIRC RES, V100, P70, DOI 10.1161/01.RES.0000254788.47304.6e
   Tong HY, 2000, CIRC RES, V87, P309, DOI 10.1161/01.RES.87.4.309
   Tong HY, 2002, CIRC RES, V90, P377, DOI 10.1161/01.RES.0000012567.95445.55
   Weinbrenner C, 1997, J MOL CELL CARDIOL, V29, P2383, DOI 10.1006/jmcc.1997.0473
   Yadav SS, 1999, HEPATOLOGY, V30, P1223, DOI 10.1002/hep.510300513
   Yang QZ, 2012, ANESTHESIOLOGY, V117, P996, DOI 10.1097/ALN.0b013e31826cb469
   YTREHUS K, 1994, AM J PHYSIOL, V266, pH1145
NR 49
TC 2
Z9 2
U1 2
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-799X
J9 J ORTHOP SURG RES
JI J. Orthop. Surg. Res.
PD DEC 12
PY 2014
VL 9
AR 133
DI 10.1186/s13018-014-0133-0
PG 7
WC Orthopedics
SC Orthopedics
GA CB3XB
UT WOS:000349561600001
PM 25496472
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU LaCour, MJ
   Green, DP
AF LaCour, Michael J.
   Green, Donald P.
TI RETRACTED: When contact changes minds: An experiment on transmission of
   support for gay equality (Retracted article. See vol 348, pg 1100, 2015)
SO SCIENCE
LA English
DT Article; Retracted Publication
ID INTERGROUP CONTACT; HYPOTHESIS; PREJUDICE
AB Can a single conversation change minds on divisive social issues, such as same-sex marriage? A randomized placebo-controlled trial assessed whether gay (n = 22) or straight (n = 19) messengers were effective at encouraging voters (n = 972) to support same-sex marriage and whether attitude change persisted and spread to others in voters' social networks. The results, measured by an unrelated panel survey, show that both gay and straight canvassers produced large effects initially, but only gay canvassers' effects persisted in 3-week, 6-week, and 9-month follow-ups. We also find strong evidence of within-household transmission of opinion change, but only in the wake of conversations with gay canvassers. Contact with gay canvassers further caused substantial change in the ratings of gay men and lesbians more generally. These large, persistent, and contagious effects were confirmed by a follow-up experiment. Contact with minorities coupled with discussion of issues pertinent to them is capable of producing a cascade of opinion change.
C1 [LaCour, Michael J.] Univ Calif Los Angeles, Dept Polit Sci, Los Angeles, CA 90024 USA.
   [Green, Donald P.] Columbia Univ, Dept Polit Sci, New York, NY 10027 USA.
RP LaCour, MJ (reprint author), Univ Calif Los Angeles, Dept Polit Sci, Los Angeles, CA 90024 USA.
RI Green, Donald/E-4565-2010
OI Green, Donald/0000-0002-8850-438X
FU Williams Institute; Ford Foundation; Evelyn and Walter Haas, Jr., Fund
FX M.J.L. received research funding from the Williams Institute, Ford
   Foundation, and Evelyn and Walter Haas, Jr., Fund, which bear no
   responsibility for the findings or interpretations given here.
   Replication data and accompanying R code are available at OpenICPSR
   (http://doi.org/10.3886/E19260V1). Neither of the authors is affiliated
   with the Los Angeles LGBT Center or received compensation for this
   research. The experiments reported here were registered at the
   Experiments in Governance and Politics site before the launch of each
   study. This research was approved by the UCLA institutional review
   board, case no. 12-001750.
CR Allport G. W., 1954, NATURE PREJUDICE
   Bond RM, 2012, NATURE, V489, P295, DOI 10.1038/nature11421
   Gerber A. S., 2012, FIELD EXPT DESIGN AN
   Gile KJ, 2010, SOCIOL METHODOL, V40, P285, DOI 10.1111/j.1467-9531.2010.01223.x
   Hewstone M, 2011, BRIT J SOC PSYCHOL, V50, P374, DOI 10.1111/j.2044-8309.2011.02047.x
   Hitlin P., 2013, NEWS COVERAGE CONVEY
   Jackman S., 2012, COMMON CONTENT CODEB
   Lewin K., 1952, READINGS SOCIAL PSYC
   Paluck EL, 2009, ANNU REV PSYCHOL, V60, P339, DOI 10.1146/annurev.psych.60.110707.163607
   Pettigrew TF, 2006, J PERS SOC PSYCHOL, V90, P751, DOI 10.1037/0022-3514.90.5.751
   Scarberry NC, 1997, PERS SOC PSYCHOL B, V23, P1291, DOI 10.1177/01461672972312006
   Wright SC, 1997, J PERS SOC PSYCHOL, V73, P73, DOI 10.1037/0022-3514.73.1.73
NR 12
TC 39
Z9 41
U1 1
U2 66
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD DEC 12
PY 2014
VL 346
IS 6215
BP 1366
EP 1369
DI 10.1126/science.1256151
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AW3MA
UT WOS:000346189600051
PM 25504721
DA 2018-12-27
ER

PT J
AU Hodges, TK
   Cosme, LV
   Athrey, G
   Pathikonda, S
   Takken, W
   Slotman, MA
AF Hodges, Theresa K.
   Cosme, Luciano V.
   Athrey, Giridhar
   Pathikonda, Sharmila
   Takken, Willem
   Slotman, Michel A.
TI RETRACTED: Species-specific chemosensory gene expression in the
   olfactory organs of the malaria vector Anopheles gambiae (Retracted
   article. See vol. 16, 572, 2015)
SO BMC GENOMICS
LA English
DT Article; Retracted Publication
ID ODORANT-BINDING-PROTEIN; SENSU-STRICTO DIPTERA; YELLOW-FEVER MOSQUITO;
   L-LACTIC ACID; HOST-SEEKING; HUMAN-SWEAT; DROSOPHILA-MELANOGASTER;
   MOLECULAR-BASIS; AEDES-AEGYPTI; BEHAVIOR
AB Background: The malaria mosquito Anopheles gambiae has a high preference for human hosts, a characteristic that contributes greatly to its capacity for transmitting human malaria. A sibling species, An. quadriannulatus, has a quite different host preference and feeds mostly on bovids. For this reason it does not contribute to human malaria transmission. Host seeking in mosquitoes is modulated by the olfactory system, which is primarily housed in the antennae and maxillary palps. Therefore, the detection of differing host odors by sibling species may be reflected in the expression level of the olfactory genes involved. Accordingly, we compared the transcriptomes of the antennae and maxillary palps of An. gambiae and An. quadriannulatus.
   Results: We identified seven relatively abundant olfactory receptors, nine ionotropic receptors and three odorant binding proteins that are substantially up-regulated in An. gambiae antennae. Interestingly, we find that the maxillary palps of An. gambiae contain a species-specific olfactory receptor, Or52, and five An. gambiae-specific gustatory receptors (AgGr48-52) that are relatively abundant. These five gustatory receptors are also expressed in An. gambiae antennae, although at lower level, indicating a likely role in olfaction, rather than gustation. We also document an approximately three-fold higher overall expression of olfaction genes in the maxillary palps of An. quadriannulatus, indicating an important role of this organ in the olfaction system of this species. Finally, the expression of the CO2 receptor genes is five to six-fold higher in the zoophilic An. quadriannulatus, implying a much higher sensitivity for detecting CO2.
   Conclusions: These results identify potential human host preference genes in the malaria vector An. gambiae. Interestingly, species-specific expression of several gustatory receptors in the olfactory organs indicate a role in olfaction rather than gustation. Additionally, a more expansive role for maxillary palps in olfaction is implicated than previously thought, albeit more so in the zoophilic An. quadriannulatus.
C1 [Hodges, Theresa K.; Cosme, Luciano V.; Athrey, Giridhar; Pathikonda, Sharmila; Slotman, Michel A.] Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA.
   [Takken, Willem] Wageningen Univ, Entomol Lab, NL-6700 AP Wageningen, Netherlands.
RP Slotman, MA (reprint author), Texas A&M Univ, Dept Entomol, College Stn, TX 77843 USA.
EM maslotman@tamu.edu
FU NIH/NIAID [1R01 AI085079]
FX We are grateful to Leon Westerd for assistance with colony maintenance,
   to Jeroen Spitzen for providing odor samples, and to Craig Coates for
   providing rearing space. We also thank two anonymous reviewers for their
   help in improving an earlier version of this manuscript. This work was
   supported by NIH/NIAID grant 1R01 AI085079 to MAS.
CR Abuin L, 2011, NEURON, V69, P44, DOI 10.1016/j.neuron.2010.11.042
   Auer PL, 2010, GENETICS, V185, P405, DOI 10.1534/genetics.110.114983
   Bernier UR, 2000, ANAL CHEM, V72, P747, DOI 10.1021/ac990963k
   Biessmann H, 2005, INSECT MOL BIOL, V14, P575, DOI 10.1111/j.1365-2583.2005.00590.x
   Braks MAH, 1999, J CHEM ECOL, V25, P663, DOI 10.1023/A:1020970307748
   Braks MAH, 2001, PHYSIOL ENTOMOL, V26, P142, DOI 10.1046/j.1365-3032.2001.00227.x
   Carey AF, 2010, NATURE, V464, P66, DOI 10.1038/nature08834
   Coetzee M, 2013, ZOOTAXA, V3619, P246, DOI 10.11646/zootaxa.3619.3.2
   COLUZZI M, 1984, B WORLD HEALTH ORGAN, V62, P107
   Conesa A, 2005, BIOINFORMATICS, V21, P3674, DOI 10.1093/bioinformatics/bti610
   Croset V, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001064
   Dekker T, 2006, CURR BIOL, V16, P101, DOI 10.1016/j.cub.2005.11.075
   Dekker T, 2002, MED VET ENTOMOL, V16, P91, DOI 10.1046/j.0269-283x.2002.00345.x
   Dekker T, 1998, MED VET ENTOMOL, V12, P136, DOI 10.1046/j.1365-2915.1998.00073.x
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Foster WA, 2004, B ENTOMOL RES, V94, P145, DOI 10.1079/BER2003288
   Gillies MT, 1987, ANOPHELINAE AFRICA S, P55
   Hallem EA, 2004, NATURE, V427, P212, DOI 10.1038/427212a
   Hill CA, 2002, SCIENCE, V298, P176, DOI 10.1126/science.1076196
   Ibn-Salem J, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0423-1, 10.1186/s13059-014-0550-8]
   Jones WD, 2007, NATURE, V445, P86, DOI 10.1038/nature05466
   Kopp A, 2008, MOL BIOL EVOL, V25, P1081, DOI 10.1093/molbev/msn055
   Leal WS, 2013, ANNU REV ENTOMOL, V58, P373, DOI 10.1146/annurev-ento-120811-153635
   Li ZX, 2005, ARCH INSECT BIOCHEM, V58, P175, DOI 10.1002/arch.20047
   Liu C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000467
   Lu T, 2007, CURR BIOL, V17, P1533, DOI 10.1016/j.cub.2007.07.062
   Matsuo T, 2007, PLOS BIOL, V5, P985, DOI 10.1371/journal.pbio.0050118
   McBride CS, 2007, GENETICS, V177, P1395, DOI 10.1534/genetics.107.078683
   McBride CS, 2007, P NATL ACAD SCI USA, V104, P4996, DOI 10.1073/pnas.0608424104
   Mukabana WR, 2012, J CHEM ECOL, V38, P235, DOI 10.1007/s10886-012-0088-8
   Patel RK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030619
   Pates HV, 2014, MED VET ENTOMOL, V28, P68, DOI 10.1111/mve.12070
   Pates HV, 2005, ENTOMOL EXP APPL, V114, P153, DOI 10.1111/j.1570-7458.2005.00249.x
   Pates HV, 2001, MED VET ENTOMOL, V15, P293, DOI 10.1046/j.0269-283x.2001.00310.x
   Pates HV, 2001, B ENTOMOL RES, V91, P289, DOI 10.1079/BER200198
   Pitts RJ, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-26
   Pitts RJ, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-271
   Pitts RJ, 2004, P NATL ACAD SCI USA, V101, P5058, DOI 10.1073/pnas.0308146101
   Ramon R, 2001, J BIOL CHEM, V276, P7150, DOI 10.1074/jbc.M010368200
   Rinker DC, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-749
   Rund SSC, 2011, P NATL ACAD SCI USA, V108, pE421, DOI 10.1073/pnas.1100584108
   SHARP BL, 1984, J ENTOMOL SOC S AFR, V47, P251
   Siju KP, 2014, J COMP NEUROL, V522, P592, DOI 10.1002/cne.23434
   Smallegange RC, 2005, CHEM SENSES, V30, P145, DOI 10.1093/chemse/bji010
   Spitzen J, 2008, PHYSIOL ENTOMOL, V33, P116, DOI 10.1111/j.1365-3032.2008.00612.x
   Syed Z, 2007, CHEM SENSES, V32, P727, DOI 10.1093/chemse/bjm040
   Takken W, 1999, ANNU REV ENTOMOL, V44, P131, DOI 10.1146/annurev.ento.44.1.131
   Takken W, 1998, J MED ENTOMOL, V35, P639, DOI 10.1093/jmedent/35.5.639
   TAKKEN W, 1991, INSECT SCI APPL, V12, P287, DOI 10.1017/S1742758400020816
   Takken W, 1999, T ROY SOC TROP MED H, V93, P578, DOI 10.1016/S0035-9203(99)90054-8
   van den Broek IVF, 1999, J INSECT PHYSIOL, V45, P1001, DOI 10.1016/S0022-1910(99)00081-5
   Verhulst NO, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-28
   Verhulst NO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015829
   Vogt RG, 2002, J CHEM ECOL, V28, P2371, DOI 10.1023/A:1021009311977
   Wang GR, 2010, P NATL ACAD SCI USA, V107, P4418, DOI 10.1073/pnas.0913392107
   Xia YF, 2008, P NATL ACAD SCI USA, V105, P6433, DOI 10.1073/pnas.0801007105
   Xu PX, 2003, INSECT MOL BIOL, V12, P549, DOI 10.1046/j.1365-2583.2003.00440.x
   Xu PX, 2005, NEURON, V45, P193, DOI 10.1016/j.neuron.2004.12.031
   Zhang YLV, 2013, SCIENCE, V340, P1334, DOI 10.1126/science.1234133
   Zhou JJ, 2004, GENE, V327, P117, DOI 10.1016/j.gene.2003.11.007
   Zwiebel LJ, 2004, INSECT BIOCHEM MOLEC, V34, P645, DOI 10.1016/j.ibmb.2004.03.017
NR 61
TC 9
Z9 10
U1 3
U2 43
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD DEC 11
PY 2014
VL 15
AR 1089
DI 10.1186/1471-2164-15-1089
PG 16
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA AX0WQ
UT WOS:000346671000001
PM 25495232
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yang, JM
   Wang, NF
   Tong, XS
   Ye, XH
   Zhou, L
   Tong, GX
   Shen, Y
   Lv, SZ
AF Yang, Jianmin
   Wang, Ningfu
   Tong, Xiaoshan
   Ye, Xianhua
   Zhou, Liang
   Tong, Guoxin
   Shen, Yun
   Lv, Shuzheng
TI RETRACTED: Impact of guidewire selection and operator expertise on
   radiation exposure in transradial angiography (Retracted article. See
   vol. 10, pg. 42, 2015)
SO JOURNAL OF CARDIOTHORACIC SURGERY
LA English
DT Article; Retracted Publication
DE Coronary angiography; Transradial approach; Fluoroscopy time; Procedure
   time
ID PERCUTANEOUS CORONARY INTERVENTION; ARTERY SPASM; CARDIOVASCULAR
   PROCEDURES; CARDIAC-CATHETERIZATION; FEMORAL ROUTES; ACCESS; RISK;
   PREVENTION; EXPERIENCE
AB Background: Several studies have implied that the time of radiation exposure for patients and operators during the transradial approach for coronary angiography (TRA) is associated with the use of different guidewire or catheter and operator's finesse. This study aimed to assess the effects of non-hydrophilic or hydrophilic guidewire and operator expertise on fluoroscopy time and procedure time of TRA and further effects on the procedure safety.
   Methods: A total of 1035 consecutive patients undergoing TRA were recruited prospectively and respectively divided into non-hydrophilic guidewire and hydrophilic guidewire group, or well-experienced group and less-experienced group. The primary endpoints were fluoroscopy time and procedure time. Secondary endpoints included contrast volume, cost, guidewire exchange, switchover and complications.
   Results: TRA by non-hydrophilic guidewire group showed shorter fluoroscopy time and procedure time compared with hydrophilic guidewire group, similar results were found between well-experienced group and less-experienced group. Moreover, using of non-hydrophilic guidewire significantly reduced the incidence of hematoma and abnormal guidewie advancement, well-experienced group showed less dosage of contrast volume, lower incidence of radial artery spasm and frequency of guidewire exchange.
   Conclusions: TRA by non-hydrophilic guidewire and well-experienced operator can decrease radiation exposure of patients and operators through reducing the fluoroscopy time and procedure time and further increase procedure safety. These will contribute to the optimization of TRA procedure and promote its widely application.
C1 [Yang, Jianmin; Lv, Shuzheng] Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Beijing 100029, Peoples R China.
   [Yang, Jianmin; Wang, Ningfu; Tong, Xiaoshan; Ye, Xianhua; Zhou, Liang; Tong, Guoxin; Shen, Yun] Nanjing Med Univ, Hangzhou Municipal Hosp 1, Hangzhou Hosp, Dept Cardiol, Hangzhou, Zhejiang, Peoples R China.
RP Lv, SZ (reprint author), Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, 2 Anzhen Rd, Beijing 100029, Peoples R China.
EM shuzhenglv0829@163.com
CR Andreassi MG, 2007, EUR HEART J, V28, P2195, DOI 10.1093/eurheartj/ehm225
   Barbeau GR, 2003, CATHETER CARDIO INTE, V59, P442, DOI 10.1002/ccd.10586
   Borghini A, 2013, ATHEROSCLEROSIS, V230, P40, DOI 10.1016/j.atherosclerosis.2013.06.010
   Brasselet C, 2008, EUR HEART J, V29, P63, DOI 10.1093/eurheartj/ehm508
   Brix G, 2013, EUR J RADIOL, V82, P1926, DOI 10.1016/j.ejrad.2013.07.015
   Chen CW, 2006, CARDIOLOGY, V105, P43, DOI 10.1159/000089246
   Coppola John, 2006, J Invasive Cardiol, V18, P155
   Dominici M, 2013, HEART, V99, P480, DOI 10.1136/heartjnl-2012-302895
   Farman MT, 2011, ANADOLU KARDIYOL DER, V11, P607, DOI 10.5152/akd.2011.163
   Frangos Noble C, 2011, Rev Med Suisse, V7, P528
   Godino C, 2013, J INVASIVE CARDIOL, V25, P441
   Goldsmit A, 2014, CATHETER CARDIO INTE, V83, pE32, DOI 10.1002/ccd.25082
   Hamon M, 2007, STROKE, V38, P2176, DOI 10.1161/STROKEAHA.107.482414
   Jang JS, 2012, EUROINTERVENTION, V8, P501, DOI 10.4244/EIJV8I4A78
   Jia DA, 2010, CHINESE MED J-PEKING, V123, P843, DOI 10.3760/cma.j.issn.0366-6999.2010.07.015
   Kawashima O, 2004, CATHETER CARDIO INTE, V61, P333, DOI 10.1002/ccd.10769
   Kiemeneij F, 2003, CATHETER CARDIO INTE, V59, P161, DOI 10.1002/ccd.10444
   Koga S, 2004, INT J CARDIOL, V96, P255, DOI 10.1016/j.ijcard.2003.07.016
   Kristic I, 2011, J INVASIVE CARDIOL, V23, P527
   Lo TS, 2012, AM HEART J, V164, P455, DOI 10.1016/j.ahj.2012.06.011
   McConnell E A, 1997, Nursing, V27, P26
   Nathan S, 2012, CURR CARDIOL REP, V14, P502, DOI 10.1007/s11886-012-0287-5
   Pelliccia F, 2012, AM J CARDIOL, V110, P771, DOI 10.1016/j.amjcard.2012.05.005
   Rao SV, 2010, J AM COLL CARDIOL, V55, P2187, DOI 10.1016/j.jacc.2010.01.039
   Rodriguez-Leor O, 2013, AM HEART J, V165, P280, DOI 10.1016/j.ahj.2012.08.011
   Schussler Jeffrey M, 2011, Proc (Bayl Univ Med Cent), V24, P205
   Sciahbasi A, 2011, AM J CARDIOL, V108, P185, DOI 10.1016/j.amjcard.2011.03.022
   Sciahbasi A, 2011, AM HEART J, V161, DOI 10.1016/j.ahj.2010.10.003
   Shah B, 2013, AM HEART J, V165, P286, DOI 10.1016/j.ahj.2012.08.016
   Varenne O, 2006, CATHETER CARDIO INTE, V68, P231, DOI 10.1002/ccd.20812
   Yuan MK, 2013, AM J ROENTGENOL, V201, P626, DOI 10.2214/AJR.12.9652
   Zhao Y, 2011, HEBEI MED J, V33, P2934
NR 32
TC 1
Z9 1
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-8090
J9 J CARDIOTHORAC SURG
JI J. Cardiothorac. Surg.
PD DEC 5
PY 2014
VL 9
AR 194
DI 10.1186/s13019-014-0194-5
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AW7LF
UT WOS:000346444900001
PM 25477256
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Yao, J
   Wang, JY
   Liu, Y
   Wang, B
   Li, YX
   Zhang, R
   Wang, LS
   Liu, L
AF Yao, Jun
   Wang, Jian-yao
   Liu, Yi
   Wang, Bin
   Li, Ying-xue
   Zhang, Ru
   Wang, Li-Sheng
   Liu, Lei
TI RETRACTED: A randomized phase II study of everolimus for advanced
   pancreatic neuroendocrine tumors in Chinese patients (Retracted article.
   See vol. 32, 221, 2015)
SO MEDICAL ONCOLOGY
LA English
DT Article; Retracted Publication
DE Pancreatic neuroendocrine tumors; Everolimus; Progression-free survival;
   Adverse event
ID ENDOCRINE TUMORS; STREPTOZOCIN; DOXORUBICIN; EFFICACY
AB Everolimus, an oral inhibitor of mammalian target of mTOR, has been recently shown to have antitumor effect in a phase III, double-blind, randomized trial (RADIANT-3) of 410 patients with advanced pancreatic neuroendocrine tumors (PNETs). The purpose of this study was to investigate the specific efficacy and safety of everolimus in the Chinese patient with PNETs. In this randomized phase II study, the analysis on Chinese patients was performed comparing efficacy and safety between everolimus 10 mg/day orally (n = 44) and matching placebo (n = 35). The primary endpoint was progression-free survival (PFS). Adverse events were also examined. The median PFS was 15.47 months with everolimus [95 % confidence interval (CI) 10.52-26.37], as compared to 4.29 months with placebo (95 % CI 2.22-10.75), representing a 72 % reduction in the risk of progression or death (hazard ratio 0.27; 95 % CI 0.13-0.59; P < 0.001). Drug-associated adverse events (AEs) were mostly grade 1 or 2, observed in all 44 (100 %) patients receiving everolimus and in 29 (83 %) patients receiving placebo. The most common AEs (grade 1-4) associated with everolimus were rash (n = 38; 86 %), stomatitis (n = 30; 68 %), infections (n = 33; 75 %), epistaxis (n = 32; 73 %), pneumonitis (n = 27; 61 %) and anemia (n = 22; 50 %). Everolimus when compared with placebo is effectively in improving PFS in Chinese patients with PNETs.
C1 [Yao, Jun; Li, Ying-xue; Zhang, Ru; Wang, Li-Sheng] Jinan Univ Med Sci, Shenzhen Municipal Peoples Hosp, Dept Gastroenterol, Shenzhen 518020, Guangdong, Peoples R China.
   [Wang, Jian-yao; Wang, Bin; Liu, Lei] Shenzhen Childrens Hosp, Dept Gen Surg, Shenzhen 518026, Guangdong, Peoples R China.
   [Liu, Yi] Acad Mil Med Sci, Affiliated Hosp, Translat Med Ctr, Lab Oncol, Beijing 100071, Peoples R China.
RP Wang, LS (reprint author), Jinan Univ Med Sci, Shenzhen Municipal Peoples Hosp, Dept Gastroenterol, 1017 East Gate Rd, Shenzhen 518020, Guangdong, Peoples R China.
EM wangls168@163.com; liulei3322@yahoo.com.cn
FU Outstanding Doctoral Thesis Support Project of Guangdong Province
   [85514045]; Technical Research and Development Project of Shenzhen
   [JCYJ20130402092657774]; Medical Research Foundation of Guangdong
   Province [B2013347]
FX The study was supported by the Outstanding Doctoral Thesis Support
   Project of Guangdong Province (85514045) for L.S.W., the Technical
   Research and Development Project of Shenzhen (JCYJ20130402092657774) for
   L.L. and the Medical Research Foundation of Guangdong Province
   (B2013347) for L.L.
CR Basu B, 2010, ENDOCR-RELAT CANCER, V17, pR75, DOI 10.1677/ERC-09-0108
   Ben QW, 2011, INT J CANCER, V128, P1179, DOI 10.1002/ijc.25426
   Capurso G, 2009, CRIT REV ONCOL HEMAT, V72, P110, DOI 10.1016/j.critrevonc.2009.01.008
   Cheng PNM, 1999, CANCER, V86, P944, DOI 10.1002/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P
   Clark OH, 2009, J NATL COMPR CANC NE, V7, P712
   Ehehalt F, 2009, ONCOLOGIST, V14, P456, DOI 10.1634/theoncologist.2008-0259
   Granberg D, 2009, EXPERT OPIN INV DRUG, V18, P601, DOI [10.1517/13543780902850432, 10.1517/13543780902850432 ]
   Halfdanarson TR, 2008, ANN ONCOL, V19, P1727, DOI 10.1093/annonc/mdn351
   Ito T, 2012, JPN J CLIN ONCOL, V42, P903, DOI 10.1093/jjco/hys123
   Lam KY, 1998, AM J GASTROENTEROL, V93, P1232
   McCollum AD, 2004, AM J CLIN ONCOL-CANC, V27, P485, DOI 10.1097/01.coc.0000135343.06038.eb
   Missiaglia E, 2010, J CLIN ONCOL, V28, P245, DOI 10.1200/JCO.2008.21.5988
   Yao JC, 2008, J CLIN ONCOL, V26, P4311, DOI 10.1200/JCO.2008.16.7858
   Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377
   Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290
   Yao JC, 2010, J CLIN ONCOL, V28, P69, DOI 10.1200/JCO.2009.24.2669
NR 16
TC 11
Z9 11
U1 3
U2 10
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD DEC
PY 2014
VL 31
IS 12
AR 251
DI 10.1007/s12032-014-0251-x
PG 6
WC Oncology
SC Oncology
GA CK8QH
UT WOS:000356502600002
PM 25395378
DA 2018-12-27
ER

PT J
AU Basaranoglu, M
   Canbakan, B
   Yildiz, K
   Ceylan, B
   Baysal, B
   Uysal, O
   Senturk, H
AF Basaranoglu, Metin
   Canbakan, Billur
   Yildiz, Kemal
   Ceylan, Bahadir
   Baysal, Birol
   Uysal, Omer
   Senturk, Hakan
TI RETRACTED: Fatty liver disease might increase the risk of abdominal
   operation in patients with fatty liver and the prevalence of cancer in
   first-degree relatives (Retracted article. See vol. 26, pg. 290, 2015)
SO TURKISH JOURNAL OF GASTROENTEROLOGY
LA English
DT Article; Proceedings Paper; Retracted Publication
CT 63rd Annual Meeting of the
   American-Association-for-the-Study-of-Liver-Disease (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
DE Abdominal operation; cancer; dyspepsia; fatty liver; hepatitis C;
   nonalcoholic
ID INSULIN-RESISTANCE; HEPATIC APOPTOSIS; AMINOTRANSFERASE; PATHOGENESIS;
   BIOMARKER; OBESITY
AB Background/Aims: We investigated the risk of abdominal operation in patients with fatty liver and the risk of any cancer in first-degree relatives of patients with fatty liver.
   Materials and Methods: We evaluated 105 patients with nonalcoholic fatty liver disease (NAFLD), 121 patients with biopsy-proven hepatitis C (61 patients with fatty liver and 60 patients without fatty liver), 50 patients with inflammatory bowel disease (IBD), and 109 patients with dyspepsia.
   Results: There was no difference in sex, mean age, and marital status among the groups except that patients with IBD were younger than the others (p<0.001). The frequency of cancer among family members was 18% in IBD, 9% in dyspepsia, 28% in hepatitis C with steatosis, 21.5% in hepatitis C without steatosis, and 27% in NAFLD (p=0.006). Then, we divided the study group into two groups as follows: group 1: (IBD + dyspepsia + hepatitis C without steatosis) and group 2: (hepatitis C with steatosis + NAFLD). We found that the frequency of cancer was 16% in group 1 versus 24.4 % in group 2 (p=0.037). We also investigated the risk of abdominal operation in patients with fatty liver. The results were as follows: 33% in group without fatty liver versus 43% in group with fatty liver (p=0.043).
   Conclusion: Understanding the underlying causes of fatty liver forms might decrease the cancer frequency in the population and number of operations in patients with fatty liver.
C1 [Basaranoglu, Metin] Turkiye Yuksek Ihtisas Hosp, Dept Gastroenterol, Ankara, Turkey.
   [Canbakan, Billur] Istanbul Univ, Cerrahpasa Fac Med, Dept Gastroenterol, Istanbul, Turkey.
   [Yildiz, Kemal; Baysal, Birol; Senturk, Hakan] Bezmialem Vakif Univ, Dept Gastroenterol, Fac Med, Istanbul, Turkey.
   [Ceylan, Bahadir] Medipol Univ Hosp, Dept Clin Microbiol & Infect Dis, Istanbul, Turkey.
   [Uysal, Omer] Bezmialem Vakif Univ, Dept Biostat, Fac Med, Istanbul, Turkey.
RP Senturk, H (reprint author), Bezmialem Vakif Univ, Dept Gastroenterol, Fac Med, Istanbul, Turkey.
EM drhakansenturk@yahoo.com
RI Basaranoglu, Metin/X-2412-2018
CR Basaranoglu M, 2002, CAN J GASTROENTEROL, V16, P813
   Basaranoglu M, 2001, J HEPATOL, V35, P684, DOI 10.1016/S0168-8278(01)00164-7
   Basaranoglu M, 2014, TURK J GASTROENTEROL, V25, P127, DOI 10.5152/tjg.2014.7675
   Basaranoglu M, 2013, WORLD J GASTROENTERO, V19, P1166, DOI 10.3748/wjg.v19.i8.1166
   Basaranoglu M, 2013, WORLD J GASTROENTERO, V19, P1158, DOI 10.3748/wjg.v19.i8.1158
   Basaranoglu M, 2011, WORLD J GASTROENTERO, V17, P4055, DOI 10.3748/wjg.v17.i36.4055
   Basaranoglu Metin, 2006, Gastroenterol Hepatol (N Y), V2, P282
   Basaranoglu M, 2011, WORLD J GASTROENTERO, V17, P2172, DOI 10.3748/wjg.v17.i17.2172
   Basaranoglu M, 2010, WORLD J GASTROENTERO, V16, P2223, DOI 10.3748/wjg.v16.i18.2223
   Braun S, 2011, INT J BIOL SCI, V7, P1003, DOI 10.7150/ijbs.7.1003
   Brunt EM, 2012, DIGEST DIS, V30, P61, DOI 10.1159/000341127
   Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Canbakan B, 2007, ACTA GASTRO-ENT BELG, V70, P277
   Canbakan B, 2010, BIOMARK MED, V4, P205, DOI 10.2217/BMM.09.88
   Canbakan B, 2008, ANN HEPATOL, V7, P249
   Canbakan B, 2011, BIOMARK MED, V5, P813, DOI [10.2217/BMM.11.70, 10.2217/bmm.11.70]
   Gallagher EJ, 2010, CURR DIABETES REP, V10, P93, DOI 10.1007/s11892-010-0101-y
   Ipekci SH, 2003, J CLIN GASTROENTEROL, V36, P371, DOI 10.1097/00004836-200304000-00021
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Neuschwander-Tetri BA, 2012, LIPIDS, V47, P941, DOI 10.1007/s11745-012-3709-7
   Tahan V, 2008, HEPATO-GASTROENTEROL, V55, P1433
   Tarcin O, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-45
   Tetri LH, 2008, AM J PHYSIOL-GASTR L, V295, pG987, DOI 10.1152/ajpgi.90272.2008
NR 24
TC 3
Z9 3
U1 2
U2 12
PU AVES
PI SISLI
PA BUYUKDERE CAD 105-9, MECIDIYEKOY, SISLI, ISTANBUL 34394, TURKEY
SN 1300-4948
EI 2148-5607
J9 TURK J GASTROENTEROL
JI Turk. J. Gastroenterol.
PD DEC
PY 2014
VL 25
SU 1
BP 138
EP 141
DI 10.5152/tjg.2014.7674
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA CG8JO
UT WOS:000353553700026
PM 25910292
OA Bronze
DA 2018-12-27
ER

PT J
AU Sun, LJ
   Yu, XB
   Dai, CQ
   Hu, W
   Guo, XS
   Chen, H
AF Sun, Liao-Jun
   Yu, Xian-Bin
   Dai, Cheng-Qian
   Hu, Wei
   Guo, Xiao-Shan
   Chen, Hua
TI RETRACTED: A randomised prospective study of two different combined
   internal and external fixation techniques for distal tibia shaft
   fractures (Retracted article. See vol. 46, pg. 1700, 2015)
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article; Retracted Publication
DE Distal tibia fracture; Fracture fixation; External fixator; Limited
   internal fixation; Functional outcome
ID INVASIVE PLATE OSTEOSYNTHESIS; ANTERIOR KNEE PAIN; NAIL
AB Background: External fixation combined with limited open reduction and internal fixation (EF + LORIF) is a well-accepted and effective method for distal tibia shaft fractures, but it was also related to complications. The objective of this study was to compare external fixation combined with closed reduction and internal fixation (EF + CRIF) with EF + LORIF in the treatment of distal tibia shaft fractures, and explore the benefits and defects of these two techniques.
   Methods: Fifty-six patients were randomised to operative stabilisation either by an external fixator combined with two closed titanium elastic nails or by external fixation combined with limited open reduction and internal fixation. Pre-operative variables included the patients' age, sex, the affected side, cause of injury, Tscherne classification of soft tissue injury, fracture pattern, and time from injury to surgery. Peri-operative variables were the operating time and the radiation time. Postoperative variables were wound problems and other complications, union time, time of recovery to work, the functional American Orthopaedic Foot and Ankle surgery (AOFAS) score.
   Results: There was no significant difference in the mean operating time (72.6 +/- 11.5 vs. 78.5 +/- 16.4 min, P = 0.125), the time to union (21.2 +/- 11.0 vs. 22.5 +/- 12.3 weeks, P = 0.678), the time of recovery to work (25.0 +/- 14.5 vs. 26.4 +/- 13.6 weeks, P = 0.711), pin track infection (3/28 vs. 4/28, P = 1.000), delayed union (2/28 vs. 3/28, P = 1.000), pain (38.3 +/- 1.6 vs. 38.7 +/- 1.5, P = 0.339), function (44.4 +/- 6.0 vs. 45.0 +/- 5.5, P = 0.698), and total AOFAS scores (91.5 +/- 7.4 vs. 93.4 +/- 6.8, P = 0.322) between the two groups. However, the mean radiation time was longer in the EF + CRIF group than in the EF + LORIF group (2.0 +/- 1.2 vs. 0.3 +/- 0.1 min, P < 0.01). The EF + CRIF group had no wound complications while the EF + LORIF group had five wound complications, though the difference was not statistically significant (P = 0.052). Acceptable alignment was obtained in 50 patients (22 in EF + CRIF vs. 28 in EF + LORIF, P = 0.023). Two cases with EF + CRIF had a 6 degrees of recurvatum deformity and four had 6-9 degrees of valgus deformity.
   Conclusion: Our results indicated that both EF + CRIF and EF + LORIF were reliable methods in treatment of distal tibia shaft fractures. EF + CRIF had fewer wound complications and broader indications while EF + LORIF had lower radiation exposure and better alignment. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Chen, Hua] Wenzhou Med Coll, Affiliated Hosp 2, Dept Orthopaed Surg, Wenzhou 325000, Zhejiang, Peoples R China.
   Wenzhou Med Coll, Yuying Children Hosp, Wenzhou 325000, Zhejiang, Peoples R China.
RP Chen, H (reprint author), Wenzhou Med Coll, Affiliated Hosp 2, Dept Orthopaed Surg, 109 Xueyuanxi Rd, Wenzhou 325000, Zhejiang, Peoples R China.
EM chenhuayishi@163.com
CR Babis GC, 2010, INJURY, V41, P253, DOI 10.1016/j.injury.2009.09.014
   Borg T, 2004, INJURY, V35, P608, DOI 10.1016/j.injury.2003.08.015
   Braten M, 2005, ARCH ORTHOP TRAUM SU, V125, P21, DOI 10.1007/s00402-004-0768-0
   Casstevens C, 2012, J AM ACAD ORTHOP SUR, V20, P675, DOI 10.5435/JAAOS-20-11-675
   Dall'Oca C, 2010, ARCH ORTHOP TRAUM SU, V130, P1377, DOI 10.1007/s00402-010-1090-7
   Farouk O, 1997, Injury, V28 Suppl 1, pA7, DOI 10.1016/S0020-1383(97)90110-8
   Gugala Z, 2001, INJURY, V32, pD21
   Guo JJ, 2010, J BONE JOINT SURG BR, V92B, P984, DOI 10.1302/0301-620X.92B7.22959
   Hasenboehler E, 2007, INJURY, V38, P365, DOI 10.1016/j.injury.2006.10.024
   Hazarika S, 2006, INJURY, V37, P877, DOI 10.1016/j.injury.2006.06.002
   Iqbal HJ, 2013, FOOT ANKLE SURG, V19, P143, DOI 10.1016/j.fas.2013.04.007
   Janssen KW, 2007, INT ORTHOP, V31, P709, DOI 10.1007/s00264-006-0237-1
   Katsoulis E, 2006, J BONE JOINT SURG BR, V88B, P576, DOI 10.1302/0301-620X.88B5.16875
   KITAOKA HB, 1994, FOOT ANKLE INT, V15, P349, DOI 10.1177/107110079401500701
   Lau TW, 2008, INT ORTHOP, V32, P697, DOI 10.1007/s00264-007-0384-z
   Li YC, 2014, INT ORTHOP, V38, P1261, DOI 10.1007/s00264-014-2294-1
   Newman SDS, 2011, INJURY, V42, P975, DOI 10.1016/j.injury.2010.02.019
   Salem KH, 2012, INT ORTHOP, V36, P1471, DOI 10.1007/s00264-012-1505-x
   Sathiyakumar V, 2014, INT ORTHOP, V38, P1483, DOI 10.1007/s00264-014-2345-7
   Vaisto O, 2005, J ORTHOP TRAUMA, V19, P311
   Vallier HA, 2008, J ORTHOP TRAUMA, V22, P307, DOI 10.1097/BOT.0b013e31816ed974
   Vallier HA, 2011, J ORTHOP TRAUMA, V25, P736, DOI 10.1097/BOT.0b013e318213f709
   Yaligod V, 2014, J ORTHOP, V11, P10, DOI 10.1016/j.jor.2013.12.002
   Zelle BA, 2006, J ORTHOP TRAUMA, V20, P76, DOI 10.1097/01.bot.0000202997.45274.a1
NR 24
TC 5
Z9 6
U1 2
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
EI 1879-0267
J9 INJURY
JI Injury-Int. J. Care Inj.
PD DEC
PY 2014
VL 45
IS 12
BP 1990
EP 1995
DI 10.1016/j.injury.2014.10.044
PG 6
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA CA1DB
UT WOS:000348652100031
PM 25457344
DA 2018-12-27
ER

PT J
AU Xu, F
   Teng, X
   Yuan, X
   Sun, JK
   Wu, HC
   Zheng, Z
   Tang, Y
   Hu, SS
AF Xu, Fei
   Teng, Xiao
   Yuan, Xin
   Sun, Jiakang
   Wu, Hengchao
   Zheng, Zhe
   Tang, Yue
   Hu, Shengshou
TI RETRACTED: LCK: a new biomarker candidate for the early diagnosis of
   acute myocardial infarction (Retracted article. See vol. 42, pg. 1487,
   2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Acute myocardial infarction; Differentially expressed genes; LCK;
   Transcription factors; Protein-protein interaction network
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; ACUTE CORONARY SYNDROMES;
   DIFFERENTIAL EXPRESSION; TYROSINE KINASE; HUMAN LYMPHOMAS;
   ARTERY-DISEASE; DEFICIENT MICE; ATHEROSCLEROSIS; RECEPTOR; ACTIVATION
AB Acute myocardial infarction (AMI) is one of the most common cardiovascular emergencies, of which the molecular pathogenesis is still not fully understood. This study aimed to explore the differentially expressed genes (DEGs) and then identify the critical genes in AMI thus screening out potential biomarkers for the early diagnosis of this serious heart disease. The gene expression data of AMI patients (GSE19339) were downloaded from gene expression omnibus database. After preprocessing with affy package, the DEGs were screened out by significance analysis of microarray (SAM) algorithm within samr package. Then function and pathway enrichment analyses of the DEGs were carried out using DAVID (database for annotation visualization and integrated discovery software) online tools. Further, the relevant genes of AMI were screened out with GENETIC_ASSOCIATION_DB_DISEASE analysis and blastp alignment. Finally, the novel genes were subjected to transcription factor and protein protein interaction network analyses. A total of 633 DEGs, including 378 up-regulated and 255 down-regulated, were screened out between AMI patients and normal control samples. Among those genes, several important ones such as PPAR, CCL2, HMOX1 and NPR1 were demonstrated to be related to AMI. Most importantly, a novel gene LCK (lymphocyte-specific protein tyrosine kinase) was significantly differentially expressed in AMI. Further analyses showed that LCK was involved in the expression regulation of CXCL12 (chemokine (C-X-C motif) ligand 12) and the expression of LCK can be regulated by different transcription factors. In this study, we provided a new insight into the mechanism of AMI and raised LCK as an attractive marker candidate in the diagnosis of this serious heart disease.
C1 [Xu, Fei; Teng, Xiao; Yuan, Xin; Sun, Jiakang; Wu, Hengchao; Zheng, Zhe; Tang, Yue; Hu, Shengshou] Fuwai Hosp, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Beijing 100037, Peoples R China.
   [Xu, Fei; Yuan, Xin; Sun, Jiakang; Wu, Hengchao; Zheng, Zhe; Tang, Yue; Hu, Shengshou] Chinese Acad Med Sci, Peking Union Med Coll, Fuwai Hosp, Dept Surg,Ctr Regenerat Med, Beijing 100037, Peoples R China.
   [Tang, Yue] Chinese Acad Med Sci, Peking Union Med Coll, Zoopery Ctr, Fuwai Hosp, Beijing 100037, Peoples R China.
RP Yuan, X (reprint author), Chinese Acad Med Sci, Peking Union Med Coll, Fuwai Hosp, Dept Surg,Ctr Regenerat Med, 167A Beilishi Rd, Beijing 100037, Peoples R China.
EM weidongzangwz@163.com
FU National Natural Science Foundation of China [81270302]; PUMC Youth Fund
   [2012XHQN08]; Fuwai science &technology star project [2012FWXX05]
FX This study was supported by National Natural Science Foundation of China
   (81270302), PUMC Youth Fund (2012XHQN08), and Fuwai science &technology
   star project (2012FWXX05).
CR Aiello RJ, 1999, ARTERIOSCL THROM VAS, V19, P1518, DOI 10.1161/01.ATV.19.6.1518
   Baines CP, 1998, J MOL CELL CARDIOL, V30, P383, DOI 10.1006/jmcc.1997.0601
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Bernardes A, 2013, J MOL BIOL, V425, P2878, DOI 10.1016/j.jmb.2013.05.010
   Blum A, 2003, EUR J INTERN MED, V14, P407, DOI [10.1016/j.ejim.2003.09.002, DOI 10.1016/J.EJIM.2003.09.002]
   Bodi V, 2008, AM HEART J, V156, P1065, DOI 10.1016/j.ahj.2008.07.008
   Boersma E, 2003, LANCET, V361, P847, DOI 10.1016/S0140-6736(03)12712-2
   Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788
   Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354
   Caligiuri G, 2006, EUR HEART J, V27, P2485, DOI 10.1093/eurheartj/ehl222
   Daubert MA, 2010, VASC HEALTH RISK MAN, V6, P691
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Devaux Y, 2010, FUNCT INTEGR GENOMIC, V10, P329, DOI 10.1007/s10142-010-0169-0
   Doney Alex S F, 2005, Nucl Recept, V3, P4, DOI 10.1186/1478-1336-3-4
   Frazer KA, 2004, NUCLEIC ACIDS RES, V32, pW273, DOI 10.1093/nar/gkh458
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gerhardt W, 1999, SCAND J CLIN LAB INV, V59, P83
   Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2
   Hamilton ST, 2013, J GEN VIROL, V94, P2495, DOI 10.1099/vir.0.052878-0
   He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467
   Ikeda U, 2002, CLIN CARDIOL, V25, P143, DOI 10.1002/clc.4960250403
   Inngjerdingen M, 2002, BLOOD, V99, P4318, DOI 10.1182/blood.V99.12.4318
   Ishikawa K, 2000, J ATHEROSCLER THROMB, V8, P63
   Jaffe AS, 2006, J AM COLL CARDIOL, V48, P1, DOI 10.1016/j.jacc.2006.02.056
   Lloyd-Jones D, 2009, CIRCULATION, V119, P480, DOI [10.1161/CIRCULATIONAHA.108.191261, 10.1161/CIRCULATIONAHA.108.191259]
   MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7400, DOI 10.1073/pnas.83.19.7400
   Morrow DA, 2007, CLIN CHEM, V53, P552, DOI 10.1373/clinchem.2006.084194
   Nikitin AG, 2010, HEART VESSELS, V25, P229, DOI 10.1007/s00380-009-1159-9
   Ono K, 2004, ATHEROSCLEROSIS, V173, P315, DOI 10.1016/j.atherosclerosis.2003.11.021
   Paterson JC, 2006, HAEMATOL-HEMATOL J, V91, P772
   Ping PP, 2002, J CLIN INVEST, V109, P499, DOI 10.1172/JC1200213200
   Punta M, 2012, NUCLEIC ACIDS RES, V40, pD290, DOI 10.1093/nar/gkr1065
   Recchioni R, 2013, BIOMARKERS, V18, P547, DOI 10.3109/1354750X.2013.833294
   Rhee I, 2012, NAT IMMUNOL, V13, P439, DOI 10.1038/ni.2246
   Richards AM, 2003, CIRCULATION, V107, P2786, DOI 10.1161/01.CIR.0000070953.76250.B9
   Sanderson JE, 2007, HEART, V93, P1175, DOI 10.1136/hrt.2007.131060
   Schwender H, 2006, NEWSLETTER R PROJECT, V6, P45
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973
   Talab F, 2013, MOL CANCER RES, V11, P541, DOI 10.1158/1541-7786.MCR-12-0415-T
   Wang GK, 2010, EUR HEART J, V31, P659, DOI 10.1093/eurheartj/ehq013
   WRIGHT DD, 1994, MOL CELL BIOL, V14, P2429, DOI 10.1128/MCB.14.4.2429
NR 42
TC 3
Z9 3
U1 2
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD DEC
PY 2014
VL 41
IS 12
BP 8047
EP 8053
DI 10.1007/s11033-014-3702-8
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CA6FQ
UT WOS:000349005800035
PM 25209966
DA 2018-12-27
ER

PT J
AU Li, J
   Bi, LT
   Sun, YX
   Lu, ZX
   Lin, YM
   Bai, O
   Shao, H
AF Li, Jun
   Bi, Lintao
   Sun, Yanxia
   Lu, Zhenxia
   Lin, Yumei
   Bai, Ou
   Shao, Hui
TI RETRACTED: Text mining and network analysis of molecular interaction in
   non-small cell lung cancer by using natural language processing
   (Retracted article. See vol. 42, pg. 1489, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Non-small cell lung cancer; Molecular networks; Text mining using
   natural language processing; KEGG pathway analysis
ID MAMMALIAN PHENOTYPE ONTOLOGY; GENE-EXPRESSION; RAS MUTATIONS;
   ADENOCARCINOMA; ASSOCIATION; CARCINOMAS; MECHANISM; PATHWAYS; MOTILITY;
   PREDICT
AB Lung cancer including non-small cell lung cancer (NSCLC) and small cell lung cancer is one of the most aggressive tumors with high incidence and low survival rate. The typical NSCLC patients account for 80-85 % of the total lung cancer patients. To systemically explore the molecular mechanisms of NSCLC, we performed a molecular network analysis between human and mouse to identify key genes (pathways) involved in the occurrence of NSCLC. We automatically extracted the human-to-mouse orthologous interactions using the GeneWays system by natural language processing and further constructed molecular (gene and its products) networks by mapping the human-to-mouse interactions to NSCLC-related mammalian phenotypes, followed by module analysis using ClusterONE of Cytoscape and pathway enrichment analysis using the database for annotation, visualization and integrated discovery (DAVID) successively. A total of 70 genes were proven to be related to the mammalian phenotypes of NSCLC, and seven genes (ATAD5, BECN1, CDKN2A, FNTB, E2F1, KRAS and PTE1V) were found to have a bearing on more than one mammalian phenotype (MP) each. Four network clusters centered by four genes thyroglobulin (TG), neurofibromatosis type-1 (NF1), neurofibromatosis type 2 (NF2) and E2F transcription factor 1 (E2F1) were generated. Genes in the four network modules were enriched in eight KEGG pathways (p value <0.05), including pathways in cancer, small cell lung cancer, cell cycle and p53 signaling pathway. Genes p53 and E2F1 may play important roles in NSCLC occurrence, and thus can be considered as therapeutic targets for NSCLC.
C1 [Li, Jun; Bi, Lintao; Sun, Yanxia; Lu, Zhenxia; Lin, Yumei; Shao, Hui] Jilin Univ, China Japan Union Hosp, Dept Hematol & Oncol, Changchun 130031, Jilin, Peoples R China.
   [Bai, Ou] Jilin Univ, Hosp 1, Tumor Ctr, Changchun 130021, Jilin, Peoples R China.
RP Bai, O (reprint author), Jilin Univ, Hosp 1, Tumor Ctr, 261 Xinminda St, Changchun 130021, Jilin, Peoples R China.
EM oubai16@163.com
CR Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998
   Blake JA, 2011, NUCLEIC ACIDS RES, V39, pD842, DOI 10.1093/nar/gkq1008
   Bremner R, 2010, CANCER RES, V70, P6114, DOI 10.1158/0008-5472.CAN-10-0358
   Bult CJ, 2013, NUCLEIC ACIDS RES, V41, pD885, DOI 10.1093/nar/gks1115
   Chen HX, 2013, CHIN J CANCER, V32, P242, DOI 10.5732/cjc.012.10263
   Dempke WCM, 2010, LUNG CANCER, V67, P257, DOI 10.1016/j.lungcan.2009.10.012
   Doddrell RDS, 2013, BRAIN, V136, P549, DOI 10.1093/brain/aws353
   Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245
   Eymin B, 2001, ONCOGENE, V20, P1678, DOI 10.1038/sj.onc.1204242
   Fiala O, 2013, CANCER GENET-NY, V206, P26, DOI 10.1016/j.cancergen.2012.12.003
   Flowers S, 2013, CANCER RES, V73, P2150, DOI 10.1158/0008-5472.CAN-12-1745
   Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798
   Giaccone G, 1996, CHEST, V109, pS130, DOI 10.1378/chest.109.5_Supplement.130S
   Goel A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.141
   Goldenberg-Furmanov M, 2004, CANCER RES, V64, P1058, DOI 10.1158/0008-5472.CAN-03-2420
   Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320
   Hann CL, 2008, ONCOLOGY-NY, V22, P1486
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Iossifov I, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000559
   Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7
   Liu KH, 2011, J BIOMED INFORM, V44, P163, DOI 10.1016/j.jbi.2010.07.006
   Ma YH, 2013, MOL CANCER THER, V12, P286, DOI 10.1158/1535-7163.MCT-12-0650
   Maqbool SB, 2010, J CELL SCI, V123, P4095, DOI 10.1242/jcs.064519
   MATSUOKA S, 1994, J BIOL CHEM, V269, P11030
   McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127
   MITSUDOMI T, 1992, ONCOGENE, V7, P171
   Moalem J, 2011, THYROID, V21, P319, DOI 10.1089/thy.2010.0395
   Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598
   NAKAGAWA K, 1995, ONCOGENE, V11, P1843
   Nepusz T, 2012, NAT METHODS, V9, P471, DOI [10.1038/nmeth.1938, 10.1038/NMETH.1938]
   O'Donnell P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-210
   Perez BA, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00072
   Ray BK, 2013, CANCER RES, V73, P736, DOI 10.1158/0008-5472.CAN-12-2601
   Rodriguez-Esteban R, 2006, PLOS COMPUT BIOL, V2, P1031, DOI 10.1371/journal.pcbi.0020118
   Rodriguez-Penagos C, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-293
   Rosell R, 2002, CURR OPIN ONCOL, V14, P171, DOI 10.1097/00001622-200203000-00006
   Rzhetsky A, 2006, P NATL ACAD SCI USA, V103, P4940, DOI 10.1073/pnas.0600591103
   Rzhetsky A, 2004, J BIOMED INFORM, V37, P43, DOI 10.1016/j.jbi.2003.10.001
   Rzhetsky A, 2000, BIOINFORMATICS, V16, P1120, DOI 10.1093/bioinformatics/16.12.1120
   Rzhetsky A, 2008, CELL, V134, P9, DOI 10.1016/j.cell.2008.06.029
   Rzhetsky A, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000061
   Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273
   SEKIDO Y, 1995, CANCER RES, V55, P1227
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Singh T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060749
   Smith CL, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2004-6-1-r7
   Smith CL, 2012, MAMM GENOME, V23, P653, DOI 10.1007/s00335-012-9421-3
   Strauss GM, 2004, J CLIN ONCOL, V22, P7019
   Vandin F, 2011, J COMPUT BIOL, V18, P507, DOI 10.1089/cmb.2010.0265
   Verweij KJH, 2010, BIOL PSYCHOL, V85, P306, DOI 10.1016/j.biopsycho.2010.07.018
   Xu QX, 2013, BIOMATERIALS, V34, P5149, DOI 10.1016/j.biomaterials.2013.03.044
   Yang X, 2013, J PHARMACOL SCI, V121, P272, DOI 10.1254/jphs.12234FP
   Zhang LA, 2010, CLIN CANCER RES, V16, P4478, DOI 10.1158/1078-0432.CCR-10-0859
NR 55
TC 6
Z9 6
U1 2
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD DEC
PY 2014
VL 41
IS 12
BP 8071
EP 8079
DI 10.1007/s11033-014-3705-5
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CA6FQ
UT WOS:000349005800038
PM 25205120
DA 2018-12-27
ER

PT J
AU Yu, XL
   Zhang, J
   Zhao, F
   Pan, XM
AF Yu, Xiao-Ling
   Zhang, Jun
   Zhao, Fei
   Pan, Xiao-Ming
TI RETRACTED: Relationships of COX2 and MMP12 genetic polymorphisms with
   chronic obstructive pulmonary disease risk: a meta-analysis (Retracted
   article. See vol. 42, pg. 1491, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE COX2; MMP12; Chronic obstructive pulmonary disease; Meta-analysis
ID MACROPHAGE METALLOELASTASE MMP-12; MATRIX METALLOPROTEINASES; TUMOR
   MICROENVIRONMENT; PROSTAGLANDIN E-2; LUNG-FUNCTION; COPD;
   CYCLOOXYGENASE-2; POPULATION; ASSOCIATION; ASTHMA
AB We performed the present meta-analysis in an attempt to confirm the correlation of genetic polymorphisms in the COX2 and MMP12 genes with the susceptibility to chronic obstructive pulmonary disease (COPD). We searched English database such as PubMed, CISCOM, CINAHL, Web of Science, Google Scholar and several Chinese database for meta-analysis. There were no specific language restrictions. Two investigators systematically extracted relevant data within those included studies. Crude ORs with its corresponding 95 % CI were calculated. STATA 12.0 software was adopted for statistical analysis. The impact of COX2 and MMP12 genetic polymorphisms on the pathogenesis of COPD was investigated in the current study with a total of 10 case-control studies, which includes 1,751 COPD patients and 2,472 healthy subjects. Four common polymorphisms, including rs689466 G > A and rs20417 G > C in the COX2 gene, rs652438 A > G and rs2276109 A > G were evaluated in the MMP12 gene. Pooled OR of the present studies and results showed that the frequency of COX2 rs20417 polymorphism was prevalent in COPD patients than those of healthy subjects (C allele vs. G allele OR = 1.33, 95 % CI 1.06-1.67, P = 0.014; GC + CC vs. GG OR = 1.86, 95 % CI 1.07-3.24, P = 0.029; respectively). However, we found no significant correlation between COX2 rs689466 polymorphism and the risk of COPD (all P > 0.05). Furthermore, our meta-analysis illustrated that individuals with MMP12 rs652438 polymorphism had significantly increased risk of developing COPD (G allele vs. A allele OR = 1.62, 95 % CI 1.08-2.42, P = 0.020; AG + GG vs. AA OR = 2.14, 95 % CI 1.12-4.09, P = 0.021; respectively). Nevertheless, no positive relation was detected between MMP12 rs2276109 variant and the risk of COPD. Our meta-analysis indicates that COX2 and MMP12 genetic polymorphisms may be strongly implicated in the development of COPD, especially for the COX2 rs20417 and MMP12 rs652438 polymorphisms. Thus, COX2 and MMP12 genetic polymorphisms could potentially be utilized as helpful biomarkers for early diagnosis of COPD.
C1 [Yu, Xiao-Ling; Zhang, Jun; Zhao, Fei; Pan, Xiao-Ming] China Med Univ, Affiliated Hosp 4, Dept Resp Med, Shenyang 110005, Peoples R China.
RP Yu, XL (reprint author), China Med Univ, Affiliated Hosp 4, Dept Resp Med, South Seven Rd 102, Shenyang 110005, Peoples R China.
EM yuxiaoling1220@163.com
CR Amirian ES, 2011, PROSTATE, V71, P1382, DOI 10.1002/pros.21354
   Arif E, 2008, CLIN CHIM ACTA, V397, P46, DOI 10.1016/j.cca.2008.07.010
   Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001
   Bourboulia D, 2010, SEMIN CANCER BIOL, V20, P161, DOI 10.1016/j.semcancer.2010.05.002
   Cerella C, 2010, BIOCHEM PHARMACOL, V80, P1801, DOI 10.1016/j.bcp.2010.06.050
   Chang Y, 2014, AM J PHYSIOL-LUNG C, V306, pL132, DOI 10.1152/ajplung.00111.2013
   Chaudhuri R, 2012, J ALLERGY CLIN IMMUN, V129, P655, DOI 10.1016/j.jaci.2011.12.996
   Chen LJ, 2013, CHINESE MED J-PEKING, V126, P2215, DOI 10.3760/cma.j.issn.0366-6999.20121456
   Chen Y, 2008, RESPIROLOGY, V13, P1014, DOI 10.1111/j.1440-1843.2008.01365.x
   Dannhardt G, 2000, CURR MED CHEM, V7, P1101, DOI 10.2174/0929867003374237
   de Marco R, 2011, AM J RESP CRIT CARE, V183, P891, DOI 10.1164/rccm.201007-1125OC
   Dong L, 2011, J BIOL CHEM, V286, P19035, DOI 10.1074/jbc.M111.231969
   Elkington PT, 2010, NEW ENGL J MED, V362, P1241, DOI 10.1056/NEJMc1000959
   Ganesan S, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-131
   Gangwar R, 2011, SURGERY, V149, P126, DOI 10.1016/j.surg.2010.04.004
   Gardner Aaron, 2010, Expert Rev Respir Med, V4, P647, DOI 10.1586/ers.10.62
   Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014
   Haq I, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-7
   Hentschke MR, 2013, J LIPID RES, V54, P2658, DOI 10.1194/jlr.M036699
   Hunninghake GM, 2009, NEW ENGL J MED, V361, P2599, DOI 10.1056/NEJMoa0904006
   Kabesch M, 2012, BIOCHIMIE, V94, P2231, DOI 10.1016/j.biochi.2012.07.017
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Lagente V, 2009, EXPERT OPIN THER TAR, V13, P287, DOI [10.1517/14728220902751632, 10.1517/14728220902751632 ]
   Lee SY, 2010, RESPIRATION, V80, P133, DOI 10.1159/000284926
   Li H, 2013, AM J RESP CRIT CARE, V187, P812, DOI 10.1164/rccm.201211-2073OC
   Li JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052699
   Lopez-Campos JL, 2012, RESP PHYSIOL NEUROBI, V180, P119, DOI 10.1016/j.resp.2011.11.001
   Mogulkoc U, 2012, GENET TEST MOL BIOMA, V16, P519, DOI 10.1089/gtmb.2011.0271
   Molet S, 2005, INFLAMM RES, V54, P31, DOI 10.1007/s00011-004-1319-4
   Morita H, 2010, NEW ENGL J MED, V362, P1241
   Nakatani Y, 2011, PROSTAG OTH LIPID M, V94, P112, DOI 10.1016/j.prostaglandins.2011.02.001
   Pellicoro A, 2012, HEPATOLOGY, V55, P1965, DOI 10.1002/hep.25567
   Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Pietras T, 2012, MOL BIOL REP, V39, P2163, DOI 10.1007/s11033-011-0964-2
   Qin YW, 2013, FUTUR CARDIOL, V9, P89, DOI [10.2217/FCA.12.71, 10.2217/fca.12.71]
   Roca-Ferrer J, 2011, ARCH BRONCONEUMOL, V47, P584, DOI 10.1016/j.arbres.2011.05.015
   Sato T, 2010, AM J RESP CRIT CARE, V182, P1020, DOI 10.1164/rccm.201001-0055OC
   Schirmer H, 2009, GENET MOL RES, V8, P1028, DOI 10.4238/vol8-3gmr596
   Shi J, 2008, CLIN EXP ALLERGY, V38, P913, DOI 10.1111/j.1365-2222.2008.02986.x
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Suh HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035115
   Sun CJ, 2012, CHIN J CLIN ELECT ED, V6, P5826, DOI [10.3877/cma.j.issn.1674-0785.2012.19.015, DOI 10.3877/CMA.J.ISSN.1674-0785.2012.19.015]
   van Diemen CC, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-57
   van Durme YMTA, 2009, CHEST, V135, P368, DOI 10.1378/chest.08-0684
   Vernooy JHJ, 2004, CHEST, V126, P1802, DOI 10.1378/chest.126.6.1802
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Weyerbrock A, 2011, NEURO-ONCOLOGY, V13, P203, DOI 10.1093/neuonc/noq161
   Wu LA, 2011, RESP MED, V105, P506, DOI 10.1016/j.rmed.2010.08.002
   Xue H, 2012, MOL BIOL REP, V39, P5033, DOI 10.1007/s11033-011-1300-6
   Zhang HT, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-14
   Zhang Rong-bao, 2005, Zhonghua Liu Xing Bing Xue Za Zhi, V26, P907
   Zintzaras E, 2005, BIOINFORMATICS, V21, P3672, DOI 10.1093/bioinformatics/bti536
   Zitka O, 2010, CURR MED CHEM, V17, P3751, DOI 10.2174/092986710793213724
NR 54
TC 5
Z9 6
U1 3
U2 20
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD DEC
PY 2014
VL 41
IS 12
BP 8149
EP 8162
DI 10.1007/s11033-014-3715-3
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CA6FQ
UT WOS:000349005800046
PM 25209967
DA 2018-12-27
ER

PT J
AU Yang, ZH
   Zheng, R
   Gao, Y
   Zhang, Q
AF Yang, Zehui
   Zheng, Rui
   Gao, Yuan
   Zhang, Qiang
TI RETRACTED: Gene expression profiles on predicting protein interaction
   network and exploring of new treatments for lung cancer (Retracted
   article. See vol. 42, pg. 1493, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Lung cancer; Differentially expressed genes; Protein-protein interaction
   network
ID SMALL-CELL-CARCINOMA; SURGICAL RESECTION; DATABASE; FAMILY;
   CHEMOTHERAPY; DISEASE; TRENDS
AB In the present study, we aimed to explore disease-associated genes and their functions in lung cancer. We downloaded the gene expression profile GSE4115 from Gene Expression Omnibus (GEO) database. Total 97 lung cancer and 90 adjacent non-tumor lung tissue (normal) samples were applied to identify the differentially expressed genes (DEGs) by paired t test and variance analysis in spectral angle mapper (SAM) package in R. Gene Ontology (GO) functional enrichment analysis of DEGs were performed with Database for Annotation Visualization and Integrated Discovery, followed by construction of protein-protein interaction (PPI) network from Human Protein Reference Database (HPRD). Finally, network modules were analyzed by the MCODE algorithm to detect protein complexes in the PPI network. Total 3,102 genes were identified as DEGs at FDR\0.05, including 1,146 downregulated and 1,956 up-regulated DEGs. GO functional enrichment analysis revealed that up-regulated DEGs mainly participated in cell cycle and intracellular related functions, and down-regulated DEGs might influence cell functions. There were 39,240 pairs of PPIs in human obtained from HPRD databases, 3,102 DEGs were mapped to this PPI network, in which 2,429 pairs of PPIs and 1,342 genes were identified. With MCODE algorithm, 48 modules were selected, including five corresponding modules and three modules with differences in gene expressing profiles. In addition, three DGEs, FXR2, ARFGAP1 and ELAVL1 were discovered as potential lung cancer related genes. The discovery of featured genes which were probably related to lung cancer, has a great significance on studying mechanism, distinguishing normal and cancer tissues, and exploring new treatments for lung cancer.
C1 [Yang, Zehui; Zheng, Rui; Gao, Yuan; Zhang, Qiang] China Med Univ, Shengjing Hosp, Dept Resp Med, Shenyang 110004, Peoples R China.
RP Zheng, R (reprint author), China Med Univ, Shengjing Hosp, Dept Resp Med, 36 Sanhao St, Shenyang 110004, Peoples R China.
EM ruizhengrui@hotmail.com
CR Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056
   Bandettini WP, 2012, J CARDIOVASC MAGN R, V14, DOI 10.1186/1532-429X-14-83
   Brock MV, 2005, J THORAC CARDIOV SUR, V129, P64, DOI 10.1016/j.jtcvs.2004.08.022
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Droge W, 2002, PHYSIOL REV, V82, P47
   Dubey S, 2009, AM J RESP CRIT CARE, V179, P860, DOI 10.1164/rccm.200902-0289UP
   Eb WDT, 2004, WHO CLASSIFICATION T
   Eberhardt W, 1999, BRIT J CANCER, V81, P1206, DOI 10.1038/sj.bjc.6690830
   Eilam R, 2003, NEUROSCIENCE, V121, P83, DOI 10.1016/S0306-4522(03)00322-1
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Fu JH, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-68
   Fukushima T, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0623-7
   Garnon J, 2005, J BIOL CHEM, V280, P5750, DOI 10.1074/jbc.M401988200
   Gordon GJ, 2002, CANCER RES, V62, P4963
   Gustafson AM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000251
   Hermjakob H, 2004, NUCLEIC ACIDS RES, V32, pD452, DOI 10.1093/nar/gkh052
   Huang C, 2003, CURR OPIN GENET DEV, V13, P246, DOI 10.1016/S0959-437X(03)00054-6
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Inoue M, 2000, ANN THORAC SURG, V70, P1615, DOI 10.1016/S0003-4975(00)01401-6
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Lam WK, 2004, INT J TUBERC LUNG D, V8, P1045
   Lodish H, 2008, MOL CELL BIOL
   Ouyang YD, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-100
   Pastorino U, 2010, BRIT J CANCER, V102, P1681, DOI 10.1038/sj.bjc.6605660
   Peri S, 2004, NUCLEIC ACIDS RES, V32, pD497, DOI 10.1093/nar/gkh070
   Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467
   PRASAD US, 1989, THORAX, V44, P784, DOI 10.1136/thx.44.10.784
   Sabe H, 2006, CURR OPIN CELL BIOL, V18, P558, DOI 10.1016/j.ceb.2006.08.002
   Sanchez-Palencia A, 2011, INT J CANCER, V129, P355, DOI 10.1002/ijc.25704
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   SHEPHERD FA, 1988, J CLIN ONCOL, V6, P832, DOI 10.1200/JCO.1988.6.5.832
   Spira A, 2007, NAT MED, V13, P361, DOI 10.1038/nm1556
   Tan HR, 2002, ARCH MICROBIOL, V177, P274, DOI 10.1007/s00203-001-0382-2
   Wang J, 2011, MED ONCOL, V28, pS577, DOI 10.1007/s12032-010-9734-6
   Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918
   Wu Shi-wu, 2013, Zhonghua Zhong Liu Za Zhi, V35, P124, DOI 10.3760/cma.j.issn.0253-3766.2013.02.010
   Youlden DR, 2008, J THORAC ONCOL, V3, P819, DOI 10.1097/JTO.0b013e31818020eb
   Zhang CG, 2000, GENOMICS, V63, P400, DOI 10.1006/geno.1999.6095
NR 38
TC 4
Z9 4
U1 4
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD DEC
PY 2014
VL 41
IS 12
BP 8203
EP 8210
DI 10.1007/s11033-014-3722-4
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CA6FQ
UT WOS:000349005800052
PM 25205123
DA 2018-12-27
ER

PT J
AU Kong, LY
   Li, GP
   Yang, P
   Wu, W
   Shi, JH
   Li, XL
   Wang, WZ
AF Kong, Ling-Yu
   Li, Guang-Peng
   Yang, Ping
   Wu, Wei
   Shi, Jin-He
   Li, Xue-Liang
   Wang, Wei-Zhen
TI RETRACTED: Identification of gene expression profile in the rat brain
   resulting from acute alcohol intoxication (Retracted article. See vol.
   42, pg. 1241, 2015)
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article; Retracted Publication
DE Acute alcohol intoxication; Gene expression profile; Rat model;
   Real-time PCR
ID CEREBELLAR GRANULE CELLS; ETHANOL INTOXICATION; NETWORK; MECHANISMS;
   BIOLOGY; SYSTEM; MICE; ORGANIZATION; DYSFUNCTION; TOLERANCE
AB This study aimed to identify gene expression profile in the rat brain resulting from acute alcohol intoxication (AAI). Eighteen SD rats were divided into the alcoholtreated group (n = 9) and saline control group (n = 9). Periorbital blood samples were taken to determine their blood alcohol content by gas chromatography. Tissue sections were analyzed by H and E staining and biochemical assays. Realtime reverse transcription PCR was used to validate microarray data. Statistical analysis was carried out using SPSS18.0 software (Version 18.0, SPSS Inc., Chicago, IL, USA). H and E staining demonstrated that alcohol-treated rats showed no obvious pathological changes in nerve cells compared with those in the control group. Biochemical tests revealed that alcohol-treated rats had lower superoxide dismutase activity than those in the control group (167.3 10.3 U/mg vs. 189.2 +/- 5.9 U/mg, P < 0.05). Furthermore, the malondialdehyde levels in alcohol-treated rats were higher than those in the control group (3.48 +/- 0.24 mmol/mg vs. 2.51 +/- 0.23 mmol/mg, P < 0.05). Microarray data presented 366 upregulated genes and 300 down-regulated genes in the AAI rat brain. Gene ontology analysis identified 31 genes up-regulated and 39 down-regulated among all differentially expressed genes. Twenty-four pathways showed significant differences, including 12 pathways involved with up-regulated genes and 12 pathways involved with down-regulated genes. Selected genes showed significantly different expression in both alcohol-treated and control groups (P < 0.05). Gene expression analysis enabled clustering of alcohol intoxication-related genes by function. These genes expression may be potential targets for treatment or drug screening for acute alcohol intoxication.
C1 [Kong, Ling-Yu; Li, Guang-Peng; Yang, Ping; Wu, Wei; Shi, Jin-He; Wang, Wei-Zhen] Xinxiang Med Univ, Dept Emergency, Affiliated Hosp 1, Weihui 453100, Peoples R China.
   [Li, Xue-Liang] Xinxiang Med Univ, Dept Crit Care Med, Affiliated Hosp 1, Weihui 453100, Peoples R China.
RP Shi, JH (reprint author), Xinxiang Med Univ, Dept Emergency, Affiliated Hosp 1, 88 Hlth Rd, Weihui 453100, Peoples R China.
EM shijinhe_888@163.com
CR Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Augustyniak A, 2010, METAB BRAIN DIS, V25, P381, DOI 10.1007/s11011-010-9217-7
   Banan A, 2000, J PHARMACOL EXP THER, V294, P997
   Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   Bjork JM, 2014, NEUROPHARMACOLOGY, V84, P101, DOI 10.1016/j.neuropharm.2013.07.039
   Brown RC, 2005, ENVIRON HEALTH PERSP, V113, P1250, DOI 10.1289/ehp.7567
   Chizhikov V, 2003, MOL GENET METAB, V80, P54, DOI 10.1016/j.ymgme.2003.08.019
   Clarke R, 2008, NAT REV CANCER, V8, P37, DOI 10.1038/nrc2294
   Darke S, 2013, ADDICTION, V108, P1411, DOI 10.1111/add.12191
   Maia CDF, 2009, NEUROTOXICOLOGY, V30, P23, DOI 10.1016/j.neuro.2008.11.008
   Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607
   Goral J, 2008, ALCOHOL, V42, P237, DOI 10.1016/j.alcohol.2008.02.003
   Heinz AJ, 2011, NAT REV NEUROSCI, V12, P400, DOI 10.1038/nrn3042
   Himes R, 2008, ALCOHOL CLIN EXP RES, V32, P1167, DOI 10.1111/j.1530-0277.2008.00736.x
   Hu W, 2008, J PHARMACOL EXP THER, V326, P792, DOI 10.1124/jpet.108.137521
   Huang CM, 2007, ALCOHOL CLIN EXP RES, V31, P336, DOI 10.1111/j.1530-0277.2006.00309.x
   Husain K, 2001, ALCOHOL, V25, P89, DOI 10.1016/S0741-8329(01)00176-8
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jordaan GP, 2012, METAB BRAIN DIS, V27, P67, DOI 10.1007/s11011-011-9273-7
   Jorntell H, 2006, J NEUROSCI, V26, P11786, DOI 10.1523/JNEUROSCI.2939-06.2006
   Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615
   Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063
   Keyes KM, 2012, EPIDEMIOL REV, V34, P89, DOI 10.1093/epirev/mxr018
   Kong EC, 2010, ALCOHOL CLIN EXP RES, V34, P302, DOI 10.1111/j.1530-0277.2009.01093.x
   Kong LM, 2012, AM J NEURORADIOL, V33, P928, DOI 10.3174/ajnr.A2873
   Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P123, DOI 10.1097/HTR.0b013e31820e6840
   Langfelder P, 2008, BIOINFORMATICS, V24, P719, DOI 10.1093/bioinformatics/btm563
   Le Moal M, 2007, EUR NEUROPSYCHOPHARM, V17, P377, DOI 10.1016/j.euroneuro.2006.10.006
   Liang J, 2007, J NEUROSCI, V27, P12367, DOI 10.1523/JNEUROSCI.2786-07.2007
   Liu PD, 2010, MOL BIOL EVOL, V27, P2628, DOI 10.1093/molbev/msq151
   Luo J, 2012, CEREBELLUM, V11, P145, DOI 10.1007/s12311-010-0219-0
   Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a
   Martin LJ, 2009, CEREB CORTEX, V19, P1273, DOI 10.1093/cercor/bhn167
   McClung CA, 2008, NEUROPSYCHOPHARMACOL, V33, P3, DOI 10.1038/sj.npp.1301544
   McKay JR, 2011, ALCOHOL RES HEALTH, V33, P356
   Mulligan MK, 2011, ALCOHOL CLIN EXP RES, V35, P659, DOI 10.1111/j.1530-0277.2010.01384.x
   Oner P, 2002, NEUROCHEM RES, V27, P1619, DOI 10.1023/A:1021678809464
   Prieto C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003911
   Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7
   Pujana MA, 2007, NAT GENET, V39, P1338, DOI 10.1038/ng.2007.2
   Ruggeri B, 2010, ALCOHOL CLIN EXP RES, V34, P90, DOI 10.1111/j.1530-0277.2009.01070.x
   Schlitt T, 2003, GENOME RES, V13, P2568, DOI 10.1101/gr.1111403
   Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Seymen P, 2013, INT J NEUROSCI, V123, P99, DOI 10.3109/00207454.2012.738732
   Tabakoff B, 2008, MAMM GENOME, V19, P352, DOI 10.1007/s00335-008-9115-z
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345
   Yi M, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-30
   Zhang B, 2005, STAT APPL GENET MO B, V4, DOI 10.2202/1544-6115.1128
   Zimatkin SM, 2006, ALCOHOL CLIN EXP RES, V30, P1500, DOI 10.1111/j.1530-0277.2006.00181.x
   Zoethout RWM, 2011, BRIT J CLIN PHARMACO, V71, P331, DOI 10.1111/j.1365-2125.2010.03846.x
NR 52
TC 1
Z9 1
U1 2
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD DEC
PY 2014
VL 41
IS 12
BP 8303
EP 8317
DI 10.1007/s11033-014-3731-3
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA CA6FQ
UT WOS:000349005800062
PM 25218841
DA 2018-12-27
ER

PT J
AU Kumari, P
   Chandran, P
   Khan, SS
AF Kumari, Pooja
   Chandran, Preethy
   Khan, S. Sudheer
TI RETRACTED: Synthesis and characterization of silver sulfide
   nanoparticles for photocatalytic and antimicrobial
   applications(Retracted article.See vol.166,pg.341,2017)
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article; Retracted Publication
ID VISIBLE-LIGHT; AG2S NANOPARTICLES; ANTIBACTERIAL PROPERTIES; FACILE
   PREPARATION; CDS NANOPARTICLES; CARBON NANOTUBES; METHYLENE-BLUE;
   DEGRADATION; FABRICATION; TIO2
AB The study describes a simple and novel method for the synthesis of silver sulfide nanoparticles (Ag2S NPs). The synthesized NPs were characterized by SEM (scanning electron microscope), XRD (X-ray diffraction), particle size analyzer, zeta sizer and EDX (Energy dispersive X-ray). The Ag2S NPs were spherical in shape with an effective diameter size of 30 nm. The synthesized particles possess photocatalytic activity under visible light and exhibited excellent antimicrobial effect. The photocatalytic property of Ag2S NPs was also evaluated by the degradation of methylene blue dye under visible light. NPs degraded 87% of methylene blue with in 1 h at pH 8. The NPs of 0.1 mu g/mL showed a growth inhibition of more than 75% against S. aureus (ATCC 25923), E. coli (ATCC 13534), and E. coli (ATCC 25922). (C) 2014 Elsevier B.V. All rights reserved.
C1 [Kumari, Pooja; Chandran, Preethy; Khan, S. Sudheer] SASTRA Univ, Sch Chem & Biotechnol, Ctr Nanotechnol & Adv Biomat, Thanjavur 613401, Tamil Nadu, India.
RP Khan, SS (reprint author), SASTRA Univ, Sch Chem & Biotechnol, CeNTAB, Thanjavur 613401, Tamil Nadu, India.
EM ssudheerkhan@gmail.com
CR Aazam ES, 2014, J IND ENG CHEM, V20, P4033, DOI 10.1016/j.jiec.2013.12.106
   Anthony SP, 2009, MATER LETT, V63, P773, DOI 10.1016/j.matlet.2008.12.051
   Das DP, 2011, J MOL CATAL A-CHEM, V349, P36, DOI 10.1016/j.molcata.2011.08.012
   Dong LH, 2008, J COLLOID INTERF SCI, V317, P485, DOI 10.1016/j.jcis.2007.09.055
   HODES G, 1976, NATURE, V261, P403, DOI 10.1038/261403a0
   Hong RY, 2009, POWDER TECHNOL, V189, P426, DOI 10.1016/j.powtec.2008.07.004
   Lim WP, 2004, ANGEW CHEM INT EDIT, V43, P5685, DOI 10.1002/anie.200460566
   Lu XF, 2005, NANOTECHNOLOGY, V16, P2233, DOI 10.1088/0957-4484/16/10/043
   Ma J, 2014, PHYSICA E, V58, P24, DOI 10.1016/j.physe.2013.11.006
   Ma XH, 2012, CHEMPHYSCHEM, V13, P2531, DOI 10.1002/cphc.201101013
   Meng ZD, 2012, J MATER CHEM, V22, P16127, DOI 10.1039/c2jm32344c
   Mo ZL, 2012, MATER LETT, V68, P416, DOI 10.1016/j.matlet.2011.11.006
   Nagasuna K, 2011, LANGMUIR, V27, P7294, DOI 10.1021/la200587s
   Neelgund GM, 2012, COLLOID SURFACE B, V100, P215, DOI 10.1016/j.colsurfb.2012.05.012
   Neelgund GM, 2011, APPL CATAL B-ENVIRON, V110, P99, DOI 10.1016/j.apcatb.2011.08.031
   Pang ML, 2010, J AM CHEM SOC, V132, P10771, DOI 10.1021/ja102105q
   Pourahmad A, 2012, SUPERLATTICE MICROST, V52, P276, DOI 10.1016/j.spmi.2012.05.009
   Soltani N, 2014, APPL SURF SCI, V290, P440, DOI 10.1016/j.apsusc.2013.11.104
   Soltani N, 2013, SOL ENERGY, V97, P147, DOI 10.1016/j.solener.2013.08.023
   Subash B, 2012, SEP PURIF TECHNOL, V96, P204, DOI 10.1016/j.seppur.2012.06.002
   Sun B, 2013, MATER LETT, V91, P142, DOI 10.1016/j.matlet.2012.09.074
   Wang DS, 2008, ADV MATER, V20, P2628, DOI 10.1002/adma.200800138
   Wang HL, 2008, ADV FUNCT MATER, V18, P1249, DOI 10.1002/adfm.200700953
   Wang WY, 2007, COLLOID SURFACE A, V302, P261, DOI 10.1016/j.colsurfa.2007.02.037
   Wei XJ, 2014, APPL SURF SCI, V290, P274, DOI 10.1016/j.apsusc.2013.11.067
   Wu CD, 2001, WATER RES, V35, P3927, DOI 10.1016/S0043-1354(01)00133-6
   Xie Y, 2012, MATER SCI ENG B-ADV, V177, P106, DOI 10.1016/j.mseb.2011.09.021
   Yang WS, 2013, COLLOID SURFACE A, V433, P55, DOI 10.1016/j.colsurfa.2013.05.007
NR 28
TC 18
Z9 18
U1 1
U2 52
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD DEC
PY 2014
VL 141
BP 235
EP 240
DI 10.1016/j.jphotobiol.2014.09.010
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA AY6FJ
UT WOS:000347662400028
PM 25463672
DA 2018-12-27
ER

PT J
AU Yin, AL
   Qiu, YW
   Jia, B
   Song, TR
   Yu, YH
   Alberts, I
   Zhong, M
AF Yin, Ailan
   Qiu, Yuwen
   Jia, Bei
   Song, Tianrong
   Yu, Yanhong
   Alberts, Ian
   Zhong, Mei
TI RETRACTED: The developmental pattern of the RAS/RAF/Erk1/2 pathway in
   the BTBR autism mouse model (Retracted article. See vol. 44, pg. 102,
   2015)
SO INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE
LA English
DT Article; Retracted Publication
DE Ras/Raf/Erk 1/2 signaling; Autism; BTBR mice; Autism mouse model;
   Synapse
ID SPECTRUM DISORDERS; SYNAPTIC PLASTICITY; NEURODEVELOPMENTAL DISORDERS;
   GENETIC VARIANT; INBRED STRAINS; CELL-LINE; MICE; ERK; MEMORY; BEHAVIOR
AB BTBR mice exhibit several autistic-like behaviors and are currently used as a model for understanding mechanisms that may be responsible for the pathogenesis of autism. Ras/Raf/ERK1/2 signaling has been suggested to play an important role in neural development, learning, memory, and cognition. Two studies reported that a deletion of a locus on chromosome 16 containing the mitogen-activated protein kinase 3 (MAPK3) gene, which encodes ERK1, is associated with autism. In the present study, Ras/Raf/ERK1/2 signaling was found to be up-regulated in BTBR mice relative to matched control B6 mice, to further suggest involvement in the pathogenesis of autism. To further characterize the developmental pattern of Ras/Raf/ERK1/2 signaling, varying stages during development were sampled to reveal an up-regulation in newborn and 2-week old BTBR mice relative to age-matched B6 mice. By the age of 3-week, Ras/Raf/ERK1/2 signaling in the brain of BTBR mice was unaltered relative to B6 mice, with this trend maintained in 6-week samples. These results suggest that the alteration of Ras/Raf/ERK signaling in the early developmental stages in mice could contribute to the noted autistic phenotype. Furthermore, these findings support the value of BTBR mice to serve as a human analog for autistic etiological research and aid in a better understanding of the developmental mechanisms of autism. (C) 2014 ISDN. Published by Elsevier Ltd. All rights reserved.
C1 [Yin, Ailan; Qiu, Yuwen; Jia, Bei; Song, Tianrong; Zhong, Mei] Nanfang Hosp, Dept Obstet & Gynecol, Guangzhou, Guangdong, Peoples R China.
   [Yin, Ailan; Yu, Yanhong] Southern Med Univ, Guangzhou, Guangdong, Peoples R China.
   [Alberts, Ian] CUNY, LarGuardia CC, Dept Nat Sci, New York, NY 11101 USA.
RP Zhong, M (reprint author), Nanfang Hosp, Dept Obstet & Gynecol, Guangzhou, Guangdong, Peoples R China.
EM drmzhong@gmail.com
CR Adams JP, 2002, ANNU REV PHARMACOL, V42, P135, DOI 10.1146/annurev.pharmtox.42.082701.145401
   Alarcon M, 2008, AM J HUM GENET, V82, P150, DOI 10.1016/j.ajhg.2007.09.005
   Araghi-Niknam M, 2003, CELL MOL NEUROBIOL, V23, P945, DOI 10.1023/B:CEMN.0000005322.27203.73
   Arking DE, 2008, AM J HUM GENET, V82, P160, DOI 10.1016/j.ajhg.2007.09.015
   Bakkaloglu B, 2008, AM J HUM GENET, V82, P165, DOI 10.1016/j.ajhg.2007.09.017
   Beaudoin GMJ, 2012, J NEUROSCI, V32, P99, DOI 10.1523/JNEUROSCI.4565-11.2012
   Belmonte MK, 2006, NAT NEUROSCI, V9, P1221, DOI 10.1038/nn1765
   Biou V, 2008, EUR J NEUROSCI, V27, P2847, DOI 10.1111/j.1460-9568.2008.06269.x
   Bolivar VJ, 2007, BEHAV BRAIN RES, V176, P21, DOI 10.1016/j.bbr.2006.09.007
   Butler MG, 2005, J MED GENET, V42, P318, DOI 10.1136/jmg.2004.024646
   Campbell DB, 2006, P NATL ACAD SCI USA, V103, P16834, DOI 10.1073/pnas.0605296103
   Chalhoub N, 2009, GENE DEV, V23, P1619, DOI 10.1101/gad.1799609
   Chen XH, 2009, BIOCHEM BIOPH RES CO, V379, P944, DOI 10.1016/j.bbrc.2008.12.177
   Courchesne E, 2011, BRAIN RES, V1380, P138, DOI 10.1016/j.brainres.2010.09.101
   Davis S, 2006, GENES BRAIN BEHAV, V5, P61, DOI 10.1111/j.1601-183X.2006.00230.x
   Durand CM, 2007, NAT GENET, V39, P25, DOI 10.1038/ng1933
   Ecker C, 2012, ARCH GEN PSYCHIAT, V69, P195, DOI 10.1001/archgenpsychiatry.2011.1251
   Elkobi A, 2008, NAT NEUROSCI, V11, P1149, DOI 10.1038/nn.2190
   Fatemi SH, 2001, NEUROREPORT, V12, P929, DOI 10.1097/00001756-200104170-00013
   Fatemi SH, 2001, SYNAPSE, V42, P281, DOI 10.1002/syn.10002
   Froemke RC, 2011, NEUROSCI BIOBEHAV R, V35, P2105, DOI 10.1016/j.neubiorev.2011.02.006
   Fujita E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030151
   Goffin A, 2001, AM J MED GENET, V105, P521, DOI 10.1002/ajmg.1477
   Gu Y, 2007, ACTA PHARMACOL SIN, V28, P928, DOI 10.1111/j.1745-7254.2007.00609.x
   Huang F, 2007, J NEUROSCI, V27, P9054, DOI 10.1523/JNEUROSCI.2410-07.2007
   Jones-Davis DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061829
   Kalkman HO, 2012, NEUROSCI BIOBEHAV R, V36, P2206, DOI 10.1016/j.neubiorev.2012.07.008
   Kim HG, 2008, AM J HUM GENET, V82, P199, DOI 10.1016/j.ajhg.2007.09.011
   Koike H, 2006, P NATL ACAD SCI USA, V103, P3693, DOI 10.1073/pnas.0511189103
   Kumar RA, 2008, HUM MOL GENET, V17, P628, DOI 10.1093/hmg/ddm376
   Lesuisse C, 2002, J CEREBR BLOOD F MET, V22, P935, DOI 10.1097/00004647-200208000-00005
   Levitt P, 2009, J CLIN INVEST, V119, P747, DOI 10.1172/JCI37934
   Longuet C, 2005, ENDOCRINOLOGY, V146, P643, DOI 10.1210/en.2004-0841
   Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4
   Marshall CR, 2008, AM J HUM GENET, V82, P477, DOI 10.1016/j.ajhg.2007.12.009
   Mazzucchelli C, 2000, CELL MOL LIFE SCI, V57, P604, DOI 10.1007/PL00000722
   Mazzucchelli C, 2002, NEURON, V34, P807, DOI 10.1016/S0896-6273(02)00716-X
   McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x
   McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394
   Mogha A, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2011.58
   Morrow EM, 2008, SCIENCE, V321, P218, DOI 10.1126/science.1157657
   Moy SS, 2007, BEHAV BRAIN RES, V176, P4, DOI 10.1016/j.bbr.2006.07.030
   Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009
   Peng FW, 2010, J BIOL CHEM, V285, P21615, DOI 10.1074/jbc.M110.107003
   Satoh Y, 2007, J NEUROSCI, V27, P10765, DOI 10.1523/JNEUROSCI.0117-07.2007
   Satoh Y, 2011, J NEUROSCI, V31, P1149, DOI 10.1523/JNEUROSCI.2243-10.2011
   Scattoni ML, 2009, NEUROSCI BIOBEHAV R, V33, P508, DOI 10.1016/j.neubiorev.2008.08.003
   Sgambato V, 1998, J NEUROSCI, V18, P8814
   Shalin SC, 2004, J NEUROSCI RES, V75, P760, DOI 10.1002/jnr.20052
   Sheikh AM, 2010, NEUROSCIENCE, V165, P363, DOI 10.1016/j.neuroscience.2009.10.035
   Sheikh AM, 2010, J NEUROSCI RES, V88, P2641, DOI 10.1002/jnr.22416
   Silverman JL, 2010, NEUROPSYCHOPHARMACOL, V35, P976, DOI 10.1038/npp.2009.201
   Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200
   Subramaniam S, 2010, FEBS J, V277, P22, DOI 10.1111/j.1742-4658.2009.07367.x
   Tada T, 2006, CURR OPIN NEUROBIOL, V16, P95, DOI 10.1016/j.conb.2005.12.001
   Thomas GM, 2004, NAT REV NEUROSCI, V5, P173, DOI 10.1038/nrn1346
   Vidal CN, 2008, PSYCHIAT RES-NEUROIM, V163, P106, DOI 10.1016/j.pscychresns.2007.11.002
   Wegiel J, 2010, ACTA NEUROPATHOL, V119, P755, DOI 10.1007/s00401-010-0655-4
   Weiss LA, 2008, NEW ENGL J MED, V358, P667, DOI 10.1056/NEJMoa075974
   Yang G, 2012, DEV NEUROBIOL, V72, P1391, DOI 10.1002/dneu.20996
   Yang M, 2007, FRONT BEHAV NEUROSCI, V1, DOI [10.3389/neuro.08.001.2007, 10.3389/neuro.08/001.2007]
   Yang M, 2007, INT J DEV NEUROSCI, V25, P515, DOI 10.1016/j.ijdevneu.2007.09.008
   Zoghbi HY, 2003, SCIENCE, V302, P826, DOI 10.1126/science.1089071
NR 63
TC 6
Z9 7
U1 1
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0736-5748
EI 1873-474X
J9 INT J DEV NEUROSCI
JI Int. J. Dev. Neurosci.
PD DEC
PY 2014
VL 39
SI SI
BP 2
EP 8
DI 10.1016/j.ijdevneu.2014.01.006
PG 7
WC Developmental Biology; Neurosciences
SC Developmental Biology; Neurosciences & Neurology
GA AZ1NT
UT WOS:000348006300002
PM 24631207
DA 2018-12-27
ER

PT J
AU Telleria, JL
AF Luis Telleria, Jose
TI RETRACTED: HAS THE NUMBER OF EUROPEAN ROBINS ERITHACUS RUBECULA
   WINTERING IN SPAIN DECREASED? (Retracted article. See vol. 62, pg. 185,
   2015)
SO ARDEOLA
LA English
DT Article; Retracted Publication
AB This paper explores the numerical trends of winter ring recoveries of the European robin Erithacus rubecula in Spain to determine whether the number of extra-Iberian individuals has decreased in recent decades. Results show that despite the increasing numbers of ringed and controlled robins, the number of recoveries of individuals of northern origin has decreased since the 1970s. This pattern is congruent with the northwards retreat of the wintering grounds of some partially migratory bird species that may be due to global warming.
C1 Univ Complutense, Fac Ciencias Biol, Dept Zool & Antropol Fis, E-28040 Madrid, Spain.
RP Telleria, JL (reprint author), Univ Complutense, Fac Ciencias Biol, Dept Zool & Antropol Fis, E-28040 Madrid, Spain.
EM telleria@bio.ucm.es
RI Telleria, Jose Luis/K-2944-2013
OI Telleria, Jose Luis/0000-0001-6170-8860
FU Spanish Ministry of Economy and Competitiveness [CGL2011-22953/BOS]
FX We are grateful to all bird ringers. Ricardo Gomez Calmaestra and Eva
   Banda of the Spanish Ministry of Agriculture, Food and Environment, and
   Chris du Feu of the European Union for Bird Ringing (EURING) kindly
   provided all facilities for working with robin ring recoveries. Two
   anonymous referees and E. Garcia considerably improved an early version
   of this paper. This note is a contribution to project CGL2011-22953/BOS
   (Conservation of migratory birds in Iberia and the Maghreb: present
   patterns and future changes) of the Spanish Ministry of Economy and
   Competitiveness.
CR Bueno Jose Manuel, 1998, Ardeola, V45, P193
   du Feu C.R., 2009, EURING DATA BANK GEO
   Onrubia A, 2012, ARDEOLA, V59, P123, DOI 10.13157/arla.59.1.2012.123
   Pautasso M, 2012, ITAL J ZOOL, V79, P296, DOI 10.1080/11250003.2011.627381
   SANTOS T., 1988, INVERNADA AVES PENIN, P167
   Speek G., 2001, EURING EXCHANGE CODE
   Visser ME, 2009, GLOBAL CHANGE BIOL, V15, P1859, DOI 10.1111/j.1365-2486.2009.01865.x
NR 7
TC 1
Z9 1
U1 2
U2 13
PU SOC ESPANOLA ORNITOLGIA
PI MADRID
PA MELQUIADAS BIENCINTO 34, E-28053 MADRID, SPAIN
SN 0570-7358
J9 ARDEOLA
JI Ardeola
PD DEC
PY 2014
VL 61
IS 2
BP 389
EP 391
DI 10.13157/arla.61.2.2014.389
PG 3
WC Ornithology
SC Zoology
GA AY2CF
UT WOS:000347395300012
DA 2018-12-27
ER

PT J
AU Collins, CS
AF Collins, Christopher S.
TI RETRACTED: Can funding for university partnerships between Africa and
   the US contribute to social development and poverty reduction?
   (Retracted article. See vol. 69, pg. 883, 2015)
SO HIGHER EDUCATION
LA English
DT Article; Retracted Publication
DE International partnerships; Development funding; Bureaucracy
AB This study explores US funding for university partnerships between the US and Africa. The primary objective was to study how funds are facilitated through partnerships to promote social development and poverty reduction. Findings include the innovative and resilient nature of the 11 projects included in the study as well as pitfalls in the bureaucratic system that administers the grants.
C1 Azusa Pacific Univ, Dept Higher Educ, Azusa, CA 91702 USA.
RP Collins, CS (reprint author), Azusa Pacific Univ, Dept Higher Educ, POB 7000, Azusa, CA 91702 USA.
EM christopher.s.collins@gmail.com
CR Assie-Lumumba N. D. T., 2006, HIGHER ED AFRICA CRI
   Bloom D., 2006, HIGHER ED EC DEV AFR
   Bradley M., 2007, N S RES PARTNERSHIPS
   Bradley M., 2008, NORRAG NEWS, V41, P26
   Clark B. R., 2004, SUSTAINING CHANGE U
   Collins C. S., 2011, HIGHER ED GLOBAL POV
   Collins CS, 2012, REV HIGH EDUC, V36, P91, DOI 10.1353/rhe.2012.0065
   Creswell J. W., 2003, RES DESIGN QUALITATI
   Deem R., 2008, HIGH EDUC POLICY, V21, P83, DOI DOI 10.1057/PALGRAVE.HEP.8300179
   Denzin N. K., 1970, RES ACT SOCIOLOGY TH
   Ernst John, 1998, FORGING FATEFUL ALLI
   Flyvbjerg B, 2011, SAGE HDB QUALITATIVE
   Jones N., 2007, RES CAPACITY STRENGT
   Kubler J., 2005, AFRICAN UK U PARTNER
   Kubler J., 2005, AFRICAN HIGHER ED AC
   Morfit C., 2008, US AFRICA HIGHER ED
   Obamba M., 2009, HIGH EDUC POLICY, V22, P349, DOI DOI 10.1057/HEP.2009.12
   Rhoads R. A., 2011, UCLA J ED INFORM STU, V7
   Roberts L., 2005, AFRICAN HIGHER ED DE
   Sale M. L., 2010, RES HIGHER ED, P6
   Samoff J., 2004, AFR STUD REV, V47, P67
   Scigliano R., 1965, TECHNICAL ASSISTANCE
   Slaughter S., 2004, ACAD CAPITALISM NEW
   Ssekamwa J. C., 2000, DEV ADM ED UGANDA
   Vincent-Lancrin S., 2009, HIGHER ED 2030, V2
   Wanni N, 2010, GOOD PRACTICES ED PA
   Yin R. K., 2003, CASE STUDY RES DESIG
NR 27
TC 6
Z9 6
U1 3
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0018-1560
EI 1573-174X
J9 HIGH EDUC
JI High. Educ.
PD DEC
PY 2014
VL 68
IS 6
BP 943
EP 958
DI 10.1007/s10734-014-9753-x
PG 16
WC Education & Educational Research
SC Education & Educational Research
GA AX5KA
UT WOS:000346963500010
DA 2018-12-27
ER

PT J
AU Bishop, J
AF Bishop, Jonathan
TI RETRACTED: Transforming the UK Home Office into a Department for
   Homeland Security: Reflecting on an Interview with a Litigant Defending
   Against Online Retaliatory Feedback in the US (Retracted article. See
   vol. 13, pg. 1, 2016)
SO JOURNAL OF HOMELAND SECURITY AND EMERGENCY MANAGEMENT
LA English
DT Article; Retracted Publication
DE community policing; constitutional reform; fake conferences; homeland
   security; retaliatory feedback
AB Retaliatory feedback is a significant problem on the Internet, which is not just confined to online auction websites, but other online environments dependent on reputation systems. Explored in this paper are the acts of an Internet troller who spread malicious and false allegations that the series of conferences called WORLDCOMP are "fake." This paper interviews one of the organisers of this conference to ask how they went about dealing with the retaliatory feedback, and in particular their engagement with law enforcement agencies, such as the FBI, which now forms part of the US Department of Homeland Security. To reform the UK Home Office to learn lessons from this, the paper proposes making greater use of National Crime Agency and Police and Crime Commissioners to provide a better strategic set-up for law enforcement under the UK Home Office. It also suggest using publicly funded solicitors and community wardens, as opposed to the current set-up of police constables, to deal with community policing. The paper concludes that in order for the promise made by the New Labour Government to be "tough on crime and tough on the causes of crime" to become a reality, encouraging peaceful discourses between community members and former offenders is essential.
C1 Ctr Res Online Commun & E Learning Syst, Swansea, W Glam, Wales.
RP Bishop, J (reprint author), Ctr Res Online Commun & E Learning Syst, Swansea, W Glam, Wales.
EM jonathan@jonathanbishop.com
OI Bishop, Jonathan/0000-0002-9919-7602
CR Beyene Y., 2008, INFOCOM WORKSH 2008, P1
   Binnendijk H., 2006, SEEING ELEPHANT US R
   Bishop J., 2010, INT REV LAW COMPUTER, V24, P299, DOI [10.1080/13600869.2010.522336, DOI 10.1080/13600869.2010.522336]
   Bishop J., 2014, EUROPEAN J LAW REFOR, V16, P154
   Bishop J., 2013, INT REV LAW COMPUTER, V27, P301, DOI DOI 10.1080/13600869.2013.796706
   Bishop J., 2012, 11 INT C SEC MAN SAM
   Bishop J, 2014, ADV HUM SOC ASPEC T, P1, DOI 10.4018/978-1-4666-5071-8.ch001
   Boynton F. D., 1929, MUSIC SUPERVISORS J, V15, P9
   Brown GW, 2006, HIST POLIT THOUGHT, V27, P661
   Buchanan H, 2007, PATIENT EDUC COUNS, V66, P263, DOI 10.1016/j.pec.2006.12.011
   Bush George W, 2002, NATL SECURITY STRATE
   Cannon R., 1996, FED COMM LJ, V49, P51
   Collier PM, 2008, MANAGING TO IMPROVE PUBLIC SERVICES, P46
   Edwards L., 2013, HDB INTERNET CRIME, P413
   Edwards Lilian, 2012, SCL J, V23
   Fowles T., 2012, HOWARD J PENAL JUSTI, V51, P100
   Fowles T., 2009, HOWARD J CRIMINAL JU, V48, P92
   Gadd B., 1989, PUBLIC MONEY MANAGE, V9, P49
   Gilling D., 2000, CORE ISSUES POLICING, P124
   Gowland J., 2013, J CRIMINAL LAW, V77, P387
   James Nalita, 2009, ONLINE INTERVIEWING
   Kapley D. J., 2007, STALKING PSYCHIAT PE, P141
   LOVEDAY B, 1990, LOCAL GOV STUD, V16, P37, DOI 10.1080/03003939008433516
   Malaga R. A., 2013, RETALIATORY FEEDBACK, P246
   Mali P., 2014, CYBER LAW CYBER CRIM
   Miller K. L., 2014, SO CALIFORNIA INTERD, V23, P217
   Mugabi I., HDB RES NEW THREATS
   Munir A. B., 2003, J MARSHALL J COMPUTE, V22, P731
   Newburn T., 2012, HOWARD J CRIMINAL JU, V51, P331
   Palfrey C., 1974, HOWARD J CRIMINAL JU, V14, P78
   Starmer K., 2013, GUIDELINES PROSECUTI
   Tarapdar S, 2013, CHILD INDIC RES, V6, P461, DOI 10.1007/s12187-012-9177-z
   Whitehead C. M., 1999, APPL EC EVALUATION P
NR 33
TC 1
Z9 1
U1 1
U2 11
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 2194-6361
EI 1547-7355
J9 J HOMEL SECUR EMERG
JI J. Homel. Secur. Emerg. Manag.
PD DEC
PY 2014
VL 11
IS 4
BP 511
EP 531
DI 10.1515/jhsem-2014-0038
PG 21
WC Public Administration
SC Public Administration
GA AX5XG
UT WOS:000346997400004
DA 2018-12-27
ER

PT J
AU Kaur, P
   Tomechko, S
   Kiselar, J
   Shi, WX
   Deperalta, G
   Wecksler, AT
   Gokulrangan, G
   Ling, V
   Chance, MR
AF Kaur, Parminder
   Tomechko, Sara
   Kiselar, Janna
   Shi, Wuxian
   Deperalta, Galahad
   Wecksler, Aaron T.
   Gokulrangan, Giridharan
   Ling, Victor
   Chance, Mark R.
TI RETRACTED: Characterizing monoclonal antibody structure by
   carbodiimide/GEE footprinting (Retracted article. See vol. 7, pg. 651,
   2015)
SO MABS
LA English
DT Article; Retracted Publication
DE protein structure; GEE; footprinting; structural proteomics; covalent
   labeling
ID PROTEIN SECONDARY STRUCTURE; AMINO-ACID-RESIDUES; HYDROXYL RADICAL
   PROBE; X-RAY RADIOLYSIS; MASS-SPECTROMETRY; CRYSTAL-STRUCTURE; PEPTIDES;
   DYNAMICS; BINDING; THERAPEUTICS
AB Amino acid-specific covalent labeling is well suited to probe protein structure and macromolecular interactions, especially for macromolecules and their complexes that are difficult to examine by alternative means, due to size, complexity, or instability. Here we present a detailed account of carbodiimide-based covalent labeling (with GEE tagging) applied to a glycosylated monoclonal antibody therapeutic, which represents an important class of biologic drugs. Characterization of such proteins and their antigen complexes is essential to development of new biologic-based medicines. In this study, the experiments were optimized to preserve the structural integrity of the protein, and experimental conditions were varied and replicated to establish the reproducibility and precision of the technique. Homology-based models were generated and used to compare the solvent accessibility of the labeled residues, which include D, E, and the C-terminus, against the experimental surface accessibility data in order to understand the accuracy of the approach in providing an unbiased assessment of structure. Data from the protein were also compared to reactivity measures of several model peptides to explain sequence or structure-based variations in reactivity. The results highlight several advantages of this approach. These include: the ease of use at the bench top, the linearity of the dose response plots at high levels of labeling (indicating that the label does not significantly perturb the structure of the protein), the high reproducibility of replicate experiments (<2 % variation in modification extent), the similar reactivity of the 3 target probe residues (as suggested by analysis of model peptides), and the overall positive and significant correlation of reactivity and solvent accessible surface area (the latter values predicted by the homology modeling). Attenuation of reactivity, in otherwise solvent accessible probes, is documented as arising from the effects of positive charge or bond formation between adjacent amine and carboxyl groups, the latter accompanied by observed water loss. The results are also compared with data from hydroxyl radical-mediated oxidative footprinting on the same protein, showing that complementary information is gained from the 2 approaches, although the number of target residues in carbodiimide/GEE labeling is fewer. Overall, this approach is an accurate and precise method for assessing protein structure of biologic drugs.
C1 [Kaur, Parminder; Tomechko, Sara; Kiselar, Janna; Shi, Wuxian; Gokulrangan, Giridharan; Chance, Mark R.] Case Western Reserve Univ, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA.
   [Kaur, Parminder; Chance, Mark R.] NeoProte Inc, Cleveland, OH USA.
   [Shi, Wuxian; Chance, Mark R.] Case Western Reserve Univ, Sch Med, Ctr Synchrotron Biosci, Cleveland, OH 44106 USA.
   [Deperalta, Galahad; Wecksler, Aaron T.; Ling, Victor] Genentech Inc, Prot Analyt Chem, San Francisco, CA 94080 USA.
RP Deperalta, G (reprint author), Case Western Reserve Univ, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA.
EM deperalta.galahad@gene.com; mark.chance@case.edu
FU NIH [R01-EB-09998, P30-EB-09866]
FX This work was supported in part by NIH R01-EB-09998 and P30-EB-09866.
CR ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223
   Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   Brenowitz M, 2002, CURR OPIN STRUC BIOL, V12, P648, DOI 10.1016/S0959-440X(02)00366-4
   BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019
   Chance MR, 2001, BIOCHEM BIOPH RES CO, V287, P614, DOI 10.1006/bbrc.2001.5628
   Chen D H, 1992, J Enzyme Inhib, V5, P259
   Chen JW, 2010, J AM CHEM SOC, V132, P15502, DOI 10.1021/ja106518d
   DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X
   Deperalta G, 2013, MABS-AUSTIN, V5, P86, DOI 10.4161/mabs.22964
   Dhavan GM, 2002, J MOL BIOL, V315, P1027, DOI 10.1006/jmbi.2001.5303
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Federici M, 2013, BIOLOGICALS, V41, P131, DOI 10.1016/j.biologicals.2012.10.001
   FERREIRA JPM, 1994, EUR J BIOCHEM, V223, P611, DOI 10.1111/j.1432-1033.1994.tb19032.x
   Frokjaer S, 2005, NAT REV DRUG DISCOV, V4, P298, DOI 10.1038/nrd1695
   Garidel Patrick, 2008, Biotechnology Journal, V3, P1201, DOI 10.1002/biot.200800091
   Guan JQ, 2005, BIOCHEMISTRY-US, V44, P3166, DOI 10.1021/bi048021j
   GUDDAT LW, 1993, P NATL ACAD SCI USA, V90, P4271, DOI 10.1073/pnas.90.9.4271
   Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508
   Harris M, 2004, LANCET ONCOL, V5, P292, DOI 10.1016/S1470-2045(04)01467-6
   Hegyi H, 1999, J MOL BIOL, V288, P147, DOI 10.1006/jmbi.1999.2661
   HOARE DG, 1968, J AM CHEM SOC, V90, P1638, DOI 10.1021/ja01008a040
   Houde D, 2011, J PHARM SCI-US, V100, P2071, DOI 10.1002/jps.22432
   Jiang YJ, 2011, J PHARM SCI-US, V100, P4631, DOI 10.1002/jps.22686
   Kaltashov IA, 2012, BIOTECHNOL ADV, V30, P210, DOI 10.1016/j.biotechadv.2011.05.006
   Kaur P, 2009, ANAL CHEM, V81, P8141, DOI 10.1021/ac9013644
   Kiselar JG, 2003, MOL CELL PROTEOMICS, V2, P1120, DOI 10.1074/mcp.M300068-MCP200
   Kiselar JG, 2002, INT J RADIAT BIOL, V78, P101, DOI 10.1080/09553000110094805
   Konermann L, 2008, J MASS SPECTROM, V43, P1021, DOI 10.1002/jms.1435
   Kueltzo LA, 2008, J PHARM SCI-US, V97, P1801, DOI 10.1002/jps.21110
   Laue TM, 2001, CURR PROTOC PROTEIN
   Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7
   Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973
   Liu YD, 2011, J BIOL CHEM, V286, P11211, DOI 10.1074/jbc.M110.185041
   Maleknia SD, 2002, RAPID COMMUN MASS SP, V16, P53, DOI 10.1002/rcm.543
   Maleknia SD, 2001, ANAL BIOCHEM, V289, P103, DOI 10.1006/abio.2000.4910
   Marcsisin SR, 2010, ANAL BIOANAL CHEM, V397, P967, DOI 10.1007/s00216-010-3556-4
   McCamish M, 2011, MABS-AUSTIN, V3, P209, DOI 10.4161/mabs.3.2.15005
   Mendoza VL, 2008, ANAL CHEM, V80, P2895, DOI 10.1021/ac701999b
   Mendoza VL, 2009, MASS SPECTROM REV, V28, P785, DOI 10.1002/mas.20203
   Moorhouse KG, 1997, J PHARMACEUT BIOMED, V16, P593, DOI 10.1016/S0731-7085(97)00178-7
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Pelton JT, 2000, ANAL BIOCHEM, V277, P167, DOI 10.1006/abio.1999.4320
   Rader RA, 2008, NAT BIOTECHNOL, V26, P743, DOI 10.1038/nbt0708-743
   Ralston CY, 2000, METHOD ENZYMOL, V317, P353
   Reichert JM, 2008, CURR PHARM BIOTECHNO, V9, P423, DOI 10.2174/138920108786786358
   Sadowski MI, 2009, CURR OPIN STRUC BIOL, V19, P357, DOI 10.1016/j.sbi.2009.03.008
   Sali A, 2003, NATURE, V422, P216, DOI 10.1038/nature01513
   Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692
   Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797
   Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879
   STADTMAN ER, 1991, J BIOL CHEM, V266, P17201
   TAHA TSM, 1992, BIOCHEMISTRY-US, V31, P9090, DOI 10.1021/bi00152a053
   Takamoto K, 2006, ANNU REV BIOPH BIOM, V35, P251, DOI 10.1146/annurev.biophys.35.040405.102050
   Torossian K, 1996, BIOCHEM J, V319, P21, DOI 10.1042/bj3190021
   Vahidi S, 2013, ANAL CHEM, V85, P8618, DOI 10.1021/ac401148z
   Walsh G, 2010, NAT BIOTECHNOL, V28, P917, DOI 10.1038/nbt0910-917
   Watson C, 2012, AAPS J, V14, P206, DOI 10.1208/s12248-012-9336-7
   Wen JZ, 2009, P NATL ACAD SCI USA, V106, P6134, DOI 10.1073/pnas.0901691106
   Willard L, 2003, NUCLEIC ACIDS RES, V31, P3316, DOI 10.1093/nar/gkg565
   WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q
   Witze ES, 2007, NAT METHODS, V4, P798, DOI 10.1038/nmeth1100
   Xu GH, 2007, CHEM REV, V107, P3514, DOI 10.1021/cr0682047
   Xu GZ, 2005, ANAL CHEM, V77, P3029, DOI 10.1021/ac048282z
   Xu GZ, 2005, ANAL CHEM, V77, P2437, DOI 10.1021/ac0484629
   Xu GZ, 2004, ANAL CHEM, V76, P1213, DOI 10.1021/ac035422g
   Xu GZ, 2003, ANAL CHEM, V75, P6995, DOI 10.1021/ac035104h
   Yu L, 2006, J PHARMACEUT BIOMED, V42, P455, DOI 10.1016/j.jpba.2006.05.008
   Zhang H, 2012, INT J MASS SPECTROM, V312, P78, DOI 10.1016/j.ijms.2011.07.015
   Zhang H, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005678
NR 69
TC 4
Z9 4
U1 1
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1942-0862
EI 1942-0870
J9 MABS-AUSTIN
JI mAbs
PD DEC
PY 2014
VL 6
IS 6
BP 1486
EP 1499
DI 10.4161/19420862.2014.975096
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AX4BH
UT WOS:000346878600014
PM 25484052
OA Green Published
DA 2018-12-27
ER

PT J
AU Chen, ZW
   Li, WJ
   Ning, Y
   Liu, T
   Shao, JX
   Wang, YJ
AF Chen, Zhaowei
   Li, Wenjing
   Ning, Yan
   Liu, Tong
   Shao, Jingxiang
   Wang, Yaojun
TI RETRACTED: Ski diminishes TGF-beta 1-induced myofibroblast phenotype via
   up-regulating Meox2 expression (Retracted article. See vol. 100, pg.
   362, 2016)
SO EXPERIMENTAL AND MOLECULAR PATHOLOGY
LA English
DT Article; Retracted Publication
DE TGF-beta 1; Ski; Expression of Meox2
ID TRANSFORMING-GROWTH-FACTOR; C-SKI; SCAR FORMATION; SIGNALING PATHWAY;
   WOUND REPAIR; FIBROBLAST; RECEPTOR; PROLIFERATION; REGENERATION;
   REPRESSOR
AB Objective: The aim of the present work was to investigate the mechanism of transforming growth factor (TGF)-beta 1 and Sloan-Kettering Institute (Ski) in the pathogenesis of hypertrophic scars (HS).
   Background: Wound healing is an inherent process, but the aberrant wound healing of skin injury may lead to HS. There has been growing evidence suggesting a role for TGF-beta 1 and Ski in the pathogenesis of fibrosis. Material and methods: The MTT assay was used to detect the cell proliferation induced by TGF-beta 1. The Ski gene was transduced into cells with an adenovirus, and then the function of Ski in cell proliferation and differentiation was observed. Ski mRNA levels were measured by RT-PCR. Western blotting was used to detect the protein expression of alpha-SMA, E-cadherin, Meox1, Meox2, Zeb1 and Zeb2.
   Results: TGF-beta 1 can promote human skin fibroblast (HSF) cell proliferation in a time-dependent manner, but the promoting effect could be suppressed by Ski. TGF-beta 1 also induces the formation of the myofibroblast phenotype and the effect of TGF-beta 1 could be diminished by Ski. Also, Ski modulates the cardiac myofibroblast phenotype and function through suppression of Zeb2 by up-regulating the expression of Meox2.
   Conclusions: Ski diminishes the myofibroblast phenotype induced by TGF-beta 1 through the suppression of Zeb2 by up-regulating the expression of Meox2. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Chen, Zhaowei; Li, Wenjing; Ning, Yan; Liu, Tong; Shao, Jingxiang] Liao Cheng Hosp, Dept Burns & Plast Surg, Liao Cheng 252000, Peoples R China.
   [Wang, Yaojun] Xi Jing Hosp, Dept Burns & Skin Surg, Xian 710032, Peoples R China.
RP Chen, ZW (reprint author), Liao Cheng Hosp, Dept Burns & Plast Surg, Liao Cheng 252000, Peoples R China.
EM zhaowei_chen@163.com
CR Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269
   Broughton G, 2006, PLAST RECONSTR SURG, V117, p12S, DOI 10.1097/01.prs.0000225430.42531.c2
   Carthy JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019809
   Chen Y, 2010, MOL CELL BIOL, V30, P3902, DOI 10.1128/MCB.01237-09
   Colwell AS, 2005, ADV BIOCHEM ENG BIOT, V93, P83, DOI 10.1007/b99972
   Colwell AS, 2003, FRONT BIOSCI, V8, pS1240, DOI 10.2741/1183
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Crider BJ, 2011, J INVEST DERMATOL, V131, P2378, DOI 10.1038/jid.2011.219
   Cunnington RH, 2014, J CELL SCI, V127, P40, DOI 10.1242/jcs.126722
   Cunnington RH, 2011, AM J PHYSIOL-CELL PH, V300, pC176, DOI 10.1152/ajpcell.00050.2010
   Czubryt MP, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-19
   Daskalopoulos EP, 2012, MICROSC MICROANAL, V18, P35, DOI 10.1017/S143192761101227X
   Ferguson MWJ, 2009, LANCET, V373, P1264, DOI 10.1016/S0140-6736(09)60322-6
   Ferrand N, 2010, CANCER RES, V70, P8457, DOI 10.1158/0008-5472.CAN-09-4088
   Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039
   Henderson E A, 2006, J Wound Care, V15, P315
   Kim BC, 2003, J CELL PHYSIOL, V195, P331, DOI 10.1002/jcp.10301
   Klass BR, 2009, POSTGRAD MED J, V85, P9, DOI 10.1136/pgmj.2008.069831
   Krein PM, 2002, CHEST, V122, p289S, DOI 10.1378/chest.122.6_suppl.289S
   Li J, 2013, CELL SIGNAL, V25, P159, DOI 10.1016/j.cellsig.2012.09.001
   Li J, 2012, CELL PHYSIOL BIOCHEM, V30, P1059, DOI 10.1159/000341482
   Li P, 2011, J PATHOL, V223, P659, DOI 10.1002/path.2831
   Liu X, 2010, CLIN EXP DERMATOL, V35, P417, DOI 10.1111/j.1365-2230.2009.03606.x
   Nagata M, 2006, GENES CELLS, V11, P1267, DOI 10.1111/j.1365-2443.2006.01018.x
   Nall AV, 1996, ARCH OTOLARYNGOL, V122, P171
   Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199
   Parsonage G, 2005, TRENDS IMMUNOL, V26, P150, DOI 10.1016/j.it.2004.11.014
   Pastar I, 2010, MOL MED, V16, P92, DOI 10.2119/molmed.2009.00149
   ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167
   Sarrazy V, 2011, WOUND REPAIR REGEN, V19, pS10, DOI 10.1111/j.1524-475X.2011.00708.x
   SHAH M, 1994, J CELL SCI, V107, P1137
   SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137
   SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462
   Suwanmanee S., 2014, EVID-BASED COMPL ALT, V2014
   Suzuki H, 2004, ONCOGENE, V23, P5068, DOI 10.1038/sj.onc.1207690
   Valcourt U, 2007, MOL ONCOL, V1, P55, DOI 10.1016/j.molonc.2007.02.002
   Wood F, 2012, CLIN PLAST SURG, V39, P21, DOI 10.1016/j.cps.2011.09.004
   Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797
NR 38
TC 8
Z9 9
U1 3
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4800
EI 1096-0945
J9 EXP MOL PATHOL
JI Exp. Mol. Pathol.
PD DEC
PY 2014
VL 97
IS 3
BP 542
EP 549
DI 10.1016/j.yexmp.2014.11.002
PG 8
WC Pathology
SC Pathology
GA AX1CK
UT WOS:000346685700030
PM 25445500
DA 2018-12-27
ER

PT J
AU Xu, WJ
   Guo, BL
   Han, YG
   Shi, L
   Ma, WS
AF Xu, Wan-Ju
   Guo, Bao-Li
   Han, Yu-Gang
   Shi, Lei
   Ma, Wan-Shan
TI RETRACTED: Diagnostic value of alpha-fetoprotein-L3 and Golgi protein 73
   in hepatocellular carcinomas with low AFP levels (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Alpha-fetoprotein-L3; Golgi protein 73; Hepatocellular carcinoma
ID ALPHA-FETOPROTEIN; CANCER BIOMARKERS; LIVER-DISEASES; PIVKA-II; SERUM;
   GP73; METAANALYSIS; MARKER; IMMUNOASSAY; EXPRESSION
AB This study aimed to investigate the clinical values of serum alpha-fetoprotein-L3 (AFP-L3) and Golgi protein 73 (GP73) in the diagnosis of hepatocellular carcinoma (HCC) with low alpha-fetoprotein (AFP). From January 2011 to December 2013, 50 low-AFP HCC patients confirmed by the color Doppler flow imaging (CDFI) and pathological examinations were collected. Forty-five patients with chronic liver diseases were also selected, including 29 liver cirrhosis patients, 15 chronic hepatitis B patients, and one severe hepatitis patient. Furthermore, 100 health volunteers with no evidence of benign or malignant liver diseases were included. The enzyme-linked immunosorbent assay (ELISA) method was applied to the GP73 quantitative assay. Serum AFP concentrations were determined using immunoassays utilizing enhanced chemiluminescence. Diagnostic accuracy of GP73 and AFP-L3 assays for low-AFP HCC was evaluated using receiver operating characteristic (ROC) curve analysis. Statistical analyses were conducted with the GraphPad Prism 5.0 software. Low-AFP HCC patients (35/50) exhibited higher positive rates of AFP-L3 than non-HCC patients (5/45) and healthy controls (2/100) (both P<0.05). There were also significant differences in the positive rate of GP73 of low-AFP HCC patients (40/50) compared to those of non-HCC patients (3/45) and healthy controls (1/100) (both P<0.05). However, no obvious differences in the positive rates of AFPL3 and GP73 were observed between non-HCC patients and healthy controls (both P>0.05). ROC curves showed that the area under the curve (AUC) of AFP-L3 for the diagnosis of low-AFP HCC was 0.6994 (sensitivity [Sen]=70.0 %, specificity [Spe]=95.2 %, accuracy=88.7 %), while the AUC of GP73 was 0.8411 (Sen=80.0 %, Spe=97.2 %, accuracy=92.8 %). Compared with single detection, the combination of AFP-L3 and GP73 levels for the diagnosis of low-AFP HCC showed higher Sen (94.0 %), Spe (93.1 %), and better accuracy (93.3 %). Our findings provide empirical evidence that the combination of AFP-L3 and GP73 is a good diagnostic strategy for low-AFP HCC.
C1 [Xu, Wan-Ju; Ma, Wan-Shan] Qianfoshan Hosp, Dept Clin Lab, Jinan 250014, Peoples R China.
   [Guo, Bao-Li] Zhangqiu Matern & Child Care Hosp, Dept Clin Lab, Zhangqiu 250200, Peoples R China.
   [Han, Yu-Gang] Elect Hosp, Dept Clin Lab, Jinan 250000, Peoples R China.
   [Shi, Lei] Jining Med Univ, Affiliated Hosp, Dept Clin Lab, Jining 272000, Peoples R China.
RP Ma, WS (reprint author), Qianfoshan Hosp, Dept Clin Lab, Jingshi Rd 16766, Jinan 250014, Peoples R China.
EM mawanshan723@yeah.net
CR [Anonymous], 2010, GUT, V59, P1687
   Ba MC, 2012, INT J CLIN EXP PATHO, V5, P874
   Bertino G, 2012, SEMIN ONCOL, V39, P410, DOI 10.1053/j.seminoncol.2012.05.001
   Chinese Society of Hepatology Chinese Medical Association, 2005, Zhonghua Gan Zang Bing Za Zhi, V13, P881
   Choi JY, 2013, WORLD J GASTROENTERO, V19, P339, DOI 10.3748/wjg.v19.i3.339
   Council for International Organizations of Medical Sciences, 2002, Bull Med Ethics, P17
   De Ioris M, 2008, EUR J CANCER, V44, P545, DOI 10.1016/j.ejca.2007.11.022
   Debruyne EN, 2008, CLIN CHIM ACTA, V395, P19, DOI 10.1016/j.cca.2008.05.010
   Dohmen K, 2003, HEPATO-GASTROENTEROL, V50, P2072
   El Gawad IAA, 2014, J EGYPT NATL CANCER, V26, P79, DOI 10.1016/j.jnci.2014.01.001
   Gan YL, 2014, TUMOR BIOL, V35, P3953, DOI 10.1007/s13277-013-1563-8
   Gu YL, 2009, ANN CLIN BIOCHEM, V46, P38, DOI 10.1258/acb.2008.008088
   He CZ, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-87
   Hou SC, 2013, ONCOL LETT, V6, P1152, DOI 10.3892/ol.2013.1522
   Hu B, 2013, INT J MOL SCI, V14, P23559, DOI 10.3390/ijms141223559
   Huang X, 2009, PEDIATR NEUROSURG, V45, P354, DOI 10.1159/000257524
   Kagebayashi C, 2009, ANAL BIOCHEM, V388, P306, DOI 10.1016/j.ab.2009.02.030
   Kladney RD, 2000, GENE, V249, P53, DOI 10.1016/S0378-1119(00)00136-0
   Li D, 2001, CLIN CHIM ACTA, V313, P15, DOI 10.1016/S0009-8981(01)00644-1
   Li XH, 2009, HEPATOLOGY, V50, P325, DOI 10.1002/hep.23028
   Li Y, 2012, CHEM COMMUN, V48, P537, DOI 10.1039/c1cc14886a
   Liang HY, 2012, CANCER BIOMARK, V11, P161, DOI 10.3233/CBM-2012-00276
   Liang RR, 2014, CURR PHARM DESIGN, V20, P1715, DOI 10.2174/13816128113199990533
   Liu XY, 2011, CLIN CHEM LAB MED, V49, P1311, DOI 10.1515/CCLM.2011.640
   Ma WJ, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-212
   Malaguarnera G, 2010, DIGEST DIS SCI, V55, P2744, DOI 10.1007/s10620-010-1184-7
   Marrero JA, 2009, GASTROENTEROLOGY, V137, P110, DOI 10.1053/j.gastro.2009.04.005
   Morota K, 2011, CLIN CHEM LAB MED, V49, P711, DOI 10.1515/CCLM.2011.097
   Murray MJ, 2011, ARCH DIS CHILDHOOD-E, V96, P141, DOI 10.1136/adc.2011.213181
   Nakagawa T, 2008, J PROTEOME RES, V7, P2222, DOI 10.1021/pr700841q
   Norton PA, 2008, J CELL BIOCHEM, V104, P136, DOI 10.1002/jcb.21610
   Ozkan H, 2012, DIGESTION, V86, P66, DOI 10.1159/000341224
   Ozkan H, 2011, DIGESTION, V83, P83, DOI 10.1159/000320379
   Sala M, 2004, LIVER TRANSPLANT, V10, P1294, DOI 10.1002/lt.20202
   Shiha G, 2009, HEPATOL INT, V3, P323, DOI 10.1007/s12072-008-9114-x
   Tateyama M, 2011, J GASTROENTEROL, V46, P92, DOI 10.1007/s00535-010-0293-6
   Taylor AD, 2009, GENOME MED, V1, DOI 10.1186/gm57
   Toyoda H, 2011, CANCER SCI, V102, P1025, DOI 10.1111/j.1349-7006.2011.01875.x
   Turati F, 2014, J HEPATOL, V60, P606, DOI 10.1016/j.jhep.2013.10.034
   Wang MJ, 2009, CANCER EPIDEM BIOMAR, V18, P1914, DOI 10.1158/1055-9965.EPI-08-0980
   Wang NY, 2014, ASIAN PAC J CANCER P, V15, P1539, DOI 10.7314/APJCP.2014.15.4.1539
   Yamamoto K, 2010, J GASTROENTEROL, V45, P1272, DOI 10.1007/s00535-010-0278-5
   Zhou Y, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-17
NR 43
TC 18
Z9 20
U1 3
U2 35
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2014
VL 35
IS 12
BP 12069
EP 12074
DI 10.1007/s13277-014-2506-8
PG 6
WC Oncology
SC Oncology
GA AX3UI
UT WOS:000346863700043
PM 25209179
DA 2018-12-27
ER

PT J
AU Manesh, JYY
   Shafiee, R
   Pedram, B
   Malayeri, HZ
   Mohajer, S
   Ahmadi, S
   Ahmadi, S
   Javanbakht, J
   Mokarizadeh, A
   Khadivar, F
AF Manesh, Javad Yaghoobi Yeganeh
   Shafiee, Radmehr
   Pedram, Behnam
   Malayeri, Hamed Zamankhan
   Mohajer, Sheida
   Ahmadi, Sharareh
   Ahmadi, Shirin
   Javanbakht, Javad
   Mokarizadeh, Aram
   Khadivar, Farshid
TI RETRACTED: Improving the diagnosis, treatment, and biology patterns of
   feline mammary intraepithelial lesions: a potential model for human
   breast masses with evidence from epidemiologic and cytohistopathologic
   studies (Retracted article. See vol.37, pg. 16413, 2016)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Mammary gland; Feline; Masses; Diagnosis; Treatment
ID PROLIFERATIVE ACTIVITY; PROGNOSTIC FACTORS; NEEDLE ASPIRATION;
   ESTROGEN-RECEPTOR; GLAND TUMORS; CARCINOMA; CANCER; FEATURES
AB In this study, the frequency of different types of mammary masses and their relationship with cytohistopathologic changes was investigated and data on history, macroscopic description, clinical examination and treatment were collected. To determine the prevalence and types of cytohistopathologic changes, mammary glands from 12 female cats were evaluated. The mean age of cats at the time of diagnosis was 11.5 +/- 1.9 years (range 4-14 years), the mean gross size of the masses was 3.1 +/- 2.4 cm, 4/12 (33.3 %) masses were <= 3.0 cm in diameter, and the maximum diameter of the largest mass had a median of 5 cm, with a range of diameter of 6x5x4 cm. Moreover, the preferential localization of mammary masses was the abdominal lobes (%50) and thoracic lobes (%33.3), and inguinal lobes (%16.7 of cases). Furthermore, two cases of the inguinal masses affected the caudo-inguinal lobe, six cases caudo-abdominal lobe, and thoracic masses were found in four cases. Eventually, six cases (%50) of masses were found in the right mammary lobes and six cases (%50) in the left mammary lobes. The majority of the masses revealed elastic (%50 of cases), hard (%25 of cases), or soft (%25 of cases) consistency. In the present study, according to the criteria of the veterinary and the medical WHO classification system, of the 12 cats with the cytohistopathological features of six (50 %) cases qualified abscess, 3 (25 %) cases as cystic hyperplasia and 3 (25 %) cases were called situ carcinoma. Whereas, all hyperplastic lesions (case nos. 7-9 and ranging in size from, 1 to >4 cm(3)) and carcinomas in situ lesions (case nos. 10-12 and ranging in size from, 1 to >3 cm(3)) were found incidentally upon routine cytohistology. Other lesions were observed grossly and removed either at surgery (case nos. 1-6). Finally, the cats were treated with unilateral lumpectomy (3 cases) and also, nine (75%) cases had subsequent drainage, 3 (25%) of which showed cystic hyperplasia and 6 (50%) showed abscess on subsequent histopathological evaluation. Therefore, a correct diagnosis must be established quickly, and treatment must be instituted rapidly when alteration is noted in the mammary glands.
C1 [Manesh, Javad Yaghoobi Yeganeh] Shahrekord Univ, Gradute Islamic Azad Univ Shahrekord, Fac Vet Med, Shahrekord, Iran.
   [Shafiee, Radmehr; Khadivar, Farshid] Univ Tehran, Fac Vet Med, Tehran, Iran.
   [Pedram, Behnam] Islamic Azad Univ, Susangerd Branch, Dept Pathobiol, Susangerd, Iran.
   [Malayeri, Hamed Zamankhan] Univ Tehran, Fac Vet Med, Dept Internal Med, Tehran, Iran.
   [Mohajer, Sheida] Shahid Beheshti Univ Med, Massih Daneshvary Hosp, Natl Res Inst TB & Lung Dis, Chron Resp Dis Res Ctr, Tehran, Iran.
   [Ahmadi, Sharareh; Ahmadi, Shirin] Kermanshah Univ Med Sci, Fac Med, Kermanshah, Iran.
   [Javanbakht, Javad] Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
   [Mokarizadeh, Aram] Kurdistan Univ Med Sci, Dept Immunol, Fac Med, Sanandaj, Iran.
RP Javanbakht, J (reprint author), Univ Tehran, Fac Vet Med, Dept Pathol, Tehran, Iran.
EM javadpatho@gmail.com; A.mokarizadeh@muk.ac.ir
OI Mokarizadeh, Aram/0000-0002-2630-8308; Abdi,
   Mohammad/0000-0002-4766-0423
CR AMIR LH, 2004, BMC PREGNANCY CHILDB, V4, P19, DOI DOI 10.1186/1471-2393-4-19
   Baker R, 2000, COLOR ATLAS CYTOLOGY, P253
   Bibbo M, 1997, COMPREHENSIVE CYTOPA, P413
   CAMERON AM, 1971, J NATL CANCER I, V47, P1277
   Carpenter J. L., 1987, Diseases of the cat: medicine and surgery. Volume 1., P406
   Couto SS, 2002, VET PATHOL, V39, P33, DOI 10.1354/vp.39-1-33
   Crosby J H, 1996, J Med Assoc Ga, V85, P33
   Dixon J, 2006, ABC BREAST DIS, P19
   Hahn KA, 1997, FELINE PRACT, V25, P5
   Hansen Palle Bo, 2003, Ugeskr Laeger, V165, P128
   HAYES HM, 1981, VET REC, V108, P476, DOI 10.1136/vr.108.22.476
   Javanbakht J, 2014, TUMOR BIOL, V35, P5493, DOI 10.1007/s13277-014-1723-5
   Kvist LJ, 2005, BJOG-INT J OBSTET GY, V112, P1070, DOI 10.1111/j.1471-0528.2005.00659.x
   Liberman L, 1996, RADIOLOGY, V198, P121, DOI 10.1148/radiology.198.1.8539362
   MACEWEN EG, 1990, CANCER METAST REV, V9, P125, DOI 10.1007/BF00046339
   MACEWEN EG, 1984, J AM VET MED ASSOC, V185, P201
   Millanta F, 2002, VET PATHOL, V39, P120, DOI 10.1354/vp.39-1-120
   Misdorp W., 2002, Tumors in domestic animals, P575, DOI 10.1002/9780470376928.ch12
   Misdorp W, 1999, HISTOLOGIC CLASSIFIC, P3
   Morris JS, 2010, VET J, V184, P3, DOI 10.1016/j.tvjl.2009.07.003
   Murphy S, 2009, C P EUR SOC FEL MED, P11
   Nieto A, 2000, VET PATHOL, V37, P239, DOI 10.1354/vp.37-3-239
   Ogilvie GK, 1992, TRENTON VET LEARNING, P74
   Osterman K L, 2000, J Hum Lact, V16, P297, DOI 10.1177/089033440001600405
   PONTIFEX AH, 1985, ACTA CYTOL, V29, P979
   Rosen PP, 1993, TUMORS MAMMARY GLAND, P390
   Rutteman GR, 2001, SMALL ANIMAL CLIN ON, P467
   Sarli G, 2002, J VET DIAGN INVEST, V14, P25, DOI 10.1177/104063870201400106
   Schwarz RJ, 2001, AM J SURG, V182, P117, DOI 10.1016/S0002-9610(01)00683-3
   Seixas Travassos MA, 2006, THESIS U TRAS OS MON, P194
   Shafiee R, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-136
   Shafiee R, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-79
   TOMLINSON MJ, 1984, CAN VET J, V25, P435
   WEIJER K, 1972, J NATL CANCER I, V49, P1697, DOI 10.1093/jnci/49.6.1697
   WEIJER K, 1983, J NATL CANCER I, V70, P709
   Yang WY, 2006, J COMP PATHOL, V134, P70, DOI 10.1016/j.jcpa.2005.07.002
   Zappulli V, 2005, J DAIRY RES, V72, P98, DOI 10.1017/S0022029905001263
NR 37
TC 5
Z9 5
U1 1
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2014
VL 35
IS 12
BP 12109
EP 12117
DI 10.1007/s13277-014-2515-7
PG 9
WC Oncology
SC Oncology
GA AX3UI
UT WOS:000346863700049
PM 25142235
DA 2018-12-27
ER

PT J
AU Su, ZX
   Zhao, J
   Rong, ZH
   Wu, YG
   Geng, WM
   Qin, CK
AF Su, Zhong-Xue
   Zhao, Juan
   Rong, Zhong-Hou
   Wu, Ya-Guang
   Geng, Wen-Mao
   Qin, Cheng-Kun
TI RETRACTED: Diagnostic and prognostic value of circulating miR-18a in the
   plasma of patients with gastric cancer (Retracted article. See April,
   2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE mir-18a; Biomarker; Prognosis; Gastric cancer
ID HEPATOCELLULAR-CARCINOMA; BLADDER-CANCER; MICRORNA; EXPRESSION;
   BIOMARKERS; PROLIFERATION; PROFILES; CLUSTER; CELLS
AB The aim of this manuscript is to analyze the diagnostic and prognostic value of circulating miR-18a in the plasma of patients with gastric cancer. In this study, 82 patients with gastric cancer and 65 healthy controls were enrolled in the study, and 10 ml of peripheral venous blood was collected for RNA extraction. miR-18a expression was determined using TaqMan quantitative real-time polymerase chain reaction assay and was further correlated with patients' clinicopathological parameters and the follow-up data. The results indicated that plasma miR-18a was upregulated in gastric cancer patients compared with healthy controls (P<0.001). miR-18a yielded an area under the receiver-operating characteristic curve of 0.907 with 80.5 % sensitivity and 84.6 % specificity in discriminating gastric cancer from healthy controls. Plasma miR-18a expression was significantly associated with pathological grade (P=0.036) and lymph node status (P=0.025), but not with tumor stage (P=0.075). Both log-rank test and univariate Cox regression analysis showed that the higher miR-18a expression in plasma was associated with shorter disease-free survival and disease-specific survival of the patients with gastric cancer (P=0.023 and P=0.027; P=0.036 and P=0.043, respectively), which was also not proven by multivariate Cox regression analysis (P=0.238 and P=0.160, respectively). In conclusion, this study showed that miR-18a may be a promising biomarker for the detection of gastric cancer and its upregulation may be potentially associated with unfavorable prognosis of bladder cancer, suggesting that miR-18a might serve as a potential biological marker for further risk stratification in the management of gastric cancer.
C1 [Su, Zhong-Xue; Rong, Zhong-Hou; Wu, Ya-Guang; Geng, Wen-Mao; Qin, Cheng-Kun] Shandong Univ, Shandong Prov Hosp, Dept Hepatoliary Surg, Jinan 250021, Shandong, Peoples R China.
   [Zhao, Juan] Shandong Univ, Shandong Prov Hosp, Dept Hematol, Jinan 250021, Peoples R China.
RP Su, ZX (reprint author), Shandong Univ, Shandong Prov Hosp, Dept Hepatoliary Surg, 324 JingWu Rd, Jinan 250021, Shandong, Peoples R China.
EM suzhongxuesd@yeah.net
CR Chen WJ, 2013, TUMOR BIOL, V34, P455, DOI 10.1007/s13277-012-0570-5
   Etheridge A, 2011, MUTAT RES-FUND MOL M, V717, P85, DOI 10.1016/j.mrfmmm.2011.03.004
   Fang N, 2014, TUMOR BIOL, V35, P3261, DOI 10.1007/s13277-013-1426-3
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gao W, 2011, J CANCER RES CLIN, V137, P557, DOI 10.1007/s00432-010-0918-4
   Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148
   Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6
   Hirajima S, 2013, BRIT J CANCER, V108, P1822, DOI 10.1038/bjc.2013.148
   Jay C, 2007, DNA CELL BIOL, V26, P293, DOI 10.1089/dna.2006.0554
   Kim DW, 2011, J KOREAN MED SCI, V26, P875, DOI 10.3346/jkms.2011.26.7.875
   Komatsu S, 2014, IN VIVO, V28, P293
   Li C, 2013, J SURG ONCOL, V108, P89, DOI 10.1002/jso.23358
   Li LH, 2012, DIGEST DIS SCI, V57, P2910, DOI 10.1007/s10620-012-2317-y
   Liu GH, 2013, TUMOR BIOL, V34, P2175, DOI 10.1007/s13277-013-0753-8
   Liu HS, 2012, CANCER LETT, V316, P196, DOI 10.1016/j.canlet.2011.10.034
   Liu R, 2011, EUR J CANCER, V47, P784, DOI 10.1016/j.ejca.2010.10.025
   Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029
   Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283
   Murata K, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3013
   Pinto-Leite R, 2014, TUMOR BIOL, V35, P4599, DOI 10.1007/s13277-013-1604-3
   Society AC, 2012, CANC FACTS FIG
   Song LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025454
   Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228
   Tao J, 2012, MOL MED REP, V5, P167, DOI 10.3892/mmr.2011.591
   Tsujiura M, 2010, BRIT J CANCER, V102, P1174, DOI 10.1038/sj.bjc.6605608
   Wang J, 2012, SURG ONCOL, V21, P119, DOI 10.1016/j.suronc.2010.12.004
   Wang M, 2012, MOL MED REP, V5, P1514, DOI 10.3892/mmr.2012.828
   Wang YX, 2010, J DIGEST DIS, V11, P50, DOI 10.1111/j.1751-2980.2009.00413.x
   Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200
   Wu CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057036
   Wu W, 2013, BRIT J CANCER, V108, P653, DOI 10.1038/bjc.2012.587
   Yao Y, 2009, MOL MED REP, V2, P963, DOI 10.3892/mmr_00000199
NR 32
TC 35
Z9 38
U1 3
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2014
VL 35
IS 12
BP 12119
EP 12125
DI 10.1007/s13277-014-2516-6
PG 7
WC Oncology
SC Oncology
GA AX3UI
UT WOS:000346863700050
PM 25416437
DA 2018-12-27
ER

PT J
AU Li, KN
   Zhong, C
   Wang, J
   Wang, BC
   He, J
   Bi, JW
AF Li, Kainan
   Zhong, Chen
   Wang, Jun
   Wang, Baocheng
   He, Jun
   Bi, Jingwang
TI RETRACTED: Association of androgen receptor exon 1 CAG repeat length
   with risk of hepatocellular carcinoma: a case-control study (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Hepatocellular carcinoma; Androgen receptor; CAG; Repeat length
ID TRINUCLEOTIDE REPEATS; GENE; LIVER; CHINA; POLYMORPHISMS; CANCER;
   BIOTRANSFORMATION; POPULATION; METABOLISM; MUTATIONS
AB Epidemiologic and biological data suggest a role for androgens and perhaps their receptor in hepatocellular carcinoma (HCC) development. However, few studies evaluated an association between HCC risk and androgen receptor (AR) cytosine, adenine, guanine (CAG) repeat length. To examine whether the relationship between the AR CAG repeats and HCC risk was also evident in Chinese, we conducted this large population-based, case-control study of 2,000 pathologically confirmed HCC patients and 2,000 frequency-matched controls. Two different approaches for AR CAG repeat length (analyses with continuous and categorized polymorphism variables) were conducted in the statistical analyses. For AR CAG longer allele (CAG_L), we found that subjects with longer AR CAG_L repeats had a decreased risk of developing HCC (OR=0.87 for per CAG_A increase, 95% CI 0.82-0.96, P=5.33x10(-4)). Compared to those with the shorter (<23) CAG_L repeat length, subjects in the category of longer (>= 23) CAG_L repeats had a significant 20 % decreased HCC risk (OR=0.80, 95 % CI 0.71-0.91, P=6.16x10(-4)). These findings suggest that androgen signaling underlies the development of HCC.
C1 [Li, Kainan; Zhong, Chen; Wang, Jun; Wang, Baocheng; Bi, Jingwang] Gen Hosp Jinan Mil Reg, Dept Oncol, Jinan 250031, Shandong, Peoples R China.
   [He, Jun] Gen Hosp Jinan Mil Reg, Dept Emergency Med, Jinan 250031, Shandong, Peoples R China.
RP Bi, JW (reprint author), Gen Hosp Jinan Mil Reg, Dept Oncol, 25 Shifan Rd, Jinan 250031, Shandong, Peoples R China.
EM jiwangbisd@126.com
CR ABDELGADIR SE, 1990, J STEROID BIOCHEM, V37, P545, DOI 10.1016/0960-0760(90)90399-6
   CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181
   Chang C, 2014, ONCOGENE, V33, P3225, DOI 10.1038/onc.2013.274
   Clark Peter E, 2003, Methods Mol Med, V81, P255
   DAVIES HR, 1995, CLIN ENDOCRINOL, V43, P69
   Deng Y, 2014, TUMOUR BIOL
   Ferro P, 2002, MOL CELL ENDOCRINOL, V193, P109, DOI 10.1016/S0303-7207(02)00104-1
   FIRMINGER H, 1961, J NATL CANCER I, V27, P559
   Gao B, 1996, MOL CELL BIOL, V16, P5997
   Granata OM, 2009, J STEROID BIOCHEM, V113, P290, DOI 10.1016/j.jsbmb.2009.01.013
   Hsing AW, 2000, CANCER RES, V60, P5111
   LANGNER A, 1990, PHARMAZIE, V45, P636
   Liang L, 1996, Zhonghua Zhong Liu Za Zhi, V18, P214
   Long XD, 2013, EPIDEMIOLOGY, V24, P671, DOI 10.1097/EDE.0b013e31829d2744
   Mourad A, 2014, HEPATOLOGY, V59, P1471, DOI 10.1002/hep.26944
   Naveed M, 2014, GASTROENTEROLOGY
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Schildkraut JM, 2007, CANCER EPIDEM BIOMAR, V16, P473, DOI 10.1158/1055-9965.EPI-06-0868
   SLEDDENS HFBM, 1993, HUM MOL GENET, V2, P493, DOI 10.1093/hmg/2.4.493
   SLEDDENS HFBM, 1992, NUCLEIC ACIDS RES, V20, P1427
   Song PP, 2013, BIOSCI TRENDS, V7, P250, DOI 10.5582/bst.2013.v7.5.250
   Song PP, 2013, LIVER CANCER, V2, P31, DOI 10.1159/000346220
   TOH YC, 1981, CARCINOGENESIS, V2, P1219, DOI 10.1093/carcin/2.11.1219
   Wu J, 2013, GENET TEST MOL BIOMA, V17, P595, DOI 10.1089/gtmb.2013.0031
   Yeh SH, 2002, CANCER RES, V62, P4346
   Yeh SH, 2007, INT J CANCER, V120, P1610, DOI 10.1002/ijc.22479
   Yu MW, 2002, HEPATOLOGY, V36, P156, DOI 10.1053/jhep.2002.33897
   Yu MW, 2000, J NATL CANCER I, V92, P2023, DOI 10.1093/jnci/92.24.2023
   Zheng JS, 2014, TUMOR BIOL, V35, P2265, DOI 10.1007/s13277-013-1300-3
NR 29
TC 2
Z9 2
U1 3
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2014
VL 35
IS 12
BP 12519
EP 12523
DI 10.1007/s13277-014-2570-0
PG 5
WC Oncology
SC Oncology
GA AX3UI
UT WOS:000346863700096
PM 25217983
DA 2018-12-27
ER

PT J
AU Luo, KQ
   Shi, YN
   Peng, JC
AF Luo, Ke-qin
   Shi, Yi-ni
   Peng, Ji-cai
TI RETRACTED: The effect of chemokine CC motif ligand 19 on the
   proliferation and migration of hepatocellular carcinoma (Retracted
   article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Chemokines; Chemokine receptors; CCL19; CCR7; Hepatocellular carcinoma;
   Proliferation; Migration
ID ANTITUMOR EFFICACY; CANCER; METASTASIS; CELLS
AB Multiple studies have shown that CC motif chemokine ligand 19 (CCL19) promotes cell proliferation in several human cancers. The aim of this study was to investigate the expression and function of CCL19 in hepatocellular carcinoma (HCC). Quantitative reverse transcription-polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry were performed separately to detect the expression of CCL19 in HCC tissues. The expression of CCL19 and its receptor (CCR7) in different HCC cell lines were screened by Western blot. HCC cell lines were screened and processed with recombinant human CCL19 (rhCCL19) or si-CCL19 RNA. Cell proliferation assay and transwell assay were performed to evaluate the proliferation and migration of HCC cells, respectively. Low expression of CCL19 was observed in 83.72 % (72/86) of the HCC versus 16.67 % (4/24) of the adjacent non-tumorous liver tissues, the difference of CCL19 expression between HCC and adjacent non-tumorous liver tissues was statistically significant (P<0.001). The expression level of CCL19 mRNA and protein in tumor tissues was significantly lower than adjacent non-tumorous liver tissues. The proliferation and migration of HCC cells were obviously inhibited in rhCCL19-treated groups. Our data suggest that CCL19 may play a suppressive role in the regulation of aggressiveness in human HCC.
C1 [Luo, Ke-qin; Shi, Yi-ni; Peng, Ji-cai] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Emergency, Guangzhou 510120, Peoples R China.
RP Luo, KQ (reprint author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Emergency, 107 Yan Jiangxi Rd, Guangzhou 510120, Peoples R China.
EM doctorkqluo@126.com
CR Ades S, 2009, ONCOLOGY-NY, V23, P162
   Cao M, 2007, BIOTECHNOL APPL BIOC, V48, P109, DOI 10.1042/BA20070038
   Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Frangov T, 2007, Khirurgiia (Sofiia), P36
   Gao Q, 2012, CANCER RES, V72, P3546, DOI 10.1158/0008-5472.CAN-11-4032
   Hamanishi J, 2010, STEM CELLS, V28, P164, DOI 10.1002/stem.256
   Itakura M, 2013, BRIT J CANCER, V109, P1100, DOI 10.1038/bjc.2013.440
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Johrer K, 2008, EXPERT OPIN BIOL TH, V8, P269, DOI 10.1517/14712598.8.3.269 
   Kochetkova M, 2009, CELL DEATH DIFFER, V16, P664, DOI 10.1038/cdd.2008.190
   Lu J, 2014, DIGEST DIS SCI, V59, P2153, DOI 10.1007/s10620-014-3138-y
   Oliveira-Neto HH, 2013, TUMOR BIOL, V34, P65, DOI 10.1007/s13277-012-0511-3
   Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078
   Shang ZJ, 2009, ORAL ONCOL, V45, P480, DOI 10.1016/j.oraloncology.2008.06.005
   Wang WL, 2013, CANCER SCI, V104, P1523, DOI 10.1111/cas.12279
NR 16
TC 4
Z9 4
U1 4
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2014
VL 35
IS 12
BP 12575
EP 12581
DI 10.1007/s13277-014-2578-5
PG 7
WC Oncology
SC Oncology
GA AX3UI
UT WOS:000346863700103
PM 25225162
DA 2018-12-27
ER

PT J
AU Kenari, MA
AF Kenari, Mohammad Alibakhshi
TI RETRACTED: Introducing the new wideband small plate antennas with
   engraved voids to form new geometries based on CRLH MTM-TLs for wireless
   applications(Retracted article.See vol.8,pg.1265, 2016)
SO INTERNATIONAL JOURNAL OF MICROWAVE AND WIRELESS TECHNOLOGIES
LA English
DT Article; Retracted Publication
DE Engraved antennas; J- and I-formed voids; Composite right/left-handed
   transmission lines (CRLH-TLs); Metamaterial (MTM); Wideband small plate
   antennas; Wireless applications
AB In this paper, four new wideband small antennas based on the composite right/left-handed transmission line (CRLH-TL) structures are designed, tooled, and made. The proposed antennas are introduced with best in size, bandwidth, and radiation patterns. The physical size and the operational frequency of the antennas depend on size of the unit cells and the equivalent transmission line model parameters of the CRLH-TLs, including series inductance, series capacitance, shunt inductance, and shunt capacitance. To define characteristics of the antennas, the engraved J- and I-formed voids on the radiation patches are used. The physical sizes of the CRLH antennas are 0.45 lambda(0) x 0.175 lambda(0) x 0.02 lambda(0), 0.428 lambda(0) x 0.179 lambda(0) x 0.041 lambda(0), 0.564 lambda(0) x 0.175 lambda(0) x 0.02 lambda(0), and 0.556 lambda(0) x 0.179 lambda(0) x 0.041 lambda(0) in terms of free-space wavelengths at the 7.5, 7.7, 7.5, and 7.7 GHz, respectively. These metamaterial antennas can be used for frequency bands from 7.5-16.8 GHz, 7.7-18.6 GHz, 7.25-17.8 GHz, and 7.8-19.85 GHz for VSWR, 2, which correspond to 74.4, 82.88, 84.23, and 87.16% practical bandwidths, respectively. Also, the ranges of the measured gains and radiation efficiencies of the recommended antennas are 0.1 dBi, G < 2.1 dBi and 20% < eff < 44.3%, and 0.8 dBi < G < 2.35 dBi and 23% < eff < 48.2%, for J-shaped antennas, whereas 0.1.15 dBi < G < 3.11 dBi and 30.24% < eff < 58.6%, and 1.2 dBi < G < 3.4 dBi and 32.4% < eff < 68.1% for I-shaped antennas, respectively.
C1 Shahid Bahonar Univ Kermanran, Dept Elect Engn, Mazandaran, Fereydonkenar, Iran.
RP Kenari, MA (reprint author), Shahid Bahonar Univ Kermanran, Dept Elect Engn, Mazandaran, Fereydonkenar, Iran.
EM Naeem.alibakhshi@yahoo.com
FU Iran Telecommunication Research Center (ITRC) [6987/500/T]
FX The author would like to express his sincere thanks to Iran
   Telecommunication Research Center (ITRC) with Contract number of
   6987/500/T, the Microwave and Millimeter Wave Laboratory of the
   Amirkabir University of Technology (Tehran Polytechnic) and the antenna
   laboratory of the K. N. Toosi University of Technology.
CR [Anonymous], 2002, FCC 1 REPORT ORDER U
   Caloz C, 2006, ELECTROMAGNETIC METAMATERIALS: TRANSMISSION LINE THEORY AND MICROWAVE APPLICATIONS: THE ENGINEERING APPROACH, P1
   Jofre L, 2002, IEEE T ANTENN PROPAG, V50, P658, DOI 10.1109/TAP.2002.1011232
   LAI A, 2004, IEEE MICROW MAG
   Lee CJ, 2006, IEEE T ANTENN PROPAG, V54, P2283, DOI 10.1109/TAP.2006.879199
   Li Y, 2011, IEEE ANTENN WIREL PR, V10, P1162, DOI 10.1109/LAWP.2011.2171311
   LIN I, 2003, IEEE MTT INT S PHIL
   Liu L, 2002, ELECTRON LETT, V38, P1414, DOI 10.1049/el:20020977
   Pozar D, 2000, MICROWAVE RF DESIGN
   Sanada A, 2004, IEEE T MICROW THEORY, V52, P1252, DOI 10.1109/TMTT.2004.825703
   SANADA A, 2003, P AS PAC MICR C SEOU
NR 11
TC 3
Z9 3
U1 3
U2 7
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1759-0787
EI 1759-0795
J9 INT J MICROW WIREL T
JI Int. J. Microw. Wirel. Technol.
PD DEC
PY 2014
VL 6
IS 6
SI SI
BP 629
EP 637
DI 10.1017/S1759078714000099
PG 9
WC Engineering, Electrical & Electronic; Telecommunications
SC Engineering; Telecommunications
GA AW5ZH
UT WOS:000346348900010
DA 2018-12-27
ER

PT J
AU Peng, LJ
   Wang, QB
   Shen, BW
   Chen, CX
   Xiong, ZH
AF Peng, Lijuan
   Wang, Qinbo
   Shen, Binwei
   Chen, Chuxiong
   Xiong, Zhenhua
TI RETRACTED: Liquid-Liquid Equilibrium for the Ternary System Water plus
   Ethylbenzene plus Acetophenone and Water plus
   Ethylbenzene+1-Phenylethanol (Retracted article. See vol. 60, pg. 1216,
   2015)
SO JOURNAL OF CHEMICAL AND ENGINEERING DATA
LA English
DT Article; Retracted Publication
ID MUTUAL SOLUBILITIES; MIXTURES; ALKYLBENZENES; TEMPERATURES; OXIDATION;
   XYLENE
AB Liquid-liquid equilibrium (LLE) data for the ternary system water + ethylbenzene + acetophenone and water + ethylbenzene + 1-phenylethanol were determined at temperatures T = (298.2, 308.2, 318.2, and 328.2) K and atmospheric pressure. The immiscibility region was found to be relatively small and not sensitive to the change of temperature. The Othmer-Tobias and the Bachman correlations were used to test the consistency of the LLE data. The experimental data were correlated by both the nonrandom two-liquid and the universal quasichemical activity coefficient models. The relevant model interaction parameters were regressed by data fitting. The model correlated results show good agreement with the measured data. The obtained interaction parameters can be used in the calculation of LLE for the ternary system water + ethylbenzene + acetophenone and water + ethylbenzene +1-phenylethanol as well as for the design and optimization of the related separation process.
C1 [Peng, Lijuan; Wang, Qinbo] Hunan Univ, Dept Chem Engn, Changsha 410082, Hunan, Peoples R China.
   [Shen, Binwei; Chen, Chuxiong; Xiong, Zhenhua] Zhejiang Shuyang Chem Co Ltd, Quzhou 324000, Zhejiang, Peoples R China.
RP Wang, QB (reprint author), Hunan Univ, Dept Chem Engn, Changsha 410082, Hunan, Peoples R China.
EM qinbowang@l26.com
FU Key S&T Special Project of Zhejiang Province [2012C13007-2]; Fundamental
   Research Funds for the Central Universities
FX The project was granted financial support from Key S&T Special Project
   of Zhejiang Province (2012C13007-2) and the Fundamental Research Funds
   for the Central Universities.
CR ABRAMS DS, 1975, AICHE J, V21, P116, DOI 10.1002/aic.690210115
   Bachman I., 1940, IND ENG CHEM ANAL ED, V14, P38, DOI 10.1021/ac50141a013
   Barega EW, 2013, J CHEM THERMODYN, V63, P31, DOI 10.1016/j.jct.2013.03.023
   BENNAIM A, 1980, J PHYS CHEM-US, V84, P583, DOI 10.1021/j100443a004
   Brown JS, 2000, J CHEM ENG DATA, V45, P846, DOI 10.1021/je000071d
   CHEN HP, 1994, J CHEM ENG DATA, V39, P679, DOI 10.1021/je00016a008
   Coquelet C, 2008, J CHEM THERMODYN, V40, P942, DOI 10.1016/j.jct.2008.01.021
   Freire MG, 2005, J CHEM ENG DATA, V50, P237, DOI 10.1021/je049707h
   Gong X, 2014, J CHEM ENG DATA, V59, P1651, DOI 10.1021/je500099u
   Gutmann B, 2013, ACS CATAL, V3, P2669, DOI 10.1021/cs400571y
   Haruki M, 2001, J CHEM ENG DATA, V46, P950, DOI 10.1021/je010007b
   Hudlicky M., 1990, OXIDATIONS ORGANIC C
   Lei F. Q., 2012, J CHEM ENG DATA, V58, P3489
   Luszczyk M, 2006, J CHEM ENG DATA, V51, P1735, DOI 10.1021/je060157s
   Mathis J, 2004, J CHEM ENG DATA, V49, P1269, DOI 10.1021/034265c
   NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308
   Othmer DF, 1942, IND ENG CHEM, V34, P693, DOI 10.1021/ie50390a600
   OWENS JW, 1986, J CHEM ENG DATA, V31, P47, DOI 10.1021/je00043a016
   RENON H, 1969, IND ENG CHEM PROC DD, V8, P413, DOI 10.1021/i260031a019
   SANDERS HJ, 1953, IND ENG CHEM, V45, P2, DOI 10.1021/ie50517a017
   Siegel H., 2000, ULLMANNS ENCY IND CH
   STEPHENSON RM, 1992, J CHEM ENG DATA, V37, P80, DOI 10.1021/je00005a024
   Suresh AK, 2000, IND ENG CHEM RES, V39, P3958, DOI 10.1021/ie0002733
   Wang H, 2014, J CHEM ENG DATA, V59, P2805, DOI 10.1021/je500439z
   Wang H, 2014, J CHEM ENG DATA, V59, P2045, DOI 10.1021/je500195p
NR 25
TC 1
Z9 1
U1 8
U2 20
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-9568
J9 J CHEM ENG DATA
JI J. Chem. Eng. Data
PD DEC
PY 2014
VL 59
IS 12
BP 4090
EP 4098
DI 10.1021/je500726x
PG 9
WC Thermodynamics; Chemistry, Multidisciplinary; Engineering, Chemical
SC Thermodynamics; Chemistry; Engineering
GA AW5OP
UT WOS:000346324500019
DA 2018-12-27
ER

PT J
AU Barman, AS
   Singh, M
   Singh, RK
   Sarkar, T
   Lal, KK
AF Barman, Anindya Sundar
   Singh, Mamta
   Singh, Rajeev Kumar
   Sarkar, Tapas
   Lal, Kuldeep Kumar
TI RETRACTED: Molecular identification and phylogeny of Channa species from
   Indo-Myanmar biodiversity hotspots using mitochondrial COI gene
   sequences (Retracted article. See vol. 66, pg. 358, 2016)
SO BIOCHEMICAL SYSTEMATICS AND ECOLOGY
LA English
DT Article; Retracted Publication
DE Freshwater snakehead; Channa; COI; Phylogeny and mitochondrial gene
ID DNA; TAXA; CHANNIFORMES; CONFIDENCE; CRITERION; TELEOSTEI; SOFTWARE;
   NUMBER; EOCENE; MODEL
AB The fishes of genus Channa are widely recognized as staple food fish in Asia. However, the identification and phylogeny of species available in the Indian subcontinent are poorly understood. In the present study, 12 species of genus Channa were investigated using a partial sequence of the COI gene of mitochondrial genome to differentiate among them and study their phylogenetic relationship. A total of 17 haplotypes was identified in the present study and interspecies p-distances were found higher than the intraspecies distances. The highest interspecies genetic distance (0.2179) was between Channa ornatipinnis and Channa diplogramma, where as the lowest genetic distance (0.0417) was between Channa gachua and Channa stewartii. The average interspecies and intraspecies genetic distances were 0.1731 and 0.0015, respectively and no intra or interspecies distance overlaps were observed. Phylogenetic tree analyses showed three major clusters which are genetically distant from each other and exhibit distinct phylogenetic resolution. The present study also supports that Indian species Channa diplogramma warrants taxonomic recognition as being distinct from Southeast Asian species Channa micropeltes. The partial sequence of the COI gene provided sufficient phylogenetic information to distinguish all the twelve species of Channa. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Barman, Anindya Sundar; Singh, Mamta; Sarkar, Tapas] Cent Agr Univ, Coll Fisheries, Lembucherra 799210, Tripura West, India.
   [Singh, Rajeev Kumar; Lal, Kuldeep Kumar] Natl Bur Fish Genet Resource ICAR, Lucknow 226002, Uttar Pradesh, India.
RP Barman, AS (reprint author), Cent Agr Univ, Coll Fisheries, Lembucherra 799210, Tripura West, India.
EM barman.anindya@gmail.com
FU Department of Biotechnology (DBT); Ministry of Science and Technology,
   Government of India [BT/177/ NE/TBP/2011]
FX Authors are thankful to Dr. S. N. Puri, Honorable Vice Chancellor of
   Central Agricultural University, Imphal of infrastructure support.
   Kindly help of Dr. S. Khogen Singh, Lalzamliana, Rebeck Lalrinpuii and
   George Lalnuntluanga for a collection of different Channa species from
   difficult geographical areas are duly acknowledged. The authors are also
   thankful to the Department of Biotechnology (DBT), the Ministry of
   Science and Technology, Government of India for research grants (BT/177/
   NE/TBP/2011).
CR Chakraborty A, 2006, ICHTHYOL RES, V53, P93, DOI 10.1007/s10228-005-0313-3
   Chen WJ, 2003, MOL PHYLOGENET EVOL, V26, P262, DOI 10.1016/S1055-7903(02)00371-8
   Courtenay W.R., 2004, US GEOLOGICAL SURVEY
   Day F., 1985, P ZOOL SOC LOND, V36, P147
   FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x
   Gam L.H., 2006, J BIOCH MOL BIOL, V14, P25
   Hall T. A., 1997, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Hebert PDN, 2003, P ROY SOC B-BIOL SCI, V270, P313, DOI 10.1098/rspb.2002.2218
   Hebert PDN, 2004, PLOS BIOL, V2, P1657, DOI 10.1371/journal.pbio.0020312
   Hebert PDN, 2003, P ROY SOC B-BIOL SCI, V270, pS96, DOI 10.1098/rsbl.2003.0025
   HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540
   Jayaram K.C., 2010, FRESHWATER FISHES IN
   Kartavtsev YP, 2006, RUSS J GENET+, V42, P341, DOI 10.1134/S1022795406040016
   Librado P, 2009, BIOINFORMATICS, V25, P1451, DOI 10.1093/bioinformatics/btp187
   Ma HY, 2012, BIOCHEM SYST ECOL, V41, P41, DOI 10.1016/j.bse.2011.12.016
   Maddison W. P, 2009, MESQUITE MODULAR SYS
   Murray AM, 2008, J VERTEBR PALEONTOL, V28, P41, DOI 10.1671/0272-4634(2008)28[41:EAFFPW]2.0.CO;2
   Murray AM, 2006, J PALEONTOL, V80, P1172, DOI 10.1666/0022-3360(2006)80[1172:ANCTCF]2.0.CO;2
   Posada D, 2004, SYST BIOL, V53, P793, DOI 10.1080/10635150490522304
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Rainboth W. J., 1996, FISHES CAMBODIAN MEK
   ROE L J, 1991, Contributions from the Museum of Paleontology University of Michigan, V28, P93
   Sambrook J, 2001, MOL CLONING LAB MANU
   Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446
   Steinke D, 2009, MAR BIOL, V156, P2641, DOI 10.1007/s00227-009-1284-0
   Swofford D. L, 2003, PAUP PHYLOGENETIC AN
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512
   Vishwanath W., 2009, Journal of Threatened Taxa, V1, P97
   Ward RD, 2005, PHILOS T R SOC B, V360, P1847, DOI 10.1098/rstb.2005.1716
   Ward RD, 2008, AQUAT BIOL, V3, P71, DOI 10.3354/ab00068
   Xia XH, 2013, MOL BIOL EVOL, V30, P1720, DOI 10.1093/molbev/mst064
   Zhu SR, 2013, MITOCHONDR DNA, V24, P217, DOI 10.3109/19401736.2012.752469
NR 32
TC 2
Z9 2
U1 1
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0305-1978
EI 1873-2925
J9 BIOCHEM SYST ECOL
JI Biochem. Syst. Ecol.
PD DEC
PY 2014
VL 57
BP 367
EP 373
DI 10.1016/j.bse.2014.09.006
PG 7
WC Biochemistry & Molecular Biology; Ecology; Evolutionary Biology
SC Biochemistry & Molecular Biology; Environmental Sciences & Ecology;
   Evolutionary Biology
GA AW3WJ
UT WOS:000346213700061
DA 2018-12-27
ER

PT J
AU Ninomiya, Y
   Miyamoto, S
   Tenjin, T
   Ogino, S
   Miyake, N
   Kaneda, Y
   Sumiyoshi, T
   Yamaguchi, N
AF Ninomiya, Yuriko
   Miyamoto, Seiya
   Tenjin, Tomomi
   Ogino, Shin
   Miyake, Nobumi
   Kaneda, Yasuhiro
   Sumiyoshi, Tomiki
   Yamaguchi, Noboru
TI RETRACTED: Long-term efficacy and safety of blonanserin in patients with
   first-episode schizophrenia: A 1-year open-label trial (Retracted
   article. See vol. 71, pg. 506, 2017)
SO PSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article; Retracted Publication
DE blonanserin; cognition; first-episode schizophrenia; second-generation
   antipsychotics; subjective well-being
ID QUALITY-OF-LIFE; ANTIPSYCHOTIC-DRUGS; DOUBLE-BLIND; JAPANESE VERSION;
   VALIDATION; REMISSION; SYMPTOMS; SCALE; INDIVIDUALS; PREDICTION
AB AimsThe purpose of this study was to evaluate the long-term effectiveness and safety of blonanserin, a second-generation antipsychotic drug developed in Japan, in patients with first-episode schizophrenia.
   MethodsTwenty-three antipsychotic-naive patients with first-episode schizophrenia were treated within an open-label, 1-year, prospective trial of blonanserin (2-24mg/day). Clinical evaluations were conducted at baseline and 2, 6, and 12 months after the start of treatment. The main outcome measures were changes in subjective well-being and subjective quality of life, as assessed by the Subjective Well-being under Neuroleptic treatment scale Short form-Japanese version and the Schizophrenia Quality of Life Scale-Japanese version, respectively. Secondary outcome measures included the Positive and Negative Syndrome Scale, the Brief Assessment of Cognition in Schizophrenia-Japanese version, laboratory tests, bodyweight, and extrapyramidal symptoms.
   ResultsFourteen patients (60.9%) remained on the study at 1 year. In the intention-to-treat analysis, significant improvements were observed in several subscales on the Subjective Well-being under Neuroleptic treatment scale Short form-Japanese version, the Schizophrenia Quality of Life Scale-Japanese version, and the Brief Assessment of Cognition in Schizophrenia-Japanese version, and in all factor scores on the Positive and Negative Syndrome Scale. Improvement in depressive symptoms with blonanserin treatment was positively correlated with improvements in subjective well-being and subjective quality of life, as well as verbal memory. No significant changes were noted for any safety measure during the 1-year study period.
   ConclusionsBlonanserin was well tolerated and effective for the treatment of first-episode schizophrenia in terms of subjective wellness, cognition, and a wide range of pathological symptoms. Further large-scale studies are warranted to confirm our findings.
C1 [Ninomiya, Yuriko; Miyamoto, Seiya; Tenjin, Tomomi; Ogino, Shin; Miyake, Nobumi; Yamaguchi, Noboru] St Marianna Univ, Sch Med, Dept Neuropsychiat, Kawasaki, Kanagawa 2168511, Japan.
   [Kaneda, Yasuhiro] Iwaki Clin, Dept Psychiat, Tokushima, Japan.
   [Sumiyoshi, Tomiki] Natl Ctr Neurol & Psychiat, Tokyo, Japan.
RP Ninomiya, Y (reprint author), St Marianna Univ, Sch Med, Dept Neuropsychiat, Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan.
EM y2ninomiya@marianna-u.ac.jp
FU Health and Labour Sciences Research Grants, Comprehensive Research on
   Disability, Health and Welfare; Japan Society for Promotion of Sciences
FX This work was supported in part by Health and Labour Sciences Research
   Grants, Comprehensive Research on Disability, Health and Welfare, and
   grants from the Japan Society for Promotion of Sciences. The authors
   thank Jun Arai, Haruki Teramoto, Sachiko Tsukahara, Yukie Ito, Masanori
   Tadokoro, Kiriko Anai, and Yasuyuki Funamoto for cognitive assessment.
   Dr Miyamoto is a consultant for Dainippon Sumitomo and has received
   advisory board honoraria from Chugai Pharmaceutical and speaker's
   honoraria from Dainippon Sumitomo and Otsuka. Dr Tenjin has received
   speaker's honoraria from Dainippon Sumitomo. Dr Miyake has received
   speaker's honoraria from Dainippon Sumitomo, Eli Lilly, Mitsubishi
   Tanabe, Otsuka, and Yoshitomi. Dr Sumiyoshi has received advisory board
   and/or speaker's honoraria from Dainippon Sumitomo, Eli Lilly,
   Mitsubishi Tanabe, Yoshitomi, and Takeda. Dr Yamaguchi has received
   advisory board and/or speaker's honoraria from Daiichi Sankyo, Eizai,
   Eli Lilly, Janssen, Otsuka, and Takeda. No other authors have any
   conflicts of interest.
CR American Psychiatric Association, 2000, DIAGN CRIT DSM 4 TR
   Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6
   Bowie CR, 2010, AM J PSYCHIAT, V167, P1116, DOI 10.1176/appi.ajp.2010.09101406
   Deeks ED, 2010, CNS DRUGS, V24, P65, DOI 10.2165/11202620-000000000-00000
   Garcia E, 2009, CNS DRUGS, V23, P615, DOI 10.2165/00023210-200923070-00006
   Gorna K, 2008, QUAL LIFE RES, V17, P237, DOI 10.1007/s11136-007-9296-z
   Gourovitch ML, 2000, NEUROPSYCHOLOGY, V14, P353, DOI 10.1037//0894-4105.14.3.353
   Harvey Philip D, 2011, Innov Clin Neurosci, V8, P14
   Hasan A, 2012, WORLD J BIOL PSYCHIA, V13, P318, DOI 10.3109/15622975.2012.696143
   Inada T, 1996, EVALUATION DIAGNOSIS
   Kahn RS, 2008, LANCET, V371, P1085, DOI 10.1016/S0140-6736(08)60486-9
   Kaneda Y, 2002, PSYCHIAT RES, V113, P107, DOI 10.1016/S0165-1781(02)00240-8
   Kaneda Y., 2013, SEISHIN IGAKU CLIN P, V55, P167
   Kaneda Y, 2007, PSYCHIAT CLIN NEUROS, V61, P602, DOI 10.1111/j.1440-1819.2007.01725.x
   Karow A, 2002, PSYCHOPHARMACOLOGY, V162, P3, DOI 10.1007/s00213-002-1052-z
   KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261
   Kim JH, 2014, COMPR PSYCHIAT, V55, P708, DOI 10.1016/j.comppsych.2013.11.002
   Kim JH, 2012, PSYCHIAT RES, V197, P285, DOI 10.1016/j.psychres.2011.10.006
   Kinoshita T., 2008, JPN J CLIN PSYCHOPHA, V11, P135
   Kishi T, 2013, J PSYCHIATR RES, V47, P149, DOI 10.1016/j.jpsychires.2012.10.011
   Lambert M, 2008, ACTA PSYCHIAT SCAND, V118, P220, DOI 10.1111/j.1600-0447.2008.01213.x
   Lambert M, 2007, ACTA PSYCHIAT SCAND, V115, P106, DOI 10.1111/j.1600-0447.2006.00862.x
   Lambert M, 2006, J CLIN PSYCHIAT, V67, P1690, DOI 10.4088/JCP.v67n1104
   Leucht S, 2006, NEUROPSYCHOPHARMACOL, V31, P2318, DOI 10.1038/sj.npp.1301147
   LINDENMAYER JP, 1994, J NERV MENT DIS, V182, P631, DOI 10.1097/00005053-199411000-00006
   Miura S., 2008, JPN J CLIN PSYCHOPHA, V11, P297
   Miyake N, 2008, JPN J CLIN PSYCHOPHA, V11, P315
   Miyamoto S, 2008, PSYCHIATRY, P2161
   MURASAKI M, 2007, JPN J CLIN PSYCHOPHA, V10, P2059
   Naber D, 2001, SCHIZOPHR RES, V50, P79, DOI 10.1016/S0920-9964(00)00166-3
   Ohoyama K, 2011, EUR J PHARMACOL, V653, P47, DOI 10.1016/j.ejphar.2010.11.023
   Strauss GP, 2012, COMPR PSYCHIAT, V53, P1137, DOI 10.1016/j.comppsych.2012.05.009
   Tenjin T, 2013, NEUROPSYCH DIS TREAT, V9, P587, DOI 10.2147/NDT.S34433
   Tenjin T, 2012, HUM PSYCHOPHARM CLIN, V27, P90, DOI 10.1002/hup.1276
   Uzenoff SR, 2010, EARLY INTERV PSYCHIA, V4, P174, DOI 10.1111/j.1751-7893.2010.00178.x
   VANPUTTEN T, 1981, ARCH GEN PSYCHIAT, V38, P187
   Vothknecht S, 2011, AUST NZ J PSYCHIAT, V45, P182, DOI 10.3109/00048674.2010.545984
   Watanabe M, 2003, JPN J CLIN PSYCHOPHA, V6, P905
   Yang J, 2010, CLIN NEUROPHARMACOL, V33, P169, DOI 10.1097/WNF.0b013e3181dcda50
NR 39
TC 6
Z9 8
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1323-1316
EI 1440-1819
J9 PSYCHIAT CLIN NEUROS
JI Psychiatry Clin. Neurosci.
PD DEC
PY 2014
VL 68
IS 12
BP 841
EP 849
DI 10.1111/pcn.12202
PG 9
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AW0LJ
UT WOS:000345983400004
PM 24835911
DA 2018-12-27
ER

PT J
AU Jiang, YS
   Lei, JA
   Feng, F
   Liang, QM
   Wang, FR
AF Jiang, Yong-sheng
   Lei, Jing-an
   Feng, Fang
   Liang, Qi-ming
   Wang, Fu-rong
TI RETRACTED: Probucol suppresses human glioma cell proliferation in vitro
   via ROS production and LKB1-AMPK activation (Retracted article. See vol.
   39, pg. 328, 2018)
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article; Retracted Publication
DE glioma; probucol; anti-proliferation; ROS; AMPK; LKB1; 26S proteasome;
   p27(Kip1); tempol; MG132; compound C
ID PROTEIN-KINASE; NEOINTIMA FORMATION; GLIOBLASTOMA CELLS;
   ENDOTHELIAL-CELLS; MALIGNANT GLIOMA; VIVO; APOPTOSIS; AMPK;
   PHOSPHORYLATION; INHIBITION
AB Aim: Probucol, an anti-hyperlipidemic drug, has been reported to exert antitumor activities at various stages of tumor initiation, promotion and progression. In this study we examined whether the drug affected glioma cell growth in vitro and the underlying mechanisms.
   Methods: Human glioma U87 and glioblastoma SF295 cell lines were used. Cell proliferation was accessed using the cell proliferation assay and BrdU incorporation. The phosphorylation of AMPK, liver kinase B1 (LKB1) and p27(Kip1) was detected by Western blot. The activity of 26S proteasome was assessed with an in situ fluorescent substrate. siRNAs were used to suppress the expression of the relevant signaling proteins.
   Results: Treatment of U87 glioma cells with probucol (10-100 mu mol/L) suppressed the cell proliferation in dose-and time-dependent manners. Meanwhile, probucol markedly increased the ROS production, phosphorylation of AMPK at Thr172 and LKB1 at Ser428 in the cells. Furthermore, probucol significantly decreased 26S proteasome activity and increased p27(Kip1) protein level in the cells in an AMPK-dependent manner. Probucol-induced suppression of U87 cell proliferation could be reversed by pretreatment with tempol (a superoxide dismutase mimetic), MG132 (proteasome inhibitor) or compound C (AMPK inhibitor), or by gene silencing of LKB1, AMPK or p27(Kip1). Similar results were observed in probucol-treated SF295 cells.
   Conclusion: Probucol suppresses human glioma cell proliferation in vitro via ROS production and LKB1-AMPK activation, which reduces 26S proteasome-dependent degradation of p27(Kip1).
C1 [Jiang, Yong-sheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Tumor Ctr, Wuhan 430030, Peoples R China.
   [Lei, Jing-an; Feng, Fang; Liang, Qi-ming; Wang, Fu-rong] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurol, Wuhan 430030, Peoples R China.
RP Wang, FR (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurol, Wuhan 430030, Peoples R China.
EM wang010020@163.com
FU National Natural Science Foundation of China [81371222]
FX This study was supported by the National Natural Science Foundation of
   China (No 81371222).
CR Choi HC, 2008, J BIOL CHEM, V283, P20186, DOI 10.1074/jbc.M803020200
   Colle D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067658
   Ferla R, 2012, ONCOL LETT, V4, P1077, DOI 10.3892/ol.2012.843
   Fu YN, 2011, ACTA PHARMACOL SIN, V32, P879, DOI 10.1038/aps.2010.229
   Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018
   Iqbal M, 2007, MOL CELL BIOCHEM, V304, P61, DOI 10.1007/s11010-007-9486-6
   Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008
   Kyaw M, 2004, ACTA PHARMACOL SIN, V25, P977
   Lee DH, 2012, CELL SIGNAL, V24, P2216, DOI 10.1016/j.cellsig.2012.07.019
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Liu DC, 2004, ACTA PHARMACOL SIN, V25, P1312
   Liu GX, 2002, ACTA PHARMACOL SIN, V23, P516
   Ricard D, 2012, LANCET, V379, P1984, DOI 10.1016/S0140-6736(11)61346-9
   Sawayama Y, 2002, J AM COLL CARDIOL, V39, P610, DOI 10.1016/S0735-1097(01)01783-1
   Schuetz TA, 2012, IEEE ENG MED BIO, P6620, DOI 10.1109/EMBC.2012.6347512
   Song P, 2011, CIRC RES, V109, P1230, DOI 10.1161/CIRCRESAHA.111.250423
   Tanous D, 2008, REDOX REP, V13, P48, DOI 10.1179/135100008X259196
   Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601
   Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069
   Wang SX, 2008, HYPERTENSION, V52, P484, DOI 10.1161/HYPERTENSIONAHA.108.112094
   Wang SX, 2012, NAT MED, V18, P902, DOI 10.1038/nm.2711
   Wang SX, 2010, CIRC RES, V106, P1117, DOI 10.1161/CIRCRESAHA.109.212530
   Wong MLH, 2007, J CLIN NEUROSCI, V14, P301, DOI 10.1016/j.jocn.2006.11.005
   Wu YJ, 2009, J VASC SURG, V50, P1135, DOI 10.1016/j.jvs.2009.07.066
   Xie Z, 2008, CIRCULATION, V117, P952, DOI 10.1161/CIRCULATIONAHA.107.744490
   Xu J, 2007, CIRCULATION, V116, P944, DOI 10.1161/CIRCULATIONAHA.106.684795
   Yamashita S, 2009, ATHEROSCLEROSIS, V207, P16, DOI 10.1016/j.atherosclerosis.2009.04.002
   Zhou R, 2013, ACTA PHARMACOL SIN, V34, P1061, DOI 10.1038/aps.2013.39
   Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200
NR 29
TC 8
Z9 8
U1 2
U2 12
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD DEC
PY 2014
VL 35
IS 12
BP 1556
EP 1565
DI 10.1038/aps.2014.88
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA AU9KU
UT WOS:000345912300010
PM 25399650
OA Green Published, Bronze
DA 2018-12-27
ER

PT J
AU Ahmed, HH
   Salem, AM
   Atta, HM
   Ghazy, MA
   Aglan, HA
AF Ahmed, H. H.
   Salem, A. M.
   Atta, H. M.
   Ghazy, M. A.
   Aglan, H. A.
TI RETRACTED: Do adipose tissue-derived mesenchymal stem cells ameliorate
   Parkinson's disease in rat model? (Retracted article. See vol. 37, pg.
   557, 2018)
SO HUMAN & EXPERIMENTAL TOXICOLOGY
LA English
DT Article; Retracted Publication
DE Parkinson's disease; adipose tissue-derived mesenchymal stem cells;
   immunomodulatory effect; anti-inflammatory activity; neurotrophic
   capacity
ID BONE-MARROW; GROWTH-FACTOR; IN-VITRO; NEUROTROPHIC FACTOR;
   ALZHEIMERS-DISEASE; DOPAMINERGIC DEGENERATION; MITOCHONDRIAL
   DYSFUNCTION; MICROGLIAL ACTIVATION; IMMUNE-RESPONSE; NERVOUS-SYSTEM
AB Parkinson's disease (PD) is a common neurodegenerative disorder in middle-aged and elderly people. This study aimed to elucidate the role of mesenchymal stem cells (MSCs) in management of PD in ovariectomized rat model. MSCs were excised from adipose tissue of both the omentum and the inguinal fat pad of male rats, grown, and propagated in culture; then characterized morphologically; and by the detection of surface markers gene expression. In this study, 40 ovariectomized animals were classified into 5 groups; group 1 was ovariectomized control, groups 2 to 5 were subcutaneously administered with rotenone for 14 days after 1 month of ovariectomy for induction of PD. Group 2 was left untreated; groups 3, 4, and 5 were treated with Sinemet (R), Cerebrolysin (R), and a single dose of adipose tissue-derived MSCs (ADMSCs), respectively. Y-chromosome gene (sry) was assessed by polymerase chain reaction (PCR) in brain tissue of the female rats. Serum transforming growth factor beta (TGF-beta), monocyte chemoattractant protein 1 (MCP-1), and brain-derived neurotrophic factor (BDNF) levels were assayed using enzyme-linked immunosorbent assay technique. Brain dopamine level was assayed fluorometrically, while brain tyrosine hydroxylase (TH) gene expression was detected by semi-quantitative real-time PCR. The PD group showed significant increase in serum TGF-beta and MCP-1 levels associated with significant decrease in serum BDNF, brain dopamine, and brain TH gene expression levels. In contrast, all treatments produce significant decrease in serum TGF-beta and MCP-1 levels in concomitant with significant increase in serum BDNF, brain dopamine, and brain TH gene expression levels. In conclusion, the observed improvements in the studied biomarkers due to ADMSCs infusion might be attributed to their immunomodulatory, anti-inflammatory, and neurotrophic effects.
C1 [Ahmed, H. H.; Aglan, H. A.] Natl Res Ctr, Dept Hormones, Div Med Res, Cairo 12622, Egypt.
   [Salem, A. M.; Ghazy, M. A.] Ain Shams Univ, Fac Sci, Dept Biochem, Cairo, Egypt.
   [Atta, H. M.] Cairo Univ, Fac Med, Dept Biochem, Cairo, Egypt.
RP Ahmed, HH (reprint author), Natl Res Ctr, Dept Hormones, Div Med Res, El Bohouth St, Cairo 12622, Egypt.
EM hanaaomr@yahoo.com
OI Aglan, Hadeer/0000-0003-0837-0172; Salem, Ahmed/0000-0002-8789-4654;
   Ahmed, hanaa/0000-0001-8642-9251
CR Abdel-Salam OME, 2008, CNS NEUROL DISORD-DR, V7, P321, DOI 10.2174/187152708786441867
   Alhadlaq A, 2004, STEM CELLS DEV, V13, P436, DOI 10.1089/scd.2004.13.436
   Ali FK, 2008, AFR J BIOTECHNOL, V7, P1418
   ALVAREZ A, 2006, ALZHEIMERS DEMENT S1, V2, pS364
   Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P281
   An J, 1997, J ANDROL, V18, P289
   Ankrum J, 2010, TRENDS MOL MED, V16, P203, DOI 10.1016/j.molmed.2010.02.005
   Antkiewicz-Michaluk L, 2003, EUR J PHARMACOL, V466, P263, DOI 10.1016/S0014-2999(03)01565-6
   AOAC, 1995, OFFICIAL METHODS ANA
   Armitage P, 1987, STAT METHODS MED RES, P186
   Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675
   Bahat-Stroomza M, 2009, J MOL NEUROSCI, V39, P199, DOI 10.1007/s12031-008-9166-3
   Banisadr G, 2005, J COMP NEUROL, V489, P275, DOI 10.1002/cne.20598
   Banks WA, 2002, NEUROIMMUNOMODULAT, V10, P319, DOI 10.1159/000071472
   Barnes J M, 1965, Prog Med Chem, V4, P18, DOI 10.1016/S0079-6468(08)70166-8
   Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P803, DOI 10.1016/S0091-3057(99)00168-9
   Becker KJ, 2010, STROKE, V41, pS75, DOI 10.1161/STROKEAHA.110.592881
   Bouchez G, 2008, NEUROCHEM INT, V52, P1332, DOI 10.1016/j.neuint.2008.02.003
   Bousquet M, 2012, NEUROBIOL DIS, V45, P529, DOI 10.1016/j.nbd.2011.09.009
   Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9
   CHADI G, 1993, EXP BRAIN RES, V97, P145
   CIARLONE EA, 1978, AM J PHYSIOL, V125, P731
   Correia AS, 2005, ANN MED, V37, P487, DOI 10.1080/07853890500327967
   Cunningham C, 2002, NEUROPATH APPL NEURO, V28, P107, DOI 10.1046/j.1365-2990.2002.00383.x
   DIAMOND SG, 1990, NEUROLOGY, V40, P763, DOI 10.1212/WNL.40.5.763
   Dohgu S, 2004, CELL MOL NEUROBIOL, V24, P491, DOI 10.1023/B:CEMN.0000022776.47302.ce
   Eckert A, 2003, BIOCHEM PHARMACOL, V66, P1627, DOI 10.1016/S0006-2952(03)00534-3
   Feinberg MW, 2004, CIRC RES, V94, P601, DOI 10.1161/01.RES.0000119170.70818.4F
   Fleming SM, 2005, BEHAV BRAIN RES, V156, P201, DOI 10.1016/j.bbr.2004.05.024
   Fukuchi M, 2010, BRAIN RES, V1366, P18, DOI 10.1016/j.brainres.2010.10.034
   Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002
   Gaytan F, 2004, J CLIN ENDOCR METAB, V89, P400, DOI 10.1210/jc.2003-031375
   Georgy GS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064847
   Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959
   Glavaski-Joksimovic A, 2013, EXP NEUROL, V247, P25, DOI 10.1016/j.expneurol.2013.03.016
   Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085
   Gulcin I, 2007, AMINO ACIDS, V32, P431, DOI 10.1007/s00726-006-0379-x
   Hartbauer M, 2001, J NEURAL TRANSM, V108, P459, DOI 10.1007/s007020170067
   Herishanu YO, 2001, CAN J NEUROL SCI, V28, P144
   Hisata JS., 2002, FINAL SUPPLEMENTAL E
   Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415
   Jin GZ, 2008, CELL BIOL INT, V32, P1433, DOI 10.1016/j.cellbi.2008.08.014
   Kalkonde YV, 2007, BRAIN RES, V1128, P1, DOI 10.1016/j.brainres.2006.08.041
   Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]
   Kim SU, 2013, J NEUROIMMUNOL, V259, P26, DOI 10.1016/j.jneuroim.2013.03.006
   Kim YJ, 2009, GLIA, V57, P13, DOI 10.1002/glia.20731
   Kropf J, 1997, CLIN CHEM, V43, P1965
   Laske C, 2007, J PSYCHIATR RES, V41, P600, DOI 10.1016/j.jpsychires.2006.02.007
   Lattanzi W, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/468705
   Lau HY, 2007, AM J PHYSIOL-GASTR L, V292, pG1283, DOI 10.1152/ajpgi.00429.2006
   Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670
   LI DF, 2010, NAN FANG YI KE DA XU, V30, P2262
   Li Dong-fei, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P2256
   Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737
   LINDNER MD, 1995, EXP NEUROL, V132, P62, DOI 10.1016/0014-4886(95)90059-4
   Lukhanina EP, 2004, ZH NEVROPATOL PSIKH, V104, P54
   Meredith GE, 2002, BRAIN RES, V949, P218, DOI 10.1016/S0006-8993(02)03160-8
   Munoz-Fernandez R, 2006, J IMMUNOL, V177, P280, DOI 10.4049/jimmunol.177.1.280
   Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9
   O'Byrne MB, 2000, ADV EXP MED BIOL, V483, P369
   Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070
   Phinney DG, 1999, J CELL BIOCHEM, V72, P570
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Priyadarshi A, 2001, ENVIRON RES, V86, P122, DOI 10.1006/enrs.2001.4264
   Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211
   Qin H, 2011, ACTA OTO-LARYNGOL, V131, P1136, DOI 10.3109/00016489.2011.603135
   Reale M, 2009, BRAIN BEHAV IMMUN, V23, P55, DOI 10.1016/j.bbi.2008.07.003
   Ren Zhi-Wu, 2011, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V27, P385
   Riley C, 2006, J NEURAL TRANSM, V113, P103, DOI 10.1007/s00702-005-0302-8
   ROBERTS AB, 1993, GROWTH FACTORS, V8, P1
   Rochefort GY, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-125
   Rombouts WJC, 2003, LEUKEMIA, V17, P160, DOI 10.1038/sj.leu.2402763
   Rota E, 2006, NEUROL SCI, V27, P33, DOI 10.1007/s10072-006-0562-6
   Sachs PC, 2012, CELL TISSUE RES, V349, P505, DOI 10.1007/s00441-012-1423-7
   SAMBROOK L, 1989, CLONING LAB MANUAL
   Schafer S, 2012, J NEUROIMMUNOL, V249, P40, DOI 10.1016/j.jneuroim.2012.04.018
   SCHERMER S, 1967, THE BLOOD MORPHOLOGY, P42
   Selyanina NV, 2012, ZH NEVROL PSIKHIATR, V112, P46
   Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072
   Shyy JYJ, 1995, J BIOMECH, V28, P1451, DOI 10.1016/0021-9290(95)00093-3
   Sowa Y, 2012, STEM CELLS DEV, V21, P1852, DOI 10.1089/scd.2011.0403
   Steingen C, 2008, J MOL CELL CARDIOL, V44, P1072, DOI 10.1016/j.yjmcc.2008.03.010
   Taha MF, 2010, TISSUE CELL, V42, P211, DOI 10.1016/j.tice.2010.04.003
   Talpade DJ, 2000, J NEUROCHEM, V75, P2611, DOI 10.1046/j.1471-4159.2000.0752611.x
   Tomiyama K, 2008, STEM CELLS, V26, P330, DOI 10.1634/stemcells.2007-0567
   TSUKAHARA T, 1995, NEUROSURGERY, V37, P733, DOI 10.1227/00006123-199510000-00018
   Unsicker K, 2000, EUR J BIOCHEM, V267, P6972, DOI 10.1046/j.1432-1327.2000.01824.x
   WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004-0013
   Wijeyekoon R, 2009, BBA-MOL BASIS DIS, V1792, P688, DOI 10.1016/j.bbadis.2008.10.007
   Williams SN, 2009, NEUROREPORT, V20, P606, DOI 10.1097/WNR.0b013e32832a0a98
   Xie L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060200
   Ying CC, 2012, CELL MOL NEUROBIOL, V32, P1255, DOI 10.1007/s10571-012-9850-2
   Yoo SW, 2013, NEUROBIOL DIS, V58, P249, DOI 10.1016/j.nbd.2013.06.001
   Zhang XQ, 2006, BRAIN RES, V1095, P207, DOI 10.1016/j.brainres.2006.04.019
   Zhao DC, 2005, WORLD J GASTROENTERO, V11, P3431, DOI 10.3748/wjg.v11.i22.3431
NR 96
TC 13
Z9 13
U1 2
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0960-3271
EI 1477-0903
J9 HUM EXP TOXICOL
JI Hum. Exp. Toxicol.
PD DEC
PY 2014
VL 33
IS 12
BP 1217
EP 1231
DI 10.1177/0960327114524238
PG 15
WC Toxicology
SC Toxicology
GA AU8YG
UT WOS:000345878700004
PM 24567299
DA 2018-12-27
ER

PT J
AU Fang, QX
   Peng, JG
   Cao, FL
AF Fang, Qingxiang
   Peng, Jigen
   Cao, Feilong
TI RETRACTED: Synchronization analysis of linearly coupled singular systems
   (Retracted article. See vol. 273, pg. 1277, 2016)
SO APPLIED MATHEMATICS AND COMPUTATION
LA English
DT Article; Retracted Publication
DE Linearly coupled singular systems; Globally exponential synchronization;
   Synchronization manifold; Lyapunov function
ID NEURAL-NETWORKS; STABILITY; DELAYS
AB The synchronization problem of linearly coupled singular systems is investigated. The uncoupled dynamical behavior at each node is general and can be chaotic or otherwise; the coupling configuration is also general, with the coupling matrix not assumed to be symmetric or irreducible. The existence and uniqueness of the solution of coupled system and the existence and uniqueness of the synchronization state are explored. Some sufficient conditions for globally exponential synchronization are derived based on Lyapunov stability theory. These criteria, which are in terms of linear matrix inequality (LMI), indicate that the left and right eigenvector corresponding to eigenvalue zero of the coupling matrix play key roles in the stability analysis of the synchronization manifold. Finally, a numerical example is provided to illustrate the effectiveness of the proposed conditions. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Fang, Qingxiang; Peng, Jigen] Xi An Jiao Tong Univ, Dept Appl Math, Xian 710049, Peoples R China.
   [Fang, Qingxiang; Cao, Feilong] China Jiliang Univ, Coll Sci, Hangzhou 310018, Zhejiang, Peoples R China.
RP Fang, QX (reprint author), Xi An Jiao Tong Univ, Dept Appl Math, Xian 710049, Peoples R China.
EM qingxiang.fang@gmail.com; jgpeng@xjtu.edu.cn; flcao@263.net
FU NCET; NSFC [10531030, 90818020]
FX This work was supported by NCET and partially the NSFC under the contact
   10531030 and 90818020.
CR APLEVICH J. D., 1991, IMPLICIT LINEAR SYST
   DAI L, 1988, IEEE T AUTOMAT CONTR, V33, P187, DOI 10.1109/9.387
   Dhamala M., 2004, PHYS REV LETT, V92, P101
   Grammel G, 2008, SYST CONTROL LETT, V57, P505, DOI 10.1016/j.sysconle.2007.11.009
   Hoppensteadt FC, 2000, IEEE T NEURAL NETWOR, V11, P734, DOI 10.1109/72.846744
   Horn R., 2012, MATRIX ANAL
   Huygens C., 1672, HOROLOGIUM OSCILLATO
   Kim JH, 2010, AUTOMATICA, V46, P591, DOI 10.1016/j.automatica.2010.01.011
   KRINSKY VI, 1991, PHYSICA D, V49, P247, DOI 10.1016/0167-2789(91)90213-S
   KUHNERT L, 1989, NATURE, V337, P244, DOI 10.1038/337244a0
   Lashmanan M., 1996, CHAOS NONLINEAR OSCI
   Liu C, 2009, AUTOMATICA, V45, P1879, DOI 10.1016/j.automatica.2009.04.004
   Liu XP, 2002, IEEE T AUTOMAT CONTR, V47, P335, DOI 10.1109/9.983376
   Lloyd AL, 2004, MATH BIOSCI, V188, P1, DOI 10.1016/j.mbs.2003.09.003
   Lu GP, 2006, IEEE T AUTOMAT CONTR, V51, P818, DOI 10.1109/TAC.2006.875017
   Lu JQ, 2010, IEEE T SYST MAN CY B, V40, P350, DOI 10.1109/TSMCB.2009.2023509
   Lu WL, 2006, PHYSICA D, V213, P214, DOI 10.1016/j.physd.2005.11.009
   Lu WL, 2004, IEEE T CIRCUITS-I, V51, P2491, DOI 10.1109/TCSI.2004.838308
   PECORA LM, 1990, PHYS REV LETT, V64, P821, DOI 10.1103/PhysRevLett.64.821
   PEREZMUNUZURI V, 1993, IEEE T CIRCUITS-I, V40, P174, DOI 10.1109/81.222798
   Shorten R, 2009, IEEE T AUTOMAT CONTR, V54, P2714, DOI 10.1109/TAC.2009.2031586
   Uezato E., 1999, P 38 C DEC CONTR PHO, V1999, P4092, DOI DOI 10.1109/CDC.1999.828001
   VanWiggeren GD, 1998, SCIENCE, V279, P1198, DOI 10.1126/science.279.5354.1198
   Wang XF, 2002, INT J BIFURCAT CHAOS, V12, P187, DOI 10.1142/S0218127402004292
   Winfree AT, 1980, GEOMETRY BIOL TIME
   Xu SY, 2002, IEEE T AUTOMAT CONTR, V47, P1122, DOI 10.1109/TAC.2002.800651
   Xu SY, 2000, IEEE T AUTOMAT CONTR, V45, P1405
   Zhang GM, 2008, AUTOMATICA, V44, P886, DOI 10.1016/j.automatica.2007.07.017
NR 28
TC 1
Z9 1
U1 5
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0096-3003
EI 1873-5649
J9 APPL MATH COMPUT
JI Appl. Math. Comput.
PD DEC 1
PY 2014
VL 248
BP 536
EP 549
DI 10.1016/j.amc.2014.09.131
PG 14
WC Mathematics, Applied
SC Mathematics
GA AT7NP
UT WOS:000345124800051
DA 2018-12-27
ER

PT J
AU Derosa, G
   Bonaventura, A
   Bianchi, L
   Romano, D
   Fogari, E
   D'Angelo, A
   Maffioli, P
AF Derosa, G.
   Bonaventura, A.
   Bianchi, L.
   Romano, D.
   Fogari, E.
   D'Angelo, A.
   Maffioli, P.
TI RETRACTED: Comparison of vildagliptin and glimepiride: effects on
   glycaemic control, fat tolerance and inflammatory markers in people with
   Type 2 diabetes (Retracted article. See vol. 33, pg. 1154, 2016)
SO DIABETIC MEDICINE
LA English
DT Article; Retracted Publication
ID ACUTE GLUCOSE FLUCTUATIONS; BETA-CELL DYSFUNCTION; INSULIN-RESISTANCE;
   ADIPOCYTOKINE LEVELS; IV INHIBITION; LOAD; METFORMIN; DISEASE;
   ATHEROSCLEROSIS; RECOMMENDATIONS
AB Aims To compare the effects of vildagliptin with those of glimepiride on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes mellitus receiving metformin treatment.
   Methods A total of 167 participants were randomized to vildagliptin 50 mg twice a day or glimepiride 2 mg three times a day, for 6 months. We evaluated the following variables: BMI; glycaemic control; fasting plasma insulin; homeostatic model assessment of insulin resistance index; fasting plasma proinsulin; glucagon; lipid profile; adiponectin; high-sensitivity C-reactive protein; interleukin-6; and tumour necrosis factor-a. A euglycaemic-hyperinsulinaemic clamp procedure and an oral fat load test were also performed.
   Results Despite a similar decrease in HbA(1c) levels (P = 0.009, and P = 0.008, respectively), body weight increased with glimepiride (P = 0.048 vs baseline) and decreased with vildagliptin (P = 0.041 vs baseline and vs glimepiride). Fasting plasma insulin and homeostatic model assessment of insulin resistance index were significantly lower with vildagliptin compared with glimepiride (P = 0.035 and 0.047). M value, an index of insulin sensitivity, increased with vildagliptin, both compared with baseline and with glimepiride (P = 0.028 and 0.039, respectively). Vildagliptin improved all post-oral fat load peaks of lipid profile compared with glimepiride. Adiponectin levels were higher (P = 0.035) and high-sensitivity C-reactive protein levels were lower (P = 0.038) with vildagliptin vs glimepiride. During the oral fat load test, interleukin-6, high-sensitivity C-reactive protein and tumour necrosis factor-a peaks were lower and adiponectin peak was higher in the vildagliptin group than in the glimepiride group. There was a higher dropout rate as a result of hypoglycaemia in the glimepiride group than in the vildagliptin group.
   Conclusions Vildagliptin was more effective than glimepiride in reducing post-oral fat load peaks of lipid-trafficking adipocytokines and inflammatory markers.
C1 [Derosa, G.; Bonaventura, A.; Bianchi, L.; Romano, D.; Fogari, E.; D'Angelo, A.; Maffioli, P.] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy.
   [Derosa, G.; Bonaventura, A.; Bianchi, L.; Romano, D.; Fogari, E.; D'Angelo, A.; Maffioli, P.] Fdn IRCCS Policlin S Matteo, Pavia, Italy.
   [Derosa, G.] Univ Pavia, Ctr Study Endocrine Metab Pathophysiol & Clin Res, I-27100 Pavia, Italy.
RP Derosa, G (reprint author), Univ Pavia, Dept Internal Med & Therapeut, Via Palestro 3, I-27100 Pavia, Italy.
EM giuseppe.derosa@unipv.it
RI Bonaventura, Aldo/O-7712-2015
OI Bonaventura, Aldo/0000-0002-4747-5535; Derosa,
   Giuseppe/0000-0003-3573-4760
CR Ahren B, 2011, CURR DIABETES REP, V11, P83, DOI 10.1007/s11892-011-0179-x
   Azuma K, 2008, J CLIN ENDOCR METAB, V93, P459, DOI 10.1210/jc.2007-1369
   Barbieri M, 2013, ATHEROSCLEROSIS, V227, P349, DOI 10.1016/j.atherosclerosis.2012.12.018
   Bergman RN, 2002, EUR J CLIN INVEST, V32, P35, DOI 10.1046/j.1365-2362.32.s3.5.x
   Boschmann M, 2009, J CLIN ENDOCR METAB, V94, P846, DOI 10.1210/jc.2008-1400
   Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102
   Derosa G, 2011, HORM METAB RES, V43, P505, DOI 10.1055/s-0031-1275704
   Derosa G, 2010, HORM METAB RES, V42, P663, DOI 10.1055/s-0030-1255036
   Derosa G, 2013, INFLAMMATION, V36, P914, DOI 10.1007/s10753-013-9620-4
   Derosa G, 2013, PHARMACOL RES, V73, P20, DOI 10.1016/j.phrs.2013.04.005
   Derosa G, 2012, J CLIN LIPIDOL, V6, P553, DOI 10.1016/j.jacl.2012.02.010
   Derosa G, 2012, EXPERT OPIN PHARMACO, V13, P2581, DOI 10.1517/14656566.2012.734499
   Derosa G, 2012, CURR CLIN PHARMACOL, V7, P214, DOI 10.2174/157488412800958686
   Derosa G, 2012, DIABETES TECHNOL THE, V14, P475, DOI 10.1089/dia.2011.0278
   Derosa G, 2012, DIABETES TECHNOL THE, V14, P350, DOI 10.1089/dia.2011.0204
   Derosa G, 2011, EUR J LIPID SCI TECH, V113, P950, DOI 10.1002/ejlt.201000504
   Derosa G, 2011, J DIABETES COMPLICAT, V25, P258, DOI 10.1016/j.jdiacomp.2011.01.003
   Derosa G, 2011, EUR J PHARMACOL, V651, P240, DOI 10.1016/j.ejphar.2010.11.015
   Derosa G, 2010, HYPERTENS RES, V33, P790, DOI 10.1038/hr.2010.85
   Derosa G, 2010, MICROVASC RES, V80, P110, DOI 10.1016/j.mvr.2010.03.012
   Derosa G, 2010, HYPERTENS RES, V33, P209, DOI 10.1038/hr.2009.212
   Derosa G, 2009, HEART VESSELS, V24, P204, DOI 10.1007/s00380-008-1109-y
   Dunning BE, 2005, DIABETOLOGIA, V48, P1700, DOI 10.1007/s00125-005-1878-0
   European medicines Agency, SCI DISC
   Ferrannini E, 2009, DIABETES OBES METAB, V11, P157, DOI 10.1111/j.1463-1326.2008.00994.x
   Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470
   Home P, 2006, DIABETIC MED, V23, P579
   Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0
   KARPE F, 1994, ATHEROSCLEROSIS, V106, P83, DOI 10.1016/0021-9150(94)90085-X
   Klempfner R, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-60
   Lichtenstein AH, 2006, ARTERIOSCL THROM VAS, V26, P2186, DOI 10.1161/01.ATV.0000238352.25222.5e
   Matthews DR, 2010, DIABETES OBES METAB, V12, P780, DOI 10.1111/j.1463-1326.2010.01233.x
   Nordestgaard BG, 2007, JAMA-J AM MED ASSOC, V298, P299, DOI 10.1001/jama.298.3.299
   Rizzo MR, 2012, DIABETES CARE, V35, P2076, DOI 10.2337/dc12-0199
   Ryden L, 2007, EUR HEART J, V28, P88, DOI [10.1093/eurheartj/ehl260, 10.1093/eurheartj/ehm124]
NR 35
TC 10
Z9 10
U1 2
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD DEC
PY 2014
VL 31
IS 12
BP 1515
EP 1523
DI 10.1111/dme.12499
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AU0GQ
UT WOS:000345302100008
PM 24824633
DA 2018-12-27
ER

PT J
AU Fang, JJ
   Ma, CM
   Liu, CF
   Yue, XB
AF Fang, Jingjing
   Ma, Chuanming
   Liu, Cunfu
   Yue, Xiangbing
TI RETRACTED: Isotopic analysis of N and O in NO3- by selective bacterial
   reduction to N2O for groundwater pollution (Retracted article. See vol.
   24, pg. 2233, 2015)
SO ECOTOXICOLOGY
LA English
DT Article; Retracted Publication
DE Nitrate; delta N-15; delta O-18; NO3-; Groundwater; Bacterial reduction
ID FRESH-WATER; OXYGEN ISOTOPES; NITRATE; EQUILIBRATION; DENITRIFIER;
   RESPONSES; SEAWATER; BEHAVIOR; NITRITE
AB We describe a method to determine the nitrogen and oxygen isotopic composition of nitrate in groundwater samples (N-15/N-14 and O-18/O-16, respectively), which is based on the analysis of nitrous oxide gas (N2O) that is produced quantitatively from nitrate by denitrifying bacteria. This method which is simple, inexpensive and effective in the removal of nitrite is greatly selective for NO2- and was used for mixed samples containing both NO2- and NO3- with little or no measurable cross-contamination. The precision of delta N-15 and delta O-18 are 0.3 and 0.17 parts per thousand respectively, compared to that of 0.1 and 0.5 parts per thousand abroad (Brand et al. in Org Geochem 21: 585-594, 1994; Begley and Scrimgeour in Anal Chem 69(8): 1530-1535, 1997; Kornexl et al. in Rapid Commun Mass Spectrom 13(16): 1685-1693, 1999; Bohlke et al. in Rapid Commun Mass Spectrom 17: 1835-1846, 2003; Gehre and Strauch in Rapid Commun Mass Spectrom 17(13): 1497-1503, 2003; Werner in Isot Environ Health Stud 39: 85-104, 2003).
C1 [Fang, Jingjing; Ma, Chuanming; Liu, Cunfu; Yue, Xiangbing] China Univ Geosci, Sch Environm Studies, Wuhan 430074, Peoples R China.
   [Fang, Jingjing; Ma, Chuanming; Liu, Cunfu; Yue, Xiangbing] China Univ Geosci, State Key Lab Biogeol & Environm Geol, Wuhan 430074, Peoples R China.
RP Ma, CM (reprint author), China Univ Geosci, Sch Environm Studies, Wuhan 430074, Peoples R China.
EM fangjingjing0720@163.com; bjmcm@163.com
FU National Natural Science Foundation of China (NSFC) [41072179, 41002083]
FX This work was financially supported by the National Natural Science
   Foundation of China (NSFC Grant Nos. 41072179 and 41002083). The authors
   would like to thank associate editor and two anonymous reviewers for
   their constructive suggestions and comments on this manuscript.
CR Begley IS, 1997, ANAL CHEM, V69, P1530, DOI 10.1021/ac960935r
   Bohlke JK, 2007, ANAL CHEM, V79, P5888, DOI 10.1021/ac070176k
   BOHLKE JK, 1995, WATER RESOUR RES, V31, P2319, DOI 10.1029/95WR01584
   Bohlke JK, 2003, RAPID COMMUN MASS SP, V17, P1835, DOI 10.1002/rcm.1123
   Bohlke JK, 1995, IAEA TECDOC, V24, P51
   BRAND WA, 1994, ORG GEOCHEM, V21, P585, DOI 10.1016/0146-6380(94)90004-3
   Casciotti KL, 2007, ANAL CHEM, V79, P2427, DOI 10.1021/ac061598h
   Casciotti KL, 2002, ANAL CHEM, V74, P4905, DOI 10.1021/ac020113w
   CHRISTENSEN S, 1988, APPL ENVIRON MICROB, V54, P1409
   de Boer ME, 2013, ECOTOXICOLOGY, V22, P619, DOI 10.1007/s10646-013-1053-1
   Downing AL, 2008, ECOTOXICOLOGY, V17, P539, DOI 10.1007/s10646-008-0211-3
   Gehre M, 2003, RAPID COMMUN MASS SP, V17, P1497, DOI 10.1002/rcm.1076
   Handy RD, 2008, ECOTOXICOLOGY, V17, P315, DOI 10.1007/s10646-008-0206-0
   Hecht AD, 2009, ECOTOXICOLOGY, V18, P1, DOI 10.1007/s10646-008-0293-y
   Hellou J, 2009, ECOTOXICOLOGY, V18, P27, DOI 10.1007/s10646-008-0253-6
   Kim J, 2010, ECOTOXICOLOGY, V19, P662, DOI 10.1007/s10646-009-0440-0
   Kornexl BE, 1999, RAPID COMMUN MASS SP, V13, P1685
   Lundqvist A, 2010, ECOTOXICOLOGY, V19, P614, DOI 10.1007/s10646-009-0430-2
   Marigomez I, 2013, ECOTOXICOLOGY, V22, P486, DOI 10.1007/s10646-013-1042-4
   Morcillo SM, 2013, ECOTOXICOLOGY, V22, P597, DOI 10.1007/s10646-013-1051-3
   POZO C, 1994, ECOTOXICOLOGY, V3, P4, DOI 10.1007/BF00121384
   Sansone FJ, 1997, ANAL CHEM, V69, P40, DOI 10.1021/ac960241i
   Sigman DM, 2001, ANAL CHEM, V73, P4145, DOI 10.1021/ac010088e
   Sigman DM, 1997, MAR CHEM, V57, P227, DOI 10.1016/S0304-4203(97)00009-1
   Ventura SPM, 2013, ECOTOXICOLOGY, V22, P1, DOI 10.1007/s10646-012-0997-x
   Werner RA, 2003, ISOT ENVIRON HEALT S, V39, P85, DOI 10.1080/1025601031000108642
NR 26
TC 1
Z9 1
U1 4
U2 41
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0963-9292
EI 1573-3017
J9 ECOTOXICOLOGY
JI Ecotoxicology
PD DEC
PY 2014
VL 23
IS 10
SI SI
BP 2025
EP 2029
DI 10.1007/s10646-014-1360-1
PG 5
WC Ecology; Environmental Sciences; Toxicology
SC Environmental Sciences & Ecology; Toxicology
GA AT6FG
UT WOS:000345034000024
PM 25351391
DA 2018-12-27
ER

PT J
AU Lee, DB
   Suh, HS
   Choi, YS
AF Lee, Dan Bi
   Suh, Ho Seok
   Choi, Yu Sung
TI RETRACTED: A comparative study of low-fluence 1,064nm Q-Switched Nd:YAG
   laser with or without chemical peeling using Jessner's solution in
   melasma patients (Retracted article. See vol. 17, pg. 57, 2015)
SO JOURNAL OF COSMETIC AND LASER THERAPY
LA English
DT Article; Retracted Publication
DE melasma; Jessner's solution; low-fluence 1,064 nm Q-switched Nd:YAG
ID ALUMINUM-GARNET LASER; GLYCOLIC ACID PEEL; ND/YAG LASER; NEODYMIUM;
   LIGHT; PHOTOTHERMOLYSIS; EFFICACY; CREAM
AB Background: Although low-fluence 1,064-nm Q-switched Nd:YAG laser (QSNYL) is widely used for the treatment of melasma, multiple treatments are necessary for clinical improvement. Superficial chemical peeling using Jessner's solution has been used for treatment of melasma conventionally. Objectives: To evaluate the additional therapeutic effect and adverse effects of Jessner's peel when combined with 1,064 nm QSNYL for melasma patients in a double-blind, placebo-controlled design. Methods: Total of 52 patients were included. Patients who received 10 sessions of 1,064 nm QSNYL plus chemical peeling with placebo (Group A) in a two-week intervals and those who received 10 sessions of 1,064 nm QSNYL plus chemical peeling with Jessner's solution (Group B) in a 2-week intervals were analyzed. Responses were evaluated using the Melasma Area and Severity Index (MASI) score, physician's global assessment (PGA) and subjective self-assessment. Results: At 8 weeks, the mean MASI score decreased from 8.68 +/- 4.06 to 8.60 +/- 3.88 in Group A and from 8.98 +/- 3.72 to 7.13 +/- 2.57 in Group B, showing a significant difference (p < 0.001). But at 20 weeks, there was no significant difference on reduction of MASI, self-assessment, and PGA between the two groups. No serious adverse effects were reported with the additional Jessner's peeling. Conclusion: This study suggests Jessner's peel is a safe and effective method in the early course of treatment for melasma, when combined with low-fluence 1,064-nm QSNYL.
C1 [Lee, Dan Bi; Suh, Ho Seok; Choi, Yu Sung] Ulsan Univ Hosp, Dept Dermatol, Ulsan, South Korea.
RP Choi, YS (reprint author), Ulsan Univ Hosp, Dept Dermatol, Jeon Ha 1 Dong, Ulsan, South Korea.
EM uuhderma@daum.com
CR Amer M, 1998, INT J DERMATOL, V37, P449, DOI 10.1046/j.1365-4362.1998.00499.x
   Bansal Charu, 2012, J Cutan Aesthet Surg, V5, P266, DOI 10.4103/0974-2077.104915
   Cho SB, 2009, CLIN EXP DERMATOL, V34, pE847, DOI 10.1111/j.1365-2230.2009.03599.x
   Choi M, 2010, J DERMATOL TREAT, V21, P224, DOI 10.3109/09546630903401462
   Cotellessa C, 1999, DERMATOL SURG, V25, P450, DOI 10.1046/j.1524-4725.1999.08217.x
   GRIFFITHS CEM, 1993, BRIT J DERMATOL, V129, P415, DOI 10.1111/j.1365-2133.1993.tb03169.x
   GRIMES PE, 1995, ARCH DERMATOL, V131, P1453, DOI 10.1001/archderm.131.12.1453
   Gupta AK, 2006, J AM ACAD DERMATOL, V55, P1048, DOI 10.1016/j.jaad.2006.02.009
   Iizuka Hajime, 1994, Journal of Dermatological Science, V8, P215
   Jeong SY, 2010, DERMATOL SURG, V36, P909, DOI 10.1111/j.1524-4725.2010.01523.x
   Kar HK, 2012, INDIAN J DERMATOL VE, V78, P165, DOI 10.4103/0378-6323.93633
   Katz TM, 2010, DERMATOL SURG, V36, P1273, DOI 10.1111/j.1524-4725.2010.01621.x
   Lawrence N, 1997, J AM ACAD DERMATOL, V36, P589, DOI 10.1016/S0190-9622(97)70248-2
   Lim JTE, 1997, DERMATOL SURG, V23, P177, DOI 10.1111/j.1524-4725.1997.tb00016.x
   Lowe NJ, 1998, CLIN THER, V20, P945, DOI 10.1016/S0149-2918(98)80076-3
   Mizoguchi M, 1997, PIGM CELL RES, V10, P176, DOI 10.1111/j.1600-0749.1997.tb00481.x
   MONHEIT GD, 1989, J DERMATOL SURG ONC, V15, P945, DOI 10.1111/j.1524-4725.1989.tb03181.x
   Mun JY, 2011, J ELECTRON MICROSC, V60, P11, DOI 10.1093/jmicro/dfq068
   Pandya AG, 2011, J AM ACAD DERMATOL, V64, P78, DOI 10.1016/j.jaad.2009.10.051
   Park KY, 2011, CLIN EXP DERMATOL, V36, P864, DOI 10.1111/j.1365-2230.2011.04150.x
   Rashimi S, 2012, J CUTAN AESTHET SURG, V5, P247
   Rendon Marta I, 2010, J Clin Aesthet Dermatol, V3, P32
   Safoury Omar Soliman, 2009, Indian J Dermatol, V54, P41, DOI 10.4103/0019-5154.48985
   SANCHEZ NP, 1981, J AM ACAD DERMATOL, V4, P698, DOI 10.1016/S0190-9622(81)70071-9
   Taylor Anne, 2008, J Cosmet Dermatol, V7, P164, DOI 10.1111/j.1473-2165.2008.00384.x
   TSE Y, 1994, J DERMATOL SURG ONC, V20, P795, DOI 10.1111/j.1524-4725.1994.tb03707.x
   Wang CC, 2004, DERMATOL SURG, V30, P1196, DOI 10.1111/j.1524-4725.2004.30371.x
NR 27
TC 1
Z9 1
U1 4
U2 11
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1476-4172
EI 1476-4180
J9 J COSMET LASER THER
JI J. Cosmet. Laser Ther.
PD DEC
PY 2014
VL 16
IS 6
BP 264
EP 270
DI 10.3109/14764172.2013.864201
PG 7
WC Dermatology; Surgery
SC Dermatology; Surgery
GA AT9HI
UT WOS:000345238400002
PM 24245978
DA 2018-12-27
ER

PT J
AU Ye, J
   Wen, L
   Liu, DL
   Lai, GX
AF Ye, Jia
   Wen, Li
   Liu, De-Ling
   Lai, Guo-xiang
TI RETRACTED: ATF3 and Extracellular Matrix-Related Genes Associated with
   the Process of Chronic Obstructive Pulmonary (Retracted article. See
   vol. 193, pg. 871, 2015)
SO LUNG
LA English
DT Article; Retracted Publication
DE Chronic obstructive pulmonary disease; Gene interaction networks;
   Extracellular matrix-related genes
ID DISEASE; CANCER; COPD; EXPRESSION; FIBROSIS; PATHOGENESIS; INFLAMMATION;
   METASTASIS; MECHANISMS; SMOKING
AB Chronic obstructive pulmonary disease (COPD) is a major public health problem worldwide and is proved to be the number three cause of death in globally. The objective of this study was to explore the molecular mechanism of the progression of COPD.
   Using the GSE1650 affymetrix microarray data accessible from Gene Expression Omnibus database, we first identified the differentially expressed genes (DEGs) between 18 COPD samples and 12 normal samples, followed by the GO / KEGG pathway analysis and gene interaction networks analysis of the DEGs. Our study identified 134 DEGs which involved in regulation of immune response, vesicle transport system, growth regulator and extracellular matrix (ECM)-related pathways.
   Gene interaction networks analysis showed that the sub-network involved by activating transcription factor-3 (ATF3) was the most significant sub-network in gene interaction networks. Furthermore, the investigation of extracellular matrix-related genes showed that genes like collagen and insulin-like growth factor binding protein could clearly distinguish the COPD and normal control.
   The genes regulated by ATF3 transcriptional activator as well as ECM-related genes may play an important role in the process of COPD. Our study provides a comprehensive bioinformatics analysis of genes and pathways which may be involved in the progression of COPD.
C1 [Ye, Jia; Liu, De-Ling; Lai, Guo-xiang] PLA, Fuzhou Gen Hosp Nanjing Command, Dept Resp & Crit Care Med, Fuzhou 350025, Peoples R China.
   [Wen, Li] Fujian Univ Tradit Chinese Med, Peoples Hosp Fujian Prov, Dept Anesthesiol, Fuzhou 350004, Peoples R China.
RP Lai, GX (reprint author), PLA, Fuzhou Gen Hosp Nanjing Command, Dept Resp & Crit Care Med, 156 Xihuan Bei Rd, Fuzhou 350025, Peoples R China.
EM laiguoxiang2007@163.com
CR Alfarano C, 2005, NUCLEIC ACIDS RES, V33, pD418, DOI 10.1093/nar/gki051
   Anderson RH, 2001, CARDIOL YOUNG, V11, P1, DOI 10.1017/S1047951100012348
   Annoni R, 2012, EUR RESPIR J, V40, P1362, DOI 10.1183/09031936.00192611
   Arakawa Kazuharu, 2005, In Silico Biology, V5, P419
   Averous J, 2004, J BIOL CHEM, V279, P5288, DOI 10.1074/jbc.M311862200
   Barnes PJ, 2002, NAT REV DRUG DISCOV, V1, P437, DOI 10.1038/nrd820
   Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703
   Basile DP, 1998, AM J PHYSIOL-RENAL, V275, pF894, DOI 10.1152/ajprenal.1998.275.6.F894
   Beghe B, 2010, ALLERGY, V65, P474, DOI 10.1111/j.1398-9995.2009.02167.x
   Bennett BL, 2006, EUR RESPIR J, V28, P651, DOI 10.1183/09031936.06.00012106
   Birrell MA, 2011, PHARMACOL THERAPEUT, V130, P364, DOI 10.1016/j.pharmthera.2011.03.007
   Bozinovski S, 2013, PHARMACOL THERAPEUT, V140, P280, DOI 10.1016/j.pharmthera.2013.07.007
   Cho MH, 2010, NAT GENET, V42, P200, DOI 10.1038/ng.535
   DANIELSSON PE, 1980, COMPUT VISION GRAPH, V14, P227, DOI 10.1016/0146-664X(80)90054-4
   de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Eurlings IMJ, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-90
   Ezzati M, 2003, LANCET, V362, P847, DOI 10.1016/S0140-6736(03)14338-3
   Green CJ, 2014, INT J MOL EPIDEMIOL, V5, P112
   Grumelli S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018785
   Hackl C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-668
   Hai T, 2012, ENCY SIGNALING MOL, P169
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jee Y-K, 2013, WORLD ALLERGY ORG, V6, P82
   Korfei M, 2013, J PROTEOMICS, V85, P109, DOI 10.1016/j.jprot.2013.04.033
   Kranenburg AR, 2006, AM J CLIN PATHOL, V126, P725, DOI 10.1309/JC477FAEL1YKV54W
   Kunz LI, 2013, PLOS ONE, V8, P63430
   Kwon MJ, 2013, HUM PATHOL, V44, P260, DOI 10.1016/j.humpath.2012.05.019
   Lee HK, 2004, GENOME RES, V14, P1085, DOI 10.1101/gr.1910904
   Liu X-Y, 2011, CHIN J PATHOPHYSIOL, V10
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Nepusz T, 2012, NAT METHODS, V9, P471, DOI [10.1038/nmeth.1938, 10.1038/NMETH.1938]
   Parameswaran K, 2006, CELL BIOCHEM BIOPHYS, V44, P139, DOI 10.1385/CBB:44:1:139
   Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256
   Pilewski JM, 2005, AM J PATHOL, V166, P399, DOI 10.1016/S0002-9440(10)62263-8
   Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884
   Sin DD, 2002, AM J RESP CRIT CARE, V165, P704, DOI 10.1164/rccm.2104055
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027
   Sorhaug S, 2007, THESIS NTNU
   Tuder RM, 2012, J CLIN INVEST, V122, P2749, DOI 10.1172/JCI60324
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Wang JA, 2010, CANCER-AM CANCER SOC, V116, P3458, DOI 10.1002/cncr.25085
   Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410
   Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996
   Yang IV, 2013, THORAX, V68, P1114, DOI 10.1136/thoraxjnl-2012-202943
   Yuan XL, 2013, CANCER RES, V73, P3625, DOI 10.1158/0008-5472.CAN-12-3879
   Zitvogel L, 2010, CELL, V140, P798, DOI 10.1016/j.cell.2010.02.015
NR 47
TC 5
Z9 5
U1 4
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
EI 1432-1750
J9 LUNG
JI Lung
PD DEC
PY 2014
VL 192
IS 6
BP 881
EP 888
DI 10.1007/s00408-014-9631-4
PG 8
WC Respiratory System
SC Respiratory System
GA AU0TG
UT WOS:000345336800010
PM 25119290
DA 2018-12-27
ER

PT J
AU Han, CB
   Sun, L
   Ma, JT
   Li, YY
   Zhang, SL
   Bai, DM
   Zhou, Y
   Huang, LT
AF Han, Cheng-Bo
   Sun, Li
   Ma, Jie-Tao
   Li, Yao-Yong
   Zhang, Shu-Ling
   Bai, Dong-Mei
   Zhou, Yang
   Huang, Le-Tian
TI RETRACTED: The Influence of mtDNA Deletion on Lung Cancer Cells Under
   the Conditions of Hypoxia and Irradiation (Retracted article. See vol.
   193, pg. 873, 2015)
SO LUNG
LA English
DT Article; Retracted Publication
DE Mitochondrial DNA; Hypoxia; Irradiation; Lung cancer; Differentially
   expressed gene; Functional enrichment analysis
ID MITOCHONDRIAL-DNA; SUPEROXIDE-DISMUTASE; HEPATOCELLULAR-CARCINOMA;
   SEQUENCE POLYMORPHISMS; RADIATION-THERAPY; TUMOR-CELLS; COPY NUMBER;
   AUTOPHAGY; HIF-1; OVEREXPRESSION
AB This study was to evaluate the influence of mtDNA deletion on the lung cancer cells under the conditions of hypoxia or irradiation.
   The treatment conditions of lung cancer cell lines with (A549) and without mtDNA (rho 0A549: obtained by inducing from A549) included 2 h of hypoxia and 4 Gy irradiation (group 1: without treatment; group 2: 2 h of hypoxia; group 3: 4 Gy irradiation; group 4: 2 h of hypoxia plus 4 Gy irradiation). The Human OneArray (TM) microarray was used to hybridize with the Cy5-labeled aRNA in microarray sample preparation. Differentially expressed genes (DEGs) between the lung cancer cells with and without mtDNA were identified using NOISeq package in R. Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed using the online tool of DAVID.
   In the KEGG pathway analysis of down-regulated DEGs, nineteen pathways were simultaneously enriched in the four groups, which were mainly metabolism- and biosynthesis-related pathways. Nine lung cancer-related pathways were enriched in group 4, and more cancer-associated DEGs, such as MYC, MAX, and E2F1 were found in group 4 than in the other groups.
   The mtDNA deletion could inhibit the biosynthesis and metabolism of lung cancer cells and promote the effect of hypoxia and radiation on lung cancer cells. MYC might be the key gene of the cooperation of hypoxia and radiation and MYC, MAX, and E2F1 might play roles in hypoxia- and radiation-induced cell death in lung cancer cells without mtDNA.
C1 [Han, Cheng-Bo; Sun, Li; Ma, Jie-Tao; Li, Yao-Yong; Zhang, Shu-Ling; Bai, Dong-Mei; Zhou, Yang; Huang, Le-Tian] China Med Univ, Dept Oncol, Shengjing Hosp, Shenyang 110022, Peoples R China.
RP Han, CB (reprint author), China Med Univ, Dept Oncol, Shengjing Hosp, 39 Huaxiang Rd, Shenyang 110022, Peoples R China.
EM hancb@126.com
FU NSFC (Natural Science Foundation of China) [81372531]
FX This study was supported by NSFC (Natural Science Foundation of China)
   No. 81372531. We wish to express our warm thanks to Fenghe (Shanghai)
   Information Technology Co., Ltd. Their ideas and help gave a valuable
   added dimension to our research.
CR Akgul EO, 2013, RESP MED, V107, P1814, DOI 10.1016/j.rmed.2013.04.024
   Basaki K, 2006, INT J RADIAT ONCOL, V64, P449, DOI 10.1016/j.ijrobp.2005.07.967
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166
   Chang Sheng, 2012, Zhonghua Liu Xing Bing Xue Za Zhi, V33, P391
   Chen JS, 2013, BIOINFORMATICS, V29, P420, DOI 10.1093/bioinformatics/bts715
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8
   Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Ding CM, 2012, MITOCHONDR DNA, V23, P251, DOI 10.3109/19401736.2012.674120
   Ding CM, 2012, EXP THER MED, V3, P861, DOI 10.3892/etm.2012.490
   Epperly MW, 2009, RADIAT RES, V157, P568
   Eriksson D, 2010, TUMOR BIOL, V31, P363, DOI 10.1007/s13277-010-0042-8
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Garofalo C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083832
   Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036
   HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Hosgood HD, 2010, CARCINOGENESIS, V31, P847, DOI 10.1093/carcin/bgq045
   King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   Koshikawa N, 2009, J BIOL CHEM, V284, P33185, DOI 10.1074/jbc.M109.054221
   Kumar P, 2000, SEMIN HEMATOL, V37, P4, DOI 10.1053/shem.2000.18116
   Lanni TB, 2011, AM J CLIN ONCOL-CANC, V34, P494, DOI 10.1097/COC.0b013e3181ec63ae
   Lin Chen-Sung, 2008, Interact Cardiovasc Thorac Surg, V7, P954, DOI 10.1510/icvts.2008.177006
   LING X-l, 2005, ACTA ACAD MED MIL TE, V14
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928
   Motoori S, 2001, CANCER RES, V61, P5382
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Papandreou I, 2008, CELL DEATH DIFFER, V15, P1572, DOI 10.1038/cdd.2008.84
   Pelengaris S, 2003, EXPERT OPIN THER TAR, V7, P623, DOI 10.1517/eott.7.5.623.22524
   Quintero M, 2004, EJSO-EUR J SURG ONC, V30, P465, DOI 10.1016/j.ejso.2004.03.008
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Spruit MA, 2006, LUNG CANCER-J IASLC, V52, P257, DOI 10.1016/j.lungcan.2006.01.003
   STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404
   Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1
   Tarazona S, 2011, GENOME RES, V21, P2213, DOI 10.1101/gr.124321.111
   Toyooka S, 2011, GEN THORAC CARDIOVAS, V59, P527, DOI 10.1007/s11748-010-0743-3
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   Wang J, 2009, CHINESE MED J-PEKING, V122, P431, DOI 10.3760/cma.j.issn.0366-6999.2009.04.0014
   Xu RH, 2005, CANCER RES, V65, P613
   Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001
   Zhao M, 2013, NUCLEIC ACIDS RES, V41, pD970, DOI 10.1093/nar/gks937
   Zheng SZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031322
NR 45
TC 1
Z9 2
U1 4
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0341-2040
EI 1432-1750
J9 LUNG
JI Lung
PD DEC
PY 2014
VL 192
IS 6
BP 997
EP 1004
DI 10.1007/s00408-014-9639-9
PG 8
WC Respiratory System
SC Respiratory System
GA AU0TG
UT WOS:000345336800024
PM 25218334
DA 2018-12-27
ER

PT J
AU Bao, XH
   Ye, GL
   Ye, B
AF Bao, Xiao-Hua
   Ye, Guan-Lin
   Ye, Bin
TI RETRACTED: Explanation of liquefaction in after shock of the 2011 great
   east Japan earthquake using numerical analysis(Retracted article. See
   vol.86,pg.1405,2017)
SO NATURAL HAZARDS
LA English
DT Article; Retracted Publication
DE Repeated earthquake; Liquefaction; Settlement; FEM; Constitutive model
ID NUMERICAL-SIMULATION; SOIL; REINFORCEMENT; PERFORMANCE; FOUNDATION;
   ANISOTROPY; MODEL; SAND
AB During the 2011 Great East Japan Earthquake, severe liquefaction occurred in reclaimed ground in Urayasu city, Chiba prefecture. This liquefaction provided important lessons for us to re-recognize the liquefaction mechanism. A distinct feature of the liquefaction in this earthquake is that severe liquefaction happened not only in the main shock but also in an aftershock with a maximum acceleration of 25 gal. In some areas, liquefaction happened in the aftershock is even more serious than that happened in the main shock. In this paper, focus is placed on the characteristic features in the occurrence of liquefaction and consequent ground settlement. Based on the observed data, a series of dynamic-static analyses, considering not only the earthquake loading but also static loading during the consolidation after the earthquake shocks, are conducted in a sequential way just the same as the scenario in the earthquake. The calculation is conducted with 3D soil-water coupling finite element-finite difference analyses based on a cyclic elastoplastic constitutive model. From the results of analyses, it is recognized that small sequential earthquakes, which cannot cause liquefaction of a ground in an independent earthquake vibration, cannot be neglected when the ground has already experienced liquefaction after a major vibration. In addition, the aftershock has great influence on the long-term settlement of low permeability soil layer. The observed and predicted liquefaction and settlements are compared and discussed carefully. It is confirmed that the numerical method used in this study can describe the ground behavior correctly under repeated earthquake shocks.
C1 [Bao, Xiao-Hua] Shenzhen Univ, Dept Civil Engn, Shenzhen 518060, Peoples R China.
   [Ye, Guan-Lin] Shanghai Jiao Tong Univ, Dept Civil Engn, Shanghai 200240, Peoples R China.
   [Ye, Bin] Tongji Univ, Dept Geotech Engn, Shanghai 200092, Peoples R China.
RP Ye, GL (reprint author), Shanghai Jiao Tong Univ, Dept Civil Engn, Shanghai 200240, Peoples R China.
EM xiaohuabaojp@yahoo.co.jp; ygl@sjtu.edu.cn; yebinmail1977@gmail.com
FU National Nature Science Foundation of China [41372284, 51308346];
   Guangdong Natural Science Foundation [S2013040012443]
FX This work was supported by National Nature Science Foundation of China
   (Grant No. 41372284 and 51308346) and Guangdong Natural Science
   Foundation (Grant No. S2013040012443).
CR Asaoka A, 2002, SOILS FOUND, V42, P47, DOI 10.3208/sandf.42.5_47
   Asaoka A, 1998, P 4 EUR C NUM METH G, V98, P232
   Bao XH, 2014, SOIL DYN EARTHQ ENG, V61-62, P63, DOI 10.1016/j.soildyn.2014.01.019
   Bao XH, 2012, SOILS FOUND, V52, P1043, DOI 10.1016/j.sandf.2012.11.020
   Bao YF, 2012, SOILS FOUND, V52, P257, DOI 10.1016/j.sandf.2012.02.005
   Boulanger RW, 2012, P INT S ENG LESS LEA, P655
   Hashiguchi K, 1997, P 9 INT C SOIL MECH, V9, P73
   Huang Y, 2006, GEOTEXT GEOMEMBRANES, V24, P169, DOI 10.1016/j.geotexmem.2005.11.005
   Huang Y, 2008, ENVIRON GEOL, V55, P1247, DOI 10.1007/s00254-007-1069-z
   Huang Y, 2008, B ENG GEOL ENVIRON, V67, P31, DOI 10.1007/s10064-007-0097-y
   Huang Y, 2013, NAT HAZARDS, V65, P2375, DOI 10.1007/s11069-012-0433-9
   Huang Y, 2010, NAT HAZARDS, V54, P839, DOI 10.1007/s11069-010-9509-6
   Ishihara K, 2012, P INT S ENG LESS LEA, P63
   Jin Y., 2010, GEOTECHNICAL SPECIAL, V205, P111, DOI DOI 10.1061/41106(379)13
   Lombardi D, 2014, NAT HAZARDS, V73, P1749, DOI 10.1007/s11069-014-1168-6
   Sekiguchi T, 2012, P INT S ENG LESS LEA, P865
   Xia ZF, 2010, SOIL DYN EARTHQ ENG, V30, P1309, DOI 10.1016/j.soildyn.2010.06.003
   Yasuda S, 2012, P INT S ENG LESS LEA, P825
   Ye B, 2011, GEOSYNTH INT, V18, P159, DOI 10.1680/gein.2011.18.4.159
   Ye B, 2007, SOILS FOUND, V47, P547, DOI 10.3208/sandf.47.547
   Ye B, 2012, COMPUT GEOTECH, V42, P62, DOI 10.1016/j.compgeo.2011.12.009
   Ye GL, 2011, DBLEAVES USERS MANUA
   Zhang F, 2007, SOILS FOUND, V47, P635, DOI 10.3208/sandf.47.635
   Zhang F, 2011, FRONT STRUCT CIV ENG, V5, P121, DOI 10.1007/s11709-011-0104-z
   Zhang F, 2010, SOILS FOUND, V50, P679, DOI 10.3208/sandf.50.679
NR 25
TC 3
Z9 3
U1 11
U2 39
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0921-030X
EI 1573-0840
J9 NAT HAZARDS
JI Nat. Hazards
PD DEC
PY 2014
VL 74
IS 3
BP 1881
EP 1897
DI 10.1007/s11069-014-1289-y
PG 17
WC Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences;
   Water Resources
SC Geology; Meteorology & Atmospheric Sciences; Water Resources
GA AT7DK
UT WOS:000345096800032
DA 2018-12-27
ER

PT J
AU Ashraf, MA
   Khan, AM
   Ahmad, M
   Akib, S
   Balkhair, KS
   Abu Bakar, NK
AF Ashraf, Muhammad Aqeel
   Khan, Ayesha Masood
   Ahmad, Mushtaq
   Akib, Shatirah
   Balkhair, Khaled S.
   Abu Bakar, Nor Kartini
TI RETRACTED: Release, deposition and elimination of radiocesium (Cs-137)
   in the terrestrial environment (Retracted article. See vol. 39, pg. 703,
   2017)
SO ENVIRONMENTAL GEOCHEMISTRY AND HEALTH
LA English
DT Review; Retracted Publication
DE Radionuclide; Cesium; Transfer; Nuclear power plants; Contamination;
   Bioaccumulation
ID FUKUSHIMA NUCLEAR ACCIDENT; POWER-PLANT ACCIDENT; CHERNOBYL ACCIDENT;
   BALTIC SEA; VERTICAL-DISTRIBUTION; RADIOACTIVE FALLOUT; MYCORRHIZAL
   FUNGI; FOREST ECOSYSTEMS; SOIL; RADIONUCLIDES
AB Radionuclide contamination in terrestrial ecosystems has reached a dangerous level. The major artificial radionuclide present in the environment is Cs-137, which is released as a result of weapon production related to atomic projects, accidental explosions of nuclear power plants and other sources, such as reactors, evaporation ponds, liquid storage tanks, and burial grounds. The release of potentially hazardous radionuclides (radiocesium) in recent years has provided the opportunity to conduct multidisciplinary studies on their fate and transport. Radiocesium's high fission yield and ease of detection made it a prime candidate for early radio-ecological investigations. The facility setting provides a diverse background for the improved understanding of various factors that contribute toward the fate and transfer of radionuclides in the terrestrial ecosystem. In this review, we summarize the significant environmental radiocesium transfer factors to determine the damaging effects of radiocesium on terrestrial ecosystem. It has been found that Cs-137 can trace the transport of other radionuclides that have a high affinity for binding to soil particles (silts and clays). Possible remedial methods are also discussed for contaminated terrestrial systems. This review will serve as a guideline for future studies of the fate and transport of Cs-137 in terrestrial environments in the wake of the Fukushima Nuclear Power Plant disaster in 2011.
C1 [Ashraf, Muhammad Aqeel; Khan, Ayesha Masood] Univ 3of Malaya, Fac Sci, Dept Geol, Kuala Lumpur 50603, Malaysia.
   [Ahmad, Mushtaq] Quaid I Azam Univ, Dept Plant Sci, Islamabad 45320, Pakistan.
   [Akib, Shatirah] Univ Malaya, Dept Civil Engn, Kuala Lumpur 50603, Malaysia.
   [Balkhair, Khaled S.] King Abdulaziz Univ, Dept Hydrol & Water Resources Management, Jeddah 22254, Saudi Arabia.
   [Abu Bakar, Nor Kartini] Univ Malaya, Dept Chem, Kuala Lumpur 50603, Malaysia.
RP Ashraf, MA (reprint author), Univ 3of Malaya, Fac Sci, Dept Geol, Kuala Lumpur 50603, Malaysia.
EM aqeelashraf@um.edu.my
RI Ahmad, Mushtaq/I-7263-2015; Abu Bakar, Nor Kartini/B-9320-2010
OI Abu Bakar, Nor Kartini/0000-0002-4380-6704; ASHRAF, MUHAMMAD
   AQEEL/0000-0003-3151-3397; Akib, Shatirah/0000-0002-6538-0716
FU High Impact Research MoE from the Ministry of Education Malaysia
   [UM.C/625/1/HIR/MoE/SC/04]; UMRG [RG257-13AFR]; FRGS [FP038-2013B]
FX This research is supported by High Impact Research MoE Grant
   UM.C/625/1/HIR/MoE/SC/04 from the Ministry of Education Malaysia. Thanks
   also for the support by UMRG (RG257-13AFR) and FRGS (FP038-2013B).
CR Al-Masri MS, 2006, J ENVIRON RADIOACTIV, V86, P187, DOI 10.1016/j.jenvrad.2005.08.006
   [Anonymous], 2012, FUKUSHIMA PREFECTURE
   Antonio MR, 1997, INORG CHIM ACTA, V255, P13, DOI 10.1016/S0020-1693(96)05198-5
   Aoyama M, 2008, RADIOACTIV ENVIRONM, V11, P137, DOI 10.1016/S1569-4860(07)11004-4
   Aoyama M, 2011, PROG OCEANOGR, V89, P7, DOI 10.1016/j.pocean.2010.12.003
   Ashraf MA, 2014, CRIT REV ENV SCI TEC, V44, P1740, DOI 10.1080/10643389.2013.790753
   Balonov M., 2010, HDB PARAMETER VALUES
   Ben-Asher J., 2011, REGULATING RADIOACTI
   Beresford NA, 2013, RADIAT ENVIRON BIOPH, V52, P505, DOI 10.1007/s00411-013-0481-x
   Beresford NA, 2013, SCI TOTAL ENVIRON, V463, P284, DOI 10.1016/j.scitotenv.2013.06.013
   Beresford NA, 2004, J RADIOL PROT, V24, pA89, DOI 10.1088/0952-4746/24/4A/006
   Bolsunovsky A, 2011, J ENVIRON RADIOACTIV, V102, P1062, DOI 10.1016/j.jenvrad.2011.06.007
   Bossew P, 2007, J ENVIRON RADIOACTIV, V97, P5, DOI 10.1016/j.jenvrad.2007.02.008
   Bowyer TW, 2011, J ENVIRON RADIOACTIV, V102, P681, DOI 10.1016/j.jenvrad.2011.04.009
   Brandt J, 2002, ATMOS CHEM PHYS, V2, P397, DOI 10.5194/acp-2-397-2002
   Brechignac F, 2003, J ENVIRON RADIOACTIV, V70, P155, DOI 10.1016/S0265-931X(03)00131-0
   Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100
   Brito JC, 2014, BIOL REV, V89, P215, DOI 10.1111/brv.12049
   Brown JE, 2008, J ENVIRON RADIOACTIV, V99, P1371, DOI 10.1016/j.jenvrad.2008.01.008
   Butler D., 2011, NATURE NEWSBLOG
   Chiang PN, 2010, J ENVIRON RADIOACTIV, V101, P472, DOI 10.1016/j.jenvrad.2008.10.013
   CHINO M, 1993, RADIAT PROT DOSIM, V50, P145
   Chino M, 2011, J NUCL SCI TECHNOL, V48, P1129, DOI [10.3327/jnst.48.1129, 10.1080/18811248.2011.9711799]
   Cid AS, 2013, SCI TOTAL ENVIRON, V444, P115, DOI 10.1016/j.scitotenv.2012.11.092
   Cyranoski D, 2011, NATURE, V477, P139, DOI 10.1038/477139a
   Davoine X, 2007, ATMOS CHEM PHYS, V7, P1549, DOI 10.5194/acp-7-1549-2007
   de Boulois HD, 2008, J ENVIRON RADIOACTIV, V99, P785, DOI 10.1016/j.jenvrad.2007.10.008
   De Hoop L, 2013, MAR POLLUT BULL, V76, P178, DOI 10.1016/j.marpolbul.2013.09.006
   Devell L., 1996, CHERNOBYL REACTOR AC
   Diaz Leon J., 2011, J ENVIRON RADIOACTIV, V102, P1032
   Dlugosz-Lisiecka M, 2012, J RADIOANAL NUCL CH, V293, P135, DOI 10.1007/s10967-012-1690-5
   DODGE CJ, 1994, ENVIRON SCI TECHNOL, V28, P1300, DOI 10.1021/es00056a018
   Dowdall M, 2008, J ENVIRON RADIOACTIV, V99, P1736, DOI 10.1016/j.jenvrad.2008.06.012
   ECKERMAN K, 1988, 11 EPA
   Ellis EC, 2013, CURR OPIN ENV SUST, V5, P368, DOI 10.1016/j.cosust.2013.07.002
   Endo S, 2012, J ENVIRON RADIOACTIV, V111, P18, DOI 10.1016/j.jenvrad.2011.11.006
   Galmarini S, 2011, NATURE, V473, P285, DOI 10.1038/473285d
   Gherardi F., 2013, ETHOL ECOL EVOL, V26, P86
   Gjelsvik R, 2013, J ENVIRON RADIOACTIV, V126, P99, DOI 10.1016/j.jenvrad.2013.07.010
   Gyuricza V, 2010, J ENVIRON RADIOACTIV, V101, P482, DOI 10.1016/j.jenvrad.2008.04.002
   Hagan L., 1977, BIBLIO ATOMIC ENERGY, V363
   HARITONIDIS S, 1995, ENVIRON POLLUT, V89, P319, DOI 10.1016/0269-7491(94)00070-T
   Hinton TG, 2013, J ENVIRON RADIOACTIV, V115, P73, DOI 10.1016/j.jenvrad.2012.07.011
   Hirose K, 2008, APPL RADIAT ISOTOPES, V66, P1675, DOI 10.1016/j.apradiso.2007.09.019
   Hirose K, 2012, J ENVIRON RADIOACTIV, V111, P13, DOI 10.1016/j.jenvrad.2011.09.003
   HOHENEMSER C, 1988, ENVIRONMENT, V30, P4, DOI 10.1080/00139157.1988.9928895
   Hou XL, 2003, SCI TOTAL ENVIRON, V308, P97, DOI 10.1016/S0048-9697(02)00546-6
   International Atomic Energy Agency, 2011, PLEAS ADD TITL
   International Atomic Energy Agency, 2009, QUANT RAD TRANSF TER
   International Atomic Energy Agency, 2001, REP 2 FAO CLASS SOIL
   International Atomic Energy Agency, 2000, 723J9SP11142 IAEA
   International Atomic Energy Agency, 2001, PRES FUT ENV IMP CHE
   Japanese Ministry of Education Culture Sports Science and Technology, 2012, ADD TITL
   Japanese Ministry of Education Culture Sports Science and Technology, 2011, READ RAD LEV FALL PR
   Japanese Ministry of Education Culture Sports Science and Technology, 2011, RES 2 AIRB MON MEXT
   Japanese Ministry of Education Culture Sports Science and Technology, 2011, READ SEA AR MON
   Japanese Ministry of Education Culture Sports Science and Technology, 2011, ENV RAD DAT
   Japanese Ministry of Education Culture Sports Science and Technology, 2011, READ ENV RAD LEV PRE
   Japanese Ministry of Education Culture Sports Science and Technology, 2011, RES AIRB MON MEXT US
   Jargin SV, 2010, RADIAT ENVIRON BIOPH, V49, P743, DOI 10.1007/s00411-010-0313-1
   Jasiulionis R, 2007, LITH J PHYS, V47, P195, DOI 10.3952/lithjphys.47207
   Jasiulionis R., 2006, Lithuanian Journal of Physics, V46, P101
   Kinoshita N, 2011, P NATL ACAD SCI USA, V108, P19526, DOI 10.1073/pnas.1111724108
   Kitajima A, 2014, ENVIRON SCI-PROC IMP, V16, P28, DOI 10.1039/c3em00416c
   Koarashi J, 2012, SCI TOTAL ENVIRON, V431, P392, DOI 10.1016/j.scitotenv.2012.05.041
   Koizumi Akio, 2012, Environmental Health and Preventive Medicine, V17, P292, DOI 10.1007/s12199-011-0251-9
   Lee CP, 2008, J RADIOANAL NUCL CH, V275, P343, DOI 10.1007/s10967-007-7013-6
   Lide D. R., 2004, CRC HDB CHEM PHYS 20
   Lozano RL, 2011, ENVIRON INT, V37, P1259, DOI 10.1016/j.envint.2011.06.001
   Maderich V, 2014, J ENVIRON RADIOACTIV, V131, P4, DOI 10.1016/j.jenvrad.2013.09.009
   Manolopoulou M, 2011, J ENVIRON RADIOACTIV, V102, P796, DOI 10.1016/j.jenvrad.2011.04.010
   McMichael P, 2013, FOOD SOVEREIGNTY CRI
   Medici F, 2001, RADIAT PHYS CHEM, V61, P689, DOI 10.1016/S0969-806X(01)00375-9
   Mihaela T, 2012, INT J DAIRY TECHNOL, V65, P511, DOI 10.1111/j.1471-0307.2012.00859.x
   Ministry of Agriculture Forestry and Fisheries, 2011, POINT VIEW PLANT RIC
   Ministry of Land Infrastructure Transport and Tourism, 2011, SOIL MAP JAP
   Moller AP, 2013, ECOL INDIC, V24, P75, DOI 10.1016/j.ecolind.2012.06.001
   Moller AP, 2012, ENVIRON POLLUT, V164, P36, DOI 10.1016/j.envpol.2012.01.008
   Morino Y, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL048689
   Mucina L., 2013, FLORISTIC ECOLOGICAL
   Nakanishi T, 2014, J ENVIRON RADIOACTIV, V128, P9, DOI 10.1016/j.jenvrad.2013.10.019
   Niedree B., 2013, EFFECTS 137CS 90SR S
   Nimis PL, 1996, STUD GEOBOT, V15, P3
   Norman EB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024330
   Okumura T, 2014, MICROSCOPY-JPN, V63, P65, DOI 10.1093/jmicro/dft045
   PAASIKALLIO A, 1994, SCI TOTAL ENVIRON, V155, P109, DOI 10.1016/0048-9697(94)90285-2
   Peterson DL, 2014, ADV GLOB CHANGE RES, V57, P113, DOI 10.1007/978-94-007-7515-2_6
   Pittauerova D, 2011, J ENVIRON RADIOACTIV, V102, P877, DOI 10.1016/j.jenvrad.2011.06.003
   Povinec PP, 2012, J ENVIRON RADIOACTIV, V114, P81, DOI 10.1016/j.jenvrad.2012.05.008
   Prohl G, 2009, J ENVIRON RADIOACTIV, V100, P675, DOI 10.1016/j.jenvrad.2008.10.006
   Real J, 2002, J ENVIRON RADIOACTIV, V62, P1, DOI 10.1016/S0265-931X(01)00136-9
   RITCHIE JC, 1990, J ENVIRON QUAL, V19, P215, DOI 10.2134/jeq1990.00472425001900020006x
   Rochette P, 2000, SOIL SCI SOC AM J, V64, P1396, DOI 10.2136/sssaj2000.6441396x
   Sanzharova N., 2009, QUANTIFICATION RADIO, P139
   Shaw G, 2007, RADIOACTIV ENVIRONM, V10, P127, DOI 10.1016/S1569-4860(06)10006-6
   Shcheglov A. I., 2013, J GEOCHEMICAL EXPLOR
   Simpson M. F., 2013, NUCL ENERGY, P153
   Sinclair LE, 2011, J ENVIRON RADIOACTIV, V102, P1018, DOI 10.1016/j.jenvrad.2011.06.008
   Sokolov N. V., 2001, 15 YEARS CHERNOBYL A, P117
   Steiner M, 2002, J ENVIRON RADIOACTIV, V58, P217, DOI 10.1016/S0265-931X(01)00067-4
   Steinhauser G, 2013, ENVIRON SCI POLLUT R, V20, P2527, DOI 10.1007/s11356-012-1140-5
   Stohl A, 2005, ATMOS CHEM PHYS, V5, P2461, DOI 10.5194/acp-5-2461-2005
   Stohl A., 2011, ATMOS CHEM PHYS DISC, V11, P28319, DOI DOI 10.5194/ACPD-11-28319-2011
   Strand P, 1999, SCI TOTAL ENVIRON, V241, P107, DOI 10.1016/S0048-9697(99)00332-0
   Szefer P, 2002, OCEANOLOGIA, V44, P129
   Tagami K, 2013, ENVIRON SCI TECHNOL, V47, P5007, DOI 10.1021/es304730b
   Taira T, 2011, NATURE, V480, P313, DOI 10.1038/480313a
   Tateda Y, 2013, J ENVIRON RADIOACTIV, V124, P1, DOI 10.1016/j.jenvrad.2013.03.007
   Tositti L, 2012, J ENVIRON RADIOACTIV, V114, P105, DOI 10.1016/j.jenvrad.2012.01.016
   Tracy BL, 2013, J ENVIRON RADIOACTIV, V122, P1, DOI 10.1016/j.jenvrad.2013.02.015
   Tsukada H, 2003, J RADIOANAL NUCL CH, V255, P455, DOI 10.1023/A:1022507710447
   Tyler AN, 2001, CATENA, V43, P81, DOI 10.1016/S0341-8162(00)00127-2
   United Nations Scientific Committee on the Effects of Atomic Radiation, 2000, SOURC EFF ION RAD
   Valentin J, 2003, Ann ICRP, V33, P207
   Valles I, 2009, J ENVIRON RADIOACTIV, V100, P102, DOI 10.1016/j.jenvrad.2008.10.009
   Velasco H, 2012, J ENVIRON RADIOACTIV, V104, P64, DOI 10.1016/j.jenvrad.2011.09.016
   Vinichuk M, 2010, SCI TOTAL ENVIRON, V408, P2543, DOI 10.1016/j.scitotenv.2010.02.024
   Wampler JM, 2012, ENVIRON SCI TECHNOL, V46, P3837, DOI 10.1021/es2035834
   Wells T, 2014, GEODERMA, V214, P228, DOI 10.1016/j.geoderma.2013.09.007
   Wicker W. F., 1982, RADIOECOLOGY NUCL EN, V1, P153
   Willey NJ, 2010, RADIAT ENVIRON BIOPH, V49, P613, DOI 10.1007/s00411-010-0320-2
   Wood MD, 2013, J ENVIRON RADIOACTIV, V126, P314, DOI 10.1016/j.jenvrad.2013.07.022
   Yablokov AV, 2010, CHERNOBYL CONSEQUENC
   Yan D, 2013, J ENVIRON RADIOACTIV, V126, P232, DOI 10.1016/j.jenvrad.2013.08.009
   Yang LP, 2011, CHEMOSPHERE, V83, P806, DOI 10.1016/j.chemosphere.2011.02.075
   Yasunari TJ, 2011, P NATL ACAD SCI USA, V108, P19530, DOI 10.1073/pnas.1112058108
   Zaborska A, 2014, J ENVIRON RADIOACTIV, V127, P11, DOI 10.1016/j.jenvrad.2013.09.003
   Zalewska T, 2006, J ENVIRON RADIOACTIV, V91, P1, DOI 10.1016/j.jenvrad.2006.08.001
   ZAMG, 2011, ACC JAP NPP FUK SPRE
   Zheng J, 2012, SCI REP-UK, V2, DOI 10.1038/srep00304
NR 130
TC 7
Z9 8
U1 4
U2 89
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0269-4042
EI 1573-2983
J9 ENVIRON GEOCHEM HLTH
JI Environ. Geochem. Health
PD DEC
PY 2014
VL 36
IS 6
BP 1165
EP 1190
DI 10.1007/s10653-014-9620-9
PG 26
WC Engineering, Environmental; Environmental Sciences; Public,
   Environmental & Occupational Health; Water Resources
SC Engineering; Environmental Sciences & Ecology; Public, Environmental &
   Occupational Health; Water Resources
GA AS9EU
UT WOS:000344546700011
PM 24804829
DA 2018-12-27
ER

PT J
AU Bai, JM
   Liu, XP
AF Bai Jinmei
   Liu Xueping
TI RETRACTED: Heavy metal pollution in surface soils of Pearl River Delta,
   China(Retracted article. See vol. 187, pg. 112, 2015)
SO ENVIRONMENTAL MONITORING AND ASSESSMENT
LA English
DT Article; Retracted Publication
DE Heavy metals; Soil pollution; Land-use patterns; Potential ecological
   risk
ID SOUTH CHINA; URBAN-ENVIRONMENT; SEDIMENT PROFILES; BLOOD LEAD;
   HONG-KONG; ESTUARY; CADMIUM; CONTAMINATION; GUANGZHOU; CHILDREN
AB Heavy metal pollution is an increasing environmental problem in Chinese regions undergoing rapid economic and industrial development, such as the Pearl River Delta (PRD), southern China. We determined heavy metal concentrations in surface soils from the PRD. The soils were polluted with heavy metals, as defined by the Chinese soil quality standard grade II criteria. The degree of pollution decreased in the order Cd > Cu > Ni > Zn > As > Cr > Hg > Pb. The degree of heavy metal pollution by land use decreased in the order waste treatment plants (WP) > urban land (UL) > manufacturing industries (MI) > agricultural land (AL) > woodland (WL) > water sources (WS). Pollution with some of the metals, including Cd, Cu, Ni, and Zn, was attributed to the recent rapid development of the electronics and electroplating industries. Cd, Hg, and Pb (especially Cd) pose high potential ecological risks in all of the zones studied. The soils posing significantly high and high potential ecological risks from Cd covered 73.3 % of UL, 50 % of MI and WP land, and 48.5 % of AL. The potential ecological risks from heavy metals by land use decreased in the order UL > MI > AL > WP > WL > WS. The control of Cd, Hg, and Pb should be prioritized in the PRD, and emissions in wastewater, residue, and gas discharges from the electronics and electroplating industry should be decreased urgently. The use of chemical fertilizers and pesticides should also be decreased.
C1 [Bai Jinmei] Changzhou Univ, Sch Petr Engn, Changzhou 213164, Jiangsu, Peoples R China.
   [Liu Xueping] Fujian Univ Technol, Coll Ecol Environm & Urban Construct, Fuzhou 350118, Fujian, Peoples R China.
RP Bai, JM (reprint author), Changzhou Univ, Sch Petr Engn, Changzhou 213164, Jiangsu, Peoples R China.
EM baijinmei_1982@hotmail.com
CR Banat KM, 2005, ENVIRON RES, V97, P258, DOI [10.1016/j.envres.2004.07.002, 10.1006/j,envres.2004.07.002]
   Bocca B, 2004, SPECTROCHIM ACTA B, V59, P559, DOI 10.1016/j.sab.2004.02.007
   CEPA, 1995, GB156181995 CEPA
   DAVIES DJA, 1990, SCI TOTAL ENVIRON, V90, P13, DOI 10.1016/0048-9697(90)90182-T
   GEMC, 1990, SOIL ENV BACKGR VAL
   Guieu C, 1997, DEEP-SEA RES PT II, V44, P655, DOI 10.1016/S0967-0645(97)88508-6
   HAKANSON L, 1980, WATER RES, V14, P975, DOI 10.1016/0043-1354(80)90143-8
   HARRISON RM, 1981, ENVIRON SCI TECHNOL, V15, P1378, DOI 10.1021/es00093a013
   Hashisho Z, 2004, ENVIRON MONIT ASSESS, V93, P185, DOI 10.1023/B:EMAS.0000016804.88534.34
   HAYGARTH PM, 1991, SCI TOTAL ENVIRON, V103, P89, DOI 10.1016/0048-9697(91)90355-I
   Ip CCM, 2004, ENVIRON POLLUT, V132, P157, DOI 10.1016/j.envpol.2004.03.028
   Kuang C, 2004, ENVIRON SCI POLLUT R, V11, P73, DOI 10.1007/BF02979706
   Lee CS, 2006, SCI TOTAL ENVIRON, V356, P45, DOI 10.1016/j.scitotenv.2005.03.024
   Leermakers M, 2001, MAR CHEM, V75, P229, DOI 10.1016/S0304-4203(01)00039-1
   Li XD, 2000, APPL GEOCHEM, V15, P567, DOI 10.1016/S0883-2927(99)00072-4
   Li XD, 2004, ENVIRON POLLUT, V129, P113, DOI 10.1016/j.envpol.2003.09.030
   Li XD, 2001, MAR POLLUT BULL, V42, P215, DOI 10.1016/S0025-326X(00)00145-4
   Liu WX, 2003, ENVIRON POLLUT, V121, P377, DOI 10.1016/S0269-7491(02)00234-8
   Lu Y, 2007, ENVIRON MONIT ASSESS, V134, P429, DOI 10.1007/s10661-007-9634-1
   Mielke HW, 1999, ENVIRON RES, V81, P117, DOI 10.1006/enrs.1999.3966
   Munksgaard NC, 2001, MAR CHEM, V75, P165, DOI 10.1016/S0304-4203(01)00033-0
   Nagajyoti PC, 2010, ENVIRON CHEM LETT, V8, P199, DOI 10.1007/s10311-010-0297-8
   NRIAGU JO, 1988, ENVIRON POLLUT, V50, P139, DOI 10.1016/0269-7491(88)90189-3
   Raghunath R, 1999, ENVIRON RES, V80, P215, DOI 10.1006/enrs.1998.3919
   Roychowdhury T, 2002, CHEMOSPHERE, V49, P605, DOI 10.1016/S0045-6535(02)00309-0
   Schuhmacher M, 1997, B ENVIRON CONTAM TOX, V59, P861, DOI 10.1007/s001289900561
   Tao YX, 1999, WATER SCI TECHNOL, V39, P227, DOI 10.1016/S0273-1223(99)00106-7
   USEPA, 1996, MICR ASS AC DIG SIL
   Waisberg M, 2003, TOXICOLOGY, V192, P95, DOI 10.1016/S0300-483X(03)00305-6
   Wong CSC, 2003, ATMOS ENVIRON, V37, P767, DOI 10.1016/S1352-2310(02)00929-9
   Wong SC, 2002, ENVIRON POLLUT, V119, P33, DOI 10.1016/S0269-7491(01)00325-6
   Zhu BQ, 2001, APPL GEOCHEM, V16, P409
NR 32
TC 8
Z9 11
U1 6
U2 123
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6369
EI 1573-2959
J9 ENVIRON MONIT ASSESS
JI Environ. Monit. Assess.
PD DEC
PY 2014
VL 186
IS 12
BP 8051
EP 8061
DI 10.1007/s10661-014-4050-9
PG 11
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA AS6BF
UT WOS:000344349200001
DA 2018-12-27
ER

PT J
AU De la Roche, J
   Gonzalez, JM
   Restrepo-Parra, E
   Sequeda, F
   Alleh, V
   Scharf, TW
AF De la Roche, J.
   Gonzalez, J. M.
   Restrepo-Parra, E.
   Sequeda, F.
   Alleh, V.
   Scharf, T. W.
TI RETRACTED: Structure adhesion and corrosion resistance study of tungsten
   bisulfide doped with titanium deposited by DC magnetron co-sputtering
   (Retracted article. See vol. 349, pg. 997, 2015)
SO APPLIED SURFACE SCIENCE
LA English
DT Article; Retracted Publication
DE Solid lubricant; DMT; TEM; EIS; Doping
ID CHEMICAL-VAPOR-DEPOSITION; DISULFIDE THIN-FILMS; TRIBOLOGICAL BEHAVIOR;
   LUBRICANT COATINGS; GROWTH; MICROSTRUCTURE; SUBSTRATE; FRICTION
AB Titanium-doped tungsten bisulfide thin films (WS2-Ti) were grown using a DC magnetron co-sputtering technique on AISI 304 stainless steel and silicon substrates. The films were produced by varying the Ti cathode power from 0 to 25W. Using energy dispersive spectroscopy (EDS), the concentration of Ti in the WS2 was determined, and a maximum of 10% was obtained for the sample grown at 25W. Moreover, the S/W ratio was calculated and determined to increase as a function of the Ti cathode power. According to transmission electron microscopy (TEM) results, at high titanium concentrations (greater than 6%), nanocomposite formation was observed, with nanocrystals of Ti embedded in an amorphous matrix of WS2. Using the scratch test, the coatings' adhesion was analyzed, and it was observed that as the Ti percentage was increased, the critical load (Lc) also increased. Furthermore, the failure type changed from plastic to elastic. Finally, the corrosion resistance was evaluated using the electrochemical impedance spectroscopy (EIS) technique, and it was observed that at high Ti concentrations, the corrosion resistance was improved, as Ti facilitates coating densification and generates a protective layer. (C) 2014 Elsevier B.V. All rights reserved.
C1 [De la Roche, J.; Restrepo-Parra, E.] Univ Nacl Colombia, Lab Fis Plasma, Manizales, Colombia.
   [Gonzalez, J. M.; Sequeda, F.] Univ Valle, Lab Recubrimientos Duros & Aplicac Ind RDAI, Cali, Colombia.
   [Alleh, V.; Scharf, T. W.] Univ N Texas, Dept Mat Sci & Engn, Denton, TX 76203 USA.
RP Restrepo-Parra, E (reprint author), Univ Nacl Colombia, Lab Fis Plasma, Km 9 Via Aeropuerto,Campus La Nubia, Manizales, Colombia.
EM erestrepop@unal.edu.co
OI Restrepo-Parra, Elisabeth/0000-0002-1734-1173
FU La Direccion Nacional de Investigaciones de la Universidad Nacional de
   Colombia sede Manizales [19271, 18780]; Colciencias
FX The authors gratefully acknowledge the financial support of La Direccion
   Nacional de Investigaciones de la Universidad Nacional de Colombia sede
   Manizales during the course of this research under the projects 19271
   and 18780. Moreover, we acknowledge Colciencias for financial support
   with the Jovenes Investigadores e Innovadores Project of 2012.
CR Agudelo-Morimitsu LC, 2014, CERAM INT, V40, P7037, DOI 10.1016/j.ceramint.2013.12.033
   Alm SH, 2004, SURF COAT TECH, V177, P638, DOI 10.1016/S0257-8972(03)00939-3
   An V, 2011, MATER LETT, V65, P2381, DOI 10.1016/j.matlet.2011.05.048
   [Anonymous], C162405 ASTM
   Balagna C, 2012, MAT SCI ENG C-MATER, V32, P887, DOI 10.1016/j.msec.2012.02.007
   BERTRAND PA, 1989, J MATER RES, V4, P180, DOI 10.1557/JMR.1989.0180
   Carmalt CJ, 2003, POLYHEDRON, V22, P1499, DOI 10.1016/S0277-5387(03)00194-3
   Colomban P, 2009, OPT MATER, V31, P1759, DOI 10.1016/j.optmat.2008.12.030
   Díaz-Reyes J., 2008, Superf. vacío, V21, P12
   Du GY, 2012, PHYSCS PROC, V32, P532, DOI 10.1016/j.phpro.2012.03.597
   GENUT M, 1992, THIN SOLID FILMS, V219, P30, DOI 10.1016/0040-6090(92)90720-V
   Guangyu D., 2011, PHYS P, V18, P256
   HILTON MR, 1992, SURF COAT TECH, V55, P435, DOI 10.1016/S0257-8972(07)80062-4
   Kelly PJ, 2000, VACUUM, V56, P159, DOI 10.1016/S0042-207X(99)00189-X
   Li SP, 2014, APPL SURF SCI, V309, P209, DOI 10.1016/j.apsusc.2014.05.012
   Mitropoulos AC, 2008, J ENG SCI TECHNOL RE, V1, P25
   Muratore C, 2009, ANNU REV MATER RES, V39, P297, DOI 10.1146/annurev-matsci-082908-145259
   Nossa A, 2003, SURF COAT TECH, V163, P552, DOI 10.1016/S0257-8972(02)00622-9
   Petrov I, 2003, J VAC SCI TECHNOL A, V21, pS117, DOI 10.1116/1.1601610
   Polcar T, 2011, SURF COAT TECH, V206, P686, DOI 10.1016/j.surfcoat.2011.03.004
   Ramana CV, 2006, J PHYS CHEM B, V110, P10430, DOI 10.1021/jp056664i
   Sadale SB, 2007, APPL SURF SCI, V253, P3489, DOI 10.1016/j.apsusc.2006.07.056
   Scharf TW, 2006, ACTA MATER, V54, P4731, DOI 10.1616/j.actamat.2006.06.009
   Scharf TW, 2009, THIN SOLID FILMS, V517, P5666, DOI 10.1016/j.tsf.2009.02.103
   Seshan K., 2002, METHODS EQUIPMENT AP, P321
   Tagtstrom P, 1999, THIN SOLID FILMS, V352, P107, DOI 10.1016/S0040-6090(99)00379-X
   Weiss I, 1998, MAT SCI ENG A-STRUCT, V243, P46, DOI 10.1016/S0921-5093(97)00783-1
   Winston Revie R., 2008, CORROSION CORROSION, P425
   Xu SS, 2014, APPL SURF SCI, V298, P36, DOI 10.1016/j.apsusc.2014.01.002
   Zheng XH, 2008, THIN SOLID FILMS, V516, P5404, DOI 10.1016/j.tsf.2007.07.102
NR 30
TC 1
Z9 1
U1 3
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-4332
EI 1873-5584
J9 APPL SURF SCI
JI Appl. Surf. Sci.
PD NOV 30
PY 2014
VL 320
BP 538
EP 543
DI 10.1016/j.apsusc.2014.09.094
PG 6
WC Chemistry, Physical; Materials Science, Coatings & Films; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA AU1SG
UT WOS:000345399900071
DA 2018-12-27
ER

PT J
AU Zhao, L
   Sun, LN
   Nie, HB
   Wang, XL
   Guan, GJ
AF Zhao, Long
   Sun, Li-Na
   Nie, Hui-Bin
   Wang, Xue-Ling
   Guan, Guang-Ju
TI RETRACTED: Berberine Improves Kidney Function in Diabetic Mice via AMPK
   Activation (Retracted article. See vol.12, artn. e0190562, 2017)
SO PLOS ONE
LA English
DT Article; Retracted Publication
ID SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE; IN-VIVO; ENDOTHELIAL DYSFUNCTION;
   BLOOD-PRESSURE; NEPHROPATHY; INHIBITION; EXPRESSION; PATHWAY;
   MACROPHAGES
AB Diabetic nephropathy is a major cause of morbidity and mortality in diabetic patients. Effective therapies to prevent the development of this disease are required. Berberine (BBR) has several preventive effects on diabetes and its complications. However, the molecular mechanism of BBR on kidney function in diabetes is not well defined. Here, we reported that activation of AMP-activated protein kinase (AMPK) is required for BBR-induced improvement of kidney function in vivo. AMPK phosphorylation and activity, productions of reactive oxygen species (ROS), kidney function including serum blood urea nitrogen (BUN), creatinine clearance (Ccr), and urinary protein excretion, morphology of glomerulus were determined in vitro or in vivo. Exposure of cultured human glomerulus mesangial cells (HGMCs) to BBR time-or dose-dependently activates AMPK by increasing the thr172 phosphorylation and its activities. Inhibition of LKB1 by siRNA or mutant abolished BBR-induced AMPK activation. Incubation of cells with high glucose (HG, 30 mM) markedly induced the oxidative stress of HGMCs, which were abolished by 5-aminoimidazole-4-carboxamide ribonucleoside, AMPK gene overexpression or BBR. Importantly, the effects induced by BBR were bypassed by AMPK siRNA transfection in HG-treated HGMCs. In animal studies, streptozotocin-induced hyperglycemia dramatically promoted glomerulosclerosis and impaired kidney function by increasing serum BUN, urinary protein excretion, and decreasing Ccr, as well as increased oxidative stress. Administration of BBR remarkably improved kidney function in wildtype mice but not in AMPK alpha 2-deficient mice. We conclude that AMPK activation is required for BBR to improve kidney function in diabetic mice.
C1 [Zhao, Long; Sun, Li-Na; Nie, Hui-Bin; Wang, Xue-Ling; Guan, Guang-Ju] Shandong Univ, Hosp 2, Nephrol Res Inst, Jinan, Shandong, Peoples R China.
RP Guan, GJ (reprint author), Shandong Univ, Hosp 2, Nephrol Res Inst, Jinan, Shandong, Peoples R China.
EM guangj@sdu.edu.cn
FU Ministry of Science and Technology of China [2011BA110B05]
FX This work was supported by the National Key Technology Research and
   Development Program of the Ministry of Science and Technology of China
   2011BA110B05.
CR Cao SJ, 2013, J ETHNOPHARMACOL, V149, P576, DOI 10.1016/j.jep.2013.07.025
   Chang WG, 2013, METABOLISM, V62, P1159, DOI 10.1016/j.metabol.2013.02.007
   Chatuphonprasert W., 2013, PHARM BIOL
   Cho BJ, 2005, MOL CELLS, V20, P429
   Dugan LL, 2013, J CLIN INVEST, V123, P4888, DOI 10.1172/JCI66218
   Fan LX, 2013, BBA-GEN SUBJECTS, V1830, P5175, DOI 10.1016/j.bbagen.2013.07.010
   Fernandes DC, 2007, AM J PHYSIOL-CELL PH, V292, pC413, DOI 10.1152/ajpcell.00188.2006
   Forbes JM, 2008, DIABETES, V57, P1446, DOI 10.2337/db08-0057
   Han YY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015420
   Homolya L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091921
   Jeong HW, 2009, AM J PHYSIOL-ENDOC M, V296, pE955, DOI 10.1152/ajpendo.90599.2008
   Jha JC, 2014, ADV CHRONIC KIDNEY D, V21, P318, DOI 10.1053/j.ackd.2014.03.008
   Li Z, 2014, EVID-BASED COMPL ALT, DOI 10.1155/2014/289264
   Liang KW, 2008, EUR J PHARMACOL, V590, P343, DOI 10.1016/j.ejphar.2008.06.034
   Liang KW, 2006, BIOCHEM PHARMACOL, V71, P806, DOI 10.1016/j.bcp.2005.12.028
   Liao J, 2010, NEPHRON EXP NEPHROL, V114, pE61, DOI 10.1159/000254567
   Lv XX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047351
   Mo CF, 2014, ANTIOXID REDOX SIGN, V20, P574, DOI 10.1089/ars.2012.5116
   Molitch Mark E, 2004, Diabetes Care, V27 Suppl 1, pS79
   Qi ZH, 2005, DIABETES, V54, P2628, DOI 10.2337/diabetes.54.9.2628
   Roglic G, 2005, DIABETES CARE, V28, P2130, DOI 10.2337/diacare.28.9.2130
   Shen N, 2012, EUR J PHARMACOL, V694, P120, DOI 10.1016/j.ejphar.2012.07.052
   Shen Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087894
   Tang LQ, 2014, MOL BIOL REP, V41, P3339, DOI 10.1007/s11033-014-3196-4
   Viollet B, 2003, BIOCHEM SOC T, V31, P216, DOI 10.1042/bst0310216
   Wan X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059794
   Wang QL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025436
   Wang SX, 2008, CARDIOVASC RES, V80, P255, DOI 10.1093/cvr/cvn179
   Wang SX, 2008, HYPERTENSION, V52, P484, DOI 10.1161/HYPERTENSIONAHA.108.112094
   Wang SX, 2011, HYPERTENSION, V57, P1010, DOI 10.1161/HYPERTENSIONAHA.110.168906
   Wang SX, 2012, NAT MED, V18, P902, DOI 10.1038/nm.2711
   Wang SX, 2010, CIRC RES, V106, P1117, DOI 10.1161/CIRCRESAHA.109.212530
   Wang SX, 2009, DIABETES, V58, P1893, DOI 10.2337/db09-0267
   Yang Y, 2014, J RECEPT SIG TRANSD, V22, P1
   Yin Jun, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P99, DOI 10.2174/187153008784534330
   Zhang MZ, 2012, J ETHNOPHARMACOL, V141, P111, DOI 10.1016/j.jep.2012.02.007
   Zhao HL, 2012, DIABETES, V61, P933, DOI 10.2337/db11-1164
   Zhou LB, 2011, BBA-MOL BASIS DIS, V1812, P527, DOI 10.1016/j.bbadis.2010.10.001
NR 38
TC 19
Z9 21
U1 1
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 19
PY 2014
VL 9
IS 11
AR e113398
DI 10.1371/journal.pone.0113398
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU3SG
UT WOS:000345533200109
PM 25409232
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Port, D
   Perez, JAA
   de Menezes, JT
AF Port, Dagoberto
   Alvarez Perez, Jose Angel
   de Menezes, Joao Thadeu
TI RETRACTED: Energy direct inputs and greenhouse gas emissions of the main
   industrial trawl fishery of Brazil (Retracted article. See vol. 105, pg.
   439, 2016)
SO MARINE POLLUTION BULLETIN
LA English
DT Article; Retracted Publication
DE Industrial trawl fisheries; Fuel use intensity; Greenhouse gas
   emissions; Southeast and south of Brazil; SW Atlantic
ID IMPACTS
AB This study provides first-time estimates of direct fuel inputs and greenhouse gas emissions produced by the trawl fishing fleet operating off southeastern and southern Brazil. Analyzed data comprised vessel characteristics, landings, fishing areas and trawling duration of 10,144 fishing operations monitored in Santa Catarina State from 2003 to 2011. Three main fishing strategies were differentiated: 'shrimp trawling', 'slope trawling' and 'pair trawling'. Jointly these operations burned over 9.1 million liters of diesel to land 342.3 million kilograms of fish and shellfish. Annually, 0.023-0.0311 were consumed for every kg of catch landed. Because all fishing strategies relied on multispecific catches to raise total incomes, estimates of fuel use intensity were generally low but increased 200-900% if only nominal targets were considered. In nine years, trawling operations emitted 6.69 GgC to the atmosphere, between 2300 and 3300 tons CO2 per year. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Port, Dagoberto; Alvarez Perez, Jose Angel; de Menezes, Joao Thadeu] Univ Vale Itajai, Programa Posgrad Ciencia & Tecnol Ambiental, Ctr Ciencias Tecnol Terra & Mar, BR-88302202 Itajai, SC, Brazil.
RP Port, D (reprint author), Univ Vale Itajai, Programa Posgrad Ciencia & Tecnol Ambiental, Ctr Ciencias Tecnol Terra & Mar, Rua Uruguai,458,Bloco D8,Sala 104,Caixa Postal 36, BR-88302202 Itajai, SC, Brazil.
EM dagoberto_port@hotmail.com
RI Port, Dagoberto/C-3311-2011
OI Port, Dagoberto/0000-0003-3909-7957
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES;
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq
   [309837/2010-3]
FX We are indebted to all monitors of the industrial fishing statistical
   service (UNIVALI) and in special to Martin C. Dias and Rodrigo Sant'Ana
   for their assistance compiling trawl fishery data. D. Port is grateful
   to Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - CAPES
   for his Doctoral Scholarship (Edital Ciencias do Mar 09/2009 - Projeto
   IGEPESCA). J.A.A. Perez is supported by Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPq (Process 309837/2010-3).
CR Alvares Junior O.M., 2002, METODOLOGIA SIMPLIFI
   Perez JAA, 2009, LAT AM J AQUAT RES, V37, P513, DOI 10.3856/vol37-issue3-fulltext-18
   Auster Peter J., 1999, American Fisheries Society Symposium, V22, P150
   Beninca E.M, 2013, THESIS U VALE DO ITA, P109
   Brasil, 1999, MIN MIN EN, P153
   Brasil, 2006, EM DIOX CARB QUEIM C
   D'Incao F., 2002, AVALIACAO PESCA CAMA, P1965
   DAY RW, 1989, ECOL MONOGR, V59, P433, DOI 10.2307/1943075
   Degnbol P., 2009, WORKSH CHANG MAR TER, P15
   EPE - Empresa de Pesquisa Energetica (Brasil), 2013, BAL EN NAC 2013 AN B, P288
   EPE - Empresa de Pesquisa Energetica (Brasil), 2011, BAL EN NAC 2011 AN B, P266
   FAO, 2012, STAT WORLD FISH AQ, P230
   *FAO, 2007, STAT WORLD FISH AQ 2, P162
   Fulton S., 2010, THESIS DALHOUSIE U H, P123
   Furuya A., 2011, ERSA C PAPERS
   Garcia SM, 2005, PHILOS T R SOC B, V360, P21, DOI 10.1098/rstb.2004.1580
   Gasalla MA, 2004, ECOL MODEL, V172, P283, DOI 10.1016/j.ecolmodel.2003.09.012
   Haimovici M., 1997, RECURSOS PESQUEIROS, P80
   Haimovici M, 2006, PROGRAMA REVIZEE AVA, P79
   Hiddink JG, 2006, CAN J FISH AQUAT SCI, V63, P721, DOI 10.1139/F05-266
   IBGE, 2011, PESQ ORC FAM 2008 20
   IPCC, 1996, GOOD PRACT GUID UNC
   Kaiser MJ, 2006, MAR ECOL PROG SER, V311, P1, DOI 10.3354/meps311001
   Kelleher K., 2008, 470 FAO FISH DEP, P147
   Lima L.M.T., 2007, AN 15 S INT IN CIENT
   Macedo R.F., 2004, HOLOS ANO, V20
   de Almeida TCM, 2011, MAR POLLUT BULL, V62, P2190, DOI 10.1016/j.marpolbul.2011.06.034
   Notti E., 2012, EUROFISH MAG, V6, P27
   Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860
   Pauly D, 2005, PHILOS T ROY SOC B, V360, P5, DOI 10.1098/rstb.2004.1574
   PAULY D, 1995, NATURE, V374, P255, DOI 10.1038/374255a0
   Pellico Netto S., 2008, REV ACAD CIENC AGRAR, V6, P293
   Perez J, 2001, P C C I D, V2, P1
   Perez J.A.A., 2006, BRAZ J AQUAT SCI TEC, V10, P1, DOI DOI 10.14210/BJAST.V10N2.P1-11
   PEREZ J. A. A., 2006, BOL INST PESCA, V32, P127
   Perez J.A.A., 2007, SERIE DOCUMENTOS REV, P104
   Perez J.A.A., 1998, NOT TEC FACIMAR, V2, P93
   Perez JAA, 1998, J SHELLFISH RES, V17, P303
   Perez JAA, 2002, BOL INST PESCA, V28, P205
   Pinto F.C.V., 2004, ENGEVISTA, V6, P64
   Rossi-Wongtshchowski CLDB, 2006, PROGRAMA REVIZEE AVA, P21
   Schau EM, 2009, J CLEAN PROD, V17, P325, DOI 10.1016/j.jclepro.2008.08.015
   Suuronen P, 2012, FISH RES, V119, P135, DOI 10.1016/j.fishres.2011.12.009
   Thurstan RH, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1013
   Tyedmers P., 2012, 201203 ISSF
   Tyedmers P., 2004, ENCY ENERGY, P683
   Tyedmers PH, 2005, AMBIO, V34, P635, DOI 10.1639/0044-7447(2005)034[0635:FGFF]2.0.CO;2
   UNIVALI/CTTMar, 2004, B EST PESC IND SANT, P80
   UNIVALI/CTTMar, 2007, B EST PESC IND SANT, P80
   UNIVALI/CTTMar, 2009, B EST PESC IND SANT, P73
   UNIVALI/CTTMar, 2010, B EST PESC IND SANT, P85
   UNIVALI/CTTMar, 2008, B EST PESC IND SANT, P71
   UNIVALI/CTTMar, 2013, B EST PESC IND SANT, P76
   UNIVALI/CTTMar, 2011, B EST PESC IND SANT, P69
   UNIVALI/CTTMar, 2006, B EST PESC IND SANT, P63
   Valentini H., 2006, SERIE DOCUMENTOS REV, P56
   Wileman D., 1984, PROJECT OILFISH INVE, P42
   Winther U., 2009, SHF80A096068 SINTEC, P91
   Zar J.H., 2010, BIOSTAT ANAL, P944
   Ziegler F, 2003, J CLEAN PROD, V11, P303, DOI 10.1016/S0959-6526(02)00050-1
   Ziegler F., 2006, 746 SIK, P36
   Ziegler F, 2008, INT J LIFE CYCLE ASS, V13, P487, DOI 10.1007/s11367-008-0024-x
NR 62
TC 1
Z9 1
U1 3
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0025-326X
EI 1879-3363
J9 MAR POLLUT BULL
JI Mar. Pollut. Bull.
PD NOV 15
PY 2014
VL 88
IS 1-2
BP 334
EP 343
DI 10.1016/j.marpolbul.2014.08.017
PG 10
WC Environmental Sciences; Marine & Freshwater Biology
SC Environmental Sciences & Ecology; Marine & Freshwater Biology
GA AU3CG
UT WOS:000345489800052
PM 25173595
DA 2018-12-27
ER

PT J
AU Bandyopadhyay, A
   Sarkar, K
AF Bandyopadhyay, Arghya
   Sarkar, Keka
TI RETRACTED: Localized surface plasmon resonance-based DNA detection in
   solution using gold-decorated superparamagnetic Fe3O4 nanocomposite
   (Retracted article. See vol. 501, pg. 82, 2016)
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE Magneto-optical nanocomposite; Gold nanoparticle; Sensors; SPR
ID MAGNETIC NANOPARTICLES; OPTICAL-PROPERTIES; ULTRASENSITIVE DETECTION;
   SENSITIVITY; PROBES; NANOTECHNOLOGY; FABRICATION; PROTEINS; CELLS; SHELL
AB In the field of nucleic acid-based biosensor technology, DNA-conjugated nanocomposites have attracted much attention due to their unique properties and multimodal applicability. However, quantitative estimation of sequence-specific oligonucleotide in a simpler way is still a challenge. Precise positioning of DNA probes over the surface of the nanocomposite can overcome problems such as steric hindrance of the surface-bound molecules to enable further sensing as well as nonspecific folding of the DNA molecule over the surface of the gold (Au) nanolayer. Considering such objectives, we have developed glutathionated Fe3O4@Au core/shell nanocomposite, fabricated with DNA molecules and applied for sensing complementary oligo spectrophotometrically, using the localized surface plasmon resonance (LSPR) properties of the synthesized nanocomposite. When hybridization experiments were performed with 10 to 100 fM complementary DNA and DNA-conjugated nanocomposite, a strong linear relationship was observed between DNA concentration and surface plasmon resonance (SPR). Discrimination even at the single-base level was also observed when further experiments were performed with complementary DNA, but with a sequential decrease of bases from the single level to the fifth level. (c) 2014 Elsevier Inc. All rights reserved.
C1 [Bandyopadhyay, Arghya; Sarkar, Keka] Univ Kalyani, Dept Microbiol, Nadia 741235, W Bengal, India.
RP Sarkar, K (reprint author), Univ Kalyani, Dept Microbiol, Nadia 741235, W Bengal, India.
EM drkekasarkar@yahoo.com
FU Department of Science and Technology, Government of India
   [SR/NM/NS-48/2009]; DST-PURSE Programme, University of Kalyani, Nadia,
   West Bengal; University of Kalyani
FX This work was jointly supported by funding from the Department of
   Science and Technology, Government of India (Project Nanomission,
   SR/NM/NS-48/2009), and the DST-PURSE Programme, University of Kalyani,
   Nadia, West Bengal. A.B. is personally grateful for the scholarship
   support from the University of Kalyani. We are also thankful to the
   Biophysics Division of the Saha Institute of Nuclear Physics (SINP,
   Kolkata, India) for the electron microscope facility and to the Indian
   Association for the Cultivation of Science (IACS, Kolkata) for XRD,
   SQUID, SEM, and AFM facilities.
CR Ackerson CJ, 2005, P NATL ACAD SCI USA, V102, P13383, DOI 10.1073/pnas.0506290102
   Bandyopadhyay A, 2011, CURR SCI INDIA, V101, P210
   Chin SF, 2007, CHEM COMMUN, P1948, DOI 10.1039/b618596g
   Chin SF, 2009, CRYST GROWTH DES, V9, P2685, DOI 10.1021/cg8013199
   Choi J, 2007, CHEM COMMUN, P1644, DOI 10.1039/b617608a
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Haes AJ, 2002, J AM CHEM SOC, V124, P10596, DOI 10.1021/ja020393x
   He L, 2000, J AM CHEM SOC, V122, P9071, DOI 10.1021/ja001215b
   Hirsch LR, 2003, ANAL CHEM, V75, P2377, DOI 10.1021/ac0262210
   Hostetler MJ, 1999, LANGMUIR, V15, P3782, DOI 10.1021/la981598f
   Huang XH, 2007, NANOMEDICINE-UK, V2, P681, DOI 10.2217/17435889.2.5.681
   Kim J, 2008, ADV MATER, V20, P478, DOI 10.1002/adma.200701726
   Lazarides AA, 2000, J PHYS CHEM B, V104, P460, DOI 10.1021/jp992179+
   Lim J, 2008, ADV MATER, V20, P1721, DOI 10.1002/adma.200702196
   Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789
   Mandal M, 2005, J COLLOID INTERF SCI, V286, P187, DOI 10.1016/j.jcis.2005.01.013
   Mann S, 2000, ADV MATER, V12, P147, DOI 10.1002/(SICI)1521-4095(200001)12:2<147::AID-ADMA147>3.0.CO;2-U
   Martin BR, 1999, ADV MATER, V11, P1021, DOI 10.1002/(SICI)1521-4095(199908)11:12<1021::AID-ADMA1021>3.0.CO;2-S
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   Niemeyer CM, 2003, ANGEW CHEM INT EDIT, V42, P5796, DOI 10.1002/anie.200301703
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Sarma TK, 2004, LANGMUIR, V20, P3520, DOI 10.1021/la049970g
   Schaaff TG, 2000, J PHYS CHEM B, V104, P2630, DOI 10.1021/jp993691y
   Selvan ST, 2007, ANGEW CHEM INT EDIT, V46, P2448, DOI 10.1002/anie.200604245
   Seol Y, 2006, OPT LETT, V31, P2429, DOI 10.1364/OL.31.002429
   Shamim N, 2007, COLLOID SURFACE B, V55, P51, DOI 10.1016/j.colsurfb.2006.11.007
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Tkachenko AG, 2003, J AM CHEM SOC, V125, P4700, DOI 10.1021/ja0296935
   Turner APF, 2000, SCIENCE, V290, P1315, DOI 10.1126/science.290.5495.1315
   Wang LY, 2005, J PHYS CHEM B, V109, P21593, DOI 10.1021/jp0543429
   Wang RH, 2004, BIOSENS BIOELECTRON, V20, P967, DOI 10.1016/j.bios.2004.06.013
   Wang SH, 2007, ADV FUNCT MATER, V17, P3043, DOI 10.1002/adfm.200601139
   Xu ZC, 2007, J AM CHEM SOC, V129, P8698, DOI 10.1021/ja073057v
NR 36
TC 5
Z9 5
U1 3
U2 75
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD NOV 15
PY 2014
VL 465
BP 156
EP 163
DI 10.1016/j.ab.2014.07.025
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA AS3YP
UT WOS:000344211300023
PM 25089662
DA 2018-12-27
ER

PT J
AU Pak, CS
   Lee, J
   Lee, H
   Jeong, J
   Kim, EH
   Jeong, J
   Choi, H
   Kim, B
   Oh, S
   Kim, I
   Heo, CY
AF Pak, Chang Sik
   Lee, Jongho
   Lee, Hobin
   Jeong, Jaehoon
   Kim, Eun-Hee
   Jeong, Jinwook
   Choi, Hyeyeon
   Kim, Byunghwi
   Oh, Sujin
   Kim, Iksoo
   Heo, Chan Yeong
TI RETRACTED: A Phase III, Randomized, Double-Blind, Matched-Pairs,
   Active-Controlled Clinical Trial and Preclinical Animal Study to Compare
   the Durability, Efficacy and Safety between Polynucleotide Filler and
   Hyaluronic Acid Filler in the Correction of Crow's Feet: A New Concept
   of Regenerative Filler (Retracted article. See vol. 31, pg. 330, 2016)
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article; Retracted Publication
DE Polynucleotides; Polydeoxyribonucleotides; Rejuvenation; Wound Healing
ID POLYDEOXYRIBONUCLEOTIDE
AB The Rejuran (R) is a new filler product made from purified polynucleotides. Here we present data from an animal study and a clinical trial to examine the durability, efficacy and safety of the Rejuran (R) on crow's feet. For the animal study, 25 mice were divided into three groups: Group 1 received phosphate buffered saline (PBS); Group 2 were treated with Yvoire (R); and Group 3 were treated with Rejuran (R). The durability and efficacy of each treatment were assessed by microscopy and staining. In the clinical trial, 72 patients were randomized to receive Rejuran (R) treatment for crow's feet on one side and Yvoire-Hydro (R) on the contralateral side, at a ratio of 1:1. Repeated treatments were performed every two weeks for a total of three times, over a total of 12 weeks' observation. All injections and observations of efficacy and safety were performed by the same two investigators. In the animal study, the Rejuran (R) group showed similar durability and inflammatory response to the Yvoire (R) group. Upon efficacy assessment, the Rejuran (R) group showed the greatest elasticity and collagen composition, and a significant difference in skin surface roughness and wrinkle depth. In the clinical trial, the primary and secondary objective efficacy outcome measure showed no statistical significance between the two groups, and in safety outcomes there were no unexpected adverse effects. Our data suggest that the Rejuran (R), as a new regenerative filler, can be useful to reduce wrinkles, by showing evidence for its efficacy and safety.
C1 [Pak, Chang Sik; Lee, Jongho; Lee, Hobin; Jeong, Jaehoon; Kim, Eun-Hee; Jeong, Jinwook; Choi, Hyeyeon; Kim, Byunghwi; Heo, Chan Yeong] Seoul Natl Univ, Bundang Hosp, Dept Plast & Reconstruct Surg, Songnam 463707, South Korea.
   [Oh, Sujin] Kyung Hee Univ, Skin Biotechnol Ctr, Gyeonggi Bioctr, Suwon, South Korea.
   [Kim, Iksoo] Pharmares Prod R&D Ctr, Seoul, South Korea.
RP Heo, CY (reprint author), Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Plast & Reconstruct Surg, 82 Gumi Ro 170 Beon Gil, Songnam 463707, South Korea.
EM lionheo@snu.ac.kr
FU regional innovation center program of the Ministry of Trade, Industry
   and Energy at the Skin Biotechnology Center of Kyung Hee University,
   Korea
FX This study was supported by the regional innovation center program of
   the Ministry of Trade, Industry and Energy at the Skin Biotechnology
   Center of Kyung Hee University, Korea.
CR Avantaggiato A, 2013, ANN ORAL MAXILLOFACI, V1, P11
   Cavallini M, 2004, J APPL COSMETOL, V22, P125
   Cavallini M, 2007, INT J PLAST DERMATOL, V3, P27
   De Aloe G, 2004, WOUNDS, V16, P258
   Do ER, 2012, ARCH PLAST SURG-APS, V39, P267, DOI 10.5999/aps.2012.39.3.267
   RATHBONE MP, 1992, MED HYPOTHESES, V37, P232, DOI 10.1016/0306-9877(92)90193-G
   Rubegni P, 2001, CURR MED RES OPIN, V17, P128, DOI 10.1185/030079901317010793
   Squadrito F, 2014, J CLIN ENDOCR METAB, V99, pE746, DOI 10.1210/jc.2013-3569
   Sung HM, 2012, ARCH PLAST SURG-APS, V39, P51, DOI 10.5999/aps.2012.39.1.51
NR 9
TC 2
Z9 2
U1 2
U2 10
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD NOV
PY 2014
VL 29
SU 3
BP S201
EP S209
DI 10.3346/jkms.2014.29.S3.S201
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA CI3EZ
UT WOS:000354631700008
PM 25473210
OA Other Gold, Green Published
DA 2018-12-27
ER

PT J
AU Tanaka, Y
   Moriyama, S
   Nakamura, Y
   Naito, M
AF Tanaka, Yoshitsugu
   Moriyama, Shigeaki
   Nakamura, Yoshinari
   Naito, Masatoshi
TI RETRACTED: Analysis of medialisation of the femoral head in
   periacetabular osteotomy using three-dimensional computed tomography
   (Retracted article. See vol. 25, pg. 292, 2015)
SO HIP INTERNATIONAL
LA English
DT Article; Retracted Publication
DE Acetabular retroversion; Dysplastic hip; Medialisation of the femoral
   head; Periacetabular osteotomy; 3DCT
ID ROTATIONAL ACETABULAR OSTEOTOMY; DYSPLASTIC HIP; PELVIC OSTEOTOMY;
   FOLLOW-UP; OSTEOARTHRITIS; RETROVERSION; OLDER; AGE; IMPINGEMENT
AB Background: Periacetabular osteotomy has been established as an effective treatment for osteoarthritis caused by developmental dysplasia of the hip. Medialisation of the femoral head during periacetabular osteotomy is crucial for providing significant reduction in joint contact stress. The purpose of this study was to evaluate effective procedures for medialisation of the femoral head during periacetabular osteotomy using three-dimensional computed tomography (3DCT).
   Methods: Thirty hips in 30 patients with hip dysplasia underwent both radiographic and 3DCT scans before and after surgery. The direction of the rotation of the acetabular fragment and movement of the femoral head were evaluated to analyse which parameters contributed to medialisation of the femoral head.
   Results: Anterior coverage of the acetabular fragment and internal rotation in the axial plane contributed to both medialisation of the femoral head and anteversion of the retroverted acetabulum.
   Conclusions: This study demonstrated that re-orientation of the acetabulum was spatially confirmed by the method using 3DCT images.
C1 [Tanaka, Yoshitsugu; Nakamura, Yoshinari; Naito, Masatoshi] Fukuoka Univ, Fac Med, Dept Orthopaed Surg, Fukuoka 8140180, Japan.
   [Moriyama, Shigeaki] Fukuoka Univ, Dept Mech Engn, Fukuoka 8140180, Japan.
RP Tanaka, Y (reprint author), Fukuoka Univ, Fac Med, Dept Orthopaed Surg, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8140180, Japan.
EM gaudi406@hotmail.com
CR GANZ R, 1988, CLIN ORTHOP RELAT R, P26
   HARRIS WH, 1986, CLIN ORTHOP RELAT R, P20
   HEYMAN CH, 1950, J BONE JOINT SURG AM, V32-A, P767, DOI 10.2106/00004623-195032040-00004
   Karami M, 2010, INT ORTHOP, V34, P329, DOI 10.1007/s00264-009-0769-2
   Kiyama T, 2009, INT ORTHOP, V33, P625, DOI 10.1007/s00264-007-0507-6
   Kralj M, 2005, ACTA ORTHOP, V76, P833, DOI 10.1080/17453670510045453
   Maeyama A, 2008, J BONE JOINT SURG AM, V90A, P85, DOI 10.2106/JBJS.G.00029
   MASSIE WK, 1950, J BONE JOINT SURG AM, V32-A, P519, DOI 10.2106/00004623-195032030-00005
   Myers SR, 1999, CLIN ORTHOP RELAT R, P93
   Naito M, 2005, CLIN ORTHOP RELAT R, P129, DOI 10.1097/01.blo.0000153281.75265.1d
   NINOMIYA S, 1989, CLIN ORTHOP RELAT R, P127
   Reynolds D, 1999, J BONE JOINT SURG BR, V81B, P281, DOI 10.1302/0301-620X.81B2.8291
   SALTER RB, 1961, J BONE JOINT SURG BR, V43, P518
   Siebenrock KA, 2003, J BONE JOINT SURG AM, V85A, P278, DOI 10.2106/00004623-200302000-00015
   SOLOMON L, 1976, J BONE JOINT SURG BR, V58, P176
   STEEL HH, 1973, J BONE JOINT SURG AM, VA 55, P343, DOI 10.2106/00004623-197355020-00010
   Steppacher SD, 2008, CLIN ORTHOP RELAT R, V466, P1633, DOI 10.1007/s11999-008-0242-3
   Teratani T, 2008, ACTA ORTHOP, V79, P474, DOI 10.1080/17453670710015454
   Teratani T, 2011, J BONE JOINT SURG AM, V93A, P30, DOI 10.2106/JBJS.J.01126
   Teratani T, 2010, J BONE JOINT SURG AM, V92A, P31, DOI 10.2106/JBJS.H.01556
   TONNIS D, 1994, J PEDIATR ORTHOP B, V3, P54
   Tonnis D., 1987, CONGENITAL DYSPLASIA, P167
   Uechi J, 2006, AM J ORTHOD DENTOFAC, V130, P786, DOI 10.1016/j.ajodo.2006.03.025
   Xie J, 2010, INT ORTHOP, V34, P473, DOI 10.1007/s00264-009-0785-2
   Yasunaga Y, 2003, J BONE JOINT SURG AM, V85A, P266, DOI 10.2106/00004623-200302000-00013
NR 25
TC 1
Z9 1
U1 2
U2 5
PU WICHTIG PUBLISHING
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-7000
EI 1724-6067
J9 HIP INT
JI Hip Int.
PD NOV-DEC
PY 2014
VL 24
IS 6
BP 624
EP 630
DI 10.5301/hipint.5000171
PG 7
WC Orthopedics
SC Orthopedics
GA CB3PY
UT WOS:000349541900011
PM 25096450
DA 2018-12-27
ER

PT J
AU Chen, Z
   Wong, C
   Lubner, S
   Yee, S
   Miller, J
   Jang, W
   Hardin, C
   Fong, A
   Garay, JE
   Dames, C
AF Chen, Zhen
   Wong, Carlaton
   Lubner, Sean
   Yee, Shannon
   Miller, John
   Jang, Wanyoung
   Hardin, Corey
   Fong, Anthony
   Garay, Javier E.
   Dames, Chris
TI RETRACTED: A photon thermal diode (Retracted article. See vol. 8, Artn
   16134, 2017)
SO NATURE COMMUNICATIONS
LA English
DT Article; Retracted Publication
ID HEAT-FLOW; RECTIFICATION; RECTIFIER; TRANSPORT
AB A thermal diode is a two-terminal nonlinear device that rectifies energy carriers (for example, photons, phonons and electrons) in the thermal domain, the heat transfer analogue to the familiar electrical diode. Effective thermal rectifiers could have an impact on diverse applications ranging from heat engines to refrigeration, thermal regulation of buildings and thermal logic. However, experimental demonstrations have lagged far behind theoretical proposals. Here we present the first experimental results for a photon thermal diode. The device is based on asymmetric scattering of ballistic energy carriers by pyramidal reflectors. Recent theoretical work has predicted that this ballistic mechanism also requires a nonlinearity in order to yield asymmetric thermal transport, a requirement of all thermal diodes arising from the second Law of Thermodynamics, and realized here using an ' inelastic thermal collimator' element. Experiments confirm both effects: with pyramids and collimator the thermal rectification is 10.9 +/- 0.8%, while without the collimator no rectification is detectable ( < 0.3%).
C1 [Chen, Zhen; Lubner, Sean; Yee, Shannon; Jang, Wanyoung; Dames, Chris] Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA.
   [Wong, Carlaton; Miller, John; Hardin, Corey; Fong, Anthony; Garay, Javier E.] Univ Calif Riverside, Dept Mech Engn, Riverside, CA 92521 USA.
   [Dames, Chris] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA.
RP Dames, C (reprint author), Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA.
EM cdames@berkeley.edu
RI Chen, Zhen/M-2072-2015
OI Chen, Zhen/0000-0002-5422-8807
FU DARPA YFA [N66001-09-1-2098]; AFOSR MURI [FA9550-08-1-0407]
FX This work was supported in part by a DARPA YFA (Grant No.
   N66001-09-1-2098) and an AFOSR MURI (Grant No. FA9550-08-1-0407).
CR Chang CW, 2006, SCIENCE, V314, P1121, DOI 10.1126/science.1132898
   Chaves J, 2008, INTRO NONIMAGING OPT
   Chu S, 2012, NATURE, V488, P294, DOI 10.1038/nature11475
   Dames C, 2009, J HEAT TRANS-T ASME, V131, DOI 10.1115/1.3089552
   Harman TC, 2000, J ELECTRON MATER, V29, pL1, DOI 10.1007/s11664-000-0117-1
   Horowitz P., 1989, ART ELECT
   JEZOWSKI A, 1978, PHYS STATUS SOLIDI A, V47, P229, DOI 10.1002/pssa.2210470126
   Jiang JW, 2010, EPL-EUROPHYS LETT, V89, DOI 10.1209/0295-5075/89/46005
   Li BW, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.184301
   Li NB, 2012, REV MOD PHYS, V84, P1045, DOI 10.1103/RevModPhys.84.1045
   Lienhard J, 2003, HEAT TRANSFER TXB
   Maznev AA, 2013, WAVE MOTION, V50, P776, DOI 10.1016/j.wavemoti.2013.02.006
   Miller J., 2009, 2009 ASME SUMM HEAT, V2, P317
   Otey CR, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.154301
   Roberts NA, 2008, INTERSOC C THERMAL T, P993, DOI 10.1109/ITHERM.2008.4544374
   Roberts NA, 2011, INT J THERM SCI, V50, P648, DOI 10.1016/j.ijthermalsci.2010.12.004
   Ross FM, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.146104
   Saha S., 2006, 2006 ASME INT MECH E, V1, P549
   Schmotz M, 2011, NEW J PHYS, V13, DOI 10.1088/1367-2630/13/11/113027
   Segal D, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.034301
   Song AM, 1998, PHYS REV LETT, V80, P3831, DOI 10.1103/PhysRevLett.80.3831
   Terraneo M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.094302
   THOMAS TR, 1970, INT J HEAT MASS TRAN, V13, P789, DOI 10.1016/0017-9310(70)90126-2
   Touloukian Y S, 1970, THERMOPHYSICAL PROPE
   Varga S, 2002, ENERG BUILDINGS, V34, P227, DOI 10.1016/S0378-7788(01)00090-1
   Wang LP, 2013, NANOSC MICROSC THERM, V17, P337, DOI 10.1080/15567265.2013.776154
   Yan Y, 2013, ENERG ENVIRON SCI, V6, P1267, DOI 10.1039/c3ee24158k
NR 27
TC 54
Z9 54
U1 4
U2 43
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV
PY 2014
VL 5
DI 10.1038/ncomms6446
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AU9JR
UT WOS:000345909000001
PM 25399761
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU An, Y
   Gu, D
   Lee, J
   Ha, J
   Kim, Y
   Ahn, B
   Noh, J
   Choi, B
AF An, YoungSu
   Gu, DongSik
   Lee, JongMyeong
   Ha, JungMin
   Kim, YongHwi
   Ahn, ByungHyun
   Noh, JungPil
   Choi, ByeongKeun
TI RETRACTED: Development and application of intensified envelope analysis
   for the condition monitoring system using acoustic emission signal
   (Retracted article. See vol. 29, pg. 1327, 2015)
SO JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY
LA English
DT Article; Retracted Publication
DE Condition monitoring; Early fault detection; Acoustic emission; Signal
   processing; Envelope analysis; Discrete wavelet transform
ID GEARBOXES; VIBRATION; DEFECTS
AB The application of the high-frequency acoustic-emission (AE) technique in the condition monitoring of rotating machinery has been increasing of late. It has a major drawback, though, the attenuation of the signal, and as such, the AE sensor has to be close to its source. Two signal-processing methods, envelope analysis and wavelet transform, were found to be useful for detecting faults in the rolling element bearing and gearboxes. These methods have a disadvantage, though: their application is focused only on a component of the assembled machine. For example, envelope analysis is a powerful method for detecting faults in the bearing system, but it is not proper for use in the gear system. Thus, these methods could not be used to detect combined faults in the common assembled machines. Therefore, we propose a signal-processing method consisting of envelope analysis and DWT (discrete wavelet transform). In addition, a novel mother function optimized for the AE signal for DWT was extracted through a fatigue crack growth test, and is also proposed herein. Then the proposed method, called intensified envelope analysis (IEA), was used to detect the faults in the rolling element bearing and rotating shaft. According to the results, IEA can be a better signal processing method for the condition monitoring system using AE technique.
C1 [An, YoungSu] Gyeongsang Natl Univ, Inst Marine Ind, Training Ship Management Ctr, Tongyeong City 650160, South Korea.
   [Gu, DongSik] Hyosung Goodsprings Inc, Changwon Plant, Chang Won 642290, South Korea.
   [Lee, JongMyeong; Ha, JungMin; Kim, YongHwi; Ahn, ByungHyun; Noh, JungPil; Choi, ByeongKeun] Gyeongsang Natl Univ, Inst Marine Ind, Dept Energy & Mech Engn, Tongyeong City 650160, South Korea.
RP Choi, B (reprint author), Gyeongsang Natl Univ, Inst Marine Ind, Dept Energy & Mech Engn, Tongyeong City 650160, South Korea.
EM bgchoi@gnu.ac.kr
FU Korea Aerospace Industries Ltd. (KAI); Ministry of Trade, Industry
   Energy (MOTIV); Korea Institute for Advancement of Technology (KIAT);
   Dongnam Institute for Regional Program Evaluation through Leading
   Industry Development for Economic Region
FX This research was financially supported by Korea Aerospace Industries
   Ltd. (KAI), the Ministry of Trade, Industry & Energy (MOTIV), Korea
   Institute for Advancement of Technology (KIAT) and Dongnam Institute for
   Regional Program Evaluation through the Leading Industry Development for
   Economic Region.
CR Altmann J, 2001, MECH SYST SIGNAL PR, V15, P963, DOI 10.1006/mssp.2001.1410
   BURRUS CS, 1997, INTRO WAVELET WAVELE
   Eshleman R. L., 1997, VIBRATIONS, V13, P11
   Gu D. S., 2011, INTECH, P171
   Gu D, 2011, J MECH SCI TECHNOL, V25, P1279, DOI 10.1007/s12206-011-0231-4
   HOLROYD TJ, 1993, BRIT J NONDESTR TEST, V35, P75
   Johnson M, 2003, NDT&E INT, V36, P319, DOI 10.1016/S0963-8695(03)00004-5
   Kaphle Marindra, 2012, ANAL ACOUSTIC EMISSI, P4
   Kim Y. H., 2007, 12 AS PAC VIBR C AUG
   Kosse V., 2006, INT P WCEAM GOLD COA
   Mba D, 1999, P I MECH ENG E-J PRO, V213, P153, DOI 10.1243/0954408991529906
   Mba D., 2001, 14 INT C COND MON DI
   Mba D., 2003, INT C COND MON QUEEN
   Misiti M., 2009, WAVELET TOOLBOX TM 4
   Randall R.B., 1987, FREQUENCY ANAL
   Sheen YT, 2004, MECH SYST SIGNAL PR, V18, P119, DOI 10.1016/S0888-3270(03)00046-3
   Siores E, 1997, MATER EVAL, V55, P183
   Sophocles S., 1996, INTRO SIGNAL PROCESS
   Tan CK, 2005, J NONDESTRUCT EVAL, V24, P11, DOI 10.1007/s10921-005-6657-9
   Tandon N, 2007, MECH SYST SIGNAL PR, V21, P244, DOI 10.1016/j.ymssp.2005.08.005
   Tandon N, 1999, TRIBOL INT, V32, P469, DOI 10.1016/S0301-679X(99)00077-8
   Widodo A., FAULT DIAGNOSIS LOW
NR 22
TC 2
Z9 2
U1 2
U2 20
PU KOREAN SOC MECHANICAL ENGINEERS
PI SEOUL
PA KSTC NEW BLD. 7TH FLOOR, 635-4 YEOKSAM-DONG KANGNAM-KU, SEOUL 135-703,
   SOUTH KOREA
SN 1738-494X
EI 1976-3824
J9 J MECH SCI TECHNOL
JI J. Mech. Sci. Technol.
PD NOV
PY 2014
VL 28
IS 11
BP 4431
EP 4439
DI 10.1007/s12206-014-1011-8
PG 9
WC Engineering, Mechanical
SC Engineering
GA AU1ZF
UT WOS:000345415300010
DA 2018-12-27
ER

PT J
AU Ye, YH
   Zhou, XC
   Li, XY
   Tang, YH
   Sun, YS
   Fang, J
AF Ye, Yinghai
   Zhou, Xiaocong
   Li, Xiaoyang
   Tang, Yinhe
   Sun, Yusheng
   Fang, Jun
TI RETRACTED: Inhibition of epidermal growth factor receptor signaling
   prohibits metastasis of gastric cancer via downregulation of MMP7 and
   MMP13 (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Gastric cancer; Epidermal growth factor receptor; PI3K; Akt; ERK/MAPK;
   MMP7; MMP13
ID EXPRESSION; PATHWAY; ANGIOGENESIS; INVASION; ERK/MAPK; EGFR
AB The molecular pathway regulating gastric carcinoma (GC) invasiveness and metastasis remains elusive. Here, we detected significant increase in the phosphorylated epidermal growth factor receptor (pEGFR), MMP7, and MMP13 in the resected GC, compared with the adjacent normal tissue, in patients. Moreover, strong positive correlation was detected between pEGFR and MMP7, and between pEGFR and MMP13 in GC. To examine whether a causal link exists, we used two human GC lines, SNU-5 and AGS, to study the cross talk between EGFR signaling activation, and expression of MMP7 and MMP13. We found that EGF-induced EGFR phosphorylation activated both MMP7 and MMP13, and consequently cancer invasiveness. EGF-induced activation of MMP7 and MMP13 can be both inhibited by use of an inhibitor for EGFR. EGF-induced activation of MMP7 can be also significantly inhibited by use of an inhibitor for Akt, but not an inhibitor for ERK1/2, while EGF-induced activation of MMP13 can be significantly inhibited by use of an inhibitor for ERK1/2, but not by an inhibitor for Akt. These data suggest that EGF-induced activation of MMP7 and MMP13 in GC is through phosphatidylinositol 3-kinase (PI3K) and extracellular-related kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway, respectively. Our study thus highlights EGFR signaling regulated MMP7 and MMP13 activation as molecular basis for metastasis of GC, and further demonstrate that different signaling pathway cascades are involved in the downstream signaling transduction.
C1 [Ye, Yinghai; Zhou, Xiaocong; Li, Xiaoyang] Wenzhou Cent Hosp, Dept Surg, Wenzhou, Peoples R China.
   [Tang, Yinhe] Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Wenzhou 32500, Peoples R China.
   [Sun, Yusheng; Fang, Jun] Wenzhou Med Univ, Affiliated Hosp 1, Dept Trauma Surg, Wenzhou 32500, Peoples R China.
RP Sun, YS (reprint author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Trauma Surg, 2 Fuxue Lane, Wenzhou 32500, Peoples R China.
EM sys20132014@163.com
CR Balbin M, 1999, APMIS, V107, P45, DOI 10.1111/j.1699-0463.1999.tb01525.x
   Cao WG, 2014, TUMOR BIOL, V35, P1287, DOI 10.1007/s13277-013-1171-7
   Cardoso AP, 2014, ONCOGENE, V33, P2123, DOI 10.1038/onc.2013.154
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   del Casar Lizcano J M, 2003, Gastroenterol Hepatol, V26, P1
   Hotz B, 2012, GASTRIC CANCER, V15, P252, DOI 10.1007/s10120-011-0102-9
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Kim JW, 2008, CANCER LETT, V272, P296, DOI 10.1016/j.canlet.2008.07.018
   Kim S, 2009, CELL SIGNAL, V21, P892, DOI 10.1016/j.cellsig.2009.01.034
   Koskensalo S, 2010, TUMOR BIOL, V31, P149, DOI 10.1007/s13277-010-0020-1
   Li Z, 2014, TUMOR BIOL, V35, P3463, DOI 10.1007/s13277-013-1458-8
   McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Schneider MR, 2009, J CELL PHYSIOL, V218, P460, DOI 10.1002/jcp.21635
   Shi M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-269
   Whelan JT, 2012, J CELL PHYSIOL, V227, P1235, DOI 10.1002/jcp.22899
   Xiao XW, 2013, J BIOL CHEM, V288, P8636, DOI 10.1074/jbc.M112.422949
   Yonemura Y, 2000, GASTRIC CANCER, V3, P63, DOI DOI 10.1007/PL00011698]
   Zhang JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044618
   Zhao CH, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-224
   Zhao XN, 2013, FRONT BIOSCI-LANDMRK, V18, P803, DOI 10.2741/4144
NR 21
TC 35
Z9 35
U1 4
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2014
VL 35
IS 11
BP 10891
EP 10896
DI 10.1007/s13277-014-2383-1
PG 6
WC Oncology
SC Oncology
GA AU1YJ
UT WOS:000345413100034
PM 25085584
DA 2018-12-27
ER

PT J
AU Wang, JJ
   Su, HY
   Han, XJ
   Xu, K
AF Wang, Jiajun
   Su, Hongying
   Han, Xiangjun
   Xu, Ke
TI RETRACTED: Inhibition of fibroblast growth factor receptor signaling
   impairs metastasis of hepatocellular carcinoma (Retracted article. See
   April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Fibroblast growth factor receptor 2; Hepatocellular carcinoma; MMP7;
   MMP26; HepG2; HuH-7; ERK/MAPK; PI3K; JNK
ID SQUAMOUS-CELL CARCINOMA; CANCER INVASION; UP-REGULATION; EXPRESSION;
   MMP-26; ACTIVATION; TRANSITION; MATRILYSIN; PATHWAYS; COMPLEX
AB The molecular mechanism underlying metastasis of hepatocellular carcinoma (HCC) remains elusive. Here, we showed that matrix metalloproteinase (MMP) 7 and MMP26 levels are significantly higher in the resected HCC than in the adjacent healthy hepatic cells from the patients. Moreover, a strong correlation of the levels of MMP7 or MMP26 with the phosphorylated fibroblast growth factor receptor 2 (FGFR2) was detected. To prove a causal link between the activation of FGFR signaling pathway and expression of MMP7 and MMP26, we used two human HCC lines, HepG2 and HuH-7, to study the underlying molecular basis. We found that FGF1-induced FGFR2 phosphorylation in either line resulted in significant activation of MMP7 and MMP26 and consequently an increase in cancer invasiveness. Inhibition of FGFR2 phosphorylation in HCC abolished FGF1-stimulated MMP7 and MMP26 expression, suggesting that activation of the FGFR signaling pathway in HCC may promote cancer metastasis by inducing MMP7 and MMP26 expression. To define the signal transduction cascades downstream of FGFR2 activation for MMP7 and MMP26 activation, we applied specific inhibitors for phosphatidylinositol-3 kinase (PI3K), extracellular signal-related kinase/mitogen-activated protein kinase (ERK/MAPK), and Jun N-terminal kinase (JNK), respectively, to the FGF1-stimulated HCC cells. We found that only inhibition of JNK significantly decreased the activation of MMP26 in response to FGF1 stimulation, and only inhibition of PI3K significantly decreased the activation of MMP7 in response to FGF1 stimulation, suggesting that the activation of the FGFR2 signaling may activate PI3K to activate MMP7 and activate JNK to activate MMP26, in HCC. Our study thus highlights the FGFR2 signaling pathway and MMP7 and MMP26 as novel therapeutic targets for HCC.
C1 [Wang, Jiajun; Su, Hongying; Han, Xiangjun; Xu, Ke] China Med Univ, Hosp 1, Dept Radiol, Shenyang 110001, Liaoning, Peoples R China.
RP Su, HY (reprint author), China Med Univ, Hosp 1, Dept Radiol, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China.
EM hongying_su14@163.com
CR Balbin M, 1999, APMIS, V107, P45, DOI 10.1111/j.1699-0463.1999.tb01525.x
   Fletcher MNC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3464
   Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748
   Fujimoto J, 1996, TUMOR BIOL, V17, P226, DOI 10.1159/000217984
   Han MS, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-567
   Ii M, 2006, EXP BIOL MED, V231, P20
   JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y
   Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947
   Kang M, 2012, BIOCHEM J, V443, P691, DOI 10.1042/BJ20111584
   Koskensalo S, 2011, TUMOR BIOL, V32, P259, DOI 10.1007/s13277-010-0080-2
   Koskensalo S, 2010, TUMOR BIOL, V31, P149, DOI 10.1007/s13277-010-0020-1
   Kuslak SL, 2007, DIFFERENTIATION, V75, P638, DOI 10.1111/j.1432-0436.2006.00161.x
   Li DS, 2006, CELL RES, V16, P741, DOI 10.1038/sj.cr.7310094
   Liao RG, 2013, CANCER RES, V73, P5195, DOI 10.1158/0008-5472.CAN-12-3950
   Liu G, 2014, TUMOUR BIOL
   Soundararajan P, 2010, J NEUROSCI, V30, P6595, DOI 10.1523/JNEUROSCI.4932-09.2010
   Takaishi H, 2008, CURR PHARM BIOTECHNO, V9, P47, DOI 10.2174/138920108783497659
   Tanimoto H, 1999, TUMOR BIOL, V20, P88, DOI 10.1159/000030051
   Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401
   Wang HY, 2013, J GASTROEN HEPATOL, V28, P43, DOI 10.1111/jgh.12091
   Wang L, 2014, TUMOR BIOL, V35, P9, DOI 10.1007/s13277-013-1141-0
   Wang X, 2014, TUMOUR BIOL
   Williamson AJK, 2004, J BIOL CHEM, V279, P47912, DOI 10.1074/jbc>M409035200
   Xiao XW, 2014, P NATL ACAD SCI USA, V111, pE1211, DOI 10.1073/pnas.1321347111
   Xu YR, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.212597
   Yamamoto H, 2004, CARCINOGENESIS, V25, P2353, DOI 10.1093/carcin/bgh270
   Zhang Y, 2011, MOL MED REP, V4, P1201, DOI 10.3892/mmr.2011.540
NR 27
TC 16
Z9 17
U1 4
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2014
VL 35
IS 11
BP 11005
EP 11011
DI 10.1007/s13277-014-2384-0
PG 7
WC Oncology
SC Oncology
GA AU1YJ
UT WOS:000345413100047
PM 25091573
DA 2018-12-27
ER

PT J
AU Duan, JH
   Fang, L
AF Duan, Jian-Hua
   Fang, Long
TI RETRACTED: MicroRNA-92 promotes gastric cancer cell proliferation and
   invasion through targeting FXR (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE miR-92; Farnesoid X receptor; Gastric cancer; Invasion
ID FARNESOID-X-RECEPTOR; BILE-ACID RECEPTOR; EXPRESSION; TUMORIGENESIS;
   HOMEOSTASIS; PROTECTS
AB MicroRNAs (miRNAs), a class of small noncoding RNAs, play critical roles in human carcinogenesis through downregulation of various target genes. In the present study, we found that miR-92 is upregulated in gastric cancer tissues compared with adjacent normal tissues. Interestingly, miR-92 expression is significantly associated with clinical characteristics of patients. Gain or loss-of-function in vitro experiments further show that miR-92 mimics significantly promoted, while its antisense oligos inhibited gastric cancer cell proliferation and invasion. Moreover, luciferase reporter assays and western blot indicated that farnesoid X receptor (FXR), is a direct target of miR-92. Therefore, our data suggest that upregulation of miR-92 may represent an important mechanism for the development of gastric cancer.
C1 [Duan, Jian-Hua] Second Hosp Shaoxing City, Dept Gastroenterol, Shaoxing 312000, Zhejiang, Peoples R China.
   [Fang, Long] China Japan Friendship Hosp, Dept Gastroenterol, Beijing 100029, Peoples R China.
RP Duan, JH (reprint author), Second Hosp Shaoxing City, Dept Gastroenterol, Shaoxing 312000, Zhejiang, Peoples R China.
EM jianhuaduan@126.com
CR Al-Nakhle H, 2010, CANCER RES, V70, P4778, DOI 10.1158/0008-5472.CAN-09-4104
   Ameres SL, 2013, NAT REV MOL CELL BIO, V14, P475, DOI 10.1038/nrm3611
   Haug BH, 2011, CARCINOGENESIS, V32, P1005, DOI 10.1093/carcin/bgr073
   Li F, 2014, FEBS LETT, V588, P538, DOI 10.1016/j.febslet.2013.12.009
   Lian F, 2011, BIOCHEM J, V438, P315, DOI 10.1042/BJ20102096
   Lin YS, 2011, WORLD J GASTROENTERO, V17, P4421, DOI 10.3748/wjg.v17.i39.4421
   Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140
   Lu Y, 2014, GUT, V63, P170, DOI 10.1136/gutjnl-2012-303150
   Ma K, 2006, J CLIN INVEST, V116, P1102, DOI 10.1172/JCI25604
   Modica S, 2008, CANCER RES, V68, P9589, DOI 10.1158/0008-5472.CAN-08-1791
   Ohno T, 2012, CANCER LETT, V323, P215, DOI 10.1016/j.canlet.2012.04.015
   Pritchard CC, 2012, NAT REV GENET, V13, P358, DOI 10.1038/nrg3198
   Rottiers V, 2012, NAT REV MOL CELL BIO, V13, P239, DOI 10.1038/nrm3313
   Scapoli L, 2010, INT J IMMUNOPATH PH, V23, P1229, DOI 10.1177/039463201002300427
   Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3
   Sun KL, 2013, NAT REV GENET, V14, P535, DOI 10.1038/nrg3471
   Swales KE, 2006, CANCER RES, V66, P10120, DOI 10.1158/0008-5472.CAN-06-2399
   Szabo G, 2013, NAT REV GASTRO HEPAT, V10, P542, DOI 10.1038/nrgastro.2013.87
   Tsuchida A, 2011, CANCER SCI, V102, P2264, DOI 10.1111/j.1349-7006.2011.02081.x
   Urdinguio RG, 2010, EPIGENETICS-US, V5, P656, DOI 10.4161/epi.5.7.13055
   Wadhwa R, 2013, NAT REV CLIN ONCOL, V10, P643, DOI 10.1038/nrclinonc.2013.170
   Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025
   Yang F, 2007, CANCER RES, V67, P863, DOI 10.1158/0008-5472.CAN-06-1078
   Yu Y, 2013, ONCOL LETT, V6, P468, DOI 10.3892/ol.2013.1404
   Zhang BG, 2012, ONCOL REP, V27, P1019, DOI 10.3892/or.2012.1645
   Zhang CZ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-367
NR 26
TC 17
Z9 17
U1 3
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2014
VL 35
IS 11
BP 11013
EP 11019
DI 10.1007/s13277-014-2342-x
PG 7
WC Oncology
SC Oncology
GA AU1YJ
UT WOS:000345413100048
PM 25095974
DA 2018-12-27
ER

PT J
AU Piao, YR
   Jin, ZH
   Yuan, KC
   Jin, XS
AF Piao, Yong-Rui
   Jin, Zhe-Hu
   Yuan, Kui-Chang
   Jin, Xuan-Shun
TI RETRACTED: Analysis of Tim-3 as a therapeutic target in prostate cancer
   (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Prostate cancer; Tim-3; CD4+Tcells; CD8+Tcells
ID T-CELLS; EXPRESSION; IMMUNITY
AB T cell immunoglobulin domain and mucin domain-containing molecule 3 (Tim-3) is a newly discovered immunomodulatory, which plays an important role in immunity regulation. Recent evidence suggests that Tim-3 is differentially regulated in a variety of tumors and has a potential as a therapeutic target. The aim of this study was to investigate the effect of Tim-3 on the development of prostate cancer (PCa). Tim-3 expressing on peripheral CD4+ T and CD8+ T cells was analyzed by flow cytometry. The relationships between Tim-3 expression and clinicopathological features were analyzed. Immunohistochemical expression of Tim-3 was examined in our large numbers of paraffin-fixed prostate tissues. Flow cytometry revealed that expression of Tim-3 was significantly increased on both CD4+ and CD8+ T cells in PCa patients than that in benign prostate hyperplasia (BPH) patients. Also, the level of Tim-3 on CD4+ T cells was positively correlated with CD8+ T cells in patients. Further analyses revealed that the levels of Tim-3 on CD4+ T cells and CD8+ T cells exhibited different expression patterns in terms of localization depending on pathological category of PCa and metastasis. Immunohistochemical analysis revealed that positive staining of Tim-3 in PCa but little or no staining of Tim-3 was observed in BPH epithelium. Tim-3 may affect the development and progression of PCa, which may provide knowledge for using Tim-3 as a novel therapy for effective PCa management.
C1 [Piao, Yong-Rui] Yan Bian Univ, Dept Urol, Affiliated Hosp, Yan Ji 133000, Peoples R China.
   [Jin, Zhe-Hu] Yan Bian Univ, Dept Dermatol & Venereol, Affiliated Hosp, Yan Ji 133000, Peoples R China.
   [Yuan, Kui-Chang; Jin, Xuan-Shun] Yan Bian Univ, Dept Cardiol, Affiliated Hosp, Yan Ji 133000, Peoples R China.
RP Jin, XS (reprint author), Yan Bian Univ, Dept Cardiol, Affiliated Hosp, 1327 Ju Zi St, Yan Ji 133000, Peoples R China.
EM yrpiao@126.com
CR Anderson AC, 2007, SCIENCE, V318, P1141, DOI 10.1126/science.1148536
   Anderson AC, 2012, CURR OPIN IMMUNOL, V24, P213, DOI 10.1016/j.coi.2011.12.005
   Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637
   Gao X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030676
   Han S, 2014, DNA CELL BIOL, V33, P245, DOI 10.1089/dna.2013.2306
   Heidenreich A, 2011, EUR UROL, V59, P61, DOI 10.1016/j.eururo.2010.10.039
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
   Jones RB, 2008, J EXP MED, V205, P2763, DOI 10.1084/jem.20081398
   Kikushige Y, 2012, ANN NY ACAD SCI, V1266, P118, DOI 10.1111/j.1749-6632.2012.06550.x
   Kozlowska A, 2013, GENE, V525, P200, DOI 10.1016/j.gene.2013.03.056
   Pontes J, 2010, PROSTATE, V70, P1189, DOI 10.1002/pros.21153
   Raheem O, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-185
   Ren SC, 2013, ASIAN J ANDROL, V15, P350, DOI 10.1038/aja.2013.37
   Saad F, 2012, FUTURE ONCOL, V8, P321, DOI [10.2217/fon.12.3, 10.2217/FON.12.3]
   Sakuishi K, 2011, TRENDS IMMUNOL, V32, P345, DOI 10.1016/j.it.2011.05.003
   Wu J, 2013, DNA CELL BIOL, V32, P648, DOI 10.1089/dna.2013.2116
   Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271
NR 17
TC 18
Z9 24
U1 5
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2014
VL 35
IS 11
BP 11409
EP 11414
DI 10.1007/s13277-014-2464-1
PG 6
WC Oncology
SC Oncology
GA AU1YJ
UT WOS:000345413100094
PM 25119597
OA Green Published, Other Gold
DA 2018-12-27
ER

PT J
AU Liu, SL
   Gong, ZY
   Chen, MR
   Liu, BL
   Bian, DH
   Wu, K
AF Liu, Shunli
   Gong, Zhenyu
   Chen, Mingrui
   Liu, Benli
   Bian, Donghui
   Wu, Kai
TI RETRACTED: Lgr5-positive cells are cancer stem cells in skin squamous
   cell carcinoma (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Skin squamous cell carcinoma; Cancer stem cell; Lgr5; Aldeflour; Side
   population; CD133
ID ALDEHYDE DEHYDROGENASE-ACTIVITY; PROGENITOR CELLS; CD133; LGR5
AB Cancer stem cells (CSCs) in most human tumors are commonly identified and enriched using similar strategies for identifying normal stem cells, including flow cytometry assays for side population, high aldehyde dehydrogenase (ALDH) activity, and CD133 positivity. Thus, development of a method for isolating a specific cancer using cancer-specific characteristic appears to be potentially important. Here, we reported extremely high Lgr5 levels in the specimen from skin squamous cell carcinoma (SCC) in patients. Using SCC cell line A431, we detected high Lgr5 and CD133 levels in ALDH-high or side population from these cancer cells. To figure out whether Lgr5 is a marker of CSCs in SCC, we transfected A431 cells with a Lgr5-creERT-2A-DTR/Cag-Loxp-GFP-STOP-Loxp-RFP plasmid and purified transfected cells (tA431) based on GFP by flow cytometry. 4-Hydroxytamoxifen (4-OHT) was given to label Lgr5-positive cells with RFP, for comparison to GFP-positive Lgr5-negative cells. Lgr5-positive cells grew significantly faster than Lgr5-negative cells, and the fold increase in growth of Lgr5-positive vs Lgr5-negative cells is significantly higher than SP vs non-SP, or ALDH-high vs ALDH-low, or CD133-positive vs CD133-negative cells. Moreover, in Lgr5-negative population, Lgr5-positive re-appeared in culture with time, suggesting that Lgr5-positive cells can be regenerated from Lgr5-negative cells. Furthermore, the growth of tA431 cells significantly decreased upon a single dose of diphtheria toxin (DT)/4-OHT to eliminate Lgr5-positive cell lineage, while multiple doses of DT/4-OHT nearly completely inhibited tA431 cell growth. Taken together, our data provide compelling data to demonstrate that Lgr5-positive cells are CSCs in skin SCC.
C1 [Liu, Shunli; Chen, Mingrui; Liu, Benli; Bian, Donghui; Wu, Kai] Gen Hosp Jinan Mil Reg, Dept Burn & Plast, Jinan 250031, Peoples R China.
   [Gong, Zhenyu] Peoples Liberat Army, Dept Burns & Plast Surg, Hosp 181, Guilin 541002, Peoples R China.
RP Chen, MR (reprint author), Gen Hosp Jinan Mil Reg, Dept Burn & Plast, 25 Shifan Rd, Jinan 250031, Peoples R China.
EM mingrui_chen14@163.com
CR Armstrong L, 2004, STEM CELLS, V22, P1142, DOI 10.1634/stemcells.2004.0170
   Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x
   Fang DD, 2010, BRIT J CANCER, V102, P1265, DOI 10.1038/sj.bjc.6605610
   Haegebarth A, 2009, AM J PATHOL, V174, P715, DOI 10.2353/ajpath.2009.080758
   Hess DA, 2004, BLOOD, V104, P1648, DOI 10.1182/blood-2004-02-0448
   Hess DA, 2006, BLOOD, V107, P2162, DOI 10.1182/blood-2005-06-2284
   Hess DA, 2008, STEM CELLS, V26, P611, DOI 10.1634/stemcells.2007-0429
   Kinzel B, 2014, DEV BIOL, V390, P181, DOI 10.1016/j.ydbio.2014.03.009
   Liu Y, 2014, HISTOCHEM CELL BIOL
   Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4
   Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035
   Magni M, 1996, BLOOD, V87, P1097
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Nagata T, 2011, ANTICANCER RES, V31, P495
   Ottaiano A, 2010, CELL CYCLE, V9, P4431, DOI 10.4161/cc.9.22.13823
   Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095
   Petersson M, 2012, CURR MED CHEM, V19, P5984
   Rahimi S, 2013, CLIN TER, V164, P143, DOI 10.7417/CT.2013.1534
   Shi CJ, 2010, CANCER BIOL THER, V10, P1183, DOI 10.4161/cbt.10.11.13664
   Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175
   Takubo K, 2008, CELL STEM CELL, V2, P170, DOI 10.1016/j.stem.2007.10.023
   Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130
   Xiao XW, 2013, J CLIN INVEST, V123, P2207, DOI 10.1172/JCI66323
   Zhang LJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096204
NR 24
TC 8
Z9 8
U1 3
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2014
VL 35
IS 11
BP 11605
EP 11612
DI 10.1007/s13277-014-2488-6
PG 8
WC Oncology
SC Oncology
GA AU1YJ
UT WOS:000345413100118
PM 25135431
DA 2018-12-27
ER

PT J
AU Schietroma, M
   Cecilia, EM
   Sista, F
   Carlei, F
   Pessia, B
   Amicucci, G
AF Schietroma, Mario
   Cecilia, Emanuela M.
   Sista, Federico
   Carlei, Francesco
   Pessia, Beatrice
   Amicucci, Gianfranco
TI RETRACTED: High-concentration supplemental perioperative oxygen and
   surgical site infection following elective colorectal surgery for rectal
   cancer: a prospective, randomized, double-blind, controlled, single-site
   trial (Retracted article. See vol. 215, pg. 534, 2018)
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article; Retracted Publication
DE Rectal cancer; Colorectal surgery; Surgical site infection
ID WOUND-INFECTION; INSPIRED OXYGEN; CLINICAL-TRIALS; RISK-FACTORS;
   METAANALYSIS; REDUCE; COMPLICATIONS; DEFINITIONS; ANASTOMOSIS; INDICATOR
AB BACKGROUND: Perioperative supplemental oxygen has been proposed to decrease the incidence of surgical site infection (SSI) in colorectal surgery with controversial results. We have assessed the influence of hyperoxygenation on SSI by using the most homogeneous study population.
   METHODS: We studied, in a prospective randomized study, 81 patients, who underwent elective open infraperitoneal anastomosis for rectal cancer. Patients were assigned randomly to an oxygen/air mixture with a fraction of inspired oxygen (FiO(2)) of 30% (n = 41) or 80% (n = 40). Administration was commenced after induction of anesthesia and maintained for 6 hours after surgery.
   RESULTS: The overall wound infection rate was 21%: 11 patients (26.8%) had wound infections in the 30% FiO(2) group and 6 (15%) in the 80% FiO(2) group (P < .05). The risk of SSI was 41% lower in the 80% FiO(2) group.
   CONCLUSION: Supplemental 80% FiO(2) reduced postoperative SSI with few risks to the patient and little associated cost. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Schietroma, Mario; Cecilia, Emanuela M.; Sista, Federico; Carlei, Francesco; Pessia, Beatrice; Amicucci, Gianfranco] Univ Aquila, Dept Surg, I-67100 Laquila, Italy.
RP Pessia, B (reprint author), Univ Aquila, Dept Surg, I-67100 Laquila, Italy.
EM pessiabeatrice87@gmail.com
OI Carlei, Francesco/0000-0003-4556-7548; SCHIETROMA,
   Mario/0000-0002-2698-5501
CR Al-Niaimi A, 2009, J EVAL CLIN PRACT, V15, P360, DOI 10.1111/j.1365-2753.2008.01016.x
   Belda FJ, 2005, JAMA-J AM MED ASSOC, V294, P2035, DOI 10.1001/jama.294.16.2035
   Blumetti J, 2007, SURGERY, V142, P704, DOI 10.1016/j.surg.2007.05.012
   Brar MS, 2011, J SURG RES, V166, P227, DOI 10.1016/j.jss.2009.06.007
   BURKE JF, 1961, SURGERY, V50, P161
   BYRNE DJ, 1989, BIOMED PHARMACOTHER, V43, P669, DOI 10.1016/0753-3322(89)90085-1
   Chura Justin C, 2007, Surg Infect (Larchmt), V8, P455
   CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501
   CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z
   Dimick JB, 2004, J AM COLL SURGEONS, V199, P531, DOI 10.1016/j.jamcollsurg.2004.05.276
   Franchi M, 1997, OBSTET GYNECOL, V90, P622, DOI 10.1016/S0029-7844(97)00359-1
   Garcia-Botello SA, 2006, BRIT J SURG, V93, P698, DOI 10.1002/bjs.5370
   Gardella C, 2008, OBSTET GYNECOL, V112, P545, DOI 10.1097/AOG.0b013e318182340c
   Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303
   HALEY RW, 1985, AM J EPIDEMIOL, V121, P206, DOI 10.1093/oxfordjournals.aje.a113991
   Hopf HW, 2008, BEST PRACT RES-CLIN, V22, P553, DOI 10.1016/j.bpa.2008.06.001
   HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606
   HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8
   Hunt TK, 2009, JAMA-J AM MED ASSOC, V302, P1588, DOI 10.1001/jama.2009.1478
   Kabon B, 2006, CURR OPIN ANESTHESIO, V19, P11, DOI 10.1097/01.aco.0000192775.24774.15
   KNIGHTON DR, 1984, ARCH SURG-CHICAGO, V119, P199
   Kondrup J, 2003, CLIN NUTR, V22, P321, DOI 10.1016/S0261-5614(02)00214-5
   Konishi T, 2006, ANN SURG, V244, P758, DOI 10.1097/01.sla.0000219017.78611.49
   Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901
   Mayzler O, 2005, Minerva Anestesiol, V71, P21
   Meyhoff CS, 2009, JAMA-J AM MED ASSOC, V302, P1543, DOI 10.1001/jama.2009.1452
   MILES AA, 1957, BRIT J EXP PATHOL, V38, P79
   MISHRIKI SF, 1990, J HOSP INFECT, V16, P223, DOI 10.1016/0195-6701(90)90110-A
   Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3
   MONTGOMERY AB, 1989, AM REV RESPIR DIS, V139, P1548, DOI 10.1164/ajrccm/139.6.1548
   Pineda CE, 2008, J GASTROINTEST SURG, V12, P2037, DOI 10.1007/s11605-008-0594-8
   Pryor KO, 2004, JAMA-J AM MED ASSOC, V291, P79, DOI 10.1001/jama.291.1.79
   Qadan M, 2009, ARCH SURG-CHICAGO, V144, P359, DOI 10.1001/archsurg.2009.1
   Sala C, 1994, BRIT J SURG, V81, P35
   Schietroma M, 2013, ANN SURG ONCOL, V20, P1584, DOI 10.1245/s10434-012-2714-7
   Schietroma M, 2012, J GASTROINTEST SURG, V16, P427, DOI 10.1007/s11605-011-1717-1
   Togioka B, 2012, ANESTH ANALG, V114, P334, DOI 10.1213/ANE.0b013e31823fada8
   Weber WP, 2008, INFECT CONT HOSP EP, V29, P623, DOI 10.1086/589331
   Wilson APR, 2004, BRIT MED J, V329, P720, DOI 10.1136/bmj.38232.646227.DE
   WILSON APR, 1986, LANCET, V1, P311
NR 40
TC 17
Z9 25
U1 2
U2 12
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
EI 1879-1883
J9 AM J SURG
JI Am. J. Surg.
PD NOV
PY 2014
VL 208
IS 5
BP 719
EP 726
DI 10.1016/j.amjsurg.2014.04.002
PG 8
WC Surgery
SC Surgery
GA AT4TO
UT WOS:000344935500006
PM 25060545
DA 2018-12-27
ER

PT J
AU Li, F
   Liu, J
   Rozovsky, S
AF Li, Fei
   Liu, Jun
   Rozovsky, Sharon
TI RETRACTED: Glutathione peroxidase's reaction intermediate selenenic acid
   is stabilized by the protein microenvironment (Retracted Article)
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article; Retracted Publication
DE Selenoproteins; Selenenic acid; Sulfenic acid; Glutathione peroxidase;
   Selenocysteine
ID TYROSINE-PHOSPHATASE 1B; SULFENIC ACID; CHEMICAL PROBES; OXIDATION;
   SELENIUM; SELENOCYSTEINE; MECHANISM; CYSTEINE; INACTIVATION; CHEMISTRY
AB Selenenic acids are highly reactive intermediates of selenoproteins' enzymatic reactions. Knowledge of how the protein environment protects and stabilizes them is fundamental not only to descriptions of selenoproteins' reactivity but also potentially for proteomics and therapeutics. However, selenenic acids are considered particularly short-lived and are not yet identified in wild-type selenoproteins. Here, we report trapping the selenenic acid in glutathione peroxidase, an antioxidant enzyme that efficiently eliminates hydroperoxides. It has long been thought that selenium-containing glutathione peroxidases form a selenenic acid intermediate. However, this putative species has eluded detection. Here, we report its identification. The selenenic acid in bovine glutathione peroxidase 1 was chemically trapped using dimedone, an alkylating agent specific to sulfenic and selenenic acids. The alkylation of the catalytic selenocysteine was verified by electrospray ionization mass spectrometry. In the presence of glutathione, the selenocysteine was not alkylated because the selenenic acid condenses faster with glutathione than the alkylation reaction. In the absence of thiols, the selenenic acid was surprisingly long-lived with 95% of the protein still able to react with dimedone 10 min after hydrogen peroxide was removed, indicating that the protein environment stabilizes the selenenic acid by shielding it from reactive groups in the protein. After 30 min, the selenocysteine was no longer modified but became accessible once the protein was exposed to reducing agents. This suggests that the selenenic acid reacted with a protein's amide or amine to form a selenylamide bond. Such a modification may play a role in protecting glutathione peroxidase's reactivity. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Li, Fei; Liu, Jun; Rozovsky, Sharon] Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.
RP Rozovsky, S (reprint author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.
EM rozovsky@udel.edu
FU National Institute of General Medical Sciences of the NIH [8 P20
   GM103541]; NSF [MCB-1054447]
FX We thank Dr. Joe Fox for helpful discussions. We acknowledge service
   from the University of Delaware's proteomics and mass spectrometry core
   facility. This work was supported by the National Institute of General
   Medical Sciences of the NIH through Grant 8 P20 GM103541, and by the NSF
   through Grant MCB-1054447 "CAREER: Reactivity of Selenoproteins."
CR BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6
   Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020
   BULL C, 1983, J AM CHEM SOC, V105, P5290, DOI 10.1021/ja00354a019
   Cho CS, 2010, ANTIOXID REDOX SIGN, V12, P1235, DOI 10.1089/ars.2009.2701
   CRAINE L, 1989, CHEM REV, V89, P689, DOI 10.1021/cr00094a001
   D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256
   EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x
   FISCHER H, 1987, B SOC CHIM BELG, V96, P757
   FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987
   FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0
   Flohe L, 2011, ADV TOP SCI TECH CHI, P1
   Flohe L, 2012, SELENIUM: ITS MOLECULAR BIOLOGY AND ROLE IN HUMAN HEALTH, THIRD EDITION, P167, DOI 10.1007/978-1-4614-1025-6_13
   Flohe L, 2011, ANTIOXID REDOX SIGN, V15, P763, DOI 10.1089/ars.2010.3397
   Furdui CM, 2014, MASS SPECTROM REV, V33, P126, DOI 10.1002/mas.21384
   GETTINS P, 1992, ARCH BIOCHEM BIOPHYS, V294, P511, DOI 10.1016/0003-9861(92)90718-C
   Goto K, 2001, ORG LETT, V3, P3569, DOI 10.1021/ol016682s
   GUNZLER WA, 1972, H-S Z PHYSIOL CHEM, V353, P1001
   Gupta V, 1840, BIOCHIM BIOPHYS ACTA, V2014, P847
   Hatfield DL, 2014, TRENDS BIOCHEM SCI, V39, P112, DOI 10.1016/j.tibs.2013.12.007
   Haynes AC, 2013, J BIOL CHEM, V288, P29714, DOI 10.1074/jbc.M113.473470
   Herbette S, 2007, FEBS J, V274, P2163, DOI 10.1111/j.1742-4658.2007.05774.x
   Klomsiri C, 2010, METHOD ENZYMOL, V473, P77, DOI 10.1016/S0076-6879(10)73003-2
   Lee JW, 2007, P NATL ACAD SCI USA, V104, P8743, DOI 10.1073/pnas.0702081104
   Liu J, 2013, BIOCHEMISTRY-US, V52, P5514, DOI 10.1021/bi400741c
   Lubos E, 2011, ANTIOXID REDOX SIGN, V15, P1957, DOI 10.1089/ars.2010.3586
   Maiorino M, 2007, J MOL BIOL, V365, P1033, DOI 10.1016/j.jmb.2006.10.033
   Maiorino M, 2012, SELENIUM: ITS MOLECULAR BIOLOGY AND ROLE IN HUMAN HEALTH, THIRD EDITION, P181, DOI 10.1007/978-1-4614-1025-6_14
   Mauri P, 2003, BIOL CHEM, V384, P575, DOI 10.1515/BC.2003.065
   Nogueira CW, 2004, CHEM REV, V104, P6255, DOI 10.1021/cr0406559
   Orian L, 2014, FREE RADICAL BIO MED, V66, P65, DOI 10.1016/j.freeradbiomed.2013.03.006
   Paulsen CE, 2013, CHEM REV, V113, P4633, DOI 10.1021/cr300163e
   Poole LB, 2005, BIOCONJUGATE CHEM, V16, P1624, DOI 10.1021/bc050257s
   Poole LB, 2008, CURR OPIN CHEM BIOL, V12, P18, DOI 10.1016/j.cbpa.2008.01.021
   Poole T. H., 2014, J AM CHEM SOC
   ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588
   Ruggles EL, 2012, SELENIUM: ITS MOLECULAR BIOLOGY AND ROLE IN HUMAN HEALTH, THIRD EDITION, P73, DOI 10.1007/978-1-4614-1025-6_6
   Salmeen A, 2003, NATURE, V423, P769, DOI 10.1038/nature01680
   Salsbury FR, 2008, PROTEIN SCI, V17, P299, DOI 10.1110/ps.073096508
   Seo YH, 2011, ANGEW CHEM INT EDIT, V50, P1342, DOI 10.1002/anie.201007175
   Seo YH, 2009, P NATL ACAD SCI USA, V106, P16163, DOI 10.1073/pnas.0903015106
   SIES H, 1994, METHOD ENZYMOL, V234, P476
   Snider GW, 2013, BIOCHEMISTRY-US, V52, P5472, DOI [10.1021/bi400452j, 10.1021/bi400462j]
   Toppo S, 2009, BBA-GEN SUBJECTS, V1790, P1486, DOI 10.1016/j.bbagen.2009.04.007
   Tosatto SCE, 2008, ANTIOXID REDOX SIGN, V10, P1515, DOI 10.1089/ars.2008.2055
   van Montfort RLM, 2003, NATURE, V423, P773, DOI 10.1038/nature01681
   Wang SK, 2011, FREE RADICAL BIO MED, V51, P197, DOI 10.1016/j.freeradbiomed.2011.03.018
   Yang J, 2007, BIOCHEMISTRY-US, V46, P709, DOI 10.1021/bi061546m
   Zielinski Z, 2014, J AM CHEM SOC, V136, P1570, DOI 10.1021/ja411493t
NR 48
TC 4
Z9 4
U1 3
U2 41
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV
PY 2014
VL 76
BP 127
EP 135
DI 10.1016/j.freeradbiomed.2014.07.041
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AT9NW
UT WOS:000345254800014
PM 25124921
OA Green Accepted
DA 2018-12-27
ER

PT J
AU Sakar, Y
   Duca, FA
   Langelier, B
   Devime, F
   Blottiere, H
   Delorme, C
   Renault, P
   Covasa, M
AF Sakar, Y.
   Duca, F. A.
   Langelier, B.
   Devime, F.
   Blottiere, H.
   Delorme, C.
   Renault, P.
   Covasa, M.
TI RETRACTED: Impact of high-fat feeding on basic helix-loop-helix
   transcription factors controlling enteroendocrine cell differentiation
   (Retracted article. See vol. 40, pg. 1468, 2016)
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article; Retracted Publication
DE intestinal chemosensation; enteroendocrine cells; gut peptides; GLP-1
ID INTESTINAL EPITHELIUM; GASTROINTESTINAL-TRACT; OBESE MICE; ENDOCRINE;
   GENE; NEUROGENIN3; PROLIFERATION; ACCUMULATION; REQUIREMENT; SENSITIVITY
AB BACKGROUND AND OBJECTIVES: Gut hormones secreted by enteroendocrine cells (EECs) play a major role in energy regulation. Differentiation of EEC is controlled by the expression of basic helix-loop-helix (bHLH) transcription factors. High-fat (HF) feeding alters gut hormone levels; however, the impact of HF feeding on bHLH transcription factors in mediating EEC differentiation and subsequent gut hormone secretion and expression is not known.
   METHODS: Outbred Sprague-Dawley rats were maintained on chow or HF diet for 12 weeks. Gene and protein expression of intestinal bHLH transcription factors, combined with immunofluorescence studies, were analyzed for both groups in the small intestine and colon. Gut permeability, intestinal lipid and carbohydrate transporters as well as circulating levels and intestinal protein expression of gut peptides were determined.
   RESULTS: We showed that HF feeding resulted in hyperphagia and increased adiposity. HF-fed animals exhibited decreased expression of bHLH transcription factors controlling EEC differentiation (MATH1, NGN3, NEUROD1) and increased expression of bHLH factors modulating enterocyte expression. Furthermore, HF-fed animals had decreased number of total EECs and L-cells. This was accompanied by increased gut permeability and expression of lipid and carbohydrate transporters, and a decrease in circulating and intestinal gut hormone levels.
   CONCLUSIONS: Taken together, our results demonstrate that HF feeding caused decreased secretory lineage (that is, EECs) differentiation through downregulation of bHLH transcription factors, resulting in reduced EEC number and gut hormone levels. Thus, impaired EEC differentiation pathways by HF feeding may promote hyperphagia and subsequent obesity.
C1 [Sakar, Y.; Duca, F. A.; Langelier, B.; Devime, F.; Blottiere, H.; Delorme, C.; Renault, P.; Covasa, M.] INRA Ctr Rech Jouy en Josas, MICALIS UMR1913, Domaine Vilvert, F-78350 Jouy En Josas, France.
   [Sakar, Y.; Duca, F. A.; Langelier, B.; Devime, F.; Blottiere, H.; Delorme, C.; Renault, P.; Covasa, M.] AgroParisTech, MICALIS UMR1913, Jouy En Josas, France.
   [Covasa, M.] Western Univ Hlth Sci, Coll Osteopath Med, Dept Basic Med Sci, Pomona, CA USA.
   [Covasa, M.] Univ Suceava, Dept Human Hlth & Dev, Suceava, Romania.
RP Covasa, M (reprint author), INRA Ctr Rech Jouy en Josas, MICALIS UMR1913, Domaine Vilvert, F-78350 Jouy En Josas, France.
EM mcovasa@jouy.inra.fr
RI Suceava, USV/E-8611-2011
OI BLOTTIERE, Herve/0000-0002-8390-0607
FU INRA; Romanian National Program, 'Analysis of novel risk factors
   influencing control of food intake and regulation of body weight'
   [PN-II-ID-PCE-2012-4-0608, 48/02.09.2013]
FX We thank the ANAXEM team for their assistance in the animal facilities,
   and Julie Cadiou for assisting with the behavioral experiments. This
   study was supported by INRA through a scientific package to MC and by
   the Romanian National Program PN-II-ID-PCE-2012-4-0608 no.
   48/02.09.2013, 'Analysis of novel risk factors influencing control of
   food intake and regulation of body weight'.
CR Ait-Omar A, 2011, DIABETES, V60, P2598, DOI 10.2337/db10-1740
   Attig L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066816
   Bar Y, 2008, DIABETES, V57, P2413, DOI 10.2337/db07-1323
   Barbara PD, 2003, CELL MOL LIFE SCI, V60, P1322, DOI 10.1007/s00018-003-2289-3
   Bergstrom KSB, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000902
   Beucher A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036449
   Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886
   Covasa M, 2010, AM J PHYSIOL-REG I, V299, pR1423, DOI 10.1152/ajpregu.00126.2010
   Crosnier C, 2005, DEVELOPMENT, V132, P1093, DOI 10.1242/dev.01644
   Crosnier C, 2006, NAT REV GENET, V7, P349, DOI 10.1038/nrg1840
   Duca FA, 2012, INT J OBES LOND, V37, P375, DOI DOI 10.1038/IJ0.2012.45)
   Duca FA, 2013, DIABETES, V62, P2410, DOI 10.2337/db12-1204
   Duca FA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039748
   Fujimori M, 2001, CANCER RES, V61, P6656
   Gerbe F, 2011, J CELL BIOL, V192, P767, DOI 10.1083/jcb.201010127
   Gniuli D, 2010, INT J OBESITY, V34, P1726, DOI 10.1038/ijo.2010.99
   Gniuli D, 2010, DIABETOLOGIA, V53, P2233, DOI 10.1007/s00125-010-1830-9
   Gu DF, 2013, METABOLISM, V62, P1137, DOI 10.1016/j.metabol.2013.01.025
   Hill ME, 1999, MOL ENDOCRINOL, V13, P1474, DOI 10.1210/me.13.9.1474
   Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000
   Hyland NP, 2007, PEPTIDES, V28, P1185, DOI 10.1016/j.peptides.2007.03.011
   Jenny M, 2002, EMBO J, V21, P6338, DOI 10.1093/emboj/cdf649
   Kamoi K, 2012, ENDOCR J, V59, P353, DOI 10.1507/endocrj.EJ11-0245
   Kwon MC, 2009, J BIOL CHEM, V284, P33634, DOI 10.1074/jbc.M109.059840
   Lee JC, 2001, DIABETES, V50, P928, DOI 10.2337/diabetes.50.5.928
   Li HJ, 2011, DIABETES OBES METAB, V13, P5, DOI 10.1111/j.1463-1326.2011.01438.x
   Lopez-Diaz L, 2007, DEV BIOL, V309, P298, DOI 10.1016/j.ydbio.2007.07.015
   Mao JM, 2013, DIABETES, V62, P3736, DOI 10.2337/db13-0035
   Miyamoto Y, 2004, EXP MOL PATHOL, V77, P238, DOI 10.1016/j.yexmp.2004.05.007
   Moran Gordon W, 2008, Therap Adv Gastroenterol, V1, P51, DOI 10.1177/1756283X08093943
   Mumphrey MB, 2012, NEUROGASTROENT MOTIL, V25, pe70
   Murphy KG, 2006, NATURE, V444, P854, DOI 10.1038/nature05484
   Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323
   Ogaki S, 2013, STEM CELLS, V31, P1086, DOI 10.1002/stem.1344
   Pearl EJ, 2011, DEV BIOL, V351, P135, DOI 10.1016/j.ydbio.2010.12.043
   Porat S, 2011, CELL METAB, V13, P440, DOI 10.1016/j.cmet.2011.02.012
   Ratineau C, 2002, J BIOL CHEM, V277, P8847, DOI 10.1074/jbc.M110747200
   Sakar Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007935
   Schonhoff SE, 2004, ENDOCRINOLOGY, V145, P2639, DOI 10.1210/en.2004-0051
   Schonhoff SE, 2004, DEV BIOL, V270, P443, DOI 10.1016/j.ydbio.2004.03.013
   Smith SB, 2003, J BIOL CHEM, V278, P38254, DOI 10.1074/jbc.M302229200
   Soyer J, 2010, DEVELOPMENT, V137, P203, DOI 10.1242/dev.041673
   Suzuki K, 2013, J BIOL CHEM, V288, P1929, DOI 10.1074/jbc.M112.423137
   Swartz TD, 2012, BRIT J NUTR, V107, P621, DOI 10.1017/S0007114511003412
   Turner JR, 2006, AM J PATHOL, V169, P1901, DOI 10.2353/ajpath.2006.060681
   VanDussen KL, 2010, DEV BIOL, V346, P215, DOI 10.1016/j.ydbio.2010.07.026
   Vollmer K, 2008, DIABETES, V57, P678, DOI 10.2337/db07-1124
   Wei XC, 2012, CELL HOST MICROBE, V11, P140, DOI 10.1016/j.chom.2011.12.006
   Yang BT, 2012, MOL ENDOCRINOL, V26, P1203, DOI 10.1210/me.2012-1004
   Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718
   Ye DZ, 2009, GASTROENTEROLOGY, V137, P2052, DOI 10.1053/j.gastro.2009.08.059
   Zambrowicz B, 2012, CLIN PHARMACOL THER, V92, P158, DOI 10.1038/clpt.2012.58
   Zhao JY, 2012, DIABETES, V61, P542, DOI 10.2337/db11-1048
   Zheng H, 2009, AM J PHYSIOL-GASTR L, V296, pG490, DOI 10.1152/ajpgi.90393.2008
   Zheng Y, 2012, SURGERY, V151, P13, DOI 10.1016/j.surg.2011.07.010
NR 55
TC 17
Z9 17
U1 2
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD NOV
PY 2014
VL 38
IS 11
BP 1440
EP 1448
DI 10.1038/ijo.2014.20
PG 9
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA AT8BE
UT WOS:000345158000009
PM 24480860
DA 2018-12-27
ER

PT J
AU Zhao, P
   Zhou, Q
   Bi, LJ
   Shen, JH
   Yang, XZ
   Liu, QH
AF Zhao Ping
   Zhou Qi
   Bi Long-Jun
   Shen Jin-Hua
   Yang Xin-Zhou
   Liu Qing-Hua
TI RETRACTED: Munc18c is Dispensable for Insulin-stimulated GLUT4
   Translocation in Adipocytes (Retracted article. See vol. 43, pg. 90,
   2016)
SO PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
LA Chinese
DT Article; Retracted Publication
DE adipocytes; glucose uptake; SM proteins; GLUT4 trafficking; Syntaxin4
ID 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; SNARE COMPLEX; PROTEIN FUNCTION;
   KNOCKOUT MICE; V-SNARES; TRAFFICKING; SYNTAXIN-4; STABILIZES; EXOCYTOSIS
AB The insulin-dependent uptake of glucose by adipose and muscle tissues is accomplished through the regulated vesicle trafficking of the GLUT4 glucose transporter to the plasma membrane. The Sec 1p homologue Munc18c is believed to play a central role in the docking of GLUT4 vesicles by controlling SNARE complex assembly. In the present study we have examined the function of SM proteins in insulin-stimulated GLUT4 trafficking in adipocytes. Syntaxin4 at the plasma membrane is not dependent on the presence of Munc18c. We found that absence of Munc18c did not affect GLUT4 externalization at the plasma membrane and GLUT4 trafficking was normal in the absence of Munc18c and functional Syntaxin2, known to be associated with Munc18b. Syntaxin4 demonstrates a robust interaction with Munc18c but not either Munc18a or Munc18b in 3T3-L1 adipocytes. However, Munc18a and Munc18b exhibited weak interaction with Syntaxin4 in the background of absence of Munc18c. These data suggest that Syntaxin4 may play an important role in insulin-stimulated GLUT4 trafficking and its interaction with SM proteins are complementary.
C1 [Zhao Ping; Zhou Qi; Bi Long-Jun; Shen Jin-Hua; Liu Qing-Hua] South Cent Univ Nationalities, Coll Life Sci, Wuhan 430074, Peoples R China.
   [Yang Xin-Zhou] South Cent Univ Nationalities, Coll Pharm, Wuhan 430074, Peoples R China.
RP Zhao, P (reprint author), South Cent Univ Nationalities, Coll Life Sci, Wuhan 430074, Peoples R China.
EM zping0124@163.com
RI Bai, Li/N-8311-2013
FU National Natural Science Foundation of China [31070744, 81102798];
   Fundamental Research Funds for the Central Universities [CZY14013];
   National Innovative and Entrepreneurial Training Project for College
   Students [BCX13102]
FX This work was supported by grants from The National Natural Science
   Foundation of China (31070744, 81102798), the Fundamental Research Funds
   for the Central Universities (CZY14013) and The National Innovative and
   Entrepreneurial Training Project for College Students (BCX13102).
CR Bai L, 2007, CELL METAB, V5, P47, DOI 10.1016/j.cmet.2006.11.013
   Borisovska M, 2005, EMBO J, V24, P2114, DOI 10.1038/sj.emboj.7600696
   Bryant NJ, 2001, EMBO J, V20, P3380, DOI 10.1093/emboj/20.13.3380
   Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2
   Carr CM, 2010, CURR OPIN CELL BIOL, V22, P488, DOI 10.1016/j.ceb.2010.04.006
   Colbert KN, 2013, P NATL ACAD SCI USA, V110, P12637, DOI 10.1073/pnas.1303753110
   Dulubova I, 2007, P NATL ACAD SCI USA, V104, P2697, DOI 10.1073/pnas.0611318104
   Jain SS, 2012, FEBS LETT, V586, P2428, DOI 10.1016/j.febslet.2012.05.061
   Kanda H, 2005, J CLIN INVEST, V115, P291, DOI 10.1172/JCI200522681
   Khan AH, 2001, J BIOL CHEM, V276, P4063, DOI 10.1074/jbc.M007419200
   Kioumourtzoglou D, 2014, MOL CELL BIOL, V34, P1271, DOI 10.1128/MCB.01203-13
   Lam PPL, 2013, DIABETES, V62, P2416, DOI 10.2337/db12-1380
   Larance M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200
   Li CH, 2004, CELL RES, V14, P480, DOI 10.1038/sj.cr.7290251
   Liu YT, 2002, MOL BIOL CELL, V13, P3314, DOI 10.1091/mbc.E02-04-0204
   Lizunov VA, 2012, AM J PHYSIOL-ENDOC M, V302, pE950, DOI 10.1152/ajpendo.00466.2011
   NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858
   Park M, 2012, DEV CELL, V22, P989, DOI 10.1016/j.devcel.2012.03.002
   Ramalingam L, 2012, DIABETES, V61, P2424, DOI 10.2337/db11-1525
   Ren WY, 2013, ADIPOCYTE, V2, P17, DOI 10.4161/adip.22117
   Rickman C, 2007, J BIOL CHEM, V282, P12097, DOI 10.1074/jbc.M700227200
   Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335
   Shen JS, 2007, CELL, V128, P183, DOI 10.1016/j.cell.2006.12.016
   Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099
   Spurlin BA, 2004, DIABETES, V53, P2223, DOI 10.2337/diabetes.53.9.2223
   Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740
   Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179
   TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857
   Van Dam J, 2006, RADIAT PROT DOSIM, V117, P185, DOI 10.1093/rpd/nci713
   Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864
   Volchuk A, 1996, MOL BIOL CELL, V7, P1075
   Widberg CH, 2003, J BIOL CHEM, V278, P35093, DOI 10.1074/jbc.M304261200
   Yang CM, 2001, J CLIN INVEST, V107, P1311, DOI 10.1172/JCI12274
   Zhao P, 2009, J CELL SCI, V122, P3472, DOI 10.1242/jcs.047449
NR 34
TC 1
Z9 1
U1 5
U2 13
PU CHINESE ACAD SCIENCES, INST BIOPHYSICS
PI BEIJING
PA 15 DATUN RD, CHAOYAND DISTRICT, BEIJING, 100101, PEOPLES R CHINA
SN 1000-3282
J9 PROG BIOCHEM BIOPHYS
JI Prog. Biochem. Biophys.
PD NOV
PY 2014
VL 41
IS 11
BP 1144
EP 1154
DI 10.3724/SP.J.1206.2014.00089
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA AT9SY
UT WOS:000345267500006
DA 2018-12-27
ER

PT J
AU Mirzaei, MJ
   Kazemi, A
   Homaee, O
AF Mirzaei, Mohammad Javad
   Kazemi, Ahad
   Homaee, Omid
TI RETRACTED: Real-world based approach for optimal management of electric
   vehicles in an intelligent parking lot considering simultaneous
   satisfaction of vehicle owners and parking operator (Retracted article.
   See vol. 85, pg. 687, 2015)
SO ENERGY
LA English
DT Article; Retracted Publication
DE Intelligent parking lot; Electric vehicle; Optimal energy management;
   Transparency of financial transactions
ID RENEWABLE ENERGY; POWER; OPTIMIZATION; NETWORKS; SYSTEM; IMPACT; LOAD
AB In this paper, an optimal energy management system for EVs (electric vehicles) parking is proposed. The presented model has the capability of management and optimal scheduling of charging and discharging of a large number of electric vehicles while considering technical and economic aspects. This model takes parking operator's benefit as well as vehicle owners' benefit into considerations, simultaneously. The benefit of parking operator is maximized by considering total daily costs and income of the parking lot. Furthermore, in order to maximize vehicles owners' profit and satisfying them, lost opportunity cost and penalty cost functions have been introduced. The parking lot is fined if requested final state of charge by vehicle owners is not met. In Addition, financial transactions of parking operator with vehicle owners and distribution system operator are accurately investigated. The obtained results imply that the presented energy management system provides maximum profits for parking operator and meanwhile it fulfills preferences of vehicle owners. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Mirzaei, Mohammad Javad; Kazemi, Ahad; Homaee, Omid] Iran Univ Sci & Technol, Ctr Excellence Power Syst Automat & Operat, Dept Elect Engn, Tehran, Iran.
RP Homaee, O (reprint author), Iran Univ Sci & Technol, Ctr Excellence Power Syst Automat & Operat, Dept Elect Engn, Tehran, Iran.
EM mj_mirzaei@elec.iust.ac.ir; kazemi@iust.ac.ir; homaee@elec.iust.ac.ir
RI Kazemi, Ahad/T-2228-2018
CR Amirioun MH, 2014, ENERGY, V69, P186, DOI 10.1016/j.energy.2014.02.063
   Arslan O, 2013, ENERGY, V60, P116, DOI 10.1016/j.energy.2013.08.039
   Clement-Nyns K, 2010, IEEE T POWER SYST, V25, P371, DOI 10.1109/TPWRS.2009.2036481
   Clerc M., 2010, PARTICLE SWARM OPTIM
   Fazelpour F, 2014, ENERG CONVERS MANAGE, V77, P250, DOI 10.1016/j.enconman.2013.09.006
   Green RC, 2011, RENEW SUST ENERG REV, V15, P544, DOI 10.1016/j.rser.2010.08.015
   Hedegaard K, 2012, ENERGY, V48, P356, DOI 10.1016/j.energy.2012.06.012
   Honarmand M, 2014, ENERGY, V65, P572, DOI 10.1016/j.energy.2013.11.045
   Nguyen HK, 2012, J COMMUN NETW-S KOR, V14, P662, DOI 10.1109/JCN.2012.00032
   Hutson C, 2008, IEEE EN 2030 C
   Jin CR, 2013, IEEE T SMART GRID, V4, P311, DOI 10.1109/TSG.2012.2218834
   Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1942, DOI 10.1109/ICNN.1995.488968
   Kiviluoma J, 2010, ENERGY, V35, P1244, DOI 10.1016/j.energy.2009.11.004
   Ma ZJ, 2013, IEEE T CONTR SYST T, V21, P67, DOI 10.1109/TCST.2011.2174059
   Madzharov D, 2014, ENERGY, V65, P285, DOI 10.1016/j.energy.2013.12.009
   Masoum AS, 2011, IET GENER TRANSM DIS, V5, P877, DOI 10.1049/iet-gtd.2010.0574
   Moradijoz M, 2013, INT J ELEC POWER, V46, P115, DOI 10.1016/j.ijepes.2012.10.041
   Moradijoz M, 2012, INT C EL POW DISTR N, P2
   Morais H, 2014, ENERG CONVERS MANAGE, V82, P268, DOI 10.1016/j.enconman.2014.03.032
   Moura SJ, 2011, IEEE T CONTR SYST T, V19, P545, DOI 10.1109/TCST.2010.2043736
   Parsons GR, 2014, ENERG ECON, V42, P313, DOI 10.1016/j.eneco.2013.12.018
   Poli Riccardo, 2007, Swarm Intelligence, V1, P33, DOI 10.1007/s11721-007-0002-0
   Rotering N, 2011, IEEE T POWER SYST, V26, P1021, DOI 10.1109/TPWRS.2010.2086083
   Saber A. Y., 2009, IEEE BUCH POW TECH C, P1
   Schuller A, 2014, IEEE T POWER SYST, V29, P2014, DOI 10.1109/TPWRS.2014.2301024
   Shafiee S, 2012, INT C ADV POW SYST C, P18
   Shafiee S, 2013, IEEE T SMART GRID, V4, P1351, DOI 10.1109/TSG.2013.2251483
   Shariatpanah H, 2012, INT C SMARTGR ICSG, P24
   Sheikhi A, 2013, INT J ELEC POWER, V53, P499, DOI 10.1016/j.ijepes.2013.04.025
   Su WC, 2012, IEEE T SMART GRID, V3, P308, DOI 10.1109/TSG.2011.2151888
   Voelcker J, 2011, IEEE SPECTRUM, V48, P11, DOI [10.1109/MSPEC.2011.5738384, 10.1109/MSPEC.2011.5738377]
   Xu H, 2013, INT J ELEC POWER, V53, P159, DOI 10.1016/j.ijepes.2013.04.022
   Zakariazadeh A, 2014, ENERG CONVERS MANAGE, V79, P43, DOI 10.1016/j.enconman.2013.11.042
   Zhang T, 2014, IEEE T VEH TECHNOL, V63, P2600, DOI 10.1109/TVT.2013.2295591
NR 34
TC 7
Z9 7
U1 3
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0360-5442
EI 1873-6785
J9 ENERGY
JI Energy
PD NOV 1
PY 2014
VL 76
BP 345
EP 356
DI 10.1016/j.energy.2014.08.026
PG 12
WC Thermodynamics; Energy & Fuels
SC Thermodynamics; Energy & Fuels
GA AS7OH
UT WOS:000344444600035
DA 2018-12-27
ER

PT J
AU Li, JY
   Yu, J
   Liu, A
   Wang, YL
AF Li, Jianying
   Yu, Jun
   Liu, An
   Wang, Yili
TI RETRACTED: beta-Elemene against human lung cancer via up-regulation of
   P53 protein expression to promote the release of exosome (Retracted
   article. See vol. 96, pg. 120, 2016)
SO LUNG CANCER
LA English
DT Review; Retracted Publication
DE beta-Elemene; Lung cancer; P53; Exosome; Bcl-2; Bcl-xl
ID TUMOR-DERIVED EXOSOMES; PROTEOMIC ANALYSIS; MEMBRANE-FRAGMENTS;
   CELL-CYCLE; IN-VITRO; APOPTOSIS; BINDING; MICROVESICLES; INDUCTION;
   CARCINOMA
AB Background: beta-Elemene, a novel antitumor plant drug extracted from the traditional Chinese medicinal herb Zedoary, has been shown to be effective against a wide variety of tumors. Recent studies have indicated that beta-elemene can inhibit the growth of lung cancer cells; however, the exact mechanism of beta-element's action in lung cancer remains largely unknown. In the present study, the antitumor effect of beta-elemene on human lung cancer cells and the mechanism involved has been investigated.
   Methods: The inhibitory effects of beta-elemene on cell growth were measured by Trypan Blue exclusion and MTT assay. Flow cytometric analysis was used to detect the cells' apoptotic rate. The expression of P53 mRNA and protein were measured by RT-PCR and Western blot analysis, respectively. Exosomes were isolated by differential centrifugation steps and analyzed by electron microscopy and western blotting. P53 knockdown cells were established through transfection with P53 siRNA. To investigate the effect of beta-elemene on the tumor growth in vivo, a Xenograft nude mouse model was established by injecting the A549 cells into the back of a BABL/c nude mouse.
   Results: beta-Elemene markedly inhibited growth and induced apoptosis in lung cancer cells. The levels of the anti-apoptotic genes Bcl-2 and Bcl-xl in A549 cells decreased, while expression of P53 and production of exosomes increased after beta-elemene treatment. Further siRNA studies suggested that the effect of beta-elemene on A549 cells is dependent on P53 expression. Exosomes derived from A549 cultured with a human lung cancer cell line exhibited decreased tumor cell proliferation. The in vivo study demonstrated that beta-elemene inhibited tumor growth, and up-regulated the expression of P53 and the release of exosome.
   Conclusion: Our results demonstrated beta-elemene acts on lung cancer cells in a P53 dependent manner and exosomes are involved in the regulation of cell proliferation. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Li, Jianying; Liu, An] Xi An Jiao Tong Univ, Affiliated Xian Cent Hosp, Sch Med, Dept Resp Dis, Xian 710003, Peoples R China.
   [Li, Jianying; Wang, Yili] Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Canc Res, Xian 710003, Peoples R China.
   [Yu, Jun] Xi An Jiao Tong Univ, Affiliated Xian Cent Hosp, Sch Med, Dept Surg, Xian 710003, Peoples R China.
RP Wang, YL (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Canc Res, Xian 710003, Peoples R China.
EM yiliwangs@163.com
FU Natural Science Foundation of Shaanxi Provinces of China [2012jc_06]
FX Financial support was provided by Natural Science Foundation of Shaanxi
   Provinces of China (No.2012jc_06).
CR Amano Y, 2009, J STEROID BIOCHEM, V114, P144, DOI 10.1016/j.jsbmb.2009.01.022
   Bacso Z, 2000, CANCER RES, V60, P4623
   Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062
   Bard MP, 2004, AM J RESP CELL MOL, V31, P114, DOI 10.1165/rcmb.2003-0238OC
   Chaput N, 2005, POTENTIAL EXOSOMES I
   Chen WL, 2006, EUR J IMMUNOL, V36, P1598, DOI 10.1002/eji.200535501
   Choi DS, 2007, J PROTEOME RES, V6, P4646, DOI 10.1021/pr070192y
   Ettinger DS, 2010, J NATL COMPR CANC NE, V8, P740, DOI 10.6004/jnccn.2010.0056
   Heijnen HFG, 1999, BLOOD, V94, P3791
   Jiang H, 2009, CHINESE GERMAN J CLI, V8, P12, DOI DOI 10.1007/S10330-008-0139-3
   Koga K, 2005, ANTICANCER RES, V25, P3703
   Li L, 2011, MOL MED REP, V4, P1243, DOI 10.3892/mmr.2011.548
   Li LJ, 2011, PHYTOTHER RES, V25, P1095, DOI 10.1002/ptr.3367
   Li QDQ, 2009, ONCOL REP, V22, P161, DOI 10.3892/or_00000420
   Li X, 2005, CELL MOL LIFE SCI, V62, P894, DOI 10.1007/s00018-005-5027-1
   Liu B, 2009, LUNG CANCER, V66, P169, DOI 10.1016/j.lungcan.2009.01.010
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Olver Christine, 2007, V43, P99, DOI 10.1007/978-1-4020-5943-8_7
   Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631
   Ries L, 2008, SEER CANC STAT REV, P1975
   Shen CX, 2003, FEBS LETT, V539, P111, DOI 10.1016/S0014-5793(03)00209-6
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Tao L, 2006, CANCER CHEMOTH PHARM, V58, P24, DOI 10.1007/s00280-005-0137-x
   TAYLOR DD, 1979, ANAL BIOCHEM, V98, P53, DOI 10.1016/0003-2697(79)90704-8
   TAYLOR DD, 1980, CANCER RES, V40, P4064
   Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033
   Tu KS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068574
   Valente L, 2013, BIODISCOVERY
   Wang G, 2005, CELL MOL LIFE SCI, V62, P881, DOI 10.1007/s00018-005-5017-3
   Wang PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010202
   Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438
   Yang C. J, 2011, CLIN DEV IMMUNOL, V2011
   Yao YQ, 2008, CANCER LETT, V264, P127, DOI 10.1016/j.canlet.2008.01.049
   Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579
   Zhao J, 2007, INT J ONCOL, V31, P241
NR 35
TC 13
Z9 16
U1 1
U2 41
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD NOV
PY 2014
VL 86
IS 2
BP 144
EP 150
DI 10.1016/j.lungcan.2014.08.015
PG 7
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA AS7LU
UT WOS:000344438400006
PM 25204604
DA 2018-12-27
ER

PT J
AU Wang, GB
   Liu, HM
   Zhang, ZC
   Zhang, FF
   Li, SF
   Chen, Y
   Zhao, HL
AF Wang, Guibin
   Liu Hongmei
   Zhang, Zhenchun
   Zhang, Fengfang
   Li, Shufa
   Chen, Yang
   Zhao, Huanli
TI RETRACTED: Oolong Tea Drinking Could Help Prevent Bone Loss in
   Postmenopausal Han Chinese Women (Retracted article. See vol. 76, pg.
   325, 2018)
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article; Retracted Publication
DE Oolong tea; Postmenopausal women; Bone density; Cross-sectional study
ID MINERAL DENSITY; OLDER WOMEN; CATECHINS; OSTEOPOROSIS; POLYPHENOLS;
   CONSUMPTION; MECHANISM; CANCER; HEALTH
AB The aim of this study was to analyze the relationship between oolong tea drinking and bone mineral density in postmenopausal Han Chinese women, while living and diet habits, fertility, disease elements and other baseline conditions were controlled. One group included 124 cases who routinely drank oolong tea, and the other included 556 who did not drink tea. Data were collected on participant age, lifestyle habits, fertility condition, disease elements, and lumbar, and hip bone densities. It was found that the bone densities of the greater trochanteric bone in tea drinkers were higher (0.793 +/- 0.119 kg/cm(2)) than that in non-tea drinkers (0.759 +/- 0.116 kg/cm(2), F = 6.248, p = 0.013). Similarly, the bone density of Ward's triangular bone in tea drinkers was higher (0.668 +/- 0.133 kg/cm(2)) than that in non-tea drinkers (0.637 +/- 0.135 kg/cm(2), F = 6.152, p = 0.013). Oolong tea drinking could help prevent bone loss in postmenopausal Chinese women.
C1 [Wang, Guibin; Zhao, Huanli] Linyi Peoples Hosp, Radiol Dept Xray Room, Linyi, Shandong, Peoples R China.
   [Liu Hongmei] Linyi Peoples Hosp, Dept Surg, Linyi, Shandong, Peoples R China.
   [Zhang, Zhenchun; Li, Shufa] Linyi Peoples Hosp, Dept Orthoped, Linyi, Shandong, Peoples R China.
   [Zhang, Fengfang] Linyi Peoples Hosp, Dept Endocrinol, Linyi, Shandong, Peoples R China.
   [Chen, Yang] Linyi Peoples Hosp, Dept Rheumatol, Linyi, Shandong, Peoples R China.
RP Zhao, HL (reprint author), Linyi Peoples Hosp, Radiol Dept Xray Room, Linyi, Shandong, Peoples R China.
EM drhuanlizhao@163.com
CR Amiri Somayeh, 2011, ZAHEDAN J RES MED SC, V13, P18
   Bettuzzi S, 2006, CANCER RES, V66, P1234, DOI 10.1158/0008-5472.CAN-05-1145
   Chen CH, 2005, OSTEOPOROSIS INT, V16, P2039, DOI 10.1007/s00198-005-1995-0
   Chen Z, 2003, AM J EPIDEMIOL, V158, P772, DOI [10.1093/aje/kwg214, 10.1098/aje/kwg214]
   Devine A, 2007, AM J CLIN NUTR, V86, P1243
   Du F, 2011, J NUTR HEALTH AGING, V15, P327, DOI 10.1007/s12603-010-0270-z
   Hegarty VM, 2000, AM J CLIN NUTR, V71, P1003
   Kao Y, 2000, AM J CLIN NUTR, V72, P1232
   Kondo K, 2001, METHOD ENZYMOL, V335, P203
   Muraki S, 2007, J ORTHOP SCI, V12, P317, DOI 10.1007/s00776-007-1143-0
   Nakagawa H, 2002, BIOCHEM BIOPH RES CO, V292, P94, DOI 10.1006/bbrc.2002.6622
   Shen CL, 2008, OSTEOPOROSIS INT, V19, P979, DOI 10.1007/s00198-007-0527-5
   Velayutham P, 2008, CURR MED CHEM, V15, P1840
   Wu CH, 2002, ARCH INTERN MED, V162, P1001, DOI 10.1001/archinte.162.9.1001
   Yang CS, 2001, ADV EXP MED BIOL, V492, P39
NR 15
TC 5
Z9 5
U1 2
U2 22
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085-9195
EI 1559-0283
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD NOV
PY 2014
VL 70
IS 2
BP 1289
EP 1293
DI 10.1007/s12013-014-0053-y
PG 5
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA AQ9DN
UT WOS:000343143500071
PM 24989680
DA 2018-12-27
ER

PT J
AU Su, Q
   Liu, HS
   Yuan, XL
   Xiao, Y
   Zhang, X
   Sun, RJ
   Dang, W
   Zhang, JB
   Qin, YH
   Men, BZ
   Zhao, XD
AF Su, Qin
   Liu, Hongsheng
   Yuan, Xiaoling
   Xiao, Yan
   Zhang, Xian
   Sun, Rongju
   Dang, Wei
   Zhang, Jianbo
   Qin, Yuhong
   Men, Baozhong
   Zhao, Xiaodong
TI RETRACTED: The Interaction Effects of Temperature and Humidity on
   Emergency Room Visits for Respiratory Diseases in Beijing, China
   (Retracted article. See vol. 76, pg. 327, 2018)
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article; Retracted Publication
DE Temperature; Humidity; Respiratory; Emergency visit
ID AIRBORNE MYCOPLASMA-PNEUMONIAE; OUTDOOR AIR-POLLUTION;
   AMBIENT-TEMPERATURE; CLIMATE-CHANGE; HOSPITAL ADMISSIONS;
   RELATIVE-HUMIDITY; DAILY MORTALITY; PUBLIC-HEALTH; TIME-SERIES; NMMAPS
   DATA
AB Few epidemiological studies have been reported as to whether there was any interactive effect between temperature and humidity on respiratory morbidity, especially in Asian countries. The present study used time-series analysis to explore the modification effects of humidity on the association between temperature and emergency room (ER) visits for respiratory, upper respiratory tract infection (URI), pneumonia, and bronchitis in Beijing between 2009 and 2011. Results showed that an obvious joint effect of temperature and humidity was revealed on ER visits for respiratory, URI, pneumonia, and bronchitis. Below temperature threshold, the temperature effect was stronger in low humidity level and presented a trend fall with humidity level increase. The effect estimates per 1 degrees C increase in temperature in low humidity level were -2.88 % (95 % confidence interval (CI) -3.08, -2.67) for all respiratory, -3.24 % (-3.59, -2.88) for URI, -1.48 % (-1.93, -1.03) for pneumonia, and -3.79 % (-4.37, -3.21) for bronchitis ER visits, respectively. However, above temperature threshold, temperature effect was greater in high humidity level and trending upward with humidity level increasing. In high humidity level, a 1 degrees C increase in temperature, the effect estimates were 1.84 % (1.55, 2.13) for all respiratory, 1.76 % (1.41, 2.11) for URI, and 7.48 % (4.41, 10.65) for bronchitis ER visits. But, there was no statistically significant for pneumonia. This suggests that the modifying effects of the humidity should be considered when analyzing health impacts of temperature.
C1 [Su, Qin; Liu, Hongsheng; Yuan, Xiaoling; Zhang, Xian; Dang, Wei; Zhang, Jianbo; Qin, Yuhong; Men, Baozhong; Zhao, Xiaodong] Gen Hosp PLA, Emergency Dept, Affiliated Hosp 1, Beijing, Peoples R China.
   [Xiao, Yan] Gen Hosp PLA, Resp Dept, Affiliated Hosp 1, Beijing, Peoples R China.
   [Sun, Rongju] Gen Hosp PLA, Emergency Dept, Beijing, Peoples R China.
RP Zhao, XD (reprint author), Gen Hosp PLA, Emergency Dept, Affiliated Hosp 1, Beijing, Peoples R China.
EM drxiaodongzhao@163.com
CR ARUNDEL AV, 1986, ENVIRON HEALTH PERSP, V65, P351, DOI 10.2307/3430203
   Basu R, 2002, EPIDEMIOL REV, V24, P190, DOI 10.1093/epirev/mxf007
   BLIGH J, 1963, J PHYSIOL-LONDON, V168, P747, DOI 10.1113/jphysiol.1963.sp007220
   Cao JS, 2009, SCI TOTAL ENVIRON, V407, P5531, DOI 10.1016/j.scitotenv.2009.07.021
   Chan PKS, 2009, J MED VIROL, V81, P1797, DOI 10.1002/jmv.21551
   Cheng YX, 2012, J EPIDEMIOL, V22, P28, DOI 10.2188/jea.JE20110049
   Curriero FC, 2002, AM J EPIDEMIOL, V155, P80, DOI 10.1093/aje/155.1.80
   Danielides V, 2002, ACTA OTO-LARYNGOL, V122, P655, DOI 10.1080/000164802320396358
   Frumkin H, 2008, AM J PUBLIC HEALTH, V98, P435, DOI 10.2105/AJPH.2007.119362
   Haines A, 2000, CAN MED ASSOC J, V163, P729
   Hastie T, 1995, Stat Methods Med Res, V4, P187, DOI 10.1177/096228029500400302
   HEMMES JH, 1960, NATURE, V188, P430, DOI 10.1038/188430a0
   Kan HD, 2009, ENVIRON HEALTH PERSP, V117, pA187, DOI 10.1289/ehp.12737
   Kan HD, 2003, BIOMED ENVIRON SCI, V16, P133
   Kovats RS, 2008, ANNU REV PUBL HEALTH, V29, P41, DOI 10.1146/annurev.publhealth.29.020907.090843
   Kovats RS, 2004, OCCUP ENVIRON MED, V61, P893, DOI 10.1136/oem.2003.012047
   Li GX, 2011, SCI TOTAL ENVIRON, V409, P1811, DOI 10.1016/j.scitotenv.2011.02.005
   Liang WM, 2008, INT J BIOMETEOROL, V52, P223, DOI 10.1007/s00484-007-0116-5
   Lin S, 2009, EPIDEMIOLOGY, V20, P738, DOI 10.1097/EDE.0b013e3181ad5522
   Makinen TM, 2009, RESP MED, V103, P456, DOI 10.1016/j.rmed.2008.09.011
   Martens WJM, 1996, CLIMATE RES, V6, P107, DOI 10.3354/cr006107
   MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564
   Michelozzi P, 2009, AM J RESP CRIT CARE, V179, P383, DOI 10.1164/rccm.200802-217OC
   Nastos PT, 2006, INT J BIOMETEOROL, V50, P358, DOI 10.1007/s00484-006-0031-1
   Papadopoulos NG, 1999, J MED VIROL, V58, P100, DOI 10.1002/(SICI)1096-9071(199905)58:1<100::AID-JMV16>3.0.CO;2-D
   Qian ZM, 2008, ENVIRON HEALTH PERSP, V116, P1172, DOI 10.1289/ehp.10847
   Ren C, 2008, OCCUP ENVIRON MED, V65, P255, DOI 10.1136/oem.2007.033878
   Ren C, 2008, ENVIRON INT, V34, P451, DOI 10.1016/j.envint.2007.10.001
   Ren CZ, 2006, INT J BIOMETEOROL, V51, P87, DOI 10.1007/s00484-006-0054-7
   REZENDE L. G., 2009, INT ARCH OTORHINOLAR, V13, P172
   Roberts S, 2004, ENVIRON RES, V96, P328, DOI 10.1016/j.envres.2004.01.015
   Smith JB, 2009, P NATL ACAD SCI USA, V106, P4133, DOI 10.1073/pnas.0812355106
   WRIGHT DN, 1969, J BACTERIOL, V99, P491
   WRIGHT DN, 1968, J BACTERIOL, V96, P970
NR 34
TC 5
Z9 6
U1 2
U2 18
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085-9195
EI 1559-0283
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD NOV
PY 2014
VL 70
IS 2
BP 1377
EP 1384
DI 10.1007/s12013-014-0067-5
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA AQ9DN
UT WOS:000343143500085
PM 24948474
DA 2018-12-27
ER

PT J
AU Calvo-Guirado, JL
   Ramirez-Fernandez, MP
   Delgado-Ruiz, RA
   Mate-Sanchez, JE
   Velasquez, P
   de Aza, PN
AF Calvo-Guirado, Jose L.
   Ramirez-Fernandez, Maria P.
   Delgado-Ruiz, Rafael A.
   Mate-Sanchez, Jose E.
   Velasquez, Pablo
   de Aza, Piedad N.
TI RETRACTED: Influence of Biphasic beta-TCP with and without the use of
   collagen membranes on bone healing of surgically critical size defects.
   A radiological, histological, and histomorphometric study (Retracted
   article. See vol. 29, pg. 663, 2018)
SO CLINICAL ORAL IMPLANTS RESEARCH
LA English
DT Article; Retracted Publication
DE bone substitute; collagen membrane; critical size defects; guide bone
   regeneration; hydroxyapatite; tricalcium phosphate
ID GUIDED TISSUE REGENERATION; PARTIALLY EDENTULOUS PATIENTS;
   DEHISCENCE-TYPE DEFECTS; TRICALCIUM PHOSPHATE; BARRIER MEMBRANES;
   IMPLANT PLACEMENT; AUGMENTATION PROCEDURES; RIDGE AUGMENTATION; DENTAL
   IMPLANTS; GRAFT
AB Objectives: The aim of this study was to investigate, by means of radiological and histomorphometric analysis, the effect of resorbable collagen membranes on critical size defects (CSD) in rabbit tibiae filled with biphasic calcium phosphate.
   Materials and methods: Three CSD of 6 mm diameter were created in both tibiae of 20 New Zealand rabbits and divided into three groups according to the filling material: Group A (Ossceram), Group B (Ossceram plus Alveoprotect membrane), and Group C (unfilled control group). Five animals from each group were sacrificed after 15, 30, 45, and 60 days. Anteroposterior and lateral radiographs were taken. Samples were processed for observation under light microscopy.
   Results: At the end of treatment, radiological analysis found that cortical defect closure was greater in Group B than Group A, and radiopacity was clearly lower and more heterogeneous in the Group A cortical defects than in Group B. There was no cortical defect closure in Group C. Histomorphometric evaluation showed significant differences in newly formed bone and cortical closure in Group B compared with Groups A and C, with the presence of higher density newly formed bone in cortical and medullar zones. There was no cortical defect closure or medullar bone formation in Group C.
   Conclusions: Biphasic calcium phosphate functioned well as a scaffolding material allowing mineralized tissue formation. Furthermore, the addiction of absorbable collagen membranes enhanced bone gain compared with non-membrane-treated sites.
C1 [Calvo-Guirado, Jose L.; Ramirez-Fernandez, Maria P.; Mate-Sanchez, Jose E.] Univ Murcia, Fac Med & Dent, Dept Implant Dent, Murcia, Spain.
   [Delgado-Ruiz, Rafael A.] SUNY Stony Brook, Dept New Technol, New York, NY USA.
   [Velasquez, Pablo; de Aza, Piedad N.] Miguel Hernandez Univ, Bioengn Inst, Elche, Spain.
RP Ramirez-Fernandez, MP (reprint author), Hosp Morales Meseguer, Murcia 30530, Spain.
EM mpramirezfern@hotmail.com
RI Velasquez, Pablo/O-5857-2015; Mate Sanchez de Va, Jose
   Eduardo/R-9750-2018; De Aza, Piedad/A-7621-2015
OI Velasquez, Pablo/0000-0002-5142-4992; Mate Sanchez de Va, Jose
   Eduardo/0000-0002-4216-421X; De Aza, Piedad/0000-0001-9316-4407; calvo
   guirado, jose luis/0000-0002-4067-2253
CR AABOE M, 1993, CLIN ORAL IMPLAN RES, V4, P172, DOI 10.1034/j.1600-0501.1993.040402.x
   Aghaloo TL, 2007, INT J ORAL MAX IMPL, V22, P49
   Al Ruhaimi KA, 2000, INT J ORAL MAX IMPL, V15, P859
   Becker J, 2009, CLIN ORAL IMPLAN RES, V20, P742, DOI 10.1111/j.1600-0501.2008.01689.x
   Becker W, 1990, INT J PERIODONT REST, V10, P377
   Blanco J, 2005, CLIN ORAL IMPLAN RES, V16, P294, DOI 10.1111/j.1600-0501.2005.01106.x
   Boix D, 2004, J PERIODONTOL, V75, P663, DOI 10.1902/jop.2004.75.5.663
   Bornstein MM, 2007, J PERIODONTOL, V78, P1943, DOI 10.1902/jop.2007.070102
   Bornstein MM, 2009, J PERIODONTOL, V80, P1289, DOI 10.1902/jop.2009.090075
   Bunyaratavej P, 2001, J PERIODONTOL, V72, P215, DOI 10.1902/jop.2001.72.2.215
   Calvo-Guirado JL, 2012, CLIN ORAL IMPLAN RES, V23, P667, DOI 10.1111/j.1600-0501.2011.02193.x
   Carpio L, 2000, J PERIODONTOL, V71, P1743, DOI 10.1902/jop.2000.71.11.1743
   Chazono M, 2004, J BIOMED MATER RES A, V70A, P542, DOI 10.1002/jbm.a.30094
   Chiapasco M, 2006, CLIN ORAL IMPLAN RES, V17, P136, DOI 10.1111/j.1600-0501.2006.01357.x
   CHUNG KM, 1990, J PERIODONTOL, V61, P732, DOI 10.1902/jop.1990.61.12.732
   COOPERMAN L, 1984, J AM ACAD DERMATOL, V10, P638, DOI 10.1016/S0190-9622(84)80271-6
   Cordaro L, 2002, CLIN ORAL IMPLAN RES, V13, P103, DOI 10.1034/j.1600-0501.2002.130113.x
   Dahlin C, 1995, Int J Oral Maxillofac Implants, V10, P312
   DAHLIN C, 1988, PLAST RECONSTR SURG, V81, P672, DOI 10.1097/00006534-198805000-00004
   Esposito M, 2006, INT J ORAL MAX IMPL, V21, P696
   Fan HS, 2007, J NANOSCI NANOTECHNO, V7, P808, DOI 10.1166/jnn.2007.501
   Fotek PD, 2009, J PERIODONTOL, V80, P776, DOI 10.1902/jop.2009.080514
   Hammerle CHF, 2002, J CLIN PERIODONTOL, V29, P226, DOI 10.1034/j.1600-051X.29.s3.14.x
   Horch HH, 2006, INT J ORAL MAX SURG, V35, P708, DOI 10.1016/j.ijom.2006.03.017
   Jovanovic SA, 2007, CLIN ORAL IMPLAN RES, V18, P224, DOI 10.1111/j.1600-0501.2006.01324.x
   Le Guehennec L, 2005, J BIOMED MATER RES B, V72B, P69, DOI 10.1002/jbm.b.30118
   Legeros RZ, 2003, J MATER SCI-MATER M, V14, P201, DOI 10.1023/A:1022872421333
   LeGeros RZ, 2002, CLIN ORTHOP RELAT R, P81
   Machtei EE, 2001, J PERIODONTOL, V72, P512, DOI 10.1902/jop.2001.72.4.512
   de Val JEMS, 2012, J BIOMED MATER RES A, V100A, P3446, DOI 10.1002/jbm.a.34259
   Moses O, 2005, CLIN ORAL IMPLAN RES, V16, P210, DOI 10.1111/j.1600-0501.2004.01100.x
   Nagahara K, 1995, Int J Oral Maxillofac Implants, V10, P109
   Nemcovsky CE, 2002, J PERIODONTOL, V73, P754, DOI 10.1902/jop.2002.73.7.754
   Ogose A, 2006, BIOMATERIALS, V27, P1542, DOI 10.1016/j.biomaterials.2005.08.034
   Oh TJ, 2003, CLIN ORAL IMPLAN RES, V14, P80, DOI 10.1034/j.1600-0501.2003.140111.x
   Park SH, 2008, CLIN ORAL IMPLAN RES, V19, P32, DOI 10.1111/j.1600-0501.2007.01408.x
   Rimondini L, 2005, ORAL SURG ORAL MED O, V99, P148, DOI 10.1016/j.tripleo.2004.05.010
   Rossa Maria Leticia, 2006, J Int Acad Periodontol, V8, P115
   Rothamel D, 2005, CLIN ORAL IMPLAN RES, V16, P369, DOI 10.1111/j.1600-0501.2005.01108.x
   Rothamel D, 2004, CLIN ORAL IMPLAN RES, V15, P443, DOI 10.1111/j.1600-0501.2004.01039.x
   Schwarz F, 2014, CLIN ORAL IMPLAN RES, V25, P1010, DOI 10.1111/clr.12220
   Simion M, 2007, CLIN ORAL IMPLAN RES, V18, P86, DOI 10.1111/j.1600-0501.2006.01291.x
   Sogal A, 1999, J PERIODONTOL, V70, P1053, DOI 10.1902/jop.1999.70.9.1053
   Walsh WR, 2008, BIOMATERIALS, V29, P266, DOI 10.1016/j.biomaterials.2007.09.035
   Wang HL, 2002, J PERIODONTAL RES, V37, P340, DOI 10.1034/j.1600-0765.2002.01625.x
   Zitzmann NU, 1997, INT J ORAL MAX IMPL, V12, P844
   Zitzmann NU, 2001, INT J ORAL MAX IMPL, V16, P355
NR 47
TC 18
Z9 18
U1 2
U2 26
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-7161
EI 1600-0501
J9 CLIN ORAL IMPLAN RES
JI Clin. Oral Implant. Res.
PD NOV
PY 2014
VL 25
IS 11
BP 1228
EP 1238
DI 10.1111/clr.12258
PG 11
WC Dentistry, Oral Surgery & Medicine; Engineering, Biomedical
SC Dentistry, Oral Surgery & Medicine; Engineering
GA AQ6FI
UT WOS:000342905100003
PM 24025159
DA 2018-12-27
ER

PT J
AU Ezzat, MH
   Shaheen, KY
AF Ezzat, M. H.
   Shaheen, K. Y.
TI RETRACTED: Serum Mucosa-Associated Epithelial Chemokine in Atopic
   Dermatitis: A Specific Marker for Severity: Retraction (Retracted
   Article)
SO INDIAN JOURNAL OF DERMATOLOGY
LA English
DT Correction; Retracted Publication
CR Ezzat M H M, 2009, Indian J Dermatol, V54, P229, DOI 10.4103/0019-5154.55630
   Ezzat MH, 2005, EGYPT J PEDIATR ALLE, V3, P64
   Ezzat MHM, 2009, INT J DERMATOL, V48, P822, DOI 10.1111/j.1365-4632.2009.04069.x
NR 3
TC 0
Z9 0
U1 2
U2 7
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0019-5154
EI 1998-3611
J9 INDIAN J DERMATOL
JI Indian J. Dermatol.
PD NOV-DEC
PY 2014
VL 59
IS 6
BP 629
EP 629
DI 10.4103/0019-5154.143618
PG 1
WC Dermatology
SC Dermatology
GA V44XT
UT WOS:000209782400030
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Li, XD
   Zhang, YJ
   Han, JC
AF Li, Xian-Dong
   Zhang, Yi-Jie
   Han, Ji-Chang
TI RETRACTED: Betulin inhibits lung carcinoma proliferation through
   activation of AMPK signaling (Retracted article. See April, 2017)
SO TUMOR BIOLOGY
LA English
DT Article; Retracted Publication
DE Betulin; Lung carcinoma; Proliferation; AMPK signaling
ID CANCER-CELLS; IN-VIVO; LKB1-AMPK PATHWAY; METFORMIN; GROWTH;
   DERIVATIVES; VITRO; ACID
AB Betulin (lup-20(29)-ene-3 beta, 28-diol) is an abundant, naturally occurring triterpene. It is commonly isolated from the bark of birch trees and forms up to 30 % of the dry weight of the extractive. In the present study, we revealed its antiproliferative effects and mechanisms using two lung carcinoma cells (A549 and NCI-292). By 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and bromodeoxyuridine (BrdU) incorporation assays, we found that betulin could efficiently inhibit cell growth and proliferation. Besides, several key genes of cell-cycle regulators were also affected by betulin treatment. At the molecular level, our results demonstrated that treatment with betulin was also associated with activation of AMP kinase and inhibition of mTOR/p70S6K/pS6 signaling in these cells. In agreement, inhibition of AMPK signaling largely reversed the antiproliferative roles of betulin. Taken together, these data provide evidence for a mechanism that may contribute to the antineoplastic effects of betulin and justify further work to explore its potential roles in lung cancer prevention and treatment.
C1 [Li, Xian-Dong; Zhang, Yi-Jie; Han, Ji-Chang] Henan Univ, Huaihe Hosp, Dept Pneumol, Kaifeng 475000, Henan Province, Peoples R China.
RP Zhang, YJ (reprint author), Henan Univ, Huaihe Hosp, Dept Pneumol, Baobei Rd 8, Kaifeng 475000, Henan Province, Peoples R China.
EM YiJie_Zhang@yeah.net
CR Alakurtti S, 2006, EUR J PHARM SCI, V29, P1, DOI 10.1016/j.ejps.2006.04.006
   Algire C, 2008, ENDOCR-RELAT CANCER, V15, P833, DOI 10.1677/ERC-08-0038
   Ali R, 2012, ANTICANCER RES, V32, P2999
   Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769
   Berkovich L, 2012, HAREFUAH, V151, P654
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Dehaen W, 2011, MOLECULES, V16, P2443, DOI 10.3390/molecules16032443
   Dehelean CA, 2012, NAT PROD COMMUN, V7, P981
   Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557
   Keith RL, 2013, NAT REV CLIN ONCOL, V10, P334, DOI 10.1038/nrclinonc.2013.64
   Kommera H, 2011, INVEST NEW DRUG, V29, P266, DOI 10.1007/s10637-009-9358-x
   Krycer JR, 2012, BIOCHEM J, V446, P191, DOI 10.1042/BJ20120545
   Lai HC, 2013, INVEST NEW DRUG, V31, P230, DOI 10.1007/s10637-012-9873-z
   Li Y, 2010, MOL CARCINOGEN, V49, P630, DOI 10.1002/mc.20638
   Linehan WM, 2010, NAT REV UROL, V7, P277, DOI 10.1038/nrurol.2010.47
   McLeod HL, 2013, SCIENCE, V339, P1563, DOI 10.1126/science.1234139
   Pyo JS, 2009, PLANTA MED, V75, P127, DOI 10.1055/s-0028-1088366
   Rzeski W, 2009, BASIC CLIN PHARMACOL, V105, P425, DOI 10.1111/j.1742-7843.2009.00471.x
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Tang JJ, 2011, CELL METAB, V13, P44, DOI 10.1016/j.cmet.2010.12.004
   Wan Y, 2013, INT IMMUNOPHARMACOL, V17, P184, DOI 10.1016/j.intimp.2013.06.012
   Wang HM, 2012, NAT PROD COMMUN, V7, P289
   Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500
NR 23
TC 39
Z9 49
U1 3
U2 16
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2014
VL 35
IS 11
BP 11153
EP 11158
DI 10.1007/s13277-014-2426-7
PG 6
WC Oncology
SC Oncology
GA AU1YJ
UT WOS:000345413100064
PM 25104091
DA 2018-12-27
ER

PT J
AU Li, Y
   Wang, LQ
   Wu, JC
   Ma, YF
   Wang, JF
   Wang, YL
   Luo, YF
AF Li, Yan
   Wang, Liqian
   Wu, Jinchuan
   Ma, Yufei
   Wang, Jinfeng
   Wang, Yuanliang
   Luo, Yanfeng
TI RETRACTED: Poly(vinyl alcohol) and hyaluronic acid derived hydrogel: A
   novel synthesis method using thiol-yne click reaction (Retracted
   article. See vol. 150, pg. 139, 2015)
SO MATERIALS LETTERS
LA English
DT Article; Retracted Publication
DE Poly(vinyl alcohol); Hyaluronic acid; Hydrogels; Thiol-yne click
   reaction; Polymers; Biomaterials
ID BIOMEDICAL APPLICATIONS; CHEMISTRY; REAGENT
AB Poly(vinyl alcohol) and hyaluronic acid derived hydrogel was synthesized by a novel synthesis route using click reaction under mild condition. First, we synthesized two kinds of soluble polymers by linking propargylamine and L-cysteine on the poly(vinyl alcohol) and hyaluronic acid, respectively. The polymers were named as PVAPA and HASH, and characterized by H-1 NMR and Ellman's test. The hydrogels were obtained through thiol-yne click reaction in the presence of photoinitiator after 3 min UV light. The swelling ratio in various pH solution and rheology of hydrogels were detected to confirm that the hydrogels process a certain pH-sensitive property and a stable network system. The click reaction of PVAPA and HASH provided a simple and versatile method to get hydrogel network under a mild condition and have a vast potential for biomedical applications. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Li, Yan; Wu, Jinchuan; Ma, Yufei; Wang, Jinfeng; Wang, Yuanliang; Luo, Yanfeng] Chongqing Univ, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400030, Peoples R China.
   [Li, Yan; Wu, Jinchuan; Ma, Yufei; Wang, Jinfeng; Wang, Yuanliang; Luo, Yanfeng] Chongqing Univ, Coll Bioengn, Res Ctr Bioinspired Mat Sci & Engn, Chongqing 400030, Peoples R China.
   [Wang, Liqian] Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy.
   [Wang, Liqian] Univ Roma Tor Vergata, NAST Ctr, I-00133 Rome, Italy.
RP Luo, YF (reprint author), Chongqing Univ, Coll Bioengn, Campus A, Chongqing 400030, Peoples R China.
EM yfluo@cqu.edu.cn
FU National Natural Science Foundation of China [30970700, 11032012]
FX This work was supported by Grants from the National Natural Science
   Foundation of China (no. 30970700, no. 11032012).
CR Collins MN, 2013, CARBOHYD POLYM, V92, P1262, DOI 10.1016/j.carbpol.2012.10.028
   Crescenzi V, 2007, BIOMACROMOLECULES, V8, P1844, DOI 10.1021/bm0700800
   Hoffman AS, 2012, ADV DRUG DELIVER REV, V64, P18, DOI 10.1016/j.addr.2012.09.010
   Hu XH, 2011, ACTA BIOMATER, V7, P1618, DOI 10.1016/j.actbio.2010.12.005
   Jiang S, 2011, J MECH BEHAV BIOMED, V4, P1228, DOI 10.1016/j.jmbbm.2011.04.005
   Kim J, 2007, BIOMATERIALS, V28, P1830, DOI 10.1016/j.biomaterials.2006.11.050
   Kim K., 2011, J BIOMATER NANOBIOTE, V2, P353, DOI DOI 10.4236/JBNB.2011.24044
   KOBAYASHI H, 1991, BIOMATERIALS, V12, P747, DOI 10.1016/0142-9612(91)90024-5
   Luo YF, 2011, EUR POLYM J, V47, P40, DOI 10.1016/j.eurpolymj.2010.11.001
   Lutolf MP, 2009, NAT MATER, V8, P451, DOI 10.1038/nmat2458
   MOSS RA, 1988, J ORG CHEM, V53, P5860, DOI 10.1021/jo00260a013
   Ossipov DA, 2006, MACROMOLECULES, V39, P1709, DOI 10.1021/ma052545p
   Ossipov DA, 2008, MACROMOLECULES, V41, P3971, DOI 10.1021/ma800332c
   Ouasti S, 2011, BIOMATERIALS, V32, P6456, DOI 10.1016/j.biomaterials.2011.05.044
   Riener CK, 2002, ANAL BIOANAL CHEM, V373, P266, DOI 10.1007/s00216-002-1347-2
   ROSSMURPHY SB, 1995, J TEXTURE STUD, V26, P391, DOI 10.1111/j.1745-4603.1995.tb00979.x
   Schultz KM, 2013, SOFT MATTER, V9, P1570, DOI 10.1039/c2sm27303a
   Teramura Y, 2007, BIOMATERIALS, V28, P4818, DOI 10.1016/j.biomaterials.2007.07.050
   Van VS, 2011, BIOMACROMOLECULES, V12, P1387
   Zhang XZ, 2002, MATER LETT, V52, P5, DOI 10.1016/S0167-577X(01)00355-X
NR 20
TC 4
Z9 4
U1 9
U2 93
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-577X
EI 1873-4979
J9 MATER LETT
JI Mater. Lett.
PD NOV 1
PY 2014
VL 134
BP 9
EP 12
DI 10.1016/j.matlet.2014.07.030
PG 4
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA AP7GE
UT WOS:000342245000003
DA 2018-12-27
ER

PT J
AU Shen, YZ
   Tantai, JC
   Zhao, H
AF Shen, Yuzhou
   Tantai, Jicheng
   Zhao, Heng
TI RETRACTED: Ranking candidate genes of esophageal squamous cell
   carcinomas based on differentially expressed genes and the topological
   properties of the co-expression network (Retracted article. See vol. 20,
   37, 2015)
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article; Retracted Publication
DE Esophageal squamous cell carcinomas; Differentially expressed genes;
   Topological properties; Co-expression network; Candidate genes
ID MICROARRAY ANALYSIS REVEALS; COPY NUMBER ALTERATION; CANCER; THERAPY;
   GROWTH; HETEROZYGOSITY; NORMALIZATION; CORNULIN; SURGERY; MARKERS
AB Background: The aim of this study was to identify the candidate genes of esophageal squamous cell carcinoma (ESCC).
   Methods: Gene expression profiling of 17 ESCC samples and 17 adjacent normal samples, GSE20347, was downloaded from Gene Expression Omnibus database. The raw data were preprocessed, and the differentially expressed genes (DEGs) between ESCC and normal samples were identified by using SAM software (false discovery rate <0.001). Then, the co-expression network of DEGs was constructed based on Pearson's correlation test (r-value >= 0.8). Furthermore, the topological properties of the co-expression network were analyzed through NetworkAnalyzer (default settings) of Cytoscape. The expression fold changes of DEGs and topological properties were utilized to identify the candidate genes of ESCC (Cri(n) score >4), which were further analyzed based on DAVID functional enrichment analysis (P-value <0.05).
   Results: A total of 1,063 DEGs were identified, including 490 up-regulated and 573 down-regulated DEGs. Then, the co-expression network of DEGs was constructed, containing 999 nodes and 46,323 edges. Based on the expression fold changes of DEGs and the topological properties of the co-expression network, DEGs were ranked, and the top 24 genes were candidate genes of ESCC, such as CRISP3, EREG, CXCR2, and CRNN. Furthermore, the 24 genes were significantly enriched in bio-functions regarding cell differentiation, glucan biosynthetic process and immune response.
   Conclusion: The present study suggested that CRISP3, EREG, CXCR2, and CRNN might be causative genes of ESCC, and play vital roles in the development of ESCC. However, further experimental studies are needed to confirm our results.
C1 [Shen, Yuzhou; Tantai, Jicheng; Zhao, Heng] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai 200030, Peoples R China.
RP Zhao, H (reprint author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, 241 Huaihai West Rd, Shanghai 200030, Peoples R China.
EM hengzhao2233@hotmail.com
CR Allocco DJ, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-18
   Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   BANKSSCHLEGEL SP, 1986, CANCER RES, V46, P250
   Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
   Brucher BLDM, 2001, ANN SURG, V233, P300
   Contzler R, 2005, J INVEST DERMATOL, V124, P990, DOI 10.1111/j.0022-202X.2005.23694.x
   Deza M, 2009, ENCY DISTANCES, P94
   Gao HY, 2012, GENET MOL BIOL, V35, P530, DOI 10.1590/S1415-47572012000300021
   Hu N, 1999, CLIN CANCER RES, V5, P3476
   Hu N, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-299
   Hu N, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-576
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Kadowaki Y, 1999, CLIN CANCER RES, V5, P4233
   Kimura S, 2010, ONCOL REP, V23, P1625, DOI 10.3892/or_00000804
   Ko WC, 2012, ONCOL LETT, V3, P75, DOI 10.3892/ol.2011.418
   Kosari F, 2002, CANCER EPIDEM BIOMAR, V11, P1419
   Lam AKY, 2000, CRIT REV ONCOL HEMAT, V33, P71, DOI 10.1016/S1040-8428(99)00054-2
   Luo AP, 2004, ONCOGENE, V23, P1291, DOI 10.1038/sj.onc.1207218
   Mischel PS, 2004, NAT REV NEUROSCI, V5, P782, DOI 10.1038/nrn1518
   Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7
   Pan J, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-157
   Pawar H, 2013, ACTA HISTOCHEM, V115, P89, DOI 10.1016/j.acthis.2012.04.003
   Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999
   Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032
   Risinger JI, 2003, CANCER RES, V63, P6
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Stahl M, 2005, J CLIN ONCOL, V23, P2310, DOI 10.1200/JCO.2005.00.034
   Su H, 2011, CLIN CANCER RES, V17, P2955, DOI 10.1158/1078-0432.CCR-10-2724
   Szekely GJ, 2005, J CLASSIF, V22, P151, DOI 10.1007/s00357-005-0012-9
   Tepper J, 2008, J CLIN ONCOL, V26, P1086, DOI 10.1200/JCO.2007.12.9593
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Udby L, 2002, J IMMUNOL METHODS, V263, P43, DOI 10.1016/S0022-1759(02)00033-9
   Wang B, 2006, CANCER RES, V66, P3071, DOI 10.1158/0008-5472.CAN-05-2871
   Wang B, 2009, MOL CANCER RES, V7, P755, DOI 10.1158/1541-7786.MCR-08-0472
   Wieder HA, 2004, J CLIN ONCOL, V22, P900, DOI 10.1200/JCO.2004.07.122
   Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5
   Yun J, 2012, LAB INVEST, V92, P1033, DOI 10.1038/labinvest.2012.61
   Zhang H, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-141
NR 39
TC 2
Z9 2
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
EI 2047-783X
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD OCT 29
PY 2014
VL 19
AR 52
DI 10.1186/s40001-014-0052-x
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AS9MB
UT WOS:000344565700001
PM 25358439
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

PT J
AU Peng, CY
   Yang, JS
   Zheng, Y
   Xu, ZQ
   Jiang, XD
AF Peng, Chaoyong
   Yang, Jiansi
   Zheng, Yu
   Xu, Zhiqiang
   Jiang, Xudong
TI RETRACTED: Early magnitude estimation for the M(W)7.9 Wenchuan
   earthquake using progressively expanded P-wave time window (Retracted
   article. See vol. 5, 7602, 2015)
SO SCIENTIFIC REPORTS
LA English
DT Article; Retracted Publication
ID EARLY WARNING SYSTEM; SOUTHERN CALIFORNIA; RAPID-DETERMINATION; TAIWAN;
   AFTERSHOCKS; PARAMETERS; TAU(C)
AB More and more earthquake early warning systems (EEWS) are developed or currently being tested in many active seismic regions of the world. A well-known problem with real-time procedures is the parameter saturation, which may lead to magnitude underestimation for large earthquakes. In this paper, the method used to the M(W)9.0 Tohoku-Oki earthquake is explored with strong-motion records of the M(W)7.9, 2008 Wenchuan earthquake. We measure two early warning parameters by progressively expanding the P-wave time window (PTW) and distance range, to provide early magnitude estimates and a rapid prediction of the potential damage area. This information would have been available 40 s after the earthquake origin time and could have been refined in the successive 20 s using data from more distant stations. We show the suitability of the existing regression relationships between early warning parameters and magnitude, provided that an appropriate PTW is used for parameter estimation. The reason for the magnitude underestimation is in part a combined effect of high-pass filtering and frequency dependence of the main radiating source during the rupture process. Finally we suggest only using P-d alone for magnitude estimation because of its slight magnitude saturation compared to the tau(c) magnitude.
C1 [Peng, Chaoyong; Yang, Jiansi; Zheng, Yu; Xu, Zhiqiang; Jiang, Xudong] China Earthquake Adm, Inst Geophys, Beijing 100081, Peoples R China.
RP Peng, CY (reprint author), China Earthquake Adm, Inst Geophys, 5 Minzudaxue South Rd, Beijing 100081, Peoples R China.
EM pcy@geodevice.cn
FU National Natural Science Foundation of China [41404048]; Seismological
   Research Project [201108002]; National Key Technologies R&D Program of
   the Ministry of Science and Technology of the People's Republic of China
   [2012BAF14B12]
FX We greatly appreciate Alessio Piatanesi for his very constructive
   suggestions, which helped improve the manuscript. We also thank China
   Strong Motion Networks Center for providing acceleration seismograms of
   the Wenchuan mainshock (http://www.csmnc.net/). This research was
   supported by the National Natural Science Foundation of China
   (41404048). Research was also partially funded by the Seismological
   Research Project 201108002 and the National Key Technologies R&D Program
   of the Ministry of Science and Technology of the People's Republic of
   China 2012BAF14B12.
CR Alcik H, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036659
   Allen R. M., 2009, GEOPHYS RES LETT, V36
   Allen RM, 2003, SCIENCE, V300, P786, DOI 10.1126/science.1080912
   ALLEN RV, 1978, B SEISMOL SOC AM, V68, P1521
   Bose M, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029396
   Bose M, 2008, B SEISMOL SOC AM, V98, P366, DOI 10.1785/0120070002
   Boore DM, 2002, B SEISMOL SOC AM, V92, P1543, DOI 10.1785/0120000926
   Bormann P., 2009, ENCY COMPLEXITY SYST, P2473
   Carranza M, 2013, GEOPHYS RES LETT, V40, P4588, DOI 10.1002/grl.50903
   Colombelli S., 2012, GEOPHYS RES LETT, V39
   Colombelli S, 2012, B SEISMOL SOC AM, V102, P1266, DOI 10.1785/0120110149
   Cua G, 2007, EARTHQUAKE EARLY WARNING SYSTEMS, P97, DOI 10.1007/978-3-540-72241-0_7
   Deng QD, 2003, SCI CHINA SER D, V46, P356
   Espinosa-Aranda JM, 2009, SEISMOL RES LETT, V80, P694, DOI 10.1785/gssrl.80.5.694
   Festa G, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035576
   Font Y, 2004, GEOPHYS J INT, V158, P655, DOI 10.1111/j.1365-246X.2004.02317.x
   Hoshiba M, 2008, EOS T AGU, V89, P73, DOI DOI 10.1029/2008E0080001
   Hoshiba M, 2011, EARTH PLANETS SPACE, V63, P553, DOI 10.5047/eps.2011.06.015
   Hsiao NC, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036596
   Kamigaichi O, 2009, SEISMOL RES LETT, V80, P717, DOI 10.1785/gssrl.80.5.717
   Kanamori H, 2005, ANNU REV EARTH PL SC, V33, P195, DOI 10.1146/annurev.earth.33.092203.122626
   Kuyuk HS, 2013, GEOPHYS RES LETT, V40, P6329, DOI 10.1002/2013GL058580
   Lancieri M., 2008, J GEOPHYS RES, V113
   Lomax A, 2009, GEOPHYS J INT, V176, P200, DOI 10.1111/j.1365-246X.2008.03974.x
   Nakamura H, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036470
   Nakamura Y., 1988, P 9 WORLD C EARTHQ E, VVII, P673
   Olson EL, 2005, NATURE, V438, P212, DOI 10.1038/nature04214
   Peng CY, 2013, CHINESE J GEOPHYS-CH, V56, P3404, DOI 10.6038/cjg20131016
   Peng CY, 2014, SOIL DYN EARTHQ ENG, V57, P86, DOI 10.1016/j.soildyn.2013.11.005
   Peng HS, 2011, SEISMOL RES LETT, V82, P394, DOI 10.1785/gssrl.82.3.394
   Reza H., 2013, GEOPHYS J INT, V192, P275
   Rydelek P, 2006, NATURE, V442, pE5, DOI 10.1038/nature04963
   Rydelek P, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029387
   Satriano C, 2008, B SEISMOL SOC AM, V98, P1482, DOI 10.1785/0120060159
   Satriano C, 2011, SOIL DYN EARTHQ ENG, V31, P137, DOI 10.1016/j.soildyn.2010.06.008
   Shieh JT, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL035611
   Simons FJ, 2006, EARTH PLANET SC LETT, V250, P214, DOI 10.1016/j.epsl.2006.07.039
   Wald D. J., 1999, EARTHQ SPECTRA, V15, P557, DOI DOI 10.1193/1.1586058
   Wessel P, 1998, EOS T AGU, V79, P579, DOI DOI 10.1029/98E000426
   Wu Y.-M., 2006, GEOPHYS RES LETT, V33
   Wu YM, 2008, SENSORS-BASEL, V8, P1, DOI 10.3390/s8010001
   Wu YM, 2007, GEOPHYS J INT, V170, P711, DOI 10.1111/j.1365-246X.2007.03430.x
   Wu YM, 2005, B SEISMOL SOC AM, V95, P347, DOI 10.1785/0120040097
   Wu YM, 2005, B SEISMOL SOC AM, V95, P1181, DOI 10.1785/0120040193
   Zhang Y, 2009, SCI CHINA SER D, V52, P145, DOI 10.1007/s11430-008-0148-7
   Zollo A, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036689
   Zollo A, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027795
   Zollo A, 2010, GEOPHYS J INT, V183, P963, DOI 10.1111/j.1365-246X.2010.04765.x
   Zollo A, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL030560
NR 49
TC 2
Z9 2
U1 2
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 27
PY 2014
VL 4
AR 6770
DI 10.1038/srep06770
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AS0PA
UT WOS:000343978700002
PM 25346344
OA DOAJ Gold, Green Published
DA 2018-12-27
ER

EF